<SEC-DOCUMENT>0000950170-22-005243.txt : 20220331
<SEC-HEADER>0000950170-22-005243.hdr.sgml : 20220331
<ACCEPTANCE-DATETIME>20220331170153
ACCESSION NUMBER:		0000950170-22-005243
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220331
DATE AS OF CHANGE:		20220331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Finch Therapeutics Group, Inc.
		CENTRAL INDEX KEY:			0001733257
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823433558
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40227
		FILM NUMBER:		22793885

	BUSINESS ADDRESS:	
		STREET 1:		200 INNER BELT ROAD
		CITY:			SOMERVILLE
		STATE:			MA
		ZIP:			02143
		BUSINESS PHONE:		617-229-6499

	MAIL ADDRESS:	
		STREET 1:		200 INNER BELT ROAD
		CITY:			SOMERVILLE
		STATE:			MA
		ZIP:			02143
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fnch-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-31T16:48:32.3265+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:fnch="http://finchtherapeutics.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4a3ab359-83a0-467a-832c-81187a39bb66" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484">http://fasb.org/us-gaap/2021-01-31#LiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_2d1cab61-360a-4886-82f1-f7e9f31c3925" name="dei:DocumentFiscalPeriodFocus" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d">FY</ix:nonNumeric><ix:nonFraction id="F_5221a7d6-7634-49ee-a6f1-36478875109c" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7ea1798d-7710-41a8-88de-a9818d271ecd" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a" unitRef="U_pure" decimals="0" scale="3" format="ixt:numdotdecimal">0.069</ix:nonFraction><ix:nonNumeric id="F_ce0870bb-8eeb-44d5-b5e5-d0584b753fb3" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_957127f4-c475-441f-b556-eccb47c51b83" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric id="F_a2193164-9e2a-4221-9f68-b893cedb3694" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_5948ec9b-5280-4aa5-aed5-af79546d9c6d" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonFraction id="F_21ec6a53-bfc8-4b44-8ee4-633109b93d1e" name="us-gaap:NumberOfOperatingSegments" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" unitRef="U_Segment" decimals="INF">1</ix:nonFraction><ix:nonNumeric id="F_ef49ada0-6575-4ae4-a962-ef5ca9c297f6" name="dei:CurrentFiscalYearEndDate" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d">--12-31</ix:nonNumeric><ix:nonNumeric id="F_a0f8a908-b2a1-4ec4-b4e9-5040c0d7f77c" name="dei:AmendmentFlag" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_82684cf4-53e2-4fe6-90df-5260ddc9184d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_68d05483-5dc7-4b5f-80b7-0dd35e2effcb" name="dei:EntityCentralIndexKey" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d">0001733257</ix:nonNumeric><ix:nonNumeric id="F_38192f5a-105d-43eb-b508-0d9616c597fd" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d">http://fasb.org/us-gaap/2021-01-31#LiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fnch-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_3c431cec-8ef4-41d1-91de-5a171c2fbc40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f83ae0d-7bba-4546-b75f-1d3582c586e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:CherryStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d132eb44-d5fe-4db6-90fa-ee1cb44369fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67b625c9-9b8a-4bea-b722-36d695553d6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_089fb034-da86-4331-8cab-1b70dc0cd490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36ebf60e-e0c4-40dd-910b-838e10c9ca42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12c08bf0-f65b-48fb-8e06-4a1f508e55aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eea5819-27f3-44f8-90a5-9ad45f546635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab627a9f-a180-4add-89be-437938d49551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06a32a5b-3613-45c4-bbd2-cb0a2ad1a82b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c775cfd2-628d-4919-8429-a954d20061c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7eff636f-c2ac-47da-b8b3-a7419771eb22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42702fe8-9f6e-4d52-96bc-bf7ff5642f9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17959f69-52c0-4bd7-b17b-2b07c6a89b83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:CherryStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_736b82ab-77e3-4d3c-b1d1-93ec2b7be5f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83341027-5973-4448-a037-4a0f2e02d99e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_799a1f7a-7972-48f7-b715-47a07a846536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4603d1f8-8b00-442d-96f0-6e9d5d761ed9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2836ed65-af3b-490c-89b2-d07fef0677d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3997c41e-c3c8-4da2-92c5-b9b78945ec5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b373c5e-3287-41b4-b4c9-314d0744c150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb5222a4-6edc-4157-b8f3-0776d5488397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95503824-281a-48bb-a70d-4346f1e2af47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f617c4d-2130-4a03-be94-001eafeeb878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78dd3234-e5d1-4ad1-9914-de28cdc240bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e102589d-5e6a-4e44-bd66-a82362df7fb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:LMICLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1f90607-ba2b-41a5-bea3-4ef6520ec07b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1c89c9b-52b3-4ae8-bb9f-118f289a32ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">fnch:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a179872-937f-42ac-8d8c-e1ded8315d35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8d19c5f-3b27-462c-bd7a-dd8adf6bc783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab725e4-2f52-4e39-862f-22ef20e05710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3c21c56-3f76-4284-9b46-d59d04095b4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6dc934d-3979-4343-93cf-f35734ec869e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c26cc83f-e31e-4451-9562-469d6a32f396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46125c65-4c5f-4d12-825a-13db653d8482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5285cda-f062-40ab-908f-8ca5f466181d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8093822b-1d40-4764-a04f-b8bfd74d9e7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90fcacc1-0f06-47c8-b90f-1fbdb93ceffd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e78abb46-6208-4d28-9564-457e5c7c89e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84da10c1-11ac-42c7-a238-2c5259bce7ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6c10679-4ab6-409c-8105-7146e8e77be9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4f0fa8f-0e53-4dd0-96a5-34610a065137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_318f64ea-ab2c-4f3a-8c39-bea1e8b5efee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b073b84-8eb2-412a-a07e-959c86d508ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54d8859b-3cf9-4f25-81a8-0121817ec070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc5421c3-a799-4980-a188-637fac870fba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a6aef8a-3ebf-43c8-a1d9-cb65a4f2ce4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee5e5087-1f48-495c-a0c7-df7f666bcc55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fnch:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbf098e4-d64a-4024-bd56-afb40e7ad714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c284ec5c-9fd7-4308-a062-488f6fa155dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">fnch:PaycheckProtectionProgramCARESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2986efa3-0d9a-4a27-8474-473277d39a68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fnch:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60b68536-8ed1-43da-ac13-d5bdb8aa1b26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4537122-5c97-4483-a0d3-0abbbe078b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e1cbdf0-abb9-4321-a134-6b908bc1cb74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63ccd21b-b4e9-4f84-b09c-125598219f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1545e700-f4cb-462d-bda2-6aea5fb1b1f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96bb2e98-4d79-4650-8af9-3a931a612483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb1c3a83-faee-4108-875a-e75af3e55f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28d6c4c4-95d2-4950-aa5c-95cb9369b506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53f088f1-6942-4a33-8ec0-d9a352aa8473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb5c3d76-f6ae-465b-9ade-c84c08d30d59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f567ce58-d36b-4cfd-9d2d-43b08b57d11c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_734ba92d-986a-46d1-aeee-fd929b61447a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_389a0f17-bc7e-475d-9cc4-8f35d0418848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa678b92-859d-4297-a5ea-40baf1bbd70e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b15bab6a-f44e-4005-a4ff-bbdc0471e1f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f587b93-a68e-4011-af1c-8223963a66b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_101a8fc8-ab99-4053-8a20-c0d1e9fba7b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d380522-affd-4af4-a507-2ff7a0457581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">fnch:PaycheckProtectionProgramCARESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3e50907-6887-4220-a0d9-4a36fa444e7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94c65693-07a8-42cf-9bcf-fe65d1cb5868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30f83225-a823-4c68-b24e-432bbb423504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bd4a0ca-99c2-4074-b339-97461c98088b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:LMICLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1de77ba6-205b-42f6-acd1-060d987f64f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8192ae4f-1c2b-4a80-a43c-6831f9eb30f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_773d9f64-92e0-471f-87fd-c693d0fedbc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17ff663a-6142-4c26-8780-a4ce862a5484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ef89633-4500-4c18-944c-7f047f6e3e2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_516796e2-fbe9-4963-858d-72b0827743bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24547a48-6a37-4b99-8269-4b7bace32f46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6252e38b-5c6e-4c8e-8aa8-5c056fef33a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:MaterialAccessAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e162eb52-c156-467f-9465-7e2422f556b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1241508-27ea-4aa7-a3a8-f0e51e38ba2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61cd82ea-f358-4082-bca8-78e13843b66f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_049c3cdd-3341-4084-9a6d-e1edee63342e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c2fd835-a216-403d-821e-6c8b06fd2c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d09ee6b-925b-4309-b34d-5e1eb3247ba6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fe6991f-9dcc-4a7d-a873-78e8fd832d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d35ab3f0-886e-4614-bb8e-288d6e18d8a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2f7e686-a500-4145-884d-a28aca2133c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80eb5b83-cbf6-469c-a34a-c9f03f095627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5aa5df0-f902-4636-ba9a-661aa8e20277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee5015be-b0fc-4255-b8a6-7d92826e8809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4277bcb-d35b-4f32-8ff6-cdca824e9d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dc28e60-afc9-4c19-b43d-868677e6583f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23263f47-404c-4325-867d-c627433086e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97f8bd01-bf35-4029-b59b-fedcc19e7fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea0a073d-aea6-481f-bcbd-2d2464476655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_958aeacf-f69f-4b11-a72c-34559a9f8235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92ff62b1-b286-46a8-8e9a-bd9133b65f3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58649b84-b6a5-4536-b8e2-c6e68450eebd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">fnch:PaycheckProtectionProgramCARESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-08</xbrli:startDate><xbrli:endDate>2021-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b80e0856-efdb-45ee-8c35-7042653d6f4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b8eb604-10e3-4861-ab49-2e0d36d00d64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20b17903-cb4b-42fd-9bb7-362bbcc58c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48646751-72ab-4bdf-9554-d01586c1b9b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec838299-1fe2-441c-a5b8-80818b17a987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9eb4f167-eaf7-4d4b-98b2-e2d8c89215f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">fnch:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb463b4-797e-452d-873d-48619c046805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d858d07b-3375-4198-87a7-a594e75f4620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02bc5fe6-52dc-428c-a5bc-9f4b8b799841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_309231a5-1644-42cc-8f57-4efa7d95eb14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb5e464a-84a9-4eb3-ad80-f75e327f7bbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e407f9da-0025-4449-9d33-474e81924957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9450f23f-f434-468a-8008-c54520274c6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fc799d2-e7ca-49cd-94bd-3368b8b30296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fnch:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb9e58de-8667-4321-b6aa-911f48db159f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78f74fe2-9b23-4570-b2d6-32c1291e24ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e585cf8d-a59f-4d43-8477-6b3d9ed99d06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f6ab27f-7051-4656-8340-31bd75faefe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2016132-69da-4b8f-8d71-133d0638c922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e5ad697-00fd-45d8-8d53-5221838de719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08797998-db85-4999-b501-d07c4980c203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b66a4bb1-f047-4756-b7b4-61d3d88e063e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_826e7f83-9582-40fb-b568-89f02012f782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa2b03ad-bfcf-4d93-bc04-01ee6362dafd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f59b9e4d-a520-4962-b1b1-8256ad30502f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34e7a81f-7394-49b9-84da-068d88b1e719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da1fc6b8-eb04-4fd7-aefa-1b1663c0cbad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9606295d-3592-4e4f-80a8-99a45144d61e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aee05aaf-8f6d-4638-a8fe-67e2f46277b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_754cfea2-fdc5-4ff8-a708-49bbef66cbaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0df70676-9619-40e8-853f-19a8b73a703f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7977ced-72d5-4903-b7c8-1bf202956756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:RoyaltiesRevenueFromRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83dde824-9020-47ce-a70f-8cacb2aad84b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d0e0e4a-c148-42f2-b8d6-c5dcb9f5fb6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9b8ef89-619c-4cf1-98e8-3318a7630899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad20da32-3929-4b8f-8211-81be4d8ad10d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3403fa8-bacc-4e4b-a517-c82e4d4d547a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af126580-e6a9-4bc4-b56f-9a9ed89d3577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4017af1-75f3-41f0-9528-da23823df46b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29237393-f7a6-4fe4-b6e8-04815b077862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1290669d-3ef4-4091-b2fe-97c62f8ec90f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4de9218f-505d-4ec5-a79e-948264f8faaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf8db871-33e8-4b48-96d6-27807a718a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32730e64-85f4-497d-935f-ef876cb18554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68b03d20-efc1-47c4-97fe-d09e37d99bd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3685552-54f1-4285-9365-be9a43f57bfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:RoyaltiesRevenueFromRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e29d9cb5-46b0-4d57-96ad-b94780aa228e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_566912aa-b2e7-4130-a031-93d7d2de01cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ac98b6d-c24a-449b-91fb-dcb878c6c9ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d183d8f2-6271-4193-aa8f-606f93e1458d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_894a98a6-c6bc-4f3a-98ca-fb68d588713d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_248b74bb-bfef-43a3-8d20-9cef789c8fff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-25</xbrli:startDate><xbrli:endDate>2021-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0483dbaf-2c53-4e42-b419-593696b5f428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e109216b-8e95-4dc3-9229-87d798ee0e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd8cbba4-d765-4c03-adf6-a6cf25b63c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5ab9bc6-ee73-4ce5-9025-8b3e49b4281c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db4e3207-e9fa-4152-a818-87c22ab1f012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5da05409-533d-466c-be18-f590067b6927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76e74e59-dc68-499b-b05c-f96331eeeafa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_beb9a9a0-b07a-43a6-96d5-dca4ca792d9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:MaterialAccessAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffad40cc-645b-45db-bb47-731c0e92c8ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34820dd6-125a-4651-9d74-471c92bb1554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f9e11d5-5772-4d8d-aeba-f92855030d1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe91f7aa-3290-4bec-8ded-b59274901189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db086534-a8d4-4c38-a41b-514f72bc36c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:LMICLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a999a1-8dfb-4ba6-8758-e876879ab568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcacd18f-13a2-4b4f-b905-5a7daa5bf83a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6981439-53f3-412e-bd72-c7b736c9fa1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-10</xbrli:startDate><xbrli:endDate>2020-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05c62255-213e-4926-a804-309677cebed5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e63bb9f3-addf-44bf-9079-4ef73a7b1858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcc33dd7-e5c8-4f20-b7fe-48ad8567599e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12ceb0d9-027f-4047-880f-0f426157ce04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caa9d4b6-a795-41fe-9dbc-e8ef123673de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29953980-7bf1-4fdd-b181-4be7a82bb370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_583cd02a-6b47-4c6a-9fda-94aade34f36d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d564718-6e70-47c3-b45e-478a924b707b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfcf15ad-e5a5-482c-921c-d2c853db7126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e96af31-f869-445b-b59a-14d832388be8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5f06605-6037-48e4-9be3-dc6adc0731f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6ce2584-4ad0-4ec8-bee7-5bf80eddbb4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_193c9642-0dfc-4b03-beda-cbe44093e952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1444436-ad66-46ea-8295-6f51e32cc67c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71180d5f-f125-42b1-a289-021fbd6caff4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e9b7d9d-0899-469e-840d-b1a8fd63c115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3854077f-36a9-4171-af92-3885c504f8ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed564ca9-9a3a-412d-9d64-5fd1ffc81119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bd85910-ac68-4113-bf19-049baf264c14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92dda7ef-0294-4c60-82b0-253ca681399b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29c6a1db-39a6-4d51-92a7-9d1ef5ec34c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60325954-cd50-4585-85cc-6fc0b138b87d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_619dbd5a-3d31-4dff-bdde-1c37501aef02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85b5348c-0723-4afb-be02-9db714b74dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001733257</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>fnch:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_dbc6dd0c-c53b-49de-8c39-5c46ef9abcc8" fromRefs="F_826c8495-19c0-4a28-9e18-0cfd4c276ecc F_63fcec9a-5520-4869-afa6-b24df4aa3a63"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d610c817-b7ce-47ac-89d1-d17113fbe941" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b52ab163-1099-4172-96de-c972e64a706f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49b74151-4927-4c4c-b8e1-8f1641a0ac66" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31adbbed-3ba7-43d0-a2bd-d44c9a028c07" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> 2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66e1b697-bdcc-422e-97f5-2310141cdd03" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_402b542f-5a66-4c82-919f-8235f2e322d1" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-40227</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3e7612c-4351-4b06-90e0-6d6abdafa208" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2045e421-8201-48f1-a592-81b4b0be98f8" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67461d0d-03fe-4ab8-b8d9-f771590b84cb" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">82-3433558</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1401ef6-2cab-446e-a225-ca1716503173" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">200 Inner Belt Road</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c6f0261-48fb-4309-b8ea-48f4dbcf4b57" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 400</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74e59df9-6fb4-4e55-90bf-b9d57f213388" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Somerville</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07df74b7-6554-49f7-ab83-e8e38d8f8ce5" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4273939b-f612-4c81-be97-4e3c20ee3028" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">02143</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93e0d8bc-e0d9-4bb0-959e-8792e6a16cf3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">617)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89a9a856-f73b-49f0-80d5-1fd02ce75f69" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">229-6499</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35844f50-e613-439b-8316-9a33d9d880d8" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e32c4219-03ac-48bc-95c9-6854b51fd8d3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">FNCH</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aec1d9b5-dddf-4e4b-b0a2-693b48545206" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Nasdaq</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Stock Market LLC</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97fd24ec-e75d-489f-8e0a-3c87479c82ef" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95d83c9b-eb6f-448a-af15-a3e19a855b1f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d85a889d-61c2-49bf-a271-0de323f4e228" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4b09e5f-b75d-4604-95b2-ac0ceff702f6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.298%;"></td>
    <td style="width:0.595%;"></td>
    <td style="width:55.849%;"></td>
    <td style="width:1.062%;"></td>
    <td style="width:20.498%;"></td>
    <td style="width:0.595%;"></td>
    <td style="width:2.103%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3506e94a-0d52-4550-842d-ae0f26d20403" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bebce2f-f72f-4c48-af9d-bc07bfc0695c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4ea5a14-9110-48c4-8354-976ae4bb143b" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad45a029-4954-47f5-84ec-1a8894d02d79" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06612c23-46fa-4840-9604-bb409cb4775c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca796b43-e177-47aa-a7ce-6b2f23d55476" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">     NO &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The aggregate market value of common stock held by non-affiliates of the registrant computed by reference to the price of the registrant&#x2019;s common stock as of June 30, 2021, the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, was approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89e4abd2-3238-4d3e-96b8-dc2c7495fc93" contextRef="C_101a8fc8-ab99-4053-8a20-c0d1e9fba7b6" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">354.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million (based on the last reported sale price on the Nasdaq Global Select Market as of such date). For this computation, the registrant has excluded the market value of all shares of common stock reported as beneficially owned by its executive officers, directors </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">and stockholders that the registrant has concluded are affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of March 24, 2022, there were </span><span style="font-size:8.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02e3cd35-2d45-4076-9189-b3f70148ec10" contextRef="C_0483dbaf-2c53-4e42-b419-593696b5f428" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">47,532,573</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">outstanding shares of the registrant's common stock, par value of $0.001 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_c649fc5e-47b1-4941-9b2d-8cd09636f9bf" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant&#x2019;s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:81.996%;"></td>
    <td style="width:7.003%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7_mda"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item8_financial_statements_supplementary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                 </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will&#x201d; or &#x201c;would,&#x201d; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs, including our ability to resolve the clinical hold on our investigational new drug application for CP101;                         </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain regulatory approval of CP101, FIN-211 and any other current or future product candidates that we develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to identify and develop additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to advance product candidates into, and successfully complete, preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including a public health emergency, such as the ongoing COVID-19 pandemic and any variants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding the potential market size and the rate and degree of market acceptance for any product candidates that we develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effects of competition with respect to CP101, FIN-211 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to fund our working capital requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our financial performance and our ability to effectively manage our anticipated growth; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain additional funding for our operations; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other risks and uncertainties, including those listed under the section titled &#x201c;Risk Factors.&#x201d;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These forward-looking statements are based on our management&#x2019;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#x2019;s beliefs and assumptions and are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under &#x201c;Risk Factors&#x201d; and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING COMPANY REFERENCES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless the context otherwise requires, references in this Annual Report on Form 10-K to &#x201c;FTG,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Finch Therapeutics Group, Inc. and its subsidiaries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING TRADEMARKS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RISK FACTORS SUMMARY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a summary of the principal risks that could adversely affect our business, financial condition, operating results, cash flows or stock price. Discussion of the risks listed below, and other risks that we face, are discussed in the section titled &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business and operations may be adversely affected by the evolving and ongoing COVID-19 global pandemic.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently subject to a clinical hold on our IND for CP101. We need to resolve the FDA clinical hold issues in order to proceed with enrollment in our PRISM4 clinical trial and initiate our Phase 1b clinical trial in Autism Spectrum Disorder (ASD). Our business may be adversely affected if the clinical hold is not resolved in a timely manner or if regulatory concerns lead to additional delays and/or FDA enforcement actions.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a limited operating history, have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our product development programs or other operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are heavily dependent on the success of our product candidates, which are in clinical and preclinical development. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates are based on microbiome therapeutics, which is an unproven approach to therapeutic intervention.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may be associated with serious adverse, undesirable or unacceptable side effects or other properties or safety risks, which may delay or halt their clinical development, or prevent marketing approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third-party donors of biological material to manufacture certain product candidates such as CP101 and FIN-211, and if we do not obtain an adequate supply of acceptable material from those qualified donors, the clinical and commercial supply of these product candidates may be adversely impacted.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate our own manufacturing facility for certain product candidates, which requires significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining regulatory approval for our current or future product candidates for our initial or potential additional indications.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Our Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. We believe that our differentiated platform, rich pipeline and the broad therapeutic potential of this new field of medicine position us to transform care for a wide range of unmet medical needs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, or CDI. In June 2020, we reported positive topline data from our Phase 2 placebo-controlled clinical trial of CP101 for the prevention of recurrent CDI, which we refer to as the PRISM3 trial, and in November 2021, we reported positive topline data from our open-label, Phase 2 clinical trial of CP101 for the prevention of recurrent CDI, which we refer to as the PRISM-EXT trial. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have designed a Phase 3 clinical trial, which we refer to as the PRISM4 trial, to serve as our second pivotal trial of CP101 for the prevention of recurrent CDI.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 1, 2022, we announced that enrollment in PRISM4 was paused following receipt of a clinical hold letter on February 24, 2022 from the U.S. Food and Drug Administration, or the FDA, in connection with our investigational new drug application, or IND, for CP101, requesting additional information regarding our SARS-CoV-2 donor screening protocols, including, among other things, that we address the risk of SARS-CoV-2 transmission in the informed consent process, additional detail on how samples are shipped to the vendor performing the SARS-CoV-2 testing of the donor material and how inconclusive test results will be handled. We are also preparing to initiate a Phase 1b clinical trial of FIN-211 in autism spectrum disorder, or ASD; however, because FIN-211 includes donor-derived components, the clinical hold related to our IND for CP101 will also delay initiation of our clinical trial in ASD.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to manufacture additional lots of CP101 and FIN-211 to satisfy the FDA's requests related to SARS-CoV-2 screening and testing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently evaluating the extent of the delay the clinical hold and related manufacturing activities will have on the timing for our clinical trials in CDI and ASD, which we expect to be at least one quarter based on manufacturing timelines; we describe the clinical hold and related matters further in the section entitled &#x201c;Our Clinical Programs&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CP101: Our Lead Product Candidate for the Prevention of Recurrent CDI</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead candidate, CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Patients with CDI suffer from severe diarrhea, which can progress to toxic megacolon and death, with more than 44,000 CDI-attributable deaths annually in the United States. In addition to the human cost, the economic impact of CDI is significant, with 2.4 million in-patient days and more than $5 billion in direct treatment costs each year in the United States alone. CDI often returns after cessation of antibiotic treatment because antibiotics do not address the dysbiosis that underlies this disease. We estimate there are approximately 200,000 cases of recurrent CDI annually in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, we announced that PRISM3, the first pivotal trial of CP101, which was a randomized, blinded, placebo-controlled multi-center Phase 2 clinical trial, met its primary efficacy endpoint. Overall, 74.5% of participants who received a single administration of CP101 achieved a sustained clinical cure, defined as the absence of CDI through week 8, achieving statistical significance for the primary efficacy endpoint, with a clinically meaningful 33.8% relative risk reduction for CDI recurrence compared to placebo. In October 2021, we shared additional data from PRISM3 showing that the proportion of participants with sustained clinical cure (defined as absence of CDI recurrence) through week 24 remained significantly higher in the CP101 arm compared to the placebo arm. In PRISM3, the prevalence of adverse events was similar across CP101 and placebo arms, with no treatment-related serious adverse events in the CP101 arm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced positive topline results from the 132-participant PRISM-EXT trial. The primary efficacy endpoint of the PRISM-EXT trial was sustained clinical cure (defined as absence of CDI recurrence) through 8 weeks post-treatment. Overall, 80.3% of participants who received a single oral administration of CP101 following standard-of-care, or SOC, antibiotics in PRISM-EXT achieved sustained clinical cure through week 8. At week 24, 78.8% of participants had</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sustained clinical cure. In the PRISM-EXT trial, there were no treatment-related serious adverse events reported and CP101 exhibited an overall safety profile consistent with the profile observed in PRISM3. The PRISM-EXT results are consistent with and build on our previously reported PRISM3 results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CP101 Program for the Treatment of Chronic HBV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following a strategic review of our pipeline and business, we announced in March 2022 the decision to pause the development of CP101 for the treatment of chronic hepatitis B virus, or HBV. We believe this decision will allow us to maximize our working capital available for investment in our wholly-owned recurrent CDI and ASD programs.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may continue our research efforts in HBV in the future as our portfolio continues to mature.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Developing Capabilities for Targeted and Enriched Consortia Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to developing CP101, a Complete Consortia product candidate designed to address community-level dysbiosis, or disruption across many functional pathways and species, we are also developing Targeted Consortia product candidates that consist of individual bacteria grown from master cell banks to engage narrower pathway-level dysbiosis. The ability to pursue both of these product strategies enables us to tailor our product candidates to the pathophysiology of each indication. This combination of capabilities also enables us to pursue a third product strategy, Enriched Consortia, which addresses dysbiosis at both the community and pathway level. These product strategies are summarized in the schema below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_0.jpg" alt="img102364508_0.jpg" style="width:528px;height:376px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Human-First Discovery platform informs each of these product strategies using clinical interventional data, through a process of reverse translation. Core to this strategy is our ability to deploy our proprietary machine learning algorithms to mine clinical data generated internally and by third parties, including experience with fecal microbiota transplantation, or FMT, a procedure that has been used to restore the gut microbiome and address community-level dysbiosis. FMT is a procedure, not a product. It is not approved by the FDA, and there are no standards for testing, processing and delivery of FMT, though it typically requires a colonoscopy. Despite these limitations, FMT has been used to treat more than 60,000 patients, with hundreds of clinical studies ongoing across a range of disease areas. We believe that this data can be used to (1) identify diseases where addressing dysbiosis provides therapeutic benefit, (2) reveal the mechanisms that underlie these results and (3) uncover key microbes and functional pathways that drive these clinical outcomes. We believe this reverse translation strategy is the optimal approach to developing microbiome therapeutics, providing causal insights that cannot be gleaned from preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> experiments alone. We further believe that we are uniquely positioned to execute</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on this strategy because of our proprietary FMT database and biorepository, our broad network of collaborators that supports the rapid growth of our data assets and our proprietary machine learning algorithms that enable the efficient translation of clinical data into therapeutic insights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FIN-211: Our Product Candidate to Address Gastrointestinal and Behavioral Symptoms of ASD</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have used our Human-First Discovery platform to develop FIN-211, an Enriched Consortia product candidate that we are advancing to address the gastrointestinal and behavioral symptoms of ASD. Scientific research in human and animal models have highlighted the &#x201c;gut-brain axis&#x201d; linking dysbiosis to neurological and neurobehavioral conditions, as the microbiome impacts the enteric nervous system and the production of neurotransmitters. This basic research is supported by a growing body of third-party clinical research. An open-label, proof-of-concept FMT trial observed that, two years after treatment, 33% of the study participants who had previously been diagnosed with ASD were below the ASD diagnostic cutoff score for the Childhood Autism Rating Scale (CARS), a commonly used ASD diagnostic tool. In another open-label randomized, controlled trial, children with ASD receiving FMT and behavioral therapy showed a statistically significant improvement in their behavioral symptoms compared to those receiving behavioral therapy alone. Both studies also observed marked improvements in the gastrointestinal symptoms that many autistic children suffer from. There are no FDA-approved therapies for the core symptoms of ASD and the total financial burden of care for this condition is estimated to exceed $100 billion in the United States annually. We have received feedback from the FDA that demonstrating a benefit for either gastrointestinal or behavioral symptoms of ASD could support a biologics license application. Building on our discussions with the FDA, we aim to continue to validate behavioral instruments as part of our clinical development plans. We have designed FIN-211 to address both behavioral and gastrointestinal aspects of ASD, which we plan to assess, along with safety and tolerability, in a Phase 1b clinical trial of FIN-211 in ASD. We believe FIN-211 has the potential to transform care for patients with ASD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TAK-524 (formerly FIN-524) Ulcerative Colitis Development Program in Collaboration with Takeda</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In collaboration with Takeda Pharmaceutical Company Limited, or Takeda, we are also</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developing Targeted Consortia product candidates for inflammatory bowel disease. In August 2021, we announced that Takeda elected to accelerate its leadership role in the FIN-524 ulcerative colitis development program, now known as TAK-524. Accordingly, we transferred the program to Takeda for further development. The design of product candidate TAK-524 leverages computational and molecular analysis of data from 146 patients treated with FMT and 19 observational studies of an additional 2,210 patients. We believe that the development program for TAK-524, which is a Targeted Consortia product candidate composed of strains grown from master cell banks, is not affected by the clinical hold related to our IND for CP101.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FIN-525 for the Treatment of Crohn's Disease in Collaboration with Takeda</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We continue to partner with Takeda on discovery efforts targeting the development of FIN-525 for the treatment of Crohn&#x2019;s disease. We believe that the development program for FIN-525, which is a Targeted Consortia product candidate composed of strains grown from master cell banks, is not affected by the clinical hold related to our IND for CP101.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_1.jpg" alt="img102364508_1.jpg" style="width:672px;height:278px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The Human Microbiome and its Impact on Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The human microbiome describes the community of more than 30 trillion microbes that reside on and inside the human body. By evolving together over millions of years, microbes and humans have developed an intricate and mutually beneficial relationship that has only recently been uncovered. Enabled by the genomic revolution, researchers have discovered that humans carry over 1,000-fold more microbial genes than host genes and that microbiome signaling is fundamentally intertwined with many aspects of human physiology ranging from immune and metabolic functions to neurological function and reproductive health. The deep inter-relationship between microbes and their human hosts is a co-evolution that has resulted in a learned dependency, leaving humans now reliant on inputs from this previously unrecognized organ system.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruption of the gut microbiome is associated with a large number of diseases that have dramatically increased in prevalence among populations in developed countries over the past century. We believe these epidemiological trends are linked to changes in the microbiome, which if reversed could potentially address an underlying cause of these diseases and change the epidemiology as a result. The rise of these chronic illnesses coincides with our adoption of a number of practices that disrupt the microbiome: more than 42 billion doses of antibiotics are administered annually, many killing 40-60% of microbial species in the gut; a third of babies in the United States today are born by caesarean sections, and are consequently unable to inherit this organ from their mother; and a highly sanitized and artificial environment, absent the environmental inputs expected by our microbiome, applies further pressure on this ecosystem within us. The effects of these environmental inputs coalesce around the gut microbiome resulting in dysbiosis and these changes are linked to a wide variety of chronic diseases. For example, antibiotic exposure doubles the risk of developing IBD, as well as significantly increases the risk of developing over 10 types of cancer. Early microbiome disruption is also associated with ASD, autoimmune indications such as celiac diseases, and allergies and asthma, and microbiome disruption later in life has been linked to neurodegenerative diseases, including Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. Importantly, in multiple animal models, these diseases can be induced by microbiome disruption and corrected by restoration, providing evidence of causality. For several of these therapeutic areas, this has been further bolstered by clinical data with FMT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effects of gut microbiome dysbiosis reverberates throughout the body, both because immune cells are heavily concentrated in the gut, where more than 70% of the body&#x2019;s immune cells are located, and because microbial metabolites enter systemic circulation, acting on organs throughout the body. For example, researchers at the California Institute of Technology showed that the transfer of the microbiome from human donors with ASD into microbiome-free mice promoted hallmark autistic behaviors. In addition, a large body of research has documented the connection between over a dozen different microbiome species and molecular pathways connecting the gut&#x2019;s enteric nervous system to the brain. We believe the gut-brain axis is but one example of how the microbiome can provide therapeutic benefits to diseases beyond the gut.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restoring the microbiome, or its inputs, is an opportunity to directly address the underlying causes of many diseases driven by dysbiosis. Many existing drugs target only the downstream symptoms of disease, for example, anti-tumor necrosis factor, or anti-TNF, biologics are prescribed to IBD patients to suppress systemic immunity, without addressing the underlying drivers of gut inflammation and immune dysregulation. This can lead to unintended side effects as well as an incomplete resolution of disease. Treating the root cause of disease is more likely to deliver a therapeutic breakthrough and for many diseases of dysbiosis, we believe that only through the restoration of the critical physiological role of the microbiome organ can this be achieved. Currently there are no microbiome therapeutics approved by the FDA. We believe that our ability to target both community- and pathway-level dysbiosis through our Human-First Discovery platform uniquely positions us to deliver on this transformational opportunity to improve human health through microbiome therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_2.jpg" alt="img102364508_2.jpg" style="width:605px;height:240px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We develop microbiome therapeutics following a three-stage process that combines aspects of traditional drug development with the unique opportunities enabled by our platform. In the first stage, Human-First Discovery, we use human data to identify promising clinical indications, microbial mechanisms and a consortia that engages these mechanisms. The second stage consists of IND-enabling activities, including bioprocess and formulation development, quality control and current Good Manufacturing Practices, or cGMP, production. The third stage is clinical development, in which we leverage customized pharmacokinetic and pharmacodynamic assays to understand optimal dosing and delivery. Importantly, data from clinical development can feed directly back into Human-First Discovery, enabling iterative development of differentiated follow-on product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:3.333%;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Human-First Discovery platform is designed to significantly reduce drug development time and translational risk. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have developed our Human-First Discovery platform to choose clinical indications, reveal mechanisms and create microbial compositions that engage our target mechanisms. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical Indication Selection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We aim to de-risk development by targeting indications with known underlying dysbiosis, an understanding of relevant mechanistic pathways and, critically, data from FMT that provide proof-of-concept that a microbial intervention has the potential to positively impact clinically meaningful outcomes. We have exclusive access to certain data and samples from groups that we believe are the largest providers of FMT in the world, including OpenBiome, which has delivered more than 60,000 FMTs to over 1,000 clinical sites. With more than 300 third-party clinical studies evaluating FMT around the world, we are uniquely well positioned to leverage this trove of clinical data to identify promising new drug development opportunities. We believe that by requiring a foundation of clinical data prior to indication selection and program initiation, our programs are already significantly de-risked before we begin development. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Target Identification and Validation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We use translational assays and high-throughput sequencing to generate curated datasets from FMT studies, observational clinical studies, and sometimes preclinical models, for each target indication. We then use our expertise in microbial ecology enhanced by our proprietary machine learning tools to identify microbiome compositions and functions that are deficient in our target population and whose restoration is causally linked to improved outcomes. We believe that observational clinical studies and preclinical models are valuable for generating mechanistic hypotheses which can then be validated using interventional data from FMT. Taken together, these efforts provide molecular and microbial targets, specific metabolites or bacteria, that are linked to clinical outcomes. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Candidate Selection and Consortia Design</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: To engage these targets, we deliver designed microbial consortia. The capability to deliver both a complete microbiome and targeted microbes gives us the flexibility to engage a diversity of mechanisms and therefore develop treatments for a wide range of indications. In diseases characterized by community-level dysbiosis like CDI, we are able to deploy Complete Consortia product candidates like CP101. In diseases where we are able to target pathway-level dysbiosis like IBD, we are able to deploy Targeted Consortia product candidates like TAK-524. Importantly, we have obtained exclusive access to </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a library of more than 10,000 samples from certain donors that have each been administered to patients through FMT. We are able to cryo-revive and manufacture strains from these samples, enabling precise matching of the exact strain that was associated with clinical outcomes with FMT. We believe that this direct chain of custody from a clinical sample into a Targeted Consortia significantly reduces translational risk and is uniquely enabled by our proprietary partnerships. We are also able to engage both the Targeted and Complete Consortia product strategies in a single Enriched Consortia product candidate like FIN-211 for conditions like ASD that have both community- and pathway-level dysbiosis. We believe we are uniquely positioned to align product strategy with mechanism because of our capabilities to address community- or pathway-level dysbiosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:3.333%;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our IND-enabling workflow drives accelerated advancement into the clinic. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have developed a standardized workflow of key IND-enabling activities, transforming consortia designed to engage key microbial mechanisms into IND-ready product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bioprocess and Formulation Development</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We have developed proprietary methods for growing, harvesting, purifying, preserving and delivering microbiome consortia. Of particular note, our advanced lyophilization technology enables the preservation of a complete microbiome in a stable formulation with</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at least</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years of stability at 2&#xb0;&#x2013;8&#xb0;C and up to six months of stability at room temperature to accommodate excursions during delivery and administration. Furthermore, we have developed orally administered, targeted release technologies, enabling intestinal release that facilitates robust pharmacokinetics. We believe that our deep expertise in bioprocess and formulation development have, and will continue to, enable rapid development of differentiated products. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Quality Control and Product Safety</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Unlike other product candidates in development, we have developed manufacturing processes that do not rely on non-specific biocides like ethanol to exclude potential pathogens. Instead, each of our product candidates leverages molecular screening technology to exclude potential pathogens and harmful antibiotic resistance or virulence elements. This technology enables us to exclude unwanted agents without compromising potentially beneficial microbes. In addition to these purity assays, we have also developed both culture-based and culture-independent measures of viability to provide consistent potency across lots. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">cGMP Production</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We have developed cGMP production capabilities as a strategic asset, internalizing key activities that we believe we are uniquely positioned to execute, while externalizing activities that can be completed by third parties, in order to maximize our capital efficiency. As an example of this strategy in action, we are developing cGMP production capabilities for CP101, an orally administered Complete Consortia product candidate. With nearly a decade of operational experience and know-how enabling our Complete Consortia manufacturing platform, we believe we are uniquely positioned to enable this manufacturing process. By contrast, we have worked closely with third parties for the production of certain Enriched Consortia and Targeted Consortia product candidates. For these product candidates, there are rapidly maturing providers able to leverage analogous experience with large scale fermentation, including the required capital equipment and infrastructure to enable cGMP manufacture of these product candidates.</span></div></div>
  <div style="margin-left:3.333%;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our clinical development strategy is designed to enable rapid progression, expansion and iteration. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Progression</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We have developed a suite of customized pharmacokinetic and pharmacodynamic assays to maximize learning from our clinical programs to guide progression through clinical development. Our pharmacokinetic assays quantitatively assess the engraftment, or colonization in the intestine, of our consortia. Our pharmacodynamic assays measure the production of microbial metabolites and their downstream effects on the host. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Expansion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When we initiate clinical development of a new program, we aim not only to inform the progression of the specific program under evaluation, but also to inform expansion into other indications. As an example, having determined that we are able to engraft a diverse microbial community and effectively restore missing metabolic pathways with CP101 for recurrent CDI, we are now able to use similar compositions in other indications that are tied to community-level dysbiosis. Because this community-level dysbiosis is common to many microbiome-associated diseases, we believe this particular product strategy may have broad applications, such that clinical validation in one indication de-risks the development of other indications with similar characteristics.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Iteration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to positioning our clinical development and translational medicine strategy to generate data that may inform expansion opportunities into new indications, we also believe that clinical data generated from </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the development of product candidates like FIN-211 will provide a rich pool of data that we can mine with our Human-First Discovery platform to inform follow-on product candidates in the same indication with even more favorable product attributes. In this way, our clinical development is designed to feed back into discovery, enabling iterative improvement and life cycle management as we establish franchises in new indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Clinical Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CP101 for the Treatment of Recurrent CDI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead product candidate, CP101, is an orally administered, complete microbiome therapeutic capsule designed to deliver an intact, functional microbiome to durably repair community-level dysbiosis. CP101 contains microbial communities harvested from rigorously screened, healthy human stool samples that have been purified, tested, stabilized, characterized and formulated in acid-resistant capsules to facilitate intestinal release after passage through the stomach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pathogen exclusion in CP101 is based on proprietary testing and characterization technology developed through discussions with the FDA; unlike other orally administered microbiome therapeutic candidates in development, it does not rely on non-specific biocides such as ethanol, which inactivate both beneficial and potentially pathogenic bacteria. Instead, our technology enables us to identify suitable microbial communities prior to manufacture, without requiring destructive interference in the healthy community needed to repair community-level dysbiosis. This enables CP101 to deliver a complete consortium of microbial communities rather than narrow and variable subsets of the microbiome. Our product qualification strategy is supported by the proprietary chemistry and processing techniques that optimize community viability during lyophilization, processing and administration. This fully integrated manufacturing process is designed to consistently deliver a complete microbiome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our production process for CP101 is designed to be scalable. We typically collect many samples from each donor and we are able to produce many treatments from each sample collected. As a result, a small pool of donors can support a large production base. For example, we believe a pool of 200 active donors could support production of approximately 100,000 treatments of CP101 annually. Furthermore, our process is designed to yield a favorable stability profile, with at least 24 months of stability at 2&#xb0;&#x2013;8&#xb0;C and up to six months of stability at 25&#xb0;C to allow for temperature excursions during delivery and administration. We believe this favorable stability profile will simplify supply chain logistics and enable more convenient care. CP101 has received Fast Track designation and Breakthrough Therapy designation from the FDA for the prevention of recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, or recurrent CDI. Breakthrough Therapy designation provides expedited review and access to collaborate with the FDA on rapid development of CP101.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Hold</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following receipt of a clinical hold letter from the FDA related to our IND for CP101 on February 24, 2022, or the February 2022 Clinical Hold Letter, we paused enrollment in PRISM4, our Phase 3 clinical trial of CP101 in recurrent CDI. In the February 2022 Clinical Hold Letter, the FDA requested additional information about our SARS-CoV-2 donor screening protocols, including, for example, additional detail on how samples are shipped to the vendor performing the SARS-CoV-2 testing of the donor material and how inconclusive test results will be handled, as well as updating the informed consent process to address the risk of SARS-CoV-2 transmission, including, for example, the limitations of laboratory screening.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, at the outset of the COVID-19 pandemic, the FDA issued a public safety alert regarding the potential risk of transmission of SARS-CoV-2 virus through the use of donor-derived investigational microbiome therapies and the need for additional safety precautions. At that time, the FDA placed our IND for CP101 on partial clinical hold, requiring us to implement new SARS-CoV-2 screening measures for any microbiota material donated on or after December 1, 2019 and to address the risk of SARS-CoV-2 transmission in the informed consent process. At that time, the FDA also placed the IND of OpenBiome, a manufacturer that we had contracted with to produce clinical raw material, on a partial clinical hold for the same reasons.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notwithstanding the partial clinical hold notices, we were able to continue dosing patients in our then-ongoing PRISM-EXT trial of CP101 in recurrent CDI as all of the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, OpenBiome was released from partial clinical hold after implementing, among other things, a direct testing method for SARS-CoV-2. In March 2021, we acquired certain manufacturing assets from OpenBiome, and in November</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021, we began dosing participants in PRISM4 with CP101 lots that had been screened for SARS-CoV-2 using the same testing method and vendor used by OpenBiome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following communications with the FDA in January 2022, on February 24, 2022, the FDA sent the February 2022 Clinical Hold Letter to us stating that the FDA required additional information about our SARS-CoV-2 screening protocols and related informed consent language, and that a clinical hold remains in effect until the FDA's requests have been satisfactorily addressed. The February 2022 Clinical Hold Letter did not reference any adverse clinical outcome experienced in any of our clinical trials. We have informed the FDA that participants were dosed in PRISM4 while the clinical hold was in effect and we are conducting</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a quality investigation of the matter.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are communicating with the FDA regarding the quality investigation, and we have committed to addressing any relevant findings prior to proceeding with enrollment in PRISM4. We have submitted a Complete Response to the February 2022 Clinical Hold Letter and we are communicating with the FDA to resolve the clinical hold as soon as possible.</span><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 17, 2022, we received</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an additional letter from the FDA, or the March 2022 Letter,</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requesting changes to the testing algorithm used to diagnose suspected CDI recurrences in PRISM4, as well as additional information about the proposed statistical analysis plan for PRISM4 and the validation package for one of our release tests</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We are unable to proceed with enrollment in PRISM4 until the FDA removes the clinical hold, we address findings from our related quality investigation, we complete related manufacturing activities to satisfy the FDA's requests related to SARS-CoV-2 screening and testing (which includes manufacturing additional lots of CP101), and we satisfactorily address the matters raised in the March 2022 Letter. We are currently evaluating the extent of the delay these activities will have on the anticipated timing for resuming enrollment in PRISM4 and, based on manufacturing timelines, we expect at least a one-quarter delay.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indication Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, is a toxin-producing, spore-forming bacterium that causes severe and persistent diarrhea in infected individuals. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> expresses toxins that lead to inflammation of the colon, severe diarrhea and abdominal pain, as well as potentially more serious clinical outcomes including toxic megacolon, perforation of the colon, and death. The Centers for Disease Control and Prevention considers CDI to be one of the top five most urgent antibiotic resistant threats and the most common healthcare-associated infection in the United States. We estimate that there are over 450,000 cases of primary CDI and approximately 200,000 cases of recurrent CDI annually in the United States, collectively resulting in more than 44,000 CDI-attributable death per year. In addition to this human toll, the economic impact is substantial, with 2.4 million inpatient days and greater than $5 billion in direct treatment costs each year in the United States. Between 2001 and 2012, there was an increase in the annual CDI incidence of 43%; however, cases of multiply recurrent CDI increased 188% over that same period.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Microbiome Therapeutics in Recurrent CDI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dysbiosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Observational clinical data suggests that patients with recurrent CDI have significant community-level dysbiosis compared to healthy controls, with reduced microbiome diversity, in part, due to the many courses of antibiotics that are typically used to treat these patients. Initial episodes of CDI are predominantly linked to treatment with antibiotics, creating a direct link between dysbiosis and disease onset.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mechanism of Action</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The microbiome plays an important role in the pathophysiology of recurrent CDI, and third-party preclinical models and human studies support our understanding of this mechanism. Among healthy individuals, an intact microbiome outcompetes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for its main energy source, primary bile acids produced by the host. This competitive exclusion enabled by an intact microbiome is described as colonization resistance. However, when there is community-level dysbiosis and competitors are eliminated, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, typically a poor competitor for bile acid metabolism, is able to overcome colonization resistance, resulting in infection. In addition to competing for resources, a healthy microbiome generates microbiome-derived secondary bile acids that inhibit residual </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> spores from germinating into their vegetative, toxin-producing form. Organisms that are able to convert primary bile acids into </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-inhibiting secondary bile acids remove a food resource (primary bile acids) and create a potent inhibitor of toxin production (secondary bile acids). Antibiotics are able to suppress vegetative, toxin-producing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, but residual </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> spores are not susceptible to antibiotics and are able to persist. Accordingly, when an antibiotic course is complete, the residual </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> spores can germinate into vegetative, toxin-producing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, driving CDI recurrence, a key element of morbidity, mortality and cost in CDI care. Until the underlying microbiome dysbiosis is addressed, patients remain susceptible to CDI recurrence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third-Party Clinical Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Numerous cohort studies, observations from clinical practice and small randomized clinical trials have demonstrated that FMT is able to prevent recurrent CDI. CP101 builds on these human data that suggest repairing community-level dysbiosis may restore colonization resistance and break the cycle of CDI recurrence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Existing Therapeutics and Their Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibiotics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although antibiotics are considered standard of care to treat CDI, they also impair the diversity of the resident microbiome, affording a potential microbial niche for resident </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">spores to germinate into toxin-producing cells. Recurrence rates following antibiotic therapy are high as these agents exacerbate community-level dysbiosis. A commonly used CDI antibiotic, vancomycin, is non-specific and causes significant disruption to the microbiome. New generation medications, such as fidaxomicin, were designed as an alternative, narrow-spectrum antibiotic, with reduced activity against other microbes compared to vancomycin. Increasingly sophisticated and precision-targeted antibiotics can mitigate further harm to the microbiome but they do not address what we believe to be the root cause of recurrent CDI&#x2014;the dysbiosis caused by antimicrobials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibodies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bezlotoxumab is an approved intravenous monoclonal antibody product that targets the toxins produced by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. However, like antibiotic therapy, it fails to repair dysbiosis, the underlying cause of recurrent CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Probiotics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probiotics are dietary supplements or foods that contain microbes and are typically derived from fermented foods such as yogurt. However, probiotics are not designed to durably colonize the human intestine and no clinical trials have demonstrated durable repair of dysbiosis with probiotics to date. Recent ACG guidelines have recommended against the use of probiotics for the prevention of CDI.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fecal Microbiota Transplantation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FMT is the process of transplanting stool and accompanying microbes from healthy donors into patients suffering from diseases of dysbiosis. FMT has generated remarkable outcomes in CDI, supporting the rationale for targeting dysbiosis. However, FMT is a procedure, not a product, and often requires a colonoscopy for administration. There are no defined regulatory standards for screening, processing and delivery of FMT, and this treatment has not been approved by the FDA. There is no FDA-approved agent that addresses the community-level dysbiosis that underlies recurrent CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Product Candidate: CP101</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have designed CP101 to break the cycle of CDI recurrence by restoring a complete microbiome. We believe that CP101 has the following advantages when compared to existing therapeutic approaches and other microbiome therapeutic candidates in development for the treatment of recurrent CDI:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Differentiated manufacturing enables the delivery of a complete microbiome</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our manufacturing technology enables us to exclude pathogens through donor and stool screening, without destruction of the majority of the microbiome through non-specific biocides like ethanol. Besides enabling CP101 to address community-level dysbiosis, rather than a limited subset of the microbiome, we believe that creating a manufacturing process that moves beyond reliance on biocides enables higher yields and more efficient, less costly manufacturing. We believe these advantages will be particularly important as we evaluate CP101 in new indications where ethanol-sensitive organisms, which comprise the majority of the microbiome, are likely to play a critical role and scalable manufacturing will enable us to serve large markets. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Novel class of therapy that addresses the underlying cause of disease by restoring the microbiome.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> While antibiotics are the current standard of care for the treatment of recurrent CDI, they fail to address the underlying community-level dysbiosis that causes recurrence of the disease. CP101 is designed to durably repair community-level dysbiosis, restoring colonization resistance and production of protective microbiome-derived secondary bile acids. Through its novel mechanism, CP101 also avoids contributing to antibiotic resistance. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Achieved primary endpoint in a broad patient population.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CP101 is the only orally administered, microbiome therapeutic candidate drug in development that achieved its primary endpoint in a pivotal trial that included </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patients across all stages of recurrent CDI, including first recurrence, which represents more than half of all recurrent CDI episodes. PRISM3 included participants 65 years of age or older who were experiencing their first recurrence of CDI and PRISM-EXT included adults of all ages who were experiencing their first recurrence of CDI. Other drugs in development have focused on patients with multiple recurrences, rather than the more challenging hurdle of delivering meaningful clinical outcomes in front-line care for recurrent CDI. CP101 achieved its primary endpoint in a population that included patients diagnosed by either polymerase chain reaction, or PCR, testing or toxin enzyme immunoassay, or EIA, testing. Other drugs in development failed to demonstrate efficacy among patients diagnosed by PCR and have subsequently focused development exclusively on those diagnosed by toxin EIA. This is commercially important because PCR is the method used to diagnose more than 80% of all CDI cases each year in the United States. By incorporating patients with first recurrence and diagnosed by PCR testing into our study design, we expanded the addressable patient population more than 10-fold relative to products in development that were evaluated only in patients with multiple recurrences and diagnosed by toxin EIA testing. We believe based on the results of our PRISM3 trial, CP101 will have broad applicability across all stages of recurrent CDI and all methods of CDI diagnosis. Data from our PRISM-EXT trial also supports the use of CP101 as rescue therapy for patients who do not respond to a first dose of treatment.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Favorable tolerability profile with no treatment-related SAEs observed.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In our PRISM3 trial, CP101 was observed to be well-tolerated, with a similar prevalence of adverse events across the CP101 and placebo arms and no treatment-related SAEs within the CP101 group. We believe this promising tolerability profile is enabled by our robust product and process design.  </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Market Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recurrent CDI represents a robust market opportunity and we estimate there are approximately 200,000 cases each year in the United States. As shown in the figure below, the first recurrence of CDI represents more than half of these cases. Unlike pivotal trials for other microbiome programs, the PRISM3 trial design included first recurrence CDI for patients 65 years of age or older, demonstrating benefit in a broad patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_3.jpg" alt="img102364508_3.jpg" style="width:557px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that prescriptions of CP101 will be predominantly fulfilled in the outpatient setting, through the specialty pharmacy channel. While initial presentation of recurrent CDI may occur either in the hospital setting or in the outpatient setting, the majority of hospitalized patients are discharged while being treated with standard-of-care antibiotics, prior to when CP101 would be administered. We believe that this outpatient setting, which provides favorable pricing and reimbursement dynamics relative to the hospital setting, will allow us to better realize value in the recurrent CDI market opportunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Trials of CP101 for the Treatment of Recurrent CDI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development of CP101 for the prevention of recurrent CDI is supported by positive topline results from a Phase 1 open-label clinical trial (n=49), a Phase 2 placebo-controlled clinical trial referred to as the PRISM3 trial (n=198), and a Phase 2 open-label clinical trial referred to as the PRISM-EXT trial (n=132), as further summarized elsewhere in this Annual Report. CP101 is currently in late-stage clinical development and being evaluated in a Phase 3 clinical trial, referred to as the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PRISM4 trial, anticipated to enroll approximately 300 participants. We plan to have further discussions with the FDA regarding the size and make-up of the safety database for CP101, which could result in the need for additional studies. PRISM4 is currently on clinical hold, pending product availability and resolution of matters related to the February 2022 Clinical Hold Letter and the March 2022 Letter.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"><br /><br />        PRISM4 Trial<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have designed a Phase 3 clinical trial, which we refer to as the PRISM4 trial, to serve as our second pivotal trial of CP101 for the prevention of recurrent CDI. The PRISM4 trial is a multi-center trial expected to enroll approximately 300 adult participants with recurrent CDI. PRISM4 has two parts: a randomized, double-blind, placebo-controlled part (Part A) and an optional, open-label treatment part (Part B). In Part A, eligible participants will be randomized in a 2:1 ratio to receive either a one-time oral administration of CP101 or placebo after completing standard-of-care, or SOC, CDI antibiotics for their most recent CDI recurrence. The primary efficacy endpoint of the trial will be CDI recurrence through 8 weeks post-treatment. The primary safety endpoint is the incidence of treatment emergent adverse events through week 8. Secondary endpoints include safety and CDI recurrence through 24 weeks post-treatment. The design of Part A is shown below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PRISM4 Part A Trial Design</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_4.jpg" alt="img102364508_4.jpg" style="width:605px;height:106px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Like our previously completed PRISM3 Phase 2 clinical trial, the PRISM4 trial will enroll participants with recurrent CDI, including participants experiencing their first CDI recurrence that are 65 years of age or older. At study entry, all guideline recommended test methods for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, including PCR- or toxin EIA-based test methods, will be accepted for the diagnosis of the qualifying episode of CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Participants in Part A of the PRISM4 trial that experience a CDI recurrence within 8 weeks of randomization will have the option to enroll in the open-label, Part B component of the trial, in which they will receive CP101 following completion of SOC antibiotics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 1, 2022, we announced that enrollment in PRISM4 was paused following receipt of the February 2022 Clinical Hold Letter.  We have submitted a Complete Response to the February 2022 Clinical Hold Letter and we are communicating with the FDA to resolve the clinical hold and related matters, as described above in the section entitled &#34;Clinical Hold&#34;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PRISM3 Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We evaluated CP101 for the treatment of recurrent CDI in our pivotal PRISM3 trial, which represents the first positive pivotal trial with an orally administered complete microbiome product candidate. PRISM3 was a Phase 2, 1:1 randomized, placebo-controlled, multi-national trial designed to demonstrate the superiority of CP101 following standard-of-care CDI antibiotics compared to antibiotics alone in preventing recurrence among patients with recurrent CDI. A total of 206 participants were enrolled across 51 sites, of which 198 were evaluable. Patients were recruited from across all stages of recurrent CDI, including patients experiencing their first recurrence that were 65 years of age or older. Qualifying episodes of recurrent CDI were diagnosed using all standard-of-care laboratory tests, including PCR- or toxin EIA-based test methods. All participants were treated with standard-of-care CDI antibiotic therapy prior to randomization. Following antibiotic treatment, participants were randomized to receive either a one-time oral administration of CP101 or a placebo, without the need for bowel preparation. The trial design is shown below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PRISM3 Trial Design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_5.jpg" alt="img102364508_5.jpg" style="width:614px;height:96px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Baseline characteristics were balanced between the two study arms, with no meaningful clinical differences. Participants with a first CDI recurrence at study entry represented approximately 30% of the study population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Treatment Groups Had No Meaningful Clinical Differences at Baseline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_6.jpg" alt="img102364508_6.jpg" style="width:605px;height:355px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PRISM3 achieved its primary efficacy endpoint, which was sustained clinical cure defined as the absence of CDI recurrence through eight weeks following administration of study drug. Sustained clinical cure was determined by a blinded adjudication board of independent experts evaluating the totality of clinical and laboratory data including central laboratory data with PCR, toxin EIA and toxigenic culture testing. Following standard-of-care CDI antibiotics, 74.5% of participants treated with CP101 achieved sustained clinical cure, a statistically significant improvement over those receiving placebo (61.5%; p=0.0488), meeting the primary efficacy endpoint and representing a clinically meaningful 33.8% relative risk reduction for CDI recurrence, as shown below on the left. On long-term assessment, CP101 demonstrated clinically meaningful durability and the proportion of participants with sustained clinical cure, defined as the absence of CDI recurrence, through Week 24 remained significantly higher in the CP101 arm compared to placebo (73.5% [75/102] vs 59.4% [57/96], p=0.0347). Time-to-event analysis through Week 24 showed a statistically significant and durable benefit, favoring CP101 compared to placebo (p=0.018), as shown below on the right.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.005%;"></td>
    <td style="width:49.995%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 Achieved 33.8% Relative Risk Reduction for CDI Recurrence in PRISM3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Sustained Clinical Cure at Week 8 Was Maintained Through Week 24 in PRISM3</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_7.jpg" alt="img102364508_7.jpg" style="width:672px;height:213px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PRISM3 Extension Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PRISM-EXT was an open-label Phase 2 clinical trial evaluating the safety and efficacy of CP101 for the prevention of recurrent CDI. Initially, the study only enrolled participants who had previously enrolled in the randomized, placebo-controlled PRISM3 trial and experienced a CDI recurrence. After PRISM3 enrollment was complete, a protocol amendment expanded the inclusion criteria to allow participants with recurrent CDI to enroll directly in PRISM-EXT without having previously enrolled in PRISM3. The trial design is shown below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PRISM3 Extension Trial Design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_8.jpg" alt="img102364508_8.jpg" style="width:586px;height:144px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we reported positive topline results from the PRISM-EXT trial. A total of 132 participants were analyzed, including one cohort that directly enrolled in the trial following a recent CDI recurrence without having previously participated in PRISM3 (n=82) and one cohort that enrolled after experiencing a CDI recurrence following administration of placebo or a single dose of CP101 in PRISM3 (n=50). The primary efficacy endpoint was sustained clinical cure (defined as absence of CDI recurrence) through 8 weeks post-treatment. Overall, 80.3% of participants who received a single oral administration of CP101 following standard-of-care antibiotics in PRISM-EXT achieved sustained clinical cure (defined as absence of CDI recurrence) through week 8 and 78.8% had sustained clinical cure through week 24, as shown below. The PRISM-EXT results are consistent with and build on the previously reported PRISM3 results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 Demonstrated Robust Sustained Clinical Cure in PRISM-EXT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_9.jpg" alt="img102364508_9.jpg" style="width:528px;height:324px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among the 102 participants who were treated with CP101 in PRISM3, 20 were enrolled in PRISM-EXT and treated with a second dose of CP101. Of the participants who received either a single dose of CP101 in PRISM3 (n=82) or a second dose by enrolling in PRISM-EXT (n=20), a post-hoc analysis shows that a total of 90 participants achieved sustained clinical cure through 8 weeks after their final dose, resulting in a cumulative efficacy of 88.2% (n=102).</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The first clinical trial to evaluate CP101 for the treatment of recurrent CDI was a 49 patient, single-center, open-label Phase 1 clinical trial conducted at the University of Minnesota. The trial enrolled patients who had experienced two or more recurrences of CDI. The primary endpoint was the safety and tolerability of CP101. Clinical success was defined as absence of CDI recurrence within two months post-treatment. No related SAEs occurred and 43 of the 49 patients treated achieved clinical success, resulting in an efficacy rate of 87.8% after treatment with CP101. Because the study was designed with a single arm and did not have concurrent control participants, the statistical significance of the observed efficacy rate was not assessed in this study. Approximately a third of patients reported mild, transient gastrointestinal symptoms following the treatment. Multiple doses were evaluated in this first cohort, including a high dose range (1.25-2.5x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.695pt;font-family:Times New Roman;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) and a low dose range (2.1-2.5x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.695pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), with no meaningful dose response at the dosing levels tested. An intermediate dose of 6x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.695pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was selected for further process development and tested in an additional 10-patient cohort at the University of Minnesota. In this second cohort, seven of ten patients achieved clinical success through eight weeks following CP101. These promising clinical results from Phase 1 were used to secure Fast Track designation and Breakthrough Therapy designation from the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Safety and Tolerability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CP101 has been well-tolerated throughout all stages of development to date, and there have been no treatment-related SAEs reported. In the PRISM3 safety population, treatment-emergent AEs and treatment-related AEs were similar between treatment groups, with 16.3% (17/104) of participants in the CP101 arm versus 19.2% (19/99) of participants in the placebo arm experiencing treatment-related adverse events, or AEs, through 24 weeks.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the CP101 arm, treatment-related AEs were mild (Grade 1: 16/17) and moderate (Grade 2: 1/17), and primarily gastrointestinal in nature.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The most common treatment-emergent AEs reported in the CP101 arm through week 8 were predominantly gastrointestinal symptoms, as shown in the table below. Among the five most common adverse events in the CP101 arm, four adverse events were observed more frequently in participants treated with placebo relative to participants treated with CP101. For instance, we observed significantly fewer participants with abdominal pain among those treated with CP101 (30.8%) relative to those treated with placebo (59.6%; p&lt;0.0001).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Most Frequent Adverse Events in the PRISM3 CP101 Arm Through Week 8</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_10.jpg" alt="img102364508_10.jpg" style="width:403px;height:202px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, in the 132-participant PRISM-EXT trial, there were no treatment-related SAEs reported and CP101 exhibited an overall safety profile consistent with the profile observed in PRISM3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pharmacokinetics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We used data from these clinical trials to confirm potential mechanisms underlying the clinical outcomes observed with CP101 for recurrent CDI. We used high-throughput sequencing to characterize the engraftment of CP101 Taxa, or groups of genetically similar bacteria, among participants treated in the PRISM3 study. As expected, participants treated with CP101 had dramatically higher engraftment of CP101 Taxa than patients treated with placebo, as shown in the graphic below, highlighting our ability to effectively deliver a viable consortia to the appropriate location in the gastrointestinal tract with our targeted oral capsule.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 Shows Significant Engraftment Overall</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img102364508_11.jpg" alt="img102364508_11.jpg" style="width:173px;height:182px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also observed a strong relationship between engraftment of the microbes delivered in CP101 and clinical outcomes in PRISM3. Among patients with successful engraftment at week 1 following CP101 administration, 96.0% achieved a sustained clinical cure, while 54.2% of those without successful engraftment at week 1 achieved a sustained clinical cure (p &lt; 0.001).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 Engraftment</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Shows a Bimodal Distribution</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 Engraftment Correlates with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Sustained Clinical Cure</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_12.jpg" alt="img102364508_12.jpg" style="width:278px;height:202px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_13.jpg" alt="img102364508_13.jpg" style="width:250px;height:211px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe one factor that may have reduced engraftment among some PRISM3 participants who received CP101 is the persistence of residual vancomycin, a broad spectrum antibiotic with activity against a number of CP101 microbes, prior to treatment with CP101. As part of the study protocol, all patients enrolled in PRISM3 completed a course of standard of care antibiotics, which could have included either vancomycin or fidaxomicin, prior to randomization and administration of study drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To limit the impact of residual standard of care antibiotics on CP101, participants in PRISM3 completed a minimum two-day antibiotic washout period prior to administration of study drug to provide time for antibiotic clearance from the colon. Recent scientific literature shows, however, that the stool concentration of vancomycin two days after cessation of administration remains at approximately 65% of peak concentrations and declines to approximately 15% of peak concentrations after a three-day washout. These data suggest that a two-day washout period may have been insufficient to clear residual vancomycin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To address this limitation, we have extended the minimum antibiotic washout period prior to administration of CP101 in our PRISM4 trial from two days to four days.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pharmacodynamics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe bile acid metabolism plays a key role in the pathogenesis of recurrent CDI. A healthy microbiome generates microbiome-derived secondary bile acids that inhibit residual </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> spores from germinating into their vegetative toxin-producing form. Patients with recurrent CDI have depleted secondary bile acids and a higher concentration of primary bile acids, a key energy source for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There are eight microbial genes that are critical for the conversion of primary bile acids into secondary bile acids. We used high-throughput metagenomic sequencing to measure the presence of these genes before and after treatment with CP101. At baseline, we found participants with recurrent CDI had between zero and four of these genes, missing key components of the pathway. Among participants evaluated for pharmacodynamics in Phase 1 (n=5), we found that all participants had all eight genes at all timepoints measured after treatment with CP101, highlighting the ability of CP101 to restore an important pathway in the pathogenesis of recurrent CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These data show that in keeping with similar host-targeted gene therapies, we are able to deliver a lasting transformation in the genetic capacity of the treated patient in a manner that improves clinical outcomes. With our treatment, however, we do not need to modify the host genome, instead we can deliver these genetic capabilities through microbes that are able to engraft and reproduce in the host. Importantly, because more than 99% of all genes found in humans are found in the microbiome, this opens a much broader suite of targets than those which are accessible through host-targeted gene therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 is Designed to Break the Cycle of CDI Recurrence by Restoring Bile Acid Metabolism</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_14.jpg" alt="img102364508_14.jpg" style="width:614px;height:250px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CP101 Restores Bile Acid Metabolism &#x2013; A Key Biomarker for Treatment in Recurrent CDI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_15.jpg" alt="img102364508_15.jpg" style="width:403px;height:144px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Chronic HBV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following a strategic review of our pipeline and business, we announced in March 2022 the decision to pause the development of CP101 for the treatment of chronic HBV. We believe this decision will allow us to maximize our working capital available for investment in our wholly-owned recurrent CDI and ASD programs. We continue to believe that CP101, or other product candidates that we may develop in the future, may have the potential to treat chronic HBV, a chronic infection linked to microbiome dysbiosis.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may continue our research efforts in HBV in the future as our portfolio continues to mature.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FIN-211 to Address Symptoms of Autism Spectrum Disorder</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FIN-211 is an orally administered, Enriched Consortia product candidate designed to deliver both a complete microbiome and targeted microbes not found in most healthy donors. We believe FIN-211 has the ability to address both the gastrointestinal and behavioral symptoms of autism spectrum disorder, or ASD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indication Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASD is a behaviorally defined condition characterized by reduced social interaction, impaired communication skills and the presence of repetitive or restrictive behaviors. Beyond the core symptoms by which it is defined, ASD is recognized as a heterogeneous medical condition by the FDA, and patients can exhibit highly varied symptoms and behaviors such as irritability, heightened sensitivities and movement disorders. A subset of patients with ASD, comprising at least 30% of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">population, experience significant gastrointestinal symptoms, with the most common gastrointestinal symptom being constipation (ASD-C). There is a correlation between the severity of these gastrointestinal symptoms and the severity of behavioral symptoms. Standard treatments for constipation are often ineffective, which may be because the underlying biology of gastrointestinal symptoms is distinct in children with ASD compared to neurotypical children. We believe by addressing this underlying biology with a microbiome therapeutic, we will be able to improve ASD gastrointestinal symptom and neurobehavioral development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The diagnosed prevalence of ASD is currently 1 in 44 for children in the United States, a prevalence that has increased substantially over the past few decades. Worldwide prevalence estimates vary but are thought to be similar in other developed countries. It is believed there are more than 4.6 million children and adults in the United States with ASD. By some estimates, the total financial burden of care for patients with ASD exceeds $100 billion in the United States annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Existing Therapeutics and Their Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is no FDA-approved pharmaceutical treatment for the core symptoms of ASD. The only widely accepted intervention with substantial supportive evidence is a form of long-term behavioral therapy, called Applied Behavioral Analysis, or ABA. Children with ASD usually begin ABA as soon as they are diagnosed, typically between ages 2-6 years, and are recommended to receive 30-40 hours of therapy every week. ABA may continue into adulthood and parents are often faced with making difficult choices between school or continuing ABA therapy. The only FDA-approved pharmaceutical treatment for ASD are anti-psychotics, which are only prescribed to treat the irritability that often accompanies ASD, but is not a core symptom of the disorder. While ASD-C may be treated with laxatives or enemas, these can be poorly tolerated and are often ineffective. As a result, a high unmet medical need remains across both gastrointestinal and behavioral symptoms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Microbiome Therapeutics in ASD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dysbiosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Microbiome signals, epidemiological risk factors and gut symptoms all suggest a link between ASD and the microbiome. ASD is frequently accompanied by severe gastrointestinal manifestations, revealing symptoms more proximal to the activities of the gut microbiome. Moreover, the risk of developing ASD is significantly increased among children born by caesarean section or those exposed to multiple courses of antibiotics early in life. Mouse studies have demonstrated the ability to transfer ASD-like symptoms by transferring stool from humans with ASD. Conversely, certain ASD-mouse models have shown that ASD-like symptoms can be reduced by microbiome transfer from a neurotypical donor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mechanism of Action</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Once considered a strictly neurological condition, the modern view of ASD has evolved to encompass multiple systems, including interactions between the central nervous system, the enteric nervous system and the gut microbiome, also called the gut-brain axis. Many well-known neuro-active signaling molecules such as gamma-aminobutyric acid, or GABA, serotonin and oxytocin are either produced or modulated by the microbiome, which has led to efforts to better understand the role of the microbiome across a range of behavioral and neurological conditions, including ASD. Current research highlights several pathways in the gut-brain axis that may be key to ASD. Neuro-active metabolites that are exclusively produced by the microbiome, such as 4-ethylphenylsulfate, or 4EPS, are significantly elevated among children with ASD relative to neurotypical controls, and are capable of inducing ASD-like symptoms in mice. Oxytocin, a neuropeptide responsible for regulating social bonding and behavior, has long been a target for drug development in ASD, but exogenous agonism of oxytocin has been challenging due to a short half-life of oxytocin. Certain microbes can induce endogenous production of oxytocin, providing an alternative means to engage this important pathway. Preclinical work has demonstrated that introduction of oxytocin-inducing bacteria can restore neurotypical behavior in three independent ASD murine models. This rescue is dependent on the vagus nerve which connects the enteric nervous system in the gut with the central nervous system and was eliminated when the gene for the oxytocin receptor was knocked out. This pathway-level dysbiosis and previously described community-level dysbiosis suggest the potential role for an Enriched Consortia product strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third-Party Clinical Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: At least five investigator-sponsored clinical studies have found that the restoration of a healthy microbiome by FMT is associated with marked improvements in behavioral and gastrointestinal symptoms among children with ASD. An open-label proof-of-concept trial administering FMT for 8 weeks reported that, two years after treatment, most participants reported gastrointestinal symptoms remaining improved compared to baseline and 44% of study participants who had previously been diagnosed with ASD fell below the Childhood Autism Rating Scale (CARS) score cut-off used to classify autism. Even using a more stringent CARS score cut-off of 25, we find that 33% of participants no longer meet the diagnostic criteria for ASD, as shown in the below graph. Additionally, in a randomized, controlled trial, children with ASD receiving FMT and behavioral therapy showed a statistically significant improvement in their behavioral symptoms compared to the control group receiving behavioral therapy alone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Behavioral Scores Improved Dramatically Over Two Years in an Open-Label,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proof-of-Concept FMT Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_16.jpg" alt="img102364508_16.jpg" style="width:403px;height:240px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Product Candidate: FIN-211</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FIN-211 is an orally administered, Enriched Consortia product candidate designed to deliver both a complete microbiome and targeted microbes not found in most healthy donors. Based on our understanding of the biology of ASD, we have identified species capable of inducing oxytocin production and improving gastrointestinal barrier function. We believe these organisms may have important therapeutic benefits for individuals with ASD. These organisms are not ubiquitous in healthy donors, so our Complete Consortia product strategy would not generally include these microbes. Accordingly, we have decided to pursue an Enriched Consortia product strategy that includes both strains targeting oxytocin-production and a complete microbiome to address community-level dysbiosis, which we believe best positions FIN-211 to potentially address both the gastrointestinal and behavioral symptoms of ASD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development of FIN-211 to Address Symptoms of ASD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are preparing to initiate a Phase 1b clinical trial, which we refer to as AUSPIRE, of FIN-211 in children with ASD (ages 5&#x2013;17 years) with constipation. Although FIN-211 is not directly addressed in the February 2022 Clinical Hold Letter, it is an Enriched Consortia product candidate that includes donor-derived components. Because the February 2022 Clinical Hold Letter is concerned with SARS-CoV-2 screening measures for donor-derived microbiota material, the clinical hold will delay initiation of AUSPIRE and will require us to conduct additional manufacturing activities (including manufacturing additional components of FIN-211) in order to satisfy the FDA's requests related to SARS-CoV-2 screening and testing. We have submitted a Complete Response to the February 2022 Clinical Hold Letter and we are communicating with the FDA to resolve the clinical hold as soon as possible.</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are evaluating the extent of the delay the clinical hold and the related manufacturing activities will have on the expected timing of AUSPIRE; based on manufacturing timelines, we expect at least a one-quarter delay.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on clinical FMT data and preclinical data with oxytocin-inducing strains, we believe FIN-211 is positioned to address both the gastrointestinal and behavioral symptoms of ASD. The FDA has indicated that either gastrointestinal or behavioral endpoints could support a biologics license application and we are evaluating both gastrointestinal and behavioral endpoints. Given the absence of FDA-approved therapies and building on our discussions with the FDA, we aim to continue to validate behavioral instruments as part of our clinical development plans. We believe FIN-211 can potentially address adults with ASD as well as both adults and children without gastrointestinal symptoms, expanding beyond our initial population of pediatrics with gastrointestinal symptoms where we expect to observe an enriched signal.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe this development strategy represents an attractive entry into the gut-brain axis, providing two opportunities to provide therapeutic benefit to patients with ASD, both for behavioral symptoms and lower-risk gastrointestinal endpoints. Furthermore, we believe that ASD could validate our microbiome-based approach to addressing additional gut-brain axis indications. We plan to leverage existing and emerging clinical data from our academic collaborators to inform the development strategy of future product candidates to address additional neurological disorders that are associated with the gut-brain axis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TAK-524 (Ulcerative Colitis) &amp; FIN-525 (Crohn&#x2019;s Disease) for the Treatment of Inflammatory Bowel Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TAK-524 (formerly known as FIN-524) and FIN-525 are each orally administered Targeted Consortia product candidates designed for the treatment of ulcerative colitis (TAK-524) and Crohn&#x2019;s disease (FIN-525). We initially partnered with Takeda, a global leader in inflammatory bowel disease, or IBD, to develop TAK-524. TAK-524 comprises targeted strains identified by our Human-First Discovery platform, which do not require donors. Following the achievement of certain preclinical milestones in the development of TAK-524 for ulcerative colitis, we expanded our development partnership with Takeda to include FIN-525, a program to develop a live biotherapeutic product optimized for Crohn&#x2019;s disease that also comprises targeted strains identified by our Human-First Discovery platform. In August 2021, Takeda accelerated its leadership role in TAK-524, taking responsibility for clinical development, while we continue to conduct discovery efforts on FIN-525. We believe that the development programs for TAK-524 and FIN-525, which are Targeted Consortia product candidates composed of strains grown from master cell banks, are not affected by the February 2022 Clinical Hold Letter.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indication Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ulcerative colitis and Crohn&#x2019;s disease are the two principal sub-types of IBD. IBD comprises a set of heterogeneous autoimmune conditions that cause inflammation of the gastrointestinal tract. Symptoms of IBD include severe, chronic abdominal pain, diarrhea, gastrointestinal bleeding and weight loss. Patients have substantially higher risk of colon cancer, gastrointestinal perforations and infections, and many eventually require surgical resection of portions of their gastrointestinal tract or colectomy. Patients undergo periods of active disease (flares) accompanied by intermittent periods of little or no disease activity (remission). Over 3 million Americans and 10 million people globally are thought to suffer from IBD, and the incidence has increased rapidly over the past few decades. By some estimates, the total financial burden of care for patients with IBD exceeds $31 billion in the United States annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Existing Therapeutics and Their Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current treatment options vary by disease types and severity, and are designed to reduce inflammation, but do not address the underlying cause of disease. Active mild-to-moderate ulcerative colitis is often treated with 5-ASA agents. However, over 70% of patients fail to enter remission. Active mild-moderate Crohn&#x2019;s disease have limited therapeutic options. Corticosteroids are commonly used in active disease; however, the long-term side effect profile is poor and includes increased risk of infections, type 2 diabetes, weight gain, mood disturbances and hypertension. Biologic agents that suppress inflammatory cytokines or cell trafficking are not typically orally administered agents, and have poor rates of inducing remission. There is a single, recently approved oral biologic for moderate to severe Crohn&#x2019;s disease; however, similar to other biologics, it is associated with increased risk for severe infections, blood clots and the development of malignancy. Commonly used anti-TNF biologic agents may lead to serious infections due to immunosuppression, and there have been reports of hepatosplenic T-cell lymphoma, a rare form of lymphoma that is fatal in some patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Overall, current treatments for IBD fail to address the underlying causes of inflammation, and there is a significant need for well-tolerated, easily administered, disease-modifying agents in IBD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Microbiome Therapeutics in IBD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dysbiosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Over the last decade, a number of lines of evidence have pointed to the promise of microbiome therapeutics in treating ulcerative colitis and Crohn&#x2019;s disease. Inflammatory bowel disease is one of the suite of chronic inflammatory diseases that has risen dramatically in prevalence in developed nations marked by gastrointestinal dysbiosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mechanism of Action</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Extensive preclinical work has demonstrated the criticality of the microbiome, including specific microbial metabolites, in regulating gastrointestinal tract inflammation, predicting response to therapy and determining the risk of disease recurrence after surgery. The improvement of gut barrier integrity, reduction of local immune activation and modulation of gut inflammation are all modulated by the microbiome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third-Party Clinical Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: FMT studies in IBD were key in our decision to develop Targeted Consortia product candidates for ulcerative colitis and Crohn&#x2019;s disease. Data from over 40 FMT studies, including five randomized, placebo-controlled trials in ulcerative colitis and one randomized, placebo-controlled trial in Crohn&#x2019;s disease, have shown promising clinical outcomes. Some of these interventional studies also served as our main discovery datasets to select which strains and functions to include in our Targeted Consortia approach for IBD. Clinical studies with only spore-forming compositions have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">yielded mixed results, highlighting the value of our approach, which leverages both spore-forming and non-spore forming compositions.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TAK-524 and FIN-525</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TAK-524 is a Targeted Consortia product candidate of nine bacterial strains selected for the treatment of ulcerative colitis, and is orally administered in a lyophilized formulation. We designed this consortium to target three specific modes of action: two classes of immunoregulatory metabolites, each targeting a different set of host pathways, and donor strains linked to remission following FMT in patients with ulcerative colitis. Takeda now leads development of TAK-524.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FIN-525 is a discovery-stage program designing a Targeted Consortia product candidate for the treatment of Crohn&#x2019;s disease. The strategy for this consortium, which is differentiated from ulcerative colitis, includes donor strains depleted in Crohn&#x2019;s patients and linked to remission following FMT in these patients, as well as several classes of metabolites, each targeting a different set of host pathways.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TAK-524 and FIN-525 leverage data collected from over two dozen cohorts comprising over 2,300 patients, including six FMT studies in ulcerative colitis and five in Crohn&#x2019;s disease. Our machine learning platform identified microbes and microbial functions deficient in patients with ulcerative colitis and Crohn&#x2019;s disease compared to non-IBD controls. We tested these hypotheses with FMT data to identify the subset most likely to be causal, focusing on organisms consistently shown to be enriched among successful FMTs and subjects without IBD. To reduce the translational risk of these empirical signals, we isolated target organisms directly from specific donor samples that induced remission in clinical studies of FMT in IBD. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> measurements on the isolated strains and consortia then confirmed the signals of biological activity hypothesized by our machine learning platform. We are currently conducting discovery efforts on FIN-525.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.676%;"></td>
    <td style="width:49.324%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;">Remission Rates in Active Ulcerative Colitis among Four Placebo-Controlled FMT Trials and a TNF Biologic Trial</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;">Platform Used to Identify &#x201c;Super Donor&#x201d; Strains as Potential Therapeutic Candidates</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_17.jpg" alt="img102364508_17.jpg" style="width:278px;height:154px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102364508_18.jpg" alt="img102364508_18.jpg" style="width:298px;height:144px;" />&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Selecting a strain associated with positive FMT outcomes starts with machine learning models of clinical data. For TAK-524, an analysis of data from over 1000 patients was used to quantify the relationship between each clade of bacteria (each represented as a dot) and ulcerative colitis. On the x-axis, the degree to which each clade is depleted from a patient&#x2019;s microbiome relative to healthy controls is shown. On the y-axis, the impact of each clade in driving remission when added to a patient&#x2019;s microbiome by FMT is shown. Colors indicate the higher-level phylogenetic group each dot is assigned to. The bacterial clades with the greatest effect (top right quadrant) are the targets we isolated for in-vitro validation.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Collaborations and License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Takeda Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, we entered into an agreement, or the Takeda Agreement, with Takeda, pursuant to which we granted Takeda a worldwide, exclusive license, with the right to grant sublicenses, under our rights in certain patents, patent applications and know-how to develop, have developed, manufacture, have manufactured, make, have made, use, have used, offer for sale, sell, have sold, commercialize, have commercialized and import our microbiome therapeutic candidate TAK-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans. We subsequently amended and restated the Takeda Agreement in October 2019 to provide a worldwide, exclusive license to a second microbiome therapeutic candidate, FIN-525. We further amended the Takeda Agreement in August 2021 to transition primary responsibility for further development and manufacturing activities of TAK-524 to Takeda in accordance with a transition plan, and Takeda assumed sole responsibility for regulatory matters with respect to TAK-524. In November 2021, we further amended the Takeda Agreement to enable us to carry out certain FIN-525 preliminary evaluation activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Takeda Agreement, we agreed to design TAK-524 (a product candidate optimized for ulcerative colitis) for Takeda based on selection criteria within a product-specific development plan. We also agreed to conduct feasibility studies on FIN-525 (a program to develop a live biotherapeutic product optimized for Crohn&#x2019;s disease) for Takeda, and Takeda can determine whether to initiate a full product-specific development plan for FIN-525 following its review of the data from our feasibility studies. The FIN-525 feasibility study was completed in March 2021. Takeda is to select one optimal microbial cocktail for each of TAK-524 and FIN-525 after completion of certain initial product development activities. Thereafter, prior to initiation of the first Phase 3 clinical trial for TAK-524 or FIN-525, as applicable, Takeda has the right to substitute the initially selected microbial cocktail for another microbial cocktail selected by Takeda from certain alternative cocktails that were designated by Takeda at the time of selecting the initial microbial cocktail.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Takeda Agreement, we are primarily responsible for early-stage development activities for FIN-525 pursuant to an agreed upon development plan and budget, including potentially through Phase 2 clinical trials, subject to Takeda&#x2019;s right to either co-develop a product with us at Phase 2 or assume responsibility for such development. After the successful completion of the first Phase 2 clinical trial for FIN-525, Takeda will assume primary responsibility for the Phase 3 clinical program. Initially, we are responsible for clinical supply of FIN-525; however, Takeda is required to assume responsibility for such manufacture and supply no later than six months after completion of the first Phase 2 clinical trial for the first FIN-525 product candidate. All such development and manufacturing activities will be overseen by certain joint committees. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the August 2021 amendment to the Takeda Agreement, Takeda assumed primary responsibility for early-stage development and manufacturing activities with respect to TAK-524. Takeda also assumed sole responsibility for regulatory matters with respect to TAK-524. We remain responsible for certain development activities designated in the TAK-524 development plan, for which we will continue to receive reimbursement from Takeda.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Takeda is responsible for up to 110% of our budgeted full-time equivalent costs in connection with our development activities for TAK-524 (and FIN-525, if Takeda elects to initiate a full development plan for FIN-525) as well as all costs related to chemistry, manufacturing and control development or other development costs incurred after the initial selection of an optimal microbial cocktail. Takeda is solely responsible for all commercial activities related to the TAK-524 and FIN-525 product candidates, at its cost.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have agreed that prior to completion of the first Phase 2 clinical trial for the first TAK-524 product candidate being developed with the intention of seeking U.S. regulatory approval, other than as part of any development activities under the Takeda Agreement, we shall not engage in any research and development directed toward any product candidate for the treatment of IBD, or access or use certain fecal microbiota source material or any data generated from that material in IBD for any purpose. Additionally, we have agreed that prior to completion of the first Phase 2 clinical trial for the first FIN-525 product candidate being developed with the intention of seeking U.S. regulatory approval, other than as part of any development activities under the Takeda Agreement, we shall not engage in any research and development directed toward any product for the treatment of Crohn&#x2019;s disease, or access or use certain fecal microbiota source material or any data generated from that material in Crohn&#x2019;s disease for any purpose. We have also agreed for the remainder of the term of the Takeda Agreement to certain restrictions on our access or use of certain bacterial strains having at least a threshold genetic relatedness to the strains incorporated into TAK-524 or FIN-525, our access or use of certain fecal microbiota source material, and our ability to conduct certain research and development directed toward products for the treatment of IBD and Crohn&#x2019;s disease that contain bacterial strains having less than a threshold genetic divergence from the bacterial strains in TAK-524 and FIN-525, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Takeda Agreement, we granted Takeda a right of first offer in the event that we seek to commence a program for the treatment of IBD, as well as an exclusive option to negotiate that the parties undertake an additional development program for a microbial composition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with entry into the Takeda Agreement, we received a one-time, upfront payment from Takeda in the amount of $10.0 million. Additionally, we received $4.0 million in the aggregate for the achievement of certain development milestones for TAK-524 therapeutic products and are entitled to receive up to $176.0 million in the aggregate, for the achievement of specified development, regulatory and commercial sale milestones for TAK-524 therapeutic products. We are entitled to receive up to $177.7 million in the aggregate, for the achievement of specified development, regulatory and commercial sale milestones for FIN-525 therapeutic products, subject, to certain specified reductions based upon the nature of the FIN-525 product and certain additional milestones to be negotiated by the parties. We are also entitled to receive up to $10.0 million for the first diagnostic product for each of TAK-524 and FIN-525, subject to certain reductions in the event that Takeda uses a third party to develop such diagnostic products. Pursuant to this agreement, Takeda is obligated to pay us a royalty on net sales of TAK-524 and FIN-525 products ranging from mid to high-single digits, subject to certain reductions. Such royalties are payable on a product-by-product and country-by-country basis, during the period beginning on the date of first commercial sale of such product in such country and ending on the later to occur of the expiration of the last-to-expire valid</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">claim of any patents or patent applications controlled by us and licensed in such country that covers the composition of matter of such product, the date that regulatory exclusivity of such product expires in such country, or eight years from the date of the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Takeda Agreement expires on the date of expiration of the last royalty payment obligation. Either party may terminate the Takeda Agreement in the event of an uncured material breach by the other party. Takeda has the right to terminate the Takeda Agreement, in whole or in party, on a program-by-program basis upon specified notice to us or immediately following the withdrawal of a product from any market as a result of bona fide concerns based on specific and verifiable information that such product is unsafe for administration to humans. Additionally, the parties may mutually agree to terminate the Takeda Agreement on a program-by-program basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Agreement with Arizona State University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2017, we entered into a license agreement, or the Arizona State Agreement, with Skysong Innovations LLC (formerly Arizona Science and Technology Enterprises LLC), or Skysong, pursuant to which we obtained a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses, under certain patents and patent applications of Arizona State University to make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import, have imported, export or have exported products and services that are covered by such licensed patents. In July 2018, we subsequently amended the Arizona State Agreement to include certain additional patents and patent applications of Arizona State University. The patents and patent applications that we have exclusively licensed from Arizona State University under the Arizona State Agreement relate generally to compositions and methods to treat autism spectrum disorder and related symptoms and comorbidities. If issued, the patents within the licensed intellectual property would be expected to expire beginning in 2033.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Arizona State Agreement, we are obligated to use commercially reasonable efforts in connection with the development and commercialization of products and services, the manufacture, use, sale, offering for sale, importation or exportation of which, but for the license granted under the Arizona State Agreement, would infringe one or more licensed patents, or licensed products. Such efforts are limited to the United States and include a specific performance milestone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Arizona State Agreement, we paid Skysong an upfront fee of $10,000 and reimbursed Skysong for prior patent prosecution expenses. Additionally, we have agreed to make a low-six digits milestone payment upon the first commercial sale of a product in each of the United States, England, France, Germany, Italy, Spain and Japan, and a one-time commercial milestone payment in the low-seven digits upon the achievement of cumulative, worldwide net sales of all licensed products by us, our sublicensees or respective affiliates in the low-nine digits. We are also obligated to pay Skysong a low-single digit royalty on net sales of licensed products, including a minimum annual royalty payment in the mid-four digits to low-five digits that is creditable against the royalties due in such year. The royalty obligations continue on a country-by-country basis as to each licensed product until expiry of the last to expire claim within the licensed patents that covers such licensed product in such country. Moreover, we are obligated to pay a percentage of any non-royalty consideration received by us from a sublicensee in the high-second decile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Arizona State Agreement expires on the date of expiration of all royalty obligations. Upon expiration of our royalty obligations with respect to a licensed product in a country we will have a royalty-free, irrevocable, perpetual license to such licensed product in such country. We may terminate the Arizona State Agreement earlier for any reason or upon an uncured material breach of the agreement by Skysong. Skysong may terminate the Arizona State Agreement earlier upon our uncured material breach of the agreement, our insolvency, our initiation of any proceeding or claim challenging the validity or enforceability of any licensed patent, or our failure to meet a specific performance milestone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive Patent License Agreement with University of Minnesota</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2012, CIPAC Limited, an entity under the laws of Malta, or CIPAC, entered into a license agreement, or the UMN Agreement, with Regents of the University of Minnesota, or UMN, pursuant to which CIPAC obtained a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses, under certain patents and inventions of the University of Minnesota to make, have made, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of any product or service that is covered by such licensed patents. The UMN Agreement was subsequently amended in June 2014 and October 2014. In May 2015, CIPAC transferred its interest in the UMN Agreement to us. Subsequent to such transfer, the UMN Agreement was subsequently amended in December 2016 and September 2017. We amended and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restated the UMN Agreement in January 2022, to consolidate earlier amendments and extend the deadline for satisfying performance milestones by one year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the UMN Agreement, we are obligated to use commercially reasonable efforts to commercialize the licensed inventions and to manufacture and sell licensed products, including by meeting certain specific performance milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the UMN Agreement, we paid UMN an aggregate upfront fee of $155,000, and are obligated to pay annual maintenance fees in the mid-four digits. We are also obligated to pay UMN a royalty on net sales of licensed products ranging in the low-single digits depending on which licensed patents cover such licensed product, subject to a minimum annual royalty payment escalating over time in the low-five digits to low-six digits payable at the end of each applicable year. Such minimum annual royalty payments begin in 2021. The royalty obligations continue on a country-by-country basis as to each licensed product until expiry of the last to expire claim within the licensed patents that covers such licensed product in such country. Moreover, we are obligated to pay a percentage of any non-royalty consideration received by us from a sublicensee in the high-second decile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The UMN Agreement expires on the date of expiration of all claims under the licensed patents. We may terminate the UMN Agreement earlier upon an uncured material breach of the agreement by UMN. UMN may terminate the UMN Agreement earlier upon our uncured material breach of the agreement, our insolvency, or upon the commencement by us of any proceeding asserting or alleging the invalidity or unenforceability of the licensed patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries, including the field of microbiome therapeutics, are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. While we believe that our scientific knowledge, technology and development experience provide us with competitive advantages, we face substantial competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. We are aware of a number of companies focused on developing microbiome therapeutics in various indications. For CP101, we are aware that Seres Therapeutics, Inc. and Rebiotix Inc. each have a product candidate that has completed Phase 3 trials for recurrent CDI and are pursuing FDA approval to enable subsequent commercialization. In November 2021, Rebiotix filed a BLA for RBX-2660, their lead product in recurrent CDI, and Seres has indicated that they plan to file a BLA in 2022. In addition to these late-stage competitors, we are also aware of competitive microbiome therapies in earlier stages of clinical development, including VE303 (Vedanta Biosciences), NCTD-M3 (Destiny Pharma plc), MET-2 (NuBiyota), and RBX7455 (Rebiotix). Any advances in microbiome therapies made by a competitor may be used to develop therapies that could compete against any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of a number of large pharmaceutical and biotechnology companies, as well as smaller, early-stage companies, that are pursuing the development of products and disease indications we are targeting. These companies include AbbVie Inc., Arena Pharmaceuticals Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson &amp; Johnson, Merck &amp; Co., Inc., UCB S.A. and Vir Biotechnology, Inc. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others may be based on entirely different approaches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than us, which might result in competitors establishing a strong market position before we are able to enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than us. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future product candidates, novel discoveries, product development technologies and know-how; to operate without infringing on the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to our proprietary technology that are important to the development and implementation of our business. We seek to obtain domestic and international patent protection, and endeavor to promptly file patent applications for new commercially valuable inventions. We file new patent applications as we conduct research and development, initiate new programs, and monitor the activities of others within the microbiome field. We also rely on trademarks, trade secrets, know-how, and continuing technological innovation to develop and maintain our proprietary position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent may be challenged in courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or at all, whether the claims of any patent applications, should they issue, will cover our product candidates, or whether the claims of any issued patents will provide sufficient protection from competitors or otherwise provide any competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries and patent application filings, we cannot be certain of the priority of inventions covered by pending patent applications. Accordingly, we may not have been the first to invent the subject matter disclosed in some of our patent applications or the first to file patent applications covering such subject matter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio leverages both offensive and defensive strategies to protect our business. We have a large and diverse patent portfolio consisting of more than 55 issued U.S. and foreign patents and more than 140 pending patent applications that we own or exclusively license from others. Our patent portfolio has broad applicability across the microbiome field, and provides protection for our lead product candidates CP101, FIN-211, TAK-524, FIN-525, as well as additional Complete, Enriched and Targeted Consortia product candidates that we may develop. For CP101 specifically, our patent portfolio includes more than ten U.S. patents that cover CP101 and methods of use and manufacture. These patents have expiration dates between 2031 and 2037.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foundational Protection for Multiple Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our broadest patents and patent applications originate from patent families that embody pioneering work in the microbiome by Dr. Thomas Borody, a prolific inventor and founder of the Centre for Digestive Diseases in Australia, and Drs. Alexander Khoruts and Michael Sadowsky at the University of Minnesota. These patent families have priority dates that precede the entry into the microbiome field by many of our competitors. As a result, we have been successful in obtaining broad patent coverage from these patent families over the composition formulation, method of manufacture and method of using our product candidates. These patent families include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We own a patent family that includes over fifteen issued U.S. patents, three pending U.S. patent applications, granted foreign patents in Australia, Brazil, Canada, China, Israel, Mexico, Republic of Korea, New Zealand and Japan, and three pending foreign patent applications. Representative issued U.S. patents in this family include U.S. 10,022,406, U.S. 9,962,413, U.S. 10,328,107, U.S. 10,278,997, and U.S. 10,617,724, that have claims </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">directed to pharmaceutical compositions comprising stool bacterial material and a cryoprotectant, methods of processing stool received from healthy human donors, methods of manufacturing, and formulations. Patent applications, if issued, and patents in this family are expected to expire in 2031, assuming all required maintenance fees are paid and absent any applicable patent term extension or patent term adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We exclusively in-license a patent family from the Regents of the University of Minnesota that includes over five issued U.S. patents, one pending U.S. patent application, granted foreign patents in Australia, Europe, Canada and China, and three pending foreign patent applications. Representative issued U.S. patents within this family include U.S. 10,028,980, U.S. 10,286,011, U.S. 10,286,012, and U.S. 10,251,914, that have claims directed to formulations comprising fecal bacteria, methods of increasing fecal microbiota diversity, and methods of decreasing relative abundance of a bacteria. Patent applications, if issued, and patents in this family are expected to expire in 2032, assuming all required maintenance fees are paid and absent any applicable patent term extension or patent term adjustment. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We own a patent family that includes three issued U.S. patents U.S. 9,901,603, U.S. 10,821,138 and U.S. 11,123,377, one pending U.S. patent application, granted patents in Australia, Japan and China, and nine pending foreign patent applications. These issued U.S. patents have claims directed to room temperature stable products containing human-derived bacteria. Patent applications, if issued, and patents in this family are expected to expire in 2036, assuming all required maintenance fees are paid and absent any applicable patent term extension or patent term adjustment. </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Complete Consortia Product Candidates, including CP101</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio provides comprehensive patent protection for our Complete Consortia product candidates, including CP101. Representative patents and patent applications from our foundational patent families that have claims that cover CP101 and our Complete Consortia product candidates include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One owned issued U.S. patent (U.S. 10,617,724) covering capsules containing lyophilized fecal microbiota from healthy donors, expected to expire in 2031. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Three owned issued U.S. patents (U.S. 9,962,413, U.S. 10,328,107, and 10,849,937) covering the collection and processing of stool from healthy donors, expected to expire in 2031. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One owned issued U.S. patent (U.S. 10,022,406) covering compositions comprising fecal microbiota derived from healthy donors, expected to expire in 2031. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Four in-licensed issued U.S. patents (U.S. 10,028,980, U.S. 10,286,011, U.S. 10,286,012, and U.S. 10,251,914) covering formulations of fecal microbiota derived from healthy donors and their use, expected to expire in 2032. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two owned issued U.S. patents (U.S. 9,901,603 and U.S. 10,821,138) covering room-temperature stable products containing human-derived bacteria. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One in-licensed issued U.S. patent (U.S. 10,849,936) covering a method of treating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">C. difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection using lyophilized fecal microbiota, expected to expire in 2037. </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Targeted Consortia Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our Targeted Consortia product candidates and their manufacture, our portfolio consists of several issued U.S. patents from our foundational patent families that provide patent coverage. We are also pursuing product-specific patent protection for each of our Targeted Consortia product candidates including TAK-524. Representative patents that we own and provide protection for our Targeted Consortia product candidates include issued U.S. patents (U.S. 10,610,551 and U.S. 10,278,997) covering compositions having lyophilized bacteria from the genus </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bacteroides</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or the phylum </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Firmicutes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> derived from healthy donors and their manufacture, which are expected to expire in 2031.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enriched Consortia Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Enriched Consortia product candidates, such as FIN-211, are protected by many of the same patents and patent applications that cover our Complete Consortia product candidates. We also have patent protection for these Enriched Consortia product candidates specifically as well as various pending applications directed to these product candidates. Representative patents and patent applications that have claims that cover our Enriched Consortia product candidates include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One owned issued U.S. patent (U.S. 11,207,356) covering encapsulated compositions containing donor-derived microbiota enriched with one or more cultured bacterial strains, expected to expire in 2031.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One in-licensed issued U.S. patent (U.S. 11,202,808) covering methods of treating ASD or an associated gastrointestinal symptom by orally administering a donor-derived microbial community and a bacterial isolate from a genus with potential therapeutic applications in ASD, expected to expire in 2037. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One owned issued U.S. patent (U.S. 10,022,406) covering compositions comprising fecal microbiota derived from healthy donors, expected to expire in 2031. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Three owned issued U.S. patents (U.S. 9,962,413, U.S. 10,328,107, and 10,849,937) covering the collection and processing of stool from healthy donors, expected to expire in 2031. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two owned issued U.S. patents (U.S. 9,901,603 and U.S. 10,821,138) covering room temperature stable formulations containing human-derived bacteria, expected to expire in 2036. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One in-licensed issued U.S. patent (U.S. 10,286,012) covering the use of formulations of fecal microbiota derived from healthy donors, expected to expire in 2032. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. In some cases, the term of a U.S. patent may be shortened by terminal disclaimer, which reduces its term to that of an earlier-expiring patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 is available for one U.S. patent that includes at least one claim covering the composition of matter of a first approved FDA drug product, or its methods of use or manufacture. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or fourteen years from the date of the FDA approval of the drug product, and a patent cannot be extended more than once or for more than a single product. During the period of extension, if granted, the scope of exclusivity is limited to the approved product for approved uses. Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. If and when our product candidates receive FDA approval, we expect to apply, if appropriate, for patent term extension on patents covering those product candidates, their methods of use and/or methods of manufacture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Trade Secrets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual or entities&#x2019; relationship with us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Agreements with OpenBiome</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Asset Purchase Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, we entered into an asset purchase agreement, or the OpenBiome Agreement, with Microbiome Health Research Institute, Inc., or OpenBiome, pursuant to which we acquired certain biological samples, including aliquots of human stool that have been used in clinical trials and under enforcement discretion for the treatment of CDI not responding to standard therapy, and obtained a perpetual license to certain OpenBiome technology, and, upon closing of the transaction, we acquired certain additional assets of OpenBiome, including capital equipment (comprising lab equipment) and contracts relating to the operating maintenance of a lab facility. In connection with entering into the OpenBiome Agreement, we terminated our existing agreements with OpenBiome, as such agreements were superseded by the OpenBiome Agreement and certain other agreements entered into concurrently with the OpenBiome Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the signing of the OpenBiome Agreement, OpenBiome granted us a worldwide, irrevocable and perpetual license, with the right to grant sublicenses (through multiple tiers) under certain of OpenBiome&#x2019;s technology that is necessary or useful in the manufacture of products manufactured directly from stool from a stool donor source without the use of culturing or replication, which we refer to as Natural Products, including technology pertaining to the selection of human stool donors, the collection and processing of stool from human donors and the preparation of stool-based products, and under any improvements to our intellectual property previously developed by OpenBiome or developed by OpenBiome during a specified period of time after the closing of the transaction, in each case to exploit products and services. In addition to the foregoing license, except under certain limited circumstances, OpenBiome agreed to not license or transfer to our competitors any rights to those aspects of its manufacturing technology that are not publicly available as of the date of the OpenBiome Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the OpenBiome Agreement, for the period prior to the closing of the transaction we granted OpenBiome a worldwide, non-exclusive license under certain of our intellectual property rights to make, use, sell, offer for sale, import and export certain Natural Products solely for the treatment of recurrent CDI in the United States under an FDA policy of enforcement discretion and to conduct clinical research in all fields other than the diagnosis, treatment, palliation or prevention in humans of CDI not subject to an FDA policy of enforcement discretion, IBD, ASD or HBV. Additionally, for the period beginning on the closing of the transaction, we granted OpenBiome a worldwide, non-exclusive license under certain of our intellectual property rights to sell certain Natural Products manufactured prior to the closing of the transaction solely for the treatment of recurrent CDI in the United States under enforcement discretion, and to make, use, sell, offer for sale, import and export certain Natural Products for purposes of conducting clinical research in all fields other than the diagnosis, treatment, palliation or prevention in humans of CDI not subject to an FDA policy of enforcement discretion, IBD, ASD or HBV. Notwithstanding the foregoing license, OpenBiome has agreed to certain restrictions related to the use, sale and supply of such products in connection with clinical research of our competitors. Additionally, the license grant excludes any license to exploit a Natural Product wherein processed stool is lyophilized (such as in the case of CP101).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the signing of the OpenBiome Agreement, we paid OpenBiome $1.0 million in the form of an upfront payment and $150,000 as reimbursement for OpenBiome&#x2019;s attorneys&#x2019; fees and expenses in connection the negotiation of the OpenBiome Agreement. On the closing of the transaction, we paid OpenBiome $2.25 million, plus an additional $1.6 million if no regulatory restrictions were in place preventing the sale and distribution of OpenBiome&#x2019;s products under enforcement discretion as of the date of closing. In addition to the foregoing payments, we are obligated to pay to OpenBiome a low single digit royalty on net sales of Natural Products by us and our affiliates and a high single digit royalty of certain sublicensing revenue (including royalties) received in connection with Natural Products, as well as a low single digit royalty on net sales of TAK-524, FIN-525 and any product that is not a Natural Product or a product that comprises both material manufactured directly from stool from a stool donor source without the use of culturing or replication and drug substance or drug product comprising one or more active pharmaceutical ingredients, and, in either case contains one or more isolates derived from certain stool donors that are exclusive to us, or Cultured Products, by us and our affiliates and a high single digit percentage of certain sublicensing revenue (including royalties) received in connection with Cultured Products. On a country-by-country basis, our payment obligations with respect to Natural Products expires twenty-five years after first commercial sale of such Natural Product in such country, and, with respect to Cultured Products expires fifteen years after first commercial sale of such Cultured Product in such country. We are also obligated to pay OpenBiome up to $6.0 million in the aggregate upon achievement of certain development and regulatory milestones with Natural Products and $20.0 million in the aggregate upon achievement of certain commercial milestones with Natural Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">LMIC License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, concurrently with entering into the OpenBiome Agreement, we entered into a license agreement, or the LMIC Agreement, with OpenBiome, pursuant to which we granted OpenBiome a non-exclusive license, with the right to grant sublicenses, under certain of our patents, patent applications and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from stool from a stool donor source without the use of culturing or replication, or Natural Products, to make, use, sell, have sold, offer for sale and import Natural Products and formulated liquid suspensions derived from the stool of a stool donor source that may be incorporated into a Natural Product, in either case for the treatment in humans of malnutrition and neglected tropical diseases in certain low- and middle-income countries, or the LMIC Territory. The license grant excludes any license to exploit a Natural Product wherein processed stool is lyophilized (such as in the case of CP101) or to otherwise use the licensed intellectual property to lyophilize a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LMIC Agreement, we own all improvements, enhancements or modifications to the licensed intellectual property (whether or not patentable) invented by either party during the term of the LMIC Agreement. OpenBiome has agreed to assign to us its interest in and to any such improvements, enhancements or modifications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LMIC Agreement, we are entitled to receive tiered royalties on net sales of Natural Products and products that incorporate formulated liquid suspensions derived from the stool of a stool donor source that may be incorporated into a Natural Product in the LMIC Territory ranging from mid-single digit to low-second decile. Royalties are payable on a product-by-product and country-by-country basis during the period beginning on the first commercial sale of such product in such country and ending on the later of the expiration of the last to expire valid claim from a licensed patent that covers such product or ten years from the date of the LMIC Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The LMIC Agreement expires on product-by-product and country-by-country basis upon expiry of the applicable royalty obligation for such product in such country. OpenBiome has the right to terminate the LMIC Agreement upon specified prior written notice to us. Either party may terminate the LMIC Agreement in the event of an uncured material breach by the other party of either the LMIC Agreement (or uncured breach by OpenBiome of the OpenBiome Agreement), provided that if such uncured material breach is limited to a breach of the LMIC Agreement in a particular country, our right to terminate the LMIC Agreement is limited to just such country. Either party may terminate the LMIC Agreement in the event of the insolvency of the other party. We may terminate the LMIC Agreement in the event that OpenBiome brings, or assists in bringing, a challenge to the validity, patentability, scope, construction, inventorship, ownership, enforceability or non-infringement of any licensed patent or patent application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, such as our product candidates and any future product candidates. We, along with third-party contractors, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable regulatory requirements at any time during the product development process or post-approval may subject an applicant to delays in development or approval or licensure, as well as administrative or judicial sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulatory Approval of Biological Products in the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and their implementing regulations. Biological products are also subject to other federal, state, local and foreign statutes and regulations. The process required by the FDA before biological product candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with the FDA&#x2019;s Good Laboratory Practice, or GLP, requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin and must be updated annually and when certain changes are made; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each clinical trial may be commenced; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, Good Clinical Practice, or GCP, requirements and other clinical trial-related regulations to establish the safety, purity and potency of the product candidate for each proposed indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation and submission to the FDA of a biologics license application, or BLA, after completion of all clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payment of any user fees for FDA review of the BLA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of a BLA to accept the application for review; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA Advisory Committee review, if applicable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the biological product, or components thereof, will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biological product&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the BLA, to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product biological characteristics, chemistry, toxicity, formulation and stability, as well as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may or may not result in the FDA allowing clinical trials to commence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and eligibility criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the investigational product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if, among other things, the clinical trial was conducted with qualified investigators in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of BLA submission and approval, clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, which may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the biological product candidate. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. The primary purpose of these clinical trials is to assess the safety, dosage tolerance, absorption, metabolism and distribution of the biological product candidate in humans, the side effects associated with increasing doses, and, if possible, early evidence of effectiveness.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 2 clinical trials generally involve studies conducted in a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide statistically significant evidence of clinical efficacy of the biological product candidate for its intended use, further evaluate its safety and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval and labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biological product candidate. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may, at any time while clinical trials are ongoing under the IND, impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would delay a proposed clinical study or cause suspension of an ongoing study until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. Additionally, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within fifteen calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the biological product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, companies must</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over their shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA Review Processes of Biological Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of all required testing and clinical trials of a biological product candidate in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product candidate&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product candidate, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the identity, quality, safety, purity and potency of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act, or PDUFA, each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The applicant under an approved BLA is also subject to an annual program fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA reviews a submitted BLA to determine if it is substantially complete before the FDA accepts it for filing and may request additional information from the sponsor. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission. In this event, the BLA must be resubmitted with any additional information requested. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. The FDA reviews a BLA to determine, among other things, whether the biological product candidate is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. Under the goals agreed to by the FDA under PDUFA, the FDA has ten months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification. This review typically takes twelve months from the date the BLA is submitted to the FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision. The review process and the PDUFA goal date for both standard and priority review BLAs may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission within the last three months before the PDUFA goal date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving a BLA, the FDA will typically conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether such facilities comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may inspect one or more clinical sites and audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety, purity, and potency of the product candidate. Additionally, the FDA may refer applications for novel product candidates or product candidates that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally considers such recommendations carefully when making decisions on approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product is produced, it will issue either an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the biological product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for the FDA to reconsider the application for approval. If a CRL is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months from receipt, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations to specific diseases and dosages or the indications for use for which such product may be marketed. For example, the FDA may require a Risk Evaluation and Mitigation Strategy, or REMS, to help ensure that the benefits of the biological product outweigh the potential risks to patients. A REMS is a safety strategy implemented to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#x2019;s safe use, or ETASU. An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require, or companies may voluntarily pursue, one or more post-market clinical trials, sometimes referred to as Phase 4 clinical trials, and testing and surveillance programs to further assess and monitor the product&#x2019;s safety and effectiveness after approval, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among the benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. In addition, if a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for off-label uses, the competitor&#x2019;s product could be used off-label for the orphan indication despite another product&#x2019;s orphan exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA offers a number of expedited development and review programs for qualifying product candidates intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. For example, Fast Track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and where preclinical or clinical data demonstrate the potential to address unmet medical needs for the disease condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a biological product candidate can request the FDA to designate the candidate for a specific indication for Fast Track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biological product candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#x2019;s request. The sponsor of a Fast Track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. Any product submitted to the FDA for approval, including under the Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Breakthrough Therapy designation may be granted for product candidates that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Under the Breakthrough Therapy program, the sponsor of a new biological product candidate may request that the FDA designate the candidate for a specific indication as a Breakthrough Therapy concurrent with, or after, the submission of the IND for the biological product candidate. The FDA must determine if the biological product qualifies for Breakthrough Therapy designation within 60 days of receipt of the sponsor&#x2019;s request. The FDA may take certain actions with respect to product candidates designated as breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner. The designation also includes all of the Fast Track program features, including eligibility for rolling review of BLA submissions if the relevant criteria are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Priority review may be granted for product candidates that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in the safety and effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological product designated for priority review in an effort to facilitate the review. For original BLAs, priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on the basis of an effect on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that is reasonably likely to predict the clinical benefit of the product candidate and substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is contingent on a sponsor&#x2019;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#x2019;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA prior to the intended date or dissemination or publication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Information and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a novel product (e.g. new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Best Pharmaceuticals for Children Act, or BPCA, provides a six-month extension of any exclusivity&#x2014;patent or non-patent&#x2014;for a biological product if certain conditions are met. Conditions for exclusivity include the FDA&#x2019;s determination that information relating to the use of a new biological product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements for Biological Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, reporting updated safety and efficacy information, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. Once a BLA is approved, a product will be subject to certain additional post-approval requirements, such as quality control, biological product manufacture, packaging and labeling procedures that must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Manufacturers of biological products are required to comply with applicable requirements in the cGMP regulations, including quality control, quality assurance and maintenance of records and documentation. Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, including those focused on manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning or other enforcement-related letters or holds on post-approval clinical studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA closely regulates the marketing, labeling, advertising and promotion of biological products, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of a biological product candidate, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Patent Term Restoration, Biosimilars and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of the FDA approval of the use of our biological product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The United State Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, signed into law in 2010, includes a subtitle called The Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BPCIA an application for a biosimilar or interchangeable product may not be accepted by the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date of first licensure of the reference product. &#x201c;First licensure&#x201d; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">International Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations, pharmacy benefit management organizations, and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#x2019;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Further, third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Accordingly, third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost-effectiveness of a product, to qualify for reimbursement, which could be costly and divert resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside of the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the commercial success of any approved products will also depend in large part on the availability of insurance coverage and adequate reimbursement from third-party payors, including government payors, such as the Medicare and Medicaid programs, and managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Moreover, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. If government and other healthcare payors were not to provide adequate insurance coverage and reimbursement levels for one any of our products once approved, market acceptance and commercial success would be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Healthcare Laws and Regulations and Legislative Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare Laws and Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with professionals, principal investigators, consultants, third-party payors and customers subject us to various federal and state fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Our current and future operations are subject to regulation by various federal, state, and local authorities in addition to the FDA, including but not limited to the Centers for Medicare &amp; Medicaid Services, or CMS, the U.S. Department of Health and Human Services (including the Office of Inspector General, Office for Civil Rights and the Health Resources and Services Administration), or HHS, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. The healthcare laws that may affect our ability to operate include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for, or to induce or reward either the referral of an individual for, or the purchase, lease, order or arrangement for, or recommendation of the purchase, lease, order, or arrangement for, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the ACA, signed into law in 2010, provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of or approval from the federal government, including Medicare, Medicaid and other government payors, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. Drug manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label promotion of drugs, </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things, imposes civil and criminal liability for knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense. HIPAA also creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates and their covered subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal transparency requirements under the Physician Payments Sunshine Act, created under the ACA, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to (i) payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare providers (such as physicians assistants and nurse practitioners), and teaching hospitals and (ii) physician ownership and investment interests, including such ownership and investment interests held by a physician&#x2019;s immediate family members;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">state and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers, and state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">state and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#x2019;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legislative Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the ACA, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extended manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a licensure framework for follow-on biologic products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been judicial, executive branch and congressional challenges to certain aspects of the ACA. For example, in 2017, the U.S. Congress enacted the Tax Cuts and Jobs Act of 2017, or Tax Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or congressional challenges in the future. It is unclear how any such challenges and the health reform measures of the Biden administration will impact the ACA and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, absent additional congressional action. The Coronavirus Aid, Relief and Economic Security Act, and subsequent legislation, suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In addition, in 2012, the U.S. Congress enacted the American Taxpayer Relief Act, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. Moreover, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the former Trump administration used several means to propose implementing drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, President Trump signed several executive orders aimed at lowering drug prices. As a result, the FDA released a final rule and guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. We expect that additional state and federal healthcare reform measures will be adopted in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees and Human Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 189 employees. Of these 189 employees, 156 are engaged in research and development activities and 33 are engaged in business development, finance, legal, information systems, facilities, human resources or administrative support. None of our employees is subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purpose of our 2021 Equity Incentive Plan is to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our long-term success requires a diverse and inclusive workforce. We value diversity at all levels of the organization and continue to focus on extending our diversity, equity and inclusion initiatives across our entire workforce, including through our Diversity, Equity and Inclusion Committee, which is a cross-functional group designed to create programs focused on understanding employees&#x2019; intersecting identities, honoring differences and rooting out systemic inequity. In addition, we pride ourselves on an open culture that respects co-workers, values employees&#x2019; health and well-being and fosters professional development. We conduct regular employee engagement surveys, and our board of directors provides input on important decisions relating to these matters, including with respect to employee compensation and benefits and talent acquisition and retention.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were originally incorporated in Delaware in November 2014 and until September 21, 2017, or the Merger Date, we conducted our business through Finch Therapeutics, Inc., a Delaware corporation. On the Merger Date, pursuant to the terms of the agreement and plan of merger, or the Merger Agreement, Finch Therapeutics, Inc. and Crestovo Holdings LLC, a Delaware limited liability company, completed a merger of equals. Pursuant to the terms of the Merger Agreement, each of Finch Therapeutics, Inc. and Crestovo Holdings LLC became a wholly-owned subsidiary of Finch Therapeutics Group, Inc. Crestovo Holdings LLC was renamed Finch Therapeutics Holdings LLC in November 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our principal executive office is located at 200 Inner Belt Road, Suite 400, Somerville, Massachusetts 02143. Our telephone number is (617) 229-6499. Our website address is www.finchtherapeutics.com. Information contained in, or accessible through, our website does not constitute a part of, and is not incorporated into, this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and, accordingly, file reports, proxy statements and other information with the Securities and Exchange Commission, or SEC. The SEC maintains a website (http://www.sec.gov) that contains material regarding issuers that file electronically, such as ourselves, with the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We make available free of charge on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business is subject to numerous risks. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K as well as our other public filings with the Securities and Exchange Commission, or the SEC. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects and cause the trading price of our common stock to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have a limited operating history, have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage microbiome therapeutics company with a limited operating history. Since our inception, we have focused primarily on developing and progressing our product candidates through clinical development, organizing and staffing our company, research and development activities, establishing and protecting our intellectual property portfolio, including for our Human-First Discovery platform, and raising capital. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have not yet demonstrated the ability to progress any product candidate through clinical trials, we have no products approved for commercial sale and we have not generated any revenue from product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. For the years ended December 31, 2021 and 2020, we reported net losses of $58.2 million and $39.3 million, respectively. As of December 31, 2021, we had an accumulated deficit of $161.0 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for our therapeutic product candidates CP101, for the prevention of recurrent </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, or CDI, FIN-211, to address symptoms of autism spectrum disorder, or ASD, and any other current or future product candidates we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that our expenses will increase substantially if, and as, we:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue our ongoing and planned development of CP101 for the prevention of recurrent CDI, including our Phase 3 clinical trial of CP101, and seek to resolve the clinical hold on our investigational new drug application, or IND, for CP101, which is expected to extend timelines and increase costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate preclinical studies and clinical trials for our other product candidates and any additional product candidates that we may pursue in the future, including our earlier-stage programs such as our planned Phase 1b clinical trial of FIN-211 to address symptoms of autism spectrum disorder, or ASD;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">develop, optimize and scale our manufacturing processes and capabilities, including commissioning and qualifying newly constructed facilities to support the commercial scale production of CP101 and, in the future, similar scale-up for our other drug candidates, which may include the development of new technology;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish and expand a donor program to support our clinical supply for trial and initial commercial needs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increase the amount of research and development activities to identify and develop product candidates using our proprietary discovery approach;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">make milestone, royalty or other payments under in-license or collaboration agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing, quality systems and commercialization efforts and our operations as a public company;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">invest in or in-license other technologies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience any delays or encounter any issues with any of the above, including, but not limited to, failed studies, complex results, manufacturing challenges, quality issues, safety issues or other regulatory challenges, or as a result of the ongoing COVID-19 pandemic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To become and remain profitable, we, our collaborators and any potential future collaborators must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities as to which we can make no assurances that we will be successful, including resolving the clinical hold on our IND for CP101, addressing findings from the related quality investigation,</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completing related manufacturing activities with respect to both CP101 and FIN-211, and providing additional information to the FDA regarding our PRISM4 protocol and the validation package for one of our release tests, which is utilized for both CP101 and FIN-211. We will also need to be successful in completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our product development programs or other operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have primarily funded our operations through the IPO, private placements of equity securities and upfront and milestone payments received pursuant to our collaboration agreement with Takeda Pharmaceutical Company Limited, or Takeda. We expect to spend substantial amounts to advance our product candidates into clinical development and to complete the clinical development of, seek regulatory approvals for and, if approved, commercialize, our product candidates. We will require additional capital, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable us to complete the development and potential commercialization of our product candidates. Adequate additional financing may not be available to us on acceptable terms, or at all. Our ability to raise capital is dependent on a number of factors, including the market demand for our common stock, which is uncertain. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our research and development programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our cash and cash equivalents were $133.5 million. We believe that our existing cash on hand will enable us to fund our operating expenses and capital expenditure requirements into</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-2023</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> However, we will need to obtain substantial additional funding in connection with our continuing operations and planned activities. Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, costs, progress and results of our ongoing and planned clinical trials of CP101, FIN-211 and other product candidates, including our ability to resolve the clinical hold on our IND for CP101, address findings from our related quality investigation,</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">complete related manufacturing activities with respect to both CP101 and FIN-211, and provide additional information to the FDA regarding our PRISM4 protocol and the validation package for one of our release tests, which is utilized for both CP101 and FIN-211;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the progress of preclinical development and possible clinical trials of our current earlier-stage programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of our research programs and preclinical development of other product candidates that we may pursue;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the development requirements of other product candidates that we may pursue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any possible delays or interruptions with our clinical trials, our receipt of services from our third-party service providers on whom we rely, our supply chain or other regulatory challenges, including those due to the COVID-19 pandemic or to other unforeseen global events;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our headcount growth and associated costs as we conduct our research and development and establish a commercial infrastructure;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and amount of milestone and royalty payments that we are required to make or eligible to receive under our current or future licensing and collaboration agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of establishing a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or the FDA, and any comparable foreign regulatory authority;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of future commercialization activities, including product manufacturing and related quality systems implementation, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with operating our commercial scale manufacturing facility;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of expanding, maintaining and enforcing our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of potential stockholder litigation or regulatory investigations, which may involve past or future significant announcements, transactions or disclosures since our IPO; for example, several class action plaintiff law firms have issued press releases announcing that the firms are investigating securities law claims on behalf of our stockholders following our March 1, 2022 announcement that enrollment in PRISM4 was paused following receipt of the clinical hold letter on February 24, 2022; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our product candidates, such as the complaint filed by Rebiotix Inc. and Ferring Pharmaceuticals Inc., seeking a declaratory judgment of non-infringement and invalidity with respect to seven U.S. patents owned by us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of completion of commercial-scale manufacturing capabilities for future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we partner our programs, acquire or in-license other product candidates and technologies or enter into additional strategic collaborations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the revenue, if any, received from commercial sales of CP101, FIN-211, and any future product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of equipment and physical infrastructure to support our research and development; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company, including costs associated with compliance, disclosure and insurance.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, CP101, FIN-211 and any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether terminate our research and development programs or future commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital will cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish certain valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our clinical development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Development of Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are currently subject to a clinical hold on our IND for CP101. We need to resolve the FDA clinical hold issues in order to proceed with enrollment in our PRISM4 clinical trial and initiate our Phase 1b clinical trial in ASD. Our business may be adversely affected if the clinical hold is not resolved in a timely manner or if regulatory concerns lead to additional delays and/or FDA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CP101 is our lead product candidate, and as announced on March 1, 2022, we paused enrollment in our Phase 3 clinical trial of CP101 in recurrent CDI, which we refer to as the PRISM4 trial, in response to receipt of a clinical hold letter from the FDA on February 24, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, at the outset of the COVID-19 pandemic, the FDA issued a public safety alert regarding the potential risk of transmission of SARS-CoV-2 virus through the use of donor-derived investigational microbiome therapies and the need for additional safety precautions. At that time, the FDA placed our IND for CP101 on partial clinical hold, requiring us to implement new SARS-CoV-2 screening measures for any microbiota material donated on or after December 1, 2019 and to address the risk of SARS-CoV-2 transmission in the informed consent process. Following communications with the FDA in January 2022, on February 24, 2022, the FDA sent us a clinical hold letter, stating that the FDA required additional information about our SARS-CoV-2 screening protocols and related informed consent language, and that a clinical hold remains in effect until the FDA's requests have been satisfactorily addressed. We also received</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an additional letter from the FDA, dated March 17, 2022, requesting changes to the testing algorithm used to diagnose suspected CDI recurrences in PRISM4, as well as additional information</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regarding the proposed statistical analysis plan for PRISM4 and the validation package for one of our release tests, which is utilized for both CP101 and FIN-211</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are unable to</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">proceed with enrollment in the PRISM4 trial until: the FDA removes the clinical hold; we address findings from our ongoing quality investigation in connection with the clinical hold; we conduct additional manufacturing activities with respect to CP101 to satisfy certain of the FDA's requests related to SARS-CoV-2 screening and testing; and we satisfactorily address the FDA's additional questions regarding PRISM4 and the validation package for one of our release tests. Because FIN-211, our product candidate designed to address symptoms of ASD, includes donor-derived components, the clinical hold will also delay initiation of our Phase 1b clinical trial of FIN-211 and will require us to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conduct additional manufacturing activities with respect to components of FIN-211 in order to satisfy the FDA's requests</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If we are delayed longer than anticipated in successfully addressing the FDA&#x2019;s concerns underlying the clinical hold and the subsequent letter regarding PRISM4, our costs and timelines associated with our clinical trials in recurrent CDI and ASD would change, potentially in a significant manner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we began dosing participants in our PRISM4 trial with CP101. Since we dosed participants while the clinical hold was in effect, we may be subject to an additional clinical hold or FDA administrative, advisory, or enforcement actions, which could include, among other things, a warning letter, and the participants dosed during this time may not be considered part of the per protocol population and/or efficacy analysis for PRISM4. An additional clinical hold or FDA administrative, advisory, or enforcement actions could result in a significant delay in our development of CP101, FIN-211 and other current or future product candidates, a significant increase in costs, could delay or potentially jeopardize our ability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to commence product sales and generate revenue, could result in adverse publicity, and could cause a decline in our stock price, any of which may adversely affect our business. In addition, if we are unable to resolve the clinical hold favorably or if the FDA or other regulatory agencies express any concerns regarding the use of donor material in microbiome therapeutics, it could adversely affect our ability to develop CP101, FIN-211 and other current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are heavily dependent on the success of our product candidates, which are in clinical and preclinical development. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. We are early in our product candidate development efforts, as CP101 is our only product candidate to reach clinical development to date. Because CP101 is our lead product candidate, and the IND for CP101 is currently under clinical hold by the FDA, if CP101 encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be significantly harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of CP101, FIN-211 and any other current or future product candidates we develop, which may never occur. CP101, FIN-211 and any other product candidates we develop will require additional preclinical and clinical development, management of clinical, preclinical, manufacturing and quality activities, marketing approval in the United States and other jurisdictions for specific indications for use, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales. The success of our current and future product candidates will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to resolve the clinical hold on our IND for CP101, address findings from our related quality investigation,</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">complete related manufacturing activities with respect to both CP101 and FIN-211, and provide additional information to the FDA regarding our PRISM4 protocol and the validation package for one of our release tests, which is utilized for both CP101 and FIN-211;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successful and timely completion of clinical trials and preclinical studies for which the FDA or any comparable foreign regulatory authority agree with the design, endpoints or implementation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receiving regulatory approvals or authorizations for conducting our planned clinical trials or future clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiation and successful patient enrollment in, and completion of, additional clinical trials on a timely basis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe and effective as a treatment for our targeted indications or, in the case of an applicable product candidate that is regulated as a biological product, that the applicable product is safe, pure, and potent and controlled for our targeted indications and in either case, that our quality management systems are sufficient to ensure such results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate&#x2019;s risk-benefit ratio for its proposed indication is acceptable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely receipt of marketing approvals for our product candidates from applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing that meet current Good Manufacturing Practices, or cGMP, and other legal and regulatory requirements, if any of our product candidates are approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates, both in the United States and internationally;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successfully scaling a sales and marketing organization and launching commercial sales of our product candidates, if approved;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance of our product candidates&#x2019; benefits and uses, if approved, by patients, the medical community and third-party payors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining a continued acceptable safety profile of our product candidates following approval, including long-term safety;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effectively competing with companies developing and commercializing other therapies in the indications that our product candidates target;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enforcing and defending against intellectual property rights and claims.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of these risks are beyond our control, including the risks related to clinical development, the regulatory review process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborators. If we are unable to develop, receive regulatory approval for, or successfully commercialize our current or future product candidates, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize CP101, FIN-211 or any other current or future product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for our current and future product candidates, we may not be able to continue our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates are based on microbiome therapeutics, which is an unproven approach to therapeutic intervention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of our product candidates are based on microbiome therapy, a therapeutic approach that is designed to treat disease by restoring the function of a dysbiotic microbiome. We have not, nor to our knowledge, has any other company, received regulatory approval for a therapeutic based on this approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, the efficacy potential of our microbiome therapeutics may vary based on indication and use in different patient populations including geographical areas. Finally, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on microbiome therapeutics, which could result in a longer than expected regulatory review process or evolving FDA standards and guidance, increase our expected development costs and delay or prevent commercialization of our product candidates. Regulatory requirements governing microbiome therapies are still developing and may change in the future or may be influenced by our competitors&#x2019; product candidates if they receive FDA approval before we do. Regulatory authorities and advisory groups, and the new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current or future product candidates or lead to significant post-approval limitations or restrictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Microbiome therapies in general may not be successfully developed or commercialized or gain the acceptance of the public or the medical community. Our success will depend upon physicians who specialize in the treatment of diseases targeted by our product candidates that we pursue as drugs, prescribing potential treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. Our success will also depend on consumer acceptance and adoption of our products that we commercialize. Adverse events in non-IND human clinical studies and clinical trials of our product candidates, or in non-IND human clinical studies and clinical trials of others developing similar products or products that are perceived to be similar to ours, such as fecal microbiota transplant, or FMT, materials, as well as any other adverse findings that arise in connection with research and development in the microbiome field, could result in negative publicity and a decrease in demand for any product that we may develop. In addition, responses by the federal, state or foreign governments to negative public perception or ethical concerns may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval, identify alternate regulatory pathways to market or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our microbiome therapeutics platform relies in part on third parties for biological materials, including human stool. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">biological materials could materially adversely affect our business. For example, if any supplied biological materials are contaminated with pathogens or disease organisms, we would not be able to use such biological materials. Although we have control processes and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. While we screen for a broad set of pathogens as a part of our manufacturing process, the donated human stool may contain organisms of which we are not aware and that could have an adverse effect on the safety of our product candidates and on the outcomes of our preclinical studies or clinical trials. For example, our SARS-CoV-2 donor screening protocols may not be satisfactory to regulatory authorities, as the FDA has requested information about our protocols in the clinical hold letter we received in February 2022. Improper storage or shipment of these materials, by us or any third-party suppliers, may require us to destroy some of our raw materials or products which could create supply shortages, interruptions or other delays or require identification and contracting of additional third-party suppliers which we may not be able to do in a timely manner or on favorable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationship with OpenBiome may adversely affect our ability to develop our product candidates and subject us to increased liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Microbiome Health Research Institute, Inc., or OpenBiome, is a non-profit organization that was co-founded in 2012 by our Chief Executive Officer and member of our board of directors, Mark Smith, Ph.D. OpenBiome operates a stool bank and sells and distributes fecal microbiota transplant products, or OpenBiome FMT Materials, for clinical research and for use in treating CDI not responding to standard therapy under its interpretation of the FDA&#x2019;s policy of enforcement discretion. In July 2013, the FDA issued guidance stating that it intended to exercise a policy of enforcement discretion regarding the IND regulatory requirements for the use of FMT used to treat CDI not responding to standard therapies, provided that the treating physician obtains appropriate informed consent from the patient or his or her legally authorized representative. We have historically had a close relationship with OpenBiome and are currently and have previously been party to several agreements with OpenBiome related to, among other things, the license of various technology and intellectual property rights. In addition, Carolyn Edelstein, the co-founder and former Executive Director of OpenBiome, is married to Dr. Smith. Although we believe our agreements with OpenBiome have been negotiated at an arms-length basis, there may be a perception that the terms of any such agreements have not been fairly negotiated, which could increase regulatory scrutiny, adversely impact our reputation or otherwise impair our ability to operate effectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2016, we entered into a Master Strategic Affiliation Agreement with OpenBiome, or the Strategic Agreement, pursuant to which, among other things, we manufactured OpenBiome FMT Materials to specifications defined by OpenBiome for distribution and sale by OpenBiome through February 2019. These OpenBiome FMT Materials have been and may continue to be distributed and sold by OpenBiome, and administered to patients. The FDA may not agree with OpenBiome&#x2019;s interpretation or application of the FDA&#x2019;s enforcement discretion policy to its product distribution. We terminated the Strategic Agreement in 2020 as part of signing an asset purchase agreement, or the OpenBiome Agreement, and license agreement with OpenBiome, pursuant to which we acquired certain biological materials, equipment, and other assets, and cross-licensed certain intellectual property. The OpenBiome Agreement also retained certain existing intellectual property and biological materials licenses from the Master Strategic Affiliation Agreement into a stand-alone agreement. Although we are indemnified for causes of action relating to the distribution and sale of the OpenBiome FMT Materials, we may nonetheless become parties to potential product liability claims that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products such as OpenBiome FMT Materials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the availability of OpenBiome FMT Materials under the FDA&#x2019;s policy of enforcement discretion, and for use in clinical research, may negatively prejudice and slow enrollment of clinical trials sponsored by us or our collaborators that are directed at the same or similar disease or condition, such as CDI. Additionally, while each of CP101 and FIN-211 is an orally administered biologic consisting of a complete microbiome and a distinct product from OpenBiome FMT Materials, with additional testing, manufacturing and control steps, it is possible that the FDA and others might perceive CP101, FIN-211 or any of our other product candidates as similar owing to their common raw material. The FDA has issued three safety alerts since 2019 related to the use of FMT treatment, including in March 2020 after OpenBiome reported occurrences of enteropathogenic E. coli and shigatoxin-producing E. coli in FMT recipients. This and similar adverse safety events associated with OpenBiome FMT Materials or other similar products manufactured or supplied by other third-party stool banks, physicians or others may cause the FDA to perceive CP101 or FIN-211 as unsafe and bring increased regulatory scrutiny to our clinical and manufacturing operations more broadly, lead to decreased confidence by patients and physicians in our product candidates, and result in reduced demand for any product that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OpenBiome has also supplied us with biological materials derived from human stool, which we have used as raw materials, subject to additional testing, screening and processing, in the manufacture of our product candidates, such as CP101 and FIN-211, for use in our current and planned clinical trials. During the time we engaged OpenBiome to supply us with such human stool material, OpenBiome received a clinical hold from the FDA with respect to the need for new screening measures to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mitigate the risk of transmission of SARS-CoV-2 from donor to recipient of its OpenBiome FMT materials, and the need for additional information regarding OpenBiome&#x2019;s quality systems. This clinical hold was removed in January 2021. Although the OpenBiome clinical hold did not preclude us from receiving OpenBiome-supplied biological materials for our manufacturing activities, given that some materials were received while OpenBiome was under clinical hold, we may not be able to use these materials for such purposes if the FDA or other parties perceive such materials to be unsuitable for use in an investigational drug. For example, the FDA or other regulatory agencies may determine that the materials should not be used for reasons underlying the clinical hold, or different reasons. In addition, while we have tested these materials and reviewed manufacturing records to ensure they meet our quality standards, we are using an assay to screen for COVID-19 that the FDA may not deem acceptable; moreover, in its</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 2022 clinical hold letter for our CP101 IND, the FDA requested additional information regarding this assay. In addition, we may not be able to recoup the costs associated with acquiring these biological materials from OpenBiome.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in connection with the closing of the transactions contemplated by the OpenBiome Agreement, we acquired certain capital equipment and assumed the contracts with certain service providers to which OpenBiome was a party. Although the OpenBiome Agreement is structured to exclude the assumption of any liabilities of OpenBiome, we may be subject to unknown liabilities with respect to the assets we have acquired or contracts we have assumed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical trials are difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of CP101, FIN-211 or any other current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We cannot guarantee that any of our ongoing and planned clinical trials will be conducted as planned or completed on schedule, if at all; for example, we have decided to pause development of CP101 in HBV at this time, which we believe will allow us to maximize our working capital available for investment in our wholly-owned</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> recurrent CDI and ASD programs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Moreover, even if these trials are initiated or conducted on a timely basis, issues may arise that could result in the suspension or termination of such clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience delays in our ongoing clinical trials or preclinical studies and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or in sufficient numbers, have sufficient drug supply for our product candidates on a timely basis or be completed on schedule, if at all. For example, enrollment in PRISM4 is currently paused following receipt from the FDA of a clinical hold letter on February 24, 2022. Further, because FIN-211 includes donor-derived components, the clinical hold will also delay initiation of our Phase 1b clinical trial in ASD. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. We also may experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize CP101, FIN-211 or any other current or future product candidates, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in or failure to obtain regulatory authorizations to commence clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching a consensus with regulatory agencies as to the design or implementation of our clinical trials; for example, we plan to have further discussions with the FDA regarding the size and make-up of the safety database for CP101 and we recently received a letter from the FDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> requesting changes to the testing algorithm used to diagnose suspected CDI recurrences in PRISM4, as well as additional information</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regarding the proposed statistical analysis plan for PRISM4 and the validation package for one of our release tests, any of</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> which could result in the need for additional studies or delays in our development timelines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in or failure to obtain institutional review board, or IRB, approval at each site;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in or failure to recruit a sufficient number of suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to have patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in adding new clinical trial sites;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to manufacture sufficient quantities of our product candidates at the required quality for use in clinical trials in a timely manner, including the failure to acquire sufficient starting material from third-party donors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or safety or tolerability concerns that could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to perform clinical trials in accordance with the FDA&#x2019;s or any other regulatory authority&#x2019;s good clinical practices, or GCP, requirements, or regulatory guidelines in other countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in regulatory requirements, policies and guidelines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure of our third-party research contractors to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in establishing the appropriate dosage levels in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the quality or stability of our product candidates falling below acceptable standards; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geo-political actions, including war and terrorism, an outbreak of a contagious disease, such as the COVID-19 pandemic, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing preclinical studies and clinical trials, as applicable. We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or comparable foreign regulatory authorities, or recommended for suspension or termination by the Data Safety Monitoring Board for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business and operations may be adversely affected by the evolving and ongoing COVID-19 global pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business and operations may be adversely affected by the effects of the ongoing COVID-19 global pandemic, which has resulted in various restrictions aimed at containing the virus, including public health directives and orders that, among other things and for various periods of time, directed individuals to shelter in place, directed businesses and governmental agencies to cease non-essential operations at physical locations, prohibited certain non-essential gatherings and events, and ordered cessation of non-essential travel. Future remote work policies and similar government orders or other restrictions on the conduct of business operations related to the COVID-19 pandemic, including as a result of variants of COVID-19, may negatively impact productivity and may disrupt our ongoing research and development activities and our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the COVID-19 pandemic, we experienced a slowdown to enrollment in our PRISM-EXT and PRISM4 clinical trials, as well as interruptions to operations at our donor centers, including certain periods during which we accepted limited donations due to staffing constraints. We may experience additional COVID-19 related disruptions in the future that could severely impact our clinical trials, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays, difficulties or a suspension in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruptions in our ability to manufacture and deliver drug supply for trials, including related to a lack of human donors for stool due, in part, to the fact that qualified donors may be hesitant to visit a donor center, or related to the failure of third-party manufacturers and suppliers to timely provide such supply;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in local regulations as part of a response to the COVID-19 pandemic that may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site monitoring, and the ability or willingness of subjects to travel to trial sites due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations in employee resources that would otherwise be focused on the manufacture and testing of our products and the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to accept data from clinical trials in certain affected geographies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Known or unanticipated impacts of the COVID-19 pandemic, including as a result of variants of COVID-19, may have a material adverse effect on our business. While the ultimate economic impact brought by, and the duration of, the COVID-19 pandemic are difficult to assess or predict, the pandemic has resulted, and could further result, in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this Annual Report on Form 10-K, such as the ultimate geographic spread of the disease, the duration of the outbreak, the impact of emerging variants, the duration and effect of business disruptions and the short- and long-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements, occupancy limits, vaccine mandates and business closures in the United States and other countries to contain and treat the disease, and the effectiveness and acceptance of vaccines. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The demand for vaccines for COVID-19 and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Moreover, since the Office of Vaccines Research and Review at FDA, which is responsible for review and approval of microbiome product candidates, is responsible for the review of COVID-19 vaccines, responses from FDA may be delayed. Many Review Divisions at FDA, including the Office of Vaccines Research and Review at FDA, have experienced delays in some timelines related to the Prescription Drug User Fee Act due to demands brought about by COVID-19.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To obtain the requisite regulatory approvals to market and sell any of our product candidates, including CP101, FIN-211 and any other current or future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our investigational drug products are safe and effective for use in each targeted indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. For example, in addition to gastrointestinal endpoints, our development program for FIN-211 in ASD includes exploration of behavioral endpoints, which are not yet well-established. If we fail to validate behavioral instruments for use in our ASD clinical protocols, we would not be able to rely upon those instruments or endpoints to support FDA approval. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications, patient population and regulatory agency. Prior to obtaining approval to commercialize CP101, FIN-211 and any other current or future product candidates in the United States or abroad, we, our collaborators or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. For example, we plan to have further discussions with the FDA regarding the size and make-up of the safety database for CP101 which could result in the need for additional studies or delays in our development timelines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do. More trials could be required before we submit our product candidates for approval, especially for indications such as ASD, for which clinical endpoints are not well-established. We cannot guarantee that the FDA or comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in clinical trials. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, approval of CP101, FIN-211 and any other current or future product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Initial success in third-party studies or our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later-stage trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of nonclinical and preclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, we have relied on third-party clinical research in order to inform certain aspects of our own clinical trials and preclinical studies. We have not independently verified the accuracy, safety or other results of such third-party studies, and we may be unable to replicate the results from such third-party studies. For example, insights gained from the use of FMT materials, including FMT clinical data, may not be predictive of our clinical trials, particularly given that the dosage form and potency, delivery mechanisms and manufacturing process vary significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biotechnology and pharmaceutical industries, including certain of our competitors in microbiome therapeutics, have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA approval. For example, w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e recently received a letter from the FDA requesting changes to the testing algorithm used to diagnose suspected CDI recurrences in PRISM4, which had been used in PRISM3. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, products used in small early-stage studies may be from a limited number of donors, and it is possible that efficacy might be linked to the microbial community found in a specific donor or a limited set of donors, such that the results might not apply for a broader group of donors with varying microbial compositions. Any such setbacks in our clinical development could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, some of the clinical trials we conduct, including a portion of the PRISM4 trial, may include open-label trials conducted at a limited number of clinical sites on a limited number of patients. An &#x201c;open-label&#x201d; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved product or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#x201c;patient bias&#x201d; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that we plan to in the future conduct open-label clinical trials, the results from these clinical trials may not be predictive of future clinical trial results with these or other product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may be associated with serious adverse, undesirable or unacceptable side effects or other properties or safety risks, which may delay or halt their clinical development, or prevent marketing approval. If such side effects are identified during the development of our product candidates or following approval we may suspend or abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. While we have observed no treatment-related serious adverse events, or SAEs, to date in clinical trials of our lead product candidate CP101, the results from future preclinical studies and clinical trials of our other product candidates may identify safety concerns or other undesirable properties of our product candidates. Additionally, if we expand our product development for current or future product candidates into new patient populations or disease areas, side effects or adverse events not seen by our product candidates in earlier clinical research could emerge.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of our clinical trials of CP101, FIN-211 and future clinical trials of our other product candidates may show that our product candidates cause undesirable or unacceptable side effects or even death. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, if our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, adverse developments in clinical trials of pharmaceutical and biopharmaceutical products conducted by others or with commercial products offered by others may cause the FDA or other regulatory oversight bodies to suspend or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">terminate our clinical trials or change the requirements for approval of any of our product candidates or otherwise adversely impact the clinical and commercial development of our product candidates. Such adverse developments may cause the FDA to perceive CP101 or other current or future product candidates as unsafe and bring increased regulatory scrutiny to our clinical operations more broadly, lead to decreased confidence by patients, physicians and contract research organizations, or CROs, in our product candidates, and result in reduced demand for any product that we may develop if approved. For example, in June 2019, the FDA issued a safety alert regarding the risk of serious adverse reactions due to the transmission of multi-drug resistant organisms in connection with FMT treatment provided by a local, hospital-based FMT program. Two immunocompromised adults, one of whom later died, received FMT treatment from this hospital-based FMT program and subsequently developed infections caused by extended-spectrum beta-lactamase-producing E. coli. In March 2020, the FDA issued another safety alert regarding the potential of serious or life-threatening infections with the use of FMT treatment after OpenBiome reported occurrences of enteropathogenic E. coli and shigatoxin-producing E. coli in FMT recipients. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also in March 2020, FDA issued a safety alert regarding the potential risks of transmission of COVID-19 by FMT and placed our IND for CP101 on partial clinical hold.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">site IRBs or safety monitoring committees may recommend that enrollment or dosing be placed on hold or that additional safety measures be implemented for ongoing trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may withdraw or limit approvals of such product and require us to take our approved product off the market;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to change the way the product is dosed, distributed or administered, conduct additional clinical trials or change the labeling of the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to limitations on how we may promote the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sales of the product may decrease significantly;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to litigation or product liability claims; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reputation may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our product candidates, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with, or otherwise adversely affect, clinical trials of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timely completion of our clinical trials in accordance with their protocols depends, among other things, on our ability to recruit a sufficient number of eligible patients to participate and remain in the trial until its conclusion. Patients may be unwilling to participate in our clinical trials because of negative publicity from adverse events related to novel therapeutic approaches, competitive clinical trials for similar patient populations, the existence of current treatments, such as FMT, or for other reasons, including the ongoing COVID-19 pandemic and negative perceptions of our product candidates. For example, enrollment in PRISM4 commenced later than we anticipated due to, among other things, vendor delays and staffing shortages in connection with the COVID-19 pandemic. Enrollment in PRISM4 is currently paused following receipt from the FDA of a clinical hold letter on February 24, 2022, requesting additional information about our SARS-CoV-2 donor screening protocols. Further, because FIN-211 includes donor-derived components, the clinical hold will also delay initiation of our Phase 1b clinical trial in ASD. Any delays related to patient enrollment could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by many factors, including the:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">size and nature of the patient population and process for identifying patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">proximity and availability of clinical trial sites for prospective patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eligibility and exclusion criteria for the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">design of the clinical trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">burden or perceived burden of participation in the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safety profile, to date, of the product candidate under study;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">perceived risks and benefits of the product candidate under study;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">perceived risks and benefits of our approach;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval and availability of competing product candidates currently under investigation for the treatment of similar diseases or conditions, or competing clinical trials, including several ongoing trials of our competitors of which we are aware, for similar product candidates or targeting patient populations meeting our patient eligibility criteria;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">severity of the disease under investigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">degree of progression or stage of the patient&#x2019;s disease at the time of enrollment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ability to obtain and maintain patient consent;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk that enrolled patients will drop out before completion of the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patient referral practices of physicians; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ability to adequately monitor patients during and after treatment.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enrollment risks are heightened with respect to indications that are rare or orphan diseases, which may limit the pool of patients that may be enrolled in our planned clinical trials. For example, we are developing CP101 for the prevention of recurrent CDI, which does not have a large patient population, and, as a result, we may encounter difficulties enrolling subjects in our clinical trials evaluating CP101 for the prevention of recurrent CDI due, in part, to the small size of this patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our clinical trials will compete with products that are available for use in the same therapeutic areas of our product candidates, and other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. For example, the availability of FMT materials for CDI not responding to standard therapies may affect our ability to enroll patients in our studies of CP101 in CDI. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical trials may change as more patient data become available. Preliminary or interim data from our clinical trials are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preliminary, topline and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. In addition, certain patient and product samples from our clinical trials are or will be retained by third parties and used by them for further research and studies, and the data from such studies may be inconsistent or contrary to the results from our earlier clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, interpretations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, if any, and our company in general. For example, regulatory agencies may disagree with our inclusion or exclusion of certain trial subjects from our clinical trial data or our interpretation of such data. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, if any, product candidate or our business. If the preliminary and interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before we can commence clinical trials for any product candidate, we may be required to complete extensive preclinical studies that support any future Investigational New Drug, or IND, applications in the United States, or similar applications in other jurisdictions. Conducting preclinical testing is a lengthy, time-consuming and expensive process and delays associated with product candidates for which we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. We cannot be certain of the timely completion or outcome of our preclinical testing and studies for CP101, FIN-211 or our other current or future product candidates and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and foreign clinical trials will ultimately support the further development of our other product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, laws or regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including requiring us to enroll more patients than originally expected, including with respect to the anticipated size of the safety database to be collected to support a biologics license application, or BLA, filing and possible approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective as a treatment for our targeted indications, or, in the case of a product candidate regulated as a biological product, that the product candidate is safe, pure and potent and controlled for its proposed indication, or, in either case, that our quality management systems are sufficient to ensure such results;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the population studied may not be sufficiently broad or representative to assure safety or efficacy in the population for which we seek approval, including as a result of our agreement with the FDA prior to unblinding to exclude certain patients enrolled at two GCP-non-compliant trial sites from adjudication and inclusion in our efficacy analysis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including whether our statistical analysis plan meets FDA expectations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory requirements for microbiome therapeutics may be influenced by our competitors&#x2019; interactions with the FDA or comparable foreign regulatory authorities, including the possibility that a competitor fails to receive regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may require additional preclinical studies or clinical trials beyond those that we currently anticipate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA may conclude that our product candidate is the &#x201c;same drug&#x201d; as a competitor product that has been approved and has received orphan drug exclusivity for the same intended use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes, testing regime or facilities operated by us or third-party manufacturers with which we contract for clinical and commercial supplies, including with certain technology transfer initiatives; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval policies or regulations of the FDA or any comparable foreign regulatory authorities or the laws they enforce may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, financial condition and results of operations. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, if any, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, testing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing and testing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposition of a REMS, which may include distribution or use restrictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to conduct additional post-market clinical trials to assess the safety of the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability including, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA approved labeling.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holder of a BLA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may in the future conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have previously conducted, and plan in the future to conduct, one or more clinical trials outside the United States, including in, but not limited to, Canada, Europe, Australia, New Zealand and Hong Kong. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. Results for our clinical trials may differ by jurisdiction as a result of varying standards of care or local restrictions on reimbursement from third-party payors for clinical trials, thereby affecting the willingness of the FDA or any comparable foreign regulatory authority to accept such data. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. In addition, conduct of clinical trials on a global basis may expose us to geopolitical risks impacting the ability of institutions and patients to participate in our trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may pursue the development of certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the near future, we may explore the use of our product candidates in combination with other therapies, including those that are not yet approved. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials, or we may not be able to obtain adequate reimbursement from third-party payors. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where we develop a product candidate for use in combination with a therapy that has not been approved by the FDA or comparable foreign regulatory authorities, we will not be able to market our product candidate for use in combination with such an unapproved therapy, unless and until the unapproved therapy receives regulatory approval. These unapproved therapies face the same risks described with respect to our product candidates currently in development, including serious adverse effects and delays in their clinical trials. In addition, other companies may also develop their products or product candidates in combination with the unapproved therapies with which we are developing our product candidates for use in combination. Any setbacks in these companies&#x2019; clinical trials, including the emergence of serious adverse effects, may delay or prevent the development and approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA or comparable foreign regulatory authorities do not approve or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Manufacture of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates are biologics that consist of bacteria and may include other microorganisms. The process of manufacturing our products is complex, highly regulated and subject to multiple risks. The manufacture of our product candidates involves complex processes, including obtaining biological material (human stool) from qualified third-party donors for CP101 and FIN-211. As a result of these complexities, the cost to manufacture our product candidates in particular is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, as our product candidates are developed through early- to late-stage clinical trials towards approval and commercialization, we may make alterations to these products and their method of manufacture and use, including changes to our manufacturing processes, in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently than they did in the past and affect the results of planned clinical trials or other future clinical trials. In such circumstances, the FDA or foreign regulatory authorities may require that we conduct bridging comparability testing or other additional clinical studies to confirm the clinical relevance of prior data. For example, early prototype versions of CP101 were manufactured by investigators at the University of Minnesota using certain different techniques and equipment than we have used and intend to use as we continue to advance CP101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Historically, early versions of CP101 were manufactured using unoptimized processes by third-party research collaborators that we have not used, or do not intend to use, in more advanced clinical trials or commercialization. We have, and may continue to, alter our manufacturing processes, product release criteria, dose strength or dosing regimen, and other aspects of CP101 to optimize it for late-stage clinical trials or commercialization. Although we are working to develop commercially viable processes, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability of reagents or raw materials. As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans. For example, in recent correspondence, the FDA has asked for additional information regarding the validation package for one of our release tests, which is utilized for both CP101 and FIN-211; that validation package will need to be reviewed by the FDA before we are able to proceed with enrollment in PRISM4, which could delay the trial. If we receive additional questions from the FDA regarding the validation package, the timelines for our trials could be further delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are still in the process of developing and scaling-up our manufacturing processes and quality systems for certain of our other product candidates. These products contain proprietary bacterial strains that have never been manufactured in a scale sufficient for use in a clinical trial or for commercialization. We can make no assurances that we will be able to manufacture these products, or components of these products, in a cost effective manner or at the level required for clinical trials or commercialization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we plan in the future to conduct one or more clinical trials outside the United States. Jurisdictions outside of the United States, including Europe, have distinct regulatory requirements that our facilities, materials, manufacturing processes, and quality systems may not satisfy. If we are unable to meet required standards, we may be unable to conduct trials or commercialize our product candidates in certain jurisdictions outside of the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third-party donors of biological material to manufacture certain product candidates such as CP101 and FIN-211, and if we do not obtain an adequate supply of acceptable material from those qualified donors, the clinical and commercial supply of these product candidates may be adversely impacted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use human stool from extensively-screened third-party donors as starting material in the manufacture of several of our product candidates, including CP101 and FIN-211. The stool that is received from these third-party donors is tested for certain pathogens and processed without the use of replication or culturing to form an active ingredient in our products. Our ability to manufacture CP101, FIN-211 and other product candidates using donor-derived materials at clinical and commercial scale depends on obtaining a consistent and adequate supply of stool material. We are not currently aware of alternative sources of supply that would be sufficient to meet our clinical and commercial needs. Therefore, any delay of our ability to manufacture using donor-derived materials could significantly impact our clinical timelines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the past, we have relied on stool donor programs operated by OpenBiome and the University of Minnesota for the supply of human stool material used in the manufacture of our product candidates, including CP101. In connection with the Asset Purchase Agreement with OpenBiome, we have licensed certain technology and have acquired assets that enable our internal stool donor program in support of the clinical development and commercialization of CP101 and our other product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stool donor program on which we rely involves the screening of potential human stool donors using defined screening criteria. Only a small fraction of potential human donors that we will evaluate will be able to meet these criteria and enroll in our donor program. There can be no assurances that we will have enough qualified third-party donors within our donor program, or enough material derived from donors in our program, to meet clinical or commercial demand. We may also have difficulty enrolling and retaining enough qualified donors in our donor program. If we are unable to enroll a sufficient number of qualified donors in our stool donor program, or if we are unable to retain donors within our program or receive enough stool from donors within our program, our ability to manufacture CP101, FIN-211 and other product candidates may be delayed or adversely impacted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the stool donor program on which we rely involves extensive screening of potential entrants, we can make no assurances that it will screen for, or be able to identify, all diseases and conditions that could adversely affect the health of persons who use or consume products that contain biological material from those donors. The screening processes may fail to identify certain existing diseases or conditions in the humans that we evaluate for entry into our donor program. In addition, donors enrolled in our donor program may develop new diseases or conditions, or the worsening of pre-existing or underlying diseases or conditions, that we may fail to identify. The use of stool material from a third-party donor who has a certain condition or disease may result in material adverse effects to our business, including supply chain disruptions resulting from the recall or destruction of affected starting material or product, or adverse reactions in patients who use or consume products derived from that donor. For example, in March 2020, the FDA required retrospective testing and the recall and destruction of the affected product after OpenBiome, a supplier of human stool material, reported occurrences of enteropathogenic E. coli and shigatoxin-producing E. coli in FMT recipients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we extensively test the biological materials that we receive from qualified third-party donors or suppliers for the presence of certain pathogens and other microorganisms, there can be no assurances that we will detect all pathogens and other microorganisms in our products, which could result in an adverse reaction in persons who use or consume our products. Our testing processes may fail to identify pathogens in the stool that we receive from donors within our donor program, or such testing processes may be unacceptable to regulatory authorities. For example, in the clinical hold letter we received on February 24, 2022 for our CP101 IND, the FDA requested more information with respect to, among other things, our SARS-CoV-2 testing methods. In addition, the emergence of new pathogens could affect the availability of stool donors, or require us to develop new testing processes to test both new and existing material and product, either of which could cause delays or shortage in the manufacture and distribution of our products. The presence of pathogens in the stool material that we receive from third-party donors may also result in adverse reactions in persons who use or consume products that are derived from that material. Additionally, regulatory or industry pathogen testing requirements may change over time, possibly making it more challenging to locate qualified donors, or requiring the development and validation of new test methods, which could adversely affect our ability to collect adequate supply and increase costs related to product manufacturing. For example, screening for enteropathogenic E. coli has resulted in exclusion of otherwise qualified donors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We operate our own manufacturing facility for certain product candidates, which requires significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recently completed construction of our manufacturing facility to support the manufacture of our product candidates, including CP101 and FIN-211, for use in clinical development or for potential commercial sale. We may not be able to manufacture enough product at this facility to meet the clinical and commercial demand for our product candidates. We also cannot be sure that the manufacturing processes employed by us will result in products that will be safe and effective</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or that we will be able to demonstrate to the satisfaction of the FDA or other regulatory authorities that our quality management systems are sufficient to ensure such results. Moreover, we may run into delays or cost overruns in connection with the qualification and validation of our manufacturing facility, including the transfer of technology into that recently completed facility, which would increase our net losses and have an adverse effect on our stockholders&#x2019; equity and working capital. For example, the FDA may find deficiencies in our technology transfer process or require one or more comparability studies of our drug product using test methods that we would need to develop. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates, if approved. There is a lack of third-party CMOs willing or able to manufacture whole community product candidates like CP101 and FIN-211. If we are unable to successfully manufacture and process our product candidates, we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">might not be able to produce some of our products at a level that would be sufficient to meet our clinical and commercial needs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacture of microbiome therapeutics is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of products derived from human biological material often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of raw materials or in our manufacturing facilities or manufacturing facilities operated by our third-party suppliers, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations will remain subject to review and oversight by the FDA and the FDA could object to our use of our manufacturing facility. Prior to licensure to manufacture our product candidates, we must first receive approval from the FDA, which we may never obtain. Such approval may be contingent on a pre-approval inspection of our manufacturing facility. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may fail to manage the logistics of storing and shipping our product candidates, particularly as our product candidates are required to be stored at certain pre-defined refrigerated temperatures. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients. We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to develop and commercialize our product candidates would be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Commercialization of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining regulatory approval for our current or future product candidates for our initial or potential additional indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never obtained regulatory approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned BLAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any product candidates. If the FDA does not approve any of our planned BLAs, it may require that we conduct additional costly clinical, nonclinical or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any BLA or other application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing our current or future product candidates, generating revenues and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any BLA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently have no marketing and sales organization and have no experience as a company in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing, and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have received Fast Track designation for CP101 for the prevention of recurrent CDI, and we may seek Fast Track designation for our other product candidates. Even if received, Fast Track designation may not actually lead to a faster review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received Fast Track designation for CP101 for the prevention of recurrent CDI, and we may seek Fast Track designation for our other product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for Fast Track designation for a particular indication. There is no assurance that the FDA will grant this status to any of our other proposed product candidates. If granted, Fast Track designation makes a product eligible for more frequent interactions with FDA to discuss the development plan and clinical trial design, as well as rolling review of the application, which means that the company can submit completed sections of its marketing application for review prior to completion of the entire submission. Marketing applications of product candidates with Fast Track designation may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide any assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation at any time if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have received Breakthrough Therapy designation for CP101 for the prevention of recurrent CDI, and we may seek Breakthrough Therapy designation for our other product candidates. Even if received, Breakthrough Therapy designation may not actually lead to a faster review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received Breakthrough Therapy designation for CP101 for the prevention of recurrent CDI, and may, in the future, apply for Breakthrough Therapy designation for other product candidates in the United States. A Breakthrough Therapy product candidate is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that such product candidate may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a Breakthrough Therapy product candidate receives: (i) intensive guidance on an efficient drug development program; (ii) intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review; and (iii) a rolling review process whereby the FDA may consider reviewing portions of a BLA before the sponsor submits the complete application. Product candidates designated as breakthrough therapies by the FDA may be eligible for priority review if supported by clinical data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even though CP101 has been designated as a Breakthrough Therapy product candidate, the FDA may later decide that it no longer meets the conditions for designation or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential product candidates. These decisions may prove to have been wrong and may adversely affect our ability to develop our own programs, our attractiveness as a commercial partner and may ultimately have an impact on our commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. For example, we have decided to pause development of CP101 in HBV, which we believe will allow us to maximize our working capital available for investment in our wholly-owned recurrent CDI and ASD programs. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for our lead product candidate, our business, financial condition and results of operations could be materially adversely affected and may cause us to reprioritize our planned trials and use of funds for planned trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals and others in the medical community.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The use of microbiome therapies is a recent development and may not become broadly accepted by physicians, patients, hospitals and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the clinical indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">physicians, hospitals and patients considering our product candidates as a safe and effective treatment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential and perceived advantages of our product candidates over current or future alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to demonstrate the advantages of our product candidates over other microbiome therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects for other microbiome medicines and public perception of other microbiome medicines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product labeling or product insert requirements of the FDA or comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction of our product candidates as well as competitive products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s policy of enforcement discretion for FMT materials to treat CDI not responding to standard therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment and the availability of testing for patient selection;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing of our products, if approved, and the availability of adequate coverage and reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our product candidates are approved for commercialization but fail to achieve market acceptance among physicians, patients, hospitals or others in the medical community, we will not be able to generate significant revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, although our product candidates differ in certain ways from other microbiome approaches, SAEs or deaths in other clinical trials involving the microbiome, or in clinical trials involving therapeutic approaches similar to ours, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for our product candidates are smaller than we believe they are, even assuming approval of a product candidate, our business may suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our projections of both the number of people who are affected by diseases within our potential target indications, as well as the subset of these people who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, healthcare utilization databases and market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other drugs that are able to achieve similar or better results that our product candidates. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of microbiome therapies. We are aware of a number of companies focused on developing microbiome therapeutics in various indications. For CP101, we are aware that Seres Therapeutics, Inc. and Rebiotix, Inc. each have a product candidate that has completed Phase 3 trials for recurrent CDI and are pursuing FDA approval to enable subsequent commercialization. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, Rebiotix filed a BLA for RBX-2660, their lead product in recurrent CDI, and Seres has indicated that they plan to file a BLA in 2022.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In addition, we face competition from other therapies which are designed to treat the indications targeted by our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that we will continue to face intense and increasing competition as new treatments enter the market and advanced technologies become available. There can be no assurance that our competitors are not currently developing, or will not in the future develop, products that are equally or more effective or are more economically attractive than any of our current or future product candidates. Competing products may gain faster or greater market acceptance than our products, if any, and medical advances or rapid technological development by competitors may result in our product candidates becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. If we or our product candidates do not compete effectively, it may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If either we or our collaborators obtain approval to commercialize any of our product candidates outside of the United States, a variety of risks associated with international operations could adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are approved for commercialization, we may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States. We expect that we would be subject to additional risks related to international pharmaceutical operations, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries, including the potential time and expense associated with establishing foreign manufacturing processes or facilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced protection for intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign reimbursement, pricing and insurance regimes;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability, or public health emergencies, such as the ongoing COVID-19 pandemic and related shelter-in-place orders, travel, social distancing and quarantine policies, boycotts, curtailment of trade and other business restrictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">greater difficulty with enforcing our contracts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased complexity and costs if foreign regulators require that certain manufacturing facilities, such as a stool donor program facility, be operated locally; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As an organization, we have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by individual countries in Europe with which we may need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and adequate reimbursement may not be available for CP101, FIN-211 or any other current or future product candidates, which could make it difficult for us to sell profitably or at all, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations, pharmacy benefit management organizations, and other private health insurers. Microbiome therapy is a novel therapeutic approach and neither we nor, to our knowledge, any other company has received regulatory approval for a therapeutic based on this approach. We cannot be certain that third-party payors will provide sufficient reimbursement for any product candidates that we commercialize, if approved. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#x2019;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Obtaining positive Medicare coverage and reimbursement will be critical to the commercial success of CP101, if approved, as a large portion of the patient population with CDI are Medicare beneficiaries. Even if favorable coverage and reimbursement status is attained for CP101 or any current or future product candidate for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Thus, if we are not able to secure coverage and Medicare reimbursement at sufficient levels, we may not be able to reach our intended target market for CP101, if approved, which would adversely affect our revenue and profits. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. We expect that the price of CP101, if approved, will be substantial, so the availability of coverage and reimbursement from third-party payors will be necessary to make CP101 assessable to patients. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize CP101 or any other current or future product candidates that we develop. Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we are successful in obtaining regulatory approval, commercial success of any approved products will also depend in large part on the availability of insurance coverage and adequate reimbursement from third-party payors, including government payors, such as the Medicare and Medicaid programs, and managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost-effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. If government and other healthcare payors were not to provide adequate insurance coverage and reimbursement levels for one any of our products once approved, market acceptance and commercial success would be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biopharmaceutical products. While we currently have no products that have been approved for commercial sale, from 2017 to 2019, we manufactured FMT materials, produced to specifications defined by OpenBiome, that were and may still be distributed and sold by OpenBiome for use under its interpretation of the FDA&#x2019;s policy of enforcement discretion for CDI not responding to standard therapies and for use in clinical research. This past use, as well as the current and future use of product candidates by us and our collaborators in clinical trials, and the potential sale of any approved products in the future, may expose us to liability claims. The FDA may not agree with OpenBiome&#x2019;s interpretation or application of the FDA&#x2019;s enforcement discretion policy to its product distribution activities, including its distributions to clinical sites without an IND in place with the FDA. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a product, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our products due to negative public perception;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants or difficulties in recruiting new trial participants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to defend or settle the related litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenues from product sales; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize any of our product candidates, if approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we believe we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs, and other interactions with healthcare professionals. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for, or to induce, either the referral of an individual for, or the purchase, lease, order or arrangement for or recommendation of the purchase, lease, order or arrangement for any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, and formulary managers, on the other. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. A person does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, signed into law in 2010, provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal civil and criminal false claims laws, including, without limitation, the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and the federal Civil Monetary Penalty Law that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from the federal government, including Medicare, Medicaid and other government payors, that are false or fraudulent or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#x201c;any request or demand&#x201d; for money or property presented to the United States federal government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#x2019; marketing of products for unapproved, and thus non-reimbursable, uses;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), or knowingly and willfully falsifying, concealing or covering up, by any trick or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which impose, among other things, requirements on health plans, healthcare clearinghouses and certain healthcare providers, known as &#x201c;covered entities&#x201d;, and their respective HIPAA &#x201c;business associates&#x201d;, which are independent contractors that perform certain services for or on behalf of covered entities involving the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal transparency laws, including the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to: (i) payments or other &#x201c;transfers of value&#x2019;&#x2019; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, and (ii) ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous state and foreign laws and regulations; state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action taken against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials that could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If approved, our product candidates will be regulated as biologics, and thus may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that our product candidates will be regulated as biological products. The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#x2019;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the United States pharmaceutical industry. The ACA, among other things: (i) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; (ii) expanded the entities eligible for discounts under the 340B drug pricing program; (iii) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; (iv) expanded the eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability; (v) created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected; (vi) created a new Medicare Part D coverage gap discount program in which, as a condition of coverage of its products under Medicare Part D, manufacturers must now agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of 2019); (vii) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (viii) established the Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been executive, judicial and congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued  the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or congressional challenges in the future. It is unclear how any such challenges and the healthcare reform efforts of the Biden Administration will impact the ACA and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2031, unless additional congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law,  which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These laws may result in additional reductions in Medicare, Medicaid and other healthcare funding, which could have an adverse effect on customers for our product candidates, if approved, and, accordingly, our financial operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the former Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, former President Trump announced several executive orders related to prescription drug pricing that sought to implement several of the former administration&#x2019;s proposals. As a result, the FDA released a final and guidance rule in September 2020, providing pathway for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020 CMS issued an interim final rule implementing the Most Favored Nation, or MFN, model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinded the MFN model interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, the HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. The Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#x2019;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these requirements will be interpreted and implemented and the extent to which they will impact the FDA&#x2019;s ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA&#x2019;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for CP101, FIN-211 or any other current or future product candidates. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could, among other things, require:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional clinical trials to be conducted prior to obtaining approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes to manufacturing methods;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recalls, replacements, or discontinuance of one or more of our products; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional recordkeeping.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of CP101, FIN-211 or any other current or future product candidates, and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including most recently from December 22, 2018 to January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to U.S. anti-corruption, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to anti-corruption laws, including the U.S. domestic bribery statute contained in 18 U.S.C. 201, the U.S. Travel Act, and the U.S. Foreign Corrupt Practices Act of 1977, as amended. These anti-corruption laws generally prohibit companies and their employees, agents, and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to recipients in the public or private sector. We can be held liable for the corrupt or illegal activities of our agents and intermediaries, even if we do not explicitly authorize or have actual knowledge of such activities. We are also subject to other U.S. laws and regulations governing export controls, as well as economic sanctions and embargoes on certain countries and persons.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. Likewise, any investigation of potential violations of such laws could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials in accordance with applicable regulatory requirements and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with good laboratory practices, or GLPs, as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GLPs and GCPs through periodic inspections of laboratories conducting GLP studies, trial sponsors, principal investigators and trial sites. If we, our investigators or any of our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable, the statistical analysis and clinical meaning of our datasets could be compromised and the FDA or comparable foreign regulatory authorities may limit our ability to include impacted data or require us to perform additional preclinical studies or clinical trials before approving our marketing applications. For example, we identified GCP compliance issues at two clinical trial sites that participated in our PRISM3 study. In consultation with the FDA, we terminated those two sites and excluded data from the trial participants at those sites. While we monitor our clinical trial sites, we cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our preclinical studies or clinical trials comply with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all applicable GLP or GCP regulations. In addition, our clinical trials must be conducted with product, including biologic product, produced in compliance with applicable cGMP regulations. Our failure or the failure of any third parties with whom we may contract comply with these regulations may require us to repeat preclinical studies or clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, these laboratories, investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is noncompliant, fraudulent or substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. Such laboratories, investigators and CROs may make errors while conducting trials or other clinical development activities, which could render any data derived therefrom incorrect or unusable. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if we make a general assignment for the benefit of our creditors or if we are liquidated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or clinical investigators do not successfully carry out their legal, regulatory or contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements, professional standards of integrity or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the integrity or validity of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidate or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved. The development of such product candidates and the commercialization of any products, if approved, could be stopped, delayed or made less profitable if any such third party fails to provide us with sufficient quantities of product candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance. We have not, nor to our knowledge, has any other company, received regulatory approval for a therapeutic based on this approach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently have the infrastructure or capability internally to manufacture all our product candidates for use in the conduct of our preclinical studies and clinical trials or for commercial supply, if our products are approved. We rely on, and expect to continue to rely on, contract manufacturing organizations, or CMOs. Any replacement of our CMOs could require significant effort and expertise because there may be a limited number of qualified CMOs. This could be particularly problematic where we rely on a single-source supplier. Additionally, our current CMOs may fail to manufacture our product candidates or placebo due to technical difficulties or other issues beyond our control. For example, while our CMO has experience manufacturing similar microbial products, FIN-211 contains a specific bacterial strain that our CMO has never manufactured in a scale sufficient for commercialization and which it may be unable to supply in the quantities and at the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rates we anticipate requiring. Furthermore, we have limited stability data for this material, and if we determine that its stability profile is insufficient for our needs, our trials could be delayed and the commercial potential for FIN-211 could be reduced. We can make no assurances that we will be able to manufacture our product candidates, or components of our product candidates, in a cost-effective manner or at the level required for clinical trials or commercialization. Reliance on third-party providers may expose us to more risk than if we were to manufacture our product candidates ourselves. We are dependent on our CMOs for the production of our product candidates in accordance with relevant regulations, such as cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Moreover, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting product development activities that could harm our competitive position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third-party manufacturers may be subject to damage or interruption from, among other things, fire, natural or man-made disaster, disease outbreaks or public health pandemics, power loss, telecommunications failure, unauthorized entry, computer viruses, denial-of-service attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy and similar events. For example, the extent to which COVID-19 may impact our manufacturing and supply chain will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for any of our product candidates, we could experience delays in our research or planned clinical trials or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes who could meet our timelines at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, could significantly delay our preclinical studies, our clinical trials and the commercialization of our products, if approved, which could materially adversely affect our business, financial condition and results of operation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In complying with the applicable manufacturing regulations of the FDA and comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of products and shutting down of production. We and any of these third-party suppliers may also be subject to audits by the FDA and comparable foreign regulatory authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the products could suffer significant interruptions. We face risks inherent in relying on CMOs, as any disruption, such as a fire, natural hazards, vandalism or an outbreak of contagious disease affecting the CMO or any supplier of the CMO could significantly interrupt our manufacturing capability. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as the CMO builds or locates replacement facilities and seeks and obtains necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our current and future collaborations will be important to our business. If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A part of our strategy is to strategically evaluate and, as deemed appropriate, enter into partnerships in the future when strategically attractive, including potentially with major biotechnology or pharmaceutical companies. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our product could change and our costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual property rights held by third parties, and the growth of our business may depend in part on our ability to acquire or in-license these intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we are currently party to a collaboration agreement with Takeda, pursuant to which we have agreed to collaborate in the clinical development of our product candidates TAK-524 for the treatment of ulcerative colitis and FIN-525 for the treatment of Crohn&#x2019;s disease. This and any future collaborations we enter into may pose a number of risks, including, but not limited to, the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not perform their obligations as expected;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our therapeutic collaborators.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a partnership will depend, among other things, upon an assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed partnership and the proposed collaborator&#x2019;s evaluation of a number of factors. These factors may include the design or results of preclinical studies or clinical trials, the likelihood of regulatory approval, the potential</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of any uncertainty with respect to our ownership of technology (which can exist if there is a challenge to such ownership regardless of the merits of the challenge) and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a partnership could be more attractive than the one with us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot offer any assurances about which of our patent applications will issue, the breadth of any resulting patent or whether any of the issued patents will be found to be infringed, invalid and unenforceable or will be threatened by third parties. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing and commercializing a product, including a biosimilar product that would be competitive with one or more of our product candidates. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any of our product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent prosecution process is expensive and time-consuming. We may not be able to prepare, file and prosecute all necessary or desirable patent applications at a commercially reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the protection provided by our patent estate, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not amenable to patent protection. Although we generally require all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed. Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products, if approved, and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">individuals, organizations and systems, our agreements or security measures may be breached, and we may not have adequate remedies for any breach. Also, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA is considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#x2019;s disclosure policies may change in the future. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar non-United States legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent may be extended per approved drug product, and only those claims covering the approved drug product, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be impacted and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, we could lose rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are reliant upon licenses to certain patent rights and proprietary technology for the development of our product candidates, in particular our license agreements with University of Minnesota and Skysong Innovations LLC. These license agreements impose diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations, our licensors may have the right to terminate our licenses, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from such licensor and may face other penalties. Such an occurrence would materially adversely affect our business prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licenses to additional third-party technology and materials that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. We do not control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property relating to our product candidates, and we thus require the cooperation of our licensors and any upstream licensor, including Skysong Innovations LLC and the University of Minnesota, which may not be forthcoming. Therefore, we cannot be certain that the prosecution, maintenance and enforcement of these patent rights will be in a manner consistent with the best interests of our business. If we or our licensor fail to maintain such patents, or if we or our licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future. Further, if we fail to comply with our development obligations under our license agreements, we may lose our patent rights with respect to such agreement on a territory-by-territory basis, which would affect our patent rights worldwide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Termination of our current or any future license agreements would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, intellectual property rights that we in-license in the future may be sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to obtain patents is highly uncertain because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States. Furthermore, the specific content of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the United States Patent and Trademark Office, or USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have owned or licensed or that we might obtain in the future. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States and Europe. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement, in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe the patents for which we have applied. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In certain circumstances it may not be practicable or cost effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. In an infringement proceeding, a court may decide that the patent claims we are asserting are invalid and/or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover the technology in question. Third</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">parties may also initiate legal proceedings against us claiming that our patents are not infringed, invalid and/or unenforceable. For example, on December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, &#34;Rebiotix&#34;), filed a complaint against us in the U.S. District Court for the District of Delaware. The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by us. On February 7, 2022, we filed an answer and counterclaims against Rebiotix for infringement of three of the patents. On March 7, 2022, we filed an amended answer and counterclaims, in which we, together with the Regents of the University of Minnesota (&#x201c;UMN&#x201d;), alleged infringement by Rebiotix of three United States Patents owned by UMN and exclusively licensed to us. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose some, and perhaps all, of the patent protection on our product candidates. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could have a material adverse impact on our business. Moreover, even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patent applications. An unfavorable outcome could require us to cease using the related technology or force us to take a license under the patent rights of the prevailing party, if available. Furthermore, our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A third party may hold intellectual property, including patent rights that are important or necessary to the development and commercialization of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to acquire or obtain a license to such intellectual property from these third parties, and we may be unable to do so on commercially reasonable terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, upon our ability and the ability of future collaborators, if any, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates and technology, including interference proceedings, post grant review and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review before the USPTO or equivalent foreign regulatory authority. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Numerous patents and pending applications are owned by third parties in the fields in which we are developing product candidates, both in the United States and elsewhere. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Foreign courts will have similar burdens to overcome in order to successfully challenge a third party claim of patent infringement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of a patent estate with granted claims in the United States, Japan and China that may impact our competitive position with respect to one of our preclinical product candidates. While we believe that the granted claims may not be valid and that they may be reasonably challenged for validity, there can be no assurance that any such challenge would be successful. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We employ individuals who were previously employed at other biotechnology or biopharmaceutical companies. In addition, we use publications that are subject to copyright, as well as proprietary information and materials from third parties in our research. Some of the information and materials we use from third parties may be subject to agreements that include restrictions on use or disclosure. Although we strive to ensure proper safeguards, we cannot guarantee strict compliance with such agreements, nor can we be sure that our employees, consultants and advisors do not use proprietary information, materials, or know-how of others in their work for us. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#x2019; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patent applications, our future patents, or other intellectual property, including as an inventor or co-inventor. We may be subject to ownership or inventorship disputes in the future arising, for example, from conflicting obligations of consultants, contractors or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed to others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we rely on third parties to manufacture or commercialize our product candidates, or if we collaborate with additional third parties for the development of such product candidates, we may need to, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our trade secrets and other proprietary technology in part by entering into confidentiality agreements with third parties prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing and prosecuting patent applications and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where enforcement rights are not as strong as those in the United States or Europe. These products may compete with our product candidates, and our future patents or other intellectual property rights may not be effective or sufficient defend our rights adequately.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we seek to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and Europe and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property rights, which could make it difficult for us to stop the infringement of our future patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and/or applications and any patent rights we may obtain in the future. Furthermore, the USPTO and various non-United States government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse of a patent or patent application can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patents or patent applications, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to rely on trademarks as one means to distinguish our product candidates, if approved for marketing, from the drugs of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe or otherwise violate our trademarks and we may not have adequate resources to enforce our trademarks. Any of the foregoing events may have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to make products that are similar to or otherwise competitive with our product candidates but that are not covered by the claims of our current or future patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an in-license necessary for the manufacture, use, sale, offer for sale or importation of one or more of our product candidates may be terminated by the licensor;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or future collaborators might not have been the first to make the inventions covered by our issued or future issued patents or our pending patent applications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or in-license may be held invalid or unenforceable as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or in-license may not provide coverage for all aspects of our product candidates in all countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our management team, including Mark Smith, Ph.D., our Chief Executive Officer. Each member of our management team may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. We do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Over the last several years, the challenges of recruiting and retaining employees across the biotechnology industry, and in the Boston area specifically, have increased substantially due to current industry job market dynamics. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may experience difficulties in managing the growth of our organization, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 189 full-time employees, including 156 employees engaged in research and development. As our clinical development and commercialization plans and strategies develop, and as we continue operating as a public company, we may need additional managerial, operational, sales, marketing, financial, legal and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">managing our development efforts effectively, including the clinical trials of CP101, FIN-211 and our other product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing for certain of our product candidates. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our preclinical studies or clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of our product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. The COVID-19 pandemic has generally increased the attack surface available for exploitation, as more companies and individuals work online and work remotely, and as such, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#x201c;hackers&#x201d; hoping to use the recent COVID-19 pandemic to their advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have not experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials by us or our CROs could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, cause us not to comply with federal and/or state breach notification laws and foreign law equivalents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. Security breaches and other inappropriate access can be difficult to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure, such measures may not prevent service interruptions or security breaches that could adversely affect our business and to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce certain of our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and any current and future collaborators may be subject to federal, state, municipal and foreign data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including Section 5 of the Federal Trade Commission Act, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our current or future collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain a large quantity of sensitive information, including confidential business and personal information in connection with the conduct of our clinical trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws, the requirements of which sometimes evolve with amendments, regulations and case law, can be subject to varying interpretations. In addition, new laws regulating privacy and data security continue to be passed in jurisdictions all over the world. In May 2018, a new privacy regime, the General Data Protection Regulation, or the GDPR, took effect in the European Economic Area, or the EEA. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#x201c;adequate&#x201d; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of &#x20ac;20 million or 4% of our consolidated annual worldwide gross revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, within the United States, states regularly adopt new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or the CCPA, on June 28, 2018. This law, which took effect on January 1, 2020, became enforceable by the California Attorney General on July 1, 2020, and has been dubbed the first &#x201c;GDPR-like&#x201d; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. In addition, some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States as other states develop similar laws and we have already seen other states propose laws that are similar to the CCPA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may not develop and you may not be able to resell your shares of our common stock at an attractive price, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to our IPO in March 2021, there was no public market for our common stock. Although our common stock is currently listed on The Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will develop or be sustained. If an active market for our common stock does not develop or is not sustained, it may be difficult for you to sell shares you purchased at an attractive price or at all. An inactive market may also impair our ability to raise capital to continue to fund our operations by selling our common stock and may impair our ability to acquire other companies or technologies by using our common stock as consideration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The market price of our common stock has been and is likely to continue to be volatile and fluctuate substantially, which could result in substantial losses for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock has been and is likely to continue to be volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. The market price for our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors described in this &#x201c;Risk Factors&#x201d; section:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our clinical trials of CP101, FIN-211 or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any delay in our regulatory filings for CP101, FIN-211 or any other current or future product candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including, without limitation, the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information, such as the clinical hold letter we received from the FDA on February 24, 2022 and additional requests from the FDA regarding PRISM4, including a letter from the FDA in March 2022;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse results from, delays in or termination of clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unanticipated serious safety concerns related to the use of CP101, FIN-211 or any other product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unexpected regulatory actions related to the manufacture and testing of CP101, FIN-211 or any other product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in financial estimates by us or by any equity research analysts who might cover our stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditions or trends in our industry;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the market valuations of similar companies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcement by our competitors of regulatory developments or new data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our relationships with our collaborators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investors&#x2019; general perception of our company and our business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruitment or departure of key personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">overall performance of the equity markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trading volume of our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant lawsuits, including patent or stockholder litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general political and economic conditions, including the effects of the ongoing COVID-19 pandemic; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other events or factors, many of which are beyond our control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#x2019; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#x2019;s attention and resources from our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. If at any time we do have equity research analyst coverage, we do not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales of our common stock in the public market could cause the market price of our common stock to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. Many of our existing equity holders have substantial unrecognized gains on the value of the equity they hold, and therefore they may take steps to sell their shares or otherwise secure the unrecognized gains on those shares. We are unable to predict the timing of or the effect that such sales may have on the prevailing market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we have registered the shares of common stock subject to options or other equity awards issued or reserved for future issuance under our 2017 Equity Incentive Plan, as amended, or the 2017 Plan, our 2021 Equity Incentive Plan, or the 2021 Plan, and our 2021 Employee Stock Purchase Plan, or the ESPP. Such shares will be available for sale in the public market subject to vesting arrangements and exercise of options or warrants and the restrictions of Rule 144 in the case of our affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the holders of a significant number of shares of our common stock, or their transferees, have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our executive officers, directors and beneficial owners of 5% or more of our common stock and their respective affiliates beneficially owned greater than 50% of our outstanding common stock. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company&#x201d; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until December 31, 2026 or, if earlier, (i) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (ii) the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#x201c;smaller reporting company,&#x201d; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We incur significant costs and demands upon management as a result of being a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company listed in the United States, we incur significant legal, accounting and other costs. These costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the Securities and Exchange Commission, or SEC, and the Nasdaq Stock Market, or Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#x2019;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commencing with our fiscal year ending December 31, 2022, we must provide a management certification of our internal control over financial reporting in our 2022 Annual Report on Form 10-K, as required by Section 404(a) of the Sarbanes-Oxley Act. This certification will state the responsibility of our management to establish and maintain an adequate internal control structure and procedures for financial reporting and will also contain an assessment of the effectiveness of our internal control over financial reporting. The requirement to provide an internal control over financial reporting certification will require that we incur additional professional fees and internal costs. Furthermore, when we lose our status as an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. Prior to our IPO in March 2021, we have never been required to test our internal control within a specified period, and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may identify weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#x2019;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial statements in a timely manner, which may adversely affect our business, investor confidence in our company and the market value of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. We are not yet required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This assessment will also need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 of the Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we remain an emerging growth company, we intend to take advantage of the exemption permitting us not to comply with the independent registered public accounting firm attestation requirement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, in connection with our IP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">O and in the course of reviewing our 2019 financial statement for our IPO, management and our independent registered public accounting firm identified </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">material weaknesses in our internal control over financial reporting as we did not design and maintain effective review and approval controls over certain transactions and accounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The material weaknesses in our system of internal controls as of December 31, 2019 related to (1) an ineffective control environment, including a lack of sufficient accounting personnel and personnel with financial reporting expertise; (2) ineffective controls over cutoff, recording and classification of certain accounts, and the valuation and recognition of intangible assets acquired in a business combination that occurred in 2017; (3) ineffective risk assessment controls, including those policies and practices that would identify changes in our business practices, which could significantly impact our consolidated financial statements and system of internal controls; and (4) ineffective monitoring of controls related to the financial close and reporting process. As a result, there were adjustments required in connection with closing our books and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">records and preparing our 2019 financial statements. During 2021, we hired additional finance and accounting personnel with appropriate expertise to perform specific functions and build out our financial infrastructure, implemented improved processes and internal controls and further developed and documented our accounting policies and financial reporting procedures, including ongoing senior management review and audit committee oversight. Management concluded that, as a result of the implementation of these actions, the previously-identified material weaknesses have been remediated as of December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in U.S. tax law could adversely affect our financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. tax laws on an investment in our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We might not be able to utilize a significant portion of our net operating loss carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to generate significant federal and state net operating loss, or NOL, carryforwards in the future. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs, or the Tax Act, as modified by the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, federal NOLs incurred in taxable years beginning after December 31, 2017 and in future taxable years may be carried forward indefinitely, but the deductibility of such federal NOLs incurred in the taxable year beginning after December 31, 2020 is limited. It is uncertain how various states will respond to the Tax Act and CARES Act. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#x201c;ownership change,&#x201d; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. The completion of our IPO in March 2021, together with private placements and other transactions that have occurred since our inception, may trigger such an ownership change pursuant to Section 382. We have not yet completed a Section 382 analysis. We may experience ownership changes as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should not rely on an investment in our common stock to provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are provisions in our certificate of incorporation and bylaws that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change of control was considered favorable by you and other stockholders. For example, our board of directors will have the authority to issue up to 10,000,000 shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change of control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change of control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any derivative claim or cause of action brought on our behalf;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any claim or cause of action asserting a breach of fiduciary duty;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any claim or cause of action against us arising under the Delaware General Corporation Law;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any claim or cause of action arising under or seeking to interpret our amended and restated certificate of incorporation, or our amended and restated bylaws; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any claim or cause of action against us that is governed by the internal affairs doctrine.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation will further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Properties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our principal office is located in Somerville, Massachusetts, where we lease approximately 36,285 square feet of research and development, laboratory and office space under a lease that terminates in 2026. Additionally, we entered into a ten-year lease in August 2021 for approximately 61,139 square feet of office and laboratory space in Charlestown, Massachusetts. The lease commences in 2022 upon completion of construction of the leased space (see Note 5). We believe that these facilities will be adequate for our near-term needs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal Proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, &#x201c;Rebiotix&#x201d;) filed a complaint against us in the U.S. District Court for the District of Delaware. The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by us: U.S. Patent Nos. 10,675,309 (the &#x201c;&#x2018;309 patent&#x201d;); 10,463,702 (the &#x201c;&#x2018;702 patent&#x201d;); 10,328,107 (the &#x201c;&#x2018;107 patent&#x201d;); 10,064,899; 10,022,406; 9,962,413; and 9,308,226. On February 7, 2022, we filed an answer and counterclaims against Rebiotix for infringement of the &#x2019;107, &#x2019;702, and &#x2019;309 patents. On March 7, 2022, we filed an amended answer and counterclaims, in which we, together with the Regents of the University of Minnesota (&#x201c;UMN&#x201d;), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to us: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012. The U.S. District Court for the District of Delaware set a trial date for a 5-day trial beginning on May 20, 2024. The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock trades under the symbol &#x201c;FNCH&#x201d; on the Nasdaq Global Select Market and has been publicly traded since March 19, 2021. Prior to this time, there was no public market for our common stock. On March 24, 2022, the closing price of our common stock on The Nasdaq Global Select Market was $5.19 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 24, 2022, there were approximately 77 stockholders of record of shares of our common stock, o</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ne of which is Cede &amp; Co., a nominee for Depository Trust Company, or DTC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the shares of common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are considered to be held of record by Cede &amp; Co. as one stockholder.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividends</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings for the operation and expansion of our business and, therefore, we do not anticipate declaring or paying cash dividends in the foreseeable future. The payment of dividends will be at the discretion of our board of directors and will depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements, any limitations on payment of dividends present in any future debt agreements and other factors that our board of directors may deem relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchase of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7_mda"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Manag</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ement&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section titled &#x201c;Risk Factors&#x201d; set forth in Part I, Item 1A of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#x201c;Special Note Regarding Forward-Looking Statements.&#x201d; You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Our Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. We believe that our differentiated platform, rich pipeline and the broad therapeutic potential of this new field of medicine position us to transform care for a wide range of unmet medical needs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, or CDI. In June 2020, we reported positive topline data from our Phase 2 placebo-controlled clinical trial of CP101 for the prevention of recurrent CDI, which we refer to as the PRISM3 trial, and in November 2021, we reported positive topline data from our open-label, Phase 2 clinical trial of CP101 for the prevention of recurrent CDI, which we refer to as the PRISM-EXT trial. We have designed a Phase 3 clinical trial, which we refer to as the PRISM4 trial, to serve as our second pivotal trial of CP101 for the prevention of recurrent CDI. On March 1, 2022, we announced that enrollment in PRISM4 was paused following receipt of a clinical hold letter on February 24, 2022 from the U.S. Food and Drug Administration, or the FDA, in connection with our investigational new drug application, or IND, for CP101, requesting additional information regarding our SARS-CoV-2 donor screening protocols, including, among other things, that we address the risk of SARS-CoV-2 transmission in the informed consent process, additional detail on how samples are shipped to the vendor performing the SARS-CoV-2 testing of the donor material and how inconclusive test results will be handled. We are also preparing to initiate a Phase 1b clinical trial of FIN-211 in autism spectrum disorder, or ASD; however, because FIN-211 includes donor-derived components, the clinical hold related to our IND for CP101 will also delay initiation of our clinical trial in ASD. We plan to manufacture additional lots of CP101 and FIN-211 to satisfy the FDA's requests related to SARS-CoV-2 screening and testing. We are currently evaluating the extent of the delay the clinical hold and related manufacturing activities will have on the timing for our clinical trials in CDI and ASD, which we expect to be at least one quarter; we describe the clinical hold and related matters further above in the section entitled &#x201c;Item 1. Business--Our Clinical Programs&#x201d;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following a strategic review of our pipeline and business, we announced in March 2022 the decision to pause the development of CP101 for the treatment of chronic hepatitis B virus, or HBV. We believe this decision will allow us to maximize our working capital available for investment in our wholly-owned recurrent CDI and ASD programs. We continue to partner with Takeda on the development of targeted microbiome therapeutics for inflammatory bowel disease. We believe that development of our targeted microbiome therapeutics, which are composed of strains grown from master cell banks, is not affected by the clinical hold.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have focused primarily on developing and progressing our product candidates through clinical development, organizing and staffing our company, research and development activities, establishing and protecting our intellectual property portfolio, including for our Human-First Discovery platform, and raising capital. We do not have any product candidates approved for sale and have not generated any revenue from product sales. Since our inception, we have funded our operations primarily with proceeds from the IPO, the sale of convertible preferred stock and from collaboration revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 12, 2021, we effected a 1-for-14.444 reverse stock split of our issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as effected a proportional adjustment to the existing conversion ratios for our redeemable convertible preferred stock. All historical share and per share information shown herein and in our audited financial statements and related notes have been retroactively adjusted to give effect to the reverse stock split.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2021, we completed an IPO in which we issued and sold 7,500,000 shares of our common stock at a public offering price of $17.00 per share, resulting in aggregate gross proceeds of $127.5 million. On April 20, 2021, we issued and sold 192,877 additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, at a public offering price of $17.00 per share, for aggregate gross proceeds of $3.3 million. Inclusive of the underwriters&#x2019; option to purchase additional shares, we received approximately $118.8 million in net proceeds from the IPO after deducting underwriting discounts and commissions and offering costs. Upon completion of the IPO, all 31,253,609 shares of outstanding redeemable convertible preferred stock automatically converted into 31,253,609 shares of common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have incurred significant operating losses. Our net losses were $58.2 million and $39.3 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $161.0 million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue the research and development of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate clinical trials for, or additional preclinical development of, our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">further develop and refine the manufacturing processes for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek regulatory and marketing authorizations for any of our product candidates that successfully complete development; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to identify and validate additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquire or license other product candidates, technologies or biological materials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">make milestone, royalty or other payments under any current or future license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain, maintain, protect and enforce our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to attract and retain new and existing skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incur lease and construction expenses in connection with the expansion of our corporate headquarters;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">create additional infrastructure to support our operations as a public company, and incur increased legal, accounting, investor relations and other expenses; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience delays or encounter issues with any of the above. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will not generate any revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result, we will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and, if any of our product candidates are approved, proceed to commercialization. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain funding, we will be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. Although we continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our existing cash and cash equivalents of $133.5 million as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into mid-2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#x201c;&#x2014;Liquidity and Capital Resources.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Business Update</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the ongoing global COVID-19 pandemic, we established a cross-functional task force and have implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business, including our clinical trials. We have taken measures to secure our research and development activities, while work in laboratories and facilities has been organized to reduce risk of COVID-19 transmission. The extent of the impact of the COVID-19 pandemic, including variants of COVID-19, on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak, including with respect to variants of the virus, and its impact on our clinical trial enrollment, trial sites, contract research organizations, or CROs, contract manufacturing organizations, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. Given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, our business, financial condition and results of operations ultimately could be materially adversely affected. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Our Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no products approved for commercial sale. We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of licensed products for the foreseeable future. Our revenue to date has been generated primarily through collaboration and license agreements. We recognize revenue over our expected performance period under each agreement. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreement and any additional collaborations that we may enter into in the future, and any collaboration revenue we generate will fluctuate from period to period as a result of the timing and amount of milestones and other payments. To date, we have not received any royalties under our collaboration agreement with Takeda Pharmaceutical Company Limited, or Takeda. However, during the year ended December 31, 2020, we received royalties in the aggregate of $0.3 million pursuant to our 2019 Asset Purchase and License Agreement, or APL Agreement, with OpenBiome, which was terminated in November 2020. We will continue to earn royalties under the OpenBiome Agreement based on sales of FMT materials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and License Agreement with Takeda</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, we entered into a research collaboration and exclusive license agreement, or the Takeda Agreement, with Takeda, pursuant to which we granted Takeda a worldwide, exclusive license, with the right to grant sublicenses, under our rights in certain patents, patent applications and know-how to develop, have developed, manufacture, have manufactured, make, have made, use, have used, offer for sale, sell, have sold, commercialize, have commercialized and import our microbiome therapeutic candidate TAK-524, for the prevention, diagnosis, theragnosis or treatment of diseases in humans. We subsequently amended and restated the Takeda Agreement in October 2019 to provide a similar worldwide, exclusive license to a second microbiome therapeutic candidate, FIN-525. We amended the Takeda Agreement in August 2021 to transition primary responsibility for further development and manufacturing activities with respect to TAK-524 from us to Takeda in accordance with a transition plan, and Takeda will assume sole responsibility for regulatory matters with respect to TAK-524. In November 2021, we amended the Takeda Agreement to enable us to carry out certain FIN-525 preliminary evaluation activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with entry into the Takeda Agreement, we received a one-time, upfront payment from Takeda in the amount of $10.0 million. Additionally, we received $4.0 million in the aggregate for the achievement of certain development milestones for TAK-524 therapeutic products and are entitled to receive up to $176.0 million in the aggregate, for the achievement of specified development, regulatory and commercial sale milestones for TAK-524 therapeutic products. We are entitled to receive up to $177.7 million in the aggregate, for the achievement of specified development, regulatory and commercial sale milestones for FIN-525 therapeutic products, subject, to certain specified reductions based upon the nature of the FIN-525 product and certain additional milestones to be negotiated by the parties. We are also entitled to receive up to $10.0 million for the first diagnostic product for each of TAK-524 and FIN-525, subject to certain reductions in the event that Takeda uses a third party to develop such diagnostic products. None of these milestones were impacted by the amendments to the Takeda Agreement noted above. Revenue under the Takeda Agreement is recognized as our research and development services are provided and is recorded as collaboration revenue on our consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreements with OpenBiome</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have historically collaborated with OpenBiome under several agreements related to, among other things, the license of various technology and intellectual property rights, and the supply of certain materials, as further described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2017, we entered into the Quality System and Supply Agreement, or QSS Agreement, with OpenBiome, which was subsequently amended in September 2017 and was partially terminated in February 2019. Under the QSS Agreement, OpenBiome granted us an exclusive license, eligible for sublicense, of certain OpenBiome technology and intellectual property. Additionally, we acquired certain assets of OpenBiome for use in manufacturing and supplying product. The QSS Agreement allowed us to use the licensed OpenBiome technology and intellectual property for our own research and development efforts in exchange for up to $27.5 million in milestone payments associated with development and commercialization efforts. We were responsible for providing support to OpenBiome related to manufacturing product, produced to OpenBiome&#x2019;s specifications, which has been included as service revenue in our consolidated statements of operations. Revenue under the QSS Agreement was recorded as either contract manufacturing revenue or royalty revenue in our consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 19, 2020, we entered into the LMIC License Agreement, or the LMIC Agreement, with OpenBiome, pursuant to which we granted OpenBiome a non-exclusive royalty-bearing license, with the right to grant sublicenses, under certain patents, patent applications, and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from stool from a stool donor source without the use of culturing or replication, or certain natural products. The license granted to OpenBiome excludes a license under our intellectual property to exploit a lyophilized Natural Product (such as CP101) where processed stool is lyophilized. The only consideration provided to us under the LMIC Agreement is in the form of future royalties on net sales of these products, which are not currently commercially viable. We are entitled to receive tiered royalties on net sales of certain products, ranging from mid-single digit to low second decile digits on a product-by-product and country-by-country basis. We did not recognize any revenue related to the LMIC Agreement for the years ended December 31, 2021 and 2020, as there are currently no products available for sale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also on November 19, 2020, we entered into an asset purchase agreement with OpenBiome, or the OpenBiome Agreement, the effect of which was to terminate certain existing agreements with OpenBiome and internalize some of the functions for which we have previously relied on OpenBiome. Pursuant to the OpenBiome Agreement, we acquired certain biological samples and obtained a license to certain OpenBiome technology and, upon closing of the transaction, which occurred March 1, 2021, we acquired certain additional assets, including biological samples, capital equipment and contracts. As of December 31, 2021, we have made payments of $5.0 million to OpenBiome related to the OpenBiome Agreement, which is the full amount agreed upon. We are also required to pay certain milestones up to $26.0 million upon the occurrence of certain research and development events, regulatory approvals, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upfront, milestone and maintenance fees incurred under license, acquisition and other third-party agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs of laboratory supplies and acquiring, developing and manufacturing study materials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs of outside consultants, including their fees and related travel expenses engaged in research and development functions. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we initiate and conduct clinical trials for our product candidates and continue to discover and develop additional product candidates. If any of our product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. There are numerous factors associated with the successful commercialization of any product candidates we may develop in the future, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development program and plans. We do not allocate certain employee-related costs, external costs directly related to our Human First Discovery platform, and other indirect costs to specific research and development programs because these costs are deployed across multiple product programs under development and, as such, are classified as costs of our platform research.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and potential commercialization of our product candidates and expand our corporate headquarters. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Total Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gain on Extinguishment of PPP Loan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on extinguishment of PPP Loan relates to the forgiveness of our PPP Loan, under the Paycheck Protection Program, or the PPP, of the CARES Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income primarily consists of interest earned on our cash and cash equivalents. Our interest income has not been significant due to low interest earned on cash balances related to our sweep account.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gain (Loss) on Disposal of Fixed Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on disposal of fixed assets relates to the gain we realized when we sold certain lab equipment during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other (Expense) Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net primarily consists of realized gains and losses on foreign exchange.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.133%;"></td>
    <td style="width:1.529%;"></td>
    <td style="width:1.79%;"></td>
    <td style="width:14.421%;"></td>
    <td style="width:1.193%;"></td>
    <td style="width:1.529%;"></td>
    <td style="width:1.79%;"></td>
    <td style="width:14.421%;"></td>
    <td style="width:1.193%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">REVENUE:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,376</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalties revenue from related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,719</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OPERATING EXPENSES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(57,279</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(33,144</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(21,238</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(14,011</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(78,517</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(47,155</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(59,985</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(39,436</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OTHER INCOME, NET:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on extinguishment of PPP Loan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,827</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain (loss) on disposal of fixed assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(13</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(52</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,825</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(58,160</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(39,341</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue of $18.5 million and $7.7 million for the years ended December 31, 2021 and 2020, respectively, primarily consisted of collaboration revenue earned under the Takeda Agreement. Our collaboration revenue increased by $11.2 million in 2021 primarily due to our completion of the performance obligation under the Takeda Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses for the years ended December 31, 2021 and 2020 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.089%;"></td>
    <td style="width:1.243%;"></td>
    <td style="width:1.778%;"></td>
    <td style="width:11.684%;"></td>
    <td style="width:0.746%;"></td>
    <td style="width:1.243%;"></td>
    <td style="width:1.778%;"></td>
    <td style="width:11.684%;"></td>
    <td style="width:0.746%;"></td>
    <td style="width:1.243%;"></td>
    <td style="width:1.778%;"></td>
    <td style="width:11.809%;"></td>
    <td style="width:1.181%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Increase<br />(Decrease)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CDI (CP101)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,779</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,841</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3,062</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inflammatory Bowel Diseases (TAK-524 and FIN-525)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,328</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,610</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,282</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Autism Spectrum Disorder (ASD) (FIN-211)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,842</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,164</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,678</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hepatitis B (HBV) (CP101)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,172</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">737</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,435</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Platform</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,593</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,063</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,530</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unallocated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,565</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">729</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,836</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,279</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,144</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,135</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses for the year ended December 31, 2021, were $57.3 million, as compared to $33.1 million for the year ended December 31, 2020.  The increase of $24.1 million in research and development expense for fiscal year 2021 included a $20.5 million increase in our platform related costs, which is primarily driven by a $10.4 million increase in personnel costs, a $4.4 million increase in manufacturing related expenses, a $1.9 million increase in external costs, and a $1.4 million increase in donor related costs. With the execution of the OpenBiome Agreement in the first quarter of 2021, we enhanced our internal manufacturing and platform research capabilities, which drove an overall increase in platform related costs, as we continue to build our platform and prepare for the future development of commercial supply needs. Additionally, there was a $3.7 million increase in expenses related to the expansion and development of our ASD program driven by a $2.1 million increase in external costs and a $1.0 million increase in personnel costs. The change also</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">included a $2.4 million increase in expenses related to the expansion and development of our HBV program driven by a $1.1 million increase in personnel costs and $0.8 million in contract manufacturing costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This increase was offset by a $3.1 million decrease in costs related to our CDI program, driven by a $1.2 million decrease in external costs, as we brought more of our development activities in-house upon execution of the OpenBiome Agreement, as well as a $1.0 million decrease in personnel related costs. Additionally, we had a $1.3 million decrease in IBD program expenses driven primarily by personnel costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our general and administrative expenses for the years ended December 31, 2021 and 2020 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.214%;"></td>
    <td style="width:1.243%;"></td>
    <td style="width:1.766%;"></td>
    <td style="width:11.662%;"></td>
    <td style="width:0.734%;"></td>
    <td style="width:1.243%;"></td>
    <td style="width:1.766%;"></td>
    <td style="width:11.662%;"></td>
    <td style="width:0.734%;"></td>
    <td style="width:1.243%;"></td>
    <td style="width:1.766%;"></td>
    <td style="width:11.787%;"></td>
    <td style="width:1.181%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Increase<br />(Decrease)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel expenses (including stock-based compensation)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,729</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,041</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,688</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facilities and supplies</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">327</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">581</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(254</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,459</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,479</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,980</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,723</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">910</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,813</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,238</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,011</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,227</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses were $21.2 million for the year ended December 31, 2021, as compared to $14.0 million for the year ended December 31, 2020. The increase of $7.2 million for fiscal year 2021 was primarily due to a $2.8 million increase in other expenses, a $2.7 million increase in personnel expenses, and a $2.0 million increase in legal and professional fees. The increase in other expenses is primarily related to directors and officers insurance costs, while the increase in personnel expenses is related to an increase in headcount to support our operational growth. The increase in professional fees is related to our transition to a public company in March 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income, net was $1.8 million for the year ended December 31, 2021, compared to $0.1 million for the year ended December 31, 2020. The increase of $1.7 million was primarily due to the forgiveness of the PPP Loan in full in the amount of $1.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have not recognized any product revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. We have funded our operations primarily through equity financings and from collaboration revenue. We have raised an aggregate of approximately $177.0 million from the sale of convertible preferred stock and $14.0 million in collaboration revenue from the upfront payment and milestone payments received under our collaboration agreement. In March 2021, we completed our IPO whereby we sold an aggregate of 7,500,000 shares of our common stock. In April 2021, we sold an additional 192,877 shares of our common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, at a public offering price of $17.00 per share, for aggregate gross proceeds of $3.3 million. In aggregate, we received approximately $118.8 million in net proceeds related to our IPO after deducting $9.2 million of underwriting discounts and commissions and $2.9 million of offering expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, we received proceeds of $1.8 million from the PPP Loan. We used the PPP Loan to retain current employees, maintain payroll and make lease and utility payments. On May 8, 2021, we received notice from the SBA that the entirety of the PPP Loan we received was forgiven. Accordingly, we are no longer required to repay the $1.8 million in principal and approximately $19,000 in accrued interest borrowed under the PPP Loan. Gain on extinguishment of the PPP Loan is recorded in other income on the consolidated statements of operations for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our cash flows for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.829%;"></td>
    <td style="width:1.355%;"></td>
    <td style="width:1.791%;"></td>
    <td style="width:12.808%;"></td>
    <td style="width:1.194%;"></td>
    <td style="width:1.355%;"></td>
    <td style="width:1.791%;"></td>
    <td style="width:12.683%;"></td>
    <td style="width:1.194%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(67,133</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(31,329</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(15,921</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,633</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,110</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91,475</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,056</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,513</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, cash used in operating activities was $67.1 million. This cash outflow was primarily related to our net loss of $58.2 million. The cash outflow included $4.2 million in stock-based compensation expense, $2.3 million in non-cash depreciation and amortization, and $1.8 million gain on extinguishment of PPP Loan. The outflow was also impacted by a net decrease in our operating assets and liabilities of $14.5 million. The change in operating assets and liabilities includes a $13.6 million decrease in deferred revenue, a $4.7 million decrease in other non-current assets, and a $3.2 million decrease in prepaid expenses and other current assets. This was offset by a $5.4 million increase in accrued expenses and other current liabilities, a $2.3 million increase in accounts payable, and a $0.5 million increase in accounts receivable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, cash used in operating activities was $31.3 million. This cash outflow was primarily related to our net loss of $39.3 million and was offset by non-cash charges, including $0.8 million in depreciation and amortization expense on our fixed assets and $3.1 million in stock-based compensation expense. Of the $3.1 million in stock-based compensation expense, $2.8 million was related to the sale of our common stock by certain executives and founders to SIG Global US Fund I, LLLP. The net loss was also offset by changes in our operating assets and liabilities, including a $3.7 million increase in prepaid expenses and other current assets. The changes in operating assets and liabilities also include a $3.5 million decrease in due from related party for the amounts received in 2020 related to the signing of the APL Agreement in 2019, and a $3.0 million increase in deferred revenue related to our adjustment to the amount we expect to receive for reimbursable costs under the Takeda Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended years ended December 31, 2021 and 2020, we used $15.9 million and $2.6 million, respectively, of cash in investing activities. The $15.9 million used during the year ended December 31, 2021 and $1.5 million of the cash used during the year ended December 31, 2020 was related to the purchases of property and equipment. The remaining $1.2 million of cash used in investing activities during the year ended December 31, 2020 was related to payments we made to OpenBiome in conjunction with the signing of the OpenBiome Agreement in November 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, net cash provided by financing activities was $119.1 million, primarily related to $118.6 million of proceeds received from the IPO, net of underwriting discounts and commissions and $3.0 million of proceeds from the underwriters&#x2019; exercise of their overallotment option, net of underwriting discounts and commissions. The proceeds are partially offset by $2.7 million of payments of issuance costs related to the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, net cash provided by financing activities was $91.5 million, primarily related to $90.0 million of gross proceeds received from the issuance of Series D redeemable convertible preferred stock during the year, as well as proceeds of $1.8 million from our PPP Loan. The cash provided by financing activities was offset by the payment of $0.2 million of deferred offering costs and $0.1 million in issuance costs related to the series D redeemable convertible preferred stock issuance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our cash and cash equivalents were $133.5 million. We believe that our existing cash on hand will enable us to fund our operating expenses and capital expenditure requirements into mid-2023. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. We expect that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue the research and development of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate and conduct clinical trials for, or additional preclinical development of, our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">further develop and refine the manufacturing process for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">change or add manufacturers or suppliers of product candidate materials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek regulatory and marketing authorizations for any of our product candidates that successfully complete development; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to identify and validate additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquire or license other product candidates, technologies or biological materials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">make milestone, royalty or other payments under any current or future license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain, maintain, protect and enforce our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to attract and retain new and existing skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">create additional infrastructure to support our operations and incur increased legal, accounting, investor relations and other expenses; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience delays or encounter issues with any of the above. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Material Cash Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our contractual obligations as of December 31, 2021, and the effects of such obligations are expected to have on our liquidity and cash flow in future periods (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:41.576%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:8.607%;"></td>
    <td style="width:0.663%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:8.364%;"></td>
    <td style="width:0.663%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:8.607%;"></td>
    <td style="width:0.663%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:8.607%;"></td>
    <td style="width:0.663%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:8.607%;"></td>
    <td style="width:0.663%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Payments Due by Period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less than 1<br />Year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 to 3<br />Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">4 to 5<br />Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More than<br />5 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease commitments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,629</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,046</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,791</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,402</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,390</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License agreements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">400</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,029</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,066</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,901</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,512</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,550</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into operating leases for rental space in Somerville, Cambridge, and Charlestown Massachusetts (see Note 5 to our annual consolidated financial statements appearing elsewhere in this Annual Report). The table above includes future minimum lease payments under the non-cancelable lease arrangements. The table above also includes payments due under our capital lease obligation, as related to leased equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also entered into license agreements under which we are obligated to make milestone and royalty payments and incur annual maintenance fees. We owe an annual maintenance fee of $5,000 under our agreement with University of Minnesota, as well as escalating minimum royalty amounts. We also are required to pay minimum royalties under the agreement with Arizona State University of $5,000 annually until 2023, which increases to $20,000 in 2024. Future minimum payments through 2028 have been included in the table above, but our minimum payments continue in perpetuity for University of Minnesota until the agreement is terminated. We are also obligated to make regulatory milestone payments to OpenBiome aggregating up to $6.0 million upon the achievement of regulatory approvals, and sales-based milestone payments of up to $20.0 million upon the achievement of certain net sales criteria. We were also obligated to pay OpenBiome $1.25 million upon the closing of the OpenBiome Agreement, included as a portion of the closing fees of $3.9 million, as related to milestones previously achieved. We are obligated to pay to OpenBiome a low single digit royalty on net sales of licensed natural products by us and our affiliates and a high single digit percentage of certain sublicensing revenue (including royalties) received in connection with licensed natural products. These royalties are calculated on a product-by-product and country-by-country basis. See the sections titled &#x201c;Business&#x2014;Our Collaborations and License Agreements&#x201d; and &#x201c;Business&#x2014;Agreements with OpenBiome&#x201d; elsewhere in this Annual Report as well as Note 7 to our annual consolidated financial statements appearing elsewhere in this Annual Report for a description of our license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase and Other Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enter into contracts in the normal course of business with CROs and other third parties for preclinical studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers up to one year after the date of cancellation. These payments are not included in the table above as the amount and timing and such payments are not known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements appearing in this Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, our revenues have consisted of payments received related to our licensing agreement with Takeda. We apply the revenue recognition guidance in accordance with Financial Accounting Standards Board, Accounting Standards Codification, or ASC, Subtopic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which was adopted January 1, 2017 using the full retrospective method. Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect consideration we are entitled to in exchange for the goods or services we transfer to our customer. All variable consideration, including milestones and royalties, are constrained until the cumulative revenue related to the consideration is no longer probable of reversal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. We currently measure progress according to the expenditure of research and development efforts, based on costs incurred, as this is the best indicator of performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until we satisfy our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and Acquired In-Process Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development, or IPR&amp;D, represents the fair value assigned to research and development assets that we acquire that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. Our IPR&amp;D is considered an intangible asset with an indefinite life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill and IPR&amp;D are evaluated for impairment annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors we consider important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in our use of the acquired assets or the strategy for our overall business, significant negative industry or economic trends, a significant decline in our stock price for a sustained period, or a reduction of our market capitalization relative to net book value. We have historically performed our annual goodwill and IPR&amp;D impairment assessments as of the last day in each fiscal year. During the fourth quarter of 2020, we changed our annual impairment assessment date to the first day of the fourth quarter, or October 1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit&#x2019;s carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. Our annual assessments for impairment of goodwill as of October 1, 2021 and 2020 indicated that the fair value of our reporting unit exceeded the carrying value of the reporting unit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&amp;D asset exceeds its fair value. We estimate the fair value for our IPR&amp;D asset using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. Our annual assessments for impairment of IPR&amp;D indicated that the fair value of our other IPR&amp;D asset as of October 1, 2021 and 2020 exceeded their respective carrying values.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Through December 31, 2021, there have not been any events or changes in circumstances that indicate that the carrying value of goodwill or acquired intangible assets may not be recoverable. The FDA clinical hold issues could negatively impact the fair value of IPR&amp;D and goodwill. We continue to monitor and evaluate the financial performance of our business, including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its book value. There can be no assurance that, at the time future impairment tests are completed, a material impairment charge will not be recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 2 to our annual consolidated financial statements within this Report for a description of recent accounting pronouncements applicable to our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company Status and Smaller Reporting Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company,&#x201d; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Section 107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As an EGC, we may take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may present only two years of audited financial statements and only two years of related Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may avail ourselves of the exemption from providing an auditor&#x2019;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may avail ourselves of the exemption from complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may provide reduced disclosure about our executive compensation arrangements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1883333333333335;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until December 31, 2026 or, if earlier, (i) the last day of our first fiscal year in which we have total annual gross revenues of at least $1.07 billion, (ii) the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a &#x2018;&#x2018;smaller reporting company,&#x2019;&#x2019; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue was less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our common stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to EGCs, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitative </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to certain market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in foreign currency exchange rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash and cash equivalents of $133.5 million. Our exposure to interest rate sensitivity is impacted by changes in the underlying U.S. bank interest rates. Our surplus cash has been invested in money market fund accounts as well as interest-bearing savings accounts from time to time. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our portfolio, and therefore, we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates. As of December 31, 2021, we had no debt outstanding, therefore, we are not subject to interest rate risk related to debt.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item8_financial_statements_supplementary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.004%;"></td>
    <td style="width:7.996%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PAGE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(PCAOB ID No. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7d31d35-51ce-42f7-9392-90cbbe30252e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the shareholders and Board of Directors of Finch Therapeutics Group, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Finch Therapeutics Group, Inc. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2021 and 2020, the related consolidated statements of operations, redeemable convertible preferred stock and stockholders&#x2019; equity (deficit), and cash flows, for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change in Accounting Principle</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed in Note 2 to the financial statements, effective January 1, 2021, the Company adopted FASB Accounting Standards Codification Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, using the modified retrospective approach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14234b88-e1ec-4484-89ff-6f149fda53a2" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:AuditorName"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_892ea479-9276-435e-81d4-e05bfb503054" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="dei:AuditorLocation"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.428%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:13.337%;"></td>
    <td style="width:0.745%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:13.337%;"></td>
    <td style="width:0.745%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">CURRENT ASSETS:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e755b1cf-a31c-4832-94ef-055db02347ee" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_45d34ea9-8c63-4984-b54c-15ab0b2e159c" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6a5aaa7-f1c9-47e2-a575-4dd4bb77efa6" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4eddba2-51c6-4491-b796-23a203e7fb6b" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,034</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Due from related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e053055-077e-4028-9dca-3509c53a53f4" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_74c278b3-2e6a-4a62-aea1-f524310c4b40" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9a35c0a-af6a-41a1-a80e-5c3ce0839fb0" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c32dc8dd-c0ac-4881-9727-8f60b272a124" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce3b8a0f-fe51-441a-bdad-c377a791683d" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142,551</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_06263595-3a40-4b37-a44d-43c621fc9593" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b31a5a5-86bd-4167-af04-3bd5947cb3b0" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_68c9a442-f46a-4168-9268-efafd9251084" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6182ac4-e52e-4662-80bd-5088fc3cda60" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,053</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f159e54-43d8-4420-8bba-94bd3f0765c9" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">In-process research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee2dd3a8-42d5-46e7-9654-c92c2299bb9f" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:InProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa8f8c7b-7785-4011-b636-7807f994ecd8" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:InProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0edab58d-ceec-4cf8-aa84-6f7263cf8eb2" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_36d4c9c3-9378-42d2-a98e-2b53ee9b53e5" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Deferred initial public offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_73c7be48-d105-4239-a082-4d57fe763884" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7dfbe545-cd92-4ff3-aeee-e713be21a1d5" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Restricted cash, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2177e55-b681-4309-b348-c0784e2f50ae" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_10a15d80-e4fb-4e1c-b0ac-ec656a0857a5" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2db77bc6-837c-4e11-8f1d-c429d8ddda0b" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfc0416e-0cdf-43b6-b324-b74170d1e4f1" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">TOTAL ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_639c3716-f0e4-4504-9cc9-01c8422eb2c7" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e22746ad-7f7e-48dd-8ef1-5ab24407c317" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND<br />&#160;&#160;&#160;STOCKHOLDERS&#x2019; EQUITY (DEFICIT)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">CURRENT LIABILITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_50f0195e-d2f9-47ce-8c4e-006708a1f7ca" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,737</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c45ba7c3-5653-4346-a0d5-01b2a92255fa" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,621</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d537da56-d9b1-4204-a52d-627957439914" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bed13e23-9e6a-4619-9b15-69a5456c7810" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d06ef3b6-afa1-4167-97b7-9c2b0a2e6baf" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_534f7802-0c47-473c-a277-5ba1b775ec9d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Due to related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_fee40c12-3125-414d-bdec-b89b928e6f16" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe17cadf-31de-45bf-97f4-54a562a3ec9a" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1ba3c65-8ca6-4247-b43a-494efd392bac" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_098f62b7-c93c-4c2d-a437-d147f4cb2c08" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bf3048c-2210-461c-b78f-d6c1ed829205" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ded18188-43fc-4fcc-bc23-292f98ca26df" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,486</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_730a7e87-8700-4699-9f83-dec51d3cd17f" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fe0dd99-0a74-403b-8be8-7628d1a0d365" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_165a67c4-2cf0-4c90-8e1b-25a98ce41616" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffc505d7-2c53-4e40-88c8-bdcfac14568e" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Loan payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c14b8e5-3e92-417b-9e3d-e2b6cd1bf37e" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f50110c-86c6-4f2c-a4c4-df8919e34b69" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Deferred rent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd191473-3c33-482d-b7eb-30164dfd8f8d" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d870be0-d9e5-467e-957f-ee387e8defaf" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f615c7ca-9561-4461-8f82-80c8e27db074" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,887</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f67172c6-bd8e-4efa-9fcc-99263e7d34c8" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e3e30f1-ee02-416a-9ce4-67c3a802e907" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_726bf35e-bfbd-4031-88f9-23f428488859" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_40c00ca5-4e2c-4355-a152-a77b93b62115" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e40b3ca-947e-4775-825e-7b867d361b68" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5221a7d6-7634-49ee-a6f1-36478875109c;"><span style="-sec-ix-hidden:F_82684cf4-53e2-4fe6-90df-5260ddc9184d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">COMMITMENTS AND CONTINGENCIES (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Series A redeemable convertible preferred stock, $</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cc1e9e7-0dd5-48b7-9e5b-79f169784459" contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_b0a263ed-f0b1-4275-8d84-4ee52740c031" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_10c4e30d-e92d-4f41-8046-088216a5815e" contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_98cff91f-21b3-4902-8587-3e0f3b3a1ece" contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_29cd8573-0e37-4f05-a676-3c2b536ba7ea" contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized, <br />&#160;&#160;&#160;issued or outstanding as of December 31, 2021; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff4a8f6f-4d20-4dbe-b136-932ce0fe4b37" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">167,496,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized and <br />&#160;&#160;&#160;</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_531a7267-a696-47a6-a4d2-771cd41ae402" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_484bd5b0-1411-4c15-8038-5c81b6343f37" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,596,280</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares issued and outstanding as of December 31, 2020;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f0de8ab-ba53-40dd-8759-382c06f3e9ed" contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_511cddc7-76ee-403e-963b-e21f1b05c839" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Series B redeemable convertible preferred stock, $</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_35f1874a-28ea-42e6-a243-894af58b6f59" contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_b8e3ecb1-f746-4fbf-b421-23b6b7f65926" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_49d3ffe9-4eeb-4a02-805e-8a3ac80e8cc5" contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8acae13e-fb5b-4d9d-8786-cf391bf43db3" contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b26400c8-fa1b-4dda-b218-bf22aaef7856" contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized, <br />&#160;&#160;&#160;issued or outstanding as of December 31, 2021; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_558f2074-fbb2-40ed-b9ff-999a0b0682b9" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">74,620,739</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized and <br />&#160;&#160;&#160;</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1acc9603-ecdb-403f-a0ff-0272441b3e60" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_eba3a951-7391-46e7-8ead-78051ddc9600" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,166,203</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares issued and outstanding as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_42dcfbe0-f0c5-48ed-a170-00c4ffa3f3ad" contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bb0fc52-4e59-48c7-b112-b2454e222f08" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Series C redeemable convertible preferred stock, $</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bd31cc3-b3d9-41a2-aede-16b581d1a8d4" contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_84a637fb-d91c-4933-8060-37c8f4e32536" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2156f70a-f8a7-40a6-a7d0-da8dc2f13666" contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9492801e-c3b7-4b6e-833f-8318f91088c2" contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8cb5e5f8-f43d-46f6-82c5-23e40fc64e71" contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized, <br />&#160;&#160;&#160;issued or outstanding as of December 31, 2021; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_47095aba-5a63-4a20-9b97-f7372d9133d0" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">109,604,994</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized<br />&#160;&#160;&#160;and </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd090f03-ad3f-460b-a171-b383b5a7f7c0" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_0ded1cab-f88a-4f2c-b922-2d5b8adeb01b" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,254</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares issued and outstanding as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_27ca0872-8058-4e77-9ba0-f47b03a17a96" contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb02b35a-bc44-44f1-a833-92eb3a03f224" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Series D redeemable convertible preferred stock, $</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d64e27d-9eb8-4865-951e-1ca786c9295b" contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_e3bc5608-7e5f-435a-a7ff-38153a0db5c6" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a86508a-8872-46fd-8280-d03b0cb19bf0" contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3b333d53-2c3c-4121-8cec-b2a1014e0c22" contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_31b569e9-6215-4335-a2bd-33a2557c30c1" contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized, <br />&#160;&#160;&#160;issued or outstanding as of December 31, 2021; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5ac0ccb-d0b2-4f62-ad51-1b6109b9a4c4" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">99,705,359</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized and </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8937bdc-7e0f-4eec-bb27-f72e9749e46f" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_dfde71ea-a88c-4da2-8250-ae5140c99fe8" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><br />&#160;&#160;&#160;shares issued and outstanding as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_83f94124-fe18-4d79-be29-e5b3cf8fa44d" contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c2834d1-9825-4c98-bc23-d25d49dbc5c0" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">STOCKHOLDERS&#x2019; EQUITY (DEFICIT):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc9e6405-943b-4058-8824-79016fd2dc28" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_9060829d-8e59-4424-adc9-f2129108ae45" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4dbff539-d1e9-4a03-ba34-41e3844ed423" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_df7ee4b1-d27b-4e3b-9e2d-4279964c59f6" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">598,232,153</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares authorized as<br />&#160;&#160;&#160;of December 31, 2021 and December 31, 2020, respectively; </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_488ad4a9-ecfc-416a-8627-a9e6dcf4a0ab" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c4a1723a-cdd0-4d3c-9f01-f5dcab296a71" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,512,182</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_236bdd54-af9e-4417-ace3-1415e86dc6b6" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a95daa0a-14cf-4a72-9358-08e2edf65e34" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,391,793</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;shares<br />&#160;&#160;&#160;issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdecdbc3-d1ed-4b83-be01-ff761ccd9f8b" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc2f2347-b2a4-4e08-b891-abe97a7bf097" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_48523ae7-727d-46a7-b786-cfea8acdcc6e" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,172</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_64346399-0fd4-4e05-b212-fb40dece5197" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">(</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_aac58720-68ca-4492-b382-2ea4f99bbb9e" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">160,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">(</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff2ab613-a3aa-4f02-a32a-d44ec5242c4f" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">102,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Total stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce1cb05d-18df-461a-9a33-2d80adb273e7" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">(</span><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_26bd6fc5-1178-4f13-b19f-89fa3f2c6fc7" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED<br />&#160;&#160;&#160;STOCK AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d5941a8-ce44-4d39-9cd3-1b6b12f0858e" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d14d5bac-e9db-46b5-b2b4-13f777ae0483" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See notes to consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.369%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.079%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.059%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">REVENUE:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5d4bac3-7048-4728-a09b-e16eb69f90b3" contextRef="C_b80e0856-efdb-45ee-8c35-7042653d6f4f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6bf3c93-6c53-491f-b649-5e29a0a090d1" contextRef="C_8e96af31-f869-445b-b59a-14d832388be8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,376</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalty revenue from related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec501f08-f56b-4297-b4fc-9c3fa145b731" contextRef="C_a3685552-54f1-4285-9365-be9a43f57bfe" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9aad1372-a467-4cb5-9f23-a9d5e276174c" contextRef="C_a7977ced-72d5-4903-b7c8-1bf202956756" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_289201b8-7d06-4263-8c97-5de6a6682dc9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f6e24f3-72fe-471e-9cda-5692b8469577" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OPERATING EXPENSES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_182fa20b-7c30-4199-a211-af2a75a77f82" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61245699-3a69-4b23-90e1-fb36608d8887" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f2bc7ce-0268-4c78-9d83-e39dd6e4518a" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7e5a28f-ceef-47c6-9671-ca9dd81f29d8" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,011</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36e6d470-5d1e-41a1-8df3-a27a29d37ea4" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4863a8b-7499-4489-9243-12d21d763b8d" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c07d175c-7fd2-425c-ab37-154a08e788fc" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5bd37ca-6705-4392-ba9e-8dec14e7932b" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,436</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OTHER INCOME, NET:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on extinguishment of PPP Loan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bb9ff0b-56ca-4f16-9fda-41d96bc5a10e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,827</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_643009de-b407-4e9d-9f69-62f7f3918617" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01b4ce27-9d7d-4dc8-a0f1-e6d73d3d82d0" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain (loss) on disposal of fixed assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_667c291f-461d-4ac5-8243-686c21af4279" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7713c64-7a05-43d0-a7e7-fc86b4645185" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_843fce1b-fa8b-4670-8f3b-a06dd5a92dad" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06a7cd0b-fb84-48bb-80ad-e72a9303c331" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_deffa770-fb1b-430c-89af-28ea18c694d5" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,825</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7322e97a-b25b-4376-ac1c-730858b02d5f" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8ba4ad4-95bb-497c-868b-76b2bfe71ac4" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf80f12c-a4d6-4a5a-83a4-e839bad417dc" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax provision</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23f95f6d-40c7-4116-900d-63ec9dc0792f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82e84333-fe54-4d4f-a78c-499279cb404b" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d200b45b-c1b6-4dc0-91ce-746776f33c12" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46886a6c-f7f9-4dad-bdda-f55b3c424cda" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders&#x2014;basic and diluted (Note 15)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e0cb72d-9b56-4efb-a885-93a5c747bdc2" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d095b1b6-2bfb-4e87-b66c-357e5e6262fe" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_260c431f-4942-42b7-93fe-dae9852dbfc7" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_baa123c9-bd73-411b-9b24-84d0c1837f1c" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">4.83</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common stock outstanding&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63a9c4ea-1f4b-4fbd-b9c0-2a813014fe44" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">39,202,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a2b6642-de54-48b6-84cb-09607743b3b5" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,144,855</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Convertible</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.545%;"></td>
    <td style="width:0.315%;"></td>
    <td style="width:5.527%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:4.019%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.315%;"></td>
    <td style="width:5.322%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:4.707%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.315%;"></td>
    <td style="width:5.322%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:4.963%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.315%;"></td>
    <td style="width:5.322%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:4.019%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.981%;"></td>
    <td style="width:0.981%;"></td>
    <td style="width:0.315%;"></td>
    <td style="width:5.329%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.622%;"></td>
    <td style="width:4.473%;"></td>
    <td style="width:0.315%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:6.625%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:7.181%;"></td>
    <td style="width:0.439%;"></td>
    <td style="width:0.659%;"></td>
    <td style="width:8.294%;"></td>
    <td style="width:0.439%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="23" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">REDEEMABLE CONVERTIBLE PREFERRED STOCK</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">$</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_31fef4ad-7fda-4934-b1f7-40437bdbe170" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_3c2ccb7c-38ab-464f-8d3e-b871b3ead584" contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">&#160;PAR VALUE<br />SERIES A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">$</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c670a2f-0c94-427a-9a0b-f7c4cf735e53" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_0cbe3216-eb75-4fc4-9887-511f1f2dbcc6" contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">&#160;PAR VALUE<br />SERIES B</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">$</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f71915b9-9b63-465e-bc4e-cdf293697a2e" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_f4d31af5-fafa-4d47-9141-d26446370814" contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">&#160;PAR VALUE<br />SERIES C</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">$</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_53335910-3778-4047-8a79-7193e841ed74" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_c80f5c87-8f2d-4406-8426-8131bdca26ec" contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">&#160;PAR VALUE<br />SERIES D</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">COMMON STOCK<br />$0.001 PAR VALUE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">ADDITIONAL<br />PAID-IN</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">ACCUMULATED</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">TOTAL<br />STOCKHOLDERS&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">SHARES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">AMOUNT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">SHARES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">AMOUNT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">SHARES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">AMOUNT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">SHARES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">AMOUNT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">SHARES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">AMOUNT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">CAPITAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">DEFICIT</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">EQUITY (DEFICIT)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">BALANCE, January 1, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f630d6e-d557-4a83-976c-051482113c55" contextRef="C_29237393-f7a6-4fe4-b6e8-04815b077862" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,596,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_30bff476-d0be-4391-ad2d-7ff04f3aa2ee" contextRef="C_29237393-f7a6-4fe4-b6e8-04815b077862" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2909a51-1593-4cfc-ba9f-0823e1a4dc00" contextRef="C_734ba92d-986a-46d1-aeee-fd929b61447a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,166,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef89bb64-e24a-4eed-a7da-eaf9fcf3dcab" contextRef="C_734ba92d-986a-46d1-aeee-fd929b61447a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb6723f8-05e9-4ad5-87a3-579608993326" contextRef="C_e4017af1-75f3-41f0-9528-da23823df46b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,588,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_216febd9-106f-443b-ba30-19e5dfb8f852" contextRef="C_e4017af1-75f3-41f0-9528-da23823df46b" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_74343f20-d53c-4a31-a0ab-2890c75c9b75" contextRef="C_d4277bcb-d35b-4f32-8ff6-cdca824e9d4a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,778,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_63cacca2-ae2a-42e3-a9ba-0e2831c41e2d" contextRef="C_d4277bcb-d35b-4f32-8ff6-cdca824e9d4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c21305b0-5b03-4834-a741-cb898dd84bba" contextRef="C_089fb034-da86-4331-8cab-1b70dc0cd490" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e59efb8-1904-485c-b115-59cfba63c1ed" contextRef="C_1de77ba6-205b-42f6-acd1-060d987f64f7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e479c0b-662b-4d56-a5b8-9cd58a422efb" contextRef="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Issuance of series D<br />&#160;&#160;&#160;redeemable convertible<br />&#160;&#160;&#160;preferred stock, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f04554d4-f41f-4c15-9356-c22d78d6547f" contextRef="C_1a179872-937f-42ac-8d8c-e1ded8315d35" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bc9947c-a6b5-400e-93b4-1d471c641aae" contextRef="C_1a179872-937f-42ac-8d8c-e1ded8315d35" name="fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_87d92c4d-2848-45c9-9e30-4af1ec1e5734" contextRef="C_1a179872-937f-42ac-8d8c-e1ded8315d35" name="fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Exercise of common stock<br />&#160;&#160;&#160;options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_69724fed-5764-4263-a57b-85f317ba6f4b" contextRef="C_f59b9e4d-a520-4962-b1b1-8256ad30502f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">65,881</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_43fd39eb-2804-499d-8e4e-e928bc0bc6af" contextRef="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_37c40ad5-850b-4510-b06d-72282ffa80de" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ba0343d-11fe-4543-8434-9a0f7ba7c61c" contextRef="C_f59b9e4d-a520-4962-b1b1-8256ad30502f" name="fnch:StockIssuedDuringPeriodSharesVestingOfRestrictedStock" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">547,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_56e1e3d0-c845-468c-93d9-715be90b99c9" contextRef="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce" name="fnch:StockIssuedDuringPeriodValueVestingOfRestrictedStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_26dcdbfe-2527-4998-a8f8-3ff65dfd719f" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:StockIssuedDuringPeriodValueVestingOfRestrictedStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c6b3e15-f04b-4b92-908b-7348a99be9ab" contextRef="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,091</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0922dd2d-4042-4a04-a0a4-5b3569daa499" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,091</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8ea3141-a29c-47a2-a476-96a2625e1fa0" contextRef="C_92ff62b1-b286-46a8-8e9a-bd9133b65f3d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a4a7ae5-6d0f-4126-b202-1cdefdb68edb" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">BALANCE, December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fcbdf32-8b18-446b-b5c7-5e449b0dfeea" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,596,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec34aaa7-a7ce-4e81-ad7e-83228a7ec87f" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_835a3689-4c10-45cd-a1bf-40c1bfaf6a0c" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,166,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac6b9766-5797-4601-933d-803ee2219767" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e44e7fdb-57ec-4372-9558-01eb245b7f15" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,588,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc863fc8-19c2-48a7-a9dc-447302cf9d1f" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_73813529-6eae-44ce-a597-3975cb5fdbd5" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7efed99-1b58-4ac4-bc2c-7b911e42cf2a" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_88e44c04-c73a-49d4-84c3-2ba00d70063d" contextRef="C_da1fc6b8-eb04-4fd7-aefa-1b1663c0cbad" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,391,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a9db5da-d7ba-445d-a146-53621200619c" contextRef="C_da1fc6b8-eb04-4fd7-aefa-1b1663c0cbad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_61460592-24a9-4ac9-a602-b7dd8a8de903" contextRef="C_cb5e464a-84a9-4eb3-ad80-f75e327f7bbc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b320efe9-a70c-486a-aed5-f716056b23fb" contextRef="C_7d09ee6b-925b-4309-b34d-5e1eb3247ba6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">102,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3d3f4eb-0793-4ac3-a219-e1b0823494ba" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Conversion of redeemable convertible<br />&#160;&#160;&#160;preferred stock into common stock<br />&#160;&#160;&#160;upon initial public offering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2399efa6-4ddb-46a5-96af-d8765e80bbc9" contextRef="C_5e9b7d9d-0899-469e-840d-b1a8fd63c115" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,596,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_623168ad-0742-4332-9cb1-6ef0695e3c38" contextRef="C_5e9b7d9d-0899-469e-840d-b1a8fd63c115" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ade1b8e-7674-49ee-9b72-4559665d846f" contextRef="C_e78abb46-6208-4d28-9564-457e5c7c89e6" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:numdotdecimal">5,166,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9063e2a-bc0b-488f-b51c-fa473c119096" contextRef="C_e78abb46-6208-4d28-9564-457e5c7c89e6" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_58d13ca4-fb2f-4cb9-a4b7-9f9190b63ff6" contextRef="C_d4537122-5c97-4483-a0d3-0abbbe078b74" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,588,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_830fc290-a36f-480b-94ad-738e666b8807" contextRef="C_d4537122-5c97-4483-a0d3-0abbbe078b74" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a53ca829-0923-4149-919e-a594fb74f1a7" contextRef="C_96bb2e98-4d79-4650-8af9-3a931a612483" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdf60596-940c-436c-9cd1-d9d32bc345c9" contextRef="C_96bb2e98-4d79-4650-8af9-3a931a612483" name="fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1346e58e-c832-4373-93d8-c16ffbea2c33" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bbba070-6a89-47af-90a3-350757abce89" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_60dd62cb-ca65-4fa1-9431-3826ce30a17a" contextRef="C_08797998-db85-4999-b501-d07c4980c203" name="fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2e0e27a-c673-40fe-b262-8c6594e8b822" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,053</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Initial public offering, net of<br />&#160;&#160;&#160;underwriting discounts,<br />&#160;&#160;&#160;commissions and net of<br />&#160;&#160;&#160;offering costs of $</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b617b63-d75a-4a14-b1ed-e3f1919317b0" contextRef="C_ed564ca9-9a3a-412d-9d64-5fd1ffc81119" name="fnch:InitialPublicOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,786</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f474dc8-10d8-4c3f-b81c-dee5a40776f0" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,500,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e26a295-164e-4788-8999-2c6047e93264" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_29aab447-b9f2-4b9d-85af-418be45ea76c" contextRef="C_08797998-db85-4999-b501-d07c4980c203" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_22a9426b-eb7b-427e-95ec-c70cddacba6d" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,714</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Underwriters' exercise of<br />&#160;&#160;&#160;overallotment option, net of<br />&#160;&#160;&#160;underwriting discounts,<br />&#160;&#160;&#160;commissions and initial public<br />&#160;&#160;&#160;offering costs of $</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_39f234cf-511b-4a4d-b577-82ed30d0dec7" contextRef="C_ab627a9f-a180-4add-89be-437938d49551" name="fnch:InitialPublicOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1c77ecf-6364-4052-9703-46a8546ae597" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a089959b-a9b3-44e0-a893-b38a06cfd011" contextRef="C_08797998-db85-4999-b501-d07c4980c203" name="fnch:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_df78ee53-9a85-47d1-be2b-b26bf2e8d846" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Shares repurchased for<br />&#160;&#160;&#160;cashless exercise</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_73408bad-42c7-46c9-908a-bcd234069497" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1941bdeb-bebb-48f6-9a2d-e338423649e3" contextRef="C_08797998-db85-4999-b501-d07c4980c203" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba5bbba7-f23b-4657-b9cd-e5eae5114274" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Exercise of common stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7793bdd2-2fe2-4072-b2e9-e004f127bb62" contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">155,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7492d4de-39e4-4be3-825e-31139d557095" contextRef="C_08797998-db85-4999-b501-d07c4980c203" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cdf8873-8fa3-420e-b87b-ec6d61567d4f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Exercise of common stock warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b90a06f-c884-4570-8d06-caece5064b22" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:CommonStockWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,303</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_888810f7-4620-4b02-8af4-df533aa67d5c" contextRef="C_08797998-db85-4999-b501-d07c4980c203" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d55885b-7b91-4f50-98d3-b75b6730e22a" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_32f0ab12-629b-48d4-b4e8-97f69a220f47" contextRef="C_67b625c9-9b8a-4bea-b722-36d695553d6d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5af0b80-e1f8-478d-ad52-2e23f74d81e3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">BALANCE, December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6abc89c6-0f8f-425d-bd30-d8528f1a4799" contextRef="C_48646751-72ab-4bdf-9554-d01586c1b9b2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">47,512,182</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba778483-cd02-4b8c-ab93-d17d26880c87" contextRef="C_48646751-72ab-4bdf-9554-d01586c1b9b2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3e950f8-1241-4f72-976a-8990cff48bfc" contextRef="C_e8d19c5f-3b27-462c-bd7a-dd8adf6bc783" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,172</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_549ddbda-2584-4e12-a9bb-619c103fdcef" contextRef="C_ad20da32-3929-4b8f-8211-81be4d8ad10d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">160,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f8260fe-5c72-4d65-a7c4-e62bf284c7c0" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.641%;"></td>
    <td style="width:1.54%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:12.493%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.54%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:12.493%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b588766-e98d-4a37-b175-cb377394febb" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df8dead6-1661-4a99-9549-53a60ae5874b" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef8567c0-8006-48ab-bdf7-3ea62e32c46e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de9f2eec-4372-43e1-87ee-e1e14f0760b0" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4545bc18-c7a7-4cd6-877c-d3b2c82ac30f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f55f1d13-aa8e-449a-acca-ee12b8bafb46" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on extinguishment of PPP Loan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d8c4ff3-bf19-484b-83de-6f062795712f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78ed806a-b319-4d89-9e36-96f87a161de1" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Gain) loss on sale of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8187128b-1967-4960-ba45-787014e316ed" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0f8f7d2-9ebc-4fd7-bf6e-7960156eb9d1" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other non-cash operating lease cost</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7cbcc31-553d-4f64-9771-608453972f69" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:OtherCostAndExpenseOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">913</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1bd06fc-4eb6-4f41-a1e9-6ab5e1a3d014" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:OtherCostAndExpenseOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdc44436-fa01-4615-8925-26ec178ed6b4" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd616d85-3c1b-48bc-958d-62078923b51e" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due from related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_132e9830-dc19-429b-b28c-3e25633429b2" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a0a3a6a-82d2-4caa-a5b4-e12afee7db21" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_544b679a-15f8-497a-be1c-fe3bd69d1d2f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d780b32f-0294-4aca-a578-953dd341ebd7" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f90dcd92-4f34-45a0-89e2-de5e0f903573" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ff73db7-5110-4e34-8af8-0f36bc31ad45" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a634f1b9-79d5-4e98-92f0-e5964a068fae" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_575a77c1-8c41-42a7-b2d2-9cde375293dd" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ca2dcc4-df8c-4514-8b2a-19c7470f5ca0" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_794ab2cc-63d7-42c8-80a8-ff1d8b5ad3ed" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due to related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fb81f48-3a3c-4c0c-8a27-d5a5afe50a51" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f7ab944-e25b-4142-8fdc-d8298439570c" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41b46df6-3d12-4aeb-a93d-ac0a9b771ab6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99a050aa-34a0-44b7-a44f-70d95b970db9" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred rent</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_992952c6-b6ac-4331-993c-5301c114a8b3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2f22daa-5346-4821-a6e9-e477afeb5bc1" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">309</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81bee144-81d3-4059-a6f6-7edb35637754" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29163c77-b6ca-4f78-a317-4a89cd79744b" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75c29059-81fa-4983-a30c-678257953367" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">67,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a33f956e-946e-4175-843a-34fe01f1ed52" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7586938-123b-4b22-b0d8-9593b337be5f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1cb21f6-477b-4958-8c5b-dc4ada8fee99" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from sale of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75a50b68-4061-45ee-a1ed-57d019605329" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_860390f5-f7f9-424c-af47-1b57bd7b8206" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecef4582-a948-4639-b1a0-cb51f2fc7dab" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a3a0690-db2d-4b40-a240-269c8c673249" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b204684-3edb-4334-a89b-8cd257dcd002" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_023359e4-c9e1-462b-886c-590ae0fece72" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of Series D convertible preferred stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3df367f3-9af0-49c3-879b-1fd3b94ee238" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51fbce37-6736-4698-810e-c53448fccb89" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of Series D redeemable convertible preferred stock issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_158cb015-c926-4b7a-8735-55bd589446d5" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0673d8c8-155c-4dd1-bc4c-87278512298f" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from underwriters' exercise of overallotment option, net of underwriting discounts and commissions and initial public offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc6057b3-b599-401a-8034-e3310414fcc0" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5564a781-4d9d-44a9-994c-b497fab39021" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal payments on finance lease obligation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae2cc98e-a6b3-48e0-98d3-d499499b98a3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:PrincipalPaymentsOnCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74cfd187-41d6-4836-8a2f-49451819f203" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:PrincipalPaymentsOnCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f7263c3-a8d0-45b1-944b-6aa7ccd12fbb" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e772f16-6c32-4cb9-8a14-27a3bab9f43f" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from PPP Loan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab38fcf3-5bee-40e4-ac36-02c41c016053" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ProceedsFromPaycheckProtectionProgramLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7069e808-7421-4a1e-863e-7822b629a387" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:ProceedsFromPaycheckProtectionProgramLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of deferred offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_395eb334-39f9-49ca-87da-5817075c3c8c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,659</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39f70f1d-3898-4f2b-84a1-d694eae67f3d" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e8eea4a-dfb3-464f-acb0-49efeca1c62a" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21dc4b68-f380-4c7a-bdbf-98f016e105c4" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cacc18ab-41a6-40a1-9900-22983ceab5eb" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,056</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_628cfa46-8e59-4d86-8871-2dad85410c14" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32310ddc-d0a4-4d57-808c-1b63c0e647c7" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca34780b-5567-4d33-a7ae-f24fa6df102c" contextRef="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b647c700-1af6-4f9c-ae15-ad5cd2568d16" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a540030c-0fe9-42a4-a65c-37fef82558e7" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b0926d4-bd74-49fc-8f6c-99742805e1fe" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64dfee82-20ce-4ece-9c64-cc998a97103e" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid in connection with operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa61aea8-37ee-4a3b-9aaa-fc33bff796b5" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:OperatingLeasePaymentsUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f58182b7-66ea-4053-96be-c21c334bc1d5" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:OperatingLeasePaymentsUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment in accounts payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4f4711e-2483-46f6-a0b3-eb0950dd95f4" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">381</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09e73ad2-e14a-4ced-9e77-6f0da34d1e4a" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,398</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of redeemable convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08314e40-3adb-4794-ba04-069d991d59ee" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,053</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab18eaf4-c897-4464-9f11-cad9639d0f87" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets obtained in exchange for new operating leases upon adoption of ASC 842</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bb98a99-e873-4ba6-a0c4-d81b39e76a1f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e89b4a8-0df3-4e4e-82a1-638f74c6a579" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred initial public offering costs in AP and accruals</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efe8b4bb-395a-4310-bf66-e3ea83ce9e63" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70975964-be0b-461b-b1f6-8991b67324a0" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The following table provides a reconciliation of the cash, cash equivalents and restricted cash as of each of the periods shown above:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.468%;"></td>
    <td style="width:1.601%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.252%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.601%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.242%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c50e4a24-e4d9-4b8f-83c6-c19ddcfe9038" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5d9f4c5-0563-4bd6-9670-2535d0afc9cb" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d71c9bcb-0b4a-44a3-b527-3c867c3f7522" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec33d91c-1a07-468e-b3d6-6aad23432345" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae5c92b1-a4bc-4f01-86d3-a744ac79a987" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de1f3be8-0ea5-42c1-b1c2-2f3f4a97f27f" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See notes to consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79fd0d44-f769-42e2-82dd-3e0768131418" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF OPERATIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Therapeutics Group, Inc. (the &#x201c;Company&#x201d; or &#x201c;FTG&#x201d;) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (&#x201c;Finch&#x201d;) and Crestovo Holdings LLC (&#x201c;Crestovo&#x201d;) in September 2017 (the &#x201c;Merger&#x201d;), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (&#x201c;Finch Holdings&#x201d;). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company&#x2019;s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is an orally administered complete microbiome therapeutic in development for the prevention of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, or CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19af498e-57b1-465b-8d72-13f378b50ed1" contextRef="C_dcc33dd7-e5c8-4f20-b7fe-48ad8567599e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80198b8b-5b89-4597-bec7-250f3bb77811" contextRef="C_54d8859b-3cf9-4f25-81a8-0121817ec070" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">17.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aef55308-1123-4075-90bd-9564c14b917c" contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a" name="fnch:ProceedsFromIssuanceOfCommonStockGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">127.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3806f870-04dc-466c-a0a2-4da706742263" contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">115.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e8afce3-62df-4cb2-9aa9-7e10b8538292" contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a" name="fnch:PaymentsForUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eda2d6d0-fbc0-4ef2-bad5-c8a4fdc931a5" contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a" name="fnch:PaymentOfOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.  On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57dfc800-04ac-4f2b-8b69-e2791898f687" contextRef="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">192,877</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd43b234-b209-47f3-9102-1b332c9fb7e6" contextRef="C_c6dc934d-3979-4343-93cf-f35734ec869e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">17.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f3be66e-218b-44cf-8da2-e50751e46695" contextRef="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029" name="fnch:ProceedsFromIssuanceOfCommonStockGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45085d2b-cec1-4493-9876-895e2016adfd" contextRef="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts, commissions and offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7ea1798d-7710-41a8-88de-a9818d271ecd;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-14.444</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company&#x2019;s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eca78c7c-cecc-4a52-8bda-f42bf4a3f5ab" contextRef="C_736b82ab-77e3-4d3c-b1d1-93ec2b7be5f4" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95403ef0-5d5a-4480-a2d6-1153fd0db563" contextRef="C_80eb5b83-cbf6-469c-a34a-c9f03f095627" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, the risk that its products will fail to demonstrate efficacy in clinical trials, uncertainty of market acceptance of its products, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The extent of the impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak, including with respect to variants of the virus, and its impact on clinical trial enrollment, trial sites, contract research organizations, contract manufacturing organizations, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and its key scientific and management personnel. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company&#x2019;s business, financial condition and results of operations ultimately could be materially adversely affected. The Company continues to closely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monitor the COVID-19 pandemic as it evolves its business continuity plans, clinical development plans and response strategy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At this time, it is unknown how long the adverse conditions associated with the COVID-19 pandemic will last and what the complete financial effect will be to the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred recurring losses since its inception, including net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d36285d0-aa79-41b4-bb5c-4f88b68e2a52" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">58.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a385a481-cb0c-4361-a7d7-4dd2044524ce" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">39.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d0f8a59-7d11-49d9-85e4-35e4f7f3dbb7" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">161.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company expects to continue to generate operating losses for the foreseeable future as it continues to develop its product candidates. The Company expects that its cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ee75f78-f149-4325-991d-fbf58f6b6366" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">133.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of issuance the annual consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will not generate any future revenue from product sales unless and until it successfully completes clinical development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support manufacturing, product sales, marketing and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through clinical development, seeks regulatory approval, and if any of its product candidates are approved, proceeds to commercialization.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_d0347c96-b124-4e49-9e84-10231a2339ce" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f013d52-ff26-44f0-b6b4-52ca1eebb05a" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ConsolidationPolicyTextBlock" escape="true" continuedAt="F_4f013d52-ff26-44f0-b6b4-52ca1eebb05a_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_4f013d52-ff26-44f0-b6b4-52ca1eebb05a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a81994b-c029-45b7-bf78-e57062427fdd" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_5a81994b-c029-45b7-bf78-e57062427fdd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_5a81994b-c029-45b7-bf78-e57062427fdd_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b3249a9-7230-4c0c-827c-18de1411d5f9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50c29dfd-43aa-45a4-889b-8effcadbb166" contextRef="C_aa678b92-859d-4297-a5ea-40baf1bbd70e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4b708132-97fe-48c3-bd79-66118ca96e7f" contextRef="C_2ef89633-4500-4c18-944c-7f047f6e3e2f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0981b51e-06b6-4e8b-a6d4-b52846b88a2d" contextRef="C_aa678b92-859d-4297-a5ea-40baf1bbd70e" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a6f56c24-0e13-4afb-b347-49fdbde84bcb" contextRef="C_2ef89633-4500-4c18-944c-7f047f6e3e2f" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assets or liabilities classified as Level 3 on its consolidated balance sheets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_591432b1-805f-4dc2-8b65-f5c31f8438d7" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_591432b1-805f-4dc2-8b65-f5c31f8438d7_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed the federal insurance limit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_591432b1-805f-4dc2-8b65-f5c31f8438d7_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s cash equivalents, which are funds held in a money market account, are measured at fair value on a recurring basis. The carrying amount of cash and cash equivalents was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7bc8b56-38a9-435d-845f-c78fe7aaae6d" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">133.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b59da963-02c4-4401-81ad-25b466121c49" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">99.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, which approximates fair value and was determined based upon Level 1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level 1.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4dbaf032-0b80-4d84-9c60-df4989e9f55c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true" continuedAt="F_4dbaf032-0b80-4d84-9c60-df4989e9f55c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_4dbaf032-0b80-4d84-9c60-df4989e9f55c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had restricted cash of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f5ed8de-d041-464f-b6c3-7ddec6410a82" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9d1e8d8-3a3e-47f0-80d2-14b46e203967" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, primarily related to a security deposit on its operating leases for its offices in Somerville and Charlestown, Massachusetts for the year ended December 31, 2021, and for its operating lease for its offices in Somerville, Massachusetts for the year ended December 31, 2020. This is included in restricted cash, non-current and other assets on the Company&#x2019;s consolidated balance sheets.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a09bad39-1dff-4863-8d58-0f0dbdb17848" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_a09bad39-1dff-4863-8d58-0f0dbdb17848_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a09bad39-1dff-4863-8d58-0f0dbdb17848_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December 31, 2021 and 2020, the Company&#x2019;s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbba39c0-28a9-4ff8-bf9f-453228a6182e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" escape="true" continuedAt="F_bbba39c0-28a9-4ff8-bf9f-453228a6182e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receivable are carried at the invoiced amount less an allowance for doubtful accounts. Doubtful accounts are provided for on the basis of anticipated collection losses. The estimated losses are determined from historical collection experience and a review of outstanding accounts receivable. A receivable is considered past due if the Company has not received payment within the stated payment terms. After all attempts to collect a receivable have failed, the receivable is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_bbba39c0-28a9-4ff8-bf9f-453228a6182e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">written </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">off against the allowance. Based on historical receipts and collections history, management has determined that an allowance for doubtful accounts is not necessary as of December 31, 2021 and 2020.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb7a119d-59c4-4ea8-b2f4-38d0a0a4f1a3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred, while any additions or improvements are capitalized. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd841a62-4635-4f26-82dd-3e92a56fd1c6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" escape="true" continuedAt="F_fd841a62-4635-4f26-82dd-3e92a56fd1c6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_fd841a62-4635-4f26-82dd-3e92a56fd1c6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:60.992%;"></td>
          <td style="width:2.063%;"></td>
          <td style="width:36.944%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">ESTIMATED USEFUL LIFE</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c09babb2-68c4-41e5-9ea4-40993c229032" contextRef="C_2986efa3-0d9a-4a27-8474-473277d39a68" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce2b5690-bd9c-458c-adfc-b41617c2f364" contextRef="C_f2f7e686-a500-4145-884d-a28aca2133c9" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c867d83-f46b-4533-85ee-19b9ff261236" contextRef="C_cb5222a4-6edc-4157-b8f3-0776d5488397" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_878fa8bc-5b17-4a58-a99f-43b90ffbca47" contextRef="C_6c2fd835-a216-403d-821e-6c8b06fd2c61" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7484c4fa-0601-41aa-84ca-453b0ca68ca7" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true" continuedAt="F_7484c4fa-0601-41aa-84ca-453b0ca68ca7_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and In-Process Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is the amount by which the cost of the acquired net assets in a business combination exceeds the fair value of the identifiable net assets on the date of purchase or valuation. The Company accounts for goodwill in accordance with ASC Topic 350, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#x2014;Goodwill and Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired In-Process Research and Development (&#x201c;IPR&amp;D&#x201d;) represents the fair value assigned to research and development assets that the Company acquired that had not been completed at the date of acquisition and is accounted for as an indefinite lived intangible asset in accordance with ASC Topic 350, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#x2014;Goodwill and Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The Company&#x2019;s IPR&amp;D is comprised of Crestovo&#x2019;s research and development asset related to CP101, which was acquired in the Merger.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill and IPR&amp;D are evaluated for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company&#x2019;s use of the acquired asset or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company&#x2019;s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of goodwill, the fair value of the Company&#x2019;s single reporting unit is compared to its carrying value. If the reporting unit&#x2019;s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value. The Company&#x2019;s annual assessments for impairment of goodwill as of October 1, 2021 and October 1, 2020 indicated that the fair value of its reporting unit exceeded the carrying value of the reporting unit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;D project exceeds its fair value. The Company estimates the fair value of IPR&amp;D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. The Company&#x2019;s annual assessment for impairment of IPR&amp;D indicated that the fair value of its IPR&amp;D asset as of October 1, 2021 and October 1, 2020 exceeded the respective carrying value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_7484c4fa-0601-41aa-84ca-453b0ca68ca7_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any impairments are recognized as a loss in the year the goodwill and/or IPR&amp;D are determined to be impaired. Impairment of IPR&amp;D is recorded as research and development expense and impairment of goodwill is recorded separately as a loss in other income (expense) on the Company&#x2019;s consolidated statements of operations. To date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4263e394-54e0-40c2-ab72-8b3694d3b8a7" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment loss has been recognized. Additionally, there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3a615a1-b038-4d01-a07d-42ec97f4681d" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d1f65061-a563-4942-9f83-3275ecdc72f1" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> change to the carrying value of goodwill and IPR&amp;D for the years ended December 31, 2021 and 2020.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93f4ebb7-9470-483e-9b00-11e160dc9228" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:DeferredInitialPublicOfferingCostsPolicyTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Initial Public Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred initial public offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be abandoned, the deferred initial public offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. On March 18, 2021, the Company completed the IPO; accordingly, the Company recognized the deferred initial public offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_456931b9-c535-4fa5-849d-afe504fa8e34" contextRef="C_54d8859b-3cf9-4f25-81a8-0121817ec070" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from gross proceeds associated with the IPO through additional paid-in capital in the accompanying consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a0d2e09-ef70-449f-b358-6669bdb05787" contextRef="C_4f9e11d5-5772-4d8d-aeba-f92855030d1d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">192,877</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, and the Company recognized offering costs of less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbaa4a05-9bdd-49e0-bee5-9d543da5ab3f" contextRef="C_894a98a6-c6bc-4f3a-98ca-fb68d588713d" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from gross proceeds associated with the overallotment through additional paid-in capital in the accompanying consolidated balance sheet. Accordingly, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_670aee3c-79a3-4f7f-b696-f117623d9244" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> deferred offering costs as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Deferred offering costs on the accompanying consolidated balance sheet as of December 31, 2020 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c32bc8de-c5bf-49f8-ae6b-89f750208f0b" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9484bd62-fa2a-4c0f-a0a1-dba4f971995c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU 2016-02,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Leases (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 842</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors), and replaces the existing guidance in ASC 840, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FASB subsequently issued amendments to ASC 842, which have the same effective date of January 1, 2019: (i) ASU 2018-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Codification Improvements to Topic 842,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which amends certain narrow aspects of the guidance issued in ASU 2016-02; and (ii) ASU 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and not restate prior periods presented. ASC 842 requires lessees to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. The Company adopted ASC 842 during the quarter ended December 31, 2021, with an effective date of January 1, 2021, using the modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior period financial statements continue to be presented in accordance with ASC 840.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The adoption of this standard resulted in the recognition of operating lease right-of-use assets of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db1be9c0-86f5-4bca-a48b-c8e8489114e4" contextRef="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and current and noncurrent operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_474525a4-f6c9-4365-8c4b-75d5a6965a11" contextRef="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e313c1c1-73d2-47a2-83d4-f36e712ab63d" contextRef="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, and the derecognition of deferred rent liabilities and unamortized lease incentives of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee66c061-4207-4b07-8f83-dac57eb38a43" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:DerecognitionOfDeferredRentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b2759fe-e0e7-44b6-a11b-6a6855d10491" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:UnamortizationOfLeaseIncentives" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, on the Company&#x2019;s Balance Sheets as of January 1, 2021 relating to its office leases in Somerville, MA. The adoption of this standard did not have a significant impact on the Company&#x2019;s consolidated Statements of Operations or Statements of Cash Flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to January 1, 2021, the Company accounted for leases under Accounting Standards Codification 840, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#x2018;&#x2018;ASC 840&#x2019;&#x2019;). At lease inception, the Company determined if an arrangement was an operating or capital lease.  For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent.  The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified  deferred rent as current and  noncurrent  liabilities based on  the portion of the deferred rent that was scheduled to mature within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#x2019;s control over the use of that identified asset. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use (&#x201c;ROU&#x201d;) asset and current and non-current lease liabilities, as applicable on the balance sheet. The Company elected, as allowed under ASC 842, to not recognize leases with a lease term of one year or less on its balance sheet. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and records its lease liabilities based on the present value of lease payments over the expected remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in the lease contracts if that rate is readily available. As the implicit rate has not historically been readily determinable, the Company utilizes its incremental borrowing rate (&#x201c;IBR&#x201d;), which reflects the fixed rate at which the Company could borrow on a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collateralized basis over a similar term to fund the amount of lease payments to be made in a similar economic environment. Management determines the appropriate IBR to use based on the Company&#x2019;s credit standing and market environment at lease commencement. The Company measures its ROU assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.) , non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated, based on the respective relative fair values, to the lease components and non-lease components. However, the Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement and the establishment of a ROU asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When a lease is modified and the modification is not accounted for as a separate contract, the Company remeasures its ROU assets and lease liabilities.  A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab59510f-53cd-4251-8daa-cc3ba455efab" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_ab59510f-53cd-4251-8daa-cc3ba455efab_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_ab59510f-53cd-4251-8daa-cc3ba455efab_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38a6d141-7d4c-4713-85dc-8596f4dca141" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_38a6d141-7d4c-4713-85dc-8596f4dca141_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_38a6d141-7d4c-4713-85dc-8596f4dca141_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fe60a5f-fa23-44ce-98c7-d7b46c1f89d6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_7fe60a5f-fa23-44ce-98c7-d7b46c1f89d6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_7fe60a5f-fa23-44ce-98c7-d7b46c1f89d6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, the Board and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a one-for-14.444 reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company&#x2019;s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into 31,253,609 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_368507ef-b18c-4dd1-bd43-2753e9c5b607" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true" continuedAt="F_368507ef-b18c-4dd1-bd43-2753e9c5b607_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for all stock-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#x2019;s stock-based payments are comprised of stock options. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_368507ef-b18c-4dd1-bd43-2753e9c5b607_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has historically been a private company until its IPO in March 2021 and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d73a8dd-45cb-4196-8a40-c5aa55a6a7d2" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_4d73a8dd-45cb-4196-8a40-c5aa55a6a7d2_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is primarily subject to U.S. federal and Massachusetts state income tax. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eef7532c-8b80-4c63-8718-f785289a3fda" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_4d73a8dd-45cb-4196-8a40-c5aa55a6a7d2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company maintains a reserve against certain federal and state research and development credits that are recorded net in deferred taxes. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0606e113-aa5e-4287-8651-d83a6c19ba2d" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals for interest or penalties related to income tax matters. Tax years since inception remain open to examination by federal and state tax authorities.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b9304a5-aaf1-44a1-9537-0a94c3bef0bd" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has historically generated revenue from the following sources: (1) collaboration revenue from the collaboration agreement with Takeda Pharmaceutical Company Limited (see Note 7) and (2) royalty revenue from OpenBiome&#x2019;s sales of a licensed product under the Asset Purchase and License Agreement with OpenBiome (see Note 7).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The promised goods or services in the Company&#x2019;s arrangements typically consist of (1) a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services; (2) an obligation to transfer FMT materials; or (3) an obligation to provide pre-clinical and clinical research and support services. Under the collaboration agreement, the Company provides options to additional items, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract. For performance obligations which consist of FMT materials, shipping and distribution activities occur prior to the transfer of control of FMT materials and are considered activities to fulfill the Company&#x2019;s promise to deliver goods to the customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates the transaction price based on the amount expected to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and are included in the transaction price only to the extent it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are added to the transaction price with a corresponding adjustment being made to the measure of progress, and, as necessary, recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For contracts which have more than one performance obligation, the total contract consideration is allocated based on observable standalone selling prices or, if standalone selling prices are not readily observable, based on management&#x2019;s estimate of each performance obligation&#x2019;s standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to be entitled to for the satisfaction of each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For performance obligations, revenue is recognized when control of the product is transferred to the customer and the related performance obligation is satisfied, which typically occurs upon delivery of the product to the customer, for an amount that reflects the consideration the Company expects to be entitled to receive in exchange for delivering the product. For performance obligations which consist of clinical trial participation and related support services, revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disaggregation of Revenue</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4cdba46-c69b-4965-be5c-539652d0fd08" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides revenue disaggregated by timing of revenue recognition (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:55.945%;"></td>
          <td style="width:1.804%;"></td>
          <td style="width:2.145%;"></td>
          <td style="width:17.488%;"></td>
          <td style="width:0.881%;"></td>
          <td style="width:1.804%;"></td>
          <td style="width:2.145%;"></td>
          <td style="width:16.906%;"></td>
          <td style="width:0.881%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred at a point in time</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf972f55-adec-4f96-b9bf-9a357ebcda80" contextRef="C_4de9218f-505d-4ec5-a79e-948264f8faaa" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e01f119e-db49-4bd4-855b-8be74ff5ad4e" contextRef="C_20b17903-cb4b-42fd-9bb7-362bbcc58c00" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred over time</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8d9f1d8-c821-4632-9511-2ff4b26cfe3a" contextRef="C_e1f90607-ba2b-41a5-bea3-4ef6520ec07b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,532</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a319d63b-abb6-49cd-bdb8-730ccb218531" contextRef="C_9606295d-3592-4e4f-80a8-99a45144d61e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,376</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5996628-6511-4ff4-b077-43112c42acbe" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,532</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c65d78ca-ff94-467e-8418-ddf90abc159a" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,719</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a435aa68-c648-4744-9809-7d1069411bc9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_a435aa68-c648-4744-9809-7d1069411bc9_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a435aa68-c648-4744-9809-7d1069411bc9_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021 and 2020.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ad84b0a-db95-46fd-8915-f8dc9657bdfb" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued and Adopted Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles-Goodwill and Other- Internal-Use Software</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (Subtopic<br /> 350- 40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance for capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted the standards on a prospective basis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on January 1, 2021.The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively and certain others to be made retrospectively. The Company adopted this standard on January 1, 2021, and this standard did not have a material impact on its consolidated financial statements and related disclosures for the year ended December 31, 2021. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9e54d8e-8c86-4db3-a283-91956d30758d" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. FAIR VALUE MEASUREMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f512a9b5-ee33-443e-86b3-7e7550ce55b0" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:38.815%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.931%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.931%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.981%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.981%;"></td>
        <td style="width:0.626%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DESCRIPTION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">QUOTED<br />PRICES<br />IN ACTIVE<br />MARKETS FOR<br />IDENTICAL<br />ASSETS<br />(LEVEL 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br />OBSERVABLE<br />INPUTS<br />(LEVEL 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br />OBSERVABLE<br />INPUTS<br />(LEVEL 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69501479-770a-4a45-9983-5d1d1b49fcf9" contextRef="C_97f8bd01-bf35-4029-b59b-fedcc19e7fa8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59699bd9-67ea-4457-9905-242c96347d0d" contextRef="C_aa2b03ad-bfcf-4d93-bc04-01ee6362dafd" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2a7e1b8-d4b5-4b5c-9fc9-e77419b54f80" contextRef="C_84da10c1-11ac-42c7-a238-2c5259bce7ee" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d3b058a-6425-4f75-8664-87af9cc14489" contextRef="C_d858d07b-3375-4198-87a7-a594e75f4620" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.815%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.931%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.931%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.981%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.442%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.981%;"></td>
        <td style="width:0.626%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DESCRIPTION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">QUOTED<br />PRICES<br />IN ACTIVE<br />MARKETS FOR<br />IDENTICAL<br />ASSETS<br />(LEVEL 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br />OBSERVABLE<br />INPUTS<br />(LEVEL 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br />OBSERVABLE<br />INPUTS<br />(LEVEL 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b59642d-cab7-4c39-9f24-091a1bd86d64" contextRef="C_d35ab3f0-886e-4614-bb8e-288d6e18d8a8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7778b4d-8848-4e88-9f52-78a59069b131" contextRef="C_ffad40cc-645b-45db-bb47-731c0e92c8ed" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b1904c6-15c1-43a5-9ba5-34ff160e2117" contextRef="C_193c9642-0dfc-4b03-beda-cbe44093e952" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d4de75f-a9c5-4b0b-a917-c81ea91521a0" contextRef="C_1290669d-3ef4-4091-b2fe-97c62f8ec90f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c24de56-5ca4-4306-85a3-513f6e387916" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:TransfersBetweenFairValueLevels" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b5997cce-4ac8-486c-a37b-1c6996def664" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:TransfersBetweenFairValueLevels" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between fair value levels during the years ended December 31, 2021 and 2020. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_768d4dff-890f-46d4-bcbf-4ea6f28ec093" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. PROPERTY AND EQUIPMENT, NET</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c8d0f08-88b4-45ee-ab85-02cf672eff4c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.503%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:16.696%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:15.676%;"></td>
        <td style="width:1.193%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55b8be57-3bf8-4cff-8e0d-dcd403a3eadf" contextRef="C_ee5e5087-1f48-495c-a0c7-df7f666bcc55" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0cccc11-0c51-40fa-b5b1-436ae3971652" contextRef="C_1fc799d2-e7ca-49cd-94bd-3368b8b30296" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,363</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52164a80-b98f-4c08-a1da-f9ccf6974946" contextRef="C_8192ae4f-1c2b-4a80-a43c-6831f9eb30f2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">537</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_298be6ac-5ec6-40cd-b6e4-51dc7bb56744" contextRef="C_7eff636f-c2ac-47da-b8b3-a7419771eb22" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">537</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42393eb6-a37f-4b05-aecb-20bd11298c3c" contextRef="C_c5aa5df0-f902-4636-ba9a-661aa8e20277" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,894</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5558c33c-7628-419b-854b-78e050d4ff4a" contextRef="C_b5ab9bc6-ee73-4ce5-9025-8b3e49b4281c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,143</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction work-in-progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6420f7a-4f18-45ab-9a39-9fe4faa4ffe2" contextRef="C_2bd85910-ac68-4113-bf19-049baf264c14" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a90e04c2-4733-4882-82b2-38c37016e086" contextRef="C_05c62255-213e-4926-a804-309677cebed5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,635</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_930aa7c7-c260-4c39-b15e-820480b1d4c8" contextRef="C_32730e64-85f4-497d-935f-ef876cb18554" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,883</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d798e9be-447f-4d03-8d99-36405945adb5" contextRef="C_eb9e58de-8667-4321-b6aa-911f48db159f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d33e7ed-1221-48c2-a603-988189952e9a" contextRef="C_6d564718-6e70-47c3-b45e-478a924b707b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48ccb4cd-7349-4d3f-be65-90992a9ae204" contextRef="C_d132eb44-d5fe-4db6-90fa-ee1cb44369fe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5dc3db3-2f84-46c8-b97f-66ada11006c3" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc216080-96a5-4e9c-a2be-3c0ed6ddeac0" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4aa45433-8ea7-45c1-b1d3-6e8a78a8f5f8" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,226</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38226be1-435f-40ed-9ef5-4d52057337a1" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf7db64b-6171-4f21-beb6-3acf03e215d5" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,635</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b35cd517-e76c-4a05-b084-8ce3cb52d1fc" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,004</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0697e14a-9c57-4654-9e8a-de8f678c5bf6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_160469b1-d9a8-4486-aef8-dab8a17a255e" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively. During the years ended December 31, 2021 and 2020, the Company purchased $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a122df05-3693-40cc-8588-740f0b21e4b6" contextRef="C_9450f23f-f434-468a-8008-c54520274c6a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51ab8b08-2914-4946-863c-e9c85e1e400d" contextRef="C_619dbd5a-3d31-4dff-bdde-1c37501aef02" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of software, property, and equipment from a related party, under the OpenBiome Agreement.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db602992-cb67-4d59-93a5-0f1266fbfc02" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:LeasesOfLessorDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. LEASES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">200 Inner Belt Road Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2015, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf4f96e8-93e7-458d-b8fa-e452ca1c857f" contextRef="C_f3c21c56-3f76-4284-9b46-d59d04095b4f" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease agreement (the &#34;Inner Belt Road Lease&#34;) for approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53e9c0f8-c7b2-48ae-b642-8cf27e2a61ee" contextRef="C_f3c21c56-3f76-4284-9b46-d59d04095b4f" name="fnch:LesseeOperatingLeaseLeasesArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">25,785</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The monthly rental payments under the Inner Belt Road Lease, which include base rent charges of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a97a092-b7e1-426a-afa1-1dce02c05c5e" contextRef="C_3997c41e-c3c8-4da2-92c5-b9b78945ec5f" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, are subject to periodic rent increases through September 2026.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2016, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6693e516-3871-4712-a4ca-b2116e5c1248" contextRef="C_516796e2-fbe9-4963-858d-72b0827743bd" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sublease agreement (the &#34;200 Inner Belt Road Sublease&#34;) to share its leased space under the Inner Belt Road Lease with OpenBiome, a related party, as sub-tenant. The sublease with OpenBiome is coterminous with the Inner Belt Road Lease and provides for an allocation, based on OpenBiome&#x2019;s proportionate share, of base rent and other expenses under the Inner Belt Road Lease, which is subject to change each year based on current headcount and space used. OpenBiome&#x2019;s proportionate share is reassessed on a quarterly basis over the term of the sublease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the Company amended the Inner Belt Road Lease to lease an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8e7c31b-97b6-4fd9-a1fd-6ea6727be356" contextRef="C_c2016132-69da-4b8f-8d71-133d0638c922" name="fnch:LesseeOperatingLeaseLeasesAdditionalArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">10,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The term of the Inner Belt Road Lease and the sublease with OpenBiome were not affected as a result of the amendment, although OpenBiome does occupy some of this additional space. The rental payments for the additional space under the amended Inner Belt Road Lease, which include base rent charges of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f4f440a-c82d-4a79-bced-29fa76457496" contextRef="C_92dda7ef-0294-4c60-82b0-253ca681399b" name="fnch:LeaseAndRentForAdditionalSpace" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">33,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per month, are subject to periodic rent increases through September 2026. In November 2020, pursuant to the OpenBiome Agreement, the Company and OpenBiome amended the terms of the sublease to provide for a reduction in the size of the subleased premises upon the closing of the OpenBiome Agreement (see Note 13), which occurred on March 1, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The sublease was further amended on January 15, 2021 and June 22, 2021 and terminated on December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's lease expense under the Inner Belt Road Lease was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93bd3057-d439-4ffb-a246-82917ee3b377" contextRef="C_f567ce58-d36b-4cfd-9d2d-43b08b57d11c" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_4f2d582a-ee76-495f-af9c-1d7f01ef00b1" contextRef="C_12c08bf0-f65b-48fb-8e06-4a1f508e55aa" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for each of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020. The Company recognizes sublease income under the sublease to OpenBiome as rent is received over the sublease term. Gross lease income under the sublease to OpenBiome for each of the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0bc8f194-421d-42f0-b818-31870e278535" contextRef="C_1eea5819-27f3-44f8-90a5-9ad45f546635" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6bc1eed-1ec9-4438-a877-c82f0a60730a" contextRef="C_bf8db871-33e8-4b48-96d6-27807a718a9e" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, and is presented as an offset to lease expense on the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cherry Street Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 1, 2021, the Company assumed a lease agreement (the &#x201c;Cherry Street Lease&#x201d;) in conjunction with the closing of the OpenBiome Agreement. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_935ce1f2-59a8-4b43-83b4-8dd6d73ca0ab" contextRef="C_ee5015be-b0fc-4255-b8a6-7d92826e8809" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lease term is from March 2021 through February 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company&#x2019;s lease expense under the Cherry Street Lease for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53a5b2eb-7570-4a42-911e-cdbc6b6b675c" contextRef="C_17959f69-52c0-4bd7-b17b-2b07c6a89b83" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c73aa992-c316-4c6e-8e96-00afc09b0c4c" contextRef="C_0f83ae0d-7bba-4546-b75f-1d3582c586e8" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concord Avenue Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 25, 2021, the Company entered into a lease agreement (the &#34;Concord Avenue Lease&#34;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7cc9ba9-0b10-4cdd-91c9-f4ec828ae818" contextRef="C_248b74bb-bfef-43a3-8d20-9cef789c8fff" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2021 through February 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#x2019;s lease expense under the Concord Avenue Lease for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4cad960-3012-46d3-8172-e9943b4835b7" contextRef="C_ec838299-1fe2-441c-a5b8-80818b17a987" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6095cbb6-67c3-4925-bc5a-d4a6e8f50279" contextRef="C_90fcacc1-0f06-47c8-b90f-1fbdb93ceffd" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9ce6f6b-6662-47db-83cf-6560e24507ab" contextRef="C_28d6c4c4-95d2-4950-aa5c-95cb9369b506" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 17, 2021 Finch extended the term of the lease for an additional two-month period through April 2022 and on February 4, 2022 Finch further extended the lease for an additional month through May 2022.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Concord Avenue Lease qualifies as a short-term lease and will be excluded from the balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">100 Hood Park Drive</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 3, 2021 (the &#34;Execution Date&#34;), the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_048484f4-0007-41c2-9093-eed45207d333" contextRef="C_34820dd6-125a-4651-9d74-471c92bb1554" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease agreement (the &#34;Hood Lease&#34;) with Hood Park LLC (the &#34;Landlord&#34;), pursuant to which the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36d192ba-f31c-4a54-90be-05c2a3fda3d8" contextRef="C_34820dd6-125a-4651-9d74-471c92bb1554" name="fnch:LesseeOperatingLeaseLeasesArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">61,139</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office and laboratory space (the &#34;Premises&#34;). The term of the Hood Lease commenced on the Execution Date, and Finch will become responsible for paying rent under the Hood Lease on the earlier of (i) January 1, 2022 and (ii) the date Finch&#x2019;s improvement on the Premises is substantially completed and Finch has commenced business operations in the Premises (the &#x201c;Rent Commencement Date&#x201d;). As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Rent Commencement Date had not occurred and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1918013e-0333-4b71-8c0b-60496294b04b" contextRef="C_29c6a1db-39a6-4d51-92a7-9d1ef5ec34c1" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1df664b4-9ef8-4ae9-956f-3adf9a96e70b" contextRef="C_5da05409-533d-466c-be18-f590067b6927" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4e9b6ee8-1281-476c-86e8-0f1cbf1afda2" contextRef="C_5da05409-533d-466c-be18-f590067b6927" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease expense, right-of-use asset, or lease liability was recognized under the Hood Lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2fc4d84-5a5f-4f8c-827b-1998a4b8faf4" contextRef="C_d4f0fa8f-0e53-4dd0-96a5-34610a065137" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Hood Lease provides Finch with an option to extend the lease for one additional five-year term</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Finch&#x2019;s annual base rent for the Premises will start at approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e492e1f-35dc-4b88-886e-baeff73aac5b" contextRef="C_b15bab6a-f44e-4005-a4ff-bbdc0471e1f1" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and the lease contains annual rent escalations. The Hood Lease provides for a tenant improvement allowance of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6b2e9af-2439-410e-b07d-afaf89ff2e82" contextRef="C_b15bab6a-f44e-4005-a4ff-bbdc0471e1f1" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the cost of Finch&#x2019;s work on the Premises. As of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29d4c222-95f0-4e94-bd55-fa77e4bd8d7d" contextRef="C_5da05409-533d-466c-be18-f590067b6927" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of lessor owned tenant improvements were completed by the Company and are recorded in other current assets on the consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company posted a customary letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1878571a-f8df-49e5-a3c3-604418c97067" contextRef="C_e162eb52-c156-467f-9465-7e2422f556b3" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, subject to decrease on a set schedule, as a security deposit pursuant to the Hood Lease. This is included in restricted cash, non-current on the consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a05b6650-bec3-4cbb-9949-61a876e77048" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:LeasesBalanceSheetInformationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the classification of right-of-use assets and lease liabilities as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.926%;"></td>
        <td style="width:40.813%;"></td>
        <td style="width:1.852%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:20.885%;"></td>
        <td style="width:0.746%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BALANCE SHEET CLASSIFICATION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ASSETS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c070302c-1763-4d9d-9d03-41db3430085d" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,053</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance lease assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e2d6ca4-3c27-4065-bd7a-dfb74ee69183" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72002164-5acf-4620-9a07-ec2f07bfc775" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:LeaseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,075</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1045b666-3c89-49d6-989d-a9c7192e4fc5" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Finance lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cb5f7ed-5764-4079-9ea2-3e4d127426ff" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_823d5dd6-a962-4a77-9dcd-66a9b39b1808" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Finance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e657055e-7cd5-4b55-9a7f-a0622efa46cc" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa735b8c-50ef-4afa-af19-3779bd4ea462" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:LeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b83a1e0e-5575-441f-a7cb-67463c9623ff" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table represents the components of lease cost, which are included in general and administrative and research and development expense on the statement of operations, for the year ended December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.489%;"></td>
        <td style="width:8.243%;"></td>
        <td style="width:1.815%;"></td>
        <td style="width:33.234%;"></td>
        <td style="width:1.218%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LEASE COST</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance lease cost:</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Amortization of right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b468583-762f-4d2e-af4d-d8c509c1e288" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Interest on lease liabilities</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8a3ffe6-a77e-4333-bf69-c25af795ddf8" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc5b7199-ea3a-4127-a095-5120c6a064d1" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,336</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Short-term lease cost</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08fc575e-e782-4a67-b5f3-adbcb8db1398" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96f455a1-fa0d-4709-82af-fd48a25a3bf3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sublease income</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f748d30-e8a8-4e9a-baa1-fcebdae49398" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c07bc4d8-84f3-498c-a3a2-4ecbd5524b6b" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,064</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ce7c92d-ab25-4d50-871c-08df7e8c6bf1" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:LeaseTermAndDiscountRateTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining lease term and discount rate were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.741%;"></td>
        <td style="width:2.021%;"></td>
        <td style="width:31.238%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LEASE TERM AND DISCOUNT RATE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remining lease term (years)</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26c6ab11-1ba2-47e1-8f07-97a2e34f8f35" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Finance Leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dda6c6d6-4402-4d85-98e7-5f9f20c931b5" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bf16509-200a-41dc-8113-068f6c4d9ade" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Finance Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f82749e3-24bb-41a8-a458-5c052e13def3" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">30.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7097a4e4-1ada-42d8-83ab-5d228febca2f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosure of cash flow information related to leases was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.631%;"></td>
        <td style="width:1.492%;"></td>
        <td style="width:1.803%;"></td>
        <td style="width:24.291%;"></td>
        <td style="width:0.783%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">SUPPLEMENTAL CASH FLOW INFORMATION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab29736a-80fa-433a-a665-6feed84c1e7e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Financing cash flows from finance leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41e3ffde-b525-487c-927d-a470f837d4bc" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:PrincipalPaymentsOnCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24ac26b5-5a1d-4362-a311-7ad38edfc4af" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ScheduleOfFutureLeasePaymentsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table represents a summary of the Company&#x2019;s future lease payments required as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.503%;"></td>
        <td style="width:1.203%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:10.897%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:11.066%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.283%;"></td>
        <td style="width:9.515%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.283%;"></td>
        <td style="width:9.515%;"></td>
        <td style="width:0.855%;"></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OPERATING LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">HOOD PARK LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">FINANCE LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TOTAL LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7de635a0-08fc-453e-8b28-e17f47206878" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_999384ce-d878-4195-9036-e944922d94fd" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0df06848-8823-4be7-8cce-6ec5dcea40f3" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_706d0327-d207-4320-9b04-322af442eadc" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a10b352d-7835-4a7b-a139-b0a52982d156" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f51bb5f7-6709-481d-b1f2-56ca1e503f62" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7069bb52-5d85-45a0-9a18-3a96e079ecc5" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e251b4b9-fb8a-4be1-9557-8b8e07938db6" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f49f0cc0-49b8-40dd-8abe-a2b50f767859" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba742708-3eac-44e7-8e4c-9062f4dc8c66" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,795</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e47d14c7-325d-4484-85e2-3b85e975ffb4" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7315b2c2-a5da-4db2-8906-2d6cf2033d67" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,255</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1c4856a-7f87-40ae-8e7f-ce88a8979e5d" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,496</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f98ca147-75ac-4b95-b972-fac8f95278be" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,931</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b627a5d-61c2-47af-973b-f88a9daed1f0" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b77f8c4-6083-4c57-9677-9c1aff01307b" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f11d1fc-286f-4bd9-97ec-5dd1eef918c3" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_469e6e12-a8b4-4c92-9d40-86d4cbfecb3e" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f25fca64-9ce3-4eff-8a49-7cd031bfde3c" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a026cbbe-31a0-45c6-a968-5b8dfd8328e1" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c0fc7c3-2983-4cdc-acd5-0e57f1c3d560" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d194cecf-cbb5-4c43-a7b6-02bce571d517" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,605</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_009c3b20-8c2f-4a6f-bd1d-70914718a579" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c02c30e-c842-4da8-8573-46ecb42cc912" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,605</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44d231d1-78b9-4b57-aa75-04574382adc6" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aedaca7a-5ecd-4178-8623-8e0d1227c884" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cf0e310-f18a-4951-83bc-cf643444e542" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20ce8d55-d248-4ab1-b16d-e28d39ece0c4" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae6e962b-12ae-40f0-9c2d-be15b423963b" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08587dc9-502e-4ec9-a388-ef481b210925" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07cfa1b6-eb76-4fd2-aa2a-76b3fddd7be2" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f072dc76-08a3-4772-9e66-661387b6e4b5" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">989</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9922ba61-5895-4f1e-8092-88dec3d34a16" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:PresentValueOfFutureMinimumLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,015</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f2a9392-6ddd-4a63-8596-b19fda423072" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8aa673b8-2e92-48f5-8c4d-80b898eda075" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0779dde7-a716-4f43-bc74-14491d7405b3" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,640</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c4c0b34-2dd3-4272-a03f-0861146b31ea" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following represents a summary of the Company's future minimum lease payments under non-cancelable lease agreements, presented in accordance with ASC 840, as of December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.242%;"></td>
        <td style="width:1.392%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:12.914%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.134%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.134%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OPERATING LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">FINANCE LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TOTAL LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f48a9a5e-c10b-4b2d-97cb-569d1634ac3c" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea7f107c-b99f-4b7c-b453-ff65e0946575" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_200b6061-eeac-42b3-9b1e-127e44fc2640" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e226c9db-47a2-4974-bbb3-d69a69b147bf" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1265beae-92b2-4d28-9e4b-d24996e7070b" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6723322-7e38-471f-9a42-0dc5e0172a81" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b420fbed-cbf5-450d-9359-a92ef2c06c92" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b567637-8f6e-4ca5-9697-d7d680d2da26" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2ac04c3-d27e-41df-bbe2-7078cc712197" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae8df3d0-ca17-449a-b4ae-01c1cf0f572d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39b653f0-1c0a-4f84-baee-90f1716259cc" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01c3212c-deda-4fb8-a802-21c3f2431acc" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e7dc6b3-eea0-462c-875d-5950ecdf5f73" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,496</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b8de5be-26dc-4a03-bed2-64be1e11f1ec" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f24efd4-b8b8-4800-9301-9cc04b0f3b51" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,496</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4cfa302f-b989-47b8-ae47-810f14bc16d5" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5488a370-ea8a-4e88-9f9c-cfbe152c647a" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2c133d9-56f2-4284-98ba-524490fe8e4c" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aedb844a-7b40-4896-b5fe-f1f4d643e653" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92771f55-1eca-4d95-8788-0f219c26d157" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17c36f6f-b457-4ea5-8e5b-66489454a3b1" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d4f29ae-101f-4427-b90e-097160587220" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a76e0827-72bd-47fe-8057-40821039bae8" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cef8431b-81b0-4ff3-a27b-674b4690af95" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9ec70f1-0c83-4cfd-a208-b207d105739e" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:PresentValueOfFutureMinimumLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69687429-b4c9-47c8-b44b-74f738890229" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8d1ea06-6e0d-43e7-b068-a1d27fc91c27" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1409bc24-4a0d-4d97-beb4-9f6c52420b38" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6327889a-261b-4407-a1a6-e2df869f650c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.567%;"></td>
        <td style="width:1.616%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:16.051%;"></td>
        <td style="width:0.758%;"></td>
        <td style="width:1.616%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:16.051%;"></td>
        <td style="width:0.758%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4db73eb-160e-4f0e-b98b-da5eb0a0fdc1" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,345</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91dd4de1-a70f-4de0-a09e-c0f013da3ddc" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued legal and professional fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f262b49d-3809-4cd1-85cf-250695bb64ab" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dafeb827-8584-4d2f-b891-3f0ba5fe01ce" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">711</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_399fdc08-3d32-4971-a03d-73da6dfce8a1" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ef9f851-3540-4e06-9cf2-e96277c59590" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_227bdafd-6334-4cc6-886b-2e25ea3c80b1" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ccd70f4-6753-4676-967d-e522b6e1e90f" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_876fad5b-625f-4bab-af58-5d79f460fb5a" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51345bc0-3093-4797-a333-57985f5cd61c" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_521a9978-ea9d-4939-ae68-c2d1484b48e0" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. REVENUE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Takeda Pharmaceutical Company Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the Company entered into an agreement (the &#x201c;Takeda Agreement&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), pursuant to which the Company granted Takeda a worldwide, exclusive license, with the right to grant sublicenses, under certain of its patents, patent applications and know-how to develop the Company&#x2019;s microbiome therapeutic candidate FIN-524, now known as TAK-524, for the prevention, diagnosis, theragnosis or treatment of diseases in humans. The Company subsequently amended and restated the Takeda Agreement in October 2019 to provide for the Company to allocate certain resources towards determining the feasibility of developing a second microbiome therapeutic candidate, FIN-525. The Company further amended the Takeda Agreement in August 2021 to transition primary responsibility for further development and manufacturing activities with respect to TAK-524 from the Company to Takeda in accordance with a transition plan, and Takeda assumed sole responsibility for regulatory matters with respect to TAK-524. In November 2021, Takeda Agreement was amended again to enable the Company to carry out certain FIN-525 preliminary evaluation activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Takeda Agreement, the Company agreed to design TAK-524, a product candidate optimized for ulcerative colitis, for Takeda based on selection criteria within a product-specific development plan. The Company also agreed to conduct a feasibility study to potentially further develop FIN-525, a program to develop a live biotherapeutic product optimized for the treatment of Crohn&#x2019;s disease. The Company assessed this arrangement in accordance with ASC 606, and concluded that the contract counterparty, Takeda, is a customer. The Company identified the following material promises at the outset of the Takeda Agreement: (1) an exclusive license to use the Company&#x2019;s rights in intellectual property to conduct research activities; (2) R&amp;D services for activities under the development plan; (3) two options to pursue different indications of research for the Company&#x2019;s right in product candidates; (4) manufacturing and supply for the Company&#x2019;s clinical trials; and (5) participation on a joint steering and joint development committee (&#x201c;JSC&#x201d; and &#x201c;JDC&#x201d;). The options were considered distinct from the other promises in the arrangement and analyzed for material rights; the Company concluded these were not material rights and the consideration related to them should be excluded as a performance obligation until the option is exercised. The Company determined that the remaining promises were not capable of being distinct from one another and were not distinct in the context of the contract. In accordance with the Company&#x2019;s ASC 606 assessment, the Takeda Agreement was determined to contain a single combined performance obligation made up of the promises above, excluding the options. The FIN-525 feasibility study was determined to be part of the single combined performance obligation due to its connection to the original license and research and development activities. The FIN-525 feasibility study was completed in March 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received an upfront payment from Takeda of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce2aebf6-8a3c-460d-a688-1ff15ccec3fb" contextRef="C_71180d5f-f125-42b1-a289-021fbd6caff4" name="fnch:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the year ended December 31, 2017 in exchange for the exclusive license of the Company&#x2019;s intellectual property. The Company has included the upfront payment and the estimable reimbursable R&amp;D costs in the transaction price and is recognizing revenue associated with it over the period it expects to perform R&amp;D services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the original agreement the estimated term for the R&amp;D and manufacturing services for which the Company had primary responsibility, was through Phase 1 clinical trials.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 9, 2021, the Company and Takeda entered into an amendment to the amended and restated Takeda Agreement (the &#x201c;Amendment&#x201d;). Pursuant to the Amendment, Finch and Takeda transitioned primary responsibility for such development and manufacturing activities from Finch to Takeda in accordance with an agreed upon transition plan, and Takeda also assumed sole responsibility for regulatory matters with respect to TAK-524. The Company accounted for the Amendment as a modification to the existing contract under ASC 606, as the Amendment significantly reduced the remaining performance obligations, which were then completed by September 30, 2021.  As a result, the remaining revenue that had been deferred under the Takeda Agreement was recognized in the third quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, Takeda and Finch entered into an amendment to the amended and restated Takeda Agreement (&#34;Amendment #2&#34;). Pursuant to Amendment #2, Finch is performing certain additional research activities related to the feasibility of the FIN-525 program prior to Takeda making the decision to initiate the full development program. Under the amendment, Takeda shall pay Finch for pass-through costs incurred and research services performed at the agreed-upon full-time equivalent (&#x201c;FTE&#x201d;) rate. The additional feasibility work is expected to be completed in the first quarter of 2022 at which point Takeda can determine whether to initiate a full product specific development plan for FIN-525 following its review of the data.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized revenue related to the Takeda Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87f574d5-0dcd-4d63-b5ca-3e94b7043be6" contextRef="C_caa9d4b6-a795-41fe-9dbc-e8ef123673de" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f169124-13e5-4979-b227-5fa31aa24d3e" contextRef="C_4e5ad697-00fd-45d8-8d53-5221838de719" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively, which is included under collaboration revenue in the consolidated statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Takeda reimburses the Company for certain R&amp;D costs on a quarterly basis. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded accounts receivable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d902e925-5304-4f3a-8ed4-7591570a1dcf" contextRef="C_e3e50907-6887-4220-a0d9-4a36fa444e7f" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75686484-e921-4540-a090-1361de10769c" contextRef="C_12ceb0d9-027f-4047-880f-0f426157ce04" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on its consolidated balance sheets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, and December 31, 2020, respectively. As of December 31, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_056bce46-d31c-4a34-9cfc-7df5a32457e1" contextRef="C_e3e50907-6887-4220-a0d9-4a36fa444e7f" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> remaining deferred revenue due to the Company's satisfaction of the performance obligation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2020, the Company recorded deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51fe886f-16a1-4bdd-b7c0-66a85fdc8c32" contextRef="C_12ceb0d9-027f-4047-880f-0f426157ce04" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the Takeda Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Takeda Agreement contains various milestone payments associated with development and commercialization efforts that provide for a maximum available amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3bc8b3c-dfca-4079-9d47-515e8eb96f54" contextRef="C_049c3cdd-3341-4084-9a6d-e1edee63342e" name="fnch:MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">180.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million should all of the milestones be achieved. These milestones are constrained until the Company determines it is probable that the cumulative revenue related to the milestones will not be reversed</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company has earned and received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b0e7b25-bb92-4731-be67-cc5773731bc7" contextRef="C_049c3cdd-3341-4084-9a6d-e1edee63342e" name="fnch:MilestonePaymentsReceivedUnderAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in milestone payments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is still eligible to receive royalties under the Amendment and Takeda is obligated to pay the Company mid-to-high single digit royalties based on annual aggregate net sales of the licensed products, on a product-by-product basis, subject to certain restrictions. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbca904d-d7ec-4cbb-96c5-4db638cd4dc2" contextRef="C_754cfea2-fdc5-4ff8-a708-49bbef66cbaa" name="us-gaap:ProceedsFromRoyaltiesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_89215cd8-c22b-448d-a81c-8a6839b048da" contextRef="C_60b68536-8ed1-43da-ac13-d5bdb8aa1b26" name="us-gaap:ProceedsFromRoyaltiesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t receive any payments or record any revenues related to sales-based royalties under the Takeda Agreement in the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and OpenBiome entered into an Asset Purchase and License Agreement (the &#x201c;APL Agreement&#x201d;) in February 2019 that was effective through November 2020. Under the APL Agreement, the Company licensed certain intellectual property and sold certain fecal microbiota transplantation, or FMT, materials and equipment to OpenBiome (see Note 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_025bf04d-a4a5-459c-98ad-c06573e2f699" contextRef="C_cd8cbba4-d765-4c03-adf6-a6cf25b63c61" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0ece477-8a29-4a85-b15d-15ce58fa9ee5" contextRef="C_799a1f7a-7972-48f7-b715-47a07a846536" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in royalty revenue related to the APL Agreement in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively, which is recorded as royalty revenue from related party on the Company&#x2019;s consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 19, 2020, the Company entered into the LMIC License Agreement (&#x201c;LMIC Agreement&#x201d;) with OpenBiome, pursuant to which the Company granted OpenBiome a non-exclusive license, with the right to grant sublicenses, under certain patents, patent applications, and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from donor-sourced stool without the use of culturing or replication, or certain natural products (&#x201c;OpenBiome Royalty Products&#x201d;). The license granted to OpenBiome excludes a license under the Company&#x2019;s intellectual property to exploit a lyophilized natural product (such as CP101) where processed stool is lyophilized. The Company owns all improvements and modifications made to the licensed intellectual property throughout the term of the LMIC Agreement, while OpenBiome is responsible for all manufacturing efforts and all expenses associated with these efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The LMIC Agreement was entered into separately from the asset purchase agreement with OpenBiome (the &#34;OpenBiome Agreement&#34;) (see Note 13) and the license granted under the LMIC Agreement is unrelated to the assets acquired under the OpenBiome Agreement. The only consideration provided to the Company under the LMIC Agreement is in the form of future royalties on net sales of OpenBiome Royalty Products. The Company is entitled to receive tiered royalties on net sales of certain products, ranging from mid-single digit to low second decile digits on a product-by-product and country-by-country basis. In the event that OpenBiome is required to pay a royalty to a third party to obtain rights under patents owned or controlled by such third party that are necessary for the exercise of its rights under the Company&#x2019;s intellectual property pursuant to the LMIC Agreement, then OpenBiome shall have the right to deduct a portion of the amount of the royalty due to the third party against the royalties that are due from OpenBiome to the Company. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69b85544-8602-4917-a9e9-507ed4da198b" contextRef="C_e102589d-5e6a-4e44-bd66-a82362df7fb0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t earned any of these royalty payments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The LMIC Agreement will continue in perpetuity until the last royalty is earned under the LMIC Agreement unless otherwise terminated by either party. OpenBiome has the right to terminate the LMIC Agreement for convenience upon 90 days&#x2019; specified prior written notice to the Company. Either party may terminate the LMIC Agreement in the event of an uncured material breach by the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64bc3e8a-9333-4fb4-a30e-a8d1edd2b4ea" contextRef="C_db086534-a8d4-4c38-a41b-514f72bc36c0" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7179f762-2fc2-4d68-8abc-7a3c984fd461" contextRef="C_1bd4a0ca-99c2-4074-b339-97461c98088b" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize any revenue related to the LMIC Agreement for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as there are currently no marketable OpenBiome Royalty Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0134fe1b-914d-4694-84c6-166564b5b3c4" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_0134fe1b-914d-4694-84c6-166564b5b3c4_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_930a967a-5e48-4c74-bf4a-3be9c74507ef" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate differed from the statutory federal income tax rate due to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.37%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:0.808%;"></td>
        <td style="width:16.271%;"></td>
        <td style="width:2.983%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:16.134%;"></td>
        <td style="width:2.983%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal income taxes at 21%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df6707f2-4968-495f-85a7-27ed9d5c9f0b" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">21.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f7b5c1b-85b9-42bc-bd9c-976e93349135" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">21.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit and tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21c05b8d-8d8c-487b-95ac-602afbe9631d" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">6.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd7a0cd3-e442-40fd-901c-b02068384d75" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">6.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96d7f9c9-231d-4318-9d8a-cb1237366f7c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">0.19</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9c65bd5-0f18-4049-aa81-04ea5ca6fbb8" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">1.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03495a57-519b-4577-860f-3af44b304298" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3192f7c0-24f0-4117-953e-67a5203670e6" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7ea40ab-f47e-4920-9ae6-f7942a59347e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">29.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_870b562f-dfa1-40b2-86ee-f40498006261" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">26.96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other adjustments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_326dc153-9e9c-49ba-aa0f-61a725b80c7c" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">0.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e774bad1-c6c1-48b1-abce-cbe8fd1e69c5" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc18c84e-3eb1-430a-afe5-22156f5fb8f4" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71a71898-5da2-4d08-983d-bdb74a3249f1" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dd6ada7-d0ab-4a5e-aa3d-6fcf214baf64" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company&#x2019;s net deferred tax assets and liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.807%;"></td>
        <td style="width:1.803%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:16.81%;"></td>
        <td style="width:1.194%;"></td>
        <td style="width:1.803%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:16.81%;"></td>
        <td style="width:1.194%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1d450f4-30bc-429e-83ae-095e38fcd137" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae9d15dc-d204-42d6-b383-3016689f095c" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,192</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57dbdf46-d5e1-497d-b5bf-1482b033e6a4" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cda96285-79c0-4057-8c87-a91716d1b99a" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,921</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e6c36d7-3f31-46df-b6fc-b29888e8ac53" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,057</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb72209c-91c2-4748-967b-c35d764df803" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">859</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18842ab6-0078-4590-b3ec-66929c71c69d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of Use Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79fa458c-8808-4314-9954-44c902831a92" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:RightOfUseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9154f7d9-0686-4de1-b74a-d5894d9d5f24" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:RightOfUseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4e70edb-5b3f-4cfa-87ef-5f5faccee0a8" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">548</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac305325-e8a0-4f2e-9519-dab537d96b66" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d1bd5b4-9308-46c1-9bde-0e282f7c62dc" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e00a14f5-b922-4753-a0aa-ce774fd96e49" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b90ee635-4e5a-47e1-8398-3b0f4389d136" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,079</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39a84dd1-59fa-4b65-9631-654068085aa9" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d274f82-01f1-459b-8258-dbc5a3d0495b" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78794677-899e-456f-bbbf-531cd7c32392" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,721</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangibles assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07edfeb3-4da4-4ad7-b6c6-ca7bc8846713" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47f3fdf8-82f0-4afa-bad3-fae8a900d3fe" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71c0fd61-0bfa-4740-8902-5188d4df6fa3" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">563</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd1e745d-a003-4bf8-baf3-5a828494bc1d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of Use Assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f34a1b22-5b00-4e47-9754-472c304b9730" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="fnch:RightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16507212-dac9-4831-9a09-704c0244f5ee" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="fnch:RightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67abf911-4711-4609-a557-36733fd1bace" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">330</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11cbb1cc-bcb9-4ff2-9dd8-d755483dce5d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_902f2558-5c00-43a1-bb16-d7388bb6c480" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6e7769c-8580-4ab7-a0c2-74a56e1c0662" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,182</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1c829ff-053e-4e57-8e63-1ddbd7273810" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f555058-6122-40e6-a5f2-a4ca7db64d3d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company continues to maintain a partial valuation allowance against its deferred tax assets. During the years ended December 31, 2021 and 2020, management assessed the positive and negative evidence in its U.S. operations, and concluded that it is more likely than not that a portion of its deferred tax assets as of December 31, 2021 and 2020 will not be realized given the Company&#x2019;s history of operating losses. In determining the amount of the valuation allowance to record, the Company considered the reversal of existing taxable temporary differences as a source of taxable income against which a portion of its deferred tax assets is benefitted. The Company recorded a full valuation allowance against the remaining U.S. deferred tax assets in excess of this source of taxable income. The valuation allowance against deferred tax assets increased by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff63f4cc-ab35-44ba-a49a-94e5bc329bd7" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 related to a full valuation allowance recorded against additional net operating losses and tax credits generated in the year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had federal net operating losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3904e825-7945-4b88-992f-a863827919b0" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">181.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which may be available to offset future federal income tax liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, the Company had federal net operating losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04b78387-3892-4db0-a5ed-8ae98e7d7372" contextRef="C_4fb463b4-797e-452d-873d-48619c046805" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which may be available to offset future federal income tax liabilities. The Company&#x2019;s federal net operating losses incurred prior to 2018, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cef01e45-638e-43de-b8b2-e380e9956140" contextRef="C_db4e3207-e9fa-4152-a818-87c22ab1f012" name="fnch:OperatingLossCarryForwardsPriorToTwoThousandEighteen" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, expire through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eba87563-20e7-48a9-8ec4-c4fae042add7" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:OperatingLossCarryForwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, while its federal net operating losses incurred in 2018 and onwards, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00ce897c-144d-4549-98d3-191e9f70d50e" contextRef="C_ea0a073d-aea6-481f-bcbd-2d2464476655" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">144.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, can be carried forward indefinitely.</span><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had post-apportioned state net operating losses of</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55e930ec-14ac-4468-9ecf-c67ec127a14c" contextRef="C_a3403fa8-bacc-4e4b-a517-c82e4d4d547a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million that can generally be carried forward </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb2477ef-1244-4d3a-8042-72479c993aa1" contextRef="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf" name="fnch:OperatingLossCarryForwardsExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. As of December 31, 2020, the Company had post-apportioned state net operating losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2274018f-9669-4bc8-886b-a0b6b0d4ad28" contextRef="C_e585cf8d-a59f-4d43-8477-6b3d9ed99d06" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million that can generally be carried forward </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ba10ca9-ff80-4ac5-aead-b0d2d4156f5d" contextRef="C_1f587b93-a68e-4011-af1c-8223963a66b9" name="fnch:OperatingLossCarryForwardsExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cdbed14-f8b6-4950-a058-af2b81fd5a0f" contextRef="C_c26cc83f-e31e-4451-9562-469d6a32f396" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb1b4dfd-5516-410b-b59e-8f468320e924" contextRef="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and state research and development credits, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe50ee66-53a7-42c7-8610-98eb6d2c89f6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which will expire at various dates through 2041</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2e78d60-934b-4d84-b965-8a8bd8954459" contextRef="C_d5f06605-6037-48e4-9be3-dc6adc0731f7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2889ea65-71d5-4145-adfe-fa92d46193ba" contextRef="C_1f587b93-a68e-4011-af1c-8223963a66b9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and state research and development credits, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b3ca40f-5e9e-4e52-9295-6c4fc310f912" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which will expire at various dates through 2040</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7923e2c-9814-4e27-8a0c-a86290613484" contextRef="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.  The Company has not, yet, conducted a study to determine if any such changes have occurred that could limit its ability to use the net operating loss and tax credit carryforward.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. As of December 31, 2021 and 2020, the total amount of uncertain tax liabilities relates to federal and state tax credit carryforwards and are all recorded net in deferred taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a27dde5-8edb-4e90-9bd1-f68b88bc7914" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.992%;"></td>
        <td style="width:1.889%;"></td>
        <td style="width:1.815%;"></td>
        <td style="width:16.718%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.889%;"></td>
        <td style="width:1.815%;"></td>
        <td style="width:16.88%;"></td>
        <td style="width:0.783%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d33f679-8ae3-4072-ae83-f6edc36c7453" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bb13b5c-c610-4671-89d8-d5e39aa7e482" contextRef="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,004</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Additions for tax positions of current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9968438c-dc8f-40e4-b536-fcf5c3b44426" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f651c1ff-e911-4e66-9042-3ecf39dfdc9e" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3154ea17-20c5-4208-a1e0-5147464b0da9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbbf828c-2f97-4167-8896-99b60825dc92" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, end of year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85e09d6f-9224-4bfb-b242-57bb108b091f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,822</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddb42833-2676-4d45-983d-02895fa364d8" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="fnch:UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,318</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3d449ba-4bc2-4771-b0da-2ca60553cbfe" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fe9de2b0-0626-4605-9eab-4f5eeab9a570" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_0134fe1b-914d-4694-84c6-166564b5b3c4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a868816-181e-4bc3-8e38-68c73be11649" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_5a868816-181e-4bc3-8e38-68c73be11649_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, &#x201c;Rebiotix&#x201d;) filed a complaint against the Company in the U.S. District Court for the District of Delaware. The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the &#x201c;&#x2018;309 patent&#x201d;); 10,463,702 (the &#x201c;&#x2018;702 patent&#x201d;); 10,328,107 (the &#x201c;&#x2018;107 patent&#x201d;); 10,064,899; 10,022,406; 9,962,413; and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the &#x2019;107, &#x2019;702, and &#x2019;309 patents. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota (&#x201c;UMN&#x201d;), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012. The U.S District Court for the District of Delaware set a trial date for a five-day trial beginning on May 20, 2024. The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined under ASC 450, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, that there is no probable or estimable loss contingency that is required to be recorded as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License payments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into contracts in the normal course of business with contract research organizations and other third parties for preclinical studies, clinical studies, and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancelable by the Company upon prior written notice. Payments due upon cancellation consist of payments for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">services provided or expenses incurred, including non-cancelable obligations of our service providers up to one year after the date of cancellation. Under these agreements, in exchange for access to intellectual property the Company may be obligated to provide future minimum royalty payments and milestone payments related to regulatory approvals and sales-based events. The Company entered into the OpenBiome Agreement in November 2020 (see Note 13) and the closing of the OpenBiome Agreement occurred on March 1, 2021. Under the terms of the OpenBiome Agreement, the Company is required to make certain milestone and royalty payments to OpenBiome in conjunction with the license and purchase of certain intellectual property related to the underlying CMC process used to manufacture materials for its clinical trials. The OpenBiome Agreement also effectively terminated the APL Agreement and the obligations under the Material Access License Agreement (the &#x201c;MAL Agreement&#x201d;), which the Company entered into with OpenBiome in December 2016.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the APL Agreement, which was entered into in 2019 and effective through November 2020, the Company was obligated to make certain contingent payments for milestones and royalties to OpenBiome, subject to the occurrence of specific underlying criteria that were dependent on regulatory approvals and sales-based events. The Company was obligated to make regulatory milestone payments to OpenBiome aggregating up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7b47c8f-995b-4278-81aa-466cca9f777d" contextRef="C_fc5421c3-a799-4980-a188-637fac870fba" name="fnch:MaximumRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of regulatory approvals, and sales-based milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4eaf4ce9-c6f5-447e-b246-29df16aa6739" contextRef="C_fc5421c3-a799-4980-a188-637fac870fba" name="fnch:SalesBasedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in sales-based milestone payments upon the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achievement </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of certain net sales criteria. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c91f7a93-0358-46a7-a374-ca2ee91c0e57" contextRef="C_aee05aaf-8f6d-4638-a8fe-67e2f46277b9" name="fnch:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to OpenBiome associated with milestones in 2020. The APL Agreement was terminated in November 2020 upon the execution of the OpenBiome Agreement (see Note 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the MAL Agreement, the Company was also obligated to pay to OpenBiome, a low single digit royalty on net sales of certain cultured products and a high single digit percentage of certain sublicensing revenue (including royalties) of licensed cultured products. These royalties were calculated on a product-by-product and country-by-country basis. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a6675ba-dd6c-4cc6-94fb-5640f0fae1b4" contextRef="C_6252e38b-5c6e-4c8e-8aa8-5c056fef33a0" name="fnch:RoyaltyPaymentsPaidOnNetSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to OpenBiome under the MAL Agreement in 2020 related to royalty payments. During the year ended December 31, 2020, the Company recorded an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12cf7160-0c96-4521-a097-29c03474afe0" contextRef="C_beb9a9a0-b07a-43a6-96d5-dca4ca792d9c" name="fnch:RemainingRoyaltyCommitmentAmountDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million owed to OpenBiome under the MAL Agreement, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eae9a4d2-c7af-4b7f-9b79-0aeb6d1c2608" contextRef="C_beb9a9a0-b07a-43a6-96d5-dca4ca792d9c" name="fnch:AdditionalRoyaltyCommitmentsAmountDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million remained due as of December 31, 2020. The MAL Agreement was terminated in November 2020 upon the execution of the OpenBiome Agreement (see Note 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PPP Loan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted to, amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the COVID-19 pandemic. The CARES Act includes a Paycheck Protection Program (&#x201c;PPP&#x201d;) administered through the Small Business Association (&#x201c;SBA&#x201d;). Under the PPP, beginning April 3, 2020, small businesses and other entities and individuals could apply for loans from existing SBA lenders and other approved regulated lenders that enroll in the program, subject to numerous limitations and eligibility criteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company issued a promissory note to Silicon Valley Bank, pursuant to which it received loan proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5aef370-afaa-4056-bbc0-29c8f24438c7" contextRef="C_c284ec5c-9fd7-4308-a062-488f6fa155dc" name="us-gaap:ProceedsFromLoanOriginations1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the &#x201c;PPP Loan&#x201d;) provided under the PPP and guaranteed by the SBA. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f61481a-dad3-4c37-b332-835d3018da82" contextRef="C_58649b84-b6a5-4536-b8e2-c6e68450eebd" name="fnch:DebtInstrumentForgivenDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 8, 2021, the Company received notice from the SBA that the entirely of the PPP Loan was forgiven. Accordingly, the Company is no longer required to repay the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea1524a8-d4d0-464e-af3d-da03675d4cd5" contextRef="C_9d380522-affd-4af4-a507-2ff7a0457581" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in principal and approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f89ebc56-6f0e-486b-83f0-1ec53245d893" contextRef="C_9d380522-affd-4af4-a507-2ff7a0457581" name="fnch:AccruedInterestBorrowed" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in accrued interest borrowed under the PPP Loan.</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Gain on extinguishment of the PPP Loan is recorded in the consolidated statements of operations for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span><ix:continuation id="F_5a868816-181e-4bc3-8e38-68c73be11649_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's commitments under its lease agreements are described in Note 5.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80547085-9ba1-4488-849e-908c7d7a4f16" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. REDEEMABLE CONVERTIBLE PREFERRED STOCK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1729031c-47ed-47f5-bf57-acca39df4209" contextRef="C_e407f9da-0025-4449-9d33-474e81924957" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its series D redeemable convertible preferred stock (&#x201c;Series D&#x201d;) at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31218d8f-10c5-4461-912e-b6d54f8054da" contextRef="C_e407f9da-0025-4449-9d33-474e81924957" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">13.0381</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_039171bb-d990-436d-af44-552fbf97d8f1" contextRef="C_d183d8f2-6271-4193-aa8f-606f93e1458d" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">90.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company incurred issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4636b407-bb58-464b-a4c3-c07d57afec1b" contextRef="C_d183d8f2-6271-4193-aa8f-606f93e1458d" name="fnch:TemporaryEquityIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million associated with the Series D issuance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the completion of the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a14910a-35f4-4a10-8e25-f63aa616bb5d" contextRef="C_309231a5-1644-42cc-8f57-4efa7d95eb14" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of outstanding preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3ee099b-373e-477e-9762-1e9a0ff9681e" contextRef="C_af126580-e6a9-4bc4-b56f-9a9ed89d3577" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb08dd07-4c07-4645-8602-fb535366b292" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock authorized, issued, or outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d11e186b-397e-48c6-b13a-a2002d300b97" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:TemporaryEquityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, preferred stock consisted of the following (in thousands, except share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:18.895%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:12.633%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:12.673%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:12.047%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:12.126%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:16.271%;"></td>
        <td style="width:0.626%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PREFERRED<br />STOCK<br />AUTHORIZED</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PREFERRED<br />STOCK<br />ISSUED AND<br />OUTSTANDING</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">CARRYING<br />VALUE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">LIQUIDATION<br />VALUE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">COMMON STOCK<br />ISSUABLE UPON<br />CONVERSION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6aa624be-a1e0-49d2-8c90-48ed33f17642" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">167,496,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_216503ee-7eeb-4a70-b55b-1498fd914761" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a26c2327-a690-407b-8045-b5ab35ac4c71" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,596,280</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57e291d2-d390-48ae-9041-1ed8c6dff1ba" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,593</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1090f49-614b-4315-8e37-f5e1f2b70e43" contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa233891-995e-4e93-aa28-eae1074e4a17" contextRef="C_36ebf60e-e0c4-40dd-910b-838e10c9ca42" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,596,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_261c6b34-0cf0-4e42-8d29-12e19e78d533" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">74,620,739</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fc9a544-c9d4-494b-96c8-e2e6f7f0fa15" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8a81f354-3655-4967-bdf6-ffb16c34d79c" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,166,203</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ad67cf1-b8ee-42b5-94e0-6abcad25df6e" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,336</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66f6c9b5-c1a9-4e2f-a525-d0e6fc57aaa2" contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39629975-0e9c-4ae5-bd4b-c492f8abf83e" contextRef="C_60325954-cd50-4585-85cc-6fc0b138b87d" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,166,203</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13e3d39e-e355-4281-84cd-1a389d097195" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">109,604,994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_461faa5c-9248-4d60-adaa-5a101155539b" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_aebc514b-abb5-4ffd-ad54-7f55ed9042de" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,254</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05f8b68f-498d-408c-a786-edc63fa79ec4" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,221</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_224f5c55-2cea-41b4-8bd0-c0192da26676" contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,465</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_434411fc-b0f1-4c4e-9598-ef1c25af6b3c" contextRef="C_389a0f17-bc7e-475d-9cc4-8f35d0418848" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series D</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43c4e0f7-9198-4eab-a871-b88f3d3ac36b" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">99,705,359</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83638628-ffda-4213-a3e8-0f82a8508daa" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f3fac54e-dea5-41f8-80a0-b8e979a041bb" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab0e8353-64ae-487c-b79d-151e30dca7b0" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be78e925-612c-48a4-a8e8-474cd24a4d26" contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0587e958-5237-4598-ae75-e50f551d4f34" contextRef="C_34e7a81f-7394-49b9-84da-068d88b1e719" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,902,872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d028da9-de5d-4f1d-95b7-18db28d76051" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">451,427,842</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1fc646c-c8e9-41c5-a688-84361eb64719" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_0860ff76-8e4c-4659-8e91-60307dc7307d" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b34d6111-4c17-4cd6-a535-c1b7fc94b353" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,054</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4025a4e4-50b5-4cb5-96ff-4cfbff0373f6" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">219,980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d042fb2-7eaa-41a4-afaa-1215f5efd860" contextRef="C_f59b9e4d-a520-4962-b1b1-8256ad30502f" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6a3a335-2ea7-46c8-8364-55ca0235a6e9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. STOCKHOLDERS' EQUITY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 24, 2021, the Board and the Company&#x2019;s stockholders approved the Company&#x2019;s amended and restated certificate of incorporation, which became effective immediately prior to the closing of the IPO on March 18, 2021. The certificate authorizes the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18144545-b479-446a-b3d3-4d20ba3ef101" contextRef="C_4dc28e60-afc9-4c19-b43d-868677e6583f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8dd231d-7a59-41ab-9383-8b2606b5daeb" contextRef="C_958aeacf-f69f-4b11-a72c-34559a9f8235" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value common stock and up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95f9de9c-c05f-4925-94d9-5b20853e806c" contextRef="C_d1c89c9b-52b3-4ae8-bb9f-118f289a32ab" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f7f1397-93a3-49a3-9930-3414dc17d45b" contextRef="C_9eb4f167-eaf7-4d4b-98b2-e2d8c89215f6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value undesignated preferred stock. The Board may designate the rights, preferences, privileges, and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and number of shares constituting any series or the designation of any series. The issuance of preferred stock could have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying or preventing a change in control. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9f4d111-daa5-466c-8cc1-12c393cff6e1" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock were outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In conjunction with the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f82a5e62-cc4e-41b5-aad4-2bf5bf636a43" contextRef="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e7a361f-865d-425b-a6d5-cd4ced22cc4c" contextRef="C_958aeacf-f69f-4b11-a72c-34559a9f8235" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_628837ac-8b5f-4bd9-9404-6ef632463f5d" contextRef="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">115.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and initial public offering costs. In connection with the IPO, all then outstanding shares of preferred stock were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_655109b7-5124-4e60-8603-02ff422126da" contextRef="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5630be33-4150-4373-a19c-4b3f06afa9f4" contextRef="C_c775cfd2-628d-4919-8429-a954d20061c3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">192,877</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4d2f31e-e646-4b05-b54d-1bdf7dcb0e27" contextRef="C_7b8eb604-10e3-4861-ab49-2e0d36d00d64" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">17.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26d4e2f6-c8e1-4254-9b93-f4c8f7e7818b" contextRef="C_c775cfd2-628d-4919-8429-a954d20061c3" name="fnch:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9a61e1b-aae4-4916-90cc-4377fe5bec3f" contextRef="C_c775cfd2-628d-4919-8429-a954d20061c3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriters&#x2019; discounts, commissions and offering costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_809b8a30-f513-4e4e-81be-37bdf8ff4be3" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each share of common stock entitles the holder to one vote</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, together with the holders of preferred stock, on all matters submitted to the stockholders for a vote. Common stockholders are also entitled to receive dividends. As of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1870a11c-5908-450d-9133-7ebf67fa47e1" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cash dividends have been declared or paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has issued restricted stock to founders, employees and consultants. All restricted stock was fully vested and all expense related to these shares was recognized prior to 2020.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dba4a298-59b1-4f67-99b2-bf40c3469ac9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020, the Company has reserved the following shares of common stock for potential conversion of outstanding preferred stock, the vesting of restricted stock and exercise of stock options, common stock warrants, and shares under the employee stock purchase plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.98%;"></td>
        <td style="width:1.827%;"></td>
        <td style="width:0.858%;"></td>
        <td style="width:18.523%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.827%;"></td>
        <td style="width:0.858%;"></td>
        <td style="width:18.585%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1163bf7a-5239-45c7-b660-c60bf34b123a" contextRef="C_83341027-5973-4448-a037-4a0f2e02d99e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3cf85d38-0373-4618-9391-08cdd4d691d1" contextRef="C_2836ed65-af3b-490c-89b2-d07fef0677d9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15e371a4-9237-433e-9ed5-d3fe7276c746" contextRef="C_9d0e0e4a-c148-42f2-b8d6-c5dcb9f5fb6f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,264,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2036fc5-17d7-4f07-8e50-dd71e811d2a8" contextRef="C_773d9f64-92e0-471f-87fd-c693d0fedbc4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,053,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63fcec9a-5520-4869-afa6-b24df4aa3a63" contextRef="C_bfcf15ad-e5a5-482c-921c-d2c853db7126" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_826c8495-19c0-4a28-9e18-0cfd4c276ecc" contextRef="C_318f64ea-ab2c-4f3a-8c39-bea1e8b5efee" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issuable under employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93d389df-5b8d-472a-b350-db2602d460a0" contextRef="C_6e1cbdf0-abb9-4321-a134-6b908bc1cb74" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,195</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2eb98eea-1104-4927-996b-cb02465e5c92" contextRef="C_3854077f-36a9-4171-af92-3885c504f8ab" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2478d1b5-ab2e-4d13-bf37-67191c8cfa18" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,309,965</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_680c2deb-9c6b-4d2f-905f-19958b72f412" contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,326,829</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">_________________________</span></p><p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">1 </span><ix:footnote id="FNT_dbc6dd0c-c53b-49de-8c39-5c46ef9abcc8" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During the fourth quarter of 2021, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44062ef8-24eb-43d7-90f9-0921ca111b88" contextRef="C_fe91f7aa-3290-4bec-8ded-b59274901189" name="fnch:CommonStockWarrantsExercisedGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,346</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> common stock warrants were net exercised, resulting in </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bcd6b16-dd44-4fe6-923e-139bea8b8f2d" contextRef="C_fe91f7aa-3290-4bec-8ded-b59274901189" name="fnch:CommonStockWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,303</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> net shares.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Secondary Sale</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, certain of the Company&#x2019;s stockholders sold shares of the Company&#x2019;s common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a6a0826-d4c6-4024-8632-cf3525d14e3e" contextRef="C_23263f47-404c-4325-867d-c627433086e4" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">13.0381</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share to an investor. The investor purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_641ef74d-7887-43c7-b65f-7f7f47046ab6" contextRef="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">412,323</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock from these stockholders for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86771cc9-c74e-47ca-b5d1-212ba413fc8f" contextRef="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23630869-5a5e-4fc3-8829-1d54becb70d0" contextRef="C_c1241508-27ea-4aa7-a3a8-f0e51e38ba2d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">258,924</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock, or an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3601c01b-2ca0-447b-bf7b-aca8c38e3886" contextRef="C_c1241508-27ea-4aa7-a3a8-f0e51e38ba2d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, were sold by affiliates of the Company, who are considered to be related parties. The shares were sold above fair value and the excess of the price paid over the fair value was recognized as $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab3868ea-5756-47ad-b7ad-cccb9ef7df58" contextRef="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of stock-based compensation expense. The Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3c5882b-2419-437b-bd5f-24e7af76ac4a" contextRef="C_3fe6991f-9dcc-4a7d-a873-78e8fd832d53" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as general and administrative expense in the consolidated statement of operations for the year ended December 31, 2020 (see Note 12).</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9e1b239-dfe0-48ae-a295-16e46352a105" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. STOCK-BASED COMPENSATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2017 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) in February 2017 for the issuance of stock options and other stock-based awards to employees, consultants, officers and directors. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d77843e5-fb9f-473c-a48b-6ce0c5b21ed6" contextRef="C_8093822b-1d40-4764-a04f-b8bfd74d9e7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance since all shares in the 2017 Plan ceased to be available upon the effective date of the 2021 Equity Incentive Plan, which occurred in March 2021. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90115ae6-fa92-4c61-ba25-786891959209" contextRef="C_78f74fe2-9b23-4570-b2d6-32c1291e24ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">698,601</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock available for future grants under the 2017 Plan as of December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Board adopted, and the stockholders approved, the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan became effective on the date of the underwriting agreement related to the IPO and no further grants will be made under the 2017 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company&#x2019;s affiliates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initially, the maximum number of shares of the Company&#x2019;s common stock that may be issued under the 2021 Plan will not exceed </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3890949d-f480-433f-a914-e4e6c9a418ac" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,291,446</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, which is the sum of (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a7f7cf1-beb5-4a76-8257-f498cf777fb3" contextRef="C_8093822b-1d40-4764-a04f-b8bfd74d9e7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,700,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> new shares, plus (2) an additional number of shares equal to the number of shares of common stock subject to outstanding stock options or other stock awards granted under the 2017 Plan that, on or after the 2021 Plan became effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, if any, as such shares become available from time to time. In addition, the number of shares of common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3d2c412-3852-4edd-9599-9bae5431b740" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="fnch:PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of common stock outstanding on December 31 of the year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the applicable January 1. The maximum number of shares of common stock that may be issued on the exercise of incentive stock options under the 2021 Plan will be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_974aa079-b633-42ae-b376-b865a2b6c7d5" contextRef="C_46125c65-4c5f-4d12-825a-13db653d8482" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,100,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_279b2af6-df13-4aac-a058-cc28398b2386" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,264,770</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issuable upon the exercise of outstanding options and there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8abca000-821d-4ee6-8ae5-983c1d766b4a" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,569,454</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance under the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Board adopted the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on the date of the underwriting agreement related to the IPO. The 2021 ESPP is administered by the Board or by a committee appointed by the Board. The 2021 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac795a3a-3e91-46b8-aade-83a426b3e6d6" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">500,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The first offering period of the plan commenced on December 1, 2021 under the 2021 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each offering to employees to purchase shares will begin on each June 1 and December 1 and will end on the following November 30 and May 31, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On each purchase date, which will fall on the last date of each offering period, ESPP participants will purchase ordinary shares at a price per share equal to 85% of the lesser of (1) the fair market value of the shares on the offering date or (2) the fair market value of the shares on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company&#x2019;s compensation committee.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8df4b1d0-6ba7-44ae-8583-7b49672a96a0" contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued under the 2021 ESPP in 2021 and 500,000 shares were available for future issuance.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4879d87-fd74-4aae-b91f-67fe39639661" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions that the Company used in Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2021 and 2020 were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.263%;"></td>
        <td style="width:2.009%;"></td>
        <td style="width:18.366%;"></td>
        <td style="width:2.009%;"></td>
        <td style="width:18.353%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9cd0ab13-40fb-4f89-9fb8-46d9ee59831e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92b5bbb8-aed4-424f-ad3d-ff18deb12b39" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.46</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_476d6d3f-67a5-477e-ae82-36ad4d6195e1" contextRef="C_fcacd18f-13a2-4b4f-b905-5a7daa5bf83a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce6ecfa3-856d-4c0d-bd7e-c8b4e8116561" contextRef="C_3c431cec-8ef4-41d1-91de-5a171c2fbc40" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_384b188e-58a5-4fd2-8976-820a9ef7b7f3" contextRef="C_fbf098e4-d64a-4024-bd56-afb40e7ad714" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5fd3c8d-d629-4b7e-9b7e-5a7da5128384" contextRef="C_76e74e59-dc68-499b-b05c-f96331eeeafa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e1fdebb-ccc3-4249-9344-1984edd5f7a5" contextRef="C_fcacd18f-13a2-4b4f-b905-5a7daa5bf83a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_419b919d-6c05-4919-a3c8-476f2ebf7498" contextRef="C_3c431cec-8ef4-41d1-91de-5a171c2fbc40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">93.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f127fb01-a2db-4344-9515-1c037408ae66" contextRef="C_fbf098e4-d64a-4024-bd56-afb40e7ad714" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">74.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_158dac22-6ea3-454f-9c50-ea1c0b5a8dc4" contextRef="C_76e74e59-dc68-499b-b05c-f96331eeeafa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">76.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6873d0d2-a797-4f9a-a658-9827caf92c03" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14528cda-bebd-4c8a-b90d-cf1d93f09ad4" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_130f6735-e69d-424a-b8ff-9a30bd23c0d0" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity of the Company&#x2019;s stock options under the 2021 Plan for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.349%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:10.029%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:9.641%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:10.188%;"></td>
        <td style="width:0.626%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:9.403%;"></td>
        <td style="width:0.626%;"></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">SHARES</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">WEIGHTED-<br />AVERAGE<br />EXERCISE<br />PRICE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">WEIGHTED-<br />AVERAGE<br />REMAINING<br />CONTRACTUAL<br />TERM (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">AGGREGATE<br />INTRINSIC<br />VALUE<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91316ee2-a251-4695-abcc-bf941c6a10a1" contextRef="C_fb1c3a83-faee-4108-875a-e75af3e55f7e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,053,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42634f13-df0e-4dc7-80e7-c0d46f87b3c1" contextRef="C_fb1c3a83-faee-4108-875a-e75af3e55f7e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95f0945b-f5d1-4beb-9645-b3322a2858a6" contextRef="C_06a32a5b-3613-45c4-bbd2-cb0a2ad1a82b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28209484-edad-4f79-9dcc-135228e8dec7" contextRef="C_fb1c3a83-faee-4108-875a-e75af3e55f7e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,964</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_779fb333-99cd-4031-9678-3590fb460d91" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,602,643</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc9898b8-223f-458d-aacc-9a91981f4f82" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">14.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49cd7303-9124-4c09-9b40-272d8fb78783" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">155,821</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f8cc008-ca29-4381-bfc7-4dc0ff1ee97a" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dced8cd3-883c-46e3-a8ef-910dedf10986" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">211,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9be82e4e-aa4b-4bfa-b5e6-ecbea192d3a5" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f8494d8-a2b0-45c6-a281-65c6c4c79a5c" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">23,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee2623d3-90db-482a-b768-0b8ee20ab406" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_106ea16e-4a83-419d-9dd4-7672f5f98146" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,264,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da535dc7-5e21-4337-a607-26c7b8c5a07a" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5260335b-c8b8-4bc2-be65-0f48abf7934b" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89baeab1-f290-4e9e-9529-1c0a50f658d9" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f11d6bb-7862-4e88-b10c-d18b0e546e97" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">846,024</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eff81075-b77d-4917-aa14-063d6edb6f18" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a906697-1a9a-4fae-a7d2-e0feef294c64" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37d32803-df1f-4b00-8de8-2e30f470e8ca" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options vested or expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d4c0106-4ca8-437f-ad36-ecfc1409cebf" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,264,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de2695cb-279d-4030-883d-fb3804fa04cf" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be21fb77-95d4-4b12-8924-5091c2e5cb6d" contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f97f74c3-f9aa-46f4-ae38-295da8594d0e" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options granted during the years ended December 31, 2021 and 2020 were granted to employees and consultants of the Company. As of December 31, 2021, there was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80319fb3-dbc3-41e2-8c90-bccb73d58a60" contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized compensation expense related to the stock-based compensation arrangements granted under the 2021 Plan remaining to be recognized. The Company expects to recognize this cost over a weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b20c45f-63b7-49a7-9cbc-685d3663c9ea" contextRef="C_02bc5fe6-52dc-428c-a5bc-9f4b8b799841" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.24</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stoc</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">k. The intrinsic value of options exercised in 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13751d50-dc16-402b-ba93-860fc871dabf" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48a77585-f93c-4d19-a2e1-f87027e10643" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The weighted-a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">verage grant date fair value of stock options granted in the years ended December 31, 2021 and 2020 under the Black-Scholes option pricing model was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03e0bd56-f084-4760-8e17-81252f98503a" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.87</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per option and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d3e2439-1ed4-4121-a999-d08531d84ba1" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.87</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per option, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The restricted stock was granted to the founders of the Company, as well as employees and consultants of the Company. There was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0695c19-f6a2-475e-8db4-acd4842354e4" contextRef="C_1545e700-f4cb-462d-bda2-6aea5fb1b1f6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of stock-based compensation expense recognized for the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f528cf6-139f-421d-b8fe-260c973542e5" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">547,360</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted stock vested during the year ended December 31, 2020. All restricted stock was vested as of December 31, 2020 and there is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ecd3920-103c-41be-b067-52a4188b8c5f" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="fnch:RemainingStockCompensationExpenses" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> remaining stock-compensation expense related to restricted stock to be recognized for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46826632-3457-4b7d-81c6-1a1d3413353d" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December 31, 2021 and 2020 is as follows (in thousands):</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:62.366%;"></td>
      <td style="width:1.467%;"></td>
      <td style="width:1.815%;"></td>
      <td style="width:14.753%;"></td>
      <td style="width:0.783%;"></td>
      <td style="width:1.467%;"></td>
      <td style="width:1.815%;"></td>
      <td style="width:14.753%;"></td>
      <td style="width:0.783%;"></td>
     </tr>
     <tr style="height:8.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:8.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9178d105-036d-4f69-b7c4-a1ed010a9e2c" contextRef="C_83dde824-9020-47ce-a70f-8cacb2aad84b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,605</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e8d3801-bb25-493d-baa9-fcf0449a2b29" contextRef="C_0df70676-9619-40e8-853f-19a8b73a703f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c1cebb8-98ce-467f-9465-ebe2b9ec01a8" contextRef="C_826e7f83-9582-40fb-b568-89f02012f782" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,556</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ff4fb1c-f813-4f64-b6f6-61778eb65e8e" contextRef="C_68b03d20-efc1-47c4-97fe-d09e37d99bd2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,920</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f02bc7f-153f-4bc8-9e30-48a1300045a9" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,161</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4aff623c-5d74-4add-bc4e-0fb015b1e03a" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
    </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stock-based compensation expense for the year ended December 31, 2020 includes the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82d79b1f-9824-41cb-80b3-1fabcedd6ebb" contextRef="C_29953980-7bf1-4fdd-b181-4be7a82bb370" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million recorded in relation to the secondary sale of common stock (see Note 11).</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68a21f22-159d-447d-8943-a5f5ee04f920" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. RELATED PARTY TRANSACTIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome Historical Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Master Strategic Affiliation Agreement with OpenBiome (the &#x201c;Strategic Agreement&#x201d;), OpenBiome and the Company reimbursed one another for certain administrative expenses. The Company&#x2019;s Chief Executive Officer and a member of the Board is the spouse of the co-founder and former Executive Director of OpenBiome, and certain of the OpenBiome directors are stockholders of the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company reimbursed OpenBiome $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8afab34f-774e-468f-9416-b6530f949383" contextRef="C_63ccd21b-b4e9-4f84-b09c-125598219f50" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf6dde7a-2639-4cae-b229-78c3d2e21809" contextRef="C_24547a48-6a37-4b99-8269-4b7bace32f46" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under the Strategic Agreement. Also under the Strategic Agreement, OpenBiome reimbursed the Company $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da713bbe-0197-4a18-b389-02510b770334" contextRef="C_63ccd21b-b4e9-4f84-b09c-125598219f50" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_451abaf6-a793-4b6f-bad5-6db84e1d89de" contextRef="C_24547a48-6a37-4b99-8269-4b7bace32f46" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively. As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, respectively the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ac149ce-1529-4bf3-a5c4-159f215a0e90" contextRef="C_e29d9cb5-46b0-4d57-96ad-b94780aa228e" name="us-gaap:DueFromRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9fd0168b-a811-4ade-ac32-8d3cae0fd8a1" contextRef="C_42702fe8-9f6e-4d52-96bc-bf7ff5642f9d" name="us-gaap:DueFromRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payable balance</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">due to OpenBiome, and recorded a balance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be76afeb-f6ce-44f9-8db6-583ed223d256" contextRef="C_583cd02a-6b47-4c6a-9fda-94aade34f36d" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21658304-3d7d-4f19-b58a-2f9030321fcd" contextRef="C_e29d9cb5-46b0-4d57-96ad-b94780aa228e" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due from OpenBiome as of December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until December 31, 2021, OpenBiome subleased office and lab space from the Company. The Company&#x2019;s rent income under the sublease was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a8be6ef-147c-4d8f-b89e-29e8f7de74fd" contextRef="C_30f83225-a823-4c68-b24e-432bbb423504" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c1b6c96-0ef2-4cc4-a573-2e34d100c365" contextRef="C_7ac98b6d-c24a-449b-91fb-dcb878c6c9ee" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively. As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Company </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37a651ed-c2d6-4502-9ce8-a5641731c921" contextRef="C_e109216b-8e95-4dc3-9229-87d798ee0e98" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> longer had an outstanding receivable due from OpenBiome. As of December 31, 2020, the Company had le</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ss than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4fe428d-4596-482b-9e0d-de04aad10d79" contextRef="C_78dd3234-e5d1-4ad1-9914-de28cdc240bc" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million re</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ceivable from OpenBiome related to the sublease recorded as due from related party in the consolidated balance sheets. This lease was amended as of March 1, 2021 (see Note 5).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also earned a low single digit royalty on net sales of OpenBiome&#x2019;s FMT materials under the Quality System and Supply Agreement with OpenBiome (the &#x201c;QSS Agreement&#x201d;), which was partially terminated on February 1, 2019 and, ultimately, was fully terminated in November 2020 in connection with the Company&#x2019;s execution of the OpenBiome Agreement (see OpenBiome 2020 Agreements below), which closed on March 1, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome 2020 Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Supply and Services Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 10, 2020, the Company entered into a Clinical Supply and Services Agreement (the &#x201c;CSA&#x201d;) with OpenBiome, which terminated upon closing of the OpenBiome Agreement in March 2021. In accordance with the CSA, OpenBiome agreed to supply the Company with certain manufactured material and to provide additional support services to the Company. In consideration for these materials and services, the Company agreed to pay a monthly platform fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_224f87eb-616e-437c-adcc-5b6872bf46ee" contextRef="C_a6981439-53f3-412e-bd72-c7b736c9fa1c" name="fnch:PaymentOfMonthlyPlatformFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, all direct employee overhead costs, and variable costs for consumables. Under a related payment agreement executed concurrently with the CSA, the Company paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b31d7171-7a2a-459c-8162-10e713d6a11a" contextRef="C_566912aa-b2e7-4130-a031-93d7d2de01cc" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit in the event of cost overruns under the CSA arrangement and approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ccdb38f-b541-4280-a255-411e40bb9fda" contextRef="C_566912aa-b2e7-4130-a031-93d7d2de01cc" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in prepaid fees. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_819bd385-f5f9-4e43-84a8-a0a8bdb00c74" contextRef="C_566912aa-b2e7-4130-a031-93d7d2de01cc" name="fnch:SecurityDepositsReturned" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit was returned to the Company during the same period. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f842a321-470a-4834-9557-5f560d1e95ce" contextRef="C_94c65693-07a8-42cf-9bcf-fe65d1cb5868" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total to OpenBiome under the CSA for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">year ended December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb477500-14dd-42fe-a06f-94aceac2e80c" contextRef="C_eb5c3d76-f6ae-465b-9ade-c84c08d30d59" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">year ended December 31, 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, including the security deposit that was returned. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54c80497-eda9-4a83-b805-ccca7309557e" contextRef="C_e63bb9f3-addf-44bf-9079-4ef73a7b1858" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> outstanding payable balance due to OpenBiome under the CSA as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28eb2d56-341b-4bd2-aecb-a0e783744d56" contextRef="C_95503824-281a-48bb-a70d-4346f1e2af47" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due to OpenBiome as of December 31, 2020, respectively, which is classified as due to related party in the Company&#x2019;s consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome Purchase Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 19, 2020, the Company entered into the OpenBiome Agreement in order to obtain OpenBiome&#x2019;s CMC manufacturing process to enhance its current manufacturing capabilities for its lead program, CP101; the OpenBiome Agreement was fully executed and closed on March 1, 2021. Simultaneously with entering into the OpenBiome Agreement, the Company terminated the Strategic Agreement, the MAL Agreement, the QSS Agreement and the APL Agreement, as well as certain subject matter agreements. Upon closing of the OpenBiome Agreement on March 1, 2021, the CSA was also terminated, and the Company will not incur any additional expense to be paid to OpenBiome. The Company also amended the Strategic Agreement as part of the OpenBiome Agreement (the &#x201c;A&amp;R Strategic Agreement&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the OpenBiome Agreement, the Company acquired certain biological samples, software, and a non-exclusive license to OpenBiome&#x2019;s CMC technology upon signing in November 2020, and acquired certain biological samples, a commercial lease, contract services intellectual property and capital equipment upon the closing of the transaction in March 2021. The Company previously licensed the biological samples and OpenBiome&#x2019;s CMC technology under various historical agreements with OpenBiome which terminated upon signing of the OpenBiome Agreement. As such, the acquisition of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CMC technology license was a continuation of previously granted rights. The OpenBiome Agreement also releases, for a one-year period from signing, a hiring restriction under the A&amp;R Strategic Agreement (i.e. non-solicitation) such that the Company may hire, at its discretion, certain OpenBiome employees. The Company did not acquire any such employees as part of the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the OpenBiome Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_113e4aff-3d72-40f0-b25a-5f93c2051174" contextRef="C_4603d1f8-8b00-442d-96f0-6e9d5d761ed9" name="us-gaap:PaymentsToAcquireSoftware" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the acquisition of certain assets in November 2020, which was capitalized as property and equipment as software on the Company&#x2019;s consolidated balance sheet as of December 31, 2020 and paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5aad334-f177-4cf9-98e1-8d42b17fdd1f" contextRef="C_e6ce2584-4ad0-4ec8-bee7-5bf80eddbb4a" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the closing of the OpenBiome Agreement on March 1, 2021, for the remaining assets. The Company accounted for the OpenBiome Agreement as an asset acquisition and capitalized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01244431-f8bb-474f-80cf-32a40c236684" contextRef="C_2a6aef8a-3ebf-43c8-a1d9-cb65a4f2ce4e" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of property and equipment on the consolidated balance sheet as of March 31, 2021 for the acquired software and property and equipment. The Company did not assign any value to biological samples, contract services intellectual property, or the CMC technology license, as the Company did not acquire any additional rights that were not previously granted under the legacy agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is also required to pay certain milestones up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_856d5e46-4c3f-4a4e-baf9-ee33c31f71c4" contextRef="C_85b5348c-0723-4afb-be02-9db714b74dc9" name="fnch:MaximumMilestonePaymentRequiredUnderAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the occurrence of certain R&amp;D events, regulatory approvals, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company previously granted OpenBiome a royalty-bearing, non-exclusive license to its intellectual property under the APL Agreement, which terminated upon the signing of the OpenBiome Agreement. The Company will continue to earn royalties under the OpenBiome Agreement based on sales of FMT materials.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a26d2fc-709e-40ab-9b93-c357d69e62c8" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DefinedContributionPlanTextBlock" escape="true" continuedAt="F_3a26d2fc-709e-40ab-9b93-c357d69e62c8_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. RETIREMENT PLAN</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_3a26d2fc-709e-40ab-9b93-c357d69e62c8_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. All employees are eligible to become participants of the plan at the beginning of the next full quarter subsequent to their hire date</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right to make additional contributions to this plan. The Company made contributions to the plan of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_814bd629-7eca-4a06-b913-3a3789ce015b" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ce75783-fcf4-424b-80e9-f2cbed9d4f12" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div><ix:nonNumeric id="F_e7925206-be4e-4a4b-a7f1-3c080c888479" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. LOSS PER SHARE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c31b30e-69de-49eb-ab6d-abaa70521dd2" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.262%;"></td>
        <td style="width:1.728%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:20.179%;"></td>
        <td style="width:1.057%;"></td>
        <td style="width:1.728%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:19.806%;"></td>
        <td style="width:1.057%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FOR THE YEAR<br />ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94eba688-7fbc-4480-9eb3-296d92ee5927" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9dbf254-5390-490c-bd77-4af64dea7259" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss attributable to<br />&#160;&#160;&#160;common stockholders&#x2014;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11b593e9-a006-450b-b1ab-b1f834a00e4e" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,160</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e63408c-6958-458f-a454-bf302f110572" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average common<br />&#160;&#160;&#160;stock outstanding&#x2014;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd203897-f0a8-4d72-94f3-07ec56bccfb1" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">39,202,086</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e6626c5-ab17-4801-8add-fe91d128a4a8" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,144,855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per share attributable<br />&#160;&#160;&#160;to common stockholders&#x2014;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a366acfa-b722-4690-a83f-179a2dddab97" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0431367-5543-4631-95c1-0ac252079bdb" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">4.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s potentially dilutive securities, which include preferred stock, restricted stock, stock options, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f2d26c7-3d18-401c-afe3-f00f4d2313fd" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_6f2d26c7-3d18-401c-afe3-f00f4d2313fd_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December 31, 2021 and 2020 because including them would have had an anti-dilutive effect: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_6f2d26c7-3d18-401c-afe3-f00f4d2313fd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.064%;"></td>
        <td style="width:1.505%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:15.247%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.505%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:15.595%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e5cee43-1d26-49a5-92a6-248f107564c5" contextRef="C_d9b8ef89-619c-4cf1-98e8-3318a7630899" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,253,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52e89395-1cb1-420b-9615-af628810ef52" contextRef="C_b66a4bb1-f047-4756-b7b4-61d3d88e063e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,264,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98180716-be4f-43f6-8283-fb6cea9c1431" contextRef="C_10a999a1-8dfb-4ba6-8758-e876879ab568" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,053,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20ec69ac-1429-416f-b18d-24575e2f1347" contextRef="C_53f088f1-6942-4a33-8ec0-d9a352aa8473" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issuable under employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4f11e9d-980f-4865-9d1e-41d78fd35f84" contextRef="C_a6c10679-4ab6-409c-8105-7146e8e77be9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,195</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b48a4a99-408c-4f02-86a8-64c9060934ac" contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,309,965</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b746518-a114-471a-9ee7-ef5298385cff" contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,326,829</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Rules 13(a)-13(e) and 15(d)-15(e) under the Exchange Act, management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report does not include a report of management&#x2019;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm as permitted in this transition period under the rules of the SEC for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Remediation of Previously-Identified Material Weaknesses in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with our IPO, we previously disclosed material weaknesses identified in our internal control over financial reporting relating to the following: (1) an ineffective control environment, including a lack of sufficient accounting personnel and personnel with financial reporting expertise; (2) ineffective controls over cutoff, recording and classification of certain accounts, and the valuation and recognition of intangible assets acquired in a business combination that occurred in 2017; (3) ineffective risk assessment controls, including those policies and practices that would identify changes in our business practices, which could significantly impact our consolidated financial statements and system of internal controls; and (4) ineffective monitoring of controls related to the financial close and reporting process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with oversight from our audit committee, has implemented the following remediation steps to address the material weaknesses and to improve our internal control over financial reporting:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We added finance personnel to the organization to strengthen our internal accounting team including a controller, assistant controller, associate director of SEC reporting and technical accounting, senior manager of SOX compliance and technical accounting, senior manager of accounting, and senior accountant. We reallocated responsibilities across the accounting organization to ensure that the appropriate level of knowledge and experience is applied based on risk and complexity of transactions under review. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We engaged external accounting advisory consultants to provide additional depth and breadth in our technical accounting and financial reporting capabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the support of internal control consultants, we completed risk assessment activities and the evaluation of the design of internal controls to address relevant risks, including developing remediation plans for any design deficiencies in our system of internal controls. We executed the remediation plans for the identified control design deficiencies and tested the effectiveness of the remediated controls.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We implemented a financial close policy and monitoring program, including the formation of a Disclosure Committee comprised of members of our senior management team and representatives from our accounting and legal departments to review and approve SEC filings and investor communications, the results of which are discussed with the audit committee of our board of directors quarterly. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management concluded that, as a result of the implementation of these actions, the previously-identified material weaknesses in our internal control over financial reporting have been remediated as of December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2554166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except for the remediation efforts of the previously identified material weakness as described above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;">Inherent Limitations on Effectiveness of Controls</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, including our Chief Executive Officer and Chief Financial Officer, believe that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other Information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Resignation of Chief Financial Officer; Appointment of Principal Financial Officer/Principal Accounting Officer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 30, 2022, Gregory D. Perry informed us of his intent to retire as our Chief Financial Officer effective as of April 30, 2022 (the &#x201c;Retirement Date&#x201d;). Mr. Perry is retiring for personal reasons and there are no disagreements between Mr. Perry and us on any matters relating to our operations, policies, or practices, including accounting principles and practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective as of the Retirement Date, the Board has appointed Marc Blaustein, our current Chief Operating Officer, to serve in the roles of principal financial officer and principal accounting officer. He will receive a salary increase of $15,000 for these additional appointments, resulting in an annual base salary of $415,000.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mr. Blaustein, age 59, has served as our Chief Operating Officer since September 2021. Prior to joining the Company, from 2019 to 2021, he consulted as Head of Business Development for Guide Therapeutics, which was acquired by Beam Therapeutics in 2021. Prior to that time, Mr. Blaustein served as the Chief Executive Officer of NED Biosystems from 2017 to 2019 and co-founder and Chief Executive Officer of Akashi Therapeutics from 2011 to 2017. Before founding Akashi, he served in various leadership positions across several biotechnology companies, including serving as Senior Vice President of Manufacturing, Process and Commercial Operations at Dyax Corp. (now Takeda). Prior to Dyax, Mr. Blaustein held business development and management roles at Alkermes plc and worked in business development at Genetics Institute (now Pfizer). Mr. Blaustein began his career in management consulting, first at Mercer Management Consulting, and then as a founding partner of Northbridge Consulting. Mr. Blaustein has a B.A. in biology from the University of Pennsylvania and an M.P.P. from Harvard University. He is also a Chartered Financial Analyst (CFA) charterholder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are no arrangements or understandings between Mr. Blaustein and any other persons pursuant to which he was appointed to serve in the roles of principal financial officer and principal accounting officer. There are no family relationships between Mr. Blaustein and any of our directors or executive officers, and he does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with Mr. Perry's resignation, we and Mr. Perry intend to enter into a consulting agreement pursuant to which, among other things, following the Retirement Date, Mr. Perry will provide advisory services to the Company through the end of 2022. As consideration for his advisory services, Mr. Perry will be paid a monthly retainer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Officers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> and Corporate Governance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the information set forth in the sections titled &#x201c;Information Regarding Director Nominees and Current Directors&#x201d;, &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x201d; and &#x201c;Executive Officers&#x201d; in our definitive proxy statement relating to our 2022 annual meeting of stockholders, or the 2022 Proxy Statement, to be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executive Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the information set forth in the sections titled &#x201c;Executive Compensation&#x201d; and &#x201c;Non-Employee Director Compensation&#x201d; in the 2022 Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the information set forth in the sections titled &#x201c;Executive Compensation &#x2013; Equity Compensation Plan Information&#x201d; and &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; in the 2022 Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transactions, and Director Independence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the information set forth in the sections titled &#x201c;Information Regarding the Board of Directors and Corporate Governance &#x2013; Independence of the Board of Directors&#x201d; and &#x201c;Transactions with Related Persons&#x201d; in the 2022 Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accounting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fees and Services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the information set forth in the sections titled &#x201c;Principal Accounting Fees and Services&#x201d; and &#x201c;Pre-Approval Policies and Procedures&#x201d; in the 2022 Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibit and Financial Statement Schedules.</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits:</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:2.024%;"></td>
    <td style="width:86.975%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000119312521091271/d161394dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of Finch Therapeutics Group, Inc. (incorporated by reference to Exhibit 3.1 of the Registrant&#x2019;s Current Report on Form 8-K filed March 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000119312521091271/d161394dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of Finch Therapeutics Group, Inc. (incorporated by reference to Exhibit 3.2 of the Registrant&#x2019;s Current Report on Form 8-K filed March 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amended and Restated Stockholders Agreement, by and among Finch Therapeutics Group, Inc. and certain of its stockholders, dated September 2, 2020 (incorporated by reference to Exhibit 4.1 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521080450/d54314dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Registrant&#x2019;s Securities.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2017 Equity Incentive Plan, as amended, and the forms of agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521080450/d54314dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnity Agreement between Finch Therapeutics Group, Inc. and its officers and directors (incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3*#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Exclusive License Agreement between Regents of the University of Minnesota and Finch Therapeutics Holdings LLC, dated January 28, 2022.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exclusive License Agreement by and between Crestovo, LLC and Arizona Science and Technology Enterprises LLC, dated as of July 3, 2017, as amended August 27, 2018 (incorporated by reference to Exhibit 10.4 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc., dated as of October 21, 2019 (incorporated by reference to Exhibit 10.5 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000095017021004159/fnch-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment, dated August 9, 2021, to the Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc., dated as of October 21, 2019 (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Quarterly Report on Form 10-Q filed November 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7*#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex10_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 2, dated November 12, 2021, to the Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc. dated as of October 21, 2019.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Asset Purchase Agreement by and between Finch Therapeutics, Inc. and Microbiome Health Research Institute, Inc., dated as of November  19, 2020 (incorporated by reference to Exhibit 10.6 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000119312521060632/d54314dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">LMIC License Agreement by and between Finch Therapeutics, Inc. and Microbiome Health Research Institute, Inc., dated as of November  19, 2020 (incorporated by reference to Exhibit 10.7 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease by and between NextBiome, Inc. and North River II LLC, dated as of December 21, 2015 (incorporated by reference to Exhibit 10.8 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521060632/d54314dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Lease by and between Finch Therapeutics, Inc. and North River II LLC, dated as of January 20, 2017 (incorporated by reference to Exhibit 10.9 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000095017021004159/fnch-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease, dated August 3, 2021, by and between Hood Park LLC and Finch Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Quarterly Report on Form 10-Q, filed November 10, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:2.024%;"></td>
    <td style="width:86.975%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000119312521096597/d101803dex45.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2021 Equity Incentive Plan and the forms of agreements thereunder (incorporated by reference to Exhibit 4.5 of the Registrant&#x2019;s Registration Statement on Form S-8, filed March 26, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001733257/000119312521096597/d101803dex46.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.6 of the Registrant&#x2019;s Registration Statement on Form S-8, filed March 26, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521080450/d54314dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Executive Employment Agreement, by and between Finch Therapeutics Group, Inc. and Mark Smith, dated as of March 12, 2021 (incorporated by reference to Exhibit 10.12 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521080450/d54314dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Zain Kassam, dated as of March 12, 2021 (incorporated by reference to Exhibit 10.13 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17*&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex10_17.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Release Agreement, dated November 4, 2021, by and between Finch Therapeutics Group, Inc. and Zain Kassam.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1733257/000119312521080450/d54314dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Gregory D. Perry, dated as of March 12, 2021 (incorporated by reference to Exhibit 10.14 of the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19*&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Marc Blaustein, dated as of September 8, 2021.</span></a></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20*&#134;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">          </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex10_20.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Joseph Vittiglio, dated as of March 12, 2021</span></a></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21*&#134;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">          </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex10_21.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to the Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Joseph Vittiglio, dated as of March 18, 2021</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Subsidiaries of Finch Therapeutics Group, Inc.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Deloitte &amp; Touche LLP.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fnch-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (the cover page interactive date is embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">**Furnished herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"># Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Finch Therapeutics Group, Inc. if publicly disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#134; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.223%;"></td>
    <td style="width:2.823%;"></td>
    <td style="width:5.667%;"></td>
    <td style="width:46.287%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mark Smith, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:43.304%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:21.637%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mark Smith, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;font-style:italic;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Gregory D. Perry</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gregory D. Perry</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial Officer and Principal Accounting Officer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Chris Shumway</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chris Shumway</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Domenic Ferrante</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domenic Ferrante</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Susan Graf</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Susan Graf</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Nicholas Haft</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nicholas Haft</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Samuel A. Hamood</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Samuel A. Hamood</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Christian Lange</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Christian Lange</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jeffrey Smisek</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jeffrey Smisek</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jo Viney</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jo Viney, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>fnch-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following description of our capital stock is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, the applicable provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and our stockholders agreement entered into in September 2020, which are filed as exhibits to our Annual Report on Form 10-K, of which this Exhibit 4.3 is a part, and are incorporated by reference herein. We encourage you to read our amended and restated certificate of incorporation, our amended and restated bylaws, our stockholders agreement and the applicable provisions of the Delaware General Corporation Law for more information. References herein to the terms &#x201c;we,&#x201d; &#x201c;our&#x201d; and &#x201c;us&#x201d; refer to Finch Therapeutics Group, Inc. and its subsidiaries.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation authorizes us to issue up to 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share, all of which shares of preferred stock will be undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting Rights</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our amended and restated certificate of incorporation and amended and restated bylaws, our stockholders do not have cumulative voting rights. The affirmative vote of holders of at least 66</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividends</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidation</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights and Preferences</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registration Rights</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to a stockholders agreement that provides certain holders of our common stock with rights, subject to certain conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. These shares are collectively referred to herein as registrable securities.</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stockholders agreement provides the holders of registrable securities with demand, piggyback and S-3 registration rights as described more fully below. Under the terms of the stockholders agreement, holders of registrable securities will have equivalent registration rights with respect to any additional shares of our common stock acquired by these holders.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Demand Registration Rights</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At any time beginning 180 days following the effective date of the registration statement for our initial public offering, the holders of at least 20% of the registrable securities then outstanding have the right to make up to two demands that we file a registration statement under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), subject to specified conditions and exceptions. Such request for registration must cover shares with an anticipated aggregate offering price to the public of at least $25 million.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Piggyback Registration Rights</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we register any securities for public sale, the holders of our registrable securities then outstanding will each be entitled to notice of the registration and will have the right to include their shares in the registration statement, subject to specified exceptions. The underwriters of any underwritten offering will have the right to limit the number of shares having registration rights to be included in such registration statement, but not below 25% of the total amount of securities included in such registration.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Registration on Form S-3</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are eligible to file a registration statement on Form S-3, the holders of at least 20% of the registrable securities then outstanding have the right to demand that we file registration statements on Form S-3, provided that the aggregate amount of securities to be sold under the registration statement is at least $5.0 million, net of underwriting discounts and commissions and specified expenses. We are not obligated to effect a demand for registration on Form S-3 by holders of our registrable securities more than two times during any 12-month period. The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses of Registration</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will pay all expenses relating to any demand, piggyback or Form S-3 registration, other than underwriting discounts and commissions, subject to specified conditions and limitations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Termination of Registration Rights</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The demand, piggyback and Form S-3 registration rights described above will terminate on the earliest to occur of (1) the closing of a &#x201c;Deemed Liquidation Event&#x201d; as defined in our amended and restated certificate of incorporation in effect immediately prior to the completion of our initial public offering, (2) with respect to each stockholder, at such time as Rule 144 under the Securities Act or another similar exemption is available for the sale of all of such holder&#x2019;s shares without limitation during a three-month period without registration, and (3) March 23, 2026.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Takeover Provisions</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certificate of Incorporation and Bylaws</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">power of our shares of common stock will be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide for stockholder actions at a duly called meeting of stockholders. A special meeting of stockholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer or president if the chair of our board of directors is unavailable. Our amended and restated bylaws provide an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. In addition, our amended and restated certificate of incorporation and amended and restated bylaws do not allow for the right of stockholders to act by written consent without a meeting.</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes with staggered three-year terms.</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing provisions make it more difficult for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These provisions are intended to preserve our existing control structure, facilitate our continued product innovation and the risk-taking that it requires, permit us to continue to prioritize our long-term goals rather than short-term results, enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Section 203 of the Delaware General Corporation Law</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, Section 203 defines a &#x201c;business combination&#x201d; to include the following:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></div>
  <hr style="page-break-after:always;">
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, Section 203 defines an &#x201c;interested stockholder&#x201d; as an entity or person who, together with the person&#x2019;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Choice of Forum</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law: (1) any derivative claim or cause of action brought on our behalf; (2) any claim or cause of action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (3) any claim or cause of action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (4) any claim or cause of action arising under or seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (including any right, obligation, or remedy thereunder); and (5) any claim or cause of action against us or any of our current or former directors, officers, or other employees that is governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This choice of forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction, or the Securities Act. Our amended and restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. Additionally, our amended and restated certificate of incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions.</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent&#x2019;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Listing</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#x201c;FNCH.&#x201d;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>fnch-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body>
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO FINCH THERAPEUTICS GROUP, INC. IF PUBLICLY DISCLOSED.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><img src="img118948569_0.jpg" alt="img118948569_0.jpg" style="width:193px;height:193px;">&#160;</p>
  <p style="border-top:0.750pt solid rgba(212,92,92,1);padding-top:6.0pt;text-indent:0.0%;padding-bottom:6.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;border-bottom:0.750pt solid rgba(212,92,92,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:36.0pt;font-family:Calibri;">EXCLUSIVE LICENSE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Calibri;">Regents of the University of Minnesota</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Calibri;">and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Calibri;">Finch Therapeutics Holdings LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:Calibri;">TECHNOLOGY COMMERCIALIZATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">200 Oak Street, SE </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">|</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> Suite 280 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">| Minneapolis, MN  55455</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">A20120373</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">| OTC Case Number</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">: 20100243, 20130223, 20140139, 20140293, 20170005</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Calibri;">AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;) is made as of the Effective Date by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">University</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;), and the Licensee identified below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">WHEREAS, the University and Crestovo LLC (now Finch Research and Development LLC) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Crestovo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;) are parties to that certain Exclusive Patent License Agreement dated March 26, 2012 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Original Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;), as amended by the First Amendment effective July 10, 2014, the Second Amendment effective October 23, 2014, the Third Amendment effective December 1, 2016, and the Fourth Amendment effective September 15, 2017 (collectively the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">WHEREAS, on September 21, 2017, the parent of Crestovo, Crestovo Holdings LLC (now Finch Therapeutics Holdings LLC), merged with Finch Therapeutics, Inc. to create Finch Therapeutics Group, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Finch</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;); and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">WHEREAS, Finch desires to consolidate its intellectual property in Finch Therapeutics Holdings LLC, including the transfer of the License Agreement to Finch Holdings LLC (hereinafter, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;);</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">WHEREAS, in addition to this transfer, the University and Licensee desire to amend and restate the Original Agreement, in its entirety, as set forth herein;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, the parties hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The Agreement consists of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Business Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">General Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> and any attached and referenced exhibits or schedules.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(191,191,191,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Calibri;">BUSINESS TERMS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.293%;"></td>
    <td style="width:18.64%;"></td>
    <td style="width:0.161%;"></td>
    <td style="width:71.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">1</font></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSEE</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Finch Therapeutics Holdings LLC (pursuant to S. 14.6 of the General Terms)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">2</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">TERRITORY</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Worldwide</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">3</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">FIELD OF USE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">All fields</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">4</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">TERM</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The Term commences on the Effective Date and, unless terminated earlier in accordance with Section 10 of the General Terms, expires on the date on which there are no Valid Claims anywhere in the Territory.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">5</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSED INTELLECTUAL PROPERTY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">5.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSED PATENTS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;"> </font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">5.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSED PATENT APPLICATIONS</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.293%;"></td>
    <td style="width:18.64%;"></td>
    <td style="width:0.161%;"></td>
    <td style="width:71.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">5.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">TECHNICAL INFORMATION</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#9744;	None		&#9746;	Yes.  Description is attached as Exhibit A</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">6</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">FEDERAL GOVERNMENT RIGHTS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The inventions described in the following Licensed Patents and Licensed Patent Applications claiming priority to [***] were developed with federal funding and contain Federal Government Rights.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">      </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">7</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:14.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">PATENT RELATED EXPENSES</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:14.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Include all that apply</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall either pay on University&#x2019;s behalf or reimburse University for any Patent-Related Expenses paid by University within [***] from receipt of invoice from University.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">8</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">SUBLICENSE RIGHTS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Yes</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">9</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">PERFORMANCE MILESTONES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Provided that the United States Food and Drug Administration (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">FDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d;) does not recommend or require unanticipated studies or prerequisites, including, without limitation, detailed characterization of control material for clinical trial use, as part of the regulatory approval process for obtaining a Licensed Product to treat [***], Licensee shall perform the following milestones. If the FDA does recommend or require such unanticipated studies or prerequisites, the parties will negotiate in good faith extensions to the milestones to reflect additional time that may be needed to achieve the following:</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><div style="margin-left:0.25in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:0.25in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;justify-content:flex-start;min-width:3.3413533834586464%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></div></div><div style="margin-left:0.25in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:0.25in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;justify-content:flex-start;min-width:3.3413533834586464%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">PAYMENTS</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.1</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">UPFRONT PAYMENT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">No upfront fee shall be payable.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.2</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSE MAINTENANCE FEE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Beginning on the Effective Date and each year thereafter in which Licensee, an Affiliate, or a Sublicensee does not sell Licensed Product, Licensee will pay to University a yearly maintenance fee of $[***] USD, payable on each anniversary of the Original Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">   </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.293%;"></td>
    <td style="width:18.801%;"></td>
    <td style="width:71.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.3</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">RUNNING ROYALTIES ON NET SALES</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall pay to University on a Licensed Product-by-Licensed Product and country-by-country basis royalties on Net Sales of Licensed Products, whether the sales are made by Licensee, an Affiliate of Licensee, or a Sublicensee, such royalties being equal to:</font></p><div style="margin-left:0.25in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:0.25in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3413533834586464%;">&#x25cf;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></div></div><div style="margin-left:0.25in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:0.25in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3413533834586464%;">&#x25cf;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></div></div><div style="margin-left:0.25in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:0.25in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3413533834586464%;">&#x25cf;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">determined and payable as provided in Section 4.4 of the General Terms, except as otherwise determined in Section 10.4 of the Business Terms. For clarity, a Licensed Product shall not be deemed to &#x201c;infringe&#x201d; a Valid Claim under this Section 10.3 where its manufacture, use, sale, offer for sale, import or export is deemed not infringing pursuant to 35 U.S.C. &#167; 271(e)(1).</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">ANNUAL MINIMUM AMOUNT OF RUNNING ROYALTIES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Beginning in the calendar year 2021 and for each year thereafter during the Term, if the total royalties payable by the Licensee to the University pursuant to Section 10.3 of the Business Terms do not meet the Minimum Royalty Payment for that year, then Licensee shall pay to University, within [***] after the conclusion of such year, such additional amount to ensure that the total royalties paid by the Licensee to the University during such year is at least equal to the Minimum Royalty Payment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Year(s)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">                                </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Minimum Royalty Payment</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]	[***]</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The annual Minimum Royalty Payment is not available for carryforward or carryback against royalties for years other than the applicable year or for other payments due under this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">SUBLICENSE NON-ROYALTY CONSIDERATION</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall pay to University [***]% of all Non-Royalty Consideration it receives from a Sublicensee within [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">With respect to any Sublicense of the Licensed Patent Rights, Licensee will, as part of the negotiation with a Sublicensee, allocate the various categories of payments required from a Sublicensee on a commercially reasonable basis and not with a view to undermine the fees that are due to University under this Section 10.5.  If University has a good faith objection to the allocation made by Licensee and a Sublicensee, then University will give prompt notice to Licensee and the parties shall meet and attempt to agree on which portion of the total payments received by Licensee pursuant to such sublicense would constitute Sublicense Non-Royalty Consideration. [***]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">TRANSFER FEE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Within [***] after the closing of a Transfer or Change of Control, Licensee shall pay to University, as a Transfer Fee, $[***] USD.  For clarity, Licensee shall not be obligated to pay a Transfer Fee to the extent it assigns this Agreement to an Affiliate of Licensee existing as of the Effective Date.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.293%;"></td>
    <td style="width:18.801%;"></td>
    <td style="width:71.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.7</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">MILESTONE PAYMENTS</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Not applicable/none required.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">10.8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">EARLY TERMINATION FEE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Unless waived by University in writing, Licensee shall pay to University a fee of $[***] USD in the event it terminates the Agreement early for convenience under Section 10.3(b) of the General Terms.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:2.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSEE&#x2019;S ADDRESS FOR NOTICE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);text-indent:12.05pt;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="margin-left:12.05pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Contact:	[***]</font></p><p style="margin-left:12.05pt;text-indent:-55.85pt;padding-left:55.85pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Address:	Finch Therapeutics, Inc.</font></p><p style="margin-left:12.05pt;text-indent:-55.85pt;padding-left:55.85pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#160;200 Inner Belt Road</font></p><p style="margin-left:12.05pt;text-indent:-55.85pt;padding-left:55.85pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#160;Suite 400</font></p><p style="margin-left:12.05pt;text-indent:-55.85pt;padding-left:55.85pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#160;Somerville, MA 02143</font></p><p style="margin-left:12.05pt;text-indent:-55.85pt;padding-left:55.85pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Phone	[***]</font></p><p style="margin-left:12.05pt;text-indent:-55.85pt;padding-left:55.85pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Email:	[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSEE&#x2019;S CONTACT FOR PATENT PROSECUTION CONSULTATION</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);text-indent:12.05pt;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="margin-left:12.05pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Contact:	[***]</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Address:	[***]</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Phone	[***]</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Email:	[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">13</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSEE&#x2019;S CONTACT FOR BILLING AND FINANCE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);text-indent:12.05pt;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="margin-left:12.05pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Contact:	[***]</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Address:	Finch Therapeutics, Inc.</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#160;200 Inner Belt Road</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#160;Suite 400</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#160;Somerville, MA 02143</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Phone	[***]</font></p><p style="margin-left:12.05pt;text-indent:-56.45pt;padding-left:56.45pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Email:	[***]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:88.492%;"></td>
    <td style="width:11.508%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">THE PARTIES HEREBY EXECUTE THIS AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Regents of the University of Minnesota</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Finch Therapeutics Holdings LLC</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">/s/ Rick Huebsch</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">/s/ Mark Smith</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Rick Huebsch</font></p><p style="text-indent:-252.0pt;padding-left:252.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Executive Director</font></p><p style="text-indent:-252.0pt;padding-left:252.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Technology Commercialization</font></p><p style="text-indent:-252.0pt;padding-left:252.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Mark Smith</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">CEO</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">January 19, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">1/28/2022</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The signatory warrants that they are authorized to execute this agreement on behalf of the Regents of the University of Minnesota.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.17291666666666666in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The signatory warrants that they are authorized to execute this agreement on behalf of Licensee</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(191,191,191,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;">GENERAL TERMS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">DEFINITIONS AND INTERPRETATION </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Definitions</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">In this Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means an entity that controls Licensee or the Sublicensee, as the case may be, is controlled by Licensee or Sublicensee, or along with Licensee or Sublicensee, is under the common control of a Third Party. An entity shall be deemed to have control of the controlled entity if it: (a) owns, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities of the controlled entity, or (b) has the right, power or authority, directly or indirectly, to direct or cause the direction of the policy decisions of the controlled entity, whether by ownership of securities, by representation on the controlled entity&#x2019;s governing body, by contract, or otherwise.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means (a) the acquisition by a person or group of beneficial ownership of the capital stock of Licensee if after the acquisition the person or group beneficially owns [***]% or more of either (i) the total number of the then outstanding shares of common stock of Licensee or (ii) the total number of the then outstanding shares of voting securities of Licensee; (b) a change in the composition of Licensee&#x2019;s board of directors such that less than a majority of individuals who serve as such directors as of the Effective Date or who were nominated for election to the board of directors by at least three quarters of directors in office as of the Effective Date or whose nomination and election to the board of directors was similarly approved, are serving on Licensee&#x2019;s board of directors; or (c) irrespective of whether Licensee is a surviving entity, the consummation of a merger, consolidation, reorganization involving Licensee or other exchange of shares of Licensee in one or a series of related transactions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Early Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the termination of this Agreement permitted under Section 10.3 (b) of the General Terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the date of the last signature on this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Enforcement Litigation&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">means any litigation involving the enforcement of Licensed Intellectual Property against a Third Party.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Field of Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the field(s) of use described in Section 3 of the Business Terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensed Patent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means: (i) a patent described in Section 5.1 of the Business Terms and (ii) a patent held by University that arose out of and/or claimed priority to a Licensed Patent Application. &#x201c;Licensed Patent&#x201d; also means any reissues or reexaminations or post-issuance certificates of a Licensed Patent that contain one or more Valid Claims.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensed Patent Application</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means a patent application described in Section 5.2 of the Business Terms along with continuations, continuations-in-part (but only to the extent the claims are supported by a patent application pending as of the Original Effective Date) and divisionals of such a patent application.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensed Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means a product or service or part of a product or service in the Field of Use: (a) the making, using, importing, selling, or providing of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent or is otherwise covered by a claim in a Licensed Patent Application; or (b) which is made with, uses, was derived from, identified or validated by, incorporates, or was developed in whole or in part using any Licensed Technical Information.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensed Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the Licensed Patents, Licensed Patent Applications and Licensed Technical Information, as set forth in Section 5.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Licensed Technical Information&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">means the information identified in Appendix A, as referenced at Section 5.3 of the Business Terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the entity identified in Section 1 of the Business Terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Minimum Royalty Payment&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> means the minimum royalty payments as set forth in Section 10.4 of the Business Terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Net Sales</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Non-Royalty Consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Patent-Related Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means costs and expenses (including out-of-pocket attorneys&#x2019; fees, patent agent fees and governmental fees) that University incurs in filing, prosecuting and maintaining the Licensed Patents.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Performance Milestone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means an act or event specified described in Section 9 of the Business Terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Royalty Consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means any royalty payment received by Licensee from a Sublicensee based on the Sublicensee&#x2019;s sales of Licensed Products.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Running Royalties&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> means the running royalties as set forth in Section 10.3 of the Business Terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Sublicense</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; when used as a noun, means any agreement between Licensee or an Affiliate of Licensee and a Third Party that contains a grant by Licensee or an Affiliate of Licensee to such Third Party to all or a portion of University&#x2019;s Licensed Intellectual Property regardless of the name given to the agreement by the parties; when used as a verb, means Licensee&#x2019;s act of entering into any agreement with a Third Party that contains a grant by Licensee to such Third Party to all or a portion of University&#x2019;s Licensed Intellectual Property, regardless of the name given to the agreement by the parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Sublicensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the Third Party in a Sublicense.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Territory</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means the geographical area described in Section 2 of the Business Terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Third Party&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">means any party other than University or Licensee or its Affiliates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Transfer&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">means the assignment of this License to a Third Party other than in connection with a Change of Control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Transfer Fee&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> means the fee set forth in Section 10.6 of the Business Terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">University Indemnitees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">&#x201d; means University, its respective regents, officers, employees, students, agents, faculty, representatives and volunteers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Valid Claim&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">&#x201c;Year&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">means a calendar year during the term of this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Rules of Interpretation and Convention</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">In this Agreement, unless the context requires otherwise:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">headings are for convenience only and do not affect interpretation;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">the singular includes the plural and conversely;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">a reference to any statute, rule, regulation or policy includes any amendment, and any statute, rule, regulation or policy replacing it; </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">all computations and payments made under this Agreement shall be in United States dollars. To determine the U.S. dollar value of transactions conducted in non-United States currencies on any particular day, the parties shall use the exchange rate for that currency as reported in the Wall Street Journal in the most recently published edition prior to the date of the transaction; and</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">all notices, reports, and other documents and instruments that a party elects or is required to deliver to the other party must be in English.</font></div></div>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LICENSE</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Grant of License</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, and Licensee hereby accepts, an exclusive license under University&#x2019;s rights in the Licensed Patents and Licensed Patent Applications to make, have made, use, sell, offer for sale, import, have imported, or otherwise dispose or have disposed a Licensed Product in the Territory and in the Field of Use;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">a non-exclusive license under University&#x2019;s interest in the Licensed Technical Information to use in conjunction with its exercise of rights under 2.1 (a);</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Except as provided in this section, no other rights or licenses, express or implied, are granted to Licensee.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Retained Rights</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Notwithstanding any provision of this Agreement, University retains on behalf of itself and all other non-profit research institutions, the right to practice the Licensed Intellectual Property for research, teaching, and education. The University shall have the specific right to use the Licensed Technology in commercial research projects sponsored by for-profit entities, provided that the for-profit entity that wishes to sponsor such a commercial research project is informed of the Licensee's rights hereunder and the need to negotiate with the Licensee with respect to commercial access to the Licensed Technology. The University shall have the right to sublicense its rights under this section to one or more non-profit academic or research institutions, provided that the non-profit academic or research institutions are informed of the Licensee's rights hereunder and the need to negotiate with the Licensee with respect to the commercial access to the Licensed Technology.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">SUBLICENSING</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Sublicense Requirements </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee may sublicense its rights under this Agreement, in whole or in part, through multiple tiers of sublicensees and to Third Parties and Affiliates; provided that, with respect to any sublicense to a Third Party, the Licensee shall deliver to the University a true and correct copy of the sublicense agreement or other agreement under which the Licensee purports or intends to grant such sublicense rights within [***] of the execution of such agreement, which copy may be redacted to exclude confidential information of the Licensee or the applicable sublicensee, but such copy shall not be redacted to the extent that it impairs the University&#x2019;s ability to ensure compliance with this Agreement. The Licensee shall not enter into such agreement if the terms of the agreement are inconsistent in any respect with the terms of this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Copy of Sublicenses and Sublicense Royalty Reports</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall submit to University within [***] of the effective date of a Sublicense a copy of such Sublicense in accordance with the terms of Section 3.1 of the General Terms, any subsequent amendments of the Sublicense and all copies of Sublicensee&#x2019;s royalty reports.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">PAYMENT, RECORDS, AND AUDIT</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensee&#x2019;s Payment Obligation</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall pay all amounts under Sections 7 and 10 of the Business Terms by the dates indicated therein.  Licensee shall pay such amounts by wire transfer, check (payable to the &#x201c;Regents of the University of Minnesota&#x201d; and sent to: Regents of the University of Minnesota, NW 5960, PO Box 1450, Minneapolis, MN 55485-5960; reference agreement number on check), or any other method of payment specified by University.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensee Responsible for Non-U.S. Taxes</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall pay all non-U.S. taxes related to payments made to University and invoiced to Licensee under this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Interest</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">All amounts due under this Agreement will bear compound interest at [***]% per annum on the entire unpaid balance computed from the payment due date of such amount (not to be fewer than [***] following receipt of an invoice) until the amount is paid.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Royalty Payments/Sales Reports</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Within [***] after the last day of the [***] beginning in the calendar year in which Licensee first sells a Licensed Product, Licensee shall provide to University a written report (even if there are no sales for the calendar quarter) that sets forth the amount of Net Sales for each Licensed Product within the Territory during such calendar quarter. The Licensee shall deliver along with such written report its payment for royalties (if any) accrued during such calendar quarter calculated in accordance with Section 10.3 and Section 10.4 of the Business Terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Notwithstanding the foregoing, if the Licensee, in its reasonable judgment, elects to pay royalties or similar payments to one or more Third Parties for a license to intellectual property rights owned or controlled by such Third Part(ies) that are reasonably useful or necessary for the manufacture, use, sale, offer for sale, import, or export of Licensed Products (whether to one or more Third Parties, the &#x201c;Third Party Royalty Payment&#x201d;), then Licensee may deduct an amount equal to [***] of any Third Party Royalty Payments, provided that in no event shall the royalties otherwise due University be less than [***] of the royalties that would be payable to University absent the effects of this Section 4.4. [***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">               </font>&#160;</p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">No Refund</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">With the exception of an undisputed overpayment made by Licensee to University, all amounts paid to University  by Licensee under this Agreement are non-refundable.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Termination Report</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall pay to University all amounts due under this Agreement and submit to University a written report to include contact information for any Sublicensees within [***] after the Agreement terminates.  Licensee will continue to submit any applicable royalty payments and/or reports after the license terminates, until all Licensed Products made or imported during the Term of the Agreement have been sold.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Accounting</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall maintain (and shall cause each Sublicensee to maintain) records showing manufacture, importation, sale, use, and provision of a Licensed Product for [***] from the date of sale of that Licensed Product.  Records will</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">include information in sufficient detail to enable University or its representative to determine the royalties owed under this Agreement.  Upon request by University, Licensee shall deliver to University or its representative, copies of all documents and materials (including electronic records) reasonably relevant to Licensee&#x2019;s and Sublicensee&#x2019;s performance of this Agreement, including, without limitation, copies of all Sublicenses in accordance with the terms of Section 3.1 of the General Terms.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Audit</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">No more than [***] during the Term, and during the Licensee&#x2019;s normal business hours, Licensee shall allow (and shall cause each Sublicensee to allow) University or its designee to examine Licensee&#x2019;s records to verify payments made by Licensee under this Agreement.  In connection with such audit, Licensee shall provide (and shall cause each Sublicensee to provide) commodious space at no cost to conduct the audit.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">4.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Paying for Audit</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">University will pay for any audit done under Section 4.8 of the General Terms.  But if the audit reveals an underreporting of royalties due University of [***] or more for the period being audited, Licensee shall pay the audit costs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">GOVERNMENT RIGHTS AND REGULATIONS</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Bayh-Dole Requirements </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">This Agreement is subject to Title 35, Sections 200-204 of the United States Code.  Among other things, these provisions provide the United States Government with nonexclusive rights in the Licensed Patents.  They also impose the obligation that any Licensed Products sold or produced in the United States be &#x201c;manufactured substantially in the United States.&#x201d;  Licensee shall ensure all obligations of these provisions are met.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">5.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Compliance with Laws</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall ensure that the manufacture, use, sale, or transfer of Licensed Products comply with all applicable laws and regulations.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">5.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Export Control</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee agrees to comply with U.S. export laws and regulations pertaining to the export of technical data, services and commodities, including the International Traffic in Arms Regulations (22 C.F.R., parts 120-130), the Export Administration Regulations (15 C.F.R., parts 730-744), the regulations administered by the Treasury Department&#x2019;s Office of Foreign Assets Control (31 C.F.R., parts 501-598) and the Anti-Boycott Regulations (15 C.F.R 760).   Licensee shall obtain any necessary U.S. government license or other authorization required pursuant to the U.S. export control laws and regulations for the export or re-export of any commodity, service or technical data covered by this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">5.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Cooperation with Governmental Requests</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall comply upon reasonable notice from University with all governmental requests relevant to the Licensed Intellectual Property directed to either University or Licensee and provide all information and assistance necessary to comply with the governmental requests.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">5.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Patent Marking</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee and each Sublicensee shall mark all Licensed Products in a manner consistent with their current patent marking practices for their own products provided appropriate notice is given by such marking in accordance with</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">35 USC 287 or other relevant statutes. Where marking is to be performed but the Licensed Product cannot be marked, the patent notice shall be placed on associated tags, labels, packaging, or accompanying documentation either electronic or paper as appropriate.</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">PATENT PROSECUTION AND MAINTENANCE</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">6.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Patent Prosecution and Maintenance </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The University, in consultation with the Licensee, shall control the preparation, filing, prosecution, and maintenance of the Licensed Intellectual Property. University will consult with Licensee in connection with the foregoing;      however, if Licensee is unresponsive to University&#x2019;s requests  for input, University may proceed in the exercise of its best judgment without prior consultation.         In no event shall Licensee file a patent application with respect to the Licensed Intellectual Property without first consulting with the University.  To facilitate consultation with Licensee, University will:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">keep Licensee reasonably informed as to the filing, prosecution, and maintenance of the Licensed Patents and Licensed Patent Applications;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">furnish to Licensee copies of material documents relevant to such filing, prosecution and maintenance; and</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">allow Licensee a reasonable opportunity to comment on material documents related to the Licensed Patents or Patent Applications prior to filing such documents at a patent office.  </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">6.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensee Assistance and Contact</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">At University&#x2019;s request, Licensee shall provide all information and assistance to University in the filing and prosecution of all Licensed Patents.  In furtherance of the foregoing, Licensee designates the person identified in Section 12 of the Business Terms to respond to University&#x2019;s request for consultation and cooperation on a pending matter within [***] or sooner as may be required under the circumstances.  If Licensee&#x2019;s contact fails to respond in such time period, University, exercising its own judgment and discretion, may respond to the matter as it deems appropriate.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">6.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Patent-Related Expenses </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall pay on behalf of or reimburse University for Patent-Related Expenses in accordance with Section 7 of the Business Terms, unless otherwise provided in this Agreement.</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">COMMERCIALIZATION</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Diligence  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall use its commercially reasonable efforts, consistent with sound and reasonable business practices and judgment, to commercialize the Licensed Intellectual Property and to manufacture and offer to sell and sell Licensed Products [***].</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Performance Milestones </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall perform, or cause to happen or be performed, as the case may be, all the performance milestones described in Section 9 of the Business Terms.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">7.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Commercialization Reports </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">By [***] of each year, Licensee will submit a written annual report to University covering the preceding calendar year if applicable.  Each report will describe Licensee&#x2019;s [***] Licensee will specifically describe how each Licensed Product is related to each Licensed Patent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">INFRINGEMENT</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Notification to University</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall notify University if it believes a third party is infringing a Licensed Patent and provide University with all credible evidence that is has to support this belief.  Subject to Section 8.2 of these General Terms, Licensee shall have the first right to initiate, control, defend and/or settle any proceedings involving the validity, enforceability or infringement of any Licensed Patent when in its sole judgment such action may be necessary, proper, and justified.  If Licensee elects not to initiate, control, or defend any proceedings described above, Licensee shall promptly notify University, and University may defend or bring such action at its own expense, in its own name and entirely under its own direction and control.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Good Faith Negotiations with University Prior to Commencing Infringement Action</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Prior to commencing any action to enforce a Licensed Patent, Licensee shall enter into good faith negotiations with University on the desirability of bringing suit, the parties to the action, the selection of counsel, and such other matters.  University may not be named (nor is Licensee authorized to name University) as a party in any such action      without its prior written consent. Unless otherwise agreed upon by the parties, and subject to Section 8.3 of the General Terms, the party initiating the enforcement shall bear any out-of-pocket expenses associated with the litigation (including but not limited to attorneys' fees, e-discovery costs, court costs).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Enforcement Litigation</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Settlement of any Enforcement Litigation requires the written consent of the University.  Further, any recovery in any Enforcement Litigation will be shared with University as follows:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">any recovery shall be first used to reimburse the party initiating the Enforcement Litigation for its actual fees, costs, and expenses incurred in the Enforcement Litigation;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***].</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Infringement by Licensee</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">If any suit, action or proceeding is brought or commenced against Licensee alleging the infringement of a patent or other intellectual property right owned by a Third Party by reason of the manufacture, use or sale of Licensed Products, Licensee shall give University prompt notice thereof. If the validity of a Licensed Patent is questioned in such suit, action or proceeding, Licensee shall have no right to make any settlement or compromise which affects the scope, validity, enforceability or otherwise of a Licensed Patent without University&#x2019;s prior written approval.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">UNIVERSITY NAME AND MARKS; Licensee name</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">9.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">No Use of University Name or Marks  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">No provision of this Agreement grants Licensee or Sublicensee any right or license to use the name, logo, or any marks owned by or associated with University or the names, or identities of any member of the faculty, staff, or student body of University. Licensee shall not use and shall not permit a Sublicensee to use any such logos, marks, names, or identities without University&#x2019;s prior written approval. The foregoing notwithstanding, without the consent of University, Licensee may indicate that it is licensed by the University under the Licensed Intellectual Property and identify the inventors of the Licensed Patents or Licensed Patent Applications, their affiliation with the University, and their relationship to Licensee, and further, Licensee may comply with disclosure requirements of all applicable laws relating to its business, including, without limitation, United States and securities laws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">9.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">No use of Licensee Name</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">University shall not use the name of Licensee or its Affiliates or Sublicensees in any promotional material or other public announcement without the prior written consent of Licensee or its Affiliates or Sublicensees (as applicable).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">TERMINATION</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">10.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">University&#x2019;s Right to Terminate for Breach</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Subject to Section 10.2 of the General Terms, University may terminate this Agreement if Licensee:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">is delinquent on any report or payment; </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">misses a milestone under Section 9 of the Business Terms, subject to the parties performing the obligations set forth in section 9 with respect to unanticipated studies or prerequisites required by the FDA; </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">is in breach of any material provision of this Agreement; or</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">provides any materially false report.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">10.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensee&#x2019;s Right to Remedy Breach</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Termination under Section 10.1 of the General Terms takes effect (without any further action by University) [***] after receipt by Licensee of written notice by University of any default under Section 10.1 of the General Terms, unless within that [***] period Licensee remedies the default and notifies University of the same.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">10.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Licensee&#x2019;s Right to Terminate  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee may terminate this Agreement:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">if University is in default of any material provision of this Agreement and fails to remedy the default within [***] of Licensee&#x2019;s written notice; or</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">for convenience (&#x201c;Early Termination&#x201d;) by delivering to University a written notice of termination at least [***] prior to the date of termination and upon payment of the Early Termination Fee as described in Section 10.8 of the Business Terms, if applicable.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">10.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Effect of Termination.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Upon Termination:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The grant of rights under Section 2.1 of the General Terms terminates.  Licensee may, however, sell or dispose of Licensed Products manufactured prior to termination for [***] thereafter, provided that Licensee continue to pay royalties on the sale of Licensed Products; and</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Upon request, University may grant a license to any Sublicensees on financial terms substantially similar to such terms in Sublicense provided Sublicensee has performed when due all of its obligations under the Sublicense.  </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Sublicenses granted by Licensee shall be assigned to University upon request and at University&#x2019;s discretion; provided that University&#x2019;s obligations under such Sublicense shall be consistent with and not exceed University&#x2019;s obligations to Licensee under this Agreement and provided that such Sublicensee agrees in a writing sent to University to assume all obligations of this Agreement for the benefit of University, including the obligations to make all payments and provide all reports due under this Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">10.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Sections of the Agreement Surviving Termination. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Surviving any termination or expiration are:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee's payment obligations for payments accrued prior to termination; and</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">the provisions of Sections 4.7, 8, 9, 11,12, 13, 14.1, 14.3, 14.4, 14.8, 14.9, 14.10, 14.11, 14.12 and 14.13 of the General Terms, and any other provision that by its nature is intended to survive. </font></div></div>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">INDEMNIFICATION AND INSURANCE</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">11.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Indemnification</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee shall indemnify, hold harmless, and defend all University Indemnitees against any Third Party claim of any kind arising out of or related to the exercise of any rights granted Licensee under this Agreement or Licensee&#x2019;s breach of any provision of this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">11.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Insurance</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee warrants that it now maintains and will continue to maintain liability insurance coverage appropriate to the risk involved in marketing and selling Licensed Products subject to this Agreement and that the insurance coverage lists University of Minnesota as an additional insured.  Upon University&#x2019;s request, Licensee shall present evidence to University that this coverage is being maintained.</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">DISCLAIMER OF WARRANTIES</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">12.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Warranties</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">University warrants that to the best of its actual knowledge as of the date of execution of this Agreement it has the right to grant the licenses to the Licensed Intellectual Property contained in this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">12.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Disclaimer of all Other Warranties</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">UNIVERSITY PROVIDES LICENSEE THE RIGHTS GRANTED IN THIS AGREEMENT AS IS AND WITH ALL FAULTS, IF ANY.   UNIVERSITY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED CONCERNING THE LICENSED INTELLECTUAL PROPERTY.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">AMONG OTHER THINGS, UNIVERSITY EXPRESSLY DISCLAIMS ANY WARRANTIES CONCERNING AND MAKES NO REPRESENTATIONS:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">that each Licensed Patent Application will be allowed or granted or that a patent will issue from a Licensed Patent Application;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">concerning the validity, enforceability, interpretation of claims or scope of any Licensed Patent; </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">that the exercise of the rights or licenses granted to Licensee or a Sublicensee under this Agreement will not infringe or violate a third party&#x2019;s intellectual property rights; or</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">that the exploitation of the Licensed Patents or Licensed Intellectual Property will be successful.</font></div></div>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">LIMITATION ON TYPE AND AMOUNT DAMAGES</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">13.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Limitation on Type of Damages  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">University is not liable for any special, consequential, lost profit, loss of business opportunity, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">13.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Limitation on Amount of Damages. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">With the exception of the University&#x2019;s gross negligence or willful misconduct, or an overpayment made by Licensee to University, in no event shall University&#x2019;s liability to Licensee exceed the payments made to University by Licensee during the [***] prior to the event that gave rise to the claim.</font></p>
  <div style="display:flex;padding-bottom:1.0pt;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">MISCELLANEOUS</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Choice of Law and Jurisdiction</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The internal laws of the state of Minnesota, without giving effect to its conflict of laws principles, govern the validity, construction, and enforceability of this Agreement.  A suit, claim, or other action to enforce the terms of this Agreement may be brought only in the state courts of Hennepin County, Minnesota.  Licensee hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over Licensee or its assets and property and to venue in that jurisdiction.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Amendment and Waiver</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The Agreement may be amended from time to time only by a written instrument signed by the parties. No term or provision of this Agreement may be waived, and no breach excused unless such waiver or consent is in writing and signed by the party claimed to have waived or consented. No waiver of a breach is to be deemed a waiver of a different or subsequent breach.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Data Practices Act</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The parties acknowledge that University is subject to the terms and provisions of the Minnesota Government Data Practices Act, Minnesota Statutes &#167;13.01 et seq. (the &#x201c;Act&#x201d;), and that the Act requires, with certain exceptions, University to permit the public to inspect and copy any information that University collects, creates, receives, maintains, or disseminates, including the existence of and the terms of this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Confidentiality </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">To the extent permitted by law, including as provided in the Act, University shall hold in confidence and disclose only to University employees, agents and contractors who need to know:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">the reports described in Sections 3.2, 4.4, and 7.3 of the General Terms;</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">the records inspected in accordance with Sections 4.7 and 4.8 of the General Terms. No provision of this Agreement is to be construed to further prohibit, limit, or condition University&#x2019;s right to use and disclose any information in connection with enforcing this Agreement, in court or elsewhere.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Assignment</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Except as provided in Section 14.6 of the General Terms or with University&#x2019;s prior written consent, Licensee shall not effect a Transfer of its interest under this Agreement. Any Transfer attempted to be made in violation of this section is void. Absent the consent of all the parties, an assignment or delegation will not release the assigning or delegating party from its obligations.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Change of Control</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee may assign this Agreement to an Affiliate or as part of a Change of Control upon prior and complete performance of the following conditions:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Licensee must give University [***] prior written notice of the assignment, including the new assignee&#x2019;s contact information;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">the new assignee must agree in writing to University to be bound by this Agreement; and </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:3.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">University must have received the full Transfer Fee if applicable.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Notwithstanding the foregoing in this Section 14.6, University hereby approves the Transfer of this Agreement to Licensee (i.e. Finch Therapeutics Holdings LLC) and hereby waives any Transfer Fee  (solely in connection there with) otherwise payable hereunder.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Consent and Approvals</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Except as otherwise expressly provided, in order to be effective, all consents or approvals required under this Agreement must be in writing.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Entire Agreement</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">The parties intend this Agreement (including all attachments, exhibits, and amendments hereto) to be the final and binding expression of their contract and agreement and the complete and exclusive statement of the terms thereof. The Agreement cancels, supersedes, and revokes all prior negotiations, representations and agreements among the parties, whether oral or written, relating to the subject matter of this Agreement.  No representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Enforceability</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">If a court of competent jurisdiction adjudges a provision of this Agreement to be unenforceable, invalid, or void, such determination is not to be construed as impairing the enforceability of any of the remaining provisions hereof and such provisions will remain in full force and effect.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">No Third-Party Beneficiaries</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">No provision of this Agreement, express or implied, is intended to confer upon any person other than the parties to this Agreement any rights, remedies, obligations, or liabilities hereunder. No Sublicensee may enforce or seek damages under this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Relationship of Parties</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">In entering into, and performing their duties under this Agreement, the parties are acting as independent contractors and independent employers. No provision of this Agreement creates or is to be construed as creating a partnership, joint venture, or agency relationship between the parties. No party has the authority to act for or bind the other party in any respect.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Notices</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">In order to be effective, all notices, requests, and other communications that a party is required or elects to deliver must be in writing and must be delivered personally, or by facsimile or electronic mail (provided such delivery is confirmed), or by a recognized overnight courier service or by United States mail, first-class, certified or registered, postage prepaid, return receipt requested, to the other party at its address set forth below or to such other address as such party may designate by notice given under this Section:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">If to University:			University of Minnesota</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Technology Commercialization</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">200 Oak Street, SE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Suite 280</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Minneapolis, MN  55455</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Fax: [***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">E-mail: [***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">	For notices sent	University of Minnesota</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">	under Section 8,	Office of the General Counsel</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">	with a copy to:	Attn: [***]</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">360 McNamara Alumni Center</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">200 Oak Street S.E.</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Minneapolis, MN 55455-2006</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Facsimile No.: [***]</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">Email: [***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">If to Licensee:		As indicated in Section 11 of the Business Terms.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.13</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Security Interest</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">In no event may Licensee grant, or permit any person to assert or perfect, a security interest in Licensee&#x2019;s rights under this Agreement.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:6.667%;">14.14</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;">Execution in Counterparts</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">This Agreement may be executed in counterparts and by facsimile or electronic transmission.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Agreement Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Calibri;">OTC Case Number: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;">Technical Information</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">[***]</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">     </font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>fnch-ex10_7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html>
 <head>
  <title>EX-10.7</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO FINCH THERAPEUTICS GROUP, INC. IF PUBLICLY DISCLOSED.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">AMENDMENT #2 TO AMENDED AND RESTATED AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This Amendment to Amended and Restated Agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) is entered into as of November 12, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Amendment #2 Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Finch Therapeutics, Inc.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, a Delaware corporation having its principal office at 200 Inner Belt Road, 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Floor, Somerville, Massachusetts 02143 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Finch</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Takeda Development Center Americas, Inc.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal office at 95 Hayden Avenue, Lexington, MA 02421 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Takeda</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Background</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Finch and Takeda are the parties to the Amended and Restated Agreement dated October 21, 2019, as amended by the Amendment to the Amended and Restated Agreement dated August 9, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">As a result of the parties&#x2019; discussion on the results obtained from the FIN-524 Crohn Feasibility Study performed by Finch under the Agreement, the parties have agreed for Finch to perform certain additional preliminary research activities with respect to combinations of some microbial isolates included in Optimal FIN-524 and one or more microbial isolates that are not included in Optimal FIN-524 and have been identified as relevant to Crohn&#x2019;s Disease by Finch (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">FIN-525 Preliminary Evaluation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) such that Takeda can evaluate the results and determine whether to initiate the full FIN-525 Development Program, and desire to memorialize such agreement in this Amendment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">NOW THEREFORE, in consideration of mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Finch and Takeda agree as follow:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Definitions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Unless otherwise specifically set forth herein, all capitalized terms in this Amendment, including the Background stated above, shall have the same meaning as set forth in the Agreement.</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Amendments.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  The Agreement is hereby amended as follows:</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Performance of FIN-525 Preliminary Evaluation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Finch shall have responsibility for performance of the FIN-525 Preliminary Evaluation in accordance with the relevant Development Plan attached to this Amendment as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Parties hereby confirm and agree that the FIN-525 Preliminary Evaluation shall constitute part of the FIN-525 Development Program; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, for the purpose of Section 8.2(a-1), initiation of the FIN-525 Preliminary Evaluation shall not be construed as determination by Takeda of initiation of the full FIN-525 Development Program,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided further </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that Takeda shall use commercially reasonable efforts following receipt of all the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">results of the FIN-525 Preliminary Evaluation to either make such determination or determine to not initiate the FIN-525 Development Program, and in either case to provide to Finch prompt written notice of Takeda&#x2019;s determination. In the event that such notice indicates Takeda&#x2019;s determination to not initiate the FIN-525 Development Program, upon Finch&#x2019;s receipt of the notice the FIN-525 Development Program shall be deemed terminated in accordance with Section 13 of the Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development Funding.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Notwithstanding Section 4.4(a)-(d) of the Agreement, Finch will be responsible for all costs incurred by or on behalf of Finch in performing the FIN-525 Preliminary Evaluation; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, subject to the payment schedule below, Takeda shall pay Finch a total of US$[***] in support of the FIN-525 Preliminary Evaluation, all as detailed in the Budget included in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of this Amendment.  Finch shall issue an invoice in accordance with the payment schedule below and Takeda shall pay such invoiced amount within [***] after the receipt of relevant invoice from Finch. </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Payment Schedule:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Milestone Event 1 for FIN-525.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Milestone Event 1 for FIN-525 set forth in Section 8.2(a-1) is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreements and Acknowledgement by the Parties.</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Amendment #2 Effective Date.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  This Amendment shall be effective as of the Amendment #2 Effective Date and shall apply with respect to any performance by Finch of the FIN-525 Preliminary Evaluation prior to the Amendment #2 Effective Date. This Amendment shall remain effective during the Term of the Agreement, unless terminated in accordance with the provisions of the Agreement.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Reaffirmation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  The parties hereby confirm all of the terms and covenants, and provisions of the Agreement, and except as provided or modified herein, the Agreement remains unmodified and in full force and effect.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Governing Law.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  This Amendment shall be governed by and construed in accordance with laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Incorporation of Terms and Provision of Original Agreement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  The terms and conditions of the Agreement are hereby incorporated by reference and shall be applicable to this Amendment and the matters addressed herein as if set forth herein in full.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(5)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Entire Agreement.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This Amendment, along with the Agreement, sets forth the complete, final, and exclusive agreement, and all the covenants, promises, agreements, warranties, representations, conditions, and understandings between the parties with respect to the subject matter hereof, and </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">supersedes, as of the Amendment #2 Effective Date, all prior and contemporaneous agreements and understandings between the parties with respect to the subject matter hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(6)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Further Assistance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Each party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments, and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other party may reasonably request in connection with this Amendment or to carry out more effectively the provisions and purposes hereof.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(7)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Severability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  If any one or more of the provisions of this Amendment is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Amendment and shall not serve to invalidate any remaining provisions hereof, and the invalid or unenforceable provision shall be replaced with the most nearly coextensive valid and enforceable provision that is acceptable to the court of competent jurisdiction, or otherwise, the parties shall engage in good-faith efforts to replace such invalid or unenforceable provision with a valid and enforceable provision as closely as possible commensurate with the objectives completed by the parties when entering this Amendment. </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(8)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Counterparts.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  This Amendment may be executed simultaneously in two counterparts, by facsimile or PDF copy, each of which shall be deemed an original, but all of which together shall constitute on and the same instrument.</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">INWITNESS WHEREOF, the parties have caused this Amendment to be executed on their behalf by their duly authorized representatives as of the Amendment #2 Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ Mark Smith</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name: Mark Smith</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title: Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">TAKEDA DEVELOPMENT CENTER AMERICAS, INC.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ Chinweike Ukomadu</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Print name: Chinweike Ukomadu</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title: Head of Gastroenterology Therapeutic Area Unit</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>5
<FILENAME>fnch-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10.17</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Release Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Zain Kassam, understand and agree completely to the terms set forth in this Release Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and in the Amended and Restated Executive Employment Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) dated</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Arial;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 12, 2021, by and between Finch Therapeutics Group, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and me, as a result of my voluntary resignation without Good Reason effective on November 5, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). I understand that I am not entitled to any payments set forth in Section 1 below if I do not sign this Release and return it to Company pursuant to the terms set forth herein. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payments Upon Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. On the Termination Date, I shall be paid an amount equal to (i) Forty-Three Thousand Six Hundred Dollars ($43,600), less lawful deductions (which is an amount equal to thirty percent (30%) the pro-rated amount of my Target Bonus for the period of time worked in 2021 through the Termination Date), plus (ii) Two Hundred and Eighteen Thousand Dollars ($218,000.00), less lawful deductions (which is an amount equal to the sum of six (6) times my monthly base salary as of the Termination Date).  </font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General Release and Knowing Waiver of Employment-Related</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For and in consideration of the payment described in Section 1, I, on my own behalf and on behalf of my successors and assigns (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Releasor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), hereby release and forever discharge the Company, its affiliates, and their respective stockholders, members, predecessors, successors, officers, directors, agents, representatives, employees, consultants and advisors (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Releasee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), from any and all claims, counterclaims, demands, debts, actions, causes of action, suits, expenses, costs, attorneys&#x2019; fees, damages, indemnities, obligations and/or liabilities of any nature whatsoever (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), whether known or unknown, which Releasor ever had, now has or hereafter can, shall or may have against Releasee, for, upon or by reason of any matter, cause or thing whatsoever from the beginning of the time to the day of the date of this Release, including, but not limited to, the following:</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all such Claims and demands directly or indirectly arising out of or in any way connected with my employment with Company, including but not limited to providing services to the Company, or the termination of that employment and provision of services;</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all such Claims and demands related to salary, bonuses, commissions, stock, stock options, units, profits interests or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, separation pay and/or any other form of compensation or wages to which I may be entitled whether under common law, the Massachusetts Payment of Wages Act, (M,G.L. c. 149, sections 148, 148A, 148B, 148C, 149, 150, 150A-150C, 151, 152, 152A, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">et</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">seq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.), or otherwise;</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any Claims arising under any federal, state or local law, statute or ordinance, including, without limitation, Title VII of the Civil Rights Act of 1964, , the Americans With Disabilities Act, the Civil Rights Act of 1991, the Fair Labor Standards Act, the Equal Pay Act, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act of 1993, and the Consolidated Omnibus Budget Reconciliation Act of 1985, the anti-retaliation provisions of any federal or state statute, including state workers&#x2019; compensation statutes, and any other applicable state or local statutes, including the Massachusetts Fair Employment Practices Act (M.G.L. c. 151B), the Massachusetts Equal Rights Act, the Massachusetts Equal Pay Act, the Massachusetts Privacy Statute, the Massachusetts Sick Leave Law, the Massachusetts Civil Rights Act, all as amended, the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150), the Massachusetts Overtime regulations (M.G.L. c. 151 sections 1A and 1B), the Massachusetts Meal Break regulations (M.G.L. c. 149 sections 100 and 101); the Massachusetts Parental Leave Law (M.G.L. c. 149, section 105D); the Massachusetts Family and Medical Leave Law (M.G.L. c. 175M);</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any Claims for breach of contract, express or implied, including any claim for breach of any implied covenant of good faith and fair dealing; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any Claims of constructive discharge, discrimination, harassment, retaliation, fraud, defamation, intentional tort, emotional distress and negligence; and</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Nothing in this Release shall prevent me from enforcing my rights, if any (i) to my non-forfeitable accrued benefits (within the meaning of Sections 203 and 204 of ERISA) under any tax-qualified retirement plan maintained by the Company, (ii) to receive continuation coverage pursuant to COBRA, (iii) to indemnification conferred upon me as an officer of the Company pursuant to the Company&#x2019;s governing documents, under any applicable insurance policies or in accordance with applicable law or (iv) that cannot be waived under applicable law. Further, nothing in this Release affects my rights to provide information to, participate in an investigation by or file an administrative charge or complaint with any Governmental Authorities (defined below), including, but not limited to, the Equal Employment Opportunity Commission or similar administrative agency. However, I agree not to accept any monetary relief or recovery from any charge or complaint filed against any Releasee with any such administrative agency</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,120,212,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">except where authorized by applicable law.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, Releasor does not release any Claims against Releasee that may arise after this Release has become effective.</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Representation by Counsel and Review Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. I have been advised to consult independent legal counsel before signing this Release, and I hereby represent that I have executed this Release after having the opportunity to consult independent counsel and after considering the terms of this Release. I further represent and warrant that I have read this Release carefully, that I have discussed it or have had reasonable opportunity to discuss it with my counsel, that I fully understand its terms, and that I am signing it voluntarily and of my own free will.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consideration for Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. I acknowledge that the consideration for this Release is consideration to which I would not otherwise be entitled and is in lieu of any rights or claims that I may have with respect to any other remuneration from the Company.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Representation Concerning Filing of Legal Actions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. I represent that, as of the date of this Release, I have not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against Company or any of the other Releasees in any court or with any governmental agency.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Continuing Obligations Concerning Confidential Information and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Company Property.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I acknowledge and agree that I remain subject to the restrictive covenants contained in Section 3 of the Employment Agreement and the covenants related to Confidentiality &amp; Proprietary Information contained in Section 4 of the Employment Agreement, each of which survives the termination of my employment. I further acknowledge that I am obligated to return to the Company by November [8], 2021, all Company documents, originals and copies, whether in hard or electronic form, and all Company property, including without limitation keys, computers, computer disks, pagers, phones and credit cards.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-disparagement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to the provisions of Section 8, I will not make any statements, whether verbally or in writing (including in electronic communications) that are professionally or personally disparaging of, or adverse to the interests of, the Company or its officers, directors, managers or employees. This includes, but is not limited to, any statements that disparage the products, services, finances, financial condition, capability or any other aspect of the business of the Company. I further agree not to engage in any conduct which is intended to harm, professionally or personally, the reputation of the Company or its officers, directors, managers or employees. For its part, the Company shall direct those of its executives that know of this Release not to make any statements, whether verbally or in writing (including in electronic communications) that are professionally or personally disparaging of you, or adverse to your interests.  </font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Exceptions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Nothing in this Release shall prohibit the Releasor from lawfully (A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governmental Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to the Releasor individually (and not directed to the Company and/or its subsidiaries) from any such Governmental Authorities; (C) testifying, participating or otherwise assisting in an action or proceeding by any such </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Governmental Authorities relating to a possible violation of law; or (D) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, the Releasor shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to the Releasor&#x2019;s attorney in relation to a lawsuit for retaliation against the Releasor for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement require the Releasor to obtain prior authorization from the Company before engaging in any conduct described in this Section 8, or to notify the Company that he has engaged in any such conduct.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Provision</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All payments and benefits provided under the Employment Agreement are intended to be exempt from, or to comply with, the requirements of section 409A of the Code and this Release shall be interpreted and administered in accordance with these intentions. The Severance Benefits and rights to COBRA Reimbursement under the Employment Agreement are intended to be exempt from section 409A of the Code under the &#x201c;short-term deferral&#x201d; exception of Treas. Reg. Section 1.409A-1(b)(4), to the maximum extent applicable, and then under the &#x201c;separation pay&#x201d; exception of Treas. Reg. Section 1.409A-1(b)(9)(iii), to the maximum extent applicable. All payments that are subject to Section 409A that are to be made upon a termination of the Releasee&#x2019;s employment may only be made upon the Releasee&#x2019;s &#x201c;separation from service,&#x201d; as defined in Treas. Reg. Section 1.409A-1(h), from the Company. For purposes of section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments and each such installment shall be treated as a separate payment. With respect to any payments that are subject to section 409A of the Code, in no event shall the Releasee, directly or indirectly, designate the calendar year of a payment. Any reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Treas. Reg. Section 1.409A- 3(i)(1)(iv). Notwithstanding the foregoing, the Releasee acknowledges that he has been advised to seek the advice of a tax advisor with respect to the tax consequences of all payments pursuant to the Employment Agreement, including any adverse tax consequence under section 409A and applicable State tax law, and neither the Company nor any of its members, officers, employees, agents or affiliates shall be responsible for any such adverse tax consequences or guarantees any particular tax consequences to the Releasee with respect to payments and benefits under the Employment Agreement.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment of Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release may not be amended or modified except by a writing signed by Joseph Vittiglio, SVP and General Counsel, on behalf of Company and by me.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to principles of conflicts of laws thereunder.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Neutral Interpretation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release shall be interpreted in a neutral manner, and not more strongly for or against any party based upon the source of the draftsmanship of the Release.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The various headings in this Release are inserted for convenience only and are not part of the Release.</font></div></div>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Admission of Liability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Releasee agrees that this Release, and performance of the acts required by it, does not constitute an admission of liability, culpability, negligence or wrongdoing on the part of anyone, and will not be construed for any purpose as an admission of liability, culpability, negligence or wrongdoing by any party and/or by any party&#x2019;s current, former or future parents, subsidiaries, related entities, predecessors, successors, officers, directors, stockholders, agents, employees and assigns</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">Section 15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Waiver of Notice Period.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company hereby waives the thirty (30)-day period for advance notice of the Executive&#x2019;s termination of employment required pursuant to Section 6 of the Employment Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated: 		This</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> 4th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day of November, 20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">				</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">				</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">						</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Zain Kassam				</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name: Zain Kassam</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">					`	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith				</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Therapeutics Group, Inc.</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By: Mark Smith</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title: CEO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>6
<FILENAME>fnch-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 10.19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:23.347%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:23.537%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:8.85pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">September 8, 2021 (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">FTG</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, together with all subsidiaries and affiliates hereinafter referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and Marc Blaustein (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">WHEREAS, the Company desires to employ the Executive as its Chief Operating Officer;</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:9.05pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">WHEREAS, the Executive desires to be employed by the Company as Chief Operating Officer and to perform his duties to the Company on the terms and conditions hereinafter set forth; and</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:8.2pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">WHEREAS, the Company and the Executive wish to enter into this Agreement to set forth the terms and conditions of the Executive&#x2019;s employment with the Company effective as of [the date hereof] (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.093%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Company and the Executive agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:-7.229%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:9.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Term of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company agrees to employ Executive on an at-will basis, and Executive agrees to accept such employment and serve the Company, in accordance with the terms and conditions set forth herein. The Executive&#x2019;s term of employment under this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) shall be for the period commencing on the date of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Start Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and ending when the Executive&#x2019;s employment is terminated pursuant to Section 6 hereof.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Position, Duties, and Responsibilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. During the Term, Executive shall be employed and serve as Chief Operating Officer of the Company (together with such other position or positions consistent with Executive&#x2019;s title as the Company shall specify from time to time) and shall have such duties and responsibilities commensurate therewith, and such other duties as may be assigned and/or prescribed from time to time by the Chief Executive Officer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">CEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and/or the Board of Directors of FTG (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). Executive shall report to the CEO.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Performance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive shall devote his full business time, attention, skill, and best efforts to the performance of his duties under this Agreement and shall not engage in any other paid work during the Term that (a) conflicts with the interests of the Company, (b) interferes with the proper and efficient performance of Executive&#x2019;s duties for the Company, or (c) interferes with Executive&#x2019;s exercise of judgment in the Company&#x2019;s best interests. Executive may not serve on any for-profit board of directors or board of any educational, social, religious or civic organizations without the prior written approval of the Board. Executive affirms that he has no contractual commitments or other legal obligations that would prohibit him from fully performing his duties for the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.12%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. As full compensation for all services to be rendered by the Executive to the Company in all capacities, the Executive shall receive the following compensation and benefits:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Executive shall be entitled to receive an annual base salary of $400,000 USD (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). The Base Salary, which will be reviewed annually, will be paid periodically in accordance with the Company&#x2019;s normal payroll practices and be subject to applicable withholdings.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive will be eligible to receive an annual bonus of forty percent (40%) of Executive&#x2019;s Base Salary, less applicable withholdings (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Target Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). The amount of any bonus shall be determined by the Board or the Compensation Committee of the Board in their sole discretion. Except as provided in Section 7, Executive must be employed by Company at the time of any such bonus payment in order to be eligible for any such payment. Except as set forth in Section 7.3 below, the Target Bonus is not earned until paid and no pro-rated amount will be paid if Executive&#x2019;s employment terminates for any reason prior to the payment date.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Equity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Subject to approval by the Board, Executive shall be granted an option to purchase 150,000 shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), with an exercise price equal to the fair market value of a share of common stock as determined by the closing price of a share of the Company&#x2019;s common stock as reported on the Nasdaq Global Select Market at the close of business on the date of grant, pursuant to the terms of the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and individual stock option grant notice and agreements as applicable. The Option will be subject to the terms and conditions of the Plan and the Executive&#x2019;s grant agreement and will vest 25% on the one-year anniversary of the date of grant, and thereafter over the ensuing 3 years in a series of thirty-six (36) successive equal monthly installments, subject to Executive&#x2019;s continuous service as of each such date. The Option shall be an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended to the maximum extent permissible.</font></p>
  <p style="margin-left:0.92%;text-indent:6.784%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.009%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive is entitled, during the Term, to participate in all employee benefits plans customarily granted to other executives of the Company, including medical, dental and disability insurance, life insurance and a 401(k) plan, subject to plan terms and applicable Company policies. Further, Executive shall be entitled to paid vacation in accordance with then-applicable Company policy for full- time, exempt employees, or any subsequent policy approved by the Board. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any time.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company agrees to indemnify Executive to the maximum extent allowable under the terms and conditions of its certificate of incorporation, bylaws, under applicable law, and under the indemnification agreement signed herewith. Further, Executive will be covered by the Company&#x2019;s directors&#x2019; and officers&#x2019; liability insurance coverage as in effect from time to time and that certain Indemnification Agreement by and between the Company and the Executive dated the date hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:-7.229%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Restrictive Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:9.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Acknowledgement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive understands that the nature of Executive&#x2019;s position gives him access to and knowledge of confidential, proprietary and/or trade secret, and customer information and places him in a position of trust and confidence with the Company. Executive understands and acknowledges that the intellectual services he provides to the Company are unique, special, or extraordinary. Executive further understands and acknowledges that the Company&#x2019;s ability to reserve these for the exclusive knowledge and use of the Company is of great competitive importance and commercial value to the Company, and that improper use or disclosure by Executive is likely to result in unfair or unlawful competitive activity. Executive represents and warrants that he is not in breach of any agreement requiring him to preserve  the confidentiality  of  any  information,  client lists, trade secrets  or other</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">confidential information or any agreement not to compete or interfere with any prior employer, and that neither the execution of this Agreement nor the performance by Executive of his obligations hereunder will conflict with, result in a breach of, or constitute a default under, any agreement to which he is a party or to which he may be subject. Executive further represents that he has not taken and will not take any confidential or proprietary information from any prior employer or other person and will not use or disclose any such information in performing his obligations hereunder but instead will rely on his generalized knowledge and skill in performing his services hereunder.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Non-Competition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Because of the Company&#x2019;s legitimate business interest as described herein, and the good and valuable consideration offered to Executive in this Agreement (including the mutually agreed-to consideration in accordance with Sections 7.2, 7.3 and 7.4), during the period of Executive&#x2019;s employment with Company and for a period of twelve (12) months from termination of Executive&#x2019;s employment for any reason (other than as set forth in Section 6.4) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Non-Compete Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), without the prior written consent of the Company, Executive shall not, in any capacity (whether as an employee, director, officer, partner, interest holder, investor, consultant, advisor or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company), directly or indirectly engage in any activity on behalf of any other individual or enterprise (other than the Company) that is pursuing, or is planning to pursue, activities related to microbiome therapies and diagnostics (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Competitive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Activity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) anywhere in the United States, Canada, Europe or any other country in which the Company is either doing business or actively planning to do business as of the date of Executive&#x2019;s termination of employment or two years prior. For the avoidance of doubt, engagement in any respect with Seres Therapeutics, Rebiotix, Symbiotic Health, Assembly Biosciences, Monarch Laboratories, Vedanta, ViThera, Second Genome, Synthetic Biologics, Intrexon/Actogenix, Evelo Thereapeutics, Enterome, Axial Biotherapeutics, Kallyope and/or Kaleido (so long as any of those companies pursue activities related to microbiome therapies), constitutes Competitive Activity. The Company may waive the provisions of this Section 3.2 by providing written notice to Executive upon termination of Executive&#x2019;s employment.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:7.8pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Non-Solicitation of Employees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. During the Non-Compete Period, Executive will not, and will not attempt to, directly or indirectly hire, interview, solicit, recruit, induce, procure, encourage, work with, retain or engage for employment, consulting services or otherwise any present or former employee of the Company unless such person shall have voluntarily ceased to be employed by the Company or any subsidiary or affiliate for a period of at least six (6) months.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:8.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Non-Disparagement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Subject to Section 5, below, Executive agrees that he shall not at any time, during or after his employment with Company, directly or indirectly, (a) make any public comments about (including, without limitation, by way of news interviews or the expression of personal views, opinions or judgments to the media or any other entity or person outside the Company) the Company (other than factual information or other publicly available information about the Company) without prior consultation with the Board, or any disparaging comments about any constituent entity of the Company or any of their respective officers, directors, members, partners, investors, consultants, advisors or other employees (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Company Group</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) or (b) disparage, criticize, ridicule or make any negative comments about the Company Group (or any constituent thereof) to any person or entity within the Company Group or any other individual or entity with whom the Company Group has or may have a business or personal relationship, including any current, former or prospective vendor, vendee, investor or employee. This Section 3.4 does not, in any way, restrict or impede Executive from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.944%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">provided that such compliance does not exceed that required by the law, regulation or order. Executive shall promptly provide written notice of any such order to the Board.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Injunctive Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive recognizes that irreparable injury will result to the Company in the event of any breach of any of the terms or provisions of this Section 3. Therefore, Executive agrees that in the event of such a breach, FTG and other members of the Company Group will be entitled to seek, in addition to other remedies and damages available, an injunction to restrain any such breach and all persons acting for and/or in concert with Executive. The restricted periods described in Section 3 will not expire, and will be tolled, during any period in which Executive is in violation of Section 3.2 and/or Section 3.3, as applicable, and the restriction will automatically be extended by the time period that Executive is in violation of such restriction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:-7.229%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Confidential &amp; Proprietary Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:9.1pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive understands that all confidential and/or proprietary information concerning the Company, whether written or oral, which is or has been communicated to him by any person working for or on behalf of the Company or an entity affiliated with the Company, and all confidential and/or proprietary information that he generates as a result of services performed for the Company, including but not limited to trade secrets, regulatory strategy, intellectual property strategy, research and clinical strategies, technologies, procedures, models, testing systems, research, assays, compounds, molecules, organisms, gene sequences, cell lines, complement inhibitors and other re-agents (including the composition thereof), formulas, methods, processes, test and experimental data and results, specifications, invention disclosures, patent claims, laboratory notebooks, schematics and drawings (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), is proprietary and confidential to the Company. Subject to Section 5, Executive agrees that he shall not at any time (whether during or after the term of his employment with Company or until such time as such Confidential Information has become public knowledge), without the prior written consent of the Company, directly or indirectly, use or disclose any Confidential Information except as is necessary to fulfill his obligations hereunder or as is required to be disclosed by law, court order, or similar compulsion (provided that he shall promptly give the Company written notice of a court order or similar compulsion that would require the disclosure of Confidential Information in order to permit the Company to seek an appropriate protective order). Executive&#x2019;s obligations with respect to Confidential Information will cease when the Confidential Information: (i) becomes part of the public domain through no wrongful act of Executive, or (ii) is approved for release by prior written authorization of the Company. Executive agrees to destroy or return (at Company&#x2019;s request) any and all Confidential Information to the Company upon any termination of this Agreement.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10.0pt;margin-top:7.75pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.037%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Intellectual Property; Works Made for Hire</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company shall own all right, title and interest (including without limitation patent rights and copyrights) to all tangible and intangible property, products, developments, discoveries and inventions (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Inventions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) conceived, created or produced directly or indirectly by or through Executive during the term of Executive&#x2019;s employment with the Company, which relate to the actual or anticipated business, research and development of the Company, including, but not limited to, all documents, reports, and electronic or written materials, and all computer software and biological materials, and all related patent, know-how and other intellectual property rights, including, without limitation, all technical information, records, data, reports, tests or trial results and other results, and tangible manifestations and embodiments of work (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Work</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and Executive shall provide the Company with the originals and/or all copies of any such Inventions upon request of the Company. Executive hereby assigns to the Company all right, title and interest in any Invention or discovery, whether in finished or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">incomplete form, made during the term of his employment with the Company, and in any patent application, related documents and any patent relating to such invention or discovery. To the extent that any copyrighted work produced by the Executive hereunder is not deemed a &#x201c;work made for hire&#x201d; for purposes of the copyright laws of the United States, Executive hereby assigns to Company all right, title and interest in the copyright of such work, including without limitation the right to reproduce, distribute, sublicense, perform and display the work and to create and use derivative works therefrom in any medium throughout the world. The term &#x201c;derivative works&#x201d; as used in this Agreement has the same meaning as used in the Copyright Act of the United States. Executive shall complete and execute such assignments, certificates or other instruments as the Company may from time to time deem necessary or desirable to evidence, establish, maintain, perfect, protect, enforce or defend its or any of its affiliates&#x2019; right, title and interest in or to any of the foregoing. Executive shall retain no rights in or to any work product produced hereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.517%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disclosure Exceptions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Nothing in this Agreement shall prohibit or restrict Executive from lawfully (A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Governmental Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to Executive individually (and not directed to the Company and/or its subsidiaries) from any such Governmental Authorities; (C) testifying, participating or otherwise assisting in an action or proceeding by any such Governmental Authorities relating to a possible violation of law; or (D) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to Executive&#x2019;s attorney in relation to a lawsuit for retaliation against Executive for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement require Executive to obtain prior authorization from the Company before engaging in any conduct described in this Paragraph, or to notify the Company that he has engaged in any such conduct.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive is an employee-at-will, such that the Term and Executive&#x2019;s employment hereunder may be terminated by either the Company or Executive at any time and for any reason; provided that, unless otherwise provided herein, either party shall be required to give the other party at least thirty (30) calendar days advance written notice of any termination of Executive&#x2019;s employment; provided, however, that the Company may cease accepting services from the Executive or otherwise disallow the Executive&#x2019;s access to Company facilities, computer systems, or personnel during the thirty days&#x2019; notice period. Upon termination of Executive&#x2019;s employment during the Term, Executive shall be entitled to the compensation and benefits further described in Section 7 below and shall have no further rights to any compensation or any other benefits from the Company or any of its affiliates. Should the Company elect to forego the aforementioned notice provision, it shall remit to Executive payment in lieu of notice equal to the salary he would have received during the notice period.</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:7.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination upon Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Term shall terminate as of the date of Executive&#x2019;s</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:9.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">death.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination upon Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. If Executive suffers from a Disability during the Term, the Company may terminate the Term by written notice to Executive, in which event the Term shall terminate ten (10) days after the date upon which the Company has given written notice to Executive of its determination to terminate the Executive&#x2019;s employment under this Agreement.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination by the Company for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company may immediately terminate Executive for Cause (as defined in Section 8.2 below).</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:8.2pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination by the Company without Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company may terminate the Term at any time, without Cause.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination by Executive without Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive may terminate the Term at any time, without Good Reason (as defined in Section 8.3 hereof).</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination by Executive for Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive may terminate the Term for Good Reason (such termination to comply with the notice, cure and termination provisions of the definition of Good Reason in Section 8.3 hereof) upon thirty (30) days&#x2019; written notice from Executive to the Company and the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:-7.229%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Severance Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10.0pt;margin-top:9.1pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.037%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Accrued Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Upon Executive&#x2019;s employment termination, for any reason, the Company shall pay to Executive in a lump sum, within ten (10) business days following the termination date of his employment (or such earlier date as is required under applicable law), (i) all unpaid salary accrued prior to the termination date of his employment, (ii) accrued but unused vacation through the termination date of his employment if available in accordance with then-applicable Company policy for full-time, exempt employees, and (iii) any unreimbursed business expenses for which Executive is entitled to be reimbursed by the Company pursuant to the Company&#x2019;s then-existing reimbursement policy.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination by the Company without Cause or by Executive for Good Reason Not in</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Connection with a Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. If the Company terminates Executive&#x2019;s employment with the Company for a reason other than Cause, death or Disability, or Executive terminates Executive&#x2019;s employment with the Company for Good Reason at any time other than within the 12-month period following a Change in Control (as defined in the Plan), the Company shall:</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cash Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Pay to Executive an aggregate amount (paid in nine (9) monthly installments in accordance with the Company&#x2019;s regular payroll practices), following the effective date of a Release (as defined in Section 8.1 below) and commencing on the payroll date that next follows the 65th day after the termination date, equal to the sum of nine (9) times his monthly base salary (at the monthly base salary rate in effect for Executive immediately prior to the termination of his employment). On the 65th day following Executive&#x2019;s termination date, the Company will pay Executive in a lump sum the Severance that Executive would have received on or prior to such date under the standard payroll schedule but for the delay while waiting for the 65th day in compliance with Code Section 409A, with the balance of the Severance being paid as originally scheduled; and</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Provide Executive and his dependents with the same life, accident, health and dental insurance benefits, if any, that Executive was receiving immediately prior to the termination of employment until the earlier of: (i) the date which is twelve (12) months following the date of Executive&#x2019;s termination; or (ii) the date Executive commences subsequent employment (such period, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Pre-Change</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); provided, that if the Executive&#x2019;s continued participation is not possible under the terms of any one or more of those insurance plans or results in adverse taxes to the Company or Executive, and if Executive was participating in the Company&#x2019;s group health plan immediately prior to the date of termination and timely elects COBRA health continuation, then the Company shall pay to Executive a monthly payment in a gross amount equal to the COBRA premium for the earlier of twelve (12) months following Executive&#x2019;s termination or (B) until Executive becomes eligible for coverage under another employer&#x2019;s group coverage (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Benefits Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and Executive agrees to notify the Company promptly and in writing should that eligibility occur. Subject to Executive&#x2019;s timely presentment of receipts, the reimbursements will commence within sixty-five (65) days following Executive&#x2019;s termination and will be made on a monthly basis for the duration of the Benefits Continuation Period. If such payments would violate any applicable law, then the Company shall instead pay Executive taxable monthly payments of equal value on the same schedule, which amounts may be used for such purpose as Executive may determine; and</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10.0pt;margin-top:7.85pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Pay to Executive any unpaid Target Bonus that is earned and payable and approved by the Board, payable when bonuses are paid to similarly situated executives and no later than March 15 of the year following the performance year.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination by the Company without Cause or by Executive for Good Reason in</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Connection with a Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. If the Company terminates Executive&#x2019;s employment with the Company for a reason other than Cause, death or Disability, or Executive terminates Executive&#x2019;s employment with the Company for Good Reason during the 12-month period following a Change in Control, the Company shall, in lieu of the benefits set forth in Section 7.2 above:</font></p>
  <p style="margin-left:0.92%;text-indent:13.444%;font-size:10.0pt;margin-top:8.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cash Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Pay to the Executive an aggregate amount (paid in twelve (12) monthly installments in accordance with the Company&#x2019;s regular payroll practices), following the effective date of a Release (as defined in Section 8.1 below) and commencing on the payroll date that next follows the 65th day after the termination date, equal to the sum of twelve (12) times his monthly base salary (at the monthly base salary rate in effect for Executive immediately prior to the termination of his employment). On the 65th day following Executive&#x2019;s termination date, the Company will pay Executive in a lump sum the Severance that Executive would have received on or prior to such date under the standard payroll schedule but for the delay while waiting for the 65th day in compliance with Code Section 409A, with the balance of the Severance being paid as originally scheduled; and</font></p>
  <p style="margin-left:0.92%;text-indent:13.585%;font-size:10.0pt;margin-top:7.85pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.028%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Provide Executive and his dependents with the same life, accident, health and dental insurance benefits, if any, that Executive was receiving immediately prior to the termination of employment until the earlier of: (i) the date which is twelve (12) months following the date of Executive&#x2019;s termination; or (ii) the date Executive commences subsequent employment (such period, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Change in</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Control Pre-Change Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); provided, that if Executive&#x2019;s continued participation is not possible under the terms of any one or more of those insurance plans or results in adverse taxes to the Company or Executive, and if Executive was participating in the Company&#x2019;s group health plan immediately prior to the date of termination and timely elects COBRA health continuation, then the Company shall pay to Executive a monthly payment in a gross amount equal to the COBRA premium for the earlier of twelve</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(12) months following Executive&#x2019;s termination or (B) until Executive becomes eligible for coverage under another employer&#x2019;s group coverage (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Change in Control Benefits Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and Executive agrees to notify the Company promptly and in writing should that eligibility occur. Subject to Executive&#x2019;s timely presentment of receipts, the reimbursements will commence within sixty-five (65) days following Executive&#x2019;s termination and will be made on a monthly basis for the duration of the Change in Control Benefits Continuation Period. If such payments would violate any applicable law, then the Company shall</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">instead pay Executive taxable monthly payments of equal value on the same schedule, which amounts may be used for such purpose as Executive may determine; and</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Pay to Executive any unpaid Target Bonus that is earned and payable and approved by the Board, payable when bonuses are paid to similarly situated executives and no later than March 15 of the year following the performance year.</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Bonus Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Pay to Executive an amount equal to Executive&#x2019;s pro rata Target Bonus for the calendar year in which Executive&#x2019;s termination occurs, payable subject to standard federal and state payroll withholding requirements on the Company&#x2019;s first regularly scheduled payroll date following the effective date of a Release that next follows the 65th day after the termination date; and</font></p>
  <p style="margin-left:0.92%;text-indent:13.594%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.093%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Equity Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Any equity awards with respect to Company stock then held by Executive which vest based on continued service shall become fully vested and exercisable as of the date of such termination. Any equity awards that vest based upon the achievement of performance goals shall be subject to the terms of such awards.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.037%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Termination for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. In the event Executive&#x2019;s employment with the Company is terminated by the Company for Cause, or Executive terminates his employment with the Company for any reason other than Good Reason (including his death or Disability), Executive shall not be entitled to the severance benefits or other considerations described herein by virtue of this Agreement; provided that, if the Company does not waive the provisions of Section 3.2 in connection with such termination, the Company will pay Executive an amount equal to the sum of six (6) times his monthly base salary (at the monthly base salary rate in effect for Executive immediately prior to the termination of his employment), except to the extent such termination arises from Executive&#x2019;s breach of his fiduciary duty or theft of Company property (whether physical or electronic). Such amount shall be paid in monthly installments in accordance with the Company&#x2019;s regular payroll practices following the effective date of the termination.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:-7.229%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">8.	General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10.0pt;margin-top:8.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.028%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Notwithstanding any other provision of this Agreement to the contrary, benefits, including, but not limited to severance payments under Section 7 hereof, shall be payable under this paragraph only if Executive enters into a final and binding agreement in favor of the Company, its affiliates and their respective officers and directors in a form provided by the Company, substantially in the form attached hereto as Exhibit A (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), which has not been revoked within sixty-five (65) days of his termination of employment whereby Executive releases the Company and its subsidiaries (and those affiliated with the Company and its subsidiaries) from all claims that Executive may otherwise have against them, to the extent that the basis for such claims arose on or before the date the Release is signed by Executive; except that such Release shall not adversely affect Executive&#x2019;s rights to enforce the terms of this Agreement, and shall not adversely affect Executive&#x2019;s right to vested benefits, right to indemnification or right to reimbursement of expenses by the Company to which Executive would otherwise be entitled to under, without limitation, any charter document or Company insurance policy, by reason of services he rendered for the Company or any of its subsidiaries as an officer and/or an employee thereof.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Definition of Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. For purposes of this Agreement, &#x201c;Cause&#x201d; shall mean: (i) the conviction of Executive by a court of competent jurisdiction of, or the pleading of guilty or nolo contendere to, any felony or any crime involving moral turpitude; (ii) gross negligence, breach of fiduciary duty, or breach of any confidentiality, non-competition or developments agreement by Executive in favor of the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Company that (A) cannot be cured or (B) has not been cured or corrected by Executive within thirty (30) days prior written notice of such breach or failure; (iii) Executive shall have willfully and continually failed to substantially perform Executive&#x2019;s duties with the Company after a written demand for substantial performance is delivered by the Company, which demand specifically identifies the manner in which the Company believes that Executive has not substantially performed Executive&#x2019;s duties pursuant to the disciplinary procedures of the Company, and such failure of substantial performance shall have continued for a period of thirty (30) days after such written demand; (iv) Executive has been chronically absent from work (excluding vacations, illnesses or leaves of absences); (v) the commission by Executive of an act of fraud, embezzlement or misappropriation against the Company; (vi) Executive shall have refused, after explicit notice, to obey any lawful resolution or direction by the Board which is consistent with his duties as an officer of the Company or FTG, as applicable; or (vii) a material breach or failure to follow any written policy or rule adopted by the Company or any of its subsidiaries that (A) cannot be cured or (B) has not been cured or corrected by Executive within thirty (30) days prior written notice of such breach or failure.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:7.85pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Definition of Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. For purposes of this Agreement, &#x201c;Good Reason&#x201d; shall mean one or more of the following events, as the case may be: (i) a material diminution in Executive&#x2019;s authority, duties or responsibilities; (ii) a material diminution in Executive's base salary (other than a reduction of not more than 10% that is applicable to similarly situated executives of the Company); (iii) a material change in the geographic location of Executive&#x2019;s place of business (provided, however, that travel for business purposes consistent with past practices shall not be considered a change in the place of business for the purpose of this clause; and provided, further, that a relocation of less than 50 miles from Executive&#x2019;s then present location will not be considered a material change in geographic location); (iv) a material breach by the Company of this Agreement or any agreement under which Executive provides services to the Company; and/or; provided, that the occurrence of any of the events listed in clauses (i) though (iv) shall not constitute Good Reason (x) unless Executive shall have given written notice of the event to the Company within thirty (30) days after it first existed and the Company shall have failed to remedy the condition within thirty (30) days after the written notice, in which case Executive&#x2019;s employment shall terminate thirty-one (31) days after written notice of the event to the Company, or (y) if the event follows an event or action by Executive that would constitute Cause (as defined herein) for termination.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10.0pt;margin-top:7.85pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.028%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Definition of Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. For purposes of this Agreement, &#x201c;Disability&#x201d; means an independent medical doctor (selected by the Company&#x2019;s health or disability insurer) has certified that Executive has, for six (6) months consecutive or nonconsecutive in any 12-month period been disabled in a manner that materially interferes with his ability to perform his responsibilities as an employee of Company. Any refusal by Executive to submit to a medical examination for the purpose of certifying disability shall be deemed to constitute conclusive evidence of the Executive&#x2019;s disability. Notwithstanding the foregoing, nothing herein shall abrogate Employee&#x2019;s rights under state or federal law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Certain Tax Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:13.444%;font-size:10.0pt;margin-top:8.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	This Agreement is intended to comply with section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and its corresponding regulations, or an exemption, and payments may only be made under this Agreement upon an event and in a manner permitted by section 409A, to the extent applicable. Severance benefits under the Agreement are intended to be exempt from section 409A of the Code under the &#x201c;short-term deferral&#x201d; exception, to the maximum extent applicable, and then under the &#x201c;separation pay&#x201d; exception, to the maximum extent applicable. For purposes of section 409A of the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Code, all payments to be made upon a termination of employment under this Agreement may only be made upon a &#x201c;separation from service&#x201d; within the meaning of such term under section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. In no event shall the Executive, directly or indirectly, designate the calendar year of payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of Executive&#x2019;s execution of the Release, directly or indirectly, result in Executive designating the calendar year of payment, and if a payment that is deferred compensation subject to section 409A of the Code and subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive&#x2019;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p>
  <p style="margin-left:0.92%;text-indent:13.585%;font-size:10.0pt;margin-top:7.8pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.028%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	Notwithstanding any provision in this Agreement to the contrary, if at the time of Executive&#x2019;s separation from service with the Company, the Company (or a company that is aggregated with the Company for this purpose under section 409A of the Code) has securities which are publicly-traded on an established securities market and Executive is a &#x201c;specified employee&#x201d; (as defined in section 409A of the Code) and it is necessary to postpone the commencement of any severance payments otherwise payable pursuant to this Agreement as a result of such separation from service to prevent any accelerated or additional tax under section 409A of the Code, then Company will postpone the commencement of the payment of any such payments hereunder (without any reduction in such payments ultimately paid or provided to Executive) that are not otherwise exempt from section 409A of the Code, until the first payroll date that occurs after the date that is six (6) months following Executive&#x2019;s separation from service with Company. If any payments are postponed due to such requirements, such postponed amounts will be paid in a lump sum to Executive on the first payroll date that occurs after the date that is six (6) months following Executive&#x2019;s separation from service with Company. If Executive dies during the postponement period prior to the payment of the postponed amount, the amounts withheld on account of section 409A of the Code shall be paid to the personal representative of Executive&#x2019;s estate within sixty (60) days after the date of Executive&#x2019;s death.</font></p>
  <p style="margin-left:0.92%;text-indent:13.591%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	The Company makes no representation or warranty and shall have no liability to Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Excise Tax Adjustment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:13.444%;font-size:10.0pt;margin-top:8.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	If any payment or benefit Executive will or may receive from the Company or otherwise (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">280G Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this Section, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), then any such 280G Payment provided pursuant to this Agreement (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) shall be equal to the Reduced Amount. The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Reduced Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state, foreign and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#x2019;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Pro Rata Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="margin-left:0.92%;text-indent:13.587%;font-size:10.0pt;margin-top:7.85pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	Notwithstanding any provision of this Section 8.6 to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	The Company shall appoint a nationally-recognized accounting, consulting or law firm to make the determinations required by this Section 8.6. The Company shall bear all expenses with respect to the determinations by such firm required to be made hereunder.</font></p>
  <p style="margin-left:0.92%;text-indent:13.595%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	If Executive receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 8.6.(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees (after any appeals related to the IRS&#x2019;s determination have been exhausted) to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 8.6.(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 8.6.(a), Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Binding Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Except as otherwise provided herein, this Agreement shall be binding upon the Company and inure to the benefit of the Company and any successor or assign (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) of the Company. The Company shall require any such successor to assume this Agreement expressly and to be bound by the provisions of this Agreement as if such successor or assign were the Company and for purposes of this Agreement, any such successor or assign of the Company shall be deemed to be the Company for all purposes.</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.093%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.8	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Effect on Other Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Nothing herein shall in any way limit Executive&#x2019;s obligations under any other non-competition, confidentiality, option or similar agreement between Company or any of its affiliates and Executive currently in effect or which may be entered into in the future.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.9	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Withholding; No Gross-Up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. All payments required to be made by the Company hereunder to Executive shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as the Company may reasonably determine it must withhold pursuant to any applicable law or regulation. For the avoidance of doubt, the Company shall have no obligation under this Agreement to make</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">any tax gross-up payments in respect of any tax imposed on Executive and all taxes, penalty or otherwise, imposed on Executive shall be Executive&#x2019;s sole responsibility.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.10	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Advice of Counsel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. EXECUTIVE ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, EXECUTIVE HAS THE RIGHT AND HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.11	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Except for claims arising from a breach of Section 3.2, all claims or disputes arising out of or relating to this Agreement shall be resolved by binding arbitration. Such agreement includes all claims, whether based on tort, contract, or statute, including, but not limited to, any claims of discrimination, harassment, or retaliation, whether based on Title VII of the Civil Rights Act of 1964, as amended, or any other local, state or Federal law (including, but not limited to, the Massachusetts Fair Employment Practices Law &#x2013; Mass. Gen. Laws Chapter 151B) and other state and federal laws., claims for wages or compensation, claims based in equity, or otherwise. The claim or dispute will be arbitrated in accordance with the rules of the American Arbitration Association (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">AAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) under its existing Arbitration Rules. These rules may be found at https://</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">www.adr.org/Rules.</font><font style="white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company shall pay the arbitration administrative costs and the arbitrator&#x2019;s fees subject to applicable law and the AAA Rules. Each party in the arbitration shall bear his/its own attorneys&#x2019; fees and legal costs. The Parties agree to file any demand for arbitration within the time limit established by the applicable statute of limitations for the asserted claims. Failure to demand arbitration within the prescribed time period shall result in waiver of said claims. The Parties agree that the arbitration will be in Boston, Massachusetts. EXECUTIVE UNDERSTANDS AND AGREES THAT HE IS WAIVING HIS RIGHTS TO BRING SUCH CLAIMS OR DISPUTES TO COURT, INCLUDING THE RIGHT TO A JURY TRIAL. Notwithstanding the foregoing, this Agreement expressly does not prohibit either party from seeking, exclusively in a court of competent jurisdiction located within Massachusetts, an application for a provisional remedy or other equitable or injunctive relief to prevent actual or threatened irreparable harm, or from pursuing therein any claim that cannot by law be subject to mandatory arbitration. In the event of any procedural matter not covered by the aforesaid AAA rules, the procedural law of the Commonwealth of Massachusetts shall govern.</font></p>
  <p style="margin-left:0.92%;text-indent:6.792%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.12%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.12	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to conflicts of laws principles.</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.13	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Agreement, along with equity agreements referenced in Section</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:1.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.3 above or other agreements referenced in Section 2.5 above, constitutes the entire Agreement between Executive and the Company concerning the subject matter hereof and supersedes any prior negotiations, understandings, or agreements concerning the subject matter hereof, whether oral or written, and may be amended or rescinded only upon the written consent of Company and the Executive.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.14	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Modification &amp; Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by Executive and an authorized representative of the Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:6.793%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.13%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.15	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The invalidity or unenforceability of any provision of this Agreement shall not affect the other provisions of this Agreement and this Agreement shall be construed and reformed to the fullest extent possible.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.16	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Captions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.17	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Executive may not assign any of his rights or obligations under this Agreement; the rights and obligations of the Company under this Agreement shall inure to the benefit of, and shall be binding upon, the successors and assigns of the Company.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.18	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement. For the avoidance of doubt, the covenants in Section 3 and Section 4 of this Agreement shall survive any termination or expiration of this Agreement and termination of Executive&#x2019;s employment for any reason.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.19	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and both of which taken together shall constitute one and the same instrument. Facsimile or scanned and e-mailed signatures shall be deemed valid and binding for such purposes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:25.68%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:25.806%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Remainder of Page Intentionally Left Blank</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:6.78%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.944%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above, to be effective as of the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:49.44%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.983%;"></td>
    <td style="width:58.724%;"></td>
    <td style="width:33.292%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By :</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">/s/ Mark Smith</font></p></td>
   </tr>
  </table>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:6.3pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mark Smith</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title:	CEO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:50.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">EXECUTIVE:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">							</font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.642%;"></td>
    <td style="width:34.358%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By :</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">/s/ Marc B. Blaustein</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:47.587%;text-indent:10.964%;font-size:10.0pt;margin-top:4.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name: Marc B. Blaustein</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:23.347%;text-indent:0.0%;font-size:10.0pt;margin-top:3.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:23.481%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">EXHIBIT A</font></p>
  <p style="margin-left:23.347%;text-indent:0.0%;font-size:10.0pt;margin-top:8.75pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:23.481%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Form of Release</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10.0pt;margin-top:9.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.037%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">I understand and agree completely to the separation payment terms set forth in the Amended and Restated Executive Employment Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) dated</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, by and between Finch Therapeutics Group, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and me. I understand that I am not entitled to any separation payments if I do not sign this Release and return it to the Company on or before </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[DATE &#x2013; to be inserted by the Company at the time of termination] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">pursuant to the terms set forth herein or if I revoke this Release as set forth in Section 3 below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">General Release and Knowing Waiver of Employment-Related Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. For and in consideration of the separation payments and any other benefits I am eligible to receive from the Company, I, on my own behalf and on behalf of my successors and assigns (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Releasor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), hereby release and forever discharge the Company, its affiliates, and their respective stockholders, members, predecessors, successors, officers, directors, agents, representatives, employees, consultants and advisors (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Releasee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), from any and all claims, counterclaims, demands, debts, actions, causes of action, suits, expenses, costs, attorneys&#x2019; fees, damages, indemnities, obligations and/or liabilities of any nature whatsoever (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), whether known or unknown, which Releasor ever had, now has or hereafter can, shall or may have against Releasee, for, upon or by reason of any matter, cause or thing whatsoever from the beginning of the time to the day of the date of this Release, including, but not limited to, the following:</font></p>
  <p style="margin-left:7.587%;text-indent:-7.874%;padding-left:6.667%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	all such Claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company, including but not limited to providing services to the Company, or the termination of that employment and provision of services;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.775%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	all such Claims and demands related to salary, bonuses, commissions, stock, stock options, units, profits interests or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, separation pay and/or any other form of compensation;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.775%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	any Claims arising under any federal, state or local law, statute or ordinance, including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Americans With Disabilities Act, the Civil Rights Act of 1991, the Fair Labor Standards Act, the Equal Pay Act, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act of 1993, and the Consolidated Omnibus Budget Reconciliation Act of 1985, the anti- retaliation provisions of any federal or state statute, including state workers&#x2019; compensation statutes, and any other applicable state or local statutes, including the Massachusetts Fair Employment Practices Act (M.G.L.c. 151B), the Massachusetts Equal Rights Act, the Massachusetts Equal Pay Act, the Massachusetts Privacy Statute, the Massachusetts Sick Leave Law, the Massachusetts Civil Rights Act, all as amended, the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150), the Massachusetts Overtime regulations (M.G.L. c. 151 sections 1A and 1B), the Massachusetts Meal Break regulations (M.G.L. c. 149 sections 100 and 101) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[additional state statutes to be inserted at the time of termination as applicable]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:7.587%;text-indent:-7.88%;padding-left:6.667%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.139%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	any Claims for breach of contract, express or implied, including any claim for breach of any implied covenant of good faith and fair dealing; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.88%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.139%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	any Claims of constructive discharge, discrimination, harassment, retaliation, fraud, defamation, intentional tort, emotional distress and negligence; and</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, nothing herein releases any claim Releasor has or may have against Releasee regarding the performance or non-performance of obligations arising under the Employment Agreement, and nothing in this Release shall prevent me from enforcing my rights, if any (i) to my non-forfeitable accrued benefits (within the meaning of Sections 203 and 204 of ERISA) under any tax-qualified retirement plan maintained by the Company, (ii) to receive continuation coverage pursuant to COBRA, (iii) to indemnification conferred upon me as an officer of the Company pursuant to the Company&#x2019;s governing documents, under any applicable insurance policies or in accordance with applicable law or (iv) that cannot be waived under applicable law. Further, nothing in this Release affects my rights to provide information to, participate in an investigation by or file an administrative charge or complaint with any Governmental Authorities (as defined below), including, but not limited to, the Equal Employment Opportunity Commission or similar administrative agency. However, I agree not to accept any monetary relief or recovery from any charge or complaint filed against any Releasee with any such administrative agency except where authorized by applicable law.</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:7.95pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.139%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Also, Releasor does not release any Claims against Releasee that may arise after this Release has become effective.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:8.2pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Representation by Counsel and Review Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. I have been advised to consult independent legal counsel before signing this Release, and I hereby represent that I have executed this Release after having the opportunity to consult independent counsel and after considering the terms of this Release for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[if over 40][twenty- one (21) [applies if no reduction in force]/forty-five (45) [applies if there is a reduction in force]] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days (although I may choose to voluntarily execute this Release earlier). I further represent and warrant that I have read this Release carefully, that I have discussed it or have had reasonable opportunity to discuss it with my counsel, that I fully understand its terms, and that I am signing it voluntarily and of my own free will.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 3.         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Right to Revoke Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Release shall not become effective until the eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) day following the date on which I have executed it, provided that I have not revoked it, and I may at any time prior to that effective date revoke this Release by delivering written notice of revocation to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[Name and contact information to be inserted at the time of termination]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.85pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Consideration for Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. I acknowledge that the consideration for this Release is consideration to which I would not otherwise be entitled and is in lieu of any rights or claims that I may have with respect to any other remuneration from the Company.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:8.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 5.         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Representation Concerning Filing of Legal Actions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. I represent that, as of the date of this Release, I have not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against Company or any of the other Releasees in any court or with any Governmental Authority.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Continuing Obligations Concerning Confidential Information and Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. I acknowledge and agree that I remain subject to the restrictive covenants contained in Section 3 of the Employment Agreement and the covenants related to Confidentiality &amp; Proprietary Information contained in Section 4 of the Employment Agreement, each of which survives the termination of my</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">employment. I further acknowledge that I am obligated to return to the Company by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[DATE]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, all Company documents, originals and copies, whether in hard or electronic form, and all Company property, including without limitation keys, computers, computer disks, pagers, phones and credit cards.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Nondisparagement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Subject to the provisions of Section 8, I will not make any statements, whether verbally or in writing (including in electronic communications) that are professionally or personally disparaging of, or adverse to the interests of, the Company or its officers, directors, managers or employees. This includes, but is not limited to, any statements that disparage the products, services, finances, financial condition, capability or any other aspect of the business of the Company. I further agree not to engage in any conduct which is intended to harm, professionally or personally, the reputation of the Company or its officers, directors, managers or employees. For its part, the Company shall direct those of its executives that know of this Release not to make any statements, whether verbally or in writing (including in electronic communications) that are professionally or personally disparaging of you, or adverse to your interests.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 8.         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disclosure Exceptions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Nothing in this Release shall prohibit the Releasor from lawfully</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:1.05pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Governmental Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to the Releasor individually (and not directed to the Company and/or its subsidiaries) from any such Governmental Authorities; (C) testifying, participating or otherwise assisting in an action or proceeding by any such Governmental Authorities relating to a possible violation of law; or (D) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, the Releasor shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to the Releasor&#x2019;s attorney in relation to a lawsuit for retaliation against the Releasor for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement require the Releasor to obtain prior authorization from the Company before engaging in any conduct described in this Section 8, or to notify the Company that he has engaged in any such conduct.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.8pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 9.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Tax Provision</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. All payments and benefits provided under the Employment Agreement are intended to be exempt from, or to comply with, the requirements of section 409A of the Code and this Release shall be interpreted and administered in accordance with these intentions. The severance benefits and rights to COBRA reimbursement under the Employment Agreement are intended to be exempt from section 409A of the Code under the &#x201c;short-term deferral&#x201d; exception of Treas. Reg. Section 1.409A-1(b)(4), to the maximum extent applicable, and then under the &#x201c;separation pay&#x201d; exception of Treas. Reg. Section 1.409A-1(b)(9)(iii), to the maximum extent applicable. All payments that are subject to Section 409A that are to be made upon a termination of the Releasee&#x2019;s employment may only be made upon the Releasee&#x2019;s &#x201c;separation from service,&#x201d; as defined in Treas. Reg. Section 1.409A-1(h), from the Company. For purposes of section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments and each such installment shall be treated as a separate payment. With respect to any payments that are subject to section 409A of the Code, in no event shall the Releasee, directly or indirectly, designate the calendar year of a payment. Any reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.7pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Treas. Reg. Section 1.409A- 3(i)(1)(iv). Notwithstanding the foregoing, the Releasee acknowledges that he has been advised to seek the advice of a tax advisor with respect to the tax consequences of all payments pursuant to the Employment Agreement, including any adverse tax consequence under section 409A and applicable State tax law, and neither the Company nor any of its members, officers, employees, agents or affiliates shall be responsible for any such adverse tax consequences or guarantees any particular tax consequences to the Releasee with respect to payments and benefits under the Employment Agreement.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.9pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 10.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Amendment of Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Release may not be amended or modified except by a writing signed on behalf of the Company and by me.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.95pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.093%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Release shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to principles of conflicts of laws thereunder.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:8.1pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.12%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 12.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Neutral Interpretation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Release shall be interpreted in a neutral manner, and not more strongly for or against any party based upon the source of the draftsmanship of the Release.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:8.25pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 13.    </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The various headings in this Release are inserted for convenience only and are not part of the Release.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:8.2pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Section 14. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">No Admission of Liability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Releasee agrees that this Release, and performance of the acts required by it, does not constitute an admission of liability, culpability, negligence or wrongdoing on the part of anyone, and will not be construed for any purpose as an admission of liability, culpability, negligence or wrongdoing by any party and/or by any party&#x2019;s current, former or future parents, subsidiaries, related entities, predecessors, successors, officers, directors, stockholders, agents, employees and assigns.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:9.85pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dated: This</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">           </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">day of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, 20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">WITNESSES:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">18</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>7
<FILENAME>fnch-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html>
 <head>
  <title>EX-10.20</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:8.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.741%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.20</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.741%;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:11.467%;text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:12.093%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:4.55pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This AMENDED AND RESTATED  EXECUTIVE EMPLOYMENT AGREEMENT, dated as of</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 12, 2021 (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">FTG</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, together with all subsidiaries and affiliates hereinafter referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and Joseph Vittiglio (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">W</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">HEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company desires to continue to employ the Executive as its General Counsel;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.817%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.481%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">W</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">HEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company and the Executive previously entered into an employment agreement dated as of December 7, 2020 pursuant to which the Executive served as General Counsel and Senior Vice President of Legal Affairs of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prior Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.815%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">W</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">HEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Executive desires to continue to be employed by the Company as General Counsel and to perform his duties to the Company on the terms and conditions hereinafter set forth;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.822%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">W</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">HEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Parties wish to amend and restate the terms of the Prior Agreement as set forth in this Agreement; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.819%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.509%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WHEREAS, the Company and the Executive wish to enter into this Agreement to set forth the terms and conditions of the Executive&#x2019;s continued employment with the Company effective and conditional on the pricing date of the initial public offering of the common stock of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Company and the Executive agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.794%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Term of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company agrees to employ Executive on an at-will basis, and Executive agrees to accept such employment and serve the Company, in accordance with the terms and conditions set forth herein. The Executive&#x2019;s term of employment under this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall be for the period commencing on the date of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Start Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and ending when the Executive&#x2019;s employment is terminated pursuant to</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> Section 6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Position, Duties, and Responsibilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the Term, Executive shall be employed and serve as General Counsel and Senior Vice President of Legal Affairs of the Company (together with such other position or positions consistent with Executive&#x2019;s title as the Company shall specify from time to time) and shall have such duties and responsibilities commensurate therewith, and such other duties as may be assigned and/or prescribed from time to time by the Chief Executive Officer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">CEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and/or the Board of Directors of FTG (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The Executive shall report to the CEO.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Performance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Executive shall devote his full business time, attention, skill, and best efforts to the performance of his duties under this Agreement and shall not engage in any other paid work during the Term that (a) conflicts with the interests of the Company, (b) interferes with the proper and efficient performance of Executive&#x2019;s duties for the Company, or (c) interferes with Executive&#x2019;s exercise of judgment in the Company&#x2019;s best interests. Executive may not serve on any for-profit board of directors or board of any educational, social, religious and civic organizations without the prior written approval of the Board. The Executive reaffirms that he has no contractual commitments or other legal obligations that would prohibit him from fully performing his duties for the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.82%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.528%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As full compensation for all services to be rendered by the Executive to the Company in all capacities, the Executive shall receive the following compensation and benefits:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Executive shall be entitled to receive an annual base salary of $389,000 USD (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The Base Salary, which will be reviewed annually, will be paid periodically in accordance with the Company&#x2019;s normal payroll practices and be subject to applicable withholdings.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Executive will be eligible to receive an annual bonus of forty percent (40%) of Executive&#x2019;s Base Salary, less applicable withholdings (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Target Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The amount of any bonus shall be determined by the Board or the Compensation Committee of the Board in their sole discretion. Except as provided in Section 7, Executive must be employed by Company at the time of any such bonus payment in order to be eligible for any such payment. Except as set forth in Section 7.3 below, the Target Bonus is not earned until paid and no pro-rated amount will be paid if Executive&#x2019;s employment terminates for any reason prior to the payment date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Equity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Any existing equity awards will remain subject to the terms thereof, except as set forth in Section 7.3(e). In addition, subject to approval by the Board, Executive shall be eligible for the following additional equity grant:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:9.562%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	Subject to approval by the Board, Executive shall be granted on the Effective Date an option to purchase 60,578 shares of Common Stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) of FTG. The Option is intended to qualify as an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) to the extent permissible under applicable laws. Except as otherwise provided herein, subject to Executive&#x2019;s continuous service to the Company (as defined in the Plan (as defined below)) through each applicable vesting date, the Option will vest and become exercisable as follows:</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The shares covered by the Option shall be granted with an exercise price equal to the price per share of common stock at which the Company&#x2019;s shares are first sold to the public in the proposed initial public offering (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">IPO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), as specified in the final prospectus for the IPO, in accordance with the terms of the Finch Therapeutics Group, Inc.</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.194%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and form of agreement issued thereunder. The Option will vest and become exercisable over five (5) years, with 20% of the shares covered by the Option vesting and becoming exercisable on the first year anniversary of the Effective Date, and the remaining shares covered by the Option vesting and becoming exercisable in forty-eight (48) equal monthly installments thereafter, subject to</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Executive&#x2019;s continuous service as of each such date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:9.562%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Subject to approval by the Board, Executive shall be granted an option to purchase 34,616 shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Additional Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), with all of the same terms (including grant date and exercise price) as the Option; provided, however that the Additional Option will vest 25% on the one-year anniversary of the date of grant, and thereafter over the ensuing 3 years in a series of thirty-six (36) successive equal monthly installments, subject to Executive&#x2019;s continuous service as of each such date. The Additional Option shall be an incentive stock option under Section 422 of the Code to the maximum extent permissible</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Executive is entitled, during the Term, to participate in all employee benefits plans customarily granted to other executives of the Company, including medical, dental and disability insurance, life insurance and a 401(k) plan, subject to plan terms and applicable Company policies. Further, Executive shall be entitled to paid vacation in accordance with then applicable Company policy for full-time, exempt employees, or any subsequent policy approved by the Board. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company agrees to indemnify Executive to the maximum extent allowable under the terms and conditions of its certificate of incorporation, bylaws under applicable law, and under the indemnification agreement signed herewith. Further, Executive will be covered by the Company&#x2019;s directors&#x2019; and officers&#x2019; liability insurance coverage as in effect from time to time and that certain Indemnification Agreement by and between the Company and the Executive dated the date hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictive Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acknowledgement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Executive understands that the nature of the Executive&#x2019;s position gives him access to and knowledge of confidential, proprietary and/or trade secret, and customer information and places him in a position of trust and confidence with the Company. The Executive understands and acknowledges that the intellectual services he provides to the Company are unique, special, or extraordinary. The Executive further understands and acknowledges that the Company&#x2019;s ability to reserve these for the exclusive knowledge and use of the Company is of great competitive importance and commercial value to the Company, and that improper use or disclosure by the Executive is likely to result in unfair or unlawful competitive activity. The Executive represents and warrants that he is not in breach of any agreement requiring him to preserve the confidentiality of any information, client lists, trade secrets or other confidential information or any agreement not to compete or interfere with any prior employer, and that neither the execution of this Agreement nor the performance by the Executive of his obligations hereunder will conflict with, result in a breach of, or constitute a default under, any agreement to which he is a party or to which he may be subject. The Executive further represents that he has not taken and will not take any confidential or proprietary information from any prior employer or other person and will not use or disclose any such information in performing his obligations hereunder but instead will rely on his generalized knowledge and skill in performing his services hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Competition. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the Company&#x2019;s legitimate business interest as described herein, and the good and valuable increased consideration offered to the Executive in this Agreement (including the mutually agreed-to consideration in accordance with Sections 7.2, 7.3 and 7.4), during the period of the Executive&#x2019;s employment with Company and for a period of twelve (12) months from termination of Executive&#x2019;s employment for any reason (other than as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Compete Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), without the prior written consent of the Company, the Executive shall not, in any capacity (whether as an employee, director, officer, partner, interest holder, investor, consultant, advisor or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly- held company), directly or indirectly engage in any activity on behalf of any other individual or enterprise (other than the Company) that is pursuing, or is planning to pursue, activities related to microbiome therapies and diagnostics (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Competitive Activity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) anywhere in the United States, Canada, Europe or any other country in which the Company is either doing business or actively planning to do business as of the date of the Executive&#x2019;s termination of employment or two years prior. For the avoidance of doubt, engagement in any respect with Seres Therapeutics, Rebiotix, Symbiotic Health, Assembly Biosciences, Monarch Laboratories, Vedanta, ViThera, Second Genome, Synthetic Biologics, Intrexon/Actogenix, Evelo Thereapeutics, Enterome, Axial Biotherapeutics, Kallyope and/or Kaleido (so long as any of those companies pursue activities related to microbiome therapies), constitutes Competitive Activity. Company may waive the provisions of this Section 3.2 by providing written notice to Executive upon termination of Executive&#x2019;s employment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.831%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Solicitation of Employees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the Non-Compete Period, the Executive will not, and will not attempt to, directly or indirectly hire, interview, solicit, recruit, induce, procure, encourage, work with, retain or engage for employment, consulting services or otherwise any present or former employee of the Company unless such person shall have voluntarily ceased to be employed by the Company or any subsidiary or affiliate for a period of at least six (6) months.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Disparagement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to Section 5, below, the Executive agrees that he shall not at any time, during or after his employment with Company, directly or indirectly, (a) make any public comments about (including, without limitation, by way of news interviews or the expression of personal views, opinions or judgments to the media or any other entity or person outside the Company) the Company (other than factual information or other publicly available information about the Company) without prior consultation with the Board, or any disparaging comments about any constituent entity of the Company or any of their respective officers, directors, members, partners, investors, consultants, advisors or other employees (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Company Group</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) or (b) disparage, criticize, ridicule or make any negative comments about the Company Group (or any constituent thereof) to any person or entity within the Company Group or any other individual or entity with whom the Company Group has or may have a business or personal relationship, including any current, former or prospective vendor, vendee, investor or employee. This Section 3.4 does not, in any way, restrict or impede the Executive from exercising protected rights to the extent that such rights cannot be waived by</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation or order. The Executive shall promptly provide written notice of any such order to the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.831%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Injunctive Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Executive recognizes that irreparable injury will result to the Company in the event of any breach of any of the terms or provisions of this Section 3. Therefore, the Executive agrees that in the event of such a breach, FTG and other members of the Company will be entitled to seek, in addition to other remedies and damages available, an injunction to restrain any such breach and all persons acting for and/or in concert with the Executive. The restricted periods described in Section 3 will not expire, and will be tolled, during any period in which the Executive is in violation of Section 3.2 and/or Section 3.3, as applicable, and the restriction will automatically be extended by the time period that the Executive is in violation of such restriction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Confidential &amp; Proprietary Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Executive understands that all confidential and/or proprietary information concerning the Company, whether written or oral, which is or has been communicated to him by any person working for or on behalf of the Company or an entity affiliated with the Company, and all confidential and/or proprietary information which he generates as a result of services performed for the Company, including but not limited to trade secrets, regulatory strategy, intellectual property strategy, research and clinical strategies, technologies, procedures, models, testing systems, research, assays, compounds, molecules, organisms, gene sequences, cell lines, complement inhibitors and other re-agents (including the composition thereof), formulas, methods, processes, test and experimental data and results, specifications, invention disclosures, patent claims, laboratory notebooks, schematics and drawings (collectively referred to as &#x201c;Confidential Information&#x201d;), is proprietary and confidential to the Company. Subject to Section 5, the Executive agrees that he shall not at any time (whether during or after the term of his employment with Company or until such time as such Confidential Information has become public knowledge), without the prior written consent of Company, directly or indirectly, use or disclose any Confidential Information except as is necessary to fulfill his obligations hereunder or as is required to be disclosed by law, court order, or similar compulsion (provided that he shall promptly give Company written notice of a court order or similar compulsion that would require the disclosure of Confidential Information in order to permit Company to seek an appropriate protective order). Executive&#x2019;s obligations with respect to Confidential Information will cease when the Confidential Information: (i) becomes part of the public domain through no wrongful act of Executive, or (ii) is approved for release by prior written authorization of the Company. The Executive agrees to destroy or return (at Company&#x2019;s request) any and all of Confidential Information to Company upon any termination of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property; Works Made for Hire. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company shall own all right, title and interest (including without limitation patent rights and copyrights) to all tangible and intangible property, products, developments, discoveries and inventions (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Inventions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) conceived, created or produced directly or indirectly by or through the Executive during the term of Executive&#x2019;s employment with Company which relate to the actual or anticipated business, research and development of the Company, including, but not limited to, all documents, reports, and electronic or written materials, and all computer software and biological materials, and all related patent, know-how and other intellectual property rights, including, without limitation, all technical information, records, data, reports, tests or trial results and other results, and tangible manifestations and embodiments of work (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Work</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and the Executive shall provide Company with the originals and/or all copies of any such Inventions upon request of Company. The Executive hereby assigns to Company all right, title and interest in any Invention or discovery, whether in finished or incomplete form, made during the term of his employment with Company, and in any patent application, related documents and any patent relating to such invention or discovery. To the extent that any copyrighted work produced by Company hereunder is not deemed a &#x201c;work made for hire&#x201d; for purposes of the copyright laws of the United States, the Executive hereby assigns to Company all right, title and interest in the copyright of such work, including without limitation the right to reproduce, distribute, sublicense, perform and display the work and to create and use derivative works therefrom in any medium throughout the world. The term &#x201c;derivative works&#x201d; as used in this Agreement has the same meaning as used in the Copyright Act of the United States. The Executive shall complete and execute such assignments, certificates or other instruments as Company may from time to time deem necessary or desirable</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to evidence, establish, maintain, perfect, protect, enforce or defend its or any of its affiliate&#x2019;s right, title and interest in or to any of the foregoing. The Executive shall retain no rights in or to any work product produced hereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Exceptions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nothing in this Agreement shall prohibit or restrict Executive from lawfully (A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governmental Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to Executive individually (and not directed to the Company and/or its subsidiaries) from any such Governmental Authorities; (C) testifying, participating or otherwise assisting in an action or proceeding by any such Governmental Authorities relating to a possible violation of law; or (D) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to Executive&#x2019;s attorney in relation to a lawsuit for retaliation against Executive for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement require Executive to obtain prior authorization from the Company before engaging in any conduct described in this Paragraph, or to notify the Company that he has engaged in any such conduct.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.816%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Executive is an employee-at-will such that the Term and the Executive&#x2019;s employment hereunder may be terminated by either Company or the Executive at any time and for any reason; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless otherwise provided herein, either party shall be required to give the other party at least thirty (30) calendar days advance written notice of any termination of the Executive&#x2019;s employment; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Company may cease accepting services from the Executive or otherwise allow the Executive&#x2019;s access to Company facilities, computer systems, or personnel during the thirty days&#x2019; notice period. Upon termination of the Executive&#x2019;s employment during the Term, the Executive shall be entitled to the compensation and benefits further described in Section 7 below and shall have no further rights to any compensation or any other benefits from the Company or any of its affiliates. Should Company elect to forego the aforementioned notice provision, it shall remit to the Executive payment in lieu of notice equal to the salary he would have received during the notice period.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.729%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination upon Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Term shall terminate as of the date of the Executive&#x2019;s death.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.835%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination upon Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Executive suffers from a Disability during the Term, Company may terminate the Term by written notice to the Executive, in which event the Term shall terminate ten (10) days after the date upon which Company has given written notice to the Executive of its determination to terminate the Executive&#x2019;s employment under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.834%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.528%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination by Company for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Company may immediately terminate the Executive for Cause (as defined in Section 8.2 below).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination by Company without Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Company may terminate the Term at any time, without Cause.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.832%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination by the Executive without Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Executive may terminate the Term at any time, without Good Reason (as defined in Section 8.3 hereof).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.833%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.509%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination by the Executive for Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Executive may terminate the Term for Good Reason (such termination to comply with the notice, cure and termination provisions of the definition of Good Reason in Section 8.3 hereof) upon thirty (30) days&#x2019; written notice from the Executive to Company and the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Severance Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.824%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.38%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accrued Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon the Executive&#x2019;s employment termination, for any reason, Company shall pay to the Executive in a lump sum, within ten (10) business days following the termination date of his/her employment (or such earlier date as is required under applicable law), (i) all unpaid salary accrued prior to the termination date of his/her employment, (ii) accrued but unused vacation through the termination date of his/her employment if available in accordance with then applicable Company policy for full-time, exempt employees, and (iii) any unreimbursed business expenses for which the Executive is entitled to be reimbursed by Company pursuant Company&#x2019;s then-existing reimbursement policy.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.822%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.361%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination by the Company without Cause or by the Executive for Good Reason Not in Connection with a Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Company terminates the Executive&#x2019;s employment with Company for a reason other than Cause, death or Disability, or the Executive terminates the Executive&#x2019;s employment with Company for Good Reason at any time other than within the 12-month period following a Change in Control (as defined in the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), the Company shall:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.553%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.38%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pay to the Executive an aggregate amount (paid in nine (9) monthly installments in accordance with Company&#x2019;s regular payroll practices), following the effective date of a Release (as defined in Section 8.1 below) and commencing on the payroll date that next follows the 65</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day after the termination date, equal to the sum of nine (9) times his/her monthly base salary (at the monthly base salary rate in effect for the Executive immediately prior to the termination of his/her employment). On the 65th day following Executive&#x2019;s termination date, the Company will pay Executive in a lump sum the Severance that Executive would have received on or prior to such date under the standard payroll schedule but for the delay while waiting for the 65th day in compliance with Code Section 409A, with the balance of the Severance being paid as originally scheduled; and</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.508%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.917%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Provide the Executive and his/her dependents with the same life, accident, health and dental insurance benefits, if any, that the Executive was receiving immediately prior to the termination of employment until the earlier of: (i) the date which is twelve (12) months following the date of the Executive&#x2019;s termination; or (ii) the date the Executive commences subsequent employment (such period, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Pre-Change Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, that if the Executive&#x2019;s continued participation is not possible under the terms of any one or more of those insurance plans or results in adverse taxes to the Company or Executive, and if the Executive was participating in  Company&#x2019;s group health plan immediately prior to the date of termination and timely elects COBRA health continuation, then Company shall pay to the Executive a monthly payment in a gross amount equal to the COBRA premium for the earlier of twelve (12) months following the Executive&#x2019;s termination or (B) until the Executive becomes eligible for coverage under another employer&#x2019;s group coverage (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Benefits Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and the Executive agrees to notify Company promptly and in writing should that eligibility occur. Subject to Executive&#x2019;s timely presentment of receipts, the reimbursements will commence within sixty (65) days following the Executive&#x2019;s termination and will be made on a monthly basis for the duration of the Benefits Continuation Period. If such payments would violate any applicable law, then the Company shall instead pay the Executive taxable monthly payments of equal value on the same schedule, which amounts may be used for such purpose as the Executive may determine; and</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.558%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pay to Executive any unpaid Annual Bonus that is earned and payable and approved by the Board, payable when bonuses are paid to similarly situated executives and no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">March 15 of the year following the performance year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.849%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination by the Company without Cause or by the Executive for Good Reason in Connection with a Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Company terminates the Executive&#x2019;s employment with Company for a reason other than Cause, death or Disability, or the Executive terminates the Executive&#x2019;s employment with Company for Good Reason during the 12-month period following a Change in Control, the Company shall, in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">lieu </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of the benefits set forth in Section 7.2 above:</font></p>
  <p style="margin-left:0.933%;text-indent:6.849%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.849%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1595833333333332;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pay to the Executive an aggregate amount (paid in twelve (12) monthly installments in accordance with Company&#x2019;s regular payroll practices), following the effective date</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.444%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of a Release (as defined in Section 8.1 below) and commencing on the payroll date that next follows the 65</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day after the termination date, equal to the sum of twelve (12) times his/her monthly base salary (at the monthly base salary rate in effect for the Executive immediately prior to the termination of his/her employment). On the 65th day following Executive&#x2019;s termination date, the Company will pay Executive in a lump sum the Severance that Executive would have received on or prior to such date under the standard payroll schedule but for the delay while waiting for the 65</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day in compliance with Code Section 409A, with the balance of the Severance being paid as originally scheduled; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.509%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.926%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Provide the Executive and his/her dependents with the same life, accident, health and dental insurance benefits, if any, that the Executive was receiving immediately prior to the termination of employment until the earlier of: (i) the date which is twelve (12) months following the date of the Executive&#x2019;s termination; or (ii) the date the Executive commences subsequent employment (such period, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Change in Control Pre-Change Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, that if the Executive&#x2019;s continued participation is not possible under the terms of any one or more of those insurance plans, and if the Executive was participating in Company&#x2019;s group health plan immediately prior to the date of termination and timely elects COBRA health continuation, then Company shall pay to the Executive a monthly payment in a gross amount equal to the COBRA premium for the earlier of twelve (12) months following the Executive&#x2019;s termination or (B) until the Executive becomes eligible for coverage under another employer&#x2019;s group coverage (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Change in Control Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Continuation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and the Executive agrees to notify Company promptly and in writing should that eligibility occur. Subject to Executive&#x2019;s timely presentment of receipts, the reimbursements will commence within sixty (65) days following the Executive&#x2019;s termination and will be made on a monthly basis for the duration of the Change in Control Benefits Continuation Period;</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.558%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pay to Executive any unpaid Annual Bonus that is earned and payable and approved by the Board, payable when bonuses are paid to similarly situated executives and no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">March 15 of the year following the performance year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.564%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bonus Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pay to the Executive an amount equal to the Executive&#x2019;s pro rata Target Bonus for the calendar year in which the Executive&#x2019;s termination occurs, payable subject to standard federal and state payroll withholding requirements on the Company&#x2019;s first regularly scheduled payroll date following the effective date of a Release that next follows the 65</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day after the termination date; and</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.558%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Equity Awards. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any equity awards with respect to Company stock then held by the Executive which vest based on continued service shall become fully vested and exercisable as of the date of such termination. Any equity awards that vest based upon the achievement of performance goals shall be subject to the terms of such awards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.849%;font-size:10.0pt;margin-top:0.05pt;line-height:1.1739583333333332;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Termination for Cause. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Executive&#x2019;s employment with Company is terminated by Company for Cause, or the Executive terminates his employment with Company for any reason other than Good Reason (including his death or Disability), the Executive shall not be entitled to the severance benefits or other considerations described herein by virtue of this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, if Company does not waive the provisions of Section 3.2 in connection with such termination, Company will pay Executive an amount equal to the sum of six (6) times his/her monthly base salary (at the monthly base salary rate in effect for the Executive immediately prior to the termination of his/her employment), except to the extent such termination arises from Executive&#x2019;s breach of his fiduciary duty or theft of Company property (whether physical or electronic). Such amount shall be paid in monthly installments in accordance with Company&#x2019;s regular payroll practices following the effective date of the termination.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:-7.792%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Release. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notwithstanding any other provision of this Agreement to the contrary, benefits, including, but not limited to severance payments under Section 7 hereof, shall be payable under this paragraph only if the Executive enters into a final and binding agreement in favor of the Company, its affiliates and their respective officers and directors in a form provided by the Company, substantially in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) which has not been revoked within sixty (65) days of his termination of</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employment whereby the Executive releases the Company and its subsidiaries (and those affiliated with the Company and its subsidiaries) from all claims that the Executive may otherwise have against them, to the extent that the basis for such claims arose on or before the date the Release is signed by the Executive; except that such Release shall not adversely affect the Executive&#x2019;s rights to enforce the terms of this Agreement, and shall not adversely affect the Executive&#x2019;s right to vested benefits, right to indemnification or right to reimbursement of expenses by the Company to which the Executive would otherwise be entitled to under, without limitation, any charter document or Company insurance policy, by reason of services he rendered for the Company or any of its subsidiaries as an officer and/or an employee thereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Definition of Cause. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean: (i) the conviction of the Executive by a court of competent jurisdiction of, or the pleading of guilty or nolo contendere to, any felony or any crime involving moral turpitude; (ii) gross negligence, breach of fiduciary duty or breach of any confidentiality, non-competition or developments agreement by the Executive in favor of the Company that (A) cannot be cured or (B) has not been cured or corrected by Executive within thirty (30) days prior written notice of such breach or failure; (iii) the Executive shall have willfully and continually failed to substantially perform the Executive&#x2019;s duties with the Company after a written demand for substantial performance is delivered by the Company, which demand specifically identifies the manner in which the Company believes that the Executive has not substantially performed the Executive&#x2019;s duties pursuant to the disciplinary procedures of Company, and such failure of substantial performance shall have continued for a period of thirty (30) days after such written demand; (iv) the Executive has been chronically absent from work (excluding vacations, illnesses or leaves of absences); (v) the commission by the Executive of an act of fraud, embezzlement or misappropriation against the Company; (vi) the Executive shall have refused, after explicit notice, to obey any lawful resolution or direction by the Board which is consistent with his/her duties as an officer of the Company or FTG, as applicable; or (vii) a material breach or failure to follow any written policy or rule adopted by the Company or any of its subsidiaries that (A) cannot be cured or (B) has not been cured or corrected by Executive within thirty</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(30) days prior written notice of such breach or failure.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Definition of Good Reason. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean one or more of the following events, as the case may be: (i) a material diminution in the Executive&#x2019;s authority, duties or responsibilities; (ii) a material diminution in the Executive's base salary (other than a reduction of not more than 10% that is applicable to similarly situated executives of the Company); (iii) a material change in the geographic location of the Executive&#x2019;s place of business (provided, however, that travel for business purposes consistent with past practices shall not be considered a change in the place of business for the purpose of this clause; and provided, further, that a relocation of less than 50 miles from Executive&#x2019;s then present location will not be considered a material change in geographic location); and/or (iv) a material breach by the Company of this Agreement or any agreement under which the Executive provides services to the Company; provided, that the occurrence of any of the events listed in clauses (i) though (iv) shall not constitute Good Reason (x) unless the Executive shall have given written notice of the event to the Company within thirty</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(30) days after it first existed and the Company shall have failed to remedy the condition within thirty (30) days after the written notice, in which case the Executive&#x2019;s employment shall terminate thirty-one (31) days after written notice of the event to the Company, or (y) if the event follows an event or action by the Executive that would constitute Cause (as defined herein) for termination.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Definition of Disability. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; means an independent medical doctor (selected by the Company&#x2019;s health or disability insurer) has certified that the Executive has, for six (6) months consecutive or nonconsecutive in any 12 month period been disabled in a manner that materially interferes with his/her ability to perform his/her responsibilities as an employee of Company. Any refusal by the Executive to submit to a medical examination for the purpose of certifying disability shall be deemed to constitute conclusive evidence of the Executive&#x2019;s disability. Notwithstanding the foregoing, nothing herein shall abrogate Employee&#x2019;s rights under state or federal law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.729%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Certain Tax Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:9.421%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	This Agreement is intended to comply with section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and its corresponding regulations, or an exemption, and payments may only be made under this Agreement upon an event and in a manner permitted by section 409A,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to the extent applicable. Severance benefits under the Agreement are intended to be exempt from section 409A of the Code under the &#x201c;short-term deferral&#x201d; exception, to the maximum extent applicable, and then under the &#x201c;separation pay&#x201d; exception, to the maximum extent applicable. For purposes of section 409A of the Code, all payments to be made upon a termination of employment under this Agreement may only be made upon a &#x201c;separation from service&#x201d; within the meaning of such term under section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. In no event shall the Executive, directly or indirectly, designate the calendar year of payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive&#x2019;s execution of the Release, directly or indirectly, result in the Executive designating the calendar year of payment, and if a payment that is deferred compensation subject to section 409A of the Code and subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive&#x2019;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.561%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Notwithstanding any provision in this Agreement to the contrary, if at the time of the Executive&#x2019;s separation from service with Company, Company (or a company that is aggregated with the Company for this purpose under section 409A of the Code) has securities which are publicly-traded on an established securities market and the Executive is a &#x201c;specified employee&#x201d; (as defined in section 409A of the Code) and it is necessary to postpone the commencement of any severance payments otherwise payable pursuant to this Agreement as a result of such separation from service to prevent any accelerated or additional tax under section 409A of the Code, then Company will postpone the commencement of the payment of any such payments hereunder (without any reduction in such payments ultimately paid or provided to the Executive) that are not otherwise exempt from section 409A of the Code, until the first payroll date that occurs after the date that is six</font></p>
  <p style="margin-left:0.92%;text-indent:9.565%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6) months following the Executive&#x2019;s separation from service with Company. If any payments are postponed due to such requirements, such postponed amounts will be paid in a lump sum to the Executive on the first payroll date that occurs after the date that is six (6) months following the Executive&#x2019;s separation from service with Company. If the Executive dies during the postponement period prior to the payment of the postponed amount, the amounts withheld on account of section 409A of the Code shall be paid to the personal representative of the Executive&#x2019;s estate within sixty (60) days after the date of the Executive&#x2019;s death.</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.569%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.546%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:6.729%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Excise Tax Adjustment,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:20.469%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	If any payment or benefit Executive will or may receive from the Company or otherwise (a &#x201c;280G Payment&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this Section, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;Excise Tax&#x201d;), then any such 280G Payment provided pursuant to this Agreement (a &#x201c;Payment&#x201d;) shall be equal to the Reduced Amount. The &#x201c;Reduced Amount&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state, foreign and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#x2019;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;Reduction Method&#x201d;) that results</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;Pro Rata Reduction Method&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.561%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Notwithstanding any provision of this Section 8.6 to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.56%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	The Company shall appoint a nationally-recognized accounting, consulting or law firm to make the determinations required by this Section 8.6. The Company shall bear all expenses with respect to the determinations by such firm required to be made hereunder.</font></p>
  <p style="text-indent:9.333%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:9.56%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	If Executive receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 8.6.(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees (after any appeals related to the IRS&#x2019;s determination have been exhausted) to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 8.6.(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 8.6.(a), Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Binding Effect. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except as otherwise provided herein, this Agreement shall be binding upon Company and inure to the benefit of the Company and any successor or assign (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) of the Company. Company shall require any such successor to assume this Agreement expressly and to be bound by the provisions of this Agreement as if such successor or assign were Company and for purposes of this Agreement, any such successor or assign of Company shall be deemed to be Company for all purposes.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.832%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.8	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">No Employment Agreement; Effect on Other Agreements. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nothing herein shall in any way limit the Executive&#x2019;s obligations under any other non-competition, confidentiality, option or similar agreement between Company or any of its affiliates and the Executive currently in effect or which may be entered into in the future.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.83%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.9	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Withholding; No Gross-Up. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All payments required to be made by Company hereunder to the Executive shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as Company may reasonably determine it must withhold pursuant to any applicable law or regulation. For the avoidance of doubt, Company shall have no obligation under this Agreement to make any tax gross-up payments in respect of any tax imposed on the Executive and all taxes, penalty or otherwise, imposed on the Executive shall be the Executive&#x2019;s sole responsibility.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.836%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.10	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Advice of Counsel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. EXECUTIVE ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, EXECUTIVE HAS THE RIGHT AND HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.831%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.11	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Arbitration. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except for claims arising from a breach of Section 3.2, all claims or disputes arising out of or relating to this Agreement shall be resolved by binding arbitration. Such agreement includes all claims, whether based on tort, contract, or statute, including, but not limited to, any claims of discrimination, harassment, or retaliation, whether based on Title VII of the Civil Rights Act of 1964, as</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.481%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">amended, or any other local, state or Federal law (including, but not limited to, the Massachusetts Fair Employment Practices Law &#x2013; Mass. Gen. Laws Chapter 151B) and other state and federal laws., claims for wages or compensation, claims based in equity, or otherwise. The claim or dispute will be arbitrated in accordance with the rules of the American Arbitration Association (&#x201c;AAA&#x201d;) under its existing Arbitration Rules. These rules may be found at https://</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">www.adr.org/Rules.</font><font style="white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company shall pay the arbitration administrative costs and the arbitrator&#x2019;s fees subject to applicable law and the AAA Rules. Each party in the arbitration shall bear his/its own attorneys&#x2019; fees and legal costs. The Parties agree to file any demand for arbitration within the time limit established by the applicable statute of limitations for the asserted claims. Failure to demand arbitration within the prescribed time period shall result in waiver of said claims. The Parties agree that the arbitration will be in Boston, Massachusetts. EXECUTIVE UNDERSTANDS AND AGREES THAT HE IS WAIVING HIS RIGHTS TO BRING SUCH CLAIMS OR DISPUTES TO COURT, INCLUDING THE RIGHT TO A JURY</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TRIAL. Notwithstanding the foregoing, this Agreement expressly does not prohibit either party from seeking, exclusively in a court of competent jurisdiction located within Massachusetts, an application for a provisional remedy or other equitable or injunctive relief to prevent actual or threatened irreparable harm, or from pursuing therein any claim that cannot by law be subject to mandatory arbitration. In the event of any procedural matter not covered by the aforesaid AAA rules, the procedural law of the Commonwealth of Massachusetts shall govern.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.832%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.12	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Governing Law. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to conflicts of laws principles.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.832%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.13	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Entire Agreement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement, along with equity agreements referenced in Section 2.3 above or other agreements referenced in Section 2.5 above, constitutes the entire Agreement between the Executive and Company concerning the subject matter hereof and supersedes any prior negotiations, understandings, or agreements concerning the subject matter hereof, whether oral or written, and may be amended or rescinded only upon the written consent of Company and the Executive.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.829%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.14	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Modification &amp; Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and an authorized representative of Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.15	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Severability. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The invalidity or unenforceability of any provision of this Agreement shall not affect the other provisions of this Agreement and this Agreement shall be construed and reformed to the fullest extent possible.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.837%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.16	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Captions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.834%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.528%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.17	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Successors and Assigns. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Executive may not assign any of his/her rights or obligations under this Agreement; the rights and obligations of Company under this Agreement shall inure to the benefit of, and shall be binding upon, the successors and assigns of Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.18	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Survival. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement. For the avoidance of doubt, the covenants in Section 3 and Section 4 of this Agreement shall survive any termination or expiration of this Agreement and termination of the Executive&#x2019;s employment for any reason.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.19	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Counterparts. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and both of which taken together shall constitute one and the same instrument. Facsimile or scanned and e-mailed signatures shall be deemed valid and binding for such purposes.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:11.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:12.093%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">[Remainder of Page Intentionally Left Blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:8.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above, to be effective as of the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith 	</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name: Mark Smith</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:	CEO</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXECUTIVE:</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Joseph Vittiglio	</font></p>
  <p style="margin-left:54.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">J</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">oseph Vittigli</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">o</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:8.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:39.493%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:39.991%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:11.467%;text-indent:0.0%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:12.046%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Release</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.816%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I understand and agree completely to the separation payment terms set forth in the Amended and Restated Executive Employment Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) dated</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, by and between Finch Therapeutics Group, Inc. (&#x201c;Company&#x201d;) and me. I understand that I am not entitled to any separation payments if I do not sign this Release and return it to Company on or before </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[DATE &#x2013; to be inserted by Company at the time of termination] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to the terms set forth herein or if I revoke this Release as set forth in Section 3 below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General Release and Knowing Waiver of Employment-Related Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For and in consideration of the separation payments and any other benefits I am eligible to receive from the Company, I, on my own behalf and on behalf of my successors and assigns (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Releasor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), hereby release and forever discharge the Company, its affiliates, and their respective stockholders, members, predecessors, successors, officers, directors, agents, representatives, employees, consultants and advisors (collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Releasee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), from any and all claims, counterclaims, demands, debts, actions, causes of action, suits, expenses, costs, attorneys&#x2019; fees, damages, indemnities, obligations and/or liabilities of any nature whatsoever (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), whether known or unknown, which Releasor ever had, now has or hereafter can, shall or may have against Releasee, for, upon or by reason of any matter, cause or thing whatsoever from the beginning of the time to the day of the date of this Release, including, but not limited to, the following:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.546%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	all such Claims and demands directly or indirectly arising out of or in any way connected with my employment with Company, including but not limited to providing services to the Company, or the termination of that employment and provision of services;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	all such Claims and demands related to salary, bonuses, commissions, stock, stock options, units, profits interests or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, separation pay and/or any other form of compensation;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	any Claims arising under any federal, state or local law, statute or ordinance, including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Americans With Disabilities Act, the Civil Rights Act of 1991, the Fair Labor Standards Act, the Equal Pay Act, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act of 1993, and the Consolidated Omnibus Budget Reconciliation Act of 1985, the anti- retaliation provisions of any federal or state statute, including state workers&#x2019; compensation statutes, and any other applicable state or local statutes, including the Massachusetts Fair Employment Practices Act (M.G.L.</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.509%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">c. 151B), the Massachusetts Equal Rights Act, the Massachusetts Equal Pay Act, the Massachusetts Privacy Statute, the Massachusetts Sick Leave Law, the Massachusetts Civil Rights Act, all as amended, the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150), the Massachusetts Overtime regulations (M.G.L. c. 151 sections 1A and 1B), the Massachusetts Meal Break regulations (M.G.L. c. 149 sections 100 and 101) </font><font style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[additional state statutes to be inserted at the time of termination]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	any Claims for breach of contract, express or implied, including any claim for breach of any implied covenant of good faith and fair dealing; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e)	any Claims of constructive discharge, discrimination, harassment, retaliation, fraud, defamation, intentional tort, emotional distress and negligence; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, nothing herein releases any claim Releasor has or may have against Releasee regarding the performance or non-performance of obligations arising under the Employment Agreement, and nothing in this Release shall prevent me from enforcing my rights, if any (i) to my non-forfeitable accrued benefits (within the meaning of Sections 203 and 204 of ERISA) under any tax-qualified retirement plan maintained by the Company, (ii) to receive continuation coverage pursuant to COBRA (iii) to indemnification</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conferred upon me as an officer of the Company pursuant to the Company&#x2019;s governing documents, under any applicable insurance policies, or in accordance with applicable law or (iv) that cannot be waived under applicable law. Further, nothing in this Release affects my rights to provide information to, participate in an investigation by or file an administrative charge or complaint with any Governmental Agencies (defined below), including, but not limited to, the Equal Employment Opportunity Commission or similar administrative agency. However, I agree not to accept any monetary relief or recovery from any charge or complaint filed against any Releasee with any such administrative agency except where authorized by applicable law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, Releasor does not release any Claims against Releasee that may arise after this Release has become effective.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.426%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Representation by Counsel and Review Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. I have been advised to consult independent legal counsel before signing this Release, and I hereby represent that I have executed this Release after having the opportunity to consult independent counsel and after considering the terms of this Release for </font><font style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[if over 40][twenty-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">one (21) [applies if no reduction in force]/forty-five (45) [applies if there is a reduction in force]]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">days (although I may choose to voluntarily execute this Release earlier). I further represent and warrant that I have read this Release carefully, that I have discussed it or have had reasonable opportunity to discuss it with my counsel, that I fully understand its terms, and that I am signing it voluntarily and of my own free will.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Right to Revoke Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release shall not become effective until the eighth day following the date on which I have executed it, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that I have not revoked it, and I may at any time prior to that effective date revoke this Release by delivering written notice of revocation to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[Name and contact information to be inserted at the time of termination]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consideration for Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. I acknowledge that the consideration for this Release is consideration to which I would not otherwise be entitled and is in lieu of any rights or claims that I may have with respect to any other remuneration from the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.454%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Representation Concerning Filing of Legal Actions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. I represent that, as of the date of this Release, I have not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against Company or any of the other Releasees in any court or with any governmental agency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.426%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Continuing  Obligations Concerning  Confidential Information and Company  Property.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I acknowledge and agree that I remain subject to the restrictive covenants contained in Section 3 of the Employment Agreement and the covenants related to Confidentiality &amp; Proprietary Information contained in Section 4 of the Employment Agreement, each of which survives the termination of my employment. I further acknowledge that I am obligated to return to the Company by </font><font style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[DATE]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, all Company documents, originals and copies, whether in hard or electronic form, and all Company property, including without limitation keys, computers, computer disks, pagers, phones and credit cards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.417%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Nondisparagement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to the provisions of Section 8, I will not make any statements, whether verbally or in writing (including in electronic communications) that are professionally or personally disparaging of, or adverse to the interests of, the Company or its officers, directors, managers or employees. This includes, but is not limited to, any statements that disparage the products, services, finances, financial condition, capability or any other aspect of the business of the Company. I further agree not to engage in any conduct which is intended to harm, professionally or personally, the reputation of the Company or its officers, directors, managers or employees. For its part, the Company shall direct those of its executives that know of this Release not to make any statements, whether verbally or in writing (including in electronic communications) that are professionally or personally disparaging of you, or adverse to your interests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 8.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Exceptions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Nothing in this Release shall prohibit the Releasor from lawfully (A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, &#x201c;Governmental Authorities&#x201d;) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to the Releasor individually (and not directed to the Company and/or its subsidiaries) from</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any such Governmental Authorities; (C) testifying, participating or otherwise assisting in an action or proceeding by any such Governmental Authorities relating to a possible violation of law; or (D) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, the Releasor shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to the Releasor&#x2019;s attorney in relation to a lawsuit for retaliation against the Releasor for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement require the Releasor to obtain prior authorization from the Company before engaging in any conduct described in this Section 8, or to notify the Company that he has engaged in any such conduct.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.435%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 9.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Provision</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All payments and benefits provided under the Employment Agreement are intended to be exempt from, or to comply with, the requirements of section 409A of the Code and this Release shall be interpreted and administered in accordance with these intentions. The Severance Benefits and rights to COBRA Reimbursement under the Employment Agreement are intended to be exempt from section 409A of the Code under the &#x201c;short-term deferral&#x201d; exception of Treas. Reg. Section 1.409A-1(b)(4), to the maximum extent applicable, and then under the &#x201c;separation pay&#x201d; exception of Treas. Reg. Section 1.409A-1(b)(9)(iii), to the maximum extent applicable. All payments that are subject to Section 409A that are to be made upon a termination of the Releasee&#x2019;s employment may only be made upon the Releasee&#x2019;s &#x201c;separation from service,&#x201d; as defined in Treas. Reg. Section 1.409A-1(h), from the Company. For purposes of section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments and each such installment shall be treated as a separate payment. With respect to any payments that are subject to section 409A of the Code, in no event shall the Releasee, directly or indirectly, designate the calendar year of a payment. Any reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Treas. Reg. Section 1.409A- 3(i)(1)(iv). Notwithstanding the foregoing, the Releasee acknowledges that he has been advised to seek the advice of a tax advisor with respect to the tax consequences of all payments pursuant to the Employment Agreement, including any adverse tax consequence under section 409A and applicable State tax law, and neither the Company nor any of its members, officers, employees, agents or affiliates shall be responsible for any such adverse tax consequences or guarantees any particular tax consequences to the Releasee with respect to payments and benefits under the Employment Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.509%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 10.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment of Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release may not be amended or modified except by a writing signed by</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, on behalf of Company and by me.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.528%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 11.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to principles of conflicts of laws thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.481%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 12.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Neutral Interpretation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Release shall be interpreted in a neutral manner, and not more strongly for or against any party based upon the source of the draftsmanship of the Release.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.528%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 13.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The various headings in this Release are inserted for convenience only and are not part of the Release.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.472%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 14.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Admission of Liability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Releasee agrees that this Release, and performance of the acts required by it, does not constitute an admission of liability, culpability, negligence or wrongdoing on the part of anyone, and will not be construed for any purpose as an admission of liability, culpability, negligence or wrongdoing by any party and/or by any party&#x2019;s current, former or future parents, subsidiaries, related entities, predecessors, successors, officers, directors, stockholders, agents, employees and assigns.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:	This </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">day of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, 20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WITNESSES:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">	</font>&#160;</p>
  <p style="margin-left:9.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:12.093%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>8
<FILENAME>fnch-ex10_21.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html>
 <head>
  <title>EX-10.21</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:5.507%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.787%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDMENT NO. 1</font></p>
  <p style="margin-left:5.507%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.87%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">           This AMENDMENT   NO.   1   TO   AMENDED   AND RESTATED   EXECUTIVE EMPLOYMENT AGREEMENT (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">New Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) is made as of March 18, 2021, by and between Finch Therapeutics Group, Inc., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">FTG</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, together with all subsidiaries and affiliates hereinafter referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and Joseph Vittiglio (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) This New Amendment shall amend that certain AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prior</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), by and between the Company and the Executive.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:5.507%;text-indent:0.0%;font-size:10.0pt;margin-top:4.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.806%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RECITALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.853%;text-indent:6.873%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.148%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Prior Amendment amended that certain Employment Agreement, dated on or about December 7, 2020, by and between the Company and the Executive (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;); and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.853%;text-indent:6.87%;font-size:10.0pt;margin-top:4.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the vesting commencement date set forth in the Prior Amendment was mis-stated due to an administrative error; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.853%;text-indent:6.87%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the parties desire to amend the Prior Amendment to reflect the true intention of the Company and the Executive, as set forth herein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.853%;text-indent:6.868%;font-size:10.0pt;margin-top:0.05pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOW, THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:1.0%;display:flex;margin-top:0.05pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.074%;min-width:7.519%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.594949494949495%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDMENT OF SECTION 2.3(a) OF THE PRIOR AMENDMENT. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The vesting commencement date for the Option referenced in Section 2.3(a) of the Prior Agreement shall be amended such that the vesting commencement date shall be on the first year anniversary of December 7, 2020, and the remaining shares covered by the Option vesting and becoming exercisable in forty-eight (48) equal monthly installments thereafter, subject to Executive&#x2019;s continuous service as of each such date.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:1.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.194%;min-width:7.519%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.594949494949495%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COUNTERPARTS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This New Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:1.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.102%;min-width:7.519%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.594949494949495%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GOVERNING LAW</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All issues and questions concerning the construction, validity, enforcement and interpretation of this New Amendment shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to conflicts of laws principles.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:1.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.157%;min-width:7.519%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.594949494949495%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NO OTHER AMENDMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as specifically amended by this New Amendment, all other terms and conditions of the Prior Amendment shall remain in full force and effect in accordance with their terms without modification.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.853%;text-indent:7.028%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.287%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the undersigned hereby executes this New Amendment as of the date first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:55.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:9.056%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINCH THERAPEUTICS GROUP, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:55.187%;text-indent:0.0%;font-size:10.0pt;margin-top:7.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith 	</font></p>
  <p style="margin-left:55.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:17.074%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name: Mark Smith Title: CEO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:55.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXECUTIVE:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">									                                               </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Joseph Vittiglio</font></p>
  <p style="margin-left:55.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name: Joseph Vittiglio</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>fnch-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SUBSIDIARIES</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:62.564%;"></td>
    <td style="width:37.436%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Name</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Jurisdiction of Formation</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Therapeutics, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delaware</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Therapeutics Holdings, LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delaware</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Research and Development, LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delaware</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>fnch-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;">We consent to the incorporation by reference in Registration Statement No. 333-254773 on Form S-8 of our report dated March 31, 2022, relating to the consolidated financial statements of Finch Therapeutics Group, Inc. and its subsidiaries appearing in this Annual Report on Form 10-K of Finch Therapeutics Group, Inc. and its subsidiaries for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;">March 31, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>fnch-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Mark Smith, certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Finch Therapeutics Group, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.44%;"></td>
    <td style="width:5.064%;"></td>
    <td style="width:4.038%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mark Smith, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>fnch-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Gregory D. Perry, certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Finch Therapeutics Group, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.44%;"></td>
    <td style="width:5.064%;"></td>
    <td style="width:4.038%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Gregory D. Perry</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gregory D. Perry</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>fnch-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Finch Therapeutics Group, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned officers of the company, hereby certifies, pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Smith</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mark Smith, Ph.D.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Gregory D. Perry</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gregory D. Perry</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img102364508_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_0.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" W5$W$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[^M9=Q\4 N?WOZUJL)-D?6HGT'_;%K_STIO]M6G_ #TKYKG^*VW/[[]:JO\
M%K_IM^M6L%-D/%P/IXZY:#_EI3&\06:_\M*^7Y/BV?\ GM^M5)OB\>?WWZUJ
MLOFS-XZ*/JAO$EDO_+2F'Q38C^/]:^2YOC"P)_??K5.3XQM_SV_6M%ELR/[0
M@?7I\66(_C_6FGQA8C^,?G7QU+\97_Y[?K523XSO_P ]S^=7_9<R/[2@?9O_
M  F=C_?'YT?\)G8_WQ^=?%G_  NB3_GM^M)_PNA_^>WZT_[*F+^THGVDWC6Q
M'\0_.F_\)Q8_WE_.OBJ3XT2?\]OUJ!OC5)_SW_6G_9<R?[2B?;O_  F]A_>'
M_?5)_P )Q8_WA^=?$/\ PNR3_GM^M*/C4_\ SV_6E_94P_M*)]N_\)Q8_P!X
M?G1_PG%C_>'YU\1_\+I?_GM^M'_"Z7_Y[?K1_94P_M*)]N?\)Q8_WA^='_"<
M6/\ >'YU\2+\:9/^>WZT'XU2?\]S^=']E3&LR@?;?_"<6/\ >7\Z</&UC_>'
MYU\/_P#"ZI,_ZX_G4L?QJD_Y[G\Z7]E3'_:4#[=_X32Q_O#\Z4>,K'^\/SKX
MI7XT/_SV_6IX_C,__/;]:G^RI@LRB?:7_"76/][]:<OBRQ;^/]:^,T^,K_\
M/;]:GC^,C?\ /8_G3_LN8_[2@?9"^)K)O^6GZU*OB"S;_EI7R!;_ !A9O^6Q
M_.M&'XO$X_??K4_V;,T6/@?6/]N6?_/6E&LVA_Y:U\LQ_%P\?OOUJQ'\6O\
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M!U%)N'K2T (U I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BD:FYH ?1110 4444 %%%% !36IU)B@!M/I,"EH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(I: "BB
MB@!*3;3J* $%+110 4444 %%)FEH 0C-)MIU% !124M "$T;J*6@ HHHH 3%
M+12,P7J: %HJ![I5[U7DU)5[T+45R_16/)K2K_%4#^(E7^*KY&R>=&_17,R>
M)U7^.JLGBQ5_CJO9R)]I$ZXL%ZFH9+M5[UQ<WB]>?FK/N/%RGH_ZU<:,F2ZT
M4=S+J2+WJG-K"K_%7!3>*@W\?ZUG7'B;=GYJZ(X5F$L0CT&;Q J_Q54D\4!?
MXZ\XN/$);^*L^;7'_O5LL*<[Q)Z;)XL']^J\GB__ &Z\NDUA_P"\:K/JS^M;
M+"F3Q3/4W\8_[=5I/&G'WZ\N?5)/6J\FHR>IK>.#B9/%,]/D\:?[=59/&&[^
M/]:\T:_D]:;]LD]:V^JQ(^LR/1V\6'^_4+>*B?XJ\_\ M;^IH^U/ZFCZM$GZ
MQ)G=2>)2W\50OX@+?Q5QGVEO6G"=O6J^KQ(]O(ZF37&;^*J[ZPQ[US_G&CS"
M:I4(B]M(VSJS?WJ3^U&]:QMQI-YJ_911'M&:KZDWK4+W[G/-4=QII:FHHKF9
M::^?UIGVU_6J_:DI\J(NRQ]L?^]33=/ZFHMM&VERH5Q6N'/>F&:3UIX6CRZ8
MKC/.?UI3,_O2[:?M%*P:E=I7YIOG/Z_K5AHQZ4WRQZ4[ ,$K^IIPGD]:=M%&
MT46'J)Y[^M"SOZTNT4;:5@U%%R_K3_M3^M1[:-M%@N2?:G]:<MT_K4.VEH&F
M3_;']33UO7'>JM%*Q5R^M\_K4BZB_K68&I=QI\J)YC5_M)_[U.75&]:QV8TF
MXTN1,KVC-Y=6;^\:G36&_O5S8D-.\XU/L4/VC.I3767^*IE\1E?XJXYIV]:8
MUP_K2]A$I5F=TOB<C^.IU\5$?Q5Y[]H?UI?M3^IJ7AXE>W9Z,GBPC^.K,7C#
M'\=>8_:G]:7[9(,<U/U6(_K,CU=/&>/XZF3QI_MUY)]ND'<TY=2D_O&E]4B4
ML3(]A3QD/[_ZU8C\8#^_^M>.QZI(/XC5B/5I/[U8RPB-XXIGL2>+ ?XZLQ^)
MP<?/7CT6L.,?-5N+7&'\58O"(T6*N>Q0^(E;^*KL.M*W\5>/0>(&&/FK1M_$
MI&/FKGEA6;1Q*/78]21N]6X[M&[UY5!XJQCYJT(?%RC^/]:P>'D;JO$]+616
MZ&ES7 P^,%_OU<B\7*?XZQ=&2-%6BSLZ*YB/Q0K?Q?K4Z^(E/\51[.1?M(G0
M45C1ZXK8^:K,>I*W>IY65S(T**K+>*W>IUD#=#4E#J*** "BBB@ HHHH ***
M* $VT 8HI: "BBDS0 M%%% "$XI-U*U-H ?1110 4AI:1J $W4ZF4Z@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJQE1DC=58LZFBLBWU99/XJT(;E9.]8M-&J=]B>BDI:0PHHHH **** "BBB@
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MC$VBFT^BD,;2K2T4Q!1110(****0[!1110(****8!112K0 E%/IE !112K0
M;:2GTRD 4444P"BBB@ IM.HH :M.HHH ****!A1112$%%*.])2N,****H5PH
MHHIE;A1112$%%%%, I<&DI](!E%*U)0(****8!1112!ZA12-24"V'4444#;"
MBBB@%J%%%%(84444 %%%%,04444#N%%%% @HHHH *1NE+10,93EZ4M% !2-2
MT4#&X-.HHH%L%%%%(+B,.]-_&GTFVBPU(;13Z*!#*=MI:*JX7';132HI<TE3
M<0AC%-V"GTC4AC<49Q13MM6(8TI6D^U,.E.\ND\JJT)U'+J#KWJU#JTB]ZI>
M32B/%9.*9I&3-ZUUQUQ\U;=GXA9<9:N'5BM2K=,O>LI4DS:-5H]0L_$^W'S5
MM6GBP+CY_P!:\:75'7O4BZ[(O<URRP:9TQQ;1[S;^+D_OU?A\3))CYA7@5OX
MDD7^(ULV/B9^,M7)+!V.F&+N>XPZPDG>KL-PLG>O)=/\3<C+?K73Z=XE7 RU
M<4Z#B=L*RD=S16);>((G RP_.KJZM"W>N?E:-^9,O4566^C;H:F696Z&I*'-
MTIM.ZT;: #(HHVT#B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYFR3[<\G4T>86ZT@AQ3PF*'8=F-\L-1Y"^E2JO%*>E040^2OI3O)'I3J?3U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 44E)NH =124M !1110 4444 %%%%
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MBBB@04444 %%%% !1110%PHHHH&%%%% 6"BBB@04444 %%%% !1110 4444
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M5Q<=SI4DS2HJ-)D<9#4_(]:@L6BDI: "BBB@!*;FGTW;0 JTM(.*6@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444#N%%%% @HHHH&)@4;12T4
M)M'I2=#3J*8B)G-1-,XZ&K.T4QHQ3N@$AO)%8<ULV6JO'C+5C",9I^[;4.*D
M6I.)VMCXB,>,M^M;]GXLVX^?]:\L^ULO>E75'7N:Y9892.F&(DCVRU\8*<?/
M6M;^*%DQ\_ZUX1;ZU(I'S&MJQ\0.N,M7#/"=CKCBGU/<K765F(^:M>&99%ZU
MXYIGB3;C+5UNF^*%VC+?K7GSP\HG?3KQD=W16#;^)(Y /F%78]623H17.XM'
M1S)FC14$=P).AJ>I*"DS2TE !NI:;MIU !1110 4444 %%%% !1110 4444
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MBB@ HHHI7&%%%% @HHHI, HHHH0!1113 **** "BBBF 4444@"BBB@ HHHH
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MQ:***8!24M(W2@ W44VG+TH 6BBDH 6BDW49H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !36H)HZT )3Z3;2T %%%%
M!1110 44A8#J:8T\:]7 _&@"2HY)DCY8U2O-:MK5"=X)KB/$/CJ&W5L2#\ZT
MC3E+9&<JD8K4[B;6[:#.YOUK%U#QQ:VRG#J/QKP?Q5\51;[]LOZUY'XA^,TF
MY@)C^=>I1R^=0\NMF$:9]+^(OB7"JMB4?G7E7B;XIA2VV7]:\"U+XKRW1(\X
MG\:YC4?&4MUG]X3^->[1ROEW/%K9CS['IWB+XL2@MB4_G7GNJ_$Z>9C^]/YU
MQFH7TESGYC6/);NY/)KW:.%IPW1Y$\3-LZFY\72W><N?SK,N+YKCJ:RHK=EJ
MTJ$5VJ,5L8<SEN-DA\SFHOL(JXM+5<W8GE3*RVNVI5CVU)14W860#BEW&DHH
M$%%%%# ****0!11130!1112 **** "BBBG< HHHHN 4444 %%%%*P!1115 %
M%%%2 44450!1110 4444 %%%% !1110 4444 %%%% !1110 4445(!1115 %
M%%%0 44456X!1114M %%%%-( HHHJ@"BBBI ****: ****8!1114V **** "
MBBB@ HHHIH HHHI@%%%% !1110 4444 %%%% !11128!1110@"BBBF 4445(
M!1115 %%%%3< HHHH0!1113N 44447 ****8!1110 4444 %%%%*X!1113 *
M*** "BBBH ****8!1113 **** "BBBBX!1113 **** "BBBE< I?6DI:90E+
M244$CFJ%H]U/W4X4AE5K7=3#95>VTF::D'*F54M]E6X;MK?!!Q2%<BHI(RU3
M+4-C8M/%TMJ1AR/QKIM)^)D\+ >:?SKS:2U9J(X'3N:SE2A):EQJSB]#Z(\/
M_%B7Y<RG\Z]0\,_%3=LW2_K7QY97TEOCYC71Z?XODM,?.1^->56P$9[(]&GC
M91W/O;P[\3(6"YE'YUZ#IGCNUN%4%U/XU^>&E_%26W8?O3^==WH/QEDW*#,?
MSKQ*V4O='L4<R6S/O"#7K:?&UOUJ[%<)-]TU\L>%OBQ]HV9F_6O7?#/CJ*X"
M9D'YUX=7"3IGLTL5&H>GT5FV>N6UTH^< U>6>-NC@_C7%9H[+W)**0,#T.:6
MD,2EHHH *:U.I,4 -HI=M+MH&%+110(**** "BF9-.6@!:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*7::0"44N*2J$%%+M-% "4HI*5: %VTVGTRD 4444P"BBB@ HHHI6 ****&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH ****8!1110 4444P"BBBIN 4444P"BBBJN 4445(!1112 ****8!1113
M**** "BBB@ HHHH **** "BBBI **** "BBBF 4444P"BBB@ HHHJ;C"BBBK
M$%%%%1< HHHH ****H HHHJ;@%%%%, HHHH ****8!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1112 ****5@"BBBJ ****D HHHH0!1
M113 ****0!1115 %%%% !1110 4444@"BBBD 4444 %%%%" ****IL84445
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110(****8#<TX=*3;2TP"BBBBXPHHHI,04444@"BBBF 4444M@"BBB@
MHHHJ@"BBBI ****:0!12TE4 4445.X!1110 44450!1114@%%%%, HHHH **
M** "BBB@ HHHI: %%%% !1112 ****=P"BBB@ HHHH8!1110@"BBBA@%%%%(
M HHHH ****: ****8!1112 ****2 ****; ****$ 4444P"BBBEH 4444P"B
MBB@ HHHI %%%%.P!1110 4445(!1115 %%%% !11118 HHHH **** "BBBF
M4445+ **** "BBBD 44447 ****=P"BBB@ HHHH ****8!1110 4444K@%%%
M%( HHHIH HHHH **** "BBBF@"BBBA@%%%% !1114@%%%%, HHHI %%%%4 4
M444 %%%%2 44447 ****8!1113 ****5P"BBBD 4444 %%%% !1115 %%%%2
MQA1114B"BBBK0!11138Q0:#S24Y:0$$D>[-5GM2W-:!%-I\S!I,J0QM"<BMW
M2_$$EBP^<C'O65(M5I$;M4N*GN',X['K6@?$Z6T91YI'XUZYX1^+S-L!F_6O
MD>,RQL#DUT6CZ[+9LIWD5YU? PJ+1'?0QDX;GZ"^#_B1'<!-TOZUZII/BNVN
MXU!<?G7YW^'/B9)9;<RXQ[UZGX7^,QW(IF_6OEL1ELD[H^BP^8IZ,^V([R*4
M95P:E!STKPOPC\3$OM@,N?QKUG1=>AO(U^<<UX52E*F[,]NG5C46AM;31@^M
M"NK<J0:=6!L(*6BB@!#TIN:=2;: %I&IU(1F@!!UIU)MI: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHY9A$.
M: )*KW%RL/.:SKS6TA!^;%<SJOB90K8:M8TY2,I5(Q-R^U]80?FQ7,ZEXL'S
M#?\ K7):QXD+9PU<C>ZT[,?FKTZ6%ON>=4Q78ZO5O$ADSAOUKD;_ %)Y&/-4
MGOFDZFF9W=:]:G143S9UG(8UP[-UIRL6H\L4Y5Q6^B,!V*7%%%2(**** "BB
MB@ HHHH&@HHHH$%%%% PHHHH&%%%%!%@HHHH&%%%% PHHHH ****!!1110 4
M444 %%%% )A1110 4444 %%%% PHHHH$%%%% PHHHH"X4444""BBB@ HHHH
M****!A1110(****!W"BBB@+A1110(****!A1110 4444""BBB@D****"PHHH
MH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110,****!!1110,****
M!!1110 4444 %%%% !1110 4444 %%%% !1110,****!!1110 4444 %%%%
M!1110 4444 %%%% PHHHH$%%%% PHHHH$%%%% !1110,**** "BBB@04444
M%%%% PHHHH$%%%% PHHHH$%%%% !111058****!!1110(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@04444#"BBB@=PHHHH'N%%%%!%@HHHH&%-
MP:=10 BBEHHH ****!A111038*3@TM,H+0IQ29QTI:,4AD32,IXJS:7SQL.3
M431@TW;MIW3T8OA9V&DZ\T.W+5V&E^+ N 7KR);AH^AJU;:J\;=:Y:F'4M3I
MIUW$]_T_Q&LP W5T%G>+,HYKPC1_$+(RY:N]T7Q(&5<M7C5L.X['KTJZD>C4
M5CV.M)*HYS5J35(XUR2*X>5H[.9%ZL[5-4CLHR2V#6)K'C6&RC;YP*\B\:?%
M2-5D E_6NBEAYU'L8U*\(+<[?Q!\1H['</- Q[UY%XP^+R[7 F_6O(O&WQ,>
M1GVRG\Z\?USQI/<LW[P_G7TV%RN^K/GL1F%M$ST;QE\1I+POMES^->2:QXBG
MGD;YS^=4)-5DN6^8FHF02'FOJ*-"-)6L?.U:\JC*[7TTC<DFK$;%AS2BW [5
M(L86NEV.?E#8,4NT>E+14E,#TI,4M%!(4OUHI1U-(:U$Q24_M3*H&%%%%(04
M444@"BBBF 4444 %%%%%@"BBBF 4444 %%%%) %%%%# ****D HHHJP"BBB@
M HHHHN 4444/4 HHHI %%%%, HHHI@%%%%2 4444P"BBBF 4444@"BBB@ HH
MHJ0"BBB@ HHHI[@%%%%*P!1110@"BBB@ HHHIH84444""BBBDP"BBB@ HHHH
M ****H HHHH ****$AA1110(**** "BBBDP"BBBD 4444 %%%%4 4444K %%
M%%.^@PHHHJ1!1115 %%%% !1111>PPHHHH$%%%% !1114@%%%%4 4444 %%%
M% !1110 4444K %%%%( HHHI@%%%% !1110 4444-@%%%%" ****+ %%%%)@
M%%%%- %%%% !1114W ****I %%%%4@"BBBDP"BBBI **** "BBBF@"BBBD 4
M444, HHHHL 4444[ %%%%, HHHJ0"BBB@ HHHJ0"BBBJ ****:8!1114O<84
M4452$%%%%, HHHI6 *<M-HI@.IM+25+$%-;%.IM!2$VCTJ.0E>E3+3C&#34A
MN-RC]LFCZ$UK:/KUQ;R [SQ[U4-NI[4SRQ'G%.48S5F*-XNY[/X-^(TEFR;I
M2/QKW+PK\8E54!F[>M?$\>IR6[?*2*V]+\8W%NZ_.1^->1B,NC4U/3HXZ5/0
M_13P[\4([O:/-S^->B:/XBCOE7YP<U^?'A'XD2PLFZ4C\:]X\%_%5<(&E_6O
ME\5E[I_"CZ3#8Y3^(^K58, 1R*6O./#WQ$AND4>8#^-=M8ZQ%> 8(KPI4Y0W
M/8C.,MC1HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***3- !37D6/K3)KE(E))KGM6UQ8PV&JHQ<GH3*2BM
M3:GU2.%>M<WJWB)5#8;]:Y+5O%17< ]<AJ'B5I"?FKT:>%;."IB4M$='K'B8
M\X:N2OM>:3/S5F7-\TV><U2;+=Z]:E14=SR:E9RV+$UXTK<FJK+N.:4)3]M=
MFB.?5[D7EU(J]*=BC%*X"TE/I&J1#*=2;:6J ****0!12-24 .HHHH ****
M"BBB@04444#"BBB@84444""BBB@ HHHH **** "BBB@84444""BBB@:"BBB@
M HHHH&@HHHH$%%%% !1110 4444""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ****!A1110 4444""BBB@ HHHH$%%%% PHHHH ****!H****
M84444 @HHHH!A1110(**** "BBB@84444""BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH&%%%% @HHHH&%%%% @HHHH&%%%% !1110 4444""BBB@
M HHHH&%%%% !1110(**** "BBB@ HHHH*04444$A1110 4444#"BBB@04444
M %%%% !1110 4444 %%%% !1110,****!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 T%%%% !1110 4444 %%%% !11105<*5:2B@D?3*7=24#
M"BBB@0444&@:"BFT"F IIIYIQI*BP##'F@1XJ3;1M-:("2&9HR,&MW3M6>/'
M-8'"]:=]M2%<YK*<%(UC)Q/0K'Q480-SU'K'Q 2"$_O,<>M>3ZQXL6S1L/C\
M:\Q\4?$9OF42_K7']54I'6J[Y3T#QQ\4F <++^M>%^)/B'-<R/\ O#^=8>M>
M)GOV;YR<^]<M<J\S$YKZ;"82$8W9\YBL1-RLB[J&M/>,26S68T7G<TY;9A4T
M:;:]96CHCSKN6Y MMMJ94Q4M,:F/0**0-2U# **;FG+3$%%%%2 4N:2BBX"Y
MI***H HHHH$@HHI#UIC%HI%I] #:*4]:2D 4444 %%%%, HHHHN,****0@HH
MHI7 ****8!1110P"BBBD 4444( HHHJ@"BBBAZ %%%%*X!1113 ****3 ***
M*$ 4444P"BBBAH84445*$%%%% !1113 ****8!1112N 4444K@%%%%/< HHH
MH ****5P"BBBD 44455QA1110(****& 4444@"BBBF 4444K@%%%%.X!1113
M ****: ****A@%%%% !1115 %%%% !1112 ****3 ****$ 4444V 4444 %%
M%%.]@"BBBE<84444""BBBF 4444 %%%%)@%%%%( HHHJ@"BBB@ HHHI %%%%
M, HHHJ6 4444UH,****8@HHHH ****FP!1115 %%%%*P!1110@"BBB@ HHHH
M **** "BBBI ****I %%%%58 HHHI %%%% !1110 4444P"BBBD 4445(!11
M10 4444P"BBB@ HHHH ****8!1114@%%%%, HIU#4P&T445-P"BBBF 4N324
M4ABTUEW4M+30%9[<-2);[6!JRS4VJN(L6^H/:8PU=+HOCJ:U=?WA'XUQLL9;
MI44<+(V<UE*G&:U*C.47H?27@WXHR*R R_K7OW@OXGQR*FZ7]:^"M+U22S((
M8C%=IHOQ(EL64>:1CWKP\3ERJ:I'LX?'.GN?I!H_C:VO(U!<'\:Z&WU&&X^Z
MU?"W@_XQ.60&;]:]]\$_$=+P1[I<_C7RF(P,Z6Q])0QT:I[M25E:3KL%]"OS
MC-:BR*W1@:\KE:W/333V'444AS2&+13>:4=* %HHHI@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH&%%%% @HHHH **** "BBB@ HHHH&%%%% @HHHH **** "BBB@ HHHH
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M44 %%%%, HHHH **** "BBBE< HHHI@%%%% !1112L 44447 ****8!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A- "T4FZEH ***
M* "BBB@ I*&8*,FLO4-26%3S32;$W8OS7"1*237.ZMKBPYPU8FK^*!&&&ZN'
MUCQ,92<-792P[D]3CJ5U$W-8\58W#?7':GKS39^:L?4-2>4GFLQI68U[5/#J
M)Y%2NY%BZG:8DYJL%-/7WIQQ7:ERG+N"U)3%Z4\=*&#T"F[J=3<4A"YI:3;2
MTR0HHHJ1BK010#1FFP$HI>/6DI( HHHI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444#"BBB@04444 %%%% @HHHH&%%%% !1110 4444 %
M%%% !1110 4444#"BBB@EA1110,**** "BBB@ HHHH*"BBB@ HHHH$%%%% @
MHHHH **** "BBB@>H4444""BBEH$Q**4X[4E!2"BBB@04444#"BBB@04444
M%%%% !1110.P4444""BBB@ HHHH **** "BBB@:"BBB@&%%%% @HHHH&%%%%
M ,****!6"BBB@ HHHH **** "BBB@84444""BBB@ HHHH **** "BBB@H***
M*!,****!!1110 4444#"BBB@ HHI:!,2BE/M24 %%%% !1110 4444 %%%%
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M458!1114@%%%% @HHHI@%%%%2 4444( HHHI@%%%%" ****8!1114@%%%%,
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M%0JH]#IM,M[A+B,,IS4U<9V#*<*0THZ4#%HI-U)NH$.HI-U+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% !1110 4444 %%%% @HHHH&@HHHH'8****!A11102%%%% !1110
M4444 %%%% !1110-!1110,****"0HHHH&%)M%+10(;2K1MI<8H&%%%(<]J!B
M]:38:?'[U,Q15R:H9$K"->:BN-2CB4Y-9^K:M';HWS5YUXA\:"#< _ZUFPBK
MG4:_XH2!6P]>5^)O&QRX#_K7-^(?&S3%@'K@M2UA[IC\V:5SKC3-;5_$K7+'
MYZYBZN&G;K4#NS-UI4!SS4G0E89Y)-31KMIPI:0PII:@M3">:!CUIU,4T^D
MRG"C;13$+11102%%%%!84 XHHH$Q=U)110)";112T4#"BBBF#"FE:=12 CVD
M5)'(5I",TTBI&:$-S[U?AE#8K"1BM6H;K;WKIIUG Y:E&,S=7!IDBYJG#=Y[
MU=B82"O8HXGFW/$KX5K5%=E--JX\8QFJT@Q7IQ:D>5).+U&TE%% EJ%%%%+8
M84444Q!1113 ****E@%%%%- %%%% !1112 ****& 4444P"BBB@ HHHI( HH
MHIW ****0!1113 ****0!1115 %%%% !1110 4445(!1115 %%%%2 4444T
M4444#"BBB@04444: %%%% !1111N 4444 %%%% !1112 ****H HHHI7 ***
M*8!11128!1114H HHHJ]@"BBBI ****H HHHH ****FX!1115 %%%%, HHHI
M2&%%%%3<04444TP"BBBF 4444@"BBBBUQA11136@!1111< HHHIB"BBBH **
M**8!1113 ****0!1111N 4444]@"BBBD 4444( HHHI@%%%%2 4444T 4444
MP"BBBH ****JV@!1112 **** "BBB@ HHHH ****=P"BBBF 4444F 4445*N
M,****H04444@"BBBF 4444 %%%%2 4444P"BBBFP"BBBD 4444P"BBB@ HHH
MHN 4444 %%%% !1111< HHHI@%%%%2 4445: ****3 ****D HHHJ@"BBBI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@%%%%" ****H HHHJ0"BBBJ **** "BBB@ HHHJ;@%%%%, HHHII@%%%%)L
MHHHI %%%%, HHHH ****FX!11130!1115 %%%%)@%%%%2 44450!1113 ***
M* "BBBDQA1112$%%%%4 4444 %%%%38 HHHH ****: ****8!1114V ****:
M0!1110P"BBBD 44450!1111N 4444K %%%%, HHHH ****3 ****D HHHH0!
M1115H HHHI,84444(04444 %%%%, HHHI %%%%( HHHI@%%%%, HHHI@%%%%
M( HHHH **** "BBB@ HHHJ0"BBBF@"BBBF 4444P"BBBD 4444 %%%% !111
M4@%%%%, HHHI@%%%% !112T )11128!11120!1110 4444 %%%%4 4444K %
M%%%4@"BBBE8 HHHH **** "BBBDP"BBBD 4444P"BBB@ HHHJ0&[33EHHJ@"
MBBBF HI13:7)HV'<7;3"HI:* *LY*]*DLM2FMW!#$5(8PU1O"!S3NGHP5UJ>
MB^#_ !Q+9R)F0C\:^@O ?Q:\KRU:;]:^-H[IK<Y!Q6]HGBR:UF7#G\Z\O%8&
M-572/0P^,E3=KGZ5>%_B)'J$<8\S/XUZ)8WB7D(93FO@'X?_ !/>!HP\OZU]
M+^!_B='<1H#+G\:^(Q6"E2>B/KL-C(U%JSW&BL72?$$>H*"&!S6SUKRFK:,]
M--/8*6BBD,**** "BBB@ HHHH *3-+36H 7=2TRGT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%(U-S0 ^BBB@ HHI&H 6BF9IU "TAYI:3('6@ ^Z*K7%\D*GGFH-1
MU!((SS7#:[XD$>X!JUA3<V93J*!LZUKZHIPU><:]XC+,P#?K5'5O$;2;ANKE
M;N\:X<\U[-'"VU9Y%;$WT1+>:HTSGFJ39DYIGEDMFIE6O6BE%:'EMN3U(Q'3
MU7FBG+3;'T%HHHJ1!1110 4444 %%%% !11105<****!!1110%@HHHH$%%%%
M !1110 4444#"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*3 **** "BBBA@%%%%"0!1113 ****0!1113 ****5@"BBBJ **** "BBBI
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M**$ 4444 %%%%- %%%% !1110 4444P"BBBI ****H HHHJ@"BBBLP"BBBJ
M**** "BBB@ HHHJ "BBBF 4444P"BBBA %%%%, HHHJ "BBBJN 44447 ***
M*0!1113 ****0!1115 %%%% !1111< HHHI %%%%( HHHJK@%%%%( HHHI %
M%%%.P!1110,****!!1113 ****3 ****$ 4444F 4444( HHHI@%%%%%@"BB
MB@ HHHI@%%%%38 HHHJ@"BBBI ****: ****0!1115 %%%%2 4444V 4444@
M"BBBJ **** "BBBI ****H HHHH ****8!1110 4445 !1113 ****8!1113
M8!1114 %%%%- %%%%( HHHI@%%%%, HHHJ;#"BBBJ$%%%% !1110 4444 %%
M%%2 4444QA1110D 44453$%%%%2 4444 %%%%.X!1114@%%%%, HHHH8!111
M4( IP--HJQCMU&ZFT4(8M"^E)2T!<=56X4]JL4FW=5)V%N489)(6R#CFNO\
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M130!1110 4444K %%%%, HHHI@%%%% !1110 44446&%%%% @HHHJ0"BBBJ
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M825%GUV&Q4:R/4J*K6M]'=1@JW)JS7FGHA1112 ****8!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*8!1110 4444@"BBBF 4444@"BBB@ HHHH ****$ 4444K#"BBBGN(****+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH ****"@HHHH)"BBB@ HHHH ****!(****!=0HHHH&PHHHH*04444 %%%%
M@HHHH ****!H**** "BBB@$%%%% =0HHHH!A1110%@HHHH$%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110)A1110 4444%!1110 4N:2B@D****#3
MH%%%%! 4444 %%%% !1110 4444 %%%% @HHHH ****0(**4=:>M,H:%-31R
M"/DTC2(JY)KFM>UY+-&PV*125S0US7([:)OF'2O'?&7C0+O"R53\7>._OJ)/
MUKR37-?>]=OFSFE<Z80)];\2/=2-\]<M<S&9LYJ-V9W.:=MJ&=25AJI4RKMI
MHJ2D.P4444 %%%% !1110,****!!1110%PHHHH&%%%% !1110 4444 %%%%
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MS]*L_P#"OAC_ %?Z5\S+C7#0=KGJ1R"K+6QX2VCR_P!TU&VERKV->[2?#_\
MV/TJA<^ ]O\ !^E;TN,L-5=N8F6158=#Q<6$B]J=Y#+U%>G7G@TQ@_)^E<YJ
M7A]X<X6OI,-FU'%;2/-JY?4I;HY/.VG;AZU+>6,D;'BJ@C<=:]I*,E=,\^5X
MZ6)LBBHAGO4BFH<;"O<=24X=*;0F.PY:&H%(:&,2BBBI)"BBBJ$%%%%2 444
M4P"BBBF 4444 %%%%( HHHH ****!A1113$%%%% !1110 4444 %%%% !2TE
M% !1113N,****0@HHHJ=1A1115""BBBD 4444P"BBB@ HHHI, HHHH0!1110
M 4444@"BBB@ HHHH ****H HHHI7 ****8!1112N 4444P"BBB@ IVZFT4KC
M%9=U020U.#2M3!ZD5K(ULP(/2NW\*^.)-.F0>81@^M</(N15:/?')D&LJE.-
M1694)NF]#[3^&7Q4\SRE:7]:^E_"?BZ&_MT!<'(K\S/"?BN72Y4^<C'O7T5\
M._BN5\M6E_6OD<=ES^*)]1@\?]F1]K1S)(,JV:DKS/P?XXCU"-,R9S[UZ+:W
M:7,8*G-?*SBX.S/I8R4U=$U&!2TE06)WIU)WZ4M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1137<(N30 ,P49-8^J:H(5/--U3
M5EA4\XKS_P 0^(Q\P#5T4J+FSGJ55!$WB#Q)M# -^M>=ZOK+3LV&[U#JVKM,
MQPU8OF&1N:^@HT%!7/"K5G-V$DD:1^:>J]*>(Q3L5UG+811BEHHH$%*M)10
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M<.:=Y>:%%2+BOY'I8YX/&.2/U65%5J*3(C#2K'BILB@8-?92XSKPCRQ9XO\
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M1110 4444 %%%% !1110-!1110#"BBB@04444 %%%% !1110 4444#04444
M%%%% @HHHH&%%%% @HHHH **** "BBB@ HHHI%6"E49I56I$CH$-"XJ.XF6)
M22<4MW((5)S7&>(_$BVT;C?3*C&Y9USQ*MHC?-BO(_&'C0OO ?\ 6L[Q;XR+
M,P5Z\OU;6GNI#\Q-9R.J$!=<UB2ZD;YL_C6+'(S-S4F?,Y-/6,"I.JV@*M./
M2EI&H ;3Z93J!BT4E% "T444$A11104%%%% !1110*P4444 %%%% D%%%%!0
M4444!<**** "BBB@ HHHH **** "BBB@ HHHH$%%%% PHHHH **** "BBB@
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M^H+>1@@YKXVI3E3=F?64ZBJ*Z+E+1161L%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444#"BBB@5@HHHH*L%%%%!(4444#2"BBB@ HHHH$%%%% PHHHH ****
M"BBB@04444#"BBB@ HHHH!L**** "BDI,T ]!U%)2T$H****!A1110 4444"
M"DZTM%(:$VTJ_+1156N(GCFV]ZO07&<<UDYQ4D<VWO54ZCILQG34UJ;RR!J&
M7-4+>XZ5?C8,*]RAB>;1GB8C#<NJ(=II*G=>.*AQ7HWN>/L]1=M(1BEI":9=
MA****HD****+W ****!!1114L HHHIH HHHH **** "BBBF 4444K %%%%(
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M,^OIU%45T:M%%)6)J+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10,****!!1110(****!W"BBB@H****!!1110-.X4444 %%%% @HHHH ****
M"BBB@ HHHH **** "BBB@74****!A1110 4444""BBB@8AI-M.HH$Q*6BB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10*P4444#"BBB@ HHHH **** "BBB@7+<***:U UH.HIE% /4?1110 4444
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M7P]:C*D[,^QHUE45T:]%)UHVUS'0+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<:3;0,=36IU)B@!N:5:7:*,4"%HHHH*04444"84444"04444#"BBB@ HHHH
M**** "BBB@ HHHH ****"1NZE!I-M*!B@JPM%%% @HHHH ****!A1110 444
M4 %%%% !1110 AI-QI6I-II@+2TE+4LD3%(:=36JEJ@3'QR;36C;7'O654L,
MA4T0DXO052*FCH(W# 4LD=9]O<]*O1R!Z]W#XB^C/G<3A;:HA930!4[1U$PV
MUZJU5T>5JM&)VIC4N:1A2!ADTM)@TM,04444 %%%% !1110 4444 %%%% !1
M112 ****0!1113 ****0!11138!1112N 4444 %%%%4 4444 %%%%0 4444T
M 44450!1115 %%%%18 HHHI %%%%4 4444 %%%%( HHHI %%%%5J,****D04
M444] "BBBF 4444@"BBB@ HHHI6 ****8!11118 HHHI@%%%% !11128!111
M2 ****8!1114@%%%%6 4445(!1115 %%%%2 4444 %%%% !1113Z %%%%" *
M85SS3Z*.I;U0L,QA8$&NM\-Z\8I$&ZN,DJ6RN&AD'-<^+PT,32<&BZ%:5&=T
M?2GA+Q$L@0%Z])L-06:,8.:^7_#'B0PLH+5[!X9\3"94!:OY<XQX2DI2JPB?
MK.2YM&249,]-X;FHVJOI]ZDT8.:N'#=*_GFM1GA:CC-'Z'&<:JNB G%*&I9%
MIM$7=7"P^BF@TZJ ****"10M!% Z4'I5:#$HHHJ1!2K3=U"M3&/IRG%1Y-%2
MXJ0$V0U4KRT693Q5@4_BJISEAY<T&$H*HK,XW5O#*W"M\F:\\\1>#<;B$_2O
M=I(D9>16)JFD)<*WRU^F9!Q=6PE1*<M#YG'Y1"M%M(^6]<\/O S87%<I<6<D
M;=#7TAKW@\3;L)7G6N>#C'N.S]*_J+(^+,/CJ:C?4_+,?D]2E)M(\L&5/-2J
MU:6J:2]LQ^7%8IW*V,5^@4Y*JN:+/F)1=-V99#4[-0QDXJ4=*IHJX4N:2BIU
M)%S28HHI""BBBF 4M)2TP#=11MHH 2BBBGH,****FX@HHHH **** "BBBD 4
M4450!1110VAA1110(****E@%%%%'0 HHHI( HHHIL HHHH0!1112 ****8!1
M115 %%%%( HHHH ****0!1110 4444P"BBBI ****H HHHJ0"BBBG< HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCO+H(MHA[59BTU&'2HE)JY!.%7FKM2[&3=;HS-U*WCM8R2!7G/BKQ)%9*XW
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M!J6H/<2GFH(5W=:<L>_FIHT"BD=" *%I:5J2D,**** "G+TIM% #FZ4VBB@
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M?EU1&5Q25,RU'C!KU-]4>0U83;3:=NIM0@"EVFDI]6,;BDIS=*;4W)"BBB@
MHHHHZ %%%%" ****H HHHH ****FX!1113 **** "BBBI ****$@"BBBJ **
M** "BBBDP"BBBDF 44452 ****+@%%%%.]QA1112L(**** "BBBJ&%%%%(04
M444 %%%%4,****D04444K %%%%( HHHH **** "BBBF 4444 %%%%, HHHH
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M5?KQ3P'X^2[BC!DS^->NZ;J"WD((.37PU2G*F[,^PIU%45T7J***R-@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 44Y:* &T445(!1113 ****0!1115 %%%%( HHHI %%%% !1115
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M@U\74INF[,^OIU%45T6NYI:**Q-0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_2O,;J0V,Y XYKZFG-58V/GZD73D?5'P[\9;O+4O^M>_^'=26\B4[L\5\*>
M_$CQ3(-W>OJ;X=^)A)%&"_ZUX6-P[B[H]/"UKZ,]H:,>7FJ;=Z=:WJW$(P<T
M]H^IKQ5IN>QT(J*&^6BF9A112-04&ZEIHZTZ@D****0PHHHIB"BBB@ HHHH
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M$::U2.M-P:] \T:HI:7!HQ4E"44455P"BBBD(****5@"BBBF 4444@"BBBI
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MBI$%%%%, HHHH0!1113 ****D HHHH ****8!11138PHHHJ1!1110 44447
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUZNL4=.&7UICE>U<ZFN!B/FJ[!?";'-$,=1J:19-3+:]+62-#BE9@HYXJ#S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!,4UY @YIQ.*QM7U$0JW.*J*YG83=D1ZYJJPQM@XXKRSQ+KQ9G
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M"BBB@84444 %%%% @HHHH&%%%% 6"BBB@04444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHJD 44453 ****FX!1113 ****D HHHI@%%%% !1113 ****0!1114@%%%%
M!11157 **** "BBBGH,****8@HHHI %%%% !1112 ****KH,****E""BBBF
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M6 44447&%%%% @HHHI %%%%4 4445%P"BBBJN,****!!1113 **** "BBB@
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ML=2CO(U*G)(KX&M2=.33/N*%55(W+;=:2GT5SG2%%%% !1110 4444 %%%%
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M45V1Q4CG^KH^8-2^'>T'$?Z5Q^K>!73.(_TKZXO/"\<H^Y^E8%]X"2;/[O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#()D#"OC)1<79GUT9*2NARTM%(*@L6BBB@ HHINXT .HI%I: "BBB@ HHHH
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M1A11128@HHHH ****: ****+ %%%%-L84445*$%%%%4 4444 %%%% !1110
M4444@' T$TVB@ J.9=RU)1C-" IQ9AD##BNY\(>+7T^9!OQ@^M<?)& I-4EN
M'MY@0:F=-559A&3INZ/M_P"%OQ"\[RE,GZU]->%]:2\ME^;/%?FO\/?&3V,T
M8+XY]:^N?AA\0EN(XE,F?QKXC,L$X.\4?7Y?C%)6D?28.>10*S=#OQ?6X8'/
M%:=?,VMN?27N%)2TC=* #=28I*<O2@ 6EHHH *2EII% #J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD:@!:*9DTZ@
M!:*** "D)Q2U2U"Z%O&>>:>XF[%;5]06&(\XKROQ5KQRX#5M^)M>VA@&KR_6
M;\W#MS7K8:A?5GEXBOT10OM0::0\YJMMW5$5);-6%^[7N)<JLCQWJ]1HXI:7
M%)MIH0ZBD I:&*X4444A+4**** 84444"04444#>@4444 M0HHHH!Z!1110
M4444#"BBB@04444 %%%% [!1110(****!A1110(**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1[9EKT[1-4+( 37(:?HAX(%=%9VK6N.*X*MI,[:5XH[:VF$BCFK#5SUC?;<
MFMRWD\P"N.2L=47<DI,T]EI@%06+11102%%%%(84444Q!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% PHHHH$%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110/4**** N%%%% @HHHH&@HHHH!A1110(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@:"BBB@04444 %%%% !0M!I\/S4#
MU%3Y:AU"^6&%N:DO'$,9.:\\\6^)1:HXWXH+C&Y@^.O$ C60!J\(\1ZVTTSC
M=71>+O$QN9' :O.+R8S2$U#9VPC85W,S9IT:[:;"ORU+4&PI-)110 44<44Q
MA24M%(D*2EHI(:&%: OX4\C%,+&K2N2Y6' 8JK</MJ;<?>J-VQJU!D.:9N>'
ME\Z91[U]"_#'0EG>(E<]*^>_"7-RF?6OJOX2(G[G/M7%B=$=%*USWOPKX:B6
MQ7*=JYSXBZ'&+63Y.U>G>'5C%BO/:N/^(FS[+)SVKPHM\QZ3MRGQ3\0M+$=S
M+@=Z\NO8Q&QKVCXF,JS2FO$-6N@LC5]!1A*:T/)J5(Q>I#&V&K<T.^$=PN3W
MKE8[H-WJ[9W!692#WK:5.4=R8U(RV/K3X/ZU&)(037V+X'U"&:S09&<5^=OP
MU\0&TECRV*^IO!/Q$6"W0&7'XUYM:%S1,]C^(45O+8OTSBOB;XS6B"6; [FO
MH;Q9\18[BT<>:.GK7S!\4->2]>7#9S2H1LPD[G@.J1;;MOK5*;.WBM+4/WET
M2/6I[72VNL?+7IJM&C[TB;.6B'^$=_VI/K7TMX"A:6V0$=J\A\(>$V\Y#M[U
M[_X.TT6<29&.*_$>.LTHUHM0W/J\GPTN8MZIX76\BY6N6D\"1K(6V5Z=<7T,
M4."1TKG+[6H%S\PK\9P.<8NFN2&Q]W4R-UH\]CG(=(BT\= ,5F:YJD4,+ $=
M*DU[Q"BJVUJ\Q\1>(&D+ -7Z+E&"JX^HIU#Y?&TW@TXV,?Q??+.SX-><74A6
M4FNAU*\:9CDYKG[J(LQXK^B,IPWU>FHGY]C*W.[HKM?%.].BU#<1S5.>!N:K
M#=&U?5JA"<3YN6(J0EJ=/;W <"K617,V]\4[UH0ZAN[UY%;"RC+0]BCBHN.I
MK8%-J".X##K4P;BN1QY=SM4N;84&EIN*=4&@4444"U"BBB@&%%%% @HHHH&@
MHHHH$%%%% T%%%% PHHHH **** "BBB@ HHHH **** "BBB@5PHHHH&%%%%
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M552-T7BM+117.= $4@%.HH 2DW4M-H <*6D6EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH :U"]:6B@!:*** $K.U*_$$;<U
M<N+A88R<UP/BC6O+5@&K6G!S9G4GRHR?%&N!MP#5YAJUZ9I&YK1UK5C-(W-8
M$G[PYKZ3#TU!'S]>IS,;'\U3;=M,C7;3\UUMG%8*5>M)12&/IK=:3-%!0444
M4"84444""BBB@ HHHH&%%%% @HHHH ****!A1110(**** "BBB@ HHHH ***
M*"@HHHH):"BBB@84444""BBB@ HHHH **** "BBB@=@HHHH$%%%% !1110 Y
M:1OF!I*%ZTBC)U:V\R-N*\M\6:>?GXKV2XA#QGO7&>(M'\Y6P*[\/4Y6<=>G
MS(^>=7M3'(W%9#0EN*]*\0>'6WM\M<W_ &&1)C;7T,:J:/GI4W&1C:1I;23
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP[&MZ/2V;M5B/0V;^&M%E]:L+^U:&'ZG+".0^M/6W<]J["+PX6_AJY%X8/\
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M HHHH)"BBB@ HHHH **** "BBB@ HHHH*"BBB@D**** "BBB@ HHHH$%%%%
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M4F:8#J*0&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M14L HHHH ****8!1110 4444 %%%%*P!1110 4444;@%%%%( HHHJD 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIWKZQ^'OC07T<2[\\#O7YUZ#KCVETF&QS7TU\(/&)\R(,_ZU\UF.$37,CZ'
MXEIJ)]O6,XN+=6'I5BN3\(:XEU9QC=DXKJU8,,BOAY+E=C["+NKBT445)044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)4\T26K52N+=E4YJ8J)4I,P]:N"X/-<=>#+&NJU9",YKE;QL-7I4]CSYMR9
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M/EKAJ5^4ZH4KGGLN@E%/RUEW.GF//%>MW6BJ8S\M<CK.D[,X%33K<S+G1T.
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)QUH @O)?+
MCS7$>(=:\I6&ZNBUV_$<;<UY)XHU8EV :NS#TN=G%B*G*C(U[4_.9N:Y64[F
MJ>YNC+(><U#C-?10CR*QX$Y<SN*M24P<4^M#,****5@"BBBJ ****!!1110,
M**** "BBB@=@HHHH$%%%% !1110 4444 %%%% PHHHH ****!!1110,****
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MN@M]+$('RU]]EO#JI6<D?F6<<5.M=09E6.A*JCY:V+?3EC'2K<:",=*=OK]
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MLISFOSJO3=.;1]W0GSPN2T445SG0%%%% !1110 4444 %%%% !1110 4444
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MK5.=CHJFQ4<?%2;JW.?H(U-VTXFDI$A1112$@HHHIHH****;!A1112 ****
M"BBB@04444 %%%% !1110 4444 %%%% PHHHH$%%%% @HHHH&%%%% !1110,
M**** "BBB@04444 %%%% (****!A1110(**** "BBB@ HHHH ****!A1110(
M*4&DHH 7---+12L4M!,=*<*2EH6A%KDBM@4V3#K3>:%JF[CY4C-O-+6X!XKG
MM0\))-GY*[A0.].94;J*I5)1V(]FI;GCVI>!QR0GZ5RFJ>#S%G"?I7T!<V<<
M@/%8.H:"DV[Y:[:6*DMSGJ8:-M#YQU'0GASA:Y^XLY8R>#7T'JG@\29PE<EJ
M7@<C/R5Z]/%19Y%3"RZ'CWERJW.:GB:16'-=K?>$VB8_)6:^@LK?=KM552./
MV+B5=.U*2 CYC7;Z#XH>-E!?]:Y(:)(.BU9M[&6W(."*YJRC)'52E*)[;H/B
M,3!06KN;&\2:('-?/FD:I):NH)(KT+1?$O[H M7@U:&MT>Q3K:69WFI:DMO&
M3FO)O'GBX1I(H?MZUJ^)?$P6W8[NU?/OCWQ47DD&^M\-AN9W,ZU;E1SGCGQ,
MT[R8?]:\VAU25[X?,>M7=4OFO';G.:I:;IKR72G'>OIXTU"!X;J.4CWGX47+
MR20Y-?7'@J8K:1GVKY1^%.FO&T.17U3X34QVB#VKY;'2]X]["IM7.[M[W:R\
MUT^E7*MC)KSY;@J]:L.M?9HLYQ7S]2GS;'LTYVW/3/M4$<))(%<3XL\5V]C&
M^' Q[UPWBCXE?V?"X$F,>]?/GQ ^,$LGF*)3^=&'P<ZDC2KBHQB=[XX^*B6[
M.%FQ^->1:I\7"TK?OOUKQ[Q5XYN;^1\.QR?6N&FU.\FD)RU?8X; QBM3YC$8
MIR>A](VOQ5W-_KOUK9M_B<& _>_K7RM#J5Y&W):M*'Q#<ICYFKM>"@S@^L31
M]0K\2@W_ "U_6IH_B,&_Y:?K7S+'XHGX^8U9C\52C^(_G6,L#$WCBI=3Z=@^
M(0;_ ):?K6E:^.%D8?O/UKY=M_%\B_QG\ZU;/QPT;#,GZUB\&7]:/K/2O%$<
MV,O^M==I^KPR*/F%?(>E_$KR<?O/UKL])^*R\?O?UKCJ8.70ZZ>)74^GENXF
M'!%1R2*>AKQG2?B6EQ@&3]:[/2_%4=UM^?\ 6O/E1E#<[8U8R.N[U9MF]15"
MRNXYE!S6I$%*\5DM[&DW[NA!J%TL,9S7G/BC6%^89KLO$#%8VQ7D7B:1O,;F
MOS_B7$O#P?*?I_!^#CB9KF.:UK;>,W&:Y&\\-K,Q^7]*ZC)9^:G6-3CBOQAY
MQ7A*\6?T"LDP\XV:.!?P6).B?I67J/@4JA(C_2O9M/T]9FZ5NKX02[C^Y^E?
MK/#.;XBNTI,_$^+LGPV%3<$?(FN>%98=V$/Y5QM[I$T;'@U]EZ[\,1,K$1?I
M7F^O?"\Q[CY7Z5^W4L0G'4_ :U%J6A\U/92J>0:?'&\9ZUZ9KG@M[4M^[Z5Q
M>HZ7);DC;71&=S)P&:?J3VC [L5WGAGX@/9R(/,QSZUY7<K*@. :JVT]Q',"
M,]:IQYEJ2KQ9]I>!_B/]H\M3+G\:]L\/ZZM[&IW9S7P9X)UZXMYH\L>M?4'P
MU\1/.L09J\C$4>75'I4:O<]ZA_> $5/]VJVCW"26ZDFB^OXHC]X5\OC<##&1
M<9GM4:[IN\2UNW"FN.*H6^H))QNJ[Y@9>#7P*X3HPK^T2/=_M6;I\K8FW=4-
MQ\JFIUJ.=-RU^@83#+#P44>%.I[1W9RFO:BUM&QSTKR;Q/X\>R=OWF/QKU3Q
M59L]N^!VKYN^)%C/&TA7-?386$9/4\;$2<=C2A^*K"8 R]_6O0/"_P 0ENMN
M9,_C7R!?7-U:W1Y/!KI_#?C*:S9=SD?C7K5,'&4=#SHXB47J?=NA^((;E5^8
M&ND6ZBD7@U\E^%?B<5V R_K7K7A_Q^EVJ@R?K7A5<+*#/6IXA21ZG)ANE-7<
MK5FZ7K$5TJG<*VT,;KUK@>FC.R+N)'=,O>A[PGO4<RCM59LT615R624M41[4
MW)IZ\T[6%<6G44I&*5R!*5:2E!H&+@4VG9%-IB"BBBD 4444#"BBB@04444
M%%%% !1110 4444!<****"@HHHH$%%%% @HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@:"BBB@84444$A1110 4444 %%%% !1110 4444
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M>'3_ ':GM=",;#Y:BOQ%1G1<4R\/PQ7IUE*QHZ&A55KI5^Z*R["U\H#BM,'
MK\3S.LJU9R1^^932>'H*+#UI=HI :7=7EGJL!PU,N/\ 5FG9YILGS+BB/Q)E
MW]QHY'7(RVZN)OK=MYXKTV^L?.SQ6'<:#N8G;7ZSD>;TL+!*3/Q;B#):N+JN
M44<)]G;TI5M6]*[/_A'S_=IR^'_]FOK'Q%1[GQZX7K]CC5M6]*7[*WH:[/\
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M1< HHHH&%%%%,04445(!1115( HHHI@%%%% !1110 4445(PHHHIW$%%%%,
MHHHJ0"BBBF@"BBBF 444M,!****3 ****D HHHII %%%%, HHHI %%%%!044
M4NVF2)12D8I*!A2;:6BD(,8HHHI %%%%4 I--:EI&I7&F,.:/F]:>:6J$[C1
MNI>:-U+4#W"BG;:0T!82BDW4M5<6H4F*6BBX!112T )13MM(U,=A****8!11
M168@HHI1188E/%)MHSB@+ U-H9J3=3"PM%%% @HHHH ****:&!HHHI %%%%
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MM93+@XYKZ%^%/C,^;"I?N.]?-YAAN=-GO8#$<C43[ITF\%U$"#GBK]<5\/\
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M\^M<=-"8< BNO\!W AO(S[UG):&B/N;X*Z7%);PY Z"OH-=+MTM?NCI7R_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 UG"CFN8\1:@%C;FM;5+P0H><5YOXFUK(8;JZJ--RD<U:?+$Y+
MQ+J):1L&N1>4R.>:OZM<&9V.:S$'S5]-3BHQ/FZDW*1)BE6AJ09K00_%%%+F
MI)8E%%%, S10:;02.HHHH*"BBB@84444$L**** "BBB@$%%%%!04444""BBB
M@ HHHH ****"@HHHH$%%%%!(4444 %%%% PHHHH&%%%% @HHHH **** "BBB
M@ HHHH ****!A1110 4444#"BBB@04444""BBB@;"BBE% Q**=M%-H$%%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4444#"BBB@ J>W7UJ)5S3O,\O-
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M\PGC#"I:\ ]T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI"<#- #96VH37$^)M2\M6YKI=3O!%&W->7>+-3W%^:Z
M:%/FD<U>?+$Y?7-2\UV&:Y>?]X<U-?71>0\]Z@'(KZBG'D1\[-\[&H-M2TS%
M*M4T9V'4444@L%%%%,D****!A1110%[!1110 4444 %%%% [!1110(**** "
MBBB@ HHHH*N%%%%!+"BBB@04444#"BBB@04444#"BBB@ HHHH*04444"8444
M4""BBB@ HHHH&%%%% @HHHH **** "BBB@=@HHHH$%%%% [!11103<****!A
M1110 4444#"BBB@84444""BBB@04444#L%%%.H#8;5B)-U0[:L0R!%.:3**.
MIW'V:,FO)O'?B80QR+O_ %KO?&&J+! _/8U\R_$GQ,0T@#?K7I82C[1G!BJG
M(M#AO'FM?:WD&[->2741DO,^]=%JFJFZG8%L\U%IVEFZN%.,\U]9"/LXV/G6
MW.1V'P[T<S31Y6OJOX?>'0L,9VUXO\-?#A5XB5KZA\&V(AMTX[5\YCJOO6/<
MPM/2YM6MH+>,8&*L[^U2W'RK54'FOF,;)JDY(]BCK)(D5<FG>72QU(U?S1Q!
MGM?"8EZGZ-@,%3J0*S+49J62HN]?H/">?/')1DSQ,UP?L;M(55H;@&GCI4-P
M2$-?LW1'QM]3.U#5ELU)+8KFY_B!':28,F.?6L[QMJ#V\3X/:OG7QAXRFLYG
M^<CGUKOP^&54XZM?D/K31?BA S#,P_.O1=%^)-L5&95_.OS@L/BM-;S<RGKZ
MUU^E_&V6,J/._6KK94Y;%4L<H[GZ%2>/H)H\+(/SKG]0UX71.ULU\I^'OC$]
MT5!F_6O4?#WC9+U5W/G\:\MX%T=T=?UQ5-#T20-*<]:A-N5J*RUB&51AA5QK
MA9!Q4:K0%KJ5B,4E/9=U-,9JACX6PU6KR;_1S]*IKE33Y"77%3;4KF1Y'\1H
MY)8Y-HKYG\86ERMPYP>M?:.N>'!J$;?+G->3^+/AF)MY$?Z5[.%KJ&C/+KTW
M(^4FU*XL6Y+"M[0?'TEK(H,A_.NG\6_#F2$MMC/Y5YCJ'AJYL9"0K#%>[&4*
MB/)E&4&?0OA'XF!B@:7]:]E\.>/(IHUS(/SKX8TO4KG3Y!DL,5W^@_$*6V*@
MR$?C7#7PBEJCII8AQW/M^R\1Q7 &'%7A<";H<U\T>%?B5YA4-+^M>M^'O&45
MRJY<'\:\.IAY09ZU.O&9Z D7S5::/;%679ZQ%,!AA6@;Q9(\ UR-,Z=&<)XT
M9EA?;7S#\2[>XN&D #5]9Z[I_P!L5N,UYGK_ ,/A>LV4SGVK2#L:1=CXJN/!
M]Q>79RC'GTKT?X??#5C-&6B_2O;K?X2H)LF+]*[SPUX"CL2A\O&/:MI3TT-9
M2T,WP3X#2VBC)CQ^%>K:7I:6<8PN.*-/L4M8P .E7C,%&*YKW.?<5YMG%1-)
MOJ*23=30^*0A[=:2DW9I:+B"BBBF"04444 %%%% !28I:*+C#I3U:F44ADOF
M4QFIM%,:8M)110*X4444""BBB@04444#"BBB@ HHHH ****!!1110 4444 %
M%%% !1110 4444#L%%%% @HHHH **** "BBB@ HHHH ****!A1110(**** "
MBBB@ HHHH **** "BBB@ HHHH&%%%% @HHHH **** "BBB@=PHHHH$%%%% !
M1112&%&>:*3^*J0%J%-PK-U:;[/&QS6G#(%7FN3\7:DL<+\]J3&EJ>?>,_$.
MP.-U>'^)=0^U2/SGFNI\<:T3+( U>:7%T9G.36<CT(1LBH8\R9JRGW:8%YJ2
MI-!:***"@HHHH$%%%% !1110,**** "BBB@ HHHH **** 6H4444 (:!S2-3
MXZI[7(^U8GM(MS#BNHTNP#XXK!L@ PKJ=-N%C45^?YW7J6M _1N'\/2<E*H;
M5O8K&@R*2>01@@5"VI!4ZUF7%_O)YKP,LR'$9A+FF?1YOQ)ALKCR0"^OBN<&
MN=OM2?)YK2N#Y@-9%W:ELU^BX7AR&&7O(_,,5Q14Q;]V1FS7C.3S520>95J2
MS(/2H_)*]J]A8=45:*/$EB)5M9,+7]RP-=GX=\2/9.OS8KC=M2QR-&V<TG=[
M@HKH?06B_$-D@ ,G;UK%\6>/FF4@2?K7E,.NO;IC=^M9.I:\UQ)@M6'LW<WY
MDEJ>C:!=-JU\H)W9-?1/@/X=IJ5O&3'G(]*^;OA:PFOHB>>:^[?A#;1M:P\#
MH*YJTG$J-F<Q>?">*UCW>4!QZ5S5UID>BR] N*^G/$&FK]@)"]J^9/BG<FQ:
M4CBL*=YBE+E.E\+^.(K-E4R ?C6WXF^(%O-I[?O%Z>M?(-]\1)-/NB/,Q@^M
M5-1^+4LUN5\WMZUT^Q=[F?,F>A>*O$4=UJ#;6!YKLOAFXFFC(]:^9+?Q<U]?
M E\\U[_\*=<C0Q%F]*FM=1L:THV9];^'<I8+]*\]^*TY^RR_0UTFB^*H$L%&
M\=*\X^)WB2&:WEPPZ&O(IQ?.>C.7N'Q]\5I/]*E^IKQN:ZV2'FO6/BA<":XE
M(]:\8O WF'%?>9?34DKGQF-JR@W8MQZE^\ZUTFCZ@C,N37 [9-V:TK.\D@QU
MKT,?@85*5HO4X\NQU2C64I+0]HTB^B51R*U+C54$?!KR.Q\2-%C+5ICQ,9%^
M]7XQCN&:E2OSO8_=\#Q92IX?D6C-S6=0,A;!KGFD+M3)M2$W?--20'O7VN6X
M)82DHV/SW,\<\;6<KCFJU9P^<P%4Y9!6QX?7S)EKMQ4O9TG(X::O*QV/A;1"
MTBMMKV/P\/L,"]N*Y'PIIZ[$.*ZN[D^RVYQZ5_/?$&+>-K>R9]G@J:I1YB;7
M/$WDQD;JY:'Q$DUQAF[US?BC6&7=S7#MXF:WF)W=Z];*>&E5H7BM3#$X_EGJ
M>Z2W-O-;Y)%>?>)A"S-MQ7-?\)ZPBV[_ -:RYO$S7DW+=37KY?P_B<)7YGL<
MM;'TZD+(WM'TD7%XN!GFOHWX5>&?]4=M>"^#+A7N$+>M?4WPQO((8XR2*_1X
MMPARL\&2YG='NGAC3%M[1<C'%<S\2)(H[60''2MC_A*H+2SX<=/6O%_BCX^1
MHY5$GZUSQIN4KCY[*Q\[_%Z1&FFQ[UX'<#_2C]:]2\>ZW]OFD^;/->9R1[IB
M:]6G'E1D]2S#]RI*2)?EI:U&,I5I=HI.E(!U%-'6G4#"D Q2T4Q6UN6(9S'W
MJVFI,HZUF4G-<=3"4ZVLD=E/&5*.D6:_]L-_>H_MAO[U8^TT8-<O]ET.QU_V
MKB/YC7&L-_>IXUAO[U8F#2\U/]ET.PO[7Q'<UY-9;^]5BPU9G<?-7-RDU<TO
M/F"LL5EM"-%M(O"YIB)8A)L]+T>X,BBM]?NUS.@_=6NG7[E?S_FT53KM(_I?
M)9NIAE*0RBG45XJ/;8BTV?Y4-/6F77^KJH_&BGI!LYG5KLQYYKE[G5F5NM;F
MO9^:N*O,[S7[7P_@*=:FG)'X%Q-F%6C6:BS3_M=L=:3^V&_O5C\TG-?:_P!E
M4%T/@_[6Q'<VQK#>M+_;#>M88)I232_LNAV+6;8CN;7]L-_>J&74BXZUE9-)
MDT++:,'=(4\SKS5FR::0R=ZK[:?UI:].$5%61Y4KS?,Q%IU)2&G:PF#4+2XH
MIAT%I&I:2@+"+UIZTW%+F@!6I*,T4NH!124F35!<=3'7-.%%(+E9X>:N6*[&
M%1[:>K;*'<D[?0;X0[>:[FW\0*L(&[M7C=OJ1A/!J^OB)@N-WZUQ5*7,SHA/
ME.L\3ZF+A6YKS/48]\Q/O6Q<ZHUP.M9DJ&0UTTH\J,Y2YF5(X]HJ9:>L)]*=
MY)K6Q/0:,=J6E\HTC1M4W$%%)M-+M-,+A11@T5 "'FF^73Z*M.P#/+IZKBEQ
M24^:Y(X]*;1FBIN6@HHHIA<****!A1110,****!!1110(****!A1110.P444
M4""BBB@ HHHH$%%%% AC'!J>UDYJ%EI\/RM1'W7<'[RL;MLP*BI).E9]O-C'
M-7%?=7NX2K?0^?Q='EU(V%%2%:8:]61Y"$HHHH$%%%% @HHHI@%%%%2 4444
MP"BBBD 44455QA1110(**** "BBBE< HHHHN 4444)@%%%%-L84445(@HHHH
M **** "BBBF 4444(84445=Q!11168!1113 ****D HHHJD 4444 %%%%%@"
MBBBIV ****I %%%%)@%/IE+DT *U-I:5::&)2;J5J;BD&P;JD6V,AX%)'"6:
MMJPA5>6HE-05RH1<W8SX]/8<XJS#B'K6G<30Q1GD5R&N:XEONPV*\>IC-;(]
M>G@F]3IUU.*,<D5#<:W!C[PKR35/&QA8@/6!-X]=F(W_ *UP2J2F>C3PT8;G
ML%YKD7.&%<]J'B!5SAJ\UD\9/)_'^M4I_$32?Q5E:;.Y1@D=AJ'B@KG#_K6!
M=>,)%)^<_G7.7&H--GFLZ8E^]6H/J0U%;'22^,Y3_&?SJM)XLE;/SFN;,1-)
MY)K3E1',;<GB*23^*H6U1I.IK*\HBGJI%'(@YVBZUR7[U$WS5&M.Y%+E0_:7
M&F(&C[./2G!J?NJEH1=D/V<4>34I-)3N.PSRZ/+J2BF(CVT!:<:2JN@%VTN*
M1:=4""G4VDW4 .:HV[TNZCK2 :M/6C;10 YJ/X:2C-,8UJ:.]/:F8H$2+2-W
MI5HH CQ2[>*=MHH&A-M)Y=._&BJN4VB/RZ/*S3\TJU))#]GI/LXJQ13L40+%
MMJ6,[:0T=:=D*Y;BOFC[U;C\0/#T:L<J:C>,M4<J*4FCK].\82*X!?\ 6N]\
M/^+/-VAG_6O$45HVSFMC2=::VD7YL5E*GU1I=2W/IK2]02ZC'.:OR1!ER*\H
M\)^*-VT%OUKTNQU);B(<U="NX2Y6>?B,.FKHJW2;6-0+6A<1^9TJFT>VOI*<
MKJY\Y4CRNPVDI3Q25H9!1112&%%%%( HHHJA!1112 ****5@"BBBJV&%%%%2
M]0"BBBEL(****8!1115 %%%%( HHHI %%%% !1112L 44450!1110AA1115"
M"BBBD 4445+ ****0!1115 %%%%%@"BBBD 4444( HHHJ@"BBBF 4444@"BB
MBI ****8!1114@%%%%4@"BBB@ HHHIH84444""BBB@ HHHH ****FP!1115
M%%%%( HI:&%(LCD7<*ACAVR;JM;::R[5J[Z$6U.E\,:X=/G3YL8/K7TY\)_&
MID:)?,].]?&@NFAN!@]Z]H^$NOF&XBRW<=Z\C&X=3A<]+!UW":1^B/A&_P#M
MEFISGBN@KRSX8^(%FLXQN[5ZA'()%!%?GE:')-H^[I2YHICZ**3^*L#86BBB
M@ HHHH **0]*;F@!]%(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112
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MXV)B^5W/M+X5>--JPKYGIWKZ8\,:L+Z!><Y%?GA\-?%C1W$0W]QWK[-^%GB
M7$$66SP*^%S+#<CYC['+L1SJQ['28YS3(I!(H(-25\V?0A1110 W=2@TE"T
M*:3;3J* $%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12?Q4M("&:40J:
MY/Q%JH6-AFMO6[KR8VY[5Y7XFUCYF&ZNK#T^9W.:M4Y4<YXEOO-=N:Y%F+2&
MM*_NO.<\UG[?FS7U%)<L3YVI+FD2+VIVZFCI16A ^BBG5(,;13FZ4V@D****
M!H**** ZA1110/8****"0HHHH&%%%% @HHHH **** "BBB@ HHHH&%%%% 6"
MBBB@ HHHH **** V"BBB@5PHHHH **** "BBB@KH%%%%!(4444 %%%% !111
M0 4444#N%%%% @HHHH ****"MPHHHH%8****!!111058**** "BBB@D****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E
M WW37'>)[WRE;FNHO+D11GFO-/%VH\-@UTT(<TCGK2Y8G$Z]JFYV&:YB:3S&
M-2ZM<EYFYJBC;J^DA'E1\Y4ES2)5^6G TT4HK?<SL.HHHI""C-%-;K0,=FBF
MKUIU ;,6DHHH'+4****"0HHHH*L%%%%!(4444%6"BBB@D**** "BBB@ HHHH
M'<****!!1110 4444 %%%% !1110 4444%!1110)A1110(**** "BBB@ HHH
MH&%%%% !1110(****!W"BBB@ HHHH$%%%% !1110 4444 %%%% [A1110(**
M**!L****!!1110 4444%)!1110#04444$A1110 [<::TI]:*85/%!HA^XFBD
M I:SK0]M'E"+Y7<0FD+4K4PBOS?,>#X8Z?,T?287-W05@)HW&C;2[:Y:?!%.
MG&UC>>>2EJ&ZG*U,V\=*#VJ9\$4Y]"(YW)%A6S2E,U"K581A7YUQ!P=+"Q<J
M:/>P.<>U=I,A9=M,J>3FH=M?G&78JMEN(M)V/IZ]&&)I708I:*:QK^J>&\V^
MO4HIL_+LQPOL)M@>M)2B@]:_0)*QX"=Q58K4BR'BH:<M82&3L@D&#5#4-(CN
M(SE0:N"3%.WEJ<6T+1GDWC#P.ETC[4S^%>%>+OARZNY$?Z5]DS:<ETIR,UR/
MB+P;%<(WR _A7H4<2X')4HJ2/A75_"[V;-E/TKE[N(V^>*^J?&7P^^^5C_2O
M&/$7@66-GPA_*O=H8KFW/'J4;'E8U)HIABO1_ ?B)HYH\M7*77A&9)ON'KZ5
MT?AGP_+#(N%-==25.4=3FBJD9:'U/\/?$@DCC!:O6K74D:$-FOG#P2DUJ$SD
M8KTEO$1M;7EL<5\Y6I0E+1'N4IS4=6=KK'BB*S0_,!^-<+JWQ)AC+#S!^=>9
M>.OB T8<"3]:\:U3QY/-,P#G\Z[J&!A*-VCDJXF<7HSWG7/B6F&VR?K7G6O?
M$1Y-VV3]:\[;5KF][L<TL>DW-X>0QS78J%.F<KJU*F[+6H>+I[ICAB:SD>YO
MF_B.:Z'2_ TT[+E#^5=_X=^&Y;:3'^E$JT((<:4I'EUKX3N+PCY2:[CPOX!F
M61"8SU]*]G\/_#:/:F8Q^5=_I'@.& +^['Y5PU,=I9';3PQQ7@[PR]JJ97%>
MK:3;F%0*FM=!CME&%JZD(CQBO'J5/:,].-/E-"U'2NATR$L17/6;885U&ES*
M,5X^(O8]/#M7-ZWA(6FW"D5-#<+MJ*XF6OGI1=SWXR5BE,I*FL74HS@UNR3+
MM-8FI3+@UOAXR4CFKM.)S-TN&-0+5BZ;+&JZU]1'X3YV6C%HHHJR HHHI""B
MBB@ HHHH&%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@84444!<****!!1110,****!!1110 4444#L%%%% @HHHH ****!A1110(*
M*** "BBB@ HHHH **** "BBB@ HHHH&%%%% 7"BBB@ HHHH ****!!1110 4
M444"L6;>/=5/6#Y,)/M5ZW<+6)XHO!';MSVH+6K/+/&VM^3Y@W?K7B'B35?M
M$C<YKMOB#JI\R0;J\DNKHS3-S6<CNA&Q7F7=)FI8EPHH"YYJ11@5)L&11D4V
MB@H=2TU:=0 4444 %%%% K!1110 4444#"BBB@ HHHH("BBB@84444%!1110
M 4444""BBBE8=@HHHJ@"BBD;I28DA2V%K,OKC;FKDSX6L34)#S7HX.ESRU/-
MQ=3EC8S[F8LQH@A\PU7Y9ZU;*,;:^@KVI0T/ HKVD]2SI]OMD7BO4_!JK\F:
M\V@(1A78>'-4\EE&:^"SN,Z]%V/L,#:G)'M=C9QS6XX'2N>\1Z &5B%K2\+Z
MIYZJ,UT&IV:S6Y..U?@WUFK@L79L^X5*-:E='S_K=C]E=N,5ST>L/:S#![UW
MOCBW$+R=J\NNO]<:_>\CJ?6**FSX3'WC-Q1Z-X=\?R6>W,A'XUU[?%0FWQYO
M;UKP*2=X1D&J4VN3+QN-?8T\+3J(^;J5IT=3U3Q!XY:\9OWF?QKEVU(W#<FN
M,757D;DUHV=]R.:QK9>HJ\32AF',[,Z1?FYISCY:HV]X&'6M"%?.Q7@58^PU
M9]!2E[;2)EWBDYK$N8&+'BNX_L=INU1R>&2W\-9T<XH479LTJY+B*RND<+'&
MZ-5R.Z,8%=/)X8/]VLV\\/R+_":]".<X6L[-G%+(\515U$@M]3]ZN?:O,6LA
MM-DA;H:M6T;+UK:<:-1<T&<T?;47RS07,9DS5$Z<6;I6_# & J3[,!7GRER.
MQZ,5SJYC6VGA#TK17$2\5>AL]YP!6G:^&Y+O@+FLW*^K*Y3FVO&%/AN"W6NO
M_P"%>SLN?+/Y54NO",MEU0BI4UL79F(#FG+4\EJ8C@BHJH HHHJK"L&31114
M6 ****"@I*6FM3$+D4M,I] PHHHH$%%%% !3:=10,:*7-(U)0 ^F4^B@0W;0
M.M/QQ24;"N"FG9XIG:BJ3N-H&D-1M(WK4FVD\L5I:'5&+Y^C(O.;UIWFM2^6
M*/+J?<[$VJ=P\UJ!,U+LI=E/W.P6F^H@8M2^M.5:#4-+H:QO;4;_  T4E.6H
MN-"CK3J;13+"BBB@!II5IM*M Q:;3Z*!"4N#13J0MAM*O>D;K3TZ5+&C"UYF
M6-J\J\17+"1J]>UBV\V,X%>9Z_HK/(V!6].20IZHXI)BS<U:7FK0T5U;[M3C
M3&]*ZN9'+9E"C.*T/[-;TH_LMCVI<R"S,UI*3SJTO[)=OX:7^Q7]#3YD58S/
M.-+YQK3_ +$D_NU(N@R'M2;0<K,K>:.6-;:^'W_NU/'X>?\ NU#DBE$PHX2U
M68[,MCBNB@\/MQ\OZ5H0Z"?[OZ4N8KE.473R>U']G'TKMDT/_9IYT/VHYPY#
MAO[-/I2-IY':N[_L3VJ&71/]FCG#D.&^QGTJ-K4^E=JVAG^[43:"?[OZ4^8.
M0XMK=A3#&1VKKY/#[?W?TJNWA]O[M3S"Y3E\'TI57VKHFT!_[M.7P^_]VJYD
M3RF#';F3M5JWTEI&'%=#:Z"W=:Z#3M# (RM0ZA2B<]IOATE@=M=EI.D^0%XK
M7T_2D51Q6D+=8UX%<TI.1JE8BA_=IBB1]V:;(<9Q488FJ 6BBB@04444%)A1
M110 4444 %%%% !11103<****"@HHHH&%%%%!+04444"L%%%% T%%%%.P7&5
M9MS@BJ[=:EC;;1'W7<4ES*QL0M\HI[-5*&;WJVOS"O=PM6^A\[BZ5M1#UHI^
MVF=Z]0\I;"44M)0V2%%%%" **** "BBBD 4444[ %%%%, HHHJ+ %%%%4F 4
M444P"BBBH8!1113 **** "BBBKL 4445+0!1112L 44450!1110 4444@"BB
MBI ****H HHHI6 ****I#"BBB@04445+ **** "EI**!C\T4RB@:'4GF;:2F
MM5()%JW_ 'AIU_I0FA/%)9'#5M*5>/%>7C*'M%='HX2IR/4\6\7: 5W$+7E^
MI636\AXKZ3\1:2MRK8%>6^(/"C,S$)7@J4J;Y3Z-34D>7^>4XIRS%JW+KPQ*
MKGY34 T&1?X376IIHCE9F^92[S5]M+9>U,^P-Z4<R)Y64]QI-Y]*N_8#Z4?V
M<WI3N@Y64?,-(9*OC3&]*>NDLW\-',A\K,II#31*:VO[#=OX:7_A'W(X4TN9
M#Y68WG&CSS6R/#LG]TT[_A&I3_":.9!RLQ//-'GFMU?"\O\ <_2I5\)RG^ _
ME1S(.4YX3&I8\MVKHX_",G]P_E5R'PE)Q\A_*I<AV2.:CMV?M5J/3&DQ\M=?
M:^%'&,K^E;%KX7(Q\M9N4BURG!QZ"TG\-7(?"CR?PUZ3:>&U&,K6Y9^'HQC*
M_I47F%X(\EC\$NW\'Z5,/ K_ -S]*]MM]!BX^45<708?[HI7F2ZD#PE? ;_\
M\ZF3P&_]S]*]U70H/[HJ1=#@_NBM8QFS%UHH\,7P(X_@_2G?\(0R_P 'Z5[F
M=%A'\(J)]'A_NBMXTI,YWBTCQ#_A"6_N?I4D?@MO[GZ5[*='A_NC\J5=)B'8
M5I[%D/&GC_\ PA;?W/TJ%_!;?W/TKVG^R8O[HIO]CP^@I>Q9/UP\5_X0AC_!
M^E'_  @S?W*]K71X?[HJ1='A]!^5+V+-EBT>(-X&;^Y^E1MX%?\ N?I7NAT>
M'T'Y4?V+#Z#\JB5.2']:1X*W@-_[GZ4S_A Y/[GZ5[Y_8<']T4UM#@_NBLG&
M:-57B>"?\((__//]*3_A!7_N&O>3H<']T4G]AP^@J'SHV5>!X,W@5_[GZ5&W
M@=_[GZ5[V="A_NC\JC;08?[HJ.:97/!G@_\ P@[_ -S]*7_A!WX^3]*]U_L&
M'^Z/RIRZ##_=%'-,.:'<\'_X05_[E'_"#/\ W/TKWK^P8?[M)_8,/]T4*50?
M/#N>#_\ ""O_ '/TJ2/P&Y/^K_2O=5T&'^Z*GCT&#^Z*OWV2ZD#PV/P&X_@_
M2M6Q\&F,C*?I7L?]B0CL*ADTN*/H!6T:4I[G)4Q*AL<=I&@K"1E:["QM8HD'
M JK)&L/2H&O&7H:[H8'J>=4QS>AJW$BHIVUCSW#%NM-:Z9^*8?FKTJ=-4SS)
MU'-ADM2T@XIP]ZVN0-HIWK3:9(4444F(****!A1113$%%%%*P!1110P"BBBE
M8 HHHH ****L HHHH ****0!1112 ****8!1113 ****EC"BBB@04444]P"B
MBB@ HHHI@%%%% !1114@%%%%, HHHH **** "BBBF 4444 %%%%)@%%%%( H
MHHJ@"BBB@ HHHH ****0!1112W ****>P!1114@%%%%6@"BBBAZ#"BBBIL(*
M*** "BBBD 4444P"BBBF 4M)3EIE6N1R)NID:^4V:L5#-PII+L3:QU'ACQ$;
M.Y0!L<U]4_![Q8;AH5+_ *U\16MTT=T.>]?0_P &M>,,T(+=Z\O,*"E3;/2P
M-=JHD?H%X?N!<:>C9SQ6I7!?#_7EN+&-2V>!7=1R"09%?G%2+C)H^_B[Q3'T
M445B4%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ,I5I=M&* %HHHH ****0!12-2+3 =39#M4FG5#=-
MLA8T <QK^I>2K#->6>)-3\YF&:ZOQAJ&S=@UY9J5Z9)3S7M86EU/&Q53H4+S
MYW)IL:TX_-0!7LM:'D+5C@M+MH6EH&%%%% !1BBB@08HHHH*L%%%%!(4444
M%%%% PHHHH **** "BBB@04444 %%%% PHHHH)"BBB@84444"N%%%%!04444
M""BBB@ HHHH&%%%% /8****"4%%%%!84444$A1110,****!W"BBB@3"BBB@0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 7N%%%% !1110 4444
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MT2:Z5JSIE63M7F2PLT]#U(XR-M3S2X\-]?EJDWAP_P!VO4#IRR?PTW^Q5/\
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M% PHHHH%N%%%% 6"BBB@ HHHH$@HHHH'8****!A1110 4444 %%%% !1110
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MQI4L.O=/-E6JXKXBLT+-3[6$K*/K6K':?+TI5M=K@XKFK8GF5CHHX7E=SO\
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MFXT;S2T4P$W&ES113$&:,TF:6D,,T9HHH$&:,T44 &:,FBDI@+N-)N-&:6@
MS1113&-:DIS4VI*'T444 %%%% @HI,TM PI5I**!,=NIM%% TPHHHH ****
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M***:0!11128PHHHIW$%%%%&X!1114V ****H HHHH **** "BBBB]@"BBBI
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MHH$%%%%!04444$A1110-!1110#"BBB@04444 %%%% K!1110,**** "BBB@
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MR;J?;@Q,#4UHJM2<&.#Y971[SX5\6>5;JI?MZU>U_P 0)=0-\V>*\6L=>:V
M ;%6IO%#2+@M7Y-6X6OBO;11]%''VI\K)_$!261B*Y.X7#'%:%UJ1GSS6?(=
MQK]'P-"6'@HL\2I+G=T1*#3]Q%.VTC"O2>IDA <TQH0W:GT[=23<=@:3W*OV
M,>E#6H4=*M;Q36;-:>UF1[*'8S)K8&H%L0S=*U6CW4J1XKHCB9)6.66%BW<J
MQ:>OI5E;4+VJ=3MI6:L95)2-X4H1V(Q&!2,E/-%9:FV@Z&Z-N<BM:T\526N,
M.1^-8CKFJ[PEJ5D]PN=I_P )]/MQYA_.J-YXKDNLY<FN8^SGUIZPGBER1'=E
MZ:\,QR34+?-3%7%24P$VTM%% !1110 4444 %%%% !1110(**** "BBB@ HH
MHH&%%%% !1110 4444$]0HHHH*"BBB@FX4444 %%%% 6"BBB@I!1110,****
M";A1110%PHHHH#<****!)!11104%%%% [A11102%%%%*X6#-%%% PHIM"TQ6
M'44JTM #:*** "D;I2TC=* L-IR]*;3EZ4#%HHHH$%%%% DK!36IU)0.XVGT
MC4W- Q]%)2T %%%%,D***9F@8^D:A:*0QM.HVBEH **** "BBB@04444#"BB
MB@ HHHH **** "BBB@ HHHI@%%%% !1110 4444@$:FI]ZG&FKUHD3<T;5L8
MJ^&^6LF%]M7H9-U>AA:EG8\S%4;JY,>M%.44C5]&G='S<E:5AM%%%!(JTZFT
M9H &ZTE%% !1110 4444@"BBBF 4M)13 ****D HHHH ****8!1112N 4444
M %%%% !1113 ****5P"BBBF 4444@"BBB@ HHHI %%%%58 HHHI7 ****+@%
M%%%, HHHI7 ****8!1114<P"-24ZBJ ****3 ****8!1113Y1A1112$%%%%,
M HHI#UI +12+2T@"EW4E%4,7-)112$%+244#'TC=*2B@0E%%%, HHHI, HHH
MH0!1110 4445/, 44450!1110P"BBBFM!A1114B"BBBF 4444, HHHHV ***
M* "BBBBX!1112 ****H HHHH ****D HHHJ@"BBBD 4444@"BBBJ ****=@"
MBBBD 4444F 4444= "BBBA#"BBBF(**** "BBBF 4444F 4445(!1110 444
M50!1114V ****H HHHJ; %%%%.P!1112L 44450!1110 4444 %%%% !1113
M ****D HHHH ****0!1115 %%%% !1114W ****H HHHH ****D HHHI@%%%
M%, HHHH ****5P"BBBF 4444 %%%% !1114@%%%%.X!493=4E%,!(YO(8$5Z
M5\._$!CO(AN[BO*[ML5O>"[TPWT9SCD5C7I\\&:TYN,U8_0KX0ZSY\,.6SP*
M]O1@R@BODSX->(@B0@MZ5]/:'J2W4"\YXK\UQE-PJ,^^P=3F@C7HHHKSST H
MHHH :U)3Z2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"BBB@H****!!1110 4444#"BBB@ HHHH **** "BBB@84444""BBB@04444
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M*0!1115 %%%% !1113N 4444@"BBB@ HHHI@%%%%*P!1113 ****FP!1110
M4444 . I#2CI2'K30#=U+3:=3N 4445("BEVTBT[-4 VF[:=25( !BBBB@84
M4458!1116?4 HHHK0044;J,U !112;JH!:*** "BBBI ****8!1114V ****
M: ****H HHHI %%%%&@!1112&%%%%6(****0!1112 ****D HHHJ@"BBBF 4
M444K@%%%%( HHHI@%%%%, HHHI6 ****0!1113NQA1112$%%%%, HHHI@%%%
M% !1114@%%%% !1115 %%%% !1112 ****0!1115 %%%% !1114@%%%%, HH
MHI@%%%%)@%%%%" ****0!1113 ****8!1111< HHHJ6 4444@"BBBJ0!1113
M8PHHHI""BBBBP!1113 **** "BBBE< HHHH ****2 ****-1A1113$%%%%(
MHHHIH HHHI@%%%%( HHHI %%%%4!6NEW5:T1S;W"GI4;KFA&\GD4GJK M'<^
M@_ACXH^S21#?CI7UO\//$0NX8QNSQ7YX^$?$#6]T@W8YKZZ^#OB,S+""WI7R
M69X?3F/I\OK:I'U1$VZ-3[4ZJ>DSB:SC(.>*N5\=L?6!2TG:BD $XI-U*U-H
M ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M)13:5: '4444 %%%)0!#/,(U-<%XLU ;'YKI=:O?)1N:\O\ $VJ;RPS79AX7
ME<X\14Y8V.*UVXWS-S63&<U:OW\QR:K1C%?3Q7+$^<?O2)J***0F%%%%,844
M44""BBBEL 44^FM3 2BBB@=PHHHH$%%%% !1110"T"BBB@ HHHH&%%%% @HH
MHH ****"F%%%%!(4444#"BBB@04444 %%%% !11104@HHHH#8**** N%%%%
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M2'K02)12;J-U "T444 %%%% !1110 4444#044OX4E PHHHH$%%%% @HHHH
M**** "BBB@ HHHH&%%%% @HHHH **** "BBB@ HHHH&%%%% ,**7;01B@0E%
M%% "Y-)110,*M0KE:J'/:K4##;0!FZQ+Y,3&O'_&FM;-XW5Z?XKNA';OSVKY
MW\>:L1)( :EFU-''>(K_ .T2/SFN4D3,F:MW-V99#S46W/-1<[UL+&,+3J0<
M4M(84444#"BBB@ HHHH ***2@D6BF[J6@8M%%% !1110""BBB@844AI-U #J
M*** "BBB@ HHHH&%%% YH)$IN:DVTS;0 JTM(*6@84FVEHH&)M%%+13L2%%%
M%%AA1110(****0!11104@HHHH$%+NI** "BBB@8JTN*0&C=02)112;JH!:*0
M'-%(!:*;NIU( HHHH&%%%% ";:*6B@049QFD-)NH 7(I<\4RG+TIC%HHHI %
M%%% V%%%% A#TIN:=2;:8"T$T4C=:+$@#S3J:.M.I#"BBB@H****9+"BBEVT
M@0P]: :5EYH H&.6EI%ZT;J !J2@FBD2%%%%, HHHH*V&M0#2D4FV@+CJ**;
MNIB;'44@.:6D 4444Q!1113*$-)DTII-M2 M+24M !1110%PIU-I=U,!&6DQ
M3C24@"BBEVT )10>*3=3 6BDW4M( I*6B@;&FDS3CS2;:!#J*** "BBDH$+1
M1138Q-M&*6BD 44446)"C=110,-U%%% @I-M+13*$VT8I:*0!1110 4444 %
M%%% !32>:=36H 4&BD6G4 -R:44VG+TH 6BBB@ HHHH$%%%(3B@8M%)NI: "
MDQ2T4 )BEHHH **** "F,:?36% $L#<UJV\G%9$7!K0@>NBC/E9R5X<R+I-1
MD4*U.Q7T]&7-$^3JQY9C:*7&*2J("BBBFA!1110 4444@"BBBFP"BBBI0!11
M13 ****: ****0!11130!1110P"BBBA %%%% !1111< HHHI, HHHI %%%%,
M HHHIZ %%%% !11120!1115 %%%% !1110,**** "BEI=M(!M+0>*2D%AVZD
MI**I, I0:2EI=1B[J;2[32[:& VBG8%(U K"44447"P444FZF(6B@&BF@"BB
MBD 4444%!1M%%)NH)%HH%%2 444M4 S-.6C;[4=*0!1112 ****8!1113 **
M**5P"BDW4H-( HHHI@%%%%, HHHH&%%%%*X@HHHH ***=MI@-HIVVDJ!B444
M58@HHHH ****0!1112 ****0!12TNVA 1TY>U#+0M6 ^FTN124 )12;J4'-
M!1114@%%%%, H:B@T@&Y-.I-M+5 %%%% !1114@%%.VTA&* $HHHIW ****8
M!1112 ****>X!13@*-M3HAC:*** "BBBF(**6EZT#L-HHHIVL 4444 %%%%
M"9I12;:6@0^FTNZDI7 2BBB@ HHHI@%%%%( HHHI %%%%4 4444P"BBBD 44
M44K@%%%% !1110P"BBBI ****I %%%%);C"BBBK8@HHHK, HHHJ@"BBB@ HH
MHH **** "BBEIC0E-D&13Z0TD4R*)=K9KI_#>K&VN$YQS7-L-JYJ&VO##<#!
M[T2CSJQ,9<CN?8_PC\0^8T(W>E?6?A2X^T:>IZ\5\"?![7"L\(+=Q7VW\/-6
M6:P0;NPK\_S2CR2N?:Y;5YHG>44BL&&12U\^>Z%%%%, HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $R**;2K0 ZBBB@!DC;
M5)KG=:OO+C;FMZ\;;"37GWB:_P!FX9K:E'FD95)61Q_B>^\QGYKS^\^:0UT.
ML7GF.W-8$@W,:^FHQY4?.UG>0D72I*:G IU;G/<**** "BBB@04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%!=] HHHH)"BBB@04444 %%%% PHHH
MH&%%%% @HHHH ****!!1110 4444#"BBB@=@HHHH$%%%% !1110%PHHHH"X4
M444 %&:1J;0(?112%L4 +13/,IK34[#):;4/G>]*)J=@T)A2U%YPI?-I6"Y)
M131)2YH%N+3:*4"I#8%Z4_--HI@A6ZTS%/;K24@$Q2T44Q6"FTZB@8BTM%%
M!1110 [-(U)10 4444 +M-)3Z:U(!**** "BBBF X=*#TIM% !1110 4444
M%%%% !1110 4444#044N324%!2XI*5:#.P8-)3Z904%%%% @HHHH ****!A1
M110(***?0*PTC%-:G-32,T#&TN:*86H3*0_-)GI3-]&[- NI)NHW4T&EIC'9
MI:93ZD HHHH)"BBBF,****!!11104@HHHH$%%%% @HHHH+;"BBDR*"1:*3(I
M:!!1113N.X4444A!112-0 9%+3:=0 49HIK=: '9HIJ]:=3&%%%%(D:>M%.H
MH&%%%% !1110 4444 %%%% T[!1110#=PHHHH$%%%% !1110,****!!1110,
M**** "BBB@04444#"BBB@04444 %%%% !1110 ZD:DHH&%%%% !112KUH&+M
MJ.2X\I35KR_ES6#K=Q]GC;FF!RWC35 (7^:OG3QK>&29^:]3\::UQ(-U>+^(
M+CSY&.:R9UTXG.*Q:0FK:_=JLB8:K2]*DZQ:*** "BBB@ HHHH **** "D/2
MEHH$,IPZ4M% Q,T9I&ZT+UH =1110 4444 (U-I]%!(E+1104%%%% !1110
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M@%%%--"$.HI%I:0@HHHH ****-AA11157N 4444/0 HHHI""BBBBX!1112N
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ME, HHHJ;@%%%%%AA1113$%%%% !1114@%%%%%P"BBBF 4444 %%%%, HHHI
M%%%%, HHHH8PI:2F[N:2 ?MW4?96DZ"K%K#YC 5V&@^'3>,ORY_"HG45/<UC
M'F.'_L:5^0II/["F_NFO?-*^&K7$8/E9_"M.3X4L!_J?TKB>80CH=/U235SY
MQ&AS?W32G0Y?[IKZ&_X5:_\ SQ_2E_X5:W_/']*S_M"!/U.9\['1)?[IH_L6
M7^Z:^A_^%6O_ ,\?TH_X5<W_ #Q_2J_M" ?4YGSNVB3?W31_8DN/NG\J^A_^
M%6L?^67Z4O\ PJUO^>7Z4O[0@/ZG,^>/[$F_NFD.BS?W37T1_P *M?\ YX_I
M0WPK?_GE^E"S" ?4YGSM_8LW]TT?V'-_=/Y5]$K\*WS_ *H_E4S?"E]F?)/Y
M4_[1@-8*1\XC29(^JD4OV<IUKVK6_AZUFK'R\8]J\[UK23:.1C%=5/%1J;&4
MZ#I[G,]*3-23+M-1#FNDYF*II:,44!RA1112$%%%% PHHHH ****8@HHHJ0"
MBG+0P[TRAM%%%%@W"BBBF(**7WI*!!113MM(:&T4YJ%I@)1FG8IE !2T4UJ+
M"'9I*1:6I ****=P"BBB@044450PI:2EI#04E%%,;"ES244B1<TE%% !1110
M5N+1DT>E.I7)&TE+3AQ3&,HI]-)I@-:FEJL1VKS$8%6H]!GDY"'\JSE42'9F
M9NI016J?#MQ_<;\J0Z!.O.PTO:1[AROL9U%6I=/DAZBJS?*>:M/FV"S0E+29
MS10V*PY:6F@TNZ@D;1113&(>M"DYI:3%*Y5AV324HIV*+W$,HI:!3Y1 M.I.
ME - Q*2GTTC%(!**** %7K3J;2[J!@U-I:512L*PVAFVT[:*KW+;5-4A$T;;
MFP*T;71I+H#:N:QM+D\ZX53ZU[K\.?"0U3R\IG-<V(K*C&[-\/3]K*QYJG@F
MXD7(C/Y4X>!;G_GFWY5]CZ'\&TN;=6\G/'I6M_PI%/\ GC^E>!_:L4['M?V;
M)JY\02^"[B)<F-JS+K27M<[ABOM[Q!\&4M;-F\G''I7SO\1/"8TN20!<8KKP
M^/59V1RUL$Z2NSQIOE.*2G7W[N8CWJ)6KVUKJ>6/HI0,TE78EA2TE.6D"&T4
MZFTKC84444$A1110 44447 ****8!1112 ****0!1113 ****0!1113 ****
M8!1110 4444P"BBBD 4444K@%%%% !1113 ****3 **** "BBBBX!1110 44
M44 .V\5'MJ0&AONTT.Q6-QY4@Y[UZI\+]8*W40W=Z\AO"=_%=I\/;PPWD?..
M:QQ$%*FS2C)J:/T,^$FJ"2VBY["O7@P;I7S1\']>"PQ#=V%?0VEWPN(U.<U^
M:8NGRU&?H.%GS4T:5%%%<!VA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5/49/+C/TJY61KTOEPGZ545=DRT1PWB;
M4,!AFO,=9N?,=N:ZKQ3?89QFN#NI_,D-?086%D>#B)W=BICYJG7I4?\ %4@Z
M5Z3//%IV13:*D8K4E%%, HHHH!A1110 4444""BBB@ HHHH*"BBB@2"BBB@
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M44QA1110(**** "BBB@84444 %%%% (****!!1110 4444""BBB@M!11BB@
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MUZF&@X[G#6DF]#SC4/\ 6&J<?WJMWGS,:K*M>J<Q)12T4QA29ICR;:JR76*
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M_P!0/RKG^M(T]@SX+D\!W$.28V_*J4VAR6?52/PK[DUOX*I'"V(/TKQGQO\
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M**0!1115 %%%% !1114@%%%% !1110 4444P"BBB@ HHHJD,****EB"BBBA
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M:*XADPX/'K7;AZ-53U.+$5:;CH?/OQ%MTCDEQZUXIJ6YKD@>M>J>/-:%S/(
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M***H HHHI#"BBBBP@HHHHL 4445 !11130!1115 %%%%, HHHH&.VT&B@]*
M 'WJ&X&X5)39!NXH'N-T_P#=R@UZ[\/]<^SS1C=W%>1+^[YK>\-ZP8+I!G'-
M<U>G[2+-J,^21]Y?#'7O/2(;J]XTY_,M4-?(WP9UHS&$;J^L]#?S-/C/M7YU
MCJ?LZEC[O!RYX7+]&ZANE-KS3T!]%(*6@ HHHH **** "BBB@ HHHH ****
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M\YL5WG@?PZ;J[C.W/-<3H2^=< >]?0_PJ\/B:2(E:[:SY4815V>]?!GP>JK
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MG:[4&4]?6OI+X6^+WOO*R^>E?!GA^^9;U>>]?6/P4O&9H>?2N7,,/&,+I&V
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M?-7T]%<J/G:LN9C$%*QI<4$5N8@M+2 4M(044[;3::$PHHHI#04444 %%%%
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M@]SRL4CD5_UU=[X3^\M<"O\ KA7>^$C\R5ZF(^$\RC\1['H'^I'TK7K'\/\
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M$CP*\YT/QI'?$8?-=_I=P+B'<*XZD91>IV0DGL6YO]4_TKQ;XF?ZJ6O:9?\
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MJ0!1114=1A1115B"BBBD 4445(!1110 44450!1114@%%%%, HHHI %%%%4
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M5: %:FTXTFTT"'4T]:6EH :*7(I&I* 'T444 %%%% @HHHH&@HHHH'8****
M:"BBB@ HHHH **** "BBB@5PI"M+10-,1:6BB@052ONAJ[5*^Z&F#-#PC_Q_
MI]17V?\  [_EC^%?&'A#_C_3ZU]G_ [[L/X5P8G8VH[GUWX9_P"/-/I6W6+X
M:_X\T^E;5>"]STSG/&__ ""V^AKX@^-LA6:?CN:^Y/%T)FTU@/0U\@?%WPI)
M>2S84GKVKKP[29A4V/C/7K@BY?CO6$]R=W2O6=:^',[W#'RSU]*QV^&MQG_5
M'\J^@C.-CS919P271QTI_P!H/I7>I\,[C_GF?RIX^&EQ_P \S^5#J1)Y6>?_
M &D^E-^TGTKT/_A6=Q_SS/Y4C?#.X49\L_E2]HA\K.&MY2W:GW7,==-=>#Y;
M'JA&/:N=U2,VX(-5S7V$.T'_ (^E^M?3WPA^]%^%?+WAY]]TOUKZB^$'WH?P
MKEK[&U+<^P_ ?_'O'7I<?^K7Z5YKX#_X]XZ]*3[J_2OGY_$>HMC%\7?\@I_Q
MKXS^-'WY_P :^S/%W_(*?\:^,_C1_K)_QKJPVYA5V/EGQ"/](?ZURMQ_K*ZO
MQ!_Q\-]:Y6Y_UE>_%GG,W_#?^M2OHOX6M^\A^HKYU\.?ZU/K7T1\+?\ 60_4
M5RXC8UIGV)\-F_<Q?2O2Z\R^&W^IB^@KTVO EN>E'8X[QT/W#_2ODSXKCF7\
M:^M?'/\ Q[O]*^3/BOUF_&NFAN9U-CY5\:K^\D^M</IG_(0'UKN_&O\ K)/K
M7"Z;_P A!?K7T4'[IY<MSZB^"8_>0_A7W+\._P#CSB^E?#GP3_UD'X5]R?#W
M_CSB^E>%BMST*)W=9'B?_D%O6O6/XH_Y!C_C7GK<ZCXL^/'WI_QKX[\0#_3G
M^M?8?QW_ .6_XU\=^(/^/Y_K7T&'^$\NMN-L\;15FJMK]T5:6NTQ0DGW367(
M/WPK4D^Z:SG_ -</K30V>H?#(?Z5%]:^U?A/_J8OH*^+/AG_ ,?$7UK[2^%/
M^IA^@KR\4=5$^A=%_P!0/I6C6;H?^H'TK2KQ7N=Y\_?&[_4S_C7P/\4E_P!,
ME^M??/QM_P!1/^-?!GQ.3=>2_6O9PB."L<7X5^6\4^]?6/P;O0GDC/I7R9HS
M>3<*>G->_?"WQ (9HANQTKKQ$=#"D]3[Q\%78DMX^:[JO'/ACJWVN&+YL]*]
MB3[J_2OG9*S/56QSWC*W,U@PQVKY%^+NA,S3';ZU]G:O;_:+8C&:\.^)/@_[
M5#*0F?PK>C+E9%171^>OBZV:UN'XQS7%->'S,5] ?$SP+)'-*1'Z]J\6O/#4
ML-P?D/7TKWZ<TT>7)-,J1W!VTC7!%7DTEU4#;5NW\.R3X 4FM+H6IC1RM(W2
MM6UT]YE^[72Z3X!FG=?W9_*N_P!+^&\D< )C[>E9RJ)%1BV>,W6E-$<[:M:0
M/+F45WWBCPS]A5OEQ7"1#R;P#WJ>;F0G&S/>?A8V9HOPK[+^&/\ J8OPKXP^
M$[;IHJ^T/AC_ *F+Z5Y6(1WTCT^N3\:?ZE_I765R?C3_ %+_ $KSEN=#V/E3
MXL?\MOQKY1\:_P"ND^M?5GQ8_P"6M?*7C3_72?6O;PVQYE8XF'_7&M;3S^^7
MZUDQ_P"L_&M73_\ 7+]:](PB?1WP9_X^(?J*^Z/AS_R#%_W17PK\&?\ CXA^
MHK[J^''_ "#%_P!T5X>+W/2HG8US/BH_Z+)]*Z:N8\5?\>K_ $KSX[G2?(GQ
MM'$_XU\;>+6VW[?6OLOXV?=F_&OB_P ;-MOG^M>_A]CRZVYWOPEN@+R+GN*^
M_O@G.&MX>:_.+X7W_E7D7/>OO3X(:XHA@&[TK+%QT-*#/IZJUXI:/BEL[I;B
M%6!R<5.RANM>&>@>4?$"X>SAD(]#7RQX^\?3:?<2#>1@GO7UW\2-*-Q:R;1V
M-?%GQ:\*SM<3%5.,FO0PUI;G-5;6QR2_%N?SB/-/YU?3XL38'[T_G7D=_HMS
M:SMD-UJF[3Q<<UZ_L8'%SL]K_P"%L2_\]3^=,?XKR_\ /4_G7BOVB;'>G+Y\
MG3-+V42N=GLB_%>4M_K3^=7(_B=-*O\ K#^=>/V&E7-Q(,!J[G1_!MW,@.QJ
MB<((.9FAK'C"6[4Y8FN%U+4C+(237::EX1GMHB60CBO/->B:S8@\8JJ=N@G?
MJ=U\/[P?;(^>XK[;^#,H:&'GM7Y_^ M2VWT8SWK[G^!U_OA@Y["N3%1T-J+U
M/I 5%<KNC(J2-MT:GVI2,UXIWGB'Q<T\_8YCCL:^!_C!$T5W+QW-?I3\2M'^
MV6,F%SQ7P]\8? <DUQ,1&>I[5Z>$DD]3BK1/D]9F68TZ2Z(<5U]WX'FAF;]V
M?RJDWA*5I!\AKV^9'GM,ZCX:W!:ZB^M?;?P?<M##^%?)?PU\'3+<1$H>M?9O
MPIT%[>&+*XZ5Y>(:.R@F>]:#_P >X^E:U9VCQ>7"![5HUXSW/1/%_C1_Q[S_
M $-?!_Q._P"/R7ZFOO#XT?\ 'O/]#7P?\3O^/R7ZFO5PIQ5CRR3[YIJTZ3[Y
MIJUZYR$M%%% K!1110(****"@HHHH$%%%% PHHHH$%%%% !1110%@HHHH*"B
MBB@04444 %%%% !1110 4444 )1D4C4E #Z***!!1110,**** "BBB@FXUJ?
M#Q3>XI5.#2+W-*WDX%6"VX5FQ2=*O1-NKU<+/4\;&4[(?MI:?MXIIZU[RV/G
M.HE%%%, HHHI6 **** "BBBD 4444 %%%%78 HHHJ0"BBBD 444520PHHHH$
M%%%%4 4445-AA1110(****5P"BBBAL84445-Q!1115( HHHI %%%%, HHHI@
M%%%%2P%I6^[3:5C\M-%(IM_K!7;^#O\ 71_6N(;_ %E=OX._UT?UI5?A+I?$
M?47PN_Y9_A7TYX1_U"_2OF+X7_\ ++\*^G/"/^H7Z5^>9A\3/ML#\*.EKC?&
M7^JDKLJXSQC_ *J2O)I_$>I4^$^7/BI_RU_&OEWQ=_Q\/]:^HOBI_P M?QKY
M>\7?\?#_ %K[_+?A/AL?\1S5M_K*O#[M4K;[]7?X:]UO4\B.Q"[8-7;"#SY%
M'6LV<X:M[PV@DF3/K2EI&XXZRL>I_#?PZ)KB(E<U]D_"OPY'##$2HKYP^%MB
MI:(XKZS\ QB.*/'I7PF:57)M'VN7T5%7.X2)(P J@50U;4OL$9.<<5I5R'CE
MW6W?;Z5\VH\S2/<D[*YP'C;XC?9%D'F8_&OGWQI\5'9GQ+^M:OQ0NKA&EQFO
MF[Q5J4_F/DGK7V&7X2$DFSY3&XJ<79'3:A\2IY)CB4]?6K.C^/+B69?WC?G7
MD$4LDUP.O6N^\)Z3)<3(=I/-?05<-3A$\:G7G*1].?#/Q%+=/'EB:^HO!\QF
ML<GTKY<^%N@R1F(D5]2^$H3#8@'TKX3'**EH?98)R:U-R3_5M]#7BGQ./[N7
M\:]JD_U;?2O%/B9_JY?I7-A?C.C%+W#Y(^(G^ND^IKP_Q WSM7M_Q$_UTGXU
MX;XA_P!8U?H^#^%'P>)T;+W@?_C^3ZU]L?! ?NX/PKXF\#?\?R?6OMKX(?ZN
M'\*\[-_A.S*_C/J;3/\ CSC^E6ZJZ9_QYQ_2K5?GKW/O#@/B;_QY2?2OA7XQ
MC_29OJ:^ZOB;_P ><GTKX6^,7_'U-]37TV4[GS.:['A#?\?!^M7HONU2;_CZ
M;ZU>C^[7W70^0B$G-.A.TYI",TUCL7-+<H[WP3?>7=1C/>OL#X.W0E6'GTKX
M:\+Z@8[U.>]?8/P/U/=Y +>E?.9I#W#VLNJ>_8^L[7_CWC^E,O8_,A(INFR"
M6SB/M5EEW#!KX/J?<=#R#XA:(9K:0[>U?'GQ4T5XI93M]:_0'Q-I"W=JV!GB
MOFGXG?#]KHR%8\]>U>]EV)Y)69X6/PSJ+0^&-2C>&X;@]:S;N1FXQ7M_B#X7
MS"X<B(_E7/O\+KB1\>4?RK[RGBJ;5[GQT\-.+M8YSX?PNU['QWK[@^"L!$,'
M'I7S]X#^%LT-Q&QB(Y]*^M/AAX9;3XXLKC&*^:S;$QFK(]W+</*#NSV?35VV
MJ?2K=0VJ>7"H]JFKXD^Q1Y9\5?\ CVE^E?"WQ@_U\WU-?=/Q4_X]9?I7PS\7
M1NN)OQK[#)SY;-SQ/31_Q,!]:^E_@[<".2'GTKYKLUVWN?>O;_AIJXM9HN<=
M*^CQT>:!\_@I<LC[R\!W@:UCY[5W\;;E!KPWX::\)X8EW5[98MOMD-?FN(CR
MS/T##SYHB:@<6CFO!OB1JLEKYA!(Q7O=XOF6SCVKQ#XD:"]U'*0N:UPMN?4C
M%)N.A\W^(/'D]I<-\Y'/K6"?BM,K8\T_G5CQ]X7GCED(4UY!J=C<6\AX:ON:
M%&E.)\96JU82/7(_BI*P_P!:?SI[?%"7_GJ?SKQ>*2=.#FG^?*WK71]5IG/]
M9F>P-\49/^>I_.F_\+1E_P">A_.O(T2>1N :U;'1;FXQPQIO#4DAJO49Z9'\
M1I9N/,/YU7U'Q5+=1'+&L/3/"5R<$HU:-UX?E@A.5-<;C3B]#I4JDEJ<-XBN
MFGWDUQT2_P"F ^]=AXAMC#NR*XV.3%X/K7K4G>.AYU3XCZ-^":XN(?PK[J\!
M_P#()7Z"OA/X)29N(?K7W9X#/_$I7Z"OB,V^(^ORSX3IJR/$*YLW/M6O5#6(
M_,M&'M7ST=SWY;'R+\;,JDWXU\;^+I2+Y_K7V_\ &C26DCFP/6OCCQAH3B]<
M[3UK]!RN<>74^"S*+YSE;.8[:MQS$-4UKI+@8Q5EM)=5)Q7ORE$\E)V-;PW?
M;+A.>]?4OP=OQ(T(SWKY$L2UK=#/'-?1'P;UK9-""W<5XV80YJ;:/3P,K3/N
MOPRV[34_"M23F,URG@/4EN-.09[5UG6OSF:M)H^^@[Q3.0\2JT<+D5\^_$+Q
M'+IYDPQ&*^F/$%D)K5L#M7S1\6/#LDHFVJ>]>G@7%RM(X,;S*%T>':M\3YX+
MAAYA_.FVOQ5F(_UI_.N*\6>'+F&Y<[6ZURYMY[?@[J^VIX>E*)\7*O5C(]E_
MX6E+_P ]3^=(WQ0E/_+4_G7C(GF![T]9)G/&:T^JTQ?69GKDGQ1E'_+0_G4U
MO\3I9#_K#^=>11VEQ,> :Z30_#=S<,/E8U$Z%**NRXUJDF=Y>^.IKB(C>3^-
M<1K6M-<,2374?\(;<+!DHW2N,\1::]ENR"*RH\E[(TJ\]KL31;P&Z7GO7TK\
M([@,T//I7R3INH>5> 9[U]*_!O5 TD//I6.80]PTP,_?/M3PS_R#4K4;[IK"
M\'W ETQ.>PK?KX"7Q,^ZC\*.$\:6)DM9#CM7R%\8K1H6FX]:^X=?L1<6;#':
MOE[XP^$FN%F*IGKVKVLNK*,]3Q\PI.4+H^&/$$S+>-]:SVNCY5>A>*O \R73
MGRSU]*YR3PK*JXV&OT&G5A**/A94YILQM!NC]N7ZU];? ^4LT/X5\W^'?!LS
M7B'8>M?5_P &?#<EL8<J1TKRLTJ1=/0]'+:<E4NSZN\'_P#'G']*Z:L'PO;F
M&S3Z5O5^;R^)GZ$MD8/C#_D%O]#7QA\:/]=-]37V?XP_Y!;_ $-?&'QH_P!;
M-]37T&5?&>/F/P'S)JW_ !]-]:K"K.K?\?3?6JR]*^^CLCX:3U'BBA>E%-@%
M%%%18044450!1113 ****0!1113 ****5@"BBBF 4444K %%%%)@%%%%/< H
MHHI6 ****H HHHH ****E %%%%4 4445-@"BBBF 4444P"BBBD 4444@"BBB
M@ HHHHN 44458!1FBD:LVP%W44VG4T 4C_=I:23[IIA:YFR3&.<?6O:?@_J1
MCNH<GN*\3F3,PKTWX9W)M[J+GO6&)2E3L=&&?+,_0_X7ZF'T^,9_AKT96W#-
M?/WPJUW_ $>$;NPKW33+D3Q@YK\TQ4.6;/T##U.:"+]%%%<1UA1110 4444
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M:=2 8I: "BBB@$%%-R:530,6BBB@ HHHH$@HHHH&%%%% PHHHH($IN:?3=M
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M_%;G72V/1:Y7QI&3;L?:NIW#UKF_&-PBVI!(SBO.6YT,^3/BRA'G5\H>-?\
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MM_%7C=IX@9<?-6O;^)2H^]7!+"L[XXA'JJZHA_BIW]I)ZUYFOBC'\=(?%/\
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M@_\ SU_6O+>&=SK]J?8'_"R(_P#GK^M/7XD1?\]?UKX[/Q1?_GK^M*OQ2?\
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M9<C'O7T#X*^,7V=4!F_6OC_[4UNV5.*TM/\ %$]NPPYKGG14C6,W$_0_P_\
M&9)HU'G?K7;Z9\2XK@#,OZU^>.@_$">';^\/YUZ-HGQ2DC5<R_K7GSPW8ZHU
M3[KM?&5O,HRXK0C\26C?Q+7QK8_%YE4?OOUK6C^,1"_Z[]:Y98>1I[5'UO\
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MU*65]SSJV8=CZOTWXF*\P_>_K7HF@_$)&A&9?UKX6TOQM+&X)<UW>C_$AXE
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MAU7,WZUMQ_&!?^>WZU\8V^O7=J!EFJY_PFMRH^^:\:>6Q^R>M',)6U/L5OC
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M3VZ<]JOU\4?8B$TM-:EI@+1124@%HI,BEH **** "BBB@!K4E.HP* %HHHH
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M %%%%4 4444 %%%% !1113L 4444@"BBB@ HI:2G:PPHHHJ+B"BBBJ ****
M"BBBG<84445(@HHHI %%%%.PPHHHH0!1110Q!1110 4445>X"U1NQ5VJUPNZ
MI6XWJC7\*3>3<H<]Z^I?A/K?E^4-WI7REHY\J93[U[G\-M8\N6(;J\K,*?/
M[\%/DD?;_A'5/M$,8SGBNT7[HKR'X<:EY\47->NPG,:GVK\[K1Y96/O*,N:-
MQ]%%%8&X4UJ=24 -I])@4M !1110 4444 %%)FC=0 M%%% !1110!A^(I?+B
M;Z5X_P"*+W]XPS7J?BJ?;$_TKQ/Q-<?OG^M>O@XW/*Q<K&'<2[V-0K4:ON;F
MI17O;:'C/4?1114DA1112 ****904444$A1110 4444#"BBB@ HHHH$%%%%
MPHHHH ****!!1110 4444 %%%% !1110 4444%!11102%%%% PHHHH$%%%%
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M2Y% "T4FZEH&A**6B@!**6B@04448H&%%&** "BBB@3"BBDH 6F[:7=2T#$
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M444@"BBB@ HHHH ****>P!1111N 4444@"BBBJ **** "BBB@ HHHH ****
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M "KUIU,HS0 K=:2BB@ HHHH **** 3"BBB@ HHHH ***5:!B44^F4""BBB@
MHHHH **** "BD:D% AU%%%!0F!UH\XK2-2;=U,=QWV]TZ&C^U9!W-1F'--\B
MBR#F9/\ VM(3RQH^V-)U-0?9Z>L6*7*B6VR0.6HH5<4^@:(L4HZ4X]:2@;$:
MDIU '-!(NTTE.S2'K0,2BBB@D****"@HHHH$%%%% PHHHH **** N%%%% @H
MHHH-+A11100PHHIRT"&T4ZFT"L.I&I**"D%%%% A]%,HH 5J2BBG8 HHHI"#
M%%.%#4#0VBBB@84444 %%%% @HHHH :U%.HH ****!!1110%PHHHH&%%%% T
M%%%% ,****!!1110 4444#84444""BBB@ HHHH%<****!A1110,**** "BBB
M@ HHHH!!3X3AJ:M)NVTRA-6N-MNW/:O"?B+>X\SFO7?$%[LMV&>U>"?$&\W-
M(,^M2S6FM3RC5[C?<-SWJD#E:2^?=<-1']T5FSO0JT]:;3EI#%HHHH$%%%%
M!1110,**** "BBB@ HHHH$%%%% !1110,**** "BBB@ HHHH$%%%% PHI&IM
M #Z*2EH%L%%%% ;A29I:90,?135IU !1113 92K3J*0@HHHH&%)W--[T55P'
M4M-6G4@"F4^DI"&TJ]:6EH&%%%%( HHHIBL%%%% PHHHH ****!6"BBB@844
M44""BBB@8RE6EI:5A!1113&%%%% !ZT"D-)D^E,FPZBBB@H****0@HHHH!JP
M4444 %%%% !24M-:@JP-24JTM!.PM%%% #6I*?105893Z2EH$%%%% !1110
M4JTE% #FZ4VBB@ HHHH 2@]*1J2@5@IR]**6F(*2EHIW'T"BBBI ****!A24
M&DH):'44E+0-!2-TI:*!C*<O2BEH$%%%-:@8N:6F4Z@0^D:EI&I@)24M% QE
M2+3.*7=0(5NM,IVZDXI!<=1110,**** "BBB@ HHHH)V"BE6EH&-HHHH&M H
MHHI#"BBBF2PHHHH!!1110,**** "BBB@A[B4M,I5H*Z#J*** 04444 %%%%
M!1110 4444!8**** "BBB@84444"L%%%% PHHHH **** :"BBB@5@HHHH$Q*
M6BB@I$L3<U<A>L]3@U:MVK>A+WCFQ$;Q-!:5J(^E*U?4P=XGR51>\,HHHJC-
MA1113$%%%%*X!1113 ****0!1110 4444 %%%% !1112L 4445=@"BBBD 44
M44 %%%%*X!11130!1110 4444 %%%%)@%%%%) %%%%6 4444FQA1112&%#=*
M**+$C:<O2BBF 4444 %%%-I6&.HHHI@%%%% !1112$PHHHHZ @I:2BD 444C
M4 +FBFTZJ ****0!1110 4444[#"BBB@04^F4N:D!6IM+24P"E%)10 ^D,A2
MDIK#=310_P#M)X^A-+_PD4\?1C5=H=U,:S!JG&)G[W0M?\)9<#^-OSI/^$NN
M?[Y_.J)T\9H_L\>E'+#L).?<O?\ "87/]]OSI?\ A,+G/WV_.L\Z<*3^SQ4\
MD.PVY]S2_P"$JN'_ (V_.@Z[++U8UGK8XJ1;4+VI\L>PO?+#7!EZG-(L88TB
MQ8IZ_+5:=#1>8X+BEIN:":D8C=Z***EA<=GBD/6DHI(09HIM*M5<0ZDI:2@J
MX4444K$CEI:;10 E%%% !1112 ****H HHHI6 1J2G44P"BBBI ****H HHH
MI %.6FTM*P#J92YI*8!1115#"BBBI$%%%&: "BDW4;J8"T4FZEH ***1J %S
M13:=4M %%%%4,****!!1112N 4444;@%%%%-(!:*5>E*: &4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1112L 4444P"BBB@ HHHH **** "BB
MBD 4444@"BBBG8 HHHI@%%%%( HHHJ0"BBBJ **** "BBB@ HHHI@%%%%, H
MHHI#04444P*UWPM3>'9BE\GUJ*\Y4TFC?+=J?>E+X2'\2/KWX):EM\GGTKZ]
M\,WHFL4YSQ7PS\(=0\EXN<5]?>!]4\RU09[5^>YG3]^Y]QEL_<L>AGM24D+;
MHP:>:^?/=$6G4B]*6J **** "BBB@ HHHH **** "BBB@!*P=<FV(U;QZ5R?
MB6;:K5I35V9U'9'GGB2YW,PS7 ZA\S-74^(+KYVYKD[AMQKZ/#JR/GJTKLJQ
M_+4V::J^U/ KN9S7!:6BBH)"BBB@ I:2BF(****!A11104%%%% F%%%% !11
M10 4444""BBB@ HHHH&@HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110,****!!1110 4444#"BBB@ HHHH!!1110 4444 %%%% @HHHH ***
M7M2 2BEXQ24#L%&:1NE1,35")MW3FC=TJO\ -0V_TIDD^X4;AZU6^:CYJ.4=
MRSD4;A5?YJ5=W-%A7+ 845$I-2+2L.(M%.VTA%24)1113$%%%%( HHHI@%%%
M% !1110 4444 %.'2FTH:@!<4VEW4E!:"BF[C2B@@6BBB@ HHHH *7-)10,7
M=2444""BBB@ HHHH*'4C4NZD-!(E)BG#FC;0 E%%% "8I<444 %%%%-%(***
M4"D2)2[J-M)0 4444#"BB@T"$W4M-VFG"@ HHHH$%%%% PHHHH **** "BBB
M@ HHH% !13MM-- "K2GI2 T;J $HHHH *-V*;33FG89+NI*8N:?2!A1110(*
M*** "D:EZTHA8]!2N,CHJ3[.^.E'V=_2GS!9C.U)4GDL.HINTCK1>X"JW%+F
MFK2T""BBB@ HHHH*"BBB@D**** "BBB@H****"0HHHH'8****!!1110,****
M!!1110 4444 %%%% F%%%%!2"BBB@ HHHH%8****"@HHHH$@HHHH&%%%-W4"
M'44@-+0(>BU#=-Y:FK4(R*I:J=D9[50TSB_%-]MC<9KPGQI=^8[\UZGXROMJ
MN,UXEXENO,D;FLI'931QESS,:DB^[4<PS(34L8^6H.L=@44M% !1110,*;3J
M;MH)%6EI ,4M PHHHH **** "BBB@ HHHH$@HHHH ****!A1110 4444"044
M44#$HVBEHH&%%%%!.X4444"V"DVTM% Q,8I:** "BBB@&%%%%, I**8QH$.W
M"DWK5>3=VJN_F9Z&BP&AYBT>:OK66WF^AI/WWH:=AW-7S5]:/,7UK*_?>AIR
M^;Z&BPKFIY@]:7<*SE\STJ:,MWHL!;I:C7-/S2'<6BBBIN,****8@HINZE%
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M!1113 **** "BBB@84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1104%%%%!(4444#N%%%% !1110 4444""BBB@=PHHHH$%%%% !1110 4444
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M%%% !1115 %%+@TE)#"BBBJ$%%%%(2"BBBD,**** "BBBG< HHHI %(12T4
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ML!3CBH9 6Z50#C,HIOVE?6JDEO*W0&HOL5P?X31H,T/M*^M'VE?6J(TZY/\
M"U/_ +-N/[I_*C01;^TKZTHN%]:HG3[@?PF@6DRXR#1H!H"0&G9JI'&Z]:LJ
M<50#Z*3-+4E!2;MM+4<BD]*0A3,!WIAN%'>H)(9&Z U UK,3T- &C]H7UH\X
M'%9RVLXZ@U,L4BXR#3T$7-XI#(!42J<4QXG;I2*)3<*.])]I7UJF]G.W0&D&
MGW)_A:GH27?M2^M/2=6[UG?V?<?W34L=K,N,@U6@C05P:*AC5EQFI0:5AH6B
MBBI&%)BE'6AB* N)N"]Z3S@*9(A;I59[>4] :8%IKE?6F_:5]:I?8YV[&C^S
M[C^Z:-!%W[2OK1]I7UJC_9]Q_=-)]@N/[II:#U+_ -I7UIPF4UG?8YU/0U)'
M;RCJ#3 OAP:=4$<;+UJ84 +112%L4#%II8"DW4R12W2@0YIE%-^TKZU6DMY6
MZ U%]AN&[&@"]]I7UH^TKZU2&FW/]TTITVY_NFC0-2Y]I7UI1<+5#^S[@?PF
MG+:S+U!HT%=E\2!J<>E58XV7K5@'BBPPS3J;FG5("-2;L4K5&RD]*8#C,HII
MN%'>H)()&Z U UK/D\&F!>^T+ZTX3*:SA:3CJ#4\<,BGD4!<N[A2%A3%!'6D
M8%NE,0XS 4W[0OK4$D$C= :@:UF]#0!;^T#=5VQD#2"L9;>4-R#6G802>8O%
M#V$>U?#/34O+B($9Y%?8GPU^'\-W:QDQCIZ5\E?"&%UNH<CN*^\OA2P_LU1C
MG;7AXF3.^B._X5K;_P#/-:Q/$'PW@CA8B,=/2O6*S->919L#UQ7G<S.NR/C'
MXJ>%XK*.4A<5\F>-72VNI!Z&OMCXU M%-@>M?#OQ$MIFNY< ]:][!NZU/.K^
MZ<_:7JLW6M'SE85R]C:W"R=#6Y%#+W!KT).S.5$5RNZ0&O2_A?=+:WD18XY%
M>??9RS<BN@T"^-C*I!Q@U,O>B7'1GZ%_!_QK;6=M"&=1P.]>V0^,M-E4$S!<
M^]?F_P"&_B9-IZ*%D(Q[UU\?QLN54?OV_.O#EAG*6AW1K)(^^/\ A*--QG[0
MM>7?%CQQ:363QQN" N.M?+__  O&ZVX\]OSKEO$7Q5GU!&#2DY]Z4<*T]1RJ
MJQA_%+4$NKJ4J<\FO(IO]8U=+KVM&^D8DYKFW^8FO8IKE1PR?,R)5P:?O"T;
M:BDC9NE;;DCC.H[TGVE?6J<EK,W0&H_L4Y[&@-30^TKZT?:5]:H?V?<?W32_
MV?<>AHT"[+WVE?6C[2OK5'^S[CT-!T^X'\)I:#U+WVE?6CSP>]4!93J>0:E2
MWE!Y!IZ"+JMGO3Z@C4KUJ4,*D=QU%%% K!11104%%%% !1110,****";A111
M0 4444 @HHHH$%%%%!5@HHHH)"BBB@H**** "BBB@5PHHHH*04444""BBD-
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MI3BXO0_/GXF:&MA-( N*\<G;;<$5]!_&8#SYL#UKY[N/^/IOK7Z/@9-TTV?
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MB@ HHHH **** "BBB@ HHHH&%%%% @HHHH **** "BBB@ HHI<&@!*44F**
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MGB$SDG3:/&%8]ZE#<5<U336LY""N,5FLV*Z[W,2=6RU:=AIYN6  S6+;OND
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M4#"BBB@;"BBB@FX4444 %%%% ,****"D%%%% @HHHH%<****!A11102%%%%
M!1110,****!A1110 4C4M% M!NTTM+10,*1J6B@D;M-.HI,B@8M%%% !36IU
M,8TWL-$D#?-6O:G@5C0]:U;5NE=.&=I'#BE=%UJA-2;N*CKZ>F[H^6FK,2BB
MBJ;,PHHI<9I7 2BEQ24@"BBBJ ****'J 4444 %%%%*P!1113 ****0!1113
M ****3 ****0!1111J 444M4 E%+M-%2@&D48I:*$,<M0SMM%25!<_=J[ ]@
MLB9I@.O->L_#_P *F^FC.S/->7>';<S7B#'>OJ_X+^'5G\DE?2O+Q];V<#LP
M5/VDSU?X7>!UMTB8QX_"O?--LTL[9%48XK&\+Z*EG:QG;CBNCZ5^=5JKJRNS
M] HTU3BDA:H:EJ"VL1.[%6+N;R86:O)_'_C-;&&0;\5%.FZDK(N<U!79#XV^
M(2:>L@\W&/>O O%_Q>)=P)OUKEOB7\1'FDE59._K7@>N>)9[B9CO/6OL\%EZ
M<;L^2QF/:=HGK>J?$F2=B1*?SK/A^($BM_K#^=>1QZE+)U)J3[:X[U[D<)&.
MAXKQ4I:GO&C_ !.>&1<R_K7IWA?XQ>7L!F_6OCA=5EC;@FM72_%,\$B_.17+
M7R^%1'31QTHO<_1OPG\4$OD0&7/XUK>+M;COM/8[L_+7Q9X$^(TELR;I<?C7
MJ,WQ16>R*F7MZU\O4R^4*FB/I*>.C.GJSSOXR$--,1[U\^W"_P"DM]:]=^(G
MB!=1:0ALYKR6;F8FOK\'%QII,^3Q4E*=T*3M44S<QZ5,D9DP,5T6A^&9+]U
M0G)KN<XP5V<T8N3LC'T_3Y;IP-I-=IHW@66]V_N\_A7HG@WX527&PF(G\*]L
M\)_"T0[-T7Z5X6(S",-F>M0P,JFYX!8?".290?)_2M>'X+NV/W/Z5]=Z/\.(
M%09C'Y5TEOX!LHU^91^5?/U,UE?0]VGED;:GQ,WP5D_YX_I52X^#,BY_<_I7
MW6W@:P(^Z/RJE>?#VTD4E44_A41S6?4N6619\#ZA\*9+=2?*_2N+UOP=+9;O
MDQ7W_K?PWA:-@(Q^5>3^+/A3YN_;%^E>K0S3F>IY]7+>5:'Q/>6LENQ!!J!&
M;O7N/C#X726>\^41^%>4:OHKV$A!7&*^CHXB-5:'A5:,J;U,U6^6C=S4>[;D
M&HUD_>"NAG)<U+2U^T$#%=+IOA)KO&$S5/PS;B:1,BO=_ OAE+H)E<UYU>O[
M-'HT*"J'G-G\,I)\?NOTJ[-\)Y%CSY7Z5]4^'?A_%(B'R_TKH;GX<P^21Y0Z
M>E>!+-&I6/7CEB:N?!NL>!9+//[O'X5S$FARI)C8>M?:7BSX9+)NVQ?I7GLW
MPE:2?_5=_2NZEF46M6<-3+Y1>AX-I/A22Z(^0FNTTOX7R70'[KK[5[GX7^$>
MUES%^E>M>'OA?%&JYB'Y5SXC-$OA9U4<N<MSY1C^"[LH/D_I2R?!=U4GR?TK
M[:C^'ULL8'EK3)O -OL/[L?E7D_VK.YZ"RR*/@C5_A;):*Q\K'X5P.L>')+)
MF^3%?H#XG^'$4L;XB'Y5X9X\^%YCC=A%^E>QA<RYW:3.'$8#E5T?)\T;1L01
M48:NQ\6>&WTZ1_EQBN)<E9"*^GA)3C='SDDXRLRTO-1397.*3SL8J6&(W38
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MO:LT.[!K*%-S94Y\IU3:["O4BD77X&[C\Z\;U'Q3)&Y^;O5./Q@_]\_G7?\
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MU@WEPQSGFM7X=G=?1?[U>IR<L#A;YI'VK\&=/5X(>.PKZ/TS2T6W4D=J^?\
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MC?BA2)&KV,'N>1C#D1_K*N1]*IC_ %E6U/RU[AX\=A:*3=1NI"'[:;3LTPT
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M7T(S:;/G\?6E'8S?$?Q DDD;]X?SK&TSQQ)]H'[P]?6N#UBYD+MS5/3[B19
M<U]M#"PY#Y9XB7,?57@/Q\PDC!D_6OI?P'XJ^V1QC?G\:^"/!>H2+<1C)KZQ
M^$M^[^5D^E?,9CAHQ5T>_@<1*3L?45E)YENK4E\NZV<>U0Z,V[3XS[58NO\
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M@KT3X:_\?D7U%3/X32+U/N/X._ZF'Z"OHS3/^/<?2OG+X._\>\/T%?1>E_\
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MX&ZQ@U$VC6C=8A61#X[L),98?G5V'Q38S=)/UK/ED;7BR63P[92#'E"LG4/
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MCY&KR'Q%)ND:O;P:/&Q;.=S^\-3+TJ!?O58'2O7:/(04444R@HHHH)"BBB@
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MN8;&]I^M-"1\U==I?B8C'S5YHN5-7[6]:/O7+4H*1U4ZSB>R6?B0,!EJO?\
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MHHHH&%%%% !1110,****!!1110,**** N%%%% @HHHH ****!A1110 4444
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M8%+2&%%%% !1110 4444 %%%% 7"BBB@ HHHH **** "BBB@ HHHH&T%%%%
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MJ%%%% [!36S2YHX- $3,U,,CU/M%)Y8H&0"1_6I%9N]/\L4NT"@ 6G4G%+0
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M4M)@.'2@FFT5(!11D450!1112 ****H HHHI %%%%2 44450!1114@%%%%4
M4444 %%%%# ****D HHHJ@"BBBI ****H HHHH ****3 ****0!1113 ****
M0!1113N,****8@HHHI %%%% !1112 ****8!1112 *=NIM%, />A:**5QE*^
M'RUH>%?EO$^M4;RKOAL[;I?K5R^!D+XSZT^#MSM\GGTKZM\*W&^U3Z5\>?"6
MZV^2,^E?5_@NYW6\=?GN91]YGW67R]U'>K]VAJ(_N"E:O /;&T444#N/HHHH
M$%96L-MC-:M8NNMMC:JCN3+8\W\33?>KSG5&RYKNO$LO+5P.H'<QKZ+"JR/
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MVWI=0YF-$'W:S.\FHHHICL%%%% @HHHH **** "BBB@ HHHH **** "BBB@
MHHHH!(****!!1110,**** "BBB@5PHHHH&%%%% "4M%% !3N!3:3=03N/S3:
M0-S2T#04444#"BBBE8 HHHI@%%%% !1113$)2T4E,F^H48%+11<L****0AK4
M+UI:,4ABT444 %%%% +0*,TAZ4V@&/IR]*92YH <W2FT9HIW%8***8:0Q]%-
M6G4""F4^DVB@!M*M+BEH*$I.:=100(.E+110,****!A1110,****5A!1113$
M-;K0M+BC% Q:*** "BBBF2%%%% PHHI,"G<!:*2EI#"BBBD 444A.*!"T4W=
M3J0T%%%%,044455Q6"BBBHL""BBBF4%%%%,!K=:%I<48J0%HHHIB"FM3J2@8
MVE6EVBEH&%%%% !11102]PHHHH&%%%% K!1110@84444P"BBBD,****!!111
M2L%PIE/I*8Q%IU%% KA1110 4444P"BBBD 4444 %%%%, HHHI#"BBB@ HHH
MH)"BBB@H****!!1110 4444 %%%% PHHHH **** 2"FM3J2@!M/I,4M !111
M0)C6I*=1@4 A:**:W6@H&I**5>M AU%%% !11103U"BBB@H****!!1110 4A
MZ4M(:!W&_P 57K0\UG_Q5<M3@U5+XC&M\)LQ-P*'J.(G%#&OJJ+]T^4K+WA:
M1NE)DT9K5HYA****8@HHHHN 4444P"BBBE< HHHI@%%%%2P"BBB@ HHHI@%%
M%%, HHHH **** '+2TVC)H 2BBBF 4444@"BBEI )1113L 4444 %%%% !11
M12N M%)133&+FC=244, HHHI %%%%,04JTE+0,=331FDJ1A11133$+DTE%%(
M04444%7"BBBF2%%%%58!&I*=1M%( HHHJ; %%%%5<84M)10 4444""BBBF 4
M444@"BBB@!](U)DT5("4JTE+0,=33UHR:*8A****0!1113 ****+@%%%%,84
M^F4NZ@!U-HW4E(8X&DI**$PN%%%%,D*;3J-HI7 %Z4444QA1110(**** "BB
MB@!M.HVBBF 4444 %%%% !1114@%%%%*P!2-2T4,!J]:=1BB@ HHHIW 1J2G
M8HP*+@%%%%%P%S1244;C"BBBD(****EC"BBBJ2 ?13<FC)HL(=13<FC)J@$H
MHHH *1J6B@!M.HVBBI8!11130!1111< HHHH **** "BBBD 4444]P"BBB@
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MHHH&%%%% 6"BBB@ HHHH ****!H**** "BBB@04444#"BBB@&%%%% @HHHH
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M%%, HHHI %%%%, HHHHL 4444@"BBB@ HHHI %%%% !1115 %%%%( HHHHL
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MBBB@ HHIK4 *W2FT4^@$(O2EHHH&%%%% !1110(**** "BBB@ HHHH&%%%%
M!1110 4444 %%%% !112-TH 6BF4Y>E Q:***!!1110(****!A1110(****
M"BBB@ HHHH **** "BBB@$%%%% PHHHH ****!!1110%@HHHH&%%%% @HHHH
M ****!A1110 4444 %%%% !1110 4444 %%%% !36IU% #*?1102%%%%!044
M44"N%%%% 7"BBB@84444#"BBB@D****!A11102@HHHH*"DI:*0#*L6_:H.]6
M;?M5PT9$]C0A^Z*FJ&'[HJ6OH<*^9'SN*]U@>E"THHKT6>5N%,HHI""BBBD
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MHHHH$%%%% !1110 4444 %%%% V%%%% @HHHH&%%%% @HHHH ****!H****
M"BBB@04444 %%%%!04444$A1110 4444 %%%%!04444$A1110 4444 %%%%
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M&%%%% PHHHH)"BBB@.@4444 AIZT"G44""BBB@H**** "BBB@04444 %%%%
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M****!!1110""BBB@ HHHH **** "BBB@04444 %%%%!04444$A1110 4444
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M HHHI %%%%, HHHI[@%%%%)H HHHI %%%%, HHHHL,****; ****2$%%%%,
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M***0!1115 %%%% !1110 4444 %%%%2P"BBBF 44446 ****8!1114@%%%%
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M** "BBB@ HHHH ****"@HHHH#0****"0HHHH&PHHHH!!1110#"BBB@04444
M%%%% !1110 4444 %%%% !1110(****"KA1110 4444#T"BBB@04444""BBB
M@84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH$PHHHH!!111
M04@HHHH ****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444%!11102+1Q244""BBB@84444%= HHHH)"BBB@ HHHH **** "
MBBB@84444 @HHHH$%%%% !1110 4444 %%%% "]JD6HJD6@"*X/RFN,\5/\
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M;UK]VO3P>YY.-U0DBXJO5J>JM>\?./<****I,D****8!1110 4444 %%%%0
M4444T 44455@"BBBC8 HHHJ;W&%%%%, HHHIB"BBBEJ,****!!1110P"BBBD
MM "BBBKZ %%%%0,****8@HHHJ@"BBBI ****0!1115 %%%% !1112 ****&
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M "BBB@ HHHH **** "BBB@ HHHH&%%%% @HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@84444#"BBB@3"BBB@04444
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M4#"BBB@ HHHH **** "BBB@ I&I:* &4ZEHH ****!7"BBB@84444"L%%%%
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M%% !1110 44447 ****$ 44450!1113 **** "BBBD 4444P"BBBDP"BBBI
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M\8_ZQZ\^D_UQ^M>@^,!^\>N F'[T_6LKGH1)X_NT^F1_=I]!04444#"BBB@
MHHHH **** "BBB@ I*6B@!-M&VEHH 2EHHH *2EI* $R:.M&VE% !BEHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH$%%%% PHHHI@%%%(:!"TFT4FXTZD"0
MFVC;2T4#$VT;:6B@6H4444#"BBB@ HHHH$%%%% PHHHH **** "BBB@D****
M"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH$%%%%
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M444""BBBF 4444 %%%%)@%%%%2 4444P"BBBF 4444@"BBBK ****0!1110
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MBB@ HHHH ****"TPHHHH)84444""BBB@ HHHH **** "BBB@=PHHHH$%%%%
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M%% T%%%% PHHHH$%%%% @HHHH&%%%% K!1110,****!(****"@HHHH$%%%%
M!2[:2G4 -QBBE:DH$%%%% (****!A1110 4444 )1D4C4E A]%%% !1110,*
M***!A11103<****!CJ:U%% V%%%%! 4444#"BBB@84444"84444#"BBB@ HH
MHH **** "BBB@ HHHH'<****!!1110(**2EH$%%%% KL****"PHHHH ****
M"BBB@+V"BBB@ HHHH$%%%% !1124 -IPZ4VG+0,6F&GU&U3(.I/ W-:EN_ K
M(A/(K0@;IS7IX/<\K&;%UFXIE .117T"/FY;@>E-IU%42 Z4444F 4444( H
MHHI[C"BBBI8!1113N(****6XPHHHH$%%%%5< HHHI %%%%( HHHJ@"BBBD 4
M444P"BBBD 4444/4 HHHI; -I5I:*H HHHH ****BXPHHHHW ****H04444P
M"BBB@ HHHH ****0!1113 ****FX!1113 ****JX!1112 **** "BBB@ HHH
MH ****0!1110 44446 ****-@"BBBIN 44450!1110 4444( HHHHL 4444
M%%%% !11128!11130!1113 ****@ HHHJ@"BBBG884444K""BBBC8 HHHH3
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M04N:2B@&%%%% @HHI:!B44I]J2@ HHHH&%%%% @HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH&%%%% ]PHHHH)"BBB@ HHHH&%%%% @HHHH&%%%% @HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ****!A1110(**** "BBB@ HHHH
M**** "BBB@:"BBB@&%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@84444""BBB@ HHHH'8****!!1110,**** 84444$A111058***
M*!!1110 4444 %%%% PHHHH ****!!1110 4444#"BBB@04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110*X4444#"BBB@!K5*GW:9BI4'% V
M4M0^X:\Y\7?ZN3Z5Z/??=-><^+E_=O2-*>YX5XN_UCUP4O\ K*[WQ=]]ZX*7
M_6FL6CT8HGC^[3Z9']VGTR@HHHH **** "BBB@04444#"BBB@04444 %%%%
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M %%%%2 44452 ****; ****0!1114@%%%%%BM@HHHIB"BBBF(**** "BBB@
MHHHI, HHHI %%%% !1110 44450!1110 4445(!1110 44450!1110 4445(
M!11130!1112 ****; ****D HHHJ[ %%%%38 HHHIW ****8!1114@%%%%6
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M !1110 44N*#Q0(2BBB@+A11104@HHHH **** "BBB@ HHHH$%%%% !1110
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MH *0TM(U K";J=3*?0 4444 %%%)D4#%HHHH ****!Z!1110(**** "BBB@
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M*3 ****0!1110 4444 %%%%-@%%%%( HHHJK@%%%%2 4444 %%%%- %%%%,
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M_K'KSZ3_ %Q^M>A^,A^\?ZUYW-_KC6+/0CL6H_NT^F1_=I](84444#"BBB@
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MMV_W:]/![GEXS862H:L2"J]>^CYM[A11102%%%%%P"BBBJ ****G8 HHHHW
M****6P!1115 %%%%, HHHI, HHHII#"BBB@04444 %%%% !1113N 4445(!1
M112 ****; ****D044Y:4U2&AE%%)NH&+12J10Q%58!**,BBHL 4444 %%%%
M @HHHI@%%%%( HHHH ***5:$ <TE/I-PH8QM%+N!IU.PQE+3J0FF*PE)1FBE
ML2%%%% PHHHH ****0!1111< HHHI@%%%%, HHHI6 ****8!11118 HHHI7
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M#0!ROB!<JU>6^(E^9J]7UQ<HU>7>)%P6KU,+N>7B3A;OAS4*5+>G$AJ&(U]
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M-_KC63/0CL6H?NT_-,A^[2TBQ]%(O2EH **** "BBB@04444 %%%% PHHHH
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M1FZT(I$3?>K0TT?O!6>3\QK0TW_6"E(E;GMGPO?;-%7U%H.L"UTU3GM7RO\
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M2'-=]K_AUK=6.*X26WV76T^M.CRVNA5U+9C++P^UT<A<U9NO"\D,>=F*],\
M>'TOPN5S7:>(/ J1V)8)VKGGC.6?*73PSE#F/EB^MS;N0>*K*]=3XVTLV=PX
M QS7&[BN<U[-.2E&YYLTXNQ9\P9Q6C8Z>UT1@9KGHYRTX%>N?#KP_P#VDR97
M-16G[./,.E'VDK'/0^&92N=E0W6DM;@Y7%?1T?P]5++>8^WI7EOCK25T_> ,
M5YE/%>TE9'H5,/[.-V>472A>*HK:R32845=N,R7!4>M=OX.\)G4)$)3->A*I
M[.-V<7+[1V1S.D>'9IF'RFNWTOPB[*,I^E>KZ#\.8XX58I6W_P ([;V8P0*\
M:KCN9V1ZE'"<JO(\=G\'';]RN<U;PA*JG"?I7T$NFV\K;<"KDG@>&\AR$'2L
M8XQQ>II/"\VQ\AWVBRV['*D5DR9A;!KZ*\;> !;([*GZ5X'XIT][*X88QS7N
MX?$1K(\BM1=+<CT]?/8"NFM?#[W$8(7-<[X3C,]TJGUKZ+\$^#5U"V0E,\>E
M1B:WL=2L/3=;0\)U#PU-'GY#6?!H,[2?=-?4^J_#%?+SY?Z5E6?PUC$W,?Z5
MR1S"/*=3P4N:QX79>$YY%!V&I;GPO+"F2A%?3-C\.[=(QE!65XC\$PPPMM45
MSK,%*5CI>!:C<^6+_3WB8C%16>ER3N %->E>(/#.+A@J]ZU?"7@<W$JDI^E>
MF\2E"YYJH-SL<=I?A263!*&NDMO![%>4_2O9M/\  <5O &*8ISZ+! V,"O*>
M,N]#U(X3E6IXG>>#F"\)7,:IX7ECS\AKZ6&A6\_85F:MX)ADA8A1TIPQMGJ$
M\+=:'RQ<:;)"W(Q58C9UKU?QAX;2SWD+BO*-2/DS,*]NC4]HKGC58>S=A,YH
MJ*%MU35LS(2EW4E5Y)=IIQ0FR5E+=*FM=-DF88%6]%LS?2* ,YKUGPKX :ZV
M-Y>?PKEKUU2W.NC1=1G"Z1X8EEQE#74VO@]O+&4_2O6]-\!QVL:EDQ^%:!T2
MWA&,"O(EC.9Z'IQPEMSQ>;P:Q7A/TK U3PG+%D[*^CK70[>?C JOK'@V!H6(
M45FL99V*EA+K0^3+[3)+9CE<50^Z2#7KGC;PVEJ7(6O*;R$QW!4>M>W0J>T5
MSQZL/9LK-$TG K0TW0YIV'RDUN>&/#[:A(HVYKV;PQ\.%:-6:/\ 2LJ^*C2T
M+HT'4=SS31_",DBC*5O?\(:?+^Y7L$'A."S3E0*&TZ#=MXKR)8QR>AZBPZBM
M3PO4O!SA3A/TKC]4\.S6Y/RD5]96_A."^C^Z#7)^+?AVBQ.RIVK2CCM;,PJX
M1M71\GZE;M%G(K3\&_\ '\GUK?\ &WAMK.1_EK#\*Q&'4$S_ 'J]^,U.FVCQ
M^1QJ:GUS\+7'V6/Z"NR\7./L+?2N$^%LG^BQ_2NU\5_\>+?2OBZ_\8^QHO\
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MHHJA!1112 **** "BBBF 4444K %%%%# ****0!1115 %%%% !1110 4444
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M-7#;FJ>>\:7J:JM\U>C3CR(\VI/F9&M2+3<4Y:VN1;0=11102%%%% !1110
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M:^@/ OPV5HT9X_TK!^%OA=;ZZ1BF>:^D+715TC30X3&!6M:H[V1G3CW,+3_
MUE;Q#<JU5U;P_80J0 M8/B[XC?V0[KOQCWKS#6OC$9-P\W]:RC3F]324HQ/2
M8]/LH[H8"]:]J^&ZP1Q+MQ7Q98_$Z2YOE D/7UKZ6^#_ (DEOHX\DG-.M3:C
MJ*,U)Z'HOQ3G_P")5+C^Z:^(O&W[S6'_ -ZOM+XB;IM'D)_NU\8>-AY>L-G^
M]_6EAB*FYW?PQM1A#BO8+JY-O9'''%>1?#&\3:@KUJ\A-Q9_*,\4ZOQ:EPV/
M%OB/J!D609]:^=_$4/FW+'WKZ&^(>ERJ)#@UX!KT;1W#9]:[,.<M3<R;6T J
M62W&*DMSD5)-"[+P*[69(R54+./K7K?PT;]['^%>3FW<3#(KU?X9J1-'GUK&
MH_=*AN?2WA_FR7_=KE_'"YC>NI\.K_H2_2N9\;?ZMZ\F/Q'<_A/GSQ=;[G>O
M+;ZR_P!*_&O6_%GWGKS*_;_2OQKUX;'#/4]*^$MOLN8OPK[ \)MMTU/I7R3\
M*?\ CXC^HKZT\*K_ ,2]/I7GXC<Z:)R'Q(;,4E?-_BC_ %S_ %KZ-^(W^J>O
MG+Q/_KG^M.@.H<7-_K#3H_NTV;[]/C^[7I',.ILGW33J9)]TU(6,J1<W ^M>
M]_!&/_28?PKP5O\ CX7ZU[[\$6_TF'ZBHK/W"H+WCZ]TZ/\ XDX_W:^=/C3'
MF26OH_3SG1A_NU\Z_&B,F26O(H_&==3X3Y?U:#_2'^M8OV<?:%^M=#JT969\
M^M83MMF'UKWH[' SWGX'Q[;N'ZBOL[2VVZ&/]VOC'X(3#[5#]17V=I;"30QC
M^Y7CXKXCMH['RW\?K@^9-SZU\JWC>9>/SWKZI^/MC))),0*^6;BS>.\;([UU
MX=^Z85=R":W'!KT;X7KY=Y']:X&9>@KT/X8VKR7D6!WKKJ?"8QW/LKP%>%=.
M09[5C?$EO.MWSZ5L^ [%UT]"1VK'^)&(;=\^E>#]L[NA\P>+K<+<2'WK@[KY
M6KO?&%PK7#C/>N!NOF8U[%/8XY;B1U)4<=25H,5:6FYI=U "4444""BBB@84
M444 %%%% !1110.P4444$A1110(****![B44M% !24M% PHHHH%N%%(U)DT
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MQ&.4X<J-G26^T:F&']ZOHGP$FVU3Z5\X^"F\ZZ0GUKZ7\%1[;5/I6^-T5C'
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MF9_$6****HD**** "BBB@84444""BBB@:"BBB@84444$A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444""BBB@84444#"BBB@04444 %%%% !1110
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MI1XN&^M9,[Z;T*\9XI^:C7BGK2-QU%%% !1110 4444 %%%% !1110 4444
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MWXH:@LUE)\W:O+C_ !#N?PGRYJES]FU8G./FKVSX4ZTLGE(6KY\\777EZBS
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M6PTM3VOX9_ZZ*OI/2X0VFC_=KYB^&]P$FBY[U].^&[A9K%1D=*^0S#25SZG
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MX+1G3>*\?96^E?.7CC_CX>O>O$^I*UJW/:OG[QI,)+A\>M3@$[E8YZ"^"?\
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M/D1C.?,)MI*<M+6US$?!,86!!K?TW6FC(&ZN<VU+&Q0YZ5E*"D7&;B>E:=K
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MM3Y'WFF8KT(QY4<4GS,<M+2+TI:9%PHHHHL2%%/IK4P$HHHH **** "BBB@
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ML8UR"N:\#\5?$J2SE;$F/QKD/^%O2LQ7S3^==<,.Y(P=1(^B/$/C2*QC;RW
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M IK=:=28H$*O:G&FTJT7&)13J:W6D 4F*2A: %I:*9FD!)NH:F!J=3&%%%%
M@HHHH'<*?&,XJ(]:LPCI5(SD6(5JTE1Q+P*EKWL(CYS&/4D[4UNE&XTG:O4D
M>3'42BBBIY2@HHHI6$%%%%4 4444 %%%% !1110 4444 %%%%( HHHIWT **
M**0!1113O884444""BBB@ HHHH ****FX!1113 ****+ %._AJ.G9HV*0UNM
M36[;6%1\4JG:12>I1Z)X/U@6LB$G%>\^%/'*10H"XZ>M?*-KJ1MB#G%;MGXV
MDM0/G(_&O+Q&#]L=U'%>R/K>X\5V]TG+@UFMJEIN)RM?-L?Q*E48\P_G3_\
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MCBO%89S&V:TX=>:$8#5TU:'M#"E5]F>PZUXL$T)&^O+]?O\ [1*QSGFLZ;Q
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MBB@84F*6BF FVEHHH$%%)NHI# K2;?:G450@HI-U%(8A- -!% %(!U%%+MH
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M0=S6EY8]*3RQZ5#8[$,:D=:G44NVC=2W*%HI-U+3V 3;1MI:*+@A*6EVT;:
M8E%%% D-VTY5HI5H ,"DI2W%,W4##;1TI:0B@ !IU(JT[;2 2BBBF 4"BDH
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M%%% !112KUH 2BGTUNM Q***4=Z& E%%%(!M IU(U,!:*;3J "BBB@04444
M%-+4ZD\LFF,;G-%*%Q2M04-HHIRTK"8+TI:**!!1112$*W6DHHIC"BBB@044
M44 %%%% !1110,****!!1110 4FZES2!330T-\RC?3_L[-2_967M2=@LQE.%
M&W;UHHL,****!,0]*3%.HH&AE%/V4>6:H6HREIVVBDQA1112$%%%%!(4444
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MADE%(&I:1(4444""BBB@ HHHH **** $R*6FTJU0"T4O84E0 4444P"BBB@
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M7-4J<QT0C8Y?Q(H^SM]*\&\<* SU[_XLMVAA<'CBOG_QPWSN*WHF=0\MNO\
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MH&%%%% !44YPM2U#<?=ICN5;&0M>*/>OI#X.Z,M\T.5STKYMTU?]/7ZU]7_
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M5T?Q(\6&TAD^;]:^9O$_Q*9;QE\SOZUI2HN1,JB.N\63120MMQ7EDVG-=7V
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MUJ> _B>UW>1@R9Y]:['1DE<Q]HKV/JVU\(6^IQ[M@-4]3^'=K;J6,:C\*TO
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M%%%R0HHHH$%%%%# **** "BBBD 4444T 4444P"BBB@ HHHH **** "BBBF
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M&WQ)/G/B3]:Y;1?B0QNQF3OZUUT\!.4+LQEC(1E8^M=/TFVU*'.%.17'>._
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MZ5A>,%_=M6]H?_'L/I6%XP_U;5XM/^(>Q4_AGE%Y_P ?)^M=;X3/S+7)7O\
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M!_X_D^M?8WPR8_88_I6N:$999$OQ6O&73Y,'M7Q%\0]0F.H288]:^TOBH?\
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M*** "BBB@ HHHH **** "BBB@ HHHH ****!V"BBB@04444""BBB@ HHI=U
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MB<+CJ=!X#\*O+<1MM/7TKZH\ V9TNQ7(QQ7$?#_PBMO#&SI^E=[JFHQ:19D
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M **** "BBBF 4444K %%%%4 4445-@"BBBF 44455QA11128@HHHJ0"BBB@
MHHHH0"-]VH5^_4S?=J%?O58'3^'O]8M>\?#U?]77@_AXXD3ZU[M\/Y@OEY->
M/C=$>EAOB/5KZ/\ T$_2OG+XKKM:6OHN\NE^PGGM7SK\5W#&6O+P+_>'H8M>
MX>!3'_3C]:]0\ _>2O+IO^/X_6O3O ;;7CKZC$?PSY_#_&?0/AM?]'7Z4GB1
M/W+4WPW<#[.O/:CQ%.&A;GM7R+E^\/IG'W#Q#QHN-]>2:A_Q^'ZUZYXT;/F5
MY)J"_P"F?C7UN$^$^;Q&YZU\)5S<1?45];^&(_\ B7+_ +M?)7PF8)<1?45]
M:>&;I1IJ\_PU\UFGQGO9=\)Y_P#%%<0RU\O>(O\ D(-]:^GOBA<!H9.:^8?$
M'.H'ZUWY;\!PX[XSTOX3+F:*OI:WC_XE?_ :^:OA.X6:*OI2WNE_LO&?X:\_
M,/XAZ.!^ \+^*0VM)7B]G=;-2'/\5>R_%:4,9.:\&\TQZAG_ &J]3!QO3/,Q
M;]\^M_@S?!HXAGL*]2\9V/VW27QSE:^=?A'XD6U:(%L=*^B[?6(=2T\*6!R*
M^=QD73K<Q[>%M.ERGQA\5/"LGVZ5MIZUYI#I[6K$$8K[!^('A%+XR,J9S7AF
MO>!Y(9FVQGKZ5]'A<6I029X.(PKC-M'G\<9DX J9='>;^&NIL?"$WF#*'&?2
MNJL/">U1N3]*ZY8B,=B84'+<\TAT1XV!Q7I/P[A,=U&/>EU#1D@7I5KPGB&^
M0>]<E6K[2#+C3]G-'T_X33=IJ_2O+/C-%BWE^E>E^#[Q?[-4$]J\T^,DZO;R
MX/:OG\.OWY[M=IT3Y&\0#%^_UJK_ ,LQ5OQ!_P A!_K555W1BOMX[(^/MJSH
M/!<NR_C^M?8OPIOQ]AC7/:OC#PZ_D72'WKZ3^&?B=;>.-2_I7B9E#FCH>UEU
M3EEJ>M^/K$WVGOCGBOE#QYX;>.ZD;;WKZ[6_BU2RQD'(KROQYX3%RLC*F:\?
M!5W2ERL]/&TO:+F1\F:E;F'(Q3_"]BUQ?)@=Z[?Q#X+F^T, A_*M3P/X)D2\
MC9HSU]*^IEB(JG>Y\Y"A*4[6/9_A/X=8V\1V]A7HOB:S^Q:>W&.*F^'>G1:?
M8IN &!5;XG:U##8R!6'2OBYU'5KZ'UL:<:='4^9?B1J@6XD7/>L#P+-Y^I)@
M_P 59/Q&U8RWTF&XS4OPSN-U_$3ZU]8J?+1/E74O6/N7X8PDZ7'_ +M<K\:K
M4M9R\=JZKX77:?V;&,_PU1^*]J+RSDP,\5\C3ERX@^KE'FH'P5XOA*:C)QWK
M&CM3.N *]+\9>%)9+]RJ$\^E5="\$S22#,9Z^E?;1KQ4$[GR+HRY[&?X#\-R
M27\3;.XK[,^&.G-9Z:F1CBO*? O@<6S1NT>*]NT^XBTFP R!@5\YF&(]K[J/
M>P-#V7O,XWXN7(6UD&>U?-T.I"'5LD_Q5['\5O$23QR*&S7S;J6IF/4"P/>N
M_+Z-Z>IQ8VK^\T/JKX?ZZ)+>-0W:NNUI9;BV8KGI7@'PO\3?O(E9_P!:^EM"
MD@U&Q7)!)%>1BX>QJ7/2PTO;0L?/'CRXNK+><L*\=U#QA<P7##<W7UKZK^)7
MA&.YAD*+GBOFSQ%X!F^U.50]?2O8P-6G*/O'F8NG4@]#&A\;7##[[?G5A/$U
MS<?Q-3;;P+/N'R'\JZ72O K\;D-=]2=*.QQ0C5EN<\UU<W ZM5.>PEFY(->H
MP^#UCC&5JE>:+'#QBN>.(C?0['AW;4\VCTN16R :T[2ZN;'!&X8KN-.\/I<2
M ;:U[KP%YD!(3M52Q4;VD8?5Y;Q.'MO']S8@ R,/QK>T7XH337"*9#U]:YOQ
M%X)GA9MJ'\JP]'\/74-\I*MC--PHSC<S52K"5C['^&>L'5DCW'.:]!\2>'4F
MT]FV]J\:^#K/9+%OXZ5[7K6OQ+I9!8?=KX[$)QJ^X?68=J5*\CY.^*.CK;SR
MX'>O%;Z+RY&KW/XK:DDUQ+@]Z\/U!MTAQ7UF"YN17/FL7;G=C-_BJ1>U-V_-
M3Q7KGFD,W2KNA\7"_6JLHJQIK>7*#2EL-;GNO@&0?NQFO:-/MC-:#'I7SUX(
MU98Y(P37T3X1OH[JU49[5\IC+Q=SZ+"6DK'GWC[366%SBOF?QM"5G<8[U]G^
M.-'%U:N5&>*^8?''A*5KIR$/7TKOR^NNIRXVB^AYMX:C*W2GWKZ/^'.IB&.-
M<UXEI_A^2S?<5QBNY\-ZL;&5%SC%=F+M56AQX=ND]3Z-D3^TK/ YR*\I\<>$
MWQ(VVO1O >L1WL:*S UT?B?08;RQ8J <BOG(5G0J6/=E!5H7/B#Q58FSD<$8
MK!TG][<@>]>R?$;P;(TTFQ#U/:N(T'P;.M\N4/7TKZBGB(NG=L^;J491J62.
M_P# 'AY[HQD+FOH'PWH[:?:J2,8%<S\+_#2PPQ%U[5Z=K,T.GV!P0#BOE\56
M]I4Y4?286BHPYF<#XVU@0V[J3VKYE\>W0N+B3G->H_$3Q,/,D4-7B.M7ANI&
M).:]K TN579Y6,J*3L<]"O[PU>7[HJ!4^:K Z5[+9Y:%6JU[]VK%070W+0MP
M;T#P_P#\?R?6OJ?X4R8AC&?2OEK11Y=TI]Z^AOAKK*P+&"WI7FYDFX:'9@-)
MGM'B*(S6!QSQ7SGX^TUO.D.*^BTO4OK/&<Y%><^,/"YN]S*F:^>P=3V<M3WL
M53YXZ'R]K4!CW<52\/KOU!![UZ'XL\'RQL_R'\JY31]'>UU!25QS7UT:JE3T
M/FI4W&9].?!O15GBB)'I7M&M:=]ATTE1CY:\B^#NIQVD<2D@=*]IUB_COM.*
M@@G%?$8N4O;'UF&Y?9'R_P#$;Q//8S2@,1@UX[JGC:YE9AO;\Z]N^)7A5[V:
M1E4G->/77@.;SCE#C/I7T>#E2Y5<\'$^TYK(RM#U>ZNKY<,QYKZT^"\<\D,1
M;/05X5X+\![+J,LG>OK/X7Z'%8VL?&.*X\RQ$.6T3LR^A/FNS1\<0E=)?/\
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M47>![]+%1DO>.O\ %WA&WDC8A17BVOZ''I]P6  Q7H^K?$B&XB(\P'\:\O\
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M-MZ4W[8Z=#3V7=3#"#2]0N*-2D]:=]N=N]1^2*7RJ- YF+]H-"S&DVTOET]
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MHHH*V"BBB@04444""BBB@84444""BBB@04444#04444 %%%% !1110 4444
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MPVK.PXJF2E<%C+4[[*U:MGIK-C(K4CTKY>G:L'64314FSE&A9:C/RUTMWI9
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MR5R8[GK7@'P0MW"I*9X]*W?%WP_2WL681XX]*[OX9Z4$MH\KVKIO&6DK)I[
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M:>Q\^%%%%2 4444 %%%%.X!1113W ****EH HHHJD@"BBBE8 HHHI@%%%%,
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M@KBK5G>R.ZE25KLY<Z>L/:@1(W%1ZWJ@A8X-8,>O#S/O4X1E)7%.48NQTO\
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MV5:N:C?G.RI\&AYKJ1_>'ZUF-UK2U+_6&LQJ^@AL>!-:BK2TB]*6J("BBB@
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MEFV?2N(\"ZLLT:8-=3XCU98;)B3VK@FGS'2MCP_QIHT4EPY(%>>ZIH\4<;$
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MBW!-7/@KQ1HYL9F&,<UGZ-#YLP%>A?$ZP6*ZDP.]<AX4M?-OT7'>O6A*\;G
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M;4&7"YS6#)I;B_Q@]:]H^&/AO[4T>5S7N5ZBIQN>/0IN<K,N>%/AV9]K&/\
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M<=Z[OPKX?2;9D5QMQ=+]K+>]=AX=\1QVJKEA7L5'.4=#R*?+&6IZ;I?AN*-
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M8\=:Z)--A7L*L1VD2<\5M*MS&,:/*&GJ[+S46K6X\LY%7EGCA7K61K&I*R$
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M!C&49J.20QD8J5NM5[@9IDG>?#C5'74(AGO7V_\ "^]:32XR3_#7PE\.X_\
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MH>)+:SLRH=1QZUS5).3T-Z<5%'CGQ6LU9I#BO%+68VNH<''->L_$3Q!%=M(
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M/A_J@\^)2W<5M5U1%-GT78*9++CTKR[XF0/Y,G%>Q>$8%O;!>_%<?\4O#_\
MHLA"]J\^$K2.F2T/BCQ@I%T_UJ/PRC-,N!WK?\::._VYP%[UH>!_#33SIE>]
M>LY+E.-1=ST7P/;R_)P:]8M8G6UY':HO ?@C]RC%/2NYU+P^+.S/&.*\JI--
MG=&.AX%X^X#_ $KS+3O^0@/K7IWQ(_=M(*\OTMMVH#ZUW4OA.6H]3WOP)S;I
M]*Z#Q /]'/TK$\!*/LZ?2N@\1*/LQ^E<<OB-EL>%^-%YDKQC7_\ 7&O:?&V-
MTE>*^(#^^/UKT:6QR3.A^'O_ !^1_6OKWX=_\>,?TKY$^':_Z9']:^P?ARH^
MQ1?2N7%(WI%KQH#]E;Z5\Y^+I=MTWUKZ5\:1C[&^/2OF#QV_EW3X]:QH1*J'
M7?"^8->Q?45]2:?#YFB\?W:^/_A?J(CU"/)[BOL7PC<1W>DJN<_+48C1W+HZ
MH^7?CM82>9-@'O7S+-;21WC9'>ONSXO>$!?+*P7-?+'B3P<]I=.0G?TKKH54
MXV,:L=;G(6X/EBFS1LP.!6HNFNK;=M;>G>&WNL96NGF2,EJ<;!;2;AP:[;P@
MI2YCS6NO@LQQ[BE)8V/V&\4=.:3FI+0KEL?3'PK.;>.NF\?(?[,?CM7)?"&X
M61(P37HWC:Q6;26(Y^6O(GI,[(ZQ/@_XIH?MTOUKSNU4Y->P?%;27^VRX7O7
MFL.ENN25KUZ3]TX91U(M-_X_$^M?5_P&_P"6-?+-G;F.\3([U]4_ 7&8<^U9
M8CX2J6Y]"^(U/]AG_=KXU^*_R:A(?>OM7Q BG0S_ +E?%'QH;RKR8^YKAPSN
MSHK+0S? MXJW"C/>OH;P[_I%HNWTKY*\&ZQLU!!GO7UO\+V6^MXP3GBM:\;:
MD4CF?B!I\GV:0X/0U\N^-('CNGR,<U]X^-?"RSZ>Y"Y^6OD3XF^&6M[J3"]S
M58>HMAU8GE%JI:MW0;.1[U,#O5?3]*D,^W;WKU?P/X,:YFC8I7=4DDCGBKL]
MS^!<+PQQ;AZ5ZYX^O%717&?X?Z5R/@'15TFV0D8P*A^)7B)8[&1 _:O%^.IH
M>@O=B?+/Q$D#ZQ(1_>KIOAC_ *Q*X?Q9=_:M4<@Y^:N^^&*?-'7HU8V@<:=Y
M'O>G_P#'B/I7FGQ(_P!5)]*]1L%'V$?2O,_B0H\F3Z5YU'XCHEL?*OC7_CY?
MZU7\(#_2D^M6O&PQ=/\ 6JW@_P#X^D^M>Y;W3AZGTW\.1^ZC^E>FW8/V,_2O
M-OAOCRHZ]/O /L9^E>74>IZ$-CQ7QY_'7AGB#_7-]:]W\? ?O*\)\0?Z]OK7
M51.:IN9-O5JJMO5JNHR&;L4UEW4C-\U6;9-["F]B3J/!>BF\ND&W/-?4'P_\
M" 6L;F/MZ5XK\+;!&O(LCO7V9X)TZ%=)0X&=M>3B)V>AUT8G!:]?IX;MST7:
M*\HU[XT+;R-&)1^==Y\<MT-O-Y?H>E?$GBNYO&U)P"W6KP]-35V*K4<6>UZM
M\5C>9VR9S[U8\'^+I;K4$Y)!->.>'=*NM0*@ACFO<OAOX#E\Z)V7N*VJ1C%$
MQDY'U)\/-3,FG(6]*XSXTZ@/L<H![5UWANQ_LG31GC KR#XT:T&BE4-VKS:<
M;SN=4W:)\L^+)#<:HP!S\U=]\+M.831,1WKAI(/MNJ'O\U>W_#?11''&V*]6
MI/EC8XZ>K/:]#N/LNF@9Q\M>._%[4/,CEY]:]+NKL6=F1G'%>%?$S5/.609S
M7'17O7-JFUCP/6I-U\WUK9T&W^T,O%<_JC;KT_6NV\"VOVB1.*]26QQQW/5O
MAUI)6:-MM?16E77V/2\9Q\M>9^!-%"1HV*[C5KH6=BPSCBO'JRO(]""LCQ_X
MO:IYTD@W5R7PUC$VJ(3S\U)\2-2\ZY<9[U)\*V']H1DGO7;%6IG*_B/J?2K8
M+HH('\->#_%II$DDQFOH?052;2%7/\->0?%;P^9O-(7/6N&E)<YU2^$^5-6D
M=I'S7)W2LTXP.]>CZ_H;Q3.-O>L2S\-O<W0^3O7L*22.%Q.O^$^F27%Q#E>X
MKZW\,Z&8=-5BO\->4_!CP+^\A8IZ=J^H$T-+'2.F/EKRZ]12E9'92C9'SY\2
M+K['&XSBOG/Q-J?G3/SWKW3XV7@MVE /K7S'J5\9;EQGO732C[MS&K(JS?-(
M34D?2F?>Q4JUV19SBTV3[IIU-?[IIE%!A^^'UKTSX>G$T?UKS8K^]%>@^!YA
M'-'GUJ:FP1W/I?PP?]%7'I5+Q=&S0M@=JD\%W"S0H,UT6N:.+FV) SQ7D\R4
MM3NBKH^6/'$;*\E>2WDA6ZQ[U[_\1]#:+S,+7A&H6+K?=.]>E2E='%4T9Z%\
M.=*_M":,$9R:^I_ O@Q8;='\OMZ5\^_!NU"W$.\=Q7V7X1BA_LU.F=M<.*E8
MZ**,#5-97082/NX%>8>*?BX(@ZB3'XUVGQ1MF,,FROE#QM#=K/)C=65""EN:
M5)..QT&N?%8S7! D[^M=9\.?&SWEU'\QZU\X?V==7%T,ANM>]?!KPO,UQ"64
M]17=5C&,3EC*4I'U5I&H/<:6#_LUXC\8L[)2?>OH30]!\C25R/X:\(^-EN(X
MYOQKSZ+]\[I+W3Y+U/\ Y"A_WJ^B/@'_ *Z'ZBOG75&_XFI_WJ^C_P!G\ S0
M_A7IU_@.&*]X^M)E/]@G_=KXT^/B_P"E3_4U]JS(O]@G_=KXP_:  %U/CU->
M;A_B.FI\)\U[?](;ZTLB_O%H_P"7AOK4C)\RU[:.$]>^$$RQW46?6OL;PO>(
M^EJ ?X:^'_A[?_8[B,YQS7U7X \0+<6\:;^U>9B8]3KI,QOBQ9O<+(5&>*^7
M?%&ES1S2$J:^Y]<\-IK%J3C=D5X;XZ^''EM(0GZ5G0J*.@ZD+GR/J5O+YV,'
MK7;_  YM)?M,?!ZUT=]\/RUUC9W]*]'^'/PW_?1G9^E>A.JN4YXTW<]%\$VT
MBV:9':H?&Z%;9\^E>I:#X-^RV*_+VK@_B58_9[>3CM7EQE>1TRC9'S!XF?;?
M-]:]*^#<R_;(OJ*\L\72;;YOK79?"O5A:W4>3CFO1E\!S1^(^Y]#U);?1U(/
M\->*?%;QP]G))AJ[;P[K:WFEJH;^&O+_ (I>&I=061E!.:\F"7/J>A*_+H>6
MR?%AHISF3OZU97XOKM&9?UKR_P 5>%[NQF<@-C-</<_;(I,?-7K1I0DM#BE.
M2/H:3XO'M)^M8^J?%*:X4@2'\Z\DTJSN[IE'S5U-OX4N)(]Q4U#IPBR5*3&Z
MEXJEOG.6)I-(N/,N%)YYJI?:#):9)!%0:;-Y%TH/K6RM;0EMWU/I;X7C=Y>*
M]/\ $43?V6W'\->6_!V99FB!/I7NFL:8LVD$C^[7FU-)'9#X3XE^+2$74O'>
MO([=3YQX[U[U\8M'9;J7"]Z\:ATMUF/R]Z]2DURG'-:CD!VBGU8>U,:]*KM\
MM:$A2;:*-U(8FVG*O-)2YH =3:,TW=0 ZDI-U*#F@+!MI:** "FDT;J7'- Q
M!UIU)BEH **** "BBB@ HHHH *0C-+10(0#%+113 ****8PJQ .:B5<U;ACK
M?#QO(Y,1*T2Y#TI[-3$XI37T\5:)\I-WDPI***:(844450D%%%% "TNZFT4K
MB%I***& 4444( HHHI@%%%% !1112 ****!A1114B"BBBJ ****5AA1110(*
M***: ****& 4444@"BBBJ ****5P!J;DTXTFVD O44!1VI&.U:2!]\@6B]BD
M2PS2PR J37;>&?&4^FNI+$8JGHOALZ@HPN<UHZAX+FMX2RJ17'4G3E[LC>,:
MB]Z)ZEH/QH^RQJK2X_&NJL?C)'>,!YH/XU\EZM%>6,A +"K?AK5KM;A06;K7
M'4P%*2YD=M/&U(.S/MC3?$T>K1CY@<U7UKPVFI0LP0'(KS7X=ZE(ZQ[B:]ST
MV2.2S&X]J^;K1>'E[I[U*2Q$=3YC^('@H6Y=MF/PKB/#-K]CU-1C&#7T)\3X
MH?)DQBO"+7"ZP,?WJ^@PM9U*6IX>*I*G4NCZ=^'LF[34^E<K\7%/V:3%=-\,
MP7L4'M5'XI:89K63 [5Y,)*.(U/6DN:@?&OB)3]M?ZUA7D;,AQ7<>*M(>.]?
MY>]9-OHKW# ;<U]A"K'E3/DI4VVT5? EG(VI1\'K7W!\([-ETZ/([5\X_#WP
M4?M<;%.]?6?@FS33=-7/'%?/YI74E9'NY;0<'=G/?%+$=I)]*^>/MBKJ1R?X
MJ]P^+FL)]GD ;M7RYJ6N>3J3'=_%4X&FY4Q8Z:C,^D_!.HH(4P:[2\UQH;?(
M/:O#?ASX@%QY:[J]KATLZA8Y'.17GXBFHSU._#U'.&AYWXL\?/9[\OC%>?3?
M%C;,09._K71?$[PM-&LA4&OG;6M-NX;I\!NM>QA</1J1/)Q5>K3D>W1_%D%>
M)/UJ"X^*C,#B3]:\.ABN^!\U:VGZ7=7##AJZW@Z,=3GABZLM#T"_^(DUPI <
M_G7._P#"1/=W0W-WJ2'PG.T.XJ:R;C2WL;@9&,&KA"DM(BG.H]6?1'PA=9I(
ML^U>X:Y;;M'.!_#7SA\']66&:(%L=*^FXI([_2@,Y^6OF<9>%6Y]#@[2I6/B
MOXS6<GVR7 /4UXY:PNLQR.]?67Q8\'_:9)6"9KY_U/PR]G,WR=Z^IPF(C*DD
M?.8JC*-2YBJIVBHI(F/05JPZ>[-C;6U9^'6F496NEU8QW,5!SV.5M87W#BO1
M/ JE;F//K59?"WEKDK6[X9L_LUX@QWKEJUE.+L;4Z3A)7/ICP!_QXI]*P_BM
MG[%)]#_*M[X?$?8DY[5C?%<#[#)]#7RU/2N?2R_@GQOXR_Y"+_[U=C\*_P#C
MZB^M<;XR/_$Q?_>KL_A3S=1?6OK*W\$^4I?QC[%\& _V8G^[7FOQG'^CR_0U
MZCX+4?V6O^[7FGQH4?9Y?H:^1PS_ 'Y]767[@^+O%2_\3)_K6WX/^^E8OBO_
M )"3_P"]6YX/_P!8E?=R_A'R%/\ B'OG@C[L=>FO_P >/X5YMX'4;4KTYU'V
M'\*^0K_&?3TO@/"_B0I\QZR?AO((]23/]ZN@^)$7S/7$^%KX6>H+SCYJ]B'O
M4;'CR=JUS[.\,72R:2H']VO)/BU9O-YI ]:ZOP!X@6XM40MVK5\5>'EU.V9L
M9R*^;A+V-:[/>J1]M2T/BO7;&2*=\@]:P9/E;FO;?'G@\VK2$)7CNH6+QW!&
MWO7U]"JJBN?,5*3INS*FUF'%-\B3TKH='T5[K'RYKIT\&GR=VSM6TJT8Z$JC
M*6J//%C9>HI];VM:1]BSQBN=9\-BK4N971DURNS)**%Z44AD=Q]PU1T\_P"G
M+_O5=N/]6:HV'_'\OUJUL93W/J;X(=(OPKW[74/]D'_=KP7X&X_<_A7T5JEL
M)-(./[M?$8V5JQ]A@=:)\<?%B,_:I?J:\<NE.6KW[XM:63<2D#N:\2NM.<R,
M-M?2X.HG!'S^)B^=G,I&S70P.]?0/P<LW:2+CTKRW1_#3W%TAV=Z^E?A'X7^
MS^4S+BGCL1&-.QI@Z+E.YZJEJ8]+!(_AKP/XI7 C:45]&ZULM-+89 ^6OE#X
MN:H/M$H![U\]@/WE2Y[..]R%CSVQG#ZB,'^*OIOX0+F%/I7R=H-UYNI#G^*O
MKCX.*#!%]!7K9DN6F>7E^M0ZKXB1_P#$K?\ W:^2O$S"/5FS_>K[!^(<:_V4
M_P#NU\:^.YO(U-R/[U<N5^\FCJS)\K1ZO\,;I?W8S7MRQF:RX':OE_X9:\%N
M(U+=Z^J_".R_L4R<Y%8X^'LY7-L#+VD;'BOQ*L76.0XKYM\2(8[IL\<U]J_$
MSPV&M9"%SP:^1O'.CO#>/A>]>EEU921YN84G&1RUHIDQBNN\)Z?(UY&=IZUD
M>'M+>:95VYKV_P ">"S(T;E/TKNQ->,(LY,/2=1H];^%D9M[./=Z5:^*%VGV
M!QGM6AHUFNCV([8%><?$WQ$K12)NKY.G^\K\R/IJC]G1LSQ#5'W:L<?WJ];^
M'_\ J4^E>->;]HU+/O7MG@&,"%/I7T&*_AH\+"ZU+G6:U_QZGZ5X+XZ'^D/]
M:]_UH#[&WTKP/QXO[]ZX,%\1V8O8U_A/(%OHL^M?6VDRJ^B@ _PU\8?#W4A:
MWR9..:^J_"&MI=:>B;NU8YE!\USHR^6ECR#XS6KR/*0/6OFW4[5XYWR.]?9O
MQ!\.C4(W8#.17S;XR\+M:R2$)BO0P%9<JB<6-I/FN>47!(D KO?A_;O+<1X'
M>N1GTV1KK&WO7L/PH\-M+-$67OZ5ZN(JQC3/+P\7*I8]D\):<ZV:'':G>(Y!
M;QMFO0-$T%+;35) 'RUY7\4+Y;%9,'%?(4Y>UJZ'U-2/LZ=SD;G5$^T8W=Z]
M \"S"9EQS7SG<>)B;_&[O7M?PIU83/%EJ]3$47&G<\_#U.:9ZGXFLF?36('\
M-?)'Q8L95N9>.YK[ADL8[[2_7*U\_?%#P']HED(3/6N++ZZA.S.K'4'.%T?(
MMM;2B8\'K71:;:RF1,*:[C_A &CN#^[[^E=5X?\ A[YTB9C[^E?35,5"USYR
MGAY7L:_PIM95DBR#VKWRY4KI7/I7/^ _ 7V14;9BNQ\26GV/3V&.U?*5JT:E
M30^HP]&5.GJ?*/Q>_P!=+7C>D_\ (2'UKU_XM2;IY?J:\@TG_D)#ZU]5A_X1
M\MB_XI]0_"'_ %<5>H^+ ?[*;_=KS'X/@>7%7J_BJ,'26_W:^5Q#_?GTF%7[
MD^4O%K;=58G^]7I'POO458QFO,OB%)Y&H.?>K_P[\2>7<(N[O7O5(<] \BG+
MDK'U!=?Z18_+SQ7C'Q TZ3$AQ7LOA&9-4LT!.<BL[QWX266U=@O:O HU52J6
M9[=:G[2%T?%_B&%HYVR.]95NI->@^.O#[6]S)A>]<?9Z:YDQMK["G5C*%SYB
M4&I6*<D38X%4&1UF&?6O0['PPUQ'G96=JGADV\F=N.:7MXWL-T9;G3?"_2_M
MEQ&",\U]7^$?#:VMBDFSH,]*^=/A#;K'>Q!O6OL#0X8FT<8QG;7RN956Y6/H
M\OIKEN>=^+O%RZ&C#.W%>1ZU\8 6=?,_6NF^--K+^]*9[U\LZS'=_:G'S=:Z
M<#AJ=2-Y'-C<1.F[(]+U#XE&>;B3]:[_ .&OBJ2\NH_FSS7SKI>DW-U,N0>M
M?0_P?\+2+)$S#TKLQ<*=.G9'-A)U*D[L^CH+AI](R?[M?,_QL3]Y,?K7U/'I
MXM='P?[M?+OQPQOFQ[UXV7V]KH>MF*_=:GSWI_\ R$OQKZ:^$7W8N*^9M/\
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M<IO^++H20L,]J\DU3YKAOK7;:QJGG(1FN*O/GE)K3#1Y43B)<S((U^6GI\K
MT)2FNXXC:TO4/)8<UWFBZLK* 37E,<QC:MW2]6:)A\U<-:ES([*-7E9Z==*E
MQ'7(ZIH?G.<+5W3]:$B@%JU8YXY>20:\^/-29Z#Y:B.4L?#OER [:[72%6SC
M&>*@DDBC7(K(O]8$*D T2YJNA*4:6J-K7-800L >U>8:W?>9*V#5O4M;:3(W
M5SUS,96S7?0H\B."O6YS3T6ZVS*2>]>H>']3'EJ,UX]:2F-@:ZG2=8,>T;JG
M$4^8O#U.4]$U8+>1$=:X74O#?FRD[:Z&SUA95 +5;,T4BYXKABY4]$=TU&IJ
M<G8Z$(&'RUUFEJD&VJ=Q<1QYQBL^36!&W!K1\U0F/+3.UDOD$)P:X?Q-<;]V
M#0=>W+C=6+JU]YRGFJI4G&1%:JI1L87G^7/GWKLO#^K[=HW5P%RY\S(J[IM^
MT+#FN^I3YXGGTJG)(]EANDN8NM96J:4)@2!6)I.M\ %JZ2'4HY5&37D.,J;T
M/6YHU%J<C-H.),[:V=$LUMV&15VZFCVD\5FMJ2PMP<5I>4E8S4(Q=SN[>[2.
M'&>U<KXFO ZMS5!O$&%QNK$U35?.!YI4J+YKCJ55:Q@ZDVZ0_6LMJNW4FYB:
MIM7MQT1X\GJ"TM(.E+3)&MUI5I:* '4C=:2B@ HHHH'<**** "BBB@ HHHH)
ML%%%% PHHHH ****!A1110 4444 %%%% @HHHH ****!A1110%PHHHH ****
M!!4UO]ZH:?'UH EOCNA->5^-;/S%?BO4+AMT=<7XELO-C;B@N.Y\W>)K'9*Y
MQ7%70V,17K'C.Q\MG.*\HU3Y9"*SD>A'8@C-2K5>$YJ>D6/I#TI%IU(H93EZ
M4M%,0ZANE-HH&%%%%(04444#"BBB@5PHHHH ****!A1110 444C4#N&:6F4^
M@0E%(W6A: !NM5IES5JHI%HL0=9\/I/+U"(^]?:7PSUE(=,C&[^&OA[PQ<_9
M;I&SCFOH#PCXW%G:(OF8X]:X\1%LZ:+L>@?&35EFL90&[5\3^,E\S4G/O7T)
MX\\8"^@8;\\>M?/NN_O[MF]Z,.K(55W9G6#&'!KN_!NM&WNX_F[UQ"1[5J[I
M=TUM,I!KJDKHP3L?;7PR\41M:QJ7'2NK\56\>L6;8P<BOEGP/XV:S*#?C\:]
MNT'QQ'>0J'DSQZUY52#4KH[HR35CSKQ-\-S<73.(\\^E7/"O@M=/F4LF.:]/
MGO[.9"Q*DUSFIZS;VC$J0*.>35@LEJ>@^&YK>QMU!(&!1XHUV!K5PK#I7CEU
M\0?L^0)/UK%U#X@-<*09/UK)4VW<?M%8Q?B1>"620@UYOI4F+T'WK=\4:Q]L
MW'=FN4L[CR[@'/>O4I^[$XIZL^A/!&H+';ISVK=\0:HK6YYSQ7DOAWQ%]GC4
M;L5I:GXH$D1&^L>6\CJBU8YWQA<"1GP:\AUQ=TQ/O7H&O:EYY;FN%U&/S'_&
MNJ&AQ5-S;\!MY=U']:^KO &J+':Q\]J^2O#<GV>=3TKVCPSXJ%K HWXX]:RK
M+F-Z+L>P>+]662T8;NU?-GCJ3S+AR/6N^USQ=Y\)&_->7>(+T73L<T48V1I4
MDF-\(ZM_9]ZASCFOI_X>_$!%MXT:3MZU\=M<FWDR#BNL\,^-);1U&\_G16I<
MZ,83Y6?9FJW\&M6YY!R*\N\3>!TO&=E3.:Q_"OC[SE0-)G\:]!L]>M[J,;F4
MUYRC*FSJNI'D1^&K><3Y?Z5N:;X+6S W)7I?VJSP3\M8.M:Q;P1MM85;J2EH
M3RI')ZQ:0VMNPP!Q7EVL7R1WG![UT_B[Q,&#A6KR?5-4:6X)SWKJI1=KLQFS
MZ#^%/BI;:2,%J]XN-8CU33=H8'(KXB\*^)GL9E^?%>Y^$?'HDC17D_6L:U-M
MW1K3GT&>-O _]I3.P3.37GFH?#TVL;'RZ^@(]6M;N/+%2:YKQ1-:_9WV[:F$
MY1T+E%/4^:-0TC['>#C&#7M_P7U);62($XKR_P 5,GVIBOK6EX'\0?V?.GS8
MYKMG><#EC[LC[$UC7DDT4C=_#7QU\:+D37$V#W->JW?CX2:?M\SMZUX7X_U'
M^T)G.<YKDP]-QD;U971P'A^Z:#4 <]Z^J/A+XN2U6(,^/QKY6MH?*FW>]=MX
M=\42:<ZX<BO0JT^:)R4Y<K/N:;Q!!JECMW DBO(O&W@Q=6D=E3.:Y;PI\1&D
M"*TG'UKT[2->M[Y%+L#7C\DJ;NCOYE):GD5K\+S'=!O+[^E>I>$?"\>FJA9<
M8K?DN+)5W?+6)JOBB&SC;8P%7*<IJQ/*HZG3ZEXBATNU(# 8%>%_$;QUY_F*
M)/UJIXP\?,V]5D_6O&?$'B"2\D;+$UT8>C9W9$ZG0M27OVR]W$]Z]9^'<XA*
M9->'Z9,?,!->E>&=9%KM^;%==;561SQWN?2EEJRK9CYNU><_$'4%DBDYK-A\
M9!8 -_;UKDO%'B3[4C?-FN"E3M(Z925CR;Q@?,N'^M5_"ORW*?6IM</VB9C4
M>B+Y,JGI7L?9./J?1?P_OA'&G/:O2+K5E-G][M7@7AG7A:JOS8KJYO%P:'&_
M]:\>I%N1UQEH5_&]X)/,P<UXIKQW3-]:[WQ%K7VC=\V:\^U)O,D)KLHJR,9N
MYGP<58-11KMJ1JZ2$1D?-5FUDV,*AJ-G*T@/7OASJRV]U'SCFOK/P1XI1]/1
M-X^[7P7X=UEK293NQS7NG@?Q\85C4R<?6O.KTF]4=%.=CV7XC::-:@? W9%?
M.6N_"\R7K/Y??TKWVS\607T(#N#5._ELY 6^6L*<I0T-914M3RKPGX&2SD3<
MF/PKVWPK:VUA&O"C%<'>:M;V;$J0*SYO'@M\A9,?C52YIA&T3VK7/$T5M9LJ
ML!QZU\U?%+Q%]JDD ;-7-8^(331L/-_6O+/$VLF]D8[LU=&G9D5970WP_&)]
M0!/K7T)X.5+>U0].*^=O#5R(KA6)[UZYI/BA;>U W8XK6M%LRI:'7>*=<$,+
M -VKPGQEJAN&?G-=+XH\3^<& ?\ 6O--4O#<,W-52IV'4E<Y"^7==9]Z]&^'
M*CSH\^M<)<0[I ?>NQ\&70M)E).*[)?"<\=SZI\)RI#9H<]JH>-=>6*W<!NU
M<AI/BU8;0#?VKE_%_BK[0K /G\:\OV;E([^:R.*\7:E]HNF.<\UH^ ]6%G=(
M2<<UQFI71GF)SWINGZDUK("#BO0Y?=L<CEK<^UO!/BY)K5$+]O6M;7M-CUB$
MD#.17S1X*\;M;M&#)^M>Y^&O&<5Q"@=QT]:\N5-Q=T=<9)HXKQ)\.?,D9A'^
ME<_8^!UM;@%DQS7N-]JEI/"3E37!ZWJEO S%2*T4Y-6$TKG=?#>.#3_+S@8K
MTG7O$44>FL PZ5\U6/CH6<G$F!]:N:M\2C-:LOF]O6N?V;<KFG,DCB/C5JPN
M)I<-GDU\\S.6NF^M>E^.]:_M&1SNSFO-S%^])KV*<;1L>?-W98C'RBI::OW:
M=5H6P4C=#2T47&5]GSYKH=!OOLLB\XYK$VTBSF)ABK>J%L?1GP_\3*&C4MZ5
M[CIUU'J%F!D$D5\9>%?$36LR?-CFO>?!?CA?+C#/^M>17I.]T=D*FEC<\=>#
M1?1.RIFO!M>^'K0W3-Y??TKZ>;Q!;7EO\S*>*X3Q0UJZN1MJ*4Y1=A3BI:GF
M/A*/^Q9DSQ@U[SX3\<HL")Y@Z>M?/'B#4EM)"4..:@T/QM)!,HW]_6NJ5-U%
M<R4N5GU3JLB:W">AS7E_B;X<BZ9F$><^U7O!WC1)U0._ZUW_ /:UI<09)4G%
M<RO3>AM=21X$OPV6WN,F/OZ5ZO\ #G2H-,DCR ,5'KE]:Q[BI6N<A\7I8S?*
M^*N3E40121],-KD$.F[0P^[7S7\:=62X6;#9ZU;N?B8?LY7S>WK7DWCCQ.=1
MW_/G/O11I<K+E-6/(=4^;4R?]JOH3X%WPMY(<G'2OGZZ7?>;O>O3_AUKG]G2
M1G=C%=M57C8Y8OWC[?E\0)_8>-W\-?(7QSO!<7$Q!SR:]$D^(8.G[/,[>M>&
M_$36?[1DD.[.37%1I\LC:I*Z/*%7_2&^M7/+SBF+%^])JVJ\5ZIR)&AH]X;2
M13G%>S?#_P :_9Y(P7Q7A62O2M71]6DM9 0Q%9SAS(T4N4^ZO#/C2"ZM55G!
M.*A\2_9]0C8C:<U\T>&?'DUOM'F'\Z[^S\>>=$-\GZUY<J+B]#HC4N7[S185
MN-V!UKMO!(M[>1!Q7EFI>+DSPU7O"_BAYKI0K'K1*,FBN9(^I+>_A^PX!'2O
M&_BI,LD4N*ZG2+Z::Q!R>E>=?$BZ98Y-QK&G'WC26J/FCQE'_ICGWJIX;U@Z
M?<*=V.:O>*IEDN'KBI[DPR9!KV8KFC8X)>ZSZK\ ^/QY<:-)7I_VZVUBWY(.
M17Q3X;\5R6DB_.1^->T>$?B 65%:3]:\ZM0:=T=%.KT9V/BWP-#?*Y5 <UYA
M??"G=,2(N,^E>SZ?XF@O(QN8&M)9K*1<G;6<)SCH6XQD>/Z%\,UMV7='^E=5
M+X6@M+?E0.*ZRXU"TMU)4K7(>)/$\:QN%85=Y28))'F7C:UB@WX KRB:Y\N^
MX/>NZ\8:U]H9\-7FL[%KC/O7?2C9:G+/<^A/@_XB%M-%EL=*^GK+7HK[3 NX
M'*U\(^$=>;3Y$.[%>[>$?B#^[16D_6N:O3;=T;TY:6-?XA^$1JDKL%SFO*KS
MX>FW+-Y=>\)KUM?1@LRFL/7I[7RFQMZ5E&I):#E%-GSOKNB_8P1C&*XJ[.R0
MBO5/&DT;,^TBO*M0_P!<:]&GJM3FDAL;;J6F0U-6Q%Q%I&IU%278:?K24[;2
MT ,IRTM% @I*6B@!E/7K110*XZFT44#"BBB@04444#"BBB@3"BBB@84444PM
M<0]*/2ANE(O6D!:A%7HUXJE;UH1CBO4PL=;GBXN=A:*6BO>6B/!EO<2BBBA$
MA1113$%%%% !1114, HHHH ****I %%%%, HHHH **** "BBB@ HHHJ0"BBB
M@ HHHJKC"BBBHN(****H HHHIH84444K""BBBF 4444K %%%% R.;[IJ.Q/^
MD#ZU-(,K4=LNV8'WIM71/4]J^'L<4BH&Q7JLOA^"\L^%!XKP7PCK?V-D^;%>
MQ^'_ !8DD:JS]J^9Q5.:E='OX:I&UF<KXB^' N)&*QY_"L:Q^&S6\P/EX_"O
M:[>_M;G!8K3II+-.?EK"&)J17*S:=&$G<Y?PWHYTU5R,8KKI/$PL;?:7QQ6%
MJ6L06\;;6 KS3Q5XPV;PK_K3C2>(>I7M%0CH:?Q \9+<*Z[Z\[T&Y^U:HISG
MFN3\0^))+B0C=G\:V?A_(;B^C)]:]J.'5&F>+4K.M4/K_P"%\?\ H<?TK:\<
M:8+BU88[5G?#./991GV%;?BZ\2. Y/:ODJEW6T/J::7L;,^<_$/@O[3=.0G>
MDT?X>8<$IW]*[N;4+9K@[B.M:UIJ%I''D%:]/VM2,;'G*E!NY4\/^'8M+"L5
MQBMW4?%T>FVI4.!@5S6N^*HK>-MK 5X]XN\<.S.%D/YUC3P\J\KR+J8B-%6B
M;'Q#\:"^\Q0^>M>$:Q=/)=LP/>M'4=<DO)#EB:S)(_-.37U&'HJE&QX%:HZS
MN=Y\.==-K<1[FQS7U-X+\702V:*SCI7Q7IMT;%@0<5Z%X9\>2VI5?,./K7#C
M,)[35'7A<3[+1GTMXKM;?5X6VX.17D.L?#=;F9F$??TK;T'QN+M5#OG\:[.T
MU*UG4$E:\:/M,/HCTY.%?5GCJ_"_:W^K_2M;3O *6I!*5ZFUU9_[-9&J:I;P
MJ=I K3V]66@O8TXZG+7>CP6ML00.E>4>,%C25MM=WXF\3* X5J\HU[4C=2-S
M7I86G*]V>?B)QV1L^"_$!T^[7YL8-?2?@_QXDUJB&3MZU\:1WS6LVX''-=SX
M5\:26[(/,(_&M<9A%55T3AL4Z;L?46N1PZQ&3P2:\RU[P"+AF*I5SPWXT$Z*
M'?/XUV<.K6UQ&,E:\**J8=V1ZLG"NM3R*'X<LLF?+K3C\*K9KRN*]-DNK18R
M05KC_$>L0Q*VTBMO:U*CL9JE"GJ<CJD<5O&1Q6-IURJW@QZU0\0Z_N9@&K#T
M_5C]H!)[UZ=.E+EU..I4BY:'U#X#U=8[5!N[5F?$[5%FLW .>#7G_AOQ<+:%
M1OQQ53Q?XK%Y;L-^>/6O-5!^VN=TJJ]E8\4\7?/J#G_:KKOAC-Y-S'GUKC];
M;S[HMUYK;\'WGV.93G%?25(WI6/GJ?NU;GV=X/UE8]-4;NU>>_%[4EFMY<'M
M6'H7C806H7?V]:Y?QUXF%]$X#9R*^:HT'&M<^BK5E*E8\'\4+NU!C[UL>$CL
MD2LS6(_.NBWO5_0V\EEKZZ7\.Q\U'X[GO/@R]$83FO1'U53:8W=J\)T'7/LX
M7YL5U3>*QY.-W:OFZU%N5SVZ=1<MBIX^N!+O->4?;S:W@(..:[#Q)K'VI6^;
M-><:A(?.)%>OAH>[9GF5W[UT>Z?#OQGY+1@O7ONC^)8;^U 9@3BOB#0=<>S=
M<-BO6?"OCYX]JF3]:\O&8+F?,CT,-B^5<K/7O&.AQZDC%0#FO)-0^&[27#,(
M^_I7I>D^*HKU%WL#FMV.:SD7)*UP0J5*&AV2C"MJ>6Z)X#^S$%D_2MZ]T>*U
MM3D#I737VH6UNIVE17"^)O$J"-@K5I&4ZDA.,*<3S3QPJ*S@5YK(W[XUV7B?
M4OM4C<YKCF7]X37TE!.,=3Y^MK+0FC^[3J1?NTM;7,B.?[AJE8@K>*?>K\G*
MXJM!'MG!]ZI;$25V?2'P9U 6[0Y..E?28U1+C30-W:OC/P%KWV!D^;%>UZ;X
M]7[,JF3MZU\ACL/*4[H^IP591A9D/CW0QJ$SX&<UYVOP\,TV?+KTB3Q##>2<
ML#6IIUS:'!)6IIU*E*-A2IPJ2N<5H7P[%NRL8Z]-T*.+18AT7 J*;5;6WBX*
MBN&\4>-%MT<(^/QK.2J8AV9T+DH*Z.F\;>.(UM70..GK7R[\0M7-]<2$-G)K
M6\4>-)+B1AO)_&N#OK@WC$DYS7O8+"*DKGBXK$^UT*_AO*Z@I/K7UE\)=2$-
MO'D]A7RGI<?DW*M[U[3X'\2BQC4%L5>80]I&R(P,N26I[OXZU99=,<!NU?'?
MQ'EW7TA'K7M_B+Q@+BT*[\\>M>#>+I/M=PYZ\US9;2=/<VS&:J;#? ^K-:W:
M'..:^K?ASXVC2VC5G[5\<Z:QM9 1Q7>^'?&4EDR@.1^-=>-PZK(Y<'B'1/KS
M7M0BUBS8 @Y%>)^*/A__ &A<,RIG/M5KPSXZ^TJJO)GZFO0]-U"UNE!8J:^?
MC&>&>A[<I0Q*U/)M ^&QMKA28^_I7L7AS1XM,@7< ,"G375G!R"HKGM<\81V
ML3!' XI5)5*^@Z<(4=35\6>)X[.V95<#BOG;QUXJ-U,X#Y%:7C+QH]PS@/\
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M5Z=Y,<7&*]RAXB4>U?FV,ES5#[S!QY:8^BDHKSSN%HHIK4P%I:93Z "BBB@
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MLVYU4S9^:L8!O6G+FB-.*%[24MR:1RY-,VYI5IV*TV(L, Q5B*X,>.:B(IK
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MKGW5./+&PM%%%9&@4E+10 F!2T4W=0 ZBF[J* '4F12TR@!U+35IU !1110
M4444 %96NPAK<GVK5JCJR[K8U4=&3+8\.\80?O&XK@RF)#7I_BZVW,_%>=W$
M.R1N*^GP\[QL?.8B/O$0^[2445U'(/HI*6@!5I<TVB@ I-U+3*!C\T4BTM @
MHHHH$%%%%!04444 %%%% MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO1HJBK'FUJCJNY%#ECS5C;Q0J!:=6KU(6B&8%+M'>BBD%Q****=Q!1@4447
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M""BBB@:"BBB@&%%%% @HHHH **** "BBB@!5ZTZF49H&/HIN31DT"%:FT44
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M?#M5GN8U;UKLE+2YS\NIH1^ 9)H=PC/Y5R_B'PL^GAB5QBOK?PQX2AO-.4[
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M&T445U'':P4444 %%%%0 4445H 4444@"BBBD 4444T 4444P"BBB@ HHHH
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M86_^D#CO7IWA=!'&M=F)J>Z<F'@N8V;H+:V^<8P*X/7/$ B=@&KL/$5QMMV
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MD2MPHHHH- HHHH$PHHHH$%%%% !1110,****!!11104%%%%!-PHHHH&%%%%
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M\#ZQNM4!]*A\?*EU9OQVJOX1L3# OTJSXMCQ9MGTK@^T=2^$^1/B1IXBNI&
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MUC#/G\:^#K>XF%Z.3UKZ2^"NH2(\.6/:NC'X."I71&"Q4G4LSZWUY8[[2V.
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M "BBB@ HHHJ6 4444TP"BBBF 4444F 4445-QA1115""BBBD 4444QA1112
M****!!1115 %%%%( HHHI@%%%% !11130!11128!1114@%%%%4 4444 %%%%
M !112$T@([C[E4+)"UX![UH2#<M6=%TUIKQ>.]5?E1#3;5CWGX+Z7YTT.5K[
M6\#:*L-A&=N.*^7/@CH^UX25]*^R/#< ATV,8[5^>YI4;G9'V^5TUR79HQ1^
M6N*DHINZO /?'44@.:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!.YI:** .7\26OF1MQ7DWB+3=KL<5[=J5OYR'BO._$VFX#'%>CAI
MV=CS\1"YY)<1^6Q%5E;YJU-8C\N1JR8_O&OH(/0\)Z,G'-/I%I:HAL****8!
M1112 **** "BBB@84444""BBB@84444!L%%%% !1110(****!A1110(****
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MB-2^\:VH;$5S&;[QIZTC?>I5Z5WW//%HHHI %%%% !1110,****!A11102]
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MZ\2\:[JZJD>9&=-ZGO-RW]I8[YK5T3PF) &*?I57P78MJ2QG&:]CTGPY]GM
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M% !11102@HHHH*"BBB@ HHHH&%%%% @HHHH **** "BBB@ J"1?FJ>FE:2W
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MIU(UJ?*?+GCWP7++<.0AZUA^%O \D=XI9.]?46M>%;>\W-M!KG1X;@T^7=M
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M?./SK-U+XA0-&<.*^8QXPN0,>8WYTC>*KB08+G\ZS^KFOM#U3Q/XR\_=M?\
M6O,-7U>6XD;YC51M4DN/O$FHR/,ZUTPIJ)A*39#'(TC?-5@"FK&%IU780M%%
M%(-PHI-U -(8N*7::5>E%,;&T444""BBB@ I,BBFT /HI%I: "BBB@ HHHH*
ML%%%%!+"BDS1F@0M)FEIK4 +F@FD7K0*:V&Q!UJW;]JKJN:N6Z=*UP\6YG+B
M9*,"Y'TI](@I6ZU]3"/*CY*I+F8E%%%:;F84M)12V&%%%%(044450!1112 *
M***+ %%%%%@"BBBF 4444 %%%% !1114@%%%%, HHHJ0"BBBJ ****8!1112
MN 4444 %%%% !11132 ****3 ****0!1113 ****5@"BBBG8 HHHI; %%%%2
M 4445: ****8!1114V ****=@"BBBF 4444K %%%%, HHHH ****'H,****@
M04444D!%<?=JOIS?Z8OUJQ<?=JOIH_TQ?K6T=B7NCZ5^#ZY\JO?IIO)T_.>U
M>!?!]@%CR:]JUBX"Z:<'^&OA\=[U:Q]=A-*1YQXH\2+;7#9;O63:^/(8^KC\
MZXCXCZH\=Q)@]Z\JN/$T\;'YS7JT,&JD$SRJV*=.9]'7WQ$B:(@./SKS?Q9X
MR:XW;7_6O,/^$HG;@N:1M1>X^\2:[Z>"5/4Y:F+=16%U+5)KB4_,:KIEUYJ4
M1AN:?M"UZ$;'#=W((\Q29%=5X?\ $$EFR_-C\:YME[TT3&/I3G%35BTW%W/>
M_#GQ"\E5#2?K76Q_$6%H^9!7RU_;DL'1C3U\67 XWG\Z\FIEZD[H]"GCG%6/
MH;6O',4@.UQ^=<1J7C)MS;7_ %KS3_A(YIARQJ%]1>3J:UIX-0W(GBG,[S_A
M,)&ZN<?6J5_KIN$.6KC5NV]:>+IF[UT*BHLP=5LDU)S(2:J6,SP2@@]ZG)W]
M:8R!>177I:Q@][GH'A?Q4UGLR]>IZ/\ $9$A :3]:^;EO&@Z'%/_ .$CGBX#
M'\Z\ZK@XU-3KIXET]#Z-U?QW#<1L-X_.O.=<\0)-(Q#5YQ_PDT\G\1_.FG5)
M)>I-%+"*F:5,2YG81ZX4;.ZK@\3-M^]7!_:F]:7[8WK6[I(Q]H['5:AK9F!&
MZN7OG\YB::UTS=Z9G=6D(\ISRES#;4>6P-=+IFJFW YQ7.4[[04Z&G*//N7&
M7*=VOB5@F-U9>H:P9LY-<Q]L;UI/M#-WK)44ANJV27S><Q-5K6/RY ?>I@=W
M6EV[:W6BL1YG5Z+KS68&&Q6Y-XTD:/&\_G7F_P!H*=#2?;6]:QEAXR=V:*LX
MZ'2ZGKKW).6S^-<Y>.9NM-\XOWH^]6D8\NPG+F*D,/ER9]Z[/0->>Q PV*Y?
M;BCSS'TIRBJBLR$^1W1Z5<>-I'AV[S^=<GJFL-=,23FL'[:Q[T+*6K&-!0>A
MM[5SW'S'=53YHY,BK8^:FM&*ZEHC!ZG0>'==>T=?F(Q7K'AOQ_Y*J&D_6O!1
M(8NG%2KKDL'1C7#6PL:QO3Q$J)]2+\186CYD'YUA:QXZBD!VN/SKY[_X2RX4
M??/YTC>))Y>K&N.&7J+.KZ^YJQZEJ/C1MQVO^M8LWC"1\C?^M<$VI/)U-,^U
MMZUVK"Q.=XAW.MO-<:X4Y:N;U";S,FH/M+'O4<S[EKJITU#8QG)S(8?FDQ75
M^'](:ZD0A:Y6Q3?< >]>W?#G01=>62M<V)G[.-QX>GSRL=W\.-/;3Q&Q&,5Z
M7K'BC[/IY3?CCUK%M=+73;/=C'%>>>-O$WV<.@?]:^9Y?K%2Y]+?V%.QY]\5
M-:-Y-)\V:\@7+3'/K77^)-2^W2-SFN86+#YKZO#Q]G"Q\Q6;G.Y*(\@58M9?
M)88J,"F]*U:N0=EH?B!K=A\U>C:'XV6-5W/^M>%+<M%T-2#798>C$5QU,,IG
M13K.!]06WQ"@$8^<?G3;GX@P,IPX_.OF$^++A> Y_.@>*[AOXS^=<?\ 9JO<
MZ_KSM8]G\2>,Q,C;7KRG7M;EN)&PQK.;6I;@<L343?O>3S7?2H*D<=2JZA72
M9Y&^8U95>*9Y04TZNDP"F]Z=15""BBBD,****0!1113$%%%% !1112L 4444
MP"BBBD 4444)V ****=P"BBBI **** "BBBJ ****E@%%%%" ****=@"BBBI
M8!11130!1110 4444 %%%%4 4444 %%%% !1110 4445(!1113 ****8!111
M0 4444P'4$TVBI K7$FUJT=%A^T3*.M8]XV&_&NG\$P_:+I!CO4SE:-RH^]*
MQ[1\,_#?FR1-M[^E?7/PWT86L,?RXXKQCX1^'1(D)V_I7TUX;TW[+"G&.*^"
MS&OS2L?:8"CRJYT2\*!2T45\^>Z%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %(1FEHH Q=;M0\+<5Y%XLL<,_%>VZ
M@FZ UYGXJL-V[BN_"SM(X,3"Z/';F$I(:5#BM35+/RY#QWK*?Y6KZ.+YD>$U
MRL?N-%(AS3L>M/85T(O6G444$A1110(****!A1110(**** "BBB@ HHHH **
M** "BBB@04444#"BBB@ HHHH*"BBB@D**** "BBB@ I,4M%,!-M,,>:DHHN!
M%Y-*(ZDHHN W;2[:6BD,::;MI^*3;3&,\O=1Y-2T47)(Q'BGA<4M%( HHHH&
MA,4;:6B@!NVG444 %-VTZB@0W92[:6B@>@4444"&[:-E.HH 0+BEHHH*&E*;
MLJ2B@5QF,4^C%% "M4;+3Z*0B/;2T[:*-HIC%HHHH$,9:15Q3\4;: %HHHH
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M+:O9O&>C_,YQ7E.K6_DR'M63.^#N9NZG#K4"M\U6%'>I-1:2EHH *:U.HQ0
MVG4NVDH *:W6G4F* $6G4F*6@ HHHH **** "BBB@04444#"BBB@ HHHH **
M**!!36-.I-M $31[JC-MNJR.*<O6@DI&SS2?81Z5?IM,JQ56U"U(L>VIJ3%(
M6A5=?GKTKX:Z@MG=1DG&#7GACYK5TG4S8,"#BB2NK#CN?:&@^-HHM+53(/N^
MM>0_%S7$U!9,-FO/K;XB20P[?,/3UK$UKQ0VI9RV:XHT>65SH=32QQ.IVGF7
M3'WI(K'"U>E_>2$TJC%=ZV.5D$=OMJ95VTZBD.P9I&-%(>U,!*&7=3MM/J1Z
M%9K?=4368-7J:>],+%(60J1;;;5C=2U+8K$:Q[:?2T4QA367=3J*!E=K?=49
ML_:KE%,E%,60J5+?;4]% <HU5VT,N:=12%8A:'-.6/;4E%,JP4UEW4X4[%("
MMY-/6/;4AZT4 &:0C-+1021F/-)Y-2T4QC%CQ3Z**06"HVCW5)10.Q5>UW5'
M]AJ_FDI"*<=J!5A(=HJ2BJ#<2EINZE%%R@:FT^DP*!$%R,J:701Y5\A]Z<Z[
MJ=;+Y,@:A["1]2_"/Q0EC;Q@MCCUKO?&GC2*YTUU#@\>M?*&A^,'TU0 ^/QK
M2OOB))=0E3(3^->=*@W*YTJ>AD_$.47EW(0<\UP*V7S&NAU34#>2$DYK-%=U
M/W58YY:E1;/;S4\<6VI?XJ7FK%8*5>M%% QU121[JEI&I$V*C6NZF?81Z5=I
M=M4.Q56UVTX0U8S[4E0"0Q8J=MVT[=0S<506$I&YI,TM(9#)!NJ$V57:*=Q%
M1+3;4ZQ[:DHI!<C,=,:+FIZ2F!&J8Q4HXI*6D $YJ-H]U244%$0AIZKBG44Q
M #0>:** (VCW4BPXJ6C=0389MVXIO-2TW;04-ZTUHMU2;:6@+$*PXJ55VTZB
M@G8****15R-X]U5WL]V:N44PL4!8U(MMMJW10%B 0TY8JEHH$,V4DB;EQ4E%
M,5B]X=C"WB$^M?3GPPUZ&RMX\L!Q7RY9W'V>0-78Z1XX?3XP ^/QKCK0<S>$
MN4^F_&GC2)]/=5?MZU\L>/-8-S>2$-GFM+5/'[WD17S,_C7#:E<&\D+$YS2H
MTN3<*DN8J)(7//-2[:CCCVU+769(1J81FGXS1MICL1M#NJ)K7-6J*0BE]AI1
M9U<HI@0)#MJ95Q2T4"L%%%% !2-2TE(8PDTJ]J7;2XH!CEI:;FC)H! >M%%%
M!384444"$IM/I-HH %I:2EH)"BBB@-PHHHH&%)2T4#&44[;1MH$(M.I.E.'>
M@!O2E%(U(OWJ:>HNA9A3-788\5!;K5Y5^6O7PU-7N>'BJG051BD/6EW4S=7M
M]#P^HM% HI7$(U)3J3;3 6BBBI ****+@%%%%, HHHI %%%%.X!1110P"BBB
MD 4444[@%%%%, HHHI, HHHI %%%% !1113 ****3 ****+@%%%%4 4444 %
M%%% !1110 4445(!1115 %%%%-L HHHJ0"BBBBP!1111L 4444@"BBBF 444
M4P"BBB@ HHHH ****=QA1114""BBBJ ****0!1112L R896HK%-MRI]ZG89I
M(UV.#57LK!;4]O\ AKK2V8CRV*]0U/Q9')8%=_:OF32?$#6&,-C%;,OCAY(]
MOF?K7A5L&ZD^8]BEBO9PY2UX\NENIG(.:\SN;4,YK?U+5C=L23FLEVW$FO4H
M0=.-CSJLE4=S/6SQ5F.';4OX45U.1S\M@'RT;J**D>PN:8R;J=11<96DM=U1
MBR%7A2XJKDV162UVT_R:FW4A-.XR+R:4)BGT5# !Q2GFDHJ1D;1[JA:UW5:I
M5JTV(J+9@5*L.VK%-I@1^71LI]%3<8T+3J**&(*1ES2T4AD?ETY4Q3J*6HA5
MXI=U-HJ[#&LFZF^54E%,0U5Q3AQ112 7-,9-U.HJ1D7E5(J[:6BJOW 7=06S
M245+8#67=4+VVZK%+Q5)AIU*?V,4Y;7;5RFM1=DV1 (:=Y524AIW*L-\ND9>
M*EI=N10Y#0FEQXNE)]:]]^&NH16\<>XBO!8?W3AJZK1_%3:>J@-BN'$TG5C9
M'10J*G*Y]*:YXFB6Q(##I7SYX\UPS7#X:EOO'KW$)7?^M<7JEZ;V0G.:X\+A
M73=V=E?%>T5D4FF,S'/-"KWI(TQ4GW:]>_0\L3-(>:7-)03<8R9J)K?=5BBJ
M I_80:460%75I:J[%8JI;[:F4;:6BDQBYI***!A1114W$%%%%/< HHHI;#"B
MBBF(**** "BBB@ HHHH ****FX!1110 4444 %%%%( HHHI@%%%%# **** "
MBBBF@"BBBD 4444@"BBBF 4444P"BBBBP!1110 4444P"BBBF 4445(!1112
M ****+ %%%% !1111< HHHJ@"BBHO,^;%1U&BM=1;G&*] ^&NFF2\BX[UR=I
M9FYE7 SS7M'PM\.L;B([>_I6&)GRTV;48WJ(^IO@_HX6WB.WL*]U@A$4:@>E
M><?"_3?L]M%QCBO3*_,\3+FJ,_0L-'EIH****Y3J"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".9=T9%<AX@
ML/,5CBNR(R*S-2M!)&W':M*;Y9&<X\R/#?$5EY;-Q7&7/RO7J?BZRV;^*\OU
M!2LQKZ7#RYD?/UXV8V$\5+4,/05*#74SC'=J2E[4E)#"BBBF(****!] HHHH
M$%%%% !1110 4444 %%%% !1110,****!!1110 4444 %%%% !1110 4444
M%%%% !11102%%%%!04444 %%%% @HHHH&%%%% "TE%% [6$+4 TAZTJT"%HH
MHH ****!A1110(****!,****!H**** "BBB@ HHHH ****!A1110,****"$%
M%%%!84444$A1110 4444 %%%% !1110 4444 %+Q245(!1115 %%%%2 4445
M0!1129H"PM%%+MH 2BBBF@"BC&:3;Q4C$;-1-NJ?M2;157&R./-2]*.!0S ]
M*O2PD)D4M-IU2#"BBBI9 4444%#MM(:7-(U "4444 %%%% !1110 4444 %%
M%% !1112 ****904444$A1110 4444 %%%%(84444Q!1110 4444 %%%% !1
M110-!1110*P4444 %%%% !1110 4444 %%%% !1110,****!!1114H HHHJA
MA1110(**** "BBB@ HHHH **** "BBB@H****!!1110(**** "BBB@ HHHH
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MSN[.]\)Z?]DMUXQQ7257M(!#& !BK%?$2ES.Y]C&/*K!1114E!1110 4444
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MX[U0A]ZZ/Q%9E96X[USVS:37T\)7B?-SC:1)12;J6M" HHHH&PHHHH&%%%%
MF%%%% !1110%@HHHH **** "BBB@ HHHH$%%%% !1110 4444#"BBB@84444
M$A1110-!1110 4444!<**** "BBB@04444 %%%% !1110 4444 %%%%!6@44
M44$A1110 4444 %%%% PHHHH"P4444""BBB@ HHHH **** "BBB@:"BBB@ H
MHI:!,2BBB@ HHHH **** "BBB@2"BBB@84444 %%%% !1110 4444 %%%% !
M1110-!1112$+FC=244P"BBBFP"BBBD,****!!1110 444F:0"T44FZF M%"G
M-+Q0+42BBB@84444 %%%% !11104%%%% F%%%% @HHHH **** "BBB@ HHHI
M"5PHHHIE:A1110(****!!12T4%7$HHHH"XM)110,****"0HHHH **** "BBB
M@3"BBB@:"BBB@ HHI:!W$HHHH'H%%%%!(4444 %%%% PHHHH)"BBB@84444#
M"BBB@04444 %%%% !1110 44M)0""BBB@H****"0HHHH **** "BBB@2"BEV
MT$8H&)1110 4VG4FV@!%I^ZF@4M!1(J>96-XBT\/;MQVK<MZAUB,20,/:@(N
MQ\R?$/3]K28%>.7D)6X/UKZ.^(&E^9YAQ7AVM::89F..]9,[X2NC&CX6GTQO
MDXIRG(I7-AU%(:3=0,4\TFVEW4M !1110(****!A1110 4444 %%%% F%%%%
M PHHHH ****"@HHHH)"BBB@5@HHHH&%)SZTM%,3$I:**!A1112$,I0,T;:4#
M%  !BEHHH ****8!1112*"BBB@04444 %%%% @HHHH&(U)DTK4F#0 ZBF[J-
MU #J*0'-*.:!!12[:-M ,2@'%%% Q=U)110)A112$T#%HINZEW4 +32:=32*
M #-+]ZFTHS0/0-M+VI:2@0TM0&H*T!: 'T444 %%%% !12&@&@!:*7;24 %%
M%% G<***;NI,!^ZC=312TQA112[: $HI"<4 T +1110 FVEHHH **** "BBB
M@ HHHH 2DVTZB@!*6BB@8E)NI6Z4V@0ZEI*6@04444#"G8]J;3LB@3$84UJ<
MU-:@0F33J;M-.H*$VT 8I:* "B@<TNV@3$HHHH$%%%%!H%)MI:*"1O2@=:7;
M1MQ0 M%%%,044NVC;4L8E%%%" 7;24[-(U,2$HHHH **7;24 A":0&AA0!0,
M=1110 4444"U"BBB@ HINZE!S0+46BBB@84444""BBB@84444#O<****!7"B
MBB@84444 %%%% A-M)MIU%,8@&*,4A-/0;J4=6)NRN20K6A".E5X8^E6XUQ7
MOX6GU/GL94Z$F*3%.I":]5GC^8TTVGMS3=M2A"BEI!2TQH2BBB@&%%%% @HH
MHI %%%%( HHHH ****H HHHI- %%%%) %%%%4 4444@"BBBD@"BBBJ ****E
M@%%%%, HHHJ@"BBBD 4444 %%%%( HHHH ****:&%%%%#L 4445(@HHHI@%%
M%%, HHHH ****0!1110@"BBBEH 4444 %%%%, HHHI@%%%%) %%%% !1113
M****5P"BBBF 4444@"BBBF 4444@"BBBF 4444T [=2$TE%2 4444 %%%%2
M44$XI-U5N M%%%( HHHJ@"BBBDP"BBBG< HHHJ1A1113$%%%%%P"BBBD 444
M50!1110 4444@"BBBDP"BBB@844450!1110(***6@H2DW4M)MI(D444"BF 4
M445(PHI-U+56 ****!!1110 C4 T,* * %HHHH ****D HHHJK %%%% !111
M2N,****!!1113 **** "BBB@ HHHI %%%%%P"BBBD 4444 %%%%, HHHI7 *
M***8!1113 **** "BBBDP"BBBD 44450!1110 4444 %%%%2 4444T 4444
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M*"0HHHH ****!H**** 84444""BBB@84444$A1110-!11105L%%%%!(4444
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M% !1110 4445-P"BBBG<84444;B"BBB@ HHHI@%%%% !1110 4444 %%%%2
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M%% !1110 4444 %%%% !1110 4444 )BC:*6B@!,4M%% !1110 4UEW"G44
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MHH ****!H**** "BBB@ HHHH'T"BBB@D**** 04444#84444""BBB@ HHHH
M**** "BBB@04444#"BBB@=@HHHH$%%%% !1110 4444 %%%% PHHHH ****
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M )M%%+10(1J;FG$9I-M QU%-W4HH$+1110,*=3:7=0 -24&B@ HHHH$%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"BBB@04444 %%%% !1110 4444 %%%% !1110,**** "BBB@04444#N%%%%
M@HHHH **** "BBB@84444 %%%% @HHHH&%%%% @HHHH*L%%%%!(4444%!111
M0)A1110(****!A1110(**** "E%)10 I8FF7%IYT9XI1]ZKL0#1T#6YY%X\T
MD"*0[:^<_%EN8[A^.]?6WC2Q\Z%\#-?.?C;0SYTAV]ZEG;3D>8V^=W-6Z6:U
M,#G(Q4>[FLSI)***3- Q:3-+36ZT$BTM-6G4%!1110 4444 %%%% D%%%% !
M1110 4444#04444 T%%%% @HHHH&%%%% !1110 4444""BBB@84444 %%%%
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M ****>XPHHHHL(****6PPHHHIB"BBBF 4444@"BBB@ HHHH ****FX!1113
M****8!1112 ****0!1110 44450!1110 4444KC"BBBJ\P"BBBD(****@ HH
MHJ[7&%%%%2(****: ****+ %%%%( HHHJ@"BBBI ****$ 4444[ %%%%, HH
MHH ****@ HHHJP"BBB@ HHHH **** "BBBIL 44450!1110 4444@"BBB@ H
MHHJ6 4445IT&%%%%(04444 %%%% !1110 4444 %%%%( HHHI %%%%, HHHI
M %%%%4 4444 %%%%2 4444[ %%%%, HHHJ6 4444P"BBBI ****L HHHH **
M** "BBBD 444520PHHHI""BBBIN 44455P"BBBH ****M %+BDIRT@#%&12T
MRA@+2444D 44450!1113 #TK.N&._%7]W44R.S,\PP*-M6%KG5> ]/-U<Q@C
M/-?7/PI\(ADA;9Z=J^?_ (5^'S)<Q';W%?;/POT)8K6(E>U?)9KB+:(^ERVA
M?5G:^']+%G&G&.*Z*F)&L8  I]?&-\VI]9%<JL%%%%(H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D;I2T4 (O2F3#=&PJ2D89!% 'GWBG33*KG%>5ZUIIBD;BO?M6T
M\31GBO+O%6E^67.*]/"U'>QYN)IJUSS&7Y6Q2*V:DU",QRFHH5KZ%;'A=25>
ME/IM+NJ08M-I<TE"$%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@84444""BBB@ HHHH*"BBB@3"BBB@04444#"BBB@D****"[A111
M02%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444!<**** "BBB
M@%J%%%%!7*%%%%!(4444 %%%% !1110 4444 %%%% !1110#04444 D%%%%
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M*!C6H7K2XHQ0,6F4^DVT "]*&HHH 0=:=28I:!A1110(****!A11102%%%%
M!1110)!11104%%%% !1110+4**** N%%%% !1110,**** M8**** "BBB@04
M444#"BBB@ HHHH$%%%% !1110,****!A1110)L****!!1110,****!!1110,
M****!!1110,****!A1110(****!!1110&X4444 %%%% !1110 4444 %%%%
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MI7$%%%%, HHHH **** "BBBI ****=@"BBB@ HHHH ****8!2TE% "TE%%(
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MBB@84444$A11104%%%% @HHHH&%%%% !1110 4W=2TV@0X4M(M% Q:*3(I:
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M*H HHHHN,****0!1113W$%%%%( HHHJ@"BBB@ HHHJ@"BBBI **** "BBB@
MHHHH ****8!1112&%%%%#$%%%%2 4444 %%%% !1113 ****8!1110 4445
M!1115@%%%% !1110 4444 %%%%3J 4444P"BBBH ****T **** "BBB@ HHH
MH ****D )Q3&^88IMPVU:CLY#-,%Z\U=M+@7-*TIKBZ7 SS7TW\%_#I$D)*=
MQVKS#X?^%C?S1G9GGTKZV^%O@O[+'$VS'X5\YF6*48N)[6 P[<^8]G\'Z>MK
MIT9QSBNBJIIL/V>T1:MU\')W;9]O%6204@&*6BH*"BBBF 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH!ZA1110(****"@HHHH$*IIZKN-1U)"<&@#/UJP$ENW':O#?B!H_,A
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MQ****";!1115(D****8!1110 4444-#"BBBI$%%%%4 4444 %%%% !1114V
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M113*04444 %%%% @HHHH **** L%%%% PHHHH&%%%%!(4444%!11102%%%%
M!1110 4444#04444$NX4444%(**** "BBB@04444 %%%% !1110,**** 844
M44""BBB@ HHHH*"E[>])100%%%% ,****"D%%%% /0**** "BBB@ HHHH!A1
M110 4444 %%%% !1110 4444""BEZTF*#30****" HHHH ****!!1110(***
M*!A1110 4444 %%%% !1110 4444#"BBB@ HHHH!!1110)A1110""BBB@ HH
MHH*"BBB@D****!H**** "BBB@ HHHH$%%%% !1110 4444 %%%% !11104%%
M%%!(4444 %%%% D%%%% PHHHH ****!A1110,7-)110*P4444""BBB@ HHHH
M **** "BBB@ HHHH **** N%%%% 6"BBB@ HHHH*"BBB@D**** "BBB@ HHH
MH **** "BBB@84444""BBB@:"BBB@84444"L%%%% @HHHH **** "BBB@ HH
MHH <!01Q0#2,?2@!*53BDYHH*%9MW%9FJ::)X3Q6BG+5:>,-"<^E,9\_>/M%
M$:R$+7@^O0&.X88[U]6>/--\R-\"OG?Q9I!2=SM[UFT==.1QEO5JHVA,)]*5
M6R:@Z1](:6D- "9- %&TTHH&%+244 +1110(7=2]:;1F@8ZFTN:2@0W)HR:-
MIHVF@&"FG4U13J 04NVDIV:!C66DVTYJ2@ HHHH **** "BBB@D****"@HHH
MH **** "BBB@6X4444 PHHHH ****!!2$TM-QUH$ -.IH%.H+"C!HI<B@!**
M5J2@04444#"BDW4 T +1110 4444 %%%% !1110 4444 %%%% @HHHH$%%%%
M!04444 %%%% !1110,****!!1110-A11102%%%% PHHHH$%%%% PHHHH ***
M* "BBB@204444 PHHHH!!1110,**** "BBB@ I#2TAH 3)IU-VFG4 )11104
M+3<FG4W::"112T@I: "BBB@04444#$:DR:5J3:: '4444 -+4 T8YH YH =1
M110*X4444 %%%% PHHHH%8****!A1110 4444 %%%% !1110 4444 %%%%!.
MH4444#84444#"BBB@ HHHH ****!!112$T *>::HI<\U)&F:I1YGH3)\JN6+
M=:T$'%584Q5H5]#A::BM3YG%U.9V0-24-S0*]%GFA1111H,****D044447 *
M***0!1111<84444A!1115( HHHHN 4444@"BBBD 4444TP"BBBK0!11128!1
M112N 4444@"BBB@ HHHH ****H HHHI6 **** "BBBD@"BBBJ **** "BBB@
M HHHHN 4444K@%%%%" ****8!1112 ****+ %%%%, HHHI;@%%%% !1112 *
M***H HHHJ1A1115L04444@"BBB@ HHHH ****D HHHI@%%%%, HHHH ****
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MHHH&%%%% @HHHH **** "BBB@ HHHH ****"@HHHH$PHHHH"X4444""BBB@
MHHHH ****!W"BBB@ HHHH **** "BBB@04444 %%%*M "44K4WG/M04.7[U6
M&;]V15:G;C01<P/$&G_:HV&,UXOXT\.[=[;:^AI+<3(<UP/C31@T+G;VI,VC
M*Q\JZY:_9Y&&,5CQM\QKNO&6E&.9^*XCR3&YK([XRN34M-5J=04PHHHH*&M2
MK2T+0%PVFBG4V@04UJ=24#&T^DI: "BBB@3"BBDH!!D44F*6@:0M%%% !111
M0 4444 %%%% @HHHH&%%%% !1110#U"BBB@25@HHHH*"BBB@FP4444!8****
M!!11104%%%% @I*6D:@89%+3*=0(::5:=10,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@6P4444"N%%%%!04444#N)1FD:A>M AU%%% PHHHH$%
M%%% !1110 4444""BBB@6X4444%!1110,****!!1110(****!A1110*P4444
M#"BBB@GJ%%%%!04444 %%%% !1110 4444#"BBB@04444"L%%%% PHHHH"X4
M444$[!1110,****!A1110 4444 %%%% )A1110#"BBB@%H%%%% !1110 444
M4 %%%% !1110(****!A1110 4444K@M IK4ZCK3"XU>35R!*ACCJ["F*[<+3
MNSSL55LB9%I]"TJ]:^CC&R/FI2YF&**=36ZUH182BBBI$%%%%"$%%%%*P!11
M118 HHHH ****M:C"BBBD(****5@"BBBD 4444]P"BBBE8 HHHJ@"BBBD 44
M45* ****L HHHJ6 4444 %%%%, HHHI@%%%% !1111884444P"BBBI$%%%%,
M HHHI %%%% !1110 4444@"BBBF 4444 %%%%( HHHH0!1113 ****F^HPHH
MHK0 HHHI""BBB@ HHHH **** "BBBF 4445(!1112 ****: ****H HHHI %
M%%%( HHHI@%%%% !1112 ****0!1113 ****+ %%%%, HHHI6 **** "BBBC
M< HHHHL 4444@"BBB@ HHHI@%%%%*P!1113 ****8!1114@%%%%4 4445-P"
MBBBJ ****0!1110 4444P"BBBDP"BBBI0!1115@%%%%( HHHH ****+ %%%%
M%@"BBBF 4445(!1110@"BBBK ****0!1114@%%%%.XPHHHHN 4444Q!11128
M!11120!1113L 4444 %%%% !1110 4444@"BBBG8 HHHI@%%%%,84445(@HH
MHI@%%%%( H;I12-]TTP*LDVV3%;_ (?L?MLRC&:YF12TPKU#X:Z0;JXB^7O6
M5>2A"Y=&//*QZY\+_!N^2%MGZ5]:^ =#%G!'\N.*\Y^%OA0+;Q-L_2O==+LQ
M:Q* ,<5^=X_$.I*Q]U@L.J<;E_I12TW^*O&/6'44450!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -;K0O6EVT;: %I#S2T4 5;NW$D;5YW
MXJTO=NXKTUN5-<[K=@)HVXK>E/ED95(<R/ ]6T\QR-Q6.R[.*]#\2Z7Y98XK
M@;Z,QR$5]+1GS(^>K0Y6,6EQ38JEXQ6]SF&8I:**!!1110-!1110 4444""B
MBB@84444""BBB@84444$A2YI** "BBB@84444!8**** "BBB@ HHHH ****
M"BBB@3"BBB@$%%%% PHHHH **** "BBB@&%%%% D%%%% PHHHH **** "BBB
M@ HHHH&%%%% @HHHH ****"@HHHH)"BBB@ HHHH **** "BBB@ HHHH!!111
M06[6"BBB@D****!!1110 4444 %%%% PHHHH$%%%% !1110 4444#"BBB@ H
MHHH$%%%% !1110 4444 %%%% !1110 4444#L%%%% @HHHH **** "BBB@ H
MHHH*"BBB@04444 %%%% !1110(**** "BBB@ HHHH&%%%% ,****!!1110 4
M444 %%%% !1110 4444 %+FDHH$+FDHHH&@HHHH&%%%%!(4444#"BBB@8444
MM KB4444%!11102%%%% T%%%% PHHHH)"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ****!H*7M244%A11100%%%% @HS110(7-)110#"CN***
M+,1^6L'Q%:_:(FXS6TC<5!=0^<I%!2/GKQMX?+-(=M>1ZMI_V:1N,5]2^+M#
M#PN=M> >-=-,,CX'>LV=E-GG_F?,1[U.O2J;J5F.:MQ_=J3J'4444 %%%% !
MDT444 @HHHH&%%%% @HHHH$-:A:4C-'W:!C@M(:0-[TM PHHHH ****!H***
M*!,****"0HHHH&@HHHH&%%%% !1110(****!A1110 4444""G+TIM+NH&*W2
MFTNZDH **** M8*2EHH 3 IM/INV@!5I:0<4M !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1129H *KW-N)%(JS24 ><^+--&UR!7DNM6A25N*]_\
M$%CYR-Q7E7B31BK,<5[.%K6T/+Q-.^IP"?+3MU2WL7DL>U5%;)KVEKJ>(U9D
M]%(M.H!"4444#84444$A1110,****!!1110 4444#"BBB@5@HHHH ****!A1
M110""BBB@ HHHH$%%%% !1110,****!!1110 4444 %%%% PHHHH$%%%% [A
M1110(**** "BBB@84444#L%%%%!(4444#"BBB@04444 %%%% !1110 4444
M%%%% !1110 4444!N%%%% ;!1110 4444%!11102%%%% [!112[30%A****!
M!1110 4444 %%%% !1110 4444#04444#84444$7"BBB@H**** "BBB@=@HH
MHH)"BBB@=PHHHH!A1110(**** "BBB@ HHHH'<****!!1110 4444%;!1110
M2%%%% @HHHH+V"BBB@6X4444""BBB@ HHHH **** "BBB@84444""BBB@ HH
MHH **** "BBB@84444"L%%%% PHHHH$%+244!8****"@HHHH)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@-@HHHH&%%%% !1110(**** "BBB@ HHHH
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M V\"EHHKQSU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $IM/I-HH %Z4M%% $%Q;B93FN*\3:0#&QVUWE9&N6HEA/'
M:M:<G&1G4CS(^?O$-CY<C<5SBH58UZ9XHTDEG.VN#N[7R7.17TM"IS(^=K0Y
M65EI:9NP:=GBNIF"8N:*;DTX4B'J%%.H/2@!M%%% PHHHH$%%%% !11104%%
M%% @HHHH$%%%% [!1110(****!A1110 4444 %%%*.] T)112]LT!82BBB@
MHHHH)"BBB@5PHHHH*"BBB@+!1110(**** "BBB@ HHHH **** "BBB@84444
M %%%% @HHHH$%%%%!5@HHHH$%%%% !1110 4444 %%%% !111058****"0HH
MHH ****!A11106A>U)2]J2@D****!;A1110(**** "BBB@84444""BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ****!A1110(**** "BBB@ HHH
MH ****"KA11102PHHHH **** "BBB@ HHHH&%%%% !1110(****!!1110,**
M**!A1110(**** "BBB@ HHHH **** "BBB@ HHHH&%%%% @HHHH **** "BB
MB@ HHHH&%%%% @HHHH&%%%% @HHHH&%%%% !11102%%%% PHHHH **** "BB
MB@ HHHH ****!A1110,****"1IH%+BC;0 M%%% !1110 4H;%)1058D7YS5/
M5M/$L!..U6XC\U2W'S0XICV/ OB#HO\ K"%KPG7+ QW#<5]6^,=)^TQN=N:\
M(\6>'S%(YVUFT=E.1YS'\@Q4BMFEO83"Q%01-4'26**04M KA1110,****"0
MHHHH#<****"@HHHH)U"BBB@L****!!11105N%%%%!(4444 %%%% KA1110 4
M444 %%%% PHHHH ****!7"BBB@84T]Z=28H($'6G4F*6@L*2EHH)U"BBB@H*
M*** "BBB@FP4444%!1110 4444 %%%% KA1110%PHHHH&%%%% KA1110,***
M* "BBB@ HHHH$%%%% K!1110,****!A1110(****!A1110 4444""BBB@844
M44""BBB@04444 %%%%!04444""BBB@!K4E.QFC;0 M,I])MH&"T-110 VGTF
MVEH :W6A:7%&* %HHHH$%%%% AK4E.QFC;04+36ZTZDQ0 +2TE+0,****"0H
MHHH$%%%%!204444 %%%% !1110(**** "BBB@ HHHH$%%%% ]PHHHIC"BBB@
M HIN30*!#J**0TQBT4T=:5JD!:=&NZHN]6K=<U5-<S,:DN5%B"/I5U%XJ.%<
M 5+G%?1X>GRJY\SB:G,QK4E*:2NUL\\****20PI0:2BJ&A<TE%% !1113$%%
M%%3< HHHI@%%%%)@%%%%-#"BBB@04444 %%%%( HHHI %%%%" ****L84445
M%Q!1113 ****8!1114M %%%%*P!11156 ****8!1110 4444F 4445(!1115
M@%%%%38 HHHJ@"BBBDP"BBB@ HHHI %%%%, HHHHL 44446&%%%% @HHHHL
M4444 %%%%- %%%%# ****D HHHIH HHHJF,****EB"BBBI ****=P"BBBG:X
MPHHHI""BBBCH 4444@"BBBF 4444 %%%%4 4444 %%%%/< HHHJ=@"BBBF 4
M444K@%%%%, HHHJ; %%%%4 44456P!1114/<84444A!1113 ****0!1110 4
M444[ %%%%, HHHH ****D HHHI[ %%%% !1113 **** "BBBDX@%%%%"8PHH
MHIB"BBBDP"BBBE8 HHHI6 ****M#"BBBBX!1112N 4444Q!1113&%%%%2(**
M**8!1114V **** "BBB@ HHHIH HHHI@%%%% !1110 4444 %%%%*X!1110
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MHH **** "BBB@84444"84444"04444"ZA11104%%%%!(4444%!1110 4444
M%%%% !1110(**** 04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ****!6"BBB@+!1110,****!6"BBB@H****!!1110 4444 %%%% !111
M0 4444 %%%% !1110(**** 04444#"BBB@ HHHH **3-&: %HHHH%8****!A
M1110 4444""BBB@84444 %%%% !1110 4444 %%%% @HHHH!!1110,****!!
M1110 4444#"BBB@ HHHH"X4444 %%%% !1110 4444 %%%% @HHHH&%%%% !
M2$TM-(H 4&BD44IIDC:5:2G#I0,6DI:*0Q-M!HS2KSB@D%7)J];KBHH8\U<C
MCVUZF%HZW/*Q5:R)D^[0U%%>];E1\]*3DQ****1 44450!1114@%%%%- %%%
M%, HHHJ "BBBK **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MI6 ****8!1110 4444 %%%% !1110 4444F 4444( HHHI@%%%%+0 HHHI@%
M%%%2 44450!1110 4445(!1113 ****0!1110@"BBBK ****0!1112 ****8
M!1110 4444 %%%%*P!1113 ****+@%%%% !1110 4445(!1113N,****D044
M452 ****+ %%%%%@"BBBF 4444P"BBBI8PHHHI)V$%%%%/< HHHI %%%%, H
MHHI@%%%%2 4444[@%%%%#8!1110 4444F 4444 %%%%4 4445F 4444P"BBB
MJN 4444 %%%%) %%%%4 4444@"BBBA@%%%%" ****=P"BBBD 4444@"BBBF@
M"BBBF 4445+ ****$ 4444P"BBBD 44450!11128!11120!1115 %%%% !11
M14@%%%%, HHHH ****8!1110 4444 %%%%2P"BBBF 4HI*5:8"[:0\4ZFL:"
MA****!"BC=244AH<#36-!XJ%I/FQ3!LJW6=W%=;X)TUKNYC&,\U@VMBUU(H
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M110*^H4444#84444 %%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****!W"BBB@04444#"BBB@04444 %%%% PHHHH ****";!11104%%%% V%%%
M%!(4444%!1110+J%%%% [!11102%%%% !0***!DRR?+52\M?M"L,5,M6X5#"
M@+GDOC3P\#&YVU\_>,-/^SROQWKZY\4:>)H'XKY\\>>'V,CD+WJ&=5.1XLH*
MR5<7[HJ:]T\V\IR,<U5WXP*@[-R6BD6EH!!1110,****!!1110,****"0HHH
MH+N%%%% @HHHH **** "BBB@ HHHH%8****!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110(****!!11104%%%%!.P4444%!1110(*
M*** N%%%% TPHHHH ****!A1110 4444$W"BBB@84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 UNM"]:6B@!:*** "BBFM0 ZBF4^@ HHH
MH ****!!1110,**** "BBB@ HHHH **** "BBB@ HHHH%<****!A1110*P44
M44#"BBB@ HHHH$%%%% PHHHH$%%%% !1110,**** "BBB@ HHHH **** "DI
M:*8A**6BBX,*1J6FM4LI,2I8E^84Q1FK4,=:48N4C"K)119MTXJT%XJ*-=M2
MYKZBA3Y8GRV(J<TA*2BBMV<@4444( HHHH8!1112$%%%% !1113 ****0!11
M15 %%%% !1110 4444 %%%% !1110 4444K@%%%%, HHHI@%%%%%[#"BBBD(
M****D HHHI@%%%%, HHHH>@PHHHI7$%%%%, HHHJ0"BBBBP!1115 %%%%*X!
M1113 **** "BBB@ HHHI %%%%( HHHH ****=P"BBB@ HHHI6 **** "BBBF
M 4444 %%%% !1112N 4444V 4445-P"BBBK ****=@"BBBIL 4444K %%%%-
M %%%%%P"BBBBX!1113 ****6XPHHHH:L(****@ HHHJT 4444P"BBB@ HHHJ
M6P"BBBE< HHHH ****8!1110 4444 %%%% !1115 %%%%%@"BBBBP!1114@%
M%%% !1113 ****8!1110 4444@"BBBE< HHHI@%%%% !1112 ****J^@PHHH
MI""BBBF 4444 %%%%"U&%%%% @HHHI@%%%%( HHHI %%%%%P"BBBF 4444 %
M%%%*P!1113: ****0!1110 4444@"BBBF 4444P"EI**FXQ:2BBF#"BBBF(*
M6DI"V*0Q9.]4N3-BK7F!N*MZ;I;75PN!GFG?E5V5:^QU?@G0C?31_+FOJKX7
M>!]JQ-Y?IVKRKX3^$&DFB)3]*^Q? /AM;:S0E<<5\?F6*Z(^DR_#7U9T7A?3
M_L=NHQCBM^HX81"N!4E?(R=W<^JBN56&M24^DJ2A:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444%!11102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% PHHHH$%%%% !1110 4444 %%%% !1110(****!A1110,****!!1
M110 4444 %6(9-M5Z4'% !>QBX0CK7GGB[PR)HW.VO285W=:J:S9K+;MQVI,
MN+/DCQEH9M9'PM>=3*8YB*^B?B!H>[S"%KP_6=+:&9CCO4'?"1G1'Y:?4/\
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M*** "BBB@ HHHJ6 4444 %%%%, HHHJ@"BBBH ****H HHHH ****E %%%%
M!1115 %%%%*P!1110 4444(84444/< HHHIB"BBBE8 HHHI@%%%% !1110 4
M444F 4445(!1113 ****8!1113 **** "BBBI&%%%%5T ****2$%%%% PHHH
MI""BBBF@"BBBBP!1112 ****H HHHJ0"BBB@ HHHIH HHHH ****0!1110@"
MBBBJ ****E@%%%%4D 44447 ****: ****0PHHHI6$%%%%*P!1110 4444 %
M%%%.X!1114@%%%%5884445+$%%%%, HHHI@%%%%# ****$ 4444 %%%%( HH
MHJ@"BBBEN 44446 ****0!1116@!11168!1113 **** "BBBJ ****A@%%%%
M" ****H HHHI#"BBB@04444@"BBBG8 HHHH ****8!1110 4444 %%%% !11
M12W ****$,****H04444AH****0!2;J6DVFG:PA0:* ,44#%]:AN&PM2%L5%
M,/,7 I"(+1C).%ZUZW\/O#)OYHR5SSZ5YOX?TI[B\7C/-?5'P:\*[VA+)Z=J
M\W&XA4X'H8.E[22/5/A?X+%ND3&/]*]_TFU%K:JH&*P_"VAI:6L9VXXKJ%4*
M,"OSS$575E<^ZH4E3B+1117*=(4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@"BBBA %%%%"8!1113>HPHHHH$%%%% !1113 ****@84444T(****8!1112
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6SC  QBM*OA:DN>5S[.G'EC8****S-!-HHI:* "BBB@ HHHH **** "BBB@
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M*: ****I@%%%%9@%%%% !1113 ****8!1114@%%%%, HHHHL 4444 %%%%"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@5PHHHH&%%%% !1114@%%%%4 UJ5:,4N*!HFB;:*@U!//C(Q3U:G*/,XI]
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M%%, HHHJ0"BBB@ HHHH0!1115@%%%%2P"BBBD 4444@"BBBJ0!1113 ****
M"BBB@ HHHJ; %%%%, HHHI@%%%% !11146 ****I %%%%4 4444@"BBBIN 4
M444 %%%% !1113N 4444 %%%%, HHHJ0"BBBFAA1113 ****!!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1129%  32TTTZ@#+UBS$\9XKS#Q-H?WSM
MKV"2,2+BN;U[2Q)&QVUO2J.$CFK4^='S]J5D8)#QBLU6^;%=UXFTORV;"UQ,
MT!CDZ5]11FI1/GJL.5CU^[13%;%/S6IB%%%%(H****!!1110(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ****!A1110(**** "BBB@ HHHH ****"@HHHH$%%%% !1110#"B
MBB@40HHHH&%%%% !1110 4444 %%%% ,***7% "4444""BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****!!1110,**** "BBB@ HHHH **** "
MBBB@ HHHH&%%%% @HHHH **** 2"BBB@H****!!1110""BBB@&%%%% !1110
M(**** "BBB@ HHHH ****!A1110 4444""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH"X4444%!11102%%%% PHHHH$%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=@"BBBD 4444@"BBBGS#"BBB@04444K@%%%%# ****0!1115 %%%% !1110
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M 44446 ****0!1115 %%%%*PPHHHH$%%%%.P!1110P"BBBD 4444]@"BBBD
M4M)3)'VU5@O8)F^6JUM&TTP YYJ5,S,!UKJO"OAI[RX0[,\^E1.2IJ['&+F[
M(Z7X?^$6U":,E,\U]9_##P$+6.)C'Z=JXOX2^!]OE%H_TKZB\,Z''9VJ?+CB
MOB,QQCD^5'UV P:2YF:NBV:V=JJ@8XK0I%4*,"EKYGU/HUIH%%(31NH&+111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 9NJ6?GH>*\\\2:#PQVUZFRANM9&LZ:LT)P*VIU'!F
M-2FI(^>-8L#!(W%8P!#5Z9XHT,AF(6N!O;,P2'([U]+1JJ<3YZM3<65Q14>Z
MI!T%=)SA3J;10(5J2BBD 4444 %%%% PHHHH$%%%% !1110.X4444 %%%% @
MHHHH ****!A1110(**** "BBB@84444 %%%% @HHHH **** "BBB@84444 %
M%%% !1110(**** "BBB@ HHHH ****!A1110 4444""BBB@ HHHH&%%%% [!
M11102%%%% !1110 4444 %%%% T%%%% ,****!!1110.X4444 %%%% F%%%%
M (****!A1110(**** "BBB@ HHHH&%%%% @HHHH!,**** "BBB@ HHHH&%%%
M% 6"BBB@04444 %%%% !1110,****"6PHHHH&%%%% !1110 4444 %%%%!5@
MHHHH$%%%% !1110 4444!8****"0HHHH*"BBB@ HHHH$%%%% !1110 4444%
M!11100%%%%!2"BBB@04444%,**** 04444""BBB@+A1110)ZA1110.P4444
M%%%% PHHHH$%%%% @HHHH **** "BBB@=@HHHH$%%%% [A1110%PHHHH!H**
M**!!1110 4444%= HHHH)"BBB@:"GJ=M-6E:@.HDG[P8KGM>T-;B)CMS70QG
MYN:EFB$D)IV*3L?-WCCPWY>\A?TKQO6+%H)FX[U]9^,- %Q&Y"UX3XM\-&&1
MSMK-HZ82/-(R5J56S3[ZW,#D8QS4$)S2L=2)Z***AE!1113 **** "C::%ZT
MZ@!M%%% !1110 4444 %%%% !11103<****"@HHHH **** "BBB@84444 %%
M%% @HHHH$%%%% PHHHH **** "BBB@5PHHHH&%%%% !1110"T"BBB@'J%%%%
M K!1110#"BBB@:5PHHHH$)1D4&DH';J.HHHH&%(U+10)C=IIU%% @HHHH&%)
MD4-TIM #LBC(IM% AV11FFTJ]:!CJ***!!1110,**** "BBB@5@HHHH$V%%%
M% ;A1110.P4444#"BBB@ HHHH$%%%% PHHHH$%%%%!5@HHHH)N%%%% PHHHH
M)ZA111078****!!1110 4444$W"BBB@I!1110,*2EIK4$BTM-6G4R6(:15W4
M=6JQ#'FB,7-Z"E-00ZWBJ_&M,BCJ<<5])AJ2BM3YO%5N9Z :2EI*[3S0HHHJ
MKB"BBBD 4444 %%%%( HHHIH HHHI-@%%%% !1110 4444 %%%%%@"BBBF 4
M445(!1113L 4444P"BBBE< HHHI@%%%%( HHHIK4 HHHI=1A1115""BBBD 4
M444 %%%% !1112L 4444P"BBB@ HHHI %%%% !1110 4444P"BBB@ HHHH *
M*** "BBB@ HHHH ****0!11118 HHHHL 4444P"BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D3S%(-
M/HH Y3Q!HXEC8[:\H\2Z.8V?"U[W=0B6,@BN$\2Z()5<A:[\/6Y78X,12YD>
M%S0F.3D4JMC%='K>CF%B=M<S,IC:OHJ<E)'A2BX,ES3L5#&<U+NJY$WN#4E+
MFDJ42%%%%, HHHH&%%%% ,****!!1110 4444 %%%% !1110-!1110(****
M"BBB@84444""BBB@ HHHH&%%%% !1110(****!A1110 4444 %%%% @HHHH*
M"BBB@D**** "BBB@-PHHHH **** "BBB@ I<TE% @HHHH'<****!A1110+8*
M***!H**** 84444""BBB@ HHHH$@HHHH*"BBB@ HHHH$%%%% !1110 4444%
M!11102%%%% !1110 4444#M<**** M8**** 04444 %%%% @HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!A1110(****!!11
M10,**** "BBB@:"BBB@ HHHH$%%%% T%%%% !1110 4444 %%%% !1110 44
M44""BBB@84444 %%%% !1110(**** "BBB@KH%%%%!(4444 %%%% !1110 4
M444 %%%% !1110 4444#04444""BBB@ HHHH&%%%% !1110(**** "BBB@84
M444 %%%% 6&J<&IEE[5%MH7K0!'>V*W49R*\P\:>& Z.0E>NHPVXK'UG35NH
MVXJ6:1=CY$\4: T,S?+BN3:$PL<U]$^-/"G#L$KQ'Q'I;6LC<8J3MA(PM]/J
MFK$.0?6K2GY:5C5CJ**;DTV(=12+2U)049-%% !1110(**** "BBB@84444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%%(!*S]0L1-&>*T:1AN&*I.PFKGE?BC11AB%KS'5M/:*0\=
MZ^@M9TP3*W%>:^(M"V[CMKV,+B+:,\G$4>QYERG%/1MU7-0LS"YXJBHQFO:Y
MN9'C.+BR6DI,TM( HHHJ@"BBBH&%%%%4(**** "BBB@ HHHH&PHHHH!(****
M 84444""BBB@ HHHH&%%%% @HHHH&%%%% 7"BBB@ HHHH$+BDHHH!:A1110,
M****!!1110,****!!1110 4444 %%%% T%%%% @HHHH ****!A1110 4444!
M87BCBD-%!84444&>X4444 %%%% !1110,****!!1110 4444#N%%%% @HHHH
M ****"K!11102%%%% @HHHH&%%%% !1110)!1BBB@I"X-)110-L****"0HHH
MH*"BBB@D**** "BBB@ HHHH&%%%% @HHHH **** "BBB@84444""BBB@ HHH
MH ****!A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@+A111
M0*X4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!A111
M0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH&@HHHH$%%%% PHHHH **** N%%%% A=U2J@=3FH&J2-MM!1S_B;25N(
M6XYQ7A'CCPP=SD+7TE=1"=2*XCQ1X;6>-SMJ'$UC*Q\E:EIK6LK<5G^81Q7J
M?C#PWY+.0M>9WEHT,I&.]*YVQDF"'<*7;3(VP*>#FD4] I:**0TPHI*6@ HH
MHH **** W"BBB@04444#"BBB@ HHHH%<****"@HHHH **** "BBB@04444#"
MBBB@-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH)N%%%% !1110-A1110
M-!1110#04444#"BBB@04444 %%%% @HHHH$@HHHH*"BBB@0W::-IIU% Q%I:
M**!=0HHHH*"BBB@BX4444#N%%%% !1110,**** "BBB@04444#"BBB@04444
M#"BBB@ HHHH$%%%% !1110,****";A11104%%%% !1110""BBB@84444""BB
MB@04W;3J*!)B"DW4NZ@+N-&XP W5:ABID,>:OQ1X%=^'HN3/-Q-;E5D+$NVI
MUZ4W&*3-?04X**/G*DG)W'=Z3BA:=6AG<911FB@04444 %%%% !1113LAA11
M14V$%%%%( HHHH0!1113 ****8!1110 4444P"BBB@ HHHK, HHHH ****H
MHHHI@%%%%)@%%%% !1112 ****=@"BBBF 4444 %%%% !1110 4444@"BBB@
M HHHHL 4444 %%%%%@"BBBJ&%%%%3804445(!1115 %%%%, HHHH ****$@%
MI***>P!1114[@%%%%( HHHH ****8!1110@"BBBA@%%%%( HHHIWL 4444AA
M1115""BBBDV 4444( HHHI %%%%# ****E %%%%4,****IH04444[ %%%%0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110@"BBBF 4445(!1110 4444T 44450!1114@%%%%( HHHI@%%%%, HHHI
M%%%%, HHHI %%%%( HHHIL HHHJ0"BBBJ ****5P"BBB@ HHHH **** "BBB
MD 44455@"BBB@ HHHI %%%%-@%%%%(84444[""BBBI ****?0 HHHJ0"BBBJ
M0!1115 %%%%, HHHI %%%%( HHHI@%%%%*P!11120!1115 %%%% !1110 44
M44 %%%%2P"BBBGT ****0!1115 %%%%( HHHH **** "BBBF 4444@"BBBD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -84ZF4JT *U-I])3 1:'7<I%.HI
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MHHH$%%%%!04444 %%%% !1110(****!A1110(**** "BBB@JX4444""BBB@
MHHHH$%%%% K!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH&%3+)BH:4&@1'=6_VA2,5P?BKPR)HW.W]*]%C^:JFHV2SQGC-(N,K'RK
MXN\,F%G(6O.;NS:WE.17U-XN\+B9'(6O$?%7ATV[N=N/PJ6=M.=S@/,QQ3U^
M:F75N8I"*=&>E9G024M-S2K3 1J2GT4P$I]-HR:0"M244C4 +13*=0 M-:G4
MUJ!6!:=3*?04%%%% !1110 4444""BBB@ HHHH&%%%% @HHHH ****!6"BBB
M@+A1110.X4C4M% KC*=2T4#"BBB@ HHHH **93AWH$Q:*** 04444#"BBB@
MHHHH$%%%% PHHHH **** "BBB@ HHHH!L**** 2"BBB@ HHIK4 .HIE/H&%%
M%% !1110(***90(?135IU PHHHH$%%%% PHHHH ****"0HHHH*"G+TIM% "M
M2444 %%%% @HHHH&)3:?24"!:6BBE884444Q7"G+TIM&:5Q S4!<TW[QJQ#'
MFG%.3L*4E%:BPPYJ[%%C%.ABXJ8C;7OX?#Z79X&)Q'1"8Q1DTE%>KLCQF^8*
M***D%H+2445-PN%%%%, HHHJF@"BBBD 4444P"BBBIL 4445=@"BBBIL 444
M4K %%%%, HHHIW&%%%%%@"BBB@04444@"BBBE8 HHHH ****-QA1110 4444
M""BBBF 4444P"BBBDP"BBBI **** "BBBK3 **** "BBBIL 44450!1110 4
M444 %%%%*X!1111< HHHH8!1110@"BBBDP"BBBI ****T ****2&%%%%-Z@%
M%%% @HHHJ0"BBB@ HHHI@%%%%, HHHH **** "BBBDM1A11138@HHHI %%%%
M !1112 ****H HHHH **** "BBB@ HHHI6 ****+@%%%% !1112 ****$ 44
M450!1110 4444 %%%%*X!1112 ****: ****8!1110 4444@"BBBF 4444 %
M%%% !1114 %%%%6 44446MJ,****6X!1113V ****:8@HHHJ;@%%%% !1113
M **** "BBB@ HHHJ0"BBBF 4444 %%%%.PPHHHJ!!1113 ****L HHHJ0"BB
MBE8 HHHIV ****+ %%%%*P!1110 Y:6F4595Q32444F2%%(U)NQ0F,5FVU#)
M+D8HE>EL[5KB0 #-/3<0VQLVN9P ,\U[-\./!1O)HR8\_A6#X+\%O>31G9GG
MTKZG^%W@'[.(B8\?A7BX[%J$;)GJ8/"N<KLZKX=^ UM88F,?Z5[9I&GBSA4
M8XJOH>CI9VJ<8-;'3BO@*U5U)79]O1I*G&R%I*6BN<Z HHHH **** "BBB@
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M!N30M&VE H 6BD-)NH$.HHHH ****!H3=2TF*3=0,5J0&C[U'W:!#J*;NIU
M!36IU(10(0&G4T"EH)$W4#M2=:DC2ERW>A2DHK4=''FKL,>*9#'5M%KV,+A^
MK/%Q>(Z(>ORBE8YI,45[L5RJQX$FY/42BBBI8!1110A!1112 ****8!1115,
M HHHJ "BBBF 4444 %%%%4@"BBB@ HHHJ0"BBBF 4445 !1111J,****:$%%
M%%4K#"BBB@04445(!1110,****8!1110(**** "BBBF 4444 %%%%*P!1110
M 4444@"BBBJ **** "BBBE< HHHI %%%%6 4444@"BBBI ****8!1110 444
M4@"BBBF 4444P"BBBD 4444@"BBBJ ****0!1113 ****D HHHJ@"BBB@ HH
MHI %%%%( HHHJ@"BBBF 4444@"BBBD 4444@"BBBJ **** "BBBI ****H H
MHHJ0"BBBF@"BBBF 4444@"BBBF 4444 %%%%)@%%%%*P!1110 44450!1110
M 4444 %%%%2 4444@"BBBJ ****8!1112 *6DHJABTE%%(04445.P!1113O<
M HHHH ****0!1113 ****+@%%%%2 44458!1114@%%%% !1113 ****8!111
M4@%%%%( HHHJD 4444P"BBB@ HHHH **** "BBB@ HHHIM@%%%+4H8NVD:G9
MIK4"$-02MMJ4MUJK,K,W%-(=R:&$W# "NX\'^%)+R9/ESSZ5D>$M%DO;A!M)
MYKZ?^%OP]\WRF:/]*\O%XKV,6=V%H.M(UOAC\._]46C].U?27AKPRFGPQ_+C
MCTJIX1\*QZ?&GR 8]J[95"J .!7P6)Q,JLC[?#X=4X@J[5 %+117 =H4444
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M4 %-;K3J*!#5IU%%!5PHHHH$%%%% !1110+8**** $:FT^B@!*6BB@84444
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M** "BBB@ HHHI6 ****& 4444D 4444 %%%%4 4444 %%%%( HHHHN 4444
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M>CO?3KA2>:]]^%?P]:>6(M'W]*XL3B%2B=-&BZLK&K\,/AFTDD3F+T[5]7^
M/!Z:?"F4Q@>E0_#_ ,"Q65K&S(!@>E>CV]JELN$%? XS%NM)H^UPF%5%)DB1
MK& %&*7O2TU>M>4>H.HHHH **** "BBB@!E.6EHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)NHIM "CKFG4BTM
M$4T(D4@US&MZ,)E;BNLJ&>W$JGBKC)QV(E%21X?X@\/E68A:XB]LVMW/%?0&
MM:*LBD[:\R\1:&8V<A:]K#8B^C/'Q%'JC@-Q!J53FGW5J89#Q4&[%>O?F/+M
M;<DS1GFF*<T\"@0M%%%( HHHH&%%%% @HHHS0 4444#N%%%% @HHHH&%%%%
M@HHHH ****!A1110 4444""BBB@04444%!1110(**** "BBB@84444""BBB@
M84444 %%%% @HHHH*"BBB@D**** "BBB@H****"0HHHH ****!W"BBB@0444
M4 %%%% [A1110 4444""BBB@ HHHH$%%%% PHHHH*"BBB@04444 %%%% (**
M** 84444""BBB@84444""BBB@ HHHH ****!A1110(**** "BBB@ HHHH **
M**"@HHHH$%%%% @HHHH&%%%% @HHHH ****"K!1110(****!!1110,**** "
MBBB@+!1110(**** "BBB@ HHHH&%%%% @HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH'<**** "BBB@?0****"0HHHH$%%%%!04444""BBB@:"BBB@&%%%
M% @HHHH ****!A1110(**** "BBB@ HHHH **** "BBB@84444""BBB@ I3B
MDHH'N%%%% @HHHH *7%)3EH 3;29Q3ZC:@!ZG=UJ.\LTFB.1FE4\U*#N&*HN
M]CS'QAX76X1R$_2O#/%7A5K>1R$KZUOM-6XC((KS7QAX4657(2LV;TYGRO>0
M-;L1C%1PL37=>*?"[02.=E<7-;FW8@C%18[$[BK2YJ%9.<5*OK2 =1110-!1
M110+J%%%%!0W::5:6B@04444 %%%% !1110,**** "BBB@ HHHH'L%%%%!-P
MHHHH&%%%% K!1110,**** "FM3J:U "4^F4^@ HHHH ****!!1110,****!!
M1110,**** "BBB@ HHI*!"T4E+0,**2B@F[%HHHH+L%%%%!+"BBB@.@4444"
MB%%%% [A1110 4FZEIE QV:6FK3J!!11104%)FEIK4"%W4M,I] !1110*X44
M4E !NHIM.6@!:*** "BBB@84444"$I-U*U-H#U'CFI8XLTD4>:O0P^U=E&DY
M,X<1645H-BAJTJXI54+3J]^E344?.5*CFQM -)172V<]K"M2445 !1113N 4
M444(04444P"BBBE8 HHHI@%%%%( HHHI; %%%% !1113OH,****D04444P"B
MBBF 4444(84444V(****3 ****$ 4444P"BBB@ HHHI@%%%%2 4444 %%%%.
MX!1110 4444F 4444@"BBB@ HHHH **** "BBBJW **** "BBBI8!1110 44
M452&%%%%( HHHJ6(****5P"BBBK ****0!1115 %%%%2P"BBB@ HHHH ****
M8!1113 ****FP!11130PHHHIM""BBBE8 HHHI@%%%% !1112 ****8!1112
M****0!1115=!A1111L(****3 ****0!1110 4444[ %%%%, HHHJ0"BBBJ *
M***D HHHH ****-P"BBBJ **** "BBBDP"BBB@ HHHI@%%%%( HHHH8!1114
M7 ****L HHHI@%%%%( HHHH ****+ %%%%, HHHH ****3 ****0!1115 %%
M%% !1114@%%%%4 4445 !1115 %%%%( HHHJ@"BBBI ****I %%%&:&,****
MD0449HJ; %%%%6@%QFEVT+2TRAN*#C!-#<55DN=N12W)$FF*\4^UMGO'"@9I
MD%NUY( !GFO3? ?@E[V:,F,GGTJ*E2-*-V:4X.H[(G\ > Y+R:-C'W]*^L_A
MC\/UMXXBT>.G:L[X:?#E8EB8Q?I7T#X?T%+&%?EQBOB,PS!U'RH^NP.#Y%=E
MS2-'CLX5 7%:G2CI0>U?-MW9] E86BDS2TAB;J-U(W6A>M #J*** "DS2TUJ
M %W4M,I] !1112 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% @HHHH&%%%% !1110(**92K0,=110O6@ HIU(U "4444"MJ%%%%
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M12N 4444 %%%%( HHHJ@"BBBI ****H HHHJ0"BBBJ ****D HHHI@%%%%(
MHHHH ****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****EH HHHIH
M HHHI@%%%%*X!11128!11156&%%%% @HHHIV ****0!11128!1110 44447
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MTKZ'\,^&4L;=/D KXO'X]S;29]9@L#RZL?X9\.I8PK\H&!73JH5<#I2(@C4
M4ZOF&W)W9]&DHJR"D;I2TE(8VG+THVT4 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "4FVG44 (*6BB@!*3=2GI3: '4M)1WH K7EJ)E/%<?KV@B16(6NZJM=
MVJS(>*N,W%W1G."DCP/7M!,;,=M<E<VYA8\5[MX@T%75B%KS#7]',3-\N*]_
M#U^969XE>CRG(JWK4PYIDT)C8\8I%:O2NCSR2BE6AJ13$HHHH,@HHI=M!8S=
M2@TF*5: %HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% T%%%% !11
M10(**** "BBB@84444 %%%% @HHHH&%%%% @HHHH **** "BBB@ HHHH&@HH
MHH ****!!1110 4444 %%%% T%%%% @HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH'8****!;!1110&X4444!L%%%% !1110 4444 %%%% !1110 4444#
M"BBB@04444 %%%% (****!L**** "BBB@04444 %%%% !1110 4444 %%%%
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M04444#"BBB@ HHHH$&WVHIU(U "444E Q<T9IE.% ]A:***";A1110,****
M"BBB@04444#"BBB@ HHHH 0C-&VEHH$%%%%!04444 %%%% @HHHH$%%%% PH
MHHH **** "BBB@5@HHHH&%%%% T%%%% @HHHH&PHHHH$%%%% @HHHH!!1110
M 4444#"BBB@0"G;12+2TP&T4FZEI#"BEVTV@!:;F@M2#FD(.M2QQ[C1''FKD
M,5=5&DY,Y:U9100PU;1=M(J@4^OH:-%11\[7K<S"BDIRUT;,XA,4$TK4S=57
M 6BBBIL(****& 4444D 4444V 4444@"BBB@ HHHH8!1113 ****0!11157
M****6X!1113 ****0!1111< HHHI %%%%6 4445+ ****D HHHI@%%%%, HH
MHI@%%%% !1110 4444K@%%%%, HHHI %%%%( HHHIC"BBB@04444@"BBB@ H
MHHIH HHHH8!1112 ****: **** "BBBA %%%% !11120PHHHJV(****@ HHH
MH ****L HHHI %%%%, HHHH ****0!1112N 4444@"BBBA, HHHH8PHHHH$%
M%%%- %%%%, HHHH ****:LQA1112$%%%%( HHHI %%%%.P!1110 4444 %%%
M%, HHHI %%%% !1112 ****H HHHHO< HHHH **** "BBB@ HHHI %%%%( H
MHHI@%%%%%@"BBBE< HHHH ****8!1110 4444 %%%%(84M)15[""BBBD 444
M4 %%%% !1110 4445(!11133 ****8!1110 4445* ****H HHHJ6 4444(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110.X4444""BBB@84444""BBB@ HHHH ****!A1110(**** "BBB@ HHHH
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M, HHHH ****&,****0@HHHI@%%%%)( HHHJK %%%%( HHHH **** "BBBIL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *1J6D(S0 F33J;C%&Z@!U%)2T %%%% !112=Z *-]8+<*>*X?Q!X?#;B
M%_2O1ZH:A8K.IXK:G4<&95*:DCY^UK16B9OEKFIK=HV->W^(/#P8,=M><:UH
MK0LWRU[V'Q',K,\.M0<7<Y1&J6F30M$QXIBL:]'<X=F344"BI ****!!1110
M 4444 %%%% !1110 4444 %%%% PHHHH$%%%% !1110 4444%!11102%%%%
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M(!1115 %%%%2 44450!1114 %%%%6@"BBB@ HHHI@%%%%0 4444TP"BBBG<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4444 %%%% PHHHH ****!!1110 4444 %%%%!6P4444$A1110 4444 %%%%
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M@ HHHH ****8!1112 **** "BBBBPPHHHH$%%%%%KC"BBBC804445(!1110
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M!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !124
M4 0W%NLRG(KD]<T(3*V%S79U#-;K*O2JC)Q=T1**DCPO7O#94L=M<7>:>UNQ
MXKZ%UC0UD4_+7G/B#PYMW$+7N8?%75F>17P_5'F@8JV*F6KE_IK6[GC%9Y8K
MQ7J)J2T/+<7%DM%-5LT[-,D*1J6BF58;3J7;24B0HHHH&%%%% @HHHH ****
M"MPHHHH$%%%% 7"BBB@04444 %%%% !1110 4444 %%%% @HHHH&F%%%% T%
M%%% @HHHH*04444$A1110,****!!1110 4444#"BBB@ HHHH$%%%% PHHHH!
M!1110(**** "BBB@84444""BBB@ HHHH **** "BBB@ HHHH*"BBB@EL****
M 04444%6"BBB@D****!A1110 4444 %%%% !1110(****!A1110(****!A11
M10(****!W"BBB@04444#"BBB@04444#"BBB@04444 %%%% PHHHH **** N%
M%%% @HHHH'<****!!1110,**** "BBB@04444 %%%% <H4444 %%%% !1110
M 4444#"BBB@04444 %%%% PHHHH$%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH*"BBB@04444 %%%% !1110 4444""BBB@84444#Z!1110""BBB@D****
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M ****!,****"EL%%%% !1110)ZA1110 4444 %%%% !1110.X4444$A1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%(W6A: '
M4444 %-:G44 1G-*K4XBFT@N.JO=6:3H1CFK"]*6FF!PFO>'Q(&PM><:WX>9
M&8A?TKWJXM5F!R*YG6/#ZR*WRUWT<0XLXZM%2/ +K3VA8Y&*J9V5Z1KOATJ6
MPM<3J&EO"QXKW:5931XM6DXLSU?=3ZBVF,\T\2"NAG*Q])1FBD"04444#"BB
MB@ HHHH)"BBB@84444#"BBB@04444 %%%% PHHHH **** L%%%% @HHHH&%%
M%% @HHHH **** "BBB@ HHHH **** "BBB@84444""BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ****!A1110(****!V"BBB@04444#"BBB@044
M44#"BBB@04444#"BBB@04444 %%%% PHHHH$%%%% !1110 4444#"BBB@044
M44 %%%% PHHHH ****!V"BBB@D**** :"BBB@ HHHH&%%%% @HHHH"X4444
M%%%% [A1110 4444""BBB@ HHHH'8**** N%%%% @HHHH ****!A1110):!1
M1104W<****!!1110(****!A1110,****!!1110(**** "BBB@ HHHH ****
M"BBB@ HHHH ****!A1110(**** "BBB@=@HHHH **** N%%%% @HHHH&%%%%
M !1110(**** "BBB@ I&I:* &4ZBFT /HI%I: "BD;I3: 'T4@Z4M ,****
MW"CI110%AZR&I/+$R\U!4J2[:!F/K&A)<(WRUY9XL\'AM^$_2O;6;S!@UE:E
MHZW2GY<TC2+/DOQ!X3>%F.S]*XVZL&MG.17U1XD\'K(K$)7CWBKPBT3.0GZ5
M+.R,SR_SMO%2K)NJ74-+>WD/&*J+^[X-0;;EFBHUD%/S0 M%%% @IE/I*"A%
MIU)2T %%%% @HHHH&%%%% !1110(****!A1110 4444""BBB@ HHHH&%%%%
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MBF 4444P"BBBF 4444@"BBBI ****8!11130!1112L 4444P"BBBBX!1113
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M@ HHHH 2BD;K0O6@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M- %%%%# ****E %%%%, HHHI %%%% !11130!1111< HHHHN 4444 %%%%(
MHHHIH HHHH ****8!1110 4444 %%%%2 44450!1110 4444K@%%%% !1114
M@%%%%.P!1115( HHHI@%%%%( HHHH **** "BBB@ HHHH ****D HHHH ***
M*>PPHHHI""BBBG< HHHHN 4444P"BBB@ HHHH ****E %%%% !11157 ****
M0!1113 **** "BBBE< HHHJ0"BBBF 444541A11128@HHHH0!11118 HHHI@
M%%%%, HHHI %%%%2 4444[ %%%%, HHHI#"BBB@ HHHI""BBBF@"BBB@ HHH
MI#"BBBBX@HHHJ@"BBBD 4444F 4444 %%%%- %%%%4 4445-P"BBBF 4444
M%%%%( HHHI@%%%% !1110 4444:#"BBB@04445(!11138!1110@"BBBJ; **
M**D HHHI %&:*0B@!=U.W4S::<M%ACJ0L!0QXJM(Q[4*X$K/59X7D;"TZWBD
MED  KN?"O@^34I4^0G-34J*FKLJ$7-V,+P_X<FOI5&TFO=?A]\,&N#&6BS^%
M=3\/_A*6\MFB].U?1'@_P#'8(F8\8]J^6QF8VNHL^BPN >[.>\$_#5+5(R8O
MTKU_1M&CL(U^4"KMG8QVL8"J,XJU7R=6M*H[L^GIT8TUH%%%%8&XFVBEHH *
M*** $VT4M% !1110 4444 )BC%+10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M84444 %%%% PHHHH ****!!1110,**** "BBB@04444#"BBB@ HHHH$%%%%
M!1110 4444 %%%% !1110 4444#"BBB@04444 %%%%!04444 %%%%!(4444#
ML%%%% @HHHH&%%%% @HHHH*V"BBB@D****!W"BBB@04444 %%%% !1110,**
M**!!1110 4444 %%%% [!1110(**** "BBB@84444 %%%%!-@HHHH&%%%% 6
M"BBB@84444""BBB@ HHHH%<****"@HHHH$%%%% K!1110,****!V"BBB@$@H
MHHH!A1110(**** "BBB@84444!<**** "BBB@&%%%% @HHHH&%%%% !1110
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M)R=V>_&*BK(*2EHJ2@HHHH *2EIK4 +D4M,I] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !2;J6FMUH 7=2TU>M.H **** "BBB@ HHHH **** $H
M!H/2FT /JM<VJ3*>*L4M '%ZSH*S!L+7 ZUX9*LQ"U[;);K(.16)JFBI(IPM
M==*NX'-5HJ:/G^^TMK?/RUD2*RM7KNN>&2=Q"UPVI: T1/RU[=+$*2/#J8=Q
M>AS2L:D%.N+9H6Z57\P@XKL6NQS6MN2[J=4*MFI%JB6.HI>U)2&A-U+3*?F@
M HHHH"X4444 %%%% !1110(**** "BBB@ HHHH **** "BBB@ HHHH ****"
M@HHHH)"BBB@ HHHH **** "BBB@04444#"BBB@84444 PHHHH$%%%% !1110
M,****!!1110 4444 %%%% !1110 4444 %%%% M0HHHH*"BBB@04444 %%%%
M !1110 4444 %%%% !1110,**** "BBB@ HHHH$%%%% !1110 4444 %%%%
M!11104%%%%!(4444 %%%% !1110,**** "BBB@04444""BBB@84444#N%%%%
M @HHHH ****"@HHHH)"BBB@:"BBB@EA1110,**** "BBB@;"BBB@ HHHH'>X
M4444""BBB@04444#04444 %%%%!+"BBB@84444 %%%% !1110 4444 %%%%
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M** "BBBE< HHHJ@"BBB@ HHHI %%%%, HHHH ****D HHHIV **** "BBBD
M4444 %%%%, HHHI@%%%% !1114C"BBBJL 4445(@HHHJ@"BBB@ HHHI %%%%
M !1110 4444( HHHI@%%%% !1114@%%%%- %%%% !1110 4444@"BBB@ HHH
MJ@"BBBI **** "BBBJ ****@ HHHJ@"BBB@ HHHIL84444""BBBI ****H H
MHHJ0"BBBJ ****0!2TE%.]@%I***8!1112 **** "BBBF 4444M@"BBBLV,*
M***I""BBBFD,****;=@"BBBI$%%%%, HHHI %%%%4 4444K %%%%2 4444T
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M(L:I]U0*=24A-<ITBK2TU:=0 4444 -(H IU% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444V@!U%-6G4 %%%,S0 ^FM2K10 VGTFT4M
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MX6VYX]?%]@C7%2TRBO4C!16AY,IN;U'$TVBBF9V"BBBF 4X-3:* %--VTM%
M ****0!1115 %%%%" ****8!1112 ****E@%%%%" ****L HHHI %%%% !11
M12L 4444P"BBB@ HHHI %%%%38 HHHJK %%%%(844450@HHHH ****D HHHJ
MP"BBBD 4445(!1115 %%%%0 44450!1110 4444P"BBB@ HHHI %%%%.X!11
M10P"BBBA#"BBB@04444 %%%%2 44450!1114@%%%%4 4445+8!11133 ****
M8!1112 ****8!1112N 4444KC"BBB@044450!1110 4444,84445-Q!1115
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% @HHHH*"BBB@ HHHH*5@HHHH)84444""BBB@2"BBB@H****!!1110
M4444 %%%% PHHHH$%%%% [!1110 4444""BBB@ HHHH **** "BBB@04444%
M!1110 4444 PHHHH ****!7N%%%% PHHHH$%%%% !1110,****!!1110 444
M4 %%%% !11104%%%%!(4444#"BBB@04444 %%%% PHHHH$%%%% PHHHH$%%%
M% !11105H%%%% @HHHH ****!!1110 4444#"BBB@04444#T"BBB@+A1110(
M****"@HHHH"X4444"N%%%% !1110(**** "BBB@ HHHH **** "BBB@84444
M""BBB@H**** "BBB@A!1110,**** "BBB@04444%!1110(**** "BBB@ HHH
MH&+Q2444%!1110(****!!1110(**** "BBB@84444""BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH$PHHHH&(13DXI** +*R"HY]L@QBF#I2?Q4#L
M9&HZ&ETI^7]*X;7O ZR!B$_2O68]N.:@O+2.93Q2*4FCY?\ $7@TP[L)^E><
MZKH4L#MA37UMK7AE+K=A:X#7/A_NW$1_I4N)T0J'S9)9R1MR*>BE>M>F:YX+
M:W+$)^E<-J>EO;L?EQ46.E33*(8>M+FJK[T;D4]&--FA8IK4E."YJ=Q7MN-I
MZQDU+'#G%6([?VKKI8=R..KB(Q(XX:LQPU(D>*D5:]BEAU$\2MB6]AJKMJ04
M'CI25WQCRGG\W-JQQ:FFDI-U42+12;J<.:5A"44[;24AB4444Q!1112 ****
M0!1115 %%%%2@"BBBFP"BBBD 44452 **** "BBBF 4444@"BBBC0 HHHI@%
M%%%2 4445?084444A!1110 4444 %%%% !1114@%%%%, HHHHL 4444P"BBB
MD 4444@"BBBF 4444 %%%%*PPHHHIB"BBB@84444""BBBD 4444 %%%% !11
M10 44450!1110 4444K %%%%, HHHIH HHHI-#"BBBD(****K084445(@HHH
MI@%%%%2P"BBB@ HHHH ****H HHHH ****0PHHHI6$%%%%58 HHHI %%%%,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4THK=13J* *EUI\<RGCFN3UKP\)
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M%%% PHHHH)L%%%% 7"BBB@84444 %%%% !1110 4444#"BBB@ HHHH ****
MN%%%% !1110(**** "BBB@84444 %%%% !1110(**** "BBB@ HHHH&%%%%
M(**** "BBB@ HHHH ****!!1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FEJ
M=24  I:**0!1113 3K52XL%F!XJY12 YJ^\-K(I^6N.UOPN%#86O5:H7^GK<
M*>*Z:=:46<]2DI(^?=6T-XV.%KGY=/>,]*]XU/PN),_)7*ZGX3V9PE>Q2Q2>
MYY=3"OH>5^24ZT\-MKHM2T1H<X6L"XM7C8\5Z$9J1YTHN#$WT9J'#+UIRGBK
M))**3-+0 4444""BBB@:"BBB@&%%%% @HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH%<****"@HHHH **** "BBB@ I1244""BBB@0
M4444#"BBB@ HHHH*"BBB@D**** "BBB@ HHHH&%%%% @HHHH&%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHI %%%%, IK*&&#3J* *DNGI+U K+OO#\<BGY16_2'FFFUL2XI[GF>
ML^&AAL+7#ZKX=96.%KW:ZL5FSD5C7GAI903MKT*.)<=SCJX=2V/GZYT5XV/R
MU4:U:/K7LFJ>$PH.$KC-6\/-'G"UZT,4I'F3P[CJ<26VTY9,U<O-+>-CQ5/[
M,ZGD5V*2D<;30_=2TW;MZTNX4[$BT8]J3<*6IV ****:$%%%%!20VA:=2J*!
M"44ZFT""BBB@)!1110)!1110,**** "BBB@ HHHH'<****!!1110 4444 %%
M%% PHHHH$%%%% !1110,**** "BBB@3"BBB@$@HHHH&%%%% @HHHH&%%%% @
MHHHH **** "BBB@ HHHH&@HHHH&%%%%!(4444"N%%%%!HF%%%%!(4444 %%%
M% GJ%%%% )!1110 4444 %%%% !1110 4444""BBB@84444 %%%% PHHHH$%
M%%% PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444#"B
MBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110.P4444""B
MBB@=PHHHH **** L%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBBD 4444QA1110 4444]R0HHI&I#%HIN[WI2PH
M&!:F^92'FF^4S'BJ&/\ ,I/+,E2PV+R$<5N:;H;R$96L95%$J--R,.+3'DZ"
MMG3O#[LP^6NSTGPOOQE?TKKM/\*JH'R5Y]3%+H=]/#,Y+1?#/3*_I7;Z7X;1
M5&5K7L]&6 #Y:TXXQ&, 5Y-2M*1ZE.BHHI0:0D785=CA6,<5)17/S7W.A)+8
M****0PHHHH ;GFC<*&I* ';@:CGMUN%PPIRT^@#G]0\(V]X#E5-<5X@^%\$L
M;D1#\J]5IDD8D4J1D5K&K..S,Y4XRW1\=>//A6%\S9%^E>!>*OAO/#*^(C^5
M?H[K7A&/4-WR Y]J\[\2?".*XW-Y(_*O?PN9.GI)G@8K+^?6)^=UWX1FMB<H
M16;)8M;GD5]B>,/A&(5?;%^E>(>*_A_+;L^V,_E7U%''QJ'S]7!RIGDK3!*4
M7 -7]2\-W$,A^0_E68UA)">017IQ<9:GG.Z>Q.K;J=4*?N^M2B9:&4A:*/,#
M44@"B@]*;FA"'44#I15 %%%% !1112 ****-P"BBBD 4444[@%%%%, HHHJ;
M@%%%%, HHHI %%%%4 4444@"BBBD 44450!1110 4444 %%%%, HHHI %%%%
M( HHHH ****8!1112 ****0!11133 ****H HHHH8!1114W ****=QA1112>
MH@HHHIQT&%%%%,04445 !1115( HHHH ****0!1114@%%%%4 44446N,****
M!!1113V ****FX!1110F 4444 %%%%%@"BBBKL 4444@"BBB@ HHHH ****D
M HHHJDM!A1110(**** "BBB@ HHHIV ****0!1110 4444 %%%%2 4444 %%
M%%, HHHHN 44446 ****=@"BBBE< HHHH ****+ %%%%(844453 ****@044
M45:0!1112&%%%%,04445-@"BBBF 4444@"BBB@ HHHH ****H HHHI %%%%&
MP W2FTZC:* "BBBF 4444QA1114W$%%%%, HHHI7&%%)O%-\U?6BPQQ;%,:8
M+WI&^;@4G]GR3= :=UU(OV!9@U6(K)KC@#-6--\-W$[CY":](\*> 9;ATW1G
M\JYZE>-/6YO3I2J=#SF'PC/<L,(37<^%?AO/+(F8C^5>]>$?A&+A4+0_I7L'
MAOX1Q6ZJ?*'Y5\_B<S25D>U0RURU9Y+X$^%H98]T7Z5[?X<^%\$<:$Q#\JZ_
M1_",>GA<(!^%=/#$(8PH&*^6K8R=1Z,^DHX6%-:HPK'PA;6:C"KD5M6]HEN,
M**GHKB<G+<[5%1V"BBFU)0ZBF9I5H 5NE-I])M%  O2EHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*ZS2_#0CVY6N"MB4MCT*6';W.8TWPF7Q\E=5IOA41X.VNHT_2TB XK36)5X
MKR)UY2/4A043*L-)6''%:R($& *6EKF;;.A*P4444AB;:*6B@ HHHH ****
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M08I:\Z4G)W9WQBHJR"BBBI*$VT 4M% !2;:6B@!NVE Q1FB@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH ****!A1110 4444""BBB@ HHHH ****"N@4444""BBB@04444
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M?F\/S6['*FO6C4A+J>9*,X]")9-U/J-H3#U%-^T*O>F_(E>9-2XJ%;A6J59
MU!0N*2G&FMTH **;3EZ46$+13J*95AE%%%#9(4444-#"BBBA, HHHJ;B"BBB
MF 4444F@"BBBD 4444P"BBBF 4444P"BBBE8 HHHHN 4444P"BBB@ HHHH *
M***@ HHHJ@"BBB@ HHHI7 ****H HHHH ****2 ****0!1115 %%%%.X!111
M2 ****5@"BBBF 4444P"BBBI ****0!1110 4444[ %%%%)@%%%%*X!1115
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 PHHHH$%%%% !1110 4444 %%%% !1110,****!!1110 4444 %%%%
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M)NI3TIM !FG+2;:/NT .HI-U+0 4444 %(U+2&@!N:=2;:6@!:*** "BBB@
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M]0&T4451(4444, HHHI %%%%( HHHJD 4444P"BBB@ HHHJ0"BBBF@"BBBF
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MV"BBBI*"DVTM% !33UIU-(H .M+MH"TM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBB@>P4444$A1110 4444 %%%% !1110 4444 %%%% [A1110(****!A1110
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M ****8!1110 4444 %%%% !1112 **** "BBBF 4444 %%%% !1110 4444
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M?K9I*6B/8IY:HZGDWAGX;1PJFZ(?E7INB^#;>W0%HP/PKH;?38K?&T5:50O
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M.FK'CBK]%8\[9KRI#(XQ&.*?114%A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %)2T4 %)BEHH 3;2T44 %%%% #)(Q(I!%8]]X=CNLY4<U
MMT4TVMA-7W.!U#X<PW6?W8/X5R.M?!^%U8^2/RKVRFL@D7##(K>.(J1V9A*A
M"6Z/DKQ/\(UB5]L7Z5XWXK^&TD+/MB_2OOS6/#L5XI^0?E7 ZY\,X[S=^Z!_
M"O5P^82B_>9YM? QDO=1^=^M>";B-FQ&?RKG)?#-Q&W*-^5?>>M_!5)-Q\G]
M*\^USX-"'<1#C\*^EHYI!JS/GJF6R3N?)2Z7)$>013O+\OK7MVO?#=[7=B+'
MX5YWK/A6:W9L(?RKTZ>(C4ZGG5*,J>YRGG*O4THN >]-O-*GB8_*:J+:S*>0
M:ZM)'-=W+ZN&IQJM#&Z]:FZ>U5:Q=QU+3=P]:-P]:3$.R:*3(HJ0"BBBF@"B
MEI=M,!M%*>*2@ HVBBBD 4444QA1111:P!1113$%%%%3<84444QA1112$%%!
MIN31N(=1113 **** "BBB@ HHHH ****0!1112 **** "BBB@ HHHJ@"BBBF
M@"BBBDP"BBBD 4444 %%%%( HHHJ@"BBB@ HHHH ****0!1115 %%%%3< HH
MHI@%%%% !1112L 4444@"BBBJ ****3 ****0!1115 %%%%38844455A!111
M0 4445(!11130!1112 ****: ****8!1110 4444 %%%%( HHHH8!1110@"B
MBBF 4445(!1115 %%%%2 4444P"BBBA@%%%!I %%-W&G50!3A3:7=3&A3TIM
M!;WI-PI/0=Q:3=2,P]:8W/2IW D\P4WSU]:KR1NW2HS:S,> :TT(YBWY@;O1
MY9DZ46>E7$C#Y375:/X5GG9<H?RK"<XQ-(1<CE?[+DDZ TJ^&[B1AA3^5>U:
M#\.'N-N8OTKT?0O@T)]N8?TK@J9A"F=M/!RJ'S?HW@FYE=?W9_*O4_"OPWDF
MV;HS^5>_:+\%$CVDP_I7H&B?#..SV_N@,>U>)7S1/8]BCEK6YY)X9^$:R;-T
M7Z5Z9HOP?B55)B'Y5Z7I/AV*T"_(!^%=#'&L:X48%?.U<94F]&>[3PE.*U1P
M6G_#>&U _=@?A716/AN*TQA16[17(ZDI;LZXPC'89%&(EP!3Z*2LRQ:*** "
MBBB@!**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M***$ 44450!1112 **** "BBBE< HHHI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%*P!1110 4444P"BBB@
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M[+0X[7'RBO!K8^4]F>U2P,8[GGVC_"J!5&8A^5=3:?#NT@ RJC\*ZY5"+@#
MIU>9*M.6[/1C1A'9&%;^$[:#& OY5I6^G16_W15NBLW)O<T44M@HHHJ2@HHH
MH *3:*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*-U
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M!FK72EHKG;N;A129/I2TAA24M%(!,>]+113 **** "BBDH 6BDW4M !1110
M4444 %%%% "$TFZE:FT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!K=:%ZTM% "T444 ,I5I:6@ HHHH 93EHI: "BBB@ HHHH **** "DQF
MEHH 8T*MU%1M9QMU%3T4 4WTV%NU5)M#C;HH-:]%4I-$N*9REUX?3^[6-=^'
M0<X6N_DC#5 UDKYXK=5FC)TD>67?ADG.%K(NO#+<_+7LCZ0C=JK2: C=OTK:
M.):,98=,\/N/#+C/R_I69-X?=<_+7NMQX:1@?E%9%UX77GY*Z8XPYI8,\7;1
MW7^$U&VGLO:O5KCPN.?EK*NO#1&<+79#%)G-+"M'G+6Y6H6RM=K=>'6Y^6LF
MXT%^?E-=*K19S2HM'.F3%)]HYK5DT.09^4U6DT:1?X35J<68N$BJ+BE\VI?[
M-D7M1]B<=JO0%=$?F4X/36@93TI I6FVADN:*CW8I?, ZU(N8D[TE,,PIOFB
MG8:LR6C%,604_?0)A1FFENM)N%!(^BD4TM !1110 4444 %%%% PHI]-:@+B
M4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI] #**5J2@ HHHH
M&%%.I&H$)1110,**** "BBB@ HHHH ****!!1110,****!!1110 444Y>E #
M:*5C3=PH 6BFEA32].PT245%Y@H\ZBPR6DR*B\X>M+Y@HL%R3=2;J9Y@H S3
M <7IADQ4@A+4OV-F[4M U(/.H%QS4_\ 9KMVI5TF1OX31=!9E?SLFI%^:KD.
MAR,?NFM"#09#_":RE4BC2,9,R5B+=JD6R+=JZ6U\//\ W3^5:EOX</'RUD\0
MD:1HMG$+I3-_#4\>@NW\->B6OAGI\M;%IX77CY:YYXI'3'"W/-+?PV[8^6M2
MW\+MQ\E>HVOAA!CY*T8_#J*/NBN.6+-XX0\SM?#)'\-;5IX; Q\M=RNBHO:K
M$>G*N.*YY8ALZHX=1.9M/#JC'RUKVV@QKCY:V$MU6I*YG4DS=4TBE'I,*=JE
M6QB7^&K-%9W9?*B);=%Z"I H7H*6BD4%%%% "9HW4M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 RE6EI: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% "-3:<W2FT .R*6F4Y>E "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 -:@&E(S1MH 6DS2TFV@ S11MHQ0 M%%% !1110 4444 (1FF-"K=
MJDHH K-:@]JB;3U;M5ZBE=@9S:2I[4S^QT]!6I1578N5&2VBH>PIG]@IZ"MF
MBGS,GE1B'P^A_A%-/AU#_"*W:*?/+N')$P#X9C/\(J-O"L9_A%='13]I+N+V
M<>QS)\)Q_P!T4G_")I_=_2NGHI^TEW#V<>QS+>$T_NBHF\))S\GZ5U=%'M)=
MQ>SB<A_PB2?W?TH_X1%,?<KKZ*:K3#V43C3X13^Y1_PB*?W*[&BG[:8O90.,
M;PBG]RC_ (1%/[E=G11[:0>RAV.._P"$13^X*?\ \(BG]P5UU+1[:8>QAV./
M;PDG]RF_\(BG]P5V5)1[:0>RAV./7PBG]P?E4B^$DV_<KK*6CVTQ^RCV.3_X
M1)/[E.7PDG]S]*ZJBE[:0O91.7'A-/[@_*G?\(FG]T5TU%3[27<KV<3FQX5C
M_NBG#PM'_=%=%11[27</9Q['/_\ ",1_W12_\(T@_AK?HH]I+N'LX]C"'AU!
M_"*D704'85LT5/-+N/DCV,@:(@["GC1D]!6I11S,?*C-725':I%TU5["KU%*
M['9%5;-5[5(MN%J:BD,:$"TZBB@ HI-U-H ?24VB@!]%)NI: $HS1MHVT +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4W=2TV@!PI:1:6@
MHHHH ;NI0<TVE6@!U%%% !1110 4444 %%%% !1110 4444 %%%%( HI*,BF
M M%%% !1249% "T444 %%%% !1110 4444 %%%%*P!1113 **** "BBB@ HH
MHH **** "D-+36H 7\:*;10 ^BBB@ HHHH **** "BBB@ HHHH **** "BBD
MR* %HI,BEH **** "BBB@!-U&ZD;K0O6@!U%%% !1110 4E+10 W::-M.HH
M;MHVFG44 )MI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *1J6D:@!M.IM.H 6BBB@!*3=2MTIM #Z*2EH **** "BBB@ HHHH ****
M "BBB@ HHHH C*TJK3Z*!"9HW4C4E Q]%%% !1110 4444 %%%% !2<TM% "
M<T<TM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)D44 +11
M10 4444 %%%%( I.:6BF 4444 %%%% !1110 E&12-24[ /HHHI -(H IU%
M!1110 W!I5I:* $-)NI6IM #Z*2EH **** "BBB@ HHI* %HI,BEH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***1J %HIF:?0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-/6@
M :DI>M+M% "T444@&M24[%&!3 6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **;
M2K0 -TIM/I-HH ;3EZ4;12T %%(U)0 ZBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IK9IU% #5S3J** "BBB@ HHHH **** "BBB@ HI&IN: 'T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1136H =13:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%-:@=: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %)2T4 ,IRT;110 M%%(>E "T4S-
M.H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *:U.I* &T^DP*;FF ^BD'2EI %%%% !13,T9H ?135
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%-H =12+2T %%%% !1110 4444 %%%% !1110 44
M44 %%-:B@!U%%% !1110 4444 %%%-/6@!U%-'6G4 %%%% !1110 444S- #
MZ*1:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ I#S2T4 -VTZBB@ HHHH 0TFZE:DVF@!:6DI: "BBDH 6B
MDW4M !1110 4444 %(32TUA0 ;J=3<&G4 %%%% !1110 4444 %%%% !112;
MJ %HI*6@ HHHH *3;2T4 )MI:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBD 444FZF
M M%)FEH **** $VT 8I:* "BBB@ HHHH 0C-&VBC(H 6BBB@!-U&ZD;K0O6@
M!U%%% !1110 AI-U*U)@T .HI,BB@!:***0!1113 **** "BBB@ HHHH ***
M* "BBB@!",TFVG44 %%%% !1110 4444 %%%% !1110 4444 %%%% !112;J
M %HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %(1FEHH 3;2T44 %%%% "$XI-U#4E
M #Z*** "BBB@ HI*3=0 ZBF[J6@!:*** "BBB@!":3=2M2;30 ZBBB@!",T;
M:*,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%)NH 6BDW49H #2;J4TFTT **6D%+0 4444 %%
M%% !1124 +12;J-U "T4E% "T4FZEH **** "BBB@ HHHH *2EHH ;MIU%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "$TFZE:DP: '4444 %%%)F@!:;MI=U+0 E+110 4444 -VT;:=10 @&*
M6BB@ HHHH **** "BBB@ HHI,T +12;J6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ;NI0:3::5: %HHHH *3;2T4 (!BEHHH ***3=0 M%)2T %%%
M% !1110 4444 %%%% "$9HVTM% !1110 444F: %HI-U+0 4FVEHH 3;2T44
M %%)NHH *,T4 8H 6F[:=10 @XI:3-&: %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "D;I2T4 ,IPZ44V@!]%-6G4 %%%% !1110 4444 %%%% !1110 4
M444 %%%(U !3:*=0 +2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4F:&Z4V@!]%(.E+0 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $S1FFT4#L/HHHH$%%%% !11
M10 4444 (U-I])0 4M)M%+0 4444 (U-I])B@8VG+1BEIB"BBBD 4E+36ZT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2U#
M-)M4T 2;QZT>8OK6)>:EY6>:R9O$0C/WJN,'+8RE44=SL/,7^\*/-3UKB/\
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG8]*+OJ ZTZFXQ1NI#'44@I: "BBB@ HHHH 3%&VEHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPSNVKFNP7[HKG=%M?)5>*Z#S JBO$GJSVH:(DHJ'[0M*LZM46+):*:) :=2
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M%% !132V*:9@.M $E%5VO$7J:;_:$?K3LQ7+5%0QW*2=#4U(844E1-<HO4T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K/U(?*:T*H:E_JS51W)EL>=>)AP]>6
MZVOS-7J?B7H]>8:X/F:OH\*]#P,5J<]"NZ;%=EX?TW[1MXKC[?\ X^/QKT?P
M@H9DKIQ$FD<V'5Y6.ITWPN)(P=M6Y/"*X^Y^E=9HL*F%>.U:C6ZMVKY^6(DF
M?01HQL>4ZAX5"J<+7&ZOX>:,GY:][NM-60'BN7UGPZ'5CMK6GBFGJ85,,FM#
MP.ZTUHW/%-BD-N:[G7M#\EF^6N'U*$QL17NTJBJH\2K!TV='H6N-'(HW5ZOX
M7UCSE3)S7@6F2,L@YKTWPKJ)CV FN'&45;0[<+4=]3VF"821@YJ6L+2+[S(U
MYK<7H*^>:L['O)W05%)<I&,DTV\N!#&3FN-UKQ (<_-5Q@Y$RFH[G07NM)&#
MS6#=>)$4GYOUKAM2\5$L1N_6N<O/$3NQPU>E3PM]SSJF)70]+E\4J/XOUIB^
M*5/\5>3MK$K=S2KJLH[FNOZHCF^LL]CM?$JLP^:M^QUY'Q\U>#V^O/&>6K;T
M_P 5E64;OUKGJ8/30WIXK74]UAO4E'!JPK;NE><Z'XD\['S5W&G7BS(.:\J=
M-TWJ>G&:DM"_4<TFU>M/-4KZ3;&36990OM2$.>:Q9O$2JWWOUK'\2:H8=W->
M?:AXD99#\W>O1HX9S/.J5^1GK]KXA5B/FK:M]81E^]7A6G^)FW#YOUKI+;Q.
M?+^]5U,*XA#$IGIMWKB1K]ZL"\\2*K'YOUKAM0\3,5/S?K7.W'B"1F/S&JAA
M;ZD2Q1Z9_P ),-WWOUJ_9>(E8CYOUKQW^W'_ +U6[/Q$RL/FK5X2Z,UBCWNQ
MU9) .:THYED'!KQ_1?$Y8J-WZUWVCZK]H5>:\VK1=,[Z=53.D_BIU,C^90:?
M7,=(5!-=)$.34=Y=K#&>:XO7O$0AW -6D(.;T(E-1W.AOM<2//S5@7GB158_
M-7!ZEXK+,?GK"N-?>3.&KU*>$=CS:F)L]#TIO%"_WJ='XH4D?/\ K7DS:K*Q
MZTL>K2J?O&NCZHC#ZRSV>V\2*Q'S5N6.MJ^/FKPFW\0.A&6KH-,\4$$9>N>I
MA>QO3Q.NI[;#>)*!S4VX'I7 :/XB$NWYJ[+3[L3*.:\J<' ]&,U):%XU5N+@
M1@\U:/2N?UBX,:MS41U9;=D%UJXC[UG2>(54_>KD=:UIHV/-<K<^)&#GYJ]6
MEAN97/.J8CD9ZU;^(%9OO5MV>J(ZC)KPVQ\2-O\ O5U6G^)L(/FJ:N'<=AT\
M0I'ITVJ1HO6LBZUY%;[U<3?>*MJ'YOUKF+SQ42_WZSIX5R'4Q*B>L0:XLC#Y
MJW+&Y$P'.:\9T77S-(OS5ZAX;N3,B\TJU'V:*HU><Z6F\TZBN$[ANTTZBB@!
MK4+3J* "H;K[AJ:H+K[E F<=XA^XU>4^)%^9Z]6\0?=:O*O$GWGKV\'N>3B=
M4</<9\XUN:';><RBL.X_UQ^M=5X57,BUZU:_+<\JG\5CN=$\.B9%.W-;Y\(K
MM^Y6CX7A4QIQ76^0NW&*^<J5I*5CW:=%-7/,KOPF I^7]*Y36/#9CSA:]QFL
M5D!XKG]6T-9%.%JJ>):8YX=-'S]J&DM&QXJBL9AKT[7] \O<=M<#JEL86;BO
M;HU?:*QXM6E[-DFFZLT,@YKTKPOKI?:"U>,PLRS5VOAN\,;+S6>(I)HO#U'<
M]\TR\$T8YS6C7$^']2W(HS78VTGF1YKYR<>5GT,)71-36<+U-#,%4DUA:MJR
MP*W-3&+EL4WRZLT;G4HX1UK"OO$")GYJY'6/%&W/SUR5]XD>1CAJ[J>%<M3A
MJ8E1T/0KCQ.HS\WZU5_X2E=WWJ\RDU:63.":B_M";/4UV+"HYGB6>LP^)U)^
M]6O8^(%;'S5XI'J\L9Y-:-IXF:,C+4I8730<<5KJ>\VNJ),HYJ\L@?&*\FT/
MQ1YA4%J[_1]2%PHYKS*E)P/1IU5,V^U0S2[*GSD5EZC(44FN<V>Q!=:D(\\U
MES>(%4_>_6L'7M4,6[FN(U#Q$RL?FKTZ.'YT>=5K\C/5(?$"LWWJV[/5%D Y
MKPVS\2DR?>_6NLTOQ)\@RWZTJN%<2J>(4CU"3441<YK)N]>1"?FKCK[Q0!&?
MG_6N3U#Q6=Q^>IIX5R'4Q*B>J0ZZLC8W5L6MUYJ=:\8T?Q$9I@-U>G:%=>;"
MISVJ:]'V8Z-;G+VI*K*<UR]XD6\YQ6QKU]Y$1.:\WU3Q)Y<K#=5T*;DA5JJC
MN=7&L6X=*U+&-.U>;V_B?<P^:NFT76O.8#-:5*$HHBG6C(]$M5"J,4R\O/)7
MK4>G3>9"#65X@F,<;$5P1C>5CME+EC<;<:^L;8+40^(5;^*O,]9UIX9#SWJC
M:^)&W#YOUKTXX6ZN<#Q7*['MUKJZR=ZU8;@2"O)=%\0>8R_-7H&C7WG*O-<%
M6ER'53J\YT8I&;:*5?NBH+R3RX\URG4075\(P>:QKK7%CS\U9NN:MY(;FN"U
M3Q(0S8:O0HT.<X:M;D/0#XB7=][]:OV6L";'S5XLOB)VE^]78^&]2:9EYJZN
M&Y$94\3S.QZO:2>8N:LUG:.VZ$$^E6[B988RQ->;UL>BGI<66X2(<FLJ\UI(
MP?FK$US7Q#NPU<%JOBIBQ :NJGAW,YZE91.YO/$BJ3\U9LGBA?[U>;W&O22'
MAC50ZE,W<UZ$<+;<X'BNQZE'XH4G[U7K?Q*K,/F_6O'QJ$R]S4\.NR1MRU4\
M*FM!1Q5MSW6QUQ'Q\U;4-XDRC!KP[3?%!5E^>NWT3Q$)MHW?K7GU,.X'?3Q"
MD>@YR.*!5.PNA.@YJ[7&U8ZEJ%1R3+'U-$D@C4YKG=9U<0JW-$8N3L*4N57-
M"\UA(^]8-YXB5<_-^M<9K/B@JS -7+W/B5G)^:O5HX5RW/.J8I19Z2WB90_W
M_P!:NVOB9#_%^M>-MKCLV0U3PZ]*O\1K:>$L8QQ5SU36M=2:%AN[5Y7XDG$S
MMS3IM=DD7!-8][<&;.3FM\/1Y&85JO.C/A7]YFNP\._>6N2A7YQ77>'_ +R_
M6NJM\)S4?B/4_#WW5KLK;_5BN-\/?=2NRMO]6*^8J_$?1TMB:BBBL38****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI7<;1Z4;1Z"K522,O919PX\*@?P?I3O^$67'W*[78OI2[1Z"K]M(7L8G$?\
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M%0<D3AIJ+/<M-N%:,#/:K]>?:1XB&U?F_6MS_A(EVYW5\ZZ<DSWXU$T6O$S
M6I!ZXKPKQ@P,CUZ9XA\0"2,C=VKR;Q%<><[&O5P<&MSS<7-,YRW'[[\:[/P[
M]Y:XVW'[[\:[/P]]Y:]2NO=/,H?$>J>'?NI79V_^K%<9X=^ZE=G;?ZL5\Q5W
M/I:>Q+1116!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,0-<%U-)SWKSRW?S)J_1<-[M.S/A:]I3/3OAZ?]*C^M?97PI;_1XOI7QO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ,F-NOI7V;\']&DM8X<J1TK#-I1E'0URNG*,E<^G-)??8QCVKA_'^@_VA#(
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M=7-\666''F]O6O&[32[EE&T-2W6DWNT\-7A3P].<M3UHUZD8Z'3^)OBA).K
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MM0?05\/F<E*6A]CET7&.IM7G_'K)]*\!^*4FU9J]^O!NMI![5X9\2M,>X67
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!_#3@H7H*B524MRHTU'86EHHK,U"BBB@ HHHH *3;2T4 )2T44 %-==PIU%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1^5?3+6<3=5IG]GP?W!79'&5([')+"TY;G@_A_X4I8R*1%CGTKUGPUHHTY5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@
M!,"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !13=U*#0 M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (U-IU&V@ I:** "BBB@ IK<\4ZFFD!2NM/%PIR*PK[P7%=YR@
M/X5UE%7&3CL2XI[GGDOPP@D;/EK^56+/X=0VK A!7=T5?M9]R/90[&/I^BK9
MJ,+BM91M4"G45FW<T2L(W2FTZC;2&%+110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%(32;J '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 RE6BB@!U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,HHI, I
M<FBBI -QHR:**M **6BBA@%%%%) %%%%, HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :
MU)110 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img102364508_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;]H+_HNWQD_\+34O_CU'_$/\5_S]C]S#_7BA_P ^I?>C^L7S?:CS?:OY.O\
MAXM^T%_T7;XR?^%IJ7_QZC_AXM^T%_T7;XR?^%IJ7_QZC_B'^*_Y^Q^YA_KQ
M0_Y]2^]']8OF^U'F^U?R=?\ #Q;]H+_HNWQD_P#"TU+_ ./4?\/%OV@O^B[?
M&3_PM-2_^/4?\0_Q7_/V/W,/]>*'_/J7WH_K%\WVH\WVK^3K_AXM^T%_T7;X
MR?\ A::E_P#'J/\ AXM^T%_T7;XR?^%IJ7_QZC_B'^*_Y^Q^YA_KQ0_Y]2^]
M']8OF^U'F^U?R=?\/%OV@O\ HNWQD_\ "TU+_P"/4?\ #Q;]H+_HNWQD_P#"
MTU+_ ./4?\0_Q7_/V/W,/]>*'_/J7WH_K%\WVH\WVK^3K_AXM^T%_P!%V^,G
M_A::E_\ 'J/^'BW[07_1=OC)_P"%IJ7_ ,>H_P"(?XK_ )^Q^YA_KQ0_Y]2^
M]']8OF^U'F^U?R=?\/%OV@O^B[?&3_PM-2_^/4?\/%OV@O\ HNWQD_\ "TU+
M_P"/4?\ $/\ %?\ /V/W,/\ 7BA_SZE]Z/ZQ?-]J/-]J_DZ_X>+?M!?]%V^,
MG_A::E_\>H_X>+?M!?\ 1=OC)_X6FI?_ !ZC_B'^*_Y^Q^YA_KQ0_P"?4OO1
M_6+YOM1YOM7\G7_#Q;]H+_HNWQD_\+34O_CU'_#Q;]H+_HNWQD_\+34O_CU'
M_$/\5_S]C]S#_7BA_P ^I?>C^L7S?:CS?:OY.O\ AXM^T%_T7;XR?^%IJ7_Q
MZC_AXM^T%_T7;XR?^%IJ7_QZC_B'^*_Y^Q^YA_KQ0_Y]2^]']8OF^U'F^U?R
M=?\ #Q;]H+_HNWQD_P#"TU+_ ./4?\/%OV@O^B[?&3_PM-2_^/4?\0_Q7_/V
M/W,/]>*'_/J7WH_K%\WVH\WVK^3K_AXM^T%_T7;XR?\ A::E_P#'J/\ AXM^
MT%_T7;XR?^%IJ7_QZC_B'^*_Y^Q^YA_KQ0_Y]2^]']8OF^U'F^U?R=?\/%OV
M@O\ HNWQD_\ "TU+_P"/4?\ #Q;]H+_HNWQD_P#"TU+_ ./4?\0_Q7_/V/W,
M/]>*'_/J7WH_K%\WVH\WVK^3K_AXM^T%_P!%V^,G_A::E_\ 'J/^'BW[07_1
M=OC)_P"%IJ7_ ,>H_P"(?XK_ )^Q^YA_KQ0_Y]2^]']8OF^U'F^U?R=?\/%O
MV@O^B[?&3_PM-2_^/4?\/%OV@O\ HNWQD_\ "TU+_P"/4?\ $/\ %?\ /V/W
M,/\ 7BA_SZE]Z/ZQ?-]J/-]J_DZ_X>+?M!?]%V^,G_A::E_\>H_X>+?M!?\
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M1YOM7\G1_P""BG[02G'_  O7XR?^%IJ7_P >H_X>+?M!?]%V^,G_ (6FI?\
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M*8:/]KH)?-AW#:P/0CN*^3S3*J^ K>QK+T:V:/I<KS2CC:7M:7S3W0YY-G7
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M6+YOM1YOM7\G7_#Q;]H+_HNWQD_\+34O_CU'_#Q;]H+_ *+M\9/_  M-2_\
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MM-2_^/4?\0_Q7_/V/W,/]>*'_/J7WH_K%\WVH\WVK^3K_AXM^T%_T7;XR?\
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MXM^T%_T7;XR?^%IJ7_QZC_B'^*_Y^Q^YA_KQ0_Y]2^]']8OF^U'F^U?R=?\
M#Q;]H+_HNWQD_P#"TU+_ ./4?\/%OV@O^B[?&3_PM-2_^/4?\0_Q7_/V/W,/
M]>*'_/J7WH_K%\WVH\WVK^3K_AXM^T%_T7;XR?\ A::E_P#'J/\ AXM^T%_T
M7;XR?^%IJ7_QZC_B'^*_Y^Q^YA_KQ0_Y]2^]']8OF^U'F^U?R=?\/%OV@O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MCNES"WTK^->O[*+G_4-]#7\:]?H_AY_$K>D?U/@>.-J2]0HHHK]-/ST****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** #_/7'J/ZU]C_ /!)'_@K=XD_X)P_$C^S]1^UZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGE_$F*6.67YC349/9H>,R/#/"/&X&?-%;IGX]D8/XT5]W?LP?\&]GQH_:R^
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M6N2 LP& 4R%E50IP0KI\<4?YZX_SUKDQV"I8NDZ-=73.C!XJIAJBJT79H_L
M^$OQ?\-_'GX:Z3XO\):Q:Z]X<UV 7%E>VK[DF4]B#@JRD%61@&5@590P(K&_
M:;_9G\&_M>?!O5/ OCK1XM6T/5DY!^6:TE .R>%\$QRH3E6QZ@Y!*G^=_P#X
M))?\%;O$G_!.+XD?V?J/VS7_ (6Z]<!]9T<-NDLG/R_;+7<0%F P"F0LJJ%.
M"%=/Z.?A+\8/#?QY^&FD^+O".L6>N>'==@%Q97EJVY)E/8@X*L""K(P#*P*L
MH8$5^+9UDV(RNNFKVO>,OZZGZUE.;4,QI.,K<UM4?S*?\%+O^"9_C'_@F_\
M&+^Q]82;5/".K.\GA_7XXL17\(/*2 <1W"97>F<9.5)4@U\U$8.*_KG_ &FO
MV9?!O[7GP:U3P-XZTF+5M#U9.0?EFM)0#LGA?!,<J$Y5L>H.0Q!_FM_X*7_\
M$S_&/_!-_P",9T?6$FU3PCJSO)X?U^.+$-_"#RD@'$=PF5WIG&3N4E2#7Z!P
MQQ-'&Q^K8AVJK[G_ ,$^'X@X?EA'[:BKTW]Z/FJB@C!Q17VA\KZ!1110 =N
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M_+EA<KN4>X92&5APP(()!!/.D8__ %8KUJ=2,XJ4-F>;.+C+EEN'4_AG_/\
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MZ45[QXH4444 =)\(?A'XB^//Q(TGPAX2TN36O$FN2F"QLHI$C>=PI8C+E5&
MIZFOHQ?^"&W[5A&?^%/ZQ_X,M/\ _DBJ7_!%8;O^"I/P;_[#+_\ I--7[[_\
M%3OVVM4_X)\_LGWGQ%T?1+'Q#>6^I6ED+.\F:*(K,Q!;<O.1CBOC<^S[%X3&
MT\)A8)N2ZGU639+AL3A9XG$2:4>Q_/QX\_X(^?M-?#?2I;W4_@UXP>WA3S'-
MA"FH,J\\[;=I&XQT X')P*^<;ZQGTR]EM[B&:WG@=DDCD0JZ,IP5(Z@YSG(R
M,'@]OZ"_^"57_!>NW_X*!_&S_A6_BCP-'X2\27=E->:;=V>H&YL[[R5+2QLC
MHKQL$^8<N& ;.W SXM_P=+_LE^%[+X9^#?C+IVGVUCXEFUQ/#6K30Q!7U."2
MWFEB>7'WGB-L5#?>VR8.0JA<\#Q)C(XZ. Q]-1D]K>>Q>,R'#/!O&8*;E%;W
M\CXX_8]_X($_&+]MC]G3P_\ $[PKXD^&FGZ#XD-R+:#5=0O8[R/R+F6V?>L5
MK(G,D+$ .?E(Y!R!\;_$'P7=?#;Q[KGAV^DMY;[0-0GTVY>!BT320R-&Q4L
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M7R 1VSA#W],U\;_MQ?\ !-WXK?\ !/KQ7;:?\0-%A73]2<QZ=K>FRM=:9J)
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M_+]LM<D!9@" 4R%E4!3@A73X;BCA>.*3Q.&TGU7?_@GV'#O$3P\E0K_!^7_
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ME\-?AGJO_"-ZMKVFMK>JZND227,=NTS0PQ1%P0F7BF+-M+<)M9><_G]\ _\
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M-?#5KX>_X*C>)IK6-8FU;2--O;C:,!Y?LPCW?7;&O/<YK]K_ !&N?^"2E_\
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M2U']JK4)?&'A/]FB%[*/Q!)9MK^M/9VZV^G+$)A$&N+A62,D2R$*H,K!<J,
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M1N9&A))= 55QN!.#XE_P0J_8)^-W[)M_\0?$OQJU!GU+Q=%9V]G8W&MG5+R
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M6;CNC3\0_L._\%&OV7]3E\1>$?C8GQ0CM9FG_LVYUR6ZENTS\R&WU!!$ RC
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M^ _C=\./V(])L?C->?-\K^&]/O(W.JZ3IVT;(;MR>O0I$1OB0[6;@)'\L_\
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M4?>/_"O=6Z$98_8)?U/MUK\\?^#3R_\ #J:)\8K96M4\627&FR,&(\Z2R"S
M;,X;:LA;=C@%DSVKGR7%/#91BI*',E)*SVU-LVPRQ&8T(N7*W'=;G3^#?^";
MW_!0CQA>PZUXG_:<MO#=S(PF:TMM6NI_)(Y"O!' EOC. 0I9<$_2OTO^&7@G
M7;7X&:7X?^(&K67B[7ETP6.M:A%9BUAU:39MDD,()"[P22HXR3@ 8 _-_P#X
M+,_L6?MB_M._M.6\GPMUC4I_A>]A!%;66G^)TTF&RF S*UU$TD;2N9!E742;
M5*@8(('WA^P-\"M>_9B_8T\!^ _%&H6NK>(/#>F_9[^YMYGFADE,CN<.X#,!
MNQE@"=M>+FE;VN'I5G.%V[\L59KU/5P-/V=:I14)V2WD[I^A^+__  ;?W/A'
MP/\ \%.=>TW7)[>/4I-!U'3_  VUT0=]RMS 75#_ ,]C;I-C&,J) .N*_5;_
M (*>?L@_&[]JG0=!C^#WQLU'X5MI2SB]LH))[1=5+%-CFZMR)HR@5AMPP._/
M!7YOQ6_X)R_\$X+K_@HM\:_BM8:/XNG\%^*/!N-6T>\\MFA>8W3#;(5(D3D#
M$B'*$;MK< ?;W@+PK_P5*_9NUB/1K7^P?BAH]CLCCN=4U+2[N&4#&6,TTEO>
MMP.2YW'@]<U]%GE",L:J]*M!5(I7C/T\]-3Q<IK<F$=&K3DX2D_>C^IYY^T=
M<_M_?L%_L_>.++XAWUC\6OAGXAT6[TC5=3-P=7_LF.XA:$SK(1#=I@/G?(K1
M# W $BKW_!JS^S?HWB/QA\1OBEJ5K#=:IX=6VT+1V?Y_L1F1WN9%R,!BBPH&
M'(4R*.&(/ZL?$+XGVOP\_8TOO$_QFA\/Z.MKX9$_BNUBN/,T]9F@ N+>)GY=
M6D9HU!R6W ?,3S^0W_!K_P#MA:#\+?BKXS^%7B2^M]+?QV;>]T&2YE\M)[V'
M>DEKEC_K)(W5D!P6\EAU90>>CC*^)RG$^RIJ+35W%6YE?7^NQM4PM*AF=!3F
MY*2TYNG8^U/^"GW_  3]_:9_;,^,=I=_#OXSZ?\ #_P'I5E'%;Z5;ZK?V,T]
MQR9)YOLZ88\[5!8A54$ %FS]%?L!_!;XG?!+]F+3_!_QB\7Z?\0/$FFRS0)J
MT4LURUW9M@QK.\RJ\CKEE+-DE0F23DGY6_X*]_\ !-3X^_M"_%*U\>? SXH:
M]H[R6:6NI>&?^$FNM+A>2/(6:V*-Y6YUP&5MHRF[<2Q ^7_@?_P1<_;>\=Z[
M:_\ "9?&K7O VCF3%U*_C6^U&\1,X/EQ0R&-F],RH/4\8/GTZ5+$8",:F(A%
M1Z<OO7\^K.R=6I1QDI0H3ES:7O[MC\]_^"AOPBL?@/\ MS?%CPEI5M#8Z3HW
MBB^CT^VA_P!7:VS3-)#&O)X6-T7GGBO&Z],_;0\$77PQ_:V^)/AF\U[5O$]Q
MX;\1WVE/JNIS&6\O_(F:(2RL2268(":\SSS^&?\ /T_SC%?KV"TH0UYO=6O?
M3<_,<5_'DDK:O3MJ!Y'W5;OR,]/\]O0YX%?IW_P0(_X)):W\;_BKX?\ CAXV
MLI=/\!^%;T7^A03J1)X@OHF!CE5?^?>)P&W='>,*NX!\=#_P0K_X(J>$_P!I
MKP+I/QJ^)US'KGAR2\E&C^&8@PBN7MY3&9;Q^-R>8IVQ*=KA069E)2OU;_;"
M^'WQ>\1_!*/PK\"-4\%>"=2N(OL;:KJJS+_9-NH"!+2&*)D#XX#L<(%^5&)!
M3X?B3B9-O 8=V>TI/9(^OR#AZ7*L977-'=);MGP3_P ')7_!2C1?"GPJN?V?
M?"M[!?>)-?,,_BEX'W#2+-"DL<#;0<2RL(V(R"(U.1B05^'Q!!^;[W>OU+\3
M_P#!KU\;M4NK_6-3^)_@#4+^X=[RYN+B>_DGN9"=[N[-"2S$Y)+9/3.:_+0#
M'I[@#I[?Y[Y%>YPNL%2POL,'-3:UEIU9Y/$$L74K^UQ4''^7T"BBBOICY[7J
M%%%% !1110 48S^/'OU''O\ RX^F <G_ #US_GZ8KT?]E+]E+QI^VA\:-+\"
M> ],;4M7U+YY)7RMM86X(#W$[X.R%=PR<')*JNYF"UG4K1HQ=2HTDD72HSJ3
M48J[>B2.K_X)R> ?B]\1/VO?"</P1DO+7QW:W O(=0C)6WTZ 866>Z)R/L^U
MMKA@0X;8%<N%K^JCPQ;ZA%X;L8]6FM;G58[>,7DUK$T,$LP4;VC1F9D4MNP"
MQ(!P2>M>"_\ !-__ ()O^"?^"<?P4C\.^'8UU#Q!J 2;7]?FA"W.JS@?CLA3
M)$<0)"@DY+%F;W'Q[X\T;X5>#-3\0>(=3L]'T/1K9[J]O;N41PVT2#)9F/T_
MR>*_%.)<XAF.)2H1]U:)]6?K/#^53P%!NM+5ZOLBI\6?$?AKP?\ #C7-2\8W
M6E6?A6VLI7U674B@LUMMA$GF[OE*%<@ALYSCOBOY1_VRM?\ AOXG_:;\87_P
MCTO4M'^'UU?L^DVM\^9%4XWLJXRD;/N9$8EE0J"<Y ^GO^"Q_P#P60UC_@H+
MXSF\)^$Y+O1_A%HMSFUMFS'-X@E0\75RO]SO'$?NCYF!;&SX3 P*^[X1R&K@
M8?6*S:E):1Z6\_,^/XHSFCBYJG2UC'2_]= HHHK[38^4EOJ%%%% C]N/^#3D
M$?!_XQ?]AG3QG_MA+7O?_!1S_@A;H7_!1?\ :4M?B!JWQ"U;PR(='ATAM/M-
M+CFWB)YG#B5I!@GS<8V$8'OQX)_P:>C_ (LY\8NO_(8L/_1$OX5X[_P<6?M9
M_%;X)?M^V.C^#?B9\0/".DMX3LKDV6B^(;O3[=I6GN@TACBD52Q"J"Q!)"@=
M!BOR>M0Q5;B"M#"5.2??RLC](I5L/2R2G+$PYH]OF?IU\(/AM\%_^"+_ .R
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M#75E;"^TJ.2!-06X25MSQ,S!7'E=5(!W?=7&*_0)9BQ-?-O[!O\ P3(\ _\
M!.CQ5\1KKX=OJ=OHOQ"O+6]_L>ZD$T>D&%91Y<,A_>&,^:3ARQ7&,GM^6/\
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M@Z,MC82:WHPTZ[NK(RR2*S (@EP[NHDVY)5@Q)4X_9W_ (-'3G_@G%XV[_\
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MH_9^_P"#C7]J;0/!_B[PZNJ3?$3QKXI:U70KZ[TV&:30$B6X-P8;6WA7SI)
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M_P ?>.=5^)_CK6O$NN77V[6_$5_/J>H7/EI%]HN)I&DE?8@"+N=F.U0%&<
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M8=+%XM>_O&+Z>OF?-\2<2>V;H8=^[LVNO_  G-%%%?>ZW/C=F%%%%( HHHH
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MO\7:Y<1SZQXF\(Z5K&I3A%C62XGLX996"+A5!9V.!@#TK\5_^"HO_!SMX_\
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M\"?#W2])\7Z@;2YNK#[7]HA40R293?,5S\@ZJ>IK=_X.>OVN?C1\)7T_X?\
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M-:G3=12B^7?74QIYQ3E-0<6K['[AH2>M.ID'"<8Z]!VI]>(>P%%%% !1110
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MM^"],\9_\$SOCY9ZG:PWMO;^ M9U!$E4,%GMK.6XA<#L4EB1@>Q4'K7\SO\
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M\-=-\1_\$^O"_B*2WM_[7\,^,;46UT5'F)#/;W"31J>RLRPL<=3"OI7YO_\
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MW[0&O:;/8^&M/TZXT;PT]Q&4;4;J5E6>>//6..,/'N&07E90?D:N2_X.[O\
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M)M-%ML\11CNQP"\A^9V] %5?%2<G^?O7V0?^" /[7#<_\*D;GO\ \)/HW/\
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MP!^UQ_T21O\ PI]&_P#DNC^W,N_Y_P ?O#^Q\;_SZE]Q\;T5]D?\. /VN/\
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M;_Y+H_X< ?M<?]$D;_PI]&_^2Z/[<R[_ )_Q^\/['QO_ #ZE]Q\;T5]D?\.
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M^(UQITXT$>&]&O=(6VO61C$9(V,=IY(D*[P%9MN=@)Q7Q;_P1J^#?BCXV?\
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M_;=UC1]0^*7@6Q\77F@0O!827%U<0_9D=@SJ!%(@.2 3G/05L?LL?L4?"_\
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MUW[(NA>-/[8_X5_JE[&KB2/3KKQ%?RV<9'3CS=[8X^^[=,="0?9?C-_P2/\
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MR<G.[>IA]3H<W-RJY#::?#8VT<,,:0PQ*$CCC4*L:C@  =!]*\!_:3_X)5?
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M!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4JXWV]3X4>TQ\)^ [5^,7_!X@V[X=? G^\-2UCC/_3*T-?L^J;5QS^)KYO\
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M2T4 )L%&P4M% ";!1L%+10 FP4;!2T4 )L%&P4M% ";!1L%+10 FP4;!2T4
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MZE^!_3MNHW5_,3_P\S_:$_Z++\1/_!U-_C1_P\S_ &A/^BR_$3_P=3?XT?\
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M/VI/_"BA_P#C-?%^PH_\_/P9]=[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__
M !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?
M$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_
M!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z
M/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V]N^GYT;OI^=?$/\ PY^\9?\
M1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_^,T?5Z/_ #\_!A[:M_S[_%'V
M]N^GYT;OI^=?$/\ PY^\9?\ 1XG[4G_A10__ !FC_AS]XR_Z/$_:D_\ "BA_
M^,T?5Z/_ #\_!A[:M_S[_%'V[GZ?G1G'I^=?$7_#G[QE_P!'B?M2?^%%#_\
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MX,/;5O\ GW^*/M[=]/SHW?3\Z^(?^'/WC+_H\3]J3_PHH?\ XS1_PY^\9?\
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M !JCZO1_Y^?@P]O5_P"??XH^_-WT_.C=]/SKX#_X=4^./^CP/VG_ /PHH?\
MXU1_PZI\<?\ 1X'[3_\ X44/_P :H^KT?^?GX,/;U?\ GW^*/OS=]/SHW?3\
MZ^ _^'5/CC_H\#]I_P#\**'_ .-4?\.J?''_ $>!^T__ .%%#_\ &J/J]'_G
MY^##V]7_ )]_BC[\W?3\Z-WT_.O@/_AU3XX_Z/ _:?\ _"BA_P#C5'_#JGQQ
M_P!'@?M/_P#A10__ !JCZO1_Y^?@P]O5_P"??XH^_-WT_.C=]/SKX#_X=4^.
M/^CP/VG_ /PHH?\ XU1_PZI\<?\ 1X'[3_\ X44/_P :H^KT?^?GX,/;U?\
MGW^*/OS=]/SHW?3\Z^ _^'5/CC_H\#]I_P#\**'_ .-4?\.J?''_ $>!^T__
M .%%#_\ &J/J]'_GY^##V]7_ )]_BC[\W?3\Z-WT_.O@/_AU3XX_Z/ _:?\
M_"BA_P#C5'_#JGQQ_P!'@?M/_P#A10__ !JCZO1_Y^?@P]O5_P"??XH^_-WT
M_.C=]/SKX#_X=4^./^CP/VG_ /PHH?\ XU5_0_\ @DGXUU3S=_[87[42^7C&
MWQ%#WS_TQ]J/J]'_ )^?@P]M5_Y]_BC[MW?3\Z-WT_.OB'_AS]XR_P"CQ/VI
M/_"B@_\ C-'_  Y^\9?]'B?M2?\ A10__&:GZO1_Y^?@Q^VK?\^_Q1]O;OI^
M=&[Z?G7Q#_PY^\9?]'B?M2?^%%#_ /&:/^'/WC+_ */$_:D_\**'_P",T?5Z
M/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\.?O&7_1XG[4G_A10_P#QFC_AS]XR
M_P"CQ/VI/_"BA_\ C-'U>C_S\_!A[:M_S[_%'V]N^GYT;OI^=?$/_#G[QE_T
M>)^U)_X44/\ \9H_X<_>,O\ H\3]J3_PHH?_ (S1]7H_\_/P8>VK?\^_Q1]O
M;OI^=&[Z?G7Q#_PY^\9?]'B?M2?^%%#_ /&:/^'/WC+_ */$_:D_\**'_P",
MT?5Z/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\.?O&7_1XG[4G_A10_P#QFC_A
MS]XR_P"CQ/VI/_"BA_\ C-'U>C_S\_!A[:M_S[_%'V]N^GYT;OI^=?$/_#G[
MQE_T>)^U)_X44/\ \9H_X<_>,O\ H\3]J3_PHH?_ (S1]7H_\_/P8>VK?\^_
MQ1]O;OI^=&[Z?G7Q#_PY^\9?]'B?M2?^%%#_ /&:/^'/WC+_ */$_:D_\**'
M_P",T?5Z/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\.?O&7_1XG[4G_A10_P#Q
MFC_AS]XR_P"CQ/VI/_"BA_\ C-'U>C_S\_!A[:M_S[_%'V]N^GYT;OI^=?$/
M_#G[QE_T>)^U)_X44/\ \9H_X<_>,O\ H\3]J3_PHH?_ (S1]7H_\_/P8>VK
M?\^_Q1]O;OI^=&[Z?G7Q#_PY^\9?]'B?M2?^%%#_ /&:/^'/WC+_ */$_:D_
M\**'_P",T?5Z/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\.?O&7_1XG[4G_A10
M_P#QFC_AS]XR_P"CQ/VI/_"BA_\ C-'U>C_S\_!A[:M_S[_%'V]N^GYT;OI^
M=?$/_#G[QE_T>)^U)_X44/\ \9H_X<_>,O\ H\3]J3_PHH?_ (S1]7H_\_/P
M8>VK?\^_Q1]O;OI^=&[Z?G7Q#_PY^\9?]'B?M2?^%%#_ /&:/^'/WC+_ */$
M_:D_\**'_P",T?5Z/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\.?O&7_1XG[4G
M_A10_P#QFC_AS]XR_P"CQ/VI/_"BA_\ C-'U>C_S\_!A[:M_S[_%'V]N^GYT
M;OI^=?$/_#G[QE_T>)^U)_X44/\ \9H_X<_>,O\ H\3]J3_PHH?_ (S1]7H_
M\_/P8>VK?\^_Q1]O;OI^=&[Z?G7Q#_PY^\9?]'B?M2?^%%#_ /&:/^'/WC+_
M */$_:D_\**'_P",T?5Z/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\.?O&7_1X
MG[4G_A10_P#QFC_AS]XR_P"CQ/VI/_"BA_\ C-'U>C_S\_!A[:M_S[_%'V]N
M^GYT;OI^=?$/_#G[QE_T>)^U)_X44/\ \9H_X<_>,L_\GB?M2?\ A10?_&:/
MJ]'_ )^?@P]M6_Y]_BC[>W?3\Z-WT_.O@(?\$J?'&/\ D\#]I_I_T,,/_P :
MI?\ AU3XX_Z/ _:?_P#"BA_^-57U>C_S\_!B]O5_Y]_BC[\W?3\Z-WT_.O@/
M_AU3XX_Z/ _:?_\ "BA_^-4?\.J?''_1X'[3_P#X44/_ ,:H^KT?^?GX,/;U
M?^??XH^_-WT_.C=]/SKX#_X=4^./^CP/VG__  HH?_C5'_#JGQQ_T>!^T_\
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MV]N^GYT;OI^=?$/_  Y^\9?]'B?M2?\ A10__&:/^'/WC+_H\3]J3_PHH?\
MXS1]7H_\_/P8>VK?\^_Q1]O;OI^=&[Z?G7Q#_P .?O&7_1XG[4G_ (44/_QF
MC_AS]XR_Z/$_:D_\**'_ .,T?5Z/_/S\&'MJW_/O\4?;V[Z?G1N^GYU\0_\
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M4GF+G%.J. 87KNR<YJ2N<Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0BDV?+3CTI/X/PI ?SG?\%T>/^"J/Q4_WM*_]--E7R37UM_P72_Y2H_%
M3_>TK_TTV5?)-?U1PO\ \BG#?X(_D?S7G_\ R,JW^)A1117NGCW"BBB@+A11
M10%PHHHH"X4444!<*_6[_@UC0-=?'+/]W0?_ ')5^2-?K?\ \&L7_'S\<_\
M=T'_ -R5?$^(?_(CJ^L?_2D?6<$N^;T_G^1^NZK2[?<T+_2EK^<3^@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-ON:6B@!-ON:-
MON:6B@!I7%<GJ0_XF-Q_UT;^9KK6Z5R6I?\ (1N/^NC?S- $.*,4447 ,48H
MHHN 8HQ111< Q1BBBBX!BC%%%%P#%&***+@&*,4447 ,48HHHN 8HQ111< Q
M1BBBBX!BC%%%%P#%&***+@&*,4447 ,48HHHN 8HQ111< Q1BBBBX!BC%%%%
MP#%&***+@&*V?"0XN/\ @/\ 6L:MKPCTN/\ @/\ 6@#85<CK2[?<T+TI: $V
M^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V
M^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V
M^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V^YHV^YI:* $V
M^YHV^YI:* $V^YHV^YI:* $V^YI-O/6G4=Z .+QP/H*,4=OPHHN 8HQ111<
MQ1BBBBX!BC%%%%P#%&***+@&*,4447 ,48HHHN 8HQ111< Q1BBBBX!BC%%%
M%P#%&***+@&*,4447 ,48HHHN 8HQ111< Q1BBBBX!BC%%%%P#%&***+@&*,
M4447 ,48HHHN!L^$AQ<?\!_K6RJY'6L?PCTN/^ _UK97I0 ;?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";
M?<T;?<TM% ";?<T;?<TM% ";?<T;?<TM% ";>:"F32T4  &**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ /2D_@_"E/2D_@_"D!_.=_P72_Y
M2H_%3_>TK_TTV5?)-?6W_!=+_E*C\5/][2O_ $TV5?)-?U/PO_R*,-_@C^1_
M-?$'_(RK?XF%%%%>\>.%%%% !1110 4444 %%%% !7ZW_P#!K%_Q\_'/_=T'
M_P!R5?DA7ZW_ /!K%_Q\_'/_ '=!_P#<E7Q/B%_R)*GK'_TI'UG!'_(XI_/\
MC]>%_I2TB_TI:_G$_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $;I7):E_R$;C_KHW\S76MTKDM2_Y"-Q_UT;^
M9H AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K:\(]+C_ (#_ %K%K:\(
M]+C_ (#_ %H V5Z4M(O2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[T4=Z
M .+[?A11V_"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#:\(]+C_@/]
M:V5Z5C>$>EQ_P'^M;*]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2D_@_"E/2D_@_"D!_
M.=_P72_Y2H_%3_>TK_TTV5?)-?6W_!=+_E*C\5/][2O_ $TV5?)-?U/PO_R*
M,-_@C^1_-?$'_(RK?XF%%%%>\>.%%%% !1110 4444 %%%% !7ZW_P#!K%_Q
M\_'/_=T'_P!R5?DA7ZW_ /!K%_Q\_'/_ '=!_P#<E7Q/B%_R)*GK'_TI'UG!
M'_(XI_/\C]>%_I2TB_TI:_G$_H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $;I7):E_R$;C_KHW\S76MTKDM2_Y
M"-Q_UT;^9H AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K:\(]+C_ (#_
M %K%K:\(]+C_ (#_ %H V5Z4M(O2EH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ H[T4=Z .+[?A11V_"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#:\
M(]+C_@/]:V5Z5C>$>EQ_P'^M;*]* %HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** (YY"A_#CBL*ZT5[BYDD\
MZ!?,8N,L>_/_ -:MV=0S=.O!K^<__@N>&7_@J?\ %(%F;!TH<G_J$V5?0<-9
M"\WQ;PJGR:7NU?:W^9X'$6>?V5AUB'#FN[;G]"']@/\ \][?_OH_X4?V _\
MSWM_^^C_ (5_)W^?YT?G^=?>_P#$*:O3$+_P%_YGQ7_$3%_SX_$_K$_L!_\
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M_G1^?YT?\0HJ_P#00O\ P%_YA_Q$Q?\ /C\3^L3^P'_Y[V__ 'T?\*/[ ?\
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M_P#?1_PK^3O\_P Z/S_.C_B%%7_H(7_@+_S#_B)B_P"?'XG]8G]@/_SWM_\
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M ,!?^8?\1,7_ #X_$_KB^V1_\]$_.C[9'_ST3\Z_D=HH_P"(45?^@A?^ O\
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M ,][?_OH_P"%?R=_G^='Y_G1_P 0HJ_]!"_\!?\ F'_$3%_SX_$_K$_L!_\
MGO;_ /?1_P */[ ?_GO;_P#?1_PK^3O\_P Z/S_.C_B%%7_H(7_@+_S#_B)B
M_P"?'XG]8G]@/_SWM_\ OH_X4?V _P#SWM_^^C_A7\G?Y_G1^?YT?\0HJ_\
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M$+_P%_YA_P 1,7_/C\3^N+[9'_ST3\Z/MD?_ #T3\Z_D=HH_XA15_P"@A?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A;!K&\?\ Q$T+X5^$
M[[7_ !-K>C^'=!TN/S;W4M4O([.TLT)"[I)9&5$&2!EB!DBMENM?)7_!=-?^
M-3'QN/?^Q$'T_P!*@K2C3]I44'U:1G5FX0<ET/0Q_P %-_V<3_S<!\$N.O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC')Z2IIIN[:[ONNQ^!\6U)RS2HIOFMIIT]3/ZY]^O/6L_7_#-KXA5FFC59F
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M6\]Y+=L)92"YWR,S<D#C->G4BG/^>M+7@SG*4N:6K/9C%15EL%%%%24%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 49Q03498C_ .OWI .#
M?C06IADY[?A2"7(^7TSG/!I@2J<BEIL3;E[_ $-.H **** "BBB@ HHHH **
M** "BBB@!":3)Q4.H:A#IEM)/<2QP6\2[GDD8*B#U)/ J/2M:M==MO.LKJWO
M(=VW?#()%R.V1WHY7OT"ZO;J7 :*11BEH *1B12TUWVD>YH <IR**:C;A^.*
M=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 UZ_G/_P""Z?\ RE2^*GUTK_TT65?T8/7\Y_\
MP73_ .4J7Q4^NE?^FBRK]&\+_P#D;/\ P2_-'P/B)_R+H_XE^1\DT445^_'X
MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'D8[>G:BB@#
M[\_X(\_\%A+[]CO7K7X?^/KJXU#X7ZC.1!.<R3>&I9&),D8Y+6[,29(QRN=Z
M#.Y7_=SP_P");+Q5H=GJ6FWEKJ&GZA"ES;75O(LL-S$X#(Z.O#*RD$,."".:
M_DG/(QV].U??G_!'G_@L)??L>:_:?#_Q_=7.H?"_4)R+><YDF\-2R-DR1CDM
M;LQ)DC'*YWH,[E?\IXWX(6(4L?@%[^\HKKYKS_/UW_2N$.,'0:P6-?N]'V_X
M'Y'[U1.7'-.K/\.>)+'Q5HEIJ6F7EKJ&GZA"ES;75O*)8;F)P&5T=>&5E((8
M<$$5>C8LO-?B/*XZ2W/V",E)70ZBBB@H**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FLFXTZB@#XF_X+1^%?
M">K_  @TNZU2Z^Q^)K%I'TMWBF9;E,9D@#+\BLQ5&&[KY9K\J)XEGA,4BK+$
MP'RNN5(Z]#_/G^@_?C]H7P)X;^(WPIUC3?%EK#=:+);DS>8A8Q'D!UP"0P)Z
MCG\*_#GXR?!S4OA7X\O-*9?[1B4B2"[M$+PW49Z2*>N&P3@\C..U?M7ASF49
MX26$;?-%W5^S['XYX@9=*GBXXI+W9*WS/+=:^%7AWQ%=^==:7"TBIL7R_D"C
MGL/J:XW6?V8K,V<K:?J,T<Q;]VLZAHU]CC!KUHZ+??\ /C>?]^&H.D7J+EK.
M\ ]3 W'Z5^F0Q'+LS\_Y;GSSKWP!\1:-,_DP1W\,:[FDA;IZ\'FN6MX[KP[>
MVMW/#=V,<<RGSGC*@8.>OTS7U*SJC_,V&7U/(J.^M[758A'=0V]U&IW!)<,H
M_.NB.);6P[VT+WA'Q=-IEY8ZQH]Y-#(I2XMIXF*,N>C ]C7Z/?LT_P#!7+2M
M4T#P]_PGVI:I9ZMIKKIUVEO K6VJ1R #[7(>JF+82P& ?,&!7YK6X1(%CC"K
M&@P@7&U![4]'PW!P3\PX[CI_7CIS7S6=9#A,RIVQ,=5LUNO^ >ME.>8G+JEZ
M+WW3V?\ P3^B+1-?M/$>D6^H6%Q#>65T@DAFB8,DBGD$$5::1AZ=.E?FK_P2
M:_;[TWP19P_#?Q5/]CM[JX#Z;J,\S%(I' 7R&SPJDJNT\#+MG%;W_!2C_@NC
MX7_9IEUKP9\/TC\3>.(;<1F^5U;3=-D8'.6SEY$4A@%!7YAD]J_$,5P?F$,P
M> HQ<NTNEN]_S/V3"\58.>!6,K24>CCU3]/,^P_VA_VOOA[^RGH"ZEX\\3Z?
MH<,I BC?+S2YR/EC7+L.#R!CBO%F_P""X7[-8Q_Q<#C_ +!5YS_Y"K^?GXA_
M%SQ9^T)XU:]U[5]8\5:Q=,S1*\TEU*<LSE47DJH+,<* !DU#K/[/?Q+N?A3K
M'B_2?!NM2:)H3JNHW;VK(UJ#W$9&Y_? K[#%<&\/Y70B\XQJC-VTYHQNWLDG
MJ]3YREQ9FF-K\F H7CW:>EN_ZG]+G[.?[?OPG_:NGO(? _C#3]6N=/9%FMW#
MVT_SABNV.0*SCY3DJ#C%>P)<%U[?A7\N_P"Q59?$#P#\1O#>N1V]YIOVUL27
M"D(PA8$J>#E2>.1SVK]COV$/VWO'^KZV/#>H:/JOC#3[>U3R7B4?:;4+P"[N
M5!4@]6)/R]^:_(>.L=A,@SVEE3NX5H*<);O>S32_,_8^"N'<;Q!P]6SJE*/-
M0FX3C>U]+IQ;T?H??R-N'T.*=4-E)YMNK;=NX9QZ5-6B=U<\?;0**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ /2D_@_"E/2D_@_"D!_.=_P72_Y2H_%3_>TK_TTV5?)-?6W_!=+
M_E*C\5/][2O_ $TV5?)-?U/PO_R*,-_@C^1_-?$'_(RK?XF%%%%>\>.%%%%
M!1110 4444 %%%% !7ZW_P#!K%_Q\_'/_=T'_P!R5?DA7ZW_ /!K%_Q\_'/_
M '=!_P#<E7Q/B%_R)*GK'_TI'UG!'_(XI_/\C]>%_I2TB_TI:_G$_H ****
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MR?\ 7_NOO\2?)]X@5^PJQC&!\JBE$0W5PQQLE4G4M\:=_F=<L'&5.-._PV_
M17W#W'%?F[_P=$? _P ;?'[]@7P?H_@/P?XH\:ZM:_$"SO)['0=)N-2N8H%T
M[4D:5HX49EC#2(I8C +J.I%?I'LVYQZTAAS_ (5CA:TJ%6-5='<UQ-%5J<J?
M='C_ /P3O\,:EX+_ & /@=HVLZ??:3K&D^ -!LKZQO8'M[FSGCTZ!)(I8W 9
M)%8%65@"I!!Y%>H>,/"NG^-_"^I:+J]I#J&DZM:R6=[:RC='<P2J4DC8=U96
M(([@FM)%V?G0R;F![BLY3;GSFD::4.3IL?A#JW["G[5G_!!W]I77O&?[/.C7
MGQ7^$OB1U^U:;#:/?S26JNS1PW=K#B831!F"W, *X8D[=[15Z:?^#B/]IKQO
MHLNB^$_V,_%C^+X08Y)&@U2^@CDYQNM8[2.10-K9!F'3.X<BOV/,8 V\XQZ\
M_G2+&JD<=#D5ZCS2$[2K4E*2ZZK[SSEETXW5.HXKL?&7_!'V\_:@\8^'/'WB
MS]IJUDT?4_$%]:MX<TD&"&/3K1(Y-ZK;PLQBR[C_ %Q,K;?FX"U\CK^S5\2/
M^(L(?$;_ (5_XU_X5Z3QXG_L.Z_L7_D3_L__ !][/)_U_P"Z^_\ ZSY?O$"O
MV(5.,=::(\MSR?6N:..:G.<4DI)JRV29M+!\T(Q<FW%WN-^T;3CC_.*_''6O
MV9OB4_\ P=;+\1E^'OCAOA^)X3_PDXT&Z.C8_P"$32 G[7Y?D\39C/S_ 'QM
MZ@@?LCY?/?\ .CRATYK+!XF5!MI;IK[S;$X>-9+I9W/)OVY?V;HOVQOV2?B!
M\,FO%TV3Q?HTUC!=L@=;6<_/#(R]2JRHA(') X(/(_%W]AS]LK]K;_@BWX*U
M;X-Z_P#LU^*O'&D6^JRW.ERQVMWY4,D@!D6"Z@BE@N(6*[P$.59Y,GD*O[]&
M%6XY/.<^E'V=2/ZUMA<P=&FZ52*E%ZV?<QQ&#]I-5(2<6M+G@O\ P38_:,^)
M/[5'[,\/C#XI_#^X^&/B2]U.ZBBT&XL[FUF@M48")W2X D+,,G<50'LH')]^
MI%7:*6N2I)2DVE9=CKIQ<8I-W"BBBH+"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH JZOJEOHNGW%Y=SPVMK:QM+--,XCCB10269CP  "237
MXF_M+_\ !:']H+_@I?\ M-7WP?\ V-]+NM-\/6<AAN/%$4*_:[N)7VM=O-("
MEE:DGY#CS6&,$,XB7[4_X.+OCU?? ;_@E;X\?2[B>SU'Q?+:>&(IXV*^7'<R
MYN <8.'MHYHS_O\ IG/(?\&Q_P"R]I?P4_X)JZ1XQ6T2/Q%\4KZXU;49R/WA
MAAFEMK:+=_<5(WD [&X?UKV<'3A1PSQ=2*D[V2>WJ>3BZDZN(6%B[*UVT?/&
MA?\ ! K]L74[635M7_;&\067B1G6119:_K5Q$7+ M_I!EB=<8XQ&??&*Y'4O
M'G_!1+_@D3\1O#LWCKQ)_P +@^%]]JEI87FIW4C:Y9(LLR1 RSR".]MGPPVL
M["(NP'[P\']QRBD?Q?6FW-A#?VKPS1I-#(I1TD4,KJ>""#P0?>L_[6JRTK0B
MUZ%/+(+6G)I@DICC_6E^T'/:OGW_ (*?_MWZ/_P3B_9"\0?$:_B@OM2AVZ=H
M&F2R%%U34901%#E>=H"O*V.=D3XYQ7Y9?LW_ /!/O]L;_@L?X(A^+GQ*_:!U
MSX;>%_$I-SH>GVIN&26'HLL5A#-#%#$< *SL9' WG<"KMEA\O]I3]M4ERPO:
M_=FM?&.G)4J<>:6]O(_=%I67/W<4U9V<_P /0U^$OC[XK?M8_P#!O!\:?"<W
MCWQY??&KX'^);G[*3=WDMP/EY>)#.S2V=PJDN@#F%P#G<0P7]O/A1\1M%^,O
MPUT'Q=X=O%U#0?$VGP:II]RO G@FC61&QVRK#@\@\5.,P+H*,^92C+9HO"XR
M-5N#3C)=&;XF.#]T\9^GUI1/D]*_GG_9K_X*"?MH?$3]MWXS_#KX1ZIKWQ U
MC4M5O]-LI==NWNM/\%VL=^ZF[593Y$9"A4!DR.P21BJUZ5\=_P#@B1^VSX(\
M!ZO\3%_:6U;Q9XXT6R;49+'3_$>JQ7$QC7<\5O.Q4%@!\B[8PVT*-H.!V2R=
M0FHUJBBWLN]SECFCFG*G3;2W\C]SFF(Z8_(TBW&<=.:_!C]D#_@KM^VE_P %
M%O@AI?P;^$^B6=QX\TM_)\0_$NY$:)9V#_+"\I*&&&X(68%PKO*(R8T#J[59
M_:?_ ."/?[:?[,'P@\2?&&S_ &FO$?BS7O"U@VK:G;Z?XGU6&[>VB!EN#%+)
M(!((U#-L.W>F\ 9(C:?['Y9^SKU%&3V0EFKG'GI4W)=7V/WA5MPH>3#;1U_E
M7Q'_ ,$&_P#@HSKG_!17]BYM8\8/#-XZ\'ZE)HFM744*PIJ1"K+#=!$ 5"\;
MA6  !>-R JD ?*?_  <O_MF_%C]EC]HOX(6_PW\9>+-!AU2TNI[K2M(OY8%U
MF2.Y@V1.B$%BP)7@$_,>.F>>GEM6>)>$>DD=-3,*<:"Q'1G[#>:2,CN,T>?S
MVZXZ]*_&7Q1_P3V_X*!?\%.!_P )?\1OBMI_P4T74%\S3_!]CJ%W;&RB.619
M;>V^4GYL$S322_WE3"J/)_@I^U3^TE_P0I_;R\)?"_X]>,KGQC\*?%TD"-=7
MNIRZE96]I))Y1O;.:;$T)@D/[R @*5W'8=T<E;QRE234*B<EK;7[CG>9R5FZ
M;47U/U:_X+(R>9_P2R^.DBG!'A"\(]CM'\O>OFC_ (-1D5/^"8NH;<*H\;:B
M  , ?N+2OI7_ (+&N)/^"5OQU9>5;PA>$$'.?E%?-7_!J8V/^"8>H?\ 8[ZB
M/_)>TITX_P#"9-O^9?D5/7'1[<K/TP=RG]*1YL#/3C/3FOS$_P""P?\ P57^
M)FA?M*:!^RW^S7:K<_&#Q1Y::EJHC21M%2:,R)''ORB.(<SR2N"L41!&22R>
M;6G_  ;U?M,:[8KXFU;]M3QI;^/O+\PI;R:I-##,<,56\^VI(%#9.1" ,#"@
M<#&&7I053$5%#FV3UN:2QS<G&C!RMOY'[""5O\]J_/S_ (.'?V^OB9^P!^S+
MX)\2?"_6+/1=9UKQ.-+NI+C3X+T20&UGDV!)58#+QKR.>,=Z\?\ ^"1G_!1K
MXQ?"/]MS6OV0OVE]077/%NG)+_PCOB"1WFN+YTC^T>5).0#/'+;%I8I'42#8
MR,22H7P#_@Z?_9V^)WA/Q''\1-7^)=UJWPM\3^(;.RT+P8TLQAT*YCTS;)<!
M6/E?-)#,WR@',_UKJP.7*..C1K--;I])>ASXO'-X256GHUIZ'[2?LK>/=2^)
MO[,?PY\2:O*MSJWB+PQIFIWTJQK&LD\UI%)(P5<!<LQ.!P*[[SFSC%?C)^SK
M_P $F/VSO&G[/_@?6=!_;$UC0=#UCP_87NGZ:+N_ T^VEMHWBA #[1L4JOR\
M<5]T_M/_ +77_#IK_@FOHOB;XC:I-XZ\8>'-)L= 2=IF63Q/K7D;<EWRRJ[1
MS2NYRRQHY )P#QU\&O:<M":FV[670Z,/BY.GS5H.*2O?N?6(G)3(P:#<87MQ
MZ5^)OP*_82_;*_X+'^!H?BM\2OC]K?P?\(^+%%UH6A:3%<K&UJ<F.064-Q B
M1L-I1Y9'D=?F;<"KG#^/,?[6W_!O9XV\,>--0^+6J_';X-ZQ?+I-[9ZQ-=2)
M&3ND\KR9I9?L<C1HYCDBE*[E(<$8#="RN+G[*-1.?;_@]S'^TVDJDZ;4._\
MP#]T8VW"G5S7P;^*6B_'#X4>'/&7ANY:\T#Q5IMOJNGS,A1G@FB62/<IY5MK
M#*G!!R#SFNEKR'%IV9ZD9)JZ"BBBD4%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ->OYS_ /@NG_RE2^*GUTK_ --%
ME7]&#U_.?_P73_Y2I?%3ZZ5_Z:+*OT;PO_Y&S_P2_-'P/B)_R+H_XE^1\DT4
M45^_'XB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]
M*3^#\*4]*3^#\*0'\YW_  72_P"4J/Q4_P![2O\ TTV5?)-?6W_!=+_E*C\5
M/][2O_3395\DU_4_"_\ R*,-_@C^1_-?$'_(RK?XF%%%%>\>.%%%% !1110
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M4X45QH[  VT8HHH :?E%&>E./2HYN!GV]*GJ)NR#S,Y[\XR*4-QVSWK\S/\
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M,L.K)2NWV,7_ (/#-?OX?AQ\"=+CB?\ LZ\U+6;F>0<*LL45HD:_4K-*0?\
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MM%+%)@_W')(P<#->ABJM24*=6C3C.-DMKM,XL+&G&I.G5FXROWLK'RW\.?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****  ]*3^#\*4]*3^#\*0'\YW_!
M=+_E*C\5/][2O_3395\DU];?\%TO^4J/Q4_WM*_]--E7R37]3\+_ /(HPW^"
M/Y'\U\0?\C*M_B84445[QXX4444 %%%% !1110 4444 %?K?_P &L7_'S\<_
M]W0?_<E7Y(5^M_\ P:Q?\?/QS_W=!_\ <E7Q/B%_R)*GK'_TI'UG!'_(XI_/
M\C]>%_I2TB_TI:_G$_H **** "BBB@ HHHH **** "FM$'_+&:=11Y@?/OQU
M_P""57[.W[2FO7&K>,_A#X)U75KR3S;C4([ 6=Y<OG.Z2>#9(Y]V8FN?^''_
M  16_97^%6M+J&D_!'P3+<*<K_:=L^J(I]0ETTB@^^,U]145NL562Y5)V]3#
MZK2OS<JN5],TBUT33X;2SMX;6UMT$<4,*!(XE' "J. !Z"O'?BQ_P3D^!'QU
M\?ZAXJ\9?"7P%XF\1ZJ(Q>:CJ.CPW%Q=>7&L2;W926VHBJ,] H%>U45E&I*+
MO%M,TE3C)<LEH<O\'_@KX2_9^\"6OA?P1X=TCPKX=LGDD@T[3+9;>WB:1R[D
M(H R68D_6NHHHI-MN[+2MHA"N:\T^/7[&7PI_:CU'3KOXC?#WPGXVNM)C>&R
MDUC38KMK9'(+*A<' )4'CTKTRBG"3B^:+LR914E:1\Y_\.B?V8,?\D'^%_\
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M=Q$XDBEC8+E71U# CD$5[U16KQ59[R?WLS6'I)W45]PB)Y:X%+116!L%%%%
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M;.SY][*&8#VSVXHJ1A7KXBO/:-[>NR%&4J5*C0CO+?TZGV=_P6X_X*>^*O\
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M\$:_%WAOPQ;VVAV.H65AX'T.QA.R&&W=XXF@09^Z+.*90/0<YYSI_P#!N_\
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M]EWPW\._#FB_$J.;3[=9=8OH_#]N)-7U!E'GW4A^TYRS#Y0?N($08"@#S_\
MX+,_\%T_V??^"@O["VN?#_PKI/C8^*VU&QU'29]5TF"W@M)89AYCB19G96-N
MTR @9_>$9ZUU4\#'VRH*@^6]KMZ^ISU,9+V;J*MKVMMY'[D?#[Q]H_Q4\"Z/
MXE\/ZA:ZMH6O6<6H:?>VS[H;N"5 Z2*?1E(-;%?)_P#P0UTS5=(_X)/?!.'6
M&9KMM",T988/V>2>5[?CM^Y:/CL*^L*^:KTU"I*$7=)M'T%&;G34GU04445D
M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KU_.?\
M\%T_^4J7Q4^NE?\ IHLJ_HP>OYS_ /@NG_RE2^*GUTK_ --%E7Z-X7_\C9_X
M)?FCX'Q$_P"1='_$OR/DFBBBOWX_$0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH=.N+E5N-3LGFDGBN85."R(LAB;&=AB!; 9<_I:+GYCG 49YSQQ7Y4?M5_\
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M (+$?\$BK[_@JUI?@/38_B<?A_IO@N2\N)+=?#_]J?VA+.(E1R?M,.SRUB<
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MNUAL;*.&WCCB@B4)&D:[511T  X ] .U6*C@^Z>,<U)7CGJ:]0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^B5M_X4>D__ "51_P .+?VJ/^B5M_X4>D__ "51_K1E'_01#_P)!_8.9?\
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M_ D']@YE_P ^)?<?)-%?6W_#BW]JC_HE;?\ A1Z3_P#)5'_#BW]JC_HE;?\
MA1Z3_P#)5'^M&4?]!$/_  )!_8.9?\^)?<?)-%?6W_#BW]JC_HE;?^%'I/\
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MUM_PXM_:H_Z)6W_A1Z3_ /)5'_#BW]JC_HE;?^%'I/\ \E4?ZT91_P!!$/\
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MH_Z"(?\ @2#^P<R_Y\2^X^2:*^MO^'%O[5/_ $2QO_"CTG_Y*H_X<6_M4_\
M1+&_\*/2?_DJC_6C*/\ H(A_X$@_L',O^?$ON/DFBOK;_AQ;^U3_ -$L;_PH
M])_^2J/^'%O[5/\ T2QO_"CTG_Y*H_UHRC_H(A_X$@_L',O^?$ON/DFBOK;_
M (<6_M4_]$L;_P */2?_ )*H_P"'%O[5/_1+&_\ "CTG_P"2J/\ 6C*/^@B'
M_@2#^P<R_P"?$ON/DFBOK;_AQ;^U3_T2QO\ PH])_P#DJC_AQ;^U3_T2QO\
MPH])_P#DJC_6C*/^@B'_ ($@_L',O^?$ON/DFBOK;_AQ;^U3_P!$L;_PH])_
M^2J/^'%O[5/_ $2QO_"CTG_Y*H_UHRC_ *"(?^!(/[!S+_GQ+[CY)HKZV_X<
M6_M4_P#1+&_\*/2?_DJC_AQ;^U3_ -$L;_PH])_^2J/]:,H_Z"(?^!(/[!S+
M_GQ+[CY)HKZV_P"'%O[5/_1+&_\ "CTG_P"2J/\ AQ;^U3_T2QO_  H])_\
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MX^2:*^MO^'%O[5/_ $2QO_"CTG_Y*H_X<6_M4_\ 1+&_\*/2?_DJC_6C*/\
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M_GQ+[CY)HKZV_P"'%O[5'_1*V_\ "CTG_P"2J/\ AQ;^U1_T2MO_  H])_\
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M0 4444 !Z4G\'X4IZ4G\'X4@/YSO^"Z7_*5'XJ?[VE?^FFRKY)KZV_X+I?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #)8@_\ *N:O;Z>&]F59I557( #'@ X%=.W2N2U+_D(W'_71OYF@!?[3N/\
MGXF_[[-']I7'_/Q-_P!]FH** )_[2N/^?B;_ +[-']I7'_/Q-_WV:@HH G_M
M*X_Y^)O^^S1_:5Q_S\3?]]FH** )_P"TKC_GXF_[[-']I7'_ #\3?]]FH**
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MQ_S\3?\ ?9H_M*X_Y^)O^^S4%% $_P#:5Q_S\3?]]FC^TKC_ )^)O^^S4%%
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MI_/\C]>%_I2TB_TI:_G$_H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** $;I7):E_R$;C_KHW\S76MTKDM2_Y"-Q_
MUT;^9H AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K:\(]+C_ (#_ %K%
MK:\(]+C_ (#_ %H V5Z4M(O2EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[
MT4=Z .+[?A11V_"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#:\(]+C
M_@/]:V5Z5C>$>EQ_P'^M;*]* %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:T88TZBBP#?)7%"Q[13J
M*/, Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 'I2?P?A2GI2?P?A2 _G._X+I?\ *5'XJ?[VE?\ IILJ^2:^MO\ @NE_RE1^
M*G^]I7_IILJ^2:_J?A?_ )%&&_P1_(_FOB#_ )&5;_$PHHHKWCQPH]??BBI;
M&QFU.]AMK>-IKBX<11(HRSNQPJ@>I)X^E*4E!.3Z:CC%R:BNK/MS_@G!_P %
MN?&?[#WA6'P;KFEKXX\"V[DV=L]S]GOM)#99EAEVL#$3D^6PX. I4'%?<?\
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MJ1K9A44G+L%%%%?<:=#Y$*_6_P#X-8O^/GXY_P"[H/\ [DJ_)"OUO_X-8O\
MCY^.?^[H/_N2KXGQ"_Y$E3UC_P"E(^LX(_Y'%/Y_D?KPO]*6D7^E+7\XG] !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 C=*Y+4O^0C<?]=&_F:ZUNE<EJ7_ "$;C_KHW\S0!#1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6UX1Z7'_ ?ZUBUM>$>EQ_P'^M &RO2EI%Z4M !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %'>BCO0!Q?;\**.WX44 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ;7A'I<?\!_K6RO2L;PCTN/^ _UK97I0 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 !Z4G\'X4IZ4G\'X4@/YSO^"Z7_ "E1^*G^]I7_ *:;
M*ODFOK;_ (+I?\I4?BI_O:5_Z:;*ODFOZGX7_P"11AO\$?R/YKX@_P"1E6_Q
M,****]X\<*ZKX&>+;'P!\;/!^O:E&9-.T76[*_ND ^_%%<1R..V<A3QD?K7*
MU8TBU6]U:UA?[LTJHQ'& 2!UZ]_U^M8XE1E1FGM9W-L-)JM%PW31_1__ ,%0
M_P!L36/V3OV%=8^(/@<Z?>:I-)9VVFW;(+BUA6X=0)\ [6 0DJ3\I9DR&'!_
M&+5?^"VO[4&J77F3?%:^C91MVP:1IT2C!/98 ,^_6OW2C_88\!ZM^QZOP3U"
M+5=6\"_8Q91Q7=ZTUU#$L@EC59B,XC95V?W0JJ/E %?/_P#Q#N?LWD?\@SQ=
M^.N2'^E?@?#.<9'@:4X8VCSRYG9M7=OF?M&?93F^-G&IA*O+'E6E[:GY1M_P
M6>_::F^5OBQJL@ZE?[.L<D9&<?N?I]*^7P,#^$\=0NW-?OQ>?\&\G[-\$3;=
M,\69 S\VMR%2?H1CUK\!RNT_IR,=./Z9_&OU+A?.LKQSJK+*?):U]+7/SGB/
M*\QP7(\?/FOMK<****^QD[NZ/EPK];_^#6+_ (^?CG_NZ#_[DJ_)"OUO_P"#
M6+_CY^.?^[H/_N2KXCQ"_P"1)4]8_P#I2/K."/\ D<4_G^1^O"_TI:1?Z4M?
MSB?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "-TKDM2_Y"-Q_UT;^9KK6Z5R6I?\A&X_ZZ-_,T 0T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5M>$>EQ_P'^M8M;7A'I<?\!_K0!LKTI:1>
ME+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1WHH[T <7V_"BCM^%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &UX1Z7'_ ?ZULKTK&\(]+C_@/]:V5Z
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%%  >E)_!^%*>E)_!^%(#^<[_ (+I?\I4?BI_O:5_
MZ:;*ODFOK;_@NE_RE1^*G^]I7_IILJ^2:_J?A?\ Y%&&_P $?R/YKX@_Y&5;
M_$PHHHKWCQPJ2VG:UN$ECQYD3!ERN[D=.,'OZ\5'5K18X[C6;..15=&F4,K
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M?^Q!/\4?^$LTKQKJ7_"3#2A:?\(_H$^J^5Y'VW?YOEC]WGSEVY^]AL=*_/\
MK];O^#61 T_QS_W=!_\ <E7QO'TJ:R6JYJ^L>MNJ/JN"XR>;4^7S_(^FH_\
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MH_X?Z_!G_H5?C;_X0%__ /$U]N;1_=-&T?W31[2C_)^/_ #V=?\ G_ ^(_\
MA_K\&?\ H5?C;_X0%_\ _$T?\/\ 7X,_]"K\;?\ P@+_ /\ B:^W-H_NFC:/
M[IH]I1_D_'_@![.O_/\ @?$?_#_7X,_]"K\;?_" O_\ XFC_ (?Z_!G_ *%7
MXV_^$!?_ /Q-?;FT?W31M']TT>TH_P GX_\  #V=?^?\#XC_ .'^OP9_Z%7X
MV_\ A 7_ /\ $T?\/]?@S_T*OQM_\("__P#B:^W-H_NFC:/[IH]I1_D_'_@!
M[.O_ #_@?$?_  _U^#/_ $*OQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\
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M=?\ G_ ^(_\ A_K\&?\ H5?C;_X0%_\ _$T?\/\ 7X,_]"K\;?\ P@+_ /\
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M?_" O_\ XFC_ (?Z_!G_ *%7XV_^$!?_ /Q-?;FT?W31M']TT>TH_P GX_\
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MO_A 7_\ \31_P_U^#/\ T*OQM_\ " O_ /XFOMS:/[IHVC^Z:/:4?Y/Q_P"
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MQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\ $U]N;1_=-&T?W31[2C_)^/\
MP ]G7_G_  /B/_A_K\&?^A5^-O\ X0%__P#$T?\ #_7X,_\ 0J_&W_P@+_\
M^)K[<VC^Z:-H_NFCVE'^3\?^ 'LZ_P#/^!\1_P##_7X,_P#0J_&W_P ("_\
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M?;FT?W31M']TT>TH_P GX_\  #V=?^?\#XC_ .'^OP9_Z%7XV_\ A 7_ /\
M$T?\/]?@S_T*OQM_\("__P#B:^W-H_NFC:/[IH]I1_D_'_@![.O_ #_@?$?_
M  _U^#/_ $*OQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\ $U]N;1_=-&T?
MW31[2C_)^/\ P ]G7_G_  /B/_A_K\&?^A5^-O\ X0%__P#$T?\ #_7X,_\
M0J_&W_P@+_\ ^)K[<VC^Z:-H_NFCVE'^3\?^ 'LZ_P#/^!\1_P##_7X,_P#0
MJ_&W_P ("_\ _B:/^'^OP9_Z%7XV_P#A 7__ ,37VYM']TT;1_=-'M*/\GX_
M\ /9U_Y_P/B/_A_K\&?^A5^-O_A 7_\ \31_P_U^#/\ T*OQM_\ " O_ /XF
MOMS:/[IHVC^Z:/:4?Y/Q_P" 'LZ_\_X'Q'_P_P!?@S_T*OQM_P#" O\ _P")
MH_X?Z_!G_H5?C;_X0%__ /$U]N;1_=-&T?W31[2C_)^/_ #V=?\ G_ ^(_\
MA_K\&?\ H5?C;_X0%_\ _$T?\/\ 7X,_]"K\;?\ P@+_ /\ B:^W-H_NFC:/
M[IH]I1_D_'_@![.O_/\ @?$?_#_7X,_]"K\;?_" O_\ XFC_ (?Z_!G_ *%7
MXV_^$!?_ /Q-?;FT?W31M']TT>TH_P GX_\  #V=?^?\#XC_ .'^OP9_Z%7X
MV_\ A 7_ /\ $T?\/]?@S_T*OQM_\("__P#B:^W-H_NFC:/[IH]I1_D_'_@!
M[.O_ #_@?$?_  _U^#/_ $*OQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\
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M=?\ G_ ^(_\ A_K\&?\ H5?C;_X0%_\ _$T?\/\ 7X,_]"K\;?\ P@+_ /\
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M?_" O_\ XFC_ (?Z_!G_ *%7XV_^$!?_ /Q-?;FT?W31M']TT>TH_P GX_\
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MO_A 7_\ \31_P_U^#/\ T*OQM_\ " O_ /XFOMS:/[IHVC^Z:/:4?Y/Q_P"
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MQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\ $U]N;1_=-&T?W31[2C_)^/\
MP ]G7_G_  /B/_A_K\&?^A5^-O\ X0%__P#$T?\ #_7X,_\ 0J_&W_P@+_\
M^)K[<VC^Z:-H_NFCVE'^3\?^ 'LZ_P#/^!\1_P##_7X,_P#0J_&W_P ("_\
M_B:/^'^OP9_Z%7XV_P#A 7__ ,37VYM']TT;1_=-'M*/\GX_\ /9U_Y_P/B/
M_A_K\&?^A5^-O_A 7_\ \31_P_U^#/\ T*OQM_\ " O_ /XFOMS:/[IHVC^Z
M:/:4?Y/Q_P" 'LZ_\_X'Q'_P_P!?@S_T*OQM_P#" O\ _P")H_X?Z_!G_H5?
MC;_X0%__ /$U]N;1_=-&T?W31[2C_)^/_ #V=?\ G_ ^(_\ A_K\&?\ H5?C
M;_X0%_\ _$T?\/\ 7X,_]"K\;?\ P@+_ /\ B:^W-H_NFC:/[IH]I1_D_'_@
M![.O_/\ @?$?_#_7X,_]"K\;?_" O_\ XFC_ (?Z_!G_ *%7XV_^$!?_ /Q-
M?;FT?W31M']TT>TH_P GX_\  #V=?^?\#XC_ .'^OP9_Z%7XV_\ A 7_ /\
M$T?\/]?@S_T*OQM_\("__P#B:^W-H_NFC:/[IH]I1_D_'_@![.O_ #_@?$?_
M  _U^#/_ $*OQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\ $U]N;1_=-&T?
MW31[2C_)^/\ P ]G7_G_  /B/_A_K\&?^A5^-O\ X0%__P#$T?\ #_7X,_\
M0J_&W_P@+_\ ^)K[<VC^Z:-H_NFCVE'^3\?^ 'LZ_P#/^!\1_P##_7X,_P#0
MJ_&W_P ("_\ _B:/^'^OP9_Z%7XV_P#A 7__ ,37VYM']TT;1_=-'M*/\GX_
M\ /9U_Y_P/B/_A_K\&?^A5^-O_A 7_\ \31_P_U^#/\ T*OQM_\ " O_ /XF
MOMS:/[IHVC^Z:/:4?Y/Q_P" 'LZ_\_X'Q'_P_P!?@S_T*OQM_P#" O\ _P")
MH_X?Z_!G_H5?C;_X0%__ /$U]N;1_=-&T?W31[2C_)^/_ #V=?\ G_ ^(_\
MA_K\&?\ H5?C;_X0%_\ _$T?\/\ 7X,_]"K\;?\ P@+_ /\ B:^W-H_NFC:/
M[IH]I1_D_'_@![.O_/\ @?$?_#_7X,_]"K\;?_" O_\ XFC_ (?Z_!G_ *%7
MXV_^$!?_ /Q-?;FT?W31M']TT>TH_P GX_\  #V=?^?\#XC_ .'^OP9_Z%7X
MV_\ A 7_ /\ $T?\/]?@S_T*OQM_\("__P#B:^W-H_NFC:/[IH]I1_D_'_@!
M[.O_ #_@?$?_  _U^#/_ $*OQM_\("__ /B:/^'^OP9_Z%7XV_\ A 7_ /\
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M^5?]8W;WIQJ4/Y/Q#V=?^?\  ^*?^'ZWP?\ ^A7^-/\ X0=[_A1_P_6^#_\
MT*_QI_\ "#O?\*^T-H]%_*C:/1?RJO:4/Y/Q#V=?^?\  ^+_ /A^M\'_ /H5
M_C3_ .$'>_X4?\/UO@__ -"O\:?_  @[W_"OM#:/1?RHVCT7\J/:4/Y/Q#V=
M?^?\#XO_ .'ZWP?_ .A7^-/_ (0=[_A1_P /UO@__P!"O\:?_"#O?\*^T-H]
M%_*C:/1?RH]I0_D_$/9U_P"?\#XO_P"'ZWP?_P"A7^-/_A!WO^%'_#];X/\
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M_P"$'>_X4?\ #];X/_\ 0K_&G_P@[W_"OM#:/1?RHVCT7\J/:4/Y/Q#V=?\
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M_P#A 7__ ,37VYM']TT;1_=-'M*/\GX_\ /9U_Y_P/B/_A_K\&?^A5^-O_A
M7_\ \31_P_U^#/\ T*OQM_\ " O_ /XFOMS:/[IHVC^Z:/:4?Y/Q_P" 'LZ_
M\_X'Q'_P_P!?@S_T*OQM_P#" O\ _P")H_X?Z_!G_H5?C;_X0%__ /$U]N;1
M_=-&T?W31[2C_)^/_ #V=?\ G_ ^(_\ A_K\&?\ H5?C;_X0%_\ _$T?\/\
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MVC^Z:-J_W?TH]I1_D_'_ ( >SK_S_@?GZ/\ @NO\'V4'_A%_C3R ?^1#OO\
MXFC_ (?K?!__ *%?XT_^$'>_X5]H8SV7H.U&T>B_E5^TH?R?B'LZ_P#/^!\7
M_P##];X/_P#0K_&G_P (.]_PH_X?K?!__H5_C3_X0=[_ (5]H;1Z+^5&T>B_
ME1[2A_)^(>SK_P _X'Q?_P /UO@__P!"O\:?_"#O?\*/^'ZWP?\ ^A7^-/\
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ME1[2A_)^(>SK_P _X'Q?_P /UO@__P!"O\:?_"#O?\*/^'ZWP?\ ^A7^-/\
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M $*OQM_\("__ /B:^W-H_NFC:/[IH]I1_D_'_@![.O\ S_@?$?\ P_U^#/\
MT*OQM_\ " O_ /XFC_A_K\&?^A5^-O\ X0%__P#$U]N;1_=-&T?W31[2C_)^
M/_ #V=?^?\#XC_X?Z_!G_H5?C;_X0%__ /$T?\/]?@S_ -"K\;?_  @+_P#^
M)K[<VC^Z:-H_NFCVE'^3\?\ @![.O_/^!\1_\/\ 7X,_]"K\;?\ P@+_ /\
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M !-?;FT?W31M']TT>TH_R?C_ , /9U_Y_P #XC_X?Z_!G_H5?C;_ .$!?_\
MQ-'_  _U^#/_ $*OQM_\("__ /B:^W-H_NFC:/[IH]I1_D_'_@![.O\ S_@?
M$?\ P_U^#/\ T*OQM_\ " O_ /XFC_A_K\&?^A5^-O\ X0%__P#$U]N;1_=-
M&T?W31[2C_)^/_ #V=?^?\#XC_X?Z_!G_H5?C;_X0%__ /$T?\/]?@S_ -"K
M\;?_  @+_P#^)K[<VC^Z:-H_NFCVE'^3\?\ @![.O_/^!\1_\/\ 7X,_]"K\
M;?\ P@+_ /\ B:/^'^OP9_Z%7XV_^$!?_P#Q-?;FT?W31M']TT>TH_R?C_P
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M   ]G7_G_ ^(_P#A_K\&?^A5^-O_ (0%_P#_ !-'_#_7X,_]"K\;?_" O_\
MXFOMS:/[IHVC^Z:/:4?Y/Q_X >SK_P _X'Q'_P /]?@S_P!"K\;?_" O_P#X
MFC_A_K\&?^A5^-O_ (0%_P#_ !-?;FT?W31M']TT>TH_R?C_ , /9U_Y_P #
MXC_X?Z_!G_H5?C;_ .$!?_\ Q-'_  _U^#/_ $*OQM_\("__ /B:^W-H_NFC
M:/[IH]I1_D_'_@![.O\ S_@?$?\ P_U^#/\ T*OQM_\ " O_ /XFC_A_K\&?
M^A5^-O\ X0%__P#$U]N;1_=-&T?W31[2C_)^/_ #V=?^?\#XC_X?Z_!G_H5?
MC;_X0%__ /$T?\/]?@S_ -"K\;?_  @+_P#^)K[<VC^Z:-H_NFCVE'^3\?\
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M444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M&*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,4
M44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,44
M4 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*
M,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M &*,444 (W2N2U+_ )"-Q_UT;^9KK6Z5R6I?\A&X_P"NC?S- $-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %;7A'I<?\  ?ZUBUM>$>EQ_P !_K0!LJ.*
M7%(O2EH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48
MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
M,48HHH ,48YHH[T <7V_"BCM^%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &UX1Z7'_  '^M;*CBL;PCTN/^ _UK97I0 N*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,44
M4 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*
M,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,
M444 &*,444 !&:-M%% !THHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ****  ]*3^#\*4]*3^#\*0'\YW_!=+_E*C\5/][2O_ $TV5?)-?6W_  72
M_P"4J/Q4_P![2O\ TTV5?)-?U/PO_P BC#?X(_D?S7Q!_P C*M_B84445[QX
MX4^WF:VF21&97C8.I4\Y'/X<XIE7O"OAVZ\8^*--T>QC6:^U6ZBM+>,G >61
MPB#\6(_7TJ*LH1A)U-DK_(JG%RFH0W;/?%_X*T_M'H H^+OBS..@F0;OIE!T
M[]<4'_@K5^T@/^:P>+.>#^\C/_LI_/@U^RG[(G_!%+X'_L[_  YT^TU[P?H7
MC_Q3)!&^IZGKML+V.XF !?RH) 8XX]VXJ-I;! 9FP*]H3_@G]\!77/\ PI/X
M1MGG/_"(Z?S_ .0J_',1QQD<*CA3P?,N]HK]#]4PW!^<3I*53%.+?34_FS^,
MW[3_ ,1?VA_LX\=>./%'BR*T<RV\&J:C)<00.1@LD;,55L''RKGD#ITX4=/6
MOZ@+W_@G]\!HX6*_!3X2KC!&/".G]1_VR[?UK^7]1@5]EPCQ-A\SYZ>&H^S4
M+/==;]K=CY/B?(*V6\LL15Y^;U_4****^T=KZ'RS"OUO_P"#6+_CY^.?^[H/
M_N2K\D*_6_\ X-8O^/GXY_[N@_\ N2KXGQ"_Y$E3UC_Z4CZO@C_D<4_G^1^O
M"_TI:1?Z4M?SB?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "-TKDM2_P"0C<?]=&_F:ZUNE<EJ7_(1N/\ KHW\
MS0!#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6UX1Z7'_  '^M8M;7A'I
M<?\  ?ZT ;*]*6D7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=Z*.] '%
M]OPHH[?A10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!M>$>EQ_P'^M;*
M]*QO"/2X_P" _P!:V5Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%?;/<^4>X5^M_\ P:Q?\?/QS_W=!_\ <E7Y(5^M_P#P:Q?\?/QS_P!W0?\
MW)5\1XA?\B2IZQ_]*1]7P1_R.*?S_(_7A?Z4M(O]*6OYQ/Z "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5R6I
M?\A&X_ZZ-_,UUK=*Y+4O^0C<?]=&_F: (:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *VO"/2X_P" _P!:Q:VO"/2X_P" _P!: -E>E+2+TI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *.]%'>@#B^WX44=OPHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH VO"/2X_X#_6ME>E8WA'I<?\!_K6RO2@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!KGFN3U+_D(W'_ %T;^9KJIC@_SKR/
MXA_M0?"/X:^,K[1?$WQ8^'GAO7+1E:YT[4_$%G:W5MO42+OBDE5URC*PR!D,
M"."*JG2G4?+33;\E<SJ5J=./-5:2\W8ZRBO.?^&V/@+_ -%T^$O_ (5>G_\
MQZC_ (;8^ O_ $73X2_^%7I__P ?KH^HXG_GW+[G_D8K'8;_ )^1^]?YGHU%
M><_\-L? 7_HNGPE_\*O3_P#X_1_PVQ\!?^BZ?"7_ ,*O3_\ X_1]1Q'_ #[E
M]S_R#Z]AO^?D?O7^9Z-17G/_  VQ\!?^BZ?"7_PJ]/\ _C]'_#;'P%_Z+I\)
M?_"KT_\ ^/T?4<1_S[E]S_R#Z]AO^?D?O7^9Z-17G/\ PVQ\!?\ HNGPE_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%%  >E)_!^%*>E)_!^%(#^<[_@NE_RE1^*G^]I7_IILJ^2:^MO
M^"Z7_*5'XJ?[VE?^FFRKY)K^I^%_^11AO\$?R/YKX@_Y&5;_ !,****]X\<*
M!U'?M_G_ ".G7CDK7^'_ (-N?B+X]T3P_9\7FO7\&GP$IN_>2R*B_+GYOF8<
M'BIJ5(TX<\^EV73C*HU3ANW8!\0/$#'(UO6&9N?^/R3+'\\\]N*4_$'7MQQK
MFL?^!D@/X@FOZ8/V2/V#_AM^QG\.-.T3PKX;TN.\M[=%O-8EME:_U*4 ;I)9
M2-V68%MH(12V% '%>H_\)KX?B++)JVD(RD@@W,8Q^9K\=Q'B-2=1K#852CWT
M_1,_4J/ M7DB\1B7%M;?TS^4X?$/7@>-<UC<"#D7CY7T_BSZC\:QP HPN-HX
M !R /;M^(ZU_6%?>-_#KPMC5M() S@74>1[]:_D]*LAVLK*P !##!S[U];PG
MQ'+-75C*A[+EY=NN_DCY;BC(5EZA)5O:7"BBBON)7OJ?*/R"OUO_ .#6+_CY
M^.?^[H/_ +DJ_)"OUO\ ^#6+_CY^.?\ NZ#_ .Y*OB/$+_D25/6/_I2/J^"/
M^1Q3^?Y'Z\+_ $I:1?Z4M?SB?T %%%% !1110!')/Y;8]L\"O'==_P""C/[/
MOA?6[S3-3^.GP=T_4M-G>UN[2Y\::=#-:S(Q5XW1I@RLK @J0""""*]@N!N;
M'J,<CU__ %5^!W[1W_!K-^T%\8OVB/'GBW3?%_P;ATWQ1XBU#5[6.ZU744GC
MBN+F29%=5L&4,%?! 8C/>N_+Z&'K2:Q%3E1PXZO6II>PAS,_84_\%-?V<.W[
M0'P3_P#"XTS_ ./4?\/-_P!G$#_DX#X)_P#A<:9_\?K^6_\ X*!_L ^,O^";
MOQVA^'OCG4O#.JZU-I4.KB?0IYYK7RI7D106FAB;<#$V0%(P1SG('K?_  3K
M_P""&GQ:_P""FGP5U3QWX#\0?#G2=(TG6Y=!FAU^_O+>Y:>."WG9E6&UF79M
MN4 )8'(;@  GWY\/X.%)5Y5WRO9V/'CG&*E4]DJ?O(_I=^$G[8_PF^/WB2;1
M? ?Q0^'?C;6;:V:]FL-!\1V>I7,4"LB-*T<,C,(PTB*6(P"ZC.2*]&,I4C..
M:_*7_@AK_P $-/BU_P $S?VL_$7CSQYX@^'6KZ/JWA&YT&&'0;^\N+A;B2\L
MIU9EFM8EV!;9P2&)R5X()(_43QOXRTWX;^#-8\1:U=1V.D:#93:A?7#GY8((
MHS)(Y]@JD_A7SN,HTJ=7DH3YUIJ>YA:U2=+GJQL[G!_$C]N?X+?!OQE>>'?%
M_P 7_A;X5\0:>$-SI>K^*K&QO+?>BR)OBEE5UW(RL,@9# C((K:^#W[4'PY_
M:)-__P *^^('@CQS_9/E_;_^$?UVVU/[%YF[R_,\EVV;MC8W8SM;&<&OY#_V
MKOC[J_[7_P"T_P"./B)J$5P^H>,M7NM36W(+M:PEB8H!U.(H@D8Z\)[5];?\
M&W?[6_\ PS)_P4ET30KZY\GP_P#%*W;PO=!CA$NF826<F.[^<JPCT%RYKZ"O
MPQ[/#.MSWDDG8\6GQ Y5N1QLKVN?TZ!R5KA?C-^T_P##?]G+^SO^%A?$#P3X
M%_M<2FQ_X2'7+;3/MHBV>;Y7G.N_9YD>[;G;YBYQN%=Q&=R&OQ%_X/'1B;]G
M4^@\2X]O^01_A7S^7X58G$1HMVN>SCL0Z%%U(JY^OWP;_:K^&?[1-U?6_P /
M_B)X%\<SZ6BO>Q^']>M-2>S5B0AD$$CE Q5L%L9P?0UV/B#Q%9^%M$O-3U&\
MM-/TW3H'N;JZNI5A@MHD4L\CNQ 554$EC@  GI7X;?\ !GI)M^(WQVY_YANC
M  G_ *:7F,?I47_!RM_P6''C?5=0_9S^&VJ?\2?3IMGCC5+63(O)T.?[,1L@
M;$;!EP<LX$? 20/Z$LED\=]4I.Z[G''-HK"_6)K770_6G_AYW^S?M!_X: ^"
M?/\ U/.E\?\ D>O:/#WB"Q\5Z#9:II=Y::EINI0)=6EW:RB6"YA=0R2(ZDAD
M92"&!((((XK^>7_@WL_X(LM^UIXPL_C/\3M+W?#'P_=9T;3;F(F/Q3=Q'!+(
M1A[2)EPV1B1UV<JL@K^B*%0D6 "!Z8KCS+"T<-5]E3ES-;F^7XBM7A[2I&RZ
M$@.:* ,45YYZ!P'QE_:K^&/[.U]8VOC[XC> _ ]UJB-)9P^(-?M-,>Z52 S1
MB:12X!(!*YP2*XU?^"FW[-[KD?M!?!'_ ,+G3/\ X_7Y&?\ !X0VWXW_  4_
M[ >I_C^_MS_05\6_\$X_^"*_Q2_X*=_#SQ!XF\!:]X!TNQ\-ZB-,N4\07MY!
M-)*8UD!3R;68%<,!DD$'/&,9^EPV2X>6%6*KU.5/R/G\1FU:.(>'I0YFC^D1
M_P#@IO\ LX*1_P 9 _!'G_J>=,_^/UZ;\,/C!X5^./A"'Q!X)\3>'O%VA7#/
M'%J.C:C#J%H[H=K*)869&*D8(!X-?S\'_@TC_:/_ .AU^">,'_F,:G@_A_9_
M_P!?Z5^PG_!';]B;Q9_P3[_8@T7X;>--0\/ZEKVGZE?7DL^C3S3VK+/.TB@/
M+%$Y(!YR@YKBQ^#P=&GSX>MSOM8[,'BL54G:M3Y4>^?%;XY^#?@9H?\ :?C3
MQ;X9\'Z:Q(%WK>IP6$!(Q_'*RKW'?N/45X/JW_!:S]E;1=1CM9OCEX#:20X#
M07;7$0XSS)&K(#QCENO'4XK\UO\ @O1_P39^-G[??_!573+3X;^#=2U32X?!
MNGPSZU=DVND6+?:+LL'N'&P,,@^6FZ0@@A>F?,/$O_!I+\<M'\ 2:A8>//AM
MJVOPPLYTN*6[B69@.$CG>( L>@WJBYQE@,D=6&RW >RC/$5K.71=/4Y\1CL6
MJDHT:=U'J?N[\$/VI?AS^TOI5Q??#WQQX3\:6MF0MRVC:G%>&U8]%D5&)C)'
M(# $C!'!&>\60D?2OXS?AG\3OB!^Q9\>UUKPWJ6K>"?'7@V_EMYGC/E36TT4
MA2:"9"-KKN5D>-@5< @Y&<_UQ_L3?M"+^U?^R1\._B1]E2QE\9:#:ZG<VR$L
MEM.\8,T:G)RJR;U!ST KGS?)W@K3C+FC+8URO-%BDXM6:/4"QR?TKE_BQ\;?
M"'P&\+C7/''BOPSX-T,S+;_VCKFIPZ?:^:V2J>;,RIN.#A<Y.#CI6AX^\<Z3
M\,O!^J>(M?U&STC0]%M9+V^O;J01PVL,8+,[,>@"@DFOY@_^"OO_  4G\6_\
M%9?C]JUUX=T_55^%?PXMYKC2-/5#^ZM=Z1R:C=CHLDSO"@!X0-&@R^YGQRO*
MY8RI:]HK=_Y&N89C'"QN]9=$?T>_#W]O'X)?%KQA9^'?"OQB^%GB;Q!J+,MG
MIFE>*K&\O+HJA=A'%'*SMA59CM!P%)[5ZO&^X?C7\K?_  ;VKC_@L/\ !I?^
MGC4^0,9_XE-[_B?SK^J1/E/Z49OERP554E*]PRO'2Q5-SDK6'449HKRST@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM4E>H_2G&[/U"^(_[47P[^$,+/XH\<>%?#_7"W^IPV[MCL%9@2?8<U\^^/\
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MN5C\3?#7XO\ AG/5[W18PH_\B[CW[5]^?9U/&WBJ]YX?L=0C99[6"96ZAU#
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M <EXMCED:M#"8=5(.3:;WMT3LF?M&:<,O'^RJXFO[.=DFNGJ?RRGX?:\5_Y
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MN5FU2[BDG*7NOK#AWLK=N3YKJQ8DG<(TE8988KTO_@AK_P $JO#?_!4'Q?\
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M[, .36#^UW^VE\._V&/A#=>,_B1X@M]$TN -';0#]Y=ZE,!D06\0.9)#CH.
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MZI'I^HR:60Q\7:H'PEM$P/S6T3C[W*/(I;E(T<^Y_&;_ ()6Z)_P3&_X-_\
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M_;,_X=^?L:^,OBW_ ,([_P )9_PB?V(_V4;_ .P?:_M%];VG^N\N39M\_?\
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MPJ1=G&2LT_,E4Y%+35IU:'*%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 'I2?P?A2GI2?P?A2 _G._X+I?\I4?BI_O:
M5_Z:;*ODFOK;_@NE_P I4?BI_O:5_P"FFRKY)K^I^%_^11AO\$?R/YKX@_Y&
M5;_$PHHHKWCQPK5\"^+KSP!XWT77=-P-2T6]AU"TR,_O89%=?KA@,Y['ZUE5
M<\/R"+7K)F8*JW$;')P.&&">V![\#.?3&6(C>E)=+/\ (UHZ58J]G=:_,_>O
M_@I7X_U_]L#_ ((]:IXF\":;XAM+K6K>RN]0T@021ZA' MR@NK5TX8["#N &
M'2,XRK U^&W_  S_ ./._@GQ=_X)KC_XBOZ:K3]K_P"$:0H/^%G_  ]&T8Y\
M1V?'_D2I%_:]^$2?\U0^'9^OB.S_ /CE?@&0\3XG*J4Z-/"\R<KJZ>GX'[5G
M'#V'S*4*L\3RM))V:_S/YD1^S_X\#9_X0CQ=QZ:/< @YX_A^O>N18\_C7]2U
M_P#M>?"-K=O^+G_#S&,?\C%9_P#QROY:0, <8X''7';KW^O-?I_"G$U;-G55
M6C[/EMWU_!'YWQ-D-++.5T:OM+^F@4445]M+<^5EN%?K?_P:Q?\ 'S\<_P#=
MT'_W)5^2%?K?_P &L7_'S\<_]W0?_<E7Q'B%_P B2IZQ_P#2D?5\$?\ (XI_
M/\C]>%_I2TB_TI:_G$_H **** "BBB@ IIX/Z^].H(S0!^"?_!R7^P;\:/VD
M?^"AMGXB\ _#'QIXPT./PC86;7VDZ5+=0+,DUT6C+*" P#J2.N&'K7VE_P &
MQW[.WCS]F3]@[Q=H/Q"\(Z]X-UF\\?7E_!9:O9O:SRV[:=IT:RA6 )0O'(H/
M3*$=J_1C8*7;BO4KYM5J82.$:5H_>>=2RV$,2\2GJSE/CIX[U#X9?![Q1X@T
MC1+_ ,2ZMHNE7-[8Z18PM-<:G/'$S1P(J@DL[A5'^]7\MVG?\$FOVI_C_P#'
MB&;Q'\)/B/8WWC37Q+JFLZAH<\<%O+=7&9KJ5F7"J&D:1B<  $]L#^KMT#-3
M3"&'3^M3E^:3P<9*FOBZCQF7QQ+7.]$>9^!?V-?A;X#\%:3H5G\/_!S6>C6<
M5C;F31K9Y#'$@1=S%,EL*,D\D\U\Q_\ !:__ ()IZ'^TO_P3S\8Z7X!\!Z)'
MXXT$PZYHJ:3I,4=U=2P-^\@7RU#.9+=ID51U=D]!7W4 $H<*U<M+&585553U
M3N;U,+3G3=-KI8_FQ_X(]_LI?M,_L/?\%#?A[XVOO@C\4K+P[/>?V)K[MH5P
M(UL+H>3)(_R_<B)2?MS".M?:G_!T]^R3\3OVIV^!/_"N/ ?BCQK_ &'_ &^-
M1_L;3Y+O[#YW]F^7Y@0$C=Y3XR!G8U?KP(Q^5'DKMKT*N=5*F*CBG%)Q.*GE
M,(X=X=2=F?CE_P &MO['GQ3_ &7/'OQDG^(OP_\ %?@J'6K'2HK!]8TZ2U6[
M,<EUO"%@ Q 9"0"<;O>O??\ @O[_ ,$CE_;_ /@=_P )KX+L$;XM>!;5VL4C
M&)-?L@2[V3'C+J=TD.3]\LG D+#]$-GMVQ1Y*C!QRO QVK"IFM66*^MQTD;0
MRZFL/]7EJC^7W]@C]F[]LS_@GU^TOH?Q&\(? OXI--IS?9]3TQM#N$M]8LG9
M?-M9,*1A@,JP!V.JL!D8K^F;X9>,O^%D_#S1?$']EZQH;:O:1W9T[5K0VM]8
MEUR8IHFY2122K $C(X)&"=SR@6#8^Z<CBG1C8,<X'J:>8YC+&24Y12:[#P.!
M6%7*I-@(^._XG--=0K9]L\=ZD!S01FO-1WGX+?\ !Q1_P3F^/OQ0_;TN/BE\
M/OA]XJ\3>&VTC3[>WO\ PZIN[N">!6#?N(29UVG!W!,<C!R"!\/1?'/]MBRT
MN3PPGB;]IN&'>8FL/M6M+(.,&/;][!SS&>.>G//]9&W;WY^M)M_SFOH,+Q![
M*DJ4Z49<NS9X=?)8SJNI&;5^B/Y8?V0/^"#W[2G[9/CKR[[P7KGP]T;S ]]K
MWC2SGT\8;YB8X95$UPQ'3:I3. SKG-?TB_L2?L@>%_V$OV9_#/PS\)*[:;X?
M@/G7<H GU&Y=B\]S)C^*1RQQT4;5'"@5ZP8PXP5XQBG; #T-<F99Q6QB49)*
M*Z(ZL#EM/#/F6K[G\[?_  7?_8H_:6_:>_X*5^.M4T/X=?$[QIX)T\6-MX=N
M+73[B\T^WA^PV[2I;\%%4SM,6"\%RWX?*_P__P"";W[8GPFUUM4\*_"?XW>&
M=3:)H&O-)TZ]LKAHVQN0O'M8J<#()YP*_K+VX' HQ7;A^)*M*DJ,8)I')6R.
M%2HZKF[G\M/_  SG_P %"@/^0/\ M2^G_'YJ_'_C]?L[_P &ZW@CXQ^!_P!B
MGQ5:?'"U\>6OBJ7QM=RVB>+I+B2]-D;&P"%#<$OY7F+, !QN#]\U]]!0:7;B
MN7'YS/$TO9N"CZ;G3@\KCAZG.I-^HWRQ^-?*7_!;GX=Z]\5/^"7/Q:\/^%]"
MUCQ+X@U+3[9;33-*LY+N\NRM];L1'%$K.Q"J20H)P#7UAC!IK#<._P"%>30J
M<E2-2/0[ZM)5(.#ZG\UO_!#']A?XV?"+_@JM\)_$/BOX._%'PQX?TV;4/MFI
MZMX2OK.SM@VEW:(7EDA5$R[*H)(R6 ZU_2A%T^7[HIWE*W^/2CR]OY]Z[,PS
M">,J*<U:RL<V P,<+!PB[BJ<TM HKA1W!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?"7_  <F+C_@CY\4&_B%QHW_ *=K
M.ONVOA/_ (.3.?\ @CQ\4?:XT8_^5:SKLRW7%0]4<N._W>?H'_!MEQ_P1X^&
M!_Z>=9[_ /46NZ^Z)/F!^E?"_P#P;:?\H>/AA_U\ZS_Z=KNON@\_E1F7^^5/
M46!_W>'H?A5\=1G_ (.[- 7M_:6E<?\ <OQU]\_\'&JX_P""-?QA_P"X+^NN
M:?7P-\<^?^#N[P__ -A+2O\ U'HZ^^O^#C8Y_P""-?QA_P"X)_Z?-/KUZT5[
M;">D?S/,H_PL1ZO\BA_P;;,1_P $>?A=C'_'QK';_J+7=?2G[7/[;_PR_89^
M'*^*/B=XKT_PWI\[-%9Q2!I;K490,F."% 7D8<9VC"Y!) YKYI_X-N3C_@CQ
M\+3Q_P ?&L 9_P"PM=U^=OP]\!I_P7B_X+U^-K?QW<W%]\+/AO\ ;1%ID<[P
MI-IEE<+;00(RG*>?/(L\F"&(,H!4A2N$L+"MC*LJLK1C=OOZ&L<3*CAJ2@M9
M62/L*+_@[._9JDU[[(WAWXO1V^\C[<VBV/D%><-C[;Y@!]TS[5]M?L=?M\_"
MO]O;P+=>(/A=XJM_$5KIKI%J$!MY;:ZT^1P2J30R*KJ3M;!Q@[3@G%6D_8/^
M"*>#4\/'X0_#-M#C4*M@_ABR:WX &2AC()P.IY]ZXW]F#]@3X2_\$SX_B=XD
M\ 65]X>T'Q4L.KZIIC7!GL]/%I%,2;<,-ZJ5=B49V P NT<5QUGA)P:HQDI=
M+NYTT_K4)7JM->1<_;F_X*=_![_@G;X?M;KXE>)DL]2U)"^GZ+8Q&ZU2_ ."
MR0K]U>#\\A5/E(W9&*^.?"'_  =J?LY^(=?-KJ'A?XK:'9R.!%>W&EV<T87(
M!+K%=NZD9Z*'X![\5\4?\$NOB?\ !7]M_P#;G^*'[0G[67C;P3:WT-Y"WAKP
M[XEU&&.T+.SE?W3MAXK2*.*)%8,K&1F.63-?J7\7/VO/V%_CM\,+GP;XJ^(7
MP'UKPW<0?9OL,NHV8CMU/"F+:08F7JKH593R"#7HSP-"@U2JPE*6EVM$O3N<
M:QE:K><)QBET>[_R/J/X'?'SPA^TI\,M-\8^!?$&F^)O#>K)OM;ZR?=&V.&5
M@<,CJ>&1PK*000"*\B_:(_X*E?"K]E_]K+P/\%O%5YK4/CCXA?8/[(CM].::
MV87MY)9P;Y<@)F:)P<]!@]Z_-'_@V+^*J_##]MOX_? G0/$D?B;X?6IN]:T"
M\BD66"\%I>QV8NXG7Y3Y\$L!8C/$2=.<\;_P<8_#B\^,O_!<#X >$--UR?PW
MJ/BK0/#NC6FKP!O-TJ6XU_4(4N4"LK;D9PZA64DJ.0<$94\JA]=>'G+W>5M/
MKM?4TJ9C-855DM;I>6Y^F/[4G_!=']F?]D;Q?>>'/$WQ$M]0\2:>WEW.F:'9
MS:G);OD@H\D2F%)%P<QM('']T5Z%X7_X*2?"WQ7^PZ?VB(=4U&'X9K:SW;7<
MNGR_:0L-T]HX\@ OGSD*@8YR#T.:\2_9V_X-W?V7?@;X ATG5/ <?C[5V3%]
MK/B&XDGN+ISR=J*RQQ+R>$4$C[Q8\GZ+B_8>^%>G_LP3?!:W\'V-O\+IHY8G
MT".>=;?9)<M=.H8/O"F9V8J& YQ]WY:X:WU-6C2YGW;Z^AU4_K3NZC2[?\$^
M%O$W_!VK^SCHNI-!9>%?BYJ\*2!6N8=)L8H67."R^9>*_N RKGN17NG[%7_!
M?#]GG]N7QW9^%/#^N:SX7\5ZE*(;#2/$U@+*:_<@G9%(CR0ES@@(9 [$?*&Z
MUROBS]K+_@GG^Q-N\-R7GP1T>:TQ#-;:%X>CU::-@=I$K6<$S;P2<[SN!ZU^
M4'_!<7]I?]E3XZ^)/!/C;]FO9H?CK3;V8ZS<:1H5QH4-S&NUX;CE(P)TD7B1
M%WD,-Q^5<>M0R^AB/=A2G&^S;T/-K8ZM07-.I%]T?OS^VO\ MJ>!?V#O@LWC
M[XA7&HV_AX7L.G^98VAN9/-EW%/D!'&%8YS7X.?\&_W_  5#^%/_  3F\8_&
M2\^)-WK=I;^-#IO]F"PTYKLM]G>^9]P'*X$Z8XYR?2OWS^'FB:/^TK^S%X)N
MO'.@Z'XFCUS1=/U:YM-3L(;NW-P]NDA<1NI3<&=L$#OQ7XU_\&JWP+\$_&'Q
M_P#M!Q>+?!_A;Q1'I9T8V::MI-O>K:EI-1W>6)$;9G:N=N/NCTK/+O8QPM=5
M5>UMGYFF.]K+$4I4VM3]1/V$_P#@K=\'O^"C7B[7]$^&MYK]Q?>&[)+V]&H:
M8]FJQ.^Q<,2<G/;J!7GO['7Q\_9-\>?\%#/B%X+^%_@;2]%^-7A:35E\0ZG%
MX>6TDE>&]2WN_P#21S(6G<'_ &L$U]8?#7]GCP#\&KNXNO!_@GPCX4N+Q!%/
M+H^CV]B\R@Y"LT2*6 ))P>,FOQI_X(QC_CI,_:DY8;KGQEGG_J8K>N7#T*=6
M-:5.\4HWM?SZG36K5*<J4:B3;E8_3#]I7_@K'\(OV0OVF_#/PG\=WFN:1XD\
M7"S;3KC^S6?3W6YG:"-FF!PJB1'#$CY=I)XKZ760LM?EO_P=1?L;-\9?V-=&
M^*NDVK/KWPGOMUT\0Q(^EW;QQR].3Y<PMG'/RKYQ[FOK/_@D?^V$O[;_ /P3
M\^'OCB:Y2XU[[ -*UX%OF34;;]U,S#MYA43 ?W)EK"MA8+"QQ--];/R?_!-:
M>(G]8E1GZHZ[]N/]O?X>?\$\_A39^,/B1J%Y9:3J.HII=JMG:FZN)YV1Y,+&
MO) 6-B3VP/6NY^!GQKTO]H3X/>&O'&@PZA#HOBS3XM4T];ZW-O</;RJ'C<H<
MD!D*L/9ATK\<?^"SNHWG_!4+_@LY\)/V8=%N)G\.>"WC?7W@./(>=%N[V0GI
MF.RCB5,]'=QU.#^@_P#P5^_:BNO^"??_  3.\9^(_!JQZ1K-G96WA_PX(D 3
M3Y9W2W1XQRH,,1DD48(S$H((XK6>!2C2IKXYZ^B>QE#&2<JDW\$?SZG/_MS?
M\%]OV??V#O&=YX7US5]8\7>+M.8I>:-X8M8[J6Q<8^2:622.%'&?F3>77NHK
MSW]G?_@Z"_9K^.?C&QT'56\8?#N\OI?)%WXDL(H].C<G"[YX99/+4G WR*BK
MSD@#-?,O_!!RR_8]_9N_9RT_X@_%#XA_"FZ^,WBR6>[O/^$AU.VEN= A\YA%
M!&DI(CD95$K/@.3,5SM4"O7?^"Q_Q+_8S_;3_8Q\;+9?$?X-W7Q&T'2;C4O"
M][8ZG:#4WNX5,PM(V4[G6X\ORBAR"7!QN52.[ZCAH5/8SA-].9;7^[8Y5C*[
MA[;GCWY?+S\S]4--U"'5;&*YMYH[BWN$$D4L;!DD4C(92.""".1UJ>OSV_X-
ME_VB-8^/G_!,'2[/6KZ34+KX?ZW=>%H)9>9%M8HH)X(R<\B.*X6->F%C48XK
M]"0<BO%Q6'="K*DW>S/7P]95:2J+J9OB[Q+9>#/#>H:QJ5Q':Z=I-K)>W<S_
M '88HU+NY]@H)K^?G]G/X:^)O^#E#_@ICXI\6^/-2UC3?@WX!_>1V%O,8C9V
M4DC"TL8NH2:81L\T@&3Y;D;<1A?V(_X*^:_>>%_^"8WQTO+$RBX/@V_@S']X
M++$8G(^BNQ^E?%?_  :*>&+.T_87^(FLQJO]I7WCN6TG<#YFBAT^R>,'V#7$
MO'N:]3 2]A@JN+A\5U%>7<\W'?O<5##2VLV??_PB_P""?/P.^"'A6'1_"_PE
M^'^DV<"",D:);S3S8Z&69U:25O\ :D9F/K7A'[;O_! ;]G?]L3PQ=_8_"&F?
M#;Q8T;?9->\+VB6)CEQP9K:/;#.N>6#*'(! =<DU]M(-HQZ421B3K7EPQ=:$
MN>,W?U/0EA:,H\LHJWH>>_LH_"*Z_9W_ &7OAOX O+RWU"\\#^%],T"XNX%*
MQ7$EI:Q6[2*#R%8QD@'G!YYKY8_;4_X.'OV>?V+/'>H>$[S4=>\<>*-)E-O?
M6'ABTCN5T^89_=S3RR1Q!@00RH[LA&"N>#Z'_P %G?VJ]6_8L_X)R?$7QMX=
MF6W\2+:PZ5I,Y.&MY[N>.W\Y3_?B21Y5]6C7@YKY%_X-N_\ @F!\.M._8XTC
MXT>,/#>C>+/&WQ FNI[6?5+9;Q=(LXYVA6.-) 5$CO"\C2 ;B)%7( .>S"X>
MFZ+Q6(NU>R2TNSEKUZBJQH4++O?L>J?LK_\ !S'^S?\ M,>-K/P[?S^*/ASJ
MVH2""WD\36D4=A-(S85?M$,LBQY_O3"-<\9Z9_0:-OM42LOW6P00>HZ]:_/?
M_@N]_P $M/AQ^T)^Q'X[\<:3X3T'0_B%\/\ 2[GQ+9ZM86*6\U[#;*9[FWF\
ML#S@\,<@7?DK)M((^8-I?\&W/[6>N?M2_P#!-?2[?Q%<->:Q\.=4E\)&Y=BT
MEU;0P036SL<]5AG6+)Z^3SDY)*^%HU,/]9PUTD[-/IV"C7K1K>PQ%FVKIH^,
M==0#_@\<51]W[3 /K_Q1J#ITK]6O^"B/CKX3?"O]D;Q1XD^-VAVOB'X;:.UF
M^IV4^G#4%D9[N&& ^2?O$321G/;KVK\I]=_Y7'E_Z^8/_4.2ONK_ (.-5_XT
MU_&#_N"]#C_F-Z?75BX\]3#1>GNQ1SX>3C2K-*^K/4OV(?CE\%;K]A*W^(GP
MBT.'PS\)[6WU+5(K2STK[#L%O+,+IQ /XB\,ASU8\]Z_$7Q%_P %/OA5??\
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MGK7/_MG_ /!0CX5_L ^ 8?$'Q/\ %%KHD=\733[&.-KB_P!2=1EDA@CR[8R
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M;MGH7[!W_!;'X$_\%#?$K^'_  9KFH:+XL">9'H/B*W2QO[I=I9O)VR/'*5
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MI>3>[U;\D>^_!;]IG]O[]HGP'#XF\%WGB#7=!NI'BAO8K+3XXYF1MK;0X5B
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M\,^%_#_C;1;V32-6MXK1KS[==^8(T6-"YV\GC#,&R"" <#]3/$GQRU#]E?\
M8GD\<?%#4;.ZU[P]H?VS5Y;>(01W-YL_U,2Y[R,(UYY^7UKV,+F^'Q"DX;1W
M;/RCB;PJSO(HX5XQPE+$NU.,)*3ELD]-.5W5G?J?"_\ P7#_ ."I_C;X*?&O
M0?AI\)_$$VDZMI\"W>NSVL,<TCRS#]Q:@.K<[<.<#/SIZXK[]_8K\,>./"?[
M,7A6#XBZY=>(O&US9B\U>YN$1#%-+ES" BA<1AA'QUV9[U^&7[!_CKPK\7OV
MZ-9^-'QM\2Z5INE^&9Y/%EXEY+NDU*]:3_1K:&/EG"-@[5!P(D7D&ON;P_\
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M?M$^,?V9/B39^*_ ^MWFBZO:D M%\T5TF<F.:,_+)&W=6_ @@&OW9_X)C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\?/QS_W=!_\ <E7Q/B%_R)*GK'_TI'UO!'_(XI_/\C]>%_I2TB_TI:_G$_H
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M2[-ICA5_];Y?0C@5UU,M=-/FJ1NNE]3CIX_G:M!V?6Q^CADY_KUI!-FODO\
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M:I'(@W12>0"#EAO/4*V/U=C_ ."!W[(NX?\ %E=$']W&I:AQT_Z>/85\Z?\
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MD3<A3R171@Y*->$I;)K\S#$Q<J4HKJCP7_@V*/\ QJ6\*_\ 8;U;_P!*FK]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ;7A'I<?\!_K6RO2L;PCTN/\ @/\
M6ME>E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW]RD/E69;9:PYS_%N:0@<_O!G&TU^DUK,MY LD;*R-AE93P1ZC\*^ _V4/\
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M]3\+_P#(HPW^"/Y'\U\0?\C*M_B84445[QXXH4M_>Y.!@9_K_G%?TI_\%/\
M]KWQ%^Q/^QWJGC[PC::'J&L:?>6ELD6JPRS6Q260(Q*QR1L2 >,-^=?S>>$_
M!NJ_$'Q%:Z/H>FWVLZI?%H[>QLK=KBXN3C)5(U!9S@9P 3QQ4_B/7=>\^YT[
M6+W5O-@D*7%K>2RY1P?XD;G<".C#(Z'&*^/XCX;IYKBL/.I-6IMWBU>Z=O/R
M/J,CSZIEN'K1IQ;<TK23V9]^M_P<T_'I3_R*?PD7OC^RM0_#_E]I#_P<U_'H
M'_D5/A+]/[+U#_Y-],U^=8Z< ?A1BNI<%Y(W?ZO'\?\ ,Q?%F;_\_P"7X?Y'
M]+7_  3._:ZU_P#;._8ST+X@>*[70['7-5N+R">'28I(K5%BN)(D*K))(P)5
M5)RW?/ XK^:4C:2"""#SG_\ 7_/FM+3O&.KZ1:I#::KJ5K#&<I'%<NBH>IP
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MH)5FYZ<C@<5>'JRG"IB))-QLEIWZ_(SK4U&5.A%M*6_RZ?,H?M6?L)?M9_\
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M>_\ PDNF_P#HW5*_8)HU5>/X16N9XKDJNC",4M.FNR,\#A^>E[2<F]S\$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"BAH@Q_I3J*5AB*NT4M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\!_K0!LKTI:1>E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1WHH[T <7V_
M"BCM^%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &UX1Z7'_  '^M;*]
M*QO"/2X_X#_6ME>E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU^2__$+KXE_Z*QH7_@A?_P"/4?\ $+KXE_Z*QH7_ ((7_P#CU']H9C_T#_\
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M_P#&OR7_ .(77Q+_ -%8T+_P0O\ _'J/^(77Q+_T5C0O_!"__P >H_M#,/\
MH'_\F0O]1/#[_H?/_P $R/UI7XT^#Q_S,^@_^!T?^-(/C/X/_P"AGT'_ ,#H
M_P#&OR7_ .(77Q+_ -%8T+_P0O\ _'J/^(77Q+_T5C0O_!"__P >H_M#,/\
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M)7C*K6C3M[JU?GY'TVARM+34/%.KS%L>B%%%%, HHHH **** "BBB@ HHHH
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M63U<RPGL*32=[ZG\W7'K1QZU_0L/^")7[)^/^27W'_A1ZK_\ET?\.2OV3_\
MHE]S_P"%)JO_ ,EU^G?\13R[_GU/\/\ ,_//^(<8_P#GC][_ ,C^>GCUHX]:
M_H6_X<E?LG_]$ON?_"DU7_Y+H_X<E?LG_P#1+[G_ ,*35?\ Y+H_XBGEW_/N
M?W1_S#_B'&/_ )X_>_\ (_GIX]:./6OZ%O\ AR5^R?\ ]$ON?_"DU7_Y+H_X
M<E?LG_\ 1+[G_P *35?_ )+H_P"(IY=_S[G]T?\ ,/\ B'&/_GC][_R/YZ>/
M6CCUK^A;_AR5^R?_ -$ON?\ PI-5_P#DNC_AR5^R?_T2^Y_\*35?_DNC_B*>
M7?\ /N?W1_S#_B'&/_GC][_R/YZ>/6CCUK^A;_AR5^R?_P!$ON?_  I-5_\
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M2Z/^(IY=_P ^Y_='_,/^(<8_^>/WO_(_GIX]:./6OZ%O^')7[)__ $2^Y_\
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M_"DU7_Y+H_XBGEW_ #[G]T?\P_XAQC_YX_>_\C^>DD#T]^>G3'^<C&*_1?\
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MS?TIU%#UW  NVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H(S110 TQ
M_P#ZJ/+Q3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3UC_ .E(^LX(_P"1Q3^?Y'Z\+_2EI%_I2U_.)_0 4444 %%%% !363?UIU%
M#! M*(\+CFG44 &**** "@C/K110 =J;LIU% !CBCI110 A&32D9HHH ,<T$
M9%%% #0F!2[:6B@ Q32F33J* &F,-35MU7^]USUJ2B@!%392T44 )M^;-+11
M0  8%%%%*R ,4 8HHI@ &****-P"BBB@ HHHH ****+ !&31BBB@ QQ0!BBB
MBW4 (R*3;2T4 -*9[FA8]O\ GK3J*  <4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 UQ7*:B<:C<?]=&_G76-TKDM2_P"0C<?]=&_F
M: (<_P"<T9_SFBB@ S_G-&?\YHHH ,_YS1G_ #FBB@ S_G-&?\YHHH ,_P"<
MT9_SFBB@ S_G-&?\YHHH ,_YS1G_ #FBB@ S_G-&?\YHHH ,_P"<T9_SFBB@
M S_G-&?\YHHH ,_YS1G_ #FBB@ S_G-&?\YHHH #S1T__5111Y@%%%% !111
M0 4444 %%%% !1110 5M>$>EQ_P'^M8M;7A'I<?\!_K0!LKTI:1>E+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1WHH[T <7V_"BCM^%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &UX1Z7'_ ?ZULKTK&\(]+C_@/]:V5Z4 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE<EJ7_ "$;C_KHW\S7
M6MTKDM2_Y"-Q_P!=&_F: (:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V
MO"/2X_X#_6L6MKPCTN/^ _UH V5Z4M(O2EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ H[T4=Z .+[?A11V_"B@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#:\(]+C_@/]:V5Z5C>$>EQ_P !_K6RO2@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M '=!_P#<E7Q/B%_R)*GK'_TI'UG!'_(XI_/\C]>%_I2TB_TI:_G$_H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$;I7):E_R$;C_KHW\S76MTKDM2_Y"-Q_UT;^9H AHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K:\(]+C_ (#_ %K%K:\(]+C_ (#_ %H V5Z4M(O2EH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ H[T4=Z .+[?A11V_"B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#:\(]+C_@/]:V5Z5C>$>EQ_P'^M;*]* %HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ /2D_@_"E/2D_@_"D!_.=_P72_Y2H_%3_>TK_TTV5?)
M-?6W_!=+_E*C\5/][2O_ $TV5?)-?U/PO_R*,-_@C^1_-?$'_(RK?XF%%%%>
M\>.=!\)_%47@;XI>&];N-WD:/JMK>R;5W?)',KMQ]%Z=Z_HG_P""LO[-^I?M
M=?L#>+?#OAV);[7H8H=9TF)/G^U2V[B4QIC.7DC#HH[LXYQFOYN/?G@=OS_'
MH/SK]ZO^"(7_  4LT3]IOX%:/\./$6HPVOQ&\'VB6213R@/KEG&H$=Q%G[SK
M& )%Y(*[CPWR_F/B%@\3!T,TPRO[%ZZ=-'?T/T'@7%49^WR^L[*HK)OOM9>9
M^*W[-OQTU?\ 9*_:&\/^.-.TZVNM;\)WAE2ROT=8S)L>,JZ@JW&XYP1@CGTK
MV7]OK_@J5XV_X*3Z1X5T7Q!X9\/Z;)H-[)-9+HR3--<R3*J;-KNV3Q@;>_KG
M _<#]H__ ()C_ G]K'Q#)K'C;P!INH:U*FV74+2XGL+F8@$ R/;R(9" >/,W
M=O05-\ /^":?P+_9<\20ZOX+^'6DZ9K$*,L.H7$DU]<Q;N6*RW#R,I/(R"#@
MD#@D5XM;Q RNK..-GAFZ\59.^B^?S['KT>!\RIQ>$A72HR>NFY@_\$G?V:M3
M_9 _8(\'^&_$:0VNNR13:OJD><"UEN':;RV)_BC0HC'IN1L'&*_G4^,/B:'Q
MK\6_%&L6S;K;5M6NKV$XZI),SC]&K]U?^"V'_!2;0_V4_@-JW@/0=2AG^)'C
M*U:QBMH)=TFC6TJD/<R8^ZVPD1J>68A@&"G/X#@[@#_> /'3\*]GPYPF(J/$
M9GB/^7KT\];W/*XYQ5&"HY=1VI+7UVL%%%%?IY^>+8*_6_\ X-8CBX^.?^[H
M/_N2K\D*_6[_ (-96Q/\<^@^70>3_P!Q+M7Q/B%_R(ZGK'_TI'UG [_X5Z?S
M_(_7@-2[O8TP,2.E&3_M5_-Y_0&H_=[&C=[&F9/^U1D_[5,-1^[V-&[V-,R?
M]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&
M[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-
M1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)
M_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,
MR?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V
M-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J
M@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\
M:HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V
M-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^
M[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?
M]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?
M]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&
M[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-
M1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)
M_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,
MR?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V
M-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J
M@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\
M:HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V
M-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^
M[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?
M]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?
M]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&
M[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-
M1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)
M_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,
MR?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V
M-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J
M@-1^[V-&[V-,R?\ :HR?]J@-1^[V-&[V-,R?]JC)_P!J@-1^[V-&[V-,R?\
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M]C1N]C3,G_:HR?\ :H#4?N]C1N]C3,G_ &J,G_:H#4?N]C1N]C3,G_:HR?\
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MWESI^H6D@F@N;:0Q30N#D,K+@JP/.1@YQZ"JM%3**DK2V'&3B^9;GV+\)/\
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MI7^-'_#N/]IG_H][QQ_X0FE?XU]P8HQ1]<J_TE_D'U.G_3/A_P#X=Q_M,_\
M1[WCC_PA-*_QH_X=Q_M,_P#1[WCC_P (32O\:^X,48H^N5?Z2_R#ZG3_ *9\
M/_\ #N/]IG_H][QQ_P"$)I7^-'_#N/\ :9_Z/>\<?^$)I7^-?<&*,4?7*O\
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M\<?^$)I7^-'_  [C_:9_Z/>\<?\ A":5_C7W!BC%'URK_27^0?4Z?],^'_\
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M]IG_ */>\<?^$)I7^-?<&*,4?7*O])?Y!]3I_P!,^'_^'<?[3/\ T>]XX_\
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MWCC_ ,(32O\ &C_AW'^TS_T>]XX_\(32O\:^X,48H^N5?Z2_R#ZG3_IGP_\
M\.X_VF?^CWO''_A":5_C1_P[C_:9_P"CWO''_A":5_C7W!BC%'URK_27^0?4
MZ?\ 3/A__AW'^TS_ -'O>./_  A-*_QH_P"'<?[3/_1[WCC_ ,(32O\ &ON#
M%&*/KE7^DO\ (/J=/^F?#_\ P[C_ &F?^CWO''_A":5_C1_P[C_:9_Z/>\<?
M^$)I7^-?<&*,4?7*O])?Y!]3I_TSX?\ ^'<?[3/_ $>]XX_\(32O\:/^'<?[
M3/\ T>]XX_\ "$TK_&ON#%&*/KE7^DO\@^IT_P"F?#__  [C_:9_Z/>\<?\
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MQ_X0FE?XU]P8HQ1]<J_TE_D'U.G_ $SX?_X=Q_M,_P#1[WCC_P (32O\:/\
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M*/KE7^DO\@^IT_Z9\/\ _#N/]IG_ */>\<?^$)I7^-'_  [C_:9_Z/>\<?\
MA":5_C7W!BC%'URK_27^0?4Z?],^'_\ AW'^TS_T>]XX_P#"$TK_ !H_X=Q_
MM,_]'O>./_"$TK_&ON#%&*/KE7^DO\@^IT_Z9\/_ /#N/]IG_H][QQ_X0FE?
MXT?\.X_VF?\ H][QQ_X0FE?XU]P8HQ1]<J_TE_D'U.G_ $SX?_X=Q_M,_P#1
M[WCC_P (32O\:/\ AW'^TS_T>]XX_P#"$TK_ !K[@Q1BCZY5_I+_ "#ZG3_I
MGP__ ,.X_P!IG_H][QQ_X0FE?XT?\.X_VF?^CWO''_A":5_C7W!BC%'URK_2
M7^0?4Z?],^'_ /AW'^TS_P!'O>./_"$TK_&C_AW'^TS_ -'O>./_  A-*_QK
M[@Q1BCZY5_I+_(/J=/\ IGP__P .X_VF?^CWO''_ (0FE?XT?\.X_P!IG_H]
M[QQ_X0FE?XU]P8HQ1]<J_P!)?Y!]3I_TSX?_ .'<?[3/_1[WCC_PA-*_QH_X
M=Q_M,_\ 1[WCC_PA-*_QK[@Q1BCZY5_I+_(/J=/^F?#_ /P[C_:9_P"CWO''
M_A":5_C1_P .X_VF?^CWO''_ (0FE?XU]P8HQ1]<J_TE_D'U.G_3/A__ (=Q
M_M,_]'O>./\ PA-*_P :/^'<?[3/_1[WCC_PA-*_QK[@Q1BCZY5_I+_(/J=/
M^F?#_P#P[C_:9_Z/>\<?^$)I7^-'_#N/]IG_ */>\<?^$)I7^-?<&*,4?7*O
M])?Y!]3I_P!,^'_^'<?[3/\ T>]XX_\ "$TK_&C_ (=Q_M,_]'O>./\ PA-*
M_P :^X,48H^N5?Z2_P @^IT_Z9\/_P##N/\ :9_Z/>\<?^$)I7^-'_#N/]IG
M_H][QQ_X0FE?XU]P8HQ1]<J_TE_D'U.G_3/A_P#X=Q_M,_\ 1[WCC_PA-*_Q
MH_X=Q_M,_P#1[WCC_P (32O\:^X,48H^N5?Z2_R#ZG3_ *9\/_\ #N/]IG_H
M][QQ_P"$)I7^-'_#N/\ :9_Z/>\<?^$)I7^-?<&*,4?7*O\ 27^0?4Z?],^'
M_P#AW'^TS_T>]XX_\(32O\:/^'<?[3/_ $>]XX_\(32O\:^X,48H^N5?Z2_R
M#ZG3_IGP_P#\.X_VF?\ H][QQ_X0FE?XT?\ #N/]IG_H][QQ_P"$)I7^-?<&
M*,4?7*O])?Y!]3I_TSX?_P"'<?[3/_1[WCC_ ,(32O\ &C_AW'^TS_T>]XX_
M\(32O\:^X,48H^N5?Z2_R#ZG3_IGP_\ \.X_VF?^CWO''_A":5_C1_P[C_:9
M_P"CWO''_A":5_C7W!BC%'URK_27^0?4Z?\ 3/A__AW'^TS_ -'O>./_  A-
M*_QH_P"'<?[3/_1[WCC_ ,(32O\ &ON#%&*/KE7^DO\ (/J=/^F?#_\ P[C_
M &F?^CWO''_A":5_C1_P[C_:9_Z/>\<?^$)I7^-?<&*,4?7*O])?Y!]3I_TS
MX?\ ^'<?[3/_ $>]XX_\(32O\:/^'<?[3/\ T>]XX_\ "$TK_&ON#%&*/KE7
M^DO\@^IT_P"F?#Q_X)Q?M,'_ )O>\<?^$)I7^-8%]_P3R_:02]F#?MK>-L^8
MW_,CZ6,\GWK[^8<5R>HC&HW'_71OYFJCCJJ_X9!]3IGQ1_P[U_:/_P"CUO&O
M_A$:9_C1_P .]?VC_P#H];QK_P"$1IG^-?:-%5_:%7L3]3IGQ=_P[U_:/_Z/
M6\:_^$1IG^-'_#O7]H__ */6\:_^$1IG^-?:-%']H5>P?4Z9\7?\.]?VC_\
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M\:_^$1IG^-?:-%']H5>P?4Z9\7?\.]?VC_\ H];QK_X1&F?XT?\ #O7]H_\
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M^CWO''_A":5_C1_P[C_:9_Z/>\<?^$)I7^-?<&*,4?7*O])?Y!]3I_TSX?\
M^'<?[3/_ $>]XX_\(32O\:/^'<?[3/\ T>]XX_\ "$TK_&ON#%&*/KE7^DO\
M@^IT_P"F?#__  [C_:9_Z/>\<?\ A":5_C1_P[C_ &F?^CWO''_A":5_C7W!
MBC%'URK_ $E_D'U.G_3/A_\ X=Q_M,_]'O>./_"$TK_&C_AW'^TS_P!'O>./
M_"$TK_&ON#%&*/KE7^DO\@^IT_Z9\/\ _#N/]IG_ */>\<?^$)I7^-'_  [C
M_:9_Z/>\<?\ A":5_C7W!BC%'URK_27^0?4Z?],^'_\ AW'^TS_T>]XX_P#"
M$TK_ !H_X=Q_M,_]'O>./_"$TK_&ON#%&*/KE7^DO\@^IT_Z9\/_ /#N/]IG
M_H][QQ_X0FE?XT?\.X_VF?\ H][QQ_X0FE?XU]P8HQ1]<J_TE_D'U.G_ $SX
M?_X=Q_M,_P#1[WCC_P (32O\:/\ AW'^TS_T>]XX_P#"$TK_ !K[@Q1BCZY5
M_I+_ "#ZG3_IGP__ ,.X_P!IG_H][QQ_X0FE?XT?\.X_VF?^CWO''_A":5_C
M7W!BC%'URK_27^0?4Z?],^'_ /AW'^TS_P!'O>./_"$TK_&C_AW'^TS_ -'O
M>./_  A-*_QK[@Q1BCZY5_I+_(/J=/\ IGP__P .X_VF?^CWO''_ (0FE?XT
M?\.X_P!IG_H][QQ_X0FE?XU]P8HQ1]<J_P!)?Y!]3I_TSX?_ .'<?[3/_1[W
MCC_PA-*_QH_X=Q_M,_\ 1[WCC_PA-*_QK[@Q1BCZY5_I+_(/J=/^F?#_ /P[
MC_:9_P"CWO''_A":5_C1_P .X_VF?^CWO''_ (0FE?XU]P8HQ1]<J_TE_D'U
M.G_3/A__ (=Q_M,_]'O>./\ PA-*_P :/^'<?[3/_1[WCC_PA-*_QK[@Q1BC
MZY5_I+_(/J=/^F?#_P#P[C_:9_Z/>\<?^$)I7^- _P""<?[3&>?VWO'!]O\
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MK>-?_"(TS_&OM&BC^T*O8/J=,^+O^'>O[1__ $>MXU_\(C3/\:/^'>O[1_\
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M7^-'_#N/]IG_ */>\<?^$)I7^-?<&*,4?7*O])?Y!]3I_P!,^'_^'<?[3/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ /2D_@_"E/2D_@_"D!_.=_P72_Y2H_%3_>TK_TT
MV5?)-?6W_!=+_E*C\5/][2O_ $TV5?)-?U/PO_R*,-_@C^1_-?$'_(RK?XF%
M%%%>\>.%%%% !1110 4444 %%%% !7ZW_P#!K%S<_'/_ '=!_P#<E7Y(5^M_
M_!K%_P ?/QS_ -W0?_<E7Q/B%_R)*GK'_P!*1]9P3_R.*?S_ "/UW X[TNWW
M-"_TI:_G$_H 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH 3;[FC;[FEHH
M3;[FC;[FEHH 3;[FC;[FEHH :PP.]<GJ7_(1N/\ KHW\S76MTKDM2_Y"-Q_U
MT;^9H AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 C=*Y+4O^0C<?\ 71OYFNM;I7):E_R$;C_KHW\S0!#1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6UX1Z7'_ ?ZUBUM>$>EQ_P'^M &RO2EI%
MZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %'>BCO0!Q?;\**.WX44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ;7A'I<?\  ?ZULKTK&\(]+C_@/]:V
M5Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6D7^E+7\XG] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 C=*Y+4O^0C<?\ 71OYFNM;I7):E_R$;C_KHW\S0!#1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6UX1Z7'_ ?ZUBUM>$>EQ_P'^M
M &RO2EI%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'>BCO0!Q?;\**.WX
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ;7A'I<?\  ?ZULKTK&\(]
M+C_@/]:V5Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]"K\)?\ P5ZA_P#)M'_$.<[_ )(_^!(/]?\ */YI?^ L_:#\OSH_+\Z_%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 UGVFC<:;(VUJCGO8[=?WC*H]SC%&P13;LB<-0Q
MQ7G7CS]K3X8_"R.8^(OB!X0T9K?_ %B7>K0QR)]5+9_2O&O&7_!:']FWP2&-
MQ\4-!O-O46"3WA_\AHPKFGC*$':<XI^;1[N#X7SG%KFPV%J27=0DU]Z1]5!J
M7=7P_>_\'!O[-=F2(_$NM76.\.B77/\ WT@JG'_P<0_LWO)M.K>)E]SHLO\
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M* "BBB@ HHHH **** "BBB@ /2D_@_"E/2D_@_"D!_.=_P %TO\ E*C\5/\
M>TK_ ---E7R37UM_P72_Y2H_%3_>TK_TTV5?)-?U/PO_ ,BC#?X(_D?S7Q!_
MR,JW^)A1117O'CA1110 4444 %%%% !1110 5^M__!K%_P ?/QS_ -W0?_<E
M7Y(5^M__  :Q?\?/QS_W=!_]R5?$^(7_ ")*GK'_ -*1]9P1_P CBG\_R/UX
M7^E+2+_2EK^<3^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :XS7\Y__!=$;?\ @JC\4_KI7_IILJ_HP>OYS_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %'>BCO0!Q?;\**.WX44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ;7A'I<?\  ?ZULKTK&\(]+C_@/]:V5Z4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU,\XY/W>#S[5SGPIU6ZU?X4>&;J^DDEOKK2K6:=W^\TC1*6)]R<U_.O^W/\
M\%TOVKO%_P"UEXZ\$^%/&ESH.FZ!XGO]'TW3/#.D1+/.EO=/%'ERDD[.51<_
M, 23@ &O+P.65<5.4:;2Y=[G?B\PAAXJ4D]3^DP3G*\#WSQBG)+O7-?R=^+/
M^"@'[9WP'UR&]\4?$SX\>';B_;]RNO7E_##/@=$BN/W?<9"KSQWQC]"_^"+'
M_!QKXT^*'QM\,?!_XZ3:?K0\3SKI>B>*HX%M[S[8WRPP72)A)%D;;&LBHC!F
M4ON#,R]V(X=Q%.E[6+4DNQR4,\H5)\C33?<_;EY,#M^-"OGN*YOXNZK<:)\*
M?$U]:2-;W5GI5U-!(OWHW6)F5A]" ?PK^5BW_P""UG[5\[1JOQO\<2/(RHJK
M,A+$X  ^3J>.E<N6935QO-R22MW.C,,SIX1KG5[G]9A:FO)CH5SBOY3_ /A[
M)^VAC_DJ/Q2'_;L?_C=?17_!)3_@H[^U-\7?^"C/PK\-^./B%\0-5\*:KJCQ
MZE:7T)6VGC%O,0'.P8&X*>HY KKK</U*<'4<UIYG+3SRG.:@HO4_HH5MPI:9
M#]T\8YI]> >X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,0<8QSDBHO\ @F%X!^,WPS_9*TO2?CUKG_"1?$:&^NWN[W[8MWOA:4M"-Z@
MX0@8QQ7-[%>R]IS+TZFWM'[3DL_7H?0H?/\ ^JC?498AAU-'F9]/;GK6'H;>
MI)NYIQ.!3(SN4_E2.63Z=R:8#MW-.)XJ$R8_NM]#UJ2-BRT@0H)- .33&<K_
M /JH63).-M&H$F:"::IW?_JILK[7 ]>G/7_/]*.9 .+<]:<#D5")\KU7ZY[T
M[>6I;"NAS/@T;JC,I#8V@#MG_/\ C3@^!_\ 7HN,D'2BHUE)W=,+ZT]"2.:H
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7W)58BC[*K*G>]G8*%7VE-5$K7"BBBL34**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7VZ5^1WP:_X*J_MD?%_XM^'?#?\ PJO3-+&MW\5K)>7OA?4(;>SC9AOE=V<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.+VV_P#!9;XR$%NNBDX[XT33\?7OQ7TG"O\ OOR?Z'@\1?[M\S[K_P"")?\
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M=3SK.XVLWH,QXSZM],^EE$8RQE.,MKGGYI*4<+-QWL>^_P#!O+^R/I'[,_\
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M@G#5[Q_P3$L(;+_@FW^S^L4:0JWPYT"0A%"Y9]-MV9C[EB23W))-<Y_P6/\
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M&W_@X]T3PSX2\^R^'OQ)U&SL(]-23$9T_5W$2Q,/[EM>_,I8DA(%Y.YL_O\
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M9#=WMEJUO<:<+"1A#<R1QR&-<+\T:JVY $8$,ORD&OA;]L3_ (*C?'G]O/\
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M1)(QD*RJ?E#A5\<_X:N_X*L'_FVGX*=_^8G;^O\ V':YO_@B)^P?^TM\ _\
M@I5\5OBM\8_AS8^"=%^)FD:G<W7V'6;&YM8M2N=2MKI8XHHKJ>54 ^T!=Q(
MX+9VYNM!3P\W7<.9:JS5_-:$T7R5X*CS6>]UL>[?\%;_ (7_ +9_QG^-WA'0
M?V;_ !0GA#P3+I#-KNI2WEI9PQ7GGMMS)L>\_P!7M/[E"HXS@GGYFF_X)'?\
M%&M"TZ;5+7]K2.^UB.-'%D?%VKM!,Z<[5\RW\L=^J ,<!MHY'N__  58_P""
M\$W['?QOM_@O\(_ TGQ,^,$RQ++;/%-):Z?+-'O@@$,)$US.R,K%$9 JNOSE
MB57RW2+;_@K+\<M,AU)-4^&_PMBNU\U+2>WTUI$3&0"C17;*3N'RN0PVX;:<
MY6%^L0I1NH1CTYK788CV-2K+E<I-=%T.R_X(?_\ !67XJ_'KX^^.?V>/C]8Q
M_P#"S_ T5Q-%J2P10/<?9ID@N+>=8B(VE5G5TDB4(ZA\]%9_2_\ @NK_ ,%9
M]8_X)L_"GPMH_@G2[75/B1\1I9X=+:ZB-Q;Z9#"8A).T093)(6FC6-#A2=S-
MD)L?\\/^"3GA7XB>!?\ @XXU?2?BQKVG^)/B+;V.IIKVIV!_T>\G:P1]R8BB
M'W2@.(U&0<>I^XO^#A?_ ()1>,_V_O!/@OQE\+VAN/B!\/7FB73'N8[1]4MI
M2C_NI7*JLT4D890S*K*\G.0H.N(P^%AF$.:RC))OM=_H*C6K3P<E"_,GUWL>
M-:%_P2X_X**?%_PS!XE\3?M5R^$O$EY$;G^Q+75[M(;1Y 28I3:HD*E=Y!$:
M2*N!M) 7'L/_  3 ;]N#X)?MEWGPW_:+O_\ A,OAW-H5U>Z;XFM[>*[M7NHY
M80J+=QQQRJ65Y#Y5P@=@F5& 2?F+PM_P<+?M6?L8:3:Z5^T%^SO?:JM@!;/J
MUQ9W?AZ:\ZCS&F:*6VD.0>8D53T XR?O[_@F=_P6J^%/_!3J\OM$\.0ZOX6\
M;:7:F\NO#^K*GFRP JK2P2H2LL:LZ@Y".">4QS6>,6*A3DITXN'=6T].H\)*
MA*47&<E*^SZF=_P6@_X*T6O_  3)^$.EV^@V%OXA^)WC9Y+;P_I<N6BMU7 >
M[F5?F9$9T58U(:1WP.%8CY'\%_\ !-'_ (*&_M2Z-;^-_'G[3FK_  OU;4%^
MV0>'M/U2[M_LFX[A%/#9&.W0@<;092!UP<@>&_\ !:OQOX^U?_@X2\ V_@70
M]'\6>,O"=MH:^%-&U6=8K*\ND=[N-9"980!YTA;F102HY/2OK(?M5?\ !5@Q
MA3^S/\$VXZG4[?G_ ,KE:0H2H8>'LN12DKMR:^Y7,YUO:UYQK<UD[)13//\
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M]KY&BAE#01B-E5[<80R@>6?F.!N^QD_X)I?\%/"/^3I/!*[@!QKU_P 9Z_\
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M&L?_ !IM^,7/.=%S_P"#O3^:J.96Q<:,(145))::[[BJ8&^&=:<GS-7W*O\
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M_8[B!VPS.VP,N "%V[@6&"5K1_X-TOV3_#OA'X!:E\8M1ALYM>UZZGLK2XE
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MR"UKP[?>%]4:SU"UGL;N-(V:.92C .BNA^C*P8'N&%5D?]Y\K'<ASD$@CO\
MAT'/;&>>WQ& S"IA*G-3^:/[Y\1/#K*.,LK^K8V*YO\ EW45N:+[I]5W6S/Z
MUK>;S4##D-R#4F[YL5^9O_!"C_@J1J_[0-FOPA\<-<ZEXGT.S,VE:P49_M]J
MF 8YV&0)4&,.V-Z_[0RWZ7+)N/'W>E?IV#Q<,3256&S/\LN,N$<=PSFU7*,P
M7OP>ZU33VDO)_AL3"BD0Y6EKJ/EPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ /2D_@_"E/2D_@_"D!_.=_P %TO\ E*C\5/\ >TK_
M ---E7R37UM_P72_Y2H_%3_>TK_TTV5?)-?U/PO_ ,BC#?X(_D?S7Q!_R,JW
M^)A1117O'CA1110 4444 %%%% !1110 5^M__!K%_P ?/QS_ -W0?_<E7Y(5
M^M__  :Q?\?/QS_W=!_]R5?$^(7_ ")*GK'_ -*1]9P1_P CBG\_R/UX7^E+
M2+_2EK^<3^@ HHHH **** "BBB@ HHHH :[%3_GFOY9_^#BYL_\ !9;XQD$?
M*=%Y_N_\2/3S^?\ *OZF&0,U> _&K_@EK^S[^T5\3-2\9>-_A7X7\2>)]8\O
M[9J-Y$[37'EQ)"F[# <1QHHXZ**]3)\PA@Z_M9JZM8\W-,'+$TO9Q[G@G_!L
MVG_&H;P$<8SJ6KGI_P!1"?OW^M??+1AOYUR/P*^ G@[]FCX;VGA'P'X?L/"_
MANP>22WT^S4K#$TCEW(!).68DGGO785QXJLJU:5:/5W.O#4?94HT^R/GG_@I
MW^W:/^"<'[)>J?$X>%_^$Q_LN]M+/^S#J7V R^?*(]PE\J7D9SC8<^M?S4?\
M%6?^"B1_X*=?M.V_Q(;P?_P@[0:);Z,=._M7^TL^3),_F>;Y,/7S<;=O&WJ<
MX']5/QX_9[\%_M.?#VX\)^/O#NG^*/#EU)'-+87JEH9'C;<C$ CD'D5X6/\
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MKZ-?>CHQV'=>GR+NG]QB?\%-&W?\$W?V@<#G_A6WB+C/?^S+BOB3_@T>./\
M@G#XV_[*3?#_ ,I>E5^FWCGP)I/Q,\$ZQX;UZRAU30_$%C/INHV<V3'=VTT;
M1RQ,/[K(S*<=C7*_LY_LM_#_ /9'\$W7AOX;^%=*\(:'?7SZE/9Z>A2.6Y>.
M.-I2"3\Q2*,?1!1#&1CA)X?K)I_<%3#WQ,:RZ)K[SC_^"FA)_P"";W[0/?\
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MDFMX45(MS8))*_)N^GPOL:N*C4]@^9M-O[*\SY^LJL</*'M$XVLK;^A]A?\
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &O7\Y__!=/_E*E\5/KI7_IHLJ_HP>OYS_^"Z?_ "E2^*GUTK_T
MT65?HWA?_P C9_X)?FCX'Q$_Y%T?\2_(^2:***_?C\1"BBB@ HHHH **** "
MBBB@ H_R/>C_ "/>ND^$7PC\2?'?XCZ3X3\(Z3=:UX@UJ;R+2T@&6<_Q,3T5
M54%F8\*H)) '.=2I"$'.;LEN^B15.G.I-1BKMZ)(/A%\(_$GQW^(^D^$_".D
MW6M>(-:F\BTM(!EG/\3$]%55!9F/"J"20!S_ $ ?\$T/^"9GAG_@G5\,_.F^
MRZU\2M<A5=7U@)\L"\'[-;Y&5A4X))PTC#<V $1%_P"":'_!,SPU_P $Z/AI
MYT_V76_B3KD*C5]7"96%>#]FM\C*PJ>2>&D8;FP B)](.[22,S,6=CEF]3_G
M_.*_ ^-.-)9C-X7"NU)??)_Y'[9PCPC'!1^M8I7JM;=@=V=B6.YNY]:2BBOS
MNUM#[Y6MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6UX1Z7'_ ?ZUBUM>$>EQ_P'^M &RO2EI%Z4M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %'>BCO0!Q?;\**.WX44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ;7A'I<?\  ?ZULKTK&\(]+C_@/]:V5Z4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU6C=SC/V;?V>?#?[*7P;T?P)X2BN(-!T.(QP+<3M-(2S%W9F;J69F8@8 SP
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MDJ>L?_2D?6<$?\CBG\_R/UX7^E+2+_2EK^<3^@ HHHH **** "BBB@ HHHH
M",TFWBEHH .E%%%  1DTA7-+10 A7- 7!I:*  #%%%% !CBDVTM% !THHHH
M0KGO2C@444 &,T444 &**** "BBBBP";:4C)HHH\P"C%%%  !BBBB@ HHHH
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M&C\:/]6L)_-+_P "8_\ B8CB5_\ +C#?^"(GXG_\.:/VS_\ HIT?_A;ZC_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !1WHH[T <7V_"BCM^%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &UX1Z7'_ ?ZULKTK&\(]+C_ (#_ %K97I0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 $9I-O-+10 ;:3;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+
M10 FVC;2T4 )MH Q2T4 &,4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 !Z4G\'X4IZ4G\'X4@/YSO^"Z7
M_*5'XJ?[VE?^FFRKY)KZV_X+I?\ *5'XJ?[VE?\ IILJ^2:_J?A?_D48;_!'
M\C^:^(/^1E6_Q,****]X\<**** "BBB@ HHHH **** "OUO_ .#6+_CY^.?^
M[H/_ +DJ_)"OUO\ ^#6+_CY^.?\ NZ#_ .Y*OB?$+_D25/6/_I2/K."/^1Q3
M^?Y'Z\+_ $I:1?Z4M?SB?T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX2FG_P#QBO1OS_.C\_SH^O8C_GY+[V'U'#?\^X_<O\CSG_AB?X"?]$+^$O\
MX2FG_P#QFNB^''P&^&?P9UB74O!?PU\"^$M3GB-O)=Z/HMK8S/&2"4+11JQ4
MD XSC*CTKI/S_.BIEC*\E:4VUZLJ.#H1=XP7W(=([2.69LLW)..M-HHKGV.A
MJZLPHHHH6FB **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *VO"/2X_X#_6L6MKPCTN/^ _UH V5Z4M(O2EH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ H[T4=Z .+[?A11V_"B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#:\(]+C_ (#_ %K97I6-X1Z7'_ ?ZULKTH 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ****  ]*3^#\*4]*3^#\*0'\YW_!=+_E*C\5/][2O_ $TV5?)-
M?6W_  72_P"4J/Q4_P![2O\ TTV5?)-?U/PO_P BC#?X(_D?S7Q!_P C*M_B
M84445[QXX4444 %%%% !1110 4444 %?K?\ \&L7_'S\<_\ =T'_ -R5?DA7
MZW_\&L7_ !\_'/\ W=!_]R5?$^(7_(DJ>L?_ $I'UG!'_(XI_/\ (_7A?Z4M
M(O\ 2EK^<3^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 1NE<EJ7_(1N/\ KHW\S76MTKDM2_Y"-Q_UT;^9H AH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K:\(]+C_@/]:Q:VO"/2X_X#_6
M@#97I2TB]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CO11WH XOM^%%';\
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** -KPCTN/\ @/\ 6ME>E8WA
M'I<?\!_K6RO2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH #TI/X/PI3TI/X/PI ?SG?\%TO^
M4J/Q4_WM*_\ 3395\DU];?\ !=+_ )2H_%3_ 'M*_P#3395\DU_4_"__ "*,
M-_@C^1_-?$'_ ",JW^)A1117O'CA1110 4444 %%%% !1110 5^M_P#P:Q?\
M?/QS_P!W0?\ W)5^2%?K?_P:Q?\ 'S\<_P#=T'_W)5\3XA?\B2IZQ_\ 2D?6
M<$?\CBG\_P C]>%_I2TB_P!*6OYQ/Z "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5R6I?\A&X_P"NC?S-=:W2
MN2U+_D(W'_71OYF@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS_Y#H^K5OY7]P?6J7\R/M_-&:^(/^(CG]C3_ *+"?_"3US_Y#H_XB.?V-/\
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M ,)/7/\ Y#H_XB.?V-/^BPG_ ,)/7/\ Y#H^K5OY7]P?6J7\R/M_-&:^(/\
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MS_Y#H^K5OY7]P?6J7\R/M_-&:^(/^(CG]C3_ *+"?_"3US_Y#H_XB.?V-/\
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M ,)/7/\ Y#H_XB.?V-/^BPG_ ,)/7/\ Y#H^K5OY7]P?6J7\R/M_-&:^(/\
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MS_Y#H^K5OY7]P?6J7\R/M_-&:^(/^(CG]C3_ *+"?_"3US_Y#H_XB.?V-/\
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M ,)/7/\ Y#H_XB.?V-/^BPG_ ,)/7/\ Y#H^K5OY7]P?6J7\R/M_-&:^(/\
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MS_Y#H^K5OY7]P?6J7\R/M_-&:^(/^(CG]C3_ *+"?_"3US_Y#H_XB.?V-/\
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M ,)/7/\ Y#H_XB.?V-/^BPG_ ,)/7/\ Y#H^K5OY7]P?6J7\R/M_-&:^(/\
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MS_Y#H^K5OY7]P?6J7\R/M_-&:^(/^(CG]C3_ *+"?_"3US_Y#H_XB.?V-/\
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M_P"0Z/JE;^5A];H_S'VA17Q?_P 1"G['_P#T5X?^$MK?_P AT?\ $0I^Q_\
M]%>'_A+:W_\ (='U2M_*P^MT?YC[0HKXO_XB%/V/_P#HKP_\);6__D.C_B(4
M_8__ .BO#_PEM;_^0Z/JE;^5A];H_P Q]H5M>$C@7'_ ?ZU\*_\ $0I^Q_\
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MI?S(^W\T9KX@_P"(CG]C3_HL)_\ "3US_P"0Z/\ B(Y_8T_Z+"?_  D]<_\
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MM_*P^MT?YC[0HKXO_P"(A3]C_P#Z*\/_  EM;_\ D.C_ (B%/V/_ /HKP_\
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M ,AT?5*W\K#ZW1_F/M"BOB__ (B%/V/_ /HKP_\ "6UO_P"0Z/\ B(4_8_\
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MG_183_X2>N?_ "'2^K5OY7]P_K5+^9'V_FC-?$'_ !$<_L:?]%A/_A)ZY_\
M(='_ !$<_L:?]%A/_A)ZY_\ (='U:M_*_N#ZU2_F1]OYHS7Q!_Q$<_L:?]%A
M/_A)ZY_\AT?\1'/[&G_183_X2>N?_(='U:M_*_N#ZU2_F1]OYHS7Q!_Q$<_L
M:?\ 183_ .$GKG_R'1_Q$<_L:?\ 183_ .$GKG_R'1]6K?RO[@^M4OYD?;^:
M,U\0?\1'/[&G_183_P"$GKG_ ,AT?\1'/[&G_183_P"$GKG_ ,AT?5JW\K^X
M/K5+^9'V_FC-?$'_ !$<_L:?]%A/_A)ZY_\ (='_ !$<_L:?]%A/_A)ZY_\
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M_183_P"$GKG_ ,AT?5JW\K^X/K5+^9'V_FC-?$'_ !$<_L:?]%A/_A)ZY_\
M(='_ !$<_L:?]%A/_A)ZY_\ (='U:M_*_N#ZU2_F1]OYHS7Q!_Q$<_L:?]%A
M/_A)ZY_\AT?\1'/[&G_183_X2>N?_(='U:M_*_N#ZU2_F1]OYHS7Q!_Q$<_L
M:?\ 183_ .$GKG_R'1_Q$<_L:?\ 183_ .$GKG_R'1]6K?RO[@^M4OYD?;^:
M,U\0?\1'/[&G_183_P"$GKG_ ,AT?\1'/[&G_183_P"$GKG_ ,AT?5JW\K^X
M/K5+^9'V_FC-?$'_ !$<_L:?]%A/_A)ZY_\ (='_ !$<_L:?]%A/_A)ZY_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** "BBB@ HHHH *^Z?^"*/_ "$/B-_N:;_[=U\+5]T_\$4?^0A\1O\
M<TW_ -NZ^/X]_P"1-4_[=_-'ZAX-_P#)58?TE^1]\ITIU-3I3J_G:.Q_= 44
M44P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $;I7):E_R$;C_ *Z-_,UUK=*Y+4O^0C<?]=&_F: (:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *VO"/2X_X#_6L6MKPCTN/^ _UH V5Z4M(O2EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ H[T4=Z .+[?A11V_"B@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#:\(]+C_ (#_ %K97I6-X1Z7'_ ?ZULKTH 6
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** &M][\*7^#\*1OO?A2_P 'X4NH'Y&_\%(O^3U/&W^_
M9_\ I%;UX=7N/_!2+_D]3QM_OV?_ *16]>'5_3_#G_(KH?X%^1_GCQQ_R/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 C=*Y+4O\ D(W'_71OYFNM;I7):E_R
M$;C_ *Z-_,T 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5M>$>EQ_P !
M_K6+6UX1Z7'_  '^M &RO2EI%Z4M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%'>BCO0!Q?;\**.WX44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;7A'
MI<?\!_K6RO2L;PCTN/\ @/\ 6ME>E "T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$G- "T4
MSS<GCGCMV]*>* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 (W2N2U+_D(W'_ %T;^9KK6Z5R6I?\A&X_ZZ-_,T 0T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5M>$>EQ_P'^M8M;7A'I<?\!_K0!LKTI:1>E+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1WHH[T <7V_"BCM^%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &UX1Z7'_  '^M;*]*QO"/2X_X#_6ME>E "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH BFF*-CC\:\Z\7_&+P%X1\276GZUX[\*Z1J4+;IK2[U."&:'< PW(T@(
MRI!&1R"#WKT:50YP:_)#_@I$<?MI^-NWSV?_ *16]?2<+9'#-L6\-.;C9-W2
MOV_S/S[Q'XRJ\-9:L?2IJHW)1LVUOZ'Z+_\ #0OPN_Z*=X'_ /!S:_\ QRC_
M (:%^%W_ $4[P/\ ^#FU_P#CE?CONHW5^A?\0OPW_/\ E]R_S/Q/_B8C,/\
MH#A_X%+_ "/V(_X:%^%W_13O _\ X.;7_P".4?\ #0OPN_Z*=X'_ /!S:_\
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MYA_Q,1F'_0'#_P "E_D?L1_PT+\+O^BG>!__  <VO_QRC_AH7X7?]%.\#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[1V/[H"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_@J5\7/V?]0\&Z'I.C_#>77$M]5MKJ:2ZO1I^IQV2%T(VKO63<<'J.W2OO\
M6//7+<8P:_#K_@C)S_P<F?M1_P#7SXR_]2&W_P 3^=<^%IT<1"O/E2Y8W7EJ
MCHQ$ZE&5*/,W>5F?J!_P4A_X*6^ ?^"9/P6A\6>,_M6H7FJ3FST71+ I]MU:
M<#<P7<0JQHI#22$X4%1AF9%;X L_^"UO[=GQ:\,V_C/P#^R1;R>![S,]J;G3
M=1OKF]MVYC:)EEA,@(*G>D+*PR0!VB_X.P_V;O''B[0_A1\4M#TJX\0>$_ ;
M7EMK5NL)N(M/:62WDCFEC4']S)Y)1V/R@I$#C<#7JW[-G_!TQ^SE\3O#MA'X
MV3Q5\,]8\I!<I=:;)J-BKD#/E2VHDD9!_>>),=P,5O0PL8X6->%/VC;UWT\K
M(QKXB3Q#I3J>S73S.G_X);?\%N_%'[;7[3&K?!OXC?!O4OACXYTG2)M7?SIY
M54K$\2-');3Q)+"W[U2/F<'G.WOJ?\%OO^"PWB7_ ()3?\*Q_P"$?\'Z'XJ_
MX3S^U?/&I74EO]E^QFRV[2G9A<L23TV#WKZE^!'QI^$/[70M?B!\/M:\&^.+
MC3X&L(]9T_RKB\TZ.3#M;N^/-AW;0QC;:3@$CI7Y+_\ !XN_[_\ 9UQV_P"$
MEP?_  4]/\:QP=.C7QT:<J?*NJ^3>AMB*E2EA6U*[OHSU/XT?\'$_P 3/CEX
MUU#1OV0_@3KOQ2TO1Y/)NO$VHZ)?W-F\G)&VWMRC1H5P5::1';=_JQWK?L5?
M\'-]Q)\8-4\ ?M4>";/X1ZQIT,SR:G;V=Y:PV4T:>9Y%S9SEYXV=1\C*SEF9
M%VC<&K]3OA3\'O"_P/\ A[IWA7P?H.E^&_#NE1>5:Z?I]LL%O"O?Y5'4GDL<
MEB222237XB_\'-OPGT6]_P""G?P"NIK&WD_X2S3[/3M33&T7L::F5P^,$Y29
ME)SG  [5T8'ZGB:KPZI65G9WUT.?%?6J$%7]IU2M;34];^('_!Q)\>_VC/$>
MI']E?]FW6_&'A/2Y6A.NZQHE_J2W)7N8K1XTA)P<(9G8CDA>5'I__!*G_@X'
MOOVO_P!HN;X+_%_P)'\._B1(\T5@;=9H;:XFA1GEM9H)SYMO,JHY 9F#;2IV
M-M#?HYX&\ :'\,O!NG^'_#>DZ=H.AZ5"MO9:?I]NEO;6L8Z*D:@*H'H!BOQ-
M_P""N7ANW^''_!R[^S;J6EPQ6MUXHO/"5W?.BX,[OK,]DS'W,$*+GT [<5GA
M?JV*<J$::C9-I]=$5B'7P_+6E/FNTFNFI^YD;;EIU-B&T?C3J\%'N'YR_P#!
MTAJ&N6?_  2PU"/2)9XK&Z\2Z9#K0C)"R69:1@KG^[]H6VZ\9V^U:W_!MC-\
M/'_X)<>#T\&-I']N_:+L^+%@\L7@U W,F/M(7G/D^4$W?\LPF"<5]K_&_P""
M_AG]HGX5^(/ _C#2X-:\,^)[%[#4;*7($T3\<%2&5@<%74AE8!@00#7XV?&C
M_@UL^)OP7^(-QXF_9M^-3:7N=FMX-4O;K2=2LX^T:WEH'\XCIRD0QUR>3[>%
MK4*N$>$JSY'>]^C]3Q\31JT\4L12CS:6]#]N-BR$]\?IFO/?AI^R;\.?A!\6
M/$GC;PIX1T?P[XF\8006^M76G0BV741"SM&\D:83S 9'RX4,P(#$@#'XI:_K
M/_!5#_@GIIYU74;CQ/XZ\+Z0#+<N[V?BN&:)>6,GWKU(PH)+_)@9Y')K[U_X
M(J_\%O-/_P""G=GJOA/Q-HMGX5^*'ARS%]<6MI(6LM7MMX1KBV5V,B>6[(KQ
MN6QYB$.V2$RKY;6I4G4IS4HK=IFE',*52HH3BXR\^Y-_P6__ ."P'B3_ ()/
MGX9KX>\'Z'XJ7QX-5:X.HW,L(M/LGV/;M\L'.[[4<DXQM'KQX)\;/^#C3XH?
M&OQC?:7^R3\!?$'Q.TC29#'<>(]0T'4+RWF(Y)6VM=C1(1@JTTJ.=PS&IXKS
MC_@\<9O._9U_[F7'_E)_/KW]:_9SX:?#+P[\'_ VF^&_"VBZ5X=T'28A#9Z?
MIULEO;VR]<*B@ 9))/J22<DUI'ZM1PM.I*GS2=^NFC,_]HJXBI34VDK6/RM_
M8&_X.3?%'C3]IW3/A#^TA\-[7X<^)-<OH=,MKZSL[O3ULKN9E$$%U97+22Q"
M3>@$GF?*2"5"$NOZV7.HI8VLDTSQQQPJ7D<GY4 Y))]!SS7XY_\ !W7\ M'A
M^$'PM^+%K:QVOB2PUUO#4U[$@62Y@EMY;J)7;JWEM:R%>>/-?UKU[_@JU^U_
MKFG?\&\^C>,+74+I=>^*7A;P_I]Q>!_WG^GP0R7>X_\ 32$7$9_ZZ&JKX2GB
M/8U</'E4W9K?7R)HXJI1]K3J/F<%>_D<G\>?^#B?QM\8?C9JOP]_9!^#\_Q>
MO=%W&Y\075M<7-A(JL%,D<$+1MY&X[1+)-&&/12,%L&Z_P""^W[2_P"QGXOT
M/_AJ?]F^/PWX1U6X-M)J_AZ&>'RVP6Q$9)IX99 /^61F0L Q!P#7A_\ P2)_
MX+K_ +-?_!-W]C?1_ U[X'^*%UXQN9YM0\2ZII>EZ<T.I73R-L(:2^1RL</E
M1J"JX"$XRQ)] _;X_P"#CW]FC]LO]CKXB?#63P)\6FO/%6AW-MI<FH:5IHM[
M2_5"]I.Q2_9U$4XB<LJD@+T/2NSZK&-7V*H7AMS7U]3E6*<J?M?;6EO:VGH?
ML-\'_C#H/Q[^%>@>-/">H0ZKX<\36,6H:?=Q@XEBD4,,@\JPZ%6 96!! ((K
MX=_X*??\' 7A#]A3XD#X9^"_#=S\4?BLSQPSZ5:S^5:Z9++M\N*5U5F>9@ZD
M11J3\PW,A(!\Q_X-J?V@KKP]_P $>?'6H7[7%U!\+]=UE[:&5R52!;&"_,:^
M@,DTIP.[YZG->%_\&K?P6M?V@/V@/C-\>O&D9USQAI]U#!97UPJN([N^:XFO
MK@ CB4A8U#K@A9I1R'XXZ> I495JE;6-/1+NWL=4L;5JPI0I:.>[[':ZC_P7
M1_;D^&&DMXD\:?LA7$/A14\^0Q^']8L9+6)1ES-*YD$6<'!>)0,\YQS](6W_
M  6?\6?M _\ !-2/XY?!7X*^)O&'B:/Q(GAVZ\*"";4)HRJ!YIHS:JSO$N]
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M ,B"G_U\7Y,\.HHHK]W/XY"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110!M>$>EQ_P'^M;*]*QO"/2X_X#_6ME>E
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M^'_B+XD7?Q!M_&^OZ+!JFJ06.IPV\-I).OFK$(V@8JT:.B-ECED)],>G2?\
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MFE:&V@C:61@B@LQ"J3@ DU\5'_@Y@_9%#8_X3O7-V<8_X1?4?3/_ #QKWO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_@XG_;&OM>L8)/C%O2:=$9?^$5T0;E+#(_X\QCC/^<5^P'_  ;9^"=%UO\
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MS <@UU:/3E%K26@HR3UB/48I:1?ZTM"&-:/<<\T@A S[T^B@!HCP:79Q2T4
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M^202?U7_ ."RB*/^"6OQVS]T^$KS.1Q]T?XU^<'_  4._P"5ICX&_P#<!_\
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MU_UM=69U*$,0X\\ERVLDM/D<F!IUIT>90B[[MO4^9_\ @U=^-VK>'/%/QM^
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M_6ME>E8WA'I<?\!_K6RO2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M>XQ^=_\ P0J_9OO?VB?VK=MQ<.OA7PS"NJZA"SG=*Z,!"%)'!\S:Q]54BOZ
MK>+RHU4?=4<"O[IXCQM?)LLP_#D:WM9TZ<8SGU=E;Y7Z^1^+\,Y53S#&U,YJ
M0Y4Y-QCT')'E3SWIPCP:5!@4M?FGF?IOF &**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :
MWWOPI?X/PI&^]^%+_!^%+J!^1O\ P4B_Y/4\;?[]G_Z16]>'5[C_ ,%(O^3U
M/&W^_9_^D5O7AU?T_P .?\BNA_@7Y'^>/''_ "/\9_U\E^84445[1\J%26MO
M)=W,<4*&225@BH.KDD8_(X_.HZZCX("W;XT^$!>8^Q_VU9>?DX!C^T1[N>W
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M_P#U=*]K,,VJTL3.E9.*>S2/*P>7PJ8>,[M-KN?E7_P25_X+X>(OB_\ &X?
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M!9I<=#M6,9X7Y0">(^'GQ7^-'_! #_@H/X)^%GQ ^(&I?$3X!_$JX5+*\O\
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M3K_HO^LS]WY<?-G[25<CO2F//7MTQ4U\<ZD.3V<5YI68J.#]G+F4V_4_+_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &OUK\CO^"D7_)ZGC;_ '[/_P!(K>OUQ?K7Y'?\%(O^3U/&W^_9
M_P#I%;U^@^&O_(TE_A?YH_#?'[_DGZ?_ %\7Y,\.HHHK]W/XY"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CM^'^?
MSH[?A_G\Z^S/^"?O_!/T>+Q:>/?'MF1H4>)M+TR=/^0AW$TJG_ED<95"#YGR
MG[GW_)SC.J&6T'7KO3HNK?9'TG"O"N.S['1P6"CYRD]DOZ^\;_P3_P#^"?\
M_P )>+/QYX\LV&AIB;3-,GC_ ./_ +B:53_RR.,JA!\SY2?EX?[LN[HSLH4;
M(U'RJ!T^A_+D8SCTHN[KSV 5?+C4?*H'W?H?RY&,X]*A P*_G7.LZQ&:XCZQ
MB/AZ+HC^Z.#^#\%P]@E@\(KR^U)[M@!@4445X_-?4^LYNJ"BBB@ HHHH *VO
M"/2X_P" _P!:Q:VO"/2X_P" _P!: -E>E+2+TI: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *.]%'>@#B^WX44=OPHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH VO"/2X_X#_6ME>E8WA'I<?\!_K6RO2@!:*** "BBB@ HHHH ****
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M &[?>G8HHH .E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXO@W\(_AO#.DVMZEKDOB5[96#/%#!"UO&S+S@.URX4]"8WZXK]+OV OA!??
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M%% !1110 4444 %%%% !1110 4444 !YI-OUI:* $ Q2@8%%%%@ C-!%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=\.V'BC29K#4K.UU"QN5VS6US"LT,HZX96!!_$5<HH X4_LP?#<KC_A7_@G
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M0C<?]=&_F: (:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *VO"/2X_X#_6
ML6MKPCTN/^ _UH V5Z4M(O2EH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[T
M4=Z .+[?A11V_"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#:\(]+C_
M (#_ %K97I6-X1Z7'_ ?ZULKTH 6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ QDTUDW]V_ TZB@!J)L'
MK[GO3L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 -;[WX4O\'X4C?>_"E_@_"EU _(W_@I%_R>IXV_W[/_ -(K>O#J]Q_X
M*1?\GJ>-O]^S_P#2*WKPZOZ?X<_Y%=#_  +\C_/'CC_D?XS_ *^2_,****]H
M^5 \C^8]:,_YS110 9_SFC/^<T4460!W]QT/<?C0.*** "BBB@ K[I_X(H_\
MA#XC?[FF_P#MW7PM7W3_ ,$4?^0A\1O]S3?_ &[KX_CW_D35/^W?S1^H>#?_
M "56'])?D??*=*=34Z4ZOYVCL?W0%%%%, HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5R6I?\A&X_ZZ-_,UUK=*Y+4O
M^0C<?]=&_F: (:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *VO"/2X_P"
M_P!:Q:VO"/2X_P" _P!: -E>E+2+TI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *.]%'>@#B^WX44=OPHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH V
MO"/2X_X#_6ME>E8WA'I<?\!_K6RO2@!:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :WWOPI?X/
MPI&^]^%+_!^%+J!^1O\ P4B_Y/4\;?[]G_Z16]>'5[C_ ,%(O^3U/&W^_9_^
MD5O7AU?T_P .?\BNA_@7Y'^>/''_ "/\9_U\E^84445[1\J%%%% !1110 44
M44 %%%% !7W3_P $4?\ D(?$;_<TW_V[KX6K[I_X(H_\A#XC?[FF_P#MW7Q_
M'O\ R)JG_;OYH_4/!O\ Y*K#^DOR/OE.E.IJ=*=7\[1V/[H"BBBF 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=*Y+4O
M^0C<?]=&_F:ZUNE<EJ7_ "$;C_KHW\S0!#1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6UX1Z7'_ ?ZUBUM>$>EQ_P'^M &RO2EI%Z4M !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %'>BCO0!Q?;\**.WX44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ;7A'I<?\!_K6RO2L;PCTN/^ _UK97I0 M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 -;K36<@8IYJ-C_ )-2!^2'_!2 [OVT_&W^_9_^D5O7A^*^]?VU/^"3
M/C;]IC]H;6/&GAKXHZ;X5L-7C@#Z?=:"+YDDCA6(L'\Q?E(13C!YSSS@>4_\
M.(/BO_T73P__ .$@/_CU?O>1\7930R^C1K54I1BDU9]#^/\ BCPCXAQF;8C%
M4*:<9S;6O1L^8,48KZ?_ .'$'Q7_ .BZ>'__  D!_P#'J/\ AQ!\5_\ HNGA
M_P#\) ?_ !ZO5_UVR7_G^ON9X/\ Q!7B;_GVOO/F#%&*^G_^'$'Q7_Z+IX?_
M /"0'_QZC_AQ!\5_^BZ>'_\ PD!_\>H_UVR7_G^ON8?\05XF_P"?:^\^8,48
MKZ?_ .'$'Q7_ .BZ>'__  D!_P#'J/\ AQ!\5_\ HNGA_P#\) ?_ !ZC_7;)
M?^?Z^YA_Q!7B;_GVOO/F#%&*^G_^'$'Q7_Z+IX?_ /"0'_QZC_AQ!\5_^BZ>
M'_\ PD!_\>H_UVR7_G^ON8?\05XF_P"?:^\^8,48KZ?_ .'$'Q7_ .BZ>'__
M  D!_P#'J/\ AQ!\5_\ HNGA_P#\) ?_ !ZC_7;)?^?Z^YA_Q!7B;_GVOO/F
M#%?='_!%4E=1^(O3E-._]NZ\V_X<0?%?_HNGA_\ \) ?_'J[#X3_ /!+3]I?
M]GAKUO 7[2/A70Y-5*?;FG\ PW7G"/=Y8&^4[<&1\XZY%?-\6<2Y9CLMGAL/
M53D[=^C7D?<>'?AEGF3YY2Q^+I^[&][.^ZL?HC$^Y?\ "GY-?#X_9/\ VX.W
M[67@G_PV%I_\<I?^&3OVX/\ H[+P3_X;"T_^.5^/K#1_GC^/^1_3GUB7\C_
M^W\FC)KX@_X9._;@_P"CLO!/_AL+3_XY1_PR=^W!_P!'9>"?_#86G_QRCZO'
M^>/X_P"0?6)?R/\  ^W\FC)KX@_X9._;@_Z.R\$_^&PM/_CE'_#)W[<'_1V7
M@G_PV%I_\<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_AD[]N#_H[+P3_ .&PM/\
MXY1_PR=^W!_T=EX)_P##86G_ ,<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_ (9.
M_;@_Z.R\$_\ AL+3_P".4?\ #)W[<'_1V7@G_P -A:?_ !RCZO'^>/X_Y!]8
ME_(_P/M_)HR:^(/^&3OVX/\ H[+P3_X;"T_^.4?\,G?MP?\ 1V7@G_PV%I_\
M<H^KQ_GC^/\ D'UB7\C_  /M_)HR:^(/^&3OVX/^CLO!/_AL+3_XY1_PR=^W
M!_T=EX)_\-A:?_'*/J\?YX_C_D'UB7\C_ ^W\FC)KX@_X9._;@_Z.R\$_P#A
ML+3_ ..4?\,G?MP?]'9>"?\ PV%I_P#'*/J\?YX_C_D'UB7\C_ ^W\FC)KX@
M_P"&3OVX/^CLO!/_ (;"T_\ CE'_  R=^W!_T=EX)_\ #86G_P <H^KQ_GC^
M/^0?6)?R/\#[?R:,FOB#_AD[]N#_ *.R\$_^&PM/_CE'_#)W[<'_ $=EX)_\
M-A:?_'*/J\?YX_C_ )!]8E_(_P #[?R:,FOB#_AD[]N#_H[+P3_X;"T_^.4?
M\,G?MP?]'9>"?_#86G_QRCZO'^>/X_Y!]8E_(_P/M_)HR:^(/^&3OVX/^CLO
M!/\ X;"T_P#CE'_#)W[<'_1V7@G_ ,-A:?\ QRCZO'^>/X_Y!]8E_(_P/M_)
MHR:^(/\ AD[]N#_H[+P3_P"&PM/_ (Y1_P ,G?MP?]'9>"?_  V%I_\ '*/J
M\?YX_C_D'UB7\C_ ^W\FC)KX@_X9._;@_P"CLO!/_AL+3_XY1_PR=^W!_P!'
M9>"?_#86G_QRCZO'^>/X_P"0?6)?R/\  ^W\FC)KX@_X9._;@_Z.R\$_^&PM
M/_CE'_#)W[<'_1V7@G_PV%I_\<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_AD[]N
M#_H[+P3_ .&PM/\ XY1_PR=^W!_T=EX)_P##86G_ ,<H^KQ_GC^/^0?6)?R/
M\#[?R:,FOB#_ (9._;@_Z.R\$_\ AL+3_P".4?\ #)W[<'_1V7@G_P -A:?_
M !RCZO'^>/X_Y!]8E_(_P/M_)HR:^(/^&3OVX/\ H[+P3_X;"T_^.4?\,G?M
MP?\ 1V7@G_PV%I_\<H^KQ_GC^/\ D'UB7\C_  /M_)HR:^(/^&3OVX/^CLO!
M/_AL+3_XY1_PR=^W!_T=EX)_\-A:?_'*/J\?YX_C_D'UB7\C_ ^W\FC)KX@_
MX9._;@_Z.R\$_P#AL+3_ ..4?\,G?MP?]'9>"?\ PV%I_P#'*/J\?YX_C_D'
MUB7\C_ ^W\FC)KX@_P"&3OVX/^CLO!/_ (;"T_\ CE'_  R=^W!_T=EX)_\
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M=EX)_P##86G_ ,<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_ (9._;@_Z.R\$_\
MAL+3_P".4?\ #)W[<'_1V7@G_P -A:?_ !RCZO'^>/X_Y!]8E_(_P/M_)HR:
M^(/^&3OVX/\ H[+P3_X;"T_^.4?\,G?MP?\ 1V7@G_PV%I_\<H^KQ_GC^/\
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M/M_)HR:^(/\ AD[]N#_H[+P3_P"&PM/_ (Y1_P ,G?MP?]'9>"?_  V%I_\
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M ,<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_ (9._;@_Z.R\$_\ AL+3_P".4?\
M#)W[<'_1V7@G_P -A:?_ !RCZO'^>/X_Y!]8E_(_P/M_)HR:^(/^&3OVX/\
MH[+P3_X;"T_^.4?\,G?MP?\ 1V7@G_PV%I_\<H^KQ_GC^/\ D'UB7\C_  /M
M_)HR:^(/^&3OVX/^CLO!/_AL+3_XY1_PR=^W!_T=EX)_\-A:?_'*/J\?YX_C
M_D'UB7\C_ ^W\FC)KX@_X9._;@_Z.R\$_P#AL+3_ ..4?\,G?MP?]'9>"?\
MPV%I_P#'*/J\?YX_C_D'UB7\C_ ^W\FC)KX@_P"&3OVX/^CLO!/_ (;"T_\
MCE'_  R=^W!_T=EX)_\ #86G_P <H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_AD[
M]N#_ *.R\$_^&PM/_CE'_#)W[<'_ $=EX)_\-A:?_'*/J\?YX_C_ )!]8E_(
M_P #[?R:,FOB#_AD[]N#_H[+P3_X;"T_^.4?\,G?MP?]'9>"?_#86G_QRCZO
M'^>/X_Y!]8E_(_P/M_)HR:^(/^&3OVX/^CLO!/\ X;"T_P#CE'_#)W[<'_1V
M7@G_ ,-A:?\ QRCZO'^>/X_Y!]8E_(_P/M_)HR:^(/\ AD[]N#_H[+P3_P"&
MPM/_ (Y1_P ,G?MP?]'9>"?_  V%I_\ '*/J\?YX_C_D'UB7\C_ ^W\FC)KX
M@_X9._;@_P"CLO!/_AL+3_XY1_PR=^W!_P!'9>"?_#86G_QRCZO'^>/X_P"0
M?6)?R/\  ^W\FC)KX@_X9._;@_Z.R\$_^&PM/_CE'_#)W[<'_1V7@G_PV%I_
M\<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_AD[]N#_H[+P3_ .&PM/\ XY1_PR=^
MW!_T=EX)_P##86G_ ,<H^KQ_GC^/^0?6)?R/\#[?R:,FOB#_ (9._;@_Z.R\
M$_\ AL+3_P".4?\ #)W[<'_1V7@G_P -A:?_ !RCZO'^>/X_Y!]8E_(_P/M_
M)HR:^(/^&3OVX/\ H[+P3_X;"T_^.4?\,G?MP?\ 1V7@G_PV%I_\<H^KQ_GC
M^/\ D'UB7\C_  /M_)HR:^(/^&3OVX/^CLO!/_AL+3_XY1_PR=^W!_T=EX)_
M\-A:?_'*/J\?YX_C_D'UB7\C_ ^W\FC)KX@_X9._;@_Z.R\$_P#AL+3_ ..4
M?\,G?MP?]'9>"?\ PV%I_P#'*/J\?YX_C_D'UB7\C_ ^WCFN3U,XU&?_ *Z-
M_,U\F']D[]N#_H[+P3_X;"T_^.54D_8S_;8EE9F_:O\ !6YB6/\ Q;&U[_\
M;2FL-'K47XA]8G_(_P #ZWW"C<*^1_\ AC#]M;_HZ_P7_P"&RM?_ ([1_P ,
M8?MK?]'7^"__  V5K_\ ':?U:'_/Q?B'UB?\C_ ^N-PHW"OD?_AC#]M;_HZ_
MP7_X;*U_^.T?\,8?MK?]'7^"_P#PV5K_ /':/JT/^?B_$/K$_P"1_@?7&X4;
MA7R/_P ,8?MK?]'7^"__  V5K_\ ':/^&,/VUO\ HZ_P7_X;*U_^.T?5H?\
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M^?B_$/K$_P"1_@?7&X4;A7R/_P ,8?MK?]'7^"__  V5K_\ ':/^&,/VUO\
MHZ_P7_X;*U_^.T?5H?\ /Q?B'UB?\C_ ^N-PHW"OD?\ X8P_;6_Z.O\ !?\
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M]<;A1N%?(_\ PQA^VM_T=?X+_P##96O_ ,=H_P"&,/VUO^CK_!?_ (;*U_\
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M@^L2_D?X'V_DT9-?$'_#)W[<'_1V7@G_ ,-A:?\ QRC_ (9._;@_Z.R\$_\
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MK$_Y'^!]<;A1N%?(_P#PQA^VM_T=?X+_ /#96O\ \=H_X8P_;6_Z.O\ !?\
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M?\C_  /KC<*-PKY'_P"&,/VUO^CK_!?_ (;*U_\ CM'_  QA^VM_T=?X+_\
M#96O_P =H^K0_P"?B_$/K$_Y'^!]<;A1N%?(_P#PQA^VM_T=?X+_ /#96O\
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M^&RM?_CM'U:'_/Q?B'UB?\C_  /KC<*-PKY'_P"&,/VUO^CK_!?_ (;*U_\
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M(_P/M_)HR:^(/^&3OVX/^CLO!/\ X;"T_P#CE'_#)W[<'_1V7@G_ ,-A:?\
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MMP?]'9>"?_#86G_QRCZO'^>/X_Y!]8E_(_P/M_)HR:^(/^&3OVX/^CLO!/\
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img102364508_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1FP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &92^94@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!X\
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ]8   FD          $
M                 0             )I    ]8
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ]8     4F=H=&QO;F<   FD
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   /6     %)G:'1L;VYG   )I     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "SA"24T$#      /+0
M  $   "@    0    >   '@    /$0 8  '_V/_M  Q!9&]B95]#30 "_^X
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MJS7[&LPK6LLJWN<_+?#;"VQ_H/K%FY_Z1M5=C_\ A4E,C];/JZ.<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-/'%B/LK52G9LZ*%(C]T *78COJ)9K?2K9%6-U3WE1PC2QH[#(>8A@^&)(&
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MK>HA4QB> =F8R8E@9VR0F1%!0XTDVXD9QF893'$.)>'RYY\1X4\"/B#\^_\
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MH(JNL)V?J^V>\?6+<G[!AVVLP)G9WKSKRKR 6SJ5"/9L0@HBSI-^)/5"V@N
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M\:M@J Z,A"N<AY"%.T[R$1A*N&#Q*"&5V%:RK[M:?(O0=(OKM]U3:S; U5(
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MR\4-L+PZ?#<?TN_DG=Q)9SAXH81',UV0^T7>;1(UMS-::UHFHO;PN^H1VU_
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MW&ZW;6F_8Z\TA@I#;H!#CBLM(9<(*,9>SX;PW&L*2ZUJY[CI748'/LMWH6H
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MGR0 .[GSX_3SY7GSX_3SYQRBZ7J<&M:;I^L6RE+?5;&TU*!"<E(KZ".YC0D
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MN;2>J]JR].0:U5I'85#K5O+@69)8[IXT:]/1IRQA2WA!""!49^NX2**2IK)
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M[R<;??A90!I92HR4C"T-DCJ>P*>"4VGPXR^S[L/#D(QG*5M.-^[]<I6VK/\
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ME[:>X,D5M&SO'; DAI&B!.X% ,"UQO2$O<R32I>%L.O-G1@"Y*6U[;PU#2.
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M$*990*T7"^YW[+C:/;A* 1Q8QM'MPW(8:PG":_!I>AZE;+_]8:PU95<W,>I
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MJF2\9*M$P2\A5XG$FUEDC)QM+*"H#J00,@X96VD+N_Q9<KU(ZDQ7PUZS2_\
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M3SV,EY*1&" L(.[=/\%0CN7O,@PHQCO.3]9;."_N\[5(]X'/)# =V,Y! .>
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MD((;_P!BE()CN1:S2".4Q$DK'*P3."=P&#]:-=:78ZK976IZ>=6TZ&YBGO\
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M+%S?J#4)M,?2;V..\B&.PEN5;VFU9",!90=QV@% LFXKN9=VWW1519PK.MS
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M6T'<0$6B$;C/2H[.1R*S/G6NN(!H'281%?M,G_\ F5DA$C]H&\14_(>,?=F
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MJ]=#%#47I4P0/KY;N7ET5A]KM$AUJFK>5EY=8;4F$4[G+F0<KSG/%*M<AM&
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M:NUJD&/N/3D-6"@E@+9]>OTJ,>'KU\:J9'O3UCBZG4KB5>;"L*\7>S:SKE?
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MU9D3&!S7J524!$BYL=N-"=0M^20X]!5YIUEPK!Q!#+*-'):K#")+I724[A#
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MP>.S?C !KJK?8!^U4FUUP5QMDR9K\K'@//)]S3$@0&Z@!]U/_F;8,^!U:?\
MS)1E/^_.:6%PMK?6=S("T<-S#)*H[WB613(@\BR;E'SXYJV7D+7%I<P*0'E@
ME1">X2,A"$_ /@_2OYQHV[4C3K'V@]=6B$@+N;(7&V6@<=^6P+<Y64)'FX^P
M/E/.&8+CC67!\I60EEEE"&HP1UOW9S^BSI-[J[/&=3LI;JR"6=M:,XB,UI'$
MKP36ZJ A25&#Y"LQ;)F<8 '(3JD5H(W:TN$@N TLUPJ[Q%,7='BD!(/]IU;/
M/CN"DN<U%R[$2!)D%2^O@PUXV=;HK\P"<3]\6F46LJ+=CR;5?#Q_KF#,,E,$
M"AUP92)N4.:P.AMCW,?9TDFF2VKRKJ4;VR0OL9& +ROWA8L':P*X;M,E """
M6R%W%O-#=1I/'(KPD$@C_+</ *?># $;MRC:#DCD"MJ=!V^R#=F=&UEIS+R5
M*MV+N<-AN/BY%UB@+:]@H:R3#TB(E[#%F,CD.J9P\L5A!1Q01*Q=9K%G;GI;
M7+J509>SL19@@LZ%M14O)W!07BMIDX)94R6 5P3[Z?<2_P!=TN*$L(^UNO:,
MG"LGL;;%[\MAIHFY !; &2K!>VO.+UTBG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*@
M[L5(!@:JFOR#B&A"S849]3F%Y;RVF4&,6AW+?\:6G$B*;=6CRI#:E+QC.4^,
M[OIZ,OJL&WDHDSC&,Y[)U& W!.6! .,GC(/-:G6G*:=-CO=HE .<'^XK8.,$
M A2">>_N/=7&*,O.J-V&RTK4A8BRQ%)M[T8#)NPSAL.+9XD-E!4E4Y:3CFAC
M/K_<=8Q,02W&&G5DC,EJQA65=5"W=BAC,TL9GAVR;7*-)&6R$E5'/NY .QRR
M\ X)'%&D4,5,D:9R'"DA]IQP0< J2,'.%)X(XQ6OV[F.O\QLVNQ-_L]MUOLY
MROL-52_UVPV:CK1&.2)JVXL:S#+Q6'W$'.%.."S Q+25$I97G*WT,*VUA8:K
M-92WEG;QW5K',5GA4132*0H8N8,F8+M(PRX; R!L&:\S>)#)V3D*7][+J.S.
M2, .> 3COX Y&X-D#N/T=UT10M*1KDE8IJXRDV40YFV614:[/S42 02Q%.2)
M$4#'!DJ9RX8AA]L1M3X^6R'U/DO/DO\ (NK;PW&IF *(TM4"F)2=B32@/* I
M)VD#8K#).4[\8 O&A0!+5I]H#7#Y! .>SC&Q!N8DL,[W&?\ S-9KVJL@T/JB
M3A'4L/+N;[==<%?0AU!$8\E1$NAQES"D.L.B,Y"(0M*D*;,RE6,^[&.8/331
M'7+56F6*XB2:[MD[0)+(]MV8WPC<'8P/-'([*#L !; .:]=;9ETZ50A=)F2"
M3W0RA9 Q*OD$ 2*C)SX$X.0*Y/EPK20@XYJ-+:CG7V\-.N,.)%^ =QO#N&C%
MY]R\LCX<%&\.9<'RM#K+B%C,Y3U-+UNV=V#M)@KD!1[S9][_ ,0H.'? &XC:
M02S51?9$,2@,@3AMH9MP"D>[C&2S %% ;C.[N45?18=<*PTTL10+)+CA+"4L
M88;R,I?QL8';2EMM#; ;8[#;:$H2EMIO&<8RKW9^9)3,VYGWE5"DDEFW!=S%
MF)))>1F8G/>Q[@ *A4"#  ')/  'DN ,# 4 9 \,\GDXM/[ U'?+C.Z<CVXF
MS2=<KXDA=(G,43,P++!)8R0 ; ^;'N0@\VZYE!K4$40[*+8;6;EC# WR8^XH
M[JV5+Q9)8MSD0NK&*1#AMW9LK!]I!QO7:I&1CO)^G7<GOQKM) Y(8.!R&V,
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MWYM=1)45M>W@;0_(V6>/4_3?KUF1(EQ_3GU\_"A !\ADCX>N>?UK<67[F[
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M68O&W]AV^T@2(&W*Y9X&^*A=22$>Z *\)6S42S9$/!_8G/=_/U/Y5]  D?,
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MW"5V[@0,'GD Y([@=QSC((SQ;]HM64ZN'CA$)8DI2O',0J0)90K\:^:+]?!
MASHY.0#!\K00&\IDAALAEE/NREM:DX=[+?Q6-W)I-I;7>I0Q2-:6UY(UK;7-
MPI+1I/,BDJC$88J!N4;2T88R+GZ3%IKZE91:Q<W-KI4EQ&+ZXM8ENKFWMF([
M1H('90[K@85B<98@2$=FW/=\ECK72Q*S+7VEZR$D5OR*PX<24MFPK3)$KS]Z
M=E7W&'Y&1E)$A*L$S+I@P;;N$AL$"#,L#-4R'IC\<^M0XDUSISIJ%P(I#HME
M/<O;(>!$MW?L$A95QA;:<2Y.X'@8ZPW4?X'=.SJ]KTUU5U=<1^\C:[?VUC9R
ME01D6MB"7C)SM2ZM@G&U@3NSM/IX8+:6KXUHAJ=N479!I11#%_A6PC9$'!I
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M&5HE)CRN0<]LT648'(W%@.#7;W^7.,5T>OYN.V?8"7>W^!LFOV<.>U#,2I4
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MT0,H.Q6B;8Q5@?O3YFA2%)41O9BBDNK/&PBV[5E0A6 V@1OD89D?GWES)3P
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C4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img102364508_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_3.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %E"^5Q(X0DE-! 0       \< 5H  QLE1QP"   "W_4 .$))300E
M   0%[!F+$S2BZ/ZL]P\'L9W<CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              J,   :=          $
M                 0             &G0   J,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   J,     4F=H=&QO;F<   :=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *C     %)G:'1L;VYG   &G0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      +Z0
M  $   "@    0    >   '@    +S0 8  '_V/_M  Q!9&]B95]#30 "_^X
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M13X,0KCF+XM(BMHL.?*;X(&N'61OYI/6UV,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5V%QD2-!45:AU0HD,['A\/$E-G;!)B<H-#4W5&2CI:;_Q  < 0$  04! 0
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M!KO&!$JL?K]H&S0A$>9C15ZELI7&5(BR8DA\BD8K=Z8"@B"9NW5@,-L$F)#
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MMV<@+\D( ?RKAWR@,]I&6BXG(/5*STG5>1HL?M]DY-;6A":X!V15JC^)%MY
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M'Z)TBN6'QGF.>44#F/1*;:>BU2B6$XF_23;'2"%<D=1CO^2M&KH Q>8805?
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M(88F#=SY)'!K&@<NLD#<G8>'8*,+%B&K!-9L2-A@@C?+-*\[-9&QI<YQ/R
M\NL]0!)V6@KOW9BG;+],L;ZGXP"!I8VIB'-^K0X.V[M6GGFT[VCZ2)N:^-(N
M:4YO2U-0T.KC0HVD]1Z3TW#IO&,K#A?;FVFO3CGTDY:.\:X@.Z&#FR$<AMQ2
M<(?(_?F/56HIM19-]G=S*D1,=&!W+HH0X]^0"0)9CM)*=R=^%G$61L#80S:%
MK*81,(F$3")A$PBG'Q_[.4XG?H5A9V])K\_2!ML$M[]KX\.XYI2GV&EK0W])
M#%[W,'.*4C:EZ>AJ=1'FR/7J^K=.0ZCQ<E8\++D.\U"P>713@;<#R 3T,P[R
M4 $#O9.%SXF;;-I74,VGLG'8!<^G+M%>@'/I("?C,:2&]-"[X2(D@D\49<&2
M/WWZ!C RPB1IT--8(B2\*,0'3HR_;8E0Y327F'FU?A]E:%ZWZE:TI._6E:4J
MUO6N7)X)JTTM>Q&Z*>"1\4L3QL^.1CBU[7#Y6N!'R?)N%T[!/%9ABL02-EAG
MC;+%(P[M?&\!S7 _(01Y1U'FJGEI74PB81,(F$3"+7?:NT^0LU?F$]07Q%@'
M\EZ_Q#DU-8K54$LV"OUHL$YI?.Z7@<U:K8^'O]PJ= ZR\L#'FRA%?EV;GZQ3
M5.GRT$AEA(L<JIY3>7\ZM\5Z5&$3K/S"R6FY@ZR2*0.3@#?<H;?2^W5ZF,6P
M</(ND Q@_P XJW*+M6K'R (BAJ#F.@=5MTL7SZKI +(LIN8>: &=XI]4[W:1
MUS+2>"UA9J^_' ZM67[C+E<?I/=14VDCP]F/#!=9L-/Z3545]BSEX=AK[;RH
M%\;B&!A64Z11DWY(^1'8NV5OQRK,2E<ILM3Z;=7^TV^CW9JZQIW,N;4'@5I,
M0.<%[KQ8D)D'=6CR/J-0M+)BI05-RJE81(<\%GE72U4(K\[!YIV_GMUOH"L<
ME#7 !3^N<Y\>AY9Z[G!]@L7:NC<[KO46 T.LB^>GXJ*O6Z?:PQ P<58E%9Q'
M<BM@JX1-+CM+(K01Y[W=NB]%O1KD=+JD7@U )7?M@FT=7E0#KBXPGH-H&BN3
M#(5#)JMSQ>C4:-=(R[,_3%(8L;-=>;;-UZU:#D5^2/,.ZG>C2N4\UYM1[';1
M%M<J-EG6+J! !4@+U9X36.P=.+/&0= N$V6.HYCIW(:#I,81MTD:MI+4Q0-T
M$Y&DD401?2!=K(QZ(D5XR!S!N^\EI_?QE:$=1+22C/*KV<^@Z=#)29_,Q <1
M?[*^P04V.F$E5 $[''PS-P0^;B_#D72N'GGVDL&*QN<\SYL)E7X0VOA%P.7\
M^8B[59?+BD>+G-;%TNMM<_'M@AO1(5TD=+JL4$;M.EC*@<'$7VMK;>;(LI^N
M]-Z*Q>?'[AT"T5WDMJ[!6>E7&Y=!@,0K9% #N5"Z7HW4N9R+D,@@I]P.F[^+
M(A2ENJI*(BBU.[DWJ<Y-:8=%D6(MS\C.T -]<+4#R'KG2)7%9O&.5\YILBG<
MZ<C^4O8^@#A_3Y(1#E=^$+I('>:=0Y* $'N=%@U7!DX=HO92LO@(LT1"(LBZ
MCY!&Z;QWR[\F^D6@O=^8\WZ%W:1SZL#A=0@RQ- X--+T\T)'$!PL*HK./7RI
M7'0TM:"LIAD!]6ER)S.FBI0@16'TSS<ZCRD[5*>9Y=RFUW:==>8";G6^>=;M
MYQFI5/M%]$\TYJ1<LIOCU8K;MH.7&-T,8BJR",::\S2HQ6/K8PR2D58BMZ3Z
M0RZ)-3:6SQ0>UT4M>&:S3J-+L5YV6A5Q5>Z;<&KY<)D;ECM=,5P[5.=:)5.=
MQ\]TT:6FE9\&:4$CJN5/N$4R<5\L[SU#L 3F-MY#$Y3LSS6/?8+!VT'+":/:
M@57G!&]+JABL44ARLI!Y]>NBQ>:V$41Z0&O*"(QZRHJ20,Z IXBSHPB81,(F
M$3")A$PB81,(L?;WY&U*@=UXEP G7+Y+M7=)%L9K=BA54BGGXK50I%MO,]@O
M=9;<8$X9D#JA.8CUH/*)V%GXF$2(C8(=]N>LBA4EYW5<=T@G7=\EZA(Y* [U
M7?%^Q>0S;E$;Y\'[C:25>KHBN.UZ1<F>E2JY]=[97.<SKM%IKH.'>"C<':G0
MD0E8(1%^*1YY5.ZW^C@T<HZ<#Y3UGJG0>(\?[\5<HKE!Z%T_FFKWL\$C@AMP
MG=#K8HPOF-^9I5CM%1%#;.]6G](W!;+5MTV15CC_ )R\X[JYQ(?S:IW@Y8>P
MU<AT(K7TL $R..\S@E+#7XMZZQ.0==%A(-FL]=DUJE!14PU9K:3W/DB SP.L
M7$Q7B*_;+Y>\&IODE7/%.UW<57>N6ZB0+[61A@J"@13L8K:'ZF*K@M$DNV8F
MVLG.B3)D 5'#N,R1L*7(;F[=97'PBLB\>D(\0Z=R3MG91O;J!TBM>/\ 7EV/
MHHWF-RJ-KL,**LD\#&1X,))^'"DR+!88[U<K\AXC%%E3[+PF.1W+8?;:(KJD
M^<7AS#W2-3/)[AL/728S<VB.2NEU2.S:83UGGTIB:(D.DT,2(<BXBR-6CR].
M)C2+#!E!V'7)[#C"2*_^4=G&]6M7?JM "3A,C@78VN.EI<R3'?9L!%WDG*NM
M:,CD,I2N+"T/ZK $;CR=J?\ C1,Q_2O</L:T16V]Y?\ BG'EW@>_Y(</:(<R
M&G"_11Z^GTW4^BC*U<7.>'9EMA?3'Q5?9&7QI=-D[*-1MZLVDA$:616B.HB_
M<SRY\71_-!O9)_D%R&%RTQ8)-2%7J5?:['KQ&V0GIC$ZJ0IKL]*9-H@.#B.B
M%=:2HQ!2.GN2X3+<*2IHBN6!Y$<%*U4W>A?9N8DZ56Q=3.'[<-N]=GUH0%O@
MZ 7I):>;B$'AL8;;11482KLYR3J,8@SXDJ"X^S(:6HBMDSY>^*M=LUBI9[R.
MXD'N%0;(O6NK$NFT^'8JTP)+"@1.0>#/ET$1$>$:-B1,B1/CL,MD9\>'MSWZ
M_=Z(J1-\V_#L<"JEHE^4/!6JS>99J%3[$GJM,>!6-RMFT5JQ/B2[!AP?+' ;
M"XR$,EFY&Q8PH_&@S9C,B2PVX15XOY9>,0#J<3AYOR Y *[%-L(RIQN83^@5
MF+>5V8V&$V$&!76G2*2K)4Z%/!2(.$_&;?,QRL#8Q$I<EI*B*D^/'E[P/RB<
MO</C]\"V$WS>Z7>EVVMM%P4JPC'*3>[)0/K&\,$%BKC%5MA&KSB],*RU1G#5
M>DP"#D2&\^Y$9(HW7YG%CUDNK/)/%_O/:^<<XOQKF5OZQ1I'(AX%ZX5(K] W
MZ'1JS=^H52\]!A<\/M$:_:B5>KJX[E@"'0E5^M!(7)CI(K2D^D, AG;I9[9X
M^=TK?!*!U[H'&K9Y)+5R0SS:MF^;](+<JL%GL==!]2G]>"T)FVAI34FV/\U<
M@AA:D'K#H0":FDHA%/U \AUWSR#[/P#?++Q6Y7%J_2;&5OQ@I0)-0LD'HKII
M-/17H@.XE;<EXK'K-EEK2:K8E$!H.MN>N/(G#&IA/U]RN>S^1_ *5TNO<9M_
M:>85GK-LV*36^<G+M7AER,K/R94.OM0J_+GM$G7K#,@S85?9]QITY,B28@I$
MR0PZVDBM:F>8_B?T2%=R='\D>)6<;S6OOVWH! 1TJIR8-/J45<IJ3;+!+T4U
M'&55AV#,9=LDEQ 5MZ+(:5.TXTM*2+\Q_,GQ0E\]F=7B^17'9'.8%L;H4RW,
MWZNN"(UZ>@1BS%*==1.V[JVOB)D0PQ6_=;,OAY+!9J$L<ZB2HB^UA\P?%*I0
M: 4LWD=Q,&,ZH(B6'G!(ETNHQA]TKL^3$A0['7IRRNHI"O29T^%!:.LN[$JG
M2XT/4SXEYMI1%D=A$PB818\=.+D^@6)'#:A.E0?CA[!;J]F&O+CRJG19BWF&
M@ V>RKUP[C?5,R!XM2?^L"*ZR;L*=L2V@FY>G9Z>?,7!I3'2R0]+#'9U#>A<
M628[$RN>UM."5O./)Y@L?!7(V=5I,MW06R-J"60=+U:VG\<[767KPV.@LR5-
M(XNTQLD68ST#6/DR%JN\;3X73PDBL6VN!BNY*3'XYPDA??$,["! P *'! T&
M,,$"(44:,'0VD,1(,"$RB/$B1F&]);:8CL-MLM-H3I*$(2G6OO9M=>O!4@AJ
MUHHX*]>)D$$$30R*&&)C61Q1L: &,8QK6M:!L %HUNW9OVK-V[/+:N7)Y;-J
MS.]TDUBQ.]TLTTLCB7/DED<Y[W.)+G$D]:P[\M:9W3J,(?1>=5]A=-UI@G82
M+Q\.->-$&G5+AC/AI4]I_P"C!RD-S'=O-)U*(;CK2G2![;C\C:&R6F\+8ER>
M7GE[.;Q14XF59)F01N:!).7M:6]-*'.B:!_5Q!^Y)EV9'&M\=J/,PQ8W$P1]
M@NX9;<K[,43IY&N)CA#'/#NBC(;*XD;22\&W"(MY,#/Z$_D/_ND,_2FN?\QR
M4NZ7I3ZU:_@I_548]SC5/U6M_&P>LG]"?R'_ -TAGZ4US_F/]V_\L=TO2GUJ
MU_!3^JG<XU3]5K?QL'K+C^A1Y#?[IC/TJKG_ #''=+TI]:M?P4_JIW.-4_5:
MW\;!ZRY_H3^0_P#ND-_2FN?\QQW2]*?6K7\%/ZJ=SC5/U6M_&P>LG]"?R'_W
M2&??_!_]*:Y]_P#_ +''=+TI]:M?P4_JIW.-4_5:W\;!ZRX_H4>0W^Z8S]*J
MY_S''=+TI]:M?P4_JIW.-4_5:W\;!ZR?T*/(;_=,9_L_]Z:Y^'_9_P#B..Z7
MI3ZU:_@I_53N<:I^JUOXV#UD_H4>0V_P5,9^E-<_YCCNEZ4^M6OX*?U4[G&J
M?JM;^-@]9<_T)_(?_=(;^E-<_P"8X[I>E/K5K^"G]5.YQJGZK6_C8/66>WB5
M3>Y\O'D*)T< PW3T^_)5LBR>#D70TYUW3DX3\-$G//\ T;/<<=GL[;;VF)/^
M*VK6TS]J8BW762TUFIXLEAYI1>=PQ78GUI8FSL:TB.QQ.;PB6,-$3M_ZR/@.
MX='W\GZ(Q^H\-#+C<O!'V"WBEIRLLQ2NKO)!D@X6O+NBE)=*W8;1R<?(MD'1
MYI9'ZWY,(F$3")A$PBBS7"^))#FJ]KCO+- +(1'%[$#USVI:#GBPB7N>)*&A
MFA'P10B,G*5,'39S#\F%+WN1&=:>WM>$4BN#!KK@]YT=!<=$J<4*=<B1UN#%
M.Q78+JAZU-[5"4[!>>AN;C;;VN*Z['5O;+BD;(J*&H]*KM<=IU?J%7!5%YLB
MR]5@P 2+KCK1AQ]TLTX$@Q&!BVRCLJ2X10J+M,UR0^N3IU3KFU$7YK5$I%,A
MBQ]/IM5J@\&.E!PL&M5X0"AAQ,V:@E,%BXPN'%8'CI9%MN?*@Q$,QI$UM$IU
MI;Z=.:(ANBTFS!SE=LE.JM@K]GD)F64$;KP@L'L,M*(:$RC@R?#D0BTA*!P]
M"7Y[$AW2(,-.E:U&8T@BHSO(>3O21TU[F'/'9H>L2*0)EN4JMKE"Z9+C2(4J
MHCI"ANWH-8DPY<J)( 15M"GHLF1'<B*:><0HB[U>YKSFI0HXVJT"E5D=#@D!
M<2!7JJ""PHHPJV*:*#H\4; C,,0230((T0B--ICS&PXI$AMQ(^)IDB_1;G'/
M#\VJDCM#IAHC17FY%(GEJN#)3:;(:TPEI^JRID%Y^O/-IBQ4H=$+AK1J-'TE
M6M,M^R1<$N;<[,AI%<+T*EE:]+$#*_* DJL#G!9($)+60#!) N5!=@O"!$]Q
MR:+&N,*ACY:UR8C++RU+V1?6X<^H70A#%?OU(J%X Q9D8A&"7"M!K,(CSX:5
MHASF!IJ%-A,S(B''$1I+;*7F$N+2TM&E*ULBZH_F'-1%DD7$5SRC#+?,A('2
M[4/J0"%9)0]N)'@-P)!R,/:)OPFX,2+"1%=E*81$C1XZ6],LMH215 %1J35Z
M\Y4:S3ZM7:H\F<AZL J^)$5YU!/V_I)#@4?$CC7$D/>N?')5&WJ7[Q?O].>V
MKUD5L#>(<6#2:_,$<AY>*F5.*N#598V@52#)K4)PMH\N'7WXHEIT-%6=3HTN
M..7&:46UHCM&YFM/81?+?">(;K3],WQOE6Z?*-ILTFI[Y[4?JU)LB4^PFP2
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M8.)J1BM$+>5R$XHX>@7%O9E^1KG-$C@"8JE:)DEN]/L>@J02O <_@C?LVEL
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M5DX=ZU9[FX>*1O>SVHW%C[Q!Y.CJO#HZYV(-IKWCA=6:70;[IFK.QXG:=H2
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MJ'W>BD>'N<<ED76 X<')EMUHVXF?!MWCCG9&=W[M/22<2?QRGD:@'I$F?T1
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M8^N=5T4Z<(LS_$'I_9[//['5NJ5,LY-I9TM-?N$MVVQV#5ODW_IE;+T\ (M
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M6MKW<UG<1YY(^?/:>T_6VDZVK\-+0DVCN1;SXVRYIVKVP.]XR&EW03#>*PT
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M[;'^?QUGJ=W[=TBX]7Z.9>/W6]&I)T\2=U["%R'](;8B0V-;VB&,&0VHPP3
M9]3 \9#B0HZ4LL-IUWCB,31P>-IXG'0B"G1A;#"P<W; ESY'NV''+-(72S/(
MW?(]SSS*YIOWK.2MSW;<ADGL/+WGGL/ UC!N>%C&[-8T<FM "CS,DO&F$3")
MA$PB81,(F$3\'W]_@U_Y_P#/^S\/X,$@=?Z_0Y_=N4 WY#K3>_5]_?X,;@?K
M]>#G]W-5V.^VW/?;;R_(N/7K_;K&_@_7_9 ">H$[=>P)V7.MZW^#?K_U?>_V
M^OU>K_/[W^.4W'E\Q]'Z.X\!52QPZVD<M^?R?K]JX]>M_@WK> 0>H^#?]GZ_
MS'RJA!'6/UU=?W\OOY+G*JB81,(F$3")A$PB812?QCL%[X%U"F=>YH76%N=&
M,L%Q,K7M+C2$I2MB>*),)4CXP.:'O2A1B"I:4S1LR3&VM'O/;3BLWAJ.?Q=S
M$Y&+IJER)T4C=P'L=R='-$X@\$T,@;+$\#=KV@\QN#[L;D+.+NP7JK^":!X<
M#UM<T\GQO&XXF2-):]OR'<=\ 1_0*\/_ "DH?F#PNJ=EHSJ(^R+>Q=NK3DAM
M\C3+H/:8^G*T2TC?M:5'6^S-&2%H:^D@<X65;:;:FH0G@[5.F[^E,U;P]]I)
MA=TE:P&EL=RH\NZ&S%N2"UX:6/ )Z.9DL3N^C*Z6PV5K9K'P7ZSAM(-I8]]W
M03@ R0OY#FTD$'8<3',?U.63^:ZLHF$3")A$PB81,(F$3"+\H6AS7M-K2M/M
M+3[2%:5KVFUJ0M/K3O>O:0M*D+U^%*TJ3O6MZWK"+]81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBX5O24J5O\"=;W
MO_#6O7A/N6--8U]W.\QNAR=J=Y5SXG):YA$5KUQ;I<8FGQI7IRT^OV) 8)[R
M< H?MZ6U*D*-VMKWS+]9EL:10WU5EF9EYXM/XB:1N!C)WCRF3CXH+&>(WVDJ
M5=Y:>'W'#*\VLBWB:^A*V2<F?>-@Y=.Q[LU9J&K$_5,HW$N$PLICLU-*M/7%
M>O%L&1U"!L^*,4<.\LDBRT$D_6&P ZD!,V>RE((*NUT7/-G#).0W#&B1 N*[
M-(D9\IW:6HT.'$8>D2'W%)0TTVI:MZUK-[AAEL315Z\3YIYY&0P0Q-+I)99'
M!L<;&M!+GO<0UH W)( YJ,Y)&1,?)(]L<<;7/>]Y#6L8T$N<YQY   DD\@%X
M,O24><AOS;[Q,/CGIT#CU$W-KO)*Y)TY'5H3N1K9"W%8>W%(;L-N?89ERD^K
M2QXJ,'#*VXX.>E2NX?<XT3%HS",CE#'YB^&6,I.W8\+^$=%3B?L"8*@+F^$2
M3/FE&S7M:WG75NHGY_(N,9(H52Z.FS<@.;OWUAX/]N;8$#EP,#6D<7$3KMR0
MUJB81,(F$3")A$PB81,(MCOHI8IZ9YK\CBB>2A>JC9!\2S;'#E$GWF/SRLK.
M"DS>AQM1?:B56:'D[AP8]N+M.CA2BON]Z1+E17$1O[JSJS=&90SY>;%2".0U
M&PW64CD;0@E+,=('=];CF:72NJQD/D,(=\5C@=NT2)3GZ@92CML<X"9TD#I^
MQ(N-N]INW*%S7<,8F>"UO2$?&(VG/Q6HO0ZEZ6)^M$_'URRIE]S.SSP>]\I/
MF5T+G1KIK4J)U<:,>BQ6ZS&APWQJ@-Z(Q7@$2(89?CJ6J9"?3@=57L7<]RN.
MQ%J 5A'B*\,$E#)P0MOY&OCBQ^(E>'.%DN<R0ST6.$SGP#BV$;@<G@ZUROK)
MT<N,,O';ED>+-5[W5:TD_$VZQI ,0YM;'.\&,"4[<W-(D/QV>Z)P?S7\[7'_
M !Q\B+<2/C^FA @WD/,!)SH-('WCL$0I4>DAZK>0\Z"\#=&"77 1=-:.AI6Y
M$%3C"QDE3VL9J/M7GM&:&:S4&G:T567'RRNR^3FKX^[)0Q1AMXV:U1>V1D[9
M)6-FBZ>&5H#@'MD#6GVXCLO'9[4+G8O)S.F;*UC:=2.2>%DUOCALMAL@M=&Y
MK'%CNCD:X^#8[G+>)S*L@?)WS; ^0'5K)>Z?-]')'L]J/DZ'01'6>5U,X;$S
M252,UBD"QE68Z36Q+LN?'?B#V%N,FA#C^GF-)]YJSLC-8TQHZQ@,54I7(O=#
M=7JUXKMV;%9&[! ]L5N&Q>EDL]@6)&QL<UTI:'0R\#FN)VS;:D3,SG(LC=EG
MKOTRR6>5\%:.W5@?*TOADBKQLB%B)G$X.$8< ]A(.VYU9>E0$6JN=JIM>&B:
MN)\:('.:^]XEKY^G3M%.<BF08CS=A8*ZUM\U=29#:G;V0*..EW2.H:E./A5@
MIDJ4/<J?3L8>[:DELRZFER$_OJ%\[7X<FQ\C1 Z(@=%4C9Q=ALC CX3(.4K9
M&1Z7K9EB*_7B8R%F(95B.'[&_J'U2UN[^+?X28NVZ9SMW?$(/"6DZPLE):4F
M$3")A$PB81,(F$3"+9+Z,GSL+^$W<XTPW+FR^)]%=' .K@6=/R4PHR']H%7H
M7";5_7-U-R2^XM#;;KI(%*+BT-*EOP7XD;>Z9H>+6.%/8S&-S>.$D^,F(:TR
MD@&6A*\[ 16@ &%Q CG;'(7-8).+;]'ZC?@KX;*YQQ]MS([3.9Z/K#++&_.B
M_M ?&C+AS/"O;)>+%V(X'I]A\=6N+VT&>&N%YA7H%IMHR!-%D(PV96B%5E4V
MM69DE$(17YDB0_+5%;]SL>Y#5(2\]MKC*M#CX9;,.9.3K30OZ)L52M!)(R1C
MGMG98;9GKF-['-:T-&YXN,/X>$;] /DF>R*2GV/*QX#^.21X:YC@"UT9C8\.
M!!WW.P(((*[UND]_;N%9;H0?C\N@+;$_7*7;['<QUQC.J*/).ZK X-5R@2:V
MR%U'=$J*E1ZI!13S$Q,6(A$A?Q7&*[&L&V_(MN O[%;7AK/K.'1_!=/))/'*
MS>7<2='&_ACV<TEV[5]2&R'LZ)L!BY=*9'R"0<^^Z-K6.:[O>KB<-SR.PYI)
MD]^UT]EB&'Y KC&W(_ORDFQW-'3TM;$)5*VT":J[E44XD_[34=*K$E*P^DR7
M%(F[W$2 Q78)+I,CVS[[:-L%8T3\)WN\QL"<;Q;D_ G:7O0"SOD)M=, &P&O
MRW<7R"<<N>S>#HSWVW6\=[ORWY'FO2>^+Z$::M8?D,?E*5$_J[/KUBN4SH3R
M4R&M!MFQ!*KP:W&V[$]^HG\ <EZ8DZ91%W(;4M::RC%=AQ&O)D3D/@^G9-!7
M;3'>GI>BE9.Z9VSMA'QQ-);N7AI'"C39Z9P>V 0<^ M?(9CU;<32P,'AWV>?
M!LNA3)7DBYNW_=""<0AI;&254+ZF6B^$E2S.MR?@VK?].5 3H<,5K43XE\-L
MI*1M4GW4=S2&O>?=D88"#L.7*./&.RA:KU8^&/O=S7,-F7C?\;9LG WXN[N9
MVI&;6\G2MK@<^BZ-\A)Z]NDXF-#>6V_"7>'KY+X5^7Y,KI=J<M0+AD?HB%-?
M4>'7[5?IE+E(]EOWV[63(T^"<@*TO;NFM"!!+2DZ;VKV=J7I"88468!!)E74
M]CV4Z6M4;9:>>W8\;+3XGC;;<R2, .^Q/)48;G1O,C:PFY]&&/E,9Y#;C<Z,
M.'/??A8[EM]R?%>37W.=O?07"ONN?3'LZ'?6N_\ W.=U_P!O_MOIGZFZLVC/
MN_7OX;Z!^!]O7J^+TG?M:;87LW;I<KVNZ/X_8U47>F\(Z+LKH.B/+9W2\?7N
MSENF]SH=^&MV1O\ %XY>AVW^?T?2;\//XFV_+?;FI+MD,:1IIR#:C,FM"Y@6
M2P=.AK02I\H/&=C[3,G#;<-FB2H!R-K:UQS$2? F1/92^V^PXGUIQIVW.V^V
MYVWZ]M^6_7SVZ_*O0-]AOU[#?;JW\*TY^-E0ZKU_T;_CP$\>^C//76G73HL@
MI/F=MOE:8*H9M?7A(X7U"S4"9]TVRB'GS@.Q%1X^[U2QS),,59=ES"H6P9JB
MJMC_ (O\DL/%Z7>*G8D...D>Q]CO PE]T.YWR.5!]#Z)8[R'D,1+DXZ[2WHD
M"PL"2U9#N.B73H\I8$R9TLW*GRB+1#Z.-<WF)OPYNL_EXOC>[YXG==*5ZX5F
M\'3K7G5TIU4$S Y_=!R H&MUOJM-"U8KT 0,._6RV6(9/).4@[*%UJ_QF2*3
M:1Y[>84+AEB\A2-ZYC;PMJ\8"?6UA;(=X@28Y/?-W#E@5ZP4?G_(RT7JCW&.
M5@+E>277P_8"AJW IU0KL(A=*_-)&H&B?KPK.IGO)?C_ %/QRI]B\RZAV^A]
M)Z5T(!>+C8XG%*^^!W#\?+)TBHU(D>YW KU:&[)DJ](ME:TZ-%G9P'3L.1/L
M$)M,M1%"7CSY*>3/E!</'2NUSO5?J%;Z!QSRUZW9[37^:TBX/VV%QWS(K/)^
M>,5>;,4D&)'D.?F409QAJ";9*P'72$6.R;DPK /(K!F^4GF&'\9N2=Q*=F'E
M'?(;R4-^/_L#:#R2B#>(U49T+N0L7<8EOO;LFI2KQ:7.<U/F HIT37U"9L-S
M"NM4TD=VU#.D4C4/K7F+TV[\(X(2\@PG/R5IA^8SUIZ31!7 ^L= * ^.%_')
MSFFC[@4>?Y#4>G0(G6"XRZ1!-9D R$!E!!%0!SC(IZO$_7_LK=XKY@=F[["Y
MI&Z'Y/T7Q1V*\-^3>0)6TKJ?-T0^S76UWWJM)OI"4CJBIXD7S+G;/-JQ)M("
ME2P%DCD^K"]NW8$/;"L32*M\'\J_*?J?D8,FD+/4P=!<\F^V\,N_&+3;."!(
M]:IO/)_3 -574*ZW(;\BYG;YSM5IEY)LV @1IUAI!RQD*]3Q@95;L3)%NKPB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(GX,=2+'7II(CTFR[X
M95I<F'!7!B%.QV0>\ZP^!I9';J(M.&SH[B5P[;?TM/1TJ1M,D+4&RYE*HTZ7
M7G7],SL\V;O>].A*^*(Q1V-3787O8^GBI^,1XR"9A#HLEF0UT8((DJXYMFTU
MT<SZ3GR'IFM7TWC??WE88YIVSRU=%XRPQDD>1S=?@,V:M5Y6N9/A].E[)7-<
M#%>S#J5$MFKPY-D<^#1H\,.@BA<.,/&C(<8>/@PV&XT2%!ALH8BQ(S#24MLQ
MX[#:&F66TI0VVA*4IUK6M9MT$$-:&*"O%'##!&R&&*)@9'%%&T,CCC8W8-8Q
MC6M:T -:T    !:%8L3V[$]JU-+8LV9I+%BQ,]TLT\\SW22S2R/)?)))(YSW
MO<2YSG%Q)))7ES].+Z03Z7GS?"[D9S>Q@N1$D]Y/#)"M)G%8RVY@WF++[>])
M=BBW=12]OTUM25%FQH)QU#HP[!7TW[BV@N%K-8Y6$ASVN&"@E;\5GQ9,F6.Y
M@O!=#4W [SI+ !#X'J'O=!U*.^P5)X.Q:<C(TGKV+FU-QR('>OF'/^S&=B'A
M>:'.DE$281,(F$3")A$PB81,(F$5:!V2Q5B4[.K1\U7IK["HKTL&4G"93T53
MC;JHSLB _'=<84ZRTZIE:]M[<:;7M.U(3O5BQ5K6F".U7@LL#@X,L0QS,#@"
M X-D:X!P#G $#< D;[$J[#//7<7P32P.(X2Z&1\;BWKX26.:2-_ 3LJFW?[V
MT8?L35UMK5@E14P9)UNR&$&),%&VMHAODTS=37HJ-L,;3'<?4RG;+6](UMM'
MJM''8\PMK&A2-=KS(V U8#"V0[@O;$8^ /(<X%P:'<SSYE7!=N"0S"W9$SFA
MAE$\HD+ =PPR<?$6@@$-)VW'4NQ#Z5T8><<L\"_W:#97HR(3UAAVL[%..PV_
M5[N(X68GMD%QD>RGV&%2-M)]G7J1KU:SY?B\8^ 57XZB^L'%XKNJ5W0!Y!!>
M(C&6!Q!(+@W?F>:J+UT2&86[(E+0PR=/+QE@.X:7<7$6@\PTD@'GLJ-]9[+\
M29F_6$Y\98V)$:PR_I:?\2=C2UZ<EQS+_P 1[THQ)<UIR0U.6^V\O6E.)4K6
MMY>[#J<,+.Q:_!6<U]=G01<,#V_%="WAVB<W^RY@:1X"%;[)L<4KNGFXI@6S
M.Z5_%*T]8E/%O(#L-P_<';FOC,/'" X<(GFBTX2'T[H0,F$9DD<+T_O2G]#H
M3SRXT'3RM:4[J,TUIS>M;7[6]:SZ96K12R31UX(YIMNEE9%&R67;JZ21K0]^
MW@XB=O J/GFD8R.2:5\<8(CC?(]S(P>L,:26M!\/" J3EY6DPB81,(F$3")A
M$PB81,(O3CZ#GT@NXSD+PKZX;U[A]R7*X)8";_WF7W%N32?+GY#F_O(D*W*,
M4SWZO7I_Z4KS;RM/5L:WS3[M6@N$OUCB8>1+1GJ\;3R)[R/*!HW&Q[R&YMMS
MZ.P6_P#,/$P>Y_J;C:W!79.^:'''2O/-P'?/JDD\R.;X>7-N[-]PQJ]0^<VJ
M6$PB81,(F$3"*'_(#HE Y+Q/I_2NIBM'N>TRFF3EJ ? !RCE@&18RO: 1AMA
MF#P1":<?4R*@0S$^"-DS9C#,V9%CK<?018?/>9'#>"5RL)@^.]LYTOH8FW=$
M'TJEL>-R)AVETN91 !>^!U<][&2J70)DR=>:V) 5"BG;9U$^IIUL?3G&$CE3
M2*7:[YM\GLUK/U"&(N;$\9; -6!RID6LH@71DM=>N48O9P3C5I>?&UFES.%=
M0.VN7<HU7FQJL A%10XN]9:W *$4N]*MO"^.U&MS.D.TNJ5(8<@HI8^6$C2F
M6+&*@DCD+=-K@P=-FN%PH@::L'O*\-<E!0HLR==5$&#2$Q@BB'DW5_'N\]]Z
MW1^0<ZK\TY7J[7RW5>QUNKU(?7#Q*ZA@-P"5AZS1-,FKQ/(5"SU^VRIZ&9X!
M(XT-]DK*F.R6(A%:X;LGH\3]2#52O%/'DS0;1;!CPL 'I]=(4J;:9DJOQ!UA
MD#X5?>K\/V2]HK(7ZXD6XPZ'930NNOF&#TID>HBF&G=G\92-MA56C6CGR[2R
M;+<_",@!C,;4PO.:N5SL5<JYB*-9&F6U.\SO)FS-5^?-@QC-,/:-K9,B9#31
M%99?RC\)8=<>JASJ?%6:>3KM9/D*\0<#_59=6ZG/&;JA0V,>A[#Q ][)V<8L
M5(+LL1CLPNVXUN0Z\XK"+FO>0_A75(6VZU<^1U$1S^D';>R\-"PZP#JM,><J
MLJW.#)C8<>*'JBO6"E2+G7QKZ"XMXQ6W+(+BN3!NW"*BH[GX97ZU\/YI$&4N
M]3[8KH9'E$1',D%Q51(<KL%;K-NUMF> T[S\I L-C##F]O01;FWU)>==8C[B
MOOD5<,=&YNGN-AW1_&ZQ=:Z'0R5;IO3^P42J<A8?YO/LH<(8B5PU;+U=:7<C
MTL92[& M1T+0H5N>#U<L/^)C_2<V$'DD5E0/2!\X?IA3H!CEG:JG4%<5Z1Y
M4$]8AO-$#>M\SY7&'$;64I$P3U M'$D=!3(0^("=.<YX3-A"B" V/(;'&]"R
M+) UW*BTOG]3Z#U!^9RN/<$#61M7M^H$RY:.$A4LXFJLA:60MJ3MFA"!Q0F1
M&U.98=11H@N3V^H:+G3&"*W97E9X\P29T-/ZG7X!&O5]%IFQY[16%J:"<*50
M%J=7'Y0YJ/;]HL%[I%<>BU-TU-8LEQJU>?C-FK )@RR+ZM>4WCZX0JHI?4:]
M$(7*.W)"12220I;:)#YV)!9/[)P(B*A-*S:O9H 4?;5!)YHC73H\3&F31!!B
M.17WS;J_/NOAI=AYQ8V;,%A$-#'R#$(I!9W)<'0"\9R-HK!@.38$\25&E19:
M&A\65&SHL\;,E17VW5$4B81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+A7WT
MJU_MUO\ #^#\']WW\(L>_&%B.YR<6=?UI=NLY6PFND2G4^N>_P!$T;FB[5&(
M.*U[S2P4\:JMP(J_4D<'#CAT=MJ)$8;3IVA& Z=KVY0#D[]F[:SDA'PS\UV5
M+7R$<Q/?;U)J_8,+'':"K5KUV;11, D+W4'ENK[E& N;AL75QU'3,(Y01Z:-
M&"WAY8&@EFV0JVFY2Q(TEUF[>M6I7.GGE<<0O2F>>8_POX@]"JA"([W?IT:>
M$YH+WMF0]7X_N_<%^ADH;NU(V/KB'D-B6I#;K1.R/CXRH\D?&+[CSQ[FNAY=
M99IIL,D;A,<YDV3F'$T3<^**C'(-MI;!!,A:08Z[9' AYBXH2U;J)F QY,;F
MF_:#HZ<9V/"=N_G<W?XD6XV^=(6 C;BV\*I$A/+D)Q8K-E$BA.9)($B,Z0[+
MG3Y\QY<F9-F2GU+>DRI4AUQ^0^\M;KKKBW'%J6K:M]NQ11PQQPQ,9'%$QL<<
M<;0QD<; &L8QK0 UC&@-:T<@  %SK)(^5[Y)'.>^1SGO<X[N<]QW<YQ/6YQY
MN/A/-=/+B^$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A%WQ10D#)CC0:?+%&!$Z(4%%!\AV)/'$H$AN5!GPI3"D/1I<.2TU(C2&5H=
M9>;0XVI*TIWJU-#%8AE@GC9-#-&^*6*1H?')%(TL?&]IY.8]I+7-/(@[%7(I
M9(9&2Q/=')&]LC'L):YKV$.:X$=1!&X*]V?HO?/(7YJ\/8399D.-W/FS, 'U
M .CW,?9CVVUMB+\)B(7O?T596F'-3VVVVD"K%')P-,M05"7IO$/NDZ(FT;FW
M-@8]^%R!?/BYSQ.Z,!WPM&5Y&QFJN(#3N3) Z)^Y?TK6=%Z3U"S/XYKY"UM^
ML&QW(N0XG;=Y88W??HYASZMFR![.H G9MD=+:4PB81,(F$5C=$K!^WUB2$K5
MO722KLJ#(;,_5L!;8RV8DE#[XX@!LD:1 F09Z$;9?VRY"GL;]AZ%/C/-Z5LB
MPB9]'!SAA=;B?7RV3@4#Z"FV8>5 T25/,6,-WRY^2DVTTXO%K(]7(S-RZ=>B
M^[HYSN&(:F5@;4PU<;J\ZIA348BD#L'@[S;K)8[8D$5TX^7-B2\9X'5:;("P
M]QU.3+$N?6B(5\39BUPL.@UO/G;$T0FS;1S_ )3.F:F1.?#1\DGZ_7]RO._^
M,,&S!N4"Z3T6X<KD<BIE@YM7#->C5T\231K56 M4,1F_K<(,PXMHC#ZZ&D5Z
MVZB/RA,Z/*^)A%1Q,B.DD5=YMXX5#D7,KWS+GI0W7H=VD'7VSC*XCQBM_&5(
M10:LV'7(CN,.(H-)K-2K=<V1;F.K@UD<HDY,=4^MPBAP]X"\A,]"YO>-H&R(
M?/.:<@Y-&K-IY]SF^1/JCP\[8[!2-5@K;JR3+40N_*M)2'9"E<D,N$H+(=\:
MT$/A1QUDBI,3P:,"N?<HYX!\E>GA8/#QA.K\N+1:GRETM6:F0YN=Y>WKVI5,
M?ADKO#KIQS;-W(Q)"]R6GU:"H05+)F$4A53PSYS3X8H6(,V1(<;V?FO9GA+J
MQNXA&9Q_CE0XWS:IR=(@(4BLU>!SZCVN(TPIN<Y:J\Q,<E_"R)$19%&]>]'9
MRBOVFRV)@JV[L_T[?3M3$\]YA$O/QL[R"K?D>>KISI\6IMWBR5DM<*S%KNQT
MTHSO=(?4*+N'"T$0>'$4O<_\6Q/.>L1>KA[U99TYV#V.$?#F( "9$,[[#ULG
MV D_&G-#HY$*X*-3AP-M,)]2"5;J=/'SM;6%4_,(NLYXS'AMNZR;HW=^A4*L
M]FM$B_6VGB07/RGPMWE42O4"5/KMEL%7)G! (C JH(R2!^]DR_I^-(?$' HN
M;($J(HA)^CY#'>:,<[/]JZ$:2*Y- X)4B$P!SV..I'&-OU-=MH]<K FKC13V
M^CQ*)41%VL5F58[!("A&Q0&> A3234PBR:ZOQB=T6Q\YN@#HMAYU<>;_ %LB
M"S08-5; U*$7@9 %V..\(M@<N,9*Z0+'RP9MECWPJ2S(CR(Q,,3*B9I%B CT
M9U(4;O%J*=()6^TW42:KD\S?>:\JMD@K73O41O5ID6\3I=78L=Z*QCU<I+
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MP-^9Y@>%8-^:OEGT'A7;N.\SK/7O%OA56N7$_(#K5DZ!Y1#3<JMRRG(K/PX
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MT6X=5KD<B/LG8HH&.Q# V'H\1V=(#S;<.A,[A+/"X(QZ=#6U#EM.0QPB./\
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M^A_GC]9<?)6])_\ 9.LWZ><B_F#CWVZ=\9,_ M^P3M7=^A/[\?KKGY*WI/\
M[)]F_3OD7\P<>^W3OC)GX%OV"=J[WT/\\?K)\E;TG_V3K-^G?(OY@X]]NG?&
M3/P+?L$[5W?H?YX_73Y*WI/_ +)]F_3OD7\P<>^W3OC)GX%OV"=J[WT/\\?K
M)\E;TG_V3K-^G?(OY@X]]NG?&3/P+?L$[5W?H?YX_73Y*WI/_LG6;].^1?S!
MQ[[=.^,F?@6_8)VKN_0_SQ^NGR5O2?\ V3[-^G?(OY@X]]NG?&3/P+?L$[5W
MOH?YX_63Y*WI/_LGV;].^1?S!Q[[=.^,F?@6_8)VKO?0_P \?K)\E;TG_P!D
M^S?IWR+^8./?;IWQDS\"W[!.U=[Z'^>/UD^2MZ3_ .R=9O5_\=\B_P"[[H/_
M ,\>^W3OC)GX%OV"=J[OT/\ /'ZZ?)6])_\ 9/LWZ=\B_F#CWVZ=\9,_ M^P
M3M7>^A_GC]9/DK>D_P#LG6;].^1?S!Q[[=.^,F?@6_8)VKN_0_SQ^NGR5O2?
M_9/LWZ=\B_F#CWVZ=\9,_ M^P3M7>^A_GC]9/DK>D_\ LGV;].^1?S!Q[[=.
M^,F?@6_8)VKO?0_SQ^LGR5O2?_9/LWZ=\B_F#CWVZ=\9,_ M^P3M7>^A_GC]
M9/DK>D_^R=9OT[Y%_,''OMT[XR9^!;]@G:N[]#_/'ZZ?)6])_P#9/LWZ=\B_
MF#CWVZ=\9,_ M^P3M7>^A_GC]9/DK>D_^R=9O5_\=\B_[ON@_P#SQ[[=.^,F
M?@6_8)VKN_0\_P#UQ_Y\?^B?)6])_P#9.LWZ=\B_F#CWVZ=\9,_ M^P3M7=^
MA_GC]=5$/Z&[TJE>+BCX+Q@N88X#(P3 8N,Z+RB$2%%1LEJ8/)#YL?HC<B).
M@RV6I,24PMMYA]IMUM:%ITK7R_56FY&/C?D(WLD:YCVNKVBUS7 M<UP-<@@@
MD$'D0=BOIN-OL<'MB(<T@M(?'ON#N/[?R@?]U[I/!Z]^2-[\>:>_Y:\I*<G[
MU7V]UF[P9L^K$1UODBV(Z8M]!OU,Z>@1X=DBNMO$1C[L&0-L#)B+&@Z$(&2Y
M<.Y6&C#>F;C;#;-)QXX'!LK71M>2>A>)8XW%T9Y!P#@YO"2[B+@-H@=*Z)AF
M9P2[#C ((W^4%I(V/7MON/"LN\QRO)A$PB81,(F$3")A$PB81,(F$3")A$PB
$81?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img102364508_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_4.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1YD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'DB^=U(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!X\
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              :H   FD          $
M                 0             )I    :H
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   :H     4F=H=&QO;F<   FD
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   &J     %)G:'1L;VYG   )I     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "CA"24T$#      3X@
M  $   "@    '    >   #2    3Q@ 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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M$ D0)A!#$&$0?A
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( &<"4@,!$0 "$0$#$0'_Q  >  $  04! 0$!
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MU&T/];Z!S<U_YJXS_;_[K<U_-^&_FYZ+R"Y.9X:*^K?)QFG?K+TU'_$[S_\
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M\=M(TPVDV51;4[T5+%1:T6I:R1ZZYR"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@-)-5.O2&=+2JW8].$G?,.H1^ WSC737"Z)D])@>..6>0
M6"H*BEQ0B;3:0 F PA]WNPZDHP!0FI"DA%$PGCD[2?"<;UJ''&/F<ZM1S'VX
M>K&*AC+!/:?M#0PCG9"VSX_;<BO-WSH4P ="5B?RD:8$ $A':8C):,.H++@;
M;5;#QQ<B>1'; A0^.>PQS+/A9;Y335G*DN_-ZVK9A?=V"TZLN98^B!H-6?YC
M GF6$XE>SLDPHQT./":V<$O;.P11L-ZV*>7+D<-Q7 YP C*E?#(\8+%,Q^*
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M7*1495IAO=4*^B67_-.V5>.6JWK*K)EWFYQ%6IEK-)*VTJE-$5/:#7Q,]<*
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M ^WJO3="_.**^XP?[A[#&=5B.Q>?B?<KIKU/D3)<Z2@">RAPH,$9*FBT42&
M9+& ,\1 1RXX2!@* .")CB($*%G@('GCCGAECE:UZBTU0;2-,MTM1+;+3*LM
M,M1\$TRTRMJ*BO51:LTK;Y*@2"C4K2%B$6_F7D_^VHORK"FL5=,*9M;B'4PL
M&UD$J65S2JP)44#"J7)"8C$P%(8XDC"G@2@V.(I4(SF)@ +C;,/''*UKVXV*
M3Y..T8YN/H-WS2M-N\B+@&>;:;2333M$>?T--)-&LB2M))&II4N;4+'M*TK4
M/%*K4LJ;MZLY5I.:*JR6M)SDMA\T6#M8#;P,!-Z'=2B"&;S#$-!HL>RDEX&<
MPK98A9CX$4@# ;(/'/.P>0N.=\+996QW6RO:Y[2G)U^J*_I"A'[3/]JOHR >
M*RE53.6\:2U$5;9K:1F$CV)Y,/%,SMR7;U)Z9(A_ ,%:NRZ*?;1>&=2 #=5#
M09Y30 (ZD\)%43H-\+A'#R5@C6(&S05P@KAF#!<08.X8? SQX&.[):6Y/J\9
M?+2-"J]83)=O%CH!7CMFM,EAOG%:99DLI,JDDG*2+()"1Z(K*0\4C*JBJRCM
MZB*J9U24E7%=1]#,(:P3B0&WS</:E32""&7"!1#$?2D.D!!%+X7*AAIHJ1F2
MPP+7#PXOAB#;$'@8]SMCP<=V*4GR<9>J^8CZ#8?*JJKYF,@4>3:GE+SG.Y2J
MU-<I5:551:PL+'JRC*P\5DHB)D\V]5FJRI45-E1COBPZENKO.G9'('V]7+TW
M0OSBBON,'^XQ]AC.JQ'8O/Q'BPZENKO.G9'('V]3INA;.F**^XP??STA[#&=
M5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.
M0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?[A[
M#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=
M.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?
M[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=
M7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^
MXP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%A
MU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.
M**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B
M/%AU+=7>=.R.0/MZG3="_.**^XP?[A[#&=5B.Q>?B/%AU+=7>=.R.0/MZG3=
M"RGTQ17W"#GLYZ8]AC.JQ'8O/Q'BPZENKO.G9'('V]3INA?G%%?<8/\ </88
MSJL1V+S\1XL.I;J[SIV1R!]O4Z;H7YQ17W&#_</88SJL1V+S\26X-T ZK)UD
MQMQLDPU(;.[]F=ZF[W^R'4U&BUT<#+')16UA66$HF!<(F!EP@$XIF,J*AK($
M@FE3!LP'A?I4ARHH2 A7L3TA!Q33"2=P\)%.'[Y\\5%R&&67;QI6454_J>-2
M889FJK8B\KFC8Q\\9=JX>.D5?ZGCQAIAAE,ZJJHDUN92M5JO5/;3I!TA15HS
MB@A&<:D+&#IBQ<^]WL>+@X.)^.3 'N8RNKBA\+N)0#A"@HB*")D11".=RX%Q
MC(QX\=^%TO2\9348W&1;==;+ERRJ\TX=3FR[=LV7*VVJ93;4U:6Q$]A"PKJ$
M=(Z=)BVVO]S;6=II;[DL1*D1$-JJU9V10"@% * 4 H!0"@% * 4 H!0$:30\
M%./(=EA_(AAJ%%ED1J^G>D&GXIB(K'+*C;;"HLIX[R6 ;V&26J";)@B.%2"R
MQ$(I&)PUAE;(*U[ >?N"-K-J+779!: ^%*#5E.<$_'8CGIRKX[;:4=M8T/IY
M<<M(J1#TT0Q(FHB.9-%6CB&;,MHOF,F/$PJ MZ,5EN@*#U#?+>DY^.G/IE7K
M26BJB).W"KOLX6>F8(PVT[FF!OA_D^TZQZY7FL3%'<8-((EJ'6P(\6TJ3X&F
M*<&^Z3;K/0(7>""<(EX?4F^KM18C4HK%A%8F>,"$AP3*5@GY7\7:0J2XT>:+
M=+.8^K;91P/E]Z74ID--F18UGN?TRO>42SU?X*S)*\R)TTY2-."LCL*.B#!/
M**U'C,R0T5"<DS):H35 '>5NV$UBFLCP^83CQV8WU%1)SP15V&>P9MBW9/YI
MFM:/M.+'<#\?,Y(T2H :9J&.VC\ZB./3B]=1J0\[.T]"95Q$C0*(R%)!5V>K
ML-,5TX\(#F8'#.]W1RR?&J=5Z$5)6SLFE5=N>[>733EM0Y)GV?I&!1(A-NZ-
MFY"H3A0X3A=VL*0)O2',4U"R%%AU5EDN\C$2I$:NRZ&U2:DL1;F[W)WB2CB2
MIEU=3.J8Y8LGMNPG:)6+J595(N_NT3(UU'[8J2FVF:E&=$\,M!"?T>)DXI;/
M..J3;+;[9"Q"#LB]IK[OFZ'$QBF 6&UW4%)>2O#1_%ZNI,?IM#)E%#O6GKN!
MDL5?'#1MOLVH$2^S/+;_ "EJ6R6N78Z#WO(JV2-,F3X\D!"=\?H;62W')3@!
M8>+"E5S")X@#C6XU--1:#5SB,&J$1S-QW''49B"E%%.&*-HC<0PG)U(3U0"@
M+0X%Y&:J"MN=Q*11&;[<2%)>75=0&P+D$I&1R8R@IJ1TP)>V !0B2+CFC(V=
M[8! A9YY7M;&] <H]FDU%:>W!+&TWE%-'#>FJ4T(W-/2,KAWR-Q3H\9RL9*Q
MJ@IP8N%KII^43A8>4GAD4RXLKCJ:";QQ!SP'#O$KKO1..*LZ6UU;O&I5X_F4
MCKG5(< )]1A7/M7H=>""TH:=!E/<\3)C:=?@5H\<9+%O-Y57T>8A'[)3O6+:
MIFQ,C(5$\RF1(WXS(B(O?=/34XYA<7-VA%)=;Q>6J2SU6_QFMW+5+O\ U2"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#SE;3B5-;K/U=N2T".N<VQ%+#
MT^:<7FL.-@GLC[&C12<NHUVMF0)&<\4> ;M.3D13F,4* N9BMT^D+:<CXEG"
M)D*FDS=L8LZZY>%^FKNV9)+/GFDK[):*\^F=1<W3M1];:5*>IU):T!,ITHT8
M%)["C>+LFF^\9)54F/DTDK1-+H*DBN-7&D5@R,AX*;I40$AG,XB.FG$1 9CN
M67'@8#.JZ]=E:KW;-Y+L95W7\5;S]DI[4/45$34/J"2K11J#*K&F:=7O%TC,
M'35/[4;CVU%1ZYXOLW(I\&3+U=A^Q4DT'6[C[C&!62Y<WDAA#67$$VDKZ3@G
M.4K%1?#B7D)7VSLLJKG;N[B7'-K%V@60TEK30:$&EFXEZ_&?HTCQ'<<4R\>7
M\FXZ'9'R>/+[M44R1$\FH-)*0W4I=V-H28FE[G2(QT0Z&6+9%+TG%W'C81([
M]H]KQ8DVSC%ZY&42B&8B9,SET]OY1U(Y%9?BO&FFE4E!HS*R!0GZJG7#'LBR
M<AF40)K8HI$DB-E3)-W*3#T@$LP5.5S7=5OGN5,,Q9)5C;6EZI+#,LYF%//6
MMM##"O'A1UN>/8K2F5JLTL%']([7T^R8*Q%")-1FEE?E$1$?#<4I,5E45 CR
M0!2;%<:JDNE''6G0=:PPAIJ9$#J"NEG5ING5+/KSV%JW3E-)SG?HKL4])54Q
M,'DV0&M$\;R!*3Y,BDF5&K)=3^=YP H,H#%&PST(\X5XR"0+X"&#HH"4G&A
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M,TZMJ=UI?WUM#-*L<0.P=2#L?YI-BN5',?:4;*PC;7<#[U52%W4-F*B)0Y(
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MF'6,MQ*VY)77<]S[D7TQ-;ZH:5%C%"4G&"?<<;"S5;_YJ\<V"&#/>.-DB$
M1=T@1,A$72'.48&P"VI5X-A.=I/52,ARS,;'=-T23$TFY$M[&Y;9TB%$5RY'
M4]JG'DQG&S@6\,9:YG%B$5;$PS7:N*YYR-YM;>QZ8ZM*:S(*@T78H.)ZF84F
MA"39\>;@2(W6=1:HV87?[E<#3-RR6:T0Y&RZ*A-:4G^VT]ONE&04*Z0?.?\
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M'0V)!D5D KR4RU\XYFFCOM"93N;[<D9(;J^IJ2DC)3\1W(GD1CQ\,$O@ ;,
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MUP^GM(OE#F",M%T-U/)7**6<BI;W,KB/<$L>'N.'B9M>-A$JW[TD=8P0L@@
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MK;M_EO>@*[[>FWMH#^.#GS?RE_Z?"O\ FX\^.[=P/)Y+WY^%;\[S;Z ^E *
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M **A_P!ON?\ WC5*YF?[42NN=]]Z6'"U_<NKNN/WUEQQQ68BHG"IGSWK5IT
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-RRSRRRO@9GWH!0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img102364508_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1(>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $@*^1A X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              2\   =C          $
M                 0             '8P   2\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   2\     4F=H=&QO;F<   =C
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $O     %)G:'1L;VYG   '8P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      'FP
M  $   "@    &@   >   ##    '?P 8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" !A ET# 1$  A$! Q$!_\0 'P !  $%  ,! 0
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M6VJTMFU;;+-EEJ+CX_KWCPON^/BTW/J0- - - - - - - - - - - - - -
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M+>B?7Z?C[B=6$,\X?W(8_'92P?/0F18(4<O6+8Z%J[2[20'+=I?#28PDV8&
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M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0%I/'P46"E)')S0F.1X(Q<$S1X\19B
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M1NK8G6/19HVL<]6M99:UZ77-<CE2ZJ+O0Y]Z]0<@: : : : : : : : : :
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M[H:UK2E*;>,U5K6O53EC:2]/\NOT>GHUOZ*_[GHW_P!^C_\ T1F"J_Z:H_\
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MX\P329L;++4[;]4I-"Z/HZJ6M8UTU9-'31OJ:M[:F=$I8=1&YL\C5F21\?\
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MI?J/YC5Q]FSA;R'BLQCZNH+]D@'P_37S=M+]1_,:N/LV<+>0\5F,?5U!?LD
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MI/'P"< L4RJ2$(5(H?GF6W$A3M=A%X/$XGE./O6Q!Y9%BYV919F4;4(=ZG2
M$6<9[X.)C:4VZKS+:3)W8#</*IC-#@Z8XMR$+D&)X68S@5@4)PJ4(X^C3L3B
MJ6P[$X\%EHK+\XL7H>4N)2\CJ\ACK  _D T#! ._OBER9KAB=$MH\EC;6^7S
M )E^$!<$9HL:1**E1N"ZV2&6QR:1MG.ID:PL]DN5;AK7"TUH-S99';%1-C!=
M)R%%@2RGN:=\+#BG8VQ1&0>1%MH!!K&DY0HSPW8ZA%X][B#,QV0R9[E);'[X
M:W3'Y*&8Q!J.U<ZPJ4AW]_@PRP!/!,FMR(, Z\Z : : : : : : : : : :
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M: >5/X:?M\[0?O"XN_4V@'E3^&G[?.T'[PN+OU-H!Y4_AI^WSM!^\+B[]3:
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M8F]W,/\ @V@'B#P5ZEL3>[F'_!M /$'@OU+8F]W,/^#: >(/!?J6Q-[N8?\
M!M /$'@KU+8F]W,/^#: >(/!7J6Q-[N8?\&T!KP1M&PX!FH^6AVLK'"@\K5G
MP7%S29R)OAL+/U[%^V3,3C%%]9%V)CNETZ+HM465H%I)G*\P9AF\NO[^4[CN
MD.D747Z)?TFVE90.K?T=.FDGZ/CL1E"ZON:]:=K&LA3]VM6F8VE=(M,FI.>F
MC*9*C7IKMDSJE(-<_P#2MJ'6VSI!;<UBJJOVVMUKG2HU)%O$G-<,Z!#[>,KE
MQ>,XP XI<3,2@<RBA9DB10<#*9 8#P(9!YN521M;PDY')6U3-3UK!A+EX',L
M%$AKDCW4O5G5=NX U.++;\VLB&188QB=L.O)/6"$CD4/?%"X6'QQ_N 9 E7I
M,GE2KZ22R;AH%A98B9.*65"$\K)$GHXK00::J :M>S;B"R=L**I8].*/!-G?
M\6/'LF>*6$G+CD<)Y#<PV2#R4P/OQ@!U(8+G;"PPL5<)K.P,YBA=^B\9N492
M7>/&/P!EL;F>^>92+&\5EXGP; DYKCN3DI?#X =$(O8F)FSL[D*,S(I*W\?)
MPA!J'@M0#!C9$52LS&9;C;!%P\1C$MD!("^M)#O9=YFGHB+M+QD"F>5C@YL<
MR%CV\J$P]'HUWB# 2D5N3R)'W,[CN0H=CJ52-S1@@P'1B=98A-%KWSQK,AEX
M&)L<S<05]?CMC9AU!N[E4KQRO*BA>)T#AX2U=&(.-S!#%FC602%V8!0QE)9
M_B\]>$8C2;> DE> EWC%[%FQL"^1O*^ZD5B3*&7LA!S8&>R(IM^QU 8 1QP2
M>C8>:EA2-M9[( N/@<J=GYN-AIS*IL,Z=T."2TZ'8@M=M5VHMP-(* 8G(\\;
M[HH.L<&H"Q&UI* 41:.U\7.Y'1Y#L@G10&&92=#8ED!RL_R4#*RL,RF6#8XY
MO1:CX1D4_22M1IN%*H@7TUD'?A)XT5QXWQ\]CLED%[\ UR(WCC,/WD@TN"3,
M!%\A7$&,S*"0N28^<EF,Y#*XF,O,)QZS&N2KFUBC&11!S:!BOC-X@TV0+EJ8
M^,X[:W)93*0"+TBK<@0*R"N,8_6 8]R.6O<!G ".MI7,S=CB8BK&R5TBQ:1[
M@E)L4:C*Y(#+'V0N(*_$3).(P<.">"8])C<?2ED&J75I*HRPR,P%8C:/K\CC
M;Y8R.DG6$'OC<6N;#3B:.6W0MLR;K!&\7 VYG@[N[#S":J8+!BG09E#+3P54
M^!7D[202&.P3)!IK#![.Z<1I ,M*IJS@\=(&$6]RU@\HO9;R=5:%@X&&4GF[
MM"4#Y:4B1]VPC[J:LYA!Q,)O0"C02N?L$,4?!ETE+';G*Q9G@)')<EBI\:S:
M.7)RXPV1"V$GZ4$% :V&3K?K-)A!7<F@!^&CFA*%7EHN&!6B0;N+&3^#W1^1
M2&4,YV[4ODHNU_F((K!V]+[!8J'MS#[O@QDC),X!99SN,WNXMB,'=3X3#&4C
MG >(/139E"!=A-[E*2L0:2F"1T7=96J3+I#7%TD?E)>!H8,6+,Q[)J#JD_2[
M$#KQH#CON[@O"QD.=,@K;PY,><9"'86R8?-1K(,YW#H8Z!8V/8@>8SRC(<;"
M$7Z>-AYN[$<H),Y TQC?20C$RI28W"6DGO?R*@$2SS3@W!,CRR8,1&8<K9'G
M>,U))*Y>XF&=7]A<5C?.V$\9G!DME61I2##Q.<A<J[?,<=^FDR<QTB\\&%1Z
M+A=68,PTB O483X0L_.Q$ZT"3Z.RMCF*78X.0P[E_(N.T Q%/+F]!ZIE.9BG
MV2P</G,59S-WN;6C4N!.Y@9B(Z6+@[4 2H>@N.NK^O\ C^@6:,G>"C@&'2J-
MXQCLTG "1[=]X;Z5A6UV:"#!YB]SB/;==GN.S)YD<D 8P:^?8GB."2\2+RE>
M,QJ^-J,)#'I&&'3)B]D($CE&/""QUC3+6'9B[92X)-)U*<<Y#(9 1S5FG(<@
MR=D.!IP"?0J$Y:>,)A-C4R:1'';H9-1.(I<]>X^OC)5<NG&EF#A1(";^--@^
MU3'14Q*1..U)>;F0 \'F9K*4EDV57<_;RR<C\EERLVMR&4D"$F/.98*#OVID
MJV6?BV8@4(%J,10UFR0 UOD[A5;,,OC9%'IS"I\_ADDR))<L+8\'YOS*#QP&
MR!-A4R$3B21.!!YPRBT3>3%"?RYX?MCXL>BX+FG9ALDU)W]U: N\VX8>S3(,
M98161XU,7L!>3)/EP8]&Y"GX@X/F<UB@:$RUPU-CY&W(IBCT;CX5F\!U7N%)
M.Q8\TQ:M#K%F20 GVBDF@DD@E;2Q)%.Q)*RE:UI8FG;2RRVE;JUK6EMM*4YU
MK6M>736M= <IMR7#_P PYMWK8NWCQG/0:$/L%,(?%,7PBZ*$'MO@:90R$'W
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MYDQ^3\>QO.S2!QB%9$*/6:,T3..G[%@%<B4Y):!*7;S)>)2_W?!V6XM)JTP
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ME4Y-!&D)D1,36I-<%)B)UK<28(*MXM'P)8: : : : : : : : : : : : :
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MRVR]1.ZV^W_7)JI**)7TI=2U2MUE]ML$HJ+N+AH2- - - - - - - - - -
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MY=?1RZ*=/FY=/+I_AST IZ:?V5Z.=/IZ>CGYZ<_3U4IH"O\ 'JY]/I\_1_\
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M2'^;G_Z8VZ_YJ5Z:\J<ZTZ/3I:F*9IS%BX+DH[["^=>1%AT_\<;UY5I7K_\
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MMZ5^GGS5Z:5IU5\U>OG7EI:EO^Y/'O\ "_P+%]%<E\>,ZT*B_G%AY^CNUO\
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J#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img102364508_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_6.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Z04&AO=&]S:&]P(#,N,  X0DE-! 0
M    'G2^=Y8X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X             /X
M #A"24T#\@      "@  ________   X0DE-! T       0    >.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             $.   !SH          0
M       !              <Z   $.                      !
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M;&]N9P  !#@     4F=H=&QO;F<   <Z     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M       ! 0 X0DE-!!0       0    -.$))300,     !/G     0   *
M  !=   !X   KF   !/+ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" != * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P#U5)!.7CML-9>T/:)+2YH,$N;NVN=NV[F/2^UT:^]ND@^YO+3L=^=^
M:X;4E)DD)E['B6>\ P2V'"1R/:5+U/Y+ON24S24/4_DN^Y+U/Y+ON24S24/4
M_DN^Y+U/Y+ON24T?K&YS/J_U-S'%KFXEY:YI(((K?JUS5Y(WJ5X:V7WD@"3]
MIN$QR=N_\Y>N=<JNRNBY^-16YUUV-;76TP)<YCFL;N<=K?<?SEYD/J9]:(_H
M/_@M/_I56,!C1L@:]V/)=BFI3EYF1<VFAUWJ6;@P'*NB8W;G$O\ \&QCWJTW
M'ZP]]3&>J38*W #-L,MM9=;3ZGOW5>HRGU/H?^?D?%^I_7FN)R.FOM@M+0R^
MIIT+M^VQMWZ-W\U^D_K_ .D1J/JGU9CPY_2+G-ECG Y51+B/4]1Q+;Z/IM=5
M[/\ @OYZOU%*91Z$?;_Z$M%]?Y?@Y%N9ET.#+3>UQ8VP#[5<?;8T65NTL_=<
MH#J5XY?>?#]9NG@>#UK9'U0ZZZIHIZ8^NQNT$NNJ.@%GJ>XY#_SG4LK]K/YG
MU/\ "JO_ ,S?K1_W!_\ !:?_ $JB)0[C[4'B_D&YT[,R!@8QLMNLFL\W6 _S
MMWYVY'.;:&GW6B =?6M\/ZR-A_5GKS,+'K=B$/8PM</4KT/J6O\ ])^Z]J+_
M ,V^N_\ <0_Y]?\ Z45.?SR\RS1V'DIU'5&$RRUX: 7;,AY#1[)]0A_M^FF%
M/56L#G57G3W?IWSQOW.;O]OM=[58_P";W40T1T^W=H26WULUV ?OO]WK_I=Z
ME9T'.=617TVRI\&'>NQPGT_3'M-WL_3>_P#XI-7.9]MM,$.M_P"WK"#I_66G
M]6LBVSK=+2^S9Z=DM=8]X)CG](Y5O^;?7/\ N(?^W*__ $HM'ZO]&ZIA]6JO
MR:#74&O:7;F'4CVZ,>YR2G__T.NZ]7T.WJ3!U%S6Y#6-+ _%&0"TOM96?6=C
MV_G>M^A?9Z5>_P!7TO4]ZNW?5C#MR#D%E'J.<7ESL>FQVXN+FN]2VISV^FWT
MZV_\5_I$_4,S#JRO0R:LQQV^JRS'KR'5D[K6>B'X?M]?;O\ 4K=_@U7IS.D;
M7O%74!]G)N/J4Y9,API_1[VN]3?_ *"K_!?SM7\YL26]B])R,2EM&-E>C6T@
M[*Z:F-TD;=C:]K?S/^VT>C&SJK ZW+=D-$RQS&,!GCW5LW>Q9%=W31D58XQN
MH,<T-()%Y8V6MMVV?I7M]C?T7_@=:NM^L&*[05YF[7V_8\@'31W-*2G3FS]U
MO^<?_(I39^ZW_./_ )%9E?7\6RRNMK<L&YS6L+L.]H]Q#6N>Y](;6SW?3>HC
MZQ8A94\LRPR[<6DX=^@:=FZQ@JWL]1W\VS;ZGY_\VDAU9L_=;_G'_P BE-G[
MK?\ ./\ Y%97_.+%]%EPKS#O#CL&)<7-V'98VS;7M8YKOY2OX>4W,I]:ESPT
M.<PBRMU;MS#L?[+0UWM>U)22TV>F_P!H^B>Y\/ZJI>[P'WG_ ,BKMC7^F_W?
MFGMY*E#O'\ GQ6R09M>-;CEN8X5TR"7&PUB==OO]OC]%
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1.")P1.")P1.")P1.")P1<-^4R_Y/OG$_P#A_P C_P#<#KC[WHO_ *1\B?\
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M9#I%41'PFQ0UIG(.)%4FZL"T@RF++"5R_P ?97 G!$X(G!$X(G!%]'/)&_\
M*-<KW\:)A_\ HMG?'D_3G_17E?\ !A?^9@K[7H]_:]$^\[\CETBG_P"33_\
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MM05L3]8"=7S.@U31Q8S?$GYQ$BP7+SS0B"^#HG%!V9<;X(R'$>8<[D6:V9%
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M$<0S%.4C4,63.'QI,5%A\\OC\R=N2 ,;-[13*3MTG"=JDRF9]EN,IX7]TK5
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M8-D2-GC\AD!46!  @P]^7-&B+ 6-9N7KQ!"_")$;#:7O,@, 2220  !:220
M,2+A:LF,=$<&-$W&ZT 2 ))))   !)V#&Q4]).:7%L.J'3EZ<XC;E_'FTO/,
MB4 E7G\=0Y[('4482W)MS(8[;P:./3S%ZT0*&ET4:L6)<^I1.-@9 8%:C28;
M:M81&S;6<"QQ,-M8MK1 )EHK B=L[2)@$C:(#W5I%AD2T2>W3>&AU1DR)ND1
M@+93G(&VI).PD7/P:+/$R3V09!,O@\>%BF=7CBU,.'>'#9PG6JB20R.A&+5-
M,D7=J)HVDR@ &VL=&SX@>]VNB-:YC+2Z(2&@6V-!<YQ-P:T"T]0%ZUM96:]P
M(DT-,S9.N0&M $S6<2)"ZPDD25?!N86$R6*$IU%@>2Y5$&KD8D'/1S&,W+MI
MNS*WN4VT@@*#0->_F,5KV6J]DI"LW,?>#W XR,(/@I0<1<ZQ2&.:YS&Q'M#J
MLVL)K7BLP&4VS%I,@LS!<'-:7,:XB9#GM%4@3+72F&N,[ ==Y%LO?#9\QB:Q
M MG6PN1&8X;IGU'!(W&Y$++V5C4D)Q)^W2B[@723/W[J0BG X /&BGC^4KKC
M?5M K0L,J[HCPS"Y^9;#D3-P(-CBV4K227"30)S) %ZA@O$3F@"Y]D@)2F0'
M6F<@ VTDW"9E8L:YYBL>C'N/Q9]O,XR:R0ZM;@@<AA,D&EQZ3J=QK&(A]*&*
MC"Y6-,3\\F\+CH10K1NJ]=2@:YJBD.;E78S$TF&.;#@]IB7 L(+1,-!=.X%S
MFM!-ND#)7F'D/+2QP9>0\$'1+B&$?6(:UQ( _9*S[W-,#:02.Y0M=OGD DIT
M"&8RIHP5H+192B0IQ:/R]Y>ZJU7I!BA9T*O;2MHB\%^@30Z7+*)1&KTXRS,>
M&(;8NES;B 'U9  NJAQ!M#2==MAG<H(3B]T,2#VM)<TD3FT5BT2GI 3LOF"+
M[%:]=.E>[6FM::[:4K7]/72O3?KQM6I37VZTW\:4Z4UK\VG7>N_A2FO!$TIX
M5]_AMIU\*TIOOK3:M?81*:]*Z:UTVUU]M?S=U-N")K73]/3W:^&FE*U[_972
MG!%'73V5Z:TUK6G?TI6OA6NNFM/"FO!%M,+U]9P_7_RZW=I_Z(YZTK^KW=*<
M<E/^QTC8QO\ O&#WKJH7VJ%L<?RD>]67TZ]]/#3\VO36G?OW^WCS0VYW+[RG
M]7AIMKOOT[]=:Z[5KK[R)TU]NM*]^E-J^VNW?_GIP1/'IOKUTZ;]*;UI7W5\
M-=M^")36F]*4KOUII6M-^[PU]M."*.NM>E.NM==:^'SUK^OPX9SGK1:C.YW%
M<9Q$Y.YL5H$B\<:6.RK^C1^17_MSA%FS9CQ8EJ^+F"Y0@Y:"PH,.P?F#99XR
M%"6+TB\;-E82 )GL\NM4 DRU]W6JA-\SD(CU8 S)1',E)'DD/.)#'(4/P]/3
M,U1 X[-1H#)C!Z.! Q!['6#=],HK<T5+T:W/FYYBLWLOU7M1QKBRQUMUGGL5
MJFVT2&N=EOZJTIGD2.P<G PA:A!T:R5,6\)B0@2SJ^?/RGH@Q)"SU:VMZ*#
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MELQ6PC7/LN)E'(BXQ:.$M(M:J   6\,64='D429>5#(\L6>QPBS*_/@DC)V
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M0>09W)&8N1XEG,/FD":&6R\L'C9#B^Q&%"X[)X#<P8DSP=9^@G,AWG]+=\2
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M5%%N@JFBG99:1>]6.6UHG;7%$$K:E5U<E;5V,K1*Y\:9R1[5.GJMI95Y(A[
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M'&9.$3N!3'E_Y>IT C;"&#>:N#!7T'CS^58_@N=&^0Q6'KS,GGL-N9Y+1E
M&?(,)&.C!"P,7(OL/S,9+YM[(AR!1OE<R*ZO*9\R0,AV6L\2OEK)2A(-!'F
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M$,VX]JY6JYN4L324Q>XM:2&.>=36RF23ZQ  UDDV#438LFM#B 7!L_VG3J@
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M9:2$$U(]FQNC>0&,B[)!S<(>W+BW:=%FCUFY9.G398BV[M^2_DK!O9]_Y_\
MHU_S\$3M^2_DK!O;]_Y_^C7?\W!$[?DOY*P;Z_G_ .C7@BCM^2_DK!?;]_Y_
M^C7_ #<$4]OR7\E8-]?S_7^37\_YN")V_)?R5@OU_/\ ]&O!$[?DOY*P7Z_G
M_P"C7@B=OR7\E8+]?S_]&O!$[?DOY*P7Z_G_ .C7@B=OR7\E8-]?S_\ 1KP1
M1V_)?R5@OU_/_P!&O!%/;\E_)6#?7\_U_DU_/^;@B=OR7\E8-K_'\_\ I^YK
M^K@B=OR7\E8-]?S_ /1KP1.WY+^2L&^OY_\ HUX(G;\E_)6#?7\_U_DU_/\
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M1];</%.V3ZE?Q8B&]-?QZ-=]--O^#OO]FNM:Z>SAI;-YQZM^/!31Q.X=NO\
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M-W'L99%B>3XVTE427("$Y3$2$BAHMC+(W0N)4.1MR4%HE1J[I-ZABX3$N_\
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M>! _/)WWV5XLW8#?Y))N)W>:=KENU:@0'C^-#ZE>OAZJ[>S2FFF_CQ)NZ/\
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M@R-+<M\S67)U>SP6(#8P-$>87E1=\I[&-"L879 )HB8S#(M>QD!1 G)9&1R
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M95,XEAC%ST/EWESQNA,"F%LYJQ@;RZY4E)X1)/*/O([(Y1%C#[ A=$</$Q*
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MA8_H%&C"L\QFNB%[8@?S9FXM)DU\XG]6&N< &U2+#,K=\HAZ+1"+8;6%E3G
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M),6B1@G&CCF/'V8B3"F+T$0>A"[)J15=CGJ*.,.-#B$M:36: 2US7,,C<0'
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MAA5Q=TP]%.BMP]I<2<B_AU4]&KOJHU=+,/.5K?V-16YO\.M;O-_"K6O!%%
M*E+*4"B:4328()TH-9Z)H"E//"T;*>9_8I#5?[:P3MTL9J?LV]$[M^"+PI'(
M]19ZXH!"T<$NV>D5Z"V-%G_I!%!N_P"VJT0^&Z[<@U;(///W*=I1;H)+?#L1
M3MM(O5NA\1O02:WQ:.7-D*TJBWN"#+D$:VMV[2VJ256M4TZVM6K5M2MEM*T;
MMFZ-/[6BG;:1>[: !6/[2M@0183L&T#6$K1K.U_8(MO\Y:*M>41HXM&VW_LZ
M,:*4:TO_ &5$M=^"+\[XW'5%!*J@$+>J!V!*7BV-R@6GP;;-!-]R%;AW["RR
MS_>=4?V-EMO2VE*$6:X(G!$X(G!$X(G!$X(G!$X(G!$X(G!$X(G!$X(G!$X(
MG!$X(G!%K\K_ !:.?X-=?XJ[CIH?VJC_ (K.]<]+^RTC\&)^4KES;2E>E=*=
M_CMK7IMIMK3736NF]./7KRYO/6>\Y/%*=/'7NI2GAIO3VZ;4IIOM7@B4UVZ]
M*::5VUK[ZUUIX=?=TK4BFO32G336M>ZM:^W;WUVZ>_3@B5Z:4UV]FO3W;4UI
M[.E>FG!$K3:O2M/;3O[]:[4I6N^_=6OS<$2E=/=2F^E._;3K[-.O3OKP1<I<
MPV-LVY+D>/V$2OQ:4Q"#?LI/.H--3<LCI"9RP <'F(>D2)1^*RE-_"0#Q@B?
M=12E@>LED#(2U/DGL20,1L]RTB'&B.8&<V80(+V.<YI>09M!+6NT1*<IMFZ\
MRL/1"?"8UTZ_.$28X!I# 1)Q%9PDXVMGJ%H(*WF<Q^0(9QPED,8%=G@0R.Y:
MQ=(TV5[6CB,(Y)6QO*Q$W<HNG*%S@4Q)8C3B1*P;:])MUIN/(4:5$,3+MIF]
MKA&@Q "0*\-Q%[ \ AUWU0Y@!-\B#(RD<&$<U%:2*QJN:#.3JM9I;+$B(7"V
MVK*;09JK<*8YYDXF]G4NR>OA0[D^>R" WG)B"-3\@/6A *5K7$H.!C9&. JP
M^/PZ#F93;C0:D8D57$Z-D)'.R1IX9/$2&J%#I##$=$YISWN9-P+SH F;&BJR
MJ&-)+!,DN)K$SLVQ7P7- 9S@:P/ :ZH"7D?7)#G5JSPVO8 & !@!$EJL Y1"
M;*1CQV2G\8/8QQ]&\QQ/&S0"_E8V9EF>7<XP7-S*0R@JUN"KQ*5XT(XUAXV,
ME8::>/GYQLYG;<G%"-K (QQ9136JQ2UT)@B"& '!QKQ!$K.) +2T@!M4S)TI
M@6*NI JSAAS8CS#+YU2T5(9AEK1I3#JQ)+A=9(WK&P+E(G&,\CP&5Q:=6 H>
M-<T,SB)A9/D%-AYU@RFH1G'1<;4=+ I^P>PLCBV#+R&?66R <GB!E-F;=Y-Y
MN>(-,85#="B0WM>*H)=$:"\3D7AK&B=4@L+6ESK06EU[C+*)26Q&/:YLW2 A
MES67$,+GN(D6FN'NDV0<' 2D!/I/EZC\A XW47E(5>,&ICD#+F35HL[59KOX
MRQREE699"$ 3*@]P\&TDS -)&%DOL&OGXRR6W&Z#B)!C1!ZOTT=KFPR7-JN>
M^)$J]&N\N ,K)R-LK)ZS>N>,6E^BZL&M8RM;)Q8QK21, R)!E/5)7?[.G_BZ
M5IO[?S:=_=O7C>M2BM-OH^%TI[ZZT]]==_'>F^I%-/=T]NO3;??36FU?ITIK
MOP1.E*?-TZ:Z_1OW:TTI7OZ<$2FU*ZZ:5KW=VOCKI\].OS=")2NNNFFOOZ]-
M_92M-.[O]FY%M$,_&D/W:+K4\=?]YKUZZ?KIK6G?W<E/^QTC[C?]XQ=5"^U0
MOO'\IOS?)673PTUK6OYJ=VV_OW[N/-+[RGVTVIOXZ=-*4I6O7OI3;6GZ")KI
M6NG?TZ>VGM[M>^E=_I(H^?\ K6G3]7AP1---Z_GWWI3:E?\ -7IW[<$376O3
M_7[J;?-I[]=]2)MX_12GY]Z?FU]N_!%Q5S:<H;SF3L%& >8<@8UE4?9@1(5$
M/; "<129MLC1*;'BMXF98WG#YC*7S6+MA[4T">B;U4VC 84L>!52K)]@YL[9
MY[+>]9M=*R7;KXF7=K5H9.C,G3RMR\Y #!GLK&14M-8/+D4%1]I  (R4 'M6
MF24FJ]6J#Y2/2"+B 1=%A:FY9QF:20PV;+-QCADXK@=$VV3!QMUV9FH").&,
MCLL-V.;U2>&N4:<\NLPR%)\=9FD60&<GQ[AV$A@V;$8:^\V\B64,HS3(4JE!
MO'&.(+(9#)3@[)YQ\'.DBI$F8FIN2&9ZL>JZ&N1V(:6DR,\)X8&R6P73OG85
M2X.E,2MM(ZM7OZED!G+WDV<9HR[)^8ACBR>8ZF "5X[Q[0%*IX.D4%Q,_/A2
MPJ+#XTG'10\-))&Y AI1D2?CYP]DKJ8 8WZLN1 "-1L:'523;(CKE+JZNV_K
M*5@  )@WFP6\;O<M$BW)?/H#E*'32$9&O 1VDU*R::@FTUR1:DU'HS9,J)&,
MARKUTRRBM)H"UK#)L]RBZ56;S&1SO-02Y2<3$R@Y!A!!GKMOS=C+!4O!!$C=
M9=AK[<%TORWQB1A(K-Y#* ;V*$LG9>R1DUI#R%S2KZ+@)":HTC+,DDQ<O&;0
MX8CX@=+I0.0=.+1<JDAL=<Y=J-;W2V309$F=IG;GW#N6+I3$M0 GC+.WK70V
MVW=W[;UVU]U=-]=Z]*==::<9+%1T^;O\=^O=K6FO3V4UX(GA[=O'I2GM]WL^
M;@BGIK3W]=-?GKMW>'6O=I6E*D32FNU=?;TI3?;76E=>[Z?#@B>/S]:ZTZ;:
M4II3NT\.FW3@BU*??B'./9#93TTW_:(AWTTK].OCW\1UK3U3]ZK;QUJ^^-"W
MK398@3J[B1(8)<F?0LA<OGK-FY&MG797$6D@BU5*XJ^'M5/@/";2BB=7-JGF
MKKU++;_@5MJ13ZR'OX/I/^4H1]K>")ZR'OX/I/\ E*$?:W@BU@@-&E2BIPGA
M9R0,K>JWGBKRS';@@KZCF"<@AOG':LGN7O\ 54Z:,&(_\*^OHDD4?O67F7#M
M=2\BPMT5'WR.=R)?&$I=5R9'!$:G(-V4@CF-2)H%;%AS9Z_#K2>]!0JZ"F%8
M^4>TNI4L"8!AI!-P@&&T;$6LGL00 ^Z,OE,$/!3^4R" R*:/P'W. Q"<+8S+
M#CD.&2X@SD5CTR"'$A N]<0LXL:DF;.@<C1T&=D![LBN?UD/?P?2?\I0C[6\
M$3UD/?P?2?\ *4(^UO!$]9#W\'TG_*4(^UO!$]9#W\'TG_*4(^UO!$]9#W\'
MTG_*4(^UO!$]9#W\'TG_ "E"/M;P1/60]_!])_RE"/M;P1/60]_!])_RE"/M
M;P1/60]_!])_RE"/M;P1/60]_!])_P I0C[6\$3UD/?P?2?\I0C[6\$3UD/?
MP?2?\I0C[6\$3UD/?P?2?\I0C[6\$3UD/?P?2?\ *4(^UO!$]9#W\'TG_*4(
M^UO!$]9#W\'TG_*4(^UO!$]9#W\'TG_*4(^UO!$]9#W\'TG_ "E"/M;P1/60
M]_!])_RE"/M;P1/60]_!])_RE"/M;P1/60]_!])_RE"/M;P1/60]_!])_P I
M0C[6\$3UD/?P?2?\I0C[6\$3UD/?P?2?\I0C[6\$3UD/?P?2?\I0C[6\$3UD
M/?P?2?\ *4(^UO!%BS9>1DA!%@C ))8J[:+()W*$X51.V]2RMMM;ZVRNZZEM
M*UWK2VM?97C=1X@A1H41P):Q[7$"^0,[)R[UJCL,2#%AME-[',!-P+@1,]4Y
MJFO5*>::5A)3NIL7B/2GM]8]=]]O#C[WSO1NC&]EM_M\>"^*>3*1,Z4*TD_6
M<+[;JO9?M4^J<\I^XDI7VU,1'6OO^^+N_KW\/G>B]&-[+?C3YLI'2A2^\[NJ
M^]/5.>:?B23U_P ,1'YM_6+?3V_GX?.]&Z,;V6_&GS92.E"]IWP*/5*>?(DI
MOU_;B(_1^,73\_=W4X?.]%Z,;V6_&GS72.E"]IWPIZI3SY$D_P L1'3Y[?6/
M2NO?K77V].'SO1NC&G]UO?7]R?-E(Z4+VG7^SQX)ZI3S2M/4DIX?A>(=/?ZQ
M>_N[Z_,^=Z-T8TONM[J_O3YLI'2A2^\[NJ^]3ZI3OKZDD]?\+Q'OZTU]8_;7
MNI[>_6?.]&Z$67W6]U?WI\V4CI0I?>=W5?>H]4IWII2$E-.OX8B.VO=IZQ;T
MIX5Z]^W%^=Z-T8VS1;\?BGS92.E"]IWPJ?5.>=\))]*4K^V\1^?]T7MKW_1K
M7A\[T;HQO9;\:?-E(Z4+VG?#U9%L>J4[TT]22GA^&(CMTTK2OK'UIIKTZUX?
M.]&Z,;V6_&GS92.E"]IWP)ZI3RFND)*?EB(_3O(J[Z::]?SUX?.]%Z,;V6_&
MGS72.E"]IWPI2)SRG[B2?Y8B/?U_=%3K7Z/#;3A\[T7HQO9;\:?-E(U.A>TX
M?^DIZI3O2GWDE-=]=3$1WIOUKZQ;Z;::TX?.]&Z,:7W6]U?WI\UTCI0O:=\*
M>J4\V^\DGM33\,1+3NTKIZQ^^FG?2NE:\/G>C=&-[+?C3YKI'2A>T[X4]4IW
M3]Q)/NW]+Q&E:]._UCKW]W333IIP^=Z-T8WLM^-/FRD=*%[3OAP\-J>J<\^1
M)/7_  Q$:[_/(M?;UZTI[:\/G>B]&-[+?C5^;*1TH4_O.^'W;T]4IWK^)!/:
MFE/VXB/S?NCV]].G#YWHW1C;=%OQ^"GS92.E"]IWP*:1.>4_<23_ "Q$?M'O
MOKX>.]:UX?.]&Z,;V6_&GS92.E"]IWP)ZISSY$D_RQ$>GO\ 6/77Q^GA\[T;
MHQO9;\:?-E(Z4+VG? LS'P<U%&6!%S!S%Z+552]2Q$M#[E*TO052I\"E\E3M
MUI<I376ZE/@Z]:Z4XYZ5RE C4>+"8V+6>T %P: "'M)G)QLD#V[UOH] C0H\
M.(XPRUI),BXFXBP50#;B;IV+<*7R>E-X)(:[:?A&%?IK+.OMI3YJ[Z_'YS9O
M/DOIU#B,]GZ[$^'*/D)(NGQE"NNFFGXV:Z?J[J<*^SCY;U:AQ'ECU[.*?#D^
MM=()(?9^V4+V\/W6?KVWZ\.<V<?).;V\%/PY/O\ >)(MZ?&,*IO];-J>.G#G
M-G'R4YLXCRSJXI\.3_(21>S]L857;?;\;>_6NM._ASFSCY)4.(X^"4OD]/W"
M2&G3?TE"]?;OZVTT^;3PU[ZJ^SCY:U:AQ!ZYX69[[E'PY/\ (21:?X2A73ZV
M>_\ K79SFSCY*<V<1G(R+7PY/\A)#3_YE"ZZ>RGWV=-=_'?3WN<V<?)7FSBG
MPY/2M-()(MJZ_A*%4K]/K97^O=PYS9Q\E.;.LCO\$^%)_D)(ORE"OT>MGY]?
MFX<YLX^2<V<0E;Y1\A)#I_A*%=/?ZV5^C?3V[\.<V<?)7F]O!32^3_(21=_]
M\85^?[[-?#\]._7ASFSCY*5#B./@H^%)]*_>)(ORC"OT^MGAW>/NX<YLX^2<
MV<0E+Y1M]XDBTI7IZ2A7T[RS>OOI\_ /V62QW*EAMMGPZ\\$K?**U_$215_^
M90NGYO6RM._Z/#6O#G-G'R3F]O!3\.3[?>)(O#\)0NNV^WXV4]E.[OVX<YLX
M^2G-G$*/AR?Y"2*O_P RA7S?NL]WZNF[G-G'R5YLXYS/)L4OE'R$D6G78E"M
M=?K9W=WZ.M.'.;./DG-G%/ARCY"R+IM^V4+^UO=M6GZ.'.;./DI4.(VWYQ6%
MDHZ7&XW(0K6$FT')D"8$MUG12'VMD7!(<Y9(JN+D).X6M;I*+VWK51065HG;
M=5-)2_2VL+YB4I9ZE0P@SGKVVYSMOKC!;$X(M+-9(QW&B94+(Y["P!@%#7N1
M38DU*08HF&Q\-<JLB,Z*L'SY!T.AK!XBLT>R=VDB$:N4E4%WR:J=]E"+:'Y$
M>+13<DW[(<W6>CQR2[]T@T15(%W[86*8)JN%$[+WI,F\:#A[6VZJ[U^Z;,VR
M:KA=).XB]S@B<$6*&G0AEP::"#(HJ[C96@*1-1I%H^< 3=PL8<H'-(M5E5!9
M6H4T&+T'OK4'=19880HCV1^U65(M2.Y;Q3%YK',;2;)V/8[D68HVN(C 3LTC
M8B:REO<JZ0M7CD5($FYTXC<NR>HVJC&#JRJK1TG2[X;=6EA%87!%K@V8Q$R^
M:C!$ICA4D^#72-D/&G!CY\\CUKWT;<>:M&KI5=P&M(_M?<423O8T>_[UJOY_
M^U\$7O#3P,RX-- YD26=1LMZ!D38:19OG  YZ,&FO0QI%JLJH++>AC0<MZ.?
M6H//1A8:_P#,]E?M552+*\$7IID1ZK]T*2?,U2C%JR?/1J;I"]^S9$U7R YX
MZ9VWU<-VI!86319.%D[$7:HY\FA>I>T<43(O<X(O1)E!@4>\+&2+$2*'-U79
M F3=MV ]BT1MK>LZ>/72B39JW2LI6]59=6Q-.VE;K[J4IKP1>]P18H<=!EW9
MQ@),BB;^,DT@DD9#B+1Z[CQE<0+D" @XV;+*K"2:P$X$-I,']C=TH(,"R5B5
M61!HLL197@B\%%$TD[U5;[$DDK+E%%%+K;$TT[+:W7WWWW5I;999;2MUUUU:
M6VVTK6M:4IP1:6PR9CDJG'E14^AA1*7%FH*++#9.%?I2,V_A:^2&(D&JT>K)
ME"3W'K9>=-&3*Y9PYAZ5\D13O#T[9P1>Q-<@03&XIL<R%,HO!PSTJP LBLM/
M#(\/>&RM]Z8T.T=E735%R3?W)JT:,$;[W3BB2MR25UJ2EUI%G@Y@3(1(L^ *
M#C@(X.9& IH.];$Q)@23;)/1Q0629*KLR X@S71=LGK199L[;+)+H*J)*67U
M(OT9DAQ&KRT>_9/[ASU4:0M9ND'56!%"Q)5=@\H@I?5J]127045:K_ 73L62
MOO3I:I96I%[O!$X(G!$X(G!$X(G!$X(OQJX;VN+&ERZ-'2B*KA-M56RCA1!&
M])-9>Q&MWG+T4E%T$U5+;:V)WK)6W74N4LI4BTHUE+&4<E8^"2'(L$ S@N$)
MR85#34NCXN5DXV%1=N3,@'QU\00+O0@ENP?."99LS58,$6;M5TX23;K76$7X
M8WRYBC,@=Y(L0Y.Q[E2/CR-XA^=QO-(W. [$LFU:OKQ;PG&"11DV(V,GK)Y>
MR67L<VM7;5Q5*B3A*^\BL+@B<$3@BU*6SZ#0&V/WSB8QB(6RR2C(9%O68Z,"
M5DDO-6N+Q,7 VD7+>XO("*3-XLS$#Z.'[ANS=N$T+D6JZB9%MO!$X(HNNMMM
MK==6EMMM*W7775I2VVVE-:UK6NU*4IO6M=J4WKP1<\W<WG*=:%<R6[F?Y>+8
MXR/-XL\/W9JQM0*TD[QD_)M(XY*UDM&*!YT-%$R#<0JO8079#7[M)O<@S<*)
MD5H,<F8W)RY/'XW(,((3Q6*-IVE"6,K NY<K!WCI-BSF2<;;OU#-\4=O54FC
M:16LJB%W2J;=)Y>K?;94BW?@B<$3@B<$3@B<$7IID1ZK]T*2?,U2C%JQ?/1J
M;I"]^S9$U7Z UXZ9VWU<-VI!86318N%D[$7:HY^FA>I>T<43(B9$>J_="DGS
M-4HQ:L7ST:FZ0O?LV1-5^@->.F=M]7#=J06%DT6+A9.Q%VJ.?IH7J7M'%$R+
MW."+TB1(<&'/S!A^R%"13)T2*%"3I!B.&CF*"CIZ_?O72B39FR9MDE7#ITX5
M30;H)J++*6)V774(O=X(O38D1Y-)5<:^9D$$'C\<LLQ=(.TD2 MXN.)L55$+
MU+$W@X@U<L7[6^M%VCQNNU<6)KI*66D7K+G0K4T-C;DN-;R R.+EQ 19ZW3+
M$Q4?7#M3I)@/O4HZ=L0[F0 FY-T@DHBQ6,BTW-Z=[YM10BRO!%X*JIH)J++*
M6(HHV7JJJJWVIII)IVUO4444OK2VRRRVE;K[[JTMMMI6M:TI2M>"+\6;QH1:
M-2 ]TV?,'S9!XR?,UTG31XT=)6KMG35RA=>BX;.$;[%D%T;[TE4K[5$[KK+J
M5J1>SP1>"BB:*:BRREB225EZBJJE]MB::=EM;KU%+[JTMLLLMI6Z^^ZM+;;:
M5K6M*4K7@B_%D]9DF;0B.=MGX]^V0>L7S)=)TS>LW25B[9VT<H7J(.&SA!2Q
M9!=&^])9*^Q1.^ZRZE:D7L\$3@B]&A09<34"VD6-QA)BD45$T=MZDTQCAPLT
M0(J,**=JL8K.FSALD[N2HW4<-UD;%+E$E+;2+\#)T+'6B) ^6&A6+@J"!(/"
MKUNP:K&I0<'1F-B4EW2B2:A(_(BXH$'96W5<$BY%B.:)K.W2*5Y%B%I[!V\U
M:8V7F$92R&_CZTL9090X-MESJ+MWEPY:1(QVKFA:\'80358U*T:=BJ[17;VK
MU605LL(MLX(L6P.!2KPR/&&!9)_''Z(N0L6!!H\> B;D:Q,MQQELW646%OUP
MY08619OK$'"HTBQ?6)W-7;=50BRG!$X(G!$X(G!$X(G!%\N^>'DDR;S%D\RR
M_&$CB49G$GY:@F#X&_D) PT8N4CKO/(#+<;FM@L*17]33\'RX)*@ZL_2"J.1
MX=%3ST75&,M:/2*OY]R.9TFYN=.S%T/D0ISDS[H2[4MFC)J=F;[1O.;CG/V/
M6,F&4BK@=BIYBC"$3DF%HTZCOK,DNO)6Z:-HN/"&=UA%@2G(US+O"^:7+S(T
MG+N,@2B2&A2+7F+&AHX[BSO-0[(<%CI&#.^5TP\(-,>PEJWQ8JTE4YD@XA%4
MR@<.J%;2%BI%GNS:B^D>"87-8>*8-IZPB/K,TQ9AB*24_#IO/SX<S,8C&'[.
M6-QD4G%SU6+ !I%[8K'2RIPQ+)@-)V.9JM:0$LEG1%6.#\7Y:Q+,.:$HSQYB
M82!S-S0@,L1IH"G)1K2D.*8[PWC#(9PZ/:8P8MF<[4LQL=R&U%-UBC*4'I&D
M',2D2K1](U2+U,F<I[[+',I=E61S0N-QJRQ[@=BE @2T=L0F>0,'YKG69HPZ
MG%Y2%$Y(TC<<D9"&F!-D$G,2>FGK0N*DZ9$'5)JX(N2,&\C?,4S>PUMFB<-'
M,(0RU%<BY$B$.S=-[A9=\+P3GN!3=M'*1#'V)'32+F,J3#%IUA#)01E!%\%A
MZI6=S*029M8/5DN^?CU=F^THL9%>1?.N/8G!(6'=01E"X=:B D6-6^;,D!P>
M?V#+)R,EK>5+V1*]_!W)^)MV3Q^ '-3[1T^B]D'+/'\.E4@(HW/<BPF0>4[F
M;DLX>QP&FV8"I1",KOH.?9<Q695XCRQ2VN.>1_'T%D:!].,H/\D3C&LHQ_EZ
M70<#)6(.V7LZDC!,K'WTDDZ#0BWQGR:\R1G+V7BDSGP5E!,JSZ+R M$XYEV4
M"VAZ+17FK 9&76&1R.8^B4@C*Y'!2+^$26PKD.>.#LA+O8Q4N'@%!B-A%Z#K
MD,S RLR+:.6%%7LJQY!\?1R8#,Z2Z/RR-1K%O,_ES(<8@[ZV38SR&&E48?X<
MF$ AIQF?;KWDF\1D4'=NFP\_;+Z$5WYIY8^8#)/+7RUXS:3$<(E>-W,67S.!
M@$Z)PV/3MJ.QA)XFX$Q^6SR 9B>NA@*:%@<K$M)E%'RA&H!L2[<#D0\,\:D5
M%SOR>>:)G <I"GL\2/S#(T6R%#2#^<Y@R-(VYN+$N7W&T5@\?DCMO&1(:E6^
M;X.\F9\U'8$#^#0N5E(\%Z1D!F,JLYO1>E(N2#F2.S7*A 7DDG$$)K%VHN$Q
MT%S&&!X?'T)6@<"C-,;U'CL(-\D.V<7DT<-E0$M"Y9!ME";ZDPM#L9(8D3!^
M16!D[D5RC(%LZ,HM.E L2(QC.*O+TP7S%EM@M <A23 7*=!,+R,NZ;+N'-ML
M'REB+*\QJNN]D=0RTJ'2,:R('C!9$:1;!R]PC+XKG<R47D,7D=8<-"\ROIO*
MI$UEI(?D![D?..-Y;A"-UB\YA\=A'_!+BX0?Q_'2N,9)D .F%%+NB#^,/)'0
M.[(OVKRO\Q*/,,E*E<X,;,5.LMRUS6!*3B8T+$<7.RICF*BSA <HAV!O.0G,
M(9*05Z):K7AE^7,4+9U*77M+(JS(J=QEY.68MS,.9Y7:PN6"VN:<3Y8RA+!^
M6,E*227V1;R?+SE@E$:<#TQ A>Y_7+M])I875D;>LHA\A<4-(-7;*@1T&VU%
MU>1Y9IM-,;\@\;R<<#2V?<MIV$S'*QYW)Y(HXDTFC?+'DW%AF0 BEC1H5D#Q
MYE.8QZ07N3J(KMHE,@\?TH\OH)?,YDBY<NY"\_?<:*C2TV=2C,SN185HU*US
MWD%I#[X?C[E<Q%CF1@SX*3PF9QX\'.YOA<IF14&VB\=+GFQ49.;YL.EPU$-<
M1=,X+Y:<AXOC7-0(?-(6-EF:7[Z1@IW%9K.G=A$_(<:# KVPB%DC%T2B",9F
MR)A8229R&5%2X5ZQ($'211O>S3(J)-<BN<F.1\7FH)EN: HY$\98Z"IO&^;2
MKI[$LGARLR(9/FC]ED/%>49-DD?D6V1!K2[)#)&/'4C:1^V/'5F;&HHJ)(O5
M?\K'->/Q\G'\<!8! S)O"V3L2RU&O--FF3-:S69)X3799W9R$]B]R8>2*Q>
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M)C +)7YP18EMR*9S^Z%DIT1R5*'T.EN1HV[9WVYW-C!CS#8[FAP]E!O UXH
MQ&%G@XY#\'0J2XA!%GV=)*S7:.B*%J30?DH_2*U%D7_)KS$M$9L!CTH$TM>X
MZR_ , 9$7S=E5@=Y6ESN3>8\KC>2QV)6QLJ.GKL9C7(N%X^]3,'![MG?C"R.
MJD#((>(>*D5F8VY7<M1;E.S9ADC(IDWEV1"9=Q&[K,_CR+^*LBL6AP-XUA^0
M@O+?"1L'8JD@QTVD%NQ3+&Q$P5*&SCV]:8EAH0BY_1Y'>8=@%EKBP7B9U,YQ
MA[$^-"$A&9'EXEV%#8^YC,ES<Z"&#C\!F,26-23#TW -64A?1UU"Q&1(V1%M
M<;ML>DFC!"9OSY(LE N2OF2Q_:RD]741EF36>/N6H%;+BF<)W8862Y>.;"79
M>?XX)F&^,1[0X#R#APT Q_?,+XP)HT?""+%Y";0!16BE16-C[EFYH!V?<59;
MF)F+JLA<AR^5GH=?,$QFT= QZ?9=YC<A  >-@+G&D+*4DP4)D['<1?2,M)6\
M1.1J,V"G6.F2L'A[U],]GO\ #B6D\T7)1S(Y^S#F(H,F,6C^,LD8RRKBI!"R
M<EA[0E#)YRLRG'(09-(.TQH^,ES07/I<=-W!)EE=A$FT-$!E!\"<S2TN2>5%
M>/,GR[Y9RER\XQ@>+A(. 2Z''*'KHC?F.2VX^;.$HE+@PT++S'W.2LER=#FQ
M@\P*NQ[6F/),P),1TJC<I9&XV/:D"*C#W*+S,0V-YA8X;;8V&F<@*\Z+.\TZ
MSCDJ'L""_-$76FD,R8_;-\?2U6/2'#9CS@! 0/N(+OVI)_(ATH'.J*,G3(1>
MG-.57-J4NS!F%1^RJ;;8PYGBF/,LP7)$_FV5I;))+.<1Y@Y= 8?$:L<'1YH)
MQ4RQ(SA*T8 R\@TR&T'H6.AJJ,UD=J$\??D=Z+HB<X&S;+>3\5B*F1O1V>Y2
M7CF2\F.6<NH&;R B0RF(R5F: QF0%XID/T1 M"Q;'\40?PJ2A&\1I'8J=%J!
M'SRG%14S'^1'*M48ZZD,Z..R@-&!QE@O)<V329O!F.[&F7PV38R[H#AV-H:;
MJ;CL\C0EG:G!!-7#2-B&KLAVJ) 32Q%C!?)]DS'6"Y2<N2*QS(V*N57%H/"L
M7Q+E'*>01XK-V$2V49T0+BX@]2AX66M,F21QCQ)T*) :$9 $J4@1&YB%0;W.
MB+J$O@B9'>7/&N'YE.K"4^*Y%QG.,Q$_7.2QRV6O765F>7,V1F,/PSI ^C&#
M#5&; 8C$$%VXQ.%-FD4=7-X^S=>:(N91W)7GOTY&0Y.7!RL?!T%1D?,U<R90
M<'<;8N#S#+3DOC!C!50]PB>M\C8PE<$AY@U)Y$/*LK4EB#E<HZQY '+YD(KY
MC7+/+DN3O!_+D]0$P(W#2F#T9V.A.59_V K&,>9#B1K)*4?GHX?$IM>E-H^*
M+U3&]D#(VU.VQQZY;C;E5^"+D>><G/,?%#&4Y$--3G)0R89<QRS!1P;GXV %
MF,4%^<?!DM910Z%CV%VL^B[+&&#P4C@!*8.LP3M,9"FLI=-0KEG/30^.D5G1
M'E YCP4KQ@3=GH_8TCA:$$A1%OF[*9);!,3"<PV5LHS+$<1"$(PBPRR#F&&9
MC"N7N^42I>*/:A8D@9=B;$ ,9$ID5;N/)SYC!1>)5A,E9)94><GN.\,3_*C_
M #EE-28-\J1 C89GQ$)(91&I\Z(@,Q,2,DA"DE(#['N/FI&R5C80<<IT!<$6
M;%\C^?T">)43"HR8QZ'37!DL%+9#Y@Y"7+X;^YMS=OL[9!]4@$+P7 X%-[L@
M8^K&8='A+L!$FT$;Q 9%6AA\!:M7UY%T%GWE,EL]R]-\O15N *5D4<Y;XP6B
M!&=S"$VY%B.,)SE^19#@D@- !Q.T$(,(S" F1:K9@33DCZ(/8?(T1D8/F';P
MBVGE6Y:<A8K+72W,4O=S.6,\=0&%QR]#).1Y4'C;86R*>LHA-C)EF TZHVO7
M"!&V0C 2LVF3"/M3$C48/U[V*9%O6!,633'.6.:Z0EX= (Q#LRYB&9,B*\.D
M*[XJ2O;XOQ]CTR0EX*L)C;(7() 3@SF6$'+4S(U'#@]<@[?.7;99\Z(NJN")
MP1.")P1.")P1."+YU9K:9^D?-P&!XVLRRC&@$4Y6)6@=#S%C&L-1Y"WF R>M
MGI&>@7<B&N9\5F6%(_2(AP8V,36\46?QLJXMA;BHJ7L2*FL08DYYY$7BS'*Y
M7(^/(02R7C^1Y&%!<MKJDV ^S#G,NQR@&B<N>9IS).'D#=Y4?\OU ES0Y G3
MYFQJ>$XUQ]>C($."+5(=RX<T^/1$4#1V.Y/0 0ZR<Q[(Z3+,@!?(&2HZ3YAX
M3+EK<*3HSD90Y!QLJQNS(*LV9*18O>M'+22LKDXG)C8F2JD6.R! .;YK-I1%
M($'SR!=Y-CF:)CB-45E2),%83. F$.0;'^)9IS%31G,ZLIFQA&2!^7_6>/KD
MLGEYP+;FUF\3G\=N2^"16>YQKSSR3+N4Z7NIM"<82B>1M&OHC)REB"D4#<W.
M,R#@S "I/,TZ/QJI_E30GZ<C8QJ$X1;LC3YQ'!D:,EF@&0JD5M<NF%\PX_YA
M)7,,E(Y'D@DMC5?'<3F#_*MTB$,(YCGF.YG2F/VD_ O9I:0D<I,81R%B"\3+
M5XS)S-Q =*ZRXX)D2SQ4V1:L&PES4LIP:DMLCE <8&S)%9%"HV#G[$1#B$0E
M7/YS!S'-+N2Q 4];!Y"[)\I4QQ_YI.3LW[RPNFA<'L2GHE9VB16#F/$#HOS$
M&Y_,.6@;S/0>38?Q[ 84W>+8L?UQ/*8W-,CG)H[?!\L'@#<."G+.40-X[E$#
MMD4H<.8 @R)@%;1,8N6(N02OD]Y@-Y7.;U%Q$1\MS'G/$_,#C.+8RQT.A6/F
M3]]/<J9)F>.IGDB7$9N.8Y!E@A[)XX5<RDV=%4CL09E8^&B+LJ_*LC9%T%*\
M(Y,FG-!$<K?<B=,%R,\P;D0;E0^6QSZ?PO H/ 9L$R'A1]Z'E1N0KE9*7/DF
MM6$(]8X"53R0?)/9,G>#I1^167RVPK)N-N6C*T.#XA+8^F;2>\T4HQ5"IQ,H
MIV4LAD?)V1LE8S;NY9CR:Y$4"-%$):%"GR#@A4T&)MBSAF@0:MV!(@14=R_X
MBYR'1MJEEZ494CN/@DQR;(XX(=9%1:R1T/5Q[RT+8[ RYRVS/GJ4$@5F5!>?
MG]PHEF"4W5&ND1A1TSB!5A%$R++XDP'S60V1X>D,@R/E<ZJ(>8-=9&'2G,[R
M4@7UY'#<Q#\Q?:P+TLY&$D'.2J0@J#8MFU["/OFBCW'+4&,>2!$@16#-,>2H
MWSH1+(B?+0Z:1G&#$E( N;H<OA1C(<I3DYB^10RX3D(T0G@3)S7'<5CYI:-B
MHO6)R%*0SM2.R9\Y 1R #5C9%M/-_B#)G,[B*$8=#!HS'XWD.2@2>=FT]I?(
M!PB$1T.]EEL+48Q63@GQTF8R.PA@5ZN#.6B:@&LC77=N&JS9H0(N7+L"\\DY
MB[)+(DQD;:7.1XS%<Q;!LI+"<<2&'K<L.0L<Y$G+6*B#*MC-2;9MOA^0P3A9
M%?(,11<,J"W(ZK:1H/F<X9-Z+2#W+AS"N+,4GFV,<[VC(<(C3:L>CF=H,&S8
M)/M,'YC@;YZ[R>YR[8L\"MYW)(J^LHED(PHG$EF[%((Y&-"\4H1;*0PUS^#3
M,D7M+&"!<X5H2B$BQQ-XK"HF'R]=!.6\+=E;+D=O)1YY.\3U(Q7++=>#.!<P
M)7LUUT;H"Y<E8H:C;.<[T7X N77F?@K)J/B,?R8@*CLBSNVF:B.80+J:Y"A\
MYYN<2Y(0;X8F)[(3DU!+9;@T;,6"#=^:QDY'2E S8LO&I 3!S>\BZ5P?$.80
M-S%F34C&Y;2PN2@35$0TRWD06=>0AXVC6-V8R*#K(CG7( .>DE2["9%))*Y1
MC(%,F)QT8L3R]/XR]C[!(BU%_CGGKOY@2#IA.[TL%4RVS&"$E9,+N?)XV<FQ
MO,$4G)$?1"TFXHTE(M;E+80U)[8[NQR<=R6J=HU&U>PBT7 ^%N=%W]S 9FZ?
M9@'-6<L"$<UJLIP(#L9$4&8FR2TD1F&2 5F7)\O7@TMRH[@!&R.#!^%Q#!H(
M8W!<41 8]EHM4BM+E2AW.!#\=92IFTD?E>6%X"!0'M)0;8-<>R?,HX/+*2F4
M021C<N95DT<A$U..(ZG:PMAV'0<9#L1CN,8CCQ561M5"+F.,X/Y\785X:+TF
M;4M'Y)-KH6@<GH1/) [&<NB7+%2<1&,R0UFW/+T))Y85B6=QT"-R'+YVV*G3
M($RJ3B *T8S#,YR$5J@\/<YCPH-/+27*8 '%S,#*XVAQW,;8@881VG-L4,R>
M.9><CY6='Y),LN5YPG'WBLA/3-HY07:M$3A^?AVTHL(KBY-87S415:?7\QLB
ME!:0O@T>;N7!1400QZ8GS,C*KY'-,:W(YER'(149/-7@-.R,7PC"4>&#!P=,
M7C]@:ND2ZA%2&+<,\Z!5[B(1D.59DBD0:R'&JN?57V:A!&42Z7!L&<Q3',<R
MA$@CDB+$ &&Y]F QR^N(?!058.^#71\T08XWQZ)J\0?,YSYE>V9<-YNG?,A'
MBD?,26-X4+HX<$Y%*0><^H,J?1^+Q+G56E8JPW'WXJ<(L_7:<\OCBVP00;KU
MOHL[$JH4''5K"+\I'%>9QYRY\I0V2TGDIG4?88WNYNH_BV?QR!Y-G*S;",C%
M2EM$9Y9)H(&:+ML[.HA*3M0$YAE#$:#&6@LN[8.%(S("*F%,6\Z164EFK<ME
MV.LB4NOLF4D?YBCCD$;QP0YH\+G(&PQ:('R=^[A$KQWRL#\IQ#*!="-0U68R
M]T\=MG>1GI4&?&D6OS/EHYG_ %=5%5-YAR)'UYZX.F(ZZS<@5DU8UB;RAV),
MCX'I!"\VEXQM'YDSY38U*$U9'ZPA39Z1(#U,A2-].*,BB9%EXI@'FT-33']9
M@;R%'<=DBP!C-UVN6VS#++'$8J0\_1N+0*79&B<@6F!Z1Q4%D/E3!28P#EQI
MP1/C"Q0=+I"NQD$I($5*S3!7E&,J0V['LMJ:8.9ARI&,29..6Y.I6(RV42?D
MA,QYX5)6,LQ7C([+TN;=VV3).,?X$$4NBC) ]3*9D*>-11J3-V<VR5HSC$O-
MZK=D<GCB/9FC0276R=WC8 WS1"AV3HME!3 ^!XMA^>Y?F:F1324V@$"GT9RU
M9-XT0E>3JFT"<877@,^!LFXT;)9SGL"*\! CF+PU+2F6Y13)F5&!57F-%F<=
M"IG4\+?D)+S$8^8\J+2'1)X17#PQHTQV6EM#YUFBS3! UG"V17ZR8,54;461
MYVH[S72-_C=/EJ'F$KQ2!TLYD@&8J!+ATN:GH2L!'2J/OLO8RC)J'$H\A+[7
MC@]&<SHHOK&HZV -DR:IFPBJF38BYQQ;V0FA<CRO)PLNEF52.0(H%S"/92%U
M!6_.>(.XTC>'7)J4@1&,SC[E,>R4!1W'CD*4K8DS'F9&(F[<,>'D%PG?K6S)
M8?S[%N3&+X]B+/(\<R,TRI.Y,2C\=E(,_+7,1DV7LD35B%E,QMSIATH^H]$'
MX^M(S4,SH!EGI6WSUQ.1#J'@)HBJXOC+R@)5O,+&+Z>16=EHB<0<GQV; YW%
MJ88AC:"CX;"<9#"Q1J9%9+AF1F\C)&\GR"!1]63,4) ^)24TWDT=CD<(MCD^
M!><V,L)G=BC(^1GKE_9FX,-;3?+Q.94L@OW7L0G,6BX_222QLX8SE[BIMF>/
M 9HZD(23LBQ\4E,)V+0&QLD >><45@RUGG>'<F8(<[KG$OD9?..'!KL6)*A1
MN9ZXVE7-A!&)^)LY.WS+DIFU\SBHL6 )RH_FXF5:1>E"LLF@PH@2(,F>/;?W
M8(JP!0#GK9Y"P4I<A.&D4C9EL[,D2V4$Y2Y2QD9S/E=VO ,M4<9P:1R23V%X
M,*8L!K2MEBC,)F2R@:;(-<M-W8YJ4*$6C_[5#F:'M8.?+*Y3R/E.4\I.%X1/
MY-(<S#3,= YNB4P3E63:2^+FI>+C!<(:1,$TH:I%HA)A(T\Q</4VX&JC LN1
M?AF>'<X4<P#-I@@-S']VG'47YA)5*YS9D&+R\9*96MR^\P8>$R3ELB#:3G2D
M$'^N!W'[8/&&D/@!!%-02W)@BBXN0F'A%E)CCSG^HB*2QJ+R<) IY/D,NQRE
M,,RM)7D> QFQQAFQK#\QOK.8 -#Y<".D!.:Y(-4++\RU H*21J'61\%5O2X:
M19B?\N/-2<HN[,E<MSD&]R,KDB31$1G)0065]0N>@#.L9BL:*K3>*"H:\3Y7
M:F6C<>..Q4(^+"H^A*'Z4L8LR:3.<]J+J3EIB>? \[SW9E>R<WPJ0&%GL D$
MUF2;F1T3(RJ=+W! T<C^7,IQ(2!B\5=Q$>$E8 ;B D>221I(\;5D(U_(R9%R
M4&Q3Y4"D1-MI!DA):0NL/=J^&TE012OW68^?AN,GX2-U:JQ]1J/R/AF&GLK!
MWA$\-1B^:<G$[G$@!V"F+X61;&UPISO/X9/78G(V50,B%X4=-,,AIG,Q ^]O
MD@IDC+BQ5C*F(?+N85) _&8P,1 )!Y#-<M2I-)S2/&9$4MD\=O>AG=G.;2NP
M7"N8U#E7=QVYSE9Y.JY+CI-<$2DX"-9<5PVEDN,%)W XS/K<Y99JTD!2 (RX
M1$9+(,ZK2E&TBQ;*3.'D46!<*1:)!L0\WWIB/RR3R_([6L9-84K#XJ1RLT>M
MVN/W',[FMYDP#E$<+,.8_D*=@>4^08HC$BD)ES*[2TUCJYF(2 U)&U\C>$5E
M9HPOG2?YLOD *<Y,C^.$7F Q;85#,LE8.+6C%3&5TN8*K@0#+#G-Y0C'B>/T
MF9JZVV1#EF+9[ R0<PR>/>&0BI01"^>Q +!L?29K+Y+:1 8I]<9TM/<?JA6#
M..P7)$6R+&9-8O(VLG,R*5&UX&=<O@D<*AC57#@@].LWXYPT7<47,,GY>^:K
M!>#\UG(7'LC#9A$A&1LJBI,&GXN7M[;F?DR)?BV,L<619S*CI<'/X[S#L!@]
M9$%#PUA5DM&%1I.01YJX9B1L!."*YI'@KG1?/RLSA-L[!-F:&4@V/PN0LE!I
MCF>,8HF61N1DY+( \F(_*3?M4IG37$W,H8A;MCFAE;%14DA\>MR5CQXF,OBD
MSFT#/7,NJC49YAVW)TPBXUK.Y5EY4N.1(H&)"C&<E,86YRQ1\Z;,S,0YB!-2
M$AB^-KTAHRYSS.(%I*W&I*RR?ECK\N@3J*E,>X5YT'PV %\F3C("<EC8#E_C
M;X:VRBFP!D&%N3,NB\]OI0# R8B,D<@<8:,X]51-%"DA,I'1;(C%SBDJ8/R;
M@BH2/\JG,(&A_*LW-8PS,^%85BG+>'FL>BF<8<QS"XD>.\(<].,<E$(;DQWE
M\.]1C;R2Y>Q0[C*'W1@#EK"##AJ+"@70XY'6S/#-VOM1;,KA+RAHR+2&A0S(
M3T_/1%*@Z1XOR%#X193F30Y4>4R#0W,F0E[W\/K+,01?,<(S\I,(>]%R*\ZT
M+@7GW(98$]##P)%N->7[F<BBDC1@ >?LE6F2>::2'#*F50+Q]-(3F7F_Q1F!
ML$PJ2D4U+D\<2 ]R_)9,@[99XCC=D$RAV8J[)-DTP\XM(KOQ7$.8,9S%1\XL
M#S.QPFK%%V:XC,>41TA=09NG'W%&0]L\B>?9^SR/('TFJVO(>O>-2,F$I.2)
M)GS!%!(P/ WA%]">")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1
M.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1
M.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1
M.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1.")P1."+AS)7,J?
MA/,9CT0E5LK@/UI:X)RA(>S#*,8[FK)0QG(,<."$A6(VNF5@UZVA^/: V[&Y
M,L=SH-<NG*:D3O1H37NZ]>1VK],S<W1#$&1YA%247A"$*B0C$RI+(,@R32/-
M0)C,1*=C(TO-FQ*--P$0AZ#['[\2ZDI&85JL=DD,&H,=##MP,#;8AV6K5&_/
M&^1/)AI3  4,12*X9'EBQ*>-RL:'-,K=A&/2R<R$"%8S5",RPJ/C5PPZ^C,D
M).;V[]$&D$-QXN2LM^&)G*0Q_58SLU77]AM. F-JTS ?-Y,<IY%@3BXC&VL0
MS0_QN93CI,HU(KP="7<G\+S,C"8F68M1'I1TXDI V\O<&&BY!^DT>W-$&C1.
MYJS$2)&$^"RSX9R;/&<V][+-1;%3N+*NV=V>)!BYW(T9:WD?H)1",XC(1U56
M-C@C62!Q9TAD=,9<YO'%HU&C;.K21RT?9( ZU6_5JQS9BH/>>!EAGBLD?YQ1
MXJ=3V&H#(?:I!,BQ3&!ML5FZ["6Q<E,S&/AD<G,WBED<7MC^,#Z4W<+@)5>9
MO2*NAH@>WM\Y("2T1>!]Z3OS99;LZOU5.H>4+D-E;7!;$$6$M.W'H[5LZS&R
M9$5I((Y=,KY_8OT')^' 8VWQ[(FN(BXT%-RI\:@ZCLEBLW=CQ[%P0&L77._#
MSOV<4G@1=9U^'=VV9&SGG:O3J0IP']45YH)@P$>8E<G5C8&!R$\XYO&BM\O8
MFXC2^*$Z'>76D/:/.UR<)*Y9*XB/ NGPQ)F4DR6SSV:L1=;(S0FPZC;AOSVR
M6BX;Y_I7+L.P)^) 8]FLO2$X A$GOE>8!<6E%F0\GS;'F,T#LQB4>B<J,1Z.
MS&LS3R9$2MHA)O(HK;506UNHZ;W616:STSY^UWD6GPX6/B,(+:Y+@8>3D<E@
MZ.X#D^%Q+,11>*S\*J#)JPZ:.G&-Q3V%A)(RL5D[20/73<8Y0C*:<HLL[=>Z
M^8GJG*:D^K?JU:M>!E;=.]6=+.:L[C8AA=$E;'#<6FW+^$G1$T^?*LGJLD+9
M*P9CNZ3NRS>UR.:0**CLIO9Y/BJ(]?T-%A)0VI>DR94KPR=B&S,LR[IV%?ED
MOF"R<K"N7V=11I&H:2,<S&1<9RL1+)E0-C*4 X9"N8X$.?D<B5A)PF+@LMED
M"B,PBQQC&D2#NQX!&7VJI$%K7,5GGJ6W<N/-ROS!2KU<K 6^/GX^!!I3+X7*
M)D+LRY C9V-X[DXL3)L;6M$C#<&4:3<BW82R^K8:JYC-$4K'+DNLT!V7AV]=
MQSVR?EMSX*C0?E BQ21CU3<<A4'C58L5J1&2>2N["%)E?..72,B&HV7L6+R&
MR$1>PSF@1&%XL]-14^TO"/B$OBECLVWBJ1NEF[OZ[; D[)C=QURE9;LVK%0_
MG\,S=G YDX 10:%EYK'+H#%FN1V(0@,:S#DXR+GDDWEQPF)=B#P5K,HJ5@R1
M%-.),61 14R\<U7CQ((];Y=6=6U)WRMEG5-;<&YU3LH.*V/  Z/!K7_+&S;Q
MET8=1F?M3.4N:W). Y9:YJ]'%A<B& /4Z.K$F4?JN")5*/&P*>DA9(.?<I7W
MZM6.-MB3Q[\,+)GJ7MC?*$QU_%,0S*UIC1<9EZ704&P'C,J7.CL892F78$AD
MJ93!J_B H>"G&)R^:"%F0(6L45-#+(H/O6:-*2,SZBI6D6[MLM4]>U)]5^ZR
M=MVH7^%M48HYN\DQU)C*I:4>96AJ.-\&/)Q1NJ-ND$:OR%F[FNQI;-X^#C@"
MRZ1O"<CB6(HJ;$JN1(P4"O?2=LNWJ'>#BTEFY,>[JSM/!=N9!SZ8QM,,,0D]
M$AJA')C.]&0$V,BO=B(?(;EP(E@Q7:M1CF4K1LI(#5PQ&<5C5(Z)4;M4I.N!
M5,C//$MPWG]5Q&CY3%(;#XG0/$H.;/IX-QSE,P!F>=PXN9+!IAB;&\\8ETK1
ML,)K';G!.;O(RY^$&!E7#R-D934(RC9(>M2D2L3-VO/A.:VB<<Y$R(-U!@E*
M,0J4W$G,0+.T)_4]&6-\8YZ(IRMRM9@V<10$0L=&@95P9#2)5PU="+WU["H>
M]R/;%G37LGKL';[T)L/5.P]WN*LB%\U*<?RH[Y?B3QD^/C\I&<?#9;E#)+)L
MK-DHF+P$J781MP)@8YL1R7>!RR\EMN/FXZV]PI&25*F4195X<C,\L^&*3PQ,
M[;;R/'JU3N50"O*=6'6I4F"@>/2X:."2DI-$VF8E:VOXH'C/*3+%R45:U@%R
MQ!0BPYHE1P%,_6,*/"4 >6%V\?<E'(T%2)7@C"8S[T'CKP72PSF2EK+!)#,!
MP'&SET:SO.,<3EI&US-:1:%QS/<CQ$K)+A[9F;).R<4%M!,IE N^UK?<#;F2
M"%R2R;5DN(MEN..U)V3URM&V4Y+G GSMY.'F,99$,0AK$X_?B3)B^3\1R26)
M"70N8PC+W+!C6?NA!.Z(/7)XQC293G)\# 5H[#Q:9VAG)BC]DU>#'=J7;U"S
M7KZA/]$GF[M]VJXK(2'RCI)I##LXC6-X 7&AXKDV4NA!?-+,5+8^^Q/CF3Y"
MF6.)U&@\0E+F'9)"619<&7 &%T%1I$DR472JU266O2GG6=6_Q3/9CG7O5F<S
M>?\ (D*R6(@4.-Q0*Q<I<K,C#+/GZ8XG*W>0><&!XHF4>5(NF)QO2)N(06N9
ME78<*Y-"ZGT7R"]+[V-E8JO>Y>.=FS/DQCL,;Q"-QXNL$4?RL6KD84Z/M[$X
M\D1]<8)'5A[ [.L5J29,K *S:@P(@UE0E^/>-T7K1PPL*3\L]AR5H%_/5DY>
M65B K#6-7CHQDV68MBY=3-IJT*SD$0S[/,!.6L^6;8@=.XP2/%H>G)XH)'M3
M[DP 3E=+[F;Z+4;%;+..SCN2=LL]?5[UKTOYT<CR<]A.['\=!Q)B7G8M^;4F
M<TK'HG8/-8]YH12N(\Y'+H)('^+YI&IUC&*$BK(0S+N+3M]L:\_>BT4<'$NO
M=G%)XRNG8=6J^6^Z]80SY0"23X>!#1"/B<:S:]?EQF9 /))PW:/X[9*LTX%C
M&0L4Y5:O86Z(Q15D%RVB-D9H6)?^C$O/N!J[E6EOP$KNV['# ZKOU3OU 6ZK
M1*_7MP[UGFO-S.YI,<-MU&-N,GYC(,*;2^+ISIB=CTA$2/ 7-V;3'CB9"#"B
M3&+$I=B&/R^,2MJR[;*8RI&#UXL6D\?1Y5+/;JQ0&<\-UD@=DKUE,:\[60#,
M->3%: BI/&FTVP_"VC,.>?D9L&:9EY3L296QD1D%K<1>E);9IG#(;3$%)$P'
M 623LRU+U'6LQ!JK8!/.;M:3EX3MV6;>^RU=,91YC'^.<A L>)0Y V4>#\4%
M7MM3+@:Z,LLF99;XH*78_:7B'-DH=8T5<(S&=LUW8R\;&B("Z^]&\TFX;._#
M/GV(3+]=> Q)[%0^.\[9(^Y!R_9&-2\"1<<P>>W4+F)-^\1I%X3'%6N5^R>H
MJOF$DA3U9]#(V!8-SCHP.6)O+;+4+RA-91Q+[AN2ZV9O[SW"?!5=A+R@$J6Q
MQA2.3T+""V3I5CO#A!&2E,J!HX!GY.68FP_-5QRI0I&P3(;E^7TG,I*QO'(4
M<8M.)Q O4(Z7;)O;Q-(M-X&^5TQ?JGVV733=9B=5LL]=\ETAF;FZ(8@R/,(J
M2B\(0A42$8F5)9!D&2:1YJ!,9B)3L9&EYLV)1IN B$/0?8_?B74E(S"M5CLD
MA@U!CH8=N!D&VQ4[+5J:W/*[&RX=%Y3 04127=XC0)'G\^:%XL-;9)&P-,P[
M4EH84L 9+1"69"!QN\+*7,4.R!NX#2,(-= I,/>-[+?AB9RD,?U6,\-MMH$Y
M B> OQU6K3<*\WDQR5D?%;NPC&VD0SDOB(JK&291J24@Z4YY27.9K8E%2[)J
M)N(O74D9.%*KF&BSTC8W==C;LVVK9H(D2+[QN67;DJQ)QSPCX/)"[ O%@XV,
M"IG(X(=E!N6U$TQH^CN3L8XZ1E>763@)1M#8%)V6249U%Y"H67;O8HT#OG5[
M-I)%'P"9[;99Z\%)F<K+^%DSOF%ZRW/"DT>'FA$1C0>X@9;!@[(H]3*CB\D'
M!Y=*<O:1#*\?1=PH7Z;P?'169I8JADTO;%QKXEBY\R<LQ_I8G6)4B6.[KV[.
M^].[.=O?J$=Y])?+ :\C 8VQ@Y#M4.7ALJY>9H)M%+C7,)S$$,"";;K&>+RS
M5L&C]X,S)B#]1\JZ<I>BQ[9AJZ=NV$5SCFS)47\\4EC4Y6AI6#1!S<WR"0!3
M)ZKF!R[NCZ37F PW@-];%V2F-!E7S9LOE=G)QX\RX"WW4%D!+EZDHX0(<65U
MM_?.5O>I.^8N\)V=MF9*4.<<]G+ELYOYKC'U;C)O%&$)H8BQF%3X%/Y='\D-
M\?S Q0&9CJ()T+9%X@9##TT2":\@CLI<+J4"W/&S)U=5*T3N,MQ0&<_ XG7K
MGP5@1#FSR,;R.S@1O$L<9L)#.S>/8//(E.B\S@\T-QQKCR;F'(4]?!H\BH.0
MQ+,98:2<*)V)+S?#>3H7:M3T:+*$TLFPVW6>$U<XIEKG$-8O/9G;.8ECRZ.8
MJ/1V'#R!;)Y(7(91+I3B]ADT*,N">H"X4&B\:W%@Z2Y"74\ZX9MG#>BZSJ@V
MV*9[)]GEM5?#/*(M7+AL_)PV&CX:<=R!F!DS/*'I6T<WC^8,!8N>2:;IW1 >
M-CT39L,_!YD8+M3!5N(&18_8Z5[(HW*V65QW[Y66VZ[+-R3M/#=KV67B>&I5
MS%?* RN*8GF1<I'1.5)!CR39N0,+JSEJ'?G0T=*\P4DC,GC=XV&KLC.,@@_%
MK* E9@DQ9.&[AK(2BHB]>,W,#PB_K/4+<=V\=2"X6WC7U8<;_$=1XCYJS^0,
MX&,-R"%PP)44YR,,L.1O(KR4*O"L$C. )RFFB+>PJ-5[ 0BW, &L7=4>WN61
MR-F$*,7 YRT(6M]^'G?LXH#/@;YWKGC)7/1)K&P3(4 M@JHJ$F<^63'&9')*
M8N0.5,2XOS%(3,+RDTL@1LACR:A7&.Q!=B+9N"%+EI!Y@I904Q8&#:7EM5\N
M.;,5NI/R@-'.9&^&(3%<>'3)68-8B+,&,KK QC9PI?G9N_N+M6T),ET705QA
MX50FV2']DI696VCB1)@-'&)&E[]5TL]BA/>.)'BO7CGE'(G)8>[G/H:(1L2-
MCV&S)T5)LCL!DHBS'-4<P7(XW/#P]X)9"&>'6=F8R@<GDA^?%B$#D#>LJ75H
M2)WQ-*V76)ZIC/7L.M;A/MSG!7Y*.:%G'^7.59D9M( =F\#B,0.S;'(G*8LH
M)C9J6, !5H(>S8,&**6CGX@\U.14XM%VUDK N1)ADR;L"R*Z455#2CGFD0N;
M/,6^B<5BYE'9'B,1,232>D9''@:DBS=AK%61A=Z9*-PHTC>):Y99E 1Y\-;,
M%&W9'+AJK>O<V2LKNWLEY6J3M,[,+K>.P]G:JJQEY065Q^&0V)SH="I1.S6/
MXI*XQ-9+E8##0,[?RLOE\:(B$A,/8P("1;(<@<XF*IQP(*;&691NJXN8T5=B
M%1KQ+W\,YO5R<YL749;F5GZF$<@99:Q_',:0B^?U\0"G+F8E)..H B_-*IR_
MS662V^Z-Q1"-7I!QY"6,T$7QEF,0636*/+V[)6UR G(8J:IWZ[-><R7/ 3GT
M/X]%Y%"S=*'2U^!EV;7,"DI+(2 QW+ 8'F3YEL=QN,E6K&#M@P8FP$XG APK
MI-^X8%V+F]X]((&6[<6;2Z\+M>"<??B=7EJ&I=$8$YOULVY%'Q.V*107'9&#
MR^9BQL+D.Z4%W5F))'B<0[H5#4BHADS2.C\N""#-4>;+4:KB2+93SZ"S5[<E
M8,X^!P36<Y[/<N?X5SCY$ G<B.)$RB\W!BSV0BAXY3(3D>+AT0#<X.9.6R-F
M1L;90 Q5G%HJ/C44/Y1E+N5V#Q\$!FI>V!J2-F42E<0Z\VZA9;[[585>=V<+
MS!>(,L70!-5C(H'%ERA?+9)@U+.LBYISAA&.'HV@UQN2N(1MP6Q&/E-7*KA!
MS> D;INU2=.PZ2I1G/#?O6[->9=_G9KF?.;Z8J\H6,LUP%X"QNMG/E?R?E=H
M1>$6I4M#9*VY8)!F")"(P3?-$P18R+.-?@*5)!%;"2(5Q=:+13JY32H$R!>)
M[PKGPSD[W$.=]>29T)8!>1&#"YG'I\WBI&ZN5V%K&5!W;1N5=D\66EH^%*ST
M_"0I>-E)_%F(A!R#:&6KN]Y:P=,';N*3SP[[L=2P.=><:0#&G,7$8#9#8U(L
M/L4AI K()F(MF8 D0D.,AHDX[QO>A>3;QB5@YZ5(Q"7NE:B+W8)A91,DL6<,
M@UE9-7.<X*MUN9>68-C_ *_SB4R3*S-EG?F.Q-0*REPINW9@\%XOSM/P[TN.
M:0=V_+D;QF/D6$D>-WX]PDE45+7C(X08N&12*8VVZIRZAA9O*L?(OE"P&-EX
MVFH&@V1TS\5F4M:78ER566*F0P."\S<_BA2+)7Q9E9)&DW&\N7H1C8 6,T9R
MN6N _:GB( ,0G-D<+S+M5GGOW:U;<:YFSTBF^-XR-CL%EL:R^*,EL<9,QG.G
MTZ@!U"%3=PRG5'<B:1=F-&J-,;N 4LCU$W9%F;E:\A@R9"VV.VR$K)*3[Y9P
M\%4',[SH2K'L1YFV$%C3$=(L30_-;$;(2I&U8E')-!>6QOG6-9$.1%T-M;7X
MP..G]D&$GKB:Z+F>TCP51J[3D+M(&VRLX=2NR=O'K7[\U^9<E8+!@89%YJ/:
MW&<2Y%G:$NDA-LK)UI+%LOX(%C(R&,/AJ[!X%]7<GGA2B[\.5D]T=&(%')%X
M::.RKPF<YQ6VX?YT%\I9388E5BD+#2AE)\EQN6L*90&JE;V&.YOF" +S?'8!
M^'%R"?1-628K;CBKA 4,NCZ\D5H273N V)G+*R?N]^=2D[MMQSLS=/O+B*IP
M1.")P1."+DXAS>X="2G(T3EK*6QM;',MD8$T4>0TJ5 K-(9!<9Y!ETU6*Q]L
M89AHK&8_E.-/"QB1J":M6ECQ]5/LS5:])GJZTSGR60-\V>%@8M J24D]GI1[
M(@C5JK"#S=4B=C*1916/MWKYDU"O2!.HAQ:"J@56'D$G0Y]8]3&$FCY5*_9?
MW*3X^$^[L6H_[>G 30"^.G_7H#02%]-2AJYQI,R/H!1EBB*9Q)#7I$,$("GQ
M +BR7#IJZM%O7R5 [,JJ@JHX'JM^$L^.%]ZO?GP6[&.:W"(*1*1?MTC+'ZRA
MW#1[.+0&6R?TU+!5)TT)@!3P %?LEBX=YC>8B23)=RV<#W0U&UQ8FS*B7+ZR
M)4GGKU8X;UL^%LZP3.]TZ?0%F47"PH]%!*4G?#D68J5IS?$^/,PA#<;4\_>^
M6'N(ADJ-7+5)-!SU-PI>FHV^!\"ZL56-CG,1C,[.6F,5#K-U/#LAR4&&@V@<
MRU66'XT/%@AUT[3,-&JR[8.Z86C2A5I8Y"VE'H[S#BUF>!K$$K]BD_+AGJ!*
MQ9KFGP:&,F@[HNZ>OP,M/00K>, /"B;69Q?'>1,G&HTY4:HJ7LS#*#8PEQ>C
M1_8U4<,K0:[7SS.5QIP6*JBB_.!*B^6F&.,9XQ8$1AG*;?"XJ32I,F/8K2=S
MRQLN:D =7]&).W*<3(15=>.$$ZL*&XTY\Q*D&,D1JM&K">'ON]_FK-4YM<9_
M<E/9#1*V/[(]C(_D$[(QT R*3@\9MCT7,2I&^67,8\X/1]&@<,X,VC2C9H:J
M+HWM11L?%PC<@1;$?YM,' 9 K%5W\C+G%9,5B;%E&8!+I58;E<?:9!<' @QX
M!"D&*Y@&IBN;,2;-PY;NF#L.A1=.QJ3$.7J6<]ZDU4QCGSQVWOND;  ==XN
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M^C#S?)2C>'%(K.9C$S5J3 B]C X.+S9GK#<6DC@PHS3;M6!^_ LK?%:*4I:
MONL2?76LW#1VX>Y7W_KW*SD\JOIC%G!_",2'S D)F](H=%S-V>QPF/3L'MWQ
M$LR?UATCO,408$0CU#L#2]B19.G+5(I::87A[R9SYKT)ES#P7%_J<+S"V7B$
MHEL:C1EXR;-'<@CHYV6G6/L:/QU);:P9#WC6.SS)\1'D"#A%A:U$%DI,\;,1
M*3Y9H14T5YUX$!7RW9)&=\581,<2-8\D1&(S8D(D+=AR^5SX15/VA0+E<>52
MBPZ5&4X\.4<G"<7C;MZU1[:N@SO2MEKN4!%G#JX*Q<B\R\=B2H2D6CQJ6HTR
ME'\;&GS")RQP-IVJ3'X3(FD/+#@;H7)93%94">@R<99O+73)RB[N<VI-TJK5
MLK]@GQ 2=LI&^4]5T\^17KD\Y\NH2[&^=79J1K,\HX:7EL*DB S))2+C\.,V
M\;FAN7/(^D@YBV/F+<9*8Z:ELD(AP)QR&9L43SURPC#5J-6W?IAU:[TNSL\K
M@O)QSC8$2-,H^0?RQN2?D@ -[5QC.=+C0R\HGJ^,XU?(3K:/.08X2<G5C8&,
M+*DKQ#I0H*?IO*C'Z3[B2\-NY)]TYZLVKTV'.QRZ%XN"F%3LB;1@_"&N1V)$
MQCN:C:-X$2AQZ>!9:1'OP"1(;'#T;BDA<AS3MBD+>OA-PBCJPL]%,WUEWR2?
M=/.,M<L0L@>YQ>7R*!*R8I(G]H=**EYB\( XH=DZ0T$-CQZ8KO'U\4'&O,MR
M<:BYD^(?VU4%&F"(]=@0<7GH[:5B3&>N1LOLUV+#O.=_"@XR<'E+Y4&%1L%:
M2.20]'G$?&#3*V6B>%FD-=M3=X\NTDKZ;B7#5BB\'-A[ULY&.&C]>A%"WA+5
M[QWW*YQ[IK)YVYHF.(#4:BS&(G3YV1#(;*;75[)Q:$:14YF[$^(35M_8;79U
M:3LK,H(EA05 ,K0@Y9(CE'"*CNM4J!,@8D#>I.R>J4UN$/YF\13H['HU'#)=
MV<D) Z#H-5C$@;.H_)(TI*D3D9F**P^U2(FQSF$2MHN@?L8MJ/A-K"CJKTL"
M;E(KG.=85_\ !$X(N?#/+[@ W)YP?/1M@2-3=E,$9XQ)2Z2N QL=/X1"\;3)
M(Q#UY%=&:,I!"X/# 3].H5)"ZP6W>)T3)/GKQV4LW9[BJOGF$^5F+"H?(9>,
MEDEL#',4P$02>Y:R[-SBJ^1,G@(WCU>6$2N0B):5#*S&4#$Z&I@[-]BCZKIG
M1:Z/HK,*O>JL=DS _*'CS$^1)/+XR;?P,9"Y1,)D@-R1E$Z5?Q%3!P_ DC*-
MTT9U>5?-ZX3"L(I1PT<TN119T-LE4I.I>753U]UG<IL]]OBLS)L=<N&.# :4
MO8W.5;".88G-0941D')9B*",MY>G]V(42P,+;/E L<5D<NR^1)3=J!"L@)5^
M<)S.1M2,B;VOTR6$;,Z_>O?Q7B_EY@4B @L9DC..34-NCQ!_C2N4Y=58NP'P
M!;ER@*\RB!6:F6)\:O#\8,&$<=E&3LD3(P<&=4>U-L'JCIG/F@SWZ[KUZ^21
MW*IA%B]RQ,[$:.(NMDSF&',O6Z3R<BJ0C#8Y*LDSB&0U[)7;)T^#,I(:<D*@
MQMJ8UD5]'()MFJK5I0F%_'CYK:)UR\<M,N>%)G-P[%0DZO?FR4OOR++P)))J
M"#Y*#$_@R(7+ACP?'A '*F3A1 2V>MH^P$2<PQ<LDF::*39.?<E@PMMZ]>=B
M]N(X/Y>4740R-$V?G[UI4%RM#SR61IP0'OY-3"S/ (61,F[V6.1A2Q7#ES.(
M),5FKD8YL43,JL5)*K4O<3.1F5RUU'E*Y7J C$;;1UTG')YC@CB T&:Y;R:D
M)E<*)MI&'=L';)">6-BL@M&2B1 &<TK8K.1@5\J '2)H*;-F3<EAU\<[EZ(7
M%G+,0R7,Q3$;(F\JQ[/A^5R%CO)63$(J%G^6Q61PCLW#Q2LXNBX5[+*R/(7K
M8'CPH4P,2LN[D!D:^D]S4LE;=^-MWZ9"68W;3@#?U:UDVG++A6'CFC#%S(#%
M).$=LEHNI*3\\R!'QQBS%PO Z:IB$/\ )0A*3W.<4Q-"&7LB)*RQZN,O-OJ/
MCR+]VYBJ]^;1/!>$.7,7&I:/(*8HY>HK#YJU%#WY:\^B,P4]"2@+(W" 0@-)
MR%807CHP^93=7.&1QZDK0VU()/%VR[';FQ24[#G<L@+Y;N6QB'BL>;0>,D!$
M7] 70YB9-%)-:(98["RB+1L6&4/&2CA*.PT',9:&%QU!6L?"-#Y=N@.;T=K4
MJGX8)(=<[;Y[O)69"HG 8& 9QB&K5&QQ-L'BP81;+39-@,;1>-#XL+ QI(D:
M?6@[6 ,"VHLP U8W.""1"0/TUSI J3=%55*'*ORZ+02#P1K%W"D'Q3B_[A\-
M'MLCY"JC'<:BR4$(5BBI5&8^D7US!_BV#TO*FG[Z0-TH[8QO)VM'9-N\$SM2
M^W&W>LF(P+@(!BB0839B[%,42V/*AWL2,Y"F,@8-8>7;T#L 44>R"5DBD+B(
M]%9-E#0D+( 0,4OJWMA[00LFA6T3/.=Z+U%N7;E\))*-WPM8U4K'T!#]4MDV
M>FWTB'1WUF;M2QY\2F3Q_)Y" 5ED@JTFQMP2E8AXX;KH'6SL2)48)YZE+-69
MZ^W%:X^Q_P LF,)'C&BL8L<FLH99;KP=TJ8DLQ3<SY+E[?8X3+K7F#Q1%L&7
MPCCI.,.J5L4 /G; 02>,UY0X0,7$F!G:!WGLW*ODL5<F3HJUY<4;#4@JA \Q
M8U6$JYBRS(6T9B))KAH9D/&!*1O\B/"<?JX%R+%;>-Q7MZ%P =JVB"02VI%!
MP55Q7<L7+PY?*F:QI11\#*G"5KY/(4\I?&C)?)K7-YEX/O3EU+(R_KD1%&44
M5'4'K#FZJX9G5K&GSH2N3JSJ6O'>4OE7D0]X++19&\?>Z5E3YNSR;D 391ZI
M )CB1Y)%KA,U8WI.GD.F\T$$S%;[%2)<R0DA!PXEJ:1I$B]MQ&^7?EQ%2_+H
MYJ3:U:!3S:1O1LSF4R+K"I9DLKD*2KI#2LJ)ZN%L@Y)+R1\4;II$!]IVJ"#M
MN+38LDB;/?;X]JT97EWY*G^-FRU@,=)<<1A=CCI@DRR1D&2C+"T;@ASE,%P]
MJFC,7UY*1H1>3E\7,V-:N2[R1$D"%*KS-,>817HK=9\N.$EB(TC0=(RIR+60
M=E<2*Y:RC(3U5<=R<U/X126%"DZ)$I,3 2*5FBS1[+'1<@LW*WL73AT'[.SL
M(M5$\FG*OZEWPL7C@>0A*XUD,M%W3&:&6":PK'3?$0Z0,W+J4O%V<Y'8T:-(
M4TR$S<HSQJ":-&B4BL[,A<G9G];;O=LN4EGMFK%1P=B5",KXWH/**!WD\%9?
M7&N\@SMZ><3<#.PV1!TJO.O)4O*KZ-YX"$'5FWI2H=V^0N;O6;AJ\>-7$5S?
MF2P8GEKY?V)Z/& L1;(FX#)UI;&*L99*ZTB99V\FZJ[84.3D5S,3'%WTVF5;
MH8BT1A]R[JEGH+4()M&E+.N[63:,^*]&<\O?+=E20/)=-0 F2/SR3>PJE6;R
M5K&9'K%)GBU)P<B(J3,XA(7CJ&SB7P1<@5"/GI *^H!<N'#<2*;CRN;U7L>P
M;RLY(9.;DF$U6*1$ZYQG0_(<S9F:Y*1+8MR&63'.VL[=Y(OR [(#)94PRC4O
MND-YY0$4(1ID3MC9=\&<$5NL^7K":K]4JP!.EG[;)3;):SIM/)PM>WR0'Q"W
MP(D74\W*;[$737%#=O$G >ZVT6I1.PT[&J2/4O4I8?USBJHF?*SREPJ!OV$H
MAY1E#S-0L$5')Y$RPJN:=S7'L(Y6H_&VO9II4@X(2"#AX3CMCYM>Q6JZ2)M1
MR@<<$CJI58(W%^3-L*B68'R15\UFAHW,HL1'2W+I%\0+!IH,YF)40MCC"0J.
M6M8Y,</LIJ>%NA:"8QW%58DH/MM)*QDF4/;V9_2]8O%O+SBT+S#/Y!C2=$D$
M8!#X"]&Q1L_S*ZM%0::62]\%9-)&7RP[QE/(S*C[><GKWI#',ED(M<D^',Y4
M.M9Q^T,R,]G<E^2-NS,PKK+\MG+M+R1EV0"*$7TF]<$B2#+)4]:(+^O4A@F0
M9C8Q%BIBV8C*FY! X3)GM!#1E6Q5G<Y1\RW.F:$RN;\%M,(Q#B"$18O#X31^
M-BLPO).;13;)4W(-6+6YPZ<NA\!5>RQXO HX*7=N[QL=QZM'8]&ZJWVB!HVV
ME+;2DAOEK.JT:^U5D6Y/N4^0 W<8<0MJA'I!Z:#.08#)$^C8LG>8B4UA)]A:
MQC4S%-U7)"(Y EP8FDBGVA=F11O<4N6#A5AR><Y"2$YZ^-GZV\5BW,7Y3V.1
M64+24<.)@Z.96CI!N,R1.G#*-GIV7@O,5DJ.RFQ"9T9Q]Q/"P^(35<,_;)(F
M6[MX/0;4#2,Z/*V?59L&3VI(=VLZKLXVK]C/+'R<@10V &8Y'@@66$EX""AR
M^1)<+'$C9G#K'&?JT !V2YNW1-*8C@K)J.:BFR))BG'JRT;V:1(+'*Q64LY[
M3K6J2[%7)I))V'@$FH9E,NL;G\9O5%,RY8+.0CIEBV=7D L^,?=%N>(RHOC'
MF#F_9BTF6<R<P/FM''I-1RP!KC[//9))9XY\UTS*,;XHE!..DI4U:D2./U6M
M(_<^E1E.V.$;!9)JR(6-+3:39*04$$RB38V[0O.=A=NJI/O-7W5XD]7N'?>I
M(>Z\[=MNO:N2&O)+BR+D<B2AP6/2C'20 >&IC2+RK+R9>L6QO!HI&X[CMV]=
MYS?1<FL'M@,9>LGS"'P^9DC0H59)):107.U-V=DLBV=F&KCC8LOLVGLU]AUK
MH%/EBY?EGY=XA'GMY"X\SD!A1ODG(?G6QYCFU_S*LGBR:4QI0>LCF4H^G-B-
MEC=&[M%0=R-T5L2"V1669E:U.L2<LD ;&L]R468'H#UY2</28!,LIO$2B61C
M0E<^@8"Q>2+LY+'7)]L,*#P1,81C$2(V*G ; $K5Z^JGX;_U4\1GL54"<1\C
M=LFR9C,2+.O)1!V8:+3@%]T+-Q$A=9/$<.VC13!T\F*ZA5Z1IB3$#9TN*=+.
M6"P%ND^=-?2DBJ0M^<YMQ5NSGL&Y7DSY5^7R-JQ=-@%.@%8X>-EH@BSRYE45
M459)W+50W"PJ*$\0HCB\H\3'7KX:;6?<IJY:BKDX78JQ'U0D\]>;_!0 #.?U
MF=:W@[C/$4BEZLZ)CVSZ6N4HZ(6692<RTM+.8"Y-22().@(XXT"EI!$'LA*F
MXT_>CG!L"[=HDASMHJT8KMB62V;/+W*G8WBOE;Y@N6K!H=B%(/L&WXNBS;%P
M)U.9_&R[""SS$58J&C1M^PE[*5/7SS&,MN$.A<D,%"-BCI-\I=>8:,R*)595
M:/X$SM'I-.%8W*)%Z\7QO#LHM:R.8 )./NPMEV7)Q=9)(;*Q+V'&X%DM:2R@
M/.(TX$S-LY3;'&!A=5@([+;1G/;J*@E9+#@<ZU7H./<G^2PV,)V2:&&B>4HO
MCL]BR59 R//A4L,)DT0&7P0J-'BT\4E@^5L*X(C<_EK=B]:O7;\"H<,NRSXM
M)5WDSG%)#?9M[3?VJPD<'<J^)A,7G-6X^*!,,#<=>K4B(Y.FEXR("H%%YY!\
M>)5<DI@Y;+-4HOEZ<1YLV(=LME+:6=F)I&5TA'92LI[QOU+]XO#.7'*2DGRB
MU#*.'#O,I"52:^1R63M6MN5L'RX%B-E*EXT\D=X%G>".\OD;:1=VW'(#G"<;
M3*L4:KFC*Q%//#WHM9R'B+DVF3_-F1IXX!WNZ,C>,\YR5#+$UC:+-A)X7#XX
M8@DIOC\S$LQJ!2,MX39;'4TFUM3*88PS:62OS;^I%E,?8VY8)A4WE"/1ZY!W
M2?S5K)7L@E,L05=RK'V>I(L06D HG)W \D($9JB4@D4'1)MW(08]7>D(HU'(
MFB";DB\)[B3E9P; 2LG+X_:1J,,R&*K7%D3<GAY.KF!9A5R7C5 ?:(,CWM&L
M9R?(W$EM8,UTV=[+4>2;/(X-:BV]S;U;>'!/?Q54YPKR:QZ&@L,Y6CDHN DY
M!E4DVAS>939J:M^ZY-99AR92 R4'3\<=7BF397F(S'QMKXPZ%M4)JV)W#XZ,
M JOHXF;=MZEG8.$K,\;UT..QA@R7PW(GI**KLV7,#$*1#+8F7G9 TEY@'(Q<
ME5OA<H</)"N;!/F8Z=R9HU'#";-<*U)7H!%F[)H-JW$S0 :MNLXVW[5AC/*Y
MRVR.MRQ021<.G)>3NFY1ME_)[ PSDDIFV/):?(@S@V>-2P6373K&F/B;(H%>
ML30$N%;HA'(VI(D@_B6>_P!T]VM=""Z1^/"F@5B1029!:,0*?I TN3>V.O-(
M)M&Q,H6?.RI$R\HJBLLY+/71@JX<=L=N'3IU>LH57)^#\1X:QN9NPJ;0'3W*
ML*A\2E#^3RB/..S/H]+)[F4W"[(FRDAV5-Q*H4P/G_GA\?=HW,_-V/U;$D7+
M1%L19Z7X8Y2Y63MA<B0C2!F2E)WDRH +D:11$F=(2HY'A<[DRS>*RL*Z(I$I
M.WCB#VJ]5F:<B1:J-442MEZE'Z;YYV*6;_=G=L7[K\KW*X7>(D7,>:E+WQ1R
M250<9,G+X5(2)W(N1,D7^G ZLS5#RI-UD#(F2R+%B<9%&B%9'( (]LB%NO%)
M)^&=R2!6\PC%..<8N@2\6E$O:"X>%D$/2#R/,619L.5O..(H\NND/K[-9)>7
M. FD7%CXR],7.2\9"/20D,Z9""SMFN5SGJE):GS%5Y;#5(Y%,ZC@$I(DG#2,
M XJJLHXD5HO.AX1R[/7WHP<_9E$XL5(Y-'1\T5NI5D-JZ2,)7)D@;1XQ R3-
M\L]:]B8<L?+EDU4G;)HS87]<K2)ATS&Y G 9H2;D\.FL /W@P='):,9M&"N(
MI:7A]/0S=JR02)V&$+4I"DR+(DS9L60LY?<$#29LY1B0:+UR(+R>415RCD*P
M('R$@[J41/LH^M,_5Z+NCI5Y4[(F(D:+'S0\[J?D[(T7<5?7E)#-^^]8D]B'
MEAAD"A\1EC./"L>8OQJZP/'@LKG!Y<*.QOD!A%<;+04XD<DCCUE:R-HWB<6:
MWRVXR45<+,$&3RQZ0ON<D,AV6ZS*<_/(6OBN6#%P[)+&5724@<CC"&P^!CHA
M*IQ/9D;<2R#Y#=Y/ R$_/)9D0W()D4&$[1EXL-*4"[D30"R<,B";1*C%(EF/
M5U'MUD6'<OPQOA7EH-P\%(H6%E\4CL%A)[EB:)_=/RQ$;F<-PS)IIB>R+2-)
MM/&UDB=P4ZVEC2#2^3*F)3&G#Q0W%) ,?.['E29MVXYDLD0Y3>5E1G*QRD8M
M#AI5$9!$)H""90R'%8V=CTS*2<H85D,=C\W% GQE^1R!);F4N?,+Y2.2D*C$
M.;9,ZM&Z5G?MOL&1V)89;-N=1[5L-.77EYN-2,E0/=<8DMTB3E5GW29S6TRE
M()7?)Y$.,C/7"K-T-<R<TX56$.FEPUI0X]$-VC<<9=L740@:^^6;EG3?+WA2
M;-X0X?1FKII"(V#C<+5!RV6A&K",@93!IR 'IWQJ0C42C,?)L<0HNR4(U?W6
MW!K6]%;F) HV?%5,.Y;L00"9N9]$ !X-)7[B1O2BJ60\CN@QLC*Y9+YN9+2"
M*OY:ZBD@-726>2UZ,-&@K\J :F% X!X,"M6 YK9W[?=GM25VS]%>?$1."+Y?
M2KD/4S#..8N12U*/02^6YF?R*!G;(>$D9621(IA_E]BY*V4.!\M;.2457E&.
M9*Z1AI5,*XMD+4#+UZJ7CFJ+XBL*4<E4/>$AK56>1X.W3G! [C>/.X6+ML41
M5RQB3/*^.3S1*1C$Y]" 3G":(..1<>SC]\<QU?8+L77MC+0C==]G"WA>.WK4
MZY6[-GA/LZEHAWR?0(@VD6/Q^6H['0\LA6=QC>(C<<#VCX2*S8TG3*5V@6C&
M;#T58)$9!D872'@RH<Q?%@(D5"DY'5DZ8+CYG-F<+4SFVS7PP6\)<B T;*KI
M1&YN%C5'4FCDO>@!..J-8X@7 \R.*N855K'!;69M4H\ ).<7T"KB4JO;Z'I9
M))TJ^=/GSD0Z*K#F>38W&8S/&T5/W'Y3.Z 4HB9!16.1M7$4\BW,'F[F&QOE
M)):22XDT=QR R3+C<5((JU#2$A*!<;021$N!IHM'T[>2;IF><A2T  6V2\^K
M9:5;.=N4D;EO';3'4;E+6"BV.!<T<OS15_%;IC1M%\Q005"5B:*-)'&5/2X"
M@0<03N6=KH%D[B#)TF@J[3(-8KGQSC:JL(\A3A_-D9"EDZ/BXVSGTPFPZ*!\
M2MQBHU&;,,JB38%J=9SI&Y8>NPRL25L;DA9 6T,C;# L..7.29(O9YUDVV\>
MV2DO=B )2N$\1-6Q).51"5!,0C2TAB3Q]B;#<ZQ:Q($\6")"T<EI9'H<'%S4
M:"DITR+%K1I_#FA>P"22D;0K5RHQ</6Z5E5EHKG.;U3;?D <>G!4B(90C[LJ
M&DS"3C7B>+7W;1[Q#F:QYS*/41Q(IDXR3:)NR<*)Q1NI1ZHNS'R94BHH]68K
M,RMGA,7Z\>H#-B@'Z@6\9S[4!\@9$:R',RN6PD@L9XICV&R+=]B1&@J4Q@#C
M>9XS]/RD4I/G*!'(+P1)V3JZ4-+QS1NLR.,4@50\G5'C$^NV^W;/;QG;:DO+
MKE)2)\GH*!E(L5'3X+<\BDM>RML3(8T3>R$HY5YNX/S3,+C9^DT;NR!1DVB#
MS&ZIJZQ-PZ:R4I([$6EMRT==Q7/=X=RL?.'*[]V SF4.MDF)#&N;,0FXFT#2
M/' ^93*%$%8><QH6ED(/N9@&>LHA>#FJ-AZ)LA#>J\@=WN/6Y@RE!H,5H,L[
MMQ&;)36+;09YPOO5;2'D!>FCJKUIE*+!X^G*\C2D9&F>&TTDF'W1A/,*%(!U
M7S'(8ZXJ(9LN8(JLW'DFB[!J3 U(A68-252NPG,=N;%5EX;R)*PN;N)*/R1'
M58X6*-'9J#J8E:T$-464"Y;HRS+PB^Z;*HPO(8V4\N0N;AYTF/+W#7<H>I)@
ME3P,'+&S/#QM4EOQEF\6+;8QRMUAV##6$K\I1QID"9$8L;9S\="E1JLF.XP9
MP=&/EIC!#N09)?/;G ?'\<#9+%LY"! 2B*6NH^Q$Q$.NBBW8;,V8*XYLV\5I
M,SY%B<M?ERBN4(3&4G<.-1]D,B>$6D8CX1V71Q\55<HBA.0V;=\#9S3'K61(
M,C5Q"5>B3!.-KSQ2QN'+#"DMN<G)M7K+\D*LJ$UD$=SZJ.>R)Q/)6TDT-C;A
M:,R)+(66LKYTC=CH&YR : OHN"D.5$D4G\54CDNE<39F8V\G5D6F3L0POCU^
M[."2G?*Z5V_7=LXK;X]R7NH_.L<RYO/XRB-A,RC^1'L888S((-E9>.%YM%G[
MX<4)9*,DH?'I1=FXX7=B":DS(('FKHDH>?5/$T>)GNR4E^NNPSEU+#Y2Y$DL
ME%\QD;LA!!Z&5&.9K1R1#&=IU_"S>7\?X/A/K&P(UFPNUX4B+G#"9T*Y08B'
M=RDD59]L;*#+2! DN^=MN/C(8;5L8'DS]%X&SOA,E/1QQYF7&9_$J>1'D*(K
M25M%'<=E<<C#Z>)$Y\72R!*HZUECQ5Z6'+P,8=61HM:!$.W3QVM9VC9*_9C<
MDI=_CKL6(-\F,5<SB:O%II&A(W(K\28AL:8@)'%I- S8@?BVV5,\:R"(Y4BM
MPF+$ON3!9BF'!1YE) TV54D9.9'0C5*-53QF;]>.3.<YS0C:)]5A/5?JLM[E
MJ#GR?QM=O*6EV<&KJR3Q8B#<OG^)QZ12XL=QYRRP,^?<VQR9QJ.TL?*\M0P\
MT"!(W'QHUQ+BH]&BC,8.XF<\55?A#EY(L<6WPH2=:%7@[F65YC!>@VX DYM=
M<SJW,8]A;RE")1)PX3L?DHJ-.7U9M5%TQ)5T-9VMUDJD50W\M$G!XDYAD\>S
M"*Y3,Y8C.4(P/7?AC*4HD$7-IY<=A("=R WS*/8.C\6G>0W*+>7B[H4S3$,3
M@AR(&RD\M/P[#CM4\-EF>T6+?\%XTSGC_&Y1JBYQR"E\BG9*8G:F\;.1SJ1$
M9'(H8_D1X^*B.=YM'@!9< TFP)NRCDF.#*NW$.DUJ;.P2:AYQYW<$ E=@!NS
MF:W<M@M^ZYAH_G12<B68\+8JR0B=8=8W(/+2<3?Q9TT<2YI)V"1"CAZN++#Z
MEXR6(L;V*XEJ]JQ>-+!;.<]ZN?#.NQ4CA_E"H,D$AR-)URV,94M.N9=)LGCA
MT.B)F0PG)7-!+,PQ0A-Y3&S9BDI33 7@[@@QX@*6C#0W)!+QK<X>./-D7XY&
MY(A62\<9#@\/RF."1_(,FRL7&/5H,)EU(2"RI LG!",=AK\;(XT0'*!,D9?G
MN1QAAJ6264'''.,W[1S#JT1ML\]DO!27NQU9NNUR63)<E95_,V<QLRH,16ID
M96=%&5^.%UZ.VB7,[C3F:%A6#JD_2O'.&IG'SB+/"ZZ1--Z,/6OVXD:Z&7HD
MXJK'P=RM!\68S+XVF!MED=$PA%Q961V!CD4/2@3!Q8T)%2$X>W3:2.#<V3&!
MQJ)V0@W$4 D[F3>P5#(ZRLN8WCG/ZI<M@=XBQ5*86R@V/30H4B#G^-\Q,%!!
MB^6T0-PF<A9*&>/FSHTX<KA#SR"N(^ZM3?L[%6R1;T8Z:E&ESE G5D>:KVO*
M'5M#('$0^1*CU,?ALB-!<@<1.I H_-9D"S]CE4P42NDS<=>W,&Y@*DT7&,F;
M&^+/(XL/>$I*+-WM1Q%<./,+,\<2Z1&Q!=->.D<6X?Q6"C3@6K<Y"",0VSM)
M@Z?'%2R]#BA9";5161]$BZM;1=EUR[R]Y?5 F<W+B=OY,\6VBD+B[/*;*/*Q
M/&4(QJI*(;C%I&Y6XLB^">8'!Q:4"BULQ?T"R.0,\YM9):Z5;EDQ[^ A&3M,
MTBYL7&6=H.$K]BDNK7.S.V>*SYKD=5+'(=0AEO'0L^TI(I,1"A<1O&"<J.E
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M(V,R(V1=9_#S"K1B6BK27 X(4F#W(+D@=2C,S.R!:3!GK^<).3,'?E&&/'9
M825"1N->MTA1<DSD3S8L'3 ;-;EAFN$_NLQ^]I.IKD,FUR#0,LZ&L'^6\V&\
MA6@K!Q"?$')AXVD,M4B0F]>86OB*U1UJB:I"^]NY'99G.;%1F5BL[(>!@TV(
MD3HMZ/ATD(/H03<G T<:(OR[Z)R,6_?UE;\>\$FI(TD,/&N,9*(JF&;D3"9'
M+1C![YLZK:A9Y[9J$3GM\)=RY[R_RED,M2O#D6E#A64Q.*<M^0L92S,$C8 "
ML\];GLRY=R\=DX9>\N.)@LB$$\<2N1L9H-#DV$9D-47E&_GG"#=669/DJO0
M\B$6A,?!M%I^+&A@88/ZYNA\*8Q=!V\AN8VF9A,YC[]*2WJ025I)CFT7DDF7
M=2!8H""1AQ2HN^+#;+2EN/#.<57R'D[(Z,A$;QG%\NQ./E4,6XYAJCAEC :D
M[DXK#,<>Q:+Y-O&#9Z+,>O\ >I)T$9U,F1KT3*1E0$>(A6J3$.X;LYLSC:F<
MYE=99;:@;D1 @I<G-QTM$-)!9DME/%G;/'Z#*\NQ:Y^FF>:CI$HVD]BQN1-W
MDS>0\++UU4_0D=N*6H 5[CKY*VFW>4 D ,  L!#^2]ECLIA6JN10<R.87AN)
M;&<-3@@L<4R.+PGAO/N$22RC0MD.Y!K=*Q_,.E2Q^\75$1HH"!,";HFQ)W5:
M3/#/98KGCGMM6_PWE342Y5C6"B!PD$(2CX-S(C($F$O)1"/1TL,1Q'#C-@T@
M/82*_'>.8K!8,:<,#=OK"^"%CEI]V0,.#;JDSSMG[U!GN[@JJE7(:D[+W/*Y
M?A4>>S,IG)D226Q&Q[;,'&:,GY'S J/;OE<B-#%#4-"2PZ&!D SQ(U42)(NU
ME4HX0D4:>)V[,#(^Z7!7.;>$U;%>59 7AW,N,C>315M<RRN&G49,ZB*;%,3*
MAL1Q5"6C9<:ZF"WK&D=D&.F1%F.M+"2/P3UX%)^]>H)&',3.;<]U4R+R>KLO
M*!,P'Y5CHPDPE.9Y,9&*8J)WQN?IYFRADF<D8]D=D$RO&S,GC\=CV4C\8"M$
MY",7M+,0DG4<T8-GT2),XHK.RORX!,Y)1H;#<O !HV.8I1Q\\!5 L9Z,J!6F
M\%E "5!F3"7Q^Z.&DB^)[PZ)6]0HQ(L[7K2QM8]"(.4;W9[IJ=1PW8V2OW;%
MKSWD==.7C=VEDH A:U-2HT@UNQ>HJ@E?)><T7S=VL4K+<@(T28#;AEN.T$;*
M4K>W6ODM+T:VTCUT%XUI*R5UDA*R5BQ8?D6C1T[#YJ5R%&Y\)$Y0,Y/!G%84
MJ7DLFA$BAF?A$8CA:;D,@'A19Y%GW,*4E$4G("-A&5UP4>LK%W)<D[DG%M&(
MQZ[<[TOS.S7O6E.^04 T!-A<@RYC="8!<8S 03F*F+KV1EXF^>X 0$99-)FL
MMEGC621<+R_A0KTZ/(B0:RY*Q<,QB+(,W#.EMUO5VX;NU-MGE+'?V+:F_)RP
MGD:;-F&9L?SR/V2"7M'[Y3'5IY&>8MGE\E.7P_*!F,Y2$NI[-0Z$YO=Q?(#D
M@P$(,WSYT_QT7NE\A<EIGWI*??=KNG^L]6"MG.W)W&\\S<M+3LEO!^F(IBJ-
MV/PP!!/($4=8EGD[GH<WCW(%Q*U>(NSSJ=.P4J3L!D;BD;;K"TW#6PBYOM;,
MS5SG/E7C7D,:N!Q:D@G8"LBDF-,@0J0R.'8Y?1E:^7R=[BLG$<L@DC619H[#
M32"%\1Q@XAVDH88D##=LN/2CC-@W8<4F<\<WV=TE):M6!MLPG/OG@OW_ -H:
M-9U"-6&1EBH(?))PY)1Z=Q=S)1A&&S\\ G9*/(6 I?#+TC\<R:-D$T@4E-5D
M8>-4F\B N(48')AJBT_&6KR0"4[=D^JZ^=N9+3BGDYF9N)+1@UD6-&W:8*?Q
M)G+3V+'AV5$(U)<79#QG$59D0+9->(R*70]+(#@T_D0IK%A\G="V]J4;CKUT
MZ*7"9[@-R2[YXZYYVJ_LQ\KM^7)9#Y6XF0M@K'@D!"&1Q2$5DC*1-X+G?$V<
M;;=%)4+N8MC3K&*\9(,W7IFSL,CN>T444&7M2LR,_HFRS<M2Q-R:5QCD<)-'
M$Z"R@* +2R1@XRY@9,:K#ST@/Y9<L:X]?I9$=!8H!81#*SV'/@KB)G5WR0U1
M^(+1IN9(B*D%FN?Z9*]M/E%)6FT3;C(,9)+",SS3* 2TIB=D[7.1F=5SBL^Q
MAEQ_ZWI.\EQV+NL]RMSCY9NI#V\85& G#L.<(>G'YLDK_?=NU]O9)4X"\FT,
MBUC!,#E!K=>(+14BQ*R#'=#<D)-X2"Y4QD>92\_9-AKJ3U7*\K0T_)75R8Y0
MV]FI>]O8)>,$2+PDIZ]UFJ2WN_D,!J,BC"V;,1B$H=9WOEGJ_ V@6];[M.>&
MV<&$ABJR,B6<Q;(V.%6;*+1:<+KGM&8X21J":K"!K1L2619D;%[.8< 9*:X3
M#0+'KAM+I$IS&Y"RR0-IQ@4XL B<FY!RUDXBFE!)-E['P&7I"WD];PA9H9R
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M+@M[62%!=ERS/?[\R3SNL[,R7&^$<:\^V(<3P+';(.Z5ICG$4#C@D>\F&.W
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1@B<$3@B<$3@B<$3@B<$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img102364508_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 J # 2(  A$! Q$!_\0
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M\K"?WCOP,>]/N?B%H=E?6MC>"\M[J?;F&6W(:+<VU2X[9([9XYZ5=/@KPZT
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M;Q=XB$,2QB3[/(^T8W,5;)/O4^G^(6O+Z*UDM%B,JEE99MV1R0P& =I Z^I
MJ#1+F*Y\7>(S$Q81_9XVRI&&"MD<]?KTIN_42MT.CHHHI#,3Q;;PS^&KUI8U
M<QQET)_A;UK3L)8YM/MY(G5T*##*<@\8J:2-)8VCD171A@JPR#7)%5\(:S&1
M).-(N1A@W*Q/GCD]NIH Z^D90RE6 *D8(/0U#:7EO?6XGM95EB8D!UZ'%3T
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MAZQO[J2:<2%9MAFA#?)*4^Z6'M[$=!G.*6UT&UM;>>)9)W,T:QF1V!=5484
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M*& V@XYQZ5AZ9_R.&O\ _7.U_P#07J/2;[6I[V!+RW=(BAWDQ;0>OS9XP<X
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M];_Z%_\ \FT_PH_M/6_^A?\ _)M/\* -NBL3^T];_P"A?_\ )M/\*/[3UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %9UW_R&M._W9?Y"M&LZ[_Y#6G?[LO\ (4T)FC1112&%%%% $=Q_Q[2_
M[A_E7QN.E?9%Q_Q[2_[A_E7QN.E>C@/M?(X,;]D6BBBO0.(*U_"G_(X:)_U_
MP?\ H8K(K7\*?\CAHG_7_!_Z&*F?PL<?B1]:4445X![84444 %%%% !1110
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MIT..#5>'QHA0/<6K)')(%B=3D,N(R<CJ"/,_2AXNJU:R!8:FG>YM_P!KQ_\
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M,=:>OC.S,?FM:W*Q#Y68A1M?#_+C.?X&YZ=*KE?87,NYJ_VO'_SYWW_@,_\
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MV#Q/'-<QP/8W4)9T1C( NTN6"\$Y(.T\@4^5]@YO,T8M32658Q:WBECC+V[
M#ZFKM%%04%%%% !1110 4C9V'&<X[4M% '/:5;:VEW:/>R/L6';*&E# GG@@
M#EB<'=Z<4W1/M'_"7>(_M'E9_P!'V>7G[FUL9SW]<<5T6Y=^S<-V,XSSBL+2
M_P#D<-?_ -RU_P#07IMW$E8WJ***0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"I_9>GYD/V&VS(P9_W2_,0<@GCDYYI8],L(@PCL
MK9 V=VV)1GIUX]A^0JU13NPL4CI&FMNSI]J=S;SF%>6]3QUY-2'3[)GB=K2
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M9Q] .E4]+TC4;2^MIY[X-!';O$UN"S ,6!R"3ST/49 P*+(+F[1112&%%%%
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9HW444 &ZES110 M%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img102364508_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1(\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $B"^1D X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             ;$   <&          $                          0
M           '!@   ;$                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   ;$     4F=H=&QO;F<   <&    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   &Q
M     %)G:'1L;VYG   '!@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      'G     $   "@    )P   >
M $D@   '@  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ BP(_ P$1  (1 0,1 ?_$ !X  0 " @,! 0$
M   &!P4( P0) @H!_\0 4Q   0,$ 0$""0D% @@,!P  !0,$!@ ! @<("1$5
M$A,4&2%8EI?6%A@Q0556E-/5%U%7F-@B)"-287B!ML'4)B<W.#E%<7>QM;CP
M-4)G<I&AT?_$ !P! 0 # 0$! 0$            ! @,$!08'"/_$ %D1  (!
M P($ @0+!0,'!P@+  $" P $$1(A!1,Q02)1%&%QD085,E6!DY31T^'P(U.A
ML<%"5-(D,U*6U-;Q%C0U0T1%= <E)F)R=J2F"#9C9&:"A(:TML/_V@ , P$
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M&LK2/8RXYU^JR.$1FMR5,FT$-ZOA[8#J38 >+F$:PU9HJ*;?W.&VQO<#K>>
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MOJAL1EK2$*Q:-OYJH*(#A8V2F!!'$TU6!O&K8NGFRM7MGRP.N^^>@ZGIV'7
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M!,X^?)A)F&1Q9+%1:MD<2#6V-\KTDDCAC>661(HHU+R22,J1QHHRSN[$*JJ
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MS)HD?E2),9+)^48K6FI8KNC/2<E6D>Y=@DX,YA\=LBVD1K:0N/S*.0)DZ?2
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M-#7$0PQMGY8BP;)O?+[CE5%?(TW&&7X1_P#2 2Z;X*\':19W^#B?"6Q;X7+
M)"GQ,MM>FW:_6/+MPM.,'AK7XWCY84RCEAB/K?@<4^,;D1E%X@;"8<+,A7/I
M?,BUB$MA1<&UYX@[EB0GC*U*).GMESBMCQ)=ZE8[:Q'W\4]V4QD9/4Z8S)XQ
MR<8S)KK]\,-+N%&5GN,>P'/D721:[59WCF+P=)Y_E'_DP^+Y/_*=P!O@7Z(;
M>/AW%_\ E>_ C .&?%#6#_%2\1:T_P C:\;C!M38)XKM$6Y9@L()/O<;%PO
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M?][^E]["<J?CVF_F/<?OIMY'WC[J=V]:_P"]_2^]A.5/Q[3?S'N_.FWD??\
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MI$O$P\^ SMFXD\%)SUWD.'1LJI#!X\ ?/(#9N*:2O.0!B!JT7/!@3U ._C!
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M(5? Y*"+"7#H,8+!GBC.[L24(CEVSQ:IZG?/K&<'U[@'W@'U5@P"LRAE<!B
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M4HETGUF?81J2'I*^E0<!#S3U9]#@$JA+OP&J(V7/5GB&&0KC'B4YZ;D9WQW
MQW/BT[*3TQFSVVG1B>W<2$B(K(0'Q(L>2)%0P@EF8>DB$Z(W<@*8S)%\>?\
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MBK1.+15-N'2PC(+$?;XGX^,?^:^*C ('^176P;63C]EMGF2';_3;S-=(X]<
M@CBI!5)(U(NE&A)6NWD"88:-;7UZ25PV;NXW_:OJLN&\T^FUKUKBQA/(OCO&
MFF :-Q[! 7-PR">(2(#.YHR-M:[K+^ZA1=O(6.';VI(?V;WR^FJ-P3CC,6;A
M'$RS$L2;&YR23DD_LNYKDFOXIYI9YKN&2:>1YII&FC+22R,7=V.K=F8EB?,U
M,L^HKP/4PS34Y7Z*S3SQRPSPSGH3+#/#*U\<L<L;KWMECEC>]LK7M>U[7O:]
MNRH^(N-_-'$_L-U^%6?I5M_>(/KH_P#%5+Q3D1TD8*-0#0S8_#J+"&JGC6HP
M K A;!JIWE$S/A-FC-LD@WO8M X23M9)/"UG\2CCNUK+AF&:$_$?'!L.$\4Q
MY>@W7K'[KR8CZ3YFM!Q"-5T+>H%P5TBY4+I(E4K@/C!6>8$8P1-*.DCY^#?(
M/I&25SD\D&P>&IEWF(1 9.B5]?.W%PK8RI(FHRZZS3-7R-J>67,-4?"\%J1<
M.':%DUG"V>8<#XX#D<)XH#@C(L;H'!!!&T70@D'S!(J([Z*)M<5Y'&^EUU1W
M"HVF1&C==2N#I=&9'&<,C,I!!(..>;RZ1K@?B,9[3XFQ]IY#K\,KC&"D)CN;
MB-:Q-1(W#8BX4%(-LE(F+6@L18?)_ML.6"1X0%41N-',FZ$C@G'!C'".*' (
M'^0W1 U @X_9;'N/7O5X^(QQE2MW"0B3)&K3(RQB=&20QJ7PC>,L&7!#A7Z@
M5+9IRJZ5VQSC"3; V]Q+FLB%BW00<<E1"#GBK(0]2?MW0UL_)HN7*+)9N6+M
M\F^"ED[-S!=#''%(H_P<1\2<<QI^*>*:<DZ?0;K&=LG'*QOI&_? \A51Q!!$
M8!?((2Q8PBY B+'1EC'KT%CRX\DC)Y:9/@7'\><J.E:1DPN:/]N<2GLO"&/E
M 'D[I_!USPL]9,>CB:8%5$<GK4K@D)&I)OT5L'2:;-!/!7'##LO;XFX_HT?%
M?%M WT>AW>G;4?D\O&VMST_M-_I'._QS+Z-Z'\:R>B>'_)?3F]&\!E9?V'-Y
M7A:><KX?"9I2,&1]6)DG(KI)3)_("LMV/PZDI.5N&;J3/SJL!*.SSA@@JU:K
M%7#ULLJ]SP:+KM%+KY9^4-%UVKGQK=95/(O!N/KC1POBRX! TV=V,+DD@8CV
M&6)(Z9)/4FD/&9K?1Z/Q:6#EIRH^3?O'HC+R2<M-$JZ8^9++)H7"ZY';&78G
M)NN4G2I?.8\\>[9XCNW<2)E#,8<.7L%66 E3;Y$H8?BE%$,LF3HF5;-2KY5"
M^&3DHT9D5?">LVRZ53P3CA&_">*D>$;V-U_9&E>L7]E=E\EV&U8OQ%9%99+\
M.K<DLKW08,;>,PP$@R$'D0DQ0Y_S<1,::4)%<L*Y9=,?71Y[(H3R'X\1IX[A
ML4UZ@V$36/,10F&0LI*S8"/!!;91)F)'-R\VD9!=%HDGY4X?)^/OFFS98(6;
M@W'G #<*XJWB9O%8W1)9PH8DF+))"*-]]@*UGXL;I%2XOUG"SSW.J6Z$CM/<
MK D\KL\C%I)$M8%9CXB(U!)P*XP/*7I51?-JI&]L\1@.;&6N)ZQR$O((PNQF
MSL(2C3B5L;MFZ?D9]6.F"P+(HV\4[L()OQV*MFCM=%2#P3CN6SPGBN6^7FRN
MLMN&.K]GOX@&WSN >HK)N(J[3.U\K/<Y](9KH%KC,BS'G,7)ES,B2G66S(BN
M?$H(CH_>_2!$@"<5%SCA:.C9G)UD6!,4M=-!1'-ZO$'+G-XQ09IMUU%'&OH&
MM913#+-/.%1/)++#Y.B/(QX)QTDD\)XJ23J)-C=Y+;G43RMVW)!.^Y/G4MQ)
M7D>5[\/++-Z1)(UT&DDGR[<]W,A9YM4CMS&)?+N=66.>NENSH[-\':;>7\)F
MR;Z,C(8Z3;--;-\%8F%3CB0>.7P18IXX!Q2<.A^ Y@G;!NSPB47Q;X)VCP?R
M./B/C>,?%'%,9SCT&ZQGIG'*QG&V<9QM5/3HN7RO3(^5KYG+](7E\S3IYFC7
MIUZ?#JQJT[9Q4@SY,=)Y4WC)5-H<0,Y#BQ[MQ-YN('D4Q8=_*2BS3%[=M=Q9
M&TC66-VQMG;P2:RSRW8LJIGD^(^. _\ 1'% < ?\QN@< 8 _S70#8#IC;I5A
MQ%%)9;Y5)55)6Z )54,:J2'!*K&2BJ=@GA  VJS!//\ Z?8%IFP"<GN/HABH
M_+%5&8V9QYDVS)GBKTZ<(9(-U$T\GI<T2(%B3F^-UGI)Z[>N,U'#A53*/B+C
M?S1Q/[!=?A5EZ5;?WB#ZZ/\ Q5DO.,<$O6RT9[?!?]XI\1<;^:.)_8;K\*GI
M5M_>(/KH_P#%3SC'!+ULM&>WP7_>*?$7&_FCB?V"Z_"IZ5;?WB#ZZ/\ Q4\X
MQP2];+1GM\%_WBGQ%QOYHXG]@NOPJ>E6W]X@^NC_ ,5/.,<$O6RT9[?!?]XI
M\1<;^9^)_8+K\*GI5M_>(/KH_P#%3SC'!+ULM&>WP7_>*?$7&_F?B?T6%T?_
M /*GI5M_>(/KH_\ %3SC'!+ULM&>WP7_ 'BGQ%QOYHXG]ANOPJ>E6W]X@^NC
M_P 58:1<]NGG+X^<BDJY,<>)'&),)(@)%'C<PCA0,<!EVBS J(+#7BBS0@-(
ML7"[-\R=)*MW3991%9/-//+&[XBXW\T<3^PW7X5/2K;^\0?71_XJJ4-OSI#1
MYTU? I]PS$/6(Y 0R=C_ -GS5RU&-3>$E;,4%DFN*B3=N?33,()X96LD0PQ<
MX>"IC:]I' ^.#..$\4W&#BRNNF"N#^SZ8./8<=*U7B"+G3?*N0%.FY RJQM$
MJG#C($3-& =A&S(/"2#C$=Y]*AON\)R";<@N/C38L;"G X!XRF$/'M!><F=G
MWDC+I68-6Q)P5-JRJ1Y$;OB;L>LN;)$,1^!5XN_S?$?&\!?BCB> 21_D-UMG
M&<?LMLX&<8SMG.!@>(0F%8#<P&-)'E4&6,D-(J*VG+$("(USH"ER!K+:4TRD
MUR:Z4$D-N)+(-I<0C4A=R-A+W1LHZ@CXJXE(MBU&#Y"N^<MU'*IAJ.8LF"9#
M-3)SY&R9M\E,DFJ&";XCXX1I^*.*$=<>@W6.^^.5CN?>:J;^(QB(WD9B4ZEC
M-PIC5CG+!->D$Y.X&=SYFLRUY=]+YEB+Q9[KXJ-<0@8!'0^+<M"T;"@$4%R@
M'& H^R:>-F8J/!IO,A05@AXMJ,'2J0LV:2*!A^FO'Q%QL=.$<3^PW7X54]*M
MATN8/KH_\58N0<G^E++' QU*-K\1I"X"Q5Q!A*QI[!B2@V&NAS\0O%V63M!6
M[<%F)+%AF(U+P6J8\L59I)8-R;Y->WQ+QX=.%<5&23_S*[&22I)_S?4E%)/F
MJGJ!CH3BACSHXB4RYD.B[TYD9X96<XD&7,EO!(6^47@A<G5&A7'Y<BNDEG&%
M(5EL?AU>(K6965C?C8#8+G<<3D1IEED/LVLVOFV+R^6$DE/%^'B]D\@<>%=0
MR1R<3\2\>P1\5<6((.1Z%=G((75D<O?(1<^85<]!B3Q9F#AN)LPD#B0&])#B
M40K('!EPPD6WMPX.0X@A#9$::>\SY2]+L9+0<U$;[XW!#<>,RR3#[A99&!3*
M\LFH9E'#\M=,V-T$G,E=1YJX"6+*]J]AQ8PDIXS-]FIB^)N/:2OQ3Q0@A5.;
M&Z)T*=00$Q9":L-I&VI5.,J*M\<$PR0&_1DEC@@<M<*S^C6SF6*T5RY9;03:
M)C; B$S06\I37#&5[Y;ECTM3Q<<?-[DXH%S@B3+3,87(E(4\(L9:XQ"XKR1L
M\72472-*Y1J-+*$,<_*<G,<C[JZGE(06JUJ."<<&0.$\4 .Q L;H ['KB+R)
M&_GCO6"7\<:NL=ZD:R#$BI<JJR#2RX<*X##2[KA@1I=AT8YZ.')[I2)+1APG
MM;B*FO"R+ O$5<'D%QSC906*C(08_"Y60M<<Z'"H5#6+!9MXO-HC$8OY/=/*
M/B,F=CP7CQ+9X5Q8EB2V;*[)8Y8DMF/<Y9B2>[,>YK5^+/*9C)Q-I#<,7G+W
MI?G.SS2,\NJ4\QF>XG=F?)+SRL23(Y,IB_-;IJPA5PM#=_<8HHL[&"@KI6.'
MXB%S<!P3HR]"BULAV+>ZH\2\D1]T-9YWNW9.#159NFFH_=9*U/ ^.$8/">*$
M D@&QNB 2 "?\UU( !]0 ["LGOXY%5)+U'169U5[E657=(XV959R S)#"C,
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MB>JP)]R-ETYSFB$<3*H,8ODJT$O7FO)F-R,VQ5'H% !$:JMB\;JHX7$;$@;
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M>GD%%_I_R<4^,W9?T6[?W_7_ +:J<Y!P=L=/7G(W./+M_2ISMC;<^7\<]?\
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MVWQMDU!8E53PX4L1A$5SJTYU2!=;_)&E69@F^C!8AH*+XR1D:)"CU)[L@J2
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M4S5R28C6J3-HEDJI?)13)-NBGC=3/*^>=[7RRO?*][TJ2<DDXR23L !OY
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DE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img102364508_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_9.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^?L,5D-/$RA55"22ZW5R<XE04X.HFV]K.WWG]E^BP/I^DVL,C*SQ1(CE<X)
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M?7DETL08LRJ%&22>!^-5M+\1V6N1LUC>V=XJ-L9H)1(J-Z$CH:_EP^!?P/\
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M6OX5_$W5O@I\3O#WB[0+K[#KGA?48-4L9AQY<\$BR*<#MN1<@8XXK^R[X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<'\MKY)K>YECFXF1B).<_.,@_KG\S7[T>*?^#N'P-JW@2&W\&_!_QUJ7CB^
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M_P""P?Q:CLXXX(;M]+O-J+@!Y=+LWD./5I"S'W-?MC_P;:MG_@CI\+>O%QK
M ST']K7G^-?C!_P<B-_QN%^)QRO_ ![:,1]!I-IG\OUK]G?^#;@E/^"/'PO7
MIBYUGK_V%[S I9M)RRJBWY?D&6Q2S"I;S/Q(_P"#A/\ Y3$?&?\ Z^=,_P#3
M395^X?\ P;FJ#_P1G^#^?^HUD?\ <<U"OP\_X.$1G_@L-\9B>]QIAZ=/^)39
M<_U_"OW$_P"#<Q/^--GP?!5E_P"0T"".1_Q.]0I9T[Y;0^7Y!EJOCZMEW/YC
M_C!XDOO&7Q:\5:QJ;33:GJVK7=Y>-(Y>225YG9]Q[G+$9/7J<XK^N[_@G_\
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M@O4/VHKCQ/-'JTEXGAQ=6UNSO@A00"Y$<<,S>3D&W)W*F[:,;N:]H_X(;?\
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MA_J7CO5-%>4Q)>:1HNGZ5IJNF246Y,4:L03\P+D_=!Z5\]_\%OO@;XB^!?\
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M6CWEOJ&DZO:Q7UE=0MNCN8)5#I(I_NLI# ^A%: DX[?Y_P ]*_F(_P""<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[R34-1O)+^]5KJ>1BSR%5F"@DDG@ 5]345A3JS@[P;3]3:=&$TE)7L?':_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *#37?:V.^*\&^/?_!2KX1_LT_M'^"/A+XL\0W%GX[^(4EI'HMA%
MIUQ.LQNKK[+ 7D1"D0>8,H+D8VDGBJC3E-VBB)U(PUDSWK=\U(6Q2*V\TV1B
MIV_CGKC_ #Q6?,MRR3/%(6(%?,/[:/\ P6$^ 7[!.NKHGC_QHD?B1D24Z)IE
MM)?W\*-T:58P5A!&6'FLI902NZO+/V?O^#D#]EGX^>+;70_^$MU;P7?WSB.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+_@M-\#_ (E7JO'H\5EH>JRS[>K6&K2O,HXY(C$1/<;A7Z?_ /!&G_@G*/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6XB+L%+110,****  ]:8_P#JF^E//6F/_JF^E"W)ELS\MO\ @T<_Y1Q>-_\
MLI-]_P"FO2J_4RORS_X-'/\ E'%XW_[*3??^FO2J_4RN[,O]ZGZG'EO^[0]
MHHHKA.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****  ]:8_P#JF^E//6F/_JF^E"W)ELS\
MMO\ @T<_Y1Q>-_\ LI-]_P"FO2J_4RORS_X-'/\ E'%XW_[*3??^FO2J_4RN
M[,O]ZGZG'EO^[0] HHHKA.X**** "BBB@ HHHH **** "BBB@ HHHH ****
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M3G)[#_\ 73XVW+S3 =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%  >M,?\ U3?2GGK3'_U3?2A;DRV9^6W_  :.?\HX
MO&__ &4F^_\ 37I5?J97Y9_\&CG_ "CB\;_]E)OO_37I5?J97=F7^]3]3CRW
M_=H>@4445PG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/=W<\;D#/4I:Q ^P^E?.PP>'KYK[&G\&_P!VY[3Q=:CEOM)_%L?#WB;]H?\
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M^"G]U;WCI'<:MX,U*UL0_P K/,)K:8A1U)\J&4X] ?3%?1G_  >':]I\MS\
M-,62%M2A37IWC&TO#"YTY 3W"NR-C^$F(Y(Q7N5*JI8Z. C!<C6UOQN>+&FY
MX1XN4GSW[GZC_P#!-C]LRU_;W_8P\%?$Z&U2QOM:M6BU2T0';:WT+F*X5.2?
M+,B%D).2CIGG-?!W_!S_ /\ !3/5?V=_AOX;^#?@/7K[1?&/C +K&L7VFW;V
M]WING12?N41XR&1IYD/((.R!U/$E=1_P;M_$33?V;?\ @B?J/CSQE?FS\,:3
MJNM:Z\[?\LK6(JKJF<;F,D4@4=2[;1C@5^9_[&7PK\0_\%W/^"Q-_P"*/%EI
M-+X5FU,^)_$D3$M%8Z1;NJV^G@YYWCR8 %Y*M(^#M8UXN$P-*&+J59_!3O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@#!^(?PL\,_%O1%TSQ5X?T3Q+IBR"86>JV,5Y;[P" VR167<
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M\#6_B.UU.PCU&ZTK1[M;C5])5@&$<ULP5Y)57 *P>:1GU! \-_8P_:^\7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ )IH8FE/%,F=DZ8/UJ?4!PDYQ0&S7D?[2W[=OP?\ V/5M_P#A
M9?Q$\+^#YKR)I[>UOKK_ $N>-?O.D";I64'C(4@D@=2*\Y^$_P#P6E_9<^-O
MB>UT?P_\9_";ZE?3?9H(+\S:8TTA) 5?M4<8)+# Y^8E<9W#/1'#59*\8MKT
M9C+$4UO)?>?42MN% )S389 XX(/N*))-C#ITZX^G^-8<QM=$F<T=J^8?BS_P
M69_9A^"7C2Z\/^(OC-X1AU:Q<Q7,%D\NH_9Y <-&[VZ2*LBG@H2&!Z@5ZE^S
MG^V)\,?VNO#DVJ_#3QUX;\96=KM^U#3KQ9)K(MRHFBXDA) ) D52<=*U>'JJ
M/,XNW=F2K4V^5-7/2BQHWU&)68\XZ]/\_C^E>6_M(_MN_"?]D"QMIOB7X^\,
M^#VOE9[6"^NA]JNU7[QB@7,K@$KDJIQD?6IIQE-VIJ_IJ7.48_$['JRMFE.<
MUX[^S1^WY\&_VPY+J'X9_$7PUXNO+&,37%G:7&V\AC)QO:"3;(JYXR5QDCU%
M>OF7CIS].M*5.496DFGYA"<9J\7<>#DTM><_&_\ :P^&O[-EUH\/C[QQX8\'
MS^(7>/3(]4OX[>2_="@=8E8Y<@R1@A<\NHZD ^B1ON%)QDE>0*2;LF.HHHH*
M"BBB@ /6F/\ ZIOI3SUIC_ZIOI0MR9;,_+;_ (-'/^4<7C?_ +*3??\ IKTJ
MOU,K\L_^#1S_ )1Q>-_^RDWW_IKTJOU,KNS+_>I^IQY;_NT/0****X3N"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFFVRPK(V,%W8?-)(0!EW)8XY)KM57:*6BN*4G)\TMSKC%)60A7)KRO\ :_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,?YQ1C_ #BBB@ Q_G%&/\XHHH ,?YQ1C_.*** #'^<48_SBBB@ Q_G%&/\
M.*** #'^<48_SBBB@ Q_G%&/\XHHH ,?YQ1C_.*** #'^<5^R'_!I(NZ?X_>
MP\/''_@TK\;Z_9+_ (-(_P#7_'__ '?#W_N4KY7C+_D53]5^:/HN%?\ D8P^
M9^S"#:M.I%Z4M?BI^O!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A/-17%S]G.6*
MA:F(YK\A?^#IS_CZ^!OL->'X'^S<_GTXKU,ERW^T,;#!J7+S/=^ESRLZS)8#
M!SQ35^4_7*.^1ER70>V:=]LC_P">B?G7\CIXHK](_P"(45>F)7_@/_!/S_\
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M0HJ_]!"_\!?^8?\ $3%_SX_$_KB^V1_\]$_.C[9'_P ]$_.OY':*/^(45?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** $;M]:&_I0W;ZT-_2I _DX_X**?\ *07X[?\
M90_$'_IRN*\;KV3_ (**?\I!?CM_V4/Q!_Z<KBO&Z_HO+_\ =:?^%?DC\'QG
M\>?J_P PHHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K]DO\ @TC_ -?\?_\ =\/?^Y2OQMK]DO\ @TC_ -?\?_\
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M(+\=O^RA^(/_ $Y7%>-U[)_P44_Y2"_';_LH?B#_ -.5Q7C=?T7E_P#NM/\
MPK\D?@^,_CS]7^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5^R7_!I'_K_ (__ .[X>_\ <I7XVU^R7_!I'_K_
M (__ .[X>_\ <I7RO&7_ "*JGJOS1]%PK_R,H?/\C]F5Z4M(O2EK\5/UX***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &GK^%?D1_P=/?\?'P,^FO?^XVOUW/7\*_(
MC_@Z>_X^/@9]->_]QM?6<#_\CRAZO_TEGRO&G_(HJ_+\T?D@>M%!ZT5_3!_/
MH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!ZY^P%_R?9\%?^Q]T+_TX05_46W;ZU_+I^P%_P GV?!7_L?="_\ 3A!7
M]1;=OK7X?XK?[[0_P_J?L7AK_NM;_$OR%HHHK\JCL?I04444P"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 'K3'_U3?2GGK3'_P!4WTH6Y,MF
M?EM_P:.?\HXO&_\ V4F^_P#37I5?J97Y9_\ !HY_RCB\;_\ 92;[_P!->E5^
MIE=V9?[U/U./+?\ =H>@4445PG<%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 (W;ZT-_2ANWUH;^E2!_)Q_P %%/\
ME(+\=O\ LH?B#_TY7%>-U[)_P44_Y2"_';_LH?B#_P!.5Q7C=?T7E_\ NM/_
M  K\D?@^,_CS]7^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_4_8O#7_ '6M_B7Y"T445^51V/TH****8!1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRD%^.W_90_$'_IRN*\;KV3_@HI_RD%^.W_90_$'_ *<KBO&Z_HO+_P#=:?\
MA7Y(_!\9_'GZO\PHHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K]DO^#2/_7_ !__ -WP]_[E*_&VOV2_X-(_]?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK]3*[LR_WJ?J<>6_[M#T"BBBN$[@HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 'K3'_ -4WTIYZTQ_]4WTH6Y,M
MF?EM_P &CG_*.+QO_P!E)OO_ $UZ57ZF5^6?_!HY_P HXO&__92;[_TUZ57Z
MF5W9E_O4_4X\M_W:'H%%%%<)W!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "-V^M#?TH;M]:&_I4@?R<?\%%/^4@OQ
MV_[*'X@_].5Q7C=>R?\ !13_ )2"_';_ +*'X@_].5Q7C=?T7E_^ZT_\*_)'
MX/C/X\_5_F%%%%=9SA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?LE_P &D?\ K_C_ /[OA[_W*5^-M?LE_P &D?\ K_C_
M /[OA[_W*5\KQE_R*JGJOS1]%PK_ ,C*'S_(_9E>E+2+TI:_%3]>"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 'K3'_P!4WTIYZTQ_]4WT
MH6Y,MF?EM_P:.?\ *.+QO_V4F^_]->E5^IE?EG_P:.?\HXO&_P#V4F^_]->E
M5^IE=V9?[U/U./+?]VAZ!1117"=P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 C=OK0W]*&[?6AOZ5('\G'_!13_E(
M+\=O^RA^(/\ TY7%>-U[)_P44_Y2"_';_LH?B#_TY7%>-U_1>7_[K3_PK\D?
M@^,_CS]7^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^R7_!I'_K_C_P#[OA[_ -RE?C;7[)?\&D?^O^/_ /N^
M'O\ W*5\KQE_R*JGJOS1]%PK_P C*'S_ "/V97I2TB]*6OQ4_7@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :>OX5^1'_!T]_P ?'P,^FO?^XVOUW/7\*_(C_@Z>
M_P"/CX&?37O_ '&U]9P/_P CRAZO_P!)9\KQI_R**OR_-'Y('K10>M%?TP?S
MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >N?L!?\GV?!7_L?="_].$%?U%MV^M?RZ?L!?\GV?!7_ +'W0O\ TX05
M_46W;ZU^'^*W^^T/\/ZG[%X:_P"ZUO\ $OR%HHHK\JCL?I04444P"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6_Q+\A:***_*H['Z4%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(M+N;'4+6WOK*\B:">WN(UDBFC8%61E8$,K D$$8(JY14ZWN/E5K'P+\5_\
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MX/C/X\_5_F%%%%=9SA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?LE_P &D?\ K_C_ /[OA[_W*5^-M?LE_P &D?\ K_C_
M /[OA[_W*5\KQE_R*JGJOS1]%PK_ ,C*'S_(_9E>E+2+TI:_%3]>"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 'K3'_P!4WTIYZTQ_]4WT
MH6Y,MF?EM_P:.?\ *.+QO_V4F^_]->E5^IE?EG_P:.?\HXO&_P#V4F^_]->E
M5^IE=V9?[U/U./+?]VAZ!1117"=P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 C=OK0W]*&[?6AOZ5('\G'_!13_E(
M+\=O^RA^(/\ TY7%>-U[)_P44_Y2"_';_LH?B#_TY7%>-U_1>7_[K3_PK\D?
M@^,_CS]7^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^R7_!I'_K_C_P#[OA[_ -RE?C;7[)?\&D?^O^/_ /N^
M'O\ W*5\KQE_R*JGJOS1]%PK_P C*'S_ "/V97I2TB]*6OQ4_7@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :>OX5^1'_!T]_P ?'P,^FO?^XVOUW/7\*_(C_@Z>
M_P"/CX&?37O_ '&U]9P/_P CRAZO_P!)9\KQI_R**OR_-'Y('K10>M%?TP?S
MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >N?L!?\GV?!7_L?="_].$%?U%MV^M?RZ?L!?\GV?!7_ +'W0O\ TX05
M_46W;ZU^'^*W^^T/\/ZG[%X:_P"ZUO\ $OR%HHHK\JCL?I04444P"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :>OX5^1'_!T]_Q\? SZ:]_[
MC:_7<]?PK\B/^#I[_CX^!GTU[_W&U]9P/_R/*'J__26?*\:?\BBK\OS1^2!Z
MT4'K17],'\^A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'KG[ 7_)]GP5_['W0O_3A!7]1;=OK7\NG[ 7_ "?9\%?^
MQ]T+_P!.$%?U%MV^M?A_BM_OM#_#^I^Q>&O^ZUO\2_(6BBBORJ.Q^E!1113
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :>OX5^1'_!T]_Q\? SZ:]_[
MC:_7<]?PK\B/^#I[_CX^!GTU[_W&U]9P/_R/*'J__26?*\:?\BBK\OS1^2!Z
MT4'K17],'\^A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'KG[ 7_)]GP5_['W0O_3A!7]1;=OK7\NG[ 7_ "?9\%?^
MQ]T+_P!.$%?U%MV^M?A_BM_OM#_#^I^Q>&O^ZUO\2_(6BBBORJ.Q^E!1113
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M/7\*_(C_ (.GO^/CX&?37O\ W&U^NYZ_A7Y$?\'3W_'Q\#/IKW_N-KZS@?\
MY'E#U?\ Z2SY7C3_ )%%7Y?FC\D#UHH/6BOZ8/Y]"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /7/V O\ D^SX*_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?LE_P:1_Z_X_\
M^[X>_P#<I7XVU^R7_!I'_K_C_P#[OA[_ -RE?*\9?\BJIZK\T?1<*_\ (RA\
M_P C]F5Z4M(O2EK\5/UX**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &GK^%?D1_P=
M/?\ 'Q\#/IKW_N-K]=SU_"OR(_X.GO\ CX^!GTU[_P!QM?6<#_\ (\H>K_\
M26?*\:?\BBK\OS1^2!ZT4'K17],'\^A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'KG[ 7_)]GP5_['W0O_3A!7]1;
M=OK7\NG[ 7_)]GP5_P"Q]T+_ -.$%?U%MV^M?A_BM_OM#_#^I^Q>&O\ NM;_
M !+\A:***_*H['Z4%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KSS]JW]F7PY^V-^S_XD^&OBV34H_#OBB&."\;3
MYQ#<JJ2I*-CLK!3NC7G!XS7H=%.,G%\RW)E%25F?F>/^#4C]F$?\OWQ0_P#!
MW;\_7_1N?QH_XA1OV8?^@A\4O3_D.P?_ "-7Z845W_VMC'_R\?WG'_9>%_Y]
MH^1/V /^"*GP?_X)M_%?5O&7P]NO&<VK:SI+Z-<+J^I1W,/D--%,=JK$A#;H
M4YSTSQS7TW\3/A?X?^,G@+5O"OBG2;+7/#VO6S6E_I]Y$)(;F)N"I!_ @]00
M""" :Z"@C-<M7$5*D_:5'>7<Z*>'ITX>S@K+L?E'\7_^#2CX(>,/%UQJ'A7Q
MMX_\'V%P[.=-+P:C!;Y.0L32() HZ?.[G_:.:^D/^">?_!#'X(?\$Z?$Z^*/
M#EKK'BGQO'$T,6O:_/'/-9!UVR"VCC1(XMP)4L%+[25W8)!^RRH;\*4#;71/
M,\3.'LI3=C&&7X>,^>,5<;&NP?C3J**X3L/G']KK_@EU\-?VW_CIX!\=?$"X
M\4:E-\.98Y]*T:.^1-(DD683,TT)C+2%RL:N-X#)$JXQG/T8D00*.<*,4ZBM
M)5)RBHR>BV,XTXQDY):O<\&_;W_X)R?"W_@HY\,;?PQ\2=*N)6TYWETK5K&5
M8-2TB1]H=H)&5EPP5=R.CQMM4E254CX^\!_\&LWP7TOQAI]WXN\>_%;Q]H>B
MR@V.A:EJ<45GY77RI3'&)"I8DGRFBZGL2#^G++N]?PI/+!_^O6U''5Z4>6G)
MI&-7 T*CYIQ390\(^%=-\"^&-/T71K&UTO1])MH[.QLK6(0P6D$:A$C1% "J
MJ@ *!@ "M&@#%%<N^K.K;1!1110 C#-,F7?$WTJ0]:8_^J;Z41^(F7PL_+;_
M (-'/^4<7C?_ +*3??\ IKTJOU,K\L_^#1S_ )1Q>-_^RDWW_IKTJOU,KNS+
M_>I^IQY;_NT/0****X3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $;M]:&_I0W;ZT-_2I _DX_X**?\ *07X[?\
M90_$'_IRN*\;KV3_ (**?\I!?CM_V4/Q!_Z<KBO&Z_HO+_\ =:?^%?DC\'QG
M\>?J_P PHHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K]DO\ @TC_ -?\?_\ =\/?^Y2OQMK]DO\ @TC_ -?\?_\
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M(+\=O^RA^(/_ $Y7%>-U[)_P44_Y2"_';_LH?B#_ -.5Q7C=?T7E_P#NM/\
MPK\D?@^,_CS]7^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5^R7_!I'_K_ (__ .[X>_\ <I7XVU^R7_!I'_K_
M (__ .[X>_\ <I7RO&7_ "*JGJOS1]%PK_R,H?/\C]F5Z4M(O2EK\5/UX***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &GK^%?D1_P=/?\?'P,^FO?^XVOUW/7\*_(
MC_@Z>_X^/@9]->_]QM?6<#_\CRAZO_TEGRO&G_(HJ_+\T?D@>M%!ZT5_3!_/
MH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!ZY^P%_R?9\%?^Q]T+_TX05_46W;ZU_+I^P%_P GV?!7_L?="_\ 3A!7
M]1;=OK7X?XK?[[0_P_J?L7AK_NM;_$OR%HHHK\JCL?I04444P"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 'K3'_U3?2GGK3'_P!4WTH6Y,MF
M?EM_P:.?\HXO&_\ V4F^_P#37I5?J97Y9_\ !HY_RCB\;_\ 92;[_P!->E5^
MIE=V9?[U/U./+?\ =H>@4445PG<%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 (W;ZT-_2ANWUH;^E2!_)Q_P %%/\
ME(+\=O\ LH?B#_TY7%>-U[)_P44_Y2"_';_LH?B#_P!.5Q7C=?T7E_\ NM/_
M  K\D?@^,_CS]7^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 (W;ZT-_2ANWUH;^E2!_)Q_P %%/\ E(+\=O\
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MO_<;7UG _P#R/*'J_P#TEGRO&G_(HJ_+\T?D@>M%!ZT5_3!_/H4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZY^P%_
MR?9\%?\ L?="_P#3A!7]1;=OK7\NG[ 7_)]GP5_['W0O_3A!7]1;=OK7X?XK
M?[[0_P /ZG[%X:_[K6_Q+\A:***_*H['Z4%%%%, HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ-U)D49%', NZC=29%&11S +NHW4F11D4<P"[J-U)D49%', NZC=29%&11S
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M#4**,?7\J,?7\J+/M^(:GKG[ 7_)]GP5_P"Q]T+_ -.$%?U%-_*OY=?V _\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P""4/[;W_#P;]B'PG\1KJUCL=>N%DT[7;>*,I#'?P'9,T8)/[M^)%!)(60
MG(-?1U?FY_P:M^$+[PS_ ,$M5O+Q95@\0>+=2U"RW*0IA"P6Y*>J^9!)R.,Y
MZ=*_2.O)S"G&GB9PALF>K@:DIX>$Y;M!4<OWN_%24UD#=?3%<9UGPO\ MY?
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M5#YO:CYO:C^T9?R1_P# 4']FP_FE_P"!,_*__AD[_@JU_P!',?!+_P %EO\
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M,!_+^)_//_Q"F_M0_P#0^?!'_P &NI?_ "NH_P"(4W]J'_H?/@C_ .#74O\
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M,!_+^)_//_Q"F_M0_P#0^?!'_P &NI?_ "NH_P"(4W]J'_H?/@C_ .#74O\
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MCF/@E_X++?\ ^45'_#)W_!5K_HYCX)?^"RW_ /E%7ZH?-[4?-[4?VC+^2/\
MX"@_LV'\TO\ P)GY7_\ #)W_  5:_P"CF/@E_P""RW_^45'_  R=_P %6O\
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M14?\,G?\%6O^CF/@E_X++?\ ^45?JA\WM1\WM1_:,OY(_P#@*#^S8?S2_P#
MF?E?_P ,G?\ !5K_ *.8^"7_ (++?_Y14?\ #)W_  5:_P"CF/@E_P""RW_^
M45?JA\WM1\WM1_:,OY(_^ H/[-A_-+_P)GY7_P##)W_!5K_HYCX)?^"RW_\
ME%1_PR=_P5:_Z.8^"7_@LM__ )15^J'S>U'S>U']HR_DC_X"@_LV'\TO_ F?
ME?\ \,G?\%6O^CF/@E_X++?_ .45'_#)W_!5K_HYCX)?^"RW_P#E%7ZH?-[4
M?-[4?VC+^2/_ ("@_LV'\TO_  )GY7_\,G?\%6O^CF/@E_X++?\ ^45'_#)W
M_!5K_HYCX)?^"RW_ /E%7ZH?-[4?-[4?VC+^2/\ X"@_LV'\TO\ P)GY7_\
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M.8^"7_@LM_\ Y14?\,G?\%6O^CF/@E_X++?_ .45?JA\WM1\WM1_:,OY(_\
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M0O@A_P"#+4/_ )6T?\0O?[6'_10O@A_X,M0_^5M?T"_-[4?-[4?ZZ9M_S\_
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M/_E;7] OS>U'S>U'^NF;?\_/P#_5/+/^?9_/U_Q"]_M8?]%"^"'_ (,M0_\
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M4/F]J/F]JY/[1E_)'_P%'3_9L/YI?>S\K_\ AD[_ (*M?]',?!+_ ,%EO_\
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MCYO:C^T9?R1_\!0?V;#^:7_@3/RO_P"&3O\ @JU_T<Q\$O\ P66__P HJ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,ZQM)XMT&YLK5G^[#=;"UO(?]R98W_X#7\EO[+?Q=O/V5?VLO ?C:2.>WNO
MOB6SU*YA*[7V03JTL1'JT:LA'7DBO6RK*J6,I3DY-2B>;F.8SPU2"M=2/[']
M5UJVT'2KB^O9XK6SLXVFFFD;:D4:@LS$]@ .37SCX0_X+&_LR^//%FEZ'I/Q
MD\&WVK:U=Q6%C;).X:XGE<)&@RN!N9@,GCFN!_X+T?M3P?LZ_P#!*WQ]JFGW
MT:WWCFTC\+Z4Z/Q+]N&R5U/^S:"XD!']W-?RX:?)J/ANXL-8M?M-G)#/YMG=
MJI4++$4;<C="4)7ITR*VRG(UBZ,JDFU;1?(RS+-I8>I&$5?JS^V+S#C^&OEZ
M^_X+5_LLZ9>RV\_QN\$QS6[M'(IGD^5@<$9V=C6=\4?V^K67_@CGJG[05C<1
M6]U?_#TZO:B-N+?4Y[<1I"#ZI>.L9&>J^M?S8?\ !-K]F8_M?_MT_##X=M ;
MFQU[7(3J2<G_ $"'-Q=Y/O!#*,^I'K6>6Y/&O"I.K+E4"\?FDJ,J=.FKN1_7
MOHNOV_B/1+34;&5;BSOH$N8)0I DC=0RL 1GD$'&,C->)?M.?\%/?@+^QO?M
M8_$?XH>&?#^J1J'?3E=[W4$4]&:VMUDF4'L2F*^??^#@C_@I)JW_  3O_9!L
M+3P7<)9>/OB'<RZ3I-SG:VF6T<>ZYNH^H\Q \2+QPTRMSLP?QL_X(Y_\$J[S
M_@KQ\<?&%]XM\7:QIGAGPN(;S7M23%QJFJ7-V\ACC1Y2P#,(IG:5P^-B_*2^
M0L!E%.K0>*Q,G&FNVX8[,ITZBH44G)]S]O? _P#P<+?LA^/=>73;?XO6=C<2
M2,D;ZGHVHV%NX&,N9IK=8U7G^-E/!XQS7U[X3\:Z7X_\.V6L:#J.GZUI&HQ"
M>UO[&X2XM;E#T9)$)5E/JI(K\#_^"Q7_  ;K>#?V%OV3[_XK?#'Q?XPU:S\+
MW-JNMZ;X@:VN9'BFG2!)X)((8=I266/*%#E69MRA><O_ (-9OVZ/$'PZ_:R_
MX4;J6H7%UX/\>V=U=:99/)F/3M2MXFN&DB[*LD,4P=5^\RQD\@YVK93AZF&>
M*P<F^7=,SHYI5A75#$I7>UC^A1K@K_=]L^O:OF_]HO\ X+!?LV_LI>(9M'\<
M?%KPWI^L6K^7<6-BL^JW5J_]V6*TCE:-O9P".^,BOC7_ (.;/^"H?B3]E#P!
MX?\ A%\/]4N-$\5>/+.74M8U.UE\N[T_3%<Q*L+J=R-,ZR@N,$+"X!!;(^"?
M^"('_!#;3?\ @IOX5\1>._'7BK6O#O@C1=3.C00Z-Y:ZCJ5V(DEE/FRJZ1QH
MLL(/[N0N7(RNPELL)E%-X;ZYB9-1Z)=33%YE.-;ZO02<NMS]DOA+_P %\?V3
M?C-KD.FZ;\8-'TV^F.-FMV-WI$2<D#=/<Q1PC/\ O]"*^O++48=2M(;BWFAN
M+>:,2I+&X9)%(R&!'!!!R".HK^;W_@N-_P $+O#_ /P3.^'OACQ[X \3^(O$
M'A+5M471;RUUSR);ZPN7BDFB=988XU:-Q%(N/+4J57ERXV_3O_!I[^W;X@\:
M'Q=\!_$6HW&IZ?X=TQ?$7ADSR%FT^W$R0W5LI;GRP\T+*O8F4\AAC3%Y/2^J
M_7,))N*W3)P^:557^KXE)2\CRS_@[U?'[6OPJ/\ U*4P(]?]->O>/^#0/G]G
M+XO#[Q_X26T&3_UZ^M>#?\'>O'[6/PI_[%&7_P!+)*Z?_@W2_; \&_L*_P#!
M.?\ : ^)'CB[^SZ/HOB"U\JW0YGU*Y-J?*MH5/WI'88'8#+,0JDCTJE.4\E@
MH*[T_,\^,HPS63EHO^ ?KY^TA^W=\(_V/[W3+7XF?$#PYX-NM:226RAU"XVR
M7"(5#,% )QSC)XSGN"!1_9X_X**_!?\ :Q\9W7A[X;_$+0O&.L65LUY/;:=Y
MDAAA#*ID8[0JKN91DGDD 9)Q7\O?QL^+GQ8_X*^_MT?;Y+.YU[QQXYOUL-(T
M:U;=#IEN"?+MXMQ 2&)-SLYP/OR,<LS5_21_P2E_X)F>&?\ @F-^S;:^&;#[
M/J7B[6-EWXHUM4^;4;O'W$)&5@BRR1IQP2Q&YV)\?,<KHX.A%U)/VCMH>G@L
MPK8FLU"/N)[GT1\0/BAX?^$_A2ZU[Q1KFD^'=#L%WW5_J=TEI;6XSC+22$*O
MXD9[9KY5\4?\' 7[(?A'4%M;KXSZ/-(YVJ]EI.I7L)X!R9(;=T"_,/FS@^O!
MK\(?^"Z7[:WC3]K#_@H)\0-)UV^O(?#/PW\07OAG0]'69OLUG':SM;O.$^[Y
MLS1&1FQNP57.U !],_\ !-?_ (-ZOA+^W/\ LSZ#XRN/CYYWB+6[+S[K1-$M
MK9GT*?<0\$ZR.9&9<<_+&">064J3V1R.A1H*MC)M7[(YI9Q6JUG2PT5IW/V/
M^!/_  5-_9Z_:5UNWTOP9\7O!.J:O=2+%!ITM\+.]N'8[52."?9([$\852?;
MD5[]$^\=J_"G3_\ @V)^)O[)_P"UW\(_&G@/Q;I7Q*\+^'O&6D:GJT<L2Z/J
M6GP0WT4DCB.25HID5%+';(')&%C8]?W3MV!7Y17BX^CAZ;3PTG)/>_0]3 UJ
M\TU7BDUV)-V*\>_:0_;_ /@Y^R%XDT_2?B5\0/#_ (/U'5;8W=I!?R,KSQ!B
MFX84\;@1^!KU_=G\Z_ '_@[X&?VM/A7_ -BE-^'^F/595@XXK$*C)V6H9ABW
MAZ+JQ5S]F/AQ_P %#_@G\7?AKX@\9>'?B;X1OO"GA5UCUC5FO1!::>S+N422
M2;0"1T'?ZUX];_\ !P+^R%=>+H]%7XT:0MU)+Y7FR:1J26><9_X^FMQ !_M%
M\=NM?AS_ ,$G_P#@D-\0O^"IW@/Q/#I?Q$L?!?@'PUJD?VVVN$GO//OGB)61
M+12D;$1\%V<,,X&:S?\ @JU_P10\<?\ !+.TT77-0\0Z?XT\'>(+DZ?#JUI;
M/:307(1I!%-"6;;NC1V0B1@WEL/E(&?=CD>!]LZ$ZKYNAX\LVQ?L55C3T/ZC
M_"WB_3?''AVQU;1=2T_5]*U*%;BTO+.=9[>ZB8 K(CJ2K*01@@D'-6K_ %.+
M3+6:>XDC@MX%,DDKL%2-1R22>, <Y[5^&G_!IE^VYK4?Q \7_ 76+JZN]%FT
M]_$N@"64LFG2I(B7," _=642K*%& &BD)Y<FJ?\ P=)?\%+/$EQ\7H?V=_">
MJW&E^'])L8+[Q9]DE,<FIW,ZB6&UDVG)A2(QR%<X9I!D'8I'F?V+4>-^J)^=
M_([_ .UH+"?66OEYGZ0?&+_@O-^RC\$-=GTO5OB_HM_J%ON#1:)8WFL(2IP5
M$UK%)#GG'+CFN@^ /_!9S]F7]IOQ+#HOA#XO>&KG6+A_+@L]02XTF:Y?^Y&M
MY'%YC'L%R3CO7X?_ /!'G_@@5JG_  4M^&6I?$+Q%XMF\$>";>\?3K VMBMS
M>ZO/'M,CIN8)'$A;;NPQ+AAM&W)\R_X*^_\ !(#Q!_P2L\?>'8WUS_A,/!GB
MV*4:7JRVGV66.>(+YEO-'O8*XWJRD,0RY/!! ]*.38&55X6-1^T7W7."6;8N
M,%7</<9_52LV_I5/Q%XDLO"6C7&I:I>V6FZ?9QF:XNKJ988($'4N[$!0/4\"
MORT_X-A?^"E?B+]J+X0>(_A-XZU2XUKQ)\.X8KS2-1N93)<7VENVPQR,>6:"
M3:H8]4FC'\&3\0_\'/\ ^VOXT^*/[=6K_!UKZ\L? OPY@L3%IL,[QQ:I>7%I
M%=-=2C@,RK.(TSD*(V(^^V?+HY+5GBWA'IRZM^1Z%7-H0PRQ/?H?K[\0?^"\
MW[)/PRU&2UU+XU>';B2-BC'2K.\U9,Y(X>UAE4CCJ"01@@X(-=)\(O\ @L9^
MS'\<M5CL?#OQJ\#M>3G$5OJ-V=+EE;CY56Z6(LQR/E&3[<&OQ+_X)"_\$2_A
M9_P4<^#'_"1^(/CE#H_B5KVYM9/">EQ6RZA:B,@1S/YLF]ED!W#;%MP<;L@@
M>G?M<?\ !IA\1/AYX:EU7X0>.M.^(LT)9VT34[=-'O7&, 13M*T$C9S_ *PP
MC'<UW5LMRZ$W2E5:DNZTO]QRT\PQTHJHJ::?GJ?IO_P6?_:]^&WP8_8G^*7@
MGQ5XPTC1/%GC;P'K,.@Z9<2,L^INUM+$@C !',A4<GO7\U7[!7C32?AI^W/\
M%_$6NWUOINA^'O'>AZGJ-Y*-L=I;1:A!+)*V,[555+8&<XK]UO\ @X*_X)2R
M?M:_!>3XO2>.AX;?X*^!]1NFT8:-]L&K&&-KDIYWVB,0Y\O9_JWQG.*_ G]F
MOX.?\-#_ +1WP_\ A_\ VE_9'_"=>)=/\/#4/L_V@67VR[C@6;R]R;]GF!MA
M92V-N1]ZO8R"G0^IU+/OS>6G3\SS<XJUOK,+JW;S]3^K#X6_\%9?V<_C1X^T
MKPKX4^+7A'7/$.N3>186-M.[274F,[1E?05]%*V17Y*_L3_\&O9_8[_:O\#?
M$[_A> \1#P;J*ZB=-'@W[']LVHR[/.^W2;,[LYV'ITK]:8NE?&8VGAX32P\G
M)>9]/@YUY1;K)(61MN/]HXK\B/\ @Y,_X+!^(?V:#8_ _P"%VM3:+XNUJR6^
M\2:S92;;K2[27<(K:%A\T<TH!=G7#)'LVD&0$?KM*._MT]:_DA_X+!_$J\^*
MW_!4/X[:G?.TDMGXPOM'5LD8BL9/L48X]([=1^'&.*]/AO!QQ&*O/:*.#/,4
MZ-"T=V<Q^Q#^P/\ $_\ X*-?&"3PM\.]+74+J%5N=5U.^G\FQTJ)VQYT\N">
M6#8"!G;'"G!Q^A?B#_@T,^*%GX*>YT_XL>!=0\0+'N-A-8W4%J6 ^Z+@!F(]
MS$.U?=?_  ;$_ ?1_A?_ ,$MO#OBBUL[:+6?B)J5_J>H7*J/-F6"[FM($9O[
MJI!N"] 97/5F)_0X1 8Z8':NW,>(<1"NZ="RC%V];')@<DH3HJ=6[<D?SJ_\
M$2_V0OB=^P]_P6^\%^$/B1X9U3POJDVEZOL$CAK74X18S'S(9D)CN$W*IR&.
MTC!"D%5]D_X/$_\ D8?V?AU!M]?_ /0M./\ A]<5^WEWH5C?ZE:WLUG;S7EC
MO^S3R1JTEOO&UMC$97<O!QC(ZU^(G_!XK_R,W[/_ /U[^(/YZ=49?CWB\SIU
M9*SMJ7C<']6P,X1;>I^>W_!,'_@EIXH_X*C>+O%V@^%?$F@^'+OPKI\-^YU2
M.4PW*R2E-H,0)4CD_=/X5WG_  4'_P""!OQN_P"">OPJE\>Z]<>%_%G@VRDC
MBOM0T.ZFD?2_,98T::*:*-@C.ZH&CW@%AN*[A7K/_!LG^U]\,_V0?CK\3-2^
M)GC'1_!UCK&AVMK8SW\C*MQ*MP695P#R!@U]A_\ !<C_ (+?? OQ[^P]XM^%
MWPW\46OC_P 5>.X8K'-A!)]CTJ#SU>2:25T"%@(RJHA+!G1C@8)]G%8['1QZ
MHTXWA==-+'EX?"866$=2<O>L^I^=O_!"7_@I7XP_8O\ VPO!OA.36+RX^&OC
MK5;?1=7T6>8M;6KW#K%%>0H>(I(W9"Q4 LFY2"=I7^F+XR^+KKP%\'_%6NV?
MDM>Z+I%U?6_FC<GF1PLZ[AQQE0".X[U_)E_P2X_9^U7]IS_@H'\)O">D6\T_
MF^(K34KZ2-=WV>RM95N+B9L= L:-C)Y8HN<E:_KP:V2>)ED4.K#:P(X8>GTK
MQ>)J=*&(A*"UW?WGJ9!*I.C)2VV1_+-^UY_P7]_:/_;*^%^H>"]>\1:)X>\,
MZQ UMJ=GX>T[[%_:,)^_%+,[O*(RIVLJNJNN58$$@^+_ /!-'G_@HU^S[\H_
MY*3X=QP!UU.W/%?TK?\ !8;X>Z#I?_!+WXY7%KH^EVUQ#X2NVCDBM(U:,A1@
MJ0."/:OYJ_\ @FES_P %'_@!_P!E+\._^G2WKV\KQ-*OA*KIP44D_P CR<PP
M]6CB*?M).3;_ %/[ U.!7CG[?W[5%G^Q+^Q]X^^*%Y#'=-X4TTS6EO(<+=7<
MCK#;1L<CY6GDC4D= Q/:O9 O-?FQ_P '57BF;P]_P2\CM(7VQZYXPTVRF&,^
M8BI<7 '_ 'U I_"OAL#1]KB(4Y=6?7XRI[.A*:['X 2WWQ&_;]_:CM_MEY?^
M,/B-\2M9BMDFN90#<W$S!%&XX2.)?E ^ZD:*!@(N!]__ +6W_!K=\0/V9_V6
M-8^(6D_$+1_&FK>&=/;5-8T&#1VLF6WC!:8V]PTS"9HT#-M9(R55@IW$*WAW
M_!NKX:M_$G_!83X2I=(LBV9U2\VL,_O(]+NVC;ZJQ!%?U%>(]!M?$N@7VG7:
M"2SU""2WGC(X='4JP_$$U]AG6:5<'B(4*.D4E<^8RW+X8JC*M5W/Y2_^".?_
M  41US_@GQ^V+X=U9=4GB\">);V#3/%M@9,VT]G(^PW!7IYEN7,H888;77H[
M _U>(^^+C!#C.>W_ ->OXFM3L/[-U&>V8B3[/*T1)_CVDC^E?V4_LG>*+KQY
M^RO\-=<O9&FO-9\+:7?3NW5Y);2)V)^I8UQ<58>*<*\59R1V<.UI/FI-['XF
M_P#!5K_@X%_:)^!?[77Q1^%?@[4_"OA_1?#>KMIUCJ$.C+-J,<013R\S/&6.
MX\B($8&,5^1WB?Q%J'C+7[[5M8O;O5-4U2XDO+R[NY6FGNIY&+R2N[9+.SEB
M6/)))/-?VFWWP^T/4KR2XN-&TNXN)3N>62TC9V^I(R:_CG_:YA2V_:M^)T<:
M+'''XLU5551M"@7<P  ] ./H*]+AW%T:S<*=-1:2N^YY^=8:K3Y9SDY7;^1_
M6%_P3)&/^";_ .S_ /\ 9-_#O_ILMJ]PKP__ ()E_P#*-_\ 9_\ ^R;^'?\
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M^Z'C'_@X=_9"\$ZT=/N/B[:WMPLHC9M/T/4[R$ _Q"6*W9' [[&:O9?V6_\
M@I'\#_VU)6@^&7Q(\.^)K]$,K:>KO:Z@$'5OLLZQS;1W.S R,U^;W[/O_!I+
M\.KGX,:;)\2_B!X\_P"$[O+19;Z/0);.VTVQF=,F';+!+)*(V."^]-^,[5SQ
M^2W[7'P"\6_\$NOV\_$'@_3?$MU'XD^'FI0W&E:]8YM9I(WBCGMIQ@G8QAE3
M<@) ;>N6&2>NCE.!Q+E3P\WS+OLSFGFF*HVG62Y7V/Z^%D/I["N0^-'Q^\&_
ML[>#9/$7CKQ3X?\ "6AQ$*U[JMZEK"S'HJEB-S'LJY)]*\<_86_;NL?VA/\
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MA.']K_\ :R\/Z7\0OB(GAF/QQJP76/%^MR-=_9S)N)FE=W7<6;:NYW4 N"S
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MZ4C=(>N%54'UE^QE_P &O_QL_:9^'EEXJ\6ZUHGPMT_5HUFM;34(9+S5)HB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?_
M +5/QE'[.W[-7Q"\?-:K??\ "$^&]0UW[,QP+DVUM),(SCLQ3'XU_)#XY^,/
MB[]NO]J6QUKXD^++O4-<\9:S;6=WJ=W)NCT^*694'EIPB11*_P L:A5 ' '.
M?Z_/BM\.M+^+WPU\1>$];A>XT7Q1I=SI.H1(=K2V\\312J#[H[#\>]?RI_\
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MGG/_  4)%]_P0!?X%2:A_P 3VU^(26:V@?)&BL)-1#Y]!>HP^NVOI+_@T?\
MV8QXO^/WQ&^+-[; VOA/2H]!TUW7C[3>-YDK*<?>2&$*?:Y[YX_)N;X8>)H"
MRR>'==B\LE7!L)5VD<<_+U!'YU_3U_P;V?LL2?LO?\$P?!$5_9O9ZYXX,OBS
M4D=-K!KK;Y (Z@BUCMP0>0<]*K.JU'#X.<*+UF[BRNE.MB8RJK2*/@C_ (/#
M-*OA\0O@3>2!_P"S)-.UF"(X^42B2S9^?7:8S@]<8[FO@G_@F+_P2I\4?\%1
M];\7:;X2\8>$?#>I>$8K:ZN+;6#.KWD4S2#?$8HWR$9 &R0 95X/;^A__@K[
M_P $V],_X*:?LIW7@_[9:Z1XMT6;^UO#.ISKF*VNU1E\N7'S>3(K%&(R5)5L
M,4"G^</Q!\,_VCO^"0/[0,.MS:7XL^%_BS27DMK75XX ^GWT;'!5)B&MYX6P
M,KR"0,@$$5GDN,57 O#TYJ,UW*S+#NEC/;S3<7V/MC_B$2^-@0?\7+^%V[/]
M^_R?Q\C/\^]>Y_\ !-3_ (-O/BK^Q+^W#X#^*.N>// .I:3X1N;B:XM=/:[^
MT3K):S087?"JY_>#.3T!KY#_ .(I3]J?_A'&L6NO /VAA@7_ /PC^VY3YAS@
M2^7D=/\ 5D'/2O9?^"(WQ)_:8_;<_P""HW@GXL_% _$/Q1X1T?3M45-;O=/>
MVT*Q,UE*BK;JJ+;1EV*@B,!C\N<C%9XG^TH4).O."C;96NS6@\)*K'V49-]S
MR_\ X.M],OK;_@IIILUVLC6=SX)T][-B/EV"XNT('_;1).G7\J\C_P"":O\
MP1*\:?\ !4#X6:YXH\&^.? ^B-X=U5M,O+#5WN1=(QBCD24>5$Z^6P<J#GYC
M&^1P#7[2_P#!=K_@D?-_P4O^"VE:OX1EL;3XH>!5E?23=,(H=7M9-K2V;R?P
M$LBO&[?*K @[0Y=?P4^&OQ,_:,_X(]_'&YN+&W\5?"WQ(P2UO;/4].VVNJQ*
MV0CI(K13QD[MK*3]XE&YS73EN*^L8!4*$TIQ[F&.P_L<8ZM5-P9]K-_P:)_&
MHCCXD_"TKS@%K[C\/L_U_P @5]:?\$8?^"#?Q(_X)J?M=7WQ#\4^,O!>M:7=
M>'KK1_LNDO=&X:266!U)$D2+M A/.2<XX/;\_=>_X.C_ -JK6?#)L(-0\":7
M=;<?VC:^'P;G.#R!*[Q9[X\O'%?77_!N%_PT!\9/VS/B!\6OC%;?$/4;'7/"
M/]GV6N^(+2:"UN'-Y!((K8L%CV *[;(@%&2>YKDQRS"&&G]9G%*VRMJ=.$^I
MO$1=*,K]V>0_\'>I_P",LOA3_P!BE-_Z625^?_[-G[(7QB_:U^"7Q N/ ^GZ
MEJG@OX9V[>)M7@61EA:?:$_=(/\ 6W/D+(P7J(XY,'+;6_1#_@[<\)ZKXB_:
MN^%KZ?IM]?)'X3E#-;V[RA3]LD.#@<< GFO=_P#@T<\-7V@_LY_%U=0L;VQ:
M;Q';%%N8'BWC[,<X##GMS_C731QSP^4PJ0LVGM\SGK8-U\QE3U2W/R]_X(H_
MM_Z;_P $\?VXM'\6:_86MUX5UR!M!UN<VXEN=*MII%/VF(XW HZ(7"DEXQ(
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MUO4+CP]_:%C8W?EXC\R; \DE3P&<!NP)S7"_M#_M7_';_@JO\9-%3Q5?:_\
M$'Q$H^QZ/HNF6 \NUW[0XAM84"AG(4N^TL=J[B510/<EE,O[2>*E)**=]]3R
M*>91C@EAXQ;=K'TI_P &O&A:AK'_  57T>XL3)]ETOPUJEU?%1D- T:1#=[>
M;+ ?8D>]>9?\%]-(O-(_X*[_ !HCODD$DVHV<\988W1/I]LR8]MI !'/R]J_
M93_@WZ_X)$ZQ_P $Z_A?KOB[XA0V4?Q.\<I%%/;PRK-_8=@GSBV,B\-*\GSR
M;69<I& 3M);S'_@XU_X(U>)?VO9K#XS?"O39-8\;:)8#3M=T*W ^T:O9H6:*
M>W'\=Q'N*E/O.FT+\R!7SAFU"6:N5_=:Y;E2RVI_9O*M[WL>X?\ !M;XEL=:
M_P""0?PYM;-X6N-)OM7M+[:1D3-J=S,-WOY4T7!YP1Z@U\^_\'>5_IT/[)WP
MGLY)(5U*;Q9++;QE\.8$LY1,0 >55G@!/;</6ORU_8>_X*G?';_@DYK7B#PW
MX72TL[6^O!-J?AGQ1IDKP17BJJF0QAHYXI=JA&VL,@ ,"54C&_:7_:E^/7_!
M9#]H729-6T[4/&'B2*$V6CZ#X>TQO(T^)F4N(XEW, Q^9Y)&;@#<P50!5+)I
MT\P>,<UR:O?4=3,XSPGU?E?-L?6W_!I)IEY-_P %#_&EY&LGV&V^'UW%<28^
M0,^H:?L4]LDHQ'J$;'>OM_\ X+@?\$&KS_@H3X^C^)WPPUK1]+^($5FEAJVF
MZG(R6>LK%_JW$JAS'<(N(\,NQE"9,>TEO4?^"#/_  2@O/\ @FO\ -4U#QC]
MEE^)OCQX;C6$@<21Z3!&&,-FKCAF4N[2,IVLS8!*HK'\U_\ @JM^TG^TQ_P3
MH_X*J?%CQQX!O/''@_PCXLU*RN(+B73VN- UO%C;1,Q29&MW<%&3</G7L1Q7
M'*M/$YC*KA))-*VNS-8THT,!&G7BWS/[CY&^,G_!&_\ :A^ QF?7O@KXXDA@
M)=Y]'MAK$("G[V^T:0*O4Y;:!4/[(/\ P5?^/7[$'CJPO/#'CSQ!=:793I]I
M\/ZU=2WFEW:*2#$T$C?N\C<I:,HXQ]X8Q7U/:?\ !V3^TM;:"MK)X=^#]U-Y
M17[;+HM\L[$CAL+>A,C)/$>/EY4U\T?LO_\ !/CX[_\ !6'X[ZAX@T/PW>R6
MWB[6KG4-;\6W5B+/1;6:>9I+B0. $8AV8B&'+= % )Q]!&4W3FLQC!*W=:GD
MRC!5(O!N5[G]#'[7/QPT_P#:6_X(F?$?XA:5;RV>G^-/A'J.MP6\C;I+03Z7
M)+Y3$<%HRVT]LJ>U?S7_ /!-(*/^"C7[/[?=7_A9'AT9P>!_:=N3D^^.GH>?
M?^J2P_9"T71OV%&^!5C.RZ"O@EO!4=S)%O8PFR-H964$ L02Q (!)/-?RC_M
M _LS_%#_ ()_?'E=)\8:+JWA/Q-X?U SZ9J!@98;MX)04NK25@%E3<JLK*>P
MZ$$#Q>':E*5.M1B[7VOZ6/3SJ,U.E5:O;?[S^Q8,) /7&>>W'7_/K3H?N]_I
MFOP6_P""<7_!P!^TE^U_^V]\)?AWX@O/#$>@ZMJZ6^L3:5H2K<W\"QL',K%G
M5 S ',:Q@'(&!Q7[TQ_2OE\=@9X2:C5:N^Q]#A<9#$1;C<&YK^3_ /X+B_!*
M^^!/_!5#XQ:?=12+%KNN2>([27R]J7$5_B[RI[[7D>//3=&WH<_UA;,GZ5\
M_P#!<W_@C/;_ /!3'X?:?XC\)SV.D_%?PE;M;Z?<79*VVKV9+.;*9@"4PQ9H
MWZ!F8-P^Y/0R#,(X7$WJ;/0X\XP<J]#W-T>8_P#!K!^V/X?^)7[#[?".2^AB
M\6?#6^NITL';$MQIUU.UPLZ G+*L\TR-C.W]V3CS%!_4C[1V/;J<<9_SG\J_
MCM^(WP4^-7_!/+XOV=QX@T'QQ\+?%NDW&ZROU62S8N."]O<QG9*IY^9&*G!
MSS7KFM?\%U/VN/%?A/\ L&7XU>)/LLD9AW6=K:6]YS@';<Q0+/NXX;?D<X(R
M:]C'</\ MZKKX>HN66NIYN%SKV--4JT'=:']-/B#]LOX=>&?VFO#OP=F\26,
MWQ&\36]Q>6VC6W[V>WMX8FF:6?'$*E5^7>07_A! )'Y$?\'B+%O$7[/I(P?L
M_B#C\=.KS'_@W1_8H^-T_P#P4.\/_&3Q1X(\76?A*UL]1EOO$&O1-;&]DN;2
M2-'C,Q$EP6=^616 YR17KG_!WWX6U+Q!XB^ ;:?I]]?"&WUWS#;V[2>7EM.
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MJ\:IJ_B;4PK7MX!@^4@ VPPAAD1KDDXW,Y4$?49^1L>IYIX78,5ROQRUZ_\
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MB&PGTV]A/_+:":-HY%_%6(_&O,PM?V5:-5=&>ABJ?M*,H,_F*_X((_MTZ?\
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M( ?^%E_"\^A,NH<_^0..O7^70#?\&BOQK7C_ (65\+0.A^>^ QZ?ZCZ5X/\
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M1$C/'WR.!^PGAKPY8>$= LM*TNSMM.TW38$M+2TMHQ%#:PHH1(T1>%55  4
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MK]:_(K_@[X?'[)GPJSC \72Y.>G^A2G_ #]*^KO^"[/[2WQ*_9,_8)U#Q?\
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MY5TU%5&4DK)B=.+W0T0J!0B>6N!3J*DKR$(XK^?_ /X.^#C]K3X5^@\)2_\
MI9)^'ZY]J_H :O//C'^R7\*OVA]8M=0\??#7P#XWO["+R+:YU_P]::E+;QY+
M;$::-BJY).!@9)/>N[*\:L+B%6:O;H<.881XFBZ29^7?_!H+S^SE\7QMW?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#XT>%-.\<?$[7($O+C3]:@%SI_AY7PZVPMVS'),O&]W5MK K'M4$O]P^+O\
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MFZYH^I1B:TO]/N4N;6ZC/1XY$)5E/J"17R+^V)_P0?\ V;OVN?#=U&W@72_
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MC(RC@,,CCD5W-<\HN+Y9;G1&2:N@HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=^"G_!(?XT>%_".BZ=X<\.Z3X%U6*RT[3X%AM[56AD<A$7@ LS' [DU\M_\
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M B$4EE!8++D\!5N$;GU4GIFN[EB\TJMZ\L;KULCC<G]0@EUE9^ES]4_V?O\
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MPYP[>M?C%_P:N_LC?##]J:3XZ+\1O ?A?QK_ &"- &G'6+".Z-EYO]I^;LW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNHZTJ:C)]48++9.RJU')+H011+'!Y<8"JHPH QC'MV^E?@0_[.?[47_!!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 8R:*** #I1110 4444 &.:,<T44 &.:,<T44 %!YHHH 3;
M2D9HHH 0KD=:%7%+10 FSBDV4ZB@  P*3;]:6BBP 1FC'%%%  !BD*YI:*
M#%%%% "%<T;:6BERH  Q01FBBF A7-+CBBB@ HHHH *",T44 &.****  C-%
M%% !CFC%%%&P#6CW=Z-G/X8IU% ";*6BBBU@ #%)MP*6B@! N*7%%%  .***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ (S1BBBCS  ,4444 %!YHHH 3;2XXHHH
M",T@7!I:* "@#%%% !1BBB@ Q01FBBBP"!<4M%% !MYI"N32T4 &VC'%%% "
M!<&@KFEHH ",TW9S3J*+ &*.E%% !1CBBB@!"N:7;110 FW%&SFEHH *,<T4
M4 (%P*4C-%% !BDVX-+10 UDW4&/(IU%  !M%!YHHH 3;05S2T4 (5S2;<4Z
MB@  Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYI_@<Q-X+ATSQ###L8F/^S8]4MQ:E2.,C_1QG/ 8XR#Q_0(B!4P/7TK\]?\
M@WS_ ."4-[_P3S^ &H>)_&ENL'Q.^(B02ZC:Y5O[#LX]S0V88=9,NSRD':6V
M* ?+#-^AD:[%Q73G%:-3$WAJEI?N8Y71E"A[W76PJMFEH'%%>:>@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC_9%2>(/$5GX5T2\U/4;B"ST_3X7N;JXF<)';Q(I9W8G@*J@DD],5^9?[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?LZD:QH% X]ATIV/]ZBGFM:$%!*.G]U,JIEE*<G)M_>S\7S_ ,$/_P!OL_\
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img102364508_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Z\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'J"^>$ X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q >+            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              ,W   &:P         !
M                          $             !FL   ,W
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   ,W     %)G:'1L
M;VYG   &:P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #-P    !29VAT;&]N9P  !FL    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M^:$WI/\ ],_[F?\ I-+TK/\ 3/\ N9_Z324O]GH_T;/\T+.=B8FYWZO3R?\
M!,\?ZBT/2?\ Z9_W,_\ 2:I.8[<?TCN3V9X_U$Z*V3D=4.51<]N%@475B@/:
M1BE\6"P->USJF;7;Z?Z/53OM];])E>EB_I4^0^UN0VNG I(:[&]2HXX?867"
MW[18UU7ZNSTK6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( ,@!CP,!$0 "$0$#$0'_Q  >  $  00# 0$             !P$%!@@"
M! D#"O_$ '(0   & 0(# @4+"@T/!P@+ 0$#! 4&!P(($0 A,4%1$A46%V$)
M$Q155G&!E]'6UR(V4U>1DI:AU? 9(R8G-3=U=I25L;;!&!HD)3(X0D9'4E1X
ML^'Q"C,T.4-SMRA%6(23HK332&)D969G=X:'I*:G_\0 ' $!  (# 0$!
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MJ#:;J@K4Z<5 YS+KPZ<&N89P$8X;%^9_^N0]?WN3TS_%U._I7X^L?S4^3O\
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M &@I7\#Y5\_N")^C'ZL/:"E?P/E7S^X(GZ,?JO\ :"E?P/E7S^X(GZ,?JO\
M:"E?P/E7S^X(GZ,?JO\ :"E?P/E7S^X(GZ,?JO\ :"E?P/E7S^X(GZ,?JO\
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MBI3($!.9F)BQ:>2D38F'FX%Y1#.C>3&[B3&Q+SB8G'J'@K]_4<:5O_1_JO\
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MIH;%+JR%KBF9R4($IS@T%.911#D6V+#"LE* MP((()78)#"L591)19X&8%X
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MZC,VI$Q3 7*/-"X96R-V*[!O9I(*I&;X\:D.#FY8(VYT]EHTN+BOQ()PQ6*
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MKN9X)?/H4_5=]]/)!WZ#8LX[Q^H@P]F^X@$)$?AVX<G^UJ[F>"F^?0I>J_\
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MW?\ -5YV]GU@>^.X<+OZSM_'3W;$D>B._P!D\9JOD0]_;2L+T!ZS7G3;KN,
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M754WRA+5<RL*&HV5C3Q6>2N&/,NCQ3"PX-+RD!C:O89.-ZSM/IVI=*FC*-/
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M18Y1&6\Q.PJ5#>819C7.CO3;4N<4.K^KV]B50FPYI;,<7F/DK>7)'9-BP]3
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M31FAI!C@O.3Q=A?FIB(4K%*@I#@><8:.(6>B YH8>>VZ\N>]Q<W9><2X"3@
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MI>I"HK:**Y47"XN_..:LEA,;U;PWN52V ;HQ.!G8>Y2'8XDX8C4)G7WR8E;
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MU#GZ_=WI+/1=ZXR]3O[E<&EOL;QJV>#*83CGXP0^".5?ON08Y>RBMLLL?.<
MY  \QQ <1'H&6(\8JX?R-;G-CDZA/-(,77&)O8;,C@LE$MY6G@[YQD2X1-X1
MDT>U36Y-UH@N5>%,H .7KH@(XUI(P 1\$.8!YV1VY#T'(1[=]AXY)@,8$#''
M#/ ;LNN-N"Z5Q;.1UZ\L3T;?X+I"W6?[L8#SY_M:R,?@']=CKQ?G;0<]7=G^
M*K(V'?WY%/%UG^[" AUV_6UD>_XK8[=_Q#TX0[:-WXI(PP._/N3Q=9_9,(#W
M_M:R/E__ -8[^GO]>'.VC9\GOQ/X)(V'?W9;_@GBZT/=A ![/VMI%R][:V?]
MW$$.PQ&>SKZ3/&2<W8=X\$\76A[L(#V_Y-9%V=?\K/$\[:-Q\4PV'?\ @GBZ
MT!V_5A 1Y[?M;2/[@?KL#S#^D/3PYVT;CXIAL.6V?AE[%3Q=9_NP@/;_ )-9
M%]+'W>'.VC7D-V9C>G-V'?X!5\76@'28P'X*VD7O;@/G8[?1S#GOTXCG;1UQ
MCUYQMX."6[#O_! ;K/W^O& ;=!_6VD>W_BQMRVZ\_1N&_"';1ELZ<LP.@'^*
M2W8=6O\ #CH5/%UH!_CA =__ --9&',.S]MCB8=M&[\>.E);L._\..A5\76A
MV3" [;"/[6LC^'_*Q[P#MQ$.VC=T=?A\$EN.!Z,?P\4\76@/^.$!YC]K61_=
M_;8]/O\ /T\3#MHSV?CEWI+=ARV_AGW+OUB1("+'L#&1.;,Z*A@]89$',K"N
MCZ<M.+_;0 4:F7R.2FG'>N 9GZ_@L(+$O+ L$X989&&8GS..S/:LK(C##'P6
M=17Z\K0_=R.?S,8N*JRT:M9[U)6/K@DM"51J.<*(B$-TEUI<2=.WU765BIWZ
M<3.W[CA:LV1^6S*H?,V0AH@[)ABUQR11HXS(%9F#@G//]?P(H$2^JNDUW (+
M%;K0TTDU)+[<U/4K(SY';S%IXH!T5Z3)TE@\YLIKG-BF2MR9FJ7YR&!JXS7:
M)!.)<A>I4Y,*M4I9X7(I<G(L2QUWV=J)NO31,:T73"L=)Z?3/.]55PK8S+J@
MS>5^577 W0*>1R6'/]<VB,MKN'^3TE:Q*J%]B;I8:>2E22.SM"B:VX3R?'CJ
M66P#U:RB).RR^42!@8R&)JT^RG4=%V^J;HK:]9TJC,8=X2R!7=E1&$JB2*GN
M:0.-C1%)&XBX/\AC+FJ/?DGET0JB[T2F(MEK&UC7#354+K%NG3W6M.+1ED-C
MC GLS5Q6L8@SN5+V^1+!(.GAL84+2IDQJF1&TK80R0N2JWE:]ICH:YR=M;GE
M<@)QQQ@M=XAZI#;EZ3G1NMT_TDV/L&N])K 9+*C,DL6/L[FTS/3-8<9K1YRC
MLL)9W5"ZQUJ=A?GII=$R1/E-&1U9\LT3"M3*D99../Q4KQ37!*%;7%H= 8!)
M;UNFSM1VN*O8?&97)X56+.R0C29?$WKJ9R21S%DBJQ$VPZ.9I(=%8>6GB4FF
M[^;)HUY1YJU@2:2I2+I-WJC\HL(ZM8[1>EB7V-8LVKS4#,Y5#9#9T!KHFKGW
M3!=#30=OP64/ZX7TAU=T%E+5\?CKA%$+XVOIR)*O/S:F!><]MQ.,N/CUX*>7
MW6O"6_0(O]4!:HI(W: )]- ZF4<)4'(&N5J8^,#QG81A2H$Q<UHGW!-D+6H.
MP-5H"UN&>91RA/X)F9%;=0VMY@T^K[P;UU<R>9*J2H"J+\6)6!S9TRR5(+7M
M&?5<V1-D+=,TR8A[0N$"4K\U+BM3MZHMS2)O7DHE''@3@J-W[73<[9*5U;(M
M&LB\Z\6JQROVQH3(;OK-K3P6E,WQ[CD)>%,JCQ<R9'F?V"\1&=HV2"-69C8W
M#"'P]]F[<D/95+J3C)0+9'JTU-0-FC3P7&(GD8.FNG=3M@1>;7Y6M93M!%KF
MB!\Y8X%4,0DOA.=W6FW1M(<O6,"#R0CRG-='FM!+3W][*9TY%,<[]4A<8E+;
M<.:-.4IE5&T-;M$U5:=VD6)#6D40W[#Z,EL>D,3KA:7G*I,1%4]\Q8R:H%QD
M;R2M1)ZZ.+).Z K8&\BE1JU<VC8,RM9#26F![LRMJCL.;4Z\V(JM2%PI>_V?
M 6O+*2HHI"7E*H5N$+99<.$"=I4O>FIV!_3NBIBA\@9&_%S5DXR^.[O[+Y1>
MMF!ZBY33\?J^.O;HBLK36BU*RIY5J$J0*F9I!(D<0AD%F3;X)JL)U)I0VV<S
M UEY$%M2JH9Q@M-$Y.E(.(MTN")P1.")P1.")P11U9_UME^ES2_[%4/]'&ST
M3]+'V57W5K=*_11]M2]Y0!S'??+;F/(?@'M_%W;[^CCI>.#DM"J"&_\ <_B[
M]PW'T!S#IZ.H!OP16Q\2NBUE>$;&Z%,;TK:UZ5H>SF[!W+9W0](:4WNIK0<>
MD)<BF]7D2LS;C5*8M;B2*;-03@:)F,&2" ;IC!T3!U&#$QLD3M&:83B)$XB2
M)&L2,1.4A>5T#U1RNC[AU+1Z_;HG4SJ*DZDB<P.>+EJ.)5;:+Y.W.?OD)5^8
MY@@D0@:2U*@?EF$:C<?D&+"ZFFV$_,<;:)B_BYJ,$7B97=2?7;6J/>RDP.+J
MK&TWN??N\R[\JF9#9.%Z!.87L=1;4;1--C6NJ/+;K'NJ-:TL#OSA=,5&F3$#
MF G8I*T0ZE[,O"UM5<6M235D>J@\FJYS@<!KQXC\AQKZ&SFL6*3J(TZREF6K
M!G3ZR.3D4AF$I3F9,.,M,<VZ.8DL)39@9:S5GU7U@]S.::;FL80;K7,D@G-T
M$\XY7Y R"I:*+*3:+F->"X5&O<X$!SF/@&Z?DR)+!K9!Q,E3<TS6?3K5[.H6
MVOYS!4U!U?##GYH2)&PXVR+8N(^1KTY#TL6(%3@WL-60:*LKDV)F1:U9O[]9
M)QKN:I2Q=&E/R!SWVAS08918R6P.=4JWHF1):UC28$$F),8&MUC: )$U*SW7
M3)YK*=P.N['.<\#(\T2,25KA6\]O^-ZQ0T\2>\YK8#2Z4;8TK>7RW:,A%6QX
MVQ&5WK0F+J=,JZ*QZ)G6E&F)MED@-M5A<WN>91/:'E'S=.O<U28[$Q]9MH-
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MY&X$PH4BQ.TBX+D"@Y,4.2U3G-I-1C34;5<P,:&W&TV.O/)(:!>!-YSG 9Y
MDR52@VFYP8ZD'7G%SGFH]A8T07.,. +6M#G'I($[; 7)M0M-RS1%A;]A(9QY
MW&H-/]^-Z!B86E@*O3S62BTV"UX8#:UH7%O2.+Y7DNKYZ8A4FL:]#*8B\(6E
MC4L#@+HOU:3K,7OGE&\A5: (-2ZY[7MB(.!#CK$0,%-RG4;:.3!!INY:D[&>
M3O-:YCB2<((+1B1CB96_.^^W3ETW[1Y#[P"/0/>'EV!Z.WCJ&8Z,3TK N.X[
MASV 0[0 >P1'D/RCUYCSXE%<F?\ 99K$0V'QFAY;?_:B>??VB'/O[^8XJ_S-
M;[*I[A62C\]2^T9[P4Y.6WC!9_WPASWY?4X[[<AY?+N'9QR+,NWB.,Y73/SW
M^\5T0W_X]O/?8=Q^'W^+JJ?<#\_?'\?=RZ\$7EMKVLB_J#<(S9L!O&?M3:_S
M>N8ZPU\%'09ZTV1IH,F$.8YX]:F;G7Q=PE]?1YT;G]Q5,TI26# BD*I.0WM#
M))ER-46NQN+@<S!.S9&'X:QMQ5VP<('7.?4.(SV+7F^-:-\P?4A;<<16!)XN
MWP+4SIEIZKFI%6,-?M(4DAMH$T^HL1LU$ZA%49<I#5-X-B68SE<V1==8]5EI
M4V=-)HW%[(<YM@AD59<#$XC#5J.WQZ=I4@###,$XG'<,^R.PKTDUD69.*XIY
M,AJQ>F9;5MVR:OHBN9(N0)W5'#9%;LV:(BKL!0V+,#$+KE7<96R&=HV9>4:@
M?'&.(V5;A[&<#<L<CB0.O">"JM )QU8QM[C/4M;?5 I/?M 4NOMJL;[NI"H@
M==8L\>BT3H6N+59I19#*UR!U\XNI>6.,)7JH93JQ,@;2K&D<85U(T0I"0[OY
M4BP.7MK6@JZ\(@F!'!U;-DX9XJ6P9D DD[CG'P[<1KU5UF:WK_JR9V^$<L9Y
MC*&M=-5*695CG4E:0ZU].4@MNQE,U)6-.L*SWV/R!ZI"J'A:SQQ1')7Y2TXR
M(ZP42"=*+&<77!"UHJWG88G+;MXPG+4K #4 <=<C+9@>V8DS*]@+HO2"Z?:?
M?;FLMR+2QQ@0LX"6SYE+%4BD4D<6Y@BD4BF*@](0Y/4QE+NTQR-%*%*-*I<'
M5'DM5HD?LA61DF&@G' =I6,"3 V[AW?!>?\ IAN[43JJB>NZOG6[JUA-UP.V
MFEIIIQI_.&39GJ%DDNGZD+6BT?<E*LEZ1VJUQR;S%\A\]EZM$C(FIZ:4D1G"
M'D^)T;!0$F]C!P(@X=6?\-:N0 1@2,0?9O\ #!;X:7[E,U"Z=:7NU2S81QRL
MRN(M*WV.%'BI*C<F7MA'E1'2E0Y9"K(89#BZ-)*P1$51:/ _< ,V#(TR)B%0
MB"1QQ"G< Z\NS?OY?!Z=N?9ML/:'$J$VZ_R[]W8'9V[_ ,GI(K7# _7/G8]@
MP&K]M^0_7%;@^]V\8GYCJ^)65F1Z_@%D,5^O*T/W<CG\S&+BBNM=K@T;IK1N
MDV^(WJ*U%41-7&J&"F)&53#C3B5KDT(C,NETT:"7#*RJ8LM]:79.\3=]Q\;Q
M%\C2SV*8FPPSP/38*1(K"XZ JJ:XS3+53$WM;3U+Z&+L)/ [5KA_8)%/UR*X
M79));C16&HN.+VBP6=A;$R;FN>SEPG#"\OKC.VM!+4CN@>2<U)I..OI*D5AT
MG0I+(&Z6SB96-<,F+HB8Z>9&\66XQ949.H-/)@DF<E4RE%$XA$FP'E4M1EM*
M7&/(H_'V^/"+6C8"@+(/)(HB8O4^(L35\JH6?Z@M1UQZ?GVJ'&F&&G+$D-;
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M5O[U((!RD3(.O5U<;=>%6)ZGE6LS46&ABUF6_3T NBM8E4%Y5;6SA!,(=:4
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M[*R+7*3&+FA.E<%#LDP9$RX5+:0@7'+20S2EI%)AN!.=7EK6.<^+@:2Z07"
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MK^>:;*C*M(4F.#VL#;CR2.2): ";H+R(DXDF1CBM#!<%1U-]&J:KVECGE]\
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MW!/-##/LTX^-2TOGEPD[3O2!L&Y5\T4-^S3GET_75M+E_P#[+A)QQ..?3UI
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M,<3&64=0%X0^[ZMETL++;,"#I3'G!BE43\8DEXF*HO/WA*<(G-3$8B(KU+M
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KB<$3@B<$3@B<$3@B<$3@B<$3@B<$3@B<$3@B<$3@B<$3@B<$3@B<$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img102364508_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V04&AO=&]S:&]P(#,N,  X0DE-! 0
M    '72^=4 X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              B$
M  (@          $                          0             "(
M B$                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M B$     4F=H=&QO;F<   (@    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MJ-S2X"V\MIQVMR'-J].K&KQ\JC>_]6WYF+_HJTLC#^NME5X&49L98UM;32P
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M*Q5U# NL%5.3598Z88Q[7.,<^UI5#ZS=/;F=-#6V''MKNI=7<QH+V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 Q$ /P#_ *FH<'OIK+;-CL38B_;3U<7N>YKNP%Q:J,5*UT,1[>:L""J
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MU',("%#89#,.QK),-H$F2PU"$83!)3HV&I+H%J< < < < < < < < < < <
M< < < < < < < < < < < < < < < < HGM)LL_I?K+V*W#5&!DJTZHT7MK9
M-;C&X\B6&D'Z-03]G#L%XL27 E21CI 7';GQXTZ%(>BJ=;9EQW%)>0!9]),R
MK%3*C8)Z643CM8 &9B(R%MQT2B8J)-D)CMN..K0REY]>&D+=<6EO"<*<7G&5
M9 D_ ' ' 'MQGV^S.,^S/LS_ ,L_W9_NS\N. . . . . . . . . . . . .
M . . <EMR=,MO7K=5ZV17J-I;X@FC5:E6/4)J[38 'L"P%A[7A-R]AS*]IN#
M\#N,%K[5]D/_ !PB;G-HN-'&!:O8:O7H#4@L!;_53K'MG3.R95CV!/IQY;5"
M/5FQ[0&6,V2OF\CAHOK\E6#&P Q"K"VA7]$X>K6"FU9V1:K?*EB+&M]A89+T
MZ!D"T?$ ^@?W7^R5V-_!ZX\ OS57S7ZW^H5/^[P[@$]X X!![A01=U7!<(F;
ML)4/0^AK%1O=MIJ'\2,M97F<W62XQN>M&6D^@N6EY<?"G$LJ1AU>% <M-"]<
M;UK[O+V=HCY/<<G15HJ%-VV&MT_?UU48Q<K*7-1)$%$<38!Y"1%DO1;&/_WU
M&F3H<2JC'G2[Z2+2'[_Y#RO$\QXIXVWZBFOG>+FSCK>/RX9SUQ@19A-%U_4Q
M99,54-VMLJUE]TQ2C0SE*X/C>2XOR3GE^"U^'Y#X]]>W1KBYYV-*^U%5,3$U
MI$VW+_-7[0E%43:R^BQU9J50@4V#('CR=I*-2969:WK9;+%;YK;F6FF<MQY]
MD(DYD>+Y6DJQ%9>1'PZIQ[#>''7%*H!=25< < < < < < < < Q)H6V=E[5O
M7;?Q[%V:#I0$=VM6P$JU"-;B!4\F#V*-'ZUD:M1692MCSPRJ2S;,;#*[2@0X
MA PFF2M>.S1CQZ6Z!)AH7MA*UYV '6NR5=G:Y:K6J#I4W3<C8>K1).2'LT:B
MDX0LL'=V %L40DZ$DWJ+;3=XK^7&($JI%/=WBXF(!1(P/V0;T38ZH[K'L4TY
M.V=5;:$K\W==%F;A@Z@%7_5S-XUB[MQ/85THU>+2/C;+M=>G,[)?$Q:#,9JK
MUYK-B6+K<4#-E9U5XCL)O*;Z]MFSD&*]J1V[S*SNRM#1MWI@Q?2Q5YUMKF&C
M9]7<J>Y5L4[MNR5V&J/K^&9D7>*[&V?*28!JJ8&RNM@?LG7MC!FMM!-JR*PY
MU5U(,)%K-?:!9ZQ W""LEJ=M =4(;?2EDEWQRLGJY%M5T2!EURSSZW/=8MD[
M#0M1$#>G ' ,C>(!] _NO]DKL;^#UQX!?FJOFOUO]0J?]WAW )[P!P!P"B@B
MDY[)[(3A2<KQIG4.<I]N/-C&;EN3Y<X_3C&?[_9[.=ZGKOJ>I^G?7TGK[=_Y
M=_\ N<[COKOZ_O,?T_:.YC_/[?UZ_P B]><.C@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@&1O$ ^@?W7^R5V-_!ZX\ OS57S7ZW^H5/^[P[@$]X X X!BBFZ.J(7
MOGN?=T2=95VRR:%U6(GP9)E3U=;CS+)<H#RX@S+&'&5XCT4-EEM4IR*P^\3D
M-1TNSEJ1/W^1[M'CV+QJRO)&##LLVTVI3*ZVMM^7M;+O>59(^9^NJU>8]%=V
M5%B(6G@LE'-ZN>2S3.S7E3)96UO>9:TFKJ4J]>U:?A3_ +Y2)]VA89VF=K\@
M":' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ,C>(!] _NO\ 9*[&_@]<> 7YJKYK
M];_4*G_=X=P">\ < < HP)])'8_[&M0_?'<G ^_^_P#]%Y\ < < < < < <
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MGK\=O:LT+,S+),0TQ/I[KTK1$?9HC].Y?V\[#_T#<@";+YX X X X X X X
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M& /E\0#Z!_=?[)78W\'KCP"_-5?-?K?ZA4_[O#N 3W@%&['^=GKS]:+_ /\
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MMJYV<8,/QV(I3X'*8&8A2),>/)EMLY>]!WV(]=:L>3/M]F/9RAER+TX X X
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GK&Q#&*3JQ5+74]A1<D:68+$MG+V$NQ7-L>8&H96.F[N . . ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img102364508_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[26>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )8*^E@(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              F0
M  -/          $                          0             #3P
M F0                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M F0     4F=H=&QO;F<   -/    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A04YH='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HY,T8P-#<P0S5%-S5%0C$Q.34Q
M-D9$034T1#5"-T$Y0CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HP03<X034S,C5&-S5%0C$Q.34Q-D9$
M034T1#5"-T$Y0CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#Y#14(S0S%!,C(P-C0Q0C1#1C=#,4,W1$,S
M0T)$13)$-3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z.3)&,#0W,$,U13<U14(Q,3DU,39&1$$U-$0U0C=!.4(\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#(M,C)4,34Z-#(Z,#(M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.CDS1C T-S!#-44W-45",3$Y-3$V1D1!-31$
M-4(W03E"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(Q+3 R+3(R5#$U.C0R.C R+3 W.C P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,#DW.$$U,S(U1C<U14(Q,3DU,39&1$$U-$0U0C=!.4(\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#(M,C)4,34Z-#(Z,C4M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C!!-SA!-3,R-48W-45",3$Y-3$V1D1!-31$
M-4(W03E"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(Q+3 R+3(R5#$U.C0R.C(U+3 W.C P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C Y
M-SA!-3,R-48W-45",3$Y-3$V1D1!-31$-4(W03E"/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.CDS
M1C T-S!#-44W-45",3$Y-3$V1D1!-31$-4(W03E"/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/D-%
M0C-#,4$R,C V-#%"-$-&-T,Q0S=$0S-#0D1%,D0U/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E
M/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP,BTR,E0Q-3HQ
M.#HT,RTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(Q+3 R+3(R5#$U.C0R.C(U+3 W.C P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP,BTR,E0Q
M-3HT,CHR-2TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B
M/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_P  1" #$ 0\# 1$  A$! Q$!_\0 '@ !  (#  ,! 0
M  <(!08) 0,*! +_Q !.$  !! ("  (&! 4/"0D    % P0&!P " 0@1$@D3
M%!46%Q@Y=[4A.%%9ER(E)C$W05=A=K?!Q]78X2,D)T=(@9:AT2DU<7B'D;&V
M\/_$ !L! 0 " P$!               %!@$#! <"_\0 ,Q$  @(" 0(% 08&
M @,       $" P01$@4A!A,Q0? B%%%A@:&Q<9'!T>'Q%3(C0E+_V@ , P$
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MY524X;DQ0Y^CQH[9-UDP))P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MM:;7+7%M)IZ3VM[:TT8VMN.UM)-K:VD_1M;VEV[-K3]GV>K Y@R, 8 P!@#
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M):BG[-M+U^X^7.$91C*<8RFVH1<DI2:[M13>Y-+UULR^?!]# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & 4)NWG_M NA_'Y*P[H<_^XFA_^F 7VP!@# &
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M*'$ $%N ]5CYIZ._5:H&NDF<KM=HC>D 3A[@H^2 )=UM$([)7K</GSY_G9I
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M4E%]UO3+;5*<ZJIV5NJR=<)3J;4G7.44Y5N2[-PDW%M=GK:-GS4;!@# & ,
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M=**U$<<D^O\ O)EV<BWJ+8F*%KLP/5&O1I]?XK!Y!!Q9:P4$)#!I%"%2S!S
MXTJ%U/V4PMM*0Q&)PZOXW64-*Q^<B19< 'C$#%01ONRY]OAI%4@76(@2Y2_4
M2#4O-%;(:S2R9]8#[BV5#DLGQ"(;O) ^N@[5DAFA$@,A4*A4<:..2%/Q+4.V
M!! XL4TV*-DA^Z;IO[&!'&GH[:+1EUC2=F0E0]A9LU>V,;BK$-4+=LRG!BV@
MEVR,Z-GG%5<W2LE)+$#;ER<=/VD<B39(L19 X^';I!]1($7=E?1WN+2=R+Y2
M3EQ6REOZ6& O*3O2RSPD8A%E3&,3 Y'1\;3C3L<:9,WP<HH 0V-PXL)<EW*2
M\I*1XB?CA<"<;%Z*5-8L3CT2<2&=1]",W=;5]#20W2NI$[^+[M,6&8G[%879
M5=SR)^Z'6UGRAB$>H1M"819FHUVCLK&O]'3YV!^,/T(J6+#@2$*E]HPXU%[/
MJ^VXW+!)>($#H:555UK"]2Q2:+:4P>0QAZ)/TD(<QZ3,BT<(J+$3Q<^#<@2V
M@5R' ][+H-1C"+LH@@ZG7(EA5#.FT-E#X_9W\(LK23M]%3=;@%KIL8YEB6B>
M[WA+5'D3XL]6FJ_^=\ 8&'^CHH>#&RY&.O9.Q"/[)CEJ"XDU!T^-91F2QN](
MYV(;M1TS#50,MP['GEC1EENL!GED3%@.CZRH".: V30/P+ E* =3(-5UFZVC
M!I=800F^6MK>6@/;8B1C<[0MNZ+/OYXSD:96&/CS%O#;+M^;E(6I#C\5>),'
M[<1*7<J8-=$M@+2X P!@# & , H1=OU@70_\ORP[H?=-#^']. 7WP!@%5K%C
MQR?WR*A25E63 P+.HWDIW0KV1-P*CXOK,FXG19_RY&$TU]-&:^^FO&J2>_&V
MNG/K/+QSKSCW_)?U^?D#EEZ1'JHLA8E!RF(^D]M'KYV$63E\3ZXPBU+#17C-
MG6@4;MT0C'];VK'@8U<$2 X&?>.HO*T22!02&T::NW+5H_OGA'.56#U;#O\
M#"Z[TRR5%_5,NN$GDX.'!ZM5=D$IQ?"$[*E&^F5<HVV)N"DXU/Q#BNS+Z?D4
M]<_XO.BK:L''L<71EWOZHJ=<VXONU"<G7/<6H>Z3YD33T.OI5IA9=AV7/;"Z
MH2&QII4\ !';AG7#.2)3F3LCL-U7BY05)( 8')%1K ,@R1DSB#<MB24;CS89
MJU>OE%&%OH\8>"J,3%PJ*_$<,/&ZEF9-?3<?*NI5%%M5ZC8KZ<BN^5'*V4UB
M_:WY<K+')2KBHSK]OA[Q-9DWY-MG1I9-V#CT3S;::YNVV%E>X.J=$J58XPBO
M.>.^3A!1U)\H_275-$\EH6'&J=M[>E\HB(\7$; >5Y9\;VCK">A!3%O)AK<6
MSCKQ2.:(D?6JM8Z_WT?BF*S5LX3XVUXYY\?S8..198L?(QJ;YSOQ89*F['C6
M3E*F3LGWN^C497)M624I)]ST7&ERIA&5M5MM48U7RIX\//A%*Q*$6U7]6WY;
MTX)J.DD2=38@S$;,MN#O9[/)V)#A*S+BW,_.(G23!P>UF>I))LX;L!R*39;W
M4SV]7JV\WF3\=U-_U/EY3>64P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@%"+M^L#Z'_9AW0^Z:(P"^^ , @#?\:9O^7Y /?YQ6'C_1@$:]
MQ>BG7_NW$V(BWHSM\91(9*4JHM$,[?CIK4\BDPQ-EQ*XJ[9/&K=<@*>M!1MB
MR,)$!FA80.?ZM4WC5NY2F^B>(>I] O=F#?)46V4RS,.6I8^;759S=-T6FU&R
M+G7*47&7"<H[<92BXOJG1\'J]2AEU*5E<;/L^1'M=C3G'CYE4O\ ZB]2BI)I
M2BI)*237(!/T*'92>J@NL]_]X)W8'0>LPP&35B)"JC0=W;6RQ)*OG2T@?D8B
M>U^&&GQ#-T0^KF:2#<8/=Q5FP'M5@"3E&[KQ[TK&C9U7IOAW%Q?$>5;;5E3G
M"4^G+"E7&$8U0C?6_,DJJ'/C34G/SW)RC:TJPO"G4+90P,WK%^1T:B%<\>,9
M*O->3&?)RLFJFO+^NU).R;TZUKZ$SKYT]Z'T%T;8VD/HEI,&S>WIRI/I9S+Y
M8^E:^I3E%5!JQ&N7VFBZ0UBFX<^J5?*$3;S=QLH7,DMTV^R-)Z[XBZEXAGA3
MZB\=RP<:.+2Z,>-*\M--N2BVN4M+:CQKC_Z0CM[LW2^CX?1XY,,/SDLJ]Y%O
MG6RM?-IK47+NHI-ZVY2[]Y,EB'_N_7;_ "/IK^L3(,E2=, 8 P!@# & , 8
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M;E+93G3GGGG7QP"H-V_6!=#_ ,GRP[H?=-#_ .& 7WP!@%9ST;CTE[/,6TC
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M5_80X]H,9^O5XL+A1;V9DB@CZY3C33A13R>??C33C;;GC7CP L1@# & , 8
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M[]=O\CZ:_K$P"=, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8!0B[?K NA_Y?EAW0^Z:(_QP"^^ , @#?\:9M]@#W^<5ACW_ )?U^?.PG_ -
M';R8UO-24><QIRT ,AJ3MO*%5=N&;MPI[+_F^O.R.J'&W.ZZJ.J>KG9?79MO
MONGY%-?)URQZEB5WQR(RNG-QECI+E%+>Y:WRTDD]N*BT^SVF<$<J]YUN-/%E
M#'KJC..6Y?1.3U].N*2[MI+DWN+;7?MO&<AWD%P_]WZ[?Y'TU_6)@$Z8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"A%V_6!=#_ +,.Z'W3
M1& 7WP!@$ ;_ (TS?[ 'O\XK# )ED(Y,P%(AU'ZPSWJU58:/6RO"3E'=QKSI
MKLAMSMKYM^>?P<I\;<<J:<[:>/'F\>-M%CJMKM4(V>7)3X23<6HO?U)>WX^S
MTS3D5QNILIE9*M6Q=?.,E&2<DU]+?O\ N0MK1W#]-1D1L"2% 6K%JT2'Z...
M.$7C-;1397G91=VT]7ISPKJDVY:>M1]=QQRXV]3KYY9]7\MJ=>#CU7.<Y.?%
M_5&::2TE&6_3<E))J/IJ3()=!\Q<+>HY5N.JH5JM3[1LK:?+;E*+6MI1<-K:
M?+:1,( U'W^KD2$*HD5(]RB,?::K[+N&RJ&G*.FKE3?CCE7?;U.^NRVO.^FZ
MJ:NOG\^F^NL5=5=#C;;5*M7\K(-QXQDI/DW%>R^KLNVDUI:)K'OQ[%*FBZ-K
MQM56)3Y2@XKBE-^K?9[?NT_<BV'_ +OMV?R/IK^L3_IFDZ2=, 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!0B[?K ^A_P!F'=#[IHC +[X
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M@;.&W#MFJJCRNAJLERJEY_.GPHGSMQQQOQXQQ+EF, 8 P!@# & , 8 P!@#
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6 8 P!@# & , 8 P!@# & , 8 P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img102364508_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2D(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *.R^$$=CA"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #W    $     $
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M--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M      3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F
M-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M    !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G
M)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M  4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %
M!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
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M^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M  "0           0 X0DE-)Q        H  0         !.$))30/U
M!( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %
MH    &       ! #4    ! "T    &       !.$))30/X      !P  #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@  #A"24T$"       $     $   )    "0
M X0DE-!!X       0     .$))300:      ,U    !@             "A@
M   OX          0                         !              +^
M "A@                     !                         !     !
M      ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M    !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M "A@    !29VAT;&]N9P   OX    &<VQI8V5S5FQ,<P    %/8FIC     0
M      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&
MQO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&
M]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M  !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M0H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M0    $.$))300,     !YS     0   *    "'   !X   _2   !Y7 !@  ?
M_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\
MX  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /
M;6  $     TRU(4" @
M                     18W!R=    5     S9&5S8P   80   !L=W1P=
M   ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48E
MA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M"&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M    !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;G
MD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U
M)'0B!)14,V,3DV-BTR+C$
M                           %A96B        #S40 !     1;,6%E:(
M                    !865H@        ;Z(  #CU   #D%A96B
M!BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14
M,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=R
MYI96,N8V@
M          9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B
M!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2
M!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=V
MEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M            !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M%865H@      !,"58 4    %<?YVUE87,          0
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M#89-CHV6S9\=IVVOO;@-P%W(K=$-V6T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5V%QE\'6(R0G-D=(@914=I&AL=2&EO'_Q  < 0$!  ,! 0$!
M!P4&" 0! P+_Q !.$0$   ,#! L+" D"!P       0(#! 41!S5T\ 82(3$T
M05%S=;*T%U)A<9&3E*&SQ-03%195@;'!T10B4W*2PM/A\4+2(S)#5&2$I/_:
M  P# 0 "$0,1 #\ [^'/8RY*=MCM.^ IR4[/6J)PO;PQ"XL0MB^)I2LM0@1L
M YK"N[WZ4+C4-7<"$QRT)%U37]J5R8:F5QDO(9.1C*6Y/9:68A)MA>$=LC2<
M(22MI&OYVDV_8F4K,#G!P+?&5AVR)MZ,ZNGD.YJ06GK'K:%MU1T<6?;L3*<
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MGC;?BA:?XWVUUYUUYV^;T=^%SKKSOOSKQSSY>>->=]^>./L<[[<\>7D)ZP&
MP*1OC4?K%=6O8J5^_*N= Y&LVWSTC0PW>+]%Y-=_PI!E)X==NB5?;*L.6=-C
M 8%WKQ6#U:NS?MR@O<&*_?\ '_CQSSEDSQ='1M3M518\F^:[?I_N]%:6R.J*
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# \%/N:GY&WZO.!!75CU8NN/L&J#]GP]
M@3Q@,!@4C?&HO6*ZM>Q4J]^5<Z!R-9MOC#?^<*'9>7#DP\?W2#*3PZ[=$J^V
M58<LZ;& P+O/BL'JU=F_;G!^X$7_ .G[\?CSGG+)GBZ.C:G:JBQY-\UV_3_=
MZ*TOD=44P& P& P& P& P& P& P& P& P& P&!X*?<U/R-OU><""NK'JQ=<?
M8-4'[/A[ GC 8# I&^-1>L5U:]BI5_;_ +\J_OS_ -,Z!R-9MOGI"AXN"PUX
MN-(,I/#KMT2K[95ARSIL8# N]>*P>K5V;]N4%[@Q7[_B_P .>><LF>+HZ-J=
MJJ+'DWS7;]/]WHK2V1U13 8# 8# 8# 8# 8# 8# 8# 8# CRS+5 Z?'FY-8$
MVI$1S^9C1N&:L(>=)B(D))C976+&Q01%8R;*RPA?:-W3AO!C<+*2F[)D_?\
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M\^_YM[2;._:$390+JW;NLO'_ ,./JGF^Y,KYSG;.=_EE>&9!C# 8&^_6_P#
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MIBU<<:2C7C35M):<*I;\:R#?5-/5!YKY'"/&FG":FO&NOD#]ZGW-3\C;]7G
M@KJQZL77'V#U!]K[7X/A[[6!/& P&!2.\:B]8KJU[%2KWY5SH'(UFV^>D*/9
M8;NOYI!E)X==NB5?;*L&6=-C 8%WKQ6#U:NS?MR@O<&*SGG+)GBZ.C:G:JBQ
MY-\UV_3_ '>BM+9'5%,!@,!@,!@,#DT\^_YM[2;._:$390+JS?9>;CUYDROG
M.ELYW^25X9D&,,!@;[]</L4V*?G9=[[$>3BV<+M//U>O,J=W< L>C4>I!..>
M9[3 8# 8# 8# \%/N:GY&WZO.!!/5CU8>N/L&J#]GP]@3S@,!@4C?&H_6*ZM
M>Q4K]^5<Z!R-9MOGI&AV3BAQI!E)X==NB5?;*L.6=-C 8%WKQ6#U:NS?MR@O
M<&*SGG+)GBZ.C:G:JBQY-\UV_3_=Z*TMD=44P& P& P& P.3;S[_ )M[2;._
MK_XA$W[_ -7VLW^Z<W67]R/7G3&^,YVSGO%_IEU\.^]>9%C3 8&^_6_\#8I^
M=EWOL1Y.+9PNT\_5Z\53NW-]BT:CU)4XYYGM,!@,!@,#YZDM%(R;:%5DX]*8
M>-7#YG$J/&VDF[9,U$4G;QLPV4X=+M6JKANFX<));HH*+HZ*[Z[*Z<; :2\4
M_2178R<>]0<N73)NLT>MG*2[QCNY3>M$5$5=]%7+-1F[T=(:<[*M]VKG5;33
M9!7C4/VJ?<U/R-OU><""NK'JQ=<?M?@&J#[7VOP?#WVOZL">,!@,"D=XU%ZQ
M75KV+%7ORMG0.1K-M\=(4>RPW_#Y-[>2#*3PZ[=$J^V58,LZ;& P+O7BL'JU
M=F_;G!>X,7G/.63/%T=&U.U5%CR;YKM^G^[T5I;(ZHI@,!@,!@,!@<FWGW_-
MO:19W[0B;_XS?[IS=9?W(^TF_P IC?&<[9ST>K+_ )>O,BQI@,#??K?^!L4_
M.R[WV(\G%LX7:>?J]>94[MS?8M&H]25..>9[3 8# 8# Y)6YUMLDK[>3!1I4
MCX@5*;HZV6 "=DVDB#LM*5IJKPU2!M^K=95V2L[0BY$P<;'D>P@A,;D(*:XO
M5U+K/TM8<L6B0@EKT][8]4Y7T[K"R>'+$1(4X0!8SL94#=C)R+B@ 0/6.GXW
MK/"\,)!!8_JRI:L.2".YWMB%4CKM/1F!0BK:X58!VN/H<WG1_9A7YG&@<_L[
M;J<3TJ(Z&S7AEIPIPZ9_$BDZ.Z\J.?A)\Z._C'CEOYOG_0*^<_DAK4"T1V4K
MP(#@"![0":D&#BH\'PRDCUW8N)#>)&8AG"QV[YPC:39)=YLS9([.5DFS=-5?
MG??1!+7;A/4,J^;CM3])T'_1R:_6S@/FX[4_2=!_T<FOULX#YN.U/TG0?]')
MK];.!S,[U^!:=^$,+P<WOCMA/,)FOQM\*P6E?TZ-C[%2,D)3:67V?MY0M(55
MW7#K;;A-5)PW3U2\FO*.VW\OG;MC>S2]MB]"TV>[J=CGDM5:6O4C:J52K-">
M23Y.$)(R5J4(0VN_#",<<=UKU];&;NOZK0JVZ:T0FL].:G)"A4DDA&6::,T=
MM":E4QCC'?Y(0AX]%?XJ?2?'_-];O]W@/_;_ .-S9.Z[LH_873Z+7^+87N=W
M!WUO\_1^&/XJ?27TOK=_N\!__NX[KNRC]A=/HM?XL[G=P=];_/T?AC^*GTGQ
M_P W]N_9^Q^#P'_^[CNN;*/V%T^BU_BR&3RX(?Z[?Y^C\-]^XZ;]%?!8F7@]
M LV!*'[5N'\*?%#4MG%+!I*!('J<HSB4(9+5@M%FX\FW:\M&^G*B:J+A397R
M[\*ZZ_R,T_9)LFO#91:;/:KQDLTE6S49J%.%FIU*<D9)IXU(QFEGJU<9MM&.
M[",-S<PW\=CN:X[%<5"K9[#&M&G6J_+3_+SRSS;?:2R?JQEDIPA#:RPW,(QQ
MX^)O-\W':GZ3H/\ HY-?K9S768/FX[4_2=!_T<FOULX#YN.U/TG0?]')K];.
M ^;CM3])T'_1R:_6S@/FX[4_2=!_T<FOULX#YN.U/TG0?]')K];. ^;CM3])
MT'_1R:_6S@/FX[4_2=!_T<6WULX$"J]++I6=R;W?M)%<+2TS-SKKC6A(KC3A
M[/R[V:?<):\V+SSHAP\?K\()[;;[)H\)Z;**;:\[\Y:A?-LL]&G1IPH[2G+M
M9=M)&,<,8QW8PFAR\C"VBX;#::]2T5(UX3U9MM-M9Y82XX0AN0FDFC"&YO8X
M>!X_P*KH^E)%_P!PD5]8N?K\_P!OY*'FXX=?'UOQ^C5W=]:/XZ?]+=/X%5T?
M2DB_[A(KZQ<?/]OY*'FX_P"\^C5W<MH_CI_TC^!5='TI(O\ N$BOK%Q\_P!O
MY*'FX_[SZ-7=WUH_CI_TDJAU&=E08=8"\+V?$MXR.4D%6^S_ *[LG#KG:2DW
MDJXX452M)OIMQPZ?+<)>1'7G5+A/3;G?;7G?;#U*DU6I/4FPVU2::>;"&$,9
MHXQP@S=&E+0I4Z,F.UI22R2XX8X2PA"&.$(0QPA#B9/\W':GZ3H/^CDU^MG/
MX?J?-QVI^DZ#_HY-?K9P'S<=J?I.@_Z.37ZV<#/0@3NF'^,_EW<(Z;>D^A?%
M7Q75" =\6>9]+].\_P# -I_XQ]-\ZS\UY?1/0_1%/)Y_TKGS(3'@,!@,!@,!
M@,#7GM!8-K5A4[PMIT)5.2EJ2AS&29MA2:L)] !LH1Q[$Q,HZM1D@%">R'HK
M K/)9$*&B.)G9CA#?F-5=N&^L:]#6@)\("'<U]-S9.N]/YP-$6Q<4R8E5Q?2
MO"?,G>T_1_ A(U'<I&[LFOSL0G8CT<U'#!YRHV70<.V2^R3MHRT#(&_>M29C
M0N8%.OME$45<UHSE3]>I#4GJR+;VQ/"\1:9*0RKE*1-4I  'FPE39R6Q[PI8
M)/Y*%;Q+3B,;%,LF-(AA$KX3 >BB2PA_7K7V1G5*Z9%+"7Y#@V.-G6U@@PHS
M*3$&VT%)>7AVZ<-NO("Z99M/*P,H5CTRQCE%XQT+3!.'M2\)0(OW()'15;/7
M:]@A,^1#\_S9E5ZUY-E</-68._-B%'WRIX@#ZPV,G6,BL7!4 O\ +(+C)P?Y
MFAO295E82)#^]=^[Y+.4Z"2UZ"[I.UB&0ZXLI] 4A86%&&3KMC(KKUNG%,N+
M -5]X88B7,=I.O74\M+/$=?2]8U&15<Q30<?@Y6VG5:S2"Z^K_6^Y2Q",:E5
MMT+3]FDS:%07:PS<@/:]'2J90B6KIT^<MHQ*1E7*;!!P]=KHM=4DU73A3797
M<)ZP& P& P(![/VW-T;2Q'9@]&Q<M*0D_7$6FQF>'?,;LT,;-#PJ4<N/07+1
MQKLPBB)Z_;[ZN-$DW39'=SPHVU52W#7,S[L% 9=-DT]'4S,6G.1EK#M95Q$A
M,V*#CU^LYZO\]CR.1,YL_*H2%9-V;&/EHN.^*$UWJBCB%25C%$UG<DB-=?*Q
M!KX46J7LFSTTKBPXV FQ.FS /E"AV%B<X>PET,JAD8:> @R>)F<\:B XG<T!
M$%Y4+:3#. *X(L@'S=+B*;OWX2U&=VH<KMJ5IFO:E/S8O%2*PF1SRA)@L!&"
MPG7!G"@<J8^F$91&\36DK.3.RD&/Q>BLLO&0LXZD=8QQI#LYH(J?^$JAFE;5
M'9K;KW;S^([$,6Y;0,>T>@KZ6L.L50[D\4.WS&()95T&<_)]Q >CC<^WTEU9
M,R%V3GT)),Q>!X?K=^$H$T7=E,T*,N71\!"@H6QXM-L($:LTKA"@CJL;5+6%
M4RTND>-ZO$W%M1$B=6AK#/A@-BQLPW(MX^080T=/ACM=]\#*Q>P";5N+PK/K
MHH$=>&4-,#LP"6#($UF=C2HFAH5]H>BMF/(5$4&DA219^B0PQ-*R"[64=/IF
M.=[Q4)L&PM$]FWEWWG:X9&Q.D6"A56UZ20WI[;A,E5*I"^NVM,&G+]RVDGD>
MK"*J=?8:0'4$6Z#Q!*0>JR"JBCI-I'AN-@,!@,!@,!@,!@,!@:MW&:]0#Y(N
MJNY;2IA5Y6B+.P3,8F+:'A8MK%"&^*UF1Q+*L"B&+*]TCM">&\V3[.H3S#8D
MCTN7VK>;1T=!KE/C/@H>0*JC0C+>IC:M6;LHA:P-)"YP]@(E4K'&29D8M-2O
M<V0C+-FXNQF7!E/[S\B3RL:?:."E]NW)E7,@H'Z#9AX+ <ESR(.K'ZOA\]H<
MZ$!;&2U_C@;, EC+3!I)KRL&S^<")>U$83$ZA8[R9=!R8C+D,EP=*S&[]?<A
MYV")Y>T_!8P/8.?I"6W 1(U7G16FIB5TL>+$P]:QIFCFIN,Q'$0PLN-F6IQS
M2HY!L8^Z/D4T:[[H0%:QUHKF>B FB?(QPP\,<$LC;OP5[TL#H$:MSJY-ET3/
MMQP8%6O8L:(9"7/"@C)I2/WD1-2Q'^IM:$V8&A7*19 11<Z?.RDAE)!A)[3#
MM1;D^LIGHOP;38IW."(OZTQY'UG;UX'RTC(VX+1J-/*5_/2,/5\<9QRA>WB1
MR=%9]6;'@]V7,DIZ/<O)T<C7.FC^48+C\4L4[V ZE<S0+UII&T:J>.(2DP N
MJT*"2V"EHJ2IA;4G$PQW7[MA)/&I1"Q;&N)A!;B"=2>\3%,6#Z1V1:2#)=P&
MT^ P& P&!BYN)AYV'DP98$%"$P.3PDC"E@^2-&K^ EX!^U40DV,NT>Z[-5F*
M[7=35QJOQ\#73R[^77G7C;@-(A,P\&?58E!G(]<?5N#$XVQ"::C+(EKZ"Y5%
M]:<E7S03)WDE8Y*<R+PE,]:NG(F!=ZS<_*2L<$.X%DEHUA4H?1(/SS5<>#1A
M">7JDEE>NL>5,:NVA'M5D=MPZ<D+UA!5Q$;+R\57DN9_""FT=503#/WQU!0L
M-+IAPVWEWL_S&L-G>@?&#XCP6;F3 1L"/NL+XDC)4U, =F*7N//S&=>*3KN<
MLIZHYB3U<F/HMX45C(S=@1LXX((61(P*1E29DXEAMVX9A M*V]X(J[@MQP.2
MU35Z/,X(0ON";%-O#H*[%0HR=&X@(F0%)#EK.E:>@Y+5T70,I7L)* 4P+-2[
M<=/@0<6,4XJ2#8P=2\&=8SXZDPNU>OA=(-0-X5E[T*[',))R#US $(?.39C&
MK#=C[[U8-(%(8"RI67#&PNT?3@Z./".3<OF#'?0/<]V\&/H$P(@XL+JU'!]O
M*A4&'ZM;I#H94_E:I.WFX7R%$3$T9S,V6"5F2S_T>9&954G3.)-WP\?JSKQ;
MA0):ZL..H,RR+)/JFI6BR(?(2M)&"0 _9.'(ZK5UF6ESR)3$>V>.%XMDQ/"6
MS)P?])0;H2[4C=3<2H[AY!BOR&VF P& P& P& P& P&!RS+_  9T>6SUW*.;
M21W$[=*SXWC&,P-'<\4 D[9TW!$)BRBG3NZ4JO7'GDG&2.C9!M3D02:14DTB
MGA2^1B-5'P0[VX\'_=,ZO=;SKH2)OB+M9#=D*\L%X2P@E\D@,%[#C=)#<JAM
MO*E\:1,%8]>KUIQ4H$(8MD9%NZ>0[X"<ON!XCA0V9M#H;)F==RH"(W,Z"FY-
M?%[W29Z[#Q=Q"&:%X[G6ZHP41M=VQ5<T0<!.Y@R7@%9TIDQ>2<C<<J1 \IPE
M&:PP>L0Z#OJ\5$)8,N!%,E"[\JZ\HQX25YM,PCK>O^CT3T:E1B2AHXX'WZR1
M&%M98V92[4@9*P!0_CVR["?BHMRC+A\6(\&R.0X/"!J%FN]E(2CZ;I9*:U#&
M"+M5"H;^6OQ CX3TG.>47,[++?%*S#5QOHPWTXF='CIS_JW ?'KSP9L2"3D2
MX5LUL0P@A8<.9@Z\N,GDL>1L'%=AQOL)\C)DA)[J)0I=@XEQF/A5Y ,K !</
ME6S(EF$968;+<.PGJD.I4E15LSM@C=D,9(=,8P^C2X1DP7?1ZIH2=D.P_8T5
MV%B-B8MFP_J,2?8LC%)9&1&R1,EB8"%>,>!5UN[3W&[K'^W)^7A;HX# 8# 8
M& VO7D3;M7615$^\DXZ"LX"+Z^F9"%<\,YAC%&8_(#D@\BG>VBFK:2;-))99
MBOLFIJDYT2WV3WUUYUY#0VO/!WZC#F-ERRR80C(F(K8PF\FH@).F[DA;GM70
M=6HRT\XLV\+@E-Y.#B8=11NVAY6&']F;SF&80<2U0V6<#77%K%->#ENN?L1W
M3[4OXBNL>K2U".1-IL?$G9-*'=J=&Y7J"]D(%:--G93*I,5BI\3)#9>.#[&#
M:0KB(8&T_&.AJ.'@W&/NC<N<7A6-F[7*Z9 ]7OJEE1^LEQ\L=,H:0JQ@11VZ
M0FDPM2%KB!8F",ZDK.O9&IR0Q24CTF3,O3@^&4/&AAL7X.AQ"UM7E2,;D;+!
M0EUXZ14.1ZR5:>ESA*KT>LQ6Q@TLC'Z1XUCAY,WVD)>%*AU]#$^C=!6->14P
M@HQ=H2@UUU@^G8_@Y!RPP\O%=[/FQ]4GENU9 C,PL#JR?1\UV7O4!OILLLJP
MGV#Q\P!R.NH.)>,DW[!4SA]ETEWD#OYKE,,<1\&C&O(FU$YVR(=$@MFH[&JZ
M?EQ@(,/,:N["(Z_(')HLM9URVN92TZR^;V)9JZ29PND^UX:JH[QFD<W;;!N]
M2=6SU2,#N ?%T64#1!:EI64)-FXHY@)H;2MNQRVTR*!GI?<IFV17Z 3F4HVA
8)1C!B7+>#09,WS"0?:+22P37@,!@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img102364508_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    & "^840X0DE-! 0       \< 5H  QLE1QP"   "W_4 .$))300E
M   0%[!F+$S2BZ/ZL]P\'L9W<CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              P<   =D          $
M                 0             '9    P<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   P<     4F=H=&QO;F<   =D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ,'     %)G:'1L;VYG   '9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$%       !     0X0DE-! P     #:@    !    H    $(   '@
M  ![P   #8P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_
MVP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4
M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M1GOO:^(_L#<O0TDD/"?6#%ZI9T#%KR*,O(ZN"?LS\1MA<RD[9;U"VJ66<?\
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M\*1_Z+P+NG=5Y;A];&GT2'D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_XO__24-#7U!23T9)3$4
M 0F^S/[^'@ (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C
M<W!!4%!,     $%$0D4                    !  #VU@ !     -,M041"
M10
M    "F1E<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C
M  &P  "B!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R
M03$  WYT  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,
M&E4N4RX@5V5B($-O871E9" H4U=/4"D@=C(
M
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M:D)K4FQ>;6=N<6]Z<(-QC'*4<YQTHW6J=K%WMWB]><-ZR'O-?,Y]S7[,?\N
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M*^HLURW$+K$OGC",,7DR9S-5-$0U,C8B-Q$X 3CQ.>(ZTSO$/+4]ICZ8/XI
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MH)AZ4$_YG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ
MX';[HQ. 8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*
MJ?Z)C8B]I>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"
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MIQNS>X5#HPVNYW+(GTBJY%^[F]:GJ4OAF,6EXS:PEB.BZQW,E4^4)@ SCX^
M(J>YJQ7"7I:FIL2\JX36HK:W<7)BGO:R^E]CFX:ONDN<F'6M'S9[E=VDUAVG
ME0F4#0 \CR" *)^PNH1Y=([5M:MY.GW1L/QY,FQDK(MY9UHXJ&1YU$;OI*YZ
M:C'KH>9[!Q?PHG)[O@  D2B  )ZFN;:!I(Y"M,* O7UBL 6 #6OSJXQ_GEFX
MIV1_<D9LHZY_@S%LH-Y_P1>PH3N N@  D&Z  )WWN,N)U8V:L]Z(27S/KQJ&
M[FM5JJ.%[5D>IGJ%-$7AHL:$S##ZG^R$Q!>!H!R&!   C\N  )UHM_.2$(SX
MLP^/YWP:KE*-^VJJJ<Z,8UA]I:N++459H?:*5S"5GQ.*+!=<GQR*L   CSZ
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ML'2X@WH.JZ&SMFBLIQNOXU:RHN^MH$/?GSBJIR^1G"^@*1<?F[:/H@  C8Z
M )'SQ6-Y&((?O])XRW(6NGQXN6&CM6EXZE!QL*=Y4SX+K'-YY"FFJ99Z:@]F
MJUE["P  C4.  )$WQ(N YH&VOO-_^''"N9!_2F%*M&U^XE -KYY^Q#VMJU]^
MY2E=J&9_,@^%J<. 1   C/Z  )#-PY*(J(%'O@B')W%>N)Z%W&#;LW6$\T^A
MKI^$63U2JEJ$&2DCITJ$3@^OJ$^$[@  C,&  )"!PJF0:X#HO2..7W#IM[R,
ME6!KLH:+)D\ZK;**)3T J6J)DRCVIDB)XP_:IP2) @  C(R  ) LP>B83X"4
MO%N5M7"2MO"3=& +L;N1E4[HK-:0)CS#J)*/:2C7I6.0&Q $I>&*U   C%Z
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MREEX@V:NQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F
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MQ:2;&F8HOXZ8D%:#N:^6F48XM"^52S3CKUV52B&2K!B40 HTJQN&Y@  BFB
M (/^RRRESW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6VPJ1
MJA^')0  BG6  (/<RIJMIG5%Q%2I=F9*OBBF 5;"N#VCCD:$LL*BH34]K?B@
MZ2(*JH*7! KGJ4^'7P  BH"  (.^RA*UQ75%P\6PZF9DO9.L\E;RMZ.J9D;"
MLB6HWS6(K5:D,B)EJ=N700M'J+"'H   BHB  /*&>T9YBMKW>YQYI<+]>_9Y
MT:I]?%AZ')%P?,-ZBG>[?3M[%ESV?<-[JC_6?GA\7!L6?]%]#_!<>9"$[]DZ
M>@>#Z,%Q>H"#!*D5>OZ"3I =>X6!R'9Y?!>!9%NZ?+*!"CZ7?6> U!EU?E^
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MF.Z?T8JIECB<OG?@D[R9Y61CD7V75T__CXJ5/3HXC?Z4$B"IC;>2X #6BF.
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MI>=\FX(DHG!\<W!VGS1\<%W:G#E\ETHBF9M\WC2_EZU]+1K0F#5]F   C&R
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MH@6E9WYWGHJB!FS(FT:>\UINF$Z<6T<JE;*:DS)BDYV:$!E0DZ*1'0  B'R
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MKL.#-'6PJI."963\IJF!V%-OHP>!?T"]G^"!6RPOG;2!9Q(_GS^""0  B"&
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MJVRJ>',FIRRFXV)XHQ^CR5$=GVVAC3[.G#V@NBK:F<J<^1('FEV,,0  AAF
M )'[KWJW;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&
MF>:,,   A>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V
M1B12J"MVMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/
MK&YZ[CA?J-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!
M+EJ6KX^ M4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!
MM_6)&VGGLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F
M (<^O J28'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*
MH[F'H@  A/&  (;?NV*:4WA0MF>7UFDUL8B5G%EUK-^3O4CYJ(R253==I-.1
MQB/#HFN1Z MTHI2'OP  A,*  (:'NMZB7W@)M=J?9&CUL.^<KEDYK#Z::TC"
MI^R8VS<YI"R8JB.ZH9B6HPN<H92'V0  A)J  (9-NF*JE7?5M5JG'FC&L&NC
M]ED/J[.A94B:IUZ?Y3<4HZ:?"B.JH/R8'0O H+2'\@  A'N  (8-NA&S/G?
MM/BO.6BWK_.K@UCUJR.HJ$B(IKVG.3<3HOVD#R/"H&"8+0OQH!V($P  A&&
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MP7".@%[^O 2,Z% "ML*+I4!/L=^*SR]0K=R*K!O?J]"+, 6!J22#N0  @QZ
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MD^R1HX/+D="/XG'VC]R.,U]&CA:,LTM^C*6+?38JBXR*KAR/B]"*XP  A3"
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MV2]BE =^Z!54E7A_"   A 2  )A*H66(2HD-GF.'1'D8FX:&4VA.F-F%A%:
MEG.$XT.3E&2$:B[>DO^$*Q4'E#Z$@   @RB  )=^H'R0W8A#G7R/0GA'FJ&-
MO6=TE_>,6%71E8&+&D+\DWN*-2YLD@R)T13*DQN)0   @FR  );7G["9JX>7
MG+F7>G>7F=^55V;)ER^34U4OE+>1C4)[DIN00"X,D2>0#A22DA2-1@  @<Z
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MJGIVCF\ INUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6
M (NZK0U^77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_
MG39^.P  @2&  (LPJ^J&9WS/J#J%=VW#I*N$HEWKH4V#^4T1GD.#@3L F[2#
M-B;@FC6#+0T_F[6#$0  @).  (J;JOF.@WPTITV-#6T>H\&+M%U!H&**@4R)
MG4R)B3J-FL&([":4F3&(_PT_FER'/0  @!J  (H0JD&6Q'NNII:4S6R8HP62
M[%RZGZ&1.4P)G(6/T3HRF=V.]"9;F#^/6PU"F2>(]P  @ "  (FHJ9Z?('M
MI?B<JVPFHF2:1EQ(GOV8&$NAF]Z67#GCF2Z5AB8VEUZ4W U*F!&(_   @ "
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MLY]\G6-%KV=\7E0SJVA\5$0JI\)\:S*VI-5\EAZYH[5\H09RHS9]HP  @ "
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MKXZA4&&0JSV>S5*&IQN<J4*LHUR;<#&<H$J:XAYFGGR4C0=YG':%#@  @ "
M 'TVLYNL1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@
MF\6%*   @ "  '*OQ4ALWF6EP*QMM%@=O#ENGTG3M^QOE3IUM %P@2E3L31Q
M+126L>EPN   JRET>P  @ "  '*BQ'=T<&7#O[%TBU@ZNP1TU4GQMH9U0#J6
MLG9UORF-KW]V(145K\1UNP /J>EXYP  @ "  '*CPSI[N&6JOG)[15@FN;5Z
M_4G6M21Z]SJ(L0-[$BF>K?)[.!5NK=Y[! "CI]-]+@  @ "  '*5P>V"VF6
MO2:!^%?GN&J!0DFHL]* S#IFKZV EBF<K(J D!6OK#" S $AI?B Q   @ "
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MN5"EHE>[M$.C*$EKKW>A:SI%JRF@42G0I\J<11:HIH^/4@*ZG_.!V   @ "
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M@KZINH3X@>>F)G+A@2:BC& 2@)>?5DQ3@#F<V3<W?]^;M1WX?Z>41   @ "
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MCPN#LWSVC7Z#-6P)C!""N%GZBM:"6$;.B=.""3'EB3"!S1@1BA*!V0  @ "
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MBWNN\7E6B=RK.6A.B%*GD%:1AP:DE$/5A@2B]B^&A3B?'19KA4B/*   @ "
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MEUF)N7"TE1V(QV"TDP>'WD_6D1R'##V;CZ"&>BEWCL&&/@^MD!:%>P  @ "
M (U5F,:31W\7EGB1RW !E#R00& *DA^.ND\SD#.-8#TECI^,:BDBC;:,70^+
MCL")D0  @ "  (S&F!B;]WZ:E<^9^&^"DXF7U%]ZD6"5N4Z>CW63\3REC>*2
MS2C/C-B2Q0]IC9V*:P  @ "  (Q5EYFDOWXBE5*B0V\ DP.?DU[VD,V<\4X=
MCMR:U#PFC4^9W"AKC#B8&@]+C*R*5P  @ "  (P!ESVMQ'W#E/2JW&Z1DIJG
MJ%Z"D%:DD4VTCENB43O/C,:@]2@?BZ^;(0\<B_F*-P  @ "  (.)J1-H-W8\
MI?9IX&@5HQYK>%CBH'AL_DB+G@YN<C:RG#5OMR)>F^-P6@A8G:]P(   @ "
M (,2I_)P9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B
MFW1U,0  @ "  (*6II9X:'4_HXAXHF<BH)-XY5?OG=)Y/4>PFU1YH#8 F6=Y
M_B'KF,QZ%0B=F6=ZIP  @ "  (( I4* 4'20HCJ  &9?GTY_ME=.G(Q_@D<<
MFAA_:36+F"E_7R&AEW5_6 BNEXM_DP  @ "  (%DI"6(1W/PH22'>&6UGCR&
MK5:?FWF%\4:6F/J%7#4;EP^% B%:ED*%% B\E=^#T0  @ "  (#8HTN07W-H
MH$Z/&64NG6&-RU85FIB,CT83F!*+B#3(E@>*\2$KE22+8@C,E&"%\P  @ "
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MKRAP'5Q7JZ9P^4WYJ%1QW3YPI5YRO"TZHTES:ACCHZ=S1@'^H#=U80  @ "
M '8,L7QVZ&E@K=AW&UP"JD=W8$V@INMWPSXHH^QX+2T0H<=XA!CNH>EX5 )>
MG?EZ6   @ "  '6LL!U^76CIK'U^%EMWJ/-]W4TTI91]PSW'HIE]QBS0H&I]
MT1CGH%I]O *LF_I^KP  @ "  '5$KO2%X6A_JUB%+EL%I\^$ATRWI&V#\SUR
MH62#CRR0GS*#:QC9GO>#OP+MFCN!^P  @ "  '3DKA.-BF@HJG6,<EJOIN.+
M6$Q?HWF*6#T>H&B)FBQ?GAB):!C2G;:)@P,CF+:"'P  @ "  '24K665/6?F
MJ<&3REINIB.20TP8HJV0WCS4GYJ/[BPPG3N0!QC:G)6.60-6EVJ"0@  @ "
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MN-IU@%#5M,]UN$,FL.UV&311K9!V?".1JXAVK@\<K,AV)@  G(E\(@  @ "
M &FHNW)\:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V
MFVA_H0  @ "  &EZNC&#?UTUMB."VE!6LA6"2T*TKBN!US04JK>!FB.4J(6!
MG@^IJ3"!K@  FFR     @ "  &E.N3R*NUT>M1R)R5!$L0"(W$*>K0V($#/\
MJ9&'DB.=ISJ'P _FIZN&N   F9"     @ "  &DIN'^1_ET4M$>0R% _L!B/
M@D*4K!N.;#/QJ)N-X2.GIC*.11 BIEF*Z0  F-^     @ "  &D-M_.965T7
MLYZ7YE!$KUF654*2JTV5"#/DI\>4MB.<I5Z3S! _I5F*_   F$B     @ "
M &CZMX^@ZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#
ME[*     @ "  ,U0;&UF1+GG;C!H=:73;]AJD)#@<6-LE'L.<M]NC615=$]P
M?4QL=:1R4#&M=JESU@W'>#%SMLM<:>YQ5+A8:^=R9Z1M;;9S=X^?;V=TAGGC
M<09UEV,^<I9VI4MA<_IWFS"Q=-QX50SF=G1WY<F(9\E\8+:1:=Q\7*+A:\M\
M7XXF;9E\?7B1;U9\JF(2</]\WDI9<F]]!"_&<RM]! PA=.Y\@\>[9>*'4+3"
M: J&4*$;:@N%8(R::_*$AW<J;<V#TV#;;XR#+TE4<06"C2[I<9F!ZPMV<YN
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M=0.4>(C1=9&2EG:D=B.0J6.A=L&.UD^2=V.--SH9=]^+^2"_=YB+M@#]?E6
MJZEP<WB@+YDE=!>=OH?J=*.;%G7!=36896+,==J5XD[;=H"3L3F*=NN2*"!1
M=G.0S #??H> EZC*<L&J.9AS<V*G%H<K<^BCK'3_='*@.6(.=1B=$TXK=<>:
M>#C]=BR9$!_O=7J4] #'?K" AJA<<D2T6)?P<N*PBH:/<UNL8G1:<]>H.&%S
M=':D@4VE=2*AL#A\=8.?AA]W=*B51@"T?M& >:)_A<5D&9.@A19FB8.7A)QH
MPG(_A$=JT5^XA MLRDOQ@_)NK#:!A"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G
M@T5O"8* @NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !Z
MN:"+@=EVU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW
M@9IZ+   @ !^.I]F@!F )9 S?]V (H 7?Z>  V\3?WE_WES;?V1_PDF ?V9_
MK31X?WY_E!K*?^%_5P  @ "  )X[?K")?8\D?GV(SW\'?E"'_VWD?BN''5O6
M?AZ&2DB1?C*%F3.R?D*%#1HY?EF%#   @ "  )U$?9"2[HXD?661E7X*?3J0
M#VSR?1F.=UKU?0Z,^$?7?1F+L3,<?22*W1G'?/N*9@  @ "  )Q]?*J<9XU9
M?(:::7T]?%>8+FPF?#25Y%HT?"Z3R4<T?#B2"C*E?"N1)AEQ>\>.V0  @ "
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MBDUV#G88B4AVQ&74B&1W<%1]AY]X&D'7AQ-XN2U)ANYY'Q,#B']XF@  @ "
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MA-F?EG'I@^&=&V',@O2:BU#5@C>86CZY@;*6]"KP@3J61A&R@1&+]P  @ "
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MD?Q\3&G,D%U\<UJFCMI\ETI+C8Q\P#B1C)1\Y22<C%A\Y@L!C+Q]#   @ "
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MC<ZD6V;+C!>AQU>1BF>?+T>$B/>=4C8\A^6<<"+NASF7G@J5AD:'*   @ "
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MFG*!N5X>F#6!=D_(EA.!+4!HE#2 ^"]DDN^ W!NUDO6 V 2.C_V G0  @ "
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MJEUCDE4ZI[=E@T=II3MG5SA-HQUH]R<VHA=J&Q(JI']IIP  F--N8@  @ "
M &V#K!!I/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@
MERUS:0  @ "  &T7JH%PLV$YIY-Q<U28I+1R-T;>H@-S 3?MG[ESNB<;GG)T
M+A*2H!-SF   E:!X,   @ "  &RAJ.IX"&"OI@-X4U/]HRQXG$9JH'IX[S>)
MGC-Y02;=G-QY;!*7GC)X]0  E#!\8P  @ "  &PHIY!_;& XI*]_4%.!H=E_
M*T7CGR9_!#<QG-!^]":=FW!^\A*2G(9^XP  DNB     @ "  &N]IH>&\E_9
MHZ6&=U,EH,>%Y$6%G@N%4#;8FZN$Y29OFBB$U1*2FP.$N   D<:     @ "
M &MDI;>.?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0
MD-N     @ "  &LDI0^6$%]4HB:4]5*<GS.3GT3SG%^2639 F?21LR7IF&&1
MO!*"F*V,@P  D">     @ "  &KPI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8S
MF1>8SR7\EVJ6YQ*JEZF,G@ +CXJ "   @ "  &&SN'Q@B57TM7QB4DFALI!D
M&#QAK\-EPRV[K8QG)1R2K41GN A<KJ1G:P  DUARV   @ "  &$PMY%GVU7'
MM$]I DF2L15J.#QOK@MK9BWEJY]L9!SPJPILN@CQK EL:0  DA=W;@  @ "
M &#JM@MN[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0
MD.%[@   @ "  &"JM&1UV%4EL1IV&4C]K=!V83P$JJMVNBVJJ"!W"QT7IS)W
M!@FHIWIW.   C[]_%@  @ "  &!HLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.
MII5\HAT9I8Y\F0GJI8A]&0  CL&     @ "  & NL=J#\53'KH&#ETBCJR2#
M*CN;I_&"P2UOI4B"@QTEI!""H HGH\R".0  C>.     @ "  %_]L/R+%%2U
MK8V*?4B8JA^)O#N+IN&)""U=I#&(MATKHMZ)( IEHDJ&B   C3.     @ "
M %_9L%>21E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P
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M;UJ%.X$(<'6$MV_4<8.$'UVT<I2#D$I5<Y^#%S5\=$V"K1QJ<X6";P  @ "
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M=B:+AW6$=I>*D658=P:)@U0Z=WZ(@T'@=_:'KBW&>#"'+12!=\:&I@  @ "
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M?<R1!FI'?8V/MUL-?4Z.4$K<?2F-#SEF?1:,+"7U?..,.@SJ?3*(E@  @ "
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MC,5O(V+DB[QP8E1.BM!QCD2+B@URHS,NB:ESAA\VBB-SS 9WB9]T*P  @ "
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MAE25L5]=A5F4)U#UA%62?$&:@X.1,3#4@OB0R!VX@IN/U@:)@>6$:P  @ "
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ME)9TK5<KDP=U94F-D8]V$CJ9D%MVJ"GEC\%W"17>D-EVK0"BC&MY1   @ "
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MCWV9^%2YC=287T<0C""6L3ARBK&5T2@YB<65)Q3\B<F., $GA@. R   @ "
M &5BIE=;L%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@
MC91MT@  @ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5J
MB@Q/GOII_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_
MFQ%O&B#0FL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES
M/#]UFM%S]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?A
MG5-Y6$O>FSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "
M &*0GBR 5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0
MAK2     @ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&
M1 RLE'2%#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^N
ME$2,=A^+DWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%EVR4
M[SV]E2B3K"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:9$X:
MKU)<C4)DK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0  @ "
M %APL&=A?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40
MAZ!VL@  @ "  %@(KI)H:$U*K MID$'0J8EJM#4XISAKSB<8I:QLFA8*IG-L
M? 0YH_-M>   AF=ZW0  @ "  %>NK*=O.DS?JB9O_4%7IZAPN33GI55Q;2;?
MH[QQ[!8*I$YQJP2$H5QR_   A4%^B@  @ "  %=2JOUV'$R*J()VBD$$I?]V
MZC2*HZ9W,R:ZH?5W;18)HEUW*03"GP9XX0  A#Z     @ "  %;_J:U](TQ0
MIRI]2D#5I)U]3C1>HC=]/R:2H'1],Q8;H)=]%@3_G.]^%@  @UZ     @ "
M %:ZJ*"$+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@
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M:IUZX0#]?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2
M=S;H:@. 2QYK:'2 '0#J?G5_U*!C6Y"+>Y$K7D**EH$)8+B)DF_I8PF(@UWF
M94"'@DK)9S6&HS9#:%B%^!WN9JN%V@#9?I& DY]?6?F5=) R7+R3S( :7SZ1
M^V\&89N0)%T18^*.;TH39=R,\S6_9N6+X1V/93.+C #,?JB BIZ=6+N?88]S
M6XB<]W]97@V:6VY*8&R7OUQ:8KB584EH9+F3:34W9;*2-QTZ9 20-@#!?KJ
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M8EVB9W3[9"F?A&399=:<G%/89WJ:%T'!:-F84RXB:1B78!7E:4R.S@  @ "
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M;YE]%FX+<*E]5UZX<:5]>DY=<IY]FCR*<WU]NBC=<\9]PP^A=25]G@  @ "
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M=FN"WV+-=N&"K51?=T:"7$3E=ZR"$#/R> *!WR"?=^.!U0B#>A^!7   @ "
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M@)-Y_"OH@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6
M)TJU?R& ##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A
M?CJ'QE?/?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "
M &]I?2:0)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*?
M?6J!Q@  @ "  &[]?%.82V-J?&"70E;3?"R5OTD[>]:4(CJ7>XV3$BI;>TF2
M_Q=1>G6/CP*0?*"!O   @ "  &D#E']7"EW0DTA9]U&NDE5<Q411D95?8C5Y
MD25AL"1RD:)C50]/E(QC)P  B EIF@  @ !^U&@=DB->J%T?D11@_5$)D"%C
M.$/,CU%E3C47CLQG'R0^CQQH6P]ID6UG^@  AB)N9   @ "  &=1C[9F-UQ
MCLQG_5!0C>=IK4,<C1MK/32-C)%LE2/BC,)M;@]>CH)LZ0  A%YSIP  @ "
M &9^C7%MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@
M@KQXF@  @ "  &6OBWUU3%J6BKQV%4Z;B?%VPD&>B2YW4#-FB)]WR",#B*)W
M_0\,B5-WE   @4Y\Y0  @ "  &3WB>)\\%GNB3!]2TX B&=]>T$)AY]]C3+>
MAP1]F2+9ALQ]HP\+AQ)]M0  @!N     @ "  &1:B(B$BUE2A^:$=TUHAR"$
M+T!VAE2#T#):A;"#BB* A5B#B0\SA2&#1P  @ "     @ "  &/>AX",15D-
MAN^+Y4TOAA^+)$ _A2R*.S(OA&>)L"(VA :* 0[E@Z"'\@  @ "     @ "
M &-\AK&4&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P
M@ "     @ "  %S@GO%5WU)"G5E8GT; G A;13GYFOM=N"N)FGU?OAI)F\U@
MN :$G$IA!   @Z-M20  @ "  %P&G-U='5&LFUE?548WF?1A>3F5F,!C<BM1
MF!1E#!I0F1%EM ;?F-UEXP  @A!R,0  @ "  %M?FH5D0U#UF1ME_$6?E[UG
MHCD%EH1I)BKJE<5J5AHFEH=JM0<7E9QJY   @)=W%   @ "  %JVF$!K6E X
MEN=LGD31E9=MSCAJE&%NXRIJDY]OL1G=E#-OS@<NDK%P(P  @ ![90  @ "
M %H,EDQR@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@
M@ !_+@  @ "  %ESE+=YR$\&DWUZ0T.QDBYZE3=1D.EZPRF8D 1ZWQEQD"UZ
MS <[C?A[T0  @ "     @ "  %CPDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DN
MCJ6 SAD@CJF ZP=0C!R X   @ "     @ "  %B(DER(8$XOD3J(.T+GC^:'
MQ#:0CH:'-BC<C7Z'!ABWC7.'1P<KBJ.$V0  @ "     @ "  %@WD8Z/Y4X)
MD'*/HT+#CQ6.SC9OC9"-VRCBC%>-PACYC B,H0=RB52%"0  @ "     @ "
M %"FJF%4349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?
M@ !Q+@  @ "  $_&J)1;*D7$ILQ=-SJ_I1Y?,BZ%H\%@]R!;HVUB*P['I;)B
M!P  G6QE%0  @ !U^   @ "  $\]IE-A[T4MI)9CCCI!HNME&"X1H7YF>2 3
MH0=G5@[1HN%G"@  FMYI[@  @ !Z/   @ "  $['I MHIT2CHEEIWCFDH+9K
M 2VAGTEL !_ GK]LD0[&H#]L*   F'=O*P  @ !]_P  @ "  $Y+H@MO<40K
MH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "     @ "
M $W7H&IV8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5
M@ "     @ "  $USGQ-]54-_G8-]HCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]
MM0"PD@E^S@  @ "     @ "  $TDG@.$64-*G'.$<3B!FK:$,BR9F0B#WQ\*
MF!*#Y ZJF'>#>P"UD)F >P  @ "     @ "  $SQG2F+CT,HFY2+ACADF="+
M""R&F!"*CA\3EO.*KP[9EQZ(1 #=CV> E@  @ "     @ "  *G.6NI3J9FM
M7<=7?(CS8(9;-7=08RQ>S&2H9;IB0U#A:!5EE3O":=UHHR,E:7!JZ0/G>6=L
MRZ?"5J->()@46>!@_H>'7.YCQG8-7]AF>&. 8I]I$$_692)KC3K39N=MT")E
M9=AO; /(>9QQ9Z7<4LQHC99'5E5J<X7[6:=L3'257,9N'&(R7[MOWTZV8EYQ
MD#GE9!AS%2&Q8K%T&0.M><IV8J/Y3U-RW91Z4R!SVH0\5J%TU',?6?%UR&#A
M711VNTV97]!WJ#D!87QX>"$*8 1X^0.5>?)Z]:(R3$!]'9+@4$A]1(*^4_Q]
M:'&O5VU]AE_$6K-]JDR>78A]V#@Z7R%^ 2!Z7<E^'0.!>A1^WZ"P2:2'69&+
M3=V&L(&14;F%_W"=54Z%3E[#6*F$J4O86XF$'C>870V#LR !6_2#H -P>C""
M*Y]V1W&1BI!X2].0#8">3\^.AV_$4W^-"EWW5O&+JDLG6=B*=C<:6T")CQ^D
M6G6)E@-B>DB"29Z$1:R;I(^C2BZ93'_@3C^6\&\:4?^4JUU757^2GTJ.6&R0
MWS:;6;F/L!]564".U0-6>ER"0IWB1%^EAH\/2/"B27]530F?%6Z;4,Z<%ESK
M5%.9<DHU5S^72#9 6&F6(![^6$22_P-->FN"/)V'8B93@(ZD9&576'[V9I5;
M!FXZ:+=>B%QA:L5AYDE1;*EE%S2S;@9G[1O7;8)IFP  @ !M\)O$7A!==(U>
M8+%@9'W:8R=C-6U"97YEYEN$9[=H=TB2:;9JY#07:P-M 1MG:DUN(   @ !R
MTYH+6EIG68N>74-I9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ
M9Y%RSP  @ !W@YA25OUQ)HGN6B)R7WJN70-SAVIX7[9TG5D(8D5UIT9U9'%V
MI#)A985W=AHK93MWM@  @ ![EI:X5 5Z[(AU5UU[7WE)6FI[O6D>73Y\"E@"
M7^I\5D6.8BA\I#&M8QM\Y1FP8T1\[@  @ !_$I5D48*$M8<\50&$9'@K6#&#
M^F@56R6#@E<,7>.#$D358"2"N3$:8/2"@1E(8:6"H0  @ "  )113VB.<X8_
M4P:-7W=#5D^,*V<_65J*\E9"7"N)U$0K7FZ(YC"I7Q2(4AC\8$V(20  @ "
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M6.V3)VT16Y61CEWL7@*/ZDV_8#:.>SQ;8<Z-<2EO86Z-21&"9JJ*8@  @ "
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M:0QO-V< :K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "
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M7ZB8(&+;8:662E2$8V24844I9.62UC1X9;Z2&R')9&*140IK;F2'"P  @ "
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M;K!U.ENB;]YV'4X%<.=VWC\\<=9WC"Z9<GMX$AM8<>YX(@2M>!EYLP  @ "
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M VN6?X1:3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P
M@0EJ8@  @ !_-FJ$?%-B(U]O?,MD7E-V?3)F?$8N?9!H;C>+??AJ)R;J?HIK
M9Q*4?XEK/P  @ !O>@  @ "  &EM>69I^%Y.>@1KH5)1>H5M+45+>O=NF#:_
M>VAOSB9,>]MPH1(Y?(]P2   @ !T_@  @ "  &AC=M5QTUU4=Y!R]5%=>"5S
M]411>*)TT38C>0MUC27(>6!V Q'U>?AUG@  @ !YX@  @ "  &=S=*!YQ5QP
M=7AZ8E"(=AYZU4.:=IU[)35_=O][9"5]=Q][DA'7=[E[8   @ !^"0  @ "
M &:N<LB!LUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0
M@ "     @ "  &82<4F)FELT<DV)54]B<P&(O4*"<W2(!31G<[N'BR1R<XF'
MFQ%+=&J&P0  @ "     @ "  &68<!:1AEJ^<2B0ZD[K<>"/VT(3<DN.LS0+
M<GZ. B0O<B&.-A$1<S^*\   @ "     @ "  &"FC&]1F%8'B^U4W$IWBZE7
M_3V<BY5:Y"\:B]==91X(C2E>^@F CFI?*0  @ !I:0  @ !^<%^/B5)8_E4K
MB1%;NTFJB-Y>53SUB,1@O"ZAB.YBQAW)B?EC^ FDBJAC_0  @ !N*0  @ "
M %Z?AD%@8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP
M@ !S9   @ "  %VP@VAGR5,R@W=I>D?5@W%K#3MG@VIL>BU5@XEMG!SCA"1N
M& F&A&=N#   @ !X6P  @ "  %S&@.AO/5).@1)P<4;T@1QQA3J+@15R;RS
M@2=S+1QG@8YS8PEA@>-SB@  @ !\K   @ "  %OT?L=VQ%&(?PIWA48]?Q]X
M'#G=?Q=XCBPC?Q1XXAPE?RAX\0E:?[1YF0  @ "     @ "  %L\?/!^/5#7
M?4]^DD69?6]^M#E'?61^MRN;?4]^NAO1?21^Q F-?=)_,P  @ "     @ "
M %JL>WF%RU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP
M@ "     @ "  %H[>DJ-;% %>M>-*T39>O^,;3BG>LV+DBLG>G6+2!MB>=F+
M,@E,>RJ&20  @ "     @ "  %2EEMQ0/4J,E?%353^)E4]62C,FE0)8^B3/
ME7=;%A+OF%);J &"E*5=C0  @ !M%   @ "  %.>D_U7/TF\DT19X#[%DJ=<
M73*(DD1>FR1GDHA@3Q+8E.=@F0'4D0IB:0  @ !Q^   @ "  %++D0Q>/TC<
MD'E@9SX*C^QB;3'8CX=D.2/DCZ]EAQ*;D:1EC@(&C<MG9P  @ !VY   @ "
M %( CD)E0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI
M@ ![/   @ "  %$YB\AL54=$BVEMECQKBO=NM3!TBH]OGB+CBHIP/1'^B[YO
MY@(MB'AR6@  @ !_!@  @ "  %""B:MS@$:9B6=T7#O2B/UU#2_JB(QUCR)I
MB&AUUQ'BB1]UB )%AE5X2@  @ "     @ "  $_BA^)ZJ48,A[A[+3M8AU1[
M=2^ AM5[ER($AI-[IA&HAN5[BP)PA()]5P  @ "     @ "  $]@AF.!Q$6(
MAE*!\#K8A?:!UR\,A7"!IR&;A1&!IA$OA1B!PP)A@Q&!=0  @ "     @ "
M $[XA32),T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![
M@ "     @ "  $A8HG%.7S[?H3Q10C1IH&=3]BA9H"A63AG#H7-7OPBCHQM8
M90  D91?Y   @ !P>@  @ "  $='G^94_CWXGNQ7=S-XGAI9Q2>/G:];O!E%
MGJ%<V BGGW-=60  CMQD?@  @ !U40  @ "  $:;G0U;G3TTG"U=K#+"FV]?
MCB;;FOEA)!C#F[UAZ@B7F\YB4   C$-I40  @ !YJ0  @ "  $8'FCQB.CR$
MF6]CW#'VF+QE5B9 F$=FBQA'F.UG!@B F$QG7P  B=YN?   @ !]@   @ "
M $5DE[AHZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P
M@ "     @ "  $3%E9-OOCM*E0IPIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER
M9   AA!Y9P  @ "     @ "  $0[D\)VG#K/DUIW.3""DJYWEB3XD@%WO!=H
MDAYWF0B"C])XFP  A+)]R@  @ "     @ "  $/)DD%]D#IMD?9][3 RD4]]
M^"3#D(A]VA="D'-]R A2C?!^>   @T6     @ "     @ "  $. D02$QCHE
MD,Z$]"_QD#*$LR29CUF$91=*CP6$APB%C%F#6   @G&     @ "     @ "
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M2;A^36]Z3<1^<F!F479^C%!.5+]^J3[T5QU^U"OU5L!_"12'7F1_6   @ "
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M3CR$>&5;4<J$&5<85/B#L$? 5Z6#63<962:#*22F6)&#1 T\::&#$P  @ "
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M4Z.)N5LV5IZ(^$VS62J()S\'6Q:'AB[>6WR'01R=7.2'Q0;3='B$G0  @ "
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M9L1H$E3B:)QI]T?>:C9KO3E&:X1M32CP;!%N@A5=;6YNJ0#S?F5QE@  @ "
M &KC82-N1E^X8V9OI%.[961P[4;*9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3
M?BYW'@  @ "  &G%7@-V@%[(8'9W4%+G8I9W_T7T9%QXD#?-9:-Y$2?99:IY
M>!2N:)IY9P$2?C![]   @ "  &C<6TM^JUWM7>-^]%(;8!]_#$4V8?)_"S<;
M8RM_$R='8MY_+Q1Q9KM_9@$D?A-_^@  @ "  &@E60.&P%U$6[N&CU%Y7@N&
M%T2@7^.%B3:)80B%*2:T8&&%)A0&952%1 $P??Z S@  @ "  &>>5RV.QES%
M6@".,U#W7%Z--D0B7C*,(C8@7S^+:B9G7F&+B1.P9#B)\P$/?C6 N   @ "
M &3C>@Q-6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>
M@ !EG0  @ ![M&-%=<)4WUBH=L%8 DS]=[I;!4 J>*1=V#'(>8)@4R$<>F=B
M$0RT?*QB/0  @ !J2   @ !^]&'Q<:=<@U==<NY?%TON=!)AD#\O=0]CUS#Z
M=>9ET""!=GAG'@Q\>4%G&@  @ !O5@  @ "  &"P;=5D,E8;;U%F-$JP<)=H
M'3XW<:QIWS ><GYK61_5<K-L/PPP=EAL(   @ !TT0  @ "  %^$:EQKZ%4#
M; 1M7TFD;6ENO#TL;HMO\R]X;T]P^1]+;QUQB O^<]!Q;@  @ !YL@  @ "
M %YV9T9SLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P
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M&E=X?TY3?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@
M@ !M\0  @ "  %9(>UI:LTQ4?!]=0$%[?,E?JC4^?5]AUR=3?@)CD19K?OMD
M+P2*@+9E5@  @ !S)   @ "  %4K=Z)A]4LQ>))C_4!6>55EY#18>?=GFB:(
M>G]HYA73>OAI+P1S?=QJ;P  @ !X(   @ "  %0:=#EI1THI=5)JSC]5=B]L
M-C-B=M!M;"7B=S=N6!5'=X1N7@1:>VEOXP  @ !\<@  @ "  %,F<2QPJTE#
M<F]QNSZ$<V1RIC*A= 9S9R4W=#USZQ4%=(=STP1B>4-UWP  @ "     @ "
M %)1;G=X"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P
M@ "     @ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_
ML 1<>** )P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01
M;62%VQ00;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1
M:2R]C?]41!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(X
MB>94BS>UBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "
M $J%A?I89T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@
M@ !VB   @ "  $F-@E1?1T 7@LAA3S6K@R-C*RH!@X%DOQP@A#%EJPN(A+=E
MP@  @*IJW@  @ !ZZP  @ "  $B;?O%F/#\G?X]GSC3"?_YI-RD>@$]J5QN5
M@,%J^ L[@6!J_0  @ !P>0  @ !^O@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O
M:"AQ?7UP(AK[?:9P; L3?H9PAP  @ !V50  @ "     @ "  $;X>3%T73V5
M>BUU'3-<>LMUIR?F>P5V QIR>N=V$PK4?#9V;   @ ![1P  @ "     @ "
M $9/=M![;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>
M@ "     @ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"
M!@  @ "     @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)Y
MG#)24P-2F;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E4
M8B!+ED!69A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4Z
MDAE7X2L>DCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "
M #UOCGU;_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@
M@ !]6   @ "  #R:BQ1BFC-TBVED)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5H
MAP  @ !T!   @ "     @ "  #O+A_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_
MB:1KU@*FAP-N,   @ !Y.P  @ "     @ "  #L5A2EP*3'TA?YP[R?XAG=Q
M>1R-AK]QM [GAJYQA@*6A,5T4P  @ !]F   @ "     @ "  #I\@KMW"C%=
M@\]W?"=VA&5WKAPNA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "     @ "
M #H-@*I^)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "
M@ "     @ "     __\  /__  #__P  ;69T,@     $ PD   $
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MY@"#\;-+T!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2
MKXXZ,KF P8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY5
M7J> 5)?12&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM"
M8:J[=&N +J-<7BF !YN52 * !Y,[,A> ,(G^XP""O=-4S3>!ULI9MOJ!!\&:
MH(B ;KD3BB. $;"B<]I_XJ@&7;=_QI[]1ZM_T)56,=Q_^XK7WA*1XGRPR.Z/
M\7QCL[&.&'PZGCN,:'Q'B(V*WGR/<L6):7T*71&'_'VH1WN&F7Z3,E&%.7_Q
MW"J0M(:7QY2.P852LI*,](0\G3:+5X-;AXZ)Y(*V<=*(B((]7"N',X'81KF%
MZ8&B,<N$HH&=VJ./CI"5QCF-J(Y7L7*+W8P^G!6*5XIPAGB(^(C9<-"'M8=H
M6TB&=X7\1@6%1H2?,52$&8,TV4*.FYJ7Q-B,OY=LL >+!Y1KFLB)@I&DA5*(
M.8\=;]F'!8RH6H.%V(HF16^$NH>/,.R#H(2OU^Z-X:24PX>,":"!KKJ*6YR;
MF8^(WICDA#J'C95/;O"&:Y'56<Z%2HXT1.B$/8I;,)&#-88+UK6-2ZZ<PER+
M=ZF=K9F)RJ3$F(*(4J 7@TR'")M^;AJ%X9;B62N$SI(=1'.#T(S_,$6"VH=$
MU:>,T+BCP5R*_[*PK*&)4:S:EYN'W:<J@H:&FZ&*;7>%>IO06*&$8I701!*#
M<X]L, 6"C8A6U,*,:L*FP(:*G;NRJ\^(\;34EM&'>ZX2@<Z&/:=;;..%*:""
M6#:$%IE.0\&#)Y&<+]&"3HE!U 2,$\RIO]6*3<2@JQ^(H[REEB>'+;2^@3>%
M\:S>;&>$X*355]2#V9QM0WB"]).%+Z>"&XH%SD^;&WN NJ*867M1IN^5K'M&
MDPJ3)WMS?NB0QGO::JB.=7QW5HB,(GTY0I:)PGY0+T*'0G_BS)V:#X32N8&7
M/(.^I@:4EX+5DC22(((D?A./TX&M:=J-F(%C5<:+68$Q0?R)$8$W+N^&IH%Z
MRT*9$8XAN$2618PNI/F3G8I:D2Z1-XC5?2".^H=]:0*,T89*50Z*I84?072(
M<(0*+J6&&X+ZRB&8'I>.MQB58Y2YH\N2R9(!D!N05X^,?!V.+8U1:"",%(LI
M5%B)^8CY0/*'VX;!+F6%GX1>R/^79J#VM@>4K9U$HJ^2&YF_COJ/O99I>R"-
MB9,S9U&+?Y 14[Z);8S-0(J'78EA+BZ%-(6AQ^R6V*I@M/Z4(J77H:Z1DJ%P
MC@N/.9TQ>DR-"9D"9I>*^)3.4S:(\)!T0#"&[XO3+?^$V(;!QON69+._M""3
MKJY6H->1'ZD%C4&.R*/1>9Z,H9ZG9@J*DYEC4L:(@I/B/^>&CXX-+=B$C(>[
MQBZ6 [T9LV633K;$H"&0P+!\C)*.::I$>/Z,1J0198F*1)VZ4FN(-I<6/ZJ&
M09 ++;B$3(B0Q865K\9QLLV2_+\<GXF0<K?&B_Z.';!W>'N+^ZDH92")_J&R
M4AJ'_9GL/W"&$9'"+9^$&HE OR"DAWJMK,F@^GJ-FG^=?'J6B!2:'WK8=7*6
MWGM68K23I7P,4"J06WSI/>&,[GX@+&J).W_3O:*CG(-PJ^*?\H)\F<Z<<X&U
MAVZ9'X$E=,65[X#28@J2QX"N3XF/CX"F/6Z,-8#<+$F(EX%9O(.BJ8PVJMR?
M!HINF.R;A8C/AHR808=U<_.5'(9085*2 X503O..V81;/0J+D(.%+"R(!8+$
MNX*AW93LJ=">1));E]F:S(_YA967?HW"<Q.49(O-8)B15(GF3F:.-(?Z/+**
M^X80+!.'A(01NJ6A&IW#J.F=CIIEEN>:(9<TA*&6VI0F<CR3J9$_7^:0J8YK
M3>&-E(M]/&&*;XAV*_V'%84]N;R@CZ::J!Z<_:)IEB29C)Y@@]^629I_<8B3
M*Y:O7TV0(I+:37:-%8[C/"*)_HJW*^J&MX9%N.V@(*]:IV"<BJI8E6Z9&J5Q
M@S65VZ"J</>2Q)OK7M>/OY<531Z,IY(+._")FXS *]N&:(<JN#>?Q[@)IL&<
M+;(GE-:8O*Q8@J65?J:<<'.2:Z#D7FV/<)L,3->,693S.\>)2XZ,*\^&*(?K
MMZ"?><"TICZ;V;G>E%:8:K,.@BF5,*Q*< B2(*6)7AJ/*IZD3)F,()>!.Y^)
M') 4*\6%](B)L)VN*'HFGXJIS7H)CHZE?GH;?8"A2'IJ;$J=(7KX6P68\'O
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M8'6RR9&54R^KI([G1E"D38Q).B^<KXFK+Q^4N8<@)<&,A83%B.S&X:$O>W;
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M8H6EVYSZ50*@/YA#1]F:H9.0.VJ4TX[>+_".ZXHO)A2(ZX71@0W&9'/V=(K
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MPPZ"I)A L4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV
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MJG@.@'";?7B-<3R88'DG8;.50GGF4A^2''K+0N^.W7O,-$&+AGT&)LN("'Z
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MGH+@)!:(_X'[@UFQ=9'L=O>LJX_F:E.GRHWE78:BU(OS4,N=RXH31%.8J8A
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M;H\T/O6<.XP_-*25R8E9*U:/0H:)(Y6(W8/Z>'NYM*$F;2>SZIV187RM_IG
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MEXB,.UJ8^(;I,=F3,(55*4:-:H/2(C"'SH)O<'ZR]94W9@VM\),A6T*HO)#
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M_)8 EV]O=9.&A7MP^I#Y<T=RH(YL80%T<8O=3Q!V:XD_/71XG89J+,E[#8-
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M/;J!SWD:,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B
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M?MB&C)0G<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F
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M#FCC;]YOWFL_8P=QOFV75=ISOF_]2)MU[G*".]AX2G4J+Z]Z['@3).9]N'M
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MI(B#4\MK6(> 2H=M^X9303APMX4[.!=SI80[+ZEVI8-,)_%YR()?(8M\NH&
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M)BB EG_1(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0
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M)CS<VA\[QNLC5[/L*F^CWS6"EM1*D(_-79J+R&NAB<1UIH;">ZJ#P'ZL@;^
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MR,MKFKK"<*FNNG>TH[1\O9JO@<.2K(7(BZF*S(2GDL^ IIS0@*.ESX"AILZ
MH:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"A
MIL[_HC8B_Y]#-_^C14?_JD)3_K%!7_:X06KQP41SZLQ+>>#:5GS/U5Z-P,QI
MF[/#<JBGNWFSGK5_NY>Q@\*.K87&AZN(RH&IC<U\J);.>ZBBS7NIILU[J:;-
M>ZFFS7NIILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILW_
MHS8B_Y]#-_^E0T;_K$!2_[0^7?F]/V;NR$-MX]9-;]7=3H'$TUF1M<EFGZG!
M<:N@NWFSF;: NI2RA<",KX;$AJV(QX"KC,E\JI+*>JN<RGFKG\IYJY_*>:N?
MRGFKG\IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\K_HS4B
M_Z!"-_^F047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ# <*R9
MNGFTE+: NI&SA;Z+L8;!A;"(PX&NB\5]K9#&>JV7QGJMFL9ZK9K&>JV:QGJM
MFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL;_I#0B_Z%!
M-_^I/4/_LSE-^;XW5>K,.EG;W3MBR^4_=[O92(FKSE>8H,9EI)C <:R3NWJS
MD+B!N(RUA+N(LX:^A;*)P(&QB\%^L(_">["4PWJPEL-ZL);#>K"6PWJPEL-Z
ML);#>K"6PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6PWJPEL/_I#0B_Z,^-O^M
M.4'_N#1(\,8S3=_9-E#-Y39GON0[>ZW72(R@S5B9E\9GI)+!<JN.O7NPC+J!
MM(BX@[>$MX6Y@K6(NW^TBKU\LXV^>K.1OWJSD[]ZLY._>K.3OWJSD[]ZLY._
M>K.3OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJSD[__IC(B_Z8Z-/^R,SWW
MP"Y"Y-(O0<_D+E6_[S-KK^$[?J#62HV6SEN9D,AIH8S#<ZB)P'NLAKY_KX*\
M@;* NX2S?;J&M7NYB+9YN(NW=[>/N'>WD+EWMY"Y=[>0N7>WD+EWMY"Y=[>0
MN7>WD+EWMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+G_IS$B_ZPS,?^Y*S;JS"8V
MTN$F0<'O+%JP[3-NH>$]?Y7738R-T%Z6B<MKG8;'=**#Q'JF?\-]J7S!@*MZ
MP(*L>;^$K7>^AJ]UOHFP<[V,L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]
MC;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]C;'_J2XA_[,J*_+%(BS6WAPMP^TC
M1[+Y*UVB[#9OE>)"?8O:4HB%U&"0@M!LEG[,<YM[RG>>>,E[H';(?J)TQX"C
M<\:"I''%A*5PQ(>F;L2*IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=N
MPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ?_K"H@^KT?(MS9$AO%ZQHSM/HC2J/Y
M+EZ5[CQMBN5)>8/?5H)^VF2)>M9LCG;3<9%STG64<=!YE6_/>Y=MSGZ8;,Z
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M]L U1.?/.477WSQ0R>=!9+OE1G:LW$Z%G]-:DI7,9YR.QG&DBL)YJH6_?JZ
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M9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF:]RP8
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MP:B-@\&HC8/!J(V#P:B-@\&HC8/!J(V#P:C_BB<)_XLX%_^9/B#_H3XH_Z9
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MA(JBG8&*K9]_BKN??HK(GG^)R9V B,J<@(C+FX"(RYN B,N;@(C+FX"(RYN
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M=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'7_G18!_[$2 =/#"0#'T0H
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M;>UIF7'J9J%UZ&.I>.9ALGKD8+M[XE_'?.!?VGW48N%]RF/@?L-DX'^]9M^
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ML2 $[,$: ]_3%P'0W"4$Q-DU$+C502&LT$LQH,Q2/Y7)64R+Q6!7@L-F8'K
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M(RC_D"0G_YDE)O^A)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)B7_IR:?P
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M;V&5[&]AE>QO897L;V&5[&__=Q(!_XD1 ?^9$0#SJ X U[4* ,_!"@#&Q1@
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M96..\V1DC/1C9(ST8V2,]&-DC/1C9(ST8V2,]&/_<1 !_X(/ /^1#0#>GPD
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M5DJS_E9*L_Y62K/^5DJS_E;ZAP( UI@  ,FE P"]KP, L[@! *G"! "AS0@
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M#B'_B@\@_Y40'O^@$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5O
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M7BZQ?68VK'EN/*=V=4*C<WU'GW"$2YQNC$Z8;)12E6N=5))JIU>0:;)9C6G
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M6G%[^UER>OQ8<GK\6')Z_%AR>OQ8<GK\6')Z_%C_9Q$!_W4/ /^##@#TC@T
MVYD* -2A"P#,I!4 PJ0G [BB-@JPGD(5IYI,'Z"75"F9DUPQDY!C.(V-:C^(
MBG%$@XAX27Z&?TUZA(A1=H*157.!FUAO@*9:;7^T7&M_Q5QK@-]<:X#R6FN
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M55N0_E5;D/Y56Y#^55N0_E7_<PD ]80$ -B1 P#,G 4 PZ4% +NM! "SLPP
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MR2\%>\@[#73'111NQDX;:,56(6/$72=>PV0K6L)K+U;!<C-3P7LV3\"$.4S
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M/]ZF*C[?M2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[
MGP  L:<  *2P  "8N@  C<,  ('- @!VUP< ;N@/ &GH&P%CZ"<"7NDR!5CI
M.PA4Z40,3^I,#TSJ4Q))ZEL51NIB%T3K:AE!ZW(;/^M['3SKAAXZ[)$@..R>
M(3?MK"(V[;LC->[/(S3NYB,TZ_4C-.OX(S3K^",TZ_@C-.OX(S3K^".SI0
MIJT  )FW  "-P0  @,L  '75 0!IX08 9/,1 %[S' %9]"8"5/0P!$_U. 9+
M]4 (1_9'"D3V3@Q!]U4./_=<#SSW8Q$Z^&H3-_AS%#7X?18S^8@7,?F4&"_Z
MH1DN^J\:+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0
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M3G]K_TQ_:_]+?VO_2W]K_TM_:_]+?VO_2W]K_TO_7A !_VL. /]V#@#[@ T
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M3&I[_TQJ>_],:GO_3&I[_TS_9@H _W4( .&! @#4BP4 RY,& ,2:!@"]G@X
MM9\? :R>+@6DFSL,G9A%%9:53AZ/DU8EB9!=+(2.9#)_BVLW>HIR/':(>4!R
MAH%$;X6*1VN#E4IH@J!-98&L3F.!O$]B@=%/8H'K3F.!^4UC@?],9(#_2V2
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M-$.[LC1"N\4U0[OB-$*Y\S5!N/TW0+?_-T"W_S= M_\W0+?_-T"W_S?.BP
MOY@  +*A  "GJ0  G+   )&X  "&P ( >\@' '3+$@!PS"(!:\LP V;+/ =A
MRT4,7,I.$5C*5A54RET94<ED'$[);!]+R70B2,A^)$7(B"=#R)4H0<BB*C_(
ML2L^R<0K/LGA*C['\BL]QOPM/,7_+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\
M *FF  "=K@  DK<  (:_  ![QP, <,\' &?6#0!DUQH 8-@J 5S8-@-8V$$&
M5-A*"E#84@U-V%H02M=B$T?7:19%UW(80M=\&D#8AQP]V),>/-BA'SK9L" Y
MV<,@.=G?(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0  )^L
M  "3M0  A[X  'O&  !PS@, 9=8' %WC#@!:XQL 5N,G 5+D,@).Y#P$2N1$
M!D?E30A%Y54*0N5<#$#E9 X^YFP0.^9V$CGF@!0WYXP5->>9%C3GJ!<RZ+@8
M,NC,&#'HY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(
MO0  >\8  &_.  !CU@$ 6-X% %3N$ !1[QL 3>\F 4GP+P)%\#@#0?$_!#[Q
M1P4\\DX&.O)5!S?R7 @U\V0),_-M"C'T=PPO]((-+?2/#BOUG0\J]JL0*?:\
M$"CVSA$G]^81)_7Q$2?U\1$G]?$1)_7Q$2?U\1&CJ   EK(  (B[  ![Q0
M;\X  &+7  !6W@  3O ' $KZ$ !&^QD 0OLB 3_\*@$[_3("./TY C7^/P,R
M_D8#,/],!"[_4P4K_UH%*?]B!B?_:P8D_W8'(_^"""'_D @@_YT)'_^K"1[_
MN@D=_\D)'/_="1S_W0D<_]T)'/_="1S_W0F8L   BKH  'S$  !OS0  8M@
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M/I%;_SZ07/\]D%S_/(]<_SR/7/\\CUS_/(]<_SS_51$ _U\- /]I#@#_<0X
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M,XYK@3:+:HDYB&B2/(5GFS^"9J9!@&:R0WYFP41]9ME$?&?O0WQG_$%\:/]
M?&C_0'QH_S]\:/\_?&C_/WQH_S__6PP _V<) /=Q!P#>>@4 U( ' ,Z%"0#'
MAQ$ OH@B ;:',02OA#X+J(%)$Z)]4AJ<>EH@EW=A)I-U:"N/<V\OBW%W,XAO
M?C:%;H8Z@FV//7]KF3]\:Z-">6JP0WAJOT1V:M1%=FOM0W9K^T)V:_]!=FS_
M0'9L_T!V;/] =FS_0'9L_T#_70H _VD' .QT P#:? 0 T(,& ,F(!P##B@\
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M/&YZDC]K>9U!:'BJ0V9XN$1E>,Q%97CG1&5X]T-F>/]"9GC_069X_T!F>/]
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M.U"4L#U/E,,]3Y3?/$^3\CQ/DOT\3Y+_/$^1_SQ/D?\\3Y'_/$^1_SSD=
MSX$  ,*,  "XE@  K9P  *.A  "8J   D*H- (NK&P"%JRH"?JHV!GBI00QR
MJ$D2;:=1&&FF6!QDI%\A8*-F)5VB;2E9H74L5J%^+U.@B#)/GY,U39^@-TN>
MKSA*GL$X29[=.$F=\#A)G/PX29O_.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<
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M(3O"[B$YP/DB.+__)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@
MC+$  ("Y  !UOP  :L8$ %[," !9SQ( 5] A %70+@%1T#D"3M!#!$O03 9)
MT%,(1M!;"T/08PU!T&L//M!U$3S1@!,ZT8P4.-&:%C;1J1<UT;L7--+2%S70
M[!8TS_<8,\[_&C/._QHSSO\:,\[_&C/._QJSF0  IJ$  )JI  ".L0  @;D
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M!!;_Y 06_^0$%O_D!!;_Y 23K@  A;<  'C   !JR0  7=(  %#9  !$WP
M.N0  #7W P R_PP +O\2 "O_&@ H_R$ )O\G "/_+0 @_S, 'O\Y 1S_/P$9
M_T4!%_]- 17_50$3_U\!$?]J A#_> (._X<"#O^6 @W_I (,_[ "#/^^ @S_
MP@(,_\("#/_" @S_P@*'M@  >;\  &O)  !>TP  4-L  $/@   XY0  +_
M "O_   G_P@ )/\. "'_$P >_QD &_\> !C_(P 5_R@ $_\M !'_,@ 0_S@
M#O\_  S_1@$*_T\!!_]9 03_90$!_W(! /^! 0#_CP$ _YL! /^G 0#_J0$
M_ZD! /^I 0#_J0'_+"\!_S L ?\R+ +_,S "_S$V _\P00/_+TT$_RU:!O\K
M9@?_*7,(_RA^"O\GB O_)Y$,_R>9#?\FGPW_)J4._R:K#O\FL0__)K@/_R;
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M*ZE*_RNH2_\KITO_*Z=+_RNG2_\KITO_*Z=+_RO_21( _U . /]9$ #_7Q(
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M,X1<_S.$7/\SA%S_,X1<_S/_4PH _UT& /5F! #?;0, U7(& -!U"0#)=A$
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M-UYYL3A=><(Y7'G=.5UY\3A=>/XW7GC_-EYX_S5>>/\U7GC_-5YX_S7U9
MW'   ,IZ  # @P  MHD  *Z-  "DCP  G9$0 )>2( "1D2X#BI Y!X2.0PQ_
MC4P2>HM3%W6)6AMQB&$@;H9H(VJ%;R=GA'<K8X-_+F""B3%=@90S6X"A-EE_
MKS=7?\ X5W_:-U=_\#=8?OTV6'[_-5A^_S58?O\U6'[_-5A^_S7I:   U'0
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M+4:8ZRU&E_DN1I;_+D:6_RY&EO\N1I;_+D:6_R[1=P  P80  +:.  "JE0
MH)L  )6?  "*I   ?:D  '>K$ !SJQX ;ZPL 6JK-P1EJT$'8:I)"UVI40]:
MJ5@35ZA?%E.G9AE0IVX<3:9V'TJE@2%(I8PD1:69)D.DJ"="I+@H0:3.)T&C
MZB= HO@H0*'_*4"@_RE H/\I0*#_*4"@_RG)?@  NHL  *^4  "CF@  F*
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M$2['_Q(NQ_\2+L?_$B['_Q*NEP  H9X  )6E  ")K0  ?+0  '"[  !DP0
M6<8  $[+ P!%T @ /M4. #W5&@ \UB8 .]<Q #G8.P XV44!-ME- 3795@(S
MVEX",=IH S#;<P0NVW\%+-N-!2K<G08IW*T&*-W!!BC=W@8GV^\')MGY"";8
M_@DFV/X))MC^"2;8_@FDG0  F*4  (NM  !^M   <;P  &7#  !9R0  3<T
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M 0/_QP&#M   =;T  &?&  !:SP  2]4  #_<   SX0  *>4  "'L   >_0
M&O\% !?_#  5_Q  $O\4 !#_&0 ._QX #?\C  O_*  (_RX !O\U  /_/0
M_T8  /]1  #_70  _VL  /][  #_BP  _YD  /^E  #_K   _ZP  /^L  #_
MK #_)RP!_RHJ ?\K*@'_*BX!_R8T O\E/P+_(TL#_R%8 _\@9 3_'G $_QU[
M!/\=A07_'8X%_QV6!?\=G ;_':(&_QRH!O\<K@?_'+0'_QR[!_\<PP?_',X'
M_QW?!_\=ZP?\'?4'^1W^!O<>_P?W'?\(]AW_"?8=_PGV'?\)]AW_"?8=_PG_
M*2H!_RPG ?\N)P'_+2H!_RPR ?\K/0+_*4D#_R=5 _\E803_(VT$_R)X!?\B
M@@7_(8L&_R&3!O\AF@?_(: '_R&E!_\AJPC_(;$(_R&X"/\AP0C_(<L(_"'<
M"/DAZ0CV(?0(\R+]!_(B_PGQ(O\*\2'_"_ A_POP(?\+\"'_"_ A_PO_+"8!
M_S D ?\Q(P'_,28!_S(O ?\Q.@+_+T8#_RU2 _\K7@3_*6D%_RAU!?\G?P;_
M)X@'_R:0!_\FE@C_)IT(_B:C"?TFJ0G\)J\)^R:V"?HFO@GX)L@)]B;9"?(F
MZ GO)_,)[2?]"NLF_POJ)O\-Z2;_#>@F_P[H)O\.Z";_#N@F_P[_+R,!_S,@
M ?\U'P'_-R,!_S@L ?\X-P+_-D("_S1. _\R6@3_,&4%_RYP!OXM>P?\+80(
M^BR,"?@LDPGW+)D*]BN@"O0KI@KS*ZP+\BNS"_$KNPOO*\8+[BS4"^HLY@OF
M+/(+Y"S\#>(L_P_A+/\0X"S_$-\L_Q'?+/\1WRS_$=\L_Q'_,Q\!_S<; ?\Z
M&@'_/2 !_S\H ?\_,@'_/3X"_SM) _\Y503[-V$&]S5L!_4T=@CR,W\)\#*'
M"N\RCPOM,I8+[#&<#.HQH@SI,:D,Z#&P#>8QN0WE,<,-XS+1#=\RY0S<,O$/
MV#'\$=4Q_Q+2,?\3T3'_%- Q_Q30,?\4T#'_%- Q_Q3_-QL!_SL7 /\_%@#_
M0QP _T8D ?]&+@'_1#D"_$)$ _8_4 3Q/5P&[3QG!^H[<0GH.GH*Y3F#"^,X
MBPSB.)(-X#>9#=\WGP[=-Z8.VS>M#]DVMA#7-L$0U3;.$-$WXQ'--_$3RC?[
M%<@W_Q;&-_\7Q3?_&,0W_QC$-_\8Q#?_&,0W_QC_.Q< _T 3 /]%$P#_21@
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M))A+_R282_\DF$O_))A+_R3_2 P _T\( /]6" #U6PD Z5X* .1>#0#57Q4
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M+FMFL2]I9L$P:6;;,&EG\"]I9_TM:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6
MX6,  ,]L  #$<P  NW@  +-Z  "K>@0 I'L2 )Y\(@"8?"\"DGH[!8QX10J'
M=TT.@W55$G]S7!9[<F(:>'!I'75O<"!R;G@C;VV!)FULBREJ;)8K:&NA+F9K
MKR]D:K\P8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68
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M+51ZZBU4>ODL5'G_*U5Y_RI5>?\J57G_*E5Y_RKA90  S'$  +]Z  "T@@
MJX<  *&*  "5BP  C8T) (>.%@""CR0!?8\Q GB..P5SC40);XQ,#6N*5!%G
MB5H59(AA&&&':!M>AG >6X5X(5B$@B15A(TF4H.:*5""IRI/@K<K3H+,*TZ"
MZ"M.@?@J3X#_*D^ _RE/@/\I3X#_*4^ _RG;:@  QW4  +I_  "PAP  IHP
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M'SR;_Q\\F_\@/)O_(#R;_R#"?   M8@  *F0  ">E@  DYL  (>?  ![I
M;Z@  &.L! !?K1$ 7*T? %JN*P!7KC8!5*Y  U&M2 5.K4\'2ZU7"4FM7@M&
MK&8-1*QN#T&L>!$_JX03/*N1%3JKH!8YJ[ 7.*O#%SBJX1<WJ?,8-Z?^&3:F
M_QHVIO\:-J;_&C:F_QJZA   KH\  **6  "7FP  BZ$  '^F  !SJP  9Z\
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M!!_1_P2?FP  E*(  (>I  !YL0  ;;@  &"^  !4PP  2<<  #[+   UT $
M+=4& "7;"P DWA( (]X< "+?)0 AX"X (. W !_A0  >X4H '>)3 !SC7@ ;
MXVH &N1X !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C
M^@&6H@  B:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX"
M ![K"@ <[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL
M#O)I  WS>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+
MJ0  ?;(  &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X
M!@ 4^@T $OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8
M  #_9@  _W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@
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M!.@>_P7F'O\&Y1[_!N4>_P?E'O\'Y1[_!^4>_P?_*Q\ _RT< /\M&P#_+B
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M$[,V_Q.S-O\3LS;_$[,V_Q/_.1  _ST+ /]##0#_1Q  _T@4 /5'' #K1B8
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M(GE6L2-W5L$D=E;:)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30
MY5<  --?  #(9   OV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>0
M9$\*C&)7#8AA7A"%7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):
MKR1Q6K\E<%K5)6];[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H
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M)E]FZ"9@9ODD8&;_(V!F_R-A9O\B86;_(F%F_R+H6   TV,  ,1K  "Y<0
ML'4  *=W  ">=0  EG8- )!W&0"+>"< AG<S H%V/01\=48'>'-."W5R50YQ
M<5P1;G!C%&MO:A9I;G$99FYZ'&-M@QYA;(XA7VN:(UUKIR5;:[<F6FO*)EIK
MYR5;:_<D6VK_(UQJ_R)<:O\B7&K_(EQJ_R+C6P  SF8  ,!N  "V=   K'D
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M($M[_R!+>_\@2WO_($M[_R#09P  P'(  +1[  "J@@  H(8  )6(  "'B
M?(H  ':,#@!RC1H ;HXG &J.,@%FC3P#8XU$!6",3 A<BU,*6HM:#5>*81!4
MB6@248AQ%4^(>A=,AX4:2H:2'$B&H!U&AJ\>187"'D6%WQY%A/(>18/^'D6"
M_QY%@O\>18+_'D6"_Q[*;0  NG@  *^!  "EAP  FHL  (^-  "!C@  =)$
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M$3*A_Q&T@@  J(P  )V2  "2EP  AIP  'FA  !MI0  8:D  %6L  !+KP4
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M !S-B@ ;S9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0
MCY\  (*F  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9
MU0L %M<0 !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>
M?@ .WY$ #N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<
M '>N  !JM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8
M$.<-  [G$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !
MZX   .J4  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW
M  !>O@  4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*
M  ?V#@ %]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX
M /:!  #VE0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2
MR   1,T  #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_
M"   _PT  /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L
M  #_@   _Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2<
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M ],<_P32'/\$TAS_!-(<_P3_*1< _RH3 /\I$@#_+!@ _RPA /\L*P#_*3<
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M%(Q%M!6+1<06BD7<%HA&\!:&1OT6AD;_%H5'_Q6%1_\5A4?_%85'_Q7_/P
M[$@  -U/  #/4P  QE4  ,!3 P"[40P LU(9 *U3*0"H4S8!HU)" I]12P2<
M4%0&F4]<")9.8PJ436H,D4QQ#H]+> ^-2W\1BTJ'$HE*D!2'29H5A4FE%X-)
ML1B"2< 8@4K6&7]*[1A^2_P8?DO_%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP
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M<5+-''!2Z!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  #
M7P  MV(  *]A  "H7@( H5\0 )M@'@"68"P D6 X 8U>0@.)74L%A5Q2!X);
M60J 6F ,?5EG#GM8;A!X6'42=E=]%'17AQ9R5I$8;U:<&FY6J1ML5K@<:U;+
M'6I6YAQJ5_<;:E?_&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@
MLV4  *ME  "C8@  G&(. )9C' "19"D C&,U 8AB/P.$84@%@&!0!WU?5PEZ
M7ET+=UUD#75<:Q!S7'(2<%M[%&Y;A!=L6H\8:EJ:&FA:IQQF6K8=95K('65:
MY!UE6O8<95K_&V5:_QIE6O\995K_&65:_QGH3P  TUD  ,1A  "Y9@  L&@
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M&U=F_QI79O\:5V;_&E=F_QK;60  QV(  +IJ  "O<   IG,  )IS  "/<
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M%D%]_Q;":@  M74  *I]  "?@@  DH,  (6$  !YA0  :HD  &2* P!@C!
M78T; %N.)P!8CC( 58X[ 5..0P)0CDH#3HU2!4R-609)C& (1XQH"D6+<@Q"
MBWT.0(J)#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&
M_Q.\<0  KWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P 5)86
M %*6(@!0ERT 39<V $N7/P%)ET<"1Y=. T66501#EET%099E!CZ5;P@\E7H)
M.I6'"SB5E0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U
M>   JH(  )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?
M&P!&H"8 1* P $.A.@!!H4(!/Z%) 3VA40([H5D".:%A S>@:P0UH'8%,Z"#
M!C&@D@<PH*((+J"S""Z@R0@NG^<(+9WW"2V<_PHMF_\*+9O_"BV;_PJO@
MHXD  )>.  "-DP  ?Y4  '*8  !FG   6Z   $^D  !%IP  /JD, #RJ%  Z
MJA\ .:HI #BK,@ WJSL -:M# #2L2P RK%,!,:Q< 2^L9@(MK'$"*ZQ_ RJL
MC@,HK)X$)ZRP!":LQ00FJ^0#):GU!"6H_P4EI_\%):?_!26G_P6GB0  FX\
M )&4  "$F0  >)X  &NB  !?I@  4ZH  $BM   ]L   -+,# "^U#@ MM18
M++4@ "NV*0 JMC( *;<Z "BW0P GMTP )KA5 "2X7P CN&L (KAX 2"XB $?
MN)D!';FK 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;
M  ![H0  ;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4
M !S"'@ ;PR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$
M$<>D !#'N0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !Q
MJ0  9*\  %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1
M$0 -T1D #=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28
M  34JP #U<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0
M6;@  $R]   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $
MW!$  ]T8  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #D
MFP  Y:X  .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$
M $#$   SR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T
M .<1  #H%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@
M\YP  /.M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-
M   GT0  '=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *
M  #Q#@  \Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD
M /^:  #_I@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_
M T0 _P!1 /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\
MH0#] *8 ^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_
M .T _P#M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$
M_P=- /\%60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W
M J0 ]0*J /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&
M_P#F!O\ Y@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY)
M /\,50#_"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$
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M L ;_P+_)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U
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M!:@ON@6F+\H&I##B!J$P\P>?,/\(GC'_")TQ_PB<,?\(G#'_")PQ_PC_,
M_S4  .\X  #B.@  VSD$ -8U"0#.-!, QC8B +\X,0"Z.#\ MCA* ;,X5 &P
M-UT"K3=D JLV; .I-G,$J#9Y!*8U@ 6D-8<%HS6/!J$UEP>?-: 'GC6J")PU
MM@B;-<4)F37="98V[PJ4-OT*DS?_"I(W_PJ2-_\*DC?_"I(W_PK_,P  ]CH
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M$7I%YA%Y1O<1>$;_$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P
MN%0  +%2  "K3@4 I$X1 )Y/( "94"T E5 Y 9)/0P&.3DP#BTU3!(E-6@6&
M3&$&A$MH"()+;@F 2G8+?DI^#'Q)APYZ29$/>$F<$'9)J!)T2;82<TG($W)*
MXQ-Q2O42<4K_$7%+_Q%Q2_\0<4O_$'%+_Q#L0P  V4P  ,A3  "]5P  M%@
M *Q7  "E4@$ GE,/ )A4' "35"D CU0U (M30 &(4T@"A5)0!()15P5_4%X&
M?5!D"'M/:PEY3W(+=TY[#75.A YS38X0<4V9$6]-I1-M3;,4;$W%%&M.X11K
M3O03:T[_$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P  *9:
M  "?5@  F%8- ))7&0".6"8 B5@R (98/0&"5T4"?U9- WQ55 5Y5%L&=U1A
M"'53: ES4W +<5)X#6]2@0]M4HL0:U&7$FE1HQ-G4;$49E'#%652WA5E4O(4
M95+_$V52_Q)E4O\295+_$F52_Q+D2@  SU,  ,!:  "U7@  K&   *)>  ":
M60  DEH+ (U;%@"(7", A%PO (!;.@%]6T,">5I+ W994@1T6%@&<5A?!V]7
M9@EM5VT+:U9U#6E6?@]G5HD19565$F-5H11B5:\5857!%F!5VQ9@5O$58%;^
M%&!6_Q-A5O\285;_$F%6_Q+@30  RU8  +U=  "R80  J&,  )UA  "570
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M$DYE_Q+,6@  O&,  +!J  "E;P  F&X  (QM  " ;   =VT  '%N"P!M;Q0
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M"S][E T^>Z,./'NS#CQ[R X\>N8./'GW#CQX_PX\>/\./7?_#CUW_PZ\:
MKW(  *1Y  "6>@  B'H  'QZ  !P?   8W\  %R"  !7A L 4X44 %&&( !/
MABH 3H<T $R'/ %*AT0!2(=+ D:'4P)$AEH#0H9B!$"&; 8^A78'.X6#"#F%
MD0HXA* +-H2Q"S:$Q@LV@^0+-H+V"S:!_PPV@/\,-H#_##: _PRV;P  JG@
M )]_  "0?@  @W\  '>   !K@@  7H<  %6*  !.C 8 2HX0 $B/&@!'CR4
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M 1^ENP$>I=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0
M;Y0  &.8  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @
ML"D '[ Q !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2R
MM@ 3LLX $['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\
M %NC  !0J   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X
M$;TF !&]+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  '
MOL( ![[?  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O
M  !'LP  /+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<
M  7))  $RBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,
M ,O(  #,X@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [
MNP  ,+X  ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5
M&@  UB(  -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV
M  #>R   WMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ
M),<  !O+   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@
MXQ<  .4>  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #N
MM   [L(  .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$
M !'6   +VP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\
M / 3  #R&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@
M_JT  /ZO  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\
M6@#_ &4 _P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G
M /4 K0#S +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\
MZ@#_ .H _P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_
M &$ _P!K /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T
MJP#L +( Z@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_
M .$ _P#_%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P
M^@!F /8 ;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C
M *\ X0"X -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#
M_P#_&!, _Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A
M .T&:@#I!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT
MU :U -(&P #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_
M&PX _QD, /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-
M90#>#6T VPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT
M ,@.P #&#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH
M_QP$ /\?" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.
M%&@ RQ1O ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7
MO "Y%\L MQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(
M /\E @#\) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F(
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M!)$PZ 6/,/@%C3'_!8TQ_P6,,?\%C#'_!8PQ_P7_+0  ZC4  -PZ  #./0
MQCP  , W @"[,PT LS09 *XV)P"I-S0 I3=  *(W2@"?-U,!G39: 9LV80&9
M-F@"ES5O I4U=0.4-7P#DC6$!) UC02/-98%C36@!8LUJP:*-;D&B#7*!X<V
MY0>%-O8'A#?_!X,W_P>#-_\'@C?_!X(W_P?T,@  XSL  -)!  #&1   O4,
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M"VM&_PMK1O\*:T;_"FM&_PKE0   STD  ,%/  "U4@  JU(  *%/  ";2@
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M#%=4_PS130  P%8  +-<  "G7@  FET  (]<  "&6   ?UD  'E:#0!T6Q<
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M"DMBE M)8J(,2&*R#4=BQPU'8N0-2&'V#$AA_PQ(8/\+26#_"TE@_PO$6
MM6   *IF  ";9@  C68  ()E  !V9   ;F4  &AF!0!C9Q  8&@: %UI)0!;
M:B\ 66HX %=J0 %5:D<!4VI. E%J50-/:5T$36ED!4MI;09):'@'1VB$"49H
MD@I$9Z$+0V>Q#$)GQ0Q"9^(,0F;U#$-F_PM#9?\+0V7_"T-E_PN_7   L60
M *9J  "6:0  B6D  'UI  !Q:0  9VH  &)L 0!=;0T 66X6 %=O(0!5<"L
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M<0  ?G$  '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $.
M-0!"@#T 08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ
M!C!^O08P?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0
M>78  &YW  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  Z
MB3@ .(E  #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(
MN@,IB-0#*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L
M &A^  !=@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS(
M+I,Z "V300 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@
MD\\!(9+L 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%
M  !7B0  38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR
M "*>.@ AGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D
M%I[H !:<]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0
MDP  1I@  #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J
M,0 4JCD $ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?
M  RI\@ -J/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP
M/Z,  #6G   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )
MMB\ "+8Y  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "V
MY0  M?$  +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\
M "RR   CM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8
M ,(O  ##.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0
MQ.8  ,3N  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\
M   9OP  $<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D
M  #0+0  TC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X
M -C=  #8W0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0
MR0  "LP   +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A
M(0  XRH  .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#
M  #JPP!PJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U
M -D   #=    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0
M\!T  /,G  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[
ML #_"QL _P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K
M /\ <P#] 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +
M[P"X .X PP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_
M#A@ _PH5 /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /<
M;P#U '< \P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T
M .0 OP#C ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!,
M_PT1 /\&$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L
M '( Z@!Y .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@
MNP#5 ,@ T@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX-
M /\,#0#_"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T
MWP!T -T >P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #(
M ,0 Q@#7 ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0
M"0#_$ X _PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O
M ,X%=@#,!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L(
MNPC4 +H)Z0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_
M% D _Q$. /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-
M<0# #7< OPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4
M *X1ZP"K$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0
MY10& .40#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T
M%7$ LA5X +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:
MYP"?&O< G1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$!
M ,\;" #*%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP
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M WTQ_P-\,?\#?#'_ WPQ_P/M+P  VS<  ,D]  "^/@  LSP  *PX  "G,P0
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M!F!$_P;600  PTD  +9.  "G3P  FTT  ))+  ",1P  A4<$ (!'$ !\2!H
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M!E10DP=24*$(45"Q"5!0Q E04.$)4%#T"%%0_P=13_\'44__!E%/_P;)2P
MN5,  *M7  "<5@  CU4  (54  !\4   =5$  '!2"0!K4Q( :%0= &54)P!B
M5#$ 8%0Y %Y400!<5$@!6E1/ 5E45@%75%T"5E1E U14;@125'@%452$!D]4
MD0=.5* (3%2O"$Q4P@E+5-\)3%3S"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8
M *=:  "860  BU@  (%7  !W5   <%4  &I6!@!F5Q  8E<: &!8) !=6"X
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M!CUBO <\8M8'/6'O!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+80
M?V$  '1A  !I80  7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI-@!(
M:3X 1FI% $5J3 !#:E0!0FI< 4!I90(^:6\"/&E[ SMIB00Y:9@%.&BH!3=H
MN@4W:=,%-VCN!3=G_ 4X9O\%.&;_!3AF_P6T7@  IV4  )5E  "&9   >F4
M &]E  !D9@  66@  %)J  !-; 0 26X. $=N%@!%;R  1' I $)P,@!!<#H
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M 2)_]P$B?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>
M3'P  $.    [@P  ,X8  "V)"@ JBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 C
MC$( (HU* "&-5  @C5X 'XUK !V->0 <C8H &XV< !F-K@ 8C,0 &(SC !F*
M]0 9B?\!&8C_ 1F(_P&==P  C'8  'UV  !R=P  97D  %I\  !0@   1H0
M #R)   TC   +9   "63 @ ?E0P '982 !R6&@ ;ER( &I<J !F7,@ 8F#H
M%YA# !:830 5F%@ %)AD !.8<P 1F(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0
ME?P $)3_ !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3
M   MEP  )IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z
M  RD10 +I%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,
M Z'[  .A^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   F
MH@  'J4  !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P
M/   L$<  +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T
M  "N] "'B0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@
M%K$  !"T   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0
MO3P  +Y(  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]
MZP!_D@  <)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP
M  F_   "P@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#
M ,X\  #.20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!W
MG   :*$  %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*
M    S@   -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O
M  #B/   XTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0
M7ZP  %&R  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8
MW    -\   #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q
M+@  \SP  /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5
M /\ %0#_ !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8
M^0!] /@ @P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J
M ,L Z #A .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\
M$0#_ !4 _P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y
M .\ ?P#M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8
MW #: -H [ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_
M !( _P : /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T .,
M>@#B (  X "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1
M ,L YP#) /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \
M_P 5 /P ( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2
M 'L T "  ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T
MXP"\ /( NP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0
M /  &0#F "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8
MPP![ ,$ @0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P
M >\ KP'[ *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!
M$0#; AT T@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V
M +4%? "S!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_
MHPS] *(-_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#.
M"!0 Q@HB , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.
M> "H#GX IP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_
M )84_P"5%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X
MNA(; +03*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<
M%GD FQ>  )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<
M_P"*'/\ B1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5
M *@<(P"D'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0
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M FTQ_P+?,@  R3D  +L^  "L/0  H3H  )HW  "5,P  D#$* (PQ% "',B
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M EX^DP-</J #6S^O!%H_P01:/]T$63_R!%D__P-9/_\#63__ UD__P/,/P
MO$8  *M(  "<1P  D48  (A$  ""0   ?#\  '= # !S0!4 ;T$@ &Q!*@!J
M03, :$$[ &9"0P!D0DH 8T%0 &%!5P!@0EX!7D)E 5U";@);0G@"6D*$ UA"
MD -70IX$5D.M!%5#OP140]H$5$/Q!%1#_@-40_\#5$/_ U1#_P/(0@  N$D
M *=+  "82@  C4D  (-'  !]0P  =D,  '%$"@!M1!( :D4= &=%)P!D13
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M!$9/N@1&3]$$1D_M!$9._ 1&3O\#1T[_ T=._P.]3   KE(  )Q1  "-40
M@5$  '=0  !N3   9TX  &)/  !=4 T 6E 4 %=1'@!542< 4U$P %%2. !0
M4C\ 3E)& $U230!,4U4 2E-= 4E390%(4V\"1E-[ D53B0-#4Y<#0E.G!$%3
MN 1!4\\$05/L!$%2^P-"4O\#0E+_ T)1_P.Z3P  JE0  )A4  ")5   ?5,
M '-3  !I40  8E(  %Q3  !85 H 5%42 %)5&P!/5B0 3E8M $Q7-0!+5SP
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M C%A^ (Q8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@
M4F   $QB  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U
M:DD -&I2 #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH
M]@(K9_\"*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8
M $=H  ! :P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4
M+')- "MR5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C
M;_\!(V[_ 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O
M   [<@  -'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM(
M ")[4@ A>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X
M&W?_ 1MW_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U
M>@  +GT  ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&
M3  7AE8 %H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_
M !*!_P"1;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P
M)X<  "&*   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .
MD4\ #9%<  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-
M_P")<P  >W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$
M !J5   3EP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@
M )U4  "=8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ ""
M>0  =GD  &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@
M   .HP  ":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+
M  "I60  J6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@
M;X$  &&$  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   '
MKP   +(   "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X
M3@  N%T  +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL
M %J0  !.E@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O
M +X   "^    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@
MR5$  ,EB  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>
M  !&I   .JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H
M  #*    S    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,
M -]4  #?9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _
MM   ,K@  "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9
M    VP   -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&
M  #R6   \VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4
M_P ? /\ + #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T
M (0 \@") /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; .,
M[0#B /L X@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ;
M /\ * #_ #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\
MYP"% .8 B@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2
M /< T0#_ -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L
M(@#W "\ ]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"
M -@ A0#5 (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /(
MPP#^ ,( _P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K
M "D YP V ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@
M@ #& (8 Q0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z
M +0 _P"T /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "(
MUP O -$ .P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y
M ($ MP"' +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *<
M_P"G /\ I@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G
M ,, ,P"_ #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P
MJ@"" *D B0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":
M!?\ F@7_ )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#
M+ "S!#< L 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^
M )T(A0";"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\
MC@[_ (T._P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H
M#C  I0X[ *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0
M@0"0$(H CQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_
M ((5_P#M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H
MF14U )86/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%
M&(8 @QF0 ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=
M_P#E(@  T"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO
M (P>.0")'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($
M>2&, '<AEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=
M*0  R#   +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E
M- " )CT ?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB(
M &XHE !L**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P
MPC8  *\V  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W
M+#@ =2Q  ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4N
MD0%D+IX!8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L
M *DZ  ";.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30
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M DX^MP)./LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P
M@D(  'I   !S/0  ;3P  &@]!0!D/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7
M/D  53]& %0_30!3/U4 4D!< %! 90!/0&\!3D%Z 4U!AP%+098!2D&E DE"
MM0))0LL"24+H DE"^0))0?\"24'_ 4E!_P&]0P  JD4  )A%  "*10  ?T4
M '9#  !O0   :$   &-! 0!?00T 7$$4 %E"'0!70B8 54(N %-"-@!10CT
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M CM-]@([3?\!.TS_ 3Q,_P&S30  GDP  (U,  !_3   =$P  &I,  !@2@
M64L  %1,  !0304 3$X. $E/%0!'3QX 14\F $10+@!"4#4 05 ] $!11  _
M44L /E%3 #U27  \4F8 .E)R #E2?P$X4HX!-U*> 392KP$U4L0!-5+B 392
M]0$V4?\!-E#_ 3=0_P&N3P  F4\  (E/  ![3P  <$\  &9/  !<3@  5$\
M $]1  !*4@$ 1E,, $-4$@!!5!L 0%4C #Y5*P ]5C( /%8Z #M600 Z5DD
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M 21A_P&<6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P
M-&8  "]H"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B
M;%D (&QE !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH
M_P"57   @UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT
M "AP!  C<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0
M%W5@ !9U;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".
M8   ?6   &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X
M   <>P< %WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:
M  Y_:  -?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90
M=V4  &IE  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5
MA   $(<(  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)
M80 "B7$  8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H
M &=K  !;;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP
M#)(&  :3#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660
MEFD  )5Z  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R
M  !4=0  27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#
M  ">"0  GPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\
M *-Q  "CA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-
M@   0H4  #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K
M!   JPH  *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F
M  "R>0  LHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0
M.Y,  #"9   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X
MN0(  +D(  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##
M;   Q((  ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(
M "BH   =K0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@
M ,<   #)!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P
MVG,  -J*  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W
M   5NP  #;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8
M  #9    VP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4
M .]Z  #OCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_
M #4 _P!! /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X
MB0#M (\ ZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_
M -T _P#= /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$
M^P ] /@ 2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@
M (H W@"0 -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L
M_P#+ /\ RP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W
M .L 0@#G $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4
MS0"+ ,L D@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\
M /\ O #_ +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L
M/ #7 $< T@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"&
M +P C0"Z )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\
MK0#_ *T _P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#%
M $  P@!* +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X
MB "M (\ JP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_
M *  _P#_    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H
MM !# +$ 3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@
M (H G@"3 )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )(
M_P#Y!0  Z@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ]
M *0 10"B $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8
MD@&/ ) !F0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O
M#P  WA0  ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(
M/P"7"4< E0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN,
M (4,EP"##*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P
MT1X  +T=  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",
M$$$ BA!( (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2
ME !X$J  =Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4
M +,E  "E(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP
M@!=# 'X72@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N
M&IT ;!NK &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ
M  "=*@  DR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^
M '0>10!R'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH
M8R*H &(CN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6
M+P  C"T  (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE
M00!J)4< :"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE
M %HIM0!:*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P
MAC(  '\O  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B
M*D, 8"I* %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,O
MLP!3+\< 4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34
M 'DS  !S,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T
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M 4(\\P%"//\!0CS_ 4([_P&S/0  GCX  (T^  !_/@  =3X  &P]  !F.@
M8#D  %LZ  !7.@@ 4SL0 %$[& !..R  3#LH $L[+P!)/#8 1SP] $<\1 !&
M/4L 13U3 $0^7 !#/F8 0C]Q $$_?@! /XT /T"< #Y K0$]0, !/4#= 3U
M\@$]0/\!/C__ 3X__P&N0   FD   (E!  !\00  <4$  &A   !A/   6ST
M %8^  !2/@4 3C\. $P_%0!)/QT 1T E $9 + !$0#, 0T Z $)!0@!!04D
M0$%1 #]"6@ ^0F, /4-O #Q#?  [0XL .D2; #E$JP$Y1+X!.$3; 3E$\0$Y
M0_X!.4/_ 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"
M  !-0@( 24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/
M #I&5P Y1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T
M-$?_ #5&_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(
M1P  1$<* $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+
M50 T3%\ ,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_
M #!+_P"A1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P
M/TP& #M-#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N
M45P +5%G "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/
M_P"<2@  B4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5("
M #53#  S5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD
M)U=D "97<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"6
M30  A$X  '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:
M"  K6P\ *EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA
M !]>;@ >7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040
M?E$  '!1  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D
M8@P (F,1 "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E
M:@ 697H %66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4
M &M5  !@5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@<
M&6P. !AL$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .
M;G4 #6Z'  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99
M  !<6@  5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)
M  ]W#P .=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\
M!'>   -WE  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !9
M7@  3F   $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!
M#  %@1$  X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y
M  ""C0  @:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39
M26<  #]K   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@
MBPX  (L3  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".
MA0  CID  (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$
M #AV   O>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP
M )</  "8$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P
MG)   )NE  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"
M   GAP  'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+
M  "E#@  IA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4
M *R;  "KKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?
ME@  %IL  !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T
M"   M0T  +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0
M  "]I   O;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I
M$*D   FN    L@   +8   "Y    O0   +\   "_    P    ,$   ##
MQ 4  ,8*  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3
MEP  TZD  -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D
M  "]    P0   ,0   #(    RP   ,T   #-    SP   -    #2    U
M -@   #:!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB
MZYL  .RH  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\
M2 #[ %( ^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0
M .8 E@#D )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\
MUP#_ -0 _P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P
M $T [0!5 .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4
MD0#3 )D T0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_
M ,< _P#_    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $<
MW0!0 -D 6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ##
M )0 P0"< +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8
M_P#_    _P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!*
M ,< 4@#$ %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X
ML@"7 +  H "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_
M    _@   /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +<
M3 "T %, L@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1
M *( FP"@ *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]
M\    .$   #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F
M $T I !4 *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4
ME@"3 *$ D0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<
M ,P'  "_!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $<
MF !. )8 5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"&
M )T A0"I (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0
M  "Q#@  J T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %(
M (H"3@") E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H
M>0:G '@&M0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E
M%@  G!,  )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +
M20!^"T\ ?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF
M &T.M0!L#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0
MDAL  (L9  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T
M$4H <Q%0 '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5
MLP!B%<8 8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(
M ((@  !^'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4
M:1A+ &@840!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:
M',, 61W@ %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE
M  !V(P  <R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y'
M %\>30!>'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\
M42/= %$D\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O
M*   :R4  &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D
M2@!6)%  5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG:
M $HI\0!**?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P
M92H  &,G 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/
M*4T 3BE4 $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N
M[P!%+OX 12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T
M %TL  !9+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H
M2"Y1 $<N60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@!
M,OT 0#+_ $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P
M  !4, 8 43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/
M $$S5P! ,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP
M.S;_ #LV_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/
M- , 2S0, $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW
M50 [.%X .CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_
M #<Y_P"B.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.
M1C@* $0Y$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V
M/%P -3QG #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]
M_P">.P  BSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T'
M #X]#@ \/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H
M,$%E "]!<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9
M/0  ASX  '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"
M#0 W0A( -4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C
M "I&;P I1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50
M@D$  '-"  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q
M2!  +T@6 "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+
M;0 C2WP (DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0
M &]$  !D10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X
M*4X3 "=/&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =
M47D '%&* !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'
M  !@2   5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40
M "!5%@ ?5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4
M%%B' !18F@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<
M2P  4TL  $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=
M$@ 771D %EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#
M  U?E@ -7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P
M3T\  $A0  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 0
M9A0 #V8;  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5G
MD  $9J,  F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,
M $-5   [6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$
M!W 6  5P'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@
M;YX  &^R  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!2
M3T9)3$4 ! E15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .
M<P  "W8$  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z
M4   >E\  'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL
M %9;  !,7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@
M!($"  """   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20
MAU<  (=H  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A
M  !&9   /&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T
M  ".!   C@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX
M )9?  "5<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _
M;@  -70  "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";
M    G (  )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95
M  "F:   IGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P
M+8$  ".'   9C0  $9(   N7   $G    *    "C    I@   *@   "I
MJ@   *P   "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X
M7   N'$  +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I
M !N7   2G0  #*(   .G    JP   *X   "R    M@   +@   "X    N@
M +L   "]    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4
MS&0  ,UZ  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F
M   ,K    [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L
M  #-    S@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58
M .9K  #F@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_
M "T _P X /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .<
M?P#F (4 Y "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_
M -$ _P#1 /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@
M\P S /  /@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4
M '\ T@"% -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,
M_P#  /\ OP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N
M .  . #; $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H
MP0"  +\ A@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O
M /\ KP#_ +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D
M,@#& #P P@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z
M *\ @ "M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\
MH #_ *$ _P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T
M #8 L@ _ *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *
M>@"> (( G "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_
M )$ _P#W    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #
MHP X *  0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0
M 'P CP"% (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (,
M_P#L    TP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R
M ), .@"1 $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '<
M@@"  (  B@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>
M"@  Q L  +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (<
M- "% #L @P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![
M '0 A@!S )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$
MMQ$  *82  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z
M S8 > 0\ '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'
M@P!H")  9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<
M )T8  "0&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##
M;PPW &T,/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?
M#HX 70^< %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>
M  "('@  ?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R
M &01.0!C$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L
M5!69 %,5J0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!
M(P  =R(  ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7
M- !:%SL 61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7
M $L<I@!*'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P
M<28  &HE  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3
M'3< 41T] % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0B
MI !$(K8 0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H
M &4I  !@)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C,
M2B(Y $DB0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^
M)[0 /2?* #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L
M  !<*P  6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V
M $,G/ !!)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++(
M-RS( #<LY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8
M+@  4RL  % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK
M.0 \*T  .RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#'
M #(PY0 S,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0
M3R\  $LM  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TT
MXP N-/8 +S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(
M $8Q  !",@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L
M,#5# # U3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I
M./4 *C?_ "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U
M   ]-@  .C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE!
M "HZ20 J.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0
M)3O_ "4[_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y
M.@  -3L  #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_
M1P D/U  (T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^
M " __P").0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@
M,$   "U!!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >
M14X '459 !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$
M_P"$/   <ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0
M "=& 0 D1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL
M%TM5 !9+8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_
M/P  ;T   &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+
M   >308 &T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2
M !!17P /4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P
M:D0  %U$  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :
M4P  %%8) !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I8
M6@ (6&@ !UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<
M %E(  !02   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@
M$%T&  Q@#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50
M8&,  &!S  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+
M  !,3   14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$
M  AG"P #9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T
M &EM  !I@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*
M3P  05$  #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P
M"0  < T  '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F
M  !S>0  <XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50
M.U@  #)<   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@
M>@H  'L.  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  "
M<0  @(8  ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$
M "QE   C:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8
M (@*  ")#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:
MCWX  (^5  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q
M   <=P  %'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#
M  "7"   F P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0
M )^,  "?H@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4
MA0  #8L   :0    E    )@   "<    GP   *$   "B    I    *4   "G
M    J 0  *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*
M  "RF   L:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0
M!IH   "?    I    *@   "L    KP   +$   "Q    LP   +4   "V
MN    +H   "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'
MB@  R)\  ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H
M  "O    LP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0
M ,L   #-    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P
MX9$  .*B  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L
M/@#W $@ \P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "%
M -X C #< ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\
MQ@#_ ,$ _P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H
M $( XP!+ .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H
MA@#( (X Q@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_
M +8 _P#_    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T
MS@!% ,H 30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V
M (@ M "0 +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H
M_P#_    _0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _
M +< 1P"U $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($
MI "* *, E "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^
M    [@   -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *<
M00"D $@ H@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$
M )0 C@"2 )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P
MVP   ,<   "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6
M $$ E !( )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4
MB "# )0 @@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@
M +4   "J    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L
MA@!" (4 1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V
M (\ =0"< '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'
M  ";!@  DP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \
M 'D 0@!W $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H
M:0"8 &@ I@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/
M#@  A@T  ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X
M/ !L $( :P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5
M %X"HP!< [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P
M?!(  '81  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C
M!CT 8@=# &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+
MH@!3"[, 4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@
M &T7  !J%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D
M6@T_ %@-10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+
M$+( 2A'( $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<
M  !B&@  7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[
M % 200!/$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K
M0A;% $(7XP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<
M'P  61P  %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7
M/0!'%T, 1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS#
M #L<X0 ['?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P
M4R   %$>  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0!
M'$  /QU' #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4A
MWP U(?, -B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0
M $PB  !)(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T
M.2%$ #@B3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P
M)O( ,";_ #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E
M  !$)   020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9!
M #(F2@ Q)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$
M*RK^ "PI_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _
M*   /"@" #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M1P L*U$ *RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[]
M "<M_P"**P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+
M-RP  #0L"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G
M,$X )C!9 "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q
M_P"&+0  =2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S
M # Q!@ M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P
M(357 " U8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P""
M,   <3(  &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU
M @ H-@L )3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4
M !HZ8  9.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@
M;30  & U  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C
M.P@ (#P. !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_
M7@ 4/VP $T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<
M %PX  !2.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000
M&D(+ !A#$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .
M16D #D5Y  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[
M  !/.P  1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@(
M !)*#0 12A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0
M"$MT  =+AP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+
M/@  1#X  #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1
M"P +41  "E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O
M  !2@0  498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00
M04$  #M"   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &
M6 X  E@2  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9
M?   69   %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4
M #='   O20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T
M & 0  !A%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@
M8HL  &*@  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-
M   J4   (U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.
M  !J$0  :Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80
M &R:  !LL   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D
M6   '5P  !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U
M#@  =A$  '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4
M  !XJ@  >,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@
M%F<  !!K   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@
M@PT  (01  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(
MH@  A[D  (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0
M  IY   "?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@
M ),,  "5$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@
MF+   )C'  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(
M    C    )$   "5    F    )H   ";    G0   )\   "@    H@   *0%
M  "F"@  J X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<
M *NZ  "KRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8
MG0   *$   "E    J    *L   "K    K@   *\   "Q    LP   +4   "W
M 0  N0<  +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M
M  #!O  ^<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0
M +(   "V    N0   +L   "\    O@   ,    #"    Q    ,8   #(
MRP   ,X%  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<
MJP#_    _P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+
M .T 4@#J %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X
MT0"6 ,\ H0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_
M    _P   /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D
M30#4 %, T0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0
M +T FP"[ *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_
M_P   /@   #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#
M $X O@!3 +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L
ME "I *  J "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@
M .8   #7    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@
MJP!. *D 4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9
M )D EP"F )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -
M  #!    MP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!(
M )D 30"7 %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ),
MB "@ (< KP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O
M    I@   )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H
M1P"( $P AP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@":
M '@ J0!W +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?
MEP   )   @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![
M $8 >0!+ '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L
MHP!J +0 :@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B
M (,   !_  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$
M;0!& &P 2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!?
M *\ 7@## %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'
M  !T!   <0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!!
M &( 1@!@ $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L
M5 "^ %0 V@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I
M#   9PD# &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@
M0@!7 4< 5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\
M $H&U !*!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0
M7@\  %T-!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/
M"40 3@E* $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-
MU0!"#>X 0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,
M %01  !4#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$
M1@Y' $4.3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z
M$?  .A+] #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6
M  !,$P, 3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$
M #T23  \$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX
M-!;\ #06_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&
M&   118' $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<7
M20 U%U$ -!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[
M "X;_P"*'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P
M/QH# #T:#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O
M'$\ +AU9 "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?
M_P"&(   =",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX
M #<>"0 U'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P
M*2%6 "@B8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""
M(P  <24  &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B
M!@ P(@T +B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94
M "(F8  A)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0
M;B<  & I  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K
M)PL *"<0 "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK
M7@ <*VL &RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH
M %TK  !3+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@
M(RP. "(L$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7
M+VD %C!Y !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM
M  !0+@  2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$,
M !PQ$  ;,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&<
M$35W !$UB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-
M,   13   #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W
M#@ 5-Q, %#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT
M  PZA@ ,.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P
M0C,  #LS   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0
M/A  $#X5  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_
M@0 %/Y0 !#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4
M #DU   T-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X
M"D03  E$&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?
M19   $2D  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X
M   Q.   *SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1
M  %+%@  2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP
M $NA  !+M0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N
M/   )SX  ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2
M$P  4Q@  %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<
M  !2L0  4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@
M(T0  !U'   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0
M6A4  %L:  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;
MK0  6L4  %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP
M !=/   24P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$
M &46  !F'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ
M9<   &3>  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9
M   -7   "&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2
M  !R%P  <QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@
M ''4  !P[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   '
M:    &L   !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  "
M$0  @A8  (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)
M  " Y0!*3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0
M 'D   !]    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0
MDA   )06  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2
MU0!$50  .5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D
M  "-    D0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L
M *40  "H%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^
M7@  ,F,  "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?
M    H@   *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)
M  "[$   OA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@
M*W   "!X   6@   #8@   6/    E@   )P   "B    IP   *P   "P
MLP   +8   "W    N0   +L   "]    OP   ,(   #%    R    ,H   #.
M"   TA   -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P
M /\   #_  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %,
MY !9 .$ 7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #&
M *< Q "W ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\
M  #Z  $ \P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4
M ,@ 60#& %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$
ML@"O +  P@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F
M    W0 ' -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4
M4P"S %@ L0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H
M )\ N0"> -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,
MP0 " +H # "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@
M %( G@!7 )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X
ML0"- ,8 C #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K
M *8 " "A  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P
MC@!1 (T 50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!]
M +P ? #< 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0
M P"0  P C0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+
M 'T 3P!\ %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0
M;@#, &X [0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!
M  @ ?@ . 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '
M2@!O $\ ;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#"
M &$ Y !A /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  ,
M<0 + &\ $ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C
M $H 80!/ &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8
MV !6 /$ 5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P '
M &0 #0!C !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4
M5P!+ %8 40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!,
M .L 3 #Z $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!
M"0!:  X 6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!'
M $T 30!+ %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8
M0P#U $, _P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3
M!@L 40,0 $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#
M2@!#!%$ 0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S
M #H(_ ".$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08
M2@H, $D($0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \
M"D\ .@M8 #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-
M_@"($P  =Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX(
M $(-#@! #1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT
M,P]7 #(/8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#
M%@  <AD  &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1
M"@ Z$!  .! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4
M "L37P J%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0
M;AL  & =  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T
M% T ,A02 # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "88
M70 D&&H (QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX
M %T?  !3(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L
M+!@0 "H8%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?
M'6@ 'AUW !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA
M  !0(@  2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT.
M "4=$@ C'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68
M&2%U !@BAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-
M)   124  #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A
M$  >(14 '2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S
M !,FA0 2)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@
M0B<  #PF   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9
M)Q( &"<8 !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J
M@P .*I8 #BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D
M #DH   T*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$
M$RP6 !(L'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *
M+Y( "2^E  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K
M   Q*@  +2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3
M  XR&0 -,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX
M S.B  (SM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O
M+   *RP  "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX
M%@ (.!T !S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?
M   XLP  .,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P
M*2\  "0P   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%
M/AH  #XA   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^
ML   /<<  #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(
M " T   ;-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118
M $4=  !%)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0
M1,0  $/C  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ
M   7/   $C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9
M  !.(   3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$
M $OA  !*\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    3
M0P  #T8   M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6
M&P  5R,  %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=
M  !3\ !+/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P
M"T\   51    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@
M8AT  &(F  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=
M[@!'0   /S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@
M  !;    7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<
M &\@  !O*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$
M1   /D,  #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G
M    :P   &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8
M  !_(@  ?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P
M.4D  "],   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V
M>0   'P   !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2
M&0  DB4  )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$
M "A6   >7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0
M (P   ".    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0
MIAL  *8I  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B
M   7:0  #W    =W    ?@   (0   "*    CP   )0   "8    FP   )X
M  "?    H@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(
M +L?  "[,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0
M>   "8    "(    CP   )8   ";    H0   *8   "J    K@   +    "Q
M    M    +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5
M  #2)0  TC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  ,
M_P + /P $0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9
M %X U0!C -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P
MR "Z .H N0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 '
M .< #P#B !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@
MO@!= +P 8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G
M -X I@#Y *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H
M# #% !( PP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7
M *D 7 "G &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T
ME0#Q )0 _P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M
M  \ J@ 6 *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8
M50"4 %H DP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F
M (, _0"$ /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P
ME@ 1 )0 &0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$
M %0 @@!: ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ',
M] !T /\ = #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P .
M ($ % "! !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X
M<P!4 '$ 6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F
M /\ 9@#_ &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '(
M$ !Q !8 <  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!.
M &0 5 !C %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@
M6@#_ %H _P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D
M !( 8P 8 &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@
M3P!7 %8 5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_
M $\ _P"<    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \
M6  4 %< &0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!-
M %( 2P!: $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4
M_P"2!   @ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0
M $X %0!- !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X
M0@!6 $$ 7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")
M"@  > P  &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8
M$0!% !8 1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2
M #D 7  X &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0
M<0\  &00  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^
M Q( / (8 #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&
M6@ P!F8 +P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$
M %\3  !4%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1
M-@@4 #4(&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I
M#&4 * QS "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6
M  !1%P  2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1
M "\-%@ M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4
M(1!S " 0A  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-
M&0  11D  #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0
M$@ H$!@ )A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q
M !H3@@ 9%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P
M0AP  #P;   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48
M@0 4&), $QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX
M #D=   T'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0
M')( $!RE  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?
M   Q'P  +1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5
M !4<&P 4'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\
M#""B  L@M0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O
M(0  *B   "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B
M&0 0(A\ #R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>
M  <DL0 &),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P
M*"(  "0A   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,
M)QT "R<C  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $H
MKP  *,4  2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0
M "(C   ?(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H
M!BPA  4L*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0
M+,(  "S@   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F
M   =)@  &2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>
M   R)0  ,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$
M #'?   Q\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :
M*@  %BP  !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X
M(@  ."H  #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>
M   V\ !1*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P
M$S$  ! S   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@
M0"4  $ O  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]
M\ !-+@  0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<
M  PZ   )/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$
M $@J  !(-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(
M,@  /C(  #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"
M   #1    $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E
M  !2,   4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@
M.S8  #0U   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*
M30   $\   !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=
M*@  738  %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D
M #,X   K.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P
M %H   !<    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P
M:BX  &H\  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]
M   E0   '40  !9)   030  "E$   15    6@   %T   !@    8P   &8
M  !H    :@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<
M 'HU  !Y10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @
M2@  %TX  !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W
M    >0   'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK
M  "..P  C4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950
M$%L   IA   !9P   &T   !R    =P   'L   !_    @P   (8   "(
MB@   (T   "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D
M,0  HT0  *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD
M  %P    =P   'T   "#    B    (T   "1    E0   )@   ":    G
M )\   "A    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P
MN3D  +A.  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!
M    B0   (\   "6    FP   *    "D    J    *L   "L    KP   +(
M  "T    M@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\
M -!$  #/6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U
M !< ]  @ /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X
M8P#+ &@ R0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_
M *\ _P"E /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !(
MV  ; -8 ) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U
M &( LP!G +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X
M_P"8 /\ D@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6
M +D 'P"W "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L
MGP!A )X 9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"*
M /\ A0#_ (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$
M&0"@ "( GP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !:
M (H 80"( &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\
M> #_ '8 _P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "*
M !P B@ C (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H
M6@!X &$ =@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_
M &D _P#     JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !<
M>  > '< ) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H
M %L 9P!C &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T
M_P"L    F0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8
M &< 'P!G "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4
M6@!= %@ 9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=
M    BP   'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H
M&0!: !\ 60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8
M $T 8@!+ &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0
M?@   '    !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!.
M !H 3@ @ $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $,
M70!! &@ 0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,
M &@&  !=!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8
M1  ; $, ( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X
M &0 -P!Q #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +
M  !6#   3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7
M #L '  Z "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &
M+P!M "X ?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0
M#@  20X  $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #,
M&  R !T ,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K
M "<!>@ F 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0
M1!$  #X1   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K
M QD *@,> "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '
M>0 ?!XL '@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,
M #H3   U$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8
M) @; ",)(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8
M#(L & R> !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5
M   Q%   +1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8
M !X-'0 =#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T
M$1"@ !$0LP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O
M%@  *A4  "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0
M&P 7$"$ %A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>
M  T3L0 -$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&
M*!<  "06   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2
M$Q\ $1,F !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6
MK0 (%L$ "!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D
M "(8   ?&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP
M#A@C  T8*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #
M&K\  QG:  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :
M   =&0  &AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?
M  D=)P ('2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT
M !W8   =[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;
M&P  &!L  !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A
M)  "(BP  2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7
M   A[0!5'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0
M%AT  !,>   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0
M)RD  "<R   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E
M[0!1(   12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"
M !$B   /(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8
M "TO   M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-
M(@  020  #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F
M   -*   "BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K
M   S-@  ,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0
M/B8  #0G   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *
M+@  !C !  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z
M,@  .CX  #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD
M #$I   K*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0
M 3<    Y @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@
M0SD  $-'  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L
M   J*P  )2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\
M  !!    0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330
M $Q"  !,40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H
M+0  (B\  !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*
M    3    $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\
M  !72P  5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@
M'34  !8X   1/   #$    =$    1P   $H   !-    4    %,   !5
M5P   %D   !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E
M1   9%<  &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T
M !%"   ,1@  !DH   !/    4P   %8   !9    7    %\   !A    9
M &4   !G    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0
M=4\  '1C  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-
M   %4@   %<   !<    8    &0   !H    :P   &X   !Q    <P   '4
M  !W    >@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44
M (=;  "&<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:
M80   &8   !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*
M    C    (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0
M  "=9P  FH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <
M '<   !]    @@   (8   "+    CP   ),   "5    EP   )H   "=
MH    *,   "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U
M7   M'0  +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D
M  "0    E0   )H   "?    HP   *8   "H    JP   *X   "P    LP
M +8   "Z    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040
MS6@  ,N!  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T
M)0#H "X X@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I
M ,$ < "^ '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\
ME #_ (\ _P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #,
M "@ Q@ P ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L
M:0"I '$ IP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_
M (0 _P#H    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "(
MK0 J *D ,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5
M &D DP!R )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@
M_P#9    S0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D
M )0 *P"1 #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &(
M@ !K 'X =0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'
M    M0   *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (
M)0!^ "L ?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D
M &T ;@!L 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T
MH    )    "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M
M "4 :P J &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X
M9P!< ', 6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@
M '\   !U    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\
M70 E %P *@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0
M &T 3@![ $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(
M  !G    7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ?
M $\ ) !. "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &<
M0P!U $( A@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=
M    50   $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4
M'P!$ "0 0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O
M #@ @  W ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P
M30,  $<#  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z
M !\ .0 D #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\
M>P N (X +0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@
M $ (   [!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L
M,0 @ #  )  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F
M (D )@"= "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+
M   V"P  ,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 <
M "@ (  G "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4
M'P"9 !X K@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q
M#0  +0T  "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!
M'0 A "( (  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6
M !@ J@ 8 ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P
M*0X  "8.   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :
M!1\ &@4E !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&
MIP 2!;P $@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A
M "(0   @#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P
M% DB !0**0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -
M"[H #0K2  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1
M   <$   &A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@
M ! -*  /#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD
M" [0  <.Z !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :
M$@  %Q$" !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0
M)0 ,$"T "Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/
M  (1Z !5$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P
M%1(# !,2!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ (
M$RH !Q0S  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3
MZ0!2%   1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$
M !(3!@ 1$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<
M A@P  $8.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/
M%@  0Q@  #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4
M!@ 0% 8 #A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM
M   <.   '40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&
M0!H  #8;   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .
M%P0 #!D%  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A
M-0  (D$  ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P
M #,=   K'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' (
M"AT#  <?!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@
M)SX  "=+   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?
M   H'P  (QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!
M  ,D!   )@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH
M "Y(   M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F
M(0  (2   !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K
M @  +00  "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#
M   U4P  -&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P
M("(  !PA   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R
M- $  #8$   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]
M3@  /6$  #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0
M !DE   4)@  $"@   TK   )+@  !3     S    -0   #@    Z    /
M #X!  !  P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20
M1EL  $5Q  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J
M   1+0  #3    DS   #-@   #D    \    /@   $$   !#    1@   $@
M  !*    3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4
M %%J  !0@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   -
M-0  "#D   (]    0    $,   !&    20   $P   !.    40   %,   !5
M    5P   %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B
M  !>>P  7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P
M 40   !(    3    $\   !2    50   %@   !;    70   &    !B
M9    &8   !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O
M<0  ;8L  &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$
M  !5    60   %T   !A    90   &@   !K    ;0   &\   !R    =
M '<   !Z    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P
M@8$  '^;  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D
M    :0   &X   !R    =@   'H   !]    @    ((   "%    B    (L
M  ".    D@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<
M )>/  "5IP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V
M>P   (    "&    B@   (X   "1    DP   )8   "9    G    *    "C
M    IP   *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%
M  "MG  <3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP
M )0   ":    GP   *(   "D    IP   *H   "N    L0   +0   "X
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M____________________________________________
M      $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T
M-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN
M;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:G
MJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@
MXN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_____________________________
M_________________________P                     ! P0%!@@)"@L-
M#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&
M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MF:F#S92H@\Z0IX3/C*:%T(FFAM&&I8?2A*6*TH&EC=* I8_2@*6/TH"EC]*
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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M!/^O(1;_K2XO_ZD\2_>C26GHIDA_VJ=(E<RE4ZK'J%RRQ*QDML&N;KN]KWC
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MK\*(D*_"B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"_Z@8 O^I(P__IS(E_Z-
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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M"(?_&1)^_RD;=?\U(VS_/"ID_T,O7O]*-%C_4#=4_U8Z4?];/$[_8#Y+_V1
M2O]H04C_;$)&_W!#1?]T1$3_>$5"_WU&0?^!1T#_AD@__XQ)/?^12CW_D4H]
M_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4H]_Y%*KL4  )[7  "/]0 !AO\/!'S_
M&PMQ_R019_\L%U__-1Q9_STA5/]%)D__2RE,_U(L2/]7+T;_73!$_V$R0O]F
M,T#_:C4__VXV/?]S-SS_=S@[_WPY.O^!.CC_ACHW_XP[-O^2/#;_DCPV_Y(\
M-O^2/#;_DCPV_Y(\-O^2/#;_DCPV_Y(\_X,3 ?^$(@;_A344_X-&)/]_533_
M@5Y"_X%F4/]_;ESY?'=F\WJ ;^YWB'?J=8]]YW*5@N1PFH7C;IZ(X6RBB^!K
MIXW?::N.WFBOD-UGM)'=9KJ1W&7!DMQER9+;9="2TF?2D<YHTI'.:-*1SFC2
MD<YHTI'.:-*1SFC2D<YHTI'.:-*1_X,3 ?^$(@;_A344_X-&)/]_533_@5Y"
M_X%F4/]_;ESY?'=F\WJ ;^YWB'?J=8]]YW*5@N1PFH7C;IZ(X6RBB^!KIXW?
M::N.WFBOD-UGM)'=9KJ1W&7!DMQER9+;9="2TF?2D<YHTI'.:-*1SFC2D<YH
MTI'.:-*1SFC2D<YHTI'.:-*1_X,3 ?^$(@;_A344_X-&)/]_533_@5Y"_X%F
M4/]_;ESY?'=F\WJ ;^YWB'?J=8]]YW*5@N1PFH7C;IZ(X6RBB^!KIXW?::N.
MWFBOD-UGM)'=9KJ1W&7!DMQER9+;9="2TF?2D<YHTI'.:-*1SFC2D<YHTI'.
M:-*1SFC2D<YHTI'.:-*1_X03 ?^%(@;_AC44_X1&)/^ 533_A%U#_X5E4/^#
M;5WX@'5H\GU^<>QZAGGH=XU_Y763A>)RF(G@<)V,WVZBCMULII#<:ZN2VVFO
ME-IHM97:9[N5VF;#EMIFS);3:,^6S&G/E<AJSY;(:L^6R&K/ELAJSY;(:L^6
MR&K/ELAJSY;(:L^6_X42 ?^'(@;_AS44_X5&)/^$5#7_B%Q#_XAD4?Z':U[W
M@W)I\8!\<^M]A7OG>HR"XW>2A^!TEXS><IR/W'"ADMMNII39;*J6V6JPF-AI
MMIG7:+V9UVC&FM-HS)K,:LR9QFO,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,
MFL)LS)K";,R:_X82 ?^((0;_B#44_X9&)?^'4S7_BUM#_XQB4?Z*:E[VAW%J
M\(1Z=.J @WWE?8J$XGJ0BMYVEH_<=)N2VG&@E=AOI9C6;:N:U6NPF]5JMYS4
M:;^=U&G)G<QKRIW&;,F=P&W)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G;UN
MR9V];LF=_X<2 ?^)(0;_BC44_XA&)?^*4C7_CEI#_X]A4?Z.:%[VBV]J[X=X
M=>F$@7[D@(B&X'R/C-UYE)':=IJ5V'.?F=5PI9O4;JJ>TVVQG])KN*#2:\*A
MS6S'H<9NQZ' ;L>ANV_'H;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ&X
M<,>A_X@1 ?^*(0;_BS44_XE&)?^-437_DEA#_Y)>4?Z095[VCFQK[XMU=NB'
M?H#CA(:(WG^-C]M[DY38>)F9U76>G--RI)_1<*JBT&ZRH]!MNJ3.;,2EQF_$
MI+]PQ*6Z<<2EM7'$I;)RQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I+)RQ*2R<L2D
M_XD1 ?^+(0;_C#04_XI&)?^03S3_E%9#_Y1;4?Z385[VD6AK[HYP=NB+>X#B
MAX.)W8.*D=E^D9?5>I><TW>=H-!TI*//<:JFSF^SI\UNO:C'<,*HOG'!J;AR
MP:FT<\&IKW3"J*UTPJ>M=,*GK73"IZUTPJ>M=,*GK73"IZUTPJ>M=,*G_XH1
M ?^,(0;_C304_XM&)O^33C3_EE-"_Y=84/Z67E[VE&1J[I)L=N>/=H'AC("*
MW(>(DMB"CYG3?96?T'F<H\YUHZ?,<JNJRW"TJ\APOZR_<[ZLMW2^K;)UOJRN
M=K^LJG:_JZAWP*JH=\"JJ'? JJAWP*JH=\"JJ'? JJAWP*JH=\"J_XL1 ?^-
M( ;_CC04_XU%)O^633/_F5!!_YI53_^:6EWWF&!I[Y5H=>B2<(#ACWN*W(N$
MD]:&C)K2@).ASGN:ILQWHJK*=*NNR'*XK\!TO*^W=;RPL':\L*MWO*^H>+VO
MI7F^K:-YOJVC>;ZMHWF^K:-YOJVC>;ZMHWF^K:-YOJVC>;ZM_XL0 ?^.( ;_
MCS04_X]$)?^82C/_FTU _YU13O^=5UOXG%QH\)IC=.B7:G_BDW6*W(^ D]:*
MB9O1A)"CS7Z8J<EYHJ['=:VQQ'2ZL[=VN;.O>+FSJGFZLZ9ZNK*C>[NQH'N\
ML)]\O:Z??+VNGWR]KI]\O:Z??+VNGWR]KI]\O:Z??+VN_XP0 ?^/( ;_D#04
M_Y)#)?^:2#+_G4H__Y].3?^@4UKYH%AF\9]?<NJ<97WCF&^(W)-ZDM:/A)O0
MB(VCRX&6J\=[H;'%=K"UNG>WMJ]YM[:H>KBVHWRXM*!\N;.>?;JRG'Z[L9M^
MO+";?KRPFWZ\L)M^O+";?KRPFWZ\L)M^O+";?KRP_XT0 ?^/( ;_D304_Y1#
M)/^;1C'_H$@^_Z)+2_^D4%CZI%5D\Z1:<.NB87ODGVF%WIISD->5?IG0CHBC
MRH63K,1]H/_B__])0T-?4%)/1DE,10 %";2]>+"YKWFUN:9[MKBA?;>VG7ZX
MM9M_N;29?[JSF("ZLI> N[&7@+NQEX"[L9> N[&7@+NQEX"[L9> N[&7@+NQ
M_XT0 ?^0( ;_D304_Y=")/^=0S#_HD4]_Z5(2?^H3%7\J5%A]:I7;.ZI77?G
MJ&.!X:1MB]:>>9;+E8.BP(N.K;:#FK:N?JJ[I'RSO)Y^M;J:@+>WF(&XM9:!
MN;25@KJSE(*ZLI."N[&3@KNQDX*[L9."N[&3@KNQDX*[L9."N[&3@KNQ_XX0
M ?^1( ;_DC04_YE!(_^?02__I$([_ZA%1_^L25/^KDY>];!3:.RR6G+DLV%[
MVZ]NA,RF=I3 G'ZBM)*(KJF*E+>@A:2]F8*QOI6#M+N3A+:XDH2XMI&$N;20
MA+FSD(2ZLI"$NK*0A+JRD(2ZLI"$NK*0A+JRD(2ZLI"$NK*0A+JR_X\/ ?^2
M( ;_DS04_YH_(O^A/R[_IT Z_ZQ"1?^P1E#YLTM:\+=28^B[66O?O61RT;9L
M@L2L<Y.VHWJAJIF#KIZ2D+>4C9^^CHNQOXR)L[R,B;6YC(BWMHR(N+6,A[FT
MC(>ZLXR'NK*,A[JRC(>ZLHR'NK*,A[JRC(>ZLHR'NK*,A[JR_X\/ ?^2'P;_
ME#04_YP](?^C/"W_JCTX_Z] 0O^T1$SUNDE5[+]17.3&6F'8Q6)OR;QI@;NR
M<)*MJG>@H*& K9.;B[>)EIN]@Y6OOX21L[R&CK6YAXVVMX>,M[:(B[BUB8JY
MM(F*NK*)BKJRB8JZLHF*NK*)BKJRB8JZLHF*NK*)BKJR_Y / ?^3'P;_E305
M_YX[(/^E.2O_K#HU_[,]/_NZ0D?QP4A.Z,E14M_16UG/RF!MP<)G@+*Y;9"D
ML72?EZI]JXJDB+5_H)>[>)^LOGR:L[Q_E;2Z@9*VN(.0M[>$C[BUA(VYLX6-
MNK*%C;JRA8VZLH6-NK*%C;JRA8VZLH6-NK*%C;JR_Y$. ?^4'P;_EC,5_Z X
M'_^H-BG_L#@R_[@Z._; /T'LRD=%X]941=;95UC'T%YKN,AD?JK!:XZ<NG*<
MCK1ZJ("NA;)VJY2X;ZNING*EM;IWG;6Y>IFVMWV6M[9^D[FT?Y&ZLH"0N[&
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MT9-@JM&3_XP. ?^/%@+_I1X#_[45 ]K*"P+0X0X"Q.L>#;CO+!VM[C<NHNQ
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M2C?_ODLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+O[,  *Z^  "@S0
MDMX  (G_#0&!_QH%=_\C#&W_*A-D_S$97/\X'E7_0")0_T@F3/]/*4C_52M$
M_ULM0O]A+S__9S$]_VTR._]S,SG_>C4W_X(V-?^+-S/_E#@R_YPY,?^D.C#_
MKSLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([L+@  *#'  "1V   A.\
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MAY61BX2BEH:#LIF#A,N8A(/.EH2#T)2$@M*2A('3D(2!U(Z$@-:,A(#6C(2
MUHR$@-:,A(#6C(2 UHR$@-:,_W<2 ?]T&P/_@AX$_Y0G"/^@,@W_IS03^JXX
M&.^U/1SFO$8AW+],+,ZY5#_#L5U0MZIE7ZVD;&RCG71WF9A\@9&3AHJ)CY*1
M@HR?EGV*KYAZB\>8?(G.EGV(T)1^AM*2?X73D'^$U(Z @]:,@(/6C("#UHR
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M7TC;\6%)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F-)TO)C_I4  -2I  #"M0,
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MLT$4UK%'(\JK4C3 I%Q#MIYD4:V8;%REDG1FG8U];Y:(AG:/A9%]BH*<@H6
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MH.-[89OC>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^
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M<%6KZG!8INMP6:/K<%FCZW!9H^MP6:/K<%FCZW!9H^MP_W</ ?^-" #>H (
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M1C[F_T8^YO]&/N;_1C[F_T8^YO]&T)\  +VL  "NM0  HL(  )7/  "*W0,
MA/\2 7O_'@-T_RH);/\S#V3_.Q9=_T,;5_]*(%'_421,_U@G2/]@*D3_:"Q
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M2HPU_TB7./]&H#O_1:@\_T2P/O]#N#__0\%!_T+,0?]!WD+_0>M#_T#U0_]
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M;6:.[FMGB^]J:8GP:&F)\&AIB?!H:8GP:&F)\&AIB?!H_V<2 ?]Y# #_B@H
MWYH$ -.F!P#,L0@ Q[L( ,'"$P"XPB@$KK\X$*6\1!Z;N$XLD;57.(BQ7D*
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M6DZM^EI.K?I:3JWZ6DZM^EI.K?I:_W\  -R3  #*H@  O*P! +&U  "HP ,
MG\L& );9"P"1X!L!BM\L!H+?.0YYWD,7<=U-(&K<5BACVU\O7=IG-5C9<3I3
MV7L^3]F(0DO9ED5(V:9'1MJZ2$7;VT=$V/1)0M/_343)_T]%PO]01[O_4D>[
M_U)'N_]21[O_4D>[_U)'N_]2YHH  ,^;  "_IP  LK   *>[  "<Q@, D]$&
M (OJ#@"%Z!\"?N@M!G;H. YNZ$$69N=*'5_G4B-9YULI5>=D+5#G;3%,YW@U
M2>>$.$;HD3I#Z* \0.FR/C_JRSX^Z.\^/>;_/SW@_T(_U_]$0,[_1D#._T9
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MKHM@-Z>&:$"A@G!(G'YY3I9[@E22>(M9C7:578ETH&&%<ZYC@G*_9(!SWF2
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M8'-[]UYT>OE<='GZ6W5Y^UIU>?M:=7G[6G5Y^UIU>?M:_UT3 ?]L#0#_>PL
M]H@) -R3!@#5G0D T:4* ,JJ%0#!J2H$MZ8Z#ZZB1ANFGE HGII9,Y:683R/
MDVE$B8]Q3(.->5)]BH-7>(B-7'.&F6!OA*9C;(2W9&J$SV1JA/!B;(+V8&V
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M6%^-_%=?C?Q77XW\5U^-_%=?C?Q7_VH* /]\  #<C   S9@  ,.C P"ZJ@(
ML[,! *R\"@"FO1T!GKPO!I:Z/!&-N$<<A;50)WVS63!VL6 X;Z]H/VFM<$5C
MJWE*7JJ$3UJID%)5J)Y54J>O5U&HQE=0I^I74*7\5U.?_5=5FOU65Y;^5EB5
M_E58E?Y56)7^55B5_E58E?Y5_V\$ .:"  #2D0  QIT  +NF 0"RK@  JK<!
M *+"!0"<Q!@ E<,J!(W".0V%P$08?;Y.(76\5BINNEXR:+EF.&*W;CY=MGA#
M6+6"1U2TCTM0M)U.3;.N4$NTQ5!+L^I02K'_44RK_U).I?]24*'_4E&>_U%1
MGO]149[_45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P" )C&
M!@"1S!( B\PE H3+- E\R4 2=<A*&VW'4R-GQ5PJ8<1D,%S#;397PG8Z4\*!
M/T_!CD)+P9U%2,&N1D?!Q49'P>I&1+[_246Y_TI'L_]+2:W_3$JK_TQ*J_],
M2JO_3$JK_TQ*J_],Z7\  -&0  #"G@  M:<  *JO  "@N   EL$" (S+!P"$
MU0T @-4> 7G5+@5RU#P,;--'%&724!M?T5DA6M%B)U70:RQ1T'4P3<^!-$G/
MCC=&SYTY1-"N.T+0QCM#T.HZ0,W]/C[+_T! P_]"0;W_0T*Y_T1"N?]$0KG_
M1$*Y_T1"N?]$W8@  ,>8  "XHP  JZL  *"T  "5O@  B\@# (#1!P!XX0T
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MG! B_ZX1(?_%$B#_Z1,?__P3'O__$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD
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M48)L_T^!:_]-@&O_3(!K_TJ :_]*@&O_2H!K_TJ :_]*_U02 ?]A# #_;@H
M_7@) .B"" #<B0D V(\+ -"3%P#&DRL#OI [#+:,2!>NB%(AIX1<*Z& 9#.<
M?&TZEWEU0))W?46.=89*BG*03H9QFU&";Z=4?V^V57UORU9\;^M4?'#_4GMP
M_U![;_].>V__37MN_TM[;O]+>V[_2WMN_TM[;O]+_U<1 /]C"@#_< < \'P%
M -R%!0#4C @ T),) ,J6% #!ERD#N90Y"[&01A:IC5 @HHE:*IR%8C*6@FHY
MD7]R/XQ\>D6'>H-*@WB-3G]VF%%[=:14>'2S5G9TR%9U=.A5=77]4W5T_U%U
M<_]/=G+_379Q_TQV<?],=G'_3'9Q_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(
M! #/D 8 RI8( ,2:$@"\FR8"M)@W":R51!2DD4X?G8Y7*):*8#&0AV@XBX1P
M/X:">$2!?X%)?7V+37A[EE%T>J)4<7FQ5F]YQ59N>N95;GK\4V]Y_U%P=_]/
M<7;_37%U_TQQ=?],<77_3'%U_TQQ=?],_UL. /]I! #V=P  W8(  -"+ P#)
MDP4 Q)D& +Z>$ "VGR0"KITT"*::01.?EDP=F)-5)Y&07B^+C64WA8IM/8"(
M=4-[A7Y(=H.(3'*"DU!N@*!3:W^N56A_PE9G?^-5:(#Z4VE^_U%J?/]/:WO_
M36QY_TQL>?],;'G_3&QY_TQL>?],_UX, /]L 0#F>@  UH8  ,N/ @#$EP0
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M1U22_T=4DO]'_VX  -Y_  #*C0  OI@  +.@  "JIP  H:X  )>V  "1NA
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MMR(ZVM4B.M;R(S?4_R<VTO\I--'_*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9
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M"!O_X@D:__D)&O__"1G__PD9__\)&?__"1G__PD9__\)HJ<  ).Q  "%NP
M=L8  &G0  !;V@  3N   $/E   ^^P$ .O\, #;_$P R_QL +_\C "O_*@$H
M_S$!)/\W 2'_/P(?_T8"'/]. AG_6 ,6_V,#$_]P Q+_@001_Y,$$/^G! __
MO04._^ %#O_V!0[__P4.__\%#O__!0[__P4.__\%E:\  (:Z  !WQ0  :-
M %K;  !,X0  0.<  #?S   R_P  +O\' "K_#@ F_Q, (_\: !__(  ;_R8
M&/\K 17_,@$2_S@!$/]  0[_2 $,_U(!"?]= @;_:P($_WT" O^0 @'_HP(
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MY$'?(^!![R3<0/PGV$#_*=0__RK/0/\JQT+_*L)#_RK 0_\JP$/_*L!#_RK
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M/Y=:_SZ46_\\D5O_.X];_SJ/6_\ZCUO_.H];_SJ/6_\Z_TP2 /]6#0#_8 D
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M0'=J_S]W:O\^=VK_/G=J_SYW:O\^_U0, /]?  #R;   W78  -!] @#)@P0
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M/V-Z_S]C>O\__UX  .EM  #6>0  R(0  +Z,  "VDP  KI<  *:;! "@G1<
MFITI I.<-PB,FD,0AIA-&("651]ZE%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?
MBI5!7(FC1%J)M$58B<M%6(CM1%B(_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV
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MKS9'I\8V1J;I-D6D_C=%H_\W1J#_-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0
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M&#3-^QLRR_\=,<K_'S#)_R$OR/\A+\C_(2_(_R$OR/\AOH\  *^:  "BH0
MEJD  (JP  !]N   <;\  &;&  !;S ( 4-(' $?:# !&W!@ 1=PG $3=-0%!
MW4 "/]Y+ SW>500ZWU\&.-]I!S7?=@DSX(0+,>"4#"_AI@TNX;P.+>+@#BW>
M^ \KW?\2*MS_%"G:_Q8HVO\6*-K_%BC:_Q8HVO\6LY@  *6@  "9IP  B[
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M @?__P('__\"!___ @?__P('__\"D:T  (*X  !SP@  9,P  %;5  !(W0
M.^(  ##G   G[@  (_\  "#_!  <_PP &?\1 !;_%@ 3_QL $?\A  [_)P -
M_RX "O\V  ?_/@ $_T@  /]4  #_8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_
MZ@$ __,! /_S 0#_\P$ __,!A+<  '3!  !ES   5M@  $??   YY0  +>H
M "/N   <_0  &/\  !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@  _R
M /\F  #_+@  _S<  /]!  #_30  _UP  /]M  #_@@  _Y8  /^H  #_N@
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M.O8:T#K_',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?]
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M)[)&_R>P1O\GKD;_)ZI'_R:G2/\FITC_)J=(_R:G2/\F_T 4 /](#@#_3@L
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M,89;_S"%6_\OA5O_+X5;_R^%6_\O_TL, /]4  #[7@  XF4  -AK 0#/;@4
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M,FYJ_S)N:O\R_U,  /1?  #>:@  S7,  ,-Z  "[?@  M8$  *Z#"0"HA1H
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MK#A5@[\Y58/A.%6"^3=6@O\U5H'_-%A__S-9??\R67W_,EE]_S)9??\R[V
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M*D.?]2M"G?\K0IS_+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC
MJI0  )^9  "4G@  B:,  'ZH  !PK@  :K . &BQ'0!EL2P!8;$X UVP0P99
ML$P*5:]4#E*O71%.KF452ZYO&$BM>1M%K88>0JR5(#^LI2(^K;DC/:W8(CVK
M]2,\J?\E.Z?_)CNF_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@  HID
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M"R31_PPCT/\-(]#_#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !LNP
M8,(  %3&  !(RP  /M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D/P F
MY4H ).95 "/F80$AYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD
M_P08X_\%&./_!1CC_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q   4\H
M $?.   \TP  ,MH  "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X
M%_1( !7U4@ 3]E\ $O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-
M\_\!#?/_ 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8
M   OW@  )N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y
M  O_0P )_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\
M /__  #__P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   B
MY@  &>H  !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_
M,P  _ST  /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z
M  #_^@  __H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@
M$/@   [_   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P
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M#-8M_P[4+/\/TBS_$-$L_Q#/+/\0SBW_$,XM_Q#.+?\0_S(9 /\W% #_.A$
M_SP2 /\_&0#_0"( _SXM ?\\.0'Z.D4"]#A2 _ W7@3L-FH%Z35T!N8U?@CD
M-(<(XC20"> TF K>-)\*W#.G"]HSL S8,[L,U3/)#=(TWPW.-/ /RC3]$L<T
M_Q/%-/\4PS3_%<,S_Q7 -/\5OS3_%+\T_Q2_-/\4_S85 /\[$ #_/@T _T,/
M /]&% #_1AP _T8F /9$,@'O0C\!Z4!, ^0_603?/F0&VSUO"-@\>0K4/((,
MT3N+#<\[DP_-.IH0RSJB$<DZJQ+(.K43QCK"$\0ZU13 .^L5O#K[%[DZ_QBW
M.O\9MCK_&;4Z_QBR._\8L3O_&+$[_QBQ._\8_SD2 /\_#0#_0PD _T@, /]+
M$ #_3!4 ]4P? .M**@#D23<!W4E& M5'4P301E\(S$5I"\E$<PW&0WP0PT*$
M$L%"C!._0945O4&=%KM IA>Z0+ 8N$"\&;9 S!JS0>8:KT'W'*U!_QVK0?\=
MJ4'_'*E!_QRF0?\;I4'_&Z5!_QNE0?\;_ST0 /]""0#_2 4 _TT( /]0"P#Y
M40\ ZU 5 .%/( #84#$ SU!! LE/3@7$3EH)P$QD#;U+;1"Z2G83MTE^%;5(
MAQ>S1X\9L4>7&Z]&H!RM1JH>JT6V'ZE%QA^G1N @I$;T(*%&_R&?1_\@GD?_
M()Y'_Q^;1_\>FD?_'II'_QZ:1_\>_T - /]&! #_3   ^%(" .A5! #A50@
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M)7I:_R5Z6O\E_TD  /M2  #C7   TF,  ,=H  # :P  NFL" +5K#0"N;1T
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MJC!D;+PQ8VS9,&-L]"]C;/\M9&S_*V1K_REE:O\H96K_*&5J_RAE:O\H_5,
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M+5%][RQ2??\K4GS_*5-[_RA4>O\G5'K_)U1Z_R=4>O\GZ%X  -!K  # =@
MM'X  *N%  "AB0  EXL  (F-  "#CP@ ?I 7 'N1)P%VD30#<I _!FV/20MI
MCE$/98U9$V*,8!=>BV@;6XIQ'E>)>R%4B(8D48>4)T^&HBE-AK0J2X;,*DN%
M[BE,A/\I3(/_*$R#_R=-@?\F3H'_)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0
M *:*  ";C@  D9$  (23  !ZE0( =9<2 '*8(@!OF# ":I<[!&:710ABEDX,
M7Y56#UN471-8DV4759-N&E&2>!U.D80@2Y"1(TF0H21'D+(F19#*)D6/[25%
MC?\E18S_)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH  )^/
M  "5DP  BI8  'Z:  !PG0  :Y\. &B?' !FH"H!8J W E^?005;GTH(6)Y2
M"U2>6@Y1G6(23IQK%4N<=1A(FX$:19N/'4*:GQ] FK @/YK((#^9ZQ\_F/\@
M/I;_(3Z5_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".
MF   @YT  '>@  !II   8*<( %VH% !;J20 6:DQ 5:I/ )3J44$4*A.!DVH
M5PE*J%\,1Z=H#D2G<Q%!IG\4/J:-%CRFG1<ZIJ\8.:;'&#FEZA@XH_\:-Z'_
M&S>@_QPWG_\<-Y__'#>?_QPWG_\<Q'@  +6%  "ICP  G94  )*:  "&GP
M>J,  &ZH  !BK   5;   %"R#@!.LAL 3;,H $NS-0!)LS\!1K-) D2S4@1!
MLUL&/[-D"#RS;PHZLWL,-[.*#C6RF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M
M_Q4OK/\6+ZS_%B^L_Q8OK/\6NX$  *Z.  "AE0  EIH  (F@  !]I@  <:L
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M A';_P(1V_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS
M+=   "35   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +
M[E, "N]B  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M
M_P #[?\ E:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L
M !G@   2Y   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(
M /Q0  #\80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P
M_?\ B:D  'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H
M   *\0  "/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^
M  #_30  _U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\
M?+,  &R\  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R
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M ?\"D0'_ I@!_P*? ?\!I0#_ :P _P&R /\!N@#_ <0 _P'1 /\ Y #_ /$
M_P#\ /P!_P#\ O\ _ /_ /P$_P'\!?\!_ 7_ ?P%_P'\!?\!_Q\F /\A(@#_
M("$ _QXC /\8)P#_$S  _Q$\ ?\.2@'_#5<!_PMC ?\*;P'_"GH!_PJ$ ?\*
MC0'_"I0!_PJ; ?\*H@'_"J@!_PJO ?\*MP'_"L  _PK, /\*X #["N\ ]PKZ
M /4+_P'U#/\!] W_ ?0-_P+T#?\"] W_ O0-_P+T#?\"_R(B /\D'0#_)!P
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M#+PM_PR\+/\,NRS_#+LL_PR[+/\,_S$1 /\U# #_-@< _SH+ /\\$ #_.Q4
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M%XU'_Q>-1_\7_SX" /]#  #K2P  W5$  -%4  #*5 $ QE(% ,%1$0"Y4R(
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MJB1R6;HE<5G2)7!:\"-O6O\B;UK_('!:_QYP6O\=<%K_''!:_QQP6O\<_T@
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M)EYGZB5>9_XC7V?_(5]F_Q]@9O\>8&;_'F!F_QY@9O\>[T\  -I<  #&90
MNFT  +!R  "G=0  G70  )1S  "-= T B78< (5W*P&!=S@#?'9#!GAU3 ET
M=%0-<7-;$6YR8Q1K<6L7:'!S&F5O?!UB;H<@7VV4(EULHB1:;+(E66S')5AL
MZ"59;/TC66O_(5IK_Q];:_\>6VK_'EMJ_QY;:O\>ZU,  --@  #":0  MG$
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M'DA]_QU)?/\<27S_'$E\_QQ)?/\<UF$  ,)N  "T>   JH   )^%  "4AP
MB(<  'N)  !PC   :XX- &B/&@!FCRD 8I U 5^//P-<CT@%68Y0"%:.6 M3
MC6 .4(QH$$V,<A-*BWT62(J*&$6*F1I#BJH;0HJ_&T&*X1M!B/D;08;_&T&%
M_QM"A?\:0H3_&D*$_QI"A/\:S6<  +QT  "O?@  I88  )J*  ".C   @HT
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M#2JE_PTJI?\-M8   *B+  "<D0  D98  (6<  !XH   :Z4  %^H  !3K
M2*\  #VR   VM0L -+45 #.V(0 RMBP ,;<W #"W00 ON$L +KA5 "RX8 $J
MN&T!*;E[ B>YC0(EN9\#)+FT R.YT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R
M_P<ALO\'K8H  *"1  "5EP  B)T  'NC  !NJ   8:T  %6Q  !*M   /[<
M #2[   KO@, ),(, "+"%  BPQ\ (<,J "#$-  ?Q#\ 'L5* !W&5@ <QF,
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M9P  Y7L  .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\
M (*G  !TKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0
M">$   +E    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@
M\V@  /-^  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P
M  !FN   6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H
M  #U    ]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4
M /]I  #_@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9
MPP  2\L  #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_
M    _P   /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3
M  #_:0  _X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24
M_PTG /\&+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_
M )< _P"= /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C
M /\** #_ #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ),
M_P": /\ H #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X
M /\ ^ #_ /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.
M(@#_"BP _P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6
M /\ G0#_ *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\
M[P#_ .\ _P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_
M$2@ _PXT /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&
MF0#X!I\ ]@:F /0&K0#R!K4 \ 7  .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_
M .0+_P'D"_\!Y O_ >0+_P'D"_\!_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0
M_Q8O /\3/ #_$4D _Q!5 /P.80#Y#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M
M#IL ZPZB .H.J@#H#K, Y@^] .4/S #A#^, W1#S -D1_P'6$O\!U!/_ =,3
M_P+2$_\"TA/_ M(3_P+2$_\"_R43 /\E$ #_) T _R,. /\C% #_(AX _Q\I
M /\<-0#Y&4, ]!A/ .\76P#L%V8 Z1=P .87>0#D%X$ XA>) . 7D0#?%Y@
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M"*@M_PBH+?\(_R\( /\Q  #_-0  ]C<  .HV @#G,P@ Y"\/ -DN&P#/,2P
MR3,\ ,0T20# -54!O#5? KHU: *W-7 #M31X!+,T@ 6Q-(@&L#20!JXTF0>L
M-*((JS2L":DTN0FG-,H*I37E"J$U^ N?-?\,G37_#)TU_PN<-?\+G#7_"YPU
M_PN<-?\+_S," /\U  #V.@  Y3X  -Q   #4/00 TC<) ,LX%0##.B8 O3TV
M +@^1 &T/E !L3U: ZX]8P2L/6L%J3QS!J<\>PBF/(,)I#N+"J([E N@.YT,
MGCNH#9T[M Z;.\4.F3O@#I8[] ^4//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1
M//\-_S4  /\Y  #J00  W48  -!'  #)1@  QD$% ,! $0"Y0B$ LT0R *]%
M0 &K14L"IT55 Z1$7@6A1&8'GT-N")U#=@J;0GX+F4*&#9=!CPZ509D/DT&D
M$9%!L!*00< 2CD'9$HM!\1*)0O\2B$+_$8A"_Q"'0O\0AT+_#X="_P^'0O\/
M_S@  /,]  #C1P  TDP  ,A.  # 30  NTH" +9'#@"P21T JTLM *9,.P&B
M3$<"GDM1!)M+6@:92F((EDEJ"I1)<0R22'D.CTB"#XU'BQ&+1Y42B4:@%(=&
MK!6%1KL6A$;1%H)'[A: 1_\5?T?_%']'_Q)_1_\1?T?_$7]'_Q%_1_\1_SL
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M&VI5YAMJ5?L9:E7_%VI5_Q9J5?\5:U7_%&M5_Q1K5?\4\D,  -]/  #+6
MO5T  +-A  "K8@  HF   )M<  "57A  D& ? (QA+@"(83H"A&!%!(%@3@9^
M7U8)>UY="WA=90YV7&P0<UQT$W!;?15N6H@7:UJ4&6E9H1MG6; <95G#'&19
MXQQD6?H:9%G_&&19_Q=E6?\595G_%&59_Q1E6?\4[T8  -I2  #&6P  NF$
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M&%5F_Q=59?\65F7_%59E_Q569?\5XE$  ,I=  "[9@  KVP  *9Q  "9<
MCF\  (-N  !]< 4 >'(2 '5S(0!R<R\!;W,Z FQS1 1I<DP&9G)4"&-Q6PM@
M<&,-77!K$%MO=!-8;G\556Z+%U-MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K
M_Q=0:O\64&K_%5!J_Q50:O\5W54  ,5A  "W:@  K'$  *)U  "4=   B70
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M$3U^_Q$]?O\1Q68  +5Q  "J>P  GX(  )*"  "%@@  >8,  &V&  !?B@
M6(T! %2.#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_
MCW,)/8Z "SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'
M_P\VA_\/OFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4
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M@@ >LI0!'+*I 1NRP0$;L><!&Z_^ AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@
M )N/  "1E   A)H  ':?  !HH@  6Z4  $^I  !$K0  .;   "^S   FM@
M'KD% !B[#@ 7NQ8 %[P@ !:\*@ 5O34 %+U  !.^2P 2OE@ $KYG !&_>  0
MOXP $,"B  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25
M  "'FP  >:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,
M  _&!0 +R@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X
M <R4  #,JP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\
MHP  ;JH  &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1
M   !U D  -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$
M  #?FP  W[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK
M8;,  %.Z  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>
MX $  .$)  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #O
MB0  \*(  /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T
M $;$   WR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@
M .P   #N!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=
M_XT  /^F  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-
M   JT@  '=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8
M  #X    ^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8
M /^/  #_I@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_
M #( _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\
MGP#_ *4 _P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_
M /X _P#^ /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T
M_P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_
M *$ _P"G /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4
M_P#U /\ ]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V
M /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T
M]P"C /4 J@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J
M /\ Z@#_ .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\
M/@#_ $L _P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@
M .L I@#I *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\
MW0#_ -T _P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_
M!D4 ^P-1 /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$
MHP#=!*L VP2T -@%P #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\ RPO_
M ,L+_P#+"_\ _Q\0 /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S#CX
M[@U* .D,5@#E#&$ X@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .H #/
M#JD S0ZS ,L.OP#*#]  QA'I ,(2^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3
M_P&[$_\!_R(, /\A! #_(   _R$% /\?# #_'!$ ]A@< .P5* #E$S8 WQ)#
M -D33P#3%%H T!5D ,T6;0#+%G4 R1=] ,<7A0#%&(P Q!B4 ,(9G # &:4
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ML02@+< $GRW8!)PN[P69+O\&ER__!I8O_P:5+O\%E2[_!94N_P65+O\%_RP
M /\N  #J-0  W3D  -$Y  #*-@  QR\& ,$M$0"Z,"$ M#(Q + T/@"L-4H
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M#GQ!Y YZ0OD->4+_#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9   #12
MPTT  +E.  "Q30  J4D  *1%!@"?1A, FD@C )9),@"22CX!CTI( HQ*40.*
M25D$ATE@!85): >#2&\(@4AW"G]'@ M]1XH->D>5#GA&H@]V1K 0=4;"$'-&
MX!!R1_</<4?_#G%'_PUQ1_\,<4?_"W%&_PMQ1O\+\SD  .!$  #,3   OE$
M +13  "J4@  HDX  )U* 0"72Q$ DTT@ (]/+@",3SH!B$]% H5/3@.#3U8$
M@$Y=!GY.9 =\36P)>4UT"W=,?0QU3(<.<TR2#W%+GQ%O2ZT2;4N_$FQ+W!)K
M3/41:DS_#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4  +!8
M  "E5@  G%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\5%,$>E-:
M!GA38@AU4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50V!-D4/,2
M9%#_$&10_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@
M6@  EU<  )%4  "+50P AE<9 (-8)P" 630 ?5D_ 7I92 -W6% $=%A8!G)7
M7P=O5V8);59N"VM6=PUH58$/9E6-$614FA)B5*D38%2Z%%]4TQ1>5/(37E3_
M$5]4_P]?5/\.7U/_#5]3_PU?4_\-YT0  ,]0  "_6   LUT  *A?  "<70
MDEL  (M8  "%6@H @5L6 'U<) !Z73$ =UT\ 71=1@)Q74X$;UQ5!6Q<70=J
M7&0):%ML"V5:=0UC6G\/85F+$5Y9F!)<6*<46UBX%%E9T!196/ 365C_$5I8
M_Q!:6/\.6E?_#5I7_PU:5_\-XT@  ,M3  "[6P  L&$  *1B  "780  CE\
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M#4MD_PU+9/\-T50  +Y>  "Q9P  IFT  )=L  "*:P  ?VL  '-K  !M;0
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MAP8SB)@',H>J!S"(P <PA^0',(7["#"#_P@P@O\(,('_"#"!_P@P@?\(MVL
M *IV  "@?P  D'X  ()^  !V?P  :H   %Z#  !3AP  2HL  $&. @ ]D X
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M !.KM  2J], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0
M?9(  &V5  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /
MM1  #K47  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :V
MJ@ %ML4 !K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P
M &6@  !7I   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L
M L 1  '!&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0
MQ+4  ,3:  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL
M  !/L0  0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,
M  #-$0  SA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<
M -;"  #6Z0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"
MN@  -+T  "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<
M"P  W1   -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO
M  #JS@  Z^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP
M)\<  !O+   2SP  "],   +8    W0   .$   #D    Y0   .<   #I
MZP<  .T-  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\
MM@  _-(  /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(
M !#8   (W0   .$   #E    Z    .P   #O    \0   /,   #U    ]P
M /D!  #["   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H
M_[8  /_*  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\
M20#_ %8 _P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F
M /\ K0#_ +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\
M_ #_ /D _P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_
M %$ _P!> /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P
MJ0#[ +  ^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_
M /, _P#S /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P
M_P!9 /\ 8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P
M *P [@"T .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4
M_P#E /\ _Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3
M /< 7@#T &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *<
MX0"P -\ N@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3
M /\ _Q40 /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L
M6 #H &$ Y0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L
M ,X M@#, ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\
M_Q@+ /\5!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#:
M EL U0)D -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&
MM "_!L$ O0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL%
M /\8  #_%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4
MQPU> ,4-9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S
M$<  LA'5 *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<
M  #Z'@  ZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9
M +<780"T&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P
MI!W/ *$>Z@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L
M)P  X"H  -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC
M7 "H)&0 IB1L *0D<P"C)'H H26" : EBP&>)90!G26> 9LFJ@&9)K<!F";)
M I4GY@*2)_D"D"C_ H\H_P*.)_\"CB?_ HXG_P*.)_\"_R8  /(I  #C,0
MTC0  ,@T  # ,   NRD" +@C#@"Q)AP K"@K *@J. "D*T0 H2Q. )\M5P"=
M+5\ FRUG 9DM;@&8+G4!EBY] I0NA@*3+I "D2Z: X\NI@.-+K,#C"[% XHO
MX02'+_8$A2__!(0O_P.$+_\#@R__ X,O_P.#+_\#^RD  .LQ  #9.   R3P
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M"&I"_P=J0?\&:D'_!FI!_P5J0?\%[3<  -9"  #$20  MTT  *M-  "@2@
MF$<  )-"  ".0PT B44: (9&* "#1S0 @$@_ 'Y(2 %[2% ">4A7 G=(7P-U
M2&8$<T=N!7%'=@9O1X ';4:,"6M&F II1J8+9T:V"V9&S ME1NP+9$?_"61&
M_PAD1O\'9$;_!F1%_P9D1?\&Z#L  -!&  "_30  LU$  *51  ":3@  DDL
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M"%12_P=44O\'VD8  ,-0  "U6   J%L  )E:  "-6   A%<  'M4  !V5@$
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MB A":)@)0&BI"C]HO0H^:-X)/F?W"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<
M +-A  "G:0  EF@  (=G  ![9P  <6<  &5H  !<:@  6&P! %1N#@!2;Q@
M4&\D $YP+@!-<#@ 2W%! $IQ20%(<5$!1G%9 D1P8@-"<&P$0'!X!3YPA@8\
M;Y4'.F^F"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F
M  "B;0  D6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A, 1W<?
M $9W*0!%>#, 0W@\ $)X1 !!>$T!/WA5 3UX7@([>&@".7AT S=X@@0U>),%
M,W>D!3)WN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<
M<0  BW   'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_
M(P [@"T .H V #F!/P X@4@ -H%0 #6!6@$S@60!,8%P 2^!?P(M@8\#+(&A
M RJ!M@,I@=(#*7_S RE]_P,I?/\#*7O_ RE[_P,I>_\#L6H  *5T  "5=@
MA74  'AU  !M=0  87<  %=Z  !,?@  0X$  #N%   UB D ,HD1 #&)&P P
MB24 +XHO "Z*.  MBT$ +(M* "J+5  IBU\ *(MK ":+>@$DBXL!(XN> 2*+
MLP$AC,X!(8KQ 2"(_P(@AO\"((7_ B&%_P(AA?\"JW(  *%\  "/>P  @'H
M '-Z  !F?   6W\  %""  !&A@  /(H  #2-   LD0  )I,, "24$P CE!P
M(I4F "&5+P @E3@ 'Y9" !Z63  =EE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5
ME\D %I7N !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"
M  !?A   5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$;
M !.A)0 2H2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL
M"Z+F  R@_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8
MC@  3)(  $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M
M&P %K20 !*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5
M  "M]   K?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@
M1)\  #FC   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%
MN1P  +HE  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\
MZP  N_X  +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT
M #"Q   EM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0
M ,<;  #()   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@
MSO8  ,W_  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\
M   9OP  $<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1
M  #:&   W"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8
M .7X  #E_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /
MR@  !\X   #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I
M#@  [!4  .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD
M  #Y\P  ^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V
M -T   #A    Y    .@   #K    [0   .\   #Q    \P   /8   #X P
M^@L  /T1  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_
MU@  _]8 _P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!>
M /\ :0#_ '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\
M_P"Y /\ Q0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P
M /\ _P<8 /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\
M9 #_ &T _P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T
M /4 OP#T ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\
M_PL4 /\&$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[
M &@ ^0!P /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@
MN0#G ,< Y0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0
M /\)#0#_ 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &(
M[ !K .H <@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5
M ,  T@#3 -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,
M!P#_ P( _P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E
M -L ; #7 ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L
MP@#+ ,  Y0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_
M"@  _P@! /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D
M9@#& &X Q !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #'
M +( X "Q ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P
M\@T  .H*  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y
M!6@ MP9O +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+
MWP"D#?0 H@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D
M -L6  #2$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&,
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M 7TI_P%\*/\!?"C_ 7PH_P%\*/\!]20  .,N  #/-0  P3@  +0V  "K,0
MI2P  *(F!@">)A, F2@A )4J+@"2*SD CRQ$ (TM3 "++50 B2Y< (<N8P"&
M+FH!A"YR 8(N>@&!+X0!?R^/ GTOF@)[+Z<">B^W G@OS )V,.H"=3#^ G,P
M_P)S,/\"<R__ G,O_P)S+_\"\"H  -PU  #'.P  NC\  *P\  "B.   G#,
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M UU _P-=0/\#WSD  ,A#  "Y2@  J4L  )M)  "01P  B$0  (-!  !^008
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MB 5,4Y<&2U.G!TE3N@=(4]4'2%+S!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@
M +E2  "J5P  F%8  (I5  !_5   =E,  &Q1  !G4P  8E0( %]6$@!=5QX
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M!#EBM 4X8\T%.&+O!#AA_P0X8/\#.%__ SE>_P,Y7O\#O%4  *U?  "<8
MBU\  'U?  !R7P  :%\  %U@  !58@  3V0  $MF"@!)9Q( 1V@= $5H)P!$
M:3$ 0VDY $)J0@! :DH /VI2 #UJ6P$\:F4!.FIP CAJ?@(V:8T#-&F? S-I
ML@,Q:<L#,6CM S%G_P,Q9O\#,F7_ S)D_P,R9/\#MUL  *ED  "69   AF,
M 'AC  !M8P  9&0  %EE  !0:   26L  $-M! ! ;@X /F\8 #UO(@ \<"L
M.G T #EQ/0 X<44 -W%. #9Q5P T<6$!,G%M 3%Q>@$O<8H"+7&< BMQKP(J
M<<@"*G#K BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G
M  !I9P  7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN
M #!Y-P O>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!
M(GGI 2)W_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E
M;   6FX  %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"
M+P C@S@ (H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F
M !B!_0 9@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P
M5'8  $EY   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7
MCC  %HXY !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-
M^@ /B_\ $(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X
M $*"   YA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8
M"YHP  J:.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "
MF/\ !)?_  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-
M   QD@  *)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H
M  "F,@  IST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P
M *7_  "D_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   H
MG@  'Z(  !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S
M*   M#(  +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_
M  "T_P  M/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K
M%K    ^T   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0
MPR<  ,4R  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'
M_P  Q_\ @Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT
M  ;     PP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L
M -@E  #;,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P
MW_\ =Y\  &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,
M    T    -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8
M  #M)   \#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0
M:J@  %NO  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<
MX    .4   #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\
M%@  _R(  /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8
M /\ %@#_ !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#]
M ,\ ^P#G /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\
M$0#_ !$ _P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P
M /\ > #] 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,<
M[P#@ .X \@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_
M  T _P - /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /,
M<@#Q 'D [P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3
M -X ZP#< /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8
M_P ) /\ #P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B
M ', X !Z -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D
MY #( /8 Q@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $
M /\ "P#T !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T
MS !T ,H >@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W
M /  M0#_ +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8
M P#H  T X  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N
M +H = "Y 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L
MIP#[ *8 _P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:
M  < SP 1 ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P
M;P"K '4 J0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y
M )D'_P"8"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0
MP@0+ +P % "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?
M"W$ G0MX )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0
M_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$
M +(+#0"K#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP
MDA-S ) 4? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_
M&?\ ?QG_ '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05
M" "@%!, FQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO
M (4>=P"#'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\
M="'_ '0A_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5
M'A  D" ; (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG
M<P!Y)WP >"B' '8HDP!T** !<BBO 7$IP0%O*> !;2GW 6PI_P%K*?\!:RG_
M 6LH_P%K*/\!Z"@  - R  # .   KC<  *$U  "8,@  DBT  (XI  "+)PP
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M/20 :3XO &<_. !E/T  9$!( &) 3P!A0%< 7T!> 5U 9@%<0&\!6D!Z EA
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M D=&_P)'1O\"QD,  +9,  "B3   D4P  (1+  !Y2@  <$D  &E&  !D1P
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M>0$V78@!-%V9 C-=JP(Q7<(",5SE C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0
M *19  "06   @%@  '-7  !I5P  8%@  %19  !.6P  2%T  $-?! ! 8 X
M/F$7 #UA(  [8BD .F(R #EB.@ X8T( -V-+ #9C5  T8UT ,V-H #%C=@$O
M8X4!+F.6 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<
M  "+7   >UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2
M #1H&P S:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X(
M)FN3 "1KIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%
M8   =E\  &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ
M%0 I<1X *'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0
M !MSHP :<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9
M<60  &9D  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >
M>Q< ''L? !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]
MGP 0?;4 #WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D
M &)I  !7:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA
M$887 !"''P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &
MAJX !8;)  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO
M  !0<@  1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1
M  22&  "DB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8
M )&_  "1Y0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)
M?   /X   #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=
M$P  GAH  )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U
M  ">V@  G?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B
M-HP  "R1   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@
MJQ,  *P9  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "N
MR0  KN\  *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL
M ".@   :I   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T
M +H2  "[&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@
MP>,  ,#Y  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO
M   1LP  "[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+
M  #,#P  SA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D
M -GL  #9^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )
MP0   ,4   #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?
M!P  X@T  .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3
M  #P[   \/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@
M -(   #6    W    .    #C    Y    .8   #H    ZP   .T   #O
M\@(  /4*  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_
MT0  _^$ _P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6
M /\ 8 #_ &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8
M_0"N /P N0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#>
M /\ _P 1 /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\
M6P#_ &, _@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I
M .X LP#M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\
M_P - /\ "@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S
M %X \0!F .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X
MK0#< +D V@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P (
M /\  P#_    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@
MX0!@ -X 9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#'
M +, Q0#" ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\
M  #_    _P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9
M ,@ 80#& &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T
MLP"[ +$ S@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]
M    \@   .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@
M6@"V &$ M !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U
M *( Q@"A ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0
MX@0  -4   #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G
M %L I0!B *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4
MP0"3 -P D@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA
M ,(-  "[!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8
MF0%< )<!8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'
M"-@ A@GP (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6
M  "L$@  J T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8
M (P-7@"+#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L
M>A'T '@2_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@
M'   FQ<  )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($5
M6@" %6  ?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ
M &X;_P!M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)
MD"   (T<  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V
M'UP =!]C ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C
M_P!D(_\ 9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@
M (0D  ""( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD
M:R=@ &HG: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<
M*?\ 7"G_ %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK
M  !Y* , =B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y=
M &,N90!A+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\
M52__ %4N_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R
M+@  ;BX- &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT
M8@!:-&L 635U %<U@@!5-9 !5#6? 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_
M 4\T_P%/,_\!RS8  +@]  "C/   DCP  (4[  ![.@  =#<  &\U  !L,P
M:#0* &4U$P!B-AX 8#<H %XW,0!=.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4
M.F@ 4SIS %$Z?P%/.HT!3CJ= 4PZK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX
M_P%*./\!QSH  +-   ">/P  CC\  ($^  !W/0  <#L  &HX  !F.   8CD'
M %\Z$0!<.QL 6CLE %D\+@!7/3< 5CT^ %0^1@!3/DT 4CY5 %$^70!//V8
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M> % 2(<!/DB7 3Q(J0$[2+X!.DC? 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4
M *9(  "21P  @D<  '9'  !K1P  8T8  %M#  !610  4D<  $Y("@!,21(
M2DD< $A*)0!'2BX 1DLV $5+/@!#2T8 0DQ- $%,5@! 3%\ /DQJ #Q,=@ [
M3(4!.4R5 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+
M  ".2@  ?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9
M $)/(@!!3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48(
M,U&3 3)1I0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*
M30  >DT  &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4
M'@ Z52< .54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1
M "M7HP J5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40
M=E   &I0  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S
M6R( ,ELK #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=
MH0 C7;4 (EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50
M &94  !<5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT
M*6(E "AB+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;
M9+, &63. !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8
M  !96   4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@
M !YK*  =:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\
M$6S* !%K[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !5
M7   2UX  $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T
M(0 2=2D $74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#
M  ETYP *<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@
M164  #QH   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )
M?R( "'\J  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]
MX   ??<  'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT
M #5Q   L=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL
M (HC  "++   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP
MB/,  (C_  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[
M   E@   '80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<
M  "8)   F"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX
M );_  "5_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =
MC0  %)(   Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E
M'   IR0  *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[
M  "F_P  I?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G
M#J    >D    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P
MMAL  +@D  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y
M_P  N?\ ;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;
M  "T    MP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$
M ,H9  #-)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^
MT?\ 9X\  %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##
M    Q@   ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/
M  #C%P  YB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8
M7YX  %"D  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1
MV    -L   #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U
M#0  ^18  /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1
M /\ #P#_  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0
M_P!L /\ <P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W
M ,( ]@#: /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\
M"P#_  H _P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F
M /D ;0#W '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H
MYP#- .4 Z0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_
M  $ _P $ /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H
M9P#G &X Y@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0##
M ,\ WP#. /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_
M_P   /T "P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2
M &< T !M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P
MT "Z .T N0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0
M .X !0#E  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$
MO !G +L ;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I
M .0 IP#X *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X
M  #0  H R  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A
M *H 9P"H &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@
MEP#Q )8 _P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #
M  0 N  . +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L
M80": &< F !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K
M (@ _0"( /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @
MJP ) *8 $ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "-
M &( BP!I (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"
M^0![ _\ >P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H
M )L## "7 !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX
M@ =D '\(; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P
M#?\ ;PW_ &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\.
M P"."@X B0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A
M '40: !S$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\
M913_ &43_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""
M$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L8
M9 !I&&T :!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_
M %P;_P!<&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P,
M=AD/ '(:& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A
M(&D 7R%S %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B
M_P!4(O\ S2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$,
M &HB%0!G(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8
M6"AP %8H? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.
M*/\ R#   + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H
M$0!@*1P 7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN
M % N>@!.+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\
MQ#0  *LU  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:
M+Q@ 6# B %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS
M=P!(-(4 1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@
M *<X  "3.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4
M4C4? %$U* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#
M.(, 03F3 $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([
M  "/.P  ?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D<
M $LZ)0!*.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$
M/#V1 #H]HP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+
M/@  ?#X  &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_
M(@!$/RH 0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/
M #5"H0 T0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0
M>$$  &Q!  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _
M1"< /D0O #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&
MGP N1K, +4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,
M &A#  !?0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220
M.$DL #9)-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H
M2[$ )TO* "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&
M  !;1@  5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H
M #!/,  O3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\
M(5#( "!0ZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !8
M2@  4$H  $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5
M+  G53, )E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;%
M !E6Z0 :5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430
M34X  $5/   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?
M7"X '5PW !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=
MYP 26_X $UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(
M $%3   X5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D
M%&4Q !-E.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +
M8_D #&+_  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9
M   T7   +%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK
M  MN-  *;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,
M 6O_  )J_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N
M8P  )F<  !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X
M+0  >#<  'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_
M  !T_P  =/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;
M'W   !AT   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@
MA#   (0[  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  "
M_P  @/\ =V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P
M !%_   ,@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<
M )(R  "2/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P
MCO\ <6L  &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-
M   $D0   )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H
M  "B-0  HT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\
M;G$  %]R  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=
MH    *0   "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T
M*0  M#D  +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH
M %=]  !)@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L
M +0   "W    N    +D   "[    O    +X"  # "   P@X  ,04  #''@
MR"P  ,D]  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+
M  !!D0  ,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8
M  #(    R0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X
M .(N  #C0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   Z
MH@  +*D  !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:
M    VP   -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?
M  #Y,@  ^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P
M_P . /\ $P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_
M '0 _P!Z /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$
M[ #P /X [P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P (
M /\ $ #_ !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X
M\P!T /$ >@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#?
M /@ W0#_ -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\
M#0#_ !0 _0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N
M -\ = #< 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /
MQ@#_ ,0 _P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P
M !  ZP : .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,<
M;0#% ', PP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[
M +$ _P"P /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T
MTP 4 ,T 'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R
M &T L !S *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\
M_P"> /\ GP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0
M +D &0"U ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8
MGP!L )T <P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P".
M /\ C@#_ (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D
M$P"E !T H@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G
M (X ;0"- '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\
M@ #_ (  _P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8
M !< E0 A )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($
M: "  '  ?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_
M ', _P!S /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$
MB0 : (8 ) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T
M &P <P%U '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'
M_P!G!_\ WQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4
M 'P%'@!Y!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD
M:0QR &<,?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=
M#O\ U!P  +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.
M& !P#B( ;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O
M %X2>P!<$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\
MRB(  + B  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G
M%1X 918G &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:
M=P!4&H4 4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8
M *HG  "6)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H
M71TC %L>*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-
M(8( 2R*1 $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K
M  "1*P  @BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,?
M %0D* !3)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\
M12B/ $,HH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",
M+P  ?2\  '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI
M)0!-*BP 2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV-
M #TMG@ \+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@
M>3(  &TR  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'
M+RH 1C Q $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@R
MG  V,J\ -3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34
M &DU  !@-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"<
M0#0N #\U-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q
M-ZT +S?% "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X
M  !=-P  5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL
M #HY,P Y.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP
M*CO# "D[Y@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:
M.@  4SH  $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^
M,  S/C< ,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#!
M "1 Y0 D/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0
M3ST  $D]  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M
M0S0 +$0\ "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$
MXP ?1/L 'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$
M $9    ^00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$
M)4DY "1)00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  8
M2?H &4C_ !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$
M   [10  -4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U
M !U//0 <4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@
M$D[_ !--_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W
M2@  ,4P  "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16
M.0 35T( $E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_
M  U4_P .4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@
M+%$  "94   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,
M7CT "UY(  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;
M_P %6_\ @4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<
M "%:   ;70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<
M &="  !G3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P
M8_\ >E(  &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB
M   490  $&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[
M  !Q2   <58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\
M<U@  &57  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .
M;P  "G(   1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]
M0   ?4X  'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T
M &!<  !77   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P
M GX   ""    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P
MC$8  (M6  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB
M  !18@  1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T
M  "0    D@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P
M )U,  "<7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !)
M;   /7$  #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@
M    H0   *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!
M  "O5   KVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0
M-7\  "B%   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P
ML0   +,   "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$
M20  Q%X  ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\
M ""6   4G0  #:,   .I    K@   +(   "W    NP   +\   #"    P@
M ,4   #&    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@
MWU   .!H  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH
M   .KP  !;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@
M  #:    W0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$
M /=8  #X<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_
M !H _P F /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X
M>P#\ ($ ^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_
M .L _P#= /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4
M_P A /\ + #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L
M 'L Z@"" .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -,
M_P#+ /\ P0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ;
M /8 )P#T #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0
MT@![ -  @@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"]
M /\ M #_ *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .
M(0#= "L VP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S
M +H >@"X (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\
MI@#_ *$ _P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#"
M "4 OP O +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *<
M<P"E 'L HP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_
M )0 _P"2 /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\
MJ@ I *@ ,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3
M '0 D@!] )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (<
M_P"& /\ ^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C
M )< + "5 #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X
M@P!W ($ @0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X
M /\ [0   -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@
M)@"& "X A  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q
M '0 ? !R (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\
MWPL  ,(,  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z
M "@ >  P '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@
M=P!G (0 90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!
M +81  "B$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ",
M;@$K &P!,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=
M!H$ 7 >/ %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7
M  "9&   BA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF
M &,++@!B##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H
M4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2
M'0  @QX  '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1
M*0!:$3$ 6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2,
M $D4G !'%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@
M?"(  '$B  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2
M&"T 41@T $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;
MF@! &ZP /QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8
M &PF  !C)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD
M2AXQ $D?-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y
M(:H ."+  #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I
M  !?*0  6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N
M $(D- !!)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@
M,B>^ #$GX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;
M+   52L  % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI
M,@ \*CD .RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\
M "LLW@ L+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P
M42X  $PN  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V
M+S8 -2\^ #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8P
MW  F,/< )R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$
M $@Q  !$,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S,
M,#0[ "\T0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A
M-/8 (C3_ ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T
M  ! -   .C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X
M "DY0  H.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4
M'3C_ !TX_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \
M-P  -3@  #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^
M/0 B/D8 (#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_
M !@\_P 8//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@
M,CP  "X^   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;
M1$, &D1- !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"
M_P 30?\ B3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T
M "I"   E1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D
M$TI* !%*5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -
M1_\ @SX  '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'
M   A20  '$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&
M  M140 *45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\
M?4(  &M#  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <
M3P  %U$  !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %8
M3   6%H  %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<
M &9'  !92   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650
M$5@   U; @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P
M8%0  &!C  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,
M  !53   3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6
M  AC   "9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT
M &I=  !J;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !2
M4   2D\  #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N
M    ;P,  ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96
M  !V:   =GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05
M1%4  #E8   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z
M?    'P#  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%
M7P  A74  (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X
M #)A   G9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@
M (L   "- 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@
MEFP  )6&  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN
M   ?=   %7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L
M  "=    GP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$
M *EZ  "HF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7
MA   #HH   >0    E@   )H   "?    HP   *<   "J    JP   *T   "O
M    L0   +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N
M  "^BP  OJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0
M!YP   "B    IP   *P   "P    M0   +D   "\    O0   +\   #!
MPP   ,8   #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:
M?   VIH  -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X
M  "T    N0   +X   #"    R    ,L   #.    SP   -(   #4    U@
M -H   #=    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P
M](D  /6E  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\
M+0#_ #D _P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"#
M /< B@#U )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\
MQP#_ +\ _P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_
M #, _P ^ /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0
M@P#B (L WP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_
M +0 _P"P /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T
M[0 W .< 0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #(
M (0 Q0"- ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *<
M_P"C /\ _P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P
M ,P .@#( $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P
MKP"% *T D "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7
M /\ _P   /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4
M,P"P #L K0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !]
M )H B "8 )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\
M_    .P   #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + ">
M #4 FP \ )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@
M@ "& (P A ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0
M -@   #"    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X
MB@ V (< /0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W
M (8 =0"4 '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0
M  "P    H@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P
M 'D -P!X #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (
M: ". &< G0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C
M"   E @  (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T
M,@!L #@ :@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70")
M %P F0!; *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@
MB0X  'T.  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A
M #, 8  Y %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %(
ME@!1 *< 4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,
M '03  !L$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\
M6 8U %8'.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !(
M"J8 1PJZ $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8
M  !E%P  7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ
M $\.. !.#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8
M/A"[ #T0W  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?
M'   61L  %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3
M- !'$SL 11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y
M #45V  U%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0
M5!\  % >  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0!
M&3@ /QD_ #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;
MTP O'/, +QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",
M $LB  !((   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4
M.1\\ #<?1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I
M(?( *2'_ "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E
M  !$)   0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y
M #(D00 P)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?
M)"7_ "4D_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  !
M)P  /28  #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI
M/P K*4< *2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_
M " I_P A*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P
M."H  #4J   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F
M+D4 )"Y/ ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM
M_P ;+?\ C"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X
M # N   M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T(
M'S-, !TS5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6
M,?\ ARX  '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS
M   H-   )34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A)
M !<Y50 5.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\
M@S$  ' R  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D
M.0  (#H" !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^
M4@ 0/E\ #SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30
M &LV  !=-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0
M'#\  !=!!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +
M1%L "41J  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y
M  !9.@  3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0
M !-& P /20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8
M $IE  !*=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5
M/@  2CX  $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ],
M @ +3PD !U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@
M  !1<@  48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100
M1T$  $!    Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &
M5@<  %<,  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:
M;   6H$  %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140
M #Y$   U10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0
M %\)  !@#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@
M9'L  &.3  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)
M   O3   )T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%
M  !J"@  :PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',
M &^-  !OIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I
M5   (%@  !A<   18   #&0   9H    :P   &\   !R    =    '4   !W
M!   > D  'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$
M  !^H   ?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P
M&&,  !%H   +;0   W(   !V    >@   'T   "     @P   (0   "&
MAP(  (D'  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/
MEP  C[0  ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(
M  IW   "?0   ((   "&    BP   (X   "1    DP   )4   "7    F0
M )L   "=!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@
MHZL  *'0  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")
M    C@   ),   "8    G0   *$   "D    I0   *<   "I    JP   *T
M  "P    L@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(
M +?   "WZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";
MH0   *8   "K    L    +,   "W    MP   +H   "\    OP   ,$   #$
M    QP   ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P
M  #2TP  TO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP
M +@   "]    P@   ,8   #*    R@   ,T   #/    T@   -4   #9
MW0   -\   #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #Q
MN0  \=@ _P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _
M /\ 2 #_ %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T
M\0"7 .X H@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T
M /\ _P   /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D
M0@#U $H \@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/
M -4 F@#1 *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\
M_P   /\   #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#=
M $0 V !+ -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P
MD@"Z )\ MP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P
M /\   #[    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T
MO0!$ +H 2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C
M )8 H0"E )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8
M  #G    TP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ]
M *, 1 "A $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X
MC@"< (P K0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,
M    O    +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$
M/0". $, C !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4
M 'H I !Y +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W
MJ    )X   "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!]
M #T ? !# 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P
MG0!J *\ :0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP
M (T   "&    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #<
M;@ ] &P 0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!=
M *@ 70"^ %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"
M  !X    =    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X
M &  /0!? $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *,
M40"W %$ U@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L
M"@  : <  &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8
M.0!5 #\ 5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R
M $< S !' .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P
M7@X  %L,  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!-
M 3L 3 %! $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#
MR  ]!.H /07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(
M %,1  !1#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@
M1 H^ $,*10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U
M#.D -0W] #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5
M  !*$P  21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\
M #T/0P [$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P
M+1'_ "X1_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$
M&   0Q4  $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #84
M0  T%$@ ,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_
M "@5_P I%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '
M/AH  #T8   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N
M&48 +1I/ "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:
M_P C&O\ C1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X
M #@;   U' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T,
M)Q]- "8?5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >
M'O\ B2   '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@
M   P( $ +B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1*
M "$D50 ?)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\
MA2(  '$D  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K
M)0  *24' "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI
M4P 9*5\ &"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4
M &XG  !?*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0
M)"H$ "(K#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4
M+ET $BYL !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ
M  !;*P  4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\
M !PP"0 :,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL
M#C-I  TS>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8
M+@  32\  $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U
M!0 4-@P $C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE
M  <X=@ %.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0
M23$  $$Q   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0
M/ D #3T.  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^
M<@  /H8  #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0
M #XT   W-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@
M"4,-  9$$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0
M1($  $28  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW
M   U-@  ,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,
M  !)#P  2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT
M $N4  !*K   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S
M.0  +#H  "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0
M#0  41   %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/
M  !3J   4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@
M)T   "!#   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P
M6@X  %L1  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=
MHP  7,$  %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@
M !I+   33@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H
M &8.  !H$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0
M:+L  &?G  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5
M   .60  "%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)
M  !U#0  =Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,
M '7@  !T_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &
M9@   &H   !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&
M!P  B P  (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/
M  "&]P  A?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@
M 'L   !_    @P   (<   "*    C0   (X   "1    DP   )4   "8
MF@4  )T,  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";
M[@  FO\ 1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T
M  "2    E@   )H   "=    GP   *$   "D    I@   *@   "K    K@
M +$#  "T"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@
ML/P /V0  #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E
M    J@   *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8
M  #)    S@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\
M-W$  "EX   =@   $8D   B1    F@   *$   "G    K0   +,   "Y
MO@   ,(   #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A
M    Y0   .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P
M /\   #_  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L
M_P!3 /\ 6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I
M *H Y@"\ ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\
M  #_    _P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!-
M .P 4P#H %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *(
MR "R ,4 R0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]
M    ^@   /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T
M3 #* %( R !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I
M *X O "L .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R
MYP   -L   #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q
M $L K@!1 *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@
ML0"6 ,P E0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0
M +P   "T    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0
MF !* )8 3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "#
M +X @0#D (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8
M  "=    EP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!#
M (, 2 "! $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +,
M< #0 &\ ]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",
M    A0   (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '(
M0@!Q $@ ;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#"
M &  ZP!A /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\
M=P   '( !0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C
M $( 8@!( &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0
MW@!4 /L 5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0
M &8  0!C  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T
M5@!# %4 20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!)
M /, 20#_ $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L
M  !9  4 5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^
M $L 10!* $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H
M/P#_ $  _P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0
M!@  3P(( $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $(
M00!! $@ 0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y
M #8 _P W /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0
M1PH# $<'"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z
M!44 .05. #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'
M_P N!_\ D1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X
M $ -!@! "@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T,
M,@Q, # ,5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G
M#?\ BQ(  '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1
M 0 Y#P@ . X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+
M "H050 H$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\
MAA0  ',7  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S
M$@0 ,A(+ #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "04
M4P B%%\ (!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<
M &\:  !?'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@
M+!<( "L6#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =
M&5T &QIK !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=
M  !<'P  4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL%
M "4;#  D'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL
M%AYI !0?>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9
M(0  32(  $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @
M"@ >(0\ '2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G
M ! C>  .(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P
M2R0  $$D   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9
M)@T %R81 !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH
M=  **(< "2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<
M #\G   W)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL
M$BP0 !$L%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $
M+8,  BV8   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI
M   U*0  +R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-
M  TQ$@ ,,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\
M #*5   QK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R
M*P  +2L  "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W
M$  %-Q0  S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2
M   WJ0  -L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@
M*RT  "<M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@
M/1(  #X7   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]
MIP  /<,  #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\
M "0P   >,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q
M $04  !%&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I
M1,   $/H  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U
M   :.   %#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1
M  !.%0  3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P
M $OG  !+_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5
M/P  $$(   Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7
M$0  61<  %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C
M  !4_0  5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02
M"TL   5.    40   %0   !7    60   %L   != @  7@8  & +  !B#@
M9!(  &<8  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@
M_   7_\ 24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8
M  !:    70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X
M '42  !W&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P
M;O\ 1D8  $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H
M    :P   &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-
M  ")$P  BAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\
M1DL  #I,   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X
M?    ($   "$    AP   (@   "+    C@   )    "3    E@   )D'  "=
M#0  H10  * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(
M #)5   F6@  &V   !%G   );0   '0   ![    @0   (8   "+    D
M )0   "7    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@
MM0T  +@6  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA
M   >:   $W    MX    @    (<   ".    E0   )H   "?    I    *@
M  "L    K0   +    "S    M0   +@   "[    OP   ,,   #'    RP4
M -$.  #1&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6
M>0  #8$   &+    DP   )L   "B    J    *X   "T    N    +T   #
M    P@   ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&
M  #K$0  ZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_
M_P $ /\ "P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\
M %L ^@!A /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\
MU0#; /< U@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _
M /P  P#^  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0
MX@!: -\ 7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"]
M .L NP#_ +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(
M  #J  4 YP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3
M +\ 6 "] %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P
MHP#[ )\ _P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(
M    P0 * +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8
M40"C %8 H0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P
M (T _P"& /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J
MI@ % *( #0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@".
M $\ C !5 (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D
M_P!W /\ <@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ !
M (L "@") !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@
M> !. '8 5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G
M /\ 90#_ &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@
M!0!V  P =0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !(
M &8 3@!E %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\
M60#_ %@ _P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F
M  D 90 . &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@
M2 !7 $\ 5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_
M $T _P!- /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4
M6  , %< $ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!,
M $H 2@!2 $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $,
M_P!# /\ G@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ )
M $T #0!, !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4
M00!- #\ 5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y
M /\ E0,  ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0
M"P!#  \ 0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !)
M #< 4@ V %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\
MC D  '@,  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \
M 0T .P 0 #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\
M4  N %H +0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P
M '(.  !C$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H
M-08. #0%$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G
M!UD )@=E "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1
M  !>$@  4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+
M "\*$  M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@
M( UE !X-=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:
M%0  3A8  $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.
M#0 H#A$ )@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F
M !<0=@ 5$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P
M2Q@  $(9   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B
M$@\ (1(4 " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4
M=  1%(< $!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L
M #\;   W&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T
M&Q<2 !H7%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -
M&80 #!F8  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=
M   U'0  +QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0
M !4<%0 4'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H
M!QZ4  4=J@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R
M'P  +1\  "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A
M$@ 0(1@ #B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1
M   BJ   (<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0
M*B$  "8@   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +
M)A4 "B8<  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   F
MI@  )K\  "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",
M "0B   A(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q,
M!"L8  (K'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI
M*[X  "KD   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D
M   ?)   &R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5
M   Q'   ,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P
M ##D   O^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <
M)P  &"@  !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X
M&   ."   #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D
M   U_   -?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P
M%"T  !$O   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %
M0!L  $ D  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \
M_   //\ 4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,
M  TV   ).   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8
M $H>  !**   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_
M1/\ 2C,  #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^
M   #00   $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49
M  !5(@  5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\
M13<  #PW   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(
M2@   $T   !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B
M&P  8B<  &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P
M #H[   T.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@
M %D   !<    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0
M<B   '(M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^
M   N/P  )$(  !I&   22@  #$\   14    6    %T   !A    90   &@
M  !K    ;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<
M (8D  "%-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H
M2   '4P  !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^
M    @0   (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:
M  "=*0  G#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P
M%5D   U@   #9P   &X   !T    >@   (    "$    B@   (X   "2
ME0   )<   ":    G0   *    "C    IP   *L   "O    M D  +@0  "W
M'@  M3   +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD
M  5Q    >0   ($   "(    CP   )0   ":    GP   *0   "H    J0
M *P   "O    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%
MT24  - [  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$
M    C0   )4   "=    HP   *D   "O    M    +D   "\    O@   ,(
M  #%    R    ,P   #0    U    -H   #?    Y    .H   #N#   [1H
M .PO  #J20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^
M  X _P 4 /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8
M8@#T &@ \@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_
M +8 _P"H /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D
M^@ . /T %@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6
M &  T@!G ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *<
M_P": /\ D@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  +
M -L $0#: !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D
MM@!? +, 9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+
M /\ A0#_ (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +<
M#@"T !0 M  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7
M )D 7@"7 &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\
M=@#_ ', _P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8
M !  F  6 )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (,
M5@"! %X @ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_
M &< _P!E /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T
M?P 1 '\ & "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M
M %8 ; !> &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L
M_P!: /\ O0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  .
M &L $P!K !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\
M7 !7 %H 80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/
M /\ K0   )@   "&    >    &X   !G    8P   &    !=  4 7  + %L
M$ !; !4 6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1
M $T 6P!+ &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\
MGP   (D   !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!.
M !$ 3@ 6 $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $(
M50!  &  /P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP
M 'X   !N    80   %@   !1    3    $D   !'    10 % $0 "P!#  X
M0P 2 $, %P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W
M %L -0!H #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#
M  !F!0  60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0
M #D %  Y !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %<
M+0!D "P <P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?
M"@  4PL  $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$
M$0 Q !4 ,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@
M "0 ;P C (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0
M3@X  $4.   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J
M 1( *0$7 "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!
M;  < 7\ &P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A
M $ 0   Y$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q
M) 84 "(&&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6
M"'T %0>1 !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2
M   V$@  ,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2
M !T+%P <#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X
M#PV2  X-IP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R
M%   +10  "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/
M%  7#QH %@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0
M  D0I0 ($+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@
M*A8  "85   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2
M$A@ $1,> !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04
MHP #$[L  A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@
M ",7   @%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4
M#A<;  T7(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0
M%[D  !?=   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9
M   >&   &Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8
M  @<'P ''"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D
M !O>   :]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <
M&@  &1D  !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@
M'  !(2,  "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>
M   >^   'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'
M&!L  !4;   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0
M)B   "8H   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C
M^0  (_\ 51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX
M !,>   0(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T
M "PE   L+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P
M*/\ 42(  $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C
M   .)   "R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A
M   S*@  ,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\
M3"4  #\F   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +
M*@  !RP   ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [
M)@  .S$  #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD
M #LJ   R*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0
M 30    V    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0
M12P  $0Y  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N
M   O+0  *2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P
M   _    00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<
M $\T  !/0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N
M+P  *2X  " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)
M    3    $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL
M  !=/   7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@
M)#,  !LV   3.0  #CT   A!    10   $D   !,    4    %,   !6
M60   %L   !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M
M-   ;48  &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL
M !4_   .1   !TD   !-    4@   %8   !:    7@   &(   !E    :
M &L   !M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+
M@#X  'Y4  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+
M   '40   %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X
M  "     @P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,
M )=)  "48@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:
M80   &@   !N    =    'D   !_    A    (D   "-    D0   ),   "6
M    F0   )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^
M  "P5@  K',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P
M 'L   ""    B0   (X   "4    F@   )\   "D    I@   *D   "M
ML    +,   "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-
M2P  RF8  ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )
M  "7    G@   *0   "K    L0   +8   "Z    O    ,    #$    R
M ,L   #/    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P
MZEL  .=Z  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\
M&0#_ "( _P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J
M .X <@#L 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\
ME@#_ )  _P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W
M !L ]0 E /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H
M:@#( '( Q0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_
M (, _P"  /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4
MT@ > ,L )P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L
M &D J0!S *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8
M_P!T /\ X@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8
M *T ( "H "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$
MCP!J (P =0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H
M /\ SP   ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\
M&0". "$ BP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B
M '8 ; !T 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\
MO@   +$   "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W
M !H =  A '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &,
M9 !A '  7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L
M )\   "-    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4
M8P ; &$ (0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2
M &@ 4 !W $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T
M  !\    ;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6
M %( &P!1 "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$
M0P!P $( @0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O
M    8P   %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $<
M%@!% !P 1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I
M #< >@ V (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E
M6    $\   !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z
M !< .0 < #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T
M<P L (@ + "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(
M $@#  !  P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !,
M,  8 "\ '0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D
M (( (P"9 ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((
M   Z"   -0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5
M "< &0 F !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P
M' "3 !L K  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U
M"P  , L  "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "
M%@ ? !L '@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/
M !4 I@ 4 ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0
M+ T  "<-   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9
M!!@ &00> !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !
MH@ / +P #P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \
M "0.   @#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18
M% D; !,)(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *
M![< "@;;  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0
M   =$   &@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9
M ! ,'P /#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0
M PS2  (,\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;
M$0  &!$  !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0
M'0 ,$"0 "A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4
M   .\P  #O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@
M%A(  !01 P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ (
M$B$ !A,I  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1
M]0  $?\ 6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,!
M !,2!  1$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\
M A8G   7,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P
M$_\ 510  $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3
M!@ 0$P< #Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD
M   ;+0  &S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\
M418  $,8   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /
M%00 #18$  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A
M*@  (34  "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D
M #\;   T'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$
M"QH"  @< P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P
M)S(  "<_   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>
M   Q'P  *!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\
M  0A   !(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX
M "X[   N2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N
M(0  )B$  " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G
M    *0   "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V
M   V10  -5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)
M)",  !\A   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O
M,@   #0    W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  !
M0   /U(  #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4
M !\C   8)   $B4   XH   **@  !2T    P    ,P   #8    X    .P
M #X   !     0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@
M2DP  $EA  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH
M   4*@  #BT   HP   $,P   #<    Z    /0   $    !#    1@   $@
M  !+    30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8
M %=:  !5=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0
M,@  "C8   ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8
M    6@   %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2
M  !F:@  9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0
M D(   !'    3    %    !4    6    %L   !?    8@   &4   !H
M:P   &X   !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![
M80  >'\  ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$
M  !6    6P   &    !E    :0   &X   !R    =@   'D   !\    ?@
M ((   "%    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260
MD7,  (V5  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H
M    ;@   ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D
M  "=    H0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD
M *B(  "FJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\
M@P   (D   "/    E0   )L   "@    HP   *8   "I    K0   +$   "U
M    N0   +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\
M  #"G0  P;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F
M )\   "E    K0   +,   "X    N@   +X   #"    Q@   ,H   #.
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M_________________________________________________P
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MV-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$
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MUHRI<-:,J7#6C*EPUHRI<-:,J7#6C/]_&@/_?"4&_X8I"/^2+PS_FS@2_Z%
M&O^G2"7_JE$R^:E;0?.F9%'LHFYAY9IV<-R1?G_2B8:+RX*-D\5]E9G >)V>
MO'6EH;ESKJ2V<KFELG##IJMOQJ*H<<N;I'/0DZ)TU(ZB=-2.HG34CJ)TU(ZB
M=-2.HG34CJ)TU(ZB=-2.HG34CO^ &@/_?"4&_X@H"/^4+PO_G3<1_Z0_&?^J
M1R3]KD\R]JU90>^K8E+GIFMBWIYR<]*5>H'*C8*+PX>*D[V!D9JW?9F?LWFA
MHZ]WJJ:L=K2GJG;!J*-SPZ6@=<F>GG?/EIQWTI&<=]*1G'?2D9QWTI&<=]*1
MG'?2D9QWTI&<=]*1G'?2D?^ &@/_?24&_XHG"/^6+@O_GS80_Z<_&/^M1R/[
MLDXQ\[)70>NQ8%+BJFADUJ)P=,R9=X'#DG^+O(N&E+6&CIJO@96@JGZ=I*9[
MIJ>C>K"IH7F\J9MWP:B9><>@F'K-F)=[T9.7>]&3EWO1DY=[T9.7>]&3EWO1
MDY=[T9.7>]&3EWO1D_^!&@/_?B0&_XPF!_^8+@K_HC80_ZD^&/^O1B/XM4TP
M\+=60.>U7E+=KF9DT*5N<\:==8"]EGR+M9"#E*Z*BYNHAI*@HX*:I9]_HZB;
M?JVJF'VYJY1[P*J3?<:BDG[,F9%_T)21?]"4D7_0E)%_T)21?]"4D7_0E)%_
MT)21?]"4D7_0E/^!&0/_?B0&_XTF!_^:+0K_I#4/_ZP]%_ZR12+VN$PP[;Q4
M0.2X75'7LF1CRZEL<\"A<X"WFGJ+KY2 DZB/B)NBBH^@G(>7I9>$H*B4@JFJ
MD8*UJXV!OZN-@<6DC(++FXR"SY6,@L^5C(+/E8R"SY6,@L^5C(+/E8R"SY6,
M@L^5C(+/E?^"&0/_?R0&_X\E!_^<+0G_IC4._ZX]%ORU12'SO$LNZL%2/^"\
M6U'1M6-CQJUJ<KNE<7^RGG>*J9A^DZ*3A9J;CXV@EHR5I9&)G:B-AZ>KBH>R
MK(>'OZR&AL2EAX;*G(>&SI>'ALZ7AX;.EX>&SI>'ALZ7AX;.EX>&SI>'ALZ7
MAX;.E_^"&0/_@",%_Y$E!O^>+ G_J#0-_[$\%?JX1!_POTLMY\51/=S 6E#-
MN&%BP;!H<;:I;WZLHG6)I)U\DIR8@IJ5E(J@CY&2I8J.FZB&C:6K@XRPK(&-
MOJR B\.F@8O)G8&+S9B!B\V8@8O-F(&+S9B!B\V8@8O-F(&+S9B!B\V8@8O-
MF/^#&0/_@B(%_Y,D!O^@+ C_JS,-_[0\%/>\0Q[NQ$HKY,E1.]7$6$_(O&!A
MO+1G<+&M;7VGIW.)GJ)YDI:=@)F/FHB?B9>0I(.4F*A_DZ*J?)*MJWJ2NZQZ
MD<.F>Y#)GGR/S9A\C\V8?(_-F'R/S9A\C\V8?(_-F'R/S9A\C\V8?(_-F/^#
M& +_A"$%_Y4D!O^B*PC_K3,+_K<[$O3 0ASJR4DHX,U/.=#'5T[#P%Y@M[AE
M;ZNR:WRAK'&'F*=XD)"C?IB)H(6>@IV-HWV;EJ=XF:"I=9FKJG.9N*MSF,.F
M=9;)GG:5S9EVE<V9=I7-F7:5S9EVE<V9=I7-F7:5S9EVE<V9=I7-F?^$& +_
MAR %_Y<C!?^E*@?_L3(*^[LZ$/'%01GGST@EV])-.,O+54R]Q%U>L;YC;J6X
M:GN;LF^&DJYVCXFJ?):"IX.<>Z2+H7:BE*5QH9VG;J"IJ6RAMJEMH<.F;YW)
MGG"<S9APG,V8<)S-F'"<S9APG,V8<)S-F'"<S9APG,V8<)S-F/^%& +_BAX$
M_YHB!/^H*0;_M3 (]L X#NO+0!7AV$8@T]A+-L705$NWR5M<J\-B;)^^:'B4
MN6Z#B[5SC(.R>I-[KX&9=:V)GF^KDJ)KJIRD:*JGI6:JM*9FJ\6D:*;*G&FD
MS9=II,V7::3-EVFDS9=II,V7::3-EVFDS9=II,V7::3-E_^&%P+_C1P$_YXA
M!/^L)P7]NB\&[\<V"N/4/A#8WT,?R]Y*-+[64DBPT%I:I,I@:9C&9G:-P6R
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MBU;(UHM6R-:+5LC6BU;(UHM6R-:+5LC6B_^+%0+_G1<!_Z\9 ?3!& '=V!$
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M&_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA
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M"/]I-@O_;CT/_W%&%?]S41S_<UXC_W!M*?]N?##_:XDU_VF6.?]GH3W_9JI
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M+C__O"\^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,+NQ  "LO
MG\D  )/9  ")_ L!@/\7 G;_( 5L_R@)9/\P#5W_.!!7_T 34?]'%DW_3AA*
M_U891_]<&D3_8QQ"_VD=0/]P'C__>!X]_X ?._^((#K_D2$X_YLB-_^D(C;_
MK2,U_[@C-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(ZVV  "?Q   DM(
M (3A  !]_PT!<O\3 FC_&P1?_R,&6/\K"5'_,PM,_SH-1_]!#T/_2!% _TX2
M/?]4$SO_6A0Y_U\4-_]E%37_:Q8S_W(6,?]Z%R__@A<N_XL8+/^3&"O_G!DJ
M_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&:&_  "2S   A-P  'CW
M  !N_PH!8_\0 EK_%0-2_QT$2_\D!D;_+ A!_S,)//\Z"CG_0 LU_T4,,O]*
M#3#_4 TN_U0.+/]9#BK_7@\H_V0/)O]J#R7_<1 C_W@0(O^ $2#_B!$?_Y$1
M'_^1$1__D1$?_Y$1'_^1$1__D1$?_Y$1'_^1$?]<(@/_5RT%_U@S!_]?-@G_
M8ST-_V5&$O]F4!?_95X<_V1N(O]A?"?_7XHK_UZ6+O]<H3'_6ZHS_UJR-?]9
MNC;_6,,W_UC-.?]7V#G_5N Z_U7F._]4[#S_4_$\_%+U/?A2^3WU4?T]\U'_
M/?-1_SWS4?\]\U'_/?-1_SWS4?\]\U'_/?]<(@/_5RP%_UHR!_]A-0G_93P-
M_V=%$O]H3Q?_:%P=_V9M(O]C>RC_88@L_U^4+_]>GS+_7:DU_UNQ-_]:N3C_
M6L$Z_UG+._]8U3S_5]\]_U;F/O]5ZS[]5/ _^5/U/_92^4#S4OU \%+_/O!2
M_S[P4O\^\%+_/O!2_S[P4O\^\%+_/O]=(0/_6"P%_UPP!_]D,PG_:#H-_VM#
M$O]L3A?_;%H=_VIJ)/]G>"G_9(4N_V*1,O]AG#;_7Z8X_UZN.O]=MCS_7+X^
M_UO(/_]:TD'_6=U"_U?E0_U6ZD3Y5?!$]53U1?%4^D7N5/Y$[%3_0NQ4_T+L
M5/]"[%3_0NQ4_T+L5/]"[%3_0O]>(0/_62P%_U\N!O]F,@G_;#@,_V]!$?]O
M3!?_<5<>_VYG)?]K=2O_:((P_V6.-?]DF3G_8J,\_V"K/O]?LT'_7KM"_UW$
M1/]<SD;_6MQ'_EGD2/I7ZDGU5O!*\%7V2NU5^DKI5OY'YU;_1>=6_T7G5O]%
MYU;_1>=6_T7G5O]%YU;_1?]>(0/_62L%_V(M!O]J, C_;S8,_W) $?]T2AC_
M=54>_W)D)O]O<BW_;'\S_VF+./]FECS_9:! _V.H0_]AL$;_8+A(_U[!2O]=
MRTO_7-I-^EKC3O59ZD_P5_%0ZU;V4>=7^T[D6/]+X5G_2>%9_TGA6?])X5G_
M2>%9_TGA6?])X5G_2?]?( /_6BL%_V4K!O]M+@C_<S4,_W<^$?]X2!?_>5(?
M_W=@)_]T;B[_<'LU_VV'._]JDD'_9YM%_V6D2?YCK$S]8;1.^V"\4?I>QE/Y
M7=15]5OC5N]:ZECI6/)9Y5GW5N!:^U/;6_]/UUO_3==;_TW76_]-UUO_3==;
M_TW76_]-UUO_3?]@( /_72D%_V@I!O]Q*P?_>#,+_WP\$/]]1A?_?E ?_WU=
M*/]Y:C#_=78X_W&"/_QMC47Z:I=+^&>?3_9EIU/T8J]6\V"X6?%?P5SP7<U>
M[5S@8.A:[&'A6O)@VEOV6]-<^E?/7?U3S%[_4<Q>_U',7O]1S%[_4<Q>_U',
M7O]1S%[_4?]A'P/_8"<$_VLF!?]U*0?_?#$*_X$Z$/^#1!?_A$T?_X-9*/]_
M9C+\>G([^'5^0_5QB$OR;9)1[VF:5NUFHEOJ8ZI?Z&"R8^9>O&;D7,AIX5O:
M:]U:ZFO37/!FS5[U8<A?^5S$8/Q8P6'^5<%A_E7!8?Y5P6'^5<%A_E7!8?Y5
MP6'^5?]B'P/_8R4$_V\D!?]Y* ;_@3 *_X4Y#_^(0A;_B4L>_XE6*/J%8C/U
M@&X]\'IY1^QU@U#I<(Q8Y6N57N%FG63>8Z1IVV"M;==?MV_47L-PT5[2<<U=
MYW''7^YKPF'R9KYB]F&Z8_E<MV/\6+=C_%BW8_Q8MV/\6+=C_%BW8_Q8MV/\
M6/]C'P/_9B,$_W(B!/]])P;_A2X)_XHW#O^-0!7_CTD>^H]3*/2,7S3NAFH_
MZ7]T2^-X?E7><H9>V&V/9=-JF&K/9Z!MS&6H<,ECL7/&8KQTQ&')=<%AX':\
M8^IQMV3O:K1E\V6P9O9@KF?Y7*YG^5RN9_E<KF?Y7*YG^5RN9_E<KF?Y7/]C
M'@/_:"$$_W4@!/^!)07_B2T(_X\U#/^2/A3\E$<=]99/*.Z16S3GBV9!X(1O
M3ME]>5C1=X)@S'.*9\=ODVS$;)MPP&FC<[UGK':Z9K9XN&7">;9EU7FR9N9V
MKFCL;ZII\&FH:?1CIFKW7Z9J]U^F:O=?IFKW7Z9J]U^F:O=?IFKW7_]D'@/_
M:R #_W@>!/^$) 7_C2P'_Y,T"_^7/!+XF44;\)M-)^B7633AD&)"UXEL3LZ#
M=5C(?7YAPWB&:+YTCFVY<)9RMFZ>=;)LIWBO:K%[K6F]?*IIS7VH:N-ZI6SI
M<J)L[6R@;?)FGF[U8IYN]6*>;O5BGF[U8IYN]6*>;O5BGF[U8O]E'0+_;1X#
M_WL= _^'(P3_D"H&_Y<R"OV<.Q#TGT,9[*%+)>.<5C/:EF!!SXYI3L>(<EC
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MB(9SD(6.>(R"EGR(@*" A'^K@H%_N(-_?\J$@8'A?8&!YG:!@.MO@(#O:H"
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M4DCFZ%)(Y/A12.'\3TCA_$](X?Q/2.'\3TCA_$](X?Q/2.'\3^&9  #-J0
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M'"[_OQPN_[\<+O^_'"[_OQPN_[\<+O^_'*FU  ":P@  C,\  '_>  !V_P4
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MKS('TJP^%<>F2R2]H%4SM)I>/ZR594JED&U2GHQT69B(>V"3A8-ECH*+:HJ
MDVZ&?IUQ@GVG=']\M'9]?,5V?7[@<W]_[FM_?_-E?W[W7G]^^%U_?OA=?W[X
M77]^^%U_?OA=?W[X7?]E& +_=1,!_X04 ?^1%P'_G!L!\J4@ >:N)@+;M"X&
MSJ\]%,.J22.YI%,QKYY</J>99$F@E&M1F9!R69.->5^.BH!DB8>(:82%D6Z
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M9E*SZ6-4LO=?5:[Z6U:M^UI6K?M:5JW[6E:M^UI6K?M:5JW[6O]^"0#RD0(
MUJ$" ,JM!0# MP4 N,(% ++/"0"KU!< H],K!IG0.A*/SD4?A<M.*GW)5C1U
MQUT];L5E1&C$;$ECPG-.7L%[4UG!A%95P(]94K^;7$^_J%U-O[A>3,#-7DS
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M.$#L_SA [/\X0.S_.$#L_SA [/\X0.S_.,N@  "ZJP  K;0  *'   "6S $
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M9F*2YV)EE/A<9Y+]5V>1_U)GD?]29Y'_4F>1_U)GD?]29Y'_4O]N#@#_?PD
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M2TZY_TE.N?])3KG_24ZY_TE.N?])3KG_2>^%  #4E0  QZ,  +JL 0"PM
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M//@;_SW_&_\]_QO_/?\;_SW_&O\]_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?]
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M7')\Z%AU?OE1=X#_3'> _T=W@/]&=X#_1G> _T9W@/]&=X#_1O]D#P#_<@D
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M3%^7_T=@EO]&8);_1F"6_T9@EO]&8);_1O]P P#K@0  UH\  ,J: 0#!HP,
MN:H" +&R 0"JMQ$ H[<D INU- J3LD 4BJ]*'H.M4R=\JUHN=JAA-7"G:#MK
MI6] 9Z-W1&*B?TA>H8E,6J"43U>?H%%4GZY34Y_ 4U*?W5)5G_-.5Z#_2EF@
M_T99G_]%69__15F?_T59G_]%69__1?]U  #@A@  SY,  ,2? 0"ZIP$ L:X
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M-T7!_S=%P?\W1<'_-]6+  #%F@  MZ0  *NL  "@M   EKX  (O'! "!T @
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M3X%JZ$R#;?E%A&__/X5P_SN&<?\XAG'_.(9Q_SB&<?\XAG'_./];#P#_9P@
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M0VZ!_S]O@?\\;X'_/&^!_SQO@?\\;X'_//]D" #_<@  X7\  -.) 0#*D@,
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M.E:;_SI6F_\Z5IO_.O%T  #9@P  R)   +Z:  "SH0  JJ<  *&N  "7M08
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M)<.3  "UG@  J*8  )VN  "1M@  A;\  'G'  !OS@0 9-8) %[>$0!;WB
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M"B/^L HB_L0+(?_@"R']\@H@_/P*(/S\"B#\_ H@_/P*(/S\"J*G  "5L0
MA[L  'G&  !LSP  7]D  %+?  !(Z   0_\( #__$  [_QD -_\A #3_*0$P
M_S !+?\W BK_/@(G_T0")?]+ R+_4P,@_UP#'?]F!!O_<@09_X %%_^/!1;_
MGP85_Z\&%/_ !A3_U@83_^D&$__I!A/_Z083_^D&$__I!I>O  "(N@  >L4
M &S/  !>V@  4.   $3F   \]0  -_\$ #/_#0 O_Q, *_\: "C_(0 E_R<!
M(?\M 1[_,@$;_S@!&?\_ 1;_1@(4_TT"$?]6 A#_8 (._VP"#/][ PO_BP,*
M_YH#"O^H PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X  %[;
M  !/X@  0N<  #;L   Q_P  +/\  "?_!P C_PX (/\2 !S_&  8_QT %?\A
M !+_)@ 0_RP!#O\Q 0W_-P$*_SX!"/]& 07_3P$!_UD! /]F 0#_= $ _X("
M /^0 @#_G ( _Z8" /^F @#_I@( _Z8" /^F O\N+P+_,RP"_S<M O\X, +_
M-S8#_S0_!/\Q2P;_+U@'_RQF"/\J= G_*8$*_RB-"_\HEPO_*)\+_RBF#/\G
MK0S_)[0,_R>[#/\GQ S_)\X,_RC>"_\HZ0O_*/,+_RC["_\H_PK_*?\*_RG_
M"O\I_PK_*/\*_RC_"O\H_PK_*/\*_RC_"O\P+0+_-BH"_SDJ O\[+@+_.C0#
M_S@\!/\V20;_,U8'_S%C"?\O<0K_+7X+_RV*#/\LE S_+)P-_RRD#?\LJPW_
M++$-_RRY#?\KP0W_+,L-_RS:#?\LYPW_+/$-_RSZ#?\L_PS^+?\,_2W_#/TM
M_PS]+/\+_2S_"_TL_PO]+/\+_2S_"_\R*P'_.2@"_STH O\_*@+_/C #_STZ
M!/\\1@;_.5,(_S=@"?\U;0O_,WH,_S*&#?\QD [_,9D._S&A#_\QJ __,*X/
M_S"U#_\PO1#_,,<0_S#4$/\PY!#_,>\0_C'Y#_LQ_P_Y,?\/^#'_#O<Q_P[W
M,?\.]C'_#O8Q_P[V,?\.]C'_#O\U* '_/"4!_T D O]#)P+_0RP#_T0W!/]"
M0P;_0$\(_SU<"O\[:0S_.78-_SB"#_\WC!#_-Y41_S:=$?\VI!+_-JL2_S:R
M$_\UNA/_-<,3_S7/$_PUX1/Y-NT3]C;W$_,V_Q/Q-O\2\#;_$O W_Q'O-_\1
M[S?_$.\W_Q#O-_\0[S?_$/\Y)0'_0"$!_T4@ ?]'(@+_22D"_THT!/])/P7_
M1DL(_T18"O]"90W_0'$/_SY]$?\]AQ+_/9$4_CR9%?T\H!7\.Z<6^CNN%_D[
MMA?X.[\7]CO*&/0[W!CP.^H8[3OV&.H[_Q?H//\7YSS_%N8]_Q7E/?\4Y3W_
M%.4]_Q3E/?\4Y3W_%/\](@'_1!X!_TD< ?]-'@'_4"8"_U$P _]0.P7_3D8(
M_TM3"_](8 [_1FP1^T5X$_A$@A7V0XP7]$*4&/-!G!GQ0:,;[T"J&^Y LASM
M/[L=ZS_&'ND_U1[E/^@?XD#T'M] _AW=0?\;VT+_&ME"_QC80O\7V$+_%]A"
M_Q?80O\7V$+_%_] 'P'_2!H!_TX8 ?]2&P'_5B,"_U@L _]7-P3_54('_U)-
M"_E06@[U36<2\4QR%NY*?1CK2(8;Z4>/'>=&EQ_E19X@XT2F(N%$KB/@0[<D
MWD/")=Q#T";70^4FTT3S)-!%_B+-1O\@S$?_'LI'_QS)2/\;R4C_&\E(_QO)
M2/\;R4C_&_]$&P'_3!8!_U(4 ?]8& '_71\!_U\H O]>,@/]73T&]EI)"O!7
M50_J56(3YE)M&.)0=QS?3H$?W$R*(ME+DB352IHFTTFA*-%)J2G/2+(JS4B\
M*\M(R2S(2-\LQ4CO*\)*_"C 2_\EOTS_(KY-_R"]3?\?O4W_'KU-_QZ]3?\>
MO4W_'O]'& '_3Q,!_U81 /]>%0#_8AP!_V4D ?YE+0+T9#@%[6%#">9?40[@
M7%T4VEAH&M16<A[05'LBS%*$)LI0C"C'3Y0JQ4Z;+,-.HR[!3:POOTRV,+U,
MPC&[3-,RN$SI,;9.^"VT4/\JLU'_)[-2_R2R4O\BLE+_(K)2_R*R4O\BLE+_
M(O]*%0'_4Q$ _UL/ /]B$@#_:!< _VH? ?9K* 'L:S(#Y&D^!]QF3 W38E@4
MS5]C&\A<;2#$6G8DP5A^*+Y6ABN[58XNN5.6,+92GC*T4J8SLE&P-;!1O#:N
M4,LWK%#C-ZI2]#.I5/\NJ%;_*ZA7_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-
M$P#_5@X _U\- /]G$ #_;!, ^W 9 .]Q(@'D<2P"VW Z!=%L2 S):%04PV5?
M&[YB:"&Z7W$FMEUY*K-;@2VP6HDPKEB1,ZM7F36I5J$WIU:K.*55MCJC5<4[
MH57=.Y]6\#>?6/XRGUK_+IY;_RN>7/\HGES_*)Y<_RB>7/\HGES_*/]0$0#_
M60P _V,, /]K#0#_<!  ]703 .AV&@#==R4!T78V!,AR1 S!;E 4NVM;&[9G
M9"&Q96TGK6)U*ZI@?"^G7X0RI%V,-*)<E#>?6YTYG5JF.YI9L3V86;\^EUG3
M/I5:[#N57?LUEE[_,99?_RV68/\JEF#_*I9@_RJ68/\JEF#_*O]2#P#_7 H
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M.'IO_S1[</\P?'#_,'QP_S!\</\P?'#_,/];" #_9@  YW(  -I[  #/@@,
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M,F:!_S)F@?\R9H'_,O]D  #E<@  TWX  ,>'  "^CP  MI4  *Z9  "FFPP
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MK:,N1*VS+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&
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M'#C)R1PXR.@<-\?Y'#?%_QPVQ/\<-L3_'#;$_QPVQ/\<-L3_'+Z1  "PFP
MI*,  )BJ  ",L@  @+D  '3   !HQP  7<T% %/3"@!/UQ( 3=@B $O8, !)
MV#P"1MA& T393P1!V5@&/]EA"#S9:PHZV78,-]F"#C7:D \TVJ 0,MJQ$3';
MQQ$QVN<1,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD
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M P[_U0,._^T##O_P P[_\ ,.__ ##O_P Y.N  "$N   =L(  &?,  !:U0
M3-P  #_A   UY@  +?0  "K_ @ F_PL (_\1 "#_%P =_QT &?\C !;_*0 4
M_R\ $O\U !#_/0 ._T4!#/]. 0K_6 $'_V4!!?]T 0/_A0$"_Y8! ?^F 0#_
MM0$ _\8! /_* 0#_R@$ _\H! /_* 8:W  !WP0  :,P  %K7  !+W@  /N0
M #+I   G[0  (_\  !__   ;_P4 %_\, !3_$  1_Q0 #_\8  W_'0 +_R(
M"/\H  7_+@ "_S4  /\]  #_1P  _U(  /]>  #_;0  _WX! /^. 0#_FP$
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M)[))\R6P2O\BKDO_'ZY,_QVM3/\;K4W_&JU-_QJM3?\:K4W_&O]'$0#_3PT
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M*XE>_RB)7_\EB5__(XE?_R.)7_\CB5__(_]1"0#_6@  ]60  .!L  #7<0,
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M*'%O_RAQ;_\H<6__*/]9  #K90  VW   ,UX  #$?@  O((! +:$ 0"NA0X
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M+$6<P2Q%G-\K19OT*4::_R='FO\E1YK_)$>:_R1'FO\D1YK_)-1W  #"A
MMH\  *N6  "AG   EJ   (NE  !_J@  =*X% &^O% !LKR0 :*\R F2N/05?
MK48)6ZQ/#5BL5A%4JUX44:IF%TZJ;AI+J7@=2*F#($6HCR)#J)TD0:BM)4"H
MP"4_J-\E/Z;T(T"E_R) I?\A0*3_($"D_R! I/\@0*3_(,I^  "[BP  KY4
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M"BK/_@LISO\,*<W_#2G-_PTIS?\-*<W_#:Z8  "BGP  EJ8  (FN  !\M@
M;[T  &/#  !7R   3,T  $+2 P YV0D -=\0 #3?&P RX"< ,>$R ##A/0 N
MXD< +>)0 2OB6@$JXV4"*.-Q B;D?P,EY(\#(^6A!"+EM 0AY<T$(.3L!"#B
M^P0?X?\%'^#_!1_@_P4?X/\%'^#_!:2>  "8I0  BZX  'VV  !PO@  8\8
M %;+  !+T   0-4  #;<   OY0< +>T0 "ON&  I[B( )^\K "7O-  C\#P
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M  #_U@  _]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0
M&NT  !7]   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)
M_RL  /\S  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_
ML0  _[$  /^Q /\E*P'_*"D!_RDI ?\H+ '_(S(!_QX[ O\:1P+_%U4#_Q5B
M _\3< /_$GP#_Q*' _\2D0/_$ID#_Q*@ _\2IP/_$JT#_Q&T _\1NP/_$<0#
M_Q'. _\1WP/_$>L"_Q+V O\2_@+_$O\"_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_
M$O\"_Q+_ O\H*0'_*R8!_RPF ?\K*0'_*"\!_R(X O\@1 +_'5(#_QM? _\8
M; /_%WD$_Q>$!/\7C@3_%Y8$_Q:=!/\6I 3_%JH$_Q:Q!/\6N 3_%L #_Q;*
M _\6VP/_%N@#_Q?T _\7_0/\%_\"^Q?_ _L7_P/Z%_\#^A?_ _H7_P/Z%_\#
M^A?_ _\J)@'_+B,!_R\B ?\O)0'_+"L!_RHU O\G00+_)$X#_R); _\@: 3_
M'G0$_QV !/\=B@3_'9(%_QV:!?\=H07_':<%_QVM!?\=M 3_';T$_QW'!/\=
MU 3^'>8$^QWR!/<>^P/U'O\$]![_!/,>_P3S'O\$\A[_!/(>_P3R'O\$\A[_
M!/\N(@'_,A\!_S0> ?\S( '_,B8!_S(R ?\O/@+_+$H#_RI7 _\G9 3_)G %
M_R5[!?\DA07_)(X&_R26!O\DG0;_)*,&_R2J!OTDL0;\)+D&^R3#!ODDSP;V
M).,&\B3P!>XE^@7M)?\&ZR7_!NHE_P;I)?\&Z27_!NDE_P;I)?\&Z27_!O\R
M'@'_-AL _S@9 /\X&P'_.B,!_SDM ?\X.@+_-48#_S)2!/\P7P3_+FL%_RUV
M!OTL@ ?Z+(D'^2N1!_<KF0CU*Y\(]"NF"/,KK0CQ*[4(\"N_".XKRPCK*]\(
MYRSN".0L^@CB+/\)X"S_"=XL_PC>+/\(W2S_"-TL_PC=+/\(W2S_"/\U&@#_
M.A8 _ST4 /\_%P#_01\ _T$I ?] - '_/4$"_SI- _PX6@7X-F4&]#5Q!_$T
M>PCO,X0)[3.-">LRE KI,IL*Z#*B"^8RJ@OD,K(,XS*[#.$RR S?,MP,VC+L
M#=4S^ W2,_\-T#/_#,XS_PS--/\+S#3_"\PT_PO,-/\+S#3_"_\Y%@#_/A(
M_T$0 /]%$P#_2!L _T@D /]'+P'^1#L"]T)' _$_5 7L/F &Z#QK".4[=@GB
M.W\+X#J(#-TYD W;.9<.V3B>#]8XIA#4.*X1TCBW$= XPQ+..-,2RCCH$L<Y
M]Q+$.?\1PCK_$,$Z_P_ .O\.OSK_#K\Z_PZ_.O\.OSK_#O\]$P#_0@\ _T8-
M /]+$ #_3A8 _T\? /U.*0'T3#0![$A! N9'3@3@15L&VT1F"=9"< S207D.
MST""$,U BA'*/Y$3R3^9%,<^H!7%/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W
M/_\6M4#_%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1
M#0#_4Q$ _U08 /-4(@#I4BT!X5 [ =I/20/2354'S$M@"\A):@[%2',1PD=[
M$[]&@Q6]18L7NT63&+E$FAFW0Z(:M4.K&[1#MARR0\0=L$/9'JU#[1VK1?P:
MJ47_&*A&_Q:H1O\5IT?_$Z='_Q.G1_\3IT?_$_]$#@#_2@@ _U & /]5"@#_
M6 T ]UD1 .I8& #?5R0 U%<U <Q51 3&5% (P5);#+U091"Y3FT3MDUV%K1,
M?1BQ2X4:KTJ-&ZU)E1VK29T>J4BF(*=(L"&E2+TBI$C/(J%(Z"*@2?@>GTO_
M&YY+_QF=3/\7G4S_%IU,_Q:=3/\6G4S_%O]'"P#_30( _U0" /=:! #K70<
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M'7U>_QU]7O\=?5[_'?]0  #U60  X6,  -)J  #);@  PG ! +UP P"V<!
MKG$B *AP,@*A;C\&G&Q*"Y=J4Q"2:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2
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M+%-\OBU2?-HM4WSR*55\_R56?/\B5WS_(%=\_R!7?/\@5WS_(.5D  #/<
MP7H  +:#  "MB0  HXP  )F.  "-CP  AI . (&1'0!]D"P!>(\X!'..0@AN
MC4L,:HQ3$&>*6A1CB6$78(AH&UV'<!Y:AGDA5H6#)%2%CR91A)PH3X2J*DV$
MO"I-A-<J38/Q)T^#_R10@_\B4(/_'U"#_Q]0@_\?4(/_']YI  #)=0  O(
M +*(  "HC0  G9$  ).3  "%E@  ?I<+ 'F7&0!UER@!<9<U VR6/P9HE4@*
M9)10#6&35Q%=DEX56I%F&%>0;AM4CW<>48Z!($Z.C2-+C9HE28VI)DB-NR='
MC=0G1XSP)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4  *R-
M  "BD@  EY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1AGD4'79U-
M"EJ<5 U7FUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B
M09;O($*5_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";
MEP  D9L  (6?  !YHP  :J<  &6G#@!CJ!P 8*@K 5VH-@)9IT $5J=)!E.F
M40E0IED,3:5@#DJE:1%'I'(41*1]%D*CB1@_HY<:/:.G&SRCN1P[H](;.Z+O
M&SN@_AH[G_\9/)__&#R?_Q@\G_\8/)__&,1\  "VB0  JI(  )^7  "5G
MB:$  'VF  !QJ@  9*X  %JQ" !7L10 5;(C %.R, %0LCL"3;)$ TNQ305(
ML54'1;%="4.Q90M L&\-/K!Z#SNPAQ$YKY83-Z^F%#:ON!0UL-$4-:[O%#2M
M_A0TK/\4-*O_%#2K_Q0TJ_\4-*O_%+N%  "OD   HY<  )B=  ",HP  @*@
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M A?:_P(7VO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@
M.\X  #'3   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4
M[$X $NQ: !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK
M_P ,Z_\ #.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@
M "7=   =X0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\
M!_M*  3\5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0
M_/T  /S] (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE
M   3Z@  $/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z
M  #_10  _U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4
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M)@'_)20 _R4D /\C)P'_'2P!_Q@U ?\50@'_$E !_Q!= O\.:@+_#G8"_PZ
M O\.B@+_#I("_PZ: O\.H +_#J8!_PVM ?\-LP'_#;L!_PW% ?\-T0'_#>,!
M_PWO ?X-^@'Z#?\!^0[_ ?D._P'Y#O\!^ [_ ?@._P'X#O\!^ [_ ?\F(P#_
M*"  _R@@ /\F(@#_(B@!_R R ?\</P'_&4P!_Q=9 O\590+_$W$"_Q-\ O\3
MA@+_$XX"_Q*6 O\2G0+_$J,"_Q*I O\2L +_$K<"_Q+! O\2S ']$M\!^1/M
M ?43^ 'S$_\!\A/_ ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J'P#_+!P
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M"KLS_PJZ,_\)NC/_";HS_PFZ,_\)NC/_"?\Y$ #_/0L _T ) /]$#0#_1A$
M_T49 /=$(P#N02\ YC\\ > ^2@':/5<"TSQB!,\[; ;,.G4'R3I]"<<YA0K%
M.8P+PSB4#,$XFPW .*,-OCBL#KPXM@^Z.,,/N3C7$+4X[!"R.?L/L#K_#J\Z
M_PVN.O\,K3K_"ZTZ_PNM.O\+K3K_"_\\#0#_0 8 _T4$ /])"0#_2PT ^4H1
M .U)&@#C1B8 VD8V -%&10'+15$#QD1<!<)"9@B_0F\*O$%W"[I ?PVX/X8.
MMC^.$+0^E1&R/IT2L#ZF$Z\^L!2M/KT4JS[-%:D^YA6F/_<3I$#_$J- _Q"B
M0/\/HD#_#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8 ZD\+ .-,
M$ #63!X S4TP ,9-/P' 3$P$NTM7!K=)80FT2&D,L4=Q#JY&>1"L1H 1JD6(
M$ZA$D!2F1)@6I$.A%Z)#JQB@0[<9GT/'&9U#X!J;1/,7F47_%9A&_Q.81O\1
MF$;_$)=&_Q"71O\0ET;_$/]"!0#_1P  ]T\  .53  #=50$ UU4& -52"P#+
M4QD PU0K +Q4.P&V4D@$L5%2!ZU07 JI3F0-IDUL#Z1,=!&A2WL3GTJ"%9U*
MBA>;29,8F4F<&I=(IAN52+(<E$C!'9)(V!V02>\;CTK^&(]+_Q:.2_\4CDS_
M$HY,_Q*.3/\2CDS_$O]%  #_2P  Z5,  -Y8  #36P  S5L$ ,I8!P#"6!4
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M  #B7   SV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY
M!89L20B":E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D
M9F*N)65BOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=
M7P  RV@  +]O  "V<P  KG4  *9U  "=<P4 EG,4 )%T) "+<S("AG(^!(%P
M1PA];T\+>6U7#G9L7A%S:V04<&IL%VUJ<QIK:7P<:&B&'V9GD2)C9YXD86:L
M)6!FO29?9]8F7V?Q(F!H_QYA:/\<8FC_&F)H_QEB:/\98FC_&>Q7  #98@
MQVL  +QR  "S=P  JGD  *%Y  "7=P$ D'@1 (MX(0"&>"\!@7<[!'QU10=X
M=$T*=')5#G%Q7!%N<&,4:V]J%FAN<1EF;GH<8VV$'F!LCR%>;)PC7&NJ)5IK
MNR99;-,F6FSO(UML_Q]<;?\<76W_&EUM_QE=;?\976W_&>A:  #29@  PV\
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M'TI^_!Q+?O\:2W[_&4Q^_QA,?O\83'[_&-5G  ##<P  MGP  *R$  "BB0
MF(L  (V-  !\C0  =8X$ &^/$@!MD"$ :9 N 66/.0)BCD($7HY+!UN-4@I8
MC%D,5HMA#U.+:!)0BG$438E[%TJ)AQE(B)4;1HBC'42(M!U#B,H=0X?J'$2&
M^QI$AO\818;_%T6%_Q=%A?\7187_%\UM  "]>   L8(  *>*  "<C@  DI
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M#2^E_PTOI?\-+Z7_#;:$  "JC@  GI0  )29  "'G@  >Z,  &^H  !CK
M5Z\  $NR  !!M08 /K81 #VV'@ [MBD .K<T #FW/@ WMT< -K=0 32W6@$R
MMV0",+=O RZW? 0LMXL%*K><!2FWK@8HN,4%*+?F!2>U^0<FL_\')K+_"":R
M_P@FLO\()K+_"*^-  "BE   EYH  (N@  !^I@  <:L  &6P  !9M   3;<
M $*[   XO@$ +\() "W#$@ LPQX *\,I "K$,P IQ#T *,5' "?%40 FQ5P
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M ).A  "%J0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP
M$M\   WC   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3
M\EP  /)M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I
M  !YL@  :KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@
M  7S   #_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD
M /Y:  #^;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !L
MNP  7<0  $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_
M    _P   /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&
M  #_6   _VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0
M_QHD /\5)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_
M )( _P": /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\
M^ #_ /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA
M /\9(P#_$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\
M_P*6 /\"G #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X
M /\ ]P+_ /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>
M'P#_&"0 _Q4O /\2/ #_$$D _PY6 ?\,8@'_"VX!_PMY ?\+@@'_"XL!_PN2
M ?\*F0'_"I\ _PJE /\*JP#_"K( _PJ[ /T*Q@#["M0 ]PKG /,*] #P"O\
M[PO_ .X,_P#M#/\![0S_ >T,_P'M#/\![0S_ ?\E&P#_)A@ _R47 /\A& #_
M("$ _QXK /\:-P#_%T4 _Q11 ?\27@'_$6D!_Q%T ?\1?0'_$(8!_1". ?P0
ME0'Z$)L!^1"A ?<0J 'V$*\!]!"W /,0P@#Q$-  [1#E .@1\@#F$?X!Y!+_
M >,2_P'B$O\!XA+_ >$2_P'A$O\!X1+_ ?\I%@#_*A, _RD2 /\G$P#_*!P
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M!Z<S_P>G,_\'IS/_!_\W!P#_.@  _SX  /I! 0#Q008 \3\- .8\$@#;.A\
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M&VQ5O1QK5M4=:U;P&FM7_Q=K6/\4;%C_$FQ8_Q%L6/\1;%C_$?%+  #?5@
MS%X  ,!D  "W9P  KF@  *=F  "?8@8 F&,4 ))D) "-8S(!B6(] H1A1P2!
M8$\'?5]6"7I>70MW760-=5QK$'-<<Q)P6WL4;EN%%VQ:D!EJ6IP;:%FJ'&9:
MNAUE6M$=95KN&V5;_A=F6_\59ES_$V=<_Q)G7/\29US_$NU.  #:60  R&$
M +QG  "S:@  JVP  *)J  "99P( DF<1 (UG(0"(9R\!A&8[ G]E1 1[9$T&
M>&-4"75B6PMR86$-<&%I#VU@<!)K7WD4:5^#%V9>CAED7IH;8EZH'&%>N!U?
M7LX=7U[L&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0  +EJ
M  "P;@  IW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V:4H&<VA2
M"'!G60IM9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MBMAU:8LP=
M6F+J'%MC_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L
M<@  I'0  )IS  ".;P  AV\- ()O&P!]<"D >6\U 75N/P-R;4@%;FQ0!VML
M5PII:UX,9FIE#F1I;!%A:7437VA_%EQHBAA:9Y8:6&>D'%9GM!U59\H=56?H
M&U9G^QA79_\65VC_%%AG_Q-89_\36&?_$^%8  #+8P  O6L  +)R  "I=@
MH'@  )9W  "(<P  @7,+ 'QT%P!X="8 ='0R 7!S/0)M<T8$:G).!V=Q50ED
M<%P+87!C#E]O:A!<;G,26FY\%5=MB!=5;)094VRC&U%LLQQ0;,@<3VSG&U%L
M^AA1;/\54FS_%%)L_Q-2;/\34FS_$]Q<  #'9P  N6\  *]V  "E>P  G'P
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M$4" _Q! @/\00(#_$,9K  "W=@  K'\  **%  "7B0  C(L  (&-  !SC@
M98\  %V/"0!:D!0 6) A %:1+0!3D#@!49!! DZ020-,D% $2H]8!4>/8 =%
MCFD)0HYS"T"-?PT^C8T//(V<$#J-K!$YC<$1.(WA$#B+]A XBO\/.8G_#SF)
M_PXYB?\..8G_#K]R  "R?0  IX8  )R*  "1C@  AI$  'J3  !ME0  7Y<
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M!*J+  "=D0  DY<  (><  !ZH@  ;:<  &"K  !5KP  2;$  #ZT   SMP
M*KH# "2\#0 BO14 (;T@ "&]*@ @O3, '[X] !Z^1P =OE( '+]> !J_;  9
MOWP &+^. !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2
M  "6F   BIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0
M !G'!0 3RPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG
M"\Z#  K.EP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-
MG@  ?Z4  '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1
M   ,U@4 "-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS
M  #>B   WYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@
M<ZX  &6U  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #
MX0   .,'  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M
M=@  [HP  .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<
M %F_  !+Q@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP
M .L   #M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P
M_'<  /V-  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*
M   \SP  +M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8
M  #W    ^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(
M /]W  #_C0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_
M!BH _P S /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\
MG #_ *( _P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_
M /P _P#[ /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4
M_P0P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_
M )X _P"D /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0
M_P#S /\ \P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL
M /\).0#_!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L
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M /\>$ #_'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP
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M [$D_P.O)/\#KR3_ ZXD_P.N)/\#KB3_ _\O!@#_+P  _S(  /\S @#Y,@@
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M"8)!_PB"0?\(@D'_"/\\  #K0P  W$H  ,Q/  ##4   O$X  +=) 0"Q1@X
MJD@< *1)+ "@23H FTE% 9A(3@*41U<#DD=>!8]&90:-1FP'BT5S"8E%>PJ'
M1(,+A42-#(-$EPZ!0Z(/?T.O$'Y#P!!\1-H1>T3Q#WI%_PUZ1O\+>D;_"GI&
M_PEZ1O\)>D;_"?4^  #F2   TT\  ,=4  "]50  ME0  +!0  "I3 L HDT8
M )U.* "83C8 E$Y! 9!-2P*-35,$BDQ:!8=+80:%2V@(@TIO"8!*=PM^27\,
M?$F)#GI(DP]X2)\0=TBL$G5(O!)T2=(3<TGN$7)*_P]R2O\-<DK_"W)*_PMR
M2O\*<DK_"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93
M) "14S( C5,^ 8E21P*&45 $@U%7!8!07@9^3V4(>T]L"7E.<PMW3GL-=4V%
M#G--D!!Q39P2;TVI$VY-N11L3<X4;$WK$VQ._1!L3_\.;$__#&Q/_PML3_\+
M;$__"^Y%  #<4   R5<  +U<  "T7@  K%X  *1;  "<5@0 E582 )!7(0"+
M6"\ AU<[ 8-61 )_5DT#?%54!7I46P9W5&((=5-H"7-3< MQ4G@-;U*"#VU1
MC1%K49D2:5&F%&=1MA5F4<L595+I%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_
M#.I)  #54P  Q5H  +I?  "P8@  J&(  )]?  "66@  CUH0 (I;'@"%6RP
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M%%==L!567L0655[C%59>]Q)67O\05U[_#E=>_PU77O\-5U[_#=Y3  #(70
MNV0  +!J  "F;0  G6X  )-M  "%9P  ?F<) 'AG%0!T9R, <6@O &YG.0%K
M9T(":&9* V5F4@5C95@&8&5?"%YD9PI<9&\,6F-Y#EACA!!58I$24V*?$U)B
MKA518L(54&+A%5%B]A)18O\04F+_#E)B_PU28O\-4F+_#=E6  #$8   MV@
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M$$!T\P] =/\.07/_#4%S_PQ!<_\,07/_#,9D  "W;@  JW8  *)\  "7?P
MC($  (&!  !R@   97\  %U_" !9?Q, 5X @ %6 *P!3@38 48 ^ 4^ 1@)-
M@$X"2W]5 TE_705&?V8&1'YP"$)^>PD_?H@+/7V7##Q]IPTZ?;H..G[6#3I\
M\0TZ>_\,.GO_"SIZ_PLZ>O\+.GK_"\!I  "R=   IWP  )V!  "2A   AX8
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M!"*9_P0BF?\$(IG_!*R!  "@B   E8X  (N2  !_E@  <IH  &6=  !9H
M3J,  $*D   WI@  +J@% "FI#P HJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  B
MJU, (:M> ""K:@ >JWD ':N+ !NKG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF
M_P(8IO\"&*;_ J6)  "9CP  CY0  (.9  !UG@  :*(  %RF  !0J0  1*P
M #FN   OL   )K,  !ZU!@ 9MP\ &+<7 !>W(0 6MRH %;<T !2X/@ 3N$D
M$KA4 !*Y8@ 1N7$ $+F#  ^YEP .N:P #;G$  VXYP .MOL #K7_  ZT_P .
MM/\ #K3_ )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W
M   EN@  ';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)
M  7&5P #QF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\
M ,7_ )66  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;
MQ   $\<   [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #5
M20  UE@  -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_
M (R=  !^I   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@
M#-(   75    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@
MYTD  .A9  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E
M  !QK0  8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\
M  #C    Y0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@
M /=(  #X6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !E
MM@  5KX  $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M
M    [P   /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V
M  #_1P  _UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X
M_PP> /\$(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_
M (L _P"2 /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X
M\ #] /L ^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX:
M /\(' #_ "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (<
M_P". /\ E #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S
M /@ \P#_ /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,
M%P#_!1T _P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@")
M /@ D #W )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4
MYP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_
M#1D _PHD /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X
MBP#L )$ ZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#]
M -@ _P#6 /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4
M_Q$? /\.*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@
M!(P W@23 -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+
M_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8
M /\4(P#V$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@
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M ILE_P*;)?\"FR7_ O\L  #_+0  [3(  .(T  #:,P  TRX# -(E"@#))1<
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M!O$[  #?10  S$P  +]/  "V4   KD\  *=*  "@1 < FD44 )5&(@"01C
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M#6),KPYA3<(.8$WA#F!-]@Q@3O\*8$[_"6!._PA@3O\(8$[_".-'  #-4
MOE<  +-;  "J70  H5T  )A:  "-4P  AE(, (!3& !\4R4 >50Q '54/ !S
M4T0!<%-, FU24P)K4ED#:5)@!&=1: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0
MK0Y;4< .6E'>#UI1]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P  NUH
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M#DM>\0Q,7O\+3%W_"DQ=_PE,7?\(3%W_",]4  "^7@  L64  *=J  "=;0
ME&T  (EL  !X90  ;V0  &ED#@!E9!D 8F0E &!E, !>93H 7&5" 5IE2@)8
M9%$"5F18 U1D7P129&<%4&-Q!TYC>PE,8X@*2F.7"TACI@Q'8[@-1F/1#49C
M[PQ&8O\*1V+_"4=B_PE'8O\(1V+_",I8  "Z8@  KFD  *-N  ":<0  D'(
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M!S5U_P8U=/\&-73_!KEH  "M<0  HGD  )A^  "-@   @H$  ':"  !I@0
M6X$  %&!  !(@ H 18$3 $.!'@!"@BD 08(R $"".P ^@D, /8)+ #N"4P$Y
M@EP!-X)F C6"<0,S@G\#,8&.!#"!GP0N@;$%+8'(!2V!Z00M?_P%+7[_!2U]
M_P4M??\%+7W_!;-N  "H>   G7\  )*#  "(A@  ?8<  '"(  !CB0  58H
M $N*  !!B@( .XL. #F+%P XC"( -XPL #:,-0 TC#T ,XQ& #*-3P QC5@
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M :"&  "5C   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0
M(JP  !FN   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *
ML6< "+%X  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.
M  "/DP  @I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8
M !&Y   -O , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP
M +]M  "_@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%
MF@  >*   &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$
M   $QP   ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@
M  #/<@  SX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@
M;*@  %ZO  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0
MTP   -4   #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C
M8P  XW<  .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(
M %&Y  !#O@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0
M .(   #D    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P
M]68  /5\  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#
M   VQP  )\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T
M  #P    \0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,
M /]H  #_@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_
M "0 _P N /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\
ME #_ )H _P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_
M /H _P#Y /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X
M_P J /\ -P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^
M )8 _0"< /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\
M_P#P /\ [P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E
M /\ ,P#_ $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$
M\P"7 /$ G0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B
M /\ X0#_ .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\
M+0#_ #H _P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2
M .4 F #C )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\
MS@#_ ,X _P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\
M #0 ] !! .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -,
MDP#1 )H SP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_
M +\#_P"_ _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP
MY@,Y . #1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##
M!I8 P0:= +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + .
M_P"O#O\ KP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ
M - ,/@#+#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$
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M ?HI  #L,   W38  ,TX  #$-P  OC(  +HK @"U)0X KB<= *@I*P"D*C@
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M!7(YL05Q.<0&;SKB!FXZ]P5N._\$;3O_!&T[_P-M.O\#;3K_ ^HY  #50@
MQ$@  +E+  "O2P  ITD  )]$  "8/@$ D3P0 (P]'0"(/BH A#\U ($_/P!^
M/T@ ?#]/ 7H_5@%X/UT!=CYD G0^:P)R/G,#<#Y\ V\^AP1M/I,%:SZ@!FH^
MK@9I/\ '9S_>!V<_]09F0/\%9D#_!&9 _P1F/_\$9C__!.4]  #/1@  OTP
M +1/  "J4   HD\  )E*  "11   BD$- (1"&0" 0R8 ?40R 'I$/ !W1$0
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M"51,[PA43?\&54S_!E5,_P553/\%54S_!=5(  #"40  M5<  *I;  "@7
MEUP  (U9  "!4P  =T\$ '%/$ !N4!P :E H &A0,@!E4#L 8U!# &%02@%?
M4%$!75!8 EQ07P):4&<#6%!Q!%=0>P554(@&4U"6!U)0I0A04+<)4%#."4]0
M[0A04/\'4%#_!E!0_P504/\%4%#_!=!+  "_5   LEH  *=>  "=8   E&
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M!4%=_P5!7/\%05S_!<-6  "T7P  J&8  )YJ  "5;0  BFT  ']L  !O9P
M9&0  %MB!0!68A  5&(; %)C)0!08R\ 3F0X $UD0 !+9$@ 2F1/ 4AD5P%&
M9%\"161H D-D<P-!8W\$/V..!3UCG@8\8[ &.V3&!CMDY@8[8_H%.V+_!3MB
M_P4\8?\$/&'_!+Y;  "P8P  I6H  )MO  "1<@  AG(  'MQ  !L;0  8&L
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M JYL  "C=@  F7P  (Y_  "$@@  >(,  &R$  !?A   480  $>$   \A
M,X0) #"$$0 OA!H +80D "R%+0 KA34 *H4^ "F%1P HAE  )X9: ":&9@ D
MAG, (X:# "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT
M  ">?0  DX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\
M "60#  CD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X
M&)%^ !:2D  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8
M@P  CH@  (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V;
M @ 6G0P %9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW
M  R>B@ +G9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@
MB(X  'N2  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0
MJ04 "ZL-  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J
M@0  JI4  *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4
M '&:  !CG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$
M K8*  "V#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@
MN(L  +>@  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B
M  !8IP  2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($
M  #""P  PQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T
M ,F4  #(J@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-
ML0  /[4  #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/
M P  T D  -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%
M  #?G   W[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP
M,;X  "3!   9Q0  $,@   G,    SP   -,   #9    W    -T   #?
MX0   .(%  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #S
MBP  \Z(  /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@
M !?,   .T   !M4   #:    W@   .(   #F    Z0   .H   #L    [@
M /    #R    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>
M_Y   /^C  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\
M.0#_ $< _P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P";
M /\ H0#_ *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\
M^ #_ /8 _P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_
M $( _P!/ /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H
MG0#X *, ]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_
M .P _P#L /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T
M_P!* /\ 50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L
M )\ ZP"F .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T
M_P#= /\ W0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$
M /4 4 #R %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D
MVP"A -D J0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#(
M /\ R #_ /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@
M20#D %0 X != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R ";
M ,8 I #$ *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\
MN #_ /\4  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2
M $T S@!7 ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +<
MGP"U *@ LP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_
M /\6  #_$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48
MOP50 +P&6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H
M"J4 I@JP *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:
M  #W&0  ZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@])
M *\04@"L$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J(
MFA.M )@3O "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N
M(P  WR@  - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$9
M3 "?&50 G!I< )H:8@"9&FD EQMP )4;=P"4&W\ DAR( ) <D@"/')T C1VI
M (L=MP"*'LH B!_G (8@^@"$(/\!@R#_ 8,@_P&"(/\!@B#_ ?4D  #E+
MTS$  ,8S  "\,0  MBT  + E  "L'0P IAX8 *$@)@"<(3( F2(] )4B1P"3
M(T\ D2-6 (\C70"-)&0 BR1K (DD<@"()'H AB2# (0EC0"#)9@!@26D 8 F
ML@%^)L4!?2?B 7LG]P%Y*/\!>"C_ 7@H_P%X*/\!>"C_ >\K  #=,P  RCD
M +X[  "T.@  K38  *8O  "A* < FR<3 )8H( "1*2T CBHX (LK0@"(*TH
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M V Z[@-@.O\#7SK_ E\Z_P)?.O\"7SK_ MT[  #'0P  N4D  *Y+  "D3
MFTH  ))%  ")/P  @3H) 'LZ% !W.R  =#PK '(\-0!O/3X ;3U& &L]30!I
M/5, :#U: &8]80%D/6D!8SUR 6$]?0)@/8D"7CV6 UT^I0-;/K8$6C[,!%H_
M[ 19/_X#63__ UD__P)9/_\"63[_ M8_  ##1P  M4P  *I0  "@4   ET\
M (Y+  "$10  >D & '4_$0!Q0!P ;4 H &M!,@!I03L 9T%" &5!20!C05
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M TI+_P-*2_\#2DO_ \A)  "X40  K%<  *%;  "87   CEP  (-9  !V4P
M:TX  &1-"@!?3!, 7$T> %I-* !833$ 5DTZ %1-00!33D@ 4DY/ %!.5P%/
M3E\!34YH 4Q.<P)*3W\"24^- T=/G01&3ZX$14_#!$10Y 1$3_D$14__ T5/
M_P-%3O\#14[_ \1,  "U50  J5L  )]>  "58   BV   (!>  !R5P  9U,
M %Y1!P!941$ 5U$; %11)0!24B\ 45(W $]2/P!.4D8 35-- $Q350!*4UT!
M25-F 4=3< )%4WT"1%.+ T)3FP-!5*P$0%3!!#]4X@0_5/@#0%/_ T!3_P-
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M KA9  "J80  H&<  )9L  ",;@  @6X  '9L  !G:0  7&8  %%D  !(8@D
M1&(1 $)B&P!!8R0 /V,M #YC-0 ]9#T /&1% #MD30 Y9%4 .&1? #9D:0$U
M9'8!,V2% 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->
M  "G9@  G&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D.
M #IJ%@ Y:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;',
M+&R" 2ILDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C
M;   F7,  (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S
M$0 P<QH +W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_
M ")UD  A=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P
ME'D  (I\  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F
M?10 )'T< "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_
MC  7?Y\ %G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\
M (6"  ![A   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X
M&8D5 !B)'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .
MBIL #8JO  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(
M  !SBP  98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.
M  V7%0 ,EQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0
M )6H  "5O@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !J
MD@  794  %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C
M$   HQ<  *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@
M  "BM@  H=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP
M4YX  $:A   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0
MKQ$  + 8  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "Q
MK   L,8  +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@
M #JJ   MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T
M +T1  "^%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0
MP[@  ,+7  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS
M   AM@  %KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+
M  #-#P  SA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L
M -G#  #9X0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5
MP   #<0   7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?
M!P  X0P  .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R
M  #OQ@  []T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S
M M    #4    V0   -X   #B    Y0   .8   #H    Z0   .P   #N
M\ (  /()  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_
ML0  _\   /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1
M /\ 7 #_ &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0
M_P"K /\ M #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L
M /\ Z0#_ /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\
M5P#_ &$ _P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F
M /0 K@#R +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\
MX #_ /\'#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[
M %P ^ !E /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8
MJ0#C +, X0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_
M /\)"@#_ 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8
MZ@!? .< 9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/
M *T S "X ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+
M 0#_ P  _P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8
M -0 8 #1 &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *<
MNP"R +D P "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_
M!@  _P,  /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,,
M6@#  &$ O@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M
M *H N@"H ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#
M[PX  .8-  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R
M %L KP!B *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"
MM0"; \8 F07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD
M -89  #,%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4
MH@I< * *8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/
M#<4 C0[B (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E
M  "_(@  N1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6
M ),27 "1$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$
M@1?= '\8] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U
M+   KB<  *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;
M5P"%'%X A!QD ((<:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4
M '0A\ !R(?\ <2+_ '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0
MI3$  )XK  "8(P( DAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![
M)%D >21? '<D9@!V)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH
M[0%I*?\!:"G_ 6@I_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0  GSD
M )<S  "/+0  B"<, (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0
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M 5(Y_P%3.?\!4SG_ <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0
M<SL  &PX#0!H.1< 93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7
M.V  5CMH %4\<P%3/'\!4CR- 5 ]G %//:P"3C[! DT^X0)-/O@"33[_ 4T^
M_P%-/?\!33W_ <E   "X2   K$T  *%0  "740  CD\  (1+  !Y10  ;D
M &8]"P!B/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T
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M ;U*  "O4@  HU@  )E;  "070  AEP  'M9  !M4P  8D\  %=, 0!12@T
M3DH5 $Q+'P!*2R@ 24LP $=+. !&3#\ 14Q& $1,3@!#358 0DU? $!-:@ _
M378!/4Z$ 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.
M  "L5@  H5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2
M $=0' !%4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G,
M.%." 3=3D@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I
M6@  GF   )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5
M&  _5B$ /58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB
M 3%8D $O6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P
MFV4  )%I  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X
M7!T -UPF #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?
MC@ I7Z  *%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H
M (YN  "#;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD
M+V0A "YD*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B
M9IT (&:Q !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS
M  " =0  =74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP<
M "5M)  D;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH
M&&^N !9OQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\
M>P  <7L  &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW
M'@ :=R8 &7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK
M  YXPP .=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0
M:H(  %V"  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0
M@QX #H,G  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."
MNP $@=L !('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD
M %6*  !)BP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@
M X\@  &/*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M
MC<\  (SN  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3
M  ! E0  -)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:
M  "<(@  G2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8
M )KH  "9^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   V
MG@  *9\  !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J
M&@  JB(  *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>
M  "I]   J?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ
M'JD  !2K   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@
MN!D  +HA  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\
MZ@  O/<  +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0
M  RW   #N0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!
M ,H6  #,(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V
MT^T  -/V '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##
M    Q@   ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.
M  #A$P  Y!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4
M .SE &:F  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/
MTP   -D   #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q
M"P  ]1(  /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_*
M /\ $@#_ !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &(
M_P!K /\ <P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\
M +H ^@#) /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\
M#P#_  T _P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F
M /X ;0#\ '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0
M[0#! .L U0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_
M  @ _P & /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /(
M: #O &\ [0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y
M -H R@#7 .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_
M_P   /\ ! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#?
M &D W0!O -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4
MP0#" -@ P #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P
M /\   #T  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &,
MR !I ,8 ;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q
M ,L KP#G *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X
M  #G    WP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C
M +4 :0"S &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,,
MGP#> )X \@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5
M!   S@ % ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8
M8P"D &@ H@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3
M )  [0"/ /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0
MO@P  +H""@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7
M V, E0-I ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*
MZP"""_P @0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<
M *P0  "H"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T
MB UC (<-:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V
M$O\ =1+_ '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <
M  ";$P, E@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1>
M 'L590!Y%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP
M:AO_ &H;_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0
M'P  BA<, (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =
M8 !N'6< ;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_
M &$B_P!A(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*
M@"$( 'L@$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E
M)&, 8R5K &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI
M_P!9*?\ 62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H#
M '(F#P!N)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\
M7"MH %HK<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2
M+O\ 4B[_ ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL
M# !G+14 9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D
M %,Q;@!2,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\
M3#/_ ,8Z  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@
M,A( 73(< %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU
M; !,-G< 2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_
M ,$^  "R10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A
M5S<8 %0W(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'
M.G4 13N# $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"
M  "O20  HTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5
M $\['P!-.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W,
M0#^! #\_D0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L
M3   H5$  )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E
M' !'0"0 1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_
M #I$CP Y1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4
MGE4  )18  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"
M1"( 044I #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(
MC0 T29X ,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D
M ))<  "(70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X
M.THF #I*+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N
M39P +4ZO "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A
M  "&8@  >V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C
M #10*P S4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH
M)U.M "93Q0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#
M9P  >&8  &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6
M)P L5B\ *U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK
M !]9P@ ?6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;
M=6P  &IK  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D
M7BH (UXR ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@
MP  68.( %U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(
M &9Q  !8;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4
M&F8M !EG-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .
M:.  $&?W !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W
M  !3=@  1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G
M !!Q+P 0<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-(
M!W#O  AO_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-
M?@  0'T  #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\
M*0 &?#( !'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK
M  !Y^@  >?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP
M.8<  "V'   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P
MB2P  (DV  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$
M^   A/\  (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$
M "21   :D@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0
M )8N  "6.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0
MDO\  )+_ (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<
M   2G0  #)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E
M  "F+P  ICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP
M *+_ (:-  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *
MJ0   :L   "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U
M)   MS   +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^
M 'N3  !MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M
M +<   "Z    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0
MR20  ,HR  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";
M  !AH0  4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0
M  #(    RP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@
M .(D  #C-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5
MJ@  1K   #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8
M    W    -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46
M  #X)0  ^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X
M_P . /\ $ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_
M '8 _P!\ /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /<
MVP#V /  ] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P (
M /\ "@#_ !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '
M^ !W /< ?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F
M .@ Y #Z ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\
M! #_  X _P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q
M .@ =P#F 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X
MS@#S ,P _P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[
M  L ]@ 3 /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -(
M<0#0 '8 S@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K
M +D _ "W /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4
MYP / .$ &0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"]
M '  NP!V +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *<
M]0"F /\ I0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  +
M ,P $P#' !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D
MJP!O *D =0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5
M /X E #_ )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X
M#@"X !< LP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I
M )H ;P"8 '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D
MAP#_ (8 _P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K
M !$ I@ ; *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P
M:0"* '  B !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_
M 'D%_P!X!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P
MF0 4 )4 'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]
M"&H >PAR 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T.
M_P!M#O\ ;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L.
M (@+%P"$#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4
M<!!N &X0=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B
M%/\ 8A3_ -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1
M$@!Y$AP =A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I
M &07<@!B%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\
M61S_ ,TJ  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O
M&1@ ;!HB &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>
M;@!9'WD 6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_
M ,@O  "X-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!,
M8R$= &$A)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1
M)78 4"6# $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T
M  "S.P  IS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89
M %DG(@!7)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G,
M22N  $@KD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P
M/P  I$,  )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L
M'P!0+"< 3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^
M $(PC0!!,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P
MH4<  )9)  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*
M,"0 23$K $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TU
MBP \-IP .S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL
M )1-  "*3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$
M0S4H $$U+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W
M.IL -3JM #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1
M  "(4@  ?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF
M #PY+0 [.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID
M,#^K "\_P@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&
M5@  ?%4  '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^
M*@ V/S$ -3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J
M "I#P  I1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@
M>5H  &Y7  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q
M1"\ ,$0V "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(
MO@ C2.  )$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX
M &M<  !?6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL
M*DHS "A*.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =
M3MT 'DWV !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA
M  !<7@  4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O
M ")1-P A44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D
M%E/T !=2_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !9
M9   36$  $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8
M,P 96#P &%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS
M !!9_P 16/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@
M2&@  #YF   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 1
M83< $&%   ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@
M_0 *7_\ "U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W
M #AO   M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C(
M"&H\  =K1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^
M:/\  &C_ )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X
M   G=P  '78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V
M  !U00  =4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\
M ''_ ))U  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?
M@0  %H$  !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  ""
M.P  @D<  ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_
M (U\  "$@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C
M$(T   F.   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@
MD#\  )!-  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$
M  " B   <HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D
M  ";    G0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4
M *!#  "@5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !U
MC@  9Y(  %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H
M    J@   *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X
M  "Q2   L5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@
M7)H  $V?   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U
MMP   +<   "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%
M/   QDX  ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0
M $&H   RK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@
M ,8   #(    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0
MWT   .!4  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R
M   EM0  %[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<
M  #:    W    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$
M /9&  #W7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_
M !, _P ? /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\
M?@#_ (0 _@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^
M /  _P#P /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !
M_P ; /\ )P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R
M 'X \ "$ .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X
M_P#= /\ V0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6
M /P (@#Y "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '<
MWP!^ -T A #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#%
M /\ Q #_ +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L
M' #G "@ Y  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W
M ,8 ?0#$ (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\
ML #_ +  _P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1
M "( S0 M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +,
M=@"Q 'T KP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_
M )X _P"> /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L
MNP F +< ,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@
M '8 G@!^ )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T
M_P", /\ C0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @
M *< *@"D #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '
MCP!W (T @ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_
M /\ ?P#_ .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D
M(P"6 "P DP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q
M '\ >@!] (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\
M<0#_ .,1  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P")
M "4 A0 O (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!
M= !P G\ ;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_
M -8:  #$(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX
M>0<H '8(, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E
M#'H 8PR' &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA
M  "\*   KRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA
M &L.*@!I#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78
M61*# %@2D@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V
M+@  J3(  )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4
M)0!?%2T 714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_
M $\9C@!.&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-
MI3<  )HX  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7
M&RD 51LP %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?
MBP!&()P 12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P
M )<^  "-/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24
M3B$L $PA,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _
M)ID /B:K #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"
M  "*0@  @#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H
M $4F+P!$)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y<
M."NI #<LOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'
M1@  ?40  '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J
M+  ^*S, /2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G
M #(PO0 Q,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@
M>TD  '!%  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X
M+R\ -R\V #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PU
MNP L-=L +#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T
M &Y*  !B10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT
M,C0T #$T/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F
M.=@ )SGT "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/
M  !?20  5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR
M "PY.0 K.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0
M(3[S "(]_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=
M3P  4TP  $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^
M-P F/S\ )#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q
M !Q"_P =0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5
M45(  $A.   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @
M13P 'D5% !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'
M_P 71O\ %T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@
M $14   Y40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@
M%TM" !9,3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 1
M3/\ $4S_ )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];
M   U6   *U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^
M !!32  /4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\
M"U+_ )M=  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P
M8   )EX  !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;
M10 '6U$ !EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_
M )=D  ".:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0
M(6<  !AF   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0
M9$P  &1:  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L
M  ")<0  @'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$
M !)Q   -<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<
M &]4  !O9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%
M>   ?7L  '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\
M   &?0   'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.
M  ![7@  >V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P
M>((  &N#  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)
MB@   (H   ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")
M5@  B6@  (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@
M &&+  !3C0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP
M )@   "7    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930
MF5X  )ES  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3
M  !(E@  .ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4
M  "E    I0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,
M *QG  "K@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \
MGP  +:(  ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S
M    M    +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;
M  # <@  P(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0
M(:L  !.M   +L    +,   "U    N    +P   "_    P0   ,$   ##
MQ    ,8   #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;
M9   VWX  -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4
M  JX    NP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@
M -D   #;    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50
M]&T  /2(  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\
M* #_ #0 _P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$
M /H BP#Y )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\
MX0#_ -( _P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_
M "\ _P [ /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H
MA0#I (P YP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_
M ,0 _P"] /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H
M\@ U .X 0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2
M (4 T "- ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8
M_P"P /\ K0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O
M -H .0#3 $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X
MNP"& +D C@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C
M /\ H #_ /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,(
M,P"_ #T NP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_
M *< AP"E )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\
MDP#_ /T   #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M
M #8 J0 ^ *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8
M@ "4 (H D0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_
M /,   #C    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\
MF@ W )< /P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$
M (, @@"/ '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'
M  #1#   PPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q
M (@ .0"& $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T
M= "( '$ E0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&
M%   N!8  *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L
M,@!Y #D =P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"#
M &4 D0!C )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0
ML"   *4?  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M
M 3, :P$Z &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&
MC0!9!YP 5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@
M )XH  "4)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT
M8 LT %X+.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/
M#IH 3@ZL $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO
M  "/+0  ABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N
M %00-0!3$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y<
M112I $04O@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+
M-   @3$  '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5
M,0!+%C< 218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF
M #P;NP [&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@
M?C<  ',R  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#
M&S, 0ALZ $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@
MN  U(=8 -2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP
M ' X  !G,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#
M.R V #HA/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O
M)M( +R;R "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]
M  !C.   6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S
M #0E.@ S)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\
M*2OP "HK_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A
M/0  5S@  $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J
M-P N*C\ +2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N
M "4O_P E+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@
M5#T  $LY  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I
M+ST *"]& "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S
M_P @,_\ (3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,
M $D_   _.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H
M(C1# "$U30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;
M-_\ &S?_ *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%
M   ]00  ,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E!
M !PZ2P :.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\
M%CO_ *!+  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z
M1P  ,$,  "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_
M2  40%, $T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_
M )U0  "35@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@
M+$L  "-(   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /
M1E  #D=>  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5
M  "06P  AV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(
M !]0   73@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T
M!TY:  9.:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-
M8@  A&8  'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8
M   25P$ #58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97
M  !690  57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:
M@&P  '=N  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .
M80  "6 (  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?
M80  7G(  %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(
M '5T  !J=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;
M FL&  !K"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7
M:6T  &B"  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![
M  !B>P  57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"
M  !W"   =@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@
M '1\  !TD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:
M@@  3((  #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$
M P  @P@  (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U
M  ""C   @:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@
M0HL  #6-   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2
MD@$  )('  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3
M@@  DIP  )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4
M "F6   <EP  $9@   F9    FP   )P   ">    H    *    "@    H
M *$   "A!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>
MI9(  *2L  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@
M   1H0  "*,   "E    IP   *D   "L    K@   *X   "N    KP   +
M  "Q    L@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4
M +FA  "YNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   '
MK    *\   "Q    M    +@   "[    O    +P   "^    OP   ,    #"
M    Q    ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22
M  #5JP  U<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N
M +L   "^    P@   ,<   #*    S    ,P   #.    T    -(   #5
MV    -L   #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #P
MG   \+(  /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \
M /\ 1P#_ %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P
M\P"4 /( G0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#"
M /\ O0#_ /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H
M0@#V $L \@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0".
M -\ E@#= *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\
ML@#_ /\   #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C
M $4 X !- -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,<
MD #% )H PP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_
M /\   #_    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X
MR !' ,4 3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q
M )( K@"> *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\
M  #[    \    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !
M +$ 2 "N $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L
MG "6 )D HP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K
M    W0   ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\
M00"= $@ FP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/
M (@ G "& *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:
MR0   +X   "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"-
M $$ BP!' (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@
ME0!V *, =0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L
M +$)  "H!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H
M?0!! 'L 1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I
M )T 9P"N &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2
M  "=$   E0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z
M &X 0 !L $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@
M6P"I %D O !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5
M&0  C10  (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &(
M.P!@ $  7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E
M $\!N !. M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@
MA1T  'T8  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6
M!3L 5 9! %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*
MM@!$"]  1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8
M '<A  !N&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8
M2PT\ $D-0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [
M$-$ .Q'Q #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H
M  !I(P  81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W
M $$1/@! $44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T
M,Q;N #06_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E
M*@  7"0  %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6
M.@ X%D( -Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL
M "T<_P N&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P
M62H  % E  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R
M&SX ,1M' "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@
M_@ H(/\ *"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C
M $TK  !$)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L
M*R!$ "HA3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B
M)/\ (R3_ *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ
M  !!+   ."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25!
M "0E2P C)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\
M'BC_ *,^  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^
M,@  -2T  "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J
M20 >*E0 '2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_
M *%!  "51P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].
M,S0  "HO!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8
M+U$ %S!> !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%
M  "32P  B4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H
M "<V P ?,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\
M$C5< !$U:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "1
M3P  AU,  'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]
M   <.@@ %C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9
M  T[:  +.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5
MA5@  'Q;  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   8
M0@, $D + ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!
M90 $078  T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX
M 'E@  !P8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@
M#D@(  M'#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@
M2',  $B&  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E
M  !N9@  968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('
M  51#0 !4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\
M %"#  !/F   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L
M;0  86L  %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;
M"P  6@\  %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^
M  !8E   5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@
M6G$  $QP   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0
M90T  &41  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !B
MD   8:<  &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<
M $5W   X=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H
M '$.  !P$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP
M;:(  &R\  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_
M   O@   (G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*
M  !^#0  ?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP
M 'JV  !YV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   D
MB0  &(D   ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ",
M"   C0T  (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN
M  "*S0  B>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP
M#I0   :5    E@   )@   ":    FP   )L   ";    FP   )L   "<
MG04  )T+  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">
MP@  G>@  )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\
M  "A    HP   *4   "H    J0   *D   "I    J@   *L   "L    K0
M *X!  "P"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM
ML]4  +/P &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M
M    L    +0   "V    N    +@   "Y    N@   +P   "]    OP   ,
M  ##    Q0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(
M ,SB %B;  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z
MO@   ,,   #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9
M    W0   .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S"
M /\   #_    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P
M_@!4 /L 6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K
M *$ Z0"M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\
M  #_    _P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/
M .L 5@#H %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L
MT@"F ,\ M #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_
M    _P   /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -,
M4 #0 %8 S@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "?
M +D K "V +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_
M^0   .\   #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[
M %  N !6 +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4
MI0"C +0 H #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@
M -T   #/    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D
MI0!/ *, 50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0
M *P C@"_ (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@
M  "_    M0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !)
M )( 3@"0 %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0
M?0"U 'L SP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O
M    J    *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" ((
M1P"  $T ?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N
M &P Q !J .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B
MFP   )0   "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R
M $< < !, &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X
MNP!= -P 7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@
M (@   ""  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$
M8P!& &( 3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1
M ,\ 4 #O %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-
M  !W!@  <0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !!
M %8 1@!5 $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,<
M1@#I $8 ^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O
M$   : L  &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P
M00!+ $@ 20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E
M #P'^  \!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&
M81(  %H- P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!
M"$, 0 A+ #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-
M^0 S#?\ - W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H
M %04  !,#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\
M-PY' #8.4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L
M$?\ +1'_ *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;
M  !'%@  0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%#
M "X230 M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\
M)A7_ *8Q  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#
M'0  .Q<% #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@6
M2@ G%U0 )A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_
M *,T  "8.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P
M.!X! # 9"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A
M&U( (!Q> !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X
M  "5/0  BT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20
M "T@!P G'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\
M&B%< !DA:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "3
M00  B40  ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF
M P C(@L ("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259
M !0F:  3)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110
MAT@  'U*  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @
M*0D &R<. !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J
M9@ .*W< #BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P
M 'Q.  !S3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4
M%BT, !0L$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *
M,'0 "3"(  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3
M  !Q5   9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)
M  \S#@ .,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$
M C:$   VF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O
M60  95@  %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ
M#0 ).A$ "#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!
M   \EP  /*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@
M8UT  %I<  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #
M0Q   $,5  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#
ME   0JH  $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,
M %=A  !)70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X
M $P3  !+&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D
M2:<  $G   !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F
M  !#9   -V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40
M  !5%0  5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0
M %&]  !0X@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]
M:P  ,&D  "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?
M$@  7Q<  %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY
M  !:WP  6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P
M*'(  !UP   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@
M:Q(  &H9  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !E
MV   9/4  &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL
M !1Z   ->@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X
M '@3  !X&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@
M<O$  ''_ 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%
M   #A0   (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.
M  "($P  B!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P
M (+^ 'B$  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1
MD@   ),   "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8
M#0  F1,  )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X
M &V*  !?C0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP
M *$   "D    I0   *0   "E    I0   *8   "G    J    *D   "J!
MK P  *X3  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1
M  !3E0  1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +
M  "R    M    +,   "T    M0   +<   "X    N0   +L   "]    OP$
M ,,+  #%%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'
MG0  .*(  "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!
M    Q    ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L
M  #@#   X1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_
M_P   /\  0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U
M %T ] !C /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .(
MMP#? ,T W #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P
M /\   #_  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@
MX != -X 8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#%
M ,$ P@#C ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L
M  #S  $ [0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7
M ,0 70#" &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +<
MK0#0 *L \@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@
M    U0 ( ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\
M5@"N %L K !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0##
M )< YP"6 /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(
MOP # +D #0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 ";
M %4 F0!: )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4
MU@"$ /8 @@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@
M *< "0"B !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X
MB !3 (8 60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R
M .P <0#_ '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D
M P"3  P C@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !-
M '8 4@!T %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$
M8@#Z &$ _P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&
M  @ @0 . 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@
M3 !F %( 9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R
M %4 _P!4 /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  (
M=0 + '  $ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!:
M $P 6 !3 %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D
M_@!) /\ 20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P &
M &4 #0!A !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $<
M30!. $L 5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^
M /\ /P#_ +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!
M" !7  X 4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!)
M $$ 40 _ %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\
M-0#_ *P@  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.
M!@H 2@(/ $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#
M30 V U8 -01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_
M *@E  ";*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0
M00H+ #X'$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N
M"E, + I> "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J
M  "8+P  C3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! &
M #4-#  S#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E
M) Y< ",/:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5
M,P  BC8  ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1
M"  L$ X *A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A):
M !T3:  ;$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P
MB#H  'X[  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F
M$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<7
M90 6%W8 %!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX
M 'P_  !S/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D
M'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1
M''0 $!R'  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$
M  !Q0P  :$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT,
M !<<$  5'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$
M#"&%  LBF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P
M2   9T8  %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A
M#@ 1(1, $"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"
M  8FE@ $)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3
M94L  %M(  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -
M)Q$ #2@6  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   K
ME   *ZD  "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U
M %I-  !/2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A
M!RX5  8O&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0
M,:<  #"_   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3
M  !.4   14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383
M   V&0  -B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4
M #:]   VX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,
M5@  0%(  #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^
M%@  /AT  #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[
M   \W@  ._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P
M.E<  "]5   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%
M1AH  $8B  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#
MW   0O4  $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X
M "E<   ?6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8
M $\>  !/)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V
M2O4  $K_ (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D
M   88@  $&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9
M  !9(@  62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0
M %/_ (%L  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1
M:P  "6H   !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E
M'   92<  &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_
M 'UT  !W=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0
M '4   !U    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0
M<B   '(L  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[
M  !R?@  9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((
M  "#    @P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<
M ((C  "",@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H
M@P  684  $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1
M    D@   )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09
M  "4)P  E#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@
M38T  #^0   PD@  (90  !25   *E@   )<   "9    FP   )T   "?
MH    *    "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H
M'   J"T  *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098
M #.9   CG   %)T   J?    H0   *,   "F    J    *P   "N    KP
M *\   "P    L    +(   "S    M    +8   "W    N@   +T'  "_$
MOQ\  , S  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C
M   6I0  "Z<   "J    K0   +    "S    M@   +L   "]    P    +\
M  #!    P@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,
M -TE  #>.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_
M  < _P 0 /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T
M9 #K &D Z0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H
M -  _P#/ /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  (
M^P - /< %0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2
M &, T !I ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D
M]P"X /\ M #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP *
M .$ $0#< !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T
MN0!B +@ : "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B
M /\ H@#_ )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8
M#@#! !4 O0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!;
M *, 80"A &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L
MC@#_ (L _P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L
M !$ J  8 *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )
M6@"/ &  C0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_
M 'H _P!W /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T
MEP 3 ), &P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!]
M %D >P!@ 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D
M_P!I /\ 9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0
M (, %@!_ !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %,
M; !9 &H 80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!:
M /\ 6@#_ ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4
M$0!Q !@ ;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3
M %P 6P!: &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\
M30#_ +L*  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E
M !, 8@ 9 %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %
M50!. %X 3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_
M +(1  "E%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \
M5P 4 %0 &@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !#
M %D 00!C #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7
M  "?&P  DQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0
M $H %0!' !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0
M-P!? #8 :P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":
M(@  CR0  (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$
M$0 ^ !8 /  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!;
M "T 9P K '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*
MBRH  ($J  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V
M 1( ,P$7 #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%
M90 C!G0 (@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\
M 'XO  !T+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X
M*P<2 "D'%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;
M#'( &@R% !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT
M  !R,P  :#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/
M "(,$P A#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$
M$Q"$ !(0F  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P
M.   9S8  %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/
M$  9#Q4 &! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."
M  X3E@ -$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0
M93H  %LW  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4
M$A( $Q,8 !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8
MDP (&*@ !AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\
M %H\  !0.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$
M#Q<6  X8'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "
M':8  1V\  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!
M  !//0  1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4
M  L=&@ *'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0
M "&Z   AVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.
M0@  13\  #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C
M&0 $)"   B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y
M   FV0  )?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2
M1$4  #Q"   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@
M*AX  "HF   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   K
MU@  *O(  "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL
M #='   M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L
M #$C   Q+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU
M,/(  "__ (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),
M   H2   'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@
M   Y*0  .30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(
M #7_ (=5  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B
M3P  &$P  !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!
M)@  03$  $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_
M (1<  !\8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@
M$E0   Q2   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@
M2BP  $HY  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C
M  !Y9P  <FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T
M  9;    6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<
M %0T  !40@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W
M;@  <'$  &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E
M    90   &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N
M  !?/   7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@
M:W<  %UV  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q
M<0   '$   !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L
M-0  ;$8  &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P
M %-]  !$?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P
M 'X   !]    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+
M?#P  'Q/  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$
M   YA@  *X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T
M  ",    C    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(
M (Y&  ".6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   M
MCP  'I   !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";
M    G    )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z
M  "C3P  HV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0
M$IH   >;    G0   *    "B    I    *@   "J    JP   *H   "K
MK    *T   "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z
M0P  NEL  +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0
M  "G    J@   *P   "O    L@   +<   "Y    NP   +H   "\    O0
M +\   #     P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0
MV$T  -AI  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\
M%0#_ "  _  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J
M .$ < #? '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\
MO0#_ +$ _P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M
M !L Z0 E .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,<
M:0#% &\ PP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_
M *, _P"< /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8
MS@ ? ,@ *0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N
M &D K !O *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0
M_P". /\ B@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ :
M +( (@"N "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &(
MF0!H )< < "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_
M /\ ? #_ /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X
M' ": "4 EP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A
M (0 :0"" '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\
M;@#_ -\   #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"(
M !X A0 F (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ',
M8@!P &L ;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_
M ,P   "\    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D
M=0 ? ', )@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A
M &0 7P!N %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X
M  "P    I    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P :
M &4 ( !C "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X
M4@!H %  = !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F
M"P  FPP  ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@
M&@!6 "$ 5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B
M $0 ;@!" 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@
ME!(  (D1  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+
M !L 20 A $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D
M:0 W '@ -@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH
M (0:  !Z%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8
M/P ; #T (0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N
M ', + "% "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A
M  !U'P  ;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7
M #0 '  S "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '
M) "! "( E0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R
M)0  :2(  %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P
M&  J !T *0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^
M !H D@ 9 *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P
M9B@  %TD  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B
M AD (0(> " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'
MD  2!Z4 $0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X
M %LJ  !1)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4
M&0@: !@((  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -
M#*4 # V[  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO
M  !0*P  1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6
M !(,'  1#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*(
M!A"X  40U  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.
M,   12P  #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0
M&0 -$"  #! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V
M   3T0  $^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@
M1#$  #PN   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (
M%!\ !Q4F  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7
MT   %^T  !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<
M #LT   S,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T
M 1HD   :+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@
M&^T  !O\ (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ
M   S-P  *C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B
M   @*P  (38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T
M !_\ (I#  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O
M.P  )3<  !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F
M*0  )C,  "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3]
M (A(  !_3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0
M(3P  !<Y   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P
M+3$  "T]   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-
M  !]4@  =54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,
M !,_   -/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X
M #0Z   T1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![
M6   <UL  &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'
M   (1    $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW
M   \1   /%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@
M<6$  &EC  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !
M30   $P   !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%
M0   15   $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@
M &AJ  !=:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@
M %8   !4    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//
M3TL  $Y=  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O
M  !5;0  1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &
M  !?    7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8
M %E8  !9;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,
M<P  /G,  #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K
M    :@   &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92
M  !F9@  97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@
M,WL  "5[   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X
M>    '<   !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U
M7P  =7<  '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0
M !J$   .@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP
M (<   "'    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50
MB&T  (>)  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-
M   $C@   )    "1    DP   )4   "7    F    )8   "7    EP   )<
M  "8    F    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(
M )Q_  "<G   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28
MF@   )P   ">    H0   *0   "F    IP   *8   "G    IP   *@   "I
M    J@   *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P
M  "TC@  M*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@
M *D   "L    KP   +,   "U    MP   +8   "W    N    +H   "[
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M______________________________________________________\
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M______________;$FG-%)C1]S/_______________________________[6
M53 * !E@LO______________________________SW0U"P    I2I_______
M________________________EC0       !/I_______________________
M_______V:1T   D,!@E2L?_____________________________+.PX3-4Q;
M34Q>P_____________________________^I8#9@AI^VK*FXV?__________
M___________________@EXV^Y?__________________________________
M____[?G_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O9RKS'___________________________________/
MFH%M6D:(ZO_______________________________\1\/B80  !4L/______
M________________________X(,\       NA^W_____________________
M________K%,0       7;=;____________________________[@#$
M   )8<S____________________________26@(         7<S_________
M__________________^H-0          7-/_________________________
M__]]#0          5-;__________________________^Y]10
M1-3___________________________RJ9"\"   $(C=)6,[_____________
M_______________II&M!*#]C?Y6GNMK_____________________________
M_]6RK++,Y/K_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^6[EW=BR/______
M___________________________;GF<V"@ "C/______________________
M_________\A_/P4     7L______________________________V8$Y
M    /*K_____________________________GDP         (Y#_________
M___________________<;QH         $'WY________________________
M__^O2            &_N__________________________^$$P
M &3F_________________________^Q1             %?>____________
M_____________[@5             $C6_________________________W04
M             #C/________________________^:):$P           "/%
M_________________________]^;7"P           VZ________________
M___________OL7U5.2(1!P$"$2*R_______________________________?
MOZ69F)J@K+W:________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________COIV ?/O________________________________RMX17
M, X ':S______________________________]**3!4      '+S________
M____________________UG\V         $O)________________________
M___ZD3X          "^K___________________________ 6@
M !J5__________________________^-)             B$____________
M_____________^=>              !W_________________________[0E
M              !J_________________________WT               !;
M]/_______________________2L               !,Z_______________
M________I0                 \X?______________________, P
M           MV?____________________^9BF$G               GU___
M____________________[;Z)52<            EW/__________________
M_______^RIUV74H\,BTL,#E'WO_______________________________>;=
MUM+0T]GD____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^_4N];_________
M________________________Y[B/:DLO%6__________________________
M_____^2A9S0'     #S)____________________________UH([
M !*7___________________________MA3$           !O____________
M______________^F0@            !0X?_______________________^QI
M               WR?_______________________[,O               B
MMO_______________________WD                0I_______________
M________\C0                 F?______________________J0
M            C/______________________1@                  ?___
M___________________?                    =/__________________
M__^7                    :O_____________________.
M        8_______________________*2(!                8?______
M________________N:. 5S<7            :/______________________
M____^M.NE(9\=7%P<G>!E/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________;NIV"
M:6G3_______________________________(DV4]&0   !V>____________
M________________VXY,$P        !N___________________________;
M?"P           !%U_________________________^+*@             B
MM/_______________________\)$               #E_______________
M_________WT!                ?_______________________YS8
M            :O______________________G0                  6/__
M____________________1@                  1_C_________________
M___I                    ->G___________________^6
M        )=O___________________^\                    &,[_____
M_______________K                    #\+_____________________
M                    "KG_____________________)P
M    "K7_____________________<                   #;G_________
M____________X)R,<%5",R8;% \-#A(:)K__________________________
M___YY-C2SLS+S,_6X/S_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________KT[SC____________________________
M____TJF%94@L$@&%____________________________\:MQ/ \       !/
MX/_________________________5?S4            ?LO______________
M_________^-U'0              B?_______________________Y C
M            9_______________________U4,                 2/;_
M____________________B@                  +MW_________________
M____.                   %\C___________________^^
M        !+;___________________^<                     *7_____
M______________^Z                     )/____________________<
M                     (+_____________________
M     '3_____________________$P                   &C_________
M____________0@                   &#_____________________>@
M                 %W_____________________T0
M &'______________________R0                  &;_____________
M_________\FLF8E]=G%L:6=F9VMP>HS_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________BQ:J1>6%W________________
M_____________]VF=U L#      QQ/_________________________@DDX3
M            C________________________])P'0              8/__
M____________________[F\/                -^+_________________
M____EAP                 %,#_____________________0
M         */___________________^N                     (G_____
M______________^>                     '+___________________^\
M                     %_____________________:
M     $W____________________Z                     #O_________
M____________#@                   "KY____________________,P
M                 !OI____________________7@
M  _;____________________CP                    ;0____________
M________T                     #*_____________________RL
M              #(_____________________X                    #+
M______________________<6 04% P$       $&#1C+________________
M_______\Z^'8S\S-S]#2U-?<XNK_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________\=K&_______________________________QQJ.$:$TR&  5J___
M________________________N7Q&&           <?__________________
M_____]=\+P              .^/_____________________WV0)
M        #+7_____________________= ,                  (W_____
M_______________%%0                   &K___________________^9
M                     $O___________________^V
M     ##]___________________7                     !GG________
M___________V                      73____________________#@
M                  #!____________________+P
M  "O____________________4@                    ">____________
M________>0                    ".____________________I0
M              " ____________________V                     !T
M_____________________S8                   !M________________
M_____WP                   !I_____________________]<-
M          !H______________________]P                  !A____
M____________________4#Q&3E1976%D:&QP=GZ)____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________OU;NCBW-:E?__________________________^+^.9$$A
M!0      4OS_______________________>=5A@             %\'_____
M________________Y6P6                 (W_____________________
M8P                   %[___________________^=
M     #7\__________________^A                     !'9________
M___________*                      "[___________________N
M                  "A____________________#
M  "*____________________+0                    !V____________
M________30                    !D____________________;P
M              !2____________________E                     !
M____________________O                      P________________
M____Z@X                    B_____________________T0
M           5_____________________X$                    +]?__
M_________________\@+                   "[/__________________
M__]>                    Y?_____________________)'
M        VO______________________G0$             !PX7Q?______
M_________________]6YO,''SM7;X>;M]/O_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________C?S_______
M_______________________LQJ6(;50[(0< ,M[_____________________
M___7DEDI             *#______________________XDV
M     &?_____________________9@                   #+V________
M__________^5                      /(__________________^G
M                  "@___________________7
M  !\____________________                      !>____________
M________)0                    !#____________________2
M               L____________________:@                     8
M____________________BP                     %\_______________
M____KP                      X?__________________U0
M            S____________________R0                     OO__
M_________________U0                     KO__________________
M_XL                     G____________________\L.
M        DO____________________]7                    AO______
M______________^J"@                  >?______________________
M;0                  9O______________________]U4
M    1?________________________]J(RLU/TI58&IU?H>1G/__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________Z,^V
MG8-I3KG_________________________[+*#7#H= @       'O_________
M_____________\5M*0               $#_____________________@QL
M                  ?+__________________^2
M  "8__________________^D                      !J____________
M_______=                      !!____________________#@
M               =____________________.0
MZ/__________________8                       SO______________
M____A0                      M___________________J
M            H___________________RP                      D/__
M________________[Q8                     ??__________________
M_SX                     ;/___________________VD
M        6O___________________YD                     2?______
M_____________](6                    .?____________________]8
M                    *?____________________^B
M    &?_____________________U5@                  !/__________
M____________NR\                  /C______________________ZLI
M                 ,_________________________)1P     '$R N/E)H
MA.W_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________TU<G_________________________
M___ZTK"2=UU"* P  $K________________________%?447
M !'8____________________Q%                    "?____________
M______^B#                     !H__________________^4
M               V___________________:                       '
M[/__________________%0                      Q/______________
M____2                       HO__________________=0
M            @___________________G0                      :?__
M________________PP                      4O__________________
MYP\                     /O___________________S,
M        *____________________U@                     &/______
M_____________X$                     !?___________________ZP
M                     /___________________]XB
M     /+___________________]<                     -__________
M__________^?                     ,S____________________H2@
M                 +?_____________________H!8
M )S______________________WH"                 '?_____________
M__________]Z"P              !4S_________________________HE=H
M=("-G*N\T.?_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________[>/_____________
M_____________]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M              !I___________________D0P                     T
M__________________]Y                        X_______________
M___-                        LO__________________$P
M            A?__________________3P                      7?__
M________________@P                      .O__________________
ML@                      '/__________________VP,
M         O___________________RH                      /O_____
M_____________T\                      .?__________________W0
M                     -3__________________YL
M     ,#__________________\0'                     *W_________
M__________ S                     )K___________________]G
M                 (;___________________^C
M '+____________________C1                    %S_____________
M________D08                  $'_____________________ZU\
M             !W______________________\I+                  #_
M_______________________+5P  #!@D,3].8'2+I\?_________________
M_________]?G\O______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^O4S<?"OKJWL["MJ:BE________________
M____W7Y3/S C&1$) @          V_________________]V
M            I_________________^Z                        =?__
M________________!P                      1O__________________
M3@                      &O__________________C
M         /W_________________P0                       -O_____
M____________\1D                      +[__________________T0
M                     *3__________________VL
M     (W__________________Y$                      'G_________
M_________[<                      &;__________________]XA
M                 %/___________________]*
M #____________________]W                     "O_____________
M______^L"@                   !;____________________G10
M              #_____________________B@                    #_
M____________________UDT                   #]________________
M_____Z<N                  #5______________________^8*@
M    !A@M16#@________________________J&-T@8^<J[O-XOK_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\
M:D@M&0H                 ,?__________________
M         ___________________0@                       -S_____
M____________C@                       ++_________________S@
M                     (W__________________RD
M     &O__________________UH                      $[_________
M_________X8                      #3__________________ZX
M                 ![__________________]07
M  K___________________H]                      #_____________
M______]E                      #___________________^.
M              #___________________^\&0                    #O
M___________________Q3@                    #8________________
M____BP                    "_____________________S$,
M          "A_____________________Y$9                  !Z____
M__________________)T"@               !%?____________________
M___H=!,?+#A%4V)RA9NTTO7__________________________]?H]/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________^_?S\>[LZ^OL\?______
M____________V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M                     )+_________________B
M     &;_________________UP                       #W_________
M_________S,                      !C__________________VP
M                  #__________________YT
M  #__________________\D,                      #V____________
M______$U                      #?__________________];
M              #+__________________^"                      "W
M__________________^I!@                    "C________________
M___3+P                    "-____________________7@
M          !W____________________DP<                   !>____
M________________S4,                   ! ____________________
M_X<0                   <_____________________]A>
M        ______________________^_3@      #APL/E)JAJ7(________
M________________PGR,FJ>VQ=;H_?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[N'7S\G#OKJVL:VIIZ:FIZ[_________
M________OH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M                  #__________________S0
M  #V_________________W8                       #2____________
M_____[                        "R_________________^$D
M              "6__________________]1                      !\
M__________________]Y                      !F________________
M__^@                      !1___________________'(P
M           \___________________N2P                     G____
M________________=                      0____________________
MHQ8                     ____________________V$P
M        _____________________X@/                    ________
M_____________\M3                    ______________________^E
M.           "1TT3FN,________________________F3E#45]N?8Z@M<OE
M_____________________________^OY____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^O,N:RAF9&+AH%\>'1P:VAF9FCQ____________
M_____V%%,B,8#@8               ">_________________WX
M              !U_________________\,                       !2
M__________________LW                       R________________
M__]J                       6__________________^6
M            __________________^_&P                      ____
M_______________F0@                      ____________________
M:0                      ____________________D (
M        ____________________N2P                     ]/______
M____________Z%P                     V?___________________Y$8
M                    O/___________________\I3
M    G?____________________^8+@             0*49FQ/__________
M___________N?QT,&B@W1E=I?I6OS.[_________________________YZ"J
MN<C8Z?S_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________]]?#KYN+?V]C4TM'0TM?@
M_________________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ________________
M_](E$0,                     __________________]"
M            __________________]]                        ____
M______________^P"P                      ]O_________________=
M.0                      W/__________________8@
M        Q?__________________B0                      K_______
M____________KR(                     F?__________________UD@
M                    @O___________________W(
M    :?___________________Z$H                    3O__________
M_________]-<                    ,_____________________^6+@
M            %3)2=______________________@<A,   $/'R]"6'"+J,CL
M________________________RF]N?HZ>L,/8[_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________YX-+(P+JUL*RHI:*?G9N;G*"G____
M______________^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                        K?_________________,'@
M        B__________________[4@                      ;?______
M____________@                       4?__________________J1L
M                    .O__________________T$(
M    (___________________]6@                     #/__________
M_________X\4                     /___________________[@^
M                 /___________________^5M P
M /____________________^?-P              $"]0=/______________
M_______=<A0     !A<J05IUE+;:________________________O%A$5&1U
MAIJOR./______________________________]+-X?'_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________S[
M^OO]_______________________NN:B=EH^*AH)_>WAV=')S=7A_D/______
M___________K3SHP*"$;%1 +!P(         (___________________:0
M                     /__________________FPH
M     /__________________R#D                      /__________
M________\&,                      /___________________XH.
M                 /___________________[ T
M /___________________]5;                     /______________
M______^%&@                   ^S___________________^Q20
M        &#E=@?_____________________E>QX       PA.%)OC[/9____
M____________________NU@I.4E:;("7L,WM________________________
M_____[.>M,77Z_______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________KOY^'<V=;4TM#0T-'3
MV>#K]___________________N(I^=W%L:&1A7EM96%=765YE<?__________
M________OS$?%A *!0               /__________________[58
M                 .C__________________X($
M ,S__________________ZLO                     +/_____________
M_____])7                     )O___________________=\$
M             (7___________________^B-P                 %*Y3_
M___________________+80(            ,+%!VGM'_________________
M___UC3        TC.U=VF;[E________________________PV,8*CM,7W2-
MI\;G_____________________________ZA_EJB[T.?_________________
M___________________]________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________]W.Q;^\N;:TL[&RLK6YP,G5
MX____________________Y=L9%Y955%/3$I(1T9(2U!99J'_____________
M_____Z<F#@<"                 %;__________________\Y0
M             #K___________________1Y"P                   "'_
M__________________^?,@                    [_________________
M___$6                 @Q6H3____________________I?Q\
M  8G2W&:PNG_____________________ITD      A<O2FB*KM7\________
M________________TW4>)CA*7G6/J\OO____________________________
M_ZYRA9BLPMOV___________________________________?[___________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_
M__________________^*6E-/2TA&1$-"04)#1TY9:7W_________________
M__^>+@8                   #____________________#5@
M        %4'____________________G>QH             "31@B[3_____
M________________GS\         !"5*<9G"Z_______________________
MQF8/    $RI$8H.GS?7_________________________ZXXU*SY1:(&=O-[_
M_____________________________[YV?Y2IP=SY____________________
M_______________2V//_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________;R\._O[_'S
M^/W____________________________XL)^:EY:6EIB;GZ2LML+1X>[_____
M_______________^CE!*1T5$1$1%1D=+45IH@ZG_____________________
MID$!           '-F./NN'_____________________QF4*       $)TQS
MG,3L________________________Y8@O   3*D1B@J;,]/______________
M_____________ZM0-DIA>Y:TUOK______________________________]*'
M?)BQR^G____________________________________4SNW_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^WEX^/DYNCM\?G_
M_____________________________;&4DI*5F9VCJ;*\T.W_____________
M_____________YU31TE-459@<XJOUOS__________________________[)6
M !HU4&V+KM+W_____________________________\UO/E][F;?7^?______
M_________________________^Z?@Z;"X?__________________________
M___________CSNO_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______\
M
M                                                         /__
M____________________________________________________________
M____________________________________________________________
M________________________________________________     /_A09YH
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB
M[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE
M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-
M4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR
M-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HQ
M,$9#,#="-3(X-C5%0C$Q.3)$.$$P.4%$,$(Q0C,U,#PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HU,4$P
M,S0S,3(Y-C5%0C$Q.3)$.$$P.4%$,$(Q0C,U,#PO>&UP34TZ26YS=&%N8V5)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#XY-D$Y-S!&
M0S(Y1$,S-4,R0C Y,C(V-$5$1#<Y0C)"1#PO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,$9&0S W0C4R.#8U14(Q,3DR1#A!,#E!
M1#!",4(S-3 \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,#(M,#)4,3,Z,#4Z,3,K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R
M:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$P1D,P-T(U
M,C@V-45",3$Y,D0X03 Y040P0C%",S4P/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 R+3 R5#$S.C U
M.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z-3!!,#,T,S$R.38U14(Q,3DR1#A!,#E!
M1#!",4(S-3 \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,#(M,#)4,3,Z,#4Z,34K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R
M:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4Q03 S-#,Q
M,CDV-45",3$Y,D0X03 Y040P0C%",S4P/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 R+3 R5#$S.C U
M.C$U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C4P03 S-#,Q,CDV-45",3$Y,D0X03 Y040P0C%"
M,S4P/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C$P1D,P-T(U,C@V-45",3$Y,D0X03 Y040P0C%"
M,S4P/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/CDV03DW,$9#,CE$0S,U0S)",#DR,C8T141$-SE"
M,D)$/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP
M34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP
M:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @
M(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 R
M+3 R5#$Q.C4T.C4Y*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @
M/'AM<#I-;V1I9GE$871E/C(P,C$M,#(M,#)4,3,Z,#4Z,34K,#4Z,S \+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q
M+3 R+3 R5#$S.C U.C$U*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_  !$( /@"70,!$0 "$0$#$0'_Q  ?  $  00# 0$!
M            " 4&!PD! P0""@O_Q !8$  !! ("  ,$!04*" H(!P % @,$
M!@$'  @)$1(3%!DA%3%7E]86%T%8\!@B46&3E)BAL=4D,EEQ@8:1P2,F*#,W
M1V/1TO$E.$-(8G>UX35"4F:#DI;_Q  = 0$  04! 0$             !@$$
M!0<( P()_\0 71$  00! @0!!0H(" D*! <  @ ! P0%!A$'$A,A,10605'P
M%1<B559A<8&4TP@8(S*1DI6A)#,T0K'!U>$E)D97EM'2U/$U-D-$15)B972"
M=863M%-48V1RA(;_V@ , P$  A$#$0 _ -LW:ONUVJH_9'==/J>ZK0#K5;V+
M9! ,1$C %1APV'/<:C1&%2 [SZFV6\82G+KKB\XQ^^7G/SX11_\ B"=S/M^N
M'\TK7]Q<(GQ!.YGV_7#^:5K^XN$3X@G<S[?KA_-*U_<7")\03N9]OUP_FE:_
MN+A$^()W,^WZX?S2M?W%PB?$$[F?;]</YI6O[BX1/B"=S/M^N'\TK7]Q<(GQ
M!.YGV_7#^:5K^XN$3X@G<S[?KA_-*U_<7")\03N9]OUP_FE:_N+A$^()W,^W
MZX?S2M?W%PB?$$[F?;]</YI6O[BX1/B"=S/M^N'\TK7]Q<(GQ!.YGV_7#^:5
MK^XN$6VOP]O$@=V3*':3[!G&$W^6^J/1M@S$18$:Y.O.>;%9/YCHCP8EH]2\
MLA9K;$6&>:0T-=2BP8C*/$6V;:M++[#U]:*=7[Y:M8'38UR,&OU*=AMV2K%$
M+;?A%8#9&-,'3$LR&D)F#Y\5V,0@KDPUY9R]A]KPLQ%/!+$$TM<S%V">'EZD
M1;[B8\S$+[.S;B3.Q#N+]G61Q-Z'&Y*G=L8^IEJ]>83GQM]I?);D.SC)!*4$
MD4P<PN_))&8G&;";;\O*_P")3N#VG\7KI3N KJ/;?9O8R'$X<(T^WCXE<56+
M]6%/K9B6*NRWJTE649RC+!,8_P"1 ,00[!G-X5AIU[3>7RFK,+;*K:R4[MW*
M"80BZ=B+?9I =XO'T&#OS 7P2W[$7?FA-&\#N(&"AS6$TCCMVY8LA0ELWVMX
MVYRLYUK(-=]>[PS#^3L1['&^_. 15^+1XC7S_P"5AL?]'_L:K_H^NN_[?+S\
M_+].?ES%^=>H?C2?]6'[I3/WD^%7?_$S&]O_ -QD.^[/OM_#/1[;/V7/Q:/$
M:_6QV/\ R%5_#O'G7J'XTG_5A^Z3WD^%>S/YEX[;T?PC(_5_USOW^EV^C9/B
MT>(U^MCL?^0JOX=X\Z]0_&D_ZL/W2K[R?"K;_F7C=G;QZ^1[;/\ ^KW]+=V^
MCP9<?%H\1K'_ +V.R/Y&J_I_U=_\L_5QYUZA^-)_U8?NE3WE.%7R+QOAO_*+
M_P#OGZ6\?F=/BT>(U\_^5CLC]/G_ ,#5O[/R=_L^?\''G7J'XTG_ %8?ND?@
MGPJ;_(O'=G;_ *?(_P"^>';P?Q\=D^+1XC7ZV.R/E_V-5_K_ .+OS_T\>=>H
M?C2?]6'[I5]Y/A5W=]&8[YGZ^1V?U=VN=M_2WZ>ZY^+1XC7G_P"MCL?^0JO]
MGY._U\>=>H?C2?\ 5A^Z5/>3X5?(S&_:,AZ]O_SGS[^.S^OLN/BT>(U\O^5C
ML?Y?]C5OT_P_\7?GQYUZA^-)_P!6'[I5]Y/A4V[^9>.]'_3Y#T[^'\,^GNWS
M?/L^+1XC7S_Y6&R/Y&K9_MKO]G^CZ^/.O4/QI/\ JP_=*GO*<*OD7C?JGR'K
M_P#6,S_5OOZ4^+1XC7ZV.R/Y&K?AWCSKU#\:3_JP_=+Z]Y/A7\B\:[]NW7R'
MTM_UO?Z7V9N[,_IVY^+1XC7ZV.Q_Y"J_AWCSKU#\:3_JP_=*GO)\*O1HO'/]
M$^1W\/3M<^;T;^G?OV7'Q:/$:^?_ "L-D?R-5_J_XN_+^KCSKU#\:3_JP_=*
MGO*<*NW^)>-^;\OD'\=_'^&?1X^&Z?%H\1K];'9'\/\ S-5_#O\ 5]7'G7J'
MXTG_ %8?NE7WD^%7CYEX[P__ !\CV^G^&;>._?YM_'LN?BT>(U^MCL?^0JOX
M=_B_;SSQYUZA^-)_U8?ND]Y+A6W^1>.V]?E&1V_^\_H;UNW@N/BT>(U^MCLC
M^1JOX=_L^7'G7J'XTG_5A^Z1N"G"KY%XWU=Y\AZO_5^G;VW[OBT>(U^MCLC^
M1JOZ?]7?]G]7'G7J'XTG_5A^Z5/>3X5=W\R\:_T6,CZ/F\L_O[/\Z?%H\1K]
M;'9'\C5?P[QYUZA^-)_U8?NE7WD^%7R,QOK_ (_(-W]7\L^GYNS>OL^+1XC7
MZV.R/E_V-5_#OS_T\>=>H?C2?]6'[I/>3X5;?\S,;W\?R^1[-V[_ ,L]3L[^
M'UNGQ:/$:S_[V.Q_X?\ F*K^G_5W_9_!^CCSKU#\:3_JP_=*GO*<*O1HO'>C
MQGR#-^E[G;P^OOX^E\6CQ&OUL=C_ ,C5?P[_ %_IX\Z]0_&D_P"K#]TGO)\*
MO'S+QWK;\OD-MOG_ (9LW[^_;Q9/BT>(U^MCLC^1JOX=X\Z]0_&D_P"K#]TJ
MMP4X5;LS:+QOIV_+Y#^NYZ7[-OWV^G9<_%H\1KZ_W6.Q_P"0JO\ 9^3OEQYU
MZA^-)_U8?NE3WD^%7R+QW?P_A&0[^CQ\L_=[/Q\6CQ&OUL-D?IQ_S%5_#O\
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MO,S&^/IGR&_K[;7'^;9F\=US\6CQ&OUL=C_P_P#,57\._P!7U<>=>H?C2?\
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MU:XT?+P0XR<!MXDP0(Y#.2!\QZ;<L.CV4!!V5HAR6O>\O(4IM.<$5>N72FP
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MV!K6;9%6@GKA)8@!A(QD9R41>R.EM5:MU3U1N=#F[!EV'?.GYVS[7'MI*N3
MP=V%=K/KYP97F0P$5.2TX9IA@LV\1ES%I&DAT#.52H,J7+Q&1IU:U7%S5WL/
M)>J%9F:8HR '&:2!QCY(P?9SAD/X3D[ 0,_=G=YUI/4.:S69UI0R0XN.MIO-
MQ8BF5&&W'8F&2C5R3367GM3@[C!>A@Y8HXV*6*:5G$)!B'8;V"\)2K54Y0*+
MI:]V-R\7O>SNH [FR+)1+!42H<-IEK;UWN9 IK: ^1UM-I<-^+$?H-X'8N5B
M@3&3@$?)@)4XY(;^E(HRKPT[$G7GN^2!Y3)"<1 -1[<TQ%7!RKO"VS/#,S2F
MS\X"XMNM6:9XW7K<65R&?QE1L;C=.CFI1Q57(5KT5BQFVPV/H1Q9:5HLK'>D
MYS'(8\_(:QQO%8F:0ME#NW= 9M#!62]VSL3HN#K$/G70L3>0\VW7=DW==F#+
MB5#T.2&U]6;82K=A#1*+8'K1].8CCQS*A#H^:7P692C$2X!X EFER-(:P>3B
M$PO--U)K(S$$#QUXICBD!H).KS[,+<CBYL7:=4^)\>0L4\=3TIJ&3,6"RDLV
M.F&ECW@QV)DI13Y(+&4M4H;=6P=^LU08'>:8NN$@0O"[O7A'AD[:,76+2&M@
M:WCSI6T--:J3.DN6? ]LONOKV0[& "KF6J\[)R'%54<Z%,+;CKF?3JV\0(DT
M=G,U/J.F;13-#Y179WM4ZO,_5Y>:YCRR G_%[N,<0\A;-S.>^S;-N]K-Q?P\
M6/+(>Y62D!L-GLST@.H\O2P.IX]+S0MS3L+2V;4@V(-R8.@SL9B?P6IE.\.\
M]L.)JIZC=@]'6*1N[8MPUQJR*AC;8S\LINND4V7L&PP7S&L8#8NMU$3;E%9S
MEG^@#9)@/(CU\&8FRXL;/Q%IXYVJ/#D*4CWK$]>J.UL>MY-TGL2BYUAY8HAD
M<B>7IF7)M&!D3,UQ?XJ08LLPV0TKJ*J&G\50RN7-Y,+-Y .4>Z&,JRC#E9'E
MM7IJ81@U3RF"(IV.S8ACC,FNNM^&-8K-9I82'V0Z_H$8(Z$!BK+&)7"S0R-H
M[$F]CU>CU"9%HU6M;M>LT2R:U)Q+#$-NQ( P<3#&\$Y$&:WGGJ&F3DE>,<E1
MY>:@ 2,\TC%)D#LQ0Q$T,4O3E&2L32";LP@0GS.S[*QM\7Z]6G'9+26HRGZ6
MI)YJ9C2J'%4TO!BKE^[')?LTQM5):F7AEK2UF,Y989H&B>07=K* >';?S1S3
M- F;4U6 V_O5N<9H^LB?Y=OR\T<7=+52"ER,6P53"%+'1H<JD6PW@+]./FY
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MQ*A4(I%<^=:4K"XEHL\-Q/Y0>A\*'D*KZYTL[JO5VK>IU<5BY?R?>.Y;C?\
M/\6*" F_F=]I9&?X6W(#\O,Y]J<#.!ODOD>M=:4_X3\"S@L'8#^3>!Q9/(PF
M/\I;M)3J2,[5VY9YQ:QT@@_+SCY?+^S'E_M_;Z^:S77[OW[OM\S?I_IV;?;O
MX[]MUS_'^W[?/A4;?=NS=_H?P[^MFW]>[[[/\Z?M^W[?HX57?=NWAV;T-MX-
MX[N[,_?T_3XNG"INS=GW?9]NWA\^S=OHW]+._I3]OV_;_-PJ^GQ[>/I?=O4^
M_J;Q]3;^EW9W^_A'=G9^V_AW]7H;N_?T>GQW]'IX_P _]G^G'\/E_P!_"H[.
MWH^CMZ?5L[OM^_P;;?Q3_;\_V_T?P\+ZWW]&[[[-WW;MX;._;OMW;Q=<_M^W
MU<+Y?T[MW]/I]?K^GU^C?NN/ZL^7G^C_ '_VYX3?OVV;OMVV_2V^WSOOOZMW
M;LN>$^?MW9F]'T;]_H\>SL_S>+A5\-MN^WZ.V_=G^;9]MV?P=_2KNHE_O&K[
M6(O6N+=8Z+<P#SKX6T5,Q. G1CDB.[$D^YDQK\>4RB7#??AS&DN>REPWWXLA
M#L=YQM7K!8GJRA/7ED@FC=W"6(G Q=V<7V(79]G%W$F\'%W9V=G=E89+%X[,
MTYL;EJ57(T++"T].[ %BO*PDQ@YQ2"X.0&(2">S$!")@0F+.LV2>WV^RM5WQ
M6K-=B5QE]CH6N!&S+A;"1TU<9M>U:4=+UFMC2;YC$&$$S*S":F1'!<IQ X7#
M$C) P:^4C$;TLO>.*]%+,4SY!JXV992D.5XZQN<<8ESL(Q\SMN+@_86$>47)
MBCX:$TU%=TW;J8^*@&E9,K-B*-.*"&B%O+PC#;MS1= I9;')SF$G5!NI-)+,
MTLK1'';4[L_V+)5<?22.[=F3:D*J9&B0 $NX&GQL>EE1: <^K>P=EJPX">"(
M2&2-=RN*P)0D;'::A>;.?,LGD2B& KMDH0B* 8WF-Q:$AY'BVW[AR? 87W9@
M^ S,/97<.C=*PW)LC#I[$0WI[D61ELA3A&4[T,WE,=S=@=@G:P7E#S PF5C\
MO(Y2/S*B;!WUNO;(4!7MG[4O=^"U?#/T$.MED)G(X]<> R+8?1](2'EO28XU
MAD=&E25O2(X]M$%AQN*E+6/FQD+UN..*U;L6(XMNF,TIFPNP\K/\)WW=A;E8
MGW=A^"SLSNR]\7IC3V#LVKF&PF.QEFXQ#:FI58ZYR,<KS&#=(!8 .9^L<8,,
M92OSD#FS.KB)]J>RAG%4P6WKM(C^0PPR(J>9ES./J!#K%5\T@ZQ"6Y-4M*RU
M,\JE/E.*<F2*TAD(Y(4-9:C)^SRN2/I<]ZT71$QB=YC=P:2)X3V=W\2A=XG=
M]W>/X#OR]E:0Z*TC6>Z4&F\/$^1E@L76"A S6)*MQK]<CV#;EAO-Y;&(<@#:
MWGY7E=R>S=6[EVSI$[*LVH-CW+6QZ>->#$2=-/D ,@F(?<:>=%D\07VFR(Y<
MAB/*]RFH?C)EQHTI+>)$9AUOQJW;=(RDJ6)JYD/(11&0<X[L_*;,^Q#NS/L3
M.S.S/XLLEF=/X/458*F>Q=+*UX9!L11W:X3M#.S.+30N;<\4C"1 YQD+N)$!
M? ?E5]3^VG: K3#^O"783<<VD6J98I]GJ\G8=I=#V.9;S4NQVM\]%43RDPJS
M'ITPP?P0S(07(R7I<]+[SJEY]RRN3*&2N5^V\,KR%+$]B7DD>8WDE<VYOA]4
MW<Y.;?G)]RW6.CT3HZ&]6R<6F,''D*85(Z5P<95::J%&N-6D->1H>:'R2L 0
M5NFXE#& #$X"S,UFWO=^X=H5VEU'8NS+I=JQKH?@31 %F/D"XJHC$Q(D%,"O
MPY;[C(R)B' A1O814-MY:BLI]./3C//&>[<M1PQ6+,TT=<>2 ))",(AV$>6,
M7=V%M@%MF]#*^QNG<%AK5^[BL3C\?<RDO6R5BI6BAENR\\DG/:D!@>4^I)(3
MN6_,YN3[^+7$GL[V+04,FF]X;2:+V"V5F^&"C5V/M$)UWID)(VJV]R8W-3(1
M9@(U*1HTXRXT2CCDX@ID>Z^;.?1LGD&(R:[:8I)8YS)IY&(IH6Y8I7=BWZ@"
MS")M\)A^#OMV5J^C]*%#! 6G<,4-6E;QL$94*Q1QX^\?5MT6'I\ODMB5WEE@
M=GC.9^KRN;N2K:>X/:9LV>L3/8#:[!FT Q]:/S(]S,L9* A$HE/#C9##,E$7
M# B>:-3Q7LV4+&SC):;"4Q*)SG9'I[LY7GDD]T+;'+&,4A-,;<T8N3@+LS[,
MP.9N.S,XN9N+LY$[VOF'HMZU6J^E\,5>G9EMUHRI0%TK,[1!/(QD+R.\\<$$
M<S&1--'!"!L01"S=+W;OM))'4D1([![=?%ZW>"RJ .>OEB=A4^77 9*L YE>
MC+GJ:&3!=<,$P,.7%2B2T'EN#L/9B):9;H^7RCC #W[?)6<'@'K'M$\8%$#@
MV_P7&,RC9V[\C\N_*S,WV.A=&A+D)PTSA0ERC6&R,S8^NQW0MV(;=F.=W#>2
M.:W#%9,"?DZX]79C(B+&@S:NS L:B0PU_MXB/JX^8M6N$"K"4'9HMF/OAY1H
M]5'(<IEP"7*/U\&].(#EQY4AP2/6X[G,5KTVPV[0- P6)A:K(<M;ED,>A)(X
M.9P[.W3(WC!R(=G=Q9W[LLM/A,19?(O8Q5"=\Q6@IY5YJL,K9*I5&8*U>X,@
M$UB&%K,[11RL3 ,QL+,QOO?QCM/V1L!;Z=,[PV60+X)4DPB<]:RN'62FMBU@
M/T&>PE$A+;$FH';79S0%UE#:AY:PFB+&4S"<UY^XDRN2E/J27K)&Q0FQ/*3.
MQ5CDD@=MG9F>*2:4PVVY3D,F^$3N^,KZ*TE4K^35M.8F&!X\A"\;4XMBBRD%
M:MD8S<Q<B"]6I5(+3$7Y6&K!&7P(P%NH=VC[(B*Z/J8K>VUAE=$67\L1 H?>
M+%#C";/D]BTY-"\QY[;PZ9FT)Q9%YA.L-J/XP94WDE_A7*#E,D$8Q#>M#&$O
M7 1GD9@E>3JN8NQ,XN\OY5V%V9Y-S=N9W=5ET9I*>U)=GTYAI;<U3R">>3'U
MS>>GY-Y&T$S$#C*'D?\ !6<Q<GJ_P=B:%F%6/LC:NR=P'V;3M&[6.^6&,,8#
M12UF)ODY<03'ESB#0R&I]641(""!,D0]TC(:95/(SYJD*E39+KOA9MV;DC2V
MIY)Y&%@8Y2<G8&<B86W\!YB(MFV9R(B?N3N^1Q&#Q& JE2PF.JXVH<KSG#5B
M&,9)S".,I3=OA&;Q10Q\QNY=**,&^ #,U@<MUE=MNSMZ'^GT^&[LVS;^CQ=O
MK3A4V[-V[^&W??Z79V[]^WJ]#?,^7^S^KA5V[^GMMWVV]#^.^[,W9G]'9^S>
M"?M^W_WX3P;?YNW=]]MMMF[>A^[[;>EO6G"=N_;UMX[[/W;U>KP^OOOV7'E]
M7\7_ )<*FS_UMV?=N^WH].[;=_F\.^W/EY?M_HX5=MF]>V[]G?;MMZOI^9^W
MCLG"IOV;OV;MW[MO]&S_ %=F\']6[OX__+A.[>C;TMX[=]OG\';QV[^C?;LG
M[?M^W^_R)X/WV=]W\>_JVW9M^^_U]W\.SKC'RQC]'U8_S?Q>?"=OH\/7W;_B
MW=]G;?;;9D^KZ_V_;Z^$\>WH[>#>E_1W?OVWVW?OX-XK]4/@Z^#ODGFK=L^V
M=5_]&_X%8--:=L$1.<$4J0W+%[!OXJ4C/G SA;,ZI5B4A*Y:DL&S+'N>(,&9
ML_2.DOXK*Y6+M\&2G4D;Q](V+ .WAX%%$^W@QFVW*RXWXY\<^US1.BKG;>2M
MGL[6D?ML[A-C,9,#MZ6<+MR-]MG*O7+?J2+]+'8CL/JGJUJBR;BW%8V:[4:X
MQY(0G"7R]@,/H<^C*U6AN7&W2U@+O-J9@PFUH0A"7YTZ1#&0YTZ-NG!8')ZD
MR=;$8BN5BW9+9F[M'#$SMU+%B39VB@A%^:0W^8!8C(!+B3*92EAJ4U^_,,,$
M(N[N_<Y"[\D40^)R&_8!;Z7=F9W;\"O?COQM;OCM9VWV]U^O:\KK\Z)J[6$6
M8Z\'J :0ZG"IDS.,H9+6XNRS'78#ZF6U2%M,P8+4,3#A0V>YM":$QFA\8U:L
MPV,E9$"R>3(&:6U*W=HX]]RBJ1.[M##N_IDD<I"<ES#JG55W4UUY97*&E"1-
M3IL3N$0.[MSGX,<YCMSF[?\ A%F%F91!UZ1'A[]2"Q9Y,<6+MU;(DGUM./(8
M'PC$.3,>6RRVZZZEN,TXM3333CCF$Y0AM:LX3F7Y",YJ%Z&(7*26G9CC%G9G
M(SA,0%G=V9G<G9MW=F;TNS*/TS"*Y5DD?:..S 9N[.[, 2B1.[,SN^PL[[,S
MN_J7Z =Y]K>A78S:-,E7^WIL6NZCO;M6^_#V&,N) HXS;:U(_,+9J_9:UKR+
M/$]:&C(P2Y*UA+KY6YT\^\VHL)N=7Q-7SG[":5UYI[&WFH4SKY"YA--",F/E
MJ #-5M;YJM/!/?<9-0O#+(P9".:.K9KL;0R5K+BX[;R.=TIEK=;RJR$U2MD<
MP_);CG)W>>%_<Z:.6*LQ#BFD!F*J0G-%(XN32Q,[/'X^9\-A-)[$R1PS3 *Z
M/CGYVMUAY.\-EMS[%%U)7HL:NUD"<U=JL2&"']GJ+EL62*? YKY1XC!F""U
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M %72$WOMQ#W%HW4JM?V$+?&=;AR>UD.A)]EK>L) =:I RXTYNH5X_L"4) Q
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M'G0VS^CW'PGS?^7?,GP-/#-^P,K][^Y/QYQYEZ<^+W^U6_OT_&!XL_*AN_\
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MG/B]_M5O[]/Q@.+'RG']CX3^SD^!IX9OV!E?O?W)^/./,O3GQ>_VJW]^J?C
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M>5Q-/RZ:"\/*5=IJO0G>6K(PRQR-'R2#(49,; )LM/,7Q![%V-M\34=,.0]
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MT^Q_27=5Q(2.R[<GK=(47D"M&U&.\FC6HL8;E(38GJ&;#*%Z;+#Y&8)*0SK
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M3A$X1.$3A$X1,^7Z?+R_CX1:U?$')]6SU4B4#:-":V]N$BVY#UA2::MYO:4
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MU3IG#4:YQS2PQT</ QY7(U(7_-@N"<=F>U$#!.TIRRR&[.3>C65%NVV[%"J
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M4L)IRA!)IZOB89:I5 @HWIK5<HPAM13VMN><(CH#UTZKW2F]CZBS=7]H!;Y
M1:MFF+@5CD"E0M4636SXRYC*PY6@-KK[.9[16.Q8A15Z&;8@DO;N(A-Q\2C5
M&?RG C0..CQF9R&5TS<U_I:#5=O5L[YB/ :>RF0:ME<IC@$Z(XR7JG7CDL5Q
M(SDM')8BL\H,.@,_J ^,.JFR>4P> PN5IZ>R$.,@TKC_ ');(V*E<I:=>_))
M)<FON "\< 6)>6&*)HJS0,1\^R$DS7RCE>LJ9D)W,*8U,%3VG6Y,68W,@D!N
M<8=8]IA]E8XL05&=:7Z$N.I<4I;&76W-XXR]#D:;3XRS#D*%^L$\-FE8CL5K
M%<WBGBG@GB,X989'CB-B B"0&;E??E)M27(6@F#RD7@G@GY7"8"$QDY9(CC,
M"9B$A$Y&9GV<2_.[;L]X<+V3A$X1.$3A$X1=$EE4B.^PEYV.IYIQK#[&4I>9
M]HG*/:LJ6A:$NH\_4VI2%IPO&,J2K&,XS\F+F!@Q$#F)"Q@[,8.3.S$#NSLQ
M#ON+NSMNS;L[=E]QER&!N 2,!B3A(SN!\KL_(;,XNX%ML3,3.[.^SL_=:6+?
MJ+?_ (?=DV1V(UR[K+=VH7X;)W84W<)<;6]Q5X;'B1U60CC99%(D?(ASB#;T
M]U.9KZI+LB+%152,]I,U_+\*N&/".C2@Q U<]4U]?FL#9UG8>7/7=06;5B26
M,+8L!25Q$2"+R>C6J0GT6GM63DW)>W%KB]Q=U-=>[/:P9:#QT=8<=H3&11Z?
MPVGZ]:".%RI1L8C/)S,<@V,A:O31=8X:L,,/)"W3HOL'O_OGOND[?K4\YH7J
M-21]F(:OUT::EQKSV@M?Y,S!DD]:5BI+8T=1ZHHS@I7A3Q>="(&!<,AB*5?8
M?FUJ3:GR&@N&E_%\.<Q?K97B1J^"W;K\D%DZ6.QN%E@L9"OCK,E5ZLF3:)XR
MN1R2QW!JG-R1!$$O4U_B2U%K&.SJ&C!-CM,XAXXVCE, LW;5P#C@FL!'+U0J
M,3DT)BQ1%*P=S)^8/O87B!ZYU\G!;?'2KN7KUH1-)8?WD]H\(8K=;0Y,G"Y5
MCEEX%R,NUC)&!B2B9$?Q]+Y%3%X1'D1)K7M\G[V;9PZGN7J;2%^>J<EK%X^7
M)3#>KSVX""<:;ST8V(Y(K$U<I8G&)XS. C$'(6^H=<2X>*Z%S&:AIQ9"*"GE
MK4%5O([L%*>*6N-V.&R3'%%/5KV CE&0^K!%.(D48$U)*TCLWM<<0[;>%UWQ
M9V/5;3*3*E:*V["&G=9R28F!"9)UP&Y."Q2NM#4GV;,B=720>NE%2B7O<RTC
M8<ME_-U6+3F"$=):_P!$!B[59GVSF)9Z^3)YC(AO6^C(4&4 ]G;RH#L 8@[1
MPD8N*\;'NSEC?4&EM3R7X96 &QN0D>S2$8!$7JU^LW4HNS,VT#C$X.6[FS$S
MJ^.IF_;/M:\OTWO5JZ?UK[9VNU( :QJ4>>7&L;"%42G3;#9;!JF<.GDYCM7A
M1QQ-5GG/FBE7Q)?&CX=B(%)C,1KFC6/X-6E;>N=5<0VU!:U+!EIM-V\!F,)D
MKV"SFB*6)J0T"PDES'6*\K-E++RV; &T;W8K!-)CZLM2.R>Q-/\ $+,%A:.#
MM8L</8J>6PW:MN&*Y2S4M@WF:[#%8"47\EC8(XS;F>$PW"P;2G&,K:'VQU?%
M[!W#0FQ8M\TSM@O9"4/7-?VY @BJ]N,% F2O=K/IBX091 #;(Y9M:)#E:67C
M6L7Z4PI%=COQ9F$;QR&G[YX*CEZ+X_)XV&L!7I\7(<EG&SF <U?+U)!CGK%#
MMLUAHBK2[N;3D) H?2R52'+6Z5I[E.Y8F+R6&\ ##:C$B_*4+ N03-([[])Y
M&D!F$&B%V?><7(:I.G"*P-G[5UKI6E%]C;<OM.UG0P68:"]POMF"U"LCWB4U
M@:,CS#U@FCA41\F3EQ!H]N1+:5+GRH\5GUO/(0HBP/HSN]UT[!=:7>U-!V#7
MYNM E$5>=AMQ3]=L!W5/N5,B7RP5'8L*IES\>OW>K )C3I^M.2W9T)W*4X2X
MAUE;A%3.K'9';_8X=7+^<ZSDM1:5V-KR'LK5EX/;2JUBMID*:?$2*J/NNN P
MQI^D&K-5RJ;7#CPK);X0^%'<&F2 \TMN#DBL#NUXB>KNG 6WB\UZU[2W&!UV
M.V /UI4@%BE0(T.UV]G7.NG-@7<:#, ]>"[]L62S3Z[-+X>G$229:X(J5'A2
M7FB*,NQ_%U;I5LFU"O:57L.0&O78=NT':L7V-*KE2TYU09""]Y[ +SDZ;<=F
MV()?9\^E!ZZ#8)4Z5*8&S2NRQ"">(\<BK&D?%F%7%@9-W9JS.I)5FH^K+-4=
M95E[;&SMX&;+O<K=G=/:\9H#&DJO"(6:T4G7-ON\O\G[$9CB@(YL_(SBH26K
M.INBNB\>*?3JSL$?6!]+2FO+VKH_5UIE7V5=]97;6S^PM5; W[M YL.EVS6\
M2,$AZATG1T6\A#AV0I.E2R[ PZU4V_=)L\BE3U:[Q==NY#EW9T5:2AZ1K]BH
MD3\8Q6C-<D8 WZ$2(4JPPVRL5C+PVQ10Q5<=AW+!D<[ ?C'1(J5EIEPBEUPB
M<(G")PBM&^V:!3:79[034VF"$"SYS_M<)4VK#3"\(;6E?[Q277,H;RE7[W/K
M\LXSC/ERVN6 JU+%B1V8(83-]]MGV%]F??ML[]GW[;+,Z=Q5C.9W$8BHQ/8R
M%^M6CY'=B9SE'F(7;NS@#$6[=VVW;NM 6 ]CM"CYE4%P@+'"(&R[W6HPL;$A
M-1")=X? B(BBH,1UZ0+'D9DY4:8[)RLD*ANI]GA>4JX.Q^H=<\8-/<8VT[>'
M$T<1EBJ:-R6)$J-NS8Q$D<]AY[$9EO#D/R -,#!TX+<H/NT??]$0R&/HA#2A
ML14KEB_8T=I?-%;LRVY)Z5&*W:GDL7+$PC!=M5J]89:X0<E.[.!,3CN,SM ]
MKP6M=:&ZC8')MH(@B\@50GQ++Q]\]"DBL&(3$UR$IV2ZV';?88)2/W[V&EX>
M\L8=:\]Q<+N,M&'A9C-1\1)2TW9J&^)R4N7C?']3(5)2J2F(V>F_+8E!I8P!
MBZ;R%#M^1)UHOB1PBR^K,[3S^*"EA/='&>59^++2-BJ>.R,-LL=)* 2L(1AD
M9XBD@B#L^S@#DX'M!W6=%/!PAO8EAWP.VCO;8ECFVW;6KF WYN:-5')N,M0*
MQHZHFD1IL(/7H+#$)V58ISI^WRV910\^T0D1\#=?\8>%^@N..*;4NB,SB6U+
M%$+U,A6M025K0LPS!3ME6>09(GYMX3 BFJ3&Y@)@<D4DLTWC=6U<;#@]=TRF
M@IQ-#I[7&,D++48H8S9QHY2Q3*9RI?"YXK 1G)6)XY 8P&:"Q?+HR[QP#<)T
M9-$T83<(AF-1+"<$ )#<K(N8WF>,'%I\=#06.67$=;92M"6I+67HC:HS,:-S
M$1Z#XQ9;@E:T)G\]2JZBFR(U'M7KDDA%IX3B$X;5IA>2Q8GB"6,YNF3S5Y!B
MED>5Y)%- EQ5F:0BNU+>I;^#FQ\VI,50OY.,JK7:YO5NW*54I),C-0:Q$4O(
M[R1&(3.,TDTK;$.EQ3500-.K\.[U@[MNRR5G;A%%S6Y+C;V482P*A2$I],J&
M(BMMQ6<-//>332,94O*//G37"?3NG-$:6Q6D</9KR38VM''/R$+S33NQ26)I
M"!F Y;%AY[$W*[B4LDCMNRYPXY4-76KE2_)I_+8[16(KACL'+;@*$3#FYIKM
MF)W<H;%^<RG/G -SD-VY6+9I[<VJN>$X1.$3A%K/W=,[A0=T[3MFDQ&PLP15
M:@U<8!DP=>D-96NI!-07<^(N5:0>DJ/.;5C[WV8-#H"Q)E>'%ZIK@PU;6"\1
MVE>JG??V[>/?UOOV[(LF:I<['W#L'^6&R5[1H.LX5.OK]1U\J+K1%/)**[,-
MUH:+V(H2U83N+8(I-*H6Q:]+A6"*ZA>R#P-@AF"-M(.37V]O;]"*.ULV/W@?
MM5@IPAG;(<M;[!M*R:Z?#U71CK$&GTX9-%56M*'VJIRF*F/1=-DZH8OEKLUM
MV;^4(ZJFRM )!H9,I#&O3[?Z_P"KZT65 L_O%9+PZ$GRK%3*X>N<NNVBS9K.
MIW ^NQ(.S[ )BCVH8\N*9,6 1;-=U.I"K*5V*BX98NNT*]*K0L(P NE<KY%B
M<18_$CE0VWS\>T1"!:\5*,0JX&MZA@OUT?$S<8UR%UK89>KV0$D ^@G0S$,O
M9*+9F#+%3LT(??:J2M0\6%(L^;ROG9F5O&12M"P+ _!I-.U=:%MY#T7&MK:?
ML5TN;]\J>R+;:(K]F!H':UJ MNK1J \.+2+9L*OD"<[( 670R18NI)'OZ4J1
M>?:;!:@A*#6+]:8F5:RU5**R;BN#JF'1:,@&G$'Z2IHT\C;9(RS%^CK?*!?1
MHX5>K!(4$/S7M[?U_P!"*F*G]\5LTTFR/V=$)S'J56[!$>(Z@G&I\"-8]EE;
M4;0<QKR-K:LMD ]MUFY%?)Z.%FGQ&N#E/)'ZS:"3!4N130ZNC]E0M5-2=M&-
MAD+R=MMWLA85L?-/=)TSZ>M)0DS2 ,RFBAL$C3JTW(Q K,V6^6?='(;0/GM5
MUL&+'$4B>$3A$X1.$5$LKUBCUXV_4H(HG:&1<YRO#CA"2*#33"([BA\8H2AP
M24J# >DX;1*DQX$MYIK*E-L+5C&.$6KM-=V95=\;"";\K FH5SNP,"U(%:]%
M7F3,=I&T=?4NQ8@R(A"RU:M3Q=KM ++ZPYA(TC'^FP\-F3[U%D/HAD6C*)N'
M4],M<_7-5\5KQ3.A'8FJ25PJOK[Q,7EW/5I+#$AUH<LK$DB"5(@5:=[##3)X
M^93";C+S(@0BK"6\//;V_2B_2S0-97?>_5*C@.TQC2FS-D66II3=[EI5MY_6
M5RCNSI$@$5J)HI"638A$120Q6=-%,1(3IU$EX/&8"J8@+I\V_?ZM_I]F10)Z
MW]7^SG6[L9, ZVG0;/H*03G3IA"Q%/I""+0E,UL=E+#;4"3++IGN2!<DJ $.
M1W5-/S"46"^+RQ%JBF+KOK3V9T?NJ!8-9=E"]ZZY72SG3>T-%=CB!_:%EH"C
M."!',WK]N1:V[E$A)-O1&<438[EEK\,4J8L64@R\M-\I_7^[MZ/;UHM@G*HG
M")PB<(G")PB<(G")PB<(F<8S\L\(F,>6/+'U8^6.$3A$X10O[6=.Q'8Y82W!
M;F6UYMREI'9H]S0TJPA1>1A&461&G4Z?*;$2FYTV2E<N<TEDAC,2!G+LB/$]
MS=M,=@=&/J_'ZLU3I6EJV3'4)<?6I92:8ZE499NNUZI5(I*<>2@-W>&V=8Y0
M9V<"CDCAEBSDNL=>4M%Y716D]67=)4LQD8\E?M8F&"&_=*.LU5Z%O(1C'D),
M7+&P]:B%H(#+G8P.*:Q%-J^M7;+Q +?9MC]$*#*U_9MX5%(]K:7:S7, [(!Z
M<H9(:[(EK)!G  81G<A..VVQ6X@EV'$C3B'NZ8D*<*(G0F]<MB.'6GL!)Q.M
MULX.GZV-R.3I:+E""QE<[:QL4D_D^* +,D]FBW3<>E*3RSF(#U2CF"*31U#*
M:UO7CT<\F-FRCV:]:QJ2L\D=7'U[!"#R6P>".*.X[ON+QB,<;$6\;%&YM*YV
M?N/JCJG2U;T%H&P]OM>#M9MOE;3;ML:QUO8U$</1)DD@2Q9F'Y9FV&Y<R>8(
MN,HC#$LNS6YA(@6PE3\#TCJ/2G%O%UM:1YL-.0ZCCJY;$]#$7[CM0R<'4CJO
M!6D$:85X^G6F@ZDLH3P-&(M&#NTHR]'+Z,F?$M1?,1TF.I;&>]5K,]BF>Q3G
M),)=>0CZD@2[!&X3.1DYOS/'R;N#1_=:W0NFW8O6G;'HIV!L11BZ:O'L6(A5
MV"!:G"#CS$S6EUKD?-8.QQXI9EU<8S755YS,?T!"&3D6%[O+ZFG\CH>M)JS3
M%_3&K<#!"-&^(UXIPK5YY(@:*WC;&TM42/I SU9NH DS2 ,+OS8RUF:VJK#8
M3/5LW@\K-*5JN<D\C'8F!C<IHK@;C.;[&9/.#";MN).>^UJ6NH^(_P!*;*!F
M;BWC5>V'0H/<JR<V7?-FF:]3]IZJHH<O'>G&[ 5L$V$1M&8S667,BH9F_$K?
M.C-"0P0,5*0F'H'Q$T9PUXVX*CB9*]S2&:H:AP.I/<?'027<'JB; W O#@K%
M:.(VBH9"2-G/8:0U98X)CDGK0RP29G3^1UCHC)'/Y1#G\3/3N4"N6I KY'%Q
M7(2@>ZTI$+RRUQ+=GYIWE%R!A"0V-MA5SVTV%TOJ;?.B>L^Q-FZHNDQC8EPK
M]*2_2=QUBI&A,:8/M-?U.=C09=L<EHCQ<%:>/*@RZQKD>2+ADTR7_88;A[P^
MTCHZ?46G\$V!T4^0N6+KUXZY%@+F9E:*M89Y8))*N*%X8(V@*M6\@"4-^2)R
M(SRFILSDLI%C,A;AR&;CJB &8S.V2@IAS21\D9B,UMF,GZD92M,X/RBYML+2
MRTMNK6_8/70/:FJ+!BR4T_F<S$FN0"(B=%("9T@49#E@YB)!*B# 8I$E#B8T
MA#CR8LN.XA2,H]"UW&4Q=W#7IL=D86AM0<KD#21R@02",D4L4L1''+%+&0G'
M)&1"0DW??=FN*-ZMD:T=NI)U(9-V9W$P(2%W$@,)!$P,"9V(2%G9V]+;.^5>
M8]7:<(G")PB<(G"*Q]D:UH6WZ6:UULZJB+M1K%B D[5ST?WL060+*0C4!N=&
M]2,/M1R@Z%,PTO.6UN1T)=0MO*D*O<?D;V*N0Y#'69:=VOU.A9@+DEB>6(X3
M<"[\KE%(8.[=V8GV=G[JWMU*UZO)5MPA8KR\K20R-S ; 8R"Q-Z68Q$MO6S;
MK#%YJ6PJXX$N /-1G =6S)T^M4<%7)P:4BJY'/!5 XLB*0D0U/Q #GLX<:,*
MBQD2(K"6&O8X]U<Y/XKX+BY4S&/XJ!DM.:IK\.<SG=1XW2M+"9BGG;V!RE:;
M'Y2D>5'*9$<CEFPTQ2BXXZ 9[]=I@ F-JA[&T[;TR5673SU[V-+-U*F/L9&2
MW4DI06:\L5BM*-5JL#P56M1 +BU@N6$W%]G%I!@GN[NCM+I1O<_:NSFD&BG4
M/9$X6+HG8'5,<\5(Z_8)(94U7=R4LM+E/1ICDY<J0[+"LCFIB5^@&//%')0B
M!WII[3N+U[I?&CIK+SU]305!O6=.YN(:)W.>/F:7'RO%%)%)'"4<9U[@]>N?
M-'9> 0&0]"9+*VM+YJY8R^/&3#V9&KPY:A(=@:HL3,\=N)R-N4I&*3JP? -G
MYHVDW<1PAIGMF2I^]@8[I?4!.YNK._;S@[,UT(U14]'R]5%2Z6&+5<J-=P44
M'6;N'4T-F6"PC+^-CV5I4!^$BTX=9]AC5+<5=&ZASPZ$U/CM=Z=U[B@N8ELM
MD\1EKF,GLXT)9HL9EXK,T]RA)(#$-.[1C/&\A1S2B$4HR-NZUP1UK@-*2\0\
M-EM YO15N.GEO<_%ZBQ@Y-J>1..%\AC.C#!4MM'(4;6:5F<,CU'Z,,<DP'&M
MF6D>O>I]<[2V-V!<NQ+<FX-]G2^6-IV2:--NUO6[!9U^L:<UPX':P)K.N:BE
MMB-F&-\I5C/,OF[%+FD/=VX&=R&1N2UZN+D@:A6H +>1 !QN=IP;JW+;2?E)
M+4V^_,?P8XW:.(1!MR@-:"!CDMA)Y2=AW_+\PR,T3.[##$X_!&$'9^P[[GS&
M;N3NZE0=J=6M*PKMFK0"Q.5LU"LE=<.AQQ9P#8AN5Y''PJY\>0H6:@9<<S"*
MP<L3HN7%^P?;]:O/&Q6+%?J]">:#KQ'!-T93BZT$GY\,O(0]2(_Y\9\P%LVX
MOLKF2&*5P>6*.1XI!EB>0!-XY1WY9 YF?DD'=^4QV)MWV=MU<'/%>B<(O+-A
M1",5Z%.CLRHLA&6WF'VTN-N)S^C*58SCSQGR4E6/WR58PI.<*QC."+ *-==<
MM*:&KW7TVFE4_1Z:1!T>)J]ZLT:(-.U55:Q4H]/DEK,3;GV&:0KK2ASOO$^6
M8(-8<<<===]3G"*/^MNL'3/1<.GPZ]LVT,#M66V,]3X5X[9[.M8VI2=-52T"
M8NOHH^W[,(CXM.UE6;@<ES==/QL@P_K'G#XM<L*'FP2+G;O7'HEN"_X[,;*M
M%?DSXY+5U..G8>_CE7UE9;!I"_/[+U?7[Y70=X%T&WG*7<I,LF-"VF 2?0J0
MMJ1!=2U']@14:=TP\/NMQ+5K<KFNA9%AT%MK5=I!E-VGX%D>TAN'817=.X)$
MK,RYM'(D2WW";//V2[)4R04-CLP%&60H^/&8>WZ451V!U(Z*V,T>M9XN/J%S
M?V'K:]?ES5M[V/7]PJ%WUAIJ;2*#BL'P-S%3:E''Z5F&6LUL:N*(*ULH6L,\
M9+5(<*)H^WI]'=%W#>C_ $0LUOL8I 4-?KH.+7NSW<"7V[:;Q8OI';ND _76
MTD;N.(W$H9?R9TR)B4T=(L"5K@Q99(F)=8,%YY&35%(WK]ULUIUHK,NIZS=O
M+PF7]&-8S>]CWC8\Z$/"0LC@H<9.NQPW)&"!<+*F8\*"MA#JUN2IJI4UUR2L
MBSYPB<(G")PBMRWU41=ZP;J1YE3X<^/?&D&D*]"U1W\8PK*%>6?2M.<)4G.<
M9QA2<>>,X\\<\+->*W7EK3,[Q3 49LS[/RDVS[/Z'^=93"Y>[@,M0S..,8[N
M-LQVJQD/,+21ONW,.[;B[.[.S.S[.^SL_=1+GU#673'65PMD8:?NKA^4,$S&
MC,M!*<45)], <+=D2_)E@>E.$H<R^K#6<X2MU2/-;F->P8?2/"32V4L8W&14
M,-6:UD+D%2!F!F/J6+4O1A#<G+8B)A8C+80 6819MP5LSJCC?JG"X62QB]/1
M8R"]>@+'5RIUJ8Q;VKEP(:^YR67)R,6B%Y&9W$&+X(- #9UV%7",(F"-1JUO
M/K:R4MN72C=8DQ9#1##2B"9PB<\U[[ES$=A>?8O,2%*80EIU"DM*YQ]K7CEP
M XK8NMI?/5\Q4KS78#KR5Z%RL]>X3E!!:$X1/DZ8RNVY;@\9$!AR.XKH'2V+
MBQQW*60UNVJZN5\DB>#.T,Q%-#+5(AJ'6OU0-Z_(\LC,YA+$(RD\L;B\C+T6
M34NPFM7R=FG,:S+ZH159=OG7RPG(U0"UBNPX#T\B;LB3R9C B('BQWI,\ADA
MA$;V*G&UHPE+O+8?P.,ICLGCLUH37F2QM8I8)WDD'EO#",G.XC9I34 +LSAT
MIH'C)G=Y"-G<%AY-<Z#T[FKE6?.:BTOE\-;."_3>K[H%(\!LY15;].2D,H2#
MMR135W$P)^NQLY1J,O7FR3NQ]F+B]+ZRM^\P(N+*EI[+3J0?K^G+ Y$D0X;8
M"M;!O@<6LZ3B-2\)3#JD P(5"B/S_I-69&?:2#B7^#OQ9UMJZY<J:\M4-/35
MZ44%!K.0:&LT5< F :M:S!5G>2Q&4_5E?J;R#$3].*-VN[7%;0N4B"W4UK;T
MWC90;_%VM3NB=68'=IB>"I-6KV/*9-[#33.TCO(\1,T<,;-LTTOU2VI$V+4+
MQ?\ -?JHVF3'R,$4!(ND2<YYQAR-B(]+:C06&!RT.>TD1\-*R^ZU'4K/DPVG
M.P.!OX-MCA3G+>H+NIK>5N7*K5I81#R:JXM,,[R%$UBT<TW. B$LDS=,'E80
M?JOMK?67%71XZ9SV!TY+E<[<U!7CJ6;F3J!3I5HPE:8K 5RFL22V]QY(Y7D_
M)@4HLS=4R6S3G6:Y?3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1<92
MG.4YSC&<ISZDYSC&<I5Z<I\TYS]6?2I2?/'S]*LX^K.>$6#=_=9M ]IJ4[KW
ML+J:E[8J:U..QH%L$M2I8>4ZC#:R%<-L9CG:P5RWCV>"U>)#"26LJ:Q*PVM2
M<D6N4MH#=O5^MZ_Z<^'3UUG"M75-Z?LAC=>ZNPI"+J6J';(9/3ET](5J5>MS
M6U(\DVR5F5T4'K=?3&GH2@TB>1FE6M;<1M!Y+70:6CQ^L,QI(<!JC'Y^Z^(>
M1CS%6DTG-C9RCM5N02(VDC.5K5<#;>6E.[1O'F\)EH,25\I\95R7EF/GIQM:
M9G&M)-LS3@S@?<69V?EY)-NPR@W,Q;*:Y W''7K+%QFU(D1B5$9&VA-IZ20"
MJR;@@4XDW*JE<,R3A=D#(+^S6%BE#4Z?"'^EJ5-6^EQU[9/MOZ_WN_Z?TK"*
MX9\S9*+^(ACQ(%S7;@UYPP6?DO8-L$L8E>S9CQTNX3E&5IA>SQ[L^TIIR4IR
M2TXAE&=9Y*[Q2#B1A*>+Q.G)>&$F*GDSF6LV)VU#!E!"YTH:L+60#D*0<?R-
MY!8C**2X\MJ(QB$,W#%@7P=N6>S>'/C9 :E8(Q>D=;\ES'(?([L6SS;OU0(2
M&)AB,2,FR'S9BPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+&QG73+GT@NED
M8NNI1\M)-6Z?6JS6E3;:2D0&A_OQQV:.>Q.GXCQXS*R$E+\QV-'9C*>PVTS[
M*(:XP.I=64\?2Q>N\QI..GY1%.5+'X;,/<IS0R1A1Y,]3OP5:T4LASN->(7D
M(R%^7=B'(8BSCL9+8FGPM/(E/RFS2S6JK!.Q"Y6"*E+ <LI"+!S2D6VS/L[,
MXO#7=6L>W&-.OTGKI8J+$NNJK@(L531LJM-3:?MZD-C24A[7A64R_B77";9%
M^/Y&X&8J<O0H,)P@.:DR2T+%_@ST;G#I\[PYX@TLED=*Z7*#&Z+UAC0CH3W,
M%E0&[!(=9I)0L9# 2^44+[/&,1QRPE UB0":3RXEL6HX:>:T]+4@RETWM97%
M76*:'RJJ[Q21M*PL\4%\7CFA)BYQD&1C:(>0FUV6+Q%3O9MB-UP(:O[2=9^]
MNKS$FP?06I&@11Z'8JZ-DL2T,##2I6-B:Q,0)N"AVIE@ST"<(0.+02Q:'"C'
M,[LU^^2X2A3U+AM&W>+NBL_'+5*QB*\<XU7,V."+)QQSC?Q5W<'"OE:\$D4,
MW/7EZ<\K5#M^'&$P_%26]A<UK[ \)]2X5XK 0:BGL5BNQ]XIY<9*5=Z&0ACW
M9YL=-;AL2Q.,X"5>*2Q%+34B ';\;IJJ=]".N)78W1Q:S[C;ZX4^W2(HVP"@
M618"K[/W1I$KAXC .@2,IV>$K!:3,!"IY1HFA#Z"&1 FVIW[,N#BU3@-.ZIT
MOB-05(:T\6IJ<09/%W)"F*SBZ]^!W":$QAWCLL,%F:LXM9A@EYQ>VS.-K8G/
MW],7=2:;U5;PMJ0X,IIFU+-C,I5 (WAOM#*(E'(/5Y)H=Y8(K(2>3S3Q@,K[
M7@Q6(;'1R,+UXCO^TPG"_3A25-.+:<3G*%+1G*5H5CS2O./E\\XSC.,1YMG\
M/;V_<O;Z54D(0WC.$)2C&5*5G"<8QC*EJRM:L^7UJ4I2E*SGYY5G.<YSG.>5
M^?Z/'YF9F_0S,S?,R;,W@VWB_P!;ON[_ %OW?YU]<(G")PB<(G")PB<(G[?[
M.$5 M54K-YK9NG7( 'M-4LHV4&L%</CXI4*9%3FE,RQY(=-:>BRXDAI64.,O
M-+0K'EGR\\8SCVKV)ZD\-JK-+7LUY!E@GA,HY89 ?<3CD%V(2%^[.S[KSFAB
ML1'#/&$T,HN$D4@L8&+]G$A)G9V?U.R@!%\+3K! JH35XR9N87HH18;9:IF@
M!NY;Q#U39S5M?'/R5VJ R239C H7D:VD17%VEJN,KE$9<P5.G$Y\J3-2XBZC
M.S-D9&Q<N9EAK5QSDF*J'E*\-4)!%J\I \,4DO4=Y[#0/.?)&+2#'& -&VTA
MB6ACIB]T,<$DTSXP+DPTI9)B$GZH,32%'&P\L<74:,6=W<7)W)YK5;4.MJ/7
MZ94Z53PU0JVOF<1Z?6ZS&P$!@V,.YD9:B#1^6(N$N2E+EO\ K;6J5*=>D25/
M.O.J7#;ERUD+4UV]8FMV[!O)/8G,I)I3=F'F,R=W+86$69^PB(BS,PLS2*O6
M@J01UJT0000CRQ11BP@ [N^S,WK=W=W\7=W=W=W=UDCELO9.$3A$X1:R^_WA
MV1^[=AU?:D[ @UV3K^I[1UZ5I]P&;%.:\N--VVS6FK&@B/U;M[2EKCFHWY+P
MF8[V+A)"$ALJ:-- YJ,Q)$2C]_;?V;U_TLBASOSPA[]/1W%VUK38M0MFTNP?
M6G;>AANLI6N!=5J[(PYJ^BTN@3JW;B5N)FJWLR:3U^.<VOL>PE; QL8+,AAI
MP@,FL!"#%47N1X,Q^3 Q<L[?U0,VJ4OERN)2IKZZL3.MHX7?.MH7K60&#=,L
M[0:D)N@2MAFK1"OR[Q(Q,MTHH[+!O"YZHR7M[>*+X9\#Z)%+6L>/[%SA5 M'
M6@MU[-08U&,%+A=9,KK+'ZT K_>R-JV78J4U9*L"9P7AS]9T+6I8O$8B50X5
MFB%%W##;MM]2+)%3\(U9.UUVV=A-IZYW=B/V'UOO>YTV5H:-"U];F=:]42/6
M$34)%5M5^OD7#:VGA-V66(.%$)+"LLL"(WMX[\&FW^OV_I^GNBRIU/\ #.@]
M6^R5SWA$V&.NPPP[NURKI,"=F(V.&A[TV0-V;9*^7.RMTE-4$ @\Y 0AIX'I
M.LG2_N8><4+Y(0Y[Y:OU^WM]"+:GPB<(G")PB<(G"*W+94J[>0,^L6L5%- R
M;7LIH^8CULNIQGS3GY9PI*TY^:5)SC.//.//RSG&?"S5KW()*UJ()H)1Y9(S
M;<2;YV]O5X+)X;,Y/3^1K9;#W)J&0J'SP68"Y3!]MG;TLXDW9V=G;T]G9G:.
M'[B3KI[5"\4IS#:5^I4;!8A[HZGU85[)Z/EW*'&?EZ<MJQE.4*4G./+/(8W#
M30PSQV1TWBAGBD&6.4:589 D%V(3$VB8V-B9B8F)B8F8F=G;=;0]_KB:XNSY
MR-S<=AF>C5ZX/L[<\<K Q@???F9V=G9G;;929BUX'"!-5B.)@)KS(_Z*2&7&
M:>'*&Y:RPN$[%>2XT_'<:4IMYIY*TO)4O#F%^I7G-XXPB (XP$(P%A !;81%
MNS,S,M2W+EK(6K%V[/)9MVI3FL3RES22RF^Y&3^MW]#,S,VS,S,S,JLTTVPV
MVRRVAEEE"&FFFD);;:;;3A#;;;:,82A"$XPE"$XPE*<8QC&,8QCGVK9??")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PBP'M'J_H7<MG$WK8.M@9:_@*[9JK7
M]@P5SZ]?00*W BU<-01%QKLP588*5BCA9 YUDBEX++GR"09R 27F7S,X[4&9
MQ4$E2A?FAIS6*]J>D3!/2GFK2QS1'-4G"2O)L<0<['&[2B+!*Q@W*L=<Q..O
M2QSV:L<EB*.6&*PW-'8CCFC*.08YXR"0=Q,N5V+<'=R#E)^9=FE.L'7[KI7I
M59TKJ:FZ_'$6E-&9 <6AP]8L+QY+=M%H(*F66SR5XQCU2CQ8C(SY8_X3&,8Q
MCYR^?S6>E:;,9*U?,7_)C-([00MMMRP5PY8(!V[<L,8#MVVV5<?BL=BX^E0I
MPUA?\XHP;J2>'>24MY)'?9G=S,GW[^*S2-%CP\-N +AL08;67%-QHR,-M)4Z
MM3CBL)Q]:EN*4M2LYSG*LYSG/,0L@O?PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G"+K>>:CM.OON-LL,-K>>>=6EMIIIM.5N..+
M5G"4-H0G*EK5G"4IQG.<XQC.>$7Y[-2^->7+-]CK'?=>"YM9BDJ)=>J#6!EN
MU&.M&DMA]B7.N(JT[*V%?Q\^NY"@9Q76VSKALBDCS52#4[9PL:TQ,/"ID/E-
M_3[>WK]2+)I[Q,]T1ME[3ITT!U^'U^I6+HT/JL[6.X?SHGS2.QF] >HKO)@/
M3J:$"W*CPILHQ"5;142O3ZC*AC!LP62-V%Q%5;_\?]7]/Z$7J/>,RT)K%F*I
MZU'(IBD;8IW6^\LG=@J@UJD=DK!8MQ0#VN;'81U ,3&P=6K6J15B3<H ":H_
M+VQK,%!K[&#4DM#KO_J]O;THLO;E\00]#UIT;,U>7K'KP0[H%2[9C9F_2HNU
MZQT.*J6LCNP[*/)D:[=*=6K?<#,T0W4*&RJ[@0Q6:]**2<N9@J#/$4H 7:2F
M5CJWL;>EOVG0-W9T#0[):MOV31 QQ@1+DUNCQ]FX@AZE+M%KF@#1:A%ZR:C@
M"MGG+;2=@RU3D#IC#J2+4MCQ>]PD3MZM6:QJ\71*T2/2!0.IWV!L&N)"Z(Z@
M6+M-O1-@V[$JL5B2Z^0OFA=3SEUBK38].NDLU"'$K(T\W-D4]G\?;U?O14VF
M>(/WU@7$37=UXU*&9A6GK-K&U1M9@YQ^P?G@WC2W>Q=]K<82:"LMLA-3];11
M,E-'1)Y4_$L*HD1XU:5&42:U5%E2\^+U8)>IJ!MNI5&@5^OW36^Y=]#&*WM:
MO[BLD'6FK-$$+[%K&WZX+K8:/K#8)B]W/1U<F5<58+2_"DWB/!;/+=9DH<(L
M_=2?$5N>Z=Z0NK]JU3B1;J&-L-(W#LZ'9QH9V+MW5U1J<O895&J9 M#X[7!V
MW'902G$Q=N/F,8R'G%Z^,#&X!+--_;T^/]#]T6VOE43A$X1.$3A$X1.$3A$X
M1.$3A$X1.$4)_$8JNX[MTKWS5NO[%SE;?+UX$S3(VO;$[4[I(DLW2M2RC->L
M3!FO.BYK@&.51E]LV-4MC+S&)*?:^E1%J\%Z\\0NL65-QU=1MX =6#=G=B+%
MH>A;VN0'>NX-4UN3TSDUVJ.6R78]PV&07K]G[)-OSJ+1#&UC1 0+DIA%900;
M-;BLT_U]OT?N]7_%%?.FIGC"W$.ZW>3%QUY,!]?M^GA<JQUWKI89&R=WAK()
M&:6#37X&OJ6JCA[0-EE3+ F?5HD\8.&MQK(1DOO(EON^_M_Q]G[-V18=V+V<
M\4B&C7PLG6]YZM,[<V/%IU&JH36O68YM,HBL="';E;'!\(U)LM$ABIW:6N'S
M,F783,$I'J;SX^ P,:1##1:^WM_?W15>8QXQ](8W44CR-MGKO>;]UFL)9D,K
M2EIH%&U^1Z[4.%O''7.#9X)Q(NRUW?PPU7YU0G B@.30OI>ZC 9Z]&W+;.>W
MH_3[?H17@#'>)YLCLKU!>W6#V>UK_7-\T7<;3)J8#45)U<4#O=<-H!]LVO:"
M!=M,;%;V-G<IJ",:UP#GD-:BJWD450,>*^Z38M._[_W?O]O4BRSV$1XJ1'L#
MM9O2]TM]4TLJ[V"NZ\CB*'H$W#B4N-TT@W@-;X1"Y5TG9)9*?VL%.:YRV<D2
MHS<"Q%4?1;<%D09%U]O;NWM^ARQ>U)\3X0<.6B72]G4\!L;8>ICVV"^DJSHJ
MV;<@M1NC>IV2,77]4V^9(T'%8QV@BVZK79Z1&D&1\ >SD(\P$=DGVJ=]W]7H
M_K17)L(CXLHVL6:SCK#LZ5#,]E^PP&%5=<ZRZU$-E43254SMQWK4;K3%O8>K
MEF![+.2-7C-D3CSI*R@JF-C21:!$R;:+ JOM[;(L$R*IXLS>P]^*Q3KNEW=-
M)E%MC5Z/G5!/03QC/AKU.JDF-;'BMAF;,!7"-W $1*Y5J^#>ATLH)=L9P\N2
MRZLTFGT_N[>W?=%D?-B\8,!-M@*L52T,(!:9V .IX=5:T;,U9!AA>I5>EZ9.
MUJS3YTG81C?Y#M.@K6;A5;4]-URBJMO2$B(PQ(\Y+?I]?]WM]7S%7,3/&;K!
M2YK F9.SEQU]B %'&["I>BJY72"6NN%(OND[<2)5 =7"3,_'8 G<=6CHKTR*
M"EAPD--IA)PZ];'ZHI\>'X9[5FM/61_MOBUYN[.Q";=3=O56H=4M^:,]6ZK,
MCQ33&N,0JN7=&V>59QL<Y%KE8<F18K4?Z.(1H<:QFWM[;(IU\(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(OE:$.H6VXA+C;B5(<;6G"T+0O&4K0M*L92I*DYR
ME258SA6,YQG&<9X145ZL5J1&;A2*\#?AM"WP;41X3 =C-!9*6DR [;"XZFD"
MY"6&$OCTHQ$=2RUAQE6&T821>5JE4UA<)QBI5EEP</BB1[C0$4VN +@S624(
M;"6B(E44?#(QX\^+#8RW&CS6&93+:'VD.)(M2Z?%)T/"$K ;+TO=[ BRV>_/
M7J;1Z+2BE K]3K_<6P]-Q%NOT:U7P><*.2K^!KS95 ,%:22XI",6B#4Q(TB*
M-(L<@O%LU?[D2K&_NLUP$CY&X-T536.N*?6*)L0F.U?UWVW&TB=V7; ^+MD:
MY('; <=%MUB@0CUFC/"3SE>!GZ\+'6L^19TNWB55\2-J174_4_<VSJ%LOM5$
MZSPKM'3IZHU389U5JNNN;P:I3![9$4V9E!K10IM>BQMA@M?P+*G+4N,<0%CN
MSFR*U*OXF?706'"BK?IX[C"3%RA7DE0*!4%434E!=[;6[IK2K'=(QFV03TJ!
M<[[K^*)FP:$$NA!F$,<-% HL%$A)33?V]OT>M/;V]G4CNLO>31W:/9QJ@4O6
M&QZA8!U9/[2!6#8%3HXT3=@E4V79= V2R5:?6;E:R2)8BWU0E6W<V*#7BDD3
MF,[":DC5J]G5%-6-2*7#9>CPZA5XL>0N:[(8C !+#+[A-^/*(N/--1$(=60E
M0XDF:M:5*EOQ8[S^7'&&E)(J@Q7@$4Q-L48&'CV E':AD3K R$R8GQ(_I]A%
MFDVV$S94=GT(]DP^^XTWZ$^A*?3CR(JQPB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G"+"QGL3I0"+MYF=L,(^/H5XE:UN#@9,^QO@KX.K,.Z&*O+@UZ&4G**5
M^HS46>S-QXSS=8 Q2Q6P.#800R] ?U(K](7NGBK+7*>2L(V#8[>+,&*P-E/9
M96<@ 9E?@%7!\A:<0WWX\JT@6VX*9'OTM,[+T*-(8BS7(Q%2JUM77]M1*6%L
ML3*H9H-6Y,<K'GUV:W8;!4*_?0X3$"PQ!4UPK-J5I!&$P&HZY334[,:0TU.B
M38L8BOJ3)C0HS\R9(9B1(K+LB5*DNH8CQH[*%.//OO.J2VRRTVE3CKKBDH;0
ME2UJPG&<XH[LS.[NS,S.[N[[,S-W=W=^S,S>+KZ$2,A !(S,A$ $7(B(G9A$
M19G<B)W9F9F=W=]F1Z5&C1WI4A]F/%CM./2)+[B&F&&6D9<=>>=<REMMIMM*
MEN.+5A"$8RI6<)QG/#NS,[N^S,V[N_9F9N[N^_AMZ=_!49G)V$6<B)V$1%G(
MB(GV$1%MW<G=V9F9G=W=F9MUVH6AQ.%MJ2M"L84E:<X4E2<XQG"DJQYX4G.,
MXSC.,YQG&?/&>55/2[/V=G=G9_0[>+?5X/\ /V6*;=O#5]!L;57NEF76"#XD
MH98G&05DA59Z,$KQZW%H;-W=#XICIZ!4ZM9+1(K"#ZK(FN RAS G(R$_*01>
ME&YM9YIHF_OVAD;4C-@35(I0V.,@5Q;+BPRJG)!'!IH= +5LH-LL"<$-0[%!
M%O R,*9',)@KC/X;(JDO9]#:/O5J38XL,LP(/V!:9[$X>.4"JT:BRSYEDW-B
ML!)(L:SLJE>VGQR+L5;IA<=EUV0*,M#B*^&7F9++4B.\U(CR&FWF'V7$.LO,
MNHPXT\TZWE2'&G$*2MMQ"E(6A6%)SG&<9X1=O")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PBCP]U*ZS2&IS#VC-:.LDXLV$0:75AJD3(A':R]YSHT
MA.6?)QF7N%QS9+Z%>:7+@M1K./>\Y<X1>"U]-NJUXAA8%LT%K Y%KMDO-M"(
MF58?E8\_LZQ2+=L>:R^TVW(4W?+/*?/7" ZZX-L912)9>)+=994V14XKT@ZB
M')UU)E.NVJ9<_8MCA7&Y2\U2 T\:MH\U^4<>SK6PAK,*P+L&5FYA@;[F0(E7
M7YY"1*E/O.K(O;-Z8]3R):F'9W7K4\HOKPP7L%-GOTT0M\$7.WF9LXI-CYS'
M]+ZI&R"$V_-M34R6(ERDNV6$U',J]\X19 H^AM,:T,1+!K_65,IYN#73-2AE
M  .&.FQJQ8;F1V(<!,OQVTK0,*WHN3MDZ)C/LGSL^406G+[JE9(LM<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G"*-XSKP))&-X?G830]KTO<&R@VRH=
M+.:W:Q&K)$'0J=KF)%F235GM$"R9_)ZAU]S,QL'7W/I)^P.994.+1Q8PBL3L
M!H^C;ZM6HK)+V-20T(>]:M>"VWP8:R&K$0DW37FR2@O6EF=L@Y-5O@61U]F-
M/2X JS3X Z+8I.!D*:!3-B/;V_0BPW#\-RKP1] @9V%*--4F(($NPCPBSQPQ
M<4/U;USUJ^^J!1ME466W8L9ZX5XZ'(DRAT$+=L9V#,JIG+8Z=&>WMX?UHL]]
MGALC:-(O^B[3ULV9MG6%[JRPUB-U*\:?JL-^-.0E]Q$%RV[5J%EA$0TIEB2W
M+<%)AYE,-*0J;%]JA=M<JP7:L]2R+E!/&\<C,[B_*_?=B;NSB[,3/X,[-NSM
MNRRV"S.1T]F,=FL3(T61QMF.S4,HQF'JCNW*<1LXR!()%&8[;N)/RN);$WY1
MPO;7?^RXE,\.ZT[!O9/J5)WA8-.-;W%3*",V)M.DUF#!DANO7YWB=[:TH_*3
MF0-#RS(Z\D/I<88 QFG2]=>C!3VKX[]FW+'IR;*<V&\L.HV88#"2Y%& $&-:
MP[='G=R:(C=]I!<=B.)Q&7LBUIS$X?'VN+>/T?RZ_+!U<W)H4YZ\M; 7K=B>
M*?5A8H#\N\G<8CN157#GKRM(Y1PV@EDJ_H_ZD[VW:_NK8O5>?T4V=I'KSH83
M2ZGJG<QJU5*=7)(>)K6GDH]4(,+MAF1:9T";.FBF;+KD_L >SEA@=;OH [$+
M9QM6&*."**"(>6*&,(HAW<N6.,6$&W)W=]A9FW=W=]MW=W=UQ9?O6LG=MY&[
M*\]R_9FN6YW  >:S8D*6:3D 0 .<R=V  $1\!%A9F:4MNTD<N^Y@-^LULJ]D
MUL K9,&/U#9]=N&HH\A8@M@KULLPT_BY01BCEG G/R7G/V.F69 ^G?3M< )$
M,W.VRBWHK1<[)Z\UFU:MKVKJ-!I-!"U&ZU"\5T1)H,2RTADC4K>Q=,1B=*B&
M:JV0BEC+;\P@XR9@3'",ITJN2Y-4M;A%#F!T0U4Y3:;6 F]6I3%E#!)VNY4;
MW5H?;&ZT!ZA$8,T,U3K?6IYJJ8A=4 !9P=2SP7W2O7)]D*;$L@A))XBV':KH
M4+5VNZ?KX>J&J%4@D4/'R.9,1A_HC^K.<0(UAL-M-Q825K4F)%)V8[+C1\-L
M.DY66_:9(K_X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%II[A
M^--UTZF=@J7HEZ!/V*\P:3&WI8JK*8D1M2CI420W$B,1D8<S9[="GK@S[!78
MKL=0D&B2Q[P_876Q,>(Y;6&.Q5^"B3%._.S79(G9VJ 3=NWC)*).Q21MLX Q
M-WD=@6\M#\!]5:UTU?U'$<6-!Z[GIZM=$@/.2@;.9,3NWDU,XQEBKV38FGL<
MKL+5A.9]MM(NU2V14:[?:)815LIMM$PSM;L8.6U.%&!,]K#T6;"E,Y4AQMQ&
M?)2<^EQEU*V7D-O-N-IE,,T5B*.>"0)8918XY ?F P)MV(7]+.WUL^[/L[.R
MTQ?H7,7=M8[(UIJ5ZE,=>W5L \<T$\;\IQR _=B9_3W8F=B%W%V=[IYZJT3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6J.'T;W@U=MC6L[?->W.
MO6_9 :[.ZG*N'Z[KNVN0F^P<268LT&FUP,H6<1^=/6AV&F5&OQ24;T^%<-7(
MA/CU>P50GM[>WI7IN'1+:EFML Y)O-3,8&SMEE1%I(FKV+OU2C7>K=B*LS1:
M23@-38U> NJW)7[&1LS&5FF2U8<BJ%&8$.M8$$4Z.NVN+#J33M0U[:204J:K
MV;"EZ77QXX8*1#)VDV9$0&(P<!4@ZWA0@C!%SIHBI5,43GPY)(=5JY"EL!H1
M%6MV:EK^]]37[3MJ*VD'7-B5N?6#)6E'I-:L\. 03A+ZQ1B,ES+"UI3[*3&E
M1Y@PE#<D#"T">+F3(3]M<JA=JSU)#E".Q$41G";QRB)ML[@;;[/ZV=G$FW$F
M(7=GRV"S%G3^8QN;J0T[%K&6HKD$-^L%NH<L3[BTT![,;,_PA(2"2,V&6(XY
M0 QP=:^A_6*V]6VNGLO6XT=I4>':' !@O"&#=;+QO:O1;L'.OMR9J+PV1?D%
M9-CF9ERB\V7/2;22A$B,.592X3&RXWW)>L TQ#EC .QQ&W=I@/9R:9B=S>1]
MR,G+GYF(F?/TN(>K:6KBUM'EII,]+.4MF>9W*&U">PR4+%=G&,L>40C"-06"
M.&,(^ATSBB,)+T2GC]?4JI403//%1E.K@6L#R5H-3K'8Y\(&.CC8TPZ>)NO3
MRY:2S&0]/(2G%/2I2W7E83ZL)3D88A@ABA!S(88PC$I#*20A 6%G,R=R,W9M
MR)WW=]W=17(79<E?NY":.O#+>M3VY(JD$=6K$=B0I2CKUXF:.&$")VCC!M@!
MF'OMN]U*PK*583G"593G"593ZL)5Y?+.4X4G*L8SY9RGU)\\?+U8^OGJK1:I
MM1='=V4.0%FW6YZVV1#B7.3:)]&GN6"O46/8B(*AC)6UJZ+J-;K@\7>!1*H&
MBM>!K"/HC-7DQ'GWF>;B*M!0BMIWP\]NR(P1DSL*IV@L"UI6*<W>YANVC;Y+
M2-TYJ[6Q:E-$2 *WB(.OG[/1;3L/,<F'M ^RD=C'1EOI)2&]8%6NGK_X?Z_T
MHMF6F*:=UYJC7U&LQ,48/U2JB 94D$',B1,J6/BH86L>.C1X42+&1A*6FT0A
MHB K",N00@2(MD3#JBR;PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G"+1]W$I-0#^*SX7TQRAUUJNVF-V@#FW/R7&)#G3L_6TI,5HKGW'$(F2:D
M$&)J$3,O2FUN(E)QA2DKS"\O%&&J=-D40-%*.2 WZ8\AR%7+L?;8BW(2W+=]
M]G^=N@=#W[D_!GBY$.0L/;IR:3G@'RJ5YZ]:/)Q\Q0['SQ0N,1QOT^4'$7!^
MS;+=>(#!P$!D4!%#0@R/EU4<:(@Q1L!A3[JWWE,PX;3,=K+S[CCSN4-IRXZM
M;B_-:E9S,A  %A 1 6WV$181;=]WV9F9FW?N_P ZT'-/-8D*:Q-+/*6W-+-(
M<LA<K,(\QFY$_*+,+;N^S,S-V9E4N?2\DX1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X10. =E-@FO$?OG5)$2L?FJIG5:O;@>((&S_RO
MQL YL)@ B"\6R6R,P#S79&)#4!(-,W,O&9&22F<^PYA(\C.>H)\6PQ^2PXN.
MVY\I=;R@[/38>?GY'C>/OLP;L3=R]"V%9TICJ_##':R*:W[KY#5]K"!!U(_(
MO<VMC2LE*T70:;REK3,+R>4O'TR86A8F<U/'F;6O4X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1:@?%*?12-F>&ONV3YLCZ)W?I5
M,,3<8^4$+M4*1&DY+RL?-,?#%>]DYE7DC*W&4*4GUX\XIJ;\E8T[<=W88<U!
M";^A@M 8$[_-L&V^[;;_ #K=G"$7OXKBKI\68I<EP^OWJX/VZEC#6(9X@'9V
M=RYIV)A9G=V9RV=@=EM^Y*UI-.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A%I_P"I3SNP?%/\2_8Z$9<#Z\ ]=-'A9N,>;;DEFI3#
MEJAH7\T^T@'A64R$)5C+?MF/:(PMSSQ%,6[SZFU'/XA!'CZ49;/XM"\DHL[^
MEI-^;;MX+=FLV'&\(.%&*WY9LE:U3J*P'9GY3N1U:<A,V[['6D;D=]M^4FV^
M SK<!R5K2:<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(M8GC$:^GWOP^]WSPB,_E-JU-2W-7)*4>MR!+UI;!%@+S6L8QE6'&JFS8
MD86GTY1AU2LY].%8S&]6P%-@;I WY2MTK<;[;N+UI0E,F[MX1#(V[>#.[[.M
ML\$,E'CN)6GXIWVJ9A[N!MB[[-+'EJ4]:"-_0[%=*J_*[.SNS;,S[.T\M-[&
M%[?U)K#:X1:5B-E4"H7H=E&4YPB):@$ VTSGTY5A*V$S?8N(\\Y0XVI"OWR<
MXYG*E@+=6O:!]PL013#\S2 )LS_.W-L_SK76;Q<V$S.6P]AG:;%9*]CY-_%R
MIV9(')O#=BZ?,+^D79_2LD\N%BTX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A%YY<J/"BR)DIYN/%B,.R9,AY6&V6(["%.O/.K5G"4-M-I
M4MQ:LXPE*<JS\L<H[LS.[NS,S.[N_@S,V[N_S-Z5]"!&0@ D9F0@ "VY$1.P
MB(LW=W=W9F9N[OV;NM1O@X(E7?2V_NSI"*ZP]VQ[:[NV^%4^C*7$TU)QJK@(
M*,J3A:F!T\(?88_?90E"O0C&,)SG,6TES3TKV1)MGRF5NVP[;;0\[11C] O&
M;,_Z>[;ON?C@X4,_IS2<1L0:-T7@,).S.SL]XJ[W+4C[?SI!L0$[/WW^%OL3
M,VWKDJ6EDX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X16U<ZF'OE0M-(L,=,L#<*X;JYN*K&,IDB3XR4)(L9PK&<9P[$EO(^>,_XW
M/.:()XI89&WCFC.(V]8&+B3=_6SNRNJ-R?'7:>0K$X6:-JO<KFV^XS5I0FB+
MMW[& OV[]NRU@>#M;SL?K)9.MMX<Q^<?IQN#8O7VSMK7G+TD8#/RS%2+-(SY
M9^BI @MD.(?3CV4B/7W%M_O<>7(WI*4VQLF.F?\ A&(MV*$F_9W )'.$V;QY
M7C-@%^S.P;MV6VN-U*N>K*FJL>S>Y>NL'B]3U'%O@A-9K!!>A)]F_*C8@>:9
MN[B5C9WWW6V3DH6FTX1.$3A%I<\6_N-V+T,O3NK>G^#T_=)2!L/?]]@U?59+
M<$Y.C],@<H=KAD *KEE?K C:^Q[!4J0B^O1Q\:M,L&)JRX_V/M%/;V[.BMMK
MQ7=AW7=E4#ZCUSJRQZ!N>V>INIP-U+VNUQ;_ #)O;WKC*W=2SV ,$')K[(RI
MDHBQ-EC.E?I.1%5[O$A,36G9&"+7W+\4'MN<ZBBK_-W+4FMQXZ=]Q+^<):N=
MI#L"G[&TULW05="P=H4<K0R2Z[M(' V 56L!&)B L&LE Y$M6C$XO'F#Z>/@
M_K;V^A%)"5XM^WW25;MK%/#;&%:^MO>0 MCK?<X]KU#V2@:!ZKT[=%;FURPG
M* 2L1O(BPV2;5"\VEE \ ?9*^8F8Q9(F,5N+7]_T?,B] _Q6NPEZV%UZ'A+%
MU4 :WE]L1NDMG[K!6XH<Z[;(&7GJXG==7K%6V&<&X>!6VK623.H]ABQ"B9DS
M8<"J 6LM1C9L1!IO[>COX=_[T57Z_>*SLDB+T34+:0T_7W[+K&P[0+W?L_M!
MBG6;=+R^SNU]/-ZRT@]3Z#6:F=N]4"TB 1(X= H5'9.UB"2$(B+)7);?Z/TH
MI1=(O$-O7<3KSV>V"6 TBCWG2H>>TW#U^7C7RN!CDS7,ZXP6(M_%EKAK;821
M:L07$%JO8'L26EI58:E6,R8,6?5%JNUQXF_9N9UQL=S%]DY79:)CH[J'?&U;
MU5*KJ6K'^L?8^U;AU?4)NE,W"HZZEZ\<58Z_9K?)S2[C2C]^ ,U:4^_.CLR4
MR6GM_P $4O+3XSU]K=[[>4[.K-6R%]?S2!-;D1+V]9:X,KLOL33]"Q]J;EO]
M#E6T31JN!9L)2Z; IQ\%3;]48X1X4T--1HQX^ H[OZOW_1\WK\?4S;]T5U3O
M%OOP?;U UNP)ZR[+A%2N@@N9VJ=G64V3[%(WINO8FIBEKZC1GQ:H=XK6C8=)
M:.[<<F22<4;.R>$M&XXX9!L15_1Z_P"C;QW^?P^9%'FZ>+WV[L77>_WFN4'2
MFL#TGKB [+ZZM8TU8[@D!4 7<,9UNV&/O :S5EH0B0\-]\L<>=$5+' POO\
M(E3')C#+\1OX_P"OU;_H]NR+,F/$H["#MHWNAZ]8U!N ];=_ ]=4TX6O\F7H
ML6)8\/P%VJ(G=8G*+1D64M2#Q:,2P"6>(VN<79*,SF[")@2V(HROM]';]_?^
ME%5*IXTDL\3U$ ,:\H-5M6ZJ]X;MJH5.*W*<FQV<%W-,' NW"E8AO18KUA&:
M5F#Q<=@E C*C.R"T9BP?1[K[#2WI]M_T(L5U[QP]LG:WLRPD-':=H\<08IX4
M4N[;LJ$27HR78^P@G21>3VIIM?MMCV?1*Y4QI\9:C%I.4374/!-N966X68BH
M%GF/J]O;_BBVA>&+NW8?87J>.VAL^Y"+[:26Y>R@-%GKWT>NN3JY3^P6R:G4
M&:Y)&P!C!"NP*L&$0 91Z)B>4%1HD\D])GR)$APBV"\(G")PBU\>*7NR3HOH
MYO X%<=S=+R!9T_KZ%$^9(C<-J244^(T);PI*W2(\61+'6$-^;F$B''$X_>>
M>,#J:Z]'#73!WZT\?DE<1_.*:R_1%@;Q<A$BD9F] /Z=ELKA%@ U#Q T_6L"
MSX_'V"SF4,NT45##@]Z0IG=G88I)8H:Y.7P7>9A?LZD%U,TLUUTZT:.TBC$?
M,K6^M:M7#+\7YQYMF8&,/VLFUG"4^:2MFD%B7GZ<9SF5G.<>><\O\73;'XZE
M3;;>O6BC)V\'D86>4F__ )R.1?6HUK+/%J?5>H=0$Y..5RURW Q]B"J<I#3B
M)MWV>*J,,>V_\SZU(7E^HTG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PBTS6)7[C_Q: -K4VX.T[XB]!B4@Y*]?H%#NRVJF4XJ
MS\E.%>SBN6FJNQP0UI*,.EK%9"$GYIB2G$Q&1VQ.J8Y?S:FH(&@D+P$,C4;\
MDY>AGFB)@%NSG(9/WY76\JO^.W!FS29VESG"_)'D*XOWFETGF7_A@@[]R&E=
M$K$KL^T->M$+[=0-]S/)<M&IPB<(G"+X]FCU^T]"/:91[/*_3CUY1Y^KT>KR
M]7H]7S]/GY>?S\O/A%\)C1T>6$,,IPG*%)PEI"?)3>,I0K'DG'EE"<Y2C./F
MG&<XQY8SPB^4PXB?7Z8L=/M5.+<]+#6/:+>RE3JU^2?WZG5(1EQ2O/*\I3E6
M<Y3CR(OM$=AO",-LM(PWEQ3>$-H3AM3N<J=RC"4X].7%*4IS*?+*\JSE7GG.
M>$72V/@-1TQ&H41J*ASVR(S<9E$=#WMLR/:I92C#:7/>,Y?]IA.%>VSEWS]>
M?5PB^U0XBE1U*BQU*B+6[%4IAK*HSCB5H6Y'SE.<LK6AQ:%K;RE2DK6G.<X5
MG&2+EB+%BM98C1F([.5.+RRPRVRUE;RE+=7EMM*494ZM2EN*SCS6I2E*SG.<
MYX1?6(["6\LI9:PSGYY:PVC#><^?J\\HPGT_7C&?J^O'G]?"+X3#B(5)4B+&
M2J;GSF*2PTE4O.&\-8S)SA.,OYPUC#?F[Z\^SQA'^+\N$7PD? 0J(M$*(A<!
MM;,!28S*50FG$);<:B*PC&8S;C:$(6AG*$J0E*58RE.,8(NWW:/Z<H]@SZ5-
MJ94GV2/3EE><Y6UE/I\LMKSG.5(SCTJSG.<XSYYX1<)C1D83A$=A&$>7HPEI
MM.$^EO#2?3C"<>GTM8PWCR\O)O&$8_>_+A%Q[G$]HAWW6/[5MM++;GL&O:-M
M)7AQ+2%^GU);2XE*TH3G"<+3A6,>K&,\(NM0^ K,O*H,-69^$8G95&9SF;AM
M&&T8EYRC/O.$-XPA&'O7Z48PG'DGY<(O4E"$8]*$I0GS4KR2G"<>I2LJ5GRQ
MC&/-2LY4K/UY5G.<_/.>$7UPB<(G"+3-V.5GMSXF/7+K)!PR3U?TZ'?NJ]YI
MPOVT)>R)C.!^E:G-1GS:26&.28EJQ#>3G$VO6 BK&?.(I/(CD-LKJ/'XYMCK
M8D/=.[Z1>P7P:4)/X<X[M-R_SHS+QY7VWGIAGT5PHU1JR1R@R^N9GT;I[?X,
MGN3$[39^]%VYNC+RG2<V?X%BO'_WV=]S./EC&/X.2Y:,3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4&/$4ZOS>UG6*UTRI
MO9&[<I) 7MC1E@9=Q&F@MLT-;Q*MKAS,X5B&LTPLC6792DJ3#9-KG)3AZ*RX
MC"Y_&ED\=+#"7):B(+5*3?9X[4#N4;L^W;G9RB=W[,QN7BRV!PRU;%H[5M*_
M=#K86_%-AM05G;F"SA<DS16Q,?YW0)H[8CXD=<09VYG5P]#NTH[M[UIHNU\M
M-C;LPT_3=N5C#*XDFH;7JN&8-Q!RH#W^$#T.RU-&Q463_A"09<6M[R=6O&/3
M"9,<KCH+3LPSMO#;BV=GAM1;#-&0OW'OL8L_?D,7=6O$+2,FB=59#"[O+0(F
MOX2YS,87L+<=Y:%F.4?@2;1OT)2'X/7AEY?@\KO,;F64)3A$X118VHG<,'>-
M(M=)UD1O=:K^H=F@8+S%OJ  %'V+=[!1)0F7;HQT^/.-B0HJBOPTEJV!LQ!B
M+;S"6!KSS*6'2*,.N:CWD@2E/;'7?3E<G6.UGP &O7>@URQUXDBIZ9558]\G
MDM@7I4BDJM [=&':[6+M<6'GCP5$X-#!MP, 2+(NH=6=GM4=2C.NY9Y5@W=7
MF U=!FPQ"M,AR=9'-UMB>7US&.-(B![>2KKMCE+=V?*()G;F44*%"RM=2 #4
M)[>M%VZNT[L4#>B&]MWM6:VSM8ZPL4'3=<G&6;S::VU8]B[FMAT?F.'20;+[
M#QJB=I;61 ^+<($S\^JEH$<W9X<E!<JV]O4BQGKG6_>D]7 Y"S7Z\4PBO6KE
MA(B+1::%-(%M\@:8V/B#RZZR,/M5O3MWMEJ?GHJ]9G-&A(S5 N<8F"S%U.!I
M+V]O;^\J.<U1W5F^XV (3V$V6&B=O3]<(M^PJ"4/TBR&Z?U_!B9&QX(,V-IM
MIE%2M;[#'J2#%3[34:\2O]4%&)%3JK$@?72+TG=6]R36O;M42I;;AR2=U+9(
M5$FC;QKFC.U<]9BFS63P*ZX;V);SA^WQ:P8HHV@3E7NVU> Z%:G$+M7RV"I
M@17\.U)VV"FWWJ/985; W6;L4Y9X]M+B"9BO.:\=HU?T"+65$02I"S%-H5:H
M1!VTS\XG/E5ZI/G!H<@T>8J[L0BR=I,3V&I^C-@3-HPK3MO9DUV?/ T&T3J'
M59Y1U%2!"Y(-D\'O^P*L)$6BSQ39I$A9Z'!#L%GFQM2K<!F%7(Q%8VF.GX9
M#65IM JQZHMM1V1:-H.ZVJ\?7(6C@3QPE2'%A:D K,B^BJ=5T0]<A833M.M8
MZQ6$-9=D-V^:Y(V?<QSQ%9FT=.]H;ENK;ABGH*5FKW$Q7:7**&+%0RE&M>A'
M]< Z;-!Q:4^X8,)NE;V#<MI;0<G6,:.'9!@1%8#X+/7:QCTO;V_O_P!3HJSH
M'5O;&L[3K<K8)R37==-/V&_%:O5\5@G3Y);9XBR7&_4NPDGKTT><L W>=\-E
M1)(1K4F*13J938PJ_#4&+=79I%12]>[T$MJWJQOQ;$/U-)LZ!,FB4RYTZ':[
M'36+-:FAAC61VR7Z>*K<_($)K]^RRIS&I"KHB[["A#A1"V5RI'5D5KV71':8
MX:G@RC5J)5(K<:[L)),-<M;#VI)#7^U;9.CL[)AYR#(;$L]KU#K3KE60;1"+
M*J< J6O4H_-%M#!<=LBF[UD![: :J@P]V32,^]N&#$B3(+DX\\JZ,]X3&%2B
M<6!8;D)KY(E&C8*DJT!NUPKX:?/DQ@9I(SW82,(I!<(G"+"78W>]*ZRZ2V-O
M/8,K$>LZ\KDLT^REQ#<DN1SEN&"KH_*\92HG8SDD>#&I5C*/?)[*G<H:2XM-
MG?NPXZG8NSOM%7C(W;TD7@$8_P#BD-Q 6_[Q,L]IC3U_5>?Q>GL8#G<REH*X
M%MN,,?<[%F3U15:X2V)7]$<9;=W9GA=X6>C[I2]-VSL5NF/Y=A^Y5P>WOL[+
MT5R+*KX8VVX[KN@H9?\ \*A#JM7)JI<</)\G@<P^0#+QG ]O.,/IJE-#4FR%
MQOX?EYGO6=VV>,#;>O S/W$8HR[ _<",A\&93OB]J"A?SM+3.!/?3&A:(Z=Q
M'*?,%J:N[-D\D3M\$Y+EL.4I1[3A7BF;O(ZV?<DBU,G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+2!M>0YX:7>/]T(WE
MR#TT[MGQM9WTA.5Y$:=[#J1(S7]I.LH:2T- 7A&)";--RXI.9DBQD2+F5PZN
M.<AEK_%W,^7MN.(S,@QW]OS*=_OT[3ML[#'/N[2OV^$YF1?!C%]^X86XJ\/W
MTR[=377#^M+;TV[\O6SNE]P>UAQ)WYY;.-=V*G&S,_3:O%$+L=J0=WC3K;S:
M'6EI<:<3A;;B%84A:%8\TK0I.<I4E6,XRE2<YPK&<9QG.,\F?CX+07@[L[.S
ML[L[.VSL[=G9V?NSL_9V?NSK[X1.$4..VDOL!"QK\GH<.4(SJHY9+>65$D2L
MC);SSU8UBV).!H*GI5I;$U#:5^VT%K>!)M!&RZD#98%$2S(L=-(HM$=K>(=
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M"BL5+<3ULOA[@];&9BB;.,E6[7?<2;E(^E*+=2$B+;F Y8Y(M=4.P':G5FX
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ML#SQ/9ELO7B=@:5H9&@KD<8NQ&[B[FX%(X$9$Q>Y1PU3K=9J'H+5DL85BS'
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L$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img102364508_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %&B^4B0X0DE-! 0       \< 5H  QLE1QP"   "W_4 .$))300E
M   0%[!F+$S2BZ/ZL]P\'L9W<CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ;0   37          $
M                 0             $UP   ;0
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ;0     4F=H=&QO;F<   37
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   &T     %)G:'1L;VYG   $UP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      * @
M  $   "@    .    >   &D    )Y@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M(\%2T? S)
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MR7=%/1O5O?=+Y!W^[XX#5=Q/E,Z2<,INZCR7]%9&-L<)+K&;QT@BY7*05!2
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MA(O5EG3QTJHLLH8QNZ///)42NEE<"YU@  &L8QH#61QL: V.-C0&L8T!K6@
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M6$V ZIT4T8.I.0)5K5-O:<YM#>8>4B;JKVH6V&-*&/9JZS9I12%>(N=EZO\
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MSF HE #%,<";L:YL@ZV=PN1UTI<T:EH)%A?0!PY"#SVOJXM+#K #;3+& XZ
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M,\1UHV/PL?\ WO!/X@M361N]49S[=/5']L7@7P.^M9&$3&B-HB81$1$>'G?
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M?>]-]95JTV>?4Q:U)+/%%O S @V(JH)$71N?(R9B& $NUZ5!26,<2#U%*40
M.GD ""F0)WU#G.@&2 /($%0;R-==I#HRT.C>R4]<6EKB"UI-[Z*QIFPM;OP+
MI"QMY(M-' @A^3,S,QMCUI+@;AUPX&,8-$4R%5:NRFD&IU%! Y!%L;K,F8H
MD=-4AA#I$I1'U)U"B1<$R&Y%&M9+'$"U[364\<K0UP9-)*:QC1F,1<^7?(R;
M]<7-;&1;KKW,U[7N ?&_>) T-((+W!N>_7 M?8@@D%KK,>"PO(N6Y>%[=%V+
M83K=D+853I+%,44C 8@$*4#&'ES*<%!. $ZP4Y"F AR)-HP^.<PF69S#3LEW
MJ9HS0YGN$;,^^..8,!:YMG Y \N!-C%K3&^(2!K<^^AF=A:0\%KB27 #-8C)
M8EULEP]P)+MJRT56L*]E!2$@LU8YP3O[0JCTB:G4!RD B8$Z^9C"8/YHB42B
M7D83% "?%Z>G^H4/<.ASJ4NW'4*!#FWGQ#F$H"4W2)MWWTP@(E,8O,#"(=QC
M!W (&, ]0VF+=DT_P5@WTX31_1S'E&NE[*)1^M2>^ZW[9.IZ$0* F,( 4 $1
M$1    #F(B(]P  =XB/< 95$AH+G$  $DG8 -22>0 :D\@U4O;L7Y-KPVVM_
M;Y3IFS*5NO4M&HUOL"M9M6DX$L#1)>S^)[5'KS4YL>[L:_9K'5:^""9&22FN
M0J%UN<RS?-(6?J\1$VB8R#?4;$]/'Z?$MFF.)ZBZRN-NUK3=O5OBLV'(V5L[
MCN&:[6[5]#WM'P:\O*)6Z!U2YM,928W:1&KYJXE*[5K6[;O4'3(T*I?0CYF
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M:F6F,=F1_!N"_1@U HU)ZR?=ZK[5,IZRK4E,(ODQR$#J.8I"\REYF,!0ZC&
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M(BG9 V*HWHE[C#+)'D$[ ]Y>U\[99F6$;)6Q ,'1D09(^0/?^4L7,+BYF86
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M 5>5:R)MG*T8YZEC,GS26KC]89J!E4DMZJG;$62P.=)23YG02.MF:6VWRGF
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M+W"(#W_V" @/N"&2HI8YHVR1/:]CAHYA#FFQ(-B.8@@^$+0@M)!!!&T';SK
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MAN[+E][TWUE6K39Y]3$PB81!'D C[G?A%AUG[PB*)B,$SK' _:D4=H)D0$"
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M2A%"@)#%$2+E=('""R!CJIE6242,H@J=!<@*$$@G162,51%4H&ZDU4S%.F<
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M\R )CE#O,0PE,!3 !BF$A.HI@$# '(0$!$!(OE"+CVRA%D&J:2J91(0Y1/S
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img102364508_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1QV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '%J^<E@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   +?]0 X
M0DE-!"4      ! 1[:$#&>N,*L:-.>=28VNC.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0'7@           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             U4   6N          $                          0
M           %K@   U4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   U4     4F=H=&QO;F<   6N    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   -5
M     %)G:'1L;VYG   %K@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      1U0    $   "@    7@   >
M +!    1N0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 7@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MH_[=?^$2E^CD''OC_N5D_P#GZU7UBMR_K'^C:WIU+ \^]_J" 7!EGJ>F/?\
M2M>U_P#PF/=_I:+5H=.NSKL??GT-QKM[AZ;7;QM!]CMR2D?5>I?LZJJST+<C
MU+&UEM37.V@_GNVM=_8W?3>H=+S/MKW9.S9OIKT!W-,69+-U5D,]2I^W?59L
M]]2O6WTT@&ZQM8<=K2\ALF)VC=\$&E[+,NRRMP>Q]-1:YID$%U^K7!)3D9UG
M5,;J3\ESGG&K(?#7#::O:TL](N^EKM^A]-4^I96-G5-O90
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU1#;&1=AON)8)1^$'91D9E']_P#:=)_](OIRNPFR)C9@4[5%Z\<+2Y%U.N[
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M&9N4--[VW+)[VOVRX/,;2 *X%=R;^NI&1F/N^NK18>NZ8"+6D, %),1/>?\
MAYZO*Q3"J;=]@:_G=;0FF8K7\Y%JJ<^_ 'Z?O-[V"_9SA+?6)T.T6;9]AO\
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ML:T>ZU*]A#L>.YB![=Q'N/$U5H2EM*4IQXPC&,)\?J]/Y>,_GYQ^K/GSRXR
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MXI_-.OBLE\7D,2U&*;OKKL/GM-#L!:&&P-: .R?IUO\ ,VIS/Q!-)1<ZN)$
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MC^.RLGUFR+U%8 "E$2M[52T@;)9C6S LV@B%F"]P##7)RT_M^?M^IU_S(?\
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M@M:RG$><,XD%@M(S^-W.?3[:\3D/B/P6/C,^$<C-RF4FJ@X]N.@8^WJVW)6
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M]=F=F=V9W=F=W8EF9F)9F9B22S$DDD[),DZJJJJJ JJ JJ  %4#0  \  #0
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M6_;)72TQ0*+&VC8D9:!K>U-7C,;(DHUT;)3RH*4RG'G?Z?W_ ']_Z_:;49N
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M^U:9S99V1GL;+V;!8/6TO[*@;)@&)$]H=IC*0Q?E'/:2[[7O.X]:O4\XXO\
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M=6PP@:B^MT:QC0>Q6JN-OJ'TW5EL+N$;U#J==9=8)F-G@9N\$QV!(PEDT>(
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M<4MI&&<O83ZW<YY^%W[>7[0O6_-_%/GOA9PG.<CPG1G1QP^/S,#C,N_"'/\
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MGTCM6Z6(Q5T971@=%64AE8$>Q! (/YE%;;U-G<2K[U-EHAV(?=4MD27=+'+
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MMTHFI;A-3L[^@>LQ?66J:J9MD,]*+-I>Q^QM7)M:HDLF/9C:M8@8>P H_/\
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B<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img102364508_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '>B^=E8X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   +?]0 X
M0DE-!"4      ! 1[:$#&>N,*L:-.>=28VNC.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             <T   ->          $                          0
M           #7@   <T                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   <T     4F=H=&QO;F<   ->    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '-
M     %)G:'1L;VYG   #7@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      39     $   "@    5@   >
M *%    32  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 5@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M_P!+Z/\ @EK))*<C)N^LOVBYN/12W':X>@^=SW-&S?O#K*FLW_I=CO\ P/\
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MEU"K/]#.<Z]AQW4O]*D,EPT;[G.]CG?X5J@CM'R7G<NF>2N6^NWUHZC]7W8
MP:Z+/M8N-GH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( )0!% ,!$0 "$0$#$0'_Q  ?   !! (# 0$
M    !08'" D* 00+ @/_Q !C$  !! ( ! $' P@4"0<- 0 % @,$!@$'  @1
M(3$)$A,4%4%1"A9A.7%W>(&1MK<7&"(D)2<S-38W.%5U=I2AM+74\",F,D:Q
ML\'1X3126')TDI<9*$)#5V)E9FB'E:;6\?_$ !T! 0 " @,! 0
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M%*+G[$!BE&:]!44(#"*OFH.>,;M N.HANCIU=M8N$->SJ7=3-DAL.WEATA+
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M*,^V+UC^#NP>+EL+W]'F=1TQ*(QL7P^3RV'XKE8QODJO;:W.']CW4WX2W/\
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M=E?8U@7O50_1V76N,3'^4*RWMF4\U^N-^0^F[19O_DT^<Y\H1L#KG.<?E/\
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MY88R>,ZUT9 +KCE (!6$VEPY[PP4<&KB+F&/6W+VO6_^-[+(U7^2KEII8ZK
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MLAID# X.[$-OK:_4Q\;)!&W-ZX \7[$6;:POK<Y=W/S<MZJ)^JW+^-;/W?\
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MV]OAU^_Q8N$?M.$_;*OHB\)_)XE';/\ 95%_]EORCS ="VW=&_LI)?P#(_K
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/$<$1P1'!$<$1P1'!%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img102364508_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102364508_18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &V2^<!(X0DE-! 0       \< 5H  QLE1QP"   "W_4 .$))300E
M   0%[!F+$S2BZ/ZL]P\'L9W<CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ;@   .7          $
M                 0             #EP   ;@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ;@     4F=H=&QO;F<   .7
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   &X     %)G:'1L;VYG   #EP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      0_0
M  $   "@    30   >   )!@   0X0 8  '_V/_M  Q!9&]B95]#30 "_^X
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M/0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MMM/4(R0E)B<R,S1%D98U-D)'9W%S@86&LL/P_\0 ' $!  $% 0$
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M1"@RP9:;CZU)X1*[\"/8A0T8:0[[:F-1(1PQ9=DP95![/T[%1Q['G!V_ _\
M8'[^PI50>0/M[P#CG[#DCW_QY8_./</UGZV-<]:#:+BT?\ZYDLZM>JDTKW3J
MJ\J5==4]+>E0%A(M"]17UMF-K5D1,X:](\V8; LAV6L6RKYSL6YO$!7,?J_/
MK'+/\NDOX[MF5I.Q0\!=@SD J?<+[<>_!]LJ7:,_/40$JG=E^3JC@<<_G !_
M@_P_M/V--Q?B;^E>KR-6TO5H2*A^8!=(>W$Q?=RJ@F,8V#D5:#YN(W5Y8?IK
MT?9EVJFQ'(N<P7$='OE@,_/5'#QC37_T'8J2OX@[&7TTC&\VX=U"N?5X;8#T
MXR$^DR=68GE01PQH_%R#P1"!QR3\G4_A<CZ?_0>Y]_R]ORS(M_Q+O1L15.TK
MG2KGT;$6.=S#A\XH_9[1,W7]+M'":NE85HV-".DM65<OLMQ1K94];;-;(G57
MU#C=),V9KE1="^$2,0'781 ^I]4F_P!H #&LK$-UV3$<^C(%8\(2IX;@\YZ=
ML>"1Z#>P^U*K[@D?;]1_]H<_G_U9%!OQ._6':]14]JIZQ6DPL4TMEZ=9M=DG
M,:G)#8.^I-A6MG,MFF22]!?6SJ%@*B4!,8PU*J2">;5RLL:E)=/@RB(RB6\[
M#@+$FZW;2,2D;<<"]P/>0+R3P#P>0"#E/XNQ8*5A'Y]C3I\#CGD\B'GVX]QQ
MS[\<9/%/XB?IK<+-R.H<SZ!8^H/NP7I=1%8M/4]$QI4"6<U["$;]((L(R(>B
MKS&O.;2L3 V&4*QVB5:8954;M2M:, ;1\**I8>8;"%:T+S,7WNV/<(BNRIUV
M+%V"LI) *CLH+#G*AMB2@7T&+L%_]3J^Q)*CGF#@>X/\_&;\_D0&?_I,<_S?
MS.G/Q^'^G_U_X8^/Q^/[?A^S'^GXY\U'X+2_]_9?TUN?Z_F3\Y-^RO\ ]CJ?
M[#)]1OFQ6QM=I)9/I,'T&FT\TI$F(AW[."#3:6?>27?$4,<<6GS[[9QIIKCX
M_L\ZG\/RY\6J!Y)I3%L/(8$>>:6Q+Z-;R/;5X$::=Y)7$4$4<2%W8K&BKSPH
MS0[@ 7Y"JHG:"BY"(L:]Y*-:1V"(%5>SLS'J .23Q[Y+O)GFKQXQCQC'C&/&
M,>,8\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,>,8\8S6>
M_7'3GB#N=_E4,+!#1QW]OE1J) (FKF&M\Y1N9%:V5J6 LB8,-0MA0Y&!P8.D
M\L>Q9,$.-Y=>&+'ZWEOFD08*9?*J4?8\D OXGXHO/L">!SR?YCDH[=-?K&X)
MZZ]B0.!SQL+_ -N>./;]N?"@/VD]"F/)J+9^K>F=_HK_ )PICKPBFFB5BS)J
M4QM7!2O?%TIKUP87>K*KGMSKE9TO:M<61%]1'>H__)XG9WC\K@.F1I[19Y5@
MV,3K-^L8.661U1UK!F18B4$CCTN4()4</[ '-:)*Y0=H6''(]C[#L.Y'/;WX
M^_N/YN>>#:G$.S_AWJ=:;Z,4OAG7]*LSZO4T"F[6),!HNM73N66B_P#+J3U)
MO>5G0(>AZ-H[CZAMJPA?:(E#!7'5ZN'"CK]-R+&!:M5MMVEV+VZXDBB8>E&[
M$QQ.BNT2*T93@1RAR"QY)YY+<94DE;A8/3<*6'N?_>!X#$AN0>0 /\7^ T(X
M]@_27EUH[SP_F/J!5DKT.TWCUEK&KZW.ZX-;E]GEVXGUQNU/N',[YS>E\L4#
M<I4T^N!2&W^5O IHR/;G:"OMX<194=393QU)Y[Y9"B6V58T/0JOJPQJ(F21Y
M6# L1T'NQ#L0O:V7A5I%2'W!*+R?R/TD_4"H XX'N?<\D _;P>D_6_P[SN>]
M1U7<"ZZ>Y]?.=Y[4[<V )Q>.E7?FW>:CSCLP*^](^8)ZW%9)65GZJY5ST%10
MK3R_F<-.-N=H84Z%\L,:^WX=LTT16U#&MJ580J]45)(S(O>,R%^O58PP82+*
M[-UC5BH ]B:OU;F-B44L23R2& ]B 1[<MQ[#@>Q)]SGT#3L_2/C87&[O3>$W
MPBQ>T/.77**LL8*K,MN"SCE8KRYQ?%3L;V!M],VI=%1J$2(QV NG%=72!:@:
M5Q+;X15QD&K,6TLO8A>U"%HS+*S IU,K2,L945XW+-V)X5QQ&6(;K[\7NT$:
MHPC8^JO7CDGA2/<?60 .!QR..?VC-+Z3[&?A+VV?0ZN>JM_7S7)RHHKUH)6D
M\,%22H[=Z6#U'HPSFL]>."#K3%_W#U2M=8OW(37EG:ZQPVS7.Q"HPPC.>IOD
M/U7XSZ:>HH+>[=TL$IPT/NP6*4%9/H'L > "+/>J?_9'ZCQ[$>W!4@CAOVD'
MD>_\X]LP"WV^_#NLT=F8G^J+(7DQ^^FJ.VFM"2>C=#7O^9>L?3:E9$BD&PE2
MHG-R;<P]=1Z\=;N@U6RI"J%3[3:":@V"<B@U_)[=2@6^#. K.H51$A::9"I/
MI@L!ZDOLJ$-VZ@<=>'J5R6_5<+P??D]SPJG]O /LO!)]A_.>?.X]W/P]Z_RZ
M)Y:O29LRN#>C=1Z9^KH&:C6^M2D\QL_M;]S3+C9RKI*$IMCBI6'V*OV1'];F
MJK=-<+<&C>6J? ,4WOX;MC+PNP B+QJ9"&23ZXH&+H@CX**R1H.K \KP0"6&
M/6K]?>$EN">H/(]BP /)]O8EC[?GEFF^S/X:'*K&9T4GU8[R+9O6VXKJ0+?F
M%09N55?M%;.OL#X&?JE@ZL5S["[ACC].TK5Y>KD%5ZMA\=IS=HXKEL&,;6FI
M;N53$;U<I:1F=.54LKJJ$]!"'YE7J#T')^S<$ &H2UE(81/RA !))'()(]RQ
M'TDG@,?SY ]O;[ZPRQSPQ3PYTWBFCCEBWCWUWUVTDTQOIOKOIG.NV-M<ZYQM
MKOG7;&?CC;.,X^,28%693]U)!_G!X.;')51__F[%_P :V3_I*W\G?P__ /FO
M7_YV\H__ )1N<U>Y_P#7V_\ PNN_\.J9+?)IFKQXQCQC'C&/&,>,8\8QXQCQ
MC'C&/&,>,8\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,>,8\8RI6-1L,S*U;1KZ
MRT46,_!.X[5F;#F065"I3E!&@XKS(66*7*^;&^N9I(YAY\:2:8^.^N>17O$_
M+5WWD6PUL'CUBGN-I!L:[7-ULM?;A$>DT^K>*6"OX[LHN1+K7D21+;=HY$Y5
M&!42"&_KS4IPSM;22M7:!Q'6AFC;FU9G5@SW(6_@SJI#)[,IX)!'$'8<.1ME
M4J%KR/C#-'.T4/)DS $(U5*ZKRX!.@<2+B:'*'(T1J52M6G8;0[%K%RT $*:
M 4,:*/T:'X@JW9:WC0;J5[#RO= ]2Q8KR/#_ ."6)8C[<GGCG'S6H(X+7>.>
M>/D*W'/''/'XC^SV_F]OMGOCY$-$QC<1\UY/&WA.V9PM=-8M&43+=FZ=;L(C
MM:/@J,[=S9+$VV+UEP1LS?NS\R9+:G33TGQ_S\@J:OC)4C@@^5;K@CJJ\$?H
M?P1U51P?R4#\L"WJ >0]T'[\BC6!]B2/_I']I)S%M>#5Q[^EOYYQWB;G]/ME
M>U[_ #9:O8_IKE'M'NDS;?NZ#-^D>4^\,6ZO+G[W*_:*+(GT<QZ_"I=%\04Z
M!:_C2B/GTPOE>Z'3L"&Z\>'_ $]@2#QQR">?O@VM0>>7NGM]^:%;WX__ %',
MK!R2 8XQH/S?E,#-B(R7L&,.(HCSP' Z8-N":9'1]2"@VHE<KXK(:>22$X9$
MG@*TEB6!:P4GQ_S\@ U?&" 0P!\JW/LP)(8?\#OX0+$@_?DD\^^!:U /(>Z"
M01R*%8>QX!'ML?M[#.VP<KQ;0E"VU\\Y;9ER!DO<H5]AWU=!)'"G&=5352(R
MI!4"YDLQG;"\X/2$H+&<X&FBUSG&2>/^?1LSQU/&$9P0[)Y5NE9@3R06'AX)
MY(!///N,]:WJ6X#/=(4\@&A6/'\W_P H^V1Q5P"GUD7(Z/AW%E0.LLA&0*RD
M0+]MYI3:\REEA%S2U(&Y$K&HU0_?>8H?&YU8KQ>\OUTBW<;R73>?QJTLE#2V
ME4?5#2\HORW'7AAU@2_XYKJCOPS*$GO5HR&/,JCV/BSZ@D*LMB/D^S2T8A&"
M2/=S#<GD"^P)*12'V "GGD87/*^)*06*QIQCG]77N=V^SD)GS>J!I6,UA@W$
M>Y9GBK)ZVPF?"[[C-M)CR)&@^^T!F)]-LQYT-KR";7=6W\6Y\==2J&7=Q204
MHV'O&C;NO+:T)<GGTTBVLCM^2@D YD=-)N14-:Z/<A:K=Y6!]RPJNL=P*/NQ
M:LH4^_M]\_&.4<%V+AC6<>YBW:"H"JU! EYQ5#S!:PUB;ZEU[><=1B!57VL5
MA?1D+SB@DQNCUOI-B35F;];T>1B>=J>MLWMW>X65J.D]793J756BDMR0.:FN
M290/1M[2S2K.0 + ^^>&ET0231Q5HCRHEM<0(0#PX3N/4F*\GM'7260>_P"K
M/'MZIO6?FS+;)4_KOP;.T^:]+MJZJM4W88VJ8N0:I]W@.D-1<35<+.P=?^BQ
M+T2B;9'63#PYS'C?1:OX@SHLL='55$=24@V/E-V*]$KDDK8CUN@VU&.0GDLE
M;8VXQ]Q,W)XQ6FTZ,5,L\A'L7AH1F)B.1RC3VZ\K*0?O)!&WWY7+@_);M^[:
MO_\ $C7]G_!C/Z*?'X?_ ._F\M?HQYQ_%_BG_>?;_P"YN5?/:O\ ^MO_ /8J
M_P#_ &.32L+3%*: (_[?[O!+,J; DLDX^FS!H8PQ'%-+ +)+B+4K6/,FX\.=
M]M,[?3UQG&/.@>)ZJYI=%6H; UC<6SM;<XIRRSUD;9;:]LA%%/-!5EF6%;:Q
M&5ZT!=D+>D@(&:G86([5IYH0XC,5:)/454<B"M#!V9%>15+&(MU#MP#QR<S_
M )(\PL>,8\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,A%(Z+2NGU**\<YLZBX54
MLJPKP+ C)U-5&'U=VTK3N$8K3X1D87ODS)=)+%G:&643?>"26#:.7=C->^1*
M.Y]"Y1S"_-/8%B$SO'/*5<&(:_F?/< "'V:MK'1@P6"5LY&!("#9(AL3SSS8
MATTQ+-+O\V^S&6'^KCLG](MY_#3F_P#5'C&/U<=D_I%O/X:<W_JCQC'ZN.R?
MTBWG\-.;_P!4>,9QGG/8]<9SGV+>8QC'QSG]6G-_YL?_ *1XQF/4TWJ[M<*U
M7>QUAD",C^J/O/RN@A2[:?-MI\=Q340Y4.?CKGX:S0Q[9Q\-L8^7;&<U.C(S
M(W 93P0"K '[_=20?O\ D3ER6)X)'BD $B'A@KHX!X!]G1F1OO\ =6(_+[YD
M?U<=D_I%O/X:<W_JCRG+>>0"C]:9B0G!>R#V86?&^8I,\PYY%G;&DFT6W_<Y
MDD<NOPWTVU_P]-<Y^'QQ\=<XSFS!/%9B2>%B\3\]&*LG(5BI^EPK#W4_<#G[
MCV(RE6#J&4\@_8\$?Z" ?\8SU_JX[)_2+>?PTYO_ %1Y>RK,<73NJ FJUY7L
MF[B,<S$CK(<\QYYMDJ8024XC3&^B3:./Z8L$LN=IMX]=L:?)IMM)G77-01F5
MV Y5 "YY'L"P4?<\GEB![ _M/MEQ(I'261%Y2%5:5N0.BNZQJ>"03R[*.%!/
MOR1P"1#VS7H].,K4C/MCABML=L-ILTS[E=?7_EQPVID8Q@8:M6N.8CGLQQP1
MS/J;+-A#/S+$WV\6TNO*/B7L_+JNX^'/C?B6YIZ*WYCY!M-?<V=C5UMX*]/7
M>);SR+A*4]NI$96?5I&X-B*10Q #,!&TET&LK6%V\MRH=A\AJHMA#6@O)6[]
M[56-^\Z"4*T=>>20Q%>X= A7L>,MD)1T!CL;HO[*I-V7&R+C]1:,DGR$?#'%
M+,$5B)SMF J*.:'>2"3Y9=-9=,[:XQMCXX[>(?&)>I;XNZQ>ZAU[?#+7CLI)
M 8<^1#D$@@'[>QRE[OC\80R>+VD]1!)&6WEA>\;$@.G-'ZD)5@&'()!'/MGM
M_1;J/^M<3^'RG^M_*?T2^,'\K^J_S9Z[_>+*/Q'QO^]JQ_3TW]1Q^BW4?]:X
MG\/E/];^/T2^,'\K^J_S9Z[_ 'BQ^(^-_P![5C^GIOZCG&:OU#&<8SU@/&<Y
M^&,9Y\I_;_P8_P#"_P#/_P"_Q^B7Q@_E?U7^;/7?[Q8_$?&_[VK']/3_ -1S
MG]%NH_ZUQ/X?*?ZW\?HE\8/Y7]5_FSUW^\6/Q'QO^]JQ_3TW]1Q^BW4?]:XG
M\/E/];^/T2^,'\K^J_S9Z[_>+'XCXW_>U8_IZ;^HX_1;J/\ K7$_A\I_K?Q^
MB7Q@_E?U7^;/7?[Q8_$?&_[VK']/3?U'.,U7J&?Y^K!Y^./AGX\]4Y^./]'_
M ,K_ ,W@^)?%\@@_%_5$'V(/PSUW!'[#_P (L?B/C?\ >U8_IZ?^HYU04WI
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MA,$+UTL(%CE@F9)RC+/ LS-&W9Y RL<O4.B^PSJX(&I]"@=)6*72)66&LU$
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MNG2GX#2ZNO7I^,K+1%TR5K]BVJ3R5Q0N6-C0O2,)T19IO3@3O6@MOZ\J1-+
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MH[7(J\#&M3KPP+'1L/\ *2WI$EBDN)Z=L#]&9PKV#Y$R46!\Y.7+8UL+-6G
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M_P#<$-C_ /J\H_!-*?OJ-6?_ ,A4_P!EEOYJU_=,_P#EI/\ 6SG\I5?NQ?\
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MC]0_L=_3DZC_  <];?[J_&,AW)/7+VEI'L;;.H7WW4N73>0-42=<OXVVH%
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MIO?CU.L88C"O]2F> &3%XU-44#IK$41:#O2M2K2VG$IDT2.BQXZ)39,= <[
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M?F&S&4TUF]!T ]P/AN%]WN%.M%M%L3FL=*]C<=LN-D=!EU&U( [8JL@_1^J
M3">M1:$\%<ZL57K\7#"I"-TT/.C"U#&?FT'>G7<65M[5TIN]9"3\FHE/9<@>
MW.90K8HTMH[)O5V32K5FYQUFRNF#ZQ6X59);SROT%:50:S?-435\CR-C//2*
M_P"A8W6TW/ZVOM\MQ*)%N$E@;7CK+BLV"XU2_P#-BUE8=VES<CU'1K/5[Q4*
MK*,ECEM:*GL:LZ2%$)2Y#U#%C/:$)Z#52O(:E7X73])8Z+2Z[4$>]GZL>LFX
MU[#7SUYI@1M$:7:PAHM^=+&K;B!K[6FMYIZ4HU%'A!%/92*6;&7ER+C7K!=#
MJ'VWF@%D>14EW:K!S1BVM/7L5NO,+XNL.73>G4VZ-X$0RAXBZ&]PE,4H<H)4
M+T?-=DRM%3Y#8S<#QC'C&/&,>,8\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,>,
M8\8QXQCQC'C&/&,>,96?2>45GJ,=5W>E6-2UH]BFM-3L-2L+*LOTC8RN/J>R
MW%8+98\RC-*M:'Z4P0N,B#$;#5@)H*Z7*68#&4E%Z/\ K]IL1F9%8C8\C-E2
MJ RXV&4>M5AM3^OT?:FUN+4W3595ER/O/5-5"W'U=UI%FBW')Q @K8ZAC,8Y
M]'N2.^N3=1*,M4(;*,<VRTD*PN D=JLRQQS!R@>/"!F$9DHJ(GD5)G$0BY&7
MSG+,DF[$#G-06#&=%._#]]8*35;;2UU,9G5V]4Z\T&T@-;0\GT9U3HE8Y/3;
M*MU^U+"U7[S5SB7. 1&"S4-D'.E(;Q&?G3ANQ-8_?]_W_P#CDFJ_IIQ>H6&G
M6=-%;H&-+E4EAC0VM@N1-V=>87EC7&MAK27"NO,C$,O2KO$OTU6#@YB>8V-"
M,)4(2%3&>BX>GG&;R[MSM[!</C?#7T]O5 71\ D>JKBFIJ._U4I<.5KI'5.@
MA<\I&UP2B[P1,2:X+./(%DUOABQDQZ3ZW<@ZZ;8#.A5B2PXM26OURPAS-FHR
M]JDK2[IJE:N($",'CQ!E=U^^"F9A^E*9HU@S/)MNN V'8RC]OP[_ %FF+2'&
M5^R&%(AHA!I-[0>'I/"(S(:K<3P*]5X\6P!!A6)-U\0.SO,L15HR]8 +#0F,
ML./T]XEI$S#W66.=6R6VU3&HGMKV1:I OC[GMJN,*:'[O$H/Z06?F-6?F[_6
MEWC8:,\AY%&:&#2,?O\ O_/^>>ZJ^K?-*]S[NW."Q)F:+V,N_7;GT[Z$YRF5
MGOUV<P5FM!W'/GG4Q+:QNO0P3+"!-9B@B7T0P1S,F/5C,'9/2WA5E-C;3K+6
MH>#LVC8)]7;O9DCA>6^==M</\@%AL-?M]'6OL7V)0;C73.\:>W;# ;A$)T1:
MQC]_\7^G.S'I9Z[_ /BGMO3"Y9:.OZFLK1$EDL.9P!NR(IZU>LR;ZL=<'3EI
M3&(*F=AJ5+7M6C21)L#,P*DD8S&Y](>'Z,YW 6>@JSXV!K2NRK>BV@;2D,&]
MX&Z18"J9!][O DGLEUB,=O9=8YY#=G#4#&\2N8<$5C,#3_P]O6.B/EUBKE9L
MHK!/7.?U=7F:[V8O :SF9W#656S@B=ANP**'+]<>1R3D'FEYWQ7CM8-1L62R
M?FK&7YQ7AO/^ U9C4.<@& *6]C/M;/4PS).Q+QB$M7$EQ#Q1C+5VD@2==I,.
AI  ',,B*=L(BW[9RU8,9;_C&/&,>,8\8QXQCQC'C&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img118948569_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img118948569_0.jpg
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MR1VPEVK&]E) [L8RS)DIGYCG[LB+2V<EC!IFW[%<:;8QWH0P1)^_T:_<C C
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M2NW5F:-22?J37+ZQIR^&+M8+72/-\,W\R_:;'3X8(?\ 2',4,<;Y9 T+DY8
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MZ=S.GP_T<!=V@>%LXY(T5?\ XJI/^%?Z*#QH/A<?]P5/_BJIM\/;$GY-'\)
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MQC R0,8."01BNMBNO%;2?OM(T9%R/N:I*QQSGK;CVK%T=+B>V\9)?V42W/\
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M7JOS>FI(KQB16#(1D,#P1ZUR5MJMIK7Q$9-/?SUT6RGMKR50"B3320E8P>[
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MILW#&[:"%&3BW=H]MKFBZK+!?6IFOA#/'?7GFYWV\@'EPB1T4[R@)C 8 /\
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M)ZC();W KKJ***XGQ5::7=^)?#Z:_%#+I?EW2I'<\P-=D1F/<I^4GRQ<8+#
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M3,9=XAD^=$WO(@))SY1.3SANA2^(+W5_%!O-25&M;U[2RMEA5K>-#%')'(V
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M@XQU(/%(OASP_LWCX90 [-^W['89S_=_UF,_I[UBP6EG:77CF*TT"#2(1HL
M:U98HTDXNLN?*8@ C SP<#I75,PD\<Z#(&+!M'O3DC&?WEI74T45D^(+^32/
M#FIZE$B/+:6DLZ(YPK,B%@">PR*Y/0M @T'QC96<E_<:G=O8W%[<O<2';%<-
M*O[V.$'9%YGG3C@=$(!_UA;4\8R);+HUS>;_ .S+;5(I;QO,VJB;7$;OR,JL
MQA8]<;=QX%<I\1OBUI^A:"H\-ZE87VJWA,<;0S+,+<8YD(&1GD  \$\\A2#C
M>&O@\^FZ?_PDFM>(;^P\2 />-=12ILMB5)/F%@=_4[_F ()'3YCZ#<:U?O\
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M R>&8O&@.#@.3C(%1_#ZR%I8:FK-<W=S'J%Q:MJ-W*TLMTD4C*F6;!P@)3
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M7D: HR,0IA^8]-G)7@M5N@NM>&WTFRGU'48/LK6SVV@V<=G9RQLI"E)9LK@
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M9O\ PC/B/0)5;2H)4@#N&BT345B1@S%MRVMTCQ18ST23N3WP)DTWQ=JUVJW
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MBXO)%2VMHH1@S""$E3(?+!*.=PPW$K<J?2J3C-<Q>WVF^(YKWP]9:Y=07L"
MW,NFD;X 6*[#*594<D'Y<A^,CIFJ'A6?6-%UB7PMKU_)J<J6XNK#4FB*F:$8
M1T?C&]&VDG<Q82*3BL;QKX2GF=-(TK5/L&G^)+]EO+=K?S )MC3M*C;E(W>0
M%*YP=Q(P<Y[#0M:GO[F^TZ_2*/4].=$N!%G9(KJ&25,\A6Y&#G!5ADXR>@KE
MO%AEBNO#=RCQ((=8CWO*C,H$D4L6/EZ$F0*I/&XKFN*^(44DW@'XCK$C.PU.
MV;"C)P(;(D_0 $_2NMCT?1_(\Y9_$FUE7A[W4MV&&1\I?(/KQD=#@UR.JZ+8
M>,O'T7ANVGU@Z39Q&[UJ.:]NBDK,RF*';(Q"]-W 'R_=((X]4MK>&TMHK:VA
M2&") D<<:A510,  #@ #M5NBBBBBBBBBC%)@>@HP/2@@$8-4+G2M/OH_+N[&
MUN$Y^6:)7')!/!'J!^0K-E\%^%9I7EF\-:-)*[%F=["(LQ/)))7DT[_A!?"'
M_0J:'_X+HO\ XFD_X0/P?G_D5=$_\%\7_P 32_\ "">$/^A5T/\ \%\7_P 3
M69<?#+P7<FYW^&;!?M  ?RD\O ']W:1L^JXSWKR+7?#/@34/'!\-Z:VG:!8:
M8RMJ6I3ZC^\E;G]S"KN02/XF(RI!SC;A^LT[P9X(U.VGE^'>HK9Z_IX26*]A
MN9756.["R!B5*MM(8 'CJ".#WO@SQ&_B;PS!?SP_9[U&:WO+?&##.AVNI!Y7
MGD \@$9K"^+K[_!<>FOO']IZC:V8**7*YD#Y"K\Q.$/"ACZ#N+DNG:%""S2^
M+"H./DN]5;T]&]^O^!J-[?P_"&+-XNPC%3MFU=N0,]CR/?IVK)\.WNCVOBOQ
M=J5E]LVZ=IEMNEU)KEI8^)I&#?:/WB@@(<#@@ CK6KX?LWLM2\'64^#/;>'9
MXWX(^8&S4G! (Z'J :[VLS6M231M#O\ 5)8VDCL[:2X9%."P12V![G%>>W'A
MBX/BG0GUO5M0O=6U:65M4M+:21;(VL<3D1[!QY22/&HWGYS*V0=Q [[7=7MO
M#NAW>JW;!;:SA,C*"%+8'"KD@9)P .Y(%:,;B2-7!4A@#E3D?@>]5[R]MM-M
M'NKVYAMH%(WRSR!$7) &2>!DD#ZFKU>?^(Y8M3\70Z<QT>Y6TA^33]3E BO9
MY""0O#;98D1&SL<[;C&$#!C'J$LFF6MW"NHS:9$L;H(/$@^U64Z$XW&?>6!<
MG 5Y"0N[]UT-=#X4TN#3/#T1ATZWT]KDFZDM8(C&L3/SMP><J,+G ^[PJC"C
MHZ***\_\4V.GZ+X@A\1^;H=G=7KQ6@O-4@!6W=%D?S0P*Y9D&S!9<X3YOEVM
M0>PMKV&YNM2BFU=;=AYVH^(QY%E$"HW/#;D!6VG!!VKN#$>::Z'P5J#SV,NE
M31N'TORX(YC826B7$6P;72-Q\HR'3 )'R9& P%9^BV9D\:>*=,UR5[F[N$$M
MG</-L8V$@VF.)5;,81TPS+M+$HQYVFN%NO'GAKX3ZQJ.E>&XQJ6GW,:3K:07
M89;:Z!V2 R$,<,@4XRQ5DQ@!N&Z?:_%/Q=XITKQ3=6%M80Z6[R6EG<X@+HWR
M2Q@%7<%U7&YP ,Y7'%>OZYHEKX@T]K.\\Q1N62.6%]LD,BG*R(W9E(R#^!R"
M17GNG77B'1?[7\73ZRVN)8W$UCJMB]K'#*EM!(Y21"N!YBJYDP0 RR8X(!KU
M='61%D1@RL 5(.01ZUS?CNX6S\+O>R!VAM+NSNIO+0N5BCN8G=L#D@*K$^PK
M(U+3Y)]<\:Z);S$SZSHT<\,3YV>84E@8CMT2'/3J*TO ^IS:SX"T6^MKI',E
ME&C/)&[8E1=DF<D$X=2/?!Y.0:S?!Z$_$7QX]PZ"^,MDLD<>=GEB#Y'!(ZM\
MV5YVXQD]3Z#111111111111111111156XG6VMI)Y25CC0NQ"DX &3P.3^%>?
M_"[0+.;P=9>(-1TNVEUO4)9;Z>\FM@)7=Y&96&X#:,;2 N%[CKDO^%=M!"?&
M'DPQQ[?$MW$ B!<(NS:O'89.!VS5WP!)#+=^+OLQ)B'B"X4Y4+AQ'$'Z ?Q;
MN>IZG))-4_B$K:KX@\&Z';-LO&U8:BLCH6C1+="QW $'G< /QY%=FQU-;A-@
MM)H2OS9+1,K =OO;@3],#^]5I#+@[]N=QQ@D\9X_3_/>O)1+]KT?XHZT\4IN
MK^\?1(H(EW;VCC%O"1WRSR\^GX5W69[CXF!2B"#3]&SN!^8O<3=/H!:_K74U
MQ&OQV^O:[=Z7J5W/;:+INGBYOHUF:!+KSO,4!W&"(T6)R<-ABXS]S!/AWI<-
MOX7M=2*W,EQ>JSQW%Y,9IS:F1F@5F). (RGRC@$GC)-,\?\ A#4O&MK;:0NJ
M)I^D ^;=,BL\L[@C:F,A0G5LDGY@O'&:\W!^(WP?3<Y77_"\1P.2WE+G _VX
MOE4?WHQN[DUW=C\5O!6O>'-0N9+I<0V[M<:;=JJRRKALHJL=LA8*> 3]X XS
MBK/@B+4/"OPNMI]?N+JXGM[1[N2.7&^&/!81#<%(*K@$.>#D9"@8I0W-[9VH
MAUFYEL[O40/M=EJUHLNG2NZ?.D<T?RQ!FR@#N2>28V9]S6;G29+QO^$>+ZAI
MD=]$R3V,,D4UL\ 5%E,3N"\:@,D8 "?>RL8Y<>A"BBBBLK5M*36+,VTLLT ,
MD<J20D;T>-U=&&X$<,H.""#W%<19R2R11ZU<N@N; /;S:]K[(D5O+G9((;>-
MP@(<-$S;DZ##RCJVXNCH6IV/B"2:]2WDGBMK[4-9NQ;&\B8,J*EN0JIY;/O)
M*1, C8W[V)M?%CPU=>(/"%S+I@N?[4LXV,26[$&:)BOFQ$#[P8*#MZDHH[\W
M?!WPS\-^#T66RLUGU <F^N0'ESS]WLG#$?*!D8SFNWKSSP9XPF\0^-?%&E17
M/V_3-/EC:UO J+LW AXCC&X!@P5@IX4Y8Y4EGQ$\/VJZ9J.MQ7-_8+.D-OJK
M6/(N+0R(LC2)M;)2(N0X&X#(.5XK1\.O>:9K$&D/K#:UI5W8&ZTV\E*M,J1^
M6CJ[J LBGS497QGE@<\$]'J^F1:QH][IDSNL-Y ]O(T9 8*ZE21D$9P?2N0T
MS4;BYT[PGXAO5E6ZC+Z3J9F4 J[D1.<+_$;F&)01P%=B0!RN!HEMH_A?Q!K/
MA?47U\>5.;[3HK"2]9/LDF"%5(&. DA=22!DD=>TFC:KIN@_%>>&,:C;V7B&
MTB5)]5BN(V:[A)41JTX!(*,.N[YMH!Y KURBBBBBBBBBBBBBBBBBBBJ\L$<\
M+Q2HKQNI5E89# ]01WKR+X=^,=:TOP7#8W?AC5M13297L9I[.6.:165F.SRB
MP<;1L4#ICTP :^B>+]5T#7?$<MEX'\4RZ;J4IOK>"33V1X[ME <,?F^1R =V
M?EQPIS7??#_0;KP_X72/43G5;R5[[4'&.9Y#ENA(X&%XX.W(ZUR45W8:S\0-
M>U?4;+6EMK98].TZYT^UOLR+&[F;+P AAYO YQ\@XXYW6?PTP (\; #/1-9'
M\A69KFI^&-&T2]U$GQ>#;Q,R+<3ZO#&[XPB%V^5=S$+D]S4^B:,]AIO@_P *
MWDTKW:;M7U&.64%B4;>5)4\XN9HV'8B-LDXP>@\+K]HU#7=8*MBZOVMH6=\D
M16_[K;C. /-$[#'7?D\G%/\ &VM2:!X<FN+>ZM+>\GDCM;5KJ41HLDCA Q)!
MR%!+D8/"'MFN0@\%>&[KXEQV_P!C?5I=/TXMJEQJ,K77F3.46$/O8C?L65L;
M< $8 ^7'4>._&%MX+\.37999-0E1UL[?!8R.!DDJ"#L4?,QR,#ODC/0V%[;Z
MEI]M?6LGF6US$LT3X(W(P!!P>>015ZO)+[P1X=U?XQ6UQ86BV[Z8@U'5)(&&
MV2=F'D(5W?(WR/(WR\C&?O9K<\9:I;R7EO8O?6MO9VCE[N:\L7GLUF(40Q3D
M,JJ"'+@$\,L3$C*AT66?08]DTK>'Q'RIED^UZ6_0;59MK1!1A53,(W'@. :G
M\"P17JSZY%;6=O;ONL[2"TNVN88ECD=7:)B%5$<JGR(H&(U)R3A>YHHHHHK@
M]>M8M"UP:O&VD645SG_3]4+LEE-SN*(6"YE4X.UHN4RQ<D+562ZG@N?MOGW-
MA!(J1KK.JC?=W+-G=#:VA \MR$7^ ;F4?NI.&K8\&220Z>VAFWOHH=-CB2SE
MOC%YLUL01&S*F"I!1EPRJV%&?FW8V-<UFTT#1;W5[]]EM:1-*^" 6QT49(!8
MG  SR2!7E$WQ/\8>(?!&J:II7@NXCM'C>*&_AO,O%P%+JFT,^UB3N7@8Y^Z:
MU_AM9:1\/OAC;:OJ][:VCZD@O)KB1A\VY"T<:\!F(3G9R=Q?&<UM?#/QJGC?
MPK%/+(#J5IB&]4E<LX'$F!C"OR1P "& SMS6)JGA+0=(\=6D;+<Z38ZC:/;Z
M?<V-[- +6\+$LB!?D0R*RE0?E)B(VDFNK\'Z\VJV^H:=>7<,^J:1=O9W3QE/
MW@!_=R;48[=RXR.,.KK@;<52DT*"VU_6-)F55T;Q+$\A4%$VW>S;*JX4'+QA
M7').8Y&X[X>LQZO);PZWIP6Y\:>& \%W;; ?MT+C&]D4J2&4"9%!P&W(,L#B
M[J&AWWQ'\)+')KVAWNEWB^9#/%I$P9&&0'4FY^5P<C!''((ZBBUG^)'ABP6R
MFTRS\5*AV0745X+6?8"<&82+M)(P/E)/')).:L?\);\0O^B8_P#E?M_\*OQ>
M)?$C7.VY\"ZA'!Y:G?'?VCMO[C:9 ,>ASD^@J^OB+52.?!FMY[XGLO\ Y(K
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M\S8/!X8="-5M3OH=*EUV*WEBUOQ!/%9Z=;S*28(OF\HN%! "H9;AL@$;BA/
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MC ^;!QZC/O56X\+>$[>,-)X0TUE)QB/3(Y#^2J>*C'A/P>7VCPCI8_>&//\
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MXPEE%))=M8EMW[ZYDP0AE;"GYBN]68,^Z1QNWGAFWN_%FE^(0(1=64,L#%X
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M "54L=MXB6-A+JVEM)MP&73I% ;/7!G/&,#&>O.>U1_8_%^/^0[H?_@FE_\
MDJD^R^+O^@[H?_@GE_\ DJI4A\1;7WZGI3,4 C*Z=( &XR3^_.1UXXQD<G'+
M9[7Q09F:WUG2(XL#"RZ5(Y'XBX7^51I:^*U=?-UO160'Y@ND2J2._/VDX_*G
ME->M[1WFU;259(F+2_V<ZHK9SN(,_"@=1GWR.E8,WBLQ3R*?B#X,CVL1LDM_
MF7V/^ECG\*P4^(VKZB@/ANYC\12N6B'V+P]<11128^3S)9+@*@)(R>> >G!I
M^H_\);>:&UQX\\16'A;2MI$L&E'%Q-P3L,C%L,-H(6/<7!85LZ?91V.F"WL;
M./PMX5A7?/-*1#<70( #;MV805"Y=SYO;", U2+#:^)M/CFO+?\ L[P99QDK
M974*0K=K&P*2.I&8X%"!E4[2V?F 4 -@Z_J_B36M#TC7H[*Q@TMM1LI['2I;
MAQ<7VZ7$?F.I")]Z.0)AP"N6)VE3V6BZ-J$>K7.LZ[<I+?RH8+>WMV)@LX,Y
MV)D LS$*6<@9(4  **ZBBBBN6\2ZCG=HMO\ ;A+-"9;F73S&9[:#(7>%8,22
M<@ *20K[?F"@Y<CJD,6JBZ<'R\'78H]FTHY&R]@RN0HX8D#8?..(,9J&PTXZ
MCK=U911FTMI$,NK26#(;343("%PI#%79<LY4JP!0%I,HX]" Q2T4444444A
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MY9&.6=W8EF8^I)/ '0"M>BBBLW4=1M](LVNKMV6!&5<I&TC%F8*H"J"S$L0
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M+/)(P544=22> *P;GQOX>BM))[/4X-3D7A;737%S/(VUF"JB$G)"L><# ))
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M%TRXL75'B\A[E[M0%;[0B^8A6!PR[>&R#][I3=&\6:MXOU/4M(TOQ#X?MYK
MA?/@@>Y:Y&0?-C4NJJG(4C,F&SSC:3FV?C>\U#Q+?:=J_C#2M)T^R8"WO].B
M18[]MH+*LLYDC4Q[X]R#)RW7 IJ:QJ.HZL6FNO$FM>$!,8X-1T^#RI'GV@,&
M^S;))(%P^'10"S$'?A34;^&KJ[U"/4-,\(ZAJ.A6<++#I&O:HZ)/.791+'#+
MOV[5W#][MR'!"@C)WX?!VHZKJ\&OS06_A748K<B,:2T<TCLX 87#-$%D"@*
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M;WNBZ=<P6J;+>.:U1UA7 &%!'RC ' ]!Z5H6]O%;01PV\2111J$C2-0JJH&
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M#;<O\O<T44444A(49)P/6N8UOQCINCP3R)'/J+VT,MQ/%8F-FBBC)5W;<R@
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GHHHHHHHHHHHHIG;\*7O2CJ:6BBBBBBBBBBBBBBBBBBBBBBBBBO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>fnch-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T16:48:41.6911+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf" xlink:href="fnch-20211231.xsd#DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1" xlink:href="fnch-20211231.xsd#DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" xlink:href="fnch-20211231.xsd#DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InProcessResearchAndDevelopment" xlink:label="fnch_InProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="fnch_AccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="fnch_InProcessResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CollaborationRevenueMember" xlink:label="fnch_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RoyaltiesRevenueFromRelatedPartyMember" xlink:label="fnch_RoyaltiesRevenueFromRelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fnch_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fnch_RoyaltiesRevenueFromRelatedPartyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:label="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" xlink:label="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:label="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercised" xlink:label="fnch_CommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_CommonStockWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InitialPublicOfferingCosts" xlink:label="fnch_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_InitialPublicOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromIssuanceOfCommonStockGross" xlink:label="fnch_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentsForUnderwritingDiscountsAndCommissions" xlink:label="fnch_PaymentsForUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfOfferingCosts" xlink:label="fnch_PaymentOfOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_PaymentsForUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_PaymentOfOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DerecognitionOfDeferredRentLiabilities" xlink:label="fnch_DerecognitionOfDeferredRentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UnamortizationOfLeaseIncentives" xlink:label="fnch_UnamortizationOfLeaseIncentives"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fnch_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fnch_DerecognitionOfDeferredRentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fnch_UnamortizationOfLeaseIncentives" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ComputerEquipmentAndSoftwareMember" xlink:label="fnch_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fnch_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="us-gaap_TransferredAtPointInTimeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TransferredAtPointInTimeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TransferredOverTimeMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LabEquipmentMember" xlink:label="fnch_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fnch_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RelatedPartyMember" xlink:label="fnch_RelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_RelatedPartyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_OpenBiomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="us-gaap_CapitalLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InnerBeltRoadLeaseMember" xlink:label="fnch_InnerBeltRoadLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CapitalLeaseArrangementMember" xlink:label="fnch_CapitalLeaseArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="us-gaap_MajorPropertyClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquipmentOnLease" xlink:label="us-gaap_PaymentsToAcquireEquipmentOnLease"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CherryStreetLeaseMember" xlink:label="fnch_CherryStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LesseeOperatingLeaseLeasesArea" xlink:label="fnch_LesseeOperatingLeaseLeasesArea"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConcordAvenueLeaseMember" xlink:label="fnch_ConcordAvenueLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkDriveMember" xlink:label="fnch_HoodParkDriveMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LesseeOperatingLeaseLeasesAdditionalArea" xlink:label="fnch_LesseeOperatingLeaseLeasesAdditionalArea"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseAndRentForAdditionalSpace" xlink:label="fnch_LeaseAndRentForAdditionalSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_InnerBeltRoadLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_CapitalLeaseArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquipmentOnLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_OpenBiomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_MajorPropertyClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_CherryStreetLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="fnch_LesseeOperatingLeaseLeasesArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_ConcordAvenueLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_HoodParkDriveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="fnch_LesseeOperatingLeaseLeasesAdditionalArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="fnch_LeaseAndRentForAdditionalSpace" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CollaborationRevenueMember" xlink:label="fnch_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="fnch_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TakedaAgreementMember" xlink:label="fnch_TakedaAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UpfrontPaymentReceived" xlink:label="fnch_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAndLicenseAgreementMember" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LMICLicenseAgreementMember" xlink:label="fnch_LMICLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" xlink:label="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MilestonePaymentsReceivedUnderAgreement" xlink:label="fnch_MilestonePaymentsReceivedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fnch_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fnch_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_TakedaAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fnch_UpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fnch_OpenBiomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_AssetPurchaseAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_LMICLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fnch_MilestonePaymentsReceivedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsExpirationYear" xlink:label="fnch_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" xlink:label="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsExpirationPeriod" xlink:label="fnch_OperatingLossCarryForwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" xlink:label="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_OperatingLossCarryForwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_OperatingLossCarryForwardsExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumRegulatoryMilestonePayments" xlink:label="fnch_MaximumRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaycheckProtectionProgramCARESMember" xlink:label="fnch_PaycheckProtectionProgramCARESMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InnerBeltRoadLeaseMember" xlink:label="fnch_InnerBeltRoadLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAndLicenseAgreementMember" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SalesBasedMilestonePayments" xlink:label="fnch_SalesBasedMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CherryStreetLeaseMember" xlink:label="fnch_CherryStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaterialAccessAndLicenseAgreementMember" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MilestonePaymentsPaid" xlink:label="fnch_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConcordStreetLeaseMember" xlink:label="fnch_ConcordStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RoyaltyPaymentsPaidOnNetSales" xlink:label="fnch_RoyaltyPaymentsPaidOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodLeaseMember" xlink:label="fnch_HoodLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RemainingRoyaltyCommitmentAmountDue" xlink:label="fnch_RemainingRoyaltyCommitmentAmountDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AdditionalRoyaltyCommitmentsAmountDue" xlink:label="fnch_AdditionalRoyaltyCommitmentsAmountDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedInterestBorrowed" xlink:label="fnch_AccruedInterestBorrowed"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DebtInstrumentForgivenDescription" xlink:label="fnch_DebtInstrumentForgivenDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_MaximumRegulatoryMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:to="fnch_PaycheckProtectionProgramCARESMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_InnerBeltRoadLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_OpenBiomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_AssetPurchaseAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_SalesBasedMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_CherryStreetLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_MaterialAccessAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_MilestonePaymentsPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_ConcordStreetLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_RoyaltyPaymentsPaidOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_HoodLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_RemainingRoyaltyCommitmentAmountDue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_AdditionalRoyaltyCommitmentsAmountDue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromLoanOriginations1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_AccruedInterestBorrowed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_DebtInstrumentForgivenDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CrestovoMember" xlink:label="fnch_CrestovoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_NotesMember" xlink:label="fnch_NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesB1RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPurchasePrice" xlink:label="fnch_RedeemableConvertiblePreferredStockPurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPostSplit" xlink:label="fnch_RedeemableConvertiblePreferredStockPostSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedInterestOnConvertiblePromissoryNotes" xlink:label="fnch_AccruedInterestOnConvertiblePromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityIssuanceCosts" xlink:label="fnch_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="fnch_CrestovoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fnch_NotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesB1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_RedeemableConvertiblePreferredStockPurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_RedeemableConvertiblePreferredStockPostSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_AccruedInterestOnConvertiblePromissoryNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_TemporaryEquityIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecondarySaleMember" xlink:label="fnch_SecondarySaleMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UndesignatedPreferredStockMember" xlink:label="fnch_UndesignatedPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GrossProceedsFromIssuanceOfCommonStock" xlink:label="fnch_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fnch_SecondarySaleMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="fnch_UndesignatedPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OptionsToPurchaseCommonStockMember" xlink:label="fnch_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsMember" xlink:label="fnch_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fnch_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fnch_CommonStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercisedGross" xlink:label="fnch_CommonStockWarrantsExercisedGross"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercised" xlink:label="fnch_CommonStockWarrantsExercised"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_CommonStockWarrantsExercisedGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_CommonStockWarrantsExercised" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecondarySaleMember" xlink:label="fnch_SecondarySaleMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="fnch_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IncentiveStockOptionsMember" xlink:label="fnch_IncentiveStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" xlink:label="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" xlink:label="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RemainingStockCompensationExpenses" xlink:label="fnch_RemainingStockCompensationExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fnch_SecondarySaleMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandSeventeenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fnch_IncentiveStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fnch_RemainingStockCompensationExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StrategicAgreementMember" xlink:label="fnch_StrategicAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ClinicalSupplyAndServicesAgreementMember" xlink:label="fnch_ClinicalSupplyAndServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAgreementMember" xlink:label="fnch_AssetPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RelatedPartyTransactionTerm" xlink:label="fnch_RelatedPartyTransactionTerm"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfMonthlyPlatformFee" xlink:label="fnch_PaymentOfMonthlyPlatformFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecurityDepositsReturned" xlink:label="fnch_SecurityDepositsReturned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumMilestonePaymentRequiredUnderAgreement" xlink:label="fnch_MaximumMilestonePaymentRequiredUnderAgreement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_StrategicAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_OpenBiomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_ClinicalSupplyAndServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_AssetPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_RelatedPartyTransactionTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_PaymentOfMonthlyPlatformFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_SecurityDepositsReturned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireSoftware" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_MaximumMilestonePaymentRequiredUnderAgreement" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>fnch-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T16:48:37.9441+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://finchtherapeutics.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:fnch="http://finchtherapeutics.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fnch-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fnch-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fnch-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fnch-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperations" id="Role_DisclosureNatureOfOperations">
        <link:definition>100080 - Disclosure -  Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100110 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1" id="DisclosureLeases1">
        <link:definition>100120 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100130 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>100140 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100170 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholderSEquity" id="Role_DisclosureStockholderSEquity">
        <link:definition>100180 - Disclosure - Stockholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>100190 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100200 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>100210 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" id="Role_DisclosureLossPerShare">
        <link:definition>100220 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100230 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100270 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>100280 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100300 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" id="Role_DisclosureRedeemableConvertiblePreferredStockTables">
        <link:definition>100320 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100330 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>100340 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" id="Role_DisclosureLossPerShareTables">
        <link:definition>100350 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" id="Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails">
        <link:definition>100380 - Disclosure - Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails" id="Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails">
        <link:definition>100390 - Disclosure - Significant Accounting Policies - Schedule of Disaggregation of Revenue by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails" id="DisclosureLeasesLeasesBalanceSheetInformationDetails">
        <link:definition>100450 - Disclosure - Leases - Leases Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" id="DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails">
        <link:definition>100460 - Disclosure - Leases - Summary of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" id="DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>100470 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails" id="DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails">
        <link:definition>100480 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" id="DisclosureLeasesScheduleOfFutureLeasePaymentsDetails">
        <link:definition>100490 - Disclosure - Leases - Schedule of Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>100500 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100510 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" id="Role_DisclosureRevenueAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails">
        <link:definition>100580 - Disclosure - Redeemable Convertible Preferred Stock - Additional Informations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails">
        <link:definition>100590 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf" id="DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf">
        <link:definition>100610 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1" id="DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1">
        <link:definition>100620 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" id="Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails">
        <link:definition>100640 - Disclosure - Stock Based Compensation - Assumptions Used to Value Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" id="DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails">
        <link:definition>100650 - Disclosure - Stock Based Compensation - Summary of Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails" id="DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails">
        <link:definition>100660 - Disclosure - Stock Based Compensation - Schedule of Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails">
        <link:definition>100670 - Disclosure - Stock Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100700 - Disclosure - Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100710 - Disclosure - Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fnch_FinanceLeaseObligationAbstract" name="FinanceLeaseObligationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_HoodParkLeaseObligationsAbstract" name="HoodParkLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_OperatingLeaseObligationsAbstract" name="OperatingLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_AccruedInterestBorrowed" name="AccruedInterestBorrowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_AccruedInterestOnConvertiblePromissoryNotes" name="AccruedInterestOnConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_AdditionalRoyaltyCommitmentsAmountDue" name="AdditionalRoyaltyCommitmentsAmountDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" name="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_CommonStockWarrantsExercised" name="CommonStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_CommonStockWarrantsExercisedGross" name="CommonStockWarrantsExercisedGross" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" name="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" name="ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_DebtInstrumentForgivenDescription" name="DebtInstrumentForgivenDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" name="DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_DerecognitionOfDeferredRentLiabilities" name="DerecognitionOfDeferredRentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" name="EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_ForgivenessOfPaycheckProtectionProgram" name="ForgivenessOfPaycheckProtectionProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" name="GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDue" name="HoodParkLeaseFutureMinimumPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent" name="HoodParkLeaseFutureMinimumPaymentsDueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" name="HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears" name="HoodParkLeaseFutureMinimumPaymentsDueInFourYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" name="HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" name="HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter" name="HoodParkLeaseFutureMinimumPaymentsDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" name="HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" name="HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" name="IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_InitialPublicOfferingCosts" name="InitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_InProcessResearchAndDevelopment" name="InProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" name="InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" name="IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" name="IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" name="IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" name="IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_LeaseAndRentForAdditionalSpace" name="LeaseAndRentForAdditionalSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_LeaseAssets" name="LeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_LeaseLiabilities" name="LeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_LesseeOperatingLeaseLeasesAdditionalArea" name="LesseeOperatingLeaseLeasesAdditionalArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fnch_LesseeOperatingLeaseLeasesArea" name="LesseeOperatingLeaseLeasesArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" name="MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_MaximumMilestonePaymentRequiredUnderAgreement" name="MaximumMilestonePaymentRequiredUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_MaximumRegulatoryMilestonePayments" name="MaximumRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_MilestonePaymentsPaid" name="MilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_MilestonePaymentsReceivedUnderAgreement" name="MilestonePaymentsReceivedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" name="OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OperatingLossCarryForwardsExpirationPeriod" name="OperatingLossCarryForwardsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" name="OperatingLossCarryForwardsPriorToTwoThousandEighteen" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" name="OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_PaymentOfMonthlyPlatformFee" name="PaymentOfMonthlyPlatformFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_PaymentOfOfferingCosts" name="PaymentOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" name="PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_PaymentsForUnderwritingDiscountsAndCommissions" name="PaymentsForUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" name="PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" name="PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" name="PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_PresentValueOfFutureMinimumLeasePayments" name="PresentValueOfFutureMinimumLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_PrincipalPaymentsOnCapitalLeaseObligation" name="PrincipalPaymentsOnCapitalLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" name="ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_ProceedsFromPaycheckProtectionProgramLoan" name="ProceedsFromPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" name="ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_RedeemableConvertiblePreferredStockPostSplit" name="RedeemableConvertiblePreferredStockPostSplit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fnch_RedeemableConvertiblePreferredStockPurchasePrice" name="RedeemableConvertiblePreferredStockPurchasePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fnch_RelatedPartyTransactionTerm" name="RelatedPartyTransactionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_RemainingRoyaltyCommitmentAmountDue" name="RemainingRoyaltyCommitmentAmountDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_RemainingStockCompensationExpenses" name="RemainingStockCompensationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_RightOfUseAsset" name="RightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_RightOfUseLiabilities" name="RightOfUseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_RoyaltyPaymentsPaidOnNetSales" name="RoyaltyPaymentsPaidOnNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_SalesBasedMilestonePayments" name="SalesBasedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_SecurityDepositsReturned" name="SecurityDepositsReturned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" name="StockIssuedDuringPeriodValueVestingOfRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" name="TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" name="TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fnch_TransfersBetweenFairValueLevels" name="TransfersBetweenFairValueLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_UnamortizationOfLeaseIncentives" name="UnamortizationOfLeaseIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" name="UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_AssetPurchaseAndLicenseAgreementMember" name="AssetPurchaseAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_CapitalLeaseArrangementMember" name="CapitalLeaseArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_CherryStreetLeaseMember" name="CherryStreetLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_ClinicalSupplyAndServicesAgreementMember" name="ClinicalSupplyAndServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_ConcordAvenueLeaseMember" name="ConcordAvenueLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_ConcordStreetLeaseMember" name="ConcordStreetLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_CrestovoMember" name="CrestovoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_HoodLeaseMember" name="HoodLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_HoodParkDriveMember" name="HoodParkDriveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_IncentiveStockOptionsMember" name="IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_InnerBeltRoadLeaseMember" name="InnerBeltRoadLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_LMICLicenseAgreementMember" name="LMICLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_MaterialAccessAndLicenseAgreementMember" name="MaterialAccessAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_NotesMember" name="NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_OpenBiomeMember" name="OpenBiomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_PaycheckProtectionProgramCARESMember" name="PaycheckProtectionProgramCARESMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_RelatedPartyMember" name="RelatedPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_RoyaltiesRevenueFromRelatedPartyMember" name="RoyaltiesRevenueFromRelatedPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SecondarySaleMember" name="SecondarySaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SeriesB1RedeemableConvertiblePreferredStockMember" name="SeriesB1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SeriesDRedeemableConvertiblePreferredStockMember" name="SeriesDRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_StrategicAgreementMember" name="StrategicAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_TakedaAgreementMember" name="TakedaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock" name="DeferredInitialPublicOfferingCostsPolicyTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" name="SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_LeasesBalanceSheetInformationTableTextBlock" name="LeasesBalanceSheetInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_LeaseTermAndDiscountRateTableTextBlock" name="LeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock" name="RedeemableConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock" name="ScheduleOfFutureLeasePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" name="ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>36
<FILENAME>fnch-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T16:48:41.8670+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="fnch-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="fnch-20211231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesLeasesBalanceSheetInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="fnch_AccruedExpensesAndOtherCurrentLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="fnch_InProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InProcessResearchAndDevelopment" xlink:label="fnch_InProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fnch_PrincipalPaymentsOnCapitalLeaseObligation" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fnch_ProceedsFromPaycheckProtectionProgramLoan" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="14" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="15" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" xlink:label="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" xlink:label="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" xlink:label="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PrincipalPaymentsOnCapitalLeaseObligation" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="fnch_ProceedsFromPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" xlink:label="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_LeaseLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_LeaseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_LeaseLiabilities" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_LeaseAssets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_LeaseLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_LeaseLiabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseLiabilities" xlink:label="fnch_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseAssets" xlink:label="fnch_LeaseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="fnch_AccruedResearchAndDevelopment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedResearchAndDevelopment" xlink:label="fnch_AccruedResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="fnch_DeferredTaxLiabilitiesFixedAssets" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="fnch_RightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fnch_RightOfUseLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredTaxLiabilitiesFixedAssets" xlink:label="fnch_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RightOfUseAsset" xlink:label="fnch_RightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RightOfUseLiabilities" xlink:label="fnch_RightOfUseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>37
<FILENAME>fnch-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T16:48:40.9651+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AdditionalRoyaltyCommitmentsAmountDue" xlink:label="fnch_AdditionalRoyaltyCommitmentsAmountDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="us-gaap_MajorPropertyClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="us-gaap_CapitalLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RelatedPartyTransactionTerm" xlink:label="fnch_RelatedPartyTransactionTerm"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesB1RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaterialAccessAndLicenseAgreementMember" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LMICLicenseAgreementMember" xlink:label="fnch_LMICLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PresentValueOfFutureMinimumLeasePayments" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GrossProceedsFromIssuanceOfCommonStock" xlink:label="fnch_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InitialPublicOfferingCosts" xlink:label="fnch_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityIssuanceCosts" xlink:label="fnch_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConcordAvenueLeaseMember" xlink:label="fnch_ConcordAvenueLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConcordStreetLeaseMember" xlink:label="fnch_ConcordStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TakedaAgreementMember" xlink:label="fnch_TakedaAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CrestovoMember" xlink:label="fnch_CrestovoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAgreementMember" xlink:label="fnch_AssetPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="fnch_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" xlink:label="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentsForUnderwritingDiscountsAndCommissions" xlink:label="fnch_PaymentsForUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" xlink:label="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UpfrontPaymentReceived" xlink:label="fnch_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedInterestBorrowed" xlink:label="fnch_AccruedInterestBorrowed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodLeaseMember" xlink:label="fnch_HoodLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecurityDepositsReturned" xlink:label="fnch_SecurityDepositsReturned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPostSplit" xlink:label="fnch_RedeemableConvertiblePreferredStockPostSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RemainingStockCompensationExpenses" xlink:label="fnch_RemainingStockCompensationExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" xlink:label="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UndesignatedPreferredStockMember" xlink:label="fnch_UndesignatedPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedInterestOnConvertiblePromissoryNotes" xlink:label="fnch_AccruedInterestOnConvertiblePromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CapitalLeaseArrangementMember" xlink:label="fnch_CapitalLeaseArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RoyaltyPaymentsPaidOnNetSales" xlink:label="fnch_RoyaltyPaymentsPaidOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" xlink:label="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LesseeOperatingLeaseLeasesArea" xlink:label="fnch_LesseeOperatingLeaseLeasesArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CherryStreetLeaseMember" xlink:label="fnch_CherryStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RightOfUseAsset" xlink:label="fnch_RightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ForgivenessOfPaycheckProtectionProgram" xlink:label="fnch_ForgivenessOfPaycheckProtectionProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RelatedPartyMember" xlink:label="fnch_RelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredTaxLiabilitiesFixedAssets" xlink:label="fnch_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumMilestonePaymentRequiredUnderAgreement" xlink:label="fnch_MaximumMilestonePaymentRequiredUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" xlink:label="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:label="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CollaborationRevenueMember" xlink:label="fnch_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedResearchAndDevelopment" xlink:label="fnch_AccruedResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsExpirationPeriod" xlink:label="fnch_OperatingLossCarryForwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseObligationsAbstract" xlink:label="fnch_HoodParkLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercised" xlink:label="fnch_CommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IncentiveStockOptionsMember" xlink:label="fnch_IncentiveStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" xlink:label="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsMember" xlink:label="fnch_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="fnch_ProceedsFromPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumRegulatoryMilestonePayments" xlink:label="fnch_MaximumRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" xlink:label="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseAssets" xlink:label="fnch_LeaseAssets"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_FinanceLeaseObligationAbstract" xlink:label="fnch_FinanceLeaseObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="us-gaap_TransferredAtPointInTimeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RoyaltiesRevenueFromRelatedPartyMember" xlink:label="fnch_RoyaltiesRevenueFromRelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLeaseObligationsAbstract" xlink:label="fnch_OperatingLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeasesBalanceSheetInformationTableTextBlock" xlink:label="fnch_LeasesBalanceSheetInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LesseeOperatingLeaseLeasesAdditionalArea" xlink:label="fnch_LesseeOperatingLeaseLeasesAdditionalArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseAndRentForAdditionalSpace" xlink:label="fnch_LeaseAndRentForAdditionalSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaycheckProtectionProgramCARESMember" xlink:label="fnch_PaycheckProtectionProgramCARESMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsExpirationYear" xlink:label="fnch_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ClinicalSupplyAndServicesAgreementMember" xlink:label="fnch_ClinicalSupplyAndServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseLiabilities" xlink:label="fnch_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" xlink:label="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkDriveMember" xlink:label="fnch_HoodParkDriveMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_NotesMember" xlink:label="fnch_NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MilestonePaymentsReceivedUnderAgreement" xlink:label="fnch_MilestonePaymentsReceivedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TransfersBetweenFairValueLevels" xlink:label="fnch_TransfersBetweenFairValueLevels"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ComputerEquipmentAndSoftwareMember" xlink:label="fnch_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="us-gaap_TransferredOverTimeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" xlink:label="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPurchasePrice" xlink:label="fnch_RedeemableConvertiblePreferredStockPurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAndLicenseAgreementMember" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MilestonePaymentsPaid" xlink:label="fnch_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:label="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecondarySaleMember" xlink:label="fnch_SecondarySaleMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:label="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UnamortizationOfLeaseIncentives" xlink:label="fnch_UnamortizationOfLeaseIncentives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InnerBeltRoadLeaseMember" xlink:label="fnch_InnerBeltRoadLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquipmentOnLease" xlink:label="us-gaap_PaymentsToAcquireEquipmentOnLease"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfFutureLeasePaymentsTableTextBlock" xlink:label="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfOfferingCosts" xlink:label="fnch_PaymentOfOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DebtInstrumentForgivenDescription" xlink:label="fnch_DebtInstrumentForgivenDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" xlink:label="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RemainingRoyaltyCommitmentAmountDue" xlink:label="fnch_RemainingRoyaltyCommitmentAmountDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RightOfUseLiabilities" xlink:label="fnch_RightOfUseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" xlink:label="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock" xlink:label="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" xlink:label="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LabEquipmentMember" xlink:label="fnch_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseTermAndDiscountRateTableTextBlock" xlink:label="fnch_LeaseTermAndDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StrategicAgreementMember" xlink:label="fnch_StrategicAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PrincipalPaymentsOnCapitalLeaseObligation" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfMonthlyPlatformFee" xlink:label="fnch_PaymentOfMonthlyPlatformFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InProcessResearchAndDevelopment" xlink:label="fnch_InProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" xlink:label="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OptionsToPurchaseCommonStockMember" xlink:label="fnch_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromIssuanceOfCommonStockGross" xlink:label="fnch_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SalesBasedMilestonePayments" xlink:label="fnch_SalesBasedMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DerecognitionOfDeferredRentLiabilities" xlink:label="fnch_DerecognitionOfDeferredRentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" xlink:label="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercisedGross" xlink:label="fnch_CommonStockWarrantsExercisedGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" xlink:label="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDue" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="fnch_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AdditionalRoyaltyCommitmentsAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional royalty commitments amount due.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AdditionalRoyaltyCommitmentsAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Royalty Commitments Amount Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AdditionalRoyaltyCommitmentsAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional royalty amount due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major Property Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Property Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rental charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Insured or Guaranteed by Government Authorities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING EXPENSES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RelatedPartyTransactionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction, term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RelatedPartyTransactionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RelatedPartyTransactionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REDEEMABLE CONVERTIBLE PREFERRED STOCK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares available for future grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 and 598,232,153 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 47,512,182 and 8,391,793 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Disaggregation of Revenue by Timing of Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of series D redeemable convertible preferred stock net of issuance costs of $96 share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of series c redeemable convertible preferred stock net of issuance costs shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Series C Redeemable Convertible Preferred Stock Net Of Issuance Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Under Non-Cancellable Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MAL Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Material access and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Material Access And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material Access And License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Shares Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issued from conversion of note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments Due Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common stock outstanding&#8212;basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due in five years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company's contribution to plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursed from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments interest included in payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series C</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LMICLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LMIC License Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LMICLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">L M I C License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LMICLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LMIC Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used to Value Stock Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due in three years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUE:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE EXERCISE PRICE, Cancelled or forfeited | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due from Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Diluted Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of series d redeemable convertible preferred stock net of issuance costs shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Series D Redeemable Convertible Preferred Stock Net Of Issuance Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of series D redeemable convertible preferred stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Present Value of Future Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Present value of future minimum lease payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock issued during period, shares | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliated Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OpenBiomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">OpenBiome.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OpenBiomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Biome [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OpenBiomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open Biome</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock upon initial public offering, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary Equity, Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConcordAvenueLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concord Avenue Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConcordAvenueLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concord Avenue Lease Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConcordAvenueLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concord Avenue Lease Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConcordStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concord street lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConcordStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concord Street Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConcordStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concord Street Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TakedaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TakedaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TakedaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CrestovoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Crestovo.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CrestovoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Crestovo [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CrestovoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Crestovo</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-Based Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders&#8212; basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from underwriters exercise of overallotment option net of underwriting discounts and commissions and initial public offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from underwriters' exercise of overallotment option, net of underwriting discounts and commissions and initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsForUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsForUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsForUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Portion of Operating Leases Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest portion of operating leases future minimum payments due.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders - basic and diluted (Note 15)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluding from computation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedInterestBorrowed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest borrowed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedInterestBorrowed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Borrowed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedInterestBorrowed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest borrowed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Other Payables [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Held Under Capital Leases [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing Of Transfer Of Good Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Timing of Transfer of Good or Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessor Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Purchases From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood Lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hood Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SecurityDepositsReturned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Security deposits returned.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SecurityDepositsReturned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposits Returned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SecurityDepositsReturned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit returned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursed to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number shares issued upon conversion of redeemable convertible preferred stock | shares | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COMMON STOCK ISSUABLE UPON CONVERSION</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock upon initial public offering, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPostSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPostSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Post Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPostSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, post split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, face amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RemainingStockCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining stock compensation expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RemainingStockCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Stock Compensation Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RemainingStockCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions of current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, vesting of restricted stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Vesting Of Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">state [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beginning balance, Share at January 1, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid in connection with operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments, Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedInterestOnConvertiblePromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest on convertible promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedInterestOnConvertiblePromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Convertible Promissory Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedInterestOnConvertiblePromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest on convertible promissory notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CapitalLeaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Lease Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CapitalLeaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital Lease Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization, consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RoyaltyPaymentsPaidOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payments paid on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RoyaltyPaymentsPaidOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payments Paid On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RoyaltyPaymentsPaidOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Tax Credits Research Expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Credits, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LesseeOperatingLeaseLeasesArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and laboratory space for lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LesseeOperatingLeaseLeasesArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Leases Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LesseeOperatingLeaseLeasesArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Leases Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CherryStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cherry street lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CherryStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cherry Street Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CherryStreetLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cherry Street Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Non-vested ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Non-vested beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments To Acquire Property And Equipment Purchases From Related Party, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire property and equipment, purchases from related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property And Equipment Purchases From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGGREGATE INTRINSIC VALUE, Options vested or expected to vest | $</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased for cashless exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due in four years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ForgivenessOfPaycheckProtectionProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forgiveness of paycheck protection program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ForgivenessOfPaycheckProtectionProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forgiveness Of Paycheck Protection Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ForgivenessOfPaycheckProtectionProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forgiveness of PPP Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">SHARES, Cancelled or forfeited | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Seventeen And Two Thousand Twenty One Equity Incentive Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen And Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen and two thousand twenty one equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Expenses, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, total fixed assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' exercise of overallotment option, net of underwriting discounts, commissions and initial public offering costs of $276, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Ending Balance | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Beginning Balance | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments present value of net minimum payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumMilestonePaymentRequiredUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment required under agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumMilestonePaymentRequiredUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment Required Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumMilestonePaymentRequiredUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required to pay certain milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate, Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ordinary shares at a price per share equal to the fair market value on offering date or purchase date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Share Price Equal To Fair Value Price On Offering Date Or Purchase Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ordinary shares at a price per share equal to the fair market value on offering date or purchase date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">SHARES, Outstanding, Ending Balance | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">SHARES, Outstanding, Beginning Balance | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Lease Payments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Future Minimum Lease Payments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate, Finance leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance | $</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance | $</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate And Accumulated Depreciation Name Of Property [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carry Forwards Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock warrants exercised net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in shares of common stock reserved for issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Shares Of Common Stock Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in shares of common stock reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (loss) on disposal of fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on sale of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from paycheck protection program loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Paycheck Protection Program Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from PPP Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum regulatory milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Regulatory Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforward percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit and tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets obtained in exchange for new operating leases upon adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Right-Of-Use Assets Obtained in Exchange for New Operating Leases Upon Adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Right-Of-Use Assets Obtained in Exchange for New Operating Leases Upon Adoption of ASC 842.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of redeemable convertible preferred stock into common stock upon initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_FinanceLeaseObligationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Obligation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_FinanceLeaseObligationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MajorPropertyClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major Property Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MajorPropertyClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Property Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHARES, Options vested or expected to vest | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransferredAtPointInTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transferred At Point In Time [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransferredAtPointInTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred at a Point in Time</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments, Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due in four years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RoyaltiesRevenueFromRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Revenue From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RoyaltiesRevenueFromRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties Revenue From Related Party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RoyaltiesRevenueFromRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Revenue From Related Party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments, Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due in three years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OverAllotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Excluding Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of series d redeemable convertible preferred stock net of issuance costs value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Series D Redeemable Convertible Preferred Stock Net Of Issuance Costs Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of series D redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeasesBalanceSheetInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases Balance Sheet Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeasesBalanceSheetInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases Balance Sheet Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeasesBalanceSheetInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases balance sheet information table text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issuable upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Issued1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LesseeOperatingLeaseLeasesAdditionalArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Space for primary office and laboratory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LesseeOperatingLeaseLeasesAdditionalArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Leases Additional Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LesseeOperatingLeaseLeasesAdditionalArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Leases Additional Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Other Productive Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to acquire remaining assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due from Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due From Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Due from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE EXERCISE PRICE, Granted | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of series D redeemable convertible preferred stock, net of issuance costs of $96</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of series c redeemable convertible preferred stock net of issuance costs value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Series C Redeemable Convertible Preferred Stock Net Of Issuance Costs Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary equity, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE EXERCISE PRICE, Expired | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sublease agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAndRentForAdditionalSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent for additional space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAndRentForAdditionalSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rent For Additional Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseAndRentForAdditionalSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease And Rent For Additional Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-cash operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Cost and Expense, Operating</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Cost and Expense, Operating, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capital Leased Asssets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capital Leased Asssets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaycheckProtectionProgramCARESMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaycheckProtectionProgramCARESMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program C A R E S [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaycheckProtectionProgramCARESMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck Protection Program, CARES Act.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration year of each operating loss carryforward included in operating loss carryforward.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ClinicalSupplyAndServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Supply and Services Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ClinicalSupplyAndServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Supply And Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ClinicalSupplyAndServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Supply and Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Loan Originations1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gains (losses) on extinguishment of debt includes accrued interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt Includes Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on extinguishment of PPP Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments, Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due in five years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment associated with development and commercialization upon milestone to be achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment Associated With Development And Commercialization Upon Milestone To Be Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment associated with development and commercialization upon milestone to be achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due in two years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkDriveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">100 Hood Park Drive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkDriveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Drive Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkDriveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood Park Drive Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Sublease Rentals1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Rent income under sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHARES, Options exercisable | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested (per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Observable Inputs (Level 2)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Income Tax Contingencies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Total Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software, Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">SHARES, Exercised | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MilestonePaymentsReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments received under agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MilestonePaymentsReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MilestonePaymentsReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TransfersBetweenFairValueLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfers between fair value levels.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TransfersBetweenFairValueLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfers Between Fair Value Levels</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TransfersBetweenFairValueLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers between fair value levels</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Insured or Guaranteed by Government Authorities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Observevable Inputs (Level 3)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization, consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments present value of net minimum payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments interest included in payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIQUIDATION VALUE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHARES, Granted | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining revenue performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransferredOverTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transferred Over Time [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransferredOverTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred over Time</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued penalties and interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits penalties and interest accrued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock purchase price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Total Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment and Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase And License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase and license Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE EXERCISE PRICE, Options exercisable | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating and Finance Lease Obligation, Future Minimum Payments, Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease obligation future minimum payments due in two years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercise of common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, vesting of restricted stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vesting Of Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SecondarySaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SecondarySaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secondary Sale [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SecondarySaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Secondary sale member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' exercise of overallotment option, net of underwriting discounts, commissions and initial public offering costs of $276</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital stock issued issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing Of Transfer Of Good Or Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Timing of Transfer of Good or Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UnamortizationOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortization of lease incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UnamortizationOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortization Of Lease Incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_UnamortizationOfLeaseIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unamortization of lease incentives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction Work-In-Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InnerBeltRoadLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inner belt road lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InnerBeltRoadLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inner Belt Road Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InnerBeltRoadLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inner Belt Road Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective income tax rate reconciliation, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issuable upon the exercise of outstanding options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Including Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquipmentOnLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire equipment on lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquipmentOnLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Equipment On Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Lease Payments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of future lease payments table text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on extinguishment of PPP Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term, Financing leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense remaining to be recognized, period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DebtInstrumentForgivenDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument forgiven description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DebtInstrumentForgivenDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Forgiven Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DebtInstrumentForgivenDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument forgiven, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred initial public offering coasts in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Initial Public Offering Costs In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred initial public offering costs in AP and accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common stock to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE EXERCISE PRICE, Options vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term, Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RemainingRoyaltyCommitmentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining royalty commitment amount due.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RemainingRoyaltyCommitmentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Royalty Commitment Amount Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RemainingRoyaltyCommitmentAmountDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining royalty amount due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RightOfUseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RightOfUseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_RightOfUseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of use liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of common shares reserved for potential conversion of outstanding preferred stock, vesting of restricted stock and exercise of stock options and common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Common Shares Reserved For Potential Conversion Of Outstanding Preferred Stock Vesting Of Restricted Stock And Exercise Of Stock Options And Common Stock Warrants Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred initial public offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Initial Public Offering Costs Policy Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Initial Public Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal and professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">SHARES, Expired | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate And Accumulated Depreciation Description Of Property [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Non-vested ending balance (per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Non-vested beginning balance (per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beginning Balance, Share at January 1, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock outstanding | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance , Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards prior period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Prior To Two Thousand Eighteen</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carry forwards Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Remaining Lease Term and Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_LeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term and discount rate table text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StrategicAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StrategicAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_StrategicAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows from finance leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on finance lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Principal payments on capital lease obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Payments On Capital Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Security Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, liquidation preference per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends declared or paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfMonthlyPlatformFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of monthly platform fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfMonthlyPlatformFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Monthly Platform Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfMonthlyPlatformFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of monthly platform fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Goodwill and Intangible Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In-process research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_InProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property and equipment estimated useful lives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property And Equipment Estimated Useful Lives Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax, accruals for interest or penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of redeemable convertible preferred stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Redeemable Convertible Preferred Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of Series D redeemable convertible preferred stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes at 21%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY (DEFICIT):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deferred Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE EXERCISE PRICE, Exercised | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Royalties Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock, gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock for potential conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock selling price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-based milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DerecognitionOfDeferredRentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of deferred rent liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DerecognitionOfDeferredRentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition of Deferred Rent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_DerecognitionOfDeferredRentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of deferred rent liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in due to related parties current excluding acccounts payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due To Related Parties Current Excluding Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER INCOME, NET:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to acquire certain assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary Equity, Conversion of redeemable convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of redeemable convertible preferred stock into common stock upon initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense remaining to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercisedGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants exercised gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercisedGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Exercised Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_CommonStockWarrantsExercisedGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants exercised gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of series D convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Series D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series D convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGGREGATE INTRINSIC VALUE, Options exercisable | $</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hood Park Lease, Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hood park lease future minimum payments due.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda Pharmaceutical Company Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fnch_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda Pharmaceutical Company Limited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions of prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds after deducting underwriting discounts, commissions and offering costs | $</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AdditionalRoyaltyCommitmentsAmountDue" xlink:to="fnch_AdditionalRoyaltyCommitmentsAmountDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasedAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="fnch_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RelatedPartyTransactionTerm" xlink:to="fnch_RelatedPartyTransactionTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:to="fnch_SeriesB1RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:to="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_MaterialAccessAndLicenseAgreementMember" xlink:to="fnch_MaterialAccessAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LMICLicenseAgreementMember" xlink:to="fnch_LMICLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:to="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:to="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PresentValueOfFutureMinimumLeasePayments" xlink:to="fnch_PresentValueOfFutureMinimumLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_GrossProceedsFromIssuanceOfCommonStock" xlink:to="fnch_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_InitialPublicOfferingCosts" xlink:to="fnch_InitialPublicOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OpenBiomeMember" xlink:to="fnch_OpenBiomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TemporaryEquityIssuanceCosts" xlink:to="fnch_TemporaryEquityIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:to="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ConcordAvenueLeaseMember" xlink:to="fnch_ConcordAvenueLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ConcordStreetLeaseMember" xlink:to="fnch_ConcordStreetLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TakedaAgreementMember" xlink:to="fnch_TakedaAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CrestovoMember" xlink:to="fnch_CrestovoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AssetPurchaseAgreementMember" xlink:to="fnch_AssetPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="fnch_TwoThousandSeventeenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" xlink:to="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PaymentsForUnderwritingDiscountsAndCommissions" xlink:to="fnch_PaymentsForUnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" xlink:to="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_UpfrontPaymentReceived" xlink:to="fnch_UpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AccruedInterestBorrowed" xlink:to="fnch_AccruedInterestBorrowed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodLeaseMember" xlink:to="fnch_HoodLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SecurityDepositsReturned" xlink:to="fnch_SecurityDepositsReturned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RedeemableConvertiblePreferredStockPostSplit" xlink:to="fnch_RedeemableConvertiblePreferredStockPostSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RemainingStockCompensationExpenses" xlink:to="fnch_RemainingStockCompensationExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" xlink:to="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_UndesignatedPreferredStockMember" xlink:to="fnch_UndesignatedPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AccruedInterestOnConvertiblePromissoryNotes" xlink:to="fnch_AccruedInterestOnConvertiblePromissoryNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fnch_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CapitalLeaseArrangementMember" xlink:to="fnch_CapitalLeaseArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RoyaltyPaymentsPaidOnNetSales" xlink:to="fnch_RoyaltyPaymentsPaidOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" xlink:to="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LesseeOperatingLeaseLeasesArea" xlink:to="fnch_LesseeOperatingLeaseLeasesArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CherryStreetLeaseMember" xlink:to="fnch_CherryStreetLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RightOfUseAsset" xlink:to="fnch_RightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" xlink:to="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ForgivenessOfPaycheckProtectionProgram" xlink:to="fnch_ForgivenessOfPaycheckProtectionProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RelatedPartyMember" xlink:to="fnch_RelatedPartyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_DeferredTaxLiabilitiesFixedAssets" xlink:to="fnch_DeferredTaxLiabilitiesFixedAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_MaximumMilestonePaymentRequiredUnderAgreement" xlink:to="fnch_MaximumMilestonePaymentRequiredUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" xlink:to="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:to="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CollaborationRevenueMember" xlink:to="fnch_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AccruedResearchAndDevelopment" xlink:to="fnch_AccruedResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingLossCarryForwardsExpirationPeriod" xlink:to="fnch_OperatingLossCarryForwardsExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CommonStockWarrantsExercised" xlink:to="fnch_CommonStockWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_IncentiveStockOptionsMember" xlink:to="fnch_IncentiveStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" xlink:to="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CommonStockWarrantsMember" xlink:to="fnch_CommonStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ProceedsFromPaycheckProtectionProgramLoan" xlink:to="fnch_ProceedsFromPaycheckProtectionProgramLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_MaximumRegulatoryMilestonePayments" xlink:to="fnch_MaximumRegulatoryMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" xlink:to="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LeaseAssets" xlink:to="fnch_LeaseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:to="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="fnch_FinanceLeaseObligationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_MajorPropertyClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferredAtPointInTimeMember" xlink:to="us-gaap_TransferredAtPointInTimeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RoyaltiesRevenueFromRelatedPartyMember" xlink:to="fnch_RoyaltiesRevenueFromRelatedPartyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:to="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="fnch_OperatingLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LeasesBalanceSheetInformationTableTextBlock" xlink:to="fnch_LeasesBalanceSheetInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LesseeOperatingLeaseLeasesAdditionalArea" xlink:to="fnch_LesseeOperatingLeaseLeasesAdditionalArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:to="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LeaseAndRentForAdditionalSpace" xlink:to="fnch_LeaseAndRentForAdditionalSpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PaycheckProtectionProgramCARESMember" xlink:to="fnch_PaycheckProtectionProgramCARESMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingLossCarryForwardsExpirationYear" xlink:to="fnch_OperatingLossCarryForwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ClinicalSupplyAndServicesAgreementMember" xlink:to="fnch_ClinicalSupplyAndServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LeaseLiabilities" xlink:to="fnch_LeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" xlink:to="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" xlink:to="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkDriveMember" xlink:to="fnch_HoodParkDriveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_NotesMember" xlink:to="fnch_NotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_MilestonePaymentsReceivedUnderAgreement" xlink:to="fnch_MilestonePaymentsReceivedUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TransfersBetweenFairValueLevels" xlink:to="fnch_TransfersBetweenFairValueLevels_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ComputerEquipmentAndSoftwareMember" xlink:to="fnch_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferredOverTimeMember" xlink:to="us-gaap_TransferredOverTimeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" xlink:to="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RedeemableConvertiblePreferredStockPurchasePrice" xlink:to="fnch_RedeemableConvertiblePreferredStockPurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AssetPurchaseAndLicenseAgreementMember" xlink:to="fnch_AssetPurchaseAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_MilestonePaymentsPaid" xlink:to="fnch_MilestonePaymentsPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:to="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:to="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SecondarySaleMember" xlink:to="fnch_SecondarySaleMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:to="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="fnch_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_UnamortizationOfLeaseIncentives" xlink:to="fnch_UnamortizationOfLeaseIncentives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_InnerBeltRoadLeaseMember" xlink:to="fnch_InnerBeltRoadLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquipmentOnLease" xlink:to="us-gaap_PaymentsToAcquireEquipmentOnLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock" xlink:to="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PaymentOfOfferingCosts" xlink:to="fnch_PaymentOfOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_DebtInstrumentForgivenDescription" xlink:to="fnch_DebtInstrumentForgivenDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" xlink:to="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RemainingRoyaltyCommitmentAmountDue" xlink:to="fnch_RemainingRoyaltyCommitmentAmountDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_RightOfUseLiabilities" xlink:to="fnch_RightOfUseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" xlink:to="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock" xlink:to="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" xlink:to="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LabEquipmentMember" xlink:to="fnch_LabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_LeaseTermAndDiscountRateTableTextBlock" xlink:to="fnch_LeaseTermAndDiscountRateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_StrategicAgreementMember" xlink:to="fnch_StrategicAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PrincipalPaymentsOnCapitalLeaseObligation" xlink:to="fnch_PrincipalPaymentsOnCapitalLeaseObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PaymentOfMonthlyPlatformFee" xlink:to="fnch_PaymentOfMonthlyPlatformFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_InProcessResearchAndDevelopment" xlink:to="fnch_InProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" xlink:to="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_OptionsToPurchaseCommonStockMember" xlink:to="fnch_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ProceedsFromIssuanceOfCommonStockGross" xlink:to="fnch_ProceedsFromIssuanceOfCommonStockGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SalesBasedMilestonePayments" xlink:to="fnch_SalesBasedMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_DerecognitionOfDeferredRentLiabilities" xlink:to="fnch_DerecognitionOfDeferredRentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" xlink:to="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireSoftware" xlink:to="us-gaap_PaymentsToAcquireSoftware_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:to="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="fnch_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_CommonStockWarrantsExercisedGross" xlink:to="fnch_CommonStockWarrantsExercisedGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" xlink:to="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_HoodParkLeaseFutureMinimumPaymentsDue" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fnch_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="fnch_TakedaPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>38
<FILENAME>fnch-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T16:48:41.4542+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="fnch-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="fnch-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="fnch-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="fnch-20211231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperations" xlink:href="fnch-20211231.xsd#Role_DisclosureNatureOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="fnch-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1" xlink:href="fnch-20211231.xsd#DisclosureLeases1" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="fnch-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenue" xlink:href="fnch-20211231.xsd#Role_DisclosureRevenue" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="fnch-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:href="fnch-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholderSEquity" xlink:href="fnch-20211231.xsd#Role_DisclosureStockholderSEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="fnch-20211231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="fnch-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:href="fnch-20211231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" xlink:href="fnch-20211231.xsd#Role_DisclosureLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="fnch-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="fnch-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables" xlink:href="fnch-20211231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="fnch-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="fnch-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" xlink:href="fnch-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="fnch-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="fnch-20211231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" xlink:href="fnch-20211231.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesLeasesBalanceSheetInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="fnch-20211231.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails" xlink:href="fnch-20211231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf" xlink:href="fnch-20211231.xsd#DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1" xlink:href="fnch-20211231.xsd#DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" xlink:href="fnch-20211231.xsd#DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails" xlink:href="fnch-20211231.xsd#DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fnch-20211231.xsd#Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InProcessResearchAndDevelopment" xlink:label="fnch_InProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="fnch_AccruedExpensesAndOtherCurrentLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="fnch_InProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" xlink:label="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CollaborationRevenueMember" xlink:label="fnch_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RoyaltiesRevenueFromRelatedPartyMember" xlink:label="fnch_RoyaltiesRevenueFromRelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fnch_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fnch_RoyaltiesRevenueFromRelatedPartyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:label="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:label="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" xlink:label="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:label="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" xlink:label="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:label="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" xlink:label="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercised" xlink:label="fnch_CommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_24"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_25"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_27"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_CommonStockWarrantsExercised" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InitialPublicOfferingCosts" xlink:label="fnch_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fnch_InitialPublicOfferingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" xlink:label="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" xlink:label="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" xlink:label="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" xlink:label="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ForgivenessOfPaycheckProtectionProgram" xlink:label="fnch_ForgivenessOfPaycheckProtectionProgram"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" xlink:label="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" xlink:label="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PrincipalPaymentsOnCapitalLeaseObligation" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" xlink:label="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="fnch_ProceedsFromPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fnch_ForgivenessOfPaycheckProtectionProgram" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fnch_PrincipalPaymentsOnCapitalLeaseObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fnch_ProceedsFromPaycheckProtectionProgramLoan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholderSEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock" xlink:label="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fnch_RedeemableConvertiblePreferredStockPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeasesBalanceSheetInformationTableTextBlock" xlink:label="fnch_LeasesBalanceSheetInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseTermAndDiscountRateTableTextBlock" xlink:label="fnch_LeaseTermAndDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfFutureLeasePaymentsTableTextBlock" xlink:label="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:label="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_LeasesBalanceSheetInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_LeaseTermAndDiscountRateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_ScheduleOfFutureLeasePaymentsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" xlink:label="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ProceedsFromIssuanceOfCommonStockGross" xlink:label="fnch_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentsForUnderwritingDiscountsAndCommissions" xlink:label="fnch_PaymentsForUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfOfferingCosts" xlink:label="fnch_PaymentOfOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_ProceedsFromIssuanceOfCommonStockGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_PaymentsForUnderwritingDiscountsAndCommissions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="fnch_PaymentOfOfferingCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:label="fnch_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DerecognitionOfDeferredRentLiabilities" xlink:label="fnch_DerecognitionOfDeferredRentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UnamortizationOfLeaseIncentives" xlink:label="fnch_UnamortizationOfLeaseIncentives"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fnch_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesTable" xlink:to="fnch_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fnch_DerecognitionOfDeferredRentLiabilities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fnch_UnamortizationOfLeaseIncentives" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ComputerEquipmentAndSoftwareMember" xlink:label="fnch_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fnch_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="us-gaap_TransferredAtPointInTimeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TransferredAtPointInTimeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TransferredOverTimeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TransfersBetweenFairValueLevels" xlink:label="fnch_TransfersBetweenFairValueLevels"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="fnch_TransfersBetweenFairValueLevels" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LabEquipmentMember" xlink:label="fnch_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fnch_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RelatedPartyMember" xlink:label="fnch_RelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_OpenBiomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InnerBeltRoadLeaseMember" xlink:label="fnch_InnerBeltRoadLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CapitalLeaseArrangementMember" xlink:label="fnch_CapitalLeaseArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="us-gaap_MajorPropertyClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="us-gaap_MajorPropertyClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="us-gaap_CapitalLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquipmentOnLease" xlink:label="us-gaap_PaymentsToAcquireEquipmentOnLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CherryStreetLeaseMember" xlink:label="fnch_CherryStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LesseeOperatingLeaseLeasesArea" xlink:label="fnch_LesseeOperatingLeaseLeasesArea"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConcordAvenueLeaseMember" xlink:label="fnch_ConcordAvenueLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_4"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkDriveMember" xlink:label="fnch_HoodParkDriveMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LesseeOperatingLeaseLeasesAdditionalArea" xlink:label="fnch_LesseeOperatingLeaseLeasesAdditionalArea"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseAndRentForAdditionalSpace" xlink:label="fnch_LeaseAndRentForAdditionalSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_InnerBeltRoadLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_CapitalLeaseArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquipmentOnLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_OpenBiomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_CherryStreetLeaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="fnch_LesseeOperatingLeaseLeasesArea" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_ConcordAvenueLeaseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_CapitalLeasedAssetsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_HoodParkDriveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="fnch_LesseeOperatingLeaseLeasesAdditionalArea" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="fnch_LeaseAndRentForAdditionalSpace" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_SubleaseIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_TenantImprovements" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseAssets" xlink:label="fnch_LeaseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LeaseLiabilities" xlink:label="fnch_LeaseLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_LiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_LeaseAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_LeaseLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PrincipalPaymentsOnCapitalLeaseObligation" xlink:label="fnch_PrincipalPaymentsOnCapitalLeaseObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_PrincipalPaymentsOnCapitalLeaseObligation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLeaseObligationsAbstract" xlink:label="fnch_OperatingLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseObligationsAbstract" xlink:label="fnch_HoodParkLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_FinanceLeaseObligationAbstract" xlink:label="fnch_FinanceLeaseObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsDue" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" xlink:label="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PresentValueOfFutureMinimumLeasePayments" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="fnch_PresentValueOfFutureMinimumLeasePayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_HoodParkLeaseObligationsAbstract" xlink:to="fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingLeaseObligationsAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_HoodParkLeaseObligationsAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_FinanceLeaseObligationAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLeaseObligationsAbstract" xlink:label="fnch_OperatingLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_FinanceLeaseObligationAbstract" xlink:label="fnch_FinanceLeaseObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" xlink:label="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PresentValueOfFutureMinimumLeasePayments" xlink:label="fnch_PresentValueOfFutureMinimumLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_FinanceLeaseObligationAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fnch_OperatingLeaseObligationsAbstract" xlink:to="fnch_PresentValueOfFutureMinimumLeasePayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_OperatingLeaseObligationsAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fnch_FinanceLeaseObligationAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedResearchAndDevelopment" xlink:label="fnch_AccruedResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="fnch_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fnch_AccruedResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fnch_AccruedExpensesAndOtherCurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TakedaAgreementMember" xlink:label="fnch_TakedaAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UpfrontPaymentReceived" xlink:label="fnch_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="fnch_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CollaborationRevenueMember" xlink:label="fnch_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAndLicenseAgreementMember" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_LMICLicenseAgreementMember" xlink:label="fnch_LMICLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" xlink:label="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MilestonePaymentsReceivedUnderAgreement" xlink:label="fnch_MilestonePaymentsReceivedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_TakedaAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fnch_UpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fnch_TakedaPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fnch_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fnch_OpenBiomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_AssetPurchaseAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_LMICLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fnch_MilestonePaymentsReceivedUnderAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RightOfUseLiabilities" xlink:label="fnch_RightOfUseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DeferredTaxLiabilitiesFixedAssets" xlink:label="fnch_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RightOfUseAsset" xlink:label="fnch_RightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fnch_RightOfUseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fnch_DeferredTaxLiabilitiesFixedAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fnch_RightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsExpirationYear" xlink:label="fnch_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" xlink:label="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OperatingLossCarryForwardsExpirationPeriod" xlink:label="fnch_OperatingLossCarryForwardsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" xlink:label="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_OperatingLossCarryForwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_OperatingLossCarryForwardsExpirationPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" xlink:label="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAndLicenseAgreementMember" xlink:label="fnch_AssetPurchaseAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumRegulatoryMilestonePayments" xlink:label="fnch_MaximumRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaycheckProtectionProgramCARESMember" xlink:label="fnch_PaycheckProtectionProgramCARESMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_InnerBeltRoadLeaseMember" xlink:label="fnch_InnerBeltRoadLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaterialAccessAndLicenseAgreementMember" xlink:label="fnch_MaterialAccessAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SalesBasedMilestonePayments" xlink:label="fnch_SalesBasedMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CherryStreetLeaseMember" xlink:label="fnch_CherryStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MilestonePaymentsPaid" xlink:label="fnch_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ConcordStreetLeaseMember" xlink:label="fnch_ConcordStreetLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RoyaltyPaymentsPaidOnNetSales" xlink:label="fnch_RoyaltyPaymentsPaidOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_HoodLeaseMember" xlink:label="fnch_HoodLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RemainingRoyaltyCommitmentAmountDue" xlink:label="fnch_RemainingRoyaltyCommitmentAmountDue"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AdditionalRoyaltyCommitmentsAmountDue" xlink:label="fnch_AdditionalRoyaltyCommitmentsAmountDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedInterestBorrowed" xlink:label="fnch_AccruedInterestBorrowed"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_DebtInstrumentForgivenDescription" xlink:label="fnch_DebtInstrumentForgivenDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_OpenBiomeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_AssetPurchaseAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_MaximumRegulatoryMilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:to="fnch_PaycheckProtectionProgramCARESMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_InnerBeltRoadLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_MaterialAccessAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_SalesBasedMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_CherryStreetLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_MilestonePaymentsPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_ConcordStreetLeaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_RoyaltyPaymentsPaidOnNetSales" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="fnch_HoodLeaseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_RemainingRoyaltyCommitmentAmountDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_AdditionalRoyaltyCommitmentsAmountDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LossContingenciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_AccruedInterestBorrowed" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="fnch_DebtInstrumentForgivenDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CrestovoMember" xlink:label="fnch_CrestovoMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_NotesMember" xlink:label="fnch_NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesB1RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPurchasePrice" xlink:label="fnch_RedeemableConvertiblePreferredStockPurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RedeemableConvertiblePreferredStockPostSplit" xlink:label="fnch_RedeemableConvertiblePreferredStockPostSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AccruedInterestOnConvertiblePromissoryNotes" xlink:label="fnch_AccruedInterestOnConvertiblePromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TemporaryEquityIssuanceCosts" xlink:label="fnch_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_13"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_19"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="fnch_CrestovoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fnch_NotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesB1RedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_RedeemableConvertiblePreferredStockPurchasePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_RedeemableConvertiblePreferredStockPostSplit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_AccruedInterestOnConvertiblePromissoryNotes" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_TemporaryEquityIssuanceCosts" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="fnch_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fnch_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecondarySaleMember" xlink:label="fnch_SecondarySaleMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_UndesignatedPreferredStockMember" xlink:label="fnch_UndesignatedPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_GrossProceedsFromIssuanceOfCommonStock" xlink:label="fnch_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fnch_SecondarySaleMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="fnch_UndesignatedPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_GrossProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OptionsToPurchaseCommonStockMember" xlink:label="fnch_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsMember" xlink:label="fnch_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fnch_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fnch_CommonStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercisedGross" xlink:label="fnch_CommonStockWarrantsExercisedGross"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_CommonStockWarrantsExercised" xlink:label="fnch_CommonStockWarrantsExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_CommonStockWarrantsExercisedGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fnch_CommonStockWarrantsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecondarySaleMember" xlink:label="fnch_SecondarySaleMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="fnch_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_IncentiveStockOptionsMember" xlink:label="fnch_IncentiveStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" xlink:label="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" xlink:label="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RemainingStockCompensationExpenses" xlink:label="fnch_RemainingStockCompensationExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fnch_SecondarySaleMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandSeventeenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fnch_IncentiveStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fnch_RemainingStockCompensationExpenses" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="fnch_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fnch_TwoThousandTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_StrategicAgreementMember" xlink:label="fnch_StrategicAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_OpenBiomeMember" xlink:label="fnch_OpenBiomeMember_0"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_ClinicalSupplyAndServicesAgreementMember" xlink:label="fnch_ClinicalSupplyAndServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_AssetPurchaseAgreementMember" xlink:label="fnch_AssetPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_RelatedPartyTransactionTerm" xlink:label="fnch_RelatedPartyTransactionTerm"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_PaymentOfMonthlyPlatformFee" xlink:label="fnch_PaymentOfMonthlyPlatformFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_SecurityDepositsReturned" xlink:label="fnch_SecurityDepositsReturned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:loc xlink:type="locator" xlink:href="fnch-20211231.xsd#fnch_MaximumMilestonePaymentRequiredUnderAgreement" xlink:label="fnch_MaximumMilestonePaymentRequiredUnderAgreement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_StrategicAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fnch_OpenBiomeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fnch_OpenBiomeMember_0" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_ClinicalSupplyAndServicesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fnch_AssetPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_RelatedPartyTransactionTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_PaymentOfMonthlyPlatformFee" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SecurityDeposit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_SecurityDepositsReturned" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireSoftware" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fnch_MaximumMilestonePaymentRequiredUnderAgreement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307673848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001733257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text"> 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FINCH THERAPEUTICS GROUP, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3433558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Inner Belt Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Somerville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">229-6499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FNCH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,532,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant&#8217;s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255304427224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 133,481<span></span>
</td>
<td class="nump">$ 99,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,576<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">142,551<span></span>
</td>
<td class="nump">106,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">19,635<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">32,900<span></span>
</td>
<td class="nump">32,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">18,057<span></span>
</td>
<td class="nump">18,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Deferred initial public offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">2,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,905<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">225,369<span></span>
</td>
<td class="nump">165,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,925<span></span>
</td>
<td class="nump">5,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,790<span></span>
</td>
<td class="nump">11,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,461<span></span>
</td>
<td class="nump">3,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Loan payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,145<span></span>
</td>
<td class="nump">28,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 and 598,232,153 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 47,512,182 and 8,391,793 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">363,172<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(160,995)<span></span>
</td>
<td class="num">(102,835)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">202,224<span></span>
</td>
<td class="num">(95,718)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">225,369<span></span>
</td>
<td class="nump">165,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 89,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306954344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,427,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">598,232,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">47,512,182<span></span>
</td>
<td class="nump">8,391,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">47,512,182<span></span>
</td>
<td class="nump">8,391,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,496,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74,620,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,604,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,705,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255304315816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 18,532<span></span>
</td>
<td class="nump">$ 7,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(57,279)<span></span>
</td>
<td class="num">(33,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(21,238)<span></span>
</td>
<td class="num">(14,011)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(78,517)<span></span>
</td>
<td class="num">(47,155)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss from operations</a></td>
<td class="num">(59,985)<span></span>
</td>
<td class="num">(39,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest', window );">Gain on extinguishment of PPP Loan</a></td>
<td class="nump">1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on disposal of fixed assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(58,160)<span></span>
</td>
<td class="num">(39,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,160)<span></span>
</td>
<td class="num">(39,341)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - basic and diluted (Note 15)</a></td>
<td class="num">$ (58,160)<span></span>
</td>
<td class="num">$ (39,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (4.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common stock outstanding&#8212;basic and diluted</a></td>
<td class="nump">39,202,086<span></span>
</td>
<td class="nump">8,144,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fnch_CollaborationRevenueMember', window );">Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 18,532<span></span>
</td>
<td class="nump">$ 7,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fnch_RoyaltiesRevenueFromRelatedPartyMember', window );">Royalty Revenue From Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (losses) on extinguishment of debt includes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fnch_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fnch_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fnch_RoyaltiesRevenueFromRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fnch_RoyaltiesRevenueFromRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306320456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series D Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="num">$ (59,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 3,951<span></span>
</td>
<td class="num">$ (63,494)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,593<span></span>
</td>
<td class="nump">$ 36,336<span></span>
</td>
<td class="nump">$ 53,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,778,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue', window );">Issuance of series D redeemable convertible preferred stock, net of issuance costs of $96</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares', window );">Issuance of series D redeemable convertible preferred stock net of issuance costs of $96 share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">SHARES, Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock', window );">Vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock', window );">Vesting of restricted stock</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,341<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance , Shares at Dec. 31, 2020</a></td>
<td class="nump">31,253,609<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 233,054<span></span>
</td>
<td class="nump">$ 53,593<span></span>
</td>
<td class="nump">$ 36,336<span></span>
</td>
<td class="nump">$ 53,221<span></span>
</td>
<td class="nump">$ 89,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,391,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="num">(95,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
<td class="num">(102,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">SHARES, Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares', window );">Conversion of redeemable convertible preferred stock into common stock upon initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
<td class="num">(5,166,203)<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering', window );">Conversion of redeemable convertible preferred stock into common stock initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,593<span></span>
</td>
<td class="nump">$ 36,336<span></span>
</td>
<td class="nump">$ 53,221<span></span>
</td>
<td class="nump">$ 89,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares', window );">Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering', window );">Conversion of redeemable convertible preferred stock into common stock upon initial public offering</a></td>
<td class="nump">233,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">233,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786</a></td>
<td class="nump">$ 115,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 115,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Underwriters' exercise of overallotment option, net of underwriting discounts, commissions and initial public offering costs of $276, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares', window );">Underwriters' exercise of overallotment option, net of underwriting discounts, commissions and initial public offering costs of $276</a></td>
<td class="nump">3,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased for cashless exercise</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_CommonStockWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">19,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance , Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,512,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 202,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 363,172<span></span>
</td>
<td class="num">$ (160,995)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital stock issued issuance costs, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_CommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_CommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock into common stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of series c redeemable convertible preferred stock net of issuance costs shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of series c redeemable convertible preferred stock net of issuance costs value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, vesting of restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, vesting of restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of redeemable convertible preferred stock into common stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306898408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 2,659<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_InitialPublicOfferingCosts', window );">Initial public offering costs</a></td>
<td class="nump">11,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">OverAllotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_InitialPublicOfferingCosts', window );">Initial public offering costs</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock, $0.001 Par Value, Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_InitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_InitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306173960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (58,160)<span></span>
</td>
<td class="num">$ (39,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of PPP Loan</a></td>
<td class="num">(1,808)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on sale of property and equipment</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other non-cash operating lease cost</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Due from related party</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,217)<span></span>
</td>
<td class="num">(3,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(4,689)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,261<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,435<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable', window );">Due to related party</a></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(13,631)<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,006)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(67,133)<span></span>
</td>
<td class="num">(31,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty', window );">Purchases of property and equipment</a></td>
<td class="num">(15,983)<span></span>
</td>
<td class="num">(2,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15,921)<span></span>
</td>
<td class="num">(2,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">118,576<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock', window );">Proceeds from issuance of Series D convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts', window );">Payment of Series D redeemable convertible preferred stock issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts', window );">Proceeds from underwriters' exercise of overallotment option, net of underwriting discounts and commissions and initial public offering costs</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PrincipalPaymentsOnCapitalLeaseObligation', window );">Principal payments on finance lease obligation</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, net</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ProceedsFromPaycheckProtectionProgramLoan', window );">Proceeds from PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(2,659)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">119,110<span></span>
</td>
<td class="nump">91,475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">36,056<span></span>
</td>
<td class="nump">57,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">99,909<span></span>
</td>
<td class="nump">42,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">135,965<span></span>
</td>
<td class="nump">99,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Cash paid in connection with operating lease liabilities</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="nump">233,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842', window );">Operating right-of-use assets obtained in exchange for new operating leases upon adoption of ASC 842</a></td>
<td class="nump">5,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses', window );">Deferred initial public offering costs in AP and accruals</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred initial public offering coasts in accounts payable and accrued expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in due to related parties current excluding acccounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Right-Of-Use Assets Obtained in Exchange for New Operating Leases Upon Adoption of ASC 842.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of redeemable convertible preferred stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire property and equipment, purchases from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PrincipalPaymentsOnCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal payments on capital lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PrincipalPaymentsOnCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of series D convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ProceedsFromPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ProceedsFromPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from underwriters exercise of overallotment option net of underwriting discounts and commissions and initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310727368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 133,481<span></span>
</td>
<td class="nump">$ 99,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</a></td>
<td class="nump">$ 135,965<span></span>
</td>
<td class="nump">$ 99,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305320120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF OPERATIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finch Therapeutics Group, Inc. (the &#8220;Company&#8221; or &#8220;FTG&#8221;) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (&#8220;Finch&#8221;) and Crestovo Holdings LLC (&#8220;Crestovo&#8221;) in September 2017 (the &#8220;Merger&#8221;), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (&#8220;Finch Holdings&#8221;). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company&#8217;s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is an orally administered complete microbiome therapeutic in development for the prevention of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clostridioides difficile </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, or CDI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.  On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">192,877</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#8217; partial exercise of their overallotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts, commissions and offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, the Company&#8217;s board of directors (the &#8220;Board&#8221;) and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7ea1798d-7710-41a8-88de-a9818d271ecd;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-14.444</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of the Company&#8217;s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company&#8217;s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, the risk that its products will fail to demonstrate efficacy in clinical trials, uncertainty of market acceptance of its products, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The extent of the impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak, including with respect to variants of the virus, and its impact on clinical trial enrollment, trial sites, contract research organizations, contract manufacturing organizations, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and its key scientific and management personnel. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company&#8217;s business, financial condition and results of operations ultimately could be materially adversely affected. The Company continues to closely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monitor the COVID-19 pandemic as it evolves its business continuity plans, clinical development plans and response strategy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At this time, it is unknown how long the adverse conditions associated with the COVID-19 pandemic will last and what the complete financial effect will be to the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred recurring losses since its inception, including net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company expects to continue to generate operating losses for the foreseeable future as it continues to develop its product candidates. The Company expects that its cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of issuance the annual consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will not generate any future revenue from product sales unless and until it successfully completes clinical development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support manufacturing, product sales, marketing and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through clinical development, seeks regulatory approval, and if any of its product candidates are approved, proceeds to commercialization.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305304536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assets or liabilities classified as Level 3 on its consolidated balance sheets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed the federal insurance limit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s cash equivalents, which are funds held in a money market account, are measured at fair value on a recurring basis. The carrying amount of cash and cash equivalents was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, which approximates fair value and was determined based upon Level 1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level 1.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had restricted cash of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, primarily related to a security deposit on its operating leases for its offices in Somerville and Charlestown, Massachusetts for the year ended December 31, 2021, and for its operating lease for its offices in Somerville, Massachusetts for the year ended December 31, 2020. This is included in restricted cash, non-current and other assets on the Company&#8217;s consolidated balance sheets.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December 31, 2021 and 2020, the Company&#8217;s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receivable are carried at the invoiced amount less an allowance for doubtful accounts. Doubtful accounts are provided for on the basis of anticipated collection losses. The estimated losses are determined from historical collection experience and a review of outstanding accounts receivable. A receivable is considered past due if the Company has not received payment within the stated payment terms. After all attempts to collect a receivable have failed, the receivable is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">written </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">off against the allowance. Based on historical receipts and collections history, management has determined that an allowance for doubtful accounts is not necessary as of December 31, 2021 and 2020.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred, while any additions or improvements are capitalized. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:60.992%;"/>
          <td style="width:2.063%;"/>
          <td style="width:36.944%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">ESTIMATED USEFUL LIFE</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and In-Process Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is the amount by which the cost of the acquired net assets in a business combination exceeds the fair value of the identifiable net assets on the date of purchase or valuation. The Company accounts for goodwill in accordance with ASC Topic 350, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired In-Process Research and Development (&#8220;IPR&amp;D&#8221;) represents the fair value assigned to research and development assets that the Company acquired that had not been completed at the date of acquisition and is accounted for as an indefinite lived intangible asset in accordance with ASC Topic 350, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The Company&#8217;s IPR&amp;D is comprised of Crestovo&#8217;s research and development asset related to CP101, which was acquired in the Merger.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill and IPR&amp;D are evaluated for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company&#8217;s use of the acquired asset or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company&#8217;s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of goodwill, the fair value of the Company&#8217;s single reporting unit is compared to its carrying value. If the reporting unit&#8217;s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value. The Company&#8217;s annual assessments for impairment of goodwill as of October 1, 2021 and October 1, 2020 indicated that the fair value of its reporting unit exceeded the carrying value of the reporting unit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;D project exceeds its fair value. The Company estimates the fair value of IPR&amp;D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. The Company&#8217;s annual assessment for impairment of IPR&amp;D indicated that the fair value of its IPR&amp;D asset as of October 1, 2021 and October 1, 2020 exceeded the respective carrying value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any impairments are recognized as a loss in the year the goodwill and/or IPR&amp;D are determined to be impaired. Impairment of IPR&amp;D is recorded as research and development expense and impairment of goodwill is recorded separately as a loss in other income (expense) on the Company&#8217;s consolidated statements of operations. To date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment loss has been recognized. Additionally, there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> change to the carrying value of goodwill and IPR&amp;D for the years ended December 31, 2021 and 2020.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Initial Public Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred initial public offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be abandoned, the deferred initial public offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. On March 18, 2021, the Company completed the IPO; accordingly, the Company recognized the deferred initial public offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from gross proceeds associated with the IPO through additional paid-in capital in the accompanying consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">192,877</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#8217; partial exercise of their overallotment option, and the Company recognized offering costs of less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from gross proceeds associated with the overallotment through additional paid-in capital in the accompanying consolidated balance sheet. Accordingly, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> deferred offering costs as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Deferred offering costs on the accompanying consolidated balance sheet as of December 31, 2020 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU 2016-02,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Leases (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 842</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors), and replaces the existing guidance in ASC 840, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FASB subsequently issued amendments to ASC 842, which have the same effective date of January 1, 2019: (i) ASU 2018-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Codification Improvements to Topic 842,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which amends certain narrow aspects of the guidance issued in ASU 2016-02; and (ii) ASU 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and not restate prior periods presented. ASC 842 requires lessees to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. The Company adopted ASC 842 during the quarter ended December 31, 2021, with an effective date of January 1, 2021, using the modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior period financial statements continue to be presented in accordance with ASC 840.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The adoption of this standard resulted in the recognition of operating lease right-of-use assets of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and current and noncurrent operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, and the derecognition of deferred rent liabilities and unamortized lease incentives of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, on the Company&#8217;s Balance Sheets as of January 1, 2021 relating to its office leases in Somerville, MA. The adoption of this standard did not have a significant impact on the Company&#8217;s consolidated Statements of Operations or Statements of Cash Flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to January 1, 2021, the Company accounted for leases under Accounting Standards Codification 840, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8216;&#8216;ASC 840&#8217;&#8217;). At lease inception, the Company determined if an arrangement was an operating or capital lease.  For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent.  The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified  deferred rent as current and  noncurrent  liabilities based on  the portion of the deferred rent that was scheduled to mature within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#8217;s control over the use of that identified asset. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use (&#8220;ROU&#8221;) asset and current and non-current lease liabilities, as applicable on the balance sheet. The Company elected, as allowed under ASC 842, to not recognize leases with a lease term of one year or less on its balance sheet. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and records its lease liabilities based on the present value of lease payments over the expected remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in the lease contracts if that rate is readily available. As the implicit rate has not historically been readily determinable, the Company utilizes its incremental borrowing rate (&#8220;IBR&#8221;), which reflects the fixed rate at which the Company could borrow on a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collateralized basis over a similar term to fund the amount of lease payments to be made in a similar economic environment. Management determines the appropriate IBR to use based on the Company&#8217;s credit standing and market environment at lease commencement. The Company measures its ROU assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.) , non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated, based on the respective relative fair values, to the lease components and non-lease components. However, the Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement and the establishment of a ROU asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When a lease is modified and the modification is not accounted for as a separate contract, the Company remeasures its ROU assets and lease liabilities.  A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, the Board and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a one-for-14.444 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company&#8217;s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into 31,253,609 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for all stock-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#8217;s stock-based payments are comprised of stock options. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has historically been a private company until its IPO in March 2021 and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is primarily subject to U.S. federal and Massachusetts state income tax. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company maintains a reserve against certain federal and state research and development credits that are recorded net in deferred taxes. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals for interest or penalties related to income tax matters. Tax years since inception remain open to examination by federal and state tax authorities.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has historically generated revenue from the following sources: (1) collaboration revenue from the collaboration agreement with Takeda Pharmaceutical Company Limited (see Note 7) and (2) royalty revenue from OpenBiome&#8217;s sales of a licensed product under the Asset Purchase and License Agreement with OpenBiome (see Note 7).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The promised goods or services in the Company&#8217;s arrangements typically consist of (1) a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services; (2) an obligation to transfer FMT materials; or (3) an obligation to provide pre-clinical and clinical research and support services. Under the collaboration agreement, the Company provides options to additional items, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract. For performance obligations which consist of FMT materials, shipping and distribution activities occur prior to the transfer of control of FMT materials and are considered activities to fulfill the Company&#8217;s promise to deliver goods to the customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates the transaction price based on the amount expected to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and are included in the transaction price only to the extent it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are added to the transaction price with a corresponding adjustment being made to the measure of progress, and, as necessary, recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For contracts which have more than one performance obligation, the total contract consideration is allocated based on observable standalone selling prices or, if standalone selling prices are not readily observable, based on management&#8217;s estimate of each performance obligation&#8217;s standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to be entitled to for the satisfaction of each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For performance obligations, revenue is recognized when control of the product is transferred to the customer and the related performance obligation is satisfied, which typically occurs upon delivery of the product to the customer, for an amount that reflects the consideration the Company expects to be entitled to receive in exchange for delivering the product. For performance obligations which consist of clinical trial participation and related support services, revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disaggregation of Revenue</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides revenue disaggregated by timing of revenue recognition (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:55.945%;"/>
          <td style="width:1.804%;"/>
          <td style="width:2.145%;"/>
          <td style="width:17.488%;"/>
          <td style="width:0.881%;"/>
          <td style="width:1.804%;"/>
          <td style="width:2.145%;"/>
          <td style="width:16.906%;"/>
          <td style="width:0.881%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred at a point in time</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred over time</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,376</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,719</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021 and 2020.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued and Adopted Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles-Goodwill and Other- Internal-Use Software</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (Subtopic<br/> 350- 40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance for capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted the standards on a prospective basis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on January 1, 2021.The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively and certain others to be made retrospectively. The Company adopted this standard on January 1, 2021, and this standard did not have a material impact on its consolidated financial statements and related disclosures for the year ended December 31, 2021. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305439144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. FAIR VALUE MEASUREMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:38.815%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DESCRIPTION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.815%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DESCRIPTION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between fair value levels during the years ended December 31, 2021 and 2020. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305334248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. PROPERTY AND EQUIPMENT, NET</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.503%;"/>
        <td style="width:1.591%;"/>
        <td style="width:1.778%;"/>
        <td style="width:16.696%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.591%;"/>
        <td style="width:1.778%;"/>
        <td style="width:15.676%;"/>
        <td style="width:1.193%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">537</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">537</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,143</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction work-in-progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">329</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,635</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,883</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">368</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,226</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,029</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,635</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively. During the years ended December 31, 2021 and 2020, the Company purchased $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of software, property, and equipment from a related party, under the OpenBiome Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255393660088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. LEASES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">200 Inner Belt Road Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2015, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease agreement (the "Inner Belt Road Lease") for approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,785</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The monthly rental payments under the Inner Belt Road Lease, which include base rent charges of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, are subject to periodic rent increases through September 2026.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2016, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sublease agreement (the "200 Inner Belt Road Sublease") to share its leased space under the Inner Belt Road Lease with OpenBiome, a related party, as sub-tenant. The sublease with OpenBiome is coterminous with the Inner Belt Road Lease and provides for an allocation, based on OpenBiome&#8217;s proportionate share, of base rent and other expenses under the Inner Belt Road Lease, which is subject to change each year based on current headcount and space used. OpenBiome&#8217;s proportionate share is reassessed on a quarterly basis over the term of the sublease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the Company amended the Inner Belt Road Lease to lease an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The term of the Inner Belt Road Lease and the sublease with OpenBiome were not affected as a result of the amendment, although OpenBiome does occupy some of this additional space. The rental payments for the additional space under the amended Inner Belt Road Lease, which include base rent charges of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per month, are subject to periodic rent increases through September 2026. In November 2020, pursuant to the OpenBiome Agreement, the Company and OpenBiome amended the terms of the sublease to provide for a reduction in the size of the subleased premises upon the closing of the OpenBiome Agreement (see Note 13), which occurred on March 1, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The sublease was further amended on January 15, 2021 and June 22, 2021 and terminated on December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's lease expense under the Inner Belt Road Lease was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for each of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020. The Company recognizes sublease income under the sublease to OpenBiome as rent is received over the sublease term. Gross lease income under the sublease to OpenBiome for each of the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, and is presented as an offset to lease expense on the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cherry Street Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 1, 2021, the Company assumed a lease agreement (the &#8220;Cherry Street Lease&#8221;) in conjunction with the closing of the OpenBiome Agreement. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lease term is from March 2021 through February 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company&#8217;s lease expense under the Cherry Street Lease for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concord Avenue Lease</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 25, 2021, the Company entered into a lease agreement (the "Concord Avenue Lease") </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2021 through February 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#8217;s lease expense under the Concord Avenue Lease for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 17, 2021 Finch extended the term of the lease for an additional two-month period through April 2022 and on February 4, 2022 Finch further extended the lease for an additional month through May 2022.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Concord Avenue Lease qualifies as a short-term lease and will be excluded from the balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">100 Hood Park Drive</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 3, 2021 (the "Execution Date"), the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease agreement (the "Hood Lease") with Hood Park LLC (the "Landlord"), pursuant to which the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,139</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office and laboratory space (the "Premises"). The term of the Hood Lease commenced on the Execution Date, and Finch will become responsible for paying rent under the Hood Lease on the earlier of (i) January 1, 2022 and (ii) the date Finch&#8217;s improvement on the Premises is substantially completed and Finch has commenced business operations in the Premises (the &#8220;Rent Commencement Date&#8221;). As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Rent Commencement Date had not occurred and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lease expense, right-of-use asset, or lease liability was recognized under the Hood Lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Hood Lease provides Finch with an option to extend the lease for one additional five-year term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Finch&#8217;s annual base rent for the Premises will start at approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and the lease contains annual rent escalations. The Hood Lease provides for a tenant improvement allowance of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the cost of Finch&#8217;s work on the Premises. As of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of lessor owned tenant improvements were completed by the Company and are recorded in other current assets on the consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company posted a customary letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, subject to decrease on a set schedule, as a security deposit pursuant to the Hood Lease. This is included in restricted cash, non-current on the consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the classification of right-of-use assets and lease liabilities as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.926%;"/>
        <td style="width:40.813%;"/>
        <td style="width:1.852%;"/>
        <td style="width:1.778%;"/>
        <td style="width:20.885%;"/>
        <td style="width:0.746%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BALANCE SHEET CLASSIFICATION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ASSETS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,053</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance lease assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,075</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Finance lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Finance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,041</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table represents the components of lease cost, which are included in general and administrative and research and development expense on the statement of operations, for the year ended December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.489%;"/>
        <td style="width:8.243%;"/>
        <td style="width:1.815%;"/>
        <td style="width:33.234%;"/>
        <td style="width:1.218%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LEASE COST</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance lease cost:</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Amortization of right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Interest on lease liabilities</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,336</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Short-term lease cost</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">525</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sublease income</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,064</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining lease term and discount rate were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.741%;"/>
        <td style="width:2.021%;"/>
        <td style="width:31.238%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LEASE TERM AND DISCOUNT RATE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remining lease term (years)</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Finance Leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Finance Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosure of cash flow information related to leases was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.631%;"/>
        <td style="width:1.492%;"/>
        <td style="width:1.803%;"/>
        <td style="width:24.291%;"/>
        <td style="width:0.783%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">SUPPLEMENTAL CASH FLOW INFORMATION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,006</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Financing cash flows from finance leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table represents a summary of the Company&#8217;s future lease payments required as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.503%;"/>
        <td style="width:1.203%;"/>
        <td style="width:1.273%;"/>
        <td style="width:10.897%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.066%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.283%;"/>
        <td style="width:9.515%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.283%;"/>
        <td style="width:9.515%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OPERATING LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">HOOD PARK LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">FINANCE LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TOTAL LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,046</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,440</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,663</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,109</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,795</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,255</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,931</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,427</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,071</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,605</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,605</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">984</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">989</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following represents a summary of the Company's future minimum lease payments under non-cancelable lease agreements, presented in accordance with ASC 840, as of December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.242%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.914%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.134%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.134%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OPERATING LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">FINANCE LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TOTAL LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,351</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,411</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,430</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,115</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,115</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,233</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,233</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305486008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.567%;"/>
        <td style="width:1.616%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.051%;"/>
        <td style="width:0.758%;"/>
        <td style="width:1.616%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.051%;"/>
        <td style="width:0.758%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,345</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued legal and professional fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">711</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,401</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,062</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">904</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310149416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. REVENUE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Takeda Pharmaceutical Company Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the Company entered into an agreement (the &#8220;Takeda Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), pursuant to which the Company granted Takeda a worldwide, exclusive license, with the right to grant sublicenses, under certain of its patents, patent applications and know-how to develop the Company&#8217;s microbiome therapeutic candidate FIN-524, now known as TAK-524, for the prevention, diagnosis, theragnosis or treatment of diseases in humans. The Company subsequently amended and restated the Takeda Agreement in October 2019 to provide for the Company to allocate certain resources towards determining the feasibility of developing a second microbiome therapeutic candidate, FIN-525. The Company further amended the Takeda Agreement in August 2021 to transition primary responsibility for further development and manufacturing activities with respect to TAK-524 from the Company to Takeda in accordance with a transition plan, and Takeda assumed sole responsibility for regulatory matters with respect to TAK-524. In November 2021, Takeda Agreement was amended again to enable the Company to carry out certain FIN-525 preliminary evaluation activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Takeda Agreement, the Company agreed to design TAK-524, a product candidate optimized for ulcerative colitis, for Takeda based on selection criteria within a product-specific development plan. The Company also agreed to conduct a feasibility study to potentially further develop FIN-525, a program to develop a live biotherapeutic product optimized for the treatment of Crohn&#8217;s disease. The Company assessed this arrangement in accordance with ASC 606, and concluded that the contract counterparty, Takeda, is a customer. The Company identified the following material promises at the outset of the Takeda Agreement: (1) an exclusive license to use the Company&#8217;s rights in intellectual property to conduct research activities; (2) R&amp;D services for activities under the development plan; (3) two options to pursue different indications of research for the Company&#8217;s right in product candidates; (4) manufacturing and supply for the Company&#8217;s clinical trials; and (5) participation on a joint steering and joint development committee (&#8220;JSC&#8221; and &#8220;JDC&#8221;). The options were considered distinct from the other promises in the arrangement and analyzed for material rights; the Company concluded these were not material rights and the consideration related to them should be excluded as a performance obligation until the option is exercised. The Company determined that the remaining promises were not capable of being distinct from one another and were not distinct in the context of the contract. In accordance with the Company&#8217;s ASC 606 assessment, the Takeda Agreement was determined to contain a single combined performance obligation made up of the promises above, excluding the options. The FIN-525 feasibility study was determined to be part of the single combined performance obligation due to its connection to the original license and research and development activities. The FIN-525 feasibility study was completed in March 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received an upfront payment from Takeda of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the year ended December 31, 2017 in exchange for the exclusive license of the Company&#8217;s intellectual property. The Company has included the upfront payment and the estimable reimbursable R&amp;D costs in the transaction price and is recognizing revenue associated with it over the period it expects to perform R&amp;D services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the original agreement the estimated term for the R&amp;D and manufacturing services for which the Company had primary responsibility, was through Phase 1 clinical trials.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 9, 2021, the Company and Takeda entered into an amendment to the amended and restated Takeda Agreement (the &#8220;Amendment&#8221;). Pursuant to the Amendment, Finch and Takeda transitioned primary responsibility for such development and manufacturing activities from Finch to Takeda in accordance with an agreed upon transition plan, and Takeda also assumed sole responsibility for regulatory matters with respect to TAK-524. The Company accounted for the Amendment as a modification to the existing contract under ASC 606, as the Amendment significantly reduced the remaining performance obligations, which were then completed by September 30, 2021.  As a result, the remaining revenue that had been deferred under the Takeda Agreement was recognized in the third quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, Takeda and Finch entered into an amendment to the amended and restated Takeda Agreement ("Amendment #2"). Pursuant to Amendment #2, Finch is performing certain additional research activities related to the feasibility of the FIN-525 program prior to Takeda making the decision to initiate the full development program. Under the amendment, Takeda shall pay Finch for pass-through costs incurred and research services performed at the agreed-upon full-time equivalent (&#8220;FTE&#8221;) rate. The additional feasibility work is expected to be completed in the first quarter of 2022 at which point Takeda can determine whether to initiate a full product specific development plan for FIN-525 following its review of the data.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized revenue related to the Takeda Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively, which is included under collaboration revenue in the consolidated statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Takeda reimburses the Company for certain R&amp;D costs on a quarterly basis. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded accounts receivable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on its consolidated balance sheets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, and December 31, 2020, respectively. As of December 31, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> remaining deferred revenue due to the Company's satisfaction of the performance obligation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2020, the Company recorded deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the Takeda Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Takeda Agreement contains various milestone payments associated with development and commercialization efforts that provide for a maximum available amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million should all of the milestones be achieved. These milestones are constrained until the Company determines it is probable that the cumulative revenue related to the milestones will not be reversed</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company has earned and received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in milestone payments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is still eligible to receive royalties under the Amendment and Takeda is obligated to pay the Company mid-to-high single digit royalties based on annual aggregate net sales of the licensed products, on a product-by-product basis, subject to certain restrictions. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t receive any payments or record any revenues related to sales-based royalties under the Takeda Agreement in the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and OpenBiome entered into an Asset Purchase and License Agreement (the &#8220;APL Agreement&#8221;) in February 2019 that was effective through November 2020. Under the APL Agreement, the Company licensed certain intellectual property and sold certain fecal microbiota transplantation, or FMT, materials and equipment to OpenBiome (see Note 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company earned $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in royalty revenue related to the APL Agreement in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively, which is recorded as royalty revenue from related party on the Company&#8217;s consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 19, 2020, the Company entered into the LMIC License Agreement (&#8220;LMIC Agreement&#8221;) with OpenBiome, pursuant to which the Company granted OpenBiome a non-exclusive license, with the right to grant sublicenses, under certain patents, patent applications, and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from donor-sourced stool without the use of culturing or replication, or certain natural products (&#8220;OpenBiome Royalty Products&#8221;). The license granted to OpenBiome excludes a license under the Company&#8217;s intellectual property to exploit a lyophilized natural product (such as CP101) where processed stool is lyophilized. The Company owns all improvements and modifications made to the licensed intellectual property throughout the term of the LMIC Agreement, while OpenBiome is responsible for all manufacturing efforts and all expenses associated with these efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The LMIC Agreement was entered into separately from the asset purchase agreement with OpenBiome (the "OpenBiome Agreement") (see Note 13) and the license granted under the LMIC Agreement is unrelated to the assets acquired under the OpenBiome Agreement. The only consideration provided to the Company under the LMIC Agreement is in the form of future royalties on net sales of OpenBiome Royalty Products. The Company is entitled to receive tiered royalties on net sales of certain products, ranging from mid-single digit to low second decile digits on a product-by-product and country-by-country basis. In the event that OpenBiome is required to pay a royalty to a third party to obtain rights under patents owned or controlled by such third party that are necessary for the exercise of its rights under the Company&#8217;s intellectual property pursuant to the LMIC Agreement, then OpenBiome shall have the right to deduct a portion of the amount of the royalty due to the third party against the royalties that are due from OpenBiome to the Company. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t earned any of these royalty payments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The LMIC Agreement will continue in perpetuity until the last royalty is earned under the LMIC Agreement unless otherwise terminated by either party. OpenBiome has the right to terminate the LMIC Agreement for convenience upon 90 days&#8217; specified prior written notice to the Company. Either party may terminate the LMIC Agreement in the event of an uncured material breach by the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize any revenue related to the LMIC Agreement for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as there are currently no marketable OpenBiome Royalty Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305468616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. INCOME TAXES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate differed from the statutory federal income tax rate due to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.37%;"/>
        <td style="width:1.84%;"/>
        <td style="width:0.808%;"/>
        <td style="width:16.271%;"/>
        <td style="width:2.983%;"/>
        <td style="width:1.84%;"/>
        <td style="width:0.771%;"/>
        <td style="width:16.134%;"/>
        <td style="width:2.983%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal income taxes at 21%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit and tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.90</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.03</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other adjustments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company&#8217;s net deferred tax assets and liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.807%;"/>
        <td style="width:1.803%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.81%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.803%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.81%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,419</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,192</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,921</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,057</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">859</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of Use Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">289</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,079</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,756</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,721</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangibles assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,952</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,891</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of Use Assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,372</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">330</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,182</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company continues to maintain a partial valuation allowance against its deferred tax assets. During the years ended December 31, 2021 and 2020, management assessed the positive and negative evidence in its U.S. operations, and concluded that it is more likely than not that a portion of its deferred tax assets as of December 31, 2021 and 2020 will not be realized given the Company&#8217;s history of operating losses. In determining the amount of the valuation allowance to record, the Company considered the reversal of existing taxable temporary differences as a source of taxable income against which a portion of its deferred tax assets is benefitted. The Company recorded a full valuation allowance against the remaining U.S. deferred tax assets in excess of this source of taxable income. The valuation allowance against deferred tax assets increased by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 related to a full valuation allowance recorded against additional net operating losses and tax credits generated in the year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had federal net operating losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which may be available to offset future federal income tax liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, the Company had federal net operating losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which may be available to offset future federal income tax liabilities. The Company&#8217;s federal net operating losses incurred prior to 2018, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, expire through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, while its federal net operating losses incurred in 2018 and onwards, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, can be carried forward indefinitely.</span><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had post-apportioned state net operating losses of</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million that can generally be carried forward </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. As of December 31, 2020, the Company had post-apportioned state net operating losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million that can generally be carried forward </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and state research and development credits, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which will expire at various dates through 2041</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and state research and development credits, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which will expire at various dates through 2040</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.  The Company has not, yet, conducted a study to determine if any such changes have occurred that could limit its ability to use the net operating loss and tax credit carryforward.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. As of December 31, 2021 and 2020, the total amount of uncertain tax liabilities relates to federal and state tax credit carryforwards and are all recorded net in deferred taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.992%;"/>
        <td style="width:1.889%;"/>
        <td style="width:1.815%;"/>
        <td style="width:16.718%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.889%;"/>
        <td style="width:1.815%;"/>
        <td style="width:16.88%;"/>
        <td style="width:0.783%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Additions for tax positions of current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">314</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, end of year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,822</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,318</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255393660088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. COMMITMENTS AND CONTINGENCIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, &#8220;Rebiotix&#8221;) filed a complaint against the Company in the U.S. District Court for the District of Delaware. The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the &#8220;&#8216;309 patent&#8221;); 10,463,702 (the &#8220;&#8216;702 patent&#8221;); 10,328,107 (the &#8220;&#8216;107 patent&#8221;); 10,064,899; 10,022,406; 9,962,413; and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the &#8217;107, &#8217;702, and &#8217;309 patents. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota (&#8220;UMN&#8221;), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012. The U.S District Court for the District of Delaware set a trial date for a five-day trial beginning on May 20, 2024. The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined under ASC 450, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, that there is no probable or estimable loss contingency that is required to be recorded as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License payments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into contracts in the normal course of business with contract research organizations and other third parties for preclinical studies, clinical studies, and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancelable by the Company upon prior written notice. Payments due upon cancellation consist of payments for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">services provided or expenses incurred, including non-cancelable obligations of our service providers up to one year after the date of cancellation. Under these agreements, in exchange for access to intellectual property the Company may be obligated to provide future minimum royalty payments and milestone payments related to regulatory approvals and sales-based events. The Company entered into the OpenBiome Agreement in November 2020 (see Note 13) and the closing of the OpenBiome Agreement occurred on March 1, 2021. Under the terms of the OpenBiome Agreement, the Company is required to make certain milestone and royalty payments to OpenBiome in conjunction with the license and purchase of certain intellectual property related to the underlying CMC process used to manufacture materials for its clinical trials. The OpenBiome Agreement also effectively terminated the APL Agreement and the obligations under the Material Access License Agreement (the &#8220;MAL Agreement&#8221;), which the Company entered into with OpenBiome in December 2016.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the APL Agreement, which was entered into in 2019 and effective through November 2020, the Company was obligated to make certain contingent payments for milestones and royalties to OpenBiome, subject to the occurrence of specific underlying criteria that were dependent on regulatory approvals and sales-based events. The Company was obligated to make regulatory milestone payments to OpenBiome aggregating up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of regulatory approvals, and sales-based milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in sales-based milestone payments upon the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achievement </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of certain net sales criteria. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to OpenBiome associated with milestones in 2020. The APL Agreement was terminated in November 2020 upon the execution of the OpenBiome Agreement (see Note 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the MAL Agreement, the Company was also obligated to pay to OpenBiome, a low single digit royalty on net sales of certain cultured products and a high single digit percentage of certain sublicensing revenue (including royalties) of licensed cultured products. These royalties were calculated on a product-by-product and country-by-country basis. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to OpenBiome under the MAL Agreement in 2020 related to royalty payments. During the year ended December 31, 2020, the Company recorded an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million owed to OpenBiome under the MAL Agreement, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million remained due as of December 31, 2020. The MAL Agreement was terminated in November 2020 upon the execution of the OpenBiome Agreement (see Note 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PPP Loan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted to, amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the COVID-19 pandemic. The CARES Act includes a Paycheck Protection Program (&#8220;PPP&#8221;) administered through the Small Business Association (&#8220;SBA&#8221;). Under the PPP, beginning April 3, 2020, small businesses and other entities and individuals could apply for loans from existing SBA lenders and other approved regulated lenders that enroll in the program, subject to numerous limitations and eligibility criteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company issued a promissory note to Silicon Valley Bank, pursuant to which it received loan proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the &#8220;PPP Loan&#8221;) provided under the PPP and guaranteed by the SBA. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 8, 2021, the Company received notice from the SBA that the entirely of the PPP Loan was forgiven. Accordingly, the Company is no longer required to repay the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in principal and approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in accrued interest borrowed under the PPP Loan.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Gain on extinguishment of the PPP Loan is recorded in the consolidated statements of operations for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's commitments under its lease agreements are described in Note 5.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305490152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">REDEEMABLE CONVERTIBLE PREFERRED STOCK</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. REDEEMABLE CONVERTIBLE PREFERRED STOCK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,902,872</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its series D redeemable convertible preferred stock (&#8220;Series D&#8221;) at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.0381</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company incurred issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million associated with the Series D issuance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the completion of the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of outstanding preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock authorized, issued, or outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, preferred stock consisted of the following (in thousands, except share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:18.895%;"/>
        <td style="width:1.551%;"/>
        <td style="width:0.646%;"/>
        <td style="width:12.633%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:0.646%;"/>
        <td style="width:12.673%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.047%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.126%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:0.636%;"/>
        <td style="width:16.271%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PREFERRED<br/>STOCK<br/>AUTHORIZED</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PREFERRED<br/>STOCK<br/>ISSUED AND<br/>OUTSTANDING</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">CARRYING<br/>VALUE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">LIQUIDATION<br/>VALUE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">COMMON STOCK<br/>ISSUABLE UPON<br/>CONVERSION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167,496,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,596,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,593</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,596,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,620,739</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,166,203</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,336</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,166,203</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109,604,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,465</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series D</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99,705,359</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,902,872</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,904</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,902,872</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">451,427,842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233,054</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305503432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. STOCKHOLDERS' EQUITY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 24, 2021, the Board and the Company&#8217;s stockholders approved the Company&#8217;s amended and restated certificate of incorporation, which became effective immediately prior to the closing of the IPO on March 18, 2021. The certificate authorizes the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value common stock and up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value undesignated preferred stock. The Board may designate the rights, preferences, privileges, and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and number of shares constituting any series or the designation of any series. The issuance of preferred stock could have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying or preventing a change in control. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock were outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In conjunction with the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and initial public offering costs. In connection with the IPO, all then outstanding shares of preferred stock were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">192,877</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#8217; partial exercise of their overallotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriters&#8217; discounts, commissions and offering costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each share of common stock entitles the holder to one vote</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, together with the holders of preferred stock, on all matters submitted to the stockholders for a vote. Common stockholders are also entitled to receive dividends. As of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cash dividends have been declared or paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has issued restricted stock to founders, employees and consultants. All restricted stock was fully vested and all expense related to these shares was recognized prior to 2020.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020, the Company has reserved the following shares of common stock for potential conversion of outstanding preferred stock, the vesting of restricted stock and exercise of stock options, common stock warrants, and shares under the employee stock purchase plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.98%;"/>
        <td style="width:1.827%;"/>
        <td style="width:0.858%;"/>
        <td style="width:18.523%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.827%;"/>
        <td style="width:0.858%;"/>
        <td style="width:18.585%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,053,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,346</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issuable under employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,195</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309,965</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,326,829</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">_________________________</span></p><p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During the fourth quarter of 2021, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,346</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> common stock warrants were net exercised, resulting in </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,303</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> net shares.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Secondary Sale</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, certain of the Company&#8217;s stockholders sold shares of the Company&#8217;s common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.0381</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share to an investor. The investor purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">412,323</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock from these stockholders for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">258,924</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock, or an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, were sold by affiliates of the Company, who are considered to be related parties. The shares were sold above fair value and the excess of the price paid over the fair value was recognized as $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of stock-based compensation expense. The Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as general and administrative expense in the consolidated statement of operations for the year ended December 31, 2020 (see Note 12).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305331816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. STOCK-BASED COMPENSATION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2017 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) in February 2017 for the issuance of stock options and other stock-based awards to employees, consultants, officers and directors. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance since all shares in the 2017 Plan ceased to be available upon the effective date of the 2021 Equity Incentive Plan, which occurred in March 2021. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">698,601</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock available for future grants under the 2017 Plan as of December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Board adopted, and the stockholders approved, the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan became effective on the date of the underwriting agreement related to the IPO and no further grants will be made under the 2017 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company&#8217;s affiliates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initially, the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2021 Plan will not exceed </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,291,446</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, which is the sum of (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,700,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> new shares, plus (2) an additional number of shares equal to the number of shares of common stock subject to outstanding stock options or other stock awards granted under the 2017 Plan that, on or after the 2021 Plan became effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, if any, as such shares become available from time to time. In addition, the number of shares of common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of common stock outstanding on December 31 of the year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the applicable January 1. The maximum number of shares of common stock that may be issued on the exercise of incentive stock options under the 2021 Plan will be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,100,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issuable upon the exercise of outstanding options and there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,569,454</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance under the 2021 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Board adopted the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on the date of the underwriting agreement related to the IPO. The 2021 ESPP is administered by the Board or by a committee appointed by the Board. The 2021 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">500,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The first offering period of the plan commenced on December 1, 2021 under the 2021 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each offering to employees to purchase shares will begin on each June 1 and December 1 and will end on the following November 30 and May 31, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On each purchase date, which will fall on the last date of each offering period, ESPP participants will purchase ordinary shares at a price per share equal to 85% of the lesser of (1) the fair market value of the shares on the offering date or (2) the fair market value of the shares on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company&#8217;s compensation committee.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued under the 2021 ESPP in 2021 and 500,000 shares were available for future issuance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions that the Company used in Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2021 and 2020 were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.263%;"/>
        <td style="width:2.009%;"/>
        <td style="width:18.366%;"/>
        <td style="width:2.009%;"/>
        <td style="width:18.353%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity of the Company&#8217;s stock options under the 2021 Plan for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.349%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.626%;"/>
        <td style="width:10.029%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.641%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.716%;"/>
        <td style="width:10.188%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.403%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">SHARES</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">AGGREGATE<br/>INTRINSIC<br/>VALUE<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,053,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,964</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,602,643</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155,821</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">211,987</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.24</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.18</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,228</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">846,024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,589</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options vested or expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,228</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options granted during the years ended December 31, 2021 and 2020 were granted to employees and consultants of the Company. As of December 31, 2021, there was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized compensation expense related to the stock-based compensation arrangements granted under the 2021 Plan remaining to be recognized. The Company expects to recognize this cost over a weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.24</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stoc</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">k. The intrinsic value of options exercised in 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The weighted-a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">verage grant date fair value of stock options granted in the years ended December 31, 2021 and 2020 under the Black-Scholes option pricing model was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per option and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per option, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The restricted stock was granted to the founders of the Company, as well as employees and consultants of the Company. There was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of stock-based compensation expense recognized for the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">547,360</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted stock vested during the year ended December 31, 2020. All restricted stock was vested as of December 31, 2020 and there is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> remaining stock-compensation expense related to restricted stock to be recognized for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December 31, 2021 and 2020 is as follows (in thousands):</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:62.366%;"/>
      <td style="width:1.467%;"/>
      <td style="width:1.815%;"/>
      <td style="width:14.753%;"/>
      <td style="width:0.783%;"/>
      <td style="width:1.467%;"/>
      <td style="width:1.815%;"/>
      <td style="width:14.753%;"/>
      <td style="width:0.783%;"/>
     </tr>
     <tr style="height:8.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:8.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,605</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">179</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,556</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,920</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,161</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,099</span></p></td>
      <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
    </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stock-based compensation expense for the year ended December 31, 2020 includes the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million recorded in relation to the secondary sale of common stock (see Note 11).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305499912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. RELATED PARTY TRANSACTIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome Historical Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Master Strategic Affiliation Agreement with OpenBiome (the &#8220;Strategic Agreement&#8221;), OpenBiome and the Company reimbursed one another for certain administrative expenses. The Company&#8217;s Chief Executive Officer and a member of the Board is the spouse of the co-founder and former Executive Director of OpenBiome, and certain of the OpenBiome directors are stockholders of the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company reimbursed OpenBiome $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under the Strategic Agreement. Also under the Strategic Agreement, OpenBiome reimbursed the Company $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively. As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, respectively the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payable balance</span><span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">due to OpenBiome, and recorded a balance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due from OpenBiome as of December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until December 31, 2021, OpenBiome subleased office and lab space from the Company. The Company&#8217;s rent income under the sublease was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020, respectively. As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Company </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> longer had an outstanding receivable due from OpenBiome. As of December 31, 2020, the Company had le</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ss than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million re</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ceivable from OpenBiome related to the sublease recorded as due from related party in the consolidated balance sheets. This lease was amended as of March 1, 2021 (see Note 5).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also earned a low single digit royalty on net sales of OpenBiome&#8217;s FMT materials under the Quality System and Supply Agreement with OpenBiome (the &#8220;QSS Agreement&#8221;), which was partially terminated on February 1, 2019 and, ultimately, was fully terminated in November 2020 in connection with the Company&#8217;s execution of the OpenBiome Agreement (see OpenBiome 2020 Agreements below), which closed on March 1, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome 2020 Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Supply and Services Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 10, 2020, the Company entered into a Clinical Supply and Services Agreement (the &#8220;CSA&#8221;) with OpenBiome, which terminated upon closing of the OpenBiome Agreement in March 2021. In accordance with the CSA, OpenBiome agreed to supply the Company with certain manufactured material and to provide additional support services to the Company. In consideration for these materials and services, the Company agreed to pay a monthly platform fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, all direct employee overhead costs, and variable costs for consumables. Under a related payment agreement executed concurrently with the CSA, the Company paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit in the event of cost overruns under the CSA arrangement and approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in prepaid fees. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit was returned to the Company during the same period. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total to OpenBiome under the CSA for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">year ended December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">year ended December 31, 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, including the security deposit that was returned. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> outstanding payable balance due to OpenBiome under the CSA as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due to OpenBiome as of December 31, 2020, respectively, which is classified as due to related party in the Company&#8217;s consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OpenBiome Purchase Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 19, 2020, the Company entered into the OpenBiome Agreement in order to obtain OpenBiome&#8217;s CMC manufacturing process to enhance its current manufacturing capabilities for its lead program, CP101; the OpenBiome Agreement was fully executed and closed on March 1, 2021. Simultaneously with entering into the OpenBiome Agreement, the Company terminated the Strategic Agreement, the MAL Agreement, the QSS Agreement and the APL Agreement, as well as certain subject matter agreements. Upon closing of the OpenBiome Agreement on March 1, 2021, the CSA was also terminated, and the Company will not incur any additional expense to be paid to OpenBiome. The Company also amended the Strategic Agreement as part of the OpenBiome Agreement (the &#8220;A&amp;R Strategic Agreement&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the OpenBiome Agreement, the Company acquired certain biological samples, software, and a non-exclusive license to OpenBiome&#8217;s CMC technology upon signing in November 2020, and acquired certain biological samples, a commercial lease, contract services intellectual property and capital equipment upon the closing of the transaction in March 2021. The Company previously licensed the biological samples and OpenBiome&#8217;s CMC technology under various historical agreements with OpenBiome which terminated upon signing of the OpenBiome Agreement. As such, the acquisition of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CMC technology license was a continuation of previously granted rights. The OpenBiome Agreement also releases, for a one-year period from signing, a hiring restriction under the A&amp;R Strategic Agreement (i.e. non-solicitation) such that the Company may hire, at its discretion, certain OpenBiome employees. The Company did not acquire any such employees as part of the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the OpenBiome Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the acquisition of certain assets in November 2020, which was capitalized as property and equipment as software on the Company&#8217;s consolidated balance sheet as of December 31, 2020 and paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the closing of the OpenBiome Agreement on March 1, 2021, for the remaining assets. The Company accounted for the OpenBiome Agreement as an asset acquisition and capitalized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of property and equipment on the consolidated balance sheet as of March 31, 2021 for the acquired software and property and equipment. The Company did not assign any value to biological samples, contract services intellectual property, or the CMC technology license, as the Company did not acquire any additional rights that were not previously granted under the legacy agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is also required to pay certain milestones up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the occurrence of certain R&amp;D events, regulatory approvals, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company previously granted OpenBiome a royalty-bearing, non-exclusive license to its intellectual property under the APL Agreement, which terminated upon the signing of the OpenBiome Agreement. The Company will continue to earn royalties under the OpenBiome Agreement based on sales of FMT materials.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305455144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. RETIREMENT PLAN</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. All employees are eligible to become participants of the plan at the beginning of the next full quarter subsequent to their hire date</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right to make additional contributions to this plan. The Company made contributions to the plan of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305532264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. LOSS PER SHARE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.262%;"/>
        <td style="width:1.728%;"/>
        <td style="width:1.591%;"/>
        <td style="width:20.179%;"/>
        <td style="width:1.057%;"/>
        <td style="width:1.728%;"/>
        <td style="width:1.591%;"/>
        <td style="width:19.806%;"/>
        <td style="width:1.057%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FOR THE YEAR<br/>ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,160</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39,341</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss attributable to<br/>&#160;&#160;&#160;common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,160</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average common<br/>&#160;&#160;&#160;stock outstanding&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39,202,086</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,144,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per share attributable<br/>&#160;&#160;&#160;to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s potentially dilutive securities, which include preferred stock, restricted stock, stock options, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December 31, 2021 and 2020 because including them would have had an anti-dilutive effect: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.064%;"/>
        <td style="width:1.505%;"/>
        <td style="width:0.771%;"/>
        <td style="width:15.247%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.505%;"/>
        <td style="width:0.771%;"/>
        <td style="width:15.595%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br/>DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,053,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,346</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issuable under employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,195</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309,965</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,326,829</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307054328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assets or liabilities classified as Level 3 on its consolidated balance sheets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed the federal insurance limit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s cash equivalents, which are funds held in a money market account, are measured at fair value on a recurring basis. The carrying amount of cash and cash equivalents was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, which approximates fair value and was determined based upon Level 1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level 1.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had restricted cash of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively, primarily related to a security deposit on its operating leases for its offices in Somerville and Charlestown, Massachusetts for the year ended December 31, 2021, and for its operating lease for its offices in Somerville, Massachusetts for the year ended December 31, 2020. This is included in restricted cash, non-current and other assets on the Company&#8217;s consolidated balance sheets.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December 31, 2021 and 2020, the Company&#8217;s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receivable are carried at the invoiced amount less an allowance for doubtful accounts. Doubtful accounts are provided for on the basis of anticipated collection losses. The estimated losses are determined from historical collection experience and a review of outstanding accounts receivable. A receivable is considered past due if the Company has not received payment within the stated payment terms. After all attempts to collect a receivable have failed, the receivable is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">written </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">off against the allowance. Based on historical receipts and collections history, management has determined that an allowance for doubtful accounts is not necessary as of December 31, 2021 and 2020.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred, while any additions or improvements are capitalized. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:60.992%;"/>
          <td style="width:2.063%;"/>
          <td style="width:36.944%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">ESTIMATED USEFUL LIFE</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and In-Process Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and In-Process Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is the amount by which the cost of the acquired net assets in a business combination exceeds the fair value of the identifiable net assets on the date of purchase or valuation. The Company accounts for goodwill in accordance with ASC Topic 350, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired In-Process Research and Development (&#8220;IPR&amp;D&#8221;) represents the fair value assigned to research and development assets that the Company acquired that had not been completed at the date of acquisition and is accounted for as an indefinite lived intangible asset in accordance with ASC Topic 350, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The Company&#8217;s IPR&amp;D is comprised of Crestovo&#8217;s research and development asset related to CP101, which was acquired in the Merger.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill and IPR&amp;D are evaluated for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company&#8217;s use of the acquired asset or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company&#8217;s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of goodwill, the fair value of the Company&#8217;s single reporting unit is compared to its carrying value. If the reporting unit&#8217;s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value. The Company&#8217;s annual assessments for impairment of goodwill as of October 1, 2021 and October 1, 2020 indicated that the fair value of its reporting unit exceeded the carrying value of the reporting unit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;D project exceeds its fair value. The Company estimates the fair value of IPR&amp;D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. The Company&#8217;s annual assessment for impairment of IPR&amp;D indicated that the fair value of its IPR&amp;D asset as of October 1, 2021 and October 1, 2020 exceeded the respective carrying value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any impairments are recognized as a loss in the year the goodwill and/or IPR&amp;D are determined to be impaired. Impairment of IPR&amp;D is recorded as research and development expense and impairment of goodwill is recorded separately as a loss in other income (expense) on the Company&#8217;s consolidated statements of operations. To date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment loss has been recognized. Additionally, there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> change to the carrying value of goodwill and IPR&amp;D for the years ended December 31, 2021 and 2020.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock', window );">Deferred Initial Public Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Initial Public Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred initial public offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be abandoned, the deferred initial public offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. On March 18, 2021, the Company completed the IPO; accordingly, the Company recognized the deferred initial public offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from gross proceeds associated with the IPO through additional paid-in capital in the accompanying consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 20, 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">192,877</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, pursuant to the underwriters&#8217; partial exercise of their overallotment option, and the Company recognized offering costs of less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from gross proceeds associated with the overallotment through additional paid-in capital in the accompanying consolidated balance sheet. Accordingly, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> deferred offering costs as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Deferred offering costs on the accompanying consolidated balance sheet as of December 31, 2020 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU 2016-02,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Leases (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 842</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors), and replaces the existing guidance in ASC 840, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FASB subsequently issued amendments to ASC 842, which have the same effective date of January 1, 2019: (i) ASU 2018-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Codification Improvements to Topic 842,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which amends certain narrow aspects of the guidance issued in ASU 2016-02; and (ii) ASU 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and not restate prior periods presented. ASC 842 requires lessees to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. The Company adopted ASC 842 during the quarter ended December 31, 2021, with an effective date of January 1, 2021, using the modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior period financial statements continue to be presented in accordance with ASC 840.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The adoption of this standard resulted in the recognition of operating lease right-of-use assets of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and current and noncurrent operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, and the derecognition of deferred rent liabilities and unamortized lease incentives of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, on the Company&#8217;s Balance Sheets as of January 1, 2021 relating to its office leases in Somerville, MA. The adoption of this standard did not have a significant impact on the Company&#8217;s consolidated Statements of Operations or Statements of Cash Flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to January 1, 2021, the Company accounted for leases under Accounting Standards Codification 840, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8216;&#8216;ASC 840&#8217;&#8217;). At lease inception, the Company determined if an arrangement was an operating or capital lease.  For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent.  The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified  deferred rent as current and  noncurrent  liabilities based on  the portion of the deferred rent that was scheduled to mature within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#8217;s control over the use of that identified asset. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use (&#8220;ROU&#8221;) asset and current and non-current lease liabilities, as applicable on the balance sheet. The Company elected, as allowed under ASC 842, to not recognize leases with a lease term of one year or less on its balance sheet. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and records its lease liabilities based on the present value of lease payments over the expected remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in the lease contracts if that rate is readily available. As the implicit rate has not historically been readily determinable, the Company utilizes its incremental borrowing rate (&#8220;IBR&#8221;), which reflects the fixed rate at which the Company could borrow on a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collateralized basis over a similar term to fund the amount of lease payments to be made in a similar economic environment. Management determines the appropriate IBR to use based on the Company&#8217;s credit standing and market environment at lease commencement. The Company measures its ROU assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.) , non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated, based on the respective relative fair values, to the lease components and non-lease components. However, the Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement and the establishment of a ROU asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When a lease is modified and the modification is not accounted for as a separate contract, the Company remeasures its ROU assets and lease liabilities.  A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for all stock-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#8217;s stock-based payments are comprised of stock options. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has historically been a private company until its IPO in March 2021 and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is primarily subject to U.S. federal and Massachusetts state income tax. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company maintains a reserve against certain federal and state research and development credits that are recorded net in deferred taxes. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals for interest or penalties related to income tax matters. Tax years since inception remain open to examination by federal and state tax authorities.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has historically generated revenue from the following sources: (1) collaboration revenue from the collaboration agreement with Takeda Pharmaceutical Company Limited (see Note 7) and (2) royalty revenue from OpenBiome&#8217;s sales of a licensed product under the Asset Purchase and License Agreement with OpenBiome (see Note 7).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The promised goods or services in the Company&#8217;s arrangements typically consist of (1) a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services; (2) an obligation to transfer FMT materials; or (3) an obligation to provide pre-clinical and clinical research and support services. Under the collaboration agreement, the Company provides options to additional items, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract. For performance obligations which consist of FMT materials, shipping and distribution activities occur prior to the transfer of control of FMT materials and are considered activities to fulfill the Company&#8217;s promise to deliver goods to the customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates the transaction price based on the amount expected to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and are included in the transaction price only to the extent it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are added to the transaction price with a corresponding adjustment being made to the measure of progress, and, as necessary, recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For contracts which have more than one performance obligation, the total contract consideration is allocated based on observable standalone selling prices or, if standalone selling prices are not readily observable, based on management&#8217;s estimate of each performance obligation&#8217;s standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to be entitled to for the satisfaction of each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For performance obligations, revenue is recognized when control of the product is transferred to the customer and the related performance obligation is satisfied, which typically occurs upon delivery of the product to the customer, for an amount that reflects the consideration the Company expects to be entitled to receive in exchange for delivering the product. For performance obligations which consist of clinical trial participation and related support services, revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disaggregation of Revenue</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides revenue disaggregated by timing of revenue recognition (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:55.945%;"/>
          <td style="width:1.804%;"/>
          <td style="width:2.145%;"/>
          <td style="width:17.488%;"/>
          <td style="width:0.881%;"/>
          <td style="width:1.804%;"/>
          <td style="width:2.145%;"/>
          <td style="width:16.906%;"/>
          <td style="width:0.881%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred at a point in time</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred over time</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,376</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,719</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#8217;s common shares and participating securities. The Company&#8217;s preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021 and 2020.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued and Adopted Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles-Goodwill and Other- Internal-Use Software</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (Subtopic<br/> 350- 40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance for capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted the standards on a prospective basis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on January 1, 2021.The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively and certain others to be made retrospectively. The Company adopted this standard on January 1, 2021, and this standard did not have a material impact on its consolidated financial statements and related disclosures for the year ended December 31, 2021. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255387684392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Lives</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:60.992%;"/>
          <td style="width:2.063%;"/>
          <td style="width:36.944%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">ESTIMATED USEFUL LIFE</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue by Timing of Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides revenue disaggregated by timing of revenue recognition (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:55.945%;"/>
          <td style="width:1.804%;"/>
          <td style="width:2.145%;"/>
          <td style="width:17.488%;"/>
          <td style="width:0.881%;"/>
          <td style="width:1.804%;"/>
          <td style="width:2.145%;"/>
          <td style="width:16.906%;"/>
          <td style="width:0.881%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred at a point in time</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferred over time</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,376</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,532</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,719</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305454024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:38.815%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DESCRIPTION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.815%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.931%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.442%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.981%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DESCRIPTION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">QUOTED<br/>PRICES<br/>IN ACTIVE<br/>MARKETS FOR<br/>IDENTICAL<br/>ASSETS<br/>(LEVEL 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SIGNIFICANT<br/>OBSERVABLE<br/>INPUTS<br/>(LEVEL 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305536152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.503%;"/>
        <td style="width:1.591%;"/>
        <td style="width:1.778%;"/>
        <td style="width:16.696%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.591%;"/>
        <td style="width:1.778%;"/>
        <td style="width:15.676%;"/>
        <td style="width:1.193%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">537</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">537</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,143</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction work-in-progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">329</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,635</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,883</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">368</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,226</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,029</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,635</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310983304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LeasesBalanceSheetInformationTableTextBlock', window );">Leases Balance Sheet Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the classification of right-of-use assets and lease liabilities as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.926%;"/>
        <td style="width:40.813%;"/>
        <td style="width:1.852%;"/>
        <td style="width:1.778%;"/>
        <td style="width:20.885%;"/>
        <td style="width:0.746%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BALANCE SHEET CLASSIFICATION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ASSETS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,053</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance lease assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,075</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Finance lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Finance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,041</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table represents the components of lease cost, which are included in general and administrative and research and development expense on the statement of operations, for the year ended December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.489%;"/>
        <td style="width:8.243%;"/>
        <td style="width:1.815%;"/>
        <td style="width:33.234%;"/>
        <td style="width:1.218%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LEASE COST</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finance lease cost:</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Amortization of right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Interest on lease liabilities</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,336</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;Short-term lease cost</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">525</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sublease income</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,064</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LeaseTermAndDiscountRateTableTextBlock', window );">Summary of Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining lease term and discount rate were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.741%;"/>
        <td style="width:2.021%;"/>
        <td style="width:31.238%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LEASE TERM AND DISCOUNT RATE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remining lease term (years)</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Finance Leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                 </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Finance Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosure of cash flow information related to leases was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.631%;"/>
        <td style="width:1.492%;"/>
        <td style="width:1.803%;"/>
        <td style="width:24.291%;"/>
        <td style="width:0.783%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">SUPPLEMENTAL CASH FLOW INFORMATION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DECEMBER 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,006</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Financing cash flows from finance leases</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td>
        <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ScheduleOfFutureLeasePaymentsTableTextBlock', window );">Schedule of Future Lease Payments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table represents a summary of the Company&#8217;s future lease payments required as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.503%;"/>
        <td style="width:1.203%;"/>
        <td style="width:1.273%;"/>
        <td style="width:10.897%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.273%;"/>
        <td style="width:11.066%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.283%;"/>
        <td style="width:9.515%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.283%;"/>
        <td style="width:9.515%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OPERATING LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">HOOD PARK LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">FINANCE LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TOTAL LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,046</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,440</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,663</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,109</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,795</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,255</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,931</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,427</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,071</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,605</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,605</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">984</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">989</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following represents a summary of the Company's future minimum lease payments under non-cancelable lease agreements, presented in accordance with ASC 840, as of December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.242%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.914%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.134%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.134%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OPERATING LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">FINANCE LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TOTAL LEASE OBLIGATIONS</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,351</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,411</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,430</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,115</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,115</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,233</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,233</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term and discount rate table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LeasesBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases balance sheet information table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LeasesBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ScheduleOfFutureLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of future lease payments table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ScheduleOfFutureLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Future Minimum Lease Payments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305495016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.567%;"/>
        <td style="width:1.616%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.051%;"/>
        <td style="width:0.758%;"/>
        <td style="width:1.616%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.051%;"/>
        <td style="width:0.758%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,345</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued legal and professional fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">711</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,401</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,062</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">904</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306868104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate differed from the statutory federal income tax rate due to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.37%;"/>
        <td style="width:1.84%;"/>
        <td style="width:0.808%;"/>
        <td style="width:16.271%;"/>
        <td style="width:2.983%;"/>
        <td style="width:1.84%;"/>
        <td style="width:0.771%;"/>
        <td style="width:16.134%;"/>
        <td style="width:2.983%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal income taxes at 21%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit and tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.90</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.03</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other adjustments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company&#8217;s net deferred tax assets and liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.807%;"/>
        <td style="width:1.803%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.81%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.803%;"/>
        <td style="width:1.79%;"/>
        <td style="width:16.81%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,419</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,192</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,921</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,057</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">859</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of Use Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">289</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,079</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,756</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,721</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangibles assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,952</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,891</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of Use Assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,372</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">330</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,182</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Reconciliation of Total Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.992%;"/>
        <td style="width:1.889%;"/>
        <td style="width:1.815%;"/>
        <td style="width:16.718%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.889%;"/>
        <td style="width:1.815%;"/>
        <td style="width:16.88%;"/>
        <td style="width:0.783%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Additions for tax positions of current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">314</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, end of year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,822</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,318</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310145224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, preferred stock consisted of the following (in thousands, except share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:18.895%;"/>
        <td style="width:1.551%;"/>
        <td style="width:0.646%;"/>
        <td style="width:12.633%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:0.646%;"/>
        <td style="width:12.673%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.047%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.126%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.551%;"/>
        <td style="width:0.636%;"/>
        <td style="width:16.271%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PREFERRED<br/>STOCK<br/>AUTHORIZED</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">PREFERRED<br/>STOCK<br/>ISSUED AND<br/>OUTSTANDING</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">CARRYING<br/>VALUE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">LIQUIDATION<br/>VALUE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">COMMON STOCK<br/>ISSUABLE UPON<br/>CONVERSION</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167,496,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,596,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,593</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,596,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,620,739</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,166,203</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,336</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,166,203</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series C</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109,604,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,465</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series D</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99,705,359</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,902,872</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,904</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,902,872</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">451,427,842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233,054</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305295112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock', window );">Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020, the Company has reserved the following shares of common stock for potential conversion of outstanding preferred stock, the vesting of restricted stock and exercise of stock options, common stock warrants, and shares under the employee stock purchase plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.98%;"/>
        <td style="width:1.827%;"/>
        <td style="width:0.858%;"/>
        <td style="width:18.523%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.827%;"/>
        <td style="width:0.858%;"/>
        <td style="width:18.585%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DECEMBER 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,053,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,346</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issuable under employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,195</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309,965</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,326,829</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">_________________________</span></p><p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During the fourth quarter of 2021, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,346</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> common stock warrants were net exercised, resulting in </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,303</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> net shares.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common shares reserved for potential conversion of outstanding preferred stock, vesting of restricted stock and exercise of stock options and common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255387682168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options Granted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions that the Company used in Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2021 and 2020 were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.263%;"/>
        <td style="width:2.009%;"/>
        <td style="width:18.366%;"/>
        <td style="width:2.009%;"/>
        <td style="width:18.353%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity of Stock Options</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity of the Company&#8217;s stock options under the 2021 Plan for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.349%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.626%;"/>
        <td style="width:10.029%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.641%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.716%;"/>
        <td style="width:10.188%;"/>
        <td style="width:0.626%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.403%;"/>
        <td style="width:0.626%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">SHARES</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">AGGREGATE<br/>INTRINSIC<br/>VALUE<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,053,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,964</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,602,643</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155,821</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">211,987</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.24</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.18</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,228</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">846,024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,589</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options vested or expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,228</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Total Stock-Based Compensation Expense</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December 31, 2021 and 2020 is as follows (in thousands):</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310723896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.262%;"/>
        <td style="width:1.728%;"/>
        <td style="width:1.591%;"/>
        <td style="width:20.179%;"/>
        <td style="width:1.057%;"/>
        <td style="width:1.728%;"/>
        <td style="width:1.591%;"/>
        <td style="width:19.806%;"/>
        <td style="width:1.057%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">FOR THE YEAR<br/>ENDED DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,160</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39,341</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss attributable to<br/>&#160;&#160;&#160;common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,160</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average common<br/>&#160;&#160;&#160;stock outstanding&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39,202,086</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,144,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per share attributable<br/>&#160;&#160;&#160;to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December 31, 2021 and 2020 because including them would have had an anti-dilutive effect: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.064%;"/>
        <td style="width:1.505%;"/>
        <td style="width:0.771%;"/>
        <td style="width:15.247%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.505%;"/>
        <td style="width:0.771%;"/>
        <td style="width:15.595%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">YEAR ENDED<br/>DECEMBER 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,253,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,264,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,053,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,346</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issuable under employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,195</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,309,965</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,326,829</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255301147864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock outstanding | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,160)<span></span>
</td>
<td class="num">$ (39,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160,995)<span></span>
</td>
<td class="num">(102,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,481<span></span>
</td>
<td class="nump">$ 99,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares | shares | shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds after deducting underwriting discounts, commissions and offering costs | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number shares issued upon conversion of redeemable convertible preferred stock | shares | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ProceedsFromIssuanceOfCommonStockGross', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PaymentsForUnderwritingDiscountsAndCommissions', window );">Payments for underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PaymentOfOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock outstanding | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number shares issued upon conversion of redeemable convertible preferred stock | shares | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">OverAllotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares | shares | shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_ProceedsFromIssuanceOfCommonStockGross', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds after deducting underwriting discounts, commissions and offering costs | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">OverAllotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares | shares | shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization, consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PaymentOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PaymentOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PaymentsForUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PaymentsForUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock, gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306476696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,500,000<span></span>
</td>
<td class="nump">$ 99,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Change in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Effective income tax rate reconciliation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax, accruals for interest or penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,053,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,887,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_DerecognitionOfDeferredRentLiabilities', window );">Derecognition of deferred rent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_UnamortizationOfLeaseIncentives', window );">Unamortization of lease incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786 | shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">OverAllotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786 | shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">OverAllotment Option | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786 | shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">OverAllotment Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">I P O [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">I P O [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Observevable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_DerecognitionOfDeferredRentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of deferred rent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_DerecognitionOfDeferredRentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_UnamortizationOfLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortization of lease incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_UnamortizationOfLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307817096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fnch_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful life</a></td>
<td class="text">Shorter of useful life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fnch_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fnch_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307888840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Disaggregation of Revenue by Timing of Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 18,532<span></span>
</td>
<td class="nump">$ 7,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Transferred at a Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 18,532<span></span>
</td>
<td class="nump">$ 7,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307846280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total financial assets</a></td>
<td class="nump">$ 225,369<span></span>
</td>
<td class="nump">$ 165,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total financial assets</a></td>
<td class="nump">132,275<span></span>
</td>
<td class="nump">98,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total financial assets</a></td>
<td class="nump">132,275<span></span>
</td>
<td class="nump">98,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total financial assets</a></td>
<td class="nump">132,275<span></span>
</td>
<td class="nump">98,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total financial assets</a></td>
<td class="nump">$ 132,275<span></span>
</td>
<td class="nump">$ 98,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310679496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_TransfersBetweenFairValueLevels', window );">Transfers between fair value levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_TransfersBetweenFairValueLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfers between fair value levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_TransfersBetweenFairValueLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307863368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 23,861<span></span>
</td>
<td class="nump">$ 9,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(4,226)<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">19,635<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fnch_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">3,850<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">13,894<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction Work-In-Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">4,883<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fnch_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fnch_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306910696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment held</a></td>
<td class="nump">23,861<span></span>
</td>
<td class="nump">9,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Software, Property and Equipment | Open Biome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment held</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255300021400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 17, 2021</div></th>
<th class="th">
<div>Aug. 03, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>May 25, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease term is from March 2021 through February 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,053,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Decrease in security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_InnerBeltRoadLeaseMember', window );">Inner Belt Road Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LesseeOperatingLeaseLeasesArea', window );">Office and laboratory space for lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Sublease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LesseeOperatingLeaseLeasesAdditionalArea', window );">Additional Space for primary office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LeaseAndRentForAdditionalSpace', window );">Rent for additional space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_OpenBiomeMember', window );">Open Biome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_CherryStreetLeaseMember', window );">Cherry Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_ConcordAvenueLeaseMember', window );">Concord Avenue Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term description</a></td>
<td class="text">On August 17, 2021 Finch extended the term of the lease for an additional two-month period through April 2022 and on February 4, 2022 Finch further extended the lease for an additional month through May 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 2021 through February 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_HoodParkDriveMember', window );">100 Hood Park Drive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LesseeOperatingLeaseLeasesArea', window );">Office and laboratory space for lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Sublease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Hood Lease provides Finch with an option to extend the lease for one additional five-year term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LeaseAndRentForAdditionalSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease And Rent For Additional Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LeaseAndRentForAdditionalSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LesseeOperatingLeaseLeasesAdditionalArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Leases Additional Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LesseeOperatingLeaseLeasesAdditionalArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LesseeOperatingLeaseLeasesArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Leases Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LesseeOperatingLeaseLeasesArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_InnerBeltRoadLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_InnerBeltRoadLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_OpenBiomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_OpenBiomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_CherryStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_CherryStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_ConcordAvenueLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_ConcordAvenueLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_HoodParkDriveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fnch_HoodParkDriveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255300930264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Leases Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">$ 5,053<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property Plant And Equipment Net<span></span>
</td>
<td class="text">Property Plant And Equipment Net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property Plant And Equipment Net</a></td>
<td class="nump">$ 19,635<span></span>
</td>
<td class="nump">$ 7,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LeaseAssets', window );">Lease Assets, Total</a></td>
<td class="nump">5,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities Current<span></span>
</td>
<td class="text">Liabilities Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Liabilities Current</a></td>
<td class="nump">$ 14,790<span></span>
</td>
<td class="nump">$ 11,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities Noncurrent<span></span>
</td>
<td class="text">Other Liabilities Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities Noncurrent</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_LeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">$ 6,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307686984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Components of Lease Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 2,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255309888008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Financing leases</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Finance leases</a></td>
<td class="nump">30.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307813448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (1,006)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PrincipalPaymentsOnCapitalLeaseObligation', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PrincipalPaymentsOnCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal payments on capital lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PrincipalPaymentsOnCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255299798632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="nump">$ 1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">6,109<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">6,427<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">27,605<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">58,629<span></span>
</td>
<td class="nump">8,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
<td class="nump">989<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of minimum lease payments</a></td>
<td class="nump">57,640<span></span>
</td>
<td class="nump">8,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingLeaseObligationsAbstract', window );"><strong>Operating Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">6,999<span></span>
</td>
<td class="nump">8,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue', window );">Less: amount representing interest</a></td>
<td class="num">(984)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PresentValueOfFutureMinimumLeasePayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">6,015<span></span>
</td>
<td class="nump">8,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseObligationsAbstract', window );"><strong>Hood Park Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">4,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">4,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">4,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">4,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">5,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">27,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">51,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">51,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_FinanceLeaseObligationAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_FinanceLeaseObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_FinanceLeaseObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due in five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due in four years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due in three years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due in two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments due thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments interest included in payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease future minimum payments present value of net minimum payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_HoodParkLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hood park lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_HoodParkLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest portion of operating leases future minimum payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in four years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in three years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments interest included in payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments present value of net minimum payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PresentValueOfFutureMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of future minimum lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PresentValueOfFutureMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255301152664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="nump">$ 1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">6,109<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">6,427<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">27,605<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">58,629<span></span>
</td>
<td class="nump">8,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
<td class="nump">989<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of minimum lease payments</a></td>
<td class="nump">57,640<span></span>
</td>
<td class="nump">8,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingLeaseObligationsAbstract', window );"><strong>Operating Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">6,999<span></span>
</td>
<td class="nump">8,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue', window );">Less: amount representing interest</a></td>
<td class="num">(984)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PresentValueOfFutureMinimumLeasePayments', window );">Present Value of Future Minimum Lease Payments</a></td>
<td class="nump">6,015<span></span>
</td>
<td class="nump">8,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_FinanceLeaseObligationAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_FinanceLeaseObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_FinanceLeaseObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest portion of operating leases future minimum payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in four years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in three years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due in two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments due thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments interest included in payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease obligation future minimum payments present value of net minimum payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PresentValueOfFutureMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of future minimum lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PresentValueOfFutureMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255307825976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">$ 1,345<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">3,062<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,925<span></span>
</td>
<td class="nump">$ 5,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255300885000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fnch_TakedaAgreementMember', window );">Takeda Agreement | Sales-Based Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Royalties received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fnch_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Takeda Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved', window );">Maximum milestone payment associated with development and commercialization upon milestone to be achieved</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_MilestonePaymentsReceivedUnderAgreement', window );">Milestone payments received under agreement</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining revenue performance obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fnch_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Takeda Agreement | Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fnch_OpenBiomeMember', window );">Open Biome | Asset Purchase And License Agreement | Sales-Based Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Royalty revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fnch_OpenBiomeMember', window );">Open Biome | LMIC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fnch_OpenBiomeMember', window );">Open Biome | LMIC Agreement | Sales-Based Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Royalty revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment associated with development and commercialization upon milestone to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_MilestonePaymentsReceivedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_MilestonePaymentsReceivedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_TakedaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_TakedaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fnch_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fnch_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fnch_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fnch_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fnch_OpenBiomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fnch_OpenBiomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_LMICLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_LMICLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306808504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 21%</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">State income taxes, net of federal benefit and tax credits</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.19%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="nump">2.12%<span></span>
</td>
<td class="nump">2.03%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(29.30%)<span></span>
</td>
<td class="num">(26.96%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.53%)<span></span>
</td>
<td class="num">(0.51%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255397811016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 48,419<span></span>
</td>
<td class="nump">$ 30,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">4,376<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued expenses</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_RightOfUseLiabilities', window );">Right of use liabilities</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">55,835<span></span>
</td>
<td class="nump">36,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(49,079)<span></span>
</td>
<td class="num">(31,963)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">6,756<span></span>
</td>
<td class="nump">4,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangibles assets</a></td>
<td class="nump">7,952<span></span>
</td>
<td class="nump">7,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_DeferredTaxLiabilitiesFixedAssets', window );">Fixed assets</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_RightOfUseAsset', window );">Right of Use Assets</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">10,217<span></span>
</td>
<td class="nump">8,182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total net deferred tax liabilities</a></td>
<td class="num">$ (3,461)<span></span>
</td>
<td class="num">$ (3,461)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, total fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_RightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_RightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_RightOfUseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_RightOfUseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306970344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 49,079,000<span></span>
</td>
<td class="nump">$ 31,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">$ 181,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingLossCarryForwardsExpirationYear', window );">Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="nump">2.12%<span></span>
</td>
<td class="nump">2.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="nump">$ 57,279,000<span></span>
</td>
<td class="nump">$ 33,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate', window );">Research and Development Credits, Expiration year</a></td>
<td class="text">which will expire at various dates through 2041<span></span>
</td>
<td class="text">which will expire at various dates through 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income Tax Examination, Penalties and Interest Accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credit carryforward percent</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,400,000<span></span>
</td>
<td class="nump">$ 144,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen', window );">Operating Loss Carry forwards Prior Period</a></td>
<td class="nump">$ 37,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">state [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_OperatingLossCarryForwardsExpirationPeriod', window );">Operating Loss Carry Forwards Expiration Period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credit carryforward percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Tax Credits Research Expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingLossCarryForwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingLossCarryForwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration year of each operating loss carryforward included in operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards prior period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310411992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Total Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,318<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions of current year</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued', window );">Accrued penalties and interest</a></td>
<td class="nump">$ 1,822<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits penalties and interest accrued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255301076104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 08, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis=fnch_PaycheckProtectionProgramCARESMember', window );">Paycheck Protection Program C A R E S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_AccruedInterestBorrowed', window );">Accrued interest borrowed</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_DebtInstrumentForgivenDescription', window );">Debt instrument forgiven, description</a></td>
<td class="text">On May 8, 2021, the Company received notice from the SBA that the entirely of the PPP Loan was forgiven. Accordingly, the Company is no longer required to repay the $1.8 million in principal and approximately $19,000 in accrued interest borrowed under the PPP Loan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember', window );">Open Biome | Asset Purchase And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_MaximumRegulatoryMilestonePayments', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_MilestonePaymentsPaid', window );">Milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember', window );">Open Biome | Material Access And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_RoyaltyPaymentsPaidOnNetSales', window );">Royalty payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_RemainingRoyaltyCommitmentAmountDue', window );">Remaining royalty amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_AdditionalRoyaltyCommitmentsAmountDue', window );">Additional royalty amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_AccruedInterestBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest borrowed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_AccruedInterestBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_AdditionalRoyaltyCommitmentsAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional royalty commitments amount due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_AdditionalRoyaltyCommitmentsAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_DebtInstrumentForgivenDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument forgiven description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_DebtInstrumentForgivenDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_MaximumRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_MaximumRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_RemainingRoyaltyCommitmentAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining royalty commitment amount due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_RemainingRoyaltyCommitmentAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_RoyaltyPaymentsPaidOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payments paid on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_RoyaltyPaymentsPaidOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_SalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales-based milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_SalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis=fnch_PaycheckProtectionProgramCARESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis=fnch_PaycheckProtectionProgramCARESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_MaterialAccessAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_MaterialAccessAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255300337272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Informations (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,427,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Share at January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,512,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,391,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Share at January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Redeemable convertible preferred stock purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,496,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Share at January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,620,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Share at January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,604,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Share at January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,705,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">6,902,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of redeemable preferred stock</a></td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_TemporaryEquityIssuanceCosts', window );">Preferred stock issuance cost</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Share at January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Redeemable convertible preferred stock purchase price per share</a></td>
<td class="nump">$ 13.0381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255300158392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">451,427,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 233,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">LIQUIDATION VALUE</a></td>
<td class="nump">$ 219,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">167,496,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">11,596,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">11,596,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 53,593<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">LIQUIDATION VALUE</a></td>
<td class="nump">$ 40,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">74,620,739<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">5,166,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">5,166,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,166,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 36,336<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">LIQUIDATION VALUE</a></td>
<td class="nump">$ 36,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">109,604,994<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">7,588,254<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">7,588,254<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 53,221<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">LIQUIDATION VALUE</a></td>
<td class="nump">$ 53,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">99,705,359<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">6,902,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Shares Outstanding</a></td>
<td class="nump">6,902,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 89,904<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">LIQUIDATION VALUE</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">COMMON STOCK ISSUABLE UPON CONVERSION</a></td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">COMMON STOCK ISSUABLE UPON CONVERSION</a></td>
<td class="nump">11,596,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">COMMON STOCK ISSUABLE UPON CONVERSION</a></td>
<td class="nump">5,166,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series C Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">COMMON STOCK ISSUABLE UPON CONVERSION</a></td>
<td class="nump">7,588,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series D Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">COMMON STOCK ISSUABLE UPON CONVERSION</a></td>
<td class="nump">6,902,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fnch_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306327416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">598,232,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared or paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock entitles the holder to one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,238<span></span>
</td>
<td class="nump">$ 14,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember', window );">Secondary Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember', window );">Secondary Sale | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="nump">192,877<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Offering price per share</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Secondary Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock selling price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=fnch_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=fnch_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=fnch_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306314072">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for potential conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,309,965<span></span>
</td>
<td class="nump">32,326,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for potential conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fnch_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for potential conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,264,770<span></span>
</td>
<td class="nump">1,053,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fnch_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for potential conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for potential conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During the fourth quarter of 2021, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,346</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> common stock warrants were net exercised, resulting in </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,303</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> net shares.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fnch_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fnch_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fnch_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fnch_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310390104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_CommonStockWarrantsExercised', window );">Common stock warrants exercised net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_CommonStockWarrantsExercisedGross', window );">Common stock warrants exercised gross</a></td>
<td class="nump">19,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_CommonStockWarrantsExercised', window );">Common stock warrants exercised net</a></td>
<td class="nump">19,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_CommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_CommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_CommonStockWarrantsExercisedGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants exercised gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_CommonStockWarrantsExercisedGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306575240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Aggregate purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for potential conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309,965<span></span>
</td>
<td class="nump">32,326,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.87<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,161,000<span></span>
</td>
<td class="nump">$ 3,099,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_RemainingStockCompensationExpenses', window );">Remaining stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember', window );">Secondary Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786</a></td>
<td class="nump">412,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fnch_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">698,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of common stock to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense remaining to be recognized, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fnch_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,569,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of common stock to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,291,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance', window );">Percentage of increase in shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares issuable upon the exercise of outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,264,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense remaining to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fnch_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan | Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of common stock to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in shares of common stock reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_RemainingStockCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining stock compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_RemainingStockCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fnch_SecondarySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fnch_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fnch_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fnch_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fnch_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fnch_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fnch_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306565416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Assumptions Used to Value Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.88%<span></span>
</td>
<td class="nump">0.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.70%<span></span>
</td>
<td class="nump">74.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">76.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255300845224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Activity of Stock Options (Details) - 2021 Equity Incentive Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">SHARES, Outstanding, Beginning Balance | shares</a></td>
<td class="nump">1,053,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">SHARES, Granted | shares</a></td>
<td class="nump">2,602,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">SHARES, Exercised | shares</a></td>
<td class="num">(155,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">SHARES, Cancelled or forfeited | shares</a></td>
<td class="num">(211,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">SHARES, Expired | shares</a></td>
<td class="num">(23,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">SHARES, Outstanding, Ending Balance | shares</a></td>
<td class="nump">3,264,770<span></span>
</td>
<td class="nump">1,053,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">SHARES, Options exercisable | shares</a></td>
<td class="nump">846,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">SHARES, Options vested or expected to vest | shares</a></td>
<td class="nump">3,264,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Granted | $ / shares</a></td>
<td class="nump">14.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Exercised | $ / shares</a></td>
<td class="nump">1.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Cancelled or forfeited | $ / shares</a></td>
<td class="nump">13.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Expired | $ / shares</a></td>
<td class="nump">12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">11.04<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Options exercisable | $ / shares</a></td>
<td class="nump">4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">WEIGHTED AVERAGE EXERCISE PRICE, Options vested or expected to vest</a></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options exercisable</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options vested or expected to vest</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance | $</a></td>
<td class="nump">$ 7,228<span></span>
</td>
<td class="nump">$ 4,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance | $</a></td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">$ 4,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">AGGREGATE INTRINSIC VALUE, Options exercisable | $</a></td>
<td class="nump">5,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE, Options vested or expected to vest | $</a></td>
<td class="nump">$ 7,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fnch_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fnch_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255310334328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Total Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,161<span></span>
</td>
<td class="nump">$ 3,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 2,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306552616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Feb. 10, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember', window );">Open Biome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Rent income under sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember', window );">Open Biome | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fnch_StrategicAgreementMember', window );">Strategic Agreement | Open Biome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Reimbursed to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Reimbursed from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fnch_StrategicAgreementMember', window );">Strategic Agreement | Open Biome | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fnch_ClinicalSupplyAndServicesAgreementMember', window );">Clinical Supply and Services Agreement | Open Biome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_PaymentOfMonthlyPlatformFee', window );">Payment of monthly platform fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_SecurityDepositsReturned', window );">Security deposit returned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Open Biome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireSoftware', window );">Payment to acquire certain assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Payment to acquire remaining assets</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fnch_MaximumMilestonePaymentRequiredUnderAgreement', window );">Required to pay certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_MaximumMilestonePaymentRequiredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment required under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_MaximumMilestonePaymentRequiredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_PaymentOfMonthlyPlatformFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of monthly platform fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_PaymentOfMonthlyPlatformFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fnch_SecurityDepositsReturned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Security deposits returned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fnch_SecurityDepositsReturned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fnch_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fnch_OpenBiomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_StrategicAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_StrategicAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_ClinicalSupplyAndServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_ClinicalSupplyAndServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fnch_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255305442728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company's contribution to plan</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255304266600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,160)<span></span>
</td>
<td class="num">$ (39,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders&#8212; basic and diluted</a></td>
<td class="num">$ (58,160)<span></span>
</td>
<td class="num">$ (39,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common stock outstanding&#8212;basic and diluted</a></td>
<td class="nump">39,202,086<span></span>
</td>
<td class="nump">8,144,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (4.83)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140255306311992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluding from computation of diluted net loss per share</a></td>
<td class="nump">3,309,965<span></span>
</td>
<td class="nump">32,326,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluding from computation of diluted net loss per share</a></td>
<td class="nump">45,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluding from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,253,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluding from computation of diluted net loss per share</a></td>
<td class="nump">3,264,770<span></span>
</td>
<td class="nump">1,053,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluding from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>fnch-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:fnch="http://finchtherapeutics.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fnch-20211231.xsd" xlink:type="simple"/>
    <context id="C_3c431cec-8ef4-41d1-91de-5a171c2fbc40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0f83ae0d-7bba-4546-b75f-1d3582c586e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:CherryStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d132eb44-d5fe-4db6-90fa-ee1cb44369fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_67b625c9-9b8a-4bea-b722-36d695553d6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_089fb034-da86-4331-8cab-1b70dc0cd490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_36ebf60e-e0c4-40dd-910b-838e10c9ca42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_12c08bf0-f65b-48fb-8e06-4a1f508e55aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1eea5819-27f3-44f8-90a5-9ad45f546635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ab627a9f-a180-4add-89be-437938d49551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_06a32a5b-3613-45c4-bbd2-cb0a2ad1a82b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c775cfd2-628d-4919-8429-a954d20061c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="C_7eff636f-c2ac-47da-b8b3-a7419771eb22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_42702fe8-9f6e-4d52-96bc-bf7ff5642f9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17959f69-52c0-4bd7-b17b-2b07c6a89b83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:CherryStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_736b82ab-77e3-4d3c-b1d1-93ec2b7be5f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="C_83341027-5973-4448-a037-4a0f2e02d99e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_799a1f7a-7972-48f7-b715-47a07a846536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4603d1f8-8b00-442d-96f0-6e9d5d761ed9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_703e5c2d-7a7f-413a-842f-a40f1f56526b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2836ed65-af3b-490c-89b2-d07fef0677d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3997c41e-c3c8-4da2-92c5-b9b78945ec5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0b373c5e-3287-41b4-b4c9-314d0744c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb5222a4-6edc-4157-b8f3-0776d5488397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_95503824-281a-48bb-a70d-4346f1e2af47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9f617c4d-2130-4a03-be94-001eafeeb878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_78dd3234-e5d1-4ad1-9914-de28cdc240bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e102589d-5e6a-4e44-bd66-a82362df7fb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:LMICLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e1f90607-ba2b-41a5-bea3-4ef6520ec07b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d1c89c9b-52b3-4ae8-bb9f-118f289a32ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">fnch:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_1a179872-937f-42ac-8d8c-e1ded8315d35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e8d19c5f-3b27-462c-bd7a-dd8adf6bc783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eab725e4-2f52-4e39-862f-22ef20e05710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f3c21c56-3f76-4284-9b46-d59d04095b4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_c6dc934d-3979-4343-93cf-f35734ec869e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="C_c26cc83f-e31e-4451-9562-469d6a32f396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d4472afe-992b-4a5e-9cca-abeb72f9257d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_46125c65-4c5f-4d12-825a-13db653d8482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c5285cda-f062-40ab-908f-8ca5f466181d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8093822b-1d40-4764-a04f-b8bfd74d9e7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_90fcacc1-0f06-47c8-b90f-1fbdb93ceffd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e78abb46-6208-4d28-9564-457e5c7c89e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_84da10c1-11ac-42c7-a238-2c5259bce7ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a6c10679-4ab6-409c-8105-7146e8e77be9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d4f0fa8f-0e53-4dd0-96a5-34610a065137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_318f64ea-ab2c-4f3a-8c39-bea1e8b5efee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5b073b84-8eb2-412a-a07e-959c86d508ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_54d8859b-3cf9-4f25-81a8-0121817ec070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_fc5421c3-a799-4980-a188-637fac870fba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a6aef8a-3ebf-43c8-a1d9-cb65a4f2ce4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_ee5e5087-1f48-495c-a0c7-df7f666bcc55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fnch:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fbf098e4-d64a-4024-bd56-afb40e7ad714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c284ec5c-9fd7-4308-a062-488f6fa155dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">fnch:PaycheckProtectionProgramCARESMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_2986efa3-0d9a-4a27-8474-473277d39a68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fnch:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_60b68536-8ed1-43da-ac13-d5bdb8aa1b26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d4537122-5c97-4483-a0d3-0abbbe078b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6e1cbdf0-abb9-4321-a134-6b908bc1cb74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_63ccd21b-b4e9-4f84-b09c-125598219f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1545e700-f4cb-462d-bda2-6aea5fb1b1f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_96bb2e98-4d79-4650-8af9-3a931a612483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fb1c3a83-faee-4108-875a-e75af3e55f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_28d6c4c4-95d2-4950-aa5c-95cb9369b506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="C_53f088f1-6942-4a33-8ec0-d9a352aa8473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eb5c3d76-f6ae-465b-9ade-c84c08d30d59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f567ce58-d36b-4cfd-9d2d-43b08b57d11c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_734ba92d-986a-46d1-aeee-fd929b61447a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_389a0f17-bc7e-475d-9cc4-8f35d0418848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_aa678b92-859d-4297-a5ea-40baf1bbd70e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b15bab6a-f44e-4005-a4ff-bbdc0471e1f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="C_1f587b93-a68e-4011-af1c-8223963a66b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_101a8fc8-ab99-4053-8a20-c0d1e9fba7b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9d380522-affd-4af4-a507-2ff7a0457581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">fnch:PaycheckProtectionProgramCARESMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-08</instant>
        </period>
    </context>
    <context id="C_e3e50907-6887-4220-a0d9-4a36fa444e7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_94c65693-07a8-42cf-9bcf-fe65d1cb5868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_30f83225-a823-4c68-b24e-432bbb423504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1bd4a0ca-99c2-4074-b339-97461c98088b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:LMICLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1de77ba6-205b-42f6-acd1-060d987f64f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8192ae4f-1c2b-4a80-a43c-6831f9eb30f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_773d9f64-92e0-471f-87fd-c693d0fedbc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_17ff663a-6142-4c26-8780-a4ce862a5484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2ef89633-4500-4c18-944c-7f047f6e3e2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_516796e2-fbe9-4963-858d-72b0827743bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="C_24547a48-6a37-4b99-8269-4b7bace32f46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6252e38b-5c6e-4c8e-8aa8-5c056fef33a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:MaterialAccessAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e162eb52-c156-467f-9465-7e2422f556b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="C_c1241508-27ea-4aa7-a3a8-f0e51e38ba2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_61cd82ea-f358-4082-bca8-78e13843b66f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_049c3cdd-3341-4084-9a6d-e1edee63342e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6c2fd835-a216-403d-821e-6c8b06fd2c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7d09ee6b-925b-4309-b34d-5e1eb3247ba6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3fe6991f-9dcc-4a7d-a873-78e8fd832d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d35ab3f0-886e-4614-bb8e-288d6e18d8a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f2f7e686-a500-4145-884d-a28aca2133c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_80eb5b83-cbf6-469c-a34a-c9f03f095627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-12</instant>
        </period>
    </context>
    <context id="C_c5aa5df0-f902-4636-ba9a-661aa8e20277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ee5015be-b0fc-4255-b8a6-7d92826e8809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_d4277bcb-d35b-4f32-8ff6-cdca824e9d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4dc28e60-afc9-4c19-b43d-868677e6583f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_23263f47-404c-4325-867d-c627433086e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="C_97f8bd01-bf35-4029-b59b-fedcc19e7fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ea0a073d-aea6-481f-bcbd-2d2464476655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_958aeacf-f69f-4b11-a72c-34559a9f8235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_92ff62b1-b286-46a8-8e9a-bd9133b65f3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_58649b84-b6a5-4536-b8e2-c6e68450eebd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">fnch:PaycheckProtectionProgramCARESMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-08</startDate>
            <endDate>2021-05-08</endDate>
        </period>
    </context>
    <context id="C_b80e0856-efdb-45ee-8c35-7042653d6f4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7b8eb604-10e3-4861-ab49-2e0d36d00d64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="C_20b17903-cb4b-42fd-9bb7-362bbcc58c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_48646751-72ab-4bdf-9554-d01586c1b9b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ec838299-1fe2-441c-a5b8-80818b17a987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9eb4f167-eaf7-4d4b-98b2-e2d8c89215f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">fnch:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_4fb463b4-797e-452d-873d-48619c046805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d858d07b-3375-4198-87a7-a594e75f4620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02bc5fe6-52dc-428c-a5bc-9f4b8b799841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_309231a5-1644-42cc-8f57-4efa7d95eb14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cb5e464a-84a9-4eb3-ad80-f75e327f7bbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e407f9da-0025-4449-9d33-474e81924957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_9450f23f-f434-468a-8008-c54520274c6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1fc799d2-e7ca-49cd-94bd-3368b8b30296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fnch:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_eb9e58de-8667-4321-b6aa-911f48db159f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_78f74fe2-9b23-4570-b2d6-32c1291e24ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fnch:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e585cf8d-a59f-4d43-8477-6b3d9ed99d06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="C_5f6ab27f-7051-4656-8340-31bd75faefe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c2016132-69da-4b8f-8d71-133d0638c922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4e5ad697-00fd-45d8-8d53-5221838de719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_08797998-db85-4999-b501-d07c4980c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b66a4bb1-f047-4756-b7b4-61d3d88e063e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_826e7f83-9582-40fb-b568-89f02012f782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aa2b03ad-bfcf-4d93-bc04-01ee6362dafd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f59b9e4d-a520-4962-b1b1-8256ad30502f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_34e7a81f-7394-49b9-84da-068d88b1e719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_da1fc6b8-eb04-4fd7-aefa-1b1663c0cbad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9606295d-3592-4e4f-80a8-99a45144d61e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_aee05aaf-8f6d-4638-a8fe-67e2f46277b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_754cfea2-fdc5-4ff8-a708-49bbef66cbaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0df70676-9619-40e8-853f-19a8b73a703f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a7977ced-72d5-4903-b7c8-1bf202956756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:RoyaltiesRevenueFromRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_83dde824-9020-47ce-a70f-8cacb2aad84b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9d0e0e4a-c148-42f2-b8d6-c5dcb9f5fb6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d9b8ef89-619c-4cf1-98e8-3318a7630899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ad20da32-3929-4b8f-8211-81be4d8ad10d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a3403fa8-bacc-4e4b-a517-c82e4d4d547a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_af126580-e6a9-4bc4-b56f-9a9ed89d3577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e4017af1-75f3-41f0-9528-da23823df46b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_29237393-f7a6-4fe4-b6e8-04815b077862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_1290669d-3ef4-4091-b2fe-97c62f8ec90f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4de9218f-505d-4ec5-a79e-948264f8faaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bf8db871-33e8-4b48-96d6-27807a718a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_32730e64-85f4-497d-935f-ef876cb18554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_68b03d20-efc1-47c4-97fe-d09e37d99bd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a3685552-54f1-4285-9365-be9a43f57bfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:RoyaltiesRevenueFromRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e29d9cb5-46b0-4d57-96ad-b94780aa228e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_566912aa-b2e7-4130-a031-93d7d2de01cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-10</instant>
        </period>
    </context>
    <context id="C_7ac98b6d-c24a-449b-91fb-dcb878c6c9ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_d183d8f2-6271-4193-aa8f-606f93e1458d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_894a98a6-c6bc-4f3a-98ca-fb68d588713d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="C_248b74bb-bfef-43a3-8d20-9cef789c8fff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:ConcordAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-25</startDate>
            <endDate>2021-05-25</endDate>
        </period>
    </context>
    <context id="C_0483dbaf-2c53-4e42-b419-593696b5f428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="C_e109216b-8e95-4dc3-9229-87d798ee0e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cd8cbba4-d765-4c03-adf6-a6cf25b63c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b5ab9bc6-ee73-4ce5-9025-8b3e49b4281c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_db4e3207-e9fa-4152-a818-87c22ab1f012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5da05409-533d-466c-be18-f590067b6927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76e74e59-dc68-499b-b05c-f96331eeeafa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_beb9a9a0-b07a-43a6-96d5-dca4ca792d9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:MaterialAccessAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ffad40cc-645b-45db-bb47-731c0e92c8ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_34820dd6-125a-4651-9d74-471c92bb1554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="C_4f9e11d5-5772-4d8d-aeba-f92855030d1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="C_fe91f7aa-3290-4bec-8ded-b59274901189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_db086534-a8d4-4c38-a41b-514f72bc36c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:LMICLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10a999a1-8dfb-4ba6-8758-e876879ab568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fcacd18f-13a2-4b4f-b905-5a7daa5bf83a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a6981439-53f3-412e-bd72-c7b736c9fa1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-10</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="C_05c62255-213e-4926-a804-309677cebed5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e63bb9f3-addf-44bf-9079-4ef73a7b1858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:ClinicalSupplyAndServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dcc33dd7-e5c8-4f20-b7fe-48ad8567599e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_12ceb0d9-027f-4047-880f-0f426157ce04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_caa9d4b6-a795-41fe-9dbc-e8ef123673de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_29953980-7bf1-4fdd-b181-4be7a82bb370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fnch:SecondarySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_583cd02a-6b47-4c6a-9fda-94aade34f36d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:StrategicAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6d564718-6e70-47c3-b45e-478a924b707b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bfcf15ad-e5a5-482c-921c-d2c853db7126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fnch:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8e96af31-f869-445b-b59a-14d832388be8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fnch:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d5f06605-6037-48e4-9be3-dc6adc0731f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e6ce2584-4ad0-4ec8-bee7-5bf80eddbb4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="C_193c9642-0dfc-4b03-beda-cbe44093e952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f1444436-ad66-46ea-8295-6f51e32cc67c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_71180d5f-f125-42b1-a289-021fbd6caff4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fnch:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_5e9b7d9d-0899-469e-840d-b1a8fd63c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3854077f-36a9-4171-af92-3885c504f8ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ed564ca9-9a3a-412d-9d64-5fd1ffc81119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2bd85910-ac68-4113-bf19-049baf264c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_92dda7ef-0294-4c60-82b0-253ca681399b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:InnerBeltRoadLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="C_29c6a1db-39a6-4d51-92a7-9d1ef5ec34c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fnch:HoodParkDriveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_60325954-cd50-4585-85cc-6fc0b138b87d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fnch:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_619dbd5a-3d31-4dff-bdde-1c37501aef02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_85b5348c-0723-4afb-be02-9db714b74dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fnch:OpenBiomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fnch:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>fnch:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      id="F_4a3ab359-83a0-467a-832c-81187a39bb66">http://fasb.org/us-gaap/2021-01-31#LiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_2d1cab61-360a-4886-82f1-f7e9f31c3925">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      id="F_5221a7d6-7634-49ee-a6f1-36478875109c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a"
      decimals="0"
      id="F_7ea1798d-7710-41a8-88de-a9818d271ecd"
      unitRef="U_pure">69.000</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      id="F_ce0870bb-8eeb-44d5-b5e5-d0584b753fb3">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      id="F_957127f4-c475-441f-b556-eccb47c51b83">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      id="F_a2193164-9e2a-4221-9f68-b893cedb3694">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      id="F_5948ec9b-5280-4aa5-aed5-af79546d9c6d">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="INF"
      id="F_21ec6a53-bfc8-4b44-8ee4-633109b93d1e"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_ef49ada0-6575-4ae4-a962-ef5ca9c297f6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_a0f8a908-b2a1-4ec4-b4e9-5040c0d7f77c">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      id="F_82684cf4-53e2-4fe6-90df-5260ddc9184d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_68d05483-5dc7-4b5f-80b7-0dd35e2effcb">0001733257</dei:EntityCentralIndexKey>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      id="F_38192f5a-105d-43eb-b508-0d9616c597fd">http://fasb.org/us-gaap/2021-01-31#LiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_d610c817-b7ce-47ac-89d1-d17113fbe941">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_b52ab163-1099-4172-96de-c972e64a706f">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_49b74151-4927-4c4c-b8e1-8f1641a0ac66">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_31adbbed-3ba7-43d0-a2bd-d44c9a028c07">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_66e1b697-bdcc-422e-97f5-2310141cdd03">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_402b542f-5a66-4c82-919f-8235f2e322d1">001-40227</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_e3e7612c-4351-4b06-90e0-6d6abdafa208">FINCH THERAPEUTICS GROUP, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_2045e421-8201-48f1-a592-81b4b0be98f8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_67461d0d-03fe-4ab8-b8d9-f771590b84cb">82-3433558</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_e1401ef6-2cab-446e-a225-ca1716503173">200 Inner Belt Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_9c6f0261-48fb-4309-b8ea-48f4dbcf4b57">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_74e59df9-6fb4-4e55-90bf-b9d57f213388">Somerville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_07df74b7-6554-49f7-ab83-e8e38d8f8ce5">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_4273939b-f612-4c81-be97-4e3c20ee3028">02143</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_93e0d8bc-e0d9-4bb0-959e-8792e6a16cf3">617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_89a9a856-f73b-49f0-80d5-1fd02ce75f69">229-6499</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_35844f50-e613-439b-8316-9a33d9d880d8">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_e32c4219-03ac-48bc-95c9-6854b51fd8d3">FNCH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_aec1d9b5-dddf-4e4b-b0a2-693b48545206">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_97fd24ec-e75d-489f-8e0a-3c87479c82ef">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_95d83c9b-eb6f-448a-af15-a3e19a855b1f">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_d85a889d-61c2-49bf-a271-0de323f4e228">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_f4b09e5f-b75d-4604-95b2-ac0ceff702f6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_3506e94a-0d52-4550-842d-ae0f26d20403">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_5bebce2f-f72f-4c48-af9d-bc07bfc0695c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_a4ea5a14-9110-48c4-8354-976ae4bb143b">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_ad45a029-4954-47f5-84ec-1a8894d02d79">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_06612c23-46fa-4840-9604-bb409cb4775c">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_ca796b43-e177-47aa-a7ce-6b2f23d55476">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_101a8fc8-ab99-4053-8a20-c0d1e9fba7b6"
      decimals="-5"
      id="F_89e4abd2-3238-4d3e-96b8-dc2c7495fc93"
      unitRef="U_USD">354900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0483dbaf-2c53-4e42-b419-593696b5f428"
      decimals="0"
      id="F_02e3cd35-2d45-4076-9189-b3f70148ec10"
      unitRef="U_shares">47532573</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_c649fc5e-47b1-4941-9b2d-8cd09636f9bf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Portions of the registrant&#x2019;s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_c7d31d35-51ce-42f7-9392-90cbbe30252e">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_14234b88-e1ec-4484-89ff-6f149fda53a2">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_892ea479-9276-435e-81d4-e05bfb503054">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_e755b1cf-a31c-4832-94ef-055db02347ee"
      unitRef="U_USD">133481000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_45d34ea9-8c63-4984-b54c-15ab0b2e159c"
      unitRef="U_USD">99710000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_a6a5aaa7-f1c9-47e2-a575-4dd4bb77efa6"
      unitRef="U_USD">494000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_e4eddba2-51c6-4491-b796-23a203e7fb6b"
      unitRef="U_USD">1034000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_1e053055-077e-4028-9dca-3509c53a53f4"
      unitRef="U_USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_74c278b3-2e6a-4a62-aea1-f524310c4b40"
      unitRef="U_USD">61000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_a9a35c0a-af6a-41a1-a80e-5c3ce0839fb0"
      unitRef="U_USD">8576000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_c32dc8dd-c0ac-4881-9727-8f60b272a124"
      unitRef="U_USD">5359000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_ce3b8a0f-fe51-441a-bdad-c377a791683d"
      unitRef="U_USD">142551000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_06263595-3a40-4b37-a44d-43c621fc9593"
      unitRef="U_USD">106164000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_3b31a5a5-86bd-4167-af04-3bd5947cb3b0"
      unitRef="U_USD">19635000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_68c9a442-f46a-4168-9268-efafd9251084"
      unitRef="U_USD">7004000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f6182ac4-e52e-4662-80bd-5088fc3cda60"
      unitRef="U_USD">5053000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_2f159e54-43d8-4420-8bba-94bd3f0765c9"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <fnch:InProcessResearchAndDevelopment
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_ee2dd3a8-42d5-46e7-9654-c92c2299bb9f"
      unitRef="U_USD">32900000</fnch:InProcessResearchAndDevelopment>
    <fnch:InProcessResearchAndDevelopment
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_aa8f8c7b-7785-4011-b636-7807f994ecd8"
      unitRef="U_USD">32900000</fnch:InProcessResearchAndDevelopment>
    <us-gaap:Goodwill
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_0edab58d-ceec-4cf8-aa84-6f7263cf8eb2"
      unitRef="U_USD">18057000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_36d4c9c3-9378-42d2-a98e-2b53ee9b53e5"
      unitRef="U_USD">18057000</us-gaap:Goodwill>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_73c7be48-d105-4239-a082-4d57fe763884"
      unitRef="U_USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_7dfbe545-cd92-4ff3-aeee-e713be21a1d5"
      unitRef="U_USD">1013000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_d2177e55-b681-4309-b348-c0784e2f50ae"
      unitRef="U_USD">2268000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_10a15d80-e4fb-4e1c-b0ac-ec656a0857a5"
      unitRef="U_USD">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_2db77bc6-837c-4e11-8f1d-c429d8ddda0b"
      unitRef="U_USD">4905000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_bfc0416e-0cdf-43b6-b324-b74170d1e4f1"
      unitRef="U_USD">200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_639c3716-f0e4-4504-9cc9-01c8422eb2c7"
      unitRef="U_USD">225369000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_e22746ad-7f7e-48dd-8ef1-5ab24407c317"
      unitRef="U_USD">165338000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_50f0195e-d2f9-47ce-8c4e-006708a1f7ca"
      unitRef="U_USD">3737000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_c45ba7c3-5653-4346-a0d5-01b2a92255fa"
      unitRef="U_USD">2621000</us-gaap:AccountsPayableCurrent>
    <fnch:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_d537da56-d9b1-4204-a52d-627957439914"
      unitRef="U_USD">9925000</fnch:AccruedExpensesAndOtherCurrentLiabilities>
    <fnch:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_bed13e23-9e6a-4619-9b15-69a5456c7810"
      unitRef="U_USD">5228000</fnch:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_d06ef3b6-afa1-4167-97b7-9c2b0a2e6baf"
      unitRef="U_USD">1128000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_534f7802-0c47-473c-a277-5ba1b775ec9d"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_fee40c12-3125-414d-bdec-b89b928e6f16"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_fe17cadf-31de-45bf-97f4-54a562a3ec9a"
      unitRef="U_USD">266000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_b1ba3c65-8ca6-4247-b43a-494efd392bac"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_098f62b7-c93c-4c2d-a437-d147f4cb2c08"
      unitRef="U_USD">3371000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_4bf3048c-2210-461c-b78f-d6c1ed829205"
      unitRef="U_USD">14790000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ded18188-43fc-4fcc-bc23-292f98ca26df"
      unitRef="U_USD">11486000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_730a7e87-8700-4699-9f83-dec51d3cd17f"
      unitRef="U_USD">3461000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_8fe0dd99-0a74-403b-8be8-7628d1a0d365"
      unitRef="U_USD">3461000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_165a67c4-2cf0-4c90-8e1b-25a98ce41616"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ffc505d7-2c53-4e40-88c8-bdcfac14568e"
      unitRef="U_USD">10260000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_0c14b8e5-3e92-417b-9e3d-e2b6cd1bf37e"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_8f50110c-86c6-4f2c-a4c4-df8919e34b69"
      unitRef="U_USD">1808000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_dd191473-3c33-482d-b7eb-30164dfd8f8d"
      unitRef="U_USD">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_2d870be0-d9e5-467e-957f-ee387e8defaf"
      unitRef="U_USD">766000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f615c7ca-9561-4461-8f82-80c8e27db074"
      unitRef="U_USD">4887000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_f67172c6-bd8e-4efa-9fcc-99263e7d34c8"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_8e3e30f1-ee02-416a-9ce4-67c3a802e907"
      unitRef="U_USD">7000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_726bf35e-bfbd-4031-88f9-23f428488859"
      unitRef="U_USD">221000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_40c00ca5-4e2c-4355-a152-a77b93b62115"
      unitRef="U_USD">23145000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_5e40b3ca-947e-4775-825e-7b867d361b68"
      unitRef="U_USD">28002000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"
      decimals="INF"
      id="F_8cc1e9e7-0dd5-48b7-9e5b-79f169784459"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_b0a263ed-f0b1-4275-8d84-4ee52740c031"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"
      decimals="INF"
      id="F_10c4e30d-e92d-4f41-8046-088216a5815e"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"
      decimals="INF"
      id="F_98cff91f-21b3-4902-8587-3e0f3b3a1ece"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"
      decimals="INF"
      id="F_29cd8573-0e37-4f05-a676-3c2b536ba7ea"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_ff4a8f6f-4d20-4dbe-b136-932ce0fe4b37"
      unitRef="U_shares">167496750</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_531a7267-a696-47a6-a4d2-771cd41ae402"
      unitRef="U_shares">11596280</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_484bd5b0-1411-4c15-8038-5c81b6343f37"
      unitRef="U_shares">11596280</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"
      decimals="-3"
      id="F_4f0de8ab-ba53-40dd-8759-382c06f3e9ed"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="-3"
      id="F_511cddc7-76ee-403e-963b-e21f1b05c839"
      unitRef="U_USD">53593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"
      decimals="INF"
      id="F_35f1874a-28ea-42e6-a243-894af58b6f59"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_b8e3ecb1-f746-4fbf-b421-23b6b7f65926"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"
      decimals="INF"
      id="F_49d3ffe9-4eeb-4a02-805e-8a3ac80e8cc5"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"
      decimals="INF"
      id="F_8acae13e-fb5b-4d9d-8786-cf391bf43db3"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"
      decimals="INF"
      id="F_b26400c8-fa1b-4dda-b218-bf22aaef7856"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_558f2074-fbb2-40ed-b9ff-999a0b0682b9"
      unitRef="U_shares">74620739</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_1acc9603-ecdb-403f-a0ff-0272441b3e60"
      unitRef="U_shares">5166203</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_eba3a951-7391-46e7-8ead-78051ddc9600"
      unitRef="U_shares">5166203</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"
      decimals="-3"
      id="F_42dcfbe0-f0c5-48ed-a170-00c4ffa3f3ad"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="-3"
      id="F_5bb0fc52-4e59-48c7-b112-b2454e222f08"
      unitRef="U_USD">36336000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"
      decimals="INF"
      id="F_6bd31cc3-b3d9-41a2-aede-16b581d1a8d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_84a637fb-d91c-4933-8060-37c8f4e32536"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"
      decimals="INF"
      id="F_2156f70a-f8a7-40a6-a7d0-da8dc2f13666"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"
      decimals="INF"
      id="F_9492801e-c3b7-4b6e-833f-8318f91088c2"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"
      decimals="INF"
      id="F_8cb5e5f8-f43d-46f6-82c5-23e40fc64e71"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_47095aba-5a63-4a20-9b97-f7372d9133d0"
      unitRef="U_shares">109604994</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_bd090f03-ad3f-460b-a171-b383b5a7f7c0"
      unitRef="U_shares">7588254</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_0ded1cab-f88a-4f2c-b922-2d5b8adeb01b"
      unitRef="U_shares">7588254</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"
      decimals="-3"
      id="F_27ca0872-8058-4e77-9ba0-f47b03a17a96"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="-3"
      id="F_eb02b35a-bc44-44f1-a833-92eb3a03f224"
      unitRef="U_USD">53221000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"
      decimals="INF"
      id="F_5d64e27d-9eb8-4865-951e-1ca786c9295b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_e3bc5608-7e5f-435a-a7ff-38153a0db5c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"
      decimals="INF"
      id="F_4a86508a-8872-46fd-8280-d03b0cb19bf0"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"
      decimals="INF"
      id="F_3b333d53-2c3c-4121-8cec-b2a1014e0c22"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"
      decimals="INF"
      id="F_31b569e9-6215-4335-a2bd-33a2557c30c1"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_d5ac0ccb-d0b2-4f62-ad51-1b6109b9a4c4"
      unitRef="U_shares">99705359</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_e8937bdc-7e0f-4eec-bb27-f72e9749e46f"
      unitRef="U_shares">6902872</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_dfde71ea-a88c-4da2-8250-ae5140c99fe8"
      unitRef="U_shares">6902872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"
      decimals="-3"
      id="F_83f94124-fe18-4d79-be29-e5b3cf8fa44d"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="-3"
      id="F_2c2834d1-9825-4c98-bc23-d25d49dbc5c0"
      unitRef="U_USD">89904000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="INF"
      id="F_bc9e6405-943b-4058-8824-79016fd2dc28"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_9060829d-8e59-4424-adc9-f2129108ae45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="INF"
      id="F_4dbff539-d1e9-4a03-ba34-41e3844ed423"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_df7ee4b1-d27b-4e3b-9e2d-4279964c59f6"
      unitRef="U_shares">598232153</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="INF"
      id="F_488ad4a9-ecfc-416a-8627-a9e6dcf4a0ab"
      unitRef="U_shares">47512182</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="INF"
      id="F_c4a1723a-cdd0-4d3c-9f01-f5dcab296a71"
      unitRef="U_shares">47512182</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_236bdd54-af9e-4417-ace3-1415e86dc6b6"
      unitRef="U_shares">8391793</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_a95daa0a-14cf-4a72-9358-08e2edf65e34"
      unitRef="U_shares">8391793</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_bdecdbc3-d1ed-4b83-be01-ff761ccd9f8b"
      unitRef="U_USD">47000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_fc2f2347-b2a4-4e08-b891-abe97a7bf097"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_48523ae7-727d-46a7-b786-cfea8acdcc6e"
      unitRef="U_USD">363172000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_64346399-0fd4-4e05-b212-fb40dece5197"
      unitRef="U_USD">7109000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_aac58720-68ca-4492-b382-2ea4f99bbb9e"
      unitRef="U_USD">-160995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ff2ab613-a3aa-4f02-a32a-d44ec5242c4f"
      unitRef="U_USD">-102835000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_ce1cb05d-18df-461a-9a33-2d80adb273e7"
      unitRef="U_USD">202224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_26bd6fc5-1178-4f13-b19f-89fa3f2c6fc7"
      unitRef="U_USD">-95718000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_1d5941a8-ce44-4d39-9cd3-1b6b12f0858e"
      unitRef="U_USD">225369000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_d14d5bac-e9db-46b5-b2b4-13f777ae0483"
      unitRef="U_USD">165338000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b80e0856-efdb-45ee-8c35-7042653d6f4f"
      decimals="-3"
      id="F_b5d4bac3-7048-4728-a09b-e16eb69f90b3"
      unitRef="U_USD">18532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8e96af31-f869-445b-b59a-14d832388be8"
      decimals="-3"
      id="F_a6bf3c93-6c53-491f-b649-5e29a0a090d1"
      unitRef="U_USD">7376000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a3685552-54f1-4285-9365-be9a43f57bfe"
      decimals="-3"
      id="F_ec501f08-f56b-4297-b4fc-9c3fa145b731"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a7977ced-72d5-4903-b7c8-1bf202956756"
      decimals="-3"
      id="F_9aad1372-a467-4cb5-9f23-a9d5e276174c"
      unitRef="U_USD">343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_289201b8-7d06-4263-8c97-5de6a6682dc9"
      unitRef="U_USD">18532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_4f6e24f3-72fe-471e-9cda-5692b8469577"
      unitRef="U_USD">7719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_182fa20b-7c30-4199-a211-af2a75a77f82"
      unitRef="U_USD">57279000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_61245699-3a69-4b23-90e1-fb36608d8887"
      unitRef="U_USD">33144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_1f2bc7ce-0268-4c78-9d83-e39dd6e4518a"
      unitRef="U_USD">21238000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_c7e5a28f-ceef-47c6-9671-ca9dd81f29d8"
      unitRef="U_USD">14011000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_36e6d470-5d1e-41a1-8df3-a27a29d37ea4"
      unitRef="U_USD">78517000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_a4863a8b-7499-4489-9243-12d21d763b8d"
      unitRef="U_USD">47155000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_c07d175c-7fd2-425c-ab37-154a08e788fc"
      unitRef="U_USD">-59985000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_a5bd37ca-6705-4392-ba9e-8dec14e7932b"
      unitRef="U_USD">-39436000</us-gaap:OperatingIncomeLoss>
    <fnch:GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8bb9ff0b-56ca-4f16-9fda-41d96bc5a10e"
      unitRef="U_USD">1827000</fnch:GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_643009de-b407-4e9d-9f69-62f7f3918617"
      unitRef="U_USD">22000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_01b4ce27-9d7d-4dc8-a0f1-e6d73d3d82d0"
      unitRef="U_USD">106000</us-gaap:InvestmentIncomeNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_667c291f-461d-4ac5-8243-686c21af4279"
      unitRef="U_USD">28000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_b7713c64-7a05-43d0-a7e7-fc86b4645185"
      unitRef="U_USD">-13000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_843fce1b-fa8b-4670-8f3b-a06dd5a92dad"
      unitRef="U_USD">-52000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_06a7cd0b-fb84-48bb-80ad-e72a9303c331"
      unitRef="U_USD">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_deffa770-fb1b-430c-89af-28ea18c694d5"
      unitRef="U_USD">1825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_7322e97a-b25b-4376-ac1c-730858b02d5f"
      unitRef="U_USD">95000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_e8ba4ad4-95bb-497c-868b-76b2bfe71ac4"
      unitRef="U_USD">-58160000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_cf80f12c-a4d6-4a5a-83a4-e839bad417dc"
      unitRef="U_USD">-39341000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_23f95f6d-40c7-4116-900d-63ec9dc0792f"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_82e84333-fe54-4d4f-a78c-499279cb404b"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_d200b45b-c1b6-4dc0-91ce-746776f33c12"
      unitRef="U_USD">-58160000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_46886a6c-f7f9-4dad-bdda-f55b3c424cda"
      unitRef="U_USD">-39341000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8e0cb72d-9b56-4efb-a885-93a5c747bdc2"
      unitRef="U_USD">-58160000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_d095b1b6-2bfb-4e87-b66c-357e5e6262fe"
      unitRef="U_USD">-39341000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="2"
      id="F_260c431f-4942-42b7-93fe-dae9852dbfc7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="2"
      id="F_baa123c9-bd73-411b-9b24-84d0c1837f1c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.83</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="0"
      id="F_63a9c4ea-1f4b-4fbd-b9c0-2a813014fe44"
      unitRef="U_shares">39202086</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="0"
      id="F_6a2b6642-de54-48b6-84cb-09607743b3b5"
      unitRef="U_shares">8144855</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="3"
      id="F_31fef4ad-7fda-4934-b1f7-40437bdbe170"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_24cfd7c3-5e71-4bf0-9eb4-e240d2eb93f0"
      decimals="3"
      id="F_3c2ccb7c-38ab-464f-8d3e-b871b3ead584"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="3"
      id="F_5c670a2f-0c94-427a-9a0b-f7c4cf735e53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_9ac77e43-2aa2-46a1-9ef2-90be12509e4e"
      decimals="3"
      id="F_0cbe3216-eb75-4fc4-9887-511f1f2dbcc6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="3"
      id="F_f71915b9-9b63-465e-bc4e-cdf293697a2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_ef0ebcc5-2df4-47e4-b9c8-d32cd8b15c4a"
      decimals="3"
      id="F_f4d31af5-fafa-4d47-9141-d26446370814"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="3"
      id="F_53335910-3778-4047-8a79-7193e841ed74"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_703e5c2d-7a7f-413a-842f-a40f1f56526b"
      decimals="3"
      id="F_c80f5c87-8f2d-4406-8426-8131bdca26ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_29237393-f7a6-4fe4-b6e8-04815b077862"
      decimals="0"
      id="F_3f630d6e-d557-4a83-976c-051482113c55"
      unitRef="U_shares">11596280</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_29237393-f7a6-4fe4-b6e8-04815b077862"
      decimals="-3"
      id="F_30bff476-d0be-4391-ad2d-7ff04f3aa2ee"
      unitRef="U_USD">53593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_734ba92d-986a-46d1-aeee-fd929b61447a"
      decimals="0"
      id="F_b2909a51-1593-4cfc-ba9f-0823e1a4dc00"
      unitRef="U_shares">5166203</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_734ba92d-986a-46d1-aeee-fd929b61447a"
      decimals="-3"
      id="F_ef89bb64-e24a-4eed-a7da-eaf9fcf3dcab"
      unitRef="U_USD">36336000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e4017af1-75f3-41f0-9528-da23823df46b"
      decimals="0"
      id="F_eb6723f8-05e9-4ad5-87a3-579608993326"
      unitRef="U_shares">7588254</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_e4017af1-75f3-41f0-9528-da23823df46b"
      decimals="-3"
      id="F_216febd9-106f-443b-ba30-19e5dfb8f852"
      unitRef="U_USD">53221000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_d4277bcb-d35b-4f32-8ff6-cdca824e9d4a"
      decimals="0"
      id="F_74343f20-d53c-4a31-a0ab-2890c75c9b75"
      unitRef="U_shares">7778552</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d4277bcb-d35b-4f32-8ff6-cdca824e9d4a"
      decimals="-3"
      id="F_63cacca2-ae2a-42e3-a9ba-0e2831c41e2d"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_089fb034-da86-4331-8cab-1b70dc0cd490"
      decimals="-3"
      id="F_c21305b0-5b03-4834-a741-cb898dd84bba"
      unitRef="U_USD">3951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1de77ba6-205b-42f6-acd1-060d987f64f7"
      decimals="-3"
      id="F_1e59efb8-1904-485c-b115-59cfba63c1ed"
      unitRef="U_USD">-63494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8"
      decimals="-3"
      id="F_2e479c0b-662b-4d56-a5b8-9cd58a422efb"
      unitRef="U_USD">-59535000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_1a179872-937f-42ac-8d8c-e1ded8315d35"
      decimals="-3"
      id="F_f04554d4-f41f-4c15-9356-c22d78d6547f"
      unitRef="U_USD">96000</us-gaap:PaymentsOfStockIssuanceCosts>
    <fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares
      contextRef="C_1a179872-937f-42ac-8d8c-e1ded8315d35"
      decimals="0"
      id="F_2bc9947c-a6b5-400e-93b4-1d471c641aae"
      unitRef="U_shares">6902872</fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares>
    <fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue
      contextRef="C_1a179872-937f-42ac-8d8c-e1ded8315d35"
      decimals="-3"
      id="F_87d92c4d-2848-45c9-9e30-4af1ec1e5734"
      unitRef="U_USD">89904000</fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f59b9e4d-a520-4962-b1b1-8256ad30502f"
      decimals="0"
      id="F_69724fed-5764-4263-a57b-85f317ba6f4b"
      unitRef="U_shares">65881</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce"
      decimals="-3"
      id="F_43fd39eb-2804-499d-8e4e-e928bc0bc6af"
      unitRef="U_USD">59000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_37c40ad5-850b-4510-b06d-72282ffa80de"
      unitRef="U_USD">59000</fnch:IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue>
    <fnch:StockIssuedDuringPeriodSharesVestingOfRestrictedStock
      contextRef="C_f59b9e4d-a520-4962-b1b1-8256ad30502f"
      decimals="0"
      id="F_8ba0343d-11fe-4543-8434-9a0f7ba7c61c"
      unitRef="U_shares">547360</fnch:StockIssuedDuringPeriodSharesVestingOfRestrictedStock>
    <fnch:StockIssuedDuringPeriodValueVestingOfRestrictedStock
      contextRef="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce"
      decimals="-3"
      id="F_56e1e3d0-c845-468c-93d9-715be90b99c9"
      unitRef="U_USD">8000</fnch:StockIssuedDuringPeriodValueVestingOfRestrictedStock>
    <fnch:StockIssuedDuringPeriodValueVestingOfRestrictedStock
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_26dcdbfe-2527-4998-a8f8-3ff65dfd719f"
      unitRef="U_USD">8000</fnch:StockIssuedDuringPeriodValueVestingOfRestrictedStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_23e2bb8f-2e40-4d3a-b57c-249a60f417ce"
      decimals="-3"
      id="F_2c6b3e15-f04b-4b92-908b-7348a99be9ab"
      unitRef="U_USD">3091000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_0922dd2d-4042-4a04-a0a4-5b3569daa499"
      unitRef="U_USD">3091000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_92ff62b1-b286-46a8-8e9a-bd9133b65f3d"
      decimals="-3"
      id="F_e8ea3141-a29c-47a2-a476-96a2625e1fa0"
      unitRef="U_USD">39341000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_8a4a7ae5-6d0f-4126-b202-1cdefdb68edb"
      unitRef="U_USD">-39341000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="0"
      id="F_9fcbdf32-8b18-446b-b5c7-5e449b0dfeea"
      unitRef="U_shares">11596280</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="-3"
      id="F_ec34aaa7-a7ce-4e81-ad7e-83228a7ec87f"
      unitRef="U_USD">53593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="0"
      id="F_835a3689-4c10-45cd-a1bf-40c1bfaf6a0c"
      unitRef="U_shares">5166203</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="-3"
      id="F_ac6b9766-5797-4601-933d-803ee2219767"
      unitRef="U_USD">36336000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="0"
      id="F_e44e7fdb-57ec-4372-9558-01eb245b7f15"
      unitRef="U_shares">7588254</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="-3"
      id="F_dc863fc8-19c2-48a7-a9dc-447302cf9d1f"
      unitRef="U_USD">53221000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="0"
      id="F_73813529-6eae-44ce-a597-3975cb5fdbd5"
      unitRef="U_shares">6902872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="-3"
      id="F_e7efed99-1b58-4ac4-bc2c-7b911e42cf2a"
      unitRef="U_USD">89904000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_da1fc6b8-eb04-4fd7-aefa-1b1663c0cbad"
      decimals="0"
      id="F_88e44c04-c73a-49d4-84c3-2ba00d70063d"
      unitRef="U_shares">8391793</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_da1fc6b8-eb04-4fd7-aefa-1b1663c0cbad"
      decimals="-3"
      id="F_6a9db5da-d7ba-445d-a146-53621200619c"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb5e464a-84a9-4eb3-ad80-f75e327f7bbc"
      decimals="-3"
      id="F_61460592-24a9-4ac9-a602-b7dd8a8de903"
      unitRef="U_USD">7109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d09ee6b-925b-4309-b34d-5e1eb3247ba6"
      decimals="-3"
      id="F_b320efe9-a70c-486a-aed5-f716056b23fb"
      unitRef="U_USD">-102835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_b3d3f4eb-0793-4ac3-a219-e1b0823494ba"
      unitRef="U_USD">-95718000</us-gaap:StockholdersEquity>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares
      contextRef="C_5e9b7d9d-0899-469e-840d-b1a8fd63c115"
      decimals="0"
      id="F_2399efa6-4ddb-46a5-96af-d8765e80bbc9"
      unitRef="U_shares">11596280</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_5e9b7d9d-0899-469e-840d-b1a8fd63c115"
      decimals="-3"
      id="F_623168ad-0742-4332-9cb1-6ef0695e3c38"
      unitRef="U_USD">53593000</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares
      contextRef="C_e78abb46-6208-4d28-9564-457e5c7c89e6"
      decimals="0"
      id="F_7ade1b8e-7674-49ee-9b72-4559665d846f"
      unitRef="U_shares">-5166203</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_e78abb46-6208-4d28-9564-457e5c7c89e6"
      decimals="-3"
      id="F_a9063e2a-bc0b-488f-b51c-fa473c119096"
      unitRef="U_USD">36336000</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares
      contextRef="C_d4537122-5c97-4483-a0d3-0abbbe078b74"
      decimals="0"
      id="F_58d13ca4-fb2f-4cb9-a4b7-9f9190b63ff6"
      unitRef="U_shares">7588254</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_d4537122-5c97-4483-a0d3-0abbbe078b74"
      decimals="-3"
      id="F_830fc290-a36f-480b-94ad-738e666b8807"
      unitRef="U_USD">53221000</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares
      contextRef="C_96bb2e98-4d79-4650-8af9-3a931a612483"
      decimals="0"
      id="F_a53ca829-0923-4149-919e-a594fb74f1a7"
      unitRef="U_shares">6902872</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares>
    <fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_96bb2e98-4d79-4650-8af9-3a931a612483"
      decimals="-3"
      id="F_cdf60596-940c-436c-9cd1-d9d32bc345c9"
      unitRef="U_USD">89904000</fnch:TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="0"
      id="F_1346e58e-c832-4373-93d8-c16ffbea2c33"
      unitRef="U_shares">31253609</fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares>
    <fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="-3"
      id="F_5bbba070-6a89-47af-90a3-350757abce89"
      unitRef="U_USD">31000</fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_08797998-db85-4999-b501-d07c4980c203"
      decimals="-3"
      id="F_60dd62cb-ca65-4fa1-9431-3826ce30a17a"
      unitRef="U_USD">233022000</fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_d2e0e27a-c673-40fe-b262-8c6594e8b822"
      unitRef="U_USD">233053000</fnch:ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering>
    <fnch:InitialPublicOfferingCosts
      contextRef="C_ed564ca9-9a3a-412d-9d64-5fd1ffc81119"
      decimals="-3"
      id="F_4b617b63-d75a-4a14-b1ed-e3f1919317b0"
      unitRef="U_USD">11786000</fnch:InitialPublicOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="0"
      id="F_1f474dc8-10d8-4c3f-b81c-dee5a40776f0"
      unitRef="U_shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="-3"
      id="F_2e26a295-164e-4788-8999-2c6047e93264"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_08797998-db85-4999-b501-d07c4980c203"
      decimals="-3"
      id="F_29aab447-b9f2-4b9d-85af-418be45ea76c"
      unitRef="U_USD">115706000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_22a9426b-eb7b-427e-95ec-c70cddacba6d"
      unitRef="U_USD">115714000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <fnch:InitialPublicOfferingCosts
      contextRef="C_ab627a9f-a180-4add-89be-437938d49551"
      decimals="-3"
      id="F_39f234cf-511b-4a4d-b577-82ed30d0dec7"
      unitRef="U_USD">276000</fnch:InitialPublicOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="-3"
      id="F_a1c77ecf-6364-4052-9703-46a8546ae597"
      unitRef="U_USD">192877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <fnch:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares
      contextRef="C_08797998-db85-4999-b501-d07c4980c203"
      decimals="0"
      id="F_a089959b-a9b3-44e0-a893-b38a06cfd011"
      unitRef="U_shares">3003</fnch:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares>
    <fnch:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="0"
      id="F_df78ee53-9a85-47d1-be2b-b26bf2e8d846"
      unitRef="U_shares">3003</fnch:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="-3"
      id="F_73408bad-42c7-46c9-908a-bcd234069497"
      unitRef="U_USD">1221000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_08797998-db85-4999-b501-d07c4980c203"
      decimals="-3"
      id="F_1941bdeb-bebb-48f6-9a2d-e338423649e3"
      unitRef="U_USD">10000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_ba5bbba7-f23b-4657-b9cd-e5eae5114274"
      unitRef="U_USD">10000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f1444436-ad66-46ea-8295-6f51e32cc67c"
      decimals="0"
      id="F_7793bdd2-2fe2-4072-b2e9-e004f127bb62"
      unitRef="U_shares">155821</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_08797998-db85-4999-b501-d07c4980c203"
      decimals="-3"
      id="F_7492d4de-39e4-4be3-825e-31139d557095"
      unitRef="U_USD">181000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_1cdf8873-8fa3-420e-b87b-ec6d61567d4f"
      unitRef="U_USD">181000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <fnch:CommonStockWarrantsExercised
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="0"
      id="F_5b90a06f-c884-4570-8d06-caece5064b22"
      unitRef="U_shares">19303</fnch:CommonStockWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_08797998-db85-4999-b501-d07c4980c203"
      decimals="-3"
      id="F_888810f7-4620-4b02-8af4-df533aa67d5c"
      unitRef="U_USD">4161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_1d55885b-7b91-4f50-98d3-b75b6730e22a"
      unitRef="U_USD">4161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_67b625c9-9b8a-4bea-b722-36d695553d6d"
      decimals="-3"
      id="F_32f0ab12-629b-48d4-b4e8-97f69a220f47"
      unitRef="U_USD">-58160000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_a5af0b80-e1f8-478d-ad52-2e23f74d81e3"
      unitRef="U_USD">-58160000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_48646751-72ab-4bdf-9554-d01586c1b9b2"
      decimals="0"
      id="F_6abc89c6-0f8f-425d-bd30-d8528f1a4799"
      unitRef="U_shares">47512182</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_48646751-72ab-4bdf-9554-d01586c1b9b2"
      decimals="-3"
      id="F_ba778483-cd02-4b8c-ab93-d17d26880c87"
      unitRef="U_USD">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e8d19c5f-3b27-462c-bd7a-dd8adf6bc783"
      decimals="-3"
      id="F_d3e950f8-1241-4f72-976a-8990cff48bfc"
      unitRef="U_USD">363172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ad20da32-3929-4b8f-8211-81be4d8ad10d"
      decimals="-3"
      id="F_549ddbda-2584-4e12-a9bb-619c103fdcef"
      unitRef="U_USD">-160995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_6f8260fe-5c72-4d65-a7c4-e62bf284c7c0"
      unitRef="U_USD">202224000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8b588766-e98d-4a37-b175-cb377394febb"
      unitRef="U_USD">-58160000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_df8dead6-1661-4a99-9549-53a60ae5874b"
      unitRef="U_USD">-39341000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_ef8567c0-8006-48ab-bdf7-3ea62e32c46e"
      unitRef="U_USD">2301000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_de9f2eec-4372-43e1-87ee-e1e14f0760b0"
      unitRef="U_USD">790000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_4545bc18-c7a7-4cd6-877c-d3b2c82ac30f"
      unitRef="U_USD">4161000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_f55f1d13-aa8e-449a-acca-ee12b8bafb46"
      unitRef="U_USD">3099000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_7d8c4ff3-bf19-484b-83de-6f062795712f"
      unitRef="U_USD">1808000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_78ed806a-b319-4d89-9e36-96f87a161de1"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8187128b-1967-4960-ba45-787014e316ed"
      unitRef="U_USD">28000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_c0f8f7d2-9ebc-4fd7-bf6e-7960156eb9d1"
      unitRef="U_USD">-13000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_e7cbcc31-553d-4f64-9771-608453972f69"
      unitRef="U_USD">913000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_a1bd06fc-4eb6-4f41-a1e9-6ab5e1a3d014"
      unitRef="U_USD">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_cdc44436-fa01-4615-8925-26ec178ed6b4"
      unitRef="U_USD">-540000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_dd616d85-3c1b-48bc-958d-62078923b51e"
      unitRef="U_USD">-143000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_132e9830-dc19-429b-b28c-3e25633429b2"
      unitRef="U_USD">-61000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_2a0a3a6a-82d2-4caa-a5b4-e12afee7db21"
      unitRef="U_USD">-3507000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_544b679a-15f8-497a-be1c-fe3bd69d1d2f"
      unitRef="U_USD">3217000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_d780b32f-0294-4aca-a578-953dd341ebd7"
      unitRef="U_USD">3665000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_f90dcd92-4f34-45a0-89e2-de5e0f903573"
      unitRef="U_USD">4689000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_1ff73db7-5110-4e34-8af8-0f36bc31ad45"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_a634f1b9-79d5-4e98-92f0-e5964a068fae"
      unitRef="U_USD">2261000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_575a77c1-8c41-42a7-b2d2-9cde375293dd"
      unitRef="U_USD">440000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_4ca2dcc4-df8c-4514-8b2a-19c7470f5ca0"
      unitRef="U_USD">5435000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_794ab2cc-63d7-42c8-80a8-ff1d8b5ad3ed"
      unitRef="U_USD">481000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <fnch:IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8fb81f48-3a3c-4c0c-8a27-d5a5afe50a51"
      unitRef="U_USD">-266000</fnch:IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable>
    <fnch:IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_4f7ab944-e25b-4142-8fdc-d8298439570c"
      unitRef="U_USD">-68000</fnch:IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_41b46df6-3d12-4aeb-a93d-ac0a9b771ab6"
      unitRef="U_USD">-13631000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_99a050aa-34a0-44b7-a44f-70d95b970db9"
      unitRef="U_USD">2963000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_992952c6-b6ac-4331-993c-5301c114a8b3"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_c2f22daa-5346-4821-a6e9-e477afeb5bc1"
      unitRef="U_USD">309000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_81bee144-81d3-4059-a6f6-7edb35637754"
      unitRef="U_USD">-1006000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_29163c77-b6ca-4f78-a317-4a89cd79744b"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_75c29059-81fa-4983-a30c-678257953367"
      unitRef="U_USD">-67133000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_a33f956e-946e-4175-843a-34fe01f1ed52"
      unitRef="U_USD">-31329000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <fnch:PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_b7586938-123b-4b22-b0d8-9593b337be5f"
      unitRef="U_USD">15983000</fnch:PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty>
    <fnch:PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_b1cb21f6-477b-4958-8c5b-dc4ada8fee99"
      unitRef="U_USD">2633000</fnch:PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_75a50b68-4061-45ee-a1ed-57d019605329"
      unitRef="U_USD">62000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_860390f5-f7f9-424c-af47-1b57bd7b8206"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_ecef4582-a948-4639-b1a0-cb51f2fc7dab"
      unitRef="U_USD">-15921000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_7a3a0690-db2d-4b40-a240-269c8c673249"
      unitRef="U_USD">-2633000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_0b204684-3edb-4334-a89b-8cd257dcd002"
      unitRef="U_USD">118576000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_023359e4-c9e1-462b-886c-590ae0fece72"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <fnch:ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_3df367f3-9af0-49c3-879b-1fd3b94ee238"
      unitRef="U_USD">0</fnch:ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock>
    <fnch:ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_51fbce37-6736-4698-810e-c53448fccb89"
      unitRef="U_USD">90000000</fnch:ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock>
    <fnch:PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_158cb015-c926-4b7a-8735-55bd589446d5"
      unitRef="U_USD">0</fnch:PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts>
    <fnch:PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_0673d8c8-155c-4dd1-bc4c-87278512298f"
      unitRef="U_USD">96000</fnch:PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts>
    <fnch:ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_fc6057b3-b599-401a-8034-e3310414fcc0"
      unitRef="U_USD">3049000</fnch:ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts>
    <fnch:ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_5564a781-4d9d-44a9-994c-b497fab39021"
      unitRef="U_USD">0</fnch:ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts>
    <fnch:PrincipalPaymentsOnCapitalLeaseObligation
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_ae2cc98e-a6b3-48e0-98d3-d499499b98a3"
      unitRef="U_USD">27000</fnch:PrincipalPaymentsOnCapitalLeaseObligation>
    <fnch:PrincipalPaymentsOnCapitalLeaseObligation
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_74cfd187-41d6-4836-8a2f-49451819f203"
      unitRef="U_USD">47000</fnch:PrincipalPaymentsOnCapitalLeaseObligation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_9f7263c3-a8d0-45b1-944b-6aa7ccd12fbb"
      unitRef="U_USD">171000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_2e772f16-6c32-4cb9-8a14-27a3bab9f43f"
      unitRef="U_USD">59000</us-gaap:ProceedsFromStockOptionsExercised>
    <fnch:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_ab38fcf3-5bee-40e4-ac36-02c41c016053"
      unitRef="U_USD">0</fnch:ProceedsFromPaycheckProtectionProgramLoan>
    <fnch:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_7069e808-7421-4a1e-863e-7822b629a387"
      unitRef="U_USD">1808000</fnch:ProceedsFromPaycheckProtectionProgramLoan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_395eb334-39f9-49ca-87da-5817075c3c8c"
      unitRef="U_USD">2659000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_39f70f1d-3898-4f2b-84a1-d694eae67f3d"
      unitRef="U_USD">249000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8e8eea4a-dfb3-464f-acb0-49efeca1c62a"
      unitRef="U_USD">119110000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_21dc4b68-f380-4c7a-bdbf-98f016e105c4"
      unitRef="U_USD">91475000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_cacc18ab-41a6-40a1-9900-22983ceab5eb"
      unitRef="U_USD">36056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_628cfa46-8e59-4d86-8871-2dad85410c14"
      unitRef="U_USD">57513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_32310ddc-d0a4-4d57-808c-1b63c0e647c7"
      unitRef="U_USD">99909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8"
      decimals="-3"
      id="F_ca34780b-5567-4d33-a7ae-f24fa6df102c"
      unitRef="U_USD">42396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_b647c700-1af6-4f9c-ae15-ad5cd2568d16"
      unitRef="U_USD">135965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_a540030c-0fe9-42a4-a65c-37fef82558e7"
      unitRef="U_USD">99909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_9b0926d4-bd74-49fc-8f6c-99742805e1fe"
      unitRef="U_USD">9000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_64dfee82-20ce-4ece-9c64-cc998a97103e"
      unitRef="U_USD">11000</us-gaap:InterestPaidNet>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_fa61aea8-37ee-4a3b-9aaa-fc33bff796b5"
      unitRef="U_USD">1434000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_f58182b7-66ea-4053-96be-c21c334bc1d5"
      unitRef="U_USD">0</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_d4f4711e-2483-46f6-a0b3-eb0950dd95f4"
      unitRef="U_USD">381000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_09e73ad2-e14a-4ced-9e77-6f0da34d1e4a"
      unitRef="U_USD">1398000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_08314e40-3adb-4794-ba04-069d991d59ee"
      unitRef="U_USD">233053000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_ab18eaf4-c897-4464-9f11-cad9639d0f87"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <fnch:OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_9bb98a99-e873-4ba6-a0c4-d81b39e76a1f"
      unitRef="U_USD">5965000</fnch:OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842>
    <fnch:OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_8e89b4a8-0df3-4e4e-82a1-638f74c6a579"
      unitRef="U_USD">0</fnch:OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842>
    <fnch:DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_efe8b4bb-395a-4310-bf66-e3ea83ce9e63"
      unitRef="U_USD">0</fnch:DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses>
    <fnch:DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_70975964-be0b-461b-b1f6-8991b67324a0"
      unitRef="U_USD">764000</fnch:DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_c50e4a24-e4d9-4b8f-83c6-c19ddcfe9038"
      unitRef="U_USD">133481000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_b5d9f4c5-0563-4bd6-9670-2535d0afc9cb"
      unitRef="U_USD">99710000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_d71c9bcb-0b4a-44a3-b527-3c867c3f7522"
      unitRef="U_USD">2484000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ec33d91c-1a07-468e-b3d6-6aad23432345"
      unitRef="U_USD">199000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_ae5c92b1-a4bc-4f01-86d3-a744ac79a987"
      unitRef="U_USD">135965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_de1f3be8-0ea5-42c1-b1c2-2f3f4a97f27f"
      unitRef="U_USD">99909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_79fd0d44-f769-42e2-82dd-3e0768131418">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. NATURE OF OPERATIONS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finch Therapeutics Group, Inc. (the &#x201c;Company&#x201d; or &#x201c;FTG&#x201d;) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (&#x201c;Finch&#x201d;) and Crestovo Holdings LLC (&#x201c;Crestovo&#x201d;) in September 2017 (the &#x201c;Merger&#x201d;), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (&#x201c;Finch Holdings&#x201d;). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company&#x2019;s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;is an orally administered complete microbiome therapeutic in development for the prevention of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;recurrent &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Clostridioides difficile &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;infection, or CDI.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 18, 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;127.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and offering costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.  On April 20, 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;192,877&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriting discounts, commissions and offering costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the IPO, the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7ea1798d-7710-41a8-88de-a9818d271ecd;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one-for-14.444&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company&#x2019;s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of convertible preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, the risk that its products will fail to demonstrate efficacy in clinical trials, uncertainty of market acceptance of its products, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The extent of the impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak, including with respect to variants of the virus, and its impact on clinical trial enrollment, trial sites, contract research organizations, contract manufacturing organizations, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and its key scientific and management personnel. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company&#x2019;s business, financial condition and results of operations ultimately could be materially adversely affected. The Company continues to closely&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;monitor the COVID-19 pandemic as it evolves its business continuity plans, clinical development plans and response strategy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At this time, it is unknown how long the adverse conditions associated with the COVID-19 pandemic will last and what the complete financial effect will be to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred recurring losses since its inception, including net losses of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;161.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company expects to continue to generate operating losses for the foreseeable future as it continues to develop its product candidates. The Company expects that its cash and cash equivalents of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as of December 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of issuance the annual consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company will not generate any future revenue from product sales unless and until it successfully completes clinical development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support manufacturing, product sales, marketing and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through clinical development, seeks regulatory approval, and if any of its product candidates are approved, proceeds to commercialization.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_dcc33dd7-e5c8-4f20-b7fe-48ad8567599e"
      decimals="INF"
      id="F_19af498e-57b1-465b-8d72-13f378b50ed1"
      unitRef="U_shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_54d8859b-3cf9-4f25-81a8-0121817ec070"
      decimals="INF"
      id="F_80198b8b-5b89-4597-bec7-250f3bb77811"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:SharesIssuedPricePerShare>
    <fnch:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a"
      decimals="-5"
      id="F_aef55308-1123-4075-90bd-9564c14b917c"
      unitRef="U_USD">127500000</fnch:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a"
      decimals="-5"
      id="F_3806f870-04dc-466c-a0a2-4da706742263"
      unitRef="U_USD">115700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <fnch:PaymentsForUnderwritingDiscountsAndCommissions
      contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a"
      decimals="-5"
      id="F_2e8afce3-62df-4cb2-9aa9-7e10b8538292"
      unitRef="U_USD">8900000</fnch:PaymentsForUnderwritingDiscountsAndCommissions>
    <fnch:PaymentOfOfferingCosts
      contextRef="C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a"
      decimals="-5"
      id="F_eda2d6d0-fbc0-4ef2-bad5-c8a4fdc931a5"
      unitRef="U_USD">2900000</fnch:PaymentOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029"
      decimals="INF"
      id="F_57dfc800-04ac-4f2b-8b69-e2791898f687"
      unitRef="U_shares">192877</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_c6dc934d-3979-4343-93cf-f35734ec869e"
      decimals="INF"
      id="F_fd43b234-b209-47f3-9102-1b332c9fb7e6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:SharesIssuedPricePerShare>
    <fnch:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029"
      decimals="-5"
      id="F_1f3be66e-218b-44cf-8da2-e50751e46695"
      unitRef="U_USD">3300000</fnch:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_4f91a4c4-ebef-4aaf-bd7d-a43c47eed029"
      decimals="-5"
      id="F_45085d2b-cec1-4493-9876-895e2016adfd"
      unitRef="U_USD">3000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_736b82ab-77e3-4d3c-b1d1-93ec2b7be5f4"
      decimals="INF"
      id="F_eca78c7c-cecc-4a52-8bda-f42bf4a3f5ab"
      unitRef="U_shares">31253609</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_80eb5b83-cbf6-469c-a34a-c9f03f095627"
      decimals="INF"
      id="F_95403ef0-5d5a-4480-a2d6-1153fd0db563"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-5"
      id="F_d36285d0-aa79-41b4-bb5c-4f88b68e2a52"
      unitRef="U_USD">-58200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-5"
      id="F_a385a481-cb0c-4361-a7d7-4dd2044524ce"
      unitRef="U_USD">-39300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_6d0f8a59-7d11-49d9-85e4-35e4f7f3dbb7"
      unitRef="U_USD">-161000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_9ee75f78-f149-4325-991d-fbf58f6b6366"
      unitRef="U_USD">133500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_d0347c96-b124-4e49-9e84-10231a2339ce">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; assets or liabilities classified as Level 3 on its consolidated balance sheets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed the federal insurance limit.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s cash equivalents, which are funds held in a money market account, are measured at fair value on a recurring basis. The carrying amount of cash and cash equivalents was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;99.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively, which approximates fair value and was determined based upon Level 1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level 1.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company had restricted cash of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively, primarily related to a security deposit on its operating leases for its offices in Somerville and Charlestown, Massachusetts for the year ended December 31, 2021, and for its operating lease for its offices in Somerville, Massachusetts for the year ended December 31, 2020. This is included in restricted cash, non-current and other assets on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December 31, 2021 and 2020, the Company&#x2019;s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounts &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;receivable are carried at the invoiced amount less an allowance for doubtful accounts. Doubtful accounts are provided for on the basis of anticipated collection losses. The estimated losses are determined from historical collection experience and a review of outstanding accounts receivable. A receivable is considered past due if the Company has not received payment within the stated payment terms. After all attempts to collect a receivable have failed, the receivable is&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;written &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;off against the allowance. Based on historical receipts and collections history, management has determined that an allowance for doubtful accounts is not necessary as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred, while any additions or improvements are capitalized. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:60.992%;"/&gt;
          &lt;td style="width:2.063%;"/&gt;
          &lt;td style="width:36.944%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;ESTIMATED USEFUL LIFE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill and In-Process Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill is the amount by which the cost of the acquired net assets in a business combination exceeds the fair value of the identifiable net assets on the date of purchase or valuation. The Company accounts for goodwill in accordance with ASC Topic 350, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquired In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) represents the fair value assigned to research and development assets that the Company acquired that had not been completed at the date of acquisition and is accounted for as an indefinite lived intangible asset in accordance with ASC Topic 350, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The value assigned to the acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The Company&#x2019;s IPR&amp;amp;D is comprised of Crestovo&#x2019;s research and development asset related to CP101, which was acquired in the Merger.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill and IPR&amp;amp;D are evaluated for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company&#x2019;s use of the acquired asset or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company&#x2019;s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To conduct impairment tests of goodwill, the fair value of the Company&#x2019;s single reporting unit is compared to its carrying value. If the reporting unit&#x2019;s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value. The Company&#x2019;s annual assessments for impairment of goodwill as of October 1, 2021 and October 1, 2020 indicated that the fair value of its reporting unit exceeded the carrying value of the reporting unit.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To conduct impairment tests of IPR&amp;amp;D, the fair value of the IPR&amp;amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;amp;D project exceeds its fair value. The Company estimates the fair value of IPR&amp;amp;D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. The Company&#x2019;s annual assessment for impairment of IPR&amp;amp;D indicated that the fair value of its IPR&amp;amp;D asset as of October 1, 2021 and October 1, 2020 exceeded the respective carrying value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Any impairments are recognized as a loss in the year the goodwill and/or IPR&amp;amp;D are determined to be impaired. Impairment of IPR&amp;amp;D is recorded as research and development expense and impairment of goodwill is recorded separately as a loss in other income (expense) on the Company&#x2019;s consolidated statements of operations. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment loss has been recognized. Additionally, there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; change to the carrying value of goodwill and IPR&amp;amp;D for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Initial Public Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred initial public offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be abandoned, the deferred initial public offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. On March 18, 2021, the Company completed the IPO; accordingly, the Company recognized the deferred initial public offering costs of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a reduction from gross proceeds associated with the IPO through additional paid-in capital in the accompanying consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On April 20, 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;192,877&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, and the Company recognized offering costs of less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a reduction from gross proceeds associated with the overallotment through additional paid-in capital in the accompanying consolidated balance sheet. Accordingly, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; deferred offering costs as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Deferred offering costs on the accompanying consolidated balance sheet as of December 31, 2020 were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the FASB issued ASU 2016-02,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; Leases (&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASC 842&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors), and replaces the existing guidance in ASC 840, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The FASB subsequently issued amendments to ASC 842, which have the same effective date of January 1, 2019: (i) ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Codification Improvements to Topic 842,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which amends certain narrow aspects of the guidance issued in ASU 2016-02; and (ii) ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and not restate prior periods presented. ASC 842 requires lessees to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. The Company adopted ASC 842 during the quarter ended December 31, 2021, with an effective date of January 1, 2021, using the modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior period financial statements continue to be presented in accordance with ASC 840.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The adoption of this standard resulted in the recognition of operating lease right-of-use assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and current and noncurrent operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, and the derecognition of deferred rent liabilities and unamortized lease incentives of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, on the Company&#x2019;s Balance Sheets as of January 1, 2021 relating to its office leases in Somerville, MA. The adoption of this standard did not have a significant impact on the Company&#x2019;s consolidated Statements of Operations or Statements of Cash Flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to January 1, 2021, the Company accounted for leases under Accounting Standards Codification 840, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x2018;&#x2018;ASC 840&#x2019;&#x2019;). At lease inception, the Company determined if an arrangement was an operating or capital lease.  For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent.  The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified  deferred rent as current and  noncurrent  liabilities based on  the portion of the deferred rent that was scheduled to mature within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#x2019;s control over the use of that identified asset. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use (&#x201c;ROU&#x201d;) asset and current and non-current lease liabilities, as applicable on the balance sheet. The Company elected, as allowed under ASC 842, to not recognize leases with a lease term of one year or less on its balance sheet. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures and records its lease liabilities based on the present value of lease payments over the expected remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in the lease contracts if that rate is readily available. As the implicit rate has not historically been readily determinable, the Company utilizes its incremental borrowing rate (&#x201c;IBR&#x201d;), which reflects the fixed rate at which the Company could borrow on a&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;collateralized basis over a similar term to fund the amount of lease payments to be made in a similar economic environment. Management determines the appropriate IBR to use based on the Company&#x2019;s credit standing and market environment at lease commencement. The Company measures its ROU assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.) , non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated, based on the respective relative fair values, to the lease components and non-lease components. However, the Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After lease commencement and the establishment of a ROU asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When a lease is modified and the modification is not accounted for as a separate contract, the Company remeasures its ROU assets and lease liabilities.  A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the IPO, the Board and stockholders approved an amended and restated certificate of incorporation to, among other things, effect a one-for-14.444 reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock and redeemable convertible preferred stock, as well as to effect a proportional adjustment to the existing conversion ratios for the Company&#x2019;s redeemable convertible preferred stock. The reverse stock split was effected on March 12, 2021. Accordingly, all share and per share amounts of common stock for all periods presented in the accompanying audited consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse stock split and adjustment of preferred stock conversion ratios. Upon the closing of the IPO, all of the then-outstanding shares of redeemable convertible preferred stock automatically converted into 31,253,609 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for all stock-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#x2019;s stock-based payments are comprised of stock options. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has historically been a private company until its IPO in March 2021 and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is primarily subject to U.S. federal and Massachusetts state income tax. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company maintains a reserve against certain federal and state research and development credits that are recorded net in deferred taxes. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accruals for interest or penalties related to income tax matters. Tax years since inception remain open to examination by federal and state tax authorities.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has historically generated revenue from the following sources: (1) collaboration revenue from the collaboration agreement with Takeda Pharmaceutical Company Limited (see Note 7) and (2) royalty revenue from OpenBiome&#x2019;s sales of a licensed product under the Asset Purchase and License Agreement with OpenBiome (see Note 7).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of (1) a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services; (2) an obligation to transfer FMT materials; or (3) an obligation to provide pre-clinical and clinical research and support services. Under the collaboration agreement, the Company provides options to additional items, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract. For performance obligations which consist of FMT materials, shipping and distribution activities occur prior to the transfer of control of FMT materials and are considered activities to fulfill the Company&#x2019;s promise to deliver goods to the customers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company estimates the transaction price based on the amount expected to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and are included in the transaction price only to the extent it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are added to the transaction price with a corresponding adjustment being made to the measure of progress, and, as necessary, recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For contracts which have more than one performance obligation, the total contract consideration is allocated based on observable standalone selling prices or, if standalone selling prices are not readily observable, based on management&#x2019;s estimate of each performance obligation&#x2019;s standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to be entitled to for the satisfaction of each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For performance obligations, revenue is recognized when control of the product is transferred to the customer and the related performance obligation is satisfied, which typically occurs upon delivery of the product to the customer, for an amount that reflects the consideration the Company expects to be entitled to receive in exchange for delivering the product. For performance obligations which consist of clinical trial participation and related support services, revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides revenue disaggregated by timing of revenue recognition (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:55.945%;"/&gt;
          &lt;td style="width:1.804%;"/&gt;
          &lt;td style="width:2.145%;"/&gt;
          &lt;td style="width:17.488%;"/&gt;
          &lt;td style="width:0.881%;"/&gt;
          &lt;td style="width:1.804%;"/&gt;
          &lt;td style="width:2.145%;"/&gt;
          &lt;td style="width:16.906%;"/&gt;
          &lt;td style="width:0.881%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transferred at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transferred over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles-Goodwill and Other- Internal-Use Software&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (Subtopic&lt;br/&gt; 350- 40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance for capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted the standards on a prospective basis&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on January 1, 2021.The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively and certain others to be made retrospectively. The Company adopted this standard on January 1, 2021, and this standard did not have a material impact on its consolidated financial statements and related disclosures for the year ended December 31, 2021. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_4f013d52-ff26-44f0-b6b4-52ca1eebb05a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_5a81994b-c029-45b7-bf78-e57062427fdd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_9b3249a9-7230-4c0c-827c-18de1411d5f9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; assets or liabilities classified as Level 3 on its consolidated balance sheets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa678b92-859d-4297-a5ea-40baf1bbd70e"
      decimals="INF"
      id="F_50c29dfd-43aa-45a4-889b-8effcadbb166"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2ef89633-4500-4c18-944c-7f047f6e3e2f"
      decimals="INF"
      id="F_4b708132-97fe-48c3-bd79-66118ca96e7f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_aa678b92-859d-4297-a5ea-40baf1bbd70e"
      decimals="INF"
      id="F_0981b51e-06b6-4e8b-a6d4-b52846b88a2d"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_2ef89633-4500-4c18-944c-7f047f6e3e2f"
      decimals="INF"
      id="F_a6f56c24-0e13-4afb-b347-49fdbde84bcb"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_591432b1-805f-4dc2-8b65-f5c31f8438d7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed the federal insurance limit.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s cash equivalents, which are funds held in a money market account, are measured at fair value on a recurring basis. The carrying amount of cash and cash equivalents was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;99.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively, which approximates fair value and was determined based upon Level 1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level 1.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_f7bc8b56-38a9-435d-845f-c78fe7aaae6d"
      unitRef="U_USD">133500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-5"
      id="F_b59da963-02c4-4401-81ad-25b466121c49"
      unitRef="U_USD">99700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_4dbaf032-0b80-4d84-9c60-df4989e9f55c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company had restricted cash of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively, primarily related to a security deposit on its operating leases for its offices in Somerville and Charlestown, Massachusetts for the year ended December 31, 2021, and for its operating lease for its offices in Somerville, Massachusetts for the year ended December 31, 2020. This is included in restricted cash, non-current and other assets on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_2f5ed8de-d041-464f-b6c3-7ddec6410a82"
      unitRef="U_USD">2500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-5"
      id="F_a9d1e8d8-3a3e-47f0-80d2-14b46e203967"
      unitRef="U_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_a09bad39-1dff-4863-8d58-0f0dbdb17848">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December 31, 2021 and 2020, the Company&#x2019;s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_bbba39c0-28a9-4ff8-bf9f-453228a6182e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounts &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;receivable are carried at the invoiced amount less an allowance for doubtful accounts. Doubtful accounts are provided for on the basis of anticipated collection losses. The estimated losses are determined from historical collection experience and a review of outstanding accounts receivable. A receivable is considered past due if the Company has not received payment within the stated payment terms. After all attempts to collect a receivable have failed, the receivable is&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;written &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;off against the allowance. Based on historical receipts and collections history, management has determined that an allowance for doubtful accounts is not necessary as of December 31, 2021 and 2020.&lt;/span&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_fb7a119d-59c4-4ea8-b2f4-38d0a0a4f1a3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred, while any additions or improvements are capitalized. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:60.992%;"/&gt;
          &lt;td style="width:2.063%;"/&gt;
          &lt;td style="width:36.944%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;ESTIMATED USEFUL LIFE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <fnch:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_fd841a62-4635-4f26-82dd-3e92a56fd1c6">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:60.992%;"/&gt;
          &lt;td style="width:2.063%;"/&gt;
          &lt;td style="width:36.944%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;ESTIMATED USEFUL LIFE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</fnch:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_2986efa3-0d9a-4a27-8474-473277d39a68"
      id="F_c09babb2-68c4-41e5-9ea4-40993c229032">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f2f7e686-a500-4145-884d-a28aca2133c9"
      id="F_ce2b5690-bd9c-458c-adfc-b41617c2f364">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_cb5222a4-6edc-4157-b8f3-0776d5488397"
      id="F_3c867d83-f46b-4533-85ee-19b9ff261236">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_6c2fd835-a216-403d-821e-6c8b06fd2c61"
      id="F_878fa8bc-5b17-4a58-a99f-43b90ffbca47">Shorter of useful life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_7484c4fa-0601-41aa-84ca-453b0ca68ca7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill and In-Process Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill is the amount by which the cost of the acquired net assets in a business combination exceeds the fair value of the identifiable net assets on the date of purchase or valuation. The Company accounts for goodwill in accordance with ASC Topic 350, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquired In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) represents the fair value assigned to research and development assets that the Company acquired that had not been completed at the date of acquisition and is accounted for as an indefinite lived intangible asset in accordance with ASC Topic 350, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The value assigned to the acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The Company&#x2019;s IPR&amp;amp;D is comprised of Crestovo&#x2019;s research and development asset related to CP101, which was acquired in the Merger.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill and IPR&amp;amp;D are evaluated for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company&#x2019;s use of the acquired asset or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company&#x2019;s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To conduct impairment tests of goodwill, the fair value of the Company&#x2019;s single reporting unit is compared to its carrying value. If the reporting unit&#x2019;s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its fair value. The Company&#x2019;s annual assessments for impairment of goodwill as of October 1, 2021 and October 1, 2020 indicated that the fair value of its reporting unit exceeded the carrying value of the reporting unit.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To conduct impairment tests of IPR&amp;amp;D, the fair value of the IPR&amp;amp;D asset is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;amp;D project exceeds its fair value. The Company estimates the fair value of IPR&amp;amp;D using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not limited to, estimating the timing of and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. The Company&#x2019;s annual assessment for impairment of IPR&amp;amp;D indicated that the fair value of its IPR&amp;amp;D asset as of October 1, 2021 and October 1, 2020 exceeded the respective carrying value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Any impairments are recognized as a loss in the year the goodwill and/or IPR&amp;amp;D are determined to be impaired. Impairment of IPR&amp;amp;D is recorded as research and development expense and impairment of goodwill is recorded separately as a loss in other income (expense) on the Company&#x2019;s consolidated statements of operations. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment loss has been recognized. Additionally, there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; change to the carrying value of goodwill and IPR&amp;amp;D for the years ended December 31, 2021 and 2020.&lt;/span&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-6"
      id="F_4263e394-54e0-40c2-ab72-8b3694d3b8a7"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="INF"
      id="F_f3a615a1-b038-4d01-a07d-42ec97f4681d"
      unitRef="U_USD">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="INF"
      id="F_d1f65061-a563-4942-9f83-3275ecdc72f1"
      unitRef="U_USD">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <fnch:DeferredInitialPublicOfferingCostsPolicyTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_93f4ebb7-9470-483e-9b00-11e160dc9228">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Initial Public Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred initial public offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be abandoned, the deferred initial public offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. On March 18, 2021, the Company completed the IPO; accordingly, the Company recognized the deferred initial public offering costs of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a reduction from gross proceeds associated with the IPO through additional paid-in capital in the accompanying consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On April 20, 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;192,877&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, and the Company recognized offering costs of less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a reduction from gross proceeds associated with the overallotment through additional paid-in capital in the accompanying consolidated balance sheet. Accordingly, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; deferred offering costs as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Deferred offering costs on the accompanying consolidated balance sheet as of December 31, 2020 were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;</fnch:DeferredInitialPublicOfferingCostsPolicyTableTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_54d8859b-3cf9-4f25-81a8-0121817ec070"
      decimals="-5"
      id="F_456931b9-c535-4fa5-849d-afe504fa8e34"
      unitRef="U_USD">2900000</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4f9e11d5-5772-4d8d-aeba-f92855030d1d"
      decimals="INF"
      id="F_6a0d2e09-ef70-449f-b358-6669bdb05787"
      unitRef="U_shares">192877</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_894a98a6-c6bc-4f3a-98ca-fb68d588713d"
      decimals="-5"
      id="F_bbaa4a05-9bdd-49e0-bee5-9d543da5ab3f"
      unitRef="U_USD">100000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-6"
      id="F_670aee3c-79a3-4f7f-b696-f117623d9244"
      unitRef="U_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-5"
      id="F_c32bc8de-c5bf-49f8-ae6b-89f750208f0b"
      unitRef="U_USD">1000000.0</us-gaap:DeferredOfferingCosts>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_9484bd62-fa2a-4c0f-a0a1-dba4f971995c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the FASB issued ASU 2016-02,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; Leases (&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASC 842&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors), and replaces the existing guidance in ASC 840, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The FASB subsequently issued amendments to ASC 842, which have the same effective date of January 1, 2019: (i) ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Codification Improvements to Topic 842,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which amends certain narrow aspects of the guidance issued in ASU 2016-02; and (ii) ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and not restate prior periods presented. ASC 842 requires lessees to classify leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. The Company adopted ASC 842 during the quarter ended December 31, 2021, with an effective date of January 1, 2021, using the modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior period financial statements continue to be presented in accordance with ASC 840.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The adoption of this standard resulted in the recognition of operating lease right-of-use assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and current and noncurrent operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, and the derecognition of deferred rent liabilities and unamortized lease incentives of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, on the Company&#x2019;s Balance Sheets as of January 1, 2021 relating to its office leases in Somerville, MA. The adoption of this standard did not have a significant impact on the Company&#x2019;s consolidated Statements of Operations or Statements of Cash Flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to January 1, 2021, the Company accounted for leases under Accounting Standards Codification 840, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x2018;&#x2018;ASC 840&#x2019;&#x2019;). At lease inception, the Company determined if an arrangement was an operating or capital lease.  For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent.  The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified  deferred rent as current and  noncurrent  liabilities based on  the portion of the deferred rent that was scheduled to mature within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#x2019;s control over the use of that identified asset. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use (&#x201c;ROU&#x201d;) asset and current and non-current lease liabilities, as applicable on the balance sheet. The Company elected, as allowed under ASC 842, to not recognize leases with a lease term of one year or less on its balance sheet. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures and records its lease liabilities based on the present value of lease payments over the expected remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in the lease contracts if that rate is readily available. As the implicit rate has not historically been readily determinable, the Company utilizes its incremental borrowing rate (&#x201c;IBR&#x201d;), which reflects the fixed rate at which the Company could borrow on a&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;collateralized basis over a similar term to fund the amount of lease payments to be made in a similar economic environment. Management determines the appropriate IBR to use based on the Company&#x2019;s credit standing and market environment at lease commencement. The Company measures its ROU assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.) , non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated, based on the respective relative fair values, to the lease components and non-lease components. However, the Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After lease commencement and the establishment of a ROU asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When a lease is modified and the modification is not accounted for as a separate contract, the Company remeasures its ROU assets and lease liabilities.  A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4"
      decimals="-5"
      id="F_db1be9c0-86f5-4bca-a48b-c8e8489114e4"
      unitRef="U_USD">5800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4"
      decimals="-5"
      id="F_474525a4-f6c9-4365-8c4b-75d5a6965a11"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c73d14c8-94ae-4bf0-88d0-4cf807d271a4"
      decimals="-5"
      id="F_e313c1c1-73d2-47a2-83d4-f36e712ab63d"
      unitRef="U_USD">5900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <fnch:DerecognitionOfDeferredRentLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_ee66c061-4207-4b07-8f83-dac57eb38a43"
      unitRef="U_USD">800000</fnch:DerecognitionOfDeferredRentLiabilities>
    <fnch:UnamortizationOfLeaseIncentives
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_1b2759fe-e0e7-44b6-a11b-6a6855d10491"
      unitRef="U_USD">200000</fnch:UnamortizationOfLeaseIncentives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_ab59510f-53cd-4251-8daa-cc3ba455efab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_38a6d141-7d4c-4713-85dc-8596f4dca141">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_7fe60a5f-fa23-44ce-98c7-d7b46c1f89d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_368507ef-b18c-4dd1-bd43-2753e9c5b607">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for all stock-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#x2019;s stock-based payments are comprised of stock options. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has historically been a private company until its IPO in March 2021 and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_4d73a8dd-45cb-4196-8a40-c5aa55a6a7d2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is primarily subject to U.S. federal and Massachusetts state income tax. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company maintains a reserve against certain federal and state research and development credits that are recorded net in deferred taxes. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accruals for interest or penalties related to income tax matters. Tax years since inception remain open to examination by federal and state tax authorities.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="2"
      id="F_eef7532c-8b80-4c63-8718-f785289a3fda"
      unitRef="U_pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_0606e113-aa5e-4287-8651-d83a6c19ba2d"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_9b9304a5-aaf1-44a1-9537-0a94c3bef0bd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has historically generated revenue from the following sources: (1) collaboration revenue from the collaboration agreement with Takeda Pharmaceutical Company Limited (see Note 7) and (2) royalty revenue from OpenBiome&#x2019;s sales of a licensed product under the Asset Purchase and License Agreement with OpenBiome (see Note 7).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of (1) a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services; (2) an obligation to transfer FMT materials; or (3) an obligation to provide pre-clinical and clinical research and support services. Under the collaboration agreement, the Company provides options to additional items, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract. For performance obligations which consist of FMT materials, shipping and distribution activities occur prior to the transfer of control of FMT materials and are considered activities to fulfill the Company&#x2019;s promise to deliver goods to the customers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company estimates the transaction price based on the amount expected to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and are included in the transaction price only to the extent it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are added to the transaction price with a corresponding adjustment being made to the measure of progress, and, as necessary, recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For contracts which have more than one performance obligation, the total contract consideration is allocated based on observable standalone selling prices or, if standalone selling prices are not readily observable, based on management&#x2019;s estimate of each performance obligation&#x2019;s standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to be entitled to for the satisfaction of each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For performance obligations, revenue is recognized when control of the product is transferred to the customer and the related performance obligation is satisfied, which typically occurs upon delivery of the product to the customer, for an amount that reflects the consideration the Company expects to be entitled to receive in exchange for delivering the product. For performance obligations which consist of clinical trial participation and related support services, revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides revenue disaggregated by timing of revenue recognition (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:55.945%;"/&gt;
          &lt;td style="width:1.804%;"/&gt;
          &lt;td style="width:2.145%;"/&gt;
          &lt;td style="width:17.488%;"/&gt;
          &lt;td style="width:0.881%;"/&gt;
          &lt;td style="width:1.804%;"/&gt;
          &lt;td style="width:2.145%;"/&gt;
          &lt;td style="width:16.906%;"/&gt;
          &lt;td style="width:0.881%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transferred at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transferred over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_b4cdba46-c69b-4965-be5c-539652d0fd08">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides revenue disaggregated by timing of revenue recognition (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:55.945%;"/&gt;
          &lt;td style="width:1.804%;"/&gt;
          &lt;td style="width:2.145%;"/&gt;
          &lt;td style="width:17.488%;"/&gt;
          &lt;td style="width:0.881%;"/&gt;
          &lt;td style="width:1.804%;"/&gt;
          &lt;td style="width:2.145%;"/&gt;
          &lt;td style="width:16.906%;"/&gt;
          &lt;td style="width:0.881%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transferred at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transferred over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4de9218f-505d-4ec5-a79e-948264f8faaa"
      decimals="-3"
      id="F_cf972f55-adec-4f96-b9bf-9a357ebcda80"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20b17903-cb4b-42fd-9bb7-362bbcc58c00"
      decimals="-3"
      id="F_e01f119e-db49-4bd4-855b-8be74ff5ad4e"
      unitRef="U_USD">343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e1f90607-ba2b-41a5-bea3-4ef6520ec07b"
      decimals="-3"
      id="F_e8d9f1d8-c821-4632-9511-2ff4b26cfe3a"
      unitRef="U_USD">18532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9606295d-3592-4e4f-80a8-99a45144d61e"
      decimals="-3"
      id="F_a319d63b-abb6-49cd-bdb8-730ccb218531"
      unitRef="U_USD">7376000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_b5996628-6511-4ff4-b077-43112c42acbe"
      unitRef="U_USD">18532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_c65d78ca-ff94-467e-8418-ddf90abc159a"
      unitRef="U_USD">7719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_a435aa68-c648-4744-9809-7d1069411bc9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#x2019;s common shares and participating securities. The Company&#x2019;s preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021 and 2020.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_8ad84b0a-db95-46fd-8915-f8dc9657bdfb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board FASB or other accounting standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles-Goodwill and Other- Internal-Use Software&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (Subtopic&lt;br/&gt; 350- 40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance for capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The Company adopted the standards on a prospective basis&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on January 1, 2021.The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively and certain others to be made retrospectively. The Company adopted this standard on January 1, 2021, and this standard did not have a material impact on its consolidated financial statements and related disclosures for the year ended December 31, 2021. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_f9e54d8e-8c86-4db3-a283-91956d30758d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.815%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DESCRIPTION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;QUOTED&lt;br/&gt;PRICES&lt;br/&gt;IN ACTIVE&lt;br/&gt;MARKETS FOR&lt;br/&gt;IDENTICAL&lt;br/&gt;ASSETS&lt;br/&gt;(LEVEL 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.815%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DESCRIPTION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;QUOTED&lt;br/&gt;PRICES&lt;br/&gt;IN ACTIVE&lt;br/&gt;MARKETS FOR&lt;br/&gt;IDENTICAL&lt;br/&gt;ASSETS&lt;br/&gt;(LEVEL 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between fair value levels during the years ended December 31, 2021 and 2020. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_f512a9b5-ee33-443e-86b3-7e7550ce55b0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.815%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DESCRIPTION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;QUOTED&lt;br/&gt;PRICES&lt;br/&gt;IN ACTIVE&lt;br/&gt;MARKETS FOR&lt;br/&gt;IDENTICAL&lt;br/&gt;ASSETS&lt;br/&gt;(LEVEL 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;132,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.815%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.931%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.981%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DESCRIPTION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;QUOTED&lt;br/&gt;PRICES&lt;br/&gt;IN ACTIVE&lt;br/&gt;MARKETS FOR&lt;br/&gt;IDENTICAL&lt;br/&gt;ASSETS&lt;br/&gt;(LEVEL 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;SIGNIFICANT&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS&lt;br/&gt;(LEVEL 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:Assets
      contextRef="C_97f8bd01-bf35-4029-b59b-fedcc19e7fa8"
      decimals="-3"
      id="F_69501479-770a-4a45-9983-5d1d1b49fcf9"
      unitRef="U_USD">132275000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_aa2b03ad-bfcf-4d93-bc04-01ee6362dafd"
      decimals="-3"
      id="F_59699bd9-67ea-4457-9905-242c96347d0d"
      unitRef="U_USD">132275000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_84da10c1-11ac-42c7-a238-2c5259bce7ee"
      decimals="-3"
      id="F_e2a7e1b8-d4b5-4b5c-9fc9-e77419b54f80"
      unitRef="U_USD">132275000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_d858d07b-3375-4198-87a7-a594e75f4620"
      decimals="-3"
      id="F_1d3b058a-6425-4f75-8664-87af9cc14489"
      unitRef="U_USD">132275000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_d35ab3f0-886e-4614-bb8e-288d6e18d8a8"
      decimals="-3"
      id="F_7b59642d-cab7-4c39-9f24-091a1bd86d64"
      unitRef="U_USD">98677000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_ffad40cc-645b-45db-bb47-731c0e92c8ed"
      decimals="-3"
      id="F_c7778b4d-8848-4e88-9f52-78a59069b131"
      unitRef="U_USD">98677000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_193c9642-0dfc-4b03-beda-cbe44093e952"
      decimals="-3"
      id="F_1b1904c6-15c1-43a5-9ba5-34ff160e2117"
      unitRef="U_USD">98677000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_1290669d-3ef4-4091-b2fe-97c62f8ec90f"
      decimals="-3"
      id="F_0d4de75f-a9c5-4b0b-a917-c81ea91521a0"
      unitRef="U_USD">98677000</us-gaap:Assets>
    <fnch:TransfersBetweenFairValueLevels
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_1c24de56-5ca4-4306-85a3-513f6e387916"
      unitRef="U_USD">0</fnch:TransfersBetweenFairValueLevels>
    <fnch:TransfersBetweenFairValueLevels
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_b5997cce-4ac8-486c-a37b-1c6996def664"
      unitRef="U_USD">0</fnch:TransfersBetweenFairValueLevels>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_768d4dff-890f-46d4-bcbf-4ea6f28ec093">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consisted of the following as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.503%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:16.696%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:15.676%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction work-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively. During the years ended December 31, 2021 and 2020, the Company purchased $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of software, property, and equipment from a related party, under the OpenBiome Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_1c8d0f08-88b4-45ee-ab85-02cf672eff4c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consisted of the following as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.503%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:16.696%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:15.676%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction work-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ee5e5087-1f48-495c-a0c7-df7f666bcc55"
      decimals="-3"
      id="F_55b8be57-3bf8-4cff-8e0d-dcd403a3eadf"
      unitRef="U_USD">3850000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1fc799d2-e7ca-49cd-94bd-3368b8b30296"
      decimals="-3"
      id="F_d0cccc11-0c51-40fa-b5b1-436ae3971652"
      unitRef="U_USD">2363000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8192ae4f-1c2b-4a80-a43c-6831f9eb30f2"
      decimals="-3"
      id="F_52164a80-b98f-4c08-a1da-f9ccf6974946"
      unitRef="U_USD">537000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7eff636f-c2ac-47da-b8b3-a7419771eb22"
      decimals="-3"
      id="F_298be6ac-5ec6-40cd-b6e4-51dc7bb56744"
      unitRef="U_USD">537000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c5aa5df0-f902-4636-ba9a-661aa8e20277"
      decimals="-3"
      id="F_42393eb6-a37f-4b05-aecb-20bd11298c3c"
      unitRef="U_USD">13894000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b5ab9bc6-ee73-4ce5-9025-8b3e49b4281c"
      decimals="-3"
      id="F_5558c33c-7628-419b-854b-78e050d4ff4a"
      unitRef="U_USD">2143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2bd85910-ac68-4113-bf19-049baf264c14"
      decimals="-3"
      id="F_e6420f7a-4f18-45ab-9a39-9fe4faa4ffe2"
      unitRef="U_USD">329000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_05c62255-213e-4926-a804-309677cebed5"
      decimals="-3"
      id="F_a90e04c2-4733-4882-82b2-38c37016e086"
      unitRef="U_USD">2635000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_32730e64-85f4-497d-935f-ef876cb18554"
      decimals="-3"
      id="F_930aa7c7-c260-4c39-b15e-820480b1d4c8"
      unitRef="U_USD">4883000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb9e58de-8667-4321-b6aa-911f48db159f"
      decimals="-3"
      id="F_d798e9be-447f-4d03-8d99-36405945adb5"
      unitRef="U_USD">1150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6d564718-6e70-47c3-b45e-478a924b707b"
      decimals="-3"
      id="F_9d33e7ed-1221-48c2-a603-988189952e9a"
      unitRef="U_USD">368000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d132eb44-d5fe-4db6-90fa-ee1cb44369fe"
      decimals="-3"
      id="F_48ccb4cd-7349-4d3f-be65-90992a9ae204"
      unitRef="U_USD">205000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_a5dc3db3-2f84-46c8-b97f-66ada11006c3"
      unitRef="U_USD">23861000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_fc216080-96a5-4e9c-a2be-3c0ed6ddeac0"
      unitRef="U_USD">9033000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_4aa45433-8ea7-45c1-b1d3-6e8a78a8f5f8"
      unitRef="U_USD">4226000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_38226be1-435f-40ed-9ef5-4d52057337a1"
      unitRef="U_USD">2029000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_bf7db64b-6171-4f21-beb6-3acf03e215d5"
      unitRef="U_USD">19635000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_b35cd517-e76c-4a05-b084-8ce3cb52d1fc"
      unitRef="U_USD">7004000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-5"
      id="F_0697e14a-9c57-4654-9e8a-de8f678c5bf6"
      unitRef="U_USD">2300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-5"
      id="F_160469b1-d9a8-4486-aef8-dab8a17a255e"
      unitRef="U_USD">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9450f23f-f434-468a-8008-c54520274c6a"
      decimals="-5"
      id="F_a122df05-3693-40cc-8588-740f0b21e4b6"
      unitRef="U_USD">3900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_619dbd5a-3d31-4dff-bdde-1c37501aef02"
      decimals="-5"
      id="F_51ab8b08-2914-4946-863c-e9c85e1e400d"
      unitRef="U_USD">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:LeasesOfLessorDisclosureTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_db602992-cb67-4d59-93a5-0f1266fbfc02">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. LEASES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;200 Inner Belt Road Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2015, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; lease agreement (the "Inner Belt Road Lease") for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,785&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The monthly rental payments under the Inner Belt Road Lease, which include base rent charges of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, are subject to periodic rent increases through September 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2016, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; sublease agreement (the "200 Inner Belt Road Sublease") to share its leased space under the Inner Belt Road Lease with OpenBiome, a related party, as sub-tenant. The sublease with OpenBiome is coterminous with the Inner Belt Road Lease and provides for an allocation, based on OpenBiome&#x2019;s proportionate share, of base rent and other expenses under the Inner Belt Road Lease, which is subject to change each year based on current headcount and space used. OpenBiome&#x2019;s proportionate share is reassessed on a quarterly basis over the term of the sublease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2017, the Company amended the Inner Belt Road Lease to lease an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of space for its primary office and laboratory space in Somerville, Massachusetts. The term of the Inner Belt Road Lease and the sublease with OpenBiome were not affected as a result of the amendment, although OpenBiome does occupy some of this additional space. The rental payments for the additional space under the amended Inner Belt Road Lease, which include base rent charges of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per month, are subject to periodic rent increases through September 2026. In November 2020, pursuant to the OpenBiome Agreement, the Company and OpenBiome amended the terms of the sublease to provide for a reduction in the size of the subleased premises upon the closing of the OpenBiome Agreement (see Note 13), which occurred on March 1, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The sublease was further amended on January 15, 2021 and June 22, 2021 and terminated on December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's lease expense under the Inner Belt Road Lease was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for each of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020. The Company recognizes sublease income under the sublease to OpenBiome as rent is received over the sublease term. Gross lease income under the sublease to OpenBiome for each of the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, and is presented as an offset to lease expense on the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cherry Street Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 1, 2021, the Company assumed a lease agreement (the &#x201c;Cherry Street Lease&#x201d;) in conjunction with the closing of the OpenBiome Agreement. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The lease term is from March 2021 through February 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company&#x2019;s lease expense under the Cherry Street Lease for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concord Avenue Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On May 25, 2021, the Company entered into a lease agreement (the "Concord Avenue Lease") &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;May 2021 through February 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company&#x2019;s lease expense under the Concord Avenue Lease for the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On August 17, 2021 Finch extended the term of the lease for an additional two-month period through April 2022 and on February 4, 2022 Finch further extended the lease for an additional month through May 2022.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Concord Avenue Lease qualifies as a short-term lease and will be excluded from the balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;100 Hood Park Drive&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On August 3, 2021 (the "Execution Date"), the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; lease agreement (the "Hood Lease") with Hood Park LLC (the "Landlord"), pursuant to which the Company will lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,139&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of office and laboratory space (the "Premises"). The term of the Hood Lease commenced on the Execution Date, and Finch will become responsible for paying rent under the Hood Lease on the earlier of (i) January 1, 2022 and (ii) the date Finch&#x2019;s improvement on the Premises is substantially completed and Finch has commenced business operations in the Premises (the &#x201c;Rent Commencement Date&#x201d;). As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Rent Commencement Date had not occurred and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; lease expense, right-of-use asset, or lease liability was recognized under the Hood Lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Hood Lease provides Finch with an option to extend the lease for one additional five-year term&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Finch&#x2019;s annual base rent for the Premises will start at approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and the lease contains annual rent escalations. The Hood Lease provides for a tenant improvement allowance of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the cost of Finch&#x2019;s work on the Premises. As of December 31, 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of lessor owned tenant improvements were completed by the Company and are recorded in other current assets on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company posted a customary letter of credit in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, subject to decrease on a set schedule, as a security deposit pursuant to the Hood Lease. This is included in restricted cash, non-current on the consolidated balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the classification of right-of-use assets and lease liabilities as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.926%;"/&gt;
        &lt;td style="width:40.813%;"/&gt;
        &lt;td style="width:1.852%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:20.885%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;BALANCE SHEET CLASSIFICATION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;ASSETS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finance lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table represents the components of lease cost, which are included in general and administrative and research and development expense on the statement of operations, for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.489%;"/&gt;
        &lt;td style="width:8.243%;"/&gt;
        &lt;td style="width:1.815%;"/&gt;
        &lt;td style="width:33.234%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;LEASE COST&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finance lease cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;Amortization of right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;Interest on lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average remaining lease term and discount rate were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.741%;"/&gt;
        &lt;td style="width:2.021%;"/&gt;
        &lt;td style="width:31.238%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;LEASE TERM AND DISCOUNT RATE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;                                 &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;                                 &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental disclosure of cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.631%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:24.291%;"/&gt;
        &lt;td style="width:0.783%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Financing cash flows from finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table represents a summary of the Company&#x2019;s future lease payments required as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.503%;"/&gt;
        &lt;td style="width:1.203%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:10.897%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.066%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.283%;"/&gt;
        &lt;td style="width:9.515%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.283%;"/&gt;
        &lt;td style="width:9.515%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;OPERATING LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;HOOD PARK LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;FINANCE LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;TOTAL LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;57,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following represents a summary of the Company's future minimum lease payments under non-cancelable lease agreements, presented in accordance with ASC 840, as of December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.242%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.914%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.134%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.134%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;OPERATING LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;FINANCE LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;TOTAL LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_f3c21c56-3f76-4284-9b46-d59d04095b4f"
      id="F_cf4f96e8-93e7-458d-b8fa-e452ca1c857f">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <fnch:LesseeOperatingLeaseLeasesArea
      contextRef="C_f3c21c56-3f76-4284-9b46-d59d04095b4f"
      decimals="0"
      id="F_53e9c0f8-c7b2-48ae-b642-8cf27e2a61ee"
      unitRef="U_sqft">25785</fnch:LesseeOperatingLeaseLeasesArea>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_3997c41e-c3c8-4da2-92c5-b9b78945ec5f"
      decimals="-5"
      id="F_7a97a092-b7e1-426a-afa1-1dce02c05c5e"
      unitRef="U_USD">100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_516796e2-fbe9-4963-858d-72b0827743bd"
      id="F_6693e516-3871-4712-a4ca-b2116e5c1248">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <fnch:LesseeOperatingLeaseLeasesAdditionalArea
      contextRef="C_c2016132-69da-4b8f-8d71-133d0638c922"
      decimals="0"
      id="F_c8e7c31b-97b6-4fd9-a1fd-6ea6727be356"
      unitRef="U_sqft">10500</fnch:LesseeOperatingLeaseLeasesAdditionalArea>
    <fnch:LeaseAndRentForAdditionalSpace
      contextRef="C_92dda7ef-0294-4c60-82b0-253ca681399b"
      decimals="0"
      id="F_8f4f440a-c82d-4a79-bced-29fa76457496"
      unitRef="U_USD">33000</fnch:LeaseAndRentForAdditionalSpace>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_f567ce58-d36b-4cfd-9d2d-43b08b57d11c"
      decimals="-5"
      id="F_93bd3057-d439-4ffb-a246-82917ee3b377"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_12c08bf0-f65b-48fb-8e06-4a1f508e55aa"
      decimals="-5"
      id="F_4f2d582a-ee76-495f-af9c-1d7f01ef00b1"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="C_1eea5819-27f3-44f8-90a5-9ad45f546635"
      decimals="-5"
      id="F_0bc8f194-421d-42f0-b818-31870e278535"
      unitRef="U_USD">100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_bf8db871-33e8-4b48-96d6-27807a718a9e"
      decimals="-5"
      id="F_b6bc1eed-1ec9-4438-a877-c82f0a60730a"
      unitRef="U_USD">400000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_ee5015be-b0fc-4255-b8a6-7d92826e8809"
      id="F_935ce1f2-59a8-4b43-83b4-8dd6d73ca0ab">The lease term is from March 2021 through February 2023</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_17959f69-52c0-4bd7-b17b-2b07c6a89b83"
      decimals="-5"
      id="F_53a5b2eb-7570-4a42-911e-cdbc6b6b675c"
      unitRef="U_USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0f83ae0d-7bba-4546-b75f-1d3582c586e8"
      decimals="-6"
      id="F_c73aa992-c316-4c6e-8e96-00afc09b0c4c"
      unitRef="U_USD">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_248b74bb-bfef-43a3-8d20-9cef789c8fff"
      id="F_b7cc9ba9-0b10-4cdd-91c9-f4ec828ae818">May 2021 through February 2022</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_ec838299-1fe2-441c-a5b8-80818b17a987"
      decimals="-5"
      id="F_b4cad960-3012-46d3-8172-e9943b4835b7"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_90fcacc1-0f06-47c8-b90f-1fbdb93ceffd"
      decimals="-6"
      id="F_6095cbb6-67c3-4925-bc5a-d4a6e8f50279"
      unitRef="U_USD">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_28d6c4c4-95d2-4950-aa5c-95cb9369b506"
      id="F_a9ce6f6b-6662-47db-83cf-6560e24507ab">On August 17, 2021 Finch extended the term of the lease for an additional two-month period through April 2022 and on February 4, 2022 Finch further extended the lease for an additional month through May 2022.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_34820dd6-125a-4651-9d74-471c92bb1554"
      id="F_048484f4-0007-41c2-9093-eed45207d333">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <fnch:LesseeOperatingLeaseLeasesArea
      contextRef="C_34820dd6-125a-4651-9d74-471c92bb1554"
      decimals="0"
      id="F_36d192ba-f31c-4a54-90be-05c2a3fda3d8"
      unitRef="U_sqft">61139</fnch:LesseeOperatingLeaseLeasesArea>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_29c6a1db-39a6-4d51-92a7-9d1ef5ec34c1"
      decimals="-3"
      id="F_1918013e-0333-4b71-8c0b-60496294b04b"
      unitRef="U_USD">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5da05409-533d-466c-be18-f590067b6927"
      decimals="-3"
      id="F_1df664b4-9ef8-4ae9-956f-3adf9a96e70b"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_5da05409-533d-466c-be18-f590067b6927"
      decimals="-3"
      id="F_4e9b6ee8-1281-476c-86e8-0f1cbf1afda2"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_d4f0fa8f-0e53-4dd0-96a5-34610a065137"
      id="F_e2fc4d84-5a5f-4f8c-827b-1998a4b8faf4">The Hood Lease provides Finch with an option to extend the lease for one additional five-year term</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_b15bab6a-f44e-4005-a4ff-bbdc0471e1f1"
      decimals="-5"
      id="F_2e492e1f-35dc-4b88-886e-baeff73aac5b"
      unitRef="U_USD">4500000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_b15bab6a-f44e-4005-a4ff-bbdc0471e1f1"
      decimals="-5"
      id="F_a6b2e9af-2439-410e-b07d-afaf89ff2e82"
      unitRef="U_USD">14800000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:TenantImprovements
      contextRef="C_5da05409-533d-466c-be18-f590067b6927"
      decimals="-2"
      id="F_29d4c222-95f0-4e94-bd55-fa77e4bd8d7d"
      unitRef="U_USD">5300</us-gaap:TenantImprovements>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="C_e162eb52-c156-467f-9465-7e2422f556b3"
      decimals="-5"
      id="F_1878571a-f8df-49e5-a3c3-604418c97067"
      unitRef="U_USD">2300000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <fnch:LeasesBalanceSheetInformationTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_a05b6650-bec3-4cbb-9949-61a876e77048">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the classification of right-of-use assets and lease liabilities as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.926%;"/&gt;
        &lt;td style="width:40.813%;"/&gt;
        &lt;td style="width:1.852%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:20.885%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;BALANCE SHEET CLASSIFICATION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;ASSETS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finance lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fnch:LeasesBalanceSheetInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_c070302c-1763-4d9d-9d03-41db3430085d"
      unitRef="U_USD">5053000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_1e2d6ca4-3c27-4065-bd7a-dfb74ee69183"
      unitRef="U_USD">22000</us-gaap:FinanceLeaseRightOfUseAsset>
    <fnch:LeaseAssets
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_72002164-5acf-4620-9a07-ec2f07bfc775"
      unitRef="U_USD">5075000</fnch:LeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_1045b666-3c89-49d6-989d-a9c7192e4fc5"
      unitRef="U_USD">1128000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_5cb5f7ed-5764-4079-9ea2-3e4d127426ff"
      unitRef="U_USD">19000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_823d5dd6-a962-4a77-9dcd-66a9b39b1808"
      unitRef="U_USD">4887000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_e657055e-7cd5-4b55-9a7f-a0622efa46cc"
      unitRef="U_USD">7000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <fnch:LeaseLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_aa735b8c-50ef-4afa-af19-3779bd4ea462"
      unitRef="U_USD">6041000</fnch:LeaseLiabilities>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_b83a1e0e-5575-441f-a7cb-67463c9623ff">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table represents the components of lease cost, which are included in general and administrative and research and development expense on the statement of operations, for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.489%;"/&gt;
        &lt;td style="width:8.243%;"/&gt;
        &lt;td style="width:1.815%;"/&gt;
        &lt;td style="width:33.234%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;LEASE COST&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finance lease cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;Amortization of right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;Interest on lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_5b468583-762f-4d2e-af4d-d8c509c1e288"
      unitRef="U_USD">27000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_d8a3ffe6-a77e-4333-bf69-c25af795ddf8"
      unitRef="U_USD">10000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_bc5b7199-ea3a-4127-a095-5120c6a064d1"
      unitRef="U_USD">1336000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_08fc575e-e782-4a67-b5f3-adbcb8db1398"
      unitRef="U_USD">254000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_96f455a1-fa0d-4709-82af-fd48a25a3bf3"
      unitRef="U_USD">525000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_7f748d30-e8a8-4e9a-baa1-fcebdae49398"
      unitRef="U_USD">88000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_c07bc4d8-84f3-498c-a3a2-4ecbd5524b6b"
      unitRef="U_USD">2064000</us-gaap:LeaseCost>
    <fnch:LeaseTermAndDiscountRateTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_6ce7c92d-ab25-4d50-871c-08df7e8c6bf1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average remaining lease term and discount rate were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.741%;"/&gt;
        &lt;td style="width:2.021%;"/&gt;
        &lt;td style="width:31.238%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;LEASE TERM AND DISCOUNT RATE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;                                 &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;                                 &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fnch:LeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      id="F_26c6ab11-1ba2-47e1-8f07-97a2e34f8f35">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      id="F_dda6c6d6-4402-4d85-98e7-5f9f20c931b5">P1Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="3"
      id="F_2bf16509-200a-41dc-8113-068f6c4d9ade"
      unitRef="U_pure">0.067</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="3"
      id="F_f82749e3-24bb-41a8-a458-5c052e13def3"
      unitRef="U_pure">0.306</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_7097a4e4-1ada-42d8-83ab-5d228febca2f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental disclosure of cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.631%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:24.291%;"/&gt;
        &lt;td style="width:0.783%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;DECEMBER 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Financing cash flows from finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_ab29736a-80fa-433a-a665-6feed84c1e7e"
      unitRef="U_USD">-1006000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <fnch:PrincipalPaymentsOnCapitalLeaseObligation
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_41e3ffde-b525-487c-927d-a470f837d4bc"
      unitRef="U_USD">27000</fnch:PrincipalPaymentsOnCapitalLeaseObligation>
    <fnch:ScheduleOfFutureLeasePaymentsTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_24ac26b5-5a1d-4362-a311-7ad38edfc4af">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table represents a summary of the Company&#x2019;s future lease payments required as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.503%;"/&gt;
        &lt;td style="width:1.203%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:10.897%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:11.066%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.283%;"/&gt;
        &lt;td style="width:9.515%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.283%;"/&gt;
        &lt;td style="width:9.515%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;OPERATING LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;HOOD PARK LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;FINANCE LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;TOTAL LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;57,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fnch:ScheduleOfFutureLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_7de635a0-08fc-453e-8b28-e17f47206878"
      unitRef="U_USD">1487000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDueCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_999384ce-d878-4195-9036-e944922d94fd"
      unitRef="U_USD">4535000</fnch:HoodParkLeaseFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_0df06848-8823-4be7-8cce-6ec5dcea40f3"
      unitRef="U_USD">24000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_706d0327-d207-4320-9b04-322af442eadc"
      unitRef="U_USD">6046000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_a10b352d-7835-4a7b-a139-b0a52982d156"
      unitRef="U_USD">1440000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDueInTwoYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f51bb5f7-6709-481d-b1f2-56ca1e503f62"
      unitRef="U_USD">4663000</fnch:HoodParkLeaseFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_7069bb52-5d85-45a0-9a18-3a96e079ecc5"
      unitRef="U_USD">6000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_e251b4b9-fb8a-4be1-9557-8b8e07938db6"
      unitRef="U_USD">6109000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f49f0cc0-49b8-40dd-8abe-a2b50f767859"
      unitRef="U_USD">1460000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDueInThreeYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_ba742708-3eac-44e7-8e4c-9062f4dc8c66"
      unitRef="U_USD">4795000</fnch:HoodParkLeaseFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_e47d14c7-325d-4484-85e2-3b85e975ffb4"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_7315b2c2-a5da-4db2-8906-2d6cf2033d67"
      unitRef="U_USD">6255000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_c1c4856a-7f87-40ae-8e7f-ce88a8979e5d"
      unitRef="U_USD">1496000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDueInFourYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f98ca147-75ac-4b95-b972-fac8f95278be"
      unitRef="U_USD">4931000</fnch:HoodParkLeaseFutureMinimumPaymentsDueInFourYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_8b627a5d-61c2-47af-973b-f88a9daed1f0"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_3b77f8c4-6083-4c57-9677-9c1aff01307b"
      unitRef="U_USD">6427000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_6f11d1fc-286f-4bd9-97ec-5dd1eef918c3"
      unitRef="U_USD">1116000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDueInFiveYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_469e6e12-a8b4-4c92-9d40-86d4cbfecb3e"
      unitRef="U_USD">5071000</fnch:HoodParkLeaseFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f25fca64-9ce3-4eff-8a49-7cd031bfde3c"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_a026cbbe-31a0-45c6-a968-5b8dfd8328e1"
      unitRef="U_USD">6187000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_7c0fc7c3-2983-4cdc-acd5-0e57f1c3d560"
      unitRef="U_USD">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDueThereafter
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_d194cecf-cbb5-4c43-a7b6-02bce571d517"
      unitRef="U_USD">27605000</fnch:HoodParkLeaseFutureMinimumPaymentsDueThereafter>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_009c3b20-8c2f-4a6f-bd1d-70914718a579"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_9c02c30e-c842-4da8-8573-46ecb42cc912"
      unitRef="U_USD">27605000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_44d231d1-78b9-4b57-aa75-04574382adc6"
      unitRef="U_USD">6999000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <fnch:HoodParkLeaseFutureMinimumPaymentsDue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_aedaca7a-5ecd-4178-8623-8e0d1227c884"
      unitRef="U_USD">51600000</fnch:HoodParkLeaseFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_0cf0e310-f18a-4951-83bc-cf643444e542"
      unitRef="U_USD">30000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_20ce8d55-d248-4ab1-b16d-e28d39ece0c4"
      unitRef="U_USD">58629000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue>
    <fnch:InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_ae6e962b-12ae-40f0-9c2d-be15b423963b"
      unitRef="U_USD">984000</fnch:InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue>
    <fnch:HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_08587dc9-502e-4ec9-a388-ef481b210925"
      unitRef="U_USD">0</fnch:HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_07cfa1b6-eb76-4fd2-aa2a-76b3fddd7be2"
      unitRef="U_USD">5000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f072dc76-08a3-4772-9e66-661387b6e4b5"
      unitRef="U_USD">989000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments>
    <fnch:PresentValueOfFutureMinimumLeasePayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_9922ba61-5895-4f1e-8092-88dec3d34a16"
      unitRef="U_USD">6015000</fnch:PresentValueOfFutureMinimumLeasePayments>
    <fnch:HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_8f2a9392-6ddd-4a63-8596-b19fda423072"
      unitRef="U_USD">51600000</fnch:HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_8aa673b8-2e92-48f5-8c4d-80b898eda075"
      unitRef="U_USD">25000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_0779dde7-a716-4f43-bc74-14491d7405b3"
      unitRef="U_USD">57640000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <fnch:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_2c4c0b34-2dd3-4272-a03f-0861146b31ea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following represents a summary of the Company's future minimum lease payments under non-cancelable lease agreements, presented in accordance with ASC 840, as of December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.242%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.914%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.134%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.134%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;OPERATING LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;FINANCE LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;TOTAL LEASE OBLIGATIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fnch:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_f48a9a5e-c10b-4b2d-97cb-569d1634ac3c"
      unitRef="U_USD">1351000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ea7f107c-b99f-4b7c-b453-ff65e0946575"
      unitRef="U_USD">36000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_200b6061-eeac-42b3-9b1e-127e44fc2640"
      unitRef="U_USD">1387000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_e226c9db-47a2-4974-bbb3-d69a69b147bf"
      unitRef="U_USD">1387000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_1265beae-92b2-4d28-9e4b-d24996e7070b"
      unitRef="U_USD">24000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_c6723322-7e38-471f-9a42-0dc5e0172a81"
      unitRef="U_USD">1411000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_b420fbed-cbf5-450d-9359-a92ef2c06c92"
      unitRef="U_USD">1424000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_3b567637-8f6e-4ca5-9697-d7d680d2da26"
      unitRef="U_USD">6000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_f2ac04c3-d27e-41df-bbe2-7078cc712197"
      unitRef="U_USD">1430000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ae8df3d0-ca17-449a-b4ae-01c1cf0f572d"
      unitRef="U_USD">1460000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_39b653f0-1c0a-4f84-baee-90f1716259cc"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_01c3212c-deda-4fb8-a802-21c3f2431acc"
      unitRef="U_USD">1460000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_0e7dc6b3-eea0-462c-875d-5950ecdf5f73"
      unitRef="U_USD">1496000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_8b8de5be-26dc-4a03-bed2-64be1e11f1ec"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_2f24efd4-b8b8-4800-9301-9cc04b0f3b51"
      unitRef="U_USD">1496000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_4cfa302f-b989-47b8-ae47-810f14bc16d5"
      unitRef="U_USD">1115000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_5488a370-ea8a-4e88-9f9c-cfbe152c647a"
      unitRef="U_USD">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_a2c133d9-56f2-4284-98ba-524490fe8e4c"
      unitRef="U_USD">1115000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_aedb844a-7b40-4896-b5fe-f1f4d643e653"
      unitRef="U_USD">8233000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_92771f55-1eca-4d95-8788-0f219c26d157"
      unitRef="U_USD">66000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_17c36f6f-b457-4ea5-8e5b-66489454a3b1"
      unitRef="U_USD">8299000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue>
    <fnch:InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_3d4f29ae-101f-4427-b90e-097160587220"
      unitRef="U_USD">0</fnch:InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_a76e0827-72bd-47fe-8057-40821039bae8"
      unitRef="U_USD">14000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_cef8431b-81b0-4ff3-a27b-674b4690af95"
      unitRef="U_USD">-14000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments>
    <fnch:PresentValueOfFutureMinimumLeasePayments
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_a9ec70f1-0c83-4cfd-a208-b207d105739e"
      unitRef="U_USD">8233000</fnch:PresentValueOfFutureMinimumLeasePayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_69687429-b4c9-47c8-b44b-74f738890229"
      unitRef="U_USD">52000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_f8d1ea06-6e0d-43e7-b068-a1d27fc91c27"
      unitRef="U_USD">8285000</fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_1409bc24-4a0d-4d97-beb4-9f6c52420b38">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities consisted of the following as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.567%;"/&gt;
        &lt;td style="width:1.616%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.051%;"/&gt;
        &lt;td style="width:0.758%;"/&gt;
        &lt;td style="width:1.616%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.051%;"/&gt;
        &lt;td style="width:0.758%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_6327889a-261b-4407-a1a6-e2df869f650c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities consisted of the following as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.567%;"/&gt;
        &lt;td style="width:1.616%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.051%;"/&gt;
        &lt;td style="width:0.758%;"/&gt;
        &lt;td style="width:1.616%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.051%;"/&gt;
        &lt;td style="width:0.758%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <fnch:AccruedResearchAndDevelopment
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_a4db73eb-160e-4f0e-b98b-da5eb0a0fdc1"
      unitRef="U_USD">1345000</fnch:AccruedResearchAndDevelopment>
    <fnch:AccruedResearchAndDevelopment
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_91dd4de1-a70f-4de0-a09e-c0f013da3ddc"
      unitRef="U_USD">81000</fnch:AccruedResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f262b49d-3809-4cd1-85cf-250695bb64ab"
      unitRef="U_USD">1117000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_dafeb827-8584-4d2f-b891-3f0ba5fe01ce"
      unitRef="U_USD">711000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_399fdc08-3d32-4971-a03d-73da6dfce8a1"
      unitRef="U_USD">4401000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_3ef9f851-3540-4e06-9cf2-e96277c59590"
      unitRef="U_USD">3532000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_227bdafd-6334-4cc6-886b-2e25ea3c80b1"
      unitRef="U_USD">3062000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_0ccd70f4-6753-4676-967d-e522b6e1e90f"
      unitRef="U_USD">904000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <fnch:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_876fad5b-625f-4bab-af58-5d79f460fb5a"
      unitRef="U_USD">9925000</fnch:AccruedExpensesAndOtherCurrentLiabilities>
    <fnch:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_51345bc0-3093-4797-a333-57985f5cd61c"
      unitRef="U_USD">5228000</fnch:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_521a9978-ea9d-4939-ae68-c2d1484b48e0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. REVENUE&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2017, the Company entered into an agreement (the &#x201c;Takeda Agreement&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), pursuant to which the Company granted Takeda a worldwide, exclusive license, with the right to grant sublicenses, under certain of its patents, patent applications and know-how to develop the Company&#x2019;s microbiome therapeutic candidate FIN-524, now known as TAK-524, for the prevention, diagnosis, theragnosis or treatment of diseases in humans. The Company subsequently amended and restated the Takeda Agreement in October 2019 to provide for the Company to allocate certain resources towards determining the feasibility of developing a second microbiome therapeutic candidate, FIN-525. The Company further amended the Takeda Agreement in August 2021 to transition primary responsibility for further development and manufacturing activities with respect to TAK-524 from the Company to Takeda in accordance with a transition plan, and Takeda assumed sole responsibility for regulatory matters with respect to TAK-524. In November 2021, Takeda Agreement was amended again to enable the Company to carry out certain FIN-525 preliminary evaluation activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the terms of the Takeda Agreement, the Company agreed to design TAK-524, a product candidate optimized for ulcerative colitis, for Takeda based on selection criteria within a product-specific development plan. The Company also agreed to conduct a feasibility study to potentially further develop FIN-525, a program to develop a live biotherapeutic product optimized for the treatment of Crohn&#x2019;s disease. The Company assessed this arrangement in accordance with ASC 606, and concluded that the contract counterparty, Takeda, is a customer. The Company identified the following material promises at the outset of the Takeda Agreement: (1) an exclusive license to use the Company&#x2019;s rights in intellectual property to conduct research activities; (2) R&amp;amp;D services for activities under the development plan; (3) two options to pursue different indications of research for the Company&#x2019;s right in product candidates; (4) manufacturing and supply for the Company&#x2019;s clinical trials; and (5) participation on a joint steering and joint development committee (&#x201c;JSC&#x201d; and &#x201c;JDC&#x201d;). The options were considered distinct from the other promises in the arrangement and analyzed for material rights; the Company concluded these were not material rights and the consideration related to them should be excluded as a performance obligation until the option is exercised. The Company determined that the remaining promises were not capable of being distinct from one another and were not distinct in the context of the contract. In accordance with the Company&#x2019;s ASC 606 assessment, the Takeda Agreement was determined to contain a single combined performance obligation made up of the promises above, excluding the options. The FIN-525 feasibility study was determined to be part of the single combined performance obligation due to its connection to the original license and research and development activities. The FIN-525 feasibility study was completed in March 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company received an upfront payment from Takeda of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the year ended December 31, 2017 in exchange for the exclusive license of the Company&#x2019;s intellectual property. The Company has included the upfront payment and the estimable reimbursable R&amp;amp;D costs in the transaction price and is recognizing revenue associated with it over the period it expects to perform R&amp;amp;D services&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Under the original agreement the estimated term for the R&amp;amp;D and manufacturing services for which the Company had primary responsibility, was through Phase 1 clinical trials.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On August 9, 2021, the Company and Takeda entered into an amendment to the amended and restated Takeda Agreement (the &#x201c;Amendment&#x201d;). Pursuant to the Amendment, Finch and Takeda transitioned primary responsibility for such development and manufacturing activities from Finch to Takeda in accordance with an agreed upon transition plan, and Takeda also assumed sole responsibility for regulatory matters with respect to TAK-524. The Company accounted for the Amendment as a modification to the existing contract under ASC 606, as the Amendment significantly reduced the remaining performance obligations, which were then completed by September 30, 2021.  As a result, the remaining revenue that had been deferred under the Takeda Agreement was recognized in the third quarter of 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021, Takeda and Finch entered into an amendment to the amended and restated Takeda Agreement ("Amendment #2"). Pursuant to Amendment #2, Finch is performing certain additional research activities related to the feasibility of the FIN-525 program prior to Takeda making the decision to initiate the full development program. Under the amendment, Takeda shall pay Finch for pass-through costs incurred and research services performed at the agreed-upon full-time equivalent (&#x201c;FTE&#x201d;) rate. The additional feasibility work is expected to be completed in the first quarter of 2022 at which point Takeda can determine whether to initiate a full product specific development plan for FIN-525 following its review of the data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognized revenue related to the Takeda Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020, respectively, which is included under collaboration revenue in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Takeda reimburses the Company for certain R&amp;amp;D costs on a quarterly basis. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded accounts receivable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million on its consolidated balance sheets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, and December 31, 2020, respectively. As of December 31, 2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;there is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; remaining deferred revenue due to the Company's satisfaction of the performance obligation.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; As of December 31, 2020, the Company recorded deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to the Takeda Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Takeda Agreement contains various milestone payments associated with development and commercialization efforts that provide for a maximum available amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million should all of the milestones be achieved. These milestones are constrained until the Company determines it is probable that the cumulative revenue related to the milestones will not be reversed&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company has earned and received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in milestone payments&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is still eligible to receive royalties under the Amendment and Takeda is obligated to pay the Company mid-to-high single digit royalties based on annual aggregate net sales of the licensed products, on a product-by-product basis, subject to certain restrictions. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t receive any payments or record any revenues related to sales-based royalties under the Takeda Agreement in the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;OpenBiome&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company and OpenBiome entered into an Asset Purchase and License Agreement (the &#x201c;APL Agreement&#x201d;) in February 2019 that was effective through November 2020. Under the APL Agreement, the Company licensed certain intellectual property and sold certain fecal microbiota transplantation, or FMT, materials and equipment to OpenBiome (see Note 13).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company earned $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in royalty revenue related to the APL Agreement in the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020, respectively, which is recorded as royalty revenue from related party on the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On November 19, 2020, the Company entered into the LMIC License Agreement (&#x201c;LMIC Agreement&#x201d;) with OpenBiome, pursuant to which the Company granted OpenBiome a non-exclusive license, with the right to grant sublicenses, under certain patents, patent applications, and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from donor-sourced stool without the use of culturing or replication, or certain natural products (&#x201c;OpenBiome Royalty Products&#x201d;). The license granted to OpenBiome excludes a license under the Company&#x2019;s intellectual property to exploit a lyophilized natural product (such as CP101) where processed stool is lyophilized. The Company owns all improvements and modifications made to the licensed intellectual property throughout the term of the LMIC Agreement, while OpenBiome is responsible for all manufacturing efforts and all expenses associated with these efforts.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The LMIC Agreement was entered into separately from the asset purchase agreement with OpenBiome (the "OpenBiome Agreement") (see Note 13) and the license granted under the LMIC Agreement is unrelated to the assets acquired under the OpenBiome Agreement. The only consideration provided to the Company under the LMIC Agreement is in the form of future royalties on net sales of OpenBiome Royalty Products. The Company is entitled to receive tiered royalties on net sales of certain products, ranging from mid-single digit to low second decile digits on a product-by-product and country-by-country basis. In the event that OpenBiome is required to pay a royalty to a third party to obtain rights under patents owned or controlled by such third party that are necessary for the exercise of its rights under the Company&#x2019;s intellectual property pursuant to the LMIC Agreement, then OpenBiome shall have the right to deduct a portion of the amount of the royalty due to the third party against the royalties that are due from OpenBiome to the Company. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t earned any of these royalty payments as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The LMIC Agreement will continue in perpetuity until the last royalty is earned under the LMIC Agreement unless otherwise terminated by either party. OpenBiome has the right to terminate the LMIC Agreement for convenience upon 90 days&#x2019; specified prior written notice to the Company. Either party may terminate the LMIC Agreement in the event of an uncured material breach by the other party.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognize any revenue related to the LMIC Agreement for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, as there are currently no marketable OpenBiome Royalty Products.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <fnch:UpfrontPaymentReceived
      contextRef="C_71180d5f-f125-42b1-a289-021fbd6caff4"
      decimals="-5"
      id="F_ce2aebf6-8a3c-460d-a688-1ff15ccec3fb"
      unitRef="U_USD">10000000.0</fnch:UpfrontPaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_caa9d4b6-a795-41fe-9dbc-e8ef123673de"
      decimals="-5"
      id="F_87f574d5-0dcd-4d63-b5ca-3e94b7043be6"
      unitRef="U_USD">18500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_4e5ad697-00fd-45d8-8d53-5221838de719"
      decimals="-5"
      id="F_6f169124-13e5-4979-b227-5fa31aa24d3e"
      unitRef="U_USD">7400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_e3e50907-6887-4220-a0d9-4a36fa444e7f"
      decimals="-5"
      id="F_d902e925-5304-4f3a-8ed4-7591570a1dcf"
      unitRef="U_USD">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_12ceb0d9-027f-4047-880f-0f426157ce04"
      decimals="-5"
      id="F_75686484-e921-4540-a090-1361de10769c"
      unitRef="U_USD">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_e3e50907-6887-4220-a0d9-4a36fa444e7f"
      decimals="-6"
      id="F_056bce46-d31c-4a34-9cfc-7df5a32457e1"
      unitRef="U_USD">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_12ceb0d9-027f-4047-880f-0f426157ce04"
      decimals="-5"
      id="F_51fe886f-16a1-4bdd-b7c0-66a85fdc8c32"
      unitRef="U_USD">13600000</us-gaap:ContractWithCustomerLiability>
    <fnch:MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved
      contextRef="C_049c3cdd-3341-4084-9a6d-e1edee63342e"
      decimals="-5"
      id="F_b3bc8b3c-dfca-4079-9d47-515e8eb96f54"
      unitRef="U_USD">180000000.0</fnch:MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved>
    <fnch:MilestonePaymentsReceivedUnderAgreement
      contextRef="C_049c3cdd-3341-4084-9a6d-e1edee63342e"
      decimals="-5"
      id="F_7b0e7b25-bb92-4731-be67-cc5773731bc7"
      unitRef="U_USD">4000000.0</fnch:MilestonePaymentsReceivedUnderAgreement>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="C_754cfea2-fdc5-4ff8-a708-49bbef66cbaa"
      decimals="-3"
      id="F_dbca904d-d7ec-4cbb-96c5-4db638cd4dc2"
      unitRef="U_USD">0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="C_60b68536-8ed1-43da-ac13-d5bdb8aa1b26"
      decimals="-3"
      id="F_89215cd8-c22b-448d-a81c-8a6839b048da"
      unitRef="U_USD">0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_cd8cbba4-d765-4c03-adf6-a6cf25b63c61"
      decimals="-6"
      id="F_025bf04d-a4a5-459c-98ad-c06573e2f699"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_799a1f7a-7972-48f7-b715-47a07a846536"
      decimals="-5"
      id="F_c0ece477-8a29-4a85-b15d-15ce58fa9ee5"
      unitRef="U_USD">300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e102589d-5e6a-4e44-bd66-a82362df7fb0"
      decimals="-6"
      id="F_69b85544-8602-4917-a9e9-507ed4da198b"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_db086534-a8d4-4c38-a41b-514f72bc36c0"
      decimals="-6"
      id="F_64bc3e8a-9333-4fb4-a30e-a8d1edd2b4ea"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_1bd4a0ca-99c2-4074-b339-97461c98088b"
      decimals="-6"
      id="F_7179f762-2fc2-4d68-8abc-7a3c984fd461"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_0134fe1b-914d-4694-84c6-166564b5b3c4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. INCOME TAXES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective income tax rate differed from the statutory federal income tax rate due to the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.37%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:0.808%;"/&gt;
        &lt;td style="width:16.271%;"/&gt;
        &lt;td style="width:2.983%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:16.134%;"/&gt;
        &lt;td style="width:2.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit and tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.19&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Significant components of the Company&#x2019;s net deferred tax assets and liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.807%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.81%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.81%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of Use Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangibles assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of Use Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company continues to maintain a partial valuation allowance against its deferred tax assets. During the years ended December 31, 2021 and 2020, management assessed the positive and negative evidence in its U.S. operations, and concluded that it is more likely than not that a portion of its deferred tax assets as of December 31, 2021 and 2020 will not be realized given the Company&#x2019;s history of operating losses. In determining the amount of the valuation allowance to record, the Company considered the reversal of existing taxable temporary differences as a source of taxable income against which a portion of its deferred tax assets is benefitted. The Company recorded a full valuation allowance against the remaining U.S. deferred tax assets in excess of this source of taxable income. The valuation allowance against deferred tax assets increased by approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during 2021 related to a full valuation allowance recorded against additional net operating losses and tax credits generated in the year.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had federal net operating losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;181.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which may be available to offset future federal income tax liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, the Company had federal net operating losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which may be available to offset future federal income tax liabilities. The Company&#x2019;s federal net operating losses incurred prior to 2018, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, expire through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, while its federal net operating losses incurred in 2018 and onwards, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;144.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, can be carried forward indefinitely.&lt;/span&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had post-apportioned state net operating losses of&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million that can generally be carried forward &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years. As of December 31, 2020, the Company had post-apportioned state net operating losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million that can generally be carried forward &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of federal and state research and development credits, respectively, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which will expire at various dates through 2041&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. As of December 31, 2020, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of federal and state research and development credits, respectively, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which will expire at various dates through 2040&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.  The Company has not, yet, conducted a study to determine if any such changes have occurred that could limit its ability to use the net operating loss and tax credit carryforward.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. As of December 31, 2021 and 2020, the total amount of uncertain tax liabilities relates to federal and state tax credit carryforwards and are all recorded net in deferred taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.992%;"/&gt;
        &lt;td style="width:1.889%;"/&gt;
        &lt;td style="width:1.815%;"/&gt;
        &lt;td style="width:16.718%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.889%;"/&gt;
        &lt;td style="width:1.815%;"/&gt;
        &lt;td style="width:16.88%;"/&gt;
        &lt;td style="width:0.783%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Additions for tax positions of current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_930a967a-5e48-4c74-bf4a-3be9c74507ef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective income tax rate differed from the statutory federal income tax rate due to the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.37%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:0.808%;"/&gt;
        &lt;td style="width:16.271%;"/&gt;
        &lt;td style="width:2.983%;"/&gt;
        &lt;td style="width:1.84%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:16.134%;"/&gt;
        &lt;td style="width:2.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit and tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.19&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_df6707f2-4968-495f-85a7-27ed9d5c9f0b"
      unitRef="U_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_3f7b5c1b-85b9-42bc-bd9c-976e93349135"
      unitRef="U_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_21c05b8d-8d8c-487b-95ac-602afbe9631d"
      unitRef="U_pure">0.0690</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_bd7a0cd3-e442-40fd-901c-b02068384d75"
      unitRef="U_pure">0.0604</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_96d7f9c9-231d-4318-9d8a-cb1237366f7c"
      unitRef="U_pure">-0.0019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_b9c65bd5-0f18-4049-aa81-04ea5ca6fbb8"
      unitRef="U_pure">-0.0160</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_03495a57-519b-4577-860f-3af44b304298"
      unitRef="U_pure">0.0212</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_3192f7c0-24f0-4117-953e-67a5203670e6"
      unitRef="U_pure">0.0203</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_b7ea40ab-f47e-4920-9ae6-f7942a59347e"
      unitRef="U_pure">-0.2930</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_870b562f-dfa1-40b2-86ee-f40498006261"
      unitRef="U_pure">-0.2696</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_326dc153-9e9c-49ba-aa0f-61a725b80c7c"
      unitRef="U_pure">-0.0053</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_e774bad1-c6c1-48b1-abce-cbe8fd1e69c5"
      unitRef="U_pure">-0.0051</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_bc18c84e-3eb1-430a-afe5-22156f5fb8f4"
      unitRef="U_pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_71a71898-5da2-4d08-983d-bdb74a3249f1"
      unitRef="U_pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_8dd6ada7-d0ab-4a5e-aa3d-6fcf214baf64">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Significant components of the Company&#x2019;s net deferred tax assets and liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.807%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.81%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:16.81%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of Use Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangibles assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of Use Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f1d450f4-30bc-429e-83ae-095e38fcd137"
      unitRef="U_USD">48419000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ae9d15dc-d204-42d6-b383-3016689f095c"
      unitRef="U_USD">30192000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_57dbdf46-d5e1-497d-b5bf-1482b033e6a4"
      unitRef="U_USD">4376000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_cda96285-79c0-4057-8c87-a91716d1b99a"
      unitRef="U_USD">2921000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_9e6c36d7-3f31-46df-b6fc-b29888e8ac53"
      unitRef="U_USD">3057000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_eb72209c-91c2-4748-967b-c35d764df803"
      unitRef="U_USD">859000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_18842ab6-0078-4590-b3ec-66929c71c69d"
      unitRef="U_USD">225000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <fnch:RightOfUseLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_79fa458c-8808-4314-9954-44c902831a92"
      unitRef="U_USD">1633000</fnch:RightOfUseLiabilities>
    <fnch:RightOfUseLiabilities
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_9154f7d9-0686-4de1-b74a-d5894d9d5f24"
      unitRef="U_USD">0</fnch:RightOfUseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_b4e70edb-5b3f-4cfa-87ef-5f5faccee0a8"
      unitRef="U_USD">548000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_ac305325-e8a0-4f2e-9519-dab537d96b66"
      unitRef="U_USD">289000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_3d1bd5b4-9308-46c1-9bde-0e282f7c62dc"
      unitRef="U_USD">55835000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_e00a14f5-b922-4753-a0aa-ce774fd96e49"
      unitRef="U_USD">36684000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_b90ee635-4e5a-47e1-8398-3b0f4389d136"
      unitRef="U_USD">49079000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_39a84dd1-59fa-4b65-9631-654068085aa9"
      unitRef="U_USD">31963000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_5d274f82-01f1-459b-8258-dbc5a3d0495b"
      unitRef="U_USD">6756000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_78794677-899e-456f-bbbf-531cd7c32392"
      unitRef="U_USD">4721000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_07edfeb3-4da4-4ad7-b6c6-ca7bc8846713"
      unitRef="U_USD">7952000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_47f3fdf8-82f0-4afa-bad3-fae8a900d3fe"
      unitRef="U_USD">7891000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <fnch:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_71c0fd61-0bfa-4740-8902-5188d4df6fa3"
      unitRef="U_USD">563000</fnch:DeferredTaxLiabilitiesFixedAssets>
    <fnch:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_fd1e745d-a003-4bf8-baf3-5a828494bc1d"
      unitRef="U_USD">253000</fnch:DeferredTaxLiabilitiesFixedAssets>
    <fnch:RightOfUseAsset
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_f34a1b22-5b00-4e47-9754-472c304b9730"
      unitRef="U_USD">1372000</fnch:RightOfUseAsset>
    <fnch:RightOfUseAsset
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_16507212-dac9-4831-9a09-704c0244f5ee"
      unitRef="U_USD">0</fnch:RightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_67abf911-4711-4609-a557-36733fd1bace"
      unitRef="U_USD">330000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_11cbb1cc-bcb9-4ff2-9dd8-d755483dce5d"
      unitRef="U_USD">38000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_902f2558-5c00-43a1-bb16-d7388bb6c480"
      unitRef="U_USD">10217000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_f6e7769c-8580-4ab7-a0c2-74a56e1c0662"
      unitRef="U_USD">8182000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-3"
      id="F_e1c829ff-053e-4e57-8e63-1ddbd7273810"
      unitRef="U_USD">3461000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_8f555058-6122-40e6-a5f2-a4ca7db64d3d"
      unitRef="U_USD">3461000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-5"
      id="F_ff63f4cc-ab35-44ba-a49a-94e5bc329bd7"
      unitRef="U_USD">17100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="-5"
      id="F_3904e825-7945-4b88-992f-a863827919b0"
      unitRef="U_USD">181900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_4fb463b4-797e-452d-873d-48619c046805"
      decimals="-5"
      id="F_04b78387-3892-4db0-a5ed-8ae98e7d7372"
      unitRef="U_USD">114400000</us-gaap:OperatingLossCarryforwards>
    <fnch:OperatingLossCarryForwardsPriorToTwoThousandEighteen
      contextRef="C_db4e3207-e9fa-4152-a818-87c22ab1f012"
      decimals="-5"
      id="F_cef01e45-638e-43de-b8b2-e380e9956140"
      unitRef="U_USD">37200000</fnch:OperatingLossCarryForwardsPriorToTwoThousandEighteen>
    <fnch:OperatingLossCarryForwardsExpirationYear
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      id="F_eba87563-20e7-48a9-8ec4-c4fae042add7">2037</fnch:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ea0a073d-aea6-481f-bcbd-2d2464476655"
      decimals="-5"
      id="F_00ce897c-144d-4549-98d3-191e9f70d50e"
      unitRef="U_USD">144700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_a3403fa8-bacc-4e4b-a517-c82e4d4d547a"
      decimals="-5"
      id="F_55e930ec-14ac-4468-9ecf-c67ec127a14c"
      unitRef="U_USD">10200000</us-gaap:OperatingLossCarryforwards>
    <fnch:OperatingLossCarryForwardsExpirationPeriod
      contextRef="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf"
      id="F_fb2477ef-1244-4d3a-8042-72479c993aa1">P20Y</fnch:OperatingLossCarryForwardsExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e585cf8d-a59f-4d43-8477-6b3d9ed99d06"
      decimals="-5"
      id="F_2274018f-9669-4bc8-886b-a0b6b0d4ad28"
      unitRef="U_USD">6100000</us-gaap:OperatingLossCarryforwards>
    <fnch:OperatingLossCarryForwardsExpirationPeriod
      contextRef="C_1f587b93-a68e-4011-af1c-8223963a66b9"
      id="F_5ba10ca9-ff80-4ac5-aead-b0d2d4156f5d">P20Y</fnch:OperatingLossCarryForwardsExpirationPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c26cc83f-e31e-4451-9562-469d6a32f396"
      decimals="-5"
      id="F_2cdbed14-f8b6-4950-a058-af2b81fd5a0f"
      unitRef="U_USD">3800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf"
      decimals="-5"
      id="F_fb1b4dfd-5516-410b-b59e-8f468320e924"
      unitRef="U_USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <fnch:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_fe50ee66-53a7-42c7-8610-98eb6d2c89f6">which will expire at various dates through 2041</fnch:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d5f06605-6037-48e4-9be3-dc6adc0731f7"
      decimals="-5"
      id="F_f2e78d60-934b-4d84-b965-8a8bd8954459"
      unitRef="U_USD">2600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1f587b93-a68e-4011-af1c-8223963a66b9"
      decimals="-5"
      id="F_2889ea65-71d5-4145-adfe-fa92d46193ba"
      unitRef="U_USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <fnch:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      id="F_6b3ca40f-5e9e-4e52-9295-6c4fc310f912">which will expire at various dates through 2040</fnch:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_a15ce7ea-384c-4d8e-9b75-8e47273fbacf"
      decimals="2"
      id="F_a7923e2c-9814-4e27-8a0c-a86290613484"
      unitRef="U_pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_4a27dde5-8edb-4e90-9bd1-f68b88bc7914">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.992%;"/&gt;
        &lt;td style="width:1.889%;"/&gt;
        &lt;td style="width:1.815%;"/&gt;
        &lt;td style="width:16.718%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.889%;"/&gt;
        &lt;td style="width:1.815%;"/&gt;
        &lt;td style="width:16.88%;"/&gt;
        &lt;td style="width:0.783%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Additions for tax positions of current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_3d33f679-8ae3-4072-ae83-f6edc36c7453"
      unitRef="U_USD">1318000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9e8dccca-9f66-419b-8f65-e42f675c5ee8"
      decimals="-3"
      id="F_4bb13b5c-c610-4671-89d8-d5e39aa7e482"
      unitRef="U_USD">1004000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_9968438c-dc8f-40e4-b536-fcf5c3b44426"
      unitRef="U_USD">507000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_f651c1ff-e911-4e66-9042-3ecf39dfdc9e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_3154ea17-20c5-4208-a1e0-5147464b0da9"
      unitRef="U_USD">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_dbbf828c-2f97-4167-8896-99b60825dc92"
      unitRef="U_USD">314000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <fnch:UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_85e09d6f-9224-4bfb-b242-57bb108b091f"
      unitRef="U_USD">1822000</fnch:UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued>
    <fnch:UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_ddb42833-2676-4d45-983d-02895fa364d8"
      unitRef="U_USD">1318000</fnch:UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="0"
      id="F_f3d449ba-4bc2-4771-b0da-2ca60553cbfe"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="0"
      id="F_fe9de2b0-0626-4605-9eab-4f5eeab9a570"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_5a868816-181e-4bc3-8e38-68c73be11649">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Legal contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, &#x201c;Rebiotix&#x201d;) filed a complaint against the Company in the U.S. District Court for the District of Delaware. The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the &#x201c;&#x2018;309 patent&#x201d;); 10,463,702 (the &#x201c;&#x2018;702 patent&#x201d;); 10,328,107 (the &#x201c;&#x2018;107 patent&#x201d;); 10,064,899; 10,022,406; 9,962,413; and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the &#x2019;107, &#x2019;702, and &#x2019;309 patents. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota (&#x201c;UMN&#x201d;), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012. The U.S District Court for the District of Delaware set a trial date for a five-day trial beginning on May 20, 2024. The pending lawsuit is subject to inherent uncertainties, and the actual legal fees and costs will depend upon many unknown factors. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined under ASC 450, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, that there is no probable or estimable loss contingency that is required to be recorded as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;License payments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company enters into contracts in the normal course of business with contract research organizations and other third parties for preclinical studies, clinical studies, and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancelable by the Company upon prior written notice. Payments due upon cancellation consist of payments for &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;services provided or expenses incurred, including non-cancelable obligations of our service providers up to one year after the date of cancellation. Under these agreements, in exchange for access to intellectual property the Company may be obligated to provide future minimum royalty payments and milestone payments related to regulatory approvals and sales-based events. The Company entered into the OpenBiome Agreement in November 2020 (see Note 13) and the closing of the OpenBiome Agreement occurred on March 1, 2021. Under the terms of the OpenBiome Agreement, the Company is required to make certain milestone and royalty payments to OpenBiome in conjunction with the license and purchase of certain intellectual property related to the underlying CMC process used to manufacture materials for its clinical trials. The OpenBiome Agreement also effectively terminated the APL Agreement and the obligations under the Material Access License Agreement (the &#x201c;MAL Agreement&#x201d;), which the Company entered into with OpenBiome in December 2016.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the APL Agreement, which was entered into in 2019 and effective through November 2020, the Company was obligated to make certain contingent payments for milestones and royalties to OpenBiome, subject to the occurrence of specific underlying criteria that were dependent on regulatory approvals and sales-based events. The Company was obligated to make regulatory milestone payments to OpenBiome aggregating up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the achievement of regulatory approvals, and sales-based milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in sales-based milestone payments upon the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;achievement &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of certain net sales criteria. The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to OpenBiome associated with milestones in 2020. The APL Agreement was terminated in November 2020 upon the execution of the OpenBiome Agreement (see Note 13).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the MAL Agreement, the Company was also obligated to pay to OpenBiome, a low single digit royalty on net sales of certain cultured products and a high single digit percentage of certain sublicensing revenue (including royalties) of licensed cultured products. These royalties were calculated on a product-by-product and country-by-country basis. The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to OpenBiome under the MAL Agreement in 2020 related to royalty payments. During the year ended December 31, 2020, the Company recorded an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million owed to OpenBiome under the MAL Agreement, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million remained due as of December 31, 2020. The MAL Agreement was terminated in November 2020 upon the execution of the OpenBiome Agreement (see Note 13).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;PPP Loan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted to, amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the COVID-19 pandemic. The CARES Act includes a Paycheck Protection Program (&#x201c;PPP&#x201d;) administered through the Small Business Association (&#x201c;SBA&#x201d;). Under the PPP, beginning April 3, 2020, small businesses and other entities and individuals could apply for loans from existing SBA lenders and other approved regulated lenders that enroll in the program, subject to numerous limitations and eligibility criteria.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2020, the Company issued a promissory note to Silicon Valley Bank, pursuant to which it received loan proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the &#x201c;PPP Loan&#x201d;) provided under the PPP and guaranteed by the SBA. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On May 8, 2021, the Company received notice from the SBA that the entirely of the PPP Loan was forgiven. Accordingly, the Company is no longer required to repay the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in principal and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in accrued interest borrowed under the PPP Loan.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Gain on extinguishment of the PPP Loan is recorded in the consolidated statements of operations for the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's commitments under its lease agreements are described in Note 5.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <fnch:MaximumRegulatoryMilestonePayments
      contextRef="C_fc5421c3-a799-4980-a188-637fac870fba"
      decimals="-5"
      id="F_b7b47c8f-995b-4278-81aa-466cca9f777d"
      unitRef="U_USD">2500000</fnch:MaximumRegulatoryMilestonePayments>
    <fnch:SalesBasedMilestonePayments
      contextRef="C_fc5421c3-a799-4980-a188-637fac870fba"
      decimals="-5"
      id="F_4eaf4ce9-c6f5-447e-b246-29df16aa6739"
      unitRef="U_USD">23300000</fnch:SalesBasedMilestonePayments>
    <fnch:MilestonePaymentsPaid
      contextRef="C_aee05aaf-8f6d-4638-a8fe-67e2f46277b9"
      decimals="-5"
      id="F_c91f7a93-0358-46a7-a374-ca2ee91c0e57"
      unitRef="U_USD">100000</fnch:MilestonePaymentsPaid>
    <fnch:RoyaltyPaymentsPaidOnNetSales
      contextRef="C_6252e38b-5c6e-4c8e-8aa8-5c056fef33a0"
      decimals="-5"
      id="F_8a6675ba-dd6c-4cc6-94fb-5640f0fae1b4"
      unitRef="U_USD">200000</fnch:RoyaltyPaymentsPaidOnNetSales>
    <fnch:RemainingRoyaltyCommitmentAmountDue
      contextRef="C_beb9a9a0-b07a-43a6-96d5-dca4ca792d9c"
      decimals="-5"
      id="F_12cf7160-0c96-4521-a097-29c03474afe0"
      unitRef="U_USD">300000</fnch:RemainingRoyaltyCommitmentAmountDue>
    <fnch:AdditionalRoyaltyCommitmentsAmountDue
      contextRef="C_beb9a9a0-b07a-43a6-96d5-dca4ca792d9c"
      decimals="-5"
      id="F_eae9a4d2-c7af-4b7f-9b79-0aeb6d1c2608"
      unitRef="U_USD">100000</fnch:AdditionalRoyaltyCommitmentsAmountDue>
    <us-gaap:ProceedsFromLoanOriginations1
      contextRef="C_c284ec5c-9fd7-4308-a062-488f6fa155dc"
      decimals="-5"
      id="F_c5aef370-afaa-4056-bbc0-29c8f24438c7"
      unitRef="U_USD">1800000</us-gaap:ProceedsFromLoanOriginations1>
    <fnch:DebtInstrumentForgivenDescription
      contextRef="C_58649b84-b6a5-4536-b8e2-c6e68450eebd"
      id="F_0f61481a-dad3-4c37-b332-835d3018da82">On May 8, 2021, the Company received notice from the SBA that the entirely of the PPP Loan was forgiven. Accordingly, the Company is no longer required to repay the $1.8 million in principal and approximately $19,000 in accrued interest borrowed under the PPP Loan.</fnch:DebtInstrumentForgivenDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_9d380522-affd-4af4-a507-2ff7a0457581"
      decimals="-5"
      id="F_ea1524a8-d4d0-464e-af3d-da03675d4cd5"
      unitRef="U_USD">1800000</us-gaap:DebtInstrumentFaceAmount>
    <fnch:AccruedInterestBorrowed
      contextRef="C_9d380522-affd-4af4-a507-2ff7a0457581"
      decimals="-3"
      id="F_f89ebc56-6f0e-486b-83f0-1ec53245d893"
      unitRef="U_USD">19000000</fnch:AccruedInterestBorrowed>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_80547085-9ba1-4488-849e-908c7d7a4f16">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. REDEEMABLE CONVERTIBLE PREFERRED STOCK&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,902,872&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its series D redeemable convertible preferred stock (&#x201c;Series D&#x201d;) at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.0381&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company incurred issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million associated with the Series D issuance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon the completion of the IPO, all &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of outstanding preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. As of December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock authorized, issued, or outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, preferred stock consisted of the following (in thousands, except share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:18.895%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:12.633%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:12.673%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.047%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.126%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:16.271%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;PREFERRED&lt;br/&gt;STOCK&lt;br/&gt;AUTHORIZED&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;PREFERRED&lt;br/&gt;STOCK&lt;br/&gt;ISSUED AND&lt;br/&gt;OUTSTANDING&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;CARRYING&lt;br/&gt;VALUE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;LIQUIDATION&lt;br/&gt;VALUE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;COMMON STOCK&lt;br/&gt;ISSUABLE UPON&lt;br/&gt;CONVERSION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167,496,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,596,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,596,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,620,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,166,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,166,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series C&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;109,604,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;99,705,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,902,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,902,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;451,427,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;233,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;219,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_e407f9da-0025-4449-9d33-474e81924957"
      decimals="0"
      id="F_1729031c-47ed-47f5-bf57-acca39df4209"
      unitRef="U_shares">6902872</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e407f9da-0025-4449-9d33-474e81924957"
      decimals="4"
      id="F_31218d8f-10c5-4461-912e-b6d54f8054da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.0381</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_d183d8f2-6271-4193-aa8f-606f93e1458d"
      decimals="-5"
      id="F_039171bb-d990-436d-af44-552fbf97d8f1"
      unitRef="U_USD">90000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <fnch:TemporaryEquityIssuanceCosts
      contextRef="C_d183d8f2-6271-4193-aa8f-606f93e1458d"
      decimals="-5"
      id="F_4636b407-bb58-464b-a4c3-c07d57afec1b"
      unitRef="U_USD">100000</fnch:TemporaryEquityIssuanceCosts>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_309231a5-1644-42cc-8f57-4efa7d95eb14"
      decimals="INF"
      id="F_2a14910a-35f4-4a10-8e25-f63aa616bb5d"
      unitRef="U_shares">31253609</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_af126580-e6a9-4bc4-b56f-9a9ed89d3577"
      decimals="0"
      id="F_d3ee099b-373e-477e-9762-1e9a0ff9681e"
      unitRef="U_shares">31253609</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="0"
      id="F_bb08dd07-4c07-4645-8602-fb535366b292"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_d11e186b-397e-48c6-b13a-a2002d300b97">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, preferred stock consisted of the following (in thousands, except share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:18.895%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:12.633%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:12.673%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.047%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.126%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:16.271%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;PREFERRED&lt;br/&gt;STOCK&lt;br/&gt;AUTHORIZED&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;PREFERRED&lt;br/&gt;STOCK&lt;br/&gt;ISSUED AND&lt;br/&gt;OUTSTANDING&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;CARRYING&lt;br/&gt;VALUE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;LIQUIDATION&lt;br/&gt;VALUE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;COMMON STOCK&lt;br/&gt;ISSUABLE UPON&lt;br/&gt;CONVERSION&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167,496,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,596,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,596,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,620,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,166,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,166,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series C&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;109,604,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;99,705,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,902,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,902,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;451,427,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;233,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;219,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_6aa624be-a1e0-49d2-8c90-48ed33f17642"
      unitRef="U_shares">167496750</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_216503ee-7eeb-4a70-b55b-1498fd914761"
      unitRef="U_shares">11596280</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="INF"
      id="F_a26c2327-a690-407b-8045-b5ab35ac4c71"
      unitRef="U_shares">11596280</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="-3"
      id="F_57e291d2-d390-48ae-9041-1ed8c6dff1ba"
      unitRef="U_USD">53593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_9f617c4d-2130-4a03-be94-001eafeeb878"
      decimals="-3"
      id="F_e1090f49-614b-4315-8e37-f5e1f2b70e43"
      unitRef="U_USD">40115000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_36ebf60e-e0c4-40dd-910b-838e10c9ca42"
      decimals="INF"
      id="F_aa233891-995e-4e93-aa28-eae1074e4a17"
      unitRef="U_shares">11596280</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_261c6b34-0cf0-4e42-8d29-12e19e78d533"
      unitRef="U_shares">74620739</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_9fc9a544-c9d4-494b-96c8-e2e6f7f0fa15"
      unitRef="U_shares">5166203</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="INF"
      id="F_8a81f354-3655-4967-bdf6-ffb16c34d79c"
      unitRef="U_shares">5166203</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="-3"
      id="F_9ad67cf1-b8ee-42b5-94e0-6abcad25df6e"
      unitRef="U_USD">36336000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_61cd82ea-f358-4082-bca8-78e13843b66f"
      decimals="-3"
      id="F_66f6c9b5-c1a9-4e2f-a525-d0e6fc57aaa2"
      unitRef="U_USD">36400000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_60325954-cd50-4585-85cc-6fc0b138b87d"
      decimals="INF"
      id="F_39629975-0e9c-4ae5-bd4b-c492f8abf83e"
      unitRef="U_shares">5166203</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_13e3d39e-e355-4281-84cd-1a389d097195"
      unitRef="U_shares">109604994</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_461faa5c-9248-4d60-adaa-5a101155539b"
      unitRef="U_shares">7588254</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="INF"
      id="F_aebc514b-abb5-4ffd-ad54-7f55ed9042de"
      unitRef="U_shares">7588254</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="-3"
      id="F_05f8b68f-498d-408c-a786-edc63fa79ec4"
      unitRef="U_USD">53221000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_5f6ab27f-7051-4656-8340-31bd75faefe9"
      decimals="-3"
      id="F_224f5c55-2cea-41b4-8bd0-c0192da26676"
      unitRef="U_USD">53465000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_389a0f17-bc7e-475d-9cc4-8f35d0418848"
      decimals="INF"
      id="F_434411fc-b0f1-4c4e-9598-ef1c25af6b3c"
      unitRef="U_shares">7588254</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_43c4e0f7-9198-4eab-a871-b88f3d3ac36b"
      unitRef="U_shares">99705359</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_83638628-ffda-4213-a3e8-0f82a8508daa"
      unitRef="U_shares">6902872</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="INF"
      id="F_f3fac54e-dea5-41f8-80a0-b8e979a041bb"
      unitRef="U_shares">6902872</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="-3"
      id="F_ab0e8353-64ae-487c-b79d-151e30dca7b0"
      unitRef="U_USD">89904000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_eab725e4-2f52-4e39-862f-22ef20e05710"
      decimals="-3"
      id="F_be78e925-612c-48a4-a8e8-474cd24a4d26"
      unitRef="U_USD">90000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_34e7a81f-7394-49b9-84da-068d88b1e719"
      decimals="INF"
      id="F_0587e958-5237-4598-ae75-e50f551d4f34"
      unitRef="U_shares">6902872</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_0d028da9-de5d-4f1d-95b7-18db28d76051"
      unitRef="U_shares">451427842</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_a1fc646c-c8e9-41c5-a688-84361eb64719"
      unitRef="U_shares">31253609</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="INF"
      id="F_0860ff76-8e4c-4659-8e91-60307dc7307d"
      unitRef="U_shares">31253609</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_b34d6111-4c17-4cd6-a535-c1b7fc94b353"
      unitRef="U_USD">233054000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="-3"
      id="F_4025a4e4-50b5-4cb5-96ff-4cfbff0373f6"
      unitRef="U_USD">219980000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_f59b9e4d-a520-4962-b1b1-8256ad30502f"
      decimals="INF"
      id="F_2d042fb2-7eaa-41a4-afaa-1215f5efd860"
      unitRef="U_shares">31253609</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_d6a3a335-2ea7-46c8-8364-55ca0235a6e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. STOCKHOLDERS' EQUITY&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On February 24, 2021, the Board and the Company&#x2019;s stockholders approved the Company&#x2019;s amended and restated certificate of incorporation, which became effective immediately prior to the closing of the IPO on March 18, 2021. The certificate authorizes the issuance of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; par value common stock and up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; par value undesignated preferred stock. The Board may designate the rights, preferences, privileges, and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and number of shares constituting any series or the designation of any series. The issuance of preferred stock could have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying or preventing a change in control. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock were outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In conjunction with the IPO, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriting discounts and commissions and initial public offering costs. In connection with the IPO, all then outstanding shares of preferred stock were converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On April 20, 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;192,877&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of common stock, pursuant to the underwriters&#x2019; partial exercise of their overallotment option, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriters&#x2019; discounts, commissions and offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Each share of common stock entitles the holder to one vote&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, together with the holders of preferred stock, on all matters submitted to the stockholders for a vote. Common stockholders are also entitled to receive dividends. As of  &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; cash dividends have been declared or paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has issued restricted stock to founders, employees and consultants. All restricted stock was fully vested and all expense related to these shares was recognized prior to 2020.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and December 31, 2020, the Company has reserved the following shares of common stock for potential conversion of outstanding preferred stock, the vesting of restricted stock and exercise of stock options, common stock warrants, and shares under the employee stock purchase plan:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.98%;"/&gt;
        &lt;td style="width:1.827%;"/&gt;
        &lt;td style="width:0.858%;"/&gt;
        &lt;td style="width:18.523%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.827%;"/&gt;
        &lt;td style="width:0.858%;"/&gt;
        &lt;td style="width:18.585%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,053,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,309,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,326,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;_________________________&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;"&gt;1 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;During the fourth quarter of 2021, &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;19,346&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; common stock warrants were net exercised, resulting in &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;19,303&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; net shares.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Secondary Sale&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2020, certain of the Company&#x2019;s stockholders sold shares of the Company&#x2019;s common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.0381&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share to an investor. The investor purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;412,323&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock from these stockholders for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;258,924&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock, or an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, were sold by affiliates of the Company, who are considered to be related parties. The shares were sold above fair value and the excess of the price paid over the fair value was recognized as $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of stock-based compensation expense. The Company recognized the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as general and administrative expense in the consolidated statement of operations for the year ended December 31, 2020 (see Note 12).&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4dc28e60-afc9-4c19-b43d-868677e6583f"
      decimals="INF"
      id="F_18144545-b479-446a-b3d3-4d20ba3ef101"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_958aeacf-f69f-4b11-a72c-34559a9f8235"
      decimals="INF"
      id="F_a8dd231d-7a59-41ab-9383-8b2606b5daeb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_d1c89c9b-52b3-4ae8-bb9f-118f289a32ab"
      decimals="INF"
      id="F_95f9de9c-c05f-4925-94d9-5b20853e806c"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9eb4f167-eaf7-4d4b-98b2-e2d8c89215f6"
      decimals="INF"
      id="F_1f7f1397-93a3-49a3-9930-3414dc17d45b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="INF"
      id="F_e9f4d111-daa5-466c-8cc1-12c393cff6e1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4"
      decimals="INF"
      id="F_f82a5e62-cc4e-41b5-aad4-2bf5bf636a43"
      unitRef="U_shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_958aeacf-f69f-4b11-a72c-34559a9f8235"
      decimals="2"
      id="F_8e7a361f-865d-425b-a6d5-cd4ced22cc4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4"
      decimals="-5"
      id="F_628837ac-8b5f-4bd9-9404-6ef632463f5d"
      unitRef="U_USD">115700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_49a826e5-25e7-4b93-83f1-e61e9345c5d4"
      decimals="INF"
      id="F_655109b7-5124-4e60-8603-02ff422126da"
      unitRef="U_shares">31253609</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c775cfd2-628d-4919-8429-a954d20061c3"
      decimals="INF"
      id="F_5630be33-4150-4373-a19c-4b3f06afa9f4"
      unitRef="U_shares">192877</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_7b8eb604-10e3-4861-ab49-2e0d36d00d64"
      decimals="INF"
      id="F_f4d2f31e-e646-4b05-b54d-1bdf7dcb0e27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:SharePrice>
    <fnch:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_c775cfd2-628d-4919-8429-a954d20061c3"
      decimals="-5"
      id="F_26d4e2f6-c8e1-4254-9b93-f4c8f7e7818b"
      unitRef="U_USD">3300000</fnch:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c775cfd2-628d-4919-8429-a954d20061c3"
      decimals="-5"
      id="F_c9a61e1b-aae4-4916-90cc-4377fe5bec3f"
      unitRef="U_USD">3000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_809b8a30-f513-4e4e-81be-37bdf8ff4be3">Each share of common stock entitles the holder to one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_1870a11c-5908-450d-9133-7ebf67fa47e1"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_dba4a298-59b1-4f67-99b2-bf40c3469ac9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and December 31, 2020, the Company has reserved the following shares of common stock for potential conversion of outstanding preferred stock, the vesting of restricted stock and exercise of stock options, common stock warrants, and shares under the employee stock purchase plan:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.98%;"/&gt;
        &lt;td style="width:1.827%;"/&gt;
        &lt;td style="width:0.858%;"/&gt;
        &lt;td style="width:18.523%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.827%;"/&gt;
        &lt;td style="width:0.858%;"/&gt;
        &lt;td style="width:18.585%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;DECEMBER 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,053,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,309,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,326,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;_________________________&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;"&gt;1 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;During the fourth quarter of 2021, &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;19,346&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; common stock warrants were net exercised, resulting in &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;19,303&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; net shares.&lt;/span&gt;&lt;/p&gt;</fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_83341027-5973-4448-a037-4a0f2e02d99e"
      decimals="0"
      id="F_1163bf7a-5239-45c7-b660-c60bf34b123a"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2836ed65-af3b-490c-89b2-d07fef0677d9"
      decimals="0"
      id="F_3cf85d38-0373-4618-9391-08cdd4d691d1"
      unitRef="U_shares">31253609</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9d0e0e4a-c148-42f2-b8d6-c5dcb9f5fb6f"
      decimals="0"
      id="F_15e371a4-9237-433e-9ed5-d3fe7276c746"
      unitRef="U_shares">3264770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_773d9f64-92e0-471f-87fd-c693d0fedbc4"
      decimals="0"
      id="F_b2036fc5-17d7-4f07-8e50-dd71e811d2a8"
      unitRef="U_shares">1053874</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bfcf15ad-e5a5-482c-921c-d2c853db7126"
      decimals="0"
      id="F_63fcec9a-5520-4869-afa6-b24df4aa3a63"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_318f64ea-ab2c-4f3a-8c39-bea1e8b5efee"
      decimals="0"
      id="F_826c8495-19c0-4a28-9e18-0cfd4c276ecc"
      unitRef="U_shares">19346</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6e1cbdf0-abb9-4321-a134-6b908bc1cb74"
      decimals="0"
      id="F_93d389df-5b8d-472a-b350-db2602d460a0"
      unitRef="U_shares">45195</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3854077f-36a9-4171-af92-3885c504f8ab"
      decimals="0"
      id="F_2eb98eea-1104-4927-996b-cb02465e5c92"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="0"
      id="F_2478d1b5-ab2e-4d13-bf37-67191c8cfa18"
      unitRef="U_shares">3309965</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_17ff663a-6142-4c26-8780-a4ce862a5484"
      decimals="0"
      id="F_680c2deb-9c6b-4d2f-905f-19958b72f412"
      unitRef="U_shares">32326829</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fnch:CommonStockWarrantsExercisedGross
      contextRef="C_fe91f7aa-3290-4bec-8ded-b59274901189"
      decimals="0"
      id="F_44062ef8-24eb-43d7-90f9-0921ca111b88"
      unitRef="U_shares">19346</fnch:CommonStockWarrantsExercisedGross>
    <fnch:CommonStockWarrantsExercised
      contextRef="C_fe91f7aa-3290-4bec-8ded-b59274901189"
      decimals="0"
      id="F_4bcd6b16-dd44-4fe6-923e-139bea8b8f2d"
      unitRef="U_shares">19303</fnch:CommonStockWarrantsExercised>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_23263f47-404c-4325-867d-c627433086e4"
      decimals="INF"
      id="F_6a6a0826-d4c6-4024-8632-cf3525d14e3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.0381</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0"
      decimals="INF"
      id="F_641ef74d-7887-43c7-b65f-7f7f47046ab6"
      unitRef="U_shares">412323</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0"
      decimals="-5"
      id="F_86771cc9-c74e-47ca-b5d1-212ba413fc8f"
      unitRef="U_USD">5400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c1241508-27ea-4aa7-a3a8-f0e51e38ba2d"
      decimals="0"
      id="F_23630869-5a5e-4fc3-8829-1d54becb70d0"
      unitRef="U_shares">258924</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c1241508-27ea-4aa7-a3a8-f0e51e38ba2d"
      decimals="-5"
      id="F_3601c01b-2ca0-447b-bf7b-aca8c38e3886"
      unitRef="U_USD">3400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_806099f4-5134-4cc8-afcb-d51b33ddc2b0"
      decimals="-5"
      id="F_ab3868ea-5756-47ad-b7ad-cccb9ef7df58"
      unitRef="U_USD">2800000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3fe6991f-9dcc-4a7d-a873-78e8fd832d53"
      decimals="-5"
      id="F_f3c5882b-2419-437b-bd5f-24e7af76ac4a"
      unitRef="U_USD">2800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_c9e1b239-dfe0-48ae-a295-16e46352a105">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) in February 2017 for the issuance of stock options and other stock-based awards to employees, consultants, officers and directors. As of December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for future issuance since all shares in the 2017 Plan ceased to be available upon the effective date of the 2021 Equity Incentive Plan, which occurred in March 2021. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;698,601&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock available for future grants under the 2017 Plan as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Board adopted, and the stockholders approved, the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan became effective on the date of the underwriting agreement related to the IPO and no further grants will be made under the 2017 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company&#x2019;s affiliates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Initially, the maximum number of shares of the Company&#x2019;s common stock that may be issued under the 2021 Plan will not exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,291,446&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, which is the sum of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,700,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; new shares, plus (2) an additional number of shares equal to the number of shares of common stock subject to outstanding stock options or other stock awards granted under the 2017 Plan that, on or after the 2021 Plan became effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, if any, as such shares become available from time to time. In addition, the number of shares of common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the total number of shares of common stock outstanding on December 31 of the year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the applicable January 1. The maximum number of shares of common stock that may be issued on the exercise of incentive stock options under the 2021 Plan will be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,100,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock issuable upon the exercise of outstanding options and there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,569,454&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for future issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Board adopted the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on the date of the underwriting agreement related to the IPO. The 2021 ESPP is administered by the Board or by a committee appointed by the Board. The 2021 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;500,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. The first offering period of the plan commenced on December 1, 2021 under the 2021 ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Each offering to employees to purchase shares will begin on each June 1 and December 1 and will end on the following November 30 and May 31, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On each purchase date, which will fall on the last date of each offering period, ESPP participants will purchase ordinary shares at a price per share equal to 85% of the lesser of (1) the fair market value of the shares on the offering date or (2) the fair market value of the shares on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company&#x2019;s compensation committee.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were issued under the 2021 ESPP in 2021 and 500,000 shares were available for future issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Option Valuation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The assumptions that the Company used in Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2021 and 2020 were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.263%;"/&gt;
        &lt;td style="width:2.009%;"/&gt;
        &lt;td style="width:18.366%;"/&gt;
        &lt;td style="width:2.009%;"/&gt;
        &lt;td style="width:18.353%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity of the Company&#x2019;s stock options under the 2021 Plan for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.349%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:10.029%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.641%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:10.188%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.403%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;SHARES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE&lt;br/&gt;PRICE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;TERM (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;AGGREGATE&lt;br/&gt;INTRINSIC&lt;br/&gt;VALUE&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,053,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,602,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;155,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;211,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;846,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options vested or expected to vest as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The options granted during the years ended December 31, 2021 and 2020 were granted to employees and consultants of the Company. As of December 31, 2021, there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of unrecognized compensation expense related to the stock-based compensation arrangements granted under the 2021 Plan remaining to be recognized. The Company expects to recognize this cost over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.24&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stoc&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;k. The intrinsic value of options exercised in 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. The weighted-a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;verage grant date fair value of stock options granted in the years ended December 31, 2021 and 2020 under the Black-Scholes option pricing model was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.87&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per option and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.87&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per option, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The restricted stock was granted to the founders of the Company, as well as employees and consultants of the Company. There was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of stock-based compensation expense recognized for the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;547,360&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of restricted stock vested during the year ended December 31, 2020. All restricted stock was vested as of December 31, 2020 and there is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; remaining stock-compensation expense related to restricted stock to be recognized for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December 31, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:62.366%;"/&gt;
      &lt;td style="width:1.467%;"/&gt;
      &lt;td style="width:1.815%;"/&gt;
      &lt;td style="width:14.753%;"/&gt;
      &lt;td style="width:0.783%;"/&gt;
      &lt;td style="width:1.467%;"/&gt;
      &lt;td style="width:1.815%;"/&gt;
      &lt;td style="width:14.753%;"/&gt;
      &lt;td style="width:0.783%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The stock-based compensation expense for the year ended December 31, 2020 includes the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million recorded in relation to the secondary sale of common stock (see Note 11).&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_8093822b-1d40-4764-a04f-b8bfd74d9e7b"
      decimals="INF"
      id="F_d77843e5-fb9f-473c-a48b-6ce0c5b21ed6"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_78f74fe2-9b23-4570-b2d6-32c1291e24ba"
      decimals="INF"
      id="F_90115ae6-fa92-4c61-ba25-786891959209"
      unitRef="U_shares">698601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="INF"
      id="F_3890949d-f480-433f-a914-e4e6c9a418ac"
      unitRef="U_shares">5291446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_8093822b-1d40-4764-a04f-b8bfd74d9e7b"
      decimals="INF"
      id="F_2a7f7cf1-beb5-4a76-8257-f498cf777fb3"
      unitRef="U_shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <fnch:PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="3"
      id="F_d3d2c412-3852-4edd-9599-9bae5431b740"
      unitRef="U_pure">0.050</fnch:PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_46125c65-4c5f-4d12-825a-13db653d8482"
      decimals="INF"
      id="F_974aa079-b633-42ae-b376-b865a2b6c7d5"
      unitRef="U_shares">14100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="0"
      id="F_279b2af6-df13-4aac-a058-cc28398b2386"
      unitRef="U_shares">3264770</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="0"
      id="F_8abca000-821d-4ee6-8ae5-983c1d766b4a"
      unitRef="U_shares">2569454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="INF"
      id="F_ac795a3a-3e91-46b8-aade-83a426b3e6d6"
      unitRef="U_shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_c5285cda-f062-40ab-908f-8ca5f466181d"
      decimals="INF"
      id="F_8df4b1d0-6ba7-44ae-8583-7b49672a96a0"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_d4879d87-fd74-4aae-b91f-67fe39639661">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The assumptions that the Company used in Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2021 and 2020 were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.263%;"/&gt;
        &lt;td style="width:2.009%;"/&gt;
        &lt;td style="width:18.366%;"/&gt;
        &lt;td style="width:2.009%;"/&gt;
        &lt;td style="width:18.353%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="4"
      id="F_9cd0ab13-40fb-4f89-9fb8-46d9ee59831e"
      unitRef="U_pure">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="4"
      id="F_92b5bbb8-aed4-424f-ad3d-ff18deb12b39"
      unitRef="U_pure">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fcacd18f-13a2-4b4f-b905-5a7daa5bf83a"
      id="F_476d6d3f-67a5-477e-ae82-36ad4d6195e1">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3c431cec-8ef4-41d1-91de-5a171c2fbc40"
      id="F_ce6ecfa3-856d-4c0d-bd7e-c8b4e8116561">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fbf098e4-d64a-4024-bd56-afb40e7ad714"
      id="F_384b188e-58a5-4fd2-8976-820a9ef7b7f3">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_76e74e59-dc68-499b-b05c-f96331eeeafa"
      id="F_a5fd3c8d-d629-4b7e-9b7e-5a7da5128384">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fcacd18f-13a2-4b4f-b905-5a7daa5bf83a"
      decimals="3"
      id="F_1e1fdebb-ccc3-4249-9344-1984edd5f7a5"
      unitRef="U_pure">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3c431cec-8ef4-41d1-91de-5a171c2fbc40"
      decimals="3"
      id="F_419b919d-6c05-4919-a3c8-476f2ebf7498"
      unitRef="U_pure">0.930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fbf098e4-d64a-4024-bd56-afb40e7ad714"
      decimals="3"
      id="F_f127fb01-a2db-4344-9515-1c037408ae66"
      unitRef="U_pure">0.746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_76e74e59-dc68-499b-b05c-f96331eeeafa"
      decimals="3"
      id="F_158dac22-6ea3-454f-9c50-ea1c0b5a8dc4"
      unitRef="U_pure">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="3"
      id="F_6873d0d2-a797-4f9a-a658-9827caf92c03"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="3"
      id="F_14528cda-bebd-4c8a-b90d-cf1d93f09ad4"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_130f6735-e69d-424a-b8ff-9a30bd23c0d0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity of the Company&#x2019;s stock options under the 2021 Plan for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.349%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:10.029%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.641%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:10.188%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.403%;"/&gt;
        &lt;td style="width:0.626%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;SHARES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE&lt;br/&gt;PRICE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;TERM (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"&gt;AGGREGATE&lt;br/&gt;INTRINSIC&lt;br/&gt;VALUE&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,053,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,602,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;155,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;211,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;846,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options vested or expected to vest as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fb1c3a83-faee-4108-875a-e75af3e55f7e"
      decimals="0"
      id="F_91316ee2-a251-4695-abcc-bf941c6a10a1"
      unitRef="U_shares">1053874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fb1c3a83-faee-4108-875a-e75af3e55f7e"
      decimals="2"
      id="F_42634f13-df0e-4dc7-80e7-c0d46f87b3c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_06a32a5b-3613-45c4-bbd2-cb0a2ad1a82b"
      id="F_95f0945b-f5d1-4beb-9645-b3322a2858a6">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_fb1c3a83-faee-4108-875a-e75af3e55f7e"
      decimals="-3"
      id="F_28209484-edad-4f79-9dcc-135228e8dec7"
      unitRef="U_USD">4964000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="0"
      id="F_779fb333-99cd-4031-9678-3590fb460d91"
      unitRef="U_shares">2602643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="2"
      id="F_cc9898b8-223f-458d-aacc-9a91981f4f82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="0"
      id="F_49cd7303-9124-4c09-9b40-272d8fb78783"
      unitRef="U_shares">155821</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="2"
      id="F_3f8cc008-ca29-4381-bfc7-4dc0ff1ee97a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="0"
      id="F_dced8cd3-883c-46e3-a8ef-910dedf10986"
      unitRef="U_shares">211987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="2"
      id="F_9be82e4e-aa4b-4bfa-b5e6-ecbea192d3a5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="0"
      id="F_5f8494d8-a2b0-45c6-a281-65c6c4c79a5c"
      unitRef="U_shares">23939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      decimals="2"
      id="F_ee2623d3-90db-482a-b768-0b8ee20ab406"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="0"
      id="F_106ea16e-4a83-419d-9dd4-7672f5f98146"
      unitRef="U_shares">3264770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="2"
      id="F_da535dc7-5e21-4337-a607-26c7b8c5a07a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      id="F_5260335b-c8b8-4bc2-be65-0f48abf7934b">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="-3"
      id="F_89baeab1-f290-4e9e-9529-1c0a50f658d9"
      unitRef="U_USD">7228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="0"
      id="F_6f11d6bb-7862-4e88-b10c-d18b0e546e97"
      unitRef="U_shares">846024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="2"
      id="F_eff81075-b77d-4917-aa14-063d6edb6f18"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      id="F_6a906697-1a9a-4fae-a7d2-e0feef294c64">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="-3"
      id="F_37d32803-df1f-4b00-8de8-2e30f470e8ca"
      unitRef="U_USD">5589000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="0"
      id="F_0d4c0106-4ca8-437f-ad36-ecfc1409cebf"
      unitRef="U_shares">3264770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="2"
      id="F_de2695cb-279d-4030-883d-fb3804fa04cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0b373c5e-3287-41b4-b4c9-314d0744c150"
      id="F_be21fb77-95d4-4b12-8924-5091c2e5cb6d">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="-3"
      id="F_f97f74c3-f9aa-46f4-ae38-295da8594d0e"
      unitRef="U_USD">7228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_5b073b84-8eb2-412a-a07e-959c86d508ca"
      decimals="-5"
      id="F_80319fb3-dbc3-41e2-8c90-bccb73d58a60"
      unitRef="U_USD">19900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_02bc5fe6-52dc-428c-a5bc-9f4b8b799841"
      id="F_3b20c45f-63b7-49a7-9cbc-685d3663c9ea">P3Y2M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-5"
      id="F_13751d50-dc16-402b-ba93-860fc871dabf"
      unitRef="U_USD">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-5"
      id="F_48a77585-f93c-4d19-a2e1-f87027e10643"
      unitRef="U_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="2"
      id="F_03e0bd56-f084-4760-8e17-81252f98503a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="2"
      id="F_5d3e2439-1ed4-4121-a999-d08531d84ba1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1545e700-f4cb-462d-bda2-6aea5fb1b1f6"
      decimals="-3"
      id="F_e0695c19-f6a2-475e-8db4-acd4842354e4"
      unitRef="U_USD">8000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="INF"
      id="F_9f528cf6-139f-421d-b8fe-260c973542e5"
      unitRef="U_shares">547360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <fnch:RemainingStockCompensationExpenses
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="INF"
      id="F_2ecd3920-103c-41be-b067-52a4188b8c5f"
      unitRef="U_USD">0</fnch:RemainingStockCompensationExpenses>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_46826632-3457-4b7d-81c6-1a1d3413353d">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December 31, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83dde824-9020-47ce-a70f-8cacb2aad84b"
      decimals="-3"
      id="F_9178d105-036d-4f69-b7c4-a1ed010a9e2c"
      unitRef="U_USD">1605000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0df70676-9619-40e8-853f-19a8b73a703f"
      decimals="-3"
      id="F_2e8d3801-bb25-493d-baa9-fcf0449a2b29"
      unitRef="U_USD">179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_826e7f83-9582-40fb-b568-89f02012f782"
      decimals="-3"
      id="F_8c1cebb8-98ce-467f-9465-ebe2b9ec01a8"
      unitRef="U_USD">2556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_68b03d20-efc1-47c4-97fe-d09e37d99bd2"
      decimals="-3"
      id="F_2ff4fb1c-f813-4f64-b6f6-61778eb65e8e"
      unitRef="U_USD">2920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_8f02bc7f-153f-4bc8-9e30-48a1300045a9"
      unitRef="U_USD">4161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_4aff623c-5d74-4add-bc4e-0fb015b1e03a"
      unitRef="U_USD">3099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_29953980-7bf1-4fdd-b181-4be7a82bb370"
      decimals="-5"
      id="F_82d79b1f-9824-41cb-80b3-1fabcedd6ebb"
      unitRef="U_USD">2800000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_68a21f22-159d-447d-8943-a5f5ee04f920">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;OpenBiome Historical Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Master Strategic Affiliation Agreement with OpenBiome (the &#x201c;Strategic Agreement&#x201d;), OpenBiome and the Company reimbursed one another for certain administrative expenses. The Company&#x2019;s Chief Executive Officer and a member of the Board is the spouse of the co-founder and former Executive Director of OpenBiome, and certain of the OpenBiome directors are stockholders of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company reimbursed OpenBiome $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, under the Strategic Agreement. Also under the Strategic Agreement, OpenBiome reimbursed the Company $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020, respectively. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and 2020, respectively the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; payable balance&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;due to OpenBiome, and recorded a balance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million due from OpenBiome as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Until December 31, 2021, OpenBiome subleased office and lab space from the Company. The Company&#x2019;s rent income under the sublease was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020, respectively. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; longer had an outstanding receivable due from OpenBiome. As of December 31, 2020, the Company had le&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ss than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million re&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ceivable from OpenBiome related to the sublease recorded as due from related party in the consolidated balance sheets. This lease was amended as of March 1, 2021 (see Note 5).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also earned a low single digit royalty on net sales of OpenBiome&#x2019;s FMT materials under the Quality System and Supply Agreement with OpenBiome (the &#x201c;QSS Agreement&#x201d;), which was partially terminated on February 1, 2019 and, ultimately, was fully terminated in November 2020 in connection with the Company&#x2019;s execution of the OpenBiome Agreement (see OpenBiome 2020 Agreements below), which closed on March 1, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;OpenBiome 2020 Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Clinical Supply and Services Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On February 10, 2020, the Company entered into a Clinical Supply and Services Agreement (the &#x201c;CSA&#x201d;) with OpenBiome, which terminated upon closing of the OpenBiome Agreement in March 2021. In accordance with the CSA, OpenBiome agreed to supply the Company with certain manufactured material and to provide additional support services to the Company. In consideration for these materials and services, the Company agreed to pay a monthly platform fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, all direct employee overhead costs, and variable costs for consumables. Under a related payment agreement executed concurrently with the CSA, the Company paid a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million security deposit in the event of cost overruns under the CSA arrangement and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in prepaid fees. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million security deposit was returned to the Company during the same period. The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in total to OpenBiome under the CSA for the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;year ended December 31, 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, including the security deposit that was returned. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; outstanding payable balance due to OpenBiome under the CSA as of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million due to OpenBiome as of December 31, 2020, respectively, which is classified as due to related party in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;OpenBiome Purchase Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On November 19, 2020, the Company entered into the OpenBiome Agreement in order to obtain OpenBiome&#x2019;s CMC manufacturing process to enhance its current manufacturing capabilities for its lead program, CP101; the OpenBiome Agreement was fully executed and closed on March 1, 2021. Simultaneously with entering into the OpenBiome Agreement, the Company terminated the Strategic Agreement, the MAL Agreement, the QSS Agreement and the APL Agreement, as well as certain subject matter agreements. Upon closing of the OpenBiome Agreement on March 1, 2021, the CSA was also terminated, and the Company will not incur any additional expense to be paid to OpenBiome. The Company also amended the Strategic Agreement as part of the OpenBiome Agreement (the &#x201c;A&amp;amp;R Strategic Agreement&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the OpenBiome Agreement, the Company acquired certain biological samples, software, and a non-exclusive license to OpenBiome&#x2019;s CMC technology upon signing in November 2020, and acquired certain biological samples, a commercial lease, contract services intellectual property and capital equipment upon the closing of the transaction in March 2021. The Company previously licensed the biological samples and OpenBiome&#x2019;s CMC technology under various historical agreements with OpenBiome which terminated upon signing of the OpenBiome Agreement. As such, the acquisition of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;CMC technology license was a continuation of previously granted rights. The OpenBiome Agreement also releases, for a one-year period from signing, a hiring restriction under the A&amp;amp;R Strategic Agreement (i.e. non-solicitation) such that the Company may hire, at its discretion, certain OpenBiome employees. The Company did not acquire any such employees as part of the transaction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the OpenBiome Agreement, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the acquisition of certain assets in November 2020, which was capitalized as property and equipment as software on the Company&#x2019;s consolidated balance sheet as of December 31, 2020 and paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the closing of the OpenBiome Agreement on March 1, 2021, for the remaining assets. The Company accounted for the OpenBiome Agreement as an asset acquisition and capitalized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of property and equipment on the consolidated balance sheet as of March 31, 2021 for the acquired software and property and equipment. The Company did not assign any value to biological samples, contract services intellectual property, or the CMC technology license, as the Company did not acquire any additional rights that were not previously granted under the legacy agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is also required to pay certain milestones up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the occurrence of certain R&amp;amp;D events, regulatory approvals, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company previously granted OpenBiome a royalty-bearing, non-exclusive license to its intellectual property under the APL Agreement, which terminated upon the signing of the OpenBiome Agreement. The Company will continue to earn royalties under the OpenBiome Agreement based on sales of FMT materials.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="C_63ccd21b-b4e9-4f84-b09c-125598219f50"
      decimals="-5"
      id="F_8afab34f-774e-468f-9416-b6530f949383"
      unitRef="U_USD">100000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="C_24547a48-6a37-4b99-8269-4b7bace32f46"
      decimals="-5"
      id="F_cf6dde7a-2639-4cae-b229-78c3d2e21809"
      unitRef="U_USD">300000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_63ccd21b-b4e9-4f84-b09c-125598219f50"
      decimals="-5"
      id="F_da713bbe-0197-4a18-b389-02510b770334"
      unitRef="U_USD">100000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_24547a48-6a37-4b99-8269-4b7bace32f46"
      decimals="-5"
      id="F_451abaf6-a793-4b6f-bad5-6db84e1d89de"
      unitRef="U_USD">300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_e29d9cb5-46b0-4d57-96ad-b94780aa228e"
      decimals="-6"
      id="F_9ac149ce-1529-4bf3-a5c4-159f215a0e90"
      unitRef="U_USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_42702fe8-9f6e-4d52-96bc-bf7ff5642f9d"
      decimals="-6"
      id="F_9fd0168b-a811-4ade-ac32-8d3cae0fd8a1"
      unitRef="U_USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_583cd02a-6b47-4c6a-9fda-94aade34f36d"
      decimals="-6"
      id="F_be76afeb-f6ce-44f9-8db6-583ed223d256"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_e29d9cb5-46b0-4d57-96ad-b94780aa228e"
      decimals="-5"
      id="F_21658304-3d7d-4f19-b58a-2f9030321fcd"
      unitRef="U_USD">100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="C_30f83225-a823-4c68-b24e-432bbb423504"
      decimals="-5"
      id="F_1a8be6ef-147c-4d8f-b89e-29e8f7de74fd"
      unitRef="U_USD">100000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="C_7ac98b6d-c24a-449b-91fb-dcb878c6c9ee"
      decimals="-5"
      id="F_0c1b6c96-0ef2-4cc4-a573-2e34d100c365"
      unitRef="U_USD">400000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_e109216b-8e95-4dc3-9229-87d798ee0e98"
      decimals="-6"
      id="F_37a651ed-c2d6-4502-9ce8-a5641731c921"
      unitRef="U_USD">0</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_78dd3234-e5d1-4ad1-9914-de28cdc240bc"
      decimals="-5"
      id="F_b4fe428d-4596-482b-9e0d-de04aad10d79"
      unitRef="U_USD">100000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <fnch:PaymentOfMonthlyPlatformFee
      contextRef="C_a6981439-53f3-412e-bd72-c7b736c9fa1c"
      decimals="-5"
      id="F_224f87eb-616e-437c-adcc-5b6872bf46ee"
      unitRef="U_USD">200000</fnch:PaymentOfMonthlyPlatformFee>
    <us-gaap:SecurityDeposit
      contextRef="C_566912aa-b2e7-4130-a031-93d7d2de01cc"
      decimals="-5"
      id="F_b31d7171-7a2a-459c-8162-10e713d6a11a"
      unitRef="U_USD">500000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="C_566912aa-b2e7-4130-a031-93d7d2de01cc"
      decimals="-5"
      id="F_2ccdb38f-b541-4280-a255-411e40bb9fda"
      unitRef="U_USD">1600000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <fnch:SecurityDepositsReturned
      contextRef="C_566912aa-b2e7-4130-a031-93d7d2de01cc"
      decimals="-5"
      id="F_819bd385-f5f9-4e43-84a8-a0a8bdb00c74"
      unitRef="U_USD">500000</fnch:SecurityDepositsReturned>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_94c65693-07a8-42cf-9bcf-fe65d1cb5868"
      decimals="-5"
      id="F_f842a321-470a-4834-9557-5f560d1e95ce"
      unitRef="U_USD">1100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_eb5c3d76-f6ae-465b-9ade-c84c08d30d59"
      decimals="-5"
      id="F_bb477500-14dd-42fe-a06f-94aceac2e80c"
      unitRef="U_USD">3800000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_e63bb9f3-addf-44bf-9079-4ef73a7b1858"
      decimals="-6"
      id="F_54c80497-eda9-4a83-b805-ccca7309557e"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_95503824-281a-48bb-a70d-4346f1e2af47"
      decimals="-5"
      id="F_28eb2d56-341b-4bd2-aecb-a0e783744d56"
      unitRef="U_USD">200000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:PaymentsToAcquireSoftware
      contextRef="C_4603d1f8-8b00-442d-96f0-6e9d5d761ed9"
      decimals="-5"
      id="F_113e4aff-3d72-40f0-b25a-5f93c2051174"
      unitRef="U_USD">1200000</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="C_e6ce2584-4ad0-4ec8-bee7-5bf80eddbb4a"
      decimals="-5"
      id="F_d5aad334-f177-4cf9-98e1-8d42b17fdd1f"
      unitRef="U_USD">3800000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="C_2a6aef8a-3ebf-43c8-a1d9-cb65a4f2ce4e"
      decimals="-5"
      id="F_01244431-f8bb-474f-80cf-32a40c236684"
      unitRef="U_USD">5000000.0</us-gaap:PropertyPlantAndEquipmentAdditions>
    <fnch:MaximumMilestonePaymentRequiredUnderAgreement
      contextRef="C_85b5348c-0723-4afb-be02-9db714b74dc9"
      decimals="-5"
      id="F_856d5e46-4c3f-4a4e-baf9-ee33c31f71c4"
      unitRef="U_USD">26000000.0</fnch:MaximumMilestonePaymentRequiredUnderAgreement>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_3a26d2fc-709e-40ab-9b93-c357d69e62c8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. RETIREMENT PLAN&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. All employees are eligible to become participants of the plan at the beginning of the next full quarter subsequent to their hire date&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right to make additional contributions to this plan. The Company made contributions to the plan of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-5"
      id="F_814bd629-7eca-4a06-b913-3a3789ce015b"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-5"
      id="F_7ce75783-fcf4-424b-80e9-f2cbed9d4f12"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_e7925206-be4e-4a4b-a7f1-3c080c888479">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. LOSS PER SHARE&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.262%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:20.179%;"/&gt;
        &lt;td style="width:1.057%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:19.806%;"/&gt;
        &lt;td style="width:1.057%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;FOR THE YEAR&lt;br/&gt;ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;39,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Net loss attributable to&lt;br/&gt;&#160;&#160;&#160;common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;39,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Weighted-average common&lt;br/&gt;&#160;&#160;&#160;stock outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;39,202,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8,144,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Net loss per share attributable&lt;br/&gt;&#160;&#160;&#160;to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s potentially dilutive securities, which include preferred stock, restricted stock, stock options, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December 31, 2021 and 2020 because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.064%;"/&gt;
        &lt;td style="width:1.505%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:15.247%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.505%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:15.595%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,053,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,309,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,326,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_6c31b30e-69de-49eb-ab6d-abaa70521dd2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.262%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:20.179%;"/&gt;
        &lt;td style="width:1.057%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:19.806%;"/&gt;
        &lt;td style="width:1.057%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;FOR THE YEAR&lt;br/&gt;ENDED DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;39,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Net loss attributable to&lt;br/&gt;&#160;&#160;&#160;common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;58,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;39,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Weighted-average common&lt;br/&gt;&#160;&#160;&#160;stock outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;39,202,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8,144,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Net loss per share attributable&lt;br/&gt;&#160;&#160;&#160;to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_94eba688-7fbc-4480-9eb3-296d92ee5927"
      unitRef="U_USD">-58160000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_e9dbf254-5390-490c-bd77-4af64dea7259"
      unitRef="U_USD">-39341000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="-3"
      id="F_11b593e9-a006-450b-b1ab-b1f834a00e4e"
      unitRef="U_USD">-58160000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="-3"
      id="F_4e63408c-6958-458f-a454-bf302f110572"
      unitRef="U_USD">-39341000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="0"
      id="F_dd203897-f0a8-4d72-94f3-07ec56bccfb1"
      unitRef="U_shares">39202086</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="0"
      id="F_2e6626c5-ab17-4801-8add-fe91d128a4a8"
      unitRef="U_shares">8144855</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="2"
      id="F_a366acfa-b722-4690-a83f-179a2dddab97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="2"
      id="F_e0431367-5543-4631-95c1-0ac252079bdb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.83</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      id="F_6f2d26c7-3d18-401c-afe3-f00f4d2313fd">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December 31, 2021 and 2020 because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.064%;"/&gt;
        &lt;td style="width:1.505%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:15.247%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.505%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:15.595%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,253,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,264,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,053,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,309,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,326,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d9b8ef89-619c-4cf1-98e8-3318a7630899"
      decimals="0"
      id="F_6e5cee43-1d26-49a5-92a6-248f107564c5"
      unitRef="U_shares">31253609</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b66a4bb1-f047-4756-b7b4-61d3d88e063e"
      decimals="0"
      id="F_52e89395-1cb1-420b-9615-af628810ef52"
      unitRef="U_shares">3264770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_10a999a1-8dfb-4ba6-8758-e876879ab568"
      decimals="0"
      id="F_98180716-be4f-43f6-8283-fb6cea9c1431"
      unitRef="U_shares">1053874</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53f088f1-6942-4a33-8ec0-d9a352aa8473"
      decimals="0"
      id="F_20ec69ac-1429-416f-b18d-24575e2f1347"
      unitRef="U_shares">19346</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a6c10679-4ab6-409c-8105-7146e8e77be9"
      decimals="0"
      id="F_a4f11e9d-980f-4865-9d1e-41d78fd35f84"
      unitRef="U_shares">45195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d4472afe-992b-4a5e-9cca-abeb72f9257d"
      decimals="0"
      id="F_b48a4a99-408c-4f02-86a8-64c9060934ac"
      unitRef="U_shares">3309965</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7d9f4544-e632-4b9f-9408-2c82d8a5fa01"
      decimals="0"
      id="F_7b746518-a114-471a-9ee7-ef5298385cff"
      unitRef="U_shares">32326829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_826c8495-19c0-4a28-9e18-0cfd4c276ecc"
          xlink:label="F_826c8495-19c0-4a28-9e18-0cfd4c276ecc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_63fcec9a-5520-4869-afa6-b24df4aa3a63"
          xlink:label="F_63fcec9a-5520-4869-afa6-b24df4aa3a63"
          xlink:type="locator"/>
        <link:footnote id="FNT_dbc6dd0c-c53b-49de-8c39-5c46ef9abcc8" xlink:label="FNT_dbc6dd0c-c53b-49de-8c39-5c46ef9abcc8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During the fourth quarter of 2021, </xhtml:span><xhtml:span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,346</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> common stock warrants were net exercised, resulting in </xhtml:span><xhtml:span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,303</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> net shares.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_826c8495-19c0-4a28-9e18-0cfd4c276ecc"
          xlink:to="FNT_dbc6dd0c-c53b-49de-8c39-5c46ef9abcc8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_63fcec9a-5520-4869-afa6-b24df4aa3a63"
          xlink:to="FNT_dbc6dd0c-c53b-49de-8c39-5c46ef9abcc8"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #6(?U0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  UB']4/O[[^^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R':@!Y/ZLK+3!H,5-G8SMMJ:Q8FQ-9*^_1*O31G; ^QHZ?>G
M3Z#61F6'A,]IB)C(8[Z;0M=G9>.6G8BB LCVA,'D>D[T<_,PI&!H?J8C1&,_
MS!%!<KZ!@&2<(0,+L(HKD>G66643&AK2!>_LBH^?J2LP9P$[#-A3!E$+8'J9
M&,]3U\(-L, (4\C?!70KL53_Q)8.L$MRRGY-C>-8CTW)S3L(>'MZ?"GK5K[/
M9'J+\Z_L%9TC;MEU\FMSO]L_,"VYE!5OJD;LI5!<*+EY7UQ_^-V$P^#\P?]C
MXZN@;N'77>@O4$L#!!0    ( #6(?U297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%G%VN.(,IX2Y 7]?"*&W)^8!Y<[GQ7]02P,$%     @ -8A_5,/U"/FM!P
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M-!#?KYBH3)H;^?J^_;G&Y3]02P,$%     @ -8A_5 ^!Q7D+!   OQ0  !@
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M>C6E=P'EF+DT][0')A??\N\#L1[IA@'8@%V[G=JOJ?V+J1^ZI]S<UZ>_[V+
M 7P@U@,#.\1^V,$;U+S!%;RL=V+.@['0>F O=%A#A[W0*\IC.1D^HV<:46GA
MEX0BN>Z^42YB=;R4YJ*<RP5XI<;5L[AAJUG6K0N7D][&J:H-=<Y@V#GMB83P
M'1;C>57U](5][)R6$.SY3NCYKM5!W1@$7ZF0[O[!NC\T8CT$8S?T(.@";A2#
MQSKFDH5]CG71:-!ZR !T(R/<;Z.J>^8WZ)[&.+A?.9=VSSCO#(:=TS;FP?WJ
MN;9[=*MHKU4/\1T/+-_N<#INQ(/[S7--\^A2T8#U$!=[DKAC"<>->'"_>:[M
M'=TI&K,>TL_<> >/$L_B_[<.-.*!FXH'QHEG,.R<MA$/W$4\,"R>EA!LA9[E
MA*'307WRT^7FXH%A\;2$^&X0@-O%VW@'[N(=&/9.2T@_<Z,=&*6=IQOT3J,=
MN*EV8)QV!L/.:1OMP%VT \/::0D)0]]R;;=#.]!H!VZN'1C63DN(%UH0^!V;
M M!H!^ZB'1C63DM(.[-YLKNDMO;^('P;9SE*Z$9F6H^^+,'+W;+R1+!]L>'T
MPH1@:7&XHR2B7 7([S>,B?<3M8=5[UG._@-02P,$%     @ -8A_5+29AAX1
M!0  C1(  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6RE6&%SHD@0_2M3
MWM954I5$9P"!G+$J,>YNJC;&TF3WOHXR"A5@/&8TR;_?'D!0&(A7^T4%NYOW
MFNE^/3-XX\FK\!F3Z#T*8W'3\:7<7'>[8NFSB(HKOF$Q_+/B240E7";KKM@D
MC'JI4Q1V2:_7[T8TB#O#07IOF@P'?"O#(&;3!(EM%-'DXXZ%_.VF@SO[&[-@
M[4MUHSL<;.B:S9E\V4P3N.H64;P@8K$(>(P2MKKIW.+K$;&50VKQ,V!OXN W
M4E06G+^JBP?OIM-3B%C(EE*%H/"U8R,6ABH2X/@O#]HIGJD<#W_OHW]-R0.9
M!15LQ,-?@2?]FX[301Y;T6TH9_SM.\L)62K>DH<B_41OF:UM==!R*R2/<F=
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MD_VK3.DP"V7!FIBAG9G;>7I-B4VA3K0ACF#0R$3;J9I(H9U)W[)X.A<.(R^
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MEX\K$BO:*0#J\R5C\O"B^%W \=<RUW\#4$L#!!0    ( #6(?U03#QTF40,
M   ,   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULM59=;]LX$/PK"R'
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MU7/\CN?,(<5S+JPNJ$<.U4B9QZ]7_6"$0U#O]=@P%C$:41\W8B? @@98X#3
M./T?A&T=116'5$]XD60Y0\4>L;PKKQ,97SL!<0<A!>M2&5=9\5(G=E9E3+C,
M%#9H0J>9KAFL;DD6UVM&D:)XP\LJ^[>^P7[!<BB8S8;UM,&1<0CU<,N"IM P
M\NSF&S: AT[ RXHG/_MR94I1PC<2WUFL0P.&C\,V5E.(>E%D!SMJP(Z<8/^,
MI>LD-NFZ72;6TN]R\5@L%NB6QX4-[LA TL<C;]3":TIU6#9JP$9.L+]+M'_4
M(0B810PQ"4BWI8R]ZEU%!_MGEVVE#C;<D8F;M%&;,IC:86-/+]&>$_A]M68E
M*GC15RFC4R5G$"80)<(*=S_K,9;H"$R-UR+4869\1"G8O02NX^*%B59:"\%@
M19!&SK/X.<O/IC@F^H'$::!QDO"=7&\@U5GV&C_GUC39SW*L:^"W%T6+$/:[
M7*A) 5/W,K1C:%7R#2#,%=5N8P@Y*TAJ/-](98L,#;QA!TC-*-A-*8N2;>,L
M/:PTM;.X"KYD5Y8RLVLO6G'[9G90@H=MZ#:Q, PZL&O2P<%'<^0\U,#$X(>C
MJ W5%.M*#<U&V$U'3:1NX_?.,+50#S%CP)3R_2Y\FGRPFWT 7[ECSA XREXK
M>I-G I\&;?06RAIU%!Y8LQ%VTY',,E5RG,LQ"P.1,&QCM$B%HPZ,FH2PFX6N
MV8J!(5- ^<J*G3T"+$R#:4B-&##E2!1V+%9$\PUQ\\T11#L1$A=I[(MN4P3*
MC0YDFED(=F=YB_K.Q.)^ME,[0G_;QFJ*=202T91$W)0T_TB!:\5L\D\_'&+:
M)FZ;',64=-E84Q7Y7 ,SF_^8+C_1P!#--^0,W^S*9!W+5>9391BQ4 @.HI%A
M(8L<"6E7>FBJ(6ZJ690\82P5-:%_OHPD)J^$I(W]P]Q#-/<0-_<8(9D5KTQ\
M)"1-JI$&)^WER";G,+@F)3+\5$3>S.;C^>03$:D)A+@)Y-2U60$FB7.TW3WG
M60).AF41K/5%=:_@\EV1LO*MS)0)TTS4U/Y%MFV;3,B-KCU_[@>J2MUN89-J
M,!X%0V.E^G!31#0A$3<AM7068A<7B0KI):"&Y+P&W! IT#5#P0)Q?F '(3M5
MJS8F+1GT8(I$'OS9E:&:NJB;NA;Q^Z$#;= #5L8VLMIR*:(U[_02/4][%I%^
M%'9HI6F/NFGOU$5-V+%2_ <J-58FF5 .XZ!<G.>\JFVPE?L&9Z)5!6@[8#L"
MWV$9DT&IY[<+:HM4E\,USU(WSRX 6))M)=C:]:JW7V6%<F5=)7#0XD5MHEBQ
M6XB4M-L6FY#?T7#1HZU"=U=XZM=C3]8A67M0*!=:H9M](!ZV5V6+4-!1)%!-
MW?1<JWB,W+790TT6-I+&%#G9#SK%J'F:GN%IO1:DAU3_0"A;FD,2!D8LV\3\
M+KMJCJ8?Y&@H)UZS%! _O^^C^3Q/4Y-_,8XP-NQMRD78'W;TX%3S-'4WC_/I
M(U2+DX?I>#F%"R1Y^XOZCZ;_?9K]&-].YX]+-)Y?HP<H*1]FD\?IM?K=JHUE
MPS+T@C8E6L2"8="UZ49U*4#=I8 \_?A2^T)6<Z]0YAV6RQ*JIC)+9(NI?H\K
M],Q>LJ*0+I*E((083ZTZF?P=19%G!)<IYA/:R2.:ZJF;ZC^G$U.EBTL;VV9G
M$(7M9M\B=ZKUZ0&()GO?<]:%RZ?%XG9Z!T$UOD77L^7D]G[Y]#!%]S>H*1DA
M#F_N'^[&C[/[N?/819.Q[R9C=2RF]LE6O 2J!!IF]@U8W^2[MJ<M(KAC&\37
MG.B[.5$CA"(?2IYB?V3ZEE7F[O&9%MJW;H?Z;35,J0YF]S4Y^NX^U.'=^?V\
MKSQ\U)O"HO+9OL _.FL[2W>6YDZ:-VYMZ-5G3/M=M'.V-7F/CMKT;1'"-.H@
M1U^3H^\FQXFJA-5A/.3X1TODHN*J6)3')UW5OV\R(Z'4"]KMN46N*V8T??IN
M^M3[0Z4\ON_S51^:W</9 W^N8AB@TH+]2M0IA4KB@KVU\T*@W5:>&*9U#2:-
M-%Y.T,@G5IU-1K6L@Q:I+HTUY_INSFWVZIPUN]1XO-"Q&>?V@!P:)\+&F;$I
M,@S]EA:#H_<1-JQ\4:]I"*0RI3[8;^XVKX*,U0L0K?O?\;=)_4*'GJ9^O^0N
M+H%Q!3AK!5-Z7X=@U;)^9:/^4O&M>NOAF5<5WZC+-8NA!9("\/N*\^KP13Z@
M>7'FZO]02P,$%     @ -8A_5/HW->*( @  . 8  !@   !X;"]W;W)K<VAE
M971S+W-H965T."YX;6R-54U3VS 0_2L:3P\P0_%7 IA)/ -):3ETR!!H#YT>
M%'L3:Y E(\D)_?==R<9U0D*Y1%_[WKY]LC:CC51/N@ PY*7D0H^]PICJTO=U
M5D!)]:FL0.#)4JJ2&ERJE:\K!31WH)+[41"<^25EPDM';F^FTI&L#6<"9HKH
MNBRI^G,-7&[&7NB];MRS56'LAI^.*KJ".9C':J9PY7<L.2M!:"8%4; <>U?A
MY61HXUW #P8;W9L36\E"RB>[N,W'7F % 8?,6 :*PQHFP+DE0AG/+:?7I;3
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MF0MSXR9R#TIVSWOHMWF?Y>LUJ$%:!"RK[7 !^0Z/D*@)S[O>+[*ZRE=57?5
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M3!@WI1(+2^J1V\Q3=O,_9^]P]NP,_9.S\Q?_<6B1FXEAO*A\8#PY4$]< <.
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MIS4*A9V'9)BGZ7 :TK.^-TQQEY /U6%4B<HU=!ZI':SZ ^^P:D@!>L\1%X1
M#3G4I )=R0IP,$=,!4ANH/+D^$#<W(JSG>S5;"UG-1T6ABJ0U"2JO^D5TB0F
MH3-(1,"RT1+I++]#\!9=E*%I[4UL7Y+=!K?:.^45X&1=&;@.]XKP)'?-ZV*G
M>V7[V+CI'=]%:PI[6 $R.>&_*(44C2(]MVV-+I3& 'XXA_(LG!B<:[41(3#.
M#>9] LV/<1Q111JNNHI$+7+,R2HOON(PW?!(6%,L-=/K0=]B#$H^:/BLBY]1
M*!(#)%P4>!=M583TCW@-#?HA[2T),"J5LCVL^O6A#@9_F;T>?B2)V_:F*B4(
MEGUSG$W>'$>:I&4@P)+J"#,*'TY,1PG[X*#&W T32F88DW^C= XF4K T@T$G
MV,,>/B3C/J8+.K.&2FDDML?@K,1TP'J2[4/8O\^/)$7&YZ7D4/P&=X'LO^Y1
ME6+ZI>_=;M^3P,E.V#G1I5 2&!R VI4+25K:9=X"VX!R1..0Y1MTU?A0P^$M
MLU?*@89H-,A>@N=(02_/'!=6*6Q3?X.#DWOY0Q57XU #YMWQ7KN]S#YV:/Q$
MPZ"GS+FGY&,7/N;,3H$9#F)FS((MLS>8*P;1.'1BNC&!676294#M[1I:-4D:
M)Y;)90%CB-:N)!>,##M,6,)(;*TZS* !;YL:19'OJQY4(O@\R^P_*>,K*0E:
M65]U++,08['R;M<+&Z7ABM0EP93F[L#_!CT)^ZK$YR+VU_2@"H!D!HG2[#[@
M<CFQACR.K$ A ,C0T-)3."#G&6QD VH/'P:QMK.39U<7LC!V%IFONQQ+CB=8
M+0IIS!O)54<9!K<$F:*N;ES(G80M"Q6\Y%K\SW]Y<_WYZOW%YS>OLR_7;]Y^
M>9>]NWK[YB\H< >4&'/V&).VZ_X6R?.,W!W_EW<Y!>W O^;)Y_+E!W*?('KH
M&F*.\,4[]+)0MZ<'?+W%>)T4;MC$VG%81?$3T"_[FTVC7C4G'R6-^LFF45^;
M-&IXH>)\HNC<U=$DCI"/0SQ?4-6EI/,1@E'4L\*SP*F*=K?2<^1PR\_D!CAA
MLJY(=YCQ1$F/(L2VBZ[_(/&K,H[R%5+)E/9!<23Q(D-\<7V9?6[W59$]>PY&
M_0I<IV93P?Q>DB8) 3^0V4-C)IM^"$6UAG?U\=._Y;O]B]>AAM<A(WMQ(Q."
M8+"_:=B;NB?C'7V#N'E9'7V#,0RJ.:K384VO=GVTK4I3>L=7O08TF'4N-.]"
MV6(RN55#Z>:J=R0Q**U*,,GP_H_1&(]S3(R$Y0)%.0\> \ZC"KAJ ZH_<(**
MZ)>.0SDC3"9A)H?LW ["EX+]^1MF1Q"\\E"@+AL,'56:5$6B_H-W,!00_:>)
M+'T1&3QDM&AQP@V:YY_*.R1;QM,$'Y#T-H8J8!EOVO#HW7QC0\W+CV>G9QK8
M8_ >*"/*^+WK-JY;#K1)6 H9*I9$X193R^%:#X8Q3?:AZ%NTK&<+KAE@L@3+
MMO </ #>"U*0DU]<Q>"2KRTL(@M6&,M'ON?][%#;8TS <Z/%>QNJF%-I+'@.
M%&B.N1@I"MU0>3Z+A6]P"A<\#U>"(/[<;!R53LP.Q8G3:KR-?J@Z"JX!P8-0
M((CJF" &LAMW!TLPS"Q(P .I_QAF2SEJD096D4!3H8A4*!(^#S48-9"] Y8/
MX;ML7Q5W.EWC-KQPH/\!WCWB.&#SFW8'@MU#$%XBGR?OE*X@ZSNS1-A]\57J
M5*1B(';V&+JB/TKU;F(3]#91],0/P*5*%!3<&S8NEK8H7 AV"K*$4MW@,/;D
M>N=[;ZN-BQG+-%HZ'$MMZ_.'INI5) D5 FO@E*0D[&0=5^IAV!=-_&B?#M82
M!XIK2D)/\2_]@"7)JQ)UZ;[UM%<5E\$DMM8Z/>&T)AK5</U0\I,J+I'9R']P
MK-//3H-\EW'%Z7E4%!@EA.=U2QYWO+\QQ>]EB*#<YCC":#^V>P\^^_]/AYPN
M6K3-0T[<%,_'I(@CLNL]6:V)^5DMZK"I$<2.K:CZAV ?;+D(@0Q#$,/ 0O>(
M3=HHO 8C*DXBJD^@3I$D&P+4()IO^1?KX@W&&NC"4PH<]I;Z!**]C64G?T#\
MA\SG" 6+3@-]&=TRG7,(>QBX$FS-*5> BP =BA91B8])%^<?*+834FN<C(<(
MXU 4'B[KB=S&G/A(<BZPQA:6Z$-@+0$G>BP22#8QN8S_L"B2I[#/U&>Q.8,V
M=1VNY@CB341_AX\E<3L?X[1*M$-YQC"Y^IAN1FO"P" N>RR#/GE0<MN@?C"]
M%."!I/I*PB8U[4B=8"J%(H5(7B"_)!G0C2/%A+E,?1 &$<2)J*([[$OJ-MI2
M@)\K/9CDRVNW=AU'714FV[./AU4-SL<'A8]=DD0G1<N0  'J" RG!D^F)IE>
M@PC0MA86L1E+"?VVZLH31)^ E^2<J9:7P"5%3Z?E6TQ%.$GL&I%%Y88H%]!;
M@I\DL YOH9(M['D+K6Z!E1*NI&;LPG@4P6H@3+RGTZ%<7?C(X. &[RX"3,P;
M&5)6MFZ6B)%)'VD>8+C?B6F6F)D@;WG\'0I9O@(*MXVF"Q]($N*?E4F(51"C
ME961&>#"CKDP>LZ*RPP[FI205$ DY0BAE=LBO/[&2=[I0Y.])V$_^U'+8FED
MH4J<3>V'%Q()HZ]X'!MT45Y_@ 9HP6+9%?:-A<B?;-G1'B)9EDW7>H%AHIF?
M.CY8*1;FV\-F&]*)N(2\*D\P^F(F4 K.(Z63:AI1ZP+L4IUAL61,+>0(>.GL
MI_/%CS_\8"?V<(Z<B\,X'#9"<<("TS[(1 %30;$5II<AF!,5R$@Q G%B_!Y"
M(+!8$MVT/1\X.1(1D#AQ+F/:4]V!T$98[CW[[](]7='_P@E<#+@/!)[*4$T;
M&6ZPR[D,N%&^0[K\H47-3'#*"_MK=K8\5;(B>HFJVU=-]M:MN@-FZ,]/S[YG
M/GI[<?U*F>CB^@M]<W)ZOM"W'E/:Z<?OSK,GV0*G18!N2#7D.S(WZHAREO'0
M2]8F(/;50@E;,,\8 ,]"4S9Y2)REN&]3H%^!36'^Y.IE3J!P;*K('E=+T)K(
M7DZ<7?QWVR& C5/P^SHOG (\*\\9]$/%23;@"][KJ>Z>73\B4;)MH1?M7LK7
MK=)):4'U'$H0P&.9(V0\ZD#-%/Z?O*&CH),[^^EG6/T3/8$?3\Y@#9=M22X\
MT>3*IJQA-DX$TGQR4@%1@JN*9KH!-P)BAYR<PI":CYOFK=#>P^F_('(]KI(5
MG46>"),_^3G[C-8"&31985A,S:X[Y1\(FBJY4=2_.>;!6U76-44"\%^S$$VO
MYB5K&J8>+H[K<61ZD-,P\4.I#J^L1"9=6#>T-"AO8+3"2+"C\A:PMI1CN=A+
M:?$11"2I\@8.9SRHH[<)[,>KYOH!^*?A]'&/.GX9$_"KHSR/JQ/4AB+5Y/S)
M;@='>RA- 6NNLA(<YU"JH3*&G#X],LCT(X5)!S#)3/?$[\"G5)29 [5PKTYS
M'Y/CH[&PM"/N=BB5/2AY#5D"8^ A'\!]8Z0\26PZO*(@9"HU^017*J26<<$F
M!8/$1<(FT[!^;B\Y*&8N<-)<-AY4!5,Q\"<1&+&+6(/.NU(FCRE@>VC170H8
MH(YJ;>WZ!.-X+=L@4NKY\L<$*64!.TW;Z)_#\2SVD<8YM8X.(:Z>QT^&@*K0
MA.,&RPYVCR9-4/AX; UXN:"@T?R+#!!01VN#N(H?YW%?PU7,1&FOQ"!>6X#F
M@.$DEXD,U!ILE4KS$&%U<=]IEA5K'E+N:9(6(\"B?U!(>9V$E!],QUDW^(Z0
M=&]1A6+-'-D7]C$2JK1H9:M-LD]N+C)-@M>R(9\:&6/ZN-QV]OT+^3]A=]F0
M_-\3D+#>'+%X@W8])C=0K0E-T'48Y3)^@JMAD6D)FLU>FNBHMQ-:>#8&Z$S*
M0));%'=02PUEPHJ\SB7WM:7S.*JCD+(IUS(&U6]!MZA&C>5A9AMN:G$<GG'C
MA5V0B1*U?8=C06H:N<W3C$@B8:FJCFII)%S#%SGC%X21$W/V:>MP4XW4K/>/
M4R"$<!%E/5B.GU-<5H>D1A87'V/Q=#QNRT&OM-C"/FK.0!%8VEET3N.^88>&
MJV\4-DV<J_0(TI[RYPPG^V#KZ1 -/U=<<FL%2YT+@9+]' A53P@Q"9&3LIS6
M+C5(L:.'9*U)]&(J6\K]6IEZ[)\, S*KA\#:UO$(0WT+08B#@68.U:M:8;O/
MGL6F<]C>Q7$=PO(H=QB=JD3&U<-2U\NZ2U0TAB]#1Y*X[I*Y3RVD8@(^??@2
M.WHY>3JVD0'D.C*-%-B(XT =(HIF2^+ ))?//8/\(OJX"(%A+:MA0-\J:(S5
MTX!J!ER"?H!23-'\@E$>+(&Q1XW$W3@%%2Q*0S^*:ZB$F$)_$*R8E\[P;J[Q
M.Z=0I87R&"('6%:(_P,+AU*EMK8JPRJP<M!/)C6' 9<CP):SG0/@+;_MDS-'
M.HR]F8$G;BK^T0D6-)[16*%J 4O,N;]FJ,1&8TDE8C DIR]#E28ZMM3TC:TM
MF(A&MP#[\8- *Y-SR"KMM+D^3.=0(E@YM!23$TOCZDCTJ&(28_&[/FK&F4<(
MQ[^J!V4P=JNEYQFT"A\7V-P5]D-1*QS-$1 WKSZI=,62$W7-2BFK^H84I=/N
M#;XI9O2H;Y(&9ZN"2$14%Y(4-68E-QU((!K X=@&8LWE^'396R?N)LB4CA!X
MU34W5=<VW"OT/@(>C4JG"4P-"/:,XQZ&ZGND4!F>&S&G3>BN,+,B7<;J;8;W
M\51 H1G87&2<V/6Y!]\F!#V<1]?D4U-R-W=5#BBU8-TR<ALV8&2D94WCT+9;
M8L9H.NH![89I*E!:VMDO8_JMMLAZ8-:>84#<K:1](\[_'$FA0SQVR\TR U57
M8DMU1?#K1>;Z8HE9)]3=,Z](:A.$,;>8SX7D\9'WO0RTB'9@.,I><:=]_HV[
MZ*1U25[E@V(VEX*B]*D7^G%(0BDPAK7NXVBT+6K& "W894F7]82;:E<,[Z7"
MX2)E0U/D"W"-6%'T"TWNCLBF-!A^L<S^79NWK>BBFA%;1\DV:2L*L<7L>/#T
MA@T->9D"]!@\Q7FANF;367-'5H3,ZN;ID7BYQ12=I[<+U*J/6MF9<"_42\(\
MTJJN_%:K&'D40*YCS835Q\4@W6*+D7_,?_Y[WC%"3C/(::9;)"QVXB8(9\V5
MB#,C/;1#++"US383- K@I[(0"!  &M")6D U7;A 1&3,V;!U-6KMF[C#P=%A
MK@6U%875;<'P;/5V8AHMI(STW'8V>!48^AAN&:K"@7F& >2LZ@V18=)0?3&:
M^"&3:E=!\BYIWA19AS%(+%[040@V>?)00XNHR*,)&)1,9.)9Y0]-)\-M\/HK
MNF<C5E5FEC!S+P1AB2:89H")X#;.O&FDT J^B[91T! #-$7=-IL3QL?*>-SE
MU)3AYA);CT^Q!N_BRQ?\<N*_"\Q2O,O11(.%(Y.C<OQSP,J);M-P:01ZP@PK
M)L6!M2QR^C[I'VSMP^TY(BX#0OC8 KLZDG^%$*K*FTN![E@#.5GDXX(>CB[M
M %@;7&=> =_"9+P&"1FOXATMVB%A6FQ2?,A"'=N &VN5$)+1&>S,*)0423_>
M75B2OP<MKQ>>7%CZFDZ.]&(1C57!6':SM.WL-#6#]P4DY5U=ST%'[$U0M@^$
MJV<^+G46(_]&Z_2?[KQ!AD^%ZOPE!Y&"LHG-,<O[AM#^2HH2 SJ 7T:A$+2N
MX&YG$-1\%\+@Y@(/,6^GIF@%;+:N>FHSY^MCY)Z" [4E$ZB,X+'ATB&^/XJ*
MW2?L,Z$TP,?:.B'IP:3Y!G>AG22+J++QF@?LQ5U@N!OM:T"V8+<9<':8=RG8
M&3PRC,P[U)_3.QZ"KX)[AX64B/03%@,/==,Y;W%V\BWZ@6A/P'?U7[W$H57#
M%RE2:4C[],1'"DV11])]H-!*B..7V4>U"8;?TM4F'BAUN(6.$] ;, DAXJ(!
M"@!%5'+IE3_.5JR8H6);%OE^1)WT:J:'W"CG0^@3TI@=7ZU$0?_=,+-E]EO;
MP*R@!KF)$B_B*8RYU#88L@#*'%%K.>GE8$W#*A5?.;#M?8 <C.!$@]WX@+W4
M;C:.!CB0X*4Q) _-F;2E415:%TNMFRR;*.77;D-+N#(<\R%XNYZ_Y;>2]. P
M  2FQ;P']5%D^0I! (H)$#\(+4N'\%#;3!LGU?Q4O$N-A"A*@JC_8ELY6S<K
M@?WI[DZ\H*X+.8O+#Z_?AY0@73+SU3Z-;OHF)U0''DM[Z(H0;&E1BKT1N35.
M.P_$ 8+1M;-KF!&XI 6^^>:* X5EW(_6#3O,,0GA[3T !)DRL9+0/H G]H<.
M35*X26^T-,D]T#[']"&S43I',3&VZ -[]-1P]+'3G/HU=1)<T>V C?3:6GP3
MV^M7+9;"2 GC\]A11]>9$(R7O'/%A4@:3WIC,:_(GJ\4;('+]VV( A9H/G'I
MDI[$#NR%%'V!*L!K)[#3D[/OEM]]]QTU"768<: E<[9AILE T1JHM4UW\#0^
M2I8<"%480NT#H01*E6-#.J/RT8KJ4C&=P%4+U(?A*HV(,1?D"8_-%\\B%2)0
M9KB%ARV(66R*,E@BX>6Q A?\W3E7$ <0)XRVB3B<28+#D+_B38X)Q32('P$P
M)I%6.1AYAHW?J\L9YL').= <;>(>]0@34$P%T9AQ2 B BJG\!5>UR(YP+7>*
M/"3M\9RP-S*E[/BHEMF7O5A"Q"D),#[(B<E8P/^:DVG&>]BQ LGZ%K4D)WGE
M22(O;.[9V>+\^;/%]Z<_S7)TK]E-K6\,=T-KI%LLB$? *@2T4T C3VRR3[!P
M=O;YO1A"+%G?B)-V:9VT),BT/:C$F^8M[;?/;ZF:K8E,E$9PDMJC L$P164^
M\??ZA\/+ C]/2.7$0C3@,0V%LN^]HL:GBB1DZF1YNA<Q+XIOH:TMHMJ=6GN*
M2(ZH_A$8*)!" 9^$D/+8CRJ.0N@<8RLNB\'KJ>(UJO-%\O1H)]:X)IA4<B;W
MKSJ=_<],;M)TID9]+R!TK@=@<.G'H0F%]!B:JF^6.F#BDZ=.0=C^ ]@S> 6Q
M/"Y\(]W*-TPOZM]LN[63BQ*&_B6,<>24FR2YD_C8(1++,C"S(6':0NO_H*V<
MGXCUL%=U#ENY+L!/0/5 PYPDM].-[V\;5[70JE8WG$^3*A:!^[EQY@.>(1NU
MT.R TWI]^B2$2:9;5)I*Z':KFQ:SZ'*?9O!*:66@P=H.\22VE8JN"]:,"%/(
M#)'PA9G1/$)99L:G\ZV=W+_"UL=1@@Q77AF7O] ^JXA2*T'OMK;/ >]D8V@<
M$1)&_?U ]<*X"+S3T+B_)%G)NL@IO6W"HF)_J=S<$C)!!E,XW94J:B^VN1@\
M4(KN$[_=TX&@6(KWKG=.D/8W'$YW%*VI9T%>W==YU9Q Q%;5=:YO)WH7K_LY
M66,U:E"D';:]D]$B)(^8/[H>^W-'>ON8'2M,OX',4!]O</S8SM()!#G0)!.N
MG(46OU97*6U#P*.JHY<X060:AJ\^H>\HZL;Z/Z]H>,=BO(9H6-/A;"9%EI3B
MTX$(>##RA\O6Q8N?"O()P-YQ12M]6V/?%GU QV$<Q<%83:3NJ\]88DL$GNZW
MUDNZPK5?+=-<;Q/$9:0WH#'V5WJZ^OS;K"X-D"%X:.XN656G@>H2O>,K: K(
M&2K8O9$<<-2SQ-C#O/R=",!9?Q?G ]_VT#7>] K<L?!!_YVY(Y!T<H"D^8!)
MXXK]:/YA%M.'\@'.SG>D4ZY/@I>Y]<@%=]0%1R <+I#3Z/ %2;#B@%V3,XOC
MKDFM#I+,4;AL1R+\.]I7NT4M3.D(XNO/4)(L87DH-&ENKC\,-QY5:[F:C2Y9
MJ*NO**>$<6*0-XM6+'@DZ7R],<CRY02*[+X)<EHUW:@6D.!T4[HV^=-QNV^Y
M8GTH"1]OE+MKY/E1J>P>DN22AL5KK+IJ=>A)LD53A3&D^*GMCI^5=^3=47*?
M;\\^IMOC6].<DZH8+OZ$%W^"BS\QF"IY'E0-W^J37&&DL E,<N.=VIR:U[ME
MB29$C.>GV;\J=6"S*\<I(4&F$&DQ050?!C^QP+]#4!SON# G&!F.HYN\)A$Q
M97_P& 5L96G :<R\Z]48D[M(X1H/JRK/_=$;]LQ%KX2+=VC!]#HQ78I5N:QD
MY^^C)^$V#9W!M6SX#ANK>P>MU.&B7K[W?D R0NI/4"QN'@L"V+.V1),BS:^^
MXD8>A70RR@L]=@'+!1E!D1]OE-3# ?R-3DJ]G^0NFD^&X^YT5F-9;'2-3;QH
MG/.-_N?L\=D3QD*MVH )&;R5?IUOP'L)=\_!SK^Z,L\^0NB]RPMWX&NR=7'O
MI)?_,9CB[+<6]O<#(T,?GS_)NO8(U#VF$WX 0KVJ@,#1C<OEQU[P)ON"L\[:
M@Q]_LX)J9]E'[6?!.=[QT]E%NN(P0[*J6=NMJYMJP+@7SJZYX(OKRY *YM:E
M[T^_7X2SI9U?!D0>#7Y)OXF$:4TS"+ZF RVS+P'N2:-Q!KSJ)Y=/( FZRT+&
MS=H5BV$ Y&+.J=U1TF!485AD?,>_56() B]%5$3C*"LRP<-*/JQ5G.(O'; /
MA#_&,%H 5RR3[B,+EHM55]WPM*XWI:'QI0'V,L4")!:'"]2U.DQ2WGX@5&M,
MMD/ N_?<2Z?EBF)82)LALBDR$2>\X :XT05Z%OQ]QVBFSL+=9!#I;7*]+U9K
MG6:PHT)*@:5E=IA^ K-C?^&!HC);/%5NP+0( :!F8#<X_LT36_*8&SV8^>G-
M2*_@S9-A:U/"^X\)%O,D.4?,:'C"DU.:87K\5#,@GDLNI%;HZ8T[P4/G3(*&
MQR+)+'4<8+0K]EDT&A+1(+]'+^1,Q:CJ_Y#@3(@-#J$_!1*NF%$5H&CC^_AQ
M=/.(E:+^N(]I8:W'HU4)ZII_$R'@Q<.G!-?Q@Z)PK)F '2::8$0:X)%TR>:,
M*Z#+?D'6!3'JX0R37T1Y^_YS+.6_P"$?/YMX7C)DF#\^">5]BB?TCV0E\K,+
M1F%]B3^H-&U!!TJ%Y_,A8X%HQXB! CNZ2RZG'R&^1G@O'Z%Q0>N[6MDI(.LI
M:]/JA3R'1KKCG9Y96%@>R":(K!$_?9Q1-Y)QO(//3!-U^NLUJH[H-?/6</)0
MLS=8G_ N:X#J2?H&_P8'AP;!VQE.(VT0F(VBYC?!E/+ES_3/$6 ^U'-][&(>
MZ6H[1^7MO3')Y9FT+IY'7A^9"89)AWJL*O1[+(/29GCUA5ZJI]T5BO8DJX@_
M"<3=EU'L1&L; .VDZ"X$J+1/VD&3\QC<ZCBC 9+SL*90>JPY4]GUE9]N9^ *
MAGUQFD X_:;C*_U*AS?]2C&*3^->Z\V=@W,&F.78J,Q$*RTROZWV>X7SXUE1
MT$OJ(T(U*&LN7<4B#D%RN JFGETR^I2HF%$)C%>OT2Q-*6;A*SXMPG@(+08"
M.8BUTKO'QC8^21N*.S?(Q5CK1Q9/]AKZQ!_N6LF/<"36%C,G>O5C@-2;[Y%J
MTZ[,="L?^106#<NA/\_@9X9*Q3&"1 U5T%'7GRF(Y4=MP<(\0K5%!1,<#2.:
MQC'3? N$MHC('62)0H>.=,]Q)@1_+H<3%;(6O8ZYBV>E/XY#7Z"=D8._XV #
M<"DP@:"V>)"5HU]1@$!?HXV[ATF@[,,37AGOU(7?%!GF3L?\28[?Q!U]4]Y=
MVI?-.4!S[4N"$)6[N+F/@OU5$[30(6'"B46=#*4DAB=^2#)MLLSYMHT^IH93
MR!?!3,(=>+N*?E:DL5U-FE,1E'5IXNUY7E#E\J=(^C!J,I&$JOR;>(%&R^S]
M'3O!QTR8-]N<*MT1[*JZX?>Q!V+Z$D&=R=[LKUL*&;X<<60W1%2LG7'<&P;1
M7)8P](6&#&70+,.?%!VV%)RDRH,7$"M_/+M:<-K/0[A#C$<3?^$FJA2VK-4Z
M7L2_$%!+^N.FROIZ3^V(,_B>0*:Q_1V@CKH"(I!TS%+2J8(_J^;\OI6.N BL
M8=(3S$_&T-\3Y/0'05QI'X2M,AM)FVJ,U$+P6FQ/#GN]95@N7R:NE)^CG4ZP
MZ:\O"I9@;=;)OD,:9QGCP3DQ*<YS&FV 8)Z0YO2WS_1'SVBDA3$?A<(3$!@4
M5"MSD"M;S$.0G+K= &6@RQ#&F+DB(6:D%,>>R]7WZ)Z'>"5@%CCYAX)-823Y
MTN&I:><JKLMCED\P.\)SFG0,Y>#0WQ8_TK1 24D#N8FLCNF"\@F?CXVSPH5+
M,:]/U)]<(=.F;WOZ49')=K+*FY6%HS,_^\<W@M0X"2+Z*_G!/:06D I_IW;V
M 55/ZAK'44V/7_Q5CJ#]K/S>D3 Q!?CI%0R J-AHJ'[_Z >=]6;9?QS*C4(8
MTS3@W"P,:9I?ID433WJ'(U?HJSNF"WSH4BP*7468HPANDV%;9WZ0>Q%^/-&8
M$+Q*RVW:OC(7XAH%:%H)!19#0*=99RCA, 6G$)]CC-.X<+'[? [11NU!*!-8
M_DS''8NWJF"6JSQ<#'Z':.LFX[6[H58<]A(B&]/;%?VNM-6-U70$%4Q%&1,K
MO#==.(@<PMK0'[Z+)6W]DOT+D\)4[P2A<!KZN-"=,\#@)[GS/Q2)B@WPILM$
M4P\S7?Q6.-E7I.<:O@4E5"SQUT-<>8?6CM)DP_/[7L3L2=#8#-6K1.]S@;F2
MVTP(F(26';1C>&XQJB7$7\IFWX#%F%V#Y4P/WXPG,>VIA45,^$G#@0;@>CWC
M0:C C'?'*2^BUY&P6,)7L4#!MZFG;(;"^O)I_^O+IY6'_Q3POZZ]A?_2S2"O
M\S[_]>4.?U[B$E0?_>)VT__RZ.R1^11+1K\\NCC[^>+\T5-X,S[^Z\L]6)OW
M>;?!DE3MUO#JZ?*'YX\XTZA_].T>A\0K&/MV1__<@A%S'3X WZ];"(SE#YS@
MMNV^TO)^_7]02P,$%     @ -8A_5%ZI?,:- P   0@  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&ULM55-;^,V$+WG5PS4HFB!U+)E9YUF;0/^4%H#
M=3:UG?10]$!+(XL(16I)RH[[ZSND'*T6;=(MBE[L(37OS0SY9C@Z*OUD<D0+
MSX609ASDUI8W86B2' MF.JI$25\RI0MF::GWH2DULM2#"A%&W>Z[L&!<!I.1
MW[O7DY&JK. 2[S68JBB8/LU0J.,XZ 4O&VN^SZW;"">CDNUQ@_:AO->T"AN6
ME!<H#5<2-&;C8-J[F0V<OW=XY'@T+1M<)3NEGMQBF8Z#KDL(!2;6,3#Z.^ <
MA7!$E,;',V?0A'3 MOW"?NMKIUIVS.!<B5]Y:O-Q<!U BAFKA%VKXT]XKN?*
M\25*&/\+Q]JW/P@@J8Q5Q1E,&11<UO_L^7P.+<!U]Q5 = 9$/N\ZD,]RP2R;
MC+0Z@G;>Q.8,7ZI'4W)<NDO96$U?.>'LY)9Q#8],5 @K9*;22"=NS2BT1.Y<
MPN1,-*N)HE>(>A&LE+2Y@5BFF'Y.$%)636K12VJSZ$W&!28=Z/<N(>I&O3?X
M^DVI?<_7_^=2%]PD0KEJ#?PVW1FK21V_OQ%CT,08^!B#_WZ<;Q*Y7KPQ)4MP
M'%"S&=0'#";]#MQ.EVMXG/[\$,,JGFX>UO$JOMMN8)LC9$I0CW&Y!\MV L$#
M*3IP67>O;X,=M298<I^KHF3R],U7UU%O^-Y QB63"6<"F#%(,"93$)SMN."6
MTTD5=44I, N9*_3@"W6DU)])I;6+33W":RR7*4^8):0+)_"  E3F%RUXSE$S
MG>0GJ"Q%^H/XK:+&LJA)[TCC(LE;_@:^Y9(X5&4HAOGNYF(1;^;KY?UV^>$.
M%O$\7LWBM=?-+P\?MO$"-LL?[Y:WR_GT;MNV+Z:NR@L2+9ZHH_033<"L(DKX
M&GK]Z#(:7GUF^7.*WG^R+K;*TF']Y=B^%/X_Y/W#]>6[X;!M_(NLOP#L9*;I
MRM@!88<H02J@WI$F0VUHQQ[=9NMR_:4;2"LO#7?S)V3DBFY& '4X%CO439=[
MV9#1[7A!)TSKDP.>;Y[$HXA#@],:*?N<^R7-]D153NDE.WGI.Q[:U!5%P6=Z
MP0S!65EJ]<RI$="E0DFV9952NB0\EZ/)E;;?.P&"9)8D?Y:MP5=:HP-_-SO"
MUE@N4._]XV/ IUI/Z&:W>=^F]5C_Y%X_CBNF]UP:.L^,H-W.\"H 73\X]<*J
MT@_YG;+T9'@SIS<:M7.@[YE2]F7A C2O_N1/4$L#!!0    ( #6(?U1L"B*?
MA0,  ) '   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*U5WV_B2 Q^
MYZ^PHCYLI6Q^ H4*D*!PNI6V+4>[=SJ=[F%('#+:)).=F2QE__KS3""EJUU.
M)]T#Q./8GS_;8V>R%_*SRA$UO)1%I:9.KG5]Z_LJR;%DRA,U5O0F$[)DFHYR
MYZM:(DNM4UGX41 ,_9+QRIE-K&XM9Q/1Z()7N):@FK)D\K# 0NRG3NB<%!N^
MR[51^+-)S7;XA/I3O99T\CN4E)=8*2XJD)A-G7EXN^@;>VOP.\>].I/!9+(5
MXK,Y?$BG3F (88&)-@B,'E_Q#HO" !&-+T=,IPMI',_E$_HO-G?*9<L4WHGB
M#Y[J?.J,'$@Q8TVA-V+_*Q[S&1B\1!3*_L.^M>T'#B2-TJ(\.A.#DE?MD[T<
MZW#F,/J90W1TB"SO-I!EN62:S292[$$::T(S@DW5>A,Y7IFF/&E);SGYZ=E:
M4G^E/@"K4EA]:7A-%=<N/*">^)H"&#,_.8(M6K#H)V!A!/>BTKF"595B^A;
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M\&X&#LAV_[<'+6J[<[="TP:W8DZ?3)3&@-YG0NC3P03H/L*S?P!02P,$%
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MGZM6O0R5]!7@/2&71*P0@L4"@8.Y0"TA.4&9+8YF3U!* =-1NN*$W1X1*"*
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MFE3%$=V=Q\H1K#Z!6;5.^:5&^;3%+]S%^&[ZV #6>OC(F-/6:$UO^?Y\-87
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MFIF?3Y1WRQ^?C,QO+K:/FU^NW/AZ21-A)!?8:G=.O+;I$XJ+5&WX%Q@SE6*
MX7_INT:IZ0&L+Q1]UVHN2$#YDYRS_P)02P,$%     @ -8A_5*K8UY'@ @
M1P8  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULM57;;MLP#'WO5Q!&
M'S8@B"]QVK1( N3BH0%Z"=)V&S#L0;'I6*@M>9+2='\_2D[<#%@[[&$OD43Q
M'!Y2)C/<2?6D"T0#+U4I],@KC*DO?5^G!59,=V6-@FYRJ2IFZ*@VOJX5LLR!
MJM*/@N#,KQ@7WGCH;$LU'LJM*;G I0*]K2JF?DZQE+N1%WH'PXIO"F,-_GA8
MLPW>HWFLEXI.?LN2\0J%YE* PGSD3<++:6S]G<-GCCM]M >;R5K*)WM89",O
ML(*PQ-18!D;+,\ZP+"T1R?BQY_3:D!9XO#^P?W*Y4RYKIG$FRR\\,\7(&WB0
M8<ZVI5G)W17N\^E;OE26VOW"KO&-SSU(M]K(:@\F!147S<I>]G4X @R"-P#1
M'A YW4T@IW+.#!L/E=R!LM[$9C<N58<F<5S81[DWBFXYX<QXDJ9JBQDD+_3,
M&C4PD<&=*5#!;*L4"@/7G*UYR0U'/?0-Q;1(/]WS3QO^Z W^,((;*4RA(1$9
M9K\3^"2V51P=%$^C=QGGF':A%W8@"J+P';Y>6X&>X^O]I0)':;:I?YNLM5'T
MY7Q_)U#<!HI=H/B_E?I=?MN^E[IF*8X\ZD^-ZAF]\5D7)K/9ZC&90_)UF=S>
M)_<PN9W#W<-5LH+9XVJ5W#[ ]6(R75PO'A;V=B\3CV5*)S/=RRR/2I5*:E!M
M""!S("_(94F=SL4&F+8V>B^LUH0^O)DCI$T '[@@B-QJLNB/ER?S9);<3$F7
M=3T^G!Q$V;R82@O'D>$S#96ZLI).(>STXCZM@[#U+G'#2N=:*YFCMI.$##F2
M[K 3AN=P'KYZI[*R&;-F6A!HC0)S;C3$G3@(H=?I]Z+6NZE(KQ.<17 1Q"</
MTMA8_U:\4[CH7$16=;\310/XTU?F'S5WA6KC1IBM^U:8IL];:SLE)\UP>'5O
M1NP-4QLN--4E)VC0/>][H)JQU1R,K-VH6$M#@\=M"YKTJ*P#W>=2FL/!!FC_
M.\:_ %!+ P04    "  UB']48W\042,/  #P+   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6RM6FESVS@2_2LH36HVKO(AR<Y]5#E.4IO99,:59&8^
M;.T'B(0D;$B"(4C+FE^_KQL'04KR>*OR);%('(T^7K]N\.7&--_L6JE6W)9%
M95]-UFU;/S\[L]E:E=*>FEI5>+,T32E;_&Q69[9NE,QY4EF<S:?3QV>EU-7D
M]4M^=MV\?FFZMM"5NFZ$[<I2-MLWJC";5Y/9)#SXK%?KEAZ<O7Y9RY7ZHMK?
MZ^L&O\[B*KDN566UJ42CEJ\FE[/G;RYH/ _X0ZN-3?X6=)*%,=_HQX?\U61*
M JE"92VM(/'?C;I214$+08SO?LU)W)(FIG^'U=_SV7&6A;3JRA1_ZKQ=OYH\
MG8A<+657M)_-YI_*G^<1K9>9PO*_8N/&7CR9B*RSK2G]9$A0ZLK]+V^]'I()
M3Z<')LS]A#G+[39B*=_*5KY^V9B-:&@T5J,_^*@\&\+IBHSRI6WP5F->^_JS
MNE%5IUZ>M5B,'IUE?N(;-W%^8.)L+CZ9JEU;\:[*53Y<X Q21%'F090W\SM7
M?*NR4W$^.Q;SZ7QVQWKG\6CGO-[YW4<3[QM3BBO(VL %Q)^Z78LK5JQJQ+\O
M%Y:?_^>.#2_BAA>\X<7_K\L[)U+@/;>US-2K"2++JN9&35X_.16?W_WQ[M??
MWXFO\IO*I;A>2_AAIKI69[+ D<I:5EOQ49>Z5;GX4(E?9-4AM*#!V9-CT:Y5
M'*2J5C48I*O6"(EH6#5*(;A:\9"&_?S3T_E\^L)O=!E>\N/9BR,X);1V/S$>
M#M8**QR+NFML)[$A!-BL=;8>R+=J\ JS_1Z2@KG($0OJ6*C;K.@L@E<4.@,>
MX!'+0_,;BCI:DA< MBS\&'LL.CAF(S+5M  G899"MU;4LL7!\-;](61=8X8D
MB+!03"Z^569SLH;EL6@.BQ:F3B6E \V>O+ (QJPQ"PTWHM>-K%DA(L,:.L?:
MXOV'7T\>S2^.!1;D5:%U*[Y>_LL]!:#RNK XW(;V/Q:YEJO*6&V/W9KNAZ"1
M0-R6[85SY-HJ()&%-<6Z*V5E3\771)G0@E7?.XPNMD)B%@*4SP;G:B6IF38>
M&YM6^RUKS0)*@P,](P74C;F!#:*P80=RHJ(P&9TS*!B+FZ[)(%9K-K+)+=0'
MIP-HZ6K%LY>06B]TH=LM'\-IE]Y*855F(.'?:?78J_71\,3+KJ'A\;"'SG?9
MK1#ZC#!T!H0^T@NGA[K1E)7H%#5<(8A)!P^+>WEY+=(F%-\M@1U=PT>@_(*U
M<'[V3EH(J8>V\3872T*BD1J]E)H25&::7%:9<@O(@7B%A'_0KB%"+/(H3FI-
MH?8)W:A55\C6X$C(7;##0;%."3E^-3>J=):? X)W=+>!ZT9/6I&YL8"JY*)0
MXQ-ELL&F( #1,[S)R-4+H$1%>E8WLNADGYE9<Z?B=XY96I%<QY*;[+/E$-P8
MS'(7L%:OJC[()'EPWN&\?5R:NH40?V$"Z:DK(*4D:B"02R&%=:'I=Z2,GPL(
MV1.)K '.-5JR/LEN88\3TJQ>PEU33R'+#9U5%M8D,I/?DX1R$!^V[7)69VT(
MIS3";3OVQ*!8?TY 8)FBE@1>XEB(IC24@D*&:F"-IQASU9AU%<'.(\[H'!88
M9#G: %*PNJQ6,=+&WGSYY4H\GCYV/HPC ])=H,J6-\]"@LY,1[FJEDV[#8YX
M+&@#SX=4,Q0#^ 3]++4/^Z4!,&TH(N'W9*>"CEQJPDN_%WS3JO:0;ST7#V='
ME"-W\@XIM[-J;SK@1,2(C!0+D@EGZ=S6-:)@FQJ:4KQLD ![QW\A'LZ/Q.>?
M95F_>"N( 6@"4K),@BM=#(ZQ@V'^^9%H-X;-2JF,/(<R+L;JY1*YG\V2QU2'
MPT<Y1N@^/!,=:2>(2."+HS$"PK*V0S[='EPQ _5AUM"28; *S7GXZ$B0N76F
M:X<(! KBOT931F^5BJN[1^GA,U."=F!,Y!V_?+GRI(.GA*=OP],CYSU!3QNH
MABQCX49$D.#IK:YPU@C6'#V]#Q'TX6GJ[K2/K&2Q#=$4/<]YQ8L!6J7.#PLX
M"2K3CF?QLCXT6#JG&V"H2^&&7I;"KDU7Y&*AG+\R0%.PP.VX9J,(-&!%*S<=
MP:4+=R[6 $66NE5-AL/EP\ *Z3L-TT91I4?VB J)\F>RYGP UUHH&C+4I:F@
MM<IIDXX6Y\5A7K4$!>HVQF= !LY38UC9YV0>:CP^]>EB;U)+#\DARAD+? 0'
M*&CS<L$O#ZBSE&!'71UD[9%F@83JJ6L>^(_W.:?ED!1W07]7+!B7 B3L<D_9
M\HX1BU@OSE7Y].7\!IQ2KY")BXAMGA]Z9,*/ =U)4O3?"P_!ZD*U7&Z(3[P@
MT8JA=S4J4\!6BAPH$!Y"4":WO!W[BS<7SOQ S*:G4W##HF"/=6ZRA:C",1*4
MCHZ]N/)Q]H3&0/=K"M$(1KMX[O4Y=J"]"#Z4?BUI6!_'.T<(P0O&#6*Y8)*F
MRP4@F7\$J,^,;2.F,-^36>"CF3,* A2Z,JM*_T6.U/BR%MYM,LU0P)&@X1XW
M/CU 8&UR>J1NB>VY=."\9#?+I*PKND5?(/:G8-B!6T:-AJ5VV? @A>V6>VN9
M'V#<Q^Q![;HQW6I-M2;,-!OGC5/Q6^3RSXX]9QTPPIXH[U2^Q&+=P5PD["V0
M=K B+9,OPQ)]2KE.JEL:&8>@8(&?K%.)>EJO#FF!U68[S+MWT<$QX_:ZNZRH
M O?L:H*#NVH,)JH_L- 8L,?,,;V>?T:=N016FIS(M$Q12]URKECU=-%QHIY=
MVM%25 _P,EP,PQ&ZS$=LDLKVXB<* >>XG*@PHTJ ;;$57U3=>M29'GN NR3!
M<?*N\#FGWR3$+:=2\O^%PHJY C<C]^RYW=XT%1# 82J#Q5HWN?C>(2]@(I#,
M27"PEB.[.O?X41$QZ;7\TWPR"H+T78@!()E7-9O05X<RS]G_B/CL,N,1WQGW
M$-HD&842""%%'A6#H)3?0@;.4:!9[T\P2TOXZ9;MBF+(JMUB*3;*/J;]RG:-
MLHP@WQ^0/+E&P)P$_ KPGG5LY$&.C1#I=4+O'=JZ^#SA^"3!3@"^\/WOG4;1
MS*KW0/3^Z[O8H@,]]/59HM!46]0>=VR/XC(2BT&R9E7H!K Z=*PYB>:BH68.
M[A6 L.JI"@8H9G>I<J53;:@@#I;(K+M(*V(-1^0%D4/M?6]ME!]RATF$V A!
M-G*:'=]UI.+IZ:-(*L@T#\23TXM]-,/NYQGS&4_#'P  CW>@%\4V((=.2(+O
M1N)DX(:1RSMQ>^(+E.4""WA+84?"<JU&'$0&]NA.$_B$LH/41WH,H35D&5Q5
M>;L""Q=P#;NKR88CWX&S]2PMT/H'8KJCLEG"S$AKCFWVYUC(@H&5[R@L 306
MVE&DRSOCQR.U,K[NGTU^ITC?E4DP-Z)K4+2GQ(F^_F&%A6+MTO.N0.3WIH1#
M DR'[".J<6=_YW?GIX^CRO[&4YU]=OS7URE6W$B 74?=Z ) 3266)Z!VAR".
MF025SE3WR4+_Y=Q1+7%F(HN4HM+6+V'HK2Z[4L@;J0MV!UF2AX1(2OFYKT@)
M&KTVHW26$$=F:PU97+5I!V^E+\:1V[FRZ:O5G:+4$KVEC-*8A6]#AE925Q(C
M(:)_  ^2'3<0FJO0A1O=4$/KH*.)H:&I"@ \5!':?4GS0%P,ZY4]YADUL>"&
M+8FBX&N:CV/">J(Q6UF,.D )6>H)&]T5.&=U9Z7,E,I;ZORD-2=KC=3DB\@<
MV[7)#K'A*:NJXSH 3D<+BDH!OI%_8E/65U%Y '<0)I.V0Q?;DP#[C#7'=#'Q
M7\\)DUL#</HL*8RCI75.T=Q&-=##J#YFGA1FPD4<VWG %EC6$W>>?1K<=S]P
M?\!'"5*KZ@W?5 QH+=[W;\94Z])2XQ$\*>/"A@9_]+7H@5+C^N.>ZSCJJ:M%
M$^[ZGCG?)YZ($'9H&4NHE U.4SHS6'KHU]&RP4K[>YK<\#-%/PQ[XWVXPVE]
MJ4/IO97NAHN2_*>OQ['7Y;I<1&WJP$![[3VT2D%^^-[L_&CH'#[JD)!\&IJ>
MGJ<!YPR^/00 @[/_H$S?)T^[LST79T$&;FU3J.SMD-Z/ _R6T/S9LWU):.!Z
M].+CIP]7^[S->QJ_/G#S&TURWVO<WH82,5R=_)@KW+ON;H]'E[<4$)1-&C!@
M0_=46P 8V+:EF*%['ZM 3)/>4%T8W<K  0*D)?4V-X=A9*HCV9ZYJ4QSXBX]
MR5:&O]YHUW3UQ2TAUV'*4 RZ:ITQ*XK,P1".5DF,D46_;S!+K\G/WJ>N_9!A
M/SNTM((%!H'D.\.6KX3<N!X'[]7]XNL^IR-:9&OJ-:H*HMPCR1&TU+9 #%Q=
MSZ:S(RH*&FZ,9NZRR.D)\9(L,HQMLZ&K>.1"71()\0' S8^D)6!=[]4[=T2L
M ]([, R6X2:6SV)#O^=X1EKL=<>1[;L>A:=#D&W8APG,B6\"*(NCQJJX#SPB
M8:[E[X>[8P\%<"B>QJY5  RL$-R.*T3.(W7,(_WL0;BZ5#+I?\=M)D=#=(W]
MRK$?]7XRDE-3+AW!*HN%0V? \V%38X\(_AZF*K:C&P[///,14[]3E%"[&F?8
M94<!FZ1]+#O@+X?#:H>7T>UB6SAQ A7!FLV 5HS7CY 5J1%=%Y&KL V)B T(
M&-9&Q1N^@J V17AE#Y(J1^)!D9LM/?9_AKKN@],(?USBX'#DT]Y&GB;*F+.(
MJ?CNDLM4>& 6CJRYBREG"(_&%*[$&!O7DT-]Z]IC# .#90(D]SC<HZ^[@ H?
MZ0SVN3]&U:,F[#BTN8?7:\%U;];R1@WS4*[\?7R-($UJPK[BX>%>74E)F9Z6
M/Y*P;3)4*]OK( ^DH!=GZ.V[UPW,A6.U$;I?MI<DJ?SV%B_[X8:*#K*<]HT(
MJ+)6;4<=H[[Z*J1MXSXZ%CT'([*K$ ?679UNR+"N:).^=:HT]XE84RF17OOV
M;31%G+9ODZ7S.3BX5E2G<[_LV53D<FN]IX1^DVNTTU5$0[?%%55\=+\RUOF[
M1#! _/9N 70:8M XW611JT_E_5WN @0$@;#8IG?)<N<^*2UV7#,KK6O&]'6/
M(NY/8$7HDC?*U=O4F^3N. 0H9?--M5Q/WP61^[Z6/$N^0BU5L^)O;:U#*/=!
M:GP:/^>]=%^Q]L/=M\"?9+.B[D:AEI@Z/7WR:.)\(OQH3<W?M"Y,VYJ2_UPK
MT(&&!N#]TB"O^1^T0?S(^?7_ %!+ P04    "  UB']4Y>Y#9A<+   7'P
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M[# 3?U:*-TXOPT\Y,^V<KL+E0G"X00OP?JYA9WU#&[2_[9W_"U!+ P04
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ML>&MF.$_"";-!3S?"Z$O&V.@^4\R_AM02P,$%     @ -8A_5(%,!G27!P
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M:"6!&WYV8C]J"]@P+*HU;L1S&[5K29WI:;W&"6FQGS?)'QN380O7S*V-&0L
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MM/\5 Z<8@1!$@JL3#%X%9E9% F<%_$EG/K.0]I@VZS9E6YPB] Q,..<,5*8
M$EYV1$J^P7".DYR!D2<H>1'B!D)5 .:$U.,ME+*%'6^AT2VPQ,255 Q<&HXB
M0"TLENF(="CX&GYE0+J]=V<!P^H-@RN?61M0>-R$X#1(T=_OR#1SC.Z0*3_\
M&TJ ? $GW-0:_[WGD1!Q+TQ0L00'LB@-0P.+M,PBT:Q7T'C8T2C[IMPK,63P
M^]P&BXQNG,3NWM?9.Y)$Y\\T!9RZ/:IAV YX_T+<=#1D#T-K0R3K-YP!JM>(
M<H!]8]+]%YMBMY=(:F_=-EXPXFB#C%T?K!1Q,,U^O0DA65Q"7A:GZ!HR$>@)
M3I>2))EC.JU+4)I5AGFXX6DA1<!+Y[]<S)X]?6HG]G"/',_$( %LA)R8&<:D
MD(@"H(H</\P7@*<I\IEAHH0PQ^!"\,] G8KKU71\X63E1+3TR+T,SYX2200U
M1&C#^3][[NF*_A_<P&6/^H#A*<-9-Y'@>KN<2FE@X'K\C>:;%C4QP1DO[,?L
M?'ZFQWI4&<4JJ_/CE5$4?QY7-O=Y$51-]L8MVCWF>R[.SG]F(GYS>?U2*?CR
M^C/]Y?3L8I;)6P\I(/?LIXOL))OAGK%T(01A\BTI8C71.?ZZ[R2>%>JI5'<+
M33+!&NC@3(-9>0@IIA4Q!@FS (7&S,%9^9S*9;"6+7M8SD%D(VT[<0/PYZ9%
MZ"SG4'95OG0*+2\]IT#V)8<?@2AYKV>Z>S:*Z8B2;<MYT>X%EM'H.>E94':0
M0B?P6.:H9@@%L,90_U=>TU40V9S_\AQ6?Z(W\.ST'-9PU13DW-"9O+4Y!YB-
M0Z0TG]Q40(_AJJ*-4(.!!:26D[D<<BMQT[P5VGNX_1=T7 _+9$7GD2;"Y"?/
MLT^HJI [DA6&Q53LU%!DAD#Q$C5&X9]CAJ!135&1CP3_-0O1P'->L)CCT\/%
M<7:7]!Y2&H;$* CDE93(GA#2#<5>2AOHQS$&]:"T!:0M, ,&,5#"8(#%2M +
M@<(9B>[H;8(9\ZHY 026>[A]W*..7\34Q.(@S^/J!!ZE&%FY?S(:@@O2YZ90
MA:.\$ER*D&O#-_7VZ9%>#@1/F&0 'YFI*_L+Z)2R:E/H,:ZDK.\B<GPT9@:W
M1-T.N;(##:/.7" ,O.0]V(Y<0T0<FPZOZ!Z92NT-@B8N)<MSR?H,W>=90B;C
M!4]<>+=7?&R@I*D\!8@*/L5 GW3 B)I&1$/>%C)Y#([;2XNV6@#;M90L;5:G
M&.'0A!9"$I_,GR601(N,JYM:_]D?SZ*N:9PS:V41M/%)_$T?N1C*$UUOV4'I
MTJ1)_0]>6PTF-@AHM#V$!PB ILE=7,6S:8!E?Q43_NM+T<;7%AK>(SB)\B(!
M-0;$J-S<AS)>WG6;1<F2AX1[&KY&WWC9W<O9ODZ<[?>F'KCM_8T@JV]0A,ZS
M#T2^L(\!4Z7I/)N'DWURV:4I!+^6#?E4R1C5QXG(\Y]?R/^$W&5#\K\3X+#.
M7+&8HG8])FI2K@B;TK;H_S,:A_.$D6BI*(1-1)%1;T:D\*0#TII@BH3]R.FA
M8D.*$2[S*I>HX(;NXZ"&0DJFG.7IP1<$*Z42->;WF6RXW,^Q;\@E7W9!QD75
MPD9V1*E<[39/8T4)AZ6B.HJE 7/U7^18:&!&#EG:IZVU3]ECL]YO/X'@/\;Z
MCMYR_)3@LC(D5;*X^!@(2,?C@D"T2I<;V$?%L3DJC' 6ZU6[KU@;YJH;+9$@
MRM7S"-R>TN<$)?N@Z^D2#3V7G(QLI&XBEP-*]K.G>AY"/HI_GB0L-:NK'I(=
M/82Q30@<@_P"A-"<W4-_TO<&K1P";5O%*PR9/P37]@::N%2O8H7U/EL6Z]9A
MX2L[E0@WI:AJ-*H2'E<+2TTO:RY1.AW^&&HAQ727G$:J(14M\?']Y]AO@</*
M0QT9T.0#U4B.C1@.5)NFV,C$"4VR'%Q-S2^BC8L8)I:RZ@9TC4(063SU3BWR
M#MD!>F):N2/% +TE,'BL%J<?IZ!43F'.C_P:2JZFV"T$X>:%,[2;:_" @\M2
M7'X(G@,L*P0? @F')*X6_2O!*F"X5\DJV9@>E2-PG./ /4 YO^V3.\=S&%HS
M/4O<8"&B$2S83B.Q0CX'EIAS95]?B W&DAQ-;TB.G8;\531LJ24'%M5AB![-
M NRY$AA:B9Q=5FDTD.O#= \%@O!#LP4R8FE<'8D>581KA 54!XW%\PCA^A=5
M+T'(9K5T@P"IPM<%.G>!E9A4A$MS!"S2RX_*73$91_T$),E7?L43I=ON#/(K
MAA.I8IL&9ZV"N%84%Q*1-6HE-[6/P!I X5CR9=7E\';96B?J)C"9CA!HU=4W
M9=O47*7X+L)GC4BG"4QV#/:,X^[[XGL@4!EV'A',=:BD,K/BN0S%VP3MXZV
M0#.XQT@XL=Y\![9-<'HXB*^1K[K@/A=ET3NI&<N6@=FP!B4CQ;+JAS;M'"-&
MXUX/2#>,D8'0TIXG,J;?:'&^!V+M&"#%E8E:(^;\\W@4.L1#-U_/,Q!U!3:;
M**FL8):Y;CG'J!/*[HE7)*X*S)A;T.Y,D@A(^UX&FD4]T!]EI\#A+O_*];M2
MIBBO\D4QF4NJ53IX+/77(0BED"&6N@^CTK9X(@-!89,E7=8)E_,O&"Q.*=59
M2H8F_1F +#'7ZF<:61X<FYY!_P_S[#^TK85E710SHNLHV"8EA,&WF!P/GEZS
MHB$K4R PO:<X+E15K#HKKKZ,F&?=/#T2V_Z,G?/X=N&TJH.FE4;,"[62,(ZT
MJ$J_T11*'AF0DV@3;O5AU@NWV#3MM]G/?\M;Q@YJ^#H-LPN'Q1X "41=8R5B
MS$CU?A_,;76SC00-'/BQ* 1")^ ,Z$8M(IY:T= A,AJO7S0?I?9-W&'OZC#6
M@M**W.IFR?AZM79B&"V$C/3>MM9YE:*&(1 UY,L#\?0=R$G1&SS#I)7#Y6#B
M^TRJ-2K)NR1Y4\PA^B Q<T)7(>#RT4L-Y>#"C\9AT&,B%<\BOZ\Z&8B$'0BI
M U%,Z4PL8:)C#J&L1HBFAQ;ADNV\KB7+"[:+%N70$#V<2=74ZU-&#LMX7+U7
M%Z&GDT$J'$NRQ/9EY\>[CZ5(CC_B BYI :/9EW]JQ-2K$%BLV+R#[?>.$UD/
M1?;W 6%'ZMU#$QVTSQD&3N(,TWMDBG[4?[ -$KJ="1/WKL?'(OS%@:P^A+R5
MWC1Q.[(&,OW(\@;M$ WM'A Z&/2\ N[<9VP9<63?QIY:6GACRLA2/,],S>V
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MU/:S'UFT@6Z@6B2%6%M68\X5C?=W %C';8R>G&ST,R%@TX%UU4#4R%K 00T
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M:6CWM.*>ECTJZT#W6RG-1;$$W=_'\ =02P,$%     @ -8A_5 =5OB9V P
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MTW.+RCK0^4[2T+<;FZ!_P.?_ 5!+ P04    "  UB']4+J1^'JH$  "R"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R=5MUOVD@0?^>O&''MJ9&,
M\1<8<DDDDG!I'ZI&(6T?3O>PV ->Q?9RNPN4^^MO9DU<$@54W0-FUKOSF]]\
M['@NMDH_F0+1PH^JK,UEM[!V==[OFZS 2AA?K;"FG872E;"TU,N^66D4N5.J
MRGX4!,-^)63=O;IP[^[UU85:VU+6>*_!K*M*Z-TUEFI[V0V[SR\>Y+*P_*)_
M=;$22YRA_;JZU[3JMRBYK+ V4M6@<7'9G83GUT,^[PY\D[@U!S*P)W.EGGCQ
M*;_L!DP(2\PL(PCZV^ -EB4#$8U_]IC=UB0K'LK/Z'\ZW\F7N3!XH\KO,K?%
M97?4A1P78EW:![7]B'M_!HR7J=*X)VR;LVG4A6QMK*KVRL2@DG7S+W[LXW"@
M, J.*$1[A<CQ;@PYEK?"BJL+K;:@^32AL>!<==I$3M:<E)G5M"M)SU[-K,J>
M>M?D5PXWJJ)<&^'"]>%1S$LT9Q=]2V;X<#_;0UXWD-$1R#""SZJVA8%IG6/^
M$J!/_%J2T3/)Z^@DXBUF/L2A!U$0A2?PXM;IV.'%Q_"DR4IEUAKAR^*EVP]8
M"NMB8:R!62$TSEUP[L6.:I'>_369&ZNIFOX^P21IF22.27*$R<30;5BQ90-?
MV8Q5\$V4:P27&/BRW[O3HK:O8]F$[K2!QP)!'!BQA;#T0.>UJ'>P9JNRANM2
M4"',LD)1UD&YX[V5EIFLEU"I'$OFEJ-%366(#F/)K'HY!0P60FK8..9J <:1
M5WN;RX8\4 MQ:CL4V@!R<0"E%JLYZC:](.J<A0"VJ)D[J974.LQYQVWS5N=!
MFJ?>0B,2<R*$QH)F%H$_&L%[^DN&\+XS_;&BN\]!)<[P@9QTEL]@X(?0@Z$?
MDS1P4OCS\$91!<A2VAVDJ9\27 _&L1^0D";^T*W3H?_"0"XW,B>'8">QS,E^
MX%C0\T2-#-H:&9Q,X:SIEQS7"?<P9D;RBP)YJS!.HG*S/S<KD>%EE[JY0;W!
MKJN6)MR<=<L=8-^NY;]H7/+$ 86#.OK]MU$4IG^85ZE?4Y*;I+ODW9>B?E$&
MQZK@O#/[.'F8SN#[]-/=Q\?I;>] FMS=/4SO)H_3SI>U-98*AME2I1"EUT@!
MA%XPB+U1FL ["/U!""GE_!TDWGB8=/;W"B)O&- OB2%,_&1,F46=2;X:'R <
M##QR#LY(/0H[-Z+.Z"-"6^0'^;) :=VY* R]\2CE<[$?)5P=4C<[L3>.Q[P1
M^>'H%UB'$'O1,/'2-&#6H1\D,/+9@]2+(D+8AQ<;FBY/QY!&R= +(M9-_""F
M6D])''B#T;B%V= %:OS!]LHH]_;_\8,353]LJW[XJU7_J*PHX>B7BF]A;?"M
M*W#:1(/K"K;7-/GL$!<;7!H],J6Y2BD6?%.$S@K7I7+<T%"SXL^"6R^Q1DV(
M+(N<NJ3D#P5/'<]8QF,$#C&]+'>>NPM8K4JU0][,J6 RJZ@[,D9-';C=A'RM
MW:7\]08JS4'[=/W/%FIM:-^<G;^5HO[!'%&A7KIIR5!4UK5M1HKV;3N039HY
MY.?Q9IK[+/124FF5N"#5P$^I&^EF0FH65JW<5#)7EF8<)Q8T5*+F [2_4,H^
M+]A .Z9>_0=02P,$%     @ -8A_5'F_W)C/ P  LP@  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&ULK5;;;N,V$'WW5PS4HH@!Q;KZ6MN ;XLMT,T:
M<=I%4?2!EL:6$$E422I._KY#RI:=8.WVH8 AD]3,F3/#0X[&!RZ>98*HX#7/
M"CFQ$J7*D>/(*,&<R0XOL: W.RYRIF@J]HXL!;+8..69X[MNS\E96EC3L5E;
MB^F85RI+"UP+D%6>,_$VQXP?)I9GG18>TWVB]((S'9=LCQM4OY5K03.G08G3
M' N9\@($[B;6S!O-N]K>&/R>XD%>C$%GLN7\64]^B2>6JPEAAI'2"(S^7G"!
M6::!B,;?1TRK":D=+\<G]$\F=\IERR0N>/8MC54RL086Q+AC5:8>^>$S'O,Q
M!".>2?.$0VW;#RV(*JEX?G0F!GE:U/_L]5B'"X>!>\7!/SKXAG<=R+!<,L6F
M8\$/(+0UH>F!2=5X$[FTT)NR48+>IN2GIK]R*:%$ 9N$"82[)[;-4+;'CB)P
M;>)$1Z!Y#>1? ?)\^,(+E4A8%3'&[P$<8M50\T_4YOY-Q"5&'0@\&WS7]V[@
M!4VJ@<$+KN"MF"C28B]AW:3[YVPKE2!E_'4#/VSP0X,?7L&?,YE&P(H8EFE6
M*8SA0W%G2HET6RE=8E <%CS/29@;Q:/GA&<Q"OF]NO_7J/$Q:G:**DW45$+$
M\]*\VKZ1U4L:4QF@H!-O3-D'6E%-2U[0THXJ03@8D6-\SUY0T)EM;'4D"73H
MI2(J&OXN+<B%5Y+FT@9\C;!41TJ:[9E@3+IMCUJ?OC["T^<5_+&:/;;TENM]
M=UL/54ZA%!>CUL.)\8]P!]V![?5<:)M),+2#T(/VV>1C4A<.%^9++#@=JAK^
MVY7DR)J8V.Z@!P01AO:@VST'.N?Q+J1FY77"P9%@V!D$T+XALFXCLN[-[5Z8
MK63F1N.[_UEI-T/K]C"2)8MP8M']+U&\H#5](E5H3JQXTWN<573VC51V/*,+
M7RMA)WANEJ+WW$]Z+?ZEE%<DR130#8'YEKQ.MX11EI8-;#%BE23U%YJ3ID$,
M<FH1519#0CM,CYC,Z:?2>T.%N@/@;D?M8M32(H35PW*UO)#BFAH&"D&4#1'X
MZ8>![_D_Z^A^-[![[K#UM=392<VYK$244+]X1QX"V^^%=K_O@F>[Y#3HAZW%
MI<&!"4&<9(/N:;'V6IOZB*525J8J%=VR C O,_Z&>'1N8I89I19V;6_8A?M6
M8 ?NT![VNA#X=N#W[($_A.^)T;EH)'3L]J9=ZONC*E3=4YK5IB//ZD9T-J_;
M^1<F]BE5(L,=N;J=/HE+U"VRGBA>FK:TY8J:G!DF]%6!0AO0^QWGZC31 9KO
ME.D_4$L#!!0    ( #6(?U2V+L!/AP4  '\9   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;,U9;6_;-A#^*X31#RV0QB)I67;A&(B=!@O0UD:S;A^&
M?6 DVB8JB2Y)Q>VP'[^C)$NV)3'N5JP)$%LOO.-SY-WSG.3)3JK/>L.Y05^3
M.-57O8TQVS?]O@XW/&'Z4FYY"G=64B7,P*E:]_56<1;E1DG<)YXW["=,I+WI
M)+^V5-.)S$PL4KY42&=)PM2W&8_E[JJ'>_L+'\5Z8^R%_G2R96M^S\VG[5+!
M6;_R$HF$IUK(%"F^NNI=XS>W=& -\A&_";[3!\?(AO(@Y6=[<A==]3R+B,<\
M--8%@Z]'/N=Q;#T!CB^ETUXUIS4\/-Y[O\V#AV >F.9S&?\N(K.YZHUZ*.(K
MEL7FH]S]PLN ?.LOE+'./]&N'.OU4)AI(Y/2&! D(BV^V==R(0X,:-!A0$H#
M<JX!+0WHB0'I@C0H#0:G!ETS^*6!?Z[!L#08YFM?+%:^TC?,L.E$R1U2=C1X
MLP?Y=N76L, BM9EU;Q3<%6!GIA^8R11'<H466ZZ8W6V-6!JA&=-"V^M+Q35/
M37X+O4;7423L(8O175IDMKWQ\H8;)F+]"KU ?:0W#*R02-&G5!A] 1?A^->-
MS#3XUI.^ >@60#\L8<X*F*0#YO5672+B7< _P9_N;]#+%Z_JB8K/%J]SM]?W
M#+SBT?=ZO3G'*RF\=CIYZW9RP\-+1/$1M$Y?M^?[\AR^^I [50*1*H%([IQV
M.%^H-4O%7T46S"%[9"RBXNP:TN@H>Q8K="M2EH8"LN<>+G+@**/1'^_ *;J#
M4_VG Q*M(-$<TJ #TE+)D/-(HY62"20>Y"O,M\T>8A%"1J^X$NGZ J7 VY#?
M61IQM5,P*%VC2.A09JE-V5 FB="Z*HB](=S0IG5'"U1!CLHR^N,4XY$?#"?]
MQ\/-:@[SJA%'\0ZJ> ?.>&'5'[DRXB'F".0%8"H>(:".\#,",=$&X%O@?^_K
M<G_0EDK%5/X!.HJ)3X?>N!VD7X'TG2 _P&K'4K<NG-^8\[4_PD/O9.'\QL*]
MIF,ZP.W AA6PH1/8=1AF219#,D96DD0H3!O&81,C(!R/_1.0;>,\,J)^.\J@
M0AFX]YCI39Z&H3W@7S+QR&);/&U8@V8B4CH8X1.HS6'C<8 [DG%4 1T]D8Q)
M J5^;[//4<OCRMWXN= +]FK-])PQYL$A((?,YDR6LP*HIY#1Q6F)N6IM5DYS
MF"QX3$9!<+Q1\Y9Q@>_9O^.!;\\8>!SR09N GRS?[9Y7V<IP!<4296'.FO^.
M0F%I7K2N"F[D)6V$.F\9A;$?=$9:ZQDF[DBSY &BV[<PQ29G6\BO,.?9O*<&
MW0".Y=#E6](-'03<2 0G^Y;8SJ=?7(LB=JOB7:F#RT('%^5>N JB%B \>#95
M6@L.=BO.\ECP86=$R&V=%NMOTZ_J]5I[QZ;>X*!C%VJQP4^HS7JM^!J"1FL%
M:EC55"N 81, L?7< :+6$NP6DY_4(,U+6/ZY-5MK#G:+SI)]*Y(('D@Z\!;B
M64-NQ3=JX!N-.]'5$H;'3G2+IQ=FW-AITCDQJ76*N'7J([=\Q4LFTMM8&)0_
MX[5A($WM&':0#JEE@[AEXT>VIC?E7(<(NY;HX.G%S?8=K @XSFQD2$W A#X7
MDB0U<Q/WL\,/:F7FI/G<X.P\2$WCY(D'AY^HQS>D^6CBUF-2*P%Q*\$"(%['
ML31V9]%B:_?=M:4UNY/@V>19S=#$S= _JF4F38H^:9F/ =8D3=PD_1^[A1EI
M4GA7MT!K J=N O^.;F%6NCIJFVE7^=&:P>FS:?SI$XW_<00UQ5,WQ;<5VOG\
M3@_>.CT;?J<UO]/_A=]GM,GOK777/W@5;7^:>,_46D 6Q'P%AMYE !Y4\;:_
M.#%RF[^=?I#&R"0_W' &:64'P/V5E&9_8E]X5[^Y3/\!4$L#!!0    ( #6(
M?U1@&B#(D@4   T:   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,U9
M;6_;-A#^*X31 2V0Q")I67;A&$CL9@N0+$&#;A^*?: EVB8JB2Y)V=FP'[^C
MK$AR)#'>,!@-D$22[X[/O?">$SW92?5-KSDWZ#F)4WW96QNS^=COZW#-$Z8O
MY(:G\,E2JH09N%6KOMXHSJ)<*8G[Q/.&_82)M#>=Y,\>U70B,Q.+E#\JI+,D
M8>K/:Q[+W64/]UX>?!:KM;$/^M/)AJWX$S=?-H\*[OJEE4@D/-5"IDCQY67O
M"G^\H8%5R"5^$WRG:]?(NK*0\IN]N8TN>YY%Q&,>&FN"P;\MG_$XMI8 Q_?"
M:*]<TRK6KU^LW^3.@S,+IOE,QK^+R*PO>Z,>BOB29;'Y+'>_\,(AW]H+9:SS
MOVA7R'H]%&;:R*10!@2)2/?_V7,1B)H""3H42*% CE6@A0)]I4 ''0J#0F'P
M>@7<H> 7"OZQ"L-"89C'?A^L/-)S9MATHN0.*2L-UNQ%GJY<&P(L4EM93T;!
MIP+TS/1)K%*Q%"%+#;H*0YFE1J0K]"AC$0JNT3FZBB)ABX#%Z#;=E[(MB?=S
M;IB(]8=)WP .:ZT?%FM>[]<D'6M>;=0%(MX9_!+\Y6F.WK_[H-=,<=UB:^:V
M=<_ %AX=9VONMC7GX06B^,#6$U_!/C*=)C\=;](K3+98N7%;N>$+"-C86L'#
M5BM]2'N9>U+FGN1F:5?N]]T$/2S16V7P]0YTT:WAB?[#L3(M5Z;YRH..E6=,
MKQ'_GHDMBVUTVW*UMQ#D%FQ_W$XQI;YG?R;];3T%3<GQ.#@4/$ Y*%$.G"@_
M<VV4" V/4 B VT#N#?BUI4DKQ!8Y!T"_!.@[ ?XL9;03<8Q$LF%"V4)M ^DW
M%N]8=UBN.W2G;\W2%4<B1:L"0=NR0\>R^ZBX) Z !26PP ELSI=<*<B77,*%
MK>!0ZO;R"AI%\QI=T$"'/4?21B7&D1/CKUFRX H0(A@/%,OWF2ZZ#/H;%0VG
M#?*H":@=RKB$,G9"^011RID=4AG*A"/#GA% XC SA#(-12SR9G^& &G8@<J]
MA.]=>-Y/CI:!O8JI/*>IVQ+C&0PDH<I8K!$0$H W'+JS07 -$Q>+C>AH_YXC
MZ8>H:OR)G:@>RB0J.\2<R^5YICEB6O/VPBOLU=/H>SYM]HP6P5<B-X5(W2%_
MY*A17%$#)D>Z%7,8W!!4P@+*P4;V#.82V&3MU5"8/2A23$8MWC4%&]XU1<8N
MYRKVP6[Z<3J7RO3<Y2!M@!J,1D&+@TW!AH--YO*='E;,A=W4->=V!P.GY[,:
M])KHI3-:O^H.M_K8I"MG555\A=V$]25EB51&_,5><.T3 .T'8$$C:H?C-\+D
M8D]<T1A^@\=DD@",)R/#;^CK/;>-V37>X(J'<'#BT0I7_(+=!'-KLP[3^B9;
MP!(E%4)EPXLJA#Q+(ZYV2N0P(J%S2'970S2$MJ^,&K$T>A$_I%+[Y!W&9\%H
M"&35.19?XQ:R&I-1$!QN@5F+7- V0<V/$#R,5T6"V$U1#UNNKN)8&LN[Z&%C
M2],U75>$1;P3%P&I:(FX:>F'* +29+!717#H7>W%Y0UV:DD9(/FW^YE4C$'H
MJ5-9]7+B[N4_1BJ;E.!,944)Q$T)':F\9\\BR1)7 *LV3X:G3EY%!.3_>B.Y
M)LU7$NQH<*0B!/(&(:!']'#4?JAZ)AF?^NB@:JO4_1YP?$AGM#GP$]> 1:O^
M2M_HKP<Q_0^]AU;-CI[\F*9V3N.>E'^$WC.CS4G:2?VT:JW4W5KK\7Q8:*ZV
M?,L6,80PW60 \/T=W_(84==I&ZU:'?5/G<BJ!U+WJ'O5^3Y:*+I.0NC1!S6T
M:HS4W1COW*\@].WS&:?('E6_=C!NORBY9VHEH"1CO@0=[R( E]3^NX?]C9&;
M_*Q\(8V127ZYY@QJW K YTLIS<N-/7XOOP&:_@-02P,$%     @ -8A_5)25
M9NC8 @  GPD  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULM5;;;N(P
M$/V549YVI6YS 4I; 5+I15NIU:*B[CZL]L$D$V+5E]1V2OG[M1TP5"KI$R^)
M;W/FS!EKQJ.55"^Z0C3PSIG0XZ@RIKZ,8YU7R(D^E34*NU-*Q8FQ4[6,=:V0
M%-Z(LSA+DK.8$RJBR<BOS=1D)!O#J,"9 MUP3M1ZBDRNQE$:;1>>Z+(R;B&>
MC&JRQ#F:YWJF["P.* 7E*#25 A26X^@JO9RF?6?@3_RFN-)[8W"A+*1\<9/[
M8APECA$RS(V#(/;WAM?(F$.R/%XWH%'PZ0SWQUOT.Q^\#69!-%Y+]H<6IAI'
MYQ$46)*&F2>Y^HF;@ 8.+Y=,^R^L-F>3"/)&&\DWQI8!IZ+]D_>-$'L&O>$!
M@VQCD'G>K2//\H88,ADIN0+E3ELT-_"A>FM+C@J7E;E1=I=:.S.9TZ6@)<V)
M,'"5Y[(1AHHES"2C.44-/V!N+T+1, 19PDS9ZZ#,&H@HX/:UH;5-D(%;;:@5
M" MXUE@V#!ZLTAJ^W: AE.GOH]A8JLYAG&]H35M:V0%::0:/4IA*PZTHL/@(
M$-L80Z#9-M!IUHEX@_DI]-(3R)(L[<#K!>%Z'J]_ .]:\KHQJ/9D<*+,96E6
M1&&'AW[PT/<>>@<\!+%GS&?G@^1_'^QIN#?(];\.7X/@:] 9S8?$XM;+"6#(
M;--FEM$2/TMG-WP/UDB4[B!Z%HB>=2(]D(54Q$BUWHG1 3L,L,.C:WT>?)T?
M5^MN^,&76E\$HA>=2+]*6Q@0[AHEJ&D4>L)W]-V-N_#39%=\DJ/+GNZ5NO2X
MPG^!_[7R:;;CFG7?<[2MII*L@'M>*_F&CFHG]*YPI;WCB[XK8FG_R*)WX\\K
MJ5P9MMUI#PBD N8D!+O'/PLDWNN9'-72OPPT^ [8ML^P&EX?5VW/W1UOGRZ/
M1"VIT-9A:4V3TZ$MAJI]#;03(VO?@1?2V'[NAY5]0:%R!^Q^*:793IR#\":;
M_ =02P,$%     @ -8A_5# 0Z%[' @  (@@  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&ULM5;?;]HP$/Y7K*@/K;0UOX#0"I *;%JE5D/0;@_3'DQR
M2:PZ-K,=:/_[V4Y(4PJT4M478E_N^^[NLW/'8,/%@\P!%'HL*)-#)U=J=>FZ
M,LZAP/*<KX#I-RD7!59Z*S)7K@3@Q((*Z@:>UW,+3)@S&EC;3(P&O%24,)@)
M),NBP.)I#)1OAH[O; USDN7*&-S18(4S6("Z7\V$WKD-2T(*8))PA@2D0^?*
MOYSXG@%8CU\$-K*U1J:4)></9G.=#!W/9 048F4HL'ZL80*4&B:=Q[^:U&EB
M&F![O67_;HO7Q2RQA FGOTFB\J'3=U "*2ZIFO/-#Z@+ZAJ^F%-I?]&F]O4<
M%)=2\:(&ZPP*PJHG?JR%: '\W@% 4 ."74#G ""L :$MM,K,EC7%"H\&@F^0
M,-Z:S2RL-A:MJR','.-""?V6:)P:+4C&2$IBS!2ZBF->,D58AF:<DIB 1%_1
M0M^<I*2 >(JF1.(L$Y!A>P;:,H<UL!+0\@G=D<) 6\8YQ%S36]_3*2A,J#S3
ME/>+*3H].4,GB#!TE_-28I;(@:MT028M-ZZ3'U?)!P>2]P-TRYG*)?K&$DA>
M$KA:B4:.8"O'.#C*.(7X'(7^%Q1X@;\GH<G[X=Z1=,+F=$++%Q[B>ZGWSV=I
M_]QH5W2MH)!_CP3J-($Z-E#G0* [KC#5GZ4EWW<0%3RR<-,:UB._WPV#@;MN
MJ_/:*XK\B\;I16K=)K7N\=0$9C(%(2!!6"&L[R;1E]7<'-U/CM3>:P+T/E?D
MJ D4?4SD"MYMR>?M"/S:(^R$^_7M-UGUWZTO7X-X2]:+AO?B<V7UO><>YGU,
MV!K_UO7=XQ:%46]'7[?5;0L0F1U"$MG>676:QMH,NBO;WG?L8S, ;1=_IJFF
MYRT6&6$244@UI7<>Z1,7U4"J-HJO;$]?<J4GA%WF>HB#, [Z?<JYVFY,@.9O
MP>@_4$L#!!0    ( #6(?U2>[+'P_P(  ,$*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;+56VV[B,!#]E5'4AU;J-C?"I0(D"HNV4BNQI>T^FV0
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M0IF\T$<\C0=P?G8!9T S>)SS7&I>V7:5+LRDY\9%$3>K(H(]10PPOH+0OX3
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M$Z#WIUS[4BS,%%-.K=W?4$L#!!0    ( #6(?U3BV^ >% (  (X$   9
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M8:#V">Z\5,KN S^3XR\H>P=02P,$%     @ -8A_5*H29F^- P  "@X  !D
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M0@JNOXKM!UH5-++Y(L%5^0NV5:SG@*A06J05V#!(6;;[)X^5$"T ](\ 4 5
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M\8V($?LV]G'=Y1NU6%SX" 4'7'NBS .;]),=U61'@V3W6I4VK9I1W<=TU.$
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M1&D%S/U""+W96 /UG!W^ E!+ P04    "  UB']4QG=5TS0&  "U'   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RU65UOVS84_2N$-PPMT,0B:?FC
M<P(D3M.D3=$@:;>'80^T35M$)=&CJ+@!]N-W*2FB8DF4UBTOB2WKG,O[=2Y%
MS?=2?4L"SC7Z'H5Q<C((M-Z]'0Z35< CEAS+'8_AEXU4$=/P56V'R4YQMLY
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M453Y.[+\BY:[[#W%4FHMH^QCP-F:*W,#_+Z14C]],:\^RC>5I_\ 4$L#!!0
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M(B<(!6;6,3#Z/>,<A7!$).-WQQGT5SK@[GK+?N-CIUA6S.!<B1\\M^4T^!A
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MKP'R3@&A"6A?Y1\"@1-U@'01> !F(+\!\D\!N28@7P="W^\ Z2+P7,<,%#1
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M]@FY ;Y?":%W-_D U;'5^"]02P,$%     @ -8A_5"#!B*@F P  -PH  !D
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M&I!8H95G5M8,*SP>"KY#PNS6;&9@S\:BM1K"3!B72NBO1./4^(&EO 3T!;^
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M=-M@AX7N[$"8#?I[SKG:3XR!IE<<_P502P,$%     @ -8A_5&R9M</$ P
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M1@#_7PBAWQ;&0'5>-/D/4$L#!!0    ( #6(?U00A^?>Z (  -D'   9
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MK0$F8Y@H:;G<H(PX&O@$XSCF+J-,P*,\U*7+[X<I6L:%^4A+OBRG\.'F(]P
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M5@'_!;Y?"0LPX31*_];@DQ*?Y/AD+S[-\3^#=.$G- 7^BB]8$ORS.Z2;$=R
M6CEH)GUO V)!@AR7H+[Q5L/'*OE8+?F,"S[3#9])FJ[JN5@*%PR1A6W3JZ=B
MEU3L@ZB\,[E9\92+9 GBESHZ]H%TG)*.HZ53R?%9)<>798ZG68[7,=K@.A5&
M"&/3(O5\W)*/J^5S-?GS83*ZN)_<? ./%U</X[JF7;5IZ'FN6=^T5S;M:9N>
MTB00 W'15O>^7]/HB2:Z?(&FU&>SDXR$E0H N\C) K4Z\Z#M$,]V+-G?&P6M
M,6T8$H@D:W3JS"T0MQA#R[.1JQ!6+9L(2V6%N(O\+E#;D%8M=TS&;<"VPY/"
M#O7*?KQ>%,#5K+6PY>'=\%0S);Q]2-NQR2(!]56BE?84&-7&B2EZMZ%Q61:@
MOBX4ZG-Y2O6110 ZW:B/E'6HU_5CU<=59K)#;&0ZV-N=-ZIETV27!0'J*\(Q
MXN,I-"QH"\;*/%<-&_@B6420V87V%*C[.=<8[N9F"ZSMX&3]0OKZ=;SR%,#5
ME,4VQO9N=*J9$MT^I.W89)5#^BK72GD*C.W&B=DT:V3%0OJ*52C/\(3*@V0]
M0:03Y4%2U5';M?]!RH/4#0 T/=LDGD=V)XYJVC0HLAR@P[8)+:0'J7L$QW)=
M9"E\5<,FOK*"(/T^XECI<=IR5@V5Y-R/M1V<+%Y(7[S^A_2H6Q4+H^P$83LZ
MU4R);A_2=FRRQB%]C6LG/5Y-X\1N6/1@6;"POF 5TC,ZH?1@65 P[$1ZL)1U
MW';S<I#T8'5;XGF.F:UQ=^9-C65#)N/*T=!A&Y@6RH/5_8;MF<AUT"[?O7N7
M40NL[<!DJ<%M#Z4.DBBLGDHU!*<:-@V&+%Y87[R.5QZL[E-<SS-W=;7&K(FT
MK%U87[M:24J!46W8,\VFU0R6A0CK"]&011&+#] +606PVXU>2"W&>BT>WEQ?
MBSZ;WM\,OX+)=/IP<7DU!@^WXMGPYMOC^&XJNK2V,]7-A/YXD$B))GJ)KNU/
M\"_HX+2,2.DFW4@WD=)-]-)]]%"0%J=/VYRD,A.],N\9BE,>'9#*27\W"W@B
M-9#H-?#XH5#7Y=J]*)$*1_0*MV<D3KF5(E+Y2#>'.$0J(-&O@X\?B9IC'-W2
MG$C))'LD4S\2IUQ96E(SK6X.\RTI@);^,.3HD;#4,_KZY951^=@<T>0E_\J?
MBE7(*N:;[\[ET_*7!!?Y]W-#FF]^AG#M)R]!G(*0/@M7\\P1K2>;+_N;&\Z6
M^:?K)\8YB_++!?7G-,D,Q/MGQOC[3=9 ^?N*P7]02P,$%     @ -8A_5*=,
M_!>;!0  41D  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULM9EA;]LV
M$(;_"F$46 NTD4A*MEPX!E+;S0JL:] LVX=A'UB)CHA*HDO23CKLQX^4%%&.
M)$;IY@)I))MW?'F\>WA2%G=<?)4II0K<YUDASR>I4KNWGB?CE.9$GO$=+?0W
M6RYRHO2MN/7D3E"2E$9YYB'?GWHY8<5DN2@_NQ++!=^KC!7T2@"YSW,BOK^C
M&;\[G\#)PP>?V6VJS ?><K$CM_2:JIO=E=!W7N,E83DM).,%$'1[/KF ;R\#
MWQB4(WYG]$ZVKH%9RA?.OYJ;#\GYQ#>*:$9C95P0_>M 5S3+C">MXUOM=-+,
M:0S;UP_>WY>+UXOY0B1=\>P/EJCT?!)-0$*W9)^IS_SN9UHO*#3^8I[)\G]P
M5X_U)R#>2\7SVE@KR%E1_2;W=2!:!C 8,$"U 1IK@&L#/-8@J V"1P;A?, @
MK W"L3-,:X/I6(-9;3 K-ZN*;KDU:Z+(<B'X'1!FM/9F+LK]+:WUCK#"I.*U
M$OI;INW4\EKQ^&O*LX0*^1/8?-LS]1V\ 1=)PDRJD Q\**J$-XGS<DT589E\
MI8?<7*_!RQ>OP O@ 9D2025@!;@IF)*O]8?Z^K>4[R4I$KGPE)9J)O3B6M:[
M2A8:D'6Q$V< ^:_U#X(]YBNW^4>BS6$T:+YVFW^*U1G L#3W>\PW;O,UC1OS
MOMG?CS?OF_URA'B_U]S3R=%D"&HR!)7^\("_54:D!)^VH$P5\.<O^GOP0=%<
M_N7PCAOON/0>#'GG>:X3JTX@LE<I%^QOF@"==(!)N2=%3/NVH'(;EFX-;P]+
M3=_JW\([M*/='1G.(X01#'$S\DA[T&@/1FDOX[(C AQ(MN\56_F)6A+\,]^'
MCX0^->I(9-B(#)TBKS3:J1 ZHJ7.UP^AUL>25+HX67';ISCL!,WOUS%M=$S=
MP2(R!0D[L(1J(NC3(LZ(4:6W>4=8TJ>A<CA[6L.LT3 ;OV$'KO3:@3!G51^A
M-FY?&Q*G52P!WX*X[9D6BJE,QUBE%%1L!8H#KNM&3TH=51,U"XF<DU>EN-N+
M.-7',-@)UE\D42>"$(8S&/2'<=[,/G?.?DD+*O3)H+,'D$0?2DPJ04Q+ >B]
M[I%DKY9YMV APM&C&IAW%0<^'*@!Z-M3SG<'C,:\2'2O!:Y)YMH!V#HXX0FX
M""UV(1JQQP:!NDJ2O3#)NJ."\>2AAGL/-M0)<Z##C 90!RVGH1O4(U-N7;MI
M[V 8^ .%"RUJH9NUY?1O3-.9F&(S65:U),,9MZY=MJ6@Z/'QL'EJU+%@BUWH
MYNX/%<G[VNE(,9:]T W?X_0'_X"+[99EC"@=S8VAU7=7REJ\PMDI2L)2#X[!
MWK-+(NJ2)XSF:(""T&(0NCDXNB2Z4,.#)8$LTY";:?5I5JIP]7F6:.@41$.M
M1M)-M-']TJIV-+(50A9B: S$GIE [U"W@X1S%,UFQR19]8R;A3T=Z6;$P.,%
M6DPB-R8_;76S5Z[*)*-96[6NWF5UP0<[2W*..19IT8C<:/R5*JV/QY3J1G K
M>-XT^H];J5[9743B3HA7/:-,ZS,888M2]$0?RXN#?E8V1X\6>]Q35XG5F]#3
MSHYCB$(\]><#@BQTD;L1O11<5^U_B.>L&T\\&"?+:O3_M*BHVZ-& W-;,",W
MF-MDU(?=Z.8/6_9B_Q0/Q1;%&(Y'I:19-JZF+VNW$+;S'I_Y.!I@)[;TQFYZ
MWQ0)E>RV*)L&^U3YU/&#6V\"\"EB:MF(W6Q\]"3L/H'PLQ[&L64?=K/O([EG
M^3[763GR^,:63'AZBOA9T.!Q3\_/?56SJOVZW]4<B[*8P6[,V'C^:'Y:JN#Y
M">(;6*8$[GZNE9_/#G'M^JA%Z8^PUWI7;/[8\)&(6U9(D-&M-O7/9MJ'J-[?
M5S>*[\K7QU^X4CPO+U-*$BK, /W]EG/U<&/>2#=_15G^"U!+ P04    "  U
MB']4^K.0+\T#   F#0  &0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6RU
M5U%OXC@0_BM67NY6XIHX"0$J0-I"3[?2KHJ*=O>AV@>3#,1J$E/;*>V_O[&3
M!@HA[0LO$-OSS7B^&8_'XYV0CRH%T.0ESPHU<5*MM]>NJ^(4<J:NQ!8*7%D+
MF3.-0[EQU58"2RPHSUS?\R(W9[QPIF,[MY#3L2AUQ@M82*+*/&?R]08RL9LX
MU'F;N.>;5)L)=SK>L@TL0?_<+B2.W$9+PG,H%!<%D;">.%_I]9P.#,!*_.*P
M4P??Q+BR$N+1#+XE$\<S.X(,8FU4,/Q[AAEDF=&$^WBJE3J-30,\_'[3_J]U
M'IU9,04SD?WFB4XGSM A":Q9F>E[L?L/:H?Z1E\L,F5_R:Z6]1P2ETJ+O ;C
M#G)>5/_LI2;B,P"_!OA' !J> 00U(/@L(*P!H66F<L7R,&>:3<=2[(@TTJC-
M?%@R+1K=YX6)^U)+7.6(T].E%O%C*K($Y%^*W#Z57+^2?\BR2@,BUF29,@F*
MW(,"^0P)P5PC"Z&AT)QE9":*9Y V"U#VKM1*LR+AQ88L,( @)2*LC1[Y!4J;
M!91#95KR6+\M$L20VQ>0,5=@C=K9NZW)#=5#*WF.%JK9WTQ*5FB<-JAZ>S\+
M](#H%,AMOLW$*T MO2AEG&)BD$7&"O+W'#3CF?J"/BJ+'+L::31DN'%-V:RB
MS#]#V1SB*Q+0'O$]G[; YY^'>^_A+@:OB:#?1-"W^H(S^F894XK<O7'V\!W7
MR3<-N?K3H3UHM =6>W@N/RIZ,21Q%0-EK9@DV#9)$#=)T,9F9:!O#9@R]#P-
M F\TBOIC]_F0MA8Y/_"CH3]J!-^Y$#8NA)TNW$,"6"Q7&=39JKGY/LK/#J[Z
MC:'^!2(1-=JC2T<B.F'8.XK!J41 _7X0>6=B,&@V/^C<?'V2B1;[ WEXJ#OX
M&38FAA=@?]1H'UV:_5%+?D?A8' <@U,YZO6#X2!L#P'U]J7>Z_2AM8IV<$,/
M+A%Z >[IOL11_\+LWWQ@X8'^:;T)_ ^/3(L('05A="9:^\)+NROOT3U6G2#R
M\ /R%<A.6O>%D8:7"-N^'M+^I0]-;>&0W;!/1\=W1XN8=R8 IMZ^G]D7,=I=
MQ=J3Y.8#U+R4INTQO<E:E%*GY*ED4F.[@L28'J)'Z*B'&?.>I5U]0,D.)) "
MGP!0-TA)#SMNA8VM4<L+B_8"*U+U-%=MT7,/FL0<Y,8VVPIMEH6N^H%FMFGH
M;VS?>S(?7<^0QM,59 )7[!O W9NH7A _F-QPO $R6*,Y[VJ L9)54UX-M-C:
M-G4E-#:]]C/%APQ((X#K:X$I4P^,@>9I-/T?4$L#!!0    ( #6(?U3;SW"G
MWP(  ,4'   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+5544_;,!#^
M*Z>\#"1&V@1*A]I*M# -:8B*"GB8]N FU\;"L8M];>'?[^RD&9O:"FWBI;'/
M]WUW]YU[[JV-?7(%(L%+J;3K1P71XCR.759@*=RQ6:#FDYFQI2#>VGGL%A9%
M'D"EBI-6JQ.70NIHT NVL1WTS)*4U#BVX)9E*>SK$)59]Z-VM#'<R7E!WA /
M>@LQQPG2_6)L>1<W++DL43MI-%B<]:.+]OFHZ_V#PX/$M7NS!E_)U)@GO[G.
M^U'+)X0*,_(,@C\K'*%2GHC3>*XYHR:D![Y=;]B_AMJYEJEP.#+J4>94]*-N
M!#G.Q%+1G5E_P[J>4\^7&>7"+ZQKWU8$V=*1*6LP9U!*77W%2ZW#&P#S; <D
M-2#Y&]#9 4AK0!H*K3(+95T*$H.>-6NPWIO9_")H$]!<C=2^BQ.R?"H91X,)
MF>RI,"I'^\G!U?-2TBM\ADG55# SF!3"HH,[=&A7F /?'!@;0DU2*!@9O4(;
M>LJ^MTMR)'0N]1S&W ^TEA$AQA$\H"-_P'Y,1E9FM#D$QL#5"]I,.@Q!@_5V
MX5OMCCA*67*$ROHHK!6:V.Q1=7KWFBL *A"NRH4RKXBU]WAILX+[#&,E-!R,
MV5NS&\E,J$,XN$024KE#KMD%IEY,+*L7)\YJ"8>5A,D."5.X,4S)ZG$.^1;\
M:#^^G>PAB+F?35.335.'R5[&2\R.(6T?0=)*VML2^F?X'^FDS1U+ U^Z@V^D
MA'-PN^GJC^]\#M>$I?NYA_VD83\)[">[V*N[X0+WNKX;@/5ERD$C;9.@(CT-
MI'[4K0;M+VDK[<6K+;F<-KF<OB>7NLX;+*=H]]78:7@['Z#@6<-^]E\*SJUQ
M6_\79]LT/.ELU[#;9-/]@'X.N^_J9_QF4I9HY^$!<9"9I:9J:#;6YHVZ"*,Y
M_NU>/7 WPLZE=J!PQM#6\1G'MM6C46W(+,+<G1KB*1Z6!;^S:+T#G\\,3]%Z
MXP,T+_?@%U!+ P04    "  UB']4\@OH4ZH%  "%%P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6S-6-]OVS80_E<(HP-:((U%2I;L(#&0Q!T68%F#
M&ED?ACW0$FT+E427I.QDV!^_(R5+LDVQ6=N'^"&1*-[QX_WX[LC+'1=?Y)HQ
MA9[RK)!7@[52FXOA4,9KEE-YSC>L@"]++G*JX%6LAG(C&$V,4)X-B>>%PYRF
MQ6!Z:<8>Q/22ERI+"_8@D"SSG(KG&Y;QW=4 #_8#G]+56NF!X?1R0U=LSM3C
MYD' V[#1DJ0Y*V3*"R38\FIPC2]FOJ\%S(P_4[:3G6>DM[+@_(M^N4NN!IY&
MQ#(6*ZV"PK\MNV59IC4!CJ^UTD&SIA;L/N^U_VHV#YM94,EN>?8Y3=3Z:C >
MH(0M:9FI3WSW&ZLW--+Z8IY)\Q?MZKG> ,6E5#ROA0%!GA;5?_I4&Z(C 'KL
M J06($<"I$_ KP7\XQ6"'H&@%@B,9:JM&#O,J*+32\%W2.C9H$T_&&,::=A^
M6FB_SY6 KRG(J>E<\?C+^QNP7()N>0[A)*EQR'MTG22I?J09NBNJ"-,?WLZ8
MHFDFW\&4Q_D,O7WS[G*H (I6.(SK96^J94G/LAC=\T*M)?I0)"RQR-]^0YXX
M% S!!HTAR-X0-\2I\6.LSI&/SQ#QB&<#Y!:?L;@1QQ;QV<O%/<=N_,:MOM'G
M][EU305#%K=>"T&+%8/,5>CF&77G/=!G,WR]HR)!?_T.*M&=8KG\VP$H:  %
M!E#0 ^B/,E\P@?@2Q3S/ 8C4@8>D7E\BNH6(HHN,(8@SM"Q5":A6@%1)FRNJ
MI49F*4ULVRG8;&M!-VK0C9SHKE<KP594,;0I1;P&<QPCM<$8G< 8>?IGQQ(V
M6$(GEGEEDF-+:<-LN ('I9"0,2^V3&CRM0$+3X#YOC>9A*,&6163EGG$)^&8
M3.Q;B)HM1,XMW!5*I% :8K2E66ELR3<Z_"1B3TS$J;3G?*4UZN#!T:%%*]RG
M\P*'X<<-ZK$3]6=3(R 1*)@6:EX5@"C18;&DJ:@V8\-=Z9UT\$S.Q^&D^SO:
MP:F$=SZ.[/@G#?Z).W ,E2],+L?=G&=/^MF*?')J21SB4XN?SM,!U6MR[+7E
MQW."_L0DQ$JLS5[%^18&K-$QJS4=Y%L0^6$?ADX)Q-_ H!NDM%C5$%YJO%KM
M"W@(DQ8+<3N106HGT(&A.<V8@WAQ6PKP*ZD%N"T&V%T-[HK4T-BF7&3 $GRY
M9$ 8JS-40*<+;%%"41<[ 9/ *4DJ8UY"*3@SC)A*:9B$%LE^^EX>ODMEJ/,-
MQF?1.+0V)J?5(\! >WZ/Z]H:@MU%Y#OR[Z96V4TL,K90WNT+)A[";LL-=M>;
M3@;.3RO=H=*V .#HE<1<R^[83>_?X9Y9K;)K]<KH?59ON1J[R9IX.$(?OI:I
M>H;N.M9E?<O00T8+5R_;TBKQ7H?]2<NRQ,VR/[4#)"[JK1ONTRGA9!QZV.XZ
MTE(T<5/T/7U*\S)'A7U#BJ,%0\!2I;W)J;4?\$_DB"G2$CWQG< >"P'58U6D
M__2$.!S4]Y6N0MG./T,;H%!N1^Q>UD?/C J)",JK(QD)H6EZEJZH:2L%<5<*
M?9SZ_WG2<C89O9(\:?F8N/GXY^;):8M/1N$D& 4]P=8R/''W^#^:!=%I,T<F
M. C"'F MSQ,WSS_  0/<HQMX )46L6#Z/)<6>Q,>0X4Q)K;@6&U1C9A"G%DQ
MNQ<>G7O>+ZX0:(L#<1>'-@1JR :5=GJY =AJS9ISE&E_2B45M$,ZK^MSEA7^
MQ'+<"X,HZB$>OZTVOKN)_Q'BL2&MESLX")K31A]'^FT5\MU5J)]/T+^= =,L
MH(\V8QXNW%8-G[P.IO$[=T1NXO[!%*ZU=^,)!]CFI6'G?C)G8F7N>24R77UU
M0]>,-G?)U^8&]6C\%E_,JAOA5DUU07U/Q2J%4T'&EJ#2.X\ EJCN?*L7Q3?F
M%G3!E>*Y>5PS"L<,/0&^+SE7^Q>]0'/S/OT/4$L#!!0    ( #6(?U3W,.;=
M'@,  &@+   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;,U676_:,!3]
M*U>1)G722KX@T J0@'9;I55#K=H]3'MPR06LQG%FFP+_?K83 JV2P*0^] 7B
MCW,XY_K@W/Z:BV>Y1%2P84DJ!\Y2J>S2=>5LB8S(%L\PU2MS+AA1>B@6KLP$
MDMB"6.(&GA>YC-#4&?;MW%0,^WRE$IKB5(!<,4;$=HP)7P\<W]E-W-'%4ID)
M=]C/R +O43UD4Z%';LD24X:II#P%@?.!,_(O)WYH ';'(\6U/'@&8^6)\V<S
MN(D'CF<488(S92B(_GK!"2:)8=(Z_A:D3OF;!GCXO&/_:LUK,T]$XH0GOVBL
ME@.GYT",<[)*U!U??\?"4,?PS7@B[2>LB[V> [.55)P58*V T33_)INB$ >
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M)$X&B/]7E/*OEV2"XEYS]"]02P,$%     @ -8A_5*G7N:3: @  R0@  !D
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M1Z^-+/IF,=%B8UO/4FAJ9'88T[\&2A- SU="Z/W$;%#]O8S^ E!+ P04
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M@.IO.V.@GV\X5\\7YL"J/&2=_0M02P,$%     @ -8A_5)AK.TM, @  .04
M !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULC53;:MM $/V5002:0&O)
MLN.&( M\:6D> B8F[4/IPUH:6TM6N^KN*$[^OGN153?$IB_2SNR<,_?-]DH_
MF0J1X*46TDRCBJBYC6-35%@S,U -2GNS5;IF9$6]BTVCD94>5(LX39))7#,N
MHSSSNI7.,]62X!)7&DQ;UTR_SE&H_30:1@?% ]]5Y!1QGC5LAVNDQV:EK13W
M+"6O41JN)&C<3J/9\'8Q=O;>X#O'O3DZ@\MDH]23$^[*:92X@%!@08Z!V=\S
M+E (1V3#^-UQ1KU+!SP^']B_^MQM+AMF<*'$#UY2-8UN(BAQRUI!#VK_#;M\
MKAU?H83Q7]@'V\_7$12M(55W8!M!S67XLY>N#D> X>0$(.T Z5O ^ 1@U %&
M/M$0F4]KR8CEF59[T,[:LKF#KXU'VVRX=%U<D[:WW.(H?T#B&FU;"%:"2?@$
ML[+DKL),P)T,8^+J?;E$8ER8*VORN%["Y<457 "7<,^%L 8FB\G&XUCCHO,]
M#[[3$[Z'*=PK296!+[+$\E^"V";29Y,>LIFG9QF76 Q@-/P(:9(.WPEH\?_P
MY$PXH[ZX(\\W.L&W4+7=-A,*.),E'%5[R4TAE&DUPL_9QI"V _WKC,]Q[W/L
M?8[/^&3R]8.!PM96\TWKO9."QO;WO28%OHGG<TO_G">#FRQ^/J[;>S;CWB8$
M&A]-88UZYY?3A=%*"BWLM?W^S_S8O]'/[;L0UO@O37A4[IG><6E X-92)@.W
MACHL:A!(-7[6-XKLYOAC9=\VU,[ WF^5HH/@'/2O9?X'4$L#!!0    ( #6(
M?U3W;1:2[@(  !P(   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;)56
M;6_:,!#^*U963:W4$O)&TPZ0"FS:I'6JRKI^-LE!K#HVLQWH_OW.3L@H \:^
M$-NY>_P\=Y<[^FNI7G0!8,AKR84>>(4QRUO?UUD!)=4=N02!;^92E=3@5BU\
MO51 <^=4<C_L=GM^29GPAGUW]J"&?5D9S@0\***KLJ3JUPBX7 ^\P-L</+)%
M8>R!/^POZ0*F8)Z6#PIW?HN2LQ*$9E(0!?.!=Q?<CE-K[PQ^,%CKK36Q2F92
MOMC-EWS@=2TAX) 9BT#QL8(Q<&Z!D,;/!M-KK[2.V^L-^B>G';7,J(:QY,\L
M-\7 2SV2PYQ6W#S*]6=H]"06+Y-<NU^R;FR['LDJ;639.".#DHGZ25^;.&PY
M!+T##F'C$.XZQ <<HL8A<D)K9D[6A!HZ["NY)LI:(YI=N-@X;U3#A,WBU"A\
MR]#/#+]*K<D2%)D65 &Y(B.J64:HR,F$\<I 3G9,[HQ1;%89.N- C"1C69:8
MCZF1V4LA>0Y*D_,)&,JXOD# I^F$G)]=D#/B$VT1-&&"/ EF]"4>XOI[(2N-
M-^J^;U"2)>9G#?U133\\0#\(R;T4IM#DH\@A?PO@8RS:@(2;@(S"HX@3R#HD
M"BY)V V#/83&I[MWC]")VOQ$#B\Z@/>M*D%1(]7M$;"X!8L=6'P(#+L"QVSN
MBW/M>>T\[:>_&EXE:=!##:MM]7O,HILH#EJS-\22EEAR$C%"=XHKJXM+;Q77
M^W=I&(0?[,?;%&I>%^H^5<EIJO:8'5'5:U7UCN9N D+B)_NO[%VW<-='@_3L
M6A+D5W2%);& -\$AV*&UP6@PL6@B=%* ZBN3+>71C2W=M+<3HK\-TR".TR39
M'Z.T%96>EGG;8%Q[^(\:.$EA??_-=FZ#3ISNR-MC%7?2:$><O]5H\;M<N/FC
MD6$E3-UBVM-VQ-VYSKYS/L+15T^J/S#UW+RG:L&$)ASF"-GM7&/(53V+ZHV1
M2]?.9]+@<'#+ L<W*&N [^=2FLW&7M#^(1C^!E!+ P04    "  UB']4;&5<
MH$0#  "=#   &0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6S-5]]OVC 0
M_E>L/&W2VOPB 2I *K35*FT:&MKV,.W!) >QZL29[93VO]_9">''(-L;?0';
MN?O\W7W.^3+:"/FD,@!-7G)>J+&3:5W>N*Y*,LBINA8E%/AD)61.-4[EVE6E
M!)I:IYR[@>?%;DY9X4Q&=FTN)R-1:<X*F$NBJCRG\G4*7&S&CN]L%[ZR=:;-
M@CL9E70-"]#?RKG$F=NBI"R'0C%1$ FKL7/KW\S\V#A8B^\,-FIO3$PH2R&>
MS.0Q'3N>800<$FT@*/X]PPPX-TC(XW<#ZK1[&L?]\1;]P0:/P2RI@IG@/UBJ
ML[$S<$@**UIQ_55L/D(34&3P$L&5_26;QM9S2%(I+?+&&1GDK*C_Z4N3B#T'
M#/2T0] X!,<.O3,.8>,0VD!K9C:L.ZKI9"3%ADACC6AF8'-CO3$:5A@9%UKB
M4X9^>O))*$5*D&2140GDBLQ$7E::VAR+%;ECO-*0DB.[6ZTE6Z+=D@/1PGCE
MZ+#0(GG*!$]!*O+N#C1E7+U'5&6\U,C52-EL["8-O6E-+SA#SP_(9U'H3)'[
M(H7T$,#%6-N @VW TZ 3\0Z2:Q+Z'TC@!?X)0K/_=_<ZZ(1M_D.+%Y[!NRTT
M2TV.\3"3!2259)H!AON2\ HC)@]2Y >B?%F1>RH+5JP5F;>"_/R$P.110ZY^
M==#JM;1ZEE:O@]95RTOM>('EA9N3E2&6')Z6M#DM!=8?OCTQ5OM3TM<4(DO!
ME)OG21AZPV$<C=SG?45.V 5A$ ^"86MX$&34!AEU!GF?EUR\ M3'MB-K<0L8
MOR4Q^RVM_N7%[/\E4B_RA]%IA08M\T$G\SG6=) 22?Q+HF&+.'Q+$OG>K@Y[
M%Q=IUG X>)7\( IC[\RKY._=(WXG_R^EH:3,93"O9)+AU7IP*W0E*=AM$KPI
M]795W \OKMZTX7!8".->O^\=%<P3AKX7A8-^[XS*NVO![[X7]A4E/ZB4M-"J
M*X.[6NQ';TK:74WWXXM+.VLX'"@V#'OQD5[N7J.7@US;_E?AUE6AZQ:H76U[
M[%O;61ZM3TWO;1O('4S=N'^F<LWP/>:P0DCONH^<9-T+UQ,M2MM.+H7&YM0.
M,_Q^ &D,\/E*"+V=F W:+Y+)'U!+ P04    "  UB']4C?;A?C(#   4%
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M3R..8 I  X9$4?T>W'D?A:OW5+C^/^#H%U!+ P04    "  UB']4EXJ[',
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M*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>MMHLYM
M;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  UB']4/O[[^^T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  UB']4
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( #6(?U05$%;_( <   4=   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  UB']4
MP_4(^:T'  "Z(0  &               @(%B#P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ -8A_5 ^!Q7D+!   OQ0  !@
M     ("!11<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M #6(?U2TF88>$04  (T2   8              " @88;  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  UB']4WYQ"_/P&   Y(P  &
M            @('-(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ -8A_5!,/'291 P    P  !@              ("!_R<  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #6(?U2H*>@&?@@  $0C
M   8              " @88K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  UB']4^C<UXH@"   X!@  &               @($Z-
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ -8A_5-=L!H+B
M#   &2$  !@              ("!^#8  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( #6(?U0=UX;WZB@  /^%   9              "
M@1!$  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ -8A_
M5%ZI?,:- P   0@  !D              ("!,6T  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  UB']4; HBGX4#  "0!P  &0
M        @('U<   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( #6(?U1[TR2F-0P  )XC   9              " @;%T  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ -8A_5*K8UY'@ @  1P8
M !D              ("!'8$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  UB']48W\042,/  #P+   &0              @($TA
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( #6(?U3E[D-F
M%PL  !<?   9              " @8Z3  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ -8A_5 [3LO+@"@  YQL  !D
M ("!W)X  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  U
MB']4=$ZMK" $  "?"   &0              @('SJ0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #6(?U2!3 9TEP<  %<3   9
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M970R,RYX;6Q02P$"% ,4    "  UB']4_EJHK+<M  !/G@  &0
M    @($XU   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M #6(?U078$DS>P,  &L'   9              " @28" 0!X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ -8A_5&U(.)(/ P  %0<  !D
M             ("!V 4! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  UB']4AM8G7 (#  !"!@  &0              @($>"0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( #6(?U1O>X[#KP8
M /L2   9              " @5<, 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ -8A_5+PPSZG$ @  *@8  !D              ("!
M/1,! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  UB']4
M[ #M ?<$  #?"P  &0              @($X%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( #6(?U1-G("H+0,  $H&   9
M      " @68; 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ -8A_5 =5OB9V P  S <  !D              ("!RAX! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  UB']4+J1^'JH$  "R"@
M&0              @(%W(@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( #6(?U1YO]R8SP,  +,(   9              " @5@G 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ -8A_5+8NP$^'
M!0  ?QD  !D              ("!7BL! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  UB']48!H@R)(%   -&@  &0
M@($<,0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( #6(
M?U24E6;HV (  )\)   9              " @>4V 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ -8A_5# 0Z%[' @  (@@  !D
M         ("!]#D! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    "  UB']4GNRQ\/\"  #!"@  &0              @('R/ $ >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #6(?U3BV^ >% (  (X$
M   9              " @2A  0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ -8A_5*H29F^- P  "@X  !D              ("!<T(!
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  UB']49J7O
M@+("  !S!P  &0              @($W1@$ >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( #6(?U3&=U73- 8  +4<   9
M  " @2!) 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M-8A_5%*/K1[& P  Y@X  !D              ("!BT\! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    "  UB']4ZZV&F[L"  !?!P  &0
M            @(&(4P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( #6(?U13J6C%3 (  $0&   9              " @7I6 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ -8A_5$4CWJ!N @
MY@4  !D              ("!_5@! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    "  UB']4,0@)8N$$   $&@  &0              @(&B
M6P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( #6(?U3/
M^3:<:00  $T5   9              " @;I@ 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ -8A_5 $U*"RU @  A@<  !D
M     ("!6F4! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #6(?U00A^?>Z (  -D'   9              "
M@1QY 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ -8A_
M5"5YJ00<!   + T  !D              ("!.WP! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    "  UB']4ABY7[& &  #-(P  &0
M        @(&.@ $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( #6(?U25W.%/V 4  &LA   9              " @26' 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ -8A_5*=,_!>;!0  41D
M !D              ("!-(T! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    "  UB']4^K.0+\T#   F#0  &0              @($&DP$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( #6(?U3;SW"G
MWP(  ,4'   9              " @0J7 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ -8A_5/(+Z%.J!0  A1<  !D
M ("!()H! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  U
MB']4]S#FW1X#  !H"P  &0              @($!H $ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( #6(?U0BT=@]!P4  .,4   9
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M970V."YX;6Q02P$"% ,4    "  UB']4;&5<H$0#  "=#   &0
M    @($HM@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M #6(?U2-]N%^,@,  !04   -              "  :.Y 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ -8A_5)>*NQS     $P(   L              ( !
M +T! %]R96QS+RYR96QS4$L! A0#%     @ -8A_5'1WAAE2!0  RRT   \
M             ( !Z;T! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #6(
M?U27=W+D+ (  /8H   :              "  6C# 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #6(?U362",N]P$  "LH   3
M          "  <S% 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !- $T
*$A4  /3' 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>207</ContextCount>
  <ElementCount>420</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure -  Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholderSEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Significant Accounting Policies - Schedule of Disaggregation of Revenue by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Disaggregation of Revenue by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Leases Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Leases Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Summary of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Leases - Schedule of Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Total Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Redeemable Convertible Preferred Stock - Additional Informations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Informations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf</Role>
      <ShortName>Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1</Role>
      <ShortName>Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock Based Compensation - Assumptions Used to Value Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails</Role>
      <ShortName>Stock Based Compensation - Assumptions Used to Value Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stock Based Compensation - Summary of Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails</Role>
      <ShortName>Stock Based Compensation - Summary of Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Stock Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="fnch-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="fnch-20211231.htm">fnch-20211231.htm</File>
    <File>fnch-20211231.xsd</File>
    <File>fnch-20211231_cal.xml</File>
    <File>fnch-20211231_def.xml</File>
    <File>fnch-20211231_lab.xml</File>
    <File>fnch-20211231_pre.xml</File>
    <File>fnch-ex10_17.htm</File>
    <File>fnch-ex10_19.htm</File>
    <File>fnch-ex10_20.htm</File>
    <File>fnch-ex10_21.htm</File>
    <File>fnch-ex10_3.htm</File>
    <File>fnch-ex10_7.htm</File>
    <File>fnch-ex21_1.htm</File>
    <File>fnch-ex23_1.htm</File>
    <File>fnch-ex31_1.htm</File>
    <File>fnch-ex31_2.htm</File>
    <File>fnch-ex32_1.htm</File>
    <File>fnch-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img102364508_0.jpg</File>
    <File>img102364508_1.jpg</File>
    <File>img102364508_10.jpg</File>
    <File>img102364508_11.jpg</File>
    <File>img102364508_12.jpg</File>
    <File>img102364508_13.jpg</File>
    <File>img102364508_14.jpg</File>
    <File>img102364508_15.jpg</File>
    <File>img102364508_16.jpg</File>
    <File>img102364508_17.jpg</File>
    <File>img102364508_18.jpg</File>
    <File>img102364508_2.jpg</File>
    <File>img102364508_3.jpg</File>
    <File>img102364508_4.jpg</File>
    <File>img102364508_5.jpg</File>
    <File>img102364508_6.jpg</File>
    <File>img102364508_7.jpg</File>
    <File>img102364508_8.jpg</File>
    <File>img102364508_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="708">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fnch-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 207,
   "dts": {
    "calculationLink": {
     "local": [
      "fnch-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fnch-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "fnch-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fnch-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fnch-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fnch-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 648,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 14
   },
   "keyCustom": 90,
   "keyStandard": 330,
   "memberCustom": 29,
   "memberStandard": 33,
   "nsprefix": "fnch",
   "nsuri": "http://finchtherapeutics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Significant Accounting Policies",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Property and Equipment, Net",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Leases",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Revenue",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Income Taxes",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Commitments and Contingencies",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Stockholder's Equity",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholderSEquity",
     "shortName": "Stockholder's Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stock-Based Compensation",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Related Party Transactions",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Retirement Plan",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Loss per Share",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:LeasesBalanceSheetInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Leases (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:LeasesBalanceSheetInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_17ff663a-6142-4c26-8780-a4ce862a5484",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Income Taxes (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Redeemable Convertible Preferred Stock (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables",
     "shortName": "Redeemable Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Loss per Share (Tables)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Operations and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_2967eee5-9d7f-44d0-abce-47ee0feb2c6a",
      "decimals": "-5",
      "lang": null,
      "name": "fnch:ProceedsFromIssuanceOfCommonStockGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_2986efa3-0d9a-4a27-8474-473277d39a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails",
     "shortName": "Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_2986efa3-0d9a-4a27-8474-473277d39a68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Significant Accounting Policies - Schedule of Disaggregation of Revenue by Timing of Revenue Recognition (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails",
     "shortName": "Significant Accounting Policies - Schedule of Disaggregation of Revenue by Timing of Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_4de9218f-505d-4ec5-a79e-948264f8faaa",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_84da10c1-11ac-42c7-a238-2c5259bce7ee",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fnch:TransfersBetweenFairValueLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fnch:TransfersBetweenFairValueLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_ee5015be-b0fc-4255-b8a6-7d92826e8809",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Leases - Leases Balance Sheet Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
     "shortName": "Leases - Leases Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:LeasesBalanceSheetInformationTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Leases - Summary of Components of Lease Cost (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails",
     "shortName": "Leases - Summary of Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:LeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
     "shortName": "Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:LeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:ScheduleOfFutureLeasePaymentsTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Leases - Schedule of Future Lease Payments (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
     "shortName": "Leases - Schedule of Future Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:ScheduleOfFutureLeasePaymentsTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "lang": null,
      "name": "fnch:HoodParkLeaseFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:ScheduleOfFutureLeasePaymentsTableTextBlock",
       "div",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fnch:OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_9e8dccca-9f66-419b-8f65-e42f675c5ee8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_9e8dccca-9f66-419b-8f65-e42f675c5ee8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fnch:AccruedResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fnch:AccruedResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Revenue - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_754cfea2-fdc5-4ff8-a708-49bbef66cbaa",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ProceedsFromRoyaltiesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_17ff663a-6142-4c26-8780-a4ce862a5484",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Unrecognized Tax Benefits (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Total Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_9e8dccca-9f66-419b-8f65-e42f675c5ee8",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c284ec5c-9fd7-4308-a062-488f6fa155dc",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLoanOriginations1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c284ec5c-9fd7-4308-a062-488f6fa155dc",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLoanOriginations1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_17ff663a-6142-4c26-8780-a4ce862a5484",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Redeemable Convertible Preferred Stock - Additional Informations (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Informations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_af126580-e6a9-4bc4-b56f-9a9ed89d3577",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_17ff663a-6142-4c26-8780-a4ce862a5484",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_17ff663a-6142-4c26-8780-a4ce862a5484",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_ed564ca9-9a3a-412d-9d64-5fd1ffc81119",
      "decimals": "-3",
      "lang": null,
      "name": "fnch:InitialPublicOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
     "shortName": "Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_83341027-5973-4448-a037-4a0f2e02d99e",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "fnch:CommonStockWarrantsExercised",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Parenthetical) (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
     "shortName": "Stockholder's Equity - Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "fnch:SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_fe91f7aa-3290-4bec-8ded-b59274901189",
      "decimals": "0",
      "lang": null,
      "name": "fnch:CommonStockWarrantsExercisedGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Stock Based Compensation - Assumptions Used to Value Stock Options Granted (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
     "shortName": "Stock Based Compensation - Assumptions Used to Value Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_fb1c3a83-faee-4108-875a-e75af3e55f7e",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Stock Based Compensation - Summary of Activity of Stock Options (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
     "shortName": "Stock Based Compensation - Summary of Activity of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_0b373c5e-3287-41b4-b4c9-314d0744c150",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Stock Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Summary of Total Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_30f83225-a823-4c68-b24e-432bbb423504",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseSubleaseRentals1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Retirement Plan - Additional Information (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Loss per Share - Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Loss per Share - Computation of Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_c5285cda-f062-40ab-908f-8ca5f466181d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure -  Nature of Operations",
     "role": "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fnch-20211231.htm",
      "contextRef": "C_d4472afe-992b-4a5e-9cca-abeb72f9257d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "verboseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fnch_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_AccruedInterestBorrowed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest borrowed.",
        "label": "Accrued Interest Borrowed",
        "terseLabel": "Accrued interest borrowed"
       }
      }
     },
     "localname": "AccruedInterestBorrowed",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_AccruedInterestOnConvertiblePromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest on convertible promissory notes.",
        "label": "Accrued Interest On Convertible Promissory Notes",
        "terseLabel": "Accrued interest on convertible promissory notes"
       }
      }
     },
     "localname": "AccruedInterestOnConvertiblePromissoryNotes",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_AdditionalRoyaltyCommitmentsAmountDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional royalty commitments amount due.",
        "label": "Additional Royalty Commitments Amount Due",
        "terseLabel": "Additional royalty amount due"
       }
      }
     },
     "localname": "AdditionalRoyaltyCommitmentsAmountDue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital stock issued issuance costs, shares",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Underwriters' exercise of overallotment option, net of underwriting discounts, commissions and initial public offering costs of $276"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement.",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_AssetPurchaseAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase and license Agreement.",
        "label": "Asset Purchase And License Agreement [Member]",
        "terseLabel": "Asset Purchase And License Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAndLicenseAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_CapitalLeaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Lease Arrangement [Member]",
        "label": "Capital Lease Arrangement [Member]"
       }
      }
     },
     "localname": "CapitalLeaseArrangementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_CherryStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cherry street lease.",
        "label": "Cherry Street Lease [Member]",
        "terseLabel": "Cherry Street Lease"
       }
      }
     },
     "localname": "CherryStreetLeaseMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_ClinicalSupplyAndServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Supply and Services Agreement.",
        "label": "Clinical Supply And Services Agreement [Member]",
        "terseLabel": "Clinical Supply and Services Agreement"
       }
      }
     },
     "localname": "ClinicalSupplyAndServicesAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_CommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants exercised.",
        "label": "Common Stock Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants",
        "verboseLabel": "Common stock warrants exercised net"
       }
      }
     },
     "localname": "CommonStockWarrantsExercised",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_CommonStockWarrantsExercisedGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants exercised gross.",
        "label": "Common Stock Warrants Exercised Gross",
        "terseLabel": "Common stock warrants exercised gross"
       }
      }
     },
     "localname": "CommonStockWarrantsExercisedGross",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_ConcordAvenueLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concord Avenue Lease Member",
        "label": "Concord Avenue Lease Member",
        "terseLabel": "Concord Avenue Lease"
       }
      }
     },
     "localname": "ConcordAvenueLeaseMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_ConcordStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concord street lease.",
        "label": "Concord Street Lease [Member]",
        "terseLabel": "Concord Street Lease"
       }
      }
     },
     "localname": "ConcordStreetLeaseMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering.",
        "label": "Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares.",
        "label": "Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Shares",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_CrestovoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crestovo.",
        "label": "Crestovo [Member]",
        "terseLabel": "Crestovo"
       }
      }
     },
     "localname": "CrestovoMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_DebtInstrumentForgivenDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument forgiven description.",
        "label": "Debt Instrument Forgiven Description",
        "terseLabel": "Debt instrument forgiven, description"
       }
      }
     },
     "localname": "DebtInstrumentForgivenDescription",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred initial public offering coasts in accounts payable and accrued expenses",
        "label": "Deferred Initial Public Offering Costs In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred initial public offering costs in AP and accruals"
       }
      }
     },
     "localname": "DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_DeferredInitialPublicOfferingCostsPolicyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred initial public offering costs.",
        "label": "Deferred Initial Public Offering Costs Policy Table [Text Block]",
        "terseLabel": "Deferred Initial Public Offering Costs"
       }
      }
     },
     "localname": "DeferredInitialPublicOfferingCostsPolicyTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, total fixed assets.",
        "label": "Deferred Tax Liabilities Fixed Assets",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_DerecognitionOfDeferredRentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of deferred rent liabilities.",
        "label": "Derecognition of Deferred Rent Liabilities",
        "terseLabel": "Derecognition of deferred rent liabilities"
       }
      }
     },
     "localname": "DerecognitionOfDeferredRentLiabilities",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Tax Credits Research Expiration date.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research Expiration Date",
        "terseLabel": "Research and Development Credits, Expiration year"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_FinanceLeaseObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease obligation.",
        "label": "Finance Lease Obligation [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseObligationAbstract",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_ForgivenessOfPaycheckProtectionProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of paycheck protection program.",
        "label": "Forgiveness Of Paycheck Protection Program",
        "terseLabel": "Forgiveness of PPP Loan"
       }
      }
     },
     "localname": "ForgivenessOfPaycheckProtectionProgram",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (losses) on extinguishment of debt includes accrued interest.",
        "label": "Gains Losses On Extinguishment Of Debt Includes Accrued Interest",
        "terseLabel": "Gain on extinguishment of PPP Loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood Lease.",
        "label": "Hood Lease [Member]",
        "terseLabel": "Hood Lease"
       }
      }
     },
     "localname": "HoodLeaseMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_HoodParkDriveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood Park Drive Member",
        "label": "Hood Park Drive Member",
        "terseLabel": "100 Hood Park Drive"
       }
      }
     },
     "localname": "HoodParkDriveMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due.",
        "label": "Hood Park Lease, Future Minimum Payments Due",
        "terseLabel": "Total future minimum lease payments",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due current.",
        "label": "Hood Park Lease, Future Minimum Payments Due Current",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due in five years.",
        "label": "Hood Park Lease, Future Minimum Payments Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due in four years.",
        "label": "Hood Park Lease, Future Minimum Payments Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due in three years.",
        "label": "Hood Park Lease, Future Minimum Payments Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due in two years.",
        "label": "Hood Park Lease, Future Minimum Payments Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments due thereafter.",
        "label": "Hood Park Lease, Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments interest included in payments.",
        "label": "Hood Park Lease, Future Minimum Payments, Interest Included in Payments",
        "terseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsInterestIncludedInPayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease future minimum payments present value of net minimum payments.",
        "label": "Hood Park Lease, Future Minimum Payments, Present Value of Net Minimum Payments",
        "terseLabel": "Present value of future minimum lease payments",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "HoodParkLeaseFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_HoodParkLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hood park lease obligations.",
        "label": "Hood Park Lease Obligations [Abstract]"
       }
      }
     },
     "localname": "HoodParkLeaseObligationsAbstract",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_InProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-process research and development.",
        "label": "In Process Research And Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopment",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in due to related parties current excluding acccounts payable.",
        "label": "Increase Decrease In Due To Related Parties Current Excluding Accounts Payable",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_InitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering costs.",
        "label": "Initial Public Offering Costs",
        "terseLabel": "Initial public offering costs"
       }
      }
     },
     "localname": "InitialPublicOfferingCosts",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_InnerBeltRoadLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inner belt road lease.",
        "label": "Inner Belt Road Lease [Member]",
        "terseLabel": "Inner Belt Road Lease"
       }
      }
     },
     "localname": "InnerBeltRoadLeaseMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest portion of operating leases future minimum payments due.",
        "label": "Interest Portion of Operating Leases Future Minimum Payments Due",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of series c redeemable convertible preferred stock net of issuance costs shares.",
        "label": "Issuance Of Series C Redeemable Convertible Preferred Stock Net Of Issuance Costs Shares",
        "terseLabel": "Issuance of series D redeemable convertible preferred stock net of issuance costs of $96 share"
       }
      }
     },
     "localname": "IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of series c redeemable convertible preferred stock net of issuance costs value.",
        "label": "Issuance Of Series C Redeemable Convertible Preferred Stock Net Of Issuance Costs Value",
        "terseLabel": "Issuance of series D redeemable convertible preferred stock, net of issuance costs of $96"
       }
      }
     },
     "localname": "IssuanceOfSeriesCRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of series d redeemable convertible preferred stock net of issuance costs shares.",
        "label": "Issuance Of Series D Redeemable Convertible Preferred Stock Net Of Issuance Costs Shares",
        "terseLabel": "Issuance of series D redeemable convertible preferred stock, net of issuance costs, Shares"
       }
      }
     },
     "localname": "IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsShares",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of series d redeemable convertible preferred stock net of issuance costs value.",
        "label": "Issuance Of Series D Redeemable Convertible Preferred Stock Net Of Issuance Costs Value",
        "terseLabel": "Issuance of series D redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfSeriesDRedeemableConvertiblePreferredStockNetOfIssuanceCostsValue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_LMICLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LMIC License Agreement.",
        "label": "L M I C License Agreement [Member]",
        "terseLabel": "LMIC Agreement"
       }
      }
     },
     "localname": "LMICLicenseAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_LeaseAndRentForAdditionalSpace": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease And Rent For Additional Space",
        "label": "Lease And Rent For Additional Space",
        "terseLabel": "Rent for additional space"
       }
      }
     },
     "localname": "LeaseAndRentForAdditionalSpace",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_LeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease assets.",
        "label": "Lease Assets",
        "terseLabel": "Total lease assets",
        "totalLabel": "Lease Assets, Total"
       }
      }
     },
     "localname": "LeaseAssets",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_LeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities.",
        "label": "Lease Liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_LeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term and discount rate table text block.",
        "label": "Lease Term and Discount Rate [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "LeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_LeasesBalanceSheetInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases balance sheet information table text block.",
        "label": "Leases Balance Sheet Information [Table Text Block]",
        "terseLabel": "Leases Balance Sheet Information"
       }
      }
     },
     "localname": "LeasesBalanceSheetInformationTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_LesseeOperatingLeaseLeasesAdditionalArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Leases Additional Area",
        "label": "Lessee Operating Lease Leases Additional Area",
        "terseLabel": "Additional Space for primary office and laboratory"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeasesAdditionalArea",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "fnch_LesseeOperatingLeaseLeasesArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Leases Area",
        "label": "Lessee Operating Lease Leases Area",
        "terseLabel": "Office and laboratory space for lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeasesArea",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "fnch_MaterialAccessAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material access and license agreement.",
        "label": "Material Access And License Agreement [Member]",
        "terseLabel": "Material Access And License Agreement",
        "verboseLabel": "MAL Agreement"
       }
      }
     },
     "localname": "MaterialAccessAndLicenseAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment associated with development and commercialization upon milestone to be achieved.",
        "label": "Maximum Milestone Payment Associated With Development And Commercialization Upon Milestone To Be Achieved",
        "terseLabel": "Maximum milestone payment associated with development and commercialization upon milestone to be achieved"
       }
      }
     },
     "localname": "MaximumMilestonePaymentAssociatedWithDevelopmentAndCommercializationUponMilestoneToBeAchieved",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_MaximumMilestonePaymentRequiredUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment required under agreement.",
        "label": "Maximum Milestone Payment Required Under Agreement",
        "terseLabel": "Required to pay certain milestones"
       }
      }
     },
     "localname": "MaximumMilestonePaymentRequiredUnderAgreement",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_MaximumRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum regulatory milestone payments.",
        "label": "Maximum Regulatory Milestone Payments",
        "terseLabel": "Regulatory milestone payments"
       }
      }
     },
     "localname": "MaximumRegulatoryMilestonePayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_MilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments paid.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payments paid"
       }
      }
     },
     "localname": "MilestonePaymentsPaid",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_MilestonePaymentsReceivedUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received under agreement.",
        "label": "Milestone Payments Received Under Agreement",
        "terseLabel": "Milestone payments received under agreement"
       }
      }
     },
     "localname": "MilestonePaymentsReceivedUnderAgreement",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 notes.",
        "label": "Notes [Member]",
        "terseLabel": "2019 Notes"
       }
      }
     },
     "localname": "NotesMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_OpenBiomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OpenBiome.",
        "label": "Open Biome [Member]",
        "terseLabel": "Open Biome"
       }
      }
     },
     "localname": "OpenBiomeMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments Due",
        "terseLabel": "Total minimum lease payments",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due current.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments Due Current",
        "terseLabel": "2021",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due in five years.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2025",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due in four years.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2024",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due in three years.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2023",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due in two years.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2022",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments due thereafter.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments interest included in payments.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments, Interest Included in Payments",
        "terseLabel": "Less: amount representing interest",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease obligation future minimum payments present value of net minimum payments.",
        "label": "Operating and Finance Lease Obligation, Future Minimum Payments, Present Value of Net Minimum Payments",
        "terseLabel": "Present value of minimum lease payments",
        "totalLabel": "Present value of minimum lease payments"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease obligations.",
        "label": "Operating Lease Obligations [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseObligationsAbstract",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_OperatingLossCarryForwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration period.",
        "label": "Operating Loss Carry Forwards Expiration Period",
        "terseLabel": "Operating Loss Carry Forwards Expiration Period"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationPeriod",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fnch_OperatingLossCarryForwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration year of each operating loss carryforward included in operating loss carryforward.",
        "label": "Operating Loss Carry Forwards Expiration Year",
        "terseLabel": "Operating Loss Carryforwards, Expiration Year"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "fnch_OperatingLossCarryForwardsPriorToTwoThousandEighteen": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards prior period.",
        "label": "Operating Loss Carry Forwards Prior To Two Thousand Eighteen",
        "terseLabel": "Operating Loss Carry forwards Prior Period"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsPriorToTwoThousandEighteen",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Right-Of-Use Assets Obtained in Exchange for New Operating Leases Upon Adoption of ASC 842.",
        "label": "Operating Right-Of-Use Assets Obtained in Exchange for New Operating Leases Upon Adoption of ASC 842",
        "terseLabel": "Operating right-of-use assets obtained in exchange for new operating leases upon adoption of ASC 842"
       }
      }
     },
     "localname": "OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_PaycheckProtectionProgramCARESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act.",
        "label": "Paycheck Protection Program C A R E S [Member]",
        "terseLabel": "Paycheck Protection Program"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_PaymentOfMonthlyPlatformFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of monthly platform fee.",
        "label": "Payment Of Monthly Platform Fee",
        "terseLabel": "Payment of monthly platform fee"
       }
      }
     },
     "localname": "PaymentOfMonthlyPlatformFee",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_PaymentOfOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of offering costs.",
        "label": "Payment Of Offering Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "PaymentOfOfferingCosts",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of redeemable convertible preferred stock issuance costs.",
        "label": "Payment Of Redeemable Convertible Preferred Stock Issuance Costs",
        "negatedLabel": "Payment of Series D redeemable convertible preferred stock issuance costs"
       }
      }
     },
     "localname": "PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_PaymentsForUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for underwriting discounts and commissions.",
        "label": "Payments For Underwriting Discounts And Commissions",
        "terseLabel": "Payments for underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsForUnderwritingDiscountsAndCommissions",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire property and equipment, purchases from related party.",
        "label": "Payments To Acquire Property And Equipment Purchases From Related Party",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments To Acquire Property And Equipment Purchases From Related Party, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyAndEquipmentPurchasesFromRelatedParty",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in shares of common stock reserved for issuance.",
        "label": "Percentage Of Increase In Shares Of Common Stock Reserved For Issuance",
        "terseLabel": "Percentage of increase in shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "PercentageOfIncreaseInSharesOfCommonStockReservedForIssuance",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fnch_PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ordinary shares at a price per share equal to the fair market value on offering date or purchase date.",
        "label": "Percentage Of Share Price Equal To Fair Value Price On Offering Date Or Purchase Date",
        "terseLabel": "Percentage of ordinary shares at a price per share equal to the fair market value on offering date or purchase date"
       }
      }
     },
     "localname": "PercentageOfSharePriceEqualToFairValuePriceOnOfferingDateOrPurchaseDate",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fnch_PresentValueOfFutureMinimumLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of future minimum lease payments.",
        "label": "Present Value of Future Minimum Lease Payments",
        "terseLabel": "Present value of future minimum lease payments",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "PresentValueOfFutureMinimumLeasePayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_PrincipalPaymentsOnCapitalLeaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal payments on capital lease obligation.",
        "label": "Principal Payments On Capital Lease Obligation",
        "negatedLabel": "Principal payments on finance lease obligation",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "PrincipalPaymentsOnCapitalLeaseObligation",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock, gross.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of series D convertible preferred stock",
        "label": "Proceeds From Issuance Of Series D Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series D convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_ProceedsFromPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from paycheck protection program loan.",
        "label": "Proceeds From Paycheck Protection Program Loan",
        "terseLabel": "Proceeds from PPP Loan"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgramLoan",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from underwriters exercise of overallotment option net of underwriting discounts and commissions and initial public offering costs.",
        "label": "Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs",
        "terseLabel": "Proceeds from underwriters' exercise of overallotment option, net of underwriting discounts and commissions and initial public offering costs"
       }
      }
     },
     "localname": "ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_RedeemableConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_RedeemableConvertiblePreferredStockPostSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post split.",
        "label": "Redeemable Convertible Preferred Stock Post Split",
        "terseLabel": "Redeemable convertible preferred stock, post split"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPostSplit",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_RedeemableConvertiblePreferredStockPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock purchase price.",
        "label": "Redeemable Convertible Preferred Stock Purchase Price",
        "terseLabel": "Redeemable convertible preferred stock purchase price"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPurchasePrice",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fnch_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party.",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_RelatedPartyTransactionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction, term.",
        "label": "Related Party Transaction Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "RelatedPartyTransactionTerm",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fnch_RemainingRoyaltyCommitmentAmountDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining royalty commitment amount due.",
        "label": "Remaining Royalty Commitment Amount Due",
        "terseLabel": "Remaining royalty amount due"
       }
      }
     },
     "localname": "RemainingRoyaltyCommitmentAmountDue",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_RemainingStockCompensationExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining stock compensation expense.",
        "label": "Remaining Stock Compensation Expenses",
        "terseLabel": "Remaining stock compensation expense"
       }
      }
     },
     "localname": "RemainingStockCompensationExpenses",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_RightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use asset",
        "label": "Right of Use Asset",
        "terseLabel": "Right of Use Assets"
       }
      }
     },
     "localname": "RightOfUseAsset",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_RightOfUseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use liabilities",
        "label": "Right of Use Liabilities",
        "terseLabel": "Right of use liabilities"
       }
      }
     },
     "localname": "RightOfUseLiabilities",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_RoyaltiesRevenueFromRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Revenue From Related Party.",
        "label": "Royalties Revenue From Related Party [Member]",
        "terseLabel": "Royalty Revenue From Related Party"
       }
      }
     },
     "localname": "RoyaltiesRevenueFromRelatedPartyMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_RoyaltyPaymentsPaidOnNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payments paid on net sales.",
        "label": "Royalty Payments Paid On Net Sales",
        "terseLabel": "Royalty payments paid"
       }
      }
     },
     "localname": "RoyaltyPaymentsPaidOnNetSales",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_SalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone payments.",
        "label": "Sales Based Milestone Payments",
        "terseLabel": "Sales-based milestone payments"
       }
      }
     },
     "localname": "SalesBasedMilestonePayments",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_ScheduleOfFutureLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future lease payments table text block.",
        "label": "Schedule of Future Lease Payments [Table Text Block]",
        "terseLabel": "Schedule of Future Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureLeasePaymentsTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Future Minimum Lease Payments [Table Text Block]",
        "label": "Schedule Of Future Minimum Lease Payments [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property and equipment estimated useful lives.",
        "label": "Schedule Of Property And Equipment Estimated Useful Lives Table [Text Block]",
        "terseLabel": "Schedule of Property and Equipment Estimated Useful Lives"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_SecondarySaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary sale member.",
        "label": "Secondary Sale [Member]",
        "terseLabel": "Secondary Sale"
       }
      }
     },
     "localname": "SecondarySaleMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_SecurityDepositsReturned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security deposits returned.",
        "label": "Security Deposits Returned",
        "terseLabel": "Security deposit returned"
       }
      }
     },
     "localname": "SecurityDepositsReturned",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock, $0.001 Par Value, Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_SeriesB1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 redeemable convertible preferred stock.",
        "label": "Series B1 Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-1 Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesB1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock, $0.001 Par Value, Series B"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred stock.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock, $0.001 Par Value, Series C"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_SeriesDRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Redeemable convertible preferred stock.",
        "label": "Series D Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock, $0.001 Par Value, Series D"
       }
      }
     },
     "localname": "SeriesDRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_StockIssuedDuringPeriodSharesVestingOfRestrictedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, vesting of restricted stock.",
        "label": "Stock Issued During Period Shares Vesting Of Restricted Stock",
        "terseLabel": "Vesting of restricted stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_StockIssuedDuringPeriodValueVestingOfRestrictedStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, value, vesting of restricted stock.",
        "label": "Stock Issued During Period Value Vesting Of Restricted Stock",
        "terseLabel": "Vesting of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_StrategicAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic agreement.",
        "label": "Strategic Agreement [Member]",
        "terseLabel": "Strategic Agreement"
       }
      }
     },
     "localname": "StrategicAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of common shares reserved for potential conversion of outstanding preferred stock, vesting of restricted stock and exercise of stock options and common stock warrants.",
        "label": "Summary Of Common Shares Reserved For Potential Conversion Of Outstanding Preferred Stock Vesting Of Restricted Stock And Exercise Of Stock Options And Common Stock Warrants Table [Text Block]",
        "terseLabel": "Summary of Shares Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options, Common Stock Warrants, and Shares Under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "SummaryOfCommonSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOfStockOptionsAndCommonStockWarrantsTableTextBlock",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fnch_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fnch_TakedaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda agreement.",
        "label": "Takeda Agreement [Member]",
        "terseLabel": "Takeda Agreement"
       }
      }
     },
     "localname": "TakedaAgreementMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion of redeemable convertible preferred stock into common stock upon initial public offering.",
        "label": "Temporary Equity Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering",
        "negatedLabel": "Temporary Equity, Conversion of redeemable convertible preferred stock into common stock upon initial public offering",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares.",
        "label": "Temporary Equity Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Shares",
        "negatedLabel": "Temporary Equity, Conversion of redeemable convertible preferred stock into common stock upon initial public offering, shares",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering, Shares"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingShares",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issuance costs.",
        "label": "Temporary Equity Issuance Costs",
        "terseLabel": "Preferred stock issuance cost"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Temporary equity stock issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fnch_TransfersBetweenFairValueLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfers between fair value levels.",
        "label": "Transfers Between Fair Value Levels",
        "terseLabel": "Transfers between fair value levels"
       }
      }
     },
     "localname": "TransfersBetweenFairValueLevels",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen and two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Seventeen And Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Seventeen And Two Thousand Twenty One Equity Incentive Plan Member"
       }
      }
     },
     "localname": "TwoThousandSeventeenAndTwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_UnamortizationOfLeaseIncentives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unamortization of lease incentives.",
        "label": "Unamortization Of Lease Incentives",
        "terseLabel": "Unamortization of lease incentives"
       }
      }
     },
     "localname": "UnamortizationOfLeaseIncentives",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated preferred stock.",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fnch_UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits penalties and interest accrued.",
        "label": "Unrecognized Tax Benefits Penalties And Interest Accrued",
        "terseLabel": "Accrued penalties and interest"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPenaltiesAndInterestAccrued",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fnch_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://finchtherapeutics.com/20211231",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r332",
      "r487",
      "r488",
      "r490",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r62",
      "r64",
      "r114",
      "r115",
      "r238",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r266",
      "r337",
      "r339",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r553",
      "r555",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r237",
      "r266",
      "r337",
      "r339",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r553",
      "r555",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r186",
      "r312",
      "r316",
      "r511",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r186",
      "r312",
      "r316",
      "r511",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r237",
      "r266",
      "r324",
      "r337",
      "r339",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r553",
      "r555",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r237",
      "r266",
      "r324",
      "r337",
      "r339",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r553",
      "r555",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate And Accumulated Depreciation Description Of Property [Axis]",
        "terseLabel": "Name of Property"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate And Accumulated Depreciation Name Of Property [Domain]",
        "terseLabel": "Name of Property"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r63",
      "r64",
      "r114",
      "r115",
      "r238",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r495"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r30",
      "r189",
      "r190"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r56",
      "r113",
      "r488",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable Related Parties Current",
        "terseLabel": "Receivable from related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r47"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r47"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued legal and professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r210"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r373",
      "r374",
      "r375",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r340",
      "r342",
      "r379",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r281",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Underwriters' exercise of overallotment option, net of underwriting discounts, commissions and initial public offering costs of $276, Shares"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r342",
      "r369",
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities excluding from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r169",
      "r178",
      "r184",
      "r193",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r425",
      "r430",
      "r445",
      "r493",
      "r495",
      "r527",
      "r541"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "verboseLabel": "Total financial assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r61",
      "r110",
      "r193",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r425",
      "r430",
      "r445",
      "r493",
      "r495"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldUnderCapitalLeasesMember": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.",
        "label": "Assets Held Under Capital Leases [Member]",
        "terseLabel": "Equipment Acquired"
       }
      }
     },
     "localname": "AssetsHeldUnderCapitalLeasesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r343",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r336",
      "r338",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capital Leased Assets [Line Items]",
        "terseLabel": "Capital Leased Assets [Line Items]"
       }
      }
     },
     "localname": "CapitalLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases.",
        "label": "Capital Leases, Future Minimum Payments Due",
        "terseLabel": "Total future minimum lease payments",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2021",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Five Years",
        "terseLabel": "2025",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Four Years",
        "terseLabel": "2024",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Three Years",
        "terseLabel": "2023",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Two Years",
        "terseLabel": "2022",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount necessary to reduce net minimum lease payments to present value for capital leases.",
        "label": "Capital Leases, Future Minimum Payments, Interest Included in Payments",
        "negatedLabel": "Less: amount representing interest",
        "terseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.",
        "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments",
        "terseLabel": "Present value of future minimum lease payments",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r39",
      "r96"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r97",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r89",
      "r96",
      "r102"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Total cash, cash equivalents and restricted cash",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r89",
      "r446"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents At Carrying Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Stock Disclosures [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r107",
      "r110",
      "r133",
      "r134",
      "r139",
      "r142",
      "r144",
      "r151",
      "r152",
      "r153",
      "r193",
      "r221",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233",
      "r263",
      "r264",
      "r269",
      "r273",
      "r445",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r219",
      "r533",
      "r546"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Shares of common stock for potential conversion"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common shares authorized for issuance"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares, issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Number of common stock sold"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r495"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 and 598,232,153 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 47,512,182 and 8,391,793 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r157",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction Work-In-Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r292",
      "r293",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r292",
      "r293",
      "r313"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r292",
      "r293",
      "r313"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Shares Issued1",
        "terseLabel": "Conversion of stock, shares issued",
        "verboseLabel": "Common stock issuable upon conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r26",
      "r27",
      "r276",
      "r282",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r109",
      "r116",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r454",
      "r528",
      "r530",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r234",
      "r251",
      "r252",
      "r453",
      "r454",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r109",
      "r116",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r22",
      "r23",
      "r400",
      "r529",
      "r539"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities Net",
        "terseLabel": "Deferred tax liability",
        "totalLabel": "Total net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r59",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r24",
      "r457",
      "r484"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r406",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r387",
      "r403"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total net deferred tax liabilities",
        "totalLabel": "Total net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities Goodwill And Intangible Assets",
        "terseLabel": "Intangibles assets",
        "totalLabel": "Deferred Tax Liabilities, Goodwill and Intangible Assets, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Company's contribution to plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r94",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r94",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r94",
      "r167"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r312",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue by Timing of Revenue Recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends Common Stock Cash",
        "terseLabel": "Cash dividends declared or paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r5",
      "r15",
      "r29",
      "r113",
      "r224",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r488"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due From Related Parties Current",
        "terseLabel": "Due from related party",
        "totalLabel": "Due from Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r44",
      "r113",
      "r224",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r488"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Related Parties Current",
        "terseLabel": "Due to related party",
        "totalLabel": "Due to Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r111",
      "r389",
      "r415"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal income taxes at 21%"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r389",
      "r415"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r389",
      "r415"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense",
        "terseLabel": "Permanent differences",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r389",
      "r415"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "auth_ref": [
      "r389",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total",
        "verboseLabel": "Effective income tax rate reconciliation, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r389",
      "r415"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "State income taxes, net of federal benefit and tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "verboseLabel": "Tax credit carryforward percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r389",
      "r415"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and development credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized compensation expense remaining to be recognized, period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation expense remaining to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r118",
      "r119",
      "r120",
      "r122",
      "r127",
      "r129",
      "r150",
      "r194",
      "r281",
      "r289",
      "r373",
      "r374",
      "r375",
      "r411",
      "r412",
      "r434",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r556",
      "r557",
      "r558",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.",
        "label": "Extinguishment of Debt [Axis]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of debt extinguished.",
        "label": "Extinguishment of Debt, Type [Domain]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r436",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r243",
      "r251",
      "r252",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r437",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r436",
      "r437",
      "r439",
      "r440",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r243",
      "r325",
      "r326",
      "r331",
      "r333",
      "r437",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r243",
      "r251",
      "r252",
      "r325",
      "r326",
      "r331",
      "r333",
      "r437",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r243",
      "r251",
      "r252",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r437",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant Observevable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r243",
      "r251",
      "r252",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r467",
      "r474",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "fnch_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "fnch_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "fnch_LeaseAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r467",
      "r474",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r480",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term, Financing leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Country [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Office Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain Loss On Sale Of Property Plant Equipment",
        "negatedLabel": "(Gain) loss on sale of property and equipment",
        "terseLabel": "Gain (loss) on disposal of fixed assets",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r94",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gains Losses On Extinguishment Of Debt",
        "negatedLabel": "Gain on extinguishment of PPP Loan",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "negatedLabel": "General and administrative",
        "terseLabel": "General and administrative expense",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r199",
      "r201",
      "r495",
      "r526"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and In-Process Research and Development"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r94",
      "r200",
      "r202",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Change in goodwill",
        "totalLabel": "Goodwill, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r206",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r524",
      "r534",
      "r536",
      "r550"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r212",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r390",
      "r398",
      "r405",
      "r413",
      "r416",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total",
        "verboseLabel": "Income tax, accruals for interest or penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r128",
      "r129",
      "r168",
      "r388",
      "r414",
      "r417",
      "r551"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Income tax provision",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r384",
      "r385",
      "r398",
      "r399",
      "r404",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r93",
      "r508"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase Decrease In Deferred Liabilities",
        "terseLabel": "Deferred rent",
        "totalLabel": "Increase (Decrease) in Deferred Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Due From Related Parties Current",
        "negatedLabel": "Due from related party",
        "totalLabel": "Increase (Decrease) in Due from Related Parties, Current, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r93",
      "r479"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Decrease in security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r91",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r57",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory, Net",
        "totalLabel": "Inventory, Net, Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r58",
      "r105",
      "r149",
      "r195",
      "r196",
      "r197",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income Net",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rental charges",
        "totalLabel": "Operating Leases, Rent Expense, Total"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r482",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost",
        "totalLabel": "Lease, Cost, Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.",
        "label": "Leases Of Lessor Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeases1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lease agreement term",
        "verboseLabel": "Sublease agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r46",
      "r110",
      "r179",
      "r193",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r426",
      "r430",
      "r431",
      "r445",
      "r493",
      "r494"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r110",
      "r193",
      "r445",
      "r495",
      "r531",
      "r544"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r110",
      "r193",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r426",
      "r430",
      "r431",
      "r445",
      "r493",
      "r494",
      "r495"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by US and non-US government sponsored enterprise, authority, agency and program guarantees for government insured loans.",
        "label": "Loans Insured or Guaranteed by Government Authorities [Axis]"
       }
      }
     },
     "localname": "LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guarantee by US and non-US government sponsored enterprises, authorities, agencies and programs for government insured loans.",
        "label": "Loans Insured or Guaranteed by Government Authorities [Domain]"
       }
      }
     },
     "localname": "LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Loan payable",
        "totalLabel": "Long-term Debt, Excluding Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MajorPropertyClassAxis": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of property owned but leased or available for lease to third parties, by major property class.",
        "label": "Major Property Class [Axis]",
        "terseLabel": "Major Property Class"
       }
      }
     },
     "localname": "MajorPropertyClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MajorPropertyClassDomain": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major classes of assets leased or available for lease to third parties under operating lease agreements as of the balance sheet date.",
        "label": "Major Property Class [Domain]",
        "terseLabel": "Major Property Class"
       }
      }
     },
     "localname": "MajorPropertyClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r154",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r89",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r65",
      "r66",
      "r70",
      "r72",
      "r95",
      "r110",
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r140",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r193",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r435",
      "r445",
      "r535",
      "r549"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r141",
      "r144",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "terseLabel": "Net loss attributable to common stockholders\u2014 basic and diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r132",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r144"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Diluted",
        "totalLabel": "Net loss attributable to common stockholders - basic and diluted (Note 15)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued and Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "OTHER INCOME, NET:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "2019 Notes"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses",
        "totalLabel": "Operating Expenses, Total"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r169",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Net loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r475",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": 0.0,
       "parentTag": "fnch_LeaseLiabilities",
       "weight": 1.0
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "fnch_LeaseLiabilities",
       "weight": 1.0
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "auth_ref": [
      "r469",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments, Use",
        "terseLabel": "Cash paid in connection with operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePaymentsUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails": {
       "order": 0.0,
       "parentTag": "fnch_LeaseAssets",
       "weight": 1.0
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r480",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Total future minimum lease payments",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2021",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2025",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2024",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2023",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2022",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases Rent Expense Sublease Rentals1",
        "terseLabel": "Rent income",
        "verboseLabel": "Rent income under sublease"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net Operating Losses",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r47"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "fnch_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other non-cash operating lease cost",
        "totalLabel": "Other Cost and Expense, Operating, Total"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other (expense) income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "OverAllotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of deferred offering costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquipmentOnLease": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payments to acquire rented equipment which is recorded as an asset.",
        "label": "Payments To Acquire Equipment On Lease",
        "terseLabel": "Payments to acquire equipment on lease"
       }
      }
     },
     "localname": "PaymentsToAcquireEquipmentOnLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments To Acquire Other Productive Assets",
        "terseLabel": "Payment to acquire remaining assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireSoftware": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments To Acquire Software",
        "terseLabel": "Payment to acquire certain assets"
       }
      }
     },
     "localname": "PaymentsToAcquireSoftware",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r343",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred Stock Convertible Shares Issuable",
        "terseLabel": "Share issued from conversion of note"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "verboseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock authorized",
        "verboseLabel": "Preferred shares authorized for issuance"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "REDEEMABLE CONVERTIBLE PREFERRED STOCK"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r532",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense Current And Noncurrent",
        "terseLabel": "Prepaid fees"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds after deducting underwriting discounts, commissions and offering costs | $",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds From Issuance Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from issuance of redeemable preferred stock",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoanOriginations1": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.",
        "label": "Proceeds From Loan Originations1",
        "terseLabel": "Proceeds from loan"
       }
      }
     },
     "localname": "ProceedsFromLoanOriginations1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds From Royalties Received",
        "terseLabel": "Royalties received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds From Sale Of Property Plant And Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r85",
      "r372"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r65",
      "r66",
      "r70",
      "r88",
      "r110",
      "r121",
      "r128",
      "r129",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r193",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r424",
      "r428",
      "r429",
      "r432",
      "r433",
      "r435",
      "r445",
      "r536"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Additions",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r209"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "verboseLabel": "Property and equipment held"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r211",
      "r495",
      "r537",
      "r545"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesLeasesBalanceSheetInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Software, Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r211",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r36",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r332",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Purchases From Related Party",
        "terseLabel": "Payment to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party",
        "terseLabel": "Reimbursed to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r332",
      "r487",
      "r490",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r485",
      "r486",
      "r488",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r382",
      "r510",
      "r579"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "negatedLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r102",
      "r525",
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r14",
      "r96",
      "r102",
      "r525",
      "r542"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r18",
      "r102",
      "r562"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r289",
      "r376",
      "r495",
      "r543",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r118",
      "r119",
      "r120",
      "r122",
      "r127",
      "r129",
      "r194",
      "r373",
      "r374",
      "r375",
      "r411",
      "r412",
      "r434",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r165",
      "r166",
      "r176",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r311",
      "r312",
      "r511"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r165",
      "r166",
      "r176",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r311",
      "r312",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue From Contract With Customer Including Assessed Tax",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r315",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r74",
      "r224",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue From Related Parties",
        "terseLabel": "Reimbursed from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Remaining revenue performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "REVENUE:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Sales-Based Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock selling price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Computation of Diluted Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalLeasedAsssetsTable": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule Of Capital Leased Asssets [Table]",
        "terseLabel": "Schedule Of Capital Leased Asssets [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalLeasedAsssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Basic and Diluted Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r342",
      "r368",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Total Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments Under Non-Cancellable Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r343",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r347",
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Activity of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r52",
      "r107",
      "r151",
      "r152",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r269",
      "r273",
      "r279",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested ending balance (in shares)",
        "periodStartLabel": "Non-vested beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested ending balance (per share)",
        "periodStartLabel": "Non-vested beginning balance (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "terseLabel": "Restricted stock vested",
        "verboseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Maximum number of common stock to be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of common stock shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "SHARES, Options exercisable | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Options exercisable | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "SHARES, Expired | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "SHARES, Cancelled or forfeited | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "SHARES, Granted | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "AGGREGATE INTRINSIC VALUE, Outstanding, Beginning Balance | $",
        "verboseLabel": "AGGREGATE INTRINSIC VALUE, Outstanding, Ending Balance | $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r349",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "SHARES, Outstanding, Ending Balance | shares",
        "periodStartLabel": "SHARES, Outstanding, Beginning Balance | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Ending Balance | $ / shares",
        "periodStartLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Outstanding, Beginning Balance | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "SHARES, Options vested or expected to vest | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Options vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "AGGREGATE INTRINSIC VALUE, Options vested or expected to vest | $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r341",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
        "terseLabel": "Aggregate purchase of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r341",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Exercised | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Expired | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Cancelled or forfeited | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE, Granted | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r363",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "AGGREGATE INTRINSIC VALUE, Options exercisable | $"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "terseLabel": "Number of shares issuable upon the exercise of outstanding options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (in years), Options vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Redeemable convertible preferred stock purchase price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Beginning balance, Share at January 1, 2020"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r476",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software And Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "state [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r107",
      "r110",
      "r133",
      "r134",
      "r139",
      "r142",
      "r144",
      "r151",
      "r152",
      "r153",
      "r193",
      "r221",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233",
      "r263",
      "r264",
      "r269",
      "r273",
      "r281",
      "r445",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r55",
      "r68",
      "r69",
      "r70",
      "r118",
      "r119",
      "r120",
      "r122",
      "r127",
      "r129",
      "r150",
      "r194",
      "r281",
      "r289",
      "r373",
      "r374",
      "r375",
      "r411",
      "r412",
      "r434",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r556",
      "r557",
      "r558",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfSharesReservedForPotentialConversionOfOutstandingPreferredStockVestingOfRestrictedStockAndExerciseOf1",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r150",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r245",
      "r281",
      "r282",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Number shares issued upon conversion of redeemable convertible preferred stock | shares | shares",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering, Shares",
        "verboseLabel": "COMMON STOCK ISSUABLE UPON CONVERSION"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r281",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock issued during period, shares | shares",
        "terseLabel": "Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786",
        "verboseLabel": "Stock issued during period, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r281",
      "r289",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "SHARES, Exercised | shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityOfStockOptionsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r281",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering, net of underwriting discounts, commissions and net of offering costs of $11,786",
        "verboseLabel": "Stock purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r281",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "negatedLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r28",
      "r281",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Shares repurchased for cashless exercise"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r110",
      "r192",
      "r193",
      "r445",
      "r495"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r264",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r280",
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholderSEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Common Stock Valuation"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r478",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r392",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary Of Income Tax Contingencies [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Total Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r13",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r221",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "LIQUIDATION VALUE"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference Per Share",
        "terseLabel": "Temporary equity, liquidation preference per share"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Temporary equity, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized",
        "verboseLabel": "Temporary equity, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity, shares issued",
        "terseLabel": "Temporary Equity, Shares Issued",
        "verboseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Ending Balance , Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Beginning Balance, Share at January 1, 2020",
        "verboseLabel": "Convertible preferred stock outstanding | shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationsDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r13",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant Improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r312",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing Of Transfer Of Good Or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r312",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing Of Transfer Of Good Or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred at point in time.",
        "label": "Transferred At Point In Time [Member]",
        "terseLabel": "Transferred at a Point in Time"
       }
      }
     },
     "localname": "TransferredAtPointInTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred Over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueByTimingOfRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Deferred initial public offering costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r383",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions for tax positions of current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r477",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareComputationOfDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average common stock outstanding\u2014basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://finchtherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r581": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r584": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r585": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r586": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r587": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r588": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r589": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r591": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0000950170-22-005243-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-005243-xbrl.zip
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M*7FW"(&WL&P076$7M1WMC$/\_+=X=K>+0D%#*X2 #[>Z*T(SPY.RA%$5B!3
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MF_)HW(IBCVD61X^Z7H6@P-H*, 4G1J 3 X/O=-">1!9BT(*IT+\P]75P8O3
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M"!#XJ:6Y8J)WL6*KXI9_K2H,/OGS30TBSJ/D&NK;0??2T/M 5S"=<AE1H>5
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M 711SP0)R@6GK66.]\Y^WJMX_ /[9PSV\4J#/$D##:E$P3@GRAL@\M@0R=(
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M)"F LN4:,(M23;P"\9/R0OJ\MX%13Y^1_DW1HC<.WIT<QQK'KTWL*$L>Y)<
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MJA'QD08<EZ?9J!S_N5>-+M,E?&"SJH]><DK%RQI^?HGC7F2V]O67!\]&O$Q
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M)@LQE>.NH,;>=(1!\&I^?Q:N'5RES>P?;_>S6<FX2W6T5LPV3)$"E]&36*@
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MQUES7&'AKJSK]PO/V,E5TO7)-M?I5OOP; \_@@ S#MD/O-NC _4.?G?_!3O
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M*=2+SEI!I37_GA?D0W:9V?%X"M+I28RM916%TDLBU$*YPDMUNBYJ<S&YU?J
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M6_;7TL3SS 0D?-.F34OHTAC0$M?]?4Y%.J8 QP?#+S;212LL3HI_P53PE&U
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M9TW]T.^WUW=V1I]MY&F!R$<Y/-T+[USHYB+%&DR=1RO3QV>\!.&91Y@WSNQ
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MNN'#1DXJ:7IVS^A M/MT6-PA; %R]U)/+: GHMW,8_A"8Y24 ]/)+WS)T/.
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MF:TVD9'G O+,M=UU0-H7E$*%7)P<RE\:YLI6-"8]E>>$^HW:UVN]_/G=Q*Y
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M]J.UZ@!//-Q/)[QM\3X<HO(:79S1FAR:-=GGXKR[^*_I^>PLNL?D@NCPC/M
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MPUJ.:</?'$-W SFP'K\/!?<=8AH>CIB&X6 :[M3B_/ZA5K-#4*M9']3J^#R
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MOUK6@EM%(;MD\9I.$]D2->)N+15'?CU[3L +"S]A8#.2Y'MIYF4#9V]V-HD
M%&09S+]VG]!?H]:YC?[";V)+; M<+71X24-4.L/H]9M7;W\^$ROI]1HAP5,_
M5M)0<>8-+/IZ1^1K/]S;#,!/$]ZH$"NZ_KR2PU?C8(X@ ,;S]N+-V^GSXN_3
MF=JZGN:"5$E=T*Z&#6NUMXJU/8/')^0EIQD6$67'UI*&R0RJV:TL.@9(MD4"
M1E136JY#_#48AXT7J1LOPX)M6MI0"MY 0RIRR^N.GZAE78FE-4=Y4YYDB.QR
M-C]#MQHR$A/I4B(U/Q@!RFW)X&/>"=OOV-.X<EDN*'9I-.$8@;5CL'>KBK>S
M/-RN+-VDM>*.Z1FJ=(MRYU=ZU*H#G_1P)!\)@Y_CDKQ+D@+'DX@9I\%L4%>F
MMA?F^2]_?_5B>O*8A!&MXB9=>,% ![;A2K]M,T=Q0L4T0^0,F1+W9P7.4KT<
MGL[&'O_PS'>N RALJE9J0QF2^?).$U.RJY+F3'*XBGN21VS+VI9#> +"C-(6
MPPL9'2_XO./&5GEH0T.T@_(SW6;Q0KNT[DEYKDH(NQU!7TR"F*A&6G&)688#
M\!/,UHM(1VK#XPP*).K82RQ: U8Z6+52LT$O2&]MYMQ?D+:2]HIG_5%BQU<N
M]DNQ0RO#H%U='OP-RT-O";HDAJP0$F^MA;8A41Z'A>-&#R(A;C7+^,I-?H)9
MQ_TK[AQ.AHR18U,= E.-!(>?(3+^6M38*M=;E"]W[W[DA?:,OP+I1TC 7R@1
MGW9K=ZS]MDO9VN33(E\5W'L>UL[TI_]^=Y-IP[0R6>;$%G\)7$\1VU X'?Y9
M/)[@6&I*>.^2N;1']X:-2G;@DQ[.C2$E^S_II*FQ3>?'R4;N#Z%Y?3V!_5=)
MI+S3(&P:QIL"5JWFL.A/Z&5HFT58HU?8@?GP>[G/3H#3^R=2>[&P7#%*B-/.
M!C%'DX:C0]'.-#+17P&!I<OQN\CX?(>5("?'8RG(UR@%&?+B#.?T.1DT)X\A
M]T8!:GU3&K$8!A+U",N>6;<K)BL12);%<74$GG8$=<9A1SIRUE_""&PJS'=>
MQHU9[-'.N"/WR(<Q%2G2JD]W/GO+&IE-#L0I[=?9!;Q=P%!(!I"KU)"8AA-L
M")'-BX^)(/;$#OFNVK#KGJN:Q?FJ(84U4:\?% 8=2ZHT&T:(TC((X4+4D#V5
MV8'^1V6CG56 ]*QHD!6,H:),&1G&7C5R\.]NMS))FB@0S,*AX-W'B3!"=#N"
M!81_ A7-=XY%J!7G%<)T'J=;"[OB//N6$&6?AZ2K/-3*4V;(]/UQ[#K!,O5K
M%" 6T$D+J?Y\-;K67[PWWC^5P[L5V7( M!AG:8QH?(662W*PG=!$>ZE09K9#
MF;V;-+%WA&\CGI76FAI2<2%@O!W[>Y> ?"]3CJ $V$H.M9G$O;\O[^.O?-7,
M]26QIV)]8ZHMI*%-C]Q".+4N]\$U8'QF5627?=*"A$550(Q7X!>H4@"C;C"<
MONE!O -VQ6A,?5M(H(V0G#RT)M&5<2BI409_:=67AY9A3Z[=9<Y=W&IF\]3C
M9GSAS5 +F#V)-;K'5U:;N-J+;$6F<+W>B,/,9?+Q*B] ,=:@PH$ILU^\<A'Z
MA:E"Z$*00K_6(;"@>39:V;$ L)'3]G&V ZG8EFQ^']L_<^F^@-Z+EN<]2J7P
M+?!\J2GMVQB1L3_D#>D[09]I!7[UJ,6OEN0] #C#M#ELU[3],/AIQ:6I]FT-
MB59K7M.94(X6UOJ&!XRT*T_T[[[:B70'[0$*]?QV?>YA /[I]5GY).I]N6=+
M>KC12I?9/I1\10"/ON^,RGX'-/ *4,V2JF?7*R5=;V;-F*&KLQ(BJEF++@FY
MR_HG-+N=LKX'2\)@&+8^E5P6)+EP,'DE4L;?"!UAU? _>K>:9C7QQ5WMQ4!V
M&6:&Y WA"3.IAV*Y8]S@*6UNR6XU!GDP$S>6N'^VF'GEB5?&:O?1J/_]'?"[
M">IG8WC(0^Q=ZJ.[L[S@/"#%_H%.NN"1..->;0MZB869:J5ML[%MA!KP.55H
MWR)-<[:DEK4#&5G'9;DV,72@%&2PJDY(K28-QW&'O")W>S=A0Y3:!A [JCE#
M9KT0+K(LWFQ:D59F])_8O72;QR4O\Z38,!_#-D[SEB<35F1SN55%QP/]>[KQ
M_2KLTT-#6D0;LXKUI0)D[AN.M&R.Z[6D'9XSJ$"P@B^$,KG3^]'577'1+G<9
M@D\F!8SJ";%75VS)DKY$D1B96$VY$C:SO?Z"\,=0Q.=!E?P#)766RF[4E85D
MSJ[\R%JF?\NYBNAM+9V3?F5>-*X5=!DC;98$UK7H[/R8JP<78(06XCKZ<KD3
MQ%>>=(H-9\>=KW<@8EIOV#N8B2VN=!S<359+1UO93ZX4/SOC%]#3II9JCGT<
MWAGL'K?_[6F#2#)%2$5J>HLDV QM3('N#^F&3GTM->-S7FH&.[*S-#LZB^AH
M9[*&BI6+$G" 8_XK[(@M8_^W\VCNONJP0(ZL:E' <>%R4@SRP)8\,_45LEZT
MEB?\BMGQR<QVL4)>B*E;%B6?N-2Z 5A87F/Z"*0""SY>9V1T U^/FS3QN[+!
MRFYYD</ML4]-HI-'CWZ4 \"'@K/VR(D5R6CN?SVA_D:1U!(K^=G#J=]YS@N.
MXWP=RK/1(Q@]@F],\_?"<HT,VZ9Y$OTR)^OBTE8^M'FRJV:UXA"58@ 47<W:
MI"UP)8](V\0$)GE]3?<&A,WB4N)=GL2%S8UJ8I\-Y'Z++$>:7M#SN(DFX B3
M*&E<=I+I#A9%4ZI>\$9'V('"L2O88#-K--N24*<'C9LR=-9LTZI(Y(&L]$LN
M0A>[C2-?M%KO@R>Q;A3. /]^TE;XC.-S5I/B=V0[B7KT2\.&F5I@R+W6(VAL
M%(!W5 #^;)#R22OF3;JX$]V'W[7(F9 1VHF-N@$W":0:R2AGJ3)7UG:]JU*A
MP^KZ"!8[EI;)%/)*RL.L?-V08%$4FF4()#_..*XGSD%POR%7(&,[ &_LRAY%
M%PS=MU(TB -,/"UB."7Q&[<&/&-#WHV; @6#'OP/?X31F];(S@#YEIN2CD=%
M&[HP$^=VSC$-<#=6ME+-L7M)G[UWV@2)=BMEPAQ/;2=4+/S]WFT6JIL%^92&
M(37L]UMF.^N$+\Q1]&?K4%VAIY8X9M>V7F*N/!T3V'N@$@U*B;G*:3+H?;G;
MT:=)8+XPGU(9; 2[6>Y$N2Y?U48BD)HZA1O,L- #YV'2#E6XB,M>#$)?[%-T
M?+:Y;,C*HN TVFXK5=BFRY;>5@A=))T+P19;FJ_)A.+R>99IX]GZ>F8>!Z0U
M^;WB+G2QG@*QK],RNC0K(TU,)]V -A/2'D6_E"M62X'%'11J7AJF]]H3?OR*
M(2_/W=[:J5XC;%/O71-\!(C0BB)Q=SFZM[]5]T7Z<YB015 MR7A^/B Q2SD8
M(8G;O;YWWB?#)?#/PH,"ZX<1"=<=MR&O^-T^+=+0<I2XOYG$E=Z:-<!N"[.M
M4[T&8?B"<Q,APZ-D ^D.+18%@\FSG1IP #_Z;(N$0]2>8Z22) O&[?W-MA>L
MF5:?&E%UOR_!-N01#QP>V[>@=^1X3Z*$K'><V#8T%P[ >[,CC]!8>L9-4<[3
MA..V&P11,MNE&"E$YFBG)PB'Z-\<;I/C'MF.*VN#$'#8 -B5SDU\7%I*\KJR
MM#W$,:)Z9R.JWR.?PLG(IS#R*0PEI/^.8]FO.9;M"@!?Q'4\;&WU)/IKLS$E
M ZB*-6+K&FN?1(5/?FKTPP7HMZ 32Q>"P!-*])+^L]AP&YY.^;3D/Q-RI7/I
MVZ!%XR]_?A<&X)3!NLND*2P4\R;-R!\7.#S9[9(6\"TR-1FKS2V"ZOR>,"V:
M)Y-ZK(6KNS?8Q_-B^2'0,&XUJ8G..Z N1Y#.9U_GGSZD4E32 N7@6+SCB-]?
M/$/HW4'F?,?GXLL(^2 R=U=:4 Y0B0_,=+Z[ELNGJ8V+#.VD5NMV($U(1QC
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MWEMC*JMOJ>I4*] ?<2LR=,JJN&0#W2XOT+T9)00F22$ K$/P8-RNKQ'(XNR
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MPA^LRS1 *3&:S-\:F4W7,E[E!4I,Z,&7<6;M6+4X-=V#,GY<W+,SD1WV_FK
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M(IM!HE2HXO;U)G"?Z8*T_R]Z3B96/V[-MD;6@U9ZBZMJJW-*L^)<-E/N2^(
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M"Y4)W 0=?W4Z=L..HHL%6<58?H02[%*#X4V!NMNFK!ISR_BW36[PJQ3*B<\
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M.I?(W..G%5IRH&SYOBO6>!<V#GJ5+S,4KY$4W47/2(]D]@=C"X_!GZVQA<>
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M8[G='R4H].Y,F/JE=OX2:6P:B63 W-M*E\WBJ>0VA1C%=M5),O@K?I8U [5
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M.D%\"=J+:=JGW-N4>[L5TG)2$9\\]Y:Z'S?.N/$M]L1MPT#1:/JJ]SJ?*_K
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M4,Y=/9+9".],_B_ .M/UQJ?R6I8"80HQ\H]\1CJ))%L8_Q8R8Y^'/IE$TN]
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M^E]Y#R;9I"=.5KC6[AR-'.^*J]*6HV8@;^5&+=BX[]S/-MH_M+=K#)56@@^
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MF VL(II7NY!H#CTOZ&Q(5:D<[VA'(QRDD7?^D>YML136GPK,7 4PS4K4U27
MZ]##(DCEE&$,O);+$R:@U[J7#3M3EVTASW:P.!':JG,]) V9>%J\W9I6+-PE
MO0YB8H=)"R.C'&M!5%FBSO8,^+FVO.20&S9).&)Q,X-7%_2(QL_*=_KZT;>/
M/=3I.-%]9<.+(L.(YR5$T"18S;O XQ8S 8LU$SYGA@X8C9KX0/I,:-@(X].)
M6HI%"5@8H;$4=6ZP<,8/"(?OZ*5DME.RK%9.QY:=O6!WV&H2>T?B"_CRHA(
M2+).H=H^VF)##WI>"-#1[SDK[G?E1O"*0*_KH]F39H$IAW#QC>R%_&OY39"C
M)DN2];!EZJTOKP-IO?61-=:GL#&C?H5?4ANX&%,H"7=K&L?-R2V<<;/:P!%T
M%I<D(0'FG'W<#>^5RK8<TJQAU1;Y\A!)O]3=<:).-0=^6^7LUV*D.CPG07MK
M,UE#=](:4L9X,8"#)1$%*]-_Q%L<*5..]%HZV6K)0!SX0"W7S9S[:'*9LF-
MH?LB"^S#R?QQ&##+2K'I$R]!'8=Q".1X^ED#8VX@4@)^@[Y.G,]W/9I"RQA+
M7MNXW+K92/46AN"H$9!IV&^Z;'?QL@5/GT$>^<'N31+=C9'&6.(&@*3#^XX4
M7RDEY0C3ZO!,6B5-TIY( W];8^M+[;3L1GW$QP#^6JLAA4?>3A=14-,5'>U,
MX6K9W&_YKBKGY&Q9(B@)%N[(2@[O0X*P8/JT"C1UX:TE8@!P9TZTH0ZDIK%H
M$8-&$F2I2R.?%[M<P>69ZQB:N;X6LF=PN)CU>ZF_Y'WRIKQW6KHU5WO,BQB+
M$.@G#(%K#"G40'?2P;$^1*%G>'\<<E@:Z:N-XWYL_B"R*G<I<0U;'YT(X/Z3
M%CG<QD J0386&[AJ3$F@RBK")B%U%X741< SXF19+:LYJ]J$4&)TO1:+1W5^
M;*EX++Q?=J%U8H;SR%J<2Z)F12FU$_%@S<AOPQBY3N>9^7$_L7=&_L$/_%<V
MC9_]] .W2^A_TTHTQ*PXVK9JQ-=FJ1K80+<2')[W>G.(&V8?2M)U%QB3_<H;
M'^H[+ Z+JAB+PI:=@Q"J$/=_#W:/%R&@&MAU06!B@#:$>..;_:Y20ZA@ FWD
M>1:*W#.GS,>PRC;Q7/K(_/B7;7G5[ ;UJ/>Z^Y-DN*/ NB<3L&X"UGVZYN]2
M8:LE+JZ8@@4B?1Q,!8HY2:Q>Q[,\0#B,02$&0.>RUC)=<U^U@1',(XW6#-)F
M3>N*XYG=DT5_IZ6^61I$9.FJNLXBVR9],ZO$M3(LL]D382U$-F4,ZE11$4)M
M+=O\>C!*-F U+4'_8O-_7Y<[J9[/4<?:AFH+B[J9_;B,L76%^:QM[)V8@QC)
M=8.W],.C(1TA: 5M)<!9A,-6>:U]7(OM\>7Y[#M48)0K>9E 6^H429) <%(G
M!';JTN$6.0AKP57!%FB5J#5'2'9Q4EMW46J\6"5EB0E(Q-F?ERW=0AP8J62U
MCUD#"/WSJ1:F9B.A'T)9"=>5_HGN2; 'C:+/6*F8H4K%REA'5*D@1MJ"1];C
M\#/@ROD,[*7%NQPV8M_U5IMM]A.*SKY+'=67I=GCL]<,Z[T\L,CXZ;N7KS-A
M_:NV@Y87UGSBA*E,=B7OF\0*0C_ T"S#58#SRZ1YG'KOG0X%Q6\52W&1-K2E
MH/O+M5X;FQ&>;#5P7%K7+T6/>VU4/-)@(Y3U8Z8@08BIJEARS0N_*6AOV% F
M#YO'H8#N4EH"2F]"G<LB#T)+OB@K?+E'B3C7F6SVM?TVMN(3V@ XV1CNJF Q
M:AT2BFK0,#X?IMIL*+R)W[VY>/TSNT#\DQ^6^OXB^XR7;==D,^6-) 69EUP7
MUT@J(H0?-5D571]4\97"/I$6!65'?D^BOCIH<.,(-L5&T:L5QD,41Z<[=Q8N
MEF\+(4F=8 *H-@M;@X11*[G\G(%ZO4.J*$Q%$=)!-VQ\&OIRX!T+Z46JNBAI
MZB/%1NN\OA0J\@%4T02";S\%B67A9$,Z2NHQ#0Y+!MN<P%06)(; @"RJ7 TB
MB!#$&OSK=F?114[L*SU%&]I'!=H)<P0]EN[8AJ3$8K%O7:FDO1D%EFMU/>79
MW"*080/F2(X*L\S86K1:*S=64C)7*N83)1LK2SL3Q@G\&@Q)5C\1,67M54'*
M@I=.84*\MT8+IN2EKLW4>*[\*(A4EB_B-4W?\.4-KSG:?#M02?3PSCOF;>IM
MKS6NG$R>SZ'TXD=!PC%\\;F"#NAF3646MVNS/^Z.1-2,WV8&IWK!R09L %+&
M0R#DU4!6,JO\Z1H+AWE'W3RW:@;_X@A5J]'6EY[E,3_"Z@JS,E>JU55Q+40%
M]>S1 UJZ!P^2OFIC .TL"/D/^AI;0-&\WAD-3MWX%FS"')#'@>X<KECU<X3Y
MO>V;.A(Q '^U^K6C*V!N!@(*(/=>BI?<Y=6PCGF"J'\V=_?'B&M.[F2$1RKD
MT9 W?>0ZV?9)OH9O>8*7]L_-DL*,T)32D2F"M4?L7DX<!(-8'PC36R\\FGR!
MR9E;@J$!=0 XG<^.3:N1? 0\MQ!VH3MP51P4]XF")?AW'&]#4K3=*77]<I\V
M6DVJN3AUXMMS&'ICNA9W\EI<L+?4CS,<.=1\('?YN]F"Q&:I:$7S*I'YREL$
M=#@GGU8Y<&++!4-C34;B?I0^4L0:8.U*$MQ 8MM3AD<OBM+Z<$K=1%*D9)'D
M4740E5(I;Y-P9_\FN_ 57^E*6<;=0A7OR-OO0*-U"(UD"H0;@BHS \&#IKB9
MNG@M'K&1UB=V^::OYO27,8P5^E74LP-M1!_SV:S2<%N&\:+5%&"/&I/H!P:4
M:"Z'>+A6/R=&\-$[6>&8O4I"=F=U:=RJ<#2'5X2><\EL0&WJ>&7AUP:*$7 *
MF18BAS?YOV3W8G.)&-]BR(0"-9FZD>?!A@#V!Y ;<#PA)T"N.]+9Y(%)@V>:
M'SI]9.KX\GE* IB6&V<H#+?Q>.]^^%_[S_IG^(J9%P8%Y<0Y>*.S@,0]'JUJ
M44A9%!+:D$!1KX=)LUJ=<; #M\[:?87)1V\X6*&&CV$RX?AMF^>@V >W95MR
MMEQ.\L#1'IZ%25W<377AD?1>^&T@QR#7[/(<D8RQSB= )^1."-X\YS_-VR9?
MFF>2!NM3>:TO6XZHB)YF&1M.X2(XVO-\U'?1^'\%1Z0,E; ,%A\G5;,\WXI)
MUZ+60E<]%P]=%BKZ9J!%%:I?!,/GM"RJ"SMD/9<N=^E(0?2% CL)VLFQV9F$
M=F44LN+OD]-ZT5VIBB]73)]!K]S7UL]/8^6NAMFQ4_5\*VBX0O4;&CQV"0UY
MH,P]ZO5.$N2N0EN^G* MMP?:<J0#S1W08+].*/2[=UOX,B31GKL$$'R8R*##
M"8;/,X3[W[D;MT?X6!:Q@07>)10@13@)R]Y)B#5KDFJ"7A>RU(/6K_31\SY^
MJX@BH?S>D,:3+'4E;8W5XDB:<422V1.-!U-EF&(2OD<YV9N65CV-=8DADP L
MS%.0P' ['GK^T.$<"?4&7\]-EUO?\&<\/(QK'1W8==#R)L;+W H/E[<;./]^
MR<97B8TM21:KJS0OZR0B-DIS*<[>$(J<6JRP;HN8]ENFY+KO)U]"2MW,2X>.
M"U:Y##EIGY0?'95; /1PVG/UL*=;%8[D%6/;>L6+NA0@);8E=M4I=LV47]45
M^1^!L,0AIRS$1_;H:-&]C6O $*R+-K+>[A4V&HXZ!82>C873'JM6XDY\3]I<
M,?G!7'4L6+'^?+8K\@WBJEY:](0,,NC $@P*<[,C1\[*7DGH<C.]T;KFB['9
MX9N,HNA_'9VG!'$@A3:QFL B5P&#&>MQX*.$P@2+]>$:A<=)SRQ7T!KA]2GL
MWLVY3+;1M7R(;05#W&5P*$=&%#-T7.HNR![IM3XV?@:,C7AVX>6!IB#G;J/Q
M_NMXF:^Z#B"*I6-DV6\E@-D;M 0NN[2X4_(.]2'LW6B]MH=.>JZ9V(8G/070
M8MGH 5+8S&$K_AH>'K2>5PRF*X^HRA@[[%=L<W"8%@X]9)5.XG-"?/[>S*EO
MX:N1-=#L+]>0K/34PPU-CD&QH3<^Z$95BBB2 N"@@B5FX<!&2<B1&?!N9+8X
M]!A#SV)ST]BHT+H7CA01>5GJ;1-//%5N.%8B5AV2(9$I2A*!I?!-C=6D]ALI
MUDMI4Q-OEG]3-*>LBVHSI\DC3B-]D+&((VU$/!'(Z%8&8;'K:TU4E9_4XYZ'
M)\F ?+BMPCF(T?'](GOE=)O$#S9A4L/EO3?C%YHPII'!]A%R<(DYTA92\BR@
MQ_Z52UF_YGZTX7!Z78+N;,QN7'# U)D\=BSTZT:6[S6#YH@SE\L!!) ;GUV5
MBR*0#NJCVN(R;Y=2[YKJ%Z_FT,:4A\3I>KK60LFR6H6F'0G7"$*L?*<XD[1H
MFZX[0W:])!N$+SY]CFF,JB)?AD/B+3C6\H([L>8OQ;:+]K<<Z"%_)5R_(H1$
M27+6A7).)7Y'2JP6BT^&RIL,B1QAV62'1)$+>'9HS3'_+UDV2<V()?B5OS34
M8D 4DRLU*>4[J91?]6RNC]3!'Z5))6\1 -'267%KC703G>;5HY'CG&!U3:(D
M@+OGEW73E<I?P*1G*N=ML+&.7TKH&<1L>..A*NXQFR -N]D*90I9\(N$38ZN
MGI#$FN1RG 1* = O4#NF,4]34T7I 2Y98)REV-O4ISEZ"/]XQBN6M>F3$K-,
M@0D\WZAAF&.HE$DQI]/"P$01-JY,MJX<6AKVQ*HSW:PO'YR19DN8N>Y)25O8
MA4@DIKY*8'N2,=^?)-"=E$ 7(Q[>;Q-]3,UX?DS$P$:Y@_-.'P<O>H+!"S X
M5R4EMGKQKM0^$B9SM(S,)V#E9@JO#--;MJ2?<=#-7@\I[8!R11'!6Z908\ &
MV;BN1D(Q6-ST4>Z<Q$Y$I+A7"?]8BU!G[GOHIN]5LCF:/-*RX@N4EE<O6PC-
MMF/?GTRH.=EEDOO=H >:T$C?:/C)T&[PV-C3LC_QS,PKF@+'9^@P:^ %#^4A
MM7FKSX#41X.P1:!QZ)^&0,Y;VGLK6%$]ON^XPPP:&-:?C&TLE]#IREK<WG7^
M\P%LB%TE)C^.R7[?(B>F93@GI^+1[""B>ZUZ)+GIL=ZHU\TU4_((AFI5%)CS
M:E];5*SE@AL [)35=^QRT]?7U^!9,@9*1K?*K>C[,1R!X[<+!Y]41CDRB[3%
M>E.O2E0<8UG-IJ8OXCRL#GHG%??D%L,Q8O96+?1/]P_N=:&T"*66-"[W2""0
MX.7#)F9.K0UT\P"JZE>!!J]7NF;.S=SG^&8@DM=2>Z'Z*6I8[84R';*A$@K;
MOZ>3S)6A<=%"=#%=LM"34AZA$_5=CNT 64QZM"3)S+<<?=Q]MF&TM"W #16W
M*&(J)M642_NB8M-GTQ@;H^)ANF-V:4"<*(>T.WV*3"Z-B=OQT,KZ&1MM9(3<
M>D!,4#:"D.3:RJ[8A&Q/JYCKJ8'@W35%C,4@/Q*G24*)H41/8][IO3; 5\IL
M8(^MFUG5D-AKE;HWT4<^9]S#AS*5,P.UQ"9R:2,7U@^X8;2($+ ^5Z)+*2)&
M?RSKF[TW%#5T%8Y%Z6?+1BH)N)Y6%'-@*$ZS$"CXX1)]RQ3T8T)^<E,-P1V'
M=#V=(%VW!])UAV7\KX.->L5N44L.W@O/5D-"[;N(<OT\\5QW=^M_:4ENW/2?
MK!+I.[*.2:F%[C$_?0>")P$HM%(/$OR0V-<A[U&EWBO.+\\Y>I<+>(E,9#AE
MTJV,0W26J<IFQ6YQ?E_<"/A!2,HP?DG T=9+Y7UQSI$P80#95#DMPC+AKT&,
MT/<AVX:E((MXVVRCD2R$+-:::MET5DZ;+\GL+3FN81%+[K)SY%$IP&MLO-H@
M(9UCFKJ2.FDX/C.C^@$-D#3:X1U;,D,$.^%<W92D\["N2& RT33'$Z[+KH@^
M$;.SFH.0\>Z[V%!D^N>J(.:M/1Q;^+3<)<Y]I#(-T*$YNK%KG&NR:>ZD7,$Y
M_1:IZU?KG+Z_X'BA>:G/UF6U;&F/3;)\^^K9A24W!:14OCOCP+:T)>A"7N#@
M"RTD1O'%-]M\IQ8QFBG)O^QO(I'&+M@J$OI$-\,R=[-GJ>N1E. H6](@_&]9
M;E>!?ZIQH+(#'<UL:%(GBA G/W#_E8=6B]MB 6JI[XX?]W[86^VBU0(&%<&0
M'#V(PLHB&#T"5V21$7W269#;A>EE"ETR1FY[8:P)M[B3:]G B$F)'='I69&[
M"$XJ7\,9X5<X'U(\RY'K98*,\G6?6>RG::K 5H67Q$L:A'5(4$X"YO.P61&"
MNS"'^"?/^<1PDJEU[VT_!Q^9*HO@SK0YE,8CI="9Z1_:#L5TD%N^O'T8^BS:
MJYS+&Y5"'"1[ @0Q:\A%1!V"9)P[;4COJL(3!"KM\NQM46SYRTY^@CX-1IQ0
MNK0@3H4PEB@7\\?I1_VW]MLER\;4.):V DDGGH"%1;6#&;!AJ?@C8M)>@4LO
MF+@AZCR@EKOHT7UM4.GI../&"A]=>?Q2N_9>)T9Y2'(%HCDVW:&3QD+5+NSG
M<4Y&,1?Z)09H10QH&J.->V8 A!W+JJ1]F6TJUFY6.>^R,:WNSFCFNMYCT&&F
M',]; J D:BOX0Z![M)0$;2C_^->7K_J,:^=!WB5%J-HY6><FNUBR6\ #ID\U
MK5R'V.JZ4;+"T.T^M,[=I(6F?*?<XSO&6("E9<'@D)?)0.CEP[49OMNWTDD:
M9'M*/\6-25>;D-'PT*[!OH2^P"BXS34I):R 19UK1E0NJ+&?+O9XG=9&?WMR
M7]ND!8?5[PK@+I8LN2\,;B"+ +LQ-UFH7V63Y.8,I*'(G#VM2TT2?\$SB.T4
M1D4A_:IA0MC%7JG\CK9<B)[]6)\B$$VD@F2T]Y&,&J:K$)KP*>!;CESC@+@Y
MPJA<[IM?DR49R"A:PL77,@PI0G*4K^<J@5Q&#7A$>U+23D(52]O&8@5X-DL2
M7\:HR\US:/XD7+E7/+VM2KJ(XY -Q *TA1*,0PK715 #"%?HN<N1)W?MXVU
MO4LB%"I"DWED:R;+^2Y:3*(0'>NKIY3V^;H^%?M1YM6$X:K7PBGFMWY%ZM7S
MV0^22RP[)J$[:./L*^"<F*]72)?#HU-BY:2?M!E:5X)=6K&@VY6+<BO6E )G
MI.L]UZXM#H&I_F@G-GS:XPVB&CNR6"9X0'8Z8SJH*VU4U#>@@I4@E9ML.*G-
MEYAY))R:KC0!XSEE7?.  =HZBF/W7&'"QG8ESTPUEMEK- <6Q,Z'5SYC30N3
M328U)Z$&%65QLK2L)Y7U>6A-__F629QE>66C4)& J__G+\Z?//KJ3]^ 4;K*
M#W]>5<6[&U &H*=ZN3J@,P36A;]&3F+>[KYAL7)&4]IT?P8Y+KX[*H0V](OK
M<KE;8PR/G_[IKD@E6ZJRYF7A%?N@!YQ8/+\F3Y\\>OCTJR^_^/K1XZ=?/'WT
MY$^T(!R_>_3H&]M;MZGIL&[KXOWA+\F5&Z"-FWZ/D-1_@_LBU.?1M8N^7*@U
M-6V05WW8W "YU#K1C5JL[IMX<6AU]7^G"S1=H-NQ>'_XRPIERMGL.F^MCX Y
M;Z10%ZRASZPUCS2K876(HBZ^<#W(94^I3L=_.OZW^OBC4V87!;O"5(UBTYQG
M[A:>)/X[][&EELWP!Z(^81!I8Y"]X'3.JG)1H =B",-.EV2Z)+?ZDH2P>5'^
M!WY=(^2%M1$DSNP62=3,NJ+!96K9*"K>R4_A$DQG?CKSM_O,LV/.M)D+L+[
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M0F5 *Z^-Z)&DC4\/G*GK<EX:A8V^+5*PAL;/G?(,&@>"+YD)S"3(_1O10,!
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M&YP/<^@)^I>FC$"IR:M)FW\.B62.CM0&//\I0-2F//'MVNV/NR3.YE$FUH!
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M2P%Z.3T:OM&S7XR';?09V>A#F(:E:<"\DB]8)-+4Z*YS=8G(>F?K&-Y*8Q&
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MUFGFA"8Y'4^\[D7@@$C>G<2&GEG*RCDFVSCUC&C98^.]=!M=V]]9+L)KBT!
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M@07(.#U"HC15/T_91.+,X7W$0=,(@0$\0/NZ"SS@%X4'N)\#'."N QKPB<W
M+.?!E9\'_@"@K1]C5,:%)]5SG3@!$',I@=PT0=1B%8M57)-5=!M*'$)T%.2
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MO&'1WS4J[4)8:J)(A6M#=.I#4J_&8B,*18-+!EK?=7Q=9M[WW*P<G%H3$>]
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MV; GA]*WA.QUW9=5H=S8B3I[T^[RVLL7T@_$X_MA*EG^*6F0V-KJ<4>N&6$
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MBJS3(.&HQ>_PY@7,9^TT@2?/(<3UFR_?T#=6WTB-7/Y6?+GJ)"%?S&49(?N
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MQAY*UFT/9,</Y,1'3\V;@R])[Z8\*HCJLM' SWE:OTQ?U6.M++P@(>3G"M#
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M+([ FGAN-2>GOT@2\DP=(ZN> ]WX^)/'GT0X5:@ T@'9-D#_\;XWB+4%;/J
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M+M33@2*G2R9]+,'A-C5#;2:<R)&L;#,"?_C2AH)Q$UTDY'.1+LWGK7'I#_T
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M.7] _L3L1#V$6.=+SDF3!P(:LU?HE#]\2/?J7M=_U_CGK1>=(Z%Y$U_B)OY
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M$F_CY;%:/,V+^"O(M+ \6FK1[GOPI"^HRF6F).>A&FPQ"'<K(<J0C=="DUX
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MURKAT>U8F*)H6_[@#KZEB\KZ$91I*DQ,6F!]ZT-;2!\!#1M>+LM,W(I22EO
MY:6ET[0MFI):BH*&#EVOJ75V*"L?K&M[OM,25(O6J4E3[860@]QS6S6W.)8U
M7J92PJ99F_0!3 $QXF<=UM9=Q7A,Z<WB+=*MV/&?C=[[Z+-:F"Y86;P %9(*
MH95EP&[:(C#*TH$W!""","Y@Z[!>[\ YG- 6)R7$T6J#!H?/$H1"7HQ^Q_?G
M!),*V4\-92.G\VONR3. ',5C]"*DC5U/^B5]M"F#35HQY-=LG%R#;7I5_FO
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M$SC-R.-&;=.K(P2!:OTCI<;DZHBXFZH2_NPB=A$2*E.PR.PQI M7K* ^'-_
M:$QZ];Q#E\C' C:D#:U.C??V^:\U9'0!M"$"#0"P#]2V\4O3,_=5H$:/"$;M
M[8:817G-)EM#Z'O!*AR=3I!41XL7FX2\^&@!O3P"'QW#!*=9DY&MLVTO87.?
MP(X:6ZB/K>&!BEF;\380#'(1(RR2&DT%-YE[0M- X*&#^\/40CKP&4.CV4 :
MU!&O2RX1U4&3)U38DEN<:(D.>^#9? -\6/)CY4263M(4E ?YD#>F;WA<WDFG
M_<8H <##2E2'\BY=;@U/#>L A<Z[G>/YCJ!]@FGTEFGLUP-BEB@AX&W$;1?X
M%8,K8E8(),XT1X*C6PW?0[[A6T$7Z<([!I*L$=]WZIZ6T&X!>=U_];[^; %Y
M+2"O]TQP-"!PA()> 'YS 8D,8NK7(MD&>]>?\U>NR+/5P6?+?6Z[P@H,PQ>$
MQ54O%%'?4S.V\X"?GY_\]\67C[\(**$HK.R_T^\VJ/3?($OQ00H[2<)X??GX
MR^GO/&WJZTHES4+E1VHG6M>;R;6<#03(N0 NE1M(-LI8)B3+O#/J$!EI1-75
M[*"W_MKUK?_(GP>&H2AO= /)GJ.]]><O+K]\_/4?OR413._F_[S=N==V1_]I
M>D?_VONX8GN\H%H7G0SZ&HW0-=VWV+<7_I[V[9]IGH2^.[G+]_XO;LNBNZ9[
M^/RK/[Z/E/JW;'A=JK+"LF#%WN@")Q;/KLE77SY^]-77?_KBF\>??_7%5X^_
M_".<I=]@CQ\'=VE>:GI;YVXSXA&@Z6$<;UO-)?:GQND8L*([M8!J-;0-09BT
M#833E*K0QQA7^)62_UT.PW(8SODP!"5)H5]F,A[+L"-S*%3Z6C;XLL$?[ :G
M2,_=HR!P!WFBCM).S;BBK')<$8*2XR4[EP?. *I3#Z2'QW<0"@S4+9)4/B'^
M"I.S ^8#@8]D0>@Y#"F:%0E*N*$8QWPWJ/+<Y.6.N[=<8T(5G8"3#=2Z6/#
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M E[,14>[=V)T(RQRN+*V?:GP\6OO=WJ)D;9AF"T>K/2FZ9C%L2G>;U26T"
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MROV;4J=&XW1/((:2)C\2_Q1L*Q-P+++8#:0=?9#65#J-S:C;^$L,E4+&E S
M:'\I5+FEZ[K/?TU(OG5F?#F?R_E\*.?3@/-T[YOA_UE*UM =Y;-' =^W=/*6
MG;_L_ >R\Y-YCZ!*>S<!R1A*FN[UWX;(^OJC!&2]O 9<.:%+%FQOO=GT3<;L
M>0QJ-O/@NR./.J23JXM0_>^!0OS#7WXJVU?MZB<1K?51$L'"_ZK M.=AJ;/5
M]T*RO?J1 /E"K_TCB291^>QO37W;7;]'0.4' 9\\!_SM\\BNH4+"9B)Y0-/4
M.+387KFC"N'=R' IS2%TF*_/]%. 1-;^(]2&^$_O?V];4I[M-U-=56[W8>)Q
M9R*=#]SZ_\*SG-?^$FA6*9MIK>E5$%OK7+ZW>C0_TDS/RWW976>K%]>7WUWR
M--'3Z])M5]_K)EL])Z8=UURNOB=ZU;W;KYDM?N+JS._+2#Z:5E(@DJA\LWI
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M'/0&&HF% G"_-A.993<12XWCIY-Q4]0@,!=6P6]!5>=AD",(^*A<>HP.+9V
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M=W-JW4%T,F3+L(0CACQZ+"@86#2VH Z--!?+45B.POD?!=[Y8?[CFV_#H!)
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MRPY_,#L\U+MKLM ;H>AR*F@=L?!#^B4F<0^2C[,45]_2!9<#L1R(!W(@.$>
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M#?>\>R6.?"C'7SMSQ)-=;V02Z\- -U,V9GX+[6O$$87&"@U8>"/_<> &AL
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M=$E/!5"4U ALBT,W%\<&XRR[Q7/Z(CK^<LJ_QG9U&->E1$KID[UUNUS!ISI
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M,G0=#-Q^&S;9;M_0,@%]$I[J6Y)@K+'2A.1M9]""]S6JN48$&O'K\A(]C[E
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MQGGI 3+W8=_J3M4(+MB_!H<)#0,&\N)(1K,M+JF-9N!Z1BAC9DY8IC3-Q=W
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M$HI:@?W"<Y45E!.#N2PNL[L(\):K[:EP6EM-J3Z1WJN5/(^46O +,SVZ^\,
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M)EZ>I#/G0W(M(N<XS- 5GSGOOA[^SU:_NTUI^Q]//\//_>=TT#?]%E]:5[!
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M^.N'?]6SQ,X2ECC'Y&C=M^W6KJEHH-1(05#-22SFBAO!!7=>&0Y^'8/^IM$
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M[&=H(P)[5!='3EQ>^LU\<N-5F(5DPL[VU?LU*8[\M7ZOU>UL_X177>=FY8=
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M_7P;VMGMW7M#-Q0_[=ZK]FFE6K4:0KA3QL3NTR=,U.N&MZ1,[#YQEID%\N,
M&4"*?_G'FYTW32FL78^K>0;=]"[7^^^3PW/GY//QR?'?ARD8/,<G1R>_?3@Y
M1S6DV:6V:W?C3TJ,5OHTYRXLD)]=^G2M]%E'Z8-VKI4R:T9T+]<3Z!F ND)V
MM^5CEH^UNPWO9;9V-_M2VK)M5-,PU_IG3+A"WSF%_C'$K'.Y/#\/K\(\M(/C
M-JF*L^F@;0YI/']IIJVW?,@@V9V!V^FMV,'.$M0SW%#M1%E+4%:TO#I*L*)E
MO41+K^/VNG8D7G-OZ(F'E=_/CV MT =9H&%\);)'L4"?U%WZ6FU/"]2F -7*
M](?(]$[?W7O6^%B3+J?9(F%%0_&U$-%:,JLF0=5* "L!0 )TW9U5_84;20+-
MN9HG-N=L6/'9C+IIFER%6($S-)HDV-!B<^70H_6>M'.R&GX)5GEX2,ES9\_M
MK#IB\2FOU[9WM5&5)AN/5KZ\EDM80^)HCGS9Z[C;@W[S;M>*ER>/,9I E&NL
M9*&:!?$= U0-NY_FT!P:K6;_:3)@J8\9_H"]HJZ\"'LK<>-N;/*4ACZV7<('
MK".I,>+M$=+^[7B3ETQT>NH+M*K) ^ZTM^.V^SN-NEBKE=AP4S/-72N*FL*V
MK"C:/%'4'[C]SG.&<*TH6M5 ?OAXK3IH/'Y3N]N@<9=N=0O0:/JAFT+1_##N
MR9@VI M2#Q>BQN89-F#@T*MK['E<4/OW.\P2NJU$F8<4[0S*,4,X02C,^,VD
MR+$WZ-S8H+EF]]@('^=74*_T_F[9Y9YG$546"F,_*G"O;[>-;OBAG""P-?1P
MJSCG0,093T20+>Y=;(+?J_3?3^(M6CL0 %D_E ,4L-7X) $9])<GYP?0. >C
M-?GETA;B99MQW+AY>"_*$B><P#WFG)/AT;$#8<R1*T=>((2S3,AN_E'H48O+
M4,AV\MNM_AR(QEY\*>:NJ'X!"< ,Q]]U>JT=?2IS*X$::"'G5-!\O6UC#%1E
MW]0;G: I.]7SI_64O9YQ4^:+4VS]'@;E1#L:C$>K55>2&(5P3$8C^ T#\&V_
MM5T[OD]UA+]A80,D<GA@;]E2/%9AZLU0C.I#M<L[J'^!&^/C.XUI[VYYY./S
MR/:=>62O8\X->0B/[.T9V$JC>2J4H1D;L(7T$A&<B9Z&B+2K,Q9NY'V*@)#9
MX2:H=:_)6("T._=APBWG"\]9N.^+;G42*)[7 ) YF&=^J P"Q >3 GFV^"'\
M D<CR6%!"0V(R'")B]-?G%^B9.A%SN\7SD?X@W/J.I\^?3IC#JOAKYEY"6_F
MOME=>;AY'<0=EXPMO0]W%)5-W"8#6!BQ(. M].O%@)I0I&"-HW=FNL\WS_$S
MAA+!*]39>_YJ@-9Q-W+&QN'9)^=0C2GB=SI[AK"H'\DZ+Y+F"<0+_BPR'OPC
M/RO'#%X+8UZ5W"H=(17A9%BD&?6RIN&KQL"0K]YW$7CE/BT/7T,>7F<PG.HB
M1VO5;-9M+TAL-8/@;O,(:$P12?&WG;XQ+DO.S]**LHOQ9^0GP$=PN!$.@T-A
MNZ2 EKES=4GZ2G W$TR9'WUS?E>NS*)[K-2NDYK3(@7!D;%A,4U1<LA9GAAU
MG_(@.3Q *G#F%&D0G>H8LEM+B%?=GQYZ!_<R\0*:-/L%9.&'$(<PT4B]^,\B
M]DE/N [S<9VP*5^HB)S/R15_G$;>6MZ^?M1>QS8_ZCH'R]LWZ[;OX;&*[UH!
M(\=K=_9*4\2M-\!H=N..R?2,N8U2]]63\T[/OO F[CFBT51\S2^4(T+KAF'>
M=0CFO3;$+%_O &?WR:&;T<RP>T J#BI;5@P;?H:5"@_'W;)B/2=V $:6Z6XP
M&;;O389[AH:SC KWVE42F1O-NDB*&@GAX0N1XL>.X;$ ] !I]"T?XCNGM(!]
MBHH(CMK,;AGNB=9HU1%\=SB4Q$7:F1P&C)]I5[4N;0[K4:Y,:,1*VE7GRLVT
MF-T3,&HU2\ OWM)YU:&1NW9HI!T:^?@MQ5?5VF%/R,#.>2@PJ1!V?&2S;GHU
M,CDD"5FCH^O!D75)_B!F4_28]'IFF/,/X0Q%%(HKP7.I<0GQ(V1G \=18F=,
MP1!X!?02$F0%.?='Z,ZONN8K7G7?F^)5\R^#,"]2H494LT(;QK#*) RV8/L]
MVLO8@XUPO"+'2 YZ/7 T->[" PDYF?+X9]KKQ)N1^"<7QE XUVD27[+'^QJ%
M;1%)-W\@(</;244&__1ADUF2Q.28YIG;[,^V G@MB>(/'8]@%)9XF"=EN",K
MAEGNQ=+@8D]7+ Q'%^%R?)E4-4B7K32_B+P4WB.%U?&"*]+]2)\$%1D C=EU
MIN)))*!^GZ?PU4Q%T@!K@\)'31[H B>=9X3]*J!2$J(\!='>LG.,.,:#VVK:
MM-<@O*JKWMIN];N[/QV H3R-O-G^*!(_3-S=J4==#$2%HQD@&BB"0 /X&D@4
MN)L#0M M.-(DVT?N@>_6HO,$?L$C.6$/O<%/ZX+?"E1A3& AB-UK@1N 9\)D
MT.]V!KL[VWO=WF![T*4!J>04Z79U_I]QJ=5M-15X;W[&4X<8W<S)YYZ!Y>FS
ME Q \D7)5-F#]<1Y4.(U'%[^K\5OB]_- -Z;GT'(@#0 -8D]CC'C[YSL&24I
MJ(@8T@==#&0>_,647%5*<"TI6%)81U(8%2DE\TATEI7-(]@S,7]XJ!B!DL9N
M2/(X9D0:%M\MOJ\COLL<9>;K!GIC A[\,BNF4S#O4Y6)4$5O!VUKD@X6SRV>
M-QK/,R&^ R._!"L\3U).I@'T^"XX+:;(QTDJ\VN9GWOQ;+E&SS9V5OC(_D<%
MVM&8'QL)H E#$;)48:FB^52!/B[T"@(8B"RNX-J)NU<T?:O96-Q>*]SV? H5
MH!83A3X73)!JOXC+KI,+?QS#WBZIFBMUAB'] PU;J^-8C%\/C)]XWP6&YD26
M)[%PG329>5$^0WR6F*]2P;BB E4<5;0"SXP*"K$I8O%49JY%?(OXS4;\9(B%
M9*Z#R?#\$_#X'&-AE#,?@SZ/Z6:@RL/?113!7PI6:CBS?IJD^2B)PL1BNL7T
M1F.Z4MB]/$\]B=^IH#+*&!XC=%?I%]GW$% ]< #',XQ41Q:[+78W&KLQ0:%J
M=X;Q*/6R/"W()XF8CQY)8-=FXI!*U@]CGU@\YSD$3B0NO<A5M?\A)O=P)125
MF4;&FZP>J7R) _J=I15+*PVF%436-!281!0 +L_(;(5_(JH#+F,^.&7^Y&/E
MRJ3JZV%R)5K+</O5Y8K=/P_US<^_27^ <X3IC77IL3;S[C[PQ%(,4+ZCY)HJ
M.RA!-"LF6&GR%SICJ'-$3.H.*NW)$,ZD6/>R3%;DWXCN8C0"79^>R@I_7'TY
M51ES7'5!N:.RI484PJV"$)J5J;"RSY&RDI'XDB!SWL&O\G%29/!@]KYI"72O
MH##@+@WHZ@L#)*HMRG*OR!/5VA#W GBYWSZ@Q[> TR8%R!KLN7+ (F:/ "J?
MAU-%WC03^YF8>J"<:)E-K2-YZ3?S'?*OPBRD-B"S??5^39]\*= ZK?Y@!X58
M;7-'?JC=VAMT;WFFTP*1>,LSNZV=]N#6;^WL])YM/[V=[4;MIVGPV83]W#!$
M8I>H_6GFU-]SFL#N7=CFX[<G?0P]9W<EGMF4,0XO!/A;.J'>!::W=,X& .)?
M_O&FL_OF">"[TJ@B!8FFW,SSE7&N0#-G*KYR7 BL%CXC)?'%^C'?:5[1VMWU
MD]+ARXJ>M;L+*XPV7QAUK2Q:1UGT-<F]R(J>]1$]EI%91M8H;&\((_N$%394
M8]_Y^S!U_O;SOX676L9F&5MS@&H9VUIA>T,86P>C3KV2IV66J5FFUAR@6J:V
M5MC>$*:VC4RM;YF:96J6J5FFMB%,[;<DI?YV,?.UOF,YVYIQMAOB.C+_Z:Z!
MG6Y[X':WVP#I+J';76X1P'AG^-O)Q)^H2QTU/L_G\RKO06BK7-0]!=9FCJA]
MU:!M#AFL.*#[ 7=C9V\_9/;VKKO3W;/T9%F5!>W:@[8Y;,5*@;62 CMN>WO'
MDI/E5!:T:P_:YG 5*P362@AT=MW!7L?2DV55%K1K#]KFL!4K!=9+"G3<[7;7
MTI-E51:T:P_:YK 5*P762@ITNVYOKVWIZ5E9U>-%^^^7K6'C_/>*\R\TFFU@
M3MIF$LA+I2EIE++@;THBH!7I][W7[?:*\ORY4O^:=)<;0UP6J%9@O%[P6X'Q
M$!O0RHO71UL6J%9>O%[P6WGQH,B1%1BOC[@L4*W >+W@MP+#"@Q+7%9@O#10
MK<!8$_!;@?$0@;%C!4:#B>O)NA68H)0KK9388$Y+Z1@ :]@M-8?@'M"-UV8!
M-3%AL<K3NJUN'WE:D!0X4VB]%(7F4,GSYS;>XQJMPO&0[@A[;OL%NB/<?KU6
M];#R:!- :^61E4=-NMB&RZ,=M[WS_'T:K#AJ%,^TH&T"'VOZ+32':5EQM*GB
MJ+/K[K6?OV.$E4>-8IH6M$U@9$V_A>9P+2N/-E8>==Q^Y_E[5UAYU"BF:4';
M!$;6]%MH#M>R\FA3Y5&WZ_;[S]]%P\JC53-7X+\> (E^7 :.G^X-C<ZS0Z.[
M"C2:?NCFT/77L3GHP_$FL*D\<\+8R>$OA$*.-TRNX']3^/\L2_S0RT7@7(?Y
M&-Z,\]3S<QH/F],C(AXEJ2_XQ3AP(G'I1=',&<(-A/$E_8X>SJ;"#T<S!_[J
M9 "H< 3D#UL QCS)7-B!'Q7TQBC\ =]+4F<2QN&DF#B92*]"'PZ2)\Y0.$4F
M I>?<O4S\/B5EX:TC6D*3\/_)E=A%B8Q+,Z;@ U.X;<_P@F<R,G#"7XM&?%?
M_!P?=>"*1$J_T6=M*40S;_09K\QY%$27A+6.F#XW/^H.0..'<4?[80Z;]0_4
MD)NCQ2$W#[[6Q]G?J[_FU:CC#^&,O2OD0\!(@&^$,7")9"I2+T?RCO#6,P=X
ME)/"(Q[P'MP!,KR+9(*,)8J$ZQQYDV$:!I>"><71V$LCD>7)=>S\!DS0\\?
M=7+@>^\R(9S/"?"//K*CI$CAA;B =8%?4((M<<M1&'LQ<$[X7 Z_('Q#[B.
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M,EOINC2:\:]@AGC$F3B'YXJRT8AA>+&L)'%Y=2"'*,"LYDOTY"'FED?!,A^
MADRSK:1WD$)HVEQD;Z'2"S1DY&!1/C51($**J]7*2GV90N16EC; @KIBD6EK
M6#,+Q<'9UD5W9BXNN2*--%=Y7B4JJNO'5"Q&L:8 U''@A)CA#- #(]V7*6+
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M(@9^0!BS!4>:9/OH!<9W:_$+#..MZS#(Q[B'WN"G=4$X!:HP)K 0Q.ZUP W
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MK*0.J:$.:D!($=+Z(44!VZJ Q>R3%!)"M$6,<N;@4DJ0-.4^,>IH;"6B7H>
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M)'SF1)@ C%'2'% ,X+7)$%6@*1IF&9%MY!5NG$)LM81?#+5M:YX\LD-][(#
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MBF$14^RDB;V%RA$,,P0BX9X$3ZW/*WGJ%JQL,_NXW'/.H^3  @_E0AD%$U(
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M@< BL-T"%K5NJ_5+@1DN(@5;XBL0P1KP@7&(3$9AHP]RM>"WA4!K0WN]QI8
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M!],,NG2]X@J$M"+Z19<.7;H>& !"6A&GH$OW=)>.J1BBSPF89+II/67 F6R
MYZQDS%%3N])ZZIM;$*!+]]RXHK4F X]I\H"M!KY^"1>V!M[-4BQ6?G:>QC/7
M& JVY*A*6;&16/=\=C2&^HP!@466099!8T!@.PDLL@RR#!H# HLL@RR#QH#
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M,AY=[E&K!\@N>"ZE7^%J?-B6/#D]^EOPZ6_''P_/CS]_.CFZ"'[[>/;Y?!3
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MA$,Y1?!"]4<S>^?AF$Q)I6)*DB36X.&DC.191DD:<I;$.43V:;Z-5(#%QR-
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M_2&:<"5#FA"51^ /R4P0GL4)21*I$YXSENID6[SX9\7'.6[>ZP5U_M(10N;
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M892@*HW$-K(\@+Q' +SG+>[^>O>Y,?ID\K[#WL,Y]&[G)(_F(TJW-67N:?;
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MG!$I0D;"--=Y3G62FZUTJU\@5)\TS<QHNA4/+HKC49@,8 JL]^0&94*\:(<
MZT-?A>' LK?.WCK?:YV%I-R(@A'%\XPPEC*2%Y02)72>QKD."[[&6_V8W,N/
M6^<G*[CVEGDG<RR^AN6E$67>41%8G"1506:-"433F&D35'(J0!2VE]W\I:[$
MY-)8$L )7&*EF;T)9C< 24)7-],V67-X<11P%OESM,'X=?X<;2@;SY^C>5]N
M(R^@1)*AG!B>Q>"7":QR48QH3F6<FRP5M/B13$LQ45>+-KJ/>/]GQ>?&'%K
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M7JWECOV:FW$Y;0.,=27M'5-7LRDHU@3K+>^);EKUT\9<8^,L[@?;DXP_PP,
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M]M^7BIQ+>?%H<,ON,+M+*L[&3J-ZVP/^!%[LU-C >C8&^#4!_HZZ8S,+-EN
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M?0;X!=9\G5BAOILA:KL$X@4X J:!V[0O+:-X8U_[6N)P%;]I'HUXENT:AO>
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M=X[_O#(*B-K'B+WZ454REF_3&6)87YI?*K^?_TJUL@HB+@GLLL&SP9LGZV'
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M\R*/,2^2KN1%QLS(V IVUUJU&^GQ2B)4(<_KXX+.7*M7*HTV'4_E<--,=C^
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MY,UP/#/!;S(+7SN;3/RHO3 \\M*+,^]H22ZJ671)D_QTVMTF2=CVU1 [N;B
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MNT3R]D7B]YT3_9'847E'Y7VW\LY #;.T0+;(-:(2,Z0PIZ"(;:85(R9U*^/
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M&#!CMK*_#]65>+D(B]I.4PW$ C/%EZ6$E_#V1^7F6W+RC4<+;3S<X)L-9EP
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M1O=')5Q>61"-P^'XNR^?;FNIRT0FY>P:7NW6![RG<-6;\36\P>W_*N\.?X-
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ME*3.4X.YD1N%1A\V5'@Q<6ZGO&>GSFE"DKXB21)O NHC!NI<%[SD>8F$YPY
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M)'F178UK8$N?X?DC"T,X5_$?[C-<$GYUXH9J&GYH'!\RK/YPP^IB/+:AG!(
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MU)GWS9O,JZE] !E\<"$IN!I6D4G!AR^;5^^4:<&R7L'5O;5LS?9Q3#5NM\Z
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MH CD=7IC*L)R38!X7ZRBO@"J50$MSV$SO%C'8--WNI&]A$M"M8Q0W61^\C4
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M'JB7-]O)HVI))]P TI^KN'<RZ39,8X [Q*#MH-U:"=,1Z/V2%,<:UH*:5R4
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M9RQ=N-Q/M_U9<2)D\>>@6S<UWFTO/"D*<HOK\ EG_#;/HR<\SV_W0'JK!S[
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M7HOU;HHW=TLNJOVM_=CNOA>/J$V:^6XMMJX6NW;+;-^#O.M*BAY1D954&,U
M)5< U=&=J#AJSS@J8*J#-2A$$1!/)" CG$)$!P<?*(D%N8JCB$I)2F:1))PB
M[JE$6FF,+/=12VH%U_QQ:_JX(#U.54_S74*E!Y6 BICJ49.G1-YJ?0]P)ZKU
MW7.2GB0ON?3(ZV@0)UX@*[5&FC-)HI.\1"0>R/H^8+T?UA*GI&!ED?O<$,#
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MEZU9#TY6#JW!.U_[T]/3. C-C_#'Y0)^RE_++#])%XUMIO:/]DIPW#)11PZ
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M$5MUUJ/PESX25]CK> Q(956/=9/GKSU<]<204'<H?DU((B3N2,!(.JL0YQ;
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MVE0QUHUV[5L8JR;GGI!/_F4T &;/E6<U!-U1\%)#T(<:@B:1I!"=RV.[<PM
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M-0$5N24!B=9[6.#M"<CQW3GF&Q$[U:& 7>T#\EWNY,%U]W@<0@-9\Z?_^P>
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MC3?2_90+KBS72%J66] ;@S25)C>CAX>.C":^,6OI(/B6'33?7FT??SG^=@L
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M'+ RLH]X#!/>\%Z%(O24"/!6+XAT&LO6=42KGM33:_6[W5\/[T3'P<_2,=.
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MP@E@<0W.HQF@4&-4] .(OL8)!P;DBT\T]4VCDS_FF%'4\I <P0U#T69J8)B
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MOD@"(WPJ>/'R;OKK8(7ZOKJ\)IO2&?Z*$;]Y(!8'DT#^V(+Z_TPU"E.3JD&
MB_"V)K!^G!P2C9L8V-<'8W"^\-Z-'#&#+ZZ4GTPIH[/_:UU8)%\J%=*RT(K=
MZ0$W+%YU3?;['7=_..B-.MW]WGZG_VN^YU.G4R0W*T1='I:MBT?Q9F#[0F?*
M"MAERBV*+\"D_9\,*B*80BS#"_AE!<$K\)E(,5M"VTPZ HPP(-)I3$.N?AMY
M%,'T :T\T+FH<-'(+A4IR9_TIAA1K;ZOX6@9JBA7%.;.+_]-UGB@:%9WN;7Z
M*X&&N4(4^=,6&)_HV(,R,:%=T!ISP!\U5H$)H@LOCC)%4EF6U96LAL?ITDH<
MET($.)KO87052/_"S('L#+!68$I*9Z%.WQGG414#T2;R#*KOATH6Y*^@4V-*
MJG3FSZ#))J]:933/5.?DU3BLGE@]/?_BD7H"90.2B:R_KFB$?ZET%%-J0J>!
M*6ZHA-E!M9%I+# A,0?+ 64#:W%@T7*3<Y-:,+F=#7:^)^8BE_(6RP[+CLVR
MDV<(=#K/HV1K]FI%<,B7-\!!H+;B[B%^7&;PEKFBRP%\_,;DNC8Z6%4+&_PG
MN!>C=/"2)0?21]R+YJLV.NZ#I"G>AHG(["V8Z$;7G5S-3)IO\/ (MDUJ-?,'
M-K\!?ZE$*O*5VO128U;H:],EU9>4CV+-P9K#;LTAEUQGL1;@H #/@MB_$B$!
MU+V(Q6PY'B2=LNX#C>OEPJ',72>U [H K=B),Z/47I%O7++02161?Y$%64"?
MP%?"E :4X8!E* _DA3$!@( F&@3*R)C ]#M9WI=94!_@/;PPLJU">"KZ(F4E
M!]K0C4RP47/2,$V(BI+],+L4:T[*!.U*:"*?UC@2,4TW=WBT\Z\4QB?C8'&M
M7<Y!H[NE"3=E=T5&N5Q!%ZQ>13*,XGD58I<Q[F8%&S8&N>\:V9X*X+RQE&$5
M*J[+H%M=1+ICQ>.V-TVXO1%W)=21L6S.TE8:#9Z_WJ+3[_?<0?%?KPZ+?C]9
M?O?#D_.D\$^JG@MX'50MF\%9)1M[$U*92F'MQ6J,<#,&>"*D QNF!*0P6DW0
M;0]KKVXH19XLE2)/KJMX>[V2FO33.#<JDVDL*3V73+5#A<F;:L+H=II./G\L
M$"4O+:MD1INMJ-%:.('ZCE6S2;1^0^-N\Z]_NJ_:Z^H^C(89M?I;%!L@$X+I
M]DF!P6P,;HQMOUMUKO.V@]HOM UYU>52]'O4439 8P1*7F;YC&VK.<G)VE:E
M_&PU]4H1N;ACP:;S,;J"/^+&:OEY40>'Z1DON=,*8*+K3GKU2@4!*7D*RL'?
M,H[1>:09P<=)# YGRSDJGF1"8ANK]-$[DC#Y.Y3I-VBB8JRC(,7JV'*1BCQ6
M99DS3%H>"BW\3"8MYWT:(^0T5F*'8O6&6:JQHF\2F-65SD3DRVP@RZAQ#2OI
MT=MT$F,73:5L)BOUUTMU'/3<L;D#YAI3+B^@8$*6_J0:?)WHEO-&>B+5LO :
M<S455-04UM@$P<KH38/$<JRT&$%UI?-%75W3ZB-QW_A";C"-ZIE5)JJ#&$\P
M0-JH0+@O$T*[EO.-O-IKQFWJ-S,!R+*8]/*\A8(FEW>3 "-]-^F0$)=O(L"=
M7N1K#3>18^%'5Z&9( $X7%@LH' T>=V&=U$&9I@3_BZ!;XN430!/7%HG))2*
MO71V:>)2XT5&"5_!^J64P3$$UM$LSV3#ZH\Q/Q0$J<[=^ZN(7AG%>%$T-\U%
M<%5%I%'\8F+_)0[6M(Q55@T7E9AS*>2!CC!#:S*SL'(8>7+2.0R@J.P"2LZR
MD^O!_$H-8Y,!HJ911*&A29J@[B!9+WD9M8E9#N"K55XIP^.D*'3J>3*K_BJT
M(8H!54;YSD4$0\W,+^2S>83Q3M0XV;MA2H8@^M#H)&PLJA!F)A9(65QP4%:^
M_!=V#U1I73$@RV<5762^Q#9ELW9%MIY"9T416117]26^#WDZ5A$JJ^WETG3\
MK)<(YNH1.+!2+>:GI $*_B3YHI<;9D92H"+$]K5<PFS=W&&MPW=\'B$;G5=Z
M\BSU-DUO[YN6\P4'#!YG,6".A%D^:3M8R%R,(SH ;0 :A0K-43\66'R-07OH
M',WG$1@1!@^P(#WOPUR[=J_\K;*O0O9CC6C&C/J\3EGH_"EB;^ITVQ3!Z#2<
M#[&\P *7MRWG%,!HD?51 W*G9.E@SXJB'*5):24*K6%]4Y-?U>>A9QS-8Q44
M[W1>(8SFO>=?Z8DD F\!'/,^\]<MY\^X&)(V+Z;.&D1K,KS(:4&O05?L%K33
MP6A9VED%,#2Y0E.U?"+>D)+7C_:,\5KT4@L SL_X*\:<R*V%AC$7BN+Q2A5B
MI;S?2&O>Q%U<_C)Z:Y]&:IYA67+-8O_BV*-2WJW(.LKVBDP;[_L-I:.G9CL!
MA#UJMHH]YTT YG4B56C"'A2*A3N-<OEB1+ $NP:5",OX4A:;.419U]P-^QBL
M['-0K9DU%[2<C](X-+&DB 6ZD"(0I! ]U#/D /QOM]]HM]MYF%PO50"*$LYU
M(\L!F_Y#ZBHTG8WHL.5/Q@?VS!/K9&VR9-9",A'M*K(E+J33'YF^%9(??QG&
MUR3-T0I]Y3,Y3TS:PW38GZ)CC$+X3V#V/%MR3'VIBX8ID,%F7+S"Y$A,< .%
MP;SRHQ04>WB3MV*]-25YI"]0L#ZD&!?Y!G@NYC(%X"QZM*Y$I=]LO #77,R6
M+C3-94O#-$$\BBDLK4AE$6@&UT2D8:"?W[UUWJ@H"[854]PW4X2IFH+XYB3*
MPAQ%$'OCXXZ^"SU5R\/.G^EFS]S'L,,$XT?T4%QF<QLM9S9RF,.EB#$5YP2P
MIF#!X.XB\\BT%Q=- AI#RJAY5$2ER,"!%XNRD[AJPN"#R9310'8JBOH'C!H[
M936E^G#X?XHPQ>@HI<H:9CLF;>P<++>2L3$%"],)X]YO%^('_!K/6\ZK,+IR
MOHGOTA>O*U3"*U8)-)6!7S;L^14NH;JPREXRA #PGJ/@NXQ1#N:!1Q==1?%W
MLU*;GY,X'V0HB00GH4Y4@M%1&N+I! 0MSLS0<DQC>0&RCD:Q!Z:FQ+AZ=209
MH]/*3%2LZ15_PIK E96BH>/*99GM&IK*H8+<&,\+,_Z+XF0ZCA7V:)1WKHZ,
MD-5YTSIJT725(3,Q%O+W7Z&BIC;3L'$JPU O@DO@ &$"^V =MT[A?^:.CR*^
M1+@N[R* 5%G@4>!V@+%I?B_-_R, 09 1Y]7Q^Z/7&);#*Z;@40.\LN'+\/JR
MX/5;U=\4<8Q!:.-N@D8C(,#LB4^EGE4'M)18(W<@CQ1ZS+()>#1OL9./03V0
MWJLEL_F1+."E&9EY+VU<=>L\\CUV\G)36(ARI['*CF)P/4;F\Z0FY9(HKT!W
MXFV8<J&_B[(2RE]*G1AK>E%M.;M^N[?J6E*DM]?NO1*O<:1?Y45JIN:<-?]@
M\YOUP^/O:5'$G_XOQIJ*&#'UQ:!05")>&''+MCA,R,K YI:*>>$4X:UUA0$2
M-HM0L$FOX/Z#%R!U96_Z1A>]?'>6_\\;W+(&.#(-:9.%J&KQ8YU4E%Z80G0<
M,H@6!OE:SI$NLMY&S-"T1\-I[9%K+Q_CIF,*^P*H_HK4$*8T*W:$9:QH?:5N
MO\V5NK7<.-_>S%>>/#UN55MNOA;;;KT']Q7+!'X'3U'[*NL.)W?\-*LN I]K
M;A3DM45V/[L5^%.DN[WSL@[KO-AW['QB%L!:I? 9ZZRPP]_#NBM6K?=5K7PT
M0RU3M3ECD2!CN.5<*66IICT]^OK-.3DYL1NE2I7HML\+-_"\\ '/<Q_0TE4F
M/(,K <^RL3?60[AZ4RC+EAED8=AX3K5KS@<LJ*-M=RRO';-5N7^C@K\-&\OG
M_218'8%<0U427K[P&-^(*5R,KLL$ZP6]O.!WZ7E:4LK#;!9"6RG(W$Y220#/
MR<LD*H5I%1,KYU/G<S0#FF3E!L=9!K7@XKRHHG'+X\HT+9V_D(=QKN.I\DR
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M*>-0;79OJ[#L.F?.*Q7S)XF<.8.V^TJ\?M5_C?S^55[D^>.SYA\MYPB8<K[
M7T2X*)Z1OQS?O1?%Q=NN5!# VYQ)H9.RW>3.WAT[Z1P>&LM_I5(G]>?0Y^,
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M=!50D>#=._C!<1U>-<"98VLL^JY@T9 TBFC++B>IHY \2M$?+-_8\E/R2+R
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MN..ZPJP?CS@5WXG&88/AW\?58OV/[XL$[,\<QRPOF!ZN=Z*%]V^&AV1K9#,
M[)UP#3X&KX1L@) 6%B($1 2ZW4%<QQ.+)[Q.V@5V&8EP']3M!!^/+$H@.S/0
MPIW'"80@?NE3ZC\1.R=S\?7!2CCV,GMN_+7#F$^WGWU>L+09RL%I0BS886JM
M1,I''HGKRZMJ<K)7 1V0M/'$9.IOL<NWZ>VB:W'&_EHT%$IM!GQ(TO]?P!3_
M<S^1;H(=<.LKO'&B*M,=8\+5X5]!6EQCP=3*::*:W2EE@K]\MN?@K]16HY]4
M,ADM&T?+S''PJX<Y+)F "\9,! L!^RA=LAO"8 ,E!._TC.'+QO?N1,(+GAM
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MS?$3=O\3"[+@'SO];@;^ [MWE-TF\*F5@_ML>P&#-@X>[.(-+6F=9EVD>8?
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M(6[A<E.D#"GY(C<3SNNI9F7M895'M#^$94P!J2/W=ED^:CN$OUZ=N'MHS3,
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MUT0Z"%R-DN.Y1/)AKO$T) <+L HM/U/JOGJ^GQZVCT&GF9&KW/6H]2(4A]7
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M0QW860K3)=W=AHF\.L[J<_;CR8[(+_\'4$L#!!0    ( #6(?U2>!KX72#P
M %&R!  5    9FYC:"TR,#(Q,3(S,5]D968N>&UL[7U;<^,XDN[[_@J?VI?=
MV%-=EYZ9G>Z8G@WY5N,3+LLAN[IWGR9H"I*X39$>D'19\^M/@M2%%P $*)!(
MR(S8V*FV # SD0 2F5\F_O)?K^OP[(70)(BC7]Y]^N'CNS,2^?$\B):_O/OV
M\'[R<'%S\^Z__OHO?_D_[]^?75[?W)W=D>]G$S\-7LAED/AAG&24G/W;P]=_
M/_OO\]GMV6T0_?[D)>3L,O:S-8G2L_=GJS1]_OG#A^_?O_\P7P11$H=9"A],
M?O#C]8>S]^^WPU]0XK&_GUUZ*3G[^?/'SY_??_SQ_8^?'C_]Z><__/GG/WSZ
MX4\_??KT'Q\__OSQ8ZE;_+RAP7*5GOV;_^]GK!=\.XI(&&[.KH/(B_S "\\>
M=A_]OV<WD?_#V20,SV:L5W(V(PFA+V3^0S%F"!S\'.[8>$V"GQ-_1=;>;>SG
MY/WRKL3/ZQ,-?XCI\L/GCQ]__+#O)6S!_NO]KME[]J?WGSX#BS^\)O-W9S ;
M49)_6^$CN^;LUWFZ[U!N_,</Q8_[IHVAO_^8M_WTTT\_?<A_W3=- EY#&/33
MA__^>ON0B^0]3&8* B;O_OHO9V>%Y#SJTS@D,[(XV_[SV^RF25T0I1_FP?K#
MMLT'+PSAT_D(*TH60OYW+#'9_9%)[5]+/=/-,_GE71*LGT/R[L/1-,&_2<26
MQOLY67A9F':D4#A.?_3&:R^(CB>W,HQI:O/!WZ_)^HG0KJ3RQC!,YPJ&HW[V
M1-[O!=.16LE((IIW!->IA6W47Z4K0KUG ON:7^REL/E]^O3YQT\?4N\UCN+U
MYD/.P0S^W]\?4MA5V89\$;,=.)C#?\[/O9 MWX<5(6E2Y6H!'WB_&S G7W,8
M#"S=>Q1^7A$8S@L-\<<=TQ*S^S\FT\44E"L_H(Z82/EX")B<D3F!@^<I)- "
M#)<T@'_> Y^$4M8R]G^?1,7_KN)P#I;-)5D$?I":D<G1GW=9A(864W^T]"_<
M@\E[YZ7P_\NK! @]]Y( N (&$J N__-D/@_8_WKA3;2(Z3K_XR5)O2!46Z?]
M?')(43T$RRB 6?.B=.+[<1:E<+VX!W7P Y(8E,_1WT$C%&9=S[.0L'F-8;;3
M#<STU3^RX)FMFZLD#=9L)7U+R"(+;^$JEO0@L:.)0"A.Z. MEY0L\^EG^\\+
MB3)ROGD,UM!A_X<9\6,8L"==-$G/D$*^]@+ZJQ=FY"OQV'_GF_B!F?UE>Y(D
M8">!MMP&WE,0 MDDV7:93]+]*-,(V,HH!4;S7:R;I(<E:DAQ\Y;='4GEZQ(:
M=).CH:\A$)#!(^6(+_0JB .%MZ#"QYVB7<8:<I:W6Z#!6=48<:!9O(F@&7GT
M7DU-I>: 0\[G1;Q>!VF^3<.R KN?'8TD,FP,'OF5816\_1+$([GC@6GJ<\A$
M=#BH%!KW)KECJ!C47BY=J=G)!D><P8M8I\$'VFJ;Q#UDZ[5'-]/%P\J#:_0N
M''0=T_LXA0T$C,=B"I/<1I]F*0MZL!A9=3I_)4FZ-=J3E 9^>O!@7+T2Z@<)
MJ(7Z%HZ$T+<Q+9^<F9=/UK8+N \1.$G7SR1*3/NVNG\ @1B2)%L_YT?D-_CI
M,<XODGG;:?'G+]2+8#*-BJ;C1X=<S@VB]PLE!Q# RH$E4Z)8V\HU\17[^K.G
M]S%.O9#?YNJ5_9.8U*#NGQW6\@N9E_'>@UOX(VATXOF%Z]OD=;#[)X84Q6V<
M)/>$YH<,FZ0LW7H-+X,P P;*OT]2.$">H 48G8\QNPS!A%?"*%TDU2,%VH+T
MDJ<\TIXE[Y>>]UQ(C)#Y^L/5:\J"Z_#=JRA;;V,EMT%2CW"SD9)=Y+\Q'I/#
M!Q*F"?L+&SS)1?/^XZ<M7.=?V<?:R)\3F/&@("#ZO=*8,#+G9+X;@GVCW_@^
M(VM'6!C[%6I"AFZ*.3@,10FQO]0%M/WS@320 ;F!?^XG(O2>2/C+.TG##]:)
M?F0:W$9PT<@^L1>AER3;\V[R&K0*NM'>&@ME2BXKN*,:[9R&+A+]]QT63)_X
MYC[-_O+W!T*9=TO!\?"U@I?:DMIM#&NBW\9SGN"F!.>U0.RU1I:)O<@H0RTH
MT5QO:T_%O63%/*CP/^RV^^*%N4\UO? HW<!M-;]WB+1>J:\UUDJ1P!K*9.NU
MDD^4<G<,#*KIGJ2#O;53Q,^3>V^3;T@%7:+%PV]L\6#65"J,:E0RWJ6KO=[,
M\,EV;N!DTQC#NL+/B$]@SP3Z[DBJIO;<+M88V47/[T,&@ZF&T 6,2+L8TR<0
M%\W(?.O=8+OWE-VUM@(K;8(\15+O;$WPEUMUWD>!2U2)9=_6R]Z"V#MB[KT
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M_.5#32RW\)\XBV56'YBS7M?Q=JR<V3.Q8^7,L?ADUY0GV"RF-->,>8YOW-5
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M''-3WD#65NNU>,Q0T=$"- '#RR!A$LXHN?-2^/_3Q>%YK$DT9P^]).QI/9*
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MUGO6//M5&"<4K-!E 8<JLE2]PU_*%JIT(]<=Q=R[VJ7CNT2$Y$EM:0=[#[#
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M.,=8X]%P^28.]F.L2-A'B:PRO&$L7FA4PNJXDK'F85_7/'F09ZQZ:.AAD0Y
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M'KGI[UJ!6T]-=JM39"L&F-L6F5K48&4+7^5Q% R&I'A\^A;:K8"3JR'44G'
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MH/O[ Z"['/__>-M)Z!85YU8\;"YA.0OS,B.#5[%5]?<N?=IT(7NQ]ES$5/6
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M;&3/H9G46LN4\LKP3-'SW2:?P051TGPZ^UN'#N>[C>/[%[O8 ^"^4F>S_M1
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MD2B45,9JGVG]0&N.FXE=QTT;\D-!9U%5E[)<D(H1O<)9)/LZ;&K]H?,]HS(
MA5X/JF/9& 0\34&99(-F:\=0&%IR^G5-T^+:83T*E"8)H4K(&/O)2YXFNSAA
M"D=4\[DW'=W?MA1M"BLOS-Q#0[DH+O8JM%%59X,& X?N<*K6ZH\D,H3LD$L:
MKR)OF[J(Z[-##D8, HBK[F@K?G;HVZVT.\KI=/JTFWE1[GB7/(51=0BZY.$>
MO1@9X%ZIQT)YI.=/6]\6$!('#)2@ZHYL,-!P=2T ! 7)51AECL>[K5,,[U(S
MHD<4%'_'E67?#U_ E,O'J2=8PCP+.#IER>(?3::_@PN\BV"NBMJ2(,[V3-D9
M535D 'D*JJ,80M \U;51F]C2D0,JJVD6DJD?9PYMHPPD8S)>3._**P8:C>MW
MX;GSXW('Q?#<#$:GS@U]P;^40X8U&=LIFB.$1*K3(6K&FH-%8(]X*W;2[[9;
M?Z_ &:>-BRJP8YJ.[4^Q8,I9>$SDH&+ L"-VU6(=16(0[B. ])E'WJ,7<,=7
M65"X>DRO&)(*).,XD3#:5?F]-8/,*HA*+ERI2J@^,S O[E&^UEY+GK:.)Q4S
MV>A. QLL+WNJ'3D ]:YXP54X5Z.@!PT(#R][K;; H<G(H7F[Z^+5M<.,'6<
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M]N7(6)\(_=7E5C>DT@DJR1U=[2#-^]W[AZ67'.1>%CXR*'/DVZ/-D6]-!RG
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M@*0]-H2$C".SF0:=H=0<U:*^<]JQA,R=%#SH(Q*.8NF@$5D%-1B<S0?WN/<
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M)H9ZALUOIXOQ<G;S@4S_>CN]N9O>_6!/ A5\E.G-(JG<G0=I2CF@,\7W0?@
M.!P\HVJ[2_1B"[7[&<^>/?$] CL\+"D5><D1TP))RA-!IHC*%4&VB,X7N=AS
M.M)CS9FSN".&LIY: ");@0X^!5Z3 ][/UM\R)X6>U$$SKEZ"X 3VP96]CL(-
M"5-408L9$Z?"XW)%3T)M <(._OK42#10(S@)41DA"B?P/:K/"6X(SBL5SY0A
MPCCB?_I\%T_[3A\?(_KH),R*%V1)N,9(+UO%V$X,N[P\I:37>#N[,/NV5T[\
M1-9^^*)_*>PO/BJ/9RBJ=HGKXA _J^0Y0\G$)R[IDR_E#%^!$S>G]Y-T&DMN
M&0759(^MM)C"Q3Y::(?4TLTF*!/$X"!)1GN$>8NV'&L&!?*E'<P%09)$H4F
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MAQ7N+7W]N<QO.PIR[E3/I[A+MTZ!RBQ-@X"^\+];<^-TLA#I+9U+B!=.0[X
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MZD()-26"#@F=R@&H3\Q:"H,WUB7)P9I>ARL.;?GJG8XVFX,VE33)ST#58O3
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M+*P@G,4\KG1ZXS8>L@ O@D);NL )IWY6HI6&9 KDLVD4ANOD!9!H U?^J#"
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MG21P'9C3MR%3@/S_XVTGH7NJU9CS"'"2A-$D0'3H0E0Y!:R+POM'9Z!N8;
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M.-QLPP"=<Z_>J6=<2C.-^:=4F=''Z-K$3C0ICV9.Y$7IH'>@P9*SW68#21@
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M4H=Q6LYI&^6"9YEP.M9TA=8,'R1H\2BGK=A.6W[]P[4='I.Y;^%:65%[OBS
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M4VQ=O6\K>TJ.M\+>=W21FI)"K]SG-*W"^5R%$?4>@PG@7$;[5HE.@A01M#I
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MIJ6F:& UML JQ/'64 E;<9@OT?'BQ -/\D=V.+/UM /4D=7EWVT<W[_8Q5Y
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M?E;"&?;:(2.#==N=ODQ6_'8)+I8MQYV68W,;>2<C?B,!@A2&R*4&0"!1%[9
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M99RN]H:[[%HVVVP=+T)=.))-3>=KN%*OO6?J\F4V5(*<3@4](]*NQ&S;H]*
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MSD@BOU88,B%CLB!3<F<1:MF:?#D%K$+.$<%IR'B5V.Q: 1\'3X"ZW$%+!Y[
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MW%BV.4^-S$3,,P?XZ@'86!70.,@!Y@-1D94A]7+KIXI&Z4PK<L6M4'XXEV(
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M'3Q@0LVV!".WKP *5VQJ0)R+V>7B=K%>0(G[U?QZ/O\RN[R=HZOEW=?Y:KV
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M>4MG9/9;:M@]75N5-!RJI[WFJ1E$'4^V'A)(K227[U=1D&5#E99FOI]+(H4
MU3&+2??FQE8_>BR6X 3?I\FVV.3+] &GK^&F9ZTU($5S%Q@Q9\Z!H69>R52@
MTX> "T[28<I/$LM(#Y:\QA/5AS ;+M<_SU=H<7>U_#*_0'?SM<N4JZ$9X9M)
MI2O2^SCE4<R[PB"S3F:;OQ9ABA^27?YVNC5>5C$@,C&GB 3),^#"A'%)I-F
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MM7296 Q,TS5F:^O_CBX3 "S7;]G ]XLMM>QNH37=,;R.I^=;!-6!%GAVB_*
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MK\@_E^DZ>8O-LZ\UFYBH:[6:6UIZ?2@5VY$U"?TV">+ZJ]BUYP1"Y<AU"V;
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M>%?T>6+1"A\@2"A^!JVNL%0U,[?U_@0TPC.U%-7NUG<:+*XPJ 3,'4@!XP%
M4*99-/#7W-'[%OR:1$6<DPOF)HQP:ME[E4:>O\B7),;O7\C+A?.;(MXV>*[-
M+3VN^76R*;C"ODE2N-ES<*VLQ%5N/#!'=?3]SI4%9:'H4.?JLWICWYI D,*!
MS<B)907/VK$S6KKXE!,MM7$[.F).).&3X0[Y%O=%NGD)#.B:)Q'P+8#)%%X1
M%,8Q)2PB$U$?-]R>O)*?E8E%-!FL8[[PP(/Y-D?IX?@KG(>LKD+GT.BNW2?
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M*GVJP4YK/FS55CZ]^+R8A]F+K_[H_3!?8?!71XMXB[_] 5NT_4HCWQI"D+T
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M"?$72I5/W3^A+VY#*0"R ^MR?</.!6YF7O%3V++J3XL$#OESFN!GQU.(W\!
MXK50_2[0]/-Q7?#AHYTFA8Y$"X:*9T #<E]Q[+N#/Q3-,3X#Y>*!/^-O-2=2
MGSAZ!QEYC=99YJ!R[G[HUAKY.(]2&-5!QVN(81%9JJ,8N3]NP]>?ULC+YO^/
M7_&_?LS_-=L1^,_OER&(X8MGN N!OY6C^<XS\O_V0_OWGX:84@GD$XQ*F%'M
MYT$GM B"U/%7:!]&)*B(S89%#-]3&9OF3K+5=)")+N#3:_SY&]_9$F97_WV0
M*>5G]1*^&>&[;8W>_S<Z$*9&;C?H]MX \W1\8(I>"&]I-XT9^]MN.\A4"XMD
M_O6_(R>ZAIL1Y"@29Z$UU8 I_KP8HJ>6@TXSWT@ZF.1V QZ@/Y#O_^\@? L>
MD1.' 5K?PGL<1=2#1&L_X)1_#_T4+N'H<./Y($10I]IL-\@4;]U-M$A!Y@XC
MD'[@K9H)"Q2VR6@\()X8GOMT]\S8]4J3 2>V0EL/"S!!<N_L2*>'V&S "6+K
M902W</X"Q_FG+K&;6'2X#-?T^;)[#3C])^?]=HW5NMA)'T^&0P6T]@-.&9ZS
M((/'Q3] !D>?J-,EM=4ZU<\24_VL8:J76,48/0%SYTVTTG+X:69'9AD]1.&K
MAQ.U<N;:;#[\A!]"X.S^_^?MF6R!V'@8X0]_/4(.97JUGP>9$$XV[#^\@'A!
MY4BM)H-,[!''Q0 <GSX_/V&5 &%BK2:#3 R>A=@,]WC8/8<^85;UWP?%ZOK=
M?7&"+:+<X<1F0[X@\^=,_IK&$ &[(+XGF,T'%3H2A)4Z. >YDSC%A!C2!K'Y
MP/)E= E,>!M&]!=ZO=6 TWO<.;Y_D<9PZ<;T?:^W&G!ZUSL4;8'0OD3A6_*"
M-:Y.0$>1W'K(Z;Z?-%3YHY8^UW;3(;?]!5ZR/#AKC89D2B=5>>Z*47&UH+,F
M5J<!)_^0/ON>>^.'#ITK5=L,JI")3Z\OM+Z M^,& 3]TT1-Z3R[\2I) @I*&
MWW<896RN,:#<I]5?AYQ.62""/J5CBR&G=>-%NUL2#ZK_7IM2U<RSB.K3<R*W
M' S^M6:":A>K*%K\M,^R4']T7SS_.)5-%.Y(IIKR:R'!:O(AC-8H^ML//__P
M80_\$HM-?_L!7I5I#+,(][F=%_]6.&/=Y<NESB^;'(@',<I:FH]"W9)3H/%I
MJFBTS48%(I]5(@(3>0Z-QZ1AH2J ^&5JI$&QBA5P_#HU.!@6N *2?YD:)'1+
M7X'(OTX-$:I)L0#DWZ8*2,-X6<#QEZG!P3&4%K#\-DU86L;84BB;G(S*LOR6
MH$Q.5&U;F$LHE,JHXX&B:=,NX9BHI,JQH)?H3$YPY1CH2UPF)[TRO !*3"8G
MOS+<#4I,)B?"4OT:2D0F*L727"A*6"8JQ9(=-4IMVN1$V;I#2 G#Y(37MAM*
M"<7DA->VXTL)Q>0$UX:K38G#Y$14LG]/"<=$)5.:-U$)RT2%4YK/4@G+1.73
MAF=4B<9$9=.&(U:)QD1%4HK?5VG8G)Q,2G<O*R&9G'Q*<F0KP9B<A"KB.%>"
M,SF9E>"85V(Q.;E5PA.PQ&ARPFS-Q;!$0:GLZH\"@)-38PF"4DEU'""4+I0E
M!$K%TPH$__Y3"X$[^$/?>4 R72AF")=A$(>^M\[X0:4@Q"D_R8!90#9._)Q!
ME<8?MXZSSY;P$_*3N/Q+YO#Z\>=/'XL\+<6?*^OQG3@N4H8MWKUF; .__9E^
MNMV74)W)58@+,E#F3FBH;=)''+."?#RP\T8:)]O*;$K.)2/001^9G(2]+&D@
MC4B:S?23"+ -= O_RCV3IX;:)EUD86>31Z.1?H0K5<\>POR]R*5P@:Z:=Z%0
MG EM1K.MOF/JQ"\X=3G\ W..5\?'TO<BN72BZ #O,N;9%>HKO[1VFC/\E^^/
M*,)YU0527G]%A,#D;F-HVYA*604QPF)TT'<P\M*2\8-SR, FAL-R&INP T#E
MTI>R<'=M"RRK>1SK/%2F?(]HZ^+U4G;>A>OSD ZZ>&=M\)=E"W$FT*11NY""
M/;.+]E.^0BZ"6P#.+DQ'[*P3NRB^,2X4W!@28^C;AF,VV0?'@^-YZ>P]7"'N
M)&'3-H/?4=NB5C@+:0 'V8EPX;\8""?=I5D686!$GNO1*$R@H[9%%072BSJ&
M)3,ZL(\,IY/&AUZ0W6-_>,G+91HG<"E$Q]G=AX'+7)5H;\4\X5(!3Y 80]\5
MGZ*;*-Q5\FZ?Q$/:_<[J8LB16>&RH,O-MQAESRFA$]/L8Y!Z1UBMHY60GD))
M,J)U4'R6KQ2<98DQ-,J+: _W<R'2EA)M39] %1OY/95MRFT 4JJ+XJQ"C1.Y
M6$5PA5Z1'V:2*FD/>%WT/0'#8(O+#%^AYX1[E5$::W_>K;#Y /[I\9? [*)M
M(5_"</WF^<W4::V?S12!V$=3J*L9BDT1A::^J7X+G!UVZ_PGEN^?$QP C(V$
M!<^CS)W3R1!I1UR:YO<S09O&IB="0WW[@._)JGZ+NP'T#AJ?T&51)JRIYRZ!
MVMP$TN'3C&9BR;FA&)VTVFHUUE+JV#+LMK0>FJ\KYCVE;W)/:(?]V:)#_I0K
MC62+'5:$UHOQ/#@,TI$?QX2#2S2!=+2<:'/*.CW,.5X\V$GK>%((_C*6IHIK
MX5/SMJF"PD#0>FQX=L0:\;2\:*R'A^:%4X6EZ?8R%5 $'&>(IZPXAY;#1':&
M:M--RY]B$KA0O$AJW$;,&<ARN.@.KABKCJY(EF/&]U:J'4.*6]!T0!)R**I"
MQ@+8<M@DI,F*T&!I_F$5M,3U^YH.=@QF)>N#9CEH8H*Y.%E:#A=?%F6[_TT"
M'@E1@>Q;:#E*PI*HC(NCY9C)784B/I,S8!7 1/PQ^RAT8!!@<F\=GJ_G=,"2
MEE.%/4LMQU#X&I#Q:K4<,V$!@^TA.PF4Q-E7R^_6<GSD^!7)P-E+K9L01!0S
M )*["UE.Q)86!9+FX3+>S)9C)LS#A3RC)P$659'%]<JV')ZS=.\4+_ 9,JZ*
MF>Q[;FG%,W&IZN31;CD4<O*!F!^]Y9")JT:)]YM:6,R1-/F'BA<!8&E1017L
M6B#>8#KH"1P]4C!#+P"9<_[.(B]&&(6EA2W%V18]/,-R:!2YP_14"M2<DR>@
MI"-'GEA:(E6-:8$1\&)I+559-]F>@##G8)U#0!VB>2RM1:L"31%'(5O=&Q5=
M@Y0 JWZ*VS;.L+')H?.C]X)@..>8/F!DF:+O1I2.ML$5 ?YEE,UOG84./* H
M*_Q 68EH[SF!;6\+&T=Z[#F'^IQ/]TS6E!>@6:3)"]R)_T1K,9;4ZC6U5)5S
M4CT:46!ULQP9%3W,6D:M))/X6JK=YO1NG7-P%#['DG*32$\3EB7(<UD]S%D&
M\[S36ILS??XY9W;1_6@6BT82?HY,)8)RSA\PIRV94]YH]>^<DP:<Q\3;0H3E
M\5ES$."<,F .(])-2/(LJGP@]($0[,ES: %&Q +0]A1QG8,_^J8J(:6)Y0[#
MTDA112A;G3L[(M3@X+;ZX75$A\2[>W4U,\G+X/A'8.N%\S3\.BX/@SS]TW$E
M' ,VK;5^,_ 8;-;W0%6ECWV.9!FLR$:=WT^9M>4+B"7Q71C'<+2#ZW?\Q=2+
M7W*U8190$;A^ND9QD1/K-H #BF)B09?.8ZG:H#A**IL#_]7<&/@3SL"T3MT$
MI 84O7HN(O@04)OIF&CFXY7/(29Z#;#;*J.4R]"'#X8YTUNA5Q2DB&Z!8[36
MSSM:5Y[!SE4%=KQJWZUFNB>,TVN0(ONNWS$/P$ZSF$_$:/WDO+/7)#62_N(M
MQZR![ VCM]=9,H00),ZNI</NHXSYK,*#XV.'UPI-5%)*'.B,2+"G-M!OX<$?
M9S$)^4U/+P-,:JFO.A<*@'Y]V/;%>N<%'J;=Q'OE5%[B]=)_>G-HL1##.[>5
MEOJG73(146:CD7! *,&@+8-'QT?+32TAYC$;)HU^Q#KK+09$E=YIF\/N9-[K
M1?;5HI.YEF>T%"*\((7IG1[O%V@31NB8$QG%\&Z)G# "N<*)#IGLAX/KL/@!
M$FVV,N(#:(@O:H81)EMLZ 6P\0VU!C>MM3Y"1@F7K=?;F#'5Q:OC^7DT644/
M5X3Z7'E^FE!=T>3'T;;D,J=HJ;F_<&+/Q>(D<X&\7MJ6\P?"V?+0>O$*!WZ+
M[E,L7BXWV20KRE.Q578<3+=NF:-CG+"SF;!&\&@B[*Z@LQ1*G@X/(\=1G]F/
M#%UI>"0LEC[/4H#D;%]MS9OEL-!4C010Y+1[EN/&5?TU$K^PE&Q*H?HMARI
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M*O,8+V&<YOM(PM.\!&J:#R+USNZE\6#"#Q^UCO0EH!-^V+!]]$N IOD<H40
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M/9QDIM"6#6_8T)0^TFP9)#2HN<AD0E@L!U3U148)DU&*HHE\84AI5B1RQWK
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MH^5.SJ(L3<CT:3E6DL=2P8N^#T M4A+1#=Z6I\62%T2(MG7+4>IXC5)TNWV
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MWYBSD4T$PSF+D=E9C P T()T9 :@./X4/*: .-;,,0;@-_X$1@: ./[4,::
M.-8,1@;@-_[,,0: .">=& $A3@##.7>,V<=X3JHP9XR9\YX8#-J<)V'.DV L
M&YQ@0I0Y\<2X^.>T$1U;*H]1A+K/*1+.3P/05X*$X=, K.!_OI]R 2Q<-TK1
M^OI]CP(,5+!>XI$*OXP[SWGV?"_QJND"A+N,,GM L;K*,HJ%<1(*\/LI\W<K
M/K4"'.$@O, &7*%7Y(?['2+G#V!WT.:<6$SK(0HW*(ZSHW2#CKBQ<:9UTKV8
MZ]W>#P\(7:  ;;Q$;#&T3OJB%/"!IE(T+3B!W4DU^?/Y#^,H"'36?7,),Z+C
M9<;A"Y:[V$GA)<J"+/5G4H$9E=-9ZC9R%F8\AFJI@?YL7B;"Y'LQB8;XF6Z0
MG+X"3AZD:+%>>_F*;H--&.VR[XU3SHXB)]BB['$.NWL/:SK]Y0G^+0:RP*_4
MKVCW3(W[E!U%F1#RY/R)ULYB&Z'L4\1),AJJDNSB**E #O_5A!O^]!UNMW7J
M)LOH$46OGHL6[UY3-J(VTS%1O)/%'.*K<.=X 7VVA+;Z@JU"'R888F7+*VI3
MIDOYN4JF<%#1;8)VU+ KE9]0=AB^[8'=!TFA:ULA%\'GUZ330&FI;<L*MGH#
MM]4ES M?17]XR<ME&B?A#FYL]IM?M+>VY9V4-@H(Y\EY]FF1SCU\:%#.<QFF
MV#8$DDQRN'=V-!9);#;H1%=HG\+;SHG1\4II3HK*,L7[*KXF'UX<$%7<3.AQ
M_,MPMW>"PYVW\Q*TYMV< GV5S;9"NV%0'&[Z_!BMM1WX)_C"<E,Y5P1"9K?5
MQXK#@^,G!Z:X5V^C,L(\N/" 9=,WN]E$G38KCE'R4)[+ -Y(+G[Q"$B6@CTU
MBD/M*[%\N!V*\P(20+@-O'^VI(6.@RC;EKNOMY?B6\%HK5,AC9E[G M9^$J]
M1PE7'4WO8B8==2$;=53RU7G'EN:OGH_@&T%I;8:3&;H>]J;!WZ\H8>&4P@T&
M<X%??>^?V<WQ;1\&QP&>P@NT<%\\1)&?^_V@.EP:\XM+2?];L :YN#PBQ!4*
M=C7UR9#[%F%/&F#/\'_K)^>]V_.!.)*V9<-[VT5H'>/9YM>PAV+*4T^LC^X=
M7"$LZP*^#RC*=&F!6_$!8.\9IZ]V?6LWY=I1^TK1;EEJ0>+IR# L'/64I<CT
MJ=DZ$AM->V0YII*JIZHUJ0^UCN5H]Z<)*[D#685D*:P\G5D)BH2ZRF*DI)5V
MC8M81']F,7Q<L] 1+I8"SU* A#1_-?<-6=G04N"$*8NBH+3<-:C?"Y-#M99B
M>]Y=T-)26XJ2JD>LJ&;=<AC[>KMU5?-;#O>Y5,LR/%CN6=DWI;(M(I:#V_\#
MF*Q"LQQ6K=S5>K_A8810M7MH^9;TJ@KNV9YJ:?*L8;9&U*1K:6JCH1A^)_.R
MI5EJAL*<8]NV/#7(0!3-,[?WG)]A^ B>4_ .'%HXNW!2JV'TUYL-<C&FQU]7
M<,/AEW+@@G0WWLB>XWHJ60;8?O2L'MJ\1$3V9Y'<(*!:QW^$W4AA)H=:8\IR
M58QL-"SPQTLXHAZU>I#D($8O%E@DG#9X^'KPO"CB%<]8-G$XHP$X;509>:YD
MUX^#&;WXRQ=\']X"I\ZO)6B4Z9UCG)$H/\F^'[[AR^X,5&2^8C1<>1ST^K]
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MYQHA;2=3U>;:6O+,FJ'3<B1)5ET2&!.)S>4$Y4E:=RT':PX/'V/ &M\4/'6
MA4W(4K3>V08[;X?&[6A7'YE -+%ZF8J<-\5:* >*.:;8X"U'5UQ&$_$&L!PL
MM=Q5@=N"[>D&^N2BDZSWU*-\T(?721\5D29#WPJVVG;\S9*6J4Y$EM=SZOE:
M/<N/J8_24-9"+^LI97F%J7[ [9Y@S];R5/W@/)![F.4EL4:V-Q3_,LM+<1DF
M!TGYI=E> \S,O9%V;;.]$-F0VV1_S3+#B%[:1Z^7&FG6[H^P/Z#M1=3Z%98D
MJM195GM-+%$-/)=V^7'^!C\]A=G-5176LWL-GK1C3%XS)RB9$Y3,J0%T@7(4
MA"M,9N7%?]Y$",&#!@'O2%;MN,GAOJL*TCA**G#"?S6AA#]]7^%I$U*=U'\;
M?DK$F/;FKX-.ZRM(1+MT1YU8_?=AI^:\LZ=6^WU\ ?&DHX,E4>P@\H2B'2WJ
ML,</VL'WRC7]'H*0X/D@8@[%^2A?M@O6*^_56X.L.32HM>_J?DC-X22V/6('
M$+TLW1>BQ(6A;<D]M@-0EU5*"!HREJ4@].IRU""Q&4(CO+9L,[7PSG']06(I
M"(8Z<@J\EN8-T2WVT%Y>MGN1CV=GZH^W(;QOM=>[:T%XK'FW<!. (SD4KOF%
M$6:4UI=9F]Y#>J5*M<,\;D U1M3O:,_&/J>-ETT;O\ !;.HRVW8?=RY1,5N
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MRQZ86_B>0I",BBNL'G.UCU$K;5MV%8O*+RW\;'2T)B^BX%B4A0MVUK:X+RB
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MDCW#JFF5>JM:%X:MP4YYK/50?:, 8$^MDI<W#M99V7#(HPV!/JW=ID7[<=H
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M[M@DBR=_?7QW5F;ID_\'4$L#!!0    ( #6(?U00]1EK$%X  %', @ 0
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M!GD[406M))D:M6)XP3]!T)1Q$KGH=J!J./<*BD=>(P _XY32:ZQQ%ZX!0&L
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MSM@AQCM2GUM 3!3T)MI870.2#]_>)'EJG=9^7$4:[K[:"YL<+0X;9%IOR5I
M(\[13\!$I4-1YF-WW%,6JC2-%L&=S6+UW[UDG5&Z+O:\3BF=%WZ/E!G[?4TI
M?>L#F?^B)M/7P6</RWSNW)0K+K27F&>Z\V/'<?9[FV?ZMIE^MN(K^*X\4R59
M%':KVM*+W7D'K"!E)AIMPS4&*VD,/;(-,>F2-9J$E%!TD0XUX3(GDSHCN@]2
M #''CT@LK+L6X\E&/</_]<&(<\$%XYZU4=IX+N<TM/K?8WIK EJ<SH# &-2N
MC%*.6H^)7TLV@X[G:V4Y'R^F3*!:2,$HX5GS4Q*M=9U#.U"-K?3U+&QFOW(J
M9^7_CI%R@B]16BBL9]3IS.]<V41'XXP02O@7QN\UJ)_X>9+'.J4K2@[(S\I*
M3TKW4%0H2S6CR,MDBNN9[H+FU"F3,F&UK!)OP5$*F)J)4%41M#K [24WIP;&
M106L,&SC; 98[NB,K<HV^IS>*@G&QK7/#G(8*(H65>,\-KTJ2RV=X5)G7U%_
MG3!W5JPJ9>J5PO25DAEL^%0DS$1UX+P468I#D5<Y2E6"W4P-2(PJDNEAGG_!
M9T5C3>JTF"J%NF5"<3\,!:\>Z4(@^+"4^A^0\O92;T2Z!QU/RG8R?/-\:-K=
MB^+ACPN$.V!Y.R!N+':3^;8H X)2L9'+FXPN9@L2 ,RB&9&S-T+0GT3-;5[6
M-T'H%\7GNW+,%C;* =XQ(USC_L5I@-$=U>D(K=3%^6=Y(?=9-R7C>LR;R8XE
MEZ5$B K"X\-M)1R_J2KH:*E3"O-O--VCXSE'YK5!.IHYZ/!H^B]:\!ZOD)\T
MFY&T+B,?'K1PN'S>>&+C;,9$Q9-"X:XI+VM$+$GPCN+M>+=?%-9!*OU!IL5F
M8+;PU(4-XB1,1%6YRO&++GX%)_NF+,&28OMF3<EZC&%[DI\)#HGK,=+3WQ9Y
M=HU\ RJJ&DA0+D"9P/.2TK'_C2A<F%)SAK/6.C8!0.NP6$!(X=C.8G1FY#,.
M0E9U :L$)F\N70OG$:[<#$QN$JZ;A2/6<N01WI7FKHEY;69D?8=#_/ ^D.O1
M$L!D;8_XWE&_/.+[O4V%//=5Q<^B*KX.?@=MN@Q^1543-\DO<.ZLMHAN8LWY
M+,YOF6V5EE5H2MD3D[7D7'FJXSSNRZAQ E%@43^=\9^,%H&'@VG$M3CDP>9/
MHW:3GAG7$:J/L498_U3(GO$,1V2!<59;9?(%I":=V[ZL]K)QJ".R4Q%Z@G C
M328AVWD(88X7@:"'G.@O$LCC3'3X:Z.?/2!AM64@)^0@QRP,(P4$VD<VK.$4
MCBULJ&78>:MM,6%PV&%CAK2PXSRJ9:5R28"236(J  !RE@H?6VF)V<>@/:2E
M;S>#%H-::IF/JELD6"+.24E\00[T^7M,T@EOO9!4SJUQ?NL9?MW&+>_*1L>Z
MD)RT8]&VI08TJ'\PP%:@78AFG]?GBLMF(^-5HDQ\K6F)BG5(D1.S_V%])2.X
M530D&KG),(\3J=T\8@1\[W<Z2HJ>['&>H0[HP4T+7.MV(RB H)C $C6.'U[8
M4Z'YMR%#=]ZQAB8ZWAUJ(]HEZ,$JD65VGH[L3K$EP4K[4F,_H33Q7&MPV2C)
MDG),9]D:L[;&K*TQ:T^J];]XS%H/66F0"1P]QYQY-0E!$,>=^EB7OVS._R\G
MK5@" I,P^@*K*E9/8B7&7<W ;<Z'%M*DKO,:+)=Y;#1CU,78P.@$Z@I6&9TK
M5>Z<7$*4&*,?  LZ&/6"'C Q]ASF[AFQ2%],ZV*:EZZRA'TW.L3LMZUT\KN$
MV8,%6?-M!A>"S?4#(1W66>7794#RK)R3#6%@05,#K593!0N8,)TA5X8$7$Q%
MC&FJ>!1I9$AURT7SMSR;,*#)#6<6W))!3/$$@J++PD"L43TQ!H!QB,+%J923
MH-5F)J']/#L%JL3WQ1W4.F/A]BC5!'.%% 72&I?CBC7#=QI5G7,U#[BTFX2C
M'OBC%I 63:)H_A[-OI<S@RQ>A5GT94-QP6R&>6IZ7(Z>NQ:7ORX3!J_!-?J&
MB5_# !5FF+)RC/L6K6ED*\*9 WT_-(Y)S".%J8S8;ZQ'&I<4Z^B"9,._;&S/
ML>O?N1"9L,V#PB&\[1KI#N9'3S)6L]PX!QKW>YNU<IOV?IJR-=#I 4"G%>CT
MLG%.H$CMK (AW1^'2_X6X--!7X%/[UPLAROWKK[;;!!\S#$G[KI#8EFKFH+V
M' R1S+%6OAAS0Z>S8.-T$QZ45 GK2P[L00:U=;8Q6T"4H\N'K^1O'%-( XJ1
MP[6J+N>_IWK%-GR7ARTN 9!_#&T@&2])<Q+J,J 3EQ+&[C@/AB$I8@(QX8=C
MUFJBTHURLYUEVG?WSWM_($XY9(;T,:N]?IW;%R9.%9Q/B;ST5*RPB5/&Z8:5
M^CK8>+-),<Z<^=-$V"<91F5)ITGA6:F!E<BRG2=/-%FBN.ZYJG;5N+;A!A*<
M>54Z>@GDWG%LKJ2R+9H$://;34;JC&;D$W6UZ 1'L'C=*YL-23W2#$B:W?_6
MAN&S:%1I1#$F^XZR\PVPG?5+#TPCYE"AO9125[L)ED<)NMPPS6]U.V5A/CMT
M$)Q*N@"._GPYVI%&ALHT>,<JY14AK2Z%_%U4:U@VAYUT@'BH,'U>D6!@-N58
M002SC1^QL),M;H5-,R_#L']%+GX/V$6YK 87UHSUJ^:%.#ROB., #F&R[S!H
MSHD)IIP"38.\+^2WT;&4YN@$][);S3D56K:O!9@-H^LB3TQ>9'K&Y:PHP%[F
M*0*73.O%LL2FLTM=%IYWK-+F*VM"#\#T=J^3H>MA=W54TQ3LO,F9YJZC"5LG
ME83[8;4FIM*70DO&%TMTA6GE_8V*7*.(0YJL*K1;G*UDW ,!6"-LLKD&.5H&
MN\/ Z!43&*T7W(SR?%XYI58I"M^"$_!:HM<@1!K%UO(AV2H,;FB"&MA0\\Z;
M(>7T, V//0DH6YYLF4;V"KW[,V;HPYD\-FL"T2VC)C^.SV;-!#_6KR)9A?3T
MM5GT'9W>^1'R/QXR^2^&Z>A;3*##OII 5RT"/^N676TULE4&V./\W5+P:!#\
MH2 N31T@[&@S"MF)!G#^7*D;8-!>[/SUZB5X"$\/DN9A1RWYM>6I?ATTL(NA
MX4-SJJ#]W?"%RPNYLH$MYNOC*"W<,?>NM%1G7 X]V-C;W@2;+ 7M2H$$4[,2
M"7F8!+PSW_LQQ(ZN6V$P!GWP!L&;[0),-)Z,/\3B5],FIYR5AUY)"5]%QD+*
M6*>T>8VG@MAZ6N9U(Q5AG:?$(-H9#V$@\Y;F)=-I(T3!PX4#9'V7,C"<7CD(
M?GLL[^5\:>I[RC,;++W.2E?*R]:K-E4K.A-:CYCPB\LW.&:]+'?%+BPK#.L7
MWFL:I#KN?6U599&S=Q!<C@DNZU],F!5""9-/E[$T^'G" 1D=V_$U-D2(Q9N-
MMY> L[X9-U4SPS";)KH6SFU\ .P)!P.'Y8+^;@H)8)MH&$"))J"1/R/-V7V(
M>#P:'!P?S>5''J',?&1^9%>1Z)<<MCWL;1:9+R8)9O).JVJ\ZC+RRL@]WDU6
ME#V(&'I)FN))EZ;XDA=]C"OE)9E8:\C/&O+S_-OH8+F0GP>PC#\+Z*=O+..'
MO<V_F!?I8&-P;=A5E^OG(]^$J+%4E.CIRNO%O-W1-L><0F MY.%<NIRO?8>.
M^(;YA:I%&@8^8&,'C$ZV-6W.).D;--SSM2[038G6;'9GW0&Q.V+MVV"H]3<Z
M<[=%9N(83Y2Y=<_!<=P%&=@];/S[[H/C>*]O!T=?RQ/X!T>+D![=/6^Q8MRJ
MGR!7K9,@F1 ;=D45I>U&:H9GJ&/!!I6U&R59T_%PC*5#T/6PN<Q]-(]!>G(!
MW+]]U%>&_3OVD0&=]G(O=4C5!K=^HW/+VRW/ E3KWV[I*X%F:[?X=61X.;W'
MBJ(7%&=8]1WC&O^8_>)U<+$4V@N$>&9Y9&!_4";6ZDS@X>#PI6TBU&]>T@9J
M]2?8X&!HTV)B4G^7?\/65HBU#3AZZ5_?9J75O/\2$P+SW]:](Z5BG!>0;(39
M6C8?F;,-.$T+GO< $NH>.E>?';^RMP*=7M.7K@"$Y:BO$)9+!!P0E.$SQX97
M' *]/(J@I="4]ITAZ*BW0>?3*"IJ4' _.;ZO%5_9#(ZYV_?J*15A"Q_5]%!+
M.HN:M7'\B..M)[!MZDEH2T09?[.MY$2.YU&.J"$_ =GH,R;PW4I&QC)5I"MI
M!7.&,!N)E_OL=8(E;T#<-T/"?V.3ZVRJDMA 4)3,(L. 18^YOR4A8[K-W<@5
M4V>4>WJC(I.'R^0W#^Q:,FK4GL-'YP77<#8J8+;E=<K,PQ2KB[)O$Y.&MM@J
MTU^I3*DMXA8:''K"]&IU5NAD,JR+TN/)(9;/#+.=\6D=#/H^#(IP;NX130]1
M.X-@CNN->J._2F*%?1"-!/=H;2$N\<Q]"5'!NYR2B(*[RX+$-#W89,\Z"(_L
M:M#/&7J+H$U3' -KT05OQRJ[IB,-?JN*/%UU*7G>),:V]GOY2*HRJ7#,PC/P
M*I'2$D76.U5AU28O*!PV\<K?]VI_O?O(9Z\E7@7'G=TM*KAL"I4XV=PQA6T/
M'S[@<ZJRS0X=X=6W'>1H=MY;6'X>H/F"DKV_;?UNJ,WG/=P?>T"H<FQ,P54_
M"3ZWM5O,[+N^QMQ85#LGT$K024F=1-8+6(C!QHD4+D]G1 <"&X#Y0+I5NBX6
M7,R8QDR!&6PT3)O%A--(ET36[NO+>C02-F*C4BJLWD4@_H4>^!V) PMM)Y:%
MC2CSD#>Q>6O,_DHX-C)8^_)B9C0Y/("F@_K>HMKVU=NPA?:NB5C(CD]%0XWZ
MKQFI(;99-/(-R4SH^@V)^+$_W'4ZY3P%U8N2+U3GYQ3OS4'P*6MVS USQZD[
MW]>F%B)&T0*+B"YV+I%6-:@N,+Q)-9;^D/7#,!V;[4ME*%01V]E#"OT8BP&C
M76+3934R^\!>2:F8K*W9U>@Z)<C:8H;"E<[9OM3C_>V3T]"MWB%,2\9I*<V.
M#355N\6=0=5\F2T0)L8T+:;,V*6)ADY0SP\O&H:K+1K>2%++RHL%8<;TY4),
MQTJLIYK6:.GV"#%4I<D(2\A%$7&9A\%8J[0R=+1$% #"HC9[AX>!4IZ)<:U]
M3*A2S@?*17[@L=< V&'- Y(AXD?)1\PJ;T& MMI,=:M3>.?&SJX(MK;;9G&.
M@M^"UY9HWM[C.B1R2#.; ]4]J1IN'SKU6#%]&07H/\-+6*M>TX^N<Q'6N0A/
M"H#X$>A'#_YH^M&G]!B!+EJSG/I,9_QJ*P"6),G/K.;BOJ-%Z/:(.TD,[I9I
M"+$83$MJN8"<4B\%AZ4(<48NS4E>B*Z-S#%.8YB"%EX*HQB1L%,%8-#%X:I*
M?=5S--J^W22$KJ.6@M%D1+*,FBUK]9I*$8LV@\U8K(X8/<%72P@H @.<2BIR
M&;S]].;BU#PP\I8&R?U&*Q:%H)0U';UL9(5-+4MCM#?L4W[G%-.9ZXFUB9QJ
M=+<.=(^-B&K/FTU1N5PC3?D>#=N79AY?2\2W<$99.B1VU4D4IV@/N[V\]V3Y
M1O,/^GL8M$GT7?FC#NH?6PU+N)01746,"R9%'PX37AF<*Y1'45TTBJ9UK3K>
M2%,L=I%5IKP%&0I3*M@PULU(6REEIT3[-M[@,OE:S;9&V(F-PX/-=JCVGO7N
M5^@F@B;\SG?F)*5S2=1%HXK47<N _/)L!PB.1-PES$"E.WC-%AX9Z)C3*FXY
M:N"DI#M;IP<=PGQ>W*BTUL951G:=<6>8LB1\O)2&GH0BPB,3M#:47ZIL001-
MMI1>KE/D:'#\##6J>N<5B5;<*Y)G]>J[1.8]Y3.#M+B"!:*K@/HA>E*)TA5]
MTWA:P#Y3IE"4+4$GT5U"D(;V$JJ--\0'86TH)#_$%Z!;E"L$HH,QJ6KB ]*F
M+4Q G^4!'A,2^/J5J@'M')B39P;M:?DUA!>=%"S\>0U(6"(@X05F&SX.D+ &
M(ZS!"#\*&,'+?'\4ZJ #7!#Z3%,4D3(J9*DI]%6-&P1<@]U #4' ?#LH87]_
M_][0TXLA6UQ#$/[H_2^*59-\[TX8PIRS8HU$:",1_"%:@Q'68(3O!2,<WZ/@
M/X_AO7O<,\-[#4=8PQ'6<(15\+];57NUU_JSF:'+B'$B;-K!/GH<Z>@*>ZY#
MGB\RY+F\>@3+5X?Z5J!U'5U>NG2SZ2OK>/,ZWHS#\ZB%\801Z%Z /M?LTVO$
M9S\0GT<O$?'9F]'_0=$T+[S4\!I,\T?'?-9@FG7FWU-MR[@'V])%;'JX0>>\
M+!UF"^Q&#!JJYB8VQHFM_T;;QS+YW^< 0$NM=)NZ=":;C<29DKI4=HQJZIK8
M'%I@8Y@O)N$A_B01T@N<7Z.D*"L3&?8C:,UX[</#P]\<V?U>X7X_BF/YQ\A)
MS_B9-_1J'R-GL(*K67!Z"ZM^Y:7\*=;?XP8K:C#'Z+"2NFQ@ZS*H\N@+>Q*H
MDG:38)I.":P93> $BM$[U[N4<+25#-$M2#QA,[I%E :0[D6$N*^TJ_A8FYRV
MJ^FTC;U&")DL5I,<)W"L&^^0KP=<YRHM78U%[^1J! /H]?R:Y7$S/@N53/^X
M&5]"\8+>5/TXYQW#I7L>";%,G%8PS\9G1V QHK-%1MB-'K5,D#Y^M,%CG611
M6I,VP?"#.4SIYGQY50P&=I18+3WXCOAD;5EX.-_*!'4:8MWT:JUR75[L_TU2
M5+5$#OTZ0G-%?I,FP);*QV.3;I6IW-ODUC;@H[W!+@.4FA#C]F%Y+R*K0W7T
MD&IE\C78.%PUE!KR2V*18',U;%M<-7,LYJI(B$VR01;N%C3ZY> .>?XHB>LH
MP2;'=47Q6GCTB*2&%\8  8+\Y&"[TDJ8CF=E IHS7D[AU"+/DF@30Q?6?^1$
MC(%(+@<6>:_6VQK8-3'Z=W1Z]SD\W&MF]!XPHQ\/_O0>) 08N"LNX)>FO!X/
M3M;PTHYU\<S,XH]LGWA 5GS1(E,NRD)R)E%>CJU!;_6B>2W+* 9HB!8@TD,?
M16ITQ) 0X:AKI<DDJ5CU<VJ?#1@Q7,6F\$C!DM 7Z^S[\NI&3E6AKF$(0+O(
M4-#[4"]X*%;D3#)XG0*U(Q/7V#"1'MI>@$HP4C=Y8?$"K N$5.)2C4:@TI+V
M+/5.DL)8[UP)<P1:0<&_QDD!7^<%JQFHA4V<(MI4UT-"G<)P5PF!U 6'1K>H
MJE+H<:,QP.9C[&N<#),J. TV7@(2M1>[P@/AL/L%:Z.R':,S6 ,W^1<=WPEO
M$9UW,2;Z%F>XX>@I>&3*AD%!>)Z*@<H):/)% A=L\'JDX*A9I/&\3==U[Z84
MJD683JJ22=D&>V. E;;_+:CVG!VBKA4JTOALK&+;, GH;D[.,$ <LA+DX:K
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M'N]S.%CX^!CI-'>[/"J0?C[);O*44H4F.48E*^A?4M4Q'.>4D,.@]4Q?PWY
MF&CH^8F:/B)JE/N17I%G(\II MV)4MBS/-OB7B7F6(U!Q4SS*2N73MD;MO(D
M?<VO%WC--4GG&K+9&]#@\4N$;/8]!<6JD:A/;YQN!I'*)#R#54=CDV[2,'?L
M+R"AT<C5[0"UJ3'2K"PJ\89675$3[S6G>@''<)+"&UY+\:IV](@L$ RK<%";
MN008NH]_X]WB6&@8U1*'[M+50;*@^CEO+A$41=D6@[J.;V.3QCZ[$>&F&%@*
M3R\ZK'Q6U.4IZ#4@W9\L?A)@HT1L/;@@TQXBR&_4$!ZO;_2<F69FJ+/7.KZC
MW^W277%21LD4-@I*W6F11SJ&Z2CG7"+4"YPZF3">RNYQ\:;.0168H$9X8%C7
M:2X8G@!Z1W,.<&W<;+9ZSVMS3/$@ZKP:8IH*V[>W>?$EV #K4:*5IF@;NJ?2
M%&NA:0HW@K)SPWVENY'[ EYV8U2JR20IR[EJQ:2*!"HBC6I4J#H.P6@9ZG__
M.]7&AH(;"9T)FT!"9<Z(-F.*;UJTX@L]0C1T*(,"]B!88$EEBP3#Y.5#/2.=
M*%6WL#G0-96GM56"R"'ET581.-3E65.(M:QL,)CBN;Q"FH99<QW@HW^^>A_2
M1385AK.M;ZCX'"QG:#&NB+D]CJWF&!JUVTRR5+A#@QAI)%2<3SN"W'=8DBMX
MG'V'T7JT"EP3?9-LQ[UEF'NWJ([W2[%=O2YU6+#S>> ^NI2P,B6=-@RA+;4D
MB[#EZYTV<3(!.<,9Z)U%4%5=C?."C$8YZ#B[?(HG(:%7X#NQ4>]_[O\MFP@-
M#S&#+&Q@QIHIQ9-GPIY/^'%G^\\6UN_E$MZ+RF\>PYM&7?(:&MED1[SP6N<4
M'TFB(,TC-><8\%#+J>*3S)8)W7#Y_^/\%@,V0@10%2";4I+D]F*[!-H29:I
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MG!C$*3SK-7[S1$?1WH_BG?F6K; 4>=7OK: ;6X'7/Y(J<_C0AAY#^NCLMC"
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MOZCW0Q\G8W2KS<\ZDVO%X)D:G)T,O8S^GNDU#C+W[X(C2D5I@]=M!AN6'!N
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M$K'%E9ZP/--9:9>VH$I&!N0,"U @)'?YEVQ;-:!(==XR,):P')&U*,D!ZEF
M@TOPQF!<I6.NB-#O4+]"8G+(X.5-L3L5!P&I+@/?LAT<1A_Q,3CTU:%J5E*(
MM%8"+X159W=PT%,E< X_G*9JI*)>E&:U\QTJ/8GY8OE5PQH4F$03+IEX&ZD[
M2I%(@D*AQ2&K&X2_Z\ ;@DS##&1K7I)-<_<055]G+Z:GJ6D,FTVK4#=PPT8\
M;,&WM&7;YB,:1<;4->[#1"TH*;XU%M8+\A:8E+Z%'H<]#I"IN#2(9&KL(*]N
MO]'G^'8V?FXQ9EV<U9*@K4NL7VP5L6U0TRT'KCM"<W==N;[:/;<Z/O<5U;/W
MI'9]KZ^UZQ>R*'/%":M34),I>(M=]YH[JCB[0.V^9MWZWEVU]]1UX0]-1+CF
M)5P2U.U#6B\#)_%4E& 9%RYCD(JRRFUQ5DO0W3)VCBE:A3Q&@F+YE-@"*]NN
M"*.RTA%QA!)K$Z*I<B5+3"\8FL5<Q-BQ%^N]V(7A.!DUR"*6*TM!,4M$I)](
MV07''0J#S2N-0C!/;*EH;M;!^PM D2_W-KT504QPDDAF?+)D'!,+^5SH3(FX
MLBI5_ZIDR' EG'J&,3Z8;):#OH;Y-\<R8A_LGF-:\,.,>T5UF98TOW!E%O);
ME%24;W'OAQS&0C8BCACTI'R/1)\+:_=*Q<'0*9(MVH B<:/F.#MJ!=0$L(;.
M<8,?,HT9/2RG\KXD*W"?+9"8P,,3]54F9BI50E5Y58K$LOCC*@5G=U0EM:%A
M0?HUS'^1Q0N95PES@:.Y$3D&7AVGER[#@P>@58I\KEP:Z)SE'$M1<N;EFE)D
MTUO?VO;&Y=<_]W9N&$0)D;8EJL",EK_?/=(P_T:UC:_CG&Y .%[JL(JSI^6T
M;&X&.CG757XZ(IE[KR*5BI['6X*621^@.@->ZMCV+=7<PKO23'H^U9G%"7$$
MP7#@!4R;Z]ZG< M.9P,9?^%=5ICQ1'BSP.OH1F%C_K;G-[\^02'X><!%C?8;
MS<.KH]S+#INW/>HL;_ 8\56RV*&)F(]H,+67Q3%A*];\=T>QC,77X=XZK&Z1
M-9Y2/R/2E9WZ=X85;##&M;^$85521E6*V!2#)=0Z%W\R9GYGT!YQ0R@0FV++
M0SSI9^!@JZL:?7[#KR/Q[35M/%E^3TSM\,#Q?<K2K5.C@;!.O=N6WUL9B455
M[^R'1(YA'E,,A%J254/H&5#%B>$O-_4M)J"ZV ]0I1$6F\NXWAF0TV72 NT]
MG=]LU>MC82BF7I5$9L-J(-[B#N/>K5L2C!JT402O!KLAU>+C(%\-]C=KF5S=
M3F:YO=MLI.H'E*FVWK_%C4P0Z[JSN\F ED+'LW4YOM:UMS^E4;"_D6F%C3P;
MC?+<ON*W;&.4P7ZWC\WFR\#+.6$E@R^T6[N][ W 7#N-+TH W7RBYG:TD1R"
M814: F=-B#@/-FXFW)2"*SQ-_CZT2:W0)+)",C)3_(<5BDA,PQ\@F@XOQ@&!
MV<HPN?A:%9DS];!&T*^RQT'R'7#\:/=-LUSR*=^QR'B8.+F"!% WG96%KD%*
MYEL@C!-RQ'#FFV;@R9R] OM7G<#:^$IH!@XE+,_(N"TL:?"'X-=6;-M2KVI8
M>- =OB3R5GQ3.WD%]VR"L9)%KQCW0N!ZQJP6Z!#KIR,L$&Q1H4$P4Q7EV5!A
M^4!)=3BF(T>LQ#C-"BK*Z7VIU:GGL9[HM]"3@XC[XP95ORF[^BU5^.XN2R29
M"8-3D8I8A,%9A9Z^\5J-;UNE);E&BT5YA+!BES3.<*M8ZP-O01%P9,?V-E*<
MN6M$T42I+E'B#07L:5OT&V\R#5HE 3,(WFOG5UQG*C8LZW%6#>%@\UDR9$$:
M38259\;J0"2V7TL6!A<2=G:IOH7!Y7Q*_XR"7Z1(T",^*0HY'<(4WZJLH";)
MN)J_9JG(8:$^BB%NNBPG]M;?)0RFA$7^7=$#0K1Q,C@D'V2:(4KJ<@XFA\3;
MP]V2;$Q//X>UE]^R]"?8<1FX?#B.,UC5C$8IW3#/\*33?4Z^H6,+]RAK\_@O
M-,'P[>K0'?PM%;R.C2(+D@S+8PI^Z_@:T'5EP81'F4__ P[_9NB%!(J@[>0,
M[!Y"9_]&&!);"LL5!E-!AJ6Q-\"IP"@&!^ZH-9W6)2F^%%F#&0?5+$L?9+FM
M?>&'DASN/ O6ZWBG;Z[P$Q,H?8=U>4D(T=(=% .&[+9^J[5'6[22F\:D"=*%
M]9 =]B%!>&J9+37!)O /;3PB02LVLJ %PYAHE%>*S-.X0NPN2*>HPJM!&605
M(J1"[C1B8J@$@B+3C,RZD0TMHA"R9BC9C"9>YYNA.B(I"ZW^,, G<P=;;F0#
MJI1H&9GYCN.57@>UZRP!Y<Z@YHB=?DV=YW'P^;?S<+L@@JG.!#X!,SM1J,*;
M'C48E@G<%D%KWX*-0^-6KT7MROED'R7JV#="V;VGKJWX#E'[3L%-<]&/C+-7
M]&B,L(/09\5<[ >N$S&N_Y('I[>A.Q(:6("&YMV2$-TR81Q2>Z:IR>9H1@]N
M]8B)PB'&&UP$TL4@$C75*@Z1N&!RDJV;RIO"2?;"L)[*;RAC"ZT/67)BJA2O
M 0=YIE(V47/;7LDFDK'.0]1]**JMH'EH&8RA 17+IB/N\0=YWOI(]RMJ)!9U
M$DI'$\#=$2K1$5PO\SXTX1?[&+,>'(\Q80]=7JA3[KJD54\BUGM6MY;P%UHG
MU,C4QS=H9CIJ4QO\J<J-T\592 8;N[@-_',*7A5]I@,WA0O4%'ZDIK"A&B\9
MZRHY-N"H)%*[H;QA7T(0 I>2*$ZZ+3P\MK:<.J29;01R( +/#0RH?\,_<S D
MHBJAJ(,]U:G$;.BU;&XW?U/1$L!!R1<V8<EH\$W&M,SMH;,'$?=YO1N:OEOM
MU"Z$TLQ/@YL)I@46?HW99YK%G,TK48N'6"%"SC.*CXF:^05B-(TJS\D.U'8=
MYZ?M:;F6:8S!2OROE.Y4!"Y!306S-:]Y/X@S6=2BJ"#\*)]/.$62KV X:WGD
M)=HQ^Z'+EW& ,)(2[@IF(9D(5N+I8@F2_61IZJ\CD:(& 'N2_'NT)CN*,UP#
M]#MC_JX!^G=9N6N _F.[7'>NRB-UEMM[U2^'R^&Z,!*!V@*#QLF<@K,&S58O
M=,,K<SFN$@>00^R!BC5U/Z7(,')2:EI #.C  _X)GD,1J\C!Z@)1@2&;$P!J
MC-5H*7=_'<LTFH>.TM.I)1J<HI2 T8B4U#,7,5K013VH+J\^6!ID>T<F>.!T
MANZ*?G(S/.WW+;!M"ER-\YIM8AU\?H2(R!,7&C]P?.?I/ZN43=L+F2@YZK9+
MLPA0CK)Q"C_7@0\%QCNZ..R%@\B:&]PF(6<76SR2]7PMO=XL-2"S=J,UWV5^
M>W*,,X+@-\C;8C/-AY(X,GC>$%FUN0:8/"#MAS?=>=M/R*.,**3\RNZ%9NIQ
M[!BYQ)"(@02(J4 PO U7A$S@P_N ?T:.B="N"O=YX64A2#V*6G*E"LI(@JIA
MS!5E-14A2[#6V 4S[$+PZS-NCS3]U'Q\G-<U8<^E".2W&64 ;-Y@B-G&Q.<5
MT7XF!KYKF?(:-AZ^N5998O,L?F933\!]M,>\XE9[^KR'NL#,,$*!)LPPX,.-
MX8;:(XN=)J-2;#T\6X9PZ]#8CW,/6C>8>9(2SZ<IH>N*^-_O:XGGJ5]#\#<Q
MG;T)OGAE!.<N MMQA=;1>,RZ[K//=9_[':_[/*W7?77\B-Y2]DBJ7.A*+2N/
MM"6QK*Z)[:/4X"9LNLW@:8W;2MXN%C^R,:/( L40]U 2?G<ZK5)BNB'[#^OK
MB,#%AML1]6"L,_Q?'Z^ZD!PRX76+)8@7ZC]#:_X]9+:VIHSKI1".AE:5,<G1
MTC$P"UTN)6-;=MG"XH8U66@24C91ET/X18$V8)#!0-",+>5X'M;+4+F>LO2_
M1T '@0:I-A,D"-IRYGON_BZC24JX0/P+82823$_\]S2+94)7,,]U,2]*.2W<
M3=&0+,2<4F?3&6YJ^A4,ITJ8C6TL4E7@3W"5 N9D(RQC!*,.4*#I'R<&/#E1
M0X7I.,];@#V/P9>R:!: T%-UM:_)S7"& Q:*TGWE)(O-K(I"ZLEH^E2T6Z?,
MF1>+4M"G_/J*T'048#(AG2=,Z4FN3I42B11%BA*A<)J)@6;.\67*899]Q7M%
M$TEFM'95<G'#S4O]/"(\>B1S70D#6\ED%&LF@6< >&AX531KJ.M;N>X?#H+V
M]/O#\^X.*]_,OQOOTA2#+BN7H<I=['));@$3.VE4T;)Y:U%!I/(Z26_+%.];
M&7 G%*"MW'+I@!Q^'PN')>XT? VPNJ,J&:$?M;P4,\OU[VR,D(%2YLGD:5&\
M4,<N<RHO@)\5("@2D=,AJ!)"%&S48Y.3A0CBF*E#M+>]&$;T'[+D&73GFZQ*
M8C-D1EJ[XFU:WR5+Y7=2)4;<T@Y'^_H4@)WQ=D;HE\X-4DH??[DY:(/;^HM+
M&\S K^&N2P?#M<@(3T,=9=*V[1>_!MFSJ;==0? !HV[T'HPSZJ=H>BZE&:QO
MEHZQ)%U$90TE3*]O0\']5.&(*4<4P$YH.,-Y8^^:D+1UHV_A+W!\=#&ZV=F<
M0^-EE6.;*+O@;O'P/<*5FX$I8--,U$L7CA95XP!G&8=3&I#H>N7>"ODN7YZ3
MO^[T_B<<@FZ7 Y_[UMD7;9V]"?X "[8(?D7K#D_]+R!$NX[8,^>=%4IVPZ3&
MM'' <L!H+4D.6P?G66J+.#EC-6DX!]LKLSG_R>@:N#FX(MP35M_8_&FL7#+K
MXBI":RV66+LRT_SPJ(PP<6=BP]9V>P'58N=V+MW>, ZE17XAPG00GB7)!6._
M"H'M\3)H_)#).[0Z;7!T.G2^,3(?4*+-GAM7&AG36",AR64TS-VQ15DUW"AO
MLRVGY0Y;/+J0]G6<197>J+E$[IR"/5")@@)L!NPCYS0_%M^#)904OIL*UAA:
MV44V*F^05XCH375Q%W9-6/R-*:SBDQ>2R;PUR6X\-ZO=E>1#69M8&_"5#BQZ
MDC2 &M,-)K-R],+0R?+FC)X8XV)QK,;SJOE]VA>C_(0Y_K"]U A^JJT]6KGI
M,(L5X_G@A5!91.\/.BJ)GAQQET%JP2X09,%E^'3L!8S9,;;H*TR<A3?V3#<&
ML0DZ)^[8U-2VJN?$-<U?]*TP8%0@H7'AVZJW:RR=%K0/-/X?*A(OBH4]O52J
MB@F+,61BQN@%%ZE,0]B><:N NA61S@/A(!>K1IV>,R>(#Z^5''RLW=6,_.1*
M6,T*U#8+6*I%8"6#7+7VQ? 8GAXKG8=SNWS.:=7\6#$:]]A"P!PU^NG4F#58
MW&0[(.,'LRK'KIDV[6N?2@UTS:>-$N)R52^W_D23B<0A^V&X%F.E]-L!(#=4
MQA59L*P@N4#*2^J; *]+IEC.K\-]I@_#+!&<*Z75H8.2:45HJ=9@4=4U Y-O
MR#:D:!8!G_2VP$QW-37ZT 0XX.)$=S&@?69>1/-^]C6( I\7MW"K3#3] +4>
MFDI!<=S:Y7B*S?*=1&7K^VI',-DCHML614CHQ0 !>I%:&WHDYQ[L'HFJ<K/M
MBUIU[R(K.&Y)+P2#FU\6BH 3*W-!UQCA%XO77&.$[W*XUQCA%XH1[EWL!T2^
MO&9*US! ?P T<#%! PQC!<A%AHH8W)G0Q)"Q=AHT<\2A?3F2:"&P"Z)!<?B7
MS11Z =+;[ JFF/10=8B4&R-K2;LRU)7::6;"'[5[>-97Z:RPAQ$KWN-<_2!A
MU%<[!QW1YEV)2![T%1GUSB68SBC?AC[AH,O!WXY'=#]E6*LX;G$%K.M.N7C.
M'NF*OD8-'W,N)_-@XV03;J1*Q6ZH W&0YVZ#>LQ5$6486^(K^1-'O:-J:2:X
M5E3%XN>8(76YSBQL,%F 4\&(!7*>=#&CS@\:,(FK[."XGX>N,)4>#!WAFV,U
ML1+)1K'9K/[M>YSI@[\0)YQG1"ZF;N]>%UZ&%R=RKG-%[G?JL%J''./KAIWZ
M)MAXNTF)X8RY\[3*52FFL<E93.!>B4&+Z&W+*7F?EM14[^*^1VN 8B'>M3X(
MR<#'R\*1FR"1E6.!)C]XV4N ,9]N,@!G-*?@JVLMJ0$7R_>]L$5--"/).*/Y
MW4^MQ9.6K2JM*":RWQ%K@L&JL]/N861TE"F77IFOZT<&VZ, JVJ89#>R68>P
M6.0U\/KUXMDC C&1V@J(D43NUR1XQ\;=%0&H+C6KNHY9P+8Y7&Q4J>N)F3DQ
M5YC*3C@G$<';QG]BLS+;KPV'9AZ&.(F2<@D>7HM*T@S<JPZ.$/4+<7E>$_<$
M"&$*GB'2@.L-3,L">@WZ>2$_C<12DF&TW2M2,W(JM/1Y2P NQN)$EJ(L3^6<
M6[01*J'($L0CF='KL!T.G6/W>N-Y8I4.7U$1Y )>;_L^&;H9MC=N-D/!R9M:
M=IXZQ@<K56J,!.Q69;K7"0P/^6J)KC"CO'M0D1L4\<]3J H]"!> ,E'7 /P"
MCH6Y 3FZ#'O"PD#IV"+Z$7@8]?UYYQ12)(/@$WH@&1V.FNHUD)I:_\!L2!X#
M(T+J2!".@'GR9DB%.DP"924!L1B01U$K2*%G?T'F!)#)$[,G$ XTJK,S^2SX
M3"]EP]6Z_I'NOK)2PQ_#.3G:.?S!.EM_CQ5]V%>'Y:K!$6ES/UWV6;H.0ZD'
M5%2-H7E+P,T1TL=84E.-AN]A,3_9"A-P&2[=*,2 VC@1IE6JAUUM0&8]9*SE
M@;>4[6]ZR\MN/*UN;XW>+B_NU&XO;6CH'IVO8;UOT_A!'PYNNV.;O_NHYK&A
MXLV\*RV3(Q@C^/?&WO8F./T)F.\"3"0Q+Y")B_LWM-(>+.!.[SCDZV/XV'NE
MK^L[ 1<4'*GU\OZH8J[F\Z %P+4!V,=P5B?.M6Z7U_6L%HG!]N[+9)'KBVB>
M-1(1]NE3IAB*P7VFVLI2O*4RJ2&+6&*BC+0=U;5LY(K\0?!;"UGYW6:0]PPT
MGMI[9S1H&DPYEDP+UYIQ*%,YPM"7Z:S6RH?PBHD_N<68XQ!.,]>0S;+"L2_K
M/:9&K.>>UW2+EZ3XBD%P.:%:%G,A@3"I=(>R> P.Q7]/&4\E8[O&)E8%#G]I
M<WM8T;+0R6@FYJ8U0*)DI7M[X$U /;KZK$(D"%HA7 ^.B98AEPR>]=]*_2VO
M2ZV7^MQ[>PL9P:>JM>X-I..PXT75OA]-$-!W4I23;FL2SOR3Y\F"P3J2]V].
M$N,T5U<X]1*/=TO9U!WY_D=B4N@=P=YAQPNG%@^]*G0SXZZ?_/-1TUZJL,.A
M-DJ$-Y-%0\LW/IW(L%&LX4+1;M/4"!U)%#-QE<OD$-YD8P><;?:Q;=4V225:
M<KZ-17^#X$(//KUK",;(BJ5O>.)5M0G=;H*:!.&ZB/1/2</]YT@P'.P>]4T8
M=KN3CB\,O7H,#"^?8OO6KDM$7ZJI*;4Q**F5>[M <!,+-JC'[$BE=8_Q"!MV
MH<^X^:+LHYWM1S>0[G1_>@V(_-[CW^WN+DN.OZE4ZIT(:#%L:KU<:A-;TT,^
M6.GO/HO2[YO*[S9_<>/,U_6C.2 ?L,?Z!267NW[^ZWG[AT@!;Y++S8&]0+-_
MK=!'^$&DQ?.T@#O8/NZ;P#CLK\! @_JE"8O&G((-1OW40P[<-<*Q#G#((L1N
M2 S1\:]ODJ!+EC7*),[\I[5+']T<V$,RU))SC<!)2Q+1KV?7B*7[-W%8%R__
MV(6DZ^+E.Q;S8%V\O-H]MSIZ^A75-/>$GOY57S'-EPB0(C#>%X8T=+Q*;%78
MB)WG=P:>@H;^CG3!_FKT1<,5V.M9MN!5Q_$2)U&45^ @?W:4N!T_I!JF=F=2
MT#/6PP:XWJ5.=?&RF"\F)KERJYK"B:BFH6W6:A*AMJ<J941'&6+X?!8OXR<8
MW,9$%3^YOL T0FP:2WZ(%"!?$?"F(1\^P;.N(*P5-FZ&5/6'0Z_2F5"Q 8,)
M_3:Y^$M/Z7ZC";F:S]P!Z0BKE.B<KD5DJ*T<O>(]IZA&M8[0>/LLCQF@K=VL
MU)^<>2^S##[AI!66C&]QE$=^@UN7KK5R:*H0%;,15VDNU718Y85'QTC4[2D2
MB>'=EK1$\L&)!$1WMW$Q=%L_NL")C-/8DM]T/:W]-2T!3V6%/EDW(M./KU^>
M)3*]=]BSWGJO>H3-&=8+16NI&P3=WA6*"CYE!(L]172S:3R&_3V#TXE(QU)_
M5^99TG4E=CYR];(F7%7<0ZO5N&E)JVF=ID'-)2P$+VC(F$!<5P<B"A?KT/[<
MX_VWXU>T>:/QVISO[&Y-86$FI@F<4YLMK[ 9P/>VCAO;[O;N3G &NK)$,LX(
MY3C,Z4L"S]W '_2=;P-GTNV][/&Z^H>;+*O7*_*H]KJA\QXWOW(\.#AX%B+_
MOOE4&V*STRKO5!03$_+H]MD=X# 771\D^AB/D2H'_9$IC!2<%?(SD(H.=E^P
M<;P9D"1/YD2Y"F>=.5=;;/R6#B)(GH0UG7,0\\B@@]PSD2RH'9/O2,G12'=S
M,3Z&P Z]5&BU-+V[H]%>NE/ % 86$0D)JQ#SU)@31*"T4MC[^L&L P\/GOBU
M72.7;202?0+AJ-=B.:_N42[7[8V&7G*CV9/O/8:-TJ:*2+#M3BOI?L:]-/MN
MB+M .[X;NGR_[3ML7H8[A#>3):KQ_#\/9;C4<V[U;S<'P>=4;QG8Z3A)MX%;
M+*G%>=?M81V+6!*$H(M=4)7VKH?S:*D",WQ.>DX4;&#(MJ54HAY^(H_MN<#V
M8W$%OCB& "PGD41>:M@<\/F-4+;?<6WJQ$)D>]OKL\^42C3C_>WCD]"E5X?P
M>M+(%K6XB0TEWI[D#=:_:.YW>#EF:#'1#]W'MC@>[-V-6?@A -Y@76P_3=??
MFG4! ]FI5[MT.^NW,>RV;?%6%ZUV6]P/L'T1M7)H&A:QE:*QG$G:FH43"40G
MGZ@1=AF/(NHF%@83*9+2]%(A\CFP."HC*G@YB$:+FB.T]!6_$846B<1Q=4]I
M7ZLOP::#9)#H2&TVXA9OM@;&=B<M;V0"S]S8V=464C,X?$<AGS>*-[;SF_U=
M?6+:N)',%DCM,LM:@)D$/OO:K&IZ[P[#0W2@ *,$*JWX?7VA.7;[4!A'><TI
M\KCKK&6 6GK$(MXYU-_(TF,B3(L;E5@"2V<DX:&T))-92L'*:9;K<XQTATXD
MS<"J*30-+K4H0ALN!ML&KBK%-UDT23_A4J\BCPC#FT6!*,'J5)YPTT7'"M=_
M9N0ECF.YL+-2R!-Z!"*#Y4PTL4$1G'Y^>W%B;AAY!R[DS,T]TFC"VN0>KX'
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M^N+J/_P;[Z"#F[6@G@;*+3-^8/E1ER_:HP0.%G;D8/_@$]E>M/>OP? (SI+
MW?.62"-;/OHN&+DD8XJBCO2:1TH;TW!!*ANH=S.H(=Q>7LM6.]B\K=;9R_B.
M^8/4*RKA0LJQ*B(U QF#6W269Y&,X?447M9:6YOX&O7+X]?:OC;>*W282B:I
MUCS0+&[KFX=? CVC_AYPGUPWMPFN ._5":7+:0'$$(M>V9&XR?*OP0:8YQJ
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MEB+(Q!&6SH:RB*;?SW*[P@9/2A!CE+(!6S+0@[-5^S:18XMQ\!I"O"$*SM$
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MZAN!4&:J?KK1+ ?73LV256(8UU)D+45\*;+7:2EREI8(:;9'LU^"!%,>&4A
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MA5F?Y HVT)\VT7<.UJWM_*US_BGXX_SJT]GE9? 'LRZ%;8$N(MR+D'Y_ 6W
MR3]KA H;KHH1+\6MH@S<5N.2]4\(YZ!;.IG D/WL'?QZ5:&?E\?5?+ _V/T>
MJZZO^N-[/+OWYY].?\%BV(N3+V>_79V?7@8?+C[_]H5*95>UM79>GL?PO7NK
MIUOK^^3FV_GK)PMKZ!'2VL0RRCC:_IK2 +CB#QW[3\5/P:\B_QI<3K$8I74>
M3[B4P7I3KHH474SE:^_5KC7)RB)OR,+V^B^G9Y][OEGO4B4[G5 E?=U<WU76
M:!A"7O=\:_5%]?UG5LC9)/@=7!(U3E3VE_6ZKTA*_F=?+:+ZCNAV$BA[N0'6
M[]4]Z[#@.BQX;YMD[WBP;_-0STE("0,Y;C!=/7E";&42].R_?SE_>WX5G'0T
MZ_4=F^UPI1&[[\K#[J^HAFHA$;M_^$+VW7NX'P:/+V0B12%7M/NZ@ ,X?/R:
MD9T[6J4\SO;K7Q.L<X^ZA,L!B!(2"?<266+=E$;U%L1MQ^V6=3=A1+\6\ 7!
M6LN)X>H\T=0#>+<+2:RYL5=!T=:N+]C 'QI&VKZ:VFTSZ[;![8A_,:,5]W7A
MGSI<_<#AA897S7 2O5=I-$$B5KB_A%,1%=C<K9J%P7D:#1PULZ['<6^)F(#D
M(*B=6J*0/ _$E J3$+!3)EP*S26(S7-+W6S/@SBCZZF,B?*>6L_H@FIJ):XH
M!VH[/A(H?HBUUO+)X(3?$W?ZGW<G5V>.X)MSLBK5?+M>^SE-S$$LNIBF=7#^
M_^TX7K+9R;TIBS71*!*9XLO.Y77V53;><T-VN\*)H4RR&RK&)708\KGP_2E)
M;LC774/J6(ZHHWVM8RGEU7%H4RE2*N,5EK4X8Y0CWU2KC3;IN>84[0&E\5[/
MBO7-/M\9/"UZ>V7J[H-,J?V +[#_*\UN$$'\AV4I<N=IZP(;#<&Y.R4*\&X+
M-J[VXB;U!,-6V&O!K[!JTVBF63T7I>EBV(*UHH1MB>P?*'9R&4DT0HF6V6LR
M#YHW1/TVG1.7_%"""&/RO\S^!8^?SI=5SV[ $B6,[TDT18#N>@IBMN^&+6^T
MK./4:-9,"DD1$5.#.R!HM.#)P(Y5$Y!@LO[ZZSVL0X/X5[E?0%F46?05N[^"
MZ16"7L-B!&R5"F]:ZDT1>AL$=A3<,:)K8@5;KZ0/Q5A2K]HZ11I6,=")E?A/
MW/A54@J[M^-K17ON!]AG4O9FGW$C.,VLZ7=<T^4IYD_NYT#_&!(U?:1Y0PEW
MR'QW$;>**2I%%2W?L'T,;X6"?M+:W@+N**;8<P;[ML%34H70QK!6WPM/_@E$
M*NQLHFSR^/6X,"6X 0>BR.ATU+97V/L-U0>%YVTGPP#[-44E1&Q;],]0ERH9
M.1S0NYJ(&-D";^ ?!7//Y)(R0]A/(-16.+([BCD;XV(LL';)V TR1*$8,G-L
MEC.U#98EF^W!_+1ZDS*Q'YH8WG:Q:G0HP21,-?.-=:FT;Q*+>0TX:VJI]3CN
M;#G(S2:2A"R<I5""+@(QGA8Y^VIP<-2)<JC!P7[/6D9OB,V_,!D '+-3W>T3
M9+H6W%I])W/N#&+_6NSIJ0L5;P2QDJ9PF>Y/@K:C1P1 'SGKPQR EOW/#%7T
M92'S:^I?I@^6_;WF1UB@(Q"E_TRBS?+IKLS]5I5([4)N8<5N=H?.U-ZKGIVI
MX>UG*M=>*4:#1")RV,?#+*VTT3.=(JTN&4ED=NO_!-G,4JZ3H00;FEP]Y!0!
M<YK9ESRJVAOPE8N)FGD7Z("3/3W7(K+N)-IT<-0LH9(SQ6"\:CJL\H))W<.&
M'VK,+/?HD<[?^:T UR>M!R>M=V3K&Q&<--AWI_4VU4RF@U_HAI5>9TWJM(GM
M5_BSBC_-<M S2+!3L\E,#Q?7Q2Y\2.]FR@G"B7I7ZQ6-I] /^4::R^<S>M?!
M'UG^%<YM\%;3FGW)LU*'[>R5IL5E$?R!RA1N[QP<>U'[L(YW^%OJ$/I1#&'J
MEYA+$7GL_?;L7]CDZPN<;?>1=M'!=L5^$S3T\Q1.N,3P>94C(ZY]RJM]\Q1\
M;R3[?I6QPH7_*-$@=^/9LQ$'$$MID26*$G+!9_#HAA6L0Q6/)5KNV$I"Z9;:
M[O='!_PDD99JR^^ZW2#8]?:"Z?EM^Q3Z5@A_<<,OP3J<OB SO]*A$B?U&@T0
MO<WF?N$>])"FK3C;C5\''P8?EZ8%5B!/'@,5<+!]W"^!$@VX^VU;5UT^%>Y$
M+;^F=G+J%WS)%6C=.9XZWGN+EUPJT/9\3CZBF%J\HGFV0PK!((V]:2[<\F"-
M78##\ ?UZO5V58#3WC]V/+,[^T>TNW<.MEN7XC/XP.3HYG)<)3K<XM_L8,>[
MV0G?JWU5?Y6P8&\1W;GT9K61;6_SW;9W-A^0J=P]. CQ_VCO/%TZ5L3<"$$+
M 2MRBF9J]I9\;+>#.*NRZ]9FW=J!<F9=7#/KD!Q(=T0AKR(M436&IMLJ11]
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M&[KYMX<TPSE<&DMY=YN)@'>WB0+X[.+\\F33"XV4XML6>BO<(BUW;OTL$6F
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M.%<G0!POSU.Z6,6ESX* S47+S(2HX]&+NP,28'M4Q %>M( %+Q^.NWH[*SJ
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M<\7?QY&_H"OG3"6+0/S7KXGXEFS*T!=A<K"YU7Z_N_>WPSGW?1E>;09BDAS
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M&%O0;HP8]Z927(OR4@^>P-_];-+M29.^_^[+ZVQ@,QUST.SL@_3WI9H'?'$
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M 76UA V0I/"R+>Y:*U?;[%ZH>S4X_IUATY"CP&F+C@T<&S@V<-XSQU8U<GK
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M=":[<55<4NYDH@KMSIE9#7,*C!!":2+B1G FJ:,* 4"R8ARJ[C'<J,ML;:7
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M=8<!X6?QB>PH^H_<G$*C3"M>2"G"%1'ZV K%5900#@PI;?;M^A-3V8/76M-
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M>^1I">7&A#:R\ )M8M -0U&N6&1P[*[6FAC[F.:P6_KV6%P+5"5UU%7$.F"
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M\8E__OQU9[OA9HM0O!UE&^.(FES#8KBXQ])Y/M6P'[<FEKC>X5L"E#:@!2O
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MV&)<J@Z[$Y$D)D(O::5A/RV=-1.QC][5_\4\*8J(BC6F(.9.T*2OIP2P=00
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M:?IN;)O.,8BD/=O1EI8W>TQ);V>^VM<=^#"#H=O ;-.&9_&#PP@O_0W'5AS
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M#^'+H $<;0V%-S_^Z6AKH@/_^/]02P,$%     @ -8A_5(/'//R% @  /10
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M'WK!VG9)NGJRY9!@$UT79A8- UG"HJB?<6&_V?P+^_6VX0]02P,$%     @
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M]^^<@T-OD8+T2(%(%(RT[-?"1NNH] G+,>8DM09S1K+2':VC&K1C5=/=(@H
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ML%I8P+5:.%5.5"V.CXZ/1@+V*IL+60-I=8&/@/4QREBD#XY\7E5  G&EB&A
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MTL#O45V7L)/Q3.';3Q??'X8CA+TZO[U[.3'Y^OU?WKV<N[)X__]02P,$%
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MK[EG.%-$>M=0:^4CPWW,3"3QM#Y7+ D&08::H:)E[P63GO)1RU?M"6CV1#3
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M+#!H6#BF):]3KLG[EO?E- 7!D+ W8+\4>RNR1NX'5O7\=,/2' ,G/(/*N1-
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M(F B \8842A>2WD:&-=_LIP-NTJ/@7(&L)_".$J% 8..]81 -RX6N<G4H0:
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MT-:(BS6R&T$2&!/\<UL.P G[-65"$\7'_J8&_UTM%SD5"ZK*<LD!XT&))(P
MOO?4F5DY-ES1R"Z5(J-B;W, J3V'!'7?#"\3,335 ',QY=AX?IG->-'^&>:0
MI[/Z4)Q7E@< _:[5D35=-HPF^._MN&;IRY,>O4/GFOQ]7M11S&.X_5S845G/
MO O.>GSQ29K#C41-:!YJ"],B]MV@]@2ZW?K!TGII_*F[^!A7=>\-N_Q'3Y*C
M#MLXS156Y_7Q]PFJ)8K#%&0Q4!#",:?Q2+J%8[8T,C]=6"+EUR3$39L.[L9_
MS\X3VK%718VL<C4],]XN>V.J>0#4D9__S_T5]%N(?_=?:"M;I(+C7Q "6J*@
MN[^!^.^"PC\SUG3@@WD[8WCU6TKBM.2W7V3;3EUH*L@.7G[:#]! G]L1M,1/
M< #C>$>#>.PT/QVH4>A72=A>8JXB.N6^P6IQP3 A+KL!!6N;>=S)Q)YJ0K*"
M>'[&-'_23ZFL1H %"$)8."BS^OLKBR6_"M>24W5T(O.)+C*NS4W'9'V&RRC*
M,1"8UPW.<(Q/4G_W?,55J\+(7-9;4B.A?IKN3XEZ-WQ[RG>^>E/#28F0;'CN
M,598T$W5J?%=!Q5[/SSWP^AXH/3EVZG!"FX>==R&(K-ZQ<_2GUHFC;FX#$PA
M-"U6>4#?CN3DG[E,^_V\_R59;%<%BKUX!^+.Y@XV'JMI%,'#WM]<T\6TJ5BO
MN@[S<:_UD5(X49:[T9KC"(CJT"XM3[D+&]A17^R.?$7 /;E@$WI?T@9'3A7!
MM'N<9J"42O?*GN$I^<33/&HJ1L)BUCPVF$ J]^*=,^\7 1_^F_D3XMIIK\7P
M5\-[9_IFFE[.TDF23=U*?8T=(FC+"KL(5*2+6-HCXD4RRQMO2S-Y3:'[FKMR
M95T]9+@;CL/B9CU.\\G.3_3E9L!>5[RWYZGVEDKR[QATZ,I3%/]YGD\2Z29B
M:C$0HV=I,\I;["TXI?&CT?&]]<.0;M@)E$DF1H_#(GRC#V6="MOY"@/U2)+C
M 5=F%QS25L-WRNU5A4+U M@=)=*N9F_WU6F;$S)H#ON#+91]O%W3IT5)_PUH
M-W9NT__2!G2W4XCLS?Z*V$Q\ _@/;::KU03^M8=)>?,)%?PV"VW$OK;IZ*=L
M@3\M,SU:L6@9=6PKP=9Z!I@6/7^S.+1J0;>*Y$$["<#':E\"AHW.'OZ</MM&
MK?M 1D&\?:Y=VH@&X6D)@(4K&/N!W_$?^@8MQD Y<U]<^?A52]GLJ&YM'<';
MHN0G;Y/UU,-*7CQ^];*7P;$&[<^E.5R7NSVB=Q1Y2C&%6SVU>G_?'S95=VSQ
M,?&YV%FRF53Y:Z6N^SWCX>$BK,W(O?N24W0HHGEE/W,#*?F^-,<]?1+-%DVV
MG:U'+>Y6IR@TG)'U*%EX72<;QV;\!BU%(8^Y3&)-XRR%\R:% T>5O[U:FRWV
MT(OO-#DA\!I&80]<$_2^2&,318N>).J-0H OF(F$O&ACNG(;[_(X[LNR%&96
M'4*ZHG\;[<4T:A*44JKD'7X.-J[*'#0YEX40^YBLXS9U^;'5#C<UPZQ+4-N-
M/2:Q((13#F_RU9V-_!SIM_[^$:K_G@;EI[,[!RT6*$5JJ]P&.Z007CSLMX'I
MJ:N<FG800_0>!H\48HC2ZH^?0>:+ISK=K)'YF9$D<H-V$]-[P4<$ZM5Z"<X:
MLA8%^>T\FEB61V%H24NJW?/IBW=W8XH'CG3YXVO]LWZEST66"H75QI-Q!=%6
M5:674X]=^80S;+$@)&6]\9^_W+M+(S?=8 DGH8_ *,$^. XJ6X+QY2K[7GMT
ME;8H[$IH[E0_9J^ .]2GFV/O2'^TA\L]3UMN#Q[_FY.L%J.B0'])%1^K)3+W
M3NP?'6U:I"W4WOYFR>_+!!L^_EY:K&-W@5O4-YSRK43N;N;TC^];_$D#_GC3
MY:]\_H#?U8,MQK$1P'AB,ZVM=V#DG#9+]+LTL4%0C+=+$BQ MNX,7 H7<"F-
M&Z]7_-$B@%W$X&$\X#T.[CDH%*V@W%HG;7.1\3D@+FCN2<W6'5V5A[V]Q$=.
MJJ(<E)+*XK@)G++S_KTFM\QG]:"1#[5*83'AAG9X3Y1S*,?AN)+7JI1S'"WZ
M6(6;EC/ZYL0D"*E$-<%**++:*_A8NW\91=PQ %5NWC,:S]'HQ8C%'#/P'2YV
M]U'"[&=MZ4U$[ADMF^QNA!ZO/_KJ4A1"GR][\8Z)(JJ:PYTC6WM6_T ZR:-)
M5:%: );"E9%WETGU?9GM_]Q>@\>FZB A5E.U2<N5=DR..^FBFA7?^QVK=A]K
M V^9558:N;=P-M52'&M37?5G2P0;TPYE!$)N9,V6[J'D-5IRR0+N^;>LP(=(
MS#,!<6P&#!M*_)Y%=PIP])\WIK$^**3M@4R:GPF+$3O' FFK;)D)B3%E2=Q+
M=9CDMY(Q'-%[/Y,I8]DXS)+MX?<DK:VF$+5XQT4,,@1IJR*WFL^(Q;5>;ST2
MN]S;V?GJ55+/<5;C*P47!SHK*5=ZC[3$+/9 SR;YYQ84EPCH!CMZ_&B\X3HK
M6<DAW[5?%]=CMXIS,SAS^7%@WAT,?Y[+]N5W>AB/%.;:_JZTJSFM)\!=0N#8
MI2#9)()U].:Z$](.- UEBWM(T\<[MX!P \GE-IUT&OQFTEQE09KX+K==/W^Q
MJ;1OC1&V+32E&8TH%-)@VFD39S<.MBCJ/WCC6PL'?P0$;9*"C96![;D<H-]&
M([:DA"T??J,2US8OY+[8/$BEE9V-MCZA\&6+8=,JZ?N:IFHP9=M?[;R:O!<
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MA$,%#2C3&@CB*+M6M/52J#C5.\56[5JY0*Y@5N(M,?UIQ6?D*421N9V/GYV
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M%D_[TO-"].R43("S3<LIE8]KN(),/=K?T*>#J0VC0=4Y0W?';/H4WN!%-'?
MUAXO2AS>PS.;SI?-E1#L/X$]$O'ZB,32ZGCZQNF"G8$Y0Z%NK6Z/XN+YS9^:
M$$:$4=;%D4T$?^!^2"+^WS6\_MO^9]L0CFJ\A!LK(UB*IM/EI:%G9I!+>]KK
M\\>*>8QL+7W#&GU4\L.//C]2,J*-WIEHQE?<Y3^JM<M]Q-\(EC@85HHWGE)
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MZQZ["IAU%?Z8L.I0$WZN# #!D\5A7FC E0'"P'6Y+8*X/R5M_8[ELC@R"'/
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ME:?A;MFDB<6D9#$)^:V0"!8T9R6G+%8.%S ^@+*LF !VZ87$'L']-4\ J(
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MK\W!EQ  +RUH:@8;$]I^877 !A:@L@DX:TP!1-&!S*C@('&#5F9@]0% E"$
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M4-Z%=Z!VA]T,JL_T5]3<>=@L@HO_#;H!GL%IHWK:/"E=G)9B>S\O2A5X&Y.
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M72XXBXA:0G@D!XB<"U12*'2+@*>A!!G&&%Y,3G 75O%K%B:3^O?-D%K9O>6
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M*S4[,KL%S#S\NB\!?Z;E&6994"#RR%CO"KT)2L4UF-JP-!9(_0=_E!@H^60
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M_E'6H(Y"<4T9A>@IR)9^0/"B\4R&D&>1Y T_K1&YC]7M >"+=K%504&@P##
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MQ -T/Y@UU(R3S8OFZ^0;GIIS"KNH4JP=^KP*E-AW _%F<_*R> 8Q\!F,KX7
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M'?HC 2[$N7M&%QP0<-^"R"C)%&O6M"Z_K\H[?>&N3$D7^!P)\R1U#4HO#^N
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MJ;G^R5M5(SI!?KTQ1FPP?R@KWXKO:?MLJTE2UW"K]TL5Q7Q,D(2)NO/XVR?
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MID%QFV,ZIDRL*Q[T>0<E-W#S>HP]&7A;U7]%S/$!J4/KHS*LV6R' ..\06^
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M;ZI?.=(\QYOI?K>D>BWE@B/DY1K5FU?+9PK 6F-?8A2A'+XMAM='*R\BA)%
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MUMUMKN?2TW8<VFMM2237)&/7N+2ORMN3H7V#S4-V?#"!*\8_-XH#@]AY&0#
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MFRCG7?HY9(X<\H%6LH=ED-#=-8Y%%12J#_@;@4UCEO07("_?[.1_IVIZZO2
M?]#:BE)9J;R.]TD(*:?>JU"W7+$/%R&,NL@+A38]W(=S=(C><=O9W ^912_R
M4<<YF360E"BLI[:AE4'LD8X#QG0-(5&/30N\=/6@;))8$%;5R]7)*'M(@Y3Q
MGP&D?^J65VK<+MMHV./I]YE%+*J&H56F#RJVBMX8TXEDO1&_VT)9OJTXC(>*
M=8MJ5E>H]0/8U'I'\MWV+GN;Z_:>,WKO*\I&]+:OB(6V_(;X\^8F3H)S]$,(
MPE]X:6-LJO=!+G -D<!&P$N&3*:HZ]L(;7:.+XFD^D7?=L.FMM^DA=YIOH4P
M*$;R%ID:ZM3S?!:S1"9X>WH#YY.O8</U(CPGD;6*6-GQ7HU0]H<"\[FQ$\8?
M*'X4!S:\!IV;4B7?K]+$]$ ^%VX(/L;46D<XCX?ID"CH%XT\E</*:*<H!#;X
ME]';W,DV=9$.'Q%YWDLFPV;_ZAVBEC+*8F:?NT\LQCK"1KU&)WFH!0#D[24;
MDJ I_("6[*^T>3ZE\KE%9A<TU/#E\[L9PHXA,4GB+F\U2'HLE\*"J2895?'J
M+[PW$HQE1=_E=D%)$%JQ\L(/G(!MLL#:2W&$HZ:'CYU:Y=7:$I$KWC'?^UIS
MJC!#S7<M/7-<YMK9\: U61/ZK==G4(76D\0&K)+5^UQP1'.><-@X8U>=9&%;
M>\+W)V^S#M] OU(OXSQL-V5J:7KL/@.DJ99J]4 ^.WC'8AV144N4FG!GNJ/5
MC7HD/+:]S"^'U;58+AZ_/_>3A/6HKK9QVW,=LQ93!\0%@4&KZ/(^:$1L@L[K
M!TX*5?FR#(-<0_KW;P\6P*+LRKA><.I3R$Y;8W+')RYI;4"+W>U9@E%DZ&MV
MG3H[!=;V3N8N;*DA1+U7>'B\K7,8@ZA<)Q&WD+5*KA7=ND%H?YV?6POM!&FS
M#P%YFPQ)")[AG8+4BFIRCD;$V<]BN@]S^791>5@[,-49[Z<HP-.[@5]D*R0"
M#%QRX"WX+,#IABM[0K2<EU3!VW1ZE/*2A+-BVAE!PXD7NAW[XUA#JR,P<HTI
MEP6%H5:WRCX,M]\H^R N@LCW9L)25,1/&,T;DL&Q+H79=E'4P*UA<)=Z\48E
MU+-PH18?45<;$3*T6?%B[YXMBU0-<)TJP+.C*/KQ%B*CGN;3W,>>YR &(2X4
ML*ES;)=;V4[TNE>^%<I&9W5GW+9JLR!.>X-DP0M?&D[Q-BM;_I0<ZQC?XJ?^
MI@@7YG$4X/K_,+ERHEC"]4!]<50)+G5*!78LZ_H?=?O"'>:D7EF-(^N:Y9EG
M \IW!0-P?7P/T>Q%J#9-JBE5E,Y4L$UG-L\=3&IU_2/+'A6N@"K*O-P;A4^=
MH.LI-&[OF"O)=I%QP;5J+'*X-ERK"(!;1';$!T^D3<) H&;+R(:^_"\\(4AH
MY%2F4Y1J9;75\':NMGON78UB9H1')*QT]_]A[LOCH?K?M_4I+984QAZ5"!.R
MC"U+*?N^#F,+6<;8=[)40HTM.V/?=Y/,V*DPE.P,92MC)[*6O<?(]-'GN_R>
MOY[G]\?Q>IDYCG/.^WW.^[[N^[JNVX+X;V'S'T#L\M$94E,'A?92(8B$-7OM
M!%%X<?CCL]"#:# ]@UB$1%&C]]&%/@^MH:QTXE%%3M1X[R.:%[T]MVO"AI64
M?M6-;/"K<\MBSDEJU._C_C;2POSUA.,2A\2AYO;0X^OF 2A*/X4_U-1A]V0\
M.8SDV(T[E/ND'ZVMAZPZ(U10BHJ$]0D!&;K,QV76_RKI_[7%H-3Y:JWG5',C
MM670%X.@/15#Q*RZ*A3O7CNX?(/PO:^'I8:] V7!7$(M:V9UG*PN>7/)][CA
M,DP[E%^=^2LHHMX7P 67WX*C1N@O\4)DOW23NR9>OAH5D]RK_?P @6KC+^L$
ME..PZ:#ZP:0#,!"$WOB[D/1;.VY]XJA%J2]!Z?&'+RS^C[C+#@ZH@-\'+RI.
M/XXG\/O?>G04>*H3A@X/3PCV^[F$N): AP_C6WRJ_BQ!H?*[O0,>/ D2'3FA
M$@Y-O?0[)S\ H.6R>9.>CX'2ZQE6LI<U>!JZ&,4]Q^566A O/'&(CU2Z]*'E
M38 A71U W-;0,KR0+K';0WF;I:F!G](6K^Q:-[H.40ID ?D49<&0]A_BD$K+
MGT,K%O%?[3+"1=CY-5/HTC*GO*9*Z,L_9R5>\NX;/I/CB)""TXR#9TH;VE:L
M-#K\0=.B/-=/"K>CI.2;)C@'PT-?R@@5;YD&V= :H7$%ZV)#YAQ9U+I/NB&*
M$,Z8I\.+2JK9-F;X/E7-U".]O1?ELX,U-7L9/*[G%]IHOUU0]\@K "5%:$.=
M21<$$_7,JG@/<(>E[A58S_X/2)'O@W)93V3A>X'":E^]>:^$$2:^FS:M[0<
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M]#- S5?!N5HQ SP\/V1,E.@AN3'E+9X=7L$A/H)GG6G7D5:1'CSD+HBQ*!Y
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MF>I$@#IT<QG)W#2R0C#?7)S<N95?\=I,R5;5-FP85V!/I<Q#+;4MOR8L3(G
M80CYSV/D=\7-9*YF/G'@+^$M\>XI:"^-(''=,LIV\4X+BMI0!8-:Y_W)S1.?
MKP9/&;^J=>H 7K,5TRU#"KYSS>SYXI%&.F&X/^NG$^RUW $6"5E'9I;>R(K>
ME%%/DPV_[:=A%(F1G]FND;S?WW!I\<S%_=C6^3%BUT[6/>!"2!=I*\=.6LY]
M$\]S[%U+/XD4AT1:0JV"C2C"-GA/MU<W,LR4UG$Z9N^&F5@8^]Q4$-AYW?L2
MZ4>=)U6S!^S."XO0=58BY7FV=5KM_ CG3F[B7@C_AI:)F@T+*58 KT2>1E,$
M-^@ZIN6X-P'.SS#-JI6-LWQZQ<Y/+F'7Q@SK _&>37 )W /&-W1/AB9SNS_T
M_&#I7,-OD$4I*MZP(>Z=%K^K0]Z2QC43H%\.Z:I:MHYE<(NO@S%L6.]>5X/A
MKH:>GO_J(U4":N(8-0;#\D8$ P*,D[X8T7A=B^#R'GQGN<7,@+YN4?!=7_@"
MSG%#9RRXP/JE1+.-]\"'N2CB.2.*@%U^"'7;]](:!Y+];TN#:]_-&]>^(V-9
M>JH=Z+6^*ZC,>]W2>S^GO$.Z#<Y6&7\BL(H5%1>16QX,E&0J(K?U99/DRN+)
M([)E[$78?H)5)DD#=T%I3MFO9J:08KE@S;C9]3DKUZ*OG0H90&5Z+0,/!I@+
M1M-.XH=KJ;"L1F]K#L-*5'V+P;L[7P;UQW>"*7E!P58YM3=QM>04<A86(DA_
M8*-N[#V<3XM+: 8)MT)JP/A"IH:+T:DV]HA38*FLH808\!U&G\S7/A\RYWH4
MY=9.PT3ZFX4OA=[Z=CYGVL]PNOH2;'S$!<ARPT]G_N*[AACELG=5&&]%5'3W
M:IZ*H$_K <88!ZRPS!GSXI GWY-*]N\!ERZ9WPM?4?N0/)BR&3(^- J\>/!U
M"9-!^ S9<IM<,VTJ2^HYM389L<'V<O'IAK 5VL:])+SC+_?*]2<Y:%XTQ90Q
M5ES9TLOMYM(M.AJ_:T)?_OI8HB>N,[T,J2JYJUA5:;Z*0,)F[C6)EC;HO3><
MKLOL4J^H,6A_,)!2$0)H^NLV4JH/Y'*>'U;0YZ.9_V$-+%B +D-9UJ26C+.<
MQS ]<P2.UETW>]F<@$SU8</-[C9O%8W47<?)YX9)FFX-/H<_K4DM9=:8]>8/
M*^3<V3?443)H3CE-KM\B"VOQ9L[TX# 9]IKW1$JLR(:LE@T;9[*2D;N,72ZC
ME!UQ+T4(3%D",CS3Q!8&V.D9X6^&G&&]/EK9*4M.AMS8@N<1@/7^0I=[6XB7
M4Y&13I=TP[7(8C/X!RQZOPR:];]9$@<6QT2>GO]!<6Y>6J^/O<&R>RE4BQ?T
M=9\4^S)?&!P1FN/FZIU@4]']/?:%H*_-F05MP85O8J!IE(X'V6#G+D]K+:VK
MC.8)A'258'6+=?=]64Y.A>S#U5DE\'WVG]3[WV_7?R77_\_;24+B^[?;ZY/C
M]*!_QJO_;3N(W5Q4&TDX10L +O+$S[1*KUUDA^;4-:"?E\)(R;C7S.&G(R-Q
M#A=(/8>G,9[QH3XJ,P*/-M 3_I1[RPQU#GI8!,YRJUS_?4H_3@?+R^!UKLL[
MCT;E2GMR?V0IEVJ<" GD8"TZ6'+P/:PY3C D8-G8AX@LY[U[[7):."X%_AU[
MZE"3*7*J<E934SE99W=P'URFPFU2A4B5W.3>JF(%)8W0OL>Y)_,/;V(V^R,:
MN+V*V*%U$MY?ZTI(!;Z=G^!O/L# @G0O+E0=KZ3^%ZZ 5@&J-I_(1I'\MW3]
M<)&CLLZ,.PQ53Q#@$N$6X>_K<3G*X^?P@XMZ\3[S;^G%;\)3(YR3F(_TU^@<
M1M-4>$T,!S^4TSK[C;)FC\Q9Z8L(9;,4!9UT&TG1BH'8DA:G#O,*%]W+\5"
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MTMTJ#)Z#9=82_HS1KC$&JFZ/8*[@7BUEXQJ>7 ^KF'2W-W_!XGTPN>;)B@-
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MR"]HUI[H'^],71Q*80Z^EA>(O(->[DIX8U>*E%GF399[G]988]ZT^M7Y [P
M8^^Y[D>%N/.#8DK5_XSJZS?^7-LPI4W+T "^_5B_B7$?/_V]P3FCD&"C"O%!
M3,_TR):0&ED'_93:%&2()WSY7?6EA5&0?S#LO+_'-EAL'[!S(\V#)=#-5,1=
ML3 VW-:#1M;5D(IQ?-B?&PS"(DGU=84:;C/IQBWQF;R:6J\/9#NY?*.S<@!6
M_:P_ICJ[=#CUOH8,_73"-]/6)41[/^,4*-,9:PRC26 &,O3,A$7V!$<][4^<
MV9[^"G)$9):QUWOH+.^\RYLJE5)?_A GQ3MG$F.E;Z08AO+[U%3=P0!E]]JH
MX^DC69<Z!Z40?!Y;N.WQ]%,NO>K&@C')<KZNM&Z# 7%,OPY(;MA2?XK7(DMX
MEVT\I2>#<QOL11$,,-]!9XWOL=F-F\2C'8J!?8!M79;3!6\-=\&,"6UHV3[Q
MUF9OEGBJ"_5%&!]C9NQGP 9[=>ZY=/M;X$"?V\O?E9]R>R96,&>;C5#DO'.*
MR0,Q! >->#Z19V=ESX[ A%5^TS&Y8+U(W='J/3-V1G&W-Y<7H*C"4J[UYG[1
M6\%(;.7SQ-?PZ'U*]OT-YWRD9NF\%*I, G,C[=S'N=?CE_V_:;)<D/I1E'*J
ME^9'UH[6Q9&TKSZ\JRGBQE?O^VW8SC5<8WO$;>S="_BF6^Q 4C5=Z[C5X:EB
ME&HO<+E).W>1:DBP_H'\&5!WDU>]++F7^V/O5@?0Z-P:C88)>K+Z:5$?6"I-
M)( KB"'KE5!E7&ZY';W@CLZH^KQ);2ABN\&R"P[7<*=G+[GT6DOC)U&C_BD?
M6I84KYD0T$PY^$H9?&7/!?<@+OKBM'D:A-HP+*IZ@V-%FW*9R<_MJLTYIQ^J
ML*E+K+B>*(O3)@/U5HVIDN%S6OPG-[$B(F'-&YMF_ P(7'_K.5!TIN>3<]]W
M&RN_\63%]2]*% D F4TGR%UV)$RF6X 8'[D5D:'V-TKAOK >28[B,*9:@;$&
M]164AS\TFK%FH!L>6:<Q3_,:4#=WTV(/5MKC8T'\75A$] <RFF9^";OJH;L4
M.P$+8;)XMPMSL+*#.VK*#?KYQO:+MJV7:C5#[(H+AZ4'PS[ZZ$5J<T9OE-3Z
M/Y/^<2)-*LQ(M(T,5Q"DR;4P1D\E/ZP;<=Z3NZ$[S\I?<?:KVUD'^6L!1GG!
M$Q6Z6AB/.O.ILID]-8,4JZ;/%.C"UE5<?5#+2.O9;3#%>(?T +$A_Z =K+#I
MVOW3@,G^@LXE;\&)MF(]6[C>,,(AX=J<W%V]C]V\M.VA$39?=E6RML;#@766
MHQC-FC+]_DE=U,R[]L*[*2Q2"ZF,]]NE!^D+K+_12W'[LA5XFEIJK0Z>0WHJ
M\TR\JF\309>+*WX$UXB;W=)B= 86+$\61G'DPAA,/GU<T=^V[2!_LSWX(&?Q
MJJDJ4U3_CZXSG?14B'4#]W;I.MA;L?B14X/%T!\AUU@16\GW[%@_9ZZSQW_3
MTDUN=<HN]0N^>T1%+R!P^<T(02-^Y64D^0^MP-W_;^A&AS+L^YE_Z@1^2^+^
M$_N)[A^Y)97^\XU]6$G;WJMK6A47!6X_A3YUBE)Q8N89#*RS/VF&VEA\ &D9
M&0S%2ZRM$FKG&.\83M=9X(*BY!@7.I"E*GU1JC9CU3Z#E)6BTZ_,WX,21[+N
MZ[F7@20XZ;+3,SAR#MM^(?J#Q"(+3N38QSPR%2P:0HQ:&Z-.<%_)AMB&/59L
M-&_8D+"%V#^)ZQ"?_JL62>9I^UG,I[J#4^F%QH_$9F209=*+X-5LA_,=#N^U
MML!]#&<:>YSLZ3"I$EP1\'U&4J#[57&G.;T;TO8M8QU+/KCN!,^K234U+)10
MRTY+NE901P48U)W27L$TTD->J\*!D6.T*/*_B]:W4M[N,ZL>VJ1J#/-Y'],U
M;MQEM=S:CCK3MCBG(TDY6_:NQQ$X]Y.(8E-5M#C^+ 5S[(Q.?I\P7*[%F&_3
M;\"T*SZBL2[ L+<C.?0LQG=AA?5-X4OY>[X'"Q853C?XNVC.EE,'5#KG?539
M)*4">DZ\,Y9X3/=+A+>L;R&P+Z+NJ]E.BO_3;B7'1]N#U=9B_ J6YV^! SPE
MOW#W^L)F(TBZIO7ROR-;/+'8K&LX7TFM#VR67C^)(ERQ3X3?(&D:0O<*'FT@
M,^J\\NJ;'1XC5K;J0$!C2O4-I,O3M;.MI-Y1H@)<O$,/\YO0?<86=*>P:9MR
M4PNHP8Q-CT:+)TMJO34A$>?D+E7?>@C.@..\76U6V5WZWK1IU(J+*=%4SO-I
MT$S7L@"@"S8&)P%-@@DOX-O)-*P+,7N9(EQ-GQ0QL5JJTXE,(:'3*=,!1G:"
M<OR @L0\F@Y!^+T@%;%$150+SY CYJ^ @80E;NJD_-';S4?(XG@3R4/XI'?P
M 3G/O],&_1/BX><S#=Y$0!(?V*C@P5@N_L?!Y!=V(^,1@]O/2S<^!49D9JUQ
M#@>>K)KG%";A?,:8(Y0B.W077QVC&\ [F]JE7T!I*'<02<)E<GZ[ Q\>#2_1
MN7+$'\P-8N.F5K\2IAHN3<YZGC.AX*3N@'VLJ]!\<Y!1MFX)*JFHNTG7R5V\
M707 YJKX0:7@W0@7.]-@=XNB]58U!O/1COHUA%R]F(U:0U?^F :! )2D">4:
M@IL6X<N$XX4 P@?J!#G]/]72OUVSE(]]H/WRF&SZ=]7GXU_'U"F_6SD2L!H>
M)T81SHF@FHXE^ <?NEMG' !G66@H1Y;;+<?T4Q@V3M,%!<1MNAP-!25ECTN5
M5S.CQ/SF&1%*CI?#0NT0LR@5:,FHG\W,D-B]%RV-*8KJS3*-IN?:HJ?E:CW5
M,":.M'NP 4$5Z&$9"2P]@!@=G$;J+>?!&[YP;P^N_22B=PR%R>I [^TQLG4R
MV=$+C S<N;JBP@&CDAF@P8&VR@WF<?=PK^.<JL02N,(IY>9=@;(H^\2S"ZK9
M%H+>X*N6[8H<F<5WCF[DE=#,E(HPU'E<7\R:2F8T^-ZGJ'<>N<"D0<%(%T8G
MQ*Q.K6;'V2@!HT1[(4^2-FB"&4=A-S1-<K.IZ:%'RNL<+_:RO(1K]GP=ODJX
M,#H5QG$81AP\OAHE.FSRL8ZQF:^E-_0ZZRK9 L]W9SO6]BQB X (2&(*>;!Z
M:&.KD1]-Z@LEZ7=*FU&:5G!EQ.,CA/)O&US^<TLBE \3CHWG/Q>+/*>#2:MT
M6$9Z\G=+&X+NB4.> .0AAW;!3X\F%GYUR3_18 I'LI5.(,I4!8V;1IX,K!1;
M:)Z_"?O40+LYOKATE7AG>_"Y8:-^D4,3(@"Z=J53M!C8HW-YR8@K/'E=2MZ/
MSG/@5I%U@*2S!&S@<HU2(/%YV#A+X$^BB^2U]W+QUK\.CW;U:@[6DZT./[?0
M)C$MVYUVYBO:3^2R>E1TR=+##T*^J=0$E)8SM)](0\7FS)^=COZ_;U>R!"T?
M4=EQ<^,'Z8H(??I9GKP+!:52S9#N>PX(M/B=_+,Z+V%M/@HE<9:,1;44<BDC
M."0XEC[U,I8L_".HK2Y(5F+^85&6 $-Q2(<O0(2#]4UR=<(R:INCZ#)'SK#"
M'TE&_+OH+*=G=N;C$ 49:M+[.;@H^$DGZ+^) 39(.'(POPP7_X=$Y1F.Z>>2
M$,HHA]K;[;Z0F0=V'5YR(:4A]M/UO(9=<9\55_T!,[S&I91BJ99<JJVI\^0U
M6MJYME<*T.?XKA12*:TR;#,'/W;F&';%CFSJ#K>[XJJ RJBF!>.\+TDJ7Y-U
M05,?J+(H&-]ML) -?0T3*1T8]??00P!RWX'ALZQ&Z%5T3GM77FZUANI2OT(J
MD,>(36]O:);>1;H%/=-UAJ0VJR<GO$#.TB5R=CXO1[5&?;VDG*'_^_?QCTYZ
M>]+)WHP?!(HDLQDD@Y!7=]%SQDS=YCJ:NF6"L O%>8#1.9'G,L[:&6>_AIG#
MDRLML2FAZNE;-OUQ*_SF?Q66O&F%)#(Z;Y3"KMDQ5CY,7D+GRHXW:!B>+\^Y
M*N"#GF>($TH>/(/DW\5BI0<_PGMK1L;MKUP4!IBX&36P.F'4OQG7J5&"J[EY
MO17%="B_DF- ?I;4TUN%!M8>57DOV9RQ*8F)-6 9\_&?1()D);>D^RH!N-I%
M7A6=.Y'&OI"1/#<Q\7?C2W7L# *K8.%\S]OV4FP/'U1P@',>C$+/L3(#GZCH
M;$9()^<$#]Q8!?*2/)L\8S5GU!*06U(QQF? *JL]0_V3J/R9MZ:>C1/VZKSY
M?+^N[4A9K.Y-KEU-H#!DFG*V-=S&<T.E?C[Y(9VL46?0#W-IV <?.[-HX(J1
M;R=*R'=^8F,!F^8A6NHUOO=JRGH^ [Y=5YW91;'"_I0!? 464MLM?WT*:8GE
MIK2T>5/5@RU?'>PTJ_(3P+(NW?31$H.R=W'Y7HK?M$D>N)%2U'^]^T[7!_UX
MXTNC!U#>_O7Y]SX<.V2\ *WXYBZA*!IC+.D9P)C*>'35[NL<K>@F[JX/)J(&
M5Y&TF9*9$92FV6@KZK;%H;RR2O<73D:0S?LS2P-Q:>-/BL]_[LT-DC'6 ?1X
MAE]K;$E2"%\>3?*I V= OT^I.^D/289?(<6X=K\!R/CU1$U]HU QW/?&,?68
M%39H?'_-+5/HTX-(<43K;M]!K9FH[V$+5E[L372OLCRC">UNDZOWJ9[8S N"
MGNV"[)S$=!?WB"R82'JN-:59\U^H+GZ-XM3H5?[.,14[7X1AD6A"&NJ/.C>[
M&$>,.SRGA'!9F@Q4=5WP-):W-+NPL5YJ;SU3+OX K"/NQC#$;F18@09XL2Z8
MG-V%C,R2O2YY:!)<Y\6<15+P@BD"LONMQT?!R8KCP\6.AQ1/&M@E:B]#I2"S
ML3P6KEZ:AJ6M S73\31EI,SG8>]WE99+[%,^RJ4UHL4%5B09GV&-;_LS?+LA
M?L>J@&,K9KJL_+FP5;O?Y4W-[J5AVCECEQ+/\[B/%1?@.^$_[J+[J1=)7 S=
MJY=QM\(P9EWC$-D\IS5!'RFWC-%A>4]3-715#<HTI;$A=4"2TG[DGE2.DW=>
MH[YVU!6I6%A[8K:EUW0\[GV)4QP(J[>K"'-CD00*:&YZN#@DRS8MEVKI+B^.
M%B8#R32GE&MS'YZ/7'E<AS$1WD :+9LTG\RW9;9T,:'2:_(B_WA*&+)]<EQ)
MK8'[TZ*^*J?M=6I?K\S/OH5L$K#[W,YC%[L^F7>X_1_FWC.LR6WK D7=5HH*
M!*FB4J0(2 G2$93>I 4($*23A"*]"%@!#4TZA":=$)*($ A5I?>>A*K2FR 1
M4$!T7\.1?=C[.>=^WY_[?/?'@@?>E? FK+4RQYQCC@$?K,9Z:SX/IU>2D!^X
M"CRS +1\SC(&B#, =&Z'MTA7 4@:W^"9%"8[Z5SZ#090V4PH_ZOCZ4>K 4/:
M/2^$Z\CZ2Y8K%I655YR6()_XAPU8\CU$3@;X:50ZXO0'@*KM1X#MT-W+'Q]9
M S+1X!G$1S14LC)I.F9LS/9*#*S)3-$^I(H&.5&5T'V4,%OJJS81GR#U%7P7
M<#SR=V4H_*!WXG\:_PQ(_]-0I((YT<-B3_\;;=W]B?_6U:U@#U8&'ALVV8%Q
MJ>[8AE6CQ#AOL<GB%"@>S]5*9#X@:*/<[VZO-!\%OCB!.T6Y6#FD.^/K Q&E
MB%?'O85M1'9$#3+=&1T_-6+F+>F4R;Y:V/A&1.>.JZ!4(O5U>*J)A_V*;9^?
MT08+7LX)<Z'=-FYON5Z&UIZM-K_'6E)UMK)P(F0Y>IP=?^(6TFDA(J4W3:,^
MA':]3=7B_14S1>&%-Z>]O=*V<"4_&:^$+B@16YX/<#%CO-_O"4\5)[=X9:(S
MMB-S6D4<=N3-B@)\[5F$^V S/Z^X?K^6\15W1F3C8D*5(,6@6>2:AK?HR: O
M*R/-KO Q)7Z)TD$DA1Z\>"W:1D6=$=G_!682!<D7KV2ODI*?XFJ<_88%R;^<
M7%[-?&>1^.1]99*LAI>]D<3([M#'GWC6^'-Z(9$?0U392OL=G $[X^ODYA.#
MYE]&<*@Z)LKYNU4W'=MF(&XN5@.2(S\OJWF(1&[V"D][1)&>\:4?J_X%H2PH
M+/*1&A==EE9LK@??(<=OS34Y2Q6K=_.N!3"@6,8K=XF"Y56(P6'E0!_-+=2J
M3V5-6Q<$B6%7VGQ>GOSLP5/_'R@E_&;5PQRHVXOS8W41C1>9/&09WF]]_LDP
MI):A%1<C3+DHUR- BKPSL5N732]J]QXUY5L7F80%&QQ5?\TR"LGT#*&[\S%N
ML+IK%7:\KUN8DL'@&5E8?;GLFZ_$#;#"5]EVGV<5E'XZD%-UB1K=M2-<0GKW
MFP5*QL%U;<V02U!:&N*NJ.%C=&QQT9V=8+<;3_2EQ?=L@LO+/Y(SK#5!1O"<
M81R[DZPL-G3Y2G< ;C&JB'XK"'9U8:1S8FT12VZ1'\H=OG&^QSCKQ#R:?@ ?
M LXYW;Q3;2>D"LY4K'][3XBDYBW]K46>]%0N?&UK%M38*='_56 Z=P:%>:17
MS$.@DQM^1\!J7+3N)8JZA9U(3D?XJE SSONYYQ.']P)UB=/_D_5W>)C]55%#
M_-NZY8 8PT+]I8JF2\]EJ:=-OAQ009,A7KA@L0-H%7QN/.VZ.#BYAG;B ;VC
M7'\>6M XL5(VY'60\=N@U9GU^Z\7G)>T;CQ]K_SQAW"<4^K]L?EL,Z1,64V!
M$3QH127 ^PNRM;K*16NZ=HD8YF;7/6'ESZ%C2M?,:3+0@1QM;9Y(=[M< ,I!
M7WE*C=T+5XN,G!X]9"W(1>Q'W:B'AO_6NOU7"L9S28TYE<I,?+G(=QGL"U!E
MK2^9JQN'X?D_ 4]_>0V>OW$Y/0#U=:TTW<(3[-E]AHP/Q_13Q$WDGG7IC>O;
M(YVUMZK,%!2-7[&[+QOW2/6'R_W6.;M^" 4>< SWVU&HQ3T3ZDVX'L:&!T4]
MZAV6'H ]E^N_@=Z! PWUR0I>'BH$[E^E_N= CW_]O;_8AP>O$4USR$/D+S6W
M<P?PQ/8W8Y(Z??\^#VZK\"&U: U]N&M_3+M(P70<+BDMDS^;AV;_5BFI"5-Z
MH+V4TP^^J02NS+K@])-]+EDTPV*(\]H<JLW-0]LK?!/;8$#[&C=9NH+A;,I.
M+I$IUK%SC,CP%V=)+D)R7QL^4<-D=#WH.#,#=!SZZ:B)A(@>0EMK-''KMJ?F
MP'G$TB87]&5<*&R>%VS.[P)&;-H^+YSBU9.++Y#/6Q0[O9TG?R1H2X0;M%\Q
M#,:\A/?0%D]"ZJ>4F=Q/T?[$[\VU9ES)< 0AE?4[O$/R^.]+3)&OY 5U#^+5
MLL0WG/!'SMITFZ[CKR=Q.L4.04VC70J?+4&[*\9:OP'M'B&E^RLJFJENJL<-
MU8_3ZMRDIZ;AT,;"]/BS*CK90;V>\UR=R+!4@G%+8%64U#G3WK&MU.'K6/]F
M9% 7+66L82%<$O51_'Q8WP7Q=ZV_UE P?CI$IHGGHUVU2($#\!-$:N!!P*Q(
M8,B/M/!;<3;CU1=M.9U8)!J*IBS"V4W@$MFVZF/NRW&!N."-/W*3XZGKQ^C0
MVMF7Y[YPN+I\P$(4_IM*!O6'V]1_[MU_]+H=2',)F3_^O2JI/ 4EZMI!'CQP
MY/CO)CEJM]R^2C0U8?G25I]Y[%[^6S@_[#3O]2P9M"ED6K&Q1#%5LG ]] T?
MIC.XV=O&?(^/4DE\*I65N3*=?CJZ[A&:I'!LAL=9RCY4=@O'S1UFRN,3)'/M
M5I&(P8#'67C'_3/!H],UU_WI8I(VBIK$."+SG[$I@[_U\.^X8X;#^P [6T'Z
MB:5]U7FF)M$# 1@19C/9_C^,CNCG/F1,\!61?L@I"&5)_C_78:8.]F$Q,%A@
MW^I2NW<8UWR^"N@U/64;E4$^-AT-[P(=08.I1@E7.Z.RF>&/JFB(\^SX):3Z
M?(4OQKR'Q]N<,71]OB'AK)X*MS*D2)*#N\?8;5PWVF]HP]HM W3&=$5+[7)L
M8158=V"__9+_4*3RUR%\@$S_F4W>;V)R^6\DFK]Q[F6A'/,GXL-6-/.N@BHW
M>-R%NX(MBK*S$5]UGMUJO4]FFQ;A[@6]Q>XIZH,\R47=L5F^]XTYHUL<I/@(
M.&W*R0C+^\'XGC]I;./XI<G]K24N.TO&GG'1^5 WWK<S]?>Y'_OD7>Q&S <K
MYT0O:Y/1VQYZYTH\(:%">&*L!KV.928DW6.NL<X/[:9U9C7*V)S<5X5:\^$$
MOZAB3B0!S1S&9A3ZTC&N2X8[4<*TV^B\_C("R-N]144X,S0-BE=I<56?OV8"
M!H='F2ZY:5D]@IBDNV[.,"<URJ\2YC&BQ8 @DF*S&)>C-43AYH;QIQW$UXQ"
M$@I-'X&<\HV^U>TTGUD,B_*2M-HB#L35D-V$I&5*3%UCH#?*BOT^]G-X%IDY
MM2FN,9.*C(!2:F'@P:$\NNER)@Q\R?[;X]S"UKB)M3UEFAUX)3[JFCV@95'"
M;=PZI+[_?&Q!@"_.>R1W\/:@4X[C5J%>0%Z]4;J1*1<<<*&?9*3VG&:^1._B
MIVE4%QH;-#0U;#B>  9K]DWR($=+GE)JR*I1\2+.,*$X%+! 5C$M,:\P0O*^
M9$D6/'780U\?7%&G5JKF@DD^6E<.H31?;V_JY@J!#Q=<+$J7GUB^^%%S$MIU
M*FACQ89#3>K)MR<;V'(],N.4.@>0[#@<T=-/DM:>1&$*T'Y%(A_=-S'%0M\*
MOL=6. >;_A@L1<H]\#&%2IELHKU@'2NFLR0F$F&YE"M6/9:\U_Z@;,! &RG/
M.K-JZD!ZX5_B#>]41M2A[*XG;FF@.:7E*F/F/\9=88Y&"7W#ZL\T'_M.3/.<
M9G@##$SR[C2IB%2,4F8@X2@\52GFIB?G2]&KGO>HDM5UMP-WT%<6;$3B:AJ\
M+S1W"/.'N)]\4N#+'_W#QI#IQ#PAVJY'M,K!J2@=).&,+.*;_[1A<^%9;Y'%
MI.1F*<LM@[,<,AG\]5,!<Q-^9S;JO1MYYAM#D]9NG.)?,?^&O#+A/-?C]J1/
MR#!IG(>C:7.E[7;P4LA4596=*BG8V^#N*!LK+N3-NGD&)Y_7&*XIPI%7_8'0
M#^.K?>^%!IQGV4@W7Z7$-4.5Y CE<2I^@*4&P/8KRNL3*5LX"6+=62":\1QE
MU6HOSFIID$*P:_B31JMU8<$(H=\V#F'8CN7Z^M:A%TZ6LK E\AB_ZPGF6/_6
MG"(^<9OV%R9;F8JIXEUO(>R:\6F.='HJ:AO0JD@%C@A?_/[VZY=CW_%[:'15
M7?>Q)<,.[XQA?KM ]:KU93;F:?$=L_3MA*D@38[SH4F;F<VJ[L1T[Y=MGD1O
MT][&A?;H]3PWTFWK'\(#>V<_)MQ=#*X+!7Q:>.<IZ=P%<!IO@L*C1 6]K;"A
MCUVDWS@_4A=V8$<(W+[%O!LGWJ/7HH0<?LX?_0H?AFUT5&^!A[=H*!R]ZVV2
MF?D.G=>VU77"XG2+LSDA_"Y]D/(SJ7OMS0SP7B"M616!E\X;4B"(0E]TU/Q2
M7M]/YWV%-$=$[@0>)1C0+]-S"/#7KE@^\CPW7RWTO70E?SCN1?% E^58\ 0=
MT;^\RYFY#!5%\I]7[_!*O^CTR=#4-@'H( UGN_*-!:$W7/'D[F].S'[<HG=0
ME3L0"OK?\,K_5LR@/H'5[Z/OCY>Y?Q?9^G\#@H>.6\&;+_TYR]8*^A(Z4';?
M\0E8&*T;!^=T:O<'QA4=#]J]$=Q1RL)S6H6'0-\L($5=X5U-G5DS>UQ-7'6/
MTZSOD#K7VDLR$V?&AF&)^[MBW< $H),22_X2,YW1@-JE,S93^;EI*BJKO^*Y
MQ(I.T_QCQ3T\/H5#E]+4EX/&+JSJP&I3S52*1I[33->Y.BG:FO;Y'TFILW]]
M7;E\?+!XTKRJ(.CD5YGQ;[#HULA:99& 3<)CQJ#R2723]^,:]9,1>=(;* 5O
MFYO!LA3V4=9'KF91:@45(B_P]07+C*/7W[4*EU@DR45Z=P;J@3WL/V&8IID]
M1XLWY(/(P!D/3KZ6VD=7/<#K]Y79>ICO>@#-3"BWJPSCZLAG24LHR(+&5U^G
MRNL-E^%7IK5.P2C1=K-I[+5_TIR32N%[W@=\!TMVJR;@JCO+F$LLK+9+AVA!
MT6M1J;A3[O@\>-"-8\B69!;U7$&D- Z#"@O37 S&*.@NU1O<69^O_PHRK@4L
M@36:3SZ^_D?$!B[+=4ORHBRFRSH@=AJ7V7S7RD_IR=G(*%(1 ?;@G -20J%I
MAYRU,K8!J74LM_KV]5U<Z-:M!;:LNI$!3V)6D41R2^1]2>_K,GW 1:4+ZQ^0
M=Y*PSBIA_BC@,H2+$#YY@=?LG2>#-$9&QEC1BDN@X[V&Q4L7\;&2^)>@O;&*
MH.  NA/"B344$U!_A@RG&>TT-U?4*\90_ X]9_H%)+%>+6=SDS)\+[E<?M*^
MU2;@Y ]X7!U%*KZLR>S(541T\U,/M/38BY1M]")?8]^)ZFJ#AB[)74!N#K\'
MY$/'O;.\9-D'<-Y13!>44=<;%)VKB<=RL%W[ V/_ABWY3C=/#TO@WB[<N< H
MP6 +L'A#SB[N;6DD1@Q'-2=X9F_(.[K3H!SNJ%?%?(_,<M,9T5&#;PW OE_1
M]=#N( RF9PFOODK#R%J^5U9N<]BR_ZHOIVD!M7,"81_/Z)V1!:1("7.8#1DW
M-[Y6@A2R%%Q V0W:@U]5>IHG?SH&PM=EF*4]0]0/K-@Z#9:+'E$?L^L4?'\7
M2RLY$*FBQI:;7T3U@Z"E"HW_363\^*$4.#5($:'B2K\#8M,QZN[>U_/VIS[
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M-$TEF_9^&$19+6+.KI-?:^46]M5:_<3D1!?16JTW6Z=WAL4*)D^TPJZ,8!-
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M%:?.(-/O-P?(_/(G(YH;2?+KK!/Z+-")S73E<^?RYC'IU@:KNB?@W?8UOFU
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MU-8+]<3EVIMO?%"OR!P8W;($1'TQO+-$?7D:V..J% JC4"PP0EI?RA>ORXK
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MW6WN+A7V,$BDF/1D*PH1:U+1V'K-X9CTC H>(:_A#Q%T%?/3Q;=\3@95E)_
M960*0A:&5//!95ZDU9R[*EA$6[.1ZDOW%B_TJLX\8!&>G5+])H=DO5VH=8$C
M=L'<>YG1^@8OLDN290;HUW'C%;I(2_NV":J#4:U2PEN3=%]#>[P2SZ'!G,+R
MD2%I-42?4CWU(W2HK-L:O%>$6  *AU1C!Y>5S@+ZEEG&RZT2Q_.,NI=1 ,@%
M697$%Z#>['L! (@.4VV!@9O[G1CA,901\%+ YE)G1@_!8>+_X>V]HYIHUW=A
M[(J #9 FJ'1"AR =&[W70&@B/9'>NZB A"8=0Y-.""$BA%Y4FH"AAJ T)700
M)/3N1]SR;MYW[]\ZZSOKG//'K)65F4EFYIEYYK[N^[JOB\>C* D9J?\^$+SM
MVT@;AM/&2QX&!3IV=\[&G\V4)P/:X[3OMBZ*.HC.<YT@^4Z0R"0D^S^>%]2I
MA1RQ( _.-P)^#T5+\Y> #GRJG@BYLNX\V_4B[=XRZQ<H/ATN1]':HI\;/FMY
MNQ?6$#NC_(2=Q,"6&ZVI=?BPPV_S*S("N'8&^+^_U=^EH<$JUZ3A\Z3TO(<-
MBA3\KO"X%A"ILN-%4Y$Z\@!EF$E?'UU"*L(X3^P5U9O(GGINNQ.UZG2B\RJG
M&0OS^Y.";]G]9OBU4%.-WST)XQYKOOSY$H3/,3<D3!RALI0O[9T_%%?&CI3*
M*5W^&9XQFBP 6W>BV/KI^-YJ'SKC7F6G>;9"M-Y7R<H\E6;E=<$E[;:6BAC5
MBY&)'+$;M,\)+VKU&1?0F%A.+3=S_BW5UE .]>Z=P;=;7JWAM[E(T"'FLC/&
MA&T$P;KD;/3")BY>AD'IXX MC<J@H?$;P:_(A=T6=)>UBKMIOM^\BLILC&A^
MKMTN+H#;5.9A#P4N%O>H/[%&UVQ9_DN&DL[##R6V)LMK7MJ5G::74B#6D4IU
M^ 0A&D&WF0B./'&<@6UW(/\RZ-LM.9652Y>] U!63DD-K8.BHC51#2:#,=YM
M'ZK'[@<F[G9?))H#$0.VK=/TGHNLTW.6=BF1.KQI@Q;H+1?4I%-2-3?JL_HS
MP&:=+$<&#[FVK*S[Z!T;:2#?@YI<)M@0_O9$(8DN_B=56OP?E9=7,#!WI&._
M)FC(GCOJP17?L2#?OI!*\H\A+X$(ASLJ"UFZB6ET,)-/59U:3-/YHS4I!@VA
M:=NQJQZW"3_8^8=4/.RL1(G**KB$+\^.V>T<D;EUG8_7KQ_]02B_W5SN\K%3
M:WTYO \+U4A(A+1-#XGF?13]'JF&Z3\B_X=JTU%-\7<'->EW[__)!K\0_ .5
MCDA6\61_^J.?DO];PYI[Z82"779ZZ"WDCOE56#;/:%HJG0'-M2F[*BFE=9:+
M(R\_KIJ.-KQIT*)',_=Y.'&R -V%MA+.M,YOC9A1Z;.[+3A7%7X4L_7C>%.]
MH+S_1@8:['3UTD]=X^;GN]]0SK_(;#M+AXB]2[YDN.OXW.C9.[ZK57LJ%P-^
MD>$K1/?M5)JFB^<?69_QHZ&PLOKQ^FMQ*F("WE56M4KM!M:*'(1/=/@*)0M?
MCM33% 3#)Z; [W'HNK15?0W^G'>W72=%AY8%?&TWGNT,WO! O[!<U:<EWCQ8
M]Q5ZWZ6R(6X=&>F;_HOL<&U_Z.%A=2<?'A%NG*"]_Q.?N>%?>\$R9V3)$1T<
MN3I4Q4)M<M9@.O/.RR9N1F3JP+J<A*8$&G3F>:($1^^,I9!VVI/7[9 @T5;D
M1XS-SYEXX%7R7?$],5GU/1 MS'P\-_\ZN38^#G:?!>Y4SR[NGO.(SB#>":.L
MGN/,R@O*DV0LB*KI6Z1.Y4E$(21'AOL]$+=9IX%X^P8^.Y?D?6C7*9HYU8V9
MF"S@)&%E2+S%]EI-M+"[IVVEH?>"H_ AYG<8WMIR8)%;,)=N*59I;(;\D%S+
MV8KR-V,-7AY(_^%7[C8?VS?3$S$Q-;SYBPRL2-Q9W#W<R_LFD:)JMQ4^=C-Y
MM[6N>RNL"OK#\Q=9L3Y?]2)H3)9.KFX?&H/?>V0[NCJ8CD5U?&N&Y'QKOR4!
M7*-COM+T'1X7/OG8K0A37HTL@C@XM\$_347;ZV^N%Q2BJPK.*$B72BOK>=SX
M,J*M(<.-L;$@$<7_W-8D+&Y^+^2/1-C(T2JR/W<TZ3E3)]W-\8^.(?3?7JN7
MCP&S_*,OC[2O_](1^.VF2W;LSP2/W='_>I;^]&+H_'NM5><*/.",:SE%5XR[
MVS,9*.Z >2NVF#.&+QK:Q7"K%@AITQ)SXZ>2*"YJ&E),J-%UGW+[J1G*+'F-
M3<5J[:?Y/3NO3A]'.B:B>2;+Q3VK7NQE@1$O=&D#DS?"D6_BS.K[G^:G4BQ,
M)4Q9G(*;BV++9'1@S\:^F_#?0RQ\E'GZWY-H_Z^6^R[XIS?KDCMC@,W>8>"5
MQ-#Y6<PPD<D!Z\,) SXV?0KYT=0W8TM[NX!'&+BHV64S76VD,8U8<HQ\Q^RF
M-0%<TXJY7?I=PZ2+@%)68])=>"#X1\*AB.P?P>ZY1_\%J?_-T^)XA^)1C'U4
M*J>I^@/1SSRA/F8E\.,OH3JAI=.6*%D0>7XUUE+W,F*ZBBC^<GSB\]?9<<%W
M+=C[7/4^146GL&X,^15DXI"F >E[JU=JJG=1AIT9T)6]X9=>D4:[S,H?ZRK2
M>H-T\%_#FT!W? I%(WVR[>NZUK5*IM'=C>4N-/F!.?O)(3EJX8EYD#*G@O(7
M+@;%#M*M3""C7+LQ&W&T1K21+L-2[Y1^%[=UK[W(=8U>H])#U)VW%91O4%G>
M?2DX)JGF8@#O_7.=Y@%)R_-YMFR!UFDNNBB/L]:&LRJ'&.9+97^24!^J]9E0
M7WI#X]VF[P@=,.O*9PT+LUHO*TBVI ZN&#?T<\M3^EN$@2@S9+%XF$Y?L)PW
MU457P+L/D+"XYO=A97+0MN!S= Y\)>+BZC4J:'[_^F*1+&1UOL_60_+E3_:O
ME1@K<R58Z+OA9A:!L>*H!R8C!=,EWGV)6&O1!\5=!5[ #E/N. V>@8TWUFY8
ML2Z6\L/S@D^!TZX.S(IUM>0N&M/NB CO]QO#^2.FSTA!BS$]"KTK@WPJ(\7S
M!2JSJ]7N8L/IF&27_/(GWNA'\7<-(O<PG0M@KAB7D]ET$;/7<BRC^W.X;Q)J
M VY%#[2X]@YOZX*,LQ>'1/1U0/<+&$74TRL&E&\L@#H-P.$HT-FJ[=A^-K?D
M.-E^D_W=:_ %C_,T>H.<B'$W4UQQEV3XZYZG_2"+-ZVR8$)6_";FBYU(P%#G
MU7)@TYZBD^/]5NZ/3JDH@V=.HWWTH= 9:\:RV=MK'#7Q[C95BR[GL*; EO?#
M^&K*P!D(T--BX'7;2U^FJ+T(1H;/#OJL!SP=1+&ZBN+M)Z!4R)BTDDF,"$M4
M@ .YAMTV')- O]"):MN?]Q[0T22@SVN^?%JYTXVO<.^^41PIPKE@*MRDS/2+
MS$AM@R9%R1N1))<,;)D+Y('=O>!B3-R"L0C\))]"T.N"@"%(T5?8QT[<EX#3
M!S=Q7=/T)07F@SGN3P310H,"S>_$* ,5FU]'*9EQ[7>^<(6[EN?JU%2MIFP6
MWJP0X%2QKGG-7"/#J6IOZ&*>I%7 :RWOMA$I;VB]%B5PR7[R'=$L/N=K2)1W
M,=\E9:$0*>C;\IA.M<>-7N-[#:+<!6Q!=X@*=D0@0P3'18S]1?=LA<)5<WO^
M3WL$R26I>DIE.'=V<Y:\%#4/C@#@<6=W^2C=_[ 7C9%(2A)2:8,=R$Q0/$;
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MKX?G0 KE](W6ZC5^O;0_]*-X;6N8B;R/0<_*'7VV\K*D*R8F*Z\)DNL3(^[
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M.MKL=4+#0@TSKF"_PH!]_;HF+WODH0*@0]KV>V-%<8K: <V/5"^B-C9'T;6
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M6N'UGZ!$FW69 -:L$6^97ANUP?Y&BA+685I*_\2LT11K$X;-S#!9MA7IN@I
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M%?E QO6H 64]'D7&AG7ZF$?\*4K&QJD"L/-0__<25)9N)?K4)(8)?!VIB)6
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M="+*]X?@REH<%*^]J&,L8C$4VH_]SG#:'Q *%9M:1GIJ^#,G0X^_A @+QG]
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MG$P+V._C,#0:JN7AJHQL*"\16O1E:'>BDS.<F]-;UPS"6&5ON>_R+?12>LO
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M3<K!LWLSD%#ZZW6?/'Z8!++ HR3G<;8IV1,<(H(318P+JT(R>";Q4'"TMD<
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MTMJ[ EE,1$S[)<LV#/=R&ES<_E0]9*V:6<6!C6GP$WI20-]C,U0*^@WIDF2
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MOWV\B?(17-Y>)X;+(":;M;0&&<WFQ;-DW21>%T0_[+1@9 $9#0RY5LCAHB\
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M\=W\A]F/[,&DM.R0OE/S^/8]2GZ"QQ4G?01?'RH._6DNH;(4=J(F,V(OW:\
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M-8#Z,08K!9P/K<,M&C3?9GO >C']'FZ"A$<&.+W%QQ7W'[]Y%9L<#SLFF60
M'L#Y7BP"&<DHQ(GK4+_>?W#1/ )$O9<W'\ _N7\>N$$:.^HK#&_3VGQ9D@-<
M()CIINBF)*>\MTD:&[M?9UR:%WKP0!9\MZQLHNS/ XF'!_:RY#[S\&L=>5I@
M0?C +RK8D??JYE7\L5VH_)=D/4L.E(,VW.(NBW,BF#@N>!3?9P!S(]X.WJJH
MQ*EM<I*=7S&1/(.[<LML?X8B<1!,+#R:U09NUN*DKF(^9MC)E@\,/T,E;-N8
MWOIOACUP&?-TW&)P6IQ*9>!8-<98TDS]R_^"5&ED&#:_)]?(-%KK)6<08GGP
M^#M_L+#F0Z5[>7:KR<HC(*XA=>]<MN#G;NUSE^Z72OI^2E[XFJS:X2T3UCY@
MMS^>="S%[YVNTT''IOV185;FN65?0_(\#YD0X?"6_54HJJD$+ BV<N8"3ST&
M]A#\%[A,TZ_[QV!9K<26_5NA2*G,?4@''>$4"-S>!5?/6UXX5?_CB?7$ZP;?
M'\5V:)^%K:%I16)B@3^^^)YIT\EZXGUR"CIS^VAV,\>'LV):>8M-(V>/!]2=
M4@QXB2H8Q$1,X99.) IQD(<O%.UI;[#Z8?]I<(M:N?MR1T,M]G.M25K)4N>;
M!SZ9GN?G<)/58H--48Y<"W,5*5MTPE0L9!RJ>!)4-2RNR16G%Q*V7[QPH#JH
MT4YH14:5\X?ETZ4;,T<.=QY2MSSR>4+I8/ KOMD*22=+UGM67O,G#]L*=A#>
M13SRW/86P3L%J:VYZ!-J/#LI$KYP/Z.Y:,Q&UMPNRF7I3%.4X:.8H_DKS4=7
M<P>?C?O:UE7M/P1+G O,#H=/&:D>XGNHR,T[6(4J"/+*SR.I*_L4>?/<'Q-_
M\?)<0;ZAM=IK\?.O"U.,VY/,KK<'?=]40"Y\L5M'JM$T[8ZU0-!+R_H:(;(R
M\<6-!=/RSH04W)/,R!B+JSWQN#F7(465XD_6*D6MN!(,;+^FDD54/\G,X597
M1W!ISF>EL<;8PR<6C97-J<]TH.0TR;CT=G[&5V1Q]_4:L$4G)@@[7'!WV.*$
MU("O[;M?+,^U?(M'L#]J!U 0J^6B2'49'UE'0]QB[6:?OL/M"DL_,4,SIE=J
M(M)3EZ]J/,;<7MFAXE7$N?18NTF.I\!%#,OK_U#49>RK'>ISBK#N]:+0=YCF
M#!VHKBT4VW3'Y\F1^= ?G7M5WC16%NVTVSYLO\.WT.X&\EF@L#C)KS@2]T X
MC!^_)OWX,?%OJ4;S_G-M$&*!&Y-/O9GW62!=5M'Z"C!2(+@9B0R'56I$8\:E
M=K>X<:M:8,USNO1#ND^G)[:+.!?%.]QJ -TS@#W>C5,E(+WY^%D3PD1(LJ#G
ML,:'BJ:&IW#']'%(;:Y6'!68XXY1E[OS?1P8?+,J3/*S#LJ%A415J0[(J$1*
M=U1H*Z-++YXDNYG6#E.^)X=HJM6V0?32A.LUND\*O[E$CQ*#8+6(K*"^+^A\
M+F771&X3EF\-7;Z2?U?.$=/8D^M:"F\OP=;\5)JW0E:W%L]VY5Y_4K$=GZ6"
M=/6VSJD#!H@_C'@$Z;E/1!]*B;G(5&$OY0?H[X-'Z:HZC>$@/<JQ@;9=#1CO
MA&UTCH<L7GK6F5DO/>-,BI%7!F-N5V=YBGH>HGR_*H'+'2+%A^3B%$.:*[K#
M<KS8KGRY*.WDE+_@H8OSQ\B9U3_*,'B+1$5B--]I$'U#._(^I%=\\(PWV\5K
MLASRH%@)"M[98U]Z=#@N,I<H^=8-INJAEP?/YH/J74^_ B9TXX]G*H/+0@[%
M4Z;D:U#E6>?,1H_V^J,J%']RG);:V8OS&G>51!]6E)65 -D T$]1C^[C!8P3
M/-.RR6&X>D\"BPMHLI?913=J$.74^<@"N)2SSM/M_75<H/^8/GDX6DH=T%"R
M%TC**V>4'&4SW2/].\,T8M0IQ3,JGH /H,!?&14K>G0$\@>1)+ )3#:H$#VF
M&VQD0/BGO<+7WZYZ4/YU4X%MKH<D,F=[<NQTIQ7F6O9LUQ?+;C&.ZW N^4T+
MTRHAES2:%/9\QOW0'@BXAU4TJ&VKN=YQ(?0[=J3V8><7KPL])_RG*[1.D5PL
MM_;;6DX\:)ISKGJSA&J*[%J1,G@$J*&W0/-7UFTDR6Y/21=6E_\#X[V3-+E5
MBU/? ,*BD$ATI3XS&4Y1V>6+AK%<P#P\<)SG9%[33\L<,?E&3,MU6(Z]LE"1
MZ(Q$:Y3.B-+7_K&O7K[Q.:/V[Z\Z>I @V%O&) M+PK4JT=WMO3:(LC:4-UQ0
M&(K0_R/%28XIE_.4/K#]$H#-Z ;D,-G\BWW%L*W6R536>:@8.IGCQ8:JN?7,
M*3EF6X!12;VY_#]XFP&<RL8LR9@K:<HG0?&$]!R%BY)@E\SAD.>>5&D%!VZZ
M-S"1V"VU<]Q5#B9!>][=(")]I43FN&1NOH*B)*!<=II2OP\Z !&'.P>&,JQ)
M% &)!+/ E61!+&_\?R]R/L9]3P;292M-3*72+5$:G0-C(/Y;-L3U\5FGBF"&
MT(R1! 3/)L#XV:?8[0G:AE[(*I $6Q9LWFL@\!$/RILM9;%*X.35:!_Y>)2B
M?N<3;N+2U);+3ZFK8VT?^OGA>$6;#MXJ]::&[J9'XF'M(P])(ZI*68,R<P<G
MWOLU6/:=T9L_D*^@U ,7I91G\$ELJP'\Z9G4>Z.^FE_>"U%"M>]CMJ,9"\:"
MN;X 2&X)=%W7+';$<5<A11;$0X+R_19Y2K=4YM%,A;;1U$#^\(0O',E!YB3[
MBXBXDS4R#O6=C1\'?)N4DE]7IKAQ&7+#7'(IB8+]RTY7K[T/OGYFR#KWX<17
MR])?+#LE*-QS%[ SF+V^!3=9BRTR9[3URF7/1EL,8 9KB*;SIDW=*3*'9ECU
M'>UEHLMMY!M<;-$ZU^?.S.YMK-5]WA(GRG%X1MH@J8]72G'U):*,?+1(?]SQ
M]E;%QMLJ:'\USX.]7NS1O7G?Y<>TD<%[I3MF8,XDU(2S[I-0!P7,.31;,5>?
MC'E&'S1RL%+\;I2%JE/P/6_IAJPBPAEKDYI<3S74F3PALYBP 2AOUWT=-G$)
M]=8S:-?44;>PBE<%&&,^?<Q]5;$P^Q/#>=42.6=.UHV@?K%LGU]Q'Q9[E_W1
MI] @?^AUH<.WD8[DQ\G@*W]Y.XT5<34=I,C.(?C<X0A69?(_R5'^,).9G.JG
M3C(6I>0 ?1GQ Y/S@+Z.MM-L5F#.5( K#S(VUB0]"@0=.$>B3:HKIZ'%7H@T
MN64S(++ (@19\:NIAY43:\#$H3&M!OK2W"[#II1#B=GQ&34?!B-M%H-(R )/
MIW :"WZ4ZC F')S^H+$MN_MWU[R-#0&9CW-,[[:/-R=G,:<15^,2J:+H:BV8
M-_ ,^3KX>_NH8Y]="#\A*>(8G\[XEZ8"T! H[*Q.4NO<%8O8$*IML4NZ+8?H
M?)/]J_X&PQM$C%G'XHR;K3>69<XG7Z=L9=33FM]D9)HS2G()#/^!Z=M-2A(G
MUHEY:)<N PB-WDT)S(/4DJ6*(KU-#STE^+0%%&.H"I.*[#>+Z?6!I5)/F_Y-
M&)5&?PX^]>=TO:8-?&,!.Y/?P@0X69FY0)B1ZB[%[&9XP)P#W\5P+P OO!=X
MIYUU?U<:KR<Q,_P50"X'GS(C5Q[@HP5]8Z77LYIM4*!_C*<6DS:FU9\R='T.
M<S"9A7F0&6\,R!:UFV9.*F94$T\\X=4YB)]E?>U.P:D#(E78V:JRADL^<O/U
M_D+O5/G"_*Y/.Q.'/RLYS,L,["@9J=]AK<[Q??[<FVU%T1K</G<.G.;TLVSK
M%L4_-3FB.EBKU(BXG/W^V0O*<*#2:#IV[CWM:3%PQ)C4_TD+,Q\RQZQ2WH0]
MB\VR:;H[>;V\!T?FF"W>[:7+.>AJ,'6_,Q$=M5S87CL(TWHD>*'F"EE_>!=F
M='IZR%+#K\;(V=)\. O?8V";_YG)';3.]\7_=PF9#7Q=]/]!'W2>22?0FE0P
M@DO_1E+)PGSEOQVG('^VG5F/#/^+3V2]=P1S]>K.5.<PHJR<BV"W6YL1@5/K
MI3FAQVA"KT]J9S=3-=Q65[QB!1[- OW]38_2J?]$<DGA^PQH?[87AA'':=&Q
M3$6J],)SWZW"(6%$XBX0?/"^B3QSINCO%T)*'80R:9Z=IO][GBE[(-/KTO*K
M0/]E]>[&8TODS\:[OUB\\&T%38I]!HN7HR>T]F3=\33E,CIF)_[9W^'=!9&\
MJIG&G"]Y]SM#?>Z9'8/6*T5?L#UXI1(?HG]W,7M_5N_>"=Q%#-PKBMQVBD"2
M!UJ]'P4"Y2Q ,( 6(_T?&W4P-PG:2"QSDP_"!3ZF@^*\+)C::K172MR^9'+"
MT+;=);M'GVC1^Z:'I8&DKX]%OEO<H^L(%X:"@= _BXJK"(I2Y;*S%Q$7[0JR
M\F;/G"3TP;+<=X"(]W1<#B*A*G"R%(R"0.F"N#Q!"3DNATS2L3 *-ZMB0K9Z
MJU83(UF^;L-*_;<"2[9S3#.P495MB W#W5+9TJ/B[@$+>_O=LIOR!I#-+.X&
ME5'TTLRH."PK=X^!@7[E37ZL(;F%$71@/4%VS3(%&MR9L]!7Z,YN-ZKAQ*5%
M_0HZ $V/5F0APMTR/%DDQTU0Q*%4^]:_M<$VNBF'8 6KP'&N^W<0\'O!+C3-
M!9;'(K5/[2L(R>LHPI'6I*O0ES%0^)"SIZ7B14Q67V;-0=?9EMY.<LM#!0UK
M7N/8.V"]5 Z$K:Y$"/5J@ ]N&_6Y$/8<=,X'I@0ZFB0T83B@BQG>Z$WT-)UH
M>D'(>GJ*&K.JHBDTAB)+6+<P^\'<4F-Z?FU:*IZRRDE&-#<X!]B++*NFI*6<
M4):D#V=AI^]Z +B> 3C094ZQ@=PRE(!"C4I:0B(S4H/=I$/"7$9]B@OK;RY:
M/GLF@9;#T"'KBI;Q"RUPQ*C$4BMF I%_9!8QPSN]34R,BLRI1W\XW__.'J*[
M^ F,V]+H] "RA0?4?97.@/;K#0B X0-ND6$:S,3:P'#WK]^<%3GF;5[ 2ZJI
M2XX5*731F?4%)><^)WIK!"TY#$:4Z._\%!Z[4%O_GI>SW$&DI.&&SY+N2^Y+
M5X.\5(L*G^U8NO_V<>#'V-DSR6)&#F.S/[KQ_J:[W<*,2T_DC!V[F_]YWPBV
MXNS>XH5;!OK=6*TM@]&>,@@7UOG_0P*2!*C;/'7K[Q&28-%6KU-2>N%38B(B
MAAOSS/LD(8*;_<6R&YW0S-7I+"H0^TX=8F35-5C:$S:GHA0M1$+6!LB_SFV]
M;]G6<.7E<M.4'H[ZVI(@H(_[;S%.H-H /S (UHU.UTTM3)ICG;,NG@[9_G"^
M \8IX"/=#,@ 3H9ZD&-XS->)$LYO4#."3#MR'5QQ2?VS*&"]&=M_T&B$-6$6
ML$L3Z%&_Z?D=F:5"^(SSP2#$J,SY&/A3)/2?C'HZA/2;0L; 5\"3*3&%0.N,
M1S0&OV I4$R%(MMMX.&&TBH1+O^J._Z;+*K_=/PK:_W& 6%Z?SQZTV K##3.
M(I75AKRU'<)WH!#"%AY<UL[M-RI;Y=&=3SH4LWW,)A2K='[/81437DOUC$%1
M0D@T;L86.OU:?D2],VWIJ\E<LA&FV4V0V)B6\8SWB>39>$2L.RQTDA*;H"($
M)1(16K+T*;)FR'M@KHRIZH"6FTP3\)<W/.#? IX*(91OA1,R$7$W^7\K.(1@
M1QK*'2*YJ;4;*P4J!7W'IV//MT@-!W\U2F4W-0#V*?XDF(4*)D%<[IFB,42X
MX!M_"=DMCP&RG2TAB#&PBR#"ND!"NN4H%7%"+T\9;D9E\AIE[#'9;)$$ 05?
MWKB"@.< \ ]')P>=$W;SAEFGK:&.-, >HP AGW5^1L;;RM 7&171(L:4L5L.
MD,E*G!T/=@ ^'NH%]H"7=G^PA*Q29<LF<AM ;:.0HJ]U&^GY>U%P09%.TE1(
M3+MSUA'H]M^DDH*/,A01J#M>+IGD(J0V$'?;![PCNP+6$\0";_VCPO8WP@/4
MR)'4T%)9D DD,"H.UX?B0B+1"UDFK(999)/]Y=_SCI:UF;2(N(JP%:*U)<[8
M890_&F&@X@W7K$XD\? (&6?#W;*>\O%=,[8UWO&]!0F5R@86:TL\DY,-\+R9
M [(TC)E.AB%RUO4-0[D#V=_W *EKP^2$,V7DF#(21('\ 6B-R^.ZJ!08.G57
M7%0B\;9DF[YQ)GP#-%C7&7IL0ND),!9X :>!(6LE4!I!WV+K'D$59N)3&ESY
MH]EF9C]=G< 9:H21K![/.#7U'[N?3K>J!?J;,X>F!AGLK+3[T98$K0&%Y#[Z
MTP,O3RLB5<JF+I,T(,'& CAAED'2 V@J&'.6[ ,F"<G@@26<8QHRFD5P1^IO
M#J&;S".=R6K2>SDS,[M0X$H;\B;N9&OXC._469/K0IWJ9;?YYXOB+F;T'-=8
M^/:+A7NAJ)@D1L+.%5,J^KW[QZ^\7=TT[?9$[O!GJL;R;'VV0/)1J0_8M=SZ
M5U65Y5,4PK=C(&_N.D1ENYBO3I:Z0<'I>0*^$)&*_-.7^[\>6WITP"[T#M!-
M',:ELN;5Y;R-O6V]AI^O6_L.Y7G8Z1:>Y8\,P=3.Q Y[S]D9YQ@B'1:* K8;
M&R3OD/3KNIO@3N*$143"7<?L<EXV4$VQ=/Q;^IK;"N@?5DZJ4?CO<4 @XLO*
MT N,XD^&L&*._O[!WG&>CL=H&8/;=/"DXW/Z932I18\)PRB[9$$<OP6+&\HB
MC)@DQ4J!<WAU4V$.OH\6"]U;AP6KF.QW267,J2V1%\NB!F<@L[@H+,UDJJ/^
MP35U"_!88.&X!]@M$B>B766!Q[H-="LPX5PB4[< $G 4[B/TZ4/V;:;K%]H*
MER:3-QM4W@I+_YUAJ @ *QVJY1"F,RZ4S0*J@NPCO$IUH,+=+?N/9WAN<8YV
MW;QW@X^R4>JK 0PT0=GF"B+&8#=F%M]B;!MNAGY.ZX'L)_3I^;7HQ= ,:-D-
M@=P64X,E^!\X=6.]WT9T21O[H^D/7;?84W47R&33%S)P\U*.(73:>W3I9FXB
M:T*^P9>7C=4!C;@.TF=/OP#LY&VOJ??HY4]-N.)=>JPYSI36)A_L+Y:)79JJ
MA?"_WC[*\U9Q/L.CQ-\[9^I1<_&P Z<1?@^<+/@G)HD*A*0G5,;=NO='D!HN
M#*.PC/_Q>":JJ9'@BASE-N66306R^PBIY_7+XK#LDJT06= W8#"MZ%8+S28&
MT0 < ZFP2Y,''PBKF.C%_+:H'^QIU6.CWC9)C['4-KFFQU$7XP4A/!52L5X!
M>S0H)-: [R/IHJ$+&$9M<@+.4[+[G.R65KT^E^)]/(KC+E^-\$?IR]GQ<3IU
M'=WB.NG"'OL0QY+J$!<7Z==:>9,=GXH#[Z*+C< R8<IF*$2R>]/G;.H#Q"?L
MA>Q3)= $&C!5;W:2'<DX6.D^6=G?7CS6RUD(E#>"50@E;Z080UUO#UVI=J8H
M6 7!ZD+%[WJ;J!",O1%GV!:AF."R\_>(X6E$;UTO@3U/ZR)N?SJ,8JI5#R2&
M!%(7-NC-;E<JT&66>5ILBLDH2D<J&SL6DF6R^0H*HIQ8L^ZCH6Y2/2,I02I8
M(Z1NB@8133;9Q]%MH4SYK#8KDRV/593R+AWBBQ1@)^[S&\W0L+AB&:H@%VT:
M>;I4C6]^WHFT^\MX4YR#"Z$1+'T'"%#M9%(P%S?1^R8# X1CH)H6N@M.BH&V
M!!@5^@R<D95*?_IU%HF_D3@8Y45F)1)%P6"V4#<\/CWG*(<)"HSR%*S*(5;!
MY+H%N=.3;NE1..H "7X8 %KQP>DW73(9N(B-303@33F(E**I.%D3+I*J2\^$
M+E1K0[",<)F#BE"#&#XD!,/8*:2;CE[=YY2I_T!OW:5NX#M,SCHZ8B)6N6CI
M&ME1%%I*SVDD&$3J:VV'4/&PAQ8CWL>2EIU*9JU0'(<12QGO2+4*)HBW[6_N
MH@X"PQ=*XR(O9P/U2_4@T@6[Z1H_$(NT(^ZHITZDUV/&7&_'F5*WSBV>3/(D
MGG!YU]^& H,LCX\Q&0_HQ@+MIEP,5 E\JN\&1&N[J+LL__D_=3<A4U%"^52D
M,5XQTA KT?VA,*7>K[BLW,B=Y'%1N1 M@JGG?OYBZJ^,=_F&3J\F_2.F(UYJ
M.)Q6\;/LN $J7]%)SBKBFS[T8N)R_G1@7X/_T^DYBS/Y.]V^R<S])$<<+/0O
MM+;$'?*%''A\/M+@K,:U-*9(\G]SL"I(99(+6$X M99Z/6:X$<^\*3GEX:=%
M(A</=J;XX'ZQ. _@NF-\\4YP"UVQP6M3\BFXN97W.&W;'<6^PVH>5KNXWV+&
MLIMBQ=3.?#P-(>,SLS8E62<N,MNO_\-QRAM0F-LW^KZ8,1>S,_&/7'I:U$".
M-B'.D3G$;?X@.'\#5?R_5\"U(1Z_1I7R)$U!);/.M<3#*7:7"7,H*SE]B**^
M 8ZMG-@-ULKAON6'F(.EQ^^W+C@&^OY57V]+@RP(P1>88)1^ZP[Q=V1.:P=)
M'/[[)TXB&3%6H+<EG>ZL'B 'D1/^G5CY%$0.)L'&)@<&6P2IL7-+:#PZQ>RL
MI-O_*5KYBO<1R$0*^9A6(WD8>QZ]&\Q#DO1#J+16*7+F2(ZK($X1,N4_4"'*
MN!9]E!B$1K2$KO7X5QE5MRM('42"%7Z[A2;5Z(Z,,"UVB*PRU>@72L?UN;!^
M2,?5H"@ $<@!G60B(OL?!0"*0 H72Q^S^Y$YZ,<P4C;B:*T=>#24D6<DO9!J
M/Y']I7PVIKWHR!#IW%=OL0MA%9E;93_#3+:='2Y*4L?X.#Y:+D+,9):^#/+T
MJ;TCI[XL./SD@NWQQ,%BU/8\S"+ZB:1PP1%H=#YRHQ6L3:9J)H7$$_!6K9<D
M(;P;\0@CQ\]4:QNEVQ^T2T+V=W$1S9R %TB ..I+8'2V>MJ&)X'"&G3:7-._
M].*P^9VG$[ZGF:G%C>;68D#^Q?YH2!H:F_?]A6YWP[Z64HCYBE7&A'T\?S;M
MS]EPBJ*LJ4G^2JXI29ZAHX]FMF6G;D'R0)%2.]]XRJXO57L.0W*;=<'^6W@"
M%0RR.!V_2L#3'(BWV"0AH&X63]D#Y!96F&3(13-727"JXR/%CD-*8DFZC\ST
M]RE):#UQ)B#.=)T(QY-D%=L4RXG$]BQ$A3*'IS+V%I828VH&F(,/ "O,U!VP
M*=GW9TZFX=)0X"A#$46W; OD617%CCK)/GU#BRQRA04?BA)#S <81S(9;E#
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M!<S'T1PD4U)9;&S>@\SB4?V,BA%K%AOTQ]TNY*0=&"DB>7.>4=NA7/_MI+L
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M&N=HW?6YNS7:DDQYW$&_:<$Q,#ORZ2C9'+?SLZ7CPIJ.?>I%W$9YT$^9ZN^
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MN4&]CC5WS.0VAWASAO=O>12^A>I(9BE_;LD8?Y1D(XL;##5-#]+)74^38#F
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M:Q[S&0N_L@B36?(N;$ZYS1HA;>'TF27GEFNED,%CR^J?-$0.VTS-\4@BU$U
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M*@NUQ:.N3>W5502O=FEBC#'M;SZ(^'T^/A>I&W''@FS'?_RD(+&-%1<';A<
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MLH2M34J0I%<ECFG=J)GXB &]=7-!(]BOC&Z2&#CXLFAC0M0DI1J3SBY^JL9
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M %UZ"W!BV"\*IFD$=3=OH 0?587B\X%P+K7A4(SV/'^0^0N(\QV$,A#2J.?
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M0F#RO'V4U-[3\E8)II]595<N79Q%/$"+E>T2%P3LE( MPM0O&.:T:*"+5GG
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M>P:<^LD'!:IR3;X2&/K=O)L-R5C#,DN5=NX\;M**.4^I6 K>QC[;W">8)5]
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MDVH_EZ[QUA[U<H/<!6AZQ[A%RPW;[NB^B4I;54W4YDI1)2P)U(2@GY/-"!1
MX=HON#4_7%L:;8SCF$<Z&%S0ZBG5^+"6E$2_T@$NB:?H6!8&R*:?E7%GVOLS
M$(?EZT7GQW'P8=$7B8F. /8^3X@OEUC2HJIMC%+H6LV $'^E[N/L]SY!&L?[
M2F5Y"V&8"]?D&29?N;9&8PD+3I\XD$> I<=/]/F&L D0S?V9ENDV3,]/Z/)6
MPC=8H^.ZT'Y. J+V$2>2#EX7NH+-?- +#:EA=*S%SA=QHV>-'$:&(\/G6KE4
MBHQ"Q&JI*1X3R\Z?,1*<I\A3?@"9B/1[[@,0427N5YN+;?W5PC$](CG++@-
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M)XGE]PX:6'8SPKV/>8LU__0G)8[/RX;9>4YCPH''M;I?A=?IT=(#QH6*.VY
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M&Y]78PZF&0))Z?"G/4F-@9HT N=BW=%-GWJC6->\0:(#T^(<6A:T.A-BKTT
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MME$>,':RNQM*WD_(E?,HG0DURR.1_]]<GN] %!^^CWD0$IEP  S)OV#VQWW
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M1%7.\O'IMJ^T=>Q/V#WO' .C!9_S&9]NL 8]J /E&Z0GW#*Z'7_^:,1,\R[
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MYJ@5#.DX=0B^,[3PM9*NM-_N3)7],&U\#I3F3YFN;"V\0IE52^+EU_SQ4L
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M ;Y>N[ED3!Z0?CN=X#&"U"0"IS\E\(1<_%D:S-1U%^1- 5?Y,7PM\N:RS0\
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MVVP$,.5DS>#U15L*N-?^GF.[!<\A+:.0/$#71'W)K%@/<IO@P#-Z.7:RBCR
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MK].RY9+6B&7HTW;!1&%GIFR/.>IQ>,F&7*^154#J6/JO=8SDJ>Z'5/$<JUJ
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MG["3 "ZE4Q'@EJ';(OB%YY3N3+$$I2JC4]>#;0")A/A;WZO/L23%B/:\KCW
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MG.^=;1*Q?Q46'E]P:+)DI\U]EXT<),!W'BBYRU:+%GD=W9Y;"[[A:'YY/B1
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MK[!(K92Q$-\$&73F]N+)V"X&P)>/!T^J.OOR>%)(^RE,9DZ9U)M#C3"KC)!
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M$SQ"+:X!.@4/KRNPM>(+0KS[+J&K(5H7BGI.??$-V##ZOHFZ9))6F<;6F,$
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M(EZ#''$I[_K &>$ [U\AG0@ 7@&HF '4\/T/BNUTXCL9*7<BU9&TAO8>:.]
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MT4%^V(X-[\:W;1X ;X,>_ -X/5)IZB#)-7XK6R.-EG"#PO9_HI0O(,^"4Y)
MPF00[3R\SJ7["101\?<[XIU+JAP7OI^HNM\1MU2VIH<SPS8=F E<KL=(AJS9
M+7<D++UVGQGWC'2?7[."QCU1&ES!+M_R<(R7^:.!#*20'K=FLK1(V(<&(F-
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M;*""I!G/FX?\V^9#J?M"87Q\!','#4B&^C!2[]*Q"V)-FX92_C>-#M3Z92X
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MVJ 3=%E*"6RD>I[G6'-,ADZ&<&O[,4O]7(-]/8I4BL:G[J?2=2M_/T?[!/?
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MV9G>_&3K-LR =_?=SH5L%9=E[O'C=>%^^9M?&D6GY+>5P+?=,4R$5#PAAH3
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M^@-&S.K3,DZM/NGE9%:<FR4ZWS'G^CP,/M6AQ1H01%-KT3TZ,\FL>^^M@V
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MW$$TC4I988]$7J"X#L^)Z%$A;AW[ZV9DN/L8^6.EE_7OZ ;L=_RJZYT;/1D
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M'^^[SO@+.9&W'C:PSC$]9SDK]3' JL5;\3V#\I&SEW/4,K-K;]5>EPU"!/O
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MGI1=@%RC=HMSB6ZCH&<0O*,Z.7D+D)3FW+/IL"^C2R[#T&#!N+\RT;$C/Y9
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M)U6IQ"3;]6N,[<N/+E:S27EA-G\AYQ@*\"1.Y&ILYS[G-<_\9F-"R^^\W%_
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M)4^',&CW?Q"9;==9"OI7<YE7>.Z%)WB+%JS>19TKRH&K7Q;)*3Y-<TCZ-ZM
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M+S'%ZX.[I:W N(AV\,V!O-BT.14HDV98+NY\'&4[)#J8+9'NNUH_MM1HHWA
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M1^M%/?C:JNP@/NIR6XXSX=5*_:W1D>U5L!KYRK6RMXV%(/RM ]$S$3H;(9'
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MU&58SQ[C6!K-?._P+L!4M_3'+R[;4^$#SH,A.MQ-9S4XHO2.WSMW2&KDZ'W
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MC)60.*\)O^+&,$ER IX7Q]0AW;0QGZ&(PA]Y<N(C,$XR.^D?I# O:.."42$
M6;C4[?" 3L.S)S4^S[$C*/$SM>+*K(WT&U3:JAD]SPH*2D+*$Y6K^8(WR.N6
MZB2N,8^3%ZX.A]KGYAGBU5D""V JS(8[Q#L/7Y OSGI;J($VH]?A,A.B/(XV
M ?, *2:5G5<C)7$\O<:BIL)DQRA[7/RQRY853%96KS:3XD"2E188%&7HAU:(
M)[*[^?!PDIF&?]2ZV#8V?0NY*G,-9(#'.<:ILW>[.>,$/[0FTVF*7QHP$I/Q
M<!Q3E(I"NN5:KQ3D#V&N,+'S(6%IA8?&24/WMQX?0L;_T+ *)GK,)U ):E^"
M&/(-S7?TH"U701T^=YCE8LEL(/)\,&:K<1<A4&_K>XS146/[$;%^C %_WY=5
M<W8(XCQ%U<WN]I1,%>A\+S<XJ-J?P3/!H)[LE?S/ T]S^1JAQ0I]J)/QK.S'
MO9A&E5CL6 07(=?/LLW(O()F-ACP=>\>X+;D\V>>ECK*+<)V2U*788]DQ<1/
MWN"\Q8"Y_/ZW<WHPQP)J]HI'Q!&TN)Q:*%'QYG0;ST6LN'(DJ98G[;<J7(">
MLR(S5SV]8P;:FS2(KOAR8@1#%'NPU$2)_OAY)NI@F9+HD)8!">GM&+\QU.)<
M7Y/HQ1"(U\]& Q8%JJ$*4G2NZ010H=-P9^K*SA%_ZUNEEU=V*&535_W>6XGN
M58+M6+!DR7/!53\Q;6G42HNVI!K.>#O+^JV4.I0.D7O  3-;*V-JAO!TJ+<M
ML^U)^U:391?/X $>R*7^4(>PAKB#]M;PLV.9#.(@*29E:.P4\H59EG298T<
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MC,UPODM),73Q6'LNJ<Q(YRH+@R??$Y(T1=B32'^7]I@/TFV77\46-$"1]_:
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M?-Y2'N7UA0_Z)%[A ^X:C*L.Y=;L?H=]X/\/ZSG/X4/A:.\YXGJ?@&I(QJ2
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M,,'N2M#)NW"%@1^OJ 3:$Q:VW!O2XW4E<Q#R,AW?-B8U*]R1V%HG;6ND\!5
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M7PAQ5>R!ATP2)%)RU+M%>5%-SP$$[J_Z!.]5GKE[1\##:WPV?3[>Z*I&_5%
M-7[)^[9>%V9B0(U;9! XYO T?_=0D96TP))#I)VE<]!@6Z=>WO5IW:#>3GSD
M=,=]LZX]>-/XKI60N<*0B=D;P1EYLKR=)#>!MM'@$3$9ZM,O._.RN.[F:*7[
ME^-MWX5^D]#BVNDQJ3EE.SA!M\G]MB5./$U-KB6P"_/MU:'%+L7TU$JVC3@1
MG[,"B+V[T[E9\\)V\+P,R[F$6)_3:MUKWA&J J._/BXYW/IR2LN*H?*1S,>>
MZ^!-AU[O#K;-SRA^]YPOF9%6K0DGETQQ5GW)>TQRMTUK_58^&K@3'P:O"7GZ
MYE5+  .)7F_[A^D6E$&+7B9(&PA'3!JK/JU__9Z_,PZ,7 [^9<3S;G(37B00
M:C?[O%IDS>1WY:W?@(WPXN_FQK\5L [J<GG\@7-E!P6RDK7_M1?R+]#[':^-
M>_'WRCJT^1JP;(K[>T7RBN65/5CLH_:5M_S;D%WN4[,:V%T=[U>=L]26%QM!
M+>,ANVN.<OO<Y(D77QSA(<X?NLBFJO"%T)3FG<2&KMGUHD+'!G&?% @XY%:-
M"*-E\N\]#,7O&E,&2_)/J[[MWT]T4)YQ?1OO\&%&?Y,7'K=;+# %#E=2"+4F
M^>6UHUIS)00;7<'BE:B%)TYWH 0%:K]5Q?_=6?5W"_R?+:'B_PZ^_G<>_T/A
M?_=A'3U8C3\&;J"=!UM3M.2&+J>#WC1H.<1._S@D6*$3NO/L6HCDX+[*&RO)
MAX# A DYDYRC".W0FTGF=M84 2=8,>VH+%R^=&5<OB?4/ [;I^L?9^%O(!C=
M:/EBHD.,&_ :Q2\LT3&/1VH(RAD?6UX)"44LR%7RCFZ]VZ+5<U/T%![RQ*T1
M0+S34IK)L*#P:5;A$;9/.)=Z\;J)5LRPN,&2<8+'K'K9$=C(SCM=3^[]&W<B
MEU?CN0TN^A.YJ@<*TI1CE(HGD9X@U_MV[LDS[,+W?"HUJ3[,M,-5.<I0,%Z<
MII>W0C=+KINILYV>>X_>$>! )$HG2+[;QHW+[HW@8_+DU/9O6-H43(_N+UD*
M(+:]A6[82+\1(H?Z1IM]3FNNU/;;L=BJL+/#N(]:8I0J.98\?>(T*Z_0Y&J/
MAH]4A0S$IFU_2G_QN>$:8KEUA<\T0N^M[0#1N+L)GK_8P.4&@=6_8AV=2Q=L
MEF@'/SCK9[>+CE<5*HX&#8V=&16J-=4$Z,Y[S+X#G&XFG@H2 E/L0YZ1'OF4
M(P=2MA5RK-NNU\;,*()^O)OQZ*/66:MIPW.&U')%)^HF$9$.<'FK6>=(78XI
M/P,\/<:/XJ9 6'B%&!_X$  D9MLYNV*25=2O&<$M*"B99"X''1[/0URX5[0;
MLKF>/<G)87R=LNBZ#U5MO($<8[/1+NJ2*;0FBT]5W\MD]^WG_1H:7'1]H2=A
M#_JIP]KG-<N?1E[K2[]OA1V*I^5X8C<FZS)3DNRE5?R4K?"".^D%3/FIQ,3J
M#A\R]@6QN<4O03+QR['ZG>";;+?%))Y737U'OAW$? &\8+,FUR78W0(LG ]Y
M7)V'(8[MIKN<P32XQ08K#P4%]/L$[JZ?_0@7J/#(NG.6W+_8\+J1Z1881[!^
MDB^=,-1W4L6_6C'%2G^2'QSD<S. 8DNU_?:@(@0]\CZIKORG\*_=2,]1R'QT
MGUAZ&DQ=M>UI*F*9#I -L$N,=41)^SB@^(W%,%]*B^<*5JFI100]2(*("[6Z
M(!><?!'&7S\CF*"[W!K[]L;[;V6%(.&!N!6*_-!J!.%98 G86T992 GP'ADE
MTGYL>=D[Z'(H%W>/?V<VH3%+&^M>'OKA,:A/.NMP?=VLI Q;6$(C_J20.R5T
M>^Y5LO+>2%DL(61TT[.5VC\ZL'8CHR(^D/QU$]VV\2.2OC(4FVPWA*615) Z
M2LM^=$I&HAI<5GQ<.A@S=0),<:@9DWSYU/OBT'GC46KP)_>&%=$GEH&5:M7-
MLKEL*$I9W46>3N*%2W@+H0;/DI$ZK!%I<KBN;\V MUDY2 PQMR/-QT_[_-%Z
MX?5'ZI3'4V'7Z I?G:%,K+G)G1J]OEKN"F4'UM6'4+VTE3UX4MTLX-VK+EG^
M[>4H&3)+N9^#;4BCSYGAYFRU^B+"W(Q0EU#Y1GV7=)A][7[X&5QH7G34WD@Q
M/7'+L;5I7^]MT'2-DN^%R)%*Q;I_F.RBR$O\5S^"0YL[]F8=$GBGE60%SH$<
M RW)''>#\QH:$F[ZD%HGMG$N_X^M]XYG\WW?A_7=X5VEJIIJK;34J!15>R5=
M*(JBA"!I;5+4+!K29<4JBMIM[1&I$ENHE9;:(S:)O<6,")[T^WP^W]?O>5Z_
M/^Z,?W*_<EWG=9S'<=WG=9R&KOOY0[:%5S]B%KST;OV:%LI?5 A\+7VU>%VK
MEY%MC)G&0N/-EC)UD\9Z>\N\S'X*%8T_N'2NY0:IL5?- =".%!1J?3DPVWHG
M7[CO4Z8>;Z_E%YL.LPK'R6)0UVCSJ0I8E1M%J'*_,)L\:Y-F+>Q9-' ]O.V&
M=26'Z>V^"R#]K>9T6UO7(M^Y Y.&]0ZD3NK70IE"(]FAFF^+H@ZL@ FG9(G6
M+S$FM=+9P28WH%JH90?.7$ [+/-3453RTWX;C]1"@>K=HMU:O4,DJQGU,O$9
M[_>4YE/EGO2!UO>Q51>QE[JT*QQS  *[L;&MCP!$I\ ;^PWC5H-Q/M)" LM7
M&Y^F=7Q5ZC=5$O#4WJS@AXJI^'EPP4LIH L],BU^"?FLB3(XS2!]VY?0$)"T
MXY/]*/QB]>78'YI9F*WH\^Y"I")'SW_)@-^8N04O,K8_85D;HT1GF\==%C?;
MQKJ@S2\\],/)#=0^1LWQU9#4>8V3ZIQCWHZ,=/$IW &Y3@PJQV7[N:90_OD#
M=EZ3"T!ZX.2S=>Z$75K6U R:PT3&83J._D1=GC%=2?PZW>'I3\BZWB6?JIP>
M_&,6EJ"HP9FMZ^;.'XF9D@=R7[)6#"P[%&NVU];JF*A.%S2MZEC-?"WX=??*
M?.@&$P04/@F;7H-J9SFGOQ!.SJ><YK[?6O6UXZK9A/.=R"[^_DR9/QJP'I(G
MIA0[0K&G)&46#VL-UI6MGR3B<_S/O,\MPE0!>H]9;%NYLVUH@7=+L$BX\_TK
M7?+D_CF/[MW\S59%.S^L=81/P:1CE,(2B.<I]<S8EN5 5QBF?@)+OF^D*8N]
MDAYS*J:#"'CAN/BR:C1YJ@QXX6J684V=OWWTRQL?@,ZM12*/!U,SG_S.>! E
MY3.(^MYRS@>+]:?=NXI3[Z^]5_Z@0\4]_KZSSJ7.XG.A_3N ;&#B'5)2;FA;
MQ01V%=@,MA$?AZJIQ59=P%U>\5))8$[1(T##\HA;;$<KJ-]EAN?R_G*+.^%6
M!5NQNP&G0K:]Q'9?9,_<#]0/FXGJ>O9&$;MBT^792F*=C^!%B JIT/P@)$EK
M6OV?21W3<E:!P@BJW>>05X"%W2)P&SC^)ZTGI .N=V:_R[0VH.F//7.M:<#>
MXY^F'C$.G<?KG?=$2LA$SV\]SSB%2-[(G$*+]U$#K8[ Y<MU%SM"AD-Z:_U7
MQW8VJ*;]%#5M9Z'Q%O>,S4EJ\5Y+Y%[A.^#R,0OOVI?)Z[\1%%7.\\-A/E3X
M^]S%?VU.82AJ4@TOBH_X>BY!@OP^!^^7J?.K8_/A]%9QZ)<B;1&,0D.+!@5X
M8?]Y5;$HFOOR)\;X4G[/IX\%IA'FBPH7M:Z?Q-1Y/^<O$02]Z=G9JD0-# T[
M3W@]<Y!/TS%Z+P$0%K'Y1+V<P./^3V5XZ&./#*Q_><F_R0I*./4!;&V5WJOG
M2XJ92H5-!3S:'QXU5B];W99[-BW?MH -8RG>_!D2"_X$?5' I>?\W!GF&VD
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M=/SZI:[&0A#/QP$\'-0/X[?&6/;\O^92W9%ZN8;E'UN8GVJ[3Y5@K3Y8%[1
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M\K.LV7.EOYN)"0X&9)?3N%F#1&5<P ;D3;\6GQHZV^.8Y2R*B5,YH/2TP@5
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M&9UDT.N"%_<,4@80?=<;8OS.M[W/S3:AH:=_RCF>(WUUYCE;:)[J&0-'Q>L
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MF@5'IQ_F!?U2=H7$=XPZKF^T^RZ8VD*JJU"2N>B\%GMWYI:RR4AW->P7ME_
M%P"VU1UIB%[T-C5T''">6W7AZ+B+KM>,14M&57#_[,=N]5Z,[OR\F]AX=Z/B
M\YL07XN1Y@,4F/9SOZZ#)"(YA.>*7$DMOVM@\OMYV2)5GT6Q+> *C9$K_N?'
M&AT4AD^2&GF;DUQ'(39GPEZ>J)\\-?E/YRQ9[)K:TE!$,'TQK>K0#C,-,:%T
M7;MN&\V(7.N'OY(;J2&>=SH,IASW9_IOZ)OTH<XZ9IO-K;Z0H(^DOQ0T'VJ+
M;3:J!VTU7DSG!4 &2E">^&W7;:#*U<(4N[L8S??^/B%ASQU]]&&?$J.;2F
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M92< &>>\>A71O#LGEZQ%(M5)0-^T\UQ7?@/>TMGMM=#.:O-#VQ)+(E1-7V3
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M*[_+BO349=E.+SGJ6AQYAF1Y_O ]I^.3'VR6-2VST2E>Q#2B(*K3=.+^TQ,
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M>2>YUGC<P+*HS]W8O,U1%5;0OP9TS4M4-&6<<&3:-62$JC&VI%\#YZKC5:H
M"ZJJ#>G'T*./Z#*5HYLOOJ&$7][]F;],#;F@*7]5_VPV]N$&2<A(Z0?!SSLG
MH=M/V(%J(Y9&Y^,5^/P;3MPVMA)ZB@S,?B/R&H46N7$,A5)O41@Q%'"\C%;H
MHH352<MR]90N3U[,=?QUZ]UF\:NB'4FZ=DB)'TE*;"ROYK(P=GJ2._AJ4(-.
MWN-#(-$/TY[@9>6<@_)/+2S5][[:=8%)-I!4&$K7*]B24=&5LQF7<U "DA!R
M&2O53Y/<"1[)FO,*!BY^P3,KQA*"(&><P.4"!\\5S$F_XBL#IKRK5&LHGNO<
MC4'9YQ40MP+F[.AHV.0HZ1M"DU*!B%5< +9P!#,(O[^DWD5Y-W05JOJ7I8+K
M_<6SK@*M7'Q_S:>6)=P 0!\,@4G3ABN>ELY8P9=MPQ?[ZP85U#XP ^FG5TKY
M*S\>P'])-9B=+7>]6*/$0]=*1/V$7YLNAV1-AX@ <>/]P=@?YO'5VH\EO1SJ
MH7ZRHV9!^ <$;:<I*QN%^_OWT7!=9L%?6HHZZLIIQLQB=BWW*P?4E+9 _LU'
MZP*0=YK5(Y?/<&PT14*Y_^[KB!&G6N=$X:X*A#U+"L;.(=>:I$:KNXUFK/IR
M4<,?2@"6%Q&6I4!&E^ ",JU9.:JB1JM'J>Q4A=S+P>VRYVV _E?654JNZY[+
MF(C)<P<?;37$[GECGMB A7S.\;U["<*/<$7.5B0&>\BL0RJF0Z(>CC]18<V#
M]\WZ<:%7Q7W9^*"I0*LRW ^+-&&!Z@&KJZ8OBC7ID,F?/]X'>_? )\]?RU08
M/KE@>?,Q&7DO:SZ9<M-KF&WL!* TK;U/UQ[4+:0*GZ,2!47D4T)(8<S7AQ 5
M(@GS2[%4="2_F%F,EEI':MCCO =OQ_JVOINHQW#[Q4Z6(H8)_HP-/C$I2-C-
MC<P*E_KL8MH"OJU39X,YC\N@A22(UE4_<F!=>9H@QE@5/.?^CC7L4$'5[.\O
MVU2IDEL?JN0+C=M)=059515\XB>![5"_:R-*BBO@6:^0Z,C$FT[JX-H@^L-3
MHG??.U"MN0OO9JGT.1@47I8/O_P=[]PU\PLU/7)=),O/%4,_=T_H6S"V"^*W
M-)8S$8PM+/]0+3YR.Z+4KPL?A<!$],!_'%B^$DOL4%T>FHQ&OO+813N8X/8U
M+F22S6YZ?-0#V?_=M=]BW-[<+[OF/##XHO[QKTJ2=;3WQ?-F=PYVT<DM>S\&
M7CX4X(F)'925NTK)J.C]L$+,4^&C7VX3-9&F0JH+F'E"QE?XWA ;$3:?J>='
M.IID6/4T(NS BS3JJYO0UK!7&9!? N3*Q:BHNQ2A7Q4"4R>.59G4/T-;&3"S
MSK?5?Q;)<M*E/QQKWVD+QA*ZY/3QJ1CYF" E0[;+&#6Z/4I0IJZ8Q[95Y)QM
MEA7\$#N7?9U^JMZ^Q;XJ3#'PFW5*I<0X/,Q-\<0Z)(NV0^']97GQ)^M'A>>G
MLQ]ZFF\U&EM9'CNCZ:TGV-FNG))%K')&V%TJ=^;.%$P E_I.GW:QK.8Y"=S<
M"4-XD.I]=??()8Y-%W/_4QNHQ!2)!XO>;4YKWJG!QUB50PU_&551_"#?:NK<
M'4 8CEGL^K/UW2;Z JLX'#!8@5_9F#E7:^AN):2>T(! "4:SIF4S)Z;A/CF-
M<],!V4CA.J_K1]A\">+UKG.2A??GZCZ:S=(6S:.5,6L?&@7L7?@1L&PU6DB(
M!\P3A*$57X'C2\&2"ATG5H*!P.GNFWKMM?##Z[I2O]Q6J1 9RCY=3HV3A8Q/
M.'9,[I$!Q<OA4]F>%OV%G:8%GN_)MILWQ#% [)3YOBKE0COPX88Z,*I462,H
M]4D *)"D(&N5 _+C;>URLW_=Y 8NGB%R2Q$JXL8;X>U;";P9%O<GH^W+*0/>
M?,<WF61D<2!966E+"7.>,#^FA#9?\K3B#VO/G)VOL+,96M)^Y+GFZL>ZW4DM
MHR(,"B?B5RQ5]L2M71A+)R6H#]N;9#XC%RP&*\#O/MS].$.JH6I\7"R\;3*L
M=M,O_7;9[+%-/")NAGMA^6S )B2#(G)98/&7&U$8.Q^0L_<(7[=IIB58%)TT
MKXP)\_VK?T/6;Q[70HN(%8W0,YM06T<A]*>[\I]+5KD3 H(S9N:KJD[/V]*+
M4$;I\9EEOCF7$?>KR_7#>^!S+DZ^DTH[F,=T[>CXSZA-!S7&@B)\_C&X*E_8
M]/%X%[^^\RBD>,I&QZH['3BGT%2/]P+?1KM8"/TJO#O.H2P"<A*6?/25/02V
M*1*UUS^N+28 _ EF3N>'WCZ<P!*9[UKM=XT(R)DP@-Y\?VI$)M5]-RUTGS09
M_E'KIR4Y<3<IM10<Z'\7\Z#QE@=#-;\9F=?,*V4SX/<FN(N%!GY4CGN-SLRC
MDBDM<S,A5&OCPF["8"50Q:4HBF0(;V?P=8XE<050@7'/QD\LL/*$1-)CL@'0
MSE8"%G"RY0_;.0'+_"X6OHCYCKL=#_<;RJE&(4#Y8\"RU^^B&=(<?N-E>G9T
M)@E8[,D_D%6MAAXL6\4ZZMY50DL_H=E4>O". %+[#R7;RME8Y4!JIY5Y(_:H
ML'.$YN?V+USR&K%]D-\A\R9Z\0_;M%KTA% >Z]C;Y<ES/!]70TBU]1AAG6[W
MJP?+OV-29_<?)3RC8V+/;_,>8P4-4?AVS04;F1Y_U&GB)=7F]U#U. ]DUOK(
M=7$@V3#C39CNV#*""R&U]B1YHG%&CRY[X[W /J@;;)B[;7FL!U!>37\3+U5/
M;T<96'A^#2WSP<F34H.8SN0XZH!_[!BI!T6YX)F3 >R"&"Q<  ]$2(H9U_98
M/P+/J#&6)T^O'_],9Q5@__J6-()7MO @9TQQ#\"2>N'FNB<U2QRO@WQEPP*R
M5 B(+@>V*DCFS,9VC?QW-GM8LRG&%,D MANF-7I^,>FE2.-<[N<$;.>$!M0-
MJ_C?78)(J1,4U@.6#^100JIIG-'48H&V-AD?!W(:Y(Y6?^>ZB"_IR!JLZ/3/
M@A\]L+%L%?OJT:9JU*N)JT-QFS+CF62@)*)LQ*/N+E-T8ZTZD%SB)X(_:>38
M=O"B81!#0%; _;8W_N+T[E3I;%>! M1PM*:XU T>K63U..\^R]'ETN1P B)W
M.N2R:H88E(&QI/UAP_\S'7>4N=*5I53/=@P:>5;3I=^M-J0^B^EO$&WGE_<I
M8_[5J&[.S.5L_=O_72'*GS<6H9,V2AM&26CIAB(=-W[K^G1K-VK_31#XJQ+Z
M<][ZPCJ8WS#3=?@^WWRC5&JAZ!A#/32@K'P"G^2>"'5C\EJ;]9NX'_(S)Z>;
MPB%\^4&XE"W[Y.(L10.VJCN ]M8;XKFC^H_L$!YT_ABGJFI;Z 6_"@LGQLG=
M>G)OSF651Z[Y'TX09Z!2U//R:=U!U%+.OQ/#0#Y& O[O@-?0D@+06G- 3>O-
MO&B-\W&5E4^.:2IZ2\E8@"5NBE^4.:X&G$^O^YR NE%Z,D_:*KJJR:?T_MU2
MT8*@VY?4EC9^U4(> F\ C$'N"V'_XTOPZ=]WOXW_^][XRM'&T4OC3_YU+C@Z
M:GK4[@AY=,K8D;G!G8+/!5_^8IT<^J/.U"H8EHK,1Q8 SJK9S\>(M4/@9!6!
MTEL"LD.4*D]_!Y37GGF#"WWS18W[Q=]YO:L%3S5S'HPQ$_E[XWZ7XH.O0D]C
MY$[*?_-KJ+1@I6EQ-"S$F:B$5E'C&T@9'@#7?7!VOZ!Q^,&HT3>8^^/#KF3K
M#(W];DJ5?#VF@M*(+$4JJ-0%KZ #JR)0MUX5C6M5H\H2[XQ#[!PH<N??U#/R
M-ENU-$6]_;@X=M<")BUVG,WIFKT9P9S^A$$[M-RZC7FNGX,XLB5)J-^^L5-X
MUMG?NW'5D#H]U(M%RAH"%E%<K3^%HN-^-\+G4!R;*\Z%=]'SQ+83-Q^NLRJ,
MO337:H%G]6FK88 0,0&+K8FC#6-.D*!!PVJ,(2I$5%$OV)G,YRN>(09'2(D;
M6'0V:AJ#5$]/CS.KDE20.SHJCW.&F9,CN.>]##G[KA[ 5R,^V1_5K 3W,?->
M,2!+'K"AU5;8RJGKVM M2$X8UXYY.\$8A"OWU8O/$SP5S_!%H0]4%0T5'*2<
M/.NSN,(1.B/.I9LO&JN;U;FKM:)9V6KS@@X=I^FE?+9>JA1#L*3<*2]!FPGJ
M%^1N'T>C3I2>^WD2:+S97$6.N/< (T2;3 CN*6&QPGJX4=3[,#X6,MS<;!G\
M\GM@./Q:)KG!BW.JWN_$ZMMR8(R%LUGYFVA]3-03^?_#UG?'L_FU_].6#M4E
M]FI1%;$KU%9JBY&8H5JC*K%J;UU&&ZLV43L)02B-/=J:I;1$;*JH%:)652G]
M19]/G]?G^WL]?]Q]-7+G/N=<YQKO]W5?YQRGD_S9#UH$-JHF&<=_TQ$0^JG6
M:H&P4B.01OJS:K.S;[D^K1]BV#:,0D: I<B%H--]6CA*U&GZOI"+>62W(%@)
M%I1K&NC9WLU,$W)IU&YVN3A9AFYLMBZ+GY/#GNG-][([%P)??"X\-E:N:'6?
MZV67EJ$.6!7V>)B]M\EQ!!W/L5E0U,#G-/8#^]SKCF;_1G",1V@:8Z,D<R"V
M[*OI&];.]Z(B"X'3 E5X!E-KM+;1N:6]Y'>'RI<$0#1OD-?EQT@X+\0S\OZ0
M=P.05O9&3HWKN_'Y4(T+)5$TXI_=?O?E'=GS >=1$/C]XLE=X?'E#^Z,F-KU
MYIK,Z#.,('3U;O:QXMZG6R4-M>WOG9X_>:\8/'*L"&Z<FEU.X*#$=^YW7EQ:
M3[4\?GRX*:$K]T+?9L/IZ[LCX-E<KN:/!Q5[(UD4+DSM)9Y*\*K] WU)M$[R
M'8[YM8+<9SCYVK-C'VG$Z)QQU92VWC<KMY;[PA7+L+ T=1W657WY:%'E#@\/
MQ]7ST:IBNN*.T-VYX8:^$,L8:.WE5PJLFR/1OUR&]0O#U;A6\G=C.=5E:(H
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M @N*<-)K;-FH(%FV5@C1,[ HM80('M0G54<H?10?1D&(U?IM9^3="U#J5^I
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M-45W4LS&Q%&0[\<F@F&JGS=^="B4R$6 SWSR#LJEC=PS2!&M^D,XXPJ3\7'
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M76@E^)0N71>X:V*\)=CR3:CV>F72FN&UX*V%]?IG++7;%?K99@,=(A1O.2]
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M-@D7L%BP$/9IT+3 R+3!=\$$U9*/6]^LMM )^]:$7Q_)K60\+N)2=$Z<J-7
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M=KK_OQ+.Q&Z?(/;%X4$C111],@I\T\96PL-G/@SE5<8&!GI)EJ*UR HEXVW
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M(-(/NI_&6)5EY6#$'PC'4,+/1O\J+L#/H>&9C3Z>BG?@]W,A>>H,XW1*6D<
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M$!X98O2F]!6MSK^"!I<$"I/V9&Y;4E&#9) _JRH@[H<'\E,ND/J -L_G0R-
M.E/ JI$>*'F5%9O7E94<G;9B)K!^?-?-EV5_$ Y9+"IDRKAP&FS&LG]5*#U<
M<(?68 0XGQ+ 2H7#*>\]H>$3H](OT4+X9C/C!X]"G@_V'XN50>&P(VP2E(H4
MVA@?E9O&K^$^@5I#8^$V&].DIX]U_&R#@"-,MV!?0 _&<=W=:P4:,T& :\S9
M^HSFVJ-B2U-M[$;P\"^89@PT#6O?KJ:W[F85[$]6?.EYAO@!97UC?^JRI&1#
MQU=JX8^)>;\@@7=20TN89<]K'-,(S:V4KXZU7:)&%5JG8&TX?O<>2#0VQ(1\
MX=ZZ3=W,VPMN6R5%%+EOO3)_$*C0SPE*O%>-W]RHYLA7Y)5AEF35&8%N';*X
M5IGK:OBA:;$6#.RX_0G/79?RX@_-T:,\Y5B@TP<5LLYSAT1N] ?#9WR15Q^'
MH-Q<C5,TKHOFF*,+XCJ[[O/46 QQR9".C++PA^S"N8:%U 7CKJ]HN7%&)R-[
M\;P7647Z  T#'V$PDZ#DM D[!LP:5:&,Z>DCB-6:J;8A3R<MW-N.L=GO?@$K
MH;KUO!\!*P&K'>>@1#& <&MQ1H>\*\03^F%"T9",O:G?K_^059F*9CYMUN;Y
M9<%57)+2:L').K5+'O28(\*I$07'!L!Y,'?A2C6]-3OVD:#M,%C<.6P773K9
M,DK7C:K/P%FO'B&>7%P?(5C=C0I@X!Q7.^+*<7T5Q-GHU=JT ^FCQQS7H]?9
M'X!X%Z"]DRR@[J/#F+\/P2$#Z193FG,6%93F!?/D($AFSU2R <+#OL<Z$S=A
M]2H&CHEQVDJ9X6CS=]]];(Q:5*P)IT9N[W2F^*G6&*$X52IM*SUD8@&9R><8
MN(=4.>2R(I;-K%Q&B5:GQW$U.>XN'@3VNC.^_QC;T[1:[D:K-@"1,Y^T(C9Z
MSL\%).M>?2HN$L)V6M1EN,4$I.D NWSA-A:[-J#N'I3<"$M][? $M8X.Z*N>
MI6P)VRM=OVQS],WY^S:+'X^D>5>_28P-H!8ZRXB]L:AZ"Y&7:2KIF/0!3#B=
M7;*11],^);#7UOF )*(CK 62)Q%]G9MA"Y3"BWIWR'%7+(Q[^9\'":]_6+$8
M^X#FYO*"^N0U"=_NAOWPOJ@:.Q(Y5"I\]8F623QUJ TJ $NBZ^UA;#/J*E/9
M)FS"(S\=!]^XMI*1G&A,^E51'M7(P)GTO@<6[8 3!]NG?M<C.(4OA]S/52TI
MO%JAM(HSO4DTYKP8N1[5IA-?A7M">:[9[# )G!EJ2;%W5,QE4P:<9S<8F[GV
MHE#TB\K=\&X[C 7J>\5[HG<F=U^G3E[DAKB9WFD.Q7K[NMY'^QG^2V:$>V>B
MJ?KY<Q.2K?PE5YI_+&GA.*\0>MSU?JCTF!SYNN.0SB \NM@3$ B3K/F;X+G@
M9\6R6(F^V7>B8M[''T>P0O]+POL?_XJ__L.:*'F\*NF_V/'?_ZMQ^O]7T/UG
M\_V]J'XR<<O/>76,J'MIU)A$.63Q?W0G%N]1,UJU!#U+O]R3IHC+\='9LD;1
MI2/D ]XD\?0CLI3FWRU5N2N39/9RON [3<HK.:+')9_VJ+.>EJL@NOH<YXP4
MN_6W#-C'DSFI;KS.QWX+,&W^-__^&0/1>8N\(6>N^7\&%O\&33!3--<CF3?K
MQ@8F676/OI/:G9Q65P[NLP<3 ,N"H=4'G7'[O79L>XHSQE'S@.7@4->&0<]#
MEAI -Y'?C-5H$KSGW[D!7(V+;?@E=I-2O\$<R5V\LP_XN<(OO6<@LD.>\!7Z
M\FN,_;E.\H;@*T?>7%R&BO+-I [8,$AP/J3GK;X?!][6^.K@ANU?:1)5&S@I
M9MKQ[3N>4.($%^=F8P#=)I@HS7;(DM-V?Q,'NEP1FR;)%JGR.,]6C9*[VB'[
ML(I_(;@%I;Q?_17*R/X9?%%NO0!<A^C63YHT]E.]]G5S;2^=AQ%EF>$&YR^6
M/L84WKI%5 54DP@@B<4>+AJA.-$@HS<V_+7_[JM#%KUU2>6#^\<7H!ETX2VW
M/W'2?<.^'T'X4?T))5=5HX#5F_)S&]B0YN/[?/N *U_U0-U9>K,J#W(76^=L
M7C)C4EI#F;WP!(*]W2&+#6P(Z1;3!XYDOCI@[L-Z\\O:9;.9 8<L@O'[L(7Q
M\&#ZI&!?_0.F;\/<T<"B8+@XB'BMK]I39RP>UO)J/[D^>3TK*G_8>QRR VZ)
MCRNK5P5,L_$WI'HS&:7.#XK#;5?K'U/+ C4#=0N;IIT)P;[U:DR[H@C&F;6
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M8D'>;&NGGGQ$2LC/\<\#N,ZA*K6W%FI.E8FQY*D6<'S_K4'!V_YIF^,*E#K
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MO"5L6(^EE=D?Y.==5Z,R 6%29AO:WB17UY>^=R^]#N^T=4Q!GQHJ]/3D@[<
M0 :/M49X>M?-1%4JNBGZORZE\TSL&7@V^%X\#1VI&K6LP6^E%Z**S=(=-%V+
MC<M"9[:]9L9JI=GF=WUCR%]MJM?OB"]_"/KQ:;IVWG3F[4P?NEUX\$F-_OL:
MB@4Z_^SK/RU$$S&KQUSGKI-RD[4,X*QW"C94W9U)D/3H(5:1[J'!7@G*:)BF
M;0U*-8]NA4%+2#827>"ZEEWW9?R4:P,J8OF<\"_K10FLF*Y''I>>>-:4 0W
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M-B_Q9^F=X(!.59;&%7;F5  1RM4JEV,?"4@KT%ZCV$6G@3+H<\9U:6]=<6T
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M?.=7H)H:I!:^1>$E5\J;7NJ_)(?_3!"%?!R\@54\5U?2R[U?F')8W%NJXOW
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M :0#/  T1.,:R(+]\\AJ77?Y.B@B?'%53[L1B!@[F?"P&>I_1&ZDL<*8%G@
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M^<TB>C&68OJP9.C%GHTXW:P+IG[>\:MV,)R63 )_'ZTK.""^@JT-7I$N:)<
M G4BW3\U7I Y>KLAX3?"-)+]WH6W,0$L(Y_W[F3-9T;767]&4$$*GZ4D75I8
MX8MEE'W9Q-LE^]RZ:O$>E*%67+!(D$3RO/<#K9D*>RY.B@RT/=#*."*-KTS
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M:J'\+AY)2_[8R#;N@3NA.^&I_)DV:0;9JMT]$S6JL*'OE3STLG]![)<O,W7
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MD&@KW['RHGGI4#TE7&.75;$6Q(&,*.R]NC41=U*^KY!1P:U\ZJA# VTM;1+
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M95ZV*N$?L&,D#B<GK,O41'!K2*<$F[OE^P47S_G9G3-* 363!9B?/VH&[+'
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M4- 0(YSMSRS@LW'"(J/MQQY+0\.8-2NI'I%2M,<2\9*!8Z*/)JN'+EVU83S
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M\U;(Z$W?UIZQ\A7?'3)A8?=LH9REB HT AED^"BY= EV;SRTX&V\1\_] KW
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MOA%L7Z;G,*%[+.?X*@?QY63!G-UO$3M]S*41FX!'O!T*7:'!6R9?UU(?=/)
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MB#4!= C1QN-=R^?R>.,V!V\"<W/\9Y>3A_OR:1#K+(ZMZ'Y /E]BI'A;\?T
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M;Q=Z=]&JBI-U+9B<AFJ-:XJOV(TO/U9DE4@)"_AA($['/E_U8_'6N70-;4C
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M)DN2XP7)TZ\$M-#[94BO9.$+ )CI*9HF!OM$(R#<503_Q8ZK'V=S1<Y3\\O
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M]T@U>9Y6*)F1BALB"I$^I@9Q6-)5;#N;W;<HQ'V%[%,;TO2,)_B3[V)G3=Y
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M!>EJ*.#A!0]O-VA$6S1Q2[Q*BG/Z"#SNY[]WHH&3E:HJJC_ *RCYG='\YIL
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MRQ7U?%BF+8=I87'89D%]R!(-?'N>ATR ]#Q$C?ORRVX*%A1$[C9H5L\F8U*
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ML8'#A(18;*;6B2/>45#,(A,\S'8+,J:A 9BQ3??4!9DKF@8N'B+-&E.5Z/2
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M2Q6@M'T'W@]@67(OE ^1$W#OEA"!#08EYB B&UHJ=& 597\D":@3X&'YK5!
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M(U#:M,S]]?/I2EU<35>%E$2:9U&RW)0A:X6,L:B <)>#HKLE%<CJ$(0/M1Y
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M:W?RV'?JI=*32SL.;+HC>\DB,WD9(R&:Z&::A)FK40WU!D>V-(9J#$E]2&_
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MGI#"7F/N7$^;R6*D2688EV9K?G)[[&U+\UZB&/.2>DSIC;V5?V:'HQC]E>R
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M \O0"$6%1/U>7 16C$15QL&&J+?SF_.P: [$XW_G"1J)JB RL"3*7L3J/V.
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M@4#08S(U7TQ$IB#TP?G!#]%L2SS$#7Q).%4+@QY03@QC.F-$8!KTL.$EPA*
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MA83V(H9SO&?-C05! 8,YGC*XNP_%B8JB5_:XK5V7U^:_-"47>UPR*[D V17
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M?Q^X527206<6=8KT:LQX],*D,_LB/;GOXI7,5[H5!G$2C2Q=G="OQ=XEXEQ
M>MV<FH8;O+AL^*_!.QI'&BNRV-;'J%^\7<@M%U7HFBO[G N>7[$T5%7=4'"J
MO7]+0;TE495&<S4IHP9HQW"$[*BD[Y7=\=-- UI6TM"[XL/3+3J"&+8>+,:"
M&#6=\!S--Q!Q'NSQ!07*$&\Y/@8"PG/AE2!@9X):..5!*#&,]VD*T"O+H;_(
M@VC<<1#Z@WY7<V U,EA2>43HG([4#K!=A_XT!WU1TF@34\'Z?F$Q5.D1^MZL
M!I00P!?RF6S(MT$X&"S&D+8QG"=ES]F QS2I53=I7V KI@2>7LA\6]&$\_/:
MEU*98B*BCD_83XM.<[SY;5O/HH^*&TFCDB&W!_V:1CL[#3HB*_%<7'I@N/7E
M-^BE$Z47SJ1?7".^G7&@B=D?:MKSN3*ASIVBOMQ&(E4WS=QYR&T1I\UR63_9
M7F>Z5CS"J L""ZD4]'WAP$U1CQ!XVV&Q'QF[C@P33BMA3 +R1,,,$(HZTKD/
MV(,#S8K>TR2BH$\$1;7(O@.DK#!0:DLQ6:F5]KS@A'06W=^/_9A=.5-IO.#5
M&9VGK^Z7S%8LK7%RCU,;3[)_FEEDM41$+;?%COKY78N#T;&*PXI:1(-X_]^N
MQ:GD)Q5Q(G,YLB76>? I<Z#5#RJO@=?&7'3H#,$3V'[&&_5<\W4/P(.%&>D2
M@!@SYXZ#G%!R&)X_O1*);F*]''JU2)"/I*&! F :J"PE"^*2#Z3VMLP4X2_F
M*43#"=(A0I"L@6091!(+0.\Z4!=4\%08)>U 0Q+B?8#T@4"Z)B \2A)]5<8"
MB VK 0739M&86$M;1 7!ZO*6;7?G7$J)&<RU7,TEVYVR'QW4SK_&B.WT9W,P
MZK\.EYU\77?>R.3(6/Z%-MS3K NLG78]J\1JQ^Z/[EG!J8N?\!E^_J>C[ W2
MB9Y+MP^FGL_Z4[W_R:P@H_7JAU0P-\?*XNZ^JE$]:BLN\CFU;N[PA4 '14*,
M%&E(^;2G.[YA^;SB.15$HSHJF4N06AO5U.X1V+7]='$Q JVD(TP:BCS_$^G]
M;SL(\BGQ,<W".UL+JAH4\H7:R.1FWGJ6_DXX=CS\!:&WZI=Y0:%ZO3)C9>:%
M\A&,QWF,KG1ST5UD9J+1L0ZVR^FT-Z5TG\#8V)!?3AD:RFH]]_ OX4*7_D./
MSTOG/RI^,K=BELS!)+,"+F=JT>I-+?9I>='S[*R#\?<X\L\(DJ#?P;3MV_C*
M@3*R?B12^3J9[4!AC)C8/[ :?F@D!&4DX%&V *"@%EL,/CR<,37F)@H   #B
M/^GN^ !2$%+0+A5\N35!6@@-N!6G8 G5="UK, #PN =H=F%(W,\6RAW*D_?K
M$EM$>(IML:H))RJED:B)80M]-;B3*)"VJ5BLF+&Y8?,)YLU.'>>JV#KWCM=[
M.G)V+B"(GJ<]'=XF,V$:")&FQ9W?C#HX^@^W;?-A*KF;_:YQ9&GT=>7TUROZ
M[0_5FS_^=7.+GJ25 L6J[)W&/N70VO?GDN6E;^%FD559^9F>[1K+P&6B(08@
MZ<\\*6!* ]5<PP90T@A"6^].88CJ,+1I6UAZ88LMVK)9,^V%5U'A(@AM!L'?
M6(S-#O-,X=OJ .13*3'A$4UP<Y>C'IR"!=RUMY]\TW9L[(QJ\D+_(G_3K3JT
M=6M22IRQ\VY3Y@>V.FO9E1V+U70*'0]^\>@PG;2>3'&HUU#!VGN$<X[;Y(GF
M6FQWY&(;F^<8RB0 \389@RH9R@"1K%(A >,RN$DG\)XIY.L?_:-7*) X@Q)5
M6", W1LJ2AT!_T$'>L_AZ5(QL&<HY!D$%YXZ0\LT4D0+(H-%4-@1[MJ6&OY#
M?C&E0(DR740-#*3S-C3'H] #:QS^0[:-I([0NC<^MPA NZ G".Z3#;T#L9L#
MW MX%9&!@ &HUP5Z>W,WS- 1RRS+7=*9WKK47G*MVN"!2S5&>]XSPF4]=M]D
MA>M7;\>4?JPWDDJ<W/QUSEM.>8&#(V7'[)JX>T4]V^;</Z(=>O)U)V>IY#'Y
MH=%H\TFGOS%SZ^3V//"2Z=]F,6%Z:^3IYDNJ&\6^2@0:31(OV9VX>;1@3H^4
MJ$ILS>+4;^JUD8H2.YRVD^_*UQ]WVBYV-+0XMV_H25X,%A=/)K?8NZ9YLW(R
M9M[/+E&@$3&RK'\#"/F_#DG:^%S(W4(Z)6S>&*QR]4ABHU9G%0VLD.UDTYZ8
M$7>CVIX1U0\:P8N=KY6[M8U0Z[-/K+F 37AI<#>J2V^%[X$O>B7BBQA?8O?=
M[FF_7-''RT>]R#S=Y[(G>IO4P\*U9]8L<F(\R]M*3=UIZ*3VW(?C,?)VKQ5Q
MV5Y.,PCM3[=RPUM7R*>,+UV#!@2HG&B3#* SZ#C?E"HAD6FP1! )P$.JGN%@
MAL](@N-LD"8[#=W;AL_06;!B"785%20S(/2'2.%V\,XG&8Y:@D'"908ZBS1K
M?Q:_^%OP<T7V3H?9_PRZJ NWRW5\)]N1P_)C:V!D=9(&?-'W,![*C&GOQ4YT
MG3<GB:](V!Q]PGVH.DOCCN]H7^7,"ZW/9D8W2=#-3P9=J5>HC+_$.K+BE*%>
MQ^.[M&]%[X]N,=UR<E_*]1L-OTE)E)H<2TZ/2W4RVLM<X_=4*6W1\]B OY8/
M/]]R[RGU]<Y*O:$#!-=^V]?LB@6/#)P8SPMP.[P%JJDOHRX?T7E/A_XST-\.
M+)?0DB+Y&J09S^4^W^$IQR.X#_9LN*\0=/TR@D])/>H+P?#V!@BJJ]+TR?K!
M=(:QQ;J\G",-\\UK2HE2I _9EH]Z2]PVS9'0/;#VG<7GMN0A3E96D&Y1]9RK
MB9=.6-/?K]T,D0OVP"Y-VND,.NF'-$Y85]S*3 W$UN _09DVT/'-&2J')=6+
M"33;R6FN1ZFN 4@@LCH'046XX$ :OTT)?0%?" ?8Z,?F!>\Q@>4"<*!O *SM
MB$H-Z/:HT#T'"3.D@XZUL$!O(% OA.[>C=. L 2M+H1[1D!3,$']FM%MZK)
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M:'8Q780.K/[_2DS'EUP"-N!30G/_%%OCJX<"RS]D7@2'!)%*+(";P"UO1I4
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M38+@%P%? 3.XM2"P656'S%E"6$.\[6^S^)V<[DK_H<(8]ZNJ-D1W>BX]J*?
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M^D-#5M*;'"+K<%Z19D@:I6KXNRT6II:ZFQ=M0S!*V9ZW/S&W;<9&T9CMKJ!
M8;,[AMQM-3CFUUW*Y&V=.&4-SFTS7Z%M.S'[;L%])_3D9X5/P3;O#-O6:!MM
MP8Z=2G<[A63)DO"?%CW?[>WT@^%:UW4+M%)*EI,]I70K;FU#!_6RFUHYEP]T
MZY5D>=^XGIW3/(X"@TH%/JD,4^51S8L,WRQZQI\0JVS[ECJ!8X]3"%XMVZNP
MY?JT0>1X^UE&GS=:O@6_VI:Y%^\=U>3>G*\#+]71K$O%*VMV@5HKP59<VKD]
M6D%Y[G(O.^N/FS/<:5D7>DSXA&O)M.'C64&\2F8@ZIPZ7$5BQFX-WP#4EA$&
M*Q<"&/%6$E .ACE=LNP<Y,6/-U:FR,[%))F[X83#@] )LY<I;RM.X_ &5E4T
M)M R4RK42@*QQ<!'8CH'SZ/I>,F(J-S=IZQC-VB8*7OYJ']?HTEZS13?U_.]
M!IY' 1E[,<) @UB@/C+Z!FC7?K#7I)!&'0H0_@\(Y?B;_H)XA7D!,I(3F2,P
M@1^D:8'T&.ZM1!!*:E4W.-102 $J,74H+^EUCO664B'?==@>#.^7?Q/:?WD=
MVZ5KD#E.47MO? ,$-=B]WQ"*[Y,3?7(6N>S 97S@4('O/*_M2Z:JW'>\QQ,P
MA[!I;Q,B45UBN'[@LCB/N]1'673P\X?G V%35_Q  ^^+M9(%/>1:\"E*K7[W
M];N3\U20\\5^9ZP[VXP0">K0E/AJ'F/5]W'\QT^>T*VZB[\TK^,W5)1T)#GX
MQA FY[[\+#13* SZ>S[2G0QM?R7+_M,*$O^( 6ZG1J7(P=L\];+ [Q$GNT/J
M?[_BK[K=;?$%"/PA:\$?B<RE=SM_[3AK[=_*?J>)^]=$ZM0],=P)CM+"&H?+
M]54E!_L>+!72.#'%8 75N-.+;$LU?/3Q6$]Y6@\FY%YU='SYG!^W"8CW6MO1
M]"ML="JL#IB:<'&AK.X:69LFQ%)163/N_%7/ ?6L:2$Z!>1BGE4U9["<C%M2
MCQ\W]2V]*B&+(Z>]5IPRRK"J!JX=1L4*< S/JPB6YVW8[O[3KDBQ)A[S_0JH
M^K*.:#+2HK!M7KY9_>[$"P<<VM3*T-47Z-)C/(2_O\ (=55[JLIL/6?,CP)"
M9FJW2^J^EFQAOF'="P<$&H6W/-[-]J&4CJ \@%0O9U^S1A) ]TZL(6@+_40C
M/[DNU,&^5%VDFI4PP97B2\)SE7U31(EA;X>=K;@VA%ZLPPD%(U>$F"#4:T^_
M 31"9B5B68L./@_8C_ILPH!NK06S!KW[8I=BLO>P,/W+;P &HK23[66N]?P[
M-5TNW-8+"6L-SU,.-M9?(_75COUT:U+\N=(JHL]R44#JD\1D_L2BMM*$ZAQ&
M*[4O*.)^H2\?EO!27?Y-%0^AB-Z(,%I6$' 10OV%ZVZP)EK!R%M_=%(]^)/*
M UJH]Y73&LH]<. +^I,#5K"!<R:V]X'8?>>K>[^<[J)#(C50APN^4)7J0G7)
M\_"9P.^Z[MS='E3WMD3G'Q(.D!'G^=W"[$YVGVV3,7G&4]*Y[@/^,54X1; E
M7[IM.M[1?&W[-N^  K$M=DH!%>2.MY7D._G#GPG\&"?+1[4K;<+UW2/?"3C:
M#0NV9?_MQ.(_6 "V6?^O6T9PRD]3 J2'HRXZWJ-)L#CCT^?-$AEGG*#59YHC
M8FY[(-V^S3UK>*1-@H[6?142:E,%ECZN-\&R1\OD1*)Q:_,-Q[ZL,%<AJM*!
MXNDZVE/5(VL%FXS3/O3U\3$.9S;CIOJ:+QYT/GUBT@L=ZL<NU2:BLPG_\/HX
MT6B 70:ZBB@B7GE+*+<A"]2(AH"]D9TNUDWR^<^>3P:V=OK2W_\&$)M0X"!*
M)^H\"(0M.1_'NWNF:<>%^R*R!QVN#C<I*";4D*7IE=8'K7&<4^5'3G.]FI(,
M/-)L=?#% ?G\]$@QMAL9>Y*@KJU:R"=%8KID62'Z5HPS:77H:R,])%$ V>[Y
M5&'A_P#/IK_I_XK&2F<I&R$56Z)V^HUC\>0M45[0/O6 ?B@,^7V+S(H[B)5%
MJ1X:'F//ZS.)D#X'_(S(%5P]-(&E/6QQ%CGAH7WDXTOFI6(=>Z4O>0LS)2W#
MY=G&SW'N!FBZ.L*3(^LI&"M3>UI.LDY\<E%1^240<2Z'>/D$WJDK1 "?#/SL
M79!PXK-!9JMG,:RW1GP4[Y180QC)!\774GOTELO-QMIP1"(Z)+_$2&6+A'Q.
MJ88G-&:\A'JX-3[Z2)]+G8!T\L.R/O#I<^%V!'-)^_8TV(8=\=CR:CF3V2$L
M_H!N3%TC^]7W3>UAIB-SH1C=ED;/ZKN4H2>U]V*7:FGI7T:C<M;_B=)[QVB\
M[=6UF\$>V=9C_\R^M^WJ_[#+/^U^FV7MULI3X(/IKB]_0"H%P%T>U]N"^U9W
MFKV 4OTCL6_.ZO_6)2R6" SCFXVR%+>*'PF^<R0D[I(PDF%&E.\,^$MYJ%G)
M0F]5%#3OFJWI&<FD_(MO5!P"0ZJ$(0W"3895M3(-_N+8%OVC\<T:5^<_NDH'
ML-HVMY@Q)>&MQ&(WA&I*"+-'_+ E=.@3OU[=[XT5TTP.E@.K\&<1W;E,"]V7
M9>7L,\#@!238G=$2X>R]D//^>E/"W6/(IMO!N7L$I@5[#6UO_O00]W#&#OL#
M ;$16NDWV&1[<O[:',^06[JZI5/??<9EUG!&,_6@/O*42QZM;'CWGH)AL])6
M)66AE+YUCBM7LP_1<\;UN:3%GJG/TW.RY0=^E1-]_H9V/#& +-"KO[L2%+Y&
MUK&7\/6D)YX/MC7WTAJ>T6Z56"I6CA1W?TE=H=H+4<"20.[CIG:_: @U'BM*
MI>[8_/62]7"=DIPBX34K_$YX /S]I@ 165AWV0+CO_](]ZJT5]SC$4<TZHKD
M_=*7!JC&BH<95F><9B! O],QHF6BY#R$1&M7=K$%](3Y_!%3_FHYV4'O^FFT
MF$F3,*KD1&-^6@5!;GE.36G%T*,I>KD6P3@RSR4<"6?ES35#QJ=%:PL5,QZM
MM4"^2HR?SF%Z+Z7ZV/;&J49V31JMS+T"F%G[#->[ZFJP6GL8CC8+Y2%5U77U
MV.]Z;ATJ92@M"5K1;4G#)TGSZO"-+;%6;S?3U*7D$7P&_#V<:'?)$/W1/;L,
M,S_+Y+MY[,][U7;&!HKCM2?@]Q7Q8_HCW%8@\+9 ?ID\)+(Q8:>V%1G64!+6
MDF-F=R>& -[#D3,1_V3L1@#2XZ,3MA:W\,EC* D-!S$-I>D<MK?"R@,9_7G/
MD-8Z:M+#1I.+](P^'((?2VXF1%XJ9RJVYBBF<U3E<S!A*8H<J3\^*G-(TST!
MTL!^EU7MSB;\40GP7;ED!#C:CLL:(]\%$I3J<4C>%T] C\40$;E$)[SI0\VN
M@+@/KX%$9(;+=!WL\X=)ZO,2@VDWW48)S@?QIQ\_WGR_"9_E9"4J=\62<,#3
M(,(W0(.]-;Q=::&HJ0<GW=^J ._L?AI0YB!HC[9*1F;DOG_-2G0^ 4Y,!\7Y
MN(2]'?%UWY^QEU 4\D83]88=BH33/"OFS.*&RR;7RHIEE8$;,",X@%&CD5&4
MCP!P52AVAKQN)(<!GMHD4?Y?5?;]3?_+: ]#0K%40LMP09?&$>\ER1@Y0YN!
MX*@G"P,(-<,\M<NV>.;*R55T,-PM>$,HID].5M^3J39OLN_2051CS:OXR^O8
M/NVC_5/R&K*^G+3^Z2\*KF*CI!.YEXO=:PCW+I/ @J6%EQP9-/C$?K9?Y ^V
M7U"T_]"KWR^.'37WNM3\2-CRM0,)3" _1'CP)!B8:F@.9GCE\C_QZ&0T:?60
MPO:(.:3K]<9V9"6?S;8T]1=/BE)5S?[ME;!L JV<@0L?+]EFAI(E[RC]&9\Q
M30XGV6&EU?9[&9684 )IT:^V!,E_:F-_]9/5^Y_YB-U,W>+<VR'#E"R VX]T
M-WO_9T1.*$&I(4D!!N2K?\Y<3XEA5H1^3R7\0WC93NC4+91@P>LEP*Q@6NV,
M&DOJ=5I<0C>5YN5>91F^/!S?XGZ0ST..FG 5Q@RG;+D@5^.R=+TP&U&N1 QX
M9D'&<;; G2D&).QNJ'!\$= :$!=4PG"WYNI"?';RR,PQLK C:WNC'2&TBO!W
M>-M5/[1J.)828GB:XK>V?#X77_VHZ#[^:JLXMMN8"/=:@<"FYY8:@]P+@>$"
M;Q%)L@OQS6EL8LI 3@Y5$@,U#)=U;(X$;S"BS]O6Y!Z)%&-YEP)EW!_\7Z_A
M @+TK.)1 ,W2TN^'CD2+<=^#6K_Q\CQ?,*$B50Z5'![4M'"[V:MPHL$C9>PV
M$<%3Z <*[D-'0\#+K4XGHZXV<)='<F=ZVAY+.^R"CJ[1)D18(4:89\QEWM6%
M=%_L)''PI^O]<N<9WZ7<"X _^Y!R9+QF;"TUD/K+U96@](U);RQ!+/JK[LJ;
M0B^^=]*7E0/!4[R$CN?.K3(3%MX? O?K:3:W; AU8CMO7^1XKH3&/8V/=#A0
MT)F<&]]R/H57Y/XIE7O0\VT+JP/E3F]H7P]X<C?CS:\7$ V=/,GJA9[L.Q%:
MV4EZX;D?KR5?*]:'B5!]TJSISKZ+;G5,'V[/ON>4KW9BX+IH?D@V6^$1EUI'
ME^0^PY+K'.J:H_+VH_(.8G0MZ3'<VQJ ^/O.9]BA@N^B;U!+;[%S\MQ"DKD^
M.3.A/EGS3?:!U#NJJYCUOJLB5/>/=6&V>?'V&J'HTK>M^-MX82>D;/=5.U7.
M_N!J3DF2_VQW,[*+.]QRJQU%M[!]WX2?$0CY-BS[=ZG\3P)_*C)&PB6*I)')
MN&;# ?K!TO<]Q-*T8<[[:V=DJ+451Y&:O>$-_0]&EW)'#\O5:RX.].>WL)?#
MPH?;FV\X:1Z:%%ZY6=TU\5!6UPYCJMHP(=5GO\F8[&F:MIY_^*689)!I)&)-
M1$UV+^PI>T54"' 3/H^D;PBM&'E0!UORIWG[*L7%<D/H5I8EM9VSW(D\D,ST
MZ\.5<0-?[1:*]0G%#=Y\0U42*X@Z^[K]Q^0S&U81J?:D&?9D9"U5;-Z<UZ]+
M'FT5B>R?BO:RP[.U/'&WP/C8AA$">.%\7"L(S(P"!^J5Z(N#>+,CK@5.P2R,
MBUC7.+XENVKMPUI"!E>1@0U>SA<V!D'!I$7/CNIAT34I1?#D"KJ\K,")#5[2
MO7,?H#^=6="VG1-X7WK\O]\%[&_Z=Q(Y4$%/[Q656BEG;ZG.7C8IE_2\T9F9
MDS,(!]F>BA/8CR&/[6B,F)\RO4F)KF5OT>_59^N7GA6R[W,5BY/B:;XBQ^V]
M(D2WV$!F]5]-(D3. =\:<J:E"NT-+LJQ2CAG$Z)!:"OD3>]L,XZYT+5<;-XK
M)U'Q2-BM//FX=<I]DAR6+"C_DOJ!;9G<1)BHH\MD$6X<5U2Y0FO7AO^*)CI5
M&H9'/2=Q/E@3YD"16K:D?UXFRGK>(/.NPQ<F5)'M".S)9/XUM1FV#&-!?,YO
M9@=H9;\+"$"@G@N&(M/#R;+TC9]X\Y_&I/V$$/[@R*8J\%.:#G+W9W[J]<_B
MHW^^RS_!(!F21TBT8SLX))#Y D,:@&9OZ6XS H#T"S,\]C*AK.7/=* \]S@J
MZ7CW<9?-2A\=3[C[!(''BENC*IG"NP-IM65-[K?PE]RN?**O7#!J5:7J)_X)
M?7^I4,CB\%.5%F-8C6ZF?<NCCK+D[JC&R\9$#TQSFYE+"MZJHG4 GD7T0+ B
MWR:#1SB6"%]'W\[+<9J >)V'B$HN"K E=3-.27,#>-_CNS["5[49!3E*&DZY
M]G.R,XQ/%(5TJJNNHGJ-='VHO72$HN&\/'EG=%E/'&9YIJL]?- 1*23^1TL&
M3/QGL]5_#0G*Z/4(4+DEQ]9T"\N2GG#6Y T.TGS'1?2Z8*YR);2RQH8HKB!D
M"KT,:8+/DCX9T/*<=$DO5&L<.]PHWWGL\\&&V,JQ.Z$3YFY%?B<6RQGH9RP,
ML>':?6XZ+1G#+S)9/I0E2V/D(ZD?G#508!Y0H)%UX09U5PA;X/WBJ^L\5A'3
MYOEOVTP>#.;1M]:\>5Y'.Q[CR0V*\P5*J'G(M3Z\9)A#E# @%)0E/KTH%%V'
MC3\ $2Q^O*Y&2&VI8PB(FY2=JA\*D^:"Q/DN21S2]O2"$_0C7ZQ49D69L$B=
M<CLW;XX-),1[&6U.;\+#/ B;3GZ3)/:2?0)ZSD/N&\!2CY^!72RWM[]V\L9R
M96L4T9#WY?3A%X49O,)W'9JO.0J=GV^6XA[[F#=Q:8PYMP]NVZ'Q6(]E.<L%
M(ZPYZZA249WKL*?G3A;3L2UIO8+TUG*KR7R7G*$8?LAS^**85J8C2U."2X]6
M>O317:([Q2U@5T0'H_"?^>GO=C.@V#!VRM20^PC9;K:=X7)'77!!X'?[/24/
M6#0YM+OHW:[N**DQM\T8%+^$J[N" K8QI>J^,1BMY!<,,I7I=S13D2DF@*G/
MS+-TVL^/5);$C3APNZB5Q>>7#N8D+SK#'YC6ZI9\,#B0JI8?7UW$<D2?Z,%V
MZ9H$79RYFIDO0M<.OR)20I*J7 ;P<P-GG]LM%-@@:5S7!-NL7^JI&5<9%D8\
M*J?]JNECFT*(]C8""6S"AZ8##]H<R<0%@L=SP[,YL^%RPFJ<VEE>>B;I"DIF
M11$$G'IZ754GWGP 3P+;D^*584O%AH2Z!J]W(U6BW367E6V<'W[0;1M-SNY,
M$*U'Q#@L!,(^E6K?#E#3(V&1&5K1^K*RKELO(.!!M H6G>GQMK?=3ACMF&QQ
MZ*/7Y&U"G_#RY$D(]9(S/>Z>2=[$0<Z^;N%':EUB^N#@:3%S#UAW;N6T?@:;
M[]%&NR/@/:GK>69YD*  @UF7V2G9_9BL]]VH>Z2'ET=5TUTH_._/@O4W_6>0
MODFA; P0$*:5E2PH<8%^-P_.DK-<[9E.I;[F4-+2:W#,WA5BB72'NTD*\;G=
M-V>+>!+,>#/'R\8;MQDW+85TTN7S*K0V5&TU2.\$]<I)>^,&I/SQ RVDLQ]C
MIO/Y"?WNKYF-)180IF*:+M>T:?W1^Q(5HP)#\I-X>["^'@-!B)28I8+SGZCG
M7S)5X\-4CA#"%[*>V,P*AHAC1U][N1==Q=Z]GEXU16/F6I!YK37L[LU)Y\S%
M8),4]:C ())PY3'G9'.JO=+(^]:MH:R-I(&<C#;N8D7'LS*2JW<\LD. #TP#
M' 1EJ&6H%5WM,ZZF,EPH O[N#T])4)9$YG7.Y)**.\43R+M/?QKTQYBW/[4A
M[)P@ZP\8?]UJOI.5<[=[X+]">W?GC#[NM.7HD'4FJQSIP9+)E=^?I+SEZ*C:
M^R6M2F>?^RQ)UGXN SS2G> RIS>:V=RE^VG/?:]W"7=&0&H)%X<R3NA=HKJJ
M4-H?:W6;1HI_<*Q:-]61_Z&>P)@>-.O%X(H3;$#%L\F@MQ7&VR3\,,5.6&79
M%Z)HIEETJP,=7W[:3Z*.%3D9S_O+3,1!GIMAT*BZD-*"=7D>AH6$I3;0H=SF
MEE7#L>*@/M<%Q*G/=V9"&))=LXFN)'"BF4V\[!I7U JB/^VU$@A[%:IE]+G1
M>_&Y3,D;ZL,L3 JL6@JP@="&+GZ=_8[-+%I]O&ZRT5'=:4 =M!I*X58!;UXV
M+!D5]K@@Z(1>%R6RBL0-^E,]4@_JJV7K"U MZ>TRFTKE"O8Z P&E_QV6O59_
M7@!W3ZZ@_?9+_]T,DN^:W>CZ"(6% BQ'O?2&Q\_M72@(>Q-J>!^ !VXR#G4A
MP=&1[1T]X>4J]SY84*>"!^\$P*<43A(-;WMR;PC-LO(<$SG48?W:GF%T:H*Q
M3YOY;.U+![PE;[K"J<\RN&4=<D!]ZY=/(4_RI7GD_8669'2)@8S]@9X0\/LO
MVD%'.V+>HUMKJ\YE\TU%F0A/#JY_KB30/K\<Z!D(SML$)G#FJ. MKCF!#EB;
M#88N%=&8$K4G7)Y;8'R!BT;M"[,VC^\NA">HX\XABV:M7SJ-?GD3*@ZM)@&:
M9[.;AY/%!\,WX=/ZC<K9^IW)G#IGI2NH'0RG#>.F@HMT4J+RY4N%[JSF%DVW
MBN:V.8C<CG_+%M,^IE.4<MI?,;N UZ?O/+WNDOXUYD).Q]7>R'X.J,1+I.Y)
M3$Z1+$H3=Y\[1W&[X-'%R>BM:K([A6D-R6MJGJQHV,G_GDG& YKANQ;22>I=
MA7-O;.%(Q,]ZB'^5?BBX1R:RF4-_VTE2JY\<=\!-^I9,UHZPD^]@M-N+,HHT
M,1.#11\(DJ0:R3;-Q6"FXZ"JD'O4Z*N2WKRK\#V_#@ ,;*=]>B*33B=1830/
M7)<38I.<?3X2WV!X=0QL<*=EN-B8B)QXL4+KX:-]R^Y>D34DSAK\*E1?M3MF
MVO7S]"<9:.Y]G)MF%_V$>5>:WUEOSTF>%43:=.#AH!$WYAE3*;'/:/VR9#I]
M!5,L@;8]8K-@$S[H%8@OF/OPH'/"PG &M'_<.1,' <^[IP0Q*-TFS9J:O*''
M@TL.$VBW*<B1=5$WBAZC/#2 ,8V,5VK#M$D3K0A"FFC3<Z5GYUT74 0GZPGY
MA_-ZSYK.)_MGK(-O&MARK2#T'0@?NP'B>1#J#W$710#/LA$/P3WQ<TO6R@Q#
M+(:;Q\MNL]"L&,8]36*L&V-T076TU'8 ];[[0%!<H,C!.Q13^?^!WO9O^G^#
MJ YU\ UOEX!4JXKH_;Z[!W55W5N\<&#60SJ)M.P> JD!2$&!R1MLG_/IH'9C
M#ODD*"(K.);F<JT<N>=I +*U@I#CMYZ"N3ZB@N&/)\W"3,=6/I='QA,#YG0O
M [2['XO4\)1#1&?,7RR7U!'Z: H%V<\R=IW0B(II:$SFNHYOX Q -E=U(^76
ML?/WGX(09*_(9*:QE/M+12^LJA_I-WC*>3K)*'7GM;!']LU>-S_*3Q02&<>=
MAH146][1>!?/D?%RN59>"6$M$SP4&)+;EEH:V& &+M P$SRQW(]A+50K[=?J
MTU+W-.\SG7E8(7F15L0A$N-KH'P1?-NJD=&D0W+B7D_)Z1(UW0/9!R2-U-#I
MB55)JIE O6X]3A+DT&>\A?J>>)625$YQRY!QYA\\UMVJE9TRA-L;X1_*X/ZK
MA$/]7+TIDR]&\I 'L*,IH=TQ]I>[U_4^OLMCI:41S.Q"""=8>V0)'==O9I=Q
M3+Q)8YL![L,PALDX5M*%=ZY+R<W01]5&!EJOZL?S+Q65@6B?? /06MS&:;RI
M-VYC #JPB=LQTSXI=ZP[\&A.A7%DA"A?L0*!]6$)R=T*R*EX7@ZQAB=WG[Q"
M:OAARYWP>L05I_(2PB#I6YU=!O<XZFVRX-)Y?(B9UH&1^C$%[6ZL\SHW,XA_
MQNR]H5B3K,$[H#E**-[HH>KKLUX9D>6$5Z0+"QTR"KS>E<MAES##!QWK.YYX
M[+MS$JO:#$O!"#,^3-U^?GHNF*SD4@!)(L\HE-V*1^PBQU,)5COTZNRAVT$-
M@C*Z"?_S:2P%!<8NT&A*SCIYI.XWCRWM4I&\X<$%^,*:D0*3Z#@#-G<H,15L
M/3(@G.>E+!2.ER BG-1*.=/SMF)YF[!70NZZIHP%Q#7/!AXTO+PYM52<V2XP
M9F#@;$?C$>%4=#;OWN!$/-.QT97C^D2>WA4(QG6UO+XI]!1T%3&*8.,MG55^
M!J&>Q*(/U(N7\1PD%,UZQT$K6_1%;R-!^YP@=*?*Q^Y\)B*.YQ(-C5C60Q>*
MJ["?0F:DYU16$2E.H$-^W8,DD=H\TL:_D[/(O+^YZ7K"+Y^GWDM%215,:[<Z
M?9#7?EM]SY5^QC0+0["%MBQH3YB/G?:71HMDT:4K7&5HIU?2;SZ1U.@K-86[
M:]FR@)XPNI],%?T&4@V)\RB G[M\K49NO'(*5J@GXI190QB]1^H:[69]RJ+!
M!'SWX4(I_"!POJ$_K]U<H<]H[&P^[+UY4[*#C*'/F(3!70FVT\R5[B>Z=)2;
M,@^$'?$'4H-9<"A!A]1C*(%\2HGA,#*N$=E:F3L5.,YLFUE^4IV0Z0]Y^_1^
MW775SR\W8>LJBFJ5C$C(5U <,BGI^%+(1B2U&WK=N@8WD#"!W,M[4(*NJOO2
MD\IBG)DO\ )+8W'U4+Y9)ZDS(&5'/BLPW[V>W\*,,ZX6?*VTR=GL75I1FY0,
MHT=:VZ8&O];JRW"V/C6XHJGDR%OLE5Z?QV=\GOK#Z7694\056I<AX@&USVM/
M5@RU:JPKLQ_'#"X>/]%<DFN)3>I4,F^S(Q09EZQEK""@V>ML425K,2N&XDT]
M:'TC/%B54"W/Y\WBEU7E+X1S,V5<(4&=^:QUIJO*EAM"I5T!1U>@:J%+Q>)%
MUON?R+-Y^U4ELZ:ORT1/N5AO"%5U!] ]+"-/2+]7 >R9["1(9'XSTTOZD('-
MP0ESX<O=9O16D6:<V2]]KM1SU9_9C!MPL#AHR)'9N(IXY;G*6PH^\"R0NK3L
M:K9J?TWN>)[J$L^M[.,OEHI#9JZ@2?-]T"'@..J-BTX ?.".KH] MC-G7 =X
M,7[J%_NF\XS.[L3"7LL#C@,PI%!2=6(P\*%";&D(,+94CTKLD_J.J2[Z!A-9
M/_P#[@SJ=L$X.@,4_L]"L?^F_^5TH!S)3%;2D<&.>)R#@ST%"\5.I,?_N.HU
M;$F<Q?IB82]I V;W8)0'4FDN#9I@#1*5(JH$I(JA>C&_5&1=NV\.TO[8+_4F
M5/$E4_4*#ZV.5/13K\(^V_"D4]XV;T+47C*1 )#XZ#IV#IW)XYG7;7]HK XV
M?#8^W"94@["&/E+1V;9J>.DUR*.SS?R#*S[SUP!=8V9S9O, V$SDF<GX(Y\]
MN\8"@WJ=LQ\O%QM6$"JF)@KRBVD9'@E[*@$?=IP64GF$K40&/\8.CWEY5*XX
M\8TK!@3HFX%+C3O PB=F8H I]I/82Z_>LZYH&L8HD[4YN8T/*E3S1 3]AN^O
M24/G508?>>:_8NP"/=2BU[1GU89=P#B4A:@G@.4',8N #WHB5EI+L0UGLE;2
MDT(*6NP;Q2X!-Y8.![-FQ7]0J]!1714$?D\23+6#C%(T'?>\T_W'1B 2I5PX
MDAZ7NX68M#(=]_$"_UA,3/%']= Y'YV]]AAKS5$!*ONL>&#WTIRD&A0Z22TW
M>UH<J8$*>\E9^O37]/IKFKV)N<F_IA[IH6J<"=$PN'6LM\[:=E[]0N_MEZFF
M;OK? +;5GA@S/N7-X]!7QG'K<PE1 21L%,H#JG*Z2'M :9WO<9QJAFJ31HM1
MF&<NTXMRQQEG/[EO@#%(G*,)\>KGA7[MHU&9]F6N-!B)0%IMSEOSZU+3\4]9
M9Q;Z&[.#!]#QE5,H%8VKY7+=;QI<!E><]-[@YIM;S#.<\$$L*T+*$+IT=)50
MI-$3+SR]!);0 FHP,4QFWPL2OBZ4GKZ<SS#36O&N<N+.Y=E(CE\FG>5D,T#"
M3B/V8D4*R$%U#V1T99*:A(<F=ZR/AN PQH3E/M&Q@S%IR"_GKG.7#_4] ?-;
M\2@H&3$>3I#1Z_J7\>41#!*)_!^WOBIG]<P(4#D4]B=! 5(.O:2AB*=  3(>
M(@[VW^= PHL3OY)C6PPU95EE"Q$Q%TIC\@+B,-#S)<8L$D3EEU?>@N*L9D'T
MA9EZOS@Z5:271JBIV"IEL[J@V?J>LN'J2XZNYP<-*+ (D?4R_F)2">J]AO[-
MH>\2S^VI<GB7S5S9)G?ZDI]'@1_85OA.'6Q<2CMH8?$.>L+"K?/M [Z7<">1
M3_B:8W9?'9UZ(FV[IMJ$-=8W>I\R:662C4TOS=;/)8N3M4$;>WLW&2^V!KI#
MP./8*T$EZV0L!8MW'EV<M4E"A]H23%]] U#E17MYJ@8&#0P@RW'W*DD#<JW*
MQBV;OA/MKF6Q%;NOCS)B/CXY)+D<EI/WV%:A;WXXN\$8<?;.)KQE%D+WD1E2
M=:6U&A\65/5(2D!+GE[*MS".>>1#02V!L7OJJ_.*H6DR3:7%BNV;. _P/7^-
M<_R#K29O?7O#W-D*OP%P0K(>2BMZWP"_MH'@4HZZ//%05Q&'^KS N:_HG"S)
M  LD0B.M.M>1Z8$P__#]_OS8L,%DTI^-0G\':/=JM^NO!2TY8[K^J7K>N+B'
MZ272]CG]BEJ+^_=]X2#A&AE]CF 2-CJV!9ZBMSQ:J,'*6TXV/\\V/3)*2TXE
MG17:'8ZS4Z*;_.ZSJ-35M)  &,Q?^@;9N]>36M!^V $0JPO5>D<MD.$A>4,@
M<TQMDOI7691=@J <'HJJY&5D'MXO,Z\.?6!VO N^.?BTU#]74TALC$E">=U
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M<9ROVX(AO#.D=6JBV+JB1_<;(.1)D:24WSJVQE5//)Z3/]S,_C0)C(G[<PQ
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M?O7]OGQQO[[Y7VYPCI=IZD;/[OZ6\;^CU#!%MQR@H.NJ%N_T_E!_4C:?IA2
MPQ@H\A_?<D5^9[K82:M_VC)7G#<%"?@'=_]O)29@9E3X56'Y__:(7Y7Y_R<B
MZQZ=.Y$KQ?<+$6_[&>[OO8M3^I]_B @Y0-$%,!=_?PKROEKDC;[$/^:^=O;N
MK2$^]W^EQ><@D[5&W?F/E);QM^#[N_3OA6-Y^-_];.<>=/\G//[^+_G_1L19
MF#'_@->?V'%ZKQ!,+^<I5^+K/7*6M4?3X'^9"/"RK_^>X;Z:5+TO_]084YCI
M]Y^!_==@@?\=G&VOF;L;DXOJ('\W.[WR?9'@OY9F\SEE_CZQYN"(%D6+>G/U
M;\X?&@^7-+[?<R OZ^NOA_O^67WC/U9X_]^** 4 %K_R'WG1?[*<Y\EFDFG7
M/SHY[V>/U!M@1H^_U?7IZ@T *.*U^7\;H'O36<$8+=J_UP/\#UW*_R_L?.O4
M_*HN='AZ0*?F39^K/" C\97Q7ZN>W@#*]WK1,1.*-TRTU*GY=Y5DNDR&6/NK
MNN5_\,J/Z#%Y9=:7/U=>U&F?<ZVSMW'/_C_O*RNX\NU5/N^9SK^G!E>N'_^U
M[_8?^8D;Q9"9^9O]/F<F:XB9G)SCSO[U7OROBRG_!VMYZ1!3_F]T.OE/1TK9
M>]!_Z-<.@$X-\W <Q[Y( -AMS_1>1(+O]OXG%&/_2_[/B=8LTW+DWBD9Z;T_
MW*L'AO\'KG1[ &#BE&L(^+-W\?^4B#JYO1ED<H<7V7\WUD7Z/4=[(,=G:']>
M#AH@[>S\9O/OC!UF;(S^'35^58 J_25<[(W@+I_*Z?_KIBS,L.XOFPG)'_++
M 9OB?VM1] ]0>Q%W-1( EP(Z,Z]0?.4-($K_OT @_/?"=$57CE.-,_^N8=8%
M$V?F&1OWN?ZQN1>CE]MG^RPF5XH[>Z_GH3B3$O9;%C/Y.K2O9Q\2;*_H9[*/
M-X2JGY7UYW[^TXO_?!3"WTMR%E3W%V\_JGG!V/# [)M-)C.4Z.L# J2DY-*O
M'[US-U<*("7J]&?5]JL5)O#S:*I% C1G-7ZQTKX]W!7M_7^:PF=L^.LTG?ZA
MF29SJ8NO']^;LO+7KF, $W JTX+3=>XPS^QJ@O-3RN_-&__XIBMZ&6]9,N*<
MG?_\K,[UD[^?R=_QA)CKAYA&1_D3ZYA?T&Z6<R#OK[]^M:_W^I%KV?]D973%
M>?^8-J@'9<)F>Z#('[;]ALEDQ#LT_]*)JZ:GSMF9E\EBF2K[340*F+?/V;F0
M\#^22OQ+_LN(B)2&?(IIS\&4UF(!VTV""#E[RA'9EM)T\\IZP<1AJ>AL(VW/
MC_0S6PT(H"HL?!?P\FVPW[N N^IU8'\>]OD,+RQTLV\1 B8=C@A;GZ62['=^
MRMB?,[/MZM\KXE&%Q1BP']B&/QZSL5"/S.YWPCYY\CV[B&I]XV$K,-!*0<-B
MKD-_(B_C%?*0%,=3IF__FDY]US8Q4H/)'A28H5T*F#_PTG"_23Z3O_R5"* !
M6=D9;W_-@?\[%&0FYAX\64._B!<@"PK6N'X2I\0DS4Q_[1MXWP]0%:_.Y=4K
M?VK4]R>%.G!%R]FKM^+ML?+RI[9_YH9,A- 2=RYZ=''?8W$%%G!W#6:9CK.S
MAC6H;.-UI>8T7L=.FY!E\C([F5?.UWP@A[)W^86:NEI!!#%WLDPQ7Q*A"L'0
M^:42^,3T3VA=](O!IGD%5#$?D5#5S=!YMB-1>@I;%+2JD2VL#N."IX052]D-
M4J+$:.9O3(J>>EJ4]Q9XBV:U.#MER3*=]J\XIC=R_;C6X+[L?\JZ]UV-5&)B
MY0(2\##IN*")X=5LWO6BD_[F6Q?=/*RD=@'1)QZS8FN<>SP5H2!#52MH7-JJ
MQ)C6R$F?%34YJ6TX.H?QOK.17)P=ZG&K]726W_U7"KJ/"0+Q@6M/%8OQ6^AF
M$4>[8N4HS?/9OP:U MZX9O_'L9F=21"9W*SY+U-0#O#JI4)KH:RY)F:K_HBR
M%CW?'30)478E (]6<LMI 4I<=/-36,NR00LQ3XS:0J)5S,IB*Y^,<?@V!> Q
M'_MB<V2;Q)4%WI8=FC4H.BEC2']*KK1U;9=\;51*2&WMU>2\\)]-2/@J8OZ<
M%99;+/;V,-C\K)X#]$S0S7@DH)<>7[M/>_#"#F.;V@7OYCXN-:8FB< P\EY5
M"SAM4PNX?;OMD/?"6SU'L+V"ZT1ZUM8MR!CGC[CM>UJ[@,2Q8O4=KH+@;G<"
MBI)PY%Z> 'V-Z9/8B_3,G<T=^+@DS4Q]^N,VQ8R1%[8#1G0EX:$LU,NJ'5T&
MB\<@LL$8R197K*CV^5:DNM*,?#V_]J/&]1?THE2>#+Q362]=&QB?0S4<OKC1
M#"T\Q',8&&4^/*(\Q]_+3$RA&ER)<7Y[#G,^:^3ZJ:QF9J!^F_TK;4S>:]78
M<><?:%<_(55/Z.D^YM_]_RXT7##N8T4"=.$*KK\W46+GR73]HVGMVW][E9RY
MR/P6OKU,EYU)"PSW&U7\\4RZG4"Y[S,_I+D-NIN*?/_)7'B"HP_[W*U];I0^
ML;.4.<^Z"P@ Q4''6+GP7^7L:$5>C*(7>\JHR0Q]%PN*>*Y*W/M(8+"2VB\%
MHP[O D)*ZND#04_JE]!)._Y!:(C96RSZP,@V@ZE:]5\?:_8QV)9ZN M(JR\6
MVY9ZR7R12<^D)"@?)KSWKT]GOB^#S/V \TE -$U6O6*1#X*/.*D)G]EZ]!WG
MJ,062GY5S#/G9?G)>2A&\W#7TX%W1-D>:3VIJ^G7CPR\R7*(YV8F6#JU@XG_
M8$B_7[E PL&D.RPFD>^(@J3Y>[.TZBY9,^YJ97;QQX4I?3 "+9#,>69;F% _
M*I@:,$9:C PSB&M-B?8G<M7SLR0CU%=1X$1KI<CI9)4G0G.!<0+U[N<_/S G
M876PLZB$  6:R^CM3%SWA$WWN"![L)/$V>\X.\O#$LHIQLU:.:W9L<Y02:^Q
M8\A$3#]&7);)LT4'_\CU#D)UC:_H5#R+91*T(W_2+]'!O<_\(@U7],%ZY;\7
M_QT<TF(>M:_NXEDGH:<7_^X6V15YAR17/B< &,Y,_7ZGOJ__.ESD%Q971-O^
ML?CB)4-:SGB047P'VFOE_1%I8'@QO2HR=Q=PU#[CW1E(%^8%22RV_E- =SKW
M.NHD/DB9SS\#&Z2XBC*//01/Z)TR;]6*+U/#0]C!]=J<MJJVXFI44"LO2TOC
MDW:514(=K$%-12FT>]11;<7L<]?K6HE$)4YY[5KM:_'9=Y#3*\H3'KSOB#<Y
MB(GX5(2N].93JG[.!(=;ENR \;&_9;IW_\U4_V%?*+=8":EY^Y"S][&;LA;>
M@Z\'I\4XG:U I855?GUN NAF:P;VVKT7Y[8I?,$\FA?VD5FZRM<>7X$+Q=*%
M0DO\6JUU:*'%;]U4OAB2)JJANI;L)K/O'5(-#??FL=P7_8?9;?^2_QZ2';!E
MBA_L&L#.%L22KHT\7FI-@[T<0.=HJ0/A02*V"L2WU"NGYW'^/F"H=DQD2L2'
MGY@A[*HB>EVPV>KU<.I/Z)QL^8AD;\+%S,@KKGQA308_)W28'L&^"_ A^#D_
M5K\F7YREJVRZ=6W_F]Y\EO#T+7RN(\GVR$;A&W^>"S:A!1C4T;PGYZ4BU_HB
M*)O!4?LG9*RU4DCV*0>"J1#UUB(5U_7"S-Z 6^T=B26Z54!89DZB9/7*R>+E
MKGTX:ZJ-Y_@N@/7H_N?XH6]C1P?N$V.,4UZH^I@::]((B9&2%PQ_,9-7[TQ=
M'Q6./A7)*.0;.#NK-IQ6/M?\!)SQWC++;57NH]N;T+\E5"VOI.2'98H!=S2U
MRB1-9O8Y98EQLEM)]!P<,'.O%%%U,\M_!A0!D*.-_Y9=93D<)WR 9=NL[%/E
M!,VW475E7JWG.DAFX#B/#1=ZYYN]>/+>EIDI/G6FZOXF)3I^][>,MP_W(QW!
MU^]HWA(S,3ZPMT&44Q;"Q&&CC0Y]\Y/,$+=W-UA.?"^)UY7[E1L9=3XJWXR=
M^&D-\%3"?XFQ1-)'8.9.WZM+QIJD0J#+]:QW-=!^5<PE2HI(B>P)U8-7"B*3
MMGS7?E*F'&K4'I!SG@W>L"G+R$!( "T5AII.J8?O/)$)']O")PND"]<=@D+F
MG%4E?.^#Y'$<-/;I1;,M"-OE!W30M<&'4=_POISCN7/CYZ9?JPJU-EMZ))4@
M]&CW;0]M+DWD8QR+G6:1]$)4)RPMAQ/XH=> H[],+;)_U;[J !D'DSQD%;DL
M>(H1O_!\=0:I7U3VGHP!OWG',V>2EQ73+I[W)4DHU8K\QX0LINJ9F6\),;Q.
M3V%^EJK?"9(R,@M9%EB5N(O2?#[YQFBO3;.Q Q/4'[PZ9J#HM%]70EW1^<=T
M-I-?&U_YC7K]N%[\3\M <>RC#V\YU'7O^Q*CDY]C)5O1$2)TA UZ(4WXX]9U
M-\DNM,PI'F%U*3^&7^3%90^.=\E-X#9I;3!EY4R\WS10I#YT+;W6FBONPX;+
MM6**N;$61UYY5WVC<D4)[".D1C*UUS4@P4;R/7U_'HK-KVPP-/QU9-C\<=VR
M0M-[G\#B&=>=!Y[^;A8YY<^<]JV8JCN!'W>>!.AH"E7\VI%\]<YP?Z\AN@'E
M%SUV;E&_H1H:6;!G,<5]E7Z7&B973,P:G^0:_VU*J8Y1.:5\GQ2GY7Q^+4\^
MUS@X]6D+3<.UPE95LD'EP9/9"S_2F-<F]@I8&RC9J (Y[2Q09\4VL$Q#:,14
MUL=W46#HI?FA,AE@B^5G%<I\@/+I8?2<>:7XE%&]+"6-_]6G$A@:O0LPEXQ:
MHFSG6V=7#G/2.;W57J<WZ&ERF!_Z\%]@E-VOC6^%$6 ; _FC^?B[B4@JWP*2
MI')_Z'[\++@?%)>J[91VF,;7Y XC/Z!^!BX*WCG;R')Y!SZ["^ J.<;CBTI2
M,<J3&U%7I2XL;ZO8GS6(;B&\>>AW2?VT0^MFXT9?&XW+GLEOP^@H\7X4V!8
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M8MS1C<)8+.TZ:WKZ:HF!(<UB.,@/^8>!Y9^J^715P;RYF(A,A;7(![/RY!R
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M/V)[XMAIZ0E^Y: GU/2S5E;G3\QO]%LX7BIY21=P^M;#>)8O-=!WVM,&)JC
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M1YX0H W_)[70Z(T,$$$&$S[T#H1DQ%NUW>>M2><<Y9YPX:7-^QN+,H,%1DK
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M>AI/AL!'<U^!MP73;A_PU<[-ON_S8AS='!D_%8> _@3T[YP=DLH[)#([:Z6
M4.-KG,1^"S/0W:#XEKV9ZX;Z@J/=$%WSMBW3!G&AW+9%/MY6:01X!VMWL;]8
MDSO@9YK%;03_)B@:RB5FD%#5(DEQ-HOQ$50UCLZ_S<P!ZQ'(HT(G1=5Y-\O&
M=P'1FBNR,1L3A'J% "#)L0*C>7(46\:0(3E67=Z_,3N*A<E]<>[T3PZ2M#&9
MD_15V7KTO0O6$20I?L?"8P;6&Z"LGI[[@=K\",+%$9@(R0[ G@47:/<3"/&.
MG\=X1!/<1+^H4K]@>Q6&6,2* P_38L^O1=3S+AD6KO6I4E?O<M;%;7A)[PQ0
MY26_XT$'B:XY=;B^9W3>QJ6T^+6&IR>(&!^^\?$:UGB!X&,_F@DAJ@:@X[HF
MYMJ)UCXVE"E/=&$R7N6*I^MKH\)Y24@(;,WC;:T?Z.R$3 B50_^6=9TD+C-9
M&]GJ>A=K7DVKPV.6OCX^DC<^D(/VH+/:9)(6CT;Q"$ZVJ!:VPYNYEEG[L*&I
MM_':8<8I.=TV#$=2&Q?EG-7J*JH"RTH-I7#?<%E!=:'"*J,KXR;V+%\LX.XC
M^BQ$)J7'"*3=:P]/\7+L;W_\?@LD2XIYY-Q3CXL^-O,^_NK7L3EB=( U(::(
M_4'I%Q0BD\59'E%8J'9[F"X3,<9Z\ZCI'>HHUH96&66/2=0K,9@ 0]BVK>;A
M0HN+5!NGRC##^!)/R(?[C^)R.441H;];F[:'A[='='R\=7?H-I]'_OS&49P
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MUL'.U)AM.F(H )0L,,!0]@<]/YA=L/!U^V!G/5^8'N*<=1LL @FA_@TBRQD
M?VU< +DA*V#[70*8?R=JWU]TH"0LBT];."=VU(=^98)YK\C3,+"PAU)8\K J
MAT2;>ZG_+7$*NEWE,'!+5[3C*KZ"J/J!OQ.[[=?^[Z'\3ASJ5>H@H@0@FOCR
MP54S&7S5A/JQJ_A\XN&EB,)P]WZBXU'4,(BP:=PL#D( [CN&A)\N&9]M-MFY
MN8H^]&W.HVMJMD*"]KZ]$6NZHB^V)_3WX)Y08.U4;.NNM$4!0NP,$.!UG[_
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M P*Z+Z\C@1T"XYZ0:T)3JZAKL;XT&@P7(HO^_?/%1X0U>?1W%\!9\*(P'59
MA:SV;?//\AF;4[^K?1N 86(;QX:TP&3"SO ,!*GX'?\#\1OG ;AO6B":YC W
MQ[ILBMX'OUP86USIO8)_B]* /W5YZXTO03B :0Y[0J:<-=H<JD]WVLG;SMPT
M2,]/2ON,Z'[F::Q'^GK8\-UL3_E:X3/TFU9@H@_.LB:9G<*.HU8R1_T<6!K"
M]%<6(QO.8G0NH%VCLNV]2:(!?/Z,;B_B:8]/LT^HU7'I1L_!L\IK<@72 [$_
MV%UK<856\CWD:0>+:$2PQOU/VSQX;SZ!:)!19EXT^15$MSF>>U=]8=2ZU.PY
M-H:@6.MV%:\Y+!O2*:#?OM3,AGA>//KP/$'CSXG&]/6Q=;Q3@NU-LQQ76U-'
M$5)XLA<Q;@FX1@Y/=NO0*$!<9W0VLW78?:=DCB&!JQH1GS7@SI*/$H'S6IY)
M.9VD%,-.OP+F@%LS/X7);O=A52'-D2'3J7M"_Z +$*^8EKM/IQ*>N6)/3+SC
M*?<Z_2VP:AZK@D0EU*8NZ2>R.CFO^*!,NF--ZU_\%(EAXF@UZ3D"J4'#>B
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MF"=)3P0F08"=FZ+12?6EVUA<4+UQM#CGJ(X?3.+:@\3YGT;YKI4_S/@X8HJ
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M00268/[@!E&J=09"-;Z&!LICX'EA1?WUGG,(=73?P**C-BH,'+WS%:&,X;F
M%ZJ0(HA#S# ^J)!+F0)+B7)5IQ(0(K]/N'$I(RY%76[SJ0MJ_"P087.JQ7+C
M)@?2'2K!0XOBD-J,M_QU0 LQ[B)'],A?3( C1\E@V&2S'!LC/K_\' G,Y:#E
M=BYSK6 GELULO[T8)>DWE0&>458M7J N&MEX$ FT^F<=N=A0-CE^^*BZTI=5
M>*O72H9>R^TU6-ZOC"WC^9_%)'C)IG!+6/O+V\_AR^3(T39SG^/CP%^BPG3T
MHS?@3$E\'O\,[\;Q\H??N)1>MW=!>M5('1A4TP3@9M]=951>I&\%32[]V6W[
MRPNOVH>2[_ R7@-#HV"<MW'.Y[:SC7&(E[EZ/[G&4)TZ&EINQFC'2!2'L*-A
MM@^!=X8VI]KQIT7^Z8GL]9LDNE"B,A&=DZ3K71ZUK9:_-J0V+&[F,RRX;?@R
MU/&:'C%$R2_"[CH2OH0)QP(-.38AF);>+)(_TB[WLW_?)OX<I]F;[*,N[.Q4
M11V>>)PW6KLG%"-]H9[P>H5\@*@27Z>"M8?J#Y+_U0_SI(<HGZ''1S_Z"!\A
M*G-\<W-L1IP4B[6@O4::/:B(J#<E^YVIFB=FTB>#+>[:?[.2"\&',MQ;@UFG
M[Q0*,$:?(V%OZWW*=PUFS;O$3*DV.^X&7?==RK>FA5Y1-T$8T7BG$UZ?D/ Q
M]>%=$"-SL?U-:%.F:T*;R8:&Z42<365 KPW1C@:_Q;6E+GQEO.,?[)P$]!?L
M"44H'R[IAA6$>774N![4Q_EQBQ)4<7U$U\*RX=?Z!I*K(4 $H";R'B*7TM\P
M=8"CI*9?<?RH#2B7*3W0^R6 3G=4CM!W%*&?MSE06O1YEAU3)*T"/9.P"7;_
M]'<HA P0!P UIF&&GB>/Q%TR+D"L,!\;E&E,6[Y";=N2_MTV[L#29[@9TY=_
MK[>$X0*=!"\P,:#"VAZ!J"C$#Y.NY_&TJ&4(]P'P_CVAX9LP>#"0?QVX*<:T
M:$:S7E-&)P_M";TVW=V/,/)@ F"I"*59"B],@*?"G&RV&SZX_G]VO/DU=8K\
M3?O90U)TD#/HKQEL-%AP5TJ*(V *I;V$/I[)[D>:AY@/H/-1VEP=P"_C%AL.
MYCX']EM.(.$K:^'HI4?<PQPTU0]=8,C"U_!/H$NB?HM-K_3-JVX+K,X=W"8^
MBZ_KWH5=@"\,[Q02@SC40R?(G;A@20G/XJU*4@M(E),N^+@WN_ <!H:'5!ZN
M!\3<KQESF6[RRY':'6I)IL.*#"=CML=)L4AG1J*A311HB(5_.6=194SVY$11
M*XB?<1(]L=R@9M0ES+=X'T VPNB1J?GXCNS^6TFK7V9\S1R017'RP9V]X&M-
MHM'B;AU+VS4',$ASK0\?2D?'0[X<][,IN]02:ZI[[\^^_P?^L?3?XW]OV* *
MT8'P&U4LL?'(4KV8Y1!R#'8V='W"$Y9=-JQO[-9_X M>9_ARB-38GTT\A3?0
M''$U4!10ML$%%Z=VNS71<_^/F0FV^=UZ_;*?E-RK1E YA+QB"1X0G2XA4ZJ'
M.04&:[NC7;H6/'!YWR<27+_]Y>T1T1GM\I0W=&_)0NNYY]<?"CY4;;>QUD_>
M@ NE['/&)'F#AQZ8.\.]:;F7RT'0T7[>I>Y6H&-O'/5CP_.4;_;'/Y0G9M@&
M*0>Z!J-;PP+?$!9"#?Y] 8E-;36Y;>4;VY^H"3!EJEC[N1/NOGD)L,)3-ZR&
M1N'J2W-+_G(A-#7YT,HQ)QC>(U+GZ6'VKJ7%*:-@O %3-(K7TZ86^BZ45Y09
MG=<=/'7QFWW]W8\/'_78#C9>6VJ+V 4J5G\[ZQT.^5P@';T>XFJ>O86EX8K_
M",W8:+?/ QL\.U'>QQT8ZPU8L[UVO*G'.L265 Z/?(QZ2KDRD)[/*BNR2'7^
M,=0 %FVX?:F0P/;(D^BYG]A_>4#O&+!?7S?W[6C@$$"$@RAQP"\ZI>4OPH_>
MC%WWE4R,9IV__[F\LG!L6S-QL+X*-3,T&_]W^>YM\7A*<MA7EI=+B$7<E/?2
MNN-C])1VF$2<*M3\I]ALZ.<8^3LHRV%BVJ'+'Q"KZFH?&3,CZ2C""O&83PKP
M*P+\X9MLV7K&%OC0:+5INECB)9,\!P6HP9\ %GPS/W/7[@. ]3B&N(C_PSLL
M^YAH>T_T9*-96_]*4MEXH_53%^,O>!FF$D;AC<YI"NG5&_L<.36M-P/>X'[A
MX29X\YMYUY *;.[M*LQ;UB;^/B,RA_GT:T66%44]"B2M/H];%,GTM1C,W<B5
MERJN3AD[&?O#=5P3IHD.YFI7SA*5?L1G)HYN>$%,=);OCG(!5OW#3S!2^*M,
M0%15PQ&GS])-U?KCAL>\+.2U)!4V<3W*#A>3-BP#-$3KOZ(L[?:$1CZUA$JS
MQA)NA9A>*B3?K&3:# &T=>\QG6;!VL]*YHJ*\P,R[K#*#<(U_'S*38?5ED:I
MZ9@>APTM!Y.,IMUTU9X?&<,#^M=66X'V?AT9EV93C'2O]W>7UXDMH:3ZME2R
M;(*B&O5F5[Y3/GA<"X[4[ !VM#V^6FU<=B/JPN-1476-EDKMN38O1]"/T[%S
MA 4SX$-(]AFRD;WMNL])LPW"L]#P*4V\$?/ NW6MA](T;1%Q(^?U#*ZJ?@HF
MN\UP')_;LS.+?\HPFWW0^,JPS\4N32644LG1&?I@];5<\[GY&<G;U:'G=OLV
M"_)A]:"WA%\YORS#!HK?[SOPNW5R?D'AO;\6\J%0(149/,NML-C[@//[8QIM
MYNN$$(OHF>W1)I\V\=FAC\ NWO6"A@8$8?F12^I\2FS<YZB_+F,;RX9U44X7
M/4W\K^J3ZSUO;]J=1@XXM94:YK7'NX9EI(YNW*J=B$VU. 6::K(#CSS@2ELL
MIULXVT)E,IU<V'(*K^?G2D_"3YI/:>MNR2;\''S-";QA_-V3<DZ"^!VLW0ZK
M[(>ZR=KT9E,_*[BB39>K?8[^>FE351(=;Q.YN5!G< =YI-7]N2"6N7*)9ZVW
M/3O2<LL]26H^S4_/W6\/#BBKJZ(4&-Y":$;_.&P6,26G KW9XYL=I5CA@?+W
M:@])BZX^5Y XRM:+NW_N1.RL=L_1V[AUBM?A\?AIG'$Z .1D5WU)[L)6Z"O[
MC_-B$W24E-Z[\%W@FX8?+D97+)U8U_HRJO2O]KV5B^S(I$7% ;3];8@7KTB%
M;@P-S&(J2U*O0H8_6#U2,Y>'^O[81'/NW)TBV5&(&LY9!KZNA>SB4:G\90]C
MT7V6.)VGD\$?C)TC2ZH3'IL4.EE 6Z-,4FUDI1?]S^P?-E3T5"DVDB\B*X4&
M1<Q[R#MD3 V2IL=W@<JMG]TD*;&40:MW!_%_>J\;? 7>6B>)F1!R&KML,MF1
M3?9MPR+RH/TAO24?OO:B+&'7P]]\+HJ*O<N5RM#'$F&X,,#+,3U@EW^VN.$[
M1&&3>XNXU_$[L60IA>%7+>V%H88D;DJ)=+I/&_ !A"S'B3-1'K]<C6%;]+_(
M\9M6:FD*[JU34O+!A?G$X:"&B,/K:G"CI#FP&O+ ,1,U"U$Q"3_Q#I]W$#]J
MW:4N!UQ.W+F/V^:!.8 !)QV'V$6\HG-.O"/9G+&#B',T\(,>-13S<SPO(#"E
M>E^YAT-O0<E#OT[:Y^C91$ :'1E)]VK4EC"2S !L-P^2Y=0Y^W4*ND4ZY>'F
M-:464H%[3WK7=@&/%K&#=C.8I[-7GZ.?C+5?==G0A"C^F!7D&&C5CWS52T7K
M>//!!(SN&_/4RS*. QIBRSDG"*,E[<^(@!\CCB90%D!T=%NE$1(16](==@6*
MJ,]622C=KZ:H%J)<?G^0NI$G/]JXUI8A]4YSS.G]8J--P%9JE=&X&Z$(9.3Z
M0/;K-MVZ#RKN_/FC@EM-Z!;V."<H<%DM9*Z$VGGL&:D *2)[X\T@ _YH-%1*
M_-I8B['VX")1U>7^!N2"4IR">\1EQ?S*+>URZN'(9V\7<S"B\<?Z-OITXX\-
M;%!R^"SD$Y!?Z#  \H(TK."?D1;G6*_MVDZ[JO@:,92L&/]I2SO,O$_!;5\)
M+N3L/M>>JUIUC,GW&Y=F* 6+Y2[A[OV-.ZVA9L8UYYH =Z)<'D(BHCVY<AUG
M]#P?!2??W?C@#?S:>#W_;5+B*/=/[@]S*<F>D/D8_S-CT5"*B'U*4G1!-T8B
M4V?E+F&PVVOX,R'AT/#-B'*?Y9#3NP-.W"PWS*&.^^[7BS@Q>9T]4#K-R'5G
MJ,.XZ#ONBW:9>]'WG[\HEQ=;_0JS33(D1EN[BS+F HZ\W*Y(J0Z10BV6=_4<
MNXNRO)N5=[RX0#[[I<7DX>5&/24[X &#8]>5)[2'GERSS],X4(V[4IO>5SB(
M,670$66..!*W?IH']G:VIC4<^=WATJUPOF_@_XT.E_\U]OG4HU):.#V5/O^C
MO>\.:G+[WXP7$4$1$5!Z5*0+@M*4$BLE"$A+()2(2!>0$D ,04"*&$"0#M(#
MA)*($J0&Z8("TGL)2)624 ,$V'#O]^[LSNP?N[/E^_O-WC^>F<R<=\Z<\RG/
MYSGO>\Z):'=5_%YN>>T%LR0KY)D^PK6PMJQJO6CBM5'GZP?R:PEOI=<]#P&P
M/8:IVE";BNLD/53?.O"-RBD/X>]_;@V<OXDP:998HCY#B'O8N]^2VH[Y.I!I
M3Y1_R66N)FN^&?5J)>'H, 2>OA#G\ZS].A'G&R>L^S+-T]I 60!/D[H9K\*L
M-V>R&]4D/J(4>X (1 IY[S?3"D3(JJ/I]*<]"CQU:C#ZR:&-DBDQ=Z*CIDU#
MC1,>J<1XP,BTFQ4>!\6U$@MRH! HXX LL V?%B&?F1)A6G7C?0]267CC[6M1
MM;Y%%"O5=ON<^D.--=QJG3_+8.G+K'W)>2 C32&2$9T8.F,I>..Z?O?5K>>)
M3%)/W2?.$ 7\HI^(J*"X-H A&TTE! ;NJ90<JKLD]\ ,H+_[8L1M+LKF[\J.
MI=T".6/AC.*V:'/H6SEV/XZ(BF^XX8SD/MOCO/779[S5UZ*NEU"^-%T[EC[^
M,6J @"R9=CW3:N<F<A;-NR].F7L-6>.12:))SG2&39R&:0E+7O 8)E9=:WF6
M@\0I,_KIKY5%H7;]OG9RRR^IL5 C^Y69DM O!T2+:<KE9=%A85'U):2?^*L3
M*Q_QV:D.4(U@-H<[Z8\6#@'<@2/H[R/]%?CS2!-%]O)S!X0I!^$EIR^S!=L*
M PFFQV5QW)-8=:BR,#I_V@II/,U\#>.??K-(0$&Q5X2'I[78'GG!PV<RUIH*
MS?"Y1BIJO^X2MKF!FX-\X+9_WOP!W-WK'8!D&3!L'K?T9]EM(?D'Z:#=%'YX
M%KF&' +.-$KRV->"=T_=(6]X*2RL31&5@9%;D=]V?YQG&UILUU$ ?AX6:U;"
MRU-+1'>OUMZSS($^]>&:!7)<'9[M?W3"!P]DH]T?6H(<\&E\G>"5+FL'3<-O
M'0+L_1L[*7@L4<;G[DML[@B/ZDMHYQQI9F(K'IG;[">Y01.PEX!4[*3=2MTO
M[E:-FFR:7<C8#=]K()FME+Z=EYS"OU9C*R<D\V?R1_9MK3;PG?]""&./E/RU
M[M"L,[B;FG5=RWQ3?B]HP3P=G>)<E [^K3%&DXRG>(J8F<HH0[_5[7W;35KJ
MC#RX,>J\7LM+76U.&*QV+?;#4_P;/HV]&#%*JRG\U<GM<V+1J?FRPN\%>/8,
MXF(6KC/@![;-X">6/+N-&/6'[;V=S-F+X=C 1QT ?<[/GLIOC:"GSU MTX:#
ME'6HA :X02'61H#5O=(='=>9)Y<P8<V]A0.V[+)MO;X.J.AP^MSE7I:O6O"R
M754Z-H0''X2N2<5%?8E],6U- KV9.#/R(ZZ:>!"WOAU6*M+SU/4]-[[K$!!F
MR1BYR,/2DEY/-*9&D/MHK5Z-_A)[IVME9L'7[5JG/THI9\_N*\)>\@6T<LO_
M/F"FQO2_//:>>QO'9D1]Z7:\,6S08\'X4I?T4DJP%?R.OB$NZOP9S'F_.S:4
M5U+E@MZNL%\T.,5\5/VK=GISM?.5Z@BW^((O$.\$4U*$6PL#6'KN:4D<_[,;
M39:BSNH:.Y_?FQ^\S]/R\SS#W(H+_%[G#8TYG<V_!\WS 9*0$5=M,E<7+&**
M=5][*F6K(V:\3*G.DU[E]F_06\MP&/(6V>=3R&5#?E\(4T-Z:'W?$Y&K**Z5
M7=W(>*]YF6--2'40W[+-4S_4*::EOL&6T*7^M%1H!.U1Y7XC87DWU7\^CVL*
MSEXZ5QYI?GK@#/O>MEUVF.5,-*6SL?"'SK7^:MCBWKZ2G],\,"R-O3S-5"9T
M#7^QG"S05=T9/T8/,7,I$S$7Y F)U)T-#0SM4N68"BC8KXN,W88UP;F18N38
MK9Y[L4+'O? $(H\IH:;H=F3?.D_IM%145MM4_UR>@6!L:5 -,GJ3P6%#_S8C
MYQ$B=#*8;-$]#KT PFPZN[RUS>D<_L=0S, [&J3L1?',R+Q35J"NXZP\_ML2
M<F+:/RS*R>WB.>MTV-H^?,HH@>7K-_];@]0W&:.M'M)<E0-)YCZ0Y41:!-PU
M-$\[[L84A4O"0RX<-A<6\5O![";.8G9,9/$WB,12^>X04.C:EG!P5CE]9W8B
M[F7LXEV) 94WZN[>)4F8WR?Z0I5P(V#*^G !B4(=4$*R>=8('3W.SD<X.$$K
M%"] *$J?P^H]?0E\C1+1$JZ_EC313TRG6D^IUYI\&EJ GZ,J-WB[C8L8ER3O
M;D_NHS_F* <LP^43#?*XQT6[;#;SQ&$:75MSB$] 8_PYZH\1J=E=WJWO(.IF
MU(*E*B5(SZGPA1>:[#3[$=>GO^$3Y_N0MDVM>U&VZ(K%2Y*7#Q",AP#?FI:I
MEL 5:1=A21Z5M+Y9&%/#7D[M\6:ZGS9/JSHZ1N!0=K#4_;*6;OCQ%44Y8+!?
M\:1">ZH_>(=A<C7$EF#O?4E &3J8QOQ%9KCYY#+\5+(66+=EU*8U?]'K'L8=
M>-;,.>@04&7AN]]EGA=U\89).7 ,_P?PG&H%[2I5;SJBHR6=@H]%:!\"J$G
M[<(E>(3@A>3EN>'7F_@$PK70;1TLQXPB'+Q_0ZJ040^"\DZ\B^JY5T/5>U%I
M[\^RES))FZ@((2I0+29'WK[(^O$,Q+('(MDF;WU\$&TIZ*KTW7JH+;:T8OD3
M:K<3>'3]K0XYLS;$@$/5:?CJ@.=%(#B[:-YMW$R3)= -+JJ>]XE.%L5ZP^HM
M<QJ-\!,I-S'.B7/=U=:0=X-M#;FL?B,4ZZ]JCC\@H&ZB#B6OX7=PQ7OV-&+<
M[@EX>(0FSA:IH,@FX=[%;QDZY5WV3F"PR3<TY$!8M3)_'01;ER=;_ "MM8>2
MH$4T$(+O%5?ASV)>8UW8=>S#K1EJYI5W%%%7V*S\(8!7VZ=X/<V)0YN\/%IP
M#%*<3KTK+1R5.+*&EQSJSA.JZ<7JFZRK^NN_2'HC'V6->!/:7P.$4/W5V%8Z
M9TQDJ6=((H< "-U[?7D&_&45LQVIJQYXJC\B)>R L+E:7[&MP87\,@DZ.7KO
M>=*]7B]\(8I[P=4E^BFT?=;@+4QPW#(G+:_2M/D3+%?#<5+MBH^5J_.O2Q[1
MEL%/JIP?O32ZA0D?-_L4G;S#K=,3U[49$Z7R#.5',R:?>B-\^<8$ 7D(P-I?
M=QAX"(X.@N<(JE)1"5W?D!_]67:R6R9."5QYEP/"^.&89'3$OE%IMLS-YM_(
M HJ-W0LNY4]D+:-(Z6\Y1I8%'6B_W_4="(XVR38Z#W3GMY"<JJP_H$$L6S.\
M\M$S#_IR.[,]01%G"BI2-G$!!PK :_O>O^$R]YQ>N#9S&Q4++TS/XI@?BRMZ
MU%A+/##9UG&:OH\N?E,+6\-S(DTKDN^5&>X,7-]2_,)O5<!&O8M;O<*C#@IV
M.BW%ZYNH6P,+S40J49K&9K,%+:+DMU;K1UHJ2\)*.KDHM?6UH9_O>'/(V>$Q
M?H7D.6T%!=E V0#XS61WO_?CWZU!I6:4#>LE:;_":7QX^F^1W>0]MI8U_TRE
M+7R4FH0_+N6WR8SKN.(/%,><Z@L/SPE8#:DJV^ER<F'Q(:#ENY^CL\AYI#.^
MQLMS4TT<:5="M6N1RBN@49L0'DA3FU!!5U<8I4I'>B;6F54;D3.^K"+O8]C0
MDTI0M1_ <L]['HC08VCQJ];N0+P3ZFK,RKUU#JBKBJKWC;/&$7>  2ZVCY%E
MM,)NC&X<ET<G]A:!1T-[+%_SQ(WDS4X E0LW]Z:Z>F/9-(V9ZJ%L+O)$U4]R
M,3WX$,!V7YN=+D'6*8/S]0IO5?D%SQEZVZXV $^D<$\)RW;7S+:-:CCQ3A-L
M[2N/'TF45T[.ZC\9D<*^Q'ZH6D<$R(Z/']2H>AH.DSV5'D]4HGZ>O!"C9:+^
M<@M?@^"3]68VN&&I-YT.P&RX',7(TM>I?721F[4,<0B84ID7 M<MMQU"\T9V
M-IY;< =PHZ'=:6I46%LW5^@ P2>D@CP[>S.%G<X->P5*^9#(O.;>^@YTJ4*U
M/ 4V-6"_KDESZI,#HM<D<+;[3G-6)+Y"VSVTQ,9Y[_C]1".C^JY\!ST.2-(F
M&TVZ8>80@-MW8C.A]B[S/7$9)TR*:(^GR]\3+EYNX7:<,_43QE:7])GV4PNG
M-AN[94SUYB J#-/?"W_/KRW=D9_[Y*.VLG8GUCK=<6,U!,26%[(H8M\)!P_G
MV/?D/?7H^0"+8_N$.CNAVE<M_$95LD^>+B7.S>U"4VD2W:P1U;?1SR6[$9@Q
MJXM;^%>-IGV5:JML_K8X9!"EV:*0KM@X?&;WG(\.N.$C>/D3G!3Z1(N1;M-Z
MQ\9T?'^IT]-\Y7I2W0.+=&"R82PF,VF2;VQ :Q-?0CQK[F)"SSK7KT3&BA 2
M\Y$ZZD]GD>-QCC\Z=U34G</O:?O"^:8H=J,V>.3HV#069]T@D[C<(T3PW-Q9
M.A!:R22G7:,DZY1]ALX= II/M7\Q]--!O49:EC@5.@32BPH)]%:0M;RB,C:L
M=:Z;V""2:EVQ5E']=$M%\0[Q$* 'A.UZD[CZ%R[1).M*00 +*;*("%W-:2(E
MR:5;[6<>17XHG)?MRR ][>1@T'6$9?^>"%ES(40MF!U(]Z"&GC;P3'U4 PX3
M:JH?H]TL@X7S*T*/V];>+):&)6B,]YCW+B$U*$%?EX4>CINN#A/M!DK/][CP
M+S>SHJ)I]\E@RSN7V.?(^/?$*S1%1(Q!M.!^X>*G4?=/;^U^3'^,I+4"%7%%
M_3&OV'R7D(K3K5(L-&I1#?2K-_/SB2H78AP$Q#+:0#L-8MG5VKM5:%CW%JN5
M-I1-,_*7@K;O._H93G%^.?ONBNCEZCR-GR[;8L-]PT-4]=FI2['6ECI@SHP5
M7TX*EVV1.U%D(*=R(EZD>L"@ZL>OO8%/3H(,Y1+^7OX2DYO7 &,O6K;I[%9%
MWG1H,IG$ZSJ/N@;A0<ATV&XV2:KY(3P8N4S2.V[><AVU3/==#^C4!K,SK0C+
M-3?+=7$Z<WY22*ZO,T]%2#3))6BX5.5.SMLJ"'?'@T=DI(A2]G$O7*5FX]L@
M.*,!Y$/7UD_SGY_5=*AYDR#E]LOTVF5 Z0SZ55KN?C:2KL7RFL;/:\]/_.K0
MP"!_4SA(_A]FX]YNX+.^4VAE#\FRY=+.^A3CZK4%]VUN7$^#/WMNB<T?=V7\
MG)R:X*=S0S1&V&F%;UT9+<Q:W]$9>K?IEO$T=OU3GL';G]OTY<?3.*X[=)+N
M[YPV/-FR6@O;B10061GXS%):ZWPG*KE\)B!;Q%6/!R+Z<S>O.6_83?&WN4@-
M)<:!X0F=HA/:!98:J 6?J*BUA0J(W'10-BLX7KJH P=Z<P'J'71.=I880%7&
M=?I0SC_QA78*\I$9&Q-./K1;PV/5SE+5M:^)?6+O(;P8G /+?%*6T<>*CZ7M
M.S9M_-3;=OJ*DFDML:$YS=LOHWU1LL/5P*F.*.'N[\'TW.HX-]X_]_/)^RV[
M9J)B=5-CK:&Y;KK?T5?J1=1ULD5CS[?[3]<7S)U# Z0A&\ _%^UR!76&HU3?
MV-G9E]MURA^ZZ^"N/@)?'(Z^$N;5U;*V.UU1?A>^IUSGQNU)8/H);9AU-X@/
M'9SI<HO,[9NC^;9NX(]1,2)]R36[9)>R=R^A(4APCR#)YJM(^<<(\46OJ>QV
MAFG7L 0SNYCJ^)7M?2$*WH>R_=HNV>&D.JVP#:_"[&[[EZ[F5S416T%*^7K,
M#OY&G;=TJ0S]#?>D";SW?'3 18EJ #%UNB+8Q1K2P7N&)*FWL(;SZC*,R"UG
MI5;[ET-/8;YI59;BE 0=Q;/M 6FL+RV>CZMTJXUQIMJ%[Z!5=B1$_$Y<5B';
MT^:H'S(^68"]MO&RP1'H&MGPW>TI>$-_TLSE:]U$/\J%AKTP&Z2ZO\0^!W,X
M>O*]7?T3F6[T2K1&PX&T KI60=:RD%0;'C+Q^/HT!7]>CWGL;LLOU[:B!YCQ
MV]/'"K,P+,::P8ZQ486E='I!=<T>$!:(7)071,3.>C)UM?ZYY4[^F17"AG^#
MT\U#@)<)[TZJ+2]G?VA-4*.NJ^%"%.MH2ECOG/Q/J"Q)J>UNT@8NC6A@EJXC
M\-K162TFXR,F*QP@]@_^4T'B5%AUD[RJ,,!C8%<S107".!!\_/6'=(SWS+%E
MG37#;D*$EH8UCP'ZB\KTP=F^@[D%7356^ HJ;IX(]M7_E;?M!"_2[!R\OYY.
MO:>Q+:X1I+$- F_ A4%5VK_R,$"3Q'Y!T731(.A>G N0J6#ZU[[DE[5>_Y.8
MKP*,HI;/4,U,-YU(3:% J6>PP:*+;E"Q(AM1J79K+H' <+'\J^HYK&!U!X6?
MQRZOFD,L9F,^!S4YZ>O8B^#<+HQSF=Y8@[!.!#7KM5KFMO'EM]\1C@$Y+D2\
MN#\7Q_UM35Q%*&IR7RRJ'K0T@"7&AX*D+B_8@T+*=GN+;#]VJ:P-U$WOQ1'L
M2,(&9]J6LDH>+$.,N7Q9FDW>: [IHQ]:@!Z8(9'EQ8D#3R8-%]CD?XRXS+8*
M?^0PS@O]86X<45KUX%(J$9/Y%DVKP+G,U3D)V=DM6,9;0Q;%B7?]O;Y$F&I8
M,^O33;;54C=U'BB,@+DD2GV=YBKYE7' Z_.HAO%A =@L4B[6BQWJ&' /77PK
MYI."+$%*R5Q\6KX-3M74;?F%OR?&YNCZ+I3@S/LILODZAL?E15QM8&"9%RJN
MV\$74#:R-E49X,I-[RX"FI$GT1W_JSD\LE'AYXZC1!,GA.DVNBHVO(W8#9E6
M@1 X>YRLY#V"B>1DHFY;?279'QY38QRKJ)^,EPH'.<[3359O9"WT+:6>">3^
MX4+0&FK&]ZV#P_ZPIZ^C^!ZAMA]C#2QH7/\./Q%Y/:[*BF0<!13V8A_*VL+&
M_;'!U2G1'5UMWRQBD1;S\5B3HWKFA3\^//"HT2E^7+3W74]9!1(L\M.A^(3;
M]K@ !\=:O\K!&6AGJV6DM>%PRE'TV,#T!^N-LJ4ZE4O)/F_6/U46BVJ?+Y_F
M+L9?8B+W! ;/2P@;&(SF]^@/PF!B1>W_]9WT>V<I3D!LJ?YM1OF!YWGZMWD4
M^_]X1C%?W@ZYWTAWR@1@*S<Q=JM82%$ C='1]F@?J2O0&]T7]R>Q D?W);NJ
M7V]D?],##XQ\^[Y(.8KLKOTVT%$;7F.-HSOJDJK8UAI;8>-Z*=G^8 866K<H
MN\:R0HL%UHM[!0SGC3S$J(N*.I$0=$LX#2\XL9&G"/-%,S>U/8R/ATVCQ18,
M]#5/2)PZ?S30C/(O'&?B5#F/=5K.GU) P>JJR;XE(&'OC?X'+MGR.8Y@91YP
MZM,73\=9^4D2J6EL<RO0HE;;B.$,9WGF><G,)T\?D[M4\@[.'@)25HS#D'P]
MXI8)^\EI<7)>)VNP^XZW/U*4M.%,P2VM9EYJ?&<GEW$8JP?SXF.2/)#8B&FP
MK 1L*,SHM%'"V55SXW!=0D">-G]S9A9SZX[3B>GZRW=1X(U[W*I8XEU?2%>Q
MV)*UA(19VDLG$CM?T.<-7()V]X,RI>*)2ZKB=7]L<(*+,.7T'@>%^(Q8$,)2
M3YYQ]N^5+H(!#7UR$Z5SZ($;")*LI)V-+UL\F[X6/?F=>&,BFPUR,15ST505
M\;VX0CM2%S-06A*W9KA7^L)IP9@>.>S9W+'/BI'OE(H9<X;%-;C>$.M[GEJT
M/;@5?D\67UJBM&"^.1<<3Q_FRG-5\=..+R'1*9'-[H'1LS$^LJ;$&9,O9-\\
M,IV,U,#^7K%W@PA.RS-./'LG4YLB7WV<GBG^;0:_XEEH=7M>K$A85,BDZ3Y,
M+"OG8U:X&(/:GJX9FF*^3^_](2UNT !Q%"IASPU&UU_BF2)1X(Z4ND/ $K10
MOE+1$2\<J.@X],2&@RGTK4I2]:7.,4S44>L 5B$QE' J-VNK6(UP6:V8HR.#
M;+\25V)-DC]*D:ZC%.F7MPPLB;]L(!=Q,OM,B_I9ZYGB,*NU?@RFB,_5 \$E
M\%I(/B'?H?!Y7GA?5HS7H+/Y) +(PLRL['3.]20 -;=@6?2S$,$%,>-TZ>OC
M7=.0RW^09DX\^]VOK?<3.<P<21B33@LBF(://?(LB+_\4"@T_"8CN6!YCP"9
MK@=/U%D<="WHR$HBN,*+A?1L.#HNU'VO6H%\B JY?P5)&-IA7@!?UA_&]K\_
ME\WYX[LDVY4SLK"P*DB"_08&YS6B *Y[P/E(YM]]UOQ?.,8&_M9W5>TG6K:_
M3+PH(+_FU1KHG \C@G4HZB8>5$L5>Z^I]YZNY$6&%18K<OFXV<@L2WGA6#WK
MF%Q>CM&=<%"@6.W:5Y11,5F'C5:R+[E0NT0%56CM?V#:9IJ![?MB$WJQZ;+^
M]=%Z.].[1M$T]H>' "S]L?2E>5"Y>'TSXWQ@%+Z/#6NHABBCB@*!%< XUX5:
MIB?! 6L:,Y;C913\?09R7C!#1I/=51M3A)P)V"GSJ_W!L<@68!4#&?==KZ>[
M#W *;;PH&6/@/KJ YE1@49?C[W;&7GW8@U7H#@<4^]E^T7^G[A1"87J531S;
M^^BQ;!FJ!>4I=PR+-?JBAA@@GM&0M?X5U5:NJCV9 5$*W<!_M"&$6ZU?+*JJ
M9:L30>GO0+/U@ :\YI-I+.?4%%(F*\8."C<*S]<R'E@E^H-WR_18ZO5&@7$Z
M;"%6!FIW=J //XN/>+ M48'*\Q.,?>!98'<-6T,MBS5! ID!8MFL4A7D]G\%
M"50O04L$F',T&R4-Z#'I)G7.H_AT5*&_&+A^!I0^-NB!E:<XCWW "F>Q[QR'
M*N/MIW85N#N<LK*_0_C#.5,M?LK_*/)A"U?CS,WI0&9X+)OKT<0TVYM7+R(V
M\$6\;2*+&3V@S\Z'@+E$''7:\8$I_XTZ@Y0J%:'Z0P +AX[-Y:O6PS4>#;M*
M'R/41R%K0XTU'%RB\1<R<(YQ>88>OIY"VJ0+W9\WE4&EZ@T"COO2/_LZ(L;S
M8GRROTIB7??'Z3:T*T"R:2=IK1VC22XJ$"(J<0ZA>J\V[UB44A#B2^YZIUA2
MTN7F:QD-.AZH:0*#??.":1?E^AYQ<./O\B(9LEA\1[(V.(V:.O(:;_G8&PZ&
MM%T3!C29Y4HL8W#JB+C-4_+5K[$\>&4*L"%_D[7E.Y-:W\+&:X9>VP(.S[&N
M<X')G]4<^E&G<]"-=T$24YO7 AO<&D$8OU!Y] V&"L:G8SY>/&RC7 N&/R1N
MKR\^MA*:QJJ=%IA8K 57V)&A;CQT)Q>DU'_\[%<'*:;=..W_%20Q-HM03M*X
M%FH]]X%CLD!(7":JK4:HX1!P^O+GX3_]INTGS>VVQE*67_CSF+FQ;)R$2\<W
M*X>>P>:NC2LEQCMNX<,+VCJ.ZV.K7@B,\TE<P@]T^"]$)^O;&=>$F[B6P>[$
MN$IT?_3[R/I8HU(5#G,J) '=TM;A5QC_?C)0+J4Z>@?:RVK'@8"Y;B&!HUQ#
M_,Z:A4*1)F#WOC0N4FUP85XE4))["V]&/HBY:JV/?E+6WR8\GV%4R&T9%PSN
MQE;4W)+-^[@+ADFFCOZM0<$*W5VWF<OBZ5DN&4M1"]W/BI1-'8#JV--'TJ>N
M*SV?)&UC/5?SDG1K0K.EK9-DOD"]'%S;&]5&S'+B-BM@L=MZ1A_)"+^-9B&_
M>_U=W:6=2%"@)F@FC%;@2C4X.A*D,0/7CKC%ML("^CQY,%FPNVF PCS<B3M@
MSCP$Q NMY8],^OIW KN):0>=07N!471J*)<@UAJI96ONU(*I<F6?)5\HS777
MZ-6G<?":/!21M9C_&.Q[$7M^C!Z)OHG87EAR3WU]2N5)Z+/;OBPS-/U,5K "
MGT?R8BAGB# JJ\):]()'@9:6:?I-:LKDKN-U69DYT>Z*/6" ;(.,ZT6V>F+^
MT3P8M/;374 S1XE0T&3*?XU1IRKM#@D>*IF[M#\NNVR)R1E\:])[;+CT?+_\
M?#E6(7C!'"'1ECNG<PN<5M]O2[#;*@?3]5[\XMW,RGZ)A=$1CR854_(8XNXA
MH(KNOTYIM>,M5V:J P:ZB85.FB,%LTG['USIQFGR/=MLE%L4*9$(1@@,K:^&
MHMA%TMKNF[00?+^$JMR2H_8Z-TL6FW%#LUBBK8SG)242W_2.=J<)<FZ=&U.0
MEKCWK4D4K B5[79/$R;7.X;O/)P;KG[;F,XT76GK>@5EO*'+A'D@GV,HS</H
MV=VH&]\B9:XBL8(,]2-;&*7>VS76=@UB^'$(,-R%]D,M@2%W47=VC&2H[ES/
MEKCFB^J];JIEGUKR.?.6[ REIP,N"_1:K.004+ O.2*U,?A8_S5/H1IL8Q@D
M\2OM>DY2%[^P4KK*(O"D_OI>] Y$CR;N.9$NNH'/%>P6OY61?PCXG'$PF:4T
M7,+T.K?S9!>*2[@0NU82Y;C1R49]9L)(3X[?$'JX9F'8)3:XBPJ>B!IZ:%J1
M6 .Y1GC#_13E;"MT8R(S<S'=9Z'R]=0@TJCO*^L9AG3'C0))S=Y8A1MQ2IT>
M<P+6DT7N)9?9=Z#B_F0=Z!%1%S_]$JE7_:KOU(?SS!YK+*MY485G\CC)1C,E
ME.66.I3>BC^XJ):QU743CO'SOA:2^8P6F 4_5<^GS#1C 1_V*)L#;2'9$IZA
MF&D-,@=QO0O^QQ]Q_:#3"*LSB2K4\DU2EX_;BO]BD6BB48*ASV.'QC7_TS2I
M*#T;M4?T3%0OZ6$,)@*:)9^*609Q"0SLQN/5$!C#*64K79G!=3W!]H.(BUOX
MZ -QQ57AW8&^<57K7UIP89J!]:RVY98I15#Z\7[/W)C70PM@L:<E\Z<+[R\V
M>YCG5K<LZVSBIDG^BFYV_<3QXCXIMHC<54C+SS1FJDMEK!BR>FZX2AD?Z-CU
M]-Y(=^4A(&B+HG7\)F #[WK0'C#%\'@!GCXEBQ#O+=E60DK=[-%)%_I2IS_K
M3Z^Y<%VJ1!+/:WKD9,^?7>F@4]]&V*6YQT681"/' 7D3%H>T&Z35UV[#U[_$
M,)$L,1D^;G*]=,+&!5AK'BP&Z.%8XC"&'F4?N'L&Q7(PN)<I)R4PF^$6TB?;
M3?.D!%\]Y]U^9=W+@%KBWX-^^ T_(924N".TAL\4CSJGM1W+^SLO#*MGZZ''
MQKR"3,$B.<SI(4I?%-<A.<+\P7OGIC4"GWT(_&Q+_B&5_@YE/'&Z.4L)\RI(
M[0Z0L6-U$X1Q&*1QC*I;[4LN&I.KE8F3M()E?.CC*.#%8N$DHQ+):Z&&<SJ*
MD^XV6O3IC5.]2?=]7XJOO6HAO#P-D:F7.8LR5GI4 ^"J4[$QW;R5&93'&OTF
M:WY:SQA@S97GD^8I[.BU\+!YA5 _XK*T'*X/T4BB%M8Y%;BTV<G/5'ZIXU[)
ME?K%T(GQN]7_;4S]7W7.D^*16\P1GRO(I:CFU'7 @LEY=31?;?)$(%1OY'63
M[Z./ ;X7\XHKK]T)EWBR:$0-3./EW!)WV"+>/1;>E;O\1P+"70&16ALNIX]5
MG\1Y6"I.P5^+YVLV-I[Q*YS/YFWM-7*V/H5X./#@ZOT%I*@JF+V0 KPZA#P5
MR?/E!0,>XTWDH]I6HGYHH%]"2UG5CM'^2"N+OO:@R5G%1LO%FIZO2U;VE9J?
M'W W><J2RW-WK'Q9])O<VLR'/^-D9R0<XR5?,!^WK>YI IZQ[O5.%Z-[K<A
MSG',B+< (:PSQN(YK=H9A\ 'SG?+GHUJJQA"G8Z86*2KG:U5S1#72:[D<;[7
M7T:Y%N_))INE<GPUC%[7C2*;2(JO^8-72B=>BT6CFW:AA&'[=_<ZZF"G6-1E
M"AAM5!!:<:=9E=).Y2,O:G%&T2FLW0+)KN&._+/TL2@:,Y'SS?0"*@8EE:8E
M[G>1Q+_MU.I0K\<OL<6 )#;8SE"YGBG0$NGL^:J'!)_DW"1$^$I+WIPJT'-K
M.'52]?2^=,M20?43PIV<02:P0O),34=IT?4I]NN3X3.;>.869'$L743T=^E>
M=_.^2U=^*HJ65&V!+NM?050H>S[MG$YC&+V:&98>F:!8(>7XV"/;*NRTXSUL
MJ\I5$63 "[+9>WJD=O@'SH'H,F+WP/5,_<X.H['KJ8;]NATH[$>!]TU+.,,,
MGW]@50E=%H[WJ)W$D?;2NXFQH0W/<71="/E C#HNM,*2-&LLW.OV]8Z@0"9-
M0-L]KQ48YPL/K1:L=)3FX-["M5K]F6UXM=S+"$7ES+N<6S=F"/L=HU".*3UF
M5@WOUM2!+)EVF9%L!$^1M>(%3P<E<<D;<WYF)!8+92#=C1 CT/%IK2\OZ#0F
M]\S*!4LO?DS;C%Y7;>X7N>_K?EAY 0Q&"4HG?COZVZT:N%;9GE3YPR=%4D4.
M76X&?N-QWPVRL14]+(YI]9I5V5;+YJA:4A>2;Z;#J:3]TANS_/;[3Z=6WL8:
MQ25-[@[4]U7;JD'\669GJ!+H(;I>AS\DI.KT.:0/D?V?0Y^ZQ0F5M%Z5NNGB
M PH]X,2@P^^;T&N]70-,K"?N-CTL)>W.;=PQN.I8<T*2-V[&T /F::UGU:=[
M\,U"_+@MSF! X<LM-F4*4X U$?+C\0'7K.]J76.YK9HFK7!^+;,2W7O=M.&:
M$=> 'ONMES?B?7ST/'X5TGF1^V!NHVB6>I%G_==!W&9O)3];^CLC$#GJ3A6=
M]2U?>TB\<7'[?NP$LB>3QG-^37RMA HM](%_S=9C7GM2(R(@>/(0\-JX?#D[
M*FM ^)GYXHJG07U]6I.J=.?2MQ.R,+E$!HS4<X&JH^T;]?\!-O']@_]+B(G_
M][]#_K\)<7'[C.-?_[-]60##_IO]JUG_<I%+UX)ZUX)NUJMS1RN="K78U)[Y
MC!.3W<52?QT",I"G_^AP4'?H_?.J&#H,CE79__'A@0R+6-8K%GJ?QQ2BP'1[
M_-ES--8^X^36NEY6_*L_F_]G<=1-N=S?8Q(O3D9POK(1XUS\ZV_!#'C_;$Z4
MVQ4[=A/S+_O_=\%FRRK->BL<X"I76DH?XJ6<L=NGZ+/2?@#@-.#0JGPE\&C,
M'RLOKR$SQL-Y;"9-!9UX91?:.L$I-923\ >QC6*;Z"+T_(335R1BTO0:[T,1
M?Y:MCUS&-QU]J,.Z;C^I>,M/_@1@["9N@/2AL+C7W!NW#J'JR;WGF/'>P"74
MP4_/?$Z[_J1%+6X3X=:UY56QMD%VWTHH6:77CBLR S4-/[0V\$)4[TP"VFW&
M+7RSW+]/; O_NO%[LK?: .L%;M,8_0=<;8A@N62$?.5/0.FB8P_6Y,2R7%"X
MG[#,60[=G":I/V_M$3ZZKD>+/BF9];O%M_ZT\#LZE3YXY3*LZ[!A>.Q\_+_>
M2G$;/.[)SV%0=WC1+L5I\G<V/O[SYI_8TK_\J$5O OS4N?7G^9"_O _(H1OW
M%5^0[M]1GB>W*'8LM0?[WQC[W=&B6/L_P.&T?_ /_L'_!G3&P*P *<Z_-]/^
MO\7)WF$$GSW@[PHJ7MS)N>B0PRA9K&(N_JU(<I6QR3LU Q2,B#5NUE4^-Y4V
MEZ9-KF?F4X,=&#_I)/4J%)V\8S'&A>KW^[;U:,EZ85=B*+]^BA#K_$B\%^(\
MVB5Y<DR\=%&AF]N@Z__ 96E_E9"_BM\_^ ?_X/\S,(A#Z*JJ]]]Y8>/?:!/+
M^2KN;I^5P^"6+1(N\9-%W#XKA#Y&@]OT9IG_)<W]/P!O;ZS^;;:L?_^'U7\'
M& Z'_@M02P,$%     @ -8A_5(J%09FJ<0, 0ZD% !(   !I;6<Q,#(S-C0U
M,#A?,2YJ<&?LO'=44]&V+AX$I(,TZ42E-U&*B)2H2!,1$>DE*DU >H= %*1(
MBX"  H(*"$B)2),BD:[2I(8B+:'71" $",G;G';ON?>,]WOOGG_>;PPV^0)C
M)%G[FVO./><W5]:&,DJ9 9VZJ:.O Z("#EDJ61"(,@LZIQWDX@0"&1J"I$$@
M$#WP&@>(&OB+"OCYRT&9 &F!3E!1'3W^=E#34A\=)VEHJ&GI3M+1'8&>@8F!
MGIZ1GHZ.D861D8D9..@86-E8F%F/_CX:Y.CC1Y\"'LST=/3,_]<'Y1N(G9ZV
MF*68FNH<Z 0[%34[%:4-! :XTE+]Y0#][: Z04U#>Q*@Q,@$O*'Z%$"?FOH$
M0):6A@9X-0QX'43#3LMQ]N*UDYS&#^C.>7,I/$U^1R]RO:*9^VX_3E3QH4\$
M ^-I'EX^?C%Q"4DI:27E2RJ75:]HW=#6T=73OVERS]3,W,+2RM[!T<GYD8NK
MKY]_0&!0<$CDLZCHF-CG<2FI+]/2,UZ]SGR?EU_PH;"H^./GRJKJFMHO=?4M
MK6WM'9W??_P<&!P:'D&/CHW/8K!S\PN+2\LK^#];VSN$7>+>_I%=5"!JJK\?
M_](N=L"N$X /:.B.[*(Z$7CT!G8:VK,73W)<,Z9[X,UY3N$I/=?UY'<5S0PB
MBG=QW ]]^AE/BRK-BN&/3/N+9?]GAD7\CRS[AV'_8=<XB)F:"G >-3L( CHD
MO8^3!!WC&,<XQC&.<8QC'.,8QSC&,8YQC&,<XQC'.,8QCG&,8QSC&,<XQC&.
M<8QC'.,8QSC&,8YQ#$FJ%(.*H9 !V0+4E:0]KZR&(@PJE0(B!B'7:2D@[0FL
M!/ET9@8%)(P,%)G=?YU?R'_7>+YF5UT=JQYMEYIM@QPE5R0\"\C?"BO9NT(!
MQ<2'_X)NVS8IP&==BN'X%<@L9KJ*YY#',R&7:.4*)84TQ9//DF7(X9T;SO'D
MAE\44.[=@_[#AWM-0\%-PZ0W\-9VU"/Y_?/3?!!<U1"*N /&X3W'F<CQM1U&
M)#EE>;*&+DF+9$XZ1/QN/0QZ1P%I%NSF[;=OA17]GQ) $&.(R+T#<%W,/EZ+
M'&:PJ;L3OW!@O'!@_L>? F([??@6M=0 <Z" 6@;O4D#8H?_.",^&AVX1(+YL
M.Y@8TG[&%&*5IX>0UT- SJV2A>4.KL'[ X@_**"H#P444&?1OZ"$ 6-0BVOA
M"^#5=K:]'?FOX!'YK'7=K'7H#S1)W9H000&]7\<#3F R-*" $,;_DE4;I!W>
M-WK8#4''@;=6H"&04JC*.$)E')6*) ;5_A??Y?U+7K'P.&#Z*PY>P9%<D,6A
MIFVX19-GM;!G-5P"^M]G_5\2.T4!<5- $/O="Q20G22\KSALB5P!FW95GW8E
MWT;]]ZG_%\S^%@T/R(UWCH/A.!C^6S H]8R&/QMX'GXKU\9\ZRD%1(.E@"(6
M27</7Y*5V[WQ NUV\L0W,W(/4H2L^BR'G8:0LCPOSLL)!SY,.8]]]8?#^(77
M]7JX%IB>?('HB:UMM15IGV(?+MW99'5[P90E,V'V.Z48RWM9^EM$:0*US(G2
MC]_B]DJQ9]OF!XW+2NUZ'O>%2O46.9WR2$^Q%5XT%#T \T&SWF[ ^[;?B<F1
M2J@Q\">SQ,(9.9/67?ZDNGS=D@GENL;^:KZJU0.;A.=G<\XA!8J;:81'ST1<
M(X>B9@KVP>O.@ U3Q)_CFA7X+JQ.\:R<Y90A-131OA\;O<].8J493?*CI?[@
MW7LO[<R0PYX1(<K(X:-DU_M ]*_20:4@R5!=.LD=E]Q^Q-^BI!^8CKCP7S>]
M 4^@_W=.+OE+K-4/(W[WY?R[#K(_OMR/+_?CW/__9C \$-=6_C#^+03])_"O
MG^@DH?_9#W2Y>W\QH_K(#/F_S4,;]*\LOI$KT@V'/!;'49SPF3@HSBY,JW5\
M)[<%A1 6;1C:/KP9EBF1H.SV(1/3:^Y)W&W*O&[YW@DBNZ&?D*TJ%8T@U#/
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M:"/"SE6QB[O16-M==M#SHDC=I*#'%VKF[G>Q@H@A: Q0J!\!J0\F@'&GLZ*
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M;Z?G5[N X/3^ELN]\?4I:I\36LK/X3]6Z^JQ:G,]'TAOY!S_=Q>,CO'_'X@
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MPJ<OM/]9#%K,1HN'OD*_6RNXGG\N?W\UK*;_C>7MDVE0%_ZA>?&,VSF%L[M
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MAP U@]1!HXRC=^7>)#"R?VZT\-]'OO&WD1MB.__S)H^=A'CU@M?&C1KC\7Z
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MNR2.!DP&B1-^P.$IG,L"=9DZEV(AZ[GM?JTPVM+8]#7C#T$?*:H8L1/9PMI
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MC\6<?->)W&?-A>;E<I,$IS2)CAC#DZKI?,I?SR\T.W@VL*>+)UPD"%2VP_*
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MIKT![&=M3BO_@C<SP6>>H>CA'M Q%TT9V,V1ZO6'!F5FF(YIK4'Y]%XF[B=
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MR1N%SW>"UH:"E;HM.Y9D%MHM1\#_= \H$>BR(78'#H>ALU%<DYMW%!KPLF>
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MLHV14AVET.F%'50GL=*WF0QC'&-ERO=O]-7XB3[Z>+@!'SO8.4 ^)B5HT&^
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M7G2AJT'H@L)S0M#P4)^NPN$ZD=NUPL&3XJJ,D#R&7QWL%P:!G6$KS':/1F6
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MZ6P2M4EI('?P[&XKN&HJ]@ 6_<JW.[2%9[I'Y6_Y)SQ3#0^[9;Y.5M\'ZU_
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MNJWW4/-;2G1\#9__CN)!>0 QT1V\[,0L/)T1_D6HP[Q[KPF=[N:6@^6VR1G
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MT?>/)5-L,]1-B#;@-S/ IT\;<,2S[,J3EI:6F6B95)<TI^I#.OF7H>4:UK*
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M#)F]6/9<H$1[A^[_=;;6X*&T](]B&9G+@&N)08Q=!<3!')N8_Y*A:+RC%B
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M,"97-2H<L%UR$TB["O.NJ""W#DLTQLN["B4=)MDTQJ8)OCWZ<KKIVU*>3;+
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MA47#%J_ZD(^&HS,)H"N@^07&HR>&G>#CHV'0_K SN.:<(+4 A-/Q"IL[P)?
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MTI=3VDE,RC3+J>6F<G:5!2 X9O@J^%2)@Y<'3C^RJ=^S/4[@ZYTWQ^)^"@,
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MS;BW6=^\%P'%4 = _"AB0(F@4^F=>X'8 M_GQJ_OFX ,,'O?XP#U9JB%<9J
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M-&(2W'#[(8=[D556V++G\B#MO8"EX\WO[UK%/23@MG0"E0NLU]#AA.0!KG7
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MHNE2[NM-C'_JH+?*OUTXJZR.Y(*M>@1&E=JR2E^EX42Y_/JN7TWW_4/_1IZ
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M%4Y;@U2E+IYB^KNV$6TXJ*UUAB_8))G'!$ZQ,8%MX"2,Q,U/H]!,YKBIVYC
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M9G^F")ERMOK9J3XN!97:NI=LV)+=YEU?GTUV"@7-D<P):S2>HA9<N<3"[JQ
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M!,#.*/FQ;:G_WZU#4&BH&6F#6EI;0I*:@=3ETKW;*/L3 &9<GGA$7*/N1)X
MFJ2)R(NH94/S<="QF79-!&C9%[QV)%C)1)%RXSHVF]B/H?R_;I8K'KQ]^!-
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M"HY&9AN#C=H2"4/+,M4WOCD^U9O>^.X3XBQ2K"S8@XJ=YR'*8S8K64.Z>^R
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M?(>AT$"%9Z35'LNDI1VN>*=Y3"CZ_JBCL=7/ENXSUU)T[U<8ZJI.SD<+^)\
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MYNU<MJUN7-]B?VL;:E@8^CB&V^]46@G+9_T92#5Z6Q^S.\.'@;_"TW>$I6S
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M/N%0OU]64;Y[9:X!IL# )5*O'Z;VD')Z@[#Q@"Y6E[OP_>GD&([:B?""9UD
MOYQ8J>*9Z*78P/\I3:*\>41+5Q'K)X#O%NW2X0&5%"5;ZS^/#LAKM&D,H&4!
M:0BG=C--C%PM_>/-= )8]OCO19;_>*'ES"Z:*((F7V(C$30FRN&"Q..-I?M$
M2/'0'?9_70&)4=!3D_7Z89AR_?M:V(4=:\HL[@00X]%J^6%JP\YSI>)#T<;%
MPL&ZL=:X?UG82/RWA0V1+*HA6N1RFX;U A*GCR1>%3O<"JV<AH'PE+&A#SC4
M_9RXT"&G[&ZSKU/_\ 1R40+QRA..*N*YW5W)BG8H>O]@X4_%Q27Z6V67E$EM
M@MY$P632&'LF_T@IJ#M/M IO%>-6XI:9T1R%++Z=>6/":B_F<5-,AW- X&)Z
M6@2WSRW.L!M76R>PFA7J=_T)Y[\9.K!\C)64_&>4F%19=H)Z+("836727X0P
M;-"RDE)+N=GF%ER\RDWP;G#L4_NT/J?G"N38'Y;<7ILK6>3B/+$\=H[8ZIX.
M6$63F?H?$!KY&P0'N4).AWAC5;IR'8WQSF4J=E<SE@=7KSBR+M,_.*US.BP1
MP4A6(W[#^9L1K9<&!J4R27IBP@9RVQ=;54SS4J0VHSI5->.7ZN!CBT/./(MB
M+SWW=><@-5MP-2R=@W1((S;ET*E\7[/!CFBYN,#J<#1A]T!6^%/O'O5F?E[W
M!C1A'/%41M%%QNTX_M</^T.H>E1">.(UZ'AB7/@)0%L%>;A8K*Z[(6<WA .:
MG_$]MEY_T^.WA48?><'V*V&G\)<2%(^NZ2,N0)L*7C6'X4(K[.8U*EGFI^?0
MS'/QOC^*AD*^OXC,0]V;&"W;2-J_P1,.%LYO;Z@;>\(ZI^,=R)O;*=8M2=[\
MJ)HQWMU6*Q^BWSM"FSSUOJ10)06INW%NV"?Q3;\[",K'6B0E6@0_J"TWOXD[
M)$M,9Y2XE+I5- =.VW>4>W[6%SJS[2?P^<GDW5//89TO(%GCBVSG$J^5\EX0
M>N!Y:QNLW^WC _ZANJ..>*CN#U'.=5*]]SVWZOJ8Q_@F]=2FL]JJA%Q)F'SX
MR-3?2SX_RK)#:O$"R=[%-@]T0IT#(@R>QD2*QH:>9;7*TA/(5;=>K22S00FD
M$1BK"[ ;P0DF:#PK?7[LE:_YPTR*_]P>GZ9T2FDM3F$[Q^J0S)%/9<I?1$Q]
M<H!V(H'#(/80+)\O3[NUU4C %#?_2DUF,D?4J5N0MTZ$RI[K#P3?ZEP+8;SN
MMRV7L8OX04EEZK51PU@IU*:%J1Z 1WZ0@(1H2F6[ /5[V.F-AYIX;>2';JG3
MD@OR2DU?CQP?M+  A1QC\4]IP+@('W04Q/NHG@"^6*Z!CAA12.1K!)>F+>EV
MR%AEX#;$!F]5%?#CE\R@V&C1U2%+KI3/3->[GM,9ZY31Q!O;#IQC4T!^&,97
M;OC1U:2T>*ZM5,0N<E9/;^VPH_)+KX\W<"5 >#_>/7ZN=C7>:_Z;1.GHT?<'
MMEF.T+U'D@^UIL/L41N(N\@:Y#8)AR14Y.T)GB%V@\<J @BZ67/=,^#]*)EZ
MM=,U26G+Q:J]STX_X'JX\ HA=P*HLLSL 0+(>KCYILMMJ]F$\9Y,QMO77KV0
M#E$S"UGVGT8YHAX#9Y[U'[?7:ZH4NQY7QBN1GEGL/103=*MCZI#;L> 4.G@"
M'EC((D<G5DW>B]0J3-=HM(K($6N9'U1"*1*T&1=GO2_Z''ALI.4/WO9B3]@.
ME\NQ_W4LB!#Q$M2)#=1QELCV*F_P6LP)LQC[&&RM&5[[WQ4H_T$%"N^6+NP,
M31[0Z%K$]&]:A_=V@5-$E^X@WN!8[:LA$;\J/+:\;.KRDKUSF.+>O]3P?M0I
M8E98KWCI/MTN2IS'NPOU!DB4TM\^4TP=035$]WKSNG.Q.\@58C4:MUY&!R<[
MG_W$YQK]:=(QWC<><YQUJ(J0CY*Y2*GL9N\?JDK]8/1S+A>9A, 4G@#JHK>;
M\!=M^_%\V*B6SQ"#/?O?>1P9V'%Q?G+5M.W+"Z=S3G\W44]-<5]MPP,)TY0X
MI4TMA-T8R$T^^MC#_H(*;UE6745>F&?"RX4F55&@5!_=S5[X-LULIU"/T!>H
M7U%?)"+(.BS94(F$=G&W(*K(>)U5/%^,8Y-NUO2,[U&&Z@?7OA]+/_;Y2JUG
MFNNCW;#,<M@^ZOC\WM"&(L=/,'>*FNF+"V5EYX4B;M$7*Z];HW\/%__^5<AU
M[E,_,W]>N1%\O%"OX&"6O/+WR &-_!8@.4"8]POGX4(Z>/W[(\IM=SL:@BX1
ML@HN24%]PU+[KSM>2V)-T?P041Q]=DW3<;^?RE1)FP@VXC9.@LI8@@=WP9F)
M=4L+%T*@=]4-JD<"MI_8/[-W%$]VEMG2%6(>UJCJ#Q)'^:"<D$0)9+?\I'^?
M-F@,SNNF&!(T@14;*U^A)G-$DM2_VUS2I9O6:OEHM6^3-FO!?_9\/B=YDV:6
MOC,@G"TD/CQ474B5]KN0!@L(Z6N[3.UF?3MT/V+%K;8=6R-FE\@H;7;8\I;*
M3*E!>"%?SW,[>'>W*U'RE;<OF2W*UXZ4S-FKW;9\GLQ1(A1%/^)6BJ1#85J0
M=9E;Z*7HE"6L20-6O"'3<SX)2T357DE+PB 4V?7[P#NY0(]]2"T*YREI2F/\
MKW'GG>-W1@/C<0 0_AJR\HP:&;K?0&49'FT]$TQR"*$3!-9GS6M&WWH;4C#-
MZ:99J:S=(W=C?_4<>XZVO:-NWUS!L86O!71)@"7 LKZIVQYHEL'SY+'I0AUZ
MW)LHBB!STM^AN?<'ZE!J2-8,V.%,[T.!)@=0CQWHW:IL;6^PZ"\5JRC+LQ6+
M34;-EWM5>&B3]P&)LTYZ20L'8Z8Y1C16%"[9.*IIZ"D[CO3,=QOPVQ>]Q_E"
M7E@ZISK1)K!R$$54'.B>?CY!U8">*D@RA(;S_OA$-[5&=]"G-F0*OH<8,(7D
M+^#NHXFB\EV51*FD&$V5SS#=1KR3RD/.^JRAP8!GQ.WD%"NK\,6/L+U\[E[8
MJ@KSJ^ZE%2//S]#ZS:^'UR;C=1_PEIS;%7R)PIE5$N4.>\$S3(0W"%:8"CZX
M)^GE/-/(UHC)2&VN2,^$E6P FR'WW /9UM@HE_UK-V<Y'74'.*\B7!"8.7"<
MMC1Q@F;Q+MS":TUGK/?%D):'C6,'!BNC=>5Z4%(3IYRMZ;WJ&C5&.H!$+%F0
M9K5!:I\V*R4"Y$7Q7^Q_L3(NCJ,B/TTZ]!WG=J%]'KI:+L@5/X_/HU/E#SB-
M\@%A)A%'=RI?(;942D\ Z_83#;DCW67-[-VELK+S_9GIH^4'WV[7M(!N.5V-
M3@S?Q-%\_L,)@/Y,R'X7ZK(R+7!09PX:R<I%1*NG(P<G +9IP$2#=2FU>GYN
MDI7Q3F=R#NS'QJ3S_6#X%,P4[TT6 K&TWJKD8).+^S0+V=;B^QZ#I*<>56*I
MSQ)TL!+Q6=#2Z+:QNH'AO=D',+32WK>,(*VI=]5@/RAZL959O2;7/79#QK%2
MJ\\H1\2$9>C>,:@[2V([&0]>S.WO';RQ27@YH7G]:<H0#'RI\/.#*S%,[YP-
MXW:=;HNR;.Z5L'"7G!4L0&#2$3A?_5[!J0GL>,)B97R>^&AK.&["HC%Q>&/?
MRM__L^NIM_+39BNH9PKRYY;\EI\';3ON(W10%ZC\ZPB&=EY7..<OSY01?=P.
MDB7;F3$@D3N?]3V94R_<&"$JB#/;?1DD>!J%>8_@T90HG.YV+E@7D!N]U#7.
MR9A1C]8PY'"GOUF\0:?!>/"%^[-M9NT',P9[E]']JC1WC CCS]3@,.1$[ZL_
MP?6^@Q>2!RYT:'KS>5F;_XQ0[;O^%=M^FM),\_0E4 2J"M13R1G"LJ2#+XK5
M#%Q\ISV@G)Y;<-_V';E*6&9V0*CK\M+5U\LN.UF$!:)(4L],4CP$=W<WPFYE
M.=4XD,:;>]N15U/X6\M=[7Y6:9G XM?:_1_JDDP1G<T+  04D=0N3DS"EJ)?
M7P^)Z\V4"0ZKYZV]-D//6N;XI/:"A>>MV3UC6(6 JIU-C#X7W/)3[DXXG;!-
MS"\PT,NE#=TI'T<+0RO4M PVLQ?"%I(A&(_DU%1D:2N9=6==5[>..^![=EE6
M-#E7%A-O].%)@H$EX,(KGD&$-?+<;M%H^\40*^RJFY><G-(S0^<,:[F]IE<,
M3R52#+^)'BB3GY*-< >HEW"1D$C#VGWM@<*-X!MO=M4\8V0DOP'\7Z3V/Y@@
M..!DJ ;(EZ M>I<3P$>VMAWQ#T8Y4L\D"W+1$D*E:D.PG36+:*4-CX"-(_;U
MB/\+]?T?-;H&NZ-H*I,*QC@8BR"S<RW11Y.O?]R8%YX(E.4Q0QN/7%UN;6GQ
M]668X3>-^.'#T'$6(VAT'!IE?,[?SJQX4=DT(%BQ!)PG!RS!T9/YG'&0WH4S
M*$SVMP_$F:YV41R\7M.T&$U!EJ_7N!T^-#]?CTI7*/545?5XA,&V?Z-\1+@L
M,%!'D?2!NP#BC%&T+6XA1I9W?&<*Q\W"V*QBD<Q-I\]?"M 7;G%Z8!8:ZMX\
M66)1L=G&%ZR8'Q4O^5DC'U=*T"):DPP0G>=/ -YMT,XL1/="#))+^U3(QQ6Q
MYF;<6K37@4%"389-Y?V;B6_F;^=[5+%I]MZDNQ73_QM-YD11&0H+$)V6)P#G
M.&,6OM]_!+E<JW.MNWD+EX&\G8K]==L[%RNSOGPOU'FNDB_J N60A+=<D]LA
M![_7*S@!<*TY*-=(C9;RDHP#'<+ON6*N\/H5S&&/@T!,5 "B\S;*DP:ZF9&R
M<&[R72)]!<P05_F*U:.VW$C5B_N6>XZH8;&]OI*"'I?KS:\.'*\D -*$ARHT
MT*N#ST/JYXI_PIG@@W9KW=QU-\U)_F95&4\;SB*85Y9][,0MT\B_:H(?\/-2
M<O=P"\-I?06'@H6>5X?B"]:DKZ^&!R[\["=I?W[PN;3A=\AA+.II-F):GB &
M?H5@I_XJ_H8%,MG_/OZ3H)KE'R#[4W-3Q$FI1.$HEDS^#50F[N/,]2DU*,R"
M/$](7'<8J#L;E2!('WAWHNW5GTW#G7*'KY8D U?+E>KT9%8'<7,!?;[&(,IO
MUA(RR>SH=A.NZ66);I>I67P=]$,;C,-=6;6^H!D91Y6GO58O=5:P?CZ;%K$+
MG< I9(\@\.G8STX*"N'I'T@0TF.2G1N]0?#YLO;N$OCQ&V[X:U@0Y<V!]W0#
ME2$A$.??9U>4B4WP[\P(@W\H :M,WW#_HL,1$<J7*DSY+/94)$4Q,C7YCT^#
MI;?W/;.W:2I%W (+1EF30RY<>HR:%<<LB9<,E:U,#/./<)0XA!=PNIMZ/F%Q
MVW$1&-M^:G->#G=0\4%L/J?2.ZC*WE!"@0\Z*9+!\]YQ_]&9*-GO*1;>U+EJ
M^((@S@(TI=^3)X7GZIZS[T P*V740.4!;KRZ,U !Z?2*Q5-9DS)S1LE>[%P^
MR:?8JOML[U;NODBPH"P,O]%K?_EG<S#XKGH<LLXB'[U@GNSLM[(<*"CON(P@
M7H%T+UPD7Z'9R!(F@=N-4[KLV,U+0'H7,Y4K6E6G?">,UA<%;(C&WJ\H*"WA
MX8\ ^D)X!*<JL?ID71H\,?%1.4\ ":A%R+)CK^"DM8[>"2 9M'4"P!_6?#L!
M0$B5J!ZDQ+R0]99TW_47>\6%K,QCW?P>Z8:C#7VY5)<'7WS354=0W=X=NN'=
ML[Z0;!0N0+_C!, '@U->P 3SB<!.JB2^HAR*/SVT]^PRO6'C:,63%P';AKQ6
MB1Q/;;H-8FWB3V^H)T,*GMU8$ZB-XC\!O')\52[-Z6@9$*S<\\NRY#LR(.0$
M0&9'=?-F1IP '@%?3-^H*5IP4^]+Q3#3?3_N(] W--7D::F?39%R].$1M3IG
M:W.ZX&(HYX; -5P%<@G!M&$G5^G&\J%@8[S:=G[ZNXJ^_]G/9@:3P5960HF8
MK&'=J:.?WYI>[,BH&3?M9^EEW5]>KR+JE,*[D'4NY(O!A/2)5A>2YN\))">5
MC9@\L6WG<2,)H93Q>>M7=S"419S]#D_$; ?C8HQ&<*WE>A&5183RJ=7[X\!'
M(IB@B'<DME]T3-&+M&B/4%/KV[39%DF^.3U%]WA$(UH8Y?CC$7/KDD K-2".
MMX0_0(US0W.8O;;4S"QE\S,)K>8\DC"FGBA3A<\DLQ+V">_Q2=&:X5CTM/NX
ML: Y_MQ!:8B_(=UYQY%R-C65SS-=/YX,-)X 'MPK;UC%R,(24376/4G$N/,P
MO;]E0$L0HG4!'HO8TJC<@ARQ4]$G ,%GFD@:46DFG0 VM2&M-RLG7YE<'\\2
M&?#_=E#ANI25L\:1DN(^X/2N]@OL9_R#;-_@QH5:3]4E,A;%'U@YE8TUIS'Q
M\0$\#UR N-@N&+,(PJ4FT/W^/7D">&DL)+$-AZ3V3,633P PSXWS@M7:$*T3
M@+KFAY&L ?J8=+II^T_M^QXF LHIZR[^WU!>D*EF^1D^@B'Q!>Y;)9=Q:N^Q
MTO@UAVIZ>ULT^D)\FU%9\<L7W\Y$ $7PP01^2C4*ZDT47HBH\_Y[D'EK EO)
M[W;IN*Q!_4'5]-S1_6]"=+H1&^<+(["79%K/JEF%*H0RHE!ZG%YJFFO::>&Y
M!M2Z>JYK 6[-EL*%7.5(?WX]X+2QQ<L<N^$UFHMUW@"YHF- =?I;:&"\MA09
MU$ATQ-Z=,]F0K.6+T\BV?5^G=UHBH/'T[1\*P9PWGTGR(^$%EM-2T)2"M()I
M*X?$9E_?6.-9R8^Q$5W_1$[]'S7&YO82[X_KAUR9_MU0*)3OKM*(:J)J\BVQ
M=TD  (/H!-9[FX:5YSY0WJ/^RM+:L</.$\#DPMWF$9B6RY6HI5[6VRAH2PP$
MZM Z?#K#J@#Y9FGP<?S%(6%('0B#W4VR7CB%PJ2W:X;+89]IZ??N38<\D5IZ
MTOX@6&$5P_]H<3L_2Y%Z OCD_Q71674"J"9DXLRI#*4%(;V>;"!6F%E[XU@=
MSU?*8A1/87U]7/ AIT@H8,M+<+PMY[*J:;>F@T&)QI1$0\DR=L.DXLKC)UOE
M0;_V^U[1*#TCI2I0PU;9$T+HPY_+C.$9U[UD1ZWS9?7K:#B^E2'QP#%>+QP?
MNQPH+X#HO(/")(-86S54$EL-:? 5N1A.*'%['%HR9S"]DG*U1O3F@&:$QHQ+
M-W/9EK!<!QR'0_A^EQ+L/?@T.ZF#<,<-\AI?B#4=UKU0411Q7O-B^"9HV[UZ
MN%9XX@/X:L1X3M:CE+=+%#?X3__I]G :I"*I<\<@,GL<X3:>O@=*?-\^^F&F
MR)77J9K#P=PTC95#[6'0\TH9Q]QD;;5>N"U\D,;WP*@9/BJ3(.8U7 YF1'D?
MB(Z:Y\)+J:@+(-V]>,2B/PYPOE34X;C.#RC;<O)1R>THK;>!H:;-"6-B TS3
ME*ERF&.1F%%.:&%;:]+<I?1,4##'6&[."0"H WG9KDTL)]G0/+15D!<FH9($
M"PW'EV(0,5[P[\9SRPUG5E:P.AI*]<&,!<V 52[ FN\%+L+^HGZ/)]>2?+<#
M?>_\Y58'G5OX&TBZDJ+9RM,AX@E.>OT>I2Q (;QY?$<SH^*J67R]:ZN<@K)]
MI(F" T^[N"HH (\L&D\#IPZC\A!3E51&!I(K[ ZE :Y(5B?J?X8N7%1.N&N)
M&O$HG/":WP3C',J"=SYM6YDOZ]U^==/IZQ:;GG3=.N0RC:W'"-:C(S3I2\GW
M(-/V5GB71"5[\5&GJA&R_N=>W^L)P9I6^U7W;4[MR4UV>S+>B'PQ=37WMKOR
M9\F&ZEW_#+7\++\BX]J&/9!_UA-UQSVE.-^<@%44'<@)2)1IV"[\NUE-O%)(
MYB."/]K.ANS?14CT@-AV[KAF! 'WNO92HKB]SMN^\*G8>_TMX4QIG>W?Z]@P
M28AZY%8G+K('R>UQ G"K9"76/,351;I/Y[8CL>%6? WUKWF\+IA]$V([/ZKH
MH1'\"4=GD%!$$LR #[7I\FB]R7!?$PBSF,VTGJ0L6LU*AEZ;T8>L0%AI\T/W
M=^M7?8W,84V0\W3L UZ85\?!"\5CRAUT&;NRDAFKNP-8 1;R?*\> 6C*ZG0)
M $8;#[T\=0IU">2<-"V/>87J1O"$U-R*MJAMSMLT&I9?>1'X3J0ITLGD]:TG
M'>D8]GT!=9>\/'NKD,R788:7E149?=]77>8A,:^F*&C$_UK;GZE0_U/9!^%
M=&K1-!@$9_[B!," Z/&.G49T&G/=ARB"<>&)'X(]/#ZJ.=EZ;K>;P3W8E8;O
M4E;N22=)$*5(%M1A".XV<F:@"\)$U0KYOM8'8H0YB)Z?L&[.:4Y/;RM("=4C
M#+E5*8DS '>%A*0<^A_/\:>W^J6+CDI+B)77D1*#WWVS;?;4/0!9H3#5"J%(
MW%WYQ!2I3H&+K2*3VX(#\^VN--%LFDQ#D+ABSZYB?/U'P!D '#O<GDZ+N[[&
M5"J#/7XL,]W[_,.+MX;@IA!E1&=)0A)17( FNQW;/X+V'@[GJIX NIQFJ,Y'
MG%J^O[:_HT?H_9##R:L=:!/%D2QR#ZTC&@!V6E+%72&UGUZ09*F#0:7^^,A>
M 3MWN^($44].\?BOR?THR<0K/_:,,&6F%_4,K^9YNIT Z [@([S;L<1L*TJ=
MIIOWTJ[\#REO\1*E:S]\>JWVMTN$[D^I77Q^[=I[G^M1#],X[^GJLGBFCJ^F
M]*M(\%[SJZ?J;PFEH]#N9%KZBXQ&>%?&(+_0;PU@D&PP^?&K?QQ<[/"JPSL%
MC2.8-K:;GBZICPPMGP_TM2:&](?A3P!$41<R!W2)JPLTXV]'>8-R"[\5B+ZT
M_DV>+-(NE#P/C5LSH/Y:,50#H/GK>PMC]4V%)K_VI'R G:&R("FY[1(AX!Y?
M\ITQJMB<^P(3#(SETY!EZDRXVG>9<55+T2/SE,T11.G-CP5)>D4*M/1,IN12
MOEZ-L1?2,(R?V.H?8FA9E&\7)EB+K&Y("I2/0=4(=B/9W/?*A\JQ\A?<LG+_
ME/+V58.5"\P,.JU/^?TPH3_=LJM6$V^])+&U2</RMY2:5C<2B"AH^Q/A8>QX
MZ^=!$G#RX?JQ:POJ#+@^8UHE]N*9;3Z.S^167T@ =>0$4#=!5H=2&2H_$K.Q
M-TIHL/YX<5"\_Z;A]%-;37!Y*)^?P][WBE^#,DT#5UV73_L +\-X"3FUXI]F
MZC)U\H%QJ46#=BQ2,@M-!Z]STKYVOI]]_,QW'1*#.HUZ+#\C\Q>(7>$R,",B
MI9PLB$N*XW!PM;N4ROF];[Q(7.U<FLI%8;UN-_T,_>2)5<^.TAQ0TG7J^ +.
MVR6A]?J2L0YVO!0_@YFO@C4;;^=5*8_&\&@4[+6^*\S<\E-R75433JM8N=+)
MS?RSNK&))#EJ$H["'%ZGCKA)IWX:U3@!=( "'#V[<A],=*)B[>3[@:\$^/&9
M43MV^S?Q5MG>G]?W%3A<(EPS# ZE5NRA%THZZ87VL]:A7WW=IO(*G+*:&24_
M)O\_K4@X\Q!%RQ5$.22Y\"ZV:,+H!#"BFX[0 T*&$&0N,-6L\%^+ CY^1^GA
M4%0]-)F-_ NG+8SXV@S"0I+WC#E,(2C!U_]N#?__KXT^.7$^M_CC\_]1%< M
MM1^I(>ZVW*FBCJ7V-7]K 9KF(S5H(!9$UL#:RW.Z9F1EO N%%KM-OY3RAP9Z
M"V7PO<VAL]9[R&-K<"7Z+"_5R/(>4M+*L_^4OD;2)W7$<<LJZKT@\8K^UA(>
M2GA&R>"5C['+[>%]6B,]_UN KSD^.Y>.:W;((>8'W/?1O!XP(_3(=DY_24#4
MA\H287-LK.<7UG_4.K$!K^NP794K/4XP:+HE*T9N!__17HX9J%3:\-!?.2BR
M7M;?^&?+7<[Z"[WA?)PN<E;@ -^_W422MB/J,6B:OR_SF?Y!;*QCZO'JR?T>
M=DYS.4CUH(,D-B%<3(PV;)A0RH[3& C9*?<2D1(UDW0.U+J%YI\H25L=N\8Y
M9N/Y3'E.P,0W?:3_?L!JW6^2XEY,;MJ??HGX@+]?#)"<'?8F3.!\/_VQM2&^
M2 _"&')X/]93J_9\PXILA;-@"S>I)9OO]<ZS"32(#>25%(U@H9D_*Q_:<*?V
MMJP6;#!%WM*_;Z%2F53/I@SM-,J:)=^HM91JO!L0%I!WX==J6LVZ^C-#<1,[
ML0'>9;AX2'87BD7'/I<+W#3V?#8#Z=+9'^3Q8B_)-*]NK[('092RCM<T5=1?
M),D(LDRVRI_=V"3$B'X3\7$\M.=>'^'$AJ%Z01S00[R#N\"5L<J*#_'=_-7H
MIG2&;Z;;#PE<4F4K@Z8YRE!=&5WW<%-LTD5#K(-N!>_P]*!_6NQYPN?*Q[L'
M96-F_9^"(GP4J3P4F57[RFG]!SC.YPF5;'O0:(!LUU&B8<>@-7ZM#R@84M&]
M]67SXG3/CJCX_'7OJR'4RTM5%;'I6EDKGYK*)P-PBCDIQ4<6S34;##M/1E8M
M\T(>/_&[9'LV]#<B[F +NK++MTXX=HD[@/)!"UNCQC%)RGQG))CWDM?S)BM%
M\5X-%9LJWP-+!_4VG,Y>R=.[2@?66=\Q#A \I<0<W(^\*$L&O9^:<\^T_KY+
M"(E:G8S+3*4G6OK9[#\_%U)+C,WEG6U\O:=?&B[_J>Q8RJ<U7W<L7_MI1L;X
M%L6/%E /R+;$4'QTASI,YB/1!4Q$+KZM=_AV"<E9WML3?LD5?UA](S(^Q0^Z
M6264&_&5,Q^1GI[F^2@L0NO\(%P=/CC/@%?I ,?S@N-E=Z_*[BI9_S#B&K+M
MAE7$J\ZD?9W;\$],/[;% 0E?<6M]@T\F#!L;4G4GY*IU:XL"V![A2B5N]X:N
M >":B!R08>5IU<@S.:-8_E>C/8\E=EL,OPT'MQ@^)#>,V3L>+ER W1SPY5;.
M6&IZ[/"LQ?Y=,"IX]"CJD!"&;^A!SJ@CHMM9?GVHGY#?%4,!52WKAFMQF/ /
M'>B!B.< M:OT9U=1;NT,L L_X?1$\7[#7UN>GO/SXS*A.R+/=<5^Z?8==O"H
MB9*<)M HG(G\5//^;;QW8KL4L=(X49"=^/FHEJ)56,\DV_[.Z\>76N_4M'>P
MAH[-5W\JRT4<2@YO'G!7_MYHW*W$?%&^?C^IODB/U<^N_LAR;+X>DHOFDNH>
MZ^AGO9U@^$PZU6^E/9M@QR:\S;'AX5*N7J7U7_(-E/^9IB4%BL05_LMG ?U^
M[M_RM!- 6C'9X@3P[&^",DZ'I4+L$9T!J!7I__-M!P<@IA/ UWQFZGFJ_C[D
M(N+?;C;8%5#]QV-$UIL(,F_O"4 0Q'\"F/N).!2#I' >+]!X7!6B']T/.@P0
MI'RS[B'2Q*:P41Y-NPXG'^30B+I(+ +TE1("6;]K@!K.0.6 ?__CZ$_SI3Z'
MIY.=J:,"IUJ(]J2[9!W<X!^YS'9!O%Q^T;UX=4UKL[[0M>;4/EW$TSV_A5=P
M'D3G5R1.+XG#'<*I+#_-OACTRK?"[;C'4#Y>*5>;76PL#2_]'I6HS.,ZQ0GK
M>%]=_8[%<K9HV*?]1B[_G0\J>!F!2\]>Y=H9^<Q+;$B0V>*6]%+Q U2&-ASD
MX:^=E%55LD31>J:-R/6YZ8Z,B?,W?]^I4NWLTP/Z0NZ$'H$*$>(T-_(F7J6G
M68,H[G&<T/!BIW80TM5<&X7=[Y[^(7\C;_^19!Y(-AV;Z0JHKN?WG.=S7]J
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M:\-%PSNQSQ]>$7Y3_0ES,V2&I:A&.,\7$K%07;DMA8=2F<LH)9J&N%ULYJM
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M\DG*>)]_O(^$,D&!O*LON.^]S^Y=?1ED^6WKC8VVDCD3?6 _H4!<K[3T_+]
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M'6/IP_:4/T<;[3;#(&",BA"TZ"?]>08Z6BW3/LY@HWNZ!EEK/@AR1'Y$%MS
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M4B9FJ%W]7D\)R@FB$5'7##>+AR_;A\&[?T$Y+[&^J%<!16)O8CVADYU?P0W
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M7E^]6-(WZ$.CJ;,<\BHR["_2_M5YA<'X0+=^1#AS2Y]#SM5D(#'Y67Y$ZKS
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M-'9,9HSLHZO)DOK>['?MC5@'0]0^/GP?\'5/*MX6_Y8U8O)1HOZ,]I!NTR'
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MYZ(IO-NK=\<"T\12".A?N/0&=W^GG8']':;]U]#=R,19X@VFA":+T@MVH:^
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M.,,DW-F: -"[DGW./7+1ZB3?I0??X[B'-"5*'WYJWOT[DGG9]Q$5%!-T95=
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M,3)-!69%3C[54W^S;?+)-RM+^#R-[!QZSL:8TRQ43BP(]^CV,=B92O9$'J6
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MM_O]XBG0=>IP?_DM^"N,W,5R1XW+M8D%/W;-H;=[5;/ESCZPP*>&%?PW8H\
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M:8*F0O&3 6/J^P5-@!M<%J!*R2F!K6G' OZ[]Q_#F]BZPZ\UR5==+;'7%W2
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M.)6%R2YE65_9RA.U?M"4:]&\=;WH/R6#A1'X9+W+O<U]=DA#X#!X17)W"C&
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MD IY L/V^(.27&^E>LN/_8[(@U%]/8VUG9=NL$<YI*]HEU\Q'$2)GS$GU46
M#WH$;XS )GIQ2R2>K;>@/3QP)X(U/<\P_01J]08%9*A(?A\KI?.9"O K=T1Y
MF_'VJ$:2HZ&Q*!:$J=+Z@_C>4)+%]BW2>6+,V!"OHV %OIOR0N;X5DJA7DC$
M LA'8U&['-Y\G\=Y<B1TI$B^L8UXVHW$RM\ VP^WIP+/V1#TR*/^$D*,7O7Q
MUZ.4!II,ODJ>+&-]&<T7<S+DG*VI>;(Z^(EMG=;!_--<&.45IA%#E)ET6!W;
MUIA1S.0]741@?-3UZ#I'X];-ZY)O8FY/9?(_JK?A?9_)\.JYP."=V*0M4MB<
ML6&,(K/+*;?EF1419#?Z0]P"5/+>5**&#R%T#+V@A$.%*.H'?L$2Z(*5M7CJ
MOA>E).J<";&8TCIR2NC\WCOY.0KW3-RW;D#7;)/S5Q$#2^L:^+BZA6/[,.L+
MQ:T7O\CI)?G!FMSW^\:8T3ES'[\8_BC1I&U@Q+!S%?SAC!/L>3<K\X/$E,OU
MV/P>^OHK;M^HP_L5HY<0D"&H?M=C&80AL7"91FV66 UZ3QE&-5)* ^);K9*I
M0*5%:;H1PKQ&L9OM,X<@<@/Q]NK8O+OH2T39^.J"+0[]@W9]A%Q,!1RPST .
M51Z22)=DA76VM7-V[C@5.#;+Z)Y)/-QQSK7WC@[?K:/?M/?17%LHN7.9]#%@
M92<,-CF8"CAC'J$+ZQM#*>?\O?.)+\;\6CG'^U:MK+4)XX_7AH]&I>GO-;QA
M(F"S!XU^@TG&CG9/T(TC%J[[0:.Y3@85F!XRPEZ/ES7!$=6<7X^7BI:="3/J
MS"CG5SX,2XXK3$P8)!V!!A=?DC.Y!.XF^0S!6<E+4B%FBD<$NN4*^&)"29>0
M&UZJ["5'K=^;;OG:A50T<PFRH$Z /FQ<1:#K2!]B/6_'3;NW[27B0BJRR^8,
M,=UE?ZZ;7:Z%TY+/3]<XP<L?]#V4/2[6'[H5S97U0GLTJF4.CG>:11$M$$7!
M^IL<]X>'W"6R$&I@]5>#'$C;)_WO?\VN]U3A=^17 L=OT.GKT<.TYV/%HGD_
M$,)\[NOKKFK(.)3>X+$7#G#YF36J>HA(O^T$5MLIBV>2M'HJI<%:>9(40?!#
M.7XR<,PQ(WEQ_)L:(_<*NU#0Q.$T;MTSL^Z';($5[(>V!GC$"/X*@BB6]WQ;
MBF1)?)WC;X1'U(DK6SML;*77]4K2*GNP"SW[NB3 U^)VFO'(@XM6#\[2P-Z.
MX#7;J0!G'9&A3YG(KT/'0P7:.S$_MWJK(%YG8MX%5C?!/]K>M\UP#/3R!QV=
MX..@M'G[^]GNK*<OS42-BN)LM5\&)(GT&/FWYJ!=P6H;<#35%+WCB:Y/:+LA
MLK]OME*B>S%.$__M]3VKIO**NU\M#=+D8[B=%G_P/^C6;;[&N:DQUD@ZRK7^
MAOS>G\<-APJ'%077+>TE%M@8OI-\ZB\ET].C"I-\&G'R11OKS<O&3Z^>OQKF
M$W'!MAZL[F\*L+?=5K#A49_3^>Y21-:T&3Y?GE84=UR7-?1+BZA@+4VRYAKF
M;B&$J1SIP>>2I^98-UCXT5J^H_RG#S57C3YFZM^ZOZ[B?%HQG/NTJ+JVA.XL
M+J",7[LCYMJ5T?&)E-CG Y/?F-8YR#E(>605%F\T .^3Q$V%"Q/1;XDE^BZ7
MJFTD*X9[.\(_RB#OA[7RB[T2?AYKZJ5U$9A_(I4/&6ME2C?(C+5#/P7IW) \
MQ-JZ8>9/W47E7S!@_I)EC\Z$YELQECOP,TVV@0VZGC F[.BC9($.K'-;,)J-
MY+*M0YP;5R_%+ZX?3+C:(U/5)L#\Y9M+1>>]>L-0A=$C\O)TPJIJ4"&N$JK<
MI+WS^L\E?;G!%B4DV):5DWY:Y9J+,*-U44<3]J(=Y_=:_00=%=EN+E5^XDY@
M>GXRMKO"8%@)/S(_,):D<70FF?7IED.1DGF)W:'E2[3-MV[]+&D.=J=M#ONI
M 5G>Z@:;?02W6LD?F>NZ>&A,DZTCR(<5^C6YR":92 A\LKXX([[P))I>P.3!
M8-\YN[U;9HM[^$14@I#GP>J!07_%G;#*MN)+E-"2=U4W?YJQ'5A.RUNWN?+>
M]/B96JWB@0>D]M5&$C=3.LGP.WA]H U&$B!DAOK#,/Y*Y2CC+O7G[W3NN!7V
MD(>J/"_*^ZBE)@@OIAE1 >_>$K#Z+-:9"+J"/X*KX,RQYGI9.>8'79P$^#<X
MP^B:2ZU3%P-/2K^CX-Y.._>1[$?)TN-L@9[Z3'-R[DZ<JJ5V$N@ 9Y&O7F>T
MGY[C=[MMRD=V)L11#A"V+U9#YBJ<G$4%'%%]C>.F68*8IR08SU38JM84OSRS
M995@Y)LEP?K@OG2&_?"[M5GU'M\S\MDMC$,VQI<F.SM&A-Q,4U,MI>-J>@?;
MKD-]+P79-7(4[N!&%(-58_O 42H07J$S2G31GDT^UW6?:ZKPM<N$H5+=\HDO
MR_/C]H95DI[L<V'(C'I8#+N--RXZRGDYD,)8382_1WY7526V;MMX#P]01&$A
MOMT]22F+7)5MMPM\XGBMO%"^U7ON\UE\6$*\-PS/(?98!(N?4W^BVERP$J#[
M0;DS-$>R<+$B\LS4,J;*>62@O!J.UQLA*N!PC75,,(T\W;>MSAYIV3.F6>[P
M) %+/TSS8J#K25>/&016G'*,6+(MX"VFMN.)C)^PWFC=<7_H=N,VYS*B8,0R
MO>Y"C>-;*^?'9VG/M&VKEYU%:M:4%)I=^ZQR15K"U<D_7!B960HC*G:NVQI2
M 3XJ$(*("':5WAQ$=522R$E()0>P<*.J[2#I(KYC."-X?$%51:_*NH[_DWD:
MA_4L/<-P57PX>!OQ%$=QW'BL@AW7<*$"=6:(5(=8)%?[V_S.!?$[=UQLF2^Y
MN1T)$3&X>\SD/ /=&_8\[LOX!4G;XT6SBYZ&X?='BJ*0P;CB*#2A=_A=)N5A
M*!HD9J1B>M 1ITI&2\(4(2Y]%!JF+JL@=69@RR6+F53@.G1W=3DIDAV)4U1
MP*H!MKZW C*/3-:OEB*"B3<]KE,8*M^3H"L?JU*JU[%X@R7B"8T&U)ZT!RWC
M#OX^JCEC.5GG8;>[KG>>/F3KA7__L%#"[_17#3ZS@1&\:_ "SF];C_+EH[\\
MX7Z'!H%EM"#C$;BO2<Q3-N1Q;(>"<IPNBG8J\OOC$>G>>+ Z%;Y\W49UC1<.
MD57=,B0\UX<*D%C!2Y50Z3+0'8I09MO6FS[NH88O'Y]H3??N[^FSNN715#CT
M\^KU@NST<8^X^&'7BQ,P'0[)]V8Y3V(W*@+NY%7:\\(V9++&30?@>A#;LJ70
M[RV%*&H0_,XE\LC"I36(+14>VP:$3.@F;9B45Y<0$6B\NHMK9]T('H'JQQE]
M^/1TN<T@T+"T.)F#MM&=9;;X:T3:W:M9>YF[F!&:8+4../J0LC,BQR&_KU,!
M9L^V9[P"^.Z%2M3^B-/S[\?B3[[0D@YN6:8_&ZFA)SW\R4/TKG<Z)R9N"*6S
M:GTX;&_&A\6K4;Z5F2/BBA_FRK'[L:H0"YP2;B,=M:VW\IOSU6)?HKRL3*0H
MY.FLRT$5M_=GW.:@=/$>)B9E^%\AW"X*&-UNJ'C:/%DSK.!*'][I?)94Y=^'
M^W1L2S]GVM3F9+&YVX+XT@TSBSW7+@L:X&+N'%&_,.UG!I,]+7=2.EWB5E%_
MXU5;H\^GU+-_NDTB97<6.GID5B_U8=?UB;:C\*/^<&*F0#(SOCLB2)R"=K0[
MS69L.5#/\HHT\&JYE#;KRZ%2[L>@-O9&&_&49 V<*)(9B)'5?\I[DM+QJ:,.
M[/>U'F1T?.>8OE+P]7DY3^;AH.^C8\_WFA4Z)_/F$R3"W3-GCS\HZ9%_\<I5
M/._DT=JSO QG7SPU_AY8O81X;DE7DP3[I=&9_DICX)/B%PZJ,()):DO.] /:
MYH*2B*DKR>/CL-,\*6>^IS?7J:HI/7C(RC ?KJPJC>Y3:]#RL-FP"3AL<143
M=-=$(/WX0M'K[6>9]^Q/5R!-DL;;CLY4,N GW^;,;A3'VT2G#6AY^?AX\(5P
M:=H:M?&7\HEF/]92 5J%0Y0M,KSI:CF?%N4Y'5=4?9%>M>%54A+]7FX],F71
M1^#%,Q,36L'G $UT",F;G YW1#R'X^_V-NI@'H-[;F'QF/F5L7)HPO:DMJ&@
MKCWCP[&/P+6G#@.';I8HV)^PB[[Y;IE$DF ;4+5/,UW*'WA>+ZH3YZ,2M_8=
M(E9[-1Z# U:4@QK;%Y#M_3SI]9A:(K+WQHV[!&7XG=AQS:B1,,!J?GWI=(C>
MA+3&B]C]6$WX:!H<;P@[ %;+8^V=E[B\8U(_=TM(.[YQ>"YB%>Z*)__HS>NR
MX9C@/U#YWL2JF/P">VMI'[)NA$8&$9Q,TPD6%/(<HQ\Z,>0>('UO@T5N_^:U
M-07@NNC#[&RXW,XJ17A^[X(:#DX4DXLC1%=A]Z]BPI*9\'HQSK"@>:B1S!96
MCL5LCVBU1(JC%CGD3Z<G'F<_?60E_\%&\]5\[SQ')771YL5>'3M0.D)F=@R_
M'O'1S5H.N\F#(K%0 0K]%(Y'IQ9^!.N$[1>5ZZJ4\UZY4)F@U2EQ4]"?(_-S
MSI,0A0'5:[D<!S^0VAL>Y ]W3,$HC!P<Y$=(OGNM)>.,7^;0F\'F()I2Z312
MA^D?H##H^N&W;8*ODF,I'!8S!8X;])[NL.?S?>-/&@9>V1H+BY;R 7TJ.3]1
M1'DQ'-N"RJC^DV@':):&9"&:-2 8UB1Y&_P-QQDO77W<,Z=E_[A5PO]3_*R0
MF\2@!M\ RV/SL.3S2S&*,6>*N!.]3 MCHN;O&6=IL[\3L5D/8!K1L&[I>H1
M&4_K0T!N05WX[;PZ>M**:+:.ZA#X5!K"YU_TJ?1H[)?I:R-]]-+?NDM5GF-^
M7"F0T.=-P0J HQC.0"?( ,%^-.H41-N1$]=+HFTIWL5I?;"0:A'27$NS9Y;"
M?7>O;=2ELR4" B6ZYF3WX$7CF?R\?D\?A]7'O[Y-CR<L4:[.BM!4:M;S(K;5
MD]1X7&E-^5)##OG(0+]F'="W='S(\@U4C H!'%"P9(<S69F&YQFE]IS:RR!-
MZ47X!K#Z  V/S%<N!,/KNK9$:+(3 AR\-W 8GE-=1A^8$SSO> XJ=88QJ"O=
MKU<,N2Y3PY3+]P0(^*:UEME^WH=Q^3P\5S@R!:T&R/+_4&C=K[P3.?79>@2E
MD+4-,Z67@CJSS._L:==@E:'8/K''25N$AEF.*:M5G-4 ,)/I>6Y.!8(40T[3
M*J,3SCD90B;6>06JW:%E-I[I(R+L"S,A :Q [6&_^$,, 0'DF57#Z_P.\DP5
MPR3(I*MVX7AU=ZXU@I]VOW09LU'I.KA3^/L+#LO$V:X=C1BD-N_U(LUT&3FJ
M ([/P+7IJP-Z*:_HM$52'C+\)V2/M*Y#">\JE&,.NUJ_B$,@<_+0J2X#6M,S
MF7.ZVXJ+2ZMK62*IUSEO[D>)V'+C1N(]6<WWD_NG**=FMC(P^)&ZXV7<([=[
M)0I;7MW??))L$3*6<H/+=2%8U&. (^_14UT:+Y@V2\&D-7UL=N-X1CBAA<+0
MNJV:,N.+?E@X FMTW7MD:-#"L:1!#<<X:='*Q9MTBP9%N+7LX-U)H6_;O@]6
M7T<*>#]H6X\IZZAD]S_3GJ>VXK@NW2_?^G3?VZ+'%A9Y#/EJ?G%[9.WY>(WT
M!UY>N_TBM6T#R[ 6>V<L5]$]K#P]:ZI%?*HC;<"ZC!U&7\GN@-V/9">"-:K<
MA=;P6@I'YYN.PCD3@6=\CV4C9)NF3ER]E:S5I-Q[T9:NYUFOT^@AXYSF:)>A
MY! ML1,IXI\'2")GLN8&WJYF&FK:*@?Q*&P9!21YSU55J<Q"Z#_=)Q.^'WP>
MI*5&,REUW825G681ZG1S[A9W9&\P0*J%S>BEQ#P]F=>NH\9:]5_Q>OE_TO,E
M$^WRQ.K<R,IJ:A/=.UZZGTTSO=BI&40J#*\A2>1_.5(8LQ!<SQ1RG,727ZG@
MI6[ZS,<L+7^MD\D\P29%QHF)%/P$4YP@BLB/(C%_<^O77F\<#ZX_2)^+Y.EK
M%NI8;;J:5BGP0O]P;79_UC<]T/L>74O42,'/MR'?AGMZAKET#FK6R:VW\YF/
MAP%['@*T $VC7F $-HJ Y<HVC$7$M5BG"VY*JBZ]W;*GP_ME"88W8+SF&[$)
MRRQGJNW^]F&,F)]WY&EW/F ? .P':".2Z'@L]73W3K0C0LI+'B KH[1;KD-M
M9?_U89[IKUXE;_;\F@+N8+0MU69T_APG/SS3J9\!]P L@\@"\<_S&\3UM^]Q
M/GX6XZI1D8"/PGN*S=(!\7]A=-\#9D+QWQ?/06;SV$3GF$^L>KBE)@5WID7R
M>R_3MC:)YCOHN/0XF0\O^9Q/GM,&>[MG*<PG$GLUALE>@Z'9[XA8I4>KANC[
M5VV^SXW#.L-ZPBU(W\(DSA9S%DJQ"N 49,9[U9.Z*^W'2ZK@_9GC*-*1')SN
M5 U$?2UE-YY5'A^V;G+/&+;":+9XN#OH-]\[;/<PTN0Y7]A/K.Z.UZ!J+>0!
M2GO997E>+N+SL1&52&GS8>M0I1\!\1P//FV-!OZ(7]4/&P$JN+8O$<_B:BFR
M^,68<5TAW)+5<)6 B>O7S.P/\RV/Q5;F<)DDKDOXI?JX#3;>?83@9\H"'5%-
MCCY'9TVSFA2X0K0BSO]LT\8?A\&>;-PMSCK\?+IC'FV\P0#Q]7WN+OG*%]H"
M&QS;C!*OSG2!7\<J[(925R7@X:J,"^,@$RZ3K=UVLRL0APB$9K8OT!?@ZV08
ML7<"FN &6I.TY\'Q>8?<-H*#))K,"XWQSZS]=:B FNW%O_A?(,QB%@XUYL&H
M@) Z. L+QJZJ@D0AC;E+) >\'WJ34T:RA@(GO/&WQWO#EF4<$$2>G;RQI(MS
MXX@M,4XVR@$$%4!!$[\C9<0X2DA#$&0S(-N!ZP(=;L-7F:A ] DJ\*X2!G[?
MA&C4:U@N#%]*@I7 \-'3<"(/&_$[4H:HC-HIAW0817)>1E!.>!(DR<?"H;KM
ME:0"C>_^H,KP0FG8%AT5:(K$=L&9L-/^5 !_!=6#(EKS,K61PK:8*'2-%!G)
M!A0=AM3*">UI4&0W)?^@CG42E8)4("7_+3@*_4A<@_5S!),AW">^8-;8:I>V
M8' 2"_]:)H5-/Q [??L[>)!(!1JB*6SR@560JE,O4(&J:>@7+)3).!OB*#1]
M-/^.Q4/U)/FBB$&]==A54ZAA1[!4@#=U^](9*O &)+T^2+Z,WZ8$0U9W[Q>R
M(R)<E0FV(KVC#1BQ@RF, NGL+?J_D+,G%7CT&UW3XO0#JQI) EN_J$ &BR^K
MX%7T3KT(T_E+WMA_OM)T6Z%C&V0F-(7^Q=9WI#11)9@4_A?-RH03$JJAH>)%
MYL6ID@$<K <K!/]MOI$0<GG#0G04[<JG =@/B>""$X2AY.\Q[!P)P18WUB >
MQPO$!S]7/>D-UWET;U0W2VU2)T)3LROVP;J!%N;K"%&$C70\]1HY+X^NAJEO
M1*MWRHU9:YTKR5+,2V=!S>II1/^)E88GL'B-ZH/E0=O='21QZ&:X7IC J'6+
M$%RW<'%KWW5+1M@5G;.XB(-?ECUG:J9XYI80??(4>@(^<UV\?1A&ZVW:\VW+
MKL\]^QH3W*"4-US,KGAEP^Q@LGM\_,L59<MUSZ/I;.5Z"WG#&GHLQ\9&#NK:
MWO5(MGV.JDKGU3:,T]+>:AYBGL3B-5%$86[P@WZ5G+7M_ :O,N&"3NX][XBU
M0&"^2'TQ?V*""K 4\+["Y-XJB#!*?RDM>5%#V]^Y$):K^+E"E3>)4SM&-@7.
MT58P[^K^RN0KH6,RQW (V_Y RR'N1LH1J87A1\?IAF5FQ4#I1D#J7^BS&/ U
M NG&M'_9:C)-*?V!_[C*XAT: 39?18J"G]/!F8SF2BW,+!*ZT5ZH<Y&82:C)
M2CXH'>-&. /1B&%ECQ_848B/L,M(/H07V]=B.;SC?<3OPYAF6SP#9.X6YK+Z
M6>CL,[#(_W27YB36N\($[_6+/X]<(M>V?A,>C""PFW3+-#WA+'IZH3]OVM2;
MT+3\LTJE*X3B6MT(]?]S)&?;*O#(VE)0I4A)#TDVUVD8UB,.[QJ>Z;UG=4UC
M+O@B5S*IMX$@S* CE<MMREF0:2K:DK]VCNZH<951+(Q92R\QN<P)F8#L0>-=
MA)\IGW4MT@^L% NMDPN-LV:S$7/S3MW.NO?F\M1WQ3I@T7DE#N<VOX##])77
MPWY4*N&32\<"=";[>,@YZG& IP-Z43MU^XOF'.(NL@F+=\^LAS]I<\D@:73>
M415PE!KCQ._-[TZQ>;BDMCQ!R\-Y1M]K"9&*V N.IE*! @2)U:\FL):MMY^Q
MOB=M3\N8&[M%3;1VXYO+<?>-Y7Q]KDQXCE<Z;SL_^^CF(96^ -G]L\,CDMW^
M;>"V,']KG-R>S(_H92Q1>"5%GXX;-XB4L9?=?K1M#E:74 %&I$A"N,X8LB@
MOV'J7_;CVO$NF5*NZ*)+\DG']>_.9RMJ]._XOG"&$P51#9@?78-#WCDU'C9$
MY,#I_L4PRVV] XH%GPR^H[9FL^89 UP-&SANVSHT9)[&QD 6IHD\U3J9*(:J
MVNX,P@TYH9*FW\#:/A];TVC] Q=WFR<0N9 )<&8C^>^\,/2"+.!@C+_^,\2R
M0-8<C'P*9E$-6U;(7"&A>H,H+PM#R:><-^LH?YN-,#]U7AZA' XF\N?!'H*'
M*.>(>L?=F/V9"<I>N8I".$<WI3K3FTI/RDJ*V!<F6>8068><$XGY^-I+Q&X\
MS@:/>EY(]'1C\HZO<9$W+'SI7W)$.RSB\SUZNL=G+G#L/<)X_X84;\W'['5$
M]#G"594B>?W2;Y1F=*'-\VUSY#<;1F+H6%]J@@[A0=SQ-]FYY?/?6I[?<-,(
M.4_X,/]%S=]D)SXWU%Y5Y"FP^D+E(=*Y#B3;='%9-^51KKZ7'T_#VWVO0H0?
M\MUIGN6:G"^5 :N%P1L8% C9P_!A*:*'5(>_W;;B;'_81O_Q3*'LG&R'B//]
M#?N!(Z-[8\QH?3=#NV.P:I%NB$F:W&RM&_FJ'8%E,RO3-_3@YF^;#"VH0&37
MM_HMIAJL*!5P0N^\(6AL^S&POMB#=1CIVZ]"9Y[0H'N"(/_(D\.VN.23HV;4
M[?T6MAHA6M&M?%K<+\IY@B)?PG*X:)0[?$3IUBB5,1&P8Z+BRSF99=,N5HR<
M+[1F7%X3UPAS-7"\@3Y1S"WH!M%ZO"U8E85X$-]F6AJNK)&54!CE]VG\>CU#
M0(I6\MEI#E.9\W4BCL7'A5>GUB^1XTCGMMDIK<AC1/LQ!8O[($/?07?IAP*5
MKWY.?HJ&-9X.6^:MJMP/ +X.*'?>AI?J\O=)<U?4%4U.9C6(2EGV>9V,.'S&
M]9ZK;H[U.OP<=C00C=<'0Q ?L!%(N#5)H_W.:@+(Z_S JTSIPKL+7NO/4J/(
MKSZ$_\AD::RE241KDX]%J8O\X,G60/%C5]+,&WP#I/OS<VT\G?RTN Q3.>^N
MN\//0:-I((C71_V2*]SA(/;9EGARM!NNU?7;AH:#[ $)2COK/83T<>9RUG%O
M"IZC:16SLPQC$-EB(TLN!$>3;<2(()X*Z)=T*^MGVSBN# SH>AW+5JSU8L6\
M%K S##+R45[%Y-J<"0!K8FYR^?5$-5SUI'S8D(XXSH#*M^*5AZC"*O%"'@7B
M#!]&:M![B<G]2O C1./:XXHVJ7L]3C>Q$BYFCRI&O:>AB]24739;6(.N(!+3
MH4GS08UM5=(M_'"HO<\HC,;"XL+[$:UWU8=B%XXM#.8=%W+G)T6?V+RZ'!".
M#'O2[S[7U5XPG)$L>C=[-G>("AS-OI&JZ)0PXU:%9R*>$IZG'T,33\'F/V>3
ME B'1OI*CFK&]:OFQ5+NE\G.WA)H?I(W:I+$<T^>_\,7A1MXMNH$-^(I>Q)+
M7/4Z%3B\B@:(3+B2Q_Z*.;8I3M%.S >?B1OL"Q$0FAP&Q:_:'JW[Z6VP;>*\
MMM)L="KCB,HFKK_P;422@M\I-6T5M/XEQ1\*WY =XO4;&E-,\YGI.P$PX [P
M_MIJBBBQS6UTZ0D5..BOY",XM!%4F/"C8L%.M^)% WNM8$MEC^>]J*_/7WX;
M#*H;P=]U(['TCJ,65D:IP)-UQ"$9'96;(,.<EWQ9R*#3$8MGMB]N,HQ\MAN*
M"H\LE=TZ\_S13*,V0O(GK!F%T;IJ<H,UM_V.9%;#57)BVM#:IQ\)]U6PM/&D
MG>^7=J+'HN&L6+>V _Y"!43;E+XY-MYC/7ENLLSN[ZIOGPBY_$R,5DQBT?#3
MM7@R^\%"VRB1?O8>!=_.5+/^VK=%3E(Y^GT?%2J]MY%TD&W,QAX"1R$3VM>I
M34S:ONM/7X"_]:*)8#RNDD-$XO2OB.FP]:>&-#LR75]2J;N5S'$#&!5$3I]]
MR5NTV8Y7HM"7$RZ-[U"D^I%"5,-!:TX8H\.#3D<*T+FP!BO2V@.XC+[H=*#?
M?IIL=%@S=NJQ7.\#DV?KLM8/%FZM+FYSOXZ!.>H:Z:BWK[?-9VZK.& _9LZ/
MC&*#56&&Y+A1LBB/XKD]0<[!:N2)>3JNB<B*<$IG_.HQZYP0S2WCG-:7@P/1
ML[[,(2&&U@<F%!2@F056'FL'#4#!]8BG<+P-&(K@D4TZ_&UD#!LJ4YYC+4?V
M9!>(M7>_Q78FYS4;^7+2U0>8CHNE,LGFM-A19VV%YT9&8<B. ND<=5F!M"U&
MM=:[5*"PIP!'!9C\Z0BR4S5#8FJ]JGQ6?<>_SWMZB=EYNK\(>OF<_\2#Q>FY
MM;SY0YSJ7"C9L/N.E/U1W>8DN>"=Y^J/G_3M+'V[37['-B99@R7JYXDCOVSY
M])RD-#*<-OUR$U[B4[K<Q;TYXB?,/HZ]1CJL>L+_,CGR9/#X_NB4&<31(M1A
MG<.83$<CB*Q;C6@=/!4AY B;&%2G?U&VAC%A!HLTO]!3)$K99?N>->J5B/W4
M:N@IL5LYYW =IX7U*6Q[M..,#_RA,ZX_3[,M0,36@"R%H=8PRVYE:[D<ET-L
MWX?%!F23TBYL7/[Z)BZHH?-+HYY: ",T&>0@A\F@!G#K2H3@6FLM<5Q9M_BA
M+97!4"K -Z3.9]/O/KWWX?[&877/Z8;/G6X*ZQD5VFU13#Q2%/";D^C-;#UL
MCVKWHB/WZ6.PZ^M%J"]N1/E4"KT*H7$=(&<JNXR[A=APY[>O!MC7POL>>%S(
M&1@N:%U_)S!0+'=Z_X^VTW17S.;ZPT*.BF-Q>K0.Z6'U;2QF_5V#9SZ9&P07
M/*V]XK-$-&O$XLV8GJ +1R+\I4:3/-9M"6IYH>/Z],.#@[.^ ?7+Y^,'#[_(
MOO3S2KB+'$-^7?W%*=%[SO-7C&U4&L_=6)5-XHQ(?!F%S4JW1'8HYPY\)T5]
M(A?#1]]%S<R,O=KQ)T53/TX7GJKX;3J>N=N_JM%H6[$IZL"@=N+=!%]??=)1
M+@H]/0[S",9+4MN^C/Q>MI894BE'+!:6JF5YWY3"\53P=@P0GB&U\.RT-G\X
MK6CL7N8M398(*G#-P)96Q6?).D9Z__B8'L.I)==,'N4]1D:)B;E%;:THHH+7
M.C_Y+>B*I?-7QF.JO[1N!+E,?/Y$4$WN_\KIS^:QOV3[Q(M;=D>#ZB9."5XX
MD1]Y8%FR#U>-P!NY]>F/R<6,N@$D:$0<&SDTW;YYUW+@VGFO_(89@0=828$P
M=8O!6-LHK7'L]2?\/-7KZ>RLTY/&08)J#>(2T]FO#C3G9*=U+L,5L;?;GB/P
MA@L:N-XG"Q01?SA1)],?'FT0[KF=J^K-.'@\<<F!X#WEI1?BO*HMLWE^KF0U
MBX$P_"1/N_MS#E84];9=/:Y@6'<K<:D^8#^N;N20OU9&?X-P69=,>8*#P0>#
M;X2S[P1&::+."8<0T13&:?(3BB"R"O81$5IQB@#7*FI?R[6J7W'J:;\0P#C>
MY-KSX 7=",N9O15&C&D3MAD',)4ABRK34K<,N2_CU*^:=GC1&X9E9Z/>LI!"
MT7$*;<+3NDAE9'-_.5AM ([B]-G\3?+[LOS/$6DR*L/3;=Z.N)U^)U3\1.S^
M#<&ZWHT#M=D-%2\>(Q=WO*),HWDK^2BM<<.,1+KT&=HZWM,A5CP:5EVRES]2
M&@MNB4[2;(1]HS<8O7E&ARG!50"ZQ "L5I1!$(4RYQ,RB$+=8UB"T!LJT)\L
MU,U\5W)IZ)BYT'G5*]</?'>/3']V:"'YJ_*8^I-LQ'!<646<&45#T+LYUZ&S
MI*P(B=3H=+A76-BE;)SSU8KWF>'_QM/7_TXYT"K4;RE2M $TRO Z0-S8S$7\
MSY\2[O70^5E2!"K"\=:TY12&MP1-=)RP=H,Z?)+%CN*-F2ZST9]!G/$/V F(
M1VF#%[K5?[9ML)'!'XIO#)%]^@QA(U'TSLIGDMWH ,3VC]7PU;F?)&5+EP@+
M"U6F/I'N/V=Z;ERTODFAR&ZR=Q,F56^A<JV%?OZ43-)2%FG(?4Z#MXA\D(EX
MTFP>C=H4W( 1#6>QI#@-TCFQ=7TJD(* IA!!0CG0',1SRXNDIEQ."="'")CT
M2ALQF)T*3*&&J< 7BJ_W6BK*DA*$'6M"? 3)1[?1I%.R"(I.*H4[9EN8"K1+
MEE*!FFB(OT^4P<=/_1Q9603O@U_AX]P0O4N&^U$!_LT97$^$BO/6<2H0+(AL
MH@*K.HL@/JT;W)1 $>]!M:,"ERNGJ "#KAD5B()&]&>9<6!;*;F="IR!=MQ1
M%&_R$@DUE8FR5%C#3%O]4<F_J]W)9&LJH#JUH4&JI9QH@&_B-K#+\.1D%0=<
M#_:MVQ\6^_O*A?AXD;;10[ 5IEV5_#^DDJCSJQM3F5? Q+";6#6(AD0@\!I:
MH*/2 GP<53?'D8OD[M<6ZECM,[N3S.^I<'BH/CMQF6GI\/G->U:K;'K0S2Q&
M:?:U([$9DL1?) ^KQ5PN6\R4L7LYX6I:)EK;=8;O\05V 5@F=^V^],_I:<R6
M/RP:3I0\%J#G=@!H+D8  " 51O,H9)-RDB \IV!V23(T6&ZA?WVYJ,WM!'1_
M_KAY[,Z=EU%]$A1;CT/'3==C/UQRON'('C(\+'"06_,?UB6;1D=?."=C]E.I
MO,1C=2+*5+OE V2<#_VC$11S_NL;C'SG7U,/Y<S2Q4^NIO]G%V;_L42L&@X_
M5*@<"6)]0/H3LONK,&+^84%Q3/A?8ZE9B74\//XGE?#_)_L_NLKX@%,=26J
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MB]::XF;A?GUYOY=87)AT&VZ\')7J])^(ASCKA4-H^3X T6CJMS)VM62025I
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M+Q4RP(?C:F^'T2U,SD=[()DCM4EMX:G!!?*UB^M!6!M*)+ @(N%NQ'O3!#;
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MG,T3&ND]@6GN^&T,151P,\(G9 S^'ZN]\'^8I G*NV#Q]VO 5Q-EO/^X6A9
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M;JM6#WI\F-I'15\TV[61(N"MC0B,NJX:[E&-7BR45::K$HC\,JVLQ!#]BD<
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M<X)C0F-&>_J-US]G:19;=+/S@U2>JNMWWQ.E)C'<7B)=',.&SN OPU?<];Z
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M@NMUG[+':576)'5?#41CV:*X;;Q'+$'2W=?>LW]ZX/G)U.0.F[L8Z*4\WI[
M&0!0!OD.0<*MH5PVZX ,TG=&'0#&R\8$IM EZ,X#E;L$*VSA-AXSTPJY$F2)
MIF(A":1U^.JW"T3]MM!3>2X6[-SPX[U4D/L*GY"[T1<%,\^.B:+A8Y_FJ.7Q
M#JW'!;1-OC6X/^_GL\U)EZY1+ 1AC**]T:Z<N,91V<&KY_P?1:LT%-4@7MY?
MUF3+H0/5\EX(8WN3>/O!L1YP?8W 6MB)J+$K7I)X"[YVR]4+'@NF]Z5%B8,K
M5<KH#()S?!,%3JZ@A6M*WTC&K@H;@BXK"!!+( LE]+4DJ;R%\I4UTGT?"D5_
M5=T*;Y4F@ZQ1T_VJE,?M<@*#522#1(:5F0N OI^G8CZ60F9?,WZR)<[>/Q<F
M89_)>$OJBN?O1,_S#S\5WB\<MV"N1J/']B:%^Q-+>;BU/F^/$ ;?4^3\PN";
M>6X2-VGJE'NM(Q[L".,?(EBCZ9\?+ZY4E_VNE(_PPC5K1%U34V6/3;'Z;4WW
MT=]^58&SN4L/$$PCL&#B3Y3TSI4O4',<D4%_UITD?\XCJRD@Z[VV!W$8G"K<
MW?GY4?'DS875;D2A'C* 6/= 575"87FMP#'JAX@:M;H ]Y-U=A<N@<CBTJK:
M)\OS@,B?_19+?S)Z6,)^^)#XFZLC.GAD)[(VYGB&Z0ILFK\;_JA\<*\GY'KX
M<TDMVWN/FQ<QM>UZD^XD&C8\W,^H&RT4"W>(U5E8J4&QCWK-TNJ@ZK]F7+2D
M:N,/^=%546R@8LKO#_J)K7MVTDW@6D+',U'8&L8P_G7SM2&O'8A5_<BAF!Q>
M8[CZDG*#*'XK^SE:0M!.@J/4D]/9Z[GM/38ASR-DP1-<"<6^DKHG9!#=($8W
MGOB6HO!. DEP,V']%"XQI:H3Q4*?WV6 (*M35_F-IYNO/+O_2J%HP-Y&87P@
M;!2*49^?/FZ#G246!>G98T47(7$O3,J"#/FN90R<^2O1K_#FMU5!K]OM(A4S
M?5=,KA+]@"5L=SNBLKL5SN2'[V0;F@3<VTZ]ZK-76M:8;MA?A$3.A!ER5=Y^
M,VJ,1A)8X#A/BG4Q\-9'C52+>PP$56(.#+PA-\=)P8"J[[]D!U1H$_>88A,R
M7*WT5]ZK7K_GVM.(#=U#8#P>-: 'S\!;F51X-C@Z#$RWS&K*%HE"';]N%4ND
MW?*1'A1A,S"L\'8%_\@/T5 M+;$N-L[FK#O0FK9H"$C19%)Z7-+TJ;P\Z !S
MO%2X,T69)VALVCM95%CSK;0%5%N9R.'TC(YCR6#^3,O6@3_8N4;-U_?EY>+@
MNG=<]G8KU(@_=(/4/5^KN9V+O^BWRA@)O2:#BD)0>S,5EC<F.27.ST\FP)U<
MEXT:PNS!&V=9.PPDGW5\"X"5PELOPW@VX(R0A13$>=>J2=<A"0*$I_A.5]V!
MF[AE8<J'([&F'B'B>R4*=E'PBZ.;#.)P!3H'%8<H&!O:!,DH6C7J[(JYSLK*
MGYJQ5_?EF7NX=Z'0C[%CBB^VUJB!,9KP,**DFW>632$A#*GD0RC9[0/T2/25
M9%"R<I D9.[[N![)L'QKMV^_4N+X2T[IT4O(+N9059W%^-+H?^4GD++_7D*#
MPV='A#6*05YDT(H(E%6EWIB4<:ODT)V6#%IVH?Q?8@!,A18B1.>1!$[ _$/J
MK'@L\.Y?_W3_\?_)1L"B/]RZ^G?. PH*_)V2H.#OI ?+_TAZL'O?-K/=\U^F
M) !"89.J?V^#A6[\V9GK]F=G[JM_WIG;U_Y/.W/C B;VTV+*&366)D_C5TZ,
M-\"$RY4D&FOT8 2<608:8K:26H8>I 8REF<VGL_J=DY$K#PW_<" RWX8"FF@
M\EMZ"4GRF#C?YI%C$V*4:)PX37(>_'YJ?P'KLM&GP&4X':".VX?GXF\H>5EO
M:ZK-'PVPJN39W7)[Z#23=HWG8P!'"(H%\FSR/YS_UOF?\P!4./_CVVLYXP*Q
M&X<%_[$=N_]O)>Y0?^ZU0O-\&(L/X;^ANG\N]/\G4^^454KLO\A.>_6_J85_
MKYP38LFL5*L184,X@?=<^1_ON*J5Q<QS^QUH >Z+KFH6$Q([7DU".F_*W<IW
M;9DZZ9PNV?$?MK "\A0HH-""D.8M:,UJ@_<BF'K /R](HC+),8:9ZQ3[A%3C
MYLG7<]X&UV_[GLV81/N'!*B/H9P&(Y72VN,9=+P+""J8IBWS60W#W$SS^MAW
MMQ\4TMW0 -^0NZVQ]/,7ZGR16$-V\W?(&@'1U4Q[=Y!;J_&N:%$9YRX<%@PF
M7,I]DZOS[F!=V#ACM9#:[F-&?=*>4/W.IJ G9&K03?2(F711C\+UOL:C>7)M
ML)7H"SG(/-,>?DQSIM**6\&3^)J>PI OGGQ<*Y%N<C$D>P>KR\U8^L:)A%9Y
MG&L^#F,Y^Y8XD)L>U?V]P6UZ\FC:^10!2"_20UKF:93E\QQ3L3,;TT:(\P6E
M#G)?-!*^%/%DG3'!S$$?5=N+1#_83/,)F-?:8Y(RE=/7$^Y_T:^LYN1I7M0U
M$54S,+^KY)#[F,T!W\AP5_C;O2_RK-Q*.7[%E_WMP67^J!T/O/H&Y!MR^Q@=
MS^U\182B8"5D/-96OW\@5/QU=^Y^"3 Q/YIES>/O4@T9#&)@J)%@II.[]NJ1
MI[Z6M^L4.!F%\:C=B6N6 _+R@[A_[<D[-K/1?G'^)-?7[[<>]"&3FF3:Y;MP
M=#MN"VI"P18:B,TDZL7>U'EE2Z1YMR-:XMV#^J:11V>K"]Y3;P]5\,6_3U,)
MOW_'>*5P^QJ&V8PRUJF4N^Z)#;YK[-^R5'N<U-$LC#A7_/H!]])@7@/_/?LP
MN!.1PJ1"PU%. YH+>MNSBZAP$D>&KAR<1TN&+;'%AV5D09V1)F'DAR.3QZP:
MPQ&VCH,P)K):;5Q?\R<EF*W'9TUE.481#.)FAJ&(F5^D?Y/WR>>=Y80\O :E
M95@0):A&AK:"J0ELQ003+)\%YX.5*KCX3\=P51/MDL;)UI6G$B\[C,]CG4D,
ME[#'+?1*>%7L8$O#( WAWM.0U;;Q70(Q#DWM(GW'A:X.%#93=Y5=P%F31#],
M3"+<602_-DOK$M/@5*S>"=@,%-6)O$<&1;HFTU>DZ&'87G;&ORS9@]ZBF*$#
M$]"D^+(VI3]R 'BKRAFOYI%M#@DZ<R>I6*RVD69@0V/\R0MVL?B]B]\8V V?
M2WV87/R_V'L/L":Z;7]X%!01!&G2B0H(@C3I16*AB B(TJ1%I(LT 0$I49$B
M+0("4J,@(M*D=R(UTD6:@$ HTDM",Y!D\@7?]]QS[ON>^__.N<^Y][OW__'P
MK)!9LV9FK[WVK/5;.[/76#_?3BU.^7K6TSZMB<C9$.^3@&*L9<D):6B\F1_V
M<@:IPF[K\+["JZ-FJ&CW#67<-I$^^CL27/R!%/2X&+8[;M*/NP,=>C7ZJZ.
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MN2(#6:87++IK92&VUV0(_'-(_-F)E1$H)A52;)F#4_"!@2R0Y9I1;>AR4T[
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M%*LJ/:UE=][GNFB9X,\N"IHCP(Y@(]WT=P?/!FYD!!P8>QN3]*JDJ$,^APQ
MYUA?ZL/2[R7]3):A0!+!=V%6_TQ4-ONW.?"(?_M:>J"X[JPC>Y;8/UT9Z.^2
M=T;TYH&6;:)P9L7DO^!TOY.SCV86FDBS.]B^F>?Z-^5F7@*E_Z(K_+\1M5V<
MJTSI7U*H%(>][._,B!PE_:(MCRHMO7'0.?//.QY+438X6OX;;LM];[U/?X?H
M$RY,U89.09;KL!%3T,BULD(6?R&\[Y3. UR\BQ?OK:9M;V-C95:-E)G8,P\;
M3[]O4SA*<U'T&W?6 ],8"I",0I,\76>=KGD)T?C((1-"O(0;,\K4DC>,57I
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MQ]TQR*SJEXQZ"8KQ@Z'69&!7M(EB?6?7WP?$GWB[6:X_K+:JH9T!;]3]862
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MRL?]+.)M$.'$7 7U>Y][ZRYW#5D1%>,7';11U*=OGICKP7-@'G 0WYX9A=N
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M55S!I%TJ>J5_E;H8JS#-;K,C7YET2AEK-JFR.V<F(RX$Q&I=*]#([7NRK8$
M).HHIS8[P;5CZPJEH<) (L'7 G#!YT@:9MDB-(*M;W00Q0TDJHGG/M5M6B6_
M;5W4#%E!M/JBYS_-,EQWA"6BK9+A Q"M!^ X-%:+-K+=5> O@9Z =SVH79>>
MB.HY:682.=M2 ' 3"[%<ZT\NP4^'ZHPV">/C$W6.?4JV&Z*4QO=IJ,NO^VPF
MJXA.71.8\E0[DI2VS_ RS/'H33K(W3& 47\&@]L?U89T5;8.Y4%%A1X7_FA
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MDXX,M_XQ/L1X5Y>46FE,\N<V/?OX1_ZS9JX;:P=E+K;C)?S1TV-CP[]N%UZ
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M37K<5[_CP@1Y\;OY&?Q' Y)Z3&F3C"U*)5F/\ EF6'\*8(IB":;"=GXE?&A
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MX] W= 0I[H3-SO63,G00UTKZTP2YDX:KPK0MT?;3&OZ6K?,)8]O)A"R2>37
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MY0S:;--X/FD6JR47)KJ;_^T7_+YDJ$GDMO[J:W])]H)A FPNVBR\T_+U)[_
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M.AY]//TVRT^(+[Z!1>ZIQ>X;X42"F'#&6->[?#ZOQ;>UR5X(-E,SX8"N1(*
MVC5C\6+#5RS_HJ(RQQ9@U<C6/@]L_@88[]IBPU\=N=XN)(6+S<]='>R6:"_[
M#783\2SPO?3@@JW"G>-(;J0]?7 GD\_W$CAQYGGH^;"KV40+O7'9V+P #P*2
M#1(P\FE<B_3'7 \H(=YLJVV-%5G>WQQ4V]]PKI>#-KHBF5*,W@J*)!C.]5EC
MVE%VEBXY;DJ39(@V)YUX;5=I@+@T/1H J7V>!L!R$?S('))W*3]VJXFOYBO#
M\^P*/*C]0EPDS<"[GR(.+684G@L;(5>0ZXK[4.O@*9*^A7#C5;A6D'>'8;!7
M 2O8D6LI\=,W%"6]]N/,'DB6!G@.(5[)[)B/@N$>(\/F!2JDC_>LHX_*HI0A
M*WP81S<Q2;*7OBH\O> I;*L>RYU*T;[_2MT=N##\MA. %=0JZ-#+*B[".%K*
M1S?UE.VJBZ.Q1J;Q)*,-<A.E%(1*S>1NDJ;K/U_J!;+7X"X_/R)"B)=/?U1V
MYOZ;JT](&O?LVZ4PNIU[*S5JA]A-(/$J6POB''0(\L.O WR<:#[.O\5.S&FK
M5H=FGDB08I+J!P#J/Q3MB7'].2871''.NJ%D)C^2$ JSNW7KQ0^X5M/X<B<0
M=R-S$MLU_V-^0ZB)D1B7-[U"%:%CD_!]8V6<38=_-N\M*U9BMS6YI#/(8IKC
M!<SR8><0]5K>2]B 4M+EAL)1'X?Z:SFW3;\6=-E#'P7S_R4[Q!-<!%E & .&
M3QR>C :Q^#!M99R][N*[*?G>>[X\_X].RBE[;** %\0;.@LIS0R#>2"F$!"B
M,_9DJH;@(W,K@_5@YAB9/]I/:N$9=ZO-1$Z9]OC;V727,YX?,PH:KY1/%%,=
M#>H<KXY+U)02YM7)A;>#WM"QX#[Y/%WN@UP+_/704E!>8@ENC?<7X9R!EZMH
MPXU>11Y431+_.]ZH"_[89X8+'ZQ$X<YHQ-0 ]8P:*81LA2O.Y*F49D1#VD+8
M'I:.RU9$N=8["8\)O_%.S-XN$7+.F_UQ-EE!RO;5]3YH>Z$G]5ITYH+%@QUG
M?15QO92]JOQK"J.?:V?KO4&:2!0&.,F B2"?9R,$X]@BJ-PK!/7Q@B_$UUM;
M=C6CE\K86\<'A%##9>$:GUZPNFX.3/6V!D:\ CG.'U]1SS4XE9=%A+:!ZV.L
M56.=W+"QMUER0\--%9A.U;/S= F$7.VI-Z]QC"Q0ETB8E@6G3 EH"IN,697O
M=%%912FOM,5A+3>: /Z,UXF/<Z9<+3/",+RR6\)_>^L6C^V_O14^-='*/7><
MDMG _&7M0S'?U_=HTEGU/TJ>%V,?EF!C1A7B3[/DV@L(6+C<S\!\Z"S9BI4S
MY))7_,PS%'1[-KA5U5^WJ+#:$4L#;%;2I=9%8B-.AU TJJU)[=*6@K?5$;(T
MJR>@?/'XY]-J#K8[HO4_SS;\N'OP[ W6Y>I*NYM9(;)"C\R5T\YG72<%8@H6
MM@NZ7.%:='X8&\^9L!,JBG^56?R<55U@8L,RFW  _7AR:EYS?ZD^)ZTOM[!3
MP?76].@"M>^-QU1WA]:P8RL0=P<T.4. $X6QF<#@FY3<!I@KEHV3N-;3.3W>
M*;E<[\:G*N1HWYI]X]P5NVVK-Z_>O-2_&"!+YF:CGN[#SD_?QPI%X'=0@H?.
M2*X&C?-, 0Z"J!\UHY;'#1O'&MNX;M5$G\N]TU/\+E.A##!?P*^C=#7Z6&PC
M-;PT_(FY$J7!#3JK=3;O]==5"? XQ>,WV1P';@<2)1F[@NZ0F66B\OVYGGV8
MGB.6T0#@D><9X\JMY0>1PZ>Z[#R8@DLE!Q4R2QG)YV:PR(TT.A2,QL';/[L<
M- 2@W%B=OU>R<<^M>894FV1@[R1>\6+XM8/W4_PB'6^FXX>8]N+ ->#DM#,^
M-EE^:UD>KA---WQ\DSTROKQ,#9O8IJ=6^VA/D'GKWDA!:4S1NA'BTO/ U__%
M')_'$.-(8>2_KRJWUW$XL>#W[_)T0D/1"'*,*)7[( <W#T0N9.;3 !#NA0'6
M[$C)?2_BPG\Z,?8F$9;9'SL?<4!>WQ@@BFV1.7?]&RS]][NJ[)U,,&ZR]SZ#
M%B[]-I3(/+#W3+S)EK*=6;M/3L>J9R4-^JPWJLN4$/2&7R#.8,LWO%\\%#_H
M =LC$0T>9,XC]^M1NA0F_W+\,EQJTLGY?46?@C]=8]  _^C0$UM$4S?JZQ3+
MPOB%3;:_"6I';"_8J>YF_UD?L.4*KAD-+F2</03VQD5CA[,8CB,_>Q6OLZ=B
MM$O?$0-EWE%74%2VEA<$)EM<Y#;)-*@*8&MRFPN[ [F_KE;WY>\4_K].NO_>
M[/U ^&J?R;A/6@CCO8SM;8QDD-7#Z4=YOJVZD0KZ6C_4<MKG+I7CDB+\"EU4
M?,?YH)G,UM:_K>\(1_*,<OS:\#<#V"= 7B%QCT!$V5.UI+O^G=AFY.D]@Q*V
M9KY;'3(^XDV/&FY()*2']K3R !B#.?1/'%M93'&[]]A*^G)U"!)U(/#IU]T<
M<%K1S.AA N$WL1R#F*%S49$3E'WG>_#9+[.GI67Z:@W\\\Z8/YJ"XP7;CVN<
MW%-:A9QN A =45<2!,;CK+YGL8C,NE1+%5U[]7+A@IJ9P+:&!9H&"$.BLFD
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M)&%\2=XARJG0)=E -M/.V]GWV$-\H;Y4E#&I:":#" 5Z%H/5ZA0NP-?.J3%
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/CKP3';?X?4$L#!!0
M   ( #6(?U0@U!IU_L     ; 0 3    :6UG,3 R,S8T-3 X7S$P+FIP9^Q\
M!U14R]+N)F<D9Q")DG.4G..0LX"$ 8;,#"!!)$E.DC-*SCD)BHCD*#DK2 XB
MBH"" @_PZ/&$^]][__^^M]Y[BUK,GN[JJOJJJ[NK=^]A[;/ILT4 1TE.40Z
M@X.'\X3S!("S':IGZC9.KDXP&R=G:AYV3D!02E$5$1$X)ZK'SSTD?J\"URC@
M# $$<GIY"G@ ./_[+DI_V88S^.K8IZC[.1J2LWM%)5([Z+)-^*()CO2B_:)P
M*8GA#(4XNJJYN3J[N9Y7D2YXZC!7+7,G)_M+"45'5S#8T<WA1_GB6]H>>E&_
M=JFK!?&XD)""N%[H_&X3# 69.8"U9?6USUGD@!0 !9P 5\ & )^7J %50 Z0
M!M@ %8 ;$ #X $Y !M [Y\,NVR'G5]CW;EX:4X<Z.5EI@5W=G-7,;2W.V9B
M^J5!)\#J7$GK7-P5< .<+U70G7]*_^BGE+VKXV^]P#1W@]B[0APO39[7T2ZE
MI54-E+]'\-:%/#S;'Z*$]TN4U)Q=(4Z.%\X17\;"V=7Q1\?/ V,._5G1M(:I
M_MX"=93^O>+H^GM%Q=P>]K,"LG9U_UF1=;"7^5DYC_WOIJ4L[*Q_"\1W!P%-
M>2GI\R^$R[(E-;6EDYNYA-,B\(/DH8Y_X4G9_U5."FJIK>/H*D>K:>\*_$)2
M]I;4?\?7A-F[7O+5/>PE/*I^L-'=P1:N3E 9,U>SGS-)W5H=]F,F791_^Y:^
M# +8RO7OS&N?+X._XVM9V'_GJT,M) Q^LG$LH$[.>C;@\\$]'R^(H_6/B&%?
M-&B>^R3EY.KJY&#OY&C]FPKFCY8+%W[A8_W@:T*L;7YMP/C1<.[;3_;%S$'8
M^>X#0NLIW_F"A/OQ?3FK&"[;L'_O@;C?;RL6Z[)ZL::I+NND?ZPC?+JLH_W0
M@[O48L3Y'N8?P_\=!>'@LJP <%A9G;?8GU^1?U/ZSLE.3?O)X;Z\&IY??W#X
M+J]LOW,N;7ZY+)^OI+._)82-B^;_?-ME+%"_1_32+P!>XOOGMS:JGW'Z7B>[
M*"'P_?3^DA $SJMV/T/W5_J%=R%W(?\/!7[2[XD!<'2SOYA@%_D7V=S)S=$2
M]J=U:>'*]</-B\G\RT0"_C3C *F?,_.[&YH_)]YE%Y!A]A +,$S77N5BZ<#]
M 0?ILNV\@'?^0;FL*,K\8AO%&NKDYOP'%K(3%&(-^9D59;4NE-0N>>=U+#,W
M5R=YL",8:N8*MKSTWM/YQT: _EWX@G/1HNA@3?U_H/\(;E#[W[:37X+_1XXJ
MS!K\!PZRF;VKMIGU'WC8%N!S/;"'JR),05M5Y4>"0OW!_H,PFHT3U$O2'F+]
M(U+7OG=>X0?[(KJ68"LSM\L,A>8.AKK^C;CN#_8?Q3',K:6=[)V@OP07][N"
ME/S/A@LW0$Z.%]]HKD[.Y]L0#/QKX-#MSP/Y%RZF^66J^PL? WJ1T/[$OEQ!
M-[_K74QG\0_ [WS<RR+<]\R#2'!9NQA0Q,OZA3Q @/Q;P!Z??]3/BXL D'1>
MQ-\"2 "XL^FS'0!3TM+)'&PJK0K G[T'L"]K@*7?A=[9'/  P$1%145#Q41#
MP\3%0,? );R&B7F-D 0?GQ ?GP07\Y)^^_I[@L/"P,#"QL+!QL8AP,;&)KBX
M8!-\5\']5PR<O0!P4<^=?XP 1P/ X\(AX,*=O3[O*/I9!YSXN9=(<)?T6Q@1
M #AX1"1D%%0T= RX/S?" ? (/QIQ #A$. 1X1'@D%&14) 1,GO-&7 3$&WA<
M2)(:9O@T+O[<R 2QV=52M'2$FFWF/+S0@!%I%/HXK0]O/UK ^(AR:@(99.*U
M+65?YKKR$X_J+('W:A^TC[DM?Y)C3,@+JDOL&%_9SZ_OG%@]T+5R#TXJ:.B:
M7#L4D->SOAN27-C8/;7^&1> AS_W%O'2)Q1D)+Y+%VYPX2&>>^!"@X_$[1]+
M<.%!F^;(!QXZ\[?0@#AI+4(+&.]'>N0+!U 8^%Z.GCN12VPIJ\/O"E[ZZ<(_
M]H#Q=Q?.9@%,A$M,7$ <.-".4Z1GHHM35%*DB].,4Z1+R%\FS72J$!"@+]\R
MB+)SJN/+^0H ^A\F&]^T9'J '!(CWQ7#?/.,YWWSO*K[ 96ZEI2]-+B)S:,6
M7U[+6X>5ZI&&<V85(7,^K]X<#B\H4S;J-"4V?=VM]=THU74X>=(O2W@PWU])
MXFXE5B V)?3T9J50HJ".3U8Z5-14KI1CW_Z Y33JV%84Y$OYQ;&EU>;I6!%*
MLEB-P$9W$M<CY:-M?JTSX+9NZ4F44=;Z_/:FHT9QA<4)8QJ_R/**U_TI[_>G
MOB<HN6< =B'7E--1V9W-,R#[%M'$0705_T'&>GR8NSXP+]U"MMD;?GO.N)5H
M;=5+>_V^SX&Q7DZ-N./!PK>Z@3-@.D)\SU: )X^_]%%$XI9#1:[NDO[AS):7
M4S?KH]'Z?:^F^Z^L!$Y<- ]L3PY/WI)T/VG] -$4C5EVTAL]KM3UE0?'#/7Z
MA+"O)3>OQ]?7FPN5S1OO&ZZWF+[HV3*X*]9XP!IN8.Q8?TA.(8'%ZOAT)__1
M6_%15I.'A_?;S>9I=QH_7]]PCOU<^SGD33'X%&IB/WPDW3 K?!!U+;?(V(*"
M.41XCH3"@=5F__-].Q_;Y\F;_.)'=1,34U3#G]TPTKJ]TGT^[XJEL]8>A7 U
M>F?*#::+C9P!0.WT4-HVU]SV[@'<5VD3=]Y;%J9&HFJ.LZ\?KB\[?1O,*G'/
M2@>KP-A@3FG]F]5=5)N8C?MM<Y#7^R>F']P*.!S 62TAIL7N;B//)MV-S<;)
M#?9/ZEN/15LE3_--WVZ7>MV/&?>*RC3"2@*_.10>INC67T(-L5E+9GV*A56_
M4_SV@.\]X9,L(\ZI,\ ANV1=QEO-L T(/#9;Z.V]<3;\_CAH)N$6B=E2PT=(
MU0R?T->,ZT9V>?/=?"G/<Z][GX[=/Y[9>#PV[I681-8M!PB,(?<S5-T]5JFU
MV:\XM>VWKST#,"9.D_=MAYQT.C:CNDD%6D*8NVL:&L?&;+Q7COV\!;Q<?;M-
MU0Z&6]<Y5-Y,"G\+CJ,P;2Z:7K-WJS-<4/9V*BD5]39HW-=_=U!^<KUPBZX^
M1GN;4%/4)/RZ3:FGFUEGA2<FC,5"E+$EW=BJ__,9P/'N#(#L)^T03C@03G]S
M'_]<7>'F""3%T57/WC<?O*[?;/0\6O7].""*AS8O4#MJ5V17N=!<_CRF^-L)
ML\[!::I# _>S4BKF_!FB:9+7Y>7EX*>MZ6_.0_-H<?H,\-$=/P-&Z4*TWGTY
M S923VV4?Q0,Q#]%Y+^?YJ[@Q[8C]&Y+KAW;/Z$\K76H'/'!.N%A/0.0ZXJ<
M>W*>A4.IMBHL[,N'1]B<Y[NE2U_O:VJJU2Z? 3G61]D</PH">6? _JNOJ6=
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MC9FC-=A2C..'X@_&7P:&X_O(_&\8,0LGQXM?#O^-43O',3O/?F H3,P*ZN1
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M4,K6O9'6Z<QV07(.[XH/*/1_,9.9Q7G_X4WE:"8X[_Y/J8H:C%QMW41KWU1
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MY:.3@YV40V\,9D*#&]V7HY3V(6 ..YA"<5,GE:=Y-OI*'QX3:SYBB@F=\1G
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M./0[P-;PU*E3?'PX30JU?GAB0M9RH]7,KS3<%Q[/V"$HG=N:U9F.@I5;7$"
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M>#W7/9U-6O1A;_^9K#8M#&JWU17]7,0/E"K7]?JPIY5J=92=\P[PJ(EEO("
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MWM>@,7.@&B1A.2*2?"RZ3-Z:_<473Q,]@DG!]P&Y$ W9@T DF4.DX%50OM
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M__7AL_8P9(MTT;@6]] 604!O^8VV@9/X]?'#I6ON^4]H8K=76Q/0&YTQV&]
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MSQND0(U$[:3&FJ3$_4.JCD2-05Q'6M=XN/#R[N%/I#8GM'\#.F4$N=&M(/G
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MMN*)#I[J<9QE<.:;BV<VG=<180VW:0[@Z).N=&DJO<RP--Q8+'0+/0N@413
M?0>\A1VADB6]!&9WO3R"UK.D?P WA;U\+J9\NWANMB+F45X;#PW? 5L$/9?#
MU9M3CQX#+Q"-@:JJX=L7Z.&"'GWUT/,]Y\>TP4&<N>#_S7_N2G"&_L=-;=J7
MQ_^UB0=PRC\@D6LO?+X)3D-@N%]"2!5\2[90*;M#$$+Q:8=?#7GEO5YS)_'F
M'G@'?! &G)^>K,]QG1+_X+UHV2$"KW&3(]I]&O9\$O9R(KZ'(M%_ZU\,I#W[
M8[_&YP7+<XUYU/ULQP<X P.Y=W<B8Y[O+H9]#QV FX@Q?>,PO_@Q>=$%\\?B
M; AMI^P]$#;1_#E).KEW*=56;<'[8$'OQWO_4($V "*"?)<_N>@:Z [SXKF
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M4="C3-%F5Y/&5'33,SM^'C#O49I#7$O1><.B^__\C?OO9O"?]?\!4$L#!!0
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MAVVB(UMMJ.NAA@P4=6CSPR<$H0:T@^C(&^B@6:<!5P!@ !Q@ 8  Z $: #F
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M<D 4\/L\T;#20'Z;)X?W7S]ECY( L43]R;T.>I+_B:\-@GWA:R! EPV_L\^
M$' '?6L(>G#1XP6UM_J6,<)#@18Z)ADX"@6W@\'MK;Z:X'^3'(;P$Y_@&U\+
M:F7]LP#OFP =VW?VX<S!6OH2 U;MOB!ZN6%\^SR:5<Q',L(?/9#V^;H>"8Z:
MARN6]JA-^6L;Z]-1&_>;'<:1%<N9+VG^-OQ?4+#6C^X5 =R6EF@)#/U^\JO1
M%TY23.QW#M_1NQ'Z_1M'\.B=\P?GR.?GHWOT2CKX(V'-'HK_\[*C7.!\R>A1
M7 #,RU^NKS+:[WGZTJ8ZO,,2_![]$6%>0%_TWU/W._W$.]0[U/];A>_THS
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M1HY3)HEO*#.?<3VIN+O T55"D")8 DEX>,.^&Q=VERV6!Z1P^E4(F=/\F#.
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MF+Y-?SKS4JN"E3\S1[)G3^M9"]JVL]GFOL.M[^(ATHW.CF36/:;PE/,&RY"
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M*NMKJ']?H%"^BW^GC'K+#>(OX^+H\#U2V-\ZK_Q=?!E=.Y"]M=?5"H7J#8)
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ML#.##R 0< <0#G@ > A(!J0!L@!Y@&) !: :T !H ;P"= ,& +\ )@'S@$7
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M(Y=*5Q37FZ[/P7A@9W"G&Y6;K]NH.[M[N/NBAYA'LL<N1 U2X GTM/!LA!+
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M604]?"/BJ^IW8?[(@9=XP)]_)AL1"0B/@'P)Q@]K&!P<$ X1B(0$=_6O8 !
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MX:TFQX*8K^^WIXO&+;S4!KI;/-K(8W_R!41]N>5%Q=;%J)=:;?O*(4<)C^6
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M&4KDL@Y@HB&=;(D Y4)==6="928G3; B78!5.%F@G+"\5(5] F8WM@^A?5N
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M:/&[ #Q_AIYH:A1O&MM8N7&?Y5R^G9U$7;<E GW58OJ=BR$1:AA80CIYX@+
MTL#1B6G_-MGGJVE&X=K\H9EGB-[F3P](2'\]LUJ\W-HA %M7U.>W@!_WHSH
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M9<BW=-XGDW;>A^,,ZS]_P+VP4H,"C%N5_:HKCZ)[;O9<'0E%0 X,W-]O.I=
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M$^W_;9/^G^?DORV?5SGY_ZV("8'^W<[T/XP8GS#/5<3^5ZOHORDAYU7FLN9
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MZ"7$SV8 ,@"X_R&=&_F?VH [:P+@H0(& 'L(<'@ >#PX!#RXLS8 -0 . (\
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M6MJ%R9%,:Y?S"D/(=W:H/M@7<KQV&G]+$E$AJ'Z<[-_RGHOFGH2)5!RY+3%
M9G8J_]"RFY8J_![I=5$VE5&> 79.L\3KLF"M&_S ,P!%6\M:Q7YK>PE742#_
M9SI- I>>M^FOG.PD!%(_M8SY.,=Z&V!0V.CJ.(P:(GE08'=FZ&D,>/L>NU(S
M*'?/O,D7H>(\!7M\1I<EQ91CP;WQVN/V,#O6F/ZPQ>$)$??D31;;Y7'9ZE<"
MA0%196AF;%XWA+L+/E[GJU.5B?F6R!+I_!&1$)0JUVO45E"C"$]8$8MVNP7A
MWEM"K%EL>>TDV7:AD?SDA['X^3V!(6],;B-YM*0,A1?<-#%C=&^X%5S]>)HR
M4A*CM\9:58("\TODJ#U"CD+/YS1[!QH_HVH:Z&8(7RDG#Z%7R?4HH(5S#&4F
M2\6KPNY:U\UJNENO7$#;Y?E-(P;]U74'1OQ?%YM5F*TMZ!:IMH;41MIOE\U\
M?**QB/C@:5;GVS #7YW!=,V6]I%]-9;UIVZV-U')1Y@P0WD"(X%H@CD]O1QO
MH)2-J&%NJT%)&-T*S?+X7%UWV.Q>B97GTRY[,!X@P2]S;$02=C6?8$"[L><8
MS9++4K(R@Q8H.JAV>DH]>_+" DK?OU/LCV0"?ZAZB<@9*@MA)JLE/SD#+.F5
MV_76OBTIL#U >+7RJ>MY!<9$)?^>.@J_0CPO5>B#M'6#%VH\N+-5[5V+6B^F
M%Q_CH/N1$&-C]FN5=?(Z0-*^6:\M39KVUI]4S4&XP?*6"?O7GR35;406%;BF
M;,.-J'8J!>$LLRU\JO-J[I.P?OKD(^5^3RA:^-.4=3C+ /5V:[3V@:X9+K-G
MW5%]>0UJY*:T6E3YGY_+V XF#=C6Z)F1YV8*X"DTW#,N)&75.@,$[IT(J.EK
MUY--?&6OCM0@\@_DS)FC$@N(\$W*"L%X(UU*)1_,*;.D8S2[^2J;J8_<GF4K
M ZU>N!$IA<"=W/"6J<?41[D@ 30A) M$D%# V\VAA1?RPN$,"<]Q(2K0Z(S:
M%X\C7%G&2SO[/-YO;3)OYL[I/O]LXG._OA#N$4?NX2$3 XH.G>&;)UEF)AAN
MGF8-Y6^:4FX\4^(BC>=>K'I)I[?_,8J+!%\/=TR1>"/&E$/XKHR.@&^],-C4
M-UR2'VVYZ6;])C>+@QPO9&JF%X--QB@6R>4Z_ALRH!T%C47++&WNIOU7/!F\
M+0P'*G[ ,+$ZH6E6:F^PN]%T_YC_NRBMWIJQ].88;E'O628?%*7DIB@#C^-D
M.&;+GGU![8%^%PT&_W1P0M@G-,$:"9:,\3B\V$!/G<&65FQ3_#OAHK>LOF[1
MPS]%>YF5_V6XM5J.7W="AZR(#]'(/5$GF%&&WH+Q1'$C: K:*L_M[(D[+>WN
MUY\E#?ABUU=1C/2V%Q>KORJ2\;H6PT#=6B&5XUIZV?MH*8UQK"S6+OXH!UT$
MPA2471IFG!W[:G='825?AD<^V40)#\=BHA^BV>#PY)=OWUQKNY.0V.C8.!OX
MQK_)!$2*B8P ]^N#>:D9 X(&DNL@+K<+OA7O1R+2+I!UM%=@FS5.,UHZ/]^2
MLK>.M!Q<Y/U)1,/:&0^\QX&A9JG"-98AOLAR]TFHAK4Y4D5I54TGEH":_JK#
M,;AW9"B3XD&N',OF.>2B]E.=(GSJGKS<>)IX1W52?GK7.T QT!6:"L<%4(SS
M^1#@.:BS\M5%4*,FJ4HZS JC5HJ?122"GXY$D2%SO2V[1]^YA.2CKA,*9:1?
M7&;2+WM?82._'3E@@>_Z\8FV!MIU!,I$7!+&&-S$5/\GS^)+NJB( KNZ^!1[
MR\QT6[+\/S/3$6L:>YD"ET7;7CA86;OEU[=&*)7-.*I[5]<CR__6'[]_0&$=
M:SPBE>16UNU?7S 9Z;5[E1RUYK[11&<D5VW/0Z",[6F][G0?D)GG5LNGD(N;
MU=&>+,3JJ9L1.8SX=(8VIJXL/!,>/K-^9.I)%#BC:HP._;X3-_-(PM1[X+,"
MV7D.&^-^M<%QPXTBU!O;NE:@LE)9Q$\*3SI;NUX'R6*7":F8PK-:U?6$8WF_
M[HS?N#O/>3 7,]OXX.UK:L:%4GG\74_$9Y,GAM^R"_CSMC)]B)&4 WL;(>WM
M.AHLAL@:ZBU<[]ES]PQ.JXL#T6Y,19H5RY0^A)8$S'LFAB/SE";9;M0[13?E
M816)]=AMY8J\6I+.4%<HD;%;^;8P(-JSM1JNI=I7;7!P#R#AK&\AM.7\?/#3
MDT)Q:WY$?<2"+ ';]WJN@M45>"&"MKF'D-[-[D4*]N S0*^<BJ>JTWN[?N3K
M, _JG %:>T<WVSRQ=7*>KWT+>^@:RWK#>$]26Z^-+QCR$J[JJ0[F/$DY^90Z
M\88YCLKT6,7XL?TU:^.^'+H7FUF?*D.]:"<4A 8#U->8 [7<6MX:SEB99).T
MZK&)%"'(Q D)5KKP4^.-=?57;8I-,G!CT"W$&(X9N)2_'&;R\W\BA1-:.)&=
M)_%L6@?!7=V,="+P,&U3PGG]!446S8NW1>9 C^&RIL;,Y@(.='&9D=,/;9YO
M&OKVGEKG<)MO(!B)QN;IRRAEFC&PBK8/AIJGRVDOC 9O)P8>3)4@I]I#2D1V
MFK.PC0Q>M_2C?XLOIS5L[D<4T"/*[<+0 $:5%LXEQ8=U^=VDF)"ALGDQ)?D$
M110Y;:-W174IRV(A8U:0U,E;(-EARVOR;G&Y#3Y:RFP0.SF4QJ)/^GX>(U*V
MGJSF33 )MG>??]S+&Z'IW(K('9_[@Q@2UV@?XK?*X,J*!Z1V' MY4KS_TV(%
M\:X)HI<0:"VO/P\$U#F:/<L&YA3?6C^%>.QZ=RG4>N)9BT<GQ3V/\)R*N:$E
M(C#,PZFC3.P0-^<$1.F(:[BF<+,._,G73^25+KC)5@DP+K3*RXVH'/JV4_[A
M!X$^8:?92+%KD?%/PBG#@AQ/(8X0N6C4\7!C(46J5M*G&US&3+EL"[4%=X :
M9B,!@4SP3E1L!<NH=&AC<8[7#H20Z]@H6P-J(@BV%Q\IU9M\2%"!]^5!0T-#
MU0>_N;GVGFS#QW8\;M9^](VA-[.I#'9T;Y#R#>3^SDC9SCB<0P&"S%Y%N>+W
M\3P1GT2DT,!Y)76A1@[U\J+ ]TQ1-WB/D1&92V[ZOG\1,XE=B<3\@HXOTZ8%
M5&1;:B3["#C%VE*X NP4O+](K:.=T>"<:4/2-^$9D+!==]VNAM*M"2JBI0WI
M0*BF'@N[7?;M#DWW?89PZ8X#+A**7>S$.RE43"L"2\\4)"!W]EZW<Y<8@'9Q
MJ)@^G#JTU&W2I 44%EX75 U(6,:-#PQY3L74]NW1<6>B0-A3)P)JL]0.[DUQ
M.$W4G# &,MRUY7@[ZK%Z1FKK*<+A4=X@\97<98?#AGDI,=T]T[6GI;8/]GU%
M[HO.@T@I&;:JO$VO-Y#'0=60Q>3#IS<*(VS,]I8MPRR"XA[?Y+GM[4C&^/;1
ME_[P: ,C;Y>>F<+PPXT!UJU449>M\B>ER0&#4PX),S8%WN-ED&Z;7&E\S8KN
MF_H+8ERQH4.A8WD+I.;!N(&F'2.>RN5Y^V+6Y4-1[1P%7T)XQT)'=,.HBL?O
MYDR@:N2%@]YVDIIVDP EPFY9GF U2[S:P=GA=#SI8$^]=5,,/KZ=/_RC1^.+
M[(_1Q]S'MD<B'QS13CY'W(MTF37KWMO+'&2]H_B6LV:,\!7/O6"8":N[6$UG
M )B-U3- U]R;,\#KJ=/"HPO9W$%65QO1QJ(!M$L%L*,R1?S8RP6OV\T<"TST
M6S'CQ$6!<MK28QBZ\F7-81D+2C2$V2S10RL5B:^-1CYX.\RPYFS>I=$BD'/P
MG% 5ZDER&VA>=*AP>#PRF5S=#LUVR',(RN_ES[#YI!X7"@VMLLJM#"P?S4-M
MW3,%SY#*4YH&8XV8"QP?T99/<_!.99=W!&4NTS%6F>L0R"POYU6'#D6ET.PN
M!..]ZZ2:I8*^X2A_]G-KH*S^/*"U[C=TD]^"-,W(A84SUZA>V;AOJEKFH>$N
MA%2?Z97E*,]0$?V2*= BJUCJ4;.Y?L\9H$\,7:Y\FT>TR"3L6H5%5JO]$<>$
MN @^4%CH58@.15?;N^C9=O"JON^G]EW[,:O2Y+>WME9HKO/4^;0TO(S"';_C
M]-!Q1,H!BKO =;_4? *+V/ZZT=[)M3. TE1VT,1U3/0N<I(O/KXKJ;3>?(2J
MAGTA]('L/LN#I+D,P-W^M@AS4KU"Q!B])7E6Q7*IX?I ?HRQ^E%P2&[^-[*Z
M.%_+QU$O"A>@4,IG8=(DTY' E=VX^2'D[6U&@W!=3OEN4KZ";#T9?!6I@?2^
MPJVC9?I)/F?^MV\A)LDX+UNSTQ@F. HMY+">^'ZU?1N5)\AI*\EY5];3K&D#
MLA1+2%ZZF9G3C-'[)*-YT%E%DI41R$;"RE&HSW#0ED$OX^!;H6U Y';:6E<Q
M-8&%5U52+N*M+?SM141\G$O@@R4U-CG5+6E4@@*!]5,E/I^,R#ER ;?*Q!A/
M=1Q)9:OF:N_SF-R?SYT=/0Y[K9N$RE9 76CDLH^C=N_6L3CU\;VG\-ZP@+%2
M+:G[MGO839;IOF:SDK2P \]1T<F7M^X>16%F;:W5R!9LQ)KT2MN;@#CW%DM]
MJSR=9F)(:KEOO5X\ V#[K+(_7_SP83HY/Z,S^LZ$T\C)NY#A*2KU&[\].OQ]
M+%AJ?@,/2YE#8<>>R$9^DD)=G5<AL;=WBMVQ(14.N_,-+#X2<@_W)P@?L(H*
M;PQ=.X+JN?8GDF)BO/(NI"XR2MQ_C[2)J?OYV^O6%)]>H'>=,#C7]D79\AS_
MS)<S@%=&9;6\EN;?QX&0] X?UXVA*83,?QDS:W)=PH0L8O*=8V;"NMYM*1T/
MK(8.WE61HB65)87->7V"/&[4;)3Y]PP6LNC4H3=9&IQV"*##V/>&^3SVAV^7
M1(*U];TZ;K&;'>K-DB_Z9;WT&R,B)H!T8NQK,0Y_DF/LI ]!19N9*F8.R-8U
MENVK_8+LT2![FE&4%=C*]O#%;:\1Q:</-)I>-2"W/-:FQ@PR+N"P8!5T$Y#V
M+T],]L>B*,O610L6]$/F 2U^9J2+)"&LL?=[DT@44H1O0%0'-[/K:<65IB7]
MBIZ A&[WHU-;^C.+YF4NS*HQ526G/DRZ]\Y'\==]-+]XI;)\DZMIFNL'>:SR
M[TJ1>QB$U:ZA& K.I8#G0HA3E^Y6321[K#HE#LT%]=?M-AZO=8H>^"P9>\VE
M"!Y1?JX1]?%!6X-Y+\LI3'Z-:*S$+-OON" 9(;)PYLZ7,$P![]=RRQ/W6B*@
MS ^-ZIANV1=@ZX^8P]WW*B%Z,%90X3>;]JHY!':]H_FV/2!D,4 B#QG=T"86
M35RI]TO=_*(3U_4IY/='3!RDG_N!D=Z>V>5^<$?LOBBLDS!L^\4KL[JJ=:V"
MN5BW-%?^1*=0@5/G]"D?Y^76SJ\*/-&MQ6_Q2ZJU'[)_+/-OJA\(:?XT-O7:
MT=EO7NX,\/%H^]MNBFMW"F=X6-YT/KN/P!O/$XFW'XJX(L<(?W_@I4:_^T:U
M:V;/IRF@KNQ3^P2-R1C*^K?;EQE$\3V#\G3W847\VNGQ&6!$&(5!O_K@(SHU
M)P:6=^WPSU0R[17^'Z<2ZDY?E>3'[97E<<3I2+R!%7/(0D+IPV0@/2/CLRDC
MLXYV1#ES8$\OZBWKMR/!6^;.Y5&)Y1:P$&0X=S_H1$7T/0-4\=U0G-RS UE^
M(FV(C2&H#EV1"<_(6$R*D50F#,=Y1M"%)4""P)M$39D4]P0)_)R&VWN<_V[D
M@YF[$4-J)[%/K5C6HA\YV$4GHU*I-L1#J4C3M@T9YUH>D!#P^VT<XV$2:O6)
MJG8SS-,#>=TP]61ZVJF01)[<V>9I/K60]M3<M/6#S!7T(Q*,W=.AKCU"?B%A
MU3I)T ^K#PJ?R9^,LQ48MX>\.C#XX4&1U,/2B8WM+#+%A0G'Q[HSUYKCW">;
M3(S6VDWV;-?G:@2YG,U^&TV./Z()3U]:DA^01TM.6*I*%_PXE%Q! ;.I;F'I
MN<VC;_%EW.6N6'J=59Y+@Z0**JV\GGM&!/8/GH.M7Y10E.12!JN,=Y?,Z6D2
M\3+0=7I:;U4*-6PQV'A>CVE%Q>WJ;I/"ZY'.*1YXUM:GV'J=)\S[/>&0=X/;
M*]R9>]RO(QA>8@_N;=+&#(J;S6 ]I"]!4;R.R?!^N9%MD=*95^\D-/O ^P2\
M3E.)^VV:32/%G$I,S4-1872%SR+K@9@.^5H) 2]&30$;B?5H %8:&F5/BT)D
MI3GE;EA6U<-'].YT[!OK9G79="25ZN9H=(^!40[/7YE($7%@?JS3X-;@2$1\
M>KE<L/@VK?1O>4+(GWO@#U[S-8NH%:AF:+;/M7#Q)T;)&=,)4OCF'&6MWA"Z
MC%QD[D!B4>;ZAO;1R.)-N"3S2>U)Q3K70?Z BJV[,VE.,K*/'(8*P+7>U\>?
M2"^P@>QU]H?I2NM&X<4)J!  ,04'*R6M6-7(</=8^2R,V/5).]A3KFD^D \Z
M'I!Z. #>LL9MZ^VYX='2<3/>J)G1PF1S.PZI*?!9*05ZCZ 27]@V9Y:KQ>H*
M_?M"NA4#W2#\PS&D^;$B[INJX/#'1?.IU=CID[0@3\E/F19<80R9+UT?;!K"
MZ8.9M"56IS^5H-DT:QMK4*L7B!UOOHNF*NS$^RSZ>&<[_S@CO@EU-W]Z.U=/
M>"&7<F. 7*WRM,&M\2COM:B=<?AVIXA3XXQ3XSL5B=C&(X?&V0.?&4>?U11G
MYL+S/>G=Y9[TA.CGGC1,>)N=?V>3\9]6(PML-3;.?=X_?OYOJMW]@7>+'HL+
MM<IL ;:*6:2F3<N:S=].FVTF>U-*V?+-<S 14:V^J$3#X\05UQ-*,$XJ/\F6
MVG#5,YTHWUXW3V4H-)@8Q@H0*:Q3]1Z\&U8C H_C6EEKJ$<DVZ<307SDDBZ_
MK!/Z)N5;LX"E)?^)WJ)7I'I9]G/,D#KYYUZE@RY#<.MIB4^PF\!F9*PD1B77
M.\OV&=[U^FL$W87>P;RMKFT=\HZ8#4&*_,N*,)'&\X.0#6$P4<6:WJ&U']V#
MG:Z9H2>V\Q#^4&<*K.RD9S?(@U$IAF\?YK\TP5ICN\9)"?'L2DHI74I.(1?S
M:Q*B*$H?47AKH!#:O6OWLBS@/<?[GL70G'GZ@OJX;\*E</'12J(>E=8>;G]L
MS\VJ+_,.*/Q*!'%U=<3TZI:^O9X4D]J72#Q)Q3%1A4D@,=RQE= K+KI-Q/;U
MO>$'RC#+WM5F[\&'9P!.5F0-;X^9#.W]GM+WR6 0*8G/MI[8S7J!C7Z<6=37
M)V[_IN@C/-^)"RHO@_/+T\\J3.05%GEBUIWE[87UO%/F6;\<I%(^MCU)< ;2
M1U8C'T3)61\DCG*-O3QDH_IX(PXCH]VZ;+!(0W])3)&!+!,]^CJFYXB,*\5@
M*W*T]USU$7_UB'3,ET:56.7"TH08!DIPZ6RH2X=(6?CG^>-4(9VY+X4&9P 3
M@E/U :L^W7L^FOU]VR<,#4>'XER1\;N=XW?>&]P;+G,Z\5<]D*?A-CIYKRK"
M_25\]_.'@^=>8G?D^[5K3MB(SP"3B&> &+?5<PNZ3TX+W[WNQ"D]E/?Y^N5.
MW^M$;Y:7'\MM2RTM0A1M'C^D&*CQ BX06PMZM=GP]9E#B97$*L"^!:T0:^M<
M%GYYH_V)6*&1!8<:T8_[SYERK4M4%$S98VT5V;E#G>/T,U%E2#<[72FVG<#"
M%;KE4VNJP>^*R-W>!(*"IVU,21>P6<P):U(?#/^K@Y\$U^4I],CYG\Y_PWPB
M[!(2-Z5B4J@\/\3>+2\4LE(.149ZUZ"#HU/\YL@UX"LRV]=CGW^7:-TUJ??>
MO,K2GZND=UJ';8.I&RMG />5-:Y-^1+QUW$[YG>L1*S$J L;Q7P$4AJZRG(0
M$.X>SGVC(#Q>KY\S$TTR$#3*32V8",GU7#DB#I//N^8RP#M]45C]UN--TNK6
MC(78/+"7VUITGZ/6+=:$1EB1@?QTALDA7L^R&&\Y9^HIZ-4^RJ,G@(]_5&MQ
MC8V( UROVU/E0/Z%WYBK!8F+3U)TDS[>CDG'CFG"OQXW+SL\_R&#CA.4S?HV
M)J6S^*L#A&VI#[L<;]C47P;H@G$#X\J9-F>Y";U''5:Y$);44PB<;S.YQ!&;
M;,4"-_6G4REZ!J:.13 M6B0IV9.T6>!MFB*J%+JAC]$P[::\D=+G$[&BU4F&
MG8!)=_S'R)P_1'9O,3G YW&$V#+"BQ0$/G,3MY7'YL!H7?7-^U!X$)ODW?P4
M>_8@6XSJ-=O!^X9WIT[*C<CO),-\BZKK]^X5'7VLH;!YA:&Z43R]VS&]43SV
MX;/P1HGHW7#OU8N?(\KM?>\C4H+QWV_N6\:$?I.G3W!:M]^^_^/\B/SG\^-\
MP^O3!R1)NW$WMMW='53&U,V[&^UJ/IY^EK.Q#W^1\^/:F>#S]7AF6CGY2!K8
M@S26N-XPZ[L+U.UWJW9[W<O6RH-IZM\TYU=SBMPN(<+Y=?(I,W$_B<WJI[T5
MK<W9.;.A%WM,*D(KM\\/6_<I;O)MZ'J$Y[/:3Z174Q)W-X[5$\"]T.!;(HDP
M:["+WZ:A++O=II6:_E*?,$MOZT%;U5RJ?PDIKMH<Y'"?4@E+G!4.+$0-B'7-
MTN.CHPPU\F$540_M0AEO;PO K)8&6Z<I^,G'V5M0NK1P3H111,79,+  .7<H
MQ6,+1L@Y5^[( [UPI0]E&QU\Z+WZ0BP9WMYH$2^)+'B_MC?N^)JBN@0H4^D^
M]*W2BSW1AHT#?)VZ %_Q,1JTU5;K*"$ULN;3[GTD#_.Q)\7BS?DX4UO[B-LP
M[VB(=&3LA7R:*#,K*3L#K,*NQ=NG0H-"Y&]J!A346X=,2Z9^N6#Q_/V"-7-R
M.A<M]&_.IT)\NY\/:BH31?8#E6,P"CPWR[?/ *U/\WT:EWL.^CW[O0Z@WI92
MH2!2BL_C9X"FR=Q5Z+LCO.7%J98-T1/CAI[DMTWLOOS4603A/BDC_Y4K0/CW
M*X >[ IPC^3S\AG@LFQLGV_1HBF<?/\TIU78G(S=^O5YVX>&JD2TY9X"#XKG
M<H]>$667"V?\^"+#U6%U;M>)^4NDE=_@XX;71[^4#.JLCF_]GGWW'*@+:WUA
M!6/M %8RR-=Z!.:*:>Z7J;:?5AM]+J-6X6C@'!D8VQL@4MEXL\]!_E1#:RG%
MJO*?-KEUZK0_]K<&6Z[S_8WXVNG U_>WYIX>KDHN7][+GYP!2.[=:J;M4<6N
M=U=JG-+!K,CI0(#_+,Z&4J!K>?*R^>C^[U/ESB^IDO@]58[GAO$$=N^=G-ZK
M2#P9.4\9G]L'I7,3T2[<C;S)%2E;7\MWS@#ARITE/.PV_Y@^FW#F?TJ?G)/E
MZM:\!&B9HL.RDP+[5B,/HKSMU%NEOI4A_NA'*:-^!?XN;B&QP94KINXU#%%Q
MGC$84A\BK=H8WSO3ELF%>V+?P]@W**?4TZ[MOF4>D%TTSIO,76B@O8!E-W6M
MH.Q&48(0/L;X-S)5]8UU(3J]Z*K" $&RP2COR$<OT.F\DY<J%[:5'!^L8'L9
ME"7;)DPS5Q7G8BTTO3?DYG !;&9K!4B^'$.$=P,C[NBP^J=5%L[W#'IFOP B
M,O4'OV_UPKF5UA!**9,H(X?E,?%X!D'Q(+*6GS$M '4=998SBH:Y/16ELV<G
MI"YOE7IK?CY+&F=H^ICJSGY2G_.NDU!N9M6MKMPFU,[\V=T!W<.Y >'=$M'!
MRC. Z%J-\&YUPZYQ^&Y_PV[.C-V Z-UBGPF'JIWM??#J4V;1P+T_9ZF?]AD@
M]_.^!/7E/KC0P+)S;_K ^]<O9/YVB]3_M]M@[L4V. 7;!NWG-I/FH"LK>ZH\
MT#NK(E8BQ^4-O/0=L!WMZ]J]>7O-W?+/=Q_MN#@L>*;XE1A?2YY)7+\)2\V\
M3M$!F_,E)&Z?Q2>Z=)=<60[26Z5LI*M<F4E<CO7EEI& JG:EW/1UYORZ#QD)
MMCEUVZ_)61L;'#HI'#KI/L@Z^]17XV/-IT?<(^ST[JIYT5ZF.&MOF[36$]E'
M^2&X@-<L5WBM?X-B,_'NRPEC3]549FK)KW7!C^YV)(F%A/FTN*)>9V[-X3!T
MR<HTYANKC$NZ%G=L1SNG-3*&DG! R="1X)R0L%W<*'GRZ:]W]3V4Z:-;#Q8^
M5_VY<OSQY4%*1.:4:7W)RC]N0N=?8O3_N^^8L)5%CTX=-H#])^D$4/A/;_:-
M'<5\HME6A0V$YI9C%YXC@YI,G%X;BK>#60^FO!K;? 2KG>M5)71+>'*]G#&H
M84<+Q-^7"%58B?!=6B>_+!&"OSL"SZQF67NJL+C\<4UN_?O%I.+?7),1HIW$
MSP")MQ4K7I><TA'XG0'&]BONU;EYQ']EF$B^+ K;]W*,[HA\-K;0&X&[WWCB
M=(P5XN=Y6?"2S@O>6KMFO=O=)Y#,T5C!U><;EW97\S@(0Q.MM2V6AI]YC[6N
MN%P3=<A*K+XQ*L?L1 &:4J'B',LOILA9:%%T#$'G# _Y7-SSL:/)AHOPA%'7
MG)EZ#X73B,>Q0KXH*:N^0^2E\IJLEIS1%^U>?K+ZH6%RM_*BK[:KVI4C%D1+
M:B?Y?PE^U3?D%^(3T\<T.'=+/C6EP,:#+N\]:EQF='.?7?MSS]3%/MBIH+Y>
M.K=U(%#SCSF6!,NQ_]91\Y3WN^<V@&< UK#MI(VD+[[E9X#X?UE-_W(8\6]:
MCGTY/L-84A.-1*[U]!$1:YWPE F\IW+6(Q$.UINV)5@:R',%'K&>2OV#3R)!
M+F7+MU'IN%^BLA9SZ6JL25S7<VW/D$:S&WDWN:>B.U+7TKW0BX=/N #0Z^_0
MPIKL[JI-@T,8%_83*-QJ $5(F1^69Q=@*S"\?#<9I"&\(49V7_K:]((.W/32
M!S>?H9-GNBLN:6Y'(HZY!,,9PA3\"W%)K*TY]_!9A45*K@E]4]S-?!WJ_?YU
MXNH)?*/; 5V19*4\E*W)?QZ5>A M#QG[FB@-9M93H\G:B'>,EG1)[)Z?DQAL
MP(I>B;P6X?TZBA7N8[>2OPXA5LT$[F$6K"Q522@.WAOJ+AGO1_C'!@JOR,3\
M3:\%3"X4@4814]$6R]<4=]B0LN^IA#TMT^"1UK2![ON]4ZL,TG[KO.90JZR5
M)*"JU9"P$SYSCRNYWOPVWZMJ+ND1J_J\R=6HL9LW]QALLS4*!U,4Q55PHWAT
MLE%E[%YC,E"ZO+6;&.]P7#LL0J_^6(2;,*!BZRH=I,@8"$VP?D-5"<S6)%VB
M.E60IA8C.KUVE[GS>,[@]=MYB?TSP)*;Q69]^=-)(_$GMQ8GC5>]4.XZ[7[Q
M(X6),7UIK+E7WW3O=%.D>#USGT0U8^);Q<NWS7,&QR<TP1(AJ8JP\Y/ _N>I
M(YH'EU+VWZ7*R41KZ4[K[Z5F;LWY+>6<$&WI/?<6@W]SG\5OK/8>^AVUT6J7
MZ\A1]VE]DS(%8^BBQ@*&+)>Z:^QZ(8>N&;89"\JQ.Y];ZM:.0T?V%<OM6J'$
MB6+YVU%OF SXR5YH!B4D*[E"%'/#%#ILK ITR:J'PM<9L-[T"6Q/;MJ%M[NH
M%5B5=E3:C!?LC!PW[ R YVS84PO(+')AKF(7 (6Z+"TZ";SIM/6+3CL#9$;?
M*DJ:T'_P7XOE?[?17C/>CXA><ITS-KG[U5QEI"$'!Z^ \%J8M4(QW\+Z<?U4
M[BQ3"9A+],-#')J2%K2-ZB/@4[2/Y2$.)2*[<>EW9MB_V SEHHLHN6Y 9Q1)
M.S'-J29;K%UW0-5/@EMM2C2&-/@7Q/2K1QRLXO"7 NE>HF4E@()7]@6]J26:
M\C\<:LB= 9PC;^F]/#P^ S@MIZ\L/;Q%8[!]R._E-?YT*?>$8^0;D1&-DL+K
M37RV-1(:B9D#%I_:,T #3,!U6B(\]<O3>6WWNZST9X!:A9)"PSO?C9SN?AA[
M.W?S7"#JA0?9E)KI./S6JU3\=SQ"BD@&Z[ S[GJ2\*H-JT!4L:"Z5A'PT*$3
M.Y6CQ5C68U6K5E7YY9R#SYR]F%*T=IZ88NF,5H+-2@NI#%EFJ/,# 4A,):MF
M)E#DIL9UQMJ%</P6W&!!:=Q.5)G'T<>SGKD?A7$.A?@/IP86#E,%J/(.51Z<
MABO[53O3_-K@';PODD.S)!'OA?JQ)NN0I/T6T1@JRAW]E;M<(PVP4STX]5OG
MR)TU"?[W7U1EOLB)IMP;?KE+QSW_X]OKB91!/7"5J68#1ZZTMA"KK1)EAV*B
MJ6(!VA> ?3KE;0("ED^C%OYJ*5V^;/ 5W1;2P8\6K2P%9?S,M3T7&LM*9&["
MWZ&EFYT8<;-8>R61A(5G;Z@)9-(E&6Y@[DO>D)#?HF-0G\UR7$\X7I?V9!AZ
M(X])[9H)'73>B#IBW,CD0*!U>E<%-)=>01(^@N+)&8Z'OE>=R,-2_-15O=^V
MU2"7HR1S[3TK@586 "413=.*J>PSNA[CJ1)1PW45!@K"7B#?(U/\1@*X#QG7
M4>\95^U#/)0^1EY'\Y-Y8!Z6[&#R )V7E1MY1DK1Q]OS8ZMC@W\=-%&5#8%%
M1XRG0TANB0KC!L'#*BXTR2=?:2.'M"LF[";I>)=E=H^G8HVKEJ<,1<>>B>R:
M$=[=R7V$L(85FFQ.7^:L!7\&8 ]88D8Y2* 8ANKK*42<[LW5+U?$?&"L^L#Y
M440O6*:8/7>0,"@HB-1BK9J'K<0@E[#W"6#L[D(PO6&GC?#>Z,[P -[$\%X8
M1$Z76QF%YD%L=;).A0)G8\E>XWMV:>X\[1KID7T;7FLM$CO,6?_]5U37GDLS
M%>2J)E6'*D&T>^QQG?>F/U2-,8ZY+RA[ZCJGE%Y\G0ZW?E(C !EN\S3Y8F]8
MF<5XXD*<2)9"M4M1(4/!)WI-O?>IE.M01STHA-[WI/&P=HCQ+5C>2Y1E1EMC
MEK]OH!X)+EXY6E5>DY<X:1E:***OBT?':_;@Z:W"U8+C?=%PV7[[XWQ\HFA/
M>_/W&4N-+,I>^2R+1$SFA,I6K@IA'CMER(V$-[/7$\7XBMD%)]'*A.V;Q-72
M)_62%M:9!GO2(X-3X#%3@%:BMK2"R6_@<(VU.+):!>%KZ;M0W@POLM9_7>"
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M&Z2WMUTW:N4>*FNEAQ8!YLGV*"$[7YUIJ\/[=P.[Y*U6OB@=.(^V]%]&PU'
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M;BCF FAM*V['+;3(H&>E]RF;9%?H!.92C:$E&,&)<MX-!DS?,)!]HM)+!->
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MM6D:^PEB7FTP\\=A=>491NP>9&D5?<W6R*+/M A[H7(FS=9BOW(^K5Y#;<$
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M!HPBOI1<7V>+M"S<8QJ"7$'5OAJ'=#YOT;\)<>[DDVI[1'K_,2$.X=3U!45
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M,PY=Q.^1'-S^ _=<^&"M >Z<T-0H" ^0=I[\1LYNF=OJ0G*H#RAJ($ZK$C/
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ME6?Y$V"+"G;8X6'[)=E3U+!A\OJ1AWDYW>_:'^2IVPM+IN?=;')FT2'+:UY
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M(%"RE1^L<N4G!?D&A=(AXHK?5';=T/;4V_&E?=5IS7L6''%+5_I=;'N9(=P
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M9Z1N0;Y!LJ+PZ!7H!.]"]&C,^E'!S%&XHZVW*L0(I9Y5=0WE+(BH_H8FXX;
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M+]!Q)':O/B0+135%0%Z@?77D>?[HN7QLLK_ -V4Y]B#I?=I^'"2_*V,;[@<
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M#C]R3]6!YB&*)*>_?CG5DMQHRJ,]#/FMHS"2/6XK(U@+;3Z+=W("C,L'Q*P
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MD4F*Z=FS>R'ID:3ZMK_%AC!-_4\A[!-G?,HGNTQ525"F=9EX,=P)[C_TS51
M"MFSQV!5VCF<KIV<O:#G@FIN4D>;D]PKK+E^FZ3(I]@8+M2[;%2-Y]VQ;A-U
M(]O!ND.<!@)ITYZ-%DEIW] 1X][LE3U>NCE)0ZUZ%10V6'==]MV'93@CIKML
M52H$<ZQOB3*0MR#_T+*V%)+O[D.-0Z5[AB)J5V>[= \:AY-.MR[2$L(NUNU0
M!OK4& JE"UQHRD#A-)L)HGEH\=.=E %BV?\RJ.K_=N/1<&3/%C]Z#,51UL"P
MIFZBOF7^12O.3V;]1>^,N\@.9-I[]G'VLOX\'B%=YQ O#I$?<)SV_$6YS_[>
M] ]UC/U,BJ.-L3]2;M%?<I;GI3/G<.)BO[!R.3K/*>P?G)\/GQ 3A:+S[TGE
M@N6[4#+ .];(IFC1=HD3=0CI(Q^D/83/YA8Q;+D/8SV96NC31AP[ 7S\P![_
M4R,]MY%HI9HV>I44)6^I_T7&2RM$-RC=8@RIGOI%2,QATS/YY3$@XP$:X/&:
MU<<=O*?!/:]CG&DE+##].Q)/##4(ZB0DFC9,*"<?4RTABJF.\AD[&FF-XFO1
M8XQP0:X'@V6-Y-P-Q2WHS#B=A0]NN3X\@5#=D%^;1.RV3!'@R),,APA\"E7#
MVGZ=-D6Q-#J*OD^\Q6,9LP=]=,<)6S6R[%0<SM#7,O@6?Z1SK264.*&Y@P^0
MBNNB\7O)3XW7MMM1(8U-U"EZG&R1^VEF--__=EKUOP?WG*3@5NQ.')R'#QH<
M-6\GT+N7\9J)#UID^(ED7.V'[!KJ4L.XJ.VT5PJ-.X_QKZ!D;*BZY8S5B5O8
M$T<&!_)Q=_9.,)D)<X;\T9=$<A<'ET>>T=26O8"RWT2-_$(SJTZXIS+ZA/G7
MUP*+",N/U@#+B)OZ0,">E%1S&@@AEZ&=0!%%CRL =-0GV1N!&_2DJ-5@$..3
M.P>\R_IUK8E=PC(>(;#%K)K>,O80J\FXB_V0=1BIY:QF_<"6<ZK8R=M2.?]C
M#T:6 #LX/N[CP'6<QU>MF/_R%QZZSK+G3>K^AY6'3C"DL3H0>[B8/1ZNJ-[.
MQG&/9.'9[[E+(W9Q#!#.30F0P>'+M8Q!)>E@!..MO+PKC^DEK=9]8DK$$NX&
MUGCAU:H,EE!@L[6.;<,KB5C%?H:(W5PYM[FE_]M ;S>=V'^'_M)PON,W8Y/V
MCK:185']A"8S5RE<*K.9AZ2DS#LLHD@?KF G\"'76YP,^,O%;[2;K?/W==-7
M-;JU7Z97U89I8/J-FFW@!$:1CEU!9<Y5F3-=F#=EM>$+6*=$L:XJ]D,T_\(O
MFE=_PMXA&J.+W7:==K)5HI;1/1LT@!W]K+D5<YB!Z%NV&)A;5%5A7:Q,R4W7
M3#;$J[NPB;IO3]F>M[1QPYUMTVC1O;VJ?;2^=A,GGQ[?*,,L8RPP5VU9RGBO
MFQ26QOPN=W"U9;OQ!\[W43''<O9LIW;O;VW-I3X?U:BFT2+[MK%WT^ZW6Y<+
MZ7WU?V<T,VJ, :%_F/W*#1O^L-X*M*>F\R_C)X_Z\9X3HIIV\M80*0H*BB6U
M_9?8!?*[LGN(/W5[A@T\0'L9RH?#&?LV,+G?6-].W.9%,YZ,>*(<YIK&-N0T
M<YN<A#@P6YCG81-K1MEX>!U+O#F7.\Q>&_*&6\*^O<&.Z\<Y>WP(>8"<&1Z'
MN" 3&AIA" Z3;>-^XM8RCG/IW.6E*[A+H.[T.N@,%!&2#UG IRYW(1D(']L&
MM\AD@T;N1\GC^O7<+'& =!9T6]A&KX, @7>)'>3+NY#V$)J(Y@3?!=_ -UPL
MX&?NZJ-SN,V&D($DZ+/V0.U]J%CM+1X#/RCZ:5JP5N9=' _BQ5?2_,%485IP
M%9C.JW<I ?&P]O G:*SA4[\_Y%%KLEP&&TW6HC'04]],[0=>:!R*!, A16]J
M![!3NB)X.G!!Z.?B _Q!'A^>#P5VF?JR0$-;@?D?<%+C9^$W0%^+ISP#,HT?
M"I\ ?MKBU W 1D5/T$X@1VQQF0O4\Z8?*@)/C#CVMH(V_;/-+H"XLT'H#2QN
MF4[QX-RLHQ5&<\X9KZ?LXES6C O" 1.D1YS? :G\20?_ 4D'&GI7 ]=V&4PB
MP'UPN4#(Z>O*)>LXV.:^@C.<<LN'E&P.6_<SR(.S5VYQO@[,YU_;357TXJ(Z
MYLN>XE7ZK]($PB7>:O%5TCSB_T3EY.K\;<*IE _)R_@M-%/@1%X*0^[4BDYE
M_;N+(X^@:]N=I6;Z2_UDR4)&..HC:F/T$KX(XYC>>5K^3^:=I$I>/ZLF0(B2
MV0(G#A+.&=S)D'[CGFV;)"GD!FM_B!Y HXBS$(7B"3,%_N"WW//\2>"!Q'/H
M)5 2L KI!3%.VV UN'FT3')<,JYE3+Q)9-$<%9X2>L.V AS_!7XY/Y WFCN%
MMQR5)WHB?Y "_[WP-]C9R8_[#;H^DB0^I[5MOBX*5WU6[Q7<5!SFSN?+97*<
M,Z](4I83A&:+DA/JD33!*O]\. <]Y;262X2]A[>)9]?&-MT7"DV)JE."M89-
MD MO3+L2FX>.JL;OT" ]L@<)UO!.<8?_(NY-@:?3=.XXI&I():*T930M%7QI
MXBO_\"5U$A##BS*QJ@=1!SUFQW3$01T5?Q#VD'WWN\$M$94Y?H8:4-;@9]&$
M_IA&JD#0U:S<S%_6NALXA)YK:*U>B R8E=M!^)"^-'X'][)JIE\C=YHDQ_$9
ME,8K&!0(>W>O:_@N\!VJ4QSA'>D9 AS0RC9YE0Q):L!L7PSGF]SBIW,AS3&_
M"NB8;*;C+6@!?TW7-N,A[%ZSE=X)/T.2I#E)2&5>5D'$1LPK13AY7M8]V01*
M1^QR\2BMQ+=&6,0@.DSA3V2][E0; !IDPNO&TYZ)Y>HV^E;F<F4Q_2[&3^[*
M0+)");^9\3$:T1&6LV^, &&'.4SE>7&,'4?UX9!S#:"Y 1X0#:JX8 [#3Y$,
M+B\GR!R ?[<:)3.!)S'SA8^ ASZ_^7N ;P[34 "T:[^F<Q(.&T'U<0%?V*)D
M\(OIV?(87G)9F]0;S<K\(G9$*J)KA8MAML]!_D2NS&$Z<@]2MWW6.JGB#2;5
M)<4.P7Z%7(:GD60E$J3TK219U)J9)\H27(OV$FSE?? 1\'8@WQQF(!G<VVV.
M&D+-/?T3U7*#NV"F_+H61]TI[5=UE :(F^2/MUP2]DA715WD[Q.%^J2B5_F^
M#C/@^_#O5D#]H"E=[ZV4USWB;Y/'FF.I<Z1K#9:2-O$RS9LM6X4.2O<H#M]+
MFN9CC^8(@QQFP@#RI>6+FM35HNM4VK15\D[*QAH_4-B2KMK-)6M%K<;!C">"
MPYJ?4:Z\RXJU/I.17^)I_U&NZ)D6K=IJZ*XN0'&]]V]>K(S?@2'_E"0UG2GN
M$T74VF5(!04&8N0K'J0R>H\ANR5BAYG<MSRJY7S33&RVO*5N!-<$?C.+\6_P
M1XQ$8ER!IRZ==#)-J;:BX,+CY#=H09YE$CPCU[91\(#UV.+=\)':)+>K[:3-
M 7$F-DV*#S#DT>WRA[1A]*=I:U0K&6?#WLKN,,]YAHIY["FV9P73.*#96'\:
M.";#6&1 .7"R)@]8CY/I$X!Q^<LT?IP_J8U*:V!YF%;Z&8CR7"4:!%2V[_@Q
MP _3P[I!_@FIQ<SA[>2\-&:CN[#7=+'(U3RB.@:9D[I6$0YO#0N2VG*;-_X0
M?H)^V/W%:X VF];77I0/2QZ8:J7?.,X&4!*#7:@EBIIR[ZDJA)-2NN0T/BWT
MHZ0<O;OQOC !V63GR)O'%=:@M=/T Y*PFH?:"+94?T)UH9JCV:G8G)NI')3>
M28F1[1*7A8Z(]PB>;3PM&.'%V(6@!EAO_&FAU\G%YVJVF*O9B_4>1H>J/YJ5
MVJLY=Y2K57#R"]D&N4,H2^PLWK5Q6+!)8&67CFY$.$:)95Y;A'B;\6U3.:M.
M=[PNI4JL;C4MRR$JVG6/DV72(ZK&T%#1<5GTQD;^5>$QNP+D 1IB]#4?Z[TE
M^F.LZPQ@;=)5MX146:MCZI?E+%=$U7Q*CI/F:T^$SA7A%=R-8KY,O,ZN&JE'
M[RG>=,NPD^&=[1Q<&&5ULQ0O*UM17T/XF'7++"(!\09#)F53X!GU-]IR-UA>
MS$BRAD1&UI@"[3)1;L&5;4)J./E,$Y]ZMO1T'4JC98E,>'I*?*8^@I$6:%&]
M91+<!#(,ZY+U)>$ ITRQHI/.H7.?MA(X#N2,Q@KVY]+$VDKVOUEK:O(XB^(G
MZT(YVP*KE-\Y@VYBJ0#8:+-(\!2X(J_IR$/?<5-:<I ?I+Z&7&15R3%+/ERT
MM=58S+T8UZW=S$T,]%>N@JZYB20'(;Q-JL ;6B'_JYTBW0H=:::+CY)6U .B
MX!)W,RPXO]7' //Q<5D:F&<3.$>1A5S]CYKSWX#PZ[B!,EG;4<UN*+KIM HF
M-M>=5<07[S>=EZW(O*0_+_X0MUA]1'@NX+6\E=_D)A$3T$J;7OXZV$_FTF9M
M^@$^;'(SKB8&U;GKG(JS31YJCTR6WDOA%WM'[2(-"+@NGR3:Z"87/>.OM+G,
MVX7,DUYOW=^T#.QI/%FG)$ZIW66Z7+RDIE'_(]-'5Z_9$&M1=2MR _ID6@G/
M32%B"0PV;WB%R'&INI70.1_$-!):KA$.U&8U!!==J DT\[=\U_GH[\7B51%J
MGP"=S$\F<I.(W(57;2?SUJ"9R-[1J.I.6OX C+U5<:+[%-XVYT7;6X(N]57C
M/9)[Y"2+FOS'M\TPB_K)^:/*EQ&XOE%BQ[J,0"/5E,6TN'XCA5;1U76 .BWG
M?.MYZLG42PU#M%T1G\P5])N^W;I7S!4N-DH[EL5JD=B-DXXD#">R_:G?^]BL
M]Q5EG36L"SEH2POK>:JF7L%VC;ADRF#7^K9J'W)L79(4&SEC5C315J /F3AD
MCVR@FGJWPXF8;QT<KC3'I5D,_4R-JX,A0T1CS18HT=>D^0C-<\'*L\$/5N>%
MM> SN.>_4YE'#>\I$]9BS.U20=2.<TTU_"FITVH5Z+,(BI&$W/55:-;^9VL2
M62WWOO5BP1_H!YPU0%:^IGSI[I(_Q:2WG9$^V<%KO"K^-^6LY:QH042ZH4,0
MXBM0%_&P+LW2KTB#=9J P7T._]7_Q%!+V=.]6#<.L[S-29VR(ZG15=&8HK<X
MRB9&>!MFB\M\^:J#@G,N>Z3E/%=K1# ;'N3>[2^O6TV1=!E,#\I?M;896#O6
M-K1J9Z=4F^N5G1'S] I9E"]#%29ZZG)1\I;/M^[A#R-9W-[^E2U<"MKEWU!?
M?K_5RU*^8V+#"N.RE*WFZ9I7$;-TOQ1G?&'E1<F(RT.)2=!J?9Y?A3R@+S_D
M5EU<Q=YS%@OF7QB)PYW<,J,/) 3&17=L)SX-VM7X@'QZXQGS$NI5AW;-/PSW
MM=^E2M9I^IR#Y61LE7[W8_+A_&?#&RFI6];W1E-7Q^6V+Z39!8TUF.BEGN-K
M;C#..DY1'V'AUTDE DX0?>Z!(-;J*FC7;N;%_+\'_S!'MLSJF<Y\$9?1>H.5
M%O2T'L-Z[6EO'&$W.6:H=G/$ZV>)FP 9?>+^B5Q%U?:=$+0[OV'@-/17QK.N
MZV!C7$#+ %@5]*0N#=SJ&6GH![,<#<J+(&<]770/W$U[MO>3X)^JX%$B7YL/
M]N_AY6<<[#R-IL:Y-+<@%4%/:[/@5L\\_6GN2\?+R@G<F/5_BWRA@[03>VWE
M$54N(T9I:3ZI[X;8F#'<\43X*&Y]TW%!=-!K"YUWU).A^X7&.TU6I,%/K*R$
MW=QZ6OL>5%M993W\0CTE']>W4J'+Z.^PD7G$K6V:+7X2]-%\1MCJJ=8E\?%.
M'O+]:*I5@= /WD&3[9EMRJ]:/[S#@,DG]D+:E(R!=ECE';>RL5KN&?3)["\)
M]FS6GA9F.6V1A_&$5EK!'?@[C;E[N,&VRF[HI469S^KY;3R4,=KV5?L\SKKA
MD<HU>+)IETSH.:S-$GUQJI(]YPNM#@C4"/U6"_Y=E>.)5F)J];%!)U(S+M.R
MEOP2_X(_3'4C"@FV-)0<MGV$_B]U47054T.W\NAABYCJ&Z/8,=JRXTOP%31A
M_PG"(_IDTV-2,EW%TY /,#SQZZF!C%?9YVA7F7U1/8Q:EL;#AK6;W?SWV^JE
M\.2CV=B#W-2^"/QFJ+>&2;@+>:&9)"QX'3>?LA 4;7M)_1\8&/F+?A#XZ-[#
M_ %8KGE6RJ47#UNJ(R6S>U38UZ)"XSB\4O W,IT8SB=7_R#/X*W<]A?E!3(:
MN8WV%?9UCV"F0HPKC171!O:A^573M,>[9U3O5Z_02W $!<H]1?"73:[ZA[1.
M;,X*IJP6+HPX3HOC;75[P=@'>US>BHEM6GK@8N5?=93.4U6G3:=TF[$"@Q74
MA<_52"H_$K<H/F\%R5AI=$0P=408YV9F^".'_Y=2#O7H]Y^MB.V8W7&P:D+S
M5FUB]?$Z"W@ UUGSIM*%,*CSR+Q#NJ4,#[](]99,<LNF7^2MOR0H>[OS]?XI
MF-%!:ONKRK+NW1I\M5WK7> %;F'#[ H:P<GDDIE!*M)."\=2+LB8;G9T,C_]
MXN\RQ9&)^UB8]+V:]IB*+\/'U'NK>GI. KY80^MYS%W\KKJ#6RX3?QE*P_^B
M4!2-KK_HSH+TL\<8RRJM=^L9M54?6O<S[;'M:F?F*'XSL)Z50)R%><EZ3[JW
MY6]V%^52V N.G#[.M0;8R32<R:.Y4L2[V+3[U("6'KJ ^D)EQW"C63CVC(?T
M(LP49@<C;,L<EI#I$9;$UK-B73=QGK'5IYY3N."=T2?46!!JWD2;"CHJ3M+.
M 2]9G^EUP,'RB0PQT)KAQY0"BM!!UCX WO"(XP003Q:19XMGCJ23'PCW-791
M^@4X.8XJY+LQC]/8O+EED^A\Y/-F$J,#OA)JR_S&M6PPL!'(Z_@WXA6MW= [
M4K_J0T,\6:88E:VF4&5L1BN5*4DN74AK%KFG[Z<_X'\)Z6 FHHH-6UD?N)>/
M72#<KMLT>))XT&Q=;TMJ,+R73B)KM*/T-DJ;BE/B1[TC#T]?2O<2OPOQ8^P1
M9&Q8QR(C44?O$)9W> Q<)XYK\:O;2'S0,%.RF'3#?)+V/_)7 U(LI 9IW-)D
MM$9Y;_!=1I#HOLM'UDQ4>M0.+QR:/+"*@.VUKZT@QK=_%2>0@IOJ:'/));51
M14\H^PVWTA;2W-7NP7+Z#:FCRP7F,*_U2"_><5]+OXXP:_2FY3SA=K]9U$ \
MT6E'Q9+^:>HMVD%)L*Q+;:1>T*4'!])1N;7+ +.:K]B?QV56I'7?X:ZN"C8)
MH=O8F<(<J!=WBM(#20B:PE,0C02DSH,(%'$0'Y+2[C@/03>8IGVQX"AY1==I
MD$\95U,(YE)N">+!*.HH>1#TIS46O $CZ&TIV> .QN&@26 -:Y(S'9K"!O?:
M DLX-SLEP!3.">-6SGM./]^;\Y;31-K-^<'I*E@)K.4<3QX&MG&>!BJ ?<!"
MYR@P%HC=?87=(R!U>+-;^*C^*;N9)T*_L(=1)='"?H#TY;MQ;."K27\X3.['
MP.6<[]Q)SLN 1O##+A4+4/YL^\P"%)MT72RQ+ \YQ^J4, F-K,<B<UX..U)P
M*JF /<*[&S#*24;..7T YG$I.WE,M0EJ?<VL,;S4MC([=';P9>8E=3+^,&NQ
M@IC;Q *EJL0;[!DB4\ .]CY^H=-ECA:^--K'N-'\IG4^XW$#H#G-^& YS_W!
M7&'\@A_'K-:MRIW"?*IR3RQFT62K Q:Q0X1'G'9R7)#?H[,8\;V^+26,;1W_
M:.8QBEHBN.$,07T)+IWQP,3-P3$K=**$SZP9RCS_OUECXOM.]>SKO/$C#?37
M.S.;G])_#CJJ&?3OW6RHF;&P58(]PJBHU^SXQOA1(TC0,3LU4?YJEE@ZX"1G
MJWG7^TK$_IC!^B3AQ\IV19;@?C4'@/EO<-'5#ORI!*OM]3P'DE5\)II*B?4+
M012TO0X_X-=,<Z](J"*^K,,( -(+^0X^0K[-T?#J*%>KDM%3U ?9C]!Q].EQ
MNY%01MRFF["%N=?A&;R 7=6C%LQ@_:F-X2]@6\FR>3;L(+82W<(NJ,0B&K8Q
MVQE^RGX2YP)'</PW<;D'.<T.?W/3@+7=7%X+;Z;%'MV#YDD=D =( \N K(:?
M5>A@/!RQ#>&.<3MB![A;N;,W>4&?H7*'$U [.-!5B *RWV9GI$:JD;C"YR4S
MF1)XL0B/Z>$R!+>S#G(G\C-BK2 =NL_W*12'3'+8#2WFKNRD(!;]>],F^)#V
MD#B8^TF=P^CCABONE#^'!F1;L]9#0>(K,4/@"V&@;S,XRL,Z]((&.+=C%'Y9
M?[*& B^RG!<QN3$U(OH;2*]?5KX)FJ-NVFH VQ3K8[+ S1+8%POZ"AH=6D W
MA-IA Q=U@,8QKK9EE_ J=+1!1(^!IEM6EM6!L*%SZRQP@\8^^E_@A9SG&PI<
M%ND=:H$QM+C]&#QE<(FQB!O0PQ9&0GGM&;0AT-!XNVPU.,=2D-D.'-#?B6X'
MA"I/W_D + EW,  ZGD/#$\U"3)+ZK6I"93#JHG"I7DHVRRC8U\5ZR6'\M8PJ
M\73BTTB=,(&RVGLZ7T]KM:.@+YBF!B]5#7&\.D@Q0IJ&%,O>D&>2[DO]*,N*
M7HJEU.#-MX1/:6CD&D$@_:G725X=DV,G0*>QL^HKE0Y,J2I6GL<\#O.D3<S?
MI/'B/ZS((GM1$:MI<X#@&GMI1"<_@FWVDJ"'. %V>B2$\Z6.(1^#WRIC9,M@
M I<DJ>:^(5J++G,QA47"%.A'>@O_!J2+".?E0IY>6<@7\)I=,ZP$";5:V;!D
MJV*[Y(_8"A*+<X5CA!#A10%:,")(X7NG+^.]1_\-?XPJD68O9R0<#K?KYWZ'
M3EG.2V]I#LK;)1M45\!;(IEB/QX5CI/)"B;SQ9+M:0J>F\@Q'$4>\U]Z_H*[
M4:[='BZ#^\GB('6U3)#]%(MJLD$7X7,] 7=7D*4IR,?Q7BL3TI:C1IE3> "2
M*/K@.08[\85V1[ASX:_F#DE?RTH963RW812P",LL'W%I_/\9O^7]PRO1?DIM
M1=<K'X:]AN])1ST/< \+T^U.0;N1*^9D27K/ MDLT<[VUX"5<&IS*/8:O[@N
M(0]"/]:DIJ8CP]K8L!X85-AZ&KA$T=]VYR$BRM<\LEB7_^*/U>RH>,QPT9^J
M.EAQ71N.K=VQ5C6(UR5E*.82=P6_EV93QKM_$QEI)ALG_FFF7I-AND/8R-]J
M=",&THTZ,RFI(E$SGXS;WJR$*7V);V7_T.8'MTJBZ"KWAT(],\$FGS?&CE3O
MK($8OCRM_A6#2WNCS69<P=2K;C/]M\]59#,/)+*D-UG;@[>)H]FSW,\)^MCW
M;!2\&9Q+JA]&/^X2])BN%QJAS=:X0.GEKY0CX)]LG#P./)0X47('5 ;/%N6#
M9>XC_/M@@LUN=#/HJ_(S. OOH].UK8);U#2U"_],N;-B/V]TVW-9"MJ:8!!_
M0UJ#S@N5<*U[,]^>*[<90W9"=&6-/D8YA)1J+BDF4@9463+/,H/\A21E6Z$4
M$E4DA(KM!*(@H^ JK]%=R^,AC3;?D(U<M7*1KL%8"'_2N.EG4H*5@QI2V4JY
MGW)WU@O)3=FO^(<BL20PJ%3@*\2Z\]#?/-!V'GP"1A1=.KOZIS!/O<MRCWQ&
MZ5G#*NV4#>H>9X&2-'5</"*:*V\+<N ?$W]VIZ,*P7I;:[@225;LT%YH#X9=
MU3G-/'*IXG_U\:51LDC3V2Q'\7U];'R$L$%U./ 'OU#FXEZ(A@A!6T_8!ODH
M %LKR]M8J8U?*R!L4UU+U8X"BCD6&YTQV7 &GQ*MU3H04;\&90GYX09_*4!3
M6*T3@DRU8'Y+)KZ2^;/A.8&(C:[E$J4%5J;%I*.;]^DUE)71N>H?5(L?H@BG
M!VU(EF"9*ZWH H3MSJ]OGD'[P*RH[Z1'5I^S1-"[\MN-=Q@>FS-U)8R;T4M4
M=YF-?GER7Q:X8;N8P>9;G>"W<[KYBQN/@7&,\W65X+CJM>;YP,'\M89!0)?^
M4)L("*).*&\ <C\?6330M*%85 ^<M9[&>P%.X*$-0WPE(Z"VD-=7)3;-1<_F
M2?1#R*MTNB8561U%5;R#<_SF2O'<^@V5POO04^L07A3DP9M<_T!V@7[$HI=N
MKEI4$RH^FK=4]UADGSY?#0L448&*E;S?F[Y(^M"J#42A+WS9&HONX_JCC?4N
MVJ?T[>97ZHN5W4:-4I@[I/.6.Z;M4]V4G(Z:+*>)BC>]E$S@_]K $;2@ FL=
M&@^O1%/J1LW7Z<YF4HU#)<,X1[\VEZ0UJ)^D,53>BO[(H[(74F#303$J2MP
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M; Z .NA$UL"!=2.\#. /X4'C#][JLNJZ>A3=T61>A5Q,:S+\UPW1?9HC\+:
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MT]71D5>HTAO""V,4E;PM)4XR?Y)#N9ODK_SGE47"9\F_L>?X(T$D(A7-=OE
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M.TU"'D$=^ =5$M"O;%3=TY1Q^]1RS;6:8F <F%QP##@*[DR9I%D+18:_!M=
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MSQ?*81I%WX>":*FT,[.$)L--+N5T>:L:K>8I5K$+J7W*"V63F;/48](CN&>
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M*!H5.H7W RWT>"8]C:H['L1EF?HM8U(HQ@-03U:,X;BPJ6"6_CQE',E?=ZN
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M 88WC/UN\PT)W$?VU_1;Q<6SR?I\Q?52L>%WR=6\*8;MY5A:EJ&\.CDN1O^
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MHG$ZNLB\[DZ\H*<#*^IK1\G[VQ#:02?,/.AXA5X;7AM>&UX;_M<;),\->_R
M-"3F@3PTZYHBLO*L(I9T1)I6,R,JD(\+*HV#/*RMGU?5W,-FM'7369V=%*ZK
M@U#;UX85#;2BY$,M"-VP#6X<MKY"0+[A,[=A/1 %^P%9<,Q#Y9ZLZZJPBG/J
M*.)191)W5IHCFQ"5&H8$R,;^6E)S3PV]K9O)Z.J@<GK;2+R!%IQPV(F6CS4A
M=.-FA&'4B%Q\/QH\UP-QD!^0!T4_5 5GWM"$E)_31A".:>+9^Y49D@D91#\L
MAEG[A;CF'@&UK8M#[VZO9O:W4+C#S?BZ\2:,8LJ,U$QI4;IQ-5H_MMB XB>#
M)- 7* *B'VD",V[H@LO.&\+PQ_6QK#EMBGA*E:<=D9?7#TC1CAXQN:VKENIJ
M8U4/-M,X8TT4X:2-I-ZGQ:CWR;&Z"1E6-[[87ABD;H,TP!<H_:,>:0,R;AJ"
M2B^80G G3%&, \9$X;0^6SVF*3$/JA#V7CFAM4M,<;7RZ8,.-F>LH5HP9:0J
M9N0$U:R(H)T4$G03B^W_&?Q]@<HOZ@>=?_I-4T#)14LPYF1#>/6A^CC!C"5#
M,6&"&(:-4&N?#NOL4A!<#E'58#V/.:YG\Z:4#.F,L$HYRR=KIGAD[>1B XKU
M;H/'>B#S\P5JW\@?]+YIM\S^Q9>L@>A3]A#:87LL;[\]53IE+]",V2M-?6:$
MLT6#[6Z0D@;U=?0Q!8\S+>*(9GD,Y7XV73/-IFDG%]O/!KFO#]#X1#XV^J3=
MKO<MNFP+0)YN#JXZVA+%F6]+%LYVYLM'6LI,7598L]V [C8J"8-*"75,)&1-
M\6KK9E@\Y?YJEF::SM).+;;_CT'K'?'8Y)UZQ^H#N>+P0YQM"R(=[XY@'NY+
MXLWTYXL'VDN,K?;*YGH+LENCPPU(E)0QOHPQQ13S9VABY2R%IYZNJM%,+3:@
M=!MD;H/"QP?HO"*>F#U3[MJ\"JZV^,#.=P?@3PV%48].I# FA_-$KNXB8Y.S
MPF%H1'3)S-B!6AUIE*6F3U*5O'TDI6*&(-),$X6:J<4&E.O<AMWK@=++&^@]
MPI_6[TZ^Y_#(N][A57&IWQ]]9BJ<<&A_.F5X+%?8U@LQU+=5-*F:$)W"!FP?
MQ[V[:>[-3=!QIC!:\31&I9G"*+23B^UG@\K3&QAWA3UKW)EXOV5GSJT>CY++
MX_[0DX<C$5-S"=6N\6R1O:]8KVN'VJ4.='MM([[W^;M_LHDRBC543R#T_$FX
M7CD!-V@7'5#]9-#L]@+F':&@:5O\H\[M&=>'=^>?F0\LG#L6A.V?C6$[1C)D
MAIXBD]QMJ&O&M-6XMS>]@=1/LE"&,";Z",+(&869Q*-0DVS1 =7:SX!\UWJ@
MW>D)&K;N>=:R.>9._Y;D\_MVIQTZL;MD^*@?T3D=Q3,.I2OE+HBYK@W:5.,V
ML.W$KN?O_HE62A^VGC: M+ &899:=\)%!]1K/@.*G>N!8>MN8-\8^*AK?<3E
M\4TQ1XYM3AD[M[VB_9!/E6DR2B ?3%<+7$5F;CO,SFK!MM =!/=:)741;54N
M;".M!V5E]L*M-7TP*W_1O3"HMJT#EHT[0<L:GYN#JP-/'%JW9^+<NLRNLYOA
ME@,^=/E$=%WM8*::TU-L8G3"K?3G^]^]_ E.8BO.06E'-U$[$?;J+IB=W0VS
M<Q<=T*[Z#&@WK0&VU5L?N);O.COS_<ZIL\LCNF^LSFTXM1DEG_>KYD_NK6,-
M9ROH?27Z*A?<3.I"-^ ZL#9,.\&.;",YX*V49F@+S5GA9+94.%FMBPWH5GX&
MS*M7@M;OUET>7[)NYM22G3TWEL9:KZTN4)S:BN8="*173R?PJ\9R):2A4B6^
M'Z9%]R$-B!Z,">;"F:'=!$M%%ZFAK*O*6M));RSIK%YTP+#\4V#_]KO; Y\M
MG3_^X;*^:Y][VQY]%Z^\NJZ0=WH7DG8XE$+<G\3"3>?Q4>,E(OAHA;1R!"XO
M'T8I2X<PJI)!G+IH@*"!]).U!?U474$?;=$!\[>?_-#Y\6='#_WM@X$K[Z]N
M^N%S/]6CY0F\ZUORJ>=\H?@3D3C4X;0JV'P>HWRVB%TR4U93- WE%4[!:_,G
M48*\24Q=[@1.F#-!$&6/D\59XY1%!YH_^M?9Z;?_/GSIKY\X'GVP7@.6^-?^
ML":.=FM7%NYR<#'BW%Y8Q:DT=/'Q''S!40@I[T@I)>=01576(2@M\R""EG$
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MUK$L&_MH9@OW2$:WNZ&:0QG3-5-9T]RQ[.F:EP7P+PSO 9+7%X 1N )PP[>
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MC%,(HS748&OT3(I(267*Q>1:32U!KJ_!&8QLG,/$Q'6;&'B7L1K?8W"G?UF
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MGS"'/9ET!'L@Y3AV?^J)7^RUX2=#N=M0X39 =WWH_BI]!<@AJP E>BL@)_H
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M:[CX;R :S9!V< F4J:R">I7UT*&ZZ5/OX<VOSNMN'K]FLNWFL*72A4&"4>\
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M3 OK#LJ-:O<OC6_QJTMJX+>GU/F<3*OQN9)6R;^;5NIW+[58<"^E0' _^6_
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MY@_</>=O=I/.L[C7SN\([YU?$#\XCSM..S]T_.CR)^",9J#)2P)';0GP===
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M63ZD8Z6^Q*-- L+17@'^V#!J4D#H?.E/;/TSB%DI ODK$&A<@3SH78A<O[
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M("A( $U1"CCJ2\%+?RUXFV\%'DX&W*GRP'95 R9?&VAA!D!*- 5BMCD02JT
M5VL#MBVV@.VV YM3.+"^@ ?K&X3?5N/V/ZW>V'^S^F0_C?UJ_\KNF_TSW#?B
M0\)WAP=_ "0T@X.<!##DI<#]_]N+\<-L!5^[O>!-E@-W%S5@\[2!&6((M#@S
M(&=8@$.A-=A7V@*A$?<;UX&?L^NQ_V5[AO@#.TS\AGWD\!G[RF$&.^OP&O?%
MX2G^J^.H_3?23>(W\HT_^"\#^: $L Y) 4]Y"?CKK($@TRT0B-T# L=#X,-0
M!7=W;7 -, 3G*+/?3BF6/RFYV.^D,MPWAUK"%V(K\3/AJ,,LOL]Q!G^)-(V[
M2WZ+>T%^A9\A/25\IOQ#_$*]X?"5=IGTC7;I#X"\1PQHLA+ D94$7Z7%$(QV
M/:')9A!:[X80^X/@[Z0"WASM7^Z^AM]=PS!?7!*L9NF9MA]I1?@/E"KB.U*C
MXQO'3O)KAQ.4*>)YZ@OB3>H$<9(Z1IRFW77X3+]*^L*X2/[".$/YPCQ-G1]0
MT R,?1+@L4\2 O_]+(;F*H@RV@C1ECLA B\+H13E[P$LS<\^/(./GL&8=]P8
MZ]>L5+N7S#S[Y_0RQPE:'?DII8WZA'S<Z1'I#'V4=)UQE_2,<9/T@3E$_N1\
MCOK)I8_VB=7C-,LZ3I\?4'>+@<M>M'NC_3]4?A%$:ZR >(/UD&"^'>+L]GV+
M)BG,A#'4WP6ZZT_Y^IM-\B*LG[HEXAZ[9CD\<"DBWV54T6[1&QDW:%W.UZBG
M7(:IEUA7J _9@[0W[ ':C&LO_2.GF_&1T\'\R&EWGA_0T RNN\7!%^T7X7(+
M(>'P<DC16PNI9EN^IV#WS"02#[V-H:F]".?HC@?Q31_ZA5K?Y<7@1]Q3':]R
M<FE7V*6,BRXU+N>9K>RSC&.< ?I9;C]]Q.TDXX7;,>8']P[G#^XM+A_<&U@?
MW.K9T_,"IUUBX(;V[@"T7T0?7  I:O_^7[&KY[),-GW*LMKY+ATO^R*9K#06
MQ];Z)]S+9"0HP'I8$$&XZ)- /N>9X33@5N!\BE/![F4W<(^S.MV[74YY=+D,
M>7:X//5L8;WSJG=]YUG#>>=9R7WO4?$'0$<S_-LY@__M_P>D(5UE,>1HK_R6
M;[3^0[[%UI=YMGO'LQSE_DEF:EZ/=3>Y'.YG?2XXU/ZT?PSE!#^%<8R7S3KB
M6<SI<*]Q;^6V>C9QCO,:.!>\ZSBCWM7<-][E;F^]2]S?\HH\WGD5_L%_&7AH
MUPK=(0Z)LE*0I;0("C27?2HV6/.FQ&SC1(GUCM%\^T,W,IPT+B=QC,_&>%N?
M"@^T/QX<0>D*2&"T^66PFWSRN?6\"L\:ST9>I<<1GS*/,_Q2CUN^Q9ZO^ 5>
MKWURO=[X9//>>J-X\P$FVJ]\MJ"=$UV+E/V2D*>XX&>)^I+I<MT5+RN-UXY5
M6FRY78P[,)1#53^7QC(ZE>!E?31:0.@(%U*:0V*9]8$I[&I!CENY;XE7L4^M
M3X%WAV^>=Y]?CO<UOVR?%WZ9/J]\T_FO^6G\-SZI?P NZ&Q?M&]&HMTW748"
M"N2EOY6K+7I7K;5TLDY_Y6BMZ>;KY7:R@P7DP_U9SH;'4MVM.A)\"4W1P93:
MB$A&A3"171*<Z5X06.B5XU_ED^G7ZI?FURM(\;OBGRQX)D@23/DE^K_R3?!_
MS4?YS ?8Z&P!VO=BMJ)=![U'BP])?JI26?"J_O"B\6:=I7<:C#==J<+N/U/B
MJ-:;QS#LS.1:-J5XXVL2 LCE,>&,HL@X=FY8FGMF:#XO-;B"GQ34Y!<?>,P_
M-G P("9HS#\F:$H0'?3*+SKH-?]/@(.>AT"T\\9M%H4<]#XM.R#QL59!\D6S
MLO2C]L.+;S0;;1RLL]G75^&@VEU$-VC)=;6HS?3"EZ<(R(6)H8R<N!AV>G2*
M>W)D#B\^O)0?'=8@B!!V^X<)SP<(PQZBI@1APBF_,.$KWS#A:_Y\P V='8QV
MSH1-:/?>)?:S<K_X^\:#XA,=\A+_'%%9--QFL.%LHY5,3XV]2D<93;^AB&5>
MD>N!*\KT)>6D!=/3DR-920F);K%Q65Z1,<5\872M(#BJ*R PZDQ 0-0]U$M!
M8-247U#D*]^@B-?\^8 '.CMTG2@D;Q2!PAVBWVKVBKUNE1$;.[I?[-8QI867
M.O77][5:[NUNP"LW5U-TJ\M<,,5%;G:Y>3Z.Z=F!3HD9X:R8M'BW\.1TKY"D
M0GY 0K6?7WR[/S^^/\ [X5: 3\*4@!\WY><;^\K7+_8U?S[@A9Z'\+4BD+9>
M!$JVBGQJV"GZHG.[R.C)'2+7>A47G#NJNZZWTWQW>PM.L:Z>K%-6S33+*^=B
MTTMX#HF%_K3H/*%+6$XL-R@SU5.0D>?CDU;IZY7:*G!//>7OEG8=-27P2'GE
MYY7TFN^5.#_P0=<@:HT(9*(YRC>*3+=L$GEV?"URNW^+R.53\M+]O=IKNH^:
M[6KJM%6H;''4*FRDFV36NMHD57G:1Y?[4<)*0YB!15&NO@7)[KS\')Y[;CG?
M-;?9CY73Z^>2.XQZX<O.?LWG9+SVX:3/#_S0[A^W2@1R5R._:M8@KSM7(@].
M+T:NG=TD<N[,(:G>?LU5[2=,=]0>PQXJ[B)J9+<[&26WL*QB&MWQPCH^*: F
MB,ZOBG#QK$C@<LNS/%AEI3Q&::./4^EQ/JWT"FK2QZGXC0\C_XTW,^_MO" 0
M[?Y)*T2@: 4RV[@4^>?80N3&V87(Q<'U2-\%68DCY]17- P8;RT_97T@M]=>
M+>4853_VB+.YL,/--J#-F^C3$D#Q: YCN#;&LYP;,CA.]<7NE+IZ3\>Z8UX.
M]9=0SSP=:M]YDBM0Y?,#(=K]TY<C7\J7(/?;%B#7>A<@ERY((Z>'5B/'AF3$
M6RZK+:L:--A4<,YR7]H 7CFNGZP==I)I$M#+L?3I\;)S/R8@LH\**8PCL71J
M5[JS8U<1V[ZSSA7?V<W!=5U$/>78=7SDXINGN82F^4'T4@1R%R,/ZR21ZUU2
MR. I*:3_DA1R;&0YTCJR2ZSFAO+BHFMZZS.&,+OC+]O)A5UT5 ^X0-?S/N=J
MZG;6TY)UQL^6/A!*H)R.=73H3Z,0^@MI=GVU=&Q?-\.Z?Y!A#<\ S(V,Z+8X
MK*FYE0DBMJ!_G&[5-\VT[OGL;'U\?I"T"'E:*H:,-$L@@\<DD%,#XLB186FD
MY?X2I.;!=M'B^_(+,N]IKTZX8[HM_!9V?\ (4<G[AI,&]QI+S^6JA['353]S
M\G"(%7$H!HL;2L-AAPH)UD-U1,NA;@>+X4$'\^%QHOF5:4>S2S](F,&?Y/E\
MS1)'[E2+(I<ZQ)&3)\20S@L22,/( J3BZ7*D\.D.L8QQA07QXUHKP\:,-_D_
ML=[->VQ_@/.(JN3\D'68]M!#BS3JJV<_&F*$&XTQL1E-PUB-%EJ8C]998AYV
M6YD]NF!E^NB)E>GH.ROC^]^Q1O=_SNMA,8(,-8DBI[I%D<Y^,:3NB@12<F\!
MDCNU6B3UU1[QV"GE1:%3VJO]IHPW>4Q9[F2]Q.US>DDZ1'K)4+)_R57%O?16
MQ[X,U+)Z&:EC_C))SVPJU\!XJL+0\%6KD<&KD\;ZKZ^A)HWUISX;Z[_\9C2?
M:S4(TM\N@G3VBB"U%T21HA$))./I0B3IXT:1J(_[)()FE!;[S&BM<ILQVN \
M8[&-.FN[BSCK((.;=3J G64?LOKDJ6#^R4_)]%.HBM&G6#6#S^F'=3\7:>A\
MJ=74^M*II?EU0%OCVPUM]:]3J+?S&FA&D*YN!*D=0)#"(1$D];XX$OMC*2+\
MN4E4\'.OA.<OA87L7^K+G>;TUSC^-MN _VV]!0N$[99 WHD!YAX3X.PU!*]]
M^N OJP-A!S0A_I Z9,FI08F\"M0K*,,1124XK:0((ZA[\SK2@2!U)]'Y%Q$D
MY1:"1(R)(L&P0L0;-HAR8*<X PY*D4%E,0&TEV'!:)4%F*\Q ^PZ([#?H ^4
M3;K W*P%KELUP&N;&@BVJT#8#D6(WR4/6;L/0<F>@U"W]P!T[)6%4S+[X?2\
MZH^C\\^A\Z\C2/A#!/'_+H5XP#(19U@K2H&M8@38*V$#<I+FH"IM MJ+#,!H
MB2Y@EFJ!S7)UP*]0!<>5RN"T2A%8J]&JN.8@^*Z5A9!U,A"S?@^D;]@-A1MW
M0>7&G="\:0>TS:OX-#I_")W_#X+X3" (!\01)UB"$&&E"!9="W/8+F8$,N)Z
M(">A"2J2AT%32AGTI!3 6%H.S!<<!)L%^P&_4 8<%^X!IT6[@+5H!W@NW@:"
M)5L@;.DF2%BZ 3*6K8<B5,GR^8"5K!A@E"4 JR()A,/20#98"E2+M4 F; $'
MQFX@>,B";9 \6,<J@T6&&I@5:8!IE1:8-&F#<:<N&/7H@>$9U!5],+AK  :3
MJ/>&8/ %-6<(Z/?OQF#PR10,/YC-#ZSWBX&%TK\[(Y+@H"8-5+VEX&2^%FCX
M+4!VV@T.;K* ]Y<'VR@5L$X[#!8%FH"IT :S!ATP;=<#DV/Z8-QO ,87#<'H
M)NJ9$1B]17U&_3+Z98S^R0R,/F# ^(WY_/[+8*4@#@1%"2"I2/^W0\0T6PL,
MW!:@47<#F7, B'X*@(]0 6RR.ECG:H%EF0Y8U.H!IE4?,-T&8';*$$S/&X'I
M=6,P&4.]-IDSF37YB7Y]-07C:7/T;RS ]+DEF,T';- ,6#GQ_W8E:$I2X**U
M%-BF:X%MNP68I-U 8QT LH\"$(6J@$_0 -LL;; IU@/K:GVP;#($BTXCL.@Q
M!O,S)H 9,IW#/#3]@7EI]@TS8_89\\/THSF8O;8$S(05F#^Q!HOY ':?&. .
MBO^W*\&4EP+.OSM$QFO W68S<!QV@S/S #AY*0(E2 T<8C2!D*8#N'Q]L"TW
M_(VM,_YETV;RT_JHV0^K/LQWJTN8+Y9WS&<MGYM/6TZ;O[/ZCGEE!19/;<!R
M% M6MVW!>CY@BV:PEQ4'VGX)8!^2 D_U)>!MN!J\+3>#I_TNX#K)@HN;(M %
M:G/4"*V?I"2][\1LPZ^$8N//^&K33[@FS(Q=E_E'VQ,6'[#G+=]C;UB^P3ZS
M?(E];SF)_68]AOUM<]<.L-=Q8'L%/S^PDQ$#1QEQ8*+<#TH"7VTQ"/17@<!\
M(_CB=@*/LG^.RU+XSO91^\(,U9IUBM.?IJ0;O2?EF[YU*,>\MJ^WF"*T6;W$
M'[-^CA^PF<!?M7F*'[-YC'^'O8_[:G<3/X<;(OS&7R "?L!A?H!#,_R[,\+>
M+0X\64D(4%D$(3HK(,1T/01AM_\4..[[XLV4_^CAJ?:.$Z#]RB52_P4CV622
MEHUY2BFV&"-56S]V;,:..ARQO4_LL[MK?QEWR_XA_CKQ#7Z8^,7^(G&... X
M1SQ)FG,X3IX?X/>* 7VGV'^_C??;)P&A2@LA0FLY1!JO_1ENM?53*&'/^P#:
MH5=\KLJDEZ_6N)O0X!$[SO2^<[K%'7J^]4U:F>UU:AWN*KF-<(5TG'B)=,[A
M(FG$X1SIA>, :99TBOR3=(SRD]Q)^TENH_TDS0>(:-MR1ENH%RH0;7\1"M(0
MJ[%D+MY@]><X\TWOH^UVO@PCRSX-8BD]\N-IWN$%&HRX1YI==4VRNLS*LAUT
M+L2?9U3:GW%J=#Q-ZR*=HO513E"O4'NHX]2CM _43J?OM!;Z=UHCXSNUCCD_
M<$37@+U5#/AH$PU%\\3*24&2VJ)O*;HK/J28KIM*M-GZ--9A[X-PIN+-('?-
M83\_PXO>0LPYSUCKTVZI=J=<<^Q[626.QUQJR-W,5FHGH\>IG7&!WLJX3V]B
MOJ$W,+_2JUV^TBM87^EEK&].\P'*=E'@H@U0L 5M/[O$(/& Q%R:RH+93*VE
MKS.-5C_+L-@XFDS8,Q)#4[@2SM$\'^1M>%H0A#G!C[0YQDO$'?'((':X%9!;
M.174)G8CO9YUA%G+&G"N9HTX5[)>.I>S/SL7NWYF%G*^,/*Y\P/:-E%P1YMX
M()HC>H<HI.P7_YZE*/4A3WW1BWR]Y8]SS=;=2K?;/91(D3\7P]+H"_<TZ D6
M8([X"VW:?6/QS=XI#O5>.90:CQ*G2O=:1AFWW:6$>Y)5Q!UF%W G6'ENLZP<
M]T\N61Z?G3,]/C/G W3T^+W0%AR"-M$X-$^ZC-CG/#F)-T6JTD]+M1;?*S1:
M>S4'N_-"FJ-<?P)3_7BTFT%G.!_3$A)LTQ 8B:\1)#I6\#,I)=Z%]$)>E7.>
M5PLKV[/'-=/SHFN&YYAKNM='=BIOEI7"^^22S/OD/!_T+8@H>*\5!2':@A.W
MBJ!O/41GB@Z(ORQ7E'A<J;;@9JG!FDL%UCL&LHB'>E+IA[L2./HMT3Q,77B
M365H&+XT*,ZQ,""-FBO(HV?YECNG\QO9*3Y'.4D^Y[D)/@\Y\?SWKO&^,^PX
MWUE6K.\GE_F "WH>^&@#C4!;</)FD5^Y.T3?E\J(3E0?%+M?JR1]M4)_]?EB
MR^TG\^P/=F?2#K>FL/7J$CS-*F/\K$LB0_'Y8=$.V2')U/2@;$9R0(E+@G^=
M:ZR@BQ,M.,.-%-SE1OJ_Y40$S+A&^,^R4:SY !MMXH+5(A"U#FWC&T6^%VP5
M>5.Y2V2L?J_HK08%J<LUNJL&RLVW'2_"'VC/I:@U9+CH5::XFY8D\*WS8H-P
MF5$1#JD1"=3$L$Q&;&B12V1(C6MX< <W-+C?+23XIEMPR&MN2,B,:TCP##LD
M>)8U'^"@33P S1"+-O',=2*?2S:*O*S=(O*P99O(]69YR0OU.BM/5F&V'BFS
MDVTN)*E4YS)U2S.Y)OFIWE:920&XE/@PA_C8.$IT=!H]/++ )22BRC4PO)7K
M'W;*S2_\.FJ**PC_Z"H(FV'["V=9\P$W='80VL035B.0LP;Y6+X&F6A<B]QM
MWR0RU'9(\DR3UHKC=:9;VJIL]]>5.BJ7%]*U"W)=C3.SO"Q3T@5V\:FAQ*BD
M&(HP(84>%)_K+(BM8/-CFCG>,;UN7C'#J!=<7LR,JW?T#-LG:I8U'_! UR 4
M;>/)*Q'(7XF\JUZ./&E;BHQT;4 &.P](G&K36':DR7A34YV-3&454:FHS$DK
MNYAEE%+@81&?ZVL;F1UL'YH120Y,2W+R3<UF\I)+61Y)C1RWI.-<3M)EU 2'
MFS3CZI8PRW:/GV7-!WCH_/#E"*0M1[X6+T4>-BQ$;G<N0H:.KD7.'-TO?KSK
M\-*V=J.-M<U6>TKJ[15R:J@:J94N!O%E;IC(8A^;T,) ?$!^N",_-Y[JF9W)
MX&85N[ SZ]DNF4==F9D744]1,VR7]%D6*_63RWR OUP$HI<AD+4$>5*Q +G=
MO "YVKT N="["CG9NU>LZ[CJXH9N@_7E'1:[\EOQ<NE-Y,,)]4R]R%J.:4@5
MS\J_PM_.ITQH[U$:2W8M3J>Y%!4RZ(6USK3"(RQ*X7G4$Q=*X;0+->^SLU/.
M_,!_*0+Q2Y W^=+(W1HIY&J;-#)X7 KI[UN!'.W?)=IR2FEAU0F]-87',=LS
MN^T.)'8ZJD2VT[5#6ER-!$V>&.]&/QOW^A <NRZ:R*Q))=.J\ZGDZFJZ0U4G
M@UAUEF%?_8AA7_6!0:SX2G<HG1^$+$;F4A8@HR7BR/4&2>1"IR32=T(<.79V
M*=)Z;KM([5D%Z>(![559_:9;DDYB9:)ZB0HAQVGJ?D=9>KPC[L;<+KXYJS/8
MFMX>94=I2R8XMN4Y$%JK2+C6#HIMZQG4*!G;\IZ";?Y!L:N?'T0N0)YFBR W
M*\61BRT22-]1<:0;[=\MEQ8AM5<VBY1>/BB9<TEC6?*@\8:H\]:[0LX2#OH-
M4)2]3CMK</K<=)U/^1@YG0PT(Y^(M"2>2++!]^;:VO96XJQ[VPE6O0,$RQ/W
M"98][P@6Q[_;6W3_)L[G1X(H<J\00:[4B2']'6)(-]J_F\Z)(U77I)'BD;5(
M]L@^\>0;:HNCKANL";YJL=5W&+?7<XA\R/4*4XEYF7N8>LE;V_%B@)[]Q0@C
MN\$D$YO!7(SE8*6%^6"[)69PP-+LXGU+L\%WEJ;GOUN;G .;^8QE(LC5"@09
M:!9!NKO1^?VB2,4E"23_U@(D?70EDOAPMVCDJ))TT /=Y?S[F/7N_]AN8]US
MW$._2Y>EW.'(.]SA*>-O!ZC9WH[0L+J=J&5Q.U?7[':EGLF==GWC.P,&1G?O
MZQO??JMO>.N+H<'-W\;SN8FNP?DZ!#G6CB!-_WXJX+PHDGM-$DE^L!")G5@O
M$C:Y5\Q_4DF:-Z&]C#-ALH8Y8;V).F&_W6&"MILPP9*Q?>8A:_W,[Y#%A% !
M,Q&O9#*1J6(T4:IJ,-FDIC_9>UCO^3!J\K#>Q*R:SK.?ZO.Y6(4@/2T(TGP4
MG8_VWYPKHDCB'4DDXOU2)/C=)A'^.QDQ]_=*TJSW6DN<WANM<GQON0[_'K?1
M]@-IJ]4'QG;S#YQ=9A^\]QA/!\H83$?NUYM.EM7YF'=0ZV/5(8V9=CGUF=/R
MAV='4"_EU3[.SNM$ X*T=")(Q2D$R;Z((/$C(DCH8PE$\'4%XO5ULXCKM[UB
M]&_RDN3OZ@L)W_67VOXP6V'UPV8UYJ?]6I.?E/6&/YTWZO_B;M;YY;-%<RYH
MF_I<]':UN;2=*K\+=RG]KMVM"%U[%&!@KSS<V"L'$_-J:T/G]Z#SSZ'SKR%(
M\"B"^,Q((UQ8@3!AHP@9=HD1X( X%I0E+4!+&JW/BXS ?(D^8)?J@/UR3:"L
M4 ?F*E7@KE8&[S4*$+16#J+7'82T#;)0M'$_U&[<!QV;9.#DYKUP:5Y5Z#G(
M&4#G#R%(T#T$\7R&("Z_I! J+$/L8:T(%K:*FL->,6.0$]<'%0EMT)+4  ,I
M-3"55@8K:46P6R '#@L/ FVA++ 6[0//Q7O ?\DNB%BZ Y*7;8>\Y5NA$M6X
M8@MTS2NO#YU_"3W^VPCB,8X@3N\0A AB"!86(^:P4L0(-HCHPG91#9 14X5#
M8DJ@+"X'ZN('0$=B'QA*[ 4SB=U@);D3["2W@X/D%G"2V@1LJ0W DUX'0=)K
M($9Z%:0M6 7Y"U9"^;S \) 8&"J) P9EI28)-MK28&NV%&QQ:\"&OA$L/;8!
M)G WF,3(@&&Z+!@4' 2]2CG0:Y 'W78%T#FF"#I]2J ]B+JN#%ICJ-<JH#6+
M^JD"VJ#\&_5+!U2^Z('JYWF T4$Q,%80!PN4C8HDV&E* ]YT*>#LUH =;2/8
MN&T'2\%NP$3N Y.4 V"4=P@,R^3!H$X!]%L50:];"?1.*H/N.170O8IZI HZ
M4ZB/JJ#[0W5.%U1_ZH'*-SU0FS& P]/S &,T@YF<&%C+_<^G5 @:TN!@O!2(
MV#5 (&\".]?M8..[!RS#]@,F\2"89LN!28D"&%<K@5&3,AAVJH!ACRH8#*B!
MP14UT/_G,.@_/SRG/WWXA_ZWPU\-0.T+.@>=K_[6"#1>&_^?P.2 &)BC.6P/
MBH.]O 20#DL#U7 I4*S7@*/#)B"Z; ><]Q[ ALB"5=PAL,A0 $RA$IA5J(!I
MO2J8M*F!R5'T6/K4?QM?5/]E?$OCN]$SC2_&[S5FC;]J?$1G?# &S3<FH#5I
M"MH3\P!3-,._^T&$_>) .B@!3JI2P-1? DR+U>!$V AD.GJI>>P%0H LV$7)
M@4V*XF^K7)5?EJ6J/RUJ#O\P;U;_ANG2^(HYH?G%[)S69[-K6C-F8UKOS=YJ
MO<%\T7IE!CHOS4#W*0;T1BU __X\P$P678-_]R#0_NTD*PXNRE+@JK,$7,U6
M <MN(S HVX'*V3M'\CWP@Q@F_PV?H/S%+E/UDVWAX1F;"HV/UO5:'ZS:M-];
M'=-Y:WE:YXWED.XKRT>ZSZU>ZSRS_*PW9OG;X)$%&-ZQ J-KUF T;/-_ HM]
MZ!J@79>*=DV7?>+ 59 $3ZU%X&F\$MQM-OQV==SVG>F\Y[.3UX$92I#"!\=H
ME;?$E,.O";D:4_@2K1=V-3K/[9IU)VR/Z#W%GM(?QU[2?X*];_  .V5P!_O)
M:,3FM\EU&S"]; NFY^S [,P\P'J/*#B@/9.!=G\NNA8\.0GP55\(O@;+YWPL
MUWWU(FR9X3KM?L=RDWW%%"@\=PI7>49)4!\G96@]=BC0?6A?H7^?4&]X%]]N
M= O78SR".V=R'3=B.HQ[;GH9-X,9Q,V9G\.!11\!+'KLP>+X/,!VERA0MHH"
M"^6%KH?? 7$(5)7^':2[]$N@V>II@>VFU][DG9,>[/WC'&_YAR[!JO<8T9JW
M:,FZ-RC9!E=)Q49#CE4FEQV:S"X2CYA?(/99G+._8CE@/V;91WQO=8+XP[J'
M"-9'',&ZG036K?, /-K]G3;_3__G[Q2%(/3<"!6EOH5K+IH.,UKQ*L1J_;,
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M]L<^(<U/D\(:GS:*J'_>)Z+V^9RHZN<'Q).?K"4[&-E*\O>3_), >1<!$F\
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MP]!AY#^@/YE!%.E[WW_?FR<(6")&>54I0WE0K4R]4:-+=['2BNUTB1O_D8(
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M6]!D7YG?[5R6.^I6G#/K49"SY)6?<]@K-^>Z5U[N"\^\W*_N>;GH]E\PALR
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M4*=1%]>N71T[H%<9.VE0%K-H6!*SV[@XYJQQ4>Q#HZ+8#X9%<6A Z*^$@?2
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M=)/RAPT2\M88Q>4N&<?D'C&)R;U%O#:*S45#PF EC :XE4[V4 API!)@=SW
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MO=N$#/:>$C+<\T!0?_<[8?U=***W$T5_M$R>P?5# !,DOY?D-Y+\TB6 S)T
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MEJA<GX\1UXE'_](Y#U!-[C^7Y">0V0>3>W>]"&!U%4#_!H#:'0"%EP!RWUA
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M$<E9EVGI&><%F6GG9=E)YV-R$RXWY,9=7LB-NGR5'W9%N>^&5D GDNU)>F\
M$[P-989'$2QP-X(=+D?RP^DH13@2:4#=%V%+OQSJP;PU.(AC4V TSX)_,O]Z
MORRA.=\BD34^E6)3W@T2J[TZI%9Y#LB,>4S(CGBLE1_R6%(8]#BDV._QFV*O
MQU/%;L_/BEV>J-CEA0J=*Z +,YD!/7P(H8._(FGP1PP#7(IEAE]B>>!(O"SL
MB=>A;H^UHM\<[<J\$.''L38LG&=-:+S 9'":T$10KNA80(G$B'^-U)!?BTR_
M7X]<K^^H0K?/&L5.GTW*[3[[5-I\SJNT^#Y2:?;]J-SDA\J-?JBT$KJ1WAU
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M_)>--/Y+27]>%_EORKUA!?G/-4#61B">O'CP#L!C#WG@?0H8M5\-#@<,8'?
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M=17S7'4#\TQU._-$]0#SI^IIYJ'J=\P?:G>9VVHOF-_4.>87=8[]6>,CM[Z
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M^(D+G^!,2-N$_+\Q8:+^\5S(R R<_G#\-6 ,GNH$XI%V#.YII>&.9@%^TZS
M+YKC<$MS(FYJ3L%US5GX47,>OM=<A&\UE^.JYEI\K;D57VGMQR6ML[B@?1-G
M=!XQ)W7?,L=U.?;H (X]\A^XP7)P@Z3@S!7!62C351/O!QOA^< A>& \"K>-
MO/"S81AN&";B>X-L7#,HQM>&5?C*L &7#"?A@N$TYKQA!W/6< %SQK"7.678
MQYPTVL@<-]K-'#4ZP1PQ_I8Y8'*/W6OR%V^7"<?;:<KQ=IAR_.U?P%F0OJ4
MG)48G#7%,4P9SX9HX:ZY"6X-ML;W@UWPM5D +II%XYQY*DZ;YS$GS4N9XV8U
MS%&S1N:P60MSR&PZ>\"LD]UOMI#=:[:4W6VVEK?+?#MOA_EAWG;SR[PM%K?Y
M&RU>\M=;<H*UEIQPS7_@AI&^3?^Q)HN7(X5X/%P!=ZV4<7VH-JY8F>.\M0-.
MV7CAJ$TH#MG$,_MM,I@]-@7L+NMR=J=U+;O=NHFWU;J5M\6ZG;?):BY_HU4/
M?[W52L%:ZTV"-=;[!*NLSPE7VOPB7&;S3+3$AA/WVG+BQ43/%WS0I^WD\2C:
M7AV!'T?S\:V=!)=&JN&4O0D.C[+%OE&NV#4J@-D^*HK9XI#,;G3(8M?;%_'6
MVE?RU]C7\5?9-0M6VK4)5MC-$BZS6R!:8K=4U&NW3MQCMTN\R.ZD9*'=#<E\
M^\<*<^W?*<QQX!0Z_T/_L>Y+TO[-E3R?!W#)@\'9,4*<<%+"_C'ZV.DZ%%M=
M';'1U9M9ZQK*K!H3QZYP2>4M<\GE+W$N%BQV'BOL<:H7=CM-%'4Y31//=YHC
MF>?8HS#'<95TMN,V:8?3$<693M<49S@_D$US?BN;ZLSUHSCE"S@'VGY)_SIM
M[Y?(_YXD#ONPV.>IB.U>.MCH;88U/G98Z>W.+/4.9!=[1;+=GHF\+L\,P7R/
M?.%<]S)1IWNUN,.M43+3K56AW6VF=+I;E^)4M^6R-K=-\LEN!Y1:W"XK373_
M0VF"^VNE9G=.J=F#DW_)&R=Z_7B1YPPDKQ-"?3[YSSWD@[?Y2[#>7P-]@:98
M&FB+GD 7IBO EYWG'\KK](_E=_BE"&;Z9@NG^Q:*IOI42*;XU"FT>D^4MGA/
MDTWTGBMO]EJBU.BU7GF\]UZ5>N_S*N.\;ZO4^;Q2J?7AE#^A])D_J08_4>X7
M2?LHO>;VT"MW*[UFUH<(L#)$!;VA1E@8-@SSPD8SG:&>S,R0(-[TX$C^U. $
M06M0NK E,$\\,;!$TAQ0+6T,:%0<[]\F'^<_6ZG6OT>YVG^-ZEC_7:J5_F?4
M*@)^52L/>*%:'L"IE =^0/DS#^C5]CWE?8;T#\8".^+(;]&U+X)!;Z02NJ+T
M,"?* K.B[# ]THV9$NG'3HX(XT\,CQ4TA:4(&\*RQ/6AA9*ZT II34B]K"JD
M15X9/%.Y/'BA2FEPGUIQ\';UHN"3ZH4A/Q//U0I#.-5/J'SFK@^-0QAY_QCR
M_@GD_<G[K:+K$OJZ*T:&SE@=S(P;C*EQP]$:Y\),C/5FFV*">>.CHP1U48G"
MFJAT<55DGJ0RLDQ:'E$K*XV8H%0<,5VY,'R!:G[X"K7<\*WJ.>''-;(C;A)/
MU;,C.#5"]4OZS^/ZS\*.D.[.%*H!>;_E=.TF+]R9($5[HB:F))FB)<D:S8F.
M3$.B)UN7$,BKCH_@CXV+$Y;'I8I*8W,DQ;'%TL*8*EE^3*-2;LQ4E>SH>:J9
MT<O4,Z(W:Z1'']5,B_Y1,RWFB49:S'OUM!A.+3V&4_W,K6#R_I3SP62:A_UG
M0-1N+*;K//JZ/46"MA0U3$HU0E/J4-2G.C U*6[LV!0_7GER*+\T*490E)0D
M*DC,E.0E%DIS$BIE60GCE3(2VE32XN>HIL0O54^.WZ21&']8,S'^.^(QW;]3
M3XKGU C5SURG<3C=?Q9'^6^FMFLE^<^%=.V@KZ>D"S$Q0P6-F?H8EVF)ZLR1
M3&6&"U.:X<,6I0?S"]*C!+EI":+LM'1Q9FJ^0GIJN6)JRCAY<LIDY<24V:KQ
MR;WJ<<D;-&*3#VK&)%\C'M']W^JQR9P:H?J9_C/!_O.XW93_ACQ@*3$O%YA&
M7T_*9M&0HX3:'%V,S35#>>YPE.0Z,84YGFQ>3B O.SM"D)D=+TS/2A6G9.4J
M)&66*B9DULKC,B<IQV3,4HW*Z%&+S%BG$9&Q7R,\XVN-\/2'&A'I;]4CTCFU
MR'1.]3-78CZ>QVW/ =86 CU$!_G@R11'0SY04R!#9:$62@L'HJC(&OE%HYB<
M0G<VL]"?EUX8QD\IB!4F%22+$O*S)7'YQ=+HO&I99-X$I?#<=I70W&[5D-RU
MZL&Y>]6#<B^K!^7<5P_.>:L6G,.IAF3_RP6:BP<HYRVDVU=*:Z&D_PR(^OTB
MTJ=K>8D4Q:7JR"\S1D[Y4&25VS/IY6.8E'(?-JDLF!=?%B6(+4L41I=FB"-+
M"Q3"2BH50TH:Y4'%TY0#BKM4_(M6J_H5[5'S+;I(W%/S*WRCZE?(J?H5<"J?
M.4UK8 _EO(&TEU60[ZWH/P,"QA'E=%\X5H2<*A5D5NLCK<8<*34CD%CKS,37
M>+(Q-8&\J)H(?D1UO""L.DT44I4G#JPJ5_ ?.U[1=^P4N7?E?"7/RCYEC\I=
M*NZ5YU4\*NX2?ZEXE'/*GF7_<C3SXV>RUE22[Z3V>^:',R#R'$0^>?+,<2Q2
MQLN1U*"#^,:!B&VR1G33*":RR8T):_)C0QI#>4&-,?R QF2!7T.VT*>A1.PY
MOD[!?7RKU+5^KFQ,_0JY<_UVXHS<>=QMN7/=*[ES+?<!EYJ/'* YN)GR75D'
MS!]':X$83Y2-)_TF\AT3@=@6*2(GJR.\U0BAK98(:1N)H#9G)J#-B_%K"V1]
MVB)9K]8$GD=K!M^MM4@X9G*UR&GR)/'HR;,51K4LE=JW;"5.2>TG_2:UG_A2
M:C^!4[1O_I==- ?6U7[\+%!'(ZT%NM8TTQB0=DH;$$WV*&2&$ $SE>$W2Q>^
MLP;!N\,:7AVCX-'A!K<.7\:U(Y1QZ8AAG3I2V=$=>3R'695\NUG-@A&S9@IM
M9_6*;&9N%EG//$[\++*>\5QL/9T36T_[@*2?+53S/M+M:J'U2#1,IAJ0=C9I
M)\PD[]4)^) O=^]2Q)@N=;@L-(330G,X=MMB=+<C'+H]8-\= +ON"&9$=P)C
MVYW%6'>7LL.ZZ]FAW=-XEMW=/(ON#7SS[B-\LX4W>68+GO+-YK\3F,WC_F$M
MY=Y+NIUDPUH^? Z(O-\LJL$<(&H!X$]6U6T)X+"<C^$KY+!=H06;E<:P6FF)
M82N'8VB?(X;T><*R+Q 6?5$P[TO!X+Y\#.JK9DS[)C,F??,9HU5K&,.^_8Q!
MW_\8@Y6/&8/E;UF#9=P_+&\%%I#N=-)MF V4SJ5YT$5S@/QX\#+ LP\8M0:P
M(5]NODF$@9N58;I9"\:;C6&TQ0*&6VQAL,41^EL]H+<U" .VQD!W:SITMI5"
M>ULC-+=U0&/;<JAOVP6U;9>@MO4^U#:_AMHFCOE,=SO- ZIW"^5<178TCW).
M7 &$D:XW^7$GLJ6VV\@#DR\VV@-H[Q-!_8 <:@<TH'K  "H'!Q-64#[H .5#
M[I ?"B)B(3N4#<7#8R$]W J%0PLA/K0!HD/'B)_H_D^(#[XA_O[ ',J[;2'M
M!Z1=1#FGK0,B-P.^VP'G7:1/NF9DU0T/ 5I' 943#!3/B"$^*X?HK#J$9_4@
M.#L0_'-#P3MG#_:<&[T$J2$Y3R^A\[3HSM."NT"%/D\"Y^FAY\GO7_B%>$P\
M^< TRGT\U;QT-9"QD=8!_9A?_V=P2->&= >3KOX)0(-^5>D\H' )X'_-4M-!
MGO\;)>"J.G!-%_C6!/@?>?[O1P(_]#>HU!Q>ITWX!FW -QH(&N@;*X&;E-A-
M>MC-F\0O'VCZ? 9$-8_937/P .5_!+ FW8&G@0&DJW89D'T-B+X%-?\$_3I^
MX@&W),#/<C(%JL"O6M28&@"WS8"[MM0HNP /*(X'%,=#V@0?T8)_1$5_1,5^
MM(,X1ISZP%BJ?0Z-=]Q>()"T74Z2_EG2OPCH7*':DZZ4='G]NOUG,+\3=XD_
M/IV'W!>2AI0,"M7D3S7@*=7DN2GPR@IX30WS6VJ2_DX$WM'+YQW%\9X6W'M*
M_#T5_?WF#WP\<R#/KT P1N!@3M@1[D0(D4!D$R5$#=&$]VC%WYB!M^C$:RS
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M!M1__D(^O)/BF4%Q3/;EH]E7&>/]=%'K-QA5_C:H]'=$F;\'2OS]F2*_,*;
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M(!-X8#NAN=Y_D[Q-/N?O?8>!>5R3F.^R42"+ECB>?0Y?!?C.T']OICXU3?8
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MZBUG"3X<PW$@=;1(97S-)VG\/)&OL?PL*DX%TGA=A,4;(23!$D$)C@A,\$!
MHA_\$T/AERB#;U(2?)*RX9U4"J_D!DB2>^"9/ :/Y'5P3]D/MY2+Y#;<DC^&
M>_+/\$B2SZ+X9^%)EM\#\4 +J29%))LDD1C:I4B6Q6')K/M3M!"0:@"_5#/X
MIMG!.\T57FG>D*0%P3,] A[I\7!/SX!;1A%<,VKADM$%YXR%<,I8 \?,O>0\
M'#)OP2'C(SAF_ 2G=/DL,PF<"]3I(8U)BFN F .23LVX%/:?5BDL#0C,H/_/
M4H=7MAX\LXWAGF,%MQQ'N.9XP"7''\ZY87#*C8%C;BH<<O-AGU<%N[QVV.8M
M@$W>2ECG[8)5WEE8YCU+/H!5[H^PSI'#AJRDU@)J=9!:ZA63;))"W6CJ2FE=
M@[*IGPMX%(C@4J@-IR(#.!29P;[8#G;%+K M]H9-<1"L2R)A59((RY)L6)24
MP;RT&::E0S I74YVP+CD%(Q*;I+_P+CX/DR*Y+,LI=8@2_]FZE62 I)!W41:
MM*@<((2VU:^0WJN8_ILVVJY"'595NK"H,H)YE27,JAU@6NT.DVI?&%>'P:@Z
M%H8UZ:0(!C7UT*_I@U[-$NC6;"''H5-]G;P)W:IOH%OY._0JY1BC5K?B7C!2
MJK@.B*2RS[&T9^'4]J<]DI13G_;$O@:PK!=@W*0)PV9]&#2;0+_9&GHM3M!M
M\22!T&F)A'9+$K1:<J'94@7UEDZHM2R":LL,5)H/0M1\&>*F5Z#2]"E4&G\@
MOV.8_6RC7A4I))D%0$(1YV$IQZ "\*JF]ZJC/NVB)?VY<3N@WZ4&[5X=:/0:
M0KW7#*J]ME#I=8&XUQNB7BZRO3R8>IG<7G:@MXG0R/?2R/;L(32.W31L7:R@
MN[XCOZ"7.6X@941^3RY/2TBHR<W/24[+3(**9AX;26$TT17*72'?>L"MF1$Q
M$DLZ=F.::;T!0'N>"E3G:T.8K\_IQ5)L 4N/!?8L/^@X1WCJ&>&2-\)I/\(4
MC["A$?[BR!*RC9SBS]X$YK]'ON8R\1/:J5=3H;Q#++,2B*]5[@KYMW)6=@(.
M_'7+0>H/4W^4KI2.766"I?$DR] E+$>7L#1=:@(L8QQ3+$&F6 8LYVEP.9>Z
MY9Q^R]FQY6QL.7]Y.5WXU&'^[./D-?[>9^0^FJA92?(X LF**X/:>&2RSYXT
MJX[4M>2O&BT&=-D-C>6 B$EF.<TEGV7Y6DU@'>.8,5#\<YCRG\4V,HY-GLI;
MA!7+T19.O2W,Q68VN)GN=_-N?I\CM(DCM/$>^0IU',!BYCN=^8[IYI'!/GLM
MH/XX]9?2D4\#.M146T_=383I9,G/<I3L8CYVTR;LT59>J;+?"#A@P3*)<1QF
M'(I3I&)[6O'8]"/,Q9%%A(T</@X<HL4_1(]SZ(/9*W-RF.^$(1X9[+./XJH<
M]M>2NH8;./9;']J1.4B.$)IXF@CE+@F'%Z>9DS/,R3GFY#S+](LLVR\YS-VM
MP]/092X!5SC05_H(<W&%N;ARGI]S7ES^.PHYB5,7<@PF 18@<..065/7B#^F
M<P 0*W9D3L[MR#S8';DR!X>5ADJY:Z&X8^>&*O 4<_(TQ^8Y6H?;C.,%EFDO
M\E3T$N?G2QSLET<(D_KR(?((N8$LCG,<QSA$<6?4=JY*[*\Q^ZK#_HG/SVD^
M/J=Q$\HK4I['?^_4>;!+\N#I)7<$X'7.UW]S;!1V1O'DUGN<HQ_P-/$A#\>/
M.@@[_/$6POGYT;FYJS%4Y^[(T)N]*T1.%\[S+ FG0TW +W2=/Z (WZ&*;K4!
M7]'I?4&G]QF=[Z=TOA_3PWU$C_<!?=_[])O_H<]]C\[S;0Z6XCZ,?S+PU_GI
M:[B/.Y#_=7>*XDFA+\PZ<6%N1T"8O2I#<87*KW1\/\(#WR.(FM'42\4GR*5W
M+,4].L[WZ#C?03O>8AS_9AQO,(Y_,(X[C./O]+5_HR]]B=[Q-EWX+?KHYYC$
M9_@3-QG]4_3]-ZBBX$ER_7]V17Z=O2I#'Y_#@OURIIXO[C(7;R&>_<A@[/EL
MOXSIKYF],N/6[!,R>MC^(-L?8?N+V>X4I\=:3I,M>(P3^3)S\2C_?H0]OL!6
MS].%*[)_=HYS#\7PT^Q5$2)F3(>Y,V9_;-D7#VH%4B>*&DEL/PM74<#I4<8I
M6<.6&W&)X_((NMG^X.R5&6<9QVEZ\%,<DQ,\B(\Q%T?XG4.,\"!'9S]'=/]#
M5V3LGXM!H:^X*^7?LU-, T_#@'VQ8#^<V =O:H12(X;MI[#M+!XFA3PTRW"4
MXW*$\^,P6ME^-PXPCGV,8P\F.1*KN(1LYLS8RR7E%+.BN&;E%8[2YW3UO\U>
MC:% \7\P*_0_AO+!.,_-'FHB7&0N3G->G( -==S8!W]JA+/]6+:?PO:SV<,"
MME^*K9RG6QC'9L:QD7%L8!PS6(AUG!MK^/<J_N1*MK*"&9N:W</Z $LYPY="
M^7]!*_AB3O\I'E*/S"TY1S@O]O$8V<UC9 <<J.-)C4!J1##N.+:<RO:S./L*
MJ%&*:<:Q@G$LY[@LX_Q8@F%F8C'_K,08(UPT>]W*.6;H)A9P-L_GK!OF$3>?
M^@K>U0*>X;)R08?:?-W-0WN[BF*C7(MZAIQ=EM1QIHXW-8*I$4F->&JD4B.;
M1T,!-4K9\VKJ-%*CG>WV8QZ_&F3/!YB9/HZ'XEZB;AX%7<(;Z!)]B4[QKT0^
MR]\4F\Z&RDWP'7Q=;Z#\1X)I;3&6J^I@J6","<$&8R)7+!3[8D0<BODJ41A6
M2<"0:BH&5;,QH%J(/M4R]*K5H%NM&5UJW>A0GX]V]25HU9A!B^9N-&F>0J/F
M531H_0,-VE^@7N=7(I_E:2ZII[F\[^:I9H8LY]<3/ 4N8CP+]=2P4$L/\[7,
M,*1MCWYM#_3J^*-')PQ=.M'HU$E$AVXZVG1ST*I;A!;=2C3I-J!!KP/U>D.H
MU9M C=Y:5.GO0J7!25087$.YP1LH,_R&_$'DLSQFS=.8XL)0.V"%G7(W9#X_
M&V0\?5QJ^PPUT6-@B$X#2[09.*'%4()FPT T&DK18!B#>L,DU!IEH,8H#U5&
MI:@TJD&Y<2O*C/M18K((Q2:K4&BZ'06FQY%O]CCRS.X@S_Q+\@>1SW*!IY4]
M3BP%R(0SRQJ^]G*)[V0\;8REQ4(%S:9Z:# S19V9'6K,W%!EYH-*\V"4FT>B
MS#P.I18I*+;(0I%%(0HL*I%OV8@\RV[D6(T@VWH%LG@2S+ Y@G2;*TBW?05I
MMI^3WXB<7\MQRH4E@>**&)9AH^[L-U_;^74SXZEG++6,I=I&&Q761BBSL4*)
MC1.*;#Q1:../ MLPY-G*D&N;@!S;=&39Y2'3KA09]G5(L^] JL,P4AR6(=EQ
M$Q*=#I%'D>#T$A*</R6_$CF_IA.G[D:6&TLDP#S219KX=2T_KV0L98REQ%$=
M18[ZR'<T0ZZC';(=79'EY(U,IR"D.TF1YA2+5*=DI#AG(<FY"(DNU4AP:4.\
MZQ!BW98@QFT#HMT/DD<@<W\!,H]/R"]\+^=G=.+47,M28]R'3IRTDCIOZO.S
M4I:&A<Q+GIL*LEUUD>EJC'0W*Z2Z.2'%S1-);GY(= M%@GL4XMP3$.N>@1B/
M D1[5D+FV8PH23\B)1.(\)J!U&L_PKTO(,S[>?(1W_],Y+/LIMY*EAFCBETA
M?^: 5/%]*3\K8!RYC#&3I$FTD2PQ1*+$'/$2>\1)7!$C\4:T5Q!D7E)$><4B
MTCL5$=ZYD/J4(=RW$6&^O0CU&T>(WSH$^^]%D/]Y!/K?(A_R_4]$CF _.G$_
M91D\'$@'2.I).2GD9SG\7@;SDL)X$GTU$.>KAQA?$\A\;1#IZP2IGR?"_?P0
MYA>*4/]HA/@G(R0@&\$!)0@*K$=@8#<"@A;!/V@-_(+WP#?X''R"GR7O\_V/
M\ N2S[*96DN"%'=%<1QH6*I)"=_GD0S&DLSOQ_,U)E 548&ZD 89(3S($J%!
M#@@.<D-0D \"@X,1$!P)_Y $D@F_T"+XAM;")ZP3WF&C\ I;!4GX+GB&GX%'
M^-/D'M__ $F8?)8-U!JG;A]+X*8PH((4DBQ^G4+B^3T97R-"10@+TT9PF $"
MP\P0$&X+OW 7^(9[P4<:"&^I%%[2.$@BTD@!/".KX1'9#O?(!7"+FH9KU$ZX
M1)V&<]1-<I?O[\,U4C[+&K:_,)S' ZU1/2EE&9S'UW222&1$RL]"(ND[(C7@
M%Z4''YD)O&56D,@<X2GS@$>T']RC0^$6'0W7F!2XQ.3".;8"3K&M<(R=!X?8
MY;"/VTY.PB[N!GD7]K'?DS_A$"/'M%1YAU@;-:JCE+M"622%Q))P&1#,LMB?
M=L4G3A62>!VXQQO"+<$"+@EV<$YPA5."-QP3@^"0& G[Q$38)67#-JD,-DE-
ML$X:A%72,E@F;R7'89%\'>9);\,BZ5M8)OX!JT0YED8I[Q!KID[%W*Y0>HQR
M5TA&W= XUOPLB;UI5=R3!;BD:,$Q51\.:2:P2[.&;9H3;-(\89WN#ZOT<%BF
MQ\$B/0/F&44PRZB':48?3#(F89RQ"4891\E5&&;\&T;IW\ X_7>8I,DQ'J.\
M0ZR.6B5SNT(I)(Y$4#LPB?U/H?>D=72F5;'+4H-UCBXL<@UAGFL.LUP[F.:Z
MPB37&\:<R$9Y,ACFI9!\&.350#^_"WKY8]#-6T\.02?O"GD5NKE?D%^AER/'
M NJTLX]5I(!Z&2211"<S!ZF 'TV]9R;@DD/_G0=8%0 FQ9HP+-&#0:DQL81^
MJ0/TN*#IEOH3*71*$Z!=F@VMTG)HE+9"O70!U$I70[5T+U1*+T*EY 6HEGQ$
MOH=:\>\8H%;CW-UAN225Q+'/$=0.S*+WI#URS:?_IF6T*@5,RP&#*C7HU.I
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M8C^4Q6TH"\_0%.<$,Y0@&HJ@H;V=1YX,@^,-A;P.A40-A3P-(6L<\CH+PA_
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MO "[/4G@'H>I/D_0'('C'8)S'\2*9^'<!^"9G:>"&F>D[/J1#7\!7\BX,R0
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MFP:YM6J@^P#U=Q^A?A[7J\WC9O7QO$^MGG/5VVNI>GEM58O74?7TOJJ>/E^
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MUW$_RBB]S@"Y NNZ2*"^"I<X!Z]ZF8X[XS@E= DFK=<Q.,51KA[69SJ$AN?
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M98S?13E#!G\")G$4.PXY?JVUA^,OU_L9-'L)WMWD\#OA=MNQ8RL!NYD@W4C
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M12O8+U'!_AD*\B^0W;]2]H!FV0+:9#4QPYBFRF)Z"#PA<\!F<%AF_\O@,XU
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M"K#;Y&\/D5]0%$B4;U"F?(*+Y!5<*\^0GO((&2+WD ER"[G7>7A^",E8\$$
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M -R(\Z$L91Z,#>'&.TI=)&>QD^HJ=#+<!0ZV)]_!]^0Y))Y<I\H]EH#I^7'
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MUQ/C*K]]; (///\:!;P[M0Q\/JL$+%V0 ]9^G0HVKTP .]?&@;T;]X/X+7M
MPO98D+)S!\B(W7XW>_?6O_/V;+E3M'?S7[!]F_Y"[M]X&W-@PY_X@^O^I,2M
M_:,\?BS9&Q^+40W%C..!IYXF@Y=?0(.I;Q2#.>]G@<4?)X,5LP^#]?,/@&V+
M=X/=2W> @RNV@B.K-H.D-1M!^MKU(&O=.I"W?BTHW+ &P#:N!LA-JP!F\TI
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M$33/%"KC6 (8EM7WL(#TOD$Q=PI0?O49T"Y:#"Q??G/'NV#;+_6+]GS?O?S
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M^]),HKY4I[@W)2CI36F6M*6U2!K2FR6AC&:)/_/! 0)D($$&,F0@0@;R]GF
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MN*=0(N_*4U5V9FNK.HY;J]LS_9K&K(@FD!VN<>6$:VRYX1IC7D1CR(M4/RA
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M6/_ @.KIF '7$S'1Z%,QSIZGQVE_?7:B%+SQ!AO,^) $YLQ#@:5+B\'Z;[+
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M_FB8<OY(!V4@H9_2?JR?TI#43PTE]U.]*?U4SP,"L)?&@>*W'@<ED*%TZ1L
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M07]RO:@YK57DSVP1VXZWB&NS6\3:G%9156ZKL#*W3:#,:Z_X3P$D9("_^3A
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M]__CXR[#JLS^-] O-FUB)[8(2G=W=VUZL^GN[NYN06D4%!0QL+ PL<9V;,4
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MFINY,60@XT!H7\8/83V9+T*ZLS"X,PL#.[+1OST;_=JRT.=;,)1F((FR<P4
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M76)6=+E'+%_H%3*^QB=H?*]OX/*??0*7O?4)'$.?X$7H$[H O</GHM>W8 '
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MT6QI3&-+8!%;')LY8CB/(XIK.")X@$L8?R/>$?A?#-$,MN^E^I\ R*;\V%\
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MF9S^FH/4@\U3,T#GP()U %U; .JG\@]1/GEXW'D6!%_A :_K@N!Y0Q8\;NC
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M;SKH3IE^Y'MAO("QM(Y$(7B?+ I/4J3A=JH:_)AJQEQ,<>4ZE10H<#0^1NQ
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MI%0<=TRIN$?'O^U2*] FK1RMTDK1,KT$+::#T30+F=0'\O\34S6@_6_K -A
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M/RM.]<<64-J#08E0!L6I'Z(Y1#E!M1"E6H@.$ N)I<0JYI/H!/-1=)+Y('J
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MXCYO>(G[M-$#GN-&?_(=,4+^0T8H<, (!?=/88B"^Z:!9K1W*T% :_).>P%
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ML%%Z04"G[#S_0;E!_\4*_7ZKE7K])I6[_4XHS_&[H]SA_Z=RNS\JM?FC8EL
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M;-$,*SE!/- ,*_ZH'EZ,JN%%J!)1A,H1A:CT+_>BOCR3/$@UV$;[7UM+<]!
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M+6G[N7_)V ^@C'T_T?<U4\\D=](,K*?]+^VF&O13#>92#2B[8"% ZF* J*4
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M=M7TM@I&=TU@<-<*^G>'0>_N.#(5ZF?\H7HF&LI[65#<JX)X;P&$>ZS<O2/
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MS\+9PS;@KWD=!R:=H3XU;2X!&FJJK^OV7U@$Y+V0N[K]D/OT^\\: ,_3*+U
MD_ 2/?^K7*"_P3C^$T0X^;S%B_\M-O);6X&WSQ'YOISO_[H?9ZY\+Q3SG'D,
MB**NSP7 Y3+S?PVPNLFVE\^_/+K_\O+#<RBZ_9"W'NZ'J&A0C("/S;3/*/F2
MB^5O&,>WG)B_8]_XOIXF@IW[ 1/\@(4_>)LPC@</4,5\9[-]8UAG/];7Y0;U
M=?<@&3UZ_N5-G=9_G4'Y7WLA>L OS,GO-KKG@LC_7DVX[MFH\OTP\K\/PV1+
M;$SI5?(&':>=SN];Z][+9T+&X>][0.+_/_<?'CV'(3\/0WM/S%DZ_6OX@P[U
M-P;\*QWLH\_>^$&W__ IM&<BM'L?YCIDWV\+[?TP4Z"]!R0*VO,H\O,XY+,@
M\GTY+2Q_ 7['$I;?RW+74&43?L)VEK\?#W <W^$B4W.'*7J'>M\-/IWD(?(]
M*1_J]B+>DF,8/'<A^WT3'9:Z7#S<#PIEG1)8GRSJ%%.CFBF?Q?);67X'R^]F
MN2OP&?I9KP'6:R<^PB%\@#-XEZ[_'3KVMZCZ)DN0L_ZZCM>@/8_QPN!>D*QK
M0-2Z5]/!-OD-8Z@YE9HS68LH-GL*=7*I4<KR:_ >FAXYA]'-<E>RVZQCN5M8
M[EZVPC'<9RZ>X47T-/_$4_@1MZ'=I9)?[SR"9$AMX>'C9I3$B+FT8!U'4',2
M<^9%O6#\!W&,/9T:^?@7RO$L^\8]S.8E.H_E=[+<'I:_BI?O!MQ@FUS#00XC
M9W )-QG)&W@,WPR>&)*?I'ON'PP^WD:IC>'/P2T^!3YAF[S#?O$:1E-O"NOC
M2ZUPZB12(Y,9+N 058XKJ*/&;&JT46,1RUM&U34XC<TXR5P<QPD<922'>5$?
M9'L<8';E$TPR^QYA\-8R7DX/.,Q\)M]^IY0O?3WFTISU&\I:C*>>!RXC@#I1
M[/')U,BF1A$U*JA1SRMA#GM .W6Z6/Y*JF_@%;(3N_B3'1Q8MRGN8:OR$VQ6
M_X(!/0F;]"5L? 1Y#^8G\HD5AP!K#GD<_F\SKIM*(];3"H\)CCBM<,5QE3>.
MJ$-P4#\6^_53L=<@![L-B['3L H[C!JQS:@%6XTZL=EX&0:,UV*C\7:L-SF,
M=287T&]R#ZLUGV&5V>]88<;YX1&6D]\XO'XYA$/J2 Z%CAS^.>0_)D]!\E1D
M9((C)O8XH!F+/:;3L,/,']O,P['9/ &;+-*QP2(/ZRU+L=:R!OV635AM-1]]
M5DNPTKH/O=:;L=SZ );:G$.WS=/HLOT8B^Q^0Z>]A(Z'V&GY@?H?C *>&\^I
M9P*UQ])K<'C;-Y33JK4^=EI98HN-(S;:N6"=O1?6# E"GT,T5@Y-0N_03"P;
M5H"EP\K1/;P>2X;/Q>(1G5@THA>=(S9BP<@]:!]Y&FTCGT2KXP>8Z_0+FITX
MRI'9CG_S->O^QD1.15. \^20*ST?8]G"6#8Y"E@_W RK1SI@I:,SEHV:AI[1
M?E@R.@R+Q\1AX=A4=(S-P8*QQ9@_KAIMXYK0.FX^6IQ[T.R\%K.==PJSG$\(
MC>-O"/7CWQ%JQ_\DU(R7A.J'.&OYA%/^\YQ:KGO1[TVGS_"@-C_WNW!]Q=ST
MCC-&C[,M%D\8A<Z);E@P:0;F3PK"/)<HM+@F8JYK!N:X%J#)K1RSW.K1X-8J
MU+LM%FK=5@O5;MN$2K>C0L7DQX7RR6\(I9-_$$HF2T*QC-O?O,=ZWZ7^)2Y_
M#OIRR>4-K&$LRSG5=$^F]W0U0(>;)=HFCT#+U(EHGN:!V=/\,<L]# WN<:CW
M2$6M1PYJ/$I0Y5$C5'C,$<H].H52CQ5"L<=FL=#SD%C@>5G,]WQ%S/7\GDAB
MCJ<DY'CH<)>$-ZGU)+7/TG_OYK)CO3_K+N]]S*#O].1:VUV)N1YFF#U]*!J]
MQJ%^QE34SO!!M7<PJKRC4>&3A'*?3)3Z% K%/I5"D<\LH<"G7<CS62[F^&P4
MLWT.B)D^%Q09/B\HTGV^%=-\)"W>DC#(#$EXB76^3OT3G.:W!=-G<-FQA+$L
M8"RM/O0;S$NCMP:UOG:H]AN-2G\WE,_T0NG, )0$1* H(!Z% >G(#\@3<@/*
MA)R >B$K8)Z8$= CI@6L%U,"]BJ2 \XKD@*>4R0&?*U(")#>DZ3(X.#\A*3X
ML,B84*@-)#%AII9$?TF0>8[*5T-Y=7#2'PAC5OA^(2-L972S&5D]%XO5 <8H
M#[1&:9 CBH,GHC#8 _DA_L@+"45N:"RR0U.0&9HC9(26"&FAM4)*:(N8%+I$
M3 Q9JX@/V:.(#3VKB F]IX@._5(1'2*)@P1+8DR0EKO4N!C!13 7Q^LCY1,Q
M=*&,9PYCJ6,<E<Q6:8@!BD(MD1\V'+GASLB)F(JL"!]D1@8C/3(*:9%)2(G,
M%)(C"X7$R&HA/K)9C(U<)$9'KE%$1>Y21$2>481'WE6$17ZA"(N01)GP<!*F
MY38USL>P=Y UI"N:.6 \#8RGDGDI83SYD6KD1)DA*]H!&3%CD!;CAM18+R3'
M!B I-@*)<?&(CTM'7%R^$!-7*43%-8D1L9UB6&R?(C1VAR(X]I0B*/8I16#L
M9XK &$F4"8HF45IN4N-,/+"=K(RC"R5SY!T9QE/,6/+XFA4K(BU.@Y1X.R0E
M."$Q<1+B$ST0E^2'V*10Q"3%(BHI!9%)N4)X4ID0FM0H!"<M$ .35HHSD[8I
M_)-.*/R2;BM\DSX5?1/_%'T3)-$O7D><)#[.>A]/YE6:!"SCXGP^:4R0=X2H
MSW@R^#F%/TM,-D9<BA5B4D<@.FT\(M.F(B+-&^'I00A+CT)(>A*"T[,0F%XB
M!*37"?[I;:)O>J_HG;Y%]$H_)DY/OT4^%J>G_2%.3Y7$Z2DD61*]R"76_U :
M^T(JKQ NS%M(+2DA&22)/V.:$95I@/ L<X1E.2 D>PR"LUT1E..)P!Q_S,P)
M@W]N//QRT^&36PCOW!K!*[=5\,Q=*KCG#HC3<H^(4W)OBE-R/A2G9/\N3LF2
MQ"F9DC@U4Q*F9DC">>KLS>15R@5Y)VFB7B4IX/L4?A^7#41PD1R<KT1 @0;^
MA;;P*QP)GZ+Q\"Z:BAE%WO J#L+TXFAX%J? O3@7TXHK,*6X67 K7B*X%F\0
M)A4?$B867Q,F%+\O3"CZ39A0( D3\W7D2<(IZFS/X35)VJA73TI)#C\GYM$)
M%E"_"/ MI1LJ-X1'A07<*QPPK7(TIE:Z8$JE!]RJ_.!:%0:7JGA,JLK$Q.I2
MC*^>!>?J11A;O1:CJP]@5/55.%6]@U&5OPBCRB5A5)F6T:62<)0:F^330:0Y
M7WLRJ)#OTTDLC5M(&9T(S:QG-3"Y3HE)#1I,:+3&^,;A<&X<BW&SW#!VUG2,
MF16 T;.BX#0K!8Y-!1C95(OA3>T8UK0:#DU[,*3I(NR;WL20QI\PI$&"0SVI
MDP2'6DF0GQ:TAG7L*&%?)&4DER3Q^PB:MIDUP'2:ILE-P'B:%J=6?8QH,\/P
M-EL,;1L!AS9G#&F;#/OY,V W/QBV\^-@,S\+UO/+8=7> HOV7IBW[X!9^SF8
MMK\,L[8?8-Y*;]%";S%7RW;6;WD5G3#U:DD12>?GF%JV 4WTC-G %)K8\6W4
M[P <%M$5+C& >;<9L859SPCB#$W/%.(#DYXP&/<DPZBG$(8]C3#HZ8)>SR:H
MNX]#U?TTU$N^@%Z7!/W%7-<OTK*^D;,EZSF[CGV1Y/!]PBP@; [[0"LPM9V.
MG ;6:0GUEU%_!5UYGP*&_490]YM#V6\'L7\DA'Y._?V<$M=R@%_+"WXM.]I:
M5F@M@^]?36ASU]!YKJ%]7/TKT"?]A?RDY';J-;"^17Q-99TCY[,-.@'W+F B
M=9U6 D-H'"W7T973N1ML 81M^ISVZ#2W<7FXG<NS[5R.[>#R: >7)#N#M-OA
M.]FY=K*2.WOX_39"%[Z=]GG;CX3Z6[5TLYXMU*S4G<R)6PP$+F4?7*$]E3-J
M _4W Q;; 9-=@)I&FLMV#BH*8LC)CG$<81Q'[8%C\E^+,8X3G)Y/<,(YD:(]
MCB7_$UW'68'C1PAM_?&OM2=4="QD71M)(4--[F4;,&TSJ.O*NH[:27UJ6M"M
M&S_<D3E-SI/'9$3@ O-QD4OS2Q; 93M.PEPN/CY1NU2[S@GP>A9P@XU\HYNP
MP!N7R/O\_A<B#=+*/%=0-Y-A1K.^?ORU*?NTIV*&4-/\#&!T 1 OZW9C;L@G
M4\B3Y+9NE^0I%9=G1ERJF](NT#(\/P)XD7&\S.7(RYQP7N&%_BH;_=5^PLJ\
MQER\]@7YC9_IJP<X)C+/B:QO\&'MG4G.K.=0AFM.38,;.KVGR#/D.=TNQ8NZ
MDR+RJ8TW="<WWJ9]>H\Y^9!M\PEMPQ=<+G\I/[&$D\Y7Y<#7[-Q?;P6^81*_
M80'?,(YO'J"<W37C&/NA_'08ZDZ@[M";@!GKJ"?O #W<&7EX,D7>&7G_X:F4
M_W%2Y#NVSP_L)S_3LOQ.RS!X:_U,W5-;V2;2<FC_Q9B'3PEY5[<C8:'CGW>%
MS(3VJ13_]XZ$]BZ9):27K"&;R':ZV/WX@[[P=_K27YD\[1,Z'N G_O1''5_K
M=D/>>[@C,;@;HM%AJHM#OBODX5-"Y!,J\ATRV=#>G5+-\IM8?BO+[V39W2QW
M!7Y /[[' +ZC\_R&?O0K^N$OV7D^9P(_XZ=/^2<_UFG+.R+R$S'DNT3^-1B#
MO"-A".UI"'E'0MXED4^HR$]LE9\:&T"]:.JD4B,/WZ*,)=;B"SKPSS&/97>R
MW&XVRTHVSUK6;0N;:P_K=XQ-=Y&.^B[^S9^^Q&R\H-L%D7F6/*W;G=!J*W0[
M$HK!F'Z'#>OG1$U7YLV;>J%L]GAJ9.!=MLE;*&<WK,5KC.-EQO$BX_@7>MA=
M5^$^UK/K;F?Y!WC)G&%WOHDG&,T-1G^-I<L\KD,^I7%Y,(;_?@COCXSI*[;/
MQ\S%NQC'G$VCEC]U(JF1Q/(SV<J%C+^<EV@M%9IPG7%<8QQ7L91EKF;M-^$"
M=N,<<W&&WYQBK4^R14ZP=O+]5#+''T$2M=I_R%U:U\W?@C$UK7$/CM2;1"TO
MUB.(&M&XA&26G\5AJA!G&<=IQG&2^3C!.(YA$8YB.0ZS30YB&WOG0>QE)+L9
M\2Y>3#M8P^V#/?>_D1\^S)%B\$% \H[(RX/#@)KY,Z6F/?7&4&L*Z^+#F$.I
M$<L>E\I,9V,?BJA108TZ:LRAQGR6N01;V2:;F8M-@_LC)]DZ-QC5F^RUWPU>
M0:MU].GX@Y?R-QSRWY5O2#0#;G*(N:PG#\6&U+6@YG#69CSUW*GE3YUPUC">
M/2\- T(.-@K%V"!68IW8@+6*%JQ1=&*U<CE6*==CA6H7EJN.8YGZ<?3HOXIN
M@V_092AAL=%_\R-U/[+E,,3AY#JGOS,VG'XX]!]D+/OU3+!;98-M>DX8,'#%
M!D,OK#,*1+]Q%%8;)V*52096F.2AUZ04RTQJL%0S&]V:=BS1]&"Q9BT6FNY
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MOL07D Q>"M<^1L)S&0G'92RTE[,(7VZ*\ 3UY3CS\CV.1R)?!ID_!GF^]-\
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MWK./@=?EL_AK^2ZRR6_&@7-IWTZP"DR#8= #FD;P ;J+)^'_4*341>B'-D9
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M@XOX_C9^"X'<#RG<_SU!8+-C&[I6F!-Z:.]\7EMI<_4J8A#STS=)\>@-1T3
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M#%RG!8&[-!ETIB:"CFDLZ&:-!#^BX> _:"CD4PV&V'Y$,'-EHN-4E*N22$?
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M9RW$)-YTK7UOR#$Y]H?8ZR'XY!KZYOIYT@WF23K$Z$WTR4WF,7HC7%M/\HR
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M]^FP?^&XMW#0/V'RK\$SS:X3LP?#W MBGHIZE[,&\7_MP3AY'H<-KFMJ,=_
M9;Z$3WT*C_D0YO(^=KP#RWD3YO-/6-?K#)R_P0#_C!U_Q(Y7"-K?$J0OZ'H8
MYCVX[5>X[P,]X:Q_&-VWR'$&YW6GV&">16+N0S'W0GPD+_0$H"=";\-GWH13
M_1W>_T=9]3(,Z3>PI^=A.L_!M)Z!?3T%&WL"-O@XD\5CV/$PP?P@@7P?G7JW
M;B6$'M/M=,YM^M:NV]0^+M>/]X$8_>8<4O,L%%.#,&=1O S/?!Y?/(LOGE8,
M;4BUWXOR*#SW07C=??CC;OKE#MC6[;"]VV" M\ (;X)CGL".ZYA KH&E7\7
M/8[&R_CUI7CE$GK*Z#3[,,R3?4PMPMP#8NZ!>=\91K]RAK?9DG2GO!EJ%EH1
MAOQXPC,=S^8CNUQ7XH_C:D)VQRGG88PC>T;G8<>Y],L1)A5S$L9AV/Q!)!S
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M2_Y<^1?XR:\@4+X%8?(A<+PQ?&YAKCP+R^0.:70K[)%+(<2A<+5C W<A)*2
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MG9KB#NY9G F(Y4LY3]1A3QEBZR[8W@_V!&AV\F\+K^Z)O.'.FS?LLB'8!KJ
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M&20]FLA+:Q-9Z9E$1GH)D99>1Z2D=Q%):0LB(>U)Q*6CB)AT/A&5;B8BTG>
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MT%AWT3BW2 TBJ[/D(DKM(-R]+QF\W$??.9C<9Z!P]V \YN$9>+P&CX^(9S[
M&WX'C_DE//BG\-L?(**Y!QZW$,E=0V>]A$YS'L9[!L;; QXGP:,+$7<G(O)6
M2#H*XV@@;:26/.(\@R6=)YOM_SC RT&\)-SM0[?)7X\?9L]$N49$R 7$$A<0
M1UQ$+-,+W[T+T40[>+1 'T<Q8#5@X*C#0%6#N*X*@T4%C+D,47TQ#*H01IP'
MX\U&K3-P1RJY M/]PJDW._O"@Y>#8$\:9L?9LMP'6X-P@M?,]1PSXR.5B._*
MT";EB/O+$6\7(7+) X\L3!CI&+13$?&Q2#81 TD\!J]8#%S<O2CFD.6$KGH
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M=SJT,!=E+T&Y>IC2M^"5(2=+M(CX8:I/1*M58MK_B;/_8QZOI[._<;SZLZG
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MF&W(9^LS^M:$].5!V _5?>=VL."E081[+D@=.ED-=%$)(26H3!$**4 ?S;E
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M>8_][:O[0GM/FZ<U=5B55C;:UN?7VK>F53H>CRMUZ0DO]#@7D.=W^=^"PZ$
M',IG*= CB]2_'5^I_>'LAB4OKV[3?_C+;ONKUXU#CI\Q2ZD]9EE4U&13DU%O
M>S2AQK[]4(5S=U")>X]/H<_9?PM:! Z%X% Q4X$>733LC^Z5$]]>6K_XZ:VM
M^O<?[+0[>\,XN.6<65)%ET5^3JMU95*C37U4G5US2+5CAU^%:Y='F=>I?PM:
M-()QD*15,P?1ED5#/YQ:.?'W:^L6/;B_>?O-1SMLNV\9!=9?,(TO/&F1G=9A
M51+;;%,=UFA7'U#GV.15X]+F4N79^6]!BT<(T2)P.#Q3_EO[(K4W9U:.?WQK
M[8*[CS=NO_1DATW;'2/_RDO[H[-[S=,3NJSR#[;;E :UV%7Y''6H<V]P.>)8
MY]'T;T%+P*%XHB2MGR'WZ?A"U><75XR[=W_U@AN_;]C6\US?JN'N7I^BJ_L/
MIIXS3XP^9949TF63[]]I5^S1YECNW.)29=?D<?C?@I:"0RDX')TA^^;4PB&_
M7E\Q^MHCO05GWZS?VO[[=HN*7PW=LV[N#XJ[;!$5?LXZ,>"T;9K7*8<LUVZG
M7(?CK@76G9[%_Q:T'!RJ)HK_T3YCX)/S"Q6OWULZ^O0+O87'/JW;7/=FFTG^
M8T/'Q+O[O0_>L @*_,DFPN>R?;3[!:<XIW.NB79G/%(L3WNG_5O0RN&"M'Z\
MV*N3TR1NW9PK=^;)TK$=[U<MJ*=KUY=\V+8G]7=#B\A'IHZ!OUIY^/QBY^MV
MV_& TTW7(/OK'J'6U[S#+:[Z'_RWH-7#!3^W:0G?OSQ1Y.R#V0H=;W3'U=(5
M<XOH&KV,KUNW1;\W- QZ96;F\]S&VNV)H[W3(Q<GNX?N+M:_>;E9_.KK878_
MP//?@M9I"#SMU> _?W^42.>K6<JUWQ:-+:!+9Z;2U;HQ=,O:H&][MWA_-M_I
M\L%VC\,[)R.;-Z[[K%Y[[C=_Y6-J^M+?W.3W0(M_B_>=0_@NWY'AZ_Q=4[SN
MRZS!A73>J&2Z1.<@734WD&[6]:2&JYRH^5I;:KO!DCIM,O_FML7TJ^=6DR\^
MVXR_^.L;_1&TX]_B\KD!Y/AS6?ZZ/S0EB^@TY60Z>W@$7:CE2U=.<:4;9]E1
M@_F6U&RQ*;71W4<=EQE1E^5[J<<*0^J]TH#ZK=Q- U;]6]!,#2&:/EZ"9LP8
M1(L6JM'J%>-H_<8Y],BNM7_4FQB]J+5QN5?F%'HMSR/Y;*I/P<G8@.K.@R&-
MK2$1;4</1'<U^"3VUGIEG:MPR[OP3_&#PP\./SC\X/"#PP\._>*0"0XE"]3H
M87!HW#"'-NU<^_GH/N/G1ZQ<[U8YA%\I<DL[G>E5TI7H5]<6'=AZ-"*TJSXX
M\G3-@82+E7Y95PN]<R[]4W X9(!#UG1Y6@H.M>#0! XM.]9];C4V?M9LZ?9+
MG?W!2^4N&3UY[N6=:=Z-S0G^QQJB@GMJPB,N5@3'7RLXD'X]VS_[RC\%S>)Q
MR :'L@6JM'[Y.-JR?@YMUU_WN<-HW[,.<_?;C;:1%ZN=LD\6N5:U9WLT-Z;Z
MG*A-"#A7%7?P2FETXO6LT+2;*2%9/_U3_,DA!QS*P:%A^5C:!@Z=^NL^'=^[
M[VF7F<?M5NNH"_4.N=T5SH=;"]W:C^3ZG*K-#CI7EG;P2FY"W/64Z+2;\8<R
MK_U3<#AD@D,N.%2 PQ%PZ%@WYUO7]G4?3NXQ>=JSW_/6,:OH<\UV^5VUCG4M
M56[M]64^)RL* \_E9X==24N+OAZ?G'8S,B[SVC\%S>9QR .'JODJ]"@X'%LW
M^X^3V]:]ZS4P>7S.Q//F*8N8L\=L"CJ.VM?5USBWEY5YG,PK\CF;EA=X.2[K
MX+6#F<DWPM(RK_U3<#AD@4/!-#E:#0Y-R\=\ZUX[^V/OUG6OS^\V>7C9V.OZ
M.;/8DUU6!4>;;&O+#SNTY98[GT@I<C\3D^]S,2PGZ*> K.B? W+2?OJG^)-#
M(3@<!H>696.^G%PS^]W9+6M?7-EE\NOUO5Z7+IK&='1;YAU&S%U09]_,<B"Q
MO!S(@3R_RUXYX5<]<N.O_%/0''4NAZ)ILK1V_A#:MFSTI]XULUY?VKSVR<T=
M)K_\8NAU&G%WTTF+G+)6Z\JL!MLC\34.[0<KG+L"2]Q[O-$FK@7!%YSR(R_^
M4W X9&N)TQ)PJ)\WY&OGLM'OSJR9^>+G36L>W-^^[]J]/1Y=5TPB:WO,,_,[
MK$J3C]K41M79-X54.[6S'(A[F=<IQY* 7KOB\-/_%#07''+ H6RJ#&V<-_A3
MU[)1+R^LGO'XEPUZ]QYO-3[[JX%[RT\F$>6GS5,SCUL6QK;:5(8UVM4=J'<\
MZGG8I=6YVK/3KM+_N'5%</<_!<T#AUQPJ)PJ39OG*;T]M73DDVNKI]U[N%;O
MYN^;C;H?&+C67M\7FG_>+"'II&7VP6,V18%M=A7>38XUKHTN]0X-'HW6=;[-
M%K6!K?\4-%]=D.:!P^&I __HF*?X_-Q2C;MW5DVY]G2MWKDWF_8V/]KM6'K;
M."#]LEE4]%FKY.!3-EF^7?;Y[IV.Q8[MKF6VK1Z5%LV^-:9- 8?_*6@!.!2-
M&T"/3)%\<V*N_*_7=-6N/E@QM??5&KWC'S8:5#_;99M]S]@K_H99<-@5ZTC_
M\W;Q'F<<4YQ[7=+M3KEE69WPRC'K\LLW.1Y8\$]!BX8)THJQHE_:=,0?GYLC
M_=/=16H]SU=,;?NX>F7#'QMV%+S:99;T>)]CQ#USKP.W; (\KSN$NOSD$N%P
MQ3W2YI)7M.4%WSC3\P$)^\X%)_Y3T))A K1NC/#+DY-$KM_2D>A]LDB]]?WR
MJ354;VDQ7;\Y]<.N/8=>[C,/?&IIY_70SMGE5V=WAWMN7C9W/7TL[_CZF=T^
M<&#_K># ?3=#@_XI:/E0@4]M(P7N7-7@[WTT>6#KVX4:5517)X^N7)A&UZ^.
M_+9K2^ GD]U>;ZV-G5\[F-K_[FIA_<+3RO*YCXWY,W_;_4\"[?<]"74P>ASA
M^$]!ZU7X'YV1YSO]0%6P]<TDV6HZ3R.7+IJ80)?/.DC7+0F@.U=YT/WK';]9
M;['YXK#=\@_7'6:?/'?M_^BSV^3C 0/C#T%[]KX/-31\'['WG^+-\8'D['5Q
MTO)&5:2:3I;/I;.&QM/Y8T/I4AU?NG:6*]VQP(Z:Z%I2J^6FU&&E"771,Z8>
MJ_=2GS6&U'_M'AJX;C<-7;^;AO]CG.X5(ZT/)/@JJ9I8'M66BZ=358+IG!&>
M=,DX![IZDB7=-G4_-9II1"UF&U*[N0;4:=XNZC9_)_5<L(/Z+-2G_@NWTZ!%
MVVC(/P9-'BI$$\:)TWB,U5GS!M.B99JT8OT46KE#EY;OV_JQV,;T>:ZKV_U4
MG^ ;,8%QE\,C,LX%1A?T^L:7G?!,KNYRRZCK=,YM;'<L:6ZQJVEMM*ENZR]^
M</C!X0>''QS^QW-(!(=$<,@&AY*E(VG5NBFT6E^75AEO_5!F9?:LT,7C;H97
MV,\)!Q(O' K-Z0TY5'K"/[;ZN'=B0X=[6E.K2TY;LU-)9YU=Q;'#]I4=_067
MP]@!-&FJ+,V=.YB6@</AM5-H[?:EM-9HV_MJ2XLGY4Y>=W(]#EY)]4L[$Q-4
M="(\K+HS,+*QS3>NM<DSY5BC6_:).N?BGG*GLNY2Y_+C_05-&2I(D\ A98HL
MS9^K3"O H6[-%-JP;2EM,-S^KL[<\G&-@\^M(M>H2YG>63T)_F7'#P4W_)4#
M2>JM]<P^5^J:?R[?K>1DGEM9=W_Q)X?4*3*T !PJ=4?2!G XNG4I;=JS_6VC
MF=7#>CN_FV7.L>?S/')/IOA4M\<&-#=%A'8UA$3UU@8EGZT)RKN0YYEW(=.K
MN"?#J^1D?T%3P2$9'-+ H7".,JW6'4$;5T^AS5N7?FLUV/ZV9;_UPZ,V_M>K
M'>//%;D5=&5ZU;8F^K4WQH5UUT7']%8>3#I7$I9],<,_]U*R7]'I)/_BGO[B
M3P[IX% \1XG6@$/3:AW:MF7IUX[=^F\Z3&P>M%D=^+G>(?%,N4O1\7R/AM;L
M ^WUJ:'=%?&1IXNBX\_E',JXF!R<<RDNJ/!,;%!1;W_Q)X<,'1E: @Z'P:%9
M3X=V;%[ZQ_%=^F^Z]MG\=LPRX%J37=+I&J?28^6>]8WY?FU5&4'=1<D1O=GQ
M,>=38U(OQ1W*N1P95G V,JRHM[_@<$@!ATP=:5H*#G5+AM-6/9UOQS;K?CJQ
M4__5*6.;WTZ:!U[ML$GI:70L::URKS]<[--6DA/0G9,>UIN:$G4N/C'Y8F1<
MSN6PJ(*S89%%I_L+FL;CD 4.9>!0#PYM>I._=&_2?=^S4__W,WMM?SUC&G2I
MRRJEJ]FAI+'6M:ZBW*LUO]"_*STGI#<^\]"YR+2$B^%I.9>"X@O.!L45GNXO
MN!S&#* YX% ^6Y$V@$.'WN1/IS;JOCFCK__LXA[;7\Z;!)T]:9G2WF977'O$
MI:ZXVK,UL\RO*[$HJ"<J+^)L6$[\A<"<[(M^:05G_5(*3_<7-$U-D*:"0RXX
M5()#XQ*-K\=637I_>L.2EQ>W;W]TW<#VQA7CH%.GS9./(MXM;W*LS:EU:TFJ
M]#H657;@9&AQZ.D#A='GO O2SGOE%9SQS"GJ[2]H.H]#_N2!M'JV FU>HOZY
M>]6D-Q?6+WYZ?>OV^W=VV5RZ8138><XLL?JX56%>LVU-4IUCTZ%JU\Z@<J]N
MWU+_'O?BL#/.17%GG8MS3[N4%O7T%QP.:>!0" Z'P:%U\;!W/:LFOKBZ;M&#
MNUNVWOQUAW7O;:,#1R^8QA6?L,Q-;;6NB#IBUQ!4Z]CB7>7:Z5+AV6U?=N"4
M56E$CU5I\BGKLLP3_07- (?T,6*T>+(4K9\E_[ES\="79U=.>'AK[8)[CS=L
MO?A(WZKCE[V^U9?W1V?W6&3$';,N"FVQJ_)M=*QWJW<YZECKT6)=X]=N7A72
MN;\JYIA)54*_03/!(0,<RB=)TJ.SY-Z>6*3ZZ,K*<7=^U9O_T[/U6TZ]V&[1
M<-_0L^C:_O"4<Q:)!T]99QTX;E?HT>Y8YM3B6F7;Y''8LM&WWO1(T!'CALA&
MH_KHH_T%S0*'[-&BM%I;_(_VF3+/SBY2OG-GV>A+C_46]+Q:O[GU]3;3\@>&
M+AFW]@?$7+&,##YGD^#=ZY#F>M(YV[[;+<_ZN&>A6:=?L4E[4-G>MH/EAFV1
M%?T%S5$5H 6C1&C#1+'7)V9(WKVV4/[B@Z5C3[S46]#Z<=W&FG=;C7*>&MK&
MW]_O$7;+*L#OFEVX^V6G*,>+;K&VYST3+,_Z))N>/I!JW!N2;MAS,'//J<A^
M@^:!0[FFT!^MXX4?G)\B>NG>'(43+Y:.:_JT<E[5M[5K"SYOW9GTRM TXJFI
MW8$'UJX>]QR\G.ZX^MG=\@BPNN$3;'[]0.C^GX/"C'\*CS"\&G5HSY7H?H,6
MJ@C0NN$"+TYI"ERY,T;DQ+,YRD<_+AE73I?/SJ6K5Z30K9L.?C+<%?#6?)_G
M2UMSY^?.UG9/W>VL'GL[6CSR=S9]$.AB\EN(F]&O$>Z&]Z,]]]R/Z3=HZ1#^
M#^VJ?#_?E.4[\73T@*,?9@\NHPO'9-&ET^*IWL*#=,NJ ]1P@\=7BZV.G^UV
MVGQT-K!\[V%H]L[':/_; \;[W@29&+T.VV_XZI"IP<L8,X.7L>;]!6T8Q'?U
MG#@Y\42.O_'#&,DR.G-P!IVG&4.7: ?353-]Z:8%KM1PJ3TU7VE);5>;4>=U
M)M1CO3'UV6A$#VPRI$&;]WP+W;+[V\&MN[[&;-OY-;;?N'I<E'1?%B-'/L@+
MEM(Q4AETBE(4G:4> %VXTQ7:]G3#-$NZ>Y8I-9UK3&T6&%+'A0;4;?%NZK5D
M%_75W4D#='?0X*7Z-&S9-AH)1"WO+XZ?$"$--T3XBJF"<"8=*QE%M0<=H--4
M7.@\#6NZ;+0)7:=E2/4G[J+&DW902YWMU&[J-NHT;0MU SRG;Z8^TS=1_QD;
M:>#,#304".LW:(RJ((W"&'5PJC1-PIR5M42=%JP93PNWSZ'YQGHTVWK'AU17
M\Q?Q?BX/#X7ZWPV*#+_I&Q][S3,U^;)K5L8%I[R<<P[%^6?L*HI.V]25]%BU
MEA\S:ZGH#WYP^,'A!X?_H1QB>1PBITC3%'#(63*,%J\>3TNVS:%%>_5HGN7.
M=YG.EL^2?=Q_C0X.NAUZ,.K:@=BD2][)F>?=T_/...<4]SH6EIVR*Z\\85-;
MTV'96-MLV53='] X<(@>+4:CX5>GS5*@>8N'T3*]\;1\RUQ:OF?UMV+SW6_S
M':V?9'IYW4TX$/[SH;"$2\%166?]X@M[/%/*3[AFUAQWRJ_OM"]M;+>M;6JP
MKFL\;'.DKC_@<(@!AUCXM!G@4 @.%:O&T^K-<VF5P9JO%:8&KTOL;1_FN?O=
M3O&-O!(3G'8V/*+@5$!TY7'OQ+H.M[2F5N?<MF;'TLY:FXIC%?:'FTL=ZH_T
M!S1>A<LA'ARRP*%XT5!:M7(\K=TTE];N7O/U\/X]KRIM[1\4NQZXD>D=>S'Q
M0';OH="RXT&'ZMI]XUJ:/5*.'77/[6IP*SU1YE#67>A4W9;O4G>T/^!PB 6'
MA$D#:?;,0;0$'&I6:G'6@C3L6O-'_3[#E[76CK^6.P7]G.>1<"[5-_]$3&!U
M1UAX4TMP7'M38/KQ>O^\$U7>)2?S74I.9KM5=62Z'V[N#_[DD @.N>!0!@ZU
MX- (#D=WKOEXU'CO[T<LG>[7.(1<*W9+/I/I7=R5%%#;%AO1?.1@;,?AT.2N
MBJ#LDR4!Q:<R/8M[4KTJ.I.]:UKZ YK XY"D+47SP*%\H1JM6Z'%UH)\;=FQ
MYGV+T=X7+1;.]^KM0J]4N*3VYGN6=*8?J&U,"&VNB8[J*(M(Z"X,33^9&US0
MD^Q;U)O@5W$\WJ^ZM3_@<(@;)4:3P2%_ICRM (>&%9RU(%_:]->\[=B[]UF'
MF<O=)MOPB]6.Z2>*/$J:L_QJ:U."F\OB#G861,5U9QU,/946GM<;'U34&QU8
MWA456-W6'_ XB-(4MA]FACRM6JA*CX!#V_HYGSNWKWE]W-#H<9>IRZU6JX@S
MM0[IG:5N)0UYWK45Z0'-!4EA'5EQT=TIT4FG$B*S>Z/"BTY'A)9U1816M?<'
M-!$<XL$AE>V' 8=J<#@*#IWK9G_LWK;FY4D#HP<G35RO=5@</-5@E]Y2Z5)<
M4^AYN#C;ORD[+:0C)2FR.RXAX5147&9O>'31Z>!#9=W!!ZLZ^@.:.$2 PR%]
MHB0MGB%'#R]0I<W+QW[I6CO[_:FM:YZ?V6UTK]?8]>)Q\XCC339I1VJ<BLM+
M/0[G%O@VI68'=<2E'^PZE!IW,BPYO2<HN:C7/[:LVS^FLJ,_^)-#!CB4@$/=
M A7:NGS,IY-K9KTYLV7UDTL[]]X^M]?US G3\+96Z]2:!H>BPBJWFHQ2[Z/Q
MA0'MAW+#CX=DQYPXD)ERRC>KL,<KI:S;*ZFRHS^@2>"0  Y9X% V798V+!CR
MM6/YZ/>]:V;^?FF3WH.?]?=>NVSH<J)W?UCC,<N4\F;[PNQZE^JD:J\CD>7^
MK2$EH<?\BZ*ZO0J33[H7YI]RR2GK<LVLZN@/.!P2-45ISD0)6@$.C?,'?SJ^
M;-2KLZMG/+FQ<=4O=[;O.7_=P+GC_+[0PZ<LD@LZ;?-36YPJHX]XU(?4^3;[
MU02U>U0=/.9<D=#E4)'=;5]>?MR^N*J]/Z#)X) $#GD3Q&GU-)EO+?.5WYY<
M-O+IY=73?KN_;L7/][<:G+JSV_'H3\9!9>?,$M)/6.5&M]N5!34Y'?9N<&]T
MJ?5IL:\);+.J/MAA7I78:5:=WV%96]/2'] 4<$@&A\+Q VC=M(&?.N8KOCB[
M=/BO-_4FWWJX=L6Y1UMVM_^ZR[[FMK%_[F6SZ/A>J[30+MM\GW:',I=FEVK;
M1L\ZBP:_(_OK@X\:U44U&=:E-ALU%#3V!S05'%)'BM#2\6*T<:KDZQ/S!OUV
M9>G0Z_=7Z)Q[NF9%]_--NQJ>[+0NNF?DE?*S6=BABU9Q :?M4CU..F7W[0$Q
M:_<KV]<:7+&WY5"504MB]>[FC'Z!I@T6H%DCA&F5ENBG]BGBC\_-E;Y^9Y'J
MV<<K=(Z_6K.\Z?4&_?*7.\PR'AHYQ_QBYA=\W2;4^[)#E,L%EWB[LQ[)EJ=]
MTDQ[#F08GPK),CQQ*&=W=WS>SN[4?H%F@$/^<"':,%;HY<G)(C=O3)4X^W#1
MT,Y7RZ<<^:2WM/+#^LTY[W;LC7]N;!7VT,+9]YZME]MM)W^'&^[!UC][AUG\
MY!^Q_TK0(>/+X5&&EZ)B=E](B-MY(36^/Z#9RORT7%W@8YNFP+W+(P7._J8S
ML//E(O7ZS\MT2K^M6I3S;=W:Q#]VZ(>_VV?D_]+2W/V9O:WC8U='FX>>+I:_
M^;F;W@_P-+D7XF5T-\)GSR_1?KOO)/COO)URH#^@N>!0K\KW^+0BW[G[:@*=
M+W5DZSXOT"A&[)].5\R-I^N6A],=Z_R_[MOJ_LEJE^-[!T.;MV[&%J^]]YN^
M\C<S>1ED;OQ[F.7>%X>L]CR/L=[U+-%VY]-4N_Z E@WB>W-,FERX+DXZ?A\J
M7/N'CEP1G3,LE2[2BJ++IP73M?-]J/Y25[IOE1VU6FM)'3:84;?-)M^\MQI_
M]=^V]TO0=L,_PO0-/A_:L?MSS,Z=GQ)W[?B8NKL_^-PH1<[TBI'V!Y)\-5^&
MB192';D4.E/U()VOZ4^73G"G:Z8ZT&VSK*C1?#-JN6@?M5^RE[HLW4,]EQE0
MO^6[:."*G31DY0X:L4J?1NEMH_&KM]+D?N%,AS!I/2]"JM]+\>=3=;%D.D$V
M@DY1]J6SASG3Q:.LJ)Z6"=VDO9?NT=E-S:;NI#;3]:GCC.W4;>8VZC5K*_6=
MO84&S-Y,@^=LHN%S-]*HN1MH[+S^H*5+B%3])$1RJ;1 ,M40"Z=C!GI3[4$.
M=,9@,[I@Z%ZZ8O@.NEYS*]4?O9GN';N!FHU;3VVTUE&'\6NIRX0UU!WPFKB:
M^D[4HP':JV@($-XOT'#X#R&C16G %"D:.4N>)BY2H1FK1M&,K5-H^MY%--EJ
M+8UUW?GQH/_^UR'A=L_\8]T>>2;[_NJ:$737,3?LCEW1H5LV%=$WK ['7;=L
M3+AFT9ETQ>QTRNE]O:G?B_]G.-![E*Y8O-A@W8:U2U?HZ1(1L?\)K'YP^+_'
M(10< G6D:!0BCB0>A\PM4VB&X2*:8K6.QKOL^A#I9_HJ--S^Z8$8CX=>2?[W
M7=-#?G',C;AE7Q1UPZ8\]KKUX81KED>3KEITIEXPZTGK,?E^T @5 1H*#S-D
MLA2-A;>?NE"%YJP<1?,V3:$Y!HMIIOGZKRF.!N_BO"V?'PIQ?1@<Z7?/-S[L
MED=*U'67K(2KC@4IE^W*,B[:U&2?MVK,/6=YK*!K_[&"=K,3V=\+>A <PL A
M;)(D39@N1S,6#*'Y*T;1PHU3:.&NQ33/=..7+/N]KU,\;9_$!7K=#P\/N140
M$WW-.RGIDGM&YGFGO+PS]B5%O395I:>LCE1TFC57-5NTES18'<__7M"#\*S"
MP2%"6Y(F@4,6.!0NUZ2E&Z;0TIU+:+')IL_YML8O,]T<'B;Y^]V)##GX<TAD
MXD6_^*RS'JF%/<[9Y2<<BJJ[;"OK.JP:&AHMCM0=MFZIJ++M*/I>T$., SS,
M0^"0,DV6YLP?3(N7<U>H5.Q80LN,-W\JL=[W>[Z+\V_I/H$WXP)C+D=$I)\-
MB"D\A7#AN&M&7:=386.'8W73$=O#3=4V]4?*[)JJBQW:2K\7' X1X!"%B",5
M'/+ H729)JUF*U2V+_E29;3Y?87E_N<E3J[WLSU#?DXZD' A*C2W)SBRO,L_
ML;;3)^M(JV=14Y-[54NU8TU+L7UM4X%CX^%<Y];R[P6-Y' 0H=$3)&@Z.!3,
M&TS+E_%6J&Q;\KG6<,N;&G/39Y4.[G<+W,.OIONFG(D+*NP^>+"R+3BN[JA_
M6F.=3UYSC5=9:ZE;=5NN<TU+ENN1N@RWELKO!8?#07"(!8>,J3*T:)XRK5PZ
MDM:OT?G6L'7)AX8]6U[6FYH].FSK<;O$Y>#Y3,_T$XD'"MNBPBJ/A$?7UP0E
M'2T_D-52[%?<EN]=U9X&'BD>#0U)7DU5WPL:-9C+(8[MD &'8G"H7CJ"'EFM
M\Z5IRY)W309;GC?M-[M?9^UUM<PALB?7/;TCU;?P2%QP577DH?K2L/BF@N#T
MUIS _/;,@,J.!.^JCCB?^B.QODTUWPL.AT/@$,]VR(!#Z5PE>A@<CJ[6^=RZ
M><F;MEU;GK3M,[]SQ,+[?*5=9%>!:UI3IG=A35)@96EL>'W^H=BFS/"4UM30
MG(ZDD++.*/_*SL@#=8V1 4</?R^X'!#U)&B)TYRITK0,'.ITA]-FO<D?.S8M
M?GELYY:'QXS,KS>9>9^NL8UL+W%.J\_Q+"Q/\Z_,3PRMSXB-:DJ.3&J-.YC5
M$1U1W!D>4M$9%E)[-"RDL?9[0:/!(1(<DL A;XHTK0"'!EW.RHSW71L7OSBY
M8\O];D/SRVVFWB?JK0\UE3NF51>X%Q1F^59FI@;5)24>:HJ-CV\]%)/>$193
MV!ETJ*(SX&!M4V!$8^WWXD\.R>!0,&4@K9K#617QI6/5I+>G-BQZ>F;[YCNG
M]IB?ZS3QZFRT/%A?;9]:6NI:D)/O79&<%5 7DQY^-"(EMC4X*;4](#&_TS>A
MLM,GYG"S;_21NN\%C0&'*'!(U1I "\&A9HX";5JB_JEKE?:KL^L7/KRX;=/U
ML[O->KKW>;:T6$14U=NFY%<YYZ>5>);'%OC71N2&-@9E1;7X922W>67D='AD
M5':X)1]N=D\\4O>]H#'*7 [IXP;0$LR==7,&?6E;,NSMR943GE]:-__^M2T;
M+UW<9=K58^31T&D67M)DDY19[Y@;7^U>=K#<MR:P)+C!I_!0DWM!8JM+05:;
M8T%YFT-V;9-CQI&Z[P6-!8?H$2(T<YP8+=.1I$=FRW\\MECM]S,KM1Y>7SOW
MUNW-Z\]<V[&_]=Q>]ZJ3^T/S.JT2DYOMLR./N!8'U7E7^=0$UKE511QQK(QO
MLJW,;+:N+&NV*JUKM"YLK/U>T#APB &'G+&BM&JRQ+?F6;*O3RQ2>71IQ9B[
M=_5F7[Z_<7WW+?U]#5?VN!:?,PE./V41%]UEFQ'<X5S@T^I9YMH<4&U_-+S6
MJC&VWOQ(VI']#85 0[UI35/U]X+&*PG0^.'"-'^,"*V=-.!CQRSIIV<7*?UR
M:]G(*[^MFMW[</VZEOO;C2IO&SCF7-MW(.&2>63869MDGY,.V4['70NM.[Q*
MS5H#*O:UA%<;-L?6&#2G V75>]M:R[\7- $<DM6%:,EH8=JH+?KR)%L5L4#N
M\GU=S9ZGJV9W/%N[]O"CK7L*?C.P2;EGXGGHIF50P!6[2/?S3O$.9]Q3+7M\
M,O>?",@QZ@[+,S@>7;#S>'*A_K&\0OWC5=\-FJ3(3S.&"=)*3:&/[1.$'YS7
M$;UR=X[\J2>ZH]M>KYQ=]VJ-7O'O6W:D/S<PC7FRWR'XOI6G]VU[?^?KKB&V
M/WE%6%SVCS*Y&!QC="$BWN!<3,+.L\E)V\_F)&\[4YKRO: IX)"O)D ;A@L\
M/Z4I</7V&.%3CV<KMKY9,N;PQQ6SBCZL7I[Y?O/FN'<&>T)?F9KZ/K.Q=7WD
MY&3_F[N;U3T?+[-? GSWW0GUWWOK4(#!S=B@73>2@_6O9X=N^[GHNT'3%/AI
M^1#^]QVJ?#>NR_&=>C1&K.7-;.6:KXM'%WQ;-BWMJ][BV*^;5X=]-=CB]\EL
ME]L[V[T.KYWW6[_T-#=_X6>U_UF0C?'3<#O#)Y'V!H_C''<]2G;2?YCELNU!
M@>OW@N8,XJ,-@\BU<^*DYZ$<?_.;,>+57V<KY]$%FLE4=W(D734GF&Y:XD,-
M5KE2LW5VU':3Y5?G;69_>.J;?/;;:?0Q:+?AAW #@_=1AKO?Q^_=^2[%2/]M
MEO&V-_G[OA>T7)I</29*3EX:0)K>#A*HI&,E<^ETI40Z5R.<+M;RHRNGN-,-
MLQSH[OG6U'2Q&;599D*=5AA1CU6&U$_/@ :NV47#UNZDD>OT:>SZ[31IPU::
ML7$+S=WTO?CYJ!#I.B%"&G\6)65442B'CI.,ISH*H72FFC==,-*)+A]G1==I
M[Z?Z4XSHONE[J-7,W=1A]D[J.E>?>LW;1OWG;Z5!"[;0\ 6;:>3"331NT4::
MLG@]S?QN=+<*D88S0J3D5U&^3*HL'$='2P33"7(>=*JR'9VK9D9UA^^EJS5W
MT"UCME$#K2W4=/PF:CUQ(W70WD!=)ZVGGI/64=_):VF SAH:HK.:1DS1HS%3
M5M&$J=^+AN,"I/@R/TG[),X?2X<(!=+A ]SHF('6=)+\/CI3:1==.&0K7:FV
MD6X8MHYNUUA-]PQ?14U&K*06(U=0FY'+J8/F,NJBN91ZC-*EWH#_Z"4T>/1B
M&C[F>T$/(,;Q'25"/3!7!,V0H8<6*-/8%1HT?O-X&FLXDT99Z=)PU[4T*&#[
M%_]#AA^\$DS?NJ9;OW+,=7AA5^SRS+K"_8GE8:_'YHT^#TW;_1[L/W'@_KYS
M@;>,K@5=VG,]^'OP@\,/#O]'#EZ3)6C(=!D:-5^)QH-#XJ;Q-,%@)HVUT*6'
M7-;3$/\=GP,BC-_YQ%F\<D^U?^&<X_+4OM#CL4VYST/+FO_%WGN%-=&U#=M#
M5>R]W?;>"XBB]"*]=T(@A)"0D!!J((1 2.@$ H3>>^^]B!1!00$+EL>*!;"B
M@HI=KW^\W_?XCG_C =W\-KZ-\W!SG<Y:,[/.<2;R)EQ:0\8I7>%/R?V1CTE7
MHVX3;D=?=;P3]3= "-I97-0AZ-@BX)]8#@E*ZR!-:SMDFAZ"=+O3D$K1@@1O
MLU^"0-SGB$C*-"_>\TU JM]+9@YGPKLP9,R]/.*Q:VWT*+4E]J%+5_Q]RD#"
M+=+5I$&GZPD7B3<%?P.$H@X\M'%X1Q>! .V+9'1OGZFY#7*-#T&.K3QDDK0A
MU</R>P+;\6-,F.O;<('OBZ"DH'%69OAC1O[OYS#Q]]QJDNZXMJ3=HG9GCE N
M95\B7LH^[SR<VDFYGO W0!CJ$(PZA!Y9"'%H7Z0IKH4<U*' Z! 48.0AUTD'
MLMRLOZ7Z$:>%P1ZO^-'L\6!AV*. -,$]9F[2;>^2]!ONU3G779L+KE*[B_I)
MYTNZR1?SS[H,9K30KB3_#?_'(?SP0DA '3+0OL@[LQ5*# Y!L;4\%#KJ_LBC
MV7S.]"&_2PYB/(^-Y#X.CXN^%Y2<=(N5G76=450P[%Y9.NC:5-E/[:PZ1^ZJ
M;*7V%C>X#N34N@VE_0T0CO9%"+JWCSRT$))DED(6VA>%&ENA7/\0E%O)_RIU
MT/M2Y(+YD.?M\B8ST&\\(2SL 3]&>"LX,?,J.Z-HT+>@O-^[HJK/JZFFR[VC
MMHG:45M+[RFK=+^87^9Y.?-O^#\.?+1Q4E"''/DU4*RQ!2KU#D*UA?SW2IS>
M3#D9^[;8@_8\E\5^E,*+NB6(2!T.C<WK#THI.>^?77F.65+3[E-;U\)HKZ]R
M;Z\O\^BJ+/+N*RQ@7,K^&R "=0A%':+1QDF57@)Y\JNA3'T+U* .=>;R7^KL
M]*9K2-A7%6[T)P4^G%MI ;%#\2%I%Z*B\SM#$DK;..E5C>R"VEI614.57W-C
ML7=;8S[C7$V.;V]QEE]_[M_P?QP$O[_201T*3J^&"K7-4*=[X&>3F?RG)JS>
MVP8GNXEJFMO](B_NE2Q6[(4D;EJG("*_)2*NK"XDI;HR**>N-+"TL2B@OBF'
MU=J<X7>V+LV_IS25?3'_;X!(U"%LER3$_?Y"YMAB*#J]"JI0AT;= ]];34]_
M:,/HO6IUM']2Y^)^H\R=.Y#K&]N5%IC6(@S-KXV.+BN/2*PN"LFLS^45-F5Q
MJYO3."TMB0'M#0F<[G(AYT+!WP"1:&>%[92$^'U2D(4ZE)Q:!35JFZ!99_^7
M#N/34^=L])YWX.T?-#E[7*ETX_86,@1MF>RTNF1>?GE\5%E!='QU=F1:?5I8
M7E-R:$5+0FASBX#;UB@([JJ(">XK^AO^=0A''1)0AQS4H>S42JA3W0AM.OL^
M=1N=>G/>2G>\"V=WNXWD?JG6-:BSU$O0F,M*JT@/RB],"B_+BA=4IPB2ZX7\
MG*;8J+*6Z*C&UHBPUJ:(\,[*B/#>XK\!HO[7(1%UR$.OE16G5D"CZL8?9[7W
M?NPUE'O=;ZG[N-?>[GH'T:VO@1K45N$14U/HFUJ<'9B7G1Y2FI(<71V?D%@?
M'9_9%!%;W!(:6]?*BVYIYD5W5@5']Q;_#?\Z1* .R7OG0P'J4"6W II5_OG6
MJ;UGNM_PY/,A"^T'_5CL4!?!K:N%PFFL=8\N*V.DY!;XYZ;F\$KC,R*KHM*$
M]:')Z4W<I,*6P*2:%G]A2W- _+GJ@+CS)7\#\%&'2-0A%74H0J_7M>C]NTUE
M_9?S6KO?#AK(CE\SU[PU:&O;W^M(;S]+#JQNI/,+JKV2T\M8.<*BH.*HO/#*
MD)S8NL"LU$969EXS,Z.RF9'>TNR;>JZ:F7R^Y&^ :+1YH]#N3D?OG25'%D##
MR:4_SBFO^W!1<\>K:_K2CV^9GKEZU0;3,^! :^PFL4O;:5%9C9Y)B;7,;'YE
M8%%P:6AY0'%T#;,PJ=Z[(*?1HZ"\R:VPK=$]M[/*,^M\R=_PKT/T=DG(0AW*
M#TM!\XDEGWN4UKP9TMPZ?D?O\-T'QAJ7;EI;GQVVIU9?)++RNUTB4LZZ"V-:
M&!DA#>S\@+K@4I^:J$J/JH0:UZJL.I>JLGI*54N=2UE7);6XM_AO@)AUHA"[
M50)R=TM"]:'Y/\_*+IKN5UPY<4-CX\/'VH>N/3%2.W_?TK+QAAVY9)C 3!\@
MA\;VTF-#N[U3 \ZQLGW:N87N;9&EU%9AN7-+9B6QM;2*T-I<Y=344T:LO5#X
M-X  [>Z$+>)0N$L"&@Y*?NZ1D7IQ16'I@U&5]=<FM _W3QBHM3VV,*^\;TO,
MN87W%EXC<<.':?S RYX)/@-^:6X7N=DN%R+SB1>$A8Y]6<6XOI(2N[[&$OO>
MOD+<N8'<OP'B4(?43>)0MD,<VO:)OQTX)OGPWO$%U\95_[GX6NMPQRM]U=IG
M9J8%8QA\RF,\/?HAV8]WG\YCW65$>MYBQU)'> G$JQ$I#L.QZ=BAE$S,8&Z6
M]6!%EM5@>Y;-T%#:WP!"M/VST#UES5;13]V[1)_>V"EV;4QZT85)E4WMTUI'
M:M_I*1>],3%,?XW!Q+YR)(:^<*$'//=D,,:8_FZ/ X,H#T-"G.Y'A3O<C8^T
MNY/*Q]S.C;&^72JPO-4H,+_5\U= XFI1*%PO"BT;15X.KA&Y_F23Z(7)8TO:
M9U0V5W\^<[A@1E<A_:.Q=MP'C%G8!X)MX'N:H^^T%]GC+<N5]CK(W?EEF!?A
M>;2/PS,ATVX\E849R_:W'BL*L'Q:$VC^I/6O@-25(E"U2N1#[U)DY,Y"I&]R
MLWCKIV/+JWXJ;<[_J7X@Y8?V2<$/(]70'S8Z 3\(QKX_7"W=OWMCJ%]9]N3/
M7+S33#@!_R&&B'N?X&PWG4;&3&53K-\542W?5=',WS:Z_@U0L R9;EN$7+DD
MA?0]6H@T?]XB60G2*W)!?E,BJ.Z) JUC7# \Q0)K92]P/$,'F@X%O/1)P#(B
M0)") X29V4.T.1:$%IA?J58V/[.LK7X4VEA\K\"8?Z^S_1NF:N8CPUWSD.[A
M^4CCVR6B9;!M?@X<6RZ$DQO"06E[ )S9QP"#HW2PD*6 PRDBN"C@P4,)![XJ
M6 A4PT"(N@U$:EA![!E+2-2T@'0M,\C5-H42'1.HTOT;KK:*(YV]$DC]34FD
M^-<RL4S8,3\.#BT- 9DU?B"_T1W4MU- =X\CF.ZW ^PA#!"/6H/K,4OPDC$'
MO^-F$"AK"B$GC"'RI!$(Y PA0<X TD[I0^YI/2C^*[HZQ)#:RV)(P0,QD318
M(18+V^?S8.]B'SBRPA5.KB6"\C_VH+79&@RWF8/5#A/ [3($XFX#H.W1 X^]
MNN"S3P?\]VM#T'XM"#V@"9$'T# [J &)!]4A_=#?4'=>!"D809"DUV(BT;!2
M+ @V2GK#C@44V+_$ 5T7-G!ZM1FHK34$G?5Z8+)!&ZPW:H+=)@T@;%('Y\VJ
M0-NB NY;E,%[JQ(PMRH">ZL"<+?)0SA*]/:_ 5B;Q,!GKR1XRBP$]LFE$**\
M&B*T-P'?; ]$.AR#,%=YX/EI0&"8/OC'FX%ONC5XY]O]\"C%?Z-7.WVA-CI_
MIK139L@]U ^D ==WA&&W2?P-]^>XAQY/[2:\'MH^^R/_S^'_)@?T7N&[1Q*\
MI1<"Y\12"%-<#7RM32 PV0/1]L<@DJH H;Z:P TVA(!82_!+Q?Y@Y.*_>A83
M/[M5469H#;0/+FUN[\G='E.D :])IV'&"_Q-GS'<J.]]NS&_6W83/G\"_/_7
MP??H N#)+H$HA=40J[D)A$9[(!XK#0*R(D1Y:T-8D"EP^9@? 4GX+\PLYQGO
M0M?W'N4>4_1:[[?49M])2B?KE7-_P'/B%<Y3Q]M!=W$/N==PCP.'',;\_P2P
M40<FNG]AH?NXW^^"Q,BO J'&1D@VW -)&&D0$I5 X*$+40$6OT(C[+\&"9T_
M^J?3IWSRO-YXEC!?N54'O* U!CVC= 2/.U\,>X+>R.\Z_B?J*OYNQ(#C0UX?
MX3'G3T  VOY^J /[\()_WP6)0SLK27TCI.OO@31K&4@F*(.0K@\"EM6/R%#'
MF9!8ZE1@BM>D7S;KA7=1T(1[1>A36D/D8Y>ST:/DB['W2->%5QRO"_N=;D7W
M$.^'G2,]Y/V)?QU8J ,'[6X^VC@)IU?^^TY,EMYNR+*4@0R\"J30#+X+?3"?
M8[BD]Q'1[I.\1+_G_AG<,49^Q"./,L$#USKA7>K9Y/]0!M*&G 8S+A"OI'0[
MC\2WD^]$-5/NA_T)"$0=_%$'[@$IB$$=DM#.RE#[!W)U=T.>N0SDX%2_9U*,
M/J5XV4T+ UTFHR,8ST/C@YX&ID8^9.;&W_$L21EQK<FZ2FO+&:)>R.UU[L_M
M( ]FM+A<2ZRGW8JIH=V-_!,0B#:O/]J\P?NE(!9MG%2T<;)5_X$"G=U0;"KS
ML]!.]7.>L_%TI@?N=8J_ZT1L,&LTG!]V*U 8?Y69EG+9.R^SWZ,\I]>M(:^'
MWE703KU0T$ =R*EQ'4ZM<!N)+W._'?TG@(,ZL%&'L'WS07AD$62@#GDJ&Z!$
M>Q>4FTA_+;-5_5#L9#*93\=/I/NX/X@/Y(Q$AO$'>3$)%P*2TKJ96=D=C**\
M-J_JPF;/MJ)Z]][B"K>+^:4>@QF%7M<2\KUO"OX$!/VOP^_WM!+1SLHZN1P*
ME==#N=;.G]5&TI^J;%3?53B:/B^F.HYF>WJ-)+&XEV-X_-[PJ(1SW/CTEH"T
MG :_O((:W_+B2I_&DG*?GM("K]ZB7,:E[&S?J\F9OB/Q?^)?AP#4X??[2<F'
M%T+.B650HKP.JK1V?*\W//:AWDKU=9V#Z=-RLM/M?'?OH31?;J^0P^_@AR4V
MA0G2:[A)N>6!687%_L4E!:S:LCR_CK(,WY[2-+_^W%36<&J*__6$/P%<U"$0
M[<W?[\2DHN=G/NI0IK0.:C1W?&DR.#K58JGRO,G>]&$UR>E:$=WK8A8CZ%PR
MF]\4%YQ8'<7/* T3YA;PTHMR. 6E&8%5Y:D!;16)_MWE"0$7\X6!0VGQG&N)
M?P*XZ__'X??[*.F'%D"A[%*H5%S[J_[,]D^M^D??=)BKC+?:F?RGWHDP6$;S
MZL[S"FI)9_%K$H,22F,C,O*C8G,SPU.*4D)R2Q-Y9>7QO*:*&&X7RH7":-Y@
M1C3O:M*? ![JP$$=?K\#D7E("HK1ZW6UXIH?36>V?>C0._RJQU3Y<8>MR?4F
M N%BE8OGV2(/3GVV;U19:F!"?D)H>D9L3&YR=%)1?&16:4QX2454>'UE>'A7
M95A87U%XV.7,\+ K*7_B7X>@'1(0CZZ)[(-24'I\,=0IK/[6JK%EJDOOT/,+
M)HH/NC'&PZUXQYY:LD=SF5M@93XCLC"++<Q,Y:4G)4;EQL8+BZ($Z+3$%%4$
M1]=6<F,Z*X/XO<5<_J4L+G\X]4] ,.K VRX!">BQR#TX'RID%D.CPJK/'>J;
MW_;I'AB_9")_J\_::*## =_1Z.Q>5^4:4%+B%9F=[R=,S@I*BTV/R(E,B2L,
M3DPMY23DE[.%514LX=E*5GQOL7_<I6QV['#JGX!@M+M#MDE $NJ0?V ^5,DL
M_-4BO^)CM]K&5Y=T]CX>-CIUK=_*L+?;WJ&EE>A644]EYU5ZA*>6,./B"M"+
M96YH-B\KIB @([F$F99;QDBK*/=*:ZWP2NTM9B1?RO9)&D[[$Q"".H2C[9^"
MSD?1_GE0)[W@^]G3RZ8OJ*Y_?E5[U_T1 [G!00O]<WUV]G6=!'I1JXM_1KU;
MF+#:)S:RG)W,*PG.]"_DY_GD)Q9YY&65T'/+RFAYS66N>;W%;EF7LMTSAU/_
M!(2B#E&;Q2%]NSB4[I.$IJ/S/W7++7D]J++ZR1W-K3?NZ)VX<,U<K^62+;:B
MUY&6TTEF)K;1@_E-7M'!]:P$_QIN&J,J,MNM0IA/+<\L))>7%)'*&XM)%1<*
MR<67,RF%PRE_ L+0]H_9* [9V\2A<H_$S_8CDN_Z3RP8NZFT[,XC]2V#H[K'
M.V^;:M=>PV *+SM04B^2?&)Z:$$AG9Z1_F>9<=YMG"1Z2W@ZI3DNB]B4D>O8
M6)SGT-20AVN^D(NO&TIWK+Z:]"<@''7X_7Y2_E8QJ-\E-M-]0/S9U6.2=T;E
ME@Y-J&_M?:HCTSQJHEEVQ]HJ<\2>&'?%R3-LT(7-'G /\;[H&T7O"XPE]X8G
M$L['I>!Z,M*P/<7IMN<;,C"]%])M.Z\F8=M'XO\$1*X1A62T_4LWB?YJW28Z
M>6F[Z-V'N\2')DXN/_]*?7O+<VV9RG$CC=S'EF:)#^T<(NX1J(&W71B,F^X!
M]!'?8.?KG C':^%\^VOQ LRUS#CK:R7QEM>:A!8C_?&6PS<%E@.W^7\"^*M%
M(6NM"-2L%_G8LT[DX9WER-#$;HF>MR=7-K]3VU'Q1DLZ[[6^2O)+"P/^<SMK
MWC,BWF^<1O$<]W:CC;&]G9^&,!V?QOC;/TT*M'V<'63]J(1G,5H7;#;:&6PZ
M.A)L<O<![T] [$I1*%PI\JMU!7)[:"$R-+Y<I/O=[GE-,W*KRS^J;,_YH'DT
MZ;V>0O2TN29ORLZ(-46R])ZB8^GO?/"4=X%.Q'=A9/P[@8O]VV17VS?9;M:O
MB]PM7U=[F+]J]31]U>]E\O+6'X'492)0O02YV2.%7+HJA71.K1!M^+IG0=EW
MN=79WY6V)7S7.!CY35>6^\U,R>^;W1G/;R1=UV]NAN1O/J9.WP(M\-_"K'#?
M!1CLMV1;S-<L.ZLO1?86GRL=S#XWX4T_]>"-/UUV_!-0L!"YW2J)7.R;AYR]
M*874_E@E5@S[%F:"[.HXD-\<!FJ[ T#G, -,CKN![6D*$)6(0%=U!(8&#MB:
M6 C6Q@!?QQH2]"PA0]\"\@W,H,S0!.J,C.&LL1'TFOR)>S6BR,4.":3MD@12
M=7\^4@!KQ=/AP$(!'%L1#'(;_$!EJSMH[:: T0$"6!_!@:,T%JC',>!YPAJ8
M<I; .64.8?*F$*-@ DF*1I"I9 @%2@90KJP'#2JZT*;Z)P::1)'6'G&DXIH8
MDO-:2B09-DCP8?<"#AQ:RD"/!0T4-Q!!8[,]Z&^W!O-=%F"WQQ2(^XR!MM\0
MO X8@-]!?> <TH70PSH0?40;A$>U(.WH&<@]I@%ETNI0_4=:VT61\@$$R;J+
M($)8)!H)&\0#8-M\3]B[B Q'ESF W"H,J*PU!^T-1F"T41^L-NF W68M(&P]
M Y2M&N"V30V\MZL":[L*>@-6AK"=2A"]4Q&$NQ0@;9<\9._^$Q4]Z/C7$"3V
M"8*$P1)1%JP6H\-&22?8(86% XLL0&:I$<@OUP&UE9J@LTH-C-:H@,4:)<"L
M50#<.GEP6G<*R.OEP'7]2?#<< )\-\@">\-QX/XC Q'_2$/,'P'WS6) 0^\3
M%!DI\#RY&/R45D" UGH(,MD&@;A]P':5!C__4^ 3H0)>"6? /4L7Z,6&0*TR
M 4JC&9#/6@"IUPH(_3;?\4.VGW$WL!_L']I-8<?L7]N^Q#VW>><P83.-FXO_
MY_#_=]@K"=1C4L XL1C\%58 1W,]!!MO Z[]?@BDRH _4QZ886K $&J#9X8!
MN!>:@&NE.5#KK8#2A@'G'NP/8K_]%\<AW(S##?R4_4/'2>PXX87M2Z>GF'=.
MCS%3CG,!'IO$P!5UH!^5 N;Q1<"17P'!&NLAW' ;A-D>@&#R<> P%('-.P-^
M GWP23,%SSQ+<"O#_'*MM?_ATH+_3NXD?"5=)'XD##E/X6]07N-&J<_L)FB/
M;5^ZWL6^)=_&OG.>"_!$'>BH@\=A*?"77@3!IY=#N/HZB-+?!E$V!R"<* O!
MGLK "=0&-M\8_)(M@9&#_>E9[/"-7N7TA=9(_D3IH'YTON ZY33D_AI_PW,"
M]\AK%#OA?1O[PN.J_1O:L/U;ZER UT8Q</O]+.C0? @\M@C"3BT'OMHZ$.AM
M X'E > 33D"XFRH$^^L!)]SL%UMH^X.9B?_J7>C\R;V"^L&UWFW:I=WK';G7
MYS5QB/G,\19K%/>(?<-NS'\8]\RGW^&5^T6'2?I<@#?JX(XZ^*#[62[:FY%R
MRT"@L@Z$.ML@P?P@Q#F<A&B:.H3[&GP/#K;ZPA$X?&*E.'_PR:5/>99ZO:'7
M,%]36]DOR.<YSTC#O$>.=T*NXQZ$7G9XS+F 'V-U$5YX=Q)>>L[%_SCLE@2_
M_?/1R^U"B#FY#(3*:R%9>RNDF!Z$)'NY7_$4C6_1WL8SX1S;][Q(XMN !/HK
MWPS&<\\"]CB]@OO$I2%LU/E<U#WBY9@1QYN" <<[4><)#T(ZB(\#6T@3S&;2
M,Y^Y ,8_8N#Q^UG0WGD0@;9>W(FED*RT!M*UMD*F\0%(MY7[FD(Z\U'H;OHN
MVA_W*C3492(PQOLQ,RG@OF=6Z$W70OXUERK!,+DE;I#<&S_@?%W81;P9V^9\
M-[*1_)!72WG*KG89]YL+\$$=/'=+ &?//(@ZN  2T-9+4UP#V9I;(,_PP/=<
M&[F93(+FNU17\Q=QOHY/(SAN]X+"_4=8L<'#C)3(2QXY,1?HI?'G:74)7=2.
MI'/4P:1FRK7$.NJMF$K:_;!2U\><$M>G[+GXU\%KEP1PT>:-05LO^?@2R%)8
M#7D:FW\5Z>__7&0E-Y6/UWJ9Z6+Y)-&3>"?:W^MJ:##[$H<?TLM*B.KRR8AM
M]RI(:'&O3&YT:TFI<^M+K70=3BUSNQ%7Y'XG,L]CE)?K\9@S%^"+.GBC#L&_
MWX$X( 5I:.OERJ^"(O5-W\OT]GTH-Y>;++77&LMSMKJ7YN9\-9[IU1\5%- 3
M$A%ZEA/+;V*EQ-7YYB16>9>FE'O5IY5X=J47>@ZFYWE=2\CVOAV=P7@0DLX8
MY<X%,-%]O<]."0C;(0E"=%UFH->(@M,KH51MXY<JW;U3-:8GGU=BM4:+G*RO
M9[F2!I(87MT"=D!;9$AH0W!T=!4G(;[,/R.IR*\P+<^W.B/;ISTSR_=R9IKO
MU>04YDU!$O-^6"+S8?!<_.O 1#LO G5(1!VRCRV$XM,K?E6H_3-3J[-GLLGX
MQ%@M1O-.&<%J*(]*.I_NZ=F>P&(WQ'!#*R,BHXM#XN+S@E*3LP+RTM/\RS.3
M_9NS$OTO9@O]AU/CV3?B8MEW(V+9#T+G OQ0!Q;:W5$HR?OFH=N?A5!Z:OGW
M&M4-[QNU=[]L,SK^J-'FS$@5WK*_B$(\E^WNV9CBRZZ*#PPMC@Z+SHV(B4\/
M34I.YF6G"X-*LF(Y#=DQ0>>S^4%#Z7SNB# JZ$YD9-#]L+E '43!'^T\/NJ0
MBIZ?!4<70(7<LJ_U*NO>M6KM?';.4.9^JY7&<*V#Y?DR9Z?6?+I'30;#OR29
M'9(;'\Q/C^'')T8E),>&9Z3S0XNR(D)J<T)#NG)"0P<S0D.O)X2&WHD*";D7
M/A? 0ALK8*LXQ*#]GX'>-XJ.2$'UR26?FI773G9H;A_K,3QZJ\-2?:#1WN)<
M)8G04$QS+\_Q\L]+9X6D)W/YB<*(>$%L7')D=%IZ2%1!%C>J.B<PJ@/E<B8G
MZEHB)_(VGQ-Q-V(N_G7@H-T=AQZ+K#T24'IX_J_Z$XL_M"NM?MES9LNC"_I'
MKG69J_6UV)FUUCHY5I>[N!46>K R<WR#$S,"HP2I87'A28(DGC E+2 N-Y,5
M6Y'-C&W+\8V_G.47=S7)3W [VB_F3N1<@#_JP/W]2T;HL<A%KU45A^9];Y)=
M.-6IN.)9O\;&>Y=T#@_VFJEV=MB:-C0YXDMK*/2<<C=F<A&#*\AC1X9G!\=R
M,_B)_FF)J;XIV1E>R659'LG-V>XI UF>R5>3O!)O17LGW(F<"V#_?@Z#WC.2
MMHA!P2YQJ#DH^;E=1FJR3W[ITRMJZVY<T3YXL=]4I:T;8U+5CL<5-#K3TFI=
M?>,JO(,B2EGAW")N#"L_4LC(%2:[9V>DT;)+,ERR&S,I.1<R:-G7$EW3;T>[
MIMV)G L(^/T<!CTW4M']5/$.,6C8)_ZA^]B\YX-R"Q_>.;UF>$1S?_>0L5+#
M16NCDFZ<7>99HHNPA>H=V> 1P*UAAK"J.%'>Y>&Q]++8!$I)>C*II"B54%*?
MYEC:FTHLN9Y *KC-=\Z[&SD7$+A6%/BH1^9&4:C8)OJ];;?8F_Z#XH]N'9.\
M,7IJU<4[&GO;KAO*5PY9ZN?VVV&2SA.<^5T4#]Y9-S]6JT^05W- F&MC*)_<
M((@EU*<*'>H*$^SKZQ*Q]><3[>MOQ.$J[T8ZE-\+FPO@H YQ:T0A;X,(U&T2
M^=B]563L^E:1&X\.2EYZ*K^J\Y'&KOJ[^G)%-\QUTJ[:6@D&\820 3+-_P*=
MX=7+\*?UL+G.W2&ACEV"2/O.5#ZFLS#&NK-.8-5U/L:ZZS]\F]8'H3;-#X/G
M KCH^$FK1*!DC<C/UK7(R\'ER(U':T0&GA^<U_E,?DW#N,:NTB=ZLID/337B
M[]J8AMURL&/?()&\K[O2:5>]O4E7V'[XX=  [) @R&8H+=ARJ"C$?*@AU&RX
M#^5AL-G%QX'FO4\"Y@+"5XI Y@JT_Y<C]\XO0*Z-+$#Z7ZP3Z9@\N*#^M<+:
MTE?JN[)>:,L(GQFK1(S;Z 4^=3#W>4+&NCUV<R0_\B431CDT^]$(=\QHO)?5
M: ;#?+3$U_11(]/X41_3Z/$HT^CV!,/HQG/ON8#8I2)0N 2YWSH?&;X@A5RX
MM0!IG]X@5OO^T*+B:?EU&5.J.^/?:1T)?VMX.O"MM;KO&[RN^QN*L<NDAP5Q
MTL\&/\G%VDU&X3"3"7BK-UD$BS<E1-,W#223M]W.1N]ND@U?/R,;O'@Q)Y"V
M$'E8+8X,=4@B/9?F(:WW%R!57S:*%WXYLCCMRZFUL5^4MX5^T=S/_F(@S?AL
M=8K^V4&9\IFB[O3%0PO_Q4_7[@M7'_,ETLCZB]#$\FN&J=G7(G.3;S46QM_.
M6AI^NVQE\'W,2O_[RSF9*$*0*XWB2%>7!-)X11(I?[U8)!>V2*; D<71<&(U
M#Q0W,4%CISOH[W<!\R-$L)?!@_-).W [A0$?!6L(5+*$,&4S$*B:0(J:,>2J
M&T+9&0-H.*,'G9JZ<$U+!Q[,R?5J!.EJ$T/J+X@A);<DD,R?2T438;MD)-K<
M@2"]@@&GU]% ;1,1=+;CP&07!C![T; [@$;6(31VCJ#!<=0(@HX90(2T'L0=
MUX5466W(D]6"\A.:T'!2 [KD-.#"G/0T($A]IRA2-"2"I#T40^)@A6@8;)'P
MAST+/.#P$C*<6(D'I;48T-Q@ 0:;3,!BBR'8;=4#I^TZ0-VA!1X[-8&Y2P,X
MN]4A;(\J"/:J0/)>9<C>IP@E^Q2@=K\"-,Y)0ZL(4G0105)N(0C_G;A("*P4
M]84-XJZP?9X3[%^(!>DE%G!JN3&HKM0#[=7:8+3V#%BN4P/L>A7 ;U "YPT*
MX/J//!I+I\!OHQP$;3H!$9MD(7;S<4C9+ VY6Z2A<$Z*N]'QKR!(Y"B"<&">
MB#<L$Z7 :C$<;)2P@IWSC>'@ EV0670&Y)>H@NI21=!:=AH,ELN!Z?(38+7B
M.&!72@-^Y3$@K3H"U%6'P6/U(?!=?1 "5N^'X#7[@(\BF!,@;14#_'X)P,O,
M!\J)A4!77 H>FJO!RV0C>-GO '?7?4!G'P5JI"Q0DD^!<YXBD,I5P*E>#0AM
M&H _KPD. UI@/ZP-V)NZ8#NJ]]UF7/^S]2O]CU;O#*8L/QA,6GR9D_]K'!Q1
M!\*Q^4"570CN"DO!Z\QJ8!AM!!^['>!%VP_NK&/@&GX"J(GR0,E1!G*I&I!J
MSX!3JQ80NG4 WZ\+N"%]L+MA\ ,[:O@5,VXT8_/*>-KZG<D;JX\F+ZV^&L\%
M.*/[!@+J0#PZ'^@R"\'[]%+P55\-?H8;@879";[D ^#M(P,>(:> 'J<,M QU
M<"G2 G*5+C@WZP.QTQ (%XP!/VCZ$S=B_M7NH<5'VW'+*<PKJ]?64];/K6>L
MQFR^F<\%D'\[[), \N%YX"&] 'SEEH*_VFH(T-\(@=8[P9^$+C$O6? .4@"/
M:#5P2]$"6IX>N)0; ;G>%)S/F@.QS_*7XV7KKP[7,3/V#[!3V'&[5YC7]L]L
MIG%/,3.V#VR_6LT%4-"]BQ/J0#TT#[S1/;7_R27 45T-7-V-P+/8!1S"8?!W
M/P%,MA(P(L^ 1Z(>N&4; ZW8'%RJK7^26VQ_D+KMOCE=<IC!7W.<LG] >(6=
M($[83I)&,5.$.[8?':[;?;&=BW\=B'LE@'Y@'C /+P#.B240K+P*0K4W0KC9
M+@AQ. )!-#E@^ZD",U3GEW><\7>/-,NO]'S,%VHY[A.YWO$CZ2SQ@],%\I3C
M->HKW$/7,;OG]/NVKUQO8-^1A^T_. W@/N/F EQ0!Q+JX('VC3_:O,&RBR%<
M:15$:?T#T<:[(-+N"(123O_D,C2^L8,,/C/Y%A^]DK#3;EF.[VA%SF\H5=37
MI&:W%X1NSV?X(<:8PR/?V]AQYA7[EYZ7<&]<^QRFR%V.'PES =1-8N",[NF]
M]T@"Y\!\"$>;-UIA)<2>^0?B#7=!+.;H#SY)_DN8A^8'+MOD'3L<,^D3Y_C"
M(Y4R0<MU?T(N98PZU;+N.[8'WL'W<V[B[W$&<4\"^_ 3OEV.+SW/$MZX-CM-
M.\\%T% '%W1/[[M;$GAH;T:AS1LGOP(2U#= LO[.GTE61S_'.RJ\CW;5F0QC
MFC_G<'%/F5&4!YY"S]NNZ<P1EWSV%><*SB"ID7N)V!7<[W0EI(?P,+C=Z2G[
M]S.6>N=7'M7D=RYS :[HOIZ&=C<+)12=#P':FXFGED.JVGK(T-WY)</\Z/L4
MG.)KH8O>1)27]2B/[72+'4J_ZA/#N.R9Q+I(SPKLI17QNEQJ0LY1VL+:R?WA
M+>1[X77D46X598Q51GWA74R=="VFO9F5?QWH.\0A .W-"+0WX]%S(U5N&62J
MK/N>H[/C8Y[ID3=96,6)9)+^0X$;YD8XDSC$Y=(O^D?Z]/C&^W=XI06UNN>%
M--'+P^M=&R-K:#U15;21J%+:@] BUR>!^?0)WQRWU^YS 734P6.[.'#0WN2C
M:R(1[<V,DTLA5WGMET*M;5,E1H=?Y&,4'V40#&XFTC"#T0QB7UB 6V=0J$\K
M.X;=P$SBUC"R0BL\BR)+/6KX1>YGHPO<!V-R/>Y&9'D\XF9XCK/2O%YZS@6X
M_7X6A'8>#T6 KHF4P_,AY\22GX5*JS^6:FZ=K#0X-%9BK7 W%Z\_G.IB<R'>
MDWB.SZ(WA_)\:H,B RH"XGDE?FEA!;[Y43F,BIA,[Q9!NO?%V%3&;7ZRS\/@
M1)^G[ 2?Y]Y"GQ>S@CJ( F.+.(2@Q.V2@/1#\R%?=M&W4L55TY5G-K^HU3_P
MJ,)*?J00IS>02;;I2G)S:HGUI==&<7S*0\,""KD"7DY@<GB&?S8_Q:]4D,AL
MB!4RS\?%LV[%Q++NAPI83P)C6,]\Y@+<40<?]!H1AK9W NJ0=7 >%!U?^+E"
M8<7;.O6-$XUZ^^[56)P>+K77/9]+LFY+=W6J2V#0RP5LGX*HX(#L,#XOC9<0
MGAB4P8\++!+$!-3&105TQD=Q;L1&!MX+CPA\Q D/G/"=BW\=F.CY&8%Z).U$
MV_N ))1*+_A8<WKYZR:U#4]:=??<;# [-5"!U>DL=+)JS*82*E,]70L3_!C9
M BX[E1_!$X;'A<>$IO$C@_,%8;SJ^&!>1SPO^$I\</#="![O$9?'&_=#8<X&
M>&P0_??]Q2C4(P4]/_+W2?RH/"8UW7!JZ8MVE;4/.[1W76TVE>NML=5N*W6T
MK,EW<2S)=*?EI/@R4A,"V<*X,%YTC" \/"J%'QR1*^"$5\2SP]OB_<,'X]D1
M=R(#PD=Y 6'C+!2_V?C7@?W[-V)0C_3M8E"T5_QKS9%Y;UM/+AKO4EYUIUMS
MY^5VXY-=#39:C95XB_)B,CXOCTY-RV1X"U/9_M%)P=PP(3^,&Y?(9PNR!<R8
MLCB?Z.9X[YB!>!_!G2C?Z(<\WZ@QUER )^K 62\*L>B<9*'[F;+=8I\:#DF\
M.B<K]?BBPK*1/HT=%\X9R;:W6&O6U.',BRI(#IG%KBZ)^5Y>T=DL5E@&-R@H
M-3*4E2R,9"1FQ'@F%,>Z)33&N29>B'-/NA/E+GP8[!$WYC\7X(6.ST/;6XBZ
MY&X1A:J=HN];]XL_ZSTF>7](=NG0@-JV[O,&QQL[+#7*FNU-<^J<[),KJ61!
MF8='6!&3R<GG!/KEA@=[9\5&N&6F\:D9A3'DC'J!<\9Y 27K3I1+VD,>-7G,
M?R[ &W4(72T*R>O0[MPH\KU^J\B;KEVB3X;VB]V\+KVX?TAU2WN__K'J'G.U
M@@ZL<5J+(S:N@4(*KW6C!U7Y,/S* _R]2D."7(MC0LE%*1'$PH(HQ\):OD-A
M#]^Q^&X$(7^42\P>8\T%^*P3A4BTO=/7B$#9.I%/K?^(/._?('+_[D:1X=M'
M%W:/*&]J'-8]4CI@JIS5BS$0=N&M(\\Z.P:UNE+]FKT]/!O\?6EUP6SGVN@@
MQYKD8/OJO#!L=4TXIJ8KW+;V7HA=Y6..?<D$<RZ A1X# =K^.2L1J%V)O.M>
MAMR]N0BY\FBC2-_#(U)M=Q4W5-W0/IAWU5@^:=!:A]^/,^?U$>W]SM-(GMV>
M-&HGRY-TCN>#/\MG8<\F!=BTYW&LVFN"+,YV!5ETW.58MHZQK.N?,U"\9P."
MT/$3ER%0O!09:UV(C%Q<@ S]9R'2.[99M.WIL04UCQ77%3[4W)-VU_!DS$U+
MC>#K=D:LJT[6GL,N..J@)Y%XV<_%X1+/S?82W]-J()EA/I#O:SI0PS2YU,TT
MOGS?U^3B"R_3[M=NIEV3LP+A2T0@8S'RJ'H><JUC/M)_:3[2<W\ATO)BJUC5
M\V.+"Y\IKD\;U]@M>*HO$_+87,E_%*OE]9!@1'W@8DF\YXEUN,=RL+T;[&1U
M-]K9[&Z*B_'= IKAW3I7@WOG7?7O/Z 9W)ET,;PZY3P7$+L0>5DHCEQOE$0N
M=$DB';^_PWBY1*3\[7:)_+<R2U+>R*^/F53;&?Q:Y[#_*[,37B^Q2K273AK.
M+VDZCB^\#>Q?L$TP+T+-+5\(+,U>IMJ8O"S &+ZLQ1J\ZL3JOQZQTWOUTDYW
M[ -V+KZFB2$W*T61"RWB2%NO!%([,A\I^;1<)'MFIV32C/22J)G3:[DSJEN9
M,]I[W&>,#[M\Q!PG?B3(.7RD*MC->"O;S+#5K&9"-,QG8C1-/J5H&WW*TS7X
M5*FG][E-7_?S@('.E\<&VI\_H'R<E7L%"-)?)XJTGA5#JBZ)(P5WYR'I/U>)
M"G_NF1?^Z\CB@%\G5WF#\C\TT-I* L-=#F"U#PL.AVR <M02#1(S8!XW@: 3
M1A!YT@"$I_0@\[0.%,MK0YV")IQ3/ -#BAKP3$D#GL_*8"6"M#6+()7G19#<
M:Z)(TL0\1 #KQ$)@IR0+#BYTA^/+R*"P&@\:ZVU!;Y,EF&TU ]OMQD#8:0#4
MW7K@M4<'6/NTT<VH)D0=^/WMAQID'U*%DL,J4'=8&3J.*,'PT;DX6X<@E1T(
MDG,)01+N(DCDCX4B0;!6U >V2M!@KY03'%UL!W++K$!EI0EHK3$ PW6Z8+E>
M"[ ;-("P40THFU3 ?;,R,#<K0M 6>8C8>AKBM\E!QO:34+C]!%3MD(56E+99
MJ6I&Q^]#$.$(@H0\09  6"SB"2M%R?"/. YV2%K# 2D3D%FH#Z<7:X'J4G70
M7JX"ABL4P7RE/&!6G0+<JI- 7"T+U#4RX+GF&+#6'D$O_H>!O^X@)*P[ )GK
M]T/)G.1UH>,/H>,_0!#F9P2APP(1 BP3Q<!J,5/8)*Z'SHDF')RO"C)2"G!Z
MP2E062@+9Q9)@^[BHV"\^#"8+SD(-DOV@_W2O>"T=#>X+-T%'LMV '/9=@A:
MOA4BEF^!^#D!+'J_MCHD =8R\P!W0@H(BHN!J+D"2,9K@6B_$9SHVP'/W@.X
MJ -@GWP8L'G'P+9<!C#ULF#3?@*L>T^"]? IL+IS"BP?GP:+9_)@/JD 9M,*
M/TQG%+^8?E6<,?FI^,$$9N5_' Y* $9Z'N!EI8"HL!B<SZP LM%:(&,W <EU
M.Q#\]P(^XB#@$H^ ?8XTV)7)@FW=2<"TR0&FYS38#,J#]2T%L'JD");/E,#B
MM=)/\RGEKV8SRI],OZI\,/VI,F4*2K,!=MO$P!IUP!Z=!TXR4D ^O1BHZBN
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MK=Y;8WO]-D4/!TY'385,1.X(W1AQ-&PTXO?P#5$O@S;$??,9B4>WH01T'$Q
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M8_<SI68N"PV6C@L]UG8+8[:V"]OI-F=.$X_(YY^M;4^C)?T46BSG=A,Y@P&
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M_LT,17Z:H?!R_KL&2R4:VBG]_5J,BS83NIJPH+,=!SIZ<Z%]Y$JDI_.C;8D
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MTJYB<75(U?SJ%C73WX^JF_Y^3\WTRCLUT]]^J)I>1A732_]VIA-@WPC YBF
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MZUQV/*I[T?&RWCG'1WH+3A^T3[F@^@DW5#GNCHK'/%#^J ?*+H7V9*XGZ=Y
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MP?5L#MWKY9S:-UJYM&X,<VO<V,:C?O,4C_J-QSQJ?WQ:J78->56O_MOV7W>
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M?,/4<_%K(Z_%1-^[@^@BVE.YAM?#J2JL ?9@&^:OZ\$>H -WK01H1 ^O'N9
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MCJ<3R5PZD:A$FI#%2!^R"EF';*(3\1W(/N08<AZYCOQ.(Q)OD"\(^?\SF6^
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M?@-0N@D@>$P#F;>B(/56',3?R0+_G3+PWFL!][T1B'Z8#NR/=B#TT1T8GT*
M_CD9:%]* #ZW(GB1?<+F?KJ(/$$^(9__2ROF5TV>@4T Q.+<_<\!.%X"F(G9
MAIBMCMER=P$D'P'P/P#P" NXA ,BA ]"1 H81!XHH@I =)!IB#7B!']N$ G>
MD"?_0J(_SQYP' 0+34XB=_]!#>;G8GX<?BO@ H##%8 9F*U_"T#E'F"=,1N'
MSL%\-@%@(33"P/^6C7 1/B*%R"-JB!YB@=@CWG\]"X(W1-*$+$-PT9,]_X"H
MHENJZWQ%19\B<M,H(F%%$;X31;@!%.'$4D0DBT;89<A\I)TB[&ZD'UF#;$"V
M4D1X'#F ?(=<0>XASY&/@%;[%3:A_B<:Z/I:Z)>3:. XE PI(IA.$>FY.!9?
M'$L4C?#2D6*D%EF ="++D%7(,(YU$[(=V8<<1RXBMY%GU!?N!^H#EU#O>7_S
M[E\0;0T@NJI?T58'HJZ+[36CB*(=UL23(K)A-"*=1".2>4@ETHBTTXA$-]*/
MK$$V(%N1<>0P<I;Z+'&=>B_YA'HM^8YZ*4FH%\AS24+[0^K_ANBCZQLJ(NC;
M!DK83JS'Y'F0E@WVQQ7[$T@C2G$THH#]D"]!ZA"LA3S60KZ/]EE^)>V3_##M
MH_PH[;W\#MH[^0G:&_GO:"_E?Z$]DW]$>ZSPEO90@= >*!#Z?45"OX?<G43A
M;X@19D^3!6(JC:_HW*98CVGZ0(QG4,3 @2*Z/C3<_="(9@KMDT8^_;U&)?VM
M>@/]M7H;_:7Z4OH+]>7T/]17TY^I;Z _41^C/U;?0W^D?IS^0/TR_8[&0_H-
MC3>,:QJ$\8LF85Q%?D+^@UR9 C'%7 L)(#/0MV=* K&:/)/1PE^;4L1\-O79
MU)UZ9QQ,>V443__#,(O^Q*"$_LB@EO% OYEQ3[^#<5>_AW%;?X!Y4W\M\X;^
M)N8U_5W,7_6/,'_6O\2Z;'"?=<'@M= Y0R)T!CF%?(><-"2LJ9#IF&^%[FV-
MWF_+QTL*QV2'M9BM#^]M9E(O+!VIQS/\:/>G1])O6Z30;YCG,WXSKV#^;%;/
MNF+6ROK1K$OHDNDRX0NF@\+G33>PSYIN8Y\QW2]RRO2TR FSFZ)'S)Z+'C3_
M(CIA3D3V(7O-"?O?$"O,G8WN;<\&XHCC<,9Z.,G!6T<->#K'!.[9S:)NV+I3
M/\\.H?TP*Y[QO4TFZZQUD= IZRKV2:L&D>-6"T6/6B[A'+9<SCUDN89[P'*4
MM]]RE]A>RZ-B>RS_P]]I^9B_S>JCV%9KPMMB3;B;K0EGDS41G0J9A;GV+,Q%
M]W7#<7APX;V[.#QQDX?;SMKPL_,,N.CL1)UQ\J.?<(QD'IF;+'QP;H[(_CDE
MHGOM:[B[[1IYN^S:^3MLEXIOL^V7V&H[++G%=JO4)ML)J1';<](;;.])#]N]
ME1RRQRO(GO!7VQ,QA+=ZSM\0N\GYX\>5.\!;;QH\]F7!(Q]1N.W)ARN>RG#.
M:QJ<\+*C#GEZ,O9YA+#&W>+8.US3.&,N>;S-SF7\4>=:\8U.S9+K'3NDAAU[
M988<!F57.XP(5CF,RZUT."G7[W!#?KGC2]D^)R+=ZTPD$7&$WS,%,I?YYR-V
M;WW0O?$C_K<@"OX3Q(++_J)P)D .C@8:P/Y &VJ7ORMCS,]?:)-OI,@&[T3N
ML%>FV)!GH?B@1X7D2O=YTOWN"V27NW4)^MQ6R/>X#BLL==VFN,3UL%*GZT]*
M'6[/%!:Y?Q$L\B R[1Y$JMV32$SES]N+!\!#S+\6"O!#!,"Y" :<#A6"(Z'2
ML#=<![:'SZ0VASHR-H3X" T%A8H,!L9R!P)2^<O]<B1[?8NENWVK99?X-,IU
M>K?++_+N56SS6JW4ZK5998'7?M5FKPNJ35Z_JS3Z?%)H]"4"1 :1:O3[F\D:
MO,,:W$'OO!P%<!:=YW@L#0Y',V%OE#ALC]& T1AS:CC:GCX8Z2'4'QXHTA<6
MR>L.313O"LZ0[ C*EVD/+!>T!LZ3;PE8H-CDOT2YP7] I=YOHUJ=WV[U&K\S
MZM7^]]6J ]XK50<2^>H@(HO((-+?F%P'3]'_K^'\OX]#[T7G.8C^N3>!!MOC
MQ6 T016&$Z91J^)GTY?'N;*Z8_Q$.J/#N(LBX\071J1*MH3GR#2&%0OFAU;+
MSPMI4JP)Z5"I"EZN5A&\3KTL>*=&2?!)S>+@.YK%(6]52D*)0DD8D4-D$9EO
M$$_L0S# 5?3_,YA].!7ST7MVX.NF%"X,IRK"JE0C:EF*-7UIDA.K(\%;9&%\
M"+<E+IK?&),D61^=*5,;52"HCJR0KXBL5RJ+:%,I#N]5*PP?TL@/WZ:9%WY,
M*R?\IE9NQ!O5O$BBF!=%Y!$!(ON-SY-K$=W[!]QNG,3<"73/75FXU\;7=1FB
ML"I3#I9GZE-+,V;2.M(<F*VIGNRFY$!.?5($OS8A7K(J/DVZ/"Y74!I7*E\4
M6Z=4$-.JDAO=K9X=O5HS,WJK5D;T8>VTZ&O:Z3&OU#)BB5)&'%'(C"-RB. ;
MK_T ;J%[?X\U.)J![I^#OI.'OH&LSA&&Y3FRT)VK QTYTVFMV?;,QDPWX7GI
M_ISJM#"QBM18B9+D9*FBY&S9_*1B^=S$:J6LA&:5C(0N];3X59K)\9NUDN(/
M:B?&_ZR=F/!"/2F1*"<G$H641"*7DD0$W_AC\GJ<[ /6X"#F[RH V(S;KV&D
MOX )W052L+A0$UH+S&B-^;:,NEP7X:H<']&RK!!><6:T>$%&HE1N>J9L5GJ!
M?$9:I6)J:J-*<LIB]824 <VXY%&MV.0)[9B4*\AS]=A4HAR72A3C4XD\(O>-
MQW@]7)WL ]9@/VZYMN,V=&,9P"#24T)!1ZDXM):J06.I"5578L.H+'(2*BWT
M$BG,#^+EY46*9^<F2&7DI,ND9N?))6>7*R9DS5>.S5RD%IVY0B,R8Z-6>,8^
M[;#,'[3#,Y]I1&02E<@LHAB51>01N6\\" >XE(Q]P!KL+L9U@/X[7(TU0!:C
M!RZH%(.&*F6HJS*B*BNMZ"7E#JR",@]V;FD )[,DG)]6'">97)0JDU"8(X@K
M*%6(SI^G')'?IAJ6MTP])&^]9E#>'JW O O(4_7@O"_*(7E$$9$/S2-RW[B-
M6\YS>!T<Q![L* <8J<%U, ^]KQZ@%5UX?AT7:N;)0\4\/:JX;@8MO\Z>F5WC
M)IQ>[2N:4A7"2ZR,%H^K2):*+L^2C2@OE@LKJU4,+FU5"2CM5?,K&5;W+1G7
M\"DYCSQ6\RWYK.Q70A3\2XC<5*YA'[Y#_]^'/=B*^>OF8PUP"]R)S$>JFMA0
MVBP#A<W:D-ML1LMLFLU(;71F)35XL^,:@CC1\R/%(NH3),+F94@'UQ7*!M16
MR_O6MBAZUW0K>]:L576OV:7F5G-6S:WZ=Q7WZD^*'M5$'I'SK":";UQ.P3Y@
M#79AW4<Q?S4Z>"]J25L;0"52U,Z G$42D-6A!FD=QE32(BM:?/M<1G2[AU!$
MF[](Z,(P3G!KG%A :ZJ$[X(\*:^6"EGWEB8YU^:E"L[-:Y0<FW<H.32?5G)H
M>J3HV/A1WK&1")P:B:Q3P]^<R_IZ'CB&]5^'*K*B'6N 'M[8A>ZW%-T/?3BY
MAP<)O0H0UZL'T;W3J? >6WI(CPLSJ-M'R+\[F.VS-)KCN229Y[XDA^_252;I
MV-4@/;>S2]:^<[7 MG.[W.S.4W*S%S\4S.[X(&N[B,@@TE,YCC48QQZ,XOP'
MT<&[,;L5/;BF#Z  7301]2AR%1O"5DE!R* Z! V:@/^@%>4[Z$#S6N7!<%\5
MP'1=%2[DM#*![; R4]1^H)AG.U#/MQE8+&[5OTK"LG^;Y,R![R1G]C^0F+'\
M@\2,941B1A\1GSF% W@=C&'?UV+^\B4 ';VX#C"[9!7Z]Q#ZYSKT/U0CKQ$>
M>(S(@_N(#KB.F(/SR&S*<<29FCOB3;,?":;;CL0P;492658;"X1G;JQE6VQ<
M)&JV<27'=.-6SK2-)SG3-MSGF*S[P#49)ER3M?]D%ZZ!C5C_ <Q?@G-O&D#_
M10_.60^0, H0L@7 8QO G)TLL-TE#K-W*8/-+CVP'K< JW%;F#GN C/&?2F+
M\7#*;#R1-FT\AVX\7LDP'&]EZH^O8.J-;V;I[C[.U!V_Q]39^5Y(>SL1TMY&
MA*>R9?(<#/-[4 5;5TT^!P20AQZ<M!4@#%W4:QQ@[CX RP,4F!QA@]%1"3 \
MJ@P&1_5 _Y@YZ!V;#;K'74#GN!]H'X\$K1.IH'&BF%(_T4BIGNBE5$Z,4,HG
M#U/*)^Y02L?>T12/$+KBX3]A?&/MDK^>A1H$J,.Z%VP&2,'L<-11;W3AN8<P
M_RB "3JQ]AD&*%\0 86+XB!_21[D+FF!X <3Q!ID?W0$F1]]01HW(5*7,T#R
M2B5(_&<1B/\T!/RK^Y!KP+_\$O@_$.!?(A3_XM^LP/S%F%^/M2_"N:?BO",P
MV_LPYA\'F/D=@-%9 $UT<L7+ -(_,X%_2Q3XM\6!=T<>T0#N72/@W)T)HO?F
M@L@]'V#?CP+A^UG NE<+S'M+@7%O!&CWC@%U#T7^_GL$Y?W>WW1A?L.&K\\A
MI>'<(W#>WB>P_Z<!II\'T+\$H'8%0.X7 (GK -S; *+/A8']D@="+R6!\4(>
M:"_4 5[H(^C\+^P0W)2\P)OQ"[SP7^!%_P(7^LM-"+[QJ[O(&^3C?VG"_#)<
M<^E[\1H\@OFG .PQV_P' -V? )1_P[G?!!"[ R#R (#Y$H#^F0+X) SPD8N(
M(S+X:V5$&YD&\'D6P!<W!&]&7R9_#@7'07 <!!<YP4D2?&-RY[]48'XFKKFH
M8P ^YS ?YVUV%7M_#4#A%LX=R\=YA-E/ ,>,D*E\.POA(1*(X*]SD,GG068B
MSDCH7\^DU"+XH4>&_SJ/V?=?B((V$$5T;7E$6@<(WPB(R P@3 <@E"]%(!K)
M0(J1.HQ>@'0BRY!5R# RBFQ#]B!'D'/(=>0Q\@XA\/G_ U'10-2 *"-R^+6D
M'D[+# C''J?H11&A<(HP4BA"+T"JD"9D$1!:-[("68VL1[;@F'<A!Y!3R"_X
M[H_@$[SY<Q1O:0B=P!O&7S#_AJBK((I80D09OQ9,UL,$2SL+:^*&XPFF"">>
M(J+92!DR#VE%.BDBTH>LQ+JM1480K(7(/O@L<@(^BOP(;T7NPTN15_"'"(%G
MH@2><@@\X1#JWQ M='UM 1 M61P'OJI.UL0 >S,3\*X&1,J/(A+8#_$TI!#!
M6O ;J<_\=NH3?RGU@;^<>L\?I-[RUU-O^%NH5_QQ>,D_ L_Y%^ )_RX\$'\!
M]\2_4'<D"'4;N?47-Z= ]-#U]26!Z$D T<%77:R'#JX+#7,<CQT0)4]<,Z'4
M)[E$ZIU<-O5&4$J]%-11SP4MU#-!!_54T$,]%@Q0CP1#U$/!*'5?L(.Z)SA(
MW1&<HV[(W:9^E7]._23_A?:C J%=0BXB%_X%,<)L8S$$_=N$CV ]C+$6AK@V
M]:S@O;8SO-(,H)ZI1U._JZ=1#]0*J'MJE=1MM?G43;6%U VU+NJ:VC+J5[5!
MZF>U#=1/:F.TRVK[:3^HGZ)=4+]..ZOQ!_T[C<_T$YJ$?@PYBAQ!#D^!3,-\
M,U$@YL) 9N X9N"8ILO#9S,M>#7-#)X8V<%]0T^X91!*_6:00%W5SZ(NZQ?3
M+NG7T"[H-]+.Z[?3S^HOI9_67T$_I;^&<5)_E'%<?Q?CJ/Y1YA']R\P#!K\S
M]QJ\9^TV)*Q=AH2Y$]GQ+X@%!W/1O:WH0&;A.&9QX;.-)#RW5(('T_7@AL5,
MN&KN#!<M_*ESYE'4*?,4V@GS7/HQLU+&8;-:QD&S)N8!LT6L_6;=K+VF T*[
M38>%QDVW"N\TVR^\W>PL>\SL+GN3^6OVB#EA;S0GPNO-B= DZZ9 9@I]/=ZU
M!?@PAX+G<UCPW(X+]V9)P"_6*G#!QA1.S[*'8[.\J$.S0FG[;>+H>VS2F;NL
M\UD[K,N%MEG5"6^U:F9OL>H0V639*S)B.2BZP7(C9[WE+NZPY7'ND.4UWJ#5
M<^Y*:\(9L":B_=9$9(4U84^%V-#^S'_KB+</=/#KKA3\[,R"J_:B<&ZN'!QW
M-( #CC:PQ]&5VND00!^;&\G8/#>)-3(G4VB#?2%[V+Y"9,BN7G2-W0+NH&T7
M;Z7M"K%^V[7\Y;9CXLML#XKWVOXHT6WW1'R)W2>Q+GO"Z[0GG,XY>&5/X<_'
MZQS0>_'C_9HW>B?ZYSEO.IQV$X8C;E*PSUT;=GK,@"T>#K01=V_Z.K<0YI!K
MK-"@2PI[P#E'9(5S,6>94Q6OUZE!K-NQG;_$L4>BTV%0LL-A5&J1PU[I-H=S
MTJV.#Z07.'V0:'$F?(37[$RX4YD\VGZ!\[^-V3^B]YT) C@6"'#(EP%[?,1A
MFZ\ZC/J9P3H_.]IJ7W?Z@$\ <[EWI'"O5X+(4L]T3I=''G>Q>YE8NWNM^$*W
M%HD%;IU2S:XKI!M=U\LTN.Z4K7<]*:ASO2.H<W\K7>M.)&H]"!\10WC?F*S!
M8P]T3LP_C[>78WBKFT!VAU P%LB#C<'*L#;8&%8&VU#+@YSI/8&^S*Z 4.$.
M_QB1-K]D3JMO%J_9IY#?Z%,I,=^[07*>=[MTK5>?;+77D*#2:YM<N==1^3*O
MZ_*EWJ]D2WV(%")1ZDOXB-@W/N.M[3[6X IZYW=XRS^(_CN.C.'7&\,X,!0N
M#P,1^M 784DM"7>@=X1Y,A>&!@FWA$2*- 8G<.J#TGEU@7G\FH RB:J .JER
M_U:94O^E@F*_0;E"ORT*!7Z'%/+\?E',\W\AEQ= I/,"B61^(!%'^-]XZ8I]
MP!I<B, :Q$Z>OZ#W(J-Q $/1;.B/D87>&!WHBIE.M4?;TQ=$N3,;(_V%ZB/"
M1&K#8SE582F\BM!L?FEHD41Q2+5487"S;'YPER G>*5\=M"H0F;0A&)&\&6E
MC. _Y#-"B&Q&*)'*#"42B/@WGF,?K@<#G$7O/)2(-4#OVIR*OH,>O#*>!;T)
M4M"9J EM"6942_QLVOPX%T9=K(]054PPNSPZ2K0D*I%;%)G!+X@LD,B-J)#*
MCFB0S0SOD$L/7Z&0&K91,3E\KU)2^$7DJ4)2Q!?9Y @BG1Q))%,BB<0WGN"U
M\',8]@'GO1_SMZ>C]V;B7AM?^U)HT)DB#FTI:M"<8D+-3[:AU20Y,BH2O5BE
M"8'LHO@(T?RX.&YN7)I85FRN1$9,F51:3+UL<G2[7&+T,H7XZ/6*<=&[E6*B
MSR./%6)C/@OB8H@T(AD?0R2^\<@/KP?L_3&LP1[,W8K^NRX7?0-?E^#VIRV=
M#TT9RE"?80C5&9:T\O2Y].(T=U9!JK]P;DJ82%9R+#<C*44L-3%;/#FQ1"HQ
MH4XF+F&A(":^5SXJ?E@Q(GZ74GC\6>218D3")T%D I%!I*(2B.0W[N&U^'W,
MU[.P79@[FH_KH!#W^^B [3GH/#E<F)>C %6Y>E"6,YTJRK:CYV>Y,K,S?84R
M,D-$TC*B.<GI2;S$M$SQN+0BR9C4&IG(U 6"\)1N^="4(<7@E!U*02FGD0<*
MP2D?!2$I1"8DE4B%IA#);]S$Z_$,KL$)G/,VS-]0#+ *';B[!* 9QU%7( J5
MA;)06J@-A85F5&[!;%I6@3,C/=];*"4OB)V8&RD:EYO B\E)YT=F%TB$9U=*
MAV0URP9E+I$+R%RCX)>Y7=$W\SM%G\S[^/4'@5\FD?;/)%*(Y#=^Q3Z<3/EZ
M%K8%\]>B?ZZH_'H&,P_'4EXF!$5E4I!?K@'9Y2941IDU+;7,@9Y8ZL&,*_$7
MCBD)$XDLCN6$%:6*A13FB@<6EDOZ%S3*^!1T";SR!^4\\\?DW?-/('?E/?+?
MRWKF$VE$TBN?2'SC1[P>CV -=F+]1S!_-3IX3QW 0J2\&KVKA@;9->*04:L,
MJ;6&D%0[DXJOM:?'U+@R(JM]66'5(<(A5=&B@97)7+_*;#&?BE)QSXIZ*??R
MQ3*NY2MEG<NW")S*CPD<R^\(G,K>R3B7$2GG4B+A4DK$OW$N"?N :W"L#-<B
M;K]7H -W-@(T(B5(!I+<Q(6$)CF(;=:!Z&9S*J)Y%BVTR8D>W.3%"&@,9/DV
M1@A[-R2(>,S/Y+C-+Q9SKJ\3=ZQ?)#FWOE_*?MYF:;OZ(]*V\VY)V]6]E;2K
M(Q+VM40<X7_C!-9@''LP.GD.U8 U:,$:M.(Z0!<N0!]/6H3NL8@-X1U2$-JA
M!L&+C2"@PY+RZYA#\^YPHWMV^#+<%X4R71;%"CFUI['GMA>(VK?5<&W;VL1F
MM:W@6[>-BENU'1:W;+O)MVQ]P[=<0,2L6OZ$]XV#N ZW56$-<+XK%N ZP-S&
MQ=B'+H L5)*8'H# /@I\^L3 >YD\>"[3 ?=E9N"Z;!;EO,R1<ESF29N[+)!N
MWQ?)L.U+9MKTY0I9]58*S^Q=(#*]=YFH>>^(J%GO08Y9[W51T^[7HJ9+B:CI
M$J3K;W:78PUP_H,X]^X.]'_T\!K,S5^./>A'_UZ%_K<:P&F(#7.'),%^2 7L
MAO3!=JT%S%IK"S9K72BKM3[4S+6AM.EKXVCF:S/IIFO+&"9#34RCH1Z6X= &
MEL'0!$M_Z!I+?_5K(;U!(J2WB@CKK?R;R7.HM9B_#.?>T8W^C1Y>O!+]$W.C
M4<O\T4>=1P!FH;).W\(!\ZW28+95#4RW&H#)UNE@/&8+1F.N8#CF!P9C$: W
MED+IC!52VF/UE.;8$IK&V#!-?=L^FMJV7VAJ6U[253<3NNHFPE 9_9N-K7\]
MBX1S;UJ!/<#LK'4 L9@;M 7 #7W<=@<Z\#@Z^%XZ:.[G@OJ$-*A-J"+ZH#IA
M#BH'9H/R 1=0.N /B@>C0?Y@)L@=K 3!P7:0/30(,H=V@=2A'T#ZP'.0WD\H
MZ7V$DMI+:-\8[)S\>32 !0, 54, .1L!XC$[&'/=,=<6?=Q\ O-1E]70B^5.
M,D'RC"B(GY5 %(!_5@O$SID [YPUX@S<<_[ /1\+G/.Y('J^'D3.]P#[_"@(
MGS^!/ #A<Q^!?8;\@U[,;\/\FK4 >:CFB:C$(7LP'W-M,=?L*(#N"0"5TP"R
MZ.7B%]'#KS!!^"H'6%<E@/FS C!^U@3Z+\9 _6(%\*L3;H@F_U!F\@<!\8/V
M6C/>F'%A7<<WOGX>X,93?/V D/^R"'M?-_SU#"AI)T H9KL? 9A]',#T%(#V
M60"E"P!2/P+PK@*P?P.@WT3OORV$< 'NH//?E<,-L3INAM#Y'\X ^'UR<S;Y
M<"B.XPE>^$\7(H, S["PSW 2SWX'^./-?YF/O2_"VJ?@M\,. GC@G&?AG$UP
MR)J7 .1_ I#X%>=^ X!Y&[/O([__Q1,FOK<HO@\?X+DTP$ME@%<ZN$DW!WB/
M&]4/>%/^B#>C3Y//I. 'SN<U %]V(3@Y<OV_E$R>06'MPP\#>&+VK.\!C''.
MZC]C[:\!\&_AW.]AWD/D,?('\N8OWB+OD ]"7\]D/HOC>V)-B 9B\E5:_OS9
MG,EG4G <I.VO9U*PZ&3O?R$R&NCZZ)<2" ^]GZ4/!-!W80[BC40BJ4@A4HTT
M(8N0;F0%LAI9CVQ&=B(3R$GD"G(?OL!+Y,N?9QV?D(__ R*OBD-7QK$@?/Q:
M1 L(8QI^9S;B@80BB4@N4H[4(ZU_G<7T(@/($+(1&<.L/?B^1^$#7, 2W<92
M/<>2?8)7^-U)7OX/B!*ZOJ(<C@.14L!:8#TXAD#85D"8SD!H ?AOQ2 92-%?
MM6A$VI$E.,/EF#"(F>LP<S.\QEJ\A(.8? ;;=AV>XC^/X3TNG\E3&80B\/!?
M$%5T?14I'(<D$%EIK(<2$$E=K(D%$"[V@X/]8(<#$4Y&<N&+4!E\$JK#)= "
M[X0ZX VK&UZR^N$Y:PT\8VV$)ZQM0&X1XN;@$./K[^/LYND$PNQ'K'WP@/4=
MW&/]"G=8C^&6\ >X(4+@FBB!WR;A$/AU"D0#[5^##T2-!T097Y4%.$)<-0(3
MK)0-KAPW^,0/@G=BL?!*+!V>BQ7",UXE/.'-A]]YK?"0UPGW>7UPC[<*[O#6
MP2W>%KC!VPW7>,?A5][/<(7_&"Z)?X#O)0B<DR#46>2,)*%.3R+Q%:(C!D2'
M T2+#42;BZ]8(0WLF*HN?%2<#J_EY\(S@0\\D@V'>S))<%LF&V[(E, UF1KX
M5:8)KLJTPQ69I?"CS JX)+L&+LB.P'G!3C@K. QG!)?@I/P#ZJC".^J0 J$.
M*!)J0I'0]D^B\#?$ /,-F @=B!&.PQ#KH2<-;[55X:F&$=Q7LX:;*J[PBTH@
M7%:-@8NJJ7!>-0_.JI7!:;4ZZCNU9NJ$VB+JF%HW=51M@#JL/DP=5-]"3:CO
MH^W7.$W;HW&;ME/S%6V[)J&/(5O^8O,4B GKZ\5M-OF#;S1X;R8,;TUX\+N!
M#-S448>?=,S@@MX<.*/O#2?TP^"H?CQU2#^#FM OH/;IE]/VZ,^C[=9OH>W2
M[Z#MT.^E;]<?I(_I;Z1O,=C)V&QPC#%J\ MCO>$SQK#A%^:0(6&L,2*,U9,8
M_LW7;/R@L\0/)KP!W$*N31>":\9<N&BB *=,#>&HN0U,F+O"'HL :I=Y)+7=
M/(FVU3R+MMF\D#YJ5D$?,:MG;#!;P%AGUL5<:[:<-62VEK7:;*O0*K,#0BO-
M+@JM,'\DM,S\HU"O!1'JL2"L[J\PO_'G7WZ$^8_P0^[Z7(#+R/=V=#AG*0S'
M+:5APEH;QFUFP+99#K!YEC>UT2:$MLXFEK[6.H6^QCJ',6A=S%QI5<7JMVH0
M6F[5)M1GV2W<:[F*W6TY(K+$<K=(E]5IT<56=T476;\5:;,F[(4V1!@1FLID
M_G/,OXTWP!_=T#[< 8Z[H 7-8<!>.W'8/D<--LTUA?4.MC#DX$:MFAM ZY\3
M05\^)Y[1:Y_.[+;/8RVQ*Q7JM*L1[K!K%EEDNUBTS78YI]5VF-MBNYW;;'N,
MUVAW@S??[A6WWIZ((B+S[ E[WAPB_ TRZ^N-[U?,/HL?]D=]T4312L?=*!AS
MYL%&5T48<C.$56[6L-S-B>IU]:8M<0FA=[I$,Q<Y)[':G#.%6IT*V"U.%2)-
MCO6B#8YMG'K''EZ=PVJQ&H<M_&J'0_Q*QY_%*QR?BY4[$6ZY,Q%%1!#V-UYC
M#>ZY?CT5.AF(.W^TP5WXNA7'LL%3%%9[":#?6Q=ZO6? $N\Y5(>7!ZW-*X"Q
MP#.<V>01QVKP2!6N=\]AU[J7B%:[U7 JW5IXY:Y=8J6N*_DEKJ,21:[[)0K=
M+DD6N#T5SW<G8@@7$?T+D4E>8/]O> *<#\#ZHPGN#L=\-/,-P;C[]Q>"Y?[2
MT!V@"8L#S* MP)9J\7>A-?KY,NK]0IBUOM&L:I\DX0J?3':9=X%HB7<%M\BK
M@5?@U<'/\UHAD>.U03+;:X]4IM=YY'?)3._/_$P?PD,XB.@WGN(Z^!7G?"H$
M:X FN",:=][(4 3N_H,9L#18 CI"U* UU 2:0FRH^F!'6DVP%[TR*)!9'AC!
M*@F,%RX*2&47!.2*YOF7<G/\YXEE^;6)9_CU2:3Y#4NE^.V23O8[(YWD_U J
MR?^C>'( $4.X".<;CW =7L8:',?Y[T4CWXHW__7(2ORZ&W]O43@?%D0H0T.$
M(=1%6%)5$7-HY>'N])(P/T9A:"@K+S1&*"<DF9T5DB6:$5S,30NN$4L)6B">
M%-0CF1 T)!47M$,Z-N@[F9B@^]*QP1\D8H.)6%P(X2%<A#/)?>S#1:S[89S[
M+MP$;4K&&B#+$W'WC[_7$LV#^3$*4!NC!Y4QTZG2&#M:8;0+/2_*AY$3&<S,
MC(P42H](8*=&9(@FAQ=P$\.KQ.+#F\5CPI9(1H>MEHH,VR8=$79")CSLKG1$
M^'N)B'#"CPPG/(3[C<E3PG/8_P-Q -LQ>T,:P*ITM,!4-""L1WT\!ZH3!%">
MH W%"690D#"+RHEWHF7&>3+2XP*9*;'A0DFQ<<(),6DB<3%YG)CH"EY4=*-X
M>'271&C4*JF0J*W2P=''9(*B;^/K6XG@:,(/B28\A/N-:]B'[Z( ]N&\MV+V
M<!8:2#8:"+XVI !4I["A-$4:"E,T("_5!+)3K*B,E+FTU&1W>E*R/S,A*905
MFQ0C')V8(A*9F,,)3RCCA2;,YP?%+Y8(B%\IZ1^_6=HO_HBT;_Q-?'TCX1=/
M^/[QA(=POW$U^.L)W3C.>Q2SU^1]/959A*\U:,BE&4S(SY" [$P5R,@TA-3,
MF51RICTM(<.5'IOAPXA.#V9%ID<)A:4EL4/2LD2#TDJX :GSQ'Q3%XE[I_1+
M>J6,2GFD'D*N27FDO);P3"%B",\KA7"_<2G\ZPG=]DSL QKQJN*OIS(+\+4,
MQY&'9.2)06J>(B3GZT)"O@7$YL^FHO.=:!%Y7O2PO$!F2&X$*S W0=@_)T/$
M-Z>0XY5=R_/(;N.[92\7=\D:D7#./B#IE/VKA'/6*W'G+"+FDD5X+IF$^XVS
MN/[WXQK8BEEK,7M%Q==3F49\+2K%?/R]I!(.Q)7*0DRI)D2538/P,FLJM&PN
M+;C4G190ZL?P*PEE^I3$"GD6IPJ[%^>+N!95<9R*%O <BOK$YA9MX-L7[4>N
M\NT+7XK9%Q+>G +<LQ40SC<FGU8;QQZ,X+Q78W9/S==3F3HDOQ;S\==1-<(0
M5B,)(;6J$%1K  %U,\"OUI;RJ76F>=5ZTSQJ@NAN-5%,YYIDEF-UKO#<Z@JV
M776SZ.RJ'LZLJG5<ZZJ]/.OJ*USKRN=<ZPK"042MR__F$-9@6R' .LSOQ]S.
M^6C#C0 530#92"P2U$2!;S,/O)OEP:M%&SQ:IH%;BS6XMLREG%O<*<<6?]K<
MEG"Z?7,"8W9S%M.FN91EU=0H/+-I*7MZT["(1=,>$?.F'T3,&_]@FS<0MOE\
MI/YO]N3B9T+YUZ>#>IHF?SH*:[!P\LD8M*%%:$,= #YHZBZ=(N#8*0D.72HP
MITL?[+LLP*YK-LSN<@*;+B_*NBN8LNR*H<WH2J-;=!71S3KK&=,ZNYC&G4,L
MH\YQEF'G19;AXF<L@T6$9=".M!&A;VS'GJ_#_!4HJXLQNZGC[U.9N!ZL01^
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M4&M?H<:]PB3L*A?<J](643[P5]G15^C<E4,$]?;EN\1OA/AOK&9?+Z3O73N
M.OI<0.[D$T#8:?*3<^IY8/)%8"QUN>&S@.[S@.(%:NU;U/RWJ/EO&0,OTHZ7
M:,=+M.,53^ V[;C-Q?A53O:O<I)YE8/\53KX*AM]]3;Q#7__!_%H!(LWJW;F
M-!P BNASRAGRTU=/RO(I5X&)-'W,#<#@%J#U,KGO$&\04BWD;0TF0'K NT;
M^Z9,2B<!'U$L?,($_3/:\1D7HW]Q\?L7)[V[#/A==N[=IYD\ODE\3?P\@M[=
M0!/#5'**\P"YP^FOYW.J73'FY#5Y!=![C;Y+G.\1'Q'2[I3/B+M2/41.4:(-
M?&7 Y)@Q^6X\A8H-DW57X!?:\0L3@U\Y$?_*2>\W=OIO'%B_T\'?&8_?/QY!
M"\=9*?LZG?&.O 9X,<[V]'<"_34BK\[C^LMGZOK+XQTBWZEWB?R[%J)@>SK
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M4WO.9S\L (J)5"*:""#<%VAC^@(C3%LP'LX+;."TT!F."STQ=6$0IBR,AL-
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M)6*=MHBU3^"AD>H"HG]Q6GF;>)GO7Y!*T)HZN"P?C7,*2YS2<,$Q+3\<TH[
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M[WWB)RCGBM#H4V$3_1R:PQC,Y_JP$&A>Q#E!?18HEE(Y<!G@2M@1%LNI05<
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M1>]C-.O_AB8#$8U/0+KZ^B4N_9?LR$\<X/2Z8R+S.TZU:PQE6*%K@,6Z8[%
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M5>^]]]Z+5:QBJ]F2;-F6;5GNMMQ[[P7;N."""V# ]!Y"+P&34$*H24C"'R!
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M(EQ="T8KY8\G'";I10T0?G.HRQ!ALIS07$N(&E:[2[^$_9Z'>3^"3QZB(3^
M+>[C&_>@^5UXRLQY_,PI9@W&31?H\.T/<Q"NU,T"7JA^BRV>4PXX96#44_Y8
M/:INFLADFLH ]9A#^0LI?QGEK[&SZSNT6[?I()XX2?E7$QFWZSHT.D>)5^&Y
M*^5XLM"P7.[4P>R!^< 9VG^T-S4O;!8 7A1U206G0'?#^^^$]]^N-LKOIOQ)
ME#^=;FLV5E\ QC(PUE#N%LK=HS/$Z"E\<BG?.HXMCE*3(WCRAS48R,7.JWD0
M]?MFB1==S+,NCN;_"^+S7FSQ,X6 %T\IF> 44ZMJ,$:#T09&-QB3P)BF$YJE
M8^AQ"7H<QB\'M8W(V*]]?+*77^W&.CN)ONU8>!O1;$X;OE#^X4T3IVO[C=71
MQ=U#L[X#?6ZBO5Q#&SFK<"(]":QL<$JH2RWU:*(.;:",UT7$Z1[TV(T>._'+
M=N)CJS;@E5W:B$;KT7@MG?IJ++I*+Q'%G]AWF:UPMG C9HO?<PPUCT; .\W\
M1XAC&OX*=#OIXDW= JE7%'5* 2</G#+J4HO%F\!I V<\.'VTTFEX8K96N0QI
MA<LJ+1NQ54M&'- BUU,:<KU>"]SNT_R1SVN>QX>:Z_DOS?6R:8Y3S!S,X_'2
MO4D,/<C5O#X=16Y%EW^QGXOV>%BTS2U8F]QCM=XC76L\\[7*LUPKO$9IF5>3
MEGJW:[%WMQ9Y3])"GP'-]YFG>3[+-,=W@V;Y[M5,WQ.:8;E6 Y9[-=WRO*;Z
M?:2I_C;U6W^4YQ(8;ACR[V!XN18YPW!WE)1H'UWL#E*"C0$CM=KBK^66,"WQ
M2]"07Z86^!=JGK5"<ZQUFFUMUBQKAP:M/1H(F*+I 3,U-6!(_0%K-#EPIR8%
M'M7$H'.:$'2W>H.>44_PA^H.L:D[U.:X(D^"?V\N_B?MN!(Y0==^,</,SC1I
M _JMP$Y#03Z:%Q2DV<'1&@Q.T4!(CJ:%%&MJ2)7Z0QLT.;15DT*[-#%LHB:$
M35=/V#QUAZ_0N/"MZHHXI,[(*]4>^3.U13V%O*^QT?]";#_(8^#=":^^K@P;
M,-P?X;J7]YM)R59ADT7X9W:TAZ9'6-4?&:[)40GJB\K0A*A\]4:7J3NZ1N.C
M1ZLKIDV=,=WJB)FBMMA9&AN[1&/B-JDE[H":XR]74\+M&IWPN!H3WT6^1VP_
MR,/4_3:PKV:8/PG'/EB##2K-'AAI:3X\(Y.Q/7F$^N(MZHT/UOCX&'4EI*@S
M(5OM"45J2ZS4F,0ZM2:VJ"6Q4\U)?1J=-$.-R4-J2%ZO^I2+-"KUM&I3;U%-
MVF/(6ZI)_Q:Q\=HA9A[H9G#/,L0?;X#[(]M(!=>8/3!\-A,])J/'^!0?=:0$
MJ"TE0F-2$M22FJZFU#R-3BU58VJ-&M)&JSZM3:/2>U6;/DTU&0M4G;%&59E[
M5)%U4N59-ZDL^U'D#>1KQ&:7<N0>ZGP#^)?#\2]I=N[#X?5*[LU'CP'TF$",
MM&=YJ"7#7TV9H6K,C%5]9HI&96:K-JM(-5D5JLZJ5U5VJRJSQZLBIU_EN7-5
MFKM2)7D[59QW0D7Y-Z@P_Q<J*/@+\I4*"VR\9V1&[L3^UX)YFK3O,!Q\-[(1
MOK\,OC\'/?K1HQL]6@O<U)!KT:C<(-7D1JDJ-U$5>1DJS\M365ZI2O-K59+?
MK.*"+A453%9AX6P5%"Y7?M%VY14?4V[Q]<HN>0AY!?E".24VY13;N&^SGXMS
M#OR3[<0":=].9#TI^1)TF8D>D]"CDUAI(E9KBGQ4412@LJ)PE1;%J;@H545%
M.2HL+E9!<;7R2T8KKZ1=N:43E5,Z4]EE2Y55ME69Y9<HO?Q:I54\H-2*E[E^
MKO0*&_=LRD!N >=*,P]DSL3M=IX'RW41[P>PQT1\TTZ,-! SY>6>*B[W5V%Y
MB K*8Y17GJS<\BSE5!0JNZ)"697URJP<JXRJ7J57#2BM>K%2JC<KN>:PDFK.
M*;'F/B74OH1\QFL;]Y!JFVX$YPKPCH*];R(4J(]<G^M"WD_C?@_V&8N=ZO!7
M:=U(Y=58E%,3I*R:2&76)BBC-EWIM7E*JRU3ZJA12A[5JJ2Z;B7635-"_4+%
MUV]0;/U!Q31<I>B&>Q35\%ODG[RV*:;>QF<V78?=SX!W9)*TIY]X).U<P74>
M[_M)A<=CDU;\4X-OBJ!OF8T^2FVT*J4Q5,F-L4H:G:+$T=E*&%VL^*9JQ38U
M*::I2]'-4Q35/%\1S>L4WK)?82UG%=IREX);GU=(R\>\MBFLV2'GP#@)WD$H
MV:X9](UF'0K7.=-IDU"3+CX;C2X5XZ4\=$EM<U?\6#_%C@U2S-A(18]-4%1;
MNB+;\A715JZPM@:%MK<KI+U/P>US%-2Q6H$=%RF@XW)9.^Z47^>S\N_X!Z]M
M"FAWR%EL?WR:X]G,AIZN->M0D%FSB07T&8LNH[!+";IDX:/$7A=%=GLKM-NJ
MD.Y0!7?'**@[68'=V0KH+D9J9>UIE7]/K_QZ9LK2NT*^O;ODTWM*7KVWR;/W
M":[OR;OG._ETV^QRV33'N;P7S8<*0T%60=6'D(&%M,EYM <^JT2_?&R3BCXQ
M?#^D?Z2L4WSE-R4 "9>E/UZ^_6GRZ<^7=W^EO/J;Y-$_7N[]T^76OUBN_=OD
MT@^_ZC<;^R%*4_Z*?"F7*63SDVTZ"<8AL'<MH5]8YEB',F\Y?N!U._?JT*>$
MSS,7P+_1*1P;!<QUD>\<;WG,\9?;G&"YSH[2B-EF8,E&Z.1GUSDF%F?CS-D+
M'!MK9L-KS!^59SU$HX=KSH3[SR23'+3I&!C[ECOV JU;^^,ZE&ZS#H5[%="B
M7"0)W2+Y7B!B0=R7>Q(X<+IE<*EE)$%+&>R7ICH&F:5T;$L)X*6]C@<N+:6@
M)?LI'+Z[^%X:/EGK$'QWR&:70ROI&\'=C*HK-Q.+6^B7D#:D%BE$4KD?O4D*
M0BR(.^^U>:2TB<1ODS\"M]Q$$K:)P7X3@^TF!MZ-=8Z#ES;BP(UP[@V[$(CU
M>HCL.HCIVH\9E& 3:VSV.9CM6[F] Y5VTB= 2;OVT"?MQ0=0]0RN,4BP?0T*
M^/O W^^4??#;?7!^^YH4]-A'LK$_$<$G^QF,]S<[.IU]!-L^E+_HN',]"H1Y
M]]^1[^QK4<QY+)O!7$KY@P?HDPX2A[B.[E592-Q1\!'+,<F-(DAN:<S(*>?U
M)/8XB3U.D1"?0H_3Z'$:/<Z0&)VA<SUM)J*G.P[!.07 J6OX/H3Z4N+R4EC%
M"9NV4:\5%SM"9B(XK6!4GI:R,5O<9>!?+OF>E5RAZZ3I)+S(=3^1ZR$'-Q ?
M-Q ?-Y(DWQ3A2$YO8<"]I=ZY+X> OF4;B0(%WWP7\B+?PQ\W?:?58,^C?I.I
MUUCPJL'*.2?%@Q5$^3XW2"XWF?D6Q,R%W.F<"S%"4?;U(69>Y%XS)^(F/8!-
M'B(Q_P7)Z*,DIH_23LX3G^?I9,X3V.<Q]&/P_O./\=E;$(K/M!![]H/=01UK
MP<P#+P&\H-O _YD3YQ[GG,OP?IS'G/+#?ASG',7P?,CSV.2WQ,@?T.-E$M/_
MJY#^C$]>H8V\0I"_BJ%?I?!7^<&K;VD:]>X"N^YFVL =](/4+QA,[^$S6"[<
MC_.,<Z[EMT[Y82^.'&>3F/-"WI#CF37O$:\?$",?XY=/2,0^)3G[;(+T^6*$
MX/N<2G^.\3XW;-S+.>]@YB',>@RS)\;L 3%G@@SOAS'G<9CGTYJ]*.9<TD5V
MIO1OF,WWL)WOX%3?PN[,F1Q?P<J^A'U^#JO^#-;]3Q3_!";]#[XU?![IF\[Y
MCZ>=\P _KK^X< V&.1/$K$<Q9Y)6Z5]J!F,<Y4^B[ '8\US*7:2/T<,\&^5#
M]/@[+.Q]&.![,,)WX'=OP8;?)'A>QVFO\>\5?FGF/LS:DQ><V&8OR /_-0<B
M^YS0]PH"+Y9?98)70AWJ*'^LWH7GO@7O?T,S,/M<O8H>?T://Z''2^CQ._1X
M$6;X/%SW65C^T_#,IPBD)_0<[OQ Y^VGI3CF/^YUSD'<]A,=OI$YZM:=;_N#
M%T$]DL'* Z="OX?WOX!/GE4/94^A[!F4/9>RAZCI<LI>2[VV$$)[J-LAW4<'
M<H]]!\C/[.>!WH[FM]I/CG4\T=B<9&O.P[CJ AV^^(\Y"%_P@O0;;/&D,BBA
M"(P:RF^B5AW4H9>RIU#V  AS*'\AY2^C_+7P]:VZ <9_'6SY&GQR%7?.\JO+
ML<X9+&IV4)G39"YUBME5]2_G_,L[SO!^SM[<W*F3/W4)!RL1G&QL5DIIM93?
MK&O1XQSVN J_7*GIN@*^?1EZG$&/4^AA5CT<IS._!)\<YIL'*>$ %MN')R_"
MVA>NOS#RF7-:T32U)^28"KW7WAWY8*] \*+!2J4>>6"448=1E-Q,"V@'HQN,
M26!, V,6J O!6$ZYZVDI.[6#3[>BW1:TWX05-^@/]IF\=7+,+ [+>Q[@,^S\
MBF[V?JZW>SJFI,]I)+_VHTXAX,7AX71P"L"H *,.C&8PVJEQ-SA]VHP>&]%C
M _&Q3BNUACNK[!J=P#K7:@D=ZB*\.T0+6DC4FUG.8?DSW>J3P>"'PCO-\L-
MQ];02]'M"'W'?EF)]G!M5P+UR02GD%I6H'^=5J/'2O18H?'@]($S78N)CR%>
M+> ;\[#%'*PU"X_-U!U$\>-$T-L:</E:TT?8?I#GZ4Y_$>,X!NLZTI#+HJ5C
MI"0'&'IV89<M;CY@!H(7!5:28"U:[%*D(9=*+1A1IWFNS9KKVJ[9;MV:Y399
M@VXS-#!R@::/7*FI[ELUQ?V@)GM<KC[/VS31\S%-\'I3O3Y?(K8?Y$EP[TUA
M^$J']R+'>7V 5&1G%*D']EGEYZHE7A8M\ S67*\8S?9.T4SO',WP*=9TGTI-
M\ZE3OV^+IOAV:))OK_HL4S7!,EN]EJ7JMFS4.+_]ZO([HTZ_6]7N_TNU6]]2
MF_4;Q*:V )O]^BCIU\_,'$P>0WR>XPR0/:1"FQGR5L62=F&3.0$>&O"S:JI_
MF*98XS3)FJ:)UESU6DO48ZU2=T"#Q@6TJBM@G#H#^M0>.$-M@4,:$[A.K4%[
MU1QT4DW!-VET\"-J#'E=C:%?([8?Y,$LQS!_%>G7"8;9 URW\WY=EB,]G(N/
MID>XJ"_8HM[@((T/CE)72)(Z0S+5'E*@MM RC0FM56OH:+6$M:LIK%>CPZ:I
M,7R>ZL-7J2YBIT9%'E=-Y/6JCGI(55&OJ"KZ2U5'VWZ0>TA!;X177\[P>@FI
MZ-Y*8@!^N[(0OH=-!AEZ)^.;\5%>:H^P:FQDF%HCX]0<F:JFJ!PU1A6I(:I2
M]='UJHMN56WT.-7$3%9U[&Q5Q2Y71=PVE9.,E<5?J]+X^U62\$?D<Y4DVKC:
M5(K\G'I?"^[I6OS \+H;V0C/7D8Z. \]IJ%'+W'2GCA2S7%^:HP+5GU<E$;%
M):HV/D,U\?FJBB]594*-*A*:5)[8H;+$/I4FS51QTA(5)6]18?)A%:2<4U[*
MO<I+_1WR*6)3OE/N .L<^)?"K2]NE'8@ZTB_EI *SN*S*478@-2P-=U%=<F^
MJDD*4%5RN"J2XU2>G*K2Y&R5I!2I.*521:D-*DP=JX*T7N6G#2@O?9%RTS<J
M.^.@LC*O4F;FW<K(?$$969\H,\O&>QOW;;J5.E\)_G%2X/VD7-N0-4W$(O<&
MT:,//3K18S1Z5&=XJ2S=JI+T$!6E1ZLP/4GYZ1G*R\A77F:9<C-'*2>K5=E9
MW<K*GJ;,[(5*SUFOM)P#2LT]JY3<NY2<]QSR#Z7DV>R2FFO33=C^"C"/CG'N
M!8(>K3)GD:#+=/3H18\V8J4>GY7GN:LPQZ+\G"#EYD0H)R=>63EIRLS-549N
MB3+R:I2>UZRT_"ZEY/<KN6"^D@K6*K%PGQ(*KU!<T9V*+7H&^8C7-L4C"84V
M78_MSXQQ_#ET3Q?TQ*Q#X3J_W9Q% M_B\S'H.8IX+2T=H=Q"7V45!BBC,$SI
MA;%*+4Q62E&6DHL*E51<J<3B1B64="@>DAQ7.D>QI:L57;974667*;+L#D64
M_QKY0)'E-NXYY!KJ>PK\0W#[7:3@&Z%GR[G.19<IZ#$._5JP4PTQ4H1-,BN\
ME%+FIZ2R8"661RFA/%'QY>F**\]7;$6Y8BKJ%5W9ILC*B8JHFJ7PJA4*K=JM
MD.K3"JZ^34$U3R+O\_I?W+/Q&3D$]C\!_@'2S1WP^_63B4>NLZ%'D[C?B4V:
M^$XENN9CD[2ZD8JOM2BF-D#1M6&*JHU59&V*(FIS%#ZJ1*&C:A4RJE7!=3T*
MJINAP/IE"JC?(6O]2?G7WRJ_AL>1]WC]/?=LLM;9= 7U/6;H&!1Y&[Q^#91H
MT33'7IR)?;1)=*M'EU*H8S:Z)+5*44U>"AOMKY#1P0INBE)04Z("FS(4T%2
M5,G:W"3_YG'R:YDN2\MB^;9LE4_+,7FUW"#/ED>0-WC]I;R;R1R1,V < 6_O
M#,>9M"MG$8\S'7MQ>M"G!=VJT:60[Z5WP[W0.:S330'MOO)O#Y!?>Q@2*TM'
MBGP[<N7342;OC@9Y=73(HW.*W#L7R*USHT9T'I9+)]R_XT'D%;ET?(K8-**=
M? K\@V#NF@LMGN]8AS+?G D+->N"DC2@2]D W&LJ-D"?2/P4V.<BRT0O>4WP
MD\>$(+E/B)3;A$2Y3LC4B DTH ET.!/&.@PY<0ZOUR)PS0EP_PED2+T0DUZR
MMQZRN![R.?#W@[UM$71\"6,$-'T6UXF\'[.06.2S0O1+HZ@8;!3"]_W0RVN&
MIUQGD/@,,,@/,+ -,, -,, ,,/ -T/$.$,@#!/< 7YX.QYL.<9\&H9L&B9KZ
M @+7[$>'?IN.@+,'W,U\;?4J_+":KW'M@B8W<*]T&?R;S^/1*PR*9$4W;V3$
M$#QJ"&ZY$$ZWD$%^(7Q[(0/+ CC5 FRQH XAB!9@P 7\<#X$?SZD=AZD=>YO
M&(P_0KXG^&TZL-RQ%VC#>L<ZE)G(!*1U@U2%Y"%)?!:Q3@K I-Z(*Z*U<.VU
M)'YKL,4:JW--"DG'&OCV&CK5U=AB=8MCLG,UQEQE-OL<)> @E2L@J<O?!_ [
MQ&8_CV7K9GZV%36WTR>@;CLR:B<^V"6E<(U$ A#OG68-"OC<)\'CZDJR@QX[
MT6,G>NQ$CUTD8KOPR2X&O%UT;CMIW#L)^!VK'0\@WDY<;B-SWDHFO05&L\6F
M'=L<TS2+]N RJ.BX_?B \"F!HJ<A44C (? 1F34HER!'+Q07A.3S*(G?4?0X
MAA['2 Z/FZ2,I. X<7&,V#PVY'@0T%%BXA+B\LC+E$=6?]AFWPNT#-Q!L'J.
MT!\=HQV<D#(NE:)/@H\+O8;7H/!S" L)ST_$S(U<[<8 ["5=0T)\+?%Q'7I<
M3VQ<CT^NI\.]#EM<AT.O0_%K;T7@_=? JLY]JY74;S9UFPAN"U@5X&2"$T/9
M 93M.3SO<H/,'ST%H7+,A0S+\-Z<X;F1NXC5>_#-?4'2 [25!XB-!XG/!QD$
M'J(!/(@3'Z#@!Q[B]5^X?JIY8$\">RRX5>?H"Z\'WWD6K<>M3HP[G?,MPW,2
M#SOE$>?\Q'DYSB@9G@_YM:OCK-87( J_)1G\+;'Q.P; W],!OT0#> E;_.$6
MA!^\]%?U7T$,@EU#/?/ C ,S $R/>R[ ?,2),;P>Y%E=L/9$/Y[5^K)S+L2L
M"[$_0P8]/L >'Y(@?T0B\@_:ZL=T?I\0%Y]@\$\PW#_-:@17YQR$FW,^Q.R-
M,<^G-6>2FOTPYCP.\WP8<S:J60LR XXZ#Z:T6'@2]KA>7\.TOJ2A?*&+X8['
M[2<L?(+S_@%;_1#C? "3_CO?&CZ'U,Q#F+T@OW3.0?SW_(.9BS%G@ICGPF;I
MWW#,;]4 1AMEF[TH_90]2-GS*'>Q_F9_-LIZ./-6Y[-1#F&&2_4:P?H*P?,R
MAGP)-OM[?FG.X##[7W[MQ#9S$#__'SK\2Y[Z"G[WF2+U,5SW(SCFWU1%^4UZ
M [[]JB90CW[]$3U^CQZ_A46^  -[#I;Y#'H\#>]_"I;X! SY5P3S>5 >X=W#
M:/F@OK.O_;C/.?]AUE]<=X$._W;.07R(;]Z1A;J$Z,_8XB4XYHLJH?Q:]&^A
MM$YL.(&R^RE[D++G4O8BREY!O=;I'ECP77#=.^D\;J<AWZJ;P3(K0OZ@ZZG9
M\%F@YHD^Y@R,4TX=Z#'MCQMZQQE6SQ,73RD K$APDBDA%]W+:1IUE-U*V9V4
MW4OI4RA_ ,_/H3Y#E+\<OKX.+VP'_0#=R:4Z#>));'$I)1[#HD>IK3E5USQA
MR*R_,*?L?N.<?S%;OEYP-JV'B<][G&LP;E4L=4@'HX#R*V#0]41<*W7HI/P>
MRI],^=.)Q-F4OY"REQ,1&XC.G7#VPUC$K JYF>[]8>W D]N)K&WZ<?W%%OM<
MG6.IU=/.)GBOL^NY 5M<35Q<3ALYI42=P"='X?U'5(G^]>C?HGW$QUYU@S$)
MC&E@S 9CB+)7:C/_-J+!.GZY!ENLQHHK:=#+B;!EX%XHKX^DR7M3=YKRG72U
M-[HYNM[+B(OCM)'#"J(^46 E@Y,-1A$8E2#4@]%"BVC76O18HSZM0H\5Z+&,
M]K*4.XO0:B$E+,!R\ZC9'*)TMM[6+%J:>1*V6?%EKB_2O3]*=_9SNI(;N%[!
ML',"?0[3U>V3!Z7X8:\0K!M+J2G@Y%"78C JM83X6*1F<-K!Z09G$A$Z ,X\
MRE].3[()+^W35"S93^1,QA^3\(>9Y30G$/4YY<E0[&^.P&*(N9)A]T0$N1U#
MSFY2DRW89:V+-W6S@A<&5ISF*XWZY()3#$X5.'6@-F.!=K!ZB-(IE#^3LA?1
M>M9R9S?:'=<XE^O4Y7*_.D?\3AUNGZACI.T'>=3,P20RA*7 >Y'#O-[-O<WA
MI![898EEA.:Y^VJ6:X &1D1HFFN"^MW2-=DM3WTC2S1Q9)5ZW>O5X]ZB\>Z=
M&N<Q09T>T]7A.4]MGBLUQFN[6KV.JL7[&C5YWZO1/B]JM._':K38[#(:>8"N
M_.8,AN1LAGKSYQ>&VVVD(&M)RY:0%LW%)@/^(S79QZ()WD'J\8G2>)]$=?EF
MJ,,W3^V^I6JS5&N,I4&MEC%JMHQ7D]\4C?:;K0:_9:KSVZI1_D=4:SVG:NN]
MJK+^5E4!_T1L=JE&[LYP;+\]4^A8!KNG +YG]L"0@BP@+1O$)I/QU_@ 3[7[
M6S76&JI6:XR:K<EJLF:I,:! #0%EJ@^H55U DVH#.U03.%'5@8.J#%JLBJ!-
M*@L^J-+@*U42<I>*0YY34>@_5!QJ^T'N8'@_1PIZL@SNS]"V@]1G'>^7<'\.
M-IF*G7I) ]K#W=0<;%%#<*#J@B,T*CA>-2%IJ@[)455(L2I"*U4>VJ"RT+$J
M#>M12=AT%84O5&'$>N5'[%=>Y!7*C;Q3.5&_03Y43K1-N5$.N=6LQ0'[.)QV
M?S5^0-; LX?08V:>8PW(..*D)4ZJB_16=815E1&A*H^(46EDDDHB,U0<F:^B
MR#(51M6J(*I%>='CE!O3KYR8><J.7:/,V(N4$7>9TN-N5UK\4TJ-_SO7?RL]
MWF:7FZCW%> >)?W<6^\XBW45%&6!H0@EY%?YT*(L:31Z5,5[J#363T6Q02J,
MC5!^;+SR8E.5&Y>CG+AB9<=7*2M^M#(3.I61,$EIB7.4FKA**4F[E91T6HG)
MMRDA^0DEI/Q-B2G_XKU-28A)]\Z ?Q@^NYOT<^-H8H'7\[@WC<]ZT'$L,5)/
MO):GNJH@R5>YB0'*3@Q59F*,,A*3E)Z4J;2D J4F5R@EI5[)*6U*2IVHQ-19
M2DA;H;BTG8I-/ZF8]%L4E?$KY%U%9WRGF P;]QG#J/,I, ]"!7;"\S>8=2B\
MGHLN4]!C/#YJ(59J\5D)L9J=[J7T-'^EI04K)2U2R6D)2DI/4V)ZKA(R2A6?
M,4IQF6,4F]FKF*P9BH(@169O5T3V"87EW*30G,>0MWG]K<)S;(I KL;^)\ \
M *?>T4$\FG4HYD_5Z#)IM#F+1&JN(=<C9HJ(D<P\=R5G6Y20':CX['#%Y<0J
M-B=%,3G9BLXM5E1NM2+SFA6>-UYA^=,5FK]8(05;%51P3($%-RJ@\%'DKPHL
M_(9[-KN<->D_^/N@(MO@^&O@UHOAUC-)_2:B1P>IZ&CL5(5-"O!-6JFKX@I]
M%%UH551AB"(*HQ1>F*BPH@R%%A4HI+A2P<6C%53<I<"2J0HH&9*U=+/\2R^1
M7^GULI0]C+PF2^F7O"=S1"X#YQ+P]T)/MTQTKD.!Y\_@_03NMV.3!KY3CJZY
MV"P9FT17>BJTW$\AY8$*+@]74$6< BM2%5"1*VM%F?PKZ^57V2Y+U61DOGP@
MC=Y5!^55?4X>U?<C?Y!G]2?RJK)QGSR&^AXB]=\-I]_4[UB',A^./YWW/>@R
M!KO4\IUB;)6)SQ+P3WB#JP+K?&0=997?J! D6I:Z)/G69<FGKEC>=;7RJA\K
MC_J)<J^?([?Z-7*MWR^7^BL);DA"_8N\_@?RO4;4V>QG U]L]B--E];/<*Q#
MF8M,X_UX]&F"IE7R'=RK%.P2C5V"Q\+_6SWET^(GSY9 >;1$R+TE7B-;T^7:
M6J 1K01R*PJW]IB'VB"0^%;(9"MDK17BT (Q:(%WMY#!M=ATE#KO W/;+,:(
M.<3C7/K'N8Z]..W<KX.6E*!+)GK&HT\8MK%2M$^WAT:.M\AE7 "=&)WYN!A'
M9S:.#G8< 3R.(!I'8(VC,N.6(I#E+HAC%QE2)QE3)]E;!SITV!QGPH"Y>8%C
M'8IY-O$@]+2']\W0D4ITR4._9+X7.2 %4J3O5,E]*IRNGT1C"H/\%)*/*1&.
MB>W)#$"3BQ"">'*[8V'/Y"''HHI)QZ4^^%7?$P0\W'\".DRPZ>+YCKU &X;7
MH2!3EF,#WH]:0GODLW2*B($J!O-="WIY()I+DC.7!&..Q?QQ@<8<8A8Y(@PP
ML['%;!K1+/PQ"\/-,HM\-M#8(-6#$+H9C]$)OXM\2^#9M!<S;5WE6(>RQ*Q#
M0;IYW8240PVSD'@^#\6E?H@'.FI8EI,(+B<17$XRMBS L29E&0/<LC0$6RRE
M<UF*/Y;BU"44LN0 #1]BN0BR.@097/@U@X)-.]<ZSJ0=7H?2MY6V@%0C>=ND
M1*YAW/='/!"2R1_%O-^"'EO08POVV((>6]!C"SQW"X/,9@:_S:T(P;0)@V[:
MY3@?90.9\WHRZ74PFK4V;3-GTD)!%Q R_=#R#L)WE'DFSSYB  E'_!$/L_:$
M:I"TT[$[Y>)AP2\7>W(//0ZBQT'T.$1"=HB!]Q!Q<1!;'"2P+J:R%T/T#Q"7
M^Y^C,7R,V+01W,5@3@=C'.4V'*8ON$1*A9Y'',/^/YR#(L?ZDS/.^9"?BID?
MN0*;7$&<GB4QOA(]KDIV_('H*CK;J[#%E039E0"=O0Z!R%_Q-_N>G&748Q#<
M'C!'@U-ZFOZ8,B,HT_\*:>1/UZ#<Z)P+&1;[GASGW(@YK^1V%Q)4+^<9)22E
M=Q,;=^.3>QB([L86=^/ NZC(7?15=_T!^42SJ>N$DW05X):#ET'(1%Y+_:^7
MW&YTEG^;<Z[E;B<)NE\_V8LCQQ^(A^=#S)J-)SP@3NCQ&Y+V9QCXGR4^GV,@
M>)Y&\!Q.?9;"G\46S_Y5D\ ><Q7] '7,IE[18/KC+K?AN9?A_3B/Z,?U(+]V
MBID/&3Z;Y(4+YD*&STY]$]^\BQ[OT5;^QN#_/O'Y=]K(!\3%!U3\0X ^_.5/
MN+]9#V+V@)AGQ9@S2<U^&',>1Z/,6A#'7I1^6-),?0W3^!+6\06LYW,8T*>P
MR'_"QCZ&5WT$"_T ![Z/ =_#0._ I-^&<P^?P_&B<PW&P\XYB/^> S%S,8[U
M*/^"SWP#Q_Q"-93?3-E=E#T1]CQ5[Z+'V^CQ%GJ\"9-\'=;W&GK\&8[Y,LSZ
M)?M>E.LQS]VPS*?Y][Y][L.L?GG,.0=AGN1[R__0X6N-I$Y^^@>\ZN]PW7>Q
MQ9LJH_PZRAZCWVL<]9BHY]'C6?3X#;SNU_#+)]'C<?3X)8ST/ SU$;C5P[#T
M!PC6>WEW-R7<9=\IY)C_,&LPS'-(SEZ@@YD#H+7:MS:]+A_]48%@18.3"D8^
MY5=2=@.6':N'T.-^]+@7O]RC0<J>2]F+*'L%S'8#J#MH,A?#W4_1E*ZC2=VM
MJPB<*ZG9\%F@9BV&.0_C$J<.YAR0OU\P!_$4<7%>_F"%8;-X,#(IOPCO5M$4
M&RE[#"5W4?8$ZC*%\@>HSQS*'\(#*RA_(Q&Q&XPC.LK=(VAUB$9S,1%Q@&@R
M)\H8,>LOS%.7/Y=C.=-+SE WS>L>N=C78-R$+:ZSGX.1!$8VY1=3LVJZJT;*
M'T/YG93?0_F3Z3:G4_YLRAXB,E>BP6;*OPC/G*!;OY9W]Z#9"WCKG_^Q!F.U
M;/;YG]\ZFYUI\G<XNZ&KL,49XN($;>02>/\A?'( WG^12M"_6KOPRPZU$(4=
M8'2#,0F,Z6#, 6.QUO!OI7U7RB$MQ1:+J=4B/+J0EK* :)\/MI$%B#EFZ%<>
MCC- ;G%W' UENM[C]B'!&TPK]0D')UZ;:"<;X/UKT6,U?EFE>BS?HF6TVZ7H
ML1@]AO#+ N)C'G?GV%>&7$3DGM0,^PZBAS1-KQ+-7]J? M7OE*<99AZ@>[^5
MH>9JKB=Y?QA]&$*HYTA*L8 92)TBP4F@+NG4)8\ZE(!3!4X].,W@M(/3C0:3
MP1FD[(6\6JT^2IF )7OMJWCNT7C\,8[H-[OOAN718,?CT*XURQY)A0Z3ENU%
MGZWHLA:[+)<G=?,#+QAO1U%Z(O7) "</G!)PJJA]/:VD&:P.<'K19"IESR%:
MC(7,KIV#1,]9M1+9+41\,WU%,[U=LQR[ >^/8MAAN#_+4'LLT;$'9AOZK"4M
M6HI=YC,,#KIY@VD%+Q2L&%"2P,D$)Y_640)6%5CU8+6"U:46ESXUNPQJ](A%
M:ARQ7O6N^U3G>D:U;K>IQNUQ58]\1]4>7R,VN_P<W.L8VDZ3!AY"=O%Z8Q+U
MIXM?@'T& \GM+*[J\?15U\@ M8\,TUCW6+6Z)ZO%/5--'OD:[5&J1L\:U7LV
MJLZS3;5>/:KQFJ8J[_FJ]%ZC<I^]*O,YK1*?6U7L^TL5^;ZM(LLWB$W%R&U@
M7L6P=H)TXT">>0X,-H#O+R9%GHU]IF*37OS5[N^N9E^+&GT#5>\;KE&^<:KU
M35&U)4M5ED)56LI5;AFE,K\6E?J-4['?%!7YS56!_RKE^^]6KO64<JRW*-OZ
M*V4%O*/L@&\1FW*0F\&_ EY]E%1C+UQ_,]=5O%](*C8#_2:1*G?AKQ;BI"[
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M60/RL+,IWN3LBDYCBV/$Q2':R'Y%4(\$,#+0/U];T6,S>FPD3M?37M;!M]?
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MHQH_8),P;!)0,%*^>;[RRK7*(S=$[GE1&IF7)->\+(W()Y#R,6*^F;B )!=
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MN!;P L *!2N*.B6 E0I6-EB%8)6K"&T*T#(?6^1BO1PB)XL(SJ0UI=.RTQB
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M#$8TY:=0=@[Z%U-V)677V9])<A#V=P!.M0^>>Q&\:@\,?!?VV*$58)C3, [
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M$2,AJJWS$!4)>&8 GE%"/\Z#]0/ACIO(CU?$+;]_%PP(QT$_'0#ITS[0-R+
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M'5=#JALMM*)/W/P]NA]BE]>HK+-Z@@U\4!#&N C!*A^77%^^00"1ACGTS+
ML.&O_A56_@$V>"4^P "),  7$@:HA $8X;,<$S  90U<2!B M!P.X($!BN$
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MRA9F<4=AY;#9!0B2@ EQ PZ@ABTO/(,#H I,P#06X 9,"#(XX"(,(  '(&"
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M%VM*'-!DX;G#,JP_]TB>PBJN=]VSOJO@#SW4.6;,SB:&9:QQ<(N$KF(",K$
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M7/FK"G.UU#D@)<3+P4)/M8T0;1;;,0"]6[#&#<R@Q+$!F(-W@T2J$P.0CPW
M#&*&L18XH41,(?2Q +"U8.S9'E@&<AT+H(\):.2$ ^1@FM:& W@P =CS*%0P
MP"VLI1P8H$_G;P"H</AT,!S08O@W %36[YW_)*SBNB<VV(R>+*VL;^46%'V]
MN&63\XTF< <;_=^@B=;R^S>28R/#SJ"3H!-.#@Y.F%&,M:HH)R,%QL,5<PME
M,-;(@\VC8"^!P-9 EJ6P **84F)MTX G__!7U;#&137SWP#&L),UF*JP5EGA
M@,OX?P,HYX<#8&'\>ZQ5%/@[^[&,,$ E#/ ,[A_28 #4U753&%1[U!RPWE^8
M#F$EV\$KI6;J')R0U[K1X2CCU^^5-_5]P+THAR,TK2[,3HR]'4+V=7>^>-[9
MBSGEU9Y^,=#3V=K21%]'0UE>1E)42!!S'J63BQIK$02S_@WF43 !07\'R,=*
MM&!1S@#V7A'881<V6 #8!L@(+ !L,WH>UB(J[*7^EU@+TO 7YKS@ /A.\1N\
M, !LL@?5!7<Q8C  *G']%">=J '6(NH;+UH(PJ/<):1DYA%YIVF#8R2?N;L%
M1Z?GU_;-8)?A"$?_&'U[T]GTY%%Q_OT[63<STJY=2[T..RWCK)V)MK*<I# ?
M#P<K(RT%"2%\A1-[-QIL ;-U)Q8@$@.PC/4B"?PMCM-8 %@&<A<K!($M%C_'
M\G.<F( %)SB #*:JF.UP! Q0AK69# 88=84[8Q@ E;$^7*,2.H3UNLN UW<I
MB!CV*EKX7BG9X%2Q2C,5(SO?L)2\ILW>S^YL&Y[;I A'./JG:65Y:1E[5FRZ
M_$Y:8LS%L+,AI_P1/E[>OOXAF(M!$WHRPKSLS'14VXA_!?FPL8F='< &SC7X
M^B4<T(0=@F "9N$O[6"-S8M86V)A@'RLZ1X8H =K)A:NJ] =F.4$\.=_@>:Z
M4D;I(V?@-8R>^N%MR=CW&;C'%&UP^G*%V1YI30N7TTGY;9OLX"Q*?UC?N_GA
M\SC"T;^7EF;&AU_WO^SN?/[\^8NN_C<3L+/3RRX&^WFZ.-E9'[4T-S,U-3]J
M#WOMMUID%ST5*<9\+29@"K9_&L+:SGZ6$ Z [;',P5H#*<($=,)? X&N80*^
M!,(6,.![YE W,6=SMO#!3^QJL?XS3T+&?PB1#O\BJX5+PM\+R3EE31')&QW!
M7FO+N%=6Q\KG4G;#)GLT[X0DWJGXRPV<N+41'/U'T4![?75E><G#HH+"PN+R
M)\T]\-@YR<7NJ+FQOIZ.EH:ZFH;V(7,'V/:$;&X*8LPY2A-,0#M\USX\1?D<
M )](88<)D2$* U#  '48V]6WBEC 3U?]$++K5RD1C[9G2@W\2 ]4]O<( Y]!
M2,OIXH.>#68ANWQW<N_3.NH;D].RR0S$ Z_0J_=KD)M_OPUJ"#=W@:/_8U1=
M>._VK1O7,S)NW+I]_^&3M@%X;'_1PE!/6T--15E)44E97=?<&?ZN6KH@?!\&
M#% +BV+HX)NTQT^M2S!(Q(]%8IVNF*'PLY202\LSN08["VAP0*^BTNY5L3F7
MW;;1!JJ): D^>7VG,VF5FQU87(4(N7+WZ>N_6 ;M[-OX:&H<X>C_,"W.S\[,
MS,Q]^KIQ?/TU/R,E*3$Q\>JUC,S[)34OAN'+BVO1A[3455545%35U+7U+9S.
MW857<5OQ]SD4Q)*V,8^P3F=NL/\QU4+(H^.=6K?!\L1HN- /]W#V=NO&&RES
M#DEJ69]*?/ARLQW:G1<"KQ:T8$4FZZB['??R*8YP]"^GJ=%W[T;&WD_-;?)P
M7BVX$A>7D)QVZVYAY?,-QV":H;KF07V38]X7\UYNN(>AT 3:(7'(-?)!YR;?
M@-?F+F]U*KFT=]/X8#KCW.V:#<Z-_T/OVG'3E__!!$^4_]WT_T+[4<.*Z4X^
M/AXR0D)NWH+6=NXV]H*V[JY"_M8>0B*"PD*0G(*_A[7M"7L?-AM[1V>W_1PS
M%=4<;,YV^SE,)0X*'_10MG=RUCCI96]X4M?(]N0)6VD[#@5Y4CE_&7]7#U=[
M'VLV?U<7-V\9__T<WRN7 ;^C/Q;B8/L.\3FQGT,17<!F=O 0F[*[ESV;A*"8
M@*VPB B;I*2@B+B$I*0(/YNHL(BHD##X)RD@(BXC(2DC*L7VDSCD2<'_<EYV
M#C(&*FH_V8&_]G/\;)>?GY^@GYB@NY>CD(BTM#2Z&E%1 8 0\ YP\['V%W#S
MYOQ1R:]Z5.R];;V</7R<W=W8T'];V[C[^NSGX"!E6T<_V^7J<?#@;U8;JM#5
M56BC.[U]5!$^?WVGMU& A[V0@;VWNZ^7K;TJPM[-AW/CJ@SL'?Z1J@#\3Y/1
MK?[>#!D5=UM?5\!$4T4>?"!HYVPG(R*LIBPLI20AND]20E5)1$1:5&6?HK"T
MHHJPDHB2F(2PG!#6K5C5:KIY^UB[V=K_K-895"LAHB@L)BXF(BK]U]6NNQ6K
M6CTO9V"0UB[K6$M+*DI+ 8E%I564Q224196$I45%)<5!+"HEK22JI/*KV@UN
MQ:I>P]G;Q]TK0!Y#W]_-P]#>$_/37P4NSM_-Q</:R]L>K>_]'+\4SH%U _J>
M[R8@8VV+-C1Y;VN$O9V<$,9GF]_DC*U38;6_ZRJL6S>OW\_)WDU>5%A41$!8
M%/PS$A&3$9:0$1'C _^+_:[J.VKS2KS='7S\K+WL%1V!CN5_#/-#3NX^[MY.
M[AYLRH:2;+RFSFYV[G[>>W[5B'G+YE7;.EF[.=K;R0O]NO'7!U@=(_2C9_Y_
MZ#%;=S>$O9?//]!K@(\U\'[V7M[R#E[NKFS.KM:.]D+'/>P=V7S<V:P]/%R<
M;:W1=0@AW.Q^CF*/7PK[Q65=)?_&QMK9>SG_(P:Z3LK?>F+[3VOT?WM,_KW[
MQ(W)_[=Z3$+X[YY,__T>D\#UV+_2B_Z-"T%[F1\^Q][#V^%_BQ?]#VKT?W],
M_FVTB!N3F)]BAJB_PE[LD/97X/_#+-70AO5?ZV>Y[SG'/^M 8;=N5+/=/Y.+
M8-VZ4<WN_TS>L.FMV%I>I\S?6:40+*W\9]--.]O?:9Z'KY?+]Z36SE;(WL4>
M+8XW2/5$A# 2.SM;&0=W+U=K'_GUWN#/I_]J 7\[H(W3T=_%WY-2#$E_%\DH
MN[NX>QUTM[.7%Y<3VNCC#>_25%8^Y.7NX.QB+V\L:"C(9FIOPZ;L;HUVF+R&
MIGJ']K A1-=7MP[_KU8"L(._SL;AN;>,LI<]D%0%7!BN241&0EQ&0OJ7:X(A
M874 U3@[!&#5 7-O,"2\#GL?:SMK'^O_4BWKL7^IPA^?&JBHR9."6W_-#&WD
M __UA&."8X)C@F."8X)C@F."8X)C@F."8X)C@F."8X)C@F."8X)C@F."8X)C
M@F."8X)C@F."8X)C@F."8X)C@F."8X)C@F."8X)C@F."8X)C@F."8X)C@F."
M8X)C@F/R+V9"^N>L!7LWN_T<?AP*\B@DI SA_3<)7<E_MPX\U!.(>BOT%?\(
M 1XUA$^-1T"-AZJ#=D%X$!XA 2C_?:S%UBU$Q"1X!(3XI-L P(P*E./C0P2$
M6[:0;B7=2@QMP2<@),(CAK:24-/0;F=BIQ,Q37I)SZ!H-LO(H6\=?^7JC8*>
MW:+FGF?"8I]R<O.*2:G;ONB<X]JGK&'C5SPLH63@<"XN$=3,"GCB;5G/&2+"
M(]Q"O)4 GP04'Z$&C/'P"?$ VZTDI(3$$#X$I-I"1$U,0\LNLIU>47^6CH'#
MV,3:\\R5KJV,G**Q<0DW=HN)*Q4\[1GFXE8S37S1V3TG(:FLHFI@8^]SUC<T
M_J&AD:V=U_DPU"N(C  /:(& &E* D%+'EXM?W5.P\SLBG_TH%YHP?AQI1T6F
MHO&$CM&CS_OU<7$U.C;9CKLEE@TTJ8\F(MM%ED?'%>2IU5%0.(^W_-"#76U\
M5J\/<P0JRB8OKGJL.5NLO1VF?4ORNJ-TXL(GK=XO#%LSJ'3'@JH/*Z285)>5
MJ7P]ZR<VM32\TEF\6E_#4T=;GN'>2SF6D#<M2"W/EM:Z'%P6(IX;XND1,4<X
M[8A<J/V6=6(Y\KS>OYR9:UXMLN[,0#PO(GZ2J8$V)''IUHL2LCK5,SM&)MH#
M"LP5KKZ/(>*ZU5U92'_"134L(%-<HOOFT_!G<JHEKCG:0OD+"S?3K*HLBL]T
MV1Z.VK&JA6!&:!6H")0.TYWN9^PBUM$6W:'D0)E!UU?']D!'8C3U\857LT74
M>H0%A)V]8@S'TG<>S52M>FO;6B=45.2VN[U.-G+1-[9N\ )S7#:B0?ZVQ>.
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M]>5=104AT@*->8S=2--C)WA+96[775)[F)0KYI^IXQ%JT'K&ZW5TW UN&61
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M?(H-2 ]'66XQW&K0J'9A;ZR+U.EJ77FW U1K)3>#)&0@S9W4'SZ,R'CLOU>
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M-5WFCZ7)[([H1AF'Z1,PX!7V2/<5/G\[T<-^.:S2K_ "X]6'_;9YVR7)7QW
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M+5"]-J$>UU\".*2O2"OH1XS3Y6A#DT5$<\7%/PPN\'C2PY%]>>CZ$:W07L/
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M_,0G+SG.1VFK,SB67<RF"^>"+-LA<Y(%FLJ2_<@-R-=96"SL&2P!U\\R(YL
M68.1!2WB[4H$7WHMV-(X7HE5"Q4.'^<*6I'WJT 98TN$W4+M#A5P OOW3%\7
M/;W @$X_XYS6!T#$_>FV3BY<40BAVP0RMRH1700(N+\,#KK-L'>]0?NWX1Y+
MF:-NJTF ^UN[X*"F$^EX-$C8+D3)'K6 =7]FNKG0>KJXL8L\1P":7!<B]M"
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M';[62/[U,BEH.=W4^+F.X]'I%^6MJV,E"=_#;7EURS')*(7(@)A63]4WQM)
M*S( O   -UAK7NW#::0RV,G^9L[<@I.&$O0G_YE"S-<TC@&O4*4B\(II3E)X
M3<;ZXIA?O.J;-:TYAZ=RHU@D3=:? B/(1]EFN5IO;)(=$O+Z;]/]C-8HHU\/
M1',WJ/.$)(,K')[3*-A;XM1Q@'[E,5TKU]&WL/-:U8XS7048;-.P35,] HHQ
M P9J&-\52HSS!%M(3#MKL"MRM^!8 :B(6CR/Q7]VVS:<L8L<!I2;H&+%3XK\
M-N-Y/%'RO_M>8F<)03?4UX>A4!0RU?B"WM?QYA,!>GX^)$'TU?G*"LOPLYN\
MZ#L,3P.W "3CH?)-Z<PB2Q=VCQ8*,V%A8_6&;F>3]EI"_O+-'0:HSGR/=3^H
MN)V-KL$(O3[6A=^C<X\ZN,,8WU@]NL.P7]_,N,<J7,K^C2VZQ#^_WKK'MTH.
MT[29Z3COITAA!E-F79T0T+6-#MP77# MPWWW%%'[<RY. K[#L.[8UPK893Y\
M^]<>N*0PS2A#+.2#SX7I5L=V5A<C(@M>TYT!V6\&=JYT%LZ5K[6E'1O/1PH^
MTX67S1+@+]UAE+3U71ROGQ[N]_1JI>+=86B*D]RNY)__5%LI1&O4M&O]C:2@
M.P&,#B2@VD/6!SKP"20"ET+@L]5H(. .XY,_T0):)5!7VO'>^@=R!Y/H1\SG
MD/NJ.<K_FY4YJ$[Z/P5 H$\NZ"^<_"YO+08O[S".O3QN)=:#+GRCCC[=*V'5
M,:_S=RRIFG6A5DGS 9;_$"OD7JMKOYL0\W]3]38!+4YRWU6OI!9"S]O'S4GP
MYP!!1ZM+8<OE9X^5]O^*^B_4^R3W/V3TR9WEF >VW&?2*>C?,RGM=O(7:_-4
M[OMH5R&)=Q@^T'OB2BM)_T*<NPTY=''^E^C7A2%E\RA]=/QBB^1^P[\'S/J+
M\=B-# $:<1]1JF;EJOE\^;_L\5^9X6X*)&@5-/ K2_GZJDI#)((PHJE_V:]D
M_7EW;8:1Z?YK[T8_/\[&558CK]0*BGZO86ERD4C4RE4H!-2TF]#'WX0^MW=2
M1^W^ >[!H+O(]\U!Q6%P!"$>"H4:LYH VR]")!#B_O!KO=\5C;\$7]#_.'5?
M99\:/ABDEWF(^USD-WTO3NR\S*K2FTC$N\+N")+2V3B*\!S'],14>BQ-WGCG
MJ-)LZ/AL'4?*;+Y<MM\&7[)A26)N<;HAUGR\'(LG XL/BX]/T&2WR&HX3_1+
M\I58 \;8)Z$83YH("$CM[C_W\P!T&#3&?);+X![5S8+Y_Y_;*D5_<.6JM,3J
M>H%T/O]Z;D@!Q:4]79$$PV:H)H&(_#)1J*[7V0N2=_P)\-&HZH?DW<7) A]2
M>1\J]6MZA"GG*G_YO2QO*PKC*;.1FN/=3! ,/!S[DLA(*(IC_0 P",V4-YY>
MVX-"%S*"LOR[S/K*BZKTL"IG4S.M/K<J"8P37>!X*#+9:2U:$O@$%=@%I=<W
M2<=JJ6XKO5>;GG8NLQ=B0.H0O&YS+,J<>UP&B5U^#7WDH2WU525--+5H^E6O
MS!BSI4;MYA!;_.Q4IF]"D9%*/9#NV**_6R^R_8NK@6E;8#T$7 Z(-7_LO3Z\
M&\*N'9[<A^HUI#%,_(+_0@@!(?':-GL(SYNUJ:"2@LV/@G:M;U'F1)SU:-_?
M4M18,R_-^WE&P0T(=0U5-4/S_>2UFP_T7=.SWU4EVHI<I 5]C5KK"@3*10[/
MC=\9 8\X)=<..T+AXC+88-?YJ:ZKT3\HQ!7XU$9B<%F3H@#&Q8HNMP@12X_O
MT?(-D 8FL%K&)^V#4)H/%_(@+J;[SB&4Z''MK?R^DPZEDODK$)6A,WO8K8DN
M^P@Y0-,EDG!5K&%UC$W';5G4/)^PLFS(1#+(4MIKT'*+_PY#J-&Q4MRW'0&W
MMP_9@-QP+>!V#*Y=8,=?\#C&^7RG-JY;]SSA31J\R5K,()6UX@8E-B' PJR\
M $A@XX0T,0-K]]A%G7KDAE>:[8]%76\.TG<%OU)K"(M$[E?<3"NC@/$F+*R&
M]SII[_D7]MV\L_KA>6,RUK%W>X>1/$/-''7I[.[._-1N=L]9 JZJM9B3543V
M='\9Y!N\9[+E$S6/8]L9S-%G%B(M\?4.0_>4Z6+[ON<?77)9;ROR'QT/WULF
MWR.A 'H1I(@<T$V2+BSNTUT/OLTKN )?_A*<><X$I**F_/@ +:HW;=B5EF,/
M&,@D]P,'W9*YY?2X4DSF"YP4",L .[XCRG#]; F$JO/%Y<\N%(-5='Y"G5V%
MRGAO^4#,9KF;4FF!;29^7#41%ZWYKS;+G'77OP3=4,V<",?XV)^V(_C*[7P)
M0BSKBKR;L(-AOK&G)O&(]NOY%GTX,@<(M+!$V%G:[R&==J6C^TM#Z/*U\'\(
MK3V@$>W=D3;P(188&2NC$X[X[1J?VDB@W5I?W*_&JUMY>S['.))ZKJ4S=:O_
M^?.2T/6X-2 F!;C;0.1&'[P'6T@[F9/[<IF.>-9;&8XW)+VVO8TB_D+VL7W<
MQN.ZD<$.B<B[A(#.@'9>S>4+?)+JOFC=O#UQ]U/*Z\;EW*D QDH.X@Z'6Y+0
MGTUX^"Y+P)?"VZJU;]827:H:"Z$LF-J>-<K>KJRCA:W3A_R0W?'!Z63<Q8F&
MSP-4V"$+B9^,D$O !LJQ$"V5+]/-N[G9"ZDCTX,B"87Q#6%F0\IFD4OQGF[/
M]IH :NW:0@K!)" S$Z?SGW5,EEW3JG[+>F]UDE)+?'5ENTHT/C'2IA6)GFE5
MB'37;<;ZK2:+V(7W6G,0#@@H7=;+6S/9+$@_[AHT!X'.0I[9_N"VWE_E&-)B
M5MP0F^=N:'33RRZ)7)QTUR08EH0CEA_=9X(=E/_C]]]-Y[[W*&P&ZQ#,4(!S
MN\DX[Q]-\;DWKI*HO(")V*"08Y<:J6!S;NZ"=*E AI/_=ZVOU8$>:Z@Z7CY\
M2C \&5U7EXN6%VA=Q3(+-BLH*)?R[?>LM%2!><2R4PR1@4)-_;PKQ</Y5B3K
M<T::G:<2'-/'*UG83_RNVLBU:W,K1B;"[,EA@<>Q]F,59/J%DWB@_J,&D]5)
MW\Q,6D7<RUQR9-B8JQZ+G0\2G@8,:FD*-CW;@)\M LX6>X*R%MUH,NPE28C^
MH]_^M[=WY_7BLUKFIR7I%QH:EC)?- H(LI+*[ 0N64\4(IX+?(?^[%<6EU*7
M;WPNE_2;F7U$+86(F^<,X KUWC;,Y_%CBL:RP7 C?/D,Z$9Z JY*M]?\59$V
M9GD(=O'C5(-3IKD8++K&\D,)LO90:!>FF[.@5J W[I4A@JJ]B]4(JQ[VI;8+
MW@B=*S\CL&Z//E- FK<G5X\ZXXLLF,5.-C'6H0='/*:IM7[6[VCG:$D=!,1M
M]G+*57QHLJ;9$W+66-NLG%Q+5%4CGG-DK'(Q+8KK>'U(/D0N4425^HHO$R;^
M@8SD0JO,?38P75]%=U"G0,,F@BZGQ!5A>A3-Q_O$!/JTBXX#B,>*V2F6U(N'
M/YUH$QGC$)5$H\4F9FZK542N#5?[/O)=,[BRO)5].M?^Q)ZUG_]:XD^[I0_0
MRAYX"$  KXS[O,0'&#$&#W,4M6H'E]0?[[:C^L#L$,#BS[UU_6[WZ.E6TQ_^
M<P6V'0NPSDH=QRYE@\HSPOCUI*[/,?$M7H-J'JQ&!U"'W:H^RP;.ODM+W$)7
M5M:QU D%,U:6?)EH\H_%R7)!H1C&G@PA.GR0(L4-S5T3H%1K^KYI/ELCN^S\
M^)B5M<-*) 4R)Q.:E>-C!SCWL4-.?S/;7W1 AXEI!/3XR#**W6'PE>!E(6!#
M,IQ:4U@]>+89=LYSGPEC)'_W'\>N1SV/HO=@1@OA35D/:"_T&AYG<91+^ ?'
M'_C8#Z_)+Y>O@B1]3;,-;^T1=<"7ZWOH7%^OX@]O<?-9G23KU>E?.^2Q<P@?
MFV.U9$M4[2[D"P.OEQP-(FD6L+F"PMN,#M(?@+!CVWTV@P":FV8,]GSP'[,:
MT&]_YN;/6Z?/G.:FBUX&>"2/3Z77UQ0SX#,-ZV1UUN4N-P0-E'0/X< 1T_7'
M_,<"VE1=JGRG?7J$I  P'#EBM=_LRQX@80N*"C<)P?NP02;S2V@K;;AQ@/E[
ME3R"W\_,ZF)8?@TZ5JLP1N&#M=CG<FR\'?>^](UBV79<D/)TX_3$'0;&TQ1C
M;(./V]G]GN#Y2 8F@9&4 C-]!N,M?[4*H[R@J>9&3FVQ4V?=N&\59I2'PJ'N
M_00),/0CH;U])/+<Y_XR*F+/&MGD2(/"-&_UX) 6@T'C_/FVFX=>6<TQ0+L'
MLPI9F89966G^,\#2=_1O&'W!>JQ%PUDT)F12TX'O_0G8L2*(!Q/?,I-EX$:%
MJXJ%-8B8^%#GB?:R$F1ZJ\!XW>NB-Y=)*>J!_#63?Q('C87CBZK>,.K4FC^#
MB=;]8%B&%4UNXE$X-,NE\4 X5"OUL<A(,):GJ0VZ=%1D8L1T\$<LL5T7&O2'
MU$[):9)S- 4]*J*:4.9E(2_9'R?@A%E @M6Q52 L:YE1?#D%EE<8?+\,QG[S
MKM^0BSKF\,_VZU$/D=CY=7[>P*16[ZSKY2!<^/@4YXB 05U82D+TL8TL :G<
M:+NJ\:,5U=P3!P>_C<+^)%8'-9SFAJ1W?\Z'%4<K<2'..6%V: V^;Y@$SF4T
M%+;5Q ;)7@]3WQS+K$%I>.5B\5ZR>5H/>O$J=V7@7C/(^QC+D F+,3-:?\QZ
M/ZM[U;9=J_#<-0BXA/$^E7J2E4U1Y_6[S!0+Z=@2U8&42O81BK$,B=)P*HQW
M6L1>BJ;1HF]L'E[)P_MNF_0_U"ST&\0O".VV!C479+/KNHSJ];JUHT-_D2M+
M2_4AG6[WEPE*96>975SS44'EXQJE*Z2-1!.DAGL[JPFKDTWD8&=^';H7;^6<
MAP,_1^=B:J7S@"V4C736J7-4)[">!VK$B#AS(8=SXP^HKBB-2O<I8D+FR1Y<
MIL,+^W-/3K]05!UFQK^T>G+FX/W$ ,%L8F['4))90SX7;F]W*_:NCOW""^1:
M*2SNO7";M$D0,%K" 'RDB@O #&F4-"5$??M$O]P+3D88ZPX.GC^QQ-1C(N4B
MY!$[X>#DP!MJ\1L)/#C7%XZX$,VV#LX\"\SGH1GF=9V?_B$%$_?-4NPA!X'P
M^2_6J!3=C\WV J7'TK/'5(WCXZ>.,>4DXF%:>%1"$LO"-[,O&[3GA.W]Q&0.
M(AR,A&M_&M>G^D*H%%%&&_WE*L-&0%^*_!:K4MM6\20@QM$[ZE'W;DIM4W>9
MV4=#]"5-1T66951&:ZDU$X.=0JP&\;W,B$RZYG;$4:;4  5(7/Q39(X;,LLI
M2*;T^*<Q_2ONM]:<5ON/O#Y4AO=P!$ $IC:>O>;HU(3U"/HQ1>;E92+A\'IW
M*@QQY4S[BK"(W.=R^&Q8[SSA>0^-K >!C)<);&+SMO."S!&97J^-[B<Y#XHC
M;:]8DT^AGP<HL#ZY#<NB9-'B(-0N1 H&&SNN[YVMD52);\NTK9$(;%.V>QC_
M9H.4=^.A'?W&0T( HADB_>5'AU1&M'O,-VVDJT $>3?QL4MS4_**J39Q R.;
MJF[ZBYW+;E "!YHTSVL3W9^KGTRL4/A%\ML"3=3NNE1$H;*: K^A@7X.JTQY
MK(WAZ_B6R"8#J%;ZUUTQ0L\7BNTT4$WY<_?58VW#NK=)7+RDFVP!GS\Y-LUZ
MUZ*5AXP9$LDIG*NT*$:8V7=I'#<9K)Q#.J)V#\/YU@9_,X\8G)7@);'#%=EX
MMSX$W6!"3BO10R*V@\9VDU%QF4I\3DS;VF1L3$M:]*J.IVUA/WNJV&^Q>4WE
M*KP=1]H1;-W&'J. GIH@(8"RA/JQ2:Z7EU\C5\Y1J2//&&QUW6/6TWW].K&S
M7\OYXJQA;94X(@>*_G@K>\']@<K_R_IJ0"G:" #^T^P;<\W"O1'LQA)3N];N
M4O(_G!A()+)$K!BX7#:)YS^P8@XGAXE4EO=9LO:_B+4UO-P<DS*XM*: !5<3
M!"0V5+$:\6_+CJ>5&%S5IUE3: :'W ^"L0<QWUQFOWQ3*9!2>U$H9SO$5S+L
MC:,81Y-J.V 6M*F;/N?8P*QF',_Z6M4CMT*D7]0Q^(;C/;LA1]K/2=X3B_0I
M!)@ENE$U[>NS9&=2%W498A[YAYM,]>0?L46)0/P_3Z)9[9-%+&,WLG7(5Z)?
MLC(E#L'OQ^G<R"ADIKPA$GEFA_0I=/SK7T;#Z'V[DXLW*513<OV656#\N?84
M V,4_5ZQJU*^ZYWDRH^8;%X]Y7ACA9*5U6A.3(348?&#0""(N+BXU,@R'([,
MR\LKL+='H7978 L1MJ=CC?^;4A:<,WX([\&D)4<G;_]=+YV#M>\DV2Y)+YC#
MM5^AKV;Y]ZV79#*[X9;J;"81QC[DW@66&=2.#CU.P,G3#Y=K#7DXP?HLN(-O
MZB[9.;59?Z0<P0['9J)6,ZE7$ZDS.\-B_4R1><5&G VF2'61*N_4$8N#B;=U
M3'XF&M)<V=@]P^_GG-JP%HSJ>4:HX^B8OM KJKL\=&DX)NNE[9M%!&HHJ8OB
MOS'W,2EQ=I+:+S7I=:D]W9FD<]+5[IG9F+&;KGR!KUHA:9(72B0[+1%[^3!:
M*3N<KI=*UH-;EXQH^\^N88\1H11?["5 3;']1X7+=VM9@H0J^T&@+S/%KLY<
M$FRF2%RP.+VE.["LV?=3ERE5PK(&[.66V>NU2AG/71>[W.R]N(YHZJK+T@W_
MTYB7<DR?IPI;N-/#M(O8=4"8FD2?/AQ)@0]I%F@"X:M7)2M$;QX9SY4D1V:G
MA,S8]S\H\?$D8(Y\5\"@%_!.<0)*H'U=D!1N$6L!.NPG?: %+;S(&:?<5]:0
MBA_><<5='3&8*Z/6S@^')$50I-=PI/3RRZU/*$D$83JG@CXI$Q(7X3/Q:RHT
M>RIB:^>9C *DJ_$DQ*%K/)M+H1L#\ =D:\*1RLI,?':$I!Z6+!?61"*@'JEN
M7[!.E,LTP-0/C'+6Z\$9?]I;O1T=6H%\Y=Y?H&BK7]61ZM$IH%">(% .3?]N
M <5AW9B/GMM@_D;0XO7L0BB8^*K('+[B^K7J6[.:P*QJ9J &]71C!.^>*V';
M0*,U45K_2BU<[ QEPS%X247*"%&W\-WNY!7H/.YKY6EU7PK/Z34<;S$53U]Y
MC^U),.I%$)M!DESNW:V9KX2?F#\*6)#LQ\O+U%C#\& U ]_/C%X]B_52+Z>K
MTGLYP55[]0(D4XK5.C'[<\M.3SNGW#<' ^:+)EVPL<F]-\H%>D:5'NE*TI$.
MTL_K',:WOU1-/SMN3*N@M68O$J2ES<,U+3LXX>S[\8'5QC-09(J3)46)&9C!
MB6N<:7*B0:]BU\!GLT4A8_ESE2>5DZ:M] ]>?N_.*./WC8Y2+WA,\Y9 >(.$
M!BV3(RC2992FQ=ERU[@\I4N9IU;.W\ #Z),/BN.+MDMKZFA B]=XFR%_9W-]
M\)K6R.K )8W0JYXJ[&.X,%H/5!\OVV]J;1-ZI:#3]XK!2EP2*X5-O4PWDV<-
MC!F3Q'TXYW^F1I(]JNBN/V"Q$EDY9C/X-(!_D/[)\]ROIL:>H)9:X(L'"[)D
M(K/?R/A.'1<&K*.*TQ=4Y<BM0@WR1:S)6%U&(6 F##1VA@\#9UB!U9SB\>/Z
M\O]^SN/0:A52FTLQF./^W5LY^?'=BQT>HC3FQN;C[[9XRD;!@'Y[]K,$;E%-
MGM1+6Y7^P,,HV-HB;C0DV8&I_I1>U @S;%A%U' Q]0DD20J!N8> @%Q'D>H?
M\-)Q'2MX*3W5XF0E0GN?6=LQ$F"P4C.0H;2'1@8?@2"0,_N@+"?HN?NYH;UG
M>!.G"'5-RN^NB0K8K'USPR5K4VK)D/IFII=(-UDH?G>NYOM83JE@AY57URPB
M)>5[/4]CE[E<56N<1& ;RBSEV$J3<XJ,1TI5!)Y S^2M6#=((A&8;;O5[5F#
M@J5]@J*31"J>!G4+ITPRM8;%,Z!UHD_$4%&JPGQ.@$WG'E16OI<[T/4&NTX<
MK#?)XT;&_$M>#_%4S?(](H; 4V,6I<G3P[C2;S^?COC8*9G"QT24)BHW[L.-
M3;S?RBZRQP&(JK3>&OWP%)N_^PF3/ K6KP&)'X,C$1T . +B,@;R#*_K6ZT3
MJY%4TIC-H(_L7[.C%+:R2CEZJ;YB^M8>7B3L3H0L6 (?9TWSP"4#S?4WQ^\P
M6-0_OQ'97"6?.7&@19]<\]<52O1^ZGE5<3^I / E.<JU^1#GL3V!V7D#Y=>-
M=)G>TV'C$H+3+7BB)E"M:')>(CU(_,?.ET-4#1Z=X_+=$P:YPV*-JU$E'OD&
MV[4#T[36VS":':.?=QC//*MU:/RI)AN6+$ZY@'*AM<?6#Y7#L?6LZ/U0MJJO
MOY8I8@X:H)X(6Q"1L?+R/3J3ZJO]P>>_ WH0M?!YU&[2O>FWX<I5]1C6N\&5
M]T)+8@](E:.)/9U_KT9E&<*THBS\UX2@T!;Z;V(S!][3\^HK;B_XKR#,KDX_
M:6"J)[P3.!IF[&;O'O0\<32@--P(SU&=66=5?]Z7V<\9^E2D1K DFO;\YU>4
MU=9T5QO]P%:LBP"[Y/<].2;J],^3@G.3<4;-%&LNN7D/059"#QQ6?5<62-.E
M&UVNNDO=?':6YL!.(U&<D#Q:B&N"/\;+7 8OBZ8+-74'ZP/E=]]YO^5]S'I1
MI/6)/,5:1?CSB[5-R:-F9P0"\7/8A.&KD5-C1=^'/L65QQK?JBP_7H"F)GXQ
MDCQWL$F]8HI_+>3L)E_P5%4"D4*HHSD0U%H.SC%VTO8Z9/(8I>A[_3AID(N%
M^G/_4VYX;VA6;QCB_D$+ MO;>NA-90M9MJCV3G%.)]K5V+5&X!RHXC>KX=0U
MYWH^0KVQ4)=5AW'!H-M5>-2\OQD2Z$@%R%]8@PB)7[L(4C(I)^6H\:XJQ Z_
MA?JB!$(%1CCI<1OFM$.9635Y$TKM_N,"9&5!^/F%_WK1/KK4J@Z3$V7B2U;!
MC%?!R8V%Y@W&#N;-1T;-1^8A[Z]%'[/\]X%5/OOM1:Z[)7,W9*U.-$5PRMNX
M&D;4TV&=+\_&QPGTKPLKIN48!%E(X]B=N(PD5][ZA:3O-!F6#A+13')E_M$G
M0<TQ= >_1CY?:+O#R/GQQYMJH6%F+L%$KZD$IHZ(K-"H'0+L6U2OQ%4,X59_
MY']GP[VQ1@^)*R9!HBF\(\'J+U:VGC'*>[ Q]*M_,(<(:TSH+E*).\C0N&C.
M;].CW9_KW2)??(_;$4LP+7%VG9M^\+NP#U?+>S2A]CWUE+>V#(^F0\.*2\K4
M"CF0?\S-S6T\FC/^('GWU]Z/SIU,S^R%YD\T+KOAF3PPG_S?];I"G.=."PU1
MN];UM"_,LM*W#ACT7T]_7)-Y\X6;Q,_L,X,Q/=N\]^!DB)M;@1V2U"IA>7GE
MP5Z*:=F^B)@]$5?0D+1Z->\L[@B8__NS/;.&]Z=V%4Y/-M;-XZS!RG'@'@.A
M* GU!-QLHK.(Z,D4D0TZ:T$%I6I?V[.HD?"DV?0+;S_O49FY-Q Q\$Q+7LU"
MNL/)3^+;IOY)-%.)CT=&5?#;87'7>0)&P-2$#;:-N%QP)L[0X!["Y1=+6Q;)
M<N45R0*E"B<KHP7BR9XO<9R%%0@/.ZAA(;M*+,%)#06$P;5V"_VJ=9[WS8WC
M;>\HL.6CJ#ZB F*FB-_G1PCE\6DC2Q&^O@'^4D'H&^62Q7![0S3[M)/=1/49
M&^+I8LIT]/45+VL.WU8C\/&G QDVUB-QVDE_7&"M\A8CE^UL'UO#-FJ5@/(<
M;<=,Z,GAT:@ BB?PR+4T&/:*M7_>[Y%K3^L+XT_@6!49&Q&!22OZ*A1)OW"-
MBY[\6!E4_2?7M* DP)[/??N$$FS2^T-9 R$T:29AQ<CEOQZY-\,#Q<0C;2(&
M,5"_YG'G X2>6(4R]F:14N3WX!JL#UM2CDI4-/?_7NW)Y&HMA<I) EWSH3!M
M8@CV,_:L8W$AQ!U&>.N;#%Z[TK@5BA6OGVP\R9/IC?*MH*V#,BQJG=6C^%U
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M)@!,1ZG+H.WYMKU-"V@1&2JW0L\'=[AQJ/'IDL@FR8<R^9+8F5S2:@@,K+2
M645F.&[?!X@1:Y)B$O'1&O3/A2U%8CG682H\%.5KX;$4IMHAI7XFIGGOZ7I1
M?_,Y(8TY,8E?,KLCEEL/LS1;&^47^_Z,_\C!@U5RF&B-O-F!") /-_4S+K.=
M'R"FQ;>KJ?%1LEGO2M+$.,\$0XY6W#K$@9XBM8IEK[ WI5^<L6K%U-88)YGP
M6E3DR8GFZ(87FP92>9/..?U>,2Z[C[B:3P3+IY3%YJ=/P\)X0;SJJ N"D&)Y
M9&PZ>=R6<_4;CJ2.1]Y>*])7S6Z#_"'-#V>!W;ASI,'XL<M! JNB$E(E\$JV
M_I*+<V66Z"ZOE<[[B5YVK,A"/P[?J-]>R^=:#?:<YL:56,I1B\[Y&76"N*G0
M+A'TX&SQAHS(H66(=^]TVRFJX#F7:@J=C MQN;%5SAOB?2X&.A%ZE<ZD0$Z1
M$K%[?04[">I(LCOJP9?$LK'32Q' U!WWW.@/]PVUII3Y,J$/EK6!.K8L\C!A
M=P?4[\OLA#;YPDV;0_,$@28)9!C\0Z8&R4-G>9JJ,OK]('O!2A_7FO)XB>%?
M580JV_Q*N[=XNS1$S*V,GJV,Y![]W&GB<MS\RAJ7=1L=[V%4/=@%6QB)Z]/\
MYF-KG=%^#AYY6<N?-+$KAY'-$=E7,]X40@\A3Q&X,<2L494;KQL2U=77\<V+
MV<E;441?E/S%)2^U2WFRIA7COCN4PP\7>K1FB)BU=&+J-^R'[5 ;9, 4H#KI
MY"IS$4_!T[&W_/+L;X2//A*=['FWU<_\$-CV?&PK5P#,#6=$$ZRX9]'=JAP9
M-B8)K !JJT8YDA/BFC15P$7@-Z5UP&OI1M]RSX=$M#<!@;V_3E>E&T_M9A[2
M&K8X,.12J5I]JNA.QIV]6F&NZ^DT+,>P2'?:SW9C-MKO,UF'&TAC1PIG+1?]
M:V7NIJ'S)'.%'- ?\=J.KR; 1<(X:'=2J<6$+5L_QQ"7]_Z8H)']&\N=JL^8
MR8Y\OQJY*;Q].)O:Z$T/AFUYM&7_B.Z=-T[,O=?[^FZ-*;5ZFL'U98J1!-XV
MR4Y%]TL\EJM\65B>+ER]RE<A>RH506SLHMV>_=LL[+#BTL542XAG474UG73T
MQ\J-)=D?Q]*J65, 1*GJELRB]S/GSX'TCAX++ZS4L35XV37/:$)?$IN![:B@
M$J>2ERR-XB>S$55.<Z,]DEI!.I9]NZQ\B9/S<\';3E^H2H:(DUV5JU\5PIGG
MW5ZC #*%3BB!)D['][LWF3K<K,2LGY@N/%5+ML ;/-SDJNV2161+&L.@7_K:
MM<L&&K@C]XE1=1JWY>?:)0H]#"KCV0%\G)G&A3M3,E$,<CXCL-QY%#CQ,KS;
M2G?X%"3,JOIU<(1_&K3/HLF;G2\4"&:UYD$G>1-[KH>.9,XB/PPO/NU2=B=!
MA$MN;EN2\&6.[\5UX8R)7'@KO'[P@,&Q#_XA07,C\A)ECBY,$1=?DN59-7 M
MIZ_77F57GDZJN5;;/]0/"SL5Z\E+^W\S&F&>[K6HZCQ#1PN/2R<[2/XZM?D.
MIS4UL=P$V<+5PQ@-0&]5CE;Y_-P4\%S_"N[RE6M.VF+5%[N@ERF:+TG@E7J0
MN*']X;@\$904[*!-UR[.FMSZ$V/J7C9%HL1"+Z*EIAY%NXXZ[HO&M]-@T4Y?
MQOO>1F)XZU::#5IM=LG6Q2/;2?:;PHS@0JJ5[>XZDV^1?L8;<0(?=KEL1BRQ
M?6+3[AAE:2>A_<0)!?@)=(;6FSZ1_EA;^^GF\T[F]5!NZ]IU=KU]YK9-P%+R
M(YOM(.'M\MV4<(Z$T+>O62*TQ?/9TS&!_F6S6'8,\DFM._'7IH\::=%-(_P2
M6-<BWS1Y*T"7Z]4EHRN/5*^AJPV/[H]_O&M6ZG81';BQ9'H;.C.?J8"RA,UI
MLKBZ=3P[3WU?; RW5V]L3O,;RBZ=3=EKTZQ5EY)MTCF-B^:XFI@W(N,WWG@?
MPD;:Q;QQQ,R'WVFL,5NM@E8^@&!C8G\^B:#$\ JNS>^4_=TQW][9'JMKDU *
M.$0[_*W?,9\]P_;KC*BK*M8NJ=7%1.R79>\9;F 1R0E 2ZK#RQ'"PY4OO\ 4
M5M<J9?GY9T&.Y1/A4!=ZW/7E_BM:LT+%Y2\+X<C;P=H'_;6,@6D]N6XCL\CZ
M1S6Q;^/[Q>%0G>['[^Q:H3)F'6J!-(:JBT9-7<Z$L7'*2#>KV ' %&77_WF_
M-WA>9'L42*[OX: MJ2PG8:+5L9J>;9J%4KB:?C*)4_$HX#:@<*/*_0/^8T_Q
MTZO^DP2V^S3"D>X(.<00<1?N=[G5;6*;@N:Y-EJ;BN8VY\N;6GH4%W YLS6T
M6Y!.NC-J_S88\85HRQDYZ"K/'4D[V^!KU21FD&T4R^)*7 ;]1]L.R*>HA"$4
M8YZ2PJ+Y-8O:=HH!DX'&B^5(>ZGAF8 ]/R+OJ)126+^5(&KZT+F(HS+G!WA.
MQJF, 9H-6;$H')(BSS @+I[N*HVX0PH2.KM\4]3*^9Q^UZTXHPO76&%RAM5P
M!6K?1URHDD/Y@O*$\^D#^%4DHFCA79_X02^6SD&)3^4$:XEGOJ!5"==<_C2<
MMQLU"J.(U-B$7C-?GH<"_\34^?V&+ ;&+@*@58")3]9UXZ4AY Z5^M,P8C]Q
MCZAN[RI]U"'75P=N0XXL:)KG:%P3X;D//UU* W.0)KBZ<>=^38B%0]Z#MA)'
M%+5@Y8W%[%;[T1.<<X/[%<H*RY^A8N4Z:B6MHLH'V4;GQ(JT3DM\2@N8#-(2
M77KB6DD;9T>]K<Z@^#<YPSCD&3DTDR[HZ&F9YD-N)7I*NMC-8K@HO3,4$W-M
MJTG;37LWT12@8,-Z 2K8_E_(T%+2)]8Y_/+DL$>N)9,I#T4:2(TM(8PY8@ L
M?!RG<.0NY)%L[)5@6OTS^V_)@%./H/O]5?%8E#5^X!LGXOA4X<QQLKQUZ^S:
M['+<#GX<V,6KT7J^R!1-WFJE"7%M(.4QR 2R/55Q,<( *X/RL;BG9??9ECJG
MZEFF":X-D'(:9N%6G*&NCQDS$9&<+(^43H>RHRE ]Z/REBC(%@#,O(,((<<?
M+69KU/QQ54$-!Y7&4)$C\>&Q6XU9ZW3;Y)V<2N^K@D-+=&1[AWQ&[,8A.[M"
M%;*,GZ0D$L6:8_T\FPMIF.XH>.D].BF[39Z3_.%WA/%0/CQ<520ET6.UQT7[
ME80FSW](]EF.U7P*#H'+(7*^'G1Y4%LV>I1AD8W@FE!WGMGT<L]R]WUCT\V.
M*$#ZDFE;X@M#W?./S^4^WKB+BP%5I130B.D7H6A&E0N/=-SU5)V#Q*6Z8WRT
M!N\Z!6^;]_QAQAX;B(C.__@+-8W\P=5!V_)R$_K2IKEQ]L&*MT8*CJQ;^"'I
MABX$-?/( FX4N:WP#\K.JO8> RK2(GQO0CU-8 *Y"DS]Z2M>T)T$VI;.R<J[
MV]G4Y!K[29$1CP()>Y(9T0W<,;P1O)&+SS2-L<+AL4(7Y_%<>LTR6W$&>RR<
M>ME*'#*@1D4.N1^6_Y#$\<4JO"Y-_BNFO)640O%;)/S32)+>D5I>Q+]@[/@@
M'=9Q.9T--6CIJ$C>S,*%Z[CG-E-Z%I<N%VJV1N+ZCJ11V?@R#@5G:3/R+<$6
MK,6B]\<3G_#.N1ON5'3=^.Z<5!/$-M*C<4IJ/TQX00[B,_/MQ'CVKP4&P1Y0
M]_9<68?))BHY_TLKU0G=3.K@E35;DMG*U?\L#T!;RAE,)9DD@EIC\4BM^2AT
MU:R.39RYQ:*H4MNR!Y9R._:L%5-HE10KE:VB\V9X$*HZ2IT_9B(T"&1D[>1I
M1"(,F+X7H,KJ[*I'LY9\(C)55N,<81A.'8P!QV)VM.4[.GBT5GX8\93?.+]H
MC+ ]SK;'[D1@V:[B;%. -Y\ ME3=^ROG<:_GH/)IY]EQD1E_><0 -X=R0XQ
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M66'AX1Y!RE$J8-80T[.+8$:?1C4QIT8Q%EH\FUK)5J>)YYWH)=B_)5]U/V/
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M@F [2%+3U;GF#/Q3TX"EGN]<\Z465J;<DI[:]7C@BEO+:&]T;99%$,=1HCG
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MTONRCQ75#(?P'S$^X:),NZU^,[+$Q6+-8FCG'%2.!JGQE[.Y?'**W#2M1=F
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MG2ND@]P=\KR^/I+GR43K9S]M 2'R^6--GE>-)48$SBKM1!:Z1.F*YOC8T;)
M->,R_R,B(DQI-LHP2>3#.P_?QI)7J[9'UX;":>BAHJ/6_@8%@D4/;;AO\VUO
M[:+;X%S?%NA;CZ#\+Q0;V(F=:>F][;QR2UJ$4H*(OO8^;_-A\&3@ /^(B#7"
ME2>YG^-7N)=C3L'L4?#$Y'01* 9T_] 17>OH= !=/*Y,E^ XY@2=^+&XR@2]
MR^ PL">9IM)"&Q) "1.V1GNF!,31HW/+526OK=1DXJC=CRKHU(8Z(TT:8VF
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M(0*FIPA:V%?D@P2PHOMY=3Y$ &<BH"\O=3I3(*QT4$X.@^!Z,'!"%:E7]2?
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M7VA:Q>4VL7#>F/QX9I(>*S]?<CW4W^'?E=>XZ)SYQ*Y*H)+)W*_R!0C+XM;
MX6Z11U;,%R94.2*E]IVN.BK=='ZI+K3NZ2@1G[$=?MOBK0HU_G1]C<!+Z?:Z
M;Y]2DTOG:Q2W)OI(UQ<3=ILXEEOT]JO=3$1G%\C8F17 N#E/MLC2OZ*J<7J*
MD/AC8O=23I$?YJVY;D1O^$BO.S_^7G9_,=+WO8!&+Y[V\+#@4Q5I-M9Q^!QF
MKN#AQ%6D&S.N]4N1H I#]DF<Z6]0H^?/P#G7[=- =@+F5/Z3!NIPC09H7D9
M0Z$Z+D.U>M*:_V759SMCY>5G9"S6N1CY'/J!^0QA;^<_5R.ZAAFU4JC&V;(Z
MI"9]%CG$(HRA(M5[>&_#E%=(G_;?29*F^Z/HZ.GWH%","J.XY9-&$Z&*6K+G
M3BG]0J&#&0 [U#%5C8ZN21O3F6(14%=O+A"QHDALG128L].'G?VCCZ;L4]GR
MP6.&8L@#J1]3D"?;Z.7KGJ91Q2#;8W5CLE5K$GC[[^8NV/O"J1C' XCPU/P
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M%(/XS.]V_5P/D_#Q96S\TV[=8<ENHYU-[9+_'UYK^7?Q_P%02P,$%     @
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M^VO1GB*$("'@_W@M6@= ??Z.,T2DWU]Y!@!HZ"BH"$C(B!A7SN2W\0  %1%
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M.U./5'LZZ*Q',?#C,*<H5I@Z'MJN5NFK"14IZAJ<UCY]!2KY[BZI?)E+.>M
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M&CN (RI3@XUTAWWO(]_G'AQ4 H1%!F"INC-F2G(1VBFW>U EUI=+E4<%8:)
MY5%@"U93CC*IY+@HDAG+<] _0+NGW#-Z+&]N[E;6<RM9*O?0!)D^5%JL)2?E
MEH=8@6BSI$^X(V^*82N#RF@JYF&1A"<R9#O5:4*9-ZH=\[]'4WM)XD#A,9.L
M$8+>PS!+:&3(%/=D1B*JYA:&X6/J[M_<[(NE&7@3:".4/\RHR>QLC_ 2F/?Y
MA\53D$DT8B&#7H5%>OKVX#[]-/T!EV5#E3#E-<MP8^#=-G 6+TY804&VC4#W
M D@*@[P ,OGUZ#:\1]C-8Q^, AX'525C4K!YUN:D_TH'25#D6<[3 08FQ>=
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MFE*/(OBH')+Z4>N#LY<SK8#(TUD:7W.W2!N?*!/FOC?[^')BSK"2+>.C[PJ
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MPG$'(42YT6[JCV+FZ:?/TLYVA9J9-NG/I9;:8,!Y;QV:V 6^K/T?4$L#!!0
M   ( #6(?U2=.V%.@]$  !@G 0 3    :6UG,3 R,S8T-3 X7S$V+FIP9^R\
M!5A57=,W?NA&0+JDN[N[0;H;#H<^Y*%!41%$2EH)$2GI[JY#@W0*(B -T@(B
M'^"M=S[O^[SQ_Z[K^U^,GKWWFC4SOUFSUIJUU]Y<^W+J\B, 2TE.40X  P,+
MXP/C P!<;I-ZJMLZ0YS=;9U=*+C9.  "4HKWX>$!5T1JV.2F_WL10$ *8PB
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M0D3@O7&!DA,'_LH#5ZJ["%R/HG&O/6C5'/["36.YZ/8X1EH+#^C.LT>+>.T
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MY.)$/Z&FY5"^P=NQ>QC\R=PO0#QQY$C\B#R?O*M"-!+3;DR ".ES9DQ*L&6
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M=[:&>%FX@21MKF(L]F-Z__['#=):?!0,>G9.5LY>[HP_+?Y9Y5^;!MI:.-F
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MS\H@,BE]MM!#7VD"^IA30XXUM!>W,)(6^"W=FWO%*L.4%8=!WM=W.IHFS7?
M#U:.[8/>VV:-N&&_3_26\;;UDE,%E0Q? T"TA;)36@-JK=I@'(TR]?A7R-4A
MQ2H^O&SRN,'1W/OG!$5]P]%&^VDLO,')]N?99(RG?"R\9M4%!'W^<LTYDZJ8
M2C472=7,K-ZI8?DOT M-N*)QEAD4%89?DP;QA-Z3]VK/YW(H_Q@013.JHZ](
M@H*HL G.O4L"# MK>I*O[&[<TSLB'373L0I4EM)LCYR0F;6R*O!$W3*VS8H5
MQWJBP4$<U4&O:>CH]@8'O5.JBNY]Z69-;E@'8ML[ ^OVW-*WS/AH>FO[K<7
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MZHD944T?>SR,!NY'GY6.TYJ22FE'=FBO38 LR.^3*5PMH"]?ZH@#K68*5K8
M^$K,FEG3,&>O4IDU(?K5CS)7?.9,69Y/&VY.*Z.^>(J:,5T _$9Q"6! [6_!
M06SH):@[#[G;4$FS3=G;'R'4LA7.$OC,2?:NAA:LO +/*?8F+4S7"T9]M4RH
M^I<PLF_!V25*]XQ8!8$N9!@/U=Q?3B^QI6SIY%-5?9 +VYN?F=9\G]V'%WL)
M@"K5@'87[$SBP]Q,I%)>(]3,ART9.A8FJFW0/B\\HCO7/O%!)ZBLK_#W3OJ^
MDDKU<,():7'(+!7VJ7<)Z>B6Y!2+!#]22$PF1365-&6H=(A24YB%4PR'08#
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MQ%:& 6R?\&Q5GD:%'T:0,,$P);,+3Z?"B'M#\5=3!M\6Q["764R2%)Z!)L\
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M>OSA:"V>7\^!JRQ&[,TCPG-F]HI0C7&15,^0VORFMWT+&H4$T!:J:M.1G$N
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MV2+7!_4=V@SU9$JKKZ4/(,%JW?YKQ-7&UG7K9!%KN,L"!0.9EQ2DG@& XD2
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M-%L3X(8=-=)UHWOS)IN2K?I_>K-V^$G;T7DY*.*R6#>MDTPWG) ;O ;OS+:
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M^LG6,#G@V#""W_#MT(#V>5 "!V.IK>4O$ME:E^A0EP#=C@EMT'(:YO+>PTR
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M!*@>[,N16Z+6*[<)^DON$LHM,5/!Q\K5$+1R('!\''EP_/YGQ^4L]/+PM9$
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M&V9(GC7AT=[YHLG\'D Q-7?)YOA:QW"T@:6*IY6].B09I+U7P<V!TR<1,&+
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M]>:EXI'T 5QBQGT)<7Q4G/E VG)Q[R]R810/02H0!NZCZ!ZSXN-/+/ZI?L^
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MPSK(;^FAKN \/9AH&%0_A"XWI02V?"#C6,2^KE2^CEW77Q!&*DM<)CO06L+
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M_2([PE@#LX+]G(]-I[VJCDWDWQX?M0*_209^N F_3YCC0%S\,P"L9P!L%VL
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MK%=?",!W?CO5P,<2V'N>L5KW4)1T-BK1-?%$T/"2Q\V$UC%1]E:6 KA/2:K
MP5O?_,4KJ9.UY)>)&!LY+U,\!'$[*X/I'!":\ 4Z? )VR8*KE\]-U>[ED$NA
MFG+NX$80QR'@.*[%2S/CO$L^.\^P*;@J\LM85GP%O=262'RN>%(JVX"%>B"_
MWAZ/6HZDE,LGOOL,9-I9-CYPCU9Y42WJ]=Y#/P>Q6^_5:->TA(63XFM47(1D
M:=UO<1XC@175E"SHN(N/PJ"-5>JVH"O@W\]$ =[&,RJ"MO>?U&@R"Q X'F;H
MNSUC=^[%ZW3MB<G7V9"T2P$3U\31S8.\4^R,^TRSQ[BS_E%2HYV,S6GRM,OK
MI@_;M0I"#[_4L4W:X-U?[GKN3HS'UX%I;2!Z6&F]B)\ZZKJ]U(K?1LR-^V@;
M[Y'OF0)J9TU5VT9.T:R).HS;ZBL2!W^X1H\XVSJ@NEETZ5W;VIU*5E9P%R?F
M7%]BQOS"3+,UO35EP),ET0T35=NX<DI_1(:S-D)'XQCV="ES[+CQ2D, >^%D
MB.ZD#J&(X,SN<APL6)29,_[#)=FV%*QI/-QFA:>;K]X4;TX&-KUP\%H0?Z6Z
M\/Q8/"A5^*LGR=G VA>TC*Z8R?JTO/WIYY/?OC2'AP 5?Y:0XD= 42XVAR1K
M^_04(0#TT*EN&%5:%,4KQ4C^Y5OGA[ []<MQ1>SG-Z-<2@X&$YTFTC=J&M%
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M8J[YN4S1C!Q@?_'((4@VO@$DJ"Q)L9_/M@^ %)SX'ZU"3G_F_P-02P,$%
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M!*C)24I=GV!NKTTI*4WMG$WNVWT&_"0Y1]N_\23!?Y>3=#15U["%R-*H@2&
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M2$SZQ>&Z_=:]_O[)X;W]9ON=<VOSY/;:_J?7?R68KS?5__MUM[% _!'G6[\
MT/=_?'ZK(_\5IQ]EXILK&-Y?WO]H0O\US_!7Z/Y.?^#=R-W(_TN!7_1[N@#8
M.H-OAAWT#:R)G;.MJ=-?9BL0POG3S9LA_H?A!?C+. 1(_AJO/]Q0^S4<;YL
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MW"; O_%1'&_2W%_8MS.(\8?>S7 6_P;XG8]U>PGU(_/ XMZ6;CH4YK9\(P_
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MZ_"U$UD$IC(:?!#0XB\7_K4'#+^[<#4-0(6YQ<0"B .VDW:*B^B2'=)0TA:
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MN,N9XZ  -1Z-9-NI*=+U1#.?INII?&I?KCM+W'7/9>5?&+D 6DK"Q,;9^3P
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M9495]>@W&GHNV?+*EJ$%'C5M1TA,/!&CI)26"<C,(NA5[OCN-0C9-3[T7[V
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MN6R_KDQ<4*Z,S;AEQ?L)U+.7^W2>Z^;9](R)[?7/>'CJ(VFKF_SZD@B)A\P
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M'%DZ8XOG)33L#\@-S X;]=Q:/<9W* ?&0>BO!OO'>_>X&I@0!*LCWI.3).M
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M#Z9>8O??;!98E_4#J5197\ X9E<;BO!4/8NWU)_PV-(!B&C7YPE:$"T!#'<
MZR,V[79E+(_T48OX:[=DGR5#V\(]IY%J4C1Q!RT3N*H7<_2^ <P2SYW:XDYI
MS(0/\R,KNA;N/I,*O^=EOS\H:>HDO5%6/#29BJV2+2HZ0XO0A-O-GH5V$LDF
MQ7I?@8Y,$7HK#I,Z)5YP$ ,2/1G_;/.9+XJ4E%(*F?<0'$^Q0^\4X;ZU@$'#
MLQHM"XEY$T3^%77FK,RG<?$1]2IC@,9T70F.F9UDDU?([[4>JP>T1*-HCV3I
M+QI"R;X@P)A<(TC@J,<O\\ );WW%Z"["LYG=XAKRO=RF,##I8?P6.8.9#&R
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MI8P)VA$\V"-^+US"*'_*ZNJ3=0](Y76((_=6GK0 8'R.T9.DN)H29V<;,=Y
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MAG"0.#;F%BE:HZ:'&%5=J?$\'^!WJC+6\W"K==SGUKX:UX;+!^1X)Y_@^L>
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M.F_YJQ+\=67U3@QK,_5#3,FKJ'W6 %WTSWJ.?M/8"@<RA\HZA*7R*>15?DZ
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MSN/,8S;>9/G2D[-D'+<3-63-:3%H=J?6IX=8\/!X>4:67FYS*\QAH0B!%(/
MI;\^;,7]J?)6#")K<?$&OG\D_H*!F&"3B>1P\3Q$0$LPP5K;]QF9!)[J-PW3
M.E("(G7Y1:.EMOD0<NCRPG)ZAQF"(>F'RBKK6+T?$_PIZ^I*/M.CU4!C@#\_
M/X,SL9^YH@BKA19_W8$H@,=BBD !=!TJA6UC\)N7YTYN)EV2.H\,BLC+%3>^
MR+S7=LQ1)%$S%D!OFZ#_0;U^-(7^/ F*8(B+Q13S8SJU;#SS@79?WF6"L\Y-
MO+5J3:>LSG "MR2,-HSEB#&]#X8@3-U IGB )L:\&#6M(;O+C(UM.D1,'!W>
M6J"<HB65/EGW(OGKD*-WZ;2J3\D5R=OK>!/=M^@\I-C7FYS5'Q>IFVJJ_I[>
M39O'J=76Q'!ZL#R*,9W<FGGB=H85^&F.Z0:[JOBI4D-W;>N4A>*29&E/3R?J
M\(J_U6T<V5F(#/]D\*HZ:Z9>PG(H#8X77MKBX T^2BE;R4^#*B@ID*)H!5^!
MEC)7TD1+U31R\ YTFLL%#OZFX*=4GJRX[MW*.I=U(VN9CC^0]C0C[<I@530@
M5CG /O*262LM.YO4P<.4R#'?P2"132B,N3X[T-C9<7XK RE![E ;<%DPV;1&
M1F ,H+2;2^?PK4J.C"Y1&)'B*AOZS"Y8*\# ,UU3O*4'F.18Z$;@'_D3HAAP
M^Z*NF\1CB]C:7KD>Y1!:.M+&KAA7CLW._,4\GJ(&P$U=P[E_S%6Q80&-R4;\
MB1%3NZ6NZ4R0^\5)UU[0$RJ3G+AM9PD6PAF1PJT,!@%(C&;0:PB9U,@$2E50
M..%BB2S1:"4+"V26]'G>*LN=#3!<\K6V2J,;-6@3"="R,P75RZZ.+T9ZWWV:
M7]L-0%T3B%=/@Y^)D]C9^C-:4YEATYH>=\>8G-F)_DC-:G66+[IB@24S?TUW
M;WM7X&IL&4[;^-^#B%4_G>W*0!EDC1Q"\$IY9>KLZB^_:F6U.4N.0=,DRW9H
MF18M%0+A6&0A]0;7E<\Z=)W+3_W'6/"MG%STJ78;U6" "T/0B4T*%_[ BYMU
MBOE]P^NC/Q?=3+0(/"1TZ!B1UC3XUS$MKG4X"!*=F0DE&-I5,LJAT#C7)'BT
M#,]/EXG]E,NA8[YJUGGJZ,2MVWD7,Z4IP?UU/3=$T/< RIF-#FL>$>8:'^!%
M<"I#,MT%[A(--$S*BI%TE<2-FNL3"JQ<0=F>-F8.&<9((\IL.HO3"RC_0"3:
M)*DYBF&IR(QH">4@SHASY;<SC_UZT#R+C!>)?\]X= M\+XGWF2B@0'JK[R)P
MJ2PN&F 51%"+,09[FSLII*:S!5G2&VM]E![IRO%%[XIE=>36D*5D_>RQ-YV*
M=?R][=>&%$H>BJF0W1Z2GR;+0_,F.UF\S%9,9T%#MC^(0S2]_<W?\IBK@Y:0
MX+&9SF%[SJ,"92!/_:BL=CQTBN>(5P*ODP!/Q5RE=8BI:2;".OQH65AIT]8(
M+C>#NH-.VH&M:F,^+UEFP'K7N&^%Q<ZUG .O%Z;>^E V/VS;TO-PKBXZQFO<
M.I:20E)>;?B+A*4>/C:W,L\4$G[,!H,6FB*\6AM,];P3JJIE/5_4I*$B@8Q0
M0N>%6%=C74NMW:FBAWK=I$N'F@$*K@Z!7LS=;2\Z10Q77F+,4UWM&,/&&]6:
MUB"ZJO%*IP^Y,KE,4AQ$/59O4&ZCPLLE*(H%Q%--268N;D&(LT'##6HZF==J
MK_\J\[,KI9WYQ-]*NL (33V+]@-UT1P[&@:HA8<P<X!#7HK1/WQM)?#[D8-Y
ML].@@(IDF/P&SH4\4+X:UW<> ZAPHM]\?[5!X>RW !+@SD]NWY 6 BZ!EXF3
M7(Z:0 L=MN38'(1$K@SJ0.?+\$3>+P*I0(0VPYNRH4UEDY6O">]]R*2AWY>[
M?U BJU2?"I&@K'RD@[_:4<A<;@=:,@,W&F5M^Z^$6]M&R?"6LQ$FE"-Z\H,,
M#=RI%=*IWJIT#UQD^)EJD4R2H((2":/E8KG!H71C49:N3M[!+8)6.;+#J)'C
ME\J*5'D8"/QX;G7NHE^FD!A]2I[YBT]VN?S3$U1V=-C3^-WC^!HTM^(P;8[Q
MT2A(:QAXT!DHZ.0!^'0%N1C*'%@)),KPU (<=&4]Q&?];20R/J_6F^2]%1\>
MI%O\W<S))>,D-DSJ#4;>:Y9!_O$*W$B,;&YF(^/<;7]AI-)0?1*\S47?G#&H
M'#RS8FR=S.1.;:W*+?H,6-"P2IA:!S/&4?!-274:,.'9/:Q5-.9O(T;BN&'+
ME4'G6BL8N"ICTSF<(M1O'>>F(%=VI=G!;TUZ5MD<V. QW*J-N/UTP7CSP/ =
MI/JRN%*9TR_S#T19U'Y.TO&>B%^<BQV_\K;QX8T.GA3XFW.ZAD*9R8G=29+)
M,_?(9:^\U7;I]:7^ZZRK"K)O]](571%\YEWKNA;(C5/S<1IC1B,YU)$P<4I5
M065[I=3BK=/R=M(?FEV:#AL/8RECM3=8*@O6(O'"911Q7A 6&= +\VQ2?)O7
MDI:M]<MUE8QK#2.Y7KJ,]G^'?.,1%F*PS6U?WSQAM.2>6L2;OWB(T&2C0VJ6
MU]^&E3E;-TX],RGPNX[;9EGAMFC&064@)72B,Y=4PF-5Y+,IP.C-F41&W[(0
M\U0N"*[X.AG7;#YO[0PJ/\6C%XQO1TUC)S4B0T,J>GZN;HM&4JI=VATPLEZY
M/%)U0M7[VHA/Q'Z?2-_,3Z*[.#)A5^#]*&@/KF&S+2[($8UH&_ATT"'%RD]G
MS14&C2+;S*&@"@(D [7CO56E0\D[FXRTZZO4!$NY%G&SR+0R>P]9@,VUIT(T
M&O^?PU[B4CS)9L?9'7QH2<:4OMOOPWV@$LN?(>F=+\,*F611S(C@L7!Y%JO?
MTXRZE7$E 8_''-2<IDMZE(\0<L4)4\IMP$_B4!&FFQI$:J&EA_."Z./79)"5
M*/G[0[*8GC(6$.CC6'Y-"BUYOS3!3TB72FPHZ^U1/$N7-FK$?3Z.Z9MT1\:*
M=YIDZ"H;0O_P:FYB?QU@0\V:Y[.A.J-!P^>0)CD0RW>F,W1L\<W_^2,9FZ)@
M[N_4_"C>N(5;627_LK5ZP3\A<UHK;RUDF?9333[8"=]-:Z@?[FS'ZO5+8 F<
M2YA\5*.&C:,YVL=:=3D8X(>2R%=+B]$^:"M\%>[[&"#;#)OLEG)CZ"2U#T>)
MGN+=] J)Z-1>?!2R/M8W2S4FZU*M0&\6VR?V@Z=BDW(=(\J8!%JM&@<$N,JZ
M=+F6;T!ENK9]U+)77K,LUZ]^E(U<[GL'*;&:: "/*LJ)Q3\N33%2E4WQ>\QR
M:05U:;J_^9B$N'UU!C>S,G/026'32Q02B*[S6/7A.#,[=S#0=:8::7/33";>
MZTW'W!,#-_VS--IW7!Q=1JI89KEEY7WYFWI6V6 '6/_"L.7B#!I+$-]/JM(;
M%26*85KT6_;*E5EAB'NN='J6+-[)14E _*-&5#A<O?$'K0_*ZZ7L#YAT-PD!
M2JEL\/TR0B;YRA$2M=DTZUEUP9F(2AZV/*?4;;RNW!NLE0KX).=Z!_IO)XC-
M52\9",[F9!ZLZ$5\;:WKK B>V2%FWD2:7Z^LG=/M#!),6H\65.,D^EJLLG.1
MSWVRO7%PG(^VC6.D9W'B?M36LSD\[*/'BVOBCZ>1B([_&,D<_E<DK"\63SC\
M1R0P5V0'9VG]1R24[SB,5&%0*TDMI9\*3A!P)RP+U)$LFU1"RN\SS?0EVX!3
M7UK5 [+D,UEH"6(?F!Z.OP60Q9PWIX=1FB2EB7'3OC(_S9<;&_&4=G(WRE2Z
MIOGXJ/5$ZAV;9=;0^\]X]9!-?JQV+$4JOW8VP&)XP4,[-9YNB2&'U7!L>CA
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M-RV":.;?BCY&,RO6SY BL;NB9QO W!6)BX$V\<AL5O=XW9<%8C2I@+4:&Q8
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MN7FY>+@!XE(>SN9 >Q",Q@)D;>LD0;=5UTA'8VLI0:<OJ,JCZBP#LK%5](*
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MJ]S2BD=(CX]Y?UB[[F'6SB@V;:1M4@+?2P(^ ],T4I'@X==":ZZ36W0<;1<
M8P.ZH_E)JO?JE)"!;AW%?I+PX85,WGW:EY9A&>$PR[ 1F1+%,YFN>(TN3A.B
M7-9B,G9!"W_]J-S1TBV!3OKX@0)RT9Y!N5L@CPGZ5>7MA*0BAYT]^P@974PU
MT0JP86!-%54C[Z>^$XD\7\@[3G]'OAKS:=_!7&9F/)A\U-.)5@Q@EUII+!6_
MM S$K8)<T"9-Z6,;G?)T+U)AKYT>GSR\\5%D\7 P0SF%8FFU1BFL-P.Q5Z\;
MJY@Y2V*BK(TF]@V(<ZB>SRT@"(-'];WBJA77&P:U+R7%Y>MF+,8:*H9%VHDP
M'S)9UL1WCUMT]4Q")=I>1ADDV.*KQRG2OOB(C(U_!YV/\1FN*B+N2E*P]-X'
MN\420\Q;F>%L2=WB0CER/(%/@[CD*Q8+#W!8XQJ[.@<@C856Z^F6$0B&WE#C
M/ Y8OGYX@\A\,JW3"R$)1MQ>_/R&<QWZ#GQ]K-"LL=B1A$S7 JM=?J_4.%^G
MP<)[8_32JHIGXD8+UFQL E(Y#Z*%Z*I9"/-)S.310D'OWO3=:0D329=CT%P(
MM]X6M<O;1I]E:[%E1N@]C<THV>DG#5M_*+HK&Q_+&PA3V^XL.;N#)QU'L2V2
MZ?0H=0'=&$@96>NU)3@OK6A$Z@1FYTP9*6<;[""-)M7"G6(GWOM4(^$.4-V<
MK%!L!Z4!\L^83N=0,^#JUY98A5O/UO2HY>^5"GJ;+6HB!RT]AR #4P.6[J&\
MK5YE&%MA>\;1U21'BR7VU$TK-^!1<*?LLV'*QZ9OX#M$:F$H0(I!.;J,*%]2
M<Z+.:$6-_3@1H!MNQVJ\[8M81CS&4*S-UAZ=:)<0:=;HC1<\21Z+G%9M=YSN
MIC@\=*=F#$L*EP?VKQ\7+_-NG1Z?]W,*:_3@UF4SL.^SCR.L>U55+Q]05+&E
M*:Y1^-N,/%>2YKM%X).8?J;2/Q/XG3K94CR+<XGV_<?PYQ;!ANE:T?CQ;"A]
MP%$3LE!6#>SJ0=5ZYW;Y;7SA[0]"QVU98WV3&X6\N_9&_*RT#]Y$>CGY='XU
M5($',$28>2 DRYL&*LB##.^IB![SWT9\@B]:A@P@8D/+PTDO617^WO^>V*+Q
M0<Z3)0GF0)/W-E@9H?=SR4/"8)9)-0'1YI6\MJ3C%KZA=1VO]X[2)VT.AAPR
MPM*=LJ)1,<)&7HA2SW:F/C(KE,Q<0&C^_KWUFP >S$FY&!L_UA)?>BKAK9PS
M>49>"S<-%78U2M3+(I9NX=_WS%U9%1> D';J[7WR\]=ZI_,S5'X+@Q> ,^9#
MEPO 2TG&Z >X%X (^@M 8M7,(58_)U@,2[YL\;;[Z5U. M^18>$PY8K^T>5$
M\LY[[.DFHL*HT8_$"CM6%R&;96_TNQ5-@N/UN:)F,#G]U)YJ>[7BI%D9I;\2
MU/L$8>*M^F(B5/Y%)21N+'A%%'FZ-MD/6YF>I&*8R$7F^ ZE<JF5S8F45+2Q
M$_JMMSI%HL,[_'*#P6MT\O.VJY&\R>QC7V[YYC7FZ4WKB"RREEI7FARS?>"J
M%",_L?"2DMXJ5R%>M<A#$0QO\Y G$)<G)\P<5AFKRW_JE8=,QLQ$)$3:Z#>S
M$;J^> %X/B/SM:7(&AL@\V*56GOP@5*!ZT=N!M7$+1OT,+T/BYG:[$)HH%W5
M6VZONI81309:JUDFV4/]^XG)/=I!ME+/7P=/?A1V9<)RZ3)!&3VXHZW"R3T>
M7++&MOTI(=>D09B$R^:KJN,9\/5<AJI7A'A!@4@7$M-HE3_K2\-V WQ2LT]G
MC5_WPY?ME^[LC+B)5D +].P<\SLF#-,M:K. *<-&?8%C^(_E(91!D7'8EI]$
M&-Q&$8%S(,%'$V5]BRM'VJ0Q&Y\'IVJJ[M;L&GV-K4.1/5T+H_S@Z70!("EL
MX$JZ .@SPDKS9L\.,.S17-:(2#H? OCAM)L\&7N,.Q)X9+Z?70"@H3OZ/KDC
MU'FOT\<EZHA9#BCC.1?*]KZ/' =([U80G,"O>JNPVPF^3N+B=K#]8OF(3S)O
M(UBY;@B)Y /'1 .=#1UEZ"A7Q&$J3"<=P2AU1PWLV&!0,^;N^L A) ?7*NNE
M^3)+0Z#D$^LLKEZG*H>UAY5?6P)6;X7;HK_+A:RG(S85 Y-+WX^VJP>>RFY*
M[P=O"??S94X1&AV+BHY/$S5\RND6&<BA&#Z\6_>ABWJB+2]J+,RT.T_ M33X
MF^PGDG0]#.61./L!68-V(,.IM+>93(:GV<)]O0S$I*$W4V$REIM6^O2EDD_"
MOV%U]^3L<SWS2!W,33.,,!QQS.5DRW]<A ;'ZN3XJ"$,0O3(H=V'9/:UPOY0
MI\V9%&W1@X826\8>LAB2$GTXN#(13=$"FUYID42X\EFE:L<V%-C&LPDA%E)1
M6>5EYI(7%X",F87AJK-T;]KS;1/[=O[=-3JQ>U/Z8_K9HGI#>J0[R;+VRD=-
MS$X"%JQ+2GIJP?G.'X.E#[&D3,)=13($."Q:6^_ZO(TF)#I4-?7(+R,OHXDV
M2!I]34L+5/3--D<6B)6MS^_K&>2+ZB+4-T_<;\P3;<^SEJ/NU\]C$*PDS)\H
MW.(XD'W_N8O9,ZV$T:.Q(K<#T15H,U5^GI[&4[\>^]:(UV$P7]:.\IVF /[X
M8HI>Z*/7I@BQ6@O[2Z\6-6E2]D).VS%(RNZK5-YJ34B^WT\D_D*":-PH1V#@
M?GW0\2?* @XM&;P,)=/R39HP"F8^V3"\#[1\O)LJSX?WS;U&EP)M\QS16BAM
M@0643WE9/1D-,09SLS%*<N5Q@B04&.?9R 5IO_JV%*TR5LD?I]=*!!I\^%8U
MK9\?WF!JV6A@@G] /[5L_IQ7<MQ?&RF94#,!UQF>RYU\%9>0P)V]\NBEK]5R
M$7+K6&"W7J96HHI\OI*P7)5%6W6>JAGF"YQ][1X5PUG@A,&T<'TX9\'10LB2
MH%[VL29>R9@-]ZL--H$-AKB7:S+,69S/[23<(A48; 9ROWL%97&MG!CD][:^
MTVE5*]LBUAL2G>+/M/EBN5HBF,Z&!5,K]3^\ '2WW:6J ;*F>)I^H &2?M"V
M5?<W;!!8^M)2HUS2OE?A+7Q R-[/@=-@7Y(OF?=RK>]+^;Z;Q4?%5P2%*UT]
MRV@E%=GC,NXFE>D6MI:A"A1QH[EM5JU:,AQZ=-YH@^@[$D1%@O:(?.J:9#7K
MNU9MVBT2YRPYY/9]2D95NI63;YJXN.^@"Y>O.EL6+C!P/E.R4FN*A#28RTD;
M"S\GZ&DC"GE^N*G=5CDPNKWB'I(68I(>AUPMJSO"7,XB:+0\X/E"GG7/:\4"
M7X!)QG"86X8*S$Y>^L'>A#:58PU$[*Y5GM;D;=EAM5W\-6:O"K/S2[+ 1ML+
MB0G05_0)8FLK?_].XW&^/H;X6"O?<"X,Q8JVAQ:I''0J'\I:2 >5*K]56]Z3
MC<49#R1UQY( TOCQ,:@^/2BC.(B_;W]$H)6I@!HE^2Y1?-6O(MVVH+=,*TZ"
MY)V;?K'9L\6Q\JA\?P85549^))^  @I_X93G=^/3^O6H'.ID=X,T:1['#^F_
M,O /,"-G#S0)#^GMRQ+Z5/'X)#D@+#67E_QK8I"EA!!S0-<P&271[MO[_&]Q
M5=()4YN(IV.02ZW-]MI?6>L42'#V1PR5:8,YURKBGFZTV6WYYG;E0/8J*M5H
M(Q:)^ ZX[B"Z,B3(LBN0XB3$(/=ZDZU!7[([1M=7(HPSJ+IELB8S[:UV=CIT
M:+S0=]6)WP^/=N[!K>U&7^VBBAW)0[4)5?Y<&PN*?N^)<X:#:='FH+7./71B
MN#C1FGSGS2 (VD&QX\#%T YKKSG<"'4YHM0V,M+H+TJQ)FJ0'Z%BVY7!@&VH
MN+Z)$^0D%(.>UMU9I"S0+L.U^4RTIMS&X>IH.#;VBEV/*4%:@ISGX51:N<VH
M19)^]&V/A37=:,F=O/:IK"K29]!U@VZ!3 4C)8]Z?_DF)GL+G1#GJ'.SAX:&
M1T&J,W,V2W-0[$S>)LQ\_@U_5RZ1JN?2*#W2'7$C)9]['<-B"-'T<,D*X[YH
M3F]E4;-K/?6TPBIN(7AO>+_K@U%=A;G$!>!>:47PB3)NMK]ZLIL!_=[ZJ[)N
M@M(. 1XEQ+@&%ER'R UV\2 ROC96U*Q'-?E3HBH?UTAS]=<YW($[L0V//K[1
M-X%[PGC2BQR1+OBHZ$ ^,]0S[(5K*NJQ/SY)\POYB5ZJ>'&GMQ< ;W4%W[%(
MM%CSUUM.[%[N+ _&\T;'#(Y$VXV$4G$5K.RC9 CP9/3D"LV][1Y]GVIQ>O+B
M9=Z$!T,R:K#\<^9P8E_&EQ)0BH<9"M,))>LD;"*KV,0EM6K@J7AHKV&"RFT7
MUR"N$AO1K,-"R9%)W$;>9]I=V*Z+W0P:?6J35H34',XVYL=KSXE;:T\2?5V^
MN974J9OZJ8H'V(-'BP1&*6?FME[6"+$K;V%(ACHWWX=%:_)/Q>GQ,J 6< Y)
MUJ^<%M 'R[$7*DG8O@Z-;CYLSUN<M9F7C)8"263HTH@WZO.^Z;D S/"7RL$G
ML,7KX,+ZDZKTC<JX3Z:YOC29X=M+'G".U!6IL+4IOR%SSMMV9'5PJ4[O+F[#
MYQ[ OZ,<J/*M?1CT- #O?;1@PJ#!@@=\/E2.[IZI;.1QZJ @HPEY-AD[JKT
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M<EM*B5,U=G<\4'FH7QMNB:F'A"XZ@3.B&0!*(^)KVR^;SD-QS7/=]/\<)5]
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M9DZH*?PVQNG3,SU1.+OP;3X\N&FZOV'6-"LOMM>RM/_>E,KM6XN(P+,],;U
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MNR>L(ELZF0>V.'&[FT,SD:]@* H@($(L=4:Y;OEC>CD%<$G1\VR+#.;\_S;
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M]0LOD(I^*5ZP:L2&W(QV?YLV=DM7\/@.1L6KC0*8/%X.Y,Z?GE/6FYSC*0@
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M \!'OPC^!1("'0 1'P$)'^%\]J*CF.=O$20NHD1!N*+?TH@$0$!$1D%%0\?
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MKNF:KNF:KNF:KNG_.3I?$"^Q@<.=A+FX'%TXS2X?A'!:0!VX/,R<N'@XN;D
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M58&@,BA^40B4D&I!VN&2NDCZ*4 )@*@D"( IB;W!(X#,SAN4U=Z9^:9%\<+
ME#5S<ZS1FUZU\360@POO-NNQ7\\+,B_+[.W@%0R]1Q#,P03&]IH%_7F]SVDO
M%9H]:8,_E$L3#5:F(JJ< QQ$CV=\,!_,%CZ[I\UH=H\6[=: FZ5[ !'!C,>2
M G*0CRL?5:_;@?7]F=X:S<_"T^83O'3U4Q""/A,[$H&@)_>D4]HTM]^HR*":
MO>]RE._*RK/T]4]XU7PG+D2??8\2!5H$LG!QM>;MI%C6M8.8$BCFF\!%$AYS
MT6Q.#S:FZKPZ!8V*)5I7Q="EX7^2I-6_$Z]#1\? X-U)]=7^&-\01W,CHC1
MALX62*[ "BFIB"$7D. LF4KWSF Y!RQ":GBWS@&R+Z(EB[T[&"NCVW([RK_D
M%(%T%;-2)#RK43<^(2&?%CT(>O/!49=U32:/-L1RVG97U&:'CH?&VG$)+6H'
M)/GA^3X8NQ"3&T5-P#:IC.W0C?CH4(OO"7-K]V,V%B75VX/AM>/.WY#+PK\G
MNY:,46GN"HSKA+/6>5J(/?-W0@M/9<_%;?444?/4^?!U]HA1B;BVIO[Q!^_@
M4"3VB/"H&F0?!?=(/.+G+ICED':6_TLV-JE3S4FEE+[RJ@3I.(?*KFI .6^[
M;/ N=]=I;N]"!R%W8E>OK>21_?![Q1[I9SZ6>9^\[ZNSIN08FMCH#D]^;L(;
M;3+*+\3O)IPTJ#00:^@AS9^Q]69"=#6*M% D917LR]\,^>S+?^2:XTKU[&91
MR7<:>+J\S1?1=T_W;XTFW:_3PRQ0@F8>1!,Z#ACP)6P1IRA.V[._N#G4VYR%
M55Y_T"RWE.S@Z_P@6MPXS3Q[\O[=?C5UUC>;BMB* PL/2Z7E+;XH$":(AO.$
M ^]ZUJID'$#;BO/7GL)SJZA>KJX[D-QKVJ0;]?);&CX@J=1_.GW0)_^9,9%I
M4V"+Z^;N%"+9*XJ*;:2<$YU!X[J1>L/<K#55IE')\92UZ5O2ASCDSQ(>8;Q]
MU\[-7,'4'L_"<U.CO)O8ENT<8+E?W1L^-'U0Z]91K.[[TF9ZO 139B$N\*E'
MJ&Q3)I.6J'=)>.M#IXP4]&T<92W#D:$E5M<G6T7@D9.0)^ODQ*UZZJ0ZC4..
MC-H>.Y-<-B8H\3=G@H :Q8B9CMBN2E4I)QB)PR>\0'&=6UDH-=@ I%08GHO;
M4[/8/N5HM9,!W:@"'**<D6!>QB158FP.Z$)UTV=X(H:!9JI 96&4?Y4MR(>+
M@]:SUU;9_[:?R+[#H9K!7FA!]CE@[$9SU%B]3EG!S.=Q@]0IE;W9\%<X7O.Y
M5&T^B+.%G,BE+5Y!0K[/%0(>T=/ YQX-?QB]I5.=7-FAD@9<&Q]GZ]Z,77+%
M"@"7>R,(,+#?EJ9<8-<0?HC=X [F!O+<<U9.(GYY#X(K%4OWZ;N[H:!57*B/
MKUNL\)3G0\)80]JJ^OC:AUI)<>&,A5P5^O<A*9MIS_-R9J;7R*TRK(G'$F8P
MXZ1<[9R"%)<B':83C 5P9HIS,+4-:;3!=Z9\AJ<48UL8>/E<VA@BPV/?MNN)
MZK4!RP\M@W!='@R<ZF3?,PL(2Y$G2%4,:L&2]M>JWHG;I&WT%SURV*N=$UT9
M_/K]=0D;R8UGGDO!N^\;F,5-J>&'N/LM6Y3[KT.EV)5HMES1J!3>^N(J#)>D
M;I<H._]?LGWHV!TRO%-N6&#UK)%SMTI, A^6&I"Q9HM=3#=;T=+R?,-&QWNO
MUY-K8QD<"-*++J)5"[ZU<4KYD(6A4A<RM)\FD;.7QL]GIV@]NE01:C<+.J#E
M,A/=+BR!@F^Q!NL9/>9[$;25(_8J@2[$$^*<:WR_:2.*LOZ^8K1!Z^0\A=H]
MQN@=X%K^!VX8$N4K;A2KC'F^&D6;,8WYXKXVNY==0$2^W$D6NV"PF[S12J8V
MAQV'E0C#&ZO$8T_].J?6Y[[?(IE[Y FF_5C ^?NA+^&SC9KSP,*=S+A..[[M
M]K!3-FV6]Q6O0N@DX("LR<B31U8UPT4Q.G>T#A,HZ%7(1; ?/@W%"V4(#&@/
M"D# M)6)?$^D_QE]/=.WYY4J#![S/C(-UU;H*? 3KDDH?2#C<.F4JN%Q+W9[
MWGSS=%Y7KS7>2\6.>@?A'8RE"F^1S-H0_3FT(/ED^KO+"MKWR_/#*_,%+.:1
M68ACD_ ;E>Y \14PFUXXE26CD\G-O <9TEI8-#JASZ:\=1__.I 7'EQQ5[>_
MG(>'KT_H2^C7H7- %#62L$Q60RKZF@H7.W"M$T?)@@D<*RZC!R+<L>?C3#7.
MLNL7G6DA[P2SH3O2\6:NTFZD$(2_<<.9<HA/Z\F=G)IY/+XV5?MN>&[!(>UM
M#2O98EP%3WG Z6Y5^1'(XEX-NT07(JM]B5R%B-Y99E@T=MA8-=;0YLL)*CI9
MSYOZS-;!TC<:BW+T:/&J"U<P-#V<]7MN#%<\OJ,.GTL;\@(G*7T^<)F"G"C/
M2*%43MPAD1]2[=OMOW7?J)>]70=BB1[%-!F?R<,JG_O$8I1?R54_7:LAF3'Q
M:R=M OZ-N\:"0Z0,MD_Z; K[2#AZZQ@^;;D]$=G2>&@M,2 L^_4<\-SEA,6&
M1V*0NNV$Y%OCRK'G[LE11X6!9$U6P$?%#+^MW9Z5C[Y#AD:"<?8(0E,;M8N!
M+9TSZ7VCG?VJUB./-?]ATZZVTA,D]=3OQBL+H+502Q2APU1:,A5<,.).+T1W
M$#<+]F$O62#2,69X*%98.A)9Q-R3T/>8I/"A7+7Q0.A(PBVK>1$+5;6Q]?[Q
MWG434W/EQP)+=!1&'L_88E,^2*U]78[U*-!:"IS\'/C6()*FXZU#9^S^^L1
M0G4:>#/QV6860D14'O@3,;KV\TT0$9:@O>2D<MS$2)1N80D.YD)P[#>G<G86
MCM1QG>$I34<N'+"'.MDYP(0Z@<U44PB]SIT&GX<H;SE$J;B525).I9)\-YRA
MAM[IX*YD?D]<<'2VTSBLT )KP"6218/I_:9\]G!#4HDPZ][]=TF1 [?*)<=5
M<#D8WGRKSRXGKIY9BC4"<\^0;LA0M;UL7E1_D>2T;GM4&N6GM;^^J;E.R(-<
M0:4X7):)QY[*R1R*2SQN^2[3[&V^V/BLIE66X@!)"':.<[PU9H>/]2!1SK*Y
M**-)0L1!897"2Q,/$TPQZOQ6-3\33 [2,RT!T<;T0WG!+ \\BQ*2L"HL$6RU
MV^*#"S#1%USF%JM9RES;G@[[YC)K65CW)#27CPA"P/..A*D+RM]LNXWHC-9.
M"=^5J.-./??#SY.\GP3./#H4WK"E[HZH3A<\Y+!?$-R-$NHD*FG4HX'IO3%W
MI+]-JF06=I/AP2GX)I*>QX+\K>7C= 8FK205LTR6H90!"D]F->?G+-J9J3?T
MK5%)F9,9^X#B&+39P-/W'2ZAR6T%\D8N@A=G0UNZX=;BHL[*+Z@ZC7FW/0G<
M2 O5&$):/WE*FGQK15;3,?CX_?;8,?+CX#Q99O5GV#EDFLEJ/*G;RN&N?MM%
MFTP'@8CCU<04JNKE',+#\-F7JK$O4?A\5=A-3[4%\PJK^Q,#W*A;%QP1N/!A
M#M4GDSK<P[59RDB3-"JFP)!G80P0A#EN1(58C&7<&_ \2Z);_8W9W93!M':>
M!UK5*<I:67F":BXA;/LN7U65'J)_&E5Q 2(QOZ$C82!G&, GU='1,&79(%+L
M:B5)$.]5@0A*5R188 R&L)GP7:RT]P:V)@T']32S,N6K7;]85>5^L=!K-;\!
MVXI2$&,-R"\1MWM26K;WT'6F7D2U+LK*_]W!(FMKPK-[=XS\3AVG]Q'6;Q$4
M;R4]BWQ0JE>B52><(-Y51_J1X1S )EFN= JHE0*\Z97-;(25,B-S9)OH #^Z
MM+.JW&P#V-L1TJK)).&"2@.S0N+0PX9UD[0&;K3TBY<9ZQ@KI[0:NNKWYFGZ
MB4T.7-R-9'<;&3H()Q]I\WW+?S'I# S(J\E^5U5=ZY;T<">)$;1HYW#O<\\3
MY7>52ZDL0AU$): 5,T!TU"-A<V86??NZL-K63\CDTBKLB[VU43@KT4K)=M0%
M3REKQ)Z>:2]2@(H;086O*Q/F^\P;CC^;3*$(Y,2A'$OZ<V>#HF+4/O*NG-8Y
M<)P#R%/;J&;HCRK2H>OMK)^4@M!"X_5E'B?-VUL1J6SR/'SD/?A61-]5J2VJ
M85.W8UBT]C7908XX;SMK.*1+TV(N$=>8O;:L7 <]EG0;'2$\*.O%C*B%6J%;
M.?F4,XJ9XVWZHJJL>2N-0C/E7=PV!#H:M,X!F53LC&0K[G>?6IF52$!9M*H
M&;RBV!GE=YE@I*)V,R602Y3@ '>6%JL!"XNS;5R4,CGO]D"1?$1P#>V)?U=M
M8<,"JE_M.2!!Q^D<L![UX<RYG>U 38?S!LFG9<N 1Q$D&/> !%:X /HL.Q4;
MS:7XQ;O\(1Q*TK#%1ZV)F3E4+JD6K+I;C/3 @-2W862.JJ0P?@]VGU=2F Y<
MC&9LGPX20X"9#2$\23R)HPF+XC.+HJ \]+*)8+@5YO,0LD49K3#[&&8LSB2J
M\)J05%Y'\81F<N"ZWCT.,_O;G'?"2ZCVCD'-BN43R'&X1 7(-",$+*T9'Q43
M$))Y8PO!2AJF@B?*C*QJP$)P:%+X(MF Q%UGY7U./W0T8/?(/5K1V" T#A(&
MTBW356J)*#QFST]L*-2;NL/4@L>/#U8^R#R_R/KR8D3EU,7]*R0[.H?"N9T1
MIWJ*,('#SJ B^"6Z&C"+1;\5E&HM-, 3R:+C<<H/TP]\_*146@G;;NLQ&?[.
M"](6,,\B%S9O6_0BM'F *+6^5]DPXKBS27 WDL4X:U *P+-,R4] ZJS<"L;D
ME.7IB "5QV?=;M[MLN%G459V#B*:<TFX3=J9NOA82P2R,?<D:S--*6/C&2Z3
MA!54\4GP5F' FQTK/-NPEW*OK-ZYN'P(4H7Q!-"GJBPN6QF(@9X<XA'$*5Y<
M D^_'&EUY77)JM0 ZL(R!X59(VSQ08A,1N^&4A?D:FXEE9JWJX$*F8,K$LOB
M5\B,><.WE;_=W2-_8B[&RZ,LFA-.:AI'1Z5"$_:)MAN5]!8>>.4Y2LTMIXYG
MTHG FR'B\8Q* UKY8<?,JV:Q]OH+2J@U5!"4SOB6!QQ#<WJ?!)(ZG#OB%_&J
M%_'HL7I2/*NJ&QEM0$Y9.MO_@55CI=J _ 1=S]-$;W9D.LTDHGB63J*L(H[J
M:=6<H\3%2!86-8F[%H-URLK<61;CZ):U"69ACNZWR00!"+&7SQ$^6$:S?50B
M8(!0+.B^?OLM8)N_KZ@>$L=E>+?P#0;$T4MQSX]<[Y-LI.7=@D&:/H+UB.@H
M1WE/B)//46^NP4C(:5DPFW^!D>O-A(RV.ZJK B<#98X.!")L:7+P+DD=RLR/
MJZ\2W"6U@-GO+ >D#IWFC"0@(\+9Y>-GFD5&-L+L9;.B20<I%K85C]R62553
M8:VGUHP9$*3G@TC,2(Y&4B/UZN!A^W)GIKN8G&'B# L4(^/TNV4/D(.F-#D"
M#=,2G4$QW*IFGOI.PY$JG:*]D;A=>?JDS%QJJ>M4%6MD_ +KN*FK:9P''38$
MO7JK19[%)3>WQ/MF]-9O#DG2VKV-E$MVQ"]<>>B#M;%34)F0-)8F<N2?*97]
M_-&:7^9X>TNJK0[Y]P?$(:4/T,KJ1K(A<_=N*8H(5,/K]7G8BYS)M,,6L#XW
M\KM86ED8][9CY7"B>+L51U0#[LXJ:ZEC@;#S%W'!]X!O\.,)D4_3R:*1%SPC
MDF0-GP3K:IT#"HMOEVZ46"14J6@//"LTX(Y<$Q#LF8D+260!3+/Z!^=+PF>0
M$_HC8Y^('R7+-<1LWBP/9997__X<@S942=HS_+2E[DW:ZP6C%GZ.[VFW;&H'
M-;/2\'OT=/6#!Y\49V8\ZVF)#$ZB<6?O#8 OH?=F*":P[4FUOL5XFQO4W%$]
MD1<NW!_ZZN!@Z+ZT/C2BT$J@.12DHQ-+(RM68Z6$'7BGBZCFJ)BD'C@+J=&1
MUB>SU#CH )%* 07V)MMN0\!MN&YY@FBW^=)L4DNUUUC'$X<Q(\I'U9."4&9>
M9**PW;>]?_3AWBVNQ'<,<3)$9$,0R$-Q*Q135&JSG)E>GX.UK@^-S;Z&:AKC
M[D-MSJQ!KQ2+[^)WW[8#B&4:#BT^8\=, @++- S*]E 3YX;XUC^BC&7T$LF&
M9\A- 1]09+D)3.A$ 3YQCGV*9LL4KEZ)<!-@&Y]<1/S6EXV#GEW>UL?-@QT)
M-+J-X?VIM5GG]80#<^^##(R>V"RVZ0$N.X<QX82."I?"ME>&+2C?OGYV6G6_
M4Z/9G_G6O\PY3\D%XA@S/TNPPW>SZ^ =T^3;G5K(K1=/(H!3(GI%Q@?R'O=*
M&.H>H\=PIH=&SIHG]$I1(:+Y%K^]R4R"O%FR^_U^9^'4O[I"/RV'KF]]S#NI
M=7]=>D N-91B;;?JV*3#O[GT'EU7JGQ@9/T&X+U%1Q2YZFK9_<?L0'W7]\QO
M'GJJ@J4;3X@26)0_41LW<;IO%9T#ADYKD-<KBW3]AWSEN,;[=V&X8R;M06R%
MO(G'YJ@P_0-./ 4R36'2+ [M(X&>6$T8R(.."Z]'Z</3G<753FJJ<\!PCCC9
MUZ.CW?6/O-L%UO?%Q+SMY#8'&BJV-@V;,P\VV>J&;SG-]=FES!O,9=BKNHO9
M@9BRW%!/$B?QIS?J[;,8NFDM^583E.3"A!4B'CT"E.M,?C&F*O>'8GIU2E!]
M"?BRTCE0W[_&,Z*_-7EX:T3PN$D^(F<BPL)BX^04X\%@)#GJS9LK16NTFJ3/
M$=X_[7YD:FT?G8PO)1/!,/V(K,.*[*XS+N/"SDHZ_H(ZHCC-M]-S0#KY,E7C
M:I++R7YN/;X94M&=TUU?Z7W AN]8/X]AS3!&7> K ?KB*+FX_ ;3VC+D#7FB
M#$P-N4DT;FG+:2;]%P_]E"6Y/V C=293-5-+T/8KE!C-)YWD"T_DZ-H<W"P:
MJN*H&7_TQIS1UQ[:E#P]BO$,3+'1YEI\2$+U-G5C- 'V\2O,V9%O>QL5S22&
M\WYFY6ZX0JYUBK.3E(2_!+;%68R)9.!2:ZKS8EP49OGH&7.-3C-BDWVF:[-Q
M4]F^=5&T>YH"&[5SF-+H:_68;(3DXP(3CO?OZ)GQ% N/D=@4'6[F(2;N=K;%
MUHCF*VX=GS6> ]B/#T=FSP'???QWSAY.-Z3<A6?4)VZ=V<U^+LZ(*US)H\K5
MGGUD\WJM)S0@_]YMKS9:?TZU%N_DZ?E&:1&L2GN=I\!P\26]Z&#R; K/K,"G
M-(R/,"LHA+[N KZ]]M=;X4-VIZ9?F?_F[JO@Q[IX#G@U[8/YA.ESY'KFT[18
MP@FBV27-1@R;$CRK6SG6^I.E23;(B9N?P\D+[4.-8H$XBHX#AOV\!V8S;=@"
M82U?=B5,U=0' ]#:!HF1#WU*_3Y-Z/EJU:>[;;IVCFP14.N+5%1E$=82/[$Z
MB>J+A_OX&&?>5^*IELF^<?^M5&=[(P]NJ"GW>P')4"KGS+!%.QW>V^LG?L>G
M6K@2$GWF==32>UFS4S,.8&BV:X]Y0SF_1%&LH\%W4Y%PY4R6YVE]W1'L4R_*
MS\8^!$Z4*#;0TSB8!9M/T-QC;/81PB7:,K)XO<RS0RI1[+Q'.9FWN!XU*'$.
MP"L<MR@5QIK>^7QZ"*RGZB^KLJ\I:I[>]&M?+]0>R,#A?<^9IYI$M2<:+#U7
MU2G3&[K;)VP'Q^)[2UN^Q9*CB.Y"_T"'FDLT/8IRCMI_*GGKRP?\D^_W=_?S
M!$Q&4IK>X_;N:1_ZBF^E>:^"81*UZ-->D7[[6%I>S6=S)3>6F%>[C#0K'PF7
MXJS-$O0,*>>J*LJ6OZG3.GKUB-VTP-,#UV-KI].]=\,O?M#/4W#_V*IJVL?+
MS2VL/^G]FJM*@2X;EWDUEW-5Q\ :GI]DS2C/O?5S@&%^;%5XBY9J9:^QWF05
MHYU!H6R(LROZVMM'.MI%Y0\<M>]I'V:BW99(*IFH/?9,HG#IC-K^YN=1@&<E
M)M3 7^:VXA50N->SPE9W9Q[V^19A@5&':L-]Z5&^!.!K\\"XNEEL_J;'LVOX
M(&=3\1&>EN$P5I69Z0S!C3Z^^]X9.\<4[E[["Y+.4<]]\5X/"A8%;T3)-"3#
MK$=?/"XN34LOV'R^O?\$YM?RT*'P3?+[N<;UGL8 0^$$] -[:4RZ@3@_AGWI
M*:R OO0%+6X(<T(8#[OUA/^.T!;?SI</Z8/4Z<1X1DUB#2*E>TFNTB.SFG4V
M_1B-WOHCT\4A:\A]2[A-YMFZ_ 4<*$T'] E39\OR>9+D4XYZ0MQE;EJ]T:,&
M0$%F4G1KI<#4H\4WSHNIAQX>NX.#[;-1/,\]=Y'=SP&D*P.%OD_V_*94=9LT
M)H>,[O/13\\:Z3=X^90A0!]%VA)G+]$FO+;W6GBPM?A()]J'] !?W#40'Q;+
M+M]905Y^CPJ3+.ZYWWV?8W%1]T7J#I;G:,^5)!)Y5Q97YK?Y_;:B<@8=!$@<
M3M6A#;81V]7FU6,/=/5/WM?LB4&+QI_I-!'$4&$XQY<=4"U.\C6LW(\S* WM
M)0#Q:0GA.8"/A?1O@HG62G<I=L2-&SN_M'QZ1SWC([38-N&>X"]/:;51N7P.
MF!1[EE=6,AOZPK47$I)A5AWC)DNA-C[)WS/CV0!FU]$+ -@>\8DP!.R'D+[=
M6-0$06):#1Z[\7_].N#R57!_29HG*JS?7]@W?57756#"U:%!AS#WK79A_-S!
M.LY#Z:FI[+07-&9%P@2H?K1"KPUK4I?;Y+^G-2??$%=^-A'][I46W0VVIQYN
MRK;"+#5"VYU4)@,^?I3S[J1G4?X/W8"BWSR))P=U.2LV.$=MO^=I?(Y'$F '
MNS0;N4_>TJ$1TJ#=I<RA06OLG%]19N_V ,%(:51+>S>EXS^ME1K<#Z?L-.R9
MIMB.XDE/.OER_(["^B//<=14'5Z%&)](H-%(T][(K,_HL+8J#\<:2IZ[3O5P
MC("R+<W!%Z,7=$SZ3>/Y-P146->VN.^6LU0@:Y8,RG2\)\U[1/0UU"PZ8]YB
M=\!/Z/CD1%/HR\I*^O3@X6!',?^@NN\1M8[;6-M=B-BJ[K1!6ZV8RQ:U,?_-
M\>+]%14<^E+^U:VW&V&^SB5[^ULC"A.NC]92'VO3M0QSFPUTMW9:>H0#F4"[
M#3L[7W<Z1+Z+2V#BU722[1^[[[;[?I90I=J0.Q IXC=JUP6ZE(@0NMCY@P;>
MO>\NFY@GCYH^8DT<I^O,IPAU!+?ER,;4]=@=J#()"C$SAF%26LDFMKLS^Z6K
M1_JGIS_:PN79WMI%]O5NIN9<F#=BVM=?7^Z=?B:1>0N/G*Y]FK-LU7!K)&G#
M7=^V0\<DJ:%X3"4J9%S@(,]=A-B@S,\Q1/1M'FX;)7NLGFQY:5>) C6WI,O>
MF42*\X.5A?7C8K#&&=<IK5N.E^_Z[&S&1O?0_L"G@UYSPRJL!FZW3\*[8YLY
M>";6]]?U3XF-MXAJWKZ23(+G/A;=R,C X=OS*28UW)&L 5@@M8F+W__@BROF
M?'?W^??OYX (FXE\M>2),Y]ZKP"[U3/-P@,(8;QXMMU6\C3/)*4=6YEP6PGS
M5W@M[;X64W2U,>8<'C4_UMX;Y)-9D,/JT4/E<B65>EHW^JD@7$%J^N<*V\^W
MOJO[>^91G$5Z='9YNA]:XCT,<5#//50X+9K$B6C455A#L)PTSQ4S8ROV]M<;
MKD3281-*P#S#5GDOPN:YX1!!6)WK,D9O84E30(QCA$:1C$J?S 0I:;/L?E]'
MMOB9]V!0=$6"QM_ TOH<<+#8UHE$VAGU5JMN!N\N9>]KKN?%AM*:Q1W&7*>(
MCX:'A:$V=)V(HO%I6TDJCX*G0\=VGYFRR_;*66++4_B^?/KM!O").>4.BFC?
M#<#1CA\U[<[VX/Q'6]XWQZ9G@[M&+E^*$R>]:T:,+91?F\P*J+2_BLJEW;HW
M9:X3WY0;]#$S'R0PK$>P"\G7VOI8>M?,HUKK24W;\CQFG>+DL54O@SNQ>&WN
MEA!U^M+2[&==S*SZFF8X-,=X=X/IS8C78?$SM-RT]-&T@G6Q: ?WXCW*-K#"
M^D/S=<V\*>$"K3FHUUH*N)I)+XSF)0W#E/ "IZB=IED77YA[V'&'.)7>&Z&M
ME3<KX7Z3>;?%*P+W]X_'H6Z?Y3].4F*N5ZWYWW<LJ/ZZ@68J0.)]F$'>$Y'K
MKFION#6-#1&F5+&S49TMXR_47BNXI2C.BFXV64IVB@9$2<"5%NV/6L)53TKO
M/1SL26ZAQHO:DJ _F6CTS]E:CHK?*Y]I6!F)32M%'1MK[@.=TF;R65J5F'P(
MJ9V\S6[D+R"?93O9HM5!SCKHF-;<U3:VJ:#S.0YUD([9(TN"Q+BWLZ&/RM]L
M9:4E)WWIV$=4PGB+5\?)5[S!!LW%/G$S+__.6/;I\Z.HUZZ=8'X.NR("[F&#
M%IW/*[0AM5"1A!,L=Q!+-%$G;NBSX9:)K _QV'9F+2WQVXCUB^GLWU._'9-N
M+8I2?0$,KD9*[@Y2=Z]TY*^<W7;;#$LV>G1[O/MV=?_#">GI<JM-^AFZQ1R5
MO9,&JGLZR9;)U*[X+UD244BEEVBENB9 T5N&;ES,RAHQR-^$T)8%![=$Q4<7
MJ6F/M[ZSE1@G&!DUNXI&[FLL\[\W: /I-124.YZY%C&!1(\8;85LG@)>,MC1
MAO"P[_$I883+8'<JF2)-*X8=!T%)E>.1R'8&J7&_S/.C392,UX]U9PG^NYO=
M'8@C?H(!NR$J*2^,T"4J"HU@M25(-52:J4'$#$8EU#9/*I=22A?.PN)[D.(0
M:,RX<LOLX7WY<T .C=V3G2?G@$HD@0ZG)PQ#\O?S46'YI+%$-^D%5QZ/VPZC
M%[E7<Q?5+@5]"H:A?I0TZD1B"(P%VB771Y7#TUJWH^\Q"Y>4+I3+Z*B:N3G<
MN*-WYZ$.]V)=N+_$R; $!HBJ>_L)+7;E.K5KZ9PGN\OT-G!P6R7[=<YKF;WF
M!V-N)&4SA2?M<Z_/!'IZS!W:GVP8>EK6RNO6V3U%CAZXRUR]<5K7MOJ^WNX>
M883UO<;AY>"7*GKVOME*[] V@QJ4G]S"9NJ<6FMX%$^#264JP-"M^"B,#CW^
MT;=W(+HF(:3;1\>F-ST&\ [-\2""/A@WOF:R(PX/QG1!<IJ>]!"OQ/K=,/!C
M@(-W/U-J#QD8?;3U&J\8/?EB-.F*DS ;FI-O4F$L8O39_69U2C0D4\6(E=GB
M,2E=1<2M6;TP;P7M[I&I1C;/;#L2IU..K.)D\*O!G'Z<]J)*TBC\.88*0P(D
M%?@.;V,4;RE;DH@3CHK"!J473+K.HD)FTQ=*B7D<HZN/,(%3\:H;O!#-P/]4
M8U(+Y67"PX/X1]LN).PRKP176V+7YSQ/5$#U0XZTAD]LF$:@<]I*[.\>51[J
M(#=6;_5/O=&NCFQ)B$:4%D!=&.18;'QT*F3$:8H$ZWNOW[*%04.&BSYPG_ +
M3I^\ /^!NI]LF_W40  VQBV4Q/<DMVT2M5P\:#")O?AT4ZD<6ZMB0Z7O?@KK
M>RO_$JE1N8LQJTB&(< )^M9 = >2)-S;J'/P3H6RD7;@/;28<I1/YQM!*[%8
M9G#:8]0Y1=_R0^XG7472C;'E%67(!TXOL(F?6G(N#C:D3=*^[H[7BH%FR+4.
M8/!CURA;3C86!L<RD4K9.<4\C_8M<PDM?X6MR+UN>0YXQ%6YI^C@$W+G(6R.
M@@3$7UN=' ".MF=C6H["7+W!%2N08\=M$WDOUM.0]8C)@(BW<;O -!<W/)@M
M]6%TB(C:#CZI<JWI-C-MPJ1.>4F#@<^3=_ GZS6SFG8";\9  -6"$BBQ8 -/
M3TP?W#MA6C3Z]E@DIO:WFJ<UFL*=4Y!EG<1;AZ?.G^U7)C'=0*^"^B>?=I.U
M^*YAIH93[3-@CTO+%M0E<;Q&CJ,UYQ9<B%PB_13D;#2.-X!$@CF88&K%77@.
MV#;+7!3W_[(R^-P%K6.YTVVY<V:LR3O4Y^&JMNAQ7@[1W[<"^UZ"+)F>"!0:
M]KOO\7-X\%CAL&6$\ 2XKF%4-)"VXN-,/!'=:#># IV:D#5PN$/I(WCFQE1"
MUCF@/EU#8IVKY/5[CB??ZC[F1-$?4K=+N(J_\!\W,?$O-R0Y=FD7W)%P_J9Y
MJ+F&=@;>/SQE+/-/$M7\/ZIH_0=%_WWU6?5<ZOVDB?F-Q/;O][?51*-F_(G.
M1D\"SP'ZOK[?N^U-E@:)%KO..K?_MS73?,\!->> H,M8SP$CCYT_^5&< TH^
MIO\YJZF>U+7?64[S]I&^EY^<GL5.ONY]SM(9<QKUCXJLP3@<\Z39SZVX:GRA
M$99QJK&,+X3Y!>@M%;L)%LIO-P>>VDX9"4AV/F<?3FU-9\ZY3WM(X6JGH[7X
MYM*XX7]SG/X#BO+ELS*;%/OO.&*$FKRL><OHB>@6H>5S:?9=L_2CB*  +9S,
M@>$F0;H@:5 ,D5#_)\M%4NOWX184/ZR53/X[F62[5;T_7Y_TF9!UHGG(U6I5
M+T:C-[K8T(O -Q)]*5A%/C2#CDG$U-*3E:BEDQTL*KS3PLYWJJ]2]!)RB7X.
MT(ZAU_0*X L6F(=Y[4T[9#'+V*Q2!J)+XX<SHDMK3H<SLB@[AS,*=O"$6Y!V
M\$3]%K.OWYJOY#F@L+GY'&!9S;6S<CDM%H]RMG)&\4[ZUK\<J)B? S@]<J@4
MOGS/^X]VY:K/YP"_9=?=4X8RBW/ R?I%@BG.MD_)_]-P%<)_@#L'Y/_F8."/
M#LX!:S_"X/TMC(MI?0Y0/[V<__-GGN< ZG\3M_>/N%L2C__[ND6C3ZQD/;J6
M&?NIE/4#D*U LI+:I+0[')%3.'QZ8\DTM=L]C)S-;UA%E]!''E'*$R;N[(P1
M&_WQW[*I>S=DL,\&C+P"K65G\LK63^2H[U2=S@<1WT;CG.R[?83#'QAU^@%Y
M)WH(%;E57%9HNX!$+7@-R_C9>.;KAB>5"B-;12\%J9;Z0N\$5U"?"5[< 65%
M6Q;">%H #_37FJA\H6J/A^=40Z T*??BOK0&R46C;+D9+0SA(@$#:]TG@ UH
M8XW3Z]I!5:=UF8Z;\F^%78O>+34SQ-D$RK#7F%20QQ@S?,X(@4 &IV]4/H;M
M[.AIR/4@NZ[+KD&M&QN\ETA2Y/,/T4#EX6RROEEI4S;XR=J4^J\WP8PP=S)B
M,GB2E\;-=PKVY&S/^![1)#PB^(B,GD>_PNZ6R]J98$KD 'H[*Z  IMW[YL!9
M XGR6VW8Y'G7SU_@6DS"P01?H.,_!J*T"$*ZUM9PE?QE5P7>W:.[DT1Z(QS7
M-O1KZ>JQJSZ4TR'KI@%_8YP%Z+58JAVZU4:&B!3!C/V4D3D#&P$6HJ1XW'Q6
M?AM%V<%$+*O5'/9-G!!L)< FZ--FEQ!E2U+<,A=8 ,?":;HJ8[_K'99PK4O*
MQNV^7ISW*\Z8><QA(L@/WM:1!*Y0MB#BVN@3U^X:N DYDBX^I;VE?F*B_BRG
MB#_7T;(62[@X_U3EEB!*)YAOO.Q58</F:&9X9#$X(OAQ+@E>QO<JUS-;(Z!'
M>QEFOREQ  F0M*V-8JL])M$ABWCTA0(C:?47MX4),1&>8G-V@;,0FO8'KO:K
M?)-N1B$)"\NH]#BGYJPW!BRHQDU9/Q0AHO?J]ZHUY\Q"]%%X-B)R)O85OZR$
M3K50X=Q6CRH=>4%_*QI_ZGY7[3)D,M$<YM+2EC3[>F3S+NN.FLSLP'2.N13-
MD3S>=U9N)P!9IX<V?VEU48MLIK2.G6[R9"WB9F*T'3RQR[,ZLMP@V_A-V;8,
M?[BPF9U*R.W9P(>][%5?F3\B$S?6%Q&Y[70-JQ YT.([1N_HD$Y @%1$2-%"
M[-Y=6N8>?6#&:+364(9<BAHT5G7QSVB";Q@#A$@+-5+&)APW6)?3\P),H_%8
M.0<KBR,CU^A?LMAW"X5+=2;$+]2P"X1TD@+Z*PL;N2==O^4L=".'5%<_;U,8
M<72=/K:(7<*NKA<+  -GUE"YQ;(MA<1[P5,*;% -<J,7/"+X^^X0SSSCEHSW
M&9D<Y;YJ7X/H@[K*^GC$ ;PSFQYO=,SI.;[3=&F6/.T@O*B)V^$6%V5Q*=SB
MV(+ZH//4XJRNZ[OU[<9TH.?M-<_BD-E9DT90ZC]N+WT/'6:)?+U4G\FL"48L
M>D3$1QC6CVN:*JS3W2[H<7[;;X[XGI?L-C)_N$[Y$+[4P O29.*7+9@)$<<W
M#&UU\E<E-"+\W]<UY4V<^=^R&38:>FFWNH[A15*F]5XQF;SR@?E#2AQPHG"^
M99/5O!35D!!@)C"^UQG$V/YTNB^2_ F9C]:Q7^>X^#S[Q)V]SMQTV_UY1V^<
M5X?/1\;3@K(^#Y0Y^L[".2+PS=;&JEEW<WJ3I.*;U EAY5U=CA=?"*T4.271
M/(1.RB@+C&3/\,N:,7+14JV??]^X**KB7WK;(WF7?;T$3U:B.%^</'(W-X%[
M>7"5WZ2\ Q][GCW:M #.U>(_:(C-4;,A\S6Y62!*8:<C[>!28DR;O1 6?N.0
MZ8&C+%V?+S.78-@]0OL=M/3!]:\[WU8C=S](^-<L&4;,4!T=4$NZK^<8F8U3
M^GI#WQW.TCOJLQ?)=6DN<MT44I:E" ZBY__67V$YRC9V#IB41R88\=)NY1FW
M)SZ^9\$B1V9J.H26\CA*0*'@)OL8[E:;[2S]>TP_KU<FUKD"W[M#Y"?<<>R4
MZFU86T#]J8"1\9;%#4(=8 J4>"ISTAPG_3F_&]T;\[OP?-Z#E9T\>JK&-Q)-
MMNWG@%'ORNB=TZJ4[ $E#7YJV<=<\#SY_G5?+^36FK2 (X&9IKY.-&IV+"Q!
MPAE]>&AF%DO,DNBB9/CIW?*3X,-OJ HKW[1B.GS<\8]]//?[5;T.1_>*_*&(
M@Y-%Z<XQ65IGC'!=V &',+7V>LL" Q=),J:6;/R9XWNRV]2.=+.0T@%65(%0
M62TY 'L?K@%8\LWDD2E%^E.TI?5W5'3<>.XXX;OIB]1I*D/B9<3,N4WEX^OK
M\LM#-47^8W0B>1HOWS/MMX?WE[PPH*6]PV.87&# 0+?@ .&WH9).L]*R#X>>
M]'J.?>+5X(L%,*Q$&;\6#H>A*HAZ??=NK #E:)ZIKC<]GW^P?Z!;XITD-\5^
M!BUVJ]"C+)_-O'FS;<1E%Y]_>8/N59I5:3Y.IQ7XO:PB0:3IXN);P3J$!4Q(
M[L2;E?T3#Z_C1<%^GOD9)^?.])+I/NUU]Y.'KZ4VM.,*IF0*13*J;FD:VGTV
MRJJ5'H<)[U21E; <,"YI6)@KF!NLJTYQQB%\@^%K'<FRY^$K6B"2KG*D"M[=
MC3JBEOCX],3G'#!FA]N]/[/.63M7K:KL(/W6U<YD2]$!HQQJU[1F8X<#->\B
M[Y,=-ZM,;>\SJH-G#UF;?&.<6D(RO&\/#P!V/W&$O"!8Y;U+K7]\;-'P_/O6
MR7C:@S7>:45LZ#F@?8,T6\+T#+*?I&8GOL;/\27C!7M83]8:I\\[N].',:G^
M."]>I_1T?O]XKUG>>?ZYFOC]5 ]<O,Z%>Z=^/B<GF/.4#FN]DM.S=37[)B:0
MT[O5-B*A;1F;-2QBSS+9=+B+$A24;[:8/QG2G 90#EJ,Q[2'[:H9FZZ%1B2F
M,)=T9D6K=FV<G)X,GKY=##_Y+IYV#L!<EV!ZE0HJ/"#3EGRCIL; WY5/3J6F
MS;/YC(Q\H2<28Y>;G,&J/R(4 0Q.Y8X#?Y(,)U9I6TEA+JH_M=7E,A73YT?8
M.YLW2\HSJ^.@I\QE7 K)V.SGJF0IO]?PVK1['3.0T4$Y8>R$42@72^L>YT8%
M)\RIC.AQ3W(5*\B8S).6)]VX"8]"Z\/V]M:WQN_^FK.&AQENX:$+$Q_F&%@Y
M-'<\LW%)WQA_?L:*:8I?/D=:JK-EL .#X1IC?ROJ"-7'#$^T"52Q_!PH%EYT
MG%M$5W@2;N#X9:TCGU)HEB#\2Y==RPG?")<!D,$P,&6V9<)1-8K!WAK]56O%
MS=/8K[&Q].DL LQ,W+-.FC! 9Y-7AW]*JH^"FX]_U/Z@K]_&H&8*4^UP2HE7
M0HE.RD!;WC0'@<;-_LZ,JO8Y]![\@?;[+-S$!6E;@FE1\"<)J/=147*%5>&=
M&5.MA6U6( Y&>>]FB1:)*I[U=%'M4_.3QS(CNGXI19\C7I;R9[^<,"AQ=DA[
M1LQ;;/K1UJ#-5K>G\@$?CE>[(^*\36IP<1!\M K&2DB% *CD9<Z[0V]AF?WT
MV&4])7%L)E_:NC]C.<_^[!/&E.!6T1VI;;SCX15&-B3[A6KTBR5P)WN!\:)B
MO<Z\FZIR2VZ)7+><+_8DRGTW8M+O_J)^5<EN#\H07+-#R#RC0XOOXC!:$=06
M&AR,5XY$!^36OE=")CI[9C70VIER6A"AB- J5<4E:L8D<$(?0\J0&L"JDX.Q
M]JBXB,8FP<[!0<PN?:X2"_5M0-&DFWCR.%20&/35N#8]5_OV%Y+)J>RNR7##
MC$]HF*_OID:'T5$&%C+I9YAGTYC$>RQ^9W7>^X37[/]XDG-SBVTK<OA&TID3
M=GA$VNSIF('Y^I#9N&I*^42UB>6^3G/-*!VA@X!X.?O8JR*KIQ?=Z>Z3>4),
M2R.:>)L.R,K00<4L)"%S0MZ1-SN%J&-O(+9[SZBJN!=:_DX,7#JBGI*CGQQ4
M-@U/%CG)LY-+K.*S%&W7,0X*>+<E:0Q>M&<@O*$%[<!Z*)R;CT7BV6'K1Q=7
MPA?Z]GU-+]7:G($P:@.94,FZ=(/9NVV'N_H;!"/CO;):/D9W2U,U V/'&6Z+
MWDD<,F'((26;'%R/ZA47_%:A;K)6)&SQFF5:1U46.<GX(+(R#TJ\D;+<5&>X
M(5P[JFB_*4%F'C<)M_A@FV2(G"I9UI5E+!M2K0@.ZQY>4RBB#Z&D1Z#GXLL=
MKEFK*,C\>+BX2Z0[=.=E9>;!<7S@Q#,[Y2UX_R@;,*)5[8V?MZ'1LJG=Q.<Z
M4(8\4Y. "T_)*]4@N@V@ZA.6 *)S0*3'REM?-@>XOP78+;MUBOS59@ZG@;K9
MNO#WAD8QH^K!H<)S0,H+!Q"49_1X(2OW)AN#X# D:?P0_0D18B3M/50%[ ^Q
MH _/A5)!12J;V)G5T_7K_?Z97TA.0K,;=/:7%Z<!^OPS*+81D-+QM0E>5$RJ
M0=O'I=-!&9K%"<_XC[H"HG/?6'Y%@7L;7:S -.::O#H?^JI)2(Q,%&]\WDLO
MD&]X;S#O6**>#Z3J\M?SQJC;PRDT>I133?32<BW"D]8N@LW,]J3_5:?U. &(
MCIW-P>VU?W"/>ABB,MWDF.,PVQA_/AN[B3^3*WOH@H3M-YW<%JXTW?&4=R26
MN5Y3=7C6,[Y.CZ<(P7,"'"]R,3<-*NT_5)0P6;4ZV]W->Y? ^AE5L4_F;6,7
MY0I1A[_!JF-IG:(]*['M"HL.ZU/[(S723:<&%+7Q%\^4+'%YD/29=W7(*T<M
M<_LJN/!IB5F_HS\6Y7_ZUB=4)1)?>?#??VK\<W.QKD^!V5HMD55\ON-Y$MKA
M??^NQH<=J<%G)4]=NQF)GF'W"^'X$!(.%2K%A)4_\FQ)]BVE8""(O07IE%RE
M-"#EH%9KK@C]HFXDS[::H,&X[F_/$LKVRH6(TUR3CC64IKMJ[!ELW+7ACN?X
M\ISUXZ6B%&2&<X -X'A&$R+R)B8 BE05P @0QD#)W&AR"M9NTWD7NJ$V7]J5
M-YL&;3(VR)G-"?1-$-:QW8$-:6X'EF=,4T^C6F9Z0[FGE85U[B;J.7FK912+
MU]"U.;7='7$8<8@(J93;-,74M8&#G@T( C<[L(@C/-%T(3GM5EB6_;!CH-H1
MD$<(C4PD28CA0VQG8TT]2IQ%1^^7?"%#6O)#BU6'N%PECD_M<V;2-MV5<LAC
M(3@33#1@1HOL10,Q]+>J ;=3S6)W&40^WMGA<'"HM]!5I5O=:W@8>@Y0&WLL
MO58.B.YFX>:+C,U?]+&V+',:0 263B%!ZJ.4#B8MF@)/L1J((;*/0U(4)TX#
M$>Y3KM*%1E1_\'X3A"M;QY*9Q _\WOK"9#-E;EI8AN FZEO: AP_R7;@N$DW
MCQK1FW;:T25.W.J[;K3+Y2,?0T)3U7EHUJ0<[.N-\[+>VXYSLRG8&ZDVC3*3
M!1&GLI5S"\U@._?=<H( :R5@GY\/\8SRG4FOJS4D/+AO[\P.%&HQW4;5D 'H
M^Q[3LTII34E1$Q41Y48D6\QZ,^F*4(-C0N1&LACT3[2;7+1[%<V<^13Y!;WL
M'L>> ^ZO4^0W?^H]<EUXS62Z11@'K[DC,")'617;Z^ 0NR/=5\(72YB^59]I
MQX,M+:VH 2-+P."O#YMY55>'+Y+W!CX3]L&:P+2BTA2[HABW%1VT$C-YQH+\
M%,=,W>QN44;40W)';2A8G_F14J:Y8F?/85$[[4QAN$!,Z7H18,0A@/<QD97+
M@$N1ZO1:4O@MGD[>%G3JCV62WLQCWN7<R1P!EE804C2W O$D:FLSNVB91A6^
MD-?=F?%ND8:-B"K^88P:9D2;]T Y_*[I:BS_O&DT?QOFH0R>R%P7P9F'W&,;
MAI59#:3E0D$I'T>$B*EV9CESM<NQT)^CUI@JES(&ALF\RHQ$PL+)XS'TG/=*
MH+PG?&]"3"P7ZF4G_2[D'<\MS"()O=3ZM=O^5@<]QNGA OPZRP?.#CW3EEP\
M9/PP#9UG1.&?@N$%B$DA(E\9&_,,9O-].:K:%9Q+O!U]=R<'IN=;QP[Z^;7]
M2P].1D?E9(SG@IF$9\F(24"Y6AIW(T*9CTGSE"!W[GJ\R,1LG3J50/C_2'L+
MGSC K]]S*%+<BKL[%'=W=W<8G($6&;2XN[L5=X?!W9WB,$"+%P8I[NW^WMV;
M;+)WW]S<W7S^@2<Y.3G^?=AJ/.Y.Q/O-\8$PB3+S>)C\YFJ>*GGC *16S*_Q
M)\N[TW<7_P!W][02:B^="KOM'5$?OW#TH?%<XJ/11)=8<SW@F&@DP296!($F
MJOTZ]*GZMHV<M.H!Z.R \7MW'=IM\ 4\]+JLR]I?EEJ5Z-SDST(GR%J',$AH
M'#!-EV)K#3^I2B HG8]FEPNQT&G ;,[ MXJ\@RTGYWKWD&@ZZT^ZM^[NY'3S
M%ZZF!"JW54]O/]Q$HQ(LX:,\G,V%4>*3<+(+?9A]"XAO_JD3*SJ%9\M>P<F5
MA!DD_N+WJNO(>LJS_AP$Q6KUAE:]M_T.L%_>U]C+KF*$G9&T'&0B?O\<P+Q@
M-QK$%6_91?AWS,W'9 #?JLA=+/[;!-&K=X"3NUO825&]7]XI\YI0*T.6<_HF
M?U4>E@)3 7)&<%I^"(78CE[#(;5MK=<Q95Q=" /'#(GQ "%C3*;Z*)H=>I11
M/6^^%9$E?%&D>/H4+279NS-ZR)WWLD\4%!VT<[K1!W7:++"CK?Q!^!YG5=QC
MN[H3"+XCB,V BR8/0@-L%ZJZE,RT;%*?X]KU;K4<:Z;9ZE!1D;W)\QRH/@('
M3R;VKI^"A.JSU@+05TD: YT21P8WOQQO\WU4<WJG:1A34338;:"L8_&2K+M^
M8$X)KX^BNS^Z#79,PT+5)**/+2_.?<4\^LP0X/>J(PH\R!WN2*J44W"ZZFJ8
MAEV\;_0W7^2UXS(:7:#LH#C7R'*U,"^J5VO.S2.ZE9OF)C;+)%V'X3@T'K-H
M"\H;CQ _+Y7@(WQS@Q4-C'P\T#*$*TPWWA)P/1<KK_5'V61G)^^\<@'M]#14
M\6-XJAF??O.F%9)PH% _JG<Q$$ZOGTQ)-VNK:<_EFL)5"J*NX4M'GFQ5[M[H
M8^8ESWJ,>FSH<6S<-? ^V[G+FURZIPM0:]96UZ$TCG]V;'C3_=A<]#QYT[\3
M$O2:1TKT+OC]&?/<Y_WU/P6/<<%=WLJG@JK*AUJKBXL?K77=/^T4+PI\C2"T
MVBUBKHM&\Y/R"L1!#4Z3[$-.Y;H_W=)UJR$)4<Q8>'3?'#Y__Q,%#@52]/GZ
M'5>*]V??/UMWET]55>)5/;K A-=.5_U9-4Q;:6,35XM-VN<J.8\#A4WP875P
M]U/YXY37?<$+HYXIQ-@9G"_$M =NXQ32NDLKE_6:]7>AZKUJ:],G3MYW#5.=
MSB[ &J,->NG[WP)G=WU:CNU;SHO)>)-]))B]@?Q&L/1SVR83?'U_'JXH\8VK
M\8$010R-Q^>5G;7+KI67'RI-ND[+N ^$EX0S%#.0^5GYY5^FF9W&)HG6NDVU
MPB_-:F7Z!_UMJO[P8P:L6J75H#YZJFJ4+A0EF72QY_N)^>;ZH)4 _P8C6!CG
M<M:''VM,<Q'X\K,IR9<U5@DI)%5=Y5ONO%2=[#^(] V(L^MDJ2N_,941)#%-
M%_5)+HGGWNFB<J8G[/7<5Z"M>"?@@SD:"]08:7W6" LBP)L54@2V4'WC54-.
M-(;!EA;>(^KN[2[.HT2V&+D"8AQ&BOLBRNE*B0:%((K.5]2T0V&>6CKP_/V:
MAN%5=-@Y4LKZ%L4V4&&009N[NH%)>^N&1+GWIK86S_=F[QB%134&A^Y@)\4E
M"C$!VZ;.@"K^T'=9["?6B>AZN($!"6-_YN76G.Q$,)E^>-F9,:FU2JH.A%2F
M=>U9!#)8%#),$I^0%U%';++>[FAC&9/Z'0."Y(@<IRLYIY'4:+&PJ#-"27D
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M\_!0)-2F7]>=Y)WLI&G=HE7Z+_]?@NC_?]JNNE_/BHO;/4'EF\^_?[.J)3O
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M,RF5YV,E1J_P,FV98F/S:L[JY332#,NPD>;*XA7>GUWW"]@6P%:=_COBGD=
M+TITD&P9'+8C_L*Y!5_:"=HK/H-"?FPQ;_3LG+<;K?,#RCPO\T/8CR3'%Q0.
MP6A!79.V4@P'+JJ1/+$SBL.UX!^]XDG?8NS?770O$-MH=L=UL[>9/^URMW2I
M*\5H1G)6H;T/*KD/_NK>FS\3FF%VM$HEIA7<4(:H>[W&DV(2Y2.)G07L=P[.
M4;=#,U7NQN<*5&R-Y.K'FB49#+UB$QN3E1EVI)[B,*2H'T:8CV__#^+>\JD-
MJ.'V35MH<2M.H+B[>]'@[EH<@KL66MR"!??B+@$2W"$X%(?@7KQH6ZB<YYU[
MOMP[\][SZ9TS:\_^"]9L6;/V;U-""T>&#LPG['(FD *I"!'*,M1I&IAT=L+Y
MAQ[B2YH$9_8+' #(+G2Z(F+?+2=N',<9"X34T"=5\_GX!)EL\D;,8ROY45EO
MVTM$<)-MN=OP= [1?/UL9Y$S$V+XPXFA[I'*_6^E\C)Y/L6ITWBA%L[[XP-C
M%NY\','$F0299%(.+;2)<:],WBOO?X#)=@I=GQONLH5*BB^1BIUFE<FRP+EJ
M]1 *(!&4?'G=CI 4/1RT \F<X.0?H:RV.K[E#P]W6F%MD3G\',(D9GVL)#4F
M1+ F%#.Y!D[?I*Z-:I[3!Q_::.8OSQ@NN+GXX&:M18ZOK:5(^G.W:@C>0H(%
M?2S!@T2ZH9<O;T@J+J@,%^^K^ZM\UVGF!4-X_)[A?!K,1U-*SL!W]I%B5(C7
M_P!3(?M>AUD^V\JMSA3Z(&8. P:;N[^ZA'_5/?F56/K97R\&(-9]KUW8M>8?
M%.ITGI4L ;E.ET%BK]ADX(,CPKLZL:-2ELU*(QW 8.)#'UPH$0T$2Z4ZR] 6
M)S63YZ3*3^PI1/>RJ5VZ."R$HR8R,0J,R9U-(7=Q!3%K(^<\Y4R"Y[M[/46J
M_*VR(UTW<&]0#G$ED5'R&>Z.TCY[Q=/SLL=E,@E9V6#$T<V4NQ0BW=0<FU+P
MF90<NY#>Z74KB7C'1'9.IIACVZ!"G.^%F;.JBJO1FU \X>],6 *)/P+/$A>_
M]L$KS$]!+B&Y+.E:2VZ']"%>@NSS( ;.VALSU4_W/]Y0><ZW-M'X?UBQMQ#_
MN_W'MFB+(?EJ5E\/N)5189$8S2AY@W_[ROI:"3O<XE*UN:U"998_DP4+Z?5T
M(#HK>2 Z]T< <A?Q(V#5L&G[_\- ,0W9*<'FJ#;;&A Q:)49!YV?,RZ%C93/
M&M9E,9?3V>"F8W4 9TK9S7GG75@-OV":A[PR)AZ<4@Q3%3:1RYG,_/UC2P(]
M5.E+BBI>Q!:ITVJ31(#R6='$Q1KV:<-VS=/D>C.WIIEY<2<N8^?9_!M!:F_.
MVV1179J8C"?\&J];=O!JD\F?.RW+7JQ-?,VMU4;QH[7W!E+^#C^&0TG.,_\!
M&KF=NV<7-HF,@OV["U'Z^^3=BZ7^%OO#PFII5]O+[_"FK=\>[<7W",_RUH %
M+(7?4-R^RQY^CQ,JZ>VC=W2R=7=U @@\^3D ,!(/^0=HL:NG2E_AL;O@'G M
M=&SO"GVWY-@E9OYYB_2/KY"#^+:@.>3W@USB6]NXQ*YL/Q.^:V,,:1HO&>9/
MVSV8Q25IMCU%?S&0TJ*_.T[VM/#Q?':^W_R)D82=&/:MN5'%+*V'E:Q<35Y=
M9E8A4HS%>98N\Y>""S^Y;0@!TB0T+^O95ZD>H-WZC6L<NZAZD!M8:ZWLUIB_
M$6-ZP2:,="(NRIM9*V4J)?[ZU\_ =]*BE:$!3]_O-?0]MBJ\M[.Y=M@VI!9A
M?A;M:L%"X"ND'ZH3MYVKR\G@47RX@8XK2RJ<"MVX><4$OL77ILI?G--BG#YU
ML5?]$5"U;]ORJBAD<&S@3^OC"?4V\2[0:V?GU\=/GZ(#>/$F']U;OSW4=3.9
M)M1N=>NQK%C0O:?$6\Y^V8#OUK\57:G02<=[D=%KI5LOP*71*X!O-M*C0]JM
M=K/\A32="6GM[C46)JEU]O%3</C-PS^ T#1)</MC+4^C2% )@N1CT@^ERT]&
M]TDKG3U/M9KI&<NP_&;L]$4<TW,"B9:'%_8Q3*@#;Y)\H-0DGGV'M1TP+_;5
M]0CE@=3.N]W?8E=_SK0^#9_,_?[[X-G_U/MXKK00\DFE0$+3PZ4O\S+6//B'
MZD46O$R(I)X\9N<AT;YTF(=%*Q-EO8)3O/RK6LS ";.PR:RIW1TVDNC1UD[S
M @0\60V8FSN]O3K!3SEZ_/N)?8(Y5%=BJ[ZMYX(;V>!">37<ZG_>U/MQA>H:
M#'+I8&4/:]M)_:%"YM]XNVSJ$>*6PUZB/^14E?PRLWF@T9CA^%7&V-HT\(M2
MY^]_ ,X_H0$'@[<'_3V_? [9M5 2>DY+W36GF18;9OB*_K.[LQ-7W\#KP6%P
MZPK5425]\5.5[M'E5K6F2Q<I71X;<O7(R,DW@G6B449:=?E '+$3 K4YPKOK
MV]T_O8&+DN^2)95NYA9)\'U7EWUZNQ]7JQX+MD1,\TO]GY^+Q-?1A9+$ZFJ#
MBU3+L%TR5X=T'ZVI4]O<J-9SPEIC$,X\P:89OR5URT^L2RWB['.% 3^*\?'?
MO\?YF_MG[-V'=^:V=]?7^X@WBT9++&T2BZTN\[V('-*4YA,_KC&'-Q7YYP/+
MSE5?D]I'00/KOJM6+B'=#F-NE/*>Y^DTVG74SCUEY2V0U6-[RI10Q=:YIX>;
M[R?#'5^37]S-)7_LV_H'N/GP]=W_$\V5-(Y>,O@&?&C/.DT.GZF4USFC3FM]
MT6 ]9C+R*\/YXVB.DU_/$# HJ]P2(I/<,Z7YG]& S/,"JQ)7@ U:'?U3+ ><
MOJE0_ZFXRM)<N'33:[+BT7[R&\^A%F4J-K_<RG6$O:!(JN$>/:/<G>V&E)X>
M:J;3[!K&1[V38 MRBK$B#WZ8T6JR[*[C7=K*V5$R:-)A! <U3IK!C:P0EHG-
MYK[W174K7Q=NEKZ<W=Z(,'QYG%UN2@!&#IMFZK<J&AQ?X&+[5*\;?H6]D,:Q
M.DN(*0O1V-BX^@?H$6B$#Z*?N7W8P$CN6=_#B5LL,3(KB1<P^-R]PTEV>C4X
M="EZOOVJI;_YF]^W0DX%P0>OKEXG*]?7IF]=">_G&I]"O<Z[&DCP=MQQ(UN?
M259=.!M;_!H[=0)&IO\\,4N[>CX+4-!@W\"K9VSHM8@#7]Z70 ^60Q34.7_?
MD%Q^X0KK1JNV=HWYBWN^>GI7U?2A:;(>CC?K\50K/NN7N^0BW:'IXIXS/+IY
M]I3;.Z&5@;C,<7:USTN!<YIL3+O^46*B$W"J7W[8//4]K;VWU8,)G]M7KD?,
M1*0D_P/$SOT%GZ\VP5U3*C<V\O1431P?9P^02VK/_:U^X[*0NC0R$7,+AK;N
MKNH0)6,-A/%T3C)33L>Q2RHW-G"4!HV6@U;4DR[YC/'3>_QW'Z2?TG>VDM^\
MT_P': #Q2M7M,)O42LA,<?>%F%A(;,""K9)>S_!F<3=[+LUDMPCQBHQ\\ '[
M+G*?"5B&/3KNQM6+6+XS5"-GM6ES53/,15=J_ ?X<-;PQ^.BV*E^A;O8]#'S
MP&3]VU9+ZI:?(VMFD@6==NKJZ'D>?/_4N(AH5_$1^0!I'?RBK&CRBIV47VQY
M)D9!&58;'Z0+*YX^.!,H7JB:VWT?_KP2NATVYL[E*/I'K<E[8?1#3;#T=6\C
M2;A0<D?;:F3U2$['V5'6#^_UC3GU1'2#8$N\45)S:HINQ7T=Q*2D[W KI7AY
MU6K ;_W@?X!D_";8JE3LYM\5Y85N_*YOI(5&:I4/BS5;/A?/7<>V)JIFA]?0
M$!YSU*-02[+%CL@:<-5E$J_E7L'WLT%Z%3GOH%W?[1M SKKQ',73/\#$R;7N
M:V4:1XKOS\%S"[7/=/ ?W&L65P8-*5KE9TDB9P(+O:^%*VSR6KD?5V4O6(Q<
M6_R#-IY7=N-BA //*S7"FT:7XY*]PTDWH._2V8=.OS;]9R$<ZS_?DWV*_'[W
MT^?^>>4Q0 "F6VA8?1XZ'; P6QJS/CWDX2<!/&TIU7%M<QFQT'\ZOX0.O<KZ
M<]MD-,*#CU!3 JF/1RRJ"-T %9X>CNZJ[Z4^MIJOM/X0:&XOQ$?E@1;J=6P0
M'XR#"]OK+?)J/E.G&F<]%K8,+!6;#\5 DV$*6F.KS$*X_JOVQ4X4PG9)XH8\
M9Y.@+^A?X,K E'CR\8.#N\%[MIZ$G='Y7AUEAB!<#N/JQRGMI6]+)L&0Q%]5
MZ2*FI[A=+=_T+K=374-!O"YB<I/Z= <V2BU3Z5:(2E5NN1&K&=F?OZ7?]3>>
MI>V-!8K^_ ?('K@[NJU!K'>*1*$O#%<B'K*2X/9"_6Y=:$NX**)TL7K/RY#0
M[3<TFI)=AU)_K=OQ:I4'5?L!.@)O %9$@%C[Q$)MQIZ/JS.&X+_3_C&F.RO=
M%<?7]2=^Q=8A7JAD&(>9G//!>:L!N85DWTJQ:F?I[X<GL ]"R6>5]X ERL"!
M&6>\FWV)]:7J*+NFCJ94T-/?,)*N#6S/-6>+VO/D(ON?.C7Y'XS]#1>M/1\E
M53K?UTS.U]7SD="6YMDY?"(+[LAE9X^A&UI#C]#>G5$BS+;L_8_/5(\GMK8O
M?E$FZERKF&!,&J;RJ!;#'AWVOYQ67^Y0&[7&PZX(#J5:OG&ZU58\PJHC2U9E
M<TAGY&+:\CF#+[GSA4Q)6X;?ZA3S[:5OC5T_DHA.',REI#0E<W2 =0TS&L20
MNN5[*K/OLW3K@Y!>_P"N!])!0B3/_TV']7\W67.+2I\YO%QHX86Q%B[?_37$
M11Z;+[,_D)>^Z4"\0>!VQ(NW4*HUI'\FBH^>2$HM_^ '3[F!3"G3[G6QR(!1
MFI6H"D3)QZ?0S:+Q/-]##E.!8B<!11]H18B<]46.9""[]YBG89T?T\QR9UN@
MC<F>CH0Y[7C&JW5V<<("MQ^W_LV PZ87V7IPP\WE7DBY@[QE48QY+*TC=@2K
M/FB-+3WP5Q'ZPD&LEPF%<0":..'-=>\[NAOHE+UT1A&_&QG*LF1QM3#S(NRB
M>E?4[;O%P/9Y;2> /Q7T;>V-MD%SO4&=!O"KL^$_ ,JM$=(4.3S*REAGKQ4^
M2^&)SP @8O=UFT[^OO>;W!K>4E_2Y.^31;S-=P2Q%?U#!9*T;J+AB_H;KZH3
M=0!,U#M7:Q"YX:A\8G9A95KL*I-=@6-3&W S/E8L^XK19UW-FH6-*U[<KFD
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M6<U-2>>K;_P#G6. 9*J2?UZP_RI598R8'=$SCFZ]HS4/)V]]M'ZV&5YXY6!
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M1B#)<8"=-_4'M)<BU0R,=CBBH@.6>PFI"*&K1I35/P#8WN9\]_>,W("#>LF
MW[":FK&RAD2VF:RSIC'(=#)_#":JE[PGYJ4Z)W:V,V29_UNCS2745K&SK[L%
MT1TB!4*&C'L(QN;;4FT8(=*(58B;A_FY)C<542,=D!I?M]GL99%" >:??AC6
M"?M.F25%HMT2#5^J(RSG5:S.IB&V? 3EP!BLH686)AWR@W=LFAB0]G1IGF*Z
MW_&S1 OC-W^+@'-1>^P!2/UZ6[:[ A:DA^(IZC%]X8DF?SDXLP^V)$RJYAA:
M,["0V<?;.H8^+'E*?&O>6SOD?ICV2L67.7U[4Z70,(2J$'1UHAE^65^9#8]
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MR8P@Z<U0.9UM[]:&]Q>JPG8B84<O&Y.< NA_COD.)#"B\5%([6?NEY<.C-7
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M_LJ+#8ZX%(6KV+F@A^:^41EN";=&XH&G.Z/*>9R_9M,P5ED$+;R;@W$*#^>
M],_C9"Z/.'R$,*;*VG^66WM'V>:*BF)]P<-3X90<9$;@MK%_KD"IQ[)POMQ]
M'LT!VI)CE0<&VA4Y7LYHU+=I==OJ>$CXF*_;U6/E.Q3KKJ>[ZS7JB0GQ\[O
M%AO$6N79<3<[>J8=>)5']TJ):+7B9!EJA!N+%QOASR6N\V,7:9_=&TWYNC#B
M4354G\L0J1$PMLF4H#6"'/$_9L86_$OC0V(LJ8+^\R1413*O31+V(I12IWTB
M/,NRQF%)-?Z'H<:-0V=#?)H;Z5=4KAWG0/[S-K<*8.D[H4P5P\F@D6%S^Q=>
M0Y2T1!1F(T25L+AXMK>X+N!ZM473Z"E?1#O8K='W-TC"B:4O9OO8##/BT:U%
MI91OQ@6[L PN]S*&/.WE ;ZZFP[7P=)>VL4#)O'XJ?L<01Y]0 UK0V9:=N&7
M6PQVPI\2U\MU2R)6SLWMXW%C #?43.]ZX%!J0;I%=FQT)IZFV&H6BK]R+'W8
M#0+2GD.1W'PP4V]8YM_A/YN%?!7<.#?V:-,@NG*CWY]Z$MHXS>)A:N/7H))G
M2NSA?(QLX:84I3 P%H^V?X%:+7=>_<$W:=O3G<1M7;"-;!=@'Y^@LIM^%<Z>
MC3(H]J*%7+K6+KY"P#/LD4T?TC/C"E*+Y6:B(& 501,T1"NZV\TA06RIYYU=
M@L,;ZX6O-SQQ=Z]*//98#7(%+71=U.I@.%F/CS/K6GP_*(79DPW*-IG8#19]
MT-AKSZ;E"E:@%H8K8GL()N:.#(Y1K+?9%B/N1F)QP+I+]' '*AG&SW[.2T\2
M>MUV=7SC=(T]IVJZ1;"NE!RO1^Z9) ;\:",7,:3WG^#" FO=;=)R8MUF2,@Z
MO^#@#\^3RK:HW(1"#R,$/=$ 'VRQ@LIT]R7F6XM&82A_39NGH<Q'DW^ :G.W
M8:Z*.ON[?X#M'#NT\>^0*PJ*-SC#OU.3#_V*#!SG-3#'B.&*LT0+4K-<06IH
MR7RX%:*6/C'SL<2/1!DA>B<41BG^^A5>LV40KD--P(M=P.X+*%2Y4_05B_MF
M.C1,QN <%+IRBY,>'W^8GC0>^TIJ6&R _ /=CAG)Y!^WT__?YP;_(QJ\DNXO
M_KK0GS=A^L 7FI>]1IVQL6QB,4CW_KWMLO@^"(DF24)?;1&C;<RR1P_YR*DY
M*[J6(/MFKP+^BR_.#'<\"YO_]+I,A^];*EB<J6S#F O>(_*#/48M?SV+^!*G
M!6 J.N7H_)KFBMA53O_.$![D7M'3;<O9()A$^>)/=;BW/HY79^ =Q3"IHT0=
M^>MZ4.G. :@52[(2OGZ"5KV40V4OKZ0E?'#K-]IV?EGO8,]QA]NS:6GV8?.W
MSG0?LZ&I3I0)<V_LA]-(B4URN 6]R*6J2DO0%X"B& :&0_(Q >2W*QEAIB?
MZB'0[6C!;YA8QZ-YB9S\!\XH$#)MBQ['CL-_R(UA^_9(\Z]1Q1^:5%0ZU<O3
MMZTU.GS3R,7MIY7:BX2X\"R=V[V4SY28#]*V^-6&VR'L?(,6DY2&_*2\]4W
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MX67IT^]M3.F'/H'\ -83WQO].V8?-M7 @?ZP00B9:@S[*1H+U>;JT7/&./\
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MI[MHMS( VK:G[B6W)G0TK.+BY*IA#!B39.W385M%0L#480[?1YMEET:AN;B
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MC8L$HALYK>.(LJ^F9C_T.D9?X*V]3KQCZU%$+3,W[NR[S(>[\!@6:AW&-(Z
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M3*6.<G7E5<3_\>]7_7/+&G?#2X$D/YI;<OQ-RQK)B \J?>LW4=V+CW54PZE
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M>WZH6@*=A</%LW4ZUBU[&9^SAYX!AD#/Q%T]01B6O0P)03#:<N^%G\+:V[=
M+Z['%9"=(5$_E/E3%0K0MW'&I^%30GHZ.1@(;+<%/FXAS^^;Q2\-L$J354\L
MR*SG31U%@OUFWA:E]@GJ8AZN2J#N^40((;<S9V#RE>^*I4==:9<U3(D3L9+7
M&(A7L,Q>6/>F2XLJ=0SW)%&&J9-I2!X>"7P^N%.C5X9F#X\+MI.?Z53.5[,[
M+4K[V::/47#K:?' L0H+TT>1=*R"8@SM[.(9&<NCR!W=Y$6T4Q7%MNZ(HS J
M,MJIBHSR0:V;8DE8&A? &,U(JV,T)5*_C96'_??2ZW'6XQ[+D7A8/6A+0F;
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MS@8XA7>&SYW#V+QXPQ8QFBF"+[<_*+(^7?^"*%45'P!5;D1[@ZV.F_AZ?JD
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M+3"5S2)LO]IS?3^Y:9^B_;#;;)A&9_)5/?C+GX^2J),V*3%- 6_.GK:O!2V
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MD\XRZ"^A3E*@<$8U-[_IA+M5-+/+M#)7W)P3TN6ZP/+4EMRJ28G'M<2!!:I
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M*F'JIL- LNRNF (O&Q?)H8?B*:AFD6G>4MR6*^'0C:?PM5;+)3-GY$PHUWO
MK); S2I=:B.[Z6IQT8Z4Q9?B0BKJ<L580T[-'0ST!@(B9:T6E,USU8P-,MG)
M+VNXL(L(X@5O^K:&(_6<NLY#[VR44B>I[>G7]A;$0AXR )2W>Z_K;L):!9/_
M90R(:WC[8^<5RDDNJ%BM=%,#Z\]S+SS-69Q$Q:VU\,$ >6ONBI44?^1]I,WP
M5@I5JWRJ[ZS&XJ7>C],NB-^S(;UK3.^FMWM@-%#[-4ZB%U_,>'\VC88YGH$=
M_K-.!)_K 8L=GI<3?<9L<_52,=G<82L!(N#$3-2,][C7CZ9?,7HYV#.:&P/3
MULVWGCJD7_$[$[N,GK8<DC(RLC4E#VV87P$SFO[B1VE)K86SL1B.K>-#O*98
M0L-5U:3U9)46L&QE3#$^0L,Y('#,%7$<-?"HC'ON2W(8"6W$<2DGY6_>(V,8
M#*$@H,D5T:WO2+S46##W9TEYH0#T7(V:U,<%$+RV$;1B)^H7WHA["W(ZY&JX
MOA'6K@0N_;H>%* @;,S@UO$ A3,W$H^',Y-;TF!XW(OJ9"-^2)9B&8;,.A^5
MC8U!1BU:X*RDR=6A9I(%%Y=N3*\I+PPP"&Y_%0&+;425.[G(U3,1K8U'=&Q!
M@_I-UZ,%",CTIEV;9%35"F-Z@O4I+DYN1*O8:>>RF-Q?R G$P_57K_[?#H,P
M1%PGO4FI'9SA5PW]%<HBNJ[\E-S>:"PO[L^6S4.\LZHHV\QP71'#M4T1_^QW
M,.H,]&J X_5)P3,.4! ?*C!36<RU:!95EKCDSAX9L<4B:LBLJ4)BE<P?#B=[
MI8*^4F-1M$DSP9K2![-OI-D!9/2^.@!C>+8H863H]X*9BTEL/L;*)O#*<EGT
M#SO<O!%>0J)4-I;I+4:(,ZEF1M*YB$32[#A&?@8,\^VD/C+[Z'C;9A8=/52G
M=Q6M:Q0X!*8A8YU6Y8H<14P3"_BO!62T@XS=E_'/D?+U(\(_WL>UV <:'=V0
MHB2TQ_@=6I<AQP"LKIH-8B!7C#RKF:I<>/.GE+>,EZ:+T:QLLH.?H7^D/;[
MX$^ Y>=Q\VTS3P")U],!RB1#8%)IY@G,7A7"RMR&(<9-VOADHF69*GZTOK/*
M7L(O7#7+[WT6;BH3J32&#%Z$,M<$9V=[*/__V4&FW_3(7O,M0XWG9/!6UK
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MPG^&>5[J>9.X9)#V4=!*K4^(D[8#C*O+]^ N>;X*V!X4/?_[H[76LV@XB-$
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M7IM^&]:^W^=]G2S#_+^?V%&:]4V+[$'QH\3[*7K6WB#ZBPIBSX_];XCU /@
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MF.]QY='@8/0HU]J=AP7@A^9&A!/PW;EW-_O^OQ,5^9?HZ[#9D8G9F<A<E;D
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M%\N%*9KQ$Q.4F-:1'(WUH]8:OZ?Z&Z' @X3 ^?_UD\[_C>D_K?X74$L#!!0
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M .!Y+N\'7 <@G8Z=;@)PI*VAEN#;LFH Y-,M -X%!["^=VYW.@EX ,#!P,#
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MA,;K'WWM/()6[<&/?/26<[" &%D=8BLX_PX#^GD 5Q@%7@Z=!9%%:BVO)X@
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M=N7)(S%QJ[@\E(%:Q1 6]>8X_F&U/-#96J7%U#BI+IH&O7DSPM.(5&G8>0]
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M5PG*HGH>D3,U3^\=RM^XKUJG/E_GW_RYQF[;TX=^76&%^IXEPVX?!4)"=OC
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MRI'K)M:ZBW!9DB[7@8CCBI-1-A]7"["2*LWCEA3O+"J]#+]^RQ*X(&00%?U
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MS43VA/DB9M8@4: 3T_A;R7&N6G5SCKZVSV)J6@'QC32-.CPS2F-(*VUE=JA
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ML#CX"4IB/K>SK01YF_%CE%7(;]-<'<K:U;4 %#@(R8^B" M.)+QZK[L=^C\
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M+S+S*!#_1H/)Z<B:J'7O,J#79FN^YA7YR.L]2='O]=N WG&_RE!TV!=]_<!
MUE[0'D/Y?RX3SQL2^' 6Y/[)TF W#(:S)\7^PYF]Y82%,[2$T<2K4(%:YKYO
M-Z*;3N4[ U"-TVZ$#=SL.V7/6[U&$!>(ZXJ9&%U:X4(K2>GYYMB35II3B>Q<
M$2FH<>"<QW8)E:U-^-A!;)+E&+>R-]B*A A55V]VY*++@3>#4M9V^9(8XO>&
M=)KQ;S)%3Q=@=-Y19E[$__V)8FUPN4I)QOZ2<RS_-OW1I5E>9KVE1%KW> *?
MW,KV@,PU+,6^="DSE#:D12FKMX1#\_QN239LE=KV34G#2OGE:?BX+@C1@$#[
M_./^KEF#0$],;6J_N:U%P[EA]49SB+7INJ<H+V $\0'%G@K-@TC!E?373M)#
M;77AOTSUYP(K5X-96[G9$V9A*':)[9*]C=CLD=)=G36B7$)W %8-@])-S9'/
M3U;8?U=!VC2ODRMTGS_"[GK/8=U>RNVFBJ:&G@+C#A&T-IXIKILNP%UT[#H]
MW9(AFCP"K3)FX5X3$:/<2Z=/I*TE+0QBL4M+=^.].JE#B>+^&JD6YGO1RILT
MB6UX(VN"I4K"=$R6W]>M&336@%[^$*0Z[D;F3=M]N45:&O\MHYW9AM,)G7*;
M@1<UNA7YT)^CIDUJ<LTW@SX7=OC$8G!346S2*)<C%&.B5"_&]>\JWG!8-B8'
M?^K4QQ5<[*?:YD&R2GR[V<D9B7^9LP2,12&2(DDDO\-*YIRU ;;6V/*T&:<.
MS&C58>[F>N,CH0U #_ZJ&QR$D&!:/O<.#?:-A^H;7_FD+#XF*56\G?/0O-"9
M-[(MWC_5K20B@(]4EV^\V*^3O8<=)WHN/M_OE8EL_5*<J+V4V\[A(P9BMA,L
M(CIK^SK+./0[^(>;CRI7R9,P?'8:78Y#\5&OW;CCG6&S&J>D3&9[B-Y(94]J
M-?WYBCZC%OGTUJ@<,6L#0^&AA)#KQ-9[7O.0=N^2A0U$I\$2E\5#QM=Y!R-!
MO=U=0.-S^LQ5[.R,6;N2 "O_%[;  OLE43Z6F<]Q=+ERN)6Q"7[RW! 4%=HU
MTZO1T<E/"FL1A"K^Y2DZ!=NG1'BWFR?\O*I13]T'&#N2SNB]'4U5/%+F2 _>
M#:H(VUR$R#!5/D*QC_)L4'A/V%9&";2CVDQ8',%ST#1HN5DF>>\03C5NF>@W
MC5L"?\! =&SGDL-*@:M^/U[&[Y9N<E*\V+(OV.7=*"4')@'-RI!YIHJTE<DI
M09*[4>4,?<0<@H,:N<BYH1@?)LTCMH)^/YMO:]\'O=[+A.,'\*=6).0IP6L8
M#*[<,<8- +]IHF\R]K]/9G<26WX@N-^$;%)[N8:!]MC%A7!X%?;Z>,'H;42Y
M*"VCCR,S8S'L%\NITM%<!G<:-53/BAU#"4CB6;I$9W"?J05<7642GCU\"YT"
MN9Y/G/\ B/R^MV((?RD-1>!)N'I#RX],YK]5+T&O<D!^V)IPE=^%/!.L[X3N
M!HL+3VE'4]]"Q*=6ML4O?]+*G<G$K_Y%X-&L80X98VQ\X*O:.AT1QS)NC<V<
MPP5+*2U2FUI$EX5K?OM-LO@.Z-\6-P:Q;$',B1X9/\ABU%YRIP1YZ7#U\-J!
M"<E:9MJKG4T[^ BV?B^<NJS1LE<'77I.U N+N-M2G^;QS(R03-D(*T6(HL.\
M]14V&CADU6-@]&^'--(/N!I8QO*([T,6=&,RT;8>O6-IUVPFAR=,%:R.\) T
MY+0H[L3=?5HV.SWL-*6.T80:=,,'#\R:%G"H[.Q<]>FMW-C/^6II[99M),8G
M79AB%RUK7]A'+%/.->-6M4D9Y3= #!>-Y"8TSKR\4D3O%F0$'-S-#[ZBV]1Z
M5-I[666VY1&0N68^K5'7Y94IS2BYT">8"*Z&!7? UKG<:<1M/&Y%BN+2W.(*
M*I2$L8U*Y9*%1O.4ADA.*JB;6$K3R+_T%/B=!!!ED5)*H'P/FE&/S=8/'^Z+
M#QWFDUO$)TFKR3!AO-DT);<@3S'A#1AZ+;B1U^V\;[V7C08?9)^L7B (4A<?
M(5)3E_R+8C&#'MG]CEDW>%QC/Z^T-][G2;HYH=1^R/E"_;F(_"5?8U^/9N[%
MU9V'JF=S>MFA0P:K<',:6M+[X3ZQM<,B(EI[0]F4+79B*S1IBX:\AAWT)C6T
M3N -=C[ V/DMWS)1V(114K3CS&/L/>-&8SN$U'X\;I8O-[Z:?8SPJO!UFI2
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MKR!<1;!0K,\3B=WY B?X#3*M/43U6/Q '\\;PG3.>F?%K55$@0G#\VAJ4!)
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MP)L#?SJ:H!G)K9%Q*IF+H^A38^A:)E1 Z;L&/A%QLI/-,_&5O1EM_HFJZKJ
MNT,B9^<OY)! O;FW'#'KKQ WR_/W&B#O-=P/V/&F\YM)QEDRP'[XN\*ER3'?
M3/(CZ6)GOOK3'E2AX?CYW7)'9I>M'D5>C)4S"5].4\'IL"\'.47Q!^T/3TQ6
M<=J<A\V]WEA[08Q(32I2=/L Z'YRI=""[HA"9_+<33O55HFMB0@M9!LZ[H_!
M3-,$??E<R'B2H%AV9*X$0:'M-2X# YC50JM;UMS#,#S7I)0#07SX9<>>F0S6
MG&N;S>$)D2N:($'3&0")RA5S"G*%02&LJW+X4:"A<3I(%Z^3NRP)7(?<>::Z
MN9WS/'0KGBRXN$"-I+C]G*0H0:%-#IN4H0%;6F1;-"C/_2LD079[A6*4TQX(
M8=+BR@E,(R-[M :#^%9.76$'63?Z[H/")E?6U]7@-\;=:4;FW=23)F4(C]RE
M2-ZR9'*_<\3J['$13D<NE"=_.:U?@ #L#O)=7&P\?S8Q9WY:$0[YK$=MWT%Z
M&3Z"'H\7 .E:TR%'AV&T4[NY^:T X): VA'I>L]NR'A\A_)2\M[ZR^FQ+.F5
MOFV^0_5JBT$B9.>-Z)]6]2]@(OG*XR#O24_)!F-=OO.34(E@2[!&-&$'F9;A
MK[XW&B1Z9!D^BT[*0N=(Y3 1R7>QEAS6M/@9AN"OOYC4H'%*BCM;=?"RX.P
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M+6#6$>AE7"#;]_WHK^TX4H]]'SF:^M@- S6]VYCV4#YI<V;2#-HY>ZR"X^&
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M:DSDN9C-\30>;*K<Q2YW;0B\6CV+68-N"=[0:33*7ST_02#]>WZ7PH.A!X
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M*N]8O&ANH(=MU6%!;9]#W3^["SU_F/XO4$L#!!0    ( #6(?U3>@Y[R^&$
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M&!AZ=&9E@L+^R8G_YK(_T4E<HXFB^!N \I( @&R0$H"YT0_ HB $8-KDHT>
M/_RF@V\&.,H\\_.O3N+^F/[F<HN1</3D!3V^R !4C$R8'+P1/B=CQ]<5;/0Y
MB!1 ": !, )8 5SH$XP(0!(@"U $J &T ?H $X EP [@ ' &N*/O&7P!@8 0
M0#@@!I (2 -D VX"B@$5@!I /: 9\ #P!- %Z ,\!XP!9@#SZ/N>-X!W@ ^
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M@(!7=GQUV%S+L\N._Y3WP2W>*JY@YA"P$O+H\R-VS_RM+5>[VRV!N>O;4H>
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MN7Z65,!-7=?Z6CDMCR NW_7S1*(DGR 1!*7(>V/OMA=+&K7@*#M.\_5$ \;
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MFU^./]RZ8AWTQN[C0^#7GV_OVF^D&.5H-ZOPI18O6'4 8G,Y,D*N7%9L25\
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M^"' ,WK2I;)^LF0NYOI=2C(/_)K0>OF$U4DEW8'Q4I."=@E-;J\*QZ\Z$%G
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M+@C]WSEPF-KO'1CR]XZ>$Q3QO6/@@O3]WM'PA*I_[QS&\7?5JB /E]\"\=5
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M<]<D>8W&KCTQW%)I@O+(]8G=(8SAH.RQ?"H_W&M/<1L3W.= 2?&9!%BD,&Y
MG$)P7\VI,!ST\/H9FI=D_81O\0KN3L39+O8!&>>N7E@4=-,OVKE67\6KX[DL
M:5%?8RX+<A,VW'N^'Q@HV5'0L1-X&(E+\5\ (_0A%9^S"K\ L#H^SE\6$9I/
M'[CY>OOCZ_=+X]WB:LNTK!NMX0$DOU'WZT7U'ME=+MBA7I&'G^6[_HFK(R^M
MA#>+,'Z?^?Z=")CNJNG[-Y\#;3)*7(7.CO@1[#$W"Z<:/I][M^GNE)G?] 6@
M,<_?Y[MRR?QLC==Z<5FT<\CR)USOFM-S2>_,/K?]0UVL/^E2.=;5_J,NVC_K
MLO\G[&K_!W;]R[H.[6)7/O]I4/^6/.]+ &:^Z1DE$RHZ"]5>62F!^RZX*7/T
M@H_[T+@%=N438Z:B(5-"^_07U+4Z7((:HWQ7&9NM&=\%ZFJ8;$J; @52R<R,
MVUZ4E!>5^BBJ\_+3R&9,-8PC$:*P?L9$XTE)OWKB%IOR:/74RJ@D+7&;&:<L
M0;!7R_-A>+TI**.APES4S#[:KM9W:V_-[*KF!;?0D,*FM3,.E\!@!BQ9/#VE
MUWL"$]:[O@^6[EIXL'HK %<#-#*,W/67ARB!V8P"]?)>$[P20O&%Y6GU<<B)
M9"U]QF?NB[.9([R.XYIK#SDLP(F[7P"?'E<VN-BLHJ6X2BHK\R3")WL)[?E?
M&Z%'-*"U BB-N H?8Z8&J?'I;*EL61(VZ\@  3P[@( *X^5&-MP"F7=&31\#
MW9K#!ZV!&4.G:TL>LBIZG$;IC&;IFDOU(\F-.\OP:?7G)1W6GDF/.<1NK',G
M0^NIQTK2DF3+?>K=RV>>!AN$^)M7@@K3B-4%XJ9R01P>YM2"C6=3GC/4-9X.
MC]&<TJ)HP-:P6D1I];+S5:TIVJTK"NH.K,Y'1M2=(X/>Y^?,[J^+>YJ$!5S"
ML<+3@Z8IN=X1HXR@[UGLJKFB>J5$GV4?^S0KI\I5V_E6=N54EA;[L;GYBL")
MBO>BA=>UF%F?>4SW6'1HMVM:"+47-(\V>(V/ZQPL7-+4[I&3IYM$FW2YE]Q=
MX+5(EH.$X/+=31D&Y3?(/&FI1$+=[=6UT /Q/1/VSU1I#<GAJYUY^K8C/JFV
M==);)K XJO;&-T646]7;KC<?W@(J#;2%IS0L^JP^=$ALD*SR7/69+/22[:OV
MB8)4.S0*O7:HKS=PJM^!5W7KFEOTU!M33#1T&13I]V6PH+YM<*G#-4U^X7-,
MDV7"=G]P^66'QP]U3:F&L7O?"SUU4&ODVBO[%'1945#/5.)O<L YONM3C:]&
M#U.%RH7/H?\E5?)_G4[^5A7)OVC5+QS\*U7Q/ZK*_Z6JQ-G/E,$\$,8G*1(#
M[\S+K-HGG5:%]:(DRO/WWH'OKD(+(Y&24^"L[9#\*O?8ZO.S<V.0V2D N6W\
MXO9*T/HGB<TB&P(>HXVW8IZ"_-);P4B!0,&DH3GJZDR3[FAL6]^BVI+JYY!]
M&T(5I7;-<;/ZH4)0HU7ILPBN#G2;:Y>M<)OT=*5[P6S9AY9(=?9'>$UX>MQ*
M[+SD,03.)+*,I^XUW7VJ3JHYN16!.C\A,=< 76 4K.T:JYU%6CQ[U=)HT7&=
M*\UZ-2E@)7A,YRU0H%;6X1W+JJ7L"T2J^0-X>46J;_EU((B>D:%'LA+$$.=A
M$SE97Z5+3DX)YS&A9T&G_WCZ9[X8B,F0V>DT0\$JT/OJBEHQ6=DX=$7)D4$H
MG!D_49.S8 %;B:C0HT+7CE2 ZWD)J5%+74%5NK'<9$JKLJN=8NUPN>>GG(1+
MM/>,F+P''&%G:PT6Q00U?1D;J7O'HI=W7FSE\,/K8Z[HA%K9SYBL4IH/5#];
M'6S4%<"*PL-3@+JS8Y#"!$!!4\8T^IY5D3>#BL>1;9-S-@L.[M6UT?9C-B:-
M%BFKGKPZTJ>V_[* D?D"2,B8ZU ZK2_23&!4,N'O)W,-_/$6SPWE -N 4?0B
MF1,=^4IUL6TFZKP51\D[HULM=A6ZZWL9JEQS_-Y*8Z[,ETP^4-2^-FL?'S,8
MK#'Y\%P76CO(:UO=_KQB(&WNL,"#57GHF*14>8SDR^#><F.RL.[&]:WU-XN'
MP57@37E:*=6&- _?/.<1L<,8"HV)!,DR^>1)#5 $3V[?N<;W=$1@U%3D/NAJ
MYH/42,G>ZAJL=W**F!TDC/G;V+,M*K2"=D6%?L0Y/$Y],BH>?%FEU=%I\UEE
M?+E35@7NMC[I,SZ>+;-S-F,&=6;3I0T%-TU*5M]Y&5X:Z0@(.ZCL4:K.[P!?
M"3YK[3/F6_M)"\%;$7_;A3" E#JC=V*<=BN!-&*S)KLA_=G9C(G>F=OA=R*B
MAT#/GA&^T<;MW)\:GM-]S3KDOKPU<W]1K=M9]+4/]@=.S*?O/=:VB]_'KTE>
M> -]ZG5ZZ3;=^Y:03TD8+S])OO(=_:3UBJ'I@Y1W8\*N=>Q%>Y5+_8"#2UGO
M/KA=*GP79W<Q6\:VS_]WN_2#%^HZC#_V5"L-YPBN*%B 6"V-SM4J*[&6M,!F
MSY5^!EFR.C^@V6/A%XVO*!6>86,E'3LG[2D\?EGTSXY4_W<XLMGZ:T>,J[/K
MDY_)_QG]M=R[OQ#Y:]_;_\IW^[_WO<+/ZA?>Z__3WH\=>?]1M//\/Z.M9+MX
MKN.3UO9GS7]B,O^!0__49)8<N7, NG;OU]I@7P#_DZMY\ESISB\#X"$\[O>7
M 5A&R?\RG'^I[3"<EX+>?OC-!&<B7!&J88REZ=L,]ZIRRRIHB!.=AVN15;!M
M5RDO)]="%XC/E"_OC.>=G:H 1)5/G+FY)[PBU:^\O+RFVV+B7"9871U]]*G
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M9Q0<DT=*(I1[>R<VTPW2=]1[Y3$MA_P7LB+4%K."T%M-.7F"*#_1-#B1@99
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MG&M3TO13[1_.#?)P[%G#;WO Z8&G*$ /("&A'>[@"LCU&&<VHZONHE22V9R
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MA@6[(8TI&KF/M:;$<UAJ3YZAD?,UT$8F2F>V$?%X'1FW$;L^P+QHL\#H/S<
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MRQ577P!J)%\JZ!I 9VEY'Z4K5S@Q/5$B+R6;;%BGAM[YME/'%^^#/MI&'V.
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M-VB@#X=Z'%*(GU,/I^'S28QS1$EY46I%JK5\(%NV@Y2RUU ,]:F::-(#,]*
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M?U&'_M\>#)O,:\#WOH1M?/WF*PJ'+JEK "]&Q..*+DG&R]^T<ZO9QFK:%->
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M_IA1[3U2/;+9MO_8>,/*1Z1I=AK=<EVBTGV#L>HS\X0U3*8TP#%A4W:?3_;
MR+0'JCQ$]QDZ[,-=IFUM#QDOC;#:,FL59*@HA/ILD!\#WKM"GU:),5=*[X)N
ME8GB+P/&:T?=X+/36_Z?C;:$\@TV S=6K]N4'?I5<[*6=LWS\1%VE>81M+RM
M:[D1]VS\1LK!,> 5V=V#.S.9[S<^Q>0N0'.)C91:$PP>>_%U)93.&;TY!@0?
M7>O64X<SA09T'Y!/!@1F/%^UR,I0#.$3:WH05TO29!G0##:S:&SX;'E;,FTE
MX^EU6;-V7R82\P5F0\G7Y8YW2F7NT3>2ORZ71',HVY8@^;:A/W)8>>3P^!B
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M"-4/?H3:PJ)>\>^N-2[1CLJ+&XM)&ZM<A'F]5HV][33(TM^88-J&FT9+K#V
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M"5=-J_G750B>TWZ0\;-/V;K7?*-8&UPMZDF+F=L6R[4*3WC6KTK>U!Z41<8
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M8#)LT %_\8NG>* WT#(V4]>P(CJB01(-B@G2;=5]Q\91 VYP*!>B:_M0(<Y
M&^5$T4]U> =7*S X[)ELFI]+RA>FX&W=4@A'@M L#>'UJY!(FL_-%!*WUR/$
M%:_GDXV%3H%?BMH%4$IB 7,8]%Z <=.ID:&"8')Z8=,0/_2[6 ,^&,#*FU*A
M&VH.$BH23-'&7/Z\@^PJ*QQQ+5QJ';C.9#[.I+(<UYR>P_#%XN/MT[8L.Y]W
M M=<$J\,N203+XK8) L4=^1A)-I>DZ=1CE",PV=0U8TQ=1) F5#U!<_BI--4
MLRQ,&#EB32#-Y\@Z<U/4HD9 $B)A\7%$$R37AT)G:]$W,DAQ'3%OC&VPH&5:
M:#OM^*Y>5Q7 'PN!QY)D@OB]AX;M'*OM!R@0;%Y#:H<:CQ1O-@B%%_4RH4&J
MAKO8RB[3R$ ];94B34O<Y,%SDW*?RJ.TO&4(U4FX=<LZ\B#@^49\(\:J$D@1
M]BP9BT@2TUR&5A4AOTM%9U5:<5QJO$H,0,ZW6*](OABR3L]$J6 KRM)91Y ]
M)ZK/MIED-[(>R(GYE?J*!+.09^7&:"#(MQV/FX)H:,V37XZ3UQS?=25<,]S2
M>"HID>A)+$KN=CJW-,VKQ7(NLYCB;![):NOFP91#WB(#/W5J=I75(X/5=CB0
M8F62=@3LHT"9Z5III5O/JS W WUB]#S 1-2[QZGQEO+).>G 4%*+*@V;8G&H
MNJB?7W!YA8^GMR%U<(8#M@ O3WK843'D&2[3LQ 4VLBAUI_;U\^L6D 1N2+$
MJ\MT34;Y@P&#/P<31)*''TH:L&Z1[IH3$4O=:>1.<[BEQ5#A$,B!>,RO6X*(
M0WMO-^FTG,586T;I^R >6=#9='O*5B)T-H3&'"\E+"U[80@YM4E2I%"DC[%
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M>.ZC(HY"@.C^5.<K.8V UY+C&ED,A*1T C<K$@K.9,8+,O^H1_^UO[.I\99
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MD 9<;W!F\UCM5Q3R/.E\:U?QFTLZ;>K\Y0^FW]%D%2\8GKW.'# 2S#,9UWW
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M45A #V+L%".#O,2'8:+_K!AUH]52&%VRLH<,>DV%QU-G6P4P&% @[07*WJK
M QHF>.&-J6P"H0/]RZ'X0.]BCA;I281 R42Q\"X:! ;AS C28.*XD@M'] P,
MC#*]L3]UODM:Q[-W3#U00 ]LVR:ZY!CSA3O_N7GKYR.8]+7?/ 1^'=>#V5._
M%D0[>L!SW71N>I4NXZZV375Y$;*U)PEKHCOZCAR@4_VZ*\QX$QJ>5BQ>A][
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M2@_DP+;= KSRJ:<V,9:24*>+]-Q9>%B;N;O8L1Q_AS=0PSYM\Y?ACACX=,0
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M$ED/;>*;/CD]W)B+@<PBS"4V9[M!"@'[<,AZ\1251F3:3/W>\45\0P,>06(
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M;QAI,(;A]8*\9_V-*C<)8#Q<!I@G.9ZG!,,C)0X]<0TP"&IR-*:FW_78[!+
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M#J%5DJ@])/\_7&O^)U?>]=3;JWN.E>,%#=1-7D>6[/[Z#;Y[!_\A>]OY9.B
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M/0\7.U1FM8;1JYO+Z)/]J[8%),,=&ZQ\./O)38:H?<SVZM">S_&9SSS\S4R
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M-!^/N)M2R+3[#) KP3F^<MF:]C7;D=J!7(^>N-GFC<&MG=UCA,R<NX'L6]\
M,X]X6SXD*S=P(/B9+5+E'I.%T4/M^=@ 323JY7'BBK'LL0 B%VLS8N)-GHE0
MJ/OAG@"TCG>KQ)/,"5]_!))S#J^6%\U/]0$FCVORV;>/,*G*WXC/%;&9+U$#
M"\V%T@_4^J2%9%T\]0OHK)UYY99AV)LZJ"HKOAS V.=>#I5[:ILE+;A+5;!&
MG&?5&<O:NTL/+8S=-DWF-&8:F+(QR7K@("?#XLBI::1,,8@\GHKYO:R1>PG@
M]7-RRZ^H#&&?;R2/.@[<*5+S@^Z_LV#I&=%*8;#@*OB8;"IP">"3]TF-! 3$
MHV.T)N5RS*XET0V0,\'>$B=#X\4D68'[;J1RN6O6*%LQ#7LA\LQ&CK3 CUDO
M;]Z(;HI>Y"SF$V7NE?"04HF;CPY8B[$3)NU<X?HZ24%%ZD>5).U\ 39W[#=K
M<L_[T5.VIK$4L4+@>?)=P9IR*>-X8$%@QRWAG.@/CYR3!KF6WYO^VU]G=,.6
M3'@%:GC2OK@0.W^IL>),D=[2,B>()I5;LAXP)1AU^=>OJ^TWY*P1!H5HXW84
MB3JK6F]XM(C49=Z@[C-@?'$'F-H!B"D)=Q<841%)5/L^V*6CTKV1W<YTPN*7
M92I][X;?*^.B3;:F8BK@<:9'W])0H(_TKCQ A?AW]',S/@OH$PT1HB><'W:?
MADUQW>#G[C!5);<[OJ'&G=_N/C:7(7?\90W"<M/)\='=%T(>;*D2S>TD+TE2
M^W8SON;JW._+MQU\*7YFP/8[V$F3(\7-@OC'EZ,>E)5HQJTN4X[;KZ0Y-&UZ
M%][K$U7427QVJS=1*UP( ]^A4G?%/[(^L%!;[SF#!S][N8V0G@@6O+VTGOLR
M'?7\V/)'=-?@@L*7B]=RO2S?W?ND>93)Z+QE&=_U6[LYQ:SWVY<+.=0U/.)\
M VZI1,;>>Q$[L\S1I[8$6,(J_)[B$8IS[[=N?\;BEDR7VA0' KH*3/[VRBQB
MY_R%8^BQ.8:)S2W5XNY)7H,M='17E*/4E'A#HZCN/NN.SYE20\?NP(\?J97Z
MZQ^26ZVA[FD0[V2T=-86$\?M>/JP?<MT5TL9B[/&V8CQ^!&93%H,<1/IC\U<
M2VQ?B)BVZ"KMRFUPWY8R^FYWK0-T+R<C$)4[_F3[ ,@5[V[)QYB<KP9)GLY<
M%LQ@[O%=N=[N;F9W+9[SJS/8MGJH[NVK48K/'Z,]HWM-L[]%_.!GIDAB^]6D
MA2&.9WYA.:(DG$:3L_#41T)"]H.'V)& ]C,3'5+^)BN!K"WB?F66WH7B@6EY
MATY,U4LI]Z5"0ZP:/YUIQ2U+=Z-D%[/__O\P=BDD5D.Y%=72:=X-NK/^(J33
MWG\%?IZ1?"2JS&Y65YWCHY^&A(+\,;/-3:.SP>MX"T7_G>7=<>>&;W:W J%7
MIJ;Z?7R3S\8&JO)@2XT.#JWQQIU*(A7X4?F31\9@K[F8H&R#Z2J)F3RID2JD
M_R:<'ZY8!4ST\D1*;2'6H!8G(TV3AZ=X[!,N^<J1*CS:*RAM:Q:\WCPYDEZ<
M]O%>G6#*Q[N DT=S3Y-^"SB.OX][]X:+5VFE2NXQO$:4C)WT3MYD?/_QH0\P
M??1QJ4Z=?G51_'ZQL)?Z>T,/.#_#R K8]M6]O#+NZH:W*MD34Q9_D+]N9C1$
M9.2$?:1=7KG'3DVN8&;TW(6"!YC4V==+URD>WME^2VUE4-0OQZYT5*/]1@X$
M8WQ-Z&(<'^#T>-CK[E-F:3BSQQGJ[BL_*I6;;+5MOA2"7BIFR=QX4__I'8?T
MW.^KMM^)F,U N[#7SQCI'7"18UZ]B#>_N^>VHZ*I D/8,H.YE41TY!0L1E6B
M?#WQ.SYFI;QQ"216$YSOWKLC/Y\\^WP7!/-T.G+;]*GG,%D6&:AG9__XR0Y$
M4M>E[L5TO4AW!' #JFF=RSK_L!Q0F\(%N8:\\7N%YE5F;8IJN@!:ZA?R+4ON
MA:8T;_M(QUW1+#'WN$)J&W;TKR<#S4D)#(9)HPL;!>_+NMVT;D$J&:;[^[BY
M3LM^?LTQQ.KI]7T\Y[+K?!WY\Y"TW5727*[HYDNYXI>"8C0OX^_OVAJWA<C\
M[AI]ARGZ>?.&.Y$!49L+X&D2)9:GH..C:Q@CDZY1F!51."=L7G[BKN_O<6>'
M1!NM#Z%(5@;>9V&#+\5H[QJ0%NNDNO_4_+C1*^\\83X48-).U7$C,NKIW",.
MV#=JZMP!N&3)EZF5%\2:V1^L8.-.2<F<J6S7Y-+M")EGP:(;"K1!<3-B+MSR
M7[^\TIB/9,R@?ENR:,]P@^.A8[;.26.;BD+.D\)087^$@^>RD>PD,H?<P>TH
MSY(O\J$1%?.@+M*.2I#["_W0GZK! &+0-R&BQW9LC;LI NSO,QKOKI.JIMI:
MOX.R_.:Q!H.*'ZTEBIO1Y=Z23X.Y/YY12KU/Q)X&_WRZSC 5^$G-!JPHYF?L
M4^6FR6>5H(J:U!\FM48"(.%- 2GO)A_-G=4=>,!B81HR$G)&MP8_LRR41'1H
MC4C=]7J#$-LY5$D2ANK$/LZ25.W_>_3PGDLF\)C8:22M&!<@/=(T-HO3QL^.
M-/BZU3D:5/&#Y(S!&+WLIM&SV0)'@S N?K2V)VI_I&!U%E0/U4V?BY'&5T'@
M$##4X@^V?:)X% YMXK.HWU*3G.V&2R/YL UM]83IZ<VY&+GU#;PEI61Q&MS?
M>!:+E %.LH?$LY^$+(W#H9> HP0H7 [K;VQ1A1_YSQ>X+@&^G=C'IR^$ODT9
M9LV;2Z'&<.#30WS-*EI78=PKD5&XOK&DQ>+$Y]#7&.0YF8Y#1$AN F/TFR (
M2Q^+$Z/F/Z?UI^\*=3<:,-H7B8AVEQ]MFHAI3 BB 72RAV^>YI]1A4-&<M81
M/C[-Z5CP:=E(/A.5H_C$E#&CZAT][B6'>\(L$.M/B:L#H=(/<&9LO3GL;:J5
MP3;#844LE??NWGV^2,DBM)T42L&:XC]6^B7K9AJ1]W6-H3IDN-69:X9![F-Q
M5Y/T-S85UM"):"Y;2]4PM5RAU)64\6LX99/[0\P?]1]/UA[IW1)IHGLI75IC
MR*3]VR 5'E>^:6K(V0>;]:^U8V15O,6>V)[VI3#55,IBAOXNA6C\QCMYKF=+
M1?!9.9 :<Y&,@*/P UE@$G5@A924G=0R!28X\,VKQ1)7ZDG;J. ;^X#<@YO'
M7A<Q10@IF8\F:_E6O8R],IE\O)K/9/\O]MXSKJDN7/1$1411I E2I??>.RA%
M" :D2(F$#AI"A]"+(M([H84F2D# $#K2I7=\28!(#1TQ]-ZY^,ZY]YXY,W/G
MSO?YO)^^]UYK/;^]UW]1'-,DN?M)V[*EHF_3,7?1'0HPZ8Z["P-^'&903%9\
MI/)XO_]0@&YO]?4BN/:75L.\\(%C3I9S ^$(53ALO0/.L#H,"'R;$>OSR%FP
MQ6BNVD.U7XV)X[:\@8!H7&J4N?0:NX<5U2<DATNH#,/RXN<-_FE[=++;B ]M
M>:KU6^8_KR1*[<;#\N1,C<?4RUFK>]F.4MXDWJKX0)$2%]^F1\X6^U')V.EC
M7-I;7D8/^E(*I-?[4@R[B',2$5QC\C.%M*IZF30^\\0*95AEG1-A->5?$;.:
M[<]!+SOHV,2YQ2@F.Z<M9RC6/ZMH6BLA-7_[C7"9>X#]HY[0)W5N[OMM<6@-
M?WATBG>)?.QK@T!0NV'25'FQ\01T]$%*95#$M](LH-044 !D@A+0_8.I1GEC
M0<[H5O!^G\:3%=SO3<+\^GC-T::&O*\/%!R<(^\ZW^R-A.%"N:2*+$ZA*)\M
MPB(24E=G09K#AY)$!I0N LY*0=!68*DN:0YT!MLX,U-V>NF/ZT"1UO =+3"M
M@K"6AO8*$&#I;W9&D\(<I3.L(Z%;6)HY]WRZU)79[R+PT5%W:O/_F0Q2?SV!
MQF1XM(I'V:SG4_7(J,;V9N442IJNYR0E#C)H(NS-^YC;DK(V'A\ 5"17^N!?
M=3!"DX=VH.ZLS!#;FJAJ!HH^6D8!^\%^:4/XE^_)PO>>M<B%6R=76VU3TM,O
M$.\&JTOR R!?'5)(87<_]OS:Y#<]U3\, Z5E,OKI+\8DF#[H^"E?E4!L?L&\
MNG%>1.W@]\'TM[MADQZQ1$92M-Q;\+F+6L).M@#-3P]5?:R1I12+ZG2X0N('
MEI[=%=(9NDH!>(4[8:+/(BJ7B$EC?_'_RVD%_QM06T@9G("=* *$@+RV-K$)
M%DUMM+E500T_?U.#L"A(X:7498-K;4N_H<L]KNN1RK7V=#P/*+6Y-5Z#ZVD(
MT]U8*VPY/5,X6L-U(\93"6W4%G^\""B^&H6UO37L5)$%:2ZSHL#F-BX(BK/8
M;%C#A0H9>'&_\*?GNWT?7G0G]3'Q"W/_-[YV2U+1-($C#BA.W@_@[<,NYHAF
M (7=T&+UA/ .L9 _8D-Q#^86B9.+AS+K#Q-+[>88A+R]&Z.Q,*%KF%%AUSY>
MCQPJ^^>I8/:'<.+>7F9O\_HL?H_J!<N$BC+&=PSO?U3$R]72>?G9N%$G3^>0
M"!#[#ZD:,MDJG'V^]88E2X9VQGU]B?LS1@8UT.K)SEW]_I'E\ZB]KB]TXDR\
M]K'A/Z9TS&TD:[#?>N[<,(WAUDCAWFU@PS#@.J/G]B@/RMSNN[G=+$6 M&^]
MJKOA#D?Y?3/6,<>&[[ZD-,YFND]NT)U\Z$UAU?9#]A)@\@3P$E%='E-82UTM
MF4 9FM!Z?TBG_YN\U5P5#7B:4I/\L!-:_UOD[;<1,+H+%1@95$LO]XF1^ZD"
M5W&9JPQE02\BWCXLU,ST%:NCD+O$@2N9CM+ #L:T*",RB[ZW5%Q$3$=W(]&.
M.HEGY?9=.MY'INIV'+P?S"+?F)"_MR59L&5_79M*[@30[ U;^@!02<IB6KUU
M8WK:VJR0\XUL_28DU8 __!W3_8P?M]2W,F4%Z^<M*(78$M743,G+H7)CD:EO
MFH8FV7_<KD1L]YFRV*:Y2V7DVDJ_EZ7\L_3@.4T=;9(WW^'S[@D2OD0.[H&;
M0DGX A,F10MV674T0[W/\]6(!G:$YTA4?0VGW@<J3F'GGW8E,H=WL;:(E2PP
M^Q %$^9^'R<%YR,GXTH>688%M6S-C(IX* +$^4/M(Y09EO8!(G7LHFV3MFBC
M?XO0):0," ZVX?TFS5!@K!3S?C"N<W: +<-129OR#D5:?$:7@?!C-!)O^E!8
MKD[TP;W1\A\_(AQI6*UI%<MEFX=OQ[&5=T0*V['J1K*:R?5.$K$*#O&ULP9
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MV\R5QP'/Y0,.YJ+F<3/S>B&GDG-1>#RN<6J]Z#=NHHW:WPL_@[8< GOA]'#
M$@UY7\-&BPT"IA'3N%^6<TFS-1<MLW7!+#F).).:.O!-DEQ#1WCG*JNH!.<R
M.K=1.Y>"@J_OAO$L#4I^6WUS!Y.GX1^<\*#!H 7#AQ2P0%P;,FEL:9D\-LB9
M,@SEG9K:VEFK19Q?^./T7(D!1V=>6# !Y%HTM @\0BK;\(UG80MK<#.6+HWG
M%T%9X]F4CIX706K9!JT<]O+.H!#?2!.7C1J4<O#F.MA].%"&?ZK'(O#5P?_E
M"^&>96X(EY%(7A-B%YKFZ: 3UV6Z.R_61O&5^&:W-4//X!+]38<5.:*)"%TM
M,']U^]-\6W34J*EQ+1NUJW\X7>DRM8M&ON2NYLC^0:Y1SM[]%>>DS16!Q%R;
M)?&N'=61@H>]?AS='#O8$5@KSH L7D?BVU!G[%0G4TFV-?;@5QT3[!ZH1JN<
MZ#P^_5Z<+2]CKLVZS]UVS+ /T-8XSFWJ::7D#<]2DGXQ0ZL5'FQO&7U?[P^
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MHZ<JIE=$X_,'HMN3_\>MX\>B@H_RUHK"<ZN<P3#<%##0-XA;Z!"8%=S\O7]
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MHJ#71L"0&30*OXJ$8II](3;_X81WO?(R%Q'O:[)EE>-3!%X37M.]:&X>G1.
M<KCO#)U1/[^6X;%/#_1A1#>(&CI#\4<SFR=GQ:"U#AW:]?+C',C?4'2'A(N.
M_LBAI,_->%"**C"\3%4+O"Q;LH(Q(=KL+R7:&W*=R<\'B\3GT@3A*R+I/)D'
M@IJ+"PA9YL4V(*-.BWR\K^&655ZK:\N?H[.&L^._X?WE1[/<G4#.K'P)<+T.
M/^@B><LY:&H?'Y[&X7Z</$B^,Y>39@E:6_NZ+(#)"R"^F ER*6MAO%XJG+HE
M=;JH4/WU3%VE4WTNQ3C5DA3JOX9=AJDH2>T0VJ>O??^+*O\"@:FTZC>?VRP1
MBCZ&,$(7+[P7(*_%I?ZP_X0(CEY[^!R'/+UDB#>Y'*0^N2*"S4@2]'ZV8ZV%
M_B3MW+W.?&.TJ$KG4B[>N76A#5B'!W--^?B:.']O,&QNC#W;$QKZ2R//08"G
M'>70X"!3/I3D%5$-OJ2)TYVQ"?NWLER,.@>_1CWR#JURX;CNECIG'%XOY-_2
M_ WOMA+">F?0U?DHEGH<X6LX_L<  07S88-\)K.!(B;N50D.9>(/_KJH,</Z
MO?I+-;91_&P4J5V"BM+L_8Q:>\FX)6?C".8W[AQMZ#<>':U_Y%QYBOE3B.1[
MS>^UY"+[*Q!F^:O47LRZE7*.#KB#=/DO7\5=_NZI.WZT;%N7RP3)L$D.?LGH
MP)>BZ^[V(B6I_?-\O'W80G;S\H31TJUSZ!#'.(>QJ1WUV.^P"&YRA41!=?#C
M:5K!?'')BBPI"G:4GJ?*STV.57,9X0R$% )I7KL8H2<:<R >S  'Y+52TRRS
MQE8^R51;EGY<?.;'NT:K%R_!M/!&>H6X[\3HZ_O(J6^F4W._8.Q"5"K#(JF[
M4I%W:5)[.%,,JY2-Y1X-_>06\M.0G<8+(_>$=41(5]Q>QKYAJBW;N]_Q\.E'
M9.*L*IA#FX-*Q,5W17I8-.X=G'W"HTX^6)^TJ8%7XD%>OYDOP\NFE[:DBA*]
M8;."Z?+4],\E/+Y+FT<OK99T:4P,5 F:1&A&RDH.K2T:V=T2J>-W7!"U?F?7
M6U./EF Q'6.Q-W!7B[@5]5T&?A[[^/9YEM'B[PT_]>P2O33W=9W2 /_>%YZ4
MS'ONC\\J0V>JDV\B.Q=8R;6W:M4@CY8>9J-YD^+=/P6B.!C(O_0-LW2;'\YN
MO/5]5QUO!75+^D1/E[;H35O9\Q[97=_XAB'V3E*RY@FOEF#J:;S6X3]C#1,N
M 4[K%8]TXO?P\O11$1R8IE U,=U*_^Q!U?MOSM]>$:5\0[]7]6@QS[VSHK]>
M1M.O^85HL/+%B_O5YLHJ:WX"F1F'T:<4F=0NN-R>2;&O#:5]J;GG^7[4[!WM
M>V&9'A5.J;WC BN4;SCK0RS)L;0KF$Q:G;NI"X^BV!%OD\4"W:SZW-V*4"Y!
MH5M.7C^TK*"<PP66SL?_>SLN_E_@OUG.9:E3C4 I+%CRD% V P4X8Q,LLX?\
M/"%*;YB?.S>.8E*1TF591]CKY0,.;_G@7&8NFF^\P54OJQ&$U6TXAM1 @/(0
M-#$ NH[DV\"MH+QPS@>;2 $\P#B5/<=[K>ZCU%9AS2R"L#6.^+M)(Y1W-N^*
M"*64LS^),,B5-P2O608OO>H&]>M/2Y&$*,,_:?PJM%\0V\^\VR0NDIN5H_.C
MC4.0*H!3C"F.#+B>K,7U)717F_3Q<1JA1+7/>G%*>%E)_W,M&=GT7:+W=BAA
M<=IDHCHSUM?^PTP2C^;C$CFI);P0=V5>I+!9$:4X8XR\8K+:WK'>]W!\+".O
MS>[(J$0CW^0_R)E/FHU1@)/.]R16WHQU^.>GW:Y,/9'CN\6^19JB#BYAY@>Z
MDD8-2QF?:E-T7*792?69VAV3)\/N&!>;$" 04S*'^YUI(\^YV<)M1.55:V&=
MDV86(0; D2;%ZBC0HRLB[MRXN $KBNAR?@>-)%(F%[%/7A/%5HE)[V%<[!DL
M9GOC2LFBS!T9QX]F)&M.;G-Z_/Z^I%EL_<B\:O8X/SY\LLSS,Q614R$1M;#T
MA;Y[[2X1"=30S%1N#,'P Z/-C5GDKJDD<9'_&-JN321L2OFSFTLNH<_.770]
M][<X>WE!J'QWL2TM>N63W/O>LAT7*4'FQ<&"2;''I6L!=X8>WNC'*'J*1++W
MC6%\Y]*%MB"Z[L PD#G#'G\R@P0[1PSC&8C;YI\U"M(,,K_/BK*2]552*UY+
MF.X(64H#%RIN72M/;2KBE#>Z=;DT[O$IN1>#16MP(^=.BFXPFE$A3R0(/#OQ
MA2:/O/=GQ<?A/*2ZEK2/><I;R>?RVAX.C_ELJQGV2<,Z5F\QO\VP$A26GN
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M&D/AC-/6 #.@\3\X%!1\_-_8>\^PIMIN7105%125CG0$!$)5I#>E0R @H)1
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MZ2?!,=8I4&-_^8Y%&ZN&A)$U%M/+6DB*I\>9KKCT4!4=)1Z@MFJ\GOZ[L=@
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MF>NG8B,!1'*S/N34"/KBSZIG.V@ORC0<GD?W_+8);\^=%PQ%%W@4H7<3?U8
MYNZYO3Y"=T$97:7$I*S51,(?2G*Y");.@ZN>RY<G.]@+2[,_Y!+3_/(^YB8I
M0/0-A&,$O?]#NU#>0\/6PT[_@O1*U<L.&7PA2W?-&D2Z4VKB@2"MBW/$0(1
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M2L+['QDV>B K-]#R1_L;?QW<L+>-Z(:VJ2CXKQ,Q!_7+6<3K/!,RV]GVQ[/
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MKX$-HG*6KZ&Y'>QYPDI?7E^)9;O(,P>G$>I@="#8T-.?OIB_0J^:2:1\\7Y
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MV.9NPCE)X":Y)9$ ?[$X;0TQT&QHHSS>_'FK3KO>3.*,>*WN[7:U@.W:+S;
M@=VL->=[>: R$60K8+;5^ODC29?\-7SMTPDB@.!3#H\S.8KM5GJ8NM5&1?,\
M858FB9J>/+H15*!;Z^O$;6^YH@U EF15<<$YXS@?A'XV.6S]B*1WJ1Z1."X0
MPKT'VN[-> ?ESEBH98#6W"6.+3/TM.W.>7V^C7/5[SLG+!/,@#^DXE=48 JV
MP- -=KRQ@#'?E/^G\CI2*V?0!IN;S<3CVSXU7^0&D+Z0J[[;N5/B_N^,!4P.
M-IJI((7>9%()0.2)'U%64KKWQ&:;\]4?8?ROFH0[HBF M=\6=YI_&!/UG["6
M6S*TQ.WF,Y8DV9.C;'0> NAJ@JC:V OZ_F-]5 GT+$\L5G+:.:JWN/C.:Y[Z
M_4C.$,]5$"XW?_/ AYY:.H!U^Z$N2LVVY]%WE'VZB?)%@\PX7H"XG=BZF,Q3
MQJ6PU'Q)M:Q#]BEC"GF@S$/NH3/W\4?BR :YEI**R"G+UQE6$8HEIT6L.)M7
M!2XCB;1TDOY\C9]+2),$4G[(22;/0X7YDN1'@"KF1=2'/QA-P;GQI1-2-G_Z
MQ)!=P25_J(O_/T"5D?A3@8:H5\<ULW"'^U$U;(81$QGNCT-/BJN82XEWE1,7
M6F=C<GVUXWCOJJ>FV.?.P%:'6@8RZF7V;1][ZZ<$R?9E457STBMRK@1R)S<)
MID38#%,CV9@O.GGX]"Z3R+FU]/*W'NI;_IF1A&"X-=)O%OUP*UKDP]G11]AE
M#_W'EE_&X99AKA/1Z>/H!DWA5.I?&BIN3OI\K7 ZF,)@S?(#)Q5+,$I/DY!!
M>XR*I9$92&@^ +Z!8OE%1$5-W%(G6S2PUR)Z#-IXUNVYX^690",;DY.2R#*9
M_TJ93 =0_$BUQQ _^#D$49 :\8&@K.N@9%D T^DFKM)>\7K[/:<7MU+CDW]C
MJRJI\A%S#G@;(2H?H/0,V/7Y%7(-M-*T NS)$5'SY&CUIE>-*9A0K".5^9KR
M(3< &JJ@B1I"JUU@:_8Q_:BHSE%2%'OAABHX>]Y?])M-?H;H_,7*"-:JA+J=
MV^D\Q[! '_E&#Z.Z,_[LBK-8#6]=OL@<,6>/V7VQX&=M+Z.A9,&GIP"KZAC,
MH)?+]HL&,Y+$427NS5Z]B8$W<=S*==8^#VTD>G"=NX'')U7#ZJS!Y3O3)VD[
MY-H[%:",_L<>>&LKZ1^0\095L%^9>2V;K5'F^1/HV".9"CXW\SU,3G+F'(O8
M^EL%FGBA2,CZ<5)0C1WPM=C%>&V,QM C8NB6[;RBR'U9E-RAG4SAY7QIK#^:
M0J)"(\3-Z(+L7#7?RC>JF].W(PUB$UTI5FVL))$M1Q'G)E<_=T,Z5E:#G0I(
MYY#,D+7>N#WC4+8)T>)1Z*P'V9SYE[R^3+"(/N \.I,0!#$>RI^WJ8]P@9-O
M^C_&K)E"(:LZJA6UV?E'T#6&Y!5>+<_JNQ/(M+JYH,&G"1R&XMATJE?].9Z2
M?&;-#-@@7)6'E0Q"P-'IP'= S'@%(K2W %*0VI08Q1=9S)$;T5$AM\!<6(\/
M"M%"Y)6^^EE,(F)00L @Y&^%Z5R2N1W*XM@;;MRK@F=&%@M;[EA\*1;VK!',
M4Y#*7W]"F-<\NKB,_1/#2TD-BF:"G]DHFX^O!J'5O1:"K XTMX,3$%Q;K_#9
M*$6^E(5J!9D?Z425@2&+.JM22=ERAR2>1=72J\<C&>I2M?PM/V\,JWN*$,>(
M'V[WXD[:/>/79BH?#!3HZ.* E/Q=$AYQ3FKA):$,O)YC\36%H&H61H?\FH'W
MI6_UI*G#6?';G-8)0P4EO>+=YP%M0?0XS*V1G.\Z9F>/_/GS67A"XT:)DRN7
M]XDY=FPZ,G+Q3:LG@<8E#\SRHRH1CQ9H4'HE62^1#+'@,LLF; -9_&8G2-=4
M)S7?L/ 6>MJ^\5+ICN;\M_Y<M2)<IA9H5Z/,-I57^5.41CD":SGNS_-5_J1%
MO?P$QG$84F1OR$-0HSY$Q:J5' <@,&ZFK9:$6-)'[95??Q2H/\=N34CAG"1U
MOG17>0!YCT-Z6(O7HU((>"Z)DU5 WI4?9$+K^;P:)UA>9QE\B')I >=Z4!->
M!]@(SL1D.05Y.6<.LN!PH;D#DK+J2!/J^0V>DG;G.9CL C/2TE4!4H73SPA.
MVX_]%$OJ5#/K1FQ/;EA:\CXJ,6>8J%HX-2TXK$T7K;QSH85X[EP;SA;P#Z2A
MGZ#(XP9T[E+E%7\8U+?%(_&I#]%O;K+8<315LLQ1CDUY$()$W^(\!A;Y%H^_
M7M;*;U<AWL.BC;"W^ZNM.*-E%=GX1-$*F>D1C"I,+KNN"(7DGXK;4UEQU7"U
MTUDGKC(;"U][3\NKY L:EADOQ,)/-IO*-&!;4^!,B>V01PA=LJ2&Q$7/6M@*
M^';/E-(-9)9X/%CG8]D'T$[#L/^1K8[E=4-6%6.#-.3H!>8#1JT=4;+\#_G'
ML8XC#R(R3]* '65O>E+!B?CX1;63H Q1["LY-:/5J!7^[9)/^84[E^A%$7=:
MXC_W!GBG0^C%02O(WC_=XC)RI+D$^E0:7$R8JV!8VY!<Z%DV9RPZI!X8[1=#
MY>N:E5I)5D!RQ4O([BJ0,NQXR94"&?X(.JHG$,_IC(IMG7C$D4%.&J2$;%)4
MJKDVR N*<J<<E2['(+Y?TLD/X=::P_610CS\/ADK,3Y5C0M0Y#T^Y=K7Y )H
M>-7GUA4MI8SC:5;\T97B NF$<=(47@3G9/4IDS.7I6(X!%&6I2ELL$JO)?WI
MB1,OED3(9^3H)*YFY'0"E/$B]FRZT\[,51G0Q!X;M6*"(I=P%>:Q0_/EA8=!
M(%W%B1M(/E'N1F@)CCZH:C(%/OT(G6YIUB;<8G\D6V&9!87DD84J6".E;H:U
M S^HF$4R%I3/>TKH\<6RH0E<6N>ZII4/)9<',L2 )-__@LZC9M1?0(_B!B+:
MW*:/\&F/F-+>E;C)70<H4 D3&M0]:SF=&:[P"5SS\43/F#(]MI2%E1SO7^G!
ML7^XA+/MC:P02RK.X'1:R15H9-FG-7%H<#%\TA4](<'Y>8M79FT,/)R!?&18
M<GC#"C_Y6@UP:#Q,#/T'?P:L^F$02RKY/C[HMH)=D6,GM6SGCICLVQ6.]%[)
M_3%BI)EC*QQEV8*R)EP3@Z1<7;JH%[A;?]#7RJ8GQ5&%,Y(J)'ILHQ!E;Y2J
M!)3$JX U[7:MO(@/>5-4\W9+U+H%>6XZ]C_%UTOD7AH+-ZXC0:JK%0:>B"AV
M HQ4.RC:RS1,RYW7^PF=]F6UT Z>]%LJR)W= PXY"\2PQ&IPNYG:LU ]'O@Q
MBRJ&F&EZJ>@2/]28*.BI(^1K O=7)A11TH7$6F+R&]*IK4GP*/?M SH!15EB
M*_2U8!$A:&M8IS#78$8-IF6!MI H";D$'@9#+25.RY^P<R/)<34<4;TW]\G6
MDFK1M]FQ?.+EV)N\JA,)IZ/=.?@R'[DG6C&N"F)V0<)HVT9XJ3/8\,YAX*Z-
M^1X8U*V$(R&U(.F4K!-GJ#_O:/$H@-@)$Q/'[)D]");:RY8%M@1.!]NNO4M[
M0S)GHGLRQ*!S7]G'PMVVPD2S6*:O1W?-:)MF,DG&BF#-''5]):/&)/TX!I(;
MB6N/^]T$?VJ&<&GZKNN-;(G:?A]U7TL-1M+2JP;<+A.:W,RCF/4/3B\R_1:O
M8)-CS/NH3JIG,^1#'F_KF\?6AI:]$.03_#.@,D<-9;$US<KFR&?5234ZL[O:
M@6[T25[0<SNR?I\V:C[ #4LHJA\3*$2H\!6_LIV:.M]^7Z!4U&6$$S\448 $
MP:+<$6O>96?;69:X=KN3;7;T?8ZQGJ4CW.L\C")O-G7BAFA)VN5[1B'Z@$ZQ
M^?^!?>:L%&$VY92U>/M5:*Y_$\/H7Q&+I&P_7J_#J43TVF)L]H"!AKBX /+D
MT">3I7BT !\7UYC%:DA9-5NA*36S&L/B:7G7PL=D%FZYS1$9.Q;QP*J%1B9Z
M":54QH2:@ _\[6F]OL=1 =](_%W1Z$;,"V9\E\5K4UD4(;V=]$]'QG\"*/)F
M7S\]FX5B_B=)M8"QQ6*:82")\3DE)*0- H.=>XXV"C?$NGE7H?.[<-!LU?+Z
M[+MJMD'+;X ??_B0M<4IZ M31K$EF+)26L;2@5W(]X+GY>-FQV'J?D\]/J+Z
M$Q]NKMZN_S\*5NG6*PC> @3^K4:62)<!AOP#X?F)"H>M[!B$QT,3!_RI(J@6
MP0Y?85T5- !!WT#_@\:_FY+Q],FP>JYA%$@_6;N@K&)U DF\DB5.>!*@XT?\
M(BJ<K)0JV8"FS\W:9+#RR,U@1K/3_HP)D?1HT1J/B </I)-NC8EL5%W:3I9R
MK'3LMB%'MGZT,G3,[#9? 5D*R;PZD4-:@L%BBHO_"U*ZBV %D<FT/\M\7J',
M^.*WVO,KZ[ 5@!9LD<+(Z'>.RM].V4OQE=3%CA99VPS?VM5RZ$[9F%H0CRBF
M<VAK!GU8=:4TA3#[%UG>AK%2.N4@L_I09L^&S=-;5#/.V0Y(ZE@OIX N64!"
MQA\\/H1U+, 3FO0?W0A_>"D1ESH8,5QZX9&'%EK>/G?R!:,N816(3W318A*F
M\CEXSVIJ@1*^/+BAF=%S)6_1.?8GMU 9T1RM"0KQ7JFB^D]Y>-1%CRT4UOD_
M=S)_.,*D+*=B/52E%TJM:J:JSK'H9"V[@K%&G02MK)K.D;-+#>FZSBF:]1G+
MK:P^7$)'"9<-!XSV\E$I<(.IK'948H!4F#?J.M?XK><NYPG@:8E%WL*6V9!C
M';N*BMBU7*)GN"U:*K:8,UZN1)"CA*;3DD.H*M/XU6+.RXP)!K3PR9+@P4W9
MIVGGPU$^@45U#D/H\0 Q\)E/8%!2G)8YC&U&U^@_8#J+8PUESBR[S\CL@5TU
M1!BZ9["P62U!=MPM/WUM;VY:6DFO*$IO[(B\THR3<8BY+Q2P?\7\_'A"#4;K
M<GM:MO=22ZU\2IS,8G5L2L"\D,X!0UMZDB@0-R5Y-X7_4W";TG%18ND:S63A
MC+7?]V!8$]CMR=8M+)!LFBN(E[<X;<F>;=]LTRK.4W7!_C#"O74>FA<9C=(Z
M<=_/1Y[6UEZ)<@/+CDWM[!$.^"SHO-*4!=WID1]MU1SMS?P4:L/1M FVY=/S
MGPJ1W^^;DPZE?'K/E)XM7+ZG;=6ASW/)CJT(Z;DLX@ NIE7$TKRK+]Y:T?%B
MMW3DO1F31WG3S$['L91C"H@<LR;L!1(S2NE5_N@"Q<JQ$\ZVP^(P7JG4RH (
M(V:X-=QUK%C6 $;+E^O&)0VO<$G"G^O-</WI^#\*<*"F#,MEJU%A5O"LB64@
M1^=5LY@Z%R?(T@3E1'WVL+@:B7'38H\EQ--.\4;<E;SY2Y58SG6KH&J^:14J
MH,0]9$IF-8%."/VNB4OXK0<7=4DQ^09EI=4>$X-]POHO'ZA,FM48"\W20;SX
MDVF[W3>1\;R/3D#>MXFKR:]XHBC:X(Z+WD>TS33!<0QVH[R2!;+@QY"2?12U
M$3W7<_9T!I*8#*1K.U7CN+B9S?]2P]R<K2KA6W[HB7=%;68>T4>9Y/0S#@S3
MOT>9.:]J*G6<Y)#XUC\B[P%!7 L46,6BVQ*^R< Q9*+&.1A:RO#;F5.3W]#W
MASPRVH.+UPZXZ$%^:>(K3%%@.J@2(% JH3C3JCBA8/WCUVM1V*J4]'XW8R&&
M3ZR$*QU<P8Y8(Q5:L+)!TX<7?88\KYI5NO[_;A]OUJMW@C^*:E.F'H6#",!&
M#GLWZ1!A-B!,<,;Q6)E,+=M;CZQ/O2\A2$YV"\R4_)Z33:<%U!QW#+[ ]"EG
MCG1T/N14"&</L$\ZAAR2$*/0XF)Q&HRO(?+8WQBQ\ZG4SX $)HT!&@5E59*J
MXZ0.CEGV7)X0KZF@;XX95\D188GVFO.;+6*F:<I.PL1LC5_?S1PT$O1*WU"R
M8N)$<!]!I!0^G(""[IVJ1-O1\)C6#XOF#L> B&ZA0;%N+7BKQZO/%LI2/7WV
MLC):,M:=O'IB1N")<*TRB)CQ%8XO20M<+:-3Z.CI)#7E8;LOPWXL)'KH^13H
M;!ZGBT$/9,!3;YYL)/YWC$E*FAPB;T1S-<Q'V>PC/<]CG^E?VHZ5?7S8^5R6
MWUH6^3S\0T%M6XX\-\O"HKK8/HFB4W]!UU"P\Y_+FX:GDC#!C />LT*#6("
M(,BS4>!6J]NF2M5=M:-__M)QS&5%%BA&Y4+W^5AP^I_N^!Q3!C*8K(=>J?K;
M^H=INZU5"E'*;R$>P#1+="_ DW:-XOLP1VEP&WV7;=X>(<8X)T),F$U$D0/
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M^#G:YUSR94P3&\.[+*,H!B@*_P(^DA\X<O1"%GY-6!YR1IU2)7\Y/B #*\R
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M$'++SFXPY['G#N='<2T"?@,UA_G'P L"\<\<=/<G\JWOUB<ZY;]F=;L3'Q]
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MQ\.<+.M"Z LK#<"U]BW?ZL()^LF7 ZZ%17$<!8N+7C >UL%[^GKB>..L]!
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MZKIG1:Z/HK,*O>JL=DS _*'CS$^1)/+XR;?P,9"Y1,)D@-R1E$Z5?Q%3!P_
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M-OJ/CR+]VYBJ]^;1/!>$.7,7&I:/(*8HY>HK#YJU%#WY:\^B,P4]"2@+(W"
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MYE45459)W+50W"PJ*$\0HCB\H\3'7KX:;6?<IJY:BKDX78JQ'U0D\]>;_!0
M#.?UF=:W@[C/$4BEZLZ)CVSZ6N4HZ(6692<RTM+.8"Y-22().@(XXT"EI!$'
MLA*FXT_>CG!L"[=HDASMHJT8KMB62V;/+W*G8WBOE;Y@N6K!H=B%(/L&WXNB
MS;%P)U.9_&R[""SS$58J&C1M^PE[*5/7SS&,MN$.A<D,%"-BCI-\I=>8:,R*
M)595:/X$SM'I-.%8W*)%Z\7QO#LHM:R.8 )./NPMEV7)Q=9)(;*Q+V'&X%DM
M:2R@/.(TX$S-LY3;'&!A=5@([+;1G/;J*@E9+#@<ZU7H./<G^2PV,)V2:&&B
M>4HOCL]BR59 R//A4L,)DT0&7P0J-'BT\4E@^5L*X(C<_EK=B]:O7;\"H<,N
MRSXM)5WDSG%)#?9M[3?VJPD<'<J^)A,7G-6X^*!,,#<=>K4B(Y.FEXR("H%%
MYY!\>)5<DI@Y;+-4HOEZ<1YLV(=LME+:6=F)I&5TA'92LI[QOU+]XO#.7'*2
MDGRBU#*.'#O,I"52:^1R63M6MN5L'RX%B-E*EXT\D=X%G>".\OD;:1=VW'(#
MG"<;3*L4:KFC*Q%//#WHM9R'B+DVF3_-F1IXX!WNZ,C>,\YR5#+$UC:+-A)X
M7#XX8@DIOC\S$LQJ!2,MX39;'4TFUM3*88PS:62OS;^I%E,?8VY8)A4WE"/1
MZY!W2?S5K)7L@E,L05=RK'V>I(L06D HG)W \D($9JB4@D4'1)MW(08]7>D(
MHU'(FB";DB\)[B3E9P; 2LG+X_:1J,,R&*K7%D3<GAY.KF!9A5R7C5 ?:(,C
MWM&L9R?(W$EM8,UTV=[+4>2;/(X-:BV]S;U;>'!/?Q54YPKR:QZ&@L,Y6CDH
MN DY!E4DVAS>939J:M^ZY-99AR92 R4'3\<=7BF397F(S'QMKXPZ%M4)JV)W
M#XZ, JOHXF;=MZEG8.$K,\;UT..QA@R7PW(GI**KLV7,#$*1#+8F7G9 TEY@
M'(Q<E5OA<H</)"N;!/F8Z=R9HU'#";-<*U)7H!%F[)H-JW$S0 :MNLXVW[5A
MC/*YRVR.MRQ021<.G)>3NFY1ME_)[ PSDDIFV/):?(@S@V>-2P6373K&F/B;
M(H%>L30$N%;HA'(VI(D@_B6>_P!T]VM=""Z1^/"F@5B1029!:,0*?I TN3>V
M.O-()M&Q,H6?.RI$R\HJBLLY+/71@JX<=L=N'3IU>LH57)^#\1X:QN9NPJ;0
M'3W*L*A\2E#^3RB/..S/H]+)[F4W"[(FRDAV5-Q*H4P/G_GA\?=HW,_-V/U;
M$D7+1%L19Z7X8Y2Y63MA<B0C2!F2E)WDRH +D:11$F=(2HY'A<[DRS>*RL*Z
M(I$I.WCB#VJ]5F:<B1:J-442MEZE'Z;YYV*6;_=G=L7[K\KW*X7>(D7,>:E+
MWQ1R250<9,G+X5(2)W(N1,D7^G ZLS5#RI-UD#(F2R+%B<9%&B%9'( (]LB%
MNO%))^&=R2!6\PC%..<8N@2\6E$O:"X>%D$/2#R/,619L.5O..(H\NND/K[-
M9)>7. FD7%CXR],7.2\9"/20D,Z9""SMFN5SGJE):GS%5Y;#5(Y%,ZC@$I(D
MG#2, XJJLHXD5HO.AX1R[/7WHP<_9E$XL5(Y-'1\T5NI5D-JZ2,)7)D@;1XQ
M R3-\L]:]B8<L?+EDU4G;)HS87]<K2)ATS&Y G 9H2;D\.FL /W@P='):,9M
M&"N(I:7A]/0S=JR02)V&$+4I"DR+(DS9L60LY?<$#29LY1B0:+UR(+R>415R
MCD*P('R$@[J41/LH^M,_5Z+NCI5Y4[(F(D:+'S0\[J?D[(T7<5?7E)#-^^]8
MD]B'EAAD"A\1EC./"L>8OQJZP/'@LKG!Y<*.QOD!A%<;+04XD<DCCUE:R-HW
MB<6:WRVXR45<+,$&3RQZ0ON<D,AV6ZS*<_/(6OBN6#%P[)+&5724@<CC"&P^
M!CHA*IQ/9D;<2R#Y#=Y/ R$_/)9D0W()D4&$[1EXL-*4"[D30"R<,B";1*C%
M(EF/5U'MUD6'<OPQOA7EH-P\%(H6%E\4CL%A)[EB:)_=/RQ$;F<-PS)IIB>R
M+2-)M/&UDB=P4ZVEC2#2^3*F)3&G#Q0W%) ,?.['E29MVXYDLD0Y3>5E1G*Q
MRD8M#AI5$9!$)H""90R'%8V=CTS*2<H85D,=C\W% GQE^1R!);F4N?,+Y2.2
MD*C$.;9,ZM&Z5G?MOL&1V)89;-N=1[5L-.77EYN-2,E0/=<8DMTB3E5GW29S
M6TRE()7?)Y$.,C/7"K-T-<R<TX56$.FEPUI0X]$-VC<<9=L740@:^^6;EG3?
M+WA2;-X0X?1FKII"(V#C<+5!RV6A&K",@93!IR 'IWQJ0C42C,?)L<0HNR4(
MU?W6W!K6]%;F) HV?%5,.Y;L00"9N9]$ !X-)7[B1O2BJ60\CN@QLC*Y9+YN
M9+2"*OY:ZBD@-726>2UZ,-&@K\J :F% X!X,"M6 YK9W[?=GM25VS]%>?$1.
M"+Y?2KD/4S#..8N12U*/02^6YF?R*!G;(>$D9621(IA_E]BY*V4.!\M;.245
M7E&.9*Z1AI5,*XMD+4#+UZJ7CFJ+XBL*4<E4/>$AK56>1X.W3G! [C>/.X6+
MML415RQB3/*^.3S1*1C$Y]" 3G":(..1<>SC]\<QU?8+L77MC+0C==]G"WA>
M.WK4ZY6[-GA/LZEHAWR?0(@VD6/Q^6H['0\LA6=QC>(C<<#VCX2*S8TG3*5V
M@6C&;#T58)$9!D872'@RH<Q?%@(D5"DY'5DZ8+CYG-F<+4SFVS7PP6\)<B T
M;*KI1&YN%C5'4FCDO>@!..J-8X@7 \R.*N855K'!;69M4H\ ).<7T"KB4JO;
MZ'I9))TJ^=/GSD0Z*K#F>38W&8S/&T5/W'Y3.Z 4HB9!16.1M7$4\BW,'F[F
M&QOE)):22XDT=QR R3+C<5((JU#2$A*!<;021$N!IHM'T[>2;IF><A2T  6V
M2\^K9:5;.=N4D;EO';3'4;E+6"BV.!<T<OS15_%;IC1M%\Q005"5B:*-)'&5
M/2X"@0<03N6=KH%D[B#)TF@J[3(-8KGQSC:JL(\A3A_-D9"EDZ/BXVSGTPFP
MZ*!\2MQBHU&;,,JB38%J=9SI&Y8>NPRL25L;DA9 6T,C;# L..7.29(O9YUD
MVV\>V2DO=B )2N$\1-6Q).51"5!,0C2TAB3Q]B;#<ZQ:Q($\6")"T<EI9'H<
M'%S4:"DITR+%K1I_#FA>P"22D;0K5RHQ</6Z5E5EHKG.;U3;?D <>G!4B(90
MC[LJ&DS"3C7B>+7W;1[Q#F:QYS*/41Q(IDXR3:)NR<*)Q1NI1ZHNS'R94BHH
M]68K,RMGA,7Z\>H#-B@'Z@6\9S[4!\@9$:R',RN6PD@L9XICV&R+=]B1&@J4
MQ@#C>9XS]/RD4I/G*!'(+P1)V3JZ4-+QS1NLR.,4@50\G5'C$^NV^W;/;QG;
M:DO+KE)2)\GH*!E(L5'3X+<\BDM>RML3(8T3>R$HY5YNX/S3,+C9^DT;NR!1
MDVB#S&ZIJZQ-PZ:R4I([$6EMRT==Q7/=X=RL?.'*[]V SF4.MDF)#&N;,0FX
MFT#2/' ^93*%$%8><QH6ED(/N9@&>LHA>#FJ-AZ)LA#>J\@=WN/6Y@RE!H,5
MH,L[MQ&;)36+;09YPOO5;2'D!>FCJKUIE*+!X^G*\C2D9&F>&TTDF'W1A/,*
M%(!U7S'(8ZXJ(9LN8(JLW'DFB[!J3 U(A68-252NPG,=N;%5EX;R)*PN;N)*
M/R1'58X6*-'9J#J8E:T$-464"Y;HRS+PB^Z;*HPO(8V4\N0N;AYTF/+W#7<H
M>I)@E3P,'+&S/#QM4EOQEF\6+;8QRMUAV##6$K\I1QID"9$8L;9S\="E1JLF
M.XP9P=&/EIC!#N09)?/;G ?'\<#9+%LY"! 2B*6NH^Q$Q$.NBBW8;,V8*XYL
MV\5I,SY%B<M?ERBN4(3&4G<.-1]D,B>$6D8CX1V71Q\55<HBA.0V;=\#9S3'
MK61(,C5Q"5>B3!.-KSQ2QN'+#"DMN<G)M7K+\D*LJ$UD$=SZJ.>R)Q/)6TDT
M-C;A:,R)+(66LKYTC=CH&YR : OHN"D.5$D4G\54CDNE<39F8V\G5D6F3L0P
MOCU^[."2G?*Z5V_7=LXK;X]R7NH_.L<RYO/XRB-A,RC^1'L888S((-E9>.%Y
MM%G[X<4)9*,DH?'I1=FXX7=B":DS(('FKHDH>?5/$T>)GNR4E^NNPSEU+#Y2
MY$DLE%\QD;LA!!Z&5&.9K1R1#&=IU_"S>7\?X/A/K&P(UFPNUX4B+G#"9T*Y
M08B'=RDD59]L;*#+2! DN^=MN/C(8;5L8'DS]%X&SOA,E/1QQYF7&9_$J>1'
MD*(K25M%'<=E<<C#Z>)$Y\72R!*HZUECQ5Z6'+P,8=61HM:!$.W3QVM9VC9*
M_9C<DI=_CKL6(-\F,5<SB:O%II&A(W(K\28AL:8@)'%I- S8@?BVV5,\:R"(
MY4BMPF+$ON3!9BF'!1YE) TV54D9.9'0C5*-53QF;]>.3.<YS0C:)]5A/5?J
MLM[EJ#GR?QM=O*6EV<&KJR3Q8B#<OG^)QZ12XL=QYRRP,^?<VQR9QJ.TL?*\
MM0P\T"!(W'QHUQ+BH]&BC,8.XF<\55?A#EY(L<6WPH2=:%7@[F65YC!>@VX
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M^+ 5&1 U'1.N:/<C&R:LN:Z]8H!V"+DEM$L]7/?#M.9WX5QQ=1OA>>#?BHB
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MBOB'T#=*;GK&#PKWU=7HXOJ=PG=U9?N3<J7ST]6STW>K_][@-B^'__5C5[Y
M_N;G*[L L!+?/G^,4?SPT[<^R>43'-\/Z[]-H1( 0/K>AP'\VOY"N^2[Y/^'
M##_:G]L%P-$-?)EVESLLHB7$S1'H\K?5:N7*]=W,RQ3_2WH!_I:' *D?^?K-
M#*T?Z7@U!407L)T5R$4/K'*YH&!^PD&X&KMXP+V<R%5'4>8ONI%LH! WIY](
MB!"HG8W=C[U25OM22/V*=M''L'!SA<B#'$%0"U<0\,IZ+Z?O6SWJ-^9+RN6(
MHH,-Y;]A_G!N4/!/+XPKY_],476Q^?FE@F@!=M6QL/F)AFD%NI #>;HJNBCH
MJ*I\W[:0OY-_8D:QA4"])<%V-M\]A?5M\@K?R9?>!8*L+=RN]BT4=Q#4]3?L
M>M_)/[.C6=I(0\ 0Z%^<B_--0$K^Q\"E&6H0Q\L[BBO$Z>+EY +ZJ^-0P1>.
M_(6*;GFU ?Y"1X->;G-_(U^M(,9O<I?I?&L?\"<=Y^H1YMO. W_CJG<94+BK
M/OI5?F7]X;"'%Q^&B\>EB[2X2 HD/P 1 .9\YGP7@"X)A%B"S*15 ;#G>P#,
MJQX Z'<I=SX'" *@(R,CHR"CHZ"@XZ"AHN'@8Z&C8^$3X>'AX^$1X:!?M3]N
MOV\P&&AH&)@8V(#K=MVNVW6[;M?MNEVW_Y^W\V7),%M75R=A#@Y'%W:+RV,7
MNQ7$@</3PHF#BYV3 R!ZR]/)PLH>Y$II";HX_(M1OVM^3DUI!Q2CUN=3Y51U
MD@;9VBEX0T':WFHZ5M[V5D) ZEOBJ**>PIX.3@X@5PM*3P>PHXNPIQCUE7+A
MB^=+,@<UY16+J[T8]=5AC]) 58-2&@(%4?*Q\[!9<7)Q4?+SLW/Q\O'S<[%2
M<G-R<7-P7OSPLW'Q"O/Q"W,+4/[1J,51+ZZB4*"UL):,W!]P%STQZC_FY>'A
MP>[!PPZ!VG!P"0D)7:KAYF:[X&!S\7)TM?!D<W2A^:;DNQX9D(L5U.[J^QW*
MR[[%1>WB*D9-C4KYE_;'O!R<5%5_0/W6A0X.'+^3='&5=7?]CR5=+L_W'%H@
M%X@;U HDZPYR=*7YO2HMD/4_H^J"_<\I7\[Z:AK",A K-X<+$$49<0$A/FY9
M 1EN23EN62%9.5D^;DY.26XI7EE.+EE9'BY)48Y?1'Y1I^CHXFKA>%EKBE\0
MV.WL@,)<<ES\7 *RO!>:N&2EN+@D)25YA(3D^.7X>3D%.'GXOJO]B^@O:K]5
MH1;@_X:UOQ']1;V"G8LK!.HE_I.?K])"&^3\,_7[ -CN*DV<+* N5V6O&/5W
M1U/_(G I<Q5Z80NKRP03=[%P!P%%.7ZB_6,AN]_X5/ _\^DOHO]8OX<MR%&<
MFY.;DXV+FXU+4(=+0)B/Y^*'A9-/F(?SNZHKKG^LQ 5B[>IA 05)VESX6/S;
M\O[S*VII;7Y*1GT[1R#$PX7IN\:?1?ZQ:BM;"T<;$%"<X[O@=\(O@>'X%IG_
M"Q&S@CA>UO'_1-0N<"PN=CT0U$7<&@IQH+1SL+ !<=QQ ME0ND(H+9R<+FIZ
MBTL='.Z.P#]6K]-WAWU'^8N2?^-D@2"HW3^3H'^Q\H>?*/]?F_3_?$T*7:_)
M?^N:_)]'3/;_9L0$A3FYA7GXKB/VK]Q%_Y,MY'*7^;;G@)Q<K/^_LHO^/S3I
M__F:_$]/B]=K\F?JST?4[\?>7X^TWP_\W])2[C*Q_FMQ%KVJ-?Z[&^C?1'^G
M&?C/G.I_$?F=1LA_IU[XAZ*_>O<O3OQ117+\K8S\[Y:70*L?99V3&Q1\5<0"
MK3A 8-"E.2X7I1T7QT^%'-!*V!H"=;!P%?_K+O G]5]MX(^-Y_?EYX_AJR+T
M)TM_# E?_2I+%0($B?.*<OR._*\V^B)N_W&U_/?:6%@:"K)P!<E<?/YV$.,5
M$.86^KZ%_(WS;SHNIF)G[?6+CK]M0W_C_+L.D*L%T,+5XK^DY:^\OYL/!*H#
M@8#_LUWL[^S_83"^4;5DY,11+R2_?P?TNUWO7]^N0:Y!KD&N0:Y!KD&N0:Y!
MKD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N
M0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0?[%(*A__E4%D"-0C-J#
M^I;X^1Q &@#S/VR72OZG.F#.VP XR(!(V%MP,#@ 6!P8.!R8\RX !0 &  L+
M=S'^XX]'("(A(,/!H\"B7HYK8P-@X.!A8&!14!!@D=&1   $.'A$  PL$C(*
M#CXNW@UB*H.4U"D"(BY)7;VDB9>$FOII,]2T-%H6GOYU[9/T# *"0K+.'I6U
M#?M\4C;0^-RQ"Z5D%VAP5T;] (6!A8-'0$1"OA@UO# /!@X6'A8>#0$."0D9
M[7(0 (^#2X6 QR5)K7G#PCD>$9];US\Q:6QB>9]&.[>R74IGG)9'*V5RZH"
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MJW?POES;Y>1?8)V7-G!-2YM-Q8 +!F$I3:."A^"6@G#CO7;O3F /ZD-3A+T
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M X=NKO22G -2V7)/=72VJ\[>N;T]!["&G8H8?'A<^!7C<^BR0/$Y0-E3XXO
M)_RIGPQ1U3-;V&N=Q3K!7%3_(!BK_(GT/58'Y*@^V+?1^/3F)&CI/=*GRI[G
MZX.VOKKX)#O/FQ?N57$<WYQBOL>Q!!FZA?)\ZC7^V?K]ZI]-+7H)RO(6FT[]
M>LCV_!/%2XK4?0'B3Q=6/#@'&'OJG0.^)K_^R0K-LL&39]-S5.< BZ(/S_V?
M<WZEO^34/TG^6>^C9HZ]CV;@T-.0G N5&S>#%M_:H)T#H$5_-?/&2Z#OS@57
MI.\9TM%N;O,GDEM[EYP0U+ES0,+SVP.>HNUGK,[EGZ&O;KZ4Y3/$.A&;6CP]
MY#@F\39KFS@'.'VE7SP'=/_6M2-B%&]WXRY>7A/C9XBKM[#_@9U_ANJ2[VOG
M?N:IP[+9GJXHQ45D"02GOS8Z8&WG/=:->PMQ%:MW_L:6DX6TS'5\E^U7QN"2
MT-.<;[@O3+]BW/IX&:+JX'- H\Z^5^!7@U6SP_6:6T\CHMVO@DEX@B'VU^AH
MMV]@'5A%^PZFO#A[RO1T\''^11 I%L^NG%C>=<DV0G@QY5G=7LSL=P>DXUBE
MQZZ9ZDKYVO=<:ND4RN%>OC? &;/F.QC6$LM!%8MS-(T1V^_ 8%B[6UA&G2ZL
M.DA_I^"LW_,#P8@V#%SBC;$XM3)P/R--!8S#,K/DMB+X,^K[AJAY7-TPIYR;
MW> L'N+,L(-,<<8$*CBIKI1YM"!>E<=TZ:_-V_SP%6AWUZUNZ_ZZOI-A9D[D
MD)ZT8R:"[? \&V"K-DUPTFVBPP1MO/0ZD]"".^6$- /E[TN']RM64FG<_S(<
M4N]^^CRE!9QRGWM E[A<:*++]&GO,_.Y/40-MMR^T9>B1V\;=KQ*%*=Z4K?U
M9,T4:$LZ0RR@I+@(G)'1YD>'\'TM@,^=!&I$EHFU +P*8G&IDJ<C[9J&:1]T
M$=(^SJ GUB<;^, E"#/HQ_+*V=58JK"1#> OYB/A]"C2W(CI2I*GBJL?M:PL
M4>[7(+BOR!:#9:O/I4<:@F#<ZK2%<ZP[#IE^^YJ9MP[.?(O.SQ)92X?)'$M*
MASL!IF^R<9L'?SZK=Y7=/U)F8TX;(@\CRP ?'1F9A>N?7DR=WCW;2L5&MRP9
MHLAC0Q9227*Z-JXGC5@9%FC]M)2.G0/-F.4I"PA7EVY<T?6&*I! '4'3D/5
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M7JV>2_%@#6G/5B\8TSE:P4;$VUI-O^M-N:7J?F94(GHC11$[%GGF6(+8CZV
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M'.=942.F%O2S$;B3"X^*-L*+RZ4Q RM$2QN%-=LSCD\:O\)4J [5B7_5P.:
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MT!E8J7EGEDR!KTY@X$."PG+T>HI,!.-D2X+"0'Q/!/?(7A?S4S]E'NP;L(H
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M,7K /7C<'8DE4L:H&E'W>US^_58QLN@1>4K][$-13P3;.:JA<9V"O0X2\2N
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M$@7=I3M?Z/G-()5TW.%DI__#N"3O ,XDJQ@HOI(O*,A5#TI_19ID^JF9%H'
MHB)8U.!M+3$SP@^]UR=184S"3NU*;LVAM'].2^VC"MU?LG]LO-XO+2TS%L7;
MHKT+ZLA6 4DX#%O7XG"<XVC.6RL3E<:.64W5?![D9FT?D4QOX.P-=22,+XM5
M3@S$";++H[.VN0 3 Z,AW51"!;JW>$)C?UFF^M4PE^L>7K:"I-*-@ NF?U^U
MM$41LX^%'7AQJZ]LG!+%#-Q>\K>Q)= 5](]+(<7DLM@TJ+J1?[8E[)((.0JV
MU_VJ+SAIH2R.LXRPM<**MA-L!#"5U;8V5SEK6UMBA0SA(N>'8?*CNL'&5MY"
M5[Y8?+GV9,:R_,E_<1,4XM9;&$)5@Z4_I*YQ=(EYZP@Y2L/$K_/$XX):TE,1
M?>@>!D*Z^+U->*L_.,@(,^ULJIS^EOH'&'1[2$RE >E9^XA26:C32*66%MG@
MP)YE4+1]7/E,MQU6OBSML]#?GGS$\56<&G))0%8,6I<0O%ZJL):PD9'$J$_4
MP#D[_I;TC6'KH_TPGE,6@13X(2D,,C-1:S!_62(M+XY8&&JK#N*M#9BAOG-Y
M91,K2O2&6?D-S8@]<W?+9!-<M&%"*FP\U6?<2#U.1&ZP7=/+(=G#W1L8=U@B
M-G0D9QV.S\F;%H[!^:;!%P$,X'S>F_TT73:$5AC_M,/9(9]6HL:;P$K.:ERB
MX@RS82,;GUK\>&W3??R!G#8G=W3[1D&]7;0>I%4N[)WHAG=1,&*#UD74_5A7
M_/;XES62:YJ-9]WL->^G_'P2V$%98E/7\L*F6R"4@7%F\[EPQV8=>J;A4%/1
M3H&;XI4 &\B'/1UOJV,F7^HL"U3FLX821D@>OZ@/OAYF3&83,/?800)&W!0<
MA.(;<V1<F=Z!U/35Q8 0;9BA )!K>>QGX=?Q?NWLYFYI?B:<JRZB:WCU%(-9
MUJ.:DSMK9-;"AD): 38:H^MBU1:!/#=L[#$N_3!?1T2FGK4PP_(^G6JQ[J,K
M&$FKWT%K96T#S+3YF.'RTN QZOJ9B4Q^O+)X&+,UXP[*8;Z2P2*8A9!?0]V\
MX</G 9AUWX$$&P^W?2MB3&.:MS"(RTJAG'_>C*.^V8FK3QB222#+GAF^M/GI
MA);(B \#Q(-/=RD6R M<F"1J*.4 .V3199HZAP?5#OI,\"THU!V1*Z>8DTZ<
M&G^J5FU;%>VH+[E-%UEG&, D/=3$=K2G3&+S_\BMVB@;03*VU4&+'9+,G,YV
M"G:05]=6=N8QKP;$?!!TZ&9-R1</3Q[4-N3!T^V':VO)PG"Q[QBUK'6H"I;F
M<TO:"XI,;&/58F*-(B78L4=0L/B)FJ\U$Q_XEXV+VWA[%[,EG[U4P]ZZV8YC
M7+EFC%^0[O&GVU^[;W:1RB#R<1.TQTT6L!!%2A",7R-RB ,4P-$I;!KJUU82
MM[$WH("WIKRP=18>7F&@>]/9\G?ML&%GYN<]'=UBAEFK-.VL&Z*Q"SL'SA89
M,:RL9/@W^(!JQ1I\C R*Q*]DQU_(!DWE?,V3EJQE5,=C!^T8?XJ0L*'!(^_'
MS:,I6Q.@KF$KT PQ,ZO$C_9FM)8B_I7+VQ+4UY3*$CCY(VAMHD[#:^X1NH M
M(((LU4?Z:T7<;FR,1N:::P[*U5]L$:>03N0TCZP$,O28K1A/QZ"[EX]8SSL)
M<O[3\V@H;/2MTNU'-..C@CWBX,0XVYPAFP2OQ3U]::.ZX-O\YMRQ<3-;-H+I
M^EZ/STS28 W%U19K:.YB:*' 6TF6=@P19VHTF7;W]0")4]_*<LB!E9T*A?CL
M,)E>NG3-1>+9C[%$DN!5ZU8;&^BU!;CDK4?#,=*.[)O^Q(G8UN\U=E/ *-A\
M5*S!Y'%TM*EURX\L401)P^ XO%>7-P(9,(LX EKUP7WTUAC=K*P@'$PNQBB&
M6S6 N$!!9,?I59@%V^-98#O*#B9TRIE754>E,>I-E+%B5B!R6/XHDE#R:S!)
MD#%1<]" AK,$;X),3 1=KGK?4/E<,'[ ):AKT.0"HL%8_/ 4%.3U8M!M!6&C
M&UG&L,_)3I\!D543GS*#!/7=WN "3GK1T#&FSYR< %N.&EW6BKN)05T<'I0C
MT6N]$5HN?R6#Y9JAX2T>7I[FA)[J7$PT^44"<-!T DRTA\F>8_6#._Y \= W
MQ_+#ZN;:E+172;W\<X=E"]_&H1XZ3EY6I^'Q-'+2RSS!+E:+ O>VO]M=;T[6
MVS5N4[D, (A;R#3J*^7?:05K'\W4J36'A5[2+FG[W$R^Z0_CGW7*BK2122U$
MO-3)FH8$ZU&(^9MENAH[^T1T(/_FR9&'KMW&@]WW;@:90#?O<?W<RBP"^W!,
M.19R2ON45#! :T'V+B\S$4YMA*1;H#+*#'_ N^%3G<& $H.*_4%Z7#,'5;H6
M\BU.>JC8X?59LB3,9!5[UF.LO842C;(^>-L6>_+X0 (EW3C#@*WW9V&VM+ Z
M(Z;OJ4)ZV+*EURL*:?R2<.C$R3^ L^PN\P:GUIM?FV$_1*VQ<B5,XL6C?+TQ
M1]$$*A>F<M3]L5^8P[\^+ZW&R/*=M: ?1]_-_#4Y* 'GB8T).XD,'T[CXV!+
M,"W(D^9K "0$A \W+07<(1YC#G_LJ!V8V9^P&:3P#K<P"M$2()\B?RP)SG(M
MRQRZ<<!>@["S]OPY1,1.9(X-DQYL2"[R434K_2A?F<Q4]HA<@5GV1)N8@^XC
MT,R:->.#4T91.MXW=;W56?5(Q,494[YQZA%!*WY2F7"J$K' =3=X1XPJRN%4
M&K3/@. +58PY9&&9\8U*Z]0N"^\'HW5/Z* 2+%;HKL6HG5U)_AH;I3?6YCW6
M)@>)^(Y(3*D6)&EGDNX(W4!;NSX^5[+IZ_=Y0(+Y'QIDF3@/.HU:+EXN#'&,
M^!$23QYVR=T">(;/-B$^@=3IJQIL:IG)[0*,C8ZO=CX4C7_$19P:A"\C([0U
ME8<CK M^A\-N^[&\$]%BS?%Y-N'*L>P.$)5]YWW7>#GZGUA\JA>T(^8EGX[F
M,U18>FX6%^Y[)/5A82,<&Z[ )+4-$DYZR%5I"#\XY1S-,UYNG,+4<"4T3R(6
MS>+;S$W&-@D^5%"]'QH-C!RLL0GCM7*VKA1BE:,OU0Y3)$NGV!,TO/KP7#[$
M;C_0F5(<0WMSEBR/>\.X.%'Q1S*K6TVL"=D7IR?(E3*J5$\H(3P)1PQUMRAU
M8OD]];M&'W6JW32*A6E; FQ^J'/^D;RHMI2LI":GT&Y\,;4"!]HU^,$JL]&,
MX]*K%WK?_1J*$D>N YW]'0S-(PTR$P6AG-B0M*@E*V0\)^$F;R&SKVC!H0U#
MM7-%>T?X.$./\*86?\NU*B@0'^RKP)9I@Z_=Q"4$9VCM^*E.ZG#A3S[L1N;6
MU<F>[6C349X5O"VUR^?36EO0V"M^,<H;\@:Z>UJ3:[!4_:FI@6>B#]+4,,B-
M3:J *8=K(R9E) @FE6.)2E4>(IN+6DN\X:[7*8A<-?N:FV\6]QU8WX:FR4O!
M@Q@K Y?#%X9_Z*N*)J:(S30O7H+5TG,][QM^Q;$.V,TMY4!\SA"5R1Y *\Z\
MT=BK2P:*X<%O;O=A+SC:$R=6=I:95#@A(EXU<OGA/H_&Z>%#+CA=:J)]P1YU
M[+YTB:)\D]+10C:R<,=D2U-EE%BI$=+N2(D[*3_%3#M.S"9'?D;=W'5\/LN;
M6D$G2S*^(X:/,6-H/C8*R[5?H$+W(LQ\JZ-97H'HN5(#$%O20Z[H/]T >2WQ
M)O>5_J ;XP.,@XD.+PK"=36]P_'/3&K(&Y[I-SH5VAD\6R]&3$ZG8A/'Q"OP
MCKW6S%#VW:>K;^BY7AAE/?MV/,@YW8K#QZ:)?X%B&6R*Q^ 4"1]M$X2=E:N.
M_35M$2R2B)9+3*P@,V?RD>!:NU402&#3(+NA3(^(#%PC#0':@CS6SY%2QRUF
M<(LAF$VP"5VT,YL$.[M3+A8WESFVLTH2/!J?*AX$(>Z<*K M51L:G V?6>](
M[X?/6AQ"_=P^I?:C^YBEP]<[RE$]AQCQ]"WF5U9:VB1_!67O1TOXV;3$ZO05
M2?-3I4$R?(Q2ME+H!I8T!'JU53$@715LISNO5*_?;R=$1F=A!Y67YCK0Q2.>
MI!LI_C1O=AO+I@PCIV%<#<48ZKZ+JR_Z32JTQ3; 7[7YS3G4N,5NJ/:66RC+
MWB=MKZ18J'$NQM[U^+WZ8H8C9>N-'J%(B(%Q4VH?U0(<C!["ZUO0::BMIN/D
MK@TS:%DA]L0V@FAA*7E%U$XI'0:_S\Y-ARL>,< 3^WUGA,BGV%MHO*C2NM]K
M%=!7Z^2L%QVF(<._Q=89TRN:( =?%UGJ1:3EY%H<$O"RKLER0-(BGJUO#BAN
MJ.@QW6(H+R9#93KDJT22S?8UI?E$<;!)<8IS;81+ADBFHQ! ZPB1'X2UU#<Y
M?;'',B[JC. $T(^X5GZO>9H?-LW*_2AO8 21S^F1!L5GW=4JX$M(.EE9JV'?
MI!CYR]@1?(0O&3D5>!Y*9M3(L9A+G,:R"XT/+CV42V5)G<8LQ6BVJHGT6A%X
M1H.=[DR+:]0.8D"#N<>)9$<":=GE^J'D[GK9P&+OTHBII4]=YJR9Z)C.,DX4
M]$=S7>5$2\/06I8&89-I2?HU?ZG-*[(>2UOB#[EQXH6?8\=)L9L;O,7)*M4C
M)$#%19K91%=8%;Z-WA'1N#U>5?@L#X1$=.R(L*ZI83SM!UIH_ZYOKU$Y1 @E
M'2]UZ(!T.O<0:/T8D\C3<&Q?:LM1J6Q+.!VO;&K AUDR,C'5Q.JR\FP)2\5-
M!S 30]642Y"=:<>#\^-0B0QYLBJH9MZ8+)7X(BU&.R@ZH6Z:P/^]RJ<402Z\
M8-<'V-A?G?93&SS-&BI6$A):S^;\%*%H*623_CLG_=K\^MF%N31/UF1Y=ET2
M4$=&3] XBJ5M 8L-,R*/G1-2[NUE6132;@T+)R:FSVX@U4\+VEP]%L2L'FDR
MFX&.D\3:\5RGHXRG\D 0E?1Y"4*X$UROO':H\36?:9=7G5-;%>V8!#:05 Z;
M%,9R@DVJHL[T.6#8&NS -LYBETM;/30V,=_47)/ ]88/!>*YQVP89%1'E&ER
MG>@4F$>-R.UW_7;0FLFB^82,9&(^),0FAJS_QM61X^-F8^?D$G_V(AG=Q3JZ
M,U*>,^PA:[9R&9>F;=LRL3<BJ*70E1_V\0" 0/-FLA2.>G0;Y)&'"Q\J]R,\
M:)R5[96",J<\KNFL@W8,L)4G^F,;R)IG@W]_&FCSV5LR#<W3*"OSO\0&#493
MD?ZRAX MIT2;J>!T %L):]J.FK(':3_B4JK*GQ#FX$\C0O"DA 4OS37"ZM.9
M#Q[^UMXG7\;'JVNKFYK/$6Q][<^2@#X;<B1>E/DUA_)&="O^1,._53<9W5_1
M-'_\QH&IDD.25'%#.AL)([-*:-#%0Z3VR.MBUT:G";(:]1T6)>%[G0I%]A=R
MS5P.9;!)!,Q25WT-G*UQQ%WMP-W!^&E(A-G,9>]%&WY>R0OPHE/X!#5D0*K6
M1AUH^V!_S33]G\]C@Y7=-5J7-SI-=Y&1M]#"KHA)1[J8_NVX8S.\!LZ1&X:H
M;^^EAPNUW"8N&OT#DMUBEIK:Y<QL#VYTJU[63UDX5AP>VMP(4ARH"4((@ G&
M5ZDOGE&N0^2P2@]$<[X+I!-Q!^OE1"C[3/:&"2&X626.E^$!G%=C_+6E>_EN
M./7_  *U$C_OVT8M[_O 'OQ'0BT=](:L,M\@-L*/8@W2T??R%<\[K,H@@T2\
M^:8Y:1_E@2H!L R+3)3B#&T@$XD20LIV$*V;X/?!Y(,U/8H)U9N)B_%<Y*?C
MW!YYI=H7C$\@^UG#H%@Z C03N\19)]TN8]^H[\%B4_HB7?.F\WS"Q18,%E\3
MC3N4Q 1+TQ[ =[ ^8Z,H%O?!S)E*"PO^!ZC+&W_!(%1[MV@ <UO4QJO>EXV$
MZ:&B4ZRQOT\GQ4?< .TQ0;*KZ]I#:O$<&-QY8I*1@VB[16;6#B@+<<3XI:#D
M850D(8Y.>Q*H7MW3( N,R#01E22&5!%&<#D:&9<FPVWS1 E*51E%OUY]Q-(Y
M\%RB>?U*%=)0^[)7C?-%W"!GVE->S(K[Y:-00Y_;F3[_7^.,C:@;5]_Y;8E&
MU:*H299F$8!5FC1M-^19IR  /80#8SCY.)MD%<#X^U*0Y+[&NSJ5WJF8 X;^
M4Y1MG]K@#$_F!B0#29QF!>,L]7VL?ZS?[KQVV7[[R+*4!*<X%D;:O795.83R
M$B-&"T='E-4FWA,Y:5E/L1IG9M#04TW/ _#9ZF3W]B/@=3K&MTOJ.P/B(![1
MH)9]F,-L-*8^N2Q[N"&(Q(<2A<=0%K/4</LQI;#XG3(W%OB6+S=!OT>P>2)-
M#7P]C#U3334U7!QQB)*@$OVL66'Z!P2'&NF[ ZUF;:VN22\XO'\QX/7.<G)L
MLQ&=V[% 84+#W3GAR3(7"O;3U2Q3P>HEZPCD5O7)_(]2LE);R5C?FX"S_>_5
MM@>GRH+/XZG8/O$O?R3B2,DW9M)QBL2;Y<*TAR!@IO97M#]X^,J.C!)A*W?1
MOCR,/ %<)CG@OT 'DZ8 CL^KM@EM*:FSUF6U;8^F60KL&-8J^5),0\H>[]4.
M(^WY2FY(=6)'/^P)OO=R[;24I]9%8PN(,CY)X&IJ"AV,X/Q&/5,/\)GV9)^R
M-X6^F]V#2=!G&:;DC0C1GM#FL@TA/RG#9AC[*H^EUX'"]M]R%)N-U!6P8KXI
M[K'93S$K38NRS!?G'<I5387[J)BAL*@]!3>U\19Q!C?&P)>"D(^KLB:XU,%]
M9F --E2NI (-+A:]+EQ3G#U.@-/&2U!9,( SU)+NY0_U.^NR(-W 3F5\6H2<
MX[LAXZ&M%><,XZO-W%);H"FCA)68P<:+ZJ[H(8=&XZ5(A7I[>4;8XLIEACVM
M#X_ZAJ2P[;FEE.H(E<QI>F5S=_.$YUA'7:=3*EE%_*<CJ7&8( V3^N!<0V/V
M3%0!:\(,Y;XN'']$TRL-Y3VW'S@VS=* NLUS?RYD;6+QD,?VAG33<J<9;PA%
M3>ALRY=26@ APULRH?MF833S]Z6'*-"4TM#TJ%LM?'AP53"8*E5%PF*]@O:Z
MLMGAX=$]64*[FR.ZV3$^@VF8G3_^BUU1C]MQ%XEW Y1S2-X/3):]V*LB]]0_
M(I,@+C*\1T*5<VOA/AJQ(6:^E2/G[V_/!=F($A#EQ4AY-\LHN9S*QE?RF^6<
M@GXX^23L4!M@V&)KR$<6G5HS]*C$C@6T6Q C2GPQE8"9ML[6UF]8%)GW[B"O
MVJ)Y*7#WS77A>\<P]_9VS,8%4<BY.7&0FTP6#SZ&K/RZ#V9YF38AL3V-#D.C
M:IGSY<=>H_6>GHMV^]JQZX"1?P"T[:TMVOWWV_=W[UP>;,]:Z_\4[LS,3.[6
MN=W4?#:<7?WX#\#7\_.W<@ (^QO.IT<!2>.KV8C^51@SKD"6<*- W'[@0!9_
M(]A&_BR60#-MGZ7*54"E?J^9D+RECI$.93SD_@-:_Q8;J'MH$[U5?!7M?;0C
M;GJ)V1.TWMR.9="K0>6WC4O'[H_2D@Z.U8]D(*I@B93#9HP'X;)<XHW3,DT\
MG!ZBN&WS:%#<-GY9W+8!<% :GI^?/VN)G[UN34T-@S\+8BGD9:G?(3S2IOBQ
M^?5H;$G.$845/1N>K[H!&4?J- ZO'WTC7#K35C!KPIY_>9*A,C]6V6NXZ3MF
M?;[ .'8J#$S6N!5'"P+YIL(DI"+E;B#LF2:EY&.,T9]N</T=*$ J4 <B?!.=
M C NZW*.F )],AZ:&=@G#)1F2EHZH$U(XQ2@GW/#@8QW2TBJ1Y+ OG*+TQ="
MT]7#'$3&Q8U:E_IK?&1BQ9NLGQVL#, A0U)(V=AKH3&62(9WI*SQ+-_\20,X
MNE[*/-&9+=:+SJ0 +\Z$<0HER/51$IH]XPRCTJ>G&U'@IBIL*2SHH-&YW\(U
M=]\!%'0P5'+0D)(T^IP2>S]84+&'0;1-AD\]_F$PJN';E4FF /R&NG]RE(";
M?@U!XT84<RV&4V:\2;>&HV3@D6M .(=A()X=S2(>"%8&XY4'PQ :GE0U'W&^
M % K>.YVA,V;PY1\]"(&QI@]IFA7Q&1E;_S2I-V;2?'8RQH2L;)$*2843-CO
M-W!TEX:$H4U)+(BOK*YL;5/,Q#Y=B5)%@ES&QZ()/KZTOH6"2XS/: ;227!6
M3>?]?>J>\/0DJC'94? 52EN?%,[R.<HMR,V=I.:;F?*!B^:-IN3Q8L=_C"U8
MR6D7(,MP*W&5+]E15P2<;@;YDGYG>,"-]WI9JE$"72#.U (O8D_GU'@W<R#G
M-*;3!T0[%[ON<\[Z7V3N F(=PL+Q'!QFX**>B*!85J8/H>7K49OU95KEN#3D
M6W'1KG_2"7-/"DQ$TD06)J1]NL7:OA'/#G^FKODD(F5&V))DUH-42:,>M.S
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MS>O-(UW(!I6OMY=J)2#W>$:BOKK%5?VK"5B:J3?UW$EN3<16[).*C0-('@[
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M*6)GIZ.\@7;1O.QX.AM\2$YF5T(]]KD,!LOI9E(5NR+A;WX;,1]-^XK1[M8
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MP'KZ\OLC^[V>8#CO0% 1IVWYR*D=>04NF8<H3SYC$\YR#="B5JVUG11&+Y=
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MH66I-JRF\OK9-/%Y%B>I;EZM/NNM]KS_1N=U[8J!=%)_QR-:A?!@,EQVT3%
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M=?Y$XS7F!Z\IA150*NGXVC_ ^JT1O[*H>'1F,R4UO(X'O-WY8U$P,LC>%:Q
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MI4?Q4-%%<]?$0NO9#WO9>0<Q)_HX?@$Z7G0R>:* \X? AT2AH9@^(L!18=-
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MJL(US/+]9^)YQR@YEQ!7AQ"GGIP6;F-CLO1;0!@V3>P&#8'D*F&82%^-_F6
M"_APDY'2\4G9CDG\#R#IZ9E)P7"7\UX0X\U1W5#U'8'C;R#LX#?/[XK=7^O#
ME>R4@;.2?Y56V?_T*:/%7QVZMKU]/WG>EZ1M(O3[2_A3G'J2#W+J0?UDR31.
M38:Z/>YP_K0L9RN<JKS+\U86ZY&D@.J\-^]7 :*VER0W6MS]]4+9FCK_,*:H
MIL_1:2S^_3LQT:U@X7/Q5N.@=X($0;OL5>H_Y__/^ \\EP$_P0NO$WOV"_\
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M0RGP&M*:-FN8 A:TZ3M1>-XMR1J.")=!FTL^VAQ0I25_PY4M981WI)VJ*T-
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M,+56D4_"AV29ZB*S>&><QC*(PQ4L&.05+QMLX#8E>+Y#__VV--D^:S_X] )
MDG.0Y,^@ZOQAXT".D^IH$ 5>LPQBL=R9XG?F-7\<F$FOWR<==8B\+^L<-%^S
M4(/@H)BJQ7]]>/B2P\/&3)O*[]>Q=G'"]]L_P]]/GPN<\4ZJZC\OM-&@GSK)
MJ9\1=K\[+)JO%\K"_!YG]L8WVT?=4PM2O4$:\ * !E?OJ6$LEN-P;>93(;0%
M.YF%S6VV7%93GEE/7ACEO)?^AA$LIHUTI2)?_G0'3.I@?X 3N0 @O'""B#UF
M^3AD4;/?$NUVK>NB(/IQ,63BJ<&Z?NW3%%TQEB5))I=O:Y(!MYZ<I0P\-]/?
MGGJR8%XV?9Y$F?V87KE^X<49;.IGAMC\;)*K(,R5R+=IHQ )=P'20+*P 5]Q
MQ5<+>9K"_1D8BF/[\X #7Y\V-#=+PTW:[)4$2OI5+(Y42!Y)AS1MTR&&I-\Q
M^'N3]?,2UD_03=W#P;'VXWBEYS+S6;/29@X=(G.96G9EAND=K#[Z"EGIZV8U
MOJXNZ;L["*<G7S&&K[# 4A%_':G>W$<_A]?:M,ZYY6=XGJS"FUCQ5B%Z0(QW
M^_WZ=6B]IW:)P(@7*26< 3D2O\/06K!Y7\.Q"J) B#(:%*?*Y;]&F\7UL5W;
M(V_;M]Q/C,N0NXQJT_W-);H[#-#8D'N2,W8=UH<;I\[>WNWK[=]SYKI4-X%V
M[2?57P=?RJ+WJX4T):Y'CVQ\')Q)4,H?+B7DXJGY, [M? =?+!W.B,MBY546
M* M\"A_E!6"6B62;#X7\S=!R823?GR;U)H@^92A7"5O2-\IQZCV!)\();F@X
M[C;?WLSR$D[88K>\*D0/0TYIE#F6.JPS86XH:6!%-%I\0C.KHL7Z*XN\PGO@
MGB  F@E+)+'!"(:T)M)X8,KF]9LQ"@ER'=J@5ODSP[=X!?%IK"A"4)NU0"(*
MV;)PL'''.-U^,BC0T]#B>HYU29_GW.9JG<[SM=+"0/7HDZ3,M[ZZ@F!!][%W
M/!H.>0*J20O77*T,UNSS%%?@&;] 1'H\H;:3#>**-_9"$W?V7OUVRJ07[C7W
MW=91AJ7>'DRIP]_-L$?8.,&-@:A94-(%@)DH&4*.R\G'/\:PQ37LF7;9W8Q^
MU!C?RZPOMY^N_B/@VX;78GA%LYBPJ-8=4<PG ^4GMFYF3W:Q,MT;OJ6FJ2]=
M\-(DGD0S7P#H"9CAE[9+Z*]R^ L F[!Q=BYT] J\= EW*WR7](CG7]^'-6A7
MU?8ZC9P_O@#LT!"?0E%YT$,HE+L-VM<U@R/],3:Q#_H$A'Z$@>&$*7?/9XBZ
M3='0XSDO.P33_/:D#;22<6,->, *K2I>A2*@.+EX; 0N'S/<GWMK O\<[:/"
M=PW<U)K3'J#<6?!>4&9!-<^&]@K7ZV=4Y F;N5/GH'-6/,\4T%EJCF$YHX?@
ML])]]!1M&%F_=_4,?#V@(1T,=EE^E9AC%L?T-GRH(,&!AF@#]((A!5:NQ)[[
MA[C5U6%&$\3W)$*"J_KHKNU8W.UCDLQ[R6BF@1)- I!Q,]P'333AF2.,FZ>A
MJ%S@)2\I2>'V]C9<P/)I<7.NAN![':1'BY.3:AV3KN"A[JWFHVU(R<^"<EU9
M[/CT1,O4AZ'X2F/3>(/ K9;=0=^V\Q9*GN +P-F6E4_+%N*H>BT>>T;X0DK/
M29X4U%]N#>*!C"].SR!:UZ[U7&WRJ^F-+WE<$I>';C9^#=B;A]= X":$5CBJ
M$%H'?^MW#J3%/YH.8\.!-.K'CG&R6;I[]01'"91.XF3%=_KC*@&A O'5X&;-
M1VE?;.04N^6$C 7W.M,O '>2(-G92ES@&H+*_5+MP.N_"Y(TAR6?;)(S4:FC
MPJE.5J<+O'-5-EGQ[O@;N .,!E8$UXJ,?GMRP!0"Q#A''_#2QAAG(G6$M&8Q
MAF3TT5QZM3H%W*S/@BQ.WI!R-32A] *PW A] 8N&L7!.N4NVFQ;&2GFLKBA6
M?0D(1PF#/ABP9-T73O !Q\L-%H<;9V;(@DS+I48$XCR9;"K]@&*D)+0 BO:8
M04C-DV&7<;$8F1YU49RI?1ZDSEB_7%%.S=0H[E#P6O];'::1GW<=5"D%*"O#
M4DG^60!N/\H<U@7]"HH(8X-TGM^?;#BX.E*B]OU,=GS$Z0+@ F]NL4T4]X;3
MBE"*J#_S1LCA9$B.\0"WM>I%">VR[I3::C5,:#<KW)INXG0)GQXUSUUD#W U
M=Y\W9K^4+IBK))A)(%4W$<'MIJ40.)&:&IUL/%5]T.#Q  56]YA:V),=WYNN
M3@M087K,>H]##5"U,*Z8]KIH6U>Q(PUNFB&5QO%B(^]ZYJ\EP^9SW8*>2SO&
M-MN,<P\=,G56'[U)5[DW"' XWX!?@Z(Z^- @*#N$:Y6W 6V!BJI=Y$GN\9%+
MC@TQ=/,-E%M9':FO]P'ZW%"R2(,&;EPQ$V&60O/M+I'F?HY0"D65*-LBXF7I
MV7H7)<?R6_Q"H;U!LW%<L7]XB#89)IZ?FLA:OBQ%+<<(LXY&#SALB>)B2S3_
MR%=F"QF/YU/>:G.'6G2'#O=/'!<<-9/,V>(0@X*&0QL0>"9K[ <T?6<'*6.^
M /3\$K;"4"1E3VR=P9!^MH_EF^\]=XI$_HI]@!B&?O3]IC2Z6XSGOKLL%4^4
M)435VTJA.N#)!ZK&)9#^(:[F]IN>G3,2*8WM1^0CE&)>&X'6\3!QGD][3U](
M?YPH?YSM5LQQLNL1_5W()+M0U$/NYWGK!<"R:7S/H;FY.7QQ\0ZMKD"D&>_:
MQ.=)@>8W#DDZ:XG]ZX[/AGHF>:/@G^"D]+NK&=C(UT< GMO;H(GOBQ9E@\?5
M GK1^OXBPBK05X=[[C6*/E0WZJ+DCDC!^6"N'!M.\F6/0FPG/$+ND_23ZK&%
M&B56U7<8/IR6URZYJ6@[MF"M8Q:7JB!P;9M'UXC=N3-)XT'Y6J&MTJL:A.IV
M!9OLEFP;;.9Q !DH&HB&5.,3X'4'U7/M]RX=#TZTACWH;"+1)H!$[))<P;^.
ME3C*>W,LQ%\P8%$1YRQ7V;!14E:3XS2-TGN6^]#H\O!'(0L$I5N3N=RA-IZ7
M9 \"4KOG%P"[LPO T40Y=S&],D=FOMI8D:.=W->K!<HDBT;]N-L*0HKX70!2
MP,6$OG+LD8IFV$UH5S9P!^Y271P%_R,!:O(8;_&] /PY2R?6:VOI$[>XD@X,
MG/F3/J3>-<4YP1G@J [@7]KA!%9YF]"FJ*BO_T?:-?Q/M!M^\VVJ;Q+KEY3M
M))W+":LO"5NT 2&<&5-=!9+NW%M N'#PT[W?-M 1_C5!N04:HMQ=)I$422@%
MHDHX_R$I5V_G_Q5)\_\S2>=Q?"C8GC>I7SJA4)7,BU05?,,%%^S8\==,9*X:
M3A(GOFQ[-W23T<I*3N_J75>WQO?D7OH1&HLFR$'*QC9M&:1S?95D">_KMJ%&
M_:NNO)LLRT#%H<T=)%P$BMJ5BE'GQP6>WPZ1RKH_(Y=X-3CYNE[J8/'BH/NA
M2/V'/2$J0>?L8(L?4+3KGS[X]9 'A#KUFU8[B\*8ZRU@R@C.I\OPR:*6)(5S
MCZ\+K+.O7^H,\.Q$<3PL#(?\\& ]/IW=2G?*CWL*]K+_4UGXK8A0P!MIC:F.
MA:-60$S;=G0D)NB$Z$_ZA6I= '0G^9O'KZN4JT2'N_QQ:XR;MZ5ZGB;(&\2)
M]R!1)X2H#%GJ!Z$MX&^#PFI6^5C=6D-'L5WITT?FS;G4KWXW[2H(M)A& 9(4
M^3GOM#PJ?^X<9S*NP"LL_:2&,<]C=.NK :FPLF:A[E)+GMB)PR43KPIA) M1
MHSC!Y-X1;>W)ZN/*![2)_-K^SB^GCQ!M9G7F/7ETT@5)#!J@4=@N20(*25S:
M^8VPL5:^7K,9.3B[#21L\?39N'^HT[8^QWIN?S!DT7%17]!+=+ IL0] 5Y#.
M^4Q:N;GU:H-"C>("DMUMZ$/ZYLF/B3W5/>/]X*!QM?ZE>R_!IS2$ST!4,:R>
M<D]N9;C2H@]V7=7KI6>!M/9SQS(#^^+YU2\(#VH="QYI-F_$=]WJW]5$&A*!
M*+1J2#/W(FPPT[,##/:JQ!WU1>SR<DQ4<21(#]64Z_NJL]^-$G(49]EW2I4;
M(&_](2Q4KO=DJZCP]BLQALSN+Q_6,O4QZD.I6R_,Q8?:M'2%W^"F/*1Z7UFM
MN4\K- ;$)=9D4C^,2_RM\QM\^A+'A@9BBTGC_<$_G^%IMPU<H:JOK-M6AL7X
M*TG42W!]%W\1I_A%6U-28R^)*EGK!6"P!.YY@!/T0B3C!/!!#$E2#7NJ6Q8S
ML!=U&+ZW<BHQCA/[.M*")M=U"I.TGGYZ8SOTZE*;(NML+8V;77^A0]FK)A2)
MZ^Z3WMB48L@?8!G[VF)1MK+%NC:>BQ1<*8(QSGOYA;B(9:G>O?L-U=R0![UN
MF4YU(I=7S;XRB9M(=+'3RQH*@MIW;@ZF#PO(A)7E[_,E0B#?)1[)66@5_<;>
M:8ZQ*"KK>>8)3(,8XEGBL9/C).\!6ZJEC%>_Y<8X_\O.]25M*&^_!5*.YP$H
M=9$;_2I#)3O)7/;5GMWN8S":Q)PC0O[FE+HH7@QGZ.$M.K?%Z;XH"G\++<^U
M7 L.?K&T=W-^8;69&6:U)-8=ZLS,"9*W__0B-(EG $\D?" "0AZ0YI)4&73=
M6QX_H=<[,II1]2X9KL!E6:>K]1C6TU6J]OH9Q3WTSD,Q,P$H#;>CL6!"5@C/
MN1">_2>> F7 NZ2)7HP 1%'9 ]HKI];36@?%:L3W%^J8#,*>D[ZU$%A;H$Y+
MR,)[8WS.*)0SDN3NY[L>WAD62H-)=L&W"@Z_/E^89P@B0")?E6X'[OO:)3/:
M9^\0[/C(914/W:4DI,# .*L8T'!9AC*A,N$GPMO?B[R)SH0E5=,\K8/%.56M
M'+-)O"I"R(*[5B.3L3_1AE%$^M\7 *:&:NKA9:K.F>M9P7*YX4U%A[L*66*M
M5N+]0&&5!?5O.8TS?0%+:'?8GFO %_E*;Q*-:1;<F+U2=F&][^16FR@SA(<6
MYA!GWQVXW]W-_MIB0#V1L#UC[%5\FA;S':SE$ZGL,5]]RC?!AV1-1A^?Y!->
M\-E%+\)3& !A8_!Z2CS3TNH>-KX(%]\7!L!8O#T@MTI_(S<_^&(_[ZD@]O3.
M"/-M"FMRZ<XUU7*+$\9_DK2JR@N Y\'L\#<8Z^>)_C3A./>%7Y:4BXU-1B-"
M'=VW][^X." -S9!@\6'AT@B]+V[&7GYVE#)10JT>EOFGI,(_XFT4%%7#QQ$,
MJ]^R7[@ ]'X9"&/GV?G#0*0?"(%V<1(9\#U*T[70?:42B^5-//<M6FC7\S"9
MD],JV:F!"\!7S0R<]\Z(WU)=<0]L/AJ[0(A6%4,O+7M%X1^3>(Z7E7K1(,]F
MY)*>N:H?Z*VZ81V[D;SWW"E5!]O?+W<78!'X(BR+[RWV-)1=STW,< #]M;G:
M,;%DW)V8\WSJ>8N,N#1"X-Z\(%6 NSM9_9N?J(BD]B31[YXVKW9 _0>Q^+L8
M,)'Z!'-FH(Z'5"\G]P(9:N'[SL'Z QH LY15=YWD+KJ*H=EOPIG$O\$U!H0V
MCD_&B<SL6MA7[TQ8ZZX>T-HT)JX8L[Q@S?4WPMB42='4/1CH%0'H"!D!;!AR
MO]=:+KN*_DS] #)%#A]!5FYM&?@,\MG79UGS)<M9&9@H%B;)IPNEFCRXK2AY
M3Q#EKTC6 %5<0C\=Q4EY]24GPWG;02A0U*+H9#LM&G&O,TL[9HN)D/O'[C G
M/W7%.I*PC;C!T"@KVFEIVQ4[XL-'!43] B*SL#DXKT+<BCZ4[BD2$M[/H]4+
M7KPA$1#@)>H56<.I7R?R;<^G0N&8DA]L>,.XH.R%6PG(P5E\>2@_BI=[>H&8
MU4[X14-PM5KU^A/$'<:*WPKKN@  X& IG+ PG@6&N@"\Q4/^;F_+H)98()G(
M[IV!J8(V]'X-UQJ+%%<]79\V%>Z=]V$<P>OO_@RTRV@7BLI8JK,)6B_,YD0D
MAYBI;!$Y)B39/_*:&8TO/"*[<J>[JC \NTZ7$TWMO]+G6!OI,I8OI.Z1J2)B
M/UFJ5VDV/!0:*#3>RUXG&LDAF$NY:E8/9YP#I]0]79Q;%)7O=Q%B$E7($\BK
M7N]!@;Y= ) P(NT2)MKF%<9_,^;F>.-HR7;8C<FUQI_U7G=JXD168GE86A@:
M%6^J<<20W?I":(.C4N"\0%0RYK>Z8N=,_5$AR"XT;K0W[-KD_HT,PQ;^@10=
MRYOI2APOG"@";L]>V459%!.K)Q((B7J#3_;.>*'8$6T^5\Z 9-^SO"2#[=#2
M6H/UW)? PC!SDALBI7ND6,U*1"J#8M29\(\GN:PPB+?N6J5%8.DWV$3S;SHU
M.DWDSV3'5%,89+@*+*7G')R\A$E&U:(N LE:/HCI)*N.QFM4N=P\7+*5250F
M6GNIN$Y@#ZB^R?\:2=@\X#QZ_F$* B\=UE[83W<TW%ZR3$+L&>;JG&IO99OR
M&<?=3I=/!=Z=;"W"M+SNU^'X+:VTEP(:*MZ]<?Z".)V!9$CJY,4SMF*6XOR3
M>812)KW<S5>-)X\_2O1]XWVT^[T1+)S;5:AB?1?1,)D48H_-)6039<*&>54;
M.W&5RTN<$(M>SLU/ON 2MPW-+&-'I&TJJF:Q1^ 5>]K KX2C;8THOGJ_0C/A
MB9;-"T %=4^.Z2L\PZZM@_!Y!V;42N,VY06@$O0.B 8?X%EF$*1G>25Q"AA:
M:SA&[4^D[-IT/;T)$23_VU(\EGSZ4"?,E957QY+C\)O.<$Y9'/P9:78=_R;2
MZ7QH_0O 7*V:V_3TC 5F,ZX@PQ#=^4E)W2:U+$+B^V>?YV\L:2F42"G T/Z"
MJMN<O\N+L+*&E&T3A&D.@^>Q]DRX_9+7='[3Y)=6B?41EBR;/-$YKC==?,:D
M I@5GP["^Q**X:B*)=Z,'C0N @%BQ!NL7 F(UZSO<*G?T='E@K_D\/! <=S[
M/F_TTK)MI@"R2:0*.'<@#G9R>7%8X81MFJQ9V!1D<"#;J WL]UO60A*%1UE>
MPG?% #(#*(MJ2=Y(^7RKV@28QHCEVN:!20%R'VIR\]$%@$']0V[ >.<5DA'1
MA4V%W<3]K:E+DA&PZR'/R\!LO#R=4TEYE6!?CBK^N@:5N:)WZUG#]];2Q6=Y
M=  , TLX$6'\]>A5*)Z5<G4WC!KG$;IB2 ^1>CKY7@_])TK6=:1CH]DAM$9N
MOG\N55?==)UYG?];UXT"3VYY??,&5Q,37>U /Q6QC0];I@G(@/3A4H(4,,X/
M=^(X@23V2:UQI<X5&8LE!5+GS**.DOJKZGOM<75;H)&#.-*23#,@P7HX8_\5
MZ)Y4=%!C"T^;G>[RCH?=\@DUM6V_;, ;#Z1[.GE@GN+R+,H"!NVZ!4?5PYDN
M ,_@29R\\2LP)C"IS.L&#P_L-E1RF7W:OYI"[9'H"]Y@^MFN)#Y62GNSU$3!
M0VSR4.1)T69D6=%J:\T(H4;$0%Q3@04++''P6,J1T'04'?&LY#J-^<;ZS(=*
M-8'W F"5WNGW1V<]P_X5'E(T"FG\VIXJZUWPK$Z&)^_>MF'Q*HB3Q"AWDOBE
M+TD7=RX 3CNV^MH-=9/$FY!N5_$0!4??(PT.S2O@EB?7K$0TBH<8I,3M7S]-
MWIS_ULE#*"!UK(?6RR(?*3?%=@KB4GXNV<CGE5 =[_$NW '=B7*,6I03!^A\
M$^]]71A;#98:+(XIVM'3NV-KN;9:I_,SLY"J11<V;?=IA5;MU8BGN&=E-;]G
MZGW1@;=G5\B3IRL%MX=4-HM49@Z]SXU)TJD#71EP@E7%>;CBWFO;B_3)IMGW
MBW')/4'S[*DH,N%4Y\BT_'=EZ4;S 12A!<N8LXD+P)5#4C\P7OO<:5MAB9(H
MOJ11 MG1K?'0>#@]]] 4G#[V3BC.GT\*QOZLZP,]9E]<0>O[V8M#)=/\DS@3
MTV0_+3;%A.U@SIIUYVDXV@J(G'A*2""IG UB#/%8;HNLPP#G4.-^\0F.E<5M
MN8IT@Z-G ZN!@H_G5VW"%8$C7KM<YQR0-B*-[;F5*_'2^$F)AURHMZ<<C[[E
M%*]N+Z-6Q>%WW/#P#4$1T*JKDJATS]X23DD,:X@[*@J;XF/J% -9@O71PB9M
M8WO'\^D8<GHG3V"=QW/%6N9/3PA?E*(>";Q[RGN_^@W4'O0:QGH!< 4F>N.L
M42-%I?ZK^EE*FT_=Y5SJ2ZT6U8J,-_7%]>M#BEW#7BJB.,_H,A@XGW*8OTW[
M=1*J%LK +%\MVMSPV/6P*F?T5S).L!A_C:\7AGY4/4_1><,VY.%/_/."!<BK
M':U4)+VDM5C,6NI3'JKAUMJ2MPEK_EN@$IT6*SSF;YD&=3A(YJOU(@7.&$XH
M(A%H53<MY^%$FR,.VL&>]<C27ID618^*/&I"IRIQ5/_\W7F LQAP,A-2U?!)
M36NM_'1\&BK'*98NJ?#[#^-:5W7/*$[B ,^MOY)\-<1XFG@-?VDJ0[L)C:^V
MKX:T_KJNGQ6?-C3LX?24D=O%IU*1Z].;NVEF5R\ Y7]WI@\2FT!U&;M*&/O^
MLY#DZZ7+2[1+-EO[T?0\,ZG#9&1[8C?P8J>4Z.KH@[";D!F#\3WHN)R:SQF7
MRZ/$]X+C R4MPL('=]8V.L*XAK?,/M2PIDT:RJCU/RG*?Y!^J 9<-MP]Q0P3
M:;A6Y[?P,GF0HY7<ELNEG9.\NEZ9UX("9V3D^X2SO=XQC[).X1\3WI)6Y@ G
MW(U8V0-W 1G5>1">V_#Y5IO=E/F[_3]G7E4]=$@%T*'>YS97;VMCI0GO5<7.
MF8@_>-EP7LM<9M'Z:,(7;8D>$68W!7(RB<GB]E3UIU@.P#, 98%;JUI52[&-
MY>)\C[^K/Y>&K Q_JE)*%(?E8XW;Y.$,Y$QB;MF/I[3936U@>3FJT0L;OB&(
M32\\E^[YLQ!MPE>HO2'K8H@>YG'>RIY&-U%(V2"1L O&YKE+2*Q1"\;E%3[;
MOP"H1F9E,[\&X/5('KD6?W^F H@J O'P1UA-+8?S<6[KQ/*LQ<5\66X&<(NP
M$M2)PZ :BQ[8;/=\GSF<_I@=+U.$@S_U\#GL_C4Z][S%)57^T%Y5DX.Q]'!F
MW33G\U7*0Y*14GCQ8>J6DM6)BI,7@..\"\#HLK6#O\@TPJR4ZKRQU;91^L?M
M'^E,U][/M.2AH5A.0AGQ#EYA'!^(@E[!/YY152GQRC*<DAU<>ZZ0(= [PCNG
MP,3#$T268C .]4A&MF&OXL);'8AJ.#A*S:G72UF]P]M__5G3HGQ \)?GV8=&
MFS W8@00M1A)\C'D$)RT]_22J?!"CM4?N7EHUU/@,RAMV.(%H.9/7+M*V99\
M'21+?\)3JOUNF3N?VX34&"VB]M%UQH'?I3?]'(15(_G30SJ__C8KRO:<7GQA
MJ=H17J[GB7UT&DVD2B,IBFLD=,K%0Z. S!)^!+*5+_/MTVSIL+:OF)M:"G<>
M"G[<OQSE$R&ZG33<M,\01)KP%3P=R;#VQ$B"K6&\WA(YMBR0B 2I:MDM"8^*
M?:9%IZ<'-P*I CD W5=&55%Q1"LB*]Y@JI,FY#'Z3WP];?77G5RVR6=3XD[<
M@;Y=-P>*R1K7;-XD*5;OMI'RV>0\7"4ZHT?]=E/R8'1OIEE5*??SID"PZFT1
MF_,KK(B<9_;AO0\Z6/<[W/T=%4M72O02;:<S@"DPY'L4'X)AMKKO+"P"\V"T
M=Y%IZ@1LV(2TMG'[8B]+,4=&QI+TV5/+KN74-TG+'^X(FI/!AA.:)4Y:U*]O
MJ8M@0L*X7#),[KAM437(!.8:J;N7YG0+K_O^ >][X51:0N#S]LNYRJ10>$WI
M M"TDPO5PS+@9"K_OJR7O!CO^_G-WN&VW/X3A+7$TQ]F >.+SLF&-)WMZ&U#
MK;!<:)<TD0N215)NEQ:=W\,K4]<Z@3?+P[U"3CQI;/GDE$D;"<JQG/IXE[)9
M6&[_P^R,B_KQ-HXFC7MMXVP[M$'11U/3CT,\%S0!;Y U; FJ,GST1VX9AGY"
M_WCG;^'NBW_56=/:7-=>C[Y>)\[\;4/IAG_MAW*QJ_?)'1A!PX;?@//Y*VQ=
MALF\M)BTT7A5VVIKG#ZH9KIP?+_]OL_7;5TOG_=R;?M.EQSFZE,9Z"!J#-5I
M:W4(TP_+@BW!N78JLDG7"^SE6@AO0XL3]K8&\X1? 'D5=PY @\Y[(!)[(@AY
M<'<@^Z*;W0U<RHHMFWXK=,%%F0*/M'OOWJ)BS_AP9\-CD&M=&GAN>_=\)N_O
M+H,?;%:82.6+SE\9C>?<L2/9U_*5GWN[$D(YG6.5V[YS6B:W4FH#1??W[]\0
M\"&[0^/,ECJ5QZY2M+:;2J?N\;B^*-55TV[W/$^2ENQ/:));;LY*%H]5<(R'
M/RU7::6U>RG=T![U(. .9<0[;?4H>(8*0\Q2@S:>#8[-;D:W\_)/RKE*":0?
M&HC;=41'X56<6Y[4/<Q*L;?ISXI)M5#D:_=L S9> /#70*N;>.;X91%<86@%
M!&0WYF=IS_8GEWW2,WU'*\ QT=$QG3UK6'([:T)X@[PLP;GN_'*V0ZEY1;["
MS\W R77>(-EY4AWRYJ@9&)#4L?4(/@TG%?FH!1!.?#0I3#3$I0E'B;$&=6*>
M3U7>RNC.G,Z[G4E4JEQU=:C/-#W22Z31^;VO?_M!R[,!Y@,H3CP#SWJUATC]
MYEQ.N](*B=Q>5,4\J9V%@/2S89*Z9O?3MXV4#I_3O2W[6[NM!WB"9!C39@IC
MGMK.SW_?S_]D4AH-24Q5_W8$_W4\HNE5JNEG/9QY6[[E@5FM EFX>CXYX[;8
MJ3@<MW5N".VR[%23BE[&4"9U"N R>NE&K\>[!HVY3K]+50A#22/GOTE_KGM.
M29'5$:2=!$5%0QL-=[.6&S%IU>'^P_XU]WU]@9$GLYY>[MV.M29(D%+CH2_3
M5S+5)(J@VN7?IFYRY2*#QZHG.3^"QO])KZ_8*8="\O?(D' U*"H6SHOWQIP3
MJ59+<?$(NULSJOHKUEHSXE&%I3\<.^>8&K\=PCY]"CS]F+[U X XFD+/8S_@
M$H&]0(9\W'E_)=>V_'E:PW!J!5UY%\59L(4DFT".ZY.XC*X_,OF,65J9$>NX
MY-T0_12#<W/K\'9GU3/_"P"-'_@M90N)S0Q[?\X?XN^- SWAB>;IG<J8M(;*
MZF2YV;PH"<\M^TAFHVS1LNAOE[0 9.P5TNU53^?T[KY:E_\NPQJ5X#"]>=*>
MNL^1YZD #8@8E5LA!7L#@M:J%<DZ(7C*]O;FW.W#H^6EZ(W<P.SV__%PLGI#
M#'M*R"/RNP+_.6PTY,$-D8HG1.;NG1[>)K^:A_$E/_Z>>XJ0 5Y>$3U<R(4,
MU1926R+P PBGE![31%VQ(V@*P2,>EG'*[;]G>!1F-X4O#_GKIC?P4%P'.OD;
M\?*8ZO,*'$./.CV:F/,%CA7"IY]%-4DTE&D(C8RLI'W*=#+9D',T*+C,O3Y_
M B;2N^.BJ__9$@P.T9M4O5\%YEQ?"Y-K3Y3T.A!L_61Q+M\7<W7MG<)==[(W
MK>7,*3\BI<!*8HO3I^^C1_+,B^L2[&9:SK*P26&'L.(@\K5SWVEX0B2A2%V0
MKP-#BV"WN^H_7T&WJJB"5F]A/W/FTPE;@*)MI9!DV#%,PUXW;M0:%[PLT>>.
M5UK.>6#-+A"#5CVU%Q,:YK[<_ZC(MX'EI4IA]\F35%-SMS^A5Y]B*!2*Q> I
M!%.)P3G8!TRN4K]RG/KDW.]FA.H1*(</K;V$G#$@P*"H\%Q>7 V&RW*R@5:*
MMJ<2!+*QL9&;^C5F:[ZM^$(KI79<IU]QE>X;T[8TI=PI!V88>P$@%,%1C7SU
M!-@;O%+)CCFV4[ -4@^ZXC*SYUJ$?%#VW>[54*R>%L^B:^OSQK)PEI?+M59I
M;@:^0NP'M_Q79)Z:O@V=7I=(!1;CV@T=U<NPC(N6@Z&<Z<&..8]*%)7$LI/R
M4^\.[/19)VU^_ZVFR!\Q6DTJ?$;X]F1(!<)$V,^EVHQO':8K FYA9!A9=;9&
M#WW36O3)R3#(JN>:<Z"]I<<*$]58P+7*MH@&:_*9S] N,B"J 7HMC(TXWLF,
M V*X>I'%\>I\..2A&MNCC"<MX/*<RV=:C,B8(A^;'L'(%W=KD&T157>Z&G.U
MBC6GNR=-UW^Y.W(O=W\ICBU:640<JVT&AWV8;D$85!Y7QT)1*X;_<3JBC=>;
MK _5.M?M;&H>ORZ6=7MQT27"K3'N5>NU'E$=U+$<_D\88JG)"V$8 :UWCL;?
M1WGX]H7=P?A=WIYY-.Y9U#ZUVIJ^,@X.DS ;S?PMY'K-0R#H]HT62NXVH5S)
MA'(M7>N6*AFY),ZRMU]^G?/-&"SF\[SCM;_I^2S"^YO@5R,@TST$?-E0@>^6
MUL0\IGJM!XLB?(2"N<K!U7$@7E5AC/(V=:&I>E.UAB!Z[A--62D@Q3/R$ZM]
MM\B )K='==@_[\VB2G*!)%*X+U'@[TSA-<O!,'HB_S9U7LXM[.8>HVO&^Z_Z
MP?$>O1^/;FOZ/V!,FTT3OU9M8,>3^7G'-#.MJ6;$4/5Q6;&)I )R\[C 67&+
MR")['BHV>@%P8T J](!J#;])L83H8/Q[K'_S,M6 =_+9Z<6+WR:)='V3'A80
M=*$&U)4,[("^9^S5D.)GZM_SECP8\WIC=*_=3?1!](E8M8 V&AHE611WLP*E
MP7QJ;;?_0B]Q=*IS11+5T)6^+N>= 7[8Y.RI(ET<I:MF_1MJ)E;2/\.KDRHC
M7768%87JN(3(Z]I$%C+Y@$]?C0-12PSS F;H<5PK,#J $:0' S^]A:'_H%Q>
M+KG71W>>@GEM%O..,5S!8I$/[9[<!TLT!_$2Q4/$<)45N)UA].-D%[2+^JUT
MYPSM3T6B#ZAK?U<47/N\I\J8.*?&7I&;H_RXD',L0W*G-(I/-GLCS_RJZKP,
MUK9X'J]_<ER661WK[L=^W7IG6$5QKI$RURQ1W_>;N)8A*RZ6I#JI# ['0GJZ
M8>PGH^%\Y V#[0H,48[G;+'M!@Y=7L7M?#L2$@X_GC\=G#WD9_K$^H'53(CH
M0<B&HGX9(JVQJSBS8ORCR9,#&A?[WNDO!X\O &^;S-K>&W>^^7;W^XKBK=M<
M_9"%^:_WY\.IRY1$GZ2YFVD:Z(.W9\N<1I'*3P1^S-B?6;)Q9;Q$+GY4<[F]
M63VR%*YB<>BX7)T(K=?&,]IC2R?;I5RKW<)8,)21GF/^//35G#N:4\\=F6ZG
M<I_Z] EZ5G"+^#,<?G!?/?,A1,#!],+854(JGAFCK]T$YH*R6G(XUSDMN%?E
MOXI:X;X 7-/-3]& 7KO4-B-O_V&4EGW*9".AT5F+4CKI1JN'SZ ?4 F*6A_%
M"4;E8$R7/?/.[T,HM0]#7)<AZ8:L\\ABY1_9\5&M_#Y.KP&6T1+7W-?ZPSN?
MD>AL3ZI]9I;(B.H(-%>?Q7P[&^;R,DP#''T!>/>XRN*FG%KJ&GW;2^VL]93P
MT;8SFAG9>"]&5P5SMFGT+RO0 ^Q1E\C">X'+'#K[5(*<Q'M =Z]P3M@NS[D?
M;KZKU7$-V[3$$**WJ=-FVN@0ZV =KT3([GW^GN?C.0WV,"B>*S*7IA%C!;4K
M?O^I;]G[6M_$7)O,.6W"&E^E<C-H+F)5LWJ/ZUP)PH; ZJXC<1/W:Z?'@:>K
MV!@F6YC9K_KSTJKM3BUC;T^IO..QU ^F]S59GGSX__I?!_YW8#9UJRGI+L_P
MPYH%QFM,=RX_"))2TST^ 'T$-5G@.0_0[['O_Q:TR5'(D\WNT&"3C[]L+.\[
M92"YJW0%$1ZM\J]KA DV690NY[RKQ*N!\-9Q*"K#*G+]PXQ\D[F=\+CDS=Q?
M2*5G_A_3_!U/T][T4_%')'"OP*6@#GPXI7/L:T*.7Y8M5W^*"YQ--MBH)!6L
M6>GO9P8@9_.&5JCY'&F+I<HTS_QTA' [E!#LJ26\P &J-CVL4=A<!#./2@+N
M#RGB-(6-+U'M5AV$*'=2XV*=/3D?)NM,CG3LQBEMB!4DZONK7-<6QOF$6>'/
M&]LP?%U>,?JRTF!>5@PHJCJ&KE(H!_LI@#8E(4'51PN5U*>C?DI(Q$3C>;E*
M;"%V.G@@FK<?89DJ7:J>MS+3VM#HVYT:Z\HUH,RDD+<MLP@7#[F+2HZ%H4V
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M8.I[=J-7F?(L=W'&IBA7XF:?<@PA2.S' "=DAYD((2N^>WL,JK6:Y3"()43
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M\-_0*)32G.S=P68/.5C3\L5PV321MS=:!AQ6/?JVK]QHD-981-T/AQ?L4PN
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M#$O(W8C[!?X72T=6A#M 8H[0&A6B6VG4%-F-AH;.T5*?*1HKO*.- 4$6'^X
MTFJ[-.@8]*UB.T*<8D8-'(&[#4]M]J*U)BL_U(Q0KQ7->G%II?#_<+EM+CD
M:D54<09DNEN>D3A#/:!WPPG^"@C(8]245.?)B#@X3H=SH@)V[<(/J^GD_>7.
M 87\ +E>1XXON,&DTVR,"S I.C,@_\Z^)<\ OR\W1!L1,RM*UIVX8N$:8'8/
M,^W/2(GL4W:./_;NM3L+3[U*S["4R%G)8EOP>E*L/F60W7;D,*T^+H!_=XEH
MUS<8[I815+[Q8,I65[MG>>P-ZXW_BI=2IUY:FLV]SSLU1IQ=P-2P3[W!=V,8
MX6Z[<73.Q@?IH="N\.#4R[%S=17;SO%)!\OLRN0L0''3@<1@H9HM@!/18/(R
M,:[K0(,_%J9YTRN2_[?"PO5YKP:/F<*63"Y5 P87)@X5(8.'3Y]2CD%?L82'
M"C.O-NE,>(H0.6ZA&!E7T6KF5SAGVRXKU::2^EVJ*84+UIZB_^NP=][/HEO@
MRQ/O+I8[5K6'L<9Q&4+F*'MC) )."$D8WJXB3-*[,XY!(YME^[MDQ:_'H!X(
MY19\<B+Z&/1A0_EDUX*SCX 4+C@AF18Z-T-#>H7BHK=A@@IQ@8^+WA@&G6OE
M/J54O3/K?#] _OJYZXH%SS6P9 EW*M\=<^ T,]O0/:PI@3<K&8Y7S^PT4!4J
M_T/+VNK$/0[NN;*-]=AL%WZQTI8S%1&2(:O<MKRZ$E9+?#?Q:!-JC!P[&IG,
MC.Q&UM[#UJ&V<G'@!&LAAW#)OF2E4&4C6?&\GYD5EY<^^/-\$_O$O*]!I3]X
MGAX]!_84O";O6H6#$"RAA_IQ?;L4J2,L_>T0=-"7RMWP7PU1E<K#C7/++;6S
MWQ *+B9RWZIKJ6M*,C[[P[3T%DJXR-76UNBLX<7HZ-0>N#EP$3<@81A^DVG'
M(!>*/17^RVT!DX4@7T%0/X60X !OCDG'CQCNTT<;CD'@7G17G,^^QB1\')$U
MS'TT) <I1T[V9GVP6<MQ4;&R"IX(#EY?[F'@E/7K+B);WFH7:W^"$8;C"')N
MF_KD.P356W6TWC=!95Y9YNUOXC,-+]:G<"-(YF&W^DS&*5IQTMYX#%EADLK=
M90/X]16]YX(W7AA:1_[;WC!8N9:)*ZO_J*(4PO>R =3JTQ;N9NCL\-((#'FW
MP"OK(F6V'C#]XSJ5[*G/8D$PIC,AOD:."4DE4FVEMOKX6H]:IF?Z*@$+I^T<
M[EZ<G[?:U;9GME'_'B)"0I6@%=8@A(>F" QK'8*1W*5+SJ@,]>WF6YE\4(4T
M'+64ORPA^NGC:770$H?^J7Y4&N21PDSY CN5JYST(;?'3BP3X]N0:,(/)=!1
M/&_E9B4[/%P9&!/_2U-^U)41U,':DH&Q#420-0_P/PJ$_BJ@V<G36)M3\-\?
MQBJ*ZQCVS[F=GV_L-E!3)MG&36A7E\85"58B2O?(JGHCSU%F/16_B0U4KAHZ
MDRGE+HP-\$H"]3+1/5Z'.Q2C^RL0RJFK4Q2A97BION%2IKYO[F>!I9>F0TX(
M@*R&D#-)FZ2>_QM?9P;X^NC_R==G3SFA*& @X;O@//"3W7TMCD&OZ6='_SF*
MXU>[*NS-F^SG;I[C/YA.*\[H*AL.N"Q_NO]+NYZ("^> GU,7L( &O$.E58]B
M#>,D#'<?@TZOJVI,)NH(OXD/TM88@=Q<.089OY.IT6]S+$P]\]0LK>;N[#;H
M$&M7SMJ;<<\QO<8N<#N@WB;<]Y0:WCZ\P @ "G@HBS[\/-6+>,? 5S5>Z*_)
M2/?7EN*&NKW5=U%KU48#9X1;,WX&)T6.. O[%U5J_%LM.=R%#NQ2N0#B4PR0
M%4E$;[*IW<B_/S C/(9KIL]]X0)SV#1V^\D5MT2;)=!A0%_VZ2I]\VI#YKQR
M]M^81"0AA)0Y?RX;QDMX1M,RNODTT<3;YHZKSZ4=*PGL=0;.6J6P7G\9UD7)
M'LN>YG=92E#[W.7L3+%,P=O/AL"58.Y6A6+R'9Q!BOC(OSF(<>Q?DS'?9WP3
M<Y=L2]*D/*\\_W N6%VV+U,K'=H'[BK-'%Y@BY%(XE,+$@ZXI,W!9"V!;/\+
M'9VD<F!("&+<=A]0@[M9/7!N9039L [#X7U45_$C]NI"DB[&(XH3Q)SXZ>6-
MO""@&_U5)^[B"MHH2C!OHD$4S-1;'HD*-3#/O=]B+7Q'R;?6L(2<&MMG?E/0
MUN:1T#I^^EG^W3^>RC\"5BW5%^^V6C?#/<[W?7>"'.U30X#@WS&$-&#[1-L@
M>,@D!DQ^/VN]!H\Z!N&VX8G3"IVB"EU_80H$=-NBIKW:%KR^4J&2->1OU+>[
MI/@/60&UU;)= =S)13'4)O+JXH47"^!>E$!H7$]P;U^/$*DEXHLWAW#PRXX7
MRMT(#8&9E=O5BA<JOB\RY%D;L"]G?!OWTB@O@2NR+EXOBB\Y/QKQ CP!%+XJ
MD@R0I:T3+,)V88Z>_L\! 0$_2L3_&B7X"S35&XVHC6@Z4\X6')<'J3D&$9!D
M*[KH(HK:!8C[G][_<_J ")SR?&YO=8&M59T1 5CV GY4GAX+GR]7+:&JCQ=
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M@ICKO5'0IKF/>GL,PK=CJL5N'(.8H7H7";ICJ'Y('!+ZQ,QVM,(<?,9CI%C
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M W,?/]F^5N#/UA@N+61QXP(@I-3EXA1M, $59-53OO*W-X25:'91+G/!C4"
M5&\2\T2N[EO_.#<Q&E&?/Z2G5'OQD-5[/$GBUNO:9:D*<A2=7M+U</8<8:?F
M52[1Y\&G!Z'YQ+F2 ;K^!,TOHQ\@37JVW)[W8<WK'>MUU,C=*O^*VC2]^ ,5
M_A'Q*3DI(7U3&NF/X[A<D<@D)\$.X$@".T9V1?DM5AT%B;NZR]:+SO1#G[YU
MSV:$-JL%_+!SVGC\X_;>^PD4GR\WTGVY1U<635R'P_AW5)10*6??D'W)9;OF
MN\/+1X-3=\MVTOLV)-1O&TRTNMU:,=D []DC83U I-4(1ECW A"C9.8DU<&4
M::C"C^)]JJ-N6V#14MF1<SUP2>D+P%J[#A)>'Q_0])16P&;'"-JI=P$ \DSU
MV@J.T.I]5E& 1J6?GQ$! "9TQ%H)XX2]88990SC$*MDC])F#GXN[B#^N<CZ5
MA<^^?4.+5E-/F1%ZDC N?HM7ERT1VX+]Q7%=#A8/=]''B)KL36-I RK;.*LP
MM;J&H'&60:@6<C(1[J;HP6694/CJ8]JMH]EN 1+!:T(DEQ>HPV. K_7G('T9
M_E$B;;KE&#'SR6B=)TJ&+X5MDQZ/\2@H?1+*>D?R1);A:E( 3(P^LF<RN4?!
M?024N&W0L[JM:K!I8AX\TI+22&6>,*4O3>TY7:]E';A%QFCP\-\I] .BTW/B
MT- +  &VJ\?@4!]\&9</C:_KN!W:Q5U#"XOO8'=./0=&%Z%$<KZ,C]@SS04R
MJ+\9EGE2T?S+95@2%'L!0#$L[P<40[@<VZ^!$1GC>. NE&EGQ<L94Q*D[=>8
MJ;3PVDF'5M2L"$^W?7PO.9 ;_Y;P"HS@6YX[!AZI. 9VW@9W21:?@Z?%^B'Z
M/3Y$UP5?6=.?Z^Y;9@N^D^_,)3?ZNGJROEQ1*(6+O>812DN!AR;ZJ)GT=,CW
M9V1-C*C[E+4#;T XW7V!@H.1;0.+A(#<@LXJ,$*_9XANY;![R+;7^MZ$R%\P
M'2:TSTKG62M4T>UKO,Z//S3)[W.N:<D!&![".KGG@PC7ZS"%*/:>Z;?@3EI^
M70QXM8G/MV&RGMVQGM,:+S^SSDOK0<&S(;[_*8X.6J+B3BT"BTD3X6LXS%V.
M^R6PFN3+M?F7K=;=$@?/EM<SAJ=ECF!$3/875VD9N)F6 [!]QF]%L![A!BW(
M^)CMTRMG[#2I.<;75^/>QKV=GKX ('5A&(7P'C9XCRY=)[2..3E?JV@GN=].
MZ55A\<S2P&)819K?V<SH 5 ID0)-DQV?$%2.)-S+XD!,5+:G]VLJY<J7:$DM
M>Y_>C7%]?E8.#38L[YXNW;\B5R0587$+5Y*D+])\3H5[2[37:G#GT,U@$DPN
M#">)X<[;?COU[>NO\]!B1+:A3X/?M+;V3\X*ZO="&EY*TVZMG]\EY'ON=*ZX
MV#@'*6AOR@BQZ--=?UN!CV#8Q"D['GL%X';/0FN(I<Z$+L*97 _:U LP:[VG
MY]8Y6CDA0ETRNK:OF1IM-!)^Y[U?^.$=)OE)TCH;>[G#/@'D4F$,2*4@W+?8
M@C-)L=Z[NAZ?I:!7>M7]3P]ZZU/25WQ_[(82.:?+1-IUFT"+6-TSR5\)X"B/
M)5WNT;P:94]55Q-JK SA-X$57QY*AG% \(<=S!&1JK7P-Y94+X6]1!4;&'N5
MWBR/KX_O0#</34[]62=1KW\0FXK?6:X^['F-T4%F]&MVH'[))%JY*"R>'J[\
MC@OW><.K1)Z5J\DW[UP1+=-LV_BS>Z7<I'SO9?WNG[>F<?8*4NT5.=E*(Y-@
MJ<2^,7"V/ B8#993$;K,*W*9KJF#*EBY!E.(*,49V*_H>@PFS1V^0*K'F=N5
MWA:A&T(;.8X]['9A?K[F3FVR<XJC-R%0DSD1FZ6) 558[)I;0U>7HY?HQ&G-
M^Z9>NP1A[$A%_E M2^3Z^@KH,-[1V[A>/_IQ4&BT<-\G:=<]2H9;JM \=.0%
M;J0QMMHU] 5KP 7 )68%[$PW=U,5GP)W(-+J8#64VD_FJ%41"8NSZ3>T;UX$
M?RIZ.\"3$J_IY\NY>P0B4! GCPR(KP"N%($:ZC)"88CX>^.KD,BU$-N>9_-;
M,K$-S+RJMAQ%$MB"Y/4!US.#I_.-5TQ_?Y\HUS;*1_;[G[-/]8T7&DO9MT'F
MHN??;F3KQN:>$WQVUA2O_B>XKO)_0P G1<#SHG/#$7,BTRCS**3VLO\&%(&O
MC(Z<:;+$7P#V"I;!VS!MV,3@)3K['^W5M$I< -Y"2_M3+P"MCW\+Y,6L*H;]
M+S:&8ET)-5T8*@KN[ (B+>$W@GDQ$%CH")S&[6^)77W=$R6+BN79_I"F!35>
M+,>#P4IFI>+G1Q*-$F[/"BF!=;6^L U9PG55?&*;%I*<0"6+@+!8FR[)?B (
MW#J)YS$0__;PZ.P^YU"SZ\LG2:5NV8^T6 ^M-^E&\PV9L$N9H&;$9KU@/ZTS
M6)&S$<?PDT [>QFK,8K0GP9BE(9P6@;<TW4^-U5ZD.BT&\@Y:#' :SCTACK_
M5;&Q.M5WV.<_D60/SXH)5"Q$__\5TT[\[$1I9,K&B[BZUW%J[_7F8](T4@J^
MY=BS]P3,U3Y^P!'A:[EO4]&I!:N$K\0N(]\,1V%)0D=J</<QV:N@&RY<+&/N
M[NY2RH8/G]@WU]T<M$]:,K5/DK8[MC9A(%],%:IOXKF,*;1QF<,8)WV9(!3C
MN;H<U7$%6=6>CS%1GYPV;X5/DSY8LEK@99@O<&+T>E+S]>90TDBJW*KG<8BT
M8/IGSRJ)^.W&HYKCD_LO[2,,P^LN (8['A@9#P+5_)I'PI+4A HI[ND4K,W
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M&>&;(UE=<R7<E@3P!HI4A<\7=RTC];CGN[#6F!1\83[&P^JW.TZ^U%+D\_A
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MR32C-&.46.\E(X)60J?+'%GX]3).$O33)03$=>[I^;<PRP&2 $SA6/'+\.S
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M;KR^*Q0RD#E$Q7C50'-Q<-K=T#R"JJK>H<(XME5>4E"Z;!SMTQ!TSJT.[N0
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M&JSP7]/=TN;/U]0D%([8?0XP"37;:KC3.'CCN*U95KTJ7SX5-GZBO9^=$EI
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M>$C5T=5+O-2"5OZ+?>"4^]D;:3=J%W4JAR!UOWOZDA]UE%Q..IFM(QM8B#L
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MK+7W%CE9>M@JMP:I[@5*N-'FLL[-WR=8-UYXO]R^:/:JU.]&4CUMXJW1S(J
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M6)"T5]E"A;'-J?D[NU>L?/E7 ^#_K,+X9X83I;]E/-$O.65Q;G7P)[8)VX(
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M#R 4*1W( Y5\0%4!4"+T!'5]%'',R>H4>&E""^=G[Z60U9,2[/"YH$RM'S[
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M<'ZGO4;E1&5I<5&7D<$G,[:EPKF5HPU<GVGZ)TJUV+D_BMR*:K-^G"EZ!5<
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M4\\V]-I2']NAR)?5=&;)MZ4.I8C=_" >H IZ;1J6N(+B?22VKEHXAP2;17O
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MQ^!5]0;DC1!X?&1X6P!B*BZ+"FN)I)1,BFU<NJFZ(2_$<T<Q<-N,:&JKY.^
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MX)4!WWF#FZWIVC$F8]#S=A-U;\>9I_5:C8,3ED4OA"[*A!E?3* Y*;802>U
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M=#'5H;U=Y8HO>UC*93))G(DGZ97;8DP+RX1,GD7%9$<[* W'/%Q\B_1J17G
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M0Z_K#-G.^4T9C*>GQF*O>_\Q:G^,VA^C]O_2<(FOH(#+OD16IG;$T5EQ 29
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M*(H0N/'?)(CP)Z#RAQ;_E]-"%>)( 4UVD^D5,! T0]N+\$YH/(2.:(3=&CN
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ME\6TH+/O-J.RDCVW]6C$=<?>S!7U.59DNFCJ]DM:[<P2V6C)=&9S4$",H]U
M^C9.<OD#9I;%SW$I0P-W*H+I:N;0DUWF''MV2T1?3$KO)YDB<SLO'#F' J)9
MIN*ZG\^;:1>D-P-Q//-,[3/\6\HY@^E#CJ[O/]^9*FA,$T@X>^+-FY>;,4YL
MAQT67O!0?BAA-NNYR3?QH:@8_BRUN!?ON!6$^H5:R$YR6)NYWV$4D--LJ I3
M,$P@OST'\&C#>Z[BV3TK/(0%.;D>":7%_WQD;Q7-+IADX,T:<37*>O%-AF]
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ME15$L]T=W@TPFM"/FT J2!;6M3^>ET2O3\[75%7%YJ>[\#S6Y [^UH$'G36
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MK)R=$,$0WFH4=)S<]7O3 0>>#P^#08JU/LP:6@3,:+#N/:JMLQ*^$\#R#HF
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MUW.3+K!R#Y9JHH"0BDZ_^J!O4%AK)N#R2B1J[B.B1KC,R:WHGG0[E'Z-90*
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MJ",E=ZCY8TEPX*)M8]5&(*!9INN\]^'*F40"Q5'5<7J51]$P':^Z16-AO5,
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MN=V-H4[/F@<T]C>T+X8>'VI=KU2WR-GH+"_45 C[$&=T-3=RP6.\B(D?"_)
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M]I+^^X!T+]8USJIHIU.N4?M!W$*XZJ[*'Y.F9.^SP/:C54+=_QPC$7'F&*>
MO%@$ (393SG6!,6 "#=IR%:29JVE2J7PK(W^VS]2W4H)I6'RG6-*;N<MMI./
M/J"#]\A">#>R4VHR()\H<2.ZQ-&0SBM[,'&G__7%P0\1;>%?4GL.4=^":N@
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MV!.C"G,<U[W6:RIE]4W:G]53!9_:=LQF1U6&/V,%>8,2A!#8JAD#;<34C5,
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MS1#J[)<1GU@.GGWP[J7\&)5FSA?.X)"9F$7 (0,00+)^70=NH[O-UOH>2ZO
M.+?/QDC37B89,+51.B)L* OLRA0^3Z/%7[L#V>(.H1HHO8\1H[(E_ZU><.4S
M^GYXX4K8E3";*14XS@JZ(&W:$,L$?X/@>!*[=,%O4.C+C!YO%T"OBY>.;K+S
M^/=>+' .\S0]?*@.2VW8]2(Y/'5L%3TIQ*7$*"$ 1!N3B0!-)FT)_4F?HOK:
MNOHW+E&S#-,R?H5?NZP> NB^5V]P4%ES\)GE-+'2;6IO1//X/:4ECEZ-L#D[
MK=>]GNO0M/_B0\Q'1ZX.=5UX]YE-_ZR+R5DO,83G>#((9X&(A7$18U;10.\\
MMIE+7Y699/59&J>.PZS6:J":](9FO.PP'%U>!H4N/M-J+;CZ?6))!G:ZQ+,-
MJ"?G,,@V(M!'-871T:[W#.&9,I^^HI."@9PCZ]?CT#$!:C^M-2(1,0?N5Z/Z
M/V2&6P<'!<DXSM7=%DLS]1Z$>\%1&UB>W3*\,94#]*93!,H1DK.3^BBGL::Q
M]CK#$>_42%.R$N_RX-[:1IHW2<PC*WBI)[FE>GV0RII%1Q6.7X!MXI(_G-M"
M;$M(E*X2USL6<U2*XON5RFXV?II?6P_U\0H(+ N<P\//$CO(7#RKU3M96" 3
M69T(7RTZDT\A<?W61ZJHT(EZ4GZ]H=8[W=OLXW3#BH(>S?J BS^ZQ?*WMN0S
ME9D@'R XSUQO"3('N.\!.H1\9UH!OCL('MQ,H(#NH4""R''WN7C+?J/;"=9A
M"]4?=]:FW1FOOO^TU[A#7QEQF<;);U!__B\I$_< R.%EG8GVF.D46+8G%BYX
M'+=_'4K8SM][ZUGR K3YX:"Z\\?X[T?PJV2F4C(8=ZEIY9,S>M<.'/],8@KZ
M!/07=;G(8PW2_RAEH/VG+-S53ME&/XSW&VPR\?/XNC250904L$FC6Z6[GMBD
M<(<<W[?E(4 ;6^?@N72PMV\@PYVU)^B=2O;@&\\U<I%0VOCW(AA;*;4(S+=_
M(<A^VN[ZS)YHAS3#NU6+_>'7'!E)^C4@D.BKL*14]"6B,.RI33]"$.[&QA/!
M0IS CE]">X3U(9TX9O;J/[HG#^@*QO+9R2N;,D@%1;&)LD%:$3@OU9VR0%P<
MX0X^KD_;WJ1YZA <W_JKJ8FCSP7^_5'Y=17>\XI:3;J_7EM 0G.LBPS8M/0D
MPZ<,/5OPQY&,&5(]27I[_8TPFPB^UGSJ99ITN]@TM;-7DCG^@!B\.CCIZ_;B
M!4IK[Q???2W,_/BZ"^)2.YK**(H/(A'.,N!3(Q[@63-KO6J)=?VU<QY#?(O(
MYP8B]756VT,):B_ID%R$([*0/>F:EPXOI2%"$2^J-[$O5P$3]7"6WFAL\KS?
M6=-G.NC1-=JV<*XY\=@GVHE&D"Z<IR0K0U. .$NV<^/E?\)>:TB\^MDIVYF&
MG9FXW# XWXD#Y#=HMW0-]>17^NARZ,[)1%+V[.$018VYL,Z9%?:(=B2H$!J%
MKOM%R0$Y:].M?'EUO7+\-?EZMG9[#7/HT>V%9YXU@_)R#@>_MXEX[B_2*7*N
M'D&-0W0WC/S'A:-3(H+$D(2))OJJ2/CX-F0\A<S#1F4 KH['0@2T#/!@##H6
M&N&( 7$ZC)2A_YQ8U>21>H\4;H=&+7R6EZU3EZODSY>Y;7W.4C%$4#7YM=<8
MUZ?<!O!/@G^[V&]3]M)OR6O"0!I>FNC($^ONU$[7HQ/@E_>5=O^[T-*0)RF?
MK>X<R)I<ND-A?'>7%W/B9V-/96$GSMT^!?!(K#P?\X_K/,%3DS4I%R-&26<I
M8"\0GN YS>X@ZJ6)"#WOR!4*YS%WMNJ;^HD I1F^G_?[BG\4D6((56IT"!N\
M 96I@^1,7;A&!JY0PDBFD78@V?KQ\QZQTIO=*!U#CI^M?*#%0'JQ<#:;^?74
MG/<2K$XG3H,Y?(]=66TNJ\"^FY!8B6T$P;.J%3HWR9(S#3[R#LAZT.606*SQ
MI]LEWL%1UGF_)[3ZK4\!EC\9!IWR&LCK$2)G#9:9O+'(V'8I5$ER;(3Q-WM/
M.!1QT:<B8M-:7N7QYXQ[2YE=8E*YSZ5/"L[:+T8(([7.-HD:HCL&'<]_D9I5
M"7^ZU%WAJ='.W 0 ![_822]BW@MXQRZ0WI9-UJ#]"TU$T.N(P_K0' V5_EV=
M0C-D'USL7G#;5(.0W-RR@\=WX(>[P?RNO_2.+J#]D-[L%;8\66*#=ZW*_RO.
M4LJIV_0O5>H>?EAJG79DOE"V4W26GS(O0D_EAO3\^_.@-0YT3)?< <^ZHTKF
ME\97TK;\F Q</6O<1B>=</Z63@9-?=1MD 6?D,RHHYT,-;AA8I8^WCJ_>$!V
M-ZL/]:BUI3'ICI6N0OV+'SR\Q_,?W"]@ -+_"X2I@<T#<19^?IA(^8=X_4H7
M6',+[NB5DD'<6")NY-HK_J#$Q"CA_W(%DQOF^4.+7=W-&;4=,W;\)1^+9:Q*
MYW>BY+M9P(2SH 2#Q0CM66BELJQ%-YS9-\"[/,=\X'*>D/*O]XMT/JMT(H*L
M&>1LHOF^V109_&718_=%:[VJF7:Z?=1DQ<I@YD/6RC9>7G61<)O#2NB*D$4W
M#4 -?_\*-!9XJPTQ(H()3.4&_XG%AAS 95=%2=VO> ^K?U<3O(C^6 $X2GZ%
M-/39VZ@,JZW],2FQ". PF#[U*A5-E["Z@II(E#8U<3H%P#;T ^DES0TU[?>4
MX#[@N4%LW(XM7M%D$B;MJ<H/C]<R^]*+92A)@]3G%.@XZ7EJC@KFK*:^>#[\
MW"A#EG*FS%O1.#,A-D(G)3$ <7Y4.*>8N+JBG-29&EZ*&G@GOIL@-^+]HXA7
MP-;&9?<'NR3H9JKT) C3 ,29:(*(DO([;\*+-PF$;3Q'C[,CN"<+'".O@UZV
M;<M+792*$<N5KC#UKZ,_1E+B==3)EF=GY+"9$V ?"WVOT_44<QQEQ,X+9=EH
M<:\UHTQ33F;](LSA57<OY_.DI)%^TQ*MJ?.K-XK4TOG]NYRG"W.+1$^"SJ)$
M8+W4LR?6<=01U& OB-U)Y2.E1"PXS+J477KD"UHW,R'@OSOOSK4KK/D:O',U
M_$&-@'N"B:JBA&(B7<6R7 ZF&7;]S[O8VUXPOC;C:*D3 5M&4\%$]G*!FUJ7
M'BM"2A XIQ1AXLC_:CV&1_ 1&W"LXX,V_^R(R?)7^X-7%KPSI@\>=?8')/^5
MX4N[D:#[&W'TZ);VOV,2+H[*&DDIH[+\*2_QYG&BQ_<U1O]0%1;_->\K*OUW
M)7O6/O+G[<3O,J%#$MD;0YZK3_3:-1/3P_H/:B:RC9DTRI F01Y$BG)*4OYW
M]Q3N&5^=&^1K>'9XL8'O;FCAHMH8W?&SAS]:+L"O8)#[-"X@0%/G%Q_@@\F<
M\IC!M^W:>':/!C9^LFKV!,0Z63RF(=PXX_V]O]=??GD:'JJK\"V6A6\@F(/8
M2P.I99 P M-X"N B []L"7/4S1ZFL/7Z<:<4A"C>:X;*[UX"ZOS';^BJV?ZA
M]B>)4T34UQY4#\=!Y<GLY7UHG.EXE,X-)%5$[V)^BL[UD6=(#0<%,<3<;"86
M+"41,%Q?,?ECO/X[W8C@E9F9/*/T[FK?M++)014+_FIVREM?8?<_M4TCJ<OM
MVX0^(/X-G!.T8SX#/TBV.]!3IT=J(?-@<_"_GO^?7WL1OX$$H8LGW] 7.MC6
M) CN$E1^T,H1);$UV.(4 +Z-)'C$ET2&^Z$0">-Q1]F-.:NCK*MW;($.<0^;
MTDTMWXZZM]C2W3M_19>=V//NA1_$'S:9CW-"+\BM&IY5B6YSRNG2:$J;U4A\
M2 P-^.2L+.(K\%'KQX=71T6,SU\P8#OWM8:W7"3 \_65X>C?-?AYZR?,"OD:
MOJ1'Q_M4QA3LDOP@'&>&3D)]>2NCZ)D%4YK1>H.!*V@F-<E\N>>;6-'U751D
MS47;^]";4(JS[GA"XRL?B7+2\>ONT0\F OD&E@9W_+W>B$D E^:5Q,)=M&PV
M$&3V.BK#%%Z4RJB*EW\P+3993=;$U<YNJ2OG7UW6?Y*,O3+L)&TRK_#31DV$
M\T%4WW.V@VX\E."&2^E'SZ<_(AI_]:RQ)ZI:_[+O13]M.J?WZ7N\'C C-^;V
MRY++8XR2&UPCN2Z>YAG\MX/7/.NJ97K&OI5;;?[,-OBG2;NYDVWN, DR-SUF
M=*#@=_S3MFF?7L.IL2RC]@0Y,#XT&2!DV"TD??+Y2>;8I*8[F;!_'"E]K$YI
M0F!R:$H,A,D "HFV3]=3G+3E[TU/'O7"U*8J%W94F=/VH\RDUNZJ214/K"E\
M/PXNLX8Z$#-HI%*6.G4*X-2YY!AR8]4:EYR-G(T=V(9,U6?&63?K/TP./H[E
MG:O::3<3E7RA/\F9Y!_1:1OSR*9WR&Y(^T'MSHMNBPS^B6 =74JU,@O(BE*A
M(^'H:=ZODAZ(73*WEQ2]<2_S4OO[ <NCB\]#)$0[_?-IQ)(02,D)@*! 5(85
MW."*>Q_#FJ-F'YI9R?'&H5:W4']%_N.7?0_SCWTXOBFD,:"O_-#:.(O-/*OJ
M;HP_VOV'=_D/3_^F'?0M)!BSE#3LN!76<, "I30Q?G>!NO'22:9??/!-141L
M3XX+O&M#YLE? ;_5\OE?8+[;6QSZ+K)!&V[2-ND;0 *R+0R)KQGZA%_(*;C?
M&5'X17_YE?^"<FQP?*EYB:"X9/C0_OPG/A/^=S$/[JT6;:[!M&"S<-RS\5T^
MG$3?426F0P),K%S)"&6I)*0&<W7\20GB&6OXF)'Y(/#*QZR4CLV_$F\[A<C/
M*#$1CE"YFF*R$=&XPE'U1+:OQLEC<G&W>XD3<2W=]^XP-YVV7B0$!Z:RJE J
M3@&N"_JX]99R3YB"C]@Q"WW2@:=8>T-7-_LH1[?F=XETZ;8-/C5L<\I"$961
MA*=QU7V:!&$F:R/;55<:&YIF>!Y^GV@7+71H&"@($\T4=Q:V_>UFF6W6J'!N
MT?0RGW G?\B,W(/_7A?-+ D[>H6X\\B %+*\@25 G$\IF6N?IJ/\5T%7(X2)
MI>6&V"1[O4D!AXE 4LSYOR&BV6HE39\&M&8O>2SQOB3:TG&O J_#N^?I:?#7
MU/L1!<*B/1<WJJ"T?4F9($$6@-/F'(9'[@1CM>&K//W:M]M5L290(XT;29_'
MAI'60;7&@K7CSSE3!5JBQ"U)PW1[=**"^60AW;/D(_S@0%)P-X)?B^/SEHY$
MPZ^ .-PI(%XV8%N_N:TF1CP3*U#X)NU7M,SP[JO?*VS7/I0FQ57'E.3ZFS=)
M6_]MV;(JB2_+?#$.'QC\"N\NI@?B3$$"S%?SW]#(]XGW9 VDK.;[QE;X1C;5
M&(3)I]$!&_G$?)Q)I&H?/Z1W9)354:(/>=D_N'1;Y=+6LN9K@8@UU)_AA>>5
ML=V,+7P/O4_8:=N2(&P6<@7DDS)G.CZ(9J\J:L5SEU:B]9.X$FS[A5HUCHWB
M7Y[_S!&K[K+T9KV=3)++E3:^&K J4>I?)S&H;[GZWZA2RO<?B]+_D%36%T31
M4'PX]3*DRHO[]I!6YWFDC):AF*$P(>1]1\7KL O&C:DIKDF=#2?<:ERIJXA+
MFY"K$<!R#_[?B?R9*96V(T\BW6\M"4VS%QB*/EFR-:2?R\8__Q!GU.Y573MN
MPV& FLS0^4,U0&"R\NM_Q^VXD^#DV\34\M"W142X]6VO%P9\J2OUS0G&]K&,
M]#^M)9=>"@6=8!%54.:0'# ^)>Y9H,^-OU/F4\KWV;<F]U!6F0(?/NF*%I7U
M2DM>N/KN;O5Z*94Q_0RW(LPIR1&!W[;1K %"+EC5GK:X\+?2G^3H LL\)F[_
MB-WB'2#,*9+^3!?0^?T=0NGX4[)!F%)(/<\.N,2D($*+F(4%L7@^'[GF<^-I
M,F$2]8"\(+OGDJ8VE]_18+E1&?G%-:KTXU=D@=*GE/?=+A(O?3,\&E.V[;%L
M?4EL*ZK1RO)7B3F/I@*$Z Q?+SIY\1PQ7>RH=RG7K &P1F\9." E<2Z$6!QB
MUY&DL1!"Z@ZN\]+AP5]LF/(\,K^#4^[1$_N>-8=1B)JH$7BIUBTB3/^W?Q6=
MC&B@)W-!^KE1IF5E9$-B2Z#OEO-DA:RPM[2[J+#[?.7,XWA,[M#WQX$B-@?1
M-+O]1N3 (N:SJ)<C<4==5)7)L21L)9M>F^-_0Z7);@V><G+B5K(""FGL]\8F
M_7+]$FU>)0X7O7[M+EEZ@^"8XLWT0<NRA'=PJ7&'^D#AKDXN875! G^TWP_+
M(6O11(G%6<W#>">.">4_$9XX&-H$*8/I-#G)+/853;"TO61IZQ+$\(,M60.Y
MP4=TQ2K#(M2K?"\D/Q,3$^[=.QR%NR#J3%JB"2]PC#^JJH%Q2FNNOI_?>OQ+
MW6*)E O,MNJ9*MT1:T#K=@\_Y]R>SF\P>40NH[PY!6"F0*Q$I@$5_E/ P+B0
MWJI'A;BM05R O7M#3;.K^GGO+)UGJ:G=]^Z/ R.2Z7<D8MO5GZP(G1\QFMS9
MK=]5-7DE2_LJNJKKS7CS7M+5$"LKP$4  %#NR9^ZG==2>GW'P:9O]?8AWGR]
M4IIJ,/L$%^ A;6[-B[YV>%2]CJ"RYHV3M:4>I!R_#QBG,(:1ZJBL4C3?BX?]
M0M= !\;C["#=</8M#>&/E1YU2UZ&/BLDV0?&4F-<AM[QXD^/#7G-SQU4]T-0
MZ:LV ] %&^P;?&G?P"S9! NM-7A"0._P[M0QZS7*9T&9/;O=-GS!+[PW0X+I
MI )=$G*SI!T/M63^\?!UKZSRA.<W0W">=*FT%5[!-T[0K)WI!ND48))M!?LB
MD^?,JAO\XX_WL2(E#8&A*;P&MAU9');4 V(\W/7OZ01.!TK,[,G"5[CJ.M@=
MAS@?UN?L^13[O8^]%O.,Y>. H<2)*FU(.F1__/BN*.T3-HC05<@;'B1_:9)R
M,]3>O#5O0)I/7/*K0[_PDP2UB=O\^CJ6#B_9Q-:.YPF7'I;+Z$TEYF6Z^UHD
MFI?RJW@6P]7S<?8I<<$@9@2F'"A0X9N14:VE=Z,B7TYU,)C?L0ITN8;(3YFD
MV9-7I_@\<9MZ^1I&D\FS*&V_)SNYO!@BU71[&/JE]:$!='&Q#Q;;+DUEU:'=
MGVI(#J&V?0JF&"$YZ8K4>E(T)Y>#96%%4W4:PN^)]6HQ#1P7+6X-'7UB]/FM
M@EA%[I21X!%!_\L$;^KCUJ'#<Y=AVBKU,K7=[T\K_5DW2#TW][2I)7$G5?=Y
ME[0+((V5K>%FK^+(BE%N6JY/RV]]\RX75W6]YKH#%RH;/;'$_5O$0Z($9L[W
MNO<NC_&,<LZ':)8>S8\^A:_S2M=5TA^OUI!IAM&=G\]:)4]5B7#%.U<].^A@
M[S5 )XN%OWTC?@PF74>F(M<M%FW65^?)+\[BW:F3P6$)\\0<;&D?^.K]?,],
MIL<+=QS?M#E7J/SZ5G7N6/0AVP/!4X 1;7_0WR?>($-P)O+SK.,]P4CKDZS$
MP)$OLUK&X70\"<9-5G>975MN]_-?IQNX']2SUS6N4 :FSZP0\!P?P<O3\6']
MQCF\[YVT!4W\)0]6SR*N(S#[<8,['W'E:EWX@!;U36J,Y"D 9'321F6J(QE'
M&%'208\_Z?:? AB5C2L%^G]M6W.7!T*_+&RQ?K^_9J15MIK*T,6G^4+3&9'/
MAMH@'%&^P*%LESTU@/V1+@YX_:Q"QQS23?I8V6<1;Q(X9?A1J!NBWE>C[G<?
M5FO&_3U)KV3^SU-?WKZN36- SSR#206E0Y,QT??AO\5T% >>HUGE7XZ7$O*R
MQN!L&YN0"7G49:TG-=/NJ=30[4W(X-%.%ND.V9<2JR.*#FE;<6A%QK3KE7G6
M>O+PP&G\-W+=;DC&0BM<[DGJ)2>&9$Q!YQW%J+N44=H'T";=-S\9TCB6@O<%
M)\%$.I'KN#64^2:+7P'*$V;TLRGV&5.(\S\%E[>:T2YTO$/C8/;')5*3?0/&
M6::M']8>-0]D]S:W+5+4WHQ4Z]1O/960@M6?'"MN_O]:HOW_;:]+M;Y?*)]"
M]]N^:F\9W:1+2B<$$>%RA5!@%_5*^ #\UAA*N^5=HW];T,\-K?76-D<5 0&/
ME:9DS1#GAU]3OUK=T0!H^%E,6$D._9F7NFJZ"1#P*$Q(BQ:<>O!XZNOG2[P\
MP*4CSDKNE>F4$HV$\T,>L4R!D)621P2V0:6MFV%[XIR-_"Y+B].J&D]5&R=U
MM;R5%,X+">E*TTU?G:PPTT<5' LVIN TN_.$9OA)8%Q^[#,H7U-#?V?6!?,Z
M=W69;ZS^8]XE*MLIX'_=93>_O4A?2BO@JA582SP%Y/]#E6^AN/+:GA*.&AN/
M@OXR*UGHB^D+;]VEQY=;6GZ9_>HK^6?,NQ=TJ5T44_:S53Z&K%DT/"B^4S_G
M,T?8^J9I<T_$[!2 +*6-3;7YO?D\\RWIP(V:\3"])BM0P5'9S3*@5,> %I/(
M1FEI)=/YZ@<IV^#"E[]M6EC&\EE^U[\;Y1]A'C:;&/@=*'I!\/!2"T4:4QU]
M(.O9("W/2 P:-W-C]BV8*DAVOOM#,RHZC_ZWHS*7V?NT6N< [)'N/:F+#'EV
M&(NO9=(__E.KWC@%4%F):F=U74_8+AN?Q;G!@%61Y2< KW_CB?!:2$\U"OBH
M85HK$H?LTE%%?'_[H[$%2=;V+#.&"AL_T\]6D6H1PSQ^FK[<5MONU8/E<JOV
MC6-]\CHD6R[-_3>:S,\TOO,;'^&S= K@DOUB"MJ</@4<TLB98SV::;/59WH*
MM4FPKG/PDWG7\W4R6%WDZ;]MA_UN]/P431+L'']9MB72TXP%I_>EX&;V%@N=
M?N.42^L[9OK4)WK,77[IZ0F[MQ,>D=V;JJ4F)@QWK-D8OTY:+C?28&PV-B50
M(V&E5I,5WH]@U))?/2Y,=\+MQ549 OI,X$^XAA+#SF_Y35,#55]3A?[HG/ON
M[4BO/WF@:>TS(*0SJ^DQ="CUDA%56(TRFFT1'E/MB)5A+/H30OC<51Q D3RP
MS.K<D$*?)W.?_)@&OXY0I'S^_,J?DD6?V[(=M]!V6%4T9#;UN]3,2M)P;RCQ
M>J/N!48V1-FV&633^J2D.//HX:#?A2+O02EZ&^'75Z.),PE2$1/6X!>QJ2L^
MJG=LN0?!=74<5QSN,@XB!)EWZ=2.RK_E@/@#.7_?.'1.-)^XW)A:M!S6H)%@
M_4>AJJ!@?FL6# V$LDRS1Q)_WQDF;[P+V1Y]3(1B4J*UA,HBZ^[3+#N@;?QX
MW[.D^P+B:/*K\K299:E8Q4>MFK!ZU6'A@RG?XJ-3@!H-J],2TF@^Q%D@.6TV
MBS64O7+NE8E';Y[G],/;A1>!/2 IK1+JGU(STYT\JSGHNQ92/;JN"@0N79E"
M%1=FDC*>-DHO;68>$6KMQSG][8=+A%4=?VR%1;'QKK=4"F D7I'5R^4*2HF@
M'H+J\,(L%FT4)6EY$FM)#TH*K+?2+RZL^*A0RE-^SVW)=)^ , I.:R<12LW,
M'Z+%[Q<-FZ$^Z?$X_];5BN$LX_^\2J:]HX])LZ<WNEGX*N;_T,+G'!_GX"N'
MC>9]<&%R$Q/$K^S\Y\V[,9'TOTT+7[TH5&FRIMX+F\K4+D_NI-9OW=SV._@^
MQ>MR8LX4./B XGGP4,[RB#_UM:!%ZX0>W14Y24:W3WK<WYG# _U^?+[S+02;
MKW?>4") N<!FVX3[*_T2,,LN+8$NPVF5F3'LG\$\4KUTXL[.XY#J%9O8B) M
MU$9<O;9GNH#)8:*-@-^4P/3,$E./AGM,Q2SZP=1._4*@2'SEXT<NXZ8)@%T[
M2ROUH7(5<%TR@5?D84Y8=4')[4M"F].6[_V=Q(G**T"^+>G@<J)+[TG)Y%_Q
M]JF"3]VKN;7I<[#_&NM'+XWHU=F':]J'VP>0:G1Y[R,1 &:K5JD2=66W>:E<
MZQ^>KX%.']9S"*ZT,7H921D\5=S9TF=8/#?&5FW'S!@./]P\,/N^D[?F-O^(
M>6T5V>%,+%^)BR4'I^R.TNO-1KT$(&H35CTNI"9MA;'#-98+<^U-_SB4[;G_
M<>*<TI(OI629T(:S[; QU/#J28H:W=Y7NL]TN/(!+A E+)#3L:-;3_9*3$BU
M&N7[ O6V*C:NE'S=KNP4,*3N/<FF#+;[54$V+EKR/$FJ[*#$',A#_7W\>#,%
MXN>XG@8\UI4^?_?"E;NEI@ZUYCO]-__I56W@\TE*+(CZX)<Z-J> U"S3#5ZQ
MR&^@4F2N#<&J+"2HMT^E3(B25++CM9 A=\V6"^Q,1S?>$2J70:.H<Y1/]=KF
MRR?C&/GN'.,1PWN_''0QGQ34'Z>:6LV\%BD_?^[""VE4X^O-PVI[E='.MIO-
M54Z6H:&^]H=6XA+AB;%CFB'W_ H'^7'?7@(^AS$&OZ,_0FA$<JU"R[7MKPN4
M,T ?AWQ)>IJL)[75=06#NRL<-]FB*3^/[M+P+1'ZW105(0H-93I.7=0K6BC^
MBEYFYA A13MF</F]+RI^5&(J;QT_VIH_PMEI /R_R'O/KZ:Z+PPPOJB(TJ3W
MH#3IO9?8 !$A E*D145$NH! P$ 45 0I @(*"")-A!#IG="+2.\]$(KT&TH(
MI##A-__ K)E/,_/A9B5K);FG[/WL_9Q[SGZ"XC2[\P?-S>(7O4'_,E0J;%1C
M1.Z-9EV_V?G*+>6B<C2 /;X(O830':AG<AOXEZJ7DMTR\3= K62ZH%GTJ3!=
MV%\DNQV'I1\-Q'3B-Q5:^.O,CT2\E$;6I>XJ58#IGD^UKT[)JZ"TUG&@H#([
MT;A.TSO]@H5F]X5Q4;:2->K98OH2+\-2\0PLD#_?]*]^Z"TM6<V8V:,BCU=J
M=CC)O$!<['8]C2%0A<:>]=U.F7JISI1^)KTV<>#,/N?0H"6O:IFX&?2EV:".
M8C[<W32VWZ2D?'CKRJ*&[ ^;;-,9J=?G["^#)$?,/:L"5#F2XOFF?W(L\'"L
M2S)W@=II_LL$MS*8,=35NO_[%\W=K]=8C,:GO938)EDD"W]\ASL>_IG]8MGX
M<>/]^=K?"!B0UG("8GT:6;'#_"]XNJ7.R9UTH?@NRXT&4ZW,OMJ+4MGBE1P_
M,E9<WI-Y<XCJ]^QDP2:_ASQ&MFT\MH8NC.!X+WYG'$LH'C36OY<67-(A*7T%
MS>K7^Q\G'0_MSK[YA?S+U[9,W"U]*-I\IVXN^YJIW$R?[O^*2.7_%R[6=#X#
MQ'V*>S)Q>5$;<X[,B0\HR^^ZBAEZ:=<S[>+,6"#S0KM "J[Q2$/'(LK7]51P
M;')$N@3<FKD*I8>LHD)#D,UU)Z"JS+9^XC7NS6Z<-QOY_IBG/PIV&W]C6%8L
MK(5?]8Y>S]DOTFP_)?Q*NGEI6?OWPB:4#X>807:N[B"'N]1O2Y$R6E-*5$62
MS6.(+JEXV#0_]:(($$%@!(;6P>P(Y[Q_RE#>A&&3>S/KUCC19]+/]T3D#"Y]
MN@R=>^S8_1,3?S9ARV5W/'24URFV=:,7J04!C#+?\'F3N>FH%X/PESHS!>7D
M5;<@]RH2V]B>HUY=S6T.&M-VUVTJ1)5?KE03_WOTG.7<F_W?/!J6%H4/IQ2M
M V8S0I4YM7QCM.[N)G\LU0-HF0UVRWOR3Z<#246/G=@0\IR^-_!\XB..Q"I^
M2[3EAV;1I?\4!U9%QD^%48D:/01KX@D()9YV F+X.\?0^+6RK5&J3 O!%HS,
M"2.L95Q@D4H'.\5]WX<2)?*;'"[=C#.M($H#>?S7<+OU60O&;!=I1/U+[.*K
MY&[1!+]$F!1U&@EX5FT>D>[#0W=Q+7Q:9%&\^Q62*C6<FVP\V=W%;I-\626H
M_Q@M6=.WR6B5,2R;4M=SK3%U?D=YN:/56I2,<MI7[NN_NP>>^D@8(+J2N,@Z
MWNQD4WQ XH*N[-?L*FXEKNI&?] 7[!MET3XEI9+"R^GIC+@2_$[L/N9=)LM!
M/]N&->3Q($+[L<\OF'W5;-@<SY01#^FL%>0=4A=<FD_S4 YD<^<\\$">#5ZU
M*$A .P']K1>\MF4?);JMC9V_61EL+_NG4S3K8<X+I6F)4)[HU==-'65)=TO+
M13#(E*]YRCQKOBU2>\E=I.P.,! POTG)VC"W<PUE)!86V]W<1 4D<UGAN[15
MW ZUNW0H0$3LEY6&0\+IX@0IM ]<F1^U2<O#X3](+:$2(^F&SKGP7X,OC^0%
M&]<-I>JFZZJ 'W\>UM$Y=@(8*@,&H%_@?IL]J ,! A=ZOT7[?+#[.^!9_.R;
M 62L5THE(8.^5T110V"\!0S8(HG"]*V9'S+_TS'$BV Q[S9UV/%TK6JEZXFN
MP3I7YZ'CWZ-YQ6(\AQDX2(%**C<"%:::DJU,HY"3%?F;"9^]R[Q.0,$*:9WF
M<>6>QK6TQH86=XH?] OZF"285W?H[L'2P(!G"IDCSH92#G'^9MVLIS22,ZKC
M ]1@*]7'V7CE5'75G)T\9:*#7"\GW/ER(!5?YOPEL1?9W L&+#S="5"B;A99
M I#+54O!R7\8&YIQLR84]_CEN3Y?U#%X$(;V$?_7&KWPY,N+N[^78^TL%QL+
MQTY PUIB7VX\;OQ=J1=V6GD'VP@I@VVZ+TK/TMO@WW5&U9OD)Z1H&;Y#&62K
MUH7=B%R625X3?O2@8_>]1>L91Z:%':*V!<%GM()!I!ZH:M\2GV$U7PD1ZL9-
MO^DY6R^C.3L@!-)<Y90@L[%3F=:([@ 8NQ*#8XD1XABN]\%KV[^1EU.AN)WQ
MRR<&P9@K6V;+!!+E^6='*W]+"XV>Q<SHR9T^5273XPEOIYZA ;^%F.6O<7\>
M>#-.%MY6LEMRCE9B_7M'ZL;9! 7WO'R"/^\KM5R).0(I6I(2\&O5W,P!Y4=/
M."VND$5FHM3B%,BJ>$)BD1N^<Z4G>X:^9&3Q_ADG0E#8G?6:Y0$E%D?]5_O>
MU0$;4QB]T$O(YC-D>I+(":A9G\R.+UO0R_7)(B(-^:+6Y[@PR<8YT/*']M<3
M'OZ=]&_]4Y?]N?+&$X%'5RCG(K:_-2@[!DBI/#@!^;S2HS!ORA1J4(_'=SF/
M!\DJ0ORI &;:CWI1'4BD,JQ^_S<^SU%OY)-U FHQV#/,O7'^FT^0*JE]^>M_
M'^+#MMBNB-_,7MFP&<Z72B"\L XU2)(RN+R25JH[(%C^?6E\I1P#^*MOUC'G
M5:YGLHF^2S\3H')V-R #_;<9:*#:'S2I'D1LPDY YR2)ZJ20-6MVA!(^*:/D
MYT2;6,.01,R6JC2G*-.0W1].PGEA[_L6HJ"9<7T/S&4COP?AQ@,=&=HLFKXM
MKF5S@6:U!6Y\2WRF\3XAOG.6#44F*OEGDRSY(SLMFOH44X^\L9EDKGZ"!W$/
MV.EPE!D*O6KK.B<(<$^>+WE59-N;UWEI-HAZV^?H3YXK>'/W=?Q[T=<@T3$5
MX. 9FJ?*JV.X\(*VR<1Q<UKJI4?6*Z<*U?0FH3UJ&<J><OQQ'[B3[RZ?1W-'
M$";U%,,XEQX"OL%MS ^B&:,I@P ](1: ;AD#=5!\?NO.9=>Y:T!?#DMBT-/E
MRM^@TCMOZ6/UN_YZT47OGG.UHW>,LB@\GSC1ER'^S0#'(/T#O<5/LB+K4>+K
MK[@LLD0*R0PA1'ZL<X=#J^HP 3;+U4^#N!1?!TGS9Q(9BLN:,C2'J.)$"0.\
M>'C(^?PL8EB'H#&T_FVBX&Q]5ZG^U<.IKC^M$^,X%K+@8Y(769L8 >R8$*_D
MK8];( P R,>BBA 8U)W77$,V9VC5WT?3C%^PZL6+(FC_<'B<&^4#!KL F?3#
MTB8+B&N>$\87HSS11&ASL%Y,P0UPA'>NC9=GT>.HI\PEGAY:"F?9F#5Z WLD
M?P*_T6>G$]UF96K3??X6D +OFCP4V;]%2*9DO81,6F!AD=2K\"SOG%.)V*+>
M@]V)%O$:Q?<7 ZXXGUV*S;'.0#9#D-ALZAF:<WQ&J(W56P+;\VT*:ZG,>2_3
M<D<WAZ:\M?_$PCZ+QE[<B@_JM\=WRN*16V( C/#U%+<V8.RJ'3!6,L?HOC;J
MUGUU*_8S@<YTU2DOQ6[7\Z0M-^E8J])R[RQ\_B8.SX_5:R@,_7MLDI>(+4$;
MN?S,;4SS>50*RZUGGHQ]P?\A-^*3 I+./C[_W$WSSS E5]B/@STM,=L#)Y[N
MAWE;H\=!0A:DY\AF5U7(I#'U8@C00PBN I@S40_)UVL&99?&ED8S&&0PY?)3
M(_$7(L,_@Q3X.Q9].FU)JT&=7EJ+F(L0;(E<";+YSPFH+-+C''40@(5FDWQ.
M0#K^A V8?^C(/. 3M]E/DH%W;+26P<-M\1UE^9I1NV"&B=Q]M2'F D*D:!2]
M,!"@[:FC-ASO,%%4:<H1\M9KF;\N.+T:X6LI]6OW;K])L VI#LF9@O/FGB)>
M:CZNK$&(NNL*];FOM1G7_/6Y$C#%0*?] "=JW8?Y'4'FW, BR1QWM_=,B"&+
M1MEXV<\F/FIOBNS29 W_T L]N2+F?",^D5WO;\Q$5_^@D.)'DSH@&254PF>2
M:^RBY-CQY^'3UUE[9^@2DR3>] 999&M9W"_DRG2I63,HDF"&Z\IF_T,LGQZK
MI<U4+5F&]IJZ/B=90O3S7OSI D2K[<U]>]*B;>F<_D=DLM2ZFS+LHK$%,^L4
M7^B&M31*_*\^QEU*?*@D#+Z+G$3>&"[_NC^Q^1C/WYPS:U-6E(>=EE3^R>;'
M<0)Z^0G"=[RZ"&WK9R%? 0QR%V$<[GPN$61(=HN7O#^3P8+G%NI3H(O'F<3.
M E$0P]6*]N%H=U\+$[E^/QV=7"G$D"M&-F8UD>D$-)9_'MW;#T8V#V-*Y\/(
M1F(QG^=9=4S<$CBI0\,J8G;FYT,?$R(??PI_?9XUL5K 233DQO^J7IHV,M)>
M;ZC4%>CQ$FOG'XRJC,PCLQUNCZ4F?>I35Y%3ZF(^DZ"[EA@SN1A5$RJ>'K1^
M(_??/<41,3E]5;_Y[>+D/OH$@TL"C\H4=4'K[CW(9^CI5PNPK0]30V0E?$<D
M3F1A7H1TQW7SKP=Y1_G/?#5+P[)1M,LV7S>%%KX]^R,R?Z<T/R<_Q"M;5@^^
M=' D/D].;'92Q>G.?#*1RNL:_<+TZ8Y?-*)Q$<.(P<X@B9+6+1"BQ(-,GNG%
M8DS(]SANY),8F1MY]HY!)Z!GU($]^FW+,"R4]:@D'9^ZUK)<(?UXU5;R7Q_"
MZC&?*NZNB1O2H,-##IF$2,FA]?IYZ.4-2-5P:)^B';PF5%@\5^[S4T^]*_E'
M@TU[B2M'TY6;!LV3XU%SE(](+ IV%H+]WJ@[JJ,,8-I2CL=*LB>0;O;M>HE^
MS[AF[L0G,TG)O>@+I\MP[WD)^0 I*40VVZ2U!.@)#',3OFJ]W5/]-U@\=LM7
M9;4FGCIDF)CHQK/$GO'-74K#A5MC/+S6>C@_;5>MX,.*V3=):7M2@9U*7<G]
M2#@)(Z><22.1^1W@BD"RP!F2,K6+JEP/S!7@^-$<\'"3S\TACQ?21'[R2] S
MEIHDO=;Z=$OX4VW\GW%=1MV[.\G1=OMJA1_RC1QS$O1&Y@U.0+D(,4">RJQ.
M^4S5(+Z?-_(6<( K$?XM0HA&Y6LRPA;I3'LQ YTC; XCS&]7T5,9U_!]\5@,
MPZS[5$=!WEHP9TQ-;?6(O)Q3V-"4L'+#\I/+%@+;$N!<SM^C!<;).;:ACZ&7
M37."LJ71(BX^O7+N>\.+<62!99(461W/V?'-%0W/;Y]_%I_MCF*Y'23[)7JI
M\._@CJ/>[K+IC;.Q[L.0ISM$N;C-:9(S?+VUI9$3WY:L)S7Z=-?C)<H=FMKB
MWJTMZJN@4)=Q7?]3R:9N0#(L,CHH7;"!<2$V2\)9U6\3Y*>OQ#U7(Z@,+5;^
M^?]4&/9I J>'SUUTM?5*/IF+1J"4\3""$<VWPZA]C6< O1J7/*++(N=R$=]L
M?:T'MZQOJ9OB]6E'?9G,NF=@24$_6*[D4!7J_3>-FSF5"9X\%FT&.;GGZA\*
M:_Z(-S@G^\A+A*^@:"-@3FA83AY=[+FYZ;%X>KK!1^"%P?<R[1)AJ5]A1J*,
M+&Z50>@N*%$[D)"%EV^%O($Q4OG^5:7PA2;BV7:IA[8)$I*$:@_]QIYGPHC!
MLID(YX,H'>!%\&^;AT^DI11GTZO_WLS2'PEA":;\@&"7^R<CL/11Q>6O/+W;
MD*QRFS:=*AD<PPG;(T;IGL:1N5&2/MVS_$I8<)J.]66L-U&;CN"&O_VIL^ Y
MAJ->;>C<GM">?E7JM4A>G68?D23ZZ$WZ1GJ-'5K&FXP!#%A>8\Y G.?IUH\S
M7Y.E<6A>8OBMLE%5$V_'DH\/G%2 G*+*C6M/WZO.5MQSXTVZ\>R)D=[RZ3X(
M,Y(Z^06 6\L0)LH"6UE/G[>-::EH>8X(AW]+G"[RS4?_:<UP'T@OG3">K.X^
MFM_76"M"X/I?UJ..OP5NEI%\R)*4RGK%H"*$-+[C(^Z2KG8/R<TV)7:]\^_L
M\M'8KE0/UPE(SJ1N-##(.WI+X\ @_<=J;$.#]!*2*(XFLQFV((%[+!]H; M=
MSXYVFXJ+T+LJESQV[)63M3HDU+^5]LF>,:CD=RV_[YO/!KZ]Z>-_Y@&_0S)'
MN#TE0X\'_NI464DZ1KL-=GDKIW9<#B68O#Y_=T\GY[U2?;C?U:ZO IOO]:E:
M2_GA[Q#6):WJ/;,[J\A;/VP*AK*VI'<F_75W"*6GQTTPSS(G(>W6?(P9PJ/U
MR&*;ZMCMX69"Y$^QNL28O$6CJU4R6JRE;!>$7\/15X@TJ*-_3NT7NC;N5#96
M+X^'M%KM:?Q'<- :6Y\3V[;7?^',T\5C,Y&^OV4W#QC%$=6'%Y";/8"+/IZ[
M'7WA7Z@.,;=P.G=VWW:TU''MF$[K/4E&04-1N;/)U4:9VVK*\H7T!DM,)G /
M-GD"PM$,?EM%G@UQ!6 <*VVY8K2Y#_?PEKWN4+AL?[- YI6A29'B:\6HS;0>
M28QSCR0RF$!FAE-"?6AM/[)=#2)IA8YDG*&@0@6GX64+G5'E2*Y_W$R_9R:-
MD\/N_?<D6:WM4]>9LSE1Q6=XZ:[6H36C]CG):QO9[9!3%L?9,M9_;[3"TQA[
M HJJ__AUL?J)M=6@<X#A'N>+N,#GBP[%H"</!,Y]R:*^19CAN0V!B%;4K?:4
MPX'6!8JT:8I534.?4^R81C1*#EE[V:C8/H!^XH]<XDITTC"%Z?>7?K=T-]=K
MVWXGH'+K+2,LRZ3TPOZ<%#%N<8N[1>NL_#*JG3QMNWB/Z_(MGK^)=ZZ+&O*5
MI0O0A</^@Y.HS&V45+)8<;=+[K],CGHSK^@OF))!U/>*>"/^*,J/%4E?;@DF
MOJ7HI_Y@AM!^#+..R^G..UK N:MCM CE7T\M_DC+4Z57&K[5YR"=;8Q$9"NB
MA9>M%G$] 0FWTC\L:;1TA!,Z%\!D=G5""/'*PO.7F<P(0>(K=V]&O5N]>I'G
M9F=;DJ80&Y%)>9]+ >,:42&_U(V"B);'GHSZR^JUIC1.&O88RA[9UNBF%AVL
MCNI/#[U NWMO9BFF0]?Q$O\\*SRMR6^6TZ8_\J4?AW:LAJOGU'-<9T" )8\.
MX+[#<IXX;43\N/!1UKWUN#BM^/GQYR?NQA2]93E/KVQ=(4W6)&>][_&PJ]2)
M3.#&"6BRCE #S(YX8AWDFQR%GT*>C9&E/86^JB@YO8?'WU9F?'WGI>R;5LF5
M!B<J0RY)=!W\NVK3 MO_3JL8Y81VA-^>UZ=DN?+K<\[XSL_,W";QB_%T2GG9
M_[::H5,X$\<LB5T^9\'TBA!,E3#EWY"R0CVKRY[=(_^<C2<.L'!T?EI=[EQ.
M]R]F,EUH__E/>F]U$486F"1)DG5&BXNV$$:+<1Q&[A+)6SG$T!=?^YB9.A/3
M!78UL#B1U,!F#%$SA6!-K%GL>ID6QPI/;$;[!G3Z+PH*M[K9"8.&;@X5A00W
MCO)HBD0?&LJV:^S]U XLZ3Q89]K=D\[\_J;JU?W@40C+QICCM4%9?UFM]?'[
MPSM9QA_M"EVM;+R>^#/&QN:\MS*_\+B97I5FP)6'9$X6[ Z9O=,:V(IKEPTE
MZ5?C'UCTYLLV)OF%K!:)*TH<?_;,X64/CUXZMA;\/Z7L^[X^>.O4-Q<Q\.[#
M]T80^A/2HY\H!]G<(#$3?^!:J=?PB-KYJ*)IY[Z(A6GOK4MURAFW_UZ($A>\
M:W2U4?.BO@4EB@;.=;2T';/5CRN$7"2ZM*6F1) M?UXC<<4O:LO_-@E>A=1%
MMNI )7@O%[WK6J(+C\W\N?A MS"\*BNL8^&H1G.TOU2G0Q>CM9OY]@14)=$2
M%XOD]=^)R+B,'PM'PZ=;6K#KQ_I%T>-<_\V]K$H+?<"28'U;0]>V N-Z IKR
M;@&7S#?-^BVJQWFO#)$E%O:\"1M?4$]KX/4;'U"X-I_W 7]+OV-]TC/.J)X*
M/)TMH5EN EF"DG(JX0L1I,H3>QP;ALDLN)^(F[7ZF[;.[6TILD&H:<>;]^[D
MW6;B\.KT?<U"3Q^UUNR\VV9>8"8!1\F.IA/_(IY;ON5WW!OO!@\2DWY#!>^@
M$S"N\D19EA;(I NA:3#T CQUO(,-/NR8":VJ?"6KI>D1[OBGI+GVEE2END(?
MZV(*P8K6E EJ/Z32N^,;9.$$U'H"XG)+S8]2O;.:.C?ER;8[RGLU9CE1R9CO
MYQ76C)IB>4(],9S$]P\"F,F?A;]:3(E0(?7''A]T)-1RCJ2JSNPRB-7N>D S
M>783V>6M1'BZ<9Q) M(QAM#+]*_4G2D>[G:7X7Y#";,2(7'Y)R /:-PXN'1^
M$XVG6U1M_,I5HA[VDK_AL8RCQ<79<L64"_9T51H=+X+'HVE^+83$YEK/ P^0
MD_GV^(/#MULZ_&IQBT%DO4JKPRU$:5% 9<I_#EM\CS++DZ9CU?Q7:F%$Z=<G
MH)A'9/CC$]!- ]KM<K9Z0_UI?U4S7YG9"IY 4AFT<?];S_1*6PA1I(K-M[N5
M>26O4Z&;O=*'+ZZ_[E'>9;B0_UQ3PSZ^@5'4#9MK);5G;B0VU6%9HI0?%<U_
M5\USAO)]-HK.!Y;6>)D6X?).0,X8-OB0KO@B[(.M8,Z0C)/5B(H*B;5;Q.?R
MO3V0@O*7O3UF9F;(31UZW!9X$1E>3D,IY(/A Q2W395=(?^&Y-BK5]5?G!T$
MC1@O[!<S&K!5L"RV=U#Z_FA$60I^WT9,GX#.7:3-63OBE( ]AW>V'H/;C)%<
M)D&+=I+R6\SQ^9W^/#'@QW.V#Z9\@T'NZX+TMG%M?/JH?>WZM"[SEXP*S3;_
M*8^G\Q'3J!>G\88$3>)#'/A<+PE*1)J.^GO>[%M^R>OU\E7A[F\#_-?7"F&L
MY^-9>F,;W+=0<D-,\M"PL3'5J+DY18[G6E=_-IGMT^VCI"VBLAD,Y+8/0\!9
MWR1[1S_;)SK4_A@[ON0#DP^=G@=LO-^  >BLF4HF&/Z[*G(I^EXC>$BVEY##
M&AWV+T=4LZLS=:..Z*MD&(G@HXUA!L09_=%1IFK(6Q7& Q>=-5K6#UP4%#!\
M;E,Y*BM6GWC6HGENX0%=LG1XA "&_=J> ?/LIJ33;WR*3%XBY-9'O".49!PZ
M@[R(=*K[QB4?F:$U0.:C"C],@_*%EU)^WW3:4WL$KEO)0\YQKO&!/Q350W],
MK:=Z+A=GY<TWI:A5!0Q%/JZ);'H:+^A;%)W#VH0-8[F52GV%P?[#3'LOS&^9
MX?.;J!R (\J_P!W)@*Z@L+3][G%2N>3R4J+\XY.RGP_/DUS?+_TA?PNR7TO&
M9HA7E0565-UV*HEZ)_<*U?\OQ.$#U: ^@H"E5"' -"@X 1%YU=OD!?6+3+[;
MS=UXM)$[+=O>^551ZHN!/T_7TFI<\%$"A*@92+A]J0(1A%)C9IYG=&.:I]98
MEYYJ$/,T@C;F?[?IZ1 '7;V+$> 1"]/1SPZN>WVBI!O14UV/HX->KSS0B4O1
M6?S\PE]R- I-_XQ*<X;&BHN?IW/%_(E"X22NT(DY=DH]Q&56>A$6YC2:#6R7
MJ+:QRN5[5!Y>^?XU*Z2K&(OH\MGS570LQ*C2( * LK BKN!AFXD+W^RP>FG>
MN0B%$<==$ZD+'LOE]S<"92PRI>X+^JGX'@@<_'/_2<D] ;G#(F EXZTI>.NV
M?FY7/;;!P"\_DK=ZC/V%S]57/[D^9"(^T/G4K?>UJ0*3WTA^<!_'\+Q^G5J^
MQ:&;GWMOQJ<B$_X/Z-Z#4P?#.+_',R9#W/"[4]FLJG3?X\HTP&WT:2NX#/Q2
M(.?!X68\*1@A1JE%*/H7(N3P>5\7/[P$WA.F%$6Y*_GWROJJXJUL6CU?\!3S
M9#5K%*+>M W%Z6"']L4SE-XN=S-(9W3PZ\;((G9.%Y(L0NFI39)G(6SUKJ[Y
M[NIWQ*H&B[+=M^X^[S=4:+MT58!5R.37'6%VF K1CLJ<1$E&W$"%)&\?=J:*
M:I<0ZN99E%O.AQ*$@V \)R G'8+FF:$>O*I([P6U=Q:\-].6TQ-<_@&:/ZJ]
M)\<)"8#Z%@QH[.^ ,9.-\HF%K8%]@YU!S^TN;L0,UBJP\$='9[]N%8G5#U3M
MOU;=^-#KI8%1X?<?45(&'&;ZH/\_7G#HE@4-"*6)(B0.. 8Z$'H-3H("&:A?
MDQ])=JY;<L]<O\\-[OPUJZ;S55@*;X>#.[V)<IC-[,7Y-U3%H4T]Q7\I?.]S
ML^:FIEMJ0W:/$HSH?EP39][T272<),%H 4*ZD2YT+E1S&*&/MVO*;]<:BWNB
M,FT<CW+CTC/!?-GUF/;4<0MUY5D*"^IX 0+KDFE!)?P5\BGX/((=_[XDCRRF
M=AR;],-Q=JKG!,1@6CYG7]*T&5.!OIBN%!YV06-5=>UQ:,Z,I:.7^WY%G#K[
M ?I5\DSE42:-PC578@!S3!BX!+)9B$-=6HR(*]*1*'2;D]9ZARHGI"B7#X0D
MG)UC-*ON6'K<W4\?1;D*S).Y70AF>,<&I]PU&B"4&W^[99:A;0=/@39:B,8V
M<_H^HDL6?HKO#7V&;*[! '=W:$&Q*G\3@\N\3+8"Y,EBM-XM)N;9VL>XWR]1
MM*,DT$]63L%'R$.:W6>_S60D':LOT,A5%>$&$!CYD@(S)=X9.WZ?XB>X7(0!
M/F^8+!OSGS>8&G<VY:'[7]?^/<.8'_\=.:JI1WG&=R93O"<,%Y9IH2HDBWW'
MUE]-;()E7&7]:'ANO(!C=05VEWR14HS!)B/+\\EL*82!,3WET!Y"<%_#@L/=
MQ47XDT'/CJQ7^79_>T1K0V:_SNRUUB4YL^QVQ':HWQ\EX0KF6O.GNU7;(AD5
MKR08";RS&0V2,<(^\DM<NS\!F]K@\^"V\KOA[_PR[+GXN]9V)84_I?&?'H0W
M"USN5YU]TPEE$E\LSLV&/O/!*;QH$TTK,UTKCEBP;L40M8T7\ULOC0Y1)<GL
M ]X5EP(87LAXRY7SOP,'^NEK0?=>&-$]%\5'D3X2:+X='MWX'W7*47D8(>TO
MAP+F._ARPBX9@UG/VME-&H$,F8;8WGU)O_;)X"\<E$Y'6(W3XR(Z+58F4KXM
MQC'_"[WZ>RDDS?)WU+8<'"(3U1K?:>H.5%&93W<9^])P+%$%&7$"8FWD^Z?E
M$J;*PNYFK>65F[V6W556-\V:)'?U+>+WYV:KW2:+%0G>I>,OWC]QX@527FS!
M#MK9O:B#>AG[HY&4C-5U"3(W>]NAX^D9#Q.R5WV9JTBJY]F');=Z#'UT%.ZP
M>'#$OR&(-UK2.F.HP\Z<0J*'[SF>T1LL@B\:FU]?:C\7DW4=B;4P:C[H#S[F
M&FZFBE,:,=@PJV#' D*,<8>C#M'L[$>Q9LI*]L^/G F\]L>]2B*)U$E5O#>9
M#T*"NA*$.(E9@+5YYF;PC%8J'&U:E;GT*A>>75%[,3^][5%5%S93X9.>59MY
M^$-/-[/1CKO4]XF9)'^MA$&-S/)_:1;X@SP3UB1>.QXI0]UVJ>[/_<!B-70J
MD! ^@'2.H]'W]GE6LI'6C6RX\;VT^^DJ4>^?F>W>S$D/2KACI2HX.<)L G^
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M$Q9&E(2T@<$PLL&(?X&.-K"T9J$6X:P^B1O+K24]@FD]"OPE7/7X[=36"N4
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M+)UT;'V?>M9QK$JAZ\_C;DMI88=?EM:'QVHSV1L;J>17M*' Z'CF-Y.T$5>
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MNK.H0( X1@2)_8V# +[CF[-;!7 %%H^-N%3*"%-#B);U HS,Q;%*9;:EI)V
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M>-U>M3"W5*:9?6B,&<_=')"=N;J\FM4^%PN>_R:(>P#D)IW8$]!Y70PX)*@
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MN[M//@5.>/UZ#\P#I77E#Q"E#)<&X%>V3"6AIF&=@802<SSK:N&1_Z,XDH8
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M^1!^I:Z;FI$/H>TUX8X]%F/Y-/P\E7NRA2$^^9NK"@?-9"8Z((;2 X1L" C
M_0X)_0MS3&NHM('ZT@#=!U45%=7O^]1'D0PT=RUZG(3?@&C3_O6CH!=4GUP/
MGD^ 5VWGGTLA*JQ31 CP4O?$=44%Q0;MH;%2)",'7B[[LH/*'5.E\-6P1/%?
ME\.[][G,O+K!*1N:[Q3SC3AO',H]HFO35PQ^82E$L^565)$8;= ]/[C%"0Q1
MG%P#GB^F<+00M'#$>9V*>77!CK82^=3<\OH]@<DVZRMU+?4/%U!A(7_KK)Z$
MT=*$D)6!JP+#V^3D #DE MDL8 H3;D2-J3TILSL!N1$23=\PLTUHGRVY^>),
MT^=$^L8WDIUS]!"78U2/"6E7S,)_7_YA23=VY-!\/EN@#UFH!&6Z9NQN:F2Z
M]P<&M-PV? *JF.LTQD9THVFE-?@(5)U9\J$Z(P?/6A+U1F;7/'CTI0QHQ2_.
MM-F]"=I2PT/*8*HXHQ2\4.LQ*D*^3Z_F J]]9;H1NC9%XU$'2W:<WF"5!'-W
MJ0?7IY8=-^K+ODO8^J(E4967;XF\O&;M7;(9<]AI$A.*G(QV9R(HSATFXQ6:
M<3[MV/A.1"A%Y(-<^=0OPV_7.ALX;Y1.6RX-HNK"[.*5S76F&M^:^+6H -=K
M WZ^0Q"#8*9VPDY C&#G_M=M-P-R1$;\/(P85%.?7=)3T.=NS+R*JHY-*A]8
M?4G]9!SMGWP9K**6= )2+T83K?7W1K_F@U?6O;NEO/S?8>,=%@&[7O4DL;0(
M$D1D-B<#"S8X+8,*.F2XC/F/WN](16P_N5EX"7O7B$'WTBO5][QINDJ@,#XP
MB4\1\*I^O"Z)3?70$4>>>+,U\0#?C9E:0TKNKWX4H@S79-U ,0LIL!E^SO;K
M _G?.I"(_QG&>T[Y.(V?*FHI3J6H(]A]BU_0M&!3HZR%%;<Z7T#B\#S\39#'
M5=TAO X&$GIZ!^SZS\W<D<>C2))8R;7.X:Y&AP27W ?"'E&**NR6Q&FGEE[
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MKN5E-ZH\$IB:\_94E;K3GTQ)^LM$? J,L>L$Q J5)YH3, NTK2>@D%L$3(?
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MOP*FD\G_ %!+ 0(4 Q0    ( #6(?U344DUL(00% ,[B.0 1
M  "  0    !F;F-H+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( #6(?U3[D*:K
M4Q@  -LR 0 1              "  5 $!0!F;F-H+3(P,C$Q,C,Q+GAS9%!+
M 0(4 Q0    ( #6(?U1T^G[!PP\  +S=   5              "  =(<!0!F
M;F-H+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  UB']4G@:^%T@\  !1
ML@0 %0              @ '(+ 4 9FYC:"TR,#(Q,3(S,5]D968N>&UL4$L!
M A0#%     @ -8A_5/$>DIX&V   2]P) !4              ( !0VD% &9N
M8V@M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #6(?U1\_ER 5U\  -WG
M!P 5              "  7Q!!@!F;F-H+3(P,C$Q,C,Q7W!R92YX;6Q02P$"
M% ,4    "  UB']4Q3BY]$@8  ")K@  $               @ $&H08 9FYC
M:"UE>#$P7S$W+FAT;5!+ 0(4 Q0    ( #6(?U00]1EK$%X  %', @ 0
M          "  7RY!@!F;F-H+65X,3!?,3DN:'1M4$L! A0#%     @ -8A_
M5-_W(;+T80  NS$# !               ( !NA<' &9N8V@M97@Q,%\R,"YH
M=&U02P$"% ,4    "  UB']4?_BRT[X(   I=0  $               @ '<
M>0< 9FYC:"UE>#$P7S(Q+FAT;5!+ 0(4 Q0    ( #6(?U1(]35$]E$   U7
M!  /              "  <B"!P!F;F-H+65X,3!?,RYH=&U02P$"% ,4
M"  UB']4B$5P^ED1  !NO0  #P              @ 'KU < 9FYC:"UE>#$P
M7S<N:'1M4$L! A0#%     @ -8A_5(/'//R% @  /10   \
M ( !<>8' &9N8V@M97@R,5\Q+FAT;5!+ 0(4 Q0    ( #6(?U0V)NF8JP(
M !(1   /              "  2/I!P!F;F-H+65X,C-?,2YH=&U02P$"% ,4
M    "  UB']4C#CL"6$(  !O2@  #P              @ '[ZP< 9FYC:"UE
M>#,Q7S$N:'1M4$L! A0#%     @ -8A_5$3!6;!Q"   D$L   \
M     ( !B?0' &9N8V@M97@S,5\R+FAT;5!+ 0(4 Q0    ( #6(?U27E3\7
M%08  "Q.   /              "  2?]!P!F;F-H+65X,S)?,2YH=&U02P$"
M% ,4    "  UB']4?4Z:B:H7  ">D@  #@              @ %I P@ 9FYC
M:"UE>#1?,RYH=&U02P$"% ,4    "  UB']4V:TP0IR^" "0^PH $@
M        @ $_&P@ :6UG,3 R,S8T-3 X7S N:G!G4$L! A0#%     @ -8A_
M5(J%09FJ<0, 0ZD% !(              ( !"]H0 &EM9S$P,C,V-#4P.%\Q
M+FIP9U!+ 0(4 Q0    ( #6(?U0@U!IU_L     ; 0 3              "
M >5+% !I;6<Q,#(S-C0U,#A?,3 N:G!G4$L! A0#%     @ -8A_5'/!;0BI
M-@  ?HH  !,              ( !% T5 &EM9S$P,C,V-#4P.%\Q,2YJ<&=0
M2P$"% ,4    "  UB']4<LI[TWM&   YH   $P              @ 'N0Q4
M:6UG,3 R,S8T-3 X7S$R+FIP9U!+ 0(4 Q0    ( #6(?U2]=M_)OD0  *.A
M   3              "  9J*%0!I;6<Q,#(S-C0U,#A?,3,N:G!G4$L! A0#
M%     @ -8A_5(D5%V&( P< B0(* !,              ( !B<\5 &EM9S$P
M,C,V-#4P.%\Q-"YJ<&=02P$"% ,4    "  UB']45K123NAQ  "CQ@  $P
M            @ %"TQP :6UG,3 R,S8T-3 X7S$U+FIP9U!+ 0(4 Q0    (
M #6(?U2=.V%.@]$  !@G 0 3              "  5M%'0!I;6<Q,#(S-C0U
M,#A?,38N:G!G4$L! A0#%     @ -8A_5'$<P?(FA   9-<  !,
M     ( !#Q<> &EM9S$P,C,V-#4P.%\Q-RYJ<&=02P$"% ,4    "  UB']4
MCQS.FE:4  #!Y@  $P              @ %FFQX :6UG,3 R,S8T-3 X7S$X
M+FIP9U!+ 0(4 Q0    ( #6(?U2_V>6(4F<! )&] 0 2              "
M >TO'P!I;6<Q,#(S-C0U,#A?,BYJ<&=02P$"% ,4    "  UB']4L MXTL>M
M  "1" $ $@              @ %OER  :6UG,3 R,S8T-3 X7S,N:G!G4$L!
M A0#%     @ -8A_5-Z#GO+X80  /[X  !(              ( !9D4A &EM
M9S$P,C,V-#4P.%\T+FIP9U!+ 0(4 Q0    ( #6(?U0K PT3'V4  +:^   2
M              "  8ZG(0!I;6<Q,#(S-C0U,#A?-2YJ<&=02P$"% ,4
M"  UB']4ETNW(H?) 0#7-P( $@              @ '=#"( :6UG,3 R,S8T
M-3 X7S8N:G!G4$L! A0#%     @ -8A_5,P3I'VF0P  ^TH  !(
M     ( !E-8C &EM9S$P,C,V-#4P.%\W+FIP9U!+ 0(4 Q0    ( #6(?U1>
MH+MJJJH  (H" 0 2              "  6H:) !I;6<Q,#(S-C0U,#A?."YJ
M<&=02P$"% ,4    "  UB']4ZL[5E>;\ 0!UP@( $@              @ %$
KQ20 :6UG,3 R,S8T-3 X7SDN:G!G4$L%!@     E "4 ,@D  %K")@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
